﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kiernan, DF
   Mieler, WF
AF Kiernan, Daniel F.
   Mieler, William F.
TI The use of intraocular corticosteroids
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE choroidal neovascularization (CNV); clinical trials; cystoid macular
   edema (CME); dexamethasone; diabetic macular edema (DME); fluocinolone
   acetonide; intravitreal implant; retinal vein occlusion; triamcinolone
   acetonide
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; RETINAL VEIN OCCLUSION; DIABETIC
   MACULAR EDEMA; ENDOTHELIAL GROWTH-FACTOR; NONINFECTIOUS POSTERIOR
   UVEITIS; INTERNAL LIMITING MEMBRANE; PARS-PLANA VITRECTOMY;
   DRUG-DELIVERY SYSTEM; FLUOCINOLONE ACETONIDE; PHOTODYNAMIC THERAPY
AB Background: Diabetic macular edema (DME), cystoid macular edema (CME), age-related macular degeneration (AMD), retinal vascular occlusion (RVO) and uveitis are responsible for severe visual impairment worldwide. In some patients with these conditions, treatment with intraocular corticosteroids may be beneficial. Although off-label use of these agents has occurred for many years, novel agents including preservative-free and sustained-release intravitreal implants are currently being studied in clinical trials (CTs). Objective: To review the use of intraocular corticosteroids. Methods: Literature review. Results: Used alone, intravitreal corticosteroids may benefit disorders such as DME, RVO and uveitis compared with standard therapy or observation. Patients with AMD may benefit more from combination treatment with photodynamic therapy, intravitreal corticosteroid and intravitreal anti-VEGF injections. Intraoperative use of these agents may assist in visualization and manipulation of fine retinal structures. Sustained-release intraocular implants have been approved for severe posterior uveitis, and have shown benefits in ongoing CTs. Conclusion: Although intraocular corticosteroid injections have a limited duration of action requiring frequent re-treatment, and significant side effects including cataract and glaucoma development, intraocular injections may be of benefit in certain ocular disorders. Corticosteroid implants are emerging as potential treatments for macular edema due to uveitis, DME or RVO.
C1 [Mieler, William F.] Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Mieler, WF (通讯作者)，Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA.
EM wmieler@uic.edu
CR *AL SCI, 2009, AL SCI IMM REL 12 MO
   Allergan Inc, 2009, OZ PACK INS
   Andrade RE, 2004, AM J OPHTHALMOL, V137, P572, DOI 10.1016/j.ajo.2003.08.035
   Arroyo JG, 2003, ARCH OPHTHALMOL-CHIC, V121, P898, DOI 10.1001/archopht.121.6.898
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Bausch & Lomb, 2005, RETISERT FLUOCINOLON
   Beck RW, 2009, ARCH OPHTHALMOL-CHIC, V127, P245, DOI 10.1001/archophthalmol.2008.610
   Beeley NRF, 2006, J BIOMED MATER RES A, V76A, P690, DOI 10.1002/jbm.a.30567
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Boscia F, 2005, EUR J OPHTHALMOL, V15, P89, DOI 10.1177/112067210501500114
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Cakr M, 2008, RETINA-J RET VIT DIS, V28, P465, DOI 10.1097/IAE.0b013e318154b9d1
   Callanan DG, 2008, ARCH OPHTHALMOL-CHIC, V126, P1191, DOI 10.1001/archopht.126.9.1191
   CAMPOCHIARO PA, 2009, ASS RES VIS OPHTH M
   Cardillo JA, 2005, OPHTHALMOLOGY, V112, P1557, DOI 10.1016/j.ophtha.2005.03.023
   Chen SDM, 2006, AM J OPHTHALMOL, V141, P876, DOI 10.1016/j.ajo.2005.12.011
   Cheng KC, 2009, EYE, V23, P849, DOI 10.1038/eye.2008.136
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Dehghan Mohammad H., 2008, International Ophthalmology, V28, P7, DOI 10.1007/s10792-007-9097-y
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   DUGUID IGM, 1992, CURR EYE RES, V11, P153, DOI 10.3109/02713689208999526
   Dyer D, 2009, RETINA-J RET VIT DIS, V29, P38, DOI 10.1097/IAE.0b013e318188c6e2
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   ELIOTT D, 2008, ASS RES VIS OPHTH AP
   ENGLER CB, 1994, ACTA OPHTHALMOL, V72, P663
   Francis BA, 1996, OPHTHALMOLOGY, V103, P1884, DOI 10.1016/S0161-6420(96)30411-9
   Furino C, 2003, RETINA-J RET VIT DIS, V23, P771, DOI 10.1097/00006982-200312000-00004
   Galor A, 2007, ARCH OPHTHALMOL-CHIC, V125, P836, DOI 10.1001/archopht.125.6.836
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Goldstein DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P1478, DOI 10.1001/archopht.125.11.ecs70063
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hainsworth DP, 1996, J OCUL PHARMACOL TH, V12, P57, DOI 10.1089/jop.1996.12.57
   Hayreh SS, 2005, PROG RETIN EYE RES, V24, P493, DOI 10.1016/j.preteyeres.2004.12.001
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Horio N, 2005, ARCH OPHTHALMOL-CHIC, V123, P96, DOI 10.1001/archopht.123.1.96
   Ip MS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1131, DOI 10.1001/archopht.122.8.1131
   Jaffe GJ, 2000, RETINA-J RET VIT DIS, V20, P402, DOI 10.1097/00006982-200004000-00015
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jaffe GJ, 2005, OPHTHALMOLOGY, V112, P1192, DOI 10.1016/j.ophtha.2005.03.013
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jermak CM, 2007, SURV OPHTHALMOL, V52, P503, DOI 10.1016/j.survophthal.2007.06.004
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, ACTA OPHTHALMOL SCAN, V81, P540, DOI 10.1034/j.1600-0420.2003.00130.x
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P200, DOI 10.1089/jop.2006.22.200
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   Karacorlu M, 2003, ACTA OPHTHALMOL SCAN, V81, P648, DOI 10.1046/j.1395-3907.2003.0146.x
   Koutsandrea C, 2007, RETINA-J RET VIT DIS, V27, P159, DOI 10.1097/IAE.0b013e31802e3e5c
   Krammer B, 2001, ANTICANCER RES, V21, P4271
   Kreines K, 1975, Ohio State Med J, V71, P703
   KREINES K, 1975, OHIO STATE MED J, V71, P703
   Krepler K, 2005, ACTA OPHTHALMOL SCAN, V83, P71, DOI 10.1111/j.1600-0420.2005.00400.x
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   Mcallister IL, 2009, AM J OPHTHALMOL, V147, P838, DOI 10.1016/j.ajo.2008.12.006
   Moshfeghi AA, 2009, RETINA-J RET VIT DIS, V29, P689, DOI 10.1097/IAE.0b013e31819e390a
   Mruthyunjaya P, 2006, ARCH OPHTHALMOL-CHIC, V124, P1012, DOI 10.1001/archopht.124.7.1012
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ozkiris AO, 2006, EYE, V20, P13, DOI 10.1038/sj.eye.6701803
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Ramchandran RS, 2008, AM J OPHTHALMOL, V146, P285, DOI 10.1016/j.ajo.2008.03.025
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rodrigues EB, 2007, CURR OPIN OPHTHALMOL, V18, P179, DOI 10.1097/ICU.0b013e32811080b5
   Scott IU, 2009, OPHTHALMOLOGY, V116, P756, DOI 10.1016/j.ophtha.2008.11.015
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P207, DOI 10.1097/IAE.0b013e31818eccb3
   Taban M, 2008, RETINA-J RET VIT DIS, V28, P1280, DOI 10.1097/IAE.0b013e31817d8bf2
   Tognetto D, 2005, RETINA-J RET VIT DIS, V25, P462, DOI 10.1097/00006982-200506000-00011
   Ufret-Vincenty RL, 2007, AM J OPHTHALMOL, V143, P334, DOI 10.1016/j.ajo.2006.09.020
   Wang K, 2008, BIOL PHARM BULL, V31, P1541, DOI 10.1248/bpb.31.1541
   Williams GA, 2009, AM J OPHTHALMOL, V147, P1048, DOI 10.1016/j.ajo.2008.12.033
   Yilmaz T, 2009, OPHTHALMOLOGY, V116, P902, DOI 10.1016/j.ophtha.2009.02.002
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   TRIESENCE DRUG INFOR
   I VATION SUSTAINED D
NR 91
TC 51
Z9 55
U1 1
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD OCT
PY 2009
VL 10
IS 15
BP 2511
EP 2525
DI 10.1517/14656560903160671
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 509IQ
UT WOS:000271009200010
PM 19761356
DA 2022-11-30
ER

PT J
AU Cao, RH
   Jensen, LDE
   Soll, I
   Hauptmann, G
   Cao, YH
AF Cao, Renhai
   Jensen, Lasse Dahl Ejby
   Soell, Iris
   Hauptmann, Giselbert
   Cao, Yihai
TI Hypoxia-Induced Retinal Angiogenesis in Zebrafish as a Model to Study
   Retinopathy
SO PLOS ONE
LA English
DT Article
ID VASCULAR-PERMEABILITY FACTOR; INHIBITS TUMOR-GROWTH; CELLS;
   LYMPHANGIOGENESIS; BLOCKADE; VESSELS; FENESTRATIONS; EXPRESSION;
   PROMOTE; PROTEIN
AB Mechanistic understanding and defining novel therapeutic targets of diabetic retinopathy and age-related macular degeneration (AMD) have been hampered by a lack of appropriate adult animal models. Here we describe a simple and highly reproducible adult fli-EGFP transgenic zebrafish model to study retinal angiogenesis. The retinal vasculature in the adult zebrafish is highly organized and hypoxia-induced neovascularization occurs in a predictable area of capillary plexuses. New retinal vessels and vascular sprouts can be accurately measured and quantified. Orally active anti-VEGF agents including sunitinib and ZM323881 effectively block hypoxia-induced retinal neovascularization. Intriguingly, blockage of the Notch signaling pathway by the inhibitor DAPT under hypoxia, results in a high density of arterial sprouting in all optical arteries. The Notch suppression-induced arterial sprouting is dependent on tissue hypoxia. However, in the presence of DAPT substantial endothelial tip cell formation was detected only in optic capillary plexuses under normoxia. These findings suggest that hypoxia shifts the vascular targets of Notch inhibitors. Our findings for the first time show a clinically relevant retinal angiogenesis model in adult zebrafish, which might serve as a platform for studying mechanisms of retinal angiogenesis, for defining novel therapeutic targets, and for screening of novel antiangiogenic drugs.
C1 [Cao, Renhai; Jensen, Lasse Dahl Ejby; Cao, Yihai] Karolinska Inst, Dept Microbiol, Stockholm, Sweden.
   [Soell, Iris; Hauptmann, Giselbert] Sodertorns Univ Coll, Sch Life Sci, Huddinge, Sweden.
   [Soell, Iris; Hauptmann, Giselbert] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden.
C3 Karolinska Institutet; Sodertorn University; Karolinska Institutet
RP Cao, RH (通讯作者)，Karolinska Inst, Dept Microbiol, Stockholm, Sweden.
EM yihai.cao@ki.se
OI Jensen, Lasse/0000-0003-2338-357X; Hauptmann,
   Giselbert/0000-0002-1205-1011
FU Swedish Research Council; Swedish Heart and Lung Foundation; Swedish
   Cancer Foundation; Karolinska Institute; Soderberg Foundation; EU
   [504743, 013811]
FX Yihai Cao's laboratory is supported by research grants from the Swedish
   Research Council, the Swedish Heart and Lung Foundation, the Swedish
   Cancer Foundation, the Karolinska Institute fund, the Soderberg
   Foundation, the EU integrated projects of Angiotargeting (Contract No.
   504743), and VascuPlug (Contract No. STRP 013811). The Swedish Research
   Council further supports Y. Cao.
CR Aiello LP, 2005, NEW ENGL J MED, V353, P839, DOI 10.1056/NEJMe058142
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Alvarez Y, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-114
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bjorndahl MA, 2005, CANCER RES, V65, P9261, DOI 10.1158/0008-5472.CAN-04-2345
   Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB
   Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389
   Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201
   Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Eriksson A, 2003, CIRCULATION, V107, P1532, DOI 10.1161/01.CIR.0000055324.34758.32
   Ferrara N, 2005, EXP SUPPL, V94, P209
   Ferris FL, 2004, NEW ENGL J MED, V351, P2863, DOI 10.1056/NEJMe048316
   Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522
   Gardner TW, 2007, NAT MED, V13, P131, DOI 10.1038/nm0207-131
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jawa A, 2004, MED CLIN N AM, V88, P1001, DOI 10.1016/j.mcna.2004.04.012
   Leslie JD, 2007, DEVELOPMENT, V134, P839, DOI 10.1242/dev.003244
   Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085
   Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5
   Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313
   Sainson RCA, 2008, ANGIOGENESIS, V11, P41, DOI 10.1007/s10456-008-9098-0
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130
   WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143
   Weinstein BM, 1996, DEVELOPMENT, V123, P303
   Yan MH, 2007, CLIN CANCER RES, V13, P7243, DOI 10.1158/1078-0432.CCR-07-1393
   Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9
NR 44
TC 104
Z9 109
U1 2
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2008
VL 3
IS 7
AR e2748
DI 10.1371/journal.pone.0002748
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 420PY
UT WOS:000264302900019
PM 18648503
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Rosenberg, EA
   Sperazza, LC
AF Rosenberg, Eric A.
   Sperazza, Laura C.
TI The visually impaired patient
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID LOW-VISION; CARE
AB Blindness or low vision affects more than 3 million Americans 40 years and older, and this number is projected to reach 5.5 million by 2020. In addition to treating a patient's vision loss and comorbid medical issues, physicians must be aware of the physical limitations and social issues associated with vision loss to optimize health and independent living for the visually impaired patient. In the United States, the four most prevalent etiologies of vision loss in persons 40 years and older are age-related macular degeneration, cataracts, glaucoma, and diabetic retinopathy. Exudative macular degeneration is treated with laser therapy, and progression of nonexudative macular degeneration in its advanced stages may be slowed with high-dose antioxidant and zinc regimens. The value of screening for glaucoma is uncertain; management of this condition relies on topical ocular medications. Cataract symptoms include decreased visual acuity, decreased color perception, decreased contrast sensitivity, and glare disability. Lifestyle and environmental interventions can improve function in patients with cataracts, but surgery is commonly performed if the condition worsens. Diabetic retinopathy responds to tight glucose control, and severe cases marked by macular edema are treated with laser photocoagulation. Vision-enhancing devices can help magnify objects, and nonoptical interventions include special filters and enhanced lighting.
C1 [Rosenberg, Eric A.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
   [Rosenberg, Eric A.; Sperazza, Laura C.] Jewish Guild Blind, New York, NY USA.
   [Rosenberg, Eric A.] New York Presbyterian Hosp, New York, NY USA.
   [Sperazza, Laura C.] SUNY Coll Optometry, New York, NY 10010 USA.
   [Sperazza, Laura C.] Columbia Univ, Med Ctr, New York, NY USA.
C3 Cornell University; NewYork-Presbyterian Hospital; State University of
   New York (SUNY) System; SUNY Optometry; Columbia University
RP Rosenberg, EA (通讯作者)，Cornell Med Associates W Side, 12 W 72nd St, New York, NY 10023 USA.
EM ear2004@med.cornell.edu
CR Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4
   American Academy of Ophthalmology, DIAB RET PREF PRACT
   American Academy of Ophthalmology, POL STAT FREQ OC EX
   Asbell PA, 2005, LANCET, V365, P599
   Bowyer N K, 1997, J Am Optom Assoc, V68, P233
   Burack-Weiss A, 1992, AGING EYE LOW VISION, P29
   CARTER TL, 1994, GERIATRICS, V49, P37
   Castor TD, 1995, GERIATRICS, V50, P51
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   *EY DIS PREV RES G, 2004, ARCH OPHTHALMOLO APR
   FLETCHER DC, 1994, GERIATRICS, V49, P50
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kupfer C, 2000, OPHTHALMOLOGY, V107, P229, DOI 10.1016/S0161-6420(99)00094-9
   Lee JM, 2006, DIABETES CARE, V29, P1192
   Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182
   MELTON R, 2006, REV OPTOMETRY S, pA12
   Robinson B, 1997, OPTOMETRY VISION SCI, V74, P79, DOI 10.1097/00006324-199702000-00019
   Solomon R, 2003, JAMA-J AM MED ASSOC, V290, P248, DOI 10.1001/jama.290.2.248
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Taylor HR, 2002, CLIN EXP OPHTHALMOL, V30, P151, DOI 10.1046/j.1442-9071.2002.00525.x
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   *US PREV SERV TASK, SCREEN GLAUC
NR 22
TC 38
Z9 40
U1 0
U2 6
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD MAY 15
PY 2008
VL 77
IS 10
BP 1431
EP 1436
PG 6
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 303MY
UT WOS:000256045800009
PM 18533377
DA 2022-11-30
ER

PT J
AU D'souza, Y
   Jones, CJP
   Bonshek, R
AF D'souza, Yvonne
   Jones, Carolyn J. P.
   Bonshek, Richard
TI Glycoproteins of drusen and drusen-like lesions
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE drusen; lectins; eye; age-related macular degeneration; glycoproteins;
   pathology
ID CARBOHYDRATE SPECIFICITY; LINKED OLIGOSACCHARIDES; COMPLEMENT
   ACTIVATION; BINDING-SPECIFICITY; BRUCHS MEMBRANE; FUNDUS CHANGES;
   N-GLYCANS; LECTIN; GLOMERULONEPHRITIS; DEPOSITS
AB Drusen are a marker of age-related macular degeneration (AMD). Lesions similar to drusen, both in histology and their clinical appearance, are also seen in choroidal tumours, chronic inflammatory and degenerative conditions of the eye, and in mesangiocapillary glomerulonephritis type II (MCGN-II). This study aims to compare the saccharide composition of these drusen-like lesions in the various ocular pathological groups and in MCGN-II. Formalin fixed and paraffin wax embedded tissue from 21 eyes was studied. The histological diagnoses included AMD, retinal detachment, phthisis bulbi following failed retinal detachment surgery, malignant melanoma, long-standing uveitis, glaucoma and MCGN II. Glycosylation was examined using a panel of twenty biotinylated lectins and an avidin-peroxidase DAB-cobalt revealing system, with and without neuraminidase pre-treatment. High mannose, bi/tri-nonbisected and bisected complex N-glycan, N-acetyl glucosaminyl, galactosyl and sialyl residues were found to be expressed by drusen, while treatment with neuraminidase exposed subterminal N-acetyl galactosamine and galactosyl residues. Similar binding patterns were found in the various pathological groups studied. As there was no significant difference in the lectin-binding pattern in drusen in different pathologies, a common pathogenesis or at least a final common pathway for the elaboration of carbohydrate components of drusen is suggested.
C1 [D'souza, Yvonne; Bonshek, Richard] Manchester Royal Eye Hosp, Acad Unit, Manchester M13 9WH, Lancs, England.
   [Jones, Carolyn J. P.] Univ Manchester, St Marys Hosp, Maternal & Fetal Hlth Res Ctr, Manchester M13 0JH, Lancs, England.
C3 Manchester Royal Eye Hospital; University of Manchester
RP Bonshek, R (通讯作者)，Manchester Royal Eye Hosp, Acad Unit, Oxford Rd, Manchester M13 9WH, Lancs, England.
EM richard.bonshek@manchester.ac.uk
OI Jones, Carolyn/0000-0002-0026-9494
CR AHMED H, 1989, J BIOL CHEM, V264, P9365
   Baker KN, 2001, BIOTECHNOL BIOENG, V73, P188, DOI 10.1002/bit.1051
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230
   Dalziel M, 1999, GLYCOCONJUGATE J, V16, P801, DOI 10.1023/A:1007183915921
   DEBRAY H, 1981, EUR J BIOCHEM, V117, P41
   Dentchev T, 2003, MOL VIS, V9, P184
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0
   ESKO J, 2004, ESSENTIALS GLYCOBIOL, V20
   ETZLER ME, 1970, BIOCHEMISTRY-US, V9, P869, DOI 10.1021/bi00806a022
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Gemmill TR, 1998, GLYCOBIOLOGY, V8, P1087, DOI 10.1093/glycob/8.11.1087
   Guldur T, 2002, TURK J VET ANIM SCI, V26, P257
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200
   HSU SM, 1982, J HISTOCHEM CYTOCHEM, V30, P1079, DOI 10.1177/30.10.6182185
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   JONES CJP, 1992, HISTOCHEM J, V24, P327, DOI 10.1007/BF01046164
   JONES CJP, 1987, HISTOCHEM J, V19, P264, DOI 10.1007/BF01675685
   JONES CJP, 1995, HISTOCHEM J, V27, P210
   KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z
   KIVELA T, 1994, INVEST OPHTH VIS SCI, V35, P3759
   KLIFFEN M, 1994, INVEST OPHTH VIS SCI, V35, P2901
   KNIBBS RN, 1991, J BIOL CHEM, V266, P83
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   LHOTE CL, 1995, INFECT IMMUN, V63, P1927
   LIS H, 1985, PHYTOCHEMISTRY, V24, P2803, DOI 10.1016/0031-9422(85)80004-2
   MADDOX PH, 1987, J CLIN PATHOL, V40, P1256, DOI 10.1136/jcp.40.10.1256
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MATSUMOTO I, 1983, J BIOL CHEM, V258, P2886
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nangaku M, 1998, KIDNEY INT, V54, P1419, DOI 10.1046/j.1523-1755.1998.00130.x
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   OGAWA H, 1995, EUR J BIOCHEM, V230, P994, DOI 10.1111/j.1432-1033.1995.tb20647.x
   Ohkura T, 2002, J BIOCHEM, V132, P891, DOI 10.1093/oxfordjournals.jbchem.a003302
   Salim A, 2003, PROTEINS, V53, P162, DOI 10.1002/prot.10493
   SARKAR M, 1981, ARCH BIOCHEM BIOPHYS, V209, P204, DOI 10.1016/0003-9861(81)90273-3
   SHIBUYA N, 1987, J BIOL CHEM, V262, P1596
   Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200
   SOLIS D, 1994, J BIOL CHEM, V269, P11555
   TSO MOM, 1985, OPHTHALMOLOGY, V92, P628
   Uchibori-Iwaki H, 2000, GLYCOBIOLOGY, V10, P865, DOI 10.1093/glycob/10.9.865
   Wang LJ, 2006, MOL CELL PROTEOMICS, V5, P560, DOI 10.1074/mcp.D500013-MCP200
   WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8
   YAMASHITA K, 1987, J BIOL CHEM, V262, P1602
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 52
TC 8
Z9 8
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567-2379
EI 1567-2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD FEB
PY 2008
VL 39
IS 1
BP 77
EP 86
DI 10.1007/s10735-007-9130-5
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 252VP
UT WOS:000252475200009
PM 17846903
DA 2022-11-30
ER

PT J
AU Petermeier, K
   Tatar, O
   Inhoffen, W
   Volker, M
   Lafaut, BA
   Henke-Fahle, S
   Gelisken, F
   Ziemssen, F
   Bopp, S
   Bartz-Schmidt, KU
   Grisanti, S
AF Petermeier, K.
   Tatar, O.
   Inhoffen, W.
   Volker, M.
   Lafaut, B. A.
   Henke-Fahle, S.
   Gelisken, F.
   Ziemssen, F.
   Bopp, S.
   Bartz-Schmidt, K. U.
   Grisanti, S.
TI Verteporfin photodynamic therapy induced apoptosis in choroidal
   neovascular membranes
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; TAP
AB Aim: To evaluate the impact of verteporfin photodynamic therapy (PDT) on the induction of apoptosis in choroidal neovascular membranes (CNV) secondary to age related macular degeneration.
   Methods: Retrospective review of 22 surgically excised CNV. 12 of these patients had been treated with PDT 3-146 days previously. Apoptotic cells were detected with the TUNEL technique and compared to the expression of CD34 (endothelial cells, EC), CD105 (activated endothelial cells), Ki-67 (proliferation marker), and cytokeratin18 (retinal pigment epithelial cells, RPE).
   Results: CNV excised 3 days after PDT were characterised both by collapsed and patent vessels. The EC displayed a statistical significant positive TUNEL reaction when compared to the remaining treated CNV (p < 0.001) and untreated CNV (P = 0.002). The proliferative activity was reduced. CNV excised 1 5 months after PDT displayed a patent vascularisation and high proliferative activity. All membranes either treated or untreated disclosed only sporadic TUNEL positive cells within the stroma and the RPE.
   Conclusions: Verteporfin PDT leads to selective and effective damage of EC within CNV. Both patent and occluded vessels were lined by apoptotic EC. This finding and the increased expression of proliferation marker at later time points suggest that revascularisation after PDT is caused by angiogenesis rather than recanalisation.
C1 Univ Tubingen, Div Vitreoretinal Surg, Dept Ophthalmol 1, D-72076 Tubingen, Germany.
   Univ Tubingen, Univ Eye Clin, Ctr Ophthalmol, Tubingen, Germany.
   Eye Clin Univ, Bremen, Germany.
   AZ STJan, Dept Ophthalmol, Brugge, Belgium.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital
RP Grisanti, S (通讯作者)，Univ Tubingen, Div Vitreoretinal Surg, Dept Ophthalmol 1, Schleichstr 12-16, D-72076 Tubingen, Germany.
EM grisanti@med.uni-tuebingen.de
RI Bopp, Silvia/AAF-2638-2020; , Ziemssen/B-9564-2009; Ziemssen,
   Focke/AAY-1686-2021
OI , Ziemssen/0000-0002-3873-0581; 
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arroyo JG, 2003, ARCH OPHTHALMOL-CHIC, V121, P898, DOI 10.1001/archopht.121.6.898
   Belzacq AS, 2001, CANCER RES, V61, P1260
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Schwartz LM, 2001, METHODS CELL BIOL, V66
   TATAR O, IN PRESS ARCH OPHTHA
   Wiezorrek R, 2000, OPHTHALMOLOGE, V97, P79, DOI 10.1007/s003470050016
NR 21
TC 15
Z9 16
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2006
VL 90
IS 8
BP 1034
EP 1039
DI 10.1136/bjo.2006.090852
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064TC
UT WOS:000239111000030
PM 16613924
OA Green Published
DA 2022-11-30
ER

PT J
AU Fusco, R
   Gallo, GP
   Di Bernardo, E
   D'Alessio, V
   Ronchetti, M
   Cadossi, M
   Cadossi, R
AF Fusco, Roberta
   Gallo, Giacomo Perazzolo
   Di Bernardo, Elio
   D'Alessio, Valeria
   Ronchetti, Mattia
   Cadossi, Matteo
   Cadossi, Ruggero
TI In Vivo and Ex Vivo Gene Electrotransfer in Ophthalmological Disorders
SO BIOMEDICINES
LA English
DT Review
DE gene electrotransfer; ophthalmological disorders; in vivo; ex-vivo
ID MACULAR DEGENERATION; LONG-TERM; ELECTROPORATION; DELIVERY; DNA; CELLS;
   EXPRESSION; THERAPY; PLASMID; MUSCLE
AB The aim of this document is to present an overview of gene electrotransfer in ophthalmological disorders. In order to ensure an adequate variety of the assessed studies, several electronic databases were considered and studies published between January 1998 and December 2021 were analysed. Three investigators carried out data extraction and analysis, focusing on both technical (i.e., electrical protocol, type of electrode, plasmid) and medical (i.e., type of study, threated disease) aspects and highlighting the main differences in terms of results obtained. Moreover, the IGEA experience in the project "Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration" (TargetAMD) was reported in the results section. No clinical trial was found on international literature and on ClinicalTrials.gov. Twelve preclinical studies were found including in vivo and ex-vivo applications. The studied showed that electrotransfer could be very efficient for plasmid DNA transfection. Many attempts such as modification of the electric field, buffers and electrodes have been made and the optimization of electric field setting seems to be very important. Using this technique, gene replacement can be designed in cases of retinal inheritance or corneal disease and a wide range of human eye diseases could, in the future, benefitfrom these gene therapy technologies.
C1 [Fusco, Roberta; Gallo, Giacomo Perazzolo; Di Bernardo, Elio; D'Alessio, Valeria; Cadossi, Matteo; Cadossi, Ruggero] IGEA SpA, Oncol Med & Res & Dev Div, I-41012 Carpi, Italy.
   [Ronchetti, Mattia] BVI, Regulatory Affairs, Optikon 2000, I-00138 Rome, Italy.
RP D'Alessio, V (通讯作者)，IGEA SpA, Oncol Med & Res & Dev Div, I-41012 Carpi, Italy.
EM v.dalessio@igeamedical.com
RI Fusco, Roberta/I-4062-2018
OI Fusco, Roberta/0000-0002-0469-9969; Di Bernardo,
   Elio/0000-0001-5850-1391
CR Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867
   Al-Dosari MS, 2009, AAPS J, V11, P671, DOI 10.1208/s12248-009-9143-y
   Amato A, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.750586
   Anand V, 2002, MOL THER, V5, P125, DOI 10.1006/mthe.2002.0525
   Athanasopoulos T, 2017, HEMATOL ONCOL CLIN N, V31, P753, DOI 10.1016/j.hoc.2017.06.007
   Blair-Parks K, 2002, J GENE MED, V4, P92, DOI 10.1002/jgm.231
   Bloquel C, 2006, FASEB J, V20, P389, DOI 10.1096/fj.05-4737fje
   Bulcha JT, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00487-6
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cervia LD, 2018, MOL PHARMACEUT, V15, P3617, DOI 10.1021/acs.molpharmaceut.8b00207
   Chalberg TW, 2005, INVEST OPHTH VIS SCI, V46, P2140, DOI 10.1167/iovs.04-1252
   Chatterjee P R, 2000, J Indian Med Assoc, V98, P746
   Conley SM, 2008, CURR OPIN MOL THER, V10, P456
   cordis, US
   Dezawa M, 2002, MICRON, V33, P1, DOI 10.1016/S0968-4328(01)00002-6
   Dhurandhar D, 2021, INDIAN J OPHTHALMOL, V69, P2257, DOI 10.4103/ijo.IJO_3117_20
   Dujardin Nathalie, 2004, V245, P215
   Duvall CL, 2014, PRINCIPLES OF TISSUE ENGINEERING, 4TH EDITION, P687, DOI 10.1016/B978-0-12-398358-9.00035-5
   FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   FRALEY R, 1980, J BIOL CHEM, V255, P431
   Gao X, 1996, BIOCHEMISTRY-US, V35, P1027, DOI 10.1021/bi952436a
   Grodeland G, 2015, EXPERT REV VACCINES, V14, P805, DOI 10.1586/14760584.2015.1029919
   He ZG, 2010, OPHTHALMIC RES, V43, P43, DOI 10.1159/000246577
   Heller R, 1996, FEBS LETT, V389, P225, DOI 10.1016/0014-5793(96)00590-X
   Henshaw JW, 2008, J PHARM SCI-US, V97, P691, DOI 10.1002/jps.21000
   Kachi S, 2005, GENE THER, V12, P843, DOI 10.1038/sj.gt.3302475
   Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026
   Katahira T, 2003, DEV GROWTH DIFFER, V45, P361, DOI 10.1046/j.1440-169X.2003.00705.x
   KLENCHIN VA, 1991, BIOPHYS J, V60, P804, DOI 10.1016/S0006-3495(91)82115-4
   Kowalczuk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017462
   Kropp M., 2017, HUM GENE THER, V28, pA126
   Mamiya K, 2004, EXP EYE RES, V79, P405, DOI 10.1016/j.exer.2004.06.017
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   McMahon JM, 2004, BIODRUGS, V18, P155, DOI 10.2165/00063030-200418030-00002
   McMahon JM, 2001, GENE THER, V8, P1264, DOI 10.1038/sj.gt.3301522
   Mir LM, 1998, CR ACAD SCI III-VIE, V321, P893, DOI 10.1016/S0764-4469(99)80003-1
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x
   Ogunremi O, 2013, CLIN VACCINE IMMUNOL, V20, P491, DOI 10.1128/CVI.00577-12
   Oshima Y, 1998, GRAEF ARCH CLIN EXP, V236, P52, DOI 10.1007/s004170050042
   Oshima Y, 2002, EXP EYE RES, V74, P191, DOI 10.1006/exer.2001.1117
   Oshima Y, 1999, OPHTHALMOLOGY, V106, P1140, DOI 10.1016/S0161-6420(99)90249-X
   Oshima Y, 1998, GENE THER, V5, P1347, DOI 10.1038/sj.gt.3300725
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Pichi F, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/634351
   Pietrzyk J J, 1998, Folia Med Cracov, V39, P131
   Rabussay D, 2003, J PHYS D APPL PHYS, V36, P348, DOI 10.1088/0022-3727/36/4/305
   Ramamoorth M, 2015, J CLIN DIAGN RES, V9, pGE1, DOI 10.7860/JCDR/2015/10443.5394
   Sakamoto T, 1999, HUM GENE THER, V10, P2551, DOI 10.1089/10430349950016889
   Stolba U, 2017, SPEKTRUM AUGENHEILKD, V31, P206, DOI 10.1007/s00717-017-0356-7
   Sullenger BA, 2016, SCIENCE, V352, P1417, DOI 10.1126/science.aad8709
   Suzuki T, 1998, FEBS LETT, V425, P436, DOI 10.1016/S0014-5793(98)00284-1
   Tang R, 2020, MOL CELL BIOCHEM, V474, P73, DOI 10.1007/s11010-020-03834-3
   targetamd, US
   TITOMIROV AV, 1991, BIOCHIM BIOPHYS ACTA, V1088, P131, DOI 10.1016/0167-4781(91)90162-F
   Touchard E, 2018, J CONTROL RELEASE, V285, P244, DOI 10.1016/j.jconrel.2018.07.013
   Touchard E, 2012, MOL THER, V20, P1559, DOI 10.1038/mt.2011.304
   Touchard E, 2010, J GENE MED, V12, P904, DOI 10.1002/jgm.1517
   Trigueros S, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040289
   Uthra Satagopan, 2009, Oman J Ophthalmol, V2, P108, DOI 10.4103/0974-620X.57308
   Willett K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00261
   Wirth T, 2013, GENE, V525, P162, DOI 10.1016/j.gene.2013.03.137
   Young JL, 2015, ADV GENET, V89, P49, DOI 10.1016/bs.adgen.2014.10.003
   Yu WZ, 2003, OPHTHALMIC RES, V35, P239, DOI 10.1159/000072143
   Zelenin A V, 1999, Genetika, V35, P1605
   Zhang L, 1996, BIOCHEM BIOPH RES CO, V220, P633, DOI 10.1006/bbrc.1996.0455
NR 67
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD AUG
PY 2022
VL 10
IS 8
AR 1889
DI 10.3390/biomedicines10081889
PG 16
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 4D4SD
UT WOS:000847131000001
PM 36009435
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Majidnia, E
   Ahmadian, M
   Salehi, H
   Amirpour, N
AF Majidnia, Elahe
   Ahmadian, Mehdi
   Salehi, Hossein
   Amirpour, Noushin
TI Development of an electrospun poly(epsilon-caprolactone)/collagen-based
   human amniotic membrane powder scaffold for culturing retinal pigment
   epithelial cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SURFACE-MORPHOLOGY; FABRICATION; ARPE-19; BIODEGRADATION; DIAMETER; PLGA
AB The common retinal diseases are age-related macular degeneration (AMD) and retinitis pigmentosa (RP). They are usually associated with the dysfunction of retinal pigment epithelial (RPE) cells and degeneration of underlying Bruch's membrane. The RPE cell transplantation is the most promising therapeutic option to restore lost vision. This study aimed to construct an ultrathin porous fibrous film with properties similar to that of native Bruch's membrane as carriers for the RPE cells. Human amniotic membrane powder (HAMP)/Polycaprolactone (PCL) scaffolds containing different concentrations of HAMP were fabricated by electrospinning technique. The results showed that with increasing the concentration of HAMP, the diameter of fibers increased. Moreover, hydrophilicity and degradation rate were improved from 119 degrees to 92 degrees and 14 to 56% after 28 days immersion in phosphate-buffered saline (PBS) solution, respectively. All scaffolds had a porosity above 85%. Proper cell adhesion was obtained one day after culture and no toxicity was observed. However, after seven days, the rate of growth and proliferation of ARPE-19 cells, a culture model of RPE, on the PCL-30HAMP scaffold (HAMP concentration in PCL 7.2% by weight) was higher compared to other scaffolds. These results indicated that PCL-30HAMP fibrous scaffold has a great potential to be used in retinal tissue engineering applications.
C1 [Majidnia, Elahe; Ahmadian, Mehdi] Isfahan Univ Technol, Dept Mat Engn, Esfahan 8415683111, Iran.
   [Salehi, Hossein; Amirpour, Noushin] Isfahan Univ Med Sci, Sch Med, Dept Anat Sci, Esfahan 8174673461, Iran.
C3 Isfahan University of Technology; Isfahan University Medical Science
RP Ahmadian, M (通讯作者)，Isfahan Univ Technol, Dept Mat Engn, Esfahan 8415683111, Iran.
EM ahmadian@cc.iut.ac.ir
FU Research Councils of Isfahan University of Technology; Isfahan
   University of Medical Sciences, Iran [398991]
FX This study was funded by a grant from the Research Councils of Isfahan
   University of Technology and Isfahan University of Medical Sciences,
   Iran, (Grant No. 398991).
CR Aguirre-Chagala YE, 2017, MAT SCI ENG C-MATER, V76, P897, DOI 10.1016/j.msec.2017.03.118
   Birhanu G, 2018, ARTIF CELL NANOMED B, V46, P1274, DOI 10.1080/21691401.2017.1367928
   BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Chen DA, 2019, INT J NANOMED, V14, P2127, DOI 10.2147/IJN.S192699
   Chen H, 2011, INT J NANOMED, V6, P2
   Choi DJ, 2015, J BIOTECHNOL, V205, P47, DOI 10.1016/j.jbiotec.2015.01.017
   Coates J, 2004, ENCY ANAL CHEM, V2, P1
   Daranarong D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/741408
   Dias J, 2013, PROC CIRP, V5, P216, DOI 10.1016/j.procir.2013.01.043
   Dippold D, 2017, MAT SCI ENG C-MATER, V72, P278, DOI 10.1016/j.msec.2016.11.045
   Dulnik J, 2016, POLYM DEGRAD STABIL, V130, P10, DOI 10.1016/j.polymdegradstab.2016.05.022
   Duman M, 2014, USAK U J MAT SCI, V3, P121
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ekram Basma, 2017, Advances in Natural Sciences: Nanoscience & Nanotechnology, V8, DOI 10.1088/2043-6254/aa92b4
   Fong H, 1999, POLYMER, V40, P4585, DOI 10.1016/S0032-3861(99)00068-3
   Gama RD, 2018, ADV POLYM TECH, V37, DOI 10.1002/adv.21706
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Ghobeira R, 2018, POLYMER, V157, P19, DOI 10.1016/j.polymer.2018.10.022
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Heimowska A, 2017, POL J CHEM TECHNOL, V19, P120, DOI 10.1515/pjct-2017-0017
   Hong Y., 2016, ADV POLYURETHANE BIO, P543, DOI DOI 10.1016/B978-0-08-100614-6.00019-6
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Huan SQ, 2015, MATERIALS, V8, P2718, DOI 10.3390/ma8052718
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Jankovic B, 2013, INT J PHARMACEUT, V455, P338, DOI 10.1016/j.ijpharm.2013.06.083
   Jeong YW, 2020, FRONT MATER, V7, DOI 10.3389/fmats.2020.504642
   Kim HH, 2016, FIBER POLYM, V17, P1033, DOI 10.1007/s12221-016-6350-x
   Klimek K, 2020, POLYMERS-BASEL, V12, DOI 10.3390/polym12040844
   Koddermann T, 2012, CHEMPHYSCHEM, V13, P1748, DOI 10.1002/cphc.201100838
   Kovalchuk N, 2010, COLLOID J+, V72, P647, DOI 10.1134/S1061933X10050108
   Lai JY, 2010, INT J MOL SCI, V11, P5257, DOI 10.3390/ijms11125256
   Leja K, 2010, POL J ENVIRON STUD, V19, P255
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Lynn SA, 2017, TISSUE CELL, V49, P447, DOI 10.1016/j.tice.2017.06.003
   Mastropietro JD., 2013, J DEV DRUGS, V2, P2
   Mehrasa M, 2015, INT J BIOL MACROMOL, V79, P687, DOI 10.1016/j.ijbiomac.2015.05.050
   Menz A, 2021, MOL MED, V27, DOI 10.1186/s10020-021-00274-7
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Mochane MJ, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9112205
   NIVENS DE, 1993, APPL SPECTROSC, V47, P668, DOI 10.1366/0003702934067171
   Peng SM, 2016, EXP EYE RES, V151, P179, DOI 10.1016/j.exer.2016.08.021
   Pillay V, 2013, J NANOMATER, V2013, DOI 10.1155/2013/789289
   Rahmani S, 2018, INT J POLYM MATER PO, V67, P27, DOI 10.1080/00914037.2017.1297939
   Ramuta TZ, 2018, CELL TRANSPLANT, V27, P77, DOI 10.1177/0963689717725528
   Reneker DH, 2008, POLYMER, V49, P2387, DOI 10.1016/j.polymer.2008.02.002
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Sadat A, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10175918
   Seyed Mohamed Ali, 2018, Open Access Maced J Med Sci, V6, P1561, DOI 10.3889/oamjms.2018.322
   Shahmoradi S, 2017, MAT SCI ENG C-MATER, V73, P300, DOI 10.1016/j.msec.2016.11.076
   Shang P, 2018, JOVE-J VIS EXP, DOI 10.3791/56997
   Sousa I, 2013, PROCEDIA ENGINEER, V59, P279, DOI 10.1016/j.proeng.2013.05.122
   Sripriya R, 2016, PROG BIOMATER, V5, P161, DOI 10.1007/s40204-016-0053-7
   Stern J, 2015, EXP BIOL MED, V240, P1079, DOI 10.1177/1535370215587530
   Sun XM, 2018, ARTIF CELL NANOMED B, V46, P1957, DOI 10.1080/21691401.2017.1397000
   Szewczyk PK, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11010034
   Taghiabadi E, 2015, CELL J, V16, P476
   Tan EYS, 2017, J MATER CHEM B, V5, P5616, DOI 10.1039/c7tb00376e
   Tian Y, 2017, ACS BIOMATER SCI ENG, V3, P890, DOI 10.1021/acsbiomaterials.6b00757
   Trese M, 2012, MATERIALS, V5, P108, DOI 10.3390/ma5010108
   Wanasekara N., 2011, C P SOC EXP MECH SER, V2, P157, DOI [10.1007/978-1-4419-8825-6_22, DOI 10.1007/978-1-4419-8825-6_22]
   Wang WG, 2016, MATERIALS, V9, DOI 10.3390/ma9120992
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Yan J, 2012, J BIOMED MATER RES A, V100A, P527, DOI 10.1002/jbm.a.33301
   Yener F., 2010, FIB SOC SPRING 2010
   Yohe ST, 2013, ADV FUNCT MATER, V23, P3628, DOI 10.1002/adfm.201203111
   Yuan H, 2017, WOODHEAD PUBL SER TE, V186, P125, DOI 10.1016/B978-0-08-100907-9.00006-4
   Zhang Q, 2015, INT J BIOL MACROMOL, V76, P94, DOI 10.1016/j.ijbiomac.2015.01.063
   Zhang QC, 2013, POLYM DEGRAD STABIL, V98, P209, DOI 10.1016/j.polymdegradstab.2012.10.008
NR 69
TC 0
Z9 0
U1 2
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 19
PY 2022
VL 12
IS 1
AR 6469
DI 10.1038/s41598-022-09957-5
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 0P0LU
UT WOS:000783915800029
PM 35440610
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sappa, LB
   Okuwobi, IP
   Li, MC
   Zhang, YH
   Xie, S
   Yuan, ST
   Chen, Q
AF Sappa, Loza Bekalo
   Okuwobi, Idowu Paul
   Li, Mingchao
   Zhang, Yuhan
   Xie, Sha
   Yuan, Songtao
   Chen, Qiang
TI RetFluidNet: Retinal Fluid Segmentation for SD-OCT Images Using
   Convolutional Neural Network
SO JOURNAL OF DIGITAL IMAGING
LA English
DT Article
DE Age-related macular degeneration (AMD); Intra-retinal fluid (IRF);
   Subretinal fluid (SRF); Pigment epithelial detachment (PED); Retinal
   edema; Spectral-domain optical coherence tomography (SD-OCT)
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR EDEMA; LAYER
AB Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness and is characterized by fluid-related accumulations such as intra-retinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED). Spectral-domain optical coherence tomography (SD-OCT) is the primary modality used to diagnose AMD, yet it does not have algorithms that directly detect and quantify the fluid. This work presents an improved convolutional neural network (CNN)-based architecture called RetFluidNet to segment three types of fluid abnormalities from SD-OCT images. The model assimilates different skip-connect operations and atrous spatial pyramid pooling (ASPP) to integrate multi-scale contextual information; thus, achieving the best performance. This work also investigates between consequential and comparatively inconsequential hyperparameters and skip-connect techniques for fluid segmentation from the SD-OCT image to indicate the starting choice for future related researches. RetFluidNet was trained and tested on SD-OCT images from 124 patients and achieved an accuracy of 80.05%, 92.74%, and 95.53% for IRF, PED, and SRF, respectively. RetFluidNet showed significant improvement over competitive works to be clinically applicable in reasonable accuracy and time efficiency. RetFluidNet is a fully automated method that can support early detection and follow-up of AMD.
C1 [Sappa, Loza Bekalo; Okuwobi, Idowu Paul; Li, Mingchao; Zhang, Yuhan; Xie, Sha; Chen, Qiang] Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, 200 Xiaolingwei, Nanjing 210094, Peoples R China.
   [Yuan, Songtao] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
C3 Nanjing University of Science & Technology; Nanjing Medical University
RP Chen, Q (通讯作者)，Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, 200 Xiaolingwei, Nanjing 210094, Peoples R China.
EM chen2qiang@njust.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964; Chen, Qiang/0000-0002-6685-2447
FU National Natural Science Foundation of China [61671242, 61701222]; Key
   R&D Program of Jiangsu Provincial Department of Science and Technology
   [BE2018131]
FX This work was supported by the National Natural Science Foundation of
   China (61671242, 61701222) and Key R&D Program of Jiangsu Provincial
   Department of Science and Technology (BE2018131).
CR Abadi M., ARXIV160304467
   Abouammoh MA, 2015, SAUDI J OPHTHALMOL, V29, P278, DOI 10.1016/j.sjopt.2015.01.007
   [Anonymous], 2017, ANTIVASCULAR ENDOTHE
   Apostolopoulos S, SIMULTANEOUS CLASSIF
   Arunkumar R, 2017, NEURAL COMPUT APPL, V28, P329, DOI 10.1007/s00521-015-2059-9
   Bai F., 2017, ARXIV PREPRINT ARXIV
   Bekalo L, 2019, IEEE ACCESS, V7, P14894, DOI 10.1109/ACCESS.2019.2893954
   Bengio Yoshua, 2012, Neural Networks: Tricks of the Trade. Second Edition: LNCS 7700, P437, DOI 10.1007/978-3-642-35289-8_26
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chen LC, 2017, ARXIV PREPRINT ARXIV
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Dolejsi M, 2010, BIOSIGNAL
   Falkner S., 2018, ARXIV PREPRINT ARXIV
   Fang J, 2019, LECT NOTES COMPUT SC, V11855, P130, DOI 10.1007/978-3-030-32956-3_16
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Girish GN, 2019, IEEE J BIOMED HEALTH, V23, P296, DOI 10.1109/JBHI.2018.2810379
   Gopinath K, 2019, IEEE J BIOMED HEALTH, V23, P273, DOI 10.1109/JBHI.2018.2793534
   He X., 2017, ENG IEEE T BIOMED
   Huang GL, 2017, IEEE ICC
   Jeon, 2017, MICCAI RETINAL OCT F
   Khan KB, 2019, PATTERN ANAL APPL, V22, P767, DOI 10.1007/s10044-018-0754-8
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lu D., 2017, ARXIV PREPRINT ARXIV
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   Morgan JIW, 2016, OPHTHAL PHYSL OPT, V36, P218, DOI 10.1111/opo.12289
   Morley D., 2017, ARXIV PREPRINT ARXIV
   Novosel J., 2016, BIOM IM ISBI 2016 IE
   Pavuluri VK, 2015, IEEE VEHICLE POWER
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rashno A., 2017, P MICCAI RET OCT FLU, P54
   Rashno Abdolreza, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P3426, DOI 10.1109/EMBC.2018.8512998
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2161, DOI 10.1097/IAE.0000000000000881
   Sun Z., 2016, SCI REP-UK, V6
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yang MK, 2018, PROC CVPR IEEE, P3684, DOI 10.1109/CVPR.2018.00388
   Zhang L, 2014, INVEST OPHTH VIS SCI, V55, P2329, DOI 10.1167/iovs.13-13048
   Zhao Y., 2019, 10 INT C ICIG 2019 B
   Zhou ZW, 2018, LECT NOTES COMPUT SC, V11045, P3, DOI 10.1007/978-3-030-00889-5_1
NR 45
TC 6
Z9 6
U1 5
U2 27
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0897-1889
EI 1618-727X
J9 J DIGIT IMAGING
JI J. Digit. Imaging
PD JUN
PY 2021
VL 34
IS 3
BP 691
EP 704
DI 10.1007/s10278-021-00459-w
EA JUN 2021
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA TT8GR
UT WOS:000657235800002
PM 34080105
OA Green Published
DA 2022-11-30
ER

PT J
AU Rasoulinejad, SA
   Maroufi, F
AF Rasoulinejad, Seyed Ahmad
   Maroufi, Faezeh
TI CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal
   Diseases
SO MOLECULAR BIOTECHNOLOGY
LA English
DT Review
DE CRISPR-Cas9; Genome editing; Retinal diseases; Gene knock-out
ID GENE-THERAPY; EPIGENETIC MODIFICATION; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; RETINITIS-PIGMENTOSA; ON-TARGET; RNA; NUCLEASE;
   MUTATION; CAS9
AB Retinal diseases are the primary reasons for severe visual defects and irreversible blindness. Retinal diseases are also inherited and acquired. Both of them are caused by mutations in genes or disruptions in specific gene expression, which can be treated by gene-editing therapy. Clustered regularly interspaced short palindromic repeats (CRISPR-Cas9) system is a frontier of gene-editing tools with great potential for therapeutic applications in the ophthalmology field to modify abnormal genes and treat the genome or epigenome-related retinal diseases. The CRISPR system is able to edit and trim the gene include deletion, insertion, inhibition, activation, replacing, remodeling, epigenetic alteration, and modify the gene expression. CRISPR-based genome editing techniques have indicated the enormous potential to treat retinal diseases that previous treatment was not available for them. Also, recent CRISPR genome surgery experiments have shown the improvement of patient's vision who suffered from severe visual loss. In this article, we review the applications of the CRISPR-Cas9 system in human or animal models for treating retinal diseases such as retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), and proliferative vitreoretinopathy (PVR), then we survey limitations of CRISPR system for clinical therapy.
C1 [Rasoulinejad, Seyed Ahmad] Babol Univ Med Sci, Ayatollah Rouhani Hosp, Dept Ophthalmol, Babol, Iran.
   [Maroufi, Faezeh] Qazvin Univ Med Sci, Fac Allied Med, Dept Med Lab Sci, Qazvin, Iran.
C3 Babol University of Medical Sciences; Qazvin University of Medical
   Sciences (QUMS)
RP Rasoulinejad, SA (通讯作者)，Babol Univ Med Sci, Ayatollah Rouhani Hosp, Dept Ophthalmol, Babol, Iran.
EM rasolisa2@gmail.com
OI Maali, Amirhosein/0000-0002-0699-3010; Maroufi,
   Faezeh/0000-0003-1368-8636
CR Arbabi A, 2019, J OCUL PHARMACOL TH, V35, P79, DOI 10.1089/jop.2018.0087
   Arno G, 2016, AM J HUM GENET, V99, P1305, DOI 10.1016/j.ajhg.2016.10.008
   Aumann S., 2019, IMAGING MICROSCOPY O
   Bakondi B, 2016, MOL THER, V24, P556, DOI 10.1038/mt.2015.220
   Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140
   Bibikova M, 2001, MOL CELL BIOL, V21, P289, DOI 10.1128/MCB.21.1.289-297.2001
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Cabral T, 2017, CURR OPIN OPHTHALMOL, V28, P252, DOI 10.1097/ICU.0000000000000359
   Caplan AL, 2015, EMBO REP, V16, P1421, DOI 10.15252/embr.201541337
   Chan S, 2013, CURR OPIN PEDIATR, V25, P645, DOI 10.1097/MOP.0000000000000026
   Chew WL, 2016, NAT METHODS, V13, P868, DOI 10.1038/nmeth.3993
   Chiu W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094534
   Cho Galaxy Y, 2017, Curr Ophthalmol Rep, V5, P199, DOI 10.1007/s40135-017-0144-1
   Chung SH, 2020, MOL THER-METH CLIN D, V17, P409, DOI 10.1016/j.omtm.2020.01.006
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cox DBT, 2015, NAT MED, V21, P121, DOI 10.1038/nm.3793
   Dehghanifard A, 2018, CL LYMPH MYELOM LEUK, V18, P311, DOI 10.1016/j.clml.2018.03.007
   Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096
   Dow LE, 2015, NAT BIOTECHNOL, V33, P390, DOI 10.1038/nbt.3155
   Dulla K, 2018, MOL THER-NUCL ACIDS, V12, P730, DOI 10.1016/j.omtn.2018.07.010
   Fischer MD, 2020, RETINA-J RET VIT DIS, V40, P160, DOI 10.1097/IAE.0000000000002360
   Fu YW, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1251
   Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808
   Gasiunas G, 2012, P NATL ACAD SCI USA, V109, pE2579, DOI 10.1073/pnas.1208507109
   Giannelli SG, 2018, HUM MOL GENET, V27, P761, DOI 10.1093/hmg/ddx438
   Gilles AF, 2014, EVODEVO, V5, DOI 10.1186/2041-9139-5-43
   Guilinger JP, 2014, NAT BIOTECHNOL, V32, P577, DOI 10.1038/nbt.2909
   Gupta A, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108482
   Gupta RM, 2014, J CLIN INVEST, V124, P4154, DOI 10.1172/JCI72992
   Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015
   Hess GT, 2016, NAT METHODS, V13, P1036, DOI [10.1038/NMETH.4038, 10.1038/nmeth.4038]
   Huang XG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00140-3
   Huang XG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20537
   Hung SSC, 2016, PROG RETIN EYE RES, V53, P1, DOI 10.1016/j.preteyeres.2016.05.001
   Iyama T, 2013, DNA REPAIR, V12, P620, DOI 10.1016/j.dnarep.2013.04.015
   Jamal M, 2016, CURR ISSUES MOL BIOL, V20, P1
   Kantor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176240
   Kiang AS, 2005, MOL THER, V12, P555, DOI 10.1016/j.ymthe.2005.03.028
   Kim E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14500
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526
   Komor AC, 2017, CELL, V169, P559, DOI 10.1016/j.cell.2017.04.005
   Komor AC, 2017, CELL, V168, P20, DOI 10.1016/j.cell.2016.10.044
   Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136
   Kotterman MA, 2014, NAT REV GENET, V15, P445, DOI 10.1038/nrg3742
   Kouchaki R, 2020, CELL J, V22, P1, DOI 10.22074/cellj.2020.6849
   Latella MC, 2016, MOL THER-NUCL ACIDS, V5, P1, DOI 10.1038/mtna.2016.92
   Le Meur G, 2018, MOL THER, V26, P256, DOI 10.1016/j.ymthe.2017.09.014
   Ledford H, 2020, NATURE, V579, P185, DOI 10.1038/d41586-020-00655-8
   Lee CM, 2016, MOL THER, V24, P645, DOI 10.1038/mt.2016.8
   Lee CM, 2016, MOL THER, V24, P475, DOI 10.1038/mt.2016.1
   Li HY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-019-0089-y
   Li PJ, 2018, CRISPR J, V1, P55, DOI 10.1089/crispr.2017.0009
   Li SJ, 2021, GENE THER, V28, P223, DOI 10.1038/s41434-020-0134-z
   Lin MW, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gky447
   Liu B, 2019, LAB INVEST, V99, P1874, DOI 10.1038/s41374-019-0307-9
   Liu C, 2017, J CONTROL RELEASE, V266, P17, DOI 10.1016/j.jconrel.2017.09.012
   Liu Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11479-0
   Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353
   Long CZ, 2016, SCIENCE, V351, P400, DOI 10.1126/science.aad5725
   Lv JN, 2017, SCI REP-UK, V7, DOI 10.1038/srep43062
   Maali A, 2018, CURR STEM CELL RES T, V13, P665, DOI 10.2174/1574888X13666180731155038
   Maeder ML, 2019, NAT MED, V25, P229, DOI 10.1038/s41591-018-0327-9
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Makarova KS, 2011, NAT REV MICROBIOL, V9, P467, DOI 10.1038/nrmicro2577
   Maroufi F, 2020, EPIGENOMICS-UK, V12, P1845, DOI 10.2217/epi-2020-0110
   Maruyama T, 2015, NAT BIOTECHNOL, V33, P538, DOI 10.1038/nbt.3190
   Maurya S, 2020, EYE, V34, P1313, DOI 10.1038/s41433-020-0838-8
   Mishra M, 2015, INVEST OPHTH VIS SCI, V56, P5133, DOI 10.1167/iovs.15-16937
   Miyaoka Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23549
   Moradi Z, 2020, INDIAN J HEMATOL BLO, V36, P26, DOI 10.1007/s12288-019-01170-1
   Moreno AM, 2020, MOL THER, V28, P1931, DOI 10.1016/j.ymthe.2020.06.027
   Nelles DA, 2016, CELL, V165, P488, DOI 10.1016/j.cell.2016.02.054
   Palfi A, 2006, HUM MUTAT, V27, P260, DOI 10.1002/humu.20287
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   Petrs-Silva H, 2012, ADV EXP MED BIOL, V723, P215, DOI 10.1007/978-1-4614-0631-0_29
   Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014
   Priglinger CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146887
   Quinn J, 2021, HUM GENE THER, V32, P247, DOI 10.1089/hum.2020.231
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P141
   Rasoulinejad SA, 2015, OPEN OPHTHALMOL J, V9, P149, DOI 10.2174/1874364101509010149
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P224
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P77
   Roy B, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00240
   Ruan GX, 2017, MOL THER, V25, P331, DOI 10.1016/j.ymthe.2016.12.006
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Sancho-Pelluz J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.4
   Schaefer KA, 2017, NAT METHODS, V14, P547, DOI 10.1038/nmeth.4293
   Schnichels S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100880
   Sengillo JD, 2016, AM J MED GENET C, V172, P349, DOI 10.1002/ajmg.c.31534
   Shin J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701620
   Slaymaker IM, 2016, SCIENCE, V351, P84, DOI 10.1126/science.aad5227
   Smith J, 2015, EYE, V29, P1131, DOI 10.1038/eye.2015.115
   Standage-Beier K, 2015, ACS SYNTH BIOL, V4, P1217, DOI 10.1021/acssynbio.5b00132
   Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565
   Takahashi VKL, 2018, OPHTHALMIC GENET, V39, P560, DOI 10.1080/13816810.2018.1495745
   Tan SZ, 2018, J BACTERIOL, V200, DOI [10.1128/JB.00575-17, 10.1128/jb.00575-17]
   Tan W, 2012, ADV GENET, V80, P37, DOI 10.1016/B978-0-12-404742-6.00002-8
   Thakore PI, 2016, NAT METHODS, V13, P127, DOI [10.1038/NMETH.3733, 10.1038/nmeth.3733]
   Tsai SQ, 2016, NAT REV GENET, V17, P300, DOI 10.1038/nrg.2016.28
   Tsubura A, 2010, HISTOL HISTOPATHOL, V25, P933, DOI 10.14670/HH-25.933
   Wu SS, 2020, THERANOSTICS, V10, P4374, DOI 10.7150/thno.43360
   Wu WH, 2016, MOL THER, V24, P1388, DOI 10.1038/mt.2016.107
   Wu WY, 2017, INVEST OPHTH VIS SCI, V58, P6082, DOI 10.1167/iovs.17-21902
   Xu CL, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00046
   Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589
   Yang H., 2020, INT J MOL SCI, V21, P485
   Yang TT, 2015, MOL THER, V23, P1805, DOI 10.1038/mt.2015.177
   Yin H, 2016, NAT BIOTECHNOL, V34, P328, DOI 10.1038/nbt.3471
   Yin H, 2014, NAT BIOTECHNOL, V32, P551, DOI 10.1038/nbt.2884
   Yiu G, 2016, INVEST OPHTH VIS SCI, V57, P5490, DOI 10.1167/iovs.16-20296
   Yu WH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14716
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
   Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038
   Zhong H, 2015, SCI REP-UK, V5, DOI 10.1038/srep08366
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P244, DOI 10.1167/iovs.12-10854
   Ziccardi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225722
   Zischewski J, 2017, BIOTECHNOL ADV, V35, P95, DOI 10.1016/j.biotechadv.2016.12.003
NR 119
TC 2
Z9 2
U1 0
U2 17
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1073-6085
EI 1559-0305
J9 MOL BIOTECHNOL
JI Mol. Biotechnol.
PD SEP
PY 2021
VL 63
IS 9
BP 768
EP 779
DI 10.1007/s12033-021-00345-4
EA MAY 2021
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA TQ1XF
UT WOS:000656371800001
PM 34057656
DA 2022-11-30
ER

PT J
AU Supe, S
   Upadhya, A
   Singh, K
AF Supe, Shibani
   Upadhya, Archana
   Singh, Kavita
TI Role of small interfering RNA (siRNA) in targeting ocular
   neovascularization: A review
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Ocular neovascularization (NV); Vascular endothelial growth factor
   (VEGF); Small interfering RNA (siRNA); Cationic polymer; Ocular cular
   siRNA delivery; Liposomes; Polyplexes Lipoplexes siRNA formulations,
   Diabetic retinopathy, Age-related macular degeneration, Patents on siRNA
   against ocular NV, Clinical trials
ID ENDOTHELIAL GROWTH-FACTOR; ACID-CHITOSAN NANOPARTICLES; MACULAR
   DEGENERATION; ANTI-VEGF; DRUG-DELIVERY; RETINAL NEOVASCULARIZATION;
   CORNEAL NEOVASCULARIZATION; POLYMERIC NANOPARTICLES; INTRAVITREAL
   INJECTION; DIABETIC-RETINOPATHY
AB Ocular neovascularization (NV) plays a central role in the pathogenesis of various ocular diseases including diabetic retinopathy, age-related macular degeneration, retinoblastoma, retinitis pigmentosa and may lead to loss of vision if not controlled in time. Several clinical trials elucidate the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of the ocular neovascularization. The advent and extensive use of ocular anti-VEGF therapy heralded a new age in the treatment of retinal vascular and exudative diseases. RNA interference (RNAi) can be used to inhibit the in-vitro and in-vivo expression of specific genes and thus provides an extremely useful method for investigating gene activity with minimal toxicity. siRNA targeting VEGF overcomes many drawbacks associated with the conventional treatment available for the treatment of ocular neovascularization. However, delivery methods that protect the siRNA against degradation and are appropriate for long-term care will help increase the effectiveness of RNAi-based anti-VEGF ocular therapies. Several nano technology approaches have been explored by formulation scientists for delivery of siRNA to the eye; targeting particularly VEGF for the treatment of NV. This review mainly focuses on current updates in various pre-clinical and clinical siRNA strategies for targeting VEGF involved in the development of ocular neovascularization.
C1 [Supe, Shibani; Upadhya, Archana; Singh, Kavita] SVKMS NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Mumbai 400056, Maharashtra, India.
C3 SVKM's NMIMS (Deemed to be University)
RP Singh, K (通讯作者)，SVKMS NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Mumbai 400056, Maharashtra, India.
EM kavita.singh@nmims.edu
RI Upadhya, Dr. Archana/HGA-4981-2022
OI Upadhya, Dr. Archana/0000-0002-6331-5179
FU Science and Engineering Research Board, Department of Science and
   Technology, Government of India [SERB/F/9850/2017-2018]
FX We would like to acknowledge Science and Engineering Research Board,
   Department of Science and Technology, Government of India for providing
   research fund (SERB/F/9850/2017-2018).
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al-Kharashi AS, 2018, SAUDI J OPHTHALMOL, V32, P318, DOI 10.1016/j.sjopt.2018.05.002
   Al-Shabrawey M, 2013, EXPERT REV OPHTHALMO, V8, P267, DOI 10.1586/EOP.13.17
   Amadio M, 2016, PHARMACOL RES, V111, P713, DOI 10.1016/j.phrs.2016.07.042
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Audouy S, 2001, MOL MEMBR BIOL, V18, P129, DOI 10.1080/713816122
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brey E.M., 2008, PRINCIPLES REGENERAT, P1020, DOI [10.1016/B978-012369410-2.50061-9, DOI 10.1016/B978-012369410-2.50061-9]
   Burnett JC, 2011, BIOTECHNOL J, V6, P1130, DOI 10.1002/biot.201100054
   Campbell RB, 2009, J PHARM SCI-US, V98, P411, DOI 10.1002/jps.21458
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cavallaro G, 2017, INT J PHARMACEUT, V525, P313, DOI 10.1016/j.ijpharm.2017.04.008
   Chaharband F, 2020, NANOMED-NANOTECHNOL, V26, DOI 10.1016/j.nano.2020.102181
   Chen CW, 2013, INT J NANOMED, V8, P2613, DOI 10.2147/IJN.S39622
   Chen CW, 2011, INT J NANOMED, V6, P2567, DOI 10.2147/IJN.S24447
   CONNERS MS, 1995, INVEST OPHTH VIS SCI, V36, P841
   De Fougerolles AR, 2008, HUM GENE THER, V19, P125, DOI 10.1089/hum.2008.928
   de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07-1077
   Dejneka NS, 2008, MOL VIS, V14, P997
   Deng XW, 2014, BIOMATERIALS, V35, P4333, DOI 10.1016/j.biomaterials.2014.02.006
   Ding XF, 2017, ACS APPL MATER INTER, V9, P23353, DOI 10.1021/acsami.7b04971
   Dreyfuss JL, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/892043
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fakhr E, 2016, CANCER GENE THER, V23, P73, DOI 10.1038/cgt.2016.4
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fu YC, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20180552
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Godbey WT, 1999, J CONTROL RELEASE, V60, P149, DOI 10.1016/S0168-3659(99)00090-5
   Golan S., 2013, AGE RELATED MACULAR, DOI [10.5772/54198, DOI 10.5772/54198]
   Guzman-Aranguez A, 2013, BRIT J PHARMACOL, V170, P730, DOI 10.1111/bph.12330
   Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780
   Han D, 2014, CHEM COMMUN, V50, P11665, DOI 10.1039/c4cc04969a
   Han H, 2016, MACROMOL BIOSCI, V16, P1583, DOI 10.1002/mabi.201600051
   Hennig R, 2015, EUR J PHARM BIOPHARM, V95, P294, DOI 10.1016/j.ejpb.2015.02.027
   Hirschi KK, 2001, DIFFERENTIATION, V68, P186, DOI 10.1046/j.1432-0436.2001.680406.x
   Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163
   Huang XN, 2019, DRUG DISCOV TODAY, V24, P1510, DOI 10.1016/j.drudis.2019.05.005
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jiang J, 2009, J CELL PHYSIOL, V218, P66, DOI 10.1002/jcp.21566
   Jiang JJ, 2021, FUND CLIN PHARMACOL, V35, P4, DOI 10.1111/fcp.12561
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   Lares MR, 2010, TRENDS BIOTECHNOL, V28, P570, DOI 10.1016/j.tibtech.2010.07.009
   Lee DU, 2012, J OCUL PHARMACOL TH, V28, P222, DOI 10.1089/jop.2011.0116
   Lee J, 2016, MOL PHARMACEUT, V13, P1988, DOI 10.1021/acs.molpharmaceut.6b00148
   Li SD, 2006, GENE THER, V13, P1313, DOI 10.1038/sj.gt.3302838
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Liu SY, 2018, SURV OPHTHALMOL, V63, P193, DOI 10.1016/j.survophthal.2017.10.006
   Liu XX, 2016, METHODS MOL BIOL, V1364, P127, DOI 10.1007/978-1-4939-3112-5_11
   Mao SR, 2010, ADV DRUG DELIVER REV, V62, P12, DOI 10.1016/j.addr.2009.08.004
   Martens TF, 2015, J CONTROL RELEASE, V202, P83, DOI 10.1016/j.jconrel.2015.01.030
   Mastyugin V, 2001, CURR EYE RES, V23, P1, DOI 10.1076/ceyr.23.1.1.5422
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mishima K, 2007, MOL BIOL CELL, V18, P1421, DOI 10.1091/mbc.E06-09-0780
   Mok H, 2010, NAT MATER, V9, P272, DOI [10.1038/NMAT2626, 10.1038/nmat2626]
   Montier T, 2008, CURR GENE THER, V8, P296, DOI 10.2174/156652308786070989
   Murata M, 2006, CURR EYE RES, V31, P171, DOI 10.1080/02713680500514636
   Nagy JA, 2009, BRIT J CANCER, V100, P865, DOI 10.1038/sj.bjc.6604929
   Naik R, 2009, DRUG DISCOV TODAY, V14, P306, DOI 10.1016/j.drudis.2008.09.012
   Neely KA, 1998, AM J PATHOL, V153, P665, DOI 10.1016/S0002-9440(10)65607-6
   Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106
   Nicolazzi C, 2003, CURR MED CHEM, V10, P1263, DOI 10.2174/0929867033457467
   Osipova O, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12010039
   Park PJ, 2013, EXP EYE RES, V110, P1, DOI 10.1016/j.exer.2013.01.015
   Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966
   Peeters L, 2007, BIOCHEM SOC T, V35, P47, DOI 10.1042/BST0350047
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470
   Pilipenko I, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070317
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Popescu V, 2015, J Med Life, V8, P8
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Raja MAG, 2019, ASIAN J PHARM SCI, V14, P497, DOI 10.1016/j.ajps.2018.12.005
   Rao NM, 2010, CHEM PHYS LIPIDS, V163, P245, DOI 10.1016/j.chemphyslip.2010.01.001
   Reich S, 2003, MOL VIS, V9, P210
   Reischl D, 2009, NANOMED-NANOTECHNOL, V5, P8, DOI 10.1016/j.nano.2008.06.001
   Rho CR, 2015, INVEST OPHTH VIS SCI, V56, P5871, DOI 10.1167/iovs.14-14433
   Rittenhouse KD, 2014, INVEST OPHTH VIS SCI, V55, P1232, DOI 10.1167/iovs.13-13449
   Rivest V, 2007, PHARM RES-DORDR, V24, P981, DOI 10.1007/s11095-006-9224-x
   Roberts T.C., 2016, METHOD MOL BIOL, DOI [10.1007/978-1-4939-3112-5, DOI 10.1007/978-1-4939-3112-5]
   Ryoo NK, 2017, NANOSCALE, V9, P15461, DOI 10.1039/c7nr03142d
   Sarett SM, 2015, J CONTROL RELEASE, V218, P94, DOI 10.1016/j.jconrel.2015.09.066
   Seta F, 2007, PROSTAG OTH LIPID M, V84, P116, DOI 10.1016/j.prostaglandins.2007.05.001
   Shajari N, 2017, CURR DRUG DELIV, V14, P36, DOI 10.2174/1567201813666160816105408
   Shegokar R, 2011, PHARMAZIE, V66, P313, DOI 10.1691/ph.2011.0301
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shinde UA, 2014, PHARM DEV TECHNOL, V19, P813, DOI 10.3109/10837450.2013.836217
   Shukla Dhananjay, 2007, Indian Journal of Ophthalmology, V55, P427
   Singh NK, 2015, EBIOMEDICINE, V2, P1767, DOI 10.1016/j.ebiom.2015.09.042
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Stewart MW, 2012, CURR DIABETES REV, V8, P237, DOI 10.2174/157339912800840488
   Tatiparti K, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7040077
   Tekie FSM, 2015, INT J BIOL MACROMOL, V81, P828, DOI 10.1016/j.ijbiomac.2015.09.014
   Thakur A, 2012, J BIOL ENG, V6, DOI 10.1186/1754-1611-6-7
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Toth LA, 2015, RETINA-J RET VIT DIS, V35, P1957, DOI 10.1097/IAE.0000000000000583
   Triantafylla M, 2014, CLIN OPHTHALMOL, V8, P1187, DOI 10.2147/OPTH.S40350
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Wang YH, 2015, J FUNCT BIOMATER, V6, P379, DOI 10.3390/jfb6020379
   Westerhout EM, 2007, NUCLEIC ACIDS RES, V35, P4322, DOI 10.1093/nar/gkm437
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   WHO, 2019, BLIND VIS IMP PREV
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2016, CURR DRUG DELIV, V13, P590, DOI 10.2174/1567201812666150817123049
   Xu QG, 2013, J CONTROL RELEASE, V167, P76, DOI 10.1016/j.jconrel.2013.01.018
   Xue HY, 2015, CURR PHARM DESIGN, V21, P3140, DOI 10.2174/1381612821666150531164540
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zakeri A, 2018, NANO REV EXP, V9, DOI 10.1080/20022727.2018.1488497
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zuo L, 2010, CURR EYE RES, V35, P375, DOI 10.3109/02713681003597230
NR 127
TC 5
Z9 6
U1 3
U2 33
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2021
VL 202
AR 108329
DI 10.1016/j.exer.2020.108329
EA JAN 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PS8PA
UT WOS:000608184800004
PM 33198953
DA 2022-11-30
ER

PT J
AU Jo, DH
   Cho, CS
   Kim, JH
   Kim, JH
AF Jo, Dong Hyun
   Cho, Chang Sik
   Kim, Jin Hyoung
   Kim, Jeong Hun
TI Intracellular amyloid-beta disrupts tight junctions of the retinal
   pigment epithelium via NF-kappa B activation
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Age-related macular degeneration; Amyloid-beta; Retinal pigment
   epithelium; Tight junction; Zonula occludens-1; NF-kappa B
ID MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; BARRIER; SNAIL; DYSFUNCTION;
   INHIBITION; MECHANISMS; EXPRESSION; ANTIBODY; RECEPTOR
AB Drusen are focal deposits between the retinal pigment epithelium (RPE) and Bruch's membrane in the retina of patients with age-related macular degeneration. Amyloid-beta is one of the important components of drusen, which leads to local inflammation. Furthermore, intracellular amyloid-beta disrupts tight junctions of the RPE. However, the intracellular mechanisms linking intracellular amyloid-beta and tightjunction disruption are not clear. In this study, intracellular amyloid-beta oligomers activated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) p65, leading to the disorganization of tight junctions of the RPE in mice after subretinal injection of amyloid-beta. Amyloid-beta also triggered NF-kappa B activation in the RPE cells in confluent culture, which was inhibited by the suppression of the advanced glycosylation end product-specific receptor. NF-kappa B inhibition by an la kinase inhibitor prevented the suppression of expression of tight-junction proteins, zonula occuludens-1 and occludin in RPE cells. In addition, tight-junction complexes remained intact in the RPE of mice with NF-kappa B inhibition, although there were intracellular amyloid-beta oligomers. These data suggested that NF-kappa B inhibition might be a therapeutic approach to prevent amyloid-beta-mediated tight-junction disruption. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Jo, Dong Hyun] Seoul Natl Univ, Dept Anat & Cell Biol, Coll Med, Seoul, South Korea.
   [Cho, Chang Sik; Kim, Jeong Hun] Seoul Natl Univ Hosp, Biomed Res Inst, Fight Angiogenesis Related Blindness FARB Lab, Seoul, South Korea.
   [Kim, Jin Hyoung] Youth Bio Global Ltd, Seoul, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University (SNU)
RP Kim, JH (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Fight Angiogenesis Related Blindness FARB Lab, Biomed Res Inst,Seoul Natl Univ Hosp,Coll Med, Seoul 03080, South Korea.
EM steph25@snu.ac.kr
RI Jo, Dong Hyun/D-5962-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; Kim, Jeong Hun/0000-0003-2957-1766
FU Seoul National University Hospital [03-2018-0100]; National Research
   Foundation of Korea (NRF) [2015M3A9E6028949, 2018M3D1A1058826,
   2017R1A6A3A04004741]; Korea Research Institute of Standards and Science
   [KRISS - 2020 - GP2020-0004]
FX This work was supported by Seoul National University Hospital Research
   Grant (03-2018-0100 to JeHK), National Research Foundation of Korea
   (NRF) Grants (2015M3A9E6028949, 2018M3D1A1058826 to JeHK;
   2017R1A6A3A04004741 to DHJ) Korea Research Institute of Standards and
   Science (KRISS - 2020 - GP2020-0004 to JeHK).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Cao LN, 2013, INT J MOL MED, V31, P1105, DOI 10.3892/ijmm.2013.1310
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Chen C, 2017, MOL MED REP, V15, P2289, DOI 10.3892/mmr.2017.6252
   Cheng W. S., 2017, YIXUE YANJIU, V37, P121
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dong ZZ, 2018, INT J OPHTHALMOL-CHI, V11, P747, DOI 10.18240/ijo.2018.05.06
   Garcia-Ramirez M, 2016, ACTA DIABETOL, V53, P109, DOI 10.1007/s00592-015-0759-3
   Guglielmotto M, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.05.026
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hong HS, 2009, J NEUROCHEM, V108, P1097, DOI 10.1111/j.1471-4159.2008.05866.x
   Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919
   Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jo DH, 2019, GLIA, V67, P321, DOI 10.1002/glia.23542
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836
   Lee JJ, 2015, INT J BIOCHEM CELL B, V64, P1, DOI 10.1016/j.biocel.2015.03.002
   Li H, 2014, BIOCHEM BIOPH RES CO, V446, P347, DOI 10.1016/j.bbrc.2014.02.119
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Moon M, 2011, J ALZHEIMERS DIS, V23, P147, DOI 10.3233/JAD-2010-101263
   Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Omri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081600
   Panza F, 2019, NAT REV NEUROL, V15, P73, DOI 10.1038/s41582-018-0116-6
   Park R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.258
   Park SY, 2017, ONCOTARGET, V8, P110380, DOI 10.18632/oncotarget.22777
   Park SW, 2015, ONCOTARGET, V6, P35263, DOI 10.18632/oncotarget.5894
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1
   Sun JR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.502
   Tobon-Velasco JC, 2014, CNS NEUROL DISORD-DR, V13, P1615, DOI 10.2174/1871527313666140806144831
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zong HL, 2010, J BIOL CHEM, V285, P23135, DOI 10.1074/jbc.M110.133827
NR 50
TC 4
Z9 7
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD NOV
PY 2020
VL 95
BP 115
EP 122
DI 10.1016/j.neurobiolaging.2020.07.013
PG 8
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA OI5IV
UT WOS:000583312900011
PM 32795848
DA 2022-11-30
ER

PT J
AU Johra, FT
   Bepari, AK
   Bristy, AT
   Reza, HM
AF Johra, Fatima Tuj
   Bepari, Asim Kumar
   Bristy, Anika Tabassum
   Reza, Hasan Mahmud
TI A Mechanistic Review of beta-Carotene, Lutein, and Zeaxanthin in Eye
   Health and Disease
SO ANTIOXIDANTS
LA English
DT Review
DE carotenoids; xanthophylls; eye disease; cataract; age-related macular
   degeneration; diabetic retinopathy; oxidative stress; zeaxanthin;
   lutein; &#946; -carotene
ID DIABETIC MICROVASCULAR COMPLICATIONS; AGE-RELATED CATARACT; MACULAR
   PIGMENT; OXIDATIVE STRESS; HUMAN LENS; LIPID-PEROXIDATION; SINGLET
   OXYGEN; DOUBLE-BLIND; SUBCHRONIC TOXICITY; SUBACUTE TOXICITY
AB Carotenoids are natural lipid-soluble antioxidants abundantly found as colorful pigments in fruits and vegetables. At least 600 carotenoids occur naturally, although about 20 of them, including beta-carotene, alpha-carotene, lycopene, lutein, zeaxanthin, meso-zeaxanthin, and cryptoxanthin, are detectable in the human blood. They have distinct physiological and pathophysiological functions ranging from fetal development to adult homeostasis. beta-carotene is a precursor of vitamin A that essentially functions in many biological processes including vision. The human macula lutea and eye lens are rich in lutein, zeaxanthin, and meso-zeaxanthin, collectively known as macular xanthophylls, which help maintain eye health and prevent ophthalmic diseases. Ocular carotenoids absorb light from the visible region (400-500 nm wavelength), enabling them to protect the retina and lens from potential photochemical damage induced by light exposure. These natural antioxidants also aid in quenching free radicals produced by complex physiological reactions and, consequently, protect the eye from oxidative stress, apoptosis, mitochondrial dysfunction, and inflammation. This review discusses the protective mechanisms of macular xanthophylls in preventing eye diseases such as cataract, age-related macular degeneration, and diabetic retinopathy. Moreover, some preclinical animal studies and some clinical trials are discussed briefly to understand carotenoid safety and efficacy.
C1 [Johra, Fatima Tuj; Bepari, Asim Kumar; Bristy, Anika Tabassum; Reza, Hasan Mahmud] North South Univ, Sch Hlth & Life Sci, Dept Pharmaceut Sci, Dhaka 1229, Bangladesh.
C3 North South University (NSU)
RP Reza, HM (通讯作者)，North South Univ, Sch Hlth & Life Sci, Dept Pharmaceut Sci, Dhaka 1229, Bangladesh.
EM fatima.johra@northsouth.edu; asim.bepari@northsouth.edu;
   anika.bristy@northsouth.edu; hasan.reza@northsouth.edu
RI Reza, Hasan Mahmud/AFL-0151-2022; Bepari, Asim Kumar/ABC-1166-2021
OI Reza, Hasan Mahmud/0000-0003-3287-942X; Bepari, Asim
   Kumar/0000-0001-5656-1833
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Ahuja S, 2009, J BIOL CHEM, V284, P10190, DOI 10.1074/jbc.M805725200
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Arunkumar R, 2018, EYE, V32, P992, DOI 10.1038/s41433-018-0044-0
   Aso Y, 2000, ACTA DIABETOL, V37, P87, DOI 10.1007/s005920070025
   Azar G, 2017, J FR OPHTALMOL, V40, P303, DOI 10.1016/j.jfo.2016.11.009
   Babizhayev MA, 1996, BBA-MOL BASIS DIS, V1315, P87, DOI 10.1016/0925-4439(95)00091-7
   Bahrami Hossein, 2006, BMC Ophthalmol, V6, P23, DOI 10.1186/1471-2415-6-23
   Barnes DE, 2002, CURR BIOL, V12, pR262, DOI 10.1016/S0960-9822(02)00788-1
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   BHUYAN KC, 1986, LIFE SCI, V38, P1463, DOI 10.1016/0024-3205(86)90559-X
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Brown GC, 2019, J CATARACT REFR SURG, V45, P927, DOI 10.1016/j.jcrs.2019.02.006
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Celentano JC, 2002, J NUTR, V132, p535S, DOI 10.1093/jn/132.3.535S
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chang D, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/587826
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2004, OPHTHAL EPIDEMIOL, V11, P401, DOI 10.1080/09286580490515152
   CHRISTEN WG, 1994, AM J MED, V97, pS14, DOI 10.1016/0002-9343(94)90293-3
   Christen WG, 2003, ARCH OPHTHALMOL-CHIC, V121, P372, DOI 10.1001/archopht.121.3.372
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
   CONN PF, 1991, J PHOTOCH PHOTOBIO B, V11, P41, DOI 10.1016/1011-1344(91)80266-K
   Cumming RG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1296, DOI 10.1001/archopht.1997.01100160466015
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fraser PD, 2004, PROG LIPID RES, V43, P228, DOI 10.1016/j.plipres.2003.10.002
   Fujimura S, 2016, CLIN OPHTHALMOL, V10, P2149, DOI 10.2147/OPTH.S119251
   Gao SS, 2011, MOL VIS, V17, P3180
   GARNER MH, 1980, EXP EYE RES, V31, P361, DOI 10.1016/S0014-4835(80)80044-3
   GARNER WH, 1978, P NATL ACAD SCI USA, V75, P3618, DOI 10.1073/pnas.75.8.3618
   Genuth S, 2015, DIABETES, V64, P266, DOI 10.2337/db14-0215
   Girach A, 2006, INT J CLIN PRACT, V60, P1471, DOI 10.1111/j.1742-1241.2006.01175.x
   Glaser TS, 2015, OPHTHALMOLOGY, V122, P1471, DOI 10.1016/j.ophtha.2015.04.007
   Green-Gomez M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080767
   Gupta SK, 2009, INDIAN J OPHTHALMOL, V57, P175, DOI 10.4103/0301-4738.49390
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   HUBBARD R, 1952, J GEN PHYSIOL, V36, P269, DOI 10.1085/jgp.36.2.269
   Hwang JS, 2018, J FOOD BIOCHEM, V42, DOI 10.1111/jfbc.12495
   Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159
   Jomova K, 2013, EUR J MED CHEM, V70, P102, DOI 10.1016/j.ejmech.2013.09.054
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kaur A, 2017, SAUDI J OPHTHALMOL, V31, P30, DOI 10.1016/j.sjopt.2016.12.001
   Kaur J, 2012, J CLIN DIAGN RES, V6, P1629, DOI 10.7860/JCDR/2012/4856.2626
   Keegan G, 2020, EXP EYE RES, V197, DOI 10.1016/j.exer.2020.108104
   KELLOGG EW, 1975, J BIOL CHEM, V250, P8812
   Khangholi S, 2016, PLANTA MED, V82, P32, DOI 10.1055/s-0035-1558086
   Kim D, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.10
   Kim D, 2019, AM J PATHOL, V189, P1945, DOI 10.1016/j.ajpath.2019.06.004
   Kiziltoprak H, 2019, WORLD J DIABETES, V10, P140, DOI 10.4239/wjd.v10.i3.140
   Klein R, 1996, ANN INTERN MED, V124, P90, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00003
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   Kowluru RA, 2005, ANTIOXID REDOX SIGN, V7, P1581, DOI 10.1089/ars.2005.7.1581
   Kowluru RA, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-8
   KRINSKY NI, 1982, J NATL CANCER I, V69, P205
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kumar D.P., 2009, TOXICOL INT, V16, P55
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Lyle BJ, 1999, AM J CLIN NUTR, V69, P272
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Madsen-Bouterse SA, 2010, FREE RADICAL RES, V44, P313, DOI 10.3109/10715760903494168
   Manayi A, 2016, CRIT REV BIOTECHNOL, V36, P829, DOI 10.3109/07388551.2015.1049510
   MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0
   Meyer CH, 2005, DEV OPHTHALMOL, V38, P103, DOI 10.1159/000082771
   MicelliFerrari T, 1996, BRIT J OPHTHALMOL, V80, P840, DOI 10.1136/bjo.80.9.840
   Milani A, 2017, BRIT J PHARMACOL, V174, P1290, DOI 10.1111/bph.13625
   Murillo AG, 2016, ADV NUTR, V7, P14, DOI 10.3945/an.115.009803
   Nakagawa K, 2008, ANAL BIOCHEM, V381, P129, DOI 10.1016/j.ab.2008.06.038
   Namitha KK, 2010, CRIT REV FOOD SCI, V50, P728, DOI 10.1080/10408398.2010.499811
   Nidhi B, 2013, J FOOD SCI, V78, pT1636, DOI 10.1111/1750-3841.12256
   OLIVEROS E, 1994, NEW J CHEM, V18, P535
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Ouyang XL, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110577
   Papudesu C, 2018, OPHTHALMOLOGY, V125, P512, DOI 10.1016/j.ophtha.2017.10.028
   Preethi KC, 2008, INT J TOXICOL, V27, P1, DOI 10.1080/10915810701876265
   Priyadarshani AMB, 2018, CLIN NUTR ESPEN, V23, P19, DOI 10.1016/j.clnesp.2017.12.002
   Ranganathan A, 2016, MAT SCI ENG C-MATER, V69, P1318, DOI 10.1016/j.msec.2016.08.029
   Ravi KB, 2014, FOOD CHEM TOXICOL, V72, P30, DOI 10.1016/j.fct.2014.06.015
   Ravikrishnan R, 2011, FOOD CHEM TOXICOL, V49, P2841, DOI 10.1016/j.fct.2011.08.011
   Roohbakhsh A, 2017, BIOMED PHARMACOTHER, V91, P31, DOI 10.1016/j.biopha.2017.04.057
   Rutz JK, 2016, FOOD CHEM, V202, P324, DOI 10.1016/j.foodchem.2016.01.140
   Saini RK, 2015, FOOD RES INT, V76, P735, DOI 10.1016/j.foodres.2015.07.047
   Santos JM, 2012, FREE RADICAL BIO MED, V53, P1729, DOI 10.1016/j.freeradbiomed.2012.08.588
   Santos JM, 2011, CURR PHARM BIOTECHNO, V12, P352
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Scanlon G, 2019, NUTR RES REV, V32, P247, DOI 10.1017/S095442241900012X
   Shao A, 2006, REGUL TOXICOL PHARM, V45, P289, DOI 10.1016/j.yrtph.2006.05.007
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Song KH, 2019, J DIABETES INVEST, V10, P745, DOI 10.1111/jdi.12953
   SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Stringham JM, 2016, EXP EYE RES, V151, P1, DOI 10.1016/j.exer.2016.07.005
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Tapiero H, 2004, BIOMED PHARMACOTHER, V58, P100, DOI 10.1016/j.biopha.2003.12.006
   Teikari JM, 1997, ACTA OPHTHALMOL SCAN, V75, P634
   Thurnham DI, 2013, FOOD CHEM TOXICOL, V59, P455, DOI 10.1016/j.fct.2013.06.002
   Trudeau K, 2010, AM J PATHOL, V177, P447, DOI 10.2353/ajpath.2010.091029
   Truscott RJW, 2000, OPHTHALMIC RES, V32, P185, DOI 10.1159/000055612
   TRUSCOTT RJW, 1977, BIOCHIM BIOPHYS ACTA, V492, P43, DOI 10.1016/0005-2795(77)90212-4
   Wang W, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001519
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Xu XD, 2013, FOOD CONTROL, V32, P678, DOI 10.1016/j.foodcont.2013.02.007
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
NR 121
TC 26
Z9 27
U1 7
U2 34
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD NOV
PY 2020
VL 9
IS 11
AR 1046
DI 10.3390/antiox9111046
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA OX4QJ
UT WOS:000593550800001
PM 33114699
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ashok, A
   Singh, N
   Chaudhary, S
   Bellamkonda, V
   Kritikos, AE
   Wise, AS
   Rana, N
   McDonald, D
   Ayyagari, R
AF Ashok, Ajay
   Singh, Neena
   Chaudhary, Suman
   Bellamkonda, Vindhya
   Kritikos, Alexander E.
   Wise, Aaron S.
   Rana, Neil
   McDonald, Dallas
   Ayyagari, Rithvik
TI Retinal Degeneration and Alzheimer's Disease: An Evolving Link
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE glaucoma; iron; oxidative stress; inflammation; Alzheimer&#8217; s
   disease; reactive oxygen species; age related macular degeneration;
   drusen; prion protein; retinal degeneration
ID AMYLOID-BETA PEPTIDE; NERVE-FIBER LAYER; PRION PROTEIN; MACULAR
   DEGENERATION; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; PRECURSOR
   PROTEIN; OPTIC-NERVE; CELL-DEATH; GLAUCOMA
AB Age-related macular degeneration (AMD) and glaucoma are degenerative conditions of the retina and a significant cause of irreversible blindness in developed countries. Alzheimer's disease (AD), the most common dementia of the elderly, is often associated with AMD and glaucoma. The cardinal features of AD include extracellular accumulation of amyloid beta (A beta) and intracellular deposits of hyper-phosphorylated tau (p-tau). Neuroinflammation and brain iron dyshomeostasis accompany A beta and p-tau deposits and, together, lead to progressive neuronal death and dementia. The accumulation of A beta and iron in drusen, the hallmark of AMD, and A beta and p-tau in retinal ganglion cells (RGC), the main retinal cell type implicated in glaucoma, and accompanying inflammation suggest overlapping pathology. Visual abnormalities are prominent in AD and are believed to develop before cognitive decline. Some are caused by degeneration of the visual cortex, while others are due to RGC loss or AMD-associated retinal degeneration. Here, we review recent information on A beta, p-tau, chronic inflammation, and iron dyshomeostasis as common pathogenic mechanisms linking the three degenerative conditions, and iron chelation as a common therapeutic option for these disorders. Additionally discussed is the role of prion protein, infamous for prion disorders, in A beta-mediated toxicity and, paradoxically, in neuroprotection.
C1 [Ashok, Ajay; Singh, Neena; Chaudhary, Suman; Bellamkonda, Vindhya; Kritikos, Alexander E.; Wise, Aaron S.; Rana, Neil; McDonald, Dallas; Ayyagari, Rithvik] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
C3 Case Western Reserve University
RP Ashok, A; Singh, N (通讯作者)，Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
EM ajay.ashok@case.edu; neena.singh@case.edu; sxc1351@case.edu;
   vbellamkonda@health.southalabama.edu; aek103@case.edu; asw80@case.edu;
   nar66@case.edu; djm259@case.edu; rvayyagari2022@gmail.com
RI ashok, ajay/AAN-3367-2020
OI ashok, ajay/0000-0003-4354-1467; Rana, Neil/0000-0003-0688-2932; Wise,
   Aaron/0000-0002-4035-2241; Kritikos, Alex/0000-0002-5814-4141;
   Chaudhary, Suman/0000-0003-2260-6444; Singh, Neena/0000-0001-8369-7517
FU NIH [R01NS 092:145]
FX NIH (R01NS 092:145 to NS).
CR Adornetto A, 2019, NEURAL REGEN RES, V14, P391, DOI 10.4103/1673-5374.245465
   Cerquera-Jaramillo MA, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/2941783
   Alleaume-Butaux A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005073
   Altmeppen Hermann C, 2012, Am J Neurodegener Dis, V1, P15
   Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6
   Asanad S, 2019, INVEST OPHTH VIS SCI, V60, P1491, DOI 10.1167/iovs.18-25966
   Ashok A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.24
   Ashok A, 2020, EXP EYE RES, V190, DOI 10.1016/j.exer.2019.107890
   Asthana A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08821-1
   Bayer AU, 2002, AM J OPHTHALMOL, V133, P135, DOI 10.1016/S0002-9394(01)01196-5
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   Bertuchi FR, 2012, BIOCHEM BIOPH RES CO, V418, P27, DOI 10.1016/j.bbrc.2011.12.098
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   Brody AH, 2018, ADV PHARMACOL, V82, P293, DOI 10.1016/bs.apha.2017.09.007
   Brown DR, 2001, J NEUROCHEM, V76, P69, DOI 10.1046/j.1471-4159.2001.00009.x
   Butterfield DA, 2018, J ALZHEIMERS DIS, V62, P1345, DOI 10.3233/JAD-170543
   Castle AR, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00019
   Cheignon C, 2018, REDOX BIOL, V14, P450, DOI 10.1016/j.redox.2017.10.014
   Cheung CYL, 2014, ALZHEIMERS DEMENT, V10, P135, DOI 10.1016/j.jalz.2013.06.009
   Chiasseu M, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0199-3
   Chiasseu M, 2016, J NEUROSCI, V36, P5785, DOI 10.1523/JNEUROSCI.3986-15.2016
   Chiu K, 2012, AGE, V34, P633, DOI 10.1007/s11357-011-9260-2
   Choi SI, 2019, EXP EYE RES, V182, P167, DOI 10.1016/j.exer.2019.03.012
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Collin F, 2018, BIOMARK MED, V12, P201, DOI 10.2217/bmm-2017-0456
   CRONINGOLOMB A, 1995, GERONTOLOGIST, V35, P370, DOI 10.1093/geront/35.3.370
   Cui QN, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107961
   Cunha Joao Paulo, 2017, Alzheimers Dement (Amst), V8, P11, DOI 10.1016/j.dadm.2017.03.004
   d'Azy CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166915
   Davis BM, 2016, ACTA NEUROPATHOL, V132, P807, DOI 10.1007/s00401-016-1609-2
   de Boer C, 2016, MOTOR CONTROL, V20, P1, DOI 10.1123/mc.2014-0015
   de Boer C, 2014, GERIATR GERONTOL INT, V14, P880, DOI 10.1111/ggi.12183
   Dekens DW, 2020, NEUROCHEM INT, V132, DOI 10.1016/j.neuint.2019.104607
   den Haan J, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0650-x
   den Haan Jurre, 2017, Alzheimers Dement (Amst), V6, P162, DOI 10.1016/j.dadm.2016.12.014
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dong ZZ, 2018, CURR EYE RES, V43, P1326, DOI 10.1080/02713683.2018.1501070
   Dragan MC, 2017, BEHAV BRAIN RES, V322, P351, DOI 10.1016/j.bbr.2016.09.014
   Dupiereux I, 2008, J NEUROSCI RES, V86, P653, DOI 10.1002/jnr.21506
   Edwards MM, 2014, EXP EYE RES, V127, P252, DOI 10.1016/j.exer.2014.08.006
   Einarsdottir AB, 2016, J ALZHEIMERS DIS, V49, P79, DOI 10.3233/JAD-150457
   Eun Ji L., 2016, ALZHEIMERS RES THER, V8, P1
   Ezpeleta J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08110-x
   Fernandez-Albarral JA, 2019, J OPTOM, V12, P198, DOI 10.1016/j.optom.2018.07.001
   Frederikse PH, 1998, CURR EYE RES, V17, P947, DOI 10.1076/ceyr.17.9.947.5135
   Frigg R, 2006, EXP EYE RES, V83, P1350, DOI 10.1016/j.exer.2006.07.010
   Frost S, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.150
   GILMORE GC, 1991, OPTOMETRY VISION SCI, V68, P790, DOI 10.1097/00006324-199110000-00006
   Gnana-Prakasam JP, 2008, BIOCHEM J, V411, P79, DOI 10.1042/BJ20071377
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Guo LY, 2014, EXP EYE RES, V129, P31, DOI 10.1016/j.exer.2014.10.012
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Gupta VK, 2016, NEUROSCI LETT, V623, P52, DOI 10.1016/j.neulet.2016.04.059
   Haass C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006270
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Haigh CL, 2016, NEURAL REGEN RES, V11, P238, DOI 10.4103/1673-5374.177726
   Hanninen MM, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-36
   Hart NJ, 2016, ACTA NEUROPATHOL, V132, P767, DOI 10.1007/s00401-016-1613-6
   Ho CY, 2014, BRAIN PATHOL, V24, P25, DOI 10.1111/bpa.12070
   Ho WL, 2012, MOL VIS, V18, P2700
   Ibarra R, 2021, J GERIATR PSYCH NEUR, V34, P659, DOI 10.1177/0891988720944237
   Iijima A, 2003, NEUROBIOL AGING, V24, P789, DOI 10.1016/S0197-4580(02)00235-X
   Ishikawa Makoto, 2018, Neuropsychiatry (London), V8, P344, DOI 10.4172/Neuropsychiatry.1000356
   Joly S, 2017, NEUROBIOL AGING, V53, P181, DOI 10.1016/j.neurobiolaging.2017.02.004
   Jones-Odeh E, 2015, EYE, V29, P1270, DOI 10.1038/eye.2015.158
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Katsarou A, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040127
   Kawasaki A, 2020, J ALZHEIMERS DIS, V75, P1273, DOI 10.3233/JAD-200120
   Kent SA, 2020, ACTA NEUROPATHOL, V140, P417, DOI 10.1007/s00401-020-02196-w
   Kerbage C, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00062
   Kim HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.37
   Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014
   Koronyo Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93621
   Koronyo Y, 2012, NEURODEGENER DIS, V10, P285, DOI 10.1159/000335154
   Kremen WS, 2019, NEUROBIOL AGING, V83, P114, DOI 10.1016/j.neurobiolaging.2019.09.001
   Kwak DE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227618
   Lane DJR, 2018, J ALZHEIMERS DIS, V64, pS379, DOI 10.3233/JAD-179944
   Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761
   Lee AG, 2004, OPHTHALMOLOGY, V111, P376, DOI 10.1016/S0161-6420(03)00732-2
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Liao H, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00188
   Linsenrneier L, 2017, BBA-MOL CELL RES, V1864, P2128, DOI 10.1016/j.bbamcr.2017.06.022
   Liu DC, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0268-6
   Liu S S, 2017, Zhonghua Yan Ke Za Zhi, V53, P314, DOI 10.3760/cma.j.issn.0412-4081.2017.04.016
   Liu YH, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00309
   Loubet D, 2012, FASEB J, V26, P678, DOI 10.1096/fj.11-185579
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Mancino R, 2018, CURR NEUROPHARMACOL, V16, P971, DOI 10.2174/1570159X16666171206144045
   Marziani E, 2013, INVEST OPHTH VIS SCI, V54, P5953, DOI 10.1167/iovs.13-12046
   Masuzzo A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00127
   Melov S, 2005, FREE RADICAL BIO MED, V38, P258, DOI 10.1016/j.freeradbiomed.2004.10.023
   Michael R, 2014, EXP EYE RES, V119, P44, DOI 10.1016/j.exer.2013.11.016
   Mirzaei M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12858-7
   Mockett BG, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00030
   Mollica MA, 2017, J NEUROPSYCHOL, V11, P56, DOI 10.1111/jnp.12079
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Ngolab J, 2019, NEUROL THER, V8, pS57, DOI 10.1007/s40120-019-00173-4
   Nilson AN, 2017, J ALZHEIMERS DIS, V55, P1083, DOI 10.3233/JAD-160912
   Nishioka C, 2019, NEUROIMAGE, V189, P180, DOI 10.1016/j.neuroimage.2019.01.007
   Nunez MT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040109
   Nygaard HB, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt238
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olafsdottir Olof Birna, 2018, Alzheimers Dement (Amst), V10, P340, DOI 10.1016/j.dadm.2018.03.002
   Ong SS, 2019, J NEUROL, V266, P1566, DOI 10.1007/s00415-018-9028-z
   Onuska KM, 2020, J NEUROSCI, V40, P1608, DOI 10.1523/JNEUROSCI.2594-19.2020
   Ornek N, 2015, CURR EYE RES, V40, P423, DOI 10.3109/02713683.2014.930154
   Palanimuthu D, 2018, DALTON T, V47, P7190, DOI 10.1039/c8dt01099d
   Poli M, 2017, MOLECULES, V22, DOI 10.3390/molecules22040598
   Polo V, 2017, EYE, V31, P1034, DOI 10.1038/eye.2017.23
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Prasad T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03397-2
   Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363
   Purro SA, 2018, BIOL PSYCHIAT, V83, P358, DOI 10.1016/j.biopsych.2017.11.020
   Qian ZM, 2020, MED RES REV, V40, P633, DOI 10.1002/med.21631
   Rajmohan R, 2017, J ALZHEIMERS DIS, V57, P975, DOI 10.3233/JAD-160612
   Renner M, 2010, NEURON, V66, P739, DOI 10.1016/j.neuron.2010.04.029
   Rhein V, 2009, P NATL ACAD SCI USA, V106, P20057, DOI 10.1073/pnas.0905529106
   Rizzo M, 2000, NEUROPSYCHOLOGIA, V38, P1157, DOI 10.1016/S0028-3932(00)00023-3
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Russo R, 2016, EUR J PHARMACOL, V787, P134, DOI 10.1016/j.ejphar.2016.03.064
   SADUN AA, 1990, OPHTHALMOLOGY, V97, P9
   Salobrar-Garcia E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220535
   Scheckel C, 2018, NAT REV GENET, V19, P405, DOI 10.1038/s41576-018-0011-4
   Schwab C, 2020, INT OPHTHALMOL, V40, P999, DOI 10.1007/s10792-019-01268-5
   Scinto LFM, 2007, GENES BRAIN BEHAV, V6, P209, DOI 10.1111/j.1601-183X.2006.00247.x
   Shah TM, 2017, MOL PSYCHIATR, V22, P353, DOI 10.1038/mp.2016.251
   Shi HS, 2020, ACTA NEUROPATHOL, V139, P813, DOI 10.1007/s00401-020-02134-w
   Shu WT, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101469
   Shu WT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040112
   Singh A, 2013, J ALZHEIMERS DIS, V35, P541, DOI 10.3233/JAD-130218
   Singh N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004335
   Singh N, 2010, ANTIOXID REDOX SIGN, V12, P1271, DOI 10.1089/ars.2009.2628
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Sun SW, 2015, J ALZHEIMERS DIS, V45, P1139, DOI 10.3233/JAD-142154
   Tejera D, 2019, EMBO J, V38, DOI 10.15252/embj.2018101064
   Tippett WJ, 2006, BRAIN RES, V1102, P92, DOI 10.1016/j.brainres.2006.04.049
   Trebbastoni A, 2017, ALZ DIS ASSOC DIS, V31, P128, DOI 10.1097/WAD.0000000000000176
   Tsokolas G, 2020, EYE BRAIN, V12, P73, DOI 10.2147/EB.S193026
   Ueda K, 2018, P NATL ACAD SCI USA, V115, P4963, DOI 10.1073/pnas.1722601115
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   Vela D, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1399-5
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Wang L, 2019, J CELL PHYSIOL, V234, P7600, DOI 10.1002/jcp.27522
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wostyn P, 2008, CLIN NEUROL NEUROSUR, V110, P101, DOI 10.1016/j.clineuro.2007.10.011
   Wostyn P, 2019, ALZHEIMERS DEMENT, V15, P600, DOI 10.1016/j.jalz.2018.12.012
   Wright LM, 2019, J ALZHEIMERS DIS, V68, P1429, DOI 10.3233/JAD-181104
   You LH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.93
   Zeng FN, 2003, J NEUROCHEM, V84, P480, DOI 10.1046/j.1471-4159.2003.01529.x
   Zeng L, 2015, INT J CLIN EXP MED, V8, P8042
   Zhang Y, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00339
   Zhao LL, 2015, J NEUROCHEM, V135, P958, DOI 10.1111/jnc.13292
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
   Zhu SM, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/7474086
NR 161
TC 30
Z9 30
U1 5
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2020
VL 21
IS 19
AR 7290
DI 10.3390/ijms21197290
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ON0XS
UT WOS:000586435900001
PM 33023198
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shin, DH
   Kong, M
   Han, G
   Han, JC
   Ham, DI
AF Shin, Dong Hoon
   Kong, Mingui
   Han, Gyule
   Han, Jong Chul
   Ham, Don-Il
TI Clinical manifestations of cuticular drusen in Korean patients
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BASAL LAMINAR DRUSEN; POLYPOIDAL CHOROIDAL VASCULOPATHY; VITELLIFORM
   MACULAR DETACHMENT; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY;
   UNITED-STATES; DEGENERATION; CLASSIFICATION; DIAGNOSIS; FEATURES
AB Cuticular drusen show some similarities to and differences from soft drusen in age-related macular degeneration (AMD) and might thus be a unique AMD subtype. Previous studies on cuticular drusen were performed mainly in white ethnic groups, but AMD shows ethnic differences. We investigated clinical manifestations of cuticular drusen in Korean patients to evaluate possible ethnic differences. Clinical records of Korean patients with cuticular drusen were retrospectively reviewed. Fundus distribution pattern, imaging features, and presence of large drusen, drusenoid pigment epithelial detachment (PED), and macular complications, including geographic atrophy (GA), choroidal neovascularization (CNV), and acquired vitelliform lesion (AVL), were assessed via multimodal imaging in 162 eyes with cuticular drusen (n=81 patients; 67 females; mean age: 66.6 +/- 9.1 years). Diffuse distribution was found in 61.7% and peripapillary involvement in 75.3% of eyes. Large drusen, drusenoid PED, GA, CNV, and AVL were observed in 59.3%, 26.5%, 18.5%, 3.7%, and 1.2% of eyes, respectively. The macular complication prevalence was similar between patients <= 60 and those >60 years old. In Korean patients, cuticular drusen were less frequently associated with macular complications than in white patients, and the proportion of macular complications differed significantly, with AVL representing an uncommon complication.
C1 [Shin, Dong Hoon; Kong, Mingui] Hangil Eye Hosp, Retina Ctr, Incheon, South Korea.
   [Han, Gyule; Han, Jong Chul; Ham, Don-Il] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Ham, DI (通讯作者)，Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM oculus@naver.com
CR Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Barbazetto IA, 2007, OPHTHALMIC GENET, V28, P192, DOI 10.1080/13816810701538596
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   COHEN Y, 1994, BRIT J OPHTHALMOL, V78, P437
   DEUTMAN AF, 1969, ARCH OPHTHALMOL-CHIC, V82, P4, DOI 10.1001/archopht.1969.00990020006002
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Hoeg TB, 2016, BRIT J OPHTHALMOL, V100, P378, DOI 10.1136/bjophthalmol-2015-307197
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P448, DOI 10.1007/s10384-019-00692-5
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 33
TC 3
Z9 3
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 10
PY 2020
VL 10
IS 1
DI 10.1038/s41598-020-68493-2
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MJ7ZR
UT WOS:000548308300008
PM 32651454
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Polosa, A
   Lv, S
   Igrine, WA
   Chevrolat, LA
   Bessaklia, H
   Lachapelle, P
AF Polosa, Anna
   Lv, Shasha
   Igrine, Wassila Ait
   Chevrolat, Laura-Alexie
   Bessaklia, Hyba
   Lachapelle, Pierre
TI Evidences Suggesting that Distinct Immunological and Cellular Responses
   to Light Damage Distinguishes Juvenile and Adult Rat Retinas
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE light-induced retinopathy; retinal structure and function; intrinsic
   resistance; immune response; neurotrophic factors; juvenile and adult
   rats
ID INDUCED RETINOPATHY; DEGENERATION; MICROGLIA; PHOTORECEPTORS
AB To unravel the mechanisms behind the higher resistance to light damage of juvenile (JR) versus adult (AR) rats, Sprague Dawley rats were exposed to a bright luminous environment of 10, 000 lux. The light-induced retinopathy (LIR) was assessed with histology, electroretinography and immunohistochemistry (IHC). In JR, 2 days of exposure induced the typical LIR, while >3 days added little LIR. IHC revealed a subtle migration of microglia (Iba1 marker) from the inner to the outer retina after 3 days of exposure in JR contrasting with the stronger reaction seen after 1 day in AR. Similarly, in JR, the Muller cells expressed less intense GFAP, CNTF and FGF2 staining compared to AR. Our results suggest that in JR the degree of retinal damage is not proportional to the duration of light exposure (i.e., dose-independent retinopathy), contrasting with the dose-dependent LIR reported in AR. The immature immune system in JR may explain the delayed and/or weaker inflammatory response compared to AR, a finding that would also point to the devastating contribution of the immune system in generating the LIR phenotype, a claim also advanced to explain the pathophysiology of other retinal degenerative disorders such as Age-related Macular Degeneration, Diabetic Retinopathy and Retinitis Pigmentosa.
C1 [Polosa, Anna; Lv, Shasha; Igrine, Wassila Ait; Chevrolat, Laura-Alexie; Bessaklia, Hyba; Lachapelle, Pierre] McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Ophthalmol & Neurol Neurosurg, Montreal, PQ H4A 3J1, Canada.
   [Lv, Shasha] Xi An Jiao Tong Univ, Hlth Sci Ctr, 76 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
C3 McGill University; Xi'an Jiaotong University
RP Lachapelle, P (通讯作者)，McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Ophthalmol & Neurol Neurosurg, Montreal, PQ H4A 3J1, Canada.
EM anna.polosa@mail.mcgill.ca; shashalv0626@gmail.com; wassila.ait@live.ca;
   lauraalexie.chevrolat@gmail.com; amanemisa61@yahoo.fr;
   pierre.lachapelle@mcgill.ca
FU Natural Sciences and Engineering Research Council of Canada (NSCERC)
   [271604]; National Natural Science Foundation of China (NSFC) [81601222]
FX This research was funded by the Natural Sciences and Engineering
   Research Council of Canada (NSCERC; No. 271604) and the National Natural
   Science Foundation of China (NSFC; No. 81601222).
CR Behn D, 2003, DOC OPHTHALMOL, V106, P153, DOI 10.1023/A:1022511918823
   Bejarano-Escobar R, 2012, J EXP BIOL, V215, P3799, DOI 10.1242/jeb.072124
   BRAEKEVELT CR, 1970, AM J ANAT, V127, P281, DOI 10.1002/aja.1001270305
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   CICERONE CM, 1976, SCIENCE, V194, P1183, DOI 10.1126/science.996550
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Dorfman A, 2008, INVEST OPHTH VIS SCI, V49, P458, DOI 10.1167/iovs.07-0916
   Dorfman AL, 2011, INVEST OPHTH VIS SCI, V52, P1693, DOI 10.1167/iovs.10-6197
   Feng CY, 2017, MOL VIS, V23, P765
   Gordon WC, 2002, INVEST OPHTH VIS SCI, V43, P3511
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   HORSBURGH GM, 1987, J COMP NEUROL, V263, P553, DOI 10.1002/cne.902630407
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Joly S, 2007, INVEST OPHTH VIS SCI, V48, P2311, DOI 10.1167/iovs.06-1205
   Joly S, 2006, INVEST OPHTH VIS SCI, V47, P3202, DOI 10.1167/iovs.05-1515
   LACHAPELLE P, 1983, INVEST OPHTH VIS SCI, V24, P442
   Lachapelle P., 2006, PRINCIPLES PRACTICE, P565
   Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253
   Marc RE, 2008, MOL VIS, V14, P782
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Polosa A, 2017, CURR EYE RES, V42, P924, DOI 10.1080/02713683.2016.1255336
   Polosa A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158082
   Polosa A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146979
   RAPP LM, 1980, EFFECTS CONSTANT LIG, P135
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Sudharsan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18236-7
   Tanito M, 2008, EXP EYE RES, V87, P292, DOI 10.1016/j.exer.2008.06.002
   Wachtmeister L, 1998, PROG RETIN EYE RES, V17, P485, DOI 10.1016/S1350-9462(98)00006-8
   Zhang YK, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap8492
NR 30
TC 1
Z9 1
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN 1
PY 2019
VL 20
IS 11
AR 2744
DI 10.3390/ijms20112744
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IE8OX
UT WOS:000472634100138
PM 31167447
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Waldmann, NP
   Gerber, N
   Hill, W
   Goldblum, D
AF Waldmann, Nicolas Philipp
   Gerber, Nadine
   Hill, Warren
   Goldblum, David
TI Cataract Surgery in High Hyperopia
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE cataract surgery; high hyperopia; biometry; SN60AT
ID COMPLICATIONS; BIOMETRY; OUTCOMES; EYES
AB Background Although cataract surgery is a well-established and standardised procedure, it can be demanding and associated with higher complication rates in high hyperopia. We present clinical data for highly hyperopic patients who underwent cataract surgery over a 12-year period (2005-2016) and at a single centre.
   Patients and Methods Out of a total of 11434 cataract operations, 41 highly hyperopic eyes (SN60AT >= 31 dpt) were included for analysis. We compared the target spherical equivalent to the final postoperative spherical equivalent for five different formulas. We also reviewed the best corrected distance visual acuity (BCDVA) before and after surgery and any complications.
   Results LogMAR BCDVA increased significantly from a mean of 0.5 before to 0.37 after surgery (p = 0.02). The main reasons for the reduced final BCDVA were glaucoma, Fuchs corneal endothelial dystrophy, and age-related macular degeneration. One eye suffered a radial capsule tear and received a sulcus implanted intraocular lens (IOL). There was no statistically significant difference between formulas with respect to aberration of the final spherical equivalent.
   Conclusions Patients with high hyperopia often have ocular comorbidities. Such eyes may be surgically challenging, resulting in reduced benefits from cataract surgery compared to normal eyes.
C1 [Waldmann, Nicolas Philipp; Gerber, Nadine; Goldblum, David] Univ Spital Basel, Ophthalmol, Mittlere Str 91, CH-4031 Basel, Switzerland.
   [Hill, Warren] East Valley Ophthalmol, Mesa, AZ USA.
C3 University of Basel
RP Waldmann, NP (通讯作者)，Univ Spital Basel, Ophthalmol, Mittlere Str 91, CH-4031 Basel, Switzerland.
EM NicolasPhilipp.Waldmann@usb.ch
RI Goldblum, David/G-8559-2014
OI Goldblum, David/0000-0002-2119-1710
CR Aristodemou P, 2011, J CATARACT REFR SURG, V37, P63, DOI 10.1016/j.jcrs.2010.07.032
   Bellan L, 2008, GERIATR AGING, V11, P328
   Chan E, 2010, CLIN EXP OPTOM, V93, P379, DOI 10.1111/j.1444-0938.2010.00516.x
   Daien V, 2015, OPHTHALMOLOGY, V122, P1633, DOI 10.1016/j.ophtha.2015.04.017
   Day AC, 2015, EYE, V29, P552, DOI 10.1038/eye.2015.3
   Gale RP, 2006, EYE, V23, P149
   Gokce SE, 2017, J CATARACT REFR SURG, V43, P892, DOI 10.1016/j.jcrs.2017.07.004
   Lundstrom M, 2011, J CATARACT REFR SURG, V37, P1762, DOI 10.1016/j.jcrs.2011.05.022
   Sahin A, 2012, CURR OPIN OPHTHALMOL, V23, P47, DOI 10.1097/ICU.0b013e32834cd63e
   Sheard R, 2014, EYE, V28, P118, DOI 10.1038/eye.2013.248
NR 10
TC 1
Z9 1
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2018
VL 235
IS 4
BP 413
EP 415
DI 10.1055/s-0044-101010
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GD2RI
UT WOS:000430348000015
PM 29669369
DA 2022-11-30
ER

PT J
AU Pearsall, EA
   Cheng, R
   Zhou, K
   Takahashi, Y
   Matlock, HG
   Vadvalkar, SS
   Shin, Y
   Fredrick, TW
   Gantner, ML
   Meng, S
   Fu, ZJ
   Gong, Y
   Kinter, M
   Humphries, KM
   Szweda, LI
   Smith, LEH
   Ma, JX
AF Pearsall, Elizabeth A.
   Cheng, Rui
   Zhou, Kelu
   Takahashi, Yusuke
   Matlock, H. Greg
   Vadvalkar, Shraddha S.
   Shin, Younghwa
   Fredrick, Thomas W.
   Gantner, Marin L.
   Meng, Steven
   Fu, Zhongjie
   Gong, Yan
   Kinter, Michael
   Humphries, Kenneth M.
   Szweda, Luke I.
   Smith, Lois E. H.
   Ma, Jian-xing
TI PPARa is essential for retinal lipid metabolism and neuronal survival
SO BMC BIOLOGY
LA English
DT Article
DE Age-related macular degeneration; Retina; Neurodegeneration; Retinal
   energy metabolism; Mitochondria; Lipids; Fatty acid oxidation
ID GLUCOSE-METABOLISM; ENERGY-METABOLISM; DOWN-REGULATION; ALPHA; AGE;
   DEGENERATION; ISOMEROHYDROLASE; MITOCHONDRIA; DYSFUNCTION; RPE65
AB Background: Peroxisome proliferator activated receptor-alpha (PPARa) is a ubiquitously expressed nuclear receptor. The role of endogenous PPARa in retinal neuronal homeostasis is unknown. Retinal photoreceptors are the highest energy-consuming cells in the body, requiring abundant energy substrates. PPARa is a known regulator of lipid metabolism, and we hypothesized that it may regulate lipid use for oxidative phosphorylation in energetically demanding retinal neurons.
   Results: We found that endogenous PPARa is essential for the maintenance and survival of retinal neurons, with Ppara(-/-)mice developing retinal degeneration first detected at 8 weeks of age. Using extracellular flux analysis, we identified that PPARa mediates retinal utilization of lipids as an energy substrate, and that ablation of PPARa ultimately results in retinal bioenergetic deficiency and neurodegeneration. This may be due to PPARa regulation of lipid transporters, which facilitate the internalization of fatty acids into cell membranes and mitochondria for oxidation and ATP production.
   Conclusion: We identify an endogenous role for PPARa in retinal neuronal survival and lipid metabolism, and furthermore underscore the importance of fatty acid oxidation in photoreceptor survival. We also suggest PPARa as a putative therapeutic target for age-related macular degeneration, which may be due in part to decreased mitochondrial efficiency and subsequent energetic deficits.
C1 [Pearsall, Elizabeth A.; Fredrick, Thomas W.; Meng, Steven; Fu, Zhongjie; Gong, Yan; Smith, Lois E. H.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
   [Pearsall, Elizabeth A.; Cheng, Rui; Zhou, Kelu; Takahashi, Yusuke; Matlock, H. Greg; Shin, Younghwa; Ma, Jian-xing] Univ Oklahoma, Dept Physiol, Hlth Sci Ctr, 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.
   [Takahashi, Yusuke; Ma, Jian-xing] Univ Oklahoma, Sect Diabet & Endocrinol, Dept Med, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
   [Vadvalkar, Shraddha S.; Kinter, Michael; Humphries, Kenneth M.; Szweda, Luke I.] Oklahoma Med Res Fdn, Aging & Metab Res Program, Oklahoma City, OK 73104 USA.
   [Gantner, Marin L.] Lowy Med Res Inst, La Jolla, CA 92037 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; Oklahoma Medical Research Foundation
RP Ma, JX (通讯作者)，Univ Oklahoma, Dept Physiol, Hlth Sci Ctr, 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.; Ma, JX (通讯作者)，Univ Oklahoma, Sect Diabet & Endocrinol, Dept Med, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
OI Gong, Yan/0000-0002-4805-0459; FU, ZHONGJIE/0000-0002-8182-2983;
   Pearsall, Elizabeth/0000-0003-1013-6238
FU NIH [T32EY005318, P30AG050911, P20GM104934, HL125625, EY024868,
   EY017017, EY0222275, P91 HD18655, EY012231, EY018659, EY019309, JDRF
   2-SRA-2014-147-Q-R]; JDRF [3-PDF-2014-107-A-N]; Knights Templar Eye
   Foundation; Bernadotte foundation; Lowy Medical Research Institute;
   European Commission FP7 project [305485 PREVENT-ROP];  [NIH EY021725]; 
   [NIH GM103639];  [NIH GM104934]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655, U54HD090255]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY024864,
   P30EY021725, R01EY019309, R01EY018659, R01EY012231, R01EY017017,
   R01EY005318] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [R01HL125625] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM122744, P20GM104934,
   P20GM103639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [P30AG050911] Funding Source: NIH RePORTER
FX This work was supported by NIH T32EY005318 (EAP); JDRF
   3-PDF-2014-107-A-N (RC); Knights Templar Eye Foundation and Bernadotte
   foundation (ZF); NIH P30AG050911 (MK); NIH P20GM104934, NIH HL125625
   (KH); NIH EY024868, EY017017, EY0222275, P91 HD18655, Lowy Medical
   Research Institute, European Commission FP7 project 305485 PREVENT-ROP
   (LEHS); NIH EY012231, EY018659, EY019309, P20GM104934, JDRF
   2-SRA-2014-147-Q-R (JXM), and center grants NIH EY021725, NIH GM103639
   and NIH GM104934.
CR Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Cabezas-Opazo FA, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/509654
   Cahill G F Jr, 1970, N Engl J Med, V282, P668, DOI 10.1056/NEJM197003052821026
   Chen Y, 2013, DIABETES, V62, P261, DOI 10.2337/db11-0413
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Ding XQ, 2009, HUM MOL GENET, V18, P4770, DOI 10.1093/hmg/ddp440
   Houten SM, 2010, J INHERIT METAB DIS, V33, P469, DOI 10.1007/s10545-010-9061-2
   Hu Y, 2013, P NATL ACAD SCI USA, V110, P15401, DOI 10.1073/pnas.1307211110
   Humphries KM, 1998, BIOCHEMISTRY-US, V37, P552, DOI 10.1021/bi971958i
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kamasawa N, 2006, NEUROSCIENCE, V142, P1093, DOI 10.1016/j.neuroscience.2006.08.020
   Kinter CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050016
   Kooragayala K, 2015, INVEST OPHTH VIS SCI, V56, P8428, DOI 10.1167/iovs.15-17901
   Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989
   Li CB, 2001, OPTOMETRY VISION SCI, V78, P425, DOI 10.1097/00006324-200106000-00015
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mao LF, 2015, COMPUT STRUCT BIOTEC, V13, P484, DOI 10.1016/j.csbj.2015.08.002
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Moran E, 2014, INVEST OPHTH VIS SCI, V55, P4568, DOI 10.1167/iovs.13-13127
   Moran EP, 2015, PPAR RES, V2015, DOI 10.1155/2015/595426
   Murray AR, 2013, INVEST OPHTH VIS SCI, V54, P1689, DOI 10.1167/iovs.12-10921
   Perkins GA, 2011, J STRUCT BIOL, V173, P117, DOI 10.1016/j.jsb.2010.06.017
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Sato N, 2015, FRONT AGING NEUROSCI, V7, DOI [10.3339/fnagi.2015,00199, 10.3389/fnagi.2015.00199]
   Seigel GM, 2014, MOL VIS, V20, P301
   Sloane JA, 2000, BRAIN RES, V862, P1, DOI 10.1016/S0006-8993(00)02059-X
   Sun Y, 2015, ARCHAEA, V2015, DOI 10.1155/2015/397924
   Takahashi Y, 2005, FEBS LETT, V579, P5414, DOI 10.1016/j.febslet.2005.09.002
   Vadvalkar SS, 2013, BIOCHEM J, V449, P253, DOI 10.1042/BJ20121038
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Zheng L, 2007, INVEST OPHTH VIS SCI, V48, P361, DOI 10.1167/iovs.06-0510
NR 32
TC 27
Z9 27
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1741-7007
J9 BMC BIOL
JI BMC Biol.
PD NOV 28
PY 2017
VL 15
AR 113
DI 10.1186/s12915-017-0451-x
PG 14
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA FO0TP
UT WOS:000416462000003
PM 29183319
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kuse, Y
   Tsuruma, K
   Kanno, Y
   Shimazawa, M
   Hara, H
AF Kuse, Yoshiki
   Tsuruma, Kazuhiro
   Kanno, Yusuke
   Shimazawa, Masamitsu
   Hara, Hideaki
TI CCR3 Is Associated with the Death of a Photoreceptor Cell-line Induced
   by Light Exposure
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE CCR3; retinal photoreceptors; light damage; in vitro model; retina
ID NF-KAPPA-B; MACULAR DEGENERATION; OXIDATIVE STRESS; DEFICIENT MICE;
   UP-REGULATION; BLUE-LIGHT; APOPTOSIS; DAMAGE; PATHOGENESIS; INFLAMMATION
AB The C-C chemokine receptor type 3 (CCR3) is the receptor for eotaxins (CCL-11, 24, 26), RANTES (CCL-5) and MCP-3 (CCL-7). It was reported that an inhibition of CCR3 by antagonists or antibodies reduces the degree of laser-induced choroidal neovascularization in mice, a model for wet age-related macular degeneration (AMD). Although several chemokine receptors have the potential of reducing the degree of the chronic inflammation in experimental dry AMD, the association of CCR3 remains unknown. The purpose of this study was to determine the role played by CCR3 in the death of 661W cells which are cells of a murine photoreceptor-derived cell line as an in vitro model of dry AMD. The expression of CCR3 was increased in the 661W cells after light exposure. Inhibition of CCR3 reduced the rate of cell death induced by light exposure. A blockade of CCR3 signaling by CCR3 silencing and two kinds of CCR3 antagonists, SB 328437 and SB 297006, reduced the rate of light-induced cell death. In addition, CCR3 inhibition decreased the level of reactive oxygen species and the activation of caspase-3/7 induced by light exposure. These findings indicated that the CCR3 blockade should be considered for the treatment of the dry AMD.
C1 [Kuse, Yoshiki; Tsuruma, Kazuhiro; Kanno, Yusuke; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu, Japan.
C3 Gifu Pharmaceutical University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu, Japan.
EM hidehara@gifu-pu.ac.jp
RI Kuse, Yoshiki/AAB-7445-2021
OI Hara, Hideaki/0000-0003-2046-9001
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Huber MA, 2002, J BIOL CHEM, V277, P1268, DOI 10.1074/jbc.M109358200
   Kanan Y, 2007, INVEST OPHTH VIS SCI, V48, P40, DOI 10.1167/iovs.06-0592
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Lee J, 2006, BRIT J PHARMACOL, V148, P366, DOI 10.1038/sj.bjp.0706728
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Nakanishi T, 2013, J NEUROCHEM, V125, P111, DOI 10.1111/jnc.12116
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   SHAHINFAR S, 1991, CURR EYE RES, V10, P47, DOI 10.3109/02713689109007610
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Wang HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157748
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wu JM, 2002, INVEST OPHTH VIS SCI, V43, P3349
   Wu TH, 2002, INVEST OPHTH VIS SCI, V43, P2834
   Yang LP, 2007, INVEST OPHTH VIS SCI, V48, P4766, DOI 10.1167/iovs.06-0871
   Zeng HY, 2011, CURR EYE RES, V36, P264, DOI 10.3109/02713683.2010.535133
   Zhang JM, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0185-16.2016
NR 30
TC 12
Z9 14
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 18
PY 2017
VL 8
AR 207
DI 10.3389/fphar.2017.00207
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ES7ZQ
UT WOS:000399770300001
PM 28458639
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zetterlund, C
   Richter, HO
   Lundqvist, LO
AF Zetterlund, Christina
   Richter, Hans Olof
   Lundqvist, Lars-Olov
TI Visual, Musculoskeletal, and Balance Complaints in AMD: A Follow-Up
   Study
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; MACULAR DEGENERATION; OLDER-ADULTS; LOW-VISION; NECK
   PAIN; AGE; IMPAIRMENT; IMPACT; RELIABILITY; STRATEGIES
AB Purpose. To investigate whether patients with age-related macular degeneration (AMD) run a potentially higher risk of developing visual, musculoskeletal, and balance complaints than age-matched controls with normal vision. Methods. Visual assessments, self-rated visual function, self-rated visual, musculoskeletal, and balance complaints, and perceived general health were obtained in 37 AMD patients and 18 controls, at baseline and after an average of 3.8 years later. Results. At follow-up both groups reported decreased visual acuity (VA) and visual function, but only AMD patients reported significantly increased visual, musculoskeletal, and balance complaints. Decreased VA, need for larger font size when reading, need for larger magnification, and decreased self-rated visual function were identified as risk markers for increased complaints in AMD patients. These complaints were also identified as risk markers for decreased health. For controls, decreased VA and self-reported visual function were associated with increased visual and balance complaints. Conclusions. Visual deterioration was a risk marker for increased visual, musculoskeletal, balance, and health complaints in AMD patients. Specifically, magnifying visual aids, such as CCTV, were a risk marker for increased complaints in AMD patients. This calls for early and coordinated actions to treat and prevent visual, musculoskeletal, balance, and health complaints in AMD patients.
C1 [Zetterlund, Christina] Region Orebro Cty, Low Vis Ctr, Orebro, Sweden.
   [Zetterlund, Christina; Lundqvist, Lars-Olov] Univ Orebro, Fac Med & Hlth, Univ Hlth Care Res Ctr, Orebro, Sweden.
   [Zetterlund, Christina] Univ Orebro, Sch Hlth & Med Sci, Orebro, Sweden.
   [Richter, Hans Olof] Univ Gavle, Fac Hlth & Occupat Studies, Dept Occupat & Publ Hlth Sci, Ctr Musculoskeletal Res, Gavle, Sweden.
C3 Orebro University; Orebro University; University of Gavle
RP Zetterlund, C (通讯作者)，Region Orebro Cty, Low Vis Ctr, Orebro, Sweden.; Zetterlund, C (通讯作者)，Univ Orebro, Fac Med & Hlth, Univ Hlth Care Res Ctr, Orebro, Sweden.; Zetterlund, C (通讯作者)，Univ Orebro, Sch Hlth & Med Sci, Orebro, Sweden.
EM christina.zetterlund@regionorebrolan.se
RI Lundqvist, Lars-Olov/M-8547-2014
OI Lundqvist, Lars-Olov/0000-0002-6703-7575; zetterlund,
   christina/0000-0002-6364-2145
FU Research Committee of Region Orebro County
FX The authors are grateful to all participants for their participation in
   the study. They thank the Research Committee of Region Orebro County for
   financial support. They also thank Dr. Hans Hogberg, University of
   Gavle, for statistical support.
CR Anshel Jeffrey R, 2007, AAOHN J, V55, P414
   Bowers A, 2007, OPTOMETRY VISION SCI, V84, P9, DOI 10.1097/01.opx.0000254035.39055.05
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Dagnelie G, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12934
   Dev MK, 2014, CURR EYE RES, V39, P232, DOI 10.3109/02713683.2013.838973
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Holmberg C, 2014, CLIN INTERV AGING, V9, P403, DOI 10.2147/CIA.S54249
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jager R. D., 2008, NEW ENGL J MED, V358, P2544
   Johnston Alan W, 2003, Clin Exp Optom, V86, P403
   Kodjebacheva G, 2010, AM J OPHTHALMOL, V149, P330, DOI 10.1016/j.ajo.2009.09.008
   KRUEGER H, 1989, ERGONOMICS, V32, P785, DOI 10.1080/00140138908966842
   Latham K, 2012, OPTOMETRY VISION SCI, V89, P1316, DOI 10.1097/OPX.0b013e31825bff1c
   Lee EKO, 2006, HEALTH SOC WORK, V31, P289, DOI 10.1093/hsw/31.4.289
   Lee HKM, 2003, AGE AGEING, V32, P643, DOI 10.1093/ageing/afg110
   Long J, 2014, WORK, V47, P419, DOI 10.3233/WOR-141820
   Lord SR, 2006, AGE AGEING, V35, P42, DOI 10.1093/ageing/afl085
   Lovie-Kitchin J, 2011, CLIN EXP OPTOM, V94, P121, DOI 10.1111/j.1444-0938.2010.00565.x
   Lundqvist LO, 2016, OPTOMETRY VISION SCI, V93, P1147, DOI 10.1097/OPX.0000000000000902
   Lundqvist LO, 2014, ARCH PHYS MED REHAB, V95, P1656, DOI 10.1016/j.apmr.2014.05.013
   Macnaughton J., 2009, EYE ESSENTIALS LOW V
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   McPartland JM, 1997, J MANIP PHYSIOL THER, V20, P24
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mon-Williams M, 1999, J EXP PSYCHOL-APPL, V5, P35, DOI 10.1037/1076-898X.5.1.35
   Naz I, 2010, J BACK MUSCULOSKELET, V23, P143, DOI 10.3233/BMR-2010-0263
   Radvay X, 2007, J VESTIBUL RES-EQUIL, V17, P183
   Ray CT, 2008, GAIT POSTURE, V28, P58, DOI 10.1016/j.gaitpost.2007.09.010
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Richter H. O., 2007, SCANDINAVIAN J WOR S, V33, P60
   Richter HO, 2014, WORK, V47, P413, DOI 10.3233/WOR-131776
   Roos PE, 2013, HUM MOVEMENT SCI, V32, P984, DOI 10.1016/j.humov.2013.07.001
   Rosenberg EA, 2008, AM FAM PHYSICIAN, V77, P1431
   Salonen L, 2012, CURR GERONTOL GERIAT, V2012
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Twisk JWR, 2004, EUR J EPIDEMIOL, V19, P769, DOI 10.1023/B:EJEP.0000036572.00663.f2
   Willis JR, 2013, JAMA OPHTHALMOL, V131, P1049, DOI 10.1001/jamaophthalmol.2013.316
   Woodhouse A, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1326-5
   Yahia A., 2009, Annals of Physical and Rehabilitation Medicine, V52, P556, DOI 10.1016/j.rehab.2009.07.033
   Zetterlund C., 2009, J OPTOMETRY, V2, P127, DOI [DOI 10.3921/joptom.2009.127, 10.3921/joptom.2009.127]
NR 42
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 2707102
DI 10.1155/2016/2707102
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EA7LX
UT WOS:000386813600001
PM 27830084
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Chan, N
   He, SK
   Spee, CK
   Ishikawa, K
   Hinton, DR
AF Chan, Nymph
   He, Shikun
   Spee, Christine K.
   Ishikawa, Keijiro
   Hinton, David R.
TI Attenuation of Choroidal Neovascularization by Histone Deacetylase
   Inhibitor
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; HYPOXIA-INDUCIBLE
   FACTOR-1-ALPHA; MACULAR DEGENERATION; RETINAL NEOVASCULARIZATION;
   MESENCHYMAL TRANSITION; IN-VITRO; PROGENITOR CELLS; FACTOR RECEPTORS;
   TISSUE-FIBROSIS
AB Choroidal neovascularization (CNV) is a blinding complication of age-related macular degeneration that manifests as the growth of immature choroidal blood vessels through Bruch's membrane, where they can leak fluid or hemorrhage under the retina. Here, we demonstrate that the histone deacetylase inhibitor (HDACi) trichostatin A (TSA) can down-regulate the pro-angiogenic hypoxia-inducible factor-1 alpha and vascular endothelial growth factor (VEGF), and up-regulate the anti-angiogenic and neuro-protective pigment epithelium derived factor in human retinal pigment epithelial (RPE) cells. Most strikingly, TSA markedly down-regulates the expression of VEGF receptor-2 in human vascular endothelial cells and, thus, can knock down pro-angiogenic cell signaling. Additionally, TSA suppresses CNV-associated wound healing response and RPE epithelial-mesenchymal transdifferentiation. In the laser-induced model of CNV using C57Bl/6 mice, systemic administration of TSA significantly reduces fluorescein leakage and the size of CNV lesions at post-laser days 7 and 14 as well as the immunohistochemical expression of VEGF, VEGFR2, and smooth muscle actin in CNV lesions at post-laser day 7. This report suggests that TSA, and possibly HDACi's in general, should be further evaluated for their therapeutic potential for the treatment of CNV.
C1 [Chan, Nymph; He, Shikun; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [He, Shikun; Spee, Christine K.; Ishikawa, Keijiro; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Chan, Nymph] Doheny Eye Inst, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   Doheny Eye Institute
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
EM dhinton@med.usc.edu
FU Arnold and Mabel Beckman Foundation; National Institutes of Health
   [EY01545]; National Institutes of Health Core grants [EY003040,
   P30CA014089]; NATIONAL EYE INSTITUTE [R01EY001545] Funding Source: NIH
   RePORTER
FX This work was supported by a grant from the Arnold and Mabel Beckman
   Foundation to the Doheny Eye Institute (DRH, NC), National Institutes of
   Health Grant EY01545 (DRH) and National Institutes of Health Core grants
   EY003040 (DRH) and P30CA014089 (DRH). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Aurora AB, 2010, BLOOD, V116, P475, DOI 10.1182/blood-2009-07-232132
   Bartok B, 2014, J IMMUNOL, V192, P2063, DOI 10.4049/jimmunol.1300950
   Bergersen L, 1999, NEUROSCIENCE, V90, P319, DOI 10.1016/S0306-4522(98)00427-8
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Browning AC, 2005, BRIT J OPHTHALMOL, V89, P1343, DOI 10.1136/bjo.2004.063602
   Bruderer M, 2013, J VASC RES, V50, P265, DOI 10.1159/000353287
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chou CW, 2008, FEBS LETT, V582, P4059, DOI 10.1016/j.febslet.2008.10.048
   Codd R, 2009, INT J BIOCHEM CELL B, V41, P736, DOI 10.1016/j.biocel.2008.05.026
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108
   Dutta D, 2010, J BIOL CHEM, V285, P41567, DOI 10.1074/jbc.M110.190025
   ELNER VM, 1990, AM J PATHOL, V136, P745
   Fan J, 2013, INVEST OPHTH VIS SCI, V54, P4072, DOI 10.1167/iovs.12-11529
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Fong GH, 2009, J MOL MED-JMM, V87, P549, DOI 10.1007/s00109-009-0458-z
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8
   Gamulescu MA, 2006, EXP EYE RES, V83, P212, DOI 10.1016/j.exer.2005.12.007
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Geng H, 2012, J BIOL CHEM, V287, P35496, DOI 10.1074/jbc.M112.400697
   Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055
   Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200
   GRIERSON I, 1994, EYE, V8, P255, DOI 10.1038/eye.1994.54
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   He PM, 1998, BIOCHEM BIOPH RES CO, V249, P253, DOI 10.1006/bbrc.1998.9087
   He SK, 2005, INVEST OPHTH VIS SCI, V46, P4772, DOI 10.1167/iovs.05-0502
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158
   Huang J, 2014, MOL CELL BIOCHEM, V390, P115, DOI 10.1007/s11010-014-1962-1
   Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005
   Iordache F, 2012, INT J MOL SCI, V13, P15074, DOI 10.3390/ijms131115074
   IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Kim JY, 2009, EPIGENETICS-US, V4, P313, DOI 10.4161/epi.4.5.9160
   Kim JH, 2009, MOL PHARMACEUT, V6, P513, DOI 10.1021/mp800178b
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Ogata N, 2001, GRAEF ARCH CLIN EXP, V239, P87, DOI 10.1007/s004170000235
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Park JH, 2008, BIOCHEM BIOPH RES CO, V368, P318, DOI 10.1016/j.bbrc.2008.01.056
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598
   Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540
   Qin L, 2010, AM J PATHOL, V177, P1915, DOI 10.2353/ajpath.2010.100011
   Recalde S, 2011, INVEST OPHTH VIS SCI, V52, P7090, DOI 10.1167/iovs.11-7300
   Rossig L, 2005, J EXP MED, V201, P1825, DOI 10.1084/jem.20042097
   Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151
   Ruchko MV, 2009, FREE RADICAL BIO MED, V46, P352, DOI 10.1016/j.freeradbiomed.2008.09.038
   Saika Shizuya, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P69, DOI 10.2174/187153008783928343
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200
   Sasakawa Y, 2003, BIOCHEM PHARMACOL, V66, P897, DOI 10.1016/S0006-2952(03)00411-8
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   SUGASAWA K, 1994, CELL STRUCT FUNCT, V19, P21, DOI 10.1247/csf.19.21
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tandon A, 2012, J REFRACT SURG, V28, P285, DOI 10.3928/1081597X-20120210-01
   TANIWAKI T, 1995, J NEUROCHEM, V64, P2509
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Vaissiere T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Viemann D, 2006, J LEUKOCYTE BIOL, V80, P174, DOI 10.1189/jlb.0905530
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang QE, 2013, NUCLEIC ACIDS RES, V41, P1722, DOI 10.1093/nar/gks1312
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Xiao W, 2014, J CELL MOL MED, V18, P646, DOI 10.1111/jcmm.12212
   Yao QY, 2014, BLOOD, V123, P2429, DOI 10.1182/blood-2013-06-508689
   Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zgouras D, 2004, BIOCHEM BIOPH RES CO, V316, P693, DOI 10.1016/j.bbrc.2004.02.105
   ZHANG NL, 1993, INVEST OPHTH VIS SCI, V34, P2412
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
NR 99
TC 17
Z9 18
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2015
VL 10
IS 3
AR e0120587
DI 10.1371/journal.pone.0120587
PG 32
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CE5MO
UT WOS:000351880000087
PM 25807249
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fleetwood, F
   Klint, S
   Hanze, M
   Gunneriusson, E
   Frejd, FY
   Stah, S
   Lofblom, J
AF Fleetwood, Filippa
   Klint, Susanne
   Hanze, Martin
   Gunneriusson, Elin
   Frejd, Fredrik Y.
   Stah, Stefan
   Lofblom, John
TI Simultaneous targeting of two ligand-binding sites on VEGFR2 using
   biparatopic Affibody molecules results in dramatically improved affinity
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANTITUMOR-ACTIVITY; TUMOR PROGRESSION;
   SURFACE DISPLAY; ANGIOGENESIS; CANCER; INHIBITOR; SELECTION; PROTEIN;
   DOMAIN
AB Angiogenesis plays an important role in cancer and ophthalmic disorders such as age-related macular degeneration and diabetic retinopathy. The vascular endothelial growth factor (VEGF) family and corresponding receptors are regulators of angiogenesis and have been much investigated as therapeutic targets. The aim of this work was to generate antagonistic VEGFR2-specific affinity proteins having adjustable pharmacokinetic properties allowing for either therapy or molecular imaging. Two antagonistic Affibody molecules that were cross-reactive for human and murine VEGFR2 were selected by phage and bacterial display. Surprisingly, although both binders independently blocked VEGF-A binding, competition assays revealed interaction with non-overlapping epitopes on the receptor. Biparatopic molecules, comprising the two Affibody domains, were hence engineered to potentially increase affinity even further through avidity. Moreover, an albumin-binding domain was included for half-life extension in future in vivo experiments. The best-performing of the biparatopic constructs demonstrated up to 180-fold slower dissociation than the monomers. The new Affibody constructs were also able to specifically target VEGFR2 on human cells, while simultaneously binding to albumin, as well as inhibit VEGF-induced signaling. In summary, we have generated small antagonistic biparatopic Affibody molecules with high affinity for VEGFR2, which have potential for both future therapeutic and diagnostic purposes in angiogenesis-related diseases.
C1 [Fleetwood, Filippa; Hanze, Martin; Stah, Stefan; Lofblom, John] AlbaNova Univ Ctr, KTH Royal Inst Technol, Sch Biotechnol, Div Prot Technol, S-10691 Stockholm, Sweden.
   [Klint, Susanne; Gunneriusson, Elin; Frejd, Fredrik Y.] Affibody AB, S-17163 Solna, Sweden.
   [Frejd, Fredrik Y.] Uppsala Univ, Unit Biomed Radiat Sci, Uppsala, Sweden.
C3 Royal Institute of Technology; Uppsala University
RP Lofblom, J (通讯作者)，AlbaNova Univ Ctr, KTH Royal Inst Technol, Sch Biotechnol, Div Prot Technol, S-10691 Stockholm, Sweden.
EM lofblom@kth.se
OI Lofblom, John/0000-0001-9423-0541
FU Swedish Foundation for Strategic Research [RBa08-0067]; Swedish Research
   Council
FX This study was financially supported by the Swedish Foundation for
   Strategic Research (RBa08-0067) and the Swedish Research Council
   (2012-9975). Members of the Sel-tag Imaging Project (Q. Cheng, H.
   Wallberg, K. Johansson, H-S. Ahlzen, ESJ. Arner, H. Lindberg, L. Lu,
   J-O. Thorell, E. Samen, M. Hagg, S. Linder, S. Nilsson, J. Grafstrom and
   S. Stone-Elander) are acknowledged for contributing to the experimental
   design and giving scientific advice.
CR Behdani M, 2013, NEW BIOTECHNOL, V30, P205, DOI 10.1016/j.nbt.2012.09.002
   Brozzo MS, 2012, BLOOD, V119, P1781, DOI 10.1182/blood-2011-11-390922
   Choe YS, 2007, CURR PHARM DESIGN, V13, P17
   Choi HJ, 2013, MOL CANCER THER, V12, P2748, DOI 10.1158/1535-7163.MCT-13-0628
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gagner JP, 2005, BRAIN PATHOL, V15, P342
   Gronwall C, 2007, J BIOTECHNOL, V128, P162, DOI 10.1016/j.jbiotec.2006.09.013
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   He KF, 2012, ONCOTARGETS THER, V5, P59, DOI 10.2147/OTT.S29719
   Jonsson A, 2008, PROTEIN ENG DES SEL, V21, P515, DOI 10.1093/protein/gzn028
   Kontermann RE, 2011, CURR OPIN BIOTECH, V22, P868, DOI 10.1016/j.copbio.2011.06.012
   Kronqvist N, 2008, PROTEIN ENG DES SEL, V21, P247, DOI 10.1093/protein/gzm090
   Kronqvist N, 2011, PROTEIN ENG DES SEL, V24, P385, DOI 10.1093/protein/gzq118
   LaFleur DW, 2013, MABS-AUSTIN, V5, P208, DOI 10.4161/mabs.23043
   Lofblom J, 2007, J APPL MICROBIOL, V102, P736, DOI 10.1111/j.1365-2672.2006.03127.x
   Lofblom J, 2010, FEBS LETT, V584, P2670, DOI 10.1016/j.febslet.2010.04.014
   Lu D, 2003, J BIOL CHEM, V278, P43496, DOI 10.1074/jbc.M307742200
   Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634
   Malm M, 2014, BIOTECHNOL J, V9, P1215, DOI 10.1002/biot.201400009
   Malm M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062791
   Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192
   Olafsen T, 2010, SEMIN NUCL MED, V40, P167, DOI 10.1053/j.semnuclmed.2009.12.005
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Orlova A, 2006, CANCER RES, V66, P4339, DOI 10.1158/0008-5472.CAN-05-3521
   Orlova A, 2013, J NUCL MED, V54, P961, DOI 10.2967/jnumed.112.110700
   Orlova A, 2010, EUR J NUCL MED MOL I, V37, P260, DOI 10.1007/s00259-009-1268-9
   Papo N, 2011, P NATL ACAD SCI USA, V108, P14067, DOI 10.1073/pnas.1016635108
   Polverino A, 2006, CANCER RES, V66, P8715, DOI 10.1158/0008-5472.CAN-05-4665
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Price SJ, 2011, BRIT J RADIOL, V84, pS159, DOI 10.1259/bjr/26838774
   Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006
   Sessa C, 2008, NAT CLIN PRACT ONCOL, V5, P378, DOI 10.1038/ncponc1150
   Shen JQ, 2006, J BIOL CHEM, V281, P10706, DOI 10.1074/jbc.M513415200
   Sorensen J, 2014, J NUCL MED, V55, P730, DOI 10.2967/jnumed.113.131243
   Sullivan LA, 2010, MABS-AUSTIN, V2, P165, DOI 10.4161/mabs.2.2.11360
   Thiel MA, 2013, OPHTHALMOLOGY, V120, P1403, DOI 10.1016/j.ophtha.2012.12.015
   Tolcher AW, 2011, CLIN CANCER RES, V17, P363, DOI 10.1158/1078-0432.CCR-10-1411
   Tolmachev V, 2010, EUR J NUCL MED MOL I, V37, P613, DOI 10.1007/s00259-009-1283-x
   Tugues S, 2011, MOL ASPECTS MED, V32, P88, DOI 10.1016/j.mam.2011.04.004
   Wallberg H, 2008, CANCER BIOTHER RADIO, V23, P435, DOI 10.1089/cbr.2008.0464
   Wallberg H, 2010, MOL IMAGING BIOL, V12, P54, DOI 10.1007/s11307-009-0238-8
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Yu FF, 2014, MABS-AUSTIN, V6, P1598, DOI 10.4161/mabs.36089
NR 45
TC 24
Z9 26
U1 1
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 17
PY 2014
VL 4
AR 7518
DI 10.1038/srep07518
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AW6UR
UT WOS:000346404200002
PM 25515662
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Wu, YL
   Jin, QX
   Yao, K
   Zhao, JL
   Chen, JM
   Wu, XD
   Gan, LS
   Li, J
   Song, XH
   Liu, X
   Cai, XH
AF Wu, Yalin
   Jin, Qiuxia
   Yao, Ke
   Zhao, Junli
   Chen, Jingmeng
   Wu, Xiaodan
   Gan, Lishe
   Li, Jie
   Song, Xiaohui
   Liu, Xin
   Cai, Xianhui
TI Retinal metabolism in humans induces the formation of an unprecedented
   lipofuscin fluorophore 'pdA2E'
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE fluorophore; lipofuscin; pdA2E; retinal metabolism; retinal pigment
   epithelium; singlet oxygen
ID PIGMENT EPITHELIAL-CELLS; LIGHT-INDUCED DAMAGE; MACULAR DEGENERATION;
   STARGARDTS-DISEASE; TRANS; A2E; RPE; MODEL; MICE; IDENTIFICATION
AB Toxic lipofuscin in the RPE (retinal pigment epithelium) is implicated in blindness in AMD (age-related macular degeneration) or recessive Stargardt's disease patients. In the present study, we identified a novel fluorescent lipofuscin component in human and bovine RPEs. Using 1D and 2D NMR and MS, we confirmed the structure of this pigment and called it pdA2E. It exhibits absorbance maxima at 492 and 342 nm, and is susceptible to photocatalytic isomerization and oxidation. This fluorophore was also detected in the eyecup extracts of Abca4(-/-) Rdh8(-/-) (Abca4 encodes ATP-binding cassette transporter 4 and Rdh8 encodes retinol dehydrogenase 8) mice, an AMD/recessive Stargardt's disease model. Excess amassing of pdA2E within RPE cells caused significant cell viability loss and membrane damage. The formation of pdA2E occurred when atRAL (all-trans-retinal) reacted with excess ethanolamine in the absence of acetic acid, and the process is likely to involve the participation of three atRAL molecules. Our findings suggest that endogenous pdA2E may serve as a sensitizer for yielding singlet oxygen and a singlet oxygen quencher, as well as a by-product of retinal metabolism, and its complete characterization facilitates the understanding of biosynthetic pathways by which adverse RPE lipofuscin constituents form.
C1 [Wu, Yalin; Jin, Qiuxia; Zhao, Junli; Gan, Lishe; Li, Jie; Cai, Xianhui] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Wu, Yalin; Yao, Ke; Song, Xiaohui; Liu, Xin] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Eye Ctr, Hangzhou 310009, Zhejiang, Peoples R China.
   [Chen, Jingmeng] Zhejiang Univ City Coll, Sch Med, Hangzhou 310015, Zhejiang, Peoples R China.
   [Wu, Xiaodan] Zhejiang Univ, Ctr Anal & Measurement, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University City
   College; Zhejiang University
RP Wu, YL (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
EM yalinw@zju.edu.cn
RI Zhao, Junli/ABF-9729-2022; Yao, Ke/AAM-6866-2021; Zhao,
   Junli/T-3893-2019
OI Zhao, Junli/0000-0003-4751-3172; Li, Jie/0000-0001-5463-3995; Yao,
   Ke/0000-0002-6764-7365
FU National Science Foundation of the People's Republic of China [21202146,
   81271018]; Zhejiang University K.P. Chaos High Technology Development
   Foundation [2013RC025]; Fundamental Research Funds for the Central
   Universities; Zhejiang Key Laboratory Funds of China [2011E10006];
   Zhejiang Key Innovation Team Project of China [2009R50039]; Project of
   National Clinical Key Discipline of the Chinese Ministry of Health
FX This work is supported in part by the National Science Foundation of the
   People's Republic of China [grant numbers 21202146 and 81271018],
   Zhejiang University K.P. Chaos High Technology Development Foundation
   [grant number 2013RC025] and the Fundamental Research Funds for the
   Central Universities. K.Y. is grateful for support from the Zhejiang Key
   Laboratory Funds of China [grant number 2011E10006], the Zhejiang Key
   Innovation Team Project of China [grant number 2009R50039] and the
   Project of National Clinical Key Discipline of the Chinese Ministry of
   Health.
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Berchuck JE, 2013, INVEST OPHTH VIS SCI, V54, P2669, DOI 10.1167/iovs.12-11020
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Li J, 2013, J BIOL CHEM, V288, P35671, DOI 10.1074/jbc.M113.511386
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   LIU RSH, 1982, METHOD ENZYMOL, V88, P506
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Molday RS, 2006, ADV EXP MED BIOL, V572, P465
   Pang JJ, 2005, MOL VIS, V11, P152
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Rando RR, 1996, CHEM BIOL, V3, P255, DOI 10.1016/S1074-5521(96)90105-2
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   SCHULTEELTE KH, 1973, HELV CHIM ACTA, V56, P2028, DOI 10.1002/hlca.19730560625
   Sparrow JR, 2010, METHODS MOL BIOL, V652, P315, DOI 10.1007/978-1-60327-325-1_18
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Tsybovsky Y, 2011, BIOCHEMISTRY-US, V50, P6855, DOI 10.1021/bi200774w
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   WADDELL WH, 1977, J AM CHEM SOC, V99, P6457, DOI 10.1021/ja00461a057
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wu YL, 2013, J ZHEJIANG UNIV-SC B, V14, P763, DOI 10.1631/jzus.B1300051
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
NR 37
TC 6
Z9 6
U1 2
U2 28
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD JUN 15
PY 2014
VL 460
BP 343
EP 352
DI 10.1042/BJ20140089
PN 3
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AJ0JD
UT WOS:000337335900003
PM 24712709
DA 2022-11-30
ER

PT J
AU Wu, TH
   Fujihara, M
   Tian, J
   Jovanovic, M
   Grayson, C
   Cano, M
   Gehlbach, P
   Margaron, P
   Handa, JT
AF Wu, Tinghuai
   Fujihara, Masashi
   Tian, Jane
   Jovanovic, Miroslava
   Grayson, Celene
   Cano, Marisol
   Gehlbach, Peter
   Margaron, Philippe
   Handa, James T.
TI Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by
   alteration of cholesterol levels
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE age-related macular degeneration; apolipoprotein B100; basal deposits;
   Bruch's membrane; drusen; retinal pigmented epithelium
ID LOW-DENSITY-LIPOPROTEIN; FATTY-ACID COMPOSITION; STATIN-ASSOCIATED
   PLEIOTROPY; RETINAL-PIGMENT EPITHELIUM; COA REDUCTASE INHIBITORS;
   MACULAR DEGENERATION; BASAL DEPOSITS; BRUCH MEMBRANE; HEPG2 CELLS;
   IN-VITRO
AB Cholesteryl ester rich apolipoprotein B100 (apoB100) lipoproteins accumulate in Bruch's membrane before the development of age-related macular degeneration. It is not known if these lipoproteins come from the circulation or local ocular tissue. Emerging, but incomplete evidence suggests that the retinal pigmented epithelium (RPE) can secrete lipoproteins. The purpose of this investigation was to determine (i) whether human RPE cells synthesize and secrete apoB100, and (ii) whether this secretion is driven by cellular cholesterol, and if so, (iii) whether statins inhibit this response. The established, human derived ARPE-19 cells challenged with 0-0.8 mM oleic acid accumulated cellular cholesterol, but not triglycerides. Oleic acid increased the amount of apoB100 protein recovered from the medium by both western blot analysis and S-35-radiolabeled immunoprecipitation while negative stain electron microscopy showed lipoprotein-like particles. Of nine statins evaluated, lipophilic statins induced HMG-CoA reductase mRNA expression the most. The lipophilic Cerivastatin(5 mu M) reduced cellular cholesterol by 39% and abrogated apoB100 secretion by 3-fold. In contrast, the hydrophilic statin Pravastatin had minimal effect on apoB100 secretion. These data suggest that ARPE-19 cells synthesize and secrete apoB100 lipoproteins, that this secretion is driven by cellular cholesterol, and that statins can inhibit apoB100 secretion by reducing cellular cholesterol.
C1 [Wu, Tinghuai; Fujihara, Masashi; Tian, Jane; Cano, Marisol; Gehlbach, Peter; Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Jovanovic, Miroslava; Grayson, Celene; Margaron, Philippe] QLT Inc, Vancouver, BC, Canada.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Handa, JT (通讯作者)，Smith Bldg,Room 3015,400 N Broadway, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
FU QLT, Inc. [EY14005]; Research to Prevent Blindness (Wilmer Eye
   Institute); NATIONAL EYE INSTITUTE [R01EY014005, R01EY019904] Funding
   Source: NIH RePORTER
FX EY14005 (JTH), a grant from QLT, Inc. (JTH), Robert Bond Welch
   Professorship (JTH), an unrestricted grant from Research to Prevent
   Blindness (Wilmer Eye Institute), and generous gifts from Ric and Sandy
   Forsythe, the Kwok family, the Merlau family, and Aleda Wright.
CR BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959
   Bhakdi S, 1999, ARTERIOSCL THROM VAS, V19, P2348, DOI 10.1161/01.ATV.19.10.2348
   BOREN J, 1994, J BIOL CHEM, V269, P25879
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Davidson MH, 2004, PROG CARDIOVASC DIS, V47, P73, DOI 10.1016/j.pcad.2004.04.007
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   FORTE TM, 1986, METHOD ENZYMOL, V128, P442
   FUNGWE TV, 1994, J LIPID RES, V35, P311
   FUTTERMAN S, 1964, INVEST OPHTH VISUAL, V3, P441
   GOH EH, 1973, BIOCHEM BIOPH RES CO, V55, P382, DOI 10.1016/0006-291X(73)91098-X
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   Hofker MH, 1998, ATHEROSCLEROSIS, V137, P1, DOI 10.1016/S0021-9150(97)00266-9
   Hrboticky N, 1997, BBA-LIPID LIPID MET, V1349, P211, DOI 10.1016/S0005-2760(97)00136-7
   Huff MW, 1997, CURR OPIN LIPIDOL, V8, P138, DOI 10.1097/00041433-199706000-00003
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Ito MK, 2006, PHARMACOTHERAPY, V26, p85S, DOI 10.1592/phco.26.7part2.85S
   Ito MK, 2006, PHARMACOTHERAPY, V26, p98S, DOI 10.1592/phco.26.7part2.98S
   Ito MK, 2006, PHARMACOTHERAPY, V26, p106S
   Kalousova M, 2003, KIDNEY INT, V63, pS62, DOI 10.1046/j.1523-1755.63.s84.19.x
   Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999
   Leszczynska A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008499
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Listenberger LL, 2002, TRENDS CARDIOVAS MED, V12, P134, DOI 10.1016/S1050-1738(02)00152-4
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MARTINEZ M, 1988, J NEUROSCI RES, V20, P484, DOI 10.1002/jnr.490200412
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   McMillian MK, 2001, IN VITRO MOL TOXICOL, V14, P177, DOI 10.1089/109793301753407948
   Miller YI, 2003, CURR OPIN LIPIDOL, V14, P437, DOI 10.1097/00041433-200310000-00004
   Mohammadi A, 1998, ARTERIOSCL THROM VAS, V18, P783, DOI 10.1161/01.ATV.18.5.783
   Pasha MK, 2006, BIOMED CHROMATOGR, V20, P282, DOI 10.1002/bmc.561
   Ramasubbu K, 2008, J AM COLL CARDIOL, V51, P415, DOI 10.1016/j.jacc.2007.10.009
   Rise P, 2005, BIOCHEM PHARMACOL, V69, P1095, DOI 10.1016/j.bcp.2005.01.006
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005
   Sakamoto N, 2007, BLOOD, V110, P501, DOI 10.1182/blood-2007-01-066522
   SEVERS NJ, 1986, LAB INVEST, V55, P295
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   SOMA MR, 1992, TOXICOL LETT, V64-5, P1, DOI 10.1016/0378-4274(92)90167-I
   Sugii S, 2003, J LIPID RES, V44, P1033, DOI 10.1194/jlr.D200036-JLR200
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Thelen KM, 2006, J PHARMACOL EXP THER, V316, P1146, DOI 10.1124/jpet.105.094136
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623
   Uesugi N, 2004, AM J KIDNEY DIS, V44, P224, DOI 10.1053/j.ajkd.2004.04.027
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Vuletic S, 2006, DEMENT GERIATR COGN, V22, P392, DOI 10.1159/000095679
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang Xiang-bing, 2006, Zhongguo Yaolixue Tongbao, V22, P244
   Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3
   Wilcox LJ, 1999, J LIPID RES, V40, P1078
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yokoyama M, 2004, J BIOL CHEM, V279, P4204, DOI 10.1074/jbc.M311995200
   Zhang YL, 2004, J BIOL CHEM, V279, P19362, DOI 10.1074/jbc.M400220200
NR 66
TC 18
Z9 18
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD SEP
PY 2010
VL 114
IS 6
BP 1734
EP 1744
DI 10.1111/j.1471-4159.2010.06884.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 646NQ
UT WOS:000281549600019
PM 20598021
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Martin, PL
   Miller, PE
   Mata, M
   Christian, BJ
AF Martin, Pauline L.
   Miller, Paul E.
   Mata, Marielena
   Christian, Brian J.
TI Ocular Inflammation in Cynomolgus Macaques Following Intravenous
   Administration of a Human Monoclonal Antibody
SO INTERNATIONAL JOURNAL OF TOXICOLOGY
LA English
DT Article
DE ocular inflammation; eye; macaque; monoclonal antibody; angiogenesis
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR;
   SAFETY; ANGIOGENESIS; CNTO-95; INTEGRINS; UVEITIS
AB Angiogenesis is a major component of the pathogenesis of various ocular diseases, including age-related macular degeneration (AMD). CNTO95 is a fully human monoclonal antibody against alpha(nu) integrins that has shown antiangiogenic properties in cynomolgus macaques and rats. Because angiogenesis inhibitors may have the potential to treat AMD, a proof-of-concept study was conducted in a macaque model of laser-induced choroidal neovascularization. In the course of this study, transient, intense anterior chamber ocular inflammation was observed within 24 hours following the first intravitreal or intravenous administration of the human monoclonal antibody. These animals had no outward signs of ocular toxicity or discomfort. Additional ocular safety studies demonstrated that the inflammation following intravenous administration of CNTO95 was not due to a contaminant in the vehicle, not due to endotoxin, and not a nonspecific reaction in the macaques from administration of a human monoclonal antibody. The anterior chamber ocular inflammation noted following the first dose did not recur with subsequent CNTO95 dosing. In repeated-dose toxicology studies, histopathological examination of the eyes revealed no ocular toxicity. The reason for the ocular inflammation following intravenous dosing remains unresolved but may be a secondary manifestation of a first-dose systemic infusion reaction.
C1 [Martin, Pauline L.] Centocor Res & Dev Inc, Dept Toxicol & Invest Pharmacol, Radnor, PA 19087 USA.
   Univ Wisconsin, Comparat Ophthalmol Res Lab, Madison, WI USA.
   Covance Res Labs, Madison, WI USA.
C3 Johnson & Johnson; Johnson & Johnson USA; University of Wisconsin
   System; University of Wisconsin Madison; Covance
RP Martin, PL (通讯作者)，Centocor Res & Dev Inc, Dept Toxicol & Invest Pharmacol, 145 King Prussia Rd, Radnor, PA 19087 USA.
EM Pmarti27@cntus.jnj.com
FU Centocor Research and Development, Inc.
FX The authors acknowledge the many scientists from Covance Research
   Laboratories for their valuable contributions to the ocular studies, the
   scientists from Charles River Research Laboratories for their
   contributions to the general toxicity studies, Lisa Anderson and
   Jennifer Rojko for immunolocalization studies, Renu Vora for CNTO 95
   concentration analysis, Jacqueline Miller and Patricia Barr for study
   coordination, and Marian Nakada, Jeffrey Nemeth, George Treacy, and Uma
   Prabhakar for scientific input and comments. These studies were funded
   by Centocor Research and Development, Inc.
CR Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353
   Caldwelll RB, 2003, DIABETES-METAB RES, V19, P442, DOI 10.1002/dmrr.415
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chen QM, 2008, CLIN EXP METASTAS, V25, P139, DOI 10.1007/s10585-007-9132-4
   Christian BJ, 2003, TOXICOL SCI, V72, P311
   Davis HM, 2004, J CLIN ONCOL, V22, p190S
   Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   FREDDO TF, 1992, INVEST OPHTH VIS SCI, V33, P1642
   Hall WC, 2008, PRECLINICAL SAFETY E, P207
   Haller CA, 2008, CLIN PHARMACOL THER, V84, P624, DOI 10.1038/clpt.2008.158
   Harry Lorraine E., 2003, Birth Defects Research, V69, P363, DOI 10.1002/bdrc.10024
   HOGAN MJ, 1959, AM J OPHTHALMOL, V47, P155, DOI 10.1016/S0002-9394(14)78239-X
   HULTSCH E, 1997, MOD PROBL OPHTHAL, V18, P247
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Martin PL, 2005, CLIN CANCER RES, V11, P6959, DOI 10.1158/1078-0432.CCR-04-2623
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mullamitha SA, 2007, CLIN CANCER RES, V13, P2128, DOI 10.1158/1078-0432.CCR-06-2779
   ODAY S, 2008, PERSPECT MELANOMA, V12, pP64
   Rojko JL, 2008, PRECLINICAL SAFETY E, P241
   ROSENBAUM JT, 1980, NATURE, V286, P611, DOI 10.1038/286611a0
   Tabrizi MA, 2007, DRUG DISCOV TODAY, V12, P540, DOI 10.1016/j.drudis.2007.05.010
   Trikha M, 2004, INT J CANCER, V110, P326, DOI 10.1002/ijc.20116
NR 26
TC 7
Z9 8
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1091-5818
EI 1092-874X
J9 INT J TOXICOL
JI Int. J. Toxicol.
PD JAN-FEB
PY 2009
VL 28
IS 1
BP 5
EP 16
DI 10.1177/1091581809333987
PG 12
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 463IH
UT WOS:000267425000002
PM 19482826
DA 2022-11-30
ER

PT J
AU Iriyama, A
   Fujiki, R
   Inoue, Y
   Takahashi, H
   Tamaki, Y
   Takezawa, S
   Takeyama, K
   Jang, WD
   Kato, S
   Yanagi, Y
AF Iriyama, Aya
   Fujiki, Ryoji
   Inoue, Yuji
   Takahashi, Hidenori
   Tamaki, Yasuhiro
   Takezawa, Shinichiro
   Takeyama, Kenichi
   Jang, Woo-Dong
   Kato, Shigeaki
   Yanagi, Yasuo
TI A2E, a pigment of the lipofuscin of retinal pigment epithelial cells, is
   an endogenous ligand for retinoic acid receptor
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; NUCLEAR RECEPTORS;
   IN-VITRO; ANGIOGENESIS; ACTIVATION; EXPRESSION; VEGF; PATHOGENESIS;
   INHIBITION
AB Lipofuscin contains fluorophores, which represent a biomarker for cellular aging. Although it remains unsubstantiated clinically, experimental results support that the accumulation of lipofuscin is related to an increased risk of choroidal neovascularization due to age-related macular degeneration, a leading cause of legal blindness. Here, we report that a major lipofuscin component, A2E, activates the retinoic acid receptor (RAR). In vitro experiments using luciferase reporter assay, competitional binding assay, analysis of target genes, and chromatin immunoprecipitation (ChIP) assay strongly suggest that A2E is a bona fide ligand for RAR and induces sustained activation of RAR target genes. A2E-induced vascular endothelial growth factor (VEGF) expression in a human retinal pigment epithelial cell line (ARPE-19) and RAR antagonist blocked the up-regulation of VEGF. The conditioned medium of A2E-treated ARPE-19 cells induced tube formation in human umbilical vascular endothelial cells, which was blocked by the RAR antagonist and anti-VEGF antibody. These results suggest that A2E accumulation results in the phenotypic alteration of retinal pigment epithelial cells, predisposing the environment to choroidal neovascularization development. This is mediated through the agonistic function of A2E, at least in part. The results of this study provide a novel potential therapeutic target for this incurable condition.
C1 [Iriyama, Aya; Inoue, Yuji; Takahashi, Hidenori; Tamaki, Yasuhiro; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan.
   [Fujiki, Ryoji; Takezawa, Shinichiro; Takeyama, Kenichi; Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.
   [Jang, Woo-Dong] Yonsei Univ, Coll Sci, Dept Chem, Seoul 120749, South Korea.
C3 University of Tokyo; University of Tokyo; Yonsei University
RP Yanagi, Y (通讯作者)，7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Jang, Woo-Dong/I-7186-2019; Yanagi, Yasuo/AAF-2670-2020; Takahashi,
   Hidenori/H-2945-2019; Yanagi, Yasuo/AAA-5441-2022
OI Jang, Woo-Dong/0000-0002-1281-6037; Takahashi,
   Hidenori/0000-0001-5331-4730; Yanagi, Yasuo/0000-0002-0362-7285
CR Akiyama H, 2002, INVEST OPHTH VIS SCI, V43, P1367
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1982, SCIENCE, V216, P757, DOI 10.1126/science.7079738
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528
   Gaetano C, 2001, CIRC RES, V88, pE38
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200
   Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703
   Kutty RK, 2001, J BIOL CHEM, V276, P2831, DOI 10.1074/jbc.M007421200
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   MAJEWSKI S, 1993, CANCER LETT, V75, P35, DOI 10.1016/0304-3835(93)90204-M
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   PEPPER MS, 1994, J CELL BIOCHEM, V55, P419, DOI 10.1002/jcb.240550403
   Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3
   Saito A, 2007, ENDOCRINOLOGY, V148, P1412, DOI 10.1210/en.2006-0900
   Samuel W, 2001, J BIOL CHEM, V276, P28744, DOI 10.1074/jbc.M103587200
   SARKS SH, 2001, RETINA, P1064
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   WORMALD R, 2000, COCHRANE DB SYST REV, V2
   Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 34
TC 43
Z9 53
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 2
PY 2008
VL 283
IS 18
BP 11947
EP 11953
DI 10.1074/jbc.M708989200
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 293MS
UT WOS:000255340000010
PM 18326047
OA hybrid
DA 2022-11-30
ER

PT J
AU Buysschaert, I
   Carmeliet, P
   Dewerchin, M
AF Buysschaert, I.
   Carmeliet, P.
   Dewerchin, M.
TI Clinical and fundamental aspects of angiogenesis and anti-angiogenesis
SO ACTA CLINICA BELGICA
LA English
DT Article
DE angiogenesis; anti-angiogenesis; ischaemic heart disease; peripheral
   artery occlusive disease; cancer; age-related macular degeneration;
   neurodegeneration
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN;
   DOUBLE-BLIND; FACTOR RECEPTOR; GENE-TRANSFER; TUMOR ANGIOGENESIS;
   CONTROLLED-TRIAL; VEGF; THERAPY; DISEASE
AB Insight into the fundamental physiological mechanisms of blood vessel development and neoformation has led to the discovery of multiple angiogenic growth factors and inhibitors. To date, at least 5 angiogenesis inhibitors are readily available for clinical use, mainly in the treatment of cancers and age-related macular degeneration. More inhibitors are yet to come and the indications for their clinical use are expected to broaden. Conversely, the use of angiogenic stimulators, although initially promising in animal models and in small uncontrolled pilot studies in patients with ischaemic heart disease or peripheral arterial occlusive disease, could thus far not show any convincing therapeutic improvement. Challenges still remain as to which angiogenic factor or combination of factors should be administered and in which form (protein versus gene), and what route and duration of administration should be used. Further clinical perspective might come from the recent identification of vascular endothelial growth factor (VEGF) as a modifier of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), and as a promising therapy in the treatment of ALS in preclinical animal models. This review discusses the different clinical trials of angiogenic inhibitors and stimulators, preceded by some fundamental aspects of angiogenesis, giving the clinician a brief overview of the most relevant angiogenic topics.
C1 Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.
   Katholieke Univ Leuven VIB, Dept Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.
   Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Cardiol, B-3000 Louvain, Belgium.
C3 Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders
   Institute for Biotechnology (VIB); KU Leuven; KU Leuven; University
   Hospital Leuven
RP Dewerchin, M (通讯作者)，Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Herestr 49,Box 912, B-3000 Louvain, Belgium.
EM mieke.dewerchin@med.kuleuven.be
RI Carmeliet, Peter/AAQ-5140-2020
OI Carmeliet, Peter/0000-0001-7961-1821
CR Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baka S, 2006, EXPERT OPIN THER TAR, V10, P867, DOI 10.1517/14728222.10.6.867
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 2004, J INTERN MED, V255, P538, DOI 10.1111/j.1365-2796.2003.01297.x
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Eskens FALM, 2006, EUR J CANCER, V42, P3127, DOI 10.1016/j.ejca.2006.09.015
   Fam NP, 2003, CIRCULATION, V108, P2613, DOI 10.1161/01.CIR.0000102939.04279.75
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grines CL, 2003, J AM COLL CARDIOL, V42, P1339, DOI 10.1016/S0735-1097(03)00988-4
   Hedman M, 2003, CIRCULATION, V107, P2677, DOI 10.1161/01.CIR.0000070540.80780.92
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8
   Kastrup J, 2005, J AM COLL CARDIOL, V45, P982, DOI 10.1016/j.jacc.2004.12.068
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   Lederman RJ, 2002, LANCET, V359, P2053, DOI 10.1016/S0140-6736(02)08937-7
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638
   Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
   Miller KD, 2005, BREAST CANCER RES TR, V94, pS6
   Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   Rajagopalan S, 2003, CIRCULATION, V108, P1933, DOI 10.1161/01.CIR.0000093398.16124.29
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188
   Simons M, 2005, CIRCULATION, V111, P1556, DOI 10.1161/01.CIR.0000159345.00591.8F
   Simons M, 2002, CIRCULATION, V105, P788, DOI 10.1161/hc0802.104407
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stewart DJ, 2006, GENE THER, V13, P1503, DOI 10.1038/sj.gt.3302802
   Storkebaum E, 2005, NAT NEUROSCI, V8, P85, DOI 10.1038/nn1360
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Willett CG, 2005, J CLIN ONCOL, V23, P8136, DOI 10.1200/JCO.2005.02.5635
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 57
TC 11
Z9 12
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1784-3286
EI 2295-3337
J9 ACTA CLIN BELG
JI Acta Clin. Belg.
PD MAY-JUN
PY 2007
VL 62
IS 3
BP 162
EP 169
DI 10.1179/acb.2007.027
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 193SU
UT WOS:000248295700003
PM 17672180
OA Bronze
DA 2022-11-30
ER

PT J
AU Karagiannis, TC
   El-Osta, A
AF Karagiannis, TC
   El-Osta, A
TI RNA interference and potential therapeutic applications of short
   interfering RNAs
SO CANCER GENE THERAPY
LA English
DT Review
DE RNA interference; siRNA; gene silencing; functional genomics;
   therapeutic siRNAs
ID VIRUS TYPE-1 REPLICATION; ABL GENE-EXPRESSION; DOUBLE-STRANDED-RNA;
   VECTOR-BASED RNAI; MAMMALIAN-CELLS; CAENORHABDITIS-ELEGANS;
   MULTIDRUG-RESISTANCE; C-ELEGANS; IN-VIVO; STABLE EXPRESSION
AB RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs - the effector molecules of RNA interference - has had an enormous impact on experimental biology. RNA interference technologies are currently the most widely utilized techniques in functional genomic studies. Furthermore, there is an intense research effort aimed at developing short interfering RNAs for therapeutic purposes. A number of proof-of-principle experiments have demonstrated the clinical potential of appropriately designed short interfering RNAs in various diseases including viral infections, cancer and neurodegenerative disorders. Already, in such a short time from their discovery, Acuity Pharmaceuticals ( August 2004) and Sirna Therapeutics ( September 2004) have filed Investigational New Drug applications with the US FDA to begin clinical trials with modified siRNA molecules in patients with age-related macular degeneration. This review will give a brief overview of the mechanism of RNA interference and applications of the pathway in experimental biology will be discussed. The article will focus on recent developments related to the use of RNA interference technologies in mammalian systems and on potential clinical applications of short interfering RNA-mediated RNA interference.
C1 Baker Med Res Inst, Alfred Med Res & Educ Precinct, Prahran, Vic 3181, Australia.
   Peter MacCallum Canc Ctr, Trescowthick Res Labs, Melbourne, Vic, Australia.
C3 Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center
RP El-Osta, A (通讯作者)，Baker Med Res Inst, Alfred Med Res & Educ Precinct, 2nd Floor,Commercial Rd, Prahran, Vic 3181, Australia.
EM assam.el-osta@baker.edu.au
OI El-Osta, Assam/0000-0003-2969-9137; Karagiannis,
   Tom/0000-0002-9967-1546; El-Osta, Assam/0000-0001-7968-7375
CR Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110
   Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2
   Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34
   Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266
   Braasch DA, 2003, BIOCHEMISTRY-US, V42, P7967, DOI 10.1021/bi0343774
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811
   Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077
   Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798
   Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242
   Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416
   Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4
   Cioca DP, 2003, CANCER GENE THER, V10, P125, DOI 10.1038/sj.cgt.7700544
   CLAYTON J, 2004, NATURE, V431, P599
   Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002
   Cogoni C, 2000, CURR OPIN GENET DEV, V10, P638, DOI 10.1016/S0959-437X(00)00134-9
   Collis SJ, 2003, CANCER RES, V63, P1550
   Davidson BL, 2004, LANCET NEUROL, V3, P145, DOI 10.1016/S1474-4422(04)00678-7
   Dillin A, 2003, P NATL ACAD SCI USA, V100, P6289, DOI 10.1073/pnas.1232238100
   Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7
   GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9
   Gura T, 2000, NATURE, V404, P804, DOI 10.1038/35009245
   Hall J, 2004, NAT REV GENET, V5, P552, DOI 10.1038/nrg1382
   Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757
   Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964
   Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603
   Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715
   Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278
   Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27
   Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100
   Kittler R, 2003, SEMIN CANCER BIOL, V13, P259, DOI 10.1016/S1044-579X(03)00039-7
   Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432-1033.2003.03555.x
   Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476
   Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944
   Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948
   LOVINA CD, 2002, NAT MED, V8, P681
   Lu PY, 2003, CURR OPIN MOL THER, V5, P225
   Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403
   Luo B, 2004, P NATL ACAD SCI USA, V101, P5494, DOI 10.1073/pnas.0400551101
   Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5
   Marwick C, 1998, JAMA-J AM MED ASSOC, V280, P871, DOI 10.1001/jama.280.10.871
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a
   McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824
   Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497
   Moss EG, 2003, NAT CELL BIOL, V5, P771, DOI 10.1038/ncb0903-771
   NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279
   Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104
   Nieth C, 2003, FEBS LETT, V545, P144, DOI 10.1016/S0014-5793(03)00523-4
   Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a
   Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002
   Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370
   Park WS, 2002, NUCLEIC ACIDS RES, V30, P4830, DOI 10.1093/nar/gkf627
   Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505
   Peng Z, 2004, CANCER GENE THER, V11, P707, DOI 10.1038/sj.cgt.7700738
   Reich S, 2003, MOL VIS, V9, P210
   Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539
   Safinya CR, 2001, CURR OPIN STRUC BIOL, V11, P440, DOI 10.1016/S0959-440X(00)00230-X
   Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Sen G, 2004, NAT GENET, V36, P183, DOI 10.1038/ng1288
   Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290
   Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012
   Sioud M, 2004, TRENDS PHARMACOL SCI, V25, P22, DOI 10.1016/j.tips.2003.11.006
   Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038
   Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003
   Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828
   Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599
   Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002
   Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X
   Templeton NS, 2002, BIOSCIENCE REP, V22, P283
   Tsuruo T, 2003, CANCER SCI, V94, P15, DOI 10.1111/j.1349-7006.2003.tb01345.x
   Vastenhouw NL, 2003, CURR BIOL, V13, P1311, DOI 10.1016/s0960-9822(03)00539-6
   Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686
   Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8
   Volm M, 1998, ANTICANCER RES, V18, P2905
   Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140-6736(03)14637-5
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653
   Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003
   Wohlbold L, 2003, BLOOD, V102, P2236, DOI 10.1182/blood-2002-12-3899
   Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739
   Xu D, 2004, MOL PHARMACOL, V66, P268, DOI 10.1124/mol.66.2.268
   Yague E, 2004, GENE THER, V11, P1170, DOI 10.1038/sj.gt.3302269
   Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499
   Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457
   Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100
   Zhang L, 2003, BIOCHEM BIOPH RES CO, V303, P1169, DOI 10.1016/S0006-291X(03)00495-9
   Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740
   Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100
NR 110
TC 93
Z9 133
U1 0
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD OCT
PY 2005
VL 12
IS 10
BP 787
EP 795
DI 10.1038/sj.cgt.7700857
PG 9
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA 964IL
UT WOS:000231873000001
PM 15891770
DA 2022-11-30
ER

PT J
AU Breithaupt, DE
   Schlatterer, J
AF Breithaupt, DE
   Schlatterer, J
TI Lutein and zeaxanthin in new dietary supplements - analysis and
   quantification
SO EUROPEAN FOOD RESEARCH AND TECHNOLOGY
LA English
DT Article
DE lutein; marigold; Tagetes erecta; dietary supplement; high-performance
   liquid chromatography
ID MARIGOLD FLOWERS; MACULAR PIGMENT
AB Lutein and zeaxanthin, two xanthophylls supposed to delay formation of age-related macular degeneration (AMD), are found in numerous new dietary supplements appearing on the international market. Usually, the lutein concentration ranges from 0.25 to 20 mg/serving size. The lutein contents of 14 products with lutein highlighted on the label were evaluated. Oily formulations were dissolved, and powdery capsule contents were extracted with solvents before high-performance liquid chromatography (HPLC) analysis (diode-array detector, 450 nm) using a C30 column. If lutein diesters from marigold (Tagetes erecta) were present, the extracts were saponified with methanolic KOH. To unequivocally identify carotenoids, HPLC-(atmospheric pressure chemical ionization)mass spectrometry was applied. In this study only all-trans-lutein was quantified, whereas cis isomers (approximately 1-5 area% of total lutein) were not taken into account. The lutein concentration of half of the products investigated was found to be below the amount stated, varying here from 11 to 93%. With the exception of one product, all dietary supplements contained zeaxanthin in amounts typical for the use of marigold oleoresin (6.01.4 area% of all-trans-lutein). The high discrepancy found between the amounts labeled and determined in half of the products may be attributed to degradation reactions or to improper storage conditions.
C1 Univ Hohenheim, Inst Lebensmittelchem, D-70599 Stuttgart, Germany.
C3 University Hohenheim
RP Breithaupt, DE (通讯作者)，Univ Hohenheim, Inst Lebensmittelchem, Garbenstr 28, D-70599 Stuttgart, Germany.
EM breithau@uni-hohenheim.de
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Breithaupt DE, 2004, FOOD CHEM, V86, P449, DOI 10.1016/j.foodchem.2003.10.027
   Breithaupt DE, 2002, J AGR FOOD CHEM, V50, P66, DOI 10.1021/jf010970l
   Cisneros M, 2004, J CHROMATOGR B, V807, P105, DOI 10.1016/j.jchromb.2004.01.009
   DelgadoVargas F, 1997, J AGR FOOD CHEM, V45, P1097, DOI 10.1021/jf960474a
   GAZIANO JM, 1995, AM J CLIN NUTR, V61, P1248, DOI 10.1093/ajcn/61.6.1248
   Hadden WL, 1999, J AGR FOOD CHEM, V47, P4189, DOI 10.1021/jf990096k
   HORWITZ W, 2000, RECOVERY STUDIES, P20
   Khachik F, 1999, J AGR FOOD CHEM, V47, P455, DOI 10.1021/jf980823w
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   NEHER RT, 1968, ECON BOT, V22, P317, DOI 10.1007/BF02908126
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Weller P, 2003, J AGR FOOD CHEM, V51, P7044, DOI 10.1021/jf034803s
NR 15
TC 19
Z9 23
U1 0
U2 32
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1438-2377
EI 1438-2385
J9 EUR FOOD RES TECHNOL
JI Eur. Food Res. Technol.
PD MAY
PY 2005
VL 220
IS 5-6
BP 648
EP 652
DI 10.1007/s00217-004-1075-2
PG 5
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 926AE
UT WOS:000229094300033
DA 2022-11-30
ER

PT J
AU Sommer, ME
   Smith, WC
   Farrens, DL
AF Sommer, ME
   Smith, WC
   Farrens, DL
TI Dynamics of arrestin-rhodopsin interactions - Arrestin and retinal
   release are directly linked events
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PROTEIN-COUPLED RECEPTORS; LIGHT-REGULATED BINDING; VISUAL ARRESTIN;
   CONFORMATIONAL-CHANGES; METARHODOPSIN-III; SYNTHETIC PHOSPHOPEPTIDE;
   TRYPTOPHAN RESIDUES; ACTIVATED RHODOPSIN; STRUCTURAL-ANALYSIS; SPLICE
   VARIANT
AB In this study, we address the mechanism of visual arrestin release from light-activated rhodopsin using fluorescently labeled arrestin mutants. We find that two mutants, 172C and S251C, when labeled with the small, solvent-sensitive fluorophore monobromobimane, exhibit spectral changes only upon binding light-activated, phosphorylated rhodopsin. Our analysis indicates that these changes are probably due to a burying of the probes at these sites in the rhodopsin-arrestin or phospholipid-arrestin interface. Using a fluorescence approach based on this observation, we demonstrate that arrestin and retinal release are linked and are described by similar activation energies. However, at physiological temperatures, we find that arrestin slows the rate of retinal release similar to2-fold and abolishes the pH dependence of retinal release. Using fluorescence, EPR, and biochemical approaches, we also find intriguing evidence that arrestin binds to a post-Meta 11 photodecay product, possibly Meta III. We speculate that arrestin regulates levels of free retinal in the rod cell to help limit the formation of damaging oxidative retinal adducts. Such adducts may contribute to diseases like atrophic age-related macular degeneration (AMD). Thus, arrestin may serve to both attenuate rhodopsin signaling and protect the cell from excessive retinal levels under bright light conditions.
C1 Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.
   Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
   Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA.
C3 Oregon Health & Science University; State University System of Florida;
   University of Florida; State University System of Florida; University of
   Florida
RP Farrens, DL (通讯作者)，Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.
EM farrensd@ohsu.edu
RI Smith, W. Clay/AAQ-1589-2021
OI Sommer, Martha E./0000-0003-0493-8584
FU NATIONAL EYE INSTITUTE [R01EY012095] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014896] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY12095, EY06225] Funding Source: Medline; NIDA
   NIH HHS [DA14896] Funding Source: Medline
CR Chuang JZ, 2004, J CLIN INVEST, V114, P131, DOI 10.1172/JCI200421136
   Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5
   Dinculescu A, 2002, J BIOL CHEM, V277, P11703, DOI 10.1074/jbc.M111833200
   Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683
   Elias R, 2004, MOL VIS, V10, P672
   FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073
   FARRENS DL, 1999, REC BIOCH M, P289
   Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821
   Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f
   GINIGER R, 1985, CHEM PHYS LETT, V118, P240, DOI 10.1016/0009-2614(85)85308-2
   Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008
   Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849
   Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200
   Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7
   HOFMANN KP, 1992, J BIOL CHEM, V267, P15701
   Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x
   Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956
   Imamoto Y, 2003, BIOPHYS J, V85, P1186, DOI 10.1016/S0006-3495(03)74554-8
   Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377
   Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9
   KOSOWER EM, 1986, J PHYS CHEM-US, V90, P5552, DOI 10.1021/j100280a014
   KUHN H, 1982, METHOD ENZYMOL, V81, P489
   KUHN H, 1982, METHOD ENZYMOL, V81, P556
   KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389
   Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, V3rd
   Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677
   Lewis JW, 1997, VISION RES, V37, P1, DOI 10.1016/S0042-6989(96)00138-1
   Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200
   Ling Y, 2004, BIOPHYS J, V86, P2445, DOI 10.1016/S0006-3495(04)74301-5
   Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X
   Mansoor SE, 2004, BIOCHEMISTRY-US, V43, P9426, DOI 10.1021/bi036259m
   Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i
   Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p
   Nair KS, 2004, J BIOL CHEM, V279, P41240, DOI 10.1074/jbc.M406768200
   Neyroz P, 1996, J BIOL CHEM, V271, P27249, DOI 10.1074/jbc.271.44.27249
   PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027
   PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649
   Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d
   PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48
   Peterson JJ, 2003, EXP EYE RES, V76, P553, DOI 10.1016/S0014-4835(03)00032-0
   PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X
   Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200
   PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002
   Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g
   Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5
   RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035
   ROSS JBA, 1992, BIOCHEMISTRY-US, V31, P1585, DOI 10.1021/bi00121a002
   Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3
   Sachs K, 2000, METHOD ENZYMOL, V315, P238
   SATO E, 1988, BIOORG CHEM, V16, P298, DOI 10.1016/0045-2068(88)90017-X
   SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052
   Schroder K, 2002, J BIOL CHEM, V277, P43987, DOI 10.1074/jbc.M206211200
   Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186
   Shilton BH, 2002, EUR J BIOCHEM, V269, P3801, DOI 10.1046/j.1432-1033.2002.03071.x
   Smith WC, 2004, MOL VIS, V10, P392
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   STRAUME M, 1992, METHOD ENZYMOL, V210, P87
   Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200
   Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200
   Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+
   Vogel R, 2004, BIOCHEMISTRY-US, V43, P9457, DOI 10.1021/bi049337u
   Wilson CJ, 1997, J PROTEIN CHEM, V16, P755, DOI 10.1023/A:1026311832660
   Zawadzki KM, 2003, PROTEINS, V51, P552, DOI 10.1002/prot.10326
   Zimmermann K, 2004, J BIOL CHEM, V279, P48112, DOI 10.1074/jbc.M406856200
NR 67
TC 62
Z9 63
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 25
PY 2005
VL 280
IS 8
BP 6861
EP 6871
DI 10.1074/jbc.M411341200
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 902DT
UT WOS:000227332700075
PM 15591052
OA hybrid
DA 2022-11-30
ER

PT J
AU Weigel, AL
   Handa, JT
   Hjelmeland, LM
AF Weigel, AL
   Handa, JT
   Hjelmeland, LM
TI Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE cDNA microarray; oxidative stress; RPE cells; H2O2; HNE; tBH; free
   radicals
ID PIGMENT EPITHELIAL-CELLS; ZINC SUPEROXIDE-DISMUTASE; NF-KAPPA-B;
   GENE-EXPRESSION; OXIDATIVE STRESS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION;
   RESPONSIVE ELEMENTS; HEME OXYGENASE-1; REDOX REGULATION
AB Oxidative stress plays a key role in aging diseases of the posterior pole of the eye such as age-related macular degeneration. The oxidative stress response of in vitro RPE cells has been studied for a small number of genes. However, a comprehensive transcriptional response has yet to be elucidated. The purpose of this study was to determine if the transcription of a common set of genes is altered by exposure of ARPE- 19 cells to three major generators of oxidative stress, hydrogen peroxide (H2O2), 4-hydroxynonenal (HNE), and tert-butylhydroperoxide (tBH). As expected, a common response was observed that included 35 genes differentially regulated by all three treatments. Of these, only one gene was upregulated, and only by one oxidant, while all other responses were downregulation. The majority of these genes fell into five functional categories: apoptosis, cell cycle regulation, cell-cell communication, signal transduction, and transcriptional regulation. Additionally, a large number of genes were differentially regulated by one oxidant only, including the majority of the conventional oxidative stress response genes present on the Clontech Human 1.2 microarray. This study raises questions regarding the generality of results that involve the use of a single oxidant and a single cell culture condition. (C) 2002 Elsevier Science Inc.
C1 Univ Calif Davis, Vitreoretinal Res Lab, Dept Mol & Cellular Biol, Davis, CA 95616 USA.
   Johns Hopkins Med Inst, Wilmer Ophthalmol Inst, Michael Panitch Macular Degenerat Res Lab, Baltimore, MD 21205 USA.
   Univ Calif Davis, Dept Ophthalmol, Davis, CA 95616 USA.
C3 University of California System; University of California Davis; Johns
   Hopkins University; Johns Hopkins Medicine; University of California
   System; University of California Davis
RP Hjelmeland, LM (通讯作者)，Univ Calif Davis, Vitreoretinal Res Lab, Dept Mol & Cellular Biol, 2403 Tupper Hall,1 Shields Ave, Davis, CA 95616 USA.
FU NATIONAL EYE INSTITUTE [R01EY014005] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY14005, EY06473] Funding Source: Medline
CR Adachi M, 2000, CLIN CANCER RES, V6, P96
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Alizadeh M, 2000, INVEST OPHTH VIS SCI, V41, P2357
   Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7
   APPLEGATE L, 1999, CANCER RES, V51, P974
   BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216
   BOST LM, 1992, EXP EYE RES, V55, P727, DOI 10.1016/0014-4835(92)90177-T
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chu CY, 1999, ARCH TOXICOL, V73, P263, DOI 10.1007/s002040050615
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Elmlinger MW, 1996, GROWTH REGULAT, V6, P152
   Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0
   Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1
   GAUNTT CD, 1994, INVEST OPHTH VIS SCI, V35, P2916
   Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x
   He Q, 1998, BIOCHEM BIOPH RES CO, V247, P719, DOI 10.1006/bbrc.1998.8845
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2139
   Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339
   Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83
   KUTTY RK, 1994, J CELL PHYSIOL, V159, P371
   Laurent A, 2000, TOXICOL LETT, V114, P203, DOI 10.1016/S0378-4274(99)00301-X
   Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834
   Li J, 2002, J BIOL CHEM, V277, P388, DOI 10.1074/jbc.M109380200
   Li ZK, 2001, FREE RADICAL BIO MED, V30, P260, DOI 10.1016/S0891-5849(00)00468-8
   Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517
   Matsui H, 2001, INVEST OPHTH VIS SCI, V42, P2935
   MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9
   Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046
   Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   PEARSON WR, 1983, J BIOL CHEM, V258, P2052
   PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010
   RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632
   Singhal SS, 1999, INVEST OPHTH VIS SCI, V40, P2652
   Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8
   Takahashi S, 1998, CELL BIOCHEM FUNCT, V16, P183, DOI 10.1002/(SICI)1099-0844(199809)16:3<183::AID-CBF784>3.0.CO;2-0
   Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907
   Tate DJ, 1999, FREE RADICAL BIO MED, V26, P704, DOI 10.1016/S0891-5849(98)00253-6
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Wada M, 2001, CURR EYE RES, V23, P226, DOI 10.1076/ceyr.23.3.226.5467
   Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361
   YIM MB, 1993, J BIOL CHEM, V268, P4099
   YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006
   Yoneda K, 2001, AM J RESP CRIT CARE, V164, pS85, DOI 10.1164/ajrccm.164.supplement_2.2106062
   Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x
   Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697
NR 46
TC 85
Z9 88
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 15
PY 2002
VL 33
IS 10
BP 1419
EP 1432
AR PII S0891-5849(02)01082-1
DI 10.1016/S0891-5849(02)01082-1
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 613JA
UT WOS:000179128100014
PM 12419474
DA 2022-11-30
ER

PT J
AU Lavinsky, F
   Tolentino, MJ
   Lavinsky, J
AF Lavinsky, Fabio
   Tolentino, Micheal John
   Lavinsky, Jaco
TI The macular threshold protocol of the Humphrey visual field analyzer: a
   superior functional outcome of intravitreal bevacizumab for the
   treatment of neovascular age-related macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Tomography, optical; Vitreous body; Visual acuity;
   Perimetry; Injections; Choroidal neovascularisation; Antibodies,
   monoclonal
ID ENDOTHELIAL GROWTH-FACTOR; QUALITY-OF-LIFE; CHOROIDAL
   NEOVASCULARIZATION; IRIS NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   SECONDARY; AVASTIN
AB Purpose: To evaluate the decibel loss on the Macular threshold protocol of the Humphrey visual field as a reliable functional outcome of the intravitreal bevacizumab treatment. Methods: Thirteen patients were evaluated at baseline and on the week 6 for best corrected visual acuity, optical coherence tomography central macular thickness and decibel loss on Macular threshold protocol of the Humphrey visual field after 1.25 mg intravitreal injection of bevacizumab. The outcomes were analyzed separately and in correlation using the Wilcoxon signed ranks test. Results: The improvement of the optical coherence tomography and the Macular threshold protocol of the Humphrey visual field from baseline to week 6 were significant with p=0.032 and p=0.003, respectively. The visual acuity did not show a significant improvement. The correlation of the visual acuity and Macular threshold protocol of the Humphrey visual field was significant at baseline (p=0.041) and on week 6 (p=0.019). Conclusion: The Macular threshold protocol of the Humphrey visual field significantly improved despite the fact that the best corrected visual acuity did not. The Macular threshold protocol of the Humphrey visual field correlated with the visual acuities significantly. The optical coherence tomography was significant to demonstrate improvement but did not correlate with best corrected visual acuity and Macular threshold protocol of the Humphrey visual field. These findings suggest that the Macular threshold protocol of the visual field may be a more reliable tool for evaluation of global macular function after intravitreal bevacizumab treatment.
C1 [Lavinsky, Fabio; Tolentino, Micheal John; Lavinsky, Jaco] Hosp Clin Porto Alegre, Dept Ophthalmol, Porto Alegre, RS, Brazil.
RP Lavinsky, F (通讯作者)，Hacarmel St 8,Apt 22, Ganei Tikva, Israel.
EM ylavinsky@hotmail.com
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P938, DOI 10.1016/j.ajo.2008.02.020
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hofman P, 2000, CURR EYE RES, V21, P637, DOI 10.1076/0271-3683(200008)21:2;1-V;FT637
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Sharma S, 2003, OPHTHALMOLOGY, V110, P627, DOI 10.1016/S0161-6420(02)01871-7
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   SHARMA S, 2003, OPHTHALMOLOGY, V110, P1264
   SHARMA S, 2003, OPHTHALMOLOGY, V110, P1263
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tolentino MJ, 1998, INT OPHTHALMOL CLIN, V38, P77, DOI 10.1097/00004397-199803810-00007
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
NR 24
TC 0
Z9 0
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2010
VL 73
IS 2
BP 111
EP 115
DI 10.1590/S0004-27492010000200002
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 612BQ
UT WOS:000278872200002
PM 20549036
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Hammond, BR
   Renzi-Hammond, LM
AF Hammond, Billy R., Jr.
   Renzi-Hammond, Lisa M.
TI Perspective: A Critical Look at the Ancillary Age-Related Eye Disease
   Study 2: Nutrition and Cognitive Function Results in Older Individuals
   with Age-Related Macular Degeneration
SO ADVANCES IN NUTRITION
LA English
DT Article
DE AREDS; lutein/zeaxanthin; cognition; long-chain polyunsaturated fatty
   acids; aging
ID RANDOMIZED CLINICAL-TRIAL; PIGMENT OPTICAL-DENSITY;
   BASE-LINE-CHARACTERISTICS; ALZHEIMERS-DISEASE; BETA-CAROTENE;
   SUPPLEMENTATION; SMOKING; DECLINE; LUTEIN; BRAIN
AB A large body of literature suggests that the dietary carotenoids lutein and zeaxanthin and long-chain polyunsaturated fatty acids such as docosahexaenoic acid are related to improved cognitive function across the life span. A recent report by the Age-Related Eye Disease Study (AREDS) group appears to contradict the general findings of others in the field. In this review, we look critically at the methods, study designs, and analysis techniques used in the larger body of literature and compare them with the recent AREDS reports.
C1 [Hammond, Billy R., Jr.; Renzi-Hammond, Lisa M.] Univ Georgia, Dept Psychol, Behav & Brain Sci Program, Vis Sci & Human Biofactors Lab, Athens, GA 30602 USA.
C3 University System of Georgia; University of Georgia
RP Hammond, BR (通讯作者)，Univ Georgia, Dept Psychol, Behav & Brain Sci Program, Vis Sci & Human Biofactors Lab, Athens, GA 30602 USA.
EM bhammond@uga.edu
OI Renzi-Hammond, Lisa/0000-0003-4334-8202; Hammond,
   Billy/0000-0002-5762-0206
CR Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Beckett LA, 2015, ALZHEIMERS DEMENT, V11, P823, DOI 10.1016/j.jalz.2015.05.004
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Dai Q, 2006, AM J MED, V119, P751, DOI 10.1016/j.amjmed.2006.03.045
   Dentchev T, 2003, MOL VIS, V9, P184
   DoNR Coordination, 2015, NIH NUTR RES REP
   Elwood P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081877
   Feart C, 2015, J GERONTOL A-BIOL
   Feeney J, 2013, NEUROBIOL AGING, V34, P2449, DOI 10.1016/j.neurobiolaging.2013.05.007
   Hooijmans CR, 2012, J ALZHEIMERS DIS, V28, P191, DOI 10.3233/JAD-2011-111217
   Janson H, 1999, ADDICT BEHAV, V24, P239, DOI 10.1016/S0306-4603(98)00061-6
   Johnson E.J., 2013, J AGING RES
   Johnson EJ, 2008, NUTR NEUROSCI, V11, P75, DOI 10.1179/147683008X301450
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kukull WA, 2001, BIOL PSYCHIAT, V49, P194, DOI 10.1016/S0006-3223(00)01077-5
   LEE PN, 1994, NEUROEPIDEMIOLOGY, V13, P131, DOI 10.1159/000110372
   Loef M, 2012, J NUTR HEALTH AGING, V16, P626, DOI 10.1007/s12603-012-0097-x
   Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Morris MC, 2005, ARCH NEUROL-CHICAGO, V62, P1849, DOI 10.1001/archneur.62.12.noc50161
   Navarro-Meza M, 2014, NUTR NEUROSCI, V17, P260, DOI 10.1179/1476830513Y.0000000089
   Nolan JM, 2015, J ALZHEIMERS DIS, V44, P1157, DOI 10.3233/JAD-142265
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Rankin MW, 2005, OPHTHAL EPIDEMIOL, V12, P271, DOI 10.1080/09286580591003815
   Renzi LM, 2014, NEUROBIOL AGING, V35, P1695, DOI 10.1016/j.neurobiolaging.2013.12.024
   Renzi LM, 2010, OPHTHAL PHYSL OPT, V30, P351, DOI 10.1111/j.1475-1313.2010.00720.x
   Rinaldi P, 2003, NEUROBIOL AGING, V24, P915, DOI 10.1016/S0197-4580(03)00031-9
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Smyth A, 2015, NEUROLOGY, V84, P2258, DOI 10.1212/WNL.0000000000001638
   SULTANA R, 2013, J ALZH DIS SUPPL S1, V33, pS243
   Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
NR 42
TC 3
Z9 3
U1 0
U2 9
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 2161-8313
EI 2156-5376
J9 ADV NUTR
JI Adv. Nutr.
PD MAY
PY 2016
VL 7
IS 3
BP 433
EP 437
DI 10.3945/an.115.011866
PG 5
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA DM2GB
UT WOS:000376163900002
PM 27184270
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Weigert, G
   Michels, S
   Sacu, S
   Varga, A
   Prager, F
   Geitzenauer, W
   Schmidt-Erfurth, U
AF Weigert, G.
   Michels, S.
   Sacu, S.
   Varga, A.
   Prager, F.
   Geitzenauer, W.
   Schmidt-Erfurth, U.
TI Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy
   plus intravitreal triamcinolone for neovascular age-related macular
   degeneration: 6-month results of a prospective, randomised, controlled
   clinical study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; COHERENCE TOMOGRAPHY FINDINGS;
   VERTEPORFIN THERAPY; VISUAL IMPAIRMENT; UNITED-STATES; ACETONIDE;
   INJECTION; RANIBIZUMAB; PREVALENCE
AB Aims: To compare functional and anatomical outcomes of intravitreal bevacizumab (Avastin) and verteporfin (photodynamic) therapy (PDT) combined with intravitreal triamcinolone (IVTA) in patients with neovascular agerelated macular degeneration (AMD).
   Methods: Twenty-eight patients with neovascular AMD were enrolled in a prospective, randomised, controlled clinical trial. All patients randomly assigned to 1 mg intravitreal bevacizumab (0.04 ml) received three initial treatments at 4-week intervals. In further follow-up retreatment was based on optical coherence tomography (OCT). Patients randomly assigned to standard PDT received a same-day intravitreal injection of 4 mg triamcinolone (Kenalog). Retreatment was based on fluorescein angiography at 3-month intervals. Functional and anatomical results were evaluated using the Early Treatment Diabetic Retinopathy Study protocol vision charts, fluorescein angiography and OCT.
   Results: In the bevacizumab-treated group mean visual acuity (VA) improved to a 2.2 line gain at 6 months follow-up. Eyes treated in the PDT plus IVTA group had a stable mean VA at month 6 compared with baseline. There was a statistically significant difference (p = 0.03, analysis of variance (ANOVA)) between both groups as early as one day after initial treatment. The reduction in central retinal thickness (CRT) showed no significant difference between both groups (p = 0.3, ANOVA). Mean CRT was reduced from 357 mm at baseline to 239 mm at month 6 in bevacizumab-treated patients and from 326 mm to 222 mm, respectively, in PDT plus IVTA-treated patients. No significant local or systemic safety concerns were detected up to month 6.
   Conclusion: Intravitreal bevacizumab showed promising 6-month results in patients with neovascular AMD. Functional outcomes appear not only to be dependent on a reduction in CRT but also on the treatment modality used.
C1 [Michels, S.] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Weigert, G.; Michels, S.; Sacu, S.; Varga, A.; Prager, F.; Geitzenauer, W.; Schmidt-Erfurth, U.] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Weigert, G.] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
C3 University of Zurich; University Zurich Hospital; Medical University of
   Vienna; Medical University of Vienna
RP Michels, S (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklinikstr 24, CH-8091 Zurich, Switzerland.
EM stephan.michels@usz.ch
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Rhee DJ, 2006, BRIT J OPHTHALMOL, V90, P999, DOI 10.1136/bjo.2006.090340
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 32
TC 71
Z9 75
U1 0
U2 8
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2008
VL 92
IS 3
BP 356
EP 360
DI 10.1136/bjo.2007.125823
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 274HG
UT WOS:000253991800014
PM 18303156
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Bardak, H
   Uguz, AC
   Bardak, Y
AF Bardak, Handan
   Uguz, Abdulhadi Cihangir
   Bardak, Yavuz
TI Protective effects of melatonin and memantine in human retinal pigment
   epithelium (ARPE-19) cells against 2-ethylpyridine-induced oxidative
   stress: implications for age-related macular degeneration
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE ARPE-19 cells; calcium signalling; caspase-3; caspase-9; melatonin;
   memantine; oxidative stress; vascular endothelial growth factor;
   2-ethylpyridine
ID CIGARETTE-SMOKE; TOXIC COMPONENT; CALCIUM-ENTRY; APOPTOSIS; RAT; GROWTH;
   CHANNELS; SELENIUM; RELEASE; ANGIOGENESIS
AB Purpose: To investigate the possible protective effects of melatonin and memantine (MMT) against 2-ethylpyridine (2-EP)-induced oxidative stress and mitochondrial dysfunction in human RPE (ARPE-19) cells in vitro.Materials and methods: The ARPE-19 cells were divided into seven groups. Oxidative stress was triggered by incubating the ARPE-19 cells with 30M of 2-EP for 24h. Then, 200M of melatonin was administered over three days and 20M of MMT over six hours prior to the experiment. The effects of melatonin and MMT on the intracellular calcium release mechanism, reactive oxygen species production, caspase-3 and caspase-9 activities, as well as vascular endothelial growth factor levels were measured.Results: Melatonin and MMT were found to significantly decrease apoptosis levels. The intracellular calcium release was regulated by both melatonin and MMT. Further, melatonin and MMT significantly decreased both caspase-3 and caspase-9 activities, as well as pro-caspase and poly(ADP-ribose) polymerase expression, in ARPE-19 cells. Moreover, melatonin significantly increased the protective effect of MMT. The combination of melatonin and MMT significantly decreased 2-EP-induced oxidative toxicity and apoptosis by inhibiting the intracellular reactive oxygen species production and mitochondrial depolarization levels.Conclusions: These notable findings are the first to demonstrate the synergistic protective effects of melatonin and MMT against 2-EP-induced oxidative stress in ARPE-19 cells.
C1 [Bardak, Handan; Bardak, Yavuz] Haydarpasa Numune Res & Training Hosp, Dept Ophthalmol, TR-34668 Istanbul, Turkey.
   [Uguz, Abdulhadi Cihangir] Suleyman Demirel Univ, Dept Biophys, Fac Med, Isparta, Turkey.
   [Uguz, Abdulhadi Cihangir] Suleyman Demirel Univ, Neurosci Res Ctr, Isparta, Turkey.
C3 Istanbul Haydarpasa Numune Training & Research Hospital; Suleyman
   Demirel University; Suleyman Demirel University
RP Bardak, H (通讯作者)，Haydarpasa Numune Res & Training Hosp, Dept Ophthalmol, TR-34668 Istanbul, Turkey.
EM handanbardak@yahoo.com.tr
RI Uğuz, A. Cihangir/J-8531-2012
CR Altinkilic S, 2010, J MEMBRANE BIOL, V235, P211, DOI 10.1007/s00232-010-9267-0
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Argun M, 2014, EYE, V28, P752, DOI 10.1038/eye.2014.50
   Bollimuntha S, 2005, VISUAL NEUROSCI, V22, P163, DOI 10.1017/S0952523805222058
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chang YH, 2015, SCI REP-UK, V5, DOI 10.1038/srep10979
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Delhalle S, 2003, ANN NY ACAD SCI, V1010, P1, DOI 10.1196/annals.1299.001
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Gomes P, 2003, CELL CALCIUM, V34, P185, DOI 10.1016/S0143-4160(03)00083-6
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hajnoczky G, 2010, CURR BIOL, V20, pR888, DOI 10.1016/j.cub.2010.09.035
   Hajnoczky Gyorgy, 2007, Novartis Found Symp, V287, P105
   Hare WA, 2009, INVEST OPHTH VIS SCI, V50, P2940, DOI 10.1167/iovs.08-2103
   Ivanova TN, 2008, BRAIN RES, V1207, P111, DOI 10.1016/j.brainres.2008.02.025
   Ji L, 2002, TOXICOL SCI, V69, P217, DOI 10.1093/toxsci/69.1.217
   Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mansoor S, 2014, INDIAN J OPHTHALMOL, V62, P16, DOI 10.4103/0301-4738.126168
   Mansoor S, 2010, INVEST OPHTH VIS SCI, V51, P2601, DOI 10.1167/iovs.09-4121
   Melkonian G, 2003, TOXICOL SCI, V75, P393, DOI 10.1093/toxsci/kfg123
   Ozgen U, 2000, CYTOMETRY, V42, P74, DOI 10.1002/(SICI)1097-0320(20000215)42:1<74::AID-CYTO11>3.0.CO;2-6
   PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Riveles K, 2003, REPROD TOXICOL, V17, P191, DOI 10.1016/S0890-6238(02)00150-8
   Rosenthal R, 2001, FASEB J, V15, P970, DOI 10.1096/fj.00-0188com
   Rosenthal R, 2007, MOL VIS, V13, P443
   Rottingen JA, 2000, ACTA PHYSIOL SCAND, V169, P203
   Rudnitskaya EA, 2015, J ALZHEIMERS DIS, V47, P103, DOI 10.3233/JAD-150161
   Salceda R, 2000, CELL CALCIUM, V27, P223, DOI 10.1054/ceca.2000.0111
   SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4
   Sharma A, 2008, INVEST OPHTH VIS SCI, V49, P5111, DOI 10.1167/iovs.08-2060
   Stalmans P, 1998, INVEST OPHTH VIS SCI, V39, P1493
   Strauss O, 1997, FASEB J, V11, P859, DOI 10.1096/fasebj.11.11.9285484
   UEDA Y, 1995, INVEST OPHTH VIS SCI, V36, P373
   Uguz AC, 2009, J MEMBRANE BIOL, V232, P15, DOI 10.1007/s00232-009-9212-2
   Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x
   Uguz AC, 2012, NEUROCHEM RES, V37, P1631, DOI 10.1007/s11064-012-0758-5
   Vainio I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128434
   Wiechmann AF, 2008, PROG RETIN EYE RES, V27, P137, DOI 10.1016/j.preteyeres.2007.10.001
   Wimmers S, 2007, INVEST OPHTH VIS SCI, V48, P5767, DOI 10.1167/iovs.07-0412
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 46
TC 12
Z9 12
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PY 2018
VL 37
IS 2
BP 112
EP 120
DI 10.1080/15569527.2017.1354218
PG 9
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA GB7SW
UT WOS:000429276400002
PM 28707481
DA 2022-11-30
ER

PT J
AU Porter, LF
   Saptarshi, N
   Fang, YX
   Rathi, S
   den Hollander, AI
   de Jong, EK
   Clark, SJ
   Bishop, PN
   Olsen, TW
   Liloglou, T
   Chavali, VRM
   Paraoan, L
AF Porter, Louise F.
   Saptarshi, Neil
   Fang, Yongxiang
   Rathi, Sonika
   den Hollander, Anneke I.
   de Jong, Eiko K.
   Clark, Simon J.
   Bishop, Paul N.
   Olsen, Timothy W.
   Liloglou, Triantafillos
   Chavali, Venkata R. M.
   Paraoan, Luminita
TI Whole-genome methylation profiling of the retinal pigment epithelium of
   individuals with age-related macular degeneration reveals differential
   methylation of the SKI, GTF2H4, and TNXB genes
SO CLINICAL EPIGENETICS
LA English
DT Article
ID DNA-METHYLATION; IL17RC PROMOTER; EXPRESSION; HYPOMETHYLATION; DISEASE;
   ASSOCIATION; MECHANISMS; PACKAGE; REGION; BLOOD
AB BackgroundAge-related macular degeneration (AMD) is a degenerative disorder of the central retina and the foremost cause of blindness. The retinal pigment epithelium (RPE) is a primary site of disease pathogenesis. The genetic basis of AMD is relatively well understood; however, this knowledge is yet to yield a treatment for the most prevalent non-neovascular disease forms. Therefore, tissue-specific epigenetic mechanisms of gene regulation are of considerable interest in AMD. We aimed to identify differentially methylated genes associated with AMD in the RPE and differentiate local DNA methylation aberrations from global DNA methylation changes, as local DNA methylation changes may be more amenable to therapeutic manipulation.MethodsEpigenome-wide association study and targeted gene expression profiling were carried out in RPE cells from eyes of human donors. We performed genome-wide DNA methylation profiling (Illumina 450k BeadChip array) on RPE cells from 44 human donor eyes (25 AMD and 19 normal controls). We validated the findings using bisulfite pyrosequencing in 55 RPE samples (30 AMD and 25 normal controls) including technical (n=38) and independent replicate samples (n=17). Long interspersed nucleotide element 1 (LINE-1) analysis was then applied to assess global DNA methylation changes in the RPE. RT-qPCR on independent donor RPE samples was performed to assess gene expression changes.ResultsGenome-wide DNA methylation profiling identified differential methylation of multiple loci including the SKI proto-oncogene (SKI) (p=1.18x10(-9)), general transcription factor IIH subunit H4 (GTF2H4) (p=7.03x10(-7)), and Tenascin X (TNXB) (p=6.30x10(-6)) genes in AMD. Bisulfite pyrosequencing validated the differentially methylated locus cg18934822 in SKI, and cg22508626 within GTF2H4, and excluded global DNA methylation changes in the RPE in AMD. We further demonstrated the differential expression of SKI, GTF2H4, and TNXB in the RPE of independent AMD donors.ConclusionsWe report the largest genome-wide methylation analysis of RPE in AMD along with associated gene expression changes to date, for the first-time reaching genome-wide significance, and identified novel targets for functional and future therapeutic intervention studies. The novel differentially methylated genes SKI and GTF2H4 have not been previously associated with AMD, and regulate disease pathways implicated in AMD, including TGF beta signaling (SKI) and transcription-dependent DNA repair mechanisms (GTF2H4).
C1 [Porter, Louise F.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Porter, Louise F.; Saptarshi, Neil; Paraoan, Luminita] Univ Liverpool, Dept Eye & Vis Sci, William Duncan Bldg, Liverpool, Merseyside, England.
   [Fang, Yongxiang] Univ Liverpool, Ctr Genom Res, Liverpool, Merseyside, England.
   [Liloglou, Triantafillos] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.
   [Rathi, Sonika; Chavali, Venkata R. M.] Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [den Hollander, Anneke I.; de Jong, Eiko K.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Sch Biol Sci, Div Evolut & Genom Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Bishop, Paul N.] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Olsen, Timothy W.] Mayo Clin, Rochester, MN USA.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Liverpool; University of Liverpool; University of Liverpool; University
   of Pennsylvania; Radboud University Nijmegen; University of Manchester;
   Manchester Royal Eye Hospital; University of Manchester; Mayo Clinic
RP Porter, LF (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.; Porter, LF (通讯作者)，Univ Liverpool, Dept Eye & Vis Sci, William Duncan Bldg, Liverpool, Merseyside, England.
EM louise.porter@liverpool.ac.uk
RI Porter, Louise/GQP-6108-2022; Paraoan, Luminita/K-1066-2016
OI Paraoan, Luminita/0000-0001-7568-7116; Clark, Simon/0000-0001-8394-8355;
   Porter, Louise/0000-0002-7406-0319
FU NIHR; Fight for Sight New Lecturer's Small Grant Award [1732/1733];
   Academy of Medical Sciences Starter Grant for Clinical Lecturers; Fight
   for Sight Small Project Grant [24NE141]; National Eye Research Charity
   PhD Studentship; National Eye Institute of the National Institutes of
   Health [R21EY028273-01A1]; BrightFocus Foundation; Research to Prevent
   Blindness; F.M. Kirby Foundation; Paul and Evanina Bell Mackall
   Foundation Trust; National Institute for Health Research (NIHR);
   NATIONAL EYE INSTITUTE [R21EY028273] Funding Source: NIH RePORTER; MRC
   [MR/K024418/1] Funding Source: UKRI
FX LFP is a clinical lecturer funded by NIHR. This project was funded by a
   Fight for Sight New Lecturer's Small Grant Award (ref 1732/1733) and
   Academy of Medical Sciences Starter Grant for Clinical Lecturers, both
   awarded to LFP, and a Fight for Sight Small Project Grant (24NE141)
   awarded to SJC. NS is supported by a National Eye Research Charity PhD
   Studentship. This research was also supported by the National Eye
   Institute of the National Institutes of Health under Award Number
   R21EY028273-01A1. We thank the financial support received from
   BrightFocus Foundation grant (awarded to VRMC), Research to Prevent
   Blindness Unrestricted Grant Funds to Scheie Eye Institute (awarded to
   VRMC), F.M. Kirby Foundation, and The Paul and Evanina Bell Mackall
   Foundation Trust for their support. This paper presents independent
   research funded by the National Institute for Health Research (NIHR).
   The views expressed are those of the author(s) and not necessarily those
   of the NHS, the NIHR or the Department of Health. The funders had no
   role in the design, data collection, analysis or conclusions drawn from
   this study.
CR Andrews SV, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0107-z
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   BAR W, 1988, FORENSIC SCI INT, V39, P59, DOI 10.1016/0379-0738(88)90118-1
   Barrachina M, 2009, J NEUROPATH EXP NEUR, V68, P880, DOI 10.1097/NEN.0b013e3181af2e46
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brooks BP, 2011, OPHTHALMOLOGY, V118, P2335, DOI 10.1016/j.ophtha.2011.05.036
   Chiquet-Ehrismann R, 2011, COLD SPRING HARB PER, V3, P1, DOI [10.1101/cshperspect.a004960, DOI 10.1101/CSHPERSPECT.A004960]
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Daca-Roszak P, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2202-0
   Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849
   de Waard H, 2003, DNA REPAIR, V2, P13, DOI 10.1016/S1568-7864(02)00188-X
   Delaney C, 2015, METHODS MOL BIOL, V1343, P249, DOI 10.1007/978-1-4939-2963-4_19
   El-Harouny E-D, 2009, J FORENSIC SCI, P4
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gelfman S, 2013, GENOME RES, V23, P789, DOI 10.1101/gr.143503.112
   Grassmann F, 2015, NEUROMOL MED, V17, P111, DOI 10.1007/s12017-015-8342-1
   Gu HM, 2014, FASEB J, V28, P4223, DOI 10.1096/fj.13-247650
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Hutchinson JN, 2014, HUM HERED, V78, P59, DOI 10.1159/000362814
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kwa FAA, 2014, DRUG DISCOV TODAY, V19, P1387, DOI 10.1016/j.drudis.2014.03.026
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Li YF, 2015, J BIOL CHEM, V290, P11918, DOI 10.1074/jbc.M115.645903
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Llamas B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030226
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Olsen TW, 2017, INVEST OPHTH VIS SCI, V58, P5497, DOI 10.1167/iovs.17-22161
   Olsen TW, 2015, T AM OPHTHALMOL SOC, V113
   Pandiyan K, 2013, NUCLEIC ACIDS RES, V41, P3973, DOI 10.1093/nar/gkt077
   Park MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21856-2
   Pennington KL, 2015, J EXP NEUROSCI, V9, P51, DOI 10.4137/JEN.S25513
   Peters TJ, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-6
   Phipson B, 2016, BIOINFORMATICS, V32, P286, DOI 10.1093/bioinformatics/btv560
   Porter LF, 2014, CLIN GENET, V86, P1, DOI 10.1111/cge.12389
   Rhein M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00182
   Schalkwijk J, 2001, NEW ENGL J MED, V345, P1167, DOI 10.1056/NEJMoa002939
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   Uchida K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34493-6
   Vaissiere T, 2009, EPIGENETICS-US, V4, P221, DOI 10.4161/epi.8833
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001
   Ye Z, 2016, SCI REP, V6
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
NR 57
TC 31
Z9 31
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JAN 14
PY 2019
VL 11
AR 6
DI 10.1186/s13148-019-0608-2
PG 14
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA HH3CZ
UT WOS:000455597800001
PM 30642396
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rajan, RP
   Deb, AK
   Lomte, S
   Privitera, CM
   Kannan, NB
   Ramasamy, K
   Ravindran, RD
AF Rajan, Renu P.
   Deb, Amit K.
   Lomte, Sonali
   Privitera, Claudio M.
   Kannan, Naresh B.
   Ramasamy, Kim
   Ravindran, Ravilla D.
TI Quantification of relative afferent pupillary defect by an automated
   pupillometer and its relationship with visual acuity and dimensions of
   macular lesions in age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; automated pupillometer; choroidal
   neovascular membrane; relative afferent pupillary defect
ID GLAUCOMA; ELECTRORETINOGRAMS; DISEASE; DAMAGE
AB Purpose: The occurrence of relative afferent pupillary defect (RAPD) secondary to optic nerve diseases and widespread retinal disorders is well established. However, only very few reports of RAPD in macular disorders exist in the literature. In this study, we used automated pupillometer to evaluate RAPD in eyes with macular lesions. Methods: It was a prospective cross-sectional study. A total of 82 patients with choroidal neovascular membrane (CNVM) - 65 unilateral and 17 bilateral macular lesions - were enrolled. RAPD was assessed with an automated pupillometer and macular lesions evaluated with optical coherence tomography (OCT). The length of the ellipsoid zone disruption was measured as the longest length of lesion on the horizontal raster scans and the area of macular lesion was measured manually, mapping the affected area of ellipsoid zone on the enface images. Results: RAPD scores showed good correlation with the intereye difference in length of maximum ellipsoid zone disruption (r-value = 0.84, P value <0.001) and macular lesion area as measured on OCT in all unilateral cases (r-value = 0.84, P value <0.001). Best-corrected visual acuity was also found to have a significant correlation with lesion size on the OCT as well as the length of ellipsoid zone disruption in unilateral cases. Conclusion: RAPD evaluated with an automated binocular pupillometer is a noninvasive and objective method to assess macular lesions in CNVMs; it shows good correlation with structural lesion dimensions on OCT in unilateral cases. Further longitudinal studies are needed to assess the significance of these findings in disease progression as well as correlation with lesion response to treatment.
C1 [Rajan, Renu P.; Deb, Amit K.; Lomte, Sonali; Kannan, Naresh B.; Ramasamy, Kim; Ravindran, Ravilla D.] Aravind Eye Hosp, Dept Vitreoretina, Madurai, Tamil Nadu, India.
   [Deb, Amit K.] JIPMER Hosp, Dept Ophthalmol, Pondicherry, India.
   [Privitera, Claudio M.] Univ Calif Berkeley, Sch Optometry, Berkeley, CA USA.
C3 Jawaharlal Institute of Postgraduate Medical Education & Research;
   University of California System; University of California Berkeley
RP Deb, AK (通讯作者)，JIPMER Hosp, Dept Ophthalmol, Old IPD Block First Floor, Gorimedu 605006, Puducherry, India.
EM amitjipmer@yahoo.co.in
RI Rajan, Renu/Y-2679-2019
OI Rajan, Renu/0000-0001-5000-3697
CR CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Gracitelli CPB, 2016, INVEST OPHTH VIS SCI, V57, P1738, DOI 10.1167/iovs.15-18079
   Hood DC, 2013, PROG RETIN EYE RES, V32, P1, DOI 10.1016/j.preteyeres.2012.08.003
   Kalaboukhova L, 2007, ACTA OPHTHALMOL SCAN, V85, P519, DOI 10.1111/j.1600-0420.2007.00863.x
   Kardon R, 2006, OPHTHALMOLOGY, V113, P1345, DOI 10.1016/j.ophtha.2006.02.055
   KAWASAKI A, 1995, AM J OPHTHALMOL, V120, P622, DOI 10.1016/S0002-9394(14)72209-3
   Kawasaki A, 2010, OPHTHALMOLOGY, V117, P175, DOI 10.1016/j.ophtha.2009.06.053
   Lankaranian Dara, 2005, Trans Am Ophthalmol Soc, V103, P200
   LEVATIN P, 1973, CAN J OPHTHALMOL, V8, P356
   LEVATIN P, 1959, ARCH OPHTHALMOL-CHIC, V62, P768
   Link B, 2006, INVEST OPHTH VIS SCI, V47, P4947, DOI 10.1167/iovs.06-0021
   Loewenfeld IE., 1999, PUPIL ANATOMY PHYSL, P498
   NEWSOME DA, 1981, AM J OPHTHALMOL, V92, P396, DOI 10.1016/0002-9394(81)90531-6
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Ozeki N, 2013, BRIT J OPHTHALMOL, V97, P1538, DOI 10.1136/bjophthalmol-2013-303825
   Pillai MR, 2019, INDIAN J OPHTHALMOL, V67, P227, DOI 10.4103/ijo.IJO_648_18
   Rahman S, 2014, INVEST OPHTH VIS SCI, V55
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Takayama K, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004978
   Terasaki H, 1997, AM J OPHTHALMOL, V123, P207, DOI 10.1016/S0002-9394(14)71037-2
   THOMPSON HS, 1981, SURV OPHTHALMOL, V26, P39, DOI 10.1016/0039-6257(81)90124-7
   Wilhelm H, 2003, J NEURO-OPHTHALMOL, V23, P42, DOI 10.1097/00041327-200303000-00010
   Wilhelm H, 2007, J NEURO-OPHTHALMOL, V27, P263, DOI 10.1097/WNO.0b013e31815bf865
   Younis AA, 2010, INVEST OPHTH VIS SCI, V51, P4013, DOI 10.1167/iovs.09-4644
NR 25
TC 1
Z9 1
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD OCT
PY 2021
VL 69
IS 10
BP 2746
EP 2750
DI 10.4103/ijo.IJO_3509_20
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY0HY
UT WOS:000754475500039
PM 34571627
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhang, GY
   Fu, DJ
   Liefers, B
   Faes, L
   Glinton, S
   Wagner, S
   Struyven, R
   Pontikos, N
   Keane, PA
   Balaskas, K
AF Zhang, Gongyu
   Fu, Dun Jack
   Liefers, Bart
   Faes, Livia
   Glinton, Sophie
   Wagner, Siegfried
   Struyven, Robbert
   Pontikos, Nikolas
   Keane, Pearse A.
   Balaskas, Konstantinos
TI Clinically relevant deep learning for detection and quantification of
   geographic atrophy from optical coherence tomography: a model
   development and external validation study
SO LANCET DIGITAL HEALTH
LA English
DT Article
ID MACULAR DEGENERATION; OCT; SEGMENTATION; DRUSEN
AB Background Geographic atrophy is a major vision-threatening manifestation of age-related macular degeneration, one of the leading causes of blindness globally. Geographic atrophy has no proven treatment or method for easy detection. Rapid, reliable, and objective detection and quantification of geographic atrophy from optical coherence tomography (OCT) retinal scans is necessary for disease monitoring, prognostic research, and to serve as clinical endpoints for therapy development. To this end, we aimed to develop and validate a fully automated method to detect and quantify geographic atrophy from OCT. Methods We did a deep-learning model development and external validation study on OCT retinal scans at Moorfields Eye Hospital Reading Centre and Clinical AI Hub (London, UK). A modified U-Net architecture was used to develop four distinct deep-learning models for segmentation of geographic atrophy and its constituent retinal features from OCT scans acquired with Heidelberg Spectralis. A manually segmented clinical dataset for model development comprised 5049 B-scans from 984 OCT volumes selected randomly from 399 eyes of 200 patients with geographic atrophy secondary to age-related macular degeneration, enrolled in a prospective, multicentre, phase 2 clinical trial for the treatment of geographic atrophy (FILLY study). Performance was externally validated on an independently recruited dataset from patients receiving routine care at Moorfields Eye Hospital (London, UK). The primary outcome was segmentation and classification agreement between deep-learning model geographic atrophy prediction and consensus of two independent expert graders on the external validation dataset. Findings The external validation cohort included 884 B-scans from 192 OCT volumes taken from 192 eyes of 110 patients as part of real-life clinical care at Moorfields Eye Hospital between Jan 1, 2016, and Dec, 31, 2019 (mean age 78middot3 years [SD 11middot1], 58 [53%] women). The resultant geographic atrophy deep-learning model produced predictions similar to consensus human specialist grading on the external validation dataset (median Dice similarity coefficient [DSC] 0middot96 [IQR 0middot10]; intraclass correlation coefficient [ICC] 0middot93) and outperformed agreement between human graders (DSC 0middot80 [0middot28]; ICC 0middot79). Similarly, the three independent feature-specific deep-learning models could accurately segment each of the three constituent features of geographic atrophy: retinal pigment epithelium loss (median DSC 0middot95 [IQR 0middot15]), overlying photoreceptor degeneration (0middot96 [0middot12]), and hypertransmission (0middot97 [0middot07]) in the external validation dataset versus consensus grading. Interpretation We present a fully developed and validated deep-learning composite model for segmentation of geographic atrophy and its subtypes that achieves performance at a similar level to manual specialist assessment. Fully automated analysis of retinal OCT from routine clinical practice could provide a promising horizon for diagnosis and prognosis in both research and real-life patient care, following further clinical validation Funding Apellis Pharmaceuticals. Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
C1 [Zhang, Gongyu; Fu, Dun Jack; Liefers, Bart; Faes, Livia; Glinton, Sophie; Wagner, Siegfried; Struyven, Robbert; Pontikos, Nikolas; Keane, Pearse A.; Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, UCL Inst Ophthalmol, London EC1V 2PD, England.
   [Liefers, Bart] Erasmus Univ, Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   [Faes, Livia] Cantonal Hosp Lucerne, Eye Clin, Luzern, Switzerland.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Erasmus University Rotterdam; Erasmus MC; Lucerne
   Cantonal Hospital
RP Balaskas, K (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, UCL Inst Ophthalmol, London EC1V 2PD, England.
EM k.balaskas@nhs.net
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Keane,
   Pearse/0000-0002-9239-745X; Zhang, Gongyu/0000-0003-4760-359X
FU Apellis Pharmaceuticals
FX Apellis Pharmaceuticals.
CR Arslan J, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.57
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Cheng QE, 2018, OPHTHALMOL RETINA, V2, P518, DOI 10.1016/j.oret.2017.08.018
   Chiang A, 2020, INVEST OPHTH VIS SCI, V61
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P41, DOI 10.1016/j.oret.2020.07.006
   Collins GS, 2015, BRIT J SURG, V102, P148, DOI 10.1002/bjs.9736
   Collins GS, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-40
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Keenan TD, OPHTHALMOLOGY, V128, P100
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Luo W, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5870
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mishra Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66355-5
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Ruiz-Moreno JM, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8204641
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381
   Team R, 2016, RSTUD INT DEV ENV R
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 30
TC 10
Z9 10
U1 5
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2589-7500
J9 LANCET DIGIT HEALTH
JI Lancet Digit. Health
PD OCT
PY 2021
VL 3
IS 10
BP E665
EP E675
DI 10.1016/S2589-7500(21)00134-5
EA SEP 2021
PG 11
WC Medical Informatics; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Informatics; General & Internal Medicine
GA WC6VW
UT WOS:000704394700011
PM 34509423
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nuzzi, R
   Dallorto, L
   Vitale, A
AF Nuzzi, Raffaele
   Dallorto, Laura
   Vitale, Alessio
TI Cerebral Modifications and Visual Pathway Reorganization in Maculopathy:
   A Systematic Review
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE maculopathy; age-related macular degeneration; juvenile macular
   degeneration; neurodegeneration; neuroplasticity; systematic review
ID MACULAR DEGENERATION; CORTICAL REORGANIZATION; RETINAL LESIONS;
   GEOGRAPHIC ATROPHY; BRAIN CONNECTIVITY; POSITIVE NEURONS; PLASTICITY;
   DISEASE; FMRI; IMPAIRMENT
AB Background Macular degeneration (MD) is one of the most frequent causes of visual deficit, resulting in alterations affecting not only the retina but also the entire visual pathway up to the brain areas. This would seem related not just to signal deprivation but also to a compensatory neuronal reorganization, having significant implications in terms of potential rehabilitation of the patient and therapeutic perspectives. Objective This paper aimed to outline, by analyzing the existing literature, the current understanding of brain structural and functional changes detected with neuroimaging techniques in subjects affected by juvenile and age-related maculopathy. Methods Articles using various typologies of central nervous system (CNS) imaging in at least six patients affected by juvenile or age-related maculopathy were considered. A total of 142 were initially screened. Non-pertinent articles and duplicates were rejected. Finally, 19 articles, including 649 patients, were identified. Results In these sources, both structural and functional modifications were found in MD subjects' CNS. Changes in visual cortex gray matter volume were observed in both age-related MD (AMD) and juvenile MD (JMD); in particular, an involvement of not only its posterior part but also the anterior one suggests further causes besides an input-deprivation mechanism only. White matter degeneration was also found, more severe in JMD than in AMD. Moreover, functional analysis revealed differences in cortical activation patterns between MD and controls, suggesting neuronal circuit reorganization. Interestingly, attention and oculomotor training allowed better visual performances and correlated to a stronger cortical activation, even of the area normally receiving inputs from lesioned macula. Conclusion In MD, structural and functional changes in cerebral circuits and visual pathway can happen, involving both cerebral volume and activation patterns. These modifications, possibly due to neuronal plasticity (already observed and described for several brain areas), can allow patients to compensate for macular damage and gives therapeutic perspectives which could be achievable through an association between oculomotor training and biochemical stimulation of neuronal plasticity.
C1 [Nuzzi, Raffaele; Dallorto, Laura; Vitale, Alessio] Univ Turin, Dept Surg Sci, Eye Clin, Turin, Italy.
C3 University of Turin
RP Nuzzi, R (通讯作者)，Univ Turin, Dept Surg Sci, Eye Clin, Turin, Italy.
EM prof.nuzzi_raffaele@hotmail.it
CR Altschwager P, 2017, SEMIN PEDIATR NEUROL, V24, P104, DOI 10.1016/j.spen.2017.05.005
   Andrade MA, 2001, BIOL CYBERN, V84, P445, DOI 10.1007/PL00007988
   Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582
   Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   Barton B, 2015, P NATL ACAD SCI USA, V112, P5201, DOI 10.1073/pnas.1423673112
   Baseler HA, 2011, NAT NEUROSCI, V14, P649, DOI 10.1038/nn.2793
   Baseler HA, 2009, NEURO-OPHTHALMOLOGY, V33, P149, DOI 10.1080/01658100903050053
   Berry KP, 2016, ANNU REV VIS SCI, V2, P17, DOI 10.1146/annurev-vision-111815-114638
   BLODI CF, 1990, OPHTHALMIC PAED GEN, V11, P49
   Bondarenko M T, 2014, Vestn Oftalmol, V130, P72
   Botelho EP, 2014, CEREB CORTEX, V24, P1, DOI 10.1093/cercor/bhs208
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Bowes Rickman C., 2013, DRY AGE RELATED MACU
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chung STL, 2013, J NEUROSCI, V33, P18080, DOI 10.1523/JNEUROSCI.2764-13.2013
   Clarkson MJ, 2011, NEUROIMAGE, V57, P856, DOI 10.1016/j.neuroimage.2011.05.053
   de Winter F, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/3679545
   Dilks DD, 2014, OPTOMETRY VISION SCI, V91, pE199, DOI 10.1097/OPX.0000000000000325
   Dilks DD, 2009, J NEUROSCI, V29, P2768, DOI 10.1523/JNEUROSCI.5258-08.2009
   Dreher B, 2001, PROG BRAIN RES, V134, P217
   Fawcett J, 2009, PROG BRAIN RES, V175, P501, DOI 10.1016/S0079-6123(09)17534-9
   Fawcett JW, 2015, PROG BRAIN RES, V218, P213, DOI 10.1016/bs.pbr.2015.02.001
   Foscarin S, 2017, AGING-US, V9, P1607, DOI 10.18632/aging.101256
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Haak KV, 2016, OPHTHAL PHYSL OPT, V36, P335, DOI 10.1111/opo.12279
   HEINEN SJ, 1991, EXP BRAIN RES, V83, P670
   Hernowo AT, 2014, CORTEX, V56, P99, DOI 10.1016/j.cortex.2013.01.003
   Hohman TC, 2017, HANDB EXP PHARMACOL, V242, P337, DOI 10.1007/164_2016_91
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   Keck T, 2011, NEURON, V71, P869, DOI 10.1016/j.neuron.2011.06.034
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Kitajima M, 1997, AM J NEURORADIOL, V18, P1291
   Knudtson MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P807, DOI 10.1001/archopht.123.6.807
   Kollias SS, 2004, EUR J RADIOL, V49, P64, DOI 10.1016/j.ejrad.2003.09.005
   Kwok JCF, 2008, RESTOR NEUROL NEUROS, V26, P131
   Lestak J, 2013, NEURO-OPHTHALMOLOGY, V37, P192, DOI 10.3109/01658107.2013.819581
   Little DM, 2008, INVEST OPHTH VIS SCI, V49, P1728, DOI 10.1167/iovs.07-0372
   Liu TT, 2010, INVEST OPHTH VIS SCI, V51, P6826, DOI 10.1167/iovs.09-4926
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Masuda Y, 2010, INVEST OPHTH VIS SCI, V51, P5356, DOI 10.1167/iovs.09-4775
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Miki A, 2002, SURV OPHTHALMOL, V47, P562, DOI 10.1016/S0039-6257(02)00356-9
   Miki A, 2001, CURR OPIN OPHTHALMOL, V12, P424, DOI 10.1097/00055735-200112000-00007
   Molday RS, 2015, PROG MOL BIOL TRANSL, V134, P415, DOI 10.1016/bs.pmbts.2015.06.008
   North V, 2014, DEV OPHTHALMOL, V53, P44, DOI 10.1159/000357293
   Nuzzi R., 2017, J NEUROL NEUROSCI, V8, DOI [10.21767/2171-6625.1000191, DOI 10.21767/2171-6625.1000191]
   Olivo G, 2015, INVEST OPHTH VIS SCI, V56, P7388, DOI 10.1167/iovs.15-16899
   Palanza L, 2002, ACTA OPHTHALMOL SCAN, V80, P47, DOI 10.1034/j.1600-0420.80.s236.27.x
   Palejwala NV, 2016, RETINA-J RET VIT DIS, V36, P119, DOI 10.1097/IAE.0000000000000659
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pi LH, 2012, J EPIDEMIOL, V22, P37, DOI 10.2188/jea.JE20110063
   Plank T, 2017, OPTOMETRY VISION SCI, V94, P297, DOI 10.1097/OPX.0000000000001047
   Plank T, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01189
   Plank T, 2013, HUM BRAIN MAPP, V34, P2607, DOI 10.1002/hbm.22088
   Plank T, 2011, NEUROIMAGE, V56, P1556, DOI 10.1016/j.neuroimage.2011.02.055
   Prins D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146684
   Restani L, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00086
   Rosa AM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568354
   Rosengarth K, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00428
   Schumacher EH, 2008, RESTOR NEUROL NEUROS, V26, P391
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Scullica Luigi, 2001, Documenta Ophthalmologica, V102, P237, DOI 10.1023/A:1017562532731
   Sorg BA, 2016, J NEUROSCI, V36, P11459, DOI 10.1523/JNEUROSCI.2351-16.2016
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Szlyk JP, 2009, INVEST OPHTH VIS SCI, V50, P4487, DOI 10.1167/iovs.08-2258
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   VERCELLI AE, 1994, DEV BRAIN RES, V83, P85, DOI 10.1016/0165-3806(94)90182-1
   Verdina T, 2013, EUR J OPHTHALMOL, V23, P723, DOI 10.5301/ejo.5000291
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Wandell BA, 2009, NAT REV NEUROSCI, V10, P873, DOI 10.1038/nrn2741
   Whitson HE, 2015, BRAIN CONNECT, V5, P126, DOI 10.1089/brain.2014.0277
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiao QH, 2010, PFLUG ARCH EUR J PHY, V460, P559, DOI 10.1007/s00424-010-0821-5
   Yang S, 2015, EXP NEUROL, V265, P48, DOI 10.1016/j.expneurol.2014.11.013
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 82
TC 6
Z9 6
U1 1
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD AUG 21
PY 2020
VL 14
AR 755
DI 10.3389/fnins.2020.00755
PG 19
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA NM7OA
UT WOS:000568282700001
PM 32973424
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Foran, S
   Wang, JJ
   Mitchell, P
AF Foran, S
   Wang, JJ
   Mitchell, P
TI Causes of incident visual impairment - The Blue Mountains Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMMUNITY SUPPORT SERVICES; CAUSE-SPECIFIC PREVALENCE; AGE-SPECIFIC
   PREVALENCE; OLDER; POPULATION; BLINDNESS; VISION; AUSTRALIA; ACUITY;
   GLAUCOMA
AB Objective: To describe the causes of 5-year incident visual impairment and doubling of the visual angle in a population-based cohort.
   Methods: Of the 3654 participants aged older than 50 years who participated in the Blue Mountains Eye Study (BMES I, 1992-1994), 543 died and 2335 were reexamined between 1997 and 1999 (BMES II). Visual acuity was measured using a logMAR chart before and after refraction. Pupils were dilated, and a detailed eye examination was performed. For participants with incident visual impairment or doubling of the visual angle, an ophthalmologist attributed and proportioned causes. Primary causes were defined as those responsible for 50% or more of the impairment.
   Results: After refractive correction, the proportion of incident bilateral impairment worse than 20/40, worse than 20/70, and worse than 20/200 that were caused primarily by cataract decreased from 51.4% (n=19) to 40.0% (n=6) to 0%; while the proportion of cases caused primarily by age-related maculopathy increased from 24.3% (n=9) to 33.3% (n=5) to 100.0% (n=2). Similarly, the corresponding proportions of incident unilateral impairment caused primarily by cataract decreased from 53.7% (n=72) to 36.9% (n=31) to 13.6% (n=6) meanwhile, the proportion of cases caused primarily by age-related maculopathy increased from 19.4% (n=26) to 32.1% (n=27) to 54.5% (n=24). The proportions of persons with incident bilateral impairment worse than 20/40, worse than 20/70, and worse than 20/200 that could be improved with refraction were 79.4% (n=143), 73.6% (n=42), and 0%, respectively. The corresponding proportions of incident unilateral impairment improved by refraction were 66.7% (n=269), 59.0% (n=121), and 21.4% (n=12).
   Conclusion: This study has documented the 5-year incidence and causes of visual impairment in an older Australian population.
C1 Univ Sydney, Dept Ophthalmol, Save Sight & Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Save Sight & Westmead Millennium Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paulmi@westgate.wh.usyd.edu.au
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BENGTSSON B, 1991, ACTA OPHTHALMOL, V69, P288
   CAMPBELL AJ, 1981, AGE AGEING, V10, P47, DOI 10.1093/ageing/10.1.47
   DANA MR, 1990, JAMA-J AM MED ASSOC, V264, P2400, DOI 10.1001/jama.264.18.2400
   HIRVELA H, 1995, ACTA OPHTHALMOL SCAN, V73, P99
   Ivers RQ, 1999, AM J PUBLIC HEALTH, V89, P85, DOI 10.2105/AJPH.89.1.85
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   JACK CIA, 1995, GERONTOLOGY, V41, P280
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Mitchell P, 1997, MED J AUSTRALIA, V166, P73, DOI 10.5694/j.1326-5377.1997.tb138724.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   NEWLAND HS, 1994, BRIT J OPHTHALMOL, V78, P344, DOI 10.1136/bjo.78.5.344
   PONTE F, 1994, GRAEF ARCH CLIN EXP, V232, P469, DOI 10.1007/BF00195355
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wang JJ, 2000, INVEST OPHTH VIS SCI, V41, P49
   Wang JJ, 1999, AUST NZ J PUBL HEAL, V23, P147, DOI 10.1111/j.1467-842X.1999.tb01225.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
NR 27
TC 30
Z9 31
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2002
VL 120
IS 5
BP 613
EP 619
DI 10.1001/archopht.120.5.613
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 550KZ
UT WOS:000175503400010
PM 12003611
DA 2022-11-30
ER

PT J
AU Zele, AJ
   Dang, TM
   O'Loughlin, RK
   Guymer, RH
   Harper, FA
   Vingrys, AJ
   Harper, A
AF Zele, Andrew J.
   Dang, Trung M.
   O'Loughlin, Rebecca K.
   Guymer, Robyn H.
   Harper, Franzco Alex
   Vingrys, Algis J.
   Harper, Alex
TI Adaptation mechanisms, eccentricity profiles, and clinical
   implementation of red-on-white perimetry
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE perimetry; color; flicker; age-related maculopathy; diabetes
ID TEMPORAL-MODULATION PERIMETRY; CHROMATIC DISCRIMINATION; FLICKER
   PERIMETRY; VISUAL DETECTION; L-CONE; AGE; LUMINANCE; SENSITIVITY;
   THRESHOLD; SUMMATION
AB Purpose. To determine the visual adaptation and retinal eccentricity profiles for red flickering and static test stimuli and report a clinical implementation of these stimuli in visual perimetry.
   Methods. The adaptation profile for red-on-white perimetry stimuli was measured using a threshold vs. intensity (Tvl) paradigm at 0 degree and 12 degrees eccentricity and by comparing the eccentricity-related sensitivity change for red and while, static, and flickering targets in young normal trichromats (n = 5) and a group of dichromats (n = 5). A group of older normal control observers (n = 30) were tested and retinal disease was evaluated in persons having age-related maculopathy (n = 35) and diabetes (n = 12).
   Results. Adaptation and eccentricity profiles indicate red static and flickering targets are detected by two mechanisms in the paramacular region, and a single mechanism for >5 degrees eccentricity. The group data for the older normal observers has a high level of inter-observer variability with a generalized reduction in sensitivity across the entire visual field. Group data for the participants with age-related maculopathy show reduced sensitivities that were pronounced in the central retina. The group data for the diabetic observers showed sensitivities that were reduced at all eccentricities. The disease-related sensitivity decline was more apparent with red than white stimuli.
   Conclusions. The adaptation profile and change in sensitivity with retinal eccentricity for the red-on-white perimetric stimuli are consistent with two detection processes. in the macula, the putative detection mechanism is color-opponent with static targets and non-opponent with flickering targets. At peripheral field locations, the putative detection mechanism is non-opponent for both static and flicker targets. The long-wavelength stimuli are less affected by the preretinal absorption common to aging. Red-on-white static and flicker perimetry may be useful for monitoring retinal disease, revealing greater abnormalities compared with conventional white-on-white perimetry, especially in the macula where two detection mechanisms are found.
C1 [Zele, Andrew J.; Dang, Trung M.; O'Loughlin, Rebecca K.; Vingrys, Algis J.] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.
   [Zele, Andrew J.] Queensland Univ Technol, Sch Optometry, Brisbane, Qld, Australia.
   [Zele, Andrew J.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Guymer, Robyn H.; Harper, Alex] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Melbourne; Queensland University of Technology (QUT);
   Queensland University of Technology (QUT); Centre for Eye Research
   Australia; University of Melbourne
RP Vingrys, AJ (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Cnr Cardigan & Keppel St, Parkville, Vic 3010, Australia.
EM algis@unimelb.edu.au
OI Zele, Andrew/0000-0003-0291-9929; Vingrys, Algis/0000-0001-5920-4604;
   Guymer, Robyn/0000-0002-9441-4356
CR Aguila M., 1954, Optica Acta, V1, P59
   Anderson AJ, 2000, CLIN EXP OPHTHALMOL, V28, P223, DOI 10.1046/j.1442-9071.2000.00299.x
   ANDERSON RA, 1987, PERIMETRY AUTOMATION
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P807
   Bearse MA, 2006, PROG RETIN EYE RES, V25, P425, DOI 10.1016/j.preteyeres.2006.07.001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cao DC, 2006, VISUAL NEUROSCI, V23, P531, DOI 10.1017/S0952523806233376
   CASSON EJ, 1993, J OPT SOC AM A, V10, P1792, DOI 10.1364/JOSAA.10.001792
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   EISNER A, 1982, J OPT SOC AM, V72, P517, DOI 10.1364/JOSA.72.000517
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   HAAS A, 1986, AM J OPHTHALMOL, V101, P199, DOI 10.1016/0002-9394(86)90595-7
   HARWERTH RS, 1993, INVEST OPHTH VIS SCI, V34, P3011
   Harwerth RS, 2002, PROG RETIN EYE RES, V21, P91, DOI 10.1016/S1350-9462(01)00022-2
   HSIA Y, 1957, P NATL ACAD SCI USA, V43, P1011, DOI 10.1073/pnas.43.11.1011
   JAFFE GJ, 1986, ARCH OPHTHALMOL-CHIC, V104, P1021
   JOHNSON CA, 1989, INVEST OPHTH VIS SCI, V30, P2056
   JOHNSON CA, 1995, OPTOMETRY VISION SCI, V72, P75, DOI 10.1097/00006324-199502000-00006
   JOHNSON MA, 1986, AM J OPTOM PHYS OPT, V63, P97
   Keppel G., 1991, DESIGN ANAL RES HDB
   KEUNEN JEE, 1987, INVEST OPHTH VIS SCI, V28, P985
   KINGSMITH PE, 1994, VISION RES, V34, P885, DOI 10.1016/0042-6989(94)90039-6
   KINGSMITH PE, 1976, J OPT SOC AM, V66, P709, DOI 10.1364/JOSA.66.000709
   Knoblauch, 2003, NORMAL DEFECTIVE COL, P91
   Landers J, 2003, BRIT J OPHTHALMOL, V87, P690, DOI 10.1136/bjo.87.6.690
   LYNCH S, 1996, INVEST OPHTH VIS SCI, V37, pS140
   Maddess T, 2000, INVEST OPHTH VIS SCI, V41, P3827
   McKendrick AM, 2000, INVEST OPHTH VIS SCI, V41, P1239
   Neitz M, 2006, VISUAL NEUROSCI, V23, P379, DOI 10.1017/S095252380623325X
   NOORLANDER C, 1980, J OPT SOC AM, V70, P1116, DOI 10.1364/JOSA.70.001116
   NOORLANDER C, 1983, VISION RES, V23, P1, DOI 10.1016/0042-6989(83)90035-4
   Pan F, 2006, J VISION, V6, P1159, DOI 10.1167/6.11.2
   Pearson PM, 2000, J OPT SOC AM A, V17, P232, DOI 10.1364/JOSAA.17.000232
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   POKORNY J, 1972, J OPT SOC AM, V62, P111, DOI 10.1364/JOSA.62.000111
   Pokorny J, 1997, DOC OPHTH P, V59, P491
   Riva CE, 2001, INVEST OPHTH VIS SCI, V42, P756
   Sample PA, 1996, J GLAUCOMA, V5, P375
   Stavrou EP, 2005, ACTA OPHTHALMOL SCAN, V83, P574, DOI 10.1111/j.1600-0420.2005.00527.x
   STROMEYER CF, 1992, VISION RES, V32, P1865, DOI 10.1016/0042-6989(92)90047-M
   SWANSON WH, 1987, J OPT SOC AM A, V4, P1992, DOI 10.1364/JOSAA.4.001992
   TAYLOR HR, 1991, INVEST OPHTH VIS SCI, V32, P529
   Verdon W, 1996, VISION RES, V36, P373, DOI 10.1016/0042-6989(95)00103-4
   VERRIEST G, 1971, VISION RES, V11, P1407, DOI 10.1016/0042-6989(71)90063-0
   Vingrys AJ, 1999, AUST NZ J OPHTHALMOL, V27, P109, DOI 10.1046/j.1440-1606.1999.00158.x
   Vingrys AJ, 2005, INVEST OPHTH VIS SCI, V46, P4353, DOI 10.1167/iovs.04-1009
   VINGRYS AJ, 1995, PERIMETRY UPDATE 1994/1995, P159
   WATSON AB, 1987, J OPT SOC AM A, V4, P1579, DOI 10.1364/JOSAA.4.001579
   Wyszecki G., 2000, COLOR SCI CONCEPTS M, Vsecond
   Xu J, 1997, J OPT SOC AM A, V14, P953, DOI 10.1364/JOSAA.14.000953
   YEH T, 1993, VISION RES, V33, P1835, DOI 10.1016/0042-6989(93)90174-U
   Zele AJ, 2000, CLIN EXP OPHTHALMOL, V28, P227, DOI 10.1046/j.1442-9071.2000.00301.x
   Zele AJ, 2006, GRAEF ARCH CLIN EXP, V244, P425, DOI 10.1007/s00417-005-0121-5
   Zele AJ, 2005, J NEUROSCI METH, V141, P1, DOI 10.1016/j.jneumeth.2004.05.005
   Zele AJ, 2001, CLIN EXP OPHTHALMOL, V29, P197, DOI 10.1046/j.1442-9071.2001.00403.x
   Zele AJ, 2007, VISION RES, V47, P2700, DOI 10.1016/j.visres.2007.05.005
   Zele AJ, 2006, VISUAL NEUROSCI, V23, P495, DOI 10.1017/S0952523806232012
NR 58
TC 13
Z9 13
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAY
PY 2008
VL 85
IS 5
BP 309
EP 317
DI 10.1097/OPX.0b013e31816be9e3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296GU
UT WOS:000255532300004
PM 18451735
DA 2022-11-30
ER

PT J
AU Gurubaran, IS
   Hytti, M
   Kaarniranta, K
   Kauppinen, A
AF Gurubaran, Iswariyaraja Sridevi
   Hytti, Maria
   Kaarniranta, Kai
   Kauppinen, Anu
TI Epoxomicin, a Selective Proteasome Inhibitor, Activates AIM2
   Inflammasome in Human Retinal Pigment Epithelium Cells
SO ANTIOXIDANTS
LA English
DT Article
DE aging; age-related macular degeneration; oxidative stress; mitochondrial
   damage; reactive oxygen species; cytokines; IL-1 beta; antioxidants;
   inflammasomes; NLRP3; AIM2
ID OXIDATIVE STRESS; MACULAR DEGENERATION; PROTEIN-DEGRADATION; NLRP3
   INFLAMMASOME; QUALITY-CONTROL; 26S PROTEASOME; AGE; MITOCHONDRIAL;
   DYSFUNCTION; AUTOPHAGY
AB Emerging evidence suggests that the intracellular clearance system plays a vital role in maintaining homeostasis and in regulating oxidative stress and inflammation in retinal pigment epithelium (RPE) cells. Dysfunctional proteasomes and autophagy in RPE cells have been associated with the pathogenesis of age-related macular degeneration. We have previously shown that the inhibition of proteasomes using MG-132 activates the NLR family pyrin domain containing 3 (NLRP3) inflammasome in human RPE cells. However, MG-132 is a non-selective proteasome inhibitor. In this study, we used the selective proteasome inhibitor epoxomicin to study the effect of non-functional intracellular clearance systems on inflammasome activation. Our data show that epoxomicin-induced proteasome inhibition promoted both nicotinamide adenine dinucleotide phosphate oxidase and mitochondria-mediated oxidative stress and release of mitochondrial DNA to the cytosol, which resulted in potassium efflux-dependent absence in melanoma 2 (AIM2) inflammasome activation and subsequent interleukin-1 beta secretion in ARPE-19 cells. The non-specific proteasome inhibitor MG-132 activated both NLRP3 and AIM2 inflammasomes and oxidative stress predominated as the activation mechanism, but modest potassium efflux was also detected. Collectively, our data suggest that a selective proteasome inhibitor is a potent inflammasome activator in human RPE cells and emphasize the role of the AIM2 inflammasome in addition to the more commonly known NLRP3 inflammasome.
C1 [Gurubaran, Iswariyaraja Sridevi; Kaarniranta, Kai; Kauppinen, Anu] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70210, Finland.
   [Hytti, Maria; Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Immunoophthalmol, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70210, Finland.; Kauppinen, A (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Immunoophthalmol, Kuopio 70210, Finland.
EM raja.sridevigurubaran@uef.fi; maria.hytti@uef.fi;
   kai.kaarniranta@uef.fi; anu.kauppinen@uef.fi
FU European Union [722717]; Academy of Finland [AK297267, AK307341,
   AK328443]; Emil Aaltonen Foundation; Finnish Cultural Foundation-North
   Savo Regional Fund; Mary and Georg C. Ehrnrooth Foundation; Paivikki and
   Sakari Sohlberg Foundation; Paulo Foundation
FX This project received funding from the European Union's Horizon 2020
   research and innovation program under the Marie Sklodowska-Curie grant
   agreement No. 722717, the Academy of Finland (AK297267, AK307341,
   AK328443), the Emil Aaltonen Foundation, the Finnish Cultural
   Foundation-North Savo Regional Fund, the Mary and Georg C. Ehrnrooth
   Foundation, the Paivikki and Sakari Sohlberg Foundation, the Paulo
   Foundation, and the Emil Aaltonen Foundation.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Aldini G, 2018, FREE RADICAL RES, V52, P751, DOI 10.1080/10715762.2018.1468564
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Bragoszewski P, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170007
   Bronner Denise N, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1839
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Busch CJ, 2017, BBA-MOL CELL BIOL L, V1862, P398, DOI 10.1016/j.bbalip.2016.06.016
   Ciazynska M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115898
   Cui WP, 2013, AM J PHYSIOL-ENDOC M, V304, pE87, DOI 10.1152/ajpendo.00430.2012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Damby DE, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02000
   Dasgupta S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103604
   Detrick B, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P101, DOI 10.1007/978-3-030-28384-1_6
   Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x
   Dombrowski Y, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002001
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ghonime MG, 2014, J IMMUNOL, V192, P3881, DOI 10.4049/jimmunol.1301974
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Goetzke CC, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081783
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hakimi M, 2014, J VASC SURG, V59, P794, DOI 10.1016/j.jvs.2013.03.048
   Hanna J, 2019, AM J PATHOL, V189, P94, DOI 10.1016/j.ajpath.2018.09.004
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hytti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136800
   Jang EJ, 2016, ONCOTARGET, V7, P50864, DOI 10.18632/oncotarget.10854
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kao LT, 2015, J AM ACAD DERMATOL, V72, P1090, DOI 10.1016/j.jaad.2015.03.002
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4666-0
   Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kondratskyi A, 2018, AUTOPHAGY, V14, P3, DOI 10.1080/15548627.2017.1384887
   Korhonen E, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108687
   Korhonen E, 2020, FASEB J, V34, P6437, DOI 10.1096/fj.201902355RR
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lavie J, 2018, CELL REP, V23, P2852, DOI 10.1016/j.celrep.2018.05.013
   Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Lefaki M, 2017, REDOX BIOL, V13, P452, DOI 10.1016/j.redox.2017.07.005
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Liao Yingnan, 2022, Front Immunol, V13, P834289, DOI 10.3389/fimmu.2022.834289
   Liu YP, 2002, CLIN EXP PHARMACOL P, V29, P305, DOI 10.1046/j.1440-1681.2002.03649.x
   Lugrin J, 2018, IMMUNOL REV, V281, P99, DOI 10.1111/imr.12618
   McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200
   Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Qin TY, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5392432
   Qiu MR, 2002, CLIN EXP IMMUNOL, V130, P67, DOI 10.1046/j.1365-2249.2002.01965.x
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   Ranta-aho S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094875
   Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637
   Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717
   ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6
   Ross JM, 2015, INT J MOL SCI, V16, P19458, DOI 10.3390/ijms160819458
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strickland M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00158
   Sulkshane P, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111559
   Sulkshane P, 2020, J PROTEOMICS, V229, DOI 10.1016/j.jprot.2020.103949
   Sun JR, 2020, THERANOSTICS, V10, P11637, DOI 10.7150/thno.48064
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Taylor AW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724601
   Taylor EB, 2011, BIOCHEM SOC T, V39, P1509, DOI 10.1042/BST0391509
   Thibaudeau TA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03509-0
   Tschan S, 2013, ANTIMICROB AGENTS CH, V57, P3576, DOI 10.1128/AAC.00742-12
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280
   Vilchez D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6659
   Xu ZW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.609441
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
NR 78
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JUL
PY 2022
VL 11
IS 7
AR 1288
DI 10.3390/antiox11071288
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 3J1NW
UT WOS:000833170500001
PM 35883779
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ponnusamy, C
   Sugumaran, A
   Krishnaswami, V
   Palanichamy, R
   Velayutham, R
   Natesan, S
AF Ponnusamy, Chandrasekar
   Sugumaran, Abimanyu
   Krishnaswami, Venkateshwaran
   Palanichamy, Rajaguru
   Velayutham, Ravichandiran
   Natesan, Subramanian
TI Development and Evaluation of Polyvinylpyrrolidone K90 and Poloxamer 407
   Self-Assembled Nanomicelles: Enhanced Topical Ocular Delivery of
   Artemisinin
SO POLYMERS
LA English
DT Article
DE nanomicelles; artemisinin; cornea; toxicity
ID DRUG-DELIVERY; IN-VITRO; SYSTEMS; PERMEABILITY; DESIGN; DEXAMETHASONE;
   CAMPTOTHECIN; TOXICITY; MODEL
AB Age-related macular degeneration is a multifactorial disease affecting the posterior segment of the eye and is characterized by aberrant nascent blood vessels that leak blood and fluid. It ends with vision loss. In the present study, artemisinin which is poorly water-soluble and has potent anti-angiogenic and anti-inflammatory properties was formulated into nanomicelles and characterized for its ocular application and anti-angiogenic activity using a CAM assay. Artemisinin-loaded nanomicelles were prepared by varying the concentrations of PVP k90 and poloxamer 407 at different ratios and showed spherical shape particles in the size range of 41-51 nm. The transparency and cloud point of the developed artemisinin-loaded nanomicelles was found to be 99-94% and 68-70 degrees C, respectively. The in vitro release of artemisinin from the nanomicelles was found to be 96.0-99.0% within 8 h. The trans-corneal permeation studies exhibited a 1.717-2.169 mu g permeation of the artemisinin from nanomicelles through the excised rabbit eye cornea for 2 h. Drug-free nanomicelles did not exhibit noticeable DNA damage and showed an acceptable level of hemolytic potential. Artemisinin-loaded nanomicelles exhibited remarkable anti-angiogenic activity compared to artemisinin suspension. Hence, the formulated artemisinin-loaded nanomicelles might have the potential for the treatment of AMD.
C1 [Ponnusamy, Chandrasekar; Krishnaswami, Venkateshwaran] Anna Univ, Dept Pharmaceut Technol, Univ Coll Engn, Bharathidasan Inst Technol Campus, Tiruchirappalli 620024, Tamil Nadu, India.
   [Sugumaran, Abimanyu] SRM Coll Pharm, SRM Inst Sci & Technol, Dept Pharmaceut, Kattankulathur 603203, Tamil Nadu, India.
   [Palanichamy, Rajaguru] Cent Univ Tamil Nadu, Sch Life Sci, Dept Life Sci, Tiruvarur 627007, Tamil Nadu, India.
   [Velayutham, Ravichandiran; Natesan, Subramanian] Natl Inst Pharmaceut Educ & Res NIPER Kolkata, Dept Pharmaceut, 168 Maniktala Main Rd, Kolkata 700054, W Bengal, India.
C3 Anna University; Anna University of Technology Tiruchirappalli; SRM
   Institute of Science & Technology Chennai; Central University of Tamil
   Nadu
RP Natesan, S (通讯作者)，Natl Inst Pharmaceut Educ & Res NIPER Kolkata, Dept Pharmaceut, 168 Maniktala Main Rd, Kolkata 700054, W Bengal, India.
EM chandruu0079@gmail.com; abipharmastar@gmail.com; venkpharm@gmail.com;
   rajaguru62@gmail.com; directorniperkolkata@gmail.com;
   natesansubbu1@gmail.com
RI Sugumaran, Dr Abimanyu/M-5806-2019
OI Sugumaran, Dr Abimanyu/0000-0003-2321-9876; RAVICHANDIRAN,
   V/0000-0001-7820-9486
FU University Grant Commission, New Delhi
FX The author, P. Chandrasekar, gratefully acknowledges the support
   received from the University Grant Commission, New Delhi for providing
   fellowships for Junior/Senior Research Fellows.
CR Agrahari V, 2016, DRUG DELIV TRANSL RE, V6, P735, DOI 10.1007/s13346-016-0339-2
   Ahuja M, 2011, J MICROENCAPSUL, V28, P37, DOI 10.3109/02652048.2010.523794
   Amin K, 2006, J PHARM SCI-US, V95, P1173, DOI 10.1002/jps.20627
   Ansari MT, 2010, ADV CLIN EXP MED, V19, P745
   Begum G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68254-1
   Bodratti AM, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010011
   Bose A, 2021, IET NANOBIOTECHNOL, V15, P19, DOI 10.1049/nbt2.12018
   Cheong DHJ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104901
   Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002
   Danafar H, 2018, ARTIF CELL NANOMED B, V46, P1625, DOI 10.1080/21691401.2017.1386191
   El-Kamel AH, 2002, INT J PHARMACEUT, V241, P47, DOI 10.1016/S0378-5173(02)00234-X
   Elnaggar YSR, 2009, INT J PHARMACEUT, V380, P133, DOI 10.1016/j.ijpharm.2009.07.015
   Garg AK, 2013, INT J PHARM BIO SCI, V4, P934
   Giuliano E, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030159
   Gokulgandhi MR, 2012, EXPERT OPIN DRUG MET, V8, P1277, DOI 10.1517/17425255.2012.708337
   Gote V, 2019, J PHARMACOL EXP THER, V370, P602, DOI 10.1124/jpet.119.256933
   Hanafy NAN, 2018, CANCERS, V10, DOI 10.3390/cancers10070238
   Khanal P, 2021, MONATSH CHEM, V152, P387, DOI 10.1007/s00706-021-02759-x
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Li GY, 2011, INT J BIOL MACROMOL, V49, P970, DOI 10.1016/j.ijbiomac.2011.08.019
   Li H, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.192092
   Li X, 2009, DRUG DELIV, V16, P224, DOI 10.1080/10717540902850567
   Lu BW, 2019, INT J OPHTHALMOL-CHI, V12, P1793, DOI 10.18240/ijo.2019.11.20
   Majumdar S, 2009, PHARM RES-DORDR, V26, P1217, DOI 10.1007/s11095-008-9729-6
   Mandal A, 2017, J CONTROL RELEASE, V248, P96, DOI 10.1016/j.jconrel.2017.01.012
   Mohr A, 2007, J PHYS CHEM B, V111, P12985, DOI 10.1021/jp0731497
   Naguib SS, 2017, DRUG DELIV, V24, P99, DOI 10.1080/10717544.2016.1233588
   Natesan S, 2014, J DRUG TARGET, V22, P913, DOI 10.3109/1061186X.2014.948878
   Nayak K, 2018, BIOMED PHARMACOTHER, V107, P1564, DOI 10.1016/j.biopha.2018.08.138
   Paradkar A, 2004, INT J PHARM, V271, P281, DOI 10.1016/j.ijpharm.2003.11.014
   Pescina S, 2015, J PHARM SCI-US, V104, P63, DOI 10.1002/jps.24231
   Ponnusamy C, 2019, IET NANOBIOTECHNOL, V13, P868, DOI 10.1049/iet-nbt.2019.0130
   Ponnusamy C, 2014, CURR PHARM ANAL, V10, P44, DOI 10.2174/157341291001140102111031
   Rodrigues GA, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2519-x
   Saluja H, 2016, MOLECULES, V21, DOI 10.3390/molecules21060719
   Sapino S, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9060884
   Singh B, 2006, AAPS PHARMSCITECH, V7, DOI 10.1208/pt070103
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Subramanian N, 2004, BIOL PHARM BULL, V27, P1993, DOI 10.1248/bpb.27.1993
   Subramanian N, 2010, AIP CONF PROC, V1311, P416, DOI 10.1063/1.3530049
   Sugumaran A, 2018, EUR J PHARM SCI, V116, P15, DOI 10.1016/j.ejps.2017.10.005
   Swetledge S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-020-00745-9
   Toropainen E, 2001, INVEST OPHTH VIS SCI, V42, P2942
   Vaishya RD, 2014, WIRES NANOMED NANOBI, V6, P422, DOI 10.1002/wnan.1272
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Velpandian T., 2006, Indian Journal of Experimental Biology, V44, P387
   Vyas V, 2009, ACTA PHARMACEUT, V59, P453, DOI 10.2478/v10007-009-0037-4
   Wang JG, 2017, ACS CENTRAL SCI, V3, P743, DOI 10.1021/acscentsci.7b00156
   Zhang Y, 2007, J COLLOID INTERF SCI, V306, P398, DOI 10.1016/j.jcis.2006.10.073
NR 49
TC 3
Z9 3
U1 5
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4360
J9 POLYMERS-BASEL
JI Polymers
PD SEP
PY 2021
VL 13
IS 18
AR 3038
DI 10.3390/polym13183038
PG 17
WC Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Polymer Science
GA UX9TH
UT WOS:000701177800001
PM 34577939
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Sun, T
   Ding, Y
AF Sun, Tao
   Ding, Ying
TI Copula-based semiparametric regression method for bivariate data under
   general interval censoring
SO BIOSTATISTICS
LA English
DT Article
DE Bivariate; Copula; GWAS; Interval-censored; Semiparametric; Sieve
ID PROPORTIONAL HAZARDS MODEL; EFFICIENT ESTIMATION; ASSOCIATION;
   PROGRESSION
AB This research is motivated by discovering and underpinning genetic causes for the progression of a bilateral eye disease, age-related macular degeneration (AMD), of which the primary outcomes, progression times to late-AMD, are bivariate and interval-censored due to intermittent assessment times. We propose a novel class of copula-based semiparametric transformation models for bivariate data under general interval censoring, which includes the case 1 interval censoring (current status data) and case 2 interval censoring. Specifically, the joint likelihood is modeled through a two-parameter Archimedean copula, which can flexibly characterize the dependence between the two margins in both tails. The marginal distributions are modeled through semiparametric transformation models using sieves, with the proportional hazards or odds model being a special case. We develop a computationally efficient sieve maximum likelihood estimation procedure for the unknown parameters, together with a generalized score test for the regression parameter(s). For the proposed sieve estimators of finite-dimensional parameters, we establish their asymptotic normality and efficiency. Extensive simulations are conducted to evaluate the performance of the proposed method in finite samples. Finally, we apply our method to a genome-wide analysis of AMD progression using the Age-Related Eye Disease Study data, to successfully identify novel risk variants associated with the disease progression. We also produce predicted joint and conditional progression-free probabilities, for patients with different genetic characteristics.
C1 [Sun, Tao; Ding, Ying] Univ Pittsburgh, Dept Biostat, 130 DeSoto St, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Ding, Y (通讯作者)，Univ Pittsburgh, Dept Biostat, 130 DeSoto St, Pittsburgh, PA 15261 USA.
EM yingding@pitt.edu
OI Sun, Tao/0000-0003-4447-3005
CR Abe Sklar., 1959, FONCTIONS REPARTITIO, V8, P229
   [Anonymous], 1979, THEORETICAL STAT
   Chen MH, 2007, STAT MED, V26, P5147, DOI 10.1002/sim.2907
   Chen MH, 2014, COMMUN STAT-SIMUL C, V43, P1825, DOI 10.1080/03610918.2012.745557
   Chen MH, 2013, CAN J STAT, V41, P275, DOI 10.1002/cjs.11177
   Chen MH, 2009, STAT MED, V28, P3424, DOI 10.1002/sim.3715
   Chen XH, 2010, J ECONOMETRICS, V157, P129, DOI 10.1016/j.jeconom.2009.10.021
   CLAYTON DG, 1978, BIOMETRIKA, V65, P141, DOI 10.2307/2335289
   Cook RJ, 2009, BIOSTATISTICS, V10, P756, DOI 10.1093/biostatistics/kxp029
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Ding Y, 2011, ANN STAT, V39, P3032, DOI 10.1214/11-AOS934
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Goethals K, 2008, J APPL STAT, V35, P1071, DOI 10.1080/02664760802271389
   Goggins WB, 2000, BIOMETRICS, V56, P940, DOI 10.1111/j.0006-341X.2000.00940.x
   GUMBEL EJ, 1960, J AM STAT ASSOC, V55, P698, DOI 10.2307/2281591
   Hu T, 2017, CAN J STAT, V45, P410, DOI 10.1002/cjs.11344
   Huang J, 1997, J AM STAT ASSOC, V92, P960, DOI 10.2307/2965559
   Joe H., 1997, MULTIVARIATE MODELS
   Kiani Kaveh, 2012, International Journal of Modern Physics: Conference Series, V9, P112, DOI 10.1142/S2010194512005168
   Kim MY, 2002, STAT MED, V21, P3715, DOI 10.1002/sim.1265
   Kor CT, 2013, STAT MED, V32, P822, DOI 10.1002/sim.5562
   Lindfield GR., 1989, MICROCOMPUTERS NUMER
   Nelsen R.B., 2006, INTRO COPULAS, V2nd ed.
   OAKES D, 1982, J ROY STAT SOC B MET, V44, P414
   SEDDON J., 2014, PLOS ONE, V9, P1
   Sun T, 2019, LIFETIME DATA ANAL, V25, P546, DOI 10.1007/s10985-018-09459-5
   Tong XW, 2008, BIOMETRICAL J, V50, P364, DOI 10.1002/bimj.200710418
   Wang LM, 2008, LIFETIME DATA ANAL, V14, P134, DOI 10.1007/s10985-007-9058-9
   Wang NC, 2015, COMPUT STAT DATA AN, V83, P140, DOI 10.1016/j.csda.2014.10.013
   Wang WJ, 2000, J AM STAT ASSOC, V95, P62
   Wen CC, 2013, STAT SINICA, V23, P383, DOI 10.5705/ss.2011.151
   Wienke A, 2010, FRAILTY MODELS SURVI
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Zeng DL, 2017, BIOMETRIKA, V104, P505, DOI 10.1093/biomet/asx029
   Zhang SL, 2016, J ECONOMETRICS, V193, P215, DOI 10.1016/j.jeconom.2016.02.017
   Zhou QN, 2017, J AM STAT ASSOC, V112, P664, DOI 10.1080/01621459.2016.1158113
NR 36
TC 13
Z9 15
U1 4
U2 31
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1465-4644
EI 1468-4357
J9 BIOSTATISTICS
JI Biostatistics
PD APR
PY 2021
VL 22
IS 2
BP 315
EP 330
DI 10.1093/biostatistics/kxz032
PG 16
WC Mathematical & Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology; Mathematics
GA TS1BO
UT WOS:000679392100007
PM 31506682
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ma, X
   Ji, ZX
   Niu, SJ
   Leng, T
   Rubin, DL
   Chen, Q
AF Ma, Xiao
   Ji, Zexuan
   Niu, Sijie
   Leng, Theodore
   Rubin, Daniel L.
   Chen, Qiang
TI MS-CAM: Multi-Scale Class Activation Maps for Weakly-Supervised
   Segmentation of Geographic Atrophy Lesions in SD-OCT Images
SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
LA English
DT Article
DE Image segmentation; Feature extraction; Lesions; Annotations; Deep
   learning; Atrophy; Retina; Age-related macular degeneration; Geographic
   atrophy segmentation; SD-OCT images; Weakly supervised model;
   Multi-scale class activation maps
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; FUNDUS
   AUTOFLUORESCENCE; OBJECT DETECTION; PREVALENCE; EPITHELIUM; SALIENT
AB As one of the most critical characteristics in advanced stage of non-exudative Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) is one of the significant causes of sustained visual acuity loss. Automatic localization of retinal regions affected by GA is a fundamental step for clinical diagnosis. In this paper, we present a novel weakly supervised model for GA segmentation in Spectral-Domain Optical Coherence Tomography (SD-OCT) images. A novel Multi-Scale Class Activation Map (MS-CAM) is proposed to highlight the discriminatory significance regions in localization and detail descriptions. To extract available multi-scale features, we design a Scaling and UpSampling (SUS) module to balance the information content between features of different scales. To capture more discriminative features, an Attentional Fully Connected (AFC) module is proposed by introducing the attention mechanism into the fully connected operations to enhance the significant informative features and suppress less useful ones. Based on the location cues, the final GA region prediction is obtained by the projection segmentation of MS-CAM. The experimental results on two independent datasets demonstrate that the proposed weakly supervised model outperforms the conventional GA segmentation methods and can produce similar or superior accuracy comparing with fully supervised approaches. The source code has been released and is available on GitHub: https://github.com/ jizexuan/Multi-Scale-Class-Activation-Map-Tensorflow.
C1 [Ma, Xiao; Ji, Zexuan; Chen, Qiang] Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, Nanjing 210094, Peoples R China.
   [Niu, Sijie] Univ Jinan, Sch Informat Sci & Engn, Jinan 251600, Peoples R China.
   [Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94303 USA.
   [Rubin, Daniel L.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.
   [Rubin, Daniel L.] Stanford Univ, Med Biomed Informat Res, Stanford, CA 94305 USA.
C3 Nanjing University of Science & Technology; University of Jinan;
   Stanford University; Stanford University; Stanford University
RP Ji, ZX; Chen, Q (通讯作者)，Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, Nanjing 210094, Peoples R China.
EM 510961857@qq.com; jizexuan@njust.edu.cn; ise_niusj@ujn.edu.cn;
   tedleng@stanford.edu; dlrubin@stanford.edu; chen2qiang@njust.edu.cn
RI Rubin, Daniel/E-3740-2010
OI Rubin, Daniel/0000-0001-5057-4369; Leng, Theodore/0000-0002-8461-3562;
   Chen, Qiang/0000-0002-6685-2447; Ma, Xiao/0000-0002-1842-5029
FU Natural Science Foundation of Jiangsu Province [BK20180069]; Six talent
   peaks project in Jiangsu Province [SWYY-056]; National Science
   Foundation of China [61671242, 61701192]
FX This work was supported in part by the Natural Science Foundation of
   Jiangsu Province under Grant BK20180069, in part by Six talent peaks
   project in Jiangsu Province under Grant SWYY-056, and in part by the
   National Science Foundation of China under Grants 61671242 and 61701192.
CR Chattopadhay A, 2018, IEEE WINT CONF APPL, P839, DOI 10.1109/WACV.2018.00097
   Chen LC, 2018, IEEE T PATTERN ANAL, V40, P834, DOI 10.1109/TPAMI.2017.2699184
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Dikici E, 2020, J MED IMAGING, V7, DOI 10.1117/1.JMI.7.1.016502
   Durand T, 2017, PROC CVPR IEEE, P5957, DOI 10.1109/CVPR.2017.631
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gondal WM, 2017, IEEE IMAGE PROC, P2069, DOI 10.1109/ICIP.2017.8296646
   Grady L, 2006, IEEE T PATTERN ANAL, V28, P1768, DOI 10.1109/TPAMI.2006.233
   Han JW, 2018, IEEE SIGNAL PROC MAG, V35, P84, DOI 10.1109/MSP.2017.2749125
   Han JW, 2015, IEEE T GEOSCI REMOTE, V53, P3325, DOI 10.1109/TGRS.2014.2374218
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hu J, 2018, PROC CVPR IEEE, P7132, DOI [10.1109/TPAMI.2019.2913372, 10.1109/CVPR.2018.00745]
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Ji ZX, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.1.1
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kruhenbuahl, 2011, ADV NEURAL INFORM PR, V24, P109, DOI DOI 10.5555/2986459.2986472
   Liefers B., 2019, ARXIV190805621
   Lin M, 2014, PUBLIC HEALTH NUTR, V17, P2029, DOI [10.1017/S1368980013002176, 10.1109/PLASMA.2013.6634954]
   Liu JJ, 2019, PROC CVPR IEEE, P3912, DOI 10.1109/CVPR.2019.00404
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Lv P., 2019, ARXIV190910698
   Maggioni M, 2012, IEEE T IMAGE PROCESS, V21, P3952, DOI 10.1109/TIP.2012.2199324
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Oquab M, 2015, PROC CVPR IEEE, P685, DOI 10.1109/CVPR.2015.7298668
   Oquab M, 2014, PROC CVPR IEEE, P1717, DOI 10.1109/CVPR.2014.222
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Ramsey DJ, 2014, RETINA-J RET VIT DIS, V34, P1296, DOI 10.1097/IAE.0000000000000069
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saleh F, 2016, LECT NOTES COMPUT SC, V9912, P413, DOI 10.1007/978-3-319-46484-8_25
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Wang F, 2017, PROC CVPR IEEE, P6450, DOI 10.1109/CVPR.2017.683
   Wang XS, 2017, PROC CVPR IEEE, P3462, DOI 10.1109/CVPR.2017.369
   Wei YC, 2018, PROC CVPR IEEE, P7268, DOI 10.1109/CVPR.2018.00759
   Woo SH, 2018, LECT NOTES COMPUT SC, V11211, P3, DOI 10.1007/978-3-030-01234-2_1
   Wu H., 2019, ARXIV190311816
   Xu RB, 2018, LECT NOTES COMPUT SC, V10955, P493, DOI 10.1007/978-3-319-95933-7_58
   Yu F., 2015, ABS151107122 CORR
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhang DW, 2020, IEEE T PATTERN ANAL, V42, P1755, DOI 10.1109/TPAMI.2019.2900649
   Zhang DW, 2018, ACM T INTEL SYST TEC, V9, DOI 10.1145/3158674
   Zhang DW, 2017, IEEE T PATTERN ANAL, V39, P865, DOI 10.1109/TPAMI.2016.2567393
   Zhang JM, 2018, INT J COMPUT VISION, V126, P1084, DOI 10.1007/s11263-017-1059-x
   Zhang YH, 2019, I S BIOMED IMAGING, P565, DOI 10.1109/ISBI.2019.8759253
   Zhao QJ, 2019, AAAI CONF ARTIF INTE, P9259
   Zhou B, 2016, PROC CVPR IEEE, P2921, DOI 10.1109/CVPR.2016.319
   Zhou YZ, 2018, PROC CVPR IEEE, P3791, DOI 10.1109/CVPR.2018.00399
   Zhou ZH, 2018, NATL SCI REV, V5, P44, DOI 10.1093/nsr/nwx106
NR 52
TC 15
Z9 15
U1 6
U2 17
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2168-2194
EI 2168-2208
J9 IEEE J BIOMED HEALTH
JI IEEE J. Biomed. Health Inform.
PD DEC
PY 2020
VL 24
IS 12
BP 3443
EP 3455
DI 10.1109/JBHI.2020.2999588
PG 13
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Mathematical & Computational Biology;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematical & Computational Biology; Medical
   Informatics
GA PC7JM
UT WOS:000597173000011
PM 32750923
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Pawlowska, E
   Sobczuk, A
   Szczepanska, J
   Kaarniranta, K
AF Blasiak, Janusz
   Pawlowska, Elzbieta
   Sobczuk, Anna
   Szczepanska, Joanna
   Kaarniranta, Kai
TI The Aging Stress Response and Its Implication for AMD Pathogenesis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE the aging stress response; aging; age-related macular degeneration; AMD;
   insulin; IGF-1; SIRT1; PGC-1&#945; autophagy; DNA damage response;
   mitochondrial quality control
ID MITOCHONDRIAL-DNA MUTATIONS; RETINAL-PIGMENT EPITHELIUM; SKELETAL-MUSCLE
   FUNCTION; MACULAR DEGENERATION; OXIDATIVE STRESS; AMYLOID-BETA;
   LIFE-SPAN; PROTECTS MITOCHONDRIA; GENOMIC INSTABILITY; MEDITERRANEAN
   DIET
AB Aging induces several stress response pathways to counterbalance detrimental changes associated with this process. These pathways include nutrient signaling, proteostasis, mitochondrial quality control and DNA damage response. At the cellular level, these pathways are controlled by evolutionarily conserved signaling molecules, such as 5'AMP-activated protein kinase (AMPK), mechanistic target of rapamycin (mTOR), insulin/insulin-like growth factor 1 (IGF-1) and sirtuins, including SIRT1. Peroxisome proliferation-activated receptor coactivator 1 alpha (PGC-1 alpha), encoded by the PPARGC1A gene, playing an important role in antioxidant defense and mitochondrial biogenesis, may interact with these molecules influencing lifespan and general fitness. Perturbation in the aging stress response may lead to aging-related disorders, including age-related macular degeneration (AMD), the main reason for vision loss in the elderly. This is supported by studies showing an important role of disturbances in mitochondrial metabolism, DDR and autophagy in AMD pathogenesis. In addition, disturbed expression of PGC-1 alpha was shown to associate with AMD. Therefore, the aging stress response may be critical for AMD pathogenesis, and further studies are needed to precisely determine mechanisms underlying its role in AMD. These studies can include research on retinal cells produced from pluripotent stem cells obtained from AMD donors with the mutations, either native or engineered, in the critical genes for the aging stress response, including AMPK, IGF1, MTOR, SIRT1 and PPARGC1A.
C1 [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, PL-92216 Lodz, Poland.
   [Sobczuk, Anna] Med Univ Lodz, Dept Obstet & Gynaecol, PL-93338 Lodz, Poland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, PL-92216 Lodz, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70211, Finland.
C3 University of Lodz; Medical University Lodz; Medical University Lodz;
   Medical University Lodz; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl; elzbieta.pawlowska@umed.lodz.pl;
   anna.sobczuk@umed.lodz.pl; joanna.szczepanska@umed.lodz.pl;
   kai.kaarniranta@kuh.fi
RI ; Sobczuk, Anna/S-9261-2016
OI Blasiak, Janusz/0000-0001-9539-9584; Szczepanska,
   JOANNA/0000-0001-9912-5345; Kaarniranta, Kai/0000-0003-2600-8679;
   Sobczuk, Anna/0000-0002-3734-9842; Pawlowska,
   Elzbieta/0000-0002-5373-4783
FU National Science Center, Poland [2017/27/B/NZ3/00872]
FX This work was supported by the National Science Center, Poland grant
   number 2017/27/B/NZ3/00872.
CR Ahmed MS, 2018, MOL NEUROBIOL, V55, P4417, DOI 10.1007/s12035-017-0610-7
   Anderson AS, 2010, BEST PRACT RES CL RH, V24, P15, DOI 10.1016/j.berh.2009.08.006
   Anderson KA, 2017, BBA-BIOENERGETICS, V1858, P991, DOI 10.1016/j.bbabio.2017.09.005
   Andressoo JO, 2006, CELL CYCLE, V5, P2886, DOI 10.4161/cc.5.24.3565
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Arroba AI, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00203
   Arroba AI, 2016, DIS MODEL MECH, V9, P965, DOI 10.1242/dmm.026344
   Arroba AI, 2009, EUR J NEUROSCI, V30, P975, DOI 10.1111/j.1460-9568.2009.06902.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-David U, 2019, NAT REV CANCER, V19, P97, DOI 10.1038/s41568-018-0095-3
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blagosklonny MV, 2010, CELL CYCLE, V9, P683, DOI 10.4161/cc.9.4.10766
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144994
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Bonelli R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69164-y
   Boulianne B, 2018, ONCOGENE, V37, P971, DOI 10.1038/onc.2017.402
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Butterfield DA, 2018, J ALZHEIMERS DIS, V62, P1345, DOI 10.3233/JAD-170543
   Campisi J, 2009, J GERONTOL A-BIOL, V64, P175, DOI 10.1093/gerona/gln065
   Carmona JJ, 2016, REV INVEST CLIN, V68, P7
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Barbosa MC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00790
   Castellino N, 2018, AGING-US, V10, P4241, DOI 10.18632/aging.101727
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Choy KR, 2018, DEV DYNAM, V247, P33, DOI 10.1002/dvdy.24522
   Coppede Fabio, 2010, Curr Aging Sci, V3, P3
   Cui RZ, 2020, OPHTHALMIC RES, V63, P404, DOI 10.1159/000504891
   Dai DF, 2017, PROG MOL BIOL TRANSL, V146, P203, DOI 10.1016/bs.pmbts.2016.12.015
   de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174
   Denton D, 2015, IMMUNOL CELL BIOL, V93, P35, DOI 10.1038/icb.2014.85
   Desmettre TJ, 2018, J FR OPHTALMOL, V41, pE407, DOI 10.1016/j.jfo.2018.09.001
   Diot A, 2016, MAMM GENOME, V27, P381, DOI 10.1007/s00335-016-9651-x
   Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261
   Duijf PHG, 2019, TRENDS MOL MED, V25, P595, DOI 10.1016/j.molmed.2019.04.004
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286
   Evangelakou Z, 2019, GENES NUTR, V14, DOI 10.1186/s12263-019-0638-6
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrucci L, 2020, AGING CELL, V19, DOI 10.1111/acel.13080
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fusco S, 2012, CELL CYCLE, V11, P4135, DOI 10.4161/cc.22074
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241
   Giorgi C, 2018, INT REV CEL MOL BIO, V340, P209, DOI 10.1016/bs.ircmb.2018.05.006
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gorbunova V, 2007, NUCLEIC ACIDS RES, V35, P7466, DOI 10.1093/nar/gkm756
   Gorgoulis VG, 2018, J PATHOL, V246, P12, DOI 10.1002/path.5097
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Gredilla R, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/282438
   Gurd BJ, 2011, APPL PHYSIOL NUTR ME, V36, P589, DOI [10.1139/h11-070, 10.1139/H11-070]
   Gureev AP, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00435
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Haigis MC, 2010, MOL CELL, V40, P333, DOI 10.1016/j.molcel.2010.10.002
   Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hansen M, 2018, NAT REV MOL CELL BIO, V19, P579, DOI 10.1038/s41580-018-0033-y
   HERNANDEZSANCHEZ C, 1995, P NATL ACAD SCI USA, V92, P9834, DOI 10.1073/pnas.92.21.9834
   Hiona A, 2008, EXP GERONTOL, V43, P24, DOI 10.1016/j.exger.2007.10.001
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Jang KH, 2020, MOL CELLS, V43, P632, DOI 10.14348/molcells.2020.0078
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson SC, 2018, SUBCELL BIOCHEM, V90, P49, DOI 10.1007/978-981-13-2835-0_3
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002
   Kjobsted R, 2018, FASEB J, V32, P1741, DOI 10.1096/fj.201700442R
   Klionsky DJ, 2020, CELL DEATH DIFFER, V27, P831, DOI 10.1038/s41418-020-0511-6
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kovalchuk IP, 2014, RADIAT RES, V182, P683, DOI 10.1667/RR13697.1
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kubben N, 2017, NAT REV MOL CELL BIO, V18, P595, DOI 10.1038/nrm.2017.68
   Kudryavtseva AV, 2016, ONCOTARGET, V7, P44879, DOI 10.18632/oncotarget.9821
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   LaRocca TJ, 2014, EXP GERONTOL, V58, P78, DOI 10.1016/j.exger.2014.07.008
   Lee HC, 2007, EXP BIOL MED, V232, P592
   Lee IH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0302-7
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu FH, 2020, J MACH LEARN RES, V21
   Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Mahendra CK, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1904178
   Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404
   Mansoor Naima, 2019, Curr Mol Med, V19, P705, DOI 10.2174/1566524019666190828150625
   Marechal Alexandre, 2013, Cold Spring Harb Perspect Biol, V5, DOI 10.1101/cshperspect.a012716
   Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321
   Maynard S, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a025130
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Metaxakis A, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7050037
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moreno DF, 2019, ELIFE, V8, DOI 10.7554/eLife.48240
   Morgese MG, 2017, EUR J PHARMACOL, V817, P22, DOI 10.1016/j.ejphar.2017.08.031
   Muangnoi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133367
   Murphy MP, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003386
   Nakamura S, 2018, MOL CELLS, V41, P65, DOI 10.14348/molcells.2018.2333
   Narayan DS, 2017, CLIN EXP OPHTHALMOL, V45, P730, DOI 10.1111/ceo.12952
   Niedernhofer LJ, 2006, NATURE, V444, P1038, DOI 10.1038/nature05456
   Niedernhofer LJ, 2018, ANNU REV BIOCHEM, V87, P295, DOI 10.1146/annurev-biochem-062917-012239
   Oshima J, 2017, AGEING RES REV, V33, P105, DOI 10.1016/j.arr.2016.03.002
   Palazzo RP, 2018, MUTAT RES-GEN TOX EN, V836, P122, DOI 10.1016/j.mrgentox.2018.06.007
   Pan H, 2017, J BIOL CHEM, V292, P6452, DOI 10.1074/jbc.R116.771915
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Picca A, 2018, NAT REV CARDIOL, V15, P543, DOI 10.1038/s41569-018-0059-z
   Pinto M, 2015, FREE RADICAL BIO MED, V85, P250, DOI 10.1016/j.freeradbiomed.2015.05.005
   Pizzamiglio L, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9091969
   Poulose N, 2015, BBA-MOL BASIS DIS, V1852, P2442, DOI 10.1016/j.bbadis.2015.08.017
   Powell CD, 2000, LETT APPL MICROBIOL, V31, P46, DOI 10.1046/j.1472-765X.2000.00766.x
   Purushotham A, 2009, AGING-US, V1, P669, DOI 10.18632/aging.100076
   Rabanal-Ruiz Y, 2017, ESSAYS BIOCHEM, V61, P565, DOI 10.1042/EBC20170027
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Rambold AS, 2011, AUTOPHAGY, V7, P1568, DOI 10.4161/auto.7.12.17992
   Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Rosales MAB, 2019, LIFE SCI ALLIANCE, V2, DOI [10.26508/lsa.201800212, 10.26508/lsa.201900436]
   Rossi ML, 2010, DNA REPAIR, V9, P331, DOI 10.1016/j.dnarep.2009.12.011
   Rottenberg H, 2017, AGING CELL, V16, P943, DOI 10.1111/acel.12650
   Sacitharan PK, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0277-0
   Salminen A, 2016, AGEING RES REV, V28, P15, DOI 10.1016/j.arr.2016.04.003
   Samant RS, 2018, NATURE, V563, P407, DOI 10.1038/s41586-018-0678-x
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Schumacher B, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000161
   Sen P, 2016, CELL, V166, P822, DOI 10.1016/j.cell.2016.07.050
   Shin WH, 2020, BMB REP, V53, P56, DOI 10.5483/BMBRep.2020.53.1.283
   Skowronska-Krawczyk D, 2019, ADV EXP MED BIOL, V1185, P39, DOI 10.1007/978-3-030-27378-1_7
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Theurey P, 2018, GENES-BASEL, V9, DOI 10.3390/genes9010022
   Tiwari V, 2019, AM J HUM GENET, V105, P237, DOI 10.1016/j.ajhg.2019.06.005
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Valero T, 2014, CURR PHARM DESIGN, V20, P5507, DOI 10.2174/138161282035140911142118
   van Asten F, 2019, OPHTHALMOLOGY, V126, P1541, DOI 10.1016/j.ophtha.2019.06.004
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vestergaard PF, 2014, EUR J ENDOCRINOL, V170, P229, DOI 10.1530/EJE-13-0661
   Vijg J, 2013, ANNU REV PHYSIOL, V75, P645, DOI 10.1146/annurev-physiol-030212-183715
   Vilchez D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6659
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Weichhart T, 2018, GERONTOLOGY, V64, P127, DOI 10.1159/000484629
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo DK, 2009, EXP GERONTOL, V44, P390, DOI 10.1016/j.exger.2009.03.001
   Wu Y, 2019, CLIN INTERV AGING, V14, P1277, DOI 10.2147/CIA.S200637
   Xiong SQ, 2013, ARTERIOSCL THROM VAS, V33, P988, DOI 10.1161/ATVBAHA.112.301019
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhao LJ, 2020, AGING DIS, V11, P927, DOI 10.14336/AD.2019.0820
   Zhao LL, 2019, ENZYMES, V45, P311, DOI 10.1016/bs.enz.2019.08.004
   Zhong HH, 2017, ONCOTARGET, V8, P102640, DOI 10.18632/oncotarget.21123
   Zuo ZY, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00935
NR 161
TC 15
Z9 14
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 22
AR 8840
DI 10.3390/ijms21228840
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OY2XP
UT WOS:000594114600001
PM 33266495
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, X
   Jiang, C
   Sun, RX
   Yang, DD
   Liu, QH
AF Chen, Xue
   Jiang, Chao
   Sun, Ruxu
   Yang, Daidi
   Liu, Qinghuai
TI Circular Noncoding RNA NR3C1 Acts as a miR-382-5p Sponge to Protect RPE
   Functions via Regulating PTEN/AKT/mTOR Signaling Pathway
SO MOLECULAR THERAPY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; PTEN; DEDIFFERENTIATION; DEGENERATION;
   DYSFUNCTION; PROMOTES
AB Age-related macular degeneration (AMD) is a universal leading cause for irreversible blindness in the elderly population. Dedifferentiation of retinal pigment epithelium (RPE) cells initiates early pathological events in atrophic AMD. Herein, we aim to investigate effects of a circular RNA derived from the NR3C1 gene (circNR3C1) on regulating RPE function and AMDpathogenesis. circNR3C1 expression was consistently upregulated along with RPE differentiation and was downregulated in dysfunctional RPE and blood serum of AMD patients. Silencing of circNR3C1 reduced RPE characteristic transcripts and proteins, interrupted phagocytosis, accelerated intracellular reactive oxygen species (ROS) generation, and promoted RPE proliferation in vitro. circN3C1 silencing also decreased expressions of RPE characteristic markers and disturbed the ultrastructure of RPE in vivo, as shown by a thickened RPE with twisted basal infoldings and outer segments. Mechanistically, circNR3C1 acted as an endogenous microRNA-382-5p (miR382-5p) sponge to sequester its activity, which increased phosphatase and tensin homolog on chromosome 10 (PTEN) expression and inhibited the protein kinase B/mammalian target of rapamycin (AKT/mTOR) pathway. miR-382-5p overexpression and PTEN silencing mimicked effects of circNR3C1 silencing on RPE phenotypes in vivo and in vitro. In conclusion, circNR3C1 prevents AMD progression and protects RPE by directly sponging miR-382-5p to block its interaction with PTEN and subsequently blocks the AKT/mTOR pathway. Pharmacological circNR3C1 supplementations are promising therapeutic options for atrophic AMD.
C1 [Chen, Xue; Jiang, Chao; Sun, Ruxu; Yang, Daidi; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
C3 Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
EM liuqh@njmu.edu.cn
OI Chen, Xue/0000-0003-0370-6909; Liu, Qinghuai/0000-0003-1605-1964
FU National Natural Science Foundation of China [81770973, 81700877];
   National Key Research and Development Program of China [2017YFA0104100];
   Natural Science Foundation of Jiangsu Province [BK20171087]; Six Talent
   Peaks Project in Jiangsu Province [WSW-004]; Priority Academic Program
   Development (PAPD) of Jiangsu Higher Education Institutions
FX We thank all donors for sample donations. This study was supported by
   National Natural Science Foundation of China (81770973 to Q.L. and
   81700877 to X.C.); National Key Research and Development Program of
   China (2017YFA0104100 to Q.L.); Natural Science Foundation of Jiangsu
   Province (BK20171087 to X.C.); Six Talent Peaks Project in Jiangsu
   Province (WSW-004 to X.C.); and a project funded by the Priority
   Academic Program Development (PAPD) of Jiangsu Higher Education
   Institutions. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Aufiero S, 2019, NAT REV CARDIOL, V16, P503, DOI 10.1038/s41569-019-0185-2
   Bei YH, 2016, ONCOTARGET, V7, P1584, DOI 10.18632/oncotarget.6444
   BOK D, 1993, J CELL SCI, P189
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32
   Chen XY, 2017, MICROMACHINES-BASEL, V8, DOI 10.3390/mi8030064
   Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885
   Dudekulay DB, 2016, RNA BIOL, V13, P34, DOI 10.1080/15476286.2015.1128065
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   He J, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3681707
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890
   Jiang C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0481-5
   Jiang C, 2016, ONCOTARGET, V7, P52340, DOI 10.18632/oncotarget.10566
   Kang KH, 2009, TRENDS MOL MED, V15, P191, DOI 10.1016/j.molmed.2009.03.005
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Kulcheski FR, 2016, J BIOTECHNOL, V238, P42, DOI 10.1016/j.jbiotec.2016.09.011
   Lee EJ, 2011, BIOCHEM BIOPH RES CO, V414, P384, DOI 10.1016/j.bbrc.2011.09.083
   Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017
   Li DF, 2017, INT J MOL MED, V39, P757, DOI 10.3892/ijmm.2017.2863
   Li W, 2013, AGEING RES REV, V12, P1005, DOI 10.1016/j.arr.2013.05.006
   Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin XH, 2016, IN VITRO CELL DEV-AN, V52, P419, DOI 10.1007/s11626-015-9990-z
   Liu C, 2019, P NATL ACAD SCI USA, V116, P7455, DOI 10.1073/pnas.1814874116
   Liu DD, 2019, CELL SIGNAL, V54, P1, DOI 10.1016/j.cellsig.2018.11.012
   Liu YQ, 2010, INVEST OPHTH VIS SCI, V51, P3372, DOI 10.1167/iovs.09-4321
   Liu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep14867
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Panda AC, 2018, ADV EXP MED BIOL, V1087, P67, DOI 10.1007/978-981-13-1426-1_6
   Qu SB, 2017, RNA BIOL, V14, P992, DOI 10.1080/15476286.2016.1220473
   Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003
   Seok JK, 2014, NUCLEIC ACIDS RES, V42, P8062, DOI 10.1093/nar/gku515
   Shan K, 2017, CIRCULATION, V136, P1629, DOI 10.1161/CIRCULATIONAHA.117.029004
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tian B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02407-7
   Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31
   Yao J, 2019, BIOMED PHARMACOTHER, V111, P548, DOI 10.1016/j.biopha.2018.12.044
   Zhang HD, 2018, BREAST CANCER-TOKYO, V25, P1, DOI 10.1007/s12282-017-0793-9
   Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017
   Zhao C, 2006, HUM GENET, V119, P617, DOI 10.1007/s00439-006-0168-3
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zheng FX, 2019, CANCER LETT, V460, P139, DOI 10.1016/j.canlet.2019.06.018
NR 50
TC 23
Z9 26
U1 2
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD MAR 4
PY 2020
VL 28
IS 3
BP 929
EP 945
DI 10.1016/j.ymthe.2020.01.010
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA KT3AM
UT WOS:000518887200022
PM 32017889
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Young, BM
   Jones, K
   Massengill, MT
   Walsh, E
   Li, H
   Lewin, AS
   Ildefonso, CJ
AF Young, Brianna M.
   Jones, Kyle
   Massengill, Michael T.
   Walsh, Erin
   Li, Hong
   Lewin, Alfred S.
   Ildefonso, Cristhian J.
TI Expression of a CARD Slows the Retinal Degeneration of a Geographic
   Atrophy Mouse Model
SO MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
ID MITOCHONDRIAL OXIDATIVE STRESS; MACULAR DEGENERATION; PIGMENT
   EPITHELIUM; ACTIVATION; INFLAMMATION; RECRUITMENT; INDUCTION; RPE
AB Age-related macular degeneration (AMD) has been linked to oxidative damage and para-inflammation, an activation of inflammasome signaling in the retinal pigment epithelium (RPE) and the underlying choriocapillaris. Herein, we tested the efficacy of a gene-delivered caspase-1 inhibitor in controlling the retinal degeneration observed in two models of RPE-choroid oxidative damage. In an acute model of oxidative stress (NaIO3 injection), eyes pre-treated with the sGFP-TatCARD (trans-activator of transcription; caspase activation and recruitment domain) vector demonstrated a recovery of retinal function and partial protection of RPE structure 1 month after damage, in contrast with control-treated eyes. In a model of chronic oxidative stress (RPE-specific deletion of Sod2), eyes treated with the sGFP-TatCARD vector after the onset of degeneration had a significantly slower decline in retinal function when compared to control-treated eyes. Earlier treatment of this model with the same adeno-associated virus (AAV) vector resulted in a greater protection of RPE function in eyes treated with the TatCARD when compared to control-treated eyes. Our results demonstrate that intravitreal delivery of sGFP-TatCARD reduces inflammation and can protect the retina from both acute and sustained oxidative damage within the RPE and choroid. Therefore, gene therapy with a cell-penetrating inflammasome inhibitor such as CARD may stem the progression of AMD.
C1 [Young, Brianna M.; Walsh, Erin; Ildefonso, Cristhian J.] Univ Florida, Dept Ophthalmol, Coll Med, POB 100284, Gainesville, FL 32610 USA.
   [Jones, Kyle; Massengill, Michael T.; Li, Hong; Lewin, Alfred S.; Ildefonso, Cristhian J.] Univ Florida, Dept Mol Genet & Microbiol, Coll Med, Gainesville, FL 32610 USA.
   [Young, Brianna M.] Trinity Sch Med, Trinity Coll Rd,Ribishi VC0100, Kingstown, St Vincent.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Ildefonso, CJ (通讯作者)，Univ Florida, Dept Ophthalmol, Coll Med, POB 100284, Gainesville, FL 32610 USA.
EM ildefons@ufl.edu
RI Ildefonso, Cristhian/AAC-3576-2021
FU National Eye Institute [R01EY026268]; Bright Focus Foundation
   [M2017126]; Research to Prevent Blindness, Inc.; NATIONAL EYE INSTITUTE
   [R01EY026268] Funding Source: NIH RePORTER
FX This work was supported by a grant from the National Eye Institute
   (R01EY026268), a research grant from the Bright Focus Foundation
   (M2017126), and an unrestricted grant from Research to Prevent
   Blindness, Inc.
CR Appelbaum T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177224
   Berkowitz BA, 2017, INVEST OPHTH VIS SCI, V58, P3286, DOI 10.1167/iovs.17-21850
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bian ZM, 2018, EXP EYE RES, V170, P29, DOI 10.1016/j.exer.2018.02.014
   Biswal MR, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21272
   Biswal MR, 2016, ADV EXP MED BIOL, V854, P30, DOI 10.1007/978-3-319-17121-0_5
   Camelo S, 2015, MOL VIS, V21, P1051
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen W, 2017, INFLAMM RES, V66, P157, DOI 10.1007/s00011-016-1002-6
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Dexter PM, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0144-18.2018
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Feng H, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6973175
   Feng SF, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8546423
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Ildefonso CJ, 2015, MOL THER, V23, P875, DOI 10.1038/mt.2015.30
   Kay CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062097
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Liu W, 2015, J CELL MOL MED, V19, P1949, DOI 10.1111/jcmm.12570
   Lobanova ES, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04117-8
   Lu A, 2014, CELL, V156, P1193, DOI 10.1016/j.cell.2014.02.008
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pierce EA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017285
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Sorsby A, 1941, Br J Ophthalmol, V25, P58, DOI 10.1136/bjo.25.2.58
   Sudharsan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18236-7
   Wang JY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101601
   Wu J, 2004, J NEUROPHYSIOL, V91, P1134, DOI 10.1152/jn.00958.2003
   Xiao JH, 2017, INVEST OPHTH VIS SCI, V58, P1801, DOI 10.1167/iovs.16-21392
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
NR 37
TC 3
Z9 3
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2329-0501
J9 MOL THER-METH CLIN D
JI Mol.Ther.-Methods Clin. Dev.
PD SEP 13
PY 2019
VL 14
BP 113
EP 125
DI 10.1016/j.omtm.2019.06.001
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IX6AR
UT WOS:000485765700011
PM 31334304
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ibbett, P
   Goverdhan, SV
   Pipi, E
   Chouhan, JK
   Keeling, E
   Angus, EM
   Scott, JA
   Gatherer, M
   Page, A
   Teeling, JL
   Lotery, AJ
   Ratnayaka, JA
AF Ibbett, Paul
   Goverdhan, Srinivas V.
   Pipi, Elena
   Chouhan, Joe K.
   Keeling, Eloise
   Angus, Elizabeth M.
   Scott, Jenny A.
   Gatherer, Maureen
   Page, Anton
   Teeling, Jessica L.
   Lotery, Andrew J.
   Ratnayaka, J. Arjuna
TI A lasered mouse model of retinal degeneration displays progressive outer
   retinal pathology providing insights into early geographic atrophy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; FUNDUS
   AUTOFLUORESCENCE; PREVALENCE; COMPLEX; AMD; ACTIVATION; EXPRESSION;
   MORPHOLOGY; MEMBRANE
AB Early stages of geographic atrophy (GA) age-related macular degeneration is characterised by the demise of photoreceptors, which precedes the loss of underlying retinal pigment epithelial (RPE) cells. Sight-loss due to GA has no effective treatment; reflecting both the complexity of the disease and the lack of suitable animal models for testing potential therapies. We report the development and characterisation of a laser-induced mouse model with early GA-like pathology. Retinas were lasered at adjacent sites using a 810 nm laser (1.9 J/spot), resulting in the development of confluent, hypopigmented central lesions with well-defined borders. Optical Coherence Tomography over 2-months showed progressive obliteration of photoreceptors with hyper-reflective outer plexiform and RPE/Bruch's membrane (BrM) layers within lesions, but an unaffected inner retina. Light/electron microscopy after 3-months revealed lesions without photoreceptors, leaving the outer plexiform layer apposed to the RPE. We observed outer segment debris, hypo/hyperpigmented RPE, abnormal apical-basal RPE surfaces and BrM thickening. Lesions had wedge-shaped margins, extended zones of damage, activated Muller cells, microglial recruitment and functional retinal deficits. mRNA studies showed complement and inflammasome activation, microglial/macrophage phagocytosis and oxidative stress providing mechanistic insights into GA. We propose this mouse model as an attractive tool for early GA studies and drug-discovery.
C1 [Ibbett, Paul; Pipi, Elena; Chouhan, Joe K.; Teeling, Jessica L.] Univ Southampton, Biol Sci, SGH, South Lab & Path Block,MP840,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Goverdhan, Srinivas V.; Keeling, Eloise; Scott, Jenny A.; Gatherer, Maureen; Lotery, Andrew J.; Ratnayaka, J. Arjuna] Univ Southampton, Clin & Expt Sci, Fac Med, MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Goverdhan, Srinivas V.; Lotery, Andrew J.] Univ Hosp Southampton NHS Fdn Trust, Eye Unit, Southampton SO16 6YD, Hants, England.
   [Angus, Elizabeth M.; Page, Anton] Univ Southampton, Biomed Imaging Unit, MP12,Tremona Rd, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton; University Hospital Southampton NHS Foundation Trust;
   University of Southampton
RP Lotery, AJ; Ratnayaka, JA (通讯作者)，Univ Southampton, Clin & Expt Sci, Fac Med, MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.; Lotery, AJ (通讯作者)，Univ Hosp Southampton NHS Fdn Trust, Eye Unit, Southampton SO16 6YD, Hants, England.
EM A.J.Lotery@soton.ac.uk; J.Ratnayaka@soton.ac.uk
OI Teeling, Jessica/0000-0003-4004-7391; Lotery,
   Andrew/0000-0001-5541-4305; Ratnayaka, J. Arjuna/0000-0002-1027-6938;
   Chouhan, Joe/0000-0002-8067-5352
FU Fight for Sight; Macular Society
FX The authors thank Dr. Helena Lee (University of Southampton) for reading
   the manuscript, Ms Lesley Lawes (BRF, Southampton) for images and Dr.
   David A. Johnston (Biomedical Imaging Unit, University of Southampton)
   for assistance with confocal microscopy. This work was funded by awards
   from Fight for Sight and the Macular Society. We thank the Gift of Sight
   Appeal for purchasing the OCT and Micron III equipment used in this
   work.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   BIGNAMI A, 1979, EXP EYE RES, V28, P63
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Dimopoulos IS, 2013, INVEST OPHTH VIS SCI, V54, P5186, DOI 10.1167/iovs.13-12194
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Ma MW, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0150-7
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Murinello S, 2014, INVEST OPHTH VIS SCI, V55, P247, DOI 10.1167/iovs.13-11821
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Shahidi M, 2002, BRIT J OPHTHALMOL, V86, P623, DOI 10.1136/bjo.86.6.623
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yadav NK, 2014, INDIAN J OPHTHALMOL, V62, P50, DOI 10.4103/0301-4738.126179
NR 49
TC 11
Z9 11
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 16
PY 2019
VL 9
AR 7475
DI 10.1038/s41598-019-43906-z
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HY3KT
UT WOS:000468026100017
PM 31097765
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Morita, Y
   Miwa, Y
   Jounai, K
   Fujiwara, D
   Kurihara, T
   Kanauchi, O
AF Morita, Yuji
   Miwa, Yukihiro
   Jounai, Kenta
   Fujiwara, Daisuke
   Kurihara, Toshihide
   Kanauchi, Osamu
TI Lactobacillus paracasei KW3110 Prevents Blue Light-Induced Inflammation
   and Degeneration in the Retina
SO NUTRIENTS
LA English
DT Article
DE Lactobacillus paracasei KW3110; retina; light; macrophage
ID LACTIC-ACID BACTERIA; APOPTOTIC CELL-DEATH; MACROPHAGE PLASTICITY;
   M-CSF; DAMAGE; SUPPLEMENTATION; DIFFERENTIATION; PHOTORECEPTORS;
   POLARIZATION; ACTIVATION
AB Age-related macular degeneration and retinitis pigmentosa are leading causes of blindness and share a pathological feature, which is photoreceptor degeneration. To date, the lack of a potential treatment to prevent such diseases has raised great concern. Photoreceptor degeneration can be accelerated by excessive light exposure via an inflammatory response; therefore, anti-inflammatory agents would be candidates to prevent the progress of photoreceptor degeneration. We previously reported that a lactic acid bacterium, Lactobacillus paracasei KW3110 (L. paracasei KW3110), activated macrophages suppressing inflammation in mice and humans. Recently, we also showed that intake of L. paracasei KW3110 could mitigate visual display terminal (VDT) load-induced ocular disorders in humans. However, the biological mechanism of L. paracasei KW3110 to retain visual function remains unclear. In this study, we found that L. paracasei KW3110 activated M2 macrophages inducing anti-inflammatory cytokine interleukin-10 (IL-10) production in vitro using bone marrow-derived M2 macrophages. We also show that IL-10 gene expression was significantly increased in the intestinal immune tissues 6 h after oral administration of L. paracasei KW3110 in vivo. Furthermore, we demonstrated that intake of L. paracasei KW3110 suppressed inflammation and photoreceptor degeneration in a murine model of light-induced retinopathy. These results suggest that L. paracasei KW3110 may have a preventive effect against degrative retinal diseases.
C1 [Morita, Yuji; Fujiwara, Daisuke; Kanauchi, Osamu] Kirin Co Ltd, Res Labs Hlth Sci & Food Technol, Kanazawa Ku, 1-13-5 Fukuura, Yokohama, Kanagawa 2360004, Japan.
   [Miwa, Yukihiro; Kurihara, Toshihide] Keio Univ, Sch Med, Lab Photobiol, Tokyo 1608582, Japan.
   [Miwa, Yukihiro; Kurihara, Toshihide] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo 1608582, Japan.
   [Jounai, Kenta] Koiwai Dairy Prod Co Ltd, Tech Dev Ctr, Sayama, Saitama 3501321, Japan.
C3 Keio University; Keio University
RP Morita, Y (通讯作者)，Kirin Co Ltd, Res Labs Hlth Sci & Food Technol, Kanazawa Ku, 1-13-5 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM Yuji_Morita@kirin.co.jp; yukihiro226@gmail.com;
   k_jounai@koiwai-dairy.co.jp; d-fujiwara@kirin.co.jp;
   kurihara@z8.keio.jp; kanauchio@kirin.co.jp
RI Kurihara, Toshihide/ABA-7058-2020
OI Kurihara, Toshihide/0000-0002-5457-2720; Miwa,
   Yukihiro/0000-0002-5377-6772
FU Kirin Company, Limited
FX This work was supported by Kirin Company, Limited.
CR Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Choi W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139761
   Duncan D'Anne S, 2017, J Clin Cell Immunol, V8, DOI 10.4172/2155-9899.1000506
   Fleetwood AJ, 2007, J IMMUNOL, V178, P5245, DOI 10.4049/jimmunol.178.8.5245
   Fleetwood AJ, 2009, J LEUKOCYTE BIOL, V86, P411, DOI 10.1189/jlb.1108702
   Fujiwara D, 2004, INT ARCH ALLERGY IMM, V135, P205, DOI 10.1159/000081305
   Fujiwara D., 2005, ALLERGOL INT, V54, P143, DOI DOI 10.2332/ALLERGOLINT.54.143
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346
   Ichikawa S, 2009, BIOSCI BIOTECH BIOCH, V73, P1561, DOI 10.1271/bbb.90058
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Kaji R, 2010, J IMMUNOL, V184, P3505, DOI 10.4049/jimmunol.0901569
   Kishi S, 2010, JPN J OPHTHALMOL, V54, P514, DOI 10.1007/s10384-010-0849-2
   Kobayashi Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198493
   Kubota S, 2010, AM J PATHOL, V177, P1725, DOI 10.2353/ajpath.2010.100098
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kuse Y, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00207
   Lei B, 2006, INVEST OPHTH VIS SCI, V47, P2732, DOI 10.1167/iovs.05-1461
   London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202
   Fernandez EM, 2011, GUT, V60, P1444, DOI [10.1136/gut.2010.232918corr1, 10.1136/gut.2010.232918]
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   MARSHALL J, 1972, EXP EYE RES, V14, P164, DOI 10.1016/0014-4835(72)90063-2
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Mia S, 2014, SCAND J IMMUNOL, V79, P305, DOI 10.1111/sji.12162
   Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469
   Morita Y, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081058
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Narimatsu T, 2014, CLIN EXP OPHTHALMOL, V42, P555, DOI 10.1111/ceo.12253
   Noailles A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0186-3
   Platania CBM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00670
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Saenz-de-Viteri M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/637137
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   Satoh T, 2013, NATURE, V495, P524, DOI 10.1038/nature11930
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1864, DOI 10.1167/iovs.06-1065
   Tanito M, 2006, EXP EYE RES, V83, P1493, DOI 10.1016/j.exer.2006.08.006
   Uchino Y, 2012, J NUTR HEALTH AGING, V16, P478, DOI 10.1007/s12603-012-0059-3
   Wakabayashi H, 2008, INT ARCH ALLERGY IMM, V145, P141, DOI 10.1159/000108139
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 44
TC 12
Z9 12
U1 2
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD DEC
PY 2018
VL 10
IS 12
AR 1991
DI 10.3390/nu10121991
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA HG6EG
UT WOS:000455073200172
PM 30558320
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Xue, J
   Camino, A
   Bailey, ST
   Liu, XY
   Li, DW
   Jia, YL
AF Xue, Jie
   Camino, Acner
   Bailey, Steven T.
   Liu, Xiyu
   Li, Dengwang
   Jia, Yali
TI Automatic quantification of choroidal neovascularization lesion area on
   OCT angiography based on density cell-like P systems with active
   membranes
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; MACULAR DEGENERATION; ALGORITHM;
   PROJECTION; SEGMENTATION; IMAGES; OPTIMIZATION
AB Detecting and quantifying the size of choroidal neovascularization (CNV) is important for the diagnosis and assessment of neovascular age-related macular degeneration. Depth-resolved imaging of the retinal and choroidal vasculature by optical coherence tomography angiography (OCTA) has enabled the visualization of CNV. However, due to the prevalence of artifacts, it is difficult to segment and quantify the CNV lesion area automatically. We have previously described a saliency algorithm for CNV detection that could identify a CNV lesion area with 83% accuracy. However, this method works under the assumption that the CNV region is the most salient area for visual attention in the whole image and consequently, errors occur when this requirement is not met (e.g. when the lesion occupies a large portion of the image). Moreover, saliency image processing methods cannot extract the edges of the salient object very accurately. In this paper, we propose a novel and automatic CNV segmentation method based on an unsupervised and parallel machine learning technique named density cell-like P systems (DEC P systems). DEC P systems integrate the idea of a modified clustering algorithm into cell-like P systems. This method improved the accuracy of detection to 87.2% on 22 subjects and obtained clear boundaries of the CNV lesions. (C) 2018 Optical Society of America under the terms of the OSA Open Access Publishing Agreement.
C1 [Xue, Jie; Camino, Acner; Bailey, Steven T.; Jia, Yali] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Xue, Jie; Liu, Xiyu] Shandong Normal Univ, Sch Management Sci & Engn, Jinan 250014, Shandong, Peoples R China.
   [Xue, Jie; Li, Dengwang] Shandong Normal Univ, Sch Phys & Elect, Shandong Prov Key Lab Med Phys & Image Proc Techn, Jinan 250014, Shandong, Peoples R China.
C3 Oregon Health & Science University; Shandong Normal University; Shandong
   Normal University
RP Jia, YL (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
EM dengwang@sdnu.edu.cn; jiaya@ohsu.edu
RI Xue, Jie/ABC-2905-2021
OI Xue, Jie/0000-0002-4952-5583; Bailey, Steven/0000-0003-4949-1464; Li,
   Dengwang/0000-0001-5126-3888; Jia, Yali/0000-0002-2784-1905
FU National Institutes of Health [R01EY027833, DP3 DK104397, R01 EY024544,
   P30 EY010572]; Research to Prevent Blindness (New York, NY); Natural
   Science Foundation of China [61640201, 61472231, 71602103, 61502283];
   China Postdoctoral Project [40411583]; China Scholarship Council
   [201708370073]; National Natural Science Foundation of China [61471226];
   Natural Science Foundation for Distinguished Young Scholars of Shandong
   Province [JQ201516]; Taishan scholar project of Shandong Province
FX National Institutes of Health (R01EY027833, DP3 DK104397, R01 EY024544,
   P30 EY010572); unrestricted departmental funding grant and William &
   Mary Greve Special Scholar Award from Research to Prevent Blindness (New
   York, NY); Natural Science Foundation of China (No. 61640201, 61472231,
   71602103, 61502283); China Postdoctoral Project (40411583); China
   Scholarship Council (201708370073); National Natural Science Foundation
   of China (61471226); Natural Science Foundation for Distinguished Young
   Scholars of Shandong Province (JQ201516); Taishan scholar project of
   Shandong Province.
CR Birant D, 2007, DATA KNOWL ENG, V60, P208, DOI 10.1016/j.datak.2006.01.013
   Camino A, 2017, BIOMED OPT EXPRESS, V8, P3053, DOI 10.1364/BOE.8.003053
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Christinal HA, 2011, PATTERN RECOGN LETT, V32, P2206, DOI 10.1016/j.patrec.2011.05.004
   Diaz-Pernil D, 2013, PATTERN RECOGN LETT, V34, P846, DOI 10.1016/j.patrec.2012.10.014
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, P4485, DOI 10.1167/iovs.16-20080
   Gao SS, 2015, OPT LETT, V40, P2305, DOI 10.1364/OL.40.002305
   Goferman S, 2012, IEEE T PATTERN ANAL, V34, P1915, DOI 10.1109/TPAMI.2011.272
   Gutierrez-Naranjo MA, 2007, THEOR COMPUT SCI, V371, P54, DOI 10.1016/j.tcs.2006.10.013
   Hemalatha M., 2011, INT J COMPUT SCI, V8, P473
   Huang L, 2011, INFORM SCIENCES, V181, P2370, DOI 10.1016/j.ins.2010.12.015
   Jain AK, 1999, ACM COMPUT SURV, V31, P264, DOI 10.1145/331499.331504
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jie X., 2016, J COMPUT THEOR NANOS, V13, P3895
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Liew AWC, 2003, IEEE T MED IMAGING, V22, P1063, DOI 10.1109/TMI.2003.816956
   Liu L, 2015, BIOMED OPT EXPRESS, V6, P3564, DOI 10.1364/BOE.6.003564
   Malihi M, 2017, BRIT J OPHTHALMOL, V101, P45, DOI 10.1136/bjophthalmol-2016-309094
   Paun G, 2000, J COMPUT SYST SCI, V61, P108, DOI 10.1006/jcss.1999.1693
   Paun G, 2006, BIOSYSTEMS, V85, P11, DOI 10.1016/j.biosystems.2006.02.001
   Peng H, 2017, KNOWL-BASED SYST, V125, P74, DOI 10.1016/j.knosys.2017.03.024
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xue J., 2016, J COMPUT THEOR NANOS, V13, P4198
   Xue J, 2014, SOFT COMPUT, V18, P1425, DOI 10.1007/s00500-013-1155-y
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang GX, 2013, APPL SOFT COMPUT, V13, P1528, DOI 10.1016/j.asoc.2012.05.032
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 34
TC 17
Z9 17
U1 0
U2 8
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD JUL 1
PY 2018
VL 9
IS 7
BP 3208
EP 3219
DI 10.1364/BOE.9.003208
PG 12
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA GL8HV
UT WOS:000437460600023
PM 29984094
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Al-Janabi, A
   Lightman, S
   Tomkins-Netzer, O
AF Al-Janabi, Ahmed
   Lightman, Sue
   Tomkins-Netzer, Oren
TI Statins in retinal disease
SO EYE
LA English
DT Review
ID DIABETIC MACULAR EDEMA; PROLIFERATIVE VITREORETINAL DISEASES;
   ENDOTHELIAL PROGENITOR CELLS; REDUCTASE INHIBITORS STATINS;
   CONTROL-CARDIOVASCULAR-RISK; URBAN-RURAL EPIDEMIOLOGY; SERUM-LIPIDS;
   VEIN-THROMBOSIS; CURES EYE; RETINOPATHY
AB Statins are known for their blood cholesterol-lowering effect and are widely used in patients with cardiovascular and metabolic diseases. Research over the past three decades shows that statins have diverse effects on different pathophysiological pathways involved in angiogenesis, inflammation, apoptosis, and anti-oxidation, leading to new therapeutic options. Recently, statins have attracted considerable attention for their immunomodulatory effect. Since immune reactivity has been implicated in a number of retinal diseases, such as uveitis, age-related macular degeneration (AMD) and diabetic retinopathy, there is now a growing body of evidence supporting the beneficial effects of statins in these retinopathies. This review evaluates the relationship between statins and the pathophysiological basis of these diseases, focusing on their potential role in treatment. A PubMed database search and literature review was conducted. Among AMD patients, there is inconsistent evidence regarding protection against development of early AMD or delaying disease progression; though they have been found to reduce the risk of developing choroidal neovascular membranes (CNV). In patients with retinal vein occlusion, there was no evidence to support a therapeutic benefit or a protective role with statins. In patients with diabetic retinopathy, statins demonstrate a reduction in disease progression and improved resolution of diabetic macular oedema (DMO). Among patients with uveitis, statins have a protective effect by reducing the likelihood of uveitis development.
C1 [Al-Janabi, Ahmed; Lightman, Sue; Tomkins-Netzer, Oren] Moorfields Eye Hosp, London, England.
   [Al-Janabi, Ahmed; Lightman, Sue; Tomkins-Netzer, Oren] UCL, Inst Ophthalmol, London, England.
   [Tomkins-Netzer, Oren] Technion, Bnai Zion Med Ctr, Ophthalmol Dept, Haifa, Israel.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Bnai Zion Medical Center; Technion Israel Institute of Technology
RP Al-Janabi, A (通讯作者)，Moorfields Eye Hosp, London, England.; Al-Janabi, A (通讯作者)，UCL, Inst Ophthalmol, London, England.
EM a.kasb@ucl.ac.uk
OI Tomkins-Netzer, Oren/0000-0002-1015-1641
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Albert MA, 2003, CIRCULATION, V108, P161, DOI 10.1161/01.CIR.0000080289.72166.CF
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Borkar DS, 2015, AM J OPHTHALMOL, V159, P707, DOI 10.1016/j.ajo.2015.01.009
   Buse JB, 2007, AM J CARDIOL, V99, p21I, DOI 10.1016/j.amjcard.2007.03.003
   CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216
   Chataway J, 2014, LANCET, V383, P2213, DOI 10.1016/S0140-6736(13)62242-4
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2443, DOI 10.1016/j.ophtha.2014.07.019
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288
   Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004
   Chowdhury T, 2002, EYE, V16, P689, DOI 10.1038/sj.eye.6700205
   Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Cusick M, 2003, OPHTHALMOLOGY, V110, P2126, DOI 10.1016/j.ophtha.2003.01.001
   CUTHBERT JA, 1991, T ASSOC AM PHYSICIAN, V104, P97
   Denniston AKO, 2005, DIABETIC MED, V22, P665, DOI 10.1111/j.1464-5491.2005.01484.x
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DODSON PM, 1982, BRIT J OPHTHALMOL, V66, P161, DOI 10.1136/bjo.66.3.161
   DORNAN TL, 1982, DIABETOLOGIA, V22, P167, DOI 10.1007/BF00283746
   ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346
   Erie JC, 2016, OPHTHAL EPIDEMIOL, V23, P40, DOI 10.3109/09286586.2015.1077258
   Fadini GP, 2008, ATHEROSCLEROSIS, V197, P496, DOI 10.1016/j.atherosclerosis.2007.12.039
   Fried LF, 2001, J DIABETES COMPLICAT, V15, P113, DOI 10.1016/S1056-8727(01)00140-4
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245
   Garcia-Ramirez M, 2016, ACTA DIABETOL, V53, P109, DOI 10.1007/s00592-015-0759-3
   Gegg ME, 2005, J IMMUNOL, V174, P2327, DOI 10.4049/jimmunol.174.4.2327
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   GORDON B, 1991, AM J OPHTHALMOL, V112, P385, DOI 10.1016/S0002-9394(14)76244-0
   Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010
   Gupta A, 2004, AM J OPHTHALMOL, V137, P675, DOI 10.1016/j.ajo.2003.11.017
   Gustavsson C, 2008, RETINA-J RET VIT DIS, V28, P645, DOI 10.1097/IAE.0b013e31815ec32d
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hove MN, 2004, ACTA OPHTHALMOL SCAN, V82, P443, DOI 10.1111/j.1600-0420.2004.00270.x
   Ilyina Y, 2016, SPEKTRUM AUGENHEILKD, V30, P111, DOI 10.1007/s00717-016-0300-2
   Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901
   Jarvisalo MJ, 1999, ATHEROSCLEROSIS, V147, P237, DOI 10.1016/S0021-9150(99)00189-6
   Jew OM, 2012, INT J OPHTHALMOL-CHI, V5, P499, DOI 10.3980/j.issn.2222-3959.2012.04.18
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Kawahara S, 2008, DIABETES, V57, P2784, DOI 10.2337/db08-0302
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105
   Kittleson Michelle M, 2013, Clin Transpl, P135
   KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261
   Klein BEK, 1999, AM J OPHTHALMOL, V128, P652, DOI 10.1016/S0002-9394(99)00222-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003
   Kohno H, 2007, EXP EYE RES, V84, P569, DOI 10.1016/j.exer.2006.11.011
   Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219
   La Mura V, 2013, HEPATOLOGY, V57, P1172, DOI 10.1002/hep.26127
   Landmesser U, 2000, SEMIN THROMB HEMOST, V26, P529, DOI 10.1055/s-2000-13209
   Lee WJ, 2012, BRIT J OPHTHALMOL, V96, P1426, DOI 10.1136/bjophthalmol-2012-301913
   Liinamaa MJ, 2008, ANN MED, V40, P209, DOI 10.1080/07853890701749209
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   Matei VM, 2017, GRAEF ARCH CLIN EXP, V255, P761, DOI 10.1007/s00417-016-3569-6
   McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   Medina RJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002584
   Miljanovic B, 2004, DIABETES, V53, P2883, DOI 10.2337/diabetes.53.11.2883
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Murphy CC, 2005, ARCH OPHTHALMOL-CHIC, V123, P634, DOI 10.1001/archopht.123.5.634
   Musial J, 2001, INT J CARDIOL, V77, P247, DOI 10.1016/S0167-5273(00)00439-3
   Narang S, 2012, NEPAL J OPHTHALMOL, V4, P23, DOI 10.3126/nepjoph.v4i1.5846
   Nielsen SF, 2014, LANCET DIABETES ENDO, V2, P894, DOI 10.1016/S2213-8587(14)70173-1
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   O'Mahoney PRA, 2008, ARCH OPHTHALMOL-CHIC, V126, P692, DOI 10.1001/archopht.126.5.692
   Omae T, 2012, INVEST OPHTH VIS SCI, V53, P2880, DOI 10.1167/iovs.11-8841
   Ozkiris A, 2007, BRIT J OPHTHALMOL, V91, P69, DOI 10.1136/bjo.2006.098285
   Panagiotoglou TD, 2010, OPHTHAL SURG LAS IM, V41, P316, DOI 10.3928/15428877-20100430-04
   Peiretti E, 2014, EXP EYE RES, V124, P11, DOI 10.1016/j.exer.2014.04.017
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Prisco D, 2002, PATHOPHYSIOL HAEMO T, V32, P308, DOI 10.1159/000073587
   Rangaswamy S, 1997, CIRC RES, V80, P37, DOI 10.1161/01.RES.80.1.37
   Rehak M, 2010, J THROMB HAEMOST, V8, P1886, DOI 10.1111/j.1538-7836.2010.03909.x
   Rema M, 2006, DIABETIC MED, V23, P1029, DOI 10.1111/j.1464-5491.2006.01890.x
   Rema M, 2005, INVEST OPHTH VIS SCI, V46, P2328, DOI 10.1167/iovs.05-0019
   Robinson R, 2011, INVEST OPHTH VIS SCI, V52, P7423, DOI 10.1167/iovs.11-7912
   Rychwalski P J, 1997, J AAPOS, V1, P111, DOI 10.1016/S1091-8531(97)90009-4
   Sadeghi MM, 2001, TRANSPLANTATION, V71, P1262, DOI 10.1097/00007890-200105150-00014
   Sen K, 2002, DIABETES RES CLIN PR, V56, P1, DOI 10.1016/S0168-8227(01)00341-2
   Sever PS, 2004, DRUGS, V64, P43, DOI 10.2165/00003495-200464002-00005
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Talwar N, 2017, JAMA OPHTHALMOL, V135, P263, DOI 10.1001/jamaophthalmol.2016.5406
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tomkins-Netzer O, 2014, OPHTHALMOLOGY, V121, P2387, DOI 10.1016/j.ophtha.2014.07.007
   Tuuminen R, 2015, GRAEF ARCH CLIN EXP, V253, P1685, DOI 10.1007/s00417-014-2873-2
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wong TY, 2008, OPHTHALMOLOGY, V115, P1869, DOI 10.1016/j.ophtha.2008.05.014
   Wu WC, 2011, EXP EYE RES, V93, P842, DOI 10.1016/j.exer.2011.09.016
   Yoshida M, 2001, ARTERIOSCL THROM VAS, V21, P1165, DOI 10.1161/hq0701.092143
   Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158
   Yunker JJ, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-8
   Zhang J, 2007, ARCH OPHTHALMOL-CHIC, V125, P1096, DOI 10.1001/archopht.125.8.1096
   Zhang W, 2012, EXP EYE RES, V105, P1, DOI 10.1016/j.exer.2012.09.014
   Zhang Y, 2015, INT J MOL MED, V36, P399, DOI 10.3892/ijmm.2015.2244
NR 107
TC 12
Z9 13
U1 2
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2018
VL 32
IS 5
BP 981
EP 991
DI 10.1038/s41433-018-0066-7
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF3FR
UT WOS:000431831500015
PM 29556012
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Marchesi, N
   Thongon, N
   Pascale, A
   Provenzani, A
   Koskela, A
   Korhonen, E
   Smedowski, A
   Govoni, S
   Kauppinen, A
   Kaarniranta, K
   Amadio, M
AF Marchesi, Nicoletta
   Thongon, Natthakan
   Pascale, Alessia
   Provenzani, Alessandro
   Koskela, Ali
   Korhonen, Eveliina
   Smedowski, Adrian
   Govoni, Stefano
   Kauppinen, Anu
   Kaarniranta, Kai
   Amadio, Marialaura
TI Autophagy Stimulus Promotes Early HuR Protein Activation and p62/SQSTM1
   Protein Synthesis in ARPE-19 Cells by Triggering Erk1/2, p38(MAPK), and
   JNK Kinase Pathways
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MESSENGER-RNA STABILITY; NEURONAL ELAV
   PROTEINS; MACULAR DEGENERATION; OXIDATIVE STRESS; POSTTRANSCRIPTIONAL
   REGULATION; BINDING PROTEINS; GENE-EXPRESSION; EYE DEVELOPMENT; SH-SY5Y
   CELLS
AB RNA-binding protein dysregulation and altered expression of proteins involved in the autophagy/proteasome pathway play a role in many neurodegenerative disease onset/progression, including age-related macular degeneration (AMD). HuR/ELAVL1 is a master regulator of gene expression in human physiopathology. In ARPE-19 cells exposed to the proteasomal inhibitor MG132, HuR positively affects at posttranscriptional level p62 expression, a stress response gene involved in protein aggregate clearance with a role in AMD. Here, we studied the early effects of the proautophagy AICAR + MG132 cotreatment on the HuR-p62 pathway. We treated ARPE-19 cells with Erk1/2, AMPK, p38(MAPK), PKC, and JNK kinase inhibitors in the presence of AICAR + MG132 and evaluated HuR localization/phosphorylation and p62 expression. Two-hour AICAR + MG132 induces both HuR cytoplasmic translocation and threonine phosphorylation via the Erk1/2 pathway. In these conditions, p62 mRNA is loaded on polysomes and its translation in de novo protein is favored. Additionally, for the first time, we report that JNK can phosphorylate HuR, however, without modulating its localization. Our study supports HuR's role as an upstream regulator of p62 expression in ARPE-19 cells, helps to understand better the early events in response to a proautophagy stimulus, and suggests that modulation of the autophagy-regulating kinases as potential therapeutic targets for AMD may be relevant.
C1 [Marchesi, Nicoletta; Pascale, Alessia; Govoni, Stefano; Amadio, Marialaura] Univ Pavia, Dept Drug Sci, Pharmacol Sect, I-27100 Pavia, Italy.
   [Thongon, Natthakan; Provenzani, Alessandro] Univ Trento, Ctr Integrat Biol, Lab Genom Screening, I-38123 Trento, Italy.
   [Koskela, Ali; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Korhonen, Eveliina; Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland.
   [Smedowski, Adrian] Med Univ Silesia, Sch Med Katowice, Chair & Dept Physiol, Katowice, Poland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
C3 University of Pavia; University of Trento; University of Eastern
   Finland; University of Eastern Finland; Medical University Silesia;
   Kuopio University Hospital; University of Eastern Finland
RP Amadio, M (通讯作者)，Univ Pavia, Dept Drug Sci, Pharmacol Sect, I-27100 Pavia, Italy.
EM marialaura.amadio@unipv.it
RI Smedowski, Adrian/ABA-1031-2021; Marchesi, Nicoletta/GQZ-7428-2022
OI Smedowski, Adrian/0000-0001-8528-955X; Marchesi,
   Nicoletta/0000-0001-6271-1420; Korhonen, Eveliina/0000-0002-5360-7258
FU Finnish Eye Foundation; University of Eastern Finland; Fondazione
   Cariplo [40102636]
FX This work was supported by the Finnish Eye Foundation and the University
   of Eastern Finland strategy support (Kai Kaarniranta) and by Fondazione
   Cariplo (no. 40102636 to Alessandro Provenzani). The authors acknowledge
   Fondazione Banca del Monte di Lombardia for supporting Nicoletta
   Marchesi during her training. The authors are grateful to Anne Seppanen
   and Chiara Zucal for technical support.
CR Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299
   Amadio M, 2008, CURR PHARM DESIGN, V14, P2651, DOI 10.2174/138161208786264052
   Amadio M, 2008, PHARMACOL RES, V57, P60, DOI 10.1016/j.phrs.2007.11.006
   Amadio M, 2016, PHARMACOL RES, V111, P713, DOI 10.1016/j.phrs.2016.07.042
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Baek SH, 2017, MOL CELL, V65, P781, DOI 10.1016/j.molcel.2016.12.027
   Bolognani F, 2008, J NEUROSCI RES, V86, P481, DOI 10.1002/jnr.21473
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Brauer U, 2014, BIOCHEM SOC T, V42, P1147, DOI 10.1042/BST20140103
   Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854
   Brinegar AE, 2016, BRAIN RES, V1647, P1, DOI 10.1016/j.brainres.2016.02.050
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Colombrita C, 2013, MOL CELL NEUROSCI, V56, P447, DOI 10.1016/j.mcn.2013.02.003
   Dash S, 2016, WIRES RNA, V7, P527, DOI 10.1002/wrna.1355
   De Conti L, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1394
   Eberhardt W, 2012, CURR PROTEIN PEPT SC, V13, P380, DOI 10.2174/138920312801619439
   Farooq F, 2009, HUM MOL GENET, V18, P4035, DOI 10.1093/hmg/ddp352
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557
   Grammatikakis I, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1372
   Guo Y, 2012, EXP CELL RES, V318, P2004, DOI 10.1016/j.yexcr.2012.04.015
   Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6
   Hytti M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17645
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Ichimura Y, 2008, AUTOPHAGY, V4, P1063, DOI 10.4161/auto.6826
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Katsanou V., 2006, ERNST SCHERING FOUND, V1, P37
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim JH, 2014, EXP CELL RES, V327, P340, DOI 10.1016/j.yexcr.2014.08.001
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09
   Li YJ, 2015, CELL PHYSIOL BIOCHEM, V35, P1663, DOI 10.1159/000373980
   Marchesi N, 2014, J CELL PHYSIOL, V229, P1776, DOI 10.1002/jcp.24631
   Milani P, 2013, NEUROBIOL DIS, V60, P51, DOI 10.1016/j.nbd.2013.08.005
   Morel E, 2017, ANNU REV PHARMACOL, V57, P375, DOI 10.1146/annurev-pharmtox-010716-104936
   Nabors LB, 2001, CANCER RES, V61, P2154
   Nasti R, 2017, J MED CHEM, V60, P8257, DOI 10.1021/acs.jmedchem.6b01871
   Osera C, 2015, RNA BIOL, V12, P1121, DOI 10.1080/15476286.2015.1085276
   Pascale A, 2008, CELL MOL LIFE SCI, V65, P128, DOI 10.1007/s00018-007-7017-y
   Pascale A, 2005, P NATL ACAD SCI USA, V102, P12065, DOI 10.1073/pnas.0504702102
   Pascale A, 2012, CELL MOL LIFE SCI, V69, P501, DOI 10.1007/s00018-011-0810-7
   Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008
   Rubio N, 2014, FREE RADICAL BIO MED, V67, P292, DOI 10.1016/j.freeradbiomed.2013.11.010
   Salminen A, 2016, AGEING RES REV, V28, P15, DOI 10.1016/j.arr.2016.04.003
   Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790
   Smedowski A, 2018, BBA-MOL BASIS DIS, V1864, P296, DOI 10.1016/j.bbadis.2017.10.030
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su CY, 2016, TOXICOLOGY, V363, P48, DOI 10.1016/j.tox.2016.07.002
   Talman V, 2013, PHARMACOL RES, V73, P44, DOI 10.1016/j.phrs.2013.04.008
   Vegliante R, 2016, CARCINOGENESIS, V37, P233, DOI 10.1093/carcin/bgw003
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Woodhoo A, 2012, HEPATOLOGY, V56, P1870, DOI 10.1002/hep.25828
   Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003
   Yashiro T, 2013, ATHEROSCLEROSIS, V226, P95, DOI 10.1016/j.atherosclerosis.2012.09.033
   Yu KM, 2007, GRAEF ARCH CLIN EXP, V245, P993, DOI 10.1007/s00417-006-0467-3
   Yuan Z, 2010, HISTOL HISTOPATHOL, V25, P1331, DOI 10.14670/HH-25.1331
   Zisopoulou S, 2013, BEHAV BRAIN RES, V253, P280, DOI 10.1016/j.bbr.2013.07.036
   Zou TT, 2008, BIOCHEM J, V409, P389, DOI 10.1042/BJ20070860
   Zou X, 2012, J NUTR BIOCHEM, V23, P994, DOI 10.1016/j.jnutbio.2011.05.006
   Zucal C, 2015, CURR DRUG TARGETS, V16, P499, DOI 10.2174/1389450116666150223163632
NR 66
TC 14
Z9 14
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2018
VL 2018
AR 4956080
DI 10.1155/2018/4956080
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FW5ZC
UT WOS:000425397000001
PM 29576851
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Zarubina, AV
   Huisingh, CE
   Clark, ME
   Sloan, KR
   McGwin, G
   Crosson, JN
   Curcio, CA
   Owsley, C
AF Zarubina, Anna V.
   Huisingh, Carrie E.
   Clark, Mark E.
   Sloan, Kenneth R.
   McGwin, Gerald, Jr.
   Crosson, Jason N.
   Curcio, Christine A.
   Owsley, Cynthia
TI Rod-Mediated Dark Adaptation and Macular Pigment Optical Density in
   Older Adults with Normal Maculas
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Macular pigment; dark adaptation; aging; Muller cells
ID VISUAL PERFORMANCE; SPATIAL PROFILE; COHERENCE TOMOGRAPHY; DOUBLE-BLIND;
   AGE; ZEAXANTHIN; LUTEIN; SUPPLEMENTATION; CAROTENOIDS; HOLE
AB Purpose: To examine the association between macular pigment optical density (MPOD) and rod-mediated dark adaptation (RMDA) in persons 60 years old with normal maculas as determined by an accepted color fundus photography grading system.
   Methods: This cross-sectional analysis used baseline data from eyes in the Alabama Study on Early Age-Related Macular Degeneration. Eyes at step 1 in the AREDS 9-step grading system were considered normal. Eyes were additionally assessed by spectral domain optical coherence tomography (SD-OCT). Foveal MPOD was estimated via heterochromatic flicker photometry, and RMDA was assessed with a computerized dark adaptometer. The association between RMDA and MPOD was examined via Spearman correlation coefficients adjusted for age.
   Results: In 306 eyes from 306 persons (mean age 68.2years) in normal macular health, MPOD was not associated with RMDA (age-adjusted rank correlation=0.043, p=0.45). After 81 eyes with incidental macular findings by SD-OCT evaluation were excluded, the association between MPOD and RMDA remained null (N=225, age-adjusted r=0.015, p=0.82).
   Conclusion: In a large sample of normal aged eyes, RMDA, a visual function that is rate limited by retinoid availability to photoreceptors across the complex of retinal pigment epithelium, Bruch's membrane, and choriocapillaris, is not related to MPOD in the neurosensory retina.
C1 [Zarubina, Anna V.; Huisingh, Carrie E.; Clark, Mark E.; Sloan, Kenneth R.; McGwin, Gerald, Jr.; Crosson, Jason N.; Curcio, Christine A.; Owsley, Cynthia] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 South 18th St,Suite 609, Birmingham, AL 35294 USA.
   [Sloan, Kenneth R.] Univ Alabama Birmingham, Dept Comp Sci, Birmingham, AL USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Crosson, Jason N.] Retina Consultants Alabama, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 South 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
FU NIH [R01AG04212, R01EY06109]; EyeSight Foundation of Alabama; Dorsett
   Davis Discovery Fund; Alfreda J. Schueler Trust; Research to Prevent
   Blindness National Eye Institute [R01EY06109]; National Institute on
   Aging [R01AG04212]; NATIONAL EYE INSTITUTE [R01EY006109] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004212] Funding Source:
   NIH RePORTER
FX Financial support: NIH R01AG04212, R01EY06109; EyeSight Foundation of
   Alabama; Dorsett Davis Discovery Fund; Alfreda J. Schueler Trust;
   Research to Prevent Blindness National Eye Institute [R01EY06109];
   National Institute on Aging [R01AG04212].
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Anderson DMG, 2014, J AM SOC MASS SPECTR, V25, P1394, DOI 10.1007/s13361-014-0883-2
   Balaratnasingam C, 2015, INVEST OPHTH VIS SCI, V56, P7859, DOI 10.1167/iovs.15-17532
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Beirne RO, 2013, VISION RES, V86, P81, DOI 10.1016/j.visres.2013.04.002
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bovier ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108178
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Kinkelder R, 2011, EYE, V25, P105, DOI 10.1038/eye.2010.164
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P8016, DOI 10.1167/iovs.11-7610
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Distler C, 1996, VISION RES, V36, P2381, DOI 10.1016/0042-6989(96)00005-3
   Erdman JW, 2015, FOODS, V4, P547, DOI 10.3390/foods4040547
   Feeney J, 2013, NEUROBIOL AGING, V34, P2449, DOI 10.1016/j.neurobiolaging.2013.05.007
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fuijkschot J, 2008, OPHTHALMOLOGY, V115, P870, DOI 10.1016/j.ophtha.2007.05.063
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Govetto A, 2017, AM J OPHTHALMOL, V184, P167, DOI 10.1016/j.ajo.2017.10.011
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438
   Iannaccone A, 2016, FOODS, V5, DOI 10.3390/foods5020032
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Loughman J, 2012, ACTA OPHTHALMOL, V90, pe90, DOI 10.1111/j.1755-3768.2011.02294.x
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Matet A, 2015, AM J OPHTHALMOL, V159, P1142, DOI 10.1016/j.ajo.2015.02.013
   Mewborn CM, 2018, ARCH CLIN NEUROPSYCH, V33, P861, DOI 10.1093/acn/acx109
   Mohn ES, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186767
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Obana A, 2017, INVEST OPHTH VIS SCI, V58, P5157, DOI 10.1167/iovs.17-22347
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pang CE, 2016, RETINA-J RET VIT DIS, V36, P1408, DOI 10.1097/IAE.0000000000001069
   Patryas L, 2014, GRAEF ARCH CLIN EXP, V252, P657, DOI 10.1007/s00417-014-2564-z
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Renzi LM, 2010, OPHTHAL PHYSL OPT, V30, P351, DOI 10.1111/j.1475-1313.2010.00720.x
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Rudich DS, 2013, JAMA OPHTHALMOL, V131, P1244, DOI 10.1001/jamaophthalmol.2013.2374
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2015, INVEST OPHTH VIS SCI, V56, P2459, DOI 10.1167/iovs.14-15716
   Theelen T, 2014, ACTA OPHTHALMOL, V92, P138, DOI 10.1111/aos.12092
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   van der Made SM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/9035745
   van der Veen RLP, 2010, OPHTHALMOLOGY, V117, P966, DOI 10.1016/j.ophtha.2009.10.019
   Van Der Veen RLP, 2009, EUR J OPHTHALMOL, V19, P836, DOI 10.1177/112067210901900524
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   Westrup VMZ, 2014, INVEST OPHTH VIS SCI, V55, P1169, DOI 10.1167/iovs.13-12903
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
NR 83
TC 5
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2018
VL 43
IS 7
BP 913
EP 920
DI 10.1080/02713683.2018.1460380
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GJ8WY
UT WOS:000435673600011
PM 29634370
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tang, ZM
   Zhang, Y
   Wang, YY
   Zhang, DD
   Shen, BQ
   Luo, M
   Gu, P
AF Tang, Zhimin
   Zhang, Yi
   Wang, Yuyao
   Zhang, Dandan
   Shen, Bingqiao
   Luo, Min
   Gu, Ping
TI Progress of stem/progenitor cell-based therapy for retinal degeneration
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Retinal degeneration; Stem/progenitor cells; Clinical trials;
   Proliferation; Differentiation; Transplantation
ID MESENCHYMAL STEM-CELLS; PIGMENT EPITHELIAL-CELLS; RESCUE PHOTORECEPTOR
   CELLS; BONE-MARROW; PROGENITOR CELLS; IN-VITRO; RETINITIS-PIGMENTOSA;
   ADIPOSE-TISSUE; XENO-FREE; MACULAR DEGENERATION
AB Retinal degeneration (RD), such as age-related macular degeneration (AMD) and retinitis pigmentosa, is one of the leading causes of blindness. Presently, no satisfactory therapeutic options are available for these diseases principally because the retina and retinal pigmented epithelium (RPE) do not regenerate, although wet AMD can be prevented from further progression by anti-vascular endothelial growth factor therapy. Nevertheless, stem/progenitor cell approaches exhibit enormous potential for RD treatment using strategies mainly aimed at the rescue and replacement of photoreceptors and RPE. The sources of stem/progenitor cells are classified into two broad categories in this review, which are (1) ocular-derived progenitor cells, such as retinal progenitor cells, and (2) non-ocular-derived stem cells, including embryonic stem cells, induced pluripotent stem cells, and mesenchymal stromal cells. Here, we discuss in detail the progress in the study of four predominant stem/progenitor cell types used in animal models of RD. A short overview of clinical trials involving the stem/progenitor cells is also presented. Currently, stem/progenitor cell therapies for RD still have some drawbacks such as inhibited proliferation and/or differentiation in vitro (with the exception of the RPE) and limited long-term survival and function of grafts in vivo. Despite these challenges, stem/progenitor cells represent the most promising strategy for RD treatment in the near future.
C1 [Tang, Zhimin; Zhang, Yi; Wang, Yuyao; Zhang, Dandan; Shen, Bingqiao; Luo, Min; Gu, Ping] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Ophthalmol, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University
RP Luo, M; Gu, P (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Ophthalmol, Shanghai 200011, Peoples R China.
EM luomin621124@hotmail.com; guping2009@126.com
FU National High Technology Research and Development Program (863 Program)
   [2015AA020311]; National Natural Science Foundations of China
   [81570883]; Science and Technology Commission of Shanghai [14JC1493103];
   Shanghai Municipal Education Commission-Gaofeng Clinical Medicine
   [20161316]
FX This work was sponsored by the National High Technology Research and
   Development Program (863 Program) (2015AA020311), National Natural
   Science Foundations of China (81570883), Science and Technology
   Commission of Shanghai (14JC1493103), and Shanghai Municipal Education
   Commission-Gaofeng Clinical Medicine Grant Support (20161316).
CR Aftab U, 2009, EXP EYE RES, V89, P301, DOI 10.1016/j.exer.2009.03.025
   Angenieux B, 2006, STEM CELLS, V24, P696, DOI 10.1634/stemcells.2005-0190
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Ballios BG, 2015, STEM CELL REP, V4, P1031, DOI 10.1016/j.stemcr.2015.04.008
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Baranov PY, 2014, TISSUE ENG PT A, V20, P1465, DOI [10.1089/ten.tea.2013.0361, 10.1089/ten.TEA.2013.0361]
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Calejo MT, 2016, J BIOMED MATER RES A, V104, P1646, DOI 10.1002/jbm.a.35690
   Canola K, 2007, INVEST OPHTH VIS SCI, V48, P446, DOI 10.1167/iovs.06-0190
   Chang KY, 2009, ACTA BIOMATER, V5, P1937, DOI 10.1016/j.actbio.2009.02.002
   Chaudhry GR, 2009, STEM CELLS DEV, V18, P247, DOI 10.1089/scd.2008.0057
   Chen HL, 2011, INT J NANOMED, V6, P453, DOI 10.2147/IJN.S17057
   Chen MF, 2015, AGING CELL, V14, P635, DOI 10.1111/acel.12346
   Cho SJ, 2010, CELL REPROGRAM, V12, P739, DOI 10.1089/cell.2010.0009
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   Decembrini S, 2014, STEM CELL REP, V2, P853, DOI 10.1016/j.stemcr.2014.04.010
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Fan YN, 2016, NUCLEIC ACIDS RES, V44, pW135, DOI 10.1093/nar/gkw288
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Gomez MC, 2010, THERIOGENOLOGY, V74, P498, DOI 10.1016/j.theriogenology.2010.05.023
   Gong LH, 2008, CLIN EXP OPHTHALMOL, V36, P666, DOI 10.1111/j.1442-9071.2008.01857.x
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107
   Hu YM, 2014, STEM CELLS DEV, V23, P2771, DOI 10.1089/scd.2014.0021
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huang LB, 2013, OCUL IMMUNOL INFLAMM, V21, P276, DOI 10.3109/09273948.2013.791925
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jensen AM, 1997, DEV BIOL, V188, P267, DOI 10.1006/dbio.1997.8645
   Jonas JB, 2008, ACTA OPHTHALMOL, V86, P225, DOI 10.1111/j.1600-0420.2007.00987.x
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe131, DOI 10.1111/j.1755-3768.2009.01564.x
   Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Klassen H, 2008, CLONING STEM CELLS, V10, P391, DOI 10.1089/clo.2008.0010
   Klassen H, 2007, STEM CELLS, V25, P1222, DOI 10.1634/stemcells.2006-0541
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Li CY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0066-5
   Li JY, 2015, J CRANIOFAC SURG, V26, P548, DOI 10.1097/SCS.0000000000001348
   Li P, 2016, CURR MOL MED, V16, P567, DOI 10.2174/1566524016666160607090953
   Li SY, 2009, CURR EYE RES, V34, P523, DOI 10.1080/02713680902936148
   Li Y, 2016, ADV EXP MED BIOL, V854, P549, DOI 10.1007/978-3-319-17121-0_73
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Li Z, 2016, CURR MOL MED, V16, P553, DOI 10.2174/1566524016666160607090538
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liu K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173047
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   Machalinska A, 2013, INVEST OPHTH VIS SCI, V54, P8292, DOI 10.1167/iovs.13-12221
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634
   Melief SM, 2013, STEM CELL TRANSL MED, V2, P455, DOI 10.5966/sctm.2012-0184
   Meyer JS, 2006, STEM CELLS, V24, P274, DOI 10.1634/stemcells.2005-0059
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Nature, NATURE
   Ni N, 2014, SCI REP-UK, V4, DOI 10.1038/srep06671
   O'Brien KMB, 2003, MOL VIS, V9, P401
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Park JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052481
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Pasquin S, 2015, CYTOKINE GROWTH F R, V26, P507, DOI 10.1016/j.cytogfr.2015.07.007
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   PRADA C, 1991, EUR J NEUROSCI, V3, P559, DOI 10.1111/j.1460-9568.1991.tb00843.x
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Qiu GT, 2007, EXP EYE RES, V84, P1047, DOI 10.1016/j.exer.2007.01.014
   Radtke ND, 1999, AM J OPHTHALMOL, V128, P384, DOI 10.1016/S0002-9394(99)00250-0
   Ren F, 2017, ANIM REPROD SCI, V178, P59, DOI 10.1016/j.anireprosci.2017.01.009
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Rezanejad H, 2014, CELL TISSUE RES, V356, P65, DOI 10.1007/s00441-014-1795-y
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Sasahara M, 2008, AM J PATHOL, V172, P1693, DOI 10.2353/ajpath.2008.080024
   Schraermeyer U, 2001, CELL TRANSPLANT, V10, P673, DOI 10.3727/000000001783986215
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 2009, VET OPHTHALMOL, V12, P158, DOI 10.1111/j.1463-5224.2009.00693.x
   Sharma VS, 2017, BIOTECHNOL LETT, V39, P339, DOI 10.1007/s10529-016-2244-7
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Siqueira RC, 2013, BONE MARROW TRANSPL, V48, P612, DOI 10.1038/bmt.2012.185
   Siqueira RC, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0020-6
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takahashi Masayo, 2006, V330, P417
   Takemitsu H, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-150
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tian CY, 2011, TISSUE ENG PT A, V17, P2523, DOI [10.1089/ten.tea.2010.0649, 10.1089/ten.TEA.2010.0649]
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0
   Tzameret A, 2015, STEM CELL RES, V15, P387, DOI 10.1016/j.scr.2015.08.007
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang YR, 2016, MOL BIOL EVOL, V33, P2232, DOI 10.1093/molbev/msw089
   WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732
   Xu W., 2014, MATH PROBL ENG, V2014, P1, DOI DOI 10.3109/02713683.2013.824988
   Xu YH, 2015, GRAEF ARCH CLIN EXP, V253, P1085, DOI 10.1007/s00417-015-2961-y
   Yanai A., 2013, METHOD MOL BIOL, V1307, P357, DOI DOI 10.1007/7651_
   Yanai A, 2015, TISSUE ENG PT A, V21, P1763, DOI [10.1089/ten.TEA.2014.0669, 10.1089/ten.tea.2014.0669]
   Yang P, 2002, EXP NEUROL, V177, P326, DOI 10.1006/exnr.2002.7955
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Yue FM, 2010, BIOCHEM BIOPH RES CO, V394, P877, DOI 10.1016/j.bbrc.2010.03.008
   Zahabi A, 2012, STEM CELLS DEV, V21, P2262, DOI 10.1089/scd.2011.0599
   Zhang DD, 2015, SCI REP-UK, V5, DOI 10.1038/srep14326
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
   Zheng A, 2015, EXPERT OPIN BIOL TH, V15, P391, DOI 10.1517/14712598.2015.1006192
   Zhou L, 2011, STEM CELLS, V29, P972, DOI 10.1002/stem.637
   Zhou PY, 2015, J CELL SCI, V128, P2169, DOI 10.1242/jcs.169086
   Zhu Y, 2016, METHODS MOL BIOL, V1307, P345, DOI 10.1007/7651_2013_56
NR 122
TC 41
Z9 44
U1 0
U2 33
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAY 10
PY 2017
VL 15
AR 99
DI 10.1186/s12967-017-1183-y
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EV8EZ
UT WOS:000402014700001
PM 28486987
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shu, QM
   Zhuang, H
   Fan, JW
   Wang, X
   Xu, GZ
AF Shu, Qinmeng
   Zhuang, Hong
   Fan, Jiawen
   Wang, Xin
   Xu, Gezhi
TI Wogonin induces retinal neuron-like differentiation of bone marrow stem
   cells by inhibiting Notch-1 signaling
SO ONCOTARGET
LA English
DT Article
DE wogonin; bone marrow stem cells; Notch-1; retinal degenerative diseases;
   differentiation
ID ROOT GANGLION NEURONS; MACULAR DEGENERATION; LATERAL INHIBITION;
   PROGENITOR CELLS; GENE-EXPRESSION; LEUKEMIA-CELLS; NEUROGENESIS;
   PATHWAY; PHOSPHORYLATION; MECHANISMS
AB Age-related macular degeneration and retinitis pigmentosa are major causes of irreversible vision loss in the elderly and, despite sustained efforts, current treatments are largely ineffective. Wogonin is a bioactive plant flavonoid possessing a range of beneficial properties, including neuroprotective effects. We investigated the ability of wogonin to promote retinal neuron-like differentiation of bone marrow stem cells (BMSCs) and assessed the involvement of Notch-1 signaling in this process. Cultured mouse BMSCs were left untreated or exposed to neurotrophic factors in the presence or absence of wogonin, and western blotting, RT-PCR and immunofluorescence were used to identify changes in molecular markers of stemness and neuroretinal differentiation. Proteins in the Notch-1 signaling pathway, a main negative regulator of neurogenesis, were also examined by western blotting. We found that expression of stem cell markers was reduced, while markers of mature retinal neurons, bipolar cells and photoreceptors were increased in wogonin-treated BMSCs. Wogonin also dose-dependently decreased expression of Notch-1 signaling proteins. Moreover, blockade of Notch-1 both mimicked and enhanced the effect of wogonin to facilitate BMSC differentiation into retinal neuron-like cells. Wogonin thus appears to promote retinal neuron-like differentiation of BMSCs by antagonizing the inhibitory actions of Notch-1 signaling on neurogenesis and may be useful in the treatment of retinal degenerative diseases.
C1 [Shu, Qinmeng; Zhuang, Hong; Fan, Jiawen; Wang, Xin; Xu, Gezhi] Fudan Univ, Shanghai Med Coll, Eye & ENT Hosp, Dept Ophthalmol & Vis Sci, Shanghai, Peoples R China.
   [Shu, Qinmeng; Zhuang, Hong; Fan, Jiawen; Wang, Xin; Xu, Gezhi] Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.
C3 Fudan University
RP Xu, GZ (通讯作者)，Fudan Univ, Shanghai Med Coll, Eye & ENT Hosp, Dept Ophthalmol & Vis Sci, Shanghai, Peoples R China.; Xu, GZ (通讯作者)，Shanghai Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.
EM gezhixu@126.com
FU National Key Basic Research Program of China [2013CB967503]; National
   Natural Science Foundation of China [NSFC 81570854]; Youth Project of
   the National Natural Science Fund [81300780, 81500723, 81500734,
   81600739]
FX This study was supported by the National Key Basic Research Program of
   China (2013CB967503); National Natural Science Foundation of China
   (Grant No. NSFC 81570854); Youth Project of the National Natural Science
   Fund 2013 (81300780), 2015 (81500723 and 81500734) and 2016 (81600739).
CR Abdelfattah NS, 2016, OPHTHALMOLOGY
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294
   Chen FY, 2015, J MOL NEUROSCI, V55, P995, DOI 10.1007/s12031-014-0456-7
   Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355
   Chen SB, 2015, CELL MOL NEUROBIOL, V35, P523, DOI 10.1007/s10571-014-0148-4
   Chirumbolo S, 2013, TOXICOLOGY, V314, P60, DOI 10.1016/j.tox.2013.08.016
   Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fischer A, 2007, NUCLEIC ACIDS RES, V35, P4583, DOI 10.1093/nar/gkm477
   Flames N, 2005, NEURON, V46, P377, DOI 10.1016/j.neuron.2005.04.020
   Hatakeyama J, 2004, DEVELOPMENT, V131, P5539, DOI 10.1242/dev.01436
   Haubensak W, 2004, P NATL ACAD SCI USA, V101, P3196, DOI 10.1073/pnas.0308600100
   Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560
   Imayoshi I, 2013, SCIENCE, V342, P1203, DOI 10.1126/science.1242366
   Jadhav AR, 2006, DEVELOPMENT, V133, P913, DOI 10.1242/dev.02245
   Jadhav AP, 2006, P NATL ACAD SCI USA, V103, P18998, DOI 10.1073/pnas.0608155103
   Kageyama R, 2008, NAT NEUROSCI, V11, P1247, DOI 10.1038/nn.2208
   Levkovitch-Verbin H, 2010, INVEST OPHTH VIS SCI, V51, P6394, DOI 10.1167/iovs.09-4310
   Lim JS, 2010, BIOCHEM BIOPH RES CO, V402, P42, DOI 10.1016/j.bbrc.2010.09.098
   Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040
   Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522
   Lucas CD, 2015, AM J RESP CRIT CARE, V191, P626, DOI 10.1164/rccm.201408-1565OC
   Marklund U, 2010, DEVELOPMENT, V137, P437, DOI 10.1242/dev.036806
   Masai I, 2000, NEURON, V27, P251, DOI 10.1016/S0896-6273(00)00034-9
   Nam KW, 2014, BIOCHEM BIOPH RES CO, V450, P1518, DOI 10.1016/j.bbrc.2014.07.018
   Nelson BR, 2009, DEV DYNAM, V238, P2163, DOI 10.1002/dvdy.21848
   Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002
   Piao HZ, 2004, ARCH PHARM RES, V27, P930, DOI 10.1007/BF02975846
   Rapaport DH, 2004, J COMP NEUROL, V474, P304, DOI 10.1002/cne.20134
   Roberts PA, 2016, PROG RETIN EYE RES, V53, P48, DOI 10.1016/j.preteyeres.2016.04.001
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shimojo H, 2008, NEURON, V58, P52, DOI 10.1016/j.neuron.2008.02.014
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Tomita M, 2006, STEM CELLS, V24, P2270, DOI 10.1634/stemcells.2005-0507
   Yeung J, 2016, J NEUROSCI, V36, P9057, DOI 10.1523/JNEUROSCI.4385-15.2016
   Zhang HW, 2008, EUR J PHARMACOL, V591, P7, DOI 10.1016/j.ejphar.2008.06.024
   Zhang K, 2008, CANCER SCI, V99, P689, DOI 10.1111/j.1349-7006.2008.00728.x
NR 39
TC 8
Z9 9
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 25
PY 2017
VL 8
IS 17
BP 28431
EP 28441
DI 10.18632/oncotarget.16085
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA ET1SU
UT WOS:000400050000065
PM 28415701
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Stojanov, O
AF Stojanov, Oliver
TI Charles Bonnet syndrome
SO VOJNOSANITETSKI PREGLED
LA English
DT Article
DE hallucinations; vision, ocular; macular degeneration; diagnostic
   techniques and procedures; diagnosis, differental
ID VISUAL HALLUCINATIONS; PREVALENCE
AB Introduction. Charles Bonnet syndrome (CBS) is a condition that causes visual hallucinations in patients without any mental illnesses. CBS is characterized by the presence of vivid, complex and recurrent visual hallucinations, and do not occur in the setting or as part of delirium or other psychological illnesses. The condition is present in patients who have visual loss due to age-related macular degeneration (AND), cataracts and/or other ocular diseases that influence vision. Case report. A 81-year-od woman reported to ophthalmologist complaining of visual hallucinations that consisted of white pigeons. Hallucinations were present for two years and she was well aware that hallucinations were unreal. Mental illnesses were excluded by the psychiatrist. Complete ophthalmologic examination was performed, and finding revealed visual acuity of 0.3 (right eye) and 0.5 (left eye), in both eyes cataracts and AMD (wet form). Optical coherence tomography confirmed the fundoscopic finding of AMD. The patient rejected treatment of cataracts and AMD due to old age, and hallucinations persisted. Conclusion. CBS should be considered in patients with visual hallucinations and ocular diseases that influence vision. It is essential to distinguish CBS from mental illnesses, since patients with CBS are fully aware that hallucinations are not real. Awareness of CBS could help physicians upon referring patients to ophthalmologists instead of psychiatrists, and therefore avoid patients being misdiagnosed.
C1 [Stojanov, Oliver] Hlth Ctr Novi Sad, Deptartment Ophthalmol, Bul Cara Lazara 75, Novi Sad 21000, Serbia.
   [Stojanov, Oliver] Univ Novi Sad, Fac Med, Novi Sad, Serbia.
C3 University of Novi Sad
RP Stojanov, O (通讯作者)，Hlth Ctr Novi Sad, Deptartment Ophthalmol, Bul Cara Lazara 75, Novi Sad 21000, Serbia.
EM oliverstojanov23@gmail.com
OI Stojanov, Oliver/0000-0001-6455-5011
CR Doane J, 2013, J CLIN HYPERTENS, V15, P230, DOI 10.1111/jch.12063
   Hartney KE, 2011, J PSYCHIATR PRACT, V17, P137, DOI 10.1097/01.pra.0000396067.87343.fb
   Jan T, 2012, WEST J EMERG MED, V13, P544, DOI 10.5811/westjem.2012.7.12891
   Kester EM, 2009, OPTOMETRY, V80, P360, DOI 10.1016/j.optm.2008.10.017
   Madill SA, 2005, BRIT J OPHTHALMOL, V89, P785, DOI 10.1136/bjo.2005.066027
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Roever CP, 2012, ANN LONG TERM CARE, V20, P25
   Rovner BW, 2006, CURR OPIN OPHTHALMOL, V17, P275, DOI 10.1097/01.icu.0000193100.13551.ac
   Santos-Bueso E, 2014, EUR J OPHTHALMOL, V24, P960, DOI 10.5301/ejo.5000483
   Schadlu AP, 2009, CURR OPIN OPHTHALMOL, V20, P219, DOI 10.1097/ICU.0b013e328329b643
   Shiraishi Y, 2004, J PSYCHIATR RES, V38, P207, DOI 10.1016/S0022-3956(03)00090-6
   Singh A, 2012, ACTA OPHTHALMOL, V90, P476, DOI 10.1111/j.1755-3768.2010.02051.x
   Vale TC, 2014, ARQ NEURO-PSIQUIAT, V72, P333, DOI 10.1590/0004-282X20140015
   Vukicevic M, 2008, CLIN EXP OPHTHALMOL, V36, P659, DOI [10.1111/j.1442-9071.2008.01814.x, 10.1111/j.1442-9071.2008.01864.x]
   Wilkinson F, 2003, PROG BRAIN RES, V144, P305, DOI 10.1016/S0079-6123(03)14402-1
   ZERILLIZAVGOROD.T, 2014, OPTOM VIS PERF, V2, P26
NR 16
TC 2
Z9 2
U1 0
U2 11
PU MILITARY MEDICAL ACAD-INI
PI BELGRADE
PA CRNOTRAVSKA 17, PO BOX 33-35, BELGRADE, 11040, SERBIA
SN 0042-8450
EI 2406-0720
J9 VOJNOSANIT PREGL
JI Vojnosanit. Pregl.
PD SEP
PY 2016
VL 73
IS 9
BP 881
EP 884
DI 10.2298/VSP150321140S
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DX9IA
UT WOS:000384705600015
PM 29320624
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Yang, Y
   Liu, F
   Tang, M
   Yuan, M
   Hu, ADN
   Zhan, ZY
   Li, ZJ
   Li, JQ
   Ding, XY
   Lu, L
AF Yang, Yu
   Liu, Fang
   Tang, Miao
   Yuan, Miner
   Hu, Andina
   Zhan, Zongyi
   Li, Zijing
   Li, Jiaqing
   Ding, Xiaoyan
   Lu, Lin
TI Macrophage polarization in experimental and clinical choroidal
   neovascularization
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; BRUCHS MEMBRANE; RETINAL NEOVASCULARIZATION;
   IN-VIVO; MICE; CELLS; MODEL; EXPRESSION; CYTOKINE
AB Macrophages play an important role in the development of age-related macular degeneration (AMD). In this study, the spatial and temporal changes and the polarization of macrophages in murine laser-induced choroidal neovascularization (CNV) were investigated, and the polarized M1 and M2 biomarkers in the aqueous humors of neovascular AMD (nAMD) patients were studied. Macrophages, the main infiltrating inflammatory cells in CNV lesions, were evidenced by a significant increase in F4/80 mRNA expression and by the infiltration of F4/80+ cells in the lesions and the vicinity of laser-induced CNV. The mRNA expressions of M1-related markers were dramatically upregulated in the early stage, while the M2-related markers were slightly upregulated in the middle stage and sustained until the late stage. The results of immunostaining showed a similar early-but-transient M1 pattern and a delayed-but-sustained M2 pattern in laser-induced CNV. In addition, a higher M2/M1 ratio was found in both the murine models (Arg-1/iNOS and CCL22/CXCL10) and the aqueous humors of nAMD patients (CCL22/CXCL10) than in the controls. Our results suggested that the dynamic patterns of M1 and M2 were different in both the experimental and clinical CNV. The M2 macrophages were predominant and may play a more important role in the development of CNV.
C1 [Yang, Yu; Liu, Fang; Tang, Miao; Yuan, Miner; Hu, Andina; Zhan, Zongyi; Li, Zijing; Li, Jiaqing; Ding, Xiaoyan; Lu, Lin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Retina Div, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Ding, XY; Lu, L (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Retina Div, Guangzhou 510060, Guangdong, Peoples R China.
EM dingxy75@gmail.com; lulin888@126.com
OI Fang, Liu/0000-0002-7962-3854; Yuan, Miner/0000-0002-8988-3289; Zhan,
   Zongyi/0000-0002-6621-1172
FU National Natural Science Foundation of China [81341028, 81100685];
   Science and Technology Program of Guangdong Province [2013B020400003];
   Science and Technology Program of Guangzhou [15570001]; NATIONAL EYE
   INSTITUTE [R01EY015130, T32EY024234, R01EY017011] Funding Source: NIH
   RePORTER
FX Supported by National Natural Science Foundation of China 81341028 and
   81100685. Supported by Science and Technology Program of Guangdong
   Province (2013B020400003) and by Science and Technology Program of
   Guangzhou (15570001).
CR Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Chen CH, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/625048
   Crespo-Garcia S, 2015, EXP EYE RES, V139, P13, DOI 10.1016/j.exer.2015.07.012
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Furusato E, 2011, HISTOL HISTOPATHOL, V26, P1145, DOI 10.14670/HH-26.1145
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   He LZ, 2014, J BIOL CHEM, V289, P8019, DOI 10.1074/jbc.M113.535765
   Hoerster R, 2012, GRAEF ARCH CLIN EXP, V250, P1579, DOI 10.1007/s00417-012-1990-z
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Jager MJ, 2011, PROG RETIN EYE RES, V30, P129, DOI 10.1016/j.preteyeres.2010.11.004
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Koroishi E., 2015, J VIB CONTROL, P1, DOI [DOI 10.1001/JAMAOPHTHALM0L.2015.3949, 10.1001/jamaophthalmol.2015.3949]
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Li J, 2014, INVEST OPHTH VIS SCI, V55, P8267, DOI 10.1167/iovs.14-15623
   Liu F, 2016, MOL VIS, V22, P352
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sheets KG, 2013, MOL VIS, V19, P1747
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Terasaki H, 2015, CURR EYE RES, V40, P936, DOI 10.3109/02713683.2014.964417
   Tran T. H., 2015, SCI REP UK, V5
   Wang JL, 2013, INVEST OPHTH VIS SCI, V54, P7983, DOI 10.1167/iovs.13-13068
   You IC, 2015, ARCH IMMUNOL THER EX, V63, P299, DOI 10.1007/s00005-015-0335-0
   Zhao MW, 2015, JAMA OPHTHALMOL, V133, P333, DOI 10.1001/jamaophthalmol.2014.5312
   Zhu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094743
NR 36
TC 63
Z9 66
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 4
PY 2016
VL 6
AR 30933
DI 10.1038/srep30933
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DS6LN
UT WOS:000380893400001
PM 27489096
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhou, NL
   Gao, YJ
   An, JB
   Zhang, B
   Guo, CR
   Ma, JX
AF Zhou, Na-Lei
   Gao, Yan-Jun
   An, Jian-Bin
   Zhang, Bin
   Guo, Cong-Rong
   Ma, Jing-Xue
TI Tunnelled scleral intravitreal injection with vitreous reflux assessed
   by AS-OCT
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Age-related macular degeneration; anterior-segment coherence optical
   tomography; intravitreal injection; vitreous reflux; wong-baker faces
   rating scale
ID INTRAOCULAR-PRESSURE CHANGES; MACULAR DEGENERATION; TRIAMCINOLONE;
   AGENTS
AB Purpose: To compare the outcomes of tunnelled scleral intravitreal injection (TSI) with straight intravitreal injection (SII) basing on the intraocular pressure (IOP) changes, occurrence and amount of vitreous reflux, and patients' discomfort. Methods: A randomized hospital-based study. Thirty patients with exudative age-related macular degeneration were randomly (1: 1) assigned into two groups (TSI injection and SII injection). IOP was immediately measured before and after the intravitreal injection with 0.05 ml (0.5 mg) ranibizumab every 5 minutes until IOP < 30 mmHg. The occurrence and amount of vitreous reflux were followed and recorded with anterior-segment optical coherence tomography (AS-OCT). Patients' discomfort during injection was evaluated with Wong-Baker faces pain rating scale. Results: IOP (mmHg +/- SD) immediately increased to 32.03 +/- 3.22 mmHg in TSI group and 29.94 +/- 2.89 mmHg in SII group after injection, but without statistical significance (P= 0.2202). The occurrence and amount of vitreous reflux were significantly lower in TSI than in SII groups (P< 0.001). No difference was found between TSI and SII in Wong-Baker faces rating scale score (P= 0.2089). Conclusion: Tunnelled scleral intravitreal injection is better than straight intravitreal injection. The occurrence and amount of vitreous reflux in TSI were lower than in SII group, which indicated that TSI could decrease the incidence of post-injection endophthalmitis and cause less drug loss.
C1 [Zhou, Na-Lei; Gao, Yan-Jun; An, Jian-Bin; Zhang, Bin; Guo, Cong-Rong; Ma, Jing-Xue] Hebei Med Univ, Hosp 2, Dept Ophthalmol, 215 Heping West Rd, Shijiazhuang 050000, Peoples R China.
C3 Hebei Medical University
RP Ma, JX (通讯作者)，Hebei Med Univ, Hosp 2, Dept Ophthalmol, 215 Heping West Rd, Shijiazhuang 050000, Peoples R China.
EM maxuemei_ll@163.com
FU National Science Foundation of China [30973252]
FX This project was supported by the National Science Foundation of China
   (grant number 30973252). We thank Cui Yuexian and Shi Junfang for
   assistance during AS-OCT.
CR Avery Robert L, 2014, Retina, V34 Suppl 12, pS1, DOI 10.1097/IAE.0000000000000399
   Benz MS, 2006, OPHTHALMOLOGY, V113, P1174, DOI 10.1016/j.ophtha.2005.10.061
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen SDM, 2004, AM J OPHTHALMOL, V137, P1159, DOI 10.1016/j.ajo.2004.01.028
   Christoforidis JB, 2013, CLIN EXP OPHTHALMOL, V41, P614, DOI 10.1111/ceo.12074
   CODEN DJ, 1988, OPHTHALMIC SURG LAS, V19, P667
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Knecht PB, 2009, RETINA-J RET VIT DIS, V29, P1175, DOI 10.1097/IAE.0b013e3181aade74
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 14
TC 0
Z9 0
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2016
VL 9
IS 7
BP 12959
EP 12963
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EA2MT
UT WOS:000386428400065
DA 2022-11-30
ER

PT J
AU Bailey, JNC
   Pericak-Vance, MA
   Haines, JL
AF Bailey, Jessica N. Cooke
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI The Impact of the Human Genome Project on Complex Disease
SO GENES
LA English
DT Review
DE human genome project; age-related macular degeneration; Alzheimer's
   disease; multiple sclerosis; genetics; genomics; genome-wide association
   study
ID AGE-RELATED MACULOPATHY; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION;
   MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; SUSCEPTIBILITY LOCI; WIDE
   ASSOCIATION; STARGARDT-DISEASE; RISK ALLELES; OF-ONSET
AB In the decade that has passed since the initial release of the Human Genome, numerous advancements in science and technology within and beyond genetics and genomics have been encouraged and enhanced by the availability of this vast and remarkable data resource. Progress in understanding three common, complex diseases: age-related macular degeneration (AMD), Alzheimer's disease (AD), and multiple sclerosis (MS), are three exemplars of the incredible impact on the elucidation of the genetic architecture of disease. The approaches used in these diseases have been successfully applied to numerous other complex diseases. For example, the heritability of AMD was confirmed upon the release of the first genome-wide association study (GWAS) along with confirmatory reports that supported the findings of that state-of-the art method, thus setting the foundation for future GWAS in other heritable diseases. Following this seminal discovery and applying it to other diseases including AD and MS, the genetic knowledge of AD expanded far beyond the well-known APOE locus and now includes more than 20 loci. MS genetics saw a similar increase beyond the HLA loci and now has more than 100 known risk loci. Ongoing and future efforts will seek to define the remaining heritability of these diseases; the next decade could very well hold the key to attaining this goal.
C1 [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Med Ctr, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Hussman Inst Human Genom, Miller Sch Med, Miami, FL 33136 USA.
C3 Case Western Reserve University; University of Miami
RP Bailey, JNC (通讯作者)，Case Western Reserve Univ, Med Ctr, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
EM jnc43@case.edu; mpericak@med.miami.edu; jonathan.haines@case.edu
RI Cooke Bailey, Jessica Nicole/AFQ-5925-2022; Bailey, Jessica
   Cooke/Q-5062-2019; Haines, Jonathan/C-3374-2012
OI Cooke Bailey, Jessica Nicole/0000-0002-4001-8702; Bailey, Jessica
   Cooke/0000-0002-4001-8702; Haines, Jonathan/0000-0002-4351-4728
FU NIH - NIA [T32 EY007157, U01AG032984, 1R01AG027944, R01AG19085];
   BrightFocus Foundation [A2011048]; DOD grant [W81XWH-12-1-0013]; NEI
   [7R01EY012118, 1R01EY022310, 1R01EY023164, 1R01EY020928]; NINDS
   [R01NS032830]; NATIONAL EYE INSTITUTE [R01EY020928, R01EY012118,
   T32EY007157, R01EY022310, R01EY023164] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032830]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027944,
   R01AG019085, U01AG032984] Funding Source: NIH RePORTER
FX This work was supported by NIH T32 EY007157 (Jessica N. Cooke Bailey),
   Alzheimer's Disease Genetics Consortium, funded by NIA grant U01AG032984
   (Margaret A. Pericak-Vance, Jonathan L. Haines), BrightFocus Foundation
   grant A2011048 (Margaret A. Pericak-Vance), DOD grant W81XWH-12-1-0013
   (Margaret A. Pericak-Vance, Jonathan L. Haines), NEI grants 7R01EY012118
   (Margaret A. Pericak-Vance, Jonathan L. Haines), 1R01EY022310 (Jonathan
   L. Haines, Margaret A. Pericak-Vance), 1R01EY023164 (Margaret A.
   Pericak-Vance), and 1R01EY020928 (Margaret A. Pericak-Vance), NIA grants
   1R01AG027944 (Margaret A. Pericak-Vance, Jonathan L. Haines) and
   R01AG19085 (Margaret A. Pericak-Vance, Jonathan L. Haines) and NINDS
   grant R01NS032830 (Margaret A. Pericak-Vance, Jonathan L. Haines).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770
   Beecham GW, 2009, AM J HUM GENET, V84, P35, DOI 10.1016/j.ajhg.2008.12.008
   BREITNER JCS, 1984, NEW ENGL J MED, V311, P192
   BREITNER JCS, 1984, PSYCHOL MED, V14, P63, DOI 10.1017/S0033291700003081
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X
   Compston Alastair, 2002, Curr Neurol Neurosci Rep, V2, P259, DOI 10.1007/s11910-002-0085-3
   Coon KD, 2007, J CLIN PSYCHIAT, V68, P613, DOI 10.4088/JCP.v68n0419
   CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Damotte V, 2014, GENES IMMUN, V15, P126, DOI 10.1038/gene.2013.70
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   FOLSTEIN M, 1984, HOSP COMMUNITY PSYCH, V35, P111
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gourraud PA, 2013, BRAIN, V136, P1012, DOI 10.1093/brain/aws363
   Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469
   Haines JL, 2002, HUM MOL GENET, V11, P2251
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haines JL, 1998, HUM MOL GENET, V7, P1229, DOI 10.1093/hmg/7.8.1229
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hauser SL, 2013, ANN NEUROL, V74, P317, DOI 10.1002/ana.24009
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Herrup K, 2010, J NEUROSCI, V30, P16755, DOI 10.1523/JNEUROSCI.4521-10.2010
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kenealy SJ, 2006, GENES IMMUN, V7, P73, DOI 10.1038/sj.gene.6364275
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Lee PH, 2012, BIOINFORMATICS, V28, P1797, DOI 10.1093/bioinformatics/bts191
   LEVYLAHAD E, 1995, ANN NEUROL, V38, P678, DOI 10.1002/ana.410380420
   LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621
   LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622
   Li H, 2008, ARCH NEUROL-CHICAGO, V65, P45, DOI 10.1001/archneurol.2007.3
   Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796
   McCauley JL, 2009, GENES IMMUN, V10, P624, DOI 10.1038/gene.2009.53
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nylander A, 2012, J CLIN INVEST, V122, P1180, DOI 10.1172/JCI58649
   Oksenberg JR, 2013, EXPERT REV NEUROTHER, V13, P11, DOI 10.1586/14737175.2013.865867
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pericak-Vance MA, 2001, NEUROGENETICS, V3, P195
   PERICAKVANCE MA, 1995, TRENDS GENET, V11, P504, DOI 10.1016/S0168-9525(00)89161-1
   PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034
   PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8
   Powell D, 1984, J NEUROGENET, V1, P189, DOI 10.3109/01677068409107085
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Ridge PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079771
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Ryu E, 2010, MOL VIS, V16, P2811
   Sadovnick AD, 2009, AM J EPIDEMIOL, V170, P289, DOI 10.1093/aje/kwp143
   SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351
   SADOVNICK AD, 1993, ANN NEUROL, V33, P281, DOI 10.1002/ana.410330309
   SADOVNICK AD, 1993, CURR OPIN NEUROL NEU, V6, P189
   Sawcer S, 2006, EUR J HUM GENET, V14, P257, DOI 10.1038/sj.ejhg.5201561
   Sawcer S, 2005, AM J HUM GENET, V77, P454
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Scheetz TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058657
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seshadri S, 2010, JAMA-J AM MED ASSOC, V303, P1832, DOI 10.1001/jama.2010.574
   SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330
   STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399
   Thorisson GA, 2003, NUCLEIC ACIDS RES, V31, P124, DOI 10.1093/nar/gkg052
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Yan J, 2008, CNS NEUROL DISORD-DR, V7, P536, DOI 10.2174/187152708787122941
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yaspan BL, 2011, HUM GENET, V129, P563, DOI 10.1007/s00439-011-0956-2
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zerhouni E., HOUSE SUBCOMMITTEE L
NR 122
TC 12
Z9 13
U1 0
U2 39
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2073-4425
J9 GENES-BASEL
JI Genes
PD SEP
PY 2014
VL 5
IS 3
BP 518
EP 535
DI 10.3390/genes5030518
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CA4EU
UT WOS:000348857800003
PM 25032678
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nishio, N
   Teranishi, M
   Uchida, Y
   Sugiura, S
   Ando, F
   Shimokata, H
   Sone, M
   Otake, H
   Kato, K
   Yoshida, T
   Tagaya, M
   Hibi, T
   Nakashima, T
AF Nishio, Naoki
   Teranishi, Masaaki
   Uchida, Yasue
   Sugiura, Saiko
   Ando, Fujiko
   Shimokata, Hiroshi
   Sone, Michihiko
   Otake, Hironao
   Kato, Ken
   Yoshida, Tadao
   Tagaya, Mitsuhiko
   Hibi, Tatsuya
   Nakashima, Tsutomu
TI Contribution of complement factor H Y402H polymorphism to sudden
   sensorineural hearing loss risk and possible interaction with diabetes
SO GENE
LA English
DT Article
DE Complement factor H; Sudden sensorineural hearing loss; CFH Y402H;
   Diabetes; Polymorphism
ID MACULAR DEGENERATION; INFLAMMATION; ASSOCIATION; MELLITUS; DEAFNESS;
   GENE
AB Sudden sensorineural hearing loss (SSNHL) is one of the most common diseases encountered by otolaryngologists; however, the etiology is unclear. The aim of this study was to assess the association between SSNHL and polymorphism of complement factor H (CFH) Y402H, which is implicated in age-related macular degeneration. We conducted a case-control study, in which the cases were 72 SSNHL patients and the controls were 2161 residents selected randomly from the resident register. The odds ratio (OR) for SSNHL risk was determined using the additive-genetic model of CFH Y402H polymorphism. The OR for SSNHL risk was 1.788 (95% confidence interval [CI]; 1.008-3.172) with no adjustments and 1.820 (CI: 1.025-3.232) after adjusting for age and sex. Of the three lifestyle-related diseases hypertension, dyslipidemia, and diabetes, only diabetes was significantly associated with SSNHL risk. We classified both the controls and SSNHL patients into those with or without diabetes, and the OR for SSNHL risk was 6.326 (CI; 1.885-21.225) in diabetic subjects and 1.214 (CI: 0.581-2.538) in nondiabetic subjects. We conclude that CFH Y402H polymorphism and SSNHL risk are significantly related, and that diabetic CFH Y402H minor allele carriers may be susceptible to SSNHL. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Nishio, Naoki] Nagoya Univ, Grad Sch Med, Dept Otorhinolaryngol, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Uchida, Yasue; Sugiura, Saiko] Natl Ctr Geriatr & Gerontol, Dept Otorhinolaryngol, Obu City, Aichi, Japan.
   [Ando, Fujiko; Shimokata, Hiroshi] Natl Ctr Geriatr & Gerontol, Ctr Dev Adv Med Dimentia CAMD, Dept Dev Prevent Med, Obu City, Aichi, Japan.
   [Ando, Fujiko] Aichi Syukutoku Univ, Dept Hlth & Med Sci, Nagakute, Aichi, Japan.
   [Uchida, Yasue] Aichi Med Univ, Dept Otolaryngol, Nagakute, Aichi, Japan.
   [Tagaya, Mitsuhiko] Tosei Gen Hosp, Dept Otorhinolaryngol, Seto, Aichi, Japan.
   [Nishio, Naoki; Hibi, Tatsuya] Social Insurance Chukyo Hosp, Dept Otorhinolaryngol, Nagoya, Aichi, Japan.
C3 Nagoya University; National Center for Geriatrics & Gerontology;
   National Center for Geriatrics & Gerontology; Aichi Medical University;
   Tosei General Hospital
RP Nishio, N (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Otorhinolaryngol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM naokin@med.nagoya-u.ac.jp
RI Kato, Ken/D-1636-2014; Yoshida, Tadao/I-1619-2012; Nakashima,
   Tsutomu/B-8259-2012; Nishio, Naoki/M-4974-2014; Teranishi,
   Masaaki/I-1956-2012
OI Yoshida, Tadao/0000-0001-9993-0766; Nakashima,
   Tsutomu/0000-0003-3930-9120; Nishio, Naoki/0000-0003-1495-0376; 
FU Ministry of Education, Culture, Sports, Science, and Technology
   [21390460, 20591979]; Ministry of Health, Labour and Welfare of Japan
   [20shi-2, 21A-17, H20-Nanchi-021]
FX This study was supported by research grants (21390460, 20591979) from
   the Ministry of Education, Culture, Sports, Science, and Technology and
   research grants for Longevity Sciences (20shi-2, 21A-17, H20-Nanchi-021)
   from the Ministry of Health, Labour and Welfare of Japan.
CR Aimoni C, 2010, AUDIOL NEURO-OTOL, V15, P111, DOI 10.1159/000231636
   Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   Bartelink ML, 1998, DIABETES RES CLIN PR, V40, P15, DOI 10.1016/S0168-8227(98)00023-0
   Bozkurt MK, 2011, J LARYNGOL OTOL, V125, P231, DOI 10.1017/S0022215110002604
   Chau JK, 2010, LARYNGOSCOPE, V120, P1011, DOI 10.1002/lary.20873
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Geerlings SE, 1999, FEMS IMMUNOL MED MIC, V26, P259, DOI 10.1111/j.1574-695X.1999.tb01397.x
   Golden SH, 1999, DIABETES CARE, V22, P1408, DOI 10.2337/diacare.22.9.1408
   Gorur K, 2005, OTOL NEUROTOL, V26, P599
   Gross M, 2006, AUDIOL NEURO-OTOL, V11, P287, DOI 10.1159/000093957
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirota Y, 2007, METABOLISM, V56, P656, DOI 10.1016/j.metabol.2006.12.014
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lewis RD, 2010, MOL IMMUNOL, V47, P1098, DOI 10.1016/j.molimm.2009.10.035
   Liszewski MK, 1996, ADV IMMUNOL, V61, P201
   Merchant SN, 2008, ORL-J OTO-RHIN-LARYN, V70, P52, DOI 10.1159/000111048
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Niculescu F, 2004, IMMUNOL RES, V30, P73, DOI 10.1385/IR:30:1:073
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   Patscheke JH, 2001, THROMB HAEMOSTASIS, V86, P1118
   Pyykko I, 2008, ORL-J OTO-RHIN-LARYN, V70, P32, DOI 10.1159/000111046
   Rauch SD, 2008, NEW ENGL J MED, V359, P833, DOI 10.1056/NEJMcp0802129
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   RUST KR, 1992, ARCH OTOLARYNGOL, V118, P397
   SCHUKNECHT HF, 1986, ARCH OTO-RHINO-LARYN, V243, P1, DOI 10.1007/BF00457899
   Shimokata H, 2000, J Epidemiol, V10, pS1
   Teranishi M, 2007, ACTA OTO-LARYNGOL, V127, P1259, DOI 10.1080/00016480701242410
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Weng SF, 2005, LARYNGOSCOPE, V115, P1676, DOI 10.1097/01.mlg.0000184790.91675.e3
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yoshida T, 2008, LARYNGOSCOPE, V118, P1433, DOI 10.1097/MLG.0b013e318172ef85
   Yoshida Yasuyuki, 1996, Auris Nasus Larynx, V23, P63
NR 37
TC 10
Z9 12
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAY 10
PY 2012
VL 499
IS 1
BP 226
EP 230
DI 10.1016/j.gene.2012.02.027
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 936WT
UT WOS:000303621400036
PM 22426290
DA 2022-11-30
ER

PT J
AU Bull, ND
   Martin, KR
AF Bull, Natalie D.
   Martin, Keith R.
TI Concise Review: Toward Stem Cell-Based Therapies for Retinal
   Neurodegenerative Diseases
SO STEM CELLS
LA English
DT Review
DE Retina; Stem cell; Neuroprotection; Transplantation; Ganglion cell;
   Photoreceptor; Retinal pigment epithelium; Glaucoma; Age-related macular
   degeneration; Retinopathy
ID NEURAL PROGENITOR CELLS; CILIARY NEUROTROPHIC FACTOR; TRANSPLANTED
   PHOTORECEPTOR PRECURSORS; ADULT HUMAN RETINA; MACULAR DEGENERATION; RAT
   MODEL; EXPERIMENTAL GLAUCOMA; EPITHELIAL-CELLS; VISUAL FUNCTION;
   ROYAL-COLLEGE
AB Loss of sight due to irreversible retinal neurodegeneration imposes a significant disease burden on both patients and society. Glaucoma and age-related macular degeneration are the commonest neurodegenerative blinding diseases in the developed world, and both are becoming increasingly prevalent as populations age. Our heavy reliance on our sense of sight means that visual loss often severely restricts day-to-day life, making it difficult to function without additional support. Visual impairment also limits employment possibilities, adding to the economic burden. Current therapies for many degenerative retinopathies are limited in their efficacy, often treating the effects of disease rather than the underlying causes. Consequently, the development of novel adjunctive neuroprotective and neuroregenerative treatments are important goals. Evidence from animal models suggests that stem cells could be useful as part of novel new treatment strategies for eye disease. The accessibility of the eye and extensive repertoire of available surgical techniques may facilitate the translation of stem cell-based therapies, for example, via transplantation, to the retina more rapidly than to other parts of the central nervous system. This concise review will examine how cell therapies are being applied experimentally for neuroregenerative and neuroprotective treatment of currently incurable degenerative retinal diseases. Furthermore, recent progress toward clinical translation of such therapies will be highlighted. STEM CELLS 2011; 29: 1170-1175
C1 [Bull, Natalie D.; Martin, Keith R.] Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge CB2 0PY, England.
   [Martin, Keith R.] Univ Cambridge, Dept Ophthalmol, Cambridge CB2 0PY, England.
   [Martin, Keith R.] Univ Cambridge, Cambridge NIHR Biomed Res Ctr, Cambridge CB2 0PY, England.
C3 University of Cambridge; University of Cambridge; University of
   Cambridge
RP Bull, ND (通讯作者)，Univ Cambridge, Cambridge Ctr Brain Repair, Forvie Site,Robinson Way, Cambridge CB2 0PY, England.
EM ndb30@cam.ac.uk
FU Fight for Sight (U.K.); Glaucoma Research Foundation; Jukes Glaucoma
   Research Fund; Cambridge NIHR Biomedical Research Centre; Medical
   Research Council [G0800784, G0800784B] Funding Source: researchfish; MRC
   [G0800784] Funding Source: UKRI
FX This work was supported by grants from Fight for Sight (U.K.) and the
   Glaucoma Research Foundation (to N.D.B. and K.R.M.) as well as Jukes
   Glaucoma Research Fund and the Cambridge NIHR Biomedical Research Centre
   (to K.R.M.).
CR Afshari FT, 2009, EYE, V23, P1890, DOI 10.1038/eye.2008.411
   Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Bull ND, 2008, INVEST OPHTH VIS SCI, V49, P3449, DOI 10.1167/iovs.08-1770
   Bull ND, 2009, INVEST OPHTH VIS SCI, V50, P4244, DOI 10.1167/iovs.08-3239
   Chen B, 2009, BRAIN RES, V1284, P1, DOI 10.1016/j.brainres.2009.05.100
   Chen CP, 2006, HISTOL HISTOPATHOL, V21, P1209, DOI 10.14670/HH-21.1209
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   Coffey P, 2009, REGEN MED, V4, P505, DOI 10.2217/RME.09.33
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029
   Del Debbio CB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012425
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919
   Gualdoni S, 2010, STEM CELLS, V28, P1048, DOI 10.1002/stem.423
   Guo Y, 2003, INVEST OPHTH VIS SCI, V44, P3194, DOI 10.1167/iovs.02-0875
   GUST J, 2011, INVEST OPHT IN PRESS
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Inoue T, 2010, STEM CELLS, V28, P489, DOI 10.1002/stem.279
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Jiang CH, 2010, MOL VIS, V16, P983
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P960, DOI 10.1167/iovs.09-3884
   Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lawrence JM, 2007, STEM CELLS, V25, P2033, DOI 10.1634/stemcells.2006-0724
   Lee HJ, 2010, J NEUROSCI RES, V88, P3282, DOI 10.1002/jnr.22474
   Li N, 2009, GRAEF ARCH CLIN EXP, V247, P503, DOI 10.1007/s00417-008-1009-y
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Mayer EJ, 2005, BRIT J OPHTHALMOL, V89, P102, DOI 10.1136/bjo.2004.057687
   Mellough CB, 2007, RESTOR NEUROL NEUROS, V25, P177
   Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268
   Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101
   Pearson RA, 2010, CELL TRANSPLANT, V19, P487, DOI 10.3727/096368909X486057
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Singhal S, 2010, EXP EYE RES, V90, P308, DOI 10.1016/j.exer.2009.11.008
   Stitt AW, 2011, PROG RETIN EYE RES, V30, P149, DOI 10.1016/j.preteyeres.2011.02.001
   Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721
   Takeda M, 2008, INVEST OPHTH VIS SCI, V49, P1142, DOI 10.1167/iovs.07-0434
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Thanos CG, 2004, TISSUE ENG, V10, P1617, DOI 10.1089/ten.2004.10.1617
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Yu S, 2006, BIOCHEM BIOPH RES CO, V344, P1071, DOI 10.1016/j.bbrc.2006.03.231
   Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007
NR 58
TC 48
Z9 53
U1 0
U2 17
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD AUG
PY 2011
VL 29
IS 8
BP 1170
EP 1175
DI 10.1002/stem.676
PG 6
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 797NF
UT WOS:000293133900002
PM 21674700
OA Bronze
DA 2022-11-30
ER

PT J
AU Qu, Y
   Zhang, XY
   Dai, H
   Zhou, F
   Xu, XY
   Zhang, XA
   Bi, HS
   Pan, XM
   Wang, HG
   Jiang, H
   Yin, NN
   Dang, GF
AF Qu, Yi
   Zhang, Xiaoyan
   Dai, Hong
   Zhou, Fang
   Xu, Xiaoyi
   Zhang, Xiao
   Bi, Hongsheng
   Pan, Xuemei
   Wang, Hongge
   Jiang, Hua
   Yin, Ningning
   Dang, Guangfu
TI Pigment Epithelium-Derived Factor Gene Polymorphisms in Exudative
   Age-Related Degeneration in a Chinese Cohort
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related degeneration; Chinese; Pigment epithelium-derived factor;
   Polymorphism; Susceptibility
ID INHIBITS CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; MET72THR
   POLYMORPHISM; ANGIOGENESIS; RETINOPATHY; RISK; EYE
AB Purpose: To investigate polymorphisms in the pigment epithelium-derived factor (PEDF) gene in a Chinese cohort with exudative age-related macular degeneration (AMD).
   Methods: Two common single nucleotide polymorphisms (SNPs), Met72Thr (rs1136287) and -5736T>C (rs12150053), were genotyped, and four tagSNPs (tSNPs) were detected statistically in the PEDF gene of 168 exudative AMD patients and 230 age-and sex-matched control participants. Genetic analyses for additive, dominant, and recessive models were performed on all the available genotype data. All the possible haplotypes of these six SNPs were detected.
   Results: No association was found between the patients and the control participants in the allele frequencies for any individual SNP. There was evidence to suggest that heterozygotes for rs1136287 (C/T) exerted a protective effect against exudative AMD (additive model, OR 0.59, CI 0.36-0.95, p = 0.03), but none of the p-values in the other genotype groups were statistically significant. Likewise, haplotype analyses did not provide any evidence for an association between SNPs in the PEDF gene and the risk of exudative AMD in this Chinese cohort (p > 0.05).
   Conclusions: Detection of SNPs in the PEDF gene was not found to be significantly associated with exudative AMD in the Chinese cohort. Further studies of comprehensive PEDF gene variations are required to characterize the susceptibility of PEDF gene in the pathogenesis of AMD.
C1 [Qu, Yi; Zhang, Xiaoyan; Zhou, Fang; Xu, Xiaoyi; Zhang, Xiao; Jiang, Hua] Shandong Univ, Dept Ophthalmol, Qilu Hosp, Jinan 250012, Peoples R China.
   [Dai, Hong; Yin, Ningning] Beijing Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Bi, Hongsheng; Pan, Xuemei] Shierming Eye Hosp, Dept Ophthalmol, Jinan, Peoples R China.
   [Wang, Hongge] Shandong Eye Hosp, Dept Ophthalmol, Jinan, Peoples R China.
   [Dang, Guangfu] Qianfoshan Hosp, Dept Ophthalmol, Jinan, Peoples R China.
C3 Shandong University; Beijing Hospital; Shandong First Medical University
   & Shandong Academy of Medical Sciences
RP Qu, Y (通讯作者)，Shandong Univ, Dept Ophthalmol, Qilu Hosp, 107 Wenhuaxi Rd, Jinan 250012, Peoples R China.
EM drquyi@gmail.com
FU Department of Science and Technology of Shandong Province of China
   [2009GG10002016, BS2009SW056]
FX The authors thank the patients and the control subjects who participated
   in the study. This research was supported in part by the Department of
   Science and Technology of Shandong Province of China (2009GG10002016 and
   BS2009SW056).
CR Bessho H, 2009, MOL VIS, V15, P1107
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Chu JY, 1998, P NATL ACAD SCI USA, V95, P11763, DOI 10.1073/pnas.95.20.11763
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Iizuka H, 2007, BIOCHEM BIOPH RES CO, V361, P421, DOI 10.1016/j.bbrc.2007.07.025
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Mattes D, 2009, MOL VIS, V15, P343
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Tombran-Tink J, 1996, Mol Vis, V2, P11
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1202, DOI 10.1016/j.mehy.2005.01.017
NR 22
TC 8
Z9 8
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD JAN
PY 2011
VL 36
IS 1
BP 60
EP 65
DI 10.3109/02713683.2010.524343
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 697KW
UT WOS:000285513500010
PM 21174599
DA 2022-11-30
ER

PT J
AU Howard, C
   Garcia-Finana, M
   Yan, Q
   Hiscott, P
AF Howard, Claire
   Garcia-Finana, Marta
   Yan, Qi
   Hiscott, Paul
TI Human retinal pigment epithelial SPARC expression and age: an
   immunohistochemical study
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE Ageing; Retinal pigment epithelium; Secreted protein; Acidic and rich in
   cysteine; SPARC; Osteonectin
ID MACULAR DEGENERATION; HUMAN EYES; MATRICELLULAR PROTEINS; SUBRETINAL
   MEMBRANES; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; OSTEONECTIN SPARC;
   BINDING; METALLOPROTEINASES; THROMBOSPONDIN-1
AB The aim of this study was to investigate the temporal and spatial expression of the matricellular protein SPARC (Secreted Protein, Acidic and Rich in Cysteine; also known as osteonectin) in human retinal pigment epithelial (RPE) cells, and compare the results with Bruch's membrane thickness, employing immunohistochemistry.
   Eyes from 36 human donors, 16 being <= 65 and 20 >65 years old, were included in the study. Intensity of SPARC immunoreactivity was evaluated using Aequitas Image Analysis software with two-way analysis of variance (ANOVA). Bruch's membrane thickness was assessed by profile analysis and the association between RPE SPARC immunoreactivity and Bruch's membrane thickness was investigated by fitting a linear mixed effects model to the data set.
   Intensity of SPARC immunostaining in RPE cells was significantly lower in older donors (p<0.05 and p<0.001 for posterior and peripheral RPE cells, respectively). The anatomical localisation of the RPE cells also affected the intensity of SPARC staining, which was lower in posterior compared to peripheral cells (p<0.01). No correlation was observed between SPARC immunoreactivity in RPE cells and the thickness of the underlying Bruch's membrane, in either posterior or peripheral regions. Our results suggest that RPE cell SPARC levels decline with age, a change that may play a role in the pathogenesis of age-related diseases such as age-related macular degeneration.
C1 [Howard, Claire; Hiscott, Paul] Univ Liverpool, Dept Clin Sci, Unit Opthalmol, Univ Clin Dept, Liverpool L69 3GA, Merseyside, England.
   [Garcia-Finana, Marta] Ctr Med Stat & Hlth Evaluat, Liverpool, Merseyside, England.
   [Yan, Qi] Benaroya Res Inst, Hope Heart Program, Seattle, WA USA.
   [Yan, Qi] Univ Washington, Seattle, WA 98195 USA.
   [Hiscott, Paul] Royal Liverpool Univ Hosp, Dept Pathol, Liverpool, Merseyside, England.
C3 University of Liverpool; University of Liverpool; Benaroya Research
   Institute; University of Washington; University of Washington Seattle;
   Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool
RP Hiscott, P (通讯作者)，Univ Liverpool, Dept Clin Sci, Unit Opthalmol, Univ Clin Dept, Daulby St, Liverpool L69 3GA, Merseyside, England.
EM p.s.hiscott@liverpool.ac.uk
FU Research into Ageing [258]
FX The authors thank Dr. Damien Farnell for kindly developing the profile
   analysis program used, and thank Daniel Brotchie for technical
   assistance throughout. This project was funded by Research into Ageing,
   grant number 258.
CR ALEXANDER RA, 1986, MED LAB SCI, V43, P121
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200
   Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2
   BLAKE MJ, 1991, AM J PHYSIOL, V260, P663
   Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Emerson RO, 2006, J CELL BIOCHEM, V98, P701, DOI 10.1002/jcb.20867
   Friedman AD, 2007, ANN OTO RHINOL LARYN, V116, P449, DOI 10.1177/000348940711600610
   FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648
   Hiscott P, 2002, EYE, V16, P393, DOI 10.1038/sj.eye.6700196
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Jurivich DA, 2005, EXP GERONTOL, V40, P948, DOI 10.1016/j.exger.2005.08.003
   Kaarniranta K, 2005, MOL BRAIN RES, V137, P126, DOI 10.1016/j.molbrainres.2005.02.027
   Kim SY, 1997, EXP EYE RES, V65, P681, DOI 10.1006/exer.1997.0377
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   KUDO H, 1994, EXP CELL RES, V212, P219, DOI 10.1006/excr.1994.1137
   Magee RM, 2000, INVEST OPHTH VIS SCI, V41, P2707
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Martinek N, 2007, J DENT RES, V86, P296, DOI 10.1177/154405910708600402
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   NERI M, 1992, EUR J BIOCHEM, V205, P569, DOI 10.1111/j.1432-1033.1992.tb16814.x
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   Ratnayaka A, 2007, INT J BIOCHEM CELL B, V39, P85, DOI 10.1016/j.biocel.2006.08.015
   SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341
   SAGE H, 1984, J BIOL CHEM, V259, P3993
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   SAUK JJ, 1991, CALCIFIED TISSUE INT, V49, P58, DOI 10.1007/BF02555904
   Sheridan CM, 2001, AM J PATHOL, V159, P1555, DOI 10.1016/S0002-9440(10)62540-0
   Sozo F, 2007, J PHYSIOL-LONDON, V584, P625, DOI 10.1113/jphysiol.2007.138735
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Webster L, 1999, EXP EYE RES, V68, P91, DOI 10.1006/exer.1998.0585
   Yan Q, 2005, INVEST OPHTH VIS SCI, V46, P4652, DOI 10.1167/iovs.05-0460
   Zafirellis K, 2008, J SURG RES, V147, P99, DOI 10.1016/j.jss.2007.05.041
NR 35
TC 5
Z9 5
U1 0
U2 0
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN
SN 0213-3911
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD SEP
PY 2010
VL 25
IS 9
BP 1163
EP 1169
PG 7
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 621OZ
UT WOS:000279591700007
PM 20607658
DA 2022-11-30
ER

PT J
AU Perkins, SJ
   Okemefuna, AI
   Nan, RD
AF Perkins, Stephen J.
   Okemefuna, Azubuike I.
   Nan, Ruodan
TI Unravelling protein-protein interactions between complement factor H and
   C-reactive protein using a multidisciplinary strategy
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE analytical ultracentrifugation (AUC); complement; complement factor H
   (CFH); C-reactive protein (CRP); surface plasmon resonance (Sea); X-ray
   scattering
ID HEMOLYTIC-UREMIC SYNDROME; MACULAR DEGENERATION; ANALYTICAL
   ULTRACENTRIFUGATION; SOLUTION SCATTERING; NEUTRON-SCATTERING; FACTOR-I;
   X-RAY; DISEASE; POLYMORPHISM; CALCIUM
AB Experimental studies of protein-protein interactions are very much affected by whether the complexes are fully formed (strong, with nanomolar dissociation constants) or partially dissociated (weak, with micromolar dissociation constants). The functions of the complement proteins of innate immunity are governed by the weak interactions between the activated proteins and their regulators. Complement is effective in attacking pathogens, but not the human host, and imbalances in this process can lead to disease conditions. The inherent complexity in analysing complement interactions is augmented by the multivalency of its main regulator, CFH (complement factor H), for its physiological or pathophysiological ligands. The unravelling of such weak protein-protein or protein-ligand interactions requires a multidisciplinary approach. Synchrotron X-ray solution scattering and constrained modelling resulted in the determination of the solution structure of CFH and its self-associative properties, whereas AUC (analytical ultracentrifugation) identified the formation of much larger CFH multimers through the addition of metals such as zinc. The ligands of CFH, such as CRP (C-reactive protein), also undergo self-association. The combination of X-rays and AUC with SPR (surface plasmon resonance) proved to be essential to identify CRP self-association and revealed how CFH interacts with CRP. We show that CRP unexpectedly binds to CFH at two non-contiguous sites and explain its relevance to age-related macular degeneration.
C1 [Perkins, Stephen J.; Okemefuna, Azubuike I.; Nan, Ruodan] UCL, Div Biosci, Dept Struct & Mol Biol, London WC1E 6BT, England.
C3 University of London; University College London
RP Perkins, SJ (通讯作者)，UCL, Div Biosci, Dept Struct & Mol Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.
EM s.perkins@medsch.ucl.ac.uk
FU University College London; Biotechnology and Biological Sciences
   Research Council; Mercer Fund of the Fight For Sight Charity; Henry
   Smith Charity; Medical Research Council [G0801724] Funding Source:
   researchfish; MRC [G0801724] Funding Source: UKRI
FX We thank University College London, the Biotechnology and Biological
   Sciences Research Council, the Mercer Fund of the Fight For Sight
   Charity and the Henry Smith Charity for studentship and grant funding.
CR Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Blizniukov OP, 2003, MOL BIOL+, V37, P912, DOI 10.1023/B:MBIL.0000008361.22136.c8
   Christopeit T, 2009, ANAL BIOCHEM, V391, P39, DOI 10.1016/j.ab.2009.04.037
   Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hocking HG, 2008, J BIOL CHEM, V283, P9475, DOI 10.1074/jbc.M709587200
   Hurwitz S, 1996, CRIT REV BIOCHEM MOL, V31, P41, DOI 10.3109/10409239609110575
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Nan RD, 2008, J MOL BIOL, V375, P891, DOI 10.1016/j.jmb.2007.11.015
   Okemefuna AI, 2008, J MOL BIOL, V375, P80, DOI 10.1016/j.jmb.2007.09.026
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1041, DOI 10.1074/jbc.M109.044495
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Okemefuna AI, 2009, J MOL BIOL, V391, P98, DOI 10.1016/j.jmb.2009.06.010
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   PERKINS SJ, 2010, ADV EXP MED IN PRESS
   PERKINS SJ, 1986, PROTIDES BIOL FLUIDS, V34, P323
   Perkins SJ, 2008, METHOD CELL BIOL, V84, P375, DOI 10.1016/S0091-679X(07)84013-1
   Perkins SJ, 2009, J R SOC INTERFACE, V6, pS679, DOI 10.1098/rsif.2009.0164.focus
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Tanious FA, 2008, METHOD CELL BIOL, V84, P53, DOI 10.1016/S009911-679X(07)84003-9
   Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
NR 38
TC 14
Z9 14
U1 0
U2 12
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0300-5127
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD AUG
PY 2010
VL 38
BP 894
EP 900
DI 10.1042/BST0380894
PN 4
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 636QL
UT WOS:000280753600007
PM 20658973
DA 2022-11-30
ER

PT J
AU Hynes, SR
   Lavik, EB
AF Hynes, Sara Royce
   Lavik, Erin B.
TI A tissue-engineered approach towards retinal repair: Scaffolds for cell
   transplantation to the subretinal space
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Subretinal space; Retina; RPE; Scaffold; Polymer; Photoreceptors
ID PIGMENT EPITHELIAL-CELLS; EMBRYONIC STEM-CELLS; NEURAL PROGENITOR CELLS;
   ANTERIOR LENS CAPSULE; LONG-TERM SURVIVAL; VISUAL FUNCTION; RCS RATS;
   PHOTORECEPTOR TRANSPLANTATION; AMNIOTIC MEMBRANE; BRUCHS MEMBRANE
AB Several mechanisms of retina degeneration result in the deterioration of the outer retina and can lead to blindness. Currently, with the exception of anti-angiogenic treatments for wet age-related macular degeneration, there are no treatments that can restore lost vision. There is evidence that photoreceptors and embryonic retinal tissue, transplanted to the subretinal space, can form new synapses with surviving host neurons. However, these transplants have yet to result in a clinical treatment for retinal degeneration.
   This article reviews the current literature on the transplantation of scaffolds with retinal and retinal pigmented epithelial (RPE) cells to the subretinal space. We discuss the types of cells and materials that have been investigated for transplantation to the subretinal space, summarize the current findings, and present opportunities for future research and the next generation of scaffolds for retinal repair.
   Challenges to cell transplantation include limited survival upon implantation and the formation of abnormal cell architectures in vivo. Scaffolds have been shown to enhance cell survival and direct cell differentiation and organization in a number of models of retinal degeneration.
   The transplantation of cells within a scaffold represents a possible treatment to repair retinal degeneration and restore vision in effected patients. Materials have been developed for the delivery of retinal and RPE cells separately however, the development of a combined tissue-engineered scaffold targeting both cell populations represents a promising direction for retinal repair.
C1 [Lavik, Erin B.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
   [Hynes, Sara Royce] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA.
C3 Case Western Reserve University; Yale University
RP Lavik, EB (通讯作者)，Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
EM erin.lavik@case.edu
OI Lavik, Erin/0000-0002-0644-744X
CR Abe T, 2007, PROG RETIN EYE RES, V26, P302, DOI 10.1016/j.preteyeres.2007.01.003
   Aramant RB, 2004, PROG RETIN EYE RES, V23, P475, DOI 10.1016/j.preteyeres.2004.05.003
   Aramant RB, 1999, INVEST OPHTH VIS SCI, V40, P1557
   Aramant RB, 2002, PROG RETIN EYE RES, V21, P57, DOI 10.1016/S1350-9462(01)00020-9
   ARNOLD S, 2004, INVESTIG OPHTHALMOL, V45, P4251
   BERGSTROM A, 1992, EXP EYE RES, V55, P29, DOI 10.1016/0014-4835(92)90088-A
   Beutel J, 2007, GRAEF ARCH CLIN EXP, V245, P1469, DOI 10.1007/s00417-007-0566-9
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BLOMBACK B, 1994, THROMB RES, V75, P327, DOI 10.1016/0049-3848(94)90245-3
   Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Chacko DM, 2000, BIOCHEM BIOPH RES CO, V268, P842, DOI 10.1006/bbrc.2000.2153
   Chan G, 2008, TRENDS BIOTECHNOL, V26, P382, DOI 10.1016/j.tibtech.2008.03.011
   Chaum E, 2003, J CELL BIOCHEM, V88, P57, DOI 10.1002/jcb.10354
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Colthurst MJ, 2000, BIOMATERIALS, V21, P649, DOI 10.1016/S0142-9612(99)00220-3
   Coombes AGA, 2004, BIOMATERIALS, V25, P315, DOI 10.1016/S0142-9612(03)00535-0
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Djojosubroto MW, 2008, CELL TISSUE RES, V331, P347, DOI 10.1007/s00441-007-0501-8
   Doi K, 2004, J VIROL, V78, P11327, DOI 10.1128/JVI.78.20.11327-11333.2004
   Eberli D, 2009, METHODS, V47, P109, DOI 10.1016/j.ymeth.2008.10.014
   Falconnet D, 2006, BIOMATERIALS, V27, P3044, DOI 10.1016/j.biomaterials.2005.12.024
   Farrokh-Siar L, 1999, CURR EYE RES, V19, P89, DOI 10.1076/ceyr.19.2.89.5331
   Ford MC, 2006, P NATL ACAD SCI USA, V103, P2512, DOI 10.1073/pnas.0506020102
   GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   Ge ZG, 2008, BIOMED MATER, V3, DOI 10.1088/1748-6041/3/2/022001
   Ghosh F, 1999, EXP EYE RES, V68, P67, DOI 10.1006/exer.1998.0582
   Ghosh F, 2000, OPHTHALMOLOGICA, V214, P54, DOI 10.1159/000027472
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Glowacki J, 2008, BIOPOLYMERS, V89, P338, DOI 10.1002/bip.20871
   Goldner JS, 2006, BIOMATERIALS, V27, P460, DOI 10.1016/j.biomaterials.2005.06.035
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   GOURAS P, 1994, INVEST OPHTH VIS SCI, V35, P3145
   GOURAS P, 1991, Journal of Neural Transplantation and Plasticity, V2, P91
   Guenther E, 1999, VISION RES, V39, P3988, DOI 10.1016/S0042-6989(99)00128-5
   GUNATILLAKE P, 2006, BIOTECH ANN REV, V12, P1387
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Haruta Masathoshi, 2005, Semin Ophthalmol, V20, P17, DOI 10.1080/08820530590921846
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Ho TC, 1996, CURR EYE RES, V15, P991, DOI 10.3109/02713689609017645
   Hsiue GH, 2002, J BIOMED MATER RES, V61, P19, DOI 10.1002/jbm.2000
   Huang JC, 1998, CURR EYE RES, V17, P573, DOI 10.1076/ceyr.17.6.573.5184
   Hynes SR, 2009, J BIOMED MATER RES A, V89A, P499, DOI 10.1002/jbm.a.31987
   Imai H, 2007, CURR EYE RES, V32, P903, DOI 10.1080/02713680701604749
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P36, DOI 10.2106/JBJS.G.01260
   Khodair MA, 2003, INVEST OPHTH VIS SCI, V44, P4976, DOI 10.1167/iovs.03-0036
   KIM SY, 2002, RETINA, V4, P471
   KIM SY, 2002, RETINA, V4, P464
   Kobsa S, 2008, PEDIATR RES, V63, P513, DOI 10.1203/PDR.0b013e318165f14d
   Kohane DS, 2008, PEDIATR RES, V63, P487, DOI 10.1203/01.pdr.0000305937.26105.e7
   Kwan ASL, 1999, EXP NEUROL, V159, P21, DOI 10.1006/exnr.1999.7157
   Lai CC, 2000, INVEST OPHTH VIS SCI, V41, P3134
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Langer R, 2000, ACCOUNTS CHEM RES, V33, P94, DOI 10.1021/ar9800993
   Lavik E, 2004, APPL MICROBIOL BIOT, V65, P1, DOI 10.1007/s00253-004-1580-z
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Lee CH, 2001, INT J PHARMACEUT, V221, P1, DOI 10.1016/S0378-5173(01)00691-3
   Lee CJ, 2007, BIOMATERIALS, V28, P2192, DOI 10.1016/j.biomaterials.2007.01.018
   LEI M, 2004, P 26 ANN INT C IEEE
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   LI LX, 1988, EXP EYE RES, V47, P771, DOI 10.1016/0014-4835(88)90044-9
   LI W, 2009, STEM CELLS
   Lim JM, 2004, INVEST OPHTH VIS SCI, V45, P4210, DOI 10.1167/iovs.03-1036
   LOPEZ R, 1989, INVESTIG OPHTHALMOL, V3, P586
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142-9612(99)00011-3
   Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012
   Mano JF, 2007, J R SOC INTERFACE, V4, P999, DOI 10.1098/rsif.2007.0220
   MIKOS AG, 1993, BIOTECHNOL BIOENG, V42, P716, DOI 10.1002/bit.260420606
   MIKOS AG, 1994, BIOMATERIALS, V15, P55, DOI 10.1016/0142-9612(94)90197-X
   Mizumoto H, 2003, VISION RES, V43, P1699, DOI 10.1016/S0042-6989(03)00235-9
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   NG TF, 2007, IMMUNE RESPONSE EYE, V92, P300
   Nguyen KT, 2002, BIOMATERIALS, V23, P4307, DOI 10.1016/S0142-9612(02)00175-8
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Niknejad H, 2008, EUR CELLS MATER, V15, P88
   Oganesian A, 1999, ARCH OPHTHALMOL-CHIC, V117, P1192
   PAGE WJ, 1992, APPL ENVIRON MICROB, V58, P2866, DOI 10.1128/AEM.58.9.2866-2873.1992
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   QUI G, 2004, CURR EYE RES, V28, P327
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P48, DOI 10.1007/BF01007837
   Sagdullaev BT, 2003, INVEST OPHTH VIS SCI, V44, P1686, DOI 10.1167/iovs.02-0615
   Sakuragi M, 2001, CURR EYE RES, V23, P185, DOI 10.1076/ceyr.23.3.185.5465
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Schraermeyer U, 2001, CELL TRANSPLANT, V10, P673, DOI 10.3727/000000001783986215
   Schugens C, 1996, J BIOMED MATER RES, V30, P449, DOI 10.1002/(SICI)1097-4636(199604)30:4<449::AID-JBM3>3.0.CO;2-P
   Schugens C, 1996, POLYMER, V37, P1027, DOI 10.1016/0032-3861(96)87287-9
   SCHUSCHEREBA ST, 1992, EXP NEUROL, V115, P95, DOI 10.1016/0014-4886(92)90228-I
   Seiler MJ, 2008, EUR J NEUROSCI, V28, P208, DOI 10.1111/j.1460-9568.2008.06279.x
   Seiler MJ, 2008, EXP EYE RES, V86, P92, DOI 10.1016/j.exer.2007.09.012
   SEILER MJ, 1995, CURR EYE RES, V14, P199, DOI 10.3109/02713689509033515
   SHATOS MA, 2001, J REGENERATIVE MED, V2, P13
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684
   SILVERMAN MS, 1992, EXP NEUROL, V115, P87, DOI 10.1016/0014-4886(92)90227-H
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Singhal Shweta, 2005, Indian Journal of Ophthalmology, V53, P109
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922
   Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721
   TANSLEY KATHARINE, 1933, BRIT JOUR OPHTHALMOL, V17, P321, DOI 10.1136/bjo.17.6.321
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tao SL, 2005, J CONTROL RELEASE, V109, P127, DOI 10.1016/j.jconrel.2005.09.019
   Tao SL, 2003, ADV DRUG DELIVER REV, V55, P315, DOI 10.1016/S0169-409X(02)00227-2
   Teixeira AI, 2007, CELL RES, V17, P56, DOI 10.1038/sj.cr.7310141
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   TEZCANER A, 2007, J BIOMED MATER RES A, P170
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   Thumann G, 2006, CURR EYE RES, V31, P241, DOI 10.1080/02713680600556966
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Truskett VN, 2006, TRENDS BIOTECHNOL, V24, P312, DOI 10.1016/j.tibtech.2006.05.005
   Vacanti JP, 1999, LANCET, V354, pSI32
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   VEIS A, 1960, NATURE, V186, P720, DOI 10.1038/186720a0
   von Recum H, 1998, J BIOMAT SCI-POLYM E, V9, P1241, DOI 10.1163/156856298X00758
   Vugler A, 2007, MECH DEVELOP, V124, P807, DOI 10.1016/j.mod.2007.08.002
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Wang YD, 2002, NAT BIOTECHNOL, V20, P602, DOI 10.1038/nbt0602-602
   Weibel DB, 2005, CURR OPIN NEUROBIOL, V15, P560, DOI 10.1016/j.conb.2005.08.013
   Williams RL, 2005, J MATER SCI-MATER M, V16, P1087, DOI 10.1007/s10856-005-4710-y
   Wu HJ, 2007, GRAEF ARCH CLIN EXP, V245, P135, DOI 10.1007/s00417-006-0296-4
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
NR 145
TC 132
Z9 136
U1 4
U2 37
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2010
VL 248
IS 6
BP 763
EP 778
DI 10.1007/s00417-009-1263-7
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 587PT
UT WOS:000277005600001
PM 20169358
DA 2022-11-30
ER

PT J
AU Murakami, Y
   Ikeda, Y
   Yonemitsu, Y
   Miyazaki, M
   Inoue, M
   Hasegawa, M
   Sueishi, K
   Ishibashi, T
AF Murakami, Yusuke
   Ikeda, Yasuhiro
   Yonemitsu, Yoshikazu
   Miyazaki, Masanori
   Inoue, Makoto
   Hasegawa, Mamoru
   Sueishi, Katsuo
   Ishibashi, Tatsuro
TI Inhibition of Choroidal Neovascularization via Brief Subretinal Exposure
   to a Newly Developed Lentiviral Vector Pseudotyped with Sendai Viral
   Envelope Proteins
SO HUMAN GENE THERAPY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; EFFICIENT
   GENE-TRANSFER; LEBER CONGENITAL AMAUROSIS; RETINAL-PIGMENT EPITHELIUM;
   MACULAR DEGENERATION; OCULAR NEOVASCULARIZATION; VISUAL FUNCTION;
   INTRAVITREAL INJECTION; PRECLINICAL SAFETY
AB Lentiviral vectors are promising tools for the treatment of chronic retinal diseases, including age-related macular degeneration (AMD), as they enable stable transgene expression. On the other hand, Sendai virus (SeV) vectors provide the unique advantage of rapid gene transfer. Here we show that novel simian immunodeficiency viral vectors pseudotyped with SeV envelope proteins (SeV-F/HN-SIV) achieved rapid, efficient, and long-lasting gene transfer in the mouse retina. Subretinal exposure to SeV-F/HN-SIV vectors for only a few minutes resulted in high-level gene transfer to the retinal pigment epithelium, whereas several hours were required for gene transfer by standard vesicular stomatitis virus G-pseudotyped SIV vectors. Transgene expression continued over a 1-year period. SeV-F/HN-SIV vector-mediated retinal overexpression of soluble Fms-like tyrosine kinase-1 (sFlt-1) or pigment epithelium-derived factor (PEDF) significantly suppressed laser-induced choroidal neovascularization (CNV). Histologically, 6-month-long sustained overexpression of PEDF did not adversely affect the retina; however, that with sFlt-1 resulted in photoreceptor degeneration associated with choroidal circulation defects. These data demonstrate that brief subretinal administration of SeV-F/HN-SIV vectors may facilitate safe and efficient retinal gene transfer, and suggest the therapeutic potential of PEDF with a higher safety profile for treating CNV in AMD patients.
C1 [Ikeda, Yasuhiro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan.
   [Murakami, Yusuke; Sueishi, Katsuo] Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol, Fukuoka 8128582, Japan.
   [Yonemitsu, Yoshikazu] Chiba Univ, Grad Sch Med, Dept Gene Therapy, Chiba 2608670, Japan.
   [Inoue, Makoto; Hasegawa, Mamoru] DNAVEC, Tsukuba, Ibaraki 3050856, Japan.
C3 Kyushu University; Kyushu University; Chiba University; DNAVEC
   Corporation
RP Ikeda, Y (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM ymocl@pathol1.med.kyushu-u.ac.jp
OI Inoue, Makoto/0000-0003-0804-7439
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology
   [20791259, 18390115, 19791277]
FX This work was supported in part by the Japanese Ministry of Education,
   Culture, Sports, Science, and Technology (grants-in-aid 20791259,
   18390115, and 19791277 to Y. I., Y. Y., and M. M.). The authors are
   grateful to Drs. Eiji Akiba, Katsuyuki Mitomo, and Toshiaki Tabata for
   excellent technical assistance with vector construction and large-scale
   production. The authors also thank Mr. Hiroshi Fujii and Miss Chie
   Arimatsu for assistance with the experiments.
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Fields B. N, 1996, FIELDS VIROLOGY, V1, P1177
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Hurwitz H, 2006, SEMIN ONCOL, V33, pS26, DOI 10.1053/j.seminoncol.2006.08.001
   Ikeda Y, 2003, GENE THER, V10, P1161, DOI 10.1038/sj.gt.3301973
   Ikeda Y, 2002, EXP EYE RES, V75, P39, DOI 10.1006/exer.2002.1177
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kobayashi M, 2003, J VIROL, V77, P2607, DOI 10.1128/JVI.77.4.2607-2614.2003
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884
   Li Y, 2008, J CLIN INVEST, V118, P913, DOI 10.1172/JCI33673
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Maeda Y, 1998, J MOL CELL CARDIOL, V30, P1341, DOI 10.1006/jmcc.1998.0697
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maharaj ASR, 2008, J EXP MED, V205, P491, DOI 10.1084/jem.20072041
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Masaki I, 2001, FASEB J, V15, P1294, DOI 10.1096/fj.00-0460fje
   Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, GENE THER, V10, P1503, DOI 10.1038/sj.gt.3302028
   Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Murakami Y, 2008, AM J PATHOL, V173, P1326, DOI 10.2353/ajpath.2008.080466
   Murakami Y, 2008, J GENE MED, V10, P165, DOI 10.1002/jgm.1142
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sang DN, 2008, DIABETOLOGIA, V51, P1570, DOI 10.1007/s00125-008-1078-9
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stitt AW, 1998, J PATHOL, V186, P306, DOI 10.1002/(SICI)1096-9896(1998110)186:3<306::AID-PATH183>3.0.CO;2-B
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Takita H, 2003, INVEST OPHTH VIS SCI, V44, P4497, DOI 10.1167/iovs.03-0052
   TANIWAKI T, 1995, J NEUROCHEM, V64, P2509
   Teramoto S, 1998, J VIROL, V72, P8904, DOI 10.1128/JVI.72.11.8904-8912.1998
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970, DOI 10.1038/79463
   Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474
NR 66
TC 31
Z9 32
U1 2
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD FEB
PY 2010
VL 21
IS 2
BP 199
EP 209
DI 10.1089/hum.2009.102
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 556NM
UT WOS:000274597900010
PM 19778186
DA 2022-11-30
ER

PT J
AU Sheridan, CM
   Rice, D
   Hiscott, PS
   Wong, D
   Kent, DL
AF Sheridan, CM
   Rice, D
   Hiscott, PS
   Wong, D
   Kent, DL
TI The presence of AC133-positive cells suggests a possible role of
   endothelial progenitor cells in the formation of choroidal
   neovascularization
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; BLOOD-VESSEL FORMATION; BONE-MARROW; RETINAL
   NEOVASCULARIZATION; VASCULAR ENDOTHELIUM; MACULAR DEGENERATION;
   REGENERATION; GROWTH; DIFFERENTIATION; VASCULOGENESIS
AB PURPOSE. Recent evidence suggests that vasculogenesis as well as angiogenesis occurs throughout the body during neovascularization. The recruitment of circulating stem cells is a key feature of vasculogenesis. The purpose of the present study was to determine whether markers of endothelial progenitor cells (EPCs) are present in choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   METHODS. Surgically excised CNV (n = 9) membranes from patients with AMD were probed with immunohistochemical techniques using the following monoclonal antibodies: AC133 a putative marker of EPCs and hematopoietic stem cells (HSCs); the endothelial cells markers CD31, CDA and von Willebrand factor (vWF); and cytokeratins and CD68, markers for retinal pigment epithelium (RPE) and macrophages, respectively. After secondary antibody amplification, reactions were visualized with fast red substrate.
   RESULTS. Six of nine specimens demonstrated cells positive for AC133 that were all found within predominantly cellular regions of the specimens. In the avascular fibrous stromal core of all specimens, the predominant cells were RPE cells and macrophages. The peripheral component of all CNV membranes was highly vascular and showed varying immunoreactivity for all endothelial markers. The greatest immunoreactivity for endothelial markers was observed with CD34 and vWF and least for CD31.
   CONCLUSIONS. These findings support animal studies that vasculogenesis, in addition to angiogenesis, may contribute to the neovascularization that occurs in AMD.
C1 Univ Liverpool, Sch Clin Sci, Dept Ophthalmol, Liverpool L69 3GA, Merseyside, England.
   Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   Aut Even Hosp, Eye Serv, Kilkenny, Ireland.
C3 University of Liverpool; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   Liverpool
RP Sheridan, CM (通讯作者)，Univ Liverpool, Sch Clin Sci, Dept Ophthalmol, Daulby St, Liverpool L69 3GA, Merseyside, England.
EM c.sheridan@liverpool.ac.uk
RI Wong, Sai Hung David/D-8482-2015; Sheridan, Carl/AAH-3607-2021
OI Sheridan, Carl/0000-0003-0100-9587
CR Ali J, 1997, MICROCIRCULATION-LON, V4, P267, DOI 10.3109/10739689709146790
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Caprioli A, 1998, P NATL ACAD SCI USA, V95, P1641, DOI 10.1073/pnas.95.4.1641
   Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005
   COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U
   Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   FLAMME I, 1995, DEV BIOL, V169, P699, DOI 10.1006/dbio.1995.1180
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   GREEN WR, 1992, OPHTHALMOLOGY, V100, P1519
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   HARRISON DE, 1993, EXP HEMATOL, V21, P206
   Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3
   Hilbe W, 2004, J CLIN PATHOL, V57, P965, DOI 10.1136/jcp.2004.016444
   Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150
   Kent D, 2003, MOL VIS, V9, P747
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2
   Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958
   Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168
   Robert B, 1996, AM J PHYSIOL-RENAL, V271, pF744, DOI 10.1152/ajprenal.1996.271.3.F744
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   van Bekkum DW, 2004, BLOOD CELL MOL DIS, V32, P11, DOI 10.1016/j.bcmd.2003.09.009
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424
   Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012
NR 39
TC 45
Z9 51
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2006
VL 47
IS 4
BP 1642
EP 1645
DI 10.1167/iovs.05-0779
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 029KI
UT WOS:000236560800051
PM 16565404
DA 2022-11-30
ER

PT J
AU Romano, F
   Zicarelli, F
   Cozzi, M
   Bertoni, AI
   Cereda, MG
   Bottoni, F
   Staurenghi, G
   Invernizzi, A
AF Romano, Francesco
   Zicarelli, Federico
   Cozzi, Mariano
   Bertoni, Alice Ingrid
   Cereda, Matteo Giuseppe
   Bottoni, Ferdinando
   Staurenghi, Giovanni
   Invernizzi, Alessandro
TI MULTIMODAL IMAGING CHARACTERISTICS AND FUNCTIONAL CORRELATES IN RIP
   HEALING
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE RPE tear; rip healing; multimodal imaging; OCT; healing tissue;
   microperimetry; autofluorescence; retinal pigment epithelium; rip
ID RETINAL-PIGMENT EPITHELIUM; GROWTH-FACTOR THERAPY; FUNDUS
   AUTOFLUORESCENCE; VISUAL-ACUITY; TEARS; MECHANISM; LAYERS
AB Purpose: To report the imaging and functional features of the repair tissue following retinal pigment epithelium (RPE) tears. Methods: This cross-sectional observational study included patients with RPE tears secondary to neovascular age-related macular degeneration and at least 12 months of follow-up. The following variables were analyzed: best-corrected visual acuity; retinal sensitivity using microperimetry; outer retinal layers status and RPE resurfacing on optical coherence tomography; fibrosis; autofluorescence signal recovery using blue-light and near-infrared autofluorescence. Results: Overall, 48 eyes were included (age: 82 +/- 5 years) and 34 of them showed signs of healing. Retinal pigment epithelium resurfacing was noticed in 22 cases, whereas fibrosis appeared in 21 eyes. Autofluorescence improved in 17 cases using blue-light infrared autofluorescence and 7 eyes on near-infrared autofluorescence. Outer retinal layers were more frequently preserved when RPE resurfacing and autofluorescence improvement occurred (P < 0.05). Although best-corrected visual acuity was higher for smaller RPE tears (P = 0.01), retinal sensitivity of the healing tissue was positively affected by autofluorescence improvement (P < 0.001) and by absence of fibrosis (P = 0.03). Conclusion: Autofluorescence signal recovery after rip occurrence possibly reflects the underlying status of the RPE and is associated with better functional outcomes. Our findings highlight the importance of blue-light infrared autofluorescence and especially near-infrared autofluorescence assessment in the setting of rip healing.
C1 [Romano, Francesco; Zicarelli, Federico; Cozzi, Mariano; Bertoni, Alice Ingrid; Cereda, Matteo Giuseppe; Bottoni, Ferdinando; Staurenghi, Giovanni; Invernizzi, Alessandro] Univ Milan, Luigi Sacco Hosp, Dept Biomed Sci, Eye Clin, Milan, Italy.
   [Invernizzi, Alessandro] Univ Sydney, Fac Hlth & Med, Save Sight Inst, Sydney, NSW, Australia.
C3 University of Milan; Luigi Sacco Hospital; University of Sydney
RP Romano, F (通讯作者)，Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
EM francesco.romano@unimi.it
CR Bartels S, 2014, OPHTHALMOLOGE, V111, P460, DOI 10.1007/s00347-013-2883-1
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Caramoy A, 2012, ACTA OPHTHALMOL, V90, pE328, DOI 10.1111/j.1755-3768.2011.02284.x
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Clemens CR, 2014, RETINA-J RET VIT DIS, V34, P24, DOI 10.1097/IAE.0b013e3182947811
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   HERIOT WJ, 1992, GRAEF ARCH CLIN EXP, V230, P91, DOI 10.1007/BF00166769
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Invernizzi A, 2018, OPHTHALMOLOGY, V125, P237, DOI 10.1016/j.ophtha.2017.08.039
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Okeagu CU, 2021, OPHTHALMOL RETINA, V5, P23, DOI 10.1016/j.oret.2020.09.025
   Pfau M, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100907
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Romano F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85270-x
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schmitz-Valckenberg S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100893
   STAURENGHI G, 1991, AM J OPHTHALMOL, V112, P598, DOI 10.1016/S0002-9394(14)76868-0
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
NR 30
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2022
VL 42
IS 10
BP 1844
EP 1851
DI 10.1097/IAE.0000000000003542
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4Q1OP
UT WOS:000855855500010
PM 35976222
DA 2022-11-30
ER

PT J
AU Meleppat, RK
   Ronning, KE
   Karlen, SJ
   Burns, ME
   Pugh, EN
   Zawadzki, RJ
AF Meleppat, Ratheesh K.
   Ronning, Kaitryn E.
   Karlen, Sarah J.
   Burns, Marie E.
   Pugh, Edward N., Jr.
   Zawadzki, Robert J.
TI In vivo multimodal retinal imaging of disease-related pigmentary changes
   in retinal pigment epithelium
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; RPE LIPOFUSCIN; ANTIOXIDANT PROPERTIES;
   OPTICAL-PROPERTIES; MELANIN; MELANOSOMES; A2E; MELANOLIPOFUSCIN;
   BISRETINOIDS; ACCUMULATION
AB Melanosomes, lipofuscin, and melanolipofuscin are the three principal types of pigmented granules found in retinal pigment epithelium (RPE) cells. Changes in the density of melanosomes and lipofuscin in RPE cells are considered hallmarks of various retinal diseases, including Stargardt disease and age-related macular degeneration (AMD). Herein, we report the potential of an in vivo multimodal imaging technique based on directional back-scattering and short-wavelength fundus autofluorescence (SW-FAF) to study disease-related changes in the density of melanosomes and lipofuscin granules in RPE cells. Changes in the concentration of these granules in Abca4(-/-) mice (a model of Stargardt disease) relative to age-matched wild-type (WT) controls were investigated. Directional optical coherence tomography (dOCT) was used to assess melanosome density in vivo, whereas the autofluorescence (AF) images and emission spectra acquired with a spectrometer-integrated scanning laser ophthalmoscope (SLO) were used to characterize lipofuscin and melanolipofuscin granules in the same RPE region. Subcellular-resolution ex vivo imaging using confocal fluorescence microscopy and electron microscopy was performed on the same tissue region to visualize and quantify melanosomes, lipofuscin, and melanolipofuscin granules. Comparisons between in vivo and ex vivo results confirmed an increased concentration of lipofuscin granules and decreased concentration of melanosomes in the RPE of Abca4(-/-) mice, and provided an explanation for the differences in fluorescence and directionality of RPE scattering observed in vivo between the two mouse strains.
C1 [Meleppat, Ratheesh K.; Pugh, Edward N., Jr.; Zawadzki, Robert J.] Univ Calif Davis, UC Davis Eyepod Imaging Lab, Davis, CA 95616 USA.
   [Meleppat, Ratheesh K.; Karlen, Sarah J.; Pugh, Edward N., Jr.; Zawadzki, Robert J.] Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA.
   [Ronning, Kaitryn E.; Burns, Marie E.] Univ Calif Davis, Ctr Neurosci, Davis, CA 95618 USA.
   [Meleppat, Ratheesh K.; Burns, Marie E.; Zawadzki, Robert J.] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis
RP Zawadzki, RJ (通讯作者)，Univ Calif Davis, UC Davis Eyepod Imaging Lab, Davis, CA 95616 USA.; Zawadzki, RJ (通讯作者)，Univ Calif Davis, Dept Cell Biol & Human Anat, Davis, CA 95616 USA.; Zawadzki, RJ (通讯作者)，Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
EM rjzawadzki@ucdavis.edu
RI Meleppat, Ratheesh Kumar/AAG-4806-2020
OI Meleppat, Ratheesh Kumar/0000-0003-0240-9419; Ronning,
   Kaitryn/0000-0002-6727-5776
FU NIH [EY02660, EY024320, EY026556, EY012576, T32-EY105387]; Barr Retina
   Research Foundation
FX Supported by NIH Grants EY02660, EY024320, EY026556, and EY012576 (NEI
   Core Grant), T32-EY105387, and Barr Retina Research Foundation gift to
   UC Davis Department of Ophthalmology.
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P1381, DOI 10.1136/bjo.87.11.1381
   Bermond Katharina, 2021, Ann Eye Sci, V6, DOI 10.21037/aes-2021-01
   Bhandari A, 2011, OPT EXPRESS, V19, P14549, DOI 10.1364/OE.19.014549
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Chen HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep09269
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Conley SM, 2012, BBA-MOL BASIS DIS, V1822, P1169, DOI 10.1016/j.bbadis.2011.10.007
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Ding JD, 2015, J CELL BIOL, V211, P495, DOI 10.1083/jcb.201508093
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Huang XR, 2011, INVEST OPHTH VIS SCI, V52, P6737, DOI 10.1167/iovs.11-7665
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Lenis TL, 2018, P NATL ACAD SCI USA, V115, pE11120, DOI 10.1073/pnas.1802519115
   Lin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep35414
   Lu RW, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.060504
   Meleppat RK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.1
   Meleppat RK, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.6.066011
   Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464
   Olchawa MM, 2021, PIGM CELL MELANOMA R, V34, P670, DOI 10.1111/pcmr.12914
   Paavo M, 2018, INVEST OPHTH VIS SCI, V59, P2459, DOI 10.1167/iovs.18-24213
   Pollreisz A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.13
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Sezgin M, 2004, J ELECTRON IMAGING, V13, P146, DOI 10.1117/1.1631315
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Song G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64827-2
   Song WY, 2017, BIOMED OPT EXPRESS, V8, P3966, DOI 10.1364/BOE.8.003966
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P2812, DOI 10.1167/iovs.12-11490
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Taubit T, 2018, PEERJ, V6, DOI 10.7717/peerj.5215
   Taubitz T, 2019, EBIOMEDICINE, V48, P592, DOI 10.1016/j.ebiom.2019.09.048
   Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848
   Vollmer-Snarr H. R., RETINAL DEGENERATIVE, P69
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   Warburton S, 2007, MOL VIS, V13, P318
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
   Zhang PF, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.12.126005
NR 55
TC 16
Z9 16
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 10
PY 2021
VL 11
IS 1
AR 16252
DI 10.1038/s41598-021-95320-z
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TY6PJ
UT WOS:000683904100013
PM 34376700
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Pujari, A
   Bhaskaran, K
   Sharma, P
   Singh, P
   Phuljhele, S
   Saxena, R
   Azad, SV
AF Pujari, Amar
   Bhaskaran, Karthika
   Sharma, Pradeep
   Singh, Pallavi
   Phuljhele, Swati
   Saxena, Rohit
   Azad, Shorya Vardhan
TI Optical coherence tomography angiography in neuro-ophthalmology: Current
   clinical role and future perspectives
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE optical coherence tomography angiography; optic nerve head optical
   coherence tomography angiography; ischemic optic neuropathy and OCTA;
   papilledema and OCTA; optic disc drusen and OCTA; papillitis and OCTA;
   LHON and OCTA; multiple sclerosis and OCTA; Alzheimer disease and OCTA;
   neurodegenerative diseases and OCTA
ID VESSEL DENSITY; NERVE HEAD; COGNITIVE IMPAIRMENT; NEUROPATHY; OCTA;
   MICROVASCULATURE; RETINA
AB Optical coherence tomography angiography (OCTA) is a noninvasive, depth-resolved imaging tool for the appraisement of retinal vascular changes. Since its introduction, the understanding of diabetic retinopathy, age-related macular degeneration, central serous retinopathy, and other diseases has been enriched on many fronts. Its dyeless imaging property maps retinal as well as deeper choroidal vasculature in quick succession with good reproducibility. Hence, it can play an important role in the diagnosis and management of optic nerve-related diseases as well. A detailed literature review for its role in nonarteritic anterior ischemic optic neuropathy, papilledema, optic disc drusen, papillitis, hereditary optic neuropathies, central nervous system diseases, and others highlights its role. The whole spectrum of neuro-ophthalmological diseases shows consistent peripapillary and macular capillary changes with structural and functional correlation. The superficial and deeper retinal and choroidal vasculatures are affected depending on the nature of the disease process. Hence, OCTA positions itself as a useful, noninvasive tool in the armamentarium of a neuro-ophthalmologist in future; however, there are several limitations of the OCTA with respect to its technical abilities in challenging neuroophthalmic cases. Therefore, future research should be directed to enhance the technical capabilities of OCTA and to determine the more precise role of it in the prognosis of neuro-ophthalmic diseases.
   (c) 2020 Elsevier Inc. All rights reserved.
C1 [Pujari, Amar; Bhaskaran, Karthika; Sharma, Pradeep; Singh, Pallavi; Phuljhele, Swati; Saxena, Rohit; Azad, Shorya Vardhan] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences
RP Pujari, A (通讯作者)，All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, AIIMS, Room 212,RPC 1, New Delhi, India.
EM dramarpujari@gmail.com
RI Singh, Pallavi/AAN-7316-2021
OI Singh, Pallavi/0000-0001-5043-1915
CR Abe M, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01453-6
   Aghdam KA, 2019, CAN J OPHTHALMOL, V54, P495, DOI 10.1016/j.jcjo.2018.08.002
   Al-Nashar HY, 2020, INT OPHTHALMOL, V40, P1269, DOI 10.1007/s10792-020-01293-9
   Asanad S, 2019, INTRACTABLE RARE DIS, V8, P52, DOI 10.5582/irdr.2018.01126
   Augstburger E, 2018, INVEST OPHTH VIS SCI, V59, P870, DOI 10.1167/iovs.17-22996
   Balducci N, 2018, CLIN EXP OPHTHALMOL, V46, P1055, DOI 10.1111/ceo.13326
   Balducci N, 2017, GRAEF ARCH CLIN EXP, V255, P2255, DOI 10.1007/s00417-017-3774-y
   Balducci N, 2017, MITOCHONDRION, V36, P60, DOI 10.1016/j.mito.2017.03.002
   Bicer O, 2019, TURK OFTALMOL DERG, V49, P300, DOI 10.4274/tjo.galenos.2019.14194
   Bilen FT, 2019, J NEURO-OPHTHALMOL, V39, P319, DOI 10.1097/WNO.0000000000000745
   Borrelli E, 2018, AM J OPHTHALMOL, V192, P217, DOI 10.1016/j.ajo.2018.05.029
   Brucher VC, 2019, KLIN MONATSBL AUGENH, V236, P1182, DOI 10.1055/a-0978-8360
   Bulut M, 2018, BRIT J OPHTHALMOL, V102, P233, DOI 10.1136/bjophthalmol-2017-310476
   Cennamo G, 2018, OPHTHALMIC RES, V59, P76, DOI 10.1159/000481889
   Cennamo G, 2017, AM J OPHTHALMOL, V176, P1, DOI 10.1016/j.ajo.2016.12.016
   Chen YH, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00035
   Choi JM, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01470-5
   Dallorto L, 2020, ACTA OPHTHALMOL, V98, pE585, DOI 10.1111/aos.14322
   De Rojas JO, 2016, NEUROLOGY, V87, P2065, DOI 10.1212/WNL.0000000000003313
   Engelke H, 2020, BRIT J OPHTHALMOL, V104, P1109, DOI 10.1136/bjophthalmol-2019-314096
   Falavarjani KG, 2016, RETINA-J RET VIT DIS, V36, pS168, DOI 10.1097/IAE.0000000000001259
   Fard MA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.35
   Fard MA, 2019, J NEURO-OPHTHALMOL, V39, P339, DOI 10.1097/WNO.0000000000000775
   Fard MA, 2018, AM J OPHTHALMOL, V191, P116, DOI 10.1016/j.ajo.2018.04.017
   Fard MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189237
   Feucht N, 2019, MULT SCLER J, V25, P224, DOI 10.1177/1352458517750009
   Gandhi U, 2018, INDIAN J OPHTHALMOL, V66, P1144, DOI 10.4103/ijo.IJO_179_18
   Geier ED, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199793
   Hata M, 2017, J NEURO-OPHTHALMOL, V37, P140, DOI 10.1097/WNO.0000000000000470
   Hayreh SS, 2009, PROG RETIN EYE RES, V28, P34, DOI 10.1016/j.preteyeres.2008.11.002
   Higashiyama T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172168
   Higashiyama T, 2016, NEURO-OPHTHALMOLOGY, V40, P146, DOI 10.3109/01658107.2016.1162174
   Hua DH, 2020, MICROVASC RES, V129, DOI 10.1016/j.mvr.2019.103969
   Iftikhar M, 2019, CURR EYE RES, V44, P558, DOI 10.1080/02713683.2019.1565892
   Jiang H, 2020, AM J OPHTHALMOL, V213, P34, DOI 10.1016/j.ajo.2019.12.021
   Jiang H, 2018, J NEURO-OPHTHALMOL, V38, P292, DOI 10.1097/WNO.0000000000000580
   Jiang Shangjun, 2022, Retin Cases Brief Rep, V16, P126, DOI 10.1097/ICB.0000000000000908
   Kousal B, 2019, ACTA OPHTHALMOL, V97, pE71, DOI 10.1111/aos.13817
   Kwapong WR, 2018, AM J OPHTHALMOL, V192, P47, DOI 10.1016/j.ajo.2018.04.026
   Lahme L, 2018, J ALZHEIMERS DIS, V66, P1745, DOI 10.3233/JAD-180738
   Lanzillo R, 2018, MULT SCLER J, V24, P1706, DOI 10.1177/1352458517729463
   Leal-Gonzalez M, 2020, CLIN EXP OPHTHALMOL, V48, P775, DOI 10.1111/ceo.13783
   Lee GI, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030697
   Lee GI, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59158-1
   Lee JY, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00638-x
   Ling JW, 2017, INT J OPHTHALMOL-CHI, V10, P1402, DOI 10.18240/ijo.2017.09.12
   Liu CH, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/9632647
   Mardin CY, 2019, OPHTHALMOLOGE, V116, P714, DOI 10.1007/s00347-019-0883-5
   Mastropasqua R, 2018, CURR EYE RES, V43, P778, DOI 10.1080/02713683.2018.1438630
   Matsuzaki Mitsuhiro, 2018, Am J Ophthalmol Case Rep, V9, P51, DOI 10.1016/j.ajoc.2018.01.003
   Mayes EW, 2017, J NEURO-OPHTHALMOL, V37, P358, DOI 10.1097/WNO.0000000000000493
   Moyal L, 2018, GRAEF ARCH CLIN EXP, V256, P1235, DOI 10.1007/s00417-018-3943-7
   Murphy OC, 2020, MULT SCLER J, V26, P815, DOI 10.1177/1352458519845116
   O'Bryhim BE, 2018, JAMA OPHTHALMOL, V136, P1242, DOI 10.1001/jamaophthalmol.2018.3556
   Pellegrini F, 2019, NEURO-OPHTHALMOLOGY, V43, P401, DOI 10.1080/01658107.2018.1523196
   Pellegrini F, 2020, NEURO-OPHTHALMOLOGY, V44, P114, DOI 10.1080/01658107.2019.1617748
   Pellegrini M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061706
   Pellegrini M, 2019, AM J OPHTHALMOL, V205, P43, DOI 10.1016/j.ajo.2019.03.028
   Pierro L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041094
   Rebolleda G, 2018, OPHTHALMOLOGICA, V240, P191, DOI 10.1159/000489226
   Rodriguez Torres Y, 2020, J NEUROOPHTHALMOL, DOI [10. 1097/WNO.0000000000000877, DOI 10.1097/WNO.0000000000000877]
   Rougier MB, 2017, J FR OPHTALMOL, V40, P102, DOI 10.1016/j.jfo.2016.09.020
   Rougier MB, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0109-y
   Sharma S, 2017, BRIT J OPHTHALMOL, V101, P1045, DOI 10.1136/bjophthalmol-2016-309245
   Shi C, 2020, RETINA-J RET VIT DIS, V40, P1483, DOI 10.1097/IAE.0000000000002641
   Shin YI, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63603-6
   Song Y, 2018, LASER SURG MED, V50, P194, DOI 10.1002/lsm.22712
   Spain RI, 2018, BRIT J OPHTHALMOL, V102, P520, DOI 10.1136/bjophthalmol-2017-310477
   Sung MS, 2018, AM J OPHTHALMOL, V188, P81, DOI 10.1016/j.ajo.2018.01.033
   Takayama K, 2017, ACTA OPHTHALMOL, V95, pE344, DOI 10.1111/aos.13244
   Tasli NG, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/3412490
   Ulusoy MO, 2020, NEUROL RES, V42, P319, DOI 10.1080/01616412.2020.1726585
   Urfalioglu S, 2019, PREGNANCY HYPERTENS, V17, P203, DOI 10.1016/j.preghy.2019.07.001
   van de Kreeke JA, 2020, BRIT J OPHTHALMOL, V104, P157, DOI 10.1136/bjophthalmol-2019-314127
   Vosborg F, 2020, EUR J OPHTHALMOL, V30, P235, DOI 10.1177/1120672119858891
   Vujosevic S, 2018, INVEST OPHTH VIS SCI, V59, P5074, DOI 10.1167/iovs.18-24891
   Wang L, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0104-3
   Wang XG, 2014, BRIT J OPHTHALMOL, V98, P1368, DOI 10.1136/bjophthalmol-2013-304547
   Wang Y H, 2019, Zhonghua Yan Ke Za Zhi, V55, P677, DOI 10.3760/cma.j.issn.0412-4081.2019.09.010
   Wu J, 2020, ACTA OPHTHALMOL, V98, pE781, DOI 10.1111/aos.14381
   Wylegala A, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0911-x
   Yan Y, 2020, AM J OPHTHALMOL, V218, P214, DOI 10.1016/j.ajo.2020.04.019
   Yilmaz H, 2020, EYE, V34, P771, DOI 10.1038/s41433-019-0746-y
   Yoon SP, 2019, OSLI RETINA, V50, P709, DOI 10.3928/23258160-20191031-06
   Zhang T, 2019, INVEST OPHTH VIS SCI, V60, P1863, DOI 10.1167/iovs.18-25941
   Zhang Y, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01368-2
   Zhang YS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214685
NR 87
TC 8
Z9 9
U1 5
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2021
VL 66
IS 3
BP 471
EP 481
DI 10.1016/j.survophthal.2020.10.009
EA MAR 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RI2EM
UT WOS:000636722800006
PM 33157113
DA 2022-11-30
ER

PT J
AU Jeong, YW
   Kim, HS
   Thangavelu, M
   Choi, MJ
   Lee, GW
   Song, CU
   Song, JE
   Khang, G
AF Jeong, Yong Woon
   Kim, Han Sol
   Thangavelu, Muthukumar
   Choi, Min Joung
   Lee, Gi Won
   Song, Cheol Ui
   Song, Jeong Eun
   Khang, Gilson
TI Progress in Silk Fibroin Based Composite Scaffold/Hydrogel: Silk
   Fibroin/PEG Hydrogel for the RPE Regeneration a Promising Biomaterial
   for Clinical Application
SO FRONTIERS IN MATERIALS
LA English
DT Article
DE silk fibroin; polyethylene glycol; retinal pigment epithelial; hydrogel;
   gene expression; porosity
ID RETINAL-PIGMENT EPITHELIUM; CELLS; PROLIFERATION; MECHANISM
AB Retinal pigment epithelium (RPE) plays a decisive role in the normal function of the retina, especially in the maintenance of photoreceptors. RPE dysfunction, loss of sight, and degeneration has been implicated as the cause of many retinal diseases including pigmented retinitis and age-related macular degeneration (AMD). Silk fibroin (SF) is a biodegradable natural polymer with biocompatibility, non-toxic, and non-immunological properties. In this study, hydrogel material was prepared by mixing it with PEG [poly (ethylene glycol)] a synthetic polymer. SF hydrogel (SH) and with PEG (SPH) were prepared with different sonication times. The SH and SPH were prepared with different sonication time (20s SH, 30s SH, 20s SPH, and 30s SPH were prepared, respectively. The prepared SH and SPH were physio chemically characterized by SEM, FTIR, compressive strength, porosity, and in vitro biocompatibility were analyzed using MTT assay along with cell adhesion and cell proliferation, their gene expression was analyzed using RT-PCR. As a result, the 20s SPH hydrogel exhibited superior biocompatibility, cell adhesion, and improved cell growth compared to pure SH. Their respective genes expression for retinal function and matrix production was also positively influenced by 20s SPH with an increase in gene expression folds of RPE65, CRALBP. The obtained results suggest that the 20s SPH hydrogel can be used as an alternative material for the application of retinal regeneration and delivery.
C1 [Jeong, Yong Woon; Kim, Han Sol; Thangavelu, Muthukumar; Choi, Min Joung; Lee, Gi Won; Song, Cheol Ui; Song, Jeong Eun; Khang, Gilson] Jeonbuk Natl Univ, Polymer Mat Fus Ctr, Dept BIN Convergence Technol Polymer Nano Sci & T, Jeonju, South Korea.
C3 Jeonbuk National University
RP Khang, G (通讯作者)，Jeonbuk Natl Univ, Polymer Mat Fus Ctr, Dept BIN Convergence Technol Polymer Nano Sci & T, Jeonju, South Korea.
EM gskhang@jbnu.ac.kr
RI Thangavelu, Muthukumar/E-3891-2016
OI Thangavelu, Muthukumar/0000-0002-4449-6015
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT and Future Planning
   [NRF-2017R1A2B3010270]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT and Future Planning (NRF-2017R1A2B3010270).
CR Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Binder S, 2011, BRIT J OPHTHALMOL, V95, P441, DOI 10.1136/bjo.2009.171926
   BOK D, 1993, J CELL SCI, P189
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chanasakulniyom M, 2015, LAB CHIP, V15, P208, DOI 10.1039/c4lc00774c
   Chao PHG, 2010, J BIOMED MATER RES B, V95B, P84, DOI 10.1002/jbm.b.31686
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hallab NJ, 2001, TISSUE ENG, V7, P55, DOI 10.1089/107632700300003297
   Kim HS, 2019, INT J BIOL MACROMOL, V130, P220, DOI 10.1016/j.ijbiomac.2019.01.078
   Lee GY, 2017, J TISSUE ENG REGEN M, V11, P99, DOI 10.1002/term.1882
   Li RH, 1996, BIOTECHNOL BIOENG, V50, P365, DOI 10.1002/(SICI)1097-0290(19960520)50:4<365::AID-BIT3>3.0.CO;2-J
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu QA, 2011, BIOMACROMOLECULES, V12, P1080, DOI 10.1021/bm101422j
   MANDELCORN MS, 1975, AM J OPHTHALMOL, V80, P227, DOI 10.1016/0002-9394(75)90137-3
   OHNO K, 1992, J MOL STRUCT, V268, P41, DOI 10.1016/0022-2860(92)85058-O
   Park JH, 2018, INT J BIOL MACROMOL, V117, P546, DOI 10.1016/j.ijbiomac.2018.05.127
   Samal SK, 2013, MACROMOL MATER ENG, V298, P1201, DOI 10.1002/mame.201200377
   Santin M, 1999, J BIOMED MATER RES, V46, P382, DOI 10.1002/(SICI)1097-4636(19990905)46:3<382::AID-JBM11>3.0.CO;2-R
   Shin EY, 2019, MAT SCI ENG C-MATER, V103, DOI 10.1016/j.msec.2019.109787
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strauss O, 2009, OPHTHALMOLOGE, V106, P299, DOI 10.1007/s00347-008-1869-x
   Sung HJ, 2004, BIOMATERIALS, V25, P5735, DOI 10.1016/j.biomaterials.2004.01.066
   Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013
   Wang K, 2017, J CONTROL RELEASE, V268, P212, DOI 10.1016/j.jconrel.2017.10.031
   Wang XQ, 2008, BIOMATERIALS, V29, P1054, DOI 10.1016/j.biomaterials.2007.11.003
   Yucel T, 2009, BIOPHYS J, V97, P2044, DOI 10.1016/j.bpj.2009.07.028
   Zustiak SP, 2010, BIOMACROMOLECULES, V11, P1348, DOI 10.1021/bm100137q
NR 31
TC 2
Z9 2
U1 1
U2 23
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-8016
J9 FRONT MATER
JI Front. Mater.
PD NOV 13
PY 2020
VL 7
AR 504642
DI 10.3389/fmats.2020.504642
PG 9
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA OV8EH
UT WOS:000592435400001
OA gold
DA 2022-11-30
ER

PT J
AU Elsherbiny, NM
   Sharma, I
   Kira, D
   Alhusban, S
   Samra, YA
   Jadeja, R
   Martin, P
   Al-Shabrawey, M
   Tawfik, A
AF Elsherbiny, Nehal M.
   Sharma, Isha
   Kira, Dina
   Alhusban, Suhib
   Samra, Yara A.
   Jadeja, Ravirajsinh
   Martin, Pamela
   Al-Shabrawey, Mohamed
   Tawfik, Amany
TI Homocysteine Induces Inflammation in Retina and Brain
SO BIOMOLECULES
LA English
DT Article
DE homocysteine; inflammation; diabetic retinopathy; age-related macular
   degeneration; Alzheimer's disease
ID CYSTATHIONINE-BETA-SYNTHASE; PLASMA HOMOCYSTEINE; RISK-FACTOR; KAPPA-B;
   HYPERHOMOCYSTEINEMIA; MICROGLIA; DISEASE; PROTEIN; FOLATE; MICE
AB Homocysteine (Hcy) is an amino acid that requires vitamins B-12 and folic acid for its metabolism. Vitamins B-12 and folic acid deficiencies lead to hyperhomocysteinemia (HHcy, elevated Hcy), which is linked to the development of diabetic retinopathy (DR), age-related macular degeneration (AMD), and Alzheimer's disease (AD). The goal of the current study was to explore inflammation as an underlying mechanism of HHcy-induced pathology in age related diseases such as AMD, DR, and AD. Mice with HHcy due to a lack of the enzyme cystathionine-beta-synthase (CBS) and wild-type mice were evaluated for microglia activation and inflammatory markers using immuno-fluorescence (IF). Tissue lysates isolated from the brain hippocampal area from mice with HHcy were evaluated for inflammatory cytokines using the multiplex assay. Human retinal endothelial cells, retinal pigment epithelial cells, and monocyte cell lines treated with/without Hcy were evaluated for inflammatory cytokines and NF kappa B activation using the multiplex assay, western blot analysis, and IF. HHcy induced inflammatory responses in mouse brain, retina, cultured retinal, and microglial cells. NF kappa B was activated and cytokine array analysis showed marked increase in pro-inflammatory cytokines and downregulation of anti-inflammatory cytokines. Therefore, elimination of excess Hcy or reduction of inflammation is a promising intervention for mitigating damage associated with HHcy in aging diseases such as DR, AMD, and AD.
C1 [Elsherbiny, Nehal M.; Sharma, Isha; Kira, Dina; Alhusban, Suhib; Samra, Yara A.; Al-Shabrawey, Mohamed; Tawfik, Amany] Augusta Univ, Dent Coll Georgia, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.
   [Elsherbiny, Nehal M.; Sharma, Isha; Kira, Dina; Alhusban, Suhib; Samra, Yara A.; Jadeja, Ravirajsinh; Martin, Pamela; Al-Shabrawey, Mohamed; Tawfik, Amany] Augusta Univ, MCG, James & Jean Culver Vision Discovery Inst, Augusta, GA 30912 USA.
   [Elsherbiny, Nehal M.; Samra, Yara A.] Mansoura Univ, Dept Biochem, Fac Pharm, Mansoura 35516, Egypt.
   [Jadeja, Ravirajsinh; Martin, Pamela] Augusta Univ, Dept Biochem, Med Coll Georgia MCG, Augusta, GA 30912 USA.
   [Martin, Pamela; Al-Shabrawey, Mohamed; Tawfik, Amany] Augusta Univ, Dept Ophthalmol, MCG, Augusta, GA 30912 USA.
   [Al-Shabrawey, Mohamed; Tawfik, Amany] Augusta Univ, Dept Cellular Biol & Anat, Med Coll Georgia MCG, Augusta, GA 30912 USA.
   [Al-Shabrawey, Mohamed] Mansoura Univ, Dept Anat, Fac Med, Mansoura 35516, Egypt.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; Egyptian Knowledge Bank (EKB); Mansoura
   University; University System of Georgia; Augusta University; University
   System of Georgia; Augusta University; University System of Georgia;
   Augusta University; Egyptian Knowledge Bank (EKB); Mansoura University
RP Tawfik, A (通讯作者)，Augusta Univ, Dent Coll Georgia, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, MCG, James & Jean Culver Vision Discovery Inst, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Dept Ophthalmol, MCG, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Dept Cellular Biol & Anat, Med Coll Georgia MCG, Augusta, GA 30912 USA.
EM drnehal@hotmail.com; ishashrikhand@yahoo.com; dkira@augusta.edu;
   salhusban@augusta.edu; ysamra@augusta.edu; rjadeja@augusta.edu;
   pmmartin@augusta.edu; malshabrawey@augusta.edu; amtawfik@augusta.edu
RI Elsherbiny, Nehal/AAF-9206-2019; Tawfik, Amany/AAN-9902-2020; Samra,
   Yara A/AAD-1192-2022; Samra, Yara/AGB-5593-2022
OI Elsherbiny, Nehal/0000-0001-5167-3377; Tawfik,
   Amany/0000-0002-0245-8256; Sharma, isha/0000-0001-7370-5659; adel,
   yara/0000-0002-0223-8683
FU American Heart Association (AHA) [16SDG3070001]; NEI [R01
   EY029751-01-NEI00072]
FX This research was funded by the American Heart Association (AHA)
   Scientist Development Grant award #16SDG3070001 and NEI grant award R01
   EY029751-01-NEI00072.
CR Ajith TA, 2015, CLIN CHIM ACTA, V450, P316, DOI 10.1016/j.cca.2015.09.007
   Akalin A, 2008, EUR J ENDOCRINOL, V158, P47, DOI 10.1530/EJE-07-0470
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Delfino VDA, 2007, NUTRITION, V23, P242, DOI 10.1016/j.nut.2007.01.002
   Alvarez-Sanchez N, 2020, J GERONTOL A-BIOL, V75, P1488, DOI 10.1093/gerona/glz168
   Baroni L, 2019, J ALZHEIMERS DIS, V70, P441, DOI 10.3233/JAD-190249
   Beard RS, 2011, BLOOD, V118, P2007, DOI 10.1182/blood-2011-02-338269
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Bristow LJ, 2017, J PHARMACOL EXP THER, V363, P377, DOI 10.1124/jpet.117.242784
   Capitao M, 2016, J CELL BIOCHEM, V117, P2443, DOI 10.1002/jcb.25575
   Chen S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0963-x
   Dayon L, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0270-x
   Dehdashtian E, 2018, LIFE SCI, V193, P20, DOI 10.1016/j.lfs.2017.12.001
   Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961
   Dong N, 2018, INT OPHTHALMOL, V38, P737, DOI 10.1007/s10792-017-0528-0
   Elmasry Khaled, 2018, Oncotarget, V9, P12562, DOI 10.18632/oncotarget.24333
   Fang P, 2019, ARTERIOSCL THROM VAS, V39, P2097, DOI 10.1161/ATVBAHA.119.313138
   Fotiou P, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/807209
   Fraser H S, 1984, Bull Pan Am Health Organ, V18, P359
   Ganguly P, 2015, NUTR J, V14, DOI 10.1186/1475-2891-14-6
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Gokkusu C, 2010, CYTOKINE, V50, P15, DOI 10.1016/j.cyto.2009.12.015
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Ho RCM, 2011, AM J GERIAT PSYCHIAT, V19, P607, DOI 10.1097/JGP.0b013e3181f17eed
   Holven KB, 2001, AM J MED, V110, P536, DOI 10.1016/S0002-9343(01)00696-9
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Ibrahim AS, 2016, ONCOTARGET, V7, P8532, DOI 10.18632/oncotarget.7384
   Ibrahim AS, 2011, DIABETES, V60, P1122, DOI 10.2337/db10-1160
   Kamat PK, 2016, MOL NEUROBIOL, V53, P2451, DOI 10.1007/s12035-015-9212-4
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawada T, 2013, AM J CLIN NUTR, V98, P1144, DOI 10.3945/ajcn.113.071142
   Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014
   Lazzerini PE, 2007, AUTOIMMUN REV, V6, P503, DOI 10.1016/j.autrev.2007.03.008
   Lee YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34187-z
   Liu Y, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1141-5
   Liu ZY, 2012, CIRC RES, V111, P1261, DOI [10.1161/CIRCRESAHA.112.270520, 10.1161/circresaha.112.270520]
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Martin PM, 2009, MOL VIS, V15, P362
   Minagawa H, 2010, J BIOL CHEM, V285, P38382, DOI 10.1074/jbc.M110.146258
   MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0
   Mitamura Y, 2003, DIABETOLOGIA, V46, P699, DOI 10.1007/s00125-003-1084-x
   Mohamed R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09731-y
   Moretti R, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00169
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nuru M, 2018, METAB BRAIN DIS, V33, P1923, DOI 10.1007/s11011-018-0298-z
   Oikonomidi A, 2016, J NEUROCHEM, V139, P324, DOI 10.1111/jnc.13766
   Pariente A, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107746
   Phelip JM, 2008, INFLAMM BOWEL DIS, V14, P242, DOI 10.1002/ibd.20309
   Ravetti MG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003111
   Rhodehouse BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063951
   Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613
   Shanmugam A, 2015, J NEUROCHEM, V132, P546, DOI 10.1111/jnc.13002
   Smith AD, 2018, J ALZHEIMERS DIS, V62, P561, DOI 10.3233/JAD-171042
   Srivastav K, 2016, MOL VIS, V22, P1352
   Tawfik A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010121
   Tawfik Amany, 2014, Austin J Clin Ophthalmol, V1, P1023
   Tawfik A, 2014, AM J PATHOL, V184, P2573, DOI 10.1016/j.ajpath.2014.05.018
   Tawfik A, 2013, INVEST OPHTH VIS SCI, V54, P939, DOI 10.1167/iovs.12-10536
   Tinelli C, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00049
   Vogel T, 2009, INT J CLIN PRACT, V63, P1061, DOI 10.1111/j.1742-1241.2009.02026.x
   Wakkee M, 2007, ATHEROSCLEROSIS, V190, P1, DOI 10.1016/j.atherosclerosis.2006.07.011
   WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585
   Zeng HY, 2008, MOL VIS, V14, P1075
   Zeng P, 2019, INT J NEUROPSYCHOPH, V22, P57, DOI 10.1093/ijnp/pyy090
   Zhang CE, 2008, NEUROBIOL AGING, V29, P1654, DOI 10.1016/j.neurobiolaging.2007.04.015
   Zhang CE, 2009, AM J PATHOL, V174, P1481, DOI 10.2353/ajpath.2009.081036
   Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]
   Zhao YH, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00318
   Zotova E, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt24
   Zou CG, 2010, NEUROBIOL AGING, V31, P2069, DOI 10.1016/j.neurobiolaging.2008.11.007
NR 73
TC 37
Z9 39
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD MAR
PY 2020
VL 10
IS 3
AR 393
DI 10.3390/biom10030393
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA LJ0PZ
UT WOS:000529877600044
PM 32138265
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lode, HE
   Gjolberg, TT
   Foss, S
   Sivertsen, MS
   Brustugun, J
   Andersson, Y
   Jorstad, OK
   Moe, MC
   Andersen, JT
AF Lode, Heidrun Elisabeth
   Gjolberg, Torleif Tollefsrud
   Foss, Stian
   Sivertsen, Magne Sand
   Brustugun, Jorgen
   Andersson, Yvonne
   Jorstad, Oystein Kalsnes
   Moe, Morten Carstens
   Andersen, Jan Terje
TI A new method for pharmaceutical compounding and storage of anti-VEGF
   biologics for intravitreal use in silicone oil-free prefilled plastic
   syringes
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NEONATAL FC-RECEPTOR; MACULAR DEGENERATION; BEVACIZUMAB; STABILITY;
   RANIBIZUMAB; TRANSPORT; ACCURACY; IGG; AFLIBERCEPT; PRECISION
AB Intravitreal injections of antibody-based biologics targeting vascular endothelial growth factor (VEGF) are highly effective and have markedly decreased the risk of visual impairment associated with prevalent retinal diseases, such as neovascular age-related macular degeneration and diabetes macular oedema. The diseases are chronic in their nature, and most patients need long-term therapy to suppress disease activity. We previously reported a compounding method for repackaging and storage of aflibercept (Eylea), a commonly used anti-VEGF biologic, in silicone oil-coated plastic syringes without compromising drug stability or activity. In addition to improving safety and time spent per patient, compounding of anti-VEGF biologics enables single-dose vials to be split into multiple syringes, thereby considerably reducing waste and drug expenses. However, symptomatic silicone oil droplets may deposit in the eye's vitreous body after repetitive injections. To fully avoid this complication, we here report on a novel pharmaceutical compounding method using silicone oil-free syringes and a 33G x 9 mm Low Dead Space Needle hub injection needle. We evaluate the method for three anti-VEGF biologics commonly used in ophthalmology: aflibercept, ranibizumab (Lucentis) and bevacizumab (Avastin). Our results show that compounding and storage for one week does not compromise the functional activity of the biologics and allows for safe and cost-effective compounding of anti-VEGF biologics for intravitreal injections in prefilled silicone oil-free syringes.
C1 [Lode, Heidrun Elisabeth; Gjolberg, Torleif Tollefsrud; Foss, Stian; Andersen, Jan Terje] Oslo Univ Hosp, Dept Immunol, Rikshosp, Oslo, Norway.
   [Lode, Heidrun Elisabeth; Gjolberg, Torleif Tollefsrud; Foss, Stian; Andersen, Jan Terje] Univ Oslo, Inst Clin Med, Oslo, Norway.
   [Lode, Heidrun Elisabeth; Gjolberg, Torleif Tollefsrud; Foss, Stian; Andersen, Jan Terje] Univ Oslo, Dept Pharmacol, Oslo, Norway.
   [Lode, Heidrun Elisabeth; Gjolberg, Torleif Tollefsrud; Foss, Stian; Andersen, Jan Terje] Oslo Univ Hosp, Oslo, Norway.
   [Lode, Heidrun Elisabeth; Gjolberg, Torleif Tollefsrud; Sivertsen, Magne Sand; Jorstad, Oystein Kalsnes; Moe, Morten Carstens] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
   [Lode, Heidrun Elisabeth; Gjolberg, Torleif Tollefsrud; Sivertsen, Magne Sand; Jorstad, Oystein Kalsnes; Moe, Morten Carstens] Univ Oslo, Fac Med, Oslo, Norway.
   [Foss, Stian] Univ Oslo, Dept Biosci, Oslo, Norway.
   [Brustugun, Jorgen; Andersson, Yvonne] South Eastern Norway Reg Hlth Author, Hosp Pharmacies Enterprise, Oslo, Norway.
C3 University of Oslo; National Hospital Norway; University of Oslo;
   University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; University of Oslo
RP Andersen, JT (通讯作者)，Oslo Univ Hosp, Dept Immunol, Rikshosp, Oslo, Norway.; Andersen, JT (通讯作者)，Univ Oslo, Inst Clin Med, Oslo, Norway.; Andersen, JT (通讯作者)，Univ Oslo, Dept Pharmacol, Oslo, Norway.; Andersen, JT (通讯作者)，Oslo Univ Hosp, Oslo, Norway.; Moe, MC (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.; Moe, MC (通讯作者)，Univ Oslo, Fac Med, Oslo, Norway.
EM m.c.moe@medisin.uio.no; j.t.andersen@medisin.uio.no
RI Andersen, Jan Terje/AAB-6209-2020
OI Gjolberg, Torleif Tollefsrud/0000-0002-1719-7677; Andersen, Jan
   Terje/0000-0003-1710-1628; Foss, Stian/0000-0001-6527-051X
FU South-Eastern Norway Regional Health Authority [2018052, 40109];
   Norwegian Association of Blind and Partially Sighted; Division of Head,
   Neck and Reconstructive Surgery, Oslo University Hospital; Research
   Council of Norway through its Centres of Excellence funding scheme
   [179573]; Research Council of Norway [251037/F20, 287927]; Dr. Jon S
   Larsens Foundation
FX The authors would like to thank Dag Fossum and Ban Dang at
   Sykehusapoteket in Oslo (Ulleval and Rikshospitalet) for excellent
   collaboration in the continuous development and quality control of the
   compounding procedure. H.E.L. was supported by the South-Eastern Norway
   Regional Health Authority (grant no. 40109), and in part by Dr. Jon S
   Larsens Foundation and The Norwegian Association of Blind and Partially
   Sighted. T.T.G. was supported by internal funding from Division of Head,
   Neck and Reconstructive Surgery, Oslo University Hospital. M.S.S. and
   M.C.M. was supported by an innovation grant from South-Eastern Norway
   Regional Health Authority. J.T.A. was in part supported by the Research
   Council of Norway through its Centres of Excellence funding scheme
   (grant no. 179573), the Research Council of Norway (grant no. 287927),
   and the South-Eastern Norway Regional Health Authority (grant no.
   2018052). S.F. was supported by the Research Council of Norway (grant
   no. 251037/F20).
CR Andersen JT, 2008, FEBS J, V275, P4097, DOI 10.1111/j.1742-4658.2008.06551.x
   Avery R. L., 2017, RETIN CASES BRIEF RE, V1
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Cao SJ, 2017, CAN J OPHTHALMOL, V52, P273, DOI 10.1016/j.jcjo.2016.11.012
   De Stefano VS, 2011, CLIN EXP OPHTHALMOL, V39, P236, DOI 10.1111/j.1442-9071.2010.02447.x
   Deissler HL, 2017, EXP EYE RES, V154, P39, DOI 10.1016/j.exer.2016.11.007
   Dithmer M, 2016, EXP EYE RES, V145, P187, DOI 10.1016/j.exer.2015.12.013
   Emerson GG., 2017, J VITREORETIN DIS, V1, P401, DOI [10.1177/2474126417735963, DOI 10.1177/2474126417735963]
   European Commission, RUL GOV MED PROD EUR
   Grisanti S, 2010, OPHTHALMOLOGE, V107, P1123, DOI 10.1007/s00347-010-2299-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Inc. R., 2019, FDA APPROVES EYLEA A
   International Organization for Standardization, 2018, 146441 ISO
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Khurana RN, 2017, JAMA OPHTHALMOL, V135, P800, DOI 10.1001/jamaophthalmol.2017.1815
   Kim H, 2008, INVEST OPHTH VIS SCI, V49, P2025, DOI 10.1167/iovs.07-0871
   Kim H, 2009, MOL VIS, V15
   Kim J, 2007, CLIN IMMUNOL, V122, P146, DOI 10.1016/j.clim.2006.09.001
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kuo TT, 2011, MABS-AUSTIN, V3, P422, DOI 10.4161/mabs.3.5.16983
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Melo GB, 2020, BRIT J OPHTHALMOL, V104, P291, DOI 10.1136/bjophthalmol-2019-313823
   Merani Rohan, 2015, Int J Retina Vitreous, V1, P9
   Meyer CH, 2012, ACTA OPHTHALMOL, V90, pe165, DOI 10.1111/j.1755-3768.2010.02072.x
   Moisseiev E, 2017, CURR EYE RES, V42, P1059, DOI 10.1080/02713683.2016.1276195
   Paul M., 2012, Annales Pharmaceutiques Francaises, V70, P139, DOI 10.1016/j.pharma.2012.03.006
   Pereboom Marieke, 2015, Int J Pharm Compd, V19, P70
   Phasukkijwatana Nopasak, 2015, Journal of the Medical Association of Thailand, V98, P798
   Powner MB, 2014, INVEST OPHTH VIS SCI, V55, P1607, DOI 10.1167/iovs.13-12574
   Reuter B., 2012, TECHNO PHARM, P238
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Sampat KM, 2013, OPHTHAL SURG LAS IM, V44, P385, DOI 10.3928/23258160-20130601-02
   Signorello L, 2014, CURR PHARM BIOTECHNO, V15, P113, DOI 10.2174/1389201015666140619120834
   Sivertsen MS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20525-8
   Subhi Y., 2016, DANISH MED J, V63
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi NA, 2015, JAMA OPHTHALMOL, V133, P32, DOI 10.1001/jamaophthalmol.2014.3591
   Yoshida M, 2004, IMMUNITY, V20, P769, DOI 10.1016/j.immuni.2004.05.007
   Yu Jea H, 2018, Am J Ophthalmol Case Rep, V10, P142, DOI 10.1016/j.ajoc.2017.07.009
NR 45
TC 15
Z9 16
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 2
PY 2019
VL 9
AR 18021
DI 10.1038/s41598-019-54226-7
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JS8KX
UT WOS:000500551900001
PM 31792234
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jirjees, F
   Soliman, K
   Wang, YJ
   Sonawane, R
   Sheshala, R
   Jones, D
   Singh, TRR
AF Jirjees, Feras
   Soliman, Karim
   Wang, Yujing
   Sonawane, Rahul
   Sheshala, Ravi
   Jones, David
   Singh, Thakur Raghu Raj
TI A validated size exclusion chromatography method coupled with
   fluorescence detection for rapid quantification of bevacizumab in
   ophthalmic formulations
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Protein assay; Bevacizumab; HPLC validation; Fluorescence detector
ID REVERSED-PHASE; MONOCLONAL-ANTIBODY; BIOANALYSIS; DELIVERY; RELEASE;
   AVASTIN(R); INFLIXIMAB; HYDROGELS
AB Bevacizumab is a full-length human monoclonal antibody used to treat various neovascular diseases such as wet age-related macular degeneration (AMD), diabetic eye disease and other problems of the retina. Monthly intravitreal injections of bevacizumab (Avastin (R)) are effective in the treatment of wet AMD. However, there is a growing demand in the development of sustained release ophthalmic formulations. Therefore, this study aims, for the first time, to develop a rapid, simple, and sensitive method using size exclusion chromatography coupled with fluorescence detection for routine quantification of bevacizumab in ophthalmic formulations and during in vitro release studies. The selected chromatographic conditions included an aqueous mobile phase composed of 35 mM sodium phosphate buffer and 300 mM sodium chloride (pH 6.8), a flow rate of 0.5 mL/min, and the fluorescence detector was operated at excitation and emission wavelengths of 280 and 340 nm, respectively. The peak area-concentration relationship maintained its linearity over concentration range of 0.1-20 mu g/mL (R-2 = 0.9993), and the quantitation limit was 100 ng/mL. The method was validated for specificity, accuracy, precision, and robustness. The developed method had a run time of 6 min at temperature 25 degrees C, making it a unique validated method for rapid and cost-effective quantification of bevacizumab. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Jirjees, Feras; Soliman, Karim; Wang, Yujing; Sonawane, Rahul; Jones, David; Singh, Thakur Raghu Raj] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
   [Jirjees, Feras; Soliman, Karim; Wang, Yujing; Sonawane, Rahul; Jones, David; Singh, Thakur Raghu Raj] McClay Res Ctr, Revana Therapeut, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
   [Sheshala, Ravi] Univ Teknol MARA Selangor, Fac Pharm, Dept Pharmaceut, Puncak Alam Campus, Puncak Alam 42300, Kuala Selangor, Malaysia.
C3 Queens University Belfast
RP Singh, TRR (通讯作者)，Queens Univ Belfast, Med Biol Ctr, Sch Pharm, Pharmaceut, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM r.thakur@qub.ac.uk
RI Jirjees, Feras/AAQ-6225-2020; Sheshala, Ravi/AAN-8559-2021; Singh,
   Raj/HDN-1244-2022; Sheshala, Ravi/AHA-8927-2022
OI Jirjees, Feras/0000-0001-6265-0808; Sheshala, Ravi/0000-0001-5255-3238;
   Thakur Singh, Raghu Raj/0000-0001-7582-2082
FU Re-Vana Therapeutics Ltd, Belfast, UK
FX This work was funded by Re-Vana Therapeutics Ltd, Belfast, UK.
CR [Anonymous], 1994, REV GUID VAL CHROM M
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   Daugherty AL, 2006, ADV DRUG DELIVER REV, V58, P686, DOI 10.1016/j.addr.2006.03.011
   FDA (Food and Drug Administration), 2018, BIOANALYTICAL METHOD
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Giannos SA, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2368-7
   Hirvonen LM, 2016, PHARM RES-DORDR, V33, P2025, DOI 10.1007/s11095-016-1940-2
   Hong P, 2012, J LIQ CHROMATOGR R T, V35, P2923, DOI 10.1080/10826076.2012.743724
   International conference on harmonization, 2005, VAL AN PROC TEXT MET
   Iwamoto N, 2016, DRUG METAB PHARMACOK, V31, P46, DOI 10.1016/j.dmpk.2015.11.004
   Jansen RM, 2013, MED LAW, V32, P65
   Kaja Simon, 2011, Human Antibodies, V20, P95, DOI 10.3233/HAB-2011-0244
   Kong DH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081786
   Lahlou A., 2009, ANNALES PHARMACEUTIQUES FRANCAISES, V67, P340, DOI 10.1016/j.pharma.2009.05.008
   Legeron R, 2017, J CHROMATOGR B, V1070, P43, DOI 10.1016/j.jchromb.2017.10.042
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Martinez-Ortega A, 2018, INT J BIOL MACROMOL, V116, P993, DOI 10.1016/j.ijbiomac.2018.05.142
   McAvoy K, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-017-2298-9
   Sousa F, 2017, J PHARMACEUT BIOMED, V142, P171, DOI 10.1016/j.jpba.2017.05.015
   Todoroki K, 2016, ANAL CHIM ACTA, V916, P112, DOI 10.1016/j.aca.2016.02.029
   U.S. Food and Drug Administration, 2018, FDA APPROVES BEVACIZ
   U.S. Food Drug Administration, 2017, AV BEV INJ INTR US
   van der Ven C, 2001, INT DAIRY J, V11, P83, DOI 10.1016/S0958-6946(01)00032-2
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Yamada T, 2018, CHROMATOGRAPHY, V39, P21, DOI 10.15583/jpchrom.2017.014
   [邹有土 Zou Youtu], 2015, [药物分析杂志, Chinese Journal of Pharmaceutical Analysis], V35, P1027
NR 30
TC 1
Z9 1
U1 1
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0731-7085
EI 1873-264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD SEP 10
PY 2019
VL 174
BP 145
EP 150
DI 10.1016/j.jpba.2019.05.038
PG 6
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA IO4CV
UT WOS:000479328000016
PM 31167158
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Agbaga, MP
   Merriman, DK
   Brush, RS
   Lydic, TA
   Conley, SM
   Naash, MI
   Jackson, S
   Woods, AS
   Reid, GE
   Busik, JV
   Anderson, RE
AF Agbaga, Martin-Paul
   Merriman, Dana K.
   Brush, Richard S.
   Lydic, Todd A.
   Conley, Shannon M.
   Naash, Muna I.
   Jackson, Shelley
   Woods, Amina S.
   Reid, Gavin E.
   Busik, Julia V.
   Anderson, Robert E.
TI Differential composition of DHA and very-long-chain PUFAs in rod and
   cone photoreceptors
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE rod- and cone-dominant retinas; supraenoic lipids; glycerophospholipids;
   macular degeneration; polyunsaturated fatty acids; docosahexaenoic acid
ID POLYUNSATURATED FATTY-ACIDS; OUTER SEGMENT MEMBRANES; DOCOSAHEXAENOIC
   ACID; MACULAR DEGENERATION; LIPID-COMPOSITION; MOUSE RETINA;
   DIETARY-FAT; DIPOLYUNSATURATED PHOSPHATIDYLCHOLINES; ELECTRICAL
   RESPONSE; ENDOTHELIAL-CELLS
AB Long-chain PUFAs (LC-PUFAs; C20-C22; e.g., DHA and arachidonic acid) are highly enriched in vertebrate retina, where they are elongated to very-long-chain PUFAs (VLC-PUFAs; C >= 28) by the elongation of very-long-chain fatty acids-4 (ELOVL4) enzyme. These fatty acids play essential roles in modulating neuronal function and health. The relevance of different lipid requirements in rods and cones to disease processes, such as age-related macular degeneration, however, remains unclear. To better understand the role of LC-PUFAs and VLC-PUFAs in the retina, we investigated the lipid compositions of whole retinas or photoreceptor outer segment (OS) membranes in rodents with rod- or cone-dominant retinas. We analyzed fatty acid methyl esters and the molecular species of glycerophospholipids (phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine) by GC-MS/GC-flame ionization detection and ESI-MS/MS, respectively. We found that whole retinas and OS membranes in rod-dominant animals compared with cone-dominant animals had higher amounts of LC-PUFAs and VLC-PUFAs. Compared with those of rod-dominant animals, retinas and OS membranes from cone-dominant animals also had about 2-fold lower levels of di-DHA (22:6/22:6) molecular species of glycerophospholipids. Because PUFAs are necessary for optimal G protein-coupled receptor signaling in rods, these findings suggest that cones may not have the same lipid requirements as rods.
C1 [Agbaga, Martin-Paul; Brush, Richard S.; Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
   [Agbaga, Martin-Paul; Conley, Shannon M.; Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Agbaga, Martin-Paul; Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Oklahoma City, OK 73104 USA.
   [Agbaga, Martin-Paul; Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK 73104 USA.
   [Agbaga, Martin-Paul; Brush, Richard S.; Anderson, Robert E.] Dean McGee Eye Inst, Oklahoma City, OK 73104 USA.
   [Merriman, Dana K.] Univ Wisconsin, McPherson Eye Res Inst, Oshkosh, WI 54901 USA.
   [Lydic, Todd A.; Busik, Julia V.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.
   [Naash, Muna I.] Univ Houston, Dept Biomed Engn, Houston, TX USA.
   [Jackson, Shelley; Woods, Amina S.] Natl Inst Drug Abuse, Intramural Res Program Struct Biol Unit, Baltimore, MD USA.
   [Reid, Gavin E.] Univ Melbourne, Sch Chem, Parkville, Vic, Australia.
   [Reid, Gavin E.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic, Australia.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; University of Oklahoma System; University of
   Oklahoma Health Sciences Center; University of Wisconsin System;
   Michigan State University; University of Houston System; University of
   Houston; National Institutes of Health (NIH) - USA; NIH National
   Institute on Drug Abuse (NIDA); University of Melbourne; University of
   Melbourne
RP Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA.; Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.; Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Oklahoma City, OK 73104 USA.; Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK 73104 USA.; Agbaga, MP (通讯作者)，Dean McGee Eye Inst, Oklahoma City, OK 73104 USA.
EM martin-paul-agbaga@ouhsc.edu
RI Busik, Julia V/A-2698-2010; Lydic, Todd A./ADB-0177-2022
OI Busik, Julia V/0000-0003-3453-7124; Reid, Gavin/0000-0002-9675-1444;
   Merriman, Dana/0000-0003-2780-0772; Agbaga,
   Martin-Paul/0000-0002-1920-915X
FU OU College of Medicine Alumni Association; BrightFocus Foundation; Hope
   for Vision; Knights Templar Eye Foundation; Oklahoma Center for
   Advancement of Science and Technology; National Institutes of Health
   [EY00871, EY04149, P30EY021725, GM103508, EY18656, EY010609]; Research
   to Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY004149, R01EY018656,
   R01EY010609, R56EY010609, R01EY000871, P30EY021725] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM103508]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE
   [ZIADA000593] Funding Source: NIH RePORTER
FX This work was supported by the OU College of Medicine Alumni
   Association, the BrightFocus Foundation, Hope for Vision, the Knights
   Templar Eye Foundation, and the Oklahoma Center for Advancement of
   Science and Technology to M-P. A.; National Institutes of Health Grants
   EY00871 (R.E.A.), EY04149 (R.E.A.), P30EY021725 (R.E.A.), GM103508
   (G.E.R., J.V.B.), EY18656 (M.I.N.), and EY010609 (M.I.N.); and an
   unrestricted grant from Research to Prevent Blindness to the University
   of Oklahoma Health Sciences Center's Department of Ophthalmology. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Ambasudhan R, 2004, GENOMICS, V83, P615, DOI 10.1016/j.ygeno.2003.10.004
   ANDERSON RE, 1978, BIOCHIM BIOPHYS ACTA, V510, P316, DOI 10.1016/0005-2736(78)90032-9
   ANDERSON RE, 1992, ADV EXP MED BIOL, V318, P285
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1180
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1172
   Bazan NG, 2007, INVEST OPHTH VIS SCI, V48, P4866, DOI 10.1167/iovs.07-0918
   Bazan NG, 2013, NESTLE NUTR WORKS SE, V77, P121, DOI 10.1159/000351395
   BENOLKEN RM, 1973, SCIENCE, V182, P1253, DOI 10.1126/science.182.4118.1253
   BENOLKEN RM, 1975, BIOCHIM BIOPHYS ACTA, V413, P234, DOI 10.1016/0005-2736(75)90107-8
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   Bicknell IR, 2002, MOL VIS, V8, P333
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Boudard DL, 2011, INVEST OPHTH VIS SCI, V52, P8686, DOI 10.1167/iovs.11-8162
   Busik JV, 2009, METHODS MOL BIOL, V579, P33, DOI 10.1007/978-1-60761-322-0_3
   CARLSON SE, 1986, J NUTR, V116, P718, DOI 10.1093/jn/116.5.718
   CHEN HM, 1992, EXP EYE RES, V55, P93, DOI 10.1016/0014-4835(92)90097-C
   Chen WQ, 2007, INVEST OPHTH VIS SCI, V48, P18, DOI 10.1167/iovs.06-0619
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Daniele LL, 2005, INVEST OPHTH VIS SCI, V46, P2156, DOI 10.1167/iovs.04-1427
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   Delton-Vandenbroucke I, 1998, LIPIDS, V33, P1187, DOI 10.1007/s11745-998-0322-7
   Dittrich F, 1998, EUR J BIOCHEM, V252, P477, DOI 10.1046/j.1432-1327.1998.2520477.x
   Donoso LA, 2001, SURV OPHTHALMOL, V46, P149, DOI 10.1016/S0039-6257(01)00251-X
   Edwards AO, 2001, INVEST OPHTH VIS SCI, V42, P2652
   Edwards AO, 1999, AM J OPHTHALMOL, V127, P426, DOI 10.1016/S0002-9394(98)00331-6
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   GORDON WC, 1990, J NEUROSCI, V10, P2190
   Grayson C, 2005, J BIOL CHEM, V280, P32521, DOI 10.1074/jbc.M503411200
   Haimi P, 2009, METHODS MOL BIOL, V580, P285, DOI 10.1007/978-1-60761-325-1_16
   Haimi P, 2006, ANAL CHEM, V78, P8324, DOI 10.1021/ac061390w
   JOHNSTON D, 1974, BIOCHIM BIOPHYS ACTA, V369, P269, DOI 10.1016/0005-2760(74)90141-6
   Jun B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05433-7
   Karan G, 2005, MOL VIS, V11, P657
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7
   Levant B, 2006, BIOL PSYCHIAT, V60, P987, DOI 10.1016/j.biopsych.2005.12.013
   LIN DS, 1994, INVEST OPHTH VIS SCI, V35, P794
   Liu A., 2009, INVEST OPHTH VIS SCI, V50, P3410
   Liu AH, 2013, J CHROMATOGR A, V1307, P191, DOI 10.1016/j.chroma.2013.07.103
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Logan S, 2014, J LIPID RES, V55, P698, DOI 10.1194/jlr.M045443
   Logan S, 2013, P NATL ACAD SCI USA, V110, P5446, DOI 10.1073/pnas.1217251110
   Lydic TA, 2014, J LIPID RES, V55, P1797, DOI 10.1194/jlr.D050302
   Martin RE, 2005, MOL VIS, V11, P338
   Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207
   McMahon A, 2007, MOL VIS, V13, P258
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   NEURINGER M, 1994, J PEDIATR-US, V125, pS39, DOI 10.1016/S0022-3476(06)80735-3
   NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202
   Nikonov SS, 2005, J GEN PHYSIOL, V125, P287, DOI 10.1085/jgp.200409208
   Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200
   O'Connor DL, 2001, PEDIATRICS, V108, P359, DOI 10.1542/peds.108.2.359
   Salem N, 2005, EXP EYE RES, V81, P655, DOI 10.1016/j.exer.2005.04.003
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Simonelli F, 1996, OPHTHALMIC RES, V28, P93, DOI 10.1159/000267880
   Song HW, 2009, J CHROMATOGR B, V877, P2847, DOI 10.1016/j.jchromb.2008.12.043
   Stuck MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032484
   Suh M, 2005, CURR EYE RES, V30, P959, DOI 10.1080/02713680500246957
   Tikhonenko M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055177
   Tikhonenko M, 2010, DIABETES, V59, P219, DOI 10.2337/db09-0728
   Townend BS, 2007, AM J OPHTHALMOL, V143, P932, DOI 10.1016/j.ajo.2007.03.006
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   WASSLE H, 1978, PROC R SOC SER B-BIO, V200, P441, DOI 10.1098/rspb.1978.0026
   WHEELER TG, 1975, SCIENCE, V188, P1312, DOI 10.1126/science.1145197
   WIEGAND RD, 1991, J NEUROCHEM, V57, P1690, DOI 10.1111/j.1471-4159.1991.tb06369.x
   Yu M, 2012, J LIPID RES, V53, P494, DOI 10.1194/jlr.M021386
   Yuan C, 1998, COMP BIOCHEM PHYS B, V120, P785, DOI 10.1016/S0305-0491(98)10079-2
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zhang XM, 2003, MOL VIS, V9, P301
   Zhu XM, 2003, J NEUROSCI, V23, P6152, DOI 10.1523/JNEUROSCI.23-14-06152.2003
NR 82
TC 31
Z9 31
U1 0
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD SEP
PY 2018
VL 59
IS 9
BP 1586
EP 1596
DI 10.1194/jlr.M082495
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GR8OI
UT WOS:000442983100006
PM 29986998
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chen, CL
   Chen, YH
   Liang, CM
   Tai, MC
   Lu, DW
   Chen, JT
AF Chen, Ching-Long
   Chen, Yi-Hao
   Liang, Chang-Min
   Tai, Ming-Cheng
   Lu, Da-Wen
   Chen, Jiann-Torng
TI Glucosamine-Induced Autophagy through AMPK-mTOR Pathway Attenuates
   Lipofuscin-Like Autofluorescence in Human Retinal Pigment Epithelial
   Cells In Vitro
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE glucosamine; autophagy; lipofuscin; retinal pigment epithelial cells
ID OUTER SEGMENT PHAGOCYTOSIS; MACULAR DEGENERATION; OXIDATIVE-STRESS; AGE
   PIGMENT; TNF-ALPHA; RPE CELLS; GENERATION; RECEPTOR; OSTEOARTHRITIS;
   ACCUMULATION
AB Age-related macular degeneration (AMD) is a vision-threatening age-associated disease. The retinal pigment epithelial (RPE) cells phagocytose and digest photoreceptor outer segment (POS). Incomplete digestion of POS leads to lipofuscin accumulation, which contributes to the pathology of the AMD. Autophagy could help reduce the amount of lipofuscin accumulation. In the present study, we evaluated the effects of glucosamine (GlcN), a natural supplement, on the induction of autophagy and POS-derived lipofuscin-like autofluorescence (LLAF) in ARPE-19 cells in vitro, and investigated the potential molecular pathway involved. Our results revealed that GlcN had no effect on phagocytosis of POS at the lower doses. GlcN treatment induced autophagy in cells. GlcN decreased the LLAF in native POS-treated cells, whereas malondialdehyde or 4-hydroxynonenal-modified POS attenuated this effect. 3-Methyladenine inhibited GlcN-induced autophagy and attenuated the effect of GlcN on the decrease of the native POS-derived LLAF. Furthermore, GlcN induced the phosphorylation of AMP-activated protein kinase (AMPK) and inhibited the phosphorylation of mammalian target of rapamycin (mTOR), whereas Compound C inhibited these effects of GlcN. Altogether, these results suggest that GlcN decreased the native POS-derived LLAF through induction of autophagy, at least in part, by the AMPK-mTOR pathway. This mechanism has potential for the preventive treatment of lipofuscin-related retinal degeneration such as AMD.
C1 [Chen, Ching-Long; Chen, Yi-Hao; Liang, Chang-Min; Tai, Ming-Cheng; Lu, Da-Wen; Chen, Jiann-Torng] Natl Def Med Ctr, Triserv Gen Hosp, Dept Ophthalmol, 325 Cheng Kung Rd,Sect 2, Taipei 114, Taiwan.
C3 National Defense Medical Center; Tri-Service General Hospital
RP Chen, JT (通讯作者)，Natl Def Med Ctr, Triserv Gen Hosp, Dept Ophthalmol, 325 Cheng Kung Rd,Sect 2, Taipei 114, Taiwan.
EM doc30881@mail.ndmctsgh.edu.tw; keane@ms18.url.com.tw;
   doc30875@yahoo.com.tw; mingtai1966@yahoo.com.tw; p310849@ms23.hinet.net;
   jt66chen@gmail.com
FU Ministry of Science and Technology of Taiwan [MOST-103-2314-B-016-015,
   MOST-105-2314-B-016-045, MOST-106-2314-B-016-022]
FX This research was supported in part by grants MOST-103-2314-B-016-015,
   MOST-105-2314-B-016-045, and MOST-106-2314-B-016-022 from the Ministry
   of Science and Technology of Taiwan.
CR Anderson JW, 2005, FOOD CHEM TOXICOL, V43, P187, DOI 10.1016/j.fct.2004.11.006
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Carames B, 2013, ARTHRITIS RHEUM-US, V65, P1843, DOI 10.1002/art.37977
   Chang YH, 2008, INVEST OPHTH VIS SCI, V49, P5441, DOI 10.1167/iovs.08-1784
   Chen CL, 2012, INVEST OPHTH VIS SCI, V53, P2281, DOI 10.1167/iovs.11-9291
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen JT, 2006, INVEST OPHTH VIS SCI, V47, P664, DOI 10.1167/iovs.05-1008
   Chen YJ, 2015, INVEST OPHTH VIS SCI, V56, P1506, DOI 10.1167/iovs.14-15726
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1988, INVEST OPHTH VIS SCI, V29, P708
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gouze JN, 2002, FEBS LETT, V510, P166, DOI 10.1016/S0014-5793(01)03255-0
   Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166
   Guha S, 2012, J NEUROCHEM, V122, P823, DOI 10.1111/j.1471-4159.2012.07804.x
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hua J, 2002, J LEUKOCYTE BIOL, V71, P632
   Hwang MS, 2010, BIOCHEM BIOPH RES CO, V399, P111, DOI 10.1016/j.bbrc.2010.07.050
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang LB, 2014, J ORTHOP RES, V32, P1532, DOI 10.1002/jor.22699
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kong CS, 2009, FOOD CHEM TOXICOL, V47, P2401, DOI 10.1016/j.fct.2009.06.010
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Liang CM, 2011, ACTA OPHTHALMOL, V89, pE505, DOI 10.1111/j.1755-3768.2011.02147.x
   Liang CM, 2010, MOL VIS, V16, P2559
   Ma LL, 2002, J BIOL CHEM, V277, P39343, DOI 10.1074/jbc.M204924200
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shintani T, 2010, BIOCHEM BIOPH RES CO, V391, P1775, DOI 10.1016/j.bbrc.2009.12.154
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Weimer S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4563
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 60
TC 16
Z9 16
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2018
VL 19
IS 5
AR 1416
DI 10.3390/ijms19051416
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GJ4BO
UT WOS:000435297000152
PM 29747425
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Ito, S
   Wakamatsu, K
   Sarna, T
AF Ito, Shosuke
   Wakamatsu, Kazumasa
   Sarna, Tadeusz
TI Photodegradation of Eumelanin and Pheomelanin and Its Pathophysiological
   Implications
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; ELECTRON-SPIN-RESONANCE; PHOTOINDUCED
   OXYGEN-CONSUMPTION; CULTURED HUMAN MELANOCYTES; HUMAN SKIN PIGMENTATION;
   ULTRAVIOLET-RADIATION; SINGLET OXYGEN; HYDROGEN-PEROXIDE;
   CHEMICAL-ANALYSIS; HUMAN EPIDERMIS
AB Eumelanin is photoprotective for pigmented tissues while pheomelanin is phototoxic. In this review, we summarize current understanding of how eumelanin and pheomelanin structures are modified by ultraviolet A (UVA) and also by visible light and how reactive oxygen species participate in those processes. Alkaline hydrogen peroxide oxidation was employed to characterize eumelanin and benzothiazole-type pheomelanin, giving pyrrole-2,3,5-tricarboxylic acid (PTCA) and thiazole-2,4,5-tricarboxylic acid (TTCA), respectively. Reductive hydrolysis with hydroiodic acid gives 4-amino-3-hydroxyphenylalanine (4-AHP) from the benzothiazine moiety of pheomelanin. The results show that the photoaging of eumelanin gives rise to free PTCA (produced by peroxidation in situ) and pyrrole-2,3,4,5-tetracarboxylic acid (PTeCA, produced by cross-linking). The TTCA/4-AHP ratio increases with photoaging, indicating the conversion of benzothiazine to the benzothiazole moiety. Analysis of those markers and their ratios show that both eumelanin and pheomelanin in human retinal pigment epithelium melanosomes undergo extensive structural modifications due to their lifelong exposure to blue light. Using synthetic melanins, we also found that singlet oxygen, in addition to superoxide anions, is photogenerated and quenched upon UVA irradiation. The (patho)physiological significance of those findings is discussed in relation to the tanning process, to melanomagenesis in the skin and to age-related macular degeneration in the eyes.
C1 [Ito, Shosuke; Wakamatsu, Kazumasa] Fujita Hlth Univ, Dept Chem, Sch Hlth Sci, Toyoake, Aichi, Japan.
   [Sarna, Tadeusz] Jagiellonian Univ, Dept Biophys, Fac Biochem Biophys & Biotechnol, Krakow, Poland.
C3 Fujita Health University; Jagiellonian University
RP Ito, S (通讯作者)，Fujita Hlth Univ, Dept Chem, Sch Hlth Sci, Toyoake, Aichi, Japan.
EM sito@fujita-hu.ac.jp
RI Wakamatsu, Kazumasa/AAZ-5877-2020
OI Wakamatsu, Kazumasa/0000-0003-1748-9001
FU Japan Society for the Promotion of Science (JSPS) [26461705, 23591659];
   National Science Centre of Poland [2013/08/A/NZ1/00194]
FX This work was partially supported by a Japan Society for the Promotion
   of Science (JSPS) grant (Nos 23591659 and 26461705) given to SI and KW.
   TS thanks to the support from the National Science Centre of Poland
   (2013/08/A/NZ1/00194).
CR Alaluf S, 2002, PIGM CELL RES, V15, P112, DOI 10.1034/j.1600-0749.2002.1o071.x
   Au V, 2000, ARCH BIOCHEM BIOPHYS, V384, P133, DOI 10.1006/abbi.2000.2070
   Brenner M, 2008, PHOTOCHEM PHOTOBIOL, V84, P539, DOI 10.1111/j.1751-1097.2007.00226.x
   Burke JM, 2011, MOL VIS, V17, P2864
   Burke JM, 2009, INVEST OPHTH VIS SCI, V50, P1940, DOI 10.1167/iovs.08-2671
   CHEDEKEL MR, 1980, PHOTOCHEM PHOTOBIOL, V31, P553, DOI 10.1111/j.1751-1097.1980.tb03745.x
   CHEDEKEL MR, 1978, P NATL ACAD SCI USA, V75, P5395, DOI 10.1073/pnas.75.11.5395
   Chiarelli-Neto O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113266
   Chiarelli-Neto O, 2011, FREE RADICAL BIO MED, V51, P1195, DOI 10.1016/j.freeradbiomed.2011.06.013
   Choi W, 2010, J INVEST DERMATOL, V130, P1685, DOI 10.1038/jid.2010.5
   Coelho SG, 2015, PIGM CELL MELANOMA R, V28, P210, DOI 10.1111/pcmr.12331
   d'Ischia M, 2015, PIGM CELL MELANOMA R, V28, P520, DOI 10.1111/pcmr.12393
   d'Ischia M, 2013, PIGM CELL MELANOMA R, V26, P616, DOI 10.1111/pcmr.12121
   Del Bino S, 2015, PIGM CELL MELANOMA R, V28, P707, DOI 10.1111/pcmr.12410
   Duteil L, 2014, PIGM CELL MELANOMA R, V27, P822, DOI 10.1111/pcmr.12273
   Edge R, 2006, PIGM CELL RES, V19, P443, DOI 10.1111/j.1600-0749.2006.00327.x
   Elleder M, 2001, HISTOCHEM J, V33, P273, DOI 10.1023/A:1017925023408
   FELIX CC, 1978, J AM CHEM SOC, V100, P3922, DOI 10.1021/ja00480a044
   FELIX CC, 1978, BIOCHEM BIOPH RES CO, V84, P335, DOI 10.1016/0006-291X(78)90175-4
   Greco G., 2011, PIGM CELL MELANOMA R, V22, P319
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200
   Hennessy A, 2005, PIGM CELL RES, V18, P220, DOI 10.1111/j.1600-0749.2005.00233.x
   Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h
   Honigsmann H, 2002, PHOTODERMATOL PHOTO, V18, P75, DOI 10.1034/j.1600-0781.2002.180204.x
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Ito S, 2008, PHOTOCHEM PHOTOBIOL, V84, P582, DOI 10.1111/j.1751-1097.2007.00238.x
   Ito S, 2017, PIGM CELL MELANOMA R, V30, P63, DOI 10.1111/pcmr.12556
   Ito S, 2016, PIGM CELL MELANOMA R, V29, P340, DOI 10.1111/pcmr.12469
   Ito Shosuke, 2013, Pigment Cell Melanoma Res, V26, P817, DOI 10.1111/pcmr.12137
   Ito S, 2013, PIGM CELL MELANOMA R, V26, P357, DOI 10.1111/pcmr.12078
   Ito S, 2013, ANAL BIOCHEM, V434, P221, DOI 10.1016/j.ab.2012.12.005
   Ito S, 2011, PIGM CELL MELANOMA R, V24, P605, DOI 10.1111/j.1755-148X.2011.00864.x
   Jiang S, 2010, FREE RADICAL BIO MED, V48, P1144, DOI 10.1016/j.freeradbiomed.2010.01.033
   Kaczara P, 2012, PIGM CELL MELANOMA R, V25, P804, DOI 10.1111/pcmr.12008
   Kim E, 2015, SCI REP-UK, V5, DOI 10.1038/srep18447
   Kolbe L, 2012, J INVEST DERMATOL, V132, P1756, DOI 10.1038/jid.2012.148
   KORYTOWSKI W, 1986, BIOCHIM BIOPHYS ACTA, V882, P145, DOI 10.1016/0304-4165(86)90149-2
   KORYTOWSKI W, 1985, BIOCHEM BIOPH RES CO, V131, P659, DOI 10.1016/0006-291X(85)91288-4
   KORYTOWSKI W, 1987, PHOTOCHEM PHOTOBIOL, V45, P185, DOI 10.1111/j.1751-1097.1987.tb05362.x
   Kozinska A, 2012, ISR J CHEM, V52, P745, DOI 10.1002/ijch.201200019
   Lazovich D, 2016, JAMA DERMATOL, V152, P268, DOI 10.1001/jamadermatol.2015.2938
   Liebel F, 2012, J INVEST DERMATOL, V132, P1901, DOI 10.1038/jid.2011.476
   Maeda K, 2004, J INVEST DERMATOL, V122, P503, DOI 10.1046/j.0022-202X.2004.22223.x
   Masaki H, 2009, J INVEST DERM SYMP P, V14, P50, DOI 10.1038/jidsymp.2009.12
   Mendez-Hurtado J, 2012, CHEM-EUR J, V18, P8437, DOI 10.1002/chem.201103680
   Micillo R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050746
   Mitra D, 2012, NATURE, V491, P449, DOI 10.1038/nature11624
   Miyamura Y, 2007, PIGM CELL RES, V20, P2, DOI 10.1111/j.1600-0749.2006.00358.x
   Miyamura Y, 2011, PIGM CELL MELANOMA R, V24, P136, DOI 10.1111/j.1755-148X.2010.00764.x
   Morgan AM, 2013, BIOESSAYS, V35, P672, DOI 10.1002/bies.201300020
   Nair V, 2012, CHEM SOC REV, V41, P1050, DOI 10.1039/c1cs15186j
   Napolitano A, 2014, PIGM CELL MELANOMA R, V27, P721, DOI 10.1111/pcmr.12262
   Noonan FP, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1893
   Ou-Yang H, 2004, J INVEST DERMATOL, V122, P492, DOI 10.1046/j.0022-202X.2004.22247.x
   Ozeki H, 1996, PIGM CELL RES, V9, P265, DOI 10.1111/j.1600-0749.1996.tb00116.x
   Panzella L, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12199
   Panzella L, 2013, ANGEW CHEM INT EDIT, V52, P12684, DOI 10.1002/anie.201305747
   Panzella L, 2010, PHOTOCHEM PHOTOBIOL, V86, P757, DOI 10.1111/j.1751-1097.2010.00726.x
   Premi S, 2015, SCIENCE, V347, P842, DOI 10.1126/science.1256022
   Randhawa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130949
   RHODES AR, 1987, JAMA-J AM MED ASSOC, V258, P3146, DOI 10.1001/jama.258.21.3146
   Routaboul C, 1999, EUR J DERMATOL, V9, P95
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P650, DOI 10.1111/j.1751-1097.2007.00259.x
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   SARNA T, 1986, BIOCHIM BIOPHYS ACTA, V883, P162, DOI 10.1016/0304-4165(86)90147-9
   SARNA T, 1984, PHOTOCHEM PHOTOBIOL, V39, P805, DOI 10.1111/j.1751-1097.1984.tb08863.x
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   SARNA T, 1984, PHOTOCHEM PHOTOBIOL, V39, P69, DOI 10.1111/j.1751-1097.1984.tb03406.x
   Szewczyk G, 2016, PIGM CELL MELANOMA R, V29, P669, DOI 10.1111/pcmr.12514
   Tadokoro T, 2005, J INVEST DERMATOL, V124, P1326, DOI 10.1111/j.0022-202X.2005.23760.x
   Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje
   THODY AJ, 1991, J INVEST DERMATOL, V97, P340, DOI 10.1111/1523-1747.ep12480680
   TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x
   VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328
   Wakamatsu K, 2006, PIGM CELL RES, V19, P154, DOI 10.1111/j.1600-0749.2006.00293.x
   Wakamatsu K, 2002, PIGM CELL RES, V15, P225, DOI 10.1034/j.1600-0749.2002.02009.x
   Wakamatsu K, 2012, PIGM CELL MELANOMA R, V25, P434, DOI 10.1111/j.1755-148X.2012.01011.x
   Wakamatsu K, 2009, PIGM CELL MELANOMA R, V22, P474, DOI 10.1111/j.1755-148X.2009.00580.x
   Wenczl E, 1998, J INVEST DERMATOL, V111, P678, DOI 10.1046/j.1523-1747.1998.00357.x
   Wolber R, 2008, PIGM CELL MELANOMA R, V21, P487, DOI 10.1111/j.1755-148X.2008.00470.x
   Wood SR, 2006, P NATL ACAD SCI USA, V103, P4111, DOI 10.1073/pnas.0511248103
   Ye T, 2006, PHOTOCHEM PHOTOBIOL, V82, P733, DOI 10.1562/2006-01-02-RA-762
   Zadlo A, 2007, PIGM CELL RES, V20, P52, DOI 10.1111/j.1600-0749.2006.00350.x
   Zadlo A, 2016, FREE RADICAL BIO MED, V97, P320, DOI 10.1016/j.freeradbiomed.2016.06.012
   Zareba M, 2007, PHOTOCHEM PHOTOBIOL, V83, P925, DOI 10.1111/j.1751-1097.2007.00080.x
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
NR 90
TC 51
Z9 51
U1 3
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD MAY-JUN
PY 2018
VL 94
IS 3
BP 409
EP 420
DI 10.1111/php.12837
PG 12
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GI1WO
UT WOS:000434161500002
PM 28873228
DA 2022-11-30
ER

PT J
AU Luo, X
   Gu, SJ
   Zhang, YJ
   Zhang, JH
AF Luo, Xu
   Gu, Shengjie
   Zhang, Yujiao
   Zhang, Jianhong
TI Kinsenoside Ameliorates Oxidative Stress-Induced RPE Cell Apoptosis and
   Inhibits Angiogenesis via Erk/p38/NF-kappa B/VEGF Signaling
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE age-related macular degeneration; oxidative stress; kinsenoside; retinal
   pigment epithelium; vascular endothelial growth factor; NF-kappa B; MAPK
ID PIGMENT EPITHELIAL-CELLS; SECRETION; VEGF; ANOECTOCHILUS; ACTIVATION;
   DAMAGE
AB The pathological superoxidative condition that retinal pigment epithelium (RPE) cells experience contributed to the advancement of age-related macular degeneration (AMD), which was accompanied by significant neovascularization. Therefore, the discovery of novel pharmacological candidates to ameliorate oxidative damage (H2O2) against RPE cells and inhibit the following angiogenesis simultaneously is urgently needed. Herein, we found that kinsenoside (Kin), an active component derived from Anoectochilus roxburghii, was able to protect RPE cells effectively and attenuate subsequent angiogenesis. In this study, H2O2-induced oxidative injury reduced RPE cell viability and increased cell apoptosis, which was significantly rescued by the treatment with Kin. Compared with H2O2 alone, Kin decreased the levels of Bax and increased the production of Bcl-2 in RPE cells. H2O2-stimulated VEGF up-regulation was inhibited by Kin treatment. Human umbilical vein endothelial cell (HUVEC) neovascularization induced by conditioned medium (CM) from H2O2-stimulated RPE cells was attenuated by treatment with Kin, VEGF antagonist, NF-kappa B, Erk-MAPK, and p38-MAPK inhibitors. Additionally, H2O2- activated phosphorylated expression of I kappa B alpha, p65, Erk, and p38 in RPE cells was inhibited by treatment with Kin. Taken together, Kin protected RPE from apoptosis against oxidative stress while simultaneously decreasing apoptosis-related neovascularization. This could be ascribed to the inhibition of Erk/p38/NF-kappa B signaling by Kin that contributed to the resulting decreased VEGF expression in H2O2-treated RPE cells.
C1 [Luo, Xu; Gu, Shengjie; Zhang, Yujiao; Zhang, Jianhong] Shanghai Fourth Peoples Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
RP Zhang, JH (通讯作者)，Shanghai Fourth Peoples Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
EM zhangjh_0312@aliyun.com
CR Berger S, 2012, EUR J CELL BIOL, V91, P640, DOI 10.1016/j.ejcb.2012.02.003
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   De Cilla S, 2017, CELL PHYSIOL BIOCHEM, V42, P1725, DOI 10.1159/000479441
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dinc E, 2017, CURR EYE RES, V42, P1659, DOI 10.1080/02713683.2017.1368085
   Du XM, 2001, BIOL PHARM BULL, V24, P65, DOI 10.1248/bpb.24.65
   Ebrahimi KB, 2018, ANTIOXID REDOX SIGN, V29, P389, DOI 10.1089/ars.2017.7084
   Ehrenberg M, 2018, CURR EYE RES, V43, P147, DOI 10.1080/02713683.2017.1385088
   Gu Y, 2017, FASEB J, V31, P3321, DOI 10.1096/fj.201601263R
   Hao FJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.532
   Hsiao HB, 2013, OSTEOPOROSIS INT, V24, P1663, DOI 10.1007/s00198-012-2199-z
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kannan R, 2006, MOL VIS, V12, P1649
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Klettner A, 2013, MOL VIS, V19, P281
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   Li K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057542
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Liu ZL, 2013, FITOTERAPIA, V86, P163, DOI 10.1016/j.fitote.2013.03.006
   Ma SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173700
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Oh JR, 2017, INT J OPHTHALMOL-CHI, V10, P203, DOI 10.18240/ijo.2017.02.04
   Pan WK, 2015, PEDIATR BLOOD CANCER, V62, P1414, DOI 10.1002/pbc.25453
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.255
   Sun XT, 2017, FEBS OPEN BIO, V7, P1899, DOI 10.1002/2211-5463.12326
   Swamynathan S, 2017, EXP EYE RES, V164, P118, DOI 10.1016/j.exer.2017.08.007
   Tang F, 2018, BIOCHEM BIOPH RES CO, V495, P781, DOI 10.1016/j.bbrc.2017.11.080
   Tang Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.453
   Wang SD, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.410
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wu S, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0606-0
   Xiang M, 2016, HEPATOLOGY, V64, P2135, DOI 10.1002/hep.28825
NR 38
TC 20
Z9 22
U1 1
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 20
PY 2018
VL 9
AR 240
DI 10.3389/fphar.2018.00240
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FZ8MG
UT WOS:000427862900001
PM 29615910
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Koh, JEW
   Ng, EYK
   Bhandary, SV
   Hagiwara, Y
   Laude, A
   Acharya, UR
AF Koh, Joel E. W.
   Ng, Eddie Y. K.
   Bhandary, Sulatha V.
   Hagiwara, Yuki
   Laude, Augustinus
   Acharya, U. Rajendra
TI Automated retinal health diagnosis using pyramid histogram of visual
   words and Fisher vector techniques
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Bag-of-visual-words; Computer-aided
   diagnosis System; Diabetic retinopathy; Eye diseases; Fisher vector
   encoder; Fundus images; Glaucoma; Machine learning
ID DIGITAL FUNDUS IMAGES; MODE DECOMPOSITION; TRANSFORM; ALGORITHM;
   FEATURES
AB Untreated age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma may lead to irreversible vision loss. Hence, it is essential to have regular eye screening to detect these eye diseases at an early stage and to offer treatment where appropriate. One of the simplest, non-invasive and cost-effective techniques to screen the eyes is by using fundus photo imaging. But, the manual evaluation of fundus images is tedious and challenging. Further, the diagnosis made by ophthalmologists may be subjective. Therefore, an objective and novel algorithm using the pyramid histogram of visual words (PROW) and Fisher vectors is proposed for the classification of fundus images into their respective eye conditions (normal, AMD, DR, and glaucoma). The proposed algorithm extracts features which are represented as words. These features are built and encoded into a Fisher vector for classification using random forest classifier. This proposed algorithm is 'validated with both blindfold and ten-fold cross-validation techniques. An accuracy of 90.06% is achieved with the,blindfold method, and highest accuracy of 96.79% is obtained with ten-fold cross-validation. The highest classification performance of our system shows the potential of deploying it in polyclinics to assist healthcare professionals in their initial diagnosis of the eye. Our developed system can reduce the workload of ophthalmologists significantly.
C1 [Koh, Joel E. W.; Hagiwara, Yuki; Acharya, U. Rajendra] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
   [Koh, Joel E. W.; Ng, Eddie Y. K.] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore, Singapore.
   [Bhandary, Sulatha V.] Kasturba Med Coll & Hosp, Dept Ophthalmol, Manipal, Karnataka, India.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp, Eye Inst, Singapore, Singapore.
   [Laude, Augustinus] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Acharya, U. Rajendra] Singapore Univ Social Sci, Sch Sci & Technol, Dept Biomed Engn, Singapore, Singapore.
   [Acharya, U. Rajendra] Univ Malaga, Fac Engn, Dept Biomed Engn, Malaga, Spain.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Manipal Academy of Higher
   Education (MAHE); Kasturba Medical College, Manipal; Tan Tock Seng
   Hospital; Nanyang Technological University & National Institute of
   Education (NIE) Singapore; Nanyang Technological University; Singapore
   University of Social Sciences (SUSS); Universidad de Malaga
RP Koh, JEW (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
EM falco_peregrinus14@yahoo.co.uk
RI Acharya, Rajendra U/E-3791-2010; Ng, E Y K/A-1375-2011
OI Acharya, Rajendra U/0000-0003-2689-8552; Ng, E Y K/0000-0002-5701-1080;
   Hagiwara, Yuki/0000-0002-5418-738X; Bhandary,
   Sulatha/0000-0002-3150-707X
CR Acharya R, 2008, ARTECH HSE BIOINF BI, P1
   Acharya U.R., 2017, COMPUT BIOL MED, V84
   Acharya UR, 2017, COMPUT BIOL MED, V88, P72, DOI 10.1016/j.compbiomed.2017.06.022
   Acharya UR, 2017, J COMPUT SCI-NETH, V20, P41, DOI 10.1016/j.jocs.2017.03.005
   Acharya UR, 2016, COMPUT BIOL MED, V75, P54, DOI 10.1016/j.compbiomed.2016.04.015
   Acharya UR, 2016, COMPUT BIOL MED, V73, P131, DOI 10.1016/j.compbiomed.2016.04.009
   Acharya UR, 2012, J MED SYST, V36, P2011, DOI 10.1007/s10916-011-9663-8
   Bosch A, 2007, P 6 ACM INT C IM VID, P401, DOI [10.1145/1282280.1282340, DOI 10.1145/1282280.1282340, DOI 10.1145/1282280]
   Boyd K., 2017, WHAT IS AGE RELATED
   Boyd K., 2017, WHAT IS DIABETIC RET
   Boyd K., 2017, WHAT IS GLAUCOMA
   BREIMAN L, 2001, MACH LEARN, V0045
   DEVROYE LP, 1979, IEEE T INFORM THEORY, V25, P601, DOI 10.1109/TIT.1979.1056087
   Duda RO., 2001, PATTERN CLASSIFICATI
   ETDRS, 1991, OPHTHALMOLOGY, V98
   Faust O, 2012, J MED SYST, V36, P145, DOI 10.1007/s10916-010-9454-7
   Ganesan K, 2014, MED BIOL ENG COMPUT, V52, P663, DOI 10.1007/s11517-014-1167-5
   He HB, 2008, IEEE IJCNN, P1322, DOI 10.1109/IJCNN.2008.4633969
   Koh J. E. W., 2017, APPL INTELL, P1
   Koh JEW, 2017, COMPUT BIOL MED, V84, P89, DOI 10.1016/j.compbiomed.2017.03.008
   Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94
   Maheshwari S, 2017, COMPUT BIOL MED, V88, P142, DOI 10.1016/j.compbiomed.2017.06.017
   Maheshwari S, 2017, IEEE J BIOMED HEALTH, V21, P803, DOI 10.1109/JBHI.2016.2544961
   Mookiah MRK, 2013, KNOWL-BASED SYST, V39, P9, DOI 10.1016/j.knosys.2012.09.008
   Mookiah M.R.K., 2015, KNOWL BASE SYST, V89
   Niemeijer M., IEEE T MED IMAGING, V28
   ONU World Population Ageing, 2015, WORLD POP AG, P164
   Perronnin F., 2007, P IEEE COMP SOC C CO
   Perronnin F., 2015, 2015 IEEE C COMP VIS
   Perronnin F, 2010, LECT NOTES COMPUT SC, V6314, P143, DOI 10.1007/978-3-642-15561-1_11
   Uchida Y, 2013, 2013 SECOND IAPR ASIAN CONFERENCE ON PATTERN RECOGNITION (ACPR 2013), P23, DOI 10.1109/ACPR.2013.6
   Vedaldi A., 2010, P 18 ACM INT C MULT, P1469, DOI DOI 10.1145/1873951.1874249
   WHO, 2017, WORLD REP AG HLTH
   Wood J, 2011, OPHTHAL PHYSL OPT, V31, P201, DOI 10.1111/j.1475-1313.2011.00842.x
NR 34
TC 12
Z9 13
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD JAN 1
PY 2018
VL 92
BP 204
EP 209
DI 10.1016/j.compbiomed.2017.11.019
PG 6
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA FU1WN
UT WOS:000423640300021
PM 29227822
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mao, K
   Shu, WT
   Liu, LB
   Gu, Q
   Qiu, QH
   Wu, XW
AF Mao, Ke
   Shu, Wanting
   Liu, Libin
   Gu, Qing
   Qiu, Qinghua
   Wu, XingWei
TI Salvianolic Acid A Inhibits OX-LDL Effects on Exacerbating Choroidal
   Neovascularization via Downregulating CYLD
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; NF-KAPPA-B; CYLINDROMATOSIS CYLD;
   LIPID-PEROXIDATION; OXIDATIVE STRESS; RAT MODEL; EXPRESSION; ACTIVATION;
   PATHWAY; CELLS
AB Backgrounds. Age-related macular degeneration is closely related to lipid oxidation, while relationship between OX-LDL and choroidal neovascularization is unclear. Recently, cylindromatosis is proved to regulate angiogenesis. However, its role in CNV progression remained unclear. Salvianolic acid A is widely used in vascular diseases. We investigated the relationship between OX-LDL and CNV and explore antineovascularization mechanism of Sal A. Methods. C57BL6/J mice were randomized into four groups and injected with PBS or OX-LDL, together with Sal A for one week. CNV was induced by laser; CNV severity was analyzed by fundus fluorescein angiography, H&E staining, and choroid flat mount after 1 week. In in vitro experiments, ARPE-19 and HUVECs were cultured with OX-LDL (with or without Sal A) for 48 hours. Angiogenic proteins, cell junction integrity, and tube formation were measured. CYLD siRNA and specific inhibitors were used to explore mechanisms of CYLD in promoting OX-LDL-induced CNV progression. Results. OX-LDL promoted laser-induced CNV volume by increasing VEGF, PDGF, and CYLD levels. Sal A antagonized OX-LDL effects and restrained CNV progression by decreasing VEGF/PDGF/CYLD, increasing antiangiostatin levels, and promoting P62-CYLD-TRAF6 interaction. Conclusions. We demonstrated oxidation damage exacerbates CNV progression, and Sal A could be a clinical therapeutic reagent to exudative AMD.
C1 [Mao, Ke; Shu, Wanting; Liu, Libin; Gu, Qing; Qiu, Qinghua; Wu, XingWei] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 1, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wu, XW (通讯作者)，Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 1, Dept Ophthalmol, Shanghai, Peoples R China.
EM wxweye@sina.com
FU Shanghai Natural Science Foundation [14401972600]
FX This work was supported by a grant from Shanghai Natural Science
   Foundation (14401972600). The authors would like to thank Qing Gu for
   excellent technical support.
CR Bergmann M, 2011, GRAEF ARCH CLIN EXP, V249, P1477, DOI 10.1007/s00417-011-1682-0
   Capra Sandra, 2002, Nutr Clin Pract, V17, P210, DOI 10.1177/0115426502017004210
   CHEN KC, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/429486
   Chen WJ, 2017, EXP EYE RES, V154, P151, DOI 10.1016/j.exer.2016.12.001
   Choi YS, 2009, BLOOD, V114, P3117, DOI 10.1182/blood-2009-02-203372
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Davis K. J. A., 1991, OXIDATIVE DAMAGE REP, P99
   Du Hongjun, 2016, Open J Ophthalmol, V6, P43
   Gao JM, 2010, BLOOD, V115, P4130, DOI 10.1182/blood-2009-10-248526
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Guo JY, 2014, ONCOTARGET, V5, P6353, DOI 10.18632/oncotarget.2216
   Guo JX, 2017, J OCUL PHARMACOL TH, V33, P50, DOI 10.1089/jop.2016.0153
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jin W, 2008, J CLIN INVEST, V118, P1858, DOI 10.1172/JCI34257
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Klei LR, 2016, CELL REP, V17, P221, DOI 10.1016/j.celrep.2016.08.080
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu SA, 2012, BIOCHEM BIOPH RES CO, V420, P78, DOI 10.1016/j.bbrc.2012.02.118
   Oh KS, 2011, INT IMMUNOPHARMACOL, V11, P1901, DOI 10.1016/j.intimp.2011.07.022
   Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288
   Qin RA, 2012, J TRADIT CHIN MED, V32, P63, DOI 10.1016/S0254-6272(12)60033-8
   Qiu YT, 2015, CURR EYE RES, V40, P415, DOI 10.3109/02713683.2014.927507
   Sengupta N, 2010, INVEST OPHTH VIS SCI, V51, P2697, DOI 10.1167/iovs.09-4137
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Sun H, 2013, CANCER RES, V73, P4950, DOI 10.1158/0008-5472.CAN-13-0370
   Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43
   Tomida D, 2011, INVEST OPHTH VIS SCI, V52, P3193, DOI 10.1167/iovs.10-6737
   Velez G, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/106486
   Wang XJ, 2005, J ETHNOPHARMACOL, V97, P441, DOI 10.1016/j.jep.2004.11.036
   Wang Y., 2016, NUTRIENTS, V8
   Ye FX, 2015, SCI REP-UK, V5, DOI 10.1038/srep07705
   Yin LL, 2012, AM J PATHOL, V180, P541, DOI 10.1016/j.ajpath.2011.10.015
   Yu YJ, 2016, INT J OPHTHALMOL-CHI, V9, P1112, DOI 10.18240/ijo.2016.08.05
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
NR 38
TC 6
Z9 7
U1 1
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 6210694
DI 10.1155/2017/6210694
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FF3NT
UT WOS:000408811200001
PM 29081889
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Lueck, K
   Busch, M
   Moss, SE
   Greenwood, J
   Kasper, M
   Lommatzsch, A
   Pauleikhoff, D
   Wasmuth, S
AF Lueck, Katharina
   Busch, Martin
   Moss, Stephen E.
   Greenwood, John
   Kasper, Maren
   Lommatzsch, Albrecht
   Pauleikhoff, Daniel
   Wasmuth, Susanne
TI Complement Stimulates Retinal Pigment Epithelial Cells to Undergo
   Pro-Inflammatory Changes
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Inflammation; Retinal pigment epithelium; Complement
ID MEMBRANE ATTACK COMPLEX; MONOCYTE CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B;
   SMOOTH-MUSCLE-CELLS; MACULAR DEGENERATION; GENE-EXPRESSION; RPE CELLS;
   CHEMOTACTIC PROTEIN-1; DRUSEN; INTERLEUKIN-6
AB Background/Aims: We examined the effect of human complement sera (HCS) on retinal pigment epithelial (RPE) cells with respect to pro-inflammatory mediators relevant in early age-related macular degeneration (AMD). Methods: RPE cells were treated with complement-containing HCS or with heat-inactivated (HI) HCS or C7-deficient HCS as controls. Cells were analysed for C5b-9 using immunocytochennistry and flow cytometry. Interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1) were quantified by ELISA and RT-PCR. Tumour necrosis factor-alpha (TNF-alpha), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), were analysed by Western blotting. The intracellular distribution of nuclear factor (NF)-kappa B was investigated by immunofluorescence. Results: A concentration-dependent increased staining for C5b-9 but no influence on cell viability was observed after HCS treatment. ELISA and RT-PCR analysis revealed elevated secretion and expression of IL-6, IL-8, and MCP-1. Western blot analysis showed a concentration-dependent increase in ICAM-1, VCAM-1, and TNF-alpha in response to HCS, and immunofluorescence staining revealed nuclear translocation of NF-kappa B. Conclusion: This study suggests that complement stimulates NF-kappa B activation in RPE cells that might further create a proinflammatory environment. All these factors together may support early AMD development. (C) 2015 S. Karger AG, Basel
C1 [Lueck, Katharina; Busch, Martin; Kasper, Maren; Wasmuth, Susanne] St Franziskus Hosp, Dept Ophthalmol, Ophtha Lab, DE-48145 Munster, Germany.
   [Lommatzsch, Albrecht; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, DE-48145 Munster, Germany.
   [Lueck, Katharina; Moss, Stephen E.; Greenwood, John] UCL Inst Ophthalmol, Dept Cell Biol, London, England.
C3 St. Franziskus-Hospital; St. Franziskus-Hospital; University of London;
   University College London
RP Wasmuth, S (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Ophtha Lab, Hohenzollernring 74, DE-48145 Munster, Germany.
EM susanne.wasmuth@makula-centrum-muenster.de
RI Kasper, Maren/AAS-1716-2021
OI Greenwood, John/0000-0003-4496-2984; Wasmuth,
   Susanne/0000-0003-1422-9642
FU Voltmann Foundation; Medical Research Council [MR/M02282X/1] Funding
   Source: researchfish; MRC [MR/M02282X/1] Funding Source: UKRI
FX The funding by the Voltmann Foundation included a part-time salary for
   Dr. Katharina Lueck and funded material expenses.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   BOK D, 1993, J CELL SCI, P189
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113
   Chen YW, 2007, EUR J IMMUNOL, V37, P167, DOI 10.1002/eji.200636285
   DANIELS RH, 1990, IMMUNOLOGY, V71, P312
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Elner SG, 1997, INVEST OPHTH VIS SCI, V38, P446
   ELNER VM, 1990, AM J PATHOL, V136, P745
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   FERRICK MR, 1991, INVEST OPHTH VIS SCI, V32, P1534
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Georgiannakis A, 2014, INVEST OPHTH VIS SCI, V55
   Gregerson DS, 2007, INVEST OPHTH VIS SCI, V48, P4654, DOI 10.1167/iovs.07-0286
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kilgore KS, 1996, AM J PATHOL, V149, P953
   KILGORE KS, 1995, J IMMUNOL, V155, P1434
   Kilgore KS, 1997, AM J PATHOL, V150, P2019
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Narayan S, 2003, INVEST OPHTH VIS SCI, V44, P4885, DOI 10.1167/iovs.03-0387
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PLANCK SR, 1992, INVEST OPHTH VIS SCI, V33, P78
   ROBINSON EA, 1989, P NATL ACAD SCI USA, V86, P1850, DOI 10.1073/pnas.86.6.1850
   ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966
   Rus H, 2005, IMMUNOL RES, V33, P103, DOI 10.1385/IR:33:2:103
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shankland SJ, 1999, KIDNEY INT, V56, P538, DOI 10.1046/j.1523-1755.1999.00560.x
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V49, P5574
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Takano T, 2001, AM J PHYSIOL-RENAL, V281, pF841, DOI 10.1152/ajprenal.0048.2001
   Tedesco F, 1997, J EXP MED, V185, P1619, DOI 10.1084/jem.185.9.1619
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Torzewski J, 1996, ARTERIOSCL THROM VAS, V16, P673, DOI 10.1161/01.ATV.16.5.673
   Tramontini N, 2004, ARTHRITIS RHEUM-US, V50, P2633, DOI 10.1002/art.20386
   Viedt C, 2000, FASEB J, V14, P2370
   Wang XC, 1999, INVEST OPHTH VIS SCI, V40, P477
   Weissenbach M, 2004, EUR J IMMUNOL, V34, P2895, DOI 10.1002/eji.200425237
   WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zhou JH, 2005, MOL VIS, V11, P414
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 59
TC 16
Z9 16
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2015
VL 54
IS 4
BP 195
EP 203
DI 10.1159/000439596
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CX0IE
UT WOS:000365379300004
PM 26502094
DA 2022-11-30
ER

PT J
AU Lin, TC
   Hsu, CC
   Chien, KH
   Hung, KH
   Peng, CH
   Chen, SJ
AF Lin, Tai-Chi
   Hsu, Chih-Chien
   Chien, Ke-Hung
   Hung, Kuo-Hsuan
   Peng, Chi-Hsien
   Chen, Shih-Jen
TI Retinal stem cells and potential cell transplantation treatments
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Review
DE ciliary marginal zones; embryonic stem cells; induced pluripotent stem
   cells; retinal diseases; stem cells
ID IN-VITRO DIFFERENTIATION; NEURAL PROGENITOR CELLS; MARROW-DERIVED CELLS;
   ADULT HUMAN RETINA; MESENCHYMAL STEM; EPITHELIAL-CELLS; MULLER GLIA;
   VISUAL FUNCTION; C-MYC; REGENERATION
AB The retina, histologically composed of ten delicate layers, is responsible for light perception and relaying electrochemical signals to the secondary neurons and visual cortex. Retinal disease is one of the leading clinical causes of severe vision loss, including age-related macular degeneration, Stargardt's disease, and retinitis pigmentosa. As a result of the discovery of various somatic stem cells, advances in exploring the identities of embryonic stem cells, and the development of induced pluripotent stem cells, cell transplantation treatment for retinal diseases is currently attracting much attention. The sources of stem cells for retinal regeneration include endogenous retinal stem cells (e.g., neuronal stem cells, Muller cells, and retinal stem cells from the ciliary marginal zone) and exogenous stem cells (e.g., bone mesenchymal stem cells, adipose-derived stem cells, embryonic stem cells, and induced pluripotent stem cells). The success of cell transplantation treatment depends mainly on the cell source, the timing of cell harvesting, the protocol of cell induction/transplantation, and the microenvironment of the recipient's retina. This review summarizes the different sources of stem cells for regeneration treatment in retinal diseases and surveys the more recent achievements in animal studies and clinical trials. Future directions and challenges in stem cell transplantation are also discussed. Copyright (C) 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
C1 [Lin, Tai-Chi; Hsu, Chih-Chien; Peng, Chi-Hsien; Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Lin, Tai-Chi; Hsu, Chih-Chien] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Chien, Ke-Hung] Triserv Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chien, Ke-Hung] Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan.
   [Hung, Kuo-Hsuan] Natl Yang Ming Univ Hosp, Dept Ophthalmol, Yilan, Taiwan.
   [Peng, Chi-Hsien; Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Peng, Chi-Hsien] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Peng, Chi-Hsien] Fu Jen Catholic Univ, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; Tri-Service General Hospital; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; Shin Kong Wu Ho Su
   Memorial Hospital; Fu Jen Catholic University
RP Chen, SJ (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
EM sjchen@vghtpe.gov.tw
CR Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Ahmad I, 1999, BRAIN RES, V831, P1, DOI 10.1016/S0006-8993(99)01376-1
   Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Chiou SH, 2005, BIOCHEM BIOPH RES CO, V326, P578, DOI 10.1016/j.bbrc.2004.11.061
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Du YQ, 2010, MOL VIS, V16, P2680
   Enzmann V, 2009, ARCH OPHTHALMOL-CHIC, V127, P563, DOI 10.1001/archophthalmol.2009.65
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fang IM, 2013, EXP EYE RES, V113, P49, DOI 10.1016/j.exer.2013.05.007
   Fimbel SM, 2007, J NEUROSCI, V27, P1712, DOI 10.1523/JNEUROSCI.5317-06.2007
   Fischer AJ, 2001, NAT NEUROSCI, V4, P247, DOI 10.1038/85090
   Fischer AJ, 2003, GLIA, V43, P70, DOI 10.1002/glia.10218
   Fischer AJ, 2001, DEV NEUROSCI-BASEL, V23, P268, DOI 10.1159/000048710
   Fischer AJ, 2013, EXP EYE RES, V116, P199, DOI 10.1016/j.exer.2013.08.018
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Gualdoni S, 2010, STEM CELLS, V28, P1048, DOI 10.1002/stem.423
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   John S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/465169
   Johnsen EO, 2012, EXP EYE RES, V98, P28, DOI 10.1016/j.exer.2012.03.008
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P960, DOI 10.1167/iovs.09-3884
   Kanno Hiroshi, 2013, World J Stem Cells, V5, P163, DOI 10.4252/wjsc.v5.i4.163
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   KELLEY MW, 1995, INVEST OPHTH VIS SCI, V36, P1280
   Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lawrence JM, 2007, STEM CELLS, V25, P2033, DOI 10.1634/stemcells.2006-0724
   Lewallen Michelle, 2013, J Glaucoma, V22 Suppl 5, pS42, DOI 10.1097/IJG.0b013e3182934b45
   Li Y, 2007, INVEST OPHTH VIS SCI, V48, P4321, DOI 10.1167/iovs.06-1015
   Lin TM, 2005, STEM CELLS DEV, V14, P92, DOI 10.1089/scd.2005.14.92
   Liu IH, 2005, OPHTHALMOLOGICA, V219, P171, DOI 10.1159/000085250
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mayer EJ, 2005, BRIT J OPHTHALMOL, V89, P102, DOI 10.1136/bjo.2004.057687
   Mayer EJ, 2003, BRIT J OPHTHALMOL, V87, P1154, DOI 10.1136/bjo.87.9.1154
   Meyer JS, 2006, STEM CELLS, V24, P274, DOI 10.1634/stemcells.2005-0059
   Moviglia GA, 2012, OPHTHALMIC RES, V48, P1, DOI 10.1159/000339839
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nieto-Miguel T, 2013, CURR EYE RES, V38, P933, DOI 10.3109/02713683.2013.802809
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, J PHARMACOL SCI, V109, P168, DOI 10.1254/jphs.08R19FM
   Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Roesch K, 2008, J COMP NEUROL, V509, P225, DOI 10.1002/cne.21730
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Sugitani S, 2013, EXP EYE RES, V116, P254, DOI 10.1016/j.exer.2013.09.013
   Suzuki T, 2007, CELL TRANSPLANT, V16, P493, DOI 10.3727/000000007783464966
   Suzuki T, 2006, STEM CELLS, V24, P2406, DOI 10.1634/stemcells.2005-0587
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Thummel R, 2008, DEV NEUROBIOL, V68, P392, DOI 10.1002/dneu.20596
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Wang SZ, 2010, EXPERT OPIN BIOL TH, V10, P1227, DOI 10.1517/14712598.2010.495218
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   Xu HX, 2007, INVEST OPHTH VIS SCI, V48, P1674, DOI 10.1167/iovs.06-1034
   Yang P, 2002, EXP NEUROL, V177, P326, DOI 10.1006/exnr.2002.7955
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 65
TC 9
Z9 13
U1 2
U2 34
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD NOV
PY 2014
VL 77
IS 11
BP 556
EP 561
DI 10.1016/j.jcma.2014.08.001
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AT7IH
UT WOS:000345109300002
PM 25238708
OA Bronze
DA 2022-11-30
ER

PT J
AU Hebecker, M
   Alba-Dominguez, M
   Roumenina, LT
   Reuter, S
   Hyvarinen, S
   Dragon-Durey, MA
   Jokiranta, TS
   Sanchez-Corral, P
   Jozsi, M
AF Hebecker, Mario
   Alba-Dominguez, Maria
   Roumenina, Lubka T.
   Reuter, Stefanie
   Hyvarinen, Satu
   Dragon-Durey, Marie-Agnes
   Jokiranta, T. Sakari
   Sanchez-Corral, Pilar
   Jozsi, Mihaly
TI An Engineered Construct Combining Complement Regulatory and
   Surface-Recognition Domains Represents a Minimal-Size Functional Factor
   H
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC-SYNDROME; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; DENSE
   DEPOSIT DISEASE; C-REACTIVE PROTEIN; ALTERNATIVE PATHWAY; MACULAR
   DEGENERATION; MEMBRANOPROLIFERATIVE-GLOMERULONEPHRITIS; STRUCTURAL
   BASIS; FACTOR-B; AUTOANTIBODIES
AB Complement is an essential humoral component of innate immunity; however, its inappropriate activation leads to pathology. Polymorphisms, mutations, and autoantibodies affecting factor H (FH), a major regulator of the alternative complement pathway, are associated with various diseases, including age-related macular degeneration, atypical hemolytic uremic syndrome, and C3 glomerulopathies. Restoring FH function could be a treatment option for such pathologies. In this article, we report on an engineered FH construct that directly combines the two major functional regions of FH: the N-terminal complement regulatory domains and the C-terminal surface-recognition domains. This minimal-size FH (mini-FH) binds C3b and has complement regulatory functions similar to those of the full-length protein. In addition, we demonstrate that mini-FH binds to the FH ligands C-reactive protein, pentraxin 3, and malondialdehyde epitopes. Mini-FH was functionally active when bound to the extracellular matrix and endothelial cells in vitro, and it inhibited C3 deposition on the cells. Furthermore, mini-FH efficiently inhibited complement-mediated lysis of host-like cells caused by a disease-associated FH mutation or by anti-FH autoantibodies. Therefore, mini-FH could potentially be used as a complement inhibitor targeting host surfaces, as well as to replace compromised FH in diseases associated with FH dysfunction. The Journal of Immunology, 2013, 191: 912-921.
C1 [Hebecker, Mario; Reuter, Stefanie; Jozsi, Mihaly] Hans Knoell Inst, Jr Res Grp Cellular Immunobiol, Leibniz Inst Nat Prod Res & Infect Biol, D-07745 Jena, Germany.
   [Alba-Dominguez, Maria; Sanchez-Corral, Pilar] Hosp La Paz Inst Hlth Res, Res Unit, Madrid 28046, Spain.
   [Alba-Dominguez, Maria; Sanchez-Corral, Pilar] Ctr Invest Biomed Red Enfermedades Raras, Madrid 28040, Spain.
   [Roumenina, Lubka T.; Dragon-Durey, Marie-Agnes] INSERM Unite Mixte Rech Sante 872, Ctr Rech Cordeliers, F-75006 Paris, France.
   [Roumenina, Lubka T.; Dragon-Durey, Marie-Agnes] Univ Paris 06, F-75006 Paris, France.
   [Roumenina, Lubka T.; Dragon-Durey, Marie-Agnes] Univ Paris 05, Sorbonne Paris Cite, F-75006 Paris, France.
   [Hyvarinen, Satu; Jokiranta, T. Sakari] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Immunobiol Res Program, FI-00014 Helsinki, Finland.
   [Dragon-Durey, Marie-Agnes] Hop Europeen Georges Pompidou, AP HP, Serv Immunol Biol, F-75908 Paris 15, France.
   [Jozsi, Mihaly] Eotvos Lorand Univ, Magyar Tudomanyos Akad Eotvos Lorand Tudomanyegye, Dept Immunol, H-1117 Budapest, Hungary.
C3 Hans Knoll Institute (HKI); CIBER - Centro de Investigacion Biomedica en
   Red; CIBERER; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite; UDICE-French Research Universities; Sorbonne
   Universite; UDICE-French Research Universities; Universite Paris Cite;
   University of Helsinki; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French
   Research Universities; Universite Paris Cite; Eotvos Lorand University
RP Jozsi, M (通讯作者)，Eotvos Lorand Univ, Magyar Tudomanyos Akad Eotvos Lorand Tudomanyegye, Dept Immunol, Pazmany Peter Setany 1-C, H-1117 Budapest, Hungary.
EM mihaly.jozsi@gmx.net
RI Sánchez-Corral, Pilar/GLR-0387-2022; , Dragon-Durey/AGM-3653-2022;
   Jozsi, Mihaly/I-7872-2018; Roumenina, Lubka/P-5906-2019; Roumenina,
   Lubka/L-2638-2017
OI Jozsi, Mihaly/0000-0002-5520-5535; Roumenina, Lubka/0000-0002-9940-0324;
   Reuter nee Strobel, Stefanie/0000-0002-3805-4632; Dragon-Durey,
   Marie-Agnes/0000-0002-5809-8122
FU Deutsche Forschungsgemeinschaft [JO 844/1-1]; Hungarian Academy of
   Sciences [LP2012-43/2012]; Instituto de Salud Carlos III [PS09/00268];
   Academy of Finland [128646, 259793]; Sigrid Juselius Foundation; Agence
   Nationale de la Recherche, France [Genopath 2009-2012 09geno03101I];
   INSERM; Spanish Comunidad de Madrid [S2010/BMD-2316]
FX This work was supported by the Deutsche Forschungsgemeinschaft (Grant JO
   844/1-1 to M.J.), the Hungarian Academy of Sciences (LP2012-43/2012 to
   M.J.), the Instituto de Salud Carlos III (Grant PS09/00268 to P.S. C.),
   the Academy of Finland (Projects 128646 and 259793), the Sigrid Juselius
   Foundation (T.S.J.), the Agence Nationale de la Recherche, France
   (Genopath 2009-2012 09geno03101I), and INSERM. M.A.-D. is supported by
   the Spanish Comunidad de Madrid (Grant S2010/BMD-2316).
CR Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Blanc C, 2012, J IMMUNOL, V189, P3528, DOI 10.4049/jimmunol.1200679
   Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Buttner-Mainik A, 2011, PLANT BIOTECHNOL J, V9, P373, DOI 10.1111/j.1467-7652.2010.00552.x
   Castiblanco-Valencia MM, 2012, J INFECT DIS, V205, P995, DOI 10.1093/infdis/jir875
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Dinasarapu A. R., 2012, UCSD MOLECULE PAGES, V1, P71
   Fakhouri F, 2010, NAT REV NEPHROL, V6, P494, DOI 10.1038/nrneph.2010.85
   Fakhouri F, 2010, KIDNEY INT, V78, P279, DOI 10.1038/ki.2010.132
   Ferreira VP, 2007, BLOOD, V110, P2190, DOI 10.1182/blood-2007-04-083170
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Fridkis-Hareli M, 2011, BLOOD, V118, P4705, DOI 10.1182/blood-2011-06-359646
   Goodship THJ, 2012, MOL IMMUNOL, V52, P200, DOI 10.1016/j.molimm.2012.05.009
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Ishii T, 2006, CHEM RES TOXICOL, V19, P122, DOI 10.1021/tx050231p
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Jokiranta TS, 1996, FEBS LETT, V393, P297
   Jokiranta TS, 1999, J IMMUNOL, V163, P4590
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, MOL IMMUNOL, V44, P2697, DOI 10.1016/j.molimm.2006.12.001
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   KOISTINEN V, 1989, COMPLEMENT INFLAMMAT, V6, P270, DOI 10.1159/000463102
   Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357
   KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Martinez-Barricarte R, 2010, J CLIN INVEST, V120, P3702, DOI 10.1172/JCI43343
   Meri S, 2007, ANN NY ACAD SCI, V1109, P93, DOI 10.1196/annals.1398.011
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018
   Noris M, 2008, CLIN EXP IMMUNOL, V151, P199, DOI 10.1111/j.1365-2249.2007.03552.x
   Nozal P, 2012, CLIN KIDNEY J, V5, P133, DOI 10.1093/ckj/sfs002
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Paixao-Cavalcante D, 2012, KIDNEY INT, V82, P1084, DOI 10.1038/ki.2012.250
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Risitano AM, 2012, IMMUNOBIOLOGY, V217, P1080, DOI 10.1016/j.imbio.2012.07.014
   Risitano AM, 2012, BLOOD, V119, P6307, DOI 10.1182/blood-2011-12-398792
   de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021
   Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281
   Roumenina LT, 2011, J IMMUNOL METHODS, V365, P8, DOI 10.1016/j.jim.2010.12.020
   Roumenina LT, 2009, BLOOD, V114, P2837, DOI 10.1182/blood-2009-01-197640
   Roversi P, 2011, P NATL ACAD SCI USA, V108, P12839, DOI 10.1073/pnas.1102167108
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Sartz L, 2012, J IMMUNOL, V188, P2030, DOI 10.4049/jimmunol.1100319
   Schmidt C, 2008, REV ECON POLIT, V118, P3
   Schmidt CQ, 2011, PROTEIN EXPRES PURIF, V76, P254, DOI 10.1016/j.pep.2010.12.002
   Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Strobel S, 2011, KIDNEY INT, V80, P397, DOI 10.1038/ki.2011.152
   Strobel S, 2010, NEPHROL DIAL TRANSPL, V25, P136, DOI 10.1093/ndt/gfp388
   Thiele Geoffrey M., 2008, V447, P235, DOI 10.1007/978-1-59745-242-7_17
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Zipfel PF, 2013, ADV EXP MED BIOL, V735, P173, DOI 10.1007/978-1-4614-4118-2_11
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 68
TC 55
Z9 62
U1 0
U2 19
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUL 15
PY 2013
VL 191
IS 2
BP 912
EP 921
DI 10.4049/jimmunol.1300269
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 175UW
UT WOS:000321260100044
PM 23772024
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Iezzi, R
   Guru, BR
   Glybina, IV
   Mishra, MK
   Kennedy, A
   Kannan, RM
AF Iezzi, Raymond
   Guru, Bharath R.
   Glybina, Inna V.
   Mishra, Manoj K.
   Kennedy, Alexander
   Kannan, Rangaramanujam M.
TI Dendrimer-based targeted intravitreal therapy for sustained attenuation
   of neuroinflammation in retinal degeneration
SO BIOMATERIALS
LA English
DT Article
DE PAMAM dendrimers; Neuroinflammation; Retinal degeneration; Microglia;
   Age-related macular degeneration; Retinitis pigmentosa
ID RETINITIS-PIGMENTOSA; ACTIVATED MICROGLIA; LONG-TERM; DELIVERY; BRAIN;
   NEUROPROTECTION; NANOPARTICLE; APOPTOSIS; ADHESIVES; CELLS
AB Retinal neuroinflammation, mediated by activated microglia, plays a key role in the pathogenesis of photoreceptor and retinal pigment epithelial cell loss in age-related macular degeneration and retinitis pigmentosa. Targeted drug therapy for attenuation of neuroinflammation in the retina was explored using hydroxyl-terminated polyamidoamine (PAMAM) dendrimer-drug conjugate nanodevices. We show that, upon intravitreal administration, PAMAM dendrimers selectively localize within activated outer retinal microglia in two rat models of retinal degeneration, but not in the retina of healthy controls. This pathology-dependent biodistribution was exploited for drug delivery, by covalently conjugating fluocinolone acetonide to the dendrimer. The conjugate released the drug in a sustained manner over 90 days. In vivo efficacy was assessed using the Royal College of Surgeons (RCS) rat retinal degeneration model over a four-week period when peak retinal degeneration occurs. One intravitreal injection of 1 mu g of FA conjugated to 7 mu g of the dendrimer was able to arrest retinal degeneration, preserve photoreceptor outer nuclear cell counts, and attenuate activated microglia, for an entire month. These studies suggest that PAMAM dendrimers (with no targeting ligands) have an intrinsic ability to selectively localize in activated microglia, and can deliver drugs inside these cells for a sustained period for the treatment of retinal neuroinflammation. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Iezzi, Raymond; Glybina, Inna V.; Kennedy, Alexander] Wayne State Univ, Ligon Res Ctr Vis, Detroit, MI USA.
   [Iezzi, Raymond] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
   [Guru, Bharath R.; Mishra, Manoj K.; Kannan, Rangaramanujam M.] Wayne State Univ, Dept Chem Engn & Mat Sci, Detroit, MI USA.
   [Guru, Bharath R.; Mishra, Manoj K.; Kannan, Rangaramanujam M.] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA.
C3 Wayne State University; Mayo Clinic; Wayne State University; Wayne State
   University
RP Kannan, RM (通讯作者)，Johns Hopkins Sch Med, Ophthalmol Ctr Nanomed, Baltimore, MD 21287 USA.
EM krangar1@jhmi.edu
RI Guru, Bharath Raja/P-6333-2015; Guru, Bharath/G-8822-2015
OI Guru, Bharath Raja/0000-0003-2542-7740; Guru,
   Bharath/0000-0003-2542-7740
FU Wilson Foundation; Ligon Center; Dryer Foundation; WSU; Foundation for
   preventing blindness
FX We gratefully acknowledge funding from Wilson Foundation (RMK and RI),
   Ligon Center (RI and RMK), Dryer Foundation (RMK and RI), WSU
   nanotechnology effort (RMK and RI), and an unrestricted support from
   Foundation for preventing blindness.
CR Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Choucair N, 2006, CENT EUR J BIOL, V1, P463, DOI 10.2478/s11535-006-0038-y
   Dai H, 2010, NANOMEDICINE-UK, V5, P1317, DOI 10.2217/NNM.10.89
   Dierks D, 2005, ARCH OPHTHALMOL-CHIC, V123, P1563, DOI 10.1001/archopht.123.11.1563
   Dinkel K, 2003, J NEUROCHEM, V84, P705, DOI 10.1046/j.1471-4159.2003.01604.x
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Dykens JA, 2004, BIOCHEM PHARMACOL, V68, P1971, DOI 10.1016/j.bcp.2004.06.042
   Florence AT, 2001, ADV DRUG DELIVER REV, V50, pS69, DOI 10.1016/S0169-409X(01)00184-3
   Glezer I, 2004, NEUROSCIENTIST, V10, P538, DOI 10.1177/1073858404263494
   Glybina IV, 2010, INVEST OPHTH VIS SCI, V51, P4243, DOI 10.1167/iovs.09-4492
   Glybina IV, 2009, INVEST OPHTH VIS SCI, V50, P4847, DOI 10.1167/iovs.08-2831
   Grinstaff MW, 2007, BIOMATERIALS, V28, P5205, DOI 10.1016/j.biomaterials.2007.08.041
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hayder M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002212
   Herrero-Vanrell R, 2001, ADV DRUG DELIVER REV, V52, P5, DOI 10.1016/S0169-409X(01)00200-9
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   KANNAN RM, 2010, Patent No. 2010528216
   KANNAN RM, 2010, Patent No. 60997987
   KANNAN RM, 2010, Patent No. 20101247
   KANNAN RM, 2010, Patent No. 088356936
   KANNAN RM, 2010, Patent No. 2701291
   Kannan RM, 2010, Patent, Patent No. [U510/38068, 1038068, US10/38068]
   KANNAN RM, 2010, Patent No. 12681516
   KANNAN RM, 2010, Patent No. 12797657
   Kannan S, 2011, J CEREBR BLOOD F MET, V31, P738, DOI 10.1038/jcbfm.2010.156
   Khandare J, 2005, BIOCONJUGATE CHEM, V16, P330, DOI 10.1021/bc0498018
   Kimura H, 2001, OPHTHALMOLOGICA, V215, P143, DOI 10.1159/000050849
   Kobayashi Hisataka, 2003, Mol Imaging, V2, P1, DOI 10.1162/153535003765276237
   Kojima C, 2011, NANOMED-NANOTECHNOL, V7, P1001, DOI 10.1016/j.nano.2011.03.007
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   KURZ D, 2000, OPHTHAMOL CLIN N AM, V15, P405
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Menjoge AR, 2010, DRUG DISCOV TODAY, V15, P171, DOI 10.1016/j.drudis.2010.01.009
   Mishra MK, 2011, NANOMED-NANOTECHNOL, V7, P935, DOI 10.1016/j.nano.2011.04.008
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   Navath RS, 2010, BIOMACROMOLECULES, V11, P1544, DOI 10.1021/bm100186b
   Navath RS, 2008, BIOCONJUGATE CHEM, V19, P2446, DOI 10.1021/bc800342d
   Nigavekar SS, 2004, PHARM RES-DORDR, V21, P476, DOI 10.1023/B:PHAM.0000019302.26097.cc
   Perumal O, 2009, BIOCONJUGATE CHEM, V20, P842, DOI 10.1021/bc800526z
   Rao NA, 2003, INVEST OPHTH VIS SCI, V44, P22, DOI 10.1167/iovs.02-0199
   Rattner A, 2006, AM J OPHTHALMOL, V141, P558, DOI 10.1016/j.ajo.2005.10.045
   Rojo LE, 2008, ARCH MED RES, V39, P1, DOI 10.1016/j.arcmed.2007.10.001
   Saadani-Makki F, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.090
   Sadekar S, 2011, BIOMACROMOLECULES, V12, P88, DOI 10.1021/bm101046d
   Sarin H, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-80
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   THANOS S, 1992, BRAIN RES, V588, P21, DOI 10.1016/0006-8993(92)91340-K
   Tomalia DA, 2009, J NANOPART RES, V11, P1251, DOI 10.1007/s11051-009-9632-z
   TSO MOM, 1994, INVEST OPHTH VIS SCI, V35, P2693
   Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0
   Vandamme TF, 2005, J CONTROL RELEASE, V102, P23, DOI 10.1016/j.jconrel.2004.09.015
   Velazquez AJ, 2004, ARCH OPHTHALMOL-CHIC, V122, P867, DOI 10.1001/archopht.122.6.867
   Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653
   Zeng HY, 2005, INVEST OPHTH VIS SCI, V46, P2992, DOI 10.1167/iovs.05-0118
NR 58
TC 135
Z9 140
U1 1
U2 47
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 2012
VL 33
IS 3
BP 979
EP 988
DI 10.1016/j.biomaterials.2011.10.010
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 864BQ
UT WOS:000298212400027
PM 22048009
DA 2022-11-30
ER

PT J
AU Ravikrishnan, R
   Rusia, S
   Ilamurugan, G
   Salunkhe, U
   Deshpande, J
   Shankaranarayanan, J
   Shankaranarayana, ML
   Soni, MG
AF Ravikrishnan, R.
   Rusia, Shraddha
   Ilamurugan, G.
   Salunkhe, Ulhas
   Deshpande, Jayant
   Shankaranarayanan, J.
   Shankaranarayana, M. L.
   Soni, Madhu G.
TI Safety assessment of lutein and zeaxanthin (Lutemax (TM) 2020):
   Subchronic toxicity and mutagenicity studies
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Lutein; Zeaxanthin; Food ingredient; Safety; Toxicity
ID CAROTENOIDS; SUPPLEMENTATION
AB Lutein and zeaxanthin, naturally occurring carotenoids, have shown to reduce the risk of cataracts and age-related macular degeneration. Lutemax (TM) 2020 is a lutein and zeaxanthin (including meso-isomer) enriched product obtained from Marigold flowers (Tagetes erecta L). The objective of the present study was to investigate adverse effects, if any, of Lutemax 2020 (TM) in acute and subchronic toxicity, and mutagenicity studies. In acute toxicity study in rats no lethality was noted at 2000 mg Lutemax 2020 (TM)/kg body weight (bw). In the subchronic study. Wistar rats (10/sex/group) were administered (gavage) lutein/zeaxanthin concentrate at dose levels of 0, 4, 40 and 400 mg/kg bw/day for 90-days. Compared with the control group, administration of lutein/zeaxanthin concentrate did not result in any toxicologically significant treatment-related changes in clinical observations, ophthalmic examinations, body weights, body weight gains, feed consumption, and organ weights. No toxicologically relevant findings were noted in urinalysis, hematology or clinical biochemistry parameters at the end of the treatment or recovery period. Terminal necropsy did not reveal any treatment-related gross or histopathology findings. The results of mutagenicity testing in Salmonella typhimurium did not reveal any genotoxicity. The no observed-adverse-effect level (NOAEL) for lutein/zeaxanthin concentrate was determined as 400 mg/kg bw/day, the highest dose tested. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Soni, Madhu G.] Soni & Associates Inc, Vero Beach, FL 32960 USA.
   [Ravikrishnan, R.; Rusia, Shraddha; Ilamurugan, G.] RCC Labs India Pvt Ltd, Genome Valley, Hyderabad 500078, AP, India.
   [Salunkhe, Ulhas; Deshpande, Jayant; Shankaranarayanan, J.; Shankaranarayana, M. L.] OmniAct Hlth Technol Ltd, Thane W 400607, India.
RP Soni, MG (通讯作者)，Soni & Associates Inc, 973,37th Pl, Vero Beach, FL 32960 USA.
EM sonim@bellsouth.net
CR BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Calvo MM, 2005, CRIT REV FOOD SCI, V45, P671, DOI 10.1080/10408690590957034
   Chang C. J. G., 2006, 1 INT S WIR PARV COM
   EFSA, 2010, EFSA J, V8, P1483, DOI [10. 2903/j, DOI 10.2903/J.EFSA.2010.1483]
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Hendler S. S., 2001, PDR NUTR SUPPLEMENTS, P281
   JECFA, 2004, LUT TAG ER SUMM EV P
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5476, DOI 10.1167/iovs.06-0194
   Kumar D.P., 2009, TOXICOL INT, V16, P55
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   OM I., 2000, DIETARY REFERENCE IN, P325
   Omaye ST, 1997, FUND APPL TOXICOL, V40, P163, DOI 10.1006/faat.1997.2387
   Preethi KC, 2008, INT J TOXICOL, V27, P1, DOI 10.1080/10915810701876265
   RiceEvans CA, 1997, FREE RADICAL RES, V26, P381, DOI 10.3109/10715769709097818
   Sajilata MG, 2008, COMPR REV FOOD SCI F, V7, P29, DOI 10.1111/j.1541-4337.2007.00028.x
   Shao A, 2006, REGUL TOXICOL PHARM, V45, P289, DOI 10.1016/j.yrtph.2006.05.007
   Sies H, 2003, INT J VITAM NUTR RES, V73, P95, DOI 10.1024/0300-9831.73.2.95
   US FDA, 2004, 000140 US FDA GRN
   van het Hof KH, 1999, AM J CLIN NUTR, V70, P261
NR 25
TC 40
Z9 43
U1 2
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD NOV
PY 2011
VL 49
IS 11
BP 2841
EP 2848
DI 10.1016/j.fct.2011.08.011
PG 8
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA 843OM
UT WOS:000296681600015
PM 21872637
DA 2022-11-30
ER

PT J
AU Tang, WW
   Wu, XB
   Jiang, R
   Li, YD
AF Tang, Wanwan
   Wu, Xuebing
   Jiang, Rui
   Li, Yanda
TI Epistatic Module Detection for Case-Control Studies: A Bayesian Model
   with a Gibbs Sampling Strategy
SO PLOS GENETICS
LA English
DT Article
ID INTERNATIONAL HAPMAP PROJECT; DIRICHLET PROCESS MIXTURE; AGE-RELATED
   MACULOPATHY; COMPLEMENT FACTOR-H; MACULAR DEGENERATION; GENETIC
   ASSOCIATION; QUANTITATIVE TRAITS; DRUSEN FORMATION; POLYMORPHISMS;
   FIBULIN-1
AB The detection of epistatic interactive effects of multiple genetic variants on the susceptibility of human complex diseases is a great challenge in genome-wide association studies (GWAS). Although methods have been proposed to identify such interactions, the lack of an explicit definition of epistatic effects, together with computational difficulties, makes the development of new methods indispensable. In this paper, we introduce epistatic modules to describe epistatic interactive effects of multiple loci on diseases. On the basis of this notion, we put forward a Bayesian marker partition model to explain observed case-control data, and we develop a Gibbs sampling strategy to facilitate the detection of epistatic modules. Comparisons of the proposed approach with three existing methods on seven simulated disease models demonstrate the superior performance of our approach. When applied to a genome-wide case-control data set for Age-related Macular Degeneration (AMD), the proposed approach successfully identifies two known susceptible loci and suggests that a combination of two other loci-one in the gene SGCD and the other in SCAPER-is associated with the disease. Further functional analysis supports the speculation that the interaction of these two genetic variants may be responsible for the susceptibility of AMD. When applied to a genome-wide case-control data set for Parkinson's disease, the proposed method identifies seven suspicious loci that may contribute independently to the disease.
C1 [Tang, Wanwan] Tsinghua Univ, MOE Key Lab Bioinformat, Beijing 100084, Peoples R China.
   Tsinghua Univ, Bioinformat Div, TNLIST, Beijing 100084, Peoples R China.
   Tsinghua Univ, Dept Automat, Beijing 100084, Peoples R China.
C3 Tsinghua University; Tsinghua University; Tsinghua University
RP Tang, WW (通讯作者)，Tsinghua Univ, MOE Key Lab Bioinformat, Beijing 100084, Peoples R China.
EM ruijiang@tsinghua.edu.cn; daulyd@tsinghua.edu.cn
RI Sander-Effron, Samuel/AAX-2231-2020; Wu, Xuebing/C-7189-2008; Resource
   Center, NINDS Human Genetics/AGF-2474-2022; Wu, Xuebing/C-9152-2013;
   Jiang, Rui/B-1345-2012
OI Wu, Xuebing/0000-0003-0369-5269; Jiang, Rui/0000-0002-7533-3753
FU Natural Science Foundation of China [60805010, 60234020, 60572086,
   60575014]; Hi-Tech Research and Development Program of China
   [2006AA02Z325]; National Basic Research Program of China [2004CB518605];
   Tsinghua National Laboratory for Information Science and Technology (
   TNLIST) Cross-discipline Foundation; Research Fund for the Doctoral
   Program of Higher Education of China; Scientific Research Foundation for
   Returned Overseas Chinese Scholars; Tsinghua University
FX This work was partly supported by Natural Science Foundation of China
   grants 60805010, 60234020, 60572086 and 60575014, the Hi-Tech Research
   and Development Program of China ( 863 program) grant 2006AA02Z325, the
   National Basic Research Program of China ( 973 program) grant
   2004CB518605, Tsinghua National Laboratory for Information Science and
   Technology ( TNLIST) Cross-discipline Foundation, Research Fund for the
   Doctoral Program of Higher Education of China, Scientific Research
   Foundation for Returned Overseas Chinese Scholars, and a starting up
   supporting plan at Tsinghua University. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BOTSTEIN D, 1980, AM J HUM GENET, V32, P314
   Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543
   Chatterjee N, 2006, AM J HUM GENET, V79, P1002, DOI 10.1086/509704
   Cho YM, 2004, DIABETOLOGIA, V47, P549, DOI 10.1007/s00125-003-1321-3
   Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316
   Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7
   Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463
   Culverhouse R, 2004, GENET EPIDEMIOL, V27, P141, DOI 10.1002/gepi.20006
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109
   Draviam RA, 2006, MUSCLE NERVE, V34, P691, DOI 10.1002/mus.20640
   Dufault VM, 2003, GENOMICS, V82, P644, DOI 10.1016/S0888-7543(03)00200-3
   Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Fung HC, 2006, LANCET NEUROL, V5, P911, DOI 10.1016/S1474-4422(06)70578-6
   Gambaro G, 2000, LANCET, V355, P308, DOI 10.1016/S0140-6736(99)07202-5
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Green PJ, 1995, BIOMETRIKA, V82, P711, DOI 10.1093/biomet/82.4.711
   Hoh J, 2001, GENOME RES, V11, P2115, DOI 10.1101/gr.204001
   Ishwaran H, 2001, J AM STAT ASSOC, V96, P161, DOI 10.1198/016214501750332758
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jain S, 2004, J COMPUT GRAPH STAT, V13, P158, DOI 10.1198/1061860043001
   JASON H, 2005, BIOESSAYS, V27, P637
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KRUGLYAK L, 1995, AM J HUM GENET, V57, P439
   Laura V, 2007, MOL CELL PROBE, V21, P405, DOI 10.1016/j.mcp.2007.04.001
   Lee NV, 2005, J BIOL CHEM, V280, P34796, DOI 10.1074/jbc.M506980200
   Lotery AJ, 1999, AM J HUM GENET, V65, pA459
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035
   Millstein J, 2006, AM J HUM GENET, V78, P15, DOI 10.1086/498850
   MORTON NE, 1955, AM J HUM GENET, V7, P277
   Neal RM, 2000, J COMPUT GRAPH STAT, V9, P249, DOI 10.2307/1390653
   Nelson MR, 2001, GENOME RES, V11, P458, DOI 10.1101/gr.172901
   Niu TH, 2002, AM J HUM GENET, V70, P157, DOI 10.1086/338446
   Pearson CE, 2005, NAT REV GENET, V6, P729, DOI 10.1038/nrg1689
   RISCH N, 1996, SCIENCE, V273, P1517
   Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   RONALD K, 2004, AM J OPHTHALMOL, V137, P486
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Simon-Sanchez J, 2007, HUM MOL GENET, V16, P1, DOI 10.1093/hmg/ddl436
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199
   TIRET L, 1994, LANCET, V344, P910, DOI 10.1016/S0140-6736(94)92268-3
   Tsai CT, 2004, CIRCULATION, V109, P1640, DOI 10.1161/01.CIR.0000124487.36586.26
   Tsang WY, 2007, J CELL BIOL, V178, P621, DOI 10.1083/jcb.200701166
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   WEEKS DE, 1992, AM J HUM GENET, V50, P859
   Weigell-Weber M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1184, DOI 10.1001/archopht.121.8.1184
   WILLIAMS SM, 2004, HUM HERED, V57
   Wollenhaupt M, 2002, J AAPOS, V6, P49, DOI 10.1067/mpa.2002.120642
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang Y, 2007, NAT GENET, V39, P1167, DOI 10.1038/ng2110
NR 60
TC 71
Z9 80
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAY
PY 2009
VL 5
IS 5
AR e1000464
DI 10.1371/journal.pgen.1000464
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 459EH
UT WOS:000267083000036
PM 19412524
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Stanzel, BV
   Suesskind, D
   Fimmers, R
   Helb, HM
   Eter, N
AF Stanzel, B. V.
   Suesskind, D.
   Fimmers, R.
   Helb, H. -M.
   Eter, N.
TI Reproducibility of macular edema measurements using OCT 3 versus HRT II
   in neovascular AMD
SO SPEKTRUM DER AUGENHEILKUNDE
LA English
DT Article
DE Optical coherence tomography; Heidelberg retina topography; photodynamic
   therapy; age-related macular degeneration; choroidal neovascularization
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL THICKNESS ANALYZER; SCANNING LASER
   TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; FOVEAL THICKNESS;
   DEGENERATION; SURGERY; INDEX; EYES
AB Purpose: To assess reliability of optical coherence tomography (OCT) versus Heidelberg retinal topography (HRT) to record macular alterations without-fluorescein angiography in neovascular AMD.
   Methods: Forty patients with predominantly classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) were examined by OCT, HRT macular module and fluorescein angiography (FA) before, and 6 and 12 weeks following PDT. The changes in retinal thickness in the macular area measured by OCT in 9 fields were compared to the changes in edema index obtained by HRT in corresponding 9 fields. Results were correlated with leakage determined by FA.
   Results: Following treatment, changes in most OCT thickness values were statistically significant at both follow-ups. In contrast, only edema indices measured by HRT II following manual adjustment showed significant differences. Variations in retinal thickness measured by OCT did not correlate with changes in edema index determined by HRT in any of the 9 fields. The presence of leakage on FA showed no correlation with foveal thickness and edema index at any visit.
   Conclusions: The HRT II detected fewer changes in neovascular AMD then the 0073, and may therefore be unreliable for post treatment monitoring. Due to lack of correlation, neither OCT nor HRT is able to replace the primary evaluation of therapeutic success in neovascular AMD by FA.
C1 [Stanzel, B. V.; Helb, H. -M.; Eter, N.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Suesskind, D.] Univ Tubingen, Dept Ophthalmol, Tubingen, Germany.
   [Fimmers, R.] Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-53127 Bonn, Germany.
C3 University of Bonn; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; University of Bonn
RP Eter, N (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM eter@uni-bonn.de
RI Stanzel, Boris/ADP-9221-2022; Stanzel, Boris/AAG-7010-2022
OI Stanzel, Boris/0000-0002-4316-1539; Stanzel, Boris/0000-0002-4316-1539
CR COKER JG, 1998, RETINAL PIGMENT EPIT, P235
   Drexler W, 2007, SPEKTRUM AUGENHEILKD, V21, P3, DOI 10.1007/s00717-006-0173-x
   Eter N, 2004, OPHTHALMOLOGE, V101, P794, DOI 10.1007/s0034-004-1052-y
   Eter N, 2004, OPHTHALMOLOGE, V101, P775, DOI 10.1007/s00347-004-1051-z
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Guan K, 2004, INVEST OPHTH VIS SCI, V45, P610, DOI 10.1167/iovs.03-0313
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEFNER L, 2003, OPHTHALMOLOGE S, V100
   Hudson C, 1998, BRIT J OPHTHALMOL, V82, P121, DOI 10.1136/bjo.82.2.121
   Hudson C, 1997, BRIT J OPHTHALMOL, V81, P107, DOI 10.1136/bjo.81.2.107
   Hudson C, 2003, BRIT J OPHTHALMOL, V87, P455, DOI 10.1136/bjo.87.4.455
   Kim SG, 2003, YONSEI MED J, V44, P821, DOI 10.3349/ymj.2003.44.5.821
   Konno S, 2001, RETINA-J RET VIT DIS, V21, P57, DOI 10.1097/00006982-200102000-00010
   Krebs I, 2007, SPEKTRUM AUGENHEILKD, V21, P33, DOI 10.1007/s00717-006-0169-6
   Neubauer AS, 2001, RETINA-J RET VIT DIS, V21, P596, DOI 10.1097/00006982-200112000-00006
   Nrusimhadevara R, 2003, INVEST OPHTH VIS SCI, V44, pU415
   Pires I, 2002, ARCH OPHTHALMOL-CHIC, V120, P1301, DOI 10.1001/archopht.120.10.1301
   Polito A, 2002, AM J OPHTHALMOL, V134, P240, DOI 10.1016/S0002-9394(02)01528-3
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   VEHR S, 2003, OPHTHALMOLOGE S, V44
NR 22
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-4282
EI 1613-7523
J9 SPEKTRUM AUGENHEILKD
JI Spektrum Augenheilkd.
PY 2009
VL 23
IS 4
BP 277
EP 282
DI 10.1007/s00717-009-0344-7
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 490FQ
UT WOS:000269484700008
DA 2022-11-30
ER

PT J
AU Doukas, J
   Mahesh, S
   Umeda, N
   Kachi, S
   Akiyama, H
   Yokoi, K
   Cao, J
   Chen, Z
   Dellamary, L
   Tam, B
   Racanelli-Layton, A
   Hood, J
   Martin, M
   Noronha, G
   Soll, R
   Campochiaro, PA
AF Doukas, John
   Mahesh, Sankaranarayana
   Umeda, Naoyasu
   Kachi, Shu
   Akiyama, Hideo
   Yokoi, Katsutoshi
   Cao, Jon
   Chen, Zoe
   Dellamary, Luis
   Tam, Betty
   Racanelli-Layton, Adrienne
   Hood, John
   Martin, Michael
   Noronha, Glenn
   Soll, Richard
   Campochiaro, Peter A.
TI Topical administration of a multi-targeted kinase inhibitor suppresses
   choroidal neovascularization and retinal edema
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; PDGF-B;
   EXPRESSION; RANIBIZUMAB; PHENOTYPE; INJURY; FGF2
AB Age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions are complicated by neovascularization and macular edema. Multi-targeted kinase inhibitors that inhibit select growth factor receptor tyrosine kinases and/or components of their downstream signaling cascades (such as Src kinases) are rationale treatment strategies for these disease processes. We describe the discovery and characterization of two such agents. TG100572, which inhibits Src kinases and selected receptor tyrosine kinases, induced apoptosis of proliferating endothelial cells in vitro. Systemic delivery of TG100572 in a murine model of laser-induced choroidal neovascularization (CNV) caused significant suppression of CNV, but with an associated weight loss suggestive of systemic toxicity. To minimize systemic exposure, topical delivery of TG100572 to the cornea was explored, and while substantial levels of TG100572 were achieved in the retina and choroid, superior exposure levels were achieved using TG100801, an inactive prodrug that generates TG100572 by de-esterification. Neither TG100801 nor TG100572 were detectable in plasma following topical delivery of TG100801, and adverse safety signals (such as weight loss) were not observed even with prolonged dosing schedules. Topical TG100801 significantly suppressed laser-induced CNV in mice, and reduced fluorescein leakage from the vasculature and retinal thickening measured by optical coherence tomography in a rat model of retinal vein occlusion. These data suggest that TG100801 may provide a new topically applied treatment approach for ocular neovascularization and retinal edema.
C1 [Umeda, Naoyasu; Kachi, Shu; Akiyama, Hideo; Yokoi, Katsutoshi; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Umeda, Naoyasu; Kachi, Shu; Akiyama, Hideo; Yokoi, Katsutoshi; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
   [Doukas, John; Mahesh, Sankaranarayana; Cao, Jon; Chen, Zoe; Dellamary, Luis; Tam, Betty; Racanelli-Layton, Adrienne; Hood, John; Martin, Michael; Noronha, Glenn; Soll, Richard] TargeGen Inc, San Diego, CA USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
OI Umeda, Naoyasu/0000-0001-5814-8356
FU NATIONAL EYE INSTITUTE [R01EY012609] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY012609-08, R01 EY012609] Funding Source: Medline
CR Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   CAMPOCHIARO PA, 2008, MOL THER
   Campochiaro PA, 2007, J CELL PHYSIOL, V210, P575, DOI 10.1002/jcp.20893
   de Jonge MJA, 2006, EUR J CANCER, V42, P1351, DOI 10.1016/j.ejca.2006.02.013
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Fukuchi T, 2001, GRAEF ARCH CLIN EXP, V239, P41, DOI 10.1007/s004170000205
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HACKETT RB, 1996, DERMATOXICOLOGY
   Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298
   Horio N, 2001, ARCH OPHTHALMOL-CHIC, V119, P1329
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2001
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Noronha G, 2006, BIOORG MED CHEM LETT, V16, P5546, DOI 10.1016/j.bmcl.2006.08.035
   Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3
   Sho K, 2005, JPN J OPHTHALMOL, V49, P109, DOI 10.1007/s10384-004-0150-3
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
NR 28
TC 55
Z9 72
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2008
VL 216
IS 1
BP 29
EP 37
DI 10.1002/jcp.21426
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 311LD
UT WOS:000256600800004
PM 18330892
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Taban, M
   Singh, RP
   Chung, JYH
   Lowder, CY
   Perez, VL
   Kaiser, PK
AF Taban, Mehryar
   Singh, Rishi P.
   Chung, Jeffrey Yau-Huei
   Lowder, Careen Y.
   Perez, Victor L.
   Kaiser, Peter K.
TI Sterile Endophthalmitis after intravitreal triamcinolone: A possible
   association with uveitis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NONINFECTIOUS ENDOPHTHALMITIS; ACETONIDE INJECTION; MACULAR EDEMA
AB PURPOSE: To report an association between uveitis and sterile endophthalmitis after intravitreal triamcinolone acetonide injection.
   DESIGN: Retrospective case series.
   METHODS: A retrospective analysis of all patients receiving intravitreal triamcinolone injection at the Cole Eye Institute from January 2006 through September 2006 was carried out to evaluate for the occurrence of bacterial or sterile endophthalmitis. Indication for treatment, ocular history, best-corrected Snellen visual acu- ity, and clinical examination findings were recorded from the clinical charts before injection and at last follow,up.
   RESULTS: A total of 310 eyes received intravitreal triamcinolone injection for various causes, including age,related macular degeneration (AMD), diabetic reti, nopathy, vascular occlusion, and cystoid macular edema (CME) resulting from uveitis. There were no cases of culture-positive infectious endophthalmitis. There were six cases (1.9%) of sterile endophthalmitis. Of these six cases, four had prior history of uveitis, whereas only 20 of the 310 cases had a prior history of uveitis. All six patients sought treatment within three days of injection, and all recovered rapidly. Presenting visual acuity was either counting fingers or hand movements. Median best-corrected visual acuity before injection was 20/ 100(+), whereas median final visual acuity was 20/80(-).
   CONCLUSIONS: Patients with a history of uveitis may be at increased risk of experiencing sterile endophthalmitis resulting from intravitreal triamcinolone injection.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Taban, M (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
RI Perez, Victor L./AAY-8633-2020
OI Kaiser, Peter/0000-0001-5126-045X
CR Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   Bandi N, 2001, EUR J PHARMACOL, V425, P109, DOI 10.1016/S0014-2999(01)01192-X
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   FLOMAN N, 1977, INVEST OPHTH VIS SCI, V16, P69
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   Jonas JB, 2006, AM J OPHTHALMOL, V141, P579, DOI 10.1016/j.ajo.2005.10.007
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Moshfeghi DM, 2005, OPHTHAL SURG LAS IM, V36, P24
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Ozkiris A, 2005, CAN J OPHTHALMOL, V40, P63, DOI 10.1016/S0008-4182(05)80119-X
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Wang LC, 2005, OCUL IMMUNOL INFLAMM, V13, P295, DOI 10.1080/09273940590951007
   Westfall AC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1075, DOI 10.1001/archopht.123.8.1075
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
NR 16
TC 28
Z9 29
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2007
VL 144
IS 1
BP 50
EP 54
DI 10.1016/j.ajo.2007.03.051
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 187SD
UT WOS:000247867800008
PM 17601427
DA 2022-11-30
ER

PT J
AU Barile, GR
   Schmidt, AM
AF Barile, Gaetano R.
   Schmidt, Ann M.
TI RAGE and its ligands in retinal disease
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
ID GLYCATION END-PRODUCTS; ENDOTHELIAL GROWTH-FACTOR; FACTOR-H
   POLYMORPHISM; SIGNALING PATHWAYS; DIABETIC-RETINOPATHY;
   CELL-PROLIFERATION; FACTOR EXPRESSION; UP-REGULATION; CO-LOCALIZE;
   RECEPTOR
AB RAGE, the receptor for advanced glycation endproducts (AGEs), is a multiligand signal transduction receptor of the immunoglobulin superfamily of cell surface molecules that has been implicated in the pathogenesis of diabetic complications, neurodegenerative diseases, inflammatory disorders, and cancer. These diverse biologic disorders reflect the multiplicity of ligands capable of cellular interaction via RAGE that include, in addition to AGEs, amyloid-beta (A beta) peptide, the S100/calgranulin family of proinflammatory cytokines, and amphoterin, a member of the High Mobility Group Box (HMGB) DNA-binding proteins. In the retina, RAGE expression is present in neural cells, the vasculature, and RPE cells, and it has also been detected in pathologic cellular retinal responses including epiretinal and neovascular membrane formation. Ligands for RAGE, in particular AGEs, have emerged as relevant to the pathogenesis of diabetic retinopathy and age-related macular disease. While the understanding of RAGE and its role in retinal dysfunction with aging, diabetes mellitus, and/or activation of pro-inflammatory pathways is less complete compared to other organ systems, increasing evidence indicates that RAGE can initiate and sustain significant cellular perturbations in the inner and outer retina. For these reasons, antagonism of RAGE interactions with its ligands may be a worthwhile therapeutic target in such seemingly disparate, visually threatening retinal diseases as diabetic retinopathy, age-related macular degeneration, and proliferative vitreoretinopathy.
C1 [Barile, Gaetano R.; Schmidt, Ann M.] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
C3 Columbia University
RP Barile, GR (通讯作者)，Columbia Univ, Dept Ophthalmol, 635 W 165 St, New York, NY 10032 USA.
EM grb17@columbia.edu
CR [Anonymous], 1995, DIABETES, V44, P968
   Barile GR, 2005, INVEST OPHTH VIS SCI, V46, P2916, DOI 10.1167/iovs.04-1409
   Chen BH, 2006, LIFE SCI, V79, P1040, DOI 10.1016/j.lfs.2006.03.020
   Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657
   Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Genuth S, 2005, DIABETES, V54, P3103, DOI 10.2337/diabetes.54.11.3103
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammes HP, 1999, DIABETOLOGIA, V42, P728, DOI 10.1007/s001250051221
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann
   Hirata C, 1997, BIOCHEM BIOPH RES CO, V236, P712, DOI 10.1006/bbrc.1997.7036
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135
   Hughes SJ, 2004, MOL VIS, V10, P996
   Huttunen HJ, 2004, J INTERN MED, V255, P351, DOI 10.1111/j.1365-2796.2003.01301.x
   Kaji Y, 2003, INVEST OPHTH VIS SCI, V44, P521, DOI 10.1167/iovs.02-0268
   Kaji Y, 2007, INVEST OPHTH VIS SCI, V48, P858, DOI 10.1167/iovs.06-0495
   Kern TS, 2001, DIABETES, V50, P1636, DOI 10.2337/diabetes.50.7.1636
   Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kobayashi T, 2005, EXP EYE RES, V81, P647, DOI 10.1016/j.exer.2005.04.001
   Lieth E, 2000, CLIN EXP OPHTHALMOL, V28, P3, DOI 10.1046/j.1442-9071.2000.00222.x
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Mamputu JC, 2004, DIABETES OBES METAB, V6, P95, DOI 10.1111/j.1462-8902.2004.00320.x
   Mandelcorn E, 2003, CAN J OPHTHALMOL, V38, P457, DOI 10.1016/S0008-4182(03)80023-6
   Marx N, 2004, DIABETES, V53, P2662, DOI 10.2337/diabetes.53.10.2662
   Moore TCB, 2003, INVEST OPHTH VIS SCI, V44, P4457, DOI 10.1167/iovs.02-1063
   Nakamura N, 2003, DIABETES RES CLIN PR, V61, P93, DOI 10.1016/S0168-8227(03)00109-8
   Pachydaki SI, 2006, EXP EYE RES, V82, P807, DOI 10.1016/j.exer.2005.09.022
   Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012
   Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053
   Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180
   SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987
   SEBAG J, 1993, GRAEF ARCH CLIN EXP, V231, P257, DOI 10.1007/BF00919101
   Shannon H, 2000, NEW ENGL J MED, V342, P381
   Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725
   Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826
   Stitt Alan W., 2000, Molecular Cell Biology Research Communications, V3, P380, DOI 10.1006/mcbr.2000.0243
   Stitt AW, 2005, DIABETES, V54, P785, DOI 10.2337/diabetes.54.3.785
   Stitt AW, 2003, EXP MOL PATHOL, V75, P95, DOI 10.1016/S0014-4800(03)00035-2
   Stitt AW, 1997, AM J PATHOL, V150, P523
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   TURNER RC, 1991, DIABETOLOGIA, V34, P877
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   Valencia JV, 2004, DIABETOLOGIA, V47, P844, DOI 10.1007/s00125-004-1392-9
   VINORES SA, 1990, INVEST OPHTH VIS SCI, V31, P14
   Wilton R, 2006, PROTEIN EXPRES PURIF, V47, P25, DOI 10.1016/j.pep.2006.01.008
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yamagishi S, 2005, FEBS LETT, V579, P4265, DOI 10.1016/j.febslet.2005.06.058
   Yan Shi-Fang, 2004, Diab Vasc Dis Res, V1, P10, DOI 10.3132/dvdr.2004.001
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang XY, 2005, CURR EYE RES, V30, P395, DOI 10.1080/02713680590956306
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 61
TC 35
Z9 38
U1 1
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2007
VL 7
IS 8
BP 758
EP 765
DI 10.2174/156652407783220778
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 268ON
UT WOS:000253589200008
PM 18331234
DA 2022-11-30
ER

PT J
AU Thiagarajan, M
   Evans, FR
   Smeeth, L
   Wormald, RPL
   Fletcher, AE
AF Thiagarajan, M
   Evans, FR
   Smeeth, L
   Wormald, RPL
   Fletcher, AE
TI Cause-specific visual impairment and mortality - Results from a
   population-based study of older people in the United Kingdom
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID LENS OPACITIES; EYE DISEASE; FOLLOW-UP; CATARACT; ASSOCIATION; SURVIVAL;
   ACUITY; RATES
AB Objective: To assess the association between mortality and cause-specific visual impairment in older people.
   Methods: Visual acuity and causes of visual impairment were collected in 13 569 participants 75 years and older participating in a randomized trial of health screening. Participants were followed up for mortality for a median of 6.1 years.
   Results: Compared with those with 6/6 (or 20/20 Snellen) or better visual acuity, the age- and sex-adjusted rate ratio for visually impaired people (binocular visual acuity < 6/18 or < 20/60 Snellen) was 1.60 (95% confidence interval, 1.47-1.74), which was markedly attenuated (rate ratio, 1.17; 95% confidence interval, 1.07-1.27) after adjustment for confounding factors. People whose visual impairment was due to cataract or age-related macular degeneration had excess risks of all-cause and cardiovascular mortality, which disappeared after adjustment. People with refractive error remained at small risk, despite adjustment, probably owing to residual confounding from factors associated with minimal use of eye services rather than underlying eye disease. There were no associations with cancer mortality.
   Conclusion: Associations reported for visual impairment and mortality or for specific causes of visual impairment reflect confounding by comorbidities, risk factors, and other factors related to susceptibility to death rather than an independent biological association of vision problems or specific eye diseases.
C1 London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   Moorfields Eye Hosp, London, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Fletcher, AE (通讯作者)，London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI Evans, Jennifer/F-4672-2012; Smeeth, Liam/X-5862-2018
OI Evans, Jennifer/0000-0002-6137-2030; Smeeth, Liam/0000-0002-9168-6022
FU MRC [G108/492] Funding Source: UKRI; Medical Research Council [G108/492]
   Funding Source: Medline
CR APPOLLONIO I, 1995, AGE AGEING, V24, P30, DOI 10.1093/ageing/24.1.30
   BENSON WH, 1988, OPHTHALMOLOGY, V95, P1288
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162
   Christen W G, 2000, Ophthalmic Epidemiol, V7, P115, DOI 10.1076/0928-6586(200006)7:2;1-Z;FT115
   Cochran WG., 2007, SAMPLING TECHNIQUES
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fletcher AE, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-21
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Hennis A, 2001, OPHTHALMOLOGY, V108, P498, DOI 10.1016/S0161-6420(00)00542-X
   HIRSCH RP, 1983, ARCH OPHTHALMOL-CHIC, V101, P1034
   Hu FB, 2001, AM J EPIDEMIOL, V153, P875, DOI 10.1093/aje/153.9.875
   JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Knudsen EB, 1999, ACTA OPHTHALMOL SCAN, V77, P99, DOI 10.1034/j.1600-0420.1999.770122.x
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   MCGRAW PV, 1993, OPHTHAL PHYSL OPT, V13, P400, DOI 10.1111/j.1475-1313.1993.tb00499.x
   McGwin G, 2003, OPHTHALMIC EPIDEMIOL, V10, P107, DOI 10.1076/opep.10.2.107.13900
   Meddings DR, 1999, EPIDEMIOLOGY, V10, P288, DOI 10.1097/00001648-199905000-00017
   MINASSIAN DC, 1992, B WORLD HEALTH ORGAN, V70, P219
   Ostbye T, 1999, J AM GERIATR SOC, V47, P1249, DOI 10.1111/j.1532-5415.1999.tb05207.x
   Reidy A, 2002, BRIT J OPHTHALMOL, V86, P424, DOI 10.1136/bjo.86.4.424
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Reuben DB, 1999, J AM GERIATR SOC, V47, P930, DOI 10.1111/j.1532-5415.1999.tb01286.x
   Rose G.A., 1982, CARDIOVASCULAR SURVE
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   *STAT CORP LP, 2001, STAT 8 COMP PROGR
   THOMPSON JR, 1989, AGE AGEING, V18, P83, DOI 10.1093/ageing/18.2.83
   THOMPSON JR, 1993, ARCH OPHTHALMOL-CHIC, V111, P675, DOI 10.1001/archopht.1993.01090050109039
   VARMA R, 2004, ANN M ASS RES VIS OP
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   West SK, 2000, ARCH OPHTHALMOL-CHIC, V118, P393, DOI 10.1001/archopht.118.3.393
   Williams SL, 2002, AM J EPIDEMIOL, V156, P127, DOI 10.1093/aje/kwf012
   Yablonski ME, 2001, ARCH OPHTHALMOL-CHIC, V119, P1562
NR 35
TC 57
Z9 58
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2005
VL 123
IS 10
BP 1397
EP 1403
DI 10.1001/archopht.123.10.1397
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 973DI
UT WOS:000232502700012
PM 16219731
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Lambert, V
   Munaut, C
   Carmeliet, P
   Gerard, RD
   Declerck, P
   Gils, A
   Claes, C
   Foidart, JM
   Noel, A
   Rakic, JM
AF Lambert, V
   Munaut, C
   Carmeliet, P
   Gerard, RD
   Declerck, P
   Gils, A
   Claes, C
   Foidart, JM
   Noel, A
   Rakic, JM
TI Dose-dependent modulation of choroidal neovascularization by plasminogen
   activator inhibitor type 1: Implications for clinical trials
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; TUMOR-GROWTH; UROKINASE RECEPTOR;
   ENDOTHELIAL-CELLS; GENE; ANGIOGENESIS; EXPRESSION; MICE; SERPIN; MODEL
AB PURPOSE. To explain the conflicting reports about the influence of plasminogen activator inhibitor type (PAI-1) on pathologic angiogenesis, such as occurs during the exudative form of age-related macular degeneration.
   METHODS. The expression of PAI-1 mRNA was analyzed in human and murine choroidal neovascularization (CNV) by RTPCR. The influences of increasing doses of recombinant PAI-1 were evaluated by daily intraperitoneal injections in PAI-1-1-and wild-type animals with a model of laser-induced CNV. The double mechanism of action of PAI-1 (proteolytic activity inhibition versus vitronectin binding) was explored by immunohistochemical localization of fibrinogen/fibrin and by injection of recombinant PAI-1 protein defective for vitronectin binding or with adenoviral vectors bearing a mutated binding-deficient PAI-1 gene.
   RESULTS. PAI-1 expression was present in human CNV and strongly induced in the course of experimental subretinal neovascularization. Daily injections of recombinant PAI-1 proteins in control and PAI-1(-/-) animals demonstrated that PAI-1 could exhibit both pro- and antiangiogenic effects, dependent on the dose. PAI-1 mutants defective for vitronectin binding were used to show that PAI-1 promotes choroidal pathologic angiogenesis merely through its antiproteolytic activity.
   CONCLUSIONS. These observations may help to reconcile reports with opposite results regarding the effects of PAI-1 on angiogenesis and certainly warn against uncontrolled use of PAL I modulating drugs in clinical trials.
C1 Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium.
   Univ Liege, Lab Tumor & Dev Biol, Liege, Belgium.
   Katholieke Univ Leuven, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.
   Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA.
   Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75230 USA.
   Middelheim Hosp, Dept Ophthalmol, Antwerp, Belgium.
C3 University of Liege; University of Liege; KU Leuven; University of Texas
   System; University of Texas Dallas; University of Texas Southwestern
   Medical Center Dallas; University of Texas System; University of Texas
   Dallas; University of Texas Southwestern Medical Center Dallas; ZNA
   Middelheim Hospital
RP Rakic, JM (通讯作者)，Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium.
EM jmrakic@chu.ulg.ac.be
RI Munaut, Carine/K-8138-2019; Declerck, Paul J/A-2330-2017; Carmeliet,
   Peter/AAQ-5140-2020
OI Declerck, Paul J/0000-0003-1259-9105; Carmeliet,
   Peter/0000-0001-7961-1821; Noel, Agnes/0000-0002-7670-6179
CR Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497
   Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923
   BEHRINGER RR, 1993, DEVELOPMENT, V117, P823
   BLEI F, 1993, J CELL PHYSIOL, V155, P568, DOI 10.1002/jcp.1041550315
   Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P503, DOI 10.1080/20014091111785
   Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180
   CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892
   COMI P, 1995, EXP CELL RES, V219, P304, DOI 10.1006/excr.1995.1232
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DEFALLER JM, 2000, PTERYGIUM, P159
   Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   GERARD RD, 1995, DNA CLONING PRACTICA, P285
   Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d
   Grant MB, 1996, EXP EYE RES, V63, P233, DOI 10.1006/exer.1996.0112
   Gutierrez LS, 2000, CANCER RES, V60, P5839
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413
   Masos T, 2000, INVEST OPHTH VIS SCI, V41, P1006
   McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200
   MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324
   Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y
   PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117
   PIOPLIS VA, 1998, BLOOD, V91, P2005
   PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rakic JM, 2003, CELL MOL LIFE SCI, V60, P463, DOI 10.1007/s000180300039
   Simpson-Haidaris PJ, 2001, ANN NY ACAD SCI, V936, P406
   Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323
   SOUBRANE G, 2002, OPHTHALMIC RES, V34, P3312
   Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0
   Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521
NR 39
TC 40
Z9 43
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2003
VL 44
IS 6
BP 2791
EP 2797
DI 10.1167/iovs.02-1179
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 682FU
UT WOS:000183081700058
PM 12766088
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Vanhove, M
   Wagner, JM
   Noppen, B
   Jonckx, B
   Vermassen, E
   Stitt, AW
AF Vanhove, Marc
   Wagner, Jean-Marc
   Noppen, Bernard
   Jonckx, Bart
   Vermassen, Elke
   Stitt, Alan W.
TI Systemic exposure following intravitreal administration of therapeutic
   agents: an integrated pharmacokinetic approach. 2. THR-687
SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
LA English
DT Article
DE Intravitreal administration; Systemic exposure; Integrated
   pharmacokinetics
ID DRUG; RANIBIZUMAB; CLEARANCE; EYE; MODEL
AB Intravitreal (IVT) injection remains the preferred administration route of pharmacological agents intended for the treatment of back of the eye diseases such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nvAMD). The procedure enables drugs to be delivered locally at high concentrations whilst limiting whole body exposure and associated risk of systemic adverse events. Nevertheless, intravitreally-delivered drugs do enter the general circulation and achieving an accurate understanding of systemic exposure is pivotal for the evaluation and development of drugs administered in the eye. We report here the full pharmacokinetic properties of THR-687, a pan RGD integrin antagonist currently in clinical development for the treatment of DME, in both rabbit and minipig. Pharmacokinetic characterization included description of vitreal elimination, of systemic pharmacokinetics, and of systemic exposure following IVT administration. For the latter, we present a novel pharmacokinetic model that assumes clear partition between the vitreous humor compartment itself where the drug is administered and the central systemic compartment. We also propose an analytical solution to the system of differential equations that represent the pharmacokinetic model, thereby allowing data analysis with standard nonlinear regression analysis. The model accurately describes circulating levels of THR-687 following IVT administration in relevant animal models, and we suggest that this approach is relevant to a range of drugs and analysis of subsequent systemic exposure.
C1 [Vanhove, Marc; Noppen, Bernard; Jonckx, Bart; Vermassen, Elke; Stitt, Alan W.] Oxurion NV, Gaston Geenslaan 1, B-3001 Leuven, Belgium.
   [Wagner, Jean-Marc] Haute Ecole Prov Liege, Ave Montesquieu 6, B-4101 Seraing, Belgium.
   [Stitt, Alan W.] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland.
C3 Queens University Belfast
RP Vanhove, M (通讯作者)，Oxurion NV, Gaston Geenslaan 1, B-3001 Leuven, Belgium.
EM marc.vanhove@oxurion.com
OI Stitt, Alan/0000-0002-8647-9918
CR Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   del Amo EM, 2015, EUR J PHARM BIOPHARM, V95, P215, DOI 10.1016/j.ejpb.2015.01.003
   del Amo EM, 2015, EXP EYE RES, V137, P111, DOI 10.1016/j.exer.2015.05.003
   Deng WY, 2020, QUANT IMAG MED SURG, V10, P1, DOI 10.21037/qims.2019.11.18
   Dias CS, 2002, J PHARM SCI, V91, P660, DOI 10.1002/jps.10072
   Duvvuri S, 2004, CURR DRUG METAB, V5, P507, DOI 10.2174/1389200043335342
   Gurreri A, 2021, ADV EXP MED BIOL, V1307, P375, DOI 10.1007/5584_2020_535
   Hirano T, 2018, RETINA-J RET VIT DIS, V38, P1801, DOI 10.1097/IAE.0000000000002004
   Holford Nick, 2016, Translational and Clinical Pharmacology, V24, P74
   Hu TT, 2019, EXP EYE RES, V180, P43, DOI 10.1016/j.exer.2018.11.022
   HULL CJ, 1979, BRIT J ANAESTH, V51, P579, DOI 10.1093/bja/51.7.579
   Kowluru RA, 2011, INVEST OPHTH VIS SCI, V52, P8665, DOI 10.1167/iovs.10-6768
   Lippi I, 2019, AM J VET RES, V80, P525, DOI 10.2460/ajvr.80.6.525
   Rogers CA, 2018, OPHTHALMOL RETINA, V2, P118, DOI 10.1016/j.oret.2017.05.015
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Wang WQ, 2016, MOL PHARMACEUT, V13, P2881, DOI 10.1021/acs.molpharmaceut.6b00056
   Wang XW, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw3210
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yucel Y, 2015, PROG BRAIN RES, V220, P185, DOI 10.1016/bs.pbr.2015.07.028
   Zhang Y, 2014, OPHTHALMOLOGY, V121, P2237, DOI 10.1016/j.ophtha.2014.05.012
NR 23
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1567-567X
EI 1573-8744
J9 J PHARMACOKINET PHAR
JI J. Pharmacokinet. Pharmacodyn.
PD DEC
PY 2021
VL 48
IS 6
BP 837
EP 849
DI 10.1007/s10928-021-09774-9
EA JUL 2021
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XA5AW
UT WOS:000676090900001
PM 34302261
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Xu, PJ
   Lesmes, LA
   Yu, DY
   Lu, ZL
AF Xu, Pengjing
   Lesmes, Luis Andres
   Yu, Deyue
   Lu, Zhong-Lin
TI Evaluating the Performance of qVFM in Mapping the Visual Field of
   Simulated Observers With Eye Diseases
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE Bayesian adaptive testing; active learning; perimetry; visual-field map;
   scotoma; glaucoma; age-related macular degeneration; cataract
ID BAYESIAN ADAPTIVE ESTIMATION; WAVE-FRONT ABERRATIONS; CONTRAST
   SENSITIVITY; PERIMETRY; THRESHOLD; VISION; CATARACT; FLICKER; SLOPE;
   LIFE
AB Purpose Recently, we developed a novel active learning framework, qVFM, to map visual functions in the visual field. The method has been implemented and validated in measuring light sensitivity and contrast sensitivity visual field maps (VFMs) of normal observers. In this study, we evaluated the performance of the qVFM method in mapping the light sensitivity VFM of simulated patients with peripheral scotoma, glaucoma, age-related macular degeneration (AMD), and cataract. Methods For each simulated patient, we sampled 100 locations (60 x 60 degrees) of the visual field and compared the performance of the qVFM method with a procedure that tests each location independently (the qYN method) in a cued Yes/No task. Two different switch modules, the distribution sampling method (DSM) and parameter delivering method (PDM), were implemented in the qVFM method. Simulated runs of 1,200 trials were used to compare the accuracy and precision of the qVFM-DSM, qVFM-PDM and qYN methods. Results The qVFM method with both switch modules can provide accurate, precise, and efficient assessments of the light sensitivity VFM for the simulated patients, with the qVFM-PDM method better at detecting VFM deficits in the simulated glaucoma. Conclusions The qVFM method can be used to characterize residual vision of simulated ophthalmic patients. The study sets the stage for further investigation with real patients and potential translation of the method into clinical practice.
C1 [Xu, Pengjing; Yu, Deyue] Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA.
   [Xu, Pengjing] Shanghai Technol Dev Co Ltd, Shanghai, Peoples R China.
   [Xu, Pengjing] Shanghai Warsaw Joint Lab Artificial Intelligence, Shanghai, Peoples R China.
   [Lesmes, Luis Andres] Adapt Sensory Technol Inc, San Diego, CA USA.
   [Lu, Zhong-Lin] NYU Shanghai, Div Arts & Sci, Shanghai, Peoples R China.
   [Lu, Zhong-Lin] NYU, Dept Psychol, Ctr Neural Sci, 6 Washington Pl, New York, NY 10003 USA.
   [Lu, Zhong-Lin] NYU Shanghai, NYU ECNU Inst Cognit Neurosci, Shanghai, Peoples R China.
C3 University System of Ohio; Ohio State University; NYU Shanghai; New York
   University; NYU Shanghai
RP Lu, ZL (通讯作者)，NYU Shanghai, Div Arts & Sci, Shanghai, Peoples R China.; Lu, ZL (通讯作者)，NYU, Dept Psychol, Ctr Neural Sci, 6 Washington Pl, New York, NY 10003 USA.; Lu, ZL (通讯作者)，NYU Shanghai, NYU ECNU Inst Cognit Neurosci, Shanghai, Peoples R China.
EM zhonglin@nyu.edu
RI XU, PENGJING/GZM-8511-2022
OI Lu, Zhong-Lin/0000-0002-7295-727X
FU NIH [EY025658, EY021553]
FX This research was supported by NIH grants EY025658 to DY and EY021553 to
   Z-LL.
CR Anderson AJ, 2011, OPTOMETRY VISION SCI, V88, P806, DOI 10.1097/OPX.0b013e31821861bd
   [Anonymous], 2006, VISUAL BRAIN ACTION
   Applegate RA, 2000, J REFRACT SURG, V16, P507
   Applegate RA, 1998, J REFRACT SURG, V14, P397, DOI 10.3928/1081-597X-19980701-05
   Artes PH, 2002, INVEST OPHTH VIS SCI, V43, P2654
   Aulhorn E, 1972, HDB SENSORY PHYSL, V7, P102
   BACHMAN DM, 1992, OPHTHALMOLOGY, V99, P1393
   Bengtsson B, 1998, ACTA OPHTHALMOL SCAN, V76, P268, DOI 10.1034/j.1600-0420.1998.760303.x
   Bengtsson B, 1997, ACTA OPHTHALMOL SCAN, V75, P368
   CAPRIOLI J, 1991, AM J OPHTHALMOL, V111, P235, DOI 10.1016/S0002-9394(14)72266-4
   FENDRICH R, 1992, SCIENCE, V258, P1489, DOI 10.1126/science.1439839
   FLAMMER J, 1985, INVEST OPHTH VIS SCI, V26, P176
   GOLDMANN H, 1945, OPHTHALMOLOGICA, V109, P71, DOI 10.1159/000300225
   GOLDMANN H, 1945, OPHTHALMOLOGICA, V109, P57, DOI 10.1159/000300224
   Gu HR, 2016, J VISION, V16, DOI 10.1167/16.6.15
   HARMS H, 1952, Klin Monbl Augenheilkd Augenarztl Fortbild, V121, P683
   HEIJL A, 1989, AM J OPHTHALMOL, V108, P130, DOI 10.1016/0002-9394(89)90006-8
   IANNACCONE A, 1995, DOC OPHTHALMOL, V90, P129, DOI 10.1007/BF01203333
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   Kim W, 2014, NEURAL COMPUT, V26, P2465, DOI 10.1162/NECO_a_00654
   KINGSMITH PE, 1994, VISION RES, V34, P885, DOI 10.1016/0042-6989(94)90039-6
   KingSmith PE, 1997, VISION RES, V37, P1595, DOI 10.1016/S0042-6989(96)00310-0
   Kontsevich LL, 1999, VISION RES, V39, P2729, DOI 10.1016/S0042-6989(98)00285-5
   LACHENMAYR BJ, 1994, INVEST OPHTH VIS SCI, V35, P2741
   LAM BL, 1991, OPHTHALMOLOGY, V98, P1066
   Lesmes LA, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01070
   Lesmes LA, 2006, VISION RES, V46, P3160, DOI 10.1016/j.visres.2006.04.022
   Lesmes LA, 2010, J VISION, V10, DOI 10.1167/10.3.17
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   MCKEE SP, 1985, PERCEPT PSYCHOPHYS, V37, P286, DOI 10.3758/BF03211350
   Morales J, 2000, OPHTHALMOLOGY, V107, P134, DOI 10.1016/S0161-6420(99)00026-3
   Ng M, 2012, J GLAUCOMA, V21, P551, DOI 10.1097/IJG.0b013e31821dac66
   Oshika T, 1999, INVEST OPHTH VIS SCI, V40, P1351
   Oshika T, 2006, OPHTHALMOLOGY, V113, P1807, DOI 10.1016/j.ophtha.2006.03.061
   Papageorgiou E, 2007, GRAEF ARCH CLIN EXP, V245, P1749, DOI 10.1007/s00417-007-0644-z
   Phu J, 2017, OPHTHAL PHYSL OPT, V37, P160, DOI 10.1111/opo.12355
   PORTNEY GL, 1978, OPHTHALMOLOGY, V85, P287
   RADIUS RL, 1978, ARCH OPHTHALMOL-CHIC, V96, P1574
   Rogers TJ, 2005, J SPORT EXERCISE PSY, V27, P271, DOI 10.1123/jsep.27.3.271
   Smith SD, 1996, INVEST OPHTH VIS SCI, V37, P1419
   Strasburger H, 2011, J VISION, V11, DOI 10.1167/11.5.13
   Thorne JE, 2011, OPHTHALMOLOGY, V118, P895, DOI 10.1016/j.ophtha.2010.09.017
   Townend BS, 2007, J CLIN NEUROSCI, V14, P754, DOI 10.1016/j.jocn.2006.02.022
   van Gaalen KW, 2009, J CATARACT REFR SURG, V35, P47, DOI 10.1016/j.jcrs.2008.09.016
   Weijland A., 2004, AUTOMATED PERIMETRY
   Xu P., 2019, INVEST OPHTHALMOL VI, V60
   Xu PJ, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00665
   Xu PJ, 2019, J VISION, V19, DOI 10.1167/19.14.16
   Xu PJ, 2018, INVEST OPHTH VIS SCI, V59
NR 49
TC 0
Z9 0
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JUN 21
PY 2021
VL 15
AR 596616
DI 10.3389/fnins.2021.596616
PG 23
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA TD7DL
UT WOS:000669482700001
PM 34234636
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lynn, SA
   Johnston, DA
   Scott, JA
   Munday, R
   Desai, RS
   Keeling, E
   Weaterton, R
   Simpson, A
   Davis, D
   Freeman, T
   Chatelet, DS
   Page, A
   Cree, AJ
   Lee, H
   Newman, TA
   Lotery, AJ
   Ratnayaka, JA
AF Lynn, Savannah A.
   Johnston, David A.
   Scott, Jenny A.
   Munday, Rosie
   Desai, Roshni S.
   Keeling, Eloise
   Weaterton, Ruaridh
   Simpson, Alexander
   Davis, Dillon
   Freeman, Thomas
   Chatelet, David S.
   Page, Anton
   Cree, Angela J.
   Lee, Helena
   Newman, Tracey A.
   Lotery, Andrew J.
   Ratnayaka, J. Arjuna
TI Oligomeric A beta(1-42) Induces an AMD-Like Phenotype and Accumulates in
   Lysosomes to Impair RPE Function
SO CELLS
LA English
DT Article
DE retinal pigment epithelium (RPE); amyloid beta (A&#946; ); age-related
   macular degeneration (AMD); aging; autophagy&#8211; lysosomal pathway;
   sight loss
AB Alzheimer's disease-associated amyloid beta (A beta) proteins accumulate in the outer retina with increasing age and in eyes of age-related macular degeneration (AMD) patients. To study A beta-induced retinopathy, wild-type mice were injected with nanomolar human oligomeric A beta(1-42), which recapitulate the A beta burden reported in human donor eyes. In vitro studies investigated the cellular effects of A beta in endothelial and retinal pigment epithelial (RPE) cells. Results show subretinal A beta-induced focal AMD-like pathology within 2 weeks. A beta exposure caused endothelial cell migration, and morphological and barrier alterations to the RPE. A beta co-localized to late-endocytic compartments of RPE cells, which persisted despite attempts to clear it through upregulation of lysosomal cathepsin B, revealing a novel mechanism of lysosomal impairment in retinal degeneration. The rapid upregulation of cathepsin B was out of step with the prolonged accumulation of A beta within lysosomes, and contrasted with enzymatic responses to internalized photoreceptor outer segments (POS). Furthermore, RPE cells exposed to A beta were identified as deficient in cargo-carrying lysosomes at time points that are critical to POS degradation. These findings imply that A beta accumulation within late-endocytic compartments, as well as lysosomal deficiency, impairs RPE function over time, contributing to visual defects seen in aging and AMD eyes.
C1 [Lynn, Savannah A.; Scott, Jenny A.; Munday, Rosie; Desai, Roshni S.; Keeling, Eloise; Weaterton, Ruaridh; Simpson, Alexander; Davis, Dillon; Freeman, Thomas; Cree, Angela J.; Lee, Helena; Newman, Tracey A.; Lotery, Andrew J.; Ratnayaka, J. Arjuna] Univ Southampton, Fac Med, Clin & Expt Sci, MP 806,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Johnston, David A.; Chatelet, David S.; Page, Anton] Univ Southampton, Biomed Imaging Unit, MP12,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Lee, Helena; Lotery, Andrew J.] Univ Hosp Southampton NHS Fdn Trust, Eye Unit, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton; University Hospital Southampton NHS Foundation Trust
RP Ratnayaka, JA (通讯作者)，Univ Southampton, Fac Med, Clin & Expt Sci, MP 806,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM S.A.Lynn@soton.ac.uk; D.A.Johnston@soton.ac.uk; J.A.Scott@soton.ac.uk;
   rosie.munday@seh.ox.ac.uk; rsd1e14@soton.ac.uk; E.E.Keeling@soton.ac.uk;
   rw2g14@soton.ac.uk; Alex.Simpson@soton.ac.uk;
   davis.dillon1996@gmail.com; tf7g11@soton.ac.uk;
   D.S.Chatelet@soton.ac.uk; A.Page@soton.ac.uk; A.J.Cree@soton.ac.uk;
   Helena.Lee@soton.ac.uk; T.A.Newman@soton.ac.uk; A.J.Lotery@soton.ac.uk;
   J.Ratnayaka@soton.ac.uk
RI ; Newman, Tracey A/I-8884-2012
OI Simpson, Alexander/0000-0003-3439-2236; Johnston,
   David/0000-0001-6703-6014; Ratnayaka, J. Arjuna/0000-0002-1027-6938;
   Cree, Angela/0000-0002-1987-8900; Keeling, Eloise/0000-0003-0399-359X;
   Newman, Tracey A/0000-0002-3727-9258; Lotery, Andrew/0000-0001-5541-4305
FU NC3R (National Centre for the Replacement Refinement & Reduction of
   animals in research) [NC/L001152/1]; Macular Society; Retina UK [GR590];
   Fight for Sight [1485/86]; ARUK South Coast Network award; Gift of Sight
   Appeal
FX This work was funded by awards to J.A.R. from the NC3R (National Centre
   for the Replacement Refinement & Reduction of animals in research,
   NC/L001152/1), The Macular Society, Retina UK (GR590), Fight for Sight
   (1485/86) and the Gift of Sight Appeal. We also acknowledge the ARUK
   South Coast Network award to S.A.L. The funders were not involved in
   designing this study, the collection of data, analysis and
   interpretation of data or in writing of this manuscript.
CR Alexandrov PN, 2011, NEUROREPORT, V22, P623, DOI 10.1097/WNR.0b013e3283497334
   Alizadeh P, 2006, EXP EYE RES, V83, P679, DOI 10.1016/j.exer.2006.03.009
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bandyopadhyay D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086847
   Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Broersen K, 2011, PROTEIN ENG DES SEL, V24, P743, DOI 10.1093/protein/gzr020
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Chafekar SM, 2008, BBA-MOL BASIS DIS, V1782, P523, DOI 10.1016/j.bbadis.2008.06.003
   Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]
   Criscuolo C, 2018, NEUROBIOL AGING, V67, P181, DOI 10.1016/j.neurobiolaging.2018.03.017
   Cunvong K, 2013, INVEST OPHTH VIS SCI, V54, P1516, DOI 10.1167/iovs.12-10821
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Do KV, 2019, P NATL ACAD SCI USA, V116, P24317, DOI 10.1073/pnas.1912959116
   Dumitrescu Alina V, 2015, Adv Pediatr, V62, P185, DOI 10.1016/j.yapd.2015.04.012
   Edgar JR, 2015, J CELL SCI, V128, P2520, DOI 10.1242/jcs.170233
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Finnemann SC, 2003, ADV EXP MED BIOL, V533, P337
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hu XY, 2009, P NATL ACAD SCI USA, V106, P20324, DOI 10.1073/pnas.0911281106
   Ibbett P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43906-z
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonkman JEN, 2014, CELL ADHES MIGR, V8, P440, DOI 10.4161/cam.36224
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kayser L, 1996, HISTOCHEM J, V28, P257, DOI 10.1007/BF02409013
   Keeling E, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201800951
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Liao Y, 2019, INVEST OPHTH VIS SCI, V60, P3034, DOI 10.1167/iovs.18-26360
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu RQ, 2010, J BIOL CHEM, V285, P19986, DOI 10.1074/jbc.M109.036798
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lynn Savannah A, 2018, F1000Res, V7, P1107, DOI 10.12688/f1000research.15409.1
   Lynn SA, 2017, TISSUE CELL, V49, P447, DOI 10.1016/j.tice.2017.06.003
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Marshall KE, 2020, CELL MOL LIFE SCI, V77, P5031, DOI 10.1007/s00018-020-03464-4
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Park SW, 2017, ONCOTARGET, V8, P40006, DOI 10.18632/oncotarget.16967
   Park SW, 2015, ONCOTARGET, V6, P35263, DOI 10.18632/oncotarget.5894
   Park SW, 2014, NEUROBIOL AGING, V35, P2013, DOI 10.1016/j.neurobiolaging.2014.03.008
   Parthasarathy R, 2015, EXP EYE RES, V138, P134, DOI 10.1016/j.exer.2015.06.027
   Penna I, 2011, INT J MOL SCI, V12, P5461, DOI 10.3390/ijms12095461
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Ramanathan A, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00136
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Ratnayaka JA, 2020, NEURAL REGEN RES, V15, P863, DOI 10.4103/1673-5374.268972
   Rawlings ND, 2013, HANDBOOK OF PROTEOLYTIC ENZYMES, VOLS 1 AND 2, 3RD EDITION, P1
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Shi HS, 2020, ACTA NEUROPATHOL, V139, P813, DOI 10.1007/s00401-020-02134-w
   Shoji A, 2014, J PHARMACEUT BIOMED, V95, P47, DOI 10.1016/j.jpba.2014.02.009
   Soura V, 2012, BIOCHEM J, V441, P579, DOI 10.1042/BJ20110749
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Townsend M, 2006, J PHYSIOL-LONDON, V572, P477, DOI 10.1113/jphysiol.2005.103754
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Xu HX, 2015, ANNU REV PHYSIOL, V77, P57, DOI 10.1146/annurev-physiol-021014-071649
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 77
TC 4
Z9 4
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD FEB
PY 2021
VL 10
IS 2
AR 413
DI 10.3390/cells10020413
PG 28
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA QN3KT
UT WOS:000622363600001
PM 33671133
OA gold, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Pan, J
   Zhao, LX
AF Pan, Jie
   Zhao, Luxin
TI Long non-coding RNA histone deacetylase 4 antisense RNA 1 (HDAC4-AS1)
   inhibits HDAC4 expression in human ARPE-19 cells with hypoxic stress
SO BIOENGINEERED
LA English
DT Article
DE HDAC4-AS1; HDAC4; hypoxia; HIF-1 alpha; retinal pigment epithelium
ID CHOROIDAL NEOVASCULARIZATION; VEGF; TRANSCRIPTOME; HIF-1-ALPHA; PATHWAY
AB Age-related macular degeneration (AMD) is resulted from choroidal neovascularization (CNV)-mediated cicatrization and vision loss. The sustained retinal hypoxia in retinal pigment epithelium (RPE) cells was reported to contribute to CNV. However, the underlying genetic regulatory network of hypoxia response in RPE is not fully understood. In this study, human ARPE-19 RPE cells were cultured under the anoxia for 24 h and later re-oxygenated in normoxia. Then the transcriptome was investigated via high throughput sequencing. We observed that long non-coding RNA (lncRNA) histone deacetylase 4 antisense RNA 1 (HDAC4-AS1) was increased in hypoxic condition compared to normal control and decreased after re-oxygenation addition, while the change of HDAC4 expression was reduced in hypoxic condition compared to normal control and up-regulated after re-oxygenation addition in ARPE-19 cells. Furthermore, HDAC4-AS1 knockdown could suppress the transcription activity of HDAC4 only in hypoxia condition, and fluorescence in situ hybridization and pull down assay indicated that transcripts of HDAC4-AS1 could substantially bind to the promoter of HDAC4 and facilitate the recruitment of HIF-1 alpha. Finally, we also determined the specific regions of HDAC4-AS1 that contribute to the interaction with HIF-1 alpha and the promoter of HDAC4. Taken together, these outcomes declared that HDAC4-AS1 could inhibit HDAC4 expression through regulating HIF-1 alpha in human ARPE-19 cells with hypoxic stress.
   [GRAPHICS]
   .
C1 [Pan, Jie; Zhao, Luxin] ZiBo Cent Hosp, Dept Ophthalmol, 54 Gongqingtuan West Rd, Zibo 255036, Shandong, Peoples R China.
RP Zhao, LX (通讯作者)，ZiBo Cent Hosp, Dept Ophthalmol, 54 Gongqingtuan West Rd, Zibo 255036, Shandong, Peoples R China.
EM zhaoluxin69@163.com
CR Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Chen B, 2009, SCIENCE, V323, P256, DOI 10.1126/science.1166226
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.382
   Dahbash M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030714
   de Sena Brine G., 2019, F1000RESEARCH, V8, P1874, DOI [10.12688/f1000research.21142.1, DOI 10.12688/F1000RESEARCH.21142.1, DOI 10.12688/F1000RESEARCH.21142.2]
   Frazee AC, 2015, NAT BIOTECHNOL, V33, P243, DOI 10.1038/nbt.3172
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055
   He S, 2015, BIOINFORMATICS, V31, P178, DOI 10.1093/bioinformatics/btu643
   Janardhan HP, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.143jc2
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Klettner A, 2015, MOL VIS, V21, P736
   Kurihara T, 2018, KEIJO J MED, V67, P1, DOI 10.2302/kjm.2017-0002-IR
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Pinto D, 2014, AM J HUM GENET, V94, P677, DOI 10.1016/j.ajhg.2014.03.018
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmitz SU, 2016, CELL MOL LIFE SCI, V73, P2491, DOI 10.1007/s00018-016-2174-5
   Seo HW, 2009, FEBS LETT, V583, P55, DOI 10.1016/j.febslet.2008.11.044
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Sun YZ, 2017, CELL PHYSIOL BIOCHEM, V44, P1640, DOI 10.1159/000485764
   Yan FR, 2019, SEMIN CELL DEV BIOL, V90, P174, DOI 10.1016/j.semcdb.2018.07.013
   Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004
   Yokota K, 2019, ANN SURG ONCOL, V26, P4826, DOI 10.1245/s10434-019-07780-3
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu XY, 2021, BIOCHEM BIOPH RES CO, V535, P39, DOI 10.1016/j.bbrc.2020.10.104
   Zhu MH, 2016, MOL VIS, V22, P1361
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
NR 29
TC 13
Z9 13
U1 2
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165-5979
EI 2165-5987
J9 BIOENGINEERED
JI Bioengineered
PD JAN 1
PY 2021
VL 12
IS 1
BP 2228
EP 2237
DI 10.1080/21655979.2021.1933821
PG 10
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA SK5YO
UT WOS:000656290800001
PM 34057022
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Telegina, DV
   Kozhevnikova, OS
   Fursova, AZ
   Kolosova, NG
AF Telegina, D., V
   Kozhevnikova, O. S.
   Fursova, A. Zh
   Kolosova, N. G.
TI Autophagy as a Target for the Retinoprotective Effects of the
   Mitochondria-Targeted Antioxidant SkQ1
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article
DE SkQ1; age-related macular degeneration; retinal pigment epithelium;
   autophagy; aging; OXYS rats; p62
ID RETINAL-PIGMENT EPITHELIUM; AMD-LIKE RETINOPATHY; ALZHEIMERS-DISEASE;
   PARKIN; VDAC1; DYSFUNCTION; P62/SQSTM1; MITOPHAGY; INTERPLAY; PROTECTS
AB Age-related macular degeneration (AMD) is a complex neurodegenerative disease, a main cause of vision loss in elderly people. The pathogenesis of dry AMD, the most common form of AMD (similar to 80% cases), involves degenerative changes in the retinal pigment epithelium (RPE), which are closely associated with the age-associated impairments in autophagy. Reversion of these degenerative changes is considered as a promising approach for the treatment of this incurable disease. The purpose of our study was to assess the relationship between previously identified retinoprotective effects of the mitochondrial antioxidant plastoquinonyl-decyl-triphenylphosphonium (SkQ1) and its influence on the autophagy process in senescence-accelerated OXYS rats characterized by the development of AMD-like retinopathy (Wistar rats were used as a control). The treatment with SkQ1 (250 nmol/kg body weight) during the period of active disease progression (from 12 to 18 months of age) completely prevented progression of clinical manifestations of retinopathy in the OXYS rats, suppressed atrophic changes in the RPE cells and activated autophagy in the retina, which was evidenced by a significant decrease in the content of the multifunctional adapter protein p62/Sqstm1 and increase in the level of the Beclin1 gene mRNA. In general, the results obtained earlier and in the present study have shown that SkQ1 is a promising agent for prevention and suppression of AMD.
C1 [Telegina, D., V; Kozhevnikova, O. S.; Fursova, A. Zh; Kolosova, N. G.] Russian Acad Sci, Inst Cytol & Genet, Siberian Branch, Novosibirsk 630090, Russia.
   [Kolosova, N. G.] Russian Acad Sci, Vorozhtsov Inst Organ Chem, Siberian Branch, Novosibirsk 630090, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Russian Academy of Sciences; Vorozhtsov Novosibirsk Institute of
   Organic Chemistry
RP Kolosova, NG (通讯作者)，Russian Acad Sci, Inst Cytol & Genet, Siberian Branch, Novosibirsk 630090, Russia.; Kolosova, NG (通讯作者)，Russian Acad Sci, Vorozhtsov Inst Organ Chem, Siberian Branch, Novosibirsk 630090, Russia.
EM kolosova@bionet.nsc.ru
RI Kozhevnikova, Oyuna S./H-3588-2016; fursova, anzhella/AAE-1495-2022;
   Telegina, Darya/AAQ-6062-2020
OI Kozhevnikova, Oyuna S./0000-0001-6475-4061; fursova,
   anzhella/0000-0001-6311-5452; Telegina, Darya/0000-0001-8096-0519
FU Ministry of Science and High Education of the Russian Federation [14,
   W03.31.0034]
FX The study was supported by the Ministry of Science and High Education of
   the Russian Federation (project no. 14. W03.31.0034, megagrant).
CR Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Barbosa MC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00790
   El'darov CM, 2015, BIOCHEMISTRY-MOSCOW+, V80, P604, DOI 10.1134/S0006297915050132
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Jankauskas SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44430
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kang I, 2018, FEBS LETT, V592, P793, DOI 10.1002/1873-3468.12989
   Kolosova NG, 2018, AGING-US, V10, P2136, DOI 10.18632/aging.101537
   Kozhevnikova OS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194804
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Loshchenova PS, 2015, BIOCHEMISTRY-MOSCOW+, V80, P596, DOI 10.1134/S0006297915050120
   Manczak M, 2013, BBA-MOL BASIS DIS, V1832, P2368, DOI 10.1016/j.bbadis.2013.09.008
   Manczak M, 2013, J ALZHEIMERS DIS, V37, P679, DOI 10.3233/JAD-130761
   Markovets AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021682
   Markovets AM, 2011, AGING-US, V3, P44
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Muraleva NA, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080676
   Muraleva NA, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8060177
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Novikova YP, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1101, DOI 10.1134/S0006297914100113
   Okatsu K, 2010, GENES CELLS, V15, P887, DOI 10.1111/j.1365-2443.2010.01426.x
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Picca A, 2015, MITOCHONDRION, V25, P67, DOI 10.1016/j.mito.2015.10.001
   Qi XP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040905
   Saprunova VB, 2012, BIOCHEMISTRY-MOSCOW+, V77, P648, DOI 10.1134/S0006297912060120
   Seibenhener ML, 2013, BBA-MOL CELL RES, V1833, P452, DOI 10.1016/j.bbamcr.2012.11.004
   Stefanova NA, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3984906
   Stefanova NA, 2016, AGING-US, V8, P2713, DOI 10.18632/aging.101054
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun Y, 2012, J BIOL CHEM, V287, P40652, DOI 10.1074/jbc.M112.419721
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Telegina DV, 2017, ADV GERONTOL, V7, P17, DOI 10.1134/S2079057017010155
   Telegina DV, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225632
   Telegina DV, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0493-8
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   Tyumentsev MA, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1083, DOI 10.1134/S0006297918090109
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wohlgemuth SE, 2014, J MOL CELL CARDIOL, V71, P62, DOI 10.1016/j.yjmcc.2014.03.007
   Yun HR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093289
NR 44
TC 0
Z9 0
U1 3
U2 9
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD DEC
PY 2020
VL 85
IS 12-13
SI SI
BP 1640
EP 1649
DI 10.1134/S0006297920120159
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA PL7TX
UT WOS:000603320400015
PM 33705301
DA 2022-11-30
ER

PT J
AU Whitmore, HAB
   Amarnani, D
   O'Hare, M
   Delgado-Tirado, S
   Gonzalez-Buendia, L
   An, M
   Pedron, J
   Bushweller, JH
   Arboleda-Velasquez, JF
   Kim, LA
AF Whitmore, Hannah A. B.
   Amarnani, Dhanesh
   O'Hare, Michael
   Delgado-Tirado, Santiago
   Gonzalez-Buendia, Lucia
   An, Miranda
   Pedron, Julien
   Bushweller, John H.
   Arboleda-Velasquez, Joseph F.
   Kim, Leo A.
TI TNF-alpha signaling regulates RUNX1 function in endothelial cells
SO FASEB JOURNAL
LA English
DT Article
DE angiogenesis; endothelial cell; RUNX1; TNF&#8208; &#945; signaling
   pathway
ID NECROSIS-FACTOR-ALPHA; PROLIFERATIVE DIABETIC-RETINOPATHY;
   SMALL-MOLECULE INHIBITOR; GROWTH-FACTOR; PANRETINAL PHOTOCOAGULATION;
   INTRAVITREAL BEVACIZUMAB; INDUCED APOPTOSIS; ACTIVATION; RANIBIZUMAB;
   KINASE
AB Runt-related transcription factor 1 (RUNX1) acts as a mediator of aberrant retinal angiogenesis and has been implicated in the progression of proliferative diabetic retinopathy (PDR). Patients with PDR, retinopathy of prematurity (ROP), and wet age-related macular degeneration (wet AMD) have been found to have elevated levels of Tumor Necrosis Factor-alpha (TNF-alpha) in the eye. In fibrovascular membranes (FVMs) taken from patients with PDR RUNX1 expression was increased in the vasculature, while in human retinal microvascular endothelial cells (HRMECs), TNF-alpha stimulation causes increased RUNX1 expression, which can be modulated by RUNX1 inhibitors. Using TNF-alpha pathway inhibitors, we determined that in HRMECs, TNF-alpha-induced RUNX1 expression occurs via JNK activation, while NF-kappa B and p38/MAPK inhibition did not affect RUNX1 expression. JNK inhibitors were also effective at stopping high D-glucose-stimulated RUNX1 expression. We further linked JNK to RUNX1 through Activator Protein 1 (AP-1) and investigated the JNK-AP-1-RUNX1 regulatory feedback loop, which can be modulated by VEGF. Additionally, stimulation with TNF-alpha and D-glucose had an additive effect on RUNX1 expression, which was downregulated by VEGF modulation. These data suggest that the downregulation of RUNX1 in conjunction with anti-VEGF agents may be important in future treatments for the management of diseases of pathologic ocular angiogenesis.
C1 [Whitmore, Hannah A. B.; Amarnani, Dhanesh; O'Hare, Michael; Delgado-Tirado, Santiago; Gonzalez-Buendia, Lucia; An, Miranda; Arboleda-Velasquez, Joseph F.; Kim, Leo A.] Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02143 USA.
   [Whitmore, Hannah A. B.; Amarnani, Dhanesh; O'Hare, Michael; Delgado-Tirado, Santiago; Gonzalez-Buendia, Lucia; An, Miranda; Arboleda-Velasquez, Joseph F.; Kim, Leo A.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Pedron, Julien; Bushweller, John H.] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Schepens Eye
   Research Institute; Harvard University; Harvard Medical School;
   University of Virginia
RP Kim, LA (通讯作者)，Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02143 USA.
EM leo_kim@meei.harvard.edu
RI Gonzalez-Buendia, Lucia/AAC-9445-2022
FU National Eye Institute of the National Institutes of Health
   [R01EY027739]; E. Matilda Zieger Foundation for the Blind; Karl
   Kirchgessner Foundation; National Cancer Institute of the National
   Institutes of Health [R01CA234478]
FX National Eye Institute of the National Institutes of Health, Grant/Award
   Number: R01EY027739; E. Matilda Zieger Foundation for the Blind; Karl
   Kirchgessner Foundation; Michel Plantevin; National Cancer Institute of
   the National Institutes of Health, Grant/Award Number: R01CA234478
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Bressler SB, 2017, OPHTHALMOLOGY, V124, P431, DOI 10.1016/j.ophtha.2016.12.005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200
   Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x
   CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666
   COSTAGLIOLA C, 2013, MEDIAT INFLAMM, V2013
   Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8
   Elsasser A, 2003, ONCOGENE, V22, P5646, DOI 10.1038/sj.onc.1206673
   Ennis BW, 2005, J PHARMACOL EXP THER, V313, P325, DOI 10.1124/jpet.104.078873
   FAJARDO LF, 1992, AM J PATHOL, V140, P539
   Fan YP, 2019, CANCERS, V11, DOI 10.3390/cancers11010022
   Fernandez-Vega B, 2016, CASE REP OPHTHAL, V7, P154, DOI 10.1159/000445102
   FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359
   Hellgren G, 2018, GROWTH HORM IGF RES, V39, P19, DOI 10.1016/j.ghir.2017.11.006
   Hernandez C, 2017, J ENDOCRINOL INVEST, V40, P925, DOI 10.1007/s40618-017-0648-4
   Huang H. Y., 2014, J NANOMED NANOTECHNO, V5, P1, DOI DOI 10.4172/2157-7439.1000199
   Huang H, 2011, INVEST OPHTH VIS SCI, V52, P1336, DOI 10.1167/iovs.10-5768
   Illendula A, 2016, EBIOMEDICINE, V8, P117, DOI 10.1016/j.ebiom.2016.04.032
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jayakumar AR, 2018, NEUROCHEM RES, V43, P397, DOI 10.1007/s11064-017-2434-2
   Khalilpourfarshbafi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218792
   Krishnaswamy G, 1999, J INTERF CYTOK RES, V19, P91, DOI 10.1089/107999099314234
   Lam JD, 2017, DIABETES, V66, P1950, DOI 10.2337/db16-1035
   Lepore D, 2014, OPHTHALMOLOGY, V121, P2212, DOI 10.1016/j.ophtha.2014.05.015
   Limb GA, 1996, GRAEF ARCH CLIN EXP, V234, P213, DOI 10.1007/BF00430412
   Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368
   Martinez M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149119
   Mason JO, 2006, AM J OPHTHALMOL, V142, P685, DOI 10.1016/j.ajo.2006.04.058
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Morita K, 2017, J CLIN INVEST, V127, P2815, DOI 10.1172/JCI91788
   Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756-3282(03)00026-7
   Pober JS, 2002, ARTHRITIS RES THER, V4, pS109, DOI 10.1186/ar576
   Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080
   Reiter CEN, 2003, PROG RETIN EYE RES, V22, P545, DOI 10.1016/S1350-9462(03)00035-1
   Rivera JC, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0943-1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabio G, 2014, SEMIN IMMUNOL, V26, P237, DOI 10.1016/j.smim.2014.02.009
   Sainson RCA, 2008, BLOOD, V111, P4997, DOI 10.1182/blood-2007-08-108597
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Simo-Servat O, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/5263798
   Souvannaseng L, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007418
   Spandau U, 2019, PEDIAT RETINAL VASCU, P149
   Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Watanabe H, 2018, CELL REP, V23, P3721, DOI 10.1016/j.celrep.2018.05.081
   Xiao GY, 2018, P NATL ACAD SCI USA, V115, pE9570, DOI 10.1073/pnas.1810209115
   Ye N, 2014, J MED CHEM, V57, P6930, DOI 10.1021/jm5004733
   Zhang BC, 2015, MOL MED REP, V11, P3101, DOI 10.3892/mmr.2014.3002
   Zhao Yue, 2018, Drugs Context, V7, P212532, DOI 10.7573/dic.212532
   Zhou P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00464
   Zou WJ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193256
NR 61
TC 6
Z9 6
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2021
VL 35
IS 2
DI 10.1096/fj.202001668R
EA NOV 2020
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA RY3BC
UT WOS:000586610800001
PM 33135824
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Rezapour, J
   Schuster, AK
   Nickels, S
   Korb, CA
   Elbaz, H
   Peto, T
   Michal, M
   Munzel, T
   Wild, PS
   Konig, J
   Lackner, K
   Schulz, A
   Pfeiffer, N
   Beutel, ME
AF Rezapour, Jasmin
   Schuster, Alexander K.
   Nickels, Stefan
   Korb, Christina A.
   Elbaz, Hisham
   Peto, Tunde
   Michal, Matthias
   Muenzel, Thomas
   Wild, Philipp S.
   Koenig, Jochem
   Lackner, Karl
   Schulz, Andreas
   Pfeiffer, Norbert
   Beutel, Manfred E.
TI Prevalence and new onset of depression and anxiety among participants
   with AMD in a European cohort
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PATIENT HEALTH QUESTIONNAIRE; MACULAR DEGENERATION; D PERSONALITY;
   SYMPTOMS; CLASSIFICATION; DISORDERS; VALIDITY; STRESS; PEOPLE; LIFE
AB To investigate the prevalence and new onset of depression and anxiety among subjects with age-related macular degeneration (AMD) and its association with AMD in a large European cohort with relatively good visual acuity. 11,834 participants enrolled in the German population-based Gutenberg Health Study were studied. AMD was diagnosed by grading of fundus photographs. Depression and anxiety were assessed with the Patient Health Questionnaire and the Generalized Anxiety Disorder-2 Scale, respectively. Logistic regression analyses were performed and adjusted for several parameters. 1,089 (9.2%) participants were diagnosed having AMD. Prevalence of depression in AMD and non-AMD participants was 7.2% and 8.0%, respectively and prevalence of anxiety was 4.2% and 7.0%, respectively. New onset of depression and anxiety at 5-year follow-up in AMD subjects was 2.6% and 3.6%, respectively. AMD was not associated with depression (OR 0.93; CI 95% 0.70-1.20; p=0.62). AMD was associated with less anxiety (OR 0.67; CI 95% 0.47-0.93; p=0.02). This is the first study analyzing both prevalence and new onset of depression and anxiety in AMD subjects. AMD- and non-AMD participants had a similar prevalence and new onset of depression in our population-based sample. Participants without AMD had a higher prevalence of anxiety. AMD was not associated with depression.
C1 [Rezapour, Jasmin; Schuster, Alexander K.; Nickels, Stefan; Korb, Christina A.; Elbaz, Hisham; Pfeiffer, Norbert] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, D-55131 Mainz, Germany.
   [Rezapour, Jasmin] Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Inst, Hamilton Glaucoma Ctr, La Jolla, CA 92037 USA.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London EC1V 9EL, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Elbaz, Hisham] Otto von Guericke Univ, Dept Ophthalmol, Magdeburg, Germany.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT7 1NN, Antrim, North Ireland.
   [Michal, Matthias; Beutel, Manfred E.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Psychosomat Med & Psychotherapy, D-55131 Mainz, Germany.
   [Muenzel, Thomas] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Cardiol 1, D-55131 Mainz, Germany.
   [Wild, Philipp S.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Cardiol, Prevent Cardiol & Prevent Med, D-55131 Mainz, Germany.
   [Wild, Philipp S.; Schulz, Andreas] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Ctr Thrombosis & Hemostasis CTH, D-55131 Mainz, Germany.
   [Wild, Philipp S.] German Ctr Cardiovasc Res DZHK, Partner Site Rhine Main, Mainz, Germany.
   [Koenig, Jochem] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, D-55131 Mainz, Germany.
   [Lackner, Karl] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Clin Chem & Lab Med, Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; University of California System;
   University of California San Diego; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of London; University College London; Otto von Guericke University;
   Queens University Belfast; Johannes Gutenberg University of Mainz;
   Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz; Johannes Gutenberg University of Mainz; German Centre for
   Cardiovascular Research; Johannes Gutenberg University of Mainz;
   Johannes Gutenberg University of Mainz
RP Rezapour, J (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, D-55131 Mainz, Germany.; Rezapour, J (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Inst, Hamilton Glaucoma Ctr, La Jolla, CA 92037 USA.
EM jasmin.rezapour@gmail.com
RI Munzel, Thomas/A-2912-2014; Peto, Tunde/M-2081-2013
OI Munzel, Thomas/0000-0001-5503-4150; Peto, Tunde/0000-0001-6265-0381;
   Wild, Philipp/0000-0003-4413-9752
FU government of Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur
   Innovation") [AZ 961-386261/733]; "Center for Translational Vascular
   Biology (CTVB)" of the Johannes Gutenberg-University of Mainz; PHILIPS
   Medical Systems; Federal Ministry of Education and Research [BMBF
   01EO1503]; Deutsche Ophthalmologische Gesellschaft; Berufsverband der
   Augenarzte Deutschlands e.V.; Allergan; Bayer Vital; Novartis;
   Heidelberg Engineering; Novartis Pharma; Boehringer Ingelheim
FX GHS thanks all participants who took part in this study, and the whole
   GHS team, which includes study assistants, interviewers, computer and
   laboratory technicians, research scientists, managers and statisticians.
   The Gutenberg Health Study is funded through the government of
   Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur Innovation",
   contract AZ 961-386261/733) and "Center for Translational Vascular
   Biology (CTVB)" of the Johannes Gutenberg-University of Mainz, and its
   contracts with Boehringer Ingelheim and PHILIPS Medical Systems,
   including unrestricted grants for the Gutenberg Health Study. PSW is
   funded by the Federal Ministry of Education and Research (BMBF
   01EO1503). PSW and TM are PI of the German Center for Cardiovascular
   Research (DZHK). AKS holds the professorship for ophthalmic healthcare
   research endowed by "Stiftung Auge" and financed by "Deutsche
   Ophthalmologische Gesellschaft" and "Berufsverband der Augenarzte
   Deutschlands e.V." He received research funding from Allergan, Bayer
   Vital, Novartis and Heidelberg Engineering. No competing interests
   relevant to this study. Boehringer Ingelheim, PHILIPS Medical Systems
   and Novartis Pharma provided funding towards the Gutenberg Health Study.
   There are no patents, products in development or marketed products to
   declare. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. No
   conflicting relationship exists for any author.
CR Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976
   Beutel ME, 2012, PSYCHOTHER PSYCHOSOM, V81, P108, DOI 10.1159/000331776
   Beutel ME, 2019, PSYCHOL MED, V49, P1148, DOI 10.1017/S0033291718001848
   Beutel ME, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186516
   Beutel ME, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1262-x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Denollet J, 2006, AM J CARDIOL, V97, P970, DOI 10.1016/j.amjcard.2005.10.035
   Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Heikkinen RL, 2004, ARCH GERONTOL GERIAT, V38, P239, DOI 10.1016/j.archger.2003.10.004
   Hohn R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120476
   Institute N. E., 2015, FACTS AG REL MAC DEG
   Jacob Louis, 2017, Ger Med Sci, V15, pDoc04, DOI 10.3205/000245
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Jivraj J, 2013, CAN J OPHTHALMOL, V48, P269, DOI 10.1016/j.jcjo.2013.03.007
   Jonas JB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202132
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Kocalevent RD, 2013, GEN HOSP PSYCHIAT, V35, P551, DOI 10.1016/j.genhosppsych.2013.04.006
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004
   Lampert T, 2013, BUNDESGESUNDHEITSBLA, V56, P131, DOI 10.1007/s00103-012-1583-3
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lowe B, 2004, PSYCHOTHER PSYCHOSOM, V73, P386, DOI 10.1159/000080393
   Lowe B, 2003, J PSYCHOSOM RES, V55, P515, DOI 10.1016/S0022-3999(03)00072-2
   Lowe B, 2004, J AFFECT DISORDERS, V78, P131, DOI 10.1016/S0165-0327(02)00237-9
   Luanaigh CO, 2008, INT J GERIATR PSYCH, V23, P1213, DOI 10.1002/gps.2054
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Matthias Michal, 2010, J AFFECT DISORDERS, V125, P227, DOI [10.1016/j.jad.2010.02.108, DOI 10.1016/J.JAD.2010.02.108]
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rezapour J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0831-1
   Rose MA, 2019, PSYCHOL HEALTH MED, V24, P383, DOI 10.1080/13548506.2018.1533249
   Ryu So Jung, 2017, Korean J Ophthalmol, V31, P412, DOI 10.3341/kjo.2016.0086
   Sabel BA, 2018, EPMA J, V9, P133, DOI 10.1007/s13167-018-0136-8
   Sun C, 2007, OPHTHAL EPIDEMIOL, V14, P127, DOI 10.1080/09286580601186742
   Team RC, 2016, LANG ENV STAT COMP
   Wild PS, 2012, BUNDESGESUNDHEITSBLA, V55, P824, DOI 10.1007/s00103-012-1502-7
   Wiltink J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105499
   Wiltink J, 2011, J AFFECT DISORDERS, V130, P429, DOI 10.1016/j.jad.2010.10.041
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 46
TC 8
Z9 8
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 16
PY 2020
VL 10
IS 1
AR 4816
DI 10.1038/s41598-020-61706-8
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA ND8AY
UT WOS:000562125500011
PM 32179798
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Terrell, D
   Comander, J
AF Terrell, David
   Comander, Jason
TI Current Stem-Cell Approaches for the Treatment of Inherited Retinal
   Degenerations
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Stem cells; retinal degeneration; dystrophy; retinitis pigmentosa;
   Stargardt disease
ID MULLER GLIA; MACULAR DEGENERATION; VISUAL FUNCTION; TRANSPLANTATION;
   RAT; PHOTORECEPTORS; DIFFERENTIATE; PROGENITORS; RESCUE
AB Stem cells provide a promising new therapeutic approach for the treatment of multiple acquired and inherited retinal conditions. While to date, there have been numerous clinical trials examining the ability of stem cells to treat the geographic atrophy found in advanced non-neovascular age-related macular degeneration, fewer clinical trials have specifically examined stem-cell therapy for inherited retinal disease. Moreover, it remains to be seen if human stem cells will be able to regenerate the lost retinal cell populations that represent a final common pathway for most of the inherited retinal diseases, or if stem cells will secrete a neuroprotective paracrine factor that will delay progression of these diseases. Here, we will review a number of the current clinical trials, either completed or in process, that have been designed to specifically treat inherited retinal conditions. There was considerable initial concern that using human stem cells as therapeutic agents might have the potential to form benign tumors or trigger an immune response that would have deleterious effects on the patient's retina. Currently, the majority of the clinical trials reviewed share the conclusion that intraocular stem-cell approach is generally well tolerated and safe for patients. While there are some efficacy data that have been published for a few of the reviewed trials, none of the completed studies have been empowered to demonstrate statistically significant efficacy in humans.
C1 [Terrell, David; Comander, Jason] Harvard Med Sch, Massachusetts Eye & Ear, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Terrell, D (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, Boston, MA 02115 USA.
EM david_terrell@meei.harvard.edu
CR Ajay E, 2017, NEW ENGL J MED, V376, P1047, DOI [10.1056/NEJMoa1609583, DOI 10.1056/NEJMOA1609583]
   [Anonymous], 2017, ANN OPHTH INN SUMM
   Baglio SR, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00359
   Baranov PY, 2014, TISSUE ENG PT A, V20, P1465, DOI [10.1089/ten.tea.2013.0361, 10.1089/ten.TEA.2013.0361]
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Fischer AJ, 2003, GLIA, V43, P70, DOI 10.1002/glia.10218
   Fischer AJ, 2010, MOL NEUROBIOL, V42, P199, DOI 10.1007/s12035-010-8152-2
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kim Ju Young, 2017, Retin Cases Brief Rep, V11, P227, DOI 10.1097/ICB.0000000000000327
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Lin B, 2018, EXP EYE RES, V174, P13, DOI 10.1016/j.exer.2018.05.017
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Liu Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0661-8
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   McGill TJ, 2018, ADV EXP MED BIOL, V1074, P641, DOI 10.1007/978-3-319-75402-4_78
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Reh TA, 2010, METHODS MOL BIOL, V636, P139, DOI 10.1007/978-1-60761-691-7_9
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singhal S, 2012, STEM CELL TRANSL MED, V1, P188, DOI 10.5966/sctm.2011-0005
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Wadman M, 2009, NATURE DIGEST, V6, P39
   Weiss Jeffrey N, 2018, Stem Cell Investig, V5, P18, DOI 10.21037/sci.2018.04.02
   Weiss JN, 2016, NEURAL REGEN RES, V11, P1685, DOI 10.4103/1673-5374.193251
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 39
TC 18
Z9 20
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY 19
PY 2019
VL 34
IS 4
SI SI
BP 287
EP 292
DI 10.1080/08820538.2019.1620808
EA JUN 2019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IS6PV
UT WOS:000472249100001
PM 31188052
DA 2022-11-30
ER

PT J
AU Kemp-Casey, A
   Pratt, N
   Ramsay, E
   Roughead, EE
AF Kemp-Casey, Anna
   Pratt, Nicole
   Ramsay, Emmae
   Roughead, Elizabeth E.
TI Using Post-market Utilisation Analysis to Support Medicines Pricing
   Policy: An Australian Case Study of Aflibercept and Ranibizumab Use
SO APPLIED HEALTH ECONOMICS AND HEALTH POLICY
LA English
DT Article
ID MACULAR DEGENERATION; NEOVASCULAR AMD; VERTEPORFIN; PATTERNS; OUTCOMES;
   THERAPY
AB ObjectivesTo describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies.MethodsPharmaceutical claims were used to identify initiators of aflibercept and ranibizumab in the year after aflibercept-listing (December 2012), and ranibizumab initiators in the year before aflibercept listing. The dispensing rates for each cohort were calculated, and their demographic and clinical characteristics compared using Kruskal-Wallis tests.ResultsAflibercept and ranibizumab each accounted for half the age-related macular degeneration market following aflibercept listing. Aflibercept initiators had similar dispensing rates to ranibizumab initiators in the pre- and post-aflibercept era (similar to three scripts during the first 90days, and eight to nine scripts during the following 12months). All cohorts were similar in terms of their age, sex, residential aged-care status and geographic remoteness, and no differences were observed in their overall co-morbidity scores and history of thromboembolic events.ConclusionsContrary to clinical trial protocols, post-market utilisation research for ranibizumab and aflibercept demonstrates equivalent use in practice in terms of dose frequency, and the demographic and clinical characteristics of initiators. This supports Australia's decision to pay the same price for each rather than giving a premium to aflibercept. Many other countries are likely overpaying for aflibercept if their utilization patterns are similar to Australia's, and could benefit from incorporating routine utilisation assessment.
C1 [Kemp-Casey, Anna; Pratt, Nicole; Ramsay, Emmae; Roughead, Elizabeth E.] Univ South Australia, Sch Pharm & Med Sci, Qual Use Med & Pharm Res Ctr, GPO Box 2471, Adelaide, SA 5001, Australia.
C3 University of South Australia
RP Kemp-Casey, A (通讯作者)，Univ South Australia, Sch Pharm & Med Sci, Qual Use Med & Pharm Res Ctr, GPO Box 2471, Adelaide, SA 5001, Australia.
EM anna.kemp-casey@unisa.edu.au
RI Roughead, Elizabeth E/G-4431-2010; Kemp-Casey, Anna/AAU-7292-2021;
   Pratt, Nicole/A-1348-2011
OI Roughead, Elizabeth E/0000-0002-6811-8991; Kemp-Casey,
   Anna/0000-0002-0018-962X; Pratt, Nicole/0000-0001-8730-8910
FU Australian Government National Health and Medical Research Council
   Centre of Research Excellence in Post-Marketing Surveillance of
   Medicines and Medical Devices grant [GNT1040938]
FX We are grateful to Dr Alicia Segrave, DUSC Secretary, for comments on an
   earlier draft of this paper. This work was supported by an Australian
   Government National Health and Medical Research Council Centre of
   Research Excellence in Post-Marketing Surveillance of Medicines and
   Medical Devices grant (GNT1040938). The funding organization had no role
   in the design or conduct of this research.
CR Affairs AGDoV, 2014, VET HLTH CARDS
   [Anonymous], 2017, INT LANG DRUG UT RES
   Australian Government Department of Health, 2018, PBS RPBS SECT 85 DAT
   Booth CM, 2014, BRIT J CANCER, V110, P551, DOI 10.1038/bjc.2013.725
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Department of Health, 2012, PUBL SUMM DOC AFL SO
   Department of Health, 2007, PUBL SUMM DOC RAN SO
   Department of Health and Ageing, 2017, AB PBS
   Drug Utilisation Sub-Committee, 2015, AG REL MAC DEG UT AN
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Hugo Centre for Migration and Population Research, 2017, ARIA ACC
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Lu CY, 2011, J CLIN EPIDEMIOL, V64, P223, DOI 10.1016/j.jclinepi.2010.02.015
   National Centre for Classification in Health, 2006, ICD10AM NAT CTR CLAS
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sales AE, 2003, MED CARE, V41, P753, DOI 10.1097/00005650-200306000-00008
   Skelly A, 2017, ADV THER, V34, P2585, DOI 10.1007/s12325-017-0624-6
   Vorum H, 2016, CURR MED RES OPIN, V32, P1943, DOI 10.1080/03007995.2016.1221803
NR 23
TC 3
Z9 3
U1 0
U2 5
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1175-5652
EI 1179-1896
J9 APPL HEALTH ECON HEA
JI Appl. Health Econ. Health Policy
PD JUN
PY 2019
VL 17
IS 3
BP 411
EP 417
DI 10.1007/s40258-018-0440-4
PG 7
WC Economics; Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services
GA HZ7JD
UT WOS:000469029100012
PM 30362070
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kozhevnikova, OS
   Telegina, DV
   Devyatkin, VA
   Kolosova, NG
AF Kozhevnikova, Oyuna S.
   Telegina, Darya V.
   Devyatkin, Vasiliy A.
   Kolosova, Nataliya G.
TI Involvement of the autophagic pathway in the progression of AMD-like
   retinopathy in senescence-accelerated OXYS rats
SO BIOGERONTOLOGY
LA English
DT Article
DE Aging; Senescence-accelerated OXYS rats; Age-related macular
   degeneration; Autophagy; Pik3c2b
ID RETINAL-PIGMENT EPITHELIUM; NECROTIC CELL-DEATH; MACULAR DEGENERATION;
   OXIDATIVE STRESS; PROTEIN; DYSFUNCTION; APOPTOSIS; PATHOLOGY; NECROSIS;
   DISEASE
AB Age-related macular degeneration (AMD) is a complex neurodegenerative disease resulting in a loss of central vision in the elderly. It is currently assumed that impairment of autophagy may be one of the key mechanisms leading to AMD. Here we estimated the influence of age-related autophagy alterations in the retina on the development of AMD-like retinopathy in senescence-accelerated OXYS rats. Significant changes in the expression of the autophagy proteins were absent at the age preceding the development of retinopathy (age 20 days). We found increased levels of LC3A/B, Atg7, and Atg12-Atg5 conjugated proteins in the OXYS retina during manifestation of this retinopathy at the age of 3 months. By contrast, in the retina of 18-month-old OXYS rats with a progressive stage of retinopathy, we revealed significantly decreased protein levels of Atg7 and Atg12-Atg5 as compared to age-matched Wistar rats. Simultaneously with perturbation of the autophagic response, the necrosome subunits Ripk1 and Ripk3 were detected in the OXYS retina. The downregulation of autophagy markers coincided with amyloid beta accumulation (Moab-2) in the retinal pigment epithelium and choroid. Using high-throughput RNA sequencing, we found a missense single-nucleotide polymorphism (SNP) in the Pik3c2b gene associated with autophagy regulation. This SNP was predicted to significantly affect protein structure. Our data prove participation of the autophagic pathway in the progression of AMD-like retinopathy.
C1 [Kozhevnikova, Oyuna S.; Telegina, Darya V.; Devyatkin, Vasiliy A.; Kolosova, Nataliya G.] SB RAS, Inst Cytol & Genet, Novosibirsk, Russia.
   [Devyatkin, Vasiliy A.; Kolosova, Nataliya G.] Novosibirsk State Univ, Novosibirsk, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Novosibirsk State University
RP Kozhevnikova, OS (通讯作者)，SB RAS, Inst Cytol & Genet, Novosibirsk, Russia.
EM oidopova@bionet.nsc.ru
RI Kolosova, Nataliya G/AAR-7409-2020; Devyatkin, Vasiliy/AAD-3990-2020;
   Kozhevnikova, Oyuna S./H-3588-2016; Kolosova, Nataliya G/P-3178-2015;
   Telegina, Darya/AAQ-6062-2020
OI Kolosova, Nataliya G/0000-0003-2398-8544; Devyatkin,
   Vasiliy/0000-0002-3490-2059; Kozhevnikova, Oyuna S./0000-0001-6475-4061;
   Kolosova, Nataliya G/0000-0003-2398-8544; Telegina,
   Darya/0000-0001-8096-0519
FU Russian Scientific Foundation Grant [16-15-10005]; Russian Science
   Foundation [16-15-10005] Funding Source: Russian Science Foundation
FX Microscopy was performed at the Microscopy Center of the Institute of
   Cytology and Genetics, SB RAS, Russia. This work was supported by a
   Russian Scientific Foundation Grant (16-15-10005).
CR Alliouachene S, 2015, CELL REP, V13, P1881, DOI 10.1016/j.celrep.2015.10.052
   Besirli CG, 2011, INVEST OPHTH VIS SCI, V52, P4193, DOI 10.1167/iovs.10-7090
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250
   Devereaux K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076405
   Dvoriantchikova G, 2014, EXP EYE RES, V123, P1, DOI 10.1016/j.exer.2014.04.009
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Jankauskas SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44430
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kolosova N. G., 2014, ADV GERONTOL, V4, P294, DOI DOI 10.1134/S2079057014040146
   Korbolina EE, 2016, BMC GENET, V17, DOI 10.1186/s12863-016-0461-7
   Kozhevnikova OS, 2013, BIOGERONTOLOGY, V14, P753, DOI 10.1007/s10522-013-9439-2
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Markaki M, 2011, BIOGERONTOLOGY, V12, P377, DOI 10.1007/s10522-011-9324-9
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Morel E, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3250
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Nilsson P, 2013, CELL REP, V5, P61, DOI 10.1016/j.celrep.2013.08.042
   Perusek L, 2015, J BIOL CHEM, V290, P29035, DOI 10.1074/jbc.M115.682310
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Shen HM, 2012, EXP CELL RES, V318, P1304, DOI 10.1016/j.yexcr.2012.02.006
   Stefanova NA, 2014, CELL CYCLE, V13, P898, DOI 10.4161/cc.28255
   Telegina DV, 2017, ADV GERONTOL, V7, P17, DOI 10.1134/S2079057017010155
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107
   Wei T, 2015, EXP THER MED, V9, P476, DOI 10.3892/etm.2014.2084
   Xie JX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08426-8
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44
   Youmans KL, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-8
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
NR 36
TC 18
Z9 21
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD JUL
PY 2018
VL 19
IS 3-4
BP 223
EP 235
DI 10.1007/s10522-018-9751-y
PG 13
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA GL0QT
UT WOS:000436795800004
PM 29492791
DA 2022-11-30
ER

PT J
AU Song, CG
   Zhang, YZ
   Wu, HN
   Cao, XL
   Guo, CJ
   Li, YQ
   Zheng, MH
   Han, H
AF Song, Chang-Geng
   Zhang, Yi-Zhe
   Wu, Hai-Ning
   Cao, Xiu-Li
   Guo, Chen-Jun
   Li, Yong-Qiang
   Zheng, Min-Hua
   Han, Hua
TI Stem cells: a promising candidate to treat neurological disorders
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE nerve regeneration; stem cells; transplantation; stem cell therapy;
   nervous system; neurodegenerative disease; neurological disorders;
   animal experiment; clinical trial; regenerative medicine; neural
   regeneration
ID TRAUMATIC BRAIN-INJURY; MESENCHYMAL STROMAL CELLS; BONE-MARROW;
   PROGENITOR CELLS; SPINAL-CORD; MACULAR DEGENERATION; EPITHELIAL-CELLS;
   PRECURSOR CELLS; RETINAL REPAIR; SELF-RENEWAL
AB Neurologic impairments are usually irreversible as a result of limited regeneration in the central nervous system. Therefore, based on the regenerative capacity of stem cells, transplantation therapies of various stem cells have been tested in basic research and preclinical trials, and some have shown great prospects. This manuscript overviews the cellular and molecular characteristics of embryonic stem cells, induced pluripotent stem cells, neural stem cells, retinal stem/progenitor cells, mesenchymal stem/stromal cells, and their derivatives in vivo and in vitro as sources for regenerative therapy. These cells have all been considered as candidates to treat several major neurological disorders and diseases, owing to their self-renewal capacity, multi-directional differentiation, neurotrophic properties, and immune modulation effects. We also review representative basic research and recent clinical trials using stem cells for neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and age-related macular degeneration, as well as traumatic brain injury and glioblastoma. In spite of a few unsuccessful cases, risks of tumorigenicity, and ethical concerns, most results of animal experiments and clinical trials demonstrate efficacious therapeutic effects of stem cells in the treatment of nervous system disease. In summary, these emerging findings in regenerative medicine are likely to contribute to breakthroughs in the treatment of neurological disorders. Thus, stem cells are a promising candidate for the treatment of nervous system diseases.
C1 [Song, Chang-Geng; Zhang, Yi-Zhe; Wu, Hai-Ning; Cao, Xiu-Li; Guo, Chen-Jun; Li, Yong-Qiang; Zheng, Min-Hua; Han, Hua] Fourth Mil Med Univ, Dept Med Genet & Dev Biol, Xian, Shaanxi, Peoples R China.
   [Han, Hua] Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian, Shaanxi, Peoples R China.
C3 Air Force Military Medical University; Air Force Military Medical
   University
RP Zheng, MH; Han, H (通讯作者)，Fourth Mil Med Univ, Dept Med Genet & Dev Biol, Xian, Shaanxi, Peoples R China.; Han, H (通讯作者)，Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian, Shaanxi, Peoples R China.
EM zhengmh@fmmu.edu.cn; huahan@fmmu.edu.cn
OI Zheng, Min Hua/0000-0002-5279-9366
FU National Natural Science Foundation of China [31471044]; Ministry of
   Science and Technology of China [2015AA020918]
FX This paper was supported by the National Natural Science Foundation of
   China, No. 31471044; and a grant from the Ministry of Science and
   Technology of China, No. 2015AA020918.
CR Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846
   Arnhold S, 2000, J NEUROSURG, V93, P1026, DOI 10.3171/jns.2000.93.6.1026
   Ayuso-Sacido A, 2010, J NEURO-ONCOL, V97, P323, DOI 10.1007/s11060-009-0035-x
   Bae JS, 2013, CURR ALZHEIMER RES, V10, P524
   Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100
   Ben Abdallah NMB, 2010, NEUROBIOL AGING, V31, P151, DOI 10.1016/j.neurobiolaging.2008.03.002
   Benedetti S, 2000, NAT MED, V6, P447, DOI 10.1038/74710
   Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006
   Brazzini A, 2010, J VASC INTERV RADIOL, V21, P443, DOI 10.1016/j.jvir.2010.01.008
   Cawsey T, 2015, J NEUROTRAUM, V32, P1393, DOI 10.1089/neu.2014.3575
   Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1
   Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005
   Chmielnicki E, 2004, J NEUROSCI, V24, P2133, DOI 10.1523/JNEUROSCI.1554-03.2004
   Choi YS, 2010, J CELL MOL MED, V14, P878, DOI 10.1111/j.1582-4934.2010.01009.x
   Chun YS, 2010, INT J BIOL SCI, V6, P796
   de Melo SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128922
   Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Duebgen M, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju090
   Duffy BA, 2014, CURR OPIN GENET DEV, V28, P83, DOI 10.1016/j.gde.2014.09.007
   Elder GA, 2010, MT SINAI J MED, V77, P69, DOI 10.1002/msj.20159
   Fiorelli R, 2013, GLIA, V61, P2100, DOI 10.1002/glia.22579
   Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009
   Gamm DM, 2013, EXPERT REV OPHTHALMO, V8, P213, DOI 10.1586/EOP.13.14
   Goldberg NRS, 2015, STEM CELL REP, V5, P791, DOI 10.1016/j.stemcr.2015.09.008
   Goodus MT, 2015, DEV NEUROSCI-BASEL, V37, P29, DOI 10.1159/000367784
   Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147
   Gu Q, 2017, STEM CELL REP, V9, P366, DOI 10.1016/j.stemcr.2017.04.017
   Gualdoni S, 2010, STEM CELLS, V28, P1048, DOI 10.1002/stem.423
   Gunnarsson S, 2010, J NEUROIMMUNOL, V218, P140, DOI 10.1016/j.jneuroim.2009.10.017
   Hamilton LK, 2009, NEUROSCIENCE, V164, P1044, DOI 10.1016/j.neuroscience.2009.09.006
   HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907
   Hossini A.M., 2015, BMC GENOMICS, V16
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hu Y, 2012, J MOL NEUROSCI, V48, P127, DOI 10.1007/s12031-012-9784-7
   Hunsberger JG, 2016, LANCET NEUROL, V15, P219, DOI 10.1016/S1474-4422(15)00332-4
   Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821
   Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678
   Josiah DT, 2010, MOL THER, V18, P377, DOI 10.1038/mt.2009.265
   Jung JH, 2015, AM J CANCER RES, V5, P2686
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kauer TM, 2012, NAT NEUROSCI, V15, P197, DOI 10.1038/nn.3019
   Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5
   Kim Hee Jin, 2015, Alzheimers Dement (N Y), V1, P95, DOI 10.1016/j.trci.2015.06.007
   Kim Ivana K, 2002, Ophthalmol Clin North Am, V15, P81
   Kim KS, 2013, NEUROBIOL AGING, V34, P2408, DOI 10.1016/j.neurobiolaging.2013.03.029
   Klassen H, 2007, STEM CELLS, V25, P1222, DOI 10.1634/stemcells.2006-0541
   KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702
   Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303
   Lane Emma L, 2008, Neuropsychiatr Dis Treat, V4, P835
   Lawrence JM, 2007, STEM CELLS, V25, P2033, DOI 10.1634/stemcells.2006-0724
   LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X
   Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746
   Lim DA, 2014, TRENDS NEUROSCI, V37, P563, DOI 10.1016/j.tins.2014.08.006
   Lindvall O, 2006, NATURE, V441, P1094, DOI 10.1038/nature04960
   Liu Y, 2013, NAT BIOTECHNOL, V31, P440, DOI 10.1038/nbt.2565
   Liu ZL, 2014, INT J ONCOL, V44, P1223, DOI 10.3892/ijo.2014.2284
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Luan Z, 2013, CELL TRANSPLANT, V22, pS101, DOI 10.3727/096368913X672163
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Marei HES, 2015, J CELL PHYSIOL, V230, P116, DOI 10.1002/jcp.24688
   Michelsen KA, 2015, NEURON, V85, P982, DOI 10.1016/j.neuron.2015.02.001
   Morshed RA, 2015, CANCER GENE THER, V22, P55, DOI 10.1038/cgt.2014.72
   Mothe AJ, 2005, NEUROSCIENCE, V131, P177, DOI 10.1016/j.neuroscience.2004.10.011
   Nasonkin I, 2009, STEM CELLS, V27, P2414, DOI 10.1002/stem.177
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013
   Peng YN, 2016, ZHONGGUO ZUZHI GONGC, V20, P5458
   Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060
   Pincus DW, 1998, ANN NEUROL, V43, P576, DOI 10.1002/ana.410430505
   Prince M, 2015, WORLD ALZHEIMER REPO
   Qin J, 2013, NEUROSCI LETT, V548, P95, DOI 10.1016/j.neulet.2013.05.007
   Qu ZP, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0207-x
   Reh TA, 2006, NATURE, V444, P156, DOI 10.1038/444156a
   Rodriguez-Gomez JA, 2007, STEM CELLS, V25, P918, DOI 10.1634/stemcells.2006-0386
   Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2
   Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0
   Shetty GA, 2013, AGE, V35, P2165, DOI 10.1007/s11357-012-9507-6
   Shin JY, 2014, AUTOPHAGY, V10, P32, DOI 10.4161/auto.26508
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Song K, 2015, ONCOL LETT, V10, P2905, DOI 10.3892/ol.2015.3636
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Steinbeck JA, 2015, NEURON, V86, P187, DOI 10.1016/j.neuron.2015.03.002
   STONE LS, 1950, ANAT REC, V106, P89, DOI 10.1002/ar.1091060108
   Sun JN, 2015, STEM CELLS, V33, P1543, DOI 10.1002/stem.1960
   Sweet JA, 2012, NEUROSURG CLIN N AM, V23, P331, DOI 10.1016/j.nec.2012.02.001
   Tajiri N, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00116
   Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014
   Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074857
   Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomsen GM, 2014, STEM CELL RES, V13, P48, DOI 10.1016/j.scr.2014.04.013
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tian CL, 2013, EXP CLIN TRANSPLANT, V11, P176, DOI 10.6002/ect.2012.0053
   Torrente D, 2014, HUM EXP TOXICOL, V33, P673, DOI 10.1177/0960327113509659
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Tsai YC, 2015, STEM CELLS, V33, P2537, DOI 10.1002/stem.2032
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720
   Venkataramana NK, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/931902
   Venkataramana NK, 2010, TRANSL RES, V155, P62, DOI 10.1016/j.trsl.2009.07.006
   Wang JY, 2013, CNS NEUROL DISORD-DR, V12, P413, DOI 10.2174/1871527311312030014
   Wang S, 2013, BRAIN RES, V1532, P76, DOI 10.1016/j.brainres.2013.08.001
   Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105
   Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407
   Yamazoe T, 2015, INT J ONCOL, V46, P147, DOI 10.3892/ijo.2014.2702
   Yang CS, 2017, ZHONGGUO ZUZHI GONGC, V21, P718
   Yen BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004-0098
   Yin F, 2012, CNS NEUROSCI THER, V18, P1012, DOI 10.1111/cns.12025
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yuan XP, 2006, CANCER RES, V66, P2630, DOI 10.1158/0008-5472.CAN-05-1682
   Zhang Q, 2016, J NEUROCHEM, V136, P815, DOI 10.1111/jnc.13413
   Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106
   Zhang SJ, 2014, INT J ONCOL, V45, P1989, DOI 10.3892/ijo.2014.2629
   Zhang SJ, 2012, NEUROCHEM RES, V37, P2659, DOI 10.1007/s11064-012-0879-x
   Zhang W, 2014, J NEUROSCI RES, V92, P185, DOI 10.1002/jnr.23299
   Zhang YW, 2006, STEM CELLS DEV, V15, P943, DOI 10.1089/scd.2006.15.943
   Zhao DH, 2008, MOL CANCER RES, V6, P1819, DOI 10.1158/1541-7786.MCR-08-0146
   Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579
   Zuo FX, 2015, INT J MOL SCI, V16, P26473, DOI 10.3390/ijms161125966
NR 130
TC 67
Z9 71
U1 13
U2 59
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD JUL
PY 2018
VL 13
IS 7
BP 1294
EP 1304
DI 10.4103/1673-5374.235085
PG 11
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA GN7LJ
UT WOS:000439321600032
PM 30028342
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Parmar, VM
   Parmar, T
   Arai, E
   Perusek, L
   Maeda, A
AF Parmar, Vipul M.
   Parmar, Tanu
   Arai, Eisuke
   Perusek, Lindsay
   Maeda, Akiko
TI A2E-associated cell death and inflammation in retinal pigmented
   epithelial cells from human induced pluripotent stem cells
SO STEM CELL RESEARCH
LA English
DT Article
DE iPSC-RPE; Lipofuscin; A2E; VEGF-A; Inflammation
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; MACULAR DEGENERATION;
   OXIDATIVE STRESS; CHOROIDAL NEOVASCULARIZATION; VISUAL CYCLE; RPE CELLS;
   STARGARDT DISEASE; CULTURE MODEL; MOUSE MODEL
AB Accumulation of lipofuscin in the retinal pigmented epithelium (RPE) is observed in retinal degenerative diseases including Stargardt disease and age-related macular degeneration. Bis-retinoid N-retinyl-N-retinylidene ethanolamine (A2E) is a major component of lipofuscin. A2E has been implicated in RPE atrophy and retinal inflammation; however, mice with A2E accumulation display only a mild retinal phenotype. In the current study, human iPSC-RPE (hiPSC-RPE) cells were generated from healthy individuals to examine effects of A2E in human RPE cells. hiPSC-RPE cells displayed RPE-specific features, which include expression of RPE-specific genes, tight junction formation and ability to carry out phagocytosis. hiPSC-RPE cells demonstrated cell death and increased VEGF-A production in a time-dependent manner when they were cocultured with 10 mu M of A2E. PCR array analyses revealed upregulation of 26 and 12 pro-inflammatory cytokines upon A2E and H2O2 exposure respectively, indicating that A2E and H2O2 can cause inflammation in human retinas. Notably, identified gene profiles were different between A2E- and H2O2-treated hiPSC-RPE cells. A2E caused inflammatory changes observed in retinal degenerative diseases more closely as compared to H2O2. Collectively, these data obtained with hiPSC-RPE cells provide evidence that A2E plays an important role in pathogenesis of retinal degenerative diseases in humans. (c) 2018 The Authors. Published by Elsevier B.V.
C1 [Parmar, Vipul M.; Parmar, Tanu; Arai, Eisuke; Perusek, Lindsay; Maeda, Akiko] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, 10900 Euclid Ave, Cleveland, OH 44106 USA.
   [Maeda, Akiko] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University
RP Maeda, A (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM aam19@case.edu
FU Research to Prevent Blindness; National Institutes of Health
   [R01EY022658, P30EY011373]; Prevent Blindness, Ohio Affiliate, young
   investigator student fellowship award for female scholars in vision
   research; NATIONAL EYE INSTITUTE [R01EY022658, P30EY011373] Funding
   Source: NIH RePORTER
FX This work was supported by grants from Research to Prevent Blindness
   (Catalyst Award and Unrestricted Grant) and the National Institutes of
   Health (R01EY022658 and P30EY011373). L.P. was supported by Prevent
   Blindness, Ohio Affiliate, young investigator student fellowship award
   for female scholars in vision research.
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Borooah S, 2013, PROG RETIN EYE RES, V37, P163, DOI 10.1016/j.preteyeres.2013.09.002
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cereijido M, 2008, BBA-BIOMEMBRANES, V1778, P770, DOI 10.1016/j.bbamem.2007.09.001
   Chang JY, 2008, PPAR RES, V2008, DOI 10.1155/2008/720163
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Dahrouj M, 2014, INVEST OPHTH VIS SCI, V55, P2269, DOI 10.1167/iovs.13-13334
   Deleidi M, 2016, BIOCHEM BIOPH RES CO, V473, P665, DOI 10.1016/j.bbrc.2016.02.113
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Golczak M, 2010, J BIOL CHEM, V285, P9667, DOI 10.1074/jbc.M109.063941
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hibaoui Y, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00267
   Hu J, 2001, MOL VIS, V7, P14
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jomova K, 2010, MOL CELL BIOCHEM, V345, P91, DOI 10.1007/s11010-010-0563-x
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Juopperi TA, 2011, FUTUR NEUROL, V6, P363, DOI 10.2217/FNL.11.14
   Kang KH, 2009, TRENDS MOL MED, V15, P191, DOI 10.1016/j.molmed.2009.03.005
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kim C, 2015, BMB REP, V48, P256, DOI 10.5483/BMBRep.2015.48.5.100
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lacono P, 2010, DEV OPHTHALMOL, V46, P39, DOI 10.1159/000320008
   Lenis TL, 2017, P NATL ACAD SCI USA, V114, P3987, DOI 10.1073/pnas.1620299114
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Palczewski K, 2012, J BIOL CHEM, V287, P1612, DOI 10.1074/jbc.R111.301150
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Parmar T, 2016, INVEST OPHTH VIS SCI, V57, P3257, DOI 10.1167/iovs.15-18993
   Parodi MB, 2015, BRIT J OPHTHALMOL, V99, P1268, DOI 10.1136/bjophthalmol-2014-305783
   Perusek L, 2015, J BIOL CHEM, V290, P29035, DOI 10.1074/jbc.M115.682310
   Querques G, 2010, MIDDLE EAST AFR J OP, V17, P387, DOI 10.4103/0974-9233.71586
   Rabin DM, 2013, AGING-US, V5, P51
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Sahu B, 2015, J BIOL CHEM, V290, P27239, DOI 10.1074/jbc.M115.682096
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Simunovic MP, 2015, RETINA-J RET VIT DIS, V35, P1931, DOI 10.1097/IAE.0000000000000723
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sommer Andreia Gianotti, 2012, J Vis Exp, DOI 10.3791/4327
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang HB, 2016, MOL VIS, V22, P116
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Winkler BS, 1999, MOL VIS, V5
   Wu L, 2010, ADV EXP MED BIOL, V664, P533, DOI 10.1007/978-1-4419-1399-9_61
   Ye L, 2013, CURR CARDIOL REV, V9, P63, DOI 10.2174/1573403X11309010008
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zihni C, 2016, NAT REV MOL CELL BIO, V17, P564, DOI 10.1038/nrm.2016.80
NR 104
TC 26
Z9 26
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD MAR
PY 2018
VL 27
BP 95
EP 104
DI 10.1016/j.scr.2018.01.014
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA FZ4AQ
UT WOS:000427533700020
PM 29358124
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Guo, JX
   Luo, XT
   Liang, J
   Xiao, MC
   Sun, XD
AF Guo, Jiaxian
   Luo, Xueting
   Liang, Jian
   Xiao, Meichun
   Sun, Xiaodong
TI Antiangiogenic Effects of Doxazosin on Experimental Choroidal
   Neovascularization in Mice
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE choroidal neovascularization; laser-induced; doxazosin; antiangiogenic
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; VEGF; ANGIOGENESIS;
   EXPRESSION; OUTCOMES; HIF-1-ALPHA; PREVALENCE; PATHWAYS; PROGRESS
AB Purpose: The present study was designed to evaluate the effects of doxazosin on experimental choroidal neovascularization (CNV) in mice.
   Methods: Six- to 8-week-old male C57BL/6 mice were divided into a control group and a doxazosin-treated group (5 mg/kg, i.p., daily). Experimental CNV was induced by laser photocoagulation. Seven and 14 days after laser induction, fluorescein angiography, choroidal flat mounts, and histological studies were performed to evaluate the fluorescence leakage, area, and thickness of CNV lesions, respectively. In addition, western blot analysis was carried out to assess the inhibitory effects of doxazosin on the PI3K/Akt/mTOR signaling pathway and the expression levels of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF), which are involved in CNV model.
   Results: Compared with the control group, the doxazosin-treated group demonstrated significantly less fluorescence leakage on day 7 and 14 after laser induction. Both the area and the thickness of CNV lesions in the doxazosin-treated group were significantly decreased. Mechanistically, PI3K/Akt/mTOR signaling pathway activation was significantly suppressed in the doxazosin-treated group. The expression of HIF-1 alpha and VEGF was also notably reduced by systemic doxazosin treatment.
   Conclusions: Doxazosin exerts antiangiogenic actions in an experimental mouse model of CNV and may be a potential adjunctive therapy for neovascular age-related macular degeneration in humans.
C1 [Guo, Jiaxian; Luo, Xueting; Liang, Jian; Xiao, Meichun; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Guo, Jiaxian; Luo, Xueting; Liang, Jian; Xiao, Meichun; Sun, Xiaodong] Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM xdsun@sjtu.edu.cn
FU National Science Fund for Distinguished Young Scholars of China
   [81425006]; Shanghai Science and Technology Innovation Project
   [1341195400]; Program of Subject Chief Scientists of the Shanghai Health
   System [XBR2013081]
FX The authors thank Dr. Yu Chen at the Shanghai University of Traditional
   Chinese Medicine for valuable guidance on experimental design and
   helpful scientific instructions and discussions throughout the whole
   experiment. This research was supported by The National Science Fund for
   Distinguished Young Scholars of China (81425006); the Shanghai Science
   and Technology Innovation Project (1341195400); and the Program of
   Subject Chief Scientists of the Shanghai Health System (XBR2013081).
CR Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bilbro J, 2013, ANTICANCER RES, V33, P4695
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gaelzer MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154612
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Munoz-Ortega MH, 2016, GUT LIVER, V10, P101, DOI 10.5009/gnl14459
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Keledjian K, 2005, J CELL BIOCHEM, V94, P374, DOI 10.1002/jcb.20240
   Keledjian K, 2001, PROSTATE, V48, P71, DOI 10.1002/pros.1083
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma J, 2016, INVEST OPHTH VIS SCI, V57, P3138, DOI 10.1167/iovs.15-18795
   Nguyen DH, 2013, DISCOV MED, V15, P343
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Park Mi Sun, 2014, Genes Cancer, V5, P470
   Park MS, 2014, ONCOTARGET, V5, P4935, DOI 10.18632/oncotarget.2064
   Rho CR, 2015, J OCUL PHARMACOL TH, V31, P25, DOI 10.1089/jop.2014.0023
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Sakamoto S, 2010, MOL ASPECTS MED, V31, P205, DOI 10.1016/j.mam.2010.02.001
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Su HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062399
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Zhu J, 2009, EXP EYE RES, V88, P910, DOI 10.1016/j.exer.2008.11.034
NR 35
TC 9
Z9 9
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JAN-FEB
PY 2017
VL 33
IS 1
BP 50
EP 56
DI 10.1089/jop.2016.0153
PG 7
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA EH4PB
UT WOS:000391752000009
PM 27992238
DA 2022-11-30
ER

PT J
AU Cavallero, E
   Corvi, F
   Souied, E
   Bandello, F
   Querques, G
AF Cavallero, E.
   Corvi, F.
   Souied, E.
   Bandello, F.
   Querques, G.
TI Spontaneous retinal pigment epithelium tear in geographic atrophy
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Age-related macular degeneration; Geographic atrophy; Pigment epithelial
   detachment; Retinal pigment epithelium; Tear
AB Purpose. - To report two cases of spontaneous retinal pigment epithelial (RPE) tears occurring in two patients affected with geographic atrophy (GA) due to non-exudative age-related macular degeneration (AMD).
   Case report. - Two patients (a 79-year-old man and a 71-year-old woman) presented to our department with progressive visual loss. The man had a best-corrected visual acuity (BCVA) of 20/100 in the right eye (RE) and 20/50 in the left eye (LE); the woman had a BCVA of 20/200 in the RE and 20/160 in the LE. Upon complete ophthalmologic examination, revealing a large area of atrophy (> 175 mu m in diameter) along with pigmentary changes, calcified drusen and no choroidal neovascularization (CNV) in either eye, the patients were diagnosed with GA due to non-exudative AMD. Interestingly, the imaging modalities performed, including fluorescein angiography (FA), indocyanine green angiography (ICGA) and spectral-domain optical coherence tomography (SD-OCT), clearly highlighted the presence of spontaneous RPE tears in the context of non-exudative AMD, while in general, RPE tears are a well-recognized complication of exudative AMD.
   Conclusions. - To our knowledge, this is the first description of spontaneous RPE tears as a possible complication of GA due to non-exudative AMD. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Cavallero, E.; Corvi, F.; Bandello, F.; Querques, G.] Univ Vita Salute San Raffaele, Dept Ophthalmol, IRRCS Osped San Raffaele, I-20132 Milan, Italy.
   [Cavallero, E.; Souied, E.; Querques, G.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94010 Creteil, France.
C3 Vita-Salute San Raffaele University; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI bandello, francesco/AAH-2405-2019; Corvi, Federico/AAD-7691-2021
OI bandello, francesco/0000-0003-3238-9682; Corvi,
   Federico/0000-0002-2661-5500; Querques, Giuseppe/0000-0002-3292-9581
CR BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   Yannuzzi LA, 1995, THE RETINA ATLAS, P262
NR 7
TC 3
Z9 3
U1 0
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD JAN
PY 2016
VL 39
IS 1
BP 64
EP 68
DI 10.1016/j.jfo.2015.05.010
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA9DY
UT WOS:000368109500016
PM 26679385
DA 2022-11-30
ER

PT J
AU Ratnayaka, JA
   Serpell, LC
   Lotery, AJ
AF Ratnayaka, J. A.
   Serpell, L. C.
   Lotery, A. J.
TI Dementia of the eye: the role of amyloid beta in retinal degeneration
SO EYE
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; ALZHEIMERS-DISEASE;
   PRECURSOR PROTEIN; APOLIPOPROTEIN-E; CYTOKINE PRODUCTION;
   POSSIBLE-MECHANISM; COMPLEMENT-SYSTEM; DRUSEN DEPOSITS; IN-VIVO
AB Age-related macular degeneration (AMD) is one of the most common causes of irreversible blindness affecting nearly 50 million individuals globally. The disease is characterised by progressive loss of central vision, which has significant implications for quality of life concerns in an increasingly ageing population. AMD pathology manifests in the macula, a specialised region of the retina, which is responsible for central vision and perception of fine details. The underlying pathology of this complex degenerative disease is incompletely understood but includes both genetic as well as epigenetic risk factors. The recent discovery that amyloid beta (A beta), a highly toxic and aggregate-prone family of peptides, is elevated in the ageing retina and is associated with AMD has opened up new perspectives on the aetiology of this debilitating blinding disease. Multiple studies now link A beta with key stages of AMD progression, which is both exciting and potentially insightful, as this identifies a well-established toxic agent that aggressively targets cells in degenerative brains. Here, we review the most recent findings supporting the hypothesis that A beta may be a key factor in AMD pathology. We describe how multiple A beta reservoirs, now reported in the ageing eye, may target the cellular physiology of the retina as well as associated layers, and propose a mechanistic pathway of A beta-mediated degenerative change leading to AMD.
C1 [Ratnayaka, J. A.; Lotery, A. J.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton SO16 6DY, Hants, England.
   [Serpell, L. C.] Univ Sussex, Sch Life Sci Biochem, Dementia Res Grp, Brighton, E Sussex, England.
C3 University of Southampton; University of Sussex
RP Ratnayaka, JA (通讯作者)，Univ Southampton, Fac Med, Southampton Gen Hosp, Clin & Expt Sci, LD73,MP806,South Lab & Path Block,Tremona Rd, Southampton SO16 6DY, Hants, England.
EM J.Ratnayaka@soton.ac.uk
OI Serpell, Louise/0000-0001-9335-7751; Ratnayaka, J.
   Arjuna/0000-0002-1027-6938; Lotery, Andrew/0000-0001-5541-4305
FU Fight for Sight [1485/6]; National Centre for the Replacement Refinement
   & Reduction of Animals in Research [NC/L001152/1]; Gift of Sight Appeal;
   MRC [MR/K022105/1] Funding Source: UKRI; Alzheimers Research UK
   [ARUK-EG2014B-2] Funding Source: researchfish; Medical Research Council
   [MR/K022105/1] Funding Source: researchfish
FX This work was supported by generous funding from Fight for Sight (Grant
   Number 1485/6); National Centre for the Replacement Refinement &
   Reduction of Animals in Research (Grant Number NC/L001152/1); and the
   Gift of Sight Appeal.
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   Bezprozvanny I, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.263pe16
   Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Butterfield DA, 2004, BRAIN PATHOL, V14, P426
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156
   Castello MA, 2013, AGEING RES REV, V12, P282, DOI 10.1016/j.arr.2012.06.007
   Cerf E, 2011, FASEB J, V25, P1585, DOI 10.1096/fj.10-175976
   Chafekar SM, 2008, BBA-MOL BASIS DIS, V1782, P523, DOI 10.1016/j.bbadis.2008.06.003
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0
   Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cunvong K, 2013, INVEST OPHTH VIS SCI, V54, P1516, DOI 10.1167/iovs.12-10821
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   De Strooper B, 2010, PHYSIOL REV, V90, P465, DOI 10.1152/physrev.00023.2009
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Fandrich M, 2012, J MOL BIOL, V421, P427, DOI 10.1016/j.jmb.2012.01.006
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Funato H, 1999, AM J PATHOL, V155, P23, DOI 10.1016/S0002-9440(10)65094-8
   Gharbiya M, 2014, J ALZHEIMERS DIS, V40, P907, DOI 10.3233/JAD-132039
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kim W, 2005, J BIOL CHEM, V280, P35069, DOI 10.1074/jbc.M505763200
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kumar S, 2011, EMBO J, V30, P2255, DOI 10.1038/emboj.2011.138
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
   Lee J, 2011, NAT CHEM BIOL, V7, P602, DOI [10.1038/NCHEMBIO.624, 10.1038/nchembio.624]
   Liu RQ, 2010, J BIOL CHEM, V285, P19986, DOI 10.1074/jbc.M109.036798
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942
   Lotery A, 2008, EYE, V22, P739, DOI 10.1038/sj.eye.6703035
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Luheshi LM, 2007, PLOS BIOL, V5, P2493, DOI 10.1371/journal.pbio.0050290
   Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mc Donald JM, 2010, BRAIN, V133, P1328, DOI 10.1093/brain/awq065
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
   Moghekar A, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.191262
   Morris KL, 2013, BIOCHEM J, V450, P275, DOI 10.1042/BJ20121773
   Narayan P, 2013, J AM CHEM SOC, V135, P1491, DOI 10.1021/ja3103567
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Parisi V, 2001, CLIN NEUROPHYSIOL, V112, P1860, DOI 10.1016/S1388-2457(01)00620-4
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Perrin RJ, 2009, NATURE, V461, P916, DOI 10.1038/nature08538
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Ricciarelli R, 2012, IUBMB LIFE, V64, P931, DOI 10.1002/iub.1091
   Sabate R, 2005, J PHYS CHEM B, V109, P11027, DOI 10.1021/jp050716m
   SELKOE DJ, 1991, SCI AM, V265, P40, DOI 10.1038/scientificamerican1191-68
   SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0
   Shariati SAM, 2013, FEBS LETT, V587, P2036, DOI 10.1016/j.febslet.2013.05.026
   SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760
   Song MS, 2011, NEUROSCIENCE, V178, P181, DOI 10.1016/j.neuroscience.2010.12.055
   Soura V, 2012, BIOCHEM J, V441, P579, DOI 10.1042/BJ20110749
   STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098
   SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290
   Takahashi RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051965
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tsuruma K, 2010, J NEUROCHEM, V113, P1545, DOI 10.1111/j.1471-4159.2010.06724.x
   Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085
   Wang JQ, 2011, ANAT REC, V294, P1401, DOI 10.1002/ar.21438
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V424, P704, DOI 10.1016/j.bbrc.2012.07.014
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137
   Williams TL, 2011, FEBS J, V278, P3905, DOI 10.1111/j.1742-4658.2011.08228.x
   Williams TL, 2010, LANGMUIR, V26, P17260, DOI 10.1021/la101581g
   Wu FB, 2009, AGEING RES REV, V8, P147, DOI 10.1016/j.arr.2009.03.002
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N
NR 101
TC 99
Z9 103
U1 1
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2015
VL 29
IS 8
BP 1013
EP 1026
DI 10.1038/eye.2015.100
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CO9GF
UT WOS:000359481500005
PM 26088679
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Mitter, SK
   Song, CJ
   Qi, XP
   Mao, HY
   Rao, H
   Akin, D
   Lewin, A
   Grant, M
   Dunn, W
   Ding, JD
   Rickman, CB
   Boulton, M
AF Mitter, Sayak K.
   Song, Chunjuan
   Qi, Xiaoping
   Mao, Haoyu
   Rao, Haripriya
   Akin, Debra
   Lewin, Alfred
   Grant, Maria
   Dunn, William, Jr.
   Ding, Jindong
   Rickman, Catherine Bowes
   Boulton, Michael
TI Dysregulated autophagy in the RPE is associated with increased
   susceptibility to oxidative stress and AMD
SO AUTOPHAGY
LA English
DT Article
DE age-related macular degeneration; aging; autophagy; oxidative stress;
   RPE
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; NEURODEGENERATIVE
   DISEASES; MODEL; ACCUMULATION; MECHANISMS; DEATH; CONSEQUENCES;
   MITOCHONDRIA; PATHOGENESIS
AB Autophagic dysregulation has been suggested in a broad range of neurodegenerative diseases including age-related macular degeneration (AMD). To test whether the autophagy pathway plays a critical role to protect retinal pigmented epithelial (RPE) cells against oxidative stress, we exposed ARPE-19 and primary cultured human RPE cells to both acute (3 and 24h) and chronic (14 d) oxidative stress and monitored autophagy by western blot, PCR, and autophagosome counts in the presence or absence of autophagy modulators. Acute oxidative stress led to a marked increase in autophagy in the RPE, whereas autophagy was reduced under chronic oxidative stress. Upregulation of autophagy by rapamycin decreased oxidative stress-induced generation of reactive oxygen species (ROS), whereas inhibition of autophagy by 3-methyladenine (3-MA) or by knockdown of ATG7 or BECN1 increased ROS generation, exacerbated oxidative stress-induced reduction of mitochondrial activity, reduced cell viability, and increased lipofuscin. Examination of control human donor specimens and mice demonstrated an age-related increase in autophagosome numbers and expression of autophagy proteins. However, autophagy proteins, autophagosomes, and autophagy flux were significantly reduced in tissue from human donor AMD eyes and 2 animal models of AMD. In conclusion, our data confirm that autophagy plays an important role in protection of the RPE against oxidative stress and lipofuscin accumulation and that impairment of autophagy is likely to exacerbate oxidative stress and contribute to the pathogenesis of AMD.
C1 [Mitter, Sayak K.; Qi, Xiaoping; Grant, Maria; Boulton, Michael] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Mitter, Sayak K.; Song, Chunjuan; Rao, Haripriya; Akin, Debra; Dunn, William, Jr.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL USA.
   [Mao, Haoyu; Lewin, Alfred] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA.
   [Ding, Jindong; Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Ding, Jindong; Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
C3 Indiana University System; Indiana University Bloomington; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; Duke University; Duke
   University
RP Boulton, M (通讯作者)，Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
EM mboulton@iupui.edu
RI ; Ding, Jindong/B-3324-2008
OI Song, Chunjuan/0000-0003-2510-0852; Lewin, Alfred/0000-0002-4192-9727;
   Ding, Jindong/0000-0003-0427-0369; Bowes Rickman,
   Catherine/0000-0002-8555-9596
FU NIH [EY019688, EY021626, EY020825-03, EY021721, EY019038, P30 EY005722];
   Edward N & Della L Thome Memorial Foundation Award; Research to Prevent
   Blindness, Inc.; NATIONAL EYE INSTITUTE [R01EY020825, P30EY021721,
   R01EY019038, R01EY019688, P30EY005722, R21EY021626] Funding Source: NIH
   RePORTER
FX This research was supported by NIH grants EY019688 and EY021626 to MEB,
   EY020825-03 to ASL; EY021721 UF Vision Core; NIH Grants EY019038, P30
   EY005722, Edward N & Della L Thome Memorial Foundation Award, and
   Research to Prevent Blindness, Inc. to CBR and MEB.
CR Ayala A, 2007, FRONT BIOSCI-LANDMRK, V12, P986, DOI 10.2741/2119
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boulton M. E., 2009, FUNDUS AUTOFLUORESCE, P14
   BOULTON ME, 1983, EXP EYE RES, V37, P307, DOI 10.1016/0014-4835(83)90166-5
   Boulton ME, 2011, AGE RELATED MACULAR, P45
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chen PM, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-10
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Dasuri K, 2013, FREE RADICAL BIO MED, V62, P170, DOI 10.1016/j.freeradbiomed.2012.09.016
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935
   Floor E, 1998, J NEUROCHEM, V70, P268
   Flynn JM, 2013, FREE RADICAL BIO MED, V62, P4, DOI 10.1016/j.freeradbiomed.2013.05.027
   Galluzzi L, 2008, BIOCHEM SOC T, V36, P786, DOI 10.1042/BST0360786
   Galluzzi L, 2008, CURR MOL MED, V8, P78
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   He CC, 2007, AUTOPHAGY, V3, P271, DOI 10.4161/auto.3912
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Jarrett SG, 2007, OPHTHALMIC RES, V39, P213, DOI 10.1159/000104683
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lionaki E, 2013, AGEING RES REV, V12, P413, DOI 10.1016/j.arr.2012.05.001
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Munemasa Y, 2010, ADV EXP MED BIOL, V664, P355, DOI 10.1007/978-1-4419-1399-9_41
   Park C, 2013, CELL BIOCHEM BIOPHYS, V67, P3, DOI 10.1007/s12013-013-9623-7
   Rami A, 2009, NEUROPATH APPL NEURO, V35, P449, DOI 10.1111/j.1365-2990.2009.01034.x
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Singh R., 2012, INT J CELL BIOL, V2012, DOI [10.1155/2012/282041, DOI 10.1155/2012/282041]
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025
   Stroikin Y, 2004, EUR J CELL BIOL, V83, P583, DOI 10.1078/0171-9335-00433
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wassell J, 1997, BRIT J OPHTHALMOL, V81, P911, DOI 10.1136/bjo.81.10.911
   WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Wong Michael, 2013, Biomed J, V36, P40, DOI 10.4103/2319-4170.110365
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
NR 61
TC 281
Z9 290
U1 3
U2 41
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD NOV
PY 2014
VL 10
IS 11
BP 1989
EP 2005
DI 10.4161/auto.36184
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AZ6FK
UT WOS:000348314200010
PM 25484094
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wang, MH
   Wang, X
   Zhao, L
   Ma, WX
   Rodriguez, IR
   Fariss, RN
   Wong, WT
AF Wang, Minhua
   Wang, Xu
   Zhao, Lian
   Ma, Wenxin
   Rodriguez, Ignacio R.
   Fariss, Robert N.
   Wong, Wai T.
TI Macroglia-Microglia Interactions via TSPO Signaling Regulates Microglial
   Activation in the Mouse Retina
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE DBI; gliosis; microglia; Muller cells; retina; TSPO
ID DIAZEPAM-BINDING INHIBITOR; PERIPHERAL BENZODIAZEPINE-RECEPTOR; PROTEIN
   18 KDA; CULTURED RAT ASTROCYTES; GANGLION-CELL APOPTOSIS;
   AMINO-ACID-SEQUENCE; TRANSLOCATOR PROTEIN; MACULAR DEGENERATION;
   CHOLESTEROL TRANSPORT; STEROID-BIOSYNTHESIS
AB Chronic retinal inflammation in the form of activated microglia and macrophages are implicated in the etiology of neurodegenerative diseases of the retina, including age-related macular degeneration, diabetic retinopathy, and glaucoma. However, molecular biomarkers and targeted therapies for immune cell activation in these disorders are currently lacking. To address this, we investigated the involvement and role of translocator protein (TSPO), a biomarker of microglial and astrocyte gliosis in brain degeneration, in the context of retinal inflammation. Here, we find that TSPO is acutely and specifically upregulated in retinal microglia in separate mouse models of retinal inflammation and injury. Concomitantly, its endogenous ligand, diazepam-binding inhibitor (DBI), is upregulated in the macroglia of the mouse retina such as astrocytes and Muller cells. In addition, we discover that TSPO-mediated signaling in microglia via DBI-derived ligands negatively regulates features of microglial activation, including reactive oxygen species production, TNF-alpha expression and secretion, and microglial proliferation. The inducibility and effects of DBI-TSPO signaling in the retina reveal a mechanism of coordinated macroglia-microglia interactions, the function of which is to limit the magnitude of inflammatory responses after their initiation, facilitating a return to baseline quiescence. Our results indicate that TSPO is a promising molecular marker for imaging inflammatory cell activation in the retina and highlight DBI-TSPO signaling as a potential target for immodulatory therapies.
C1 [Wang, Minhua; Wang, Xu; Zhao, Lian; Ma, Wenxin; Wong, Wai T.] NEI, NIH, Unit Neuron Glia Interact Retinal Dis, Bethesda, MD 20892 USA.
   [Rodriguez, Ignacio R.] NEI, NIH, Mech Retinal Dis Sect, Lab Retinal Cell & Mol Biol, Bethesda, MD 20892 USA.
   [Fariss, Robert N.] NEI, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Wong, WT (通讯作者)，NEI, NIH, Unit Neuron Glia Interact Retinal Dis, Bldg 6,Room 215, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Fariss, Robert/ABI-1771-2020; Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Fariss, Robert/0000-0003-3227-7170
FU National Eye Institute Intramural Research Program, National Institutes
   of Health; NATIONAL EYE INSTITUTE [ZIAEY000307, ZIAEY000463,
   ZIAEY000541, ZICEY000459, ZIAEY000505] Funding Source: NIH RePORTER
FX This study was supported by funds from the National Eye Institute
   Intramural Research Program, National Institutes of Health.
CR ALHO H, 1991, NEUROPHARMACOLOGY, V30, P1381, DOI 10.1016/S0028-3908(11)80005-5
   Barmack NH, 2004, J NEUROSCI, V24, P1023, DOI 10.1523/JNEUROSCI.3936-03.2004
   Barnett EM, 2009, P NATL ACAD SCI USA, V106, P9391, DOI 10.1073/pnas.0812884106
   Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013
   Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703
   BERKOVICH A, 1990, MOL PHARMACOL, V37, P164
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cagnin A, 2007, NEUROTHERAPEUTICS, V4, P443, DOI 10.1016/j.nurt.2007.04.006
   Capozzi ME, 2013, J OCUL PHARMACOL TH, V29, P275, DOI 10.1089/jop.2012.0279
   Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8
   Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004
   Choi HB, 2002, J NEUROCHEM, V83, P546, DOI 10.1046/j.1471-4159.2002.01122.x
   Choi J, 2011, GLIA, V59, P219, DOI 10.1002/glia.21091
   Christian CA, 2013, NEURON, V78, P1063, DOI 10.1016/j.neuron.2013.04.026
   Cinone N, 2000, J COMPUT AID MOL DES, V14, P753, DOI 10.1023/A:1008168127539
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cosenza-Nashat M, 2009, NEUROPATH APPL NEURO, V35, P306, DOI 10.1111/j.1365-2990.2008.01006.x
   COSTA E, 1991, LIFE SCI, V49, P325, DOI 10.1016/0024-3205(91)90440-M
   Cuadros M A, 2001, Prog Brain Res, V132, P51
   Daugherty DJ, 2013, EMBO MOL MED, V5, P891, DOI 10.1002/emmm.201202124
   De Mateos-Verchere JG, 1998, PEPTIDES, V19, P841
   do Rego JC, 2007, NEUROPSYCHOPHARMACOL, V32, P1641, DOI 10.1038/sj.npp.1301280
   Do-Rego JL, 1998, NEUROSCIENCE, V83, P555, DOI 10.1016/S0306-4522(97)00362-X
   FERRERO P, 1986, P NATL ACAD SCI USA, V83, P827, DOI 10.1073/pnas.83.3.827
   Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973
   Galvao J, 2013, CURR OPIN PHARMACOL, V13, P123, DOI 10.1016/j.coph.2012.08.007
   Gao ZW, 2013, MOL NEUROBIOL, V48, P690, DOI 10.1007/s12035-013-8460-4
   GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444
   Girard C, 2008, P NATL ACAD SCI USA, V105, P20505, DOI 10.1073/pnas.0811201106
   Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016
   GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084
   Hong SH, 2006, J NEUROSCI RES, V83, P1293, DOI 10.1002/jnr.20829
   Ji B, 2008, J NEUROSCI, V28, P12255, DOI 10.1523/JNEUROSCI.2312-08.2008
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   KAVALIERS M, 1986, BRAIN RES, V383, P343, DOI 10.1016/0006-8993(86)90037-5
   Kierdorf K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00044
   Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6
   Lafon-Cazal M, 2003, J BIOL CHEM, V278, P24438, DOI 10.1074/jbc.M211980200
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lecanu L, 2013, STEROIDS, V78, P137, DOI 10.1016/j.steroids.2012.10.018
   Lee M, 2013, CURR PROTEIN PEPT SC, V14, P21, DOI 10.2174/1389203711314010005
   LEFUR G, 1983, LIFE SCI, V33, P449, DOI 10.1016/0024-3205(83)90794-4
   Lesouhaitier O, 1998, J MOL ENDOCRINOL, V20, P45, DOI 10.1677/jme.0.0200045
   Li H, 1998, ENDOCRINOLOGY, V139, P4991, DOI 10.1210/en.139.12.4991
   Loomis WF, 2010, J BIOL CHEM, V285, P21359, DOI 10.1074/jbc.M110.105858
   Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054
   Mameli M, 2005, J NEUROSCI, V25, P2285, DOI 10.1523/JNEUROSCI.3877-04.2005
   Masmoudi O, 2005, J NEUROCHEM, V94, P561, DOI 10.1111/j.1471-4159.2005.03076.x
   Midzak A, 2011, J BIOL CHEM, V286, P9875, DOI 10.1074/jbc.M110.203216
   Nothdurfter C, 2012, EUR ARCH PSY CLIN N, V262, pS107, DOI 10.1007/s00406-012-0352-5
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481
   Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005
   Patte C, 1999, GLIA, V25, P404, DOI 10.1002/(SICI)1098-1136(19990215)25:4<404::AID-GLIA9>3.0.CO;2-Q
   Pocock JM, 2007, TRENDS NEUROSCI, V30, P527, DOI 10.1016/j.tins.2007.07.007
   Politis M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00096
   Qian ZY, 2008, J NEUROCHEM, V105, P1287, DOI 10.1111/j.1471-4159.2008.05229.x
   Rone MB, 2009, BBA-MOL CELL BIOL L, V1791, P646, DOI 10.1016/j.bbalip.2009.03.001
   Rupprecht R, 1999, STEROIDS, V64, P83, DOI 10.1016/S0039-128X(98)00101-9
   Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295
   Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010
   Saijo K, 2013, GLIA, V61, P104, DOI 10.1002/glia.22423
   Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Siiskonen H, 2007, MOL CELL NEUROSCI, V34, P199, DOI 10.1016/j.mcn.2006.10.013
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   SLOBODYANSKY E, 1989, J NEUROCHEM, V53, P1276, DOI 10.1111/j.1471-4159.1989.tb07425.x
   Soustiel JF, 2008, EXP NEUROL, V214, P201, DOI 10.1016/j.expneurol.2008.08.008
   STEPHENSON DT, 1995, J NEUROSCI, V15, P5263
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Tang Z., 2011, J VIS EXP
   THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x
   Tokay T, 2005, J NEUROCHEM, V94, P607, DOI 10.1111/j.1471-4159.2005.03102.x
   Veiga S, 2005, J NEUROSCI RES, V80, P129, DOI 10.1002/jnr.20430
   Venneti S, 2013, GLIA, V61, P10, DOI 10.1002/glia.22357
   Vohra R, 2013, SURV OPHTHALMOL, V58, P311, DOI 10.1016/j.survophthal.2012.08.010
   Wang MH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-173
   Yanase H, 2002, ARCH HISTOL CYTOL, V65, P27, DOI 10.1679/aohc.65.27
   Zhao L, 2011, AM J PATHOL, V179, P1265, DOI 10.1016/j.ajpath.2011.05.042
NR 85
TC 134
Z9 138
U1 1
U2 19
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAR 5
PY 2014
VL 34
IS 10
BP 3793
EP 3806
DI 10.1523/JNEUROSCI.3153-13.2014
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AC7HN
UT WOS:000332698900031
PM 24599476
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Chen, HY
   Jhanji, V
AF Chen, Haoyu
   Jhanji, Vishal
TI Survey of systematic reviews and meta-analyses published in
   ophthalmology
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
AB Purpose To analyse the types of systematic reviews and meta-analyses published in the field of ophthalmology.
   Methods The systematic reviews and meta-analysis in ophthalmology published in peer-reviewed journals were retrieved. The distribution of systematic reviews and meta-analyses in various ophthalmic subspecialties, type of study and country of origin were determined.
   Results A total of 533 records were identified as systematic reviews and meta-analysis in ophthalmology. Overall, retina and glaucoma were the two major subspecialties accounting for 35% and 21% of the published systematic reviews and meta-analyses, respectively. The major topics published in retina were age-related macular degeneration (37%), tumours (14%), and diabetic retinopathy (12%). More than half (56%) the systematic reviews and meta-analyses were interventional. The author affiliations of these studies were largely from the USA (30%) and the UK (22%). About 60% of the systematic reviews and meta-analyses were published in ophthalmology journals, followed by the Cochrane Library (15.75%) and other non-ophthalmic journals (25.14%), respectively. The number of publications increased from 3 per year in 1994 to almost 100 per year in 2010.
   Conclusions The number of published systematic reviews and meta-analyses has been increasing progressively over the past few years. Retina and glaucoma are the two most commonly published topics. Non-ophthalmology journals form a sizeable proportion of avenues for ophthalmic publications.
C1 [Chen, Haoyu; Jhanji, Vishal] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong 123456, Hong Kong, Peoples R China.
   [Chen, Haoyu; Jhanji, Vishal] Shantou Univ & Chinese Univ Hong Kong, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Jhanji, Vishal] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Centre
   for Eye Research Australia; University of Melbourne
RP Jhanji, V (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong 123456, Hong Kong, Peoples R China.
EM vishaljhanji@gmail.com
RI Chen, Haoyu/A-7432-2013; Chu, Kai On/E-2325-2016; Jhanji,
   Vishal/I-5676-2014
OI Chen, Haoyu/0000-0003-0676-4610; 
FU National Nature Science Foundation of China; Guangdong Science and
   Technology Project; Guangdong Medical Research Foundation; Science and
   Technology Project of Shantou City, China; Joint Shantou International
   Eye Center
FX Dr Haoyu Chen is supported by grants from the National Nature Science
   Foundation of China, Guangdong Science and Technology Project, Guangdong
   Medical Research Foundation, Science and Technology Project of Shantou
   City, China and, the Research Fund of Joint Shantou International Eye
   Center.
CR Bader J, 2004, J AM DENT ASSOC, V135, P464, DOI 10.14219/jada.archive.2004.0212
   CHALMERS I, 1994, BMJ-BRIT MED J, V309, P862, DOI 10.1136/bmj.309.6958.862
   Freeman SR, 2006, J INVEST DERMATOL, V126, P2357, DOI 10.1038/sj.jid.5700560
   GUYATT GH, 2002, USERS GUIDE MED LIT
   Kumar A, 2011, OPHTHALMOLOGY, V118, P1211, DOI 10.1016/j.ophtha.2010.10.023
   Ma B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020185
   Petticrew M, 2006, SYSTEMATIC REVIEWS IN THE SOCIAL SCIENCES: A PRACTICAL GUIDE, P1, DOI 10.1002/9780470754887
NR 7
TC 18
Z9 19
U1 0
U2 13
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2012
VL 96
IS 6
BP 896
EP 899
DI 10.1136/bjophthalmol-2012-301589
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 946IX
UT WOS:000304346300027
PM 22446144
DA 2022-11-30
ER

PT J
AU Suchankova, P
   Henningsson, S
   Baghaei, F
   Rosmond, R
   Holm, G
   Ekman, A
AF Suchankova, P.
   Henningsson, S.
   Baghaei, F.
   Rosmond, R.
   Holm, G.
   Ekman, A.
TI Genetic variability within the innate immune system influences
   personality traits in women
SO GENES BRAIN AND BEHAVIOR
LA English
DT Article
DE +1444C > T polymorphism; 1277T > C; complement factor H; C-reactive
   protein; impulsiveness; Karolinska Scales of Personality; monotony
   avoidance; social desirability; verbal aggression; Y402H polymorphism
ID C-REACTIVE-PROTEIN; CORONARY-HEART-DISEASE; COMPLEMENT FACTOR-H;
   DEPRESSIVE SYMPTOMS; CARDIOVASCULAR-DISEASE; MACULAR DEGENERATION;
   SERUM-LEVELS; ALZHEIMERS-DISEASE; APOPTOTIC CELLS; RISK-FACTORS
AB Raised levels of inflammation markers have been associated with several mental disorders; however, studies regarding the relationship between inflammation or the immune system and various aspects of human behaviour are not numerous. The aim of the present study was to investigate whether an association exists between personality traits and two single nucleotide polymorphisms located in genes that are associated with the innate immune system. The studied population consisted of 42-year-old women recruited from the population registry that had been assessed by means of Karolinska Scales of Personality, a self-reported inventory. The first polymorphism, +1444C > T (rs1130864), is located in the gene coding for C-reactive protein (CRP), a marker of low-grade inflammation. The T-allele has previously been suggested to be linked to raised serum levels of CRP. The second polymorphism, Y402H (1277T > C, rs1061170), is located in the gene coding for complement factor H, an important regulator of the complement system. The C-allele has consistently been associated with age-related macular degeneration. While the +1444T allele was associated with higher scores in the personality traits impulsiveness, monotony avoidance and social desirability, the 1277C polymorphism was associated with higher scores in verbal aggression and lower scores in social desirability. In conclusion, the associations between the personality traits and the studied polymorphisms further support the possible influence of the immune system on mental functions.
C1 [Suchankova, P.; Henningsson, S.; Ekman, A.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, S-40530 Gothenburg, Sweden.
   [Baghaei, F.; Rosmond, R.; Holm, G.] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Metab & Cardiovasc Res, S-40530 Gothenburg, Sweden.
C3 University of Gothenburg; University of Gothenburg
RP Suchankova, P (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, POB 431, S-40530 Gothenburg, Sweden.
EM petra.suchankova@pharm.gu.se
RI Baghaei, Fariba/AAS-3197-2020
FU Medical Research Council [8668]; Torsten and Ragnar Soderberg's
   Foundation and Swedish Brain Power
FX The authors gratefully acknowledge the technical assistance of Gunilla
   Bourghardt and Inger Oscarsson. This study was supported by the Medical
   Research Council (8668), Torsten and Ragnar Soderberg's Foundation and
   Swedish Brain Power.
CR Anisman H, 2003, ANN MED, V35, P2, DOI 10.1080/07853890310004075
   Bouchard TJ, 2001, BEHAV GENET, V31, P243
   Boyle SH, 2007, BRAIN BEHAV IMMUN, V21, P816, DOI 10.1016/j.bbi.2007.01.008
   Brull DJ, 2003, ARTERIOSCL THROM VAS, V23, P2063, DOI 10.1161/01.ATV.0000084640.21712.9C
   Caspi A, 2005, ANNU REV PSYCHOL, V56, P453, DOI 10.1146/annurev.psych.55.090902.141913
   Coccaro EF, 2006, J PSYCHIAT RES, V40, P460, DOI 10.1016/j.jpsychires.2005.04.005
   D'Aiuto F, 2005, ATHEROSCLEROSIS, V179, P413, DOI 10.1016/j.atherosclerosis.2004.10.036
   Danner M, 2003, PSYCHOSOM MED, V65, P347, DOI 10.1097/01.PSY.0000041542.29808.01
   Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Eaker ED, 2004, CIRCULATION, V109, P1267, DOI 10.1161/01.CIR.0000118535.15205.8F
   Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78
   Elovainio M, 2004, J AFFECT DISORDERS, V83, P227, DOI 10.1016/j.jad.2004.06.005
   Fan XD, 2007, PSYCHIAT RES, V149, P267, DOI 10.1016/j.psychres.2006.07.011
   Farmer A, 2003, ARCH GEN PSYCHIAT, V60, P490, DOI 10.1001/archpsyc.60.5.490
   Ford DE, 2004, ARCH INTERN MED, V164, P1010, DOI 10.1001/archinte.164.9.1010
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Graham JE, 2006, BRAIN BEHAV IMMUN, V20, P389, DOI 10.1016/j.bbi.2005.11.002
   Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074-7742(07)82002-2
   Gump BB, 2005, STROKE, V36, P98, DOI 10.1161/01.STR.0000149626.50127.d0
   Gustavsson JP, 1996, ACTA PSYCHIAT SCAND, V93, P460, DOI 10.1111/j.1600-0447.1996.tb10678.x
   Gustavsson JP, 1997, PERS INDIV DIFFER, V22, P783, DOI 10.1016/S0191-8869(96)00268-1
   HART BL, 1988, NEUROSCI BIOBEHAV R, V12, P123, DOI 10.1016/S0149-7634(88)80004-6
   Henningsson S, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-16
   Herran A, 2005, INT J NEUROPSYCHOPH, V8, P529, DOI 10.1017/S1461145705005432
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jurado D, 2005, EUR PSYCHIAT, V20, P213, DOI 10.1016/j.eurpsy.2004.12.009
   Kacira T, 2007, NEUROSURGERY, V60, P674, DOI 10.1227/01.NEU.0000255394.77538.BB
   Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237
   Kronfol Z, 2000, AM J PSYCHIAT, V157, P683, DOI 10.1176/appi.ajp.157.5.683
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527
   Liukkonen T, 2006, BIOL PSYCHIAT, V60, P825, DOI 10.1016/j.biopsych.2006.02.016
   Marsik C, 2006, CLIN CHEM, V52, P1952, DOI 10.1373/clinchem.2006.069823
   Marzari C, 2005, J GERONTOL A-BIOL, V60, P85, DOI 10.1093/gerona/60.1.85
   Matsudaira T, 2006, J CLIN PSYCHOL, V62, P97, DOI 10.1002/jclp.20215
   MOLD C, 1984, J IMMUNOL, V133, P882
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   O'Brien SM, 2006, J AFFECT DISORDERS, V90, P263, DOI 10.1016/j.jad.2005.11.015
   Painuly N, 2005, EUR ARCH PSY CLIN N, V255, P215, DOI 10.1007/s00406-004-0539-5
   Pekny M, 2007, INT REV NEUROBIOL, V82, P95, DOI 10.1016/S0074-7742(07)82005-8
   Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024
   Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Rosmond R, 1998, OBES RES, V6, P338, DOI 10.1002/j.1550-8528.1998.tb00361.x
   Rus H, 2006, J NEUROIMMUNOL, V180, P9, DOI 10.1016/j.jneuroim.2006.07.009
   SANO Y, 1985, Acta Medica Universitatis Kagoshimaensis, V27, P1
   SCHALLING D, 1987, ACTA PSYCHIAT SCAND, V76, P172, DOI 10.1111/j.1600-0447.1987.tb02881.x
   SCHUITEMAKER A, 2008, NEUROBIOL A IN PRESS
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sperner-Unterweger B, 2005, DRUGS, V65, P1493, DOI 10.2165/00003495-200565110-00004
   Steptoe A, 2008, AM J EPIDEMIOL, V167, P96, DOI 10.1093/aje/kwm252
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Suarez EC, 2004, PSYCHOSOM MED, V66, P684, DOI 10.1097/01.psy.0000138281.73634.67
   Suchankova P, 2009, REGUL PEPTIDES, V152, P28, DOI 10.1016/j.regpep.2008.11.001
   SVRAKIC DM, 1992, J AFFECT DISORDERS, V24, P217, DOI 10.1016/0165-0327(92)90106-G
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Walsh MT, 1996, IMMUNOGENETICS, V44, P62
   Weiner MF, 2005, ACTA PSYCHIAT SCAND, V111, P367, DOI 10.1111/j.1600-0447.2004.00472.x
   Westberg L, 2003, MOL PSYCHIATR, V8, P118, DOI 10.1038/sj.mp.4001192
   Williams JE, 2000, CIRCULATION, V101, P2034, DOI 10.1161/01.CIR.101.17.2034
   Wulsin LR, 2003, PSYCHOSOM MED, V65, P201, DOI 10.1097/01.PSY.0000058371.50240.E3
   Yasojima K, 2000, BRAIN RES, V887, P80, DOI 10.1016/S0006-8993(00)02970-X
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 66
TC 13
Z9 14
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1601-1848
EI 1601-183X
J9 GENES BRAIN BEHAV
JI Genes Brain Behav.
PD MAR
PY 2009
VL 8
IS 2
BP 212
EP 217
DI 10.1111/j.1601-183X.2008.00461.x
PG 6
WC Behavioral Sciences; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology
GA 412WY
UT WOS:000263756100009
PM 19077177
OA Bronze
DA 2022-11-30
ER

PT J
AU Ibarra, MS
   Hsu, J
   Mirza, N
   Wu, IH
   Ying, GS
   Mainster, MA
   Tolentino, MJ
AF Ibarra, MS
   Hsu, J
   Mirza, N
   Wu, IH
   Ying, GS
   Mainster, MA
   Tolentino, MJ
TI Retinal temperature increase during transpupillary thermotherapy:
   Effects of pigmentation, subretinal blood, and choroidal blood flow
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID INTENSE LIGHT SOURCES; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   EPITHELIAL TEAR; LASER PHOTOCOAGULATION; NEOVASCULARIZATION;
   COMPLICATIONS; VERTEPORFIN; HEMORRHAGE; INFARCTION
AB PURPOSE. To study the risk of adverse events in transpupillary thermotherapy (TTT) for age-related macular degeneration by measuring how laser-induced retinal temperature increase is affected experimentally by subretinal blood, choroidal blood flow, and chorioretinal pigmentation.
   METHODS. An ultrafine thermocouple technique was developed to measure retinal temperature increase during TTT in albino and pigmented rabbit eyes. TTT was performed with 60-second, 0.78-mm spot size, 810-nm infrared diode laser exposures with power settings ranging from 50 to 950 mW. Intraretinal and subretinal temperature increases were measured in pigmented and albino rabbits, with or without subretinal blood and choroidal blood flow.
   RESULTS. Threshold power settings for visible lesions in albino and pigmented rabbits were 950 and 90 mW, respectively, corresponding to retinal temperature increases of 11.8 degreesC and 5.28 degreesC, respectively. Power settings required to produce threshold lesions in albino rabbits caused retinal temperature increases in pigmented rabbits that were five times higher than in the albino rabbits. Temperature increases in albino rabbits were 1.5 times higher with subretinal blood than without it. Choroidal blood flow generally did not affect measured retinal temperature increases.
   CONCLUSIONS. The results confirm prior theoretical recommendations that clinicians should consider decreasing TTT power settings in darkly pigmented eyes and proceed with caution in those with subretinal hemorrhage or pigment clumping.
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Penn, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Kansas, Dept Ophthalmol, Sch Med, Kansas City, KS 66103 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of
   Kansas; University of Kansas Medical Center
RP Tolentino, MJ (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM mtolent95@aol.com
FU NATIONAL EYE INSTITUTE [K08EY013410] Funding Source: NIH RePORTER; NEI
   NIH HHS [K08-EY13410] Funding Source: Medline
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Benner JD, 2002, AM J OPHTHALMOL, V134, P765, DOI 10.1016/S0002-9394(02)01694-X
   BENSON WE, 1979, OPHTHALMOLOGY, V86, P283
   Birngruber R., 1980, LASERS BIOL MED, P77
   CAIN CP, 1974, INVEST OPHTH VISUAL, V13, P60
   Connolly BP, 2003, OPHTHALMOLOGY, V110, P415, DOI 10.1016/S0161-6420(02)01561-0
   Field S B, 1988, Recent Results Cancer Res, V107, P1
   FIELD SB, 1990, INTRO PRACTICAL ASPE, P1
   Finger PT, 1997, OPHTHALMOLOGY, V104, P731, DOI 10.1016/S0161-6420(97)30392-3
   FOLK JC, 1985, OPHTHALMOLOGY, V92, P100
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   GOLDBAUM MH, 1976, ARCH OPHTHALMOL-CHIC, V94, P1025
   Gustavsson C, 2004, ACTA OPHTHALMOL SCAN, V82, P100, DOI 10.1111/j.1395-3907.2004.0189a.x
   Hall EJ, 2018, RADIOBIOLOGY RADIOLO
   Holz ER, 2003, ARCH OPHTHALMOL-CHIC, V121, P1649, DOI 10.1001/archopht.121.11.1649
   JOHNSON MW, 1995, ARCH OPHTHALMOL-CHIC, V113, P364, DOI 10.1001/archopht.1995.01100030120034
   Keam SJ, 2004, DRUG AGING, V21, P203, DOI 10.2165/00002512-200421030-00005
   KLEINER RC, 1988, AM J OPHTHALMOL, V106, P298, DOI 10.1016/0002-9394(88)90365-0
   KORVER JGJ, 1998, TRANSPUPILLARY THERM
   Kumar A, 2004, ACTA OPHTHALMOL SCAN, V82, P205, DOI 10.1046/j.1600-0420.2004.00217.x
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Maini BB, 2001, J PETROL TECHNOL, V53, P54, DOI 10.2118/68885-JPT
   Mainster M A, 1999, Semin Ophthalmol, V14, P200
   Mainster M A, 2001, Semin Ophthalmol, V16, P55, DOI 10.1076/soph.16.2.55.4213
   MAINSTER MA, 1970, J OPT SOC AM, V60, P264, DOI 10.1364/JOSA.60.000264
   MAINSTER MA, 1986, OPHTHALMOLOGY, V93, P952
   MAINSTER MA, 1970, J OPT SOC AM, V60, P848, DOI 10.1364/JOSA.60.000848
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   MAINSTER MA, 1999, RETINA VITREOUS MACU, P61
   Margalit E, 2003, ARCH OPHTHALMOL-CHIC, V121, P130
   MESTER U, 1988, OPHTHALMIC SURG LAS, V19, P482
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   Park C H, 2001, Semin Ophthalmol, V16, P66, DOI 10.1076/soph.16.2.66.4208
   Pauleikhoff D, 1996, KLIN MONATSBL AUGENH, V209, P309, DOI 10.1055/s-2008-1035324
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Peyman GA, 2003, RETINA-J RET VIT DIS, V23, P371, DOI 10.1097/00006982-200306000-00014
   POLHAMUS GD, 1980, IEEE T BIO-MED ENG, V27, P617, DOI 10.1109/TBME.1980.326701
   PRIEBE LA, 1975, AM J OPHTHALMOL, V79, P405, DOI 10.1016/0002-9394(75)90613-3
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Robertson DM, 2002, ARCH OPHTHALMOL-CHIC, V120, P648
   ROIDER J, 1993, P NATL ACAD SCI USA, V90, P8643, DOI 10.1073/pnas.90.18.8643
   ROULIER A, 1970, B MATH BIOPHYS, V32, P403, DOI 10.1007/BF02476877
   Srivastava SK, 2002, RETINA-J RET VIT DIS, V22, P669, DOI 10.1097/00006982-200210000-00027
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
   Theodossiadis GP, 2003, GRAEF ARCH CLIN EXP, V241, P13, DOI 10.1007/s00417-002-0579-3
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   WELCH AJ, 1984, IEEE T BIO-MED ENG, V31, P633, DOI 10.1109/TBME.1984.325313
   WHITE TJ, 1971, B MATH BIOPHYS, V33, P1, DOI 10.1007/BF02476660
   WHITE TJ, 1970, B MATH BIOPHYS, V32, P315, DOI 10.1007/BF02476871
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
   ZWENG HC, 1974, T AM ACAD OPHTHALMOL, V78, pO195
NR 53
TC 15
Z9 17
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2004
VL 45
IS 10
BP 3678
EP 3682
DI 10.1167/iovs.04-0436
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 857YB
UT WOS:000224154800040
PM 15452076
DA 2022-11-30
ER

PT J
AU Margalit, E
   Sadda, TR
AF Margalit, E
   Sadda, TR
TI Retinal and optic nerve diseases
SO ARTIFICIAL ORGANS
LA English
DT Review
DE inner retina; outer retina; retinal degenerations; diabetic retinopathy;
   glaucoma; optic neuropathy; visual prostheses
ID OPEN-ANGLE GLAUCOMA; CYTOMEGALOVIRUS RETINITIS; DIABETIC-RETINOPATHY;
   PATHOLOGIC MYOPIA; VEIN; STIMULATION; THERAPY; DAMAGE; TRIAL; EYES
AB A variety of disease processes can affect the retina and/or the optic nerve. including vascular or ischemic disease. inflammatory or infectious disease, and degenerative disease. These disease processes may selectively damage certain parts of the retina or optic nerve, and the specific areas that are damaged may have implications for the design of potential therapeutic visual prosthetic devices. Outer retinal diseases include age-related macular degeneration, pathologic myopia, and retinitis pigmentosa. Although the retinal photoreceptors may be lost, the inner retina is relatively well-preserved in these diseases and may be a target for retinal prosthetic devices. Inner retinal diseases include retinal vascular diseases such as diabetic retinopathy. retinal venous occlusive disease, and retinopathy of prematurity. Other retinal diseases such as ocular infections (retinitis, endophthalmitis) may affect all retinal layers. Because the inner retinal cells, including the retinal ganglion cells, may be destroyed in these diseases (inner retinal or whole retinal), prosthetic devices that stimulate the inner retina may not be effective. Common optic nerve diseases include glaucoma, optic neuritis, and ischemic optic neuropathy. Because the ganglion cell nerve fibers themselves are damaged, visual prosthetics for these diseases will need to target more distal portions of the visual pathway, such as the visual cortex. Clearly, a sound understanding of retinal and optic nerve disease pathophysiology is critical for designing and choosing the optimal visual prosthetic device.
C1 Univ So Calif, Keck Sch Med, Doheny Retina Inst, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
C3 University of Southern California; Johns Hopkins University; Johns
   Hopkins Medicine
RP Sadda, TR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Retina Inst, 1450 San Pablo St,Suite 3610, Los Angeles, CA 90033 USA.
EM ssadda@dei.hsc.usc.edu
CR [Anonymous], 1986, Arch Ophthalmol, V104, P34
   [Anonymous], 1990, Arch Ophthalmol, V108, P958
   [Anonymous], 1995, Arch Ophthalmol, V113, P1479
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P271
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   ASHTON N, 1953, BR J OPHTHALMOL, V49, P225
   BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403
   Bennett J, 2000, CURR OPIN MOL THER, V2, P420
   BERI M, 1987, OPHTHALMOLOGY, V94, P1020
   BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BOUGHMAN JA, 1983, BRIT J OPHTHALMOL, V67, P449, DOI 10.1136/bjo.67.7.449
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   BRINTON GS, 1984, ARCH OPHTHALMOL-CHIC, V102, P547
   CAMPBELL PB, 1983, ARCH OPHTHALMOL-CHIC, V101, P1686
   Caprioli J, 1997, AM J OPHTHALMOL, V124, P516, DOI 10.1016/S0002-9394(14)70867-0
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1434
   Clermont AC, 1997, AM J OPHTHALMOL, V124, P433, DOI 10.1016/S0002-9394(14)70860-8
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURTIN BJ, 1979, OPHTHALMOLOGY, V86, P681
   De Venecia G, 1971, Arch Ophthalmol, V86, P44
   DEJUAN E, 1987, ARCH OPHTHALMOL-CHIC, V105, P21
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   DICKERSIN K, 1995, JAMA-J AM MED ASSOC, V273, P625, DOI 10.1001/jama.1995.03520320035038
   Doft BM, 2000, ARCH OPHTHALMOL-CHIC, V118, P1661, DOI 10.1001/archopht.118.12.1661
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Eckmiller R, 1997, OPHTHALMIC RES, V29, P281, DOI 10.1159/000268026
   Frank RN, 2002, AM J OPHTHALMOL, V133, P693, DOI 10.1016/S0002-9394(02)01321-1
   GARNER A, 1984, ARCH OPHTHALMOL-CHIC, V102, P1130
   Green W R, 1981, Trans Am Ophthalmol Soc, V79, P371
   GREEN WR, 1985, OPHTHALMIC PATHOLOGY, P691
   Hattenhauer MG, 1997, AM J OPHTHALMOL, V123, P103, DOI 10.1016/S0002-9394(14)70999-7
   HAYREH SS, 1983, OPHTHALMOLOGY, V90, P458
   HECKENLIVELY J, 1981, METAB PEDIATR SYST O, V5, P201
   HENDERLY DE, 1987, OPHTHALMOLOGY, V94, P425
   HENDERLY DE, 1987, AM J OPHTHALMOL, V103, P316
   HOTCHKISS ML, 1981, AM J OPHTHALMOL, V91, P177, DOI 10.1016/0002-9394(81)90170-7
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   JAY B, 1973, T AM ACAD OPHTHALMOL, V77, pOP641
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATTAN HM, 1991, OPHTHALMOLOGY, V98, P227
   Kupersmith MJ, 1997, J NEURO-OPHTHALMOL, V17, P250
   LEBER T, 1877, HDB GESAMMTEN AUGENH, P521
   MCALLISTER IL, 1995, ARCH OPHTHALMOL-CHIC, V113, P456, DOI 10.1001/archopht.1995.01100040072030
   MICHEL J, 1878, A VONGRAEFES ARCH OP, V24, P37
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   Normann RA, 1999, VISION RES, V39, P2577, DOI 10.1016/S0042-6989(99)00040-1
   OSTERLOH MD, 1988, ARCH OPHTHALMOL-CHIC, V106, P1469
   PALMBERG PF, 1977, DIABETES, V26, P703, DOI 10.2337/diab.26.7.703
   PATZ A, 1984, BRIT J OPHTHALMOL, V68, P42, DOI 10.1136/bjo.68.1.42
   PATZ A, 1957, PEDIATRICS, V19, P504
   Peyman G, 1998, OPHTHALMIC SURG LAS, V29, P234
   QUIGLEY HA, 1979, OPHTHALMOLOGY, V86, P1803
   Rizzo JF, 1997, NEUROSCIENTIST, V3, P251, DOI 10.1177/107385849700300413
   Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026
   SOUBRANE G, 2001, RETINA, P1136
   TASMAN W, 1988, ARCH OPHTHALMOL-CHIC, V106, P463
   Terry TL, 1942, AM J OPHTHALMOL, V25, P203, DOI DOI 10.1016/S0002-9394(42)92088-9
   THEODORE FH, 1978, OPHTHALMOLOGY, V85, P327, DOI 10.1016/S0161-6420(78)35661-X
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   TROBE JD, 1980, ARCH OPHTHALMOL-CHIC, V98, P1046
   Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Weiss JN, 2001, OPHTHALMOLOGY, V108, P2249, DOI 10.1016/S0161-6420(01)00875-2
   Wolter J R, 1961, Br J Ophthalmol, V45, P683, DOI 10.1136/bjo.45.10.683
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
   Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5
NR 69
TC 74
Z9 79
U1 2
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-564X
EI 1525-1594
J9 ARTIF ORGANS
JI Artif. Organs
PD NOV
PY 2003
VL 27
IS 11
BP 963
EP 974
DI 10.1046/j.1525-1594.2003.07304.x
PG 12
WC Engineering, Biomedical; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Transplantation
GA 742AE
UT WOS:000186491900002
PM 14616515
DA 2022-11-30
ER

PT J
AU Staurenghi, G
   Invernizzi, A
   de Polo, L
   Pellegrini, M
AF Staurenghi, Giovanni
   Invernizzi, Alessandro
   de Polo, Laura
   Pellegrini, Marco
TI Diagnosis and detection
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Autofluorescence; Edema; Indocyanine green; Optical coherence tomography
ID DIABETIC MACULAR EDEMA; OPTICAL-COHERENCE-TOMOGRAPHY; PHOTOCOAGULATION;
   RETINOPATHY
AB PURPOSE. To evaluate features of macular edema assessed by optical coherence tomography (OCT) and other imaging tools such as infrared, blue retinography and auto fluorescence, and fluorescein and indocyanine green angiography (ICGA) in different pathologic conditions.
   METHODS. The principal causes of macular edema were reviewed to evaluate its aspect in each pathology. Correlations between OCT and other imaging techniques were analyzed.
   RESULTS. Optical coherence tomography and other imaging tools allowed the authors to confirm the existence of different macular edema patterns for different pathologies and to describe their characteristics; in particular, some conditions, like idiopathic macular telangiectasias and age-related maculopathy, were found to present specific edema patterns.
   CONCLUSIONS. Simultaneous use of different imaging techniques allowed a better evaluation and follow-up of conditions causing cystoid macular edema.
C1 [Staurenghi, Giovanni; Invernizzi, Alessandro; de Polo, Laura; Pellegrini, Marco] Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, I-20157 Milan, Italy.
C3 University of Milan; Luigi Sacco Hospital
RP Staurenghi, G (通讯作者)，Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
EM giovanni.staurenghi@unimi.it
RI Invernizzi, Alessandro/K-8605-2016; Staurenghi, Giovanni/K-4388-2017
OI Invernizzi, Alessandro/0000-0003-3400-1987; Staurenghi,
   Giovanni/0000-0002-2299-5251; pellegrini, marco/0000-0002-3550-591X
FU Zeiss; Optovue; Canon
FX Prof. G. Staurenghi is a consultant for Heidelberg Engineering,
   GlaxoSmithKline, Allergan Inc., Pfizer Ophthalmics, and OD-OS. Grant
   support was provided by Zeiss, Optovue, and Canon, and patents/royalty
   from Ocular Instruments. Drs. M. Pellegrini, A. Invernizzi, and L. de
   Polo report no financial support or grants or proprietary interest.
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Bottoni F, 2010, RETINA-J RET VIT DIS, V30, P317, DOI 10.1097/IAE.0b013e3181b9f11e
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   IRVINE SR, 1953, AM J OPHTHALMOL, V36, P599, DOI 10.1016/0002-9394(53)90302-X
   Johnson MW, 2009, AM J OPHTHALMOL, V147, P11, DOI 10.1016/j.ajo.2008.07.024
   Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016/j.ajo.2006.04.023
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Ray Subhransu, 2002, Semin Ophthalmol, V17, P167, DOI 10.1076/soph.17.3.167.14794
   Roesel M, 2009, GRAEF ARCH CLIN EXP, V247, P1685, DOI 10.1007/s00417-009-1149-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Weinberger D, 1998, AM J OPHTHALMOL, V126, P238, DOI 10.1016/S0002-9394(98)00148-2
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 13
TC 1
Z9 1
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2011
VL 21
SU 6
BP S27
EP S36
DI 10.5301/EJO.2010.6052
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 768FB
UT WOS:000290916000005
PM 23264326
DA 2022-11-30
ER

PT J
AU Blanquez-Martinez, D
   Diaz-Villamarin, X
   Garcia-Rodriguez, S
   Antunez-Rodriguez, A
   Pozo-Agundo, A
   Martinez-Gonzalez, LJ
   Munoz-Avila, JI
   Davila-Fajardo, CL
AF Blanquez-Martinez, David
   Diaz-Villamarin, Xando
   Garcia-Rodriguez, Sonia
   Antunez-Rodriguez, Alba
   Pozo-Agundo, Ana
   Martinez-Gonzalez, Luis Javier
   Munoz-Avila, Jose Ignacio
   Davila-Fajardo, Cristina Lucia
TI Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab
   Response in High Myopia and Choroidal Neovascularization Patients
SO PHARMACEUTICS
LA English
DT Article
DE pharmacogenetics; myopia; ranibizumab; precision medicine; VEGFR;
   anti-VEGF; FLT1; KDR
ID PATHOLOGICAL MYOPIA; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
   REFRACTIVE ERRORS; INTRAVITREAL RANIBIZUMAB; LASER PHOTOCOAGULATION;
   FUNCTIONAL-RESPONSE; AGE; ASSOCIATION; BEVACIZUMAB
AB A severe form of myopia defined as pathologic/high myopia is the main cause of visual impairment and one of the most frequent causes of blindness worldwide. It is characterized by at least 6 diopters or axial length (AL) of eyeball > 26 mm and choroidal neovascularization (CNV) in 5 to 10% of cases. Ranibizumab is a humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A) used in the treatment of CNV. It acts by preventing VEGF-A from interacting with its receptors (VEGFR-1 and -2) encoded by the FLT1 and KDR genes. Several studies found that the KDR and FLT1 genotypes may represent predictive determinants of efficacy in ranibizumab-treated neovascular age-related macular degeneration (nAMD) patients. We performed a retrospective study to evaluate the association of single nucleotide polymorphisms (SNPs) in VEGFR coding genes with the response rate to ranibizumab in patients with high myopia and CNV. In the association study of genotypes in FLT1 with the response to ranibizumab, we found a significant association between two FLT1 variants (rs9582036, rs7993418) with ranibizumab efficacy at the 12-month follow-up. About the KDR gene, we found that two KDR variants (rs2305948, rs2071559) are associated with best-corrected visual acuity (BCVA) improvement and KDR (rs2239702) is associated with lower rates of BCVA worsening considering a 12-month follow-up period.
C1 [Blanquez-Martinez, David] Hosp Univ Ceuta, Pharm Dept, Ceuta 51003, Spain.
   [Diaz-Villamarin, Xando] Univ Granada UGR, Pharmacol Dept, Granada 18016, Spain.
   [Garcia-Rodriguez, Sonia; Antunez-Rodriguez, Alba; Pozo-Agundo, Ana] Inst Invest Biosanit Granada Ibs Granada, Granada 18016, Spain.
   [Garcia-Rodriguez, Sonia; Antunez-Rodriguez, Alba; Pozo-Agundo, Ana; Martinez-Gonzalez, Luis Javier] Univ Granada, Ctr Genom & Oncol Res Pfizer, Andalusian Reg Govt GENYO, Genom Unit, Granada 18016, Spain.
   [Munoz-Avila, Jose Ignacio] Hosp Univ Clin San Cecilio, Inst Invest Biosanitaria Granada Ibs Granada, Ophthalmol Dept, Granada 18016, Spain.
   [Davila-Fajardo, Cristina Lucia] Hosp Univ Virgen Nieves, Inst Invest Biosanitaria Granada Ibs Granada, Pharm Dept, Granada 18016, Spain.
C3 University of Granada; Pfizer; University of Granada; Hospital
   Universitario Virgen de las Nieves
RP Diaz-Villamarin, X (通讯作者)，Univ Granada UGR, Pharmacol Dept, Granada 18016, Spain.
EM david.blanquez.sspa@juntadeandalucia.es; xandodv@ugr.es;
   garciarodriguez.sonia@gmail.com; alba.antunez@genyo.es;
   ana.pozo@genyo.es; luisjavier.martinez@genyo.es;
   josei.munoz.sspa@juntadeandalucia.es;
   cristinal.davila.sspa@juntadeandalucia.es
RI ; Martinez-Gonzalez, Luis Javier/L-6136-2014
OI Pozo-Agundo, Ana/0000-0003-2188-6296; Martinez-Gonzalez, Luis
   Javier/0000-0003-2202-0662; Antunez-Rodriguez, Alba/0000-0002-3963-6546
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Apellaniz-Ruiz M, 2017, PHARMACOGENET GENOM, V27, P227, DOI 10.1097/FPC.0000000000000280
   Beuselinck B, 2016, BJU INT, V118, P890, DOI 10.1111/bju.13585
   Beuselinck B, 2014, ACTA ONCOL, V53, P103, DOI 10.3109/0284186X.2013.770600
   Blanquez-Martinez D, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13111973
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Chan WM, 2005, BRIT J OPHTHALMOL, V89, P1522, DOI 10.1136/bjo.2005.074716
   Chang W, 2013, MOL VIS, V19, P702
   Chuck RS, 2018, OPHTHALMOLOGY, V125, pP1, DOI 10.1016/j.ophtha.2017.10.003
   Chung YW, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8913582
   Claxton L, 2014, DRUG AGING, V31, P837, DOI 10.1007/s40266-014-0216-y
   Cobos E, 2018, ACTA OPHTHALMOL, V96, pe201, DOI 10.1111/aos.13519
   Deeks ED, 2014, BIODRUGS, V28, P403, DOI 10.1007/s40259-014-0102-5
   Diaz-Villamarin X, 2020, GENES-BASEL, V11, DOI 10.3390/genes11111335
   Dornbusch J, 2016, J CANCER RES CLIN, V142, P1171, DOI 10.1007/s00432-016-2137-0
   Escudier B, 2015, CLIN GENITOURIN CANC, V13, P328, DOI 10.1016/j.clgc.2015.02.007
   Fredrick DR, 2002, BRIT MED J, V324, P1195, DOI 10.1136/bmj.324.7347.1195
   Freeman B, 2003, BEHAV GENET, V33, P67, DOI 10.1023/A:1021055617738
   Giansanti F, 2012, RETINA-J RET VIT DIS, V32, P1547, DOI 10.1097/IAE.0b013e3182411cee
   Gomez-Martin A, 2015, CHEMOSPHERE, V139, P534, DOI 10.1016/j.chemosphere.2015.07.079
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Holz FG, 2016, OPHTHALMOLOGICA, V236, P19, DOI 10.1159/000446027
   Jain L, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-95
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lores-Motta L, 2016, PHARMACOGENET GENOM, V26, P20, DOI 10.1097/FPC.0000000000000180
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Miller DG, 2001, CURR OPIN OPHTHALMOL, V12, P222, DOI 10.1097/00055735-200106000-00014
   Miyake M, 2014, OPHTHALMOLOGY, V121, P225, DOI 10.1016/j.ophtha.2013.06.043
   Ng DSC, 2020, EXPERT OPIN BIOL TH, V20, P1385, DOI 10.1080/14712598.2021.1830969
   Park UC, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0631-z
   Parodi MB, 2010, ARCH OPHTHALMOL-CHIC, V128, P437, DOI 10.1001/archophthalmol.2009.408
   Rinaldi C, 2017, J NEUROL SCI, V380, P31, DOI 10.1016/j.jns.2017.06.043
   Ruiz-Moreno JM, 2002, EUR J OPHTHALMOL, V12, P117, DOI 10.1177/112067210201200207
   Saw SM, 2005, OPHTHAL PHYSL OPT, V25, P381, DOI 10.1111/j.1475-1313.2005.00298.x
   Scartozzi M, 2014, INT J CANCER, V135, P1247, DOI 10.1002/ijc.28772
   Scimone C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00953
   Scimone C, 2016, BMC MED GENET, V17, DOI 10.1186/s12881-016-0332-0
   Scimone C, 2015, J MOL NEUROSCI, V57, P400, DOI 10.1007/s12031-015-0606-6
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Soubrane G, 2008, SURV OPHTHALMOL, V53, P121, DOI 10.1016/j.survophthal.2007.12.004
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Uemura A, 2000, ARCH OPHTHALMOL-CHIC, V118, P344, DOI 10.1001/archopht.118.3.344
   Verteporfin in Photodynamic Therapy Study Group, 2001, OPHTHALMOLOGY, V108, P841, DOI [10.1016/S0161-6420(01)00544-9, DOI 10.1016/S0161-6420(01)00544-9]
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   Zhang LJ, 2016, AM J THER, V23, pE1663, DOI 10.1097/MJT.0000000000000231
   Zheng YB, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0209-z
NR 52
TC 0
Z9 0
U1 7
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD AUG
PY 2022
VL 14
IS 8
AR 1555
DI 10.3390/pharmaceutics14081555
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 4B3GT
UT WOS:000845671200001
PM 35893809
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wen, XW
   Li, S
   Zhang, YF
   Zhu, L
   Xi, XT
   Zhang, SY
   Li, Y
AF Wen, Xuewei
   Li, Song
   Zhang, Yanfei
   Zhu, Liang
   Xi, Xiaoting
   Zhang, Shuyuan
   Li, Yan
TI Recombinant human klotho protects against hydrogen peroxide-mediated
   injury in human retinal pigment epithelial cells via the
   PI3K/Akt-Nrf2/HO-1 signaling pathway
SO BIOENGINEERED
LA English
DT Article
DE Klotho; oxidative stress; PI3K; akt-nrf2; HO-1 signaling pathway;
   apoptosis
ID OXIDATIVE STRESS; MACULAR DEGENERATION; IN-VITRO; APOPTOSIS;
   INFLAMMATION; ACTIVATION; LENS; EYE; ROS
AB Globally, age-related macular degeneration (AMD) is a common irreversible ophthalmopathy. Oxidative stress of retinal pigment epithelial cells is involved in AMD occurrence and development. Klotho is an anti-aging protein with antioxidant properties. We investigated the protective properties of Klotho on hydrogen peroxide (H2O2)-induced injury of retinal pigment epithelial cells (ARPE-19 cells) and its associated pathomechanisms. We found that Klotho pretreatment for 24 h could up-regulate Bcl-2 levels, decrease the cleaved-caspase-3 and Bax levels, inhibit H2O2-induced ARPE-19 cell apoptosis, and promote cell proliferation. Klotho pretreatment inhibited the H2O2-mediated elevations of reactive oxygen species (ROS) in ARPE-19 cells. It enhanced antioxidant activities of the cells and restored the glutathione peroxidase (GPX), superoxide dismutase (SOD2), catalase (CAT), as well as malondialdehyde (MDA) levels to close to the normal level. N-acetylcysteine (NAC), a reactive oxygen scavenger, could reverse the harmful effects of H2O2 on proliferation, apoptosis, and oxidative stress of ARPE-19 cells. Further, Klotho pretreatment enhanced Akt phosphorylation and expression as well as nuclear translocation of Nrf2 in H2O2-treated ARPE-19 cells. This indicates that Klotho protects cells from oxidative stress by activating phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt)-nuclear factor E2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) signaling pathway. Klotho is, therefore, a potential preventive or treatment option for AMD.
C1 [Wen, Xuewei; Zhang, Yanfei; Zhu, Liang; Xi, Xiaoting; Zhang, Shuyuan; Li, Yan] Kunming Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Xichang Rd 295, Kunming 650032, Yunnan, Peoples R China.
   [Li, Song] Kunming Med Univ, Affiliated Hosp 1, Dept Sport Med, Kunming, Yunnan, Peoples R China.
C3 Kunming Medical University; Kunming Medical University
RP Li, Y (通讯作者)，Kunming Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Xichang Rd 295, Kunming 650032, Yunnan, Peoples R China.
EM liyanr0729@163.com
FU National Natural Science Foundation of China [82060178]
FX This study was funded by grants from the National Natural Science
   Foundation of China (No. 82060178)
CR Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Cossarizza D, 2000, MINERVA BIOTECNOL, V12, P57
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Cui W, 2018, MED SCI MONITOR, V24, P8489, DOI 10.12659/MSM.911202
   Dalton GD, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00323
   Fernandes WR, 2012, PESQUI VET BRASIL, V32, P677, DOI 10.1590/S0100-736X2012000700017
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Galasso M, 2021, FREE RADICAL BIO MED, V172, P264, DOI 10.1016/j.freeradbiomed.2021.06.010
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Guo Y, 2018, BBA-MOL BASIS DIS, V1864, P238, DOI 10.1016/j.bbadis.2017.09.029
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holze C, 2018, NAT IMMUNOL, V19, P130, DOI 10.1038/s41590-017-0013-y
   Husain A, 2022, BIOCHEM BIOPH RES CO, V586, P27, DOI 10.1016/j.bbrc.2021.11.030
   Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090
   Inan S, 2020, CURR EYE RES, V45, P527, DOI 10.1080/02713683.2019.1675174
   Ismayilov AS, 2019, CLIN EXP OPTOM, V102, P617, DOI 10.1111/cxo.12877
   Ji BL, 2020, J DIABETES INVEST, V11, P162, DOI 10.1111/jdi.13100
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Kimura T, 2018, AM J PHYSIOL-RENAL, V315, pF345, DOI 10.1152/ajprenal.00486.2017
   Kokkinaki M, 2013, J NEUROSCI, V33, P16346, DOI 10.1523/JNEUROSCI.0402-13.2013
   L L., 2017, INT J MOL SCI, V18, P728
   Li XL, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116773
   Li YQ, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01946-y
   Liao RF, 2018, BRIT J PHARMACOL, V175, P125, DOI 10.1111/bph.14078
   Ma ZX, 2022, OCUL IMMUNOL INFLAMM, V30, P630, DOI 10.1080/09273948.2020.1828488
   Ma ZX, 2021, CURR EYE RES, V46, P482, DOI 10.1080/02713683.2020.1805768
   Ma ZX, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106582
   Perez AAM, 2020, DNA CELL BIOL, V39, P1478, DOI 10.1089/dna.2020.5444
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Ravikumar P, 2016, J APPL PHYSIOL, V120, P723, DOI 10.1152/japplphysiol.00792.2015
   Reish NJ, 2013, INVEST OPHTH VIS SCI, V54, P6675, DOI 10.1167/iovs.13-12550
   Shaw P, 2020, J CELL PHYSIOL, V235, P3119, DOI 10.1002/jcp.29219
   Shen Y, 2018, INT UROL NEPHROL, V50, P787, DOI 10.1007/s11255-017-1765-x
   Takenaka T, 2019, ACTA PHYSIOL, V225, DOI 10.1111/apha.13190
   Tang ZM, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101971
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Zhang Y, 2022, BIOENGINEERED, V13, P735, DOI 10.1080/21655979.2021.2012627
   Zhang Y, 2017, CURR EYE RES, V42, P871, DOI 10.1080/02713683.2016.1259421
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhang ZY, 2022, BIOENGINEERED, V13, P1612, DOI 10.1080/21655979.2021.2021062
   Zhao NM, 2021, BIOENGINEERED, V12, P10187, DOI 10.1080/21655979.2021.2001217
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou HJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.755366
   Zhu LL, 2021, CLIN EXP PHARMACOL P, V48, P1412, DOI 10.1111/1440-1681.13547
NR 49
TC 1
Z9 1
U1 2
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165-5979
EI 2165-5987
J9 BIOENGINEERED
JI Bioengineered
PD MAY 2
PY 2022
VL 13
IS 5
BP 11767
EP 11781
DI 10.1080/21655979.2022.2071023
PG 15
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA 1D1QM
UT WOS:000793582500001
PM 35543385
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nair, DSR
   Zhu, DH
   Sharma, R
   Camarillo, JCM
   Bharti, K
   Hinton, DR
   Humayun, MS
   Thomas, BB
AF Nair, Deepthi S. Rajendran
   Zhu, Danhong
   Sharma, Ruchi
   Camarillo, Juan Carlos Martinez
   Bharti, Kapil
   Hinton, David R.
   Humayun, Mark S.
   Thomas, Biju B.
TI Long-Term Transplant Effects of iPSC-RPE Monolayer in Immunodeficient
   RCS Rats
SO CELLS
LA English
DT Article
DE iPSC-RPE; retinal pigment epithelium; immunodeficient RCS rat; ultrathin
   parylene; retinal degeneration; retinal transplantation
ID RETINAL-PIGMENT EPITHELIUM; EMBRYONIC STEM-CELLS; SUBRETINAL
   IMPLANTATION; SURVIVAL; DIFFERENTIATION
AB Retinal pigment epithelium (RPE) replacement therapy is evolving as a feasible approach to treat age-related macular degeneration (AMD). In many preclinical studies, RPE cells are transplanted as a cell suspension into immunosuppressed animal eyes and transplant effects have been monitored only short-term. We investigated the long-term effects of human Induced pluripotent stem-cell-derived RPE (iPSC-RPE) transplants in an immunodeficient Royal College of Surgeons (RCS) rat model, in which RPE dysfunction led to photoreceptor degeneration. iPSC-RPE cultured as a polarized monolayer on a nanoengineered ultrathin parylene C scaffold was transplanted into the subretinal space of 28-day-old immunodeficient RCS rat pups and evaluated after 1, 4, and 11 months. Assessment at early time points showed good iPSC-RPE survival. The transplants remained as a monolayer, expressed RPE-specific markers, performed phagocytic function, and contributed to vision preservation. At 11-months post-implantation, RPE survival was observed in only 50% of the eyes that were concomitant with vision preservation. Loss of RPE monolayer characteristics at the 11-month time point was associated with peri-membrane fibrosis, immune reaction through the activation of macrophages (CD 68 expression), and the transition of cell fate (expression of mesenchymal markers). The overall study outcome supports the therapeutic potential of RPE grafts despite the loss of some transplant benefits during long-term observations.
C1 [Nair, Deepthi S. Rajendran; Camarillo, Juan Carlos Martinez; Humayun, Mark S.; Thomas, Biju B.] Univ Southern Calif, Keck Sch Med, Roski Eye Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Zhu, Danhong; Hinton, David R.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Dept Pathol & Ophthalmol, Los Angeles, CA 90033 USA.
   [Sharma, Ruchi; Bharti, Kapil] NEI, Unit Ocular & Stem Cell Translat Res, NIH, Bethesda, MD 20892 USA.
   [Camarillo, Juan Carlos Martinez; Humayun, Mark S.; Thomas, Biju B.] Univ Southern Calif, USC Ginsburg Inst Biomed Therapeut, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Southern California
RP Thomas, BB (通讯作者)，Univ Southern Calif, Keck Sch Med, Roski Eye Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.; Thomas, BB (通讯作者)，Univ Southern Calif, USC Ginsburg Inst Biomed Therapeut, Los Angeles, CA 90033 USA.
EM deepthir@usc.edu; dzhu@usc.edu; fnu.ruchi2@nih.gov;
   juan.martinez@med.usc.edu; kapil.bharti@nih.gov; dhinton@usc.edu;
   humayun@med.usc.edu; biju.thomas@med.usc.edu
RI Rajendran Nair, Deepthi S./AAE-2769-2022
OI Rajendran Nair, Deepthi S./0000-0001-8851-5241
FU Bright Focus Foundation [M2016186]; National Eye Institute of the
   National Institutes of Health [P30EY029220]; CIRM (California Institute
   for Regenerative Medicine) [DISC1-09912, DR3-07438-PI]; Unrestricted
   Grant to the Department of Ophthalmology from Research to Prevent
   Blindness; National Institutes of Health
FX Funding This study was funded by a grant from the Bright Focus
   Foundation (M2016186, Thomas, PI). Research reported in this publication
   was supported by the National Eye Institute of the National Institutes
   of Health under Award Number P30EY029220. CIRM (California Institute for
   Regenerative Medicine) grants (DISC1-09912 PI-Thomas,
   DR3-07438-PI-Humayun), Unrestricted Grant to the Department of
   Ophthalmology from Research to Prevent Blindness, New York, NY. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carlsson E, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.9
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cooper AE, 2016, J OCUL PHARMACOL TH, V32, P296, DOI 10.1089/jop.2015.0134
   D'Antonio-Chronowska A, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3469
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Di Pierdomenico J, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00014
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   EKSTROM P, 1988, INVEST OPHTH VIS SCI, V29, P1363
   Ferrer-Vaquer A, 2010, CELL ADHES MIGR, V4, P447, DOI 10.4161/cam.4.3.10771
   Foltz LP, 2017, JOVE-J VIS EXP, DOI 10.3791/56274
   Fujii S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093077
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Hazim RA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0652-9
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   McGill TJ, 2018, INVEST OPHTH VIS SCI, V59, P1374, DOI 10.1167/iovs.17-22467
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sheridan CM, 2009, EYE, V23, P1910, DOI 10.1038/eye.2008.420
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   SIMINOFF R, 1966, J COMP NEUROL, V127, P435, DOI 10.1002/cne.901270402
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Thomas BB, 2018, GRAEF ARCH CLIN EXP, V256, P2113, DOI 10.1007/s00417-018-4134-2
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Westenskow PD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8470263
   White C, 2017, J BIOMED MATER RES A, V105, P1260, DOI 10.1002/jbm.a.35992
   Zhang H, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-4707
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
   Zhu DL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01608-8
   Zou H, 2020, PEERJ, V8, DOI 10.7717/peerj.10136
NR 52
TC 1
Z9 1
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2021
VL 10
IS 11
AR 2951
DI 10.3390/cells10112951
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XI0PC
UT WOS:000725824100001
PM 34831174
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Occelli, LM
   Marinho, F
   Singh, RK
   Binette, F
   Nasonkin, IO
   Petersen-Jones, SM
AF Occelli, Laurence M.
   Marinho, Felipe
   Singh, Ratnesh K.
   Binette, Francois
   Nasonkin, Igor O.
   Petersen-Jones, Simon M.
TI Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal
   Tissue in a Feline Large Animal Model
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
ID PIGMENT EPITHELIUM; GENE-THERAPY; RETINITIS-PIGMENTOSA; VISUAL FUNCTION;
   NEURAL RETINA; IMPLANTATION; SHEETS; DEGENERATION; MONOLAYER;
   DIFFERENTIATION
AB Retinal degenerative (RD) conditions associated with photoreceptor loss such as age-related macular degeneration (AMD), retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA) cause progressive and debilitating vision loss. There is an unmet need for therapies that can restore vision once photoreceptors have been lost. Transplantation of human pluripotent stem cell (hPSC)-derived retinal tissue (organoids) into the subretinal space of an eye with advanced RD brings retinal tissue sheets with thousands of healthy mutation-free photoreceptors and has a potential to treat most/all blinding diseases associated with photoreceptor degeneration with one approved protocol. Transplantation of fetal retinal tissue into the subretinal space of animal models and people with advanced RD has been developed successfully but cannot be used as a routine therapy due to ethical concerns and limited tissue supply. Large eye inherited retinal degeneration (IRD) animal models are valuable for developing vision restoration therapies utilizing advanced surgical approaches to transplant retinal cells/tissue into the subretinal space. The similarities in globe size, and photoreceptor distribution (e.g., presence of macula-like region area centralis) and availability of IRD models closely recapitulating human IRD would facilitate rapid translation of a promising therapy to the clinic. Presented here is a surgical technique of transplanting hPSC-derived retinal tissue into the subretinal space of a large animal model allowing assessment of this promising approach in animal models.
C1 [Occelli, Laurence M.; Marinho, Felipe; Petersen-Jones, Simon M.] Michigan State Univ, Coll Vet Med, Dept Small Anim Clin Sci, E Lansing, MI 48824 USA.
   [Singh, Ratnesh K.; Binette, Francois; Nasonkin, Igor O.] Lineage Cell Therapeut Inc, Carlsbad, CA USA.
C3 Michigan State University
RP Petersen-Jones, SM (通讯作者)，Michigan State Univ, Coll Vet Med, Dept Small Anim Clin Sci, E Lansing, MI 48824 USA.
EM peter315@cvm.msu.edu
FU NEI Fast-track SBIR grant [R44-EY027654-01A1]; SBIR grant [3 R44 EY
   027654 -02 S1]
FX This work was funded by NEI Fast-track SBIR grant R44-EY027654-01A1 and
   SBIR grant 3 R44 EY 027654 -02 S1 (I.O.N., Lineage Cell Therapeutics;
   Dr. Petersen-Jones is a co-PI). The authors would like to thank Ms.
   Janice Querubin (MSU RATTS) for her help with anesthesia and general
   care for the animals included in this study as well as help with
   surgical setting and instruments preparation/sterilization. The authors
   would like to thank Dr. Paige Winkler for the help in receiving the
   organoids and placing them in media on the day prior to the implantation
   and for the help on the day of the implantation. The authors are also
   grateful to Mr. Randy Garchar (LCTX) for diligent shipping of retinal
   organoids, assembling the shipper, and downloading temperature and
   G-stress-records after each shipment. This work was performed while
   author Igor Nasonkin was employed by Biotime (now Lineage).
CR Annear MJ, 2013, HUM GENE THER, V24, P883, DOI 10.1089/hum.2013.146
   Aramant RB, 2002, EXP EYE RES, V75, P115, DOI 10.1006/exer.2002.2001
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Beltran WA, 2017, MOL THER, V25, P1866, DOI 10.1016/j.ymthe.2017.05.004
   Beltran WA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090390
   Bragadottir R, 2003, VET OPHTHALMOL, V6, P135, DOI 10.1046/j.1463-5224.2003.00280.x
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Chow AY, 2002, J REHABIL RES DEV, V39, P313
   Chow AY, 2001, IEEE T NEUR SYS REH, V9, P86, DOI 10.1109/7333.918281
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Dias Marina Franca, 2018, Prog Retin Eye Res, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Eckhorn R, 2006, VISION RES, V46, P2675, DOI 10.1016/j.visres.2006.01.034
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Ghosh F, 2007, GRAEF ARCH CLIN EXP, V245, P835, DOI 10.1007/s00417-006-0437-9
   Hambright D, 2012, MOL VIS, V18, P920
   Kashani AH, 2019, ADV EXP MED BIOL, V1185, P569, DOI 10.1007/978-3-030-27378-1_93
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lin B, 2018, EXP EYE RES, V174, P13, DOI 10.1016/j.exer.2018.05.017
   Lorach H, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.30
   Lorach H, 2015, M S-MED SCI, V31, P830, DOI 10.1051/medsci/20153110006
   Machemer R, 1972, Mod Probl Ophthalmol, V10, P178
   MACHEMER R, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P462
   MACHEMER R, 1985, AM J OPHTHALMOL, V100, P590, DOI 10.1016/0002-9394(85)90687-7
   Machemer R., 1972, T AM ACAD OPHTHALMOL, V75, P813
   Mandai M, 2017, STEM CELL REP, V8, P1112, DOI 10.1016/j.stemcr.2017.03.024
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Mowat FM, 2017, INVEST OPHTH VIS SCI, V58, P3268, DOI 10.1167/iovs.17-21930
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Narfstrom K, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/906943
   Nasonkin IO, 2019, INVEST OPHTH VIS SCI, V60
   O'Malley C, 1975, Ann Ophthalmol, V7, P585
   Occelli LM, 2017, HUM GENE THER, V28, P1189, DOI 10.1089/hum.2017.155
   Occelli LM, 2016, INVEST OPHTH VIS SCI, V57, P3780, DOI 10.1167/iovs.16-19444
   Pardue MT, 2006, J REHABIL RES DEV, V43, P723, DOI 10.1682/JRRD.2005.07.0118
   Petersen-Jones SM, 2009, MOL VIS, V15, P1835
   Petersen-Jones S. M, 2013, DRUG DISCOV TODAY, V10, P215
   Petersen-Jones SM, 2018, J CLIN INVEST, V128, P190, DOI 10.1172/JCI95161
   Petersen-Jones SM, 2015, HUM GENE THER CL DEV, V26, P15, DOI 10.1089/humc.2014.155
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Sachs HG, 2005, GRAEF ARCH CLIN EXP, V243, P464, DOI 10.1007/s00417-004-1049-x
   Scruggs BA, 2019, STEM CELL TRANSL MED, V8, P797, DOI 10.1002/sctm.18-0210
   Seiler MJ, 2017, INVEST OPHTH VIS SCI, V58, P614, DOI 10.1167/iovs.15-19028
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Seiler MJ, 2009, VET OPHTHALMOL, V12, P158, DOI 10.1111/j.1463-5224.2009.00693.x
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh R, 2018, STEM CELL REV REP, V14, P463, DOI 10.1007/s12015-018-9802-4
   Singh RK, 2020, J TISSUE ENG REGEN M, V14, P388, DOI 10.1002/term.2997
   Singh RK, 2019, STEM CELLS DEV, V28, P1151, DOI 10.1089/scd.2019.0090
   Singh RK, 2015, STEM CELLS DEV, V24, P2778, DOI 10.1089/scd.2015.0144
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Villalobos J, 2013, INVEST OPHTH VIS SCI, V54, P3751, DOI 10.1167/iovs.12-10843
   Volker M, 2004, GRAEF ARCH CLIN EXP, V242, P792, DOI 10.1007/s00417-004-0935-6
   Wahlin KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00774-9
   Winkler PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072229
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 64
TC 0
Z9 0
U1 3
U2 5
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD AUG
PY 2021
IS 174
AR e61683
DI 10.3791/61683
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TX1CE
UT WOS:000682827300002
PM 34424232
DA 2022-11-30
ER

PT J
AU Rabinovitch, T
   Yehezkeli, V
   Goldenberg, D
   Loewenstein, A
   Moisseiev, E
AF Rabinovitch, Tamar
   Yehezkeli, Veronika
   Goldenberg, Dafna
   Loewenstein, Anat
   Moisseiev, Elad
TI Evaluation of Accuracy and Agreement of Optical Coherence Tomography
   Angiography Interpretation of Common Retinal Findings and Diagnoses
SO OPHTHALMOLOGICA
LA English
DT Article
DE Accuracy; Age-related macular degeneration; Agreement; Diabetic
   retinopathy; interpretation; Optical coherence tomography angiography
AB Purpose: To evaluate the accuracy and agreement of optical coherence tomography angiography (OCTA) interpretation in cases of common retinal findings and diagnoses, and to evaluate the effect of OCT B-scans on OCTA interpretations. Methods: This is a case series consisting of a questionnaire with 8 cases demonstrating common retinal conditions of normal, age-related macular degeneration (AMD) and diabetic retinopathy (DR). Each case included OCTA images, and 58 participants were asked to identify retinal findings and provide a diagnosis. Following OCTA interpretation, the corresponding OCT B-scans were revealed and the participants were asked again to identify retinal findings and provide a diagnosis. The rates of accuracy and agreement for each condition were analyzed. Results: Overall the rates of accurate diagnosis and identification of retinal findings were 37.4 and 61.6%, respectively. Following addition of the OCT B-scans, the rates increased to 61.6 and 79.4%, respectively (p < 0.001 for both). A significant improvement in correct interpretation occurred in the normal and AMD cases, but not in the DR cases. There was no correlation with length of experience or self-reported familiarity with OCTA. Discussion: Considerable variability exists in OCTA interpretation, with mediocre rates of accuracy and agreement between clinicians. Increased familiarity as well as future automation advances will be needed to improve OCTA interpretation accuracy and uniformity.
C1 [Rabinovitch, Tamar; Goldenberg, Dafna; Loewenstein, Anat] Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, Tel Aviv, Israel.
   [Yehezkeli, Veronika; Moisseiev, Elad] Meir Med Ctr, Dept Ophthalmol, 59 Tshernichovsky St, IL-4428164 Kefar Sava, Israel.
   [Goldenberg, Dafna; Loewenstein, Anat; Moisseiev, Elad] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Tel Aviv University; Sackler Faculty of Medicine
RP Moisseiev, E (通讯作者)，Meir Med Ctr, Dept Ophthalmol, 59 Tshernichovsky St, IL-4428164 Kefar Sava, Israel.
EM elad_moi@netvision.net.il
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Aharony O, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.6
   Alam M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060872
   Borrelli E, 2019, OPHTHALMOL THER, V8, P215, DOI 10.1007/s40123-019-0178-6
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Endersid C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210505
   Faes L, 2019, EYE, V33, P1327, DOI 10.1038/s41433-019-0421-3
   Hong J, 2020, ACTA OPHTHALMOL, V98, pE570, DOI 10.1111/aos.14327
   Kuwayama S, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/6319581
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Prenner S, 2019, OSLI RETINA, V50, P344, DOI 10.3928/23258160-20190605-02
   Sandhu HS, 2018, BRIT J OPHTHALMOL, V102, P1564, DOI 10.1136/bjophthalmol-2017-311489
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
NR 16
TC 0
Z9 0
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2021
VL 244
IS 2
BP 141
EP 149
DI 10.1159/000513049
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RY0TU
UT WOS:000647629000007
PM 33197909
DA 2022-11-30
ER

PT J
AU Wood, LJ
   Jolly, JK
   Buckley, TM
   Josan, AS
   MacLaren, RE
AF Wood, Laura J.
   Jolly, Jasleen K.
   Buckley, Thomas M. W.
   Josan, Amandeep S.
   MacLaren, Robert E.
TI Low luminance visual acuity as a clinical measure and clinical trial
   outcome measure: a scoping review
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Review
DE low light visual acuity; low luminance deficit; low luminance visual
   acuity; mesopic vision; mesopic visual acuity
ID GEOGRAPHIC ATROPHY SECONDARY; MACULAR DEGENERATION; CONTRAST
   SENSITIVITY; NATURAL-HISTORY; OLDER EYES; AGE; VISION; ASSOCIATION;
   MICROPERIMETRY; PERFORMANCE
AB Purpose The measurement of standard visual acuity (VA) is the most well-known part of any ophthalmic examination to indicate visual function. Despite this, it is insensitive in detecting early disease changes. Therefore, other visual function tests have been developed including low luminance VA (LLVA) and low luminance deficit (LLD). This scoping literature review aims to summarise the current published applications of LLVA and LLD assessments to evaluate their utility as clinical markers and research outcome measures in a variety of ophthalmic conditions.
   Recent findings Sixty-five peer-reviewed publications were included. LLVA was pioneered for use in geographic atrophy, a subtype of age-related macular degeneration, which remains the mainstay of its clinical application. However, other studies have reported additional useful applications in inherited retinal diseases including rare maculopathies and rod-cone dystrophies. Although there are some variations in testing methodology, use of the standard Early Treatment Diabetic Retinopathy Study (ETDRS) chart with a 2.0 log unit neutral density filter is the most popular approach. The optimal testing luminance is still to be defined.
   Overall, LLVA is an earlier clinical marker of change in central retinal function than standard VA. It has been shown to be a risk factor for disease progression and a better indicator of a patient's level of everyday visual function. It is inexpensive and simple to implement using readily available standard ophthalmic equipment.
C1 [Wood, Laura J.; Jolly, Jasleen K.; Josan, Amandeep S.; MacLaren, Robert E.] Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
   [Wood, Laura J.; Jolly, Jasleen K.; Buckley, Thomas M. W.; Josan, Amandeep S.; MacLaren, Robert E.] Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England.
C3 University of Oxford; Oxford University Hospitals NHS Foundation Trust
RP Wood, LJ (通讯作者)，Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.; Wood, LJ (通讯作者)，Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England.
EM enquires@ndcn.ox.ac.uk
RI Jolly, Jasleen Kaur/AAC-1873-2019
OI Jolly, Jasleen Kaur/0000-0001-9878-4621; MacLaren,
   Robert/0000-0002-3096-4682; (Wood) Taylor, Laura/0000-0001-7072-0853
FU National Institute for Health Research (NIHR) Oxford Biomedical Research
   Centre
FX The review was funded by a preparatory fellowship from the National
   Institute for Health Research (NIHR) Oxford Biomedical Research Centre.
   The views expressed are those of the authors and not necessarily those
   of the NIHR or the Department of Health and Social Care.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Applegate RA, 2006, OPTOMETRY VISION SCI, V83, P635, DOI 10.1097/01.opx.0000232842.60932.af
   Barrio A, 2015, GRAEF ARCH CLIN EXP, V253, P791, DOI 10.1007/s00417-014-2876-z
   Bittner AK, 2020, OPHTHALMIC RES, V63, P133, DOI 10.1159/000503931
   Carballo J, 2013, J CATARACT REFR SURG, V39, P393, DOI 10.1016/j.jcrs.2012.09.025
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Puell MC, 2019, CURR EYE RES, V44, P82, DOI 10.1080/02713683.2018.1522648
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Crosson JN, 2019, OPHTHALMOL RETINA, V3, P670, DOI 10.1016/j.oret.2019.03.019
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Frenkel REP, 2016, BRIT J OPHTHALMOL, V100, P1052, DOI 10.1136/bjophthalmol-2015-307575
   Fujita K, 2013, CLIN EXP OPTOM, V96, P100, DOI 10.1111/j.1444-0938.2012.00796.x
   Grewal MK, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041001
   Guillon Michel, 2002, CLAO Journal, V28, P88
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P673, DOI 10.1016/j.oret.2020.01.019
   Heinemann M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222045
   Hess K, 2020, RETINA-J RET VIT DIS, V40, P1988, DOI 10.1097/IAE.0000000000002689
   HIGGINS KE, 1978, AM J OPTOM PHYS OPT, V55, P172
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Hsu ST, 2019, OPHTHALMOL RETINA, V3, P637, DOI 10.1016/j.oret.2019.03.010
   Jacobs Robert J, 1998, Clin Exp Optom, V81, P163
   Jafarzadehpur E, 2004, J SPORT SCI MED, V3, P44
   Johnson CA, 1995, OPTOMETRY VISION SCI, V72, P864, DOI 10.1097/00006324-199512000-00004
   Johnson Kate L, 2007, Cont Lens Anterior Eye, V30, P29, DOI 10.1016/j.clae.2006.12.001
   Jolly JK, 2017, INVEST OPHTH VIS SCI, V58, P5575, DOI 10.1167/iovs.17-22486
   Krezel AK, 2020, BRIT J OPHTHALMOL, V104, P1196, DOI 10.1136/bjophthalmol-2019-314949
   Legras R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191141
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Lenton L, 2018, BMJ OPEN OPHTHALMOL, V3, DOI 10.1136/bmjophth-2017-000139
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lin RJ, 2015, OPTOMETRY VISION SCI, V92, P559, DOI 10.1097/OPX.0000000000000584
   Lin TP, 2015, J PARKINSON DIS, V5, P125, DOI 10.3233/JPD-140470
   McGuinness MB, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.5.3
   Melcher M H, 1992, J Am Optom Assoc, V63, P466
   Menghini M, 2020, EXPERT OPIN ORPHAN D, V8, P67, DOI 10.1080/21678707.2020.1735352
   Menghini M, 2019, INVEST OPHTH VIS SCI, V60
   Muller S, 2019, BRIT J OPHTHALMOL, V103, P398, DOI 10.1136/bjophthalmol-2017-311785
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Ou WC, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.10
   Owsley C, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0274-5
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Pilotto E, 2020, RETINA-J RET VIT DIS, V40, P1279, DOI 10.1097/IAE.0000000000002616
   Pluhacek F, 2018, GRAEF ARCH CLIN EXP, V256, P1739, DOI 10.1007/s00417-018-4017-6
   Pondorfer SG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231748
   Pondorfer SG, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.55
   Pondorfer SG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51769-7
   PUELL M, 2018, ACTA OPHTHALMOL S261, V96, P101
   Puell MC, 2014, BRIT J OPHTHALMOL, V98, P1389, DOI 10.1136/bjophthalmol-2014-304872
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   RABIN J, 1994, OPTOMETRY VISION SCI, V71, P685, DOI 10.1097/00006324-199411000-00003
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rubin GS, 2007, INVEST OPHTH VIS SCI, V48, P1483, DOI 10.1167/iovs.06-0474
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Sanders E, 2008, EYE CONTACT LENS, V34, P293, DOI 10.1097/ICL.0b013e318185d271
   Sh S, 2010, VISUAL PERCEPTION CL
   SHEEDY JE, 1984, AM J OPTOM PHYS OPT, V61, P595
   Shlaer S, 1937, J GEN PHYSIOL, V21, P165, DOI 10.1085/jgp.21.2.165
   Siderov J, 1999, ACTA OPHTHALMOL SCAN, V77, P673, DOI 10.1034/j.1600-0420.1999.770613.x
   SIVAK M, 1982, ACCIDENT ANAL PREV, V14, P87, DOI 10.1016/0001-4575(82)90075-6
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   STURGIS SP, 1982, HUM FACTORS, V24, P347, DOI 10.1177/001872088202400310
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   TAYLOR S P, 1979, British Journal of Physiological Optics, V33, P29
   Thee EF, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.26
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   Vecchi D, 2014, AVIAT SPACE ENVIR MD, V85, P60, DOI 10.3357/ASEM.3587.2014
   VONNOORDEN GK, 1959, ARCH OPHTHALMOL-CHIC, V61, P533, DOI 10.1001/archopht.1959.00940090535005
   Willcox A, 2019, EYE, V33, P295, DOI 10.1038/s41433-018-0212-2
   Wood JM, 2005, OPTOMETRY VISION SCI, V82, P698, DOI 10.1097/01.opx.0000175562.27101.51
   Wood LJ, 2021, CLIN EXP OPTOM, V104, P90, DOI 10.1111/cxo.13087
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZZ, 2008, INT J OPHTHALMOL, V8, P2023
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zele AJ, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01594
NR 84
TC 8
Z9 8
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAR
PY 2021
VL 41
IS 2
BP 213
EP 223
DI 10.1111/opo.12775
EA JAN 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QY0PY
UT WOS:000604911700001
PM 33403668
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Dewing, JM
   Carare, RO
   Lotery, AJ
   Ratnayaka, JA
AF Dewing, Jennifer M.
   Carare, Roxana O.
   Lotery, Andrew J.
   Ratnayaka, J. Arjuna
TI The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the
   Senescent Retina and Brain
SO CELLS
LA English
DT Review
DE TIMP-3; ECM; AMD; sorsby; retina; Alzheimer's disease; dementia
ID CEREBRAL AMYLOID ANGIOPATHY; ENDOTHELIAL GROWTH-FACTOR; PIGMENT
   EPITHELIAL-CELLS; MATRIX-METALLOPROTEINASE INHIBITION; FUNDUS DYSTROPHY
   MUTATIONS; AGE-RELATED-CHANGES; EXTRACELLULAR-MATRIX; MACULAR
   DEGENERATION; TISSUE INHIBITOR; ALZHEIMERS-DISEASE
AB Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a component of the extracellular environment, where it mediates diverse processes including matrix regulation/turnover, inflammation and angiogenesis. Rare TIMP-3 risk alleles and mutations are directly linked with retinopathies such as age-related macular degeneration (AMD) and Sorsby fundus dystrophy, and potentially, through indirect mechanisms, with Alzheimer's disease. Insights into TIMP-3 activities may be gleaned from studying Sorsby-linked mutations. However, recent findings do not fully support the prevailing hypothesis that a gain of function through the dimerisation of mutated TIMP-3 is responsible for retinopathy. Findings from Alzheimer's patients suggest a hitherto poorly studied relationship between TIMP-3 and the Alzheimer's-linked amyloid-beta (A beta) proteins that warrant further scrutiny. This may also have implications for understanding AMD as aged/diseased retinae contain high levels of A beta. Findings from TIMP-3 knockout and mutant knock-in mice have not led to new treatments, particularly as the latter does not satisfactorily recapitulate the Sorsby phenotype. However, recent advances in stem cell and in vitro approaches offer novel insights into understanding TIMP-3 pathology in the retina-brain axis, which has so far not been collectively examined. We propose that TIMP-3 activities could extend beyond its hitherto supposed functions to cause age-related changes and disease in these organs.
C1 [Dewing, Jennifer M.; Carare, Roxana O.; Lotery, Andrew J.; Ratnayaka, J. Arjuna] Univ Southampton, Clin & Expt Sci, Fac Med, MP806 Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Lotery, Andrew J.] Univ Hosp Southampton NHS Fdn Trust, Eye Unit, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University
   Hospital Southampton NHS Foundation Trust
RP Ratnayaka, JA (通讯作者)，Univ Southampton, Clin & Expt Sci, Fac Med, MP806 Tremona Rd, Southampton SO16 6YD, Hants, England.
EM jmd2g08@soton.ac.uk; R.O.Carare@soton.ac.uk; A.J.Lotery@soton.ac.uk;
   J.Ratnayaka@soton.ac.uk
OI Ratnayaka, J. Arjuna/0000-0002-1027-6938; Lotery,
   Andrew/0000-0001-5541-4305
FU Retina UK [GR590]; National Eye Research Centre [SAC 020]; Macular
   Society UK; Alzheimer's Research UK (ARUK) South Coast Network
FX This work was funded by awards to J.A.R. from Retina UK (GR590), the
   National Eye Research Centre (SAC 020) and the Macular Society UK, and
   to JMD from the Alzheimer's Research UK (ARUK) South Coast Network. We
   are also grateful to the Gift of Sight Appeal for their support.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Aldea R, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00001
   Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X
   Anand-Apte B, 2019, J NEUROSCI RES, V97, P88, DOI 10.1002/jnr.24317
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Arpino V, 2015, MATRIX BIOL, V44-46, P247, DOI 10.1016/j.matbio.2015.03.005
   Arris CE, 2003, BBA-MOL BASIS DIS, V1638, P20, DOI 10.1016/S0925-4439(03)00036-X
   Attems J, 2005, ACTA NEUROPATHOL, V110, P345, DOI 10.1007/s00401-005-1074-9
   Baba Y, 2009, LAB INVEST, V89, P1340, DOI 10.1038/labinvest.2009.101
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Brkic M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/620581
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Campbell WA, 2019, EXP NEUROL, V320, DOI 10.1016/j.expneurol.2019.112984
   Cao LN, 2013, INT J MOL MED, V31, P1105, DOI 10.3892/ijmm.2013.1310
   Carare RO, 2008, NEUROPATH APPL NEURO, V34, P131, DOI 10.1111/j.1365-2990.2007.00926.x
   Carare RO, 2013, NEUROPATH APPL NEURO, V39, P593, DOI 10.1111/nan.12042
   Chakraborty A, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0385-8
   Chapuis J, 2006, NEUROBIOL AGING, V27, P1212, DOI 10.1016/j.neurobiolaging.2005.07.013
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng JS, 2009, NAT NEUROSCI, V12, P119, DOI 10.1038/nn.2240
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z
   Christensen DRG, 2017, EXP EYE RES, V165, P35, DOI 10.1016/j.exer.2017.08.014
   Corsi MM, 2011, BIOGERONTOLOGY, V12, P451, DOI 10.1007/s10522-011-9335-6
   Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dewing J, 2019, INVEST OPHTH VIS SCI, V60
   Dunckley T, 2006, NEUROBIOL AGING, V27, P1359, DOI 10.1016/j.neurobiolaging.2005.08.013
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gooz M, 2010, CRIT REV BIOCHEM MOL, V45, P146, DOI 10.3109/10409231003628015
   Hansen DV, 2018, J CELL BIOL, V217, P459, DOI 10.1083/jcb.201709069
   Hartl D, 2020, MOL PSYCHIATR, V25, P629, DOI 10.1038/s41380-018-0091-8
   Hawkes CA, 2014, BRAIN PATHOL, V24, P396, DOI 10.1111/bpa.12159
   Hawkes CA, 2013, AGING CELL, V12, P224, DOI 10.1111/acel.12045
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Hoe HS, 2007, J NEUROSCI, V27, P10895, DOI 10.1523/JNEUROSCI.3135-07.2007
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Howard C, 2010, HISTOL HISTOPATHOL, V25, P1163, DOI 10.14670/HH-25.1163
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hussain A.A., 2017, J NEURODEGENER DIS, V2017, P4810232, DOI [10.1155/2017/4810232, DOI 10.1155/2017/4810232]
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Jefferies WA, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt230
   Jung KK, 2006, EMBO J, V25, P3934, DOI 10.1038/sj.emboj.7601281
   Kalaria RN, 1997, ANN NY ACAD SCI, V826, P263, DOI 10.1111/j.1749-6632.1997.tb48478.x
   Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf
   Kassiri Z, 2009, J AM SOC NEPHROL, V20, P1223, DOI 10.1681/ASN.2008050492
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Keable A, 2016, BBA-MOL BASIS DIS, V1862, P1037, DOI 10.1016/j.bbadis.2015.08.024
   Kim HE, 2000, J CLIN INVEST, V106, P857, DOI 10.1172/JCI8040
   Kim M, 2009, HUM MOL GENET, V18, P3987, DOI 10.1093/hmg/ddp323
   Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678
   Koutresi D, 2019, CLIN EXP OPHTHALMOL, V47, P1214, DOI 10.1111/ceo.13602
   Kuhn PH, 2010, EMBO J, V29, P3020, DOI 10.1038/emboj.2010.167
   Kutty RK, 2016, MOL VIS, V22, P1156
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Leivonen SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057474
   Lichtenthaler SF, 2011, J NEUROCHEM, V116, P10, DOI 10.1111/j.1471-4159.2010.07081.x
   Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Lorenzl S, 2003, NEUROCHEM INT, V43, P191, DOI 10.1016/S0197-0186(03)00004-4
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Manousopoulou A, 2017, NEUROPATH APPL NEURO, V43, P492, DOI 10.1111/nan.12342
   Mateo I, 2007, ACTA NEUROL SCAND, V116, P56, DOI 10.1111/j.1600-0404.2006.00775.x
   Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623
   Meunier I, 2016, SCI REP-UK, V6, DOI 10.1038/srep32544
   Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413
   Mohammed FF, 2003, ANN RHEUM DIS, V62, P43
   Monet-Lepretre M, 2013, BRAIN, V136, P1830, DOI 10.1093/brain/awt092
   Moore CS, 2012, AM J PATHOL, V180, P12, DOI 10.1016/j.ajpath.2011.09.008
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Naessens S, 2019, HUM MUTAT, V40, P539, DOI 10.1002/humu.23713
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Qi JH, 2009, J BIOL CHEM, V284, P19927, DOI 10.1074/jbc.M109.013763
   Raan S., 1994, INVESTIG OPHTHALMOL, V35, P2857
   Ratnayaka A, 2007, EXP EYE RES, V84, P1135, DOI 10.1016/j.exer.2006.01.030
   Ratnayaka A, 2007, INT J BIOCHEM CELL B, V39, P85, DOI 10.1016/j.biocel.2006.08.015
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140-6736(04)16051-0
   Rhodes JM, 2007, J CELL MOL MED, V11, P176, DOI 10.1111/j.1582-4934.2007.00031.x
   Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X
   Rozario T, 2010, DEV BIOL, V341, P126, DOI 10.1016/j.ydbio.2009.10.026
   Ryu JK, 2009, J NEUROSCI, V29, P3, DOI 10.1523/JNEUROSCI.2888-08.2009
   Saihan Z, 2009, MOL VIS, V15, P1218
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schnoor M, 2008, J IMMUNOL, V180, P5707, DOI 10.4049/jimmunol.180.8.5707
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Smookler DS, 2006, J IMMUNOL, V176, P721, DOI 10.4049/jimmunol.176.2.721
   Sogorb-Esteve A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1255-9
   Solda G, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-174
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Tang HD, 2013, NEUROBIOL AGING, V34, P1412, DOI 10.1016/j.neurobiolaging.2012.10.029
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Toricelli M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0405-2
   Tzaphlidou M, 2008, J BIOL PHYS, V34, P39, DOI 10.1007/s10867-008-9115-y
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Wang HB, 2016, MOL VIS, V22, P116
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Warwick A, 2016, EYE, V30, P488, DOI 10.1038/eye.2015.204
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yamamoto K, 2015, MATRIX BIOL, V44-46, P255, DOI 10.1016/j.matbio.2015.02.007
   Yin KJ, 2006, J NEUROSCI, V26, P10939, DOI 10.1523/JNEUROSCI.2085-06.2006
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 141
TC 12
Z9 12
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JAN
PY 2020
VL 9
IS 1
AR 39
DI 10.3390/cells9010039
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KO2RZ
UT WOS:000515398200039
PM 31877820
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Askou, AL
   Alsing, S
   Benckendorff, JNE
   Holmgaard, A
   Mikkelsen, JG
   Aagaard, L
   Bek, T
   Corydon, TJ
AF Askou, Anne Louise
   Alsing, Sidsel
   Benckendorff, Josephine N. E.
   Holmgaard, Andreas
   Mikkelsen, Jacob Giehm
   Aagaard, Lars
   Bek, Toke
   Corydon, Thomas J.
TI Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting
   Antiangiogenic Gene Therapy
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MULTIGENIC
   LENTIVIRAL VECTORS; OCULAR SUBRETINAL INJECTION; ADENOASSOCIATED VIRUS;
   MACULAR DEGENERATION; 7-YEAR OUTCOMES; DELIVERY; VEGF; PEDF
AB Vascular endothelial growth factor A (VEGFA) is involved in the pathogenesis of vasoproliferative retinal diseases, such as exudative age-related macular degeneration (AMD). The objective of this study was to investigate whether dual-acting therapy based on the simultaneous expression of anti-VEGFA microRNAs (miRNAs) and the secreted, antiangiogenic protein pigment endothelial-derived factor (PEDF) delivered by adeno-associated virus (AAV) vectors provides improved protection against choroidal neovascularization (CNV). To investigate this, a multigenic AAV vector allowing retina pigment epithelium (RPE)-specific expression of anti-VEGFA miRNAs and PEDF was engineered. Robust expression of PEDF, driven by the RPE-specific vitelliform macular dystrophy 2 promoter, was observed in human cells and in mouse retina. A significant reduction in CNV was observed in a laser-induced CNV mouse model 57 days post-injection of the AAV5 particles conveying either anti-VEGFA miRNA and PEDF dual therapy or anti-VEGFA miRNA monotherapy. Overall, CNV reduction was most prominent in animals receiving dual-acting therapy. In both cases, the reduction in CNV was accompanied by a significant attenuation of VEGFA. In conclusion, the presented data reveal that gene therapy targeting VEGFA via multigenic AAV vectors displays combined efficacy, suggesting that dual-acting therapy is an important tool in future eye gene therapy for the treatment of neovascular ocular diseases, including AMD.
C1 [Askou, Anne Louise; Alsing, Sidsel; Benckendorff, Josephine N. E.; Holmgaard, Andreas; Mikkelsen, Jacob Giehm; Aagaard, Lars; Corydon, Thomas J.] Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus C, Denmark.
   [Bek, Toke; Corydon, Thomas J.] Aarhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus C, Denmark.
C3 Aarhus University; Aarhus University
RP Corydon, TJ (通讯作者)，Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus C, Denmark.
EM corydon@biomed.au.dk
RI Core, Vector/CAF-4832-2022; Askou, Anne/AGW-2995-2022
OI Corydon, Thomas Juhl/0000-0003-3588-6350; Mikkelsen, Jacob
   Giehm/0000-0002-1322-3209; Bek, Toke/0000-0002-0409-2534; Askou, Anne
   Louise/0000-0002-5512-1796
FU Faculty of Health Sciences; Danish Council for Independent Research
   [4183-00017B]; Gene Therapy Initiative Aarhus (GTI-Aarhus) - Lundbeck
   Foundation [R126-2012-12456]; Lundbeck Foundation [R165-2013-15631];
   Danish Eye Research Foundation; Aase og Ejnar Danielsen's Foundation;
   Kobmand Marie Kirstine Jensens Fond; Riisfort Foundation; Svend Helge
   Schroder og hustru Ketty Lydia Larsen Schroders fond
FX The authors would like to thank Tina Hindkjaer and Kamilla Zahll Hornbek
   for their excellent technical support. This work was supported by the
   Faculty of Health Sciences (PhD scholarship to S.A. and A.H.), the
   Danish Council for Independent Research (T.J.C., grant 4183-00017B), the
   Gene Therapy Initiative Aarhus (GTI-Aarhus) funded by the Lundbeck
   Foundation (T.J.C., L.A., and J.G.M., grant R126-2012-12456), the
   Lundbeck Foundation (A.L.A., grant R165-2013-15631), the Danish Eye
   Research Foundation (T.J.C.), Aase og Ejnar Danielsen's Foundation
   (T.J.C.), Kobmand Marie Kirstine Jensens Fond (T.B.), the Riisfort
   Foundation (T.J.C.), and Svend Helge Schroder og hustru Ketty Lydia
   Larsen Schroders fond (T.J.C.).
CR Aagaard L, 2008, GENE THER, V15, P1536, DOI 10.1038/gt.2008.147
   Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316
   Askou AL, 2018, METHODS MOL BIOL, V1715, P47, DOI 10.1007/978-1-4939-7522-8_4
   Askou AL, 2017, HUM GENE THER METHOD, V28, P222, DOI 10.1089/hgtb.2017.079
   Askou AL, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2014.64
   Askou AL, 2014, ACTA OPHTHALMOL, V92, P1, DOI 10.1111/aos.12452
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Balaggan KS, 2012, GENE THER, V19, P145, DOI 10.1038/gt.2011.153
   Bemelmans AP, 2006, PLOS MED, V3, P1892, DOI 10.1371/journal.pmed.0030347
   Bennett J, 1996, HUM GENE THER, V7, P1763, DOI 10.1089/hum.1996.7.14-1763
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9
   Colella P, 2018, MOL THER-METH CLIN D, V8, P87, DOI 10.1016/j.omtm.2017.11.007
   Corti M, 2017, HUM GENE THER CL DEV, V28, P208, DOI 10.1089/humc.2017.146
   Corydon TJ, 2015, HUM GENE THER, V26, P525, DOI 10.1089/hum.2015.064
   Corydon TJ, 2007, J MED GENET, V44, P509, DOI 10.1136/jmg.2007.049536
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Daya S, 2008, CLIN MICROBIOL REV, V21, P583, DOI 10.1128/CMR.00008-08
   Dong BA, 2010, MOL THER, V18, P87, DOI 10.1038/mt.2009.258
   Dougherty CJ, 2008, MOL VIS, V14, P471
   Esumi N, 2004, J BIOL CHEM, V279, P19064, DOI 10.1074/jbc.M309881200
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Hangai M, 2001, INVEST OPHTH VIS SCI, V42, P1617
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Hirsch ML, 2013, MOL THER, V21, P2205, DOI 10.1038/mt.2013.184
   Hirsch ML, 2010, MOL THER, V18, P6, DOI 10.1038/mt.2009.280
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holmgaard A, 2017, MOL THER-NUCL ACIDS, V9, P89, DOI 10.1016/j.omtn.2017.08.016
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   Lai Y, 2010, MOL THER, V18, P75, DOI 10.1038/mt.2009.256
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   LaVail MM, 2016, ADV EXP MED BIOL, V854, P487, DOI 10.1007/978-3-319-17121-0_65
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Maddalena A, 2018, MOL THER, V26, P524, DOI 10.1016/j.ymthe.2017.11.019
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   McClements ME, 2019, HUM GENE THER, V30, P590, DOI 10.1089/hum.2018.156
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Naso MF, 2017, BIODRUGS, V31, P317, DOI 10.1007/s40259-017-0234-5
   Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Patricio MI, 2018, EXPERT OPIN BIOL TH, V18, P807, DOI 10.1080/14712598.2018.1484448
   Persons DA, 2010, MOL THER, V18, P861, DOI 10.1038/mt.2010.70
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Rafii MS, 2014, ALZHEIMERS DEMENT, V10, P571, DOI 10.1016/j.jalz.2013.09.004
   Reich SJ, 2003, HUM GENE THER, V14, P37, DOI 10.1089/10430340360464697
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Tombran-Tink J, 2005, J STRUCT BIOL, V151, P130, DOI 10.1016/j.jsb.2005.05.005
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   *US FDA, 2017, FDA APPR NOV GEN THE
   Wang JJ, 2008, AM J PHYSIOL-RENAL, V294, pF1166, DOI 10.1152/ajprenal.00375.2007
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Wu ZJ, 2010, MOL THER, V18, P80, DOI 10.1038/mt.2009.255
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Yan ZY, 2000, P NATL ACAD SCI USA, V97, P6716, DOI 10.1073/pnas.97.12.6716
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Zadeh G, 2004, J NEUROPATH EXP NEUR, V63, P978, DOI 10.1093/jnen/63.9.978
   Zhang SX, 2008, J MOL ENDOCRINOL, V41, P135, DOI 10.1677/JME-08-0011
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
NR 66
TC 29
Z9 34
U1 1
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD JUN 7
PY 2019
VL 16
BP 38
EP 50
DI 10.1016/j.omtn.2019.01.012
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IB4OC
UT WOS:000470250900004
PM 30825671
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Foreman, J
   Xie, J
   Keel, S
   van Wijngaarden, P
   Taylor, HR
   Dirani, M
AF Foreman, Joshua
   Xie, Jing
   Keel, Stuart
   van Wijngaarden, Peter
   Taylor, Hugh R.
   Dirani, Mohamed
TI The validity of self-report of eye diseases in participants with vision
   loss in the National Eye Health Survey
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VISUAL IMPAIRMENT PROJECT; OPEN-ANGLE GLAUCOMA; ANGELES LATINO EYE;
   INDIGENOUS AUSTRALIANS; MACULAR DEGENERATION; PREVALENCE; POPULATION;
   ACCURACY; ROADMAP; BURDEN
AB We assessed the validity and reliability of self-report of eye disease in participants with unilateral vision loss (presenting visual acuity worse than 6/12 in the worse eye and equal to or better than 6/12 in the better eye) or bilateral vision loss (presenting visual acuity worse than 6/12 in the better eye) in Australia's National Eye Health Survey. In total, 1738 Indigenous Australians and 3098 non-Indigenous Australians were sampled from 30 sites. Participants underwent a questionnaire and self-reported their eye disease histories. A clinical examination identified whether participants had cataract, age-related macular degeneration, diabetic retinopathy and glaucoma. For those identified as having unilateral or bilateral vision loss (438 Indigenous Australians and 709 non-Indigenous Australians), self-reports were compared with examination results using validity and reliability measures. Reliability was poor for all four diseases (Kappa 0.06 to 0.37). Measures of validity of self-report were variable, with generally high specificities (93.7% to 99.2%) in all diseases except for cataract (63.9 to 73.1%) and low sensitivities for all diseases (7.6% in Indigenous Australians with diabetic retinopathy to 44.1% of non-Indigenous Australians with cataract). This study suggests that self-report is an unreliable population-based research tool for identifying eye disease in those with vision loss.
C1 [Foreman, Joshua; Xie, Jing; Keel, Stuart; van Wijngaarden, Peter; Dirani, Mohamed] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Foreman, Joshua; Xie, Jing; Keel, Stuart; van Wijngaarden, Peter; Dirani, Mohamed] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Indigenous Eye Hlth Unit, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Foreman, J (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.; Foreman, J (通讯作者)，Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
EM foreman.j@unimelb.edu.au
RI xie, jing/GRY-1689-2022
OI van Wijngaarden, Peter/0000-0002-8800-7834; /0000-0001-6694-3587;
   Foreman, Joshua/0000-0002-3685-4054
FU Department of Health of the Australian Government; Peggy and Leslie
   Cranbourne Foundation; Novartis Australia; NHMRC Career Development
   Fellowship [1090466]; University of Melbourne, Annemarie
   Mankiewicz-Zelkin Fellowship; Sylvia and Charles Viertel Charitable
   Foundation Clinical Investigator Award [VLT2015C018]; Australian
   Postgraduate Award scholarship
FX The National Eye Health Survey was funded by the Department of Health of
   the Australian Government, and also received financial contributions
   from the Peggy and Leslie Cranbourne Foundation and Novartis Australia.
   In-kind support was received from our industry and sector partners,
   OPSM, Carl Zeiss, Designs for Vision, the Royal Flying Doctor Service,
   Optometry Australia and the Brien Holden Vision Institute. We would like
   to specifically acknowledge OPSM, who kindly donated sunglasses valued
   at $130 for each study participant. The Centre for Eye Research
   Australia receives Operational Infrastructure Support from the Victorian
   Government. The Principal Investigator, Dr Mohamed Dirani, is supported
   by a NHMRC Career Development Fellowship (#1090466). Peter van
   Wijngaarden is the recipient of a University of Melbourne, Annemarie
   Mankiewicz-Zelkin Fellowship and a Sylvia and Charles Viertel Charitable
   Foundation Clinical Investigator Award (#VLT2015C018). The PhD student,
   Joshua Foreman is supported by an Australian Postgraduate Award
   scholarship. The Centre for Eye Research Australia (CERA) and Vision
   2020 Australia wish to recognise the contributions of all the NEHS
   project steering committee members (Professor Hugh Taylor, Dr Peter van
   Wijngaarden, Jennifer Gersbeck, Dr Jason Agostino, Anna Morse, Sharon
   Bentley, Robyn Weinberg, Christine Black, Geneveive Quilty, Louis Young
   and Rhonda Stilling) and the core CERA research team who assisted with
   the survey field work (Pei Ying Lee, Rosamond Gilden, Larissa Andersen,
   Benny Phanthakesone, Celestina Pham, Alison Schokman, Megan Jackson,
   Hiba Wehbe, John Komser and Cayley Bush). Furthermore, we would like to
   acknowledge the overwhelming support of all collaborating Indigenous
   organisations who assisted with the implementation of the survey, and
   the Indigenous health workers and volunteers in each survey site who
   contributed to the field work.
CR AIHW, 2005, AIHW B, V27
   Armstrong KL, 2012, INDIAN J OPHTHALMOL, V60, P475, DOI 10.4103/0301-4738.100554
   Australian Bureau of Statistics, 2017, AUSTR STAT GEOGR STA
   BRADFORD VP, 1993, MIL MED, V158, P263, DOI 10.1093/milmed/158.4.263
   Department of Health, 2014, AUSTR GOVT DEP HLTH
   DRS, 1981, INVEST OPHTHALMOL, V21
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Foreman J, 2017, OPHTHAL EPIDEMIOL, P1
   Foreman J, 2017, CLIN EXP OPHTHALMOL, V45, P336, DOI 10.1111/ceo.12892
   Fukuda H, 2007, J PUBLIC HEALTH-UK, V29, P316, DOI 10.1093/pubmed/fdm022
   Goujon N, 2010, CLIN EXP OPHTHALMOL, V38, P796, DOI 10.1111/j.1442-9071.2010.02306.x
   Gupta N, 2014, CAN J OPHTHALMOL, V49, P403, DOI 10.1016/j.jcjo.2014.08.014
   Han JJ, 2017, JAMA ONCOL, V3, P810, DOI 10.1001/jamaoncol.2016.6192
   KLEIN R, 1986, AM J EPIDEMIOL, V124, P104, DOI 10.1093/oxfordjournals.aje.a114353
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Livingston PM, 1998, BRIT J OPHTHALMOL, V82, P780, DOI 10.1136/bjo.82.7.780
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Mukesh BN, 2002, OPHTHALMOLOGY, V109, P1047, DOI 10.1016/S0161-6420(02)01040-0
   Patty L, 2012, OPHTHALMOLOGY, V119, P1725, DOI 10.1016/j.ophtha.2012.02.029
   Salomon JA, 2012, LANCET, V380, P2129, DOI 10.1016/S0140-6736(12)61680-8
   Schnitzler A., 2016, ANN PHYS REHABIL M S, V59S, pe166, DOI 10.1016/j.rehab.2016.07.372
   Tapp RJ, 2013, DIABETIC MED, V30, P1145, DOI 10.1111/dme.12215
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Taylor HR, 2004, INVEST OPHTH VIS SCI, V45, P2539, DOI 10.1167/iovs.03-1198
   Taylor HR, 2012, MED J AUSTRALIA, V197, P613, DOI 10.5694/mja12.10544
   Taylor HR, 2010, MED J AUSTRALIA, V192, P312, DOI 10.5694/j.1326-5377.2010.tb03529.x
   Turner AW, 2011, CLIN EXP OPHTHALMOL, V39, P344, DOI 10.1111/j.1442-9071.2010.02474.x
   TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124
   Varma R, 2008, MED CARE, V46, P497, DOI 10.1097/MLR.0b013e31816080fe
   Wensor MD, 1998, OPHTHALMOLOGY, V105, P733, DOI 10.1016/S0161-6420(98)94031-3
   Yang HO, 2016, J MANIP PHYSIOL THER, V39, P459, DOI 10.1016/j.jmpt.2016.07.004
NR 31
TC 15
Z9 15
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 18
PY 2017
VL 7
AR 8757
DI 10.1038/s41598-017-09421-9
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FE1LP
UT WOS:000407980000011
PM 28821861
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zekavat, SM
   Lu, J
   Maugeais, C
   Mazer, NA
AF Zekavat, Seyedeh Maryam
   Lu, James
   Maugeais, Cyrille
   Mazer, Norman A.
TI An in silico model of retinal cholesterol dynamics (RCD model): insights
   into the pathophysiology of dry AMD
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE cell/tissue; eye/retina; high density lipoprotein/metabolism; low
   density lipoprotein/metabolism; lipoproteins/kinetics;
   lipoproteins/metabolism; macrophages/monocytes; membranes; transport;
   age-related macular degeneration
ID DENSITY-LIPOPROTEIN RECEPTOR; CONE OUTER SEGMENTS; MACULAR DEGENERATION;
   PIGMENT EPITHELIUM; NATURAL-HISTORY; BRUCHS MEMBRANE; AGE; TRANSPORT;
   DRUSEN; ROD
AB We developed an in silico mathematical model of retinal cholesterol (Ch) dynamics (RCD) to quantify the physiological rate of Ch turnover in the rod outer segment (ROS), the lipoprotein transport mechanisms by which Ch enters and leaves the outer retina, and the rates of drusen growth and macrophage-mediated clearance in dry age-related macular degeneration. Based on existing experimental data and mechanistic hypotheses, we estimated the Ch turnover rate in the ROS to be 1-6 pg/mm(2)/min, dependent on the rate of Ch recycling in the outer retina, and found comparable rates for LDL receptor-mediated endocytosis of Ch by the retinal pigment epithelium (RPE), ABCA1-mediated Ch transport from the RPE to the outer retina, ABCA1-mediated Ch efflux from the RPE to the choroid, and the secretion of 70 nm ApoB-Ch particles from the RPE. The drusen growth rate is predicted to increase from 0.7 to 4.2. mu m/year in proportion to the flux of ApoB-Ch particles. The rapid regression of drusen may be explained by macrophage-mediated clearance if the macrophage density reaches. similar to 3,500 cells/mm(2). The RCD model quantifies retinal Ch dynamics and suggests that retinal Ch turnover and recycling, ApoB-Ch particle efflux, and macrophage-mediated clearance may explain the dynamics of drusen growth and regression.
C1 [Zekavat, Seyedeh Maryam] MIT, Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Lu, James; Mazer, Norman A.] Roche Innovat Ctr Basel, Dept Clin Pharmacol, Basel, Switzerland.
   [Maugeais, Cyrille] Roche Innovat Ctr Basel, Dept Neurosci Ophthalmol & Rare Dis, Basel, Switzerland.
   [Zekavat, Seyedeh Maryam] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Zekavat, Seyedeh Maryam] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
   [Lu, James] AstraZeneca, Dept Drug Safety & Metab, Cambridge, England.
C3 Massachusetts Institute of Technology (MIT); Roche Holding; Roche
   Holding; Harvard University; Massachusetts Institute of Technology
   (MIT); Broad Institute; Harvard University; Massachusetts General
   Hospital; AstraZeneca
RP Mazer, NA (通讯作者)，Roche Innovat Ctr Basel, Dept Clin Pharmacol, Basel, Switzerland.
EM norman.mazer@roche.com
RI Zekavat, Seyedeh M/N-7570-2018
OI Zekavat, Seyedeh M/0000-0003-4026-8944
FU MIT's International Science and Technology Initiatives (MISTI) program;
   Roche Pharma Research and Early Development (pRED)
FX Funding sources for this work include MIT's International Science and
   Technology Initiatives (MISTI) program and Roche Pharma Research and
   Early Development (pRED).
CR Albert AD, 2005, PROG LIPID RES, V44, P99, DOI 10.1016/j.plipres.2005.02.001
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   BASSEN FA, 1950, BLOOD, V5, P381, DOI 10.1182/blood.V5.4.381.381
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867
   BROSNAHAN DM, 1994, OPHTHALMOLOGY, V101, P38
   BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330
   BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8
   Bungay P.M., 1973, INT J MULTIPHAS FLOW, V1, P25, DOI [DOI 10.1016/0301-9322(73)90003-7, 10.1016/0301-9322(73)90003-7]
   Chen J, 2013, CELL METAB, V17, P471, DOI 10.1016/j.cmet.2013.03.010
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Corless JM, 2012, BIOPHYS J, V102, P2697, DOI 10.1016/j.bpj.2012.04.052
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   DEEN WM, 1985, AM J PHYSIOL, V249, pF374, DOI 10.1152/ajprenal.1985.249.3.F374
   DEEN WM, 1987, AICHE J, V33, P1409, DOI 10.1002/aic.690330902
   Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Family F, 2010, PHYSCS PROC, V4, P21, DOI 10.1016/j.phpro.2010.08.006
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Frank PG, 2009, CELL TISSUE RES, V335, P41, DOI 10.1007/s00441-008-0659-8
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   Harwood HJ, 1997, BIOCHEM J, V323, P649, DOI 10.1042/bj3230649
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   HOFFMAN HN, 1965, AM J MED, V39, P582, DOI 10.1016/0002-9343(65)90081-1
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Ishibashi R., 1984, Kurume Medical Journal, V31, P309
   JAMPEL RS, 1958, ARCH OPHTHALMOL-CHIC, V59, P818
   Jeyarajah EJ, 2006, CLIN LAB MED, V26, P847, DOI 10.1016/j.cll.2006.07.006
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Lu J, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003509
   MELAMED S, 1980, BRIT J OPHTHALMOL, V64, P537, DOI 10.1136/bjo.64.7.537
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Mora S, 2009, CIRCULATION, V119, P931, DOI 10.1161/CIRCULATIONAHA.108.816181
   Ng DS, 1996, AM J MED SCI, V312, P30, DOI 10.1097/00000441-199607000-00006
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Paalvast Y, 2015, BBA-MOL CELL BIOL L, V1851, P1360, DOI 10.1016/j.bbalip.2015.05.008
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PRESSLY TA, 1987, AM J MED, V83, P991, DOI 10.1016/0002-9343(87)90667-X
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Saadane A, 2014, AM J PATHOL, V184, P2403, DOI 10.1016/j.ajpath.2014.05.024
   SALT HB, 1960, LANCET, V2, P325
   Sarin Hemant, 2010, J Angiogenes Res, V2, P14, DOI 10.1186/2040-2384-2-14
   Savic RM, 2007, J PHARMACOKINET PHAR, V34, P711, DOI 10.1007/s10928-007-9066-0
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shirinifard A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002440
   Sniderman AD, 2013, ARTERIOSCL THROM VAS, V33, P2481, DOI 10.1161/ATVBAHA.113.301517
   Stylianopoulos T, 2013, ANN BIOMED ENG, V41, P68, DOI 10.1007/s10439-012-0630-4
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   von Eckardstein A, 2009, CURR OPIN LIPIDOL, V20, P197, DOI 10.1097/MOL.0b013e32832afd63
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WANG N, 1993, EXP EYE RES, V57, P225, DOI 10.1006/exer.1993.1118
   Wang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026871
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 77
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD JUL
PY 2017
VL 58
IS 7
BP 1325
EP 1337
DI 10.1194/jlr.M074088
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EZ2YH
UT WOS:000404576500006
PM 28442497
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chirco, KR
   Tucker, BA
   Stone, EM
   Mullins, RF
AF Chirco, Kathleen R.
   Tucker, Budd A.
   Stone, Edwin M.
   Mullins, Robert F.
TI Selective accumulation of the complement membrane attack complex in
   aging choriocapillaris
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Complement; Choroid; Choriocapillaris; Age-related macular degeneration;
   Microvasculature
ID CHOROIDAL ENDOTHELIAL-CELLS; MACULAR-DEGENERATION; ACTIVATION;
   EXPRESSION; GENOTYPES; PATHWAY
AB The complement membrane attack complex (MAC) shows increased abundance in the choriocapillaris during normal aging and is especially prevalent in age-related macular degeneration (AMD). While perivascular MAC accumulation occurs in the choroid, it is not well understood whether similar deposition occurs in other aging tissues. In this study we examined the abundance of MAC across multiple human tissues. For studies on fixed tissues, paraffin sections were obtained from six human donor eyes and a commercially available tissue array containing 19 different tissues. Immunohistochemical labeling was performed using antibodies directed against the MAC and intercellular adhesion molecule-1 (ICAM-1), as well as the lectin Ulex europaeus agglutinin-1 (UEA-I). The choriocapillaris was the only tissue with high levels of the MAC, which was not detected in any of the 38 additional samples from 19 tissues. ICAM-1 was abundantly expressed in the majority of tissues evaluated, and UEA-I labeled the vasculature in all tissues. A second experiment was performed using unfixed frozen sections of RPE-choroid and 7 extraocular tissues, which confirmed the relatively limited localization of the MAC to the choriocapillaris. In comparison to other tissues assessed, the restricted accumulation of MAC in the choriocapillaris may, in part, explain the specificity of AMD to the neural retina, RPE and choroid, and the relative absence of systemic pathology in this disease. (c) 2015 Elsevier Ltd. All rights reserved.
C1 [Mullins, Robert F.] Univ Iowa, Stephen A Wynn Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Ophthalmol & Visual Sci, 375 Newton Rd, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Stephen A Wynn Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.
EM Robert-Mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Tucker, Budd/0000-0003-2178-1742; Stone, Edwin M./0000-0003-3343-4414;
   Mullins, Robert/0000-0002-5006-0891
FU NIH [EY-024605, P30CA086862]; Elmer and Sylvia Sramek Charitable
   Foundation; Martin and Ruth Carver Chair in Ocular Cell Biology; Ronald
   and Annette Massman Choroideremia Research Fund; NATIONAL EYE INSTITUTE
   [R01EY024605] Funding Source: NIH RePORTER
FX Supported in part by NIH grant EY-024605, NIH grant P30CA086862, the
   Elmer and Sylvia Sramek Charitable Foundation, and the Martin and Ruth
   Carver Chair in Ocular Cell Biology and the Ronald and Annette Massman
   Choroideremia Research Fund.
CR Al-Marzoqee FY, 2012, INT J ONCOL, V41, P1733, DOI 10.3892/ijo.2012.1608
   Biesemeier A., 2014, NEUROBIOL A IN PRESS, P1
   Birke K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076766
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   KOFFLER D, 1983, J EXP MED, V157, P1885, DOI 10.1084/jem.157.6.1885
   Morgan B.P., 2015, IMMUNOBIOLOGY
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rus H, 2001, IMMUNOL RES, V24, P79, DOI 10.1385/IR:24:1:79
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Whitmore S.S., 2014, PROG RETIN EYE RES
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 21
TC 34
Z9 35
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2016
VL 146
BP 393
EP 397
DI 10.1016/j.exer.2015.09.003
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM4QS
UT WOS:000376332400046
PM 26368849
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Li, ZY
   Grant, KB
AF Li, Ziyi
   Grant, Kathryn B.
TI DNA photo-cleaving agents in the far-red to near-infrared range - a
   review
SO RSC ADVANCES
LA English
DT Review
ID MEDIATED PHOTODYNAMIC THERAPY; PHOTOSENSITIZED SINGLET OXYGEN;
   SQUAMOUS-CELL CARCINOMA; LIGHT-INDUCED DNA; OXOVANADIUM(IV) COMPLEXES;
   OXIDOVANADIUM(IV) COMPLEX; 2-PHOTON ABSORPTION; ANTICANCER DRUGS; STRAND
   SCISSION; ROS GENERATION
AB Photosensitizing agents that oxidatively cleave DNA are important to photodynamic therapy (PDT), an emerging treatment option for patients diagnosed with age-related macular degeneration, precancerous conditions such as Barrett's esophagus, and localized cancers that include inoperable neoplasms. Excitation with low energy irradiation activates the PDT agents, causing spatially targeted, oxidative damage to DNA and other macromolecules in diseased cells. While most routinely used PDT photosensitizers rely on visible light sources that emit at wavelengths <= 689 nm, excitation that extends from the far-red into the near-infrared wavelength range is desirable. Due to low absorption by biogenic chromophores, light in this region has a greater penetration depth through tissue when compared to visible irradiation that is higher in energy. In the present review, we describe the development of new, long wavelength DNA photo-oxidizing agents. We have attempted to correlate the structural elements of the photosensitizers with their reported light-induced nuclease activities (lambda(ex) >= 690 nm). Reaction pathways that lead to DNA cleavage are discussed, including O-3(2) dependent Type I electron transfer and Type II energy transfer processes and anaerobic Type I hydrogen atom abstraction from deoxyribose. The summary discussion contained in this review is intended to contribute to the discovery of new phototherapeutic agents that are activated with far-red to near-infrared light.
C1 [Li, Ziyi; Grant, Kathryn B.] Georgia State Univ, Dept Chem, POB 3965, Atlanta, GA 30302 USA.
C3 University System of Georgia; Georgia State University
RP Grant, KB (通讯作者)，Georgia State Univ, Dept Chem, POB 3965, Atlanta, GA 30302 USA.
EM kbgrant@gsu.edu
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Andreini C, 2008, J BIOL INORG CHEM, V13, P1205, DOI 10.1007/s00775-008-0404-5
   Armitage B, 1998, CHEM REV, V98, P1171, DOI 10.1021/cr960428+
   Armitage BA, 2008, TOP HETEROCYCL CHEM, V14, P11, DOI 10.1007/7081_2007_109
   Atsumi T, 2007, ANTICANCER RES, V27, P363
   Balaji B, 2012, EUR J INORG CHEM, P126, DOI 10.1002/ejic.201100836
   Banerjee S, 2015, EUR J INORG CHEM, P447, DOI 10.1002/ejic.201402884
   Banerjee S, 2015, DALTON T, V44, P4108, DOI 10.1039/c4dt02165g
   Banerjee S, 2012, EUR J INORG CHEM, P3899, DOI 10.1002/ejic.201200344
   Banik B, 2014, RSC ADV, V4, P40120, DOI 10.1039/c4ra02687j
   Banik B, 2014, DALTON T, V43, P13358, DOI 10.1039/c4dt01487a
   Banik B, 2014, DALTON T, V43, P1321, DOI 10.1039/c3dt52087k
   Banik B, 2012, INORG CHIM ACTA, V393, P284, DOI 10.1016/j.ica.2012.06.015
   Banik B, 2011, EUR J INORG CHEM, P1425, DOI 10.1002/ejic.201001097
   Basu U, 2012, ANGEW CHEM INT EDIT, V51, P2658, DOI 10.1002/anie.201108360
   BILSKI P, 1992, J AM CHEM SOC, V114, P549, DOI 10.1021/ja00028a023
   BLAZEK ER, 1989, PHOTOCHEM PHOTOBIOL, V49, P607, DOI 10.1111/j.1751-1097.1989.tb08431.x
   BONNETT R, 1995, CHEM SOC REV, V24, P19, DOI 10.1039/cs9952400019
   BRATSCH SG, 1989, J PHYS CHEM REF DATA, V18, P1, DOI 10.1063/1.555839
   Cai XJ, 2013, PHOTODIAGN PHOTODYN, V10, P672, DOI 10.1016/j.pdpdt.2013.08.002
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4
   Cerrati EW, 2015, ENT-EAR NOSE THROAT, V94, P72, DOI 10.1177/014556131509400208
   Chakravarty AR, 2006, J CHEM SCI, V118, P443, DOI 10.1007/BF02703941
   Chakravarty AR, 2012, PROG INORG CHEM, V57, P119
   Chen HY, 2015, J MOL NEUROSCI, V56, P977, DOI 10.1007/s12031-015-0566-x
   Chen JY, 2005, NAT REV CANCER, V5, P102, DOI 10.1038/nrc1547
   Chen YJ, 2008, CANCER SCI, V99, P2019, DOI 10.1111/j.1349-7006.2008.00910.x
   Clo E, 2007, CHEMBIOCHEM, V8, P475, DOI 10.1002/cbic.200600454
   Corti L, 2007, LASER SURG MED, V39, P394, DOI 10.1002/lsm.20513
   Crespy D, 2010, CHEM COMMUN, V46, P6651, DOI 10.1039/c0cc01887b
   Da Ros T, 2001, CURR PHARM DESIGN, V7, P1781, DOI 10.2174/1381612013397140
   de Visscher SAHJ, 2013, ORAL ONCOL, V49, P192, DOI 10.1016/j.oraloncology.2012.09.011
   DeRosa MC, 2002, COORDIN CHEM REV, V233, P351, DOI 10.1016/S0010-8545(02)00034-6
   Dhar S, 2003, CHEM COMMUN, P2452, DOI 10.1039/b308344f
   Dhar S, 2005, DALTON T, P344, DOI 10.1039/b413410a
   Dhar S, 2003, J AM CHEM SOC, V125, P12118, DOI 10.1021/ja036681q
   Flowers L, 1997, BIOCHEMISTRY-US, V36, P8640, DOI 10.1021/bi970367p
   Fortner A, 2007, CHEM PHYS LETT, V434, P127, DOI 10.1016/j.cplett.2006.11.106
   FOWLER GJS, 1990, PHOTOCHEM PHOTOBIOL, V52, P489, DOI 10.1111/j.1751-1097.1990.tb01790.x
   Gorka AP, 2015, ORG BIOMOL CHEM, V13, P7584, DOI 10.1039/c5ob00788g
   Gorman A, 2004, J AM CHEM SOC, V126, P10619, DOI 10.1021/ja047649e
   Hamanaka RB, 2012, J EXP MED, V209, P211, DOI 10.1084/jem.20120162
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hatz S, 2008, PHOTOCHEM PHOTOBIOL, V84, P1284, DOI 10.1111/j.1751-1097.2008.00359.x
   Herman L, 2008, J PHYS ORG CHEM, V21, P670, DOI 10.1002/poc.1355
   Hussain A, 2012, J CHEM SCI, V124, P1327, DOI 10.1007/s12039-012-0332-3
   Istomin YP, 2009, PROC SPIE, V7380, DOI 10.1117/12.823840
   Jain A, 1996, MUTAT RES-FUND MOL M, V357, P83, DOI 10.1016/0027-5107(96)00085-1
   Joensuu H, 2008, LANCET ONCOL, V9, P304, DOI 10.1016/S1470-2045(08)70075-5
   Johnstone TC, 2014, ANTICANCER RES, V34, P471
   Josefsen LB, 2012, THERANOSTICS, V2, P916, DOI 10.7150/thno.4571
   Juzeniene A, 2007, PHOTODIAGN PHOTODYN, V4, P3, DOI 10.1016/j.pdpdt.2006.11.002
   KADISH KM, 1991, J PHYS CHEM-US, V95, P427, DOI 10.1021/j100154a075
   Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9
   Konig K., 2008, HDB BIOMEDICAL NONLI
   Lahiri D, 2009, INORG CHEM, V48, P339, DOI 10.1021/ic800806j
   Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200
   Lee PK, 2013, J DRUGS DERMATOL, V12, P925
   Lim EJ, 2013, ONCOL REP, V30, P856, DOI 10.3892/or.2013.2494
   Lim HJ, 2011, PHOTODIAGN PHOTODYN, V8, P337, DOI 10.1016/j.pdpdt.2011.06.002
   Lu P, 2015, CURR ORG CHEM, V19, P958, DOI 10.2174/1385272819666150119225337
   Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
   MAGDA D, 1995, J AM CHEM SOC, V117, P3629, DOI 10.1021/ja00117a039
   Makrigiorgos GM, 1999, MET IONS BIOL SYST, V36, P521
   Mapp CT, 2014, BIOORG MED CHEM LETT, V24, P214, DOI 10.1016/j.bmcl.2013.11.035
   Mari C, 2015, CHEM SCI, V6, P2660, DOI 10.1039/c4sc03759f
   Mari C, 2014, CHEM-EUR J, V20, P14421, DOI 10.1002/chem.201402796
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x
   Moseley H, 2006, LASER SURG MED, V38, P403, DOI 10.1002/lsm.20369
   Mozaffarieh M, 2009, MOL VIS, V15, P1194
   Murakami LS, 2015, BBA-GEN SUBJECTS, V1850, P1150, DOI 10.1016/j.bbagen.2014.12.005
   Murray V, 2014, CELL MOL LIFE SCI, V71, P1505, DOI 10.1007/s00018-013-1456-4
   Nguyen QT, 2013, NAT REV CANCER, V13, P653, DOI 10.1038/nrc3566
   Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3
   Ohashi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103126
   Ormond AB, 2013, MATERIALS, V6, P817, DOI 10.3390/ma6030817
   Overholt BF, 2005, GASTROINTEST ENDOSC, V62, P488, DOI 10.1016/j.gie.2005.06.047
   Palchaudhuri R, 2007, CURR OPIN BIOTECH, V18, P497, DOI 10.1016/j.copbio.2007.09.006
   Pawlicki M, 2009, ANGEW CHEM INT EDIT, V48, P3244, DOI 10.1002/anie.200805257
   Pogocki D, 2001, FREE RADICAL BIO MED, V31, P98, DOI 10.1016/S0891-5849(01)00559-7
   Pogozelski WK, 1998, CHEM REV, V98, P1089, DOI 10.1021/cr960437i
   Powers S. K., 1990, PHOTODYNAMIC THERAPY, V1, P307
   Prasad P, 2013, CHEM-EUR J, V19, P17445, DOI 10.1002/chem.201303487
   Prasad P, 2010, INORG CHIM ACTA, V363, P2743, DOI 10.1016/j.ica.2010.03.016
   Preihs C, 2013, INORG CHEM, V52, P12184, DOI 10.1021/ic400226g
   Przhonska OV, 2010, SPRINGER SER FLUORES, V8, P105, DOI 10.1007/978-3-642-04702-2_4
   Ralhan R, 2007, EXPERT OPIN THER PAT, V17, P1061, DOI 10.1517/13543776.17.9.1061
   Rangasamy S, 2015, J MED CHEM, V58, P6864, DOI 10.1021/acs.jmedchem.5b01095
   Rehman SU, 2015, TUMOR BIOL, V36, P1237, DOI 10.1007/s13277-014-2743-x
   Renschler M. F., 1998, OPTICAL METHODS TUMO
   Roy S, 2009, INORG CHEM, V48, P9501, DOI 10.1021/ic9015355
   Ryan DE, 1996, BIOCHEMISTRY-US, V35, P8640, DOI 10.1021/bi9521506
   Sasmal PK, 2007, INORG CHEM, V46, P11112, DOI 10.1021/ic7011793
   Sasmal PK, 2010, INORG CHEM, V49, P849, DOI 10.1021/ic900701s
   Sasmal PK, 2009, CHEM COMMUN, P1703, DOI 10.1039/b822229k
   Schatzschneider U, 2010, EUR J INORG CHEM, P1451, DOI 10.1002/ejic.201000003
   Sessler JL, 2000, BIOCHEM PHARMACOL, V59, P733, DOI 10.1016/S0006-2952(99)00314-7
   Shemesh CS, 2014, PHOTODIAGN PHOTODYN, V11, P193, DOI 10.1016/j.pdpdt.2014.02.001
   Speisky H, 2009, BIOORGAN MED CHEM, V17, P1803, DOI 10.1016/j.bmc.2009.01.069
   Stolik S, 2000, J PHOTOCH PHOTOBIO B, V57, P90, DOI 10.1016/S1011-1344(00)00082-8
   Tanaka T, 2011, GASTROINTEST ENDOSC, V73, P1, DOI 10.1016/j.gie.2010.08.049
   Tang CH, 2014, J AM CHEM SOC, V136, P13715, DOI 10.1021/ja505733u
   Taskin-Tok T., 2014, ANTICANCER DRUG FRIE
   Usuda J, 2006, J THORAC ONCOL, V1, P489, DOI 10.1097/01243894-200606000-00018
   Vahrmeijer AL, 2013, NAT REV CLIN ONCOL, V10, P507, DOI 10.1038/nrclinonc.2013.123
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   Verigos K, 2006, J ENVIRON PATHOL TOX, V25, P373, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.230
   Viola G, 2006, CURR DRUG TARGETS, V7, P1135, DOI 10.2174/138945006778226561
   Vrouenraets MB, 2003, ANTICANCER RES, V23, P505
   Wilkins PC, 2006, INORG CHEM, V45, P1471, DOI 10.1021/ic050749g
   Wilson BC, 2003, COMP SER PHOTOCHEM, V2, P127
   Wilson B, 2008, ORG BIOMOL CHEM, V6, P4026, DOI 10.1039/b810015b
   WOOD PM, 1988, BIOCHEM J, V253, P287, DOI 10.1042/bj2530287
   Woods JA, 2004, PHOTOCHEM PHOTOBIOL, V79, P105, DOI 10.1111/j.1751-1097.2004.tb09864.x
   Yoon I, 2013, CLIN ENDOSC, V46, P7, DOI 10.5946/ce.2013.46.1.7
   Yu ZQ, 2015, BIOCHEMISTRY-US, V54, P3100, DOI 10.1021/acs.biochem.5b00277
   Zheng YC, 2015, RSC ADV, V5, P770, DOI 10.1039/c4ra11133h
NR 119
TC 17
Z9 17
U1 2
U2 42
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 29
BP 24617
EP 24634
DI 10.1039/c5ra28102d
PG 18
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA DG7IA
UT WOS:000372256800076
DA 2022-11-30
ER

PT J
AU Tan, X
   Fujiu, K
   Manabe, I
   Nishida, J
   Yamagishi, R
   Nagai, R
   Yanagi, Y
AF Tan, Xue
   Fujiu, Katsuhito
   Manabe, Ichiro
   Nishida, Junko
   Yamagishi, Reiko
   Nagai, Ryozo
   Yanagi, Yasuo
TI Choroidal neovascularization is inhibited via an intraocular decrease of
   inflammatory cells in mice lacking complement component C3
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; MONOCYTE SUBSETS; MACROPHAGE; DRUSEN; MODEL;
   IDENTIFICATION; POPULATION; EXPRESSION; MUTATION; UPDATE
AB In early age-related macular degeneration (AMD), complement component C3 can be observed in drusen, which is the accumulation of material beneath the retinal pigment epithelium. The complement pathways, via the activation of C3, can upregulate the expression of cytokines and their receptors and the recruitment of inflammatory leukocytes, both of which play an important role in the development of choroidal neovascularization (CNV) in exudative AMD. Laser-induced CNV lesions were found to be significantly smaller in C3(-/-) mice than in wild-type mice. By using flow cytometry, we demonstrated that the proportions of intraocular granulocytes, CD11b(+) F4/80(+) Ly6C(hi) and CD11b(+) F4/80(+) Ly6C(lo) cells, were lower in C3(-/-) mice than in wild-type mice as early as day 1 after laser injury, and the proportions of granulocytes and three macrophage/monocyte subsets were significantly lower on day 3. In contrast, C3(-/-) mice had more granulocytes and CD11b(+) F4/80(+) Ly6C(hi) cells in peripheral blood than wild-type mice after injury. Further, the expression levels of Vegfa164 were upregulated in intraocular Ly6C(hi) macrophages/monocytes of C3(-/-) mice, but not as much as in wild-type mice. Collectively, our data demonstrate that despite a more pronounced induction of systemic inflammation, inhibition of complement factor C3 suppresses CNV by decreasing the recruitment of inflammatory cells to the lesion.
C1 [Tan, Xue; Nishida, Junko; Yamagishi, Reiko; Yanagi, Yasuo] Univ Tokyo, Dept Ophthalmol, Tokyo 113, Japan.
   [Fujiu, Katsuhito; Manabe, Ichiro] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.
   [Fujiu, Katsuhito; Manabe, Ichiro] Univ Tokyo, Fac Med, Tokyo 113, Japan.
   [Fujiu, Katsuhito; Nagai, Ryozo] Univ Tokyo, Sch Med, Dept Ubiquitous Hlth Informat, Tokyo 113, Japan.
   [Fujiu, Katsuhito] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Tokyo, Japan.
   [Yanagi, Yasuo] Jichi Med Univ, Shimotsuke, Tochigi, Japan.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore, Singapore.
   [Yanagi, Yasuo] Singapore Natl Eye Ctr, Med Retina Dept, Singapore, Singapore.
C3 University of Tokyo; University of Tokyo; University of Tokyo;
   University of Tokyo; Japan Science & Technology Agency (JST); Jichi
   Medical University; National University of Singapore; Singapore National
   Eye Center; Singapore National Eye Center
RP Yanagi, Y (通讯作者)，Univ Tokyo, Dept Ophthalmol, Tokyo 113, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAF-2670-2020; Manabe, Ichiro/AAE-5105-2021; Manabe,
   Ichiro/E-1529-2014; Yanagi, Yasuo/AAA-5441-2022
OI Yanagi, Yasuo/0000-0002-0362-7285
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Figueroa LA, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/479412
   Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Davies LC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2877
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Duffield JS, 2010, SEMIN NEPHROL, V30, P234, DOI 10.1016/j.semnephrol.2010.03.003
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Frangogiannis NG, 2012, CIRC RES, V110, P159, DOI 10.1161/CIRCRESAHA.111.243162
   Fujiu K, 2011, J CLIN INVEST, V121, P3425, DOI 10.1172/JCI57582
   Gimenez E, 2001, LAB ANIM-UK, V35, P153, DOI 10.1258/0023677011911525
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hristov M, 2011, THROMB HAEMOSTASIS, V106, P757, DOI 10.1160/TH11-07-0500
   Jawad S, 2013, INVEST OPHTH VIS SCI, V54, P5959, DOI 10.1167/iovs.12-11380
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Libby P, 2013, SEMIN IMMUNOPATHOL, V35, P553, DOI 10.1007/s00281-013-0387-3
   Mantovani A, 2009, ARTERIOSCL THROM VAS, V29, P1419, DOI 10.1161/ATVBAHA.108.180497
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179
   Sekine H, 2001, J IMMUNOL, V166, P6444, DOI 10.4049/jimmunol.166.10.6444
   Sunderkotter C, 2004, J IMMUNOL, V172, P4410, DOI 10.4049/jimmunol.172.7.4410
   Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202
   Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   VANFURTH R, 1968, J EXP MED, V128, P415, DOI 10.1084/jem.128.3.415
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1
   Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001
   Yuda K, 2012, AM J PATHOL, V181, P1464, DOI 10.1016/j.ajpath.2012.06.028
   Zhou JH, 2005, MOL VIS, V11, P414
NR 48
TC 15
Z9 16
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 28
PY 2015
VL 5
AR 15702
DI 10.1038/srep15702
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CU4TM
UT WOS:000363523000001
PM 26507897
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Duchin, KS
   Asefzadeh, B
   Poulaki, V
   Rett, D
   Marescalchi, P
   Cavallerano, A
AF Duchin, Kyla S.
   Asefzadeh, Baharak
   Poulaki, Vasiliki
   Rett, Douglas
   Marescalchi, Paul
   Cavallerano, Anthony
TI Teleretinal Imaging for Detection of Referable Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE teleretinal; macular degeneration; screening; visual impairment; aging
   population; nonmydriatic
ID DIABETIC-RETINOPATHY; PREMATURITY; RELIABILITY; SPECIFICITY;
   SENSITIVITY; DEPRESSION; PREVALENCE; RESIDENTS; DIAGNOSIS; ACCURACY
AB Purpose. The purpose of this study was to determine the sensitivity and specificity for detection of referable age-related macular degeneration (AMD) using an existing nonmydriatic telemedicine pathway for diabetic retinopathy screening with comparison to same-day face-to-face examination by a retina specialist.
   Methods. Subjects in this study underwent nonmydriatic and mydriatic digital retinal imaging on the same day as stereoscopic dilated examination of the macula by a retina specialist and the level of AMD was recorded for each eye. Images were graded by two trained readers as nonreferable or referable (AREDS [Age-Related Eye Disease Study] grading of level 3 or greater). Sensitivity and specificity were calculated by comparing referral recommendations between each reader and the retina specialist ("gold standard").
   Results. There were 47 subjects (94 eyes) enrolled in the study. Sensitivity for nonreferable AMD with nonmydriatic imaging was 1.0 (reader 1) and 1.0 (reader 2), whereas specificity was 0.75 (reader 1) and 0.91 (reader 2). Sensitivity for referable AMD with nonmydriatic imaging was 0.84 (reader 1) and 0.88 (reader 2), whereas specificity was 0.81 (reader 1) and 0.81 (reader 2).
   Conclusions. Our study showed that nonmydriatic digital retinal imaging had excellent sensitivity and specificity in identifying referable and nonreferable AMD using an existing validated telemedicine pathway for diabetic retinopathy screening.
C1 [Duchin, Kyla S.] VA Maine Healthcare Syst, Augusta, ME USA.
   [Asefzadeh, Baharak; Poulaki, Vasiliki; Rett, Douglas; Marescalchi, Paul; Cavallerano, Anthony] VA Boston Healthcare Syst, Boston, MA USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Harvard University; VA Boston Healthcare System
RP Duchin, KS (通讯作者)，Togus VAMC Lewiston Auburn CBOC, 15 Challenger Dr, Lewiston, ME 04240 USA.
EM Kyla.Duchin@va.gov
CR Ahmed J, 2006, DIABETES CARE, V29, P2205, DOI 10.2337/dc06-0295
   American Academy of Ophthalmology Retina/Vitreous Preferred Practice Pattern Panel (PPP), AG REL MAC DEG PPP U
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Bursell SE, 2001, OPHTHALMOLOGY, V108, P572, DOI 10.1016/S0161-6420(00)00604-7
   Cavallerano AA, 2005, AM J OPHTHALMOL, V139, P597, DOI 10.1016/j.ajo.2004.10.064
   Cavallerano JD, 2005, AM J OPHTHALMOL, V140, P667, DOI 10.1016/j.ajo.2005.03.075
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiang MF, 2006, ARCH OPHTHALMOL-CHIC, V124, P322, DOI 10.1001/archopht.124.3.322
   Chiang MF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1531, DOI 10.1001/archopht.125.11.1531
   De Bats F, 2014, OPHTHALMOLOGICA, V231, P172, DOI 10.1159/000356695
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gangwani R, 2014, GRAEF ARCH CLIN EXP, V252, P723, DOI 10.1007/s00417-013-2530-1
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Lim JI, 2002, RETINA-J RET VIT DIS, V22, P59, DOI 10.1097/00006982-200202000-00011
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez-Bastida J, 2007, DIABETIC MED, V24, P403, DOI 10.1111/j.1464-5491.2007.02074.x
   Maberley DAL, 2005, EYE, V19, P611, DOI 10.1038/sj.eye.6701584
   MARX MS, 1994, J VISUAL IMPAIR BLIN, V88, P462
   National Institutes of Health/National Eye Institute, PREV AD VIS IMP AG R
   National Institutes of Health/National Eye Institute, US AG SPEC PREV RAT
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Scott KE, 2008, OPHTHALMOLOGY, V115, P1222, DOI 10.1016/j.ophtha.2007.09.006
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98, P629, DOI 10.1177/0145482X0409801007
NR 30
TC 8
Z9 8
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUN
PY 2015
VL 92
IS 6
BP 714
EP 718
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ0DA
UT WOS:000355141900014
PM 25955641
DA 2022-11-30
ER

PT J
AU Yam, JCS
   Kwok, AKH
AF Yam, Jason C. S.
   Kwok, Alvin K. H.
TI Ultraviolet light and ocular diseases
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
ID BASAL-CELL CARCINOMA; POSTERIOR SUBCAPSULAR CATARACTS; SURFACE
   EPITHELIAL DYSPLASIA; NONMELANOCYTIC SKIN-CANCER; AGE-RELATED
   MACULOPATHY; BEAVER DAM EYE; RISK-FACTORS; MACULAR DEGENERATION;
   SUNLIGHT EXPOSURE; UVEAL MELANOMA
AB The objective of this study is to review the association between ultraviolet (UV) light and ocular diseases. The data are sourced from the literature search of Medline up to Nov 2012, and the extracted data from original articles, review papers, and book chapters were reviewed. There is a strong evidence that ultraviolet radiation (UVR) exposure is associated with the formation of eyelid malignancies [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)], photokeratitis, climatic droplet keratopathy (CDK), pterygium, and cortical cataract. However, the evidence of the association between UV exposure and development of pinguecula, nuclear and posterior subcapsular cataract, ocular surface squamous neoplasia (OSSN), and ocular melanoma remained limited. There is insufficient evidence to determine whether age-related macular degeneration (AMD) is related to UV exposure. It is now suggested that AMD is probably related to visible radiation especially blue light, rather than UV exposure. From the results, it was concluded that eyelid malignancies (BCC and SCC), photokeratitis, CDK, pterygium, and cortical cataract are strongly associated with UVR exposure. Evidence of the association between UV exposure and development of pinguecula, nuclear and posterior subcapsular cataract, OSSN, and ocular melanoma remained limited. There is insufficient evidence to determine whether AMD is related to UV exposure. Simple behaviural changes, appropriate clothing, wearing hats, and UV blocking spectacles, sunglasses or contact lens are effective measures for UV protection.
RP Yam, JCS (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 4-F,147 K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM yamcheuksing@gmail.com
RI Yam, Jason C. S./I-5682-2014; Yam, Jason C./AAI-2522-2020
OI Yam, Jason C. S./0000-0002-2156-1486; Yam, Jason C./0000-0002-2156-1486
CR AJANI UA, 1992, CANCER, V70, P2891, DOI 10.1002/1097-0142(19921215)70:12&lt;2891::AID-CNCR2820701228&gt;3.0.CO;2-1
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   AUSTIN P, 1983, OPHTHALMOLOGY, V90, P96
   Benjamin CL, 2007, TOXICOL APPL PHARM, V224, P241, DOI 10.1016/j.taap.2006.12.006
   Bergmanson Jan P. G., 1997, CLAO Journal, V23, P196
   BERGMANSON JPG, 1995, OPHTHAL PHYSL OPT, V15, P83, DOI 10.1046/j.1475-1313.1995.9598237h.x
   BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027
   BRILLIANT LB, 1983, AM J EPIDEMIOL, V118, P250, DOI 10.1093/oxfordjournals.aje.a113632
   Burton M, 1997, EYE, V11, P95, DOI 10.1038/eye.1997.19
   Cameron M, 1965, PTERYGIUM WORLD
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   CHATTERJEE A, 1982, BRIT J OPHTHALMOL, V66, P35, DOI 10.1136/bjo.66.1.35
   Chui J, 2008, OCUL SURF, V6, P24, DOI 10.1016/S1542-0124(12)70103-9
   COLLMAN GW, 1988, AM J PUBLIC HEALTH, V78, P1459, DOI 10.2105/AJPH.78.11.1459
   Corona R, 2001, ARCH DERMATOL, V137, P1162
   Coroneo M, 2011, EYE CONTACT LENS, V37, P214, DOI 10.1097/ICL.0b013e318223394e
   CORONEO MT, 1991, OPHTHALMIC SURG LAS, V22, P705
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   Cullen AP, 2002, INT J TOXICOL, V21, P455, DOI 10.1080/10915810290169882
   Damato B, 2004, CLIN EXP OPHTHALMOL, V32, P639, DOI 10.1111/j.1442-9071.2004.00917.x
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2000, ARCH OPHTHALMOL-CHIC, V118, P385, DOI 10.1001/archopht.118.3.385
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   DOLEZAL JM, 1989, AM J EPIDEMIOL, V129, P559, DOI 10.1093/oxfordjournals.aje.a115168
   GALLAGHER RP, 1995, ARCH DERMATOL, V131, P164, DOI 10.1001/archderm.131.2.164
   GALLAGHER RP, 1985, J NATL CANCER I, V74, P775
   GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157
   GRAY RH, 1992, SURV OPHTHALMOL, V36, P241, DOI 10.1016/0039-6257(92)90093-9
   Guenel P, 2001, CANCER CAUSE CONTROL, V12, P451, DOI 10.1023/A:1011271420974
   HILLER R, 1977, AM J EPIDEMIOL, V105, P450, DOI 10.1093/oxfordjournals.aje.a112404
   HIRVELA H, 1995, OPHTHALMOLOGY, V102, P108
   Hoffman RS, 1999, INT OPHTHALMOL CLIN, V39, P15, DOI 10.1097/00004397-199903910-00004
   HOLLOWS F, 1981, LANCET, V2, P1249
   HOLLY EA, 1990, CANCER RES, V50, P5773
   Holly EA, 1996, EPIDEMIOLOGY, V7, P55, DOI 10.1097/00001648-199601000-00010
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAVITT JC, 1994, DOC OPHTHALMOL, V88, P307, DOI 10.1007/BF01203684
   Jhappan C, 2003, ONCOGENE, V22, P3099, DOI 10.1038/sj.onc.1206450
   JOHNSON GJ, 1981, BRIT J OPHTHALMOL, V65, P270, DOI 10.1136/bjo.65.4.270
   Katoh N, 2001, ACTA OPHTHALMOL SCAN, V79, P154, DOI 10.1034/j.1600-0420.2001.079002154.x
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   KLINTWORTH GK, 1972, AM J PATHOL, V67, P327
   KRICKER A, 1995, INT J CANCER, V60, P489, DOI 10.1002/ijc.2910600411
   LEE GA, 1995, SURV OPHTHALMOL, V39, P429, DOI 10.1016/S0039-6257(05)80054-2
   LEE GA, 1994, OPHTHALMOLOGY, V101, P360
   LEE GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P525, DOI 10.1001/archopht.1992.01080160103042
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Lu Lawrence P. L., 2007, Hong Kong Medical Journal, V13, P460
   Lutz JM, 2005, CANCER CAUSE CONTROL, V16, P437, DOI 10.1007/s10552-004-5029-6
   MACKENZIE FD, 1992, OPHTHALMOLOGY, V99, P1056, DOI 10.1016/s0161-6420(92)31850-0
   MALIK MOA, 1979, CANCER, V44, P293, DOI 10.1002/1097-0142(197907)44:1<293::AID-CNCR2820440150>3.0.CO;2-R
   McCarty CA, 2000, INVEST OPHTH VIS SCI, V41, P3720
   McCarty CA, 2002, DEV OPHTHALMOL, V35, P21
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McKenzie RL, 2003, PHOTOCH PHOTOBIO SCI, V2, P5, DOI 10.1039/b211155c
   Meeran SM, 2008, J INVEST DERMATOL, V128, P2716, DOI 10.1038/jid.2008.140
   MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028
   MORAN DJ, 1984, BRIT J OPHTHALMOL, V68, P343, DOI 10.1136/bjo.68.5.343
   Naldi L, 2000, J AM ACAD DERMATOL, V42, P446, DOI 10.1016/S0190-9622(00)90217-2
   Neale RE, 2003, EPIDEMIOLOGY, V14, P707, DOI 10.1097/01.ede.0000086881.84657.98
   Newton R, 1996, LANCET, V347, P1450, DOI 10.1016/S0140-6736(96)91685-2
   Nolan TM, 2003, AM J PATHOL, V162, P567, DOI 10.1016/S0002-9440(10)63850-3
   NORN MS, 1982, ACTA OPHTHALMOL, V60, P949
   Oliva Matthew S., 2005, International Ophthalmology Clinics, V45, P1
   Ouhtit A, 1998, J NATL CANCER I, V90, P523, DOI 10.1093/jnci/90.7.523
   Pane A R, 2000, Ophthalmic Epidemiol, V7, P159, DOI 10.1076/0928-6586(200009)7:3;1-V;FT159
   Pastor-Valero Maria, 2007, BMC Ophthalmol, V7, P18, DOI 10.1186/1471-2415-7-18
   Pe'er Jacob, 2005, Ophthalmol Clin North Am, V18, P1, DOI 10.1016/j.ohc.2004.08.001
   PERKINS ES, 1985, OPHTHALMIC RES, V17, P325, DOI 10.1159/000265395
   Podskochy A, 2000, CORNEA, V19, P99, DOI 10.1097/00003226-200001000-00019
   Pola E C, 2003, Cent Afr J Med, V49, P1
   REN HW, 1994, ACTA OPHTHALMOL, V72, P447
   Rigel DS, 2008, J AM ACAD DERMATOL, V58, pS129, DOI 10.1016/j.jaad.2007.04.034
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Rosmini Francesco, 1994, Annals of Epidemiology, V4, P266
   Rosso S, 1996, BRIT J CANCER, V73, P1447, DOI 10.1038/bjc.1996.275
   SEDDON JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1274, DOI 10.1001/archopht.1990.01070110090031
   Shah CP, 2005, OPHTHALMOLOGY, V112, P1599, DOI 10.1016/j.ophtha.2005.04.020
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   STRICKLAND PT, 1989, J NATL CANCER I, V81, P1910, DOI 10.1093/jnci/81.24.1910
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Sun EC, 1997, CANCER EPIDEM BIOMAR, V6, P73
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1481, DOI 10.1001/archopht.1989.01070020555039
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201
   TAYLOR HR, 1980, BRIT J OPHTHALMOL, V64, P303, DOI 10.1136/bjo.64.5.303
   TEMPLETON AC, 1967, CANCER-AM CANCER SOC, V20, P1689, DOI 10.1002/1097-0142(196710)20:10<1689::AID-CNCR2820201019>3.0.CO;2-F
   Tse TG, 1997, CORNEA EXTERNAL DIS, VII, P601
   TUCKER MA, 1985, NEW ENGL J MED, V313, P789, DOI 10.1056/NEJM198509263131305
   Vainio H, 2000, INT J CANCER, V88, P838, DOI 10.1002/1097-0215(20001201)88:5<838::AID-IJC25>3.0.CO;2-X
   Vajdic CM, 2002, INT J CANCER, V101, P175, DOI 10.1002/ijc.10579
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   WHO (World Health Organization), 2002, GLOB SOL UV IND PRAC
   WOJNO T, 1983, ANN OPHTHALMOL, V15, P729
   WONG L, 1993, J EPIDEMIOL COMMUN H, V47, P46, DOI 10.1136/jech.47.1.46
   Yang SF, 2009, INVEST OPHTH VIS SCI, V50, P4588, DOI 10.1167/iovs.08-3147
   Youn BHCAP, 2010, OPEN TOXICOL J, V4, P13
   Young S, 1998, CLIN DERMATOL, V16, P477, DOI 10.1016/S0738-081X(98)00021-2
NR 101
TC 154
Z9 162
U1 4
U2 69
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2014
VL 34
IS 2
BP 383
EP 400
DI 10.1007/s10792-013-9791-x
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AD4XM
UT WOS:000333255100035
PM 23722672
DA 2022-11-30
ER

PT J
AU Yoshikawa, N
   Noda, K
   Shinoda, H
   Uchida, A
   Ozawa, Y
   Tsubota, K
   Mashima, Y
   Ishida, S
AF Yoshikawa, Nami
   Noda, Kousuke
   Shinoda, Hajime
   Uchida, Atsuro
   Ozawa, Yoko
   Tsubota, Kazuo
   Mashima, Yukihiko
   Ishida, Susumu
TI Serum Vascular Adhesion Protein-1 correlates with vascular endothelial
   growth factor in patients with type II diabetes
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Diabetic retinopathy; Vascular adhesion protein-1;
   Semicarbazide-sensitive amine oxidase; Vascular endothelial growth
   factor
ID SENSITIVE AMINE OXIDASE; MATRIX-METALLOPROTEINASE; OXIDATIVE STRESS;
   EXPRESSION; RETINOPATHY; MELLITUS; SSAO; CELL; OVEREXPRESSION;
   CONSEQUENCES
AB Aims: To study serum levels of soluble vascular adhesion protein (sVAP)-1 in type II diabetic patients with retinopathy.
   Methods: Serum samples were obtained from 53 consecutive patients, including 14 cases with non-angiogenic ocular diseases, i.e., epiretinal membrane (ERM) and idiopathic macular hole (MH), 19 cases with age-related macular degeneration (AMD), and 20 cases with diabetic retinopathy (DR). Protein levels of sVAP-1, intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and vascular endothelial growth factor (VEGF) were determined by enzyme-linked immunosorbent assay. Enzymatic activity of semicarbazide-sensitive amine oxidase (SSAO) was also measured.
   Results: Serum level of sVAP-1 showed a moderate correlation with SSAO activity in all cases. Patients with DR had higher levels of serum sVAP-1 than subjects with ERM and MH, or those with AMD; however, severity of DR is not related to the serum levels of sVAP-1. Serum sVAP-1 correlated positively with VEGF in patients with DR, but not in those with ERM and MH, or those with AMD. Neither soluble ICAM-1 nor VCAM-1 correlated with VEGF, even in subjects with DR.
   Conclusion: The current data demonstrate the elevated serum levels of sVAP-1 and correlation between sVAP-1 and VEGF in patients with type II diabetes. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Yoshikawa, Nami; Ozawa, Yoko; Ishida, Susumu] Keio Univ, Sch Med, Lab Retinal Cell Biol, Tokyo, Japan.
   [Yoshikawa, Nami; Mashima, Yukihiko] R Tech Ueno Ltd, Tokyo, Japan.
   [Noda, Kousuke; Ishida, Susumu] Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Sapporo, Hokkaido 0608638, Japan.
   [Shinoda, Hajime; Uchida, Atsuro; Ozawa, Yoko; Tsubota, Kazuo; Mashima, Yukihiko] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
C3 Keio University; Hokkaido University; Keio University
RP Noda, K (通讯作者)，Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Kita Ku, North 15,West 7, Sapporo, Hokkaido 0608638, Japan.
EM nodako@med.hokudai.ac.jp
RI Ozawa, Yoko/AAH-9888-2020; Uchida, Atsuro/GVT-8593-2022
OI Uchida, Atsuro/0000-0002-1378-7151
FU eye research foundation for the aged; R-Tech Ueno; Grants-in-Aid for
   Scientific Research [23592588] Funding Source: KAKEN
FX This work was supported by a grant from the eye research foundation for
   the aged (to KN) and research funds from R-Tech Ueno (to SI).The authors
   wish to thank Haruna Koizumi and Megumi Saeki for their skillful
   technical assistance in this project.
CR Abella A, 2004, DIABETOLOGIA, V47, P429, DOI 10.1007/s00125-004-1346-2
   Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I
   Boomsma F, 2005, MED SCI MONITOR, V11, pRA122
   Boomsma F, 1999, DIABETOLOGIA, V42, P233, DOI 10.1007/s001250051143
   Caldwell RB, 2005, CURR DRUG TARGETS, V6, P511, DOI 10.2174/1389450054021981
   Castillo V, 1998, NEUROCHEM INT, V33, P415, DOI 10.1016/S0197-0186(98)00045-X
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Deng YL, 1999, J CHROMATOGR SCI, V37, P317, DOI 10.1093/chromsci/37.9.317
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
   Gokturk C, 2003, AM J PATHOL, V163, P1921, DOI 10.1016/S0002-9440(10)63550-X
   Gustavsson C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012699
   Ha CH, 2008, ARTERIOSCL THROM VAS, V28, P1782, DOI 10.1161/ATVBAHA.108.172528
   HEIDENKUMMER HP, 1992, GRAEF ARCH CLIN EXP, V230, P483, DOI 10.1007/BF00175938
   Iliaki E, 2009, INVEST OPHTH VIS SCI, V50, P4898, DOI 10.1167/iovs.08-2013
   Jalkanen S, 2008, ARTERIOSCL THROM VAS, V28, P18, DOI 10.1161/ATVBAHA.107.153130
   Kurkijarvi R, 2000, GASTROENTEROLOGY, V119, P1096, DOI 10.1053/gast.2000.18163
   Li HY, 2009, CLIN CHIM ACTA, V404, P149, DOI 10.1016/j.cca.2009.03.041
   de Faria JBL, 2011, HYPERTENS RES, V34, P413, DOI 10.1038/hr.2010.263
   Lutty GA, 1997, AM J PATHOL, V151, P707
   Mahdy RA, 2011, OPHTHALMIC RES, V45, P87, DOI 10.1159/000317062
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Meszaros Z, 1999, METABOLISM, V48, P113, DOI 10.1016/S0026-0495(99)90019-7
   Murata M, 2012, INVEST OPHTH VIS SCI, V53, P4055, DOI 10.1167/iovs.12-9857
   Mysliwiec M, 2008, DIABETES RES CLIN PR, V79, P141, DOI 10.1016/j.diabres.2007.07.011
   Noda K, 2005, INVEST OPHTH VIS SCI, V46, P3817, DOI 10.1167/iovs.04-1528
   Noda K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/279037
   Noda K, 2009, EXP EYE RES, V89, P774, DOI 10.1016/j.exer.2009.07.010
   Obata T, 2006, LIFE SCI, V79, P417, DOI 10.1016/j.lfs.2006.01.017
   Ozturk BT, 2009, MOL VIS, V15, P1906
   Pan HZ, 2008, BRIT J OPHTHALMOL, V92, P548, DOI 10.1136/bjo.2007.130542
   Salmi M, 2002, AM J PATHOL, V161, P2255, DOI 10.1016/S0002-9440(10)64501-4
   Salmi M, 2001, TRENDS IMMUNOL, V22, P211, DOI 10.1016/S1471-4906(01)01870-1
   SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341
   Smith DJ, 1998, J EXP MED, V188, P17, DOI 10.1084/jem.188.1.17
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Stolen CM, 2004, FASEB J, V18, P702, DOI 10.1096/fj.03-0562fje
   YU PH, 1993, DIABETES, V42, P594, DOI 10.2337/diabetes.42.4.594
   Yu PH, 2003, BBA-PROTEINS PROTEOM, V1647, P193, DOI 10.1016/S1570-9639(03)00101-8
NR 38
TC 8
Z9 9
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1056-8727
EI 1873-460X
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAR-APR
PY 2013
VL 27
IS 2
BP 162
EP 166
DI 10.1016/j.jdiacomp.2012.09.001
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 109NG
UT WOS:000316374700010
PM 23062326
DA 2022-11-30
ER

PT J
AU Seland, JH
   Vingerling, JR
   Augood, CA
   Bentham, G
   Chakravarthy, U
   deJong, PTVM
   Rahu, M
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Fletcher, AE
AF Seland, Johan H.
   Vingerling, Johannes R.
   Augood, Cristina A.
   Bentham, Graham
   Chakravarthy, Usha
   deJong, Paulus T. V. M.
   Rahu, Mati
   Soubrane, Gisele
   Tomazzoli, Laura
   Topouzis, Fotis
   Fletcher, Astrid E.
TI Visual Impairment and quality of life in the Older European Population,
   the EUREYE study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration (AMD); blindness; visual acuity; visual
   impairment
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; MRC TRIAL; PREVALENCE;
   EYE; ACUITY; PEOPLE; MANAGEMENT; COMMUNITY; AUSTRALIA
AB Purpose: To determine the prevalence of visual impairment (VI) in populations 65 year or older from six European countries and describe the association with vision-related quality of life. VI was defined according to WHO as best corrected visual acuity < 6/18/log MAR > 0,48 (World Health Organization (1992): International Statistical Classification of Diseases and Related Health Problems, 10th revised ed. Vol 1. Geneva).
   Methods: 4166 participants in The European Eye study, 65 years and older selected randomly from the general census in the participating centres, were interviewed for vision-related quality of life and underwent an eye exam including distance visual acuity, refraction and fundus photography.
   Results: The prevalence of VI rose with increasing age and more so in women. There was a pattern of a higher prevalence of VI in the Mediterranean countries compared to Northern European countries with the exception of Tallinn (Estonia) which had higher VI prevalence rates than the other north European centres. The prevalence of low vision was 3% or less in all centres. Blindness prevalence varied from 2% to less than half a per cent. Vision-related quality of life was strongly associated with visual acuity and the presence of bilateral age-related macular degeneration.
   Conclusion: The prevalence of visual impairment in the examined ageing European populations shows a definite increasing trend from north to south.
C1 [Seland, Johan H.] Stavanger Univ Hosp, Eye Dept, N-4068 Stavanger, Norway.
   [Seland, Johan H.] Univ Bergen, N-5020 Bergen, Norway.
   [Vingerling, Johannes R.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   [Vingerling, Johannes R.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Augood, Cristina A.; Fletcher, Astrid E.] London Sch Hyg & Trop Med, Coordinating Ctr, Dept Epidemiol & Populat Hlth, London, England.
   [Bentham, Graham] Univ E Anglia, Dept Environm Risks, Norwich NR4 7TJ, Norfolk, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis Sci, Belfast BT7 1NN, Antrim, North Ireland.
   [deJong, Paulus T. V. M.] KNAW, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [deJong, Paulus T. V. M.] AMC, Dept Ophthalmol, Amsterdam, Netherlands.
   [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Soubrane, Gisele] Univ Paris 12, Clin Ophthalmol, Paris, France.
   [Tomazzoli, Laura] Univ Verona, Clin Oculist, I-37100 Verona, Italy.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Dept Ophthalmol, Sch Med, Thessaloniki, Greece.
C3 Stavanger University Hospital; University of Bergen; Erasmus University
   Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC;
   University of London; London School of Hygiene & Tropical Medicine;
   University of East Anglia; Queens University Belfast; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam;
   National Institute for Health Development - Estonia; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); University of Verona; Aristotle
   University of Thessaloniki
RP Seland, JH (通讯作者)，Stavanger Univ Hosp, Dept Ophthalmol, POB 8100, N-4068 Stavanger, Norway.
EM seland@dr.com
RI Rahu, Mati/A-9981-2008
OI Chakravarthy, Usha/0000-0002-2606-3734; Topouzis,
   Fotis/0000-0002-8966-537X
FU European Commission [QLK6-CT-1999-02094]; Macular Disease Society UK;
   Estonian Ministry of Education and Science [01921112s02, SF0940026s07]
FX EUREYE was supported by the European Commission Vth Framework
   (QLK6-CT-1999-02094). Additional funding for cameras was provided by the
   Macular Disease Society UK. M. Rahu was financed by the Estonian
   Ministry of Education and Science (target funding 01921112s02 &
   SF0940026s07).
CR Abou-Gareeb I, 2001, Ophthalmic Epidemiol, V8, P39, DOI 10.1076/opep.8.1.39.1540
   [Anonymous], 1992, INT STAT CLASS DIS R, V1-3
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fotouhi A, 2004, BRIT J OPHTHALMOL, V88, P740, DOI 10.1136/bjo.2003.031153
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   Taylor HR, 2007, AM J OPHTHALMOL, V143, P561, DOI 10.1016/j.ajo.2006.10.055
   van der Pols JC, 2000, BRIT J OPHTHALMOL, V84, P165, DOI 10.1136/bjo.84.2.165
NR 21
TC 47
Z9 48
U1 0
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2011
VL 89
IS 7
BP 608
EP 613
DI 10.1111/j.1755-3768.2009.01794.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838ZB
UT WOS:000296332000018
PM 19925518
DA 2022-11-30
ER

PT J
AU Obolensky, A
   Berenshtein, E
   Lederman, M
   Bulvik, B
   Alper-Pinus, R
   Yaul, R
   Deleon, E
   Chowers, I
   Chevion, M
   Banin, E
AF Obolensky, Alexey
   Berenshtein, Eduard
   Lederman, Michal
   Bulvik, Baruch
   Alper-Pinus, Ruslana
   Yaul, Ruth
   Deleon, Efrat
   Chowers, Itay
   Chevion, Mordechai
   Banin, Eyal
TI Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse
   model of retinitis pigmentosa
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Retinal degeneration; Iron; Oxidative stress; Metallo-complex; Free
   radicals
ID PHOTORECEPTOR CELL-DEATH; OXIDATIVE STRESS; MACULAR DEGENERATION;
   LIPID-PEROXIDATION; IRON HOMEOSTASIS; CAT RETINA; PROTECTS; MECHANISMS;
   DAMAGE; ANTIOXIDANTS
AB Iron-associated oxidative injury plays a role in retinal degeneration such as age-related macular degeneration and retinitis pigmentosa. The metallo-complex zinc desferrioxamine (Zn/DFO) may ameliorate such injury by chelation of labile iron in combination with release of zinc. We explored whether Zn/DFO can affect the course of retinal degeneration in the rd10 mouse model of retinitis pigmentosa. Zn/DFO-treated animals showed significantly higher electroretinographic responses at 3 and 4.5 weeks of age compared with saline-injected controls. Corresponding retinal (photoreceptor) structural rescue was observed by quantitative histological and immunohistochemical techniques. When administered alone, the components of the complex, Zn and DFO, showed a lesser, partial effect. TBARS, a marker of lipid peroxidation, and levels of oxidative DNA damage as quantified by 8-OHdG immunostaining were significantly lower in Zn/DFO-treated retinas compared with saline-injected controls. Reduced levels of retinal ferritin as well as reduced iron content within ferritin molecules were measured in Zn/DFO-treated retinas. The data, taken together, suggest that the protective effects of the Zn/DFO complex are mediated through modulation of iron bioavailability, leading to attenuation of oxidative injury. Reducing iron-associated oxidative stress using complexes such as Zn/DFO may serve as a "common pathway" therapeutic approach to attenuate injury in retinal degeneration. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Obolensky, Alexey; Lederman, Michal; Alper-Pinus, Ruslana; Yaul, Ruth; Deleon, Efrat; Chowers, Itay; Banin, Eyal] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   [Obolensky, Alexey; Berenshtein, Eduard; Lederman, Michal; Bulvik, Baruch; Chevion, Mordechai] Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, Hadassah Sch Med, IL-91120 Jerusalem, Israel.
   [Obolensky, Alexey; Berenshtein, Eduard; Lederman, Michal; Bulvik, Baruch; Chevion, Mordechai] Hebrew Univ Jerusalem, Dept Cellular Biochem & Human Genet, Hadassah Sch Dent Med, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Banin, E (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
EM banine@cc.huji.ac.il
FU Yedidut Research Grant; Israel Science Foundation (ISF) [316/05];
   Israeli Ministry of Health; Dr. Abraham Moshe and Paula Pepka Bergman
   Memorial Fund
FX We thank Professor A.M. Konijn for the generous gift of anti-ferritin
   antibodies. This research was supported by the Yedidut Research Grant, a
   grant from the Israel Science Foundation (ISF 316/05), an E-Rare grant
   through the Israeli Ministry of Health, and the Dr. Abraham Moshe and
   Paula Pepka Bergman Memorial Fund. M. C. is the Dr. William Ganz Chair
   for Heart Studies at the Hebrew University of Jerusalem.
CR Banin E, 2000, FREE RADICAL BIO MED, V28, P315, DOI 10.1016/S0891-5849(99)00227-0
   Barhoum R, 2008, NEUROSCIENCE, V155, P698, DOI 10.1016/j.neuroscience.2008.06.042
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cable H, 1999, J PHARM PHARMACOL, V51, P131, DOI 10.1211/0022357991772231
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   CHEVION M, 1991, FREE RADICAL RES COM, V12-3, P691, DOI 10.3109/10715769109145848
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   Deleon E, 2009, INVEST OPHTH VIS SCI, V50, P1360, DOI 10.1167/iovs.08-1856
   Dong A, 2006, J CELL PHYSIOL, V208, P516, DOI 10.1002/jcp.20683
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Galbinur T, 2009, J OCUL PHARMACOL TH, V25, P475, DOI 10.1089/jop.2009.0020
   Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hyun HJ, 2000, BRAIN RES, V869, P39, DOI 10.1016/S0006-8993(00)02340-4
   Karck M, 2001, J THORAC CARDIOV SUR, V121, P1169, DOI 10.1067/mtc.2001.113325
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Morad Y, 2005, INVEST OPHTH VIS SCI, V46, P1640, DOI 10.1167/iovs.04-1165
   Nagler R, 1998, RADIAT RES, V149, P271, DOI 10.2307/3579960
   OPHIR A, 1994, INVEST OPHTH VIS SCI, V35, P1212
   Osborne NN, 2004, INVEST OPHTH VIS SCI, V45, P3787, DOI 10.1167/iovs.04-0147
   Oteiza Patricia I., 2005, Molecular Aspects of Medicine, V26, P245, DOI 10.1016/j.mam.2005.07.012
   Padnick-Silver L, 2006, INVEST OPHTH VIS SCI, V47, P3683, DOI 10.1167/iovs.05-1284
   Picard E, 2010, MOL VIS, V16, P2612
   Ponka P, 2004, ANN NY ACAD SCI, V1012, P267, DOI 10.1196/annals.1306.022
   Rajendram R, 2007, BRIT J OPHTHALMOL, V91, P531, DOI 10.1136/bjo.2006.101576
   Sahel Jose-Alain, 2005, Retina, V25, pS38, DOI 10.1097/00006982-200512001-00015
   Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9
   Sanz MM, 2007, NEUROSCIENCE, V145, P1120, DOI 10.1016/j.neuroscience.2006.12.034
   Schmidt-Erfurth U, 2005, DEV OPHTHALMOL, V38, P120, DOI 10.1159/000082772
   Shintani K, 2009, OPTOMETRY, V80, P384, DOI 10.1016/j.optm.2008.01.026
   Siganos CS, 1998, CORNEA, V17, P191, DOI 10.1097/00003226-199803000-00013
   Sultana R, 2006, ANTIOXID REDOX SIGN, V8, P2021, DOI 10.1089/ars.2006.8.2021
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772
   Walsh N, 2004, CURR EYE RES, V29, P441, DOI 10.1080/02713680490522416
   Wardman P, 1996, RADIAT RES, V145, P523, DOI 10.2307/3579270
   Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zago MP, 2000, BIOL RES, V33, P143
NR 48
TC 46
Z9 50
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD OCT 15
PY 2011
VL 51
IS 8
BP 1482
EP 1491
DI 10.1016/j.freeradbiomed.2011.07.014
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 824MS
UT WOS:000295206600003
PM 21824515
DA 2022-11-30
ER

PT J
AU Ishikawa, K
   Nishihara, H
   Ozawa, S
   Piao, CH
   Ito, Y
   Kondo, M
   Terasaki, H
AF Ishikawa, Kohei
   Nishihara, Hiroaki
   Ozawa, Shinsuke
   Piao, Chang-Hua
   Ito, Yosuki
   Kondo, Mineo
   Terasaki, Hiroko
TI FOCAL MACULAR ELECTRORETINOGRAMS AFTER PHOTODYNAMIC THERAPY COMBINED
   WITH POSTERIOR JUXTASCLERAL TRIAMCINOLONE ACETONIDE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; electroretinogram; indocyanine green
   angiography; photodynamic therapy; triamcinolone acetonide
ID INDOCYANINE GREEN ANGIOGRAPHY; TUMOR-NECROSIS-FACTOR; MULTIFOCAL
   ELECTRORETINOGRAM; RETINAL FUNCTION; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL TRIAMCINOLONE; DEGENERATION
AB Purpose: Retinal function is commonly depressed transiently after photodynamic therapy (PDT). Additional treatment may prevent this impaired retinal function. The purpose of this study was to determine the changes in the focal macular electroretinograms (FMERGs) after PDT combined with TA for age-related macular degeneration.
   Methods: Thirty-four eyes that were successfully treated by PDT with a posterior juxtascleral injection of TA were studied. FMERGs, optical coherence tomography, and indocyanine green angiography were performed before and after the PDT.
   Results: The mean amplitudes of the FMERGs were not significantly decreased 1 week after PDT with TA (P > 0.05). The mean ratio of the FMERG b-wave 1 week after PDT to that before PDT was 1.09, with an indistinct hypofluorescence at the site of the PDT (18 eyes), and the ratio was 0.91 in the eyes with a distinct hypofluorescence border (16 eyes; P < 0.05).
   Conclusion: The combined use of TA with PDT mitigated the depression of retinal function soon after PDT. However, there were cases of severe choroidal hypoperfusion corresponding to the site of the laser spot that impaired retinal function in comparison to cases with mild hypoperfusion. Even with severe choroidal hypoperfusion, the deterioration in retinal function was relatively mild, with the b-wave FMERG reduced by only 10%. RETINA 29:803-810, 2009
C1 [Ishikawa, Kohei] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University
RP Ishikawa, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM kohei@med.nagoya-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014; Ito, Yasuki/M-4876-2014
OI Ito, Yasuki/0000-0001-9219-9261
FU Ministry of Education, Science, Sports and Culture, Japan [18791272,
   19500416, 18597913, 16390497, 18390466]
FX Grants-in Aid 18791272 (KI), 19500416 (YI), 18597913 (MK), 16390497
   (HT), and 18390466 (HT) from the Ministry of Education, Science, Sports
   and Culture, Japan.
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Iriyama A, 2008, GRAEF ARCH CLIN EXP, V246, P339, DOI 10.1007/s00417-007-0667-5
   Ishikawa K, 2008, JPN J OPHTHALMOL, V52, P182, DOI 10.1007/s10384-008-0528-8
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Jiang LB, 2003, DOC OPHTHALMOL, V107, P165, DOI 10.1023/A:1026215221569
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Luttrull JK, 2007, RETINA-J RET VIT DIS, V27, P688, DOI 10.1097/IAE.0b013e318030e999
   Mennel S, 2005, AM J OPHTHALMOL, V139, P748, DOI 10.1016/j.ajo.2004.08.072
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miyake Y, 1988, Nippon Ganka Gakkai Zasshi, V92, P1419
   MIYAKE Y, 1988, INVEST OPHTH VIS SCI, V29, P1631
   Moschos MM, 2004, J FR OPHTALMOL, V27, P1001, DOI 10.1016/S0181-5512(04)96255-9
   Moschos MN, 2003, EUR J OPHTHALMOL, V13, P461, DOI 10.1177/112067210301300507
   Nakazawa T, 2006, J NEUROSCI, V26, P12633, DOI 10.1523/JNEUROSCI.2801-06.2006
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Ruther K, 2003, OPHTHALMOLOGE, V100, P459, DOI 10.1007/s00347-002-0757-z
   SCHLEIMER RP, 1993, EUR J CLIN PHARMACOL, V45, pS3, DOI 10.1007/BF01844196
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   WAAGE A, 1988, IMMUNOLOGY, V63, P299
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
NR 32
TC 6
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP 803
EP 810
DI 10.1097/IAE.0b013e31819c631a
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HS
UT WOS:000267496600010
PM 19262429
DA 2022-11-30
ER

PT J
AU Tatar, O
   Adam, A
   Shinoda, K
   Eckert, T
   Scharioth, BB
   Klein, M
   Yoeruek, E
   Bartz-Schmidt, KU
   Grisanti, S
AF Tatar, Olcay
   Adam, Annemarie
   Shinoda, Kei
   Eckert, Tillmann
   Scharioth, Bor B.
   Klein, Micheal
   Yoeruek, Efdal
   Bartz-Schmidt, Karl Ulrich
   Grisanti, Salvatore
TI Matrix metalloproteinases in human choroidal neovascular membranes
   excised following verteporfin photodynamic therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GELATINASE-A; ENDOSTATIN; EXPRESSION; GROWTH; ANGIOGENESIS; INHIBITOR;
   CELLS; MMP-9; VEGF; ACTIVATION
AB Aim: To evaluate expression of proangiogenic matrix metalloproteinases (MMP) 2 and 9 at distinct intervals after verteporfin photodynamic therapy (PDT) in human choroidal neovascular membranes (CNV) secondary to age-related macular degeneration (AMD).
   Methods: Retrospective review of an interventional case series of 49 patients who underwent removal of CNV. Twenty-six patients were treated with PDT 3 to 383 days prior to surgery. Twenty-three CNV without previous treatment were used as controls. CNV were stained for CD34, cytokeratin 18, endostatin, MMP-2 and MMP-9 by immunohistochemistry.
   Results: CNV without previous therapy disclosed MMP-2, MMP- 9 in RPE-Bruch's membrane, vessels and stroma in different intensities. Three days after PDT, MMP- 9 expression was significantly weaker in stroma ( p = 0.0019). Endostatin was significantly reduced in vessels (p < 0.001). At longer post-PDT intervals, a significant increase of MMP- 9 in stroma ( p = 0.037) and of endostatin in RPE-Bruch's membrane (p = 0.02), vessels ( p = 0.005) and stroma (p < 0.001) were disclosed. No significant changes in MMP- 2 expression were detected.
   Conclusions: PDT induced an early, temporary decrease in MMP-9 and endostatin expression. At longer intervals, MMP-9 increase is possibly associated with the angiogenic process responsible for recurrence after PDT. MMP-9, however, acts as a double-edged sword by concomitant induction of endostatin, an endogenous inhibitor of angiogenesis.
C1 Univ Tubingen, Ctr Ophthalmol, Univ Eye Hosp, D-72076 Tubingen, Germany.
   Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany.
   Natl Inst Sensory Organs, Lab Visual Physiol, Tokyo, Japan.
   Augenklin Staedtischen Kliniken, Frankfurt, Germany.
   Augenklin Tausendfensterhaus, Duisburg, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP Grisanti, S (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Univ Eye Hosp, Schleichstr 12-15, D-72076 Tubingen, Germany.
EM Grisanti@med.uni-tuebingen.de
RI Shinoda, Kei/ABC-7993-2020
OI Shinoda, Kei/0000-0002-1543-9345
CR Ambili M, 1998, BBA-MOL CELL RES, V1403, P219, DOI 10.1016/S0167-4889(98)00030-5
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Davis GE, 2001, J CELL SCI, V114, P917
   Duncan WC, 1998, J CLIN ENDOCR METAB, V83, P2470, DOI 10.1210/jc.83.7.2470
   El Bradey M, 2004, J OCUL PHARMACOL TH, V20, P217, DOI 10.1089/1080768041223657
   Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3
   Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Heljasvaara R, 2005, EXP CELL RES, V307, P292, DOI 10.1016/j.yexcr.2005.03.021
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Kim YM, 2000, CANCER RES, V60, P5410
   Kohri T, 2003, GRAEF ARCH CLIN EXP, V241, P943, DOI 10.1007/s00417-003-0761-2
   Kraling BM, 1999, J CELL SCI, V112, P1599
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Lee SJ, 2002, FEBS LETT, V519, P147, DOI 10.1016/S0014-5793(02)02742-4
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Petermeier K, 2006, BRIT J OPHTHALMOL, V90, P1034, DOI 10.1136/bjo.2006.090852
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Rahat MA, 2006, J LEUKOCYTE BIOL, V79, P706, DOI 10.1189/jlb.0605302
   SALAMONSEN LA, 1994, CELL BIOL INT, V18, P1139, DOI 10.1006/cbir.1994.1040
   SASANO H, 2006, BIOMED PHARM S2, V59, pS334
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Shang Qing-Li, 2004, Zhonghua Yan Ke Za Zhi, V40, P266
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097/IAE.0b013e318042d3b0
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, EXP EYE RES, V83, P329, DOI 10.1016/j.exer.2005.12.017
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832
   Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97
   Zeng Jun, 2004, Yan Ke Xue Bao, V20, P191
   Zhao WL, 2005, EUR J IMMUNOL, V35, P3468, DOI 10.1002/eji.200526262
   Zhu WH, 2000, LAB INVEST, V80, P545, DOI 10.1038/labinvest.3780060
NR 51
TC 25
Z9 27
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2007
VL 91
IS 9
BP 1183
EP 1189
DI 10.1136/bjo.2007.114769
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202EN
UT WOS:000248884900025
PM 17475706
OA Green Published
DA 2022-11-30
ER

PT J
AU Hanna, RM
   Ahdoot, RS
   Kim, MS
   Jhaveri, KD
   Kalantar-Zadeh, K
   Kurtz, IB
AF Hanna, Ramy M.
   Ahdoot, Rebecaa S.
   Kim, Matthew S.
   Jhaveri, Kenar D.
   Kalantar-Zadeh, Kamyar
   Kurtz, Ira B.
TI Intravitreal vascular endothelial growth factors hypertension,
   proteinuria, and renal injury: a concise review
SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
LA English
DT Review
DE diabetic retinopathy; hypertension; nephrotic syndrome; TMA; VEGF
   blockade
ID MACULAR DEGENERATION; NEPHROTIC SYNDROME; FACTOR INHIBITORS; PRESSURE
   CHANGES; ADVERSE EVENTS; BLOOD-PRESSURE; FACTOR THERAPY; BEVACIZUMAB;
   INJECTION; RANIBIZUMAB
AB Purpose of review Nearly 20 years ago, vascular endothelial growth factor (VEGF)inhibitors (VEGFi) were adapted from systemic use from antiangiogenesis roles to intravitreal uses. Initially bevacizumab a murine immunoglobulin was injected 'off label' as a treatment for diabetic macular edema and age-related macular degeneration. Throughout the following decade aflibercept and finally ranibizumab were adapted and obtained Food and Drug Administration approval for intravitreal use. Initially systemic absorption was thought to be quite low after intravitreal injections and was quoted as being 200-fold lower than levels postulated to induce significant VEGF inhibition. Pharmacodynamic studies obtained in 2014 and again in 2017 revealed significant systemic absorption and detectable VEGF inhibition, this has since been confirmed in multiple subsequent studies. Recent findings A few case reports of renal dysfunction and glomerular disease related to VEGFi were initially identified. Mixed findings on effects on blood pressure were noted in studies. More recently, 32 cases of de-novo glomerular disease and/or proteinuria exacerbation were identified. New studies have corroborated increased blood pressure, proteinuria exacerbation in patients with pre-existing nephrotic syndrome, and systemic VEGF depletion. Further, the most common lesion of systemic VEGFi nephrotoxicity, thrombotic microangiopathy, has recently been reported by our group. We will review the pharmacokinetic, translational, and epidemiological data that year upon year establish the finite-yet real risk of intravitreal VEGFi.
C1 [Hanna, Ramy M.; Ahdoot, Rebecaa S.; Kim, Matthew S.; Kalantar-Zadeh, Kamyar] UC Irvine, Div Nephrol, Dept Med, Irvine, CA USA.
   [Jhaveri, Kenar D.] Hofstra North Shore LIJ Sch Med, North Shore Univ Hosp, Dept Med, Div Kidney Dis & Hypertens, Hempstead, NY USA.
   [Jhaveri, Kenar D.] Hofstra North Shore LIJ Sch Med, Long Isl Jewish Med Ctr, Hempstead, NY USA.
   [Jhaveri, Kenar D.] Hofstra Northwell, Donald & Barbara Zucker Sch Med, Great Neck, NY USA.
   [Kurtz, Ira B.] Brain Res Inst, Los Angeles, CA USA.
C3 University of California System; University of California Irvine;
   Hofstra University; Northwell Health; North Shore University Hospital;
   Hofstra University; Northwell Health
RP Hanna, RM (通讯作者)，333 City Dr,Suite 400, Orange, CA 92868 USA.
EM Ramyh1@uci.edu
OI Kalantar-Zadeh, Kamyar/0000-0002-8666-0725
FU NIH [R01DK077162, R21-AG047036, R01-DK078106, R01-DK096920, U01DK102163,
   K24-DK091419]; Allan Smidt Charitable Fund; Factor Family Foundation;
   Ralph Block Family Foundation
FX I.K. is supported in part by funds from the NIH (R01DK077162), the Allan
   Smidt Charitable Fund, the Factor Family Foundation, and the Ralph Block
   Family Foundation; K.K.-Z. is supported by funds from NIH R21-AG047036,
   NIH R01-DK078106, NIH R01-DK096920, NIH U01DK102163, and NIH
   K24-DK091419, as well as philanthropy from Mr. Harold Simmons and Mr.
   Louis Chang. K.D.J. is a consultant for Astex Pharmaceuticals, Natera,
   GlaxoSmithKline, ChemoCentryx, Chinook and Travere Therapeutics, a paid
   contributor to UpToDate.com, and receives honorarium from ISN and ASN.
   He is Editor in Chief for the ASN Kidney News and section editor for
   Onconephrology for Nephrology Dialysis Transplantation and serves on the
   editorial board for Journal of Onconephrology, Kidney International,
   CJASN, AJKD and CKJ.
CR Abudayyeh ASU, 2018, RENAL PROTECTION CHA, V1
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bagheri S, 2018, GALEN MED J, V7, DOI 10.22086/gmj.v0i0.1299
   Bank D., 2005, Bevacizumab
   Bank D., 2013, Aflibercept
   Cheungpasitporn W, 2015, TRANSPLANTATION, V99, P2382, DOI 10.1097/TP.0000000000000750
   Chung YR, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.4
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Georgalas I, 2014, CURR DRUG SAF, V9, P156, DOI 10.2174/1574886309666140211113635
   Glassman AR, 2018, INVEST OPHTH VIS SCI, V59, P1199, DOI 10.1167/iovs.17-22853
   Hanhart J, 2018, ACTA OPHTHALMOL, V96, pE732, DOI 10.1111/aos.13731
   Hanhart J, 2018, GRAEF ARCH CLIN EXP, V256, P651, DOI 10.1007/s00417-018-3917-9
   Hanhart J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0586-0
   Hanna RM, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.579603
   Hanna RM, 2020, SAGE OPEN MED CASE R, V8, DOI 10.1177/2050313X20952650
   Hanna RM, 2020, SAGE OPEN MED CASE R, V8, DOI 10.1177/2050313X20907033
   Hanna RM, 2019, KIDNEY INT, V96, P572, DOI 10.1016/j.kint.2019.02.042
   Hanna RM, 2019, CLIN KIDNEY J, V12, P92, DOI 10.1093/ckj/sfy060
   Hanna RM, 2016, CLIN KIDNEY J, V9, P239, DOI 10.1093/ckj/sfv139
   Hanna RM, 2017, J ONCO NEPHROLOGY, V1, pe1, DOI [10.5301/jo-n.5000021, DOI 10.5301/J0-N.5000021]
   Hirano T, 2018, RETINA-J RET VIT DIS, V38, P1801, DOI 10.1097/IAE.0000000000002004
   Izzedine H, 2014, INT J NEPHROL, V2014, DOI 10.1155/2014/143426
   Jalalonmuhali M., 2020, NEPHROL DIAL TRANSPL, V142, P590, DOI [10.1093/ndt/gfaa142.P0590, DOI 10.1093/NDT/GFAA142.P0590]
   Jampol LM, 2018, OPHTHALMOLOGY, V125, P1054, DOI 10.1016/j.ophtha.2018.01.019
   Jamrozy-Witkowska Agnieszka, 2011, Klin Oczna, V113, P127
   Kameda Y, 2018, J DIABETES INVEST, V9, P937, DOI 10.1111/jdi.12771
   Kenworthy J-A., 2019, WORSENING PROTEINURI, V3, P54
   Khneizer Gebran, 2017, J Nephropathol, V6, P134, DOI 10.15171/jnp.2017.23
   Lee K, 2009, RETINA-J RET VIT DIS, V29, P1409, DOI 10.1097/IAE.0b013e3181b21056
   Maguire MG, 2017, OPHTHALMOL RETINA, V1, P375, DOI 10.1016/j.oret.2016.12.015
   Miwako Yoshimoto NT., 2020, HYPERTENSIVE CEREBRA, V15, P403
   Miyake TM, 2013, EXPERT OPIN BIOL TH, V13, P283, DOI 10.1517/14712598.2012.745508
   Morales E, 2017, NEFROLOGIA, V37, P653, DOI [10.1016/j.nefro.2016.10.011, 10.1016/j.nefroe.2017.10.007]
   Nobakht N, 2019, KIDNEY INT REP, V4, P1508, DOI 10.1016/j.ekir.2019.07.019
   O'Neill RA, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1650-1
   Ollero M, 2015, NEPHROL DIAL TRANSPL, V30, P1449, DOI 10.1093/ndt/gfu368
   Pelle G, 2011, AM J KIDNEY DIS, V57, P756, DOI 10.1053/j.ajkd.2010.11.030
   Perez-Valdivia MA, 2014, NEFROLOGIA, V34, P421, DOI 10.3265/Nefrologia.pre2014.Mar.12388
   Phadke G., CLIN KIDNEY J, V14, P2158
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Risimic D, 2013, HELL J CARDIOL, V54, P435
   Rogers CA, 2018, OPHTHALMOL RETINA, V2, P118, DOI 10.1016/j.oret.2017.05.015
   Sato T, 2013, PEDIATR INT, V55, pe46, DOI 10.1111/ped.12017
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Shah AR, 2019, OPHTHALMOL RETINA, V3, P410, DOI 10.1016/j.oret.2019.01.019
   Shye M, 2020, CLIN KIDNEY J, V13, P969, DOI 10.1093/ckj/sfaa049
   Soria JC, 2013, ANN ONCOL, V24, P20, DOI 10.1093/annonc/mds590
   Starr Matthew R, 2019, Ophthalmic Surg Lasers Imaging Retina, V50, pe140, DOI 10.3928/23258160-20190503-14
   Touzani F, 2019, Case Rep Nephrol, V2019, P2919080, DOI 10.1155/2019/2919080
   Tschulakow A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113701
   Usui-Ouchi A, 2019, J CLIN INVEST, V129, P3032, DOI 10.1172/JCI129862
   Valsan D, 2017, AM J KIDNEY DIS, V69, pA99
   Yen W., 2019, ASN KIDNEY WEEK
   Yoon MH, 2016, J KOR OPHTHALMOL SOC, V57, P429, DOI 10.3341/jkos.2016.57.3.429
   Zeb A, 2007, JCPSP-J COLL PHYSICI, V17, P448
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zhu XL, 2007, AM J KIDNEY DIS, V49, P186, DOI 10.1053/j.ajkd.2006.11.039
NR 62
TC 2
Z9 2
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1062-4821
EI 1473-6543
J9 CURR OPIN NEPHROL HY
JI Curr. Opin. Nephrol. Hypertens.
PD JAN
PY 2022
VL 31
IS 1
BP 47
EP 56
DI 10.1097/MNH.0000000000000760
PG 10
WC Urology & Nephrology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology; Cardiovascular System & Cardiology
GA YX2TZ
UT WOS:000753961800007
PM 34750330
DA 2022-11-30
ER

PT J
AU Hsu, TJ
   Nepali, K
   Tsai, CH
   Imtiyaz, Z
   Lin, FL
   Hsiao, G
   Lai, MJ
   Cheng, YW
AF Hsu, Tai-Ju
   Nepali, Kunal
   Tsai, Chi-Hao
   Imtiyaz, Zuha
   Lin, Fan-Li
   Hsiao, George
   Lai, Mei-Jung
   Cheng, Yu-Wen
TI The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell
   Migration in RPE Cells and Neovascularization in Mice through Decreased
   VEGF Production
SO MOLECULES
LA English
DT Article
DE HDAC inhibitor; HSP90; blue light; neovascularization; pharmacophore;
   scaffold
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; EXPRESSION; PROLIFERATION; PROTECTS; HYPOXIA
AB Age-related macular degeneration (AMD) occurs due to an abnormality of retinal pigment epithelium (RPE) cells that leads to gradual degeneration of the macula. Currently, AMD drug pipelines are endowed with limited options, and anti-VEGF agents stand as the dominantly employed therapy. Despite the proven efficacy of such agents, the evidenced side effects associated with their use underscore the need to elucidate other mechanisms involved and identify additional molecular targets for the sake of therapy improvement. The previous literature provided us with a solid rationale to preliminarily explore the potential of selective HDAC6 and HSP90 inhibitors to treat wet AMD. Rather than furnishing single-target agents (either HDAC6 or HSP90 inhibitor), this study recruited scaffolds endowed with the ability to concomitantly modulate both targets (HDAC6 and HSP90) for exploration. This plan was anticipated to accomplish the important goal of extracting amplified benefits via dual inhibition (HDAC6/HSP90) in wet AMD. As a result, G570 (indoline-based hydroxamate), a dual selective HDAC6-HSP90 inhibitor exerting its effects at micromolar concentrations, was pinpointed in the present endeavor to attenuate blue light-induced cell migration and retinal neovascularization by inhibiting VEGF production. In addition to the identification of a potential chemical tool (G570), the outcome of this study validates the candidate HDAC6-HSP90 as a compelling target for the development of futuristic therapeutics for wet AMD.
C1 [Hsu, Tai-Ju; Nepali, Kunal; Tsai, Chi-Hao; Imtiyaz, Zuha; Cheng, Yu-Wen] Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei 100301, Taiwan.
   [Tsai, Chi-Hao] Univ North Carolina Chapel Hill, Dept Ophthalmol, Sch Med, Chapel Hill, NC 27599 USA.
   [Lin, Fan-Li; Hsiao, George] Taipei Med Univ, Coll Med, Sch Med, Dept Pharmacol, Taipei 100301, Taiwan.
   [Lai, Mei-Jung; Cheng, Yu-Wen] Taipei Med Univ, Coll Pharm, PhD Program Drug Discovery & Dev Ind, Taipei 100301, Taiwan.
   [Lai, Mei-Jung] Taipei Med Univ, Biomed Commercializat Ctr, Taipei 100301, Taiwan.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine
RP Cheng, YW (通讯作者)，Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei 100301, Taiwan.; Lai, MJ; Cheng, YW (通讯作者)，Taipei Med Univ, Coll Pharm, PhD Program Drug Discovery & Dev Ind, Taipei 100301, Taiwan.; Lai, MJ (通讯作者)，Taipei Med Univ, Biomed Commercializat Ctr, Taipei 100301, Taiwan.
EM nick010519@tmu.edu.tw; nepali@tmu.edu.tw; d01447001@ntu.edu.tw;
   zuhaimtiyaz@tmu.edu.tw; fllin@tmmedu.tw; geohsiao@tmu.edu.tw;
   mjl@tmu.edu.tw; ywcheng@tmu.edu.tw
OI Lin, Fan-Li/0000-0001-8348-9873; Cheng, Yu Wen/0000-0003-3714-0464;
   Hsiao, George/0000-0001-9079-3646; Imtiyaz, Zuha/0000-0001-6927-8623;
   Hsu, Tai-Ju/0000-0001-8122-3481
FU Higher Education Sprout Project by the Ministry of Education (MOE) [MOST
   109-2320-B-038-040-MY3]; Ministry of Science and Technology, Taiwan
FX This work was financially supported by the Higher Education Sprout
   Project by the Ministry of Education (MOE), and MOST
   109-2320-B-038-040-MY3 from the Ministry of Science and Technology,
   Taiwan.
CR Aguila M, 2016, ADV EXP MED BIOL, V854, P161, DOI 10.1007/978-3-319-17121-0_22
   Aguila M, 2014, HUM MOL GENET, V23, P2164, DOI 10.1093/hmg/ddt613
   Alkozi HA, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00144
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Athanasiou D, 2013, FEBS LETT, V587, P2008, DOI 10.1016/j.febslet.2013.05.020
   Cai C, 2010, ANTICANCER RES, V30, P805
   Cheng KJ, 2020, J MED CHEM, V63, P10533, DOI 10.1021/acs.jmedchem.9b01033
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Dahbash M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030714
   Eldehna WM, 2019, EUR J MED CHEM, V162, P147, DOI 10.1016/j.ejmech.2018.10.068
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Felip E, 2018, J THORAC ONCOL, V13, P576, DOI 10.1016/j.jtho.2017.11.131
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Fraunfelder FT, 2018, J OCUL PHARMACOL TH, V34, P432, DOI 10.1089/jop.2018.0019
   Goldman JW, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-152
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hu H, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5708537
   Ju YH, 2022, BRIT J PHARMACOL, V179, P1938, DOI 10.1111/bph.15303
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Kornberg LJ, 2004, INVEST OPHTH VIS SCI, V45, P4463, DOI 10.1167/iovs.03-1201
   Leyk J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.415
   Luan YP, 2019, J MED CHEM, V62, P3171, DOI 10.1021/acs.jmedchem.8b00189
   Maciulaitiene R, 2018, INVEST OPHTH VIS SCI, V59
   Mamalis A, 2015, LASER SURG MED, V47, P210, DOI 10.1002/lsm.22293
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moiseev RV, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070321
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Nickells RW, 2012, ARCH OPHTHALMOL-CHIC, V130, P508, DOI 10.1001/archopthalmol.2011.1423
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Samardzija M, 2021, CELL DEATH DIFFER, V28, P1317, DOI 10.1038/s41418-020-00653-3
   Sequist LV, 2010, J CLIN ONCOL, V28, P4953, DOI 10.1200/JCO.2010.30.8338
   Sun SG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20930-z
   Sundaramurthi H, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00689
   Wang HB, 2016, MOL VIS, V22, P116
   Wu TY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12795-5
   Wu WC, 2007, EXP EYE RES, V85, P721, DOI 10.1016/j.exer.2007.08.005
   Yu T, 2017, INT J OPHTHALMOL-CHI, V10, P524, DOI [10.18240/ijo.2017.04.04, 10.18240/1jo.2017.04.04]
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 41
TC 0
Z9 0
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2021
VL 26
IS 14
AR 4359
DI 10.3390/molecules26144359
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TN3SB
UT WOS:000676157200001
PM 34299636
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Matsuzaki, M
   Mandai, M
   Yamanari, M
   Totani, K
   Nishida, M
   Sugita, S
   Maeda, T
   Koide, N
   Takagi, S
   Hirami, Y
   Miyamoto, N
   Sugiyama, S
   Takahashi, M
   Kurimoto, Y
AF Matsuzaki, Mitsuhiro
   Mandai, Michiko
   Yamanari, Masahiro
   Totani, Kota
   Nishida, Mitsuhiro
   Sugita, Sunao
   Maeda, Tadao
   Koide, Naoshi
   Takagi, Seiji
   Hirami, Yasuhiko
   Miyamoto, Noriko
   Sugiyama, Satoshi
   Takahashi, Masayo
   Kurimoto, Yasuo
TI Polarization-sensitive optical coherence tomography for estimating
   relative melanin content of autologous induced stem-cell derived retinal
   pigment epithelium
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IN-VIVO; JONES MATRIX; HUMAN MACULA; BIREFRINGENCE; SEGMENTATION; FUNDUS
AB Transplantation of autologous human induced pluripotent stem cell-derived retinal pigment epithelial (hiPSC-RPE) sheets is a promising therapy for age-related macular degeneration (AMD). As melanin content is a representative feature of healthy RPE, we used polarization-sensitive optical coherence tomography (PS-OCT) to estimate the relative melanin content of RPE in diseased and non-diseased area, and in human iPSC-RPE sheets in vitro and in vivo by evaluating the randomness of polarization (entropy). Two aged Japanese women, one with neovascular AMD that underwent transplantation of an autologous hiPSC-RPE cell sheet and another with binocular dry AMD, were selected for this study. Entropy value was minimal in cells containing no melanin, whereas that of human RPE and hiPSC-RPE sheets was high. En face entropy of the cultured hiPSC-RPE sheet was compared with its grey-scale photo and its values were found to be inversely correlated with the extent of absence of pigmentation in vitro. En face entropy maps were compared to colour fundus photographs, fundus autofluorescence images, and fluorescein angiography images from patients. Entropy values of intact and defective RPEs and of iPSC-RPE transplant areas were determined in vivo using PS-OCT B-scan images. PS-OCT was found to be applicable in the estimation of relative melanin content of cultured and transplanted RPEs in regenerative medicine.
C1 [Matsuzaki, Mitsuhiro; Mandai, Michiko; Sugita, Sunao; Maeda, Tadao; Takagi, Seiji; Hirami, Yasuhiko; Miyamoto, Noriko; Takahashi, Masayo; Kurimoto, Yasuo] Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Matsuzaki, Mitsuhiro; Maeda, Tadao; Hirami, Yasuhiko; Miyamoto, Noriko; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Mandai, Michiko; Nishida, Mitsuhiro; Sugita, Sunao; Maeda, Tadao; Koide, Naoshi; Hirami, Yasuhiko; Takahashi, Masayo; Kurimoto, Yasuo] Riken Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo, Japan.
   [Yamanari, Masahiro; Totani, Kota; Sugiyama, Satoshi] Tomey Corp, Nagoya, Aichi, Japan.
   [Takagi, Seiji] Toho Univ, Sch Med, Dept Ophthalmol, Oomori Hosp, Tokyo, Japan.
   [Takahashi, Masayo] Vis Care Inc, Kobe, Hyogo, Japan.
C3 Kobe City Medical Center General Hospital; RIKEN; Toho University
RP Matsuzaki, M (通讯作者)，Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.; Matsuzaki, M (通讯作者)，Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
EM mmatsuzaki@kcho.jp
OI Mitsuhiro, Matsuzaki/0000-0002-4618-3696
FU Japan Agency for Medical Research and Development [JP19he1302011]
FX This study was supported by research grants (grant number JP19he1302011)
   from the Japan Agency for Medical Research and Development. We thank
   Shoko Fujino for her support in hiPSC-RPE characterization and Prof.
   Masahiro Miura (Tokyo Medical University, Ibaraki Medical Centre) for an
   insightful discussion.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Baumann B, 2015, INVEST OPHTH VIS SCI, V56, P7462, DOI 10.1167/iovs.15-17742
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2012, OPT EXPRESS, V20, DOI 10.1364/OE.20.010229
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Baumann B, 2009, J BIOPHOTONICS, V2, P426, DOI 10.1002/jbio.200910031
   Cloude S, 2009, POLARISATION APPL RE
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Hitzenberger CK, 2001, OPT EXPRESS, V9, P780, DOI 10.1364/OE.9.000780
   Kamao H, 2014, INVEST OPHTH VIS SCI, V55, P8309, DOI 10.1167/iovs.14-14694
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Lammer J, 2014, INVEST OPHTH VIS SCI, V55, P1564, DOI 10.1167/iovs.13-13539
   Lee J., 2009, POLARIMETRIC RADAR I
   Lim Y, 2012, OPT LETT, V37, P1958, DOI 10.1364/OL.37.001958
   Lippok N, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800156
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schustze C, 2014, RETINA-J RET VIT DIS, V34, P2208, DOI 10.1097/IAE.0000000000000224
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Yamanari M, 2019, PROC SPIE, V10867, DOI 10.1117/12.2511467
   Yamanari M, 2016, BIOMED OPT EXPRESS, V7, P3551, DOI 10.1364/BOE.7.003551
   Yamanari M, 2015, BIOMED OPT EXPRESS, V6, P369, DOI 10.1364/BOE.6.000369
NR 31
TC 8
Z9 8
U1 0
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 6
PY 2020
VL 10
IS 1
AR 7656
DI 10.1038/s41598-020-64601-4
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LP0PL
UT WOS:000534024000023
PM 32376945
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kuwayama, S
   Ayatsuka, Y
   Yanagisono, D
   Uta, T
   Usui, H
   Kato, A
   Takase, N
   Ogura, Y
   Yasukawa, T
AF Kuwayama, Soichiro
   Ayatsuka, Yuji
   Yanagisono, Daisuke
   Uta, Takaki
   Usui, Hideaki
   Kato, Aki
   Takase, Noriaki
   Ogura, Yuichiro
   Yasukawa, Tsutomu
TI Automated Detection of Macular Diseases by Optical Coherence Tomography
   and Artificial Intelligence Machine Learning of Optical Coherence
   Tomography Images
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Purpose. Although optical coherence tomography (OCT) is essential for ophthalmologists, reading of findings requires expertise. The purpose of this study is to test deep learning with image augmentation for automated detection of chorioretinal diseases. Methods. A retina specialist diagnosed 1,200 OCT images. The diagnoses involved normal eyes (n=570) and those with wet age-related macular degeneration (AMD) (n=136), diabetic retinopathy (DR) (n=104), epiretinal membranes (ERMs) (n=90), and another 19 diseases. Among them, 1,100 images were used for deep learning training, augmented to 59,400 by horizontal flipping, rotation, and translation. The remaining 100 images were used to evaluate the trained convolutional neural network (CNN) model. Results. Automated disease detection showed that the first candidate disease corresponded to the doctor's decision in 83 (83%) images and the second candidate disease in seven (7%) images. The precision and recall of the CNN model were 0.85 and 0.97 for normal eyes, 1.00 and 0.77 for wet AMD, 0.78 and 1.00 for DR, and 0.75 and 0.75 for ERMs, respectively. Some of rare diseases such as Vogt-Koyanagi-Harada disease were correctly detected by image augmentation in the CNN training. Conclusion. Automated detection of macular diseases from OCT images might be feasible using the CNN model. Image augmentation might be effective to compensate for a small image number for training.
C1 [Kuwayama, Soichiro; Usui, Hideaki; Kato, Aki; Takase, Noriaki; Ogura, Yuichiro; Yasukawa, Tsutomu] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
   [Ayatsuka, Yuji; Yanagisono, Daisuke; Uta, Takaki] Cresco Ltd, Technol Lab, Tokyo, Japan.
C3 Nagoya City University
RP Yasukawa, T (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
EM gifu8847@yahoo.co.jp; y-ayatsuka@cresco.co.jp; daisuke.yan@gmail.com;
   t-uta@cresco.co.jp; hideaki.usui@gmail.com; akikato@med.nagoya-cu.ac.jp;
   m41takase@yahoo.co.jp; ogura.yuichiro@me.com;
   yasukawa@med.nagoya-cu.ac.jp
OI Yasukawa, Tsutomu/0000-0001-9913-1905
FU Japan Society for the Promotion of Science [25462758]
FX The authors thank Fumie Shibuya, Yasuyo Matsuda, Sayaka Oshio, and
   Soushi Shimizu (Nagoya City University Graduate School of Medical
   Sciences) for contributing to data collection. The authors thank Lynda
   Charter for professional medical English editing. T. Yasukawa was
   supported by Grant-in-Aid for Scientific Research (C) 25462758 from the
   Japan Society for the Promotion of Science.
CR Abramoff MD, 2013, JAMA OPHTHALMOL, V131, P351, DOI 10.1001/jamaophthalmol.2013.1743
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Ayatsuka Y., 2016, IEICE TECHNICAL REPO, V116, P11
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   FUJIMOTO JG, 1995, NAT MED, V1, P970, DOI 10.1038/nm0995-970
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hussain Zeshan, 2017, AMIA Annu Symp Proc, V2017, P979
   Kermany Daniel, 2018, Mendeley Data, V3, DOI 10.17632/RSCBJBR9SJ.3
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Philip S, 2007, BRIT J OPHTHALMOL, V91, P1512, DOI 10.1136/bjo.2007.119453
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Takahashi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179790
NR 19
TC 29
Z9 29
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2019
VL 2019
AR 6319581
DI 10.1155/2019/6319581
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HU5GR
UT WOS:000465305300001
PM 31093370
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Qian, C
   Yan, PS
   Wan, GM
   Liang, SZ
   Dong, Y
   Wang, J
AF Qian, Cheng
   Yan, Panshi
   Wan, Guangming
   Liang, Shenzhi
   Dong, Yi
   Wang, Jiong
TI Facile synthetic Photoluminescent Graphene Quantum dots encapsulated
   beta-cyclodextrin drug carrier system for the management of macular
   degeneration: Detailed analytical and biological investigations
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Graphene; Quantum dots; Macular degeneration; beta-Cyclodextrin;
   Ranibizumab
ID RANIBIZUMAB; DELIVERY; NANOCARRIERS; BEVACIZUMAB; OXIDE
AB Drug administration by effective nano-carriers is an emerging and growing technology in the field of biomedicine and particularly Age related macular degeneration (AMD). This developed nanomaterials based methods with drug administration maximizes the biocompatibility and systemically increases drug delivery profile for the drugs. Herein, we described the effective drug molecules delivery profiles by the hydrothermally synthesized graphene quantum dots (GQDs) encapsulated with supramolecular beta-cyclodextrin (beta-CD) as a drug delivery system for AMD. The drug release profiles were analysed and plotted by two different types of drugs ((Bevacizumab (Bev) and Ranibizumab (Ran))) and compounds displayed an initial burst delivery percentage of 55.7 +/- 1.6% and 52.2 +/- 2.6, respectively, within 15 min. After 1 h, 94.2% (Ran) and 93.1% (Bev) of loaded drug molecules were released from the beta-CD encapsulated GQDs in sustained manner. The biocompatibility of the synthesized carriers was investigated quantitatively and qualitatively with the mouse Fibroblast L929 cell line. The biological cell analysis observed by calculated cell count and green fluorescence visualization has been clearly confirmed the samples are non-toxic and highly compatible to the cells with more than 90% cell viability after 5 days cell culture. The observed material properties and biological results demonstrated that the suitability of the developed nano-carriers for the drug delivery system in the AMD.
C1 [Qian, Cheng; Yan, Panshi; Wan, Guangming; Liang, Shenzhi; Dong, Yi; Wang, Jiong] Zhengzhou Univ, Henan Prov Eye Hosp, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou 450052, Henan, Peoples R China.
C3 Zhengzhou University
RP Wan, GM (通讯作者)，Zhengzhou Univ, Henan Prov Eye Hosp, Affiliated Hosp 1, Dept Ophthalmol, Zhengzhou 450052, Henan, Peoples R China.
EM guangmingwan@yahoo.com
CR Adeoye O, 2017, INT J PHARMACEUT, V531, P521, DOI 10.1016/j.ijpharm.2017.04.050
   Ambika S., 2014, SYNTHESIS B CYCLODEX, V3, P751
   Badruddoza AM, 2013, CARBOHYD POLYM, V91, P322, DOI 10.1016/j.carbpol.2012.08.030
   Brown D. M., 2006, OPHTHALMOLOGY, V116, DOI [10.1016/j.ophtha.2008.10.01857-65.e5, DOI 10.1016/J.OPHTHA.2008.10.01857-65.E5]
   Dong J, 2018, SENSOR ACTUAT B-CHEM, V256, P616, DOI 10.1016/j.snb.2017.09.200
   Dong YQ, 2012, CARBON, V50, P4738, DOI 10.1016/j.carbon.2012.06.002
   E. S. Material C. C. This T. R. Society, 2011, EL SUPPL INF ESI STR, V4, P1
   Einafshar E, 2018, CARBOHYD POLYM, V194, P103, DOI 10.1016/j.carbpol.2018.03.102
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gao YR, 2017, COLLOID SURFACE B, V160, P364, DOI 10.1016/j.colsurfb.2017.09.047
   Hoshikawa A, 2017, J DRUG DELIV SCI TEC, V38, P45, DOI 10.1016/j.jddst.2017.01.004
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kochkar H., 2011, SHAPE CONTROLLED SYN, P11364
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Liu JQ, 2013, ACTA BIOMATER, V9, P9243, DOI 10.1016/j.actbio.2013.08.016
   Loftsson T, 2017, INT J PHARMACEUT, V531, P413, DOI 10.1016/j.ijpharm.2017.04.010
   Pan B. D., 2010, HYDROTHERMAL ROUTE C, P734, DOI [10.1002/adma.200902825, DOI 10.1002/ADMA.200902825]
   Ramanujam K, 2015, J TEXT I, V106, P1147, DOI 10.1080/00405000.2014.977541
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Shen JH, 2012, CHEM COMMUN, V48, P3686, DOI 10.1039/c2cc00110a
   Soheilmoghaddam M, 2014, MATER LETT, V135, P210, DOI 10.1016/j.matlet.2014.07.169
   Vatanparast M, 2018, J FLUORINE CHEM, V211, P81, DOI 10.1016/j.jfluchem.2018.04.003
   Wintgens V, 2013, CARBOHYD POLYM, V98, P896, DOI 10.1016/j.carbpol.2013.06.073
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu HQ, 2013, J MEMBRANE SCI, V428, P301, DOI 10.1016/j.memsci.2012.09.063
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhang MS, 2018, ENERG POLICY, V114, P13, DOI 10.1016/j.enpol.2017.11.065
   Zhang XH, 2017, MOL THER, V25, P1606, DOI 10.1016/j.ymthe.2017.01.014
   Zhu SJ, 2011, CHEM COMMUN, V47, P6858, DOI 10.1039/c1cc11122a
NR 29
TC 6
Z9 6
U1 1
U2 26
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD DEC
PY 2018
VL 189
BP 244
EP 249
DI 10.1016/j.jphotobiol.2018.10.019
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HF6UW
UT WOS:000454374800027
PM 30419519
DA 2022-11-30
ER

PT J
AU Bae, D
   Gautam, J
   Jang, H
   Banskota, S
   Lee, SY
   Jeong, MJ
   Kim, AS
   Kim, HC
   Lee, IH
   Nam, TG
   Kim, JA
   Jeong, BS
AF Bae, Dawon
   Gautam, Jaya
   Jang, Hyeonjin
   Banskota, Suhrid
   Lee, Sang Yeul
   Jeong, Min-Ji
   Kim, A-Sol
   Kim, Hong Chul
   Lee, Iyn-Hyang
   Nam, Tae-gyu
   Kim, Jung-Ae
   Jeong, Byeong-Seon
TI Protective effects of 6-ureido/thioureido-2,4,5-trimethylpyridin-3-ols
   against 4-hydroxynonenal-induced cell death in adult retinal pigment
   epithelial-19 cells
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Retinal pigment epithelium; Apoptosis; NADPH oxidase 4;
   6-Ureido/thioureido-2,4,5-trimethylpyridin-3-ol; 4-Hydroxynonenal
ID MACULAR DEGENERATION; OXIDATIVE STRESS; ANTIANGIOGENIC ACTIVITY;
   IN-VITRO; 6-AMINO-2,4,5-TRIMETHYLPYRIDIN-3-OLS; RESVERATROL; QUERCETIN;
   MELATONIN; DAMAGE
AB Dysfunction or progressive degeneration of retinal pigment epithelium (RPE) contributes in the initial pathogenesis of age-related macular degeneration (AMD) causing irreversible vision loss, which makes RPE the prime target of the disease. The present study aimed to identify compounds to protect 4-hydroxynonenal (4-HNE)-induced RPE cell death by inhibiting NADPH oxidase 4 (NOX4) activity, not just as free radical scavengers, using ARPE-19, a human adult retinal pigment epithelial cell line, as a RPE representative. Novel thirty-two 6-ureido/thioureido-2,4,5-trimethylpyridin-3-ol derivatives 17 were synthesized and tested. We found that there was a strong correlation between level of protective effect of compounds 17 against 4-HNE-induced APRE-19 cell death and that of inhibitory activity against 4-HNE-induced superoxide production, and that most of the compounds 17 showed minimal DPPH radical scavenging activity. Compound 17-28 showed the best protective activity against 4-HNE-induced superoxide production (79.5% inhibition) and cell death (85.1% recovery) at 10 mu M concentration, which was better than that of VAS2870, a NOX2/4 inhibitor. In addition, compound 17-28 blocked 4-HNE-induced apoptosis of ARPE-19 cells in a concentration-dependent manner. The results indicate that compound 17-28 may be a lead compound to develop AMD therapeutics. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Bae, Dawon; Gautam, Jaya; Jang, Hyeonjin; Banskota, Suhrid; Jeong, Min-Ji; Kim, A-Sol; Lee, Iyn-Hyang; Kim, Jung-Ae; Jeong, Byeong-Seon] Yeungnam Univ, Coll Pharm, Gyongsan 38541, South Korea.
   [Bae, Dawon; Gautam, Jaya; Jang, Hyeonjin; Banskota, Suhrid; Jeong, Min-Ji; Kim, A-Sol; Lee, Iyn-Hyang; Kim, Jung-Ae; Jeong, Byeong-Seon] Yeungnam Univ, Inst Drug Res, Gyongsan 38541, South Korea.
   [Lee, Sang Yeul; Kim, Hong Chul; Nam, Tae-gyu] Hanyang Univ, Dept Pharm, Ansan 15588, Gyeonggi Do, South Korea.
   [Lee, Sang Yeul; Kim, Hong Chul; Nam, Tae-gyu] Hanyang Univ, Inst Pharmaceut Sci & Technol, Ansan 15588, Gyeonggi Do, South Korea.
C3 Yeungnam University; Yeungnam University; Hanyang University; Hanyang
   University
RP Kim, JA; Jeong, BS (通讯作者)，Yeungnam Univ, Coll Pharm, Gyongsan 38541, South Korea.; Kim, JA; Jeong, BS (通讯作者)，Yeungnam Univ, Inst Drug Res, Gyongsan 38541, South Korea.; Nam, TG (通讯作者)，Hanyang Univ, Dept Pharm, Ansan 15588, Gyeonggi Do, South Korea.; Nam, TG (通讯作者)，Hanyang Univ, Inst Pharmaceut Sci & Technol, Ansan 15588, Gyeonggi Do, South Korea.
EM tnam@hanyang.ac.kr; jakim@yu.ac.kr; jeongb@ynu.ac.kr
RI Banskota, Suhrid/Q-8485-2016; Banskota, Suhrid/AAF-2315-2020
OI Banskota, Suhrid/0000-0003-3183-6268; Banskota,
   Suhrid/0000-0003-3183-6268
FU Yeungnam University Research Grant
FX This work was supported by the Yeungnam University Research Grant.
CR Banskota S, 2016, BIOORG MED CHEM LETT, V26, P4587, DOI 10.1016/j.bmcl.2016.08.075
   Banskota S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148133
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BOK D, 1993, J CELL SCI, P189
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Gautam J, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0559-6
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Kang Y, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0113-z
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kim DG, 2014, EUR J MED CHEM, V78, P126, DOI 10.1016/j.ejmech.2014.03.045
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Lee H, 2014, BIOORG MED CHEM LETT, V24, P3131, DOI 10.1016/j.bmcl.2014.05.005
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Pintea A, 2011, J OCUL PHARMACOL TH, V27, P315, DOI 10.1089/jop.2010.0144
   Rosen RB, 2012, MOL VIS, V18, P1640
   Sheu SJ, 2010, J OCUL PHARMACOL TH, V26, P231, DOI 10.1089/jop.2009.0137
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wingler K, 2012, CELL MOL LIFE SCI, V69, P3159, DOI 10.1007/s00018-012-1107-1
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
NR 21
TC 10
Z9 10
U1 2
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JAN 15
PY 2018
VL 28
IS 2
BP 107
EP 112
DI 10.1016/j.bmcl.2017.11.046
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy; Chemistry
GA FU2DE
UT WOS:000423658000009
PM 29208521
DA 2022-11-30
ER

PT J
AU Tasharrofi, N
   Kouhkan, F
   Soleimani, M
   Soheili, ZS
   Kabiri, M
   Saber, MM
   Dorkoosh, FA
AF Tasharrofi, Nooshin
   Kouhkan, Fatemeh
   Soleimani, Masoud
   Soheili, Zahra-Sheila
   Kabiri, Mahboubeh
   Saber, Mohaddeseh Mahmoudi
   Dorkoosh, Farid Abedin
TI Survival Improvement in Human Retinal Pigment Epithelial Cells via Fas
   Receptor Targeting by miR-374a
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Fas RECEPTOR; miR-374a; PRIMARY HUMAN RETINAL PIGMENT EPITHELIAL CELLS;
   AGE-RELATED MACULAR DEGENERATION
ID OXIDATIVE STRESS; CHOROIDAL NEOVASCULARIZATION; DIFFERENTIAL REGULATION;
   MACULAR DEGENERATION; MICRORNA EXPRESSION; MEDIATED APOPTOSIS;
   CANCER-CELLS; PATHWAY; DEATH; RETINOBLASTOMA
AB Oxidative conditions of the eye could contribute to retinal cells loss through activating the Fas-L/Fas pathway. This phenomenon is one of the leading causes of some ocular diseases like age-related macular degeneration (AMD). By targeting proteins at their mRNA level, microRNAs (miRNAs) can regulate gene expression and cell function. The aim of the present study is to investigate Fas targeting by miR-374a and find whether it can inhibit Fas-mediated apoptosis in primary human retinal pigment epithelial (RPE) cells under oxidative stress. So, the primary human RPE cells were transfected with pre-miR-374a pLEX construct using polymeric carrier and were exposed to H2O2 (200M) as an oxidant agent for induction of Fas expression. Fas expression at mRNA and protein level was evaluated by quantitative real-time PCR and Western blot analysis, respectively. These results revealed that miR-374a could prevent Fas upregulation under oxidative conditions. Moreover, Luciferase activity assay confirmed that Fas could be a direct target of miR-374a. The cell viability studies demonstrated that caspase-3 activity was negligible in miR-374a treated cells compared to the controls. Our data suggest miR-374a is a negative regulator of Fas death receptor which is able to enhance the cell survival and protect RPE cells against oxidative conditions. J. Cell. Biochem. 118: 4854-4861, 2017. (c) 2017 Wiley Periodicals, Inc.
C1 [Tasharrofi, Nooshin; Saber, Mohaddeseh Mahmoudi] Univ Tehran Med Sci, Dept Pharmaceut Nanotechnol, Fac Pharm, Tehran, Iran.
   [Tasharrofi, Nooshin; Saber, Mohaddeseh Mahmoudi; Dorkoosh, Farid Abedin] Univ Tehran Med Sci, Dept Pharmaceut, Fac Pharm, 1462 Kargar Ave, Tehran 1439804448, Iran.
   [Tasharrofi, Nooshin; Kouhkan, Fatemeh] Stem Cell Technol Res Ctr, Tehran, Iran.
   [Soleimani, Masoud] Tarbiat Modares Univ, Dept Hematol, Fac Med Sci, Tehran, Iran.
   [Soheili, Zahra-Sheila] Natl Inst Genet Engn & Biotechnol, Inst Med Biotechnol, Fac Mol Med, Tehran, Iran.
   [Kabiri, Mahboubeh] Univ Tehran, Dept Biotechnol, Coll Sci, Tehran, Iran.
   [Saber, Mohaddeseh Mahmoudi] Univ Tehran Med Sci, Nanotechnol Res Ctr, Fac Pharm, Tehran, Iran.
   [Dorkoosh, Farid Abedin] Univ Tehran Med Sci, MBRC, Fac Pharm, 1462 Kargar Ave, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences; Tarbiat Modares University; University of Tehran; Tehran
   University of Medical Sciences; Tehran University of Medical Sciences
RP Dorkoosh, FA (通讯作者)，Univ Tehran Med Sci, Dept Pharmaceut, Fac Pharm, 1462 Kargar Ave, Tehran 1439804448, Iran.
EM dorkoosh@tums.ac.ir
RI Tasharrofi, Nooshin/Q-4426-2017; Kabiri, Mahboubeh/ABE-1182-2021;
   Dorkoosh, Farid/W-2276-2019; Soheili, Zahra-Soheila/W-8316-2018
OI Tasharrofi, Nooshin/0000-0002-6443-0961; Soheili,
   Zahra-Soheila/0000-0003-1292-465X; Dorkoosh, Farid
   Abedin/0000-0002-0417-7300
FU Tehran University of Medical Sciences [93-02-33-26133]
FX This study was supported by Tehran University of Medical Sciences (grant
   number 93-02-33-26133).
CR Agrawal Saloni, 2014, World J Biol Chem, V5, P1, DOI 10.4331/wjbc.v5.i1.1
   Akrami Hassan, 2009, J Ophthalmic Vis Res, V4, P134
   Bajt ML, 2002, ANTIOXID REDOX SIGN, V4, P733, DOI 10.1089/152308602760598873
   Bonomini F, 2008, HISTOL HISTOPATHOL, V23, P381, DOI 10.14670/HH-23.381
   Boulton M.E., 2013, AGE RELATED MACULAR, P45
   Bullock J, 2015, PEDF RETINA SERPIN F, P197
   Denning TL, 2002, FREE RADICAL BIO MED, V33, P1641, DOI 10.1016/S0891-5849(02)01141-3
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunmire JJ, 2013, EXP EYE RES, V108, P68, DOI 10.1016/j.exer.2012.10.016
   Ertekin S, 2014, MOL VIS, V20, P1057
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Ferrington DA, 2006, EXP EYE RES, V83, P638, DOI 10.1016/j.exer.2006.03.003
   Fujita T, 2002, AM J RESP CELL MOL, V27, P542, DOI 10.1165/rcmb.4775
   Ghaderi S, 2011, STEM CELLS DEV, V20, P1615, DOI 10.1089/scd.2010.0390
   Hackler L, 2010, INVEST OPHTH VIS SCI, V51, P1823, DOI 10.1167/iovs.09-4657
   Han S, 2016, CHINESE MED J-PEKING, V129, P709, DOI 10.4103/0366-6999.178013
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Howell JC, 2013, MOL VIS, V19, P544
   Hu GL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037224
   Huang Y, 2011, CELL DEATH DIFFER, V18, P1220, DOI 10.1038/cdd.2010.188
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Jo DH, 2011, J PEDIAT HEMATOL ONC, V33, P529, DOI 10.1097/MPH.0b013e318228280a
   Kawa M, 2014, J BIOCH PHARM RES, V2, P21
   Kouhkan F, 2016, J MED GENET, V53, P24, DOI 10.1136/jmedgenet-2015-103225
   Kubo E, 2013, J CELL MOL MED, V17, P1146, DOI 10.1111/jcmm.12094
   Kutty RK, 2013, MOL VIS, V19, P737
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Kwon D, 2001, J NEUROIMMUNOL, V113, P1, DOI 10.1016/S0165-5728(00)00321-0
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Luna C, 2011, J CELL PHYSIOL, V226, P1407, DOI 10.1002/jcp.22476
   Mastropasqua R, 2014, PROG RETIN EYE RES, V43, P92, DOI 10.1016/j.preteyeres.2014.07.003
   Mead B, 2015, STEM CELL RES, V14, P243, DOI 10.1016/j.scr.2015.02.003
   Mobarra N, 2015, IN VITRO CELL DEV-AN, V51, P604, DOI 10.1007/s11626-015-9872-4
   Park SM, 2008, CYTOKINE GROWTH F R, V19, P303, DOI 10.1016/j.cytogfr.2008.04.011
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tasharrofi N, 2017, INT J PHARMACEUT, V518, P66, DOI 10.1016/j.ijpharm.2016.12.048
   Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823
   Villarreal G, 2011, INVEST OPHTH VIS SCI, V52, P3391, DOI 10.1167/iovs.10-6165
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Xu SB, 2009, PROG RETIN EYE RES, V28, P87, DOI 10.1016/j.preteyeres.2008.11.003
   Zacks DN, 2004, INVEST OPHTH VIS SCI, V45, P4563, DOI 10.1167/iovs.04-0598
   Zhao JJ, 2009, CHILD NERV SYST, V25, P13, DOI 10.1007/s00381-008-0701-x
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 50
TC 14
Z9 16
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC
PY 2017
VL 118
IS 12
BP 4854
EP 4861
DI 10.1002/jcb.26160
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FK4QP
UT WOS:000413481300076
PM 28543858
DA 2022-11-30
ER

PT J
AU Calejo, MT
   Ilmarinen, T
   Jongprasitkul, H
   Skottman, H
   Kellomaki, M
AF Calejo, Maria Teresa
   Ilmarinen, Tanja
   Jongprasitkul, Hatai
   Skottman, Heli
   Kellomaki, Minna
TI Honeycomb porous films as permeable scaffold materials for human
   embryonic stem cell-derived retinal pigment epithelium
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE retinal pigment epithelium; honeycomb films; permeability; tissue
   engineering; pluripotent stem cells
ID ARTIFICIAL BRUCHS MEMBRANE; MACULAR DEGENERATION; BREATH FIGURES;
   IN-VITRO; SUBRETINAL IMPLANTATION; PROTEIN ADSORPTION; PATTERNED
   SURFACE; POLY(LACTIC ACID); SILK FIBROIN; ADHESION
AB Age-related macular degeneration (AMD) is a leading cause of blindness in developed countries, characterised by the degeneration of the retinal pigment epithelium (RPE), a pigmented cell monolayer that closely interacts with the photoreceptors. RPE transplantation is thus considered a very promising therapeutic option to treat this disease. In this work, porous honeycomb-like films are for the first time investigated as scaffold materials for human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE). By changing the conditions during film preparation, it was possible to produce films with homogeneous pore distribution and adequate pore size (approximate to 3-5 mu m), that is large enough to ensure high permeability but small enough to enable cell adherence and spreading. A brief dip-coating procedure with collagen type IV enabled the homogeneous adsorption of the protein to the walls and bottom of pores, increasing the hydrophilicity of the surface. hESC-RPE adhered and proliferated on all the collagen-coated materials, regardless of small differences in pore size. The differentiation of hESC-RPE was confirmed by the detection of specific RPE protein markers. These results suggest that the porous honeycomb films can be promising candidates for hESC-RPE tissue engineering, importantly enabling the free flow of ions and molecules across the material. (c) 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 1646-1656, 2016.
C1 [Calejo, Maria Teresa; Jongprasitkul, Hatai; Kellomaki, Minna] Tampere Univ Technol, Dept Elect & Commun Engn, BioMediTech, FIN-33101 Tampere, Finland.
   [Ilmarinen, Tanja; Skottman, Heli] Univ Tampere, BioMediTech, FIN-33101 Tampere, Finland.
C3 Tampere University; Tampere University
RP Calejo, MT (通讯作者)，Tampere Univ Technol, Dept Elect & Commun Engn, BioMediTech, FIN-33101 Tampere, Finland.
EM teresa.calejo@tut.fi
RI ; Kellomaki, Minna/G-6190-2010
OI Skottman, Heli/0000-0002-4127-8792; Kellomaki,
   Minna/0000-0003-4321-1820; Ilmarinen, Tanja/0000-0002-4609-8897;
   Jongprasitkul, Hatai/0000-0003-0646-7712
FU Finnish Funding Agency of Innovation (Tekes) Human Spare Parts Program,
   the Academy of Finland [253134, 218050, 272808, 133879]; Finnish
   Cultural Foundation; Paivikki and Sakari Sohlberg Foundation
FX Contract grant sponsor: Finnish Funding Agency of Innovation (Tekes)
   Human Spare Parts Program, the Academy of Finland; contract grant
   numbers: 253134, 218050, 272808, 133879; Contract grant sponsors: The
   Finnish Cultural Foundation and Paivikki and Sakari Sohlberg Foundation
CR Arai K, 2008, COLLOID SURFACE A, V313, P530, DOI 10.1016/j.colsurfa.2007.04.128
   Arima Y, 2007, BIOMATERIALS, V28, P3074, DOI 10.1016/j.biomaterials.2007.03.013
   Bai H, 2013, ANGEW CHEM INT EDIT, V52, P12240, DOI 10.1002/anie.201303594
   Battiston KG, 2014, BIOMATERIALS, V35, P4465, DOI 10.1016/j.biomaterials.2014.02.023
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Birch MA, 2013, TISSUE ENG PT A, V19, P2087, DOI [10.1089/ten.tea.2012.0729, 10.1089/ten.TEA.2012.0729]
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brash JL, 1996, CURR OPIN COLLOID IN, V1, P682, DOI 10.1016/S1359-0294(96)80109-9
   Carbonaro A, 2004, J MEMBRANE SCI, V241, P249, DOI 10.1016/j.memsci.2004.04.039
   Chen SS, 2015, BIOMATER SCI-UK, V3, P85, DOI 10.1039/c4bm00233d
   de Leon AS, 2013, POLYM CHEM-UK, V4, P4024, DOI 10.1039/c3py00394a
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Escale P, 2012, EUR POLYM J, V48, P1001, DOI 10.1016/j.eurpolymj.2012.03.001
   Foldberg S, 2012, COLLOID SURFACE B, V93, P92, DOI 10.1016/j.colsurfb.2011.12.018
   Fukuhira Y, 2006, BIOMATERIALS, V27, P1797, DOI 10.1016/j.biomaterials.2005.10.019
   Fukuhira Y, 2008, COLLOID SURFACE A, V313, P520, DOI 10.1016/j.colsurfa.2007.05.047
   Fukuhira Y, 2009, SOFT MATTER, V5, P2037, DOI 10.1039/b821183c
   Galeotti F, 2012, SOFT MATTER, V8, P4815, DOI 10.1039/c2sm25089f
   Hayat MA, 2012, STEM CELLS CANC STEM, V7, P187
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huang CX, 2014, ACS APPL MATER INTER, V6, P5971, DOI 10.1021/am501096k
   Kapyla E, 2014, LANGMUIR, V30, P14555, DOI 10.1021/la5023642
   Kawano T, 2014, BIOMATER SCI-UK, V2, P52, DOI 10.1039/c3bm60195a
   Kearns V, 2012, J MATER SCI-MATER M, V23, P2013, DOI 10.1007/s10856-012-4675-6
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Lu LC, 1999, BIOMATERIALS, V20, P2351, DOI 10.1016/S0142-9612(99)00164-7
   Manabe K, 2013, ACS APPL MATER INTER, V5, P11900, DOI 10.1021/am4035762
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   McMillan JR, 2007, TISSUE ENG, V13, P789, DOI 10.1089/ten.2006.0321
   Rabin DM, 2013, AGING-US, V5, P51
   Ramsden CM, 2014, DEV OPHTHALMOL, V53, P97, DOI 10.1159/000357363
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Savolainen V, 2011, ANN BIOMED ENG, V39, P3055, DOI 10.1007/s10439-011-0387-1
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Skottman H, 2010, IN VITRO CELL DEV-AN, V46, P206, DOI 10.1007/s11626-010-9286-2
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sorkio A, 2015, TISSUE ENG PT A, V21, P2301, DOI [10.1089/ten.tea.2014.0640, 10.1089/ten.TEA.2014.0640]
   Sorkio A, 2014, TISSUE ENG PT A, V20, P622, DOI 10.1089/ten.TEA.2013.0049
   Sorkio AE, 2015, BIOMATERIALS, V51, P257, DOI 10.1016/j.biomaterials.2015.02.005
   Srivastava GK, 2011, J BIOMED MATER RES A, V97A, P243, DOI 10.1002/jbm.a.33050
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sunami H, 2006, COLLOID SURFACE A, V284, P548, DOI 10.1016/j.colsurfa.2005.11.041
   Tanaka M, 2011, BBA-GEN SUBJECTS, V1810, P251, DOI 10.1016/j.bbagen.2010.10.002
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Thomson HAJ, 2011, BRIT J OPHTHALMOL, V95, P563, DOI 10.1136/bjo.2009.166728
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tian J, 2004, PHYSIOL GENOMICS, V17, P170, DOI 10.1152/physiolgenomics.00179.2003
   Treharne AJ, 2012, J BIOMED MATER RES A, V100A, P2358, DOI 10.1002/jbm.a.34178
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Wu XH, 2012, ACS APPL MATER INTER, V4, P4966, DOI 10.1021/am301334s
   Yamamoto S, 2007, LANGMUIR, V23, P8114, DOI 10.1021/la7003326
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 59
TC 25
Z9 26
U1 0
U2 48
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JUL
PY 2016
VL 104
IS 7
BP 1646
EP 1656
DI 10.1002/jbm.a.35690
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA DO1FW
UT WOS:000377524900009
PM 26914698
DA 2022-11-30
ER

PT J
AU Lee, J
   Ryoo, NK
   Han, H
   Hong, HK
   Park, JY
   Park, SJ
   Kim, YK
   Sim, C
   Kim, K
   Woo, SJ
   Park, KH
   Kim, H
AF Lee, Jihwang
   Ryoo, Na-kyung
   Han, Hyounkoo
   Hong, Hye Kyoung
   Park, Ji Yeon
   Park, Sang Jun
   Kim, Yong-Kyu
   Sim, Changbeom
   Kim, Kwangmeyung
   Woo, Se Joon
   Park, Kyu Hyung
   Kim, Hyuncheol
TI Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal
   Neovascularization
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE polysiRNA; polyplex; choroidal neovascularization; intravitreal
   injection
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; SIRNA DELIVERY;
   DRUG-DELIVERY; MODEL; NANOPARTICLES; RETINA; CHALLENGES; LIPOSOMES;
   MOVEMENT
AB Choroidal neovascularization (CNV) is a major cause of severe vision loss in patients with age-related macular degeneration (AMD). Present ocular siRNA delivery technology is limited due to poor delivery through the retina to the choroid, where CNV originates. Our goal was to develop an optimized nanosized polyRNAi-based therapeutic delivery system to the subretinal space. We developed it by siRNA multimerization (polysiRNA) followed by coating with branched polyethylenimine and hyaluronic acid, and then evaluated its efficacy in vitro and in vivo. The polysiRNA polyplex showed a narrow size distribution (260.7 +/- 43.27 nm) and negative charge (-4.98 +/- 0.47 mV) owing to the hyaluronic acid outer layer. In vitro uptake of the polysiRNA polyplex by human ARPE cells was discovered, and the direct inhibition of VEGF mRNA translation was confirmed in B16F10 cells. The intravitreally administered polysiRNA polyplex overcame both the vitreous and retina barriers in vivo and reached the subretinal space efficiently. Intravitreal injection of the polysiRNA polyplex was not toxic to the retina in histopathology. Furthermore, intravitreal injections of the polysiRNA polyplex at both 1 and 7 days after laser photocoagulation inhibited laser-induced choroidal neovascularization, compared to that of the control (p < 0.05). These results suggest that anti-VEGF polysiRNA polyplexes show great potential in delivering multimeric RNAi-based therapeutics to treat retinal or choroidal disorders.
C1 [Lee, Jihwang; Han, Hyounkoo; Sim, Changbeom; Kim, Hyuncheol] Sogang Univ, Dept Chem & Biomol Engn, 35 Baekbeom Ro, Seoul 121742, South Korea.
   [Ryoo, Na-kyung; Hong, Hye Kyoung; Park, Ji Yeon; Park, Sang Jun; Kim, Yong-Kyu; Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, 82 Gumi Ro 173 Beon Gil, Songnam 13620, Gyeonggi Do, South Korea.
   [Ryoo, Na-kyung; Park, Sang Jun; Kim, Yong-Kyu; Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Coll Med, Dept Ophthalmol, 71 Ihwajang Gil, Seoul, South Korea.
   [Kim, Kwangmeyung] KIST, Biomed Res Inst, Ctr Theragnosis, Hwarangno 14 Gil 5, Seoul 136791, South Korea.
C3 Sogang University; Seoul National University (SNU); Seoul National
   University (SNU); Korea Institute of Science & Technology (KIST)
RP Kim, H (通讯作者)，Sogang Univ, Dept Chem & Biomol Engn, 35 Baekbeom Ro, Seoul 121742, South Korea.; Park, KH (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, 82 Gumi Ro 173 Beon Gil, Songnam 13620, Gyeonggi Do, South Korea.; Park, KH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, 71 Ihwajang Gil, Seoul, South Korea.
EM jiani4@snu.ac.kr; hyuncheol@sogang.ac.kr
RI Kim, Kwangmeyung/ABB-2882-2021
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education, Science and Technology
   [NRF-2013R1A2A2A04015829]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF), funded by the
   Ministry of Education, Science and Technology (NRF-2013R1A2A2A04015829).
CR Bagley RG, 2011, CLIN CANCER RES, V17, P976, DOI 10.1158/1078-0432.CCR-10-2687
   Bochot A, 2002, INVEST OPHTH VIS SCI, V43, P253
   Chen CW, 2011, INT J NANOMED, V6, P2567, DOI 10.2147/IJN.S24447
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Draper DE, 2004, RNA, V10, P335, DOI 10.1261/rna.5205404
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   Eliaz RE, 2001, CANCER RES, V61, P2592
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim H, 2009, PHARM RES-DORDR, V26, P329, DOI 10.1007/s11095-008-9745-6
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee H, 2007, J CONTROL RELEASE, V119, P245, DOI 10.1016/j.jconrel.2007.02.011
   Lee SY, 2010, J CONTROL RELEASE, V141, P339, DOI 10.1016/j.jconrel.2009.10.007
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Liu NP, 1997, INVEST OPHTH VIS SCI, V38, P2027
   Mok H, 2010, NAT MATER, V9, P272, DOI [10.1038/NMAT2626, 10.1038/nmat2626]
   Peeters L, 2007, BIOCHEM SOC T, V35, P47, DOI 10.1042/BST0350047
   Reich S, 2003, MOL VIS, V9, P210
   Thakur A, 2012, J BIOL ENG, V6, DOI 10.1186/1754-1611-6-7
   Zhang C, 2010, GENE THER, V17, P338, DOI 10.1038/gt.2009.158
NR 25
TC 15
Z9 16
U1 0
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUN
PY 2016
VL 13
IS 6
BP 1988
EP 1995
DI 10.1021/acs.molpharmaceut.6b00148
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DN9TW
UT WOS:000377424600023
PM 27173745
DA 2022-11-30
ER

PT J
AU Carter, JG
   Gammons, MVR
   Damodaran, G
   Churchill, AJ
   Harper, SJ
   Bates, DO
AF Carter, James G.
   Gammons, Melissa V. R.
   Damodaran, Gopinath
   Churchill, Amanda J.
   Harper, Steven J.
   Bates, David O.
TI The carboxyl terminus of VEGF-A is a potential target for
   anti-angiogenic therapy
SO ANGIOGENESIS
LA English
DT Article
DE VEGF; Splicing; Bevacizumab; VEGF-A(165)b
ID ENDOTHELIAL GROWTH-FACTOR; SPLICE VARIANT; VEGF(165)B; ISOFORMS;
   BINDING; PROGRESSION; VEGF(XXX)B; MECHANISM; PROTEIN; AGENT
AB Anti-VEGF-A therapy has become a mainstay of treatment for ocular neovascularisation and in cancer; however, their effectiveness is not universal, in some cases only benefiting a minority of patients. Anti-VEGF-A therapies bind and block both pro-angiogenic VEGF-A(xxx) and the partial agonist VEGF-A(xxx)b isoforms, but their anti-angiogenic benefit only comes about from targeting the pro-angiogenic isoforms. Therefore, antibodies that exclusively target the pro-angiogenic isoforms may be more effective. To determine whether C-terminal-targeted antibodies could inhibit angiogenesis, we generated a polyclonal antibody to the last nine amino acids of VEGF-A(165) and tested it in vitro and in vivo. The exon8a polyclonal antibody (Exon8apab) did not bind VEGF-A(165)b even at greater than 100-fold excess concentration, and dose dependently inhibited VEGF-A(165) induced endothelial migration in vitro at concentrations similar to the VEGF-A antibody fragment ranibizumab. Exon8apab can inhibit tumour growth of LS174t cells implanted in vivo and blood vessel growth in the eye in models of age-related macular degeneration, with equal efficacy to non-selective anti-VEGF-A antibodies. It also showed that it was the VEGF-A(xxx) levels specifically that were upregulated in plasma from patients with proliferative diabetic retinopathy. These results suggest that VEGF-A(165)-specific antibodies can be therapeutically useful.
C1 [Carter, James G.; Gammons, Melissa V. R.; Damodaran, Gopinath; Churchill, Amanda J.; Harper, Steven J.; Bates, David O.] Univ Bristol, Sch Physiol & Pharmacol, Microvasc Res Labs, Bristol BS2 8EJ, Avon, England.
   [Carter, James G.; Bates, David O.] Univ Nottingham, Queens Med Ctr, Nottingham NG7 2UH, England.
C3 University of Bristol; University of Nottingham
RP Bates, DO (通讯作者)，Univ Nottingham, Queens Med Ctr, D Floor West Block, Nottingham NG7 2UH, England.
EM david.bates@nottingham.ac.uk
OI Damodaran, Gopinath/0000-0002-1697-0357; Carter,
   James/0000-0003-1860-9677; Bates, David/0000-0003-4850-2360; gammons,
   melissa/0000-0001-9661-9331
FU British Heart Foundation [BS06/005] Funding Source: Medline; Cancer
   Research UK [14995, A14995] Funding Source: Medline; Medical Research
   Council [GR0600920, G1002073] Funding Source: Medline; MRC [G1002073]
   Funding Source: UKRI
CR Artac RA, 2009, BIOL REPROD, V81, P978, DOI 10.1095/biolreprod.109.078097
   Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223
   Bates DO, 2006, CLIN SCI, V110, P575, DOI 10.1042/CS20050292
   Bates DO, 2002, CANCER RES, V62, P4123
   Bhattacharjee G, 2000, J BIOL CHEM, V275, P26806
   Bills VL, 2009, CLIN SCI, V116, P265, DOI 10.1042/CS20080270
   Chen J, 2011, J HUAZHONG U SCI-MED, V31, P619, DOI 10.1007/s11596-011-0571-4
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Hurwitz Herbert, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS62, DOI 10.3816/CCC.2004.s.010
   Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192
   Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-012-2022-8
   Parker MW, 2012, J BIOL CHEM, V287, P11082, DOI 10.1074/jbc.M111.331140
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390
   Pritchard-Jones RO, 2007, BRIT J CANCER, V97, P223, DOI 10.1038/sj.bjc.6603839
   Qiu Y, 2008, FASEB J, V22, P1104, DOI 10.1096/fj.07-9718com
   Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309
   Rennel ES, 2008, EUR J CANCER, V44, P1883, DOI 10.1016/j.ejca.2008.05.027
   SENGER DR, 1986, CANCER RES, V46, P5629
   Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9
   Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
NR 25
TC 14
Z9 18
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD JAN
PY 2015
VL 18
IS 1
BP 23
EP 30
DI 10.1007/s10456-014-9444-3
PG 8
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA AX8HO
UT WOS:000347150900003
PM 25274272
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Yoshida, A
   Yoshino, F
   Makita, T
   Maehata, Y
   Higashi, K
   Miyamoto, C
   Wada-Takahashi, S
   Takahashi, S
   Takahashi, O
   Lee, MC
AF Yoshida, Ayaka
   Yoshino, Fumihiko
   Makita, Tetsuya
   Maehata, Yojiro
   Higashi, Kazuyoshi
   Miyamoto, Chihiro
   Wada-Takahashi, Satoko
   Takahashi, Shun-suke
   Takahashi, Osamu
   Lee, Masaichi Chang-il
TI Reactive oxygen species production in mitochondria of human gingival
   fibroblast induced by blue light irradiation
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Blue light; Light-emitting diode; Quartz tungsten halogen; Reactive
   oxygen species; Human gingival fibroblast; Mitochondria
ID OXIDATIVE STRESS; COMPOSITE POLYMERIZATION; TEMPERATURE RISE; CURING
   UNITS; GENERATION; ACTIVATION; DAMAGE; DEATH; HEAT
AB In recent years, it has become well known that the production of reactive oxygen species (ROS) induced by blue-light irradiation causes adverse effects of photo-aging, such as age-related macular degeneration of the retina. Thus, orange-tinted glasses are used to protect the retina during dental treatment involving blue-light irradiation (e.g., dental resin restorations or tooth bleaching treatments). However, there are few studies examining the effects of blue-light irradiation on oral tissue. For the first time, we report that blue-light irradiation by quartz tungsten halogen lamp (QTH) or light-emitting diode (LED) decreased cell proliferation activity of human gingival fibroblasts (HGFs) in a time-dependent manner (<5 min). Additionally, in a morphological study, the cytotoxic effect was observed in the cell organelles, especially the mitochondria. Furthermore, ROS generation induced by the blue-light irradiation was detected in mitochondria of HGFs using fluorimetfy. In all analyses, the cytotoxicity was significantly higher after LED irradiation compared with cytotoxicity after QTH irradiation. These results suggest that blue light irradiation, especially by LED light sources used in dental aesthetic treatment, might have adverse effects on human gingival tissue. Hence, this necessitates the development of new dental aesthetic treatment methods and/or techniques to protect HGFs from blue light irradiation during dental therapy. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Yoshida, Ayaka; Yoshino, Fumihiko; Makita, Tetsuya; Maehata, Yojiro; Miyamoto, Chihiro; Wada-Takahashi, Satoko; Takahashi, Shun-suke] Kanagawa Dent Univ, Grad Sch, Dept Oral Sci, Yokosuka, Kanagawa 2388580, Japan.
   [Higashi, Kazuyoshi; Takahashi, Osamu] Kanagawa Dent Univ, Dept Neuroanat, Kanagawa, Japan.
   [Lee, Masaichi Chang-il] Kanagawa Dent Univ, Yokosuka Shonan Disaster Hlth Emergency Res Ctr, Kanagawa, Japan.
   [Lee, Masaichi Chang-il] Kanagawa Dent Univ, ESR Labs, Kanagawa, Japan.
C3 Kanagawa Dental College; Kanagawa Dental College; Kanagawa Dental
   College; Kanagawa Dental College
RP Yoshino, F (通讯作者)，82 Inaoka Cho, Yokosuka, Kanagawa, Japan.
EM yoshino@kdu.ac.jp
RI Yoshida, Ayaka/D-9382-2014; Yoshino, Fumihiko/E-5067-2012
OI Yoshida, Ayaka/0000-0001-8855-9228; Yoshino,
   Fumihiko/0000-0001-6068-6268
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [24792045]; Grants-in-Aid for Scientific Research [24792045] Funding
   Source: KAKEN
FX This study was supported by the Grant-in-Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan (24792045).
CR Andersson H, 1998, J MICROSC-OXFORD, V191, P1
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Buchalla W, 2007, DENT MATER, V23, P586, DOI 10.1016/j.dental.2006.03.018
   CAUGHMAN WF, 1995, J AM DENT ASSOC, V126, P1280
   CUNNINGHAM M L, 1985, Journal of Free Radicals in Biology and Medicine, V1, P381, DOI 10.1016/0748-5514(85)90150-3
   Eldeniz AU, 2005, J BIOMED MATER RES B, V72B, P254, DOI 10.1002/jbm.b.30144
   Evans DL, 1997, P SOC PHOTO-OPT INS, V3002, P142, DOI 10.1117/12.271036
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Goldstein R.E., 1995, COMPLETE DENT BLEACH
   Greenwall L, 2001, BLEACHING TECHNIQUES
   Grice AW, 1998, APPL PHYS LETT, V73, P629, DOI 10.1063/1.121878
   HALLIWELL B, 1993, HAEMOSTASIS, V23, P118
   Hannig M, 1999, DENT MATER, V15, P275, DOI 10.1016/S0109-5641(99)00047-0
   Hanosh F N, 1992, J Esthet Dent, V4, P90, DOI 10.1111/j.1708-8240.1992.tb00670.x
   Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255
   HUSSEY DL, 1995, J DENT, V23, P267, DOI 10.1016/0300-5712(95)91149-H
   Jandt KD, 2013, DENT MATER, V29, P605, DOI 10.1016/j.dental.2013.02.003
   Joiner A, 2006, J DENT, V34, P412, DOI 10.1016/j.jdent.2006.02.002
   Kawamoto K, 2004, J ENDODONT, V30, P45, DOI 10.1097/00004770-200401000-00010
   Kim JK, 2006, PROC SPIE, V6134, DOI 10.1117/12.661563
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Komatsu T, 2006, REDOX REP, V11, P71, DOI 10.1179/135100006X101039
   Lefeuvre M, 2005, BIOMATERIALS, V26, P5130, DOI 10.1016/j.biomaterials.2005.01.014
   Loney RW, 2001, OPER DENT, V26, P516
   Martin-Pardillos A, 2013, TOXICOL SCI, V131, P641, DOI 10.1093/toxsci/kfs313
   NIKI E, 1987, British Journal of Cancer, V55, P153
   Nomoto R, 1997, Dent Mater J, V16, P60
   Omata Y, 2006, J BIOMED MATER RES A, V77A, P470, DOI 10.1002/jbm.a.30663
   PEAK MJ, 1990, PHOTOCHEM PHOTOBIOL, V51, P649, DOI 10.1111/php.1990.51.6.649
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Spagnuolo G, 2006, BIOMATERIALS, V27, P1803, DOI 10.1016/j.biomaterials.2005.10.022
   Uhl A, 2006, J DENT, V34, P298, DOI 10.1016/j.jdent.2005.07.004
   VANNORREN D, 1990, VISION RES, V30, P1517, DOI 10.1016/0042-6989(90)90032-G
   Volk J, 2006, DENT MATER, V22, P499, DOI 10.1016/j.dental.2005.06.002
   Wataha JC, 2004, DENT MATER, V20, P150, DOI 10.1016/S0109-5641(03)00086-1
   Wataha JC, 2004, J DENT RES, V83, P104, DOI 10.1177/154405910408300204
   WATTS DC, 1984, BRIT DENT J, V156, P209, DOI 10.1038/sj.bdj.4805312
   Wiggins KM, 2004, J AM DENT ASSOC, V135, P1471, DOI 10.14219/jada.archive.2004.0059
   Yoshino F, 2012, J PHOTOCH PHOTOBIO B, V114, P73, DOI 10.1016/j.jphotobiol.2012.05.012
NR 39
TC 32
Z9 32
U1 0
U2 23
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD DEC 5
PY 2013
VL 129
BP 1
EP 5
DI 10.1016/j.jphotobiol.2013.09.003
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 275WS
UT WOS:000328710500001
PM 24141287
DA 2022-11-30
ER

PT J
AU Park, SC
   Su, D
   Tello, C
AF Park, Sung Chul
   Su, Daniel
   Tello, Celso
TI Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab
   and bevacizumab
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE anti-VEGF; bevacizumab; glaucoma filtration surgery; neovascular
   glaucoma; ranibizumab; trabeculectomy; vascular endothelial growth
   factor; wound healing
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY;
   NEOVASCULAR GLAUCOMA; IRIS NEOVASCULARIZATION; MACULAR DEGENERATION;
   INTRAVITREAL BEVACIZUMAB; FILTRATION SURGERY; RETINAL
   NEOVASCULARIZATION; SUBCONJUNCTIVAL BEVACIZUMAB; MONOCLONAL-ANTIBODY
AB Introduction: Anti-VEGF therapy has been widely used in the treatment of ocular neovascular diseases. Because of their anti-angiogenic and anti-fibrotic properties, anti-VEGF antibodies such as bevacizumab and ranibizumab have emerged as an adjunctive treatment modality in glaucoma to improve success of conventional treatments.
   Areas covered: Ranibizumab is an anti-VEGF-A antigen binding fragment currently indicated in neovascular age-related macular degeneration as well as macular edema following retinal vein occlusion. Several off-label uses include the treatment of neovascular glaucoma to regress/suppress iris and iridocorneal angle neovascularization and the modulation of wound healing after glaucoma filtration surgery. Bevacizumab is a full-length anti-VEGF antibody, which is also being used in aforementioned eye conditions off-label. An overview of these anti-VEGF antibodies and the results of preclinical and clinical studies regarding their use in the treatment of glaucoma are presented.
   Expert opinion: Early studies on the utility of both bevacizumab and ranibizumab in neovascular glaucoma and filtration surgery reported promising results. However, a large-scale randomized clinical trial as well as comparative studies between the two anti-VEGF antibodies are currently lacking. A single dose of ranibizumab costs approximately 40 times as much as a single dose of bevacizumab. Clinicians should take this into account, in addition to their differences in the efficacy and safety, when treating patients.
C1 [Park, Sung Chul; Su, Daniel; Tello, Celso] New York Eye & Ear Infirm, Einhorn Clin Res Ctr, New York, NY 10003 USA.
   [Park, Sung Chul; Tello, Celso] New York Med Coll, Dept Ophthalmol, New York, NY USA.
   [Su, Daniel] Mt Sinai Sch Med, New York, NY USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Medical College;
   Icahn School of Medicine at Mount Sinai
RP Tello, C (通讯作者)，New York Eye & Ear Infirm, Einhorn Clin Res Ctr, 310 E 14th St, New York, NY 10003 USA.
EM doctorcelsotello@yahoo.com
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bochmann F, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Caujolle JP, 2012, OPHTHALMIC RES, V47, P57, DOI 10.1159/000328633
   Chalam KV, 2008, EUR J OPHTHALMOL, V18, P255, DOI 10.1177/112067210801800214
   Cilley JC, 2007, EXPERT OPIN BIOL TH, V7, P739, DOI 10.1517/14712598.7.5.739
   Coote MA, 2008, J GLAUCOMA, V17, P517, DOI 10.1097/IJG.0b013e31815f5345
   Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   Dunavoelgyi R, 2007, CLIN EXP OPHTHALMOL, V35, P878, DOI 10.1111/j.1442-9071.2007.01632.x
   Ehlers JP, 2008, RETINA-J RET VIT DIS, V28, P696, DOI 10.1097/IAE.0b013e3181679c0b
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fujiwara M, 2005, ARCH DERMATOL RES, V297, P161, DOI 10.1007/s00403-005-0596-2
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gheith ME, 2007, J OCUL PHARMACOL TH, V23, P487, DOI 10.1089/jop.2007.0036
   Grewal DS, 2008, OPHTHALMOLOGY, V115, P2141, DOI 10.1016/j.ophtha.2008.06.009
   Grisanti S, 2006, AM J OPHTHALMOL, V142, P158, DOI 10.1016/j.ajo.2006.02.045
   How A, 2010, INVEST OPHTH VIS SCI, V51, P928, DOI 10.1167/iovs.09-3949
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iliev ME, 2006, AM J OPHTHALMOL, V142, P1054, DOI 10.1016/j.ajo.2006.06.066
   Kahook MY, 2010, AM J OPHTHALMOL, V150, P399, DOI 10.1016/j.ajo.2010.03.025
   Kahook MY, 2006, OPHTHAL SURG LAS IM, V37, P148, DOI 10.3928/1542-8877-20060301-12
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Li ZQ, 2009, INVEST OPHTH VIS SCI, V50, P5217, DOI 10.1167/iovs.08-2662
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Memarzadeh F, 2009, INVEST OPHTH VIS SCI, V50, P3233, DOI 10.1167/iovs.08-2441
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
   Nilforushan N, 2012, AM J OPHTHALMOL, V153, P352, DOI 10.1016/j.ajo.2011.08.005
   O'Neill EC, 2010, INVEST OPHTH VIS SCI, V51, P6524, DOI 10.1167/iovs.10-5669
   Oshima Y, 2006, AM J OPHTHALMOL, V142, P155, DOI 10.1016/j.ajo.2006.02.015
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Presta LG, 1997, CANCER RES, V57, P4593
   Purcell JM, 2008, INVEST OPHTHALMOL VI, p[2008, 49]
   Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shazly TA, 2009, SEMIN OPHTHALMOL, V24, P113, DOI 10.1080/08820530902800801
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SKUTA GL, 1987, SURV OPHTHALMOL, V32, P149, DOI 10.1016/0039-6257(87)90091-9
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Vasudevan SK, 2009, INVEST OPHTHALMOL VI, V50
   Wakabayashi T, 2008, OPHTHALMOLOGY, V115, P1571, DOI 10.1016/j.ophtha.2008.02.026
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   WONG J, 1994, EXP EYE RES, V58, P439, DOI 10.1006/exer.1994.1037
   Wu WS, 2006, J INVEST DERMATOL, V126, P1264, DOI 10.1038/sj.jid.5700274
NR 57
TC 16
Z9 18
U1 1
U2 17
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1471-2598
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD DEC
PY 2012
VL 12
IS 12
BP 1641
EP 1647
DI 10.1517/14712598.2012.721772
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 034QB
UT WOS:000310886900008
PM 22963411
DA 2022-11-30
ER

PT J
AU Fong, CSU
   Mitchell, P
   Rochtchina, E
   de Loryn, T
   Hong, T
   Wang, JJ
AF Fong, Calvin Sze-un
   Mitchell, Paul
   Rochtchina, Elena
   de Loryn, Tania
   Hong, Thomas
   Wang, Jie Jin
TI Sustainability of visual acuity in the first 2 years after cataract
   surgery
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; OUTCOMES; EXTRACTION; AUSTRALIA; MORTALITY;
   QUALITY; PEOPLE
AB Purpose To assess whether improved visual acuity (VA) is sustained 2 years after the cataract surgery.
   Methods The Cataract Surgery and Age-Related Macular Degeneration (CSAMD) study followed 1936 patients aged $ 65 years undergoing phacoemulsification cataract surgery at Westmead Hospital (Sydney, Australia) between 2004 and 2007. Presenting and pinhole VA were assessed and retinal photography was performed annually. VA improvement or reduction was defined if VA differed by >= 2 lines between 1 and 24 months.
   Results VA data were available for 1809 patients at 1 month and 1294 at both postoperative visits (71.5% of 1809). At the 2-year visit, 930 patients (71.9%) maintained the same pinhole VA levels that they had at 1 month postoperatively, 199 (15.4%) had an improvement and 165 (12.7%) a reduction in pinhole VA. After adjusting for age and gender, pre-existing macular conditions (early AMD, macular hole or previous laser treatment) were associated with pinhole VA reduction (p=0.02). At the 24-month visit, 58.1% of those with presenting VA improvement wore distance spectacles.
   Conclusions One in eight cataract surgical patients lost at least two lines in pinhole VA over the 2-year postoperative period. Regular eye examinations of patients after cataract surgery may help to maximise the surgical benefits over the long term.
C1 [Fong, Calvin Sze-un; Mitchell, Paul; Rochtchina, Elena; de Loryn, Tania; Hong, Thomas; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Sydney; Westmead Institute for Medical Research; Centre
   for Eye Research Australia; University of Melbourne
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI wang, jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Mitchell,
   Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; 
FU National Health and Medical Research Council (NHMRC); Australian
   National Health & Medical Research Council, Canberra, Australia
   [302010]; Retina Australia; National Health & Medical Research Council
FX National Health and Medical Research Council (NHMRC) Level 116 Marcus
   Clarke Street Canberra ACT 2601. The study was supported by the
   Australian National Health & Medical Research Council, Canberra,
   Australia (Grant No 302010, 2004-2006), and Retina Australia (2005). JJW
   is funded by a National Health & Medical Research Council Senior
   Research Fellowship (2005-2014).
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Appollonio I, 1996, AGE AGEING, V25, P89, DOI 10.1093/ageing/25.2.89
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Baranano AE, 2008, OPHTHALMOLOGY, V115, P815, DOI 10.1016/j.ophtha.2007.05.052
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Congdon NG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1546, DOI 10.1001/archopht.125.11.eeb70014
   Cugati S, 2007, OPHTHAL EPIDEMIOL, V14, P408, DOI 10.1080/09286580701316124
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   McKee M, 2005, J PUBLIC HEALTH, V27, P348, DOI 10.1093/pubmed/fdi057
   Minassian DC, 2001, BRIT J OPHTHALMOL, V85, P822, DOI 10.1136/bjo.85.7.822
   Monestam E, 1999, J CATARACT REFR SURG, V25, P1127, DOI 10.1016/S0886-3350(99)00135-2
   Norregaard JC, 2003, J CATARACT REFR SURG, V29, P2135, DOI 10.1016/S0886-3350(03)00340-7
   Pager CK, 2004, CLIN EXP OPHTHALMOL, V32, P388, DOI 10.1111/j.1442-9071.2004.00843.x
   Panchapakesan J, 2004, EYE, V18, P278, DOI 10.1038/sj.eye.6700641
   Pomberg ML, 2004, AM J OPHTHALMOL, V138, P125, DOI 10.1016/j.ajo.2004.02.022
   Rosen PN, 2005, J CATARACT REFR SURG, V31, P369, DOI 10.1016/j.jcrs.2004.04.043
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Thompson AM, 2004, BRIT J OPHTHALMOL, V88, P1042, DOI 10.1136/bjo.2003.032581
   Tsai CY, 2007, OPHTHALMOLOGICA, V221, P18, DOI 10.1159/000096517
   Zaidi FH, 2007, BRIT J OPHTHALMOL, V91, P731, DOI 10.1136/bjo.2006.104216
NR 23
TC 4
Z9 4
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2011
VL 95
IS 12
BP 1652
EP 1655
DI 10.1136/bjo.2010.197517
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 851IM
UT WOS:000297261700007
PM 21486741
DA 2022-11-30
ER

PT J
AU Markovets, AM
   Saprunova, VB
   Zhdankina, AA
   Fursova, AZ
   Bakeeva, LE
   Kolosova, NG
AF Markovets, Anton M.
   Saprunova, Valeriya B.
   Zhdankina, Anna A.
   Fursova, Anzhella Zh.
   Bakeeva, Lora E.
   Kolosova, Natalia G.
TI Alterations of retinal pigment epithelium cause AMD-like retinopathy in
   senescent-accelerated OXYS rats
SO AGING-US
LA English
DT Article
DE age-related macular degeneration; OXYS rats; molecular mechanism of
   pathogenesis; vascular endothelial growth factor; pigment
   epithelium-derived factor
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR VEGF EXPRESSION; MACULAR DEGENERATION;
   FACTOR SECRETION; CELLS; CHORIOCAPILLARIS; NEOVASCULARIZATION;
   RECEPTOR-2; SERPIN; PEDF
AB Pathogenesis of age-related macular degeneration (AMD), the leading cause of blindness in the world, remains poorly understood. This makes it necessary to create animal models for studying AMD pathogenesis and to design new therapeutic approaches. Here we showed that retinopathy in OXYS rats is similar to human AMD according to clinical signs, morphology, and vascular endothelium growth factor (VEGF) and pigment epithelium-derived factor (PEDF) genes expression. Clinical signs of retinopathy OXYS rats manifest by the age 3 months against the background of significantly reduced expression level of VEGF and PEDF genes due to the decline of the amount of retinal pigment epithelium (RPE) cells and alteration of choroidal microcirculation. The disruption in OXYS rats' retina starts at the age of 20 days and appears as reduce the area of RPE cells but does not affect their ultrastructure. Ultrastructural pathological alterations of RPE as well as develop forms of retinopathy are observed in OXYS rats from age 12 months and manifested as excessive accumulation of lipofuscin in RPE regions adjacent to the rod cells, whirling extentions of the basement membrane into the cytoplasm. These data suggest that primary cellular degenerative alterations in the RPE cells secondarily lead to choriocapillaris atrophy and results in complete loss of photoreceptor cells in the OXYS rats' retina by the age of 24 months.
C1 [Markovets, Anton M.; Fursova, Anzhella Zh.; Kolosova, Natalia G.] Inst Cytol & Genet SB RAS, Novosibirsk, Russia.
   [Saprunova, Valeriya B.; Bakeeva, Lora E.] Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia.
   [Saprunova, Valeriya B.; Bakeeva, Lora E.; Kolosova, Natalia G.] Moscow MV Lomonosov State Univ, Inst Mitoengn, Moscow, Russia.
   [Zhdankina, Anna A.] Siberian State Med Univ, Tomsk, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Lomonosov Moscow State University; Lomonosov Moscow State
   University; Siberian State Medical University
RP Kolosova, NG (通讯作者)，Inst Cytol & Genet SB RAS, Novosibirsk, Russia.
EM kolosova@bionet.nsc.ru
RI Kolosova, Nataliya G/P-3178-2015; fursova, anzhella/AAE-1495-2022;
   Kolosova, Nataliya G/AAR-7409-2020
OI Kolosova, Nataliya G/0000-0003-2398-8544; fursova,
   anzhella/0000-0001-6311-5452; Kolosova, Nataliya G/0000-0003-2398-8544
FU Presidium of RAS [N 21.13]; RFBR [N 08-04-00722]
FX This work was supported by grants from Presidium of RAS "Fundamental
   Sciences for Medicine" N 21.13 and RFBR N 08-04-00722.
CR Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Filleur S, 2009, J CELL BIOCHEM, V106, P769, DOI 10.1002/jcb.22072
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gusarevich OG, 2007, B SB RAMS, V1, P92
   He Y, 2010, ADV EXP MED BIOL, V664, P165, DOI 10.1007/978-1-4419-1399-9_20
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kolosova NG, 2003, B EXP BIOL MED+, V136, P415, DOI 10.1023/B:BEBM.0000010967.24302.78
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   KORTE GE, 1986, ACTA ANAT, V127, P171
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Obukhova LA, 2009, AGING-US, V1, P389, DOI 10.18632/aging.100043
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Perez-Mediavilla LA, 1998, BBA-GENE STRUCT EXPR, V1398, P203, DOI 10.1016/S0167-4781(98)00055-4
   REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208
   Saprunova VB, 2010, BIOCHEMISTRY-MOSCOW+, V75, P130, DOI 10.1134/S0006297910020021
   Sergeeva S, 2006, EXP GERONTOL, V41, P141, DOI 10.1016/j.exger.2005.10.009
   SOLOVEVA NA, 1975, GENETIKA+, V11, P63
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Steinle JJ, 2008, J GERONTOL A-BIOL, V63, P135, DOI 10.1093/gerona/63.2.135
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Takenaka K, 2005, LIFE SCI, V77, P3231, DOI 10.1016/j.lfs.2005.05.048
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Wang BH, 2010, MICROVASC RES, V80, P31, DOI 10.1016/j.mvr.2010.02.012
   Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
   Zhdankina AA, 2008, B EXP BIOL MED+, V146, P455, DOI 10.1007/s10517-009-0298-4
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 42
TC 51
Z9 58
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JAN
PY 2011
VL 3
IS 1
BP 44
EP 54
PG 11
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 722FS
UT WOS:000287417900012
PM 21191149
DA 2022-11-30
ER

PT J
AU Bernardes, R
   Santos, T
   Cunha-Vaz, J
AF Bernardes, Rui
   Santos, Torcato
   Cunha-Vaz, Jose
TI Increased-resolution OCT thickness mapping of the human macula: A
   statistically based registration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; TYPE-2 DIABETES-MELLITUS; BLOOD-RETINAL
   BARRIER; FOLLOW-UP; EDEMA; RETINOPATHY; TOPOGRAPHY; TEMPLATE; EYES
AB PURPOSE. To describe the development of a technique that enhances spatial resolution of retinal thickness maps of the Stratus OCT (Carl Zeiss Meditec, Inc., Dublin, CA). A retinal thickness atlas (RT-atlas) template was calculated, and a macular coordinate system was established, to pursue this objective.
   METHODS. The RT-atlas was developed from principal component analysis of retinal thickness analyzer (RTA) maps acquired from healthy volunteers. The Stratus OCT radial thickness measurements were registered on the RT-atlas, from which an improved macular thickness map was calculated. Thereafter, Stratus OCT circular scans were registered on the previously calculated map to enhance spatial resolution.
   RESULTS. The developed technique was applied to Stratus OCT thickness data from healthy volunteers and from patients with diabetic retinopathy (DR) or age-related macular degeneration (AMD). Results showed that for normal, or close to normal, macular thickness maps from healthy volunteers and patients with DR, this technique can be an important aid in determining retinal thickness. Efforts are under way to improve the registration of retinal thickness data in patients with AMD.
   CONCLUSIONS. The developed technique enhances the evaluation of data acquired by the Stratus OCT, helping the detection of early retinal thickness abnormalities. Moreover, a normative database of retinal thickness measurements gained from this technique, as referenced to the macular coordinate system, can be created without errors induced by missed fixation and eye tilt.
C1 [Bernardes, Rui; Santos, Torcato; Cunha-Vaz, Jose] AIBILI CNTM, Coimbra, Portugal.
   [Bernardes, Rui] Univ Coimbra, Inst Biofis & Biomatemat, Fac Med, IBILI, Coimbra, Portugal.
   [Cunha-Vaz, Jose] Univ Coimbra, Fac Med, IBILI, Ctr Oftalmol, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra
RP Bernardes, R (通讯作者)，AIBILI IBILI, Azinhaga Sta Comba, P-3000548 Coimbra, Portugal.
EM rcb@aibili.pt
RI Bernardes, Rui/M-4231-2013
OI Bernardes, Rui/0000-0002-6677-2754; Santos, Torcato/0000-0003-1873-4320;
   Cunha-Vaz, Jose/0000-0002-0947-9850
CR Bouma B.E., 2002, HDB OPTICAL COHERENC
   Ciulla T., 2003, RETINA OPTIC NERVE I
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Costa L. da F., 2001, SHAPE ANAL CLASSIFIC
   CUNHAVAZ J, 2002, CONT OPHTHALMOL, V1, P1
   Diedrichsen J, 2006, NEUROIMAGE, V33, P127, DOI 10.1016/j.neuroimage.2006.05.056
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Gieser JP, 1997, AM J OPHTHALMOL, V124, P648, DOI 10.1016/S0002-9394(14)70903-1
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Heitz G, 2005, P SOC PHOTO-OPT INS, V5747, P1411, DOI [10.1117/12.594802, 10.1117/12.59802]
   Jaume S, 2003, IEEE T BIO-MED ENG, V50, P383, DOI 10.1109/TBME.2003.808828
   Joshi S, 2004, NEUROIMAGE, V23, pS151, DOI 10.1016/j.neuroimage.2004.07.068
   Landau D, 1997, OPHTHALMOLOGY, V104, P639, DOI 10.1016/S0161-6420(97)30259-0
   Lobo C, 1999, DOC OPHTHALMOL, V97, P341, DOI 10.1023/A:1002479823690
   Lobo CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P1364
   Lobo CL, 2004, J CATARACT REFR SURG, V30, P752, DOI 10.1016/S0886-3350(03)00582-0
   Lobo CL, 2004, ARCH OPHTHALMOL-CHIC, V122, P211, DOI 10.1001/archopht.122.2.211
   Lobo CL, 2001, ARCH OPHTHALMOL-CHIC, V119, P1469
   PEDUTKLOIZMAN T, 1998, OPHTHALMOL CLIN N AM, V11, P465
   Petrou M., 2003, IMAGE PROCESSING FUN
   Pires I, 2002, ARCH OPHTHALMOL-CHIC, V120, P1301, DOI 10.1001/archopht.120.10.1301
   Polito A, 2002, AM J OPHTHALMOL, V134, P240, DOI 10.1016/S0002-9394(02)01528-3
   Schmitt JM, 1999, IEEE J SEL TOP QUANT, V5, P1205, DOI 10.1109/2944.796348
   SHAHIDI M, 1991, ARCH OPHTHALMOL-CHIC, V109, P1115, DOI 10.1001/archopht.1991.01080080075032
   Strom C, 2002, INVEST OPHTH VIS SCI, V43, P241
   Zeimer R, 1996, INVEST OPHTH VIS SCI, V37, P1994
NR 27
TC 8
Z9 10
U1 1
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2008
VL 49
IS 5
BP 2046
EP 2052
DI 10.1167/iovs.07-0467
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292UH
UT WOS:000255291100041
PM 18436839
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JH
   Yu, YS
   Jun, HO
   Kwon, HJ
   Park, KH
   Kim, KW
AF Kim, Jeong Hun
   Kim, Jin Hyoung
   Yu, Young Suk
   Jun, Hyoung-Oh
   Kwon, Ho Jeong
   Park, Kyu Hyung
   Kim, Kyu-Won
TI Inhibition of choroidal neovascularization by homoisoflavanone, a new
   angiogenesis inhibitor
SO MOLECULAR VISION
LA English
DT Article
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of blindness in elderly. The detailed mechanism of choroidal neovascularization (CNV) leads to severe vision loss in patients with AMD. This study was undertaken to evaluate the inhibitory effect of homoisoflavanone on CNV.
   Methods: Antiangiogenic activity of homoisoflavanone was evaluated by in vitro tube formation assay of human umbilical vein endothelial cells (HUVECs) and cell migration assay of HUVECs., Homoisoflavanone or PBS was injected intravitreously into a mouse model of laser-photocoagulation-induced CNV. Fluorescein angiography and vessel counting in cross sections were employed to examine CNV lesions. The toxicity of homoisoflavanone was evaluated through 3(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT) assay in HUVECs as well as histological examination and terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) staining in the retina.
   Results: Homoisoflavanone effectively inhibited in vitro tube formation and cell migration of HUVECs. Interestingly, homoisoflavanone significantly reduced CNV and its leakage in a mouse model of laser-photocoagulation-induced CNV. In addition, homoisoflavanone showed no effect on cell viability of HUVECs and no retinal toxicity in a concentration range of 1-10 mu M.
   Conclusions: Our data suggest that homoisoflavanone is a potent inhibitor of CNV and may be applied in the treatment of other vasoproliferative retinopathies and tumor.
C1 [Kim, Jeong Hun; Yu, Young Suk; Jun, Hyoung-Oh] Seoul Natl Univ Hosp, Coll Med, Dept Ophthalmol, Seoul 151744, South Korea.
   Seoul Natl Univ Hosp, Seoul Artificial Eye Ctr Clin Res Inst, Seoul 151744, South Korea.
   [Kim, Jin Hyoung; Kim, Kyu-Won] Seoul Natl Univ, Coll Pharm, Neurovasc Coordinat Res Ctr, Seoul, South Korea.
   Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea.
   [Kwon, Ho Jeong] Yonsei Univ, Coll Engn, Dept Biotechnol, Chem Genom Lab, Seoul 120749, South Korea.
   [Park, Kyu Hyung] Bundang Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Yonsei
   University; Seoul National University (SNU); Seoul National University
   Hospital
RP Yu, YS (通讯作者)，Seoul Natl Univ Hosp, Coll Med, Dept Ophthalmol, Seoul 151744, South Korea.
EM ysyu@snu.ac.kr
RI Yu, Young Suk/J-5551-2012; Kim, Jeong Hun/J-2748-2012; Kim, Kyu
   Won/AAJ-7213-2020; Park, Kyu Hyung/J-5481-2012; 권, 호정/AAS-3642-2021
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   KIM JH, 2007, BIOCH BIOPH IN PRESS
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298
   Shim JS, 2004, PLANTA MED, V70, P171, DOI 10.1055/s-2004-815496
NR 10
TC 26
Z9 28
U1 1
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 18
PY 2008
VL 14
IS 68
BP 556
EP 561
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 312II
UT WOS:000256662500001
PM 18385791
DA 2022-11-30
ER

PT J
AU Paik, DC
   Saito, LY
   Sugirtharaj, DD
   Holmes, JW
AF Paik, David C.
   Saito, Lynne Y.
   Sugirtharaj, Dorcas D.
   Holmes, Jeffrey W.
TI Nitrite-induced cross-linking alters remodeling and mechanical
   properties of collagenous engineered tissues
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE age-related macular degeneration; aging; biomechanics; cardiovascular
   diseases; collagen; nitrite; sodium nitrite
ID BRUCHS MEMBRANE; MACULAR DEGENERATION; EXTRACELLULAR-MATRIX;
   NONENZYMATIC GLYCATION; CIGARETTE-SMOKING; SKIN COLLAGEN; AGE; OXIDE;
   PROTEINS; NITRATION
AB Cumulative damage to long-lived connective tissue proteins play a key role in the development of age-related human diseases such as cardiovascular stiffening and age-related macular degeneration. The processes that result in the accumulation of increasingly insoluble, undigestible damaged collagen are only partially known. Nonenzymatic glycation (NEG) is one such process and has been linked to the development of diabetic-related complications and aging. An additional novel mechanism particularly relevant to smoking- and inflammation-related diseases involves the nonenzymatic nitrite (NEN) modification of connective tissue proteins. The present study was undertaken to examine the effects of NEN of fibrillar type I collagen on cell-mediated remodeling and mechanical properties of collagenous tissues. Using a modification of an in vitro fibroblast-populated collagen gel model system developed in our laboratory, we tested two hypotheses: NEN reduces the ability of primary adult cardiac fibroblasts to remodel type I collagen gels; NEN reduces the deformability of type I collagen gels subjected to mechanical testing. The results show that NEN impairs both cell-mediated remodeling and mechanical deformability in collagenous engineered tissues. Furthermore, these mechanical changes correlate with the degree of cross-linking as determined by SDS-PAGE. Thus, we concluded that NEN reactions may contribute to alterations in the biomechanical properties of collagen-containing tissues consistent with the age-related functional decline observed in human disease.
C1 Columbia Univ, Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA.
   Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.
   Columbia Univ, Dept Med, New York, NY 10027 USA.
C3 Columbia University; Columbia University; Columbia University
RP Paik, DC (通讯作者)，Columbia Univ, Coll Phys & Surg, Dept Ophthalmol, 635 W 165th St,Room 840, New York, NY 10032 USA.
EM dcp14@columbia.edu
RI Gaillard, Elizabeth/M-2627-2019
OI Holmes, Jeffrey/0000-0001-9125-7220
FU NHLBI NIH HHS [R01HL075639] Funding Source: Medline; NIA NIH HHS
   [K08AG00863] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTE [R01HL075639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   ON AGING [K08AG000863] Funding Source: NIH RePORTER
CR Ahmed N, 2005, DIABETES RES CLIN PR, V67, P3, DOI 10.1016/j.diabres.2004.09.004
   Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 1981, HLTH EFFECTS NITRATE
   Aronson D, 2003, J HYPERTENS, V21, P3, DOI 10.1097/00004872-200301000-00002
   Bailey AJ, 2001, MECH AGEING DEV, V122, P735, DOI 10.1016/S0047-6374(01)00225-1
   Barocas VH, 1997, J BIOMECH ENG-T ASME, V119, P137, DOI 10.1115/1.2796072
   BATSCHELET E., 1981, CIRCULAR STAT BIOL M
   BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81
   BOGOVSKI P, 1981, INT J CANCER, V27, P471, DOI 10.1002/ijc.2910270408
   BORLAND C, 1987, INT J EPIDEMIOL, V16, P31, DOI 10.1093/ije/16.1.31
   Boutouyrie P, 2002, HYPERTENSION, V39, P10, DOI 10.1161/hy0102.099031
   Boveris A, 2002, FREE RADICAL BIO MED, V33, P1186, DOI 10.1016/S0891-5849(02)01009-2
   Brightman AO, 2000, BIOPOLYMERS, V54, P222
   BROWN PC, 1958, NATURE, V181, P349, DOI 10.1038/181349a0
   BUTKOWSKI RJ, 1982, METHOD ENZYMOL, V82, P410
   Castegna A, 2003, J NEUROCHEM, V85, P1394, DOI 10.1046/j.1471-4159.2003.01786.x
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Costa KD, 2003, TISSUE ENG, V9, P567, DOI 10.1089/107632703768247278
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   Davies C.A., 2001, METHOD MOL BIOL, V225, P305
   Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017
   Dejam A, 2004, BLOOD CELL MOL DIS, V32, P423, DOI 10.1016/j.bcmd.2004.02.002
   DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481
   Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441
   FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676
   FURTHMAYR H, 1971, ANAL BIOCHEM, V41, P510, DOI 10.1016/0003-2697(71)90173-4
   GALLI C, 1988, CHEM REV, V88, P765, DOI 10.1021/cr00087a004
   Girton TS, 2000, J BIOMECH ENG-T ASME, V122, P216, DOI 10.1115/1.429652
   GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401
   HAAGEN-SMIT A J, 1959, AMA Arch Ind Health, V20, P399
   HALLIWELL B, 1993, J ROY SOC HEALTH, V113, P91, DOI 10.1177/146642409311300209
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103
   Karlon WJ, 1998, ANAT RECORD, V252, P612, DOI 10.1002/(SICI)1097-0185(199812)252:4<612::AID-AR12>3.0.CO;2-1
   Karlon WJ, 1999, ANN BIOMED ENG, V27, P712, DOI 10.1114/1.226
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kass DA, 2001, CIRCULATION, V104, P1464, DOI 10.1161/hc3801.097806
   Kass David A, 2002, Heart Fail Rev, V7, P51
   KATO T, 1992, FOOD CHEM TOXICOL, V30, P617, DOI 10.1016/0278-6915(92)90196-R
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Knezevic V, 2002, BIOMECH MODEL MECHAN, V1, P59, DOI 10.1007/s10237-002-0005-0
   KOHN RR, 1984, DIABETES, V33, P57, DOI 10.2337/diabetes.33.1.57
   KOHN RR, 1960, J GERONTOL, V15, P10, DOI 10.1093/geronj/15.1.10
   KUROSKY A, 1972, CAN J BIOCHEM CELL B, V50, P1282, DOI 10.1139/o72-174
   LABELLA FS, 1965, J GERONTOL, V20, P54, DOI 10.1093/geronj/20.1.54
   LAKATTA EG, 1987, J AM COLL CARDIOL, V10, pA42, DOI 10.1016/S0735-1097(87)80447-3
   Lapolla A, 2005, CLIN BIOCHEM, V38, P103, DOI 10.1016/j.clinbiochem.2004.09.007
   Mattace-Raso FUS, 2004, ATHEROSCLEROSIS, V176, P111, DOI 10.1016/j.atherosclerosis.2004.04.014
   MILLER EJ, 1982, METHOD ENZYMOL, V82, P33
   MIYAHARA T, 1982, J GERONTOL, V37, P651, DOI 10.1093/geronj/37.6.651
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   OROURKE M, 1994, J HUM HYPERTENS, V8, pS9
   Paik DC, 1997, CONNECT TISSUE RES, V36, P241, DOI 10.3109/03008209709160224
   Paik DC, 2000, EXP EYE RES, V70, P73, DOI 10.1006/exer.1999.0761
   Paik DC, 2001, CONNECT TISSUE RES, V42, P111, DOI 10.3109/03008200109014253
   Paul RG, 1996, INT J BIOCHEM CELL B, V28, P1297, DOI 10.1016/S1357-2725(96)00079-9
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101
   Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053
   SALVEMINI D, 2001, METHODS MOL BIOLL, V225, P291
   Salvemini Daniela, 2003, Methods Mol Biol, V225, P291
   SELL DR, 1989, J BIOL CHEM, V264, P21597
   Sims TJ, 1996, DIABETOLOGIA, V39, P946
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Szabo C., 2000, NITRIC OXIDE BIOL PA, P841
   Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699
   Thomopoulos S, 2005, J BIOMECH ENG-T ASME, V127, P742, DOI 10.1115/1.1992525
   VALVINI EM, 1995, BRIT J ANAESTH, V74, P338, DOI 10.1093/bja/74.3.338
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617
   VERZAR F, 1956, EXPERIENTIA        S, V4, P35
   Vione D, 2002, ENVIRON SCI TECHNOL, V36, P669, DOI 10.1021/es010101c
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   WENNMALM A, 1993, CIRC RES, V73, P1121, DOI 10.1161/01.RES.73.6.1121
   *WHO, 1997, NITR OX, V188, P88
   WILLIAMS DLH, 1983, ADV PHYS ORG CHEM, V19, P381, DOI 10.1016/S0065-3160(08)60225-7
   Winlove CP, 1996, DIABETOLOGIA, V39, P1131, DOI 10.1007/BF02658498
   Yamamoto K, 2002, CARDIOVASC RES, V55, P76, DOI 10.1016/S0008-6363(02)00341-3
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271
NR 86
TC 19
Z9 22
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300-8207
EI 1607-8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD MAY-JUN
PY 2006
VL 47
IS 3
BP 163
EP 176
DI 10.1080/03008200600721569
PG 14
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Orthopedics
GA 050AE
UT WOS:000238058800008
PM 16753810
DA 2022-11-30
ER

PT J
AU Oner, A
   Karakucuk, S
   Mirza, E
   Erkilic, K
AF Oner, A
   Karakucuk, S
   Mirza, E
   Erkilic, K
TI The changes of pattern electroretinography at the early stage of
   photodynamic therapy
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE pattern electroretinography; photodynamic therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; MULTIFOCAL
   ELECTRORETINOGRAM; VERTEPORFIN
AB Put-pose: To evaluate the short-term changes in pattern electroretinography (PERG) after photodynamic therapy (PDT). Methods: Thirty eyes of 30 patients (17 males, 13 females) with choroidal neovascularization secondary to age related macular degeneration were included in this study. Standard PDT with verteporfin was performed on each patient. Serial PERG recordings were performed before, 1 week, and 1 month after PDT. Results: Mean age of the patients was 69.6 +/- 8.4 years (range 56 and 90 years). One month after PDT, the visual acuity improved in 16 eyes, remained unchanged in 12 eyes and deteriorated in two eyes. New hemorrhages were seen in two eyes in the first week after PDT and visual acuity was decreased in those patients. No other patient complained of ocular and systemic adverse events. There was a statistically significant reduction in the amplitudes of P-50 and N-95 waves at the first week recordings after PDT. At 1 month after PDT, no significant differences in the P-50 and N-95 amplitudes were observed compared with pre-PDT PERG recordings. There were no significant changes in the latencies of P-50 and N-95 at the first week and first month recordings when compared with pre-treatment PERG values. Conclusions: Reduction in P-50 and N-95 amplitudes suggests that transient impairments in macular function occur at the first week after PDT.
C1 Erciyes Univ, Fac Med, Dept Ophthalmol, TR-38039 Kayseri, Turkey.
C3 Erciyes University
RP Oner, A (通讯作者)，Erciyes Univ, Fac Med, Dept Ophthalmol, TR-38039 Kayseri, Turkey.
EM aoner@erciyes.edu.tr
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bach Michael, 2000, Documenta Ophthalmologica, V101, P11
   BERNINGER T, 1991, PRINCIPLES PRACTICE, P291
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Jiang LB, 2003, DOC OPHTHALMOL, V107, P165, DOI 10.1023/A:1026215221569
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Maffei L, 1986, FRONTIERS CLIN NEURO, V3, P101
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Moschos MN, 2003, EUR J OPHTHALMOL, V13, P461, DOI 10.1177/112067210301300507
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Varano M, 2005, INVEST OPHTH VIS SCI, V46, P1453, DOI 10.1167/iovs.04-0903
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
NR 17
TC 12
Z9 13
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD SEP
PY 2005
VL 111
IS 2
BP 107
EP 112
DI 10.1007/s10633-005-4608-5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 032HN
UT WOS:000236765600006
PM 16514492
DA 2022-11-30
ER

PT J
AU Kobayashi, S
   Shinohara, H
   Tsuneki, H
   Nagai, R
   Horiuchi, S
AF Kobayashi, S
   Shinohara, H
   Tsuneki, H
   Nagai, R
   Horiuchi, S
TI N-epsilon-(carboxymethyl)lysine proliferated CD34(+) cells from rat
   choroidal explant in culture
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE N-epsilon-(carboxymethyl)lysine (CML); CD34(+) cell; cultured choroidal
   explant; fibrin gel; endothelial progenitor cell; age-related macular
   degeneration
ID ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS;
   STREPTOZOTOCIN-DIABETIC WISTAR; RETINAL-PIGMENT EPITHELIUM; IN-VITRO;
   MAILLARD REACTION; TUBE FORMATION; MACULAR DEGENERATION; GK RATS;
   ANGIOGENESIS
AB Action of N-epsilon-(carboxymethyl)lysine-human serum albumin (CML-HSA) on neovascularization was investigated in cultured rat choroidal explant. Choroidal explants of normal male Wistar rats were cultured in fibrin gel with Dulbecco's modified Eagle medium containing fetal bovine serum in the presence or absence of CML-HSA. Migrated cells were budded from 2nd day in culture and developed from cultured choroidal explants in a time-dependent manner. Budded and developed cells from the choroidal explant had a feature of fibroblasts, which had attenuated long cytoplasmic processes, long ellipsoid nuclei and numerous membrane-bound polymorphic vesicles. Immunostaining of the attenuated cells in fibrin bed with CD34 (a marker protein of vascular endothelial cells and endothelial progenitor cells) failed to disclose positive result. However the cells which were isolated from fibrin bed by collagenase were specifically stained with anti-CD34 antibody. The isolated cells did not form tube-like structures on collagen gel by 3 weeks in culture. CML-HSA significantly increased the number of total isolated cells and CD34(+) cells as well as the number of vessel-like structures. These results indicate that CML-HSA overproduced immature blood vessels from cultured choroidal explants in fibrin gel, which consisted of CD34(+) cells. The CML-HSA-induced formation of immature blood vessel may be implicated in various choroidal diseases such as age-related macular degeneration.
C1 Hokuriku Univ, Fac Pharmaceut Sci, Dept Pharmacol, Kanazawa, Ishikawa 9201181, Japan.
   Kanazawa Med Univ, Dept Anat, Uchinada, Ishikawa 9200293, Japan.
   Toyama Med & Pharmaceut Univ, Dept Clin Pharmacol, Sugitani, Toyama 9300194, Japan.
   Kumamoto Univ, Grad Sch Med Sci, Dept Med Biochem, Kumamoto 8600811, Japan.
C3 Hokuriku University; Kanazawa Medical University; University of Toyama;
   Kumamoto University
RP Kobayashi, S (通讯作者)，Hokuriku Univ, Fac Pharmaceut Sci, Dept Pharmacol, 3 Ho Kanagawa Machi, Kanazawa, Ishikawa 9201181, Japan.
EM s-kobayashi@hokuriku-u.ac.jp
CR AHMED MU, 1986, J BIOL CHEM, V261, P4889
   ARAKI N, 1992, J BIOL CHEM, V267, P10211
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Ash JD, 2000, DEV BIOL, V223, P383, DOI 10.1006/dbio.2000.9755
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007
   Gehling UM, 2000, BLOOD, V95, P3106
   GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8
   Hagino N, 2004, BRAIN RES BULL, V62, P537, DOI 10.1016/S0361-9230(03)00082-0
   Hammes HP, 1996, LAB INVEST, V75, P325
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harraz M, 2001, STEM CELLS, V19, P304, DOI 10.1634/stemcells.19-4-304
   Hata-Sugi N, 2002, BIOL PHARM BULL, V25, P446, DOI 10.1248/bpb.25.446
   HAYASE F, 1989, J BIOL CHEM, V264, P3758
   HORIUCHI S, 1991, J BIOL CHEM, V266, P7329
   IENAGA K, 1995, CONTRIB NEPHROL, V112, P42
   Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jeong SJ, 2003, BIOL PHARM BULL, V26, P1721, DOI 10.1248/bpb.26.1721
   KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419
   Kimura I, 2000, INT ANGIOL, V19, P26
   Kimura T, 1996, NEUROSCI LETT, V208, P53, DOI 10.1016/0304-3940(96)12537-4
   Kobayashi S, 1996, BIOL PHARM BULL, V19, P1304, DOI 10.1248/bpb.19.1304
   KOBAYASHI S, 1995, BIOL PHARM BULL, V18, P1382, DOI 10.1248/bpb.18.1382
   Kobayashi S, 1998, BIOL PHARM BULL, V21, P346, DOI 10.1248/bpb.21.346
   Kobayashi S, 1999, BIOL PHARM BULL, V22, P360, DOI 10.1248/bpb.22.360
   Kobayashi S, 1998, JPN J PHARMACOL, V78, P471, DOI 10.1254/jjp.78.471
   Kobayashi S, 1996, BIOL PHARM BULL, V19, P199
   Kobayashi S, 1996, IMMUNOPHARMACOLOGY, V35, P171, DOI 10.1016/S0162-3109(96)00143-9
   KONISHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953, DOI 10.1271/bbb.58.1953
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Liang XC, 2002, PHYTOMEDICINE, V9, P377, DOI 10.1078/09447110260571599
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Miyata TR, 1998, KIDNEY INT, V54, P1290, DOI 10.1046/j.1523-1755.1998.00093.x
   Nishikawa S, 1998, DEVELOPMENT, V125, P1747
   Niwa T, 1997, J CLIN INVEST, V99, P1272, DOI 10.1172/JCI119285
   Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327
   Schatteman GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449
   SIMMONS DL, 1992, J IMMUNOL, V148, P267
   SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723
NR 44
TC 7
Z9 7
U1 0
U2 2
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD SEP
PY 2004
VL 27
IS 9
BP 1382
EP 1387
DI 10.1248/bpb.27.1382
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 852JK
UT WOS:000223751400011
PM 15340223
OA Bronze
DA 2022-11-30
ER

PT J
AU Perez-Galvez, A
   Martin, HD
   Sies, H
   Stahl, W
AF Perez-Galvez, A
   Martin, HD
   Sies, H
   Stahl, W
TI Incorporation of carotenoids from paprika oleoresin into human
   chylomicrons
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE bioavailability; paprika carotenoids; xanthophyll esters
ID BETA-CAROTENE; ANTIOXIDANT PROPERTIES; CAPSICUM; LUTEIN;
   BIOAVAILABILITY; XANTHOPHYLLS; CAPSANTHIN; ZEAXANTHIN; INGESTION;
   QUALITY
AB The intake of a carotenoid-rich diet is epidemiologically related to a lower risk for different chronic disorders like cardiovascular disease, some types of cancer or age-related macular degeneration. Red pepper (Capsicum annuum L.) and its dietary products contain a variety of carotenoids, which may contribute to the carotenoid pattern of human blood and tissues. The objective of the present study was to assess the availability of carotenoids from paprika oleoresin, including zeaxanthin, beta-cryptoxanthin, beta-carotene and the paprika-specific oxocarotenoids capsanthin and capsorubin. After overnight fasting, the volunteers (n 9) ingested a single dose of the paprika oleoresin containing 6.4 mg zeaxanthin, 4.2 mg P-cryptoxanthin, 6.2 mg beta-carotene, 35.0 mg capsanthin and 2.0 mg capsorubin. At different time points the carotenoid pattern in the chylomicron fraction was analysed to evaluate carotenoid absorption. From the major carotenoids present in the paprika oleoresin only zeaxanthin, beta-cryptoxanthin and beta-carotene were detectable in considerable amounts. Although the xanthophylls in paprika oleoresin were mainly present as mono- or di-esters, only free zeaxanthin and beta-cryptoxanthin were found in human samples. The bioavailability of the pepper-specific carotenoids capsanthin and capsorubin from paprika oleoresin is very low. However, oleoresin is a suitable source for the provitamin A carotenoids beta-carotene and beta-cryptoxanthin and the macular pigment zeaxanthin.
C1 Univ Dusseldorf, Inst Physiol Chem 1, D-4000 Dusseldorf, Germany.
   Univ Dusseldorf, Inst Organ Chem 1, D-4000 Dusseldorf, Germany.
C3 Heinrich Heine University Dusseldorf; Heinrich Heine University
   Dusseldorf
RP Stahl, W (通讯作者)，Univ Dusseldorf, Inst Physiol Chem 1, Moorenstr 5, D-4000 Dusseldorf, Germany.
EM wilhelm.stahl@uni-duesseldorf.de
RI Sies, Helmut/B-7266-2008; Sies, Helmut/ABE-7355-2020; Wilhelm,
   Stahl/AHB-3164-2022; Pérez-Gálvez, Antonio/I-4573-2015
OI Sies, Helmut/0000-0002-1000-3198; Pérez-Gálvez,
   Antonio/0000-0001-6914-8378
CR Barua AB, 1999, BIOCHEM J, V339, P359, DOI 10.1042/0264-6021:3390359
   Beutner S, 2001, J SCI FOOD AGR, V81, P559, DOI 10.1002/jsfa.849
   Breithaupt DE, 2002, COMP BIOCHEM PHYS B, V132, P721, DOI 10.1016/S1096-4959(02)00096-9
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   CAMARA B, 1978, PHYTOCHEMISTRY, V17, P91, DOI 10.1016/S0031-9422(00)89686-7
   CURL AL, 1962, J AGR FOOD CHEM, V10, P504, DOI 10.1021/jf60124a020
   DAVIES BH, 1970, PHYTOCHEMISTRY, V9, P797, DOI 10.1016/S0031-9422(00)85183-3
   EUGSTER CH, 1995, CAROTENOIDS A, V1, P76
   Gartner C, 1996, INT J VITAM NUTR RES, V66, P119
   GOVINDARAJAN VS, 1986, CRIT REV FOOD SCI, V23, P207, DOI 10.1080/10408398609527426
   Granado F, 1998, BRIT J NUTR, V80, P445, DOI 10.1017/S0007114598001512
   Hof KHV, 2000, J NUTR, V130, P503
   King TJ, 1997, PURE APPL CHEM, V69, P2135, DOI 10.1351/pac199769102135
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Martin HD, 1999, J PRAK CHEM-CHEM ZTG, V341, P302, DOI 10.1002/(SICI)1521-3897(199904)341:3<302::AID-PRAC302>3.3.CO;2-Y
   Minguez-Mosquera MI, 1998, J AGR FOOD CHEM, V46, P5124, DOI 10.1021/jf980728n
   MINGUEZMOSQUERA MI, 1994, J AGR FOOD CHEM, V42, P640, DOI 10.1021/jf00039a007
   MINGUEZMOSQUERA MI, 1993, J AGR FOOD CHEM, V41, P1616, DOI 10.1021/jf00034a018
   Mosquera MIM, 1998, J AGR FOOD CHEM, V46, P566, DOI 10.1021/jf970632d
   Oshima S, 1997, J NUTR, V127, P1475, DOI 10.1093/jn/127.8.1475
   Parker RS, 1997, EUR J CLIN NUTR, V51, pS86
   Perez-Galvez A, 2002, BBA-GEN SUBJECTS, V1569, P31, DOI 10.1016/S0304-4165(01)00229-X
   PHILIP T, 1971, J FOOD SCI, V36, P98, DOI 10.1111/j.1365-2621.1971.tb02045.x
   Stahl W, 2002, BIOL CHEM, V383, P553, DOI 10.1515/BC.2002.056
   Stahl W, 2002, MOL ASPECTS MED, V23, P39, DOI 10.1016/S0098-2997(02)00016-X
   TERAO J, 1989, LIPIDS, V24, P659, DOI 10.1007/BF02535085
   TERPSTRA AHM, 1985, ANAL BIOCHEM, V150, P221, DOI 10.1016/0003-2697(85)90462-2
   van den Berg H, 1998, AM J CLIN NUTR, V68, P82, DOI 10.1093/ajcn/68.1.82
   Wingerath T, 1995, ARCH BIOCHEM BIOPHYS, V324, P385, DOI 10.1006/abbi.1995.0052
NR 29
TC 72
Z9 80
U1 0
U2 12
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JUN
PY 2003
VL 89
IS 6
BP 787
EP 793
DI 10.1079/BJN2003842
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 693NT
UT WOS:000183724200005
PM 12828795
OA Bronze
DA 2022-11-30
ER

PT J
AU Kim, JE
   Tomkins-Netzer, O
   Elman, MJ
   Lally, DR
   Goldstein, M
   Goldenberg, D
   Shulman, S
   Benyamini, G
   Loewenstein, A
AF Kim, Judy E.
   Tomkins-Netzer, Oren
   Elman, Michael J.
   Lally, David R.
   Goldstein, Michaella
   Goldenberg, Dafna
   Shulman, Shiri
   Benyamini, Gidi
   Loewenstein, Anat
TI Evaluation of a self-imaging SD-OCT system designed for remote home
   monitoring
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; HOME OCT; Home monitoring
ID TREAT-AND-EXTEND; MACULAR DEGENERATION; RETINAL FLUID
AB Purpose To compare identification rates of retinal fluid of the Notal Vision Home Optical Coherence Tomography (OCT) device (NVHO) when used by people with age-related macular degeneration (AMD) to those captured by a commercial OCT. Methods Prospective, cross-sectional study where patients underwent commercial OCT imaging followed by self-imaging with either the NVHO 2.5 or the NVHO 3 in clinic setting. Outcomes included patients' ability to acquire analyzable OCT images with the NVHO and to compare those with commercial images. Results Successful images were acquired with the NVHO 2.5 in 469/531 eyes (88%) in 264/290 subjects (91%) with the mean (SD) age of 78.8 (8.8); 153 (58%) were female with median visual acuity (VA) of 20/40. In the NVHO 3 cohort, 69 eyes of 45 subjects (93%) completed the self-imaging. Higher rates of successful imaging were found in eyes with VA >= 20/320. Positive percent agreement/negative percent agreement for detecting the presence of subretinal and/or intraretinal fluid when reviewing for fluid in three repeated volume scans were 97%/95%, respectively for the NVHO v3. Conclusion Self-testing with the NVHO can produce high quality images suitable for fluid identification by human graders, suggesting the device may be able to complement standard-of-care clinical assessments and treatments.
C1 [Kim, Judy E.] Med Coll Wisconsin, Eye Inst, 925 N 87th St, Milwaukee, WI 53226 USA.
   [Tomkins-Netzer, Oren] Technion, Ruth & Bruce Rappaport Fac Med, Lady Davis Carmel Med Ctr, Dept Ophthalmol, Haifa, Israel.
   [Elman, Michael J.] Elman Retina Grp PA, Baltimore, MD USA.
   [Lally, David R.] New England Retina Consultants, Retina Res Inst, Springfield, MA USA.
   [Goldstein, Michaella; Loewenstein, Anat] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel.
   [Goldenberg, Dafna; Shulman, Shiri] Assuta Med Ctr, Tel Aviv, Israel.
   [Benyamini, Gidi] Notal Vis, Tel Aviv, Israel.
C3 Medical College of Wisconsin; Clalit Health Services; Carmel Medical
   Center; Technion Israel Institute of Technology; Rappaport Faculty of
   Medicine; Tel Aviv University; Sackler Faculty of Medicine
RP Kim, JE (通讯作者)，Med Coll Wisconsin, Eye Inst, 925 N 87th St, Milwaukee, WI 53226 USA.
EM jekim@mcw.edu; oren.tomkins@gmail.com; elman@elmanretina.com;
   david.lally@neretina.com; michaellag@tlvmc.gov.il;
   dafnagoldenberg@gmail.com; shirishu@assuta.co.il; gidi@notalvision.com;
   anatl@tlvmc.gov.il
FU Notal Vision Ltd.; Tel Aviv, Israel
FX This was a company-sponsored clinical study, sponsored by Notal Vision
   Ltd. Tel Aviv, Israel.
CR Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Goldstein M., AAO 2019 SAN FRANC C
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Keenan TDL, 2021, AM J OPHTHALMOL, V224, P267, DOI 10.1016/j.ajo.2020.12.012
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mulligan K, 2020, JAMA OPHTHALMOL, V138, P40, DOI 10.1001/jamaophthalmol.2019.4557
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   von der Burchard C, 2021, GRAEF ARCH CLIN EXP, V259, P1503, DOI 10.1007/s00417-020-05035-6
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
NR 17
TC 1
Z9 1
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 10
PY 2022
VL 22
IS 1
AR 261
DI 10.1186/s12886-022-02458-z
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2A2MC
UT WOS:000809340900001
PM 35689210
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Saada, J
   McAuley, RJ
   Marcatti, M
   Tang, TZ
   Motamedi, M
   Szczesny, B
AF Saada, Jamal
   McAuley, Ryan J.
   Marcatti, Michela
   Tang, Tony Zifeng
   Motamedi, Massoud
   Szczesny, Bartosz
TI Oxidative stress induces Z-DNA-binding protein 1-dependent activation of
   microglia via mtDNA released from retinal pigment epithelial cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MITOCHONDRIAL-DNA; INFLAMMASOME ACTIVATION; RETINITIS-PIGMENTOSA; NLRP3
   INFLAMMASOME; GLUCOSE-OXIDASE; LIGASE III; DAMAGE; REPAIR; EXPRESSION;
   MECHANISM
AB Oxidative stress, inflammation, and aberrant activation of microglia in the retina are commonly observed in ocular pathologies. In glaucoma or age-related macular degeneration, the chronic activation of microglia affects retinal ganglion cells and photoreceptors, respectively, contributing to gradual vision loss. However, the molecular mechanisms that cause activation of microglia in the retina are not fully understood. Here we show that exposure of retinal pigment epithelial (RPE) cells to (mtDNA)-specific damage, and the subsequent translocation of damaged mtDNA to the cytoplasm results in the binding and activation of intracellular DNA receptor Z-DNA-binding protein 1 (ZBP1). Activation of the mtDNA/ZBP1 pathway triggers the expression of proinflammatory markers in RPE cells. In addition, we show that the enhanced release of extracellular vesicles (EVs) containing fragments of mtDNA derived from the apical site of RPE cells induces a proinflammatory phenotype of microglia via activation of ZBP1 signaling. Collectively, our report establishes oxidatively damaged mtDNA as an important signaling molecule with ZBP1 as its intracellular receptor in the development of an inflammatory response in the retina. We propose that this novel mtDNA-mediated autocrine and paracrine mechanism for triggering and maintaining inflammation in the retina may play an important role in ocular pathologies. Therefore, the molecular mechanisms identified in this report are potentially suitable therapeutic targets to ameliorate development of ocular pathologies.
C1 [Saada, Jamal; Motamedi, Massoud; Szczesny, Bartosz] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
   [Saada, Jamal; Marcatti, Michela; Szczesny, Bartosz] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA.
   [McAuley, Ryan J.; Tang, Tony Zifeng] Univ Texas Med Branch, Dept Neurosci Cell Biol & Anat, Galveston, TX 77555 USA.
   [Marcatti, Michela] Univ Texas Med Branch, Dept Neurol, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; University of Texas System; University of Texas Medical
   Branch Galveston; University of Texas System; University of Texas
   Medical Branch Galveston; University of Texas System; University of
   Texas Medical Branch Galveston
RP Szczesny, B (通讯作者)，Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.; Szczesny, B (通讯作者)，Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA.
EM baszczes@utmb.edu
OI MARCATTI, MICHELA/0000-0003-1921-4626; McAuley, Ryan/0000-0001-9857-4050
FU National Science Foundation (NSF) [1804422, 1933321]; NSF [2136421];
   Department of Ophthalmology and Visual Sciences, UTMB; NIEHS
   [T32ES007254]
FX This work was supported by a grant from the National Science Foundation
   (NSF) Project 1804422 and 1933321 (to M. M.), and NSF 2136421 and
   start-up funds from the Department of Ophthalmology and Visual Sciences,
   UTMB (to B. S.). R. J. M. was supported by the NIEHS T32ES007254
   Training Grant.
CR Arnoult D, 2011, EMBO REP, V12, P901, DOI 10.1038/embor.2011.157
   Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Brunyanszki A, 2014, MOL PHARMACOL, V86, P450, DOI 10.1124/mol.114.094318
   Caceres PS, 2020, CURR OPIN CELL BIOL, V62, P37, DOI 10.1016/j.ceb.2019.08.001
   CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777
   Devos M, 2020, J EXP MED, V217, DOI 10.1084/jem.20191913
   Durkin Marian E, 2013, Bio Protoc, V3
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Furda AM, 2012, DNA REPAIR, V11, P684, DOI 10.1016/j.dnarep.2012.06.002
   Gao YK, 2011, NATURE, V471, P240, DOI 10.1038/nature09773
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Jiao HP, 2020, NATURE, V580, P391, DOI 10.1038/s41586-020-2129-8
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kaiser WJ, 2008, J IMMUNOL, V181, P6427, DOI 10.4049/jimmunol.181.9.6427
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Kong YXG, 2011, AGING CELL, V10, P572, DOI 10.1111/j.1474-9726.2011.00690.x
   Krasich R, 2017, FRONT BIOSCI-LANDMRK, V22, P692, DOI 10.2741/4510
   Kukat C, 2015, P NATL ACAD SCI USA, V112, P11288, DOI 10.1073/pnas.1512131112
   Kuriakose T, 2018, TRENDS IMMUNOL, V39, P123, DOI 10.1016/j.it.2017.11.002
   Kuriakose T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag2045
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Malireddi RKS, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00406
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Momen-Heravi F, 2017, METHODS MOL BIOL, V1660, P25, DOI 10.1007/978-1-4939-7253-1_3
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pesole G, 1999, J MOL EVOL, V48, P427, DOI 10.1007/PL00006487
   Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1716, DOI 10.1167/iovs.02-0287
   Rai P, 2021, NAT IMMUNOL, V22, P312, DOI 10.1038/s41590-020-00859-0
   Rashid Khalid, 2019, Front Immunol, V10, P1975, DOI 10.3389/fimmu.2019.01975
   Rongvaux A, 2014, CELL, V159, P1563, DOI 10.1016/j.cell.2014.11.037
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Salazar JJ, 1997, MUTAT RES-DNA REPAIR, V385, P139, DOI 10.1016/S0921-8777(97)00047-5
   Samuel W, 2017, MOL VIS, V23, P60
   Sanders LH, 2014, NEUROBIOL DIS, V70, P214, DOI 10.1016/j.nbd.2014.06.014
   Santos Janine H, 2006, Methods Mol Biol, V314, P183
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Simsek D, 2011, NATURE, V471, P245, DOI 10.1038/nature09794
   Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947
   Sprenger HG, 2021, NAT METAB, V3, P636, DOI 10.1038/s42255-021-00385-9
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Szczesny B, 2003, P NATL ACAD SCI USA, V100, P10670, DOI 10.1073/pnas.1932854100
   Szczesny B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19216-1
   Szczesny B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143730
   Szczesny B, 2014, NUCLEIC ACIDS RES, V42, P13161, DOI 10.1093/nar/gku1089
   Szczesny B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075201
   Szczesny B, 2010, MECH AGEING DEV, V131, P330, DOI 10.1016/j.mad.2010.03.009
   Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thapa RJ, 2016, CELL HOST MICROBE, V20, P674, DOI 10.1016/j.chom.2016.09.014
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   van der Merwe Yolandi, 2017, Curr Ophthalmol Rep, V5, P276, DOI 10.1007/s40135-017-0153-0
   Wang AL, 2010, NEUROBIOL AGING, V31, P2002, DOI 10.1016/j.neurobiolaging.2008.10.019
   Wang RC, 2020, NATURE, V580, P386, DOI 10.1038/s41586-020-2127-x
   West AP, 2017, NAT REV IMMUNOL, V17, P363, DOI 10.1038/nri.2017.21
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
   White MJ, 2014, CELL, V159, P1549, DOI 10.1016/j.cell.2014.11.036
   Wong CM, 2008, APPL MICROBIOL BIOT, V78, P927, DOI 10.1007/s00253-008-1407-4
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
NR 77
TC 3
Z9 3
U1 2
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN
PY 2022
VL 298
IS 1
AR 101523
DI 10.1016/j.jbc.2021.101523
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA YO9TC
UT WOS:000748274300003
PM 34953858
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Weng, CC
   Lin, TY
   Yang, YP
   Hsiao, YJ
   Lin, TW
   Lai, WY
   Lin, YY
   Chou, YB
   Lin, TC
   Chiou, SH
   Hwang, DK
   Chen, SJ
AF Weng, Chang-Chi
   Lin, Ting-Yi
   Yang, Yi-Ping
   Hsiao, Yu-Jer
   Lin, Tzu-Wei
   Lai, Wei-Yi
   Lin, Yi-Ying
   Chou, Yu-Bai
   Lin, Tai-Chi
   Chiou, Shih-Hwa
   Hwang, De-Kuang
   Chen, Shih-Jen
TI Modifications of intravitreal injections in response to the COVID-19
   pandemic
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Review
DE Anti-vascular endothelial growth factor; Coronavirus; COVID;
   Intravitreal injection; Macular; Retina
ID MACULAR DEGENERATION; EXPERIENCE; MANAGEMENT; THERAPY
AB The Coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented disruption to the normal operation of the healthcare system. On a worldwide scale, hospitals suspended nonurgent surgeries and outpatient visits to downsize clinical loadings to redistribute manpower to counteract the pandemic's impact. So far, there is no evidence-based guideline defining a clear line between urgent and nonurgent indications of intravitreal injections (IVI). Herein, we aimed to summarize IVI algorithm modifications and discuss the patient prioritization according to medical needs in the hostile environment in the COVID crisis. Assessing current literature, we found that neovascular age-related macular degeneration is considered the utmost priority among conditions that require IVI. Other conditions assigned with a high priority include monocular or quasi-monocular patients (only one eye > 20/40), neovascular glaucoma, and new patients with significant vision loss. Although patients with central retinal vein occlusion and proliferative diabetic retinopathy are not advised to delay treatments, we found no consistent evidence that correlated with a worse outcome. Diabetic macular edema and branch retinal vein occlusion patients undertaking treatment delay should be regularly followed up every 2 to 3 months. Serving as the principle of management behind the algorithm modifications, the reduction of both patient visit and IVI therapy counts should be reckoned together with the risk of permanent visual loss and COVID infection.
C1 [Weng, Chang-Chi; Chou, Yu-Bai; Lin, Tai-Chi; Chiou, Shih-Hwa; Hwang, De-Kuang; Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Section 2,Shi Pai Rd, Taipei 112, Taiwan.
   [Lin, Ting-Yi; Yang, Yi-Ping; Hsiao, Yu-Jer; Lin, Tzu-Wei; Lai, Wei-Yi; Lin, Yi-Ying; Chou, Yu-Bai; Lin, Tai-Chi; Chiou, Shih-Hwa; Hwang, De-Kuang; Chen, Shih-Jen] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan.
   [Lin, Ting-Yi; Yang, Yi-Ping; Hsiao, Yu-Jer; Lin, Tzu-Wei; Lai, Wei-Yi; Lin, Yi-Ying; Chiou, Shih-Hwa] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; Taipei Veterans General Hospital
RP Hwang, DK; Chen, SJ (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Section 2,Shi Pai Rd, Taipei 112, Taiwan.; Hwang, DK; Chen, SJ (通讯作者)，Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan.
EM m95gbk@gmail.com; sjchen96@gmail.com
RI Hwang, DK De-Kuang/J-3931-2016
OI Hwang, DK De-Kuang/0000-0001-6346-8485; Weng,
   Chang-Chi/0000-0003-2178-5612
CR American Academy of Ophthalmology, 2020, REC URG NON PAT CAR
   American Society of Retina Specialists, 2020, COVID 19 UPD RES
   Antaki F, 2020, GRAEF ARCH CLIN EXP, V258, P1567, DOI 10.1007/s00417-020-04693-w
   Ashkenazy N, 2021, CLIN OPHTHALMOL, V15, P413, DOI 10.2147/OPTH.S296345
   Au SCL, 2020, INDIAN J OPHTHALMOL, V68, P2314, DOI 10.4103/ijo.IJO_1799_20
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Boyd MJ, 2020, CLIN EXP OPHTHALMOL, V48, P1276, DOI 10.1111/ceo.13855
   Carnevali A, 2021, EUR J OPHTHALMOL, V31, P10, DOI 10.1177/1120672120962032
   Chaurasia S, 2020, INDIAN J OPHTHALMOL, V68, P1215, DOI 10.4103/ijo.IJO_1033_20
   Comune C, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420966861
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   de Gage SB, 2021, JAMA OPHTHALMOL, V139, P240, DOI 10.1001/jamaophthalmol.2020.5594
   Denys P, 2022, EUR J OPHTHALMOL, V32, P372, DOI 10.1177/11206721211003488
   Elfalah M, 2021, CLIN OPHTHALMOL, V15, P661, DOI 10.2147/OPTH.S289068
   Fung THM, 2021, ACTA OPHTHALMOL, V99, pE285, DOI 10.1111/aos.14520
   Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539
   Groppe M, 2021, CLIN OPHTHALMOL, V15, P651, DOI 10.2147/OPTH.S269596
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Iovino C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.670468
   Korobelnik JF, 2021, GRAEF ARCH CLIN EXP, V259, P567, DOI 10.1007/s00417-021-05097-0
   Korobelnik JF, 2021, GRAEF ARCH CLIN EXP, V259, P795, DOI 10.1007/s00417-020-05042-7
   Mintz J, 2022, J TELEMED TELECARE, V28, P670, DOI 10.1177/1357633X20960636
   Moussa M, 2021, INT OPHTHALMOL, V41, P1437, DOI 10.1007/s10792-021-01719-y
   Naravane AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247161
   Royal Australian and New Zealand College of Ophthalmologists, 2020, RANZCO NZ BRANCH GUI
   Rozon JP, 2021, CLIN OPHTHALMOL, V15, P1153, DOI 10.2147/OPTH.S300239
   Saedon H, 2020, OPHTHALMOL THER, V9, P401, DOI 10.1007/s40123-020-00262-w
   Saleh OA, 2020, CLIN OPHTHALMOL, V14, P2473, DOI 10.2147/OPTH.S269179
   Shmueli O, 2020, EYE, V34, P1165, DOI 10.1038/s41433-020-0925-x
   Sindal MD, 2021, INDIAN J OPHTHALMOL, V69, P730, DOI 10.4103/ijo.IJO_2807_20
   Stone LG, 2021, GRAEF ARCH CLIN EXP, V259, P1773, DOI 10.1007/s00417-021-05174-4
   The Royal College of Ophthalmologists, 2020, MED RET MAN PLANS CO
   Viola F, 2021, RETINA-J RET VIT DIS, V41, P701, DOI 10.1097/IAE.0000000000002941
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Yang KB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.576275
   Yeter DY, 2021, J FR OPHTALMOL, V44, P299, DOI 10.1016/j.jfo.2021.02.001
   Zucchiatti I., 2020, EUR J OPHTHALMOL, V7
NR 37
TC 3
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD SEP
PY 2021
VL 84
IS 9
BP 827
EP 832
DI 10.1097/JCMA.0000000000000588
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA UM5OI
UT WOS:000693379600005
PM 34292208
OA hybrid
DA 2022-11-30
ER

PT J
AU Alshaikh, RA
   Ryan, KB
   Waeber, C
AF Alshaikh, Rasha A.
   Ryan, Katie B.
   Waeber, Christian
TI Sphingosine 1-phosphate, a potential target in neovascular retinal
   disease
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE angiogenesis; degeneration; inflammation; neovascularisation;
   pharmacology
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; MACULAR
   DEGENERATION; OPTIC-NERVE; SPHINGOSINE-1-PHOSPHATE RECEPTOR-2;
   GLIAL-CELLS; MOUSE MODEL; FACTOR-BETA; ANGIOGENESIS; KINASE
AB Neovascular ocular diseases (such as age-related macular degeneration, diabetic retinopathy and retinal vein occlusion) are characterised by common pathological processes that contribute to disease progression. These include angiogenesis, oedema, inflammation, cell death and fibrosis. Currently available therapies target the effects of vascular endothelial growth factor (VEGF), the main mediator of pathological angiogenesis. Unfortunately, VEGF blockers are expensive biological therapeutics that necessitate frequent intravitreal administration and are associated with multiple adverse effects. Thus, alternative treatment options associated with fewer side effects are required for disease management. This review introduces sphingosine 1-phosphate (S1P) as a potential pharmacological target for the treatment of neovascular ocular pathologies. S1P is a sphingolipid mediator that controls cellular growth, differentiation, survival and death. S1P actions are mediated by five G protein-coupled receptors (S1P(1-5) receptors) which are abundantly expressed in all retinal and subretinal structures. The action of S1P on S1P(1) receptors can reduce angiogenesis, increase endothelium integrity, reduce photoreceptor apoptosis and protect the retina against neurodegeneration. Conversely, S1P(2) receptor signalling can increase neovascularisation, disrupt endothelial junctions, stimulate VEGF release, and induce retinal cell apoptosis and degeneration of neural retina. The aim of this review is to thoroughly discuss the role of S1P and its different receptor subtypes in angiogenesis, inflammation, apoptosis and fibrosis in order to determine which of these S1P-mediated processes may be targeted therapeutically.
C1 [Alshaikh, Rasha A.; Ryan, Katie B.; Waeber, Christian] Univ Coll Cork, Sch Pharm, Cork, Ireland.
   [Alshaikh, Rasha A.] Tanta Univ, Dept Pharmaceut Technol, Tanta, Egypt.
   [Ryan, Katie B.] Univ Coll Cork, SSPC SFI Res Ctr Pharmaceut, Sch Pharm, Cork, Ireland.
   [Waeber, Christian] Univ Coll Cork, Dept Pharmacol & Therapeut, Cork, Ireland.
C3 University College Cork; Egyptian Knowledge Bank (EKB); Tanta
   University; University College Cork; University College Cork
RP Waeber, C (通讯作者)，Univ Coll Cork, Sch Pharm, Cork, Ireland.
EM c.waeber@ucc.ie
RI ; Waeber, Christian/A-8333-2009
OI Alshaikh, Rasha/0000-0003-2747-5084; Waeber,
   Christian/0000-0001-6078-0027; Ryan, Katie/0000-0002-6236-2977
FU Irish Research Council (IRC)
FX This work was funded by the Irish Research Council (IRC).
CR Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   Abrahan CE, 2009, J NEUROSCI RES, V87, P964, DOI 10.1002/jnr.21903
   Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bigaud M, 2014, BBA-MOL CELL BIOL L, V1841, P745, DOI 10.1016/j.bbalip.2013.11.001
   Blanco R, 2017, EXP EYE RES, V164, P37, DOI 10.1016/j.exer.2017.08.005
   Brinkmann V, 2007, PHARMACOL THERAPEUT, V115, P84, DOI 10.1016/j.pharmthera.2007.04.006
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cartier A, 2020, P NATL ACAD SCI USA, V117, P3157, DOI 10.1073/pnas.1906246117
   Chen H, 2014, SURV OPHTHALMOL, V59, P64, DOI 10.1016/j.survophthal.2013.02.005
   Chew WS, 2016, PHARMACOL RES, V113, P521, DOI 10.1016/j.phrs.2016.09.025
   Commodaro AG, 2010, INVEST OPHTH VIS SCI, V51, P2568, DOI 10.1167/iovs.09-4769
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   Cuvillier O, 2013, ADV CANCER RES, V117, P117, DOI 10.1016/B978-0-12-394274-6.00005-4
   Dan-Brezis I, 2020, ACTA OPHTHALMOL, V98, pE559, DOI 10.1111/aos.14331
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   DeCroos Francis Char, 2014, J Ophthalmic Vis Res, V9, P461, DOI 10.4103/2008-322X.150825
   dell'Omo R, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/935301
   Derfuss T, 2020, LANCET NEUROL, V19, P336, DOI 10.1016/S1474-4422(19)30391-6
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Eresch J, 2018, INVEST OPHTH VIS SCI, V59, P653, DOI 10.1167/iovs.17-22544
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fan JW, 2020, THERANOSTICS, V10, P7956, DOI 10.7150/thno.45192
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Gaengel K, 2012, DEV CELL, V23, P587, DOI 10.1016/j.devcel.2012.08.005
   Gantner ML, 2019, NEW ENGL J MED, V381, P1422, DOI 10.1056/NEJMoa1815111
   Gault Christopher R, 2010, Adv Exp Med Biol, V688, P1
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerritsen ME, 2008, HANDBOOK OF PHYSIOLOGY: MICROCIRCULATION, 2ND EDITION, P351
   Guidry C, 2005, PROG RETIN EYE RES, V24, P75, DOI 10.1016/j.preteyeres.2004.07.001
   Hughes, 2013, BRENNERS ENCY GENETI, P30
   Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100
   Inoki I, 2006, BIOCHEM BIOPH RES CO, V346, P293, DOI 10.1016/j.bbrc.2006.05.119
   Jain N, 2012, NEUROLOGY, V78, P672, DOI 10.1212/WNL.0b013e318248deea
   Joly S, 2016, J NEUROCHEM, V138, P571, DOI 10.1111/jnc.13701
   Jung B, 2012, DEV CELL, V23, P600, DOI 10.1016/j.devcel.2012.07.015
   Kanamori A, 2004, CURR EYE RES, V28, P47, DOI 10.1076/ceyr.28.1.47.23487
   Kendall RT, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00123
   Kita T, 2007, DIABETES, V56, P231, DOI 10.2337/db06-0581
   Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7
   Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Lee JF, 2009, AM J PHYSIOL-HEART C, V296, pH33, DOI 10.1152/ajpheart.00097.2008
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Lukowski ZL, 2013, J GLAUCOMA, V22, P145, DOI 10.1097/IJG.0b013e31822e8c83
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x
   Maines LW, 2006, INVEST OPHTH VIS SCI, V47, P5022, DOI 10.1167/iovs.05-1236
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Meleth AD, 2005, INVEST OPHTH VIS SCI, V46, P4295, DOI 10.1167/iovs.04-1057
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Miranda GE, 2009, INVEST OPHTH VIS SCI, V50, P4416, DOI 10.1167/iovs.09-3388
   Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005
   Norgaard TL, 2020, BASIC CLIN PHARMACOL, V126, P492, DOI 10.1111/bcpt.13381
   Obinata H, 2019, J LIPID RES, V60, P1912, DOI 10.1194/jlr.RA119000277
   Osborne NN, 2004, EYE, V18, P1075, DOI 10.1038/sj.eye.6701588
   Oyama O, 2008, CARDIOVASC RES, V78, P301, DOI 10.1093/cvr/cvn002
   Panova IG, 2017, B EXP BIOL MED+, V162, P629, DOI 10.1007/s10517-017-3673-6
   Park SH, 2003, DIABETOLOGIA, V46, P1260, DOI 10.1007/s00125-003-1177-6
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Penno A, 2010, J BIOL CHEM, V285, P11178, DOI 10.1074/jbc.M109.092973
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Porter H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123885
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   Proia RL, 2015, J CLIN INVEST, V125, P1379, DOI 10.1172/JCI76369
   Purves D, 2001, NEUROSCIENCE, V2 nd
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Qiao YB, 2012, INVEST OPHTH VIS SCI, V53, P8200, DOI 10.1167/iovs.12-10965
   Raveney BJE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1390, DOI 10.1001/archopht.126.10.1390
   Ren SY, 2009, KIDNEY INT, V76, P857, DOI 10.1038/ki.2009.297
   Rezzola S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581288
   RIVERA J, 2017, OXID MED CELL LONGEV, V2017, P1, DOI DOI 10.1155/2017/3940241
   Rizzolo LJ, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P19, DOI 10.1007/978-3-030-28384-1_2
   Roy S, 2016, EXP EYE RES, V142, P71, DOI 10.1016/j.exer.2015.04.004
   Salomone S, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00009
   Sanchez T, 2007, ARTERIOSCL THROM VAS, V27, P1312, DOI 10.1161/ATVBAHA.107.143735
   Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804
   Sawyer DB, 2018, ENCY CARDIOVASCULAR, P85
   Simon MV, 2015, INVEST OPHTH VIS SCI, V56, P5808, DOI 10.1167/iovs.14-16195
   Skoura A, 2007, J CLIN INVEST, V117, P2506, DOI 10.1172/JCI31123
   Sonne SJ, 2020, J OPHTHALMIC INFLAMM, V10, DOI 10.1186/s12348-020-00215-1
   Spiegel, 2013, LYSOPHOSPHOLIPID REC, P313, DOI DOI 10.1002/9781118531426.CH15
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Sugano E, 2019, J LIPID RES, V60, P30, DOI 10.1194/jlr.M082198
   Swaney JS, 2008, EXP EYE RES, V87, P367, DOI 10.1016/j.exer.2008.07.005
   Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200
   Terao R, 2019, PROSTAG OTH LIPID M, V145, DOI 10.1016/j.prostaglandins.2019.106365
   Terao R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153670
   Terao R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010112
   Toman RE, 2004, J CELL BIOL, V166, P381, DOI 10.1083/jcb.200402016
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Victoria Simon M, 2021, J Lipid Res, P100037, DOI 10.1194/jlr.TR120000972
   Simon MV, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00246
   Volzke A, 2014, BBA-MOL CELL BIOL L, V1841, P11, DOI 10.1016/j.bbalip.2013.09.009
   Voigt AP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020438
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/724648
   WHO, 2019, WORLD REP VIS
   Wu YP, 2008, HUM MOL GENET, V17, P2257, DOI 10.1093/hmg/ddn126
   Xiao W, 2014, J CELL MOL MED, V18, P646, DOI 10.1111/jcmm.12212
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xin CY, 2004, J BIOL CHEM, V279, P35255, DOI 10.1074/jbc.M312091200
   Xu Hui-Zhuo, 2011, J Ocul Biol Dis Infor, V4, P83, DOI 10.1007/s12177-011-9068-4
   Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200
   Yanagida K, 2020, DEV CELL, V52, P779, DOI 10.1016/j.devcel.2020.01.016
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Yoshida S, 2015, BRIT J OPHTHALMOL, V99, P960, DOI 10.1136/bjophthalmol-2014-306366
   Yoshimura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008158
   Yoshino O, 2019, REPROD SCI, V26, P1460, DOI 10.1177/1933719119828112
   Young MM, 2013, J LIPID RES, V54, P5, DOI 10.1194/jlr.R031278
   Zafar S, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1134-5
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
NR 120
TC 0
Z9 0
U1 3
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2022
VL 106
IS 9
BP 1187
EP 1195
DI 10.1136/bjophthalmol-2021-319115
EA MAY 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4D0ZF
UT WOS:000726952200001
PM 33962970
DA 2022-11-30
ER

PT J
AU Elliott, AF
   Heskett, M
   Spiker, C
   McGwin, G
   Owsley, C
AF Elliott, Amanda F.
   Heskett, Megan
   Spiker, Christopher
   McGwin, Gerald, Jr.
   Owsley, Cynthia
TI Low rates of eye care utilization among visually impaired subsidized
   senior housing residents
SO AGING & MENTAL HEALTH
LA English
DT Article
DE Vision impairment; eye care; older adults
ID NURSING-HOME RESIDENTS; VISION IMPAIRMENT; OLDER PERSONS; HEALTH;
   PREVALENCE; ADULTS; HYPERTENSION; AMERICANS; DECLINE; QUALITY
AB Objective: To examine the rate of self-reported vision impairment, eye disease, and eye care utilization among residents of subsidized senior housing (SSH) communities. Methods: In this cross-sectional, observational study, residents of 14 SSH communities in Jefferson County, AL, USA self-reported their vision status and eye care utilization as part of vision screening events held in their community. Results: Two hundred and thirty-seven residents self-reported their vision status, presence of eye disease, and eye care utilization. A third of participants (33.3%) reported difficulty with distance vision while 38% reported difficulty with near vision. Rates of eye disease among this sample were as follows: 40.3% reported having cataracts, 13.6% reported having glaucoma, 4.2% reported having age-related macular degeneration, and 5.5% reported having diabetic retinopathy. The majority of participants (52.8%) had not been to see an eye care provider within the last year. Persons with vision impairment were less likely to report having seen an eye care provider within the last year than those without impairment (p = .03). Conclusion: This study illuminates the low utilization of eye care among socioeconomically disadvantaged older adults residing in SSH, especially among those with vision impairment and eye disease. Vision-related health care is important in maintaining both physical and mental health in older adults.
C1 [Elliott, Amanda F.] Univ Florida, Coll Nursing, Gainesville, FL 32611 USA.
   [Heskett, Megan] Univ S Florida, Coll Nursing, Tampa, FL USA.
   [Spiker, Christopher; McGwin, Gerald, Jr.; Owsley, Cynthia] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Med, Dept Surg, Birmingham, AL 35294 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of South Florida; University of
   Alabama System; University of Alabama Birmingham; University of Alabama
   System; University of Alabama Birmingham; University of Alabama System;
   University of Alabama Birmingham
RP Elliott, AF (通讯作者)，Univ Florida, Coll Nursing, Gainesville, FL 32611 USA.
EM Amanda.elliott@ufl.edu
FU Lucille Beeson Trust; Prevent Blindness; EyeSight Foundation of Alabama;
   Able Trust; National Institutes of Health [P30AG22838]; Research to
   Prevent Blindness Inc.; Alfreda J. Schuler Trust
FX This work was supported by The Lucille Beeson Trust; Prevent Blindness;
   the EyeSight Foundation of Alabama; the Able Trust; the Alfreda J.
   Schuler Trust; National Institutes of Health [grant P30AG22838 to C.O.];
   and Research to Prevent Blindness Inc.
CR American Academy of Ophthalmology, 2015, FREQ OC EX 2015
   American Diabetes Association, 2013, EYE COMPL
   [Anonymous], 2015, AFR AM HEART DIS STR
   Arokiasamy P, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0402-8
   Bhargava M, 2012, J HUM HYPERTENS, V26, P71, DOI 10.1038/jhh.2011.37
   Centers for Disease Control and Prevention, 2019, 2019 BEH RISK FACT S
   Centers for Medicare & Medicaid Services, YOUR MED COV
   Centres for Disease Control and Prevention, 2015, AG SPEC RAT DIAGN DI
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Damian Javier, 2008, BMC Geriatr, V8, P5, DOI 10.1186/1471-2318-8-5
   Ehrlich JR, 2019, JAMA OPHTHALMOL, V137, P146, DOI 10.1001/jamaophthalmol.2018.5449
   Elliott AF, 2015, GERONTOLOGIST, V55, pS108, DOI 10.1093/geront/gnv028
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1019, DOI 10.1001/archopht.122.7.1019
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Goldman N, 2003, J CLIN EPIDEMIOL, V56, P148, DOI 10.1016/S0895-4356(02)00580-2
   Haley B., 2008, SECTION 202 SUPPORTI
   Hamedani AG, 2019, OPHTHAL EPIDEMIOL, V26, P279, DOI 10.1080/09286586.2019.1611879
   Hwang J, 2015, CAN J OPHTHALMOL, V50, P119, DOI 10.1016/j.jcjo.2014.11.014
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Leikauf J, 2009, J AM GERIATR SOC, V57, P1219, DOI 10.1111/j.1532-5415.2009.02313.x
   Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x
   McGwin G, 2010, CURR EYE RES, V35, P451, DOI 10.3109/02713681003664931
   Mitchell P, 1997, MED J AUSTRALIA, V166, P73, DOI 10.5694/j.1326-5377.1997.tb138724.x
   Ortman JM, 2014, CURRENT POPULATION R
   Owsley C, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.118547
   Owsley C, 2007, ARCH OPHTHALMOL-CHIC, V125, P925, DOI 10.1001/archopht.125.7.925
   Perl L., 2010, C RES SERV REPORT C
   Prevent Blindness America National Eye Institute., 2008, VIS PROBL US PREV AD
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Robison J, 2009, AGING MENT HEALTH, V13, P659, DOI 10.1080/13607860802607298
   Tay T, 2006, GERONTOLOGY, V52, P386, DOI 10.1159/000095129
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   van der Aa HPA, 2015, INVEST OPHTH VIS SCI, V56, P849, DOI 10.1167/iovs.14-15848
   Varadaraj V, 2019, JAMA OPHTHALMOL, V137, P391, DOI 10.1001/jamaophthalmol.2018.6799
   Wang JJ, 2001, MED J AUSTRALIA, V174, P271, DOI 10.5694/j.1326-5377.2001.tb143267.x
   Wang JJ, 2000, INVEST OPHTH VIS SCI, V41, P49
   Whitson HE, 2014, ASIA-PAC J PUBLIC HE, V26, P310, DOI 10.1177/1010539512443698
   Wood KM, 2005, GERONTOLOGY, V51, P131, DOI 10.1159/000082199
   Wu SC, 2000, PUBLIC HEALTH, V114, P137, DOI 10.1038/sj.ph.1900627
   Zebardast N, 2017, AM J OPHTHALMOL, V174, P134, DOI 10.1016/j.ajo.2016.11.004
   Zhang XZ, 2012, AM J OPHTHALMOL, V154, pS53, DOI 10.1016/j.ajo.2011.08.045
   Zheng YF, 2011, INVEST OPHTH VIS SCI, V52, P8799, DOI 10.1167/iovs.11-7700
NR 43
TC 1
Z9 1
U1 0
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1360-7863
EI 1364-6915
J9 AGING MENT HEALTH
JI Aging Ment. Health
PD FEB 1
PY 2021
VL 25
IS 2
BP 360
EP 366
DI 10.1080/13607863.2019.1683813
EA NOV 2019
PG 7
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA PZ5HS
UT WOS:000494904700001
PM 31694391
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rosell, M
   Giera, M
   Brabet, P
   Shchepinov, MS
   Guichardant, M
   Durand, T
   Vercauteren, J
   Galano, JM
   Crauste, C
AF Rosell, Melissa
   Giera, Martin
   Brabet, Philippe
   Shchepinov, Mikhail S.
   Guichardant, Michel
   Durand, Thierry
   Vercauteren, Joseph
   Galano, Jean-Marie
   Crauste, Celine
TI Bis-allylic Deuterated DHA Alleviates Oxidative Stress in Retinal
   Epithelial Cells
SO ANTIOXIDANTS
LA English
DT Article
DE DHA; oxidative stress; kinetic isotope effect; lipid peroxidation;
   lipophenol; phenolipid
ID POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC ACID; MACULAR DEGENERATION;
   LIPID-PEROXIDATION; STARGARDT DISEASE; IN-VIVO; LIPOFUSCIN; DAMAGE;
   BISRETINOIDS; ACCUMULATION
AB Oxidative stress plays a crucial role in developing and accelerating retinal diseases including age-related macular degeneration (AMD). Docosahexaenoic acid (DHA, C22:6, n-3), the main lipid constituent of retinal epithelial cell membranes, is highly prone to radical and enzymatic oxidation leading to deleterious or beneficial metabolites for retinal tissue. To inhibit radical oxidation while preserving enzymatic metabolism, deuterium was incorporated at specific positions of DHA, resulting in D-2-DHA when incorporated at position 6 and D-4-DHA when incorporated at the 6,9 bis-allylic positions. Both derivatives were able to decrease DHAs' toxicity and free radical processes involved in lipid peroxidation, in ARPE-19 cells (Adult Retinal Pigment Epithelial cell line), under pro-oxidant conditions. Our positive results encouraged us to prepare lipophenolic-deuterated-DHA conjugates as possible drug candidates for AMD treatment. These novel derivatives proved efficient in limiting lipid peroxidation in ARPE-19 cells. Finally, we evaluated the underlying mechanisms and the enzymatic conversion of both deuterated DHA. While radical abstraction was affected at the deuterium incorporation sites, enzymatic conversion by the lipoxygenase 15s-LOX was not impacted. Our results suggest that site-specifically deuterated DHA could be used in the development of DHA conjugates for treatment of oxidative stress driven diseases, or as biological tools to study the roles, activities and mechanisms of DHA metabolites.
C1 [Rosell, Melissa; Durand, Thierry; Vercauteren, Joseph; Galano, Jean-Marie; Crauste, Celine] Univ Montpellier, ENSCM, CNRS, IBMM, F-34093 Montpellier, France.
   [Giera, Martin] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
   [Brabet, Philippe] Hosp St Eloi, Inst Neurosci Montpellier, INSERM U1051 UM, 80 Rue Augustin Fliche, F-34091 Montpellier, France.
   [Shchepinov, Mikhail S.] Retrotope Inc, Los Altos, CA 94022 USA.
   [Guichardant, Michel] Univ Lyon, Inserm UMR 1060, Inra UMR 1397, CarMeN Lab,IMBL,INSA Lyon, F-69100 Villeurbanne, France.
C3 Centre National de la Recherche Scientifique (CNRS); Ecole nationale
   superieure de chimie de Montpellier; Universite de Montpellier; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; Universite de Montpellier; CHU de Montpellier; INRAE;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut National des Sciences Appliquees de Lyon - INSA Lyon
RP Crauste, C (通讯作者)，Univ Montpellier, ENSCM, CNRS, IBMM, F-34093 Montpellier, France.
EM celine.crauste@umontpellier.fr
RI Vercauteren, Joseph/AAF-7151-2019; Brabet, Philippe/AAO-8522-2020;
   Giera, Martin/Y-2413-2018
OI Vercauteren, Joseph/0000-0002-0201-1235; Brabet,
   Philippe/0000-0003-2739-1622; Giera, Martin/0000-0003-1684-1894;
   Crauste, Celine/0000-0002-5714-8749
FU Fondation Stargardt, under the aegis of Fondation Valentin Hauy; Retina
   France; ANR (LipoPheRet); Inserm; CNRS; University of Montpellier
FX This research was funded in part by Fondation Stargardt, under the aegis
   of Fondation Valentin Hauy, Retina France, and ANR (LipoPheRet). Inserm,
   CNRS and University of Montpellier are thanked for their support.
CR Andreyev AY, 2015, FREE RADICAL BIO MED, V82, P63, DOI 10.1016/j.freeradbiomed.2014.12.023
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345
   Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011
   Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Berbee JFP, 2017, ATHEROSCLEROSIS, V264, P100, DOI 10.1016/j.atherosclerosis.2017.06.916
   Brabet P, 2017, INVEST OPHTH VIS SCI, V58
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Crauste C, 2014, EUR J ORG CHEM, V2014, P4548, DOI 10.1002/ejoc.201402282
   Dominguez-Rebolledo AE, 2010, REPROD DOMEST ANIM, V45, pe360, DOI 10.1111/j.1439-0531.2009.01578.x
   Donato L, 2019, CELL CYCLE, V18, P84, DOI 10.1080/15384101.2018.1558873
   Donato L, 2018, MOL BIOL REP, V45, P1349, DOI 10.1007/s11033-018-4295-4
   Donato L, 2018, INVEST OPHTH VIS SCI, V59, P843, DOI 10.1167/iovs.17-22962
   Drummen GPC, 2002, FREE RADICAL BIO MED, V33, P473, DOI 10.1016/S0891-5849(02)00848-1
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Galano JM, 2017, PROG LIPID RES, V68, P83, DOI 10.1016/j.plipres.2017.09.004
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Giera M, 2012, BBA-MOL CELL BIOL L, V1821, P1415, DOI 10.1016/j.bbalip.2012.07.011
   GLICKMAN MH, 1994, J AM CHEM SOC, V116, P793, DOI 10.1021/ja00081a060
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guy A, 2014, CHEM-EUR J, V20, P6374, DOI 10.1002/chem.201400380
   Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776
   Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7
   Hill S, 2012, FREE RADICAL BIO MED, V53, P893, DOI 10.1016/j.freeradbiomed.2012.06.004
   Hill S, 2011, FREE RADICAL BIO MED, V50, P130, DOI 10.1016/j.freeradbiomed.2010.10.690
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Joumard-Cubizolles L, 2017, PROSTAG OTH LIPID M, V133, P111, DOI 10.1016/j.prostaglandins.2017.05.005
   Liu YX, 2014, J PHOTOCH PHOTOBIO B, V140, P85, DOI 10.1016/j.jphotobiol.2014.07.016
   German OL, 2015, PHOTOCH PHOTOBIO SCI, V14, P1737, DOI 10.1039/c5pp00194c
   MacDonald ML, 2007, FREE RADICAL BIO MED, V42, P1392, DOI 10.1016/j.freeradbiomed.2007.01.038
   Malinin NL, 2011, AGING-US, V3, P906, DOI 10.18632/aging.100385
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Musiek ES, 2004, J CHROMATOGR B, V799, P95, DOI 10.1016/j.jchromb.2003.10.036
   Navratil AR, 2018, J AM CHEM SOC, V140, P235, DOI 10.1021/jacs.7b09493
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Oger C, 2010, CHEM-EUR J, V16, P13976, DOI 10.1002/chem.201002304
   Querques G, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/748361
   Querques G, 2010, CLIN OPHTHALMOL, V4, P575
   Raefsky SM, 2018, NEUROBIOL AGING, V66, P165, DOI 10.1016/j.neurobiolaging.2018.02.024
   Rosell M, 2017, ASIAN J ORG CHEM, V6, P322, DOI 10.1002/ajoc.201600565
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Schlegel M, 2018, J CLIN INVEST, V128, P4711, DOI 10.1172/JCI96259
   Schnebelen C, 2009, OPHTHALMIC RES, V41, P216, DOI 10.1159/000217726
   Semchyshyn HM, 2014, SCI WORLD J, DOI 10.1155/2014/417842
   Shchepinov MS, 2007, REJUV RES, V10, P47, DOI 10.1089/rej.2006.0506
   Shchepinov MS, 2014, OMEGA-3 FATTY ACIDS IN BRAIN AND NEUROLOGICAL HEALTH, P373, DOI 10.1016/B978-0-12-410527-0.00031-4
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suh M, 1996, LIPIDS, V31, P61, DOI 10.1007/BF02522412
   Tanito M, 2009, J LIPID RES, V50, P807, DOI 10.1194/jlr.M800170-JLR200
   Vericel E, 2003, J THROMB HAEMOST, V1, P566, DOI 10.1046/j.1538-7836.2003.00076.x
   Vistoli G, 2013, FREE RADICAL RES, V47, P3, DOI 10.3109/10715762.2013.815348
   Yin HY, 2011, CHEM REV, V111, P5944, DOI 10.1021/cr200084z
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Zhu X, 2016, EXP CELL RES, V348, P87, DOI 10.1016/j.yexcr.2016.09.002
NR 63
TC 7
Z9 8
U1 3
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD OCT
PY 2019
VL 8
IS 10
AR 447
DI 10.3390/antiox8100447
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA JT1LQ
UT WOS:000500759900030
PM 31581525
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Conti, F
   Han, MM
   Song, WL
   Wai, KM
   Silva, FQ
   Singh, RP
AF Conti, Felipe
   Han, Michael M.
   Song, Weilin
   Wai, Karen M.
   Silva, Fabiana Q.
   Singh, Rishi P.
TI Characterization of Patients With Geographic Atrophy in Routine Clinical
   Practice
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   PREVALENCE; PROGRESSION; EYE; SECONDARY; IMPACT; GROWTH
AB BACKGROUND AND OBJECTIVE: Geographic atrophy (GA) affects millions of patients with age-related macular degeneration (AMD) worldwide, leading to significant, irreversible visual impairment. This study aims to characterize the visual impairment of patients with GA in a routine clinical practice.
   PATIENTS AND METHODS: This single-center, cross-sectional study used a novel natural language processing to select 1,045 GA cases utilizing the macula examination records from 19,359 patients with AMD.
   RESULTS: Patients were classified based on the diagnosis of the fellow-eye as follow: 502 in group 1 (GA:GA), 403 in group 2 (GA : choroidal neovascularization), and 234 in group 3 (GA: early/ intermediate AMD). Best-corrected visual acuity (BCVA) in the affected eye was 50.3 (+/- 22.1) letters in group 1, 52.5 (+/- 21.3) letters in group 2, and 48.5 (+/- 23.6) letters in group 3 (P < .05). Visual impairment (ineligibility for an unrestricted driver license) was present in 70.5% of group 1, 59.7% of group 2, and 39.6% of group 3. Legal blindness (BCVA < 20 letters in the best-seeing eye) was seen in 2.2% of group 1,3% of group 2, and 0.8% of group 3.
   CONCLUSION: Differences in visual impairment between subgroups of patients with GA can be seen in routine clinical practice.
C1 [Conti, Felipe; Silva, Fabiana Q.; Singh, Rishi P.] Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Han, Michael M.; Wai, Karen M.; Singh, Rishi P.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Song, Weilin] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Conti, Felipe; Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Ctr Ophthalm Bioinformat, Cleveland, OH 44106 USA.
   [Conti, Felipe] Univ Fed Sao Paulo, Sao Paulo, Brazil.
C3 Cleveland Clinic Foundation; Case Western Reserve University; Case
   Western Reserve University; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation; Universidade Federal de Sao Paulo (UNIFESP)
RP Singh, RP (通讯作者)，9500 Euclid Ave,Desk i32, Cleveland, OH 44195 USA.
EM drrishisingh@gmail.com
RI Silva, Fabiana/GWU-9143-2022
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   [Anonymous], 2017, ROCHE PROVIDES UPDAT
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Davis RP, 2010, CLIN OPHTHALMOL, V4, P703
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kandasamy R, 2017, ASIA-PAC J OPHTHALMO, V6, P508, DOI 10.22608/APO.2017262
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schick T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156778
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 36
TC 0
Z9 0
U1 1
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2019
VL 50
IS 2
BP 93
EP 98
DI 10.3928/23258160-20190129-05
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HL6KP
UT WOS:000458843200014
PM 30768216
DA 2022-11-30
ER

PT J
AU Zeng, SM
   Wen, KK
   Workalemahu, G
   Sohn, EH
   Wu, M
   Chirco, KR
   Flamme-Wiese, MJ
   Liu, XY
   Stone, EM
   Tucker, BA
   Mullins, RF
AF Zeng, Shemin
   Wen, Kuo-Kuang
   Workalemahu, Grefachew
   Sohn, Elliott H.
   Wu, Meng
   Chirco, Kathleen R.
   Flamme-Wiese, Miles J.
   Liu, Xiuying
   Stone, Edwin M.
   Tucker, Budd A.
   Mullins, Robert F.
TI Imidazole Compounds for Protecting Choroidal Endothelial Cells from
   Complement Injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MEMBRANE ATTACK COMPLEX; MACULAR DEGENERATION; TARGETED INHIBITOR;
   RANIBIZUMAB; PATHWAY; DISEASE; BEVACIZUMAB; ACTIVATION; ECONAZOLE;
   RECOVERY
AB Age-related macular degeneration (AMD) is a common, blinding disease associated with increased complement system activity. Eyes with AMD show elevated accumulation of the membrane attack complex (MAC) in the choriocapillaris and degeneration of macular choriocapillaris endothelial cells (ECs). Thus, one could reasonably conclude that the endothelial cell death that occurs in AMD is due to injury by the MAC. We therefore sought to identify strategies for protecting ECs against MAC lysis. RF/6A endothelial cells were pre-incubated with a library of FDA-approved small molecules, followed by incubation with complement intact human serum quantification of cell death. Two closely related molecules identified in the screen, econazole nitrate and miconazole nitrate, were followed in validation and mechanistic studies. Both compounds reduced lysis of choroidal ECs treated with complement-intact serum, across a range of doses from 1 to 100 mu M. Cell rescue was confirmed in mouse primary choroidal ECs. Both exosome release and cell surface roughness (assessed using a Holomonitor system) were reduced by drug pretreatment in RF/6A cells, whereas endosome formation increased with both drugs, consistent with imidazole-mediated alterations of cell surface dynamics. The results in the current study provide further proof of principle that small molecules can protect choroidal ECs from MAC-induced cell death and suggest that FDA approved compounds may be beneficial in reducing vascular loss and progression of AMD.
C1 [Zeng, Shemin; Workalemahu, Grefachew; Sohn, Elliott H.; Chirco, Kathleen R.; Flamme-Wiese, Miles J.; Liu, Xiuying; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Inst Vis Res, Iowa City, IA USA.
   [Zeng, Shemin; Workalemahu, Grefachew; Sohn, Elliott H.; Chirco, Kathleen R.; Flamme-Wiese, Miles J.; Liu, Xiuying; Stone, Edwin M.; Tucker, Budd A.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Wen, Kuo-Kuang; Wu, Meng] Univ Iowa, Dept Biochim, Iowa City, IA USA.
C3 University of Iowa; University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Inst Vis Res, Iowa City, IA USA.; Mullins, RF (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; Stone, Edwin
   M./0000-0003-3343-4414; Sohn, Elliott/0000-0002-3778-9362; Wu,
   Meng/0000-0003-2222-0736; Tucker, Budd/0000-0003-2178-1742
FU NIH [EY-024605, EY-026547, P30 EY025580]; Research to Prevent Blindness;
   Elmer and Sylvia Sramek Charitable Foundation; NATIONAL EYE INSTITUTE
   [R01EY026547, R01EY024605, P30EY025580] Funding Source: NIH RePORTER
FX Supported in part by NIH grants EY-024605, EY-026547 and P30 EY025580,
   Research to Prevent Blindness, and the Elmer and Sylvia Sramek
   Charitable Foundation.
CR Abd El-Gawad A, 2017, AAPS PHARMSCITECH, V18, P1795, DOI 10.1208/s12249-016-0609-9
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   BORGERS M, 1980, REV INFECT DIS, V2, P520
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Campestre C, 2017, J ENZYM INHIB MED CH, V32, P1053, DOI 10.1080/14756366.2017.1354858
   CARNEY DF, 1985, J IMMUNOL, V134, P1804
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Harris CL, 2003, J BIOL CHEM, V278, P36068, DOI 10.1074/jbc.M306351200
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Holers VM, 2016, SEMIN IMMUNOL, V28, P260, DOI 10.1016/j.smim.2016.05.007
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kofeler HC, 2000, BRIT J PHARMACOL, V130, P1241, DOI 10.1038/sj.bjp.0703427
   Leaderer D, 2015, J GENE MED, V17, P101, DOI 10.1002/jgm.2829
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MORGAN BP, 1987, J IMMUNOL, V138, P246
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sung DJ, 2012, BIOL PHARM BULL, V35, P1469, DOI 10.1248/bpb.b12-00002
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   TOLENTINO FI, 1982, ARCH OPHTHALMOL-CHIC, V100, P1504, DOI 10.1001/archopht.1982.01030040482021
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Xu S, 2011, J CELL SCI, V124, P3503, DOI 10.1242/jcs.088906
   YOSHIZUMI MO, 1988, RETINA-J RET VIT DIS, V8, P210, DOI 10.1097/00006982-198808030-00012
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 37
TC 4
Z9 4
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 6
PY 2018
VL 8
AR 13387
DI 10.1038/s41598-018-31846-z
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GS6KH
UT WOS:000443803300003
PM 30190604
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Acharya, NK
   Qi, X
   Goldwaser, EL
   Godsey, GA
   Wu, H
   Kosciuk, MC
   Freeman, TA
   Macphee, CH
   Wilensky, RL
   Venkataraman, V
   Nagele, RG
AF Acharya, Nimish K.
   Qi, Xin
   Goldwaser, Eric L.
   Godsey, George A.
   Wu, Hao
   Kosciuk, Mary C.
   Freeman, Theresa A.
   Macphee, Colin H.
   Wilensky, Robert L.
   Venkataraman, Venkat
   Nagele, Robert G.
TI Retinal pathology is associated with increased blood-retina barrier
   permeability in a diabetic and hypercholesterolaemic pig model:
   Beneficial effects of the LpPLA(2) inhibitor Darapladib
SO DIABETES & VASCULAR DISEASE RESEARCH
LA English
DT Article
DE Blood-retina barrier; blood-brain barrier; lipoprotein-associated
   phospholipase-A(2); diabetes; cholesterol; retina; claudin-5; occludin;
   tight junctions; endothelium; blood vessels
ID FIBRILLARY ACIDIC PROTEIN; TIGHT JUNCTION PROTEINS; BRAIN-BARRIER;
   PHOSPHOLIPASE A(2); ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT;
   ENDOTHELIAL-CELLS; RETINOPATHY; BREAKDOWN; RATS
AB Using a porcine model of diabetes mellitus and hypercholesterolaemia, we previously showed that diabetes mellitus and hypercholesterolaemia is associated with a chronic increase in blood-brain barrier permeability in the cerebral cortex, leading to selective binding of immunoglobulin G and deposition of amyloid-beta(1-42) peptide in pyramidal neurons. Treatment with Darapladib (GlaxoSmithKline, SB480848), an inhibitor of lipoprotein-associated phospholipase-A2, alleviated these effects. Here, investigation of the effects of chronic diabetes mellitus and hypercholesterolaemia on the pig retina revealed a corresponding increased permeability of the blood-retina barrier coupled with a leak of plasma components into the retina, alterations in retinal architecture, selective IgG binding to neurons in the ganglion cell layer, thinning of retinal layers due to cell loss and increased glial fibrillary acidic protein expression in Muller cells, all of which were curtailed by treatment with Darapladib. These findings suggest that chronic diabetes mellitus and hypercholesterolaemia induces increased blood-retina barrier permeability that may be linked to altered expression of blood-retina barrier-associated tight junction proteins, claudin and occludin, leading to structural changes in the retina consistent with diabetic retinopathy. Additionally, results suggest that drugs with vascular anti-inflammatory properties, such as Darapladib, may have beneficial effects on eye diseases strongly linked to vascular abnormalities such as diabetic retinopathy and age-related macular degeneration.
C1 [Acharya, Nimish K.; Goldwaser, Eric L.; Kosciuk, Mary C.; Nagele, Robert G.] Rowan Univ, New Jersey Inst Successful Aging, Sch Osteopath Med, Biomarker Discovery Ctr, Stratford, NJ 08084 USA.
   [Acharya, Nimish K.; Goldwaser, Eric L.; Godsey, George A.; Kosciuk, Mary C.; Nagele, Robert G.] Rowan Univ, Sch Osteopath Med, Dept Geriatr & Gerontol, Stratford, NJ 08084 USA.
   [Acharya, Nimish K.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Qi, Xin] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
   [Qi, Xin] Cent S Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.
   [Goldwaser, Eric L.; Godsey, George A.; Wu, Hao] Rowan Univ, Grad Sch Biomed Sci, Stratford, NJ 08084 USA.
   [Wu, Hao; Venkataraman, Venkat] Rowan Univ, Sch Osteopath Med, Dept Cell Biol, Stratford, NJ 08084 USA.
   [Freeman, Theresa A.] Thomas Jefferson Univ, Dept Orthopaed Surg, Dept Dermatol & Cutaneous Biol, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
   [Macphee, Colin H.] GlaxoSmithKline, Philadelphia, PA USA.
   [Wilensky, Robert L.] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.
C3 Rowan University; Rowan University School of Osteopathic Medicine; Rowan
   University; Rowan University School of Osteopathic Medicine; University
   of Pennsylvania; Jefferson University; Central South University; Rowan
   University; Rowan University; Rowan University School of Osteopathic
   Medicine; Jefferson University; GlaxoSmithKline; University of
   Pennsylvania; Pennsylvania Medicine
RP Nagele, RG (通讯作者)，Rowan Univ, New Jersey Inst Successful Aging, Sch Osteopath Med, Biomarker Discovery Ctr, Stratford, NJ 08084 USA.
EM nagelero@rowan.edu
RI Venkataraman, Venkat/GQI-4032-2022
OI Han, Min/0000-0002-8350-687X; Freeman, Theresa/0000-0002-5959-5884;
   Nagele, Robert/0000-0003-2691-4137
FU GlaxoSmithKline; Osteopathic Heritage Foundation
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was supported by GlaxoSmithKline and Osteopathic Heritage Foundation.
CR Acharya NK, 2013, J ALZHEIMERS DIS, V35, P179, DOI 10.3233/JAD-122254
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106
   Awad N, 2004, J CLIN EXP NEUROPSYC, V26, P1044, DOI 10.1080/13803390490514875
   Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561
   Barber AJ, 2003, INVEST OPHTH VIS SCI, V44, P5410, DOI 10.1167/iovs.03-0244
   Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X
   Canning P, 2016, P NATL ACAD SCI USA, V113, P7213, DOI 10.1073/pnas.1514213113
   Carlsson CM, 2010, J ALZHEIMERS DIS, V20, P711, DOI 10.3233/JAD-2010-100012
   Chang ML, 2007, J ANAT, V210, P54, DOI 10.1111/j.1469-7580.2006.00671.x
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387
   Fan YC, 2014, EXP EYE RES, V127, P104, DOI 10.1016/j.exer.2014.05.004
   Fernandez-Robredo P, 2005, INVEST OPHTH VIS SCI, V46, P1140, DOI 10.1167/iovs.04-0516
   Goncalves A, 2012, DIABETES OBES METAB, V14, P454, DOI 10.1111/j.1463-1326.2011.01548.x
   Goncalves A, 2014, BBA-MOL BASIS DIS, V1842, P1454, DOI 10.1016/j.bbadis.2014.04.013
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Hawkins BT, 2007, DIABETOLOGIA, V50, P202, DOI 10.1007/s00125-006-0485-z
   Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4
   Hoffman WH, 2009, BRAIN RES, V1254, P138, DOI 10.1016/j.brainres.2008.11.100
   Ikram MK, 2012, J NEUROL NEUROSUR PS, V83, P917, DOI 10.1136/jnnp-2011-301628
   Jiang X., 2012, INT J ALZHEIMERS DIS, V2012, P109324, DOI DOI 10.1155/2012/109324
   Kalayci R, 2009, INT J NEUROSCI, V119, P1881, DOI 10.1080/14647270802336650
   Klaassen I, 2009, EXP EYE RES, V89, P4, DOI 10.1016/j.exer.2009.01.006
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Leal EC, 2010, DIABETES, V59, P2637, DOI 10.2337/db09-1421
   LEWIS GP, 1988, EXP EYE RES, V47, P839, DOI 10.1016/0014-4835(88)90067-X
   Luchsinger JA, 2009, J ALZHEIMERS DIS, V16, P693, DOI 10.3233/JAD-2009-1022
   Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036
   Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445
   Moroz N, 2008, J ALZHEIMERS DIS, V15, P29
   Nagele RG, 2011, J ALZHEIMERS DIS, V25, P605, DOI 10.3233/JAD-2011-110098
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971
   Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131
   Saker S, 2014, EXP EYE RES, V121, P161, DOI 10.1016/j.exer.2014.02.016
   Sohet F, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-3
   Staurenghi G, 2015, OPHTHALMOLOGY, V122, P990, DOI 10.1016/j.ophtha.2014.12.014
   Steuer H, 2005, INVEST OPHTH VIS SCI, V46, P1047, DOI 10.1167/iovs.04-0925
   Taguchi A, 2009, J ALZHEIMERS DIS, V16, P859, DOI 10.3233/JAD-2009-0975
   TUCCARI G, 1986, BASIC APPL HISTOCHEM, V30, P425
   Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185
   Wilensky RL, 2008, NAT MED, V14, P1059, DOI 10.1038/nm.1870
   Wilensky RL, 2009, CURR OPIN LIPIDOL, V20, P415, DOI 10.1097/MOL.0b013e3283307c16
   Wilkinson-Berka Jennifer L., 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008129
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yucel I, 2005, VISION RES, V45, P1107, DOI 10.1016/j.visres.2004.11.018
   Zambon D, 2010, AM J MED, V123, P267, DOI 10.1016/j.amjmed.2009.08.015
NR 48
TC 27
Z9 31
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1479-1641
EI 1752-8984
J9 DIABETES VASC DIS RE
JI Diabetes Vasc. Dis. Res.
PD MAY
PY 2017
VL 14
IS 3
BP 200
EP 213
DI 10.1177/1479164116683149
PG 14
WC Endocrinology & Metabolism; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Cardiovascular System & Cardiology
GA EU0GE
UT WOS:000400686700005
PM 28301218
OA Bronze
DA 2022-11-30
ER

PT J
AU Dammalli, M
   Murthy, KR
   Pinto, SM
   Murthy, KB
   Nirujogi, RS
   Madugundu, AK
   Dey, G
   Nair, B
   Gowda, H
   Prasad, TSK
AF Dammalli, Manjunath
   Murthy, Krishna R.
   Pinto, Sneha M.
   Murthy, Kalpana Babu
   Nirujogi, Raja Sekhar
   Madugundu, Anil K.
   Dey, Gourav
   Nair, Bipin
   Gowda, Harsha
   Prasad, Thottethodi Subrahmanya Keshava
TI Toward Postgenomics Ophthalmology: A Proteomic Map of the Human
   Choroid-Retinal Pigment Epithelium Tissue
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
DE personalized medicine; proteomics; omics technology; innovation systems
ID FRIZZLED-RELATED PROTEIN; S-TRANSFERASE M1; MITOCHONDRIAL DYSFUNCTION;
   RETINITIS-PIGMENTOSA; OGUCHI-DISEASE; GLAUCOMA; POLYMORPHISMS; COMPLEX;
   FAMILY; GENE
AB Ophthalmology and visual health research have received relatively limited attention from the personalized medicine community, but this trend is rapidly changing. Postgenomics technologies such as proteomics are being utilized to establish a baseline biological variation map of the human eye and related tissues. In this context, the choroid is the vascular layer situated between the outer sclera and the inner retina. The choroidal circulation serves the photoreceptors and retinal pigment epithelium (RPE). The RPE is a layer of cuboidal epithelial cells adjacent to the neurosensory retina and maintains the outer limit of the blood-retina barrier. Abnormal changes in choroidRPE layers have been associated with age-related macular degeneration. We report here the proteome of the healthy human choroid-RPE complex, using reverse phase liquid chromatography and mass spectrometry-based proteomics. A total of 5309 nonredundant proteins were identified. Functional analysis of the identified proteins further pointed to molecular targets related to protein metabolism, regulation of nucleic acid metabolism, transport, cell growth, and/or maintenance and immune response. The top canonical pathways in which the choroid proteins participated were integrin signaling, mitochondrial dysfunction, regulation of eIF4 and p70S6K signaling, and clathrin-mediated endocytosis signaling. This study illustrates the largest number of proteins identified in human choroid-RPE complex to date and might serve as a valuable resource for future investigations and biomarker discovery in support of postgenomics ophthalmology and precision medicine.
C1 [Dammalli, Manjunath; Murthy, Krishna R.; Pinto, Sneha M.; Nirujogi, Raja Sekhar; Madugundu, Anil K.; Dey, Gourav; Gowda, Harsha; Prasad, Thottethodi Subrahmanya Keshava] Inst Bioinformat, Int Technol Pk, Bangalore 560066, Karnataka, India.
   [Dammalli, Manjunath] Siddaganga Inst Technol, Dept Biotechnol, Tumkur, India.
   [Murthy, Krishna R.; Nair, Bipin] Amrita VishwaVidyapeetham, Amrita Sch Biotechnol, Kollam, India.
   [Murthy, Krishna R.; Murthy, Kalpana Babu] Vittala Int Inst Ophthalmol, Bangalore 560085, Karnataka, India.
   [Pinto, Sneha M.; Prasad, Thottethodi Subrahmanya Keshava] Yenepoya Univ, YU IOB Ctr Syst Biol & Mol Med, Mangalore, India.
   [Nirujogi, Raja Sekhar; Madugundu, Anil K.] Pondicherry Univ, Sch Life Sci, Ctr Bioinformat, Pondicherry, India.
   [Dey, Gourav] Manipal Univ, Dept Biotechnol, Manipal, Karnataka, India.
   [Prasad, Thottethodi Subrahmanya Keshava] Natl Inst Mental Hlth & Neurosci, Neurobiol Res Ctr, NIMHANS IOB Bioinformat & Prote Lab, Bangalore, Karnataka, India.
C3 Siddaganga Institute of Technology; Amrita Vishwa Vidyapeetham; Amrita
   Vishwa Vidyapeetham Amritapuri; Yenepoya (Deemed to be University);
   Pondicherry University; Manipal Academy of Higher Education (MAHE);
   National Institute of Mental Health & Neurosciences - India
RP Prasad, TSK (通讯作者)，Inst Bioinformat, Int Technol Pk, Bangalore 560066, Karnataka, India.; Murthy, KR (通讯作者)，Vittala Int Inst Ophthalmol, Bangalore 560085, Karnataka, India.
EM krishna@viio.org; keshav@ibioinformatics.org
RI Madugundu, Anil Kumar/ABE-2128-2021; Prasad, Keshava/F-7631-2010; Pinto,
   Sneha/Q-7308-2018; Gowda, Harsha/A-8526-2011; Babu,
   Kalpana/AAF-2922-2020
OI Madugundu, Anil Kumar/0000-0003-4274-7316; Prasad,
   Keshava/0000-0002-6206-2384; Pinto, Sneha/0000-0001-8541-8761; Gowda,
   Harsha/0000-0002-4118-6855; Dey, Gourav/0000-0002-2703-699X; nair,
   bipin/0000-0002-4944-8805; Nirujogi, Raja Sekhar/0000-0002-3177-8566
FU Department of Biotechnology (DBT), Government of India; Infosys
   Foundation; Council of Scientific and Industrial Research (CSIR),
   Government of India; University Grants Commission (UGC), Government of
   India; Department of Biotechnology (DBT), India; DBT [BT/01/COE/08/05]
FX All authors have met the ICMJE criteria for authorship. We thank the
   Department of Biotechnology (DBT), Government of India, and the Infosys
   Foundation for research support to the Institute of Bioinformatics; M.D.
   is on deputation from Siddaganga Institute of Technology, Tumkur, to
   pursue his research work at IOBtoward PhD degree under the Faculty
   Improvement Program of Sree Siddaganga Education Society, Tumkur; R.S.N.
   is a recipient of Senior Research Fellowship from the Council of
   Scientific and Industrial Research (CSIR), Government of India; G.D. is
   a recipient of Senior Research Fellowships from University Grants
   Commission (UGC), Government of India.; A.K.M. is the recipient of BINC
   Senior Research Fellowship from Department of Biotechnology (DBT),
   India. H.G. is a Wellcome Trust/DBT India Alliance Early Career Fellow.
   Dr. T.S. Keshava Prasad and Dr. Krishna R. Murthy are the recipients of
   a research grant on "Proteomics based identification and validation of
   urinary Biomarkers for Age-related Macular Degeneration'' from DBT. Dr.
   T.S. Keshava Prasad is a recipient of a research grant on "Development
   of Infrastructure and a Computational Framework for Analysis of
   Proteomic Data (BT/01/COE/08/05)'' from DBT.
CR Abu-Amero KK, 2009, BRIT J OPHTHALMOL, V93, P1101, DOI 10.1136/bjo.2008.152983
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bruel C, 2000, P NATL ACAD SCI USA, V97, P3004, DOI 10.1073/pnas.97.7.3004
   Camelo S, 2015, MOL VIS, V21, P1051
   Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339
   Fang D, 2002, NUCLEIC ACIDS RES, V30, P3096, DOI 10.1093/nar/gkf424
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Gaudet P, 2013, J PROTEOME RES, V12, P293, DOI 10.1021/pr300830v
   Goel R, 2013, CLIN PROTEOM, V10, DOI 10.1186/1559-0275-10-9
   Hayashi T, 2007, OPHTHALMOLOGY, V114, P134, DOI 10.1016/j.ophtha.2006.05.069
   Huang LL, 2012, MOL VIS, V18, P528
   Kamaraj B, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/697051
   Kelkar DS, 2014, MOL CELL PROTEOMICS, V13, P3184, DOI 10.1074/mcp.M114.038299
   Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Lee S, 2011, EXP EYE RES, V93, P204, DOI 10.1016/j.exer.2010.07.015
   Lu H, 2011, MOL VIS, V17, P2455
   Mann M, 2013, MOL CELL, V49, P583, DOI 10.1016/j.molcel.2013.01.029
   Murthy KR, 2016, OMICS, V20, P510, DOI 10.1089/omi.2016.0100
   Murthy KR, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-29
   Muthusamy B, 2013, CURR PROTOC BIOINFOR, DOI DOI 10.1002/0471250953.BI0121S41
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259
   Osborne NN, 2014, DRUG DISCOV TODAY, V19, P1613, DOI 10.1016/j.drudis.2014.05.010
   Othman H, 2012, MOL BIOL REP, V39, P3299
   Paun CC, 2012, MOL VIS, V18, P2447
   Prasad TSK, 2009, METHODS MOL BIOL, V577, P67, DOI 10.1007/978-1-60761-232-2_6
   Priyadarsini S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113310
   Rossini Ana, 2002, Genetics and Molecular Research, V1, P233
   Safa FK, 2014, IRAN J BASIC MED SCI, V17, P332
   Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Shi HH, 2013, MOL VIS, V19, P128
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Sonoyama H, 2011, DOC OPHTHALMOL, V123, P127, DOI 10.1007/s10633-011-9286-x
   Sundin OH, 2005, P NATL ACAD SCI USA, V102, P9553, DOI 10.1073/pnas.0501451102
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529
   WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]
   Won J, 2008, VISUAL NEUROSCI, V25, P563, DOI 10.1017/S0952523808080723
   Zacharias Leandro C, 2015, Retin Cases Brief Rep, V9, P61, DOI 10.1097/ICB.0000000000000088
NR 47
TC 10
Z9 10
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
EI 1557-8100
J9 OMICS
JI OMICS
PD FEB
PY 2017
VL 21
IS 2
BP 114
EP 122
DI 10.1089/omi.2016.0170
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA EL1JB
UT WOS:000394375400006
PM 28186866
DA 2022-11-30
ER

PT J
AU Wang, JH
   Westenskow, PD
   Fang, ML
   Friedlander, M
   Siuzdak, G
AF Wang, Junhua
   Westenskow, Peter D.
   Fang, Mingliang
   Friedlander, Martin
   Siuzdak, Gary
TI Quantitative metabolomics of photoreceptor degeneration and the effects
   of stem cell-derived retinal pigment epithelium transplantation
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL
   AND ENGINEERING SCIENCES
LA English
DT Article
DE retinal degeneration; metabolomics; stem cell-derived retinal pigment
   epithelium; cell-based therapy; lipidomics; bioinformatics
ID MASS-SPECTROMETRY; BIOLOGICAL SAMPLES; METABOLISM; IDENTIFICATION;
   ACYLCARNITINE; CARNITINE; METLIN; OCT4; A2E
AB Photoreceptor degeneration is characteristic of vision-threatening diseases including age-related macular degeneration. Photoreceptors are metabolically demanding cells in the retina, but specific details about their metabolic behaviours are unresolved. The quantitative metabolomics of retinal degeneration could provide valuable insights and inform future therapies. Here, we determined the metabolomic 'fingerprint' of healthy and dystrophic retinas in rat models using optimized metabolite extraction techniques. A number of classes of metabolites were consistently dysregulated during degeneration: vitamin A analogues, fatty acid amides, long-chain polyunsaturated fatty acids, acyl carnitines and several phospholipid species. For the first time, a distinct temporal trend of several important metabolites including DHA (4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid), all-trans-retinal and its toxic end-product N-retinyl-N-retinylidene-ethanolamine were observed between healthy and dystrophic retinas. In this study, metabolomics was further used to determine the temporal effects of the therapeutic intervention of grafting stem cell-derived retinal pigment epithelium (RPE) in dystrophic retinas, which significantly prevented photoreceptor atrophy in our previous studies. The result revealed that lipid levels such as phosphatidylethanolamine in eyes were restored in those animals receiving the RPE grafts. In conclusion, this study provides insight into the metabolomics of retinal degeneration, and further understanding of the efficacy of RPE transplantation.
   This article is part of the themed issue 'Quantitative mass spectrometry'.
C1 [Wang, Junhua; Fang, Mingliang; Siuzdak, Gary] Scripps Res Inst, Ctr Metabol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Westenskow, Peter D.; Friedlander, Martin] Scripps Res Inst, Dept Cell & Mol Biol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Siuzdak, Gary] Scripps Res Inst, Dept Chem, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Siuzdak, Gary] Scripps Res Inst, Dept Mol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Siuzdak, Gary] Scripps Res Inst, Dept Computat Biol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Westenskow, Peter D.] Lowy Med Res Inst, 3366 N Torrey Pines Court,Suite 300, La Jolla, CA 92037 USA.
   [Fang, Mingliang] Nanyang Technol Univ, Sch Civil & Environm Engn, Singapore, Singapore.
C3 Scripps Research Institute; Scripps Research Institute; Scripps Research
   Institute; Scripps Research Institute; Scripps Research Institute;
   Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University
RP Siuzdak, G (通讯作者)，Scripps Res Inst, Ctr Metabol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.; Friedlander, M (通讯作者)，Scripps Res Inst, Dept Cell & Mol Biol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.; Siuzdak, G (通讯作者)，Scripps Res Inst, Dept Chem, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.; Siuzdak, G (通讯作者)，Scripps Res Inst, Dept Mol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.; Siuzdak, G (通讯作者)，Scripps Res Inst, Dept Computat Biol, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
EM friedlan@scripps.edu; siuzdak@scripps.edu
OI Siuzdak, Gary/0000-0002-4749-0014; FANG, MINGLIANG/0000-0002-2204-9783;
   Westenskow, Peter/0000-0001-9841-6220
FU National Institutes of Health [R01 GM114368-02, R01 EY11254, R24
   EY017540-04, P30 MH062261-10, P01 DA026146-02]; Lowy Medical Research
   Institute National Institutes; California Institute of Regenerative
   Medicine [TR1-01219]; NIH Ruth L. Kirschstein National Research Service
   Award [EY021416]; NATIONAL EYE INSTITUTE [R01EY011254] Funding Source:
   NIH RePORTER
FX We gratefully acknowledge financial support from the National Institutes
   of Health (grant nos. R01 GM114368-02, R01 EY11254, R24 EY017540-04, P30
   MH062261-10, P01 DA026146-02). Financial support was also received from
   the Lowy Medical Research Institute National Institutes and from the
   California Institute of Regenerative Medicine (TR1-01219). P.D.W. was
   supported by an NIH Ruth L. Kirschstein National Research Service Award
   (EY021416).
CR Alvarez-Sanchez B, 2010, TRAC-TREND ANAL CHEM, V29, P120, DOI 10.1016/j.trac.2009.12.004
   Alvarez-Sanchez B, 2010, TRAC-TREND ANAL CHEM, V29, P111, DOI 10.1016/j.trac.2009.12.003
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Clements M, 2011, ANAL CHIM ACTA, V685, P36, DOI 10.1016/j.aca.2010.11.014
   Eskelin PM, 2010, MOL GENET METAB, V100, P204, DOI 10.1016/j.ymgme.2010.03.006
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Gutierrez DB, 2010, PHOTOCH PHOTOBIO SCI, V9, P1513, DOI 10.1039/c0pp00230e
   Hammond LE, 2005, J BIOL CHEM, V280, P25629, DOI 10.1074/jbc.M503181200
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Murphy MG, 2007, CHEMOSPHERE, V68, P1692, DOI 10.1016/j.chemosphere.2007.03.049
   Palczewski K, 2001, ELS, DOI [10.1038/npg.els.0004067., DOI 10.1038/NPG.ELS.0004067]
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Rogalidou M, 2010, J PEDIAT HEMATOL ONC, V32, pE61, DOI 10.1097/MPH.0b013e3181ca9eb9
   Shen JJ, 2000, J INHERIT METAB DIS, V23, P27, DOI 10.1023/A:1005694712583
   Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
   Smith CA, 2005, THER DRUG MONIT, V27, P747, DOI 10.1097/01.ftd.0000179845.53213.39
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su X, 2005, BIOCHEMISTRY-US, V44, P5234, DOI 10.1021/bi047773a
   Sud M, 2007, NUCLEIC ACIDS RES, V35, pD527, DOI 10.1093/nar/gkl838
   Tautenhahn R, 2012, ANAL CHEM, V84, P5035, DOI 10.1021/ac300698c
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Westenskow P, 2015, JOVE-J VIS EXP, DOI 10.3791/52214
   Westenskow PD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8470263
   Westenskow PD, 2015, JOVE-J VIS EXP, DOI 10.3791/52247
   Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065
   Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021
   Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015
   Zhu ZJ, 2013, NAT PROTOC, V8, P451, DOI 10.1038/nprot.2013.004
NR 38
TC 12
Z9 12
U1 1
U2 15
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1364-503X
EI 1471-2962
J9 PHILOS T R SOC A
JI Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci.
PD OCT 28
PY 2016
VL 374
IS 2079
AR 20150376
DI 10.1098/rsta.2015.0376
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EG6FB
UT WOS:000391138800013
PM 27644974
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Marra, KV
   Wagley, S
   Kuperwaser, MC
   Campo, R
   Arroyo, JG
AF Marra, Kyle V.
   Wagley, Sushant
   Kuperwaser, Mark C.
   Campo, Rafael
   Arroyo, Jorge G.
TI Care of Older Adults: Role of Primary Care Physicians in the Treatment
   of Cataracts and Macular Degeneration
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE age-related macular degeneration; cataracts; primary care; elderly
ID LONG-TERM INCIDENCE; POSTERIOR SUBCAPSULAR CATARACTS; LOW-VISION
   SERVICE; QUALITY-OF-LIFE; RISK-FACTORS; CIGARETTE-SMOKING; YAG
   CAPSULOTOMY; LENS OPACITIES; REHABILITATION; PROGRESSION
AB This article aims to facilitate optimal management of cataracts and age-related macular degeneration (AMD) by providing information on indications, risk factors, referral guidelines, and treatments and to describe techniques to maximize quality of life (QOL) for people with irreversible vision loss. A review of PubMed and other online databases was performed for peer-reviewed English-language articles from 1980 through August 2012 on visual impairment in elderly adults. Search terms included vision loss, visual impairment, blind, low vision, QOL combined with age-related, elderly, and aging. Articles were selected that discussed vision loss in elderly adults, effects of vision impairment on QOL, and care strategies to manage vision loss in older adults. The ability of primary care physicians (PCPs) to identify early signs of cataracts and AMD in individuals at risk of vision loss is critical to early diagnosis and management of these common age-related eye diseases. PCPs can help preserve vision by issuing aptly timed referrals and encouraging behavioral modifications that reduce risk factors. With knowledge of referral guidelines for soliciting low-vision rehabilitation services, visual aids, and community support resources, PCPs can considerably increase the QOL of individuals with uncorrectable vision loss. By offering appropriately timed referrals, promoting behavioral modifications, and allocating low-vision care resources, PCPs may play a critical role in preserving visual health and enhancing the QOL for the elderly population.
C1 [Marra, Kyle V.; Wagley, Sushant; Kuperwaser, Mark C.; Campo, Rafael; Arroyo, Jorge G.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Marra, Kyle V.] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
   [Marra, Kyle V.; Wagley, Sushant; Kuperwaser, Mark C.; Arroyo, Jorge G.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
   [Wagley, Sushant] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.
C3 Harvard University; Beth Israel Deaconess Medical Center; Harvard
   Medical School; University of California System; University of
   California San Diego; Harvard University; Harvard Medical School;
   Michigan State University; Michigan State University College of Human
   Medicine
RP Arroyo, JG (通讯作者)，Beth Israel Deaconess Med Ctr, Retina Serv, 330 Brookline Ave,CC-5, Boston, MA 02215 USA.
EM jarroyo@bidmc.harvard.edu
OI Arroyo, Jorge/0000-0001-9812-296X; Marra, Kyle/0000-0003-3517-7140
CR Age-Related Eye Disease Study Research Group, 2006, ARCH OPHTHALMOL-CHIC, V121, P211
   Ainsbury EA, 2009, RADIAT RES, V172, P1, DOI 10.1667/RR1688.1
   American Academy of Ophthalmology, 2011, PREF PRACT PATT CAT
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arroyo JG, 2006, JAMA-J AM MED ASSOC, V295, P2394, DOI 10.1001/jama.295.20.2394
   Bell CM, 2009, JAMA-J AM MED ASSOC, V301, P1991, DOI 10.1001/jama.2009.683
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   Brewster S., 2007, P SIGCHI C HUM FACT
   Brewster S, 2002, PERS UBIQUIT COMPUT, V6, P188, DOI 10.1007/s007790200019
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Chaudhry M, 2011, NEPAL J OPHTHALMOL, V3, P80, DOI 10.3126/nepjoph.v3i1.4283
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   de Boer MR, 2006, OPHTHAL PHYSL OPT, V26, P535, DOI 10.1111/j.1475-1313.2006.00424.x
   Delcourt C, 2000, AM J EPIDEMIOL, V151, P497
   Ernst P, 2006, EUR RESPIR J, V27, P1168, DOI 10.1183/09031936.06.00043005
   Executive NHS, 2000, ACT CAT GOOD PRACT G
   Fiore MC, 2008, CLIN PRACTICE GUIDEL
   Forrest CB, 2002, J GEN INTERN MED, V17, P270, DOI 10.1046/j.1525-1497.2002.10309.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hakobyan L, 2013, SURV OPHTHALMOL, V58, P513, DOI 10.1016/j.survophthal.2012.10.004
   Hinds A, 2003, BRIT J OPHTHALMOL, V87, P1391, DOI 10.1136/bjo.87.11.1391
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Horowitz A, 2003, AGING MENT HEALTH, V7, P342, DOI 10.1080/1360786031000150739
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Ivers RQ, 2004, J AM GERIATR SOC, V87, P392
   Jahn CE, 2003, J CATARACT REFR SURG, V29, P925, DOI 10.1016/s0886-3350(02)01820-5
   Kanthan GL, 2009, BRIT J OPHTHALMOL, V93, P1210, DOI 10.1136/bjo.2008.153379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Lash SC, 2006, OPHTHAL PHYSL OPT, V26, P464, DOI 10.1111/j.1475-1313.2006.00408.x
   Lash SC, 2005, BRIT J GEN PRACT, V55, P965
   Lau KK, 2010, HONG KONG J EMERG ME, V17, P71, DOI 10.1177/102490791001700113
   Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9
   Marmor MF, 2015, JAMA-J AM MED ASSOC, V313, P847, DOI 10.1001/jama.2014.14558
   McIlwaine G G, 1991, Eye (Lond), V5 ( Pt 5), P607
   McLeod SD, 2005, BRIT J OPHTHALMOL, V89, P1389, DOI 10.1136/bjo.2005.074310
   Morse AR, 2010, ARCH OPHTHALMOL-CHIC, V128, P1350, DOI 10.1001/archophthalmol.2010.228
   Mulcahy R, 1998, LANCET, V352, P1147, DOI 10.1016/S0140-6736(05)79793-2
   Neale RE, 2003, EPIDEMIOLOGY, V14, P707, DOI 10.1097/01.ede.0000086881.84657.98
   Nguyen NX, 2009, ACTA OPHTHALMOL, V87, P849, DOI 10.1111/j.1755-3768.2008.01423.x
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   NILSSON UL, 1986, DOC OPHTHALMOL, V62, P345, DOI 10.1007/BF00168266
   Paek T, 2007, USER MODEL USER-ADAP, V17, P93, DOI 10.1007/s11257-006-9021-6
   Pardo-Munoz A, 2006, EUR J OPHTHALMOL, V16, P52, DOI 10.1177/112067210601600110
   Preferred Practice Pattern, 2008, AG REL MAC DEG
   Preventive US, 2009, ANN INTERN MED, V151, P37
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Rowe S, 2004, JAMA-J AM MED ASSOC, V291, P1487, DOI 10.1001/jama.291.12.1487
   Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3
   Schein OD, 2000, NEW ENGL J MED, V342, P168, DOI 10.1056/NEJM200001203420304
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smeeth L, 2003, BRIT J OPHTHALMOL, V87, P1247, DOI 10.1136/bjo.87.10.1247
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   SPERDUTO RD, 1994, AM J EPIDEMIOL, V140, P555
   Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub3
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Taylor F, 1985, Aust Fam Physician, V14, P744
   US Census, 2000, 2000 POP TABL US CEN
   vansLeeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101
   VANZANDT PL, 1994, J VISUAL IMPAIR BLIN, V88, P244
   Watson GR, 1997, OPTOMETRY VISION SCI, V74, P249, DOI 10.1097/00006324-199705000-00019
   Watson GR, 2001, J AM GERIATR SOC, V49, P317, DOI 10.1046/j.1532-5415.2001.4930317.x
   WEST SK, 1993, CURR EYE RES, V12, P123, DOI 10.3109/02713689308999480
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P152, DOI 10.1136/bjo.86.2.152
NR 78
TC 4
Z9 4
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2016
VL 64
IS 2
BP 369
EP 377
DI 10.1111/jgs.13927
PG 9
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA DF2FX
UT WOS:000371159000018
PM 26825587
DA 2022-11-30
ER

PT J
AU Groynom, R
   Shoffstall, E
   Wu, LS
   Kramer, RH
   Lavik, EB
AF Groynom, Rebecca
   Shoffstall, Erin
   Wu, Larry S.
   Kramer, Richard H.
   Lavik, Erin B.
TI Controlled release of photoswitch drugs by degradable polymer
   microspheres
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE DENAQ; eye; local delivery; ocular delivery; PLA; PLGA; QAQ; sustained
   delivery
ID AZOBENZENE PHOTOSWITCHES; MACULAR DEGENERATION; VISUAL RESPONSES; BLIND
   MICE; NANOPARTICLES; EXPRESSION; RESTORES; DELIVERY; COSTS
AB Background: QAQ (quaternary ammonium-azobenzene-quaternary ammonium) and DENAQ (diethylamine-azobenzene-quaternary ammonium) are synthetic photoswitch compounds that change conformation in response to light, altering current flow through voltage-gated ion channels in neurons. These compounds are drug candidates for restoring light sensitivity in degenerative blinding diseases, such as age-related macular degeneration (AMD).
   Purpose: However, these photoswitch compounds are cleared from the eye within several days, they must be administered through repeated intravitreal injections. Therefore, we are investigating local, sustained delivery formulations to constantly replenish these molecules and have the potential to restore sight.
   Methods: Here, we encapsulate QAQ and DENAQ into several molecular weights of poly(lactic-co-glycolic) acid (PLGA) through an emulsion technique to assess the viability of delivering the compounds in their therapeutic window over many weeks. We characterize the loading efficiency, release profile and bioactivity of the compounds after encapsulation.
   Results: A very small burst release was observed for all of the formulations with the majority being delivered over the following two months. The lowest molecular weight PLGA led to the highest loading and most linear delivery for both QAQ and DENAQ. Bioactivity was retained for both compounds across the polymers.
   Conclusion: These results present encapsulation into polymers by emulsion as a viable option for controlled release of QAQ and DENAQ.
C1 [Groynom, Rebecca; Shoffstall, Erin; Wu, Larry S.; Lavik, Erin B.] Case Western Reserve Univ, Dept Biomed Engn, Wickenden Bldg,Room 309,10900 Euclid Ave, Cleveland, OH 44106 USA.
   [Kramer, Richard H.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.
C3 Case Western Reserve University; University of California System;
   University of California Berkeley
RP Lavik, EB (通讯作者)，Case Western Reserve Univ, Dept Biomed Engn, Wickenden Bldg,Room 309,10900 Euclid Ave, Cleveland, OH 44106 USA.
EM erin.lavik@case.edu
OI Lavik, Erin/0000-0002-0644-744X
FU Foundation Fighting Blindness; Thome Memorial Foundation; National Eye
   Institute; NIH [DP20D007338]; OFFICE OF THE DIRECTOR, NATIONAL
   INSTITUTES OF HEALTH [DP2OD007338] Funding Source: NIH RePORTER
FX This work was funded through grants from the Foundation Fighting
   Blindness, the Thome Memorial Foundation and the National Eye Institute
   to RHK. The authors would also like to acknowledge NIH Director's New
   Innovator Award Grant, DP20D007338.
CR Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3
   Banghart MR, 2009, ANGEW CHEM INT EDIT, V48, P9097, DOI 10.1002/anie.200904504
   Beharry AA, 2011, CHEM SOC REV, V40, P4422, DOI 10.1039/c1cs15023e
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bramley T, 2008, ARCH OPHTHALMOL-CHIC, V126, P849, DOI 10.1001/archopht.126.6.849
   Frick KD, 2008, OPHTHALMOLOGY, V115, P11, DOI 10.1016/j.ophtha.2007.02.007
   Hamishehkar H, 2009, COLLOID SURFACE B, V74, P340, DOI 10.1016/j.colsurfb.2009.08.003
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Mourot A, 2011, ACS CHEM NEUROSCI, V2, P536, DOI 10.1021/cn200037p
   Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022
   Sadovski O, 2009, ANGEW CHEM INT EDIT, V48, P1484, DOI 10.1002/anie.200805013
   Sakai T, 2006, EXP EYE RES, V82, P657, DOI 10.1016/j.exer.2005.09.003
   Tochitsky I, 2014, NEURON, V81, P800, DOI 10.1016/j.neuron.2014.01.003
   Vay K, 2012, EUR J PHARM BIOPHARM, V81, P399, DOI 10.1016/j.ejpb.2012.02.019
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zolnik BS, 2008, J CONTROL RELEASE, V127, P137, DOI 10.1016/j.jconrel.2008.01.004
NR 20
TC 10
Z9 12
U1 2
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1061-186X
EI 1029-2330
J9 J DRUG TARGET
JI J. Drug Target.
PY 2015
VL 23
IS 7-8
BP 710
EP 715
DI 10.3109/1061186X.2015.1060978
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DK2UF
UT WOS:000374769200015
PM 26453166
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, DY
   Joe, SG
   Baek, S
   Kim, JG
   Yoon, YH
   Lee, JY
AF Kim, Dong Yoon
   Joe, Soo Geun
   Baek, Seunghee
   Kim, June-Gone
   Yoon, Young Hee
   Lee, Joo Yong
TI Acute-Onset Vitreous Hemorrhage of Unknown Origin before Vitrectomy:
   Causes and Prognosis
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Purpose. To analyze causes and prognosis of acute-onset preoperatively unknown origin vitreous hemorrhage (VH). Methods. This study included patients who underwent vitrectomy for acute-onset preoperatively unknown origin VH. The underlying causes of VH, which were identified after vitrectomy, were analyzed. And overall visual prognosis of unknown origin VH was analyzed. Risk scoring system was developed to predict visual prognosis after vitrectomy. Results. 169 eyes were included. Among these, retinal vein occlusion (RVO), retinal break, and age-related macular degeneration (AMD) were identified in 74 (43.8%), 50 (29.6%), and 21 (12.4%) patients, respectively. After vitrectomy, logMAR BCVA significantly improved from 1.93 +/- 0.59 to 0.47 +/- 0.71. However, postoperative BCVA in AMD eyes were significantly poorer than others. Poor visual prognosis after vitrectomy was associated with old age, poor preoperative vision in both eyes, and drusen in the fellow eye. Conclusions. RVO, retinal break, and AMD are the most common causes of acute-onset preoperatively unknown origin VH and the most common causes of VH change with age. The visual prognosis of unknown origin VH is relatively good, except among AMD patients. Older patients with poor preoperative BCVA in both eyes and patients with AMD in the fellow eye are at a higher risk of poor visual prognosis following vitrectomy.
C1 [Kim, Dong Yoon] Chungbuk Natl Univ, Dept Ophthalmol, Coll Med, Cheongju, South Korea.
   [Joe, Soo Geun] Univ Ulsan, Gangneung Asan Hosp, Dept Ophthalmol, Coll Med, Kangnung, South Korea.
   [Baek, Seunghee] Univ Ulsan, Dept Clin Epidemiol & Biostat, Coll Med, Asan Med Ctr, Seoul, South Korea.
   [Kim, June-Gone; Yoon, Young Hee; Lee, Joo Yong] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul 138736, South Korea.
C3 Chungbuk National University; University of Ulsan; University of Ulsan;
   University of Ulsan; Asan Medical Center
RP Lee, JY (通讯作者)，Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.
EM ophthalmo@amc.seoul.kr
FU Asan Institute for Life Sciences, Seoul, Republic of Korea [2014-7206]
FX This study was supported by a grant (2014-7206) from the Asan Institute
   for Life Sciences, Seoul, Republic of Korea.
CR [Anonymous], 1986, Arch Ophthalmol, V104, P34
   [Anonymous], 1985, Arch Ophthalmol, V103, P1644
   [Anonymous], 1984, AM J OPHTHALMOL, V98, P271
   [Anonymous], 1988, Ophthalmology, V95, P1307
   BUTNER RW, 1982, ANN OPHTHALMOL, V14, P268
   CORDIDO M, 1988, RETINA-J RET VIT DIS, V8, P96, DOI 10.1097/00006982-198808020-00003
   DANA MR, 1993, OPHTHALMOLOGY, V100, P1377
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   LEAN JS, 1980, BRIT J OPHTHALMOL, V64, P469, DOI 10.1136/bjo.64.7.469
   LINCOFF H, 1976, BRIT J OPHTHALMOL, V60, P454, DOI 10.1136/bjo.60.6.454
   Lindgren G, 1996, Curr Opin Ophthalmol, V7, P13, DOI 10.1097/00055735-199606000-00003
   LINDGREN G, 1995, AM J OPHTHALMOL, V119, P458, DOI 10.1016/S0002-9394(14)71232-2
   MORSE PH, 1974, ARCH OPHTHALMOL-CHIC, V92, P297
   SEELENFREUND MH, 1983, AM J OPHTHALMOL, V95, P659, DOI 10.1016/0002-9394(83)90386-0
   Spraul CW, 1997, SURV OPHTHALMOL, V42, P3, DOI 10.1016/S0039-6257(97)84041-6
   Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9
   Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742
   WINSLOW RL, 1980, SOUTHERN MED J, V73, P1450, DOI 10.1097/00007611-198011000-00009
   YESHAYA A, 1983, ANN OPHTHALMOL, V15, P615
NR 20
TC 2
Z9 2
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 429251
DI 10.1155/2015/429251
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT9TP
UT WOS:000363159800001
PM 26504593
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Yanai, R
   Mulki, L
   Hasegawa, E
   Takeuchi, K
   Sweigard, H
   Suzuki, J
   Gaissert, P
   Vavvas, DG
   Sonoda, KH
   Rothe, M
   Schunck, WH
   Miller, JW
   Connor, KM
AF Yanai, Ryoji
   Mulki, Lama
   Hasegawa, Eiichi
   Takeuchi, Kimio
   Sweigard, Harry
   Suzuki, Jun
   Gaissert, Philipp
   Vavvas, Demetrios G.
   Sonoda, Koh-Hei
   Rothe, Michael
   Schunck, Wolf-Hagen
   Miller, Joan W.
   Connor, Kip M.
TI Cytochrome P450-generated metabolites derived from omega-3 fatty acids
   attenuate neovascularization
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE choroidal neovascularization; immune cell recruitment; PPAR gamma;
   adhesion molecules; epoxy-metabolites
ID FATTY-ACID INTAKE; MACULAR DEGENERATION; DIETARY-FAT;
   EPOXYEICOSATRIENOIC ACIDS; PPAR-GAMMA; RISK; ENZYMES; MECHANISMS;
   TARGETS; MEDIATE
AB Ocular neovascularization, including age-related macular degeneration (AMD), is a primary cause of blindness in individuals of industrialized countries. With a projected increase in the prevalence of these blinding neovascular diseases, there is an urgent need for new pharmacological interventions for their treatment or prevention. Increasing evidence has implicated eicosanoid-like metabolites of long-chain polyunsaturated fatty acids (LCPUFAs) in the regulation of neovascular disease. In particular, metabolites generated by the cytochrome P450 (CYP)-epoxygenase pathway have been shown to be potent modulators of angiogenesis, making this pathway a reasonable previously unidentified target for intervention in neovascular ocular disease. Here we show that dietary supplementation with omega-3 LCPUFAs promotes regression of choroidal neovessels in a well-characterized mouse model of neovascular AMD. Leukocyte recruitment and adhesion molecule expression in choroidal neovascular lesions were down-regulated in mice fed omega-3 LCPUFAs. The serum of these mice showed increased levels of anti-inflammatory eicosanoids derived from eicosapentaenoic acid and docosahexaenoic acid. 17,18-epoxyeicosatetraenoic acid and 19,20-epoxydocosapentaenoic acid, the major CYP-generated metabolites of these primary omega-3 LCPUFAs, were identified as key lipid mediators of disease resolution. We conclude that CYP-derived bioactive lipid metabolites from omega-3 LCPUFAs are potent inhibitors of intraocular neovascular disease and show promising therapeutic potential for resolution of neovascular AMD.
C1 [Yanai, Ryoji; Mulki, Lama; Hasegawa, Eiichi; Takeuchi, Kimio; Sweigard, Harry; Suzuki, Jun; Gaissert, Philipp; Vavvas, Demetrios G.; Miller, Joan W.; Connor, Kip M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02114 USA.
   [Sonoda, Koh-Hei] Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, Ube, Yamaguchi 7558505, Japan.
   [Rothe, Michael] Lipidomix GmbH, D-13125 Berlin, Germany.
   [Schunck, Wolf-Hagen] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Yamaguchi University; Helmholtz Association; Max Delbruck
   Center for Molecular Medicine
RP Connor, KM (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02114 USA.
EM kip_connor@meei.harvard.edu
OI Connor, Kip/0000-0002-2048-9080; Vavvas, Demetrios/0000-0002-8622-6478;
   Miller, Joan/0000-0003-2046-3996
FU Research to Prevent Blindness; Massachusetts Lions Eye Research Fund;
   Japan Eye Bank Association; National Eye Institute of the National
   Institutes of Health [R01EY022084/S1, T32EY007145, P30EY014104];
   NATIONAL EYE INSTITUTE [R01EY022084, T32EY007145, P30EY014104] Funding
   Source: NIH RePORTER
FX This study was supported by a Special Scholar Award (to K. M. C.) and an
   unrestricted grant (to J.W.M.) from Research to Prevent Blindness; the
   Massachusetts Lions Eye Research Fund and an award from the Japan Eye
   Bank Association (to R.Y.); and by Grants R01EY022084/S1 (to K. M. C.),
   T32EY007145 (to H. S.), and P30EY014104 from the National Eye Institute
   of the National Institutes of Health.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Arnold C, 2010, J BIOL CHEM, V285, P32720, DOI 10.1074/jbc.M110.118406
   Arnold C, 2010, PHARMACOL REP, V62, P536, DOI 10.1016/S1734-1140(10)70311-X
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bensinger SJ, 2008, NATURE, V454, P470, DOI 10.1038/nature07202
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cotran R S, 1982, Monogr Pathol, P18
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Fer M, 2008, ARCH BIOCHEM BIOPHYS, V471, P116, DOI 10.1016/j.abb.2008.01.002
   Fischer R, 2014, J LIPID RES, V55, P1150, DOI 10.1194/jlr.M047357
   Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Imig JD, 2012, PHYSIOL REV, V92, P101, DOI 10.1152/physrev.00021.2011
   Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877
   Kang JX, 2013, CANCER METAST REV, V32, P201, DOI 10.1007/s10555-012-9401-9
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Konkel A, 2011, BBA-PROTEINS PROTEOM, V1814, P210, DOI 10.1016/j.bbapap.2010.09.009
   Kubota T, 2014, FASEB J, V28, P586, DOI 10.1096/fj.13-236224
   London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Morin C, 2010, AM J RESP CELL MOL, V43, P564, DOI 10.1165/rcmb.2009-0155OC
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901
   Noda K, 2008, FASEB J, V22, P2928, DOI 10.1096/fj.07-105346
   Panigrahy D, 2012, J CLIN INVEST, V122, P178, DOI 10.1172/JCI58128
   Panigrahy D, 2011, CANCER METAST REV, V30, P525, DOI 10.1007/s10555-011-9315-y
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197
   Sheets KG, 2010, MOL VIS, V16, P320
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Spector AA, 2009, J LIPID RES, V50, pS52, DOI 10.1194/jlr.R800038-JLR200
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Wang DZ, 2012, J CLIN INVEST, V122, P19, DOI 10.1172/JCI61453
   Wauthier V, 2007, CURR MED CHEM, V14, P745, DOI 10.2174/092986707780090981
   Webler AC, 2008, AM J PHYSIOL-CELL PH, V295, pC1292, DOI 10.1152/ajpcell.00230.2008
   Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200
   Zhang GD, 2013, P NATL ACAD SCI USA, V110, P6530, DOI 10.1073/pnas.1304321110
NR 49
TC 55
Z9 61
U1 0
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 1
PY 2014
VL 111
IS 26
BP 9603
EP 9608
DI 10.1073/pnas.1401191111
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AK0QG
UT WOS:000338118900064
PM 24979774
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Cheng, LB
   Cheng, L
   Bi, HE
   Zhang, ZQ
   Yao, J
   Zhou, XZ
   Jiang, Q
AF Cheng, Li-bo
   Cheng, Lei
   Bi, Hui-e
   Zhang, Zhi-qing
   Yao, Jin
   Zhou, Xiao-zhong
   Jiang, Qin
TI Alpha-melanocyte stimulating hormone protects retinal pigment epithelium
   cells from oxidative stress through activation of melanocortin 1
   receptor-Akt-mTOR signaling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Age related macular degeneration (AMD); Retinal pigment epithelium
   (RPE); alpha-Melanocyte stimulating hormone (alpha-MSH); Melanocortin 1
   receptor (MC1R); Apoptosis and Akt/mTOR signaling
ID TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; B ACTIVATION; DNA-DAMAGE;
   IN-VITRO; MSH; MIGRATION; SURVIVAL; CANCER; INHIBITOR
AB Patients with age related macular degeneration (AMD) will develop vision loss in the center of the visual field. Reactive oxygen species (ROS)-mediated retinal pigment epithelium (RPE) cell apoptosis is an important contributor of AMD. In this study, we explored the pro-survival effect of alpha-melanocyte stimulating hormone (alpha-MSH) on oxidative stressed RPE cells. We found that alpha-MSH receptor melanocortin I receptor (MC1R) was functionally expressed in primary and transformed RPE cells. RPE cells were response to alpha-MSH stimulation. alpha-MSH activated Akt/mammalian target of rapamycin (mTOR) and Erk1/2 signalings in RPE cells, which were inhibited by MC1R siRNA knockdown. alpha-MSH protected RPE cells from hydrogen peroxide (H2O2)-induced apoptosis, an effect that was almost abolished when MC1R was depleted by siRNA. alpha-MSH-mediated S6K1 activation and pro-survival effect against H2O2 was inhibited by Akt inhibitors (perifosine, MK-2206 and LY294002). Further, mTOR inhibition by rapamycin, or by mTOR siRNA knockdown, diminished alpha-MSH's pro-survival effect in RPE cells. Thus, Akt and its downstream mTOR signaling mediates alpha-MSH-induced survival in RPE cells. In summary, we have identified a new alpha-MSH-MC1R physiologic pathway that reduces H2O2-induced RPE cell damage, and might minimize the risk of developing AMD. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Cheng, Li-bo; Bi, Hui-e; Yao, Jin; Jiang, Qin] Nanjing Med Univ, Affiliated Eye Hosp, Nanjing 210029, Peoples R China.
   [Cheng, Li-bo] Liyang City Hosp Tradit Chinese Med, Eye Dept, Liyang City 213300, Peoples R China.
   [Cheng, Lei] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Dept Intervent Radiol, Suzhou 215000, Peoples R China.
   [Zhang, Zhi-qing] Soochow Univ, Inst Neurosci, Suzhou 215123, Peoples R China.
   [Zhou, Xiao-zhong] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215000, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Soochow
   University - China; Soochow University - China
RP Zhou, XZ (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Orthoped, San Xiang Rd, Suzhou 215000, Peoples R China.
EM zhouxz@suda.edu.cn; dryaojin@yahoo.com
FU National Natural Science Foundation of China [81070744, 81271028];
   post-doc fund of Jiangsu Province [1002009B]; Medical Science and
   Technology Development Project Fund of Nanjing [ZKX12047, YKK12208,
   YKK12207]
FX This work was generously supported by grants from the National Natural
   Science Foundation of China (Nos. 81070744, 81271028), post-doc fund of
   Jiangsu Province (No. 1002009B) and Medical Science and Technology
   Development Project Fund of Nanjing (ZKX12047, YKK12208, YKK12207).
CR Abdel-Malek ZA, 2006, FASEB J, V20, P1561, DOI 10.1096/fj.05-5655fje
   Adachi S, 2000, J IMMUNOL, V164, P855, DOI 10.4049/jimmunol.164.2.855
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Bohm M, 2005, J BIOL CHEM, V280, P5795, DOI 10.1074/jbc.M406334200
   Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x
   Cao GF, 2011, BIOCHEM BIOPH RES CO, V414, P499, DOI 10.1016/j.bbrc.2011.09.094
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Chhajlani V, 1996, BIOCHEM MOL BIOL INT, V38, P73
   Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gills JJ, 2009, CURR ONCOL REP, V11, P102, DOI 10.1007/s11912-009-0016-4
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012
   Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629
   ILAN AB, 1992, PROSTAGLANDINS, V43, P31, DOI 10.1016/0090-6980(92)90062-X
   Jiang Q, 2006, J OCUL PHARMACOL TH, V22, P93, DOI 10.1089/jop.2006.22.93
   Kadekaro AL, 2003, ANN NY ACAD SCI, V994, P359, DOI 10.1111/j.1749-6632.2003.tb03200.x
   Kondapaka SB, 2003, MOL CANCER THER, V2, P1093
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Li CP, 2013, BIOCHEM BIOPH RES CO, V438, P739, DOI 10.1016/j.bbrc.2013.07.097
   LIPTON JM, 1991, PEPTIDES, V12, P795, DOI 10.1016/0196-9781(91)90135-C
   Lipton JM, 1997, IMMUNOL TODAY, V18, P140, DOI 10.1016/S0167-5699(97)01009-8
   Liu Y, 2012, EUR J CELL BIOL, V91, P728, DOI 10.1016/j.ejcb.2012.03.008
   Luger TA, 2003, ANN NY ACAD SCI, V994, P133, DOI 10.1111/j.1749-6632.2003.tb03172.x
   Luger TA, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P87, DOI 10.1038/jidsymp.1997.17
   Manna SK, 1998, J IMMUNOL, V161, P2873
   Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105
   Mountjoy KG, 2003, ANN NY ACAD SCI, V994, P58, DOI 10.1111/j.1749-6632.2003.tb03162.x
   PACIFICI RE, 1991, GERONTOLOGY, V37, P166
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x
   Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627
   Thody AJ, 1999, ANN NY ACAD SCI, V885, P217, DOI 10.1111/j.1749-6632.1999.tb08679.x
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yao J, 2009, INT J MOL MED, V24, P153, DOI 10.3892/ijmm_00000218
   Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263
NR 40
TC 35
Z9 35
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 10
PY 2014
VL 443
IS 2
BP 447
EP 452
DI 10.1016/j.bbrc.2013.11.113
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AA5TQ
UT WOS:000331162900017
PM 24316214
DA 2022-11-30
ER

PT J
AU Warnke, PH
   Alamein, M
   Skabo, S
   Stephens, S
   Bourke, R
   Heiner, P
   Liu, Q
AF Warnke, Patrick H.
   Alamein, Mohammad
   Skabo, Stuart
   Stephens, Sebastien
   Bourke, Robert
   Heiner, Peter
   Liu, Qin
TI Primordium of an artificial Bruch's membrane made of nanofibers for
   engineering of retinal pigment epithelium cell monolayers
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Retinal pigment epithelial transplantation; Three-dimensional membrane;
   Needle-free electrospinning; Macular degeneration; Nanofibers
ID MACULAR DEGENERATION; EXTRACELLULAR-MATRIX; DEGRADATION BEHAVIORS;
   TRANSPLANTATION; SCAFFOLDS; DIFFERENTIATION; RPE; INTEGRATION;
   MORPHOLOGY; PROMOTES
AB Transplanted retinal pigment epithelium (RPE) cells hold promise for treatment of age-related macular degeneration (AMD) and Stargardt disease (SD), but it is conceivable that the degenerated host Bruch's membrane (BM) as a natural substrate for RPE might not optimally support transplanted cell survival with correct cellular organization. We fabricated novel ultrathin three-dimensional (3-D) nanofibrous membranes from collagen type I and poly(lactic-co-glycolic acid) (PLGA) by an advanced clinical-grade needle-free electrospinning process. The nanofibrillar 3-D networks closely mimicked the fibrillar architecture of the native inner collagenous layer of human BM. Human RPE cells grown on our nanofibrous membranes bore a striking resemblance to native human RPE. They exhibited a correctly orientated monolayer with a polygonal cell shape and abundant sheet-like microvilli on their apical surfaces. RPE cells built tight junctions and expressed RPE65 protein. Flat 2-D PLGA film and cover glass as controls delivered inferior RPE layers. Our nanofibrous membranes may imitate the natural BM to such extent that they allow for the engineering of an in vivo-like human RPE monolayer that maintains the natural bio-functional characteristics. Such ultrathin membranes may provide a promising vehicle for a functional RPE cell monolayer implantation in the subretinal space in patients with AMD or SD. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Warnke, Patrick H.; Alamein, Mohammad; Stephens, Sebastien] Griffith Univ, Griffith Hlth Inst, Gold Coast, Qld 4215, Australia.
   [Alamein, Mohammad; Skabo, Stuart; Liu, Qin] Clem Jones Res Ctr Stem Cells & Tissue Regenerat, Southport, Qld 4229, Australia.
   [Bourke, Robert; Heiner, Peter] Vis Eye Inst, Southport, Qld 4215, Australia.
C3 Griffith University; Menzies Health Institute Queensland
RP Warnke, PH (通讯作者)，Griffith Univ, Griffith Hlth Inst, Gold Coast, Qld 4215, Australia.
EM p.warnke@griffith.edu.au
OI Skabo, Stuart/0000-0002-8064-0926
FU Clem Jones Group, Brisbane, QLD, Australia
FX We greatly acknowledge the funding and support received by the Clem
   Jones Group, Brisbane, QLD, Australia, for this study. We are inspired
   by Dr Clem Jones's vision to find a cure for macular degeneration'.
CR Alamein MA, 2013, ADV HEALTHC MATER, V2, P702, DOI 10.1002/adhm.201200287
   Alamein MA, 2013, TISSUE ENG PART C-ME, V19, P458, DOI [10.1089/ten.tec.2012.0417, 10.1089/ten.TEC.2012.0417]
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cukierman E, 2010, SEMIN CANCER BIOL, V20, P139, DOI 10.1016/j.semcancer.2010.04.004
   Deberg M, 2005, OSTEOARTHR CARTILAGE, V13, P258, DOI 10.1016/j.joca.2004.12.002
   Dong YX, 2009, TISSUE ENG PART B-RE, V15, P333, DOI [10.1089/ten.teb.2008.0619, 10.1089/ten.TEB.2008.0619]
   Dong YX, 2010, TISSUE ENG PT A, V16, P283, DOI 10.1089/ten.tea.2008.0537
   Dotti F, 2007, J IND TEXT, V37, P151, DOI DOI 10.1177/1528083707078133
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Glazer Liane Clamen, 2002, Ophthalmol Clin North Am, V15, P93, DOI 10.1016/S0896-1549(01)00011-6
   GOURAS P, 1984, AN ACAD BRAS CIENC, V56, P431
   Guaccio A, 2011, BIOTECHNOL BIOENG, V108, P1965, DOI 10.1002/bit.23113
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   Harman AM, 1997, INVEST OPHTH VIS SCI, V38, P2016
   He W, 2009, J BIOMED MATER RES A, V90A, P205, DOI 10.1002/jbm.a.32081
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kuijpers AJ, 2000, J BIOMAT SCI-POLYM E, V11, P225, DOI 10.1163/156856200743670
   Lackowski M, 2011, J PHYS CONF SER, V301, DOI 10.1088/1742-6596/301/1/012013
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   Misslitz H, 2013, SMALL, V9, P2053, DOI 10.1002/smll.201202334
   Nisbet DR, 2009, J BIOMATER APPL, V24, P7, DOI 10.1177/0885328208099086
   Nur-E-Kamal A, 2006, STEM CELLS, V24, P426, DOI 10.1634/stemcells.2005-0170
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Paik DC, 2001, CONNECT TISSUE RES, V42, P111, DOI 10.3109/03008200109014253
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Prabhakaran MP, 2009, ACTA BIOMATER, V5, P2884, DOI 10.1016/j.actbio.2009.05.007
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Santos E, 2012, TRENDS BIOTECHNOL, V30, P331, DOI 10.1016/j.tibtech.2012.03.005
   Schindler M, 2005, BIOMATERIALS, V26, P5624, DOI 10.1016/j.biomaterials.2005.02.014
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Slater SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020802
   Srivastava GK, 2011, J BIOMED MATER RES A, V97A, P243, DOI 10.1002/jbm.a.33050
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun K, 2007, MOL VIS, V13, P2310
   Thieltges F, 2011, OPHTHALMIC RES, V46, P133, DOI 10.1159/000324045
   Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Vasireddy V, 2010, PROG RETIN EYE RES, V29, P191, DOI 10.1016/j.preteyeres.2010.01.001
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wang J, 2012, MATER RES SOC SYMP P, V1403, P139, DOI 10.1557/opl.2012.418
   Wenzel A, 2007, INVEST OPHTH VIS SCI, V48, P534, DOI 10.1167/iovs.06-0652
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
   Yang F, 2005, BIOMATERIALS, V26, P2603, DOI 10.1016/j.biomaterials.2004.06.051
   Zong XH, 2003, BIOMACROMOLECULES, V4, P416, DOI 10.1021/bm025717o
NR 61
TC 72
Z9 76
U1 1
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2013
VL 9
IS 12
BP 9414
EP 9422
DI 10.1016/j.actbio.2013.07.029
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 274FQ
UT WOS:000328592600016
PM 23917149
DA 2022-11-30
ER

PT J
AU Khanifar, AA
   Lederer, DE
   Ghodasra, JH
   Stinnett, SS
   Lee, JJ
   Cousins, SW
   Bearelly, S
AF Khanifar, Aziz A.
   Lederer, David E.
   Ghodasra, Jason H.
   Stinnett, Sandra S.
   Lee, Jane J.
   Cousins, Scott W.
   Bearelly, Srilaxmi
TI COMPARISON OF COLOR FUNDUS PHOTOGRAPHS AND FUNDUS AUTOFLUORESCENCE
   IMAGES IN MEASURING GEOGRAPHIC ATROPHY AREA
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; color fundus photographs; fundus
   autofluorescence; geographic atrophy
ID MACULAR DEGENERATION; PATTERNS; DISEASE; CLASSIFICATION; PROGRESSION
AB Purpose: To assess the agreement between color fundus photographs (CFP) and fundus autofluorescence (FAF) images when measuring geographic atrophy (GA) area and reproducibility of measurements between graders. Frequency and disagreement types were also determined.
   Methods: Eyes with GA secondary to age-related macular degeneration had CFP and FAF imaging on the same day. Seventy-two eyes from 72 patients were included in the analysis. Three graders calculated GA area using digital imaging software. Main outcome measures included agreement between graders for GA area on both FAF and CFP and agreement between both imaging modalities.
   Results: The intraclass correlation for the 3 graders for FAF images was 0.99 (95% confidence interval, 0.98-0.99). For CFP, it was 0.96 (95% confidence interval, 0.94-0.97). The intraclass correlation between imaging modalities for Graders 1, 2, and 3 were 0.93, 0.85, and 0.87, respectively. Sensitivities to detect involvement of fovea (CFP, 86-97%; FAF, 72-93%) and specificities to detect sparing of fovea (CFP, 74-76%; FAF, 59-88%) overlapped between imaging modalities.
   Conclusion: Both CFP and FAF imaging are reliable for measuring GA area. Interobserver agreement was slightly higher for FAF images. Although the high agreement between modalities suggests that either would be appropriate for measuring GA area, using both may be the best approach for following GA progression. RETINA 32:1884-1891, 2012
C1 Duke Ctr Macular Dis, Durham, NC USA.
   Duke Eye Ctr, Albert Eye Res Inst, Durham, NC USA.
C3 Duke University
RP Bearelly, S (通讯作者)，Columbia Univ, Med Ctr, Edward S Harkness Eye Inst, 635 W 165th St,Box EI-8, New York, NY 10032 USA.
EM sb3179@columbia.edu
OI Stinnett, Sandra/0000-0001-7192-0195
FU NEI [1K23 EY018895-01]; NIH [P30-EY005722]; NATIONAL EYE INSTITUTE
   [P30EY005722, K23EY018895] Funding Source: NIH RePORTER
FX Supported by NEI 1K23 EY018895-01 and NIH P30-EY005722 Core Grant for
   Vision Research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barnhart HX, 2002, BIOMETRICS, V58, P1020, DOI 10.1111/j.0006-341X.2002.01020.x
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hopkins J, 2006, INVEST OPHTH VIS SCI, V47, P2269, DOI 10.1167/iovs.05-1482
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
NR 17
TC 38
Z9 38
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2012
VL 32
IS 9
BP 1884
EP 1891
DI 10.1097/IAE.0b013e3182509778
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012EH
UT WOS:000309217800025
PM 22547167
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Vejux, A
   Lizard, G
AF Vejux, Anne
   Lizard, Gerard
TI Cytotoxic effects of oxysterols associated with human diseases:
   Induction of cell death (apoptosis and/or oncosis), oxidative and
   inflammatory activities, and phospholipidosis
SO MOLECULAR ASPECTS OF MEDICINE
LA English
DT Review
DE Apoptosis; Atherosclerosis; Alzheimer; Age-related macular degeneration;
   Cataract; Inflammation; Multiple sclerosis; Osteoporosis; Oxysterols;
   Phospholipidosis
ID SMOOTH-MUSCLE-CELLS; LOW-DENSITY-LIPOPROTEIN; MARROW STROMAL CELLS;
   ENDOPLASMIC-RETICULUM STRESS; PIGMENT EPITHELIAL-CELLS; POSITIVE
   CYTOPLASMIC STRUCTURES; DRUG-INDUCED PHOSPHOLIPIDOSIS; SPECTRAL IMAGING
   MICROSCOPY; RAPID HEPATIC-METABOLISM; MYELIN FIGURE FORMATION
AB Oxysterols resulting from spontaneous or enzymatic oxidation of cholesterol are present in numerous foodstuffs and have been identified at increased levels in the plasma and the vascular walls of patients with cardiovascular diseases, especially in atherosclerotic lesions. Consequently, their role in lipid disorders is widely suspected, but they may also contribute to the development of important degenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, osteoporosis, age-related macular degeneration, and cataract. Since these pathologies can be associated with the presence of apoptotic cells, oxidative and inflammatory processes, and lipid disorders, the ability of oxysterols to trigger cell death, activate oxidation and inflammation, and modulate lipid homeostasis is being extensively studied. There are several important considerations regarding the physiological/pathophysiological functions and activities of the different oxysterols. It is therefore important to determine their biological activities and identify their signaling pathways, when they are used either in isolation or as mixtures. In these conditions, oxysterols may have cytotoxic, oxidative, and/or inflammatory effects, or no effects whatsoever. Moreover, with cytotoxic oxysterols, a substantial accumulation of polar lipids in cytoplasmic multilamellar structures was observed, demonstrating that cytotoxic oxysterols were phospholipidosis inducers. This basic knowledge on oxysterols contributes to a better understanding of the associated pathologies, so that new treatments and drugs can be designed. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Lizard, Gerard] Univ Bourgogne, Ctr Rech Inserm 866, Fac Sci Gabriel, F-21000 Dijon, France.
   [Vejux, Anne] Univ Nice, Fac Med, Unite TIRO, CEA,DSV,DIEP,SBTN, F-06107 Nice, France.
C3 Institut Agro; AgroSup Dijon; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Bourgogne; CEA; UDICE-French
   Research Universities; Universite Cote d'Azur; Universite de
   Franche-Comte
RP Lizard, G (通讯作者)，Univ Bourgogne, Ctr Rech Inserm 866, Fac Sci Gabriel, 6 Bd Gabriel, F-21000 Dijon, France.
EM Gerard.Lizard@u-bourgogne.fr
RI Lizard, Gerard/B-2439-2012; VEJUX, Anne/C-1509-2019
OI VEJUX, Anne/0000-0002-4063-9680
FU INSERM; Ligue Contre Le Cancer (Comity de Cote d'Or); University
   Hospital of Dijon; Conseil Regional de Bourgogne
FX This work was supported by grants from the INSERM, the Ligue Contre Le
   Cancer (Comity cle Cote d'Or), the University Hospital of Dijon, and the
   Conseil Regional de Bourgogne. The authors are indebted to Ms. Linda
   Northrup for reviewing the English version of the manuscript.
CR Adachi J, 1996, LIPIDS, V31, P1039, DOI 10.1007/BF02522460
   ADDIS PB, 1986, FOOD CHEM TOXICOL, V24, P1021, DOI 10.1016/0278-6915(86)90283-8
   Addis PB, 1996, IFT BAS SYM, V11, P199
   Aghaloo TL, 2007, J ORTHOP RES, V25, P1488, DOI 10.1002/jor.20437
   Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002
   Amantea CM, 2008, J CELL BIOCHEM, V105, P424, DOI 10.1002/jcb.21840
   Anderson N, 2006, FEBS LETT, V580, P5533, DOI 10.1016/j.febslet.2006.08.061
   [Anonymous], 2002, CHOLESTEROL PHYTOSTE
   Antonio V, 2003, BIOCHEM J, V376, P351, DOI 10.1042/BJ20030098
   Ares MPS, 2000, ATHEROSCLEROSIS, V153, P23, DOI 10.1016/S0021-9150(00)00380-4
   Ares MPS, 1997, J LIPID RES, V38, P2049
   Babiker A, 1998, BBA-LIPID LIPID MET, V1392, P333, DOI 10.1016/S0005-2760(98)00047-2
   Bensinger SJ, 2008, CELL, V134, P97, DOI 10.1016/j.cell.2008.04.052
   Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6
   Berthier A, 2004, CELL DEATH DIFFER, V11, P897, DOI 10.1038/sj.cdd.4401434
   Biasi F, 2004, FASEB J, V18, P693, DOI 10.1096/fj.03-0401fje
   Bjorkhem I, 2006, ACTA NEUROL SCAND, V114, P43, DOI 10.1111/j.1600-0404.2006.00684.x
   Bjorkhem I, 2006, J INTERN MED, V260, P493, DOI 10.1111/j.1365-2796.2006.01725.x
   Bjorkhem I, 1999, CURR OPIN LIPIDOL, V10, P161, DOI 10.1097/00041433-199904000-00010
   BJORKHEM I, 1992, J LIPID RES, V33, P455
   Bjorkhem I, 2002, ARTERIOSCL THROM VAS, V22, P734, DOI 10.1161/01.ATV.0000013312.32196.49
   Bobryshev YV, 2006, MICRON, V37, P208, DOI 10.1016/j.micron.2005.10.007
   Bodin K, 2001, J BIOL CHEM, V276, P38685, DOI 10.1074/jbc.M105127200
   Bosco DA, 2006, NAT CHEM BIOL, V2, P249, DOI 10.1038/nchembio782
   Boselli E, 2001, J CHROMATOGR A, V917, P239, DOI 10.1016/S0021-9673(01)00688-4
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   BREUER O, 1995, J BIOL CHEM, V270, P20278, DOI 10.1074/jbc.270.35.20278
   Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8
   Brown AJ, 2000, J BIOL CHEM, V275, P27627
   Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Cao GQ, 2007, CURR ALZHEIMER RES, V4, P179, DOI 10.2174/156720507780362173
   Carpenter KLH, 2002, BRIT J NUTR, V88, P335, DOI 10.1079/BJN2002707
   CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E
   Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528
   Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691
   Chang JY, 1998, BIOCHEM BIOPH RES CO, V249, P817, DOI 10.1006/bbrc.1998.9237
   Cheng YW, 2005, FOOD CHEM TOXICOL, V43, P617, DOI 10.1016/j.fct.2005.01.007
   Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0
   CLARE K, 1995, ATHEROSCLEROSIS, V118, P67, DOI 10.1016/0021-9150(95)05594-M
   Colles SM, 2001, TRENDS CARDIOVAS MED, V11, P131, DOI 10.1016/S1050-1738(01)00106-2
   Corcoran RB, 2006, P NATL ACAD SCI USA, V103, P8408, DOI 10.1073/pnas.0602852103
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CUTHBERT JA, 1980, J IMMUNOL, V124, P2240
   de Lau LML, 2005, NEUROLOGY, V64, P2040, DOI 10.1212/01.WNL.0000166038.67153.9F
   Diczfalusy U, 2004, J AOAC INT, V87, P467
   Diestel A, 2003, J EXP MED, V198, P1729, DOI 10.1084/jem.20030975
   Dushkin M, 1998, PROSTAG OTH LIPID M, V55, P219, DOI 10.1016/S0090-6980(98)00024-0
   Dwyer JR, 2007, J BIOL CHEM, V282, P8959, DOI 10.1074/jbc.M611741200
   Dyer RG, 1997, CLIN CHIM ACTA, V260, P1, DOI 10.1016/S0009-8981(96)06499-6
   Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1
   EMANUEL HA, 1991, J FOOD SCI, V56, P843, DOI 10.1111/j.1365-2621.1991.tb05396.x
   Endo K, 2008, DIABETES RES CLIN PR, V80, P63, DOI 10.1016/j.diabres.2007.10.023
   Englund MCO, 2001, ATHEROSCLEROSIS, V158, P61, DOI 10.1016/S0021-9150(01)00407-5
   ERICKSON SK, 1977, J BIOL CHEM, V252, P5186
   Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035
   Ferderbar S, 2007, DIABETES-METAB RES, V23, P35, DOI 10.1002/dmrr.645
   Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005
   Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7
   FREDRICKSON DS, 1956, BIOCHIM BIOPHYS ACTA, V22, P183, DOI 10.1016/0006-3002(56)90236-0
   Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200
   Gackowski D, 2001, FREE RADICAL BIO MED, V31, P542, DOI 10.1016/S0891-5849(01)00614-1
   Garcia-Cruset S, 1999, FREE RADICAL RES, V30, P341, DOI 10.1080/10715769900300391
   Garcia-Cruset S, 2001, FREE RADICAL RES, V35, P31, DOI 10.1080/10715760100300571
   Garg TK, 2003, BMC OPHTHALMOL, V21, P3
   GENG YJ, 1995, AM J PATHOL, V147, P251
   Girao H, 1998, EXP EYE RES, V66, P645, DOI 10.1006/exer.1998.0465
   Girao H, 2003, MOL VIS, V9, P497
   Glass CK, 2008, NATURE, V455, P40, DOI 10.1038/455040a
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Greene EL, 2000, HYPERTENSION, V35, P942, DOI 10.1161/01.HYP.35.4.942
   Guardiola F, 1996, FOOD CHEM TOXICOL, V34, P193, DOI 10.1016/0278-6915(95)00094-1
   Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512
   Guimaraes CA, 2004, EUR J BIOCHEM, V271, P1638, DOI 10.1111/j.1432-1033.2004.04084.x
   Han JH, 2007, BRAIN RES, V1137, P11, DOI 10.1016/j.brainres.2006.12.041
   Hayden JM, 2002, J LIPID RES, V43, P26
   HEINIGER HJ, 1982, P NATL ACAD SCI-BIOL, V79, P3823, DOI 10.1073/pnas.79.12.3823
   HEMMI H, 1985, TOHOKU J EXP MED, V145, P105, DOI 10.1620/tjem.145.105
   HODIS HN, 1992, ATHEROSCLEROSIS, V96, P125, DOI 10.1016/0021-9150(92)90059-P
   HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4
   Hu G, 2008, NEUROLOGY, V70, P1972, DOI 10.1212/01.wnl.0000312511.62699.a8
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Huang RFS, 2004, BRIT J NUTR, V92, P887, DOI 10.1079/BJN20041259
   Javitt NB, 2004, TRENDS ENDOCRIN MET, V15, P393, DOI 10.1016/j.tem.2004.08.009
   JAVITT NB, 1990, J LIPID RES, V31, P1527
   Javitt NB, 2008, STEROIDS, V73, P149, DOI 10.1016/j.steroids.2007.10.004
   Javitt NB, 2007, CURR OPIN LIPIDOL, V18, P283, DOI 10.1097/MOL.0b013e328133851e
   Jessup W, 2005, REJUV RES, V8, P9, DOI 10.1089/rej.2005.8.9
   Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Johnson CC, 1999, INT J EPIDEMIOL, V28, P1102, DOI 10.1093/ije/28.6.1102
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kahn E, 2004, ANAL QUANT CYTOL, V26, P47
   Kahn E, 2001, ANAL QUANT CYTOL, V23, P47
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210
   Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115
   Khan SA, 2003, J NUTR BIOCHEM, V14, P554, DOI 10.1016/S0955-2863(03)00098-6
   KILSDONK EPC, 1995, J LIPID RES, V36, P505
   Kim OS, 2006, BIOCHEM BIOPH RES CO, V342, P9, DOI 10.1016/j.bbrc.2006.01.107
   Kim WK, 2007, J BONE MINER RES, V22, P1711, DOI 10.1359/JBMR.070710
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004
   Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kroon PA, 1997, AUST NZ J MED, V27, P492, DOI 10.1111/j.1445-5994.1997.tb02224.x
   Krut LH, 1997, ARTERIOSCL THROM VAS, V17, P778, DOI 10.1161/01.ATV.17.4.778
   KUCUK O, 1994, LIPIDS, V29, P657, DOI 10.1007/BF02536101
   KUCUK O, 1992, CELL IMMUNOL, V139, P541, DOI 10.1016/0008-8749(92)90091-3
   Kummerow FA, 2001, J NUTR BIOCHEM, V12, P602, DOI 10.1016/S0955-2863(01)00181-4
   Lagace TA, 1997, BIOCHEM J, V326, P205, DOI 10.1042/bj3260205
   Larsson DA, 2006, FREE RADICAL BIO MED, V41, P902, DOI 10.1016/j.freeradbiomed.2006.05.032
   Larsson H, 2007, FREE RADICAL BIO MED, V43, P695, DOI 10.1016/j.freeradbiomed.2007.04.033
   Lee CS, 2007, NEUROCHEM RES, V32, P87, DOI 10.1007/s11064-006-9230-8
   Lee HS, 2005, BIOCHEM BIOPH RES CO, V333, P1093, DOI 10.1016/j.bbrc.2005.05.196
   Lee TS, 2001, AM J PHYSIOL-CELL PH, V280, pC709, DOI 10.1152/ajpcell.2001.280.3.C709
   Lehto M, 2003, BBA-MOL CELL BIOL L, V1631, P1, DOI 10.1016/S1388-1981(02)00364-5
   Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Leonarduzzi G, 2005, FREE RADICAL BIO MED, V39, P1152, DOI 10.1016/j.freeradbiomed.2005.06.024
   Leonarduzzi G, 2002, J NUTR BIOCHEM, V13, P700, DOI 10.1016/S0955-2863(02)00222-X
   Leonarduzzi G, 2001, FASEB J, V15, P1619, DOI 10.1096/fj.00-0668fje
   Leonarduzzi G, 2008, AGING CELL, V7, P375, DOI 10.1111/j.1474-9726.2008.00386.x
   Leonarduzzi G, 2006, ANTIOXID REDOX SIGN, V8, P375, DOI 10.1089/ars.2006.8.375
   Leonarduzzi Gabriella, 2004, Molecular Aspects of Medicine, V25, P155, DOI 10.1016/j.mam.2004.02.016
   Leoni V, 2005, J LIPID RES, V46, P191, DOI 10.1194/jlr.C400005-JLR200
   Leoni V, 2004, CLIN CHEM LAB MED, V42, P186, DOI 10.1515/CCLM.2004.034
   Leoni V, 2002, NEUROSCI LETT, V331, P163, DOI 10.1016/S0304-3940(02)00887-X
   Li DS, 2000, STEROIDS, V65, P529, DOI 10.1016/S0039-128X(00)00131-8
   Li W, 2001, ARTERIOSCL THROM VAS, V21, P1124, DOI 10.1161/hq0701.092145
   Lim HK, 2003, LIFE SCI, V72, P1389, DOI 10.1016/S0024-3205(02)02377-9
   LIN YY, 1974, BIOCHIM BIOPHYS ACTA, V348, P189
   Linseisen J, 1998, ANN NUTR METAB, V42, P221, DOI 10.1159/000012737
   Liu HM, 2005, J CELL BIOCHEM, V96, P198, DOI 10.1002/jcb.20510
   Liu SX, 1998, ATHEROSCLEROSIS, V136, P43, DOI 10.1016/S0021-9150(97)00185-8
   Liu Y, 1997, ARTERIOSCL THROM VAS, V17, P317, DOI 10.1161/01.ATV.17.2.317
   LIZARD G, 1995, CYTOMETRY, V21, P275, DOI 10.1002/cyto.990210308
   Lizard G, 1997, FEBS LETT, V419, P276, DOI 10.1016/S0014-5793(97)01473-7
   Lizard G, 1999, ARTERIOSCL THROM VAS, V19, P1190, DOI 10.1161/01.ATV.19.5.1190
   Lizard G, 2000, FREE RADICAL BIO MED, V28, P743, DOI 10.1016/S0891-5849(00)00163-5
   Lizard G, 1996, AM J PATHOL, V148, P1625
   Lizard G, 1997, J PATHOL, V183, P330
   Lizard G, 1998, FASEB J, V12, P1651, DOI 10.1096/fasebj.12.15.1651
   LORDAN S, 2008, BR J NUTR, V11, P1
   Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316
   Luthra S, 2006, INVEST OPHTH VIS SCI, V47, P5569, DOI 10.1167/iovs.06-0333
   Lutjohann D, 2000, J LIPID RES, V41, P195
   Lyons MA, 1999, INT J BIOCHEM CELL B, V31, P369, DOI 10.1016/S1357-2725(98)00123-X
   Lyons MA, 1999, J LIPID RES, V40, P1846
   Maeda Y, 2002, STEROIDS, V67, P703, DOI 10.1016/S0039-128X(02)00027-2
   MAINO G, 1995, AM J PATHOL, V146, P3
   Malvitte L, 2006, J FR OPHTALMOL, V29, P570, DOI 10.1016/S0181-5512(06)73815-3
   Malvitte L, 2008, CURR EYE RES, V33, P769, DOI 10.1080/02713680802337397
   Martinet W, 2004, ARTERIOSCL THROM VAS, V24, P2296, DOI 10.1161/01.ATV.0000146266.65820.a1
   Massey JB, 2006, BIOCHEMISTRY-US, V45, P10747, DOI 10.1021/bi060540u
   Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399
   Mazalli MR, 2007, J AGR FOOD CHEM, V55, P2743, DOI 10.1021/jf063267b
   MCCLOUD CM, 1995, EXP MOL PATHOL, V62, P12, DOI 10.1006/exmp.1995.1002
   Meijer Alfred J., 2006, Molecular Aspects of Medicine, V27, P411, DOI 10.1016/j.mam.2006.08.002
   Meynier A, 2005, EUR J NUTR, V44, P393, DOI 10.1007/s00394-005-0539-x
   Miguet C, 2001, CELL DEATH DIFFER, V8, P83, DOI 10.1038/sj.cdd.4400792
   Miguet-Alfonsi C, 2002, BIOCHEM PHARMACOL, V64, P527, DOI 10.1016/S0006-2952(02)01110-3
   Millanvoye-Van Brussel E, 2004, BIOCHEM J, V380, P533, DOI 10.1042/BJ20040069
   Mohamad N, 2005, BIOCELL, V29, P149
   Monier S, 2003, BIOCHEM BIOPH RES CO, V303, P814, DOI 10.1016/S0006-291X(03)00412-1
   Moreira EF, 2001, J BIOL CHEM, V276, P18570, DOI 10.1074/jbc.M011259200
   MOREIRA EF, 2008, INVEST OPHTHALMOL VI
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Myoishi M, 2007, CIRCULATION, V116, P1226, DOI 10.1161/CIRCULATIONAHA.106.682054
   Naito Y, 2004, BIOL RES, V37, P231, DOI 10.4067/S0716-97602004000200009
   Napolitano M, 2005, EUR J CLIN INVEST, V35, P482, DOI 10.1111/j.1365-2362.2005.01523.x
   Neekhra A, 2007, INVEST OPHTH VIS SCI, V48, P1362, DOI 10.1167/iovs.06-0900
   Nelson TJ, 2005, BIOCHEM SOC T, V33, P1033, DOI 10.1042/BST0331033
   Nelson TJ, 2005, J BIOL CHEM, V280, P7377, DOI 10.1074/jbc.M409071200
   Nguyen DH, 2003, EXP CELL RES, V285, P268, DOI 10.1016/S0014-4827(03)00063-6
   Ninio E, 2005, CURR OPIN CLIN NUTR, V8, P123, DOI 10.1097/00075197-200503000-00004
   Nishio E, 1996, BIOCHEM BIOPH RES CO, V226, P928, DOI 10.1006/bbrc.1996.1452
   O'Callaghan YC, 2001, CELL BIOL TOXICOL, V17, P127, DOI 10.1023/A:1010914306375
   O'Sullivan AJ, 2005, INT J TOXICOL, V24, P173, DOI 10.1080/10915810590952951
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   OGISHIMA T, 1987, J BIOL CHEM, V262, P7646
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1
   Palozza P, 2007, FREE RADICAL BIO MED, V42, P1579, DOI 10.1016/j.freeradbiomed.2007.02.023
   Panini SR, 2001, CURR OPIN LIPIDOL, V12, P529, DOI 10.1097/00041433-200110000-00008
   Panini SR, 2001, J LIPID RES, V42, P1678
   Papassotiropoulos A, 2000, NEUROREPORT, V11, P1959, DOI 10.1097/00001756-200006260-00030
   Patel RP, 1996, J LIPID RES, V37, P2361
   Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004
   Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0
   PENN MS, 1994, ATHEROSCLEROSIS, V108, pS21, DOI 10.1016/0021-9150(94)90150-3
   Piccotti JR, 2005, DRUG CHEM TOXICOL, V28, P117, DOI 10.1081/DCT-200039743
   POWERS KM, 2008, PARKINSONISM RELAT D
   Prabhakara JPR, 2008, J NEUROCHEM, V107, P1722, DOI 10.1111/j.1471-4159.2008.05736.x
   Prunet C, 2005, J BIOCHEM MOL TOXIC, V19, P311, DOI 10.1002/jbt.20096
   Prunet C, 2006, CYTOM PART A, V69A, P359, DOI 10.1002/cyto.a.20272
   Przygonski K, 2000, NAHRUNG, V44, P122, DOI 10.1002/(SICI)1521-3803(20000301)44:2&lt;122::AID-FOOD122&gt;3.0.CO;2-R
   Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905
   PUNNONEN EL, 1992, J HISTOCHEM CYTOCHEM, V40, P1579, DOI 10.1177/40.10.1326577
   Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378
   Reasor MJ, 2001, EXP BIOL MED, V226, P825, DOI 10.1177/153537020122600903
   Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304
   Rho MC, 2005, J MOL CELL CARDIOL, V39, P823, DOI 10.1016/j.yjmcc.2005.07.018
   Ricciarelli R, 2004, FREE RADICAL BIO MED, V36, P1018, DOI 10.1016/j.freeradbiomed.2004.01.007
   Richardson JA, 2007, J CELL BIOCHEM, V100, P1131, DOI 10.1002/jcb.21112
   RIGGS BL, 1992, NEW ENGL J MED, V327, P620
   Rimner A, 2005, FREE RADICAL BIO MED, V38, P535, DOI 10.1016/j.freeradbiomed.2004.11.016
   Ringseis R, 2004, INT J VITAM NUTR RES, V74, P86, DOI 10.1024/0300-9831.74.1.86
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Rosenblat M, 2002, ATHEROSCLEROSIS, V160, P69, DOI 10.1016/S0021-9150(01)00563-9
   Rosklint T, 2002, EUR J CLIN INVEST, V32, P35, DOI 10.1046/j.1365-2362.2002.00931.x
   Roussi S, 2007, APOPTOSIS, V12, P87, DOI 10.1007/s10495-006-0485-y
   Rusinol AE, 2000, J BIOL CHEM, V275, P7296, DOI 10.1074/jbc.275.10.7296
   Rusinol AE, 2004, J BIOL CHEM, V279, P1392, DOI 10.1074/jbc.M308619200
   Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6
   Ryan L, 2006, INT J TOXICOL, V25, P35, DOI 10.1080/10915810500488387
   Ryan L, 2005, BRIT J NUTR, V94, P519, DOI 10.1079/BJN20051524
   Ryan L, 2004, J BIOCHEM MOL TOXIC, V18, P50, DOI 10.1002/jbt.20007
   Rydberg EK, 2003, ATHEROSCLEROSIS, V170, P245, DOI 10.1016/S0021-9150(03)00302-2
   SAITO H, 1983, TOHOKU J EXP MED, V140, P245, DOI 10.1620/tjem.140.245
   Sasaki H, 2007, METABOLISM, V56, P357, DOI 10.1016/j.metabol.2006.10.017
   Schmuth M, 2004, J INVEST DERMATOL, V123, P41, DOI 10.1111/j.0022-202X.2004.22707.x
   Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361
   Schweizer RAS, 2004, J BIOL CHEM, V279, P18415, DOI 10.1074/jbc.M313615200
   Scigliano G, 2006, STROKE, V37, P1184, DOI 10.1161/01.STR.0000217384.03237.9c
   SEVANIAN A, 1994, FREE RADICAL BIO MED, V17, P397, DOI 10.1016/0891-5849(94)90166-X
   Seye CI, 2004, CARDIOVASC RES, V64, P144, DOI 10.1016/j.cardiores.2004.05.016
   Shi YG, 2004, PROTEIN SCI, V13, P1979, DOI 10.1110/ps.04789804
   Shi YG, 2006, CURR OPIN CELL BIOL, V18, P677, DOI 10.1016/j.ceb.2006.09.006
   Shouhed D, 2005, J CELL BIOCHEM, V95, P1276, DOI 10.1002/jcb.20497
   Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460
   SMITH LL, 1990, NATO ADV SCI I A-LIF, V189, P115
   SMITH LL, 1987, CHEM PHYS LIPIDS, V44, P87, DOI 10.1016/0009-3084(87)90046-6
   Souidi M, 2003, GASTROEN CLIN BIOL, V28, P279, DOI 10.1016/S0399-8320(04)94919-6
   Sperandio S, 2004, CELL DEATH DIFFER, V11, P1066, DOI 10.1038/sj.cdd.4401465
   STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512
   STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4
   Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200
   Tabas I, 2004, CELL DEATH DIFFER, V11, pS12, DOI 10.1038/sj.cdd.4401444
   Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452
   Tang R, 2005, ARCH BIOCHEM BIOPHYS, V441, P16, DOI 10.1016/j.abb.2005.06.006
   Tang R, 2004, J INORG BIOCHEM, V98, P1678, DOI 10.1016/j.jinorgbio.2004.07.003
   Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005
   Teunissen CE, 2007, J NEUROSCI RES, V85, P1499, DOI 10.1002/jnr.21266
   Teunissen CE, 2003, NEUROSCI LETT, V347, P159, DOI 10.1016/S0304-3940(03)00667-0
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Touyz RM, 2004, HYPERTENSION, V44, P248, DOI 10.1161/01.HYP.0000138070.47616.9d
   Valenzuela A, 2003, BIOL RES, V36, P291, DOI 10.4067/S0716-97602003000300002
   van Reyk DM, 2006, REDOX REP, V11, P255, DOI 10.1179/135100006X155003
   Vaya J, 2001, FREE RADICAL RES, V34, P485, DOI 10.1080/10715760100300431
   Vaya J, 2007, J NEUROCHEM, V102, P1727, DOI 10.1111/j.1471-4159.2007.04689.x
   Vega GL, 2003, ARCH NEUROL-CHICAGO, V60, P510, DOI 10.1001/archneur.60.4.510
   Vejux A, 2005, CYTOM PART A, V64A, P87, DOI 10.1002/cyto.a.20124
   VEJUX A, 2006, THESIS U BOURGOGNE D
   Vejux A, 2009, J NUTR BIOCHEM, V20, P45, DOI 10.1016/j.jnutbio.2007.12.001
   Vejux A, 2007, CYTOM PART A, V71A, P550, DOI 10.1002/cyto.a.20410
   Vejux A, 2007, HISTOCHEM CELL BIOL, V127, P609, DOI 10.1007/s00418-006-0268-0
   Wielkoszynski T, 2006, BIOESSAYS, V28, P387, DOI 10.1002/bies.20383
   Witztum JL, 2001, TRENDS CARDIOVAS MED, V11, P93, DOI 10.1016/S1050-1738(01)00111-6
   Wohlfeil ER, 1997, BBA-LIPID LIPID MET, V1345, P109, DOI 10.1016/S0005-2760(96)00170-1
   Wolf G, 1999, Nutr Rev, V57, P196
   Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439
   YACHNIN S, 1982, ONCODEV BIOL MED, V3, P111
   Yan P S, 1999, Adv Exp Med Biol, V459, P79
   Yang GP, 2005, CONT SHELF RES, V25, P557, DOI 10.1016/j.csr.2004.11.001
   Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8
   Zhou Q, 2000, ATHEROSCLEROSIS, V149, P191, DOI 10.1016/S0021-9150(99)00343-3
   Zieden B, 1999, ARTERIOSCL THROM VAS, V19, P967, DOI 10.1161/01.ATV.19.4.967
NR 271
TC 211
Z9 215
U1 0
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0098-2997
EI 1872-9452
J9 MOL ASPECTS MED
JI Mol. Asp. Med.
PD JUN
PY 2009
VL 30
IS 3
SI SI
BP 153
EP 170
DI 10.1016/j.mam.2009.02.006
PG 18
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 459JG
UT WOS:000267097400004
PM 19248805
DA 2022-11-30
ER

PT J
AU Wang, YX
   Xu, L
   Jonas, JB
AF Wang, Yaxing
   Xu, Liang
   Jonas, Jost B.
TI Prevalence and causes of visual field loss as determined by frequency
   doubling perimetry in urban and rural adult Chinese
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-SPECIFIC PREVALENCE; CATARACT-SURGERY; LOW-VISION; REFRACTIVE ERROR;
   NORTHERN CHINA; IMPAIRMENT; BLINDNESS; POPULATION; EYE; CLASSIFICATION
AB PURPOSE: To determine prevalence and causes of visual field loss (VFL) as determined by frequency doubling perimetry in elderly Chinese individuals.
   DESIGN: Population-based, cross-sectional cohort study.
   METHODS: The Beijing Eye Study included 4439 of 5324 subjects (83.4%) who were invited to participate with an age of 40+ years. Visual field was assessed by frequency doubling threshold perimetry. Main outcome measure was an abnormal visual field defined as at least one test location of reduced sensitivity.
   RESULTS: Of the 4439 people who were examined, 4350 subjects (98.0%; 8617 eyes) provided measurement data by frequency doubling perimetry. In subjects aged 40 to 49 years, the most frequent cause for VFL was degenerative myopia followed by glaucoma, other optic nerve diseases, and cataract. In the subjects aged 60 to 69 years, the most frequent cause for VFL was cataract, followed by glaucoma and degenerative myopia. In the subjects aged 70+ years, the most frequent cause for VFL was glaucoma, followed by cataract and degenerative myopia. VFL was associated significantly with age (P <.001), myopic refractive error (P <.001), rural region (P =.001), low level of education (P =.01), degree of nuclear cataract (P <.001), and intraocular pressure (P <.001).
   CONCLUSION: In contrast to Western countries, age-related macular degeneration and diabetic retinopathy play a minor role as a cause for VFL in China.
C1 Heidelberg Univ, Augenklin, Fac Clin Med Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany.
   Capital Univ Med Sci, Beijing Inst Ophthalmol, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Capital Medical University
RP Jonas, JB (通讯作者)，Heidelberg Univ, Augenklin, Fac Clin Med Mannheim, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Cheung SW, 2000, OPHTHAL PHYSL OPT, V20, P119, DOI 10.1046/j.1475-1313.2000.00488.x
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   *EARL TREATM DIAB, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI DOI 10.1001/ARCHOPHT.1985.01050120030015
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Keltner JL, 2003, ARCH OPHTHALMOL-CHIC, V121, P643, DOI 10.1001/archopht.121.5.643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   LITTMANN H, 1982, KLIN MONATSBL AUGENH, V180, P286, DOI 10.1055/s-2008-1055068
   Liu J H, 2001, Ophthalmic Epidemiol, V8, P339
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   MOLL AC, 1994, BRIT J OPHTHALMOL, V78, P275, DOI 10.1136/bjo.78.4.275
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   PONTE F, 1994, GRAEF ARCH CLIN EXP, V232, P469, DOI 10.1007/BF00195355
   Ramrattan RS, 1999, OPHTHALMOLOGY, V106, P1588, DOI 10.1016/S0161-6420(99)90457-8
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Schwartz EC, 1997, BRIT J OPHTHALMOL, V81, P443, DOI 10.1136/bjo.81.6.443
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   Thomas D, 2001, AM J OPHTHALMOL, V131, P734, DOI 10.1016/S0002-9394(01)00837-6
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   WANG Y, BR J OPHTHALMOL
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Xu L, 2005, AM J OPHTHALMOL, V140, P913, DOI 10.1016/j.ajo.2005.04.050
   Xu L, 2005, OPHTHALMOLOGY, V112, P1676, DOI 10.1016/j.ophtha.2005.05.015
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Zerihun N, 1997, Ophthalmic Epidemiol, V4, P19
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P506, DOI 10.1016/S0002-9394(98)00275-X
NR 46
TC 32
Z9 35
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2006
VL 141
IS 6
BP 1078
EP 1086
DI 10.1016/j.ajo.2006.01.023
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 056AI
UT WOS:000238492600012
PM 16765676
DA 2022-11-30
ER

PT J
AU Xue, ZB
   Yuan, J
   Chen, FK
   Yao, YH
   Xing, SL
   Yu, XY
   Li, K
   Wang, CX
   Bao, JH
   Qu, J
   Su, JZ
   Chen, H
AF Xue, Zhengbo
   Yuan, Jian
   Chen, Fukun
   Yao, Yinghao
   Xing, Shilai
   Yu, Xiangyi
   Li, Kai
   Wang, Chenxiao
   Bao, Jinhua
   Qu, Jia
   Su, Jianzhong
   Chen, Hao
TI Genome-wide association meta-analysis of 88,250 individuals highlights
   pleiotropic mechanisms of five ocular diseases in UK Biobank
SO EBIOMEDICINE
LA English
DT Article
DE Ocular diseases; Cross-disease genetics; GWAS; Genetic correlation;
   Pleiotropy; Retinal development
ID OPEN-ANGLE GLAUCOMA; DIABETIC-RETINOPATHY; MACULAR DEGENERATION;
   RETINAL-DETACHMENT; EXPRESSION; SURVIVAL; COMMON; MYOPIA; ATLAS; TOOL
AB Background Ocular diseases may exhibit common clinical symptoms and epidemiological comorbidity. However, the extent of pleiotropic mechanisms across ocular diseases remains unclear. We aim to examine shared genetic etiology in age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, retinal detachment (RD), and myopia.
   Methods We analyzed genome-wide association analyses for the five ocular diseases in 43,877 cases and 44373 controls of European ancestry from UK Biobank, estimated their genetic relationships (LDSC, GNOVA, and Genomic SEM), and identified pleiotropic loci (ASSET and METAS OFT).
   Findings The genetic correlation of common SNPs revealed a meaningful genetic structure within these diseases, identifying genetic correlations between AMD, DR, and glaucoma. Cross-trait meta-analysis identified 23 pleiotropic loci associated with at least two ocular diseases and 14 loci unique to individual disorders (non-pleiotropic). We found that the genes associated with these shared genetic loci are involved in neuron differentiation (P = 8.80 x 10(-6)) and eye development systems (P = 3.86 x 10(-5)), and single cell RNA sequencing data reveals their heightened gene expression from multipotent progenitors to other differentiated retinal cells during retina developmental process.
   Interpretation These results highlighted the potential common genetic architectures among these ocular diseases and can deepen the understanding of the molecular mechanisms underlying the related diseases. Copyright (C) 2022 The Authors. Published by Elsevier B.V.
C1 [Xue, Zhengbo; Yuan, Jian; Chen, Fukun; Xing, Shilai; Yu, Xiangyi; Wang, Chenxiao; Bao, Jinhua; Qu, Jia; Su, Jianzhong; Chen, Hao] Wenzhou Med Univ, Eye Hosp, 27o West Xueyuan Rd, Wenzhou 325027, Zhejiang, Peoples R China.
   [Xue, Zhengbo; Yuan, Jian; Chen, Fukun; Xing, Shilai; Yu, Xiangyi; Wang, Chenxiao; Bao, Jinhua; Qu, Jia; Su, Jianzhong; Chen, Hao] Wenzhou Med Univ, Sch Ophthalmol & Optometry, 27o West Xueyuan Rd, Wenzhou 325027, Zhejiang, Peoples R China.
   [Qu, Jia; Su, Jianzhong] Zhejiang Lab Regenerat Med Vis & Brain Hlth, Oujiang Lab, Wenzhou 325101, Zhejiang, Peoples R China.
   [Yao, Yinghao; Li, Kai; Su, Jianzhong] Univ Chinese Acad Sci, Wenzhou Inst, Wenzhou 325105, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Chinese Academy
   of Sciences; University of Chinese Academy of Sciences, CAS
RP Su, JZ; Chen, H (通讯作者)，Wenzhou Med Univ, Eye Hosp, 27o West Xueyuan Rd, Wenzhou 325027, Zhejiang, Peoples R China.; Su, JZ; Chen, H (通讯作者)，Wenzhou Med Univ, Sch Ophthalmol & Optometry, 27o West Xueyuan Rd, Wenzhou 325027, Zhejiang, Peoples R China.
EM sujz@wmu.edu.cn; chenhao@mail.eye.ac.cn
RI Bao, Jinhua/GRJ-7521-2022
OI Yuan, Jian/0000-0002-1896-2561
FU National Natural Science Foundation of China [61871294]; Zhejiang
   Provincial Natural Science Foundation of China [LR19C060001]; Scientific
   Research Foundation for Talents of Wenzhou Medical University [QTJ18023]
FX The National Natural Science Foundation of China (61871294), Zhejiang
   Provincial Natural Science Foundation of China (LR19C060001), and the
   Scientific Research Foundation for Talents of Wenzhou Medical University
   (QTJ18023).
CR Antonetti DA, 2021, NAT REV ENDOCRINOL, V17, P195, DOI 10.1038/s41574-020-00451-4
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Baird PN, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00231-4
   Bhattacharjee S, 2012, AM J HUM GENET, V90, P821, DOI 10.1016/j.ajhg.2012.03.015
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Boutin TS, 2020, HUM MOL GENET, V29, P689, DOI 10.1093/hmg/ddz294
   Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406
   Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211
   Bullimore MA, 2021, OPHTHALMOLOGY, V128, P1561, DOI 10.1016/j.ophtha.2021.04.032
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x
   Calkins DJ, 2012, PROG RETIN EYE RES, V31, P702, DOI 10.1016/j.preteyeres.2012.07.001
   Cardoso-Moreira M, 2019, NATURE, V571, P505, DOI 10.1038/s41586-019-1338-5
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Craig JE, 2020, NAT GENET, V52, P160, DOI 10.1038/s41588-019-0556-y
   Ding JR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04368-5
   Erie JC, 2006, OPHTHALMOLOGY, V113, P2026, DOI 10.1016/j.ophtha.2006.05.054
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Finucane HK, 2015, NAT GENET, V47, P1228, DOI 10.1038/ng.3404
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fox SC, 2022, HUM GENET, V141, P1385, DOI 10.1007/s00439-022-02430-3
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gharahkhani P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20851-4
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grotzinger AD, 2019, NAT HUM BEHAV, V3, P513, DOI 10.1038/s41562-019-0566-x
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Han B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002555
   Han B, 2011, AM J HUM GENET, V88, P586, DOI 10.1016/j.ajhg.2011.04.014
   Han XK, 2020, JAMA OPHTHALMOL, V138, P671, DOI 10.1001/jamaophthalmol.2020.1231
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Hu CC, 2017, EYE, V31, P872, DOI 10.1038/eye.2016.325
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Hysi PG, 2020, NAT GENET, V52, P401, DOI 10.1038/s41588-020-0599-0
   Jiang L, 2021, 15461718 NAT PUBL GR
   Kang EY, 2016, G3-GENES GENOM GENET, V6, P1793, DOI 10.1534/g3.116.029439
   Kang HK, 2008, BMJ-BRIT MED J, V336, P1235, DOI 10.1136/bmj.39581.525532.47
   Kim YW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57066-7
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Kitaoka T, 1997, CURR EYE RES, V16, P396, DOI 10.1076/ceyr.16.4.396.10685
   Li YJ, 2021, CURR DIABETES REP, V21, DOI 10.1007/s11892-021-01404-5
   Liu XC, 2013, DIABETES, V62, P4228, DOI 10.2337/db12-1710
   Liu Z, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.9.21
   LOEBER G, 1994, BIOCHEM J, V304, P687, DOI 10.1042/bj3040687
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Lu QS, 2017, AM J HUM GENET, V101, P939, DOI 10.1016/j.ajhg.2017.11.001
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mardones GA, 2007, MOL BIOL CELL, V18, P3486, DOI 10.1091/mbc.E07-02-0190
   Mellough CB, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.169474
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Pruitt KD, 2014, NUCLEIC ACIDS RES, V42, pD756, DOI 10.1093/nar/gkt1114
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Socodato R, 2014, CELL DEATH DIFFER, V21, P915, DOI 10.1038/cdd.2014.11
   Solovieff N, 2013, NAT REV GENET, V14, P483, DOI 10.1038/nrg3461
   Tedja MS, 2018, NAT GENET, V50, P834, DOI 10.1038/s41588-018-0127-7
   Tezel G, 2022, PROG RETIN EYE RES, V87, DOI 10.1016/j.preteyeres.2021.100998
   Thul PJ, 2018, PROTEIN SCI, V27, P233, DOI 10.1002/pro.3307
   Vincent A, 2016, AM J HUM GENET, V98, P1011, DOI 10.1016/j.ajhg.2016.03.021
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Wang WH, 2008, J CLIN INVEST, V118, P1056, DOI 10.1172/JCI33871
   Wang Z, 2010, P NATL ACAD SCI USA, V107, P18034, DOI 10.1073/pnas.1004666107
   Wang ZX, 2019, PROG RETIN EYE RES, V70, P110, DOI 10.1016/j.preteyeres.2018.11.008
   Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5
   Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213
   Yuan J, 2021, NAR GENOM BIOINFORM, V3, DOI 10.1093/nargab/lqab050
   Zerlin M, 2008, ANGIOGENESIS, V11, P63, DOI 10.1007/s10456-008-9095-3
   Zhang JJ, 2019, BIOSCI BIOTECH BIOCH, V83, P1655, DOI 10.1080/09168451.2019.1630251
   Zhou W, 2018, NAT GENET, V50, P1335, DOI 10.1038/s41588-018-0184-y
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
NR 73
TC 0
Z9 0
U1 8
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD AUG
PY 2022
VL 82
AR 104161
DI 10.1016/j.ebiom.2022.104161
PG 15
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 3F9MD
UT WOS:000830983200005
PM 35841873
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, YP
   Fung, NSK
   Lam, WC
   Lo, ACY
AF Wang, Yipin
   Fung, Nicholas Siu Kay
   Lam, Wai-Ching
   Lo, Amy Cheuk Yin
TI mTOR Signalling Pathway: A Potential Therapeutic Target for Ocular
   Neurodegenerative Diseases
SO ANTIOXIDANTS
LA English
DT Review
DE mTOR; AMD; DR; glaucoma; oxidative stress; hypoxia; inflammation; ROS;
   rapamycin; clinical trial
ID COMPETITIVE MAMMALIAN TARGET; PIGMENT EPITHELIUM-CELLS; RETINAL
   GANGLION-CELLS; OXIDATIVE STRESS; MOUSE MODEL; CHOROIDAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY;
   SUBCONJUNCTIVAL SIROLIMUS; INTRAVITREAL SIROLIMUS
AB Recent advances in the research of the mammalian target of the rapamycin (mTOR) signalling pathway demonstrated that mTOR is a robust therapeutic target for ocular degenerative diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma. Although the exact mechanisms of individual ocular degenerative diseases are unclear, they share several common pathological processes, increased and prolonged oxidative stress in particular, which leads to functional and morphological impairment in photoreceptors, retinal ganglion cells (RGCs), or retinal pigment epithelium (RPE). mTOR not only modulates oxidative stress but is also affected by reactive oxygen species (ROS) activation. It is essential to understand the complicated relationship between the mTOR pathway and oxidative stress before its application in the treatment of retinal degeneration. Indeed, the substantial role of mTOR-mediated autophagy in the pathogenies of ocular degenerative diseases should be noted. In reviewing the latest studies, this article summarised the application of rapamycin, an mTOR signalling pathway inhibitor, in different retinal disease models, providing insight into the mechanism of rapamycin in the treatment of retinal neurodegeneration under oxidative stress. Besides basic research, this review also summarised and updated the results of the latest clinical trials of rapamycin in ocular neurodegenerative diseases. In combining the current basic and clinical research results, we provided a more complete picture of mTOR as a potential therapeutic target for ocular neurodegenerative diseases.
C1 [Wang, Yipin; Fung, Nicholas Siu Kay; Lam, Wai-Ching; Lo, Amy Cheuk Yin] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Ophthalmol, Hong Kong 999077, Peoples R China.
C3 University of Hong Kong
RP Lam, WC (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Ophthalmol, Hong Kong 999077, Peoples R China.
EM u3005138@connect.hku.hk; nfung@hku.hk; waichlam@hku.hk; amylo@hku.hk
RI ; Lo, Amy Cheuk Yin/C-1195-2009
OI Wang, Yipin/0000-0002-5782-9456; Lo, Amy Cheuk Yin/0000-0003-4239-6851
FU General Research Fund, Research Grants Council, The Government of the
   Hong Kong Special Administrative Region [17112919]
FX This research was funded by General Research Fund, Research Grants
   Council, The Government of the Hong Kong Special Administrative Region
   (17112919) to A.C.Y.L.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Abu-Hassan Diala W, 2014, J Ocul Biol, V2
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Amato R, 2018, PHARMACOL RES, V128, P167, DOI 10.1016/j.phrs.2017.09.022
   [Anonymous], 2010, PHASE 1 2 STUDY OCUL
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Armstrong A, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/7163326
   Ballou Lisa M, 2008, J Chem Biol, V1, P27, DOI 10.1007/s12154-008-0003-5
   Banerji U., 2013, P CLIN TRIALS
   Banerji U, 2012, J CLIN ONCOL, V30
   Belforte N, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00466-z
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bellmunt J, 2008, ANN ONCOL, V19, P1387, DOI 10.1093/annonc/mdn066
   Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Cai JJ, 2019, EXP CELL RES, V374, P231, DOI 10.1016/j.yexcr.2018.11.028
   Cao GF, 2011, BIOCHEM BIOPH RES CO, V414, P499, DOI 10.1016/j.bbrc.2011.09.094
   Carew JS, 2011, TARGET ONCOL, V6, P17, DOI 10.1007/s11523-011-0167-8
   Chalasani MLS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095758
   Chalke SD, 2021, CURR DRUG TARGETS, V22, P1810, DOI 10.2174/1389450122666210319113136
   Chauhan A, 2011, BEHAV BRAIN RES, V225, P603, DOI 10.1016/j.bbr.2011.08.035
   Chen CL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051416
   Cheng LB, 2014, BIOCHEM BIOPH RES CO, V443, P447, DOI 10.1016/j.bbrc.2013.11.113
   Cherra SJ, 2008, FUTUR NEUROL, V3, P309, DOI 10.2217/14796708.3.3.309
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417-013-2375-7
   Davis BM, 2016, ACTA NEUROPATHOL, V132, P807, DOI 10.1007/s00401-016-1609-2
   de Hoz R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2954721
   del Olmo-Aguado S, 2013, BRAIN RES BULL, V98, P132, DOI 10.1016/j.brainresbull.2013.08.002
   Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001
   Dugel PU, 2012, OPHTHALMOLOGY, V119, P124, DOI 10.1016/j.ophtha.2011.07.034
   Dumont F J, 2001, Curr Opin Investig Drugs, V2, P1220
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fang YM, 2013, CELL METAB, V17, P456, DOI 10.1016/j.cmet.2013.02.008
   Fang YW, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.632040
   Fernandes Stephanie A, 2021, Front Aging, V2, P707372, DOI 10.3389/fragi.2021.707372
   Fort PE, 2014, DIABETES, V63, P3077, DOI 10.2337/db14-0235
   Fox TE, 2012, INVEST OPHTH VIS SCI, V53, P7257, DOI 10.1167/iovs.11-7626
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204
   Fu YT, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3151-y
   Fung FKC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167828
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x
   Guo Y, 2021, EXP EYE RES, V210, DOI 10.1016/j.exer.2021.108703
   Ha JY, 2014, J NEUROCHEM, V129, P527, DOI [10.1111/jnc.12643, 10.1111/j.1471-4159.2013.12643.x]
   Harder JM, 2020, P NATL ACAD SCI USA, V117, P33619, DOI 10.1073/pnas.2014213117
   Hartford CM, 2009, CLIN CANCER RES, V15, P1428, DOI 10.1158/1078-0432.CCR-08-2076
   He JN, 2019, MOL NEUROBIOL, V56, P6586, DOI 10.1007/s12035-019-1559-5
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Hernandez C, 2014, AV DIABETOL, V30, P72, DOI 10.1016/j.avdiab.2014.03.003
   Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang S, 2001, CANCER METAST REV, V20, P69, DOI 10.1023/A:1013167315885
   Hwang Y, 2019, CANCER RES, V79, P3178, DOI 10.1158/0008-5472.CAN-18-3658
   Igarashi N, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108421
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Ishikawa M, 2021, AUTOPHAGY, V17, P743, DOI 10.1080/15548627.2020.1731270
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033
   Josifovska N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030813
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kern TS, 2015, J DIABETES INVEST, V6, P371, DOI 10.1111/jdi.12312
   Kim KC, 2010, INT J BIOCHEM CELL B, V42, P297, DOI 10.1016/j.biocel.2009.11.009
   Kim SY, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108391
   Kitaoka Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.391
   Kong D, 2008, CANCER RES, V68, P1927, DOI 10.1158/0008-5472.CAN-07-3241
   Krishnadev N, 2011, GRAEF ARCH CLIN EXP, V249, P1627, DOI 10.1007/s00417-011-1694-9
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178
   Lai C., 2022, FRONT IMMUNOL, V13, P218, DOI [10.3389/fimmu.2022.782434, DOI 10.3389/FIMMU.2022.782434]
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lee SH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85181-x
   Lee SHS, 2019, MOL THER-METH CLIN D, V14, P171, DOI 10.1016/j.omtm.2019.06.004
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088203
   Lin W, 2019, OPHTHALMIC RES, V61, P65, DOI 10.1159/000487486
   Liton PB, 2016, EXP EYE RES, V144, P29, DOI 10.1016/j.exer.2015.07.013
   Liu QS, 2012, J BIOL CHEM, V287, P9742, DOI 10.1074/jbc.M111.304485
   Liu YL, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01553-3
   de Faria JML, 2016, INVEST OPHTH VIS SCI, V57, P4356, DOI 10.1167/iovs.16-19197
   Losiewicz MK, 2020, EXP EYE RES, V197, DOI 10.1016/j.exer.2020.108131
   Ma J, 2016, INVEST OPHTH VIS SCI, V57, P3138, DOI 10.1167/iovs.15-18795
   Madrakhimov SB, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-020-00698-4
   Masui K, 2013, CELL METAB, V18, P726, DOI 10.1016/j.cmet.2013.09.013
   Medchalmi S, 2021, FEBS J, V288, P4576, DOI 10.1111/febs.15752
   Minturn RJ, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00281-0
   Mita M, 2008, EXPERT OPIN INV DRUG, V17, P1947, DOI [10.1517/13543780802556485, 10.1517/13543780802556485 ]
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mossmann D, 2018, NAT REV CANCER, V18, P744, DOI 10.1038/s41568-018-0074-8
   Mulfaul K, 2020, CELL REP, V30, P2209, DOI 10.1016/j.celrep.2020.01.064
   Murata H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142438
   Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Niu ZY, 2021, EXP EYE RES, V210, DOI 10.1016/j.exer.2021.108700
   Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   OCHIAI T, 1993, TRANSPLANTATION, V56, P15, DOI 10.1097/00007890-199307000-00003
   Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200
   Ozdemir G, 2014, CAN J OPHTHALMOL, V49, P443, DOI 10.1016/j.jcjo.2014.07.003
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   Park HYL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30165-7
   Park TK, 2017, MOL THER-NUCL ACIDS, V8, P26, DOI 10.1016/j.omtn.2017.05.012
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Porter K, 2015, BBA-MOL BASIS DIS, V1852, P379, DOI 10.1016/j.bbadis.2014.11.021
   Pravin N.J.D, 2010, INVESTIG OPHTHALMOL, V51, P4244
   Ran ZL, 2019, MOL MED REP, V19, P1024, DOI 10.3892/mmr.2018.9749
   Rehbein U, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.751892
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Schreiber KH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11174-0
   Schultze SM, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/S1462399411002109
   Sellami D.B., 2012, J CLIN ONCOL, V30, P3099, DOI [10.1200/jco.2012.30.15_suppl.3099, DOI 10.1200/JCO.2012.30.15_SUPPL.3099]
   Sergeys J, 2019, INVEST OPHTH VIS SCI, V60, P807, DOI 10.1167/iovs.18-25372
   Shang P, 2017, AGING CELL, V16, P349, DOI 10.1111/acel.12561
   Shigihara N, 2014, J CLIN INVEST, V124, P3634, DOI 10.1172/JCI69866
   Sifuentes-Franco S, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/1673081
   Simamora P, 2001, INT J PHARMACEUT, V213, P25, DOI 10.1016/S0378-5173(00)00617-7
   Simo R, 2018, DIABETOLOGIA, V61, P1902, DOI 10.1007/s00125-018-4692-1
   Spencer A, 2011, BLOOD, V118, P808
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Su WR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099719
   Tabernero J, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3022
   Tabernero J, 2012, P CLIN TRIALS
   Taki K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124240
   Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106
   Tan DS, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3006
   Tang LHC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168446
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Valvezan AJ, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00001
   Ventura LM, 2006, INVEST OPHTH VIS SCI, V47, P3904, DOI 10.1167/iovs.06-0161
   Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200
   Wang M, 2016, MOL NEUROBIOL, V53, P932, DOI 10.1007/s12035-014-9062-5
   Wang W, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001519
   Wen YT, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0298-z
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wu JJ, 2009, AGING-US, V1, P425, DOI 10.18632/aging.100038
   Xue GD, 2017, ONCOTARGET, V8, P69204, DOI 10.18632/oncotarget.18213
   Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008-5472.CAN-08-2058
   Yang JL, 2021, ZOOL RES, V42, P482, DOI 10.24272/j.issn.2095-8137.2021.049
   Yang XX, 2021, LIFE SCI, V269, DOI 10.1016/j.lfs.2020.119013
   Yao AN, 2020, CLIN EXP OPHTHALMOL, V48, P1072, DOI 10.1111/ceo.13819
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Ying HY, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860-015-0060-x
   Yoon MS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111176
   Yu AK, 2017, HUM MOL GENET, V26, P4929, DOI 10.1093/hmg/ddx373
   Yu Y, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0368-7
   Zafar S, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1134-5
   Zhang ML, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02951-7
   Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291
   Zhou JZ, 2021, ARCH PHYSIOL BIOCHEM, V127, P44, DOI 10.1080/13813455.2019.1609996
   Zhu XL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01006
   Zhu Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030728
NR 164
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JUL
PY 2022
VL 11
IS 7
AR 1304
DI 10.3390/antiox11071304
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 3H8YA
UT WOS:000832314900001
PM 35883796
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, H
   Wu, F
   Chen, RW
   Chen, YA
   Yao, K
   Liu, ZP
   Parikh, BH
   Jing, LZ
   Liu, TG
   Su, XY
   Sun, J
   Huang, DJ
AF Liu, Hang
   Wu, Fan
   Chen, Renwei
   Chen, Yanan
   Yao, Kai
   Liu, Zengping
   Parikh, Bhav Harshad
   Jing, Linzhi
   Liu, Tiange
   Su, Xinyi
   Sun, Jie
   Huang, Dejian
TI Electrohydrodynamic Jet-Printed Ultrathin Polycaprolactone Scaffolds
   Mimicking Bruch's Membrane for Retinal Pigment Epithelial Tissue
   Engineering
SO INTERNATIONAL JOURNAL OF BIOPRINTING
LA English
DT Article
DE Ultrathin scaffolds; Electrohydrodynamic jet printing; Polycaprolactone;
   Retinal pigment epithelium
ID CELL; MODELS
AB Age-related macular degeneration (AMD) is the leading cause of visual loss and affects millions of people worldwide. Dysfunction of the retinal pigment epithelium (RPE) is associated with the pathogenesis of AMD. The purpose of this work is to build and evaluate the performance of ultrathin scaffolds with an electrohydrodynamic jet (EHDJ) printing method for RPE cell culture. We printed two types of ultrathin (around 7 mu m) polycaprolactone scaffolds with 20 mu m and 50 mu m pores, which possess mechanical properties resembling that of native human Bruch's membrane and are biodegradable. Light microscopy and cell proliferation assay showed that adult human retinal pigment epithelial (ARPE-19) cells adhered and proliferated to form a monolayer on the scaffolds. The progress of culture matured on the scaffolds was demonstrated by immunofluorescence (actin, ZO-1, and Na+/K+-ATPase) and Western blot analysis of the respective proteins. The RPE cells cultured on EHDJ-printed scaffolds with 20 mu m pores presented higher permeability, higher transepithelial potential difference, and higher expression level of Na+/K+-ATPase than those cultured on Transwell inserts. These findings suggest that the EHDJ printing can fabricate scaffolds that mimic Bruch's membrane by promoting maturation of RPE cells to form a polarized and functional monolayered epithelium with potential as an in vitro model for studying retinal diseases and treatment methods.
C1 [Liu, Hang; Chen, Renwei; Chen, Yanan; Jing, Linzhi; Huang, Dejian] Natl Univ Singapore, Fac Sci, Dept Food Sci & Technol, Singapore, Singapore.
   [Liu, Hang; Wu, Fan; Chen, Renwei; Chen, Yanan; Jing, Linzhi; Liu, Tiange; Huang, Dejian] Natl Univ Singapore Suzhou Res Inst, Suzhou, Peoples R China.
   [Yao, Kai; Sun, Jie] Xian JiaoTong Liverpool Univ, Sch Adv Technol, Dept Mechatron & Robot, Suzhou, Peoples R China.
   [Liu, Zengping; Parikh, Bhav Harshad; Su, Xinyi] Natl Univ Singapore, Dept Ophthalmol, Yong Loo Lin Sch Med, 1E Kent Ridge Rd,NUHS Tower Block,Level 7, Singapore 119228, Singapore.
C3 National University of Singapore; National University of Singapore;
   Xi'an Jiaotong-Liverpool University; National University of Singapore
RP Su, XY (通讯作者)，Natl Univ Singapore, Dept Ophthalmol, Yong Loo Lin Sch Med, 1E Kent Ridge Rd,NUHS Tower Block,Level 7, Singapore 119228, Singapore.; Sun, J (通讯作者)，Xian JiaoTong Liverpool Univ, Dept Mechatron & Robot, 111 Renai Rd,EB326 Suzhou Ind Pk, Suzhou 215123, Jiangsu, Peoples R China.; Huang, DJ (通讯作者)，Natl Univ Singapore, Dept Food Sci & Technol, 2 Sci Dr 2,S14-06-02, Singapore 117542, Singapore.
EM ophsux@nus.edu.sg; Jie.Sun@xjtlu.edu.cn; fsthdj@nus.edu.sg
RI Liu, Zengping/GQO-9030-2022; Liu, Hang/F-4171-2019
OI Liu, Hang/0000-0002-0801-6897; Chen, Yanan/0000-0001-7840-6295
FU Key Program Special Fund in Xi'an JiaoTong-Liverpool University (XJTLU)
   [KSF-E-37]; National University of Singapore (Suzhou) Research Institute
FX This work was financially supported by Key Program Special Fund in Xi'an
   JiaoTong-Liverpool University (XJTLU) under Grant KSF-E-37. This work
   was also supported by the National University of Singapore (Suzhou)
   Research Institute under an internal grant to the Center for Peak of
   Excellence on Biological Science and Food Engineering.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   [Anonymous], TRANSW PERM SUPP
   Apel P, 2001, RADIAT MEAS, V34, P559, DOI 10.1016/S1350-4487(01)00228-1
   Bagewadi S, 2021, J MATER CHEM B, V9, P5935, DOI 10.1039/d1tb00976a
   Cao L, 2018, J CELL MOL MED, V22, P5552, DOI 10.1111/jcmm.13829
   Chan SY, 2017, ACS OMEGA, V2, P8959, DOI 10.1021/acsomega.7b01604
   Chan W.H., 2007, INVEST OPHTHALMOL VI, V48, P2187
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Harris TI, 2019, ACS BIOMATER SCI ENG, V5, P4023, DOI 10.1021/acsbiomaterials.9b00183
   He JK, 2020, BIOFABRICATION, V12, DOI 10.1088/1758-5090/aba1fa
   Hunt NC, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800226
   Jing LZ, 2021, ACS APPL BIO MATER, V4, P3189, DOI 10.1021/acsabm.0c01587
   Kim MY, 2014, J MEMBRANE SCI, V452, P460, DOI 10.1016/j.memsci.2013.11.034
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Krishna L, 2020, ACS APPL BIO MATER, V3, P823, DOI 10.1021/acsabm.9b00897
   Liu H, 2021, PROCEDIA MANUF, V53, P492, DOI 10.1016/j.promfg.2021.06.051
   Liu H, 2017, INT J BIOPRINTING, V3, P72, DOI 10.18063/IJB.2017.01.009
   Liu ZP, 2021, STEM CELL REP, V16, P237, DOI 10.1016/j.stemcr.2020.12.007
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Mondrinos MJ, 2017, LAB CHIP, V17, P3146, DOI 10.1039/c7lc00317j
   Murphy AR, 2020, ACTA BIOMATER, V104, P1, DOI 10.1016/j.actbio.2020.01.013
   Onses MS, 2015, SMALL, V11, P4237, DOI 10.1002/smll.201500593
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Ramachandran P, 2012, ASTROPHYSICS SOURCE
   Rashid A, 2016, ADV EXP MED BIOL, V854, P757, DOI 10.1007/978-3-319-17121-0_101
   Reichenbach A.., 2020, EVOLUTIONARY NEUROSC, VSecond
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Tan EYS, 2017, J MATER CHEM B, V5, P5616, DOI 10.1039/c7tb00376e
   Wetzel RK, 2001, INVEST OPHTH VIS SCI, V42, P763
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu B, 2018, J MATER SCI-MATER M, V29, DOI 10.1007/s10856-018-6148-z
   Wu Y, 2015, PROCEEDINGS OF THE ASME 10TH INTERNATIONAL MANUFACTURING SCIENCE AND ENGINEERING CONFERENCE, 2015, VOL 2
   Zhang B, 2020, VIRTUAL PHYS PROTOTY, V15, P62, DOI 10.1080/17452759.2019.1662991
NR 33
TC 1
Z9 1
U1 8
U2 8
PU WHIOCE PUBL PTE LTD
PI SINGAPORE
PA 7030 ANG MO KIO AVE 5, #04-15 NORTHSTAR@AMK, SINGAPORE, 569880,
   SINGAPORE
SN 2424-7723
EI 2424-8002
J9 INT J BIOPRINTING
JI Int. J. Bioprinting
PY 2022
VL 8
IS 3
BP 1
EP 14
AR 550
DI 10.18063/ijb.v8i3.550
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 3N2ZY
UT WOS:000836021900004
PM 36105130
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhou, XL
   Zhao, XM
AF Zhou, Xingli
   Zhao, Ximing
TI Gastrodin represses hydrogen peroxide-induced oxidative stress in
   retinal pigment epithelial cells through p38MAPK/iNOS pathway
SO QUALITY ASSURANCE AND SAFETY OF CROPS & FOODS
LA English
DT Article
DE age-related macular degeneration; apoptosis; gastrodin; hydrogen
   peroxide; inducible nitric oxide synthase; oxidative stress; retinal
   pigment epithelium
ID MACULAR DEGENERATION; PROTECTS; RATS
AB Elevated reactive oxygen species (ROS) induce oxidative damage in retinal pigment epithelium (RPE) and contribute to the development of age-related macular degeneration (AMD). Gastrodin plays an antioxidant role in distinct diseases, such as epilepsy, cerebral ischemia, Alzheimer's disease, and cardiovascular diseases. However, the function of gastrodin in AMD remains unclear. Human RPE (ARPE-19) cells were incubated with 300 mu M hydrogen peroxide (H2O2) for 24 hours. The results showed that H2O2 decreased cell viability and promoted the cell apoptosis of ARPE-19 cells. H2O2-induced ARPE-19 cells were then treated with different concentrations of gastrodin. Gastrodin increased cell viability of H2O2-induced ARPE-19 cells, suppressed the cell apoptosis of H2O2-induced ARPE-19 cells with reduced B-cell lymphoma (Bcl)-2 like protein (Bax), and enhanced Bcl-2. The levels of ROS were enhanced, malondialdehyde (MDA) was up-regulated, and superoxide dismutase (SOD) and glutathione (GSH) were down-regulated in H2O2-induced ARPE-19 cells. However, gastrodin reduced the levels of ROS and MDA and elevated SOD and GSH in H2O2-induced ARPE-19 cells. Furthermore, H2O2-induced increase of inducible nitric oxide synthase (iNOS) and p-p38 proteins in ARPE-19 was reversed by gastrodin. In conclusion, gastrodin exerted antiapoptotic and antioxidant capacities to protect against H2O2-induced oxidative stress in RPE, thereby acting as a potential agent for managing AMD.
C1 [Zhou, Xingli] Qinghai Univ, Affiliated Hosp, Dept Ophthalmol, Xining, Qinghai, Peoples R China.
   [Zhao, Ximing] Qinghai Univ, Affiliated Hosp, Dept Joint Bone, 29 Tongren Rd, Xining, Qinghai, Peoples R China.
C3 Qinghai University; Qinghai University
RP Zhao, XM (通讯作者)，Qinghai Univ, Affiliated Hosp, Dept Joint Bone, 29 Tongren Rd, Xining, Qinghai, Peoples R China.
EM z_xm123@163.com
FU Youth fund of Qinghai University [2019-QYY-15]
FX This work was supported by the Youth fund of Qinghai University. (Grant
   No. 2019-QYY-15).
CR Apte RS, 2021, NEW ENGL J MED, V385, P539, DOI 10.1056/NEJMcp2102061
   Arumugam B, 2019, MOL VIS, V25, P47
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Campello Laura, 2020, Cell Physiol Biochem, V54, P142, DOI 10.33594/000000210
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chen L, 2018, INT J MOL MED, V42, P1096, DOI 10.3892/ijmm.2018.3675
   Cia D, 2014, CURR EYE RES, V39, P944, DOI 10.3109/02713683.2014.885532
   Dai JN, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021891, 10.1371/journal.pone.0028903]
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hytti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136800
   Jiang GL, 2014, NEUROCHEM INT, V75, P79, DOI 10.1016/j.neuint.2014.06.003
   Jin M, 2018, CURR MOL MED, V18, P622, DOI 10.2174/1566524019666190107155311
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Li YM, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05025-x
   Li Y, 2015, INT J CLIN EXP PATHO, V8, P14099
   Mao K, 2017, DISCOV MED, V23, P129
   Molinari C, 2021, FOODS, V10, DOI 10.3390/foods10081885
   Raniga A, 2009, NEW ZEAL MED J, V122, P32
   Rohowetz LJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113362
   Ruan Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080761
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Song YX, 2013, LIFE SCI, V92, P1215, DOI 10.1016/j.lfs.2013.05.007
   Taylor AW, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724601
   Wang JW, 2017, INT J OPHTHALMOL-CHI, V10, P1483, DOI 10.18240/ijo.2017.10.01
   Xiao MM, 2016, SCI REP-UK, V6, DOI 10.1038/srep37251
   Yan JY, 2019, BMC NEUROSCI, V20, DOI 10.1186/s12868-019-0512-x
   Yang S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.727870
   Yuan ZL, 2009, NITRIC OXIDE-BIOL CH, V20, P9, DOI 10.1016/j.niox.2008.09.001
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang TH, 2018, MOL MED REP, V17, P7774, DOI 10.3892/mmr.2018.8841
   Zhou F, 2017, BIOCHEM BIOPH RES CO, V484, P820, DOI 10.1016/j.bbrc.2017.01.179
   Zhou JZ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20194347
   Zhu MF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3685391
NR 34
TC 0
Z9 0
U1 5
U2 6
PU CODON PUBLICATIONS
PI BRISBANE
PA LEVEL 9, 167 EAGLE ST, BRISBANE, QLD 4000, AUSTRALIA
SN 1757-8361
EI 1757-837X
J9 QUAL ASSUR SAF CROP
JI Qual. Assur. Saf. Crop. Foods
PY 2021
VL 13
IS 4
BP 24
EP 30
DI 10.15586/qas.v13i4.969
PG 7
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA YP4NU
UT WOS:000748601500002
OA hybrid
DA 2022-11-30
ER

PT J
AU Ramon, C
   Cardona, G
   Biarnes, M
   Ferraro, LL
   Mones, J
AF Ramon, Clara
   Cardona, Genis
   Biarnes, Marc
   Ferraro, Lucia L.
   Mones, Jordi
TI Longitudinal changes in outer nuclear layer thickness in soft drusen and
   reticular pseudodrusen
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; outer nuclear layer; reticular
   pseudodrusen; soft drusen; spectral domain optical coherence tomography
ID MACULAR DEGENERATION; MULTIFOCAL ELECTRORETINOGRAPHY; DARK-ADAPTATION;
   IMPACT; MICROPERIMETRY; EPIDEMIOLOGY; PREVALENCE; REGRESSION; DEPOSITS;
   ATROPHY
AB Background Drusen are seen in the early and intermediate stages of age-related macular degeneration. A retrospective, two-year observational study at a tertiary centre was designed to assess outer nuclear layer thickness in different types of drusen. Methods Patients over 50 years of age with predominant soft drusen or reticular pseudodrusen were included in the study. Fundus photography, infrared, fundus autofluorescence and spectral domain optical coherence tomography were performed at baseline, years one and two. Outer nuclear layer thickness was measured in the nine Early Treatment Diabetic Retinopathy Study subfields, and the rate of thinning was determined using generalised estimating equations models. Results Data were analysed from 17 eyes with soft drusen and nine eyes with reticular pseudodrusen. Greater outer nuclear layer thinning was seen overall and in all subfields in reticular pseudodrusen as compared to soft drusen, with statistically significant differences found mostly in superior and nasal subfields of ring 2. The outer nuclear layer was 5-12 mu m thinner in eyes with reticular pseudodrusen, and the rate of thinning was greater in eyes with reticular pseudodrusen in the outer superior subfield. Conclusions Outer nuclear layer thickness is consistently lower in patients with reticular pseudodrusen compared with soft drusen, irrespective of subfield location. These structural findings may contribute to explain the functional abnormalities observed in patients with reticular pseudodrusen.
C1 [Ramon, Clara; Biarnes, Marc; Ferraro, Lucia L.; Mones, Jordi] Inst Macula, Ophthalmol Dept, Barcelona, Spain.
   [Cardona, Genis] Univ Politecn Cataluna, Sch Opt & Optometry Terrassa, Dept Opt & Optometry, Terrassa, Spain.
   [Biarnes, Marc; Ferraro, Lucia L.; Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
C3 Universitat Politecnica de Catalunya
RP Cardona, G (通讯作者)，Univ Politecn Cataluna, Sch Opt & Optometry Terrassa, Dept Opt & Optometry, Terrassa, Spain.
EM genis.cardona@upc.edu
RI Cardona, Genis/F-3084-2016; mones, jordi/CAJ-2963-2022
OI Cardona, Genis/0000-0002-4770-8992; mones, jordi/0000-0003-3685-2160
CR Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garcia M, 2016, INVEST OPHTH VIS SCI, V57, P3706
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Hanumunthadu D, 2017, CLIN EXP OPHTHALMOL, V45, P270, DOI 10.1111/ceo.12868
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lujan BJ, 2015, RETINA-J RET VIT DIS, V35, P1511, DOI 10.1097/IAE.0000000000000527
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Ying GS, 2017, OPHTHAL EPIDEMIOL, V24, P130, DOI 10.1080/09286586.2016.1259636
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   ZEGER SL, 1992, STAT MED, V11, P1825, DOI 10.1002/sim.4780111406
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 35
TC 7
Z9 7
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD NOV
PY 2019
VL 102
IS 6
BP 601
EP 610
DI 10.1111/cxo.12894
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JH5OX
UT WOS:000492819000011
PM 30883919
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Varga, L
   Kovacs, A
   Grosz, T
   Thury, G
   Hadarits, F
   Degi, R
   Dombi, J
AF Varga, Laszlo
   Kovacs, Attila
   Grosz, Tamas
   Thury, Geza
   Hadarits, Flora
   Degi, Rozsa
   Dombi, Jozsef
TI Automatic segmentation of hyperreflective foci in OCT images
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE OCT; HF segmentation; Deep neural network; Convolutional network; Image
   processing; GPGPU
ID MACULAR DEGENERATION
AB Background and Objective: The leading cause of vision loss in the Western World is Age-related Macular Degeneration (AMD), but together with modern medicines, tracking the number of Hyperreflective Foci (HF) on Optical Coherence Tomography (OCT) images should assist the treatment of patients. Here, we developed a framework based on deep learning for the automatic segmentation of HF in OCT images.
   Methods: We collected OCT images and annotated them, then these images underwent image preprocessing, and feature extraction steps. Using the prepared data we trained different types of Conventional-, Deep- and Convolutional Neural Networks to perform the task of the automatic segmentation of HF.
   Results: We evaluated the various Neural Networks, by performing HF segmentation of clinical data belonging to patients, whose data were excluded from the training process. The results suggest that our systems can achieve reasonably high Dice Coefficient values, and they are comparable with (i.e., in most cases above 95%) the similarity between manual annotations performed by different physicians.
   Conclusion: From the results, it can be concluded that neural networks can be used to accurately segment HF in OCT images. The results are sufficiently accurate for us to incorporate them into the next phase of the research, building a decision support system for everyday clinical practice. (C) 2019 Published by Elsevier B.V.
C1 [Varga, Laszlo; Kovacs, Attila; Grosz, Tamas; Thury, Geza; Hadarits, Flora; Degi, Rozsa; Dombi, Jozsef] Univ Szeged, Interdisciplinary Excellence Ctr, Szeged, Hungary.
C3 Szeged University
RP Varga, L (通讯作者)，Univ Szeged, Interdisciplinary Excellence Ctr, Szeged, Hungary.
EM vargalg@inf.u-szeged.hu
RI Grósz, Tamás/AGL-6551-2022; Varga, László G./M-2975-2018
OI Grósz, Tamás/0000-0001-7918-9579; Varga, László G./0000-0003-2924-5573
FU project "Integrated program for training new generation of scientists in
   the fields of computer science" [EFOP-3.6.3-VEKOP-16-2017-0002];
   European Union; European Social Fund; Ministry of Human Capacities,
   Hungary [203913/2018/FEKUSTRAT]; National Research, Development and
   Innovation Office of Hungary through the Artificial Intelligence
   National Excellence Program [2018-1.2.1-NKP-2018-00008]
FX This research was supported by the project "Integrated program for
   training new generation of scientists in the fields of computer
   science", no EFOP-3.6.3-VEKOP-16-2017-0002. The project has been
   supported by the European Union and co-funded by the European Social
   Fund. Ministry of Human Capacities, Hungary grant 203913/2018/FEKUSTRAT
   is acknowledged. Tamas Grosz was supported by the National Research,
   Development and Innovation Office of Hungary through the Artificial
   Intelligence National Excellence Program (grant no.:
   2018-1.2.1-NKP-2018-00008).
CR Abadi M., 2016, TENSORFLOW LARGE SCA
   [Anonymous], 2017, COMPUT METHODS PROGR
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coscas G., 2009, OPTICAL COHERENCE TO, P195
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Faust O, 2018, COMPUT METH PROG BIO, V161, P1, DOI 10.1016/j.cmpb.2018.04.005
   Glorot X., 2011, P 14 INT C ART INT S, P315, DOI DOI 10.1002/ECS2.1832
   Kaiming He, 2016, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR), P770, DOI 10.1109/CVPR.2016.90
   Katona M, 2018, LECT NOTES COMPUT SC, V10882, P706, DOI 10.1007/978-3-319-93000-8_80
   Katona M, 2017, LECT NOTES COMPUT SC, V10484, P606, DOI 10.1007/978-3-319-68560-1_54
   Kingma J., 2014, ARXIV
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Korot E, 2016, JAMA OPHTHALMOL, V134, P15, DOI 10.1001/jamaophthalmol.2015.3949
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P1372, DOI 10.1097/IAE.0000000000000929
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Milletari F, ARXIV160604797
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Parodi MB, 2018, INVEST OPHTH VIS SCI, V59, P3314, DOI 10.1167/iovs.18-24291
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Ronneberger O, 2015, LECT NOTES COMPUTER, V9351
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Salimans T., 2016, ARXIV160207868CSLG
   Schlegl T., ARXIV180503278
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Toth L, 2005, LECT NOTES COMPUT SC, V3696, P597
   Velez-Montoya R, 2012, RETINA, V33, P1487
NR 33
TC 15
Z9 15
U1 1
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD SEP
PY 2019
VL 178
BP 91
EP 103
DI 10.1016/j.cmpb.2019.06.019
PG 13
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA IQ0HP
UT WOS:000480432000010
PM 31416566
DA 2022-11-30
ER

PT J
AU Pinto, WP
   Rabello, LP
   Ventura, MC
   Rocha, CS
   Ventura, BV
AF Pinto, Wanessa P.
   Rabello, Laura P.
   Ventura, Marcelo C.
   Rocha, Camilla S.
   Ventura, Bruna V.
TI Prevalence of macular abnormalities identified only by optical coherence
   tomography in Brazilian patients with cataract
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID RISK-FACTORS; EPIRETINAL MEMBRANE; POPULATION; DEGENERATION
AB Purpose: To assess the prevalence of macular abnormalities not suspected by the biomicroscopic fundus examination and identified only by macular optical coherence tomography (OCT) in the preoperative evaluation for cataract surgery in a large series of Brazilian patients.
   Setting: Private practice, Recife, Brazil.
   Design: Retrospective case series.
   Methods: All eyes that had cataract surgery by the same physician between August 2014 and July 2016 were eligible. Excluded were eyes with a previous diagnosis of macular abnormalities, with a suspicious biomicroscopic fundus examination, and without OCT results. Based on the preoperative macular OCT, patients were divided into the following 2 groups: those with a normal OCT and those with an abnormal OCT.
   Results: Nine hundred fifty-two eyes (614 patients) were included in the study. Macular OCT identified abnormalities in 47 eyes (4.9%) of 44 patients (7.2%). Thirty-one eyes (3.3%) had epiretinal membrane, 7 (0.7%) had age-related macular degeneration, 4 (0.4%) had intraretinal cysts, 4 (0.4%) had a lamellar hole, and 1 (0.1%) had a macular hole. Patients with an abnormal OCT had a statistically significant higher mean age (P = .004).
   Conclusion: In the preoperative evaluation for cataract surgery in Brazilian patients, 7.2% of those with a normal biomicroscopic fundus examination had macular abnormalities that were identified only by OCT. (C) 2019 ASCRS and ESCRS
C1 [Pinto, Wanessa P.; Rabello, Laura P.; Ventura, Marcelo C.; Rocha, Camilla S.; Ventura, Bruna V.] Altino Ventura Fdn, Rua Progresso 71, BR-50070020 Recife, PE, Brazil.
   [Pinto, Wanessa P.; Ventura, Marcelo C.; Ventura, Bruna V.] HOPE Eye Hosp, Recife, PE, Brazil.
RP Ventura, BV (通讯作者)，Altino Ventura Fdn, Rua Progresso 71, BR-50070020 Recife, PE, Brazil.
EM brunaventuramd@gmail.com
CR Anastasopoulos E, 2018, OPHTHAL EPIDEMIOL, V25, P457, DOI 10.1080/09286586.2018.1512634
   Aung KZ, 2013, RETINA-J RET VIT DIS, V33, P1026, DOI 10.1097/IAE.0b013e3182733f25
   Bozorg S, 2014, SEMIN OPHTHALMOL, V29, P376, DOI 10.3109/08820538.2014.959193
   Hirnschall N, 2016, J CATARACT REFR SURG, V42, P530, DOI 10.1016/j.jcrs.2016.02.029
   Huang XL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22807-7
   Ichikawa Y, 2018, AM J OPHTHALMOL, V193, P20, DOI 10.1016/j.ajo.2018.06.001
   Klein BR, 2016, J CATARACT REFR SURG, V42, P537, DOI 10.1016/j.jcrs.2016.01.036
   Neto CAM, 2015, ARQ BRAS OFTALMOL, V78, P241, DOI 10.5935/0004-2749.20150062
   Ng CH, 2011, OPHTHALMOLOGY, V118, P694, DOI 10.1016/j.ophtha.2010.08.009
   Piermarocchi S, 2016, OPHTHALMIC RES, V55, P111, DOI 10.1159/000441795
   Schaub F, 2018, GRAEF ARCH CLIN EXP, V256, P909, DOI 10.1007/s00417-018-3954-4
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Ye HH, 2015, BRIT J OPHTHALMOL, V99, P1594, DOI 10.1136/bjophthalmol-2015-307050
   Zafar S, 2017, J CATARACT REFR SURG, V43, P324, DOI 10.1016/j.jcrs.2016.12.022
NR 14
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUL
PY 2019
VL 45
IS 7
BP 915
EP 918
DI 10.1016/j.jcrs.2019.01.022
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA II7ZT
UT WOS:000475411200005
PM 31174986
DA 2022-11-30
ER

PT J
AU Oura, Y
   Nakamura, M
   Takigawa, T
   Fukushima, Y
   Wakabayashi, T
   Tsujikawa, M
   Nishida, K
AF Oura, Yoshihito
   Nakamura, Machiko
   Takigawa, Tohru
   Fukushima, Yoko
   Wakabayashi, Taku
   Tsujikawa, Motokazu
   Nishida, Kohji
TI High-Temperature Requirement A 1 Causes Photoreceptor Cell Death in
   Zebrafish Disease Models
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; GENOME-WIDE ASSOCIATION; AGE-RELATED
   MACULOPATHY; MACULAR DEGENERATION; RETICULAR PSEUDODRUSEN; GEOGRAPHIC
   ATROPHY; SERINE-PROTEASE; BINDING-PROTEIN; HUMAN HTRA1; SUSCEPTIBILITY
AB Age-related macular degeneration (AMD) is an important cause of blindness. It is characterized by a retinal pigment epithelium (RPE) disorder that leads to death of photoreceptor cells (PRCs). AMD has a strong genetic association with high-temperature requirement A 1 (HTRA1). The relationship between HTRA1 and the AMD phenotype is unknown. In this study, we show that the expression of HTRA1 in PRCs, as well as in RPE, is increased by the disease-associated HTRA1 mutation and aging. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay and quantitative PCR of apoptosis-associated caspases confirmed that PRC-specific overexpression of HTRA1 induced PRC death. Transgenic zebrafish overexpressing human HTRA1 in rod PRCs showed morphologic changes of the RPE, including PRC death and lipofuscin accumulation, features similar to those of early AMD. htra1 expression was also increased in a retinitis pigmentosa zebrafish model compared with wild type. In both fish lines, PRC death was rescued by the suppression of htra1 by the inhibitor 6-boroV. AKT forkhead box 03 signaling downstream of HTRA1 was activated via a tumor growth factor beta signal, resulting in PRC death. These findings suggest that HTRA1 derived from PRCs is associated with early AMD via PRC death. HTRA1 is a potentially effective target for neuroprotective therapy of early AMD and other degenerative diseases of PRCs.
C1 [Oura, Yoshihito; Takigawa, Tohru; Fukushima, Yoko; Wakabayashi, Taku; Tsujikawa, Motokazu; Nishida, Kohji] Osaka Univ, Med Sch, Dept Ophthalmol, Suita, Osaka, Japan.
   [Nakamura, Machiko] Daiichi Sankyo Co Ltd, Pain & Neurosci Labs, Tokyo, Japan.
C3 Osaka University; Daiichi Sankyo Company Limited
RP Tsujikawa, M (通讯作者)，Osaka Univ, Grad Sch Med, Dept Biomed Informat, Div Hlth Sci, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan.
EM moto@sahs.med.osaka-u.ac.jp
CR Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Delori F, 2007, ORIGIN FUNDUS AUTOFL, P17
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Flynn E, 2014, INVEST OPHTH VIS SCI, V55, P5643, DOI 10.1167/iovs.14-14136
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gibson JM, 2014, EXPERT OPIN DRUG SAF, V13, P1259, DOI 10.1517/14740338.2014.939951
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hamaoka T, 2002, GENESIS, V34, P215, DOI 10.1002/gene.10155
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Hou YZ, 2014, J IMMUNOL, V193, P130, DOI 10.4049/jimmunol.1302700
   Huang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075735
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2010, MOL VIS, V16, P1317
   KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim GY, 2012, MOL CELL BIOL, V32, P4482, DOI 10.1128/MCB.00872-12
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Lana TP, 2018, OPHTHALMIC GENET, V39, P46, DOI 10.1080/13816810.2017.1354382
   Latendresse JR, 2002, TOXICOL PATHOL, V30, P524, DOI 10.1080/01926230290105721
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malicki J, 2002, METHODS, V28, P427, DOI 10.1016/S1046-2023(02)00262-1
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Marinkovic D, 2007, J CLIN INVEST, V117, P2133, DOI 10.1172/JCI31807
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nakao T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032472
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6
   Rifkin DB, 2005, J BIOL CHEM, V280, P7409, DOI 10.1074/jbc.R400029200
   Ruamviboonsuk P, 2017, J HUM GENET, V62, P957, DOI 10.1038/jhg.2017.72
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yang SS, 2016, DOC OPHTHALMOL, V132, P17, DOI 10.1007/s10633-016-9523-4
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zheng WL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024019
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   1995, OPHTHALMOLOGE, V102, P647
NR 71
TC 8
Z9 8
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD DEC
PY 2018
VL 188
IS 12
BP 2729
EP 2744
DI 10.1016/j.ajpath.2018.08.012
PG 16
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA HF4EX
UT WOS:000454187100003
PM 30273602
OA Bronze
DA 2022-11-30
ER

PT J
AU Cai, BC
   Sun, S
   Li, ZQ
   Zhang, XM
   Ke, YF
   Yang, J
   Li, XR
AF Cai, Bincui
   Sun, Shuo
   Li, Zhiqing
   Zhang, Xiaomin
   Ke, Yifeng
   Yang, Jin
   Li, Xiaorong
TI Application of CRISPR/Cas9 technologies combined with iPSCs in the study
   and treatment of retinal degenerative diseases
SO HUMAN GENETICS
LA English
DT Review
ID LINKED RETINITIS-PIGMENTOSA; GENE-THERAPY; MACULAR DEGENERATION;
   CHILDHOOD BLINDNESS; CANINE MODEL; STEM-CELLS; CAS9; REPAIR; MUTATIONS;
   ACTIVATION
AB Retinal degeneration diseases, such as age-related macular degeneration and retinitis pigmentosa, affect millions of people worldwide and are major causes of irreversible blindness. Effective treatments for retinal degeneration, including drug therapy, gene augmentation or transplantation approaches, have been widely investigated. Nevertheless, more research should be dedicated to therapeutic methods to improve future clinical treatments. Recently, with the rapid development of genome-editing technology, gene therapy has become a potentially effective treatment for retinal degeneration diseases. A clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has been developed as a powerful genome-editing tool in ophthalmic studies. The CRISPR/Cas9 system has been widely applied in basic research to develop animal models and gene therapies in vivo. With the ability to self-renew and the potential to differentiate into different types of cells, induced pluripotent stem cells (iPSCs) have already been used as a promising tool for understanding disease pathophysiology and evaluating the effect of drug and gene therapeutics. iPSCs are also a cell source for autologous transplantation. In this review, we compared genome-editing strategies and highlighted the advantages and concerns of the CRISPR/Cas9 system. Moreover, the latest progress and applications of the CRISPR/Cas9 system and its combination with iPSCs for the treatment of retinal degenerative diseases are summarized.
C1 [Cai, Bincui; Sun, Shuo; Li, Zhiqing; Zhang, Xiaomin; Ke, Yifeng; Yang, Jin; Li, Xiaorong] Tianjin Med Univ, Eye Hosp, Tianjin 300384, Peoples R China.
C3 Tianjin Medical University
RP Yang, J; Li, XR (通讯作者)，Tianjin Med Univ, Eye Hosp, Tianjin 300384, Peoples R China.
EM yangjin-324@163.com; xiaorli@163.com
OI Zhang, Xiaomin/0000-0003-4898-4152
FU National Natural Science Foundation, China [81670875, 81500745]; Natural
   Science Foundation of Tianjin City [18JCQNJC10700, 17JCYBJC27200]; Dr.
   Henry Norman Bethune: LangMu Young Scientist Scholarship [BJ-LM2015008L]
FX We thank Jin Yang, Xiaomin Zhang and Xiaorong Li for comments and
   suggestions, Jin Yang and Zhiqing Li for editing the manuscript, Bincui
   Cai for writing the manuscript, and Shuo Sun for assistance in
   generating the table. This work was supported by the National Natural
   Science Foundation (81670875; 81500745), China; the Natural Science
   Foundation of Tianjin City (18JCQNJC10700); the Natural Science
   Foundation of Tianjin City (17JCYBJC27200); and a grant from the Dr.
   Henry Norman Bethune: LangMu Young Scientist Scholarship
   (BJ-LM2015008L).
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Arno G, 2016, AM J HUM GENET, V99, P1305, DOI 10.1016/j.ajhg.2016.10.008
   Auer TO, 2014, GENOME RES, V24, P142, DOI 10.1101/gr.161638.113
   Bakondi B, 2016, MOL THER, V24, P556, DOI 10.1038/mt.2015.220
   Bassuk AG, 2016, SCI REP-UK, V6, DOI 10.1038/srep19969
   Beltran WA, 2017, MOL THER, V25, P1866, DOI 10.1016/j.ymthe.2017.05.004
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Cereso N, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.11
   Chang NN, 2013, CELL RES, V23, P465, DOI 10.1038/cr.2013.45
   Chavala SH, 2005, BRIT J OPHTHALMOL, V89, P1065, DOI 10.1136/bjo.2005.068130
   Chrenek MA, 2016, ASIA-PAC J OPHTHALMO, V5, P304, DOI 10.1097/APO.0000000000000225
   Cox DBT, 2015, NAT MED, V21, P121, DOI 10.1038/nm.3793
   Da Costa R, 2016, INVEST OPHTH VIS SCI, V57, P5326, DOI 10.1167/iovs.16-19701
   Day TP, 2014, ADV EXP MED BIOL, V801, P687, DOI 10.1007/978-1-4614-3209-8_86
   De La Camara CMF, 2018, EXPERT OPIN ORPHAN D, V6, P167, DOI 10.1080/21678707.2018.1444476
   Fischer MD, 2017, MOL THER, V25, P1854, DOI 10.1016/j.ymthe.2017.05.005
   Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623
   He YX, 2015, CURR STEM CELL RES T, V10, P258, DOI 10.2174/1574888X09666141027103552
   Homma K, 2013, STEM CELLS, V31, P1149, DOI 10.1002/stem.1372
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   JACOBSON SG, 1990, INVEST OPHTH VIS SCI, V31, P827
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jasin M, 2016, DNA REPAIR, V44, P6, DOI 10.1016/j.dnarep.2016.05.001
   Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kleinstiver BP, 2016, NATURE, V529, P490, DOI 10.1038/nature16526
   Latella MC, 2016, MOL THER-NUCL ACIDS, V5, P1, DOI 10.1038/mtna.2016.92
   Liao HK, 2017, CELL, V171, P1495, DOI 10.1016/j.cell.2017.10.025
   Lim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13350
   Ma YW, 2014, CELL RES, V24, P122, DOI 10.1038/cr.2013.157
   Maeder ML, 2013, NAT METHODS, V10, P977, DOI [10.1038/nmeth.2598, 10.1038/NMETH.2598]
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   MARMOR MF, 1990, AM J OPHTHALMOL, V110, P124, DOI 10.1016/S0002-9394(14)76980-6
   Naert T, 2016, SCI REP-UK, V6, DOI 10.1038/srep35264
   Nelson CE, 2016, ANNU REV CHEM BIOMOL, V7, P637, DOI 10.1146/annurev-chembioeng-080615-034711
   Pawlyk BS, 2016, GENE THER, V23, P196, DOI 10.1038/gt.2015.93
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Schaefer KA, 2018, CORRIGENDUM FOLLOW W, DOI [10. 1101/154450, DOI 10.1101/154450]
   Schaefer KA, 2017, NAT METHODS, V14, P547, DOI 10.1038/nmeth.4293
   Schwank G, 2013, CELL STEM CELL, V13, P653, DOI 10.1016/j.stem.2013.11.002
   Senis E, 2014, BIOTECHNOL J, V9, P1402, DOI 10.1002/biot.201400046
   Shin J, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701620
   Stemmer M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124633
   Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565
   Tucker BA, 2014, HUM MOL GENET, V23, pR9, DOI 10.1093/hmg/ddu124
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Wiley LA, 2015, PROG RETIN EYE RES, V44, P15, DOI 10.1016/j.preteyeres.2014.10.002
   Wu WH, 2016, MOL THER, V24, P1388, DOI 10.1038/mt.2016.107
   Yanik M, 2017, PROG RETIN EYE RES, V56, P1, DOI 10.1016/j.preteyeres.2016.09.001
   Zetsche B, 2017, NAT BIOTECHNOL, V35, P31, DOI 10.1038/nbt.3737
   Zheng A, 2015, EXPERT OPIN BIOL TH, V15, P391, DOI 10.1517/14712598.2015.1006192
   Zhong H, 2015, SCI REP-UK, V5, DOI 10.1038/srep08366
   Zhou JK, 2014, INT J BIOCHEM CELL B, V46, P49, DOI 10.1016/j.biocel.2013.10.010
   Zhu HX, 2016, SCI REP-UK, V6, DOI 10.1038/srep25516
NR 56
TC 14
Z9 15
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD SEP
PY 2018
VL 137
IS 9
BP 679
EP 688
DI 10.1007/s00439-018-1933-9
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GT8XC
UT WOS:000444822200002
PM 30203114
DA 2022-11-30
ER

PT J
AU Lee, GY
   Kang, SJ
   Lee, SJ
   Song, JE
   Joo, CK
   Lee, D
   Khang, G
AF Lee, Ga Young
   Kang, Su Ji
   Lee, So Jin
   Song, Jeong Eun
   Joo, Choun-Ki
   Lee, Dongwon
   Khang, Gilson
TI Effects of small intestinal submucosa content on the adhesion and
   proliferation of retinal pigment epithelial cells on SIS-PLGA films
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE retinal pigment epithelium; small intestinal submucosa; PLGA; tissue
   engineering; hybrid film; regeneration
ID TISSUE-ENGINEERED BONE; IN-VITRO; MACULAR DEGENERATION; BRUCHS MEMBRANE;
   INTACT SHEETS; SCAFFOLDS; ATTACHMENT; BEHAVIOR; COLLAGEN; CULTURE
AB The retinal pigment epithelium (RPE) plays a critical role in the maintenance of the normal functions of the retina, particularly the photoreceptors. RPE dysfunction, vision loss and degeneration have been implicated as the cause of many retinal diseases, including retinitis pigmentosa and age-related macular degeneration (AMD). To overcome such disorders, tissue engineering could offer useful strategies, using biodegradable polymeric films to replace diseased or lost RPE. Synthetic/natural hybrid films have been studied as a temporary substrate for growing RPEs in biological implantations. In this study, we prepared small intestinal submucosa (SIS)-poly(lactic-co-glycolic) (PLGA) hybrid films and seeded human RPE cells (ARPE-19 cells) onto the film surface. We investigated the film suitability for RPE cell proliferation by MTT assay. The morphology of cellular adhesion on the film was confirmed by scanning electron microscopy (SEM). Reverse transcription-polymerase chain reaction (RT-PCR) and 3-amino-9-ethylcarbazole (AEC) staining were performed to examine mRNA expression and to compare cell proliferation on the films, using cytokeratin as a marker of RPE. Conclusively, we confirmed the higher cell survival rate and much stronger phenotype expression of RPEs on SIS-PLGA films compared to pure PLGA films. These results demonstrated the potential application of SIS-PLGA films in tissue-engineering strategies. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Lee, Ga Young; Kang, Su Ji; Lee, So Jin; Song, Jeong Eun; Lee, Dongwon; Khang, Gilson] Chonbuk Natl Univ, Dept BIN Fus Technol, 567 Baekje Daero, Jeonju, South Korea.
   [Lee, Ga Young; Kang, Su Ji; Lee, So Jin; Song, Jeong Eun; Lee, Dongwon; Khang, Gilson] Chonbuk Natl Univ, Dept Polymer Nano Sci & Technol, 567 Baekje Daero, Jeonju, South Korea.
   [Lee, Ga Young; Kang, Su Ji; Lee, So Jin; Song, Jeong Eun; Lee, Dongwon; Khang, Gilson] Chonbuk Natl Univ, Polymer Fus Res Ctr, 567 Baekje Daero, Jeonju, South Korea.
   [Joo, Choun-Ki] Catholic Univ, Coll Med, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
C3 Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University; Catholic University of Korea
RP Khang, G (通讯作者)，Chonbuk Natl Univ, Dept BIN Fus Technol, 567 Baekje Daero, Jeonju, South Korea.; Khang, G (通讯作者)，Chonbuk Natl Univ, Dept Polymer Nano Sci & Technol, 567 Baekje Daero, Jeonju, South Korea.; Khang, G (通讯作者)，Chonbuk Natl Univ, Polymer Fus Res Ctr, 567 Baekje Daero, Jeonju, South Korea.
EM gskhang@jbnu.ac.kr
RI song, jeong eun/P-9106-2015; Lee, Sang Jin/S-4056-2019
OI song, jeong eun/0000-0001-6879-7616; Lee, Sang Jin/0000-0002-3899-1909
FU World Class University [R31-20029]; SCRC [SC4110]
FX This research was supported by World Class University (Grant No.
   R31-20029) and SCRC (Grant No. SC4110).
CR Aramant RB, 1999, INVEST OPHTH VIS SCI, V40, P1557
   Badylak SF, 1998, J BIOMAT SCI-POLYM E, V9, P863, DOI 10.1163/156856298X00208
   Badylak SF, 2002, SEMIN CELL DEV BIOL, V13, P227
   Chiou SH, 2005, BIOCHEM BIOPH RES CO, V326, P578, DOI 10.1016/j.bbrc.2004.11.061
   Colthurst MJ, 2000, BIOMATERIALS, V21, P649, DOI 10.1016/S0142-9612(99)00220-3
   Cook AD, 1997, BIOMATERIALS, V18, P1417, DOI 10.1016/S0142-9612(97)00075-6
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Fan YW, 2002, J NEUROSCI METH, V120, P17, DOI 10.1016/S0165-0270(02)00181-4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   GIORDANO GG, 1993, INVEST OPHTH VIS SCI, V34, P2743
   Itaya H, 2004, INVEST OPHTH VIS SCI, V45, P4520, DOI 10.1167/iovs.04-0684
   Jang JW, 2004, POLYM-KOREA, V28, P382
   Jeong Su Mi, 2011, Int J Stem Cells, V4, P105
   Jo EH, 2011, BIOMED ENG-APP BAS C, V23, P119, DOI 10.4015/S1016237211002438
   Khang G, 2002, MACROMOL RES, V10, P158, DOI 10.1007/BF03218266
   Kim HL, 2011, POLYM-KOREA, V35, P7
   Kim MS, 2007, BIOMATERIALS, V28, P5137, DOI 10.1016/j.biomaterials.2007.08.014
   Kim YJ, 2011, INT J TISSUE REG, V2, P45
   Langer R, 2000, ACCOUNTS CHEM RES, V33, P94, DOI 10.1021/ar9800993
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Lee GY, 2017, J TISSUE ENG REGEN M, V11, P99, DOI 10.1002/term.1882
   Lee SJ, 2004, J BIOMAT SCI-POLYM E, V15, P1003, DOI 10.1163/1568562041526487
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lindberg K, 2001, BURNS, V27, P254, DOI 10.1016/S0305-4179(00)00113-3
   LOPEZ R, 1989, INVEST OPHTH VIS SCI, V30, P586
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   NICOLAISSEN B, 1982, ACTA OPHTHALMOL, V60, P873
   NICOLAISSEN B, 1982, ACTA OPHTHALMOL, V60, P881
   Oh SH, 2006, J MATER SCI-MATER M, V17, P131, DOI 10.1007/s10856-006-6816-2
   Pang L, 2007, SURF COAT TECH, V201, P9549, DOI 10.1016/j.surfcoat.2007.04.035
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Song SB, 2000, BIOMATER RES, V4, P13
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   VoytikHarbin SL, 1997, J CELL BIOCHEM, V67, P478, DOI 10.1002/(SICI)1097-4644(19971215)67:4<478::AID-JCB6>3.0.CO;2-P
   Wikstrom J, 2008, BIOMATERIALS, V29, P869, DOI 10.1016/j.biomaterials.2007.10.056
   Woch G, 2001, INVEST OPHTH VIS SCI, V42, P1669
   Yoshioka T, 2008, BIOMATERIALS, V29, P3438, DOI 10.1016/j.biomaterials.2008.04.011
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 44
TC 9
Z9 10
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-6254
EI 1932-7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD JAN
PY 2017
VL 11
IS 1
BP 99
EP 108
DI 10.1002/term.1882
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA EK8KW
UT WOS:000394173600009
PM 24888975
DA 2022-11-30
ER

PT J
AU Hoeg, TB
   Moldow, B
   Klein, R
   La Cour, M
   Klemp, K
   Erngaard, D
   Ellervik, C
   Buch, H
AF Hoeg, Tracy B.
   Moldow, Birgitte
   Klein, Ronald
   La Cour, Morten
   Klemp, Kristian
   Erngaard, Ditte
   Ellervik, Christina
   Buch, Helena
TI An evaluation of fundus photography and fundus autofluorescence in the
   diagnosis of cuticular drusen
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BASAL LAMINAR DRUSEN; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   POPULATION; PREVALENCE
AB Purpose To examine non-mydriatic fundus photography (FP) and fundus autofluorescence (FAF) as alternative non-invasive imaging modalities to fluorescein angiography (FA) in the detection of cuticular drusen (CD).
   Methods Among 2953 adults from the Danish Rural Eye Study (DRES) with gradable FP, three study groups were selected: (1) All those with suspected CD without age-related macular degeneration (AMD) on FP, (2) all those with suspected CD with AMD on FP and (3) a randomly selected group with early AMD. Groups 1, 2 and 3 underwent FA and FAF and group 4 underwent FAF only as part of DRES CD substudy. Main outcome measures included percentage of correct positive and correct negative diagnoses, Cohen's. and prevalence-adjusted and bias-adjusted. (PABAK) coefficients of test and grader reliability.
   Results CD was correctly identified on FP 88.9% of the time and correctly identified as not being present 83.3% of the time. CD was correctly identified on FAF 62.0% of the time and correctly identified as not being present 100.0% of the time. Compared with FA, FP has a PABAK of 0.75 (0.60 to 1.5) and FAF a PABAK of 0.44 (0.23 to 0.95).
   Conclusions FP is a promising, non-invasive substitute for FA in the diagnosis of CD. FAF was less reliable than FP to detect CD.
C1 [Hoeg, Tracy B.; Moldow, Birgitte; Erngaard, Ditte] Naestved Hosp, Dept Ophthalmol, Naestved, Denmark.
   [Hoeg, Tracy B.; La Cour, Morten; Ellervik, Christina] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [La Cour, Morten; Klemp, Kristian; Buch, Helena] Capital Reg Eye Clin, Dept Ophthalmol, Glostrup, Denmark.
   [Ellervik, Christina] Nykobing Falster Hosp, Dept Gen Populat Study, Nykobing, Denmark.
C3 Naestved Hospital; University of Copenhagen; University of Wisconsin
   System; University of Wisconsin Madison
RP Hoeg, TB (通讯作者)，Dept Ophthalmol, Ringstedgade 61, DK-4700 Naestved, Denmark.
EM tracybethhoeg@gmail.com
RI la Cour, Morten/L-1600-2013; Hesgaard, Helena Buch/E-8226-2011;
   Ellervik, Christina/H-2977-2019
OI Hesgaard, Helena Buch/0000-0002-2097-0202; Ellervik,
   Christina/0000-0002-3088-4375; Dornonville de la Cour,
   Morten/0000-0002-7712-9772; Hoeg, Tracy/0000-0002-2341-6573
FU Region Zealand Foundation; Naestved Hospital Foundation; Fight for Sight
   Denmark; Eva and Hans Carl Adolf Holms Memorial Scholarship; Ulla and
   Mogens Folmer Andersen's Fund; Mr and Mrs Johs M. Klein Memorial
   Scholarship; Edith and Henrik Henriksen's Memorial Scholarship
FX Region Zealand Foundation, Naestved Hospital Foundation, Fight for Sight
   Denmark, Eva and Hans Carl Adolf Holms Memorial Scholarship, Ulla and
   Mogens Folmer Andersen's Fund, Mr and Mrs Johs M. Klein Memorial
   Scholarship, and Edith and Henrik Henriksen's Memorial Scholarship.
CR Altman DG, 1991, PRACTICAL STAT MED R, P403, DOI [DOI 10.1002/SIM.4780101015, 10.1002/sim.4780101015]
   Bergholdt HKM, 2013, DAN MED J, V60
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Delcourt C, 2010, AGE RELATED MACULAR, P11
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Hoeg T, 2015, OPHTHALMIC IN PRESS
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Loney SW, 2008, HDB STAT, P109
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sim J, 2005, PHYS THER, V85, P257
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 22
TC 5
Z9 5
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2016
VL 100
IS 3
BP 378
EP 382
DI 10.1136/bjophthalmol-2015-307197
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DE9SN
UT WOS:000370979300017
PM 26216869
DA 2022-11-30
ER

PT J
AU Pallitto, P
   Ablonczy, Z
   Jones, EE
   Drake, RR
   Koutalos, Y
   Crouch, RK
   Donello, J
   Herrmann, J
AF Pallitto, Patrick
   Ablonczy, Zsolt
   Jones, E. Ellen
   Drake, Richard R.
   Koutalos, Yiannis
   Crouch, Rosalie K.
   Donello, John
   Herrmann, Julia
TI A2E and lipofuscin distributions in macaque retinal pigment epithelium
   are similar to human
SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
LA English
DT Article
ID RETINYLIDENE-N-RETINYLETHANOLAMINE; FUNDUS AUTOFLUORESCENCE;
   STARGARDTS-DISEASE; AGE; FLUORESCENCE; ACCUMULATION; FLUOROPHORES;
   TOPOGRAPHY; PRECURSOR; NEURONS
AB The accumulation of lipofuscin, an autofluorescent aging marker, in the retinal pigment epithelium (RPE) has been implicated in the development of age-related macular degeneration (AMD). Lipofuscin contains several visual cycle byproducts, most notably the bisretinoid N-retinylidene-N-retinylethanolamine (A2E). Previous studies with human donor eyes have shown a significant mismatch between lipofuscin autofluorescence (AF) and A2E distributions. The goal of the current project was to examine this relationship in a primate model with a retinal anatomy similar to that of humans. Ophthalmologically naive young (<10 years., N = 3) and old (>10 years., N = 4) Macaca fascicularis (macaque) eyes, were enucleated, dissected to yield RPE/choroid tissue, and flat-mounted on indium-tin-oxide-coated conductive slides. To compare the spatial distributions of lipofuscin and A2E, fluorescence and mass spectrometric imaging were carried out sequentially on the same samples. The distribution of lipofuscin fluorescence in the primate RPE reflected previously obtained human results, having the highest intensities in a perifoveal ring. Contrarily, A2E levels were consistently highest in the periphery, confirming a lack of correlation between the distributions of lipofuscin and A2E previously described in human donor eyes. We conclude that the mismatch between lipofuscin AF and A2E distributions is related to anatomical features specific to primates, such as the macula, and that this primate model has the potential to fill an important gap in current AMD research.
C1 [Pallitto, Patrick; Ablonczy, Zsolt; Koutalos, Yiannis; Crouch, Rosalie K.] Med Univ S Carolina, Dept Ophthalmol, Storm Eye Inst, Charleston, SC 29425 USA.
   [Jones, E. Ellen; Drake, Richard R.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.
   [Jones, E. Ellen; Drake, Richard R.] Med Univ S Carolina, MUSC Prote Ctr, Charleston, SC 29425 USA.
   [Donello, John; Herrmann, Julia] Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA 92715 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; AbbVie; Allergan
RP Ablonczy, Z (通讯作者)，Med Univ S Carolina, Dept Ophthalmol, Storm Eye Inst, 171 Ashley Ave, Charleston, SC 29425 USA.
EM ablonczy@musc.edu
FU Allergan, Inc., Irvine, CA; NIH [EY19065, EY014850]; Research to Prevent
   Blindness, New York, NY; state of South Carolina Smart State Endowed
   Research program; Cancer Center Support Grant [P30 CA138313]; NATIONAL
   CANCER INSTITUTE [P30CA138313] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R01EY014850, R01EY019065] Funding Source: NIH RePORTER
FX This research was supported in part by a grant from Allergan, Inc.,
   Irvine, CA; by NIH grants EY19065 (ZA), EY014850 (YK); an unrestricted
   grant to MUSC, Department of Ophthalmology, from Research to Prevent
   Blindness, New York, NY, and the state of South Carolina Smart State
   Endowed Research program to R.R.D. RKC is an RPB Senior Scientific
   Investigator. The work has in part been conducted in the MUSC Mass
   Spectrometry Institutional Research Resource Facility and in the Cell &
   Molecular Imaging Shared Resource of the Hollings Cancer Center, which
   was supported by Cancer Center Support Grant P30 CA138313 to the
   Hollings Cancer Center, MUSC. Part of the data in this paper were
   presented during the 16th International Congress on Photobiology held in
   Cordoba, Argentina, in September (8th-12th), 2014.
CR Ablonczy Z, 2014, PROTEOMICS, V14, P936, DOI 10.1002/pmic.201300406
   Ablonczy Z, 2013, ARCH BIOCHEM BIOPHYS, V539, P196, DOI 10.1016/j.abb.2013.08.005
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ablonczy Z, 2012, ADV EXP MED BIOL, V723, P75, DOI 10.1007/978-1-4614-0631-0_11
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Bajaj NPS, 1998, NEUROSCI LETT, V245, P45, DOI 10.1016/S0304-3940(98)00176-1
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   CURCIO CA, 1987, SCIENCE, V236, P579, DOI 10.1126/science.3576186
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Feldman TB, 2015, ANAL BIOANAL CHEM, V407, P1075, DOI 10.1007/s00216-014-8353-z
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Nakanishi H, 1997, J NEUROCHEM, V68, P739
   Nakano M, 1995, GERONTOLOGY, V41, P69
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   PACKER O, 1989, J COMP NEUROL, V288, P165, DOI 10.1002/cne.902880113
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Porta EA, 2002, ANN NY ACAD SCI, V959, P57, DOI 10.1111/j.1749-6632.2002.tb02083.x
   Quazi F, 2014, P NATL ACAD SCI USA, V111, P5024, DOI 10.1073/pnas.1400780111
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Tornow RP, 1998, ACTA ANAT, V162, P163
   ULFIG N, 1989, NEUROSCI RES, V6, P456, DOI 10.1016/0168-0102(89)90007-2
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WIKLER KC, 1990, J COMP NEUROL, V297, P499, DOI 10.1002/cne.902970404
   WIKLER KC, 1990, J NEUROSCI, V10, P3390
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Winkler B S, 1999, Mol Vis, V5, P32
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
NR 42
TC 20
Z9 20
U1 0
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1474-905X
EI 1474-9092
J9 PHOTOCH PHOTOBIO SCI
JI Photochem. Photobiol. Sci.
PY 2015
VL 14
IS 10
BP 1888
EP 1895
DI 10.1039/c5pp00170f
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA CS3WS
UT WOS:000362006600014
PM 26223373
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yuksel, H
   Turkcu, FM
   Sahin, A
   Sahin, M
   Cinar, Y
   Cingu, AK
   Ari, S
   Caca, I
AF Yuksel, Harun
   Turkcu, Fatih M.
   Sahin, Alparslan
   Sahin, Muhammed
   Cinar, Yasin
   Cingu, Abdullah K.
   Ari, Seyhmus
   Caca, Ihsan
TI One year results of anti-VEGF treatment in pigment epithelial detachment
   secondary to macular degeneration
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Vascular endothelial growth factor A/antagonists & Inhibitors; Retinal
   pigment epithelium/pathology; Retinal detachment; Macular
   degeneration/drug therapy; Aged
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; BRUCHS MEMBRANE;
   RANIBIZUMAB; TEARS; EDEMA
AB Purpose: Pigment epithelial detachment (PED) may be seen in all stages of age-related macular degeneration (ARMD) and may lead to poor prognosis. In this study, we retrospectively examined the effect of anti-VEGF treatments in ARMD patients with vascularized PED.
   Methods: Medical records of 15 patients with PED secondary to ARMD were re--viewed retrospectively. The diagnosis of PED was made with fundoscopy, fundus fluorescein angiography and optical coherence tomography. Patients were treated with intravitreal ranibizumab or/and bevacizumab and followed up for a minimum of one year. PED height and best corrected visual acuity (BCVA) was obtained before the first intravitreal anti-VEGF injection and again at the 1st, 3rd, 6th and 12th month after the injection.
   Results: The mean baseline BCVA was 0.71 +/- 0.48 logarithm of the minimal angle of resolution (logMAR) unit and the mean baseline PED height was 361 +/- 153 mu. The mean injection count per eye was 3.9 +/- 2.9. There was a significant reduce in mean PED height (247 +/- 177 mu) also in 2 eyes PED completely resolved at the end of the follow up period. The mean BCVA at 12th month (0,69 +/- 0,37) were not different from the baseline record.
   Conclusions: This retrospective case series showed that intravitreal anti-VEGF therapy preserved vision and reduced PED height in PED patients in a one-year follow-up period.
C1 [Yuksel, Harun; Turkcu, Fatih M.; Sahin, Alparslan; Sahin, Muhammed; Cinar, Yasin; Cingu, Abdullah K.; Ari, Seyhmus; Caca, Ihsan] Dicle Univ, Fac Med, Dept Ophthalmol, Diyarbakir, Turkey.
C3 Dicle University
RP Yuksel, H (通讯作者)，Dicle Univ, Tip Fak, Sur Diyarbakir, Turkey.
EM harunyukselll@gmail.com
RI şahin, alparslan/K-6074-2012; arı, şeyhmus/AAH-7279-2020; Cingü,
   Abdullah/J-9423-2019
OI şahin, alparslan/0000-0003-2901-9699; arı, şeyhmus/0000-0003-3450-1690;
   sahin, muhammed/0000-0002-5229-7630
CR Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   BIRD AC, 1991, EYE, V5, P1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Do DV, 2013, JAMA OPHTHALMOL, V131, P139, DOI 10.1001/2013.jamaophthalmol.91
   Epstein DL, 2012, OPHTHALMOLOGY, V119, P2587, DOI 10.1016/j.ophtha.2012.06.037
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Ladas ID, 2007, OPHTHALMOLOGICA, V221, P313, DOI 10.1159/000104761
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Wasmuth S, 2010, OPHTHALMOLOGE, V107, P1109, DOI 10.1007/s00347-010-2142-7
NR 20
TC 8
Z9 8
U1 0
U2 2
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JUL-AUG
PY 2013
VL 76
IS 4
BP 209
EP 211
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 224UI
UT WOS:000324914800002
PM 24061828
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Thanos, A
   Morizane, Y
   Murakami, Y
   Giani, A
   Mantopoulos, D
   Kayama, M
   Roh, MI
   Michaud, N
   Pawlyk, B
   Sandberg, M
   Young, LH
   Miller, JW
   Vavvas, DG
AF Thanos, Aristomenis
   Morizane, Yuki
   Murakami, Yusuke
   Giani, Andrea
   Mantopoulos, Dimosthenis
   Kayama, Maki
   Roh, Mi In
   Michaud, Norman
   Pawlyk, Basil
   Sandberg, Michael
   Young, Lucy H.
   Miller, Joan W.
   Vavvas, Demetrios G.
TI Evidence for Baseline Retinal Pigment Epithelium Pathology in the
   Trp1-Cre Mouse
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID SITE-SPECIFIC RECOMBINATION; CRE RECOMBINASE; TRANSGENIC MICE; VISUAL
   FUNCTION; YEAST GENOME; LOX SITES; IN-VIVO; EXPRESSION; CELLS; GENE
AB The increasing popularity of the Cre/loxP recombination system has led to the generation of numerous transgenic mouse lines in which Cre recombinase is expressed under the control of organ- or cell-specific promoters. Alterations in retinal pigment epithelium (RPE), a multifunctional cell monolayer that separates the retinal photoreceptors from the choroid, are prevalent in the pathogenesis of a number of ocular disorders, including age-related macular degeneration. To date, six transgenic mouse lines have been developed that target Cre to the RPE under the control of various gene promoters. However, multiple lines of evidence indicate that high levels of Cre expression can be toxic to mammalian cells. In this study, we report that in the Trp1-Cre mouse, a commonly used transgenic Cre strain for RPE gene function studies, Cre recombinase expression alone leads to RPE dysfunction and concomitant disorganization of RPE layer morphology, large areas of RPE atrophy, retinal photoreceptor dysfunction, and microglial cell activation in the affected areas. The phenotype described herein is similar to previously published reports of conditional gene knockouts that used the Trp1-Cre mouse, suggesting that Cre toxicity alone could account for some of the reported phenotypes and highlighting the importance of the inclusion of Cre-expressing mice as controls in conditional gene targeting studies. (Am J Pathol 2012, 180:1917-1927; DOI: 10.1016/j.ajpath.2012.01.017)
C1 [Thanos, Aristomenis; Morizane, Yuki; Murakami, Yusuke; Giani, Andrea; Mantopoulos, Dimosthenis; Kayama, Maki; Roh, Mi In; Michaud, Norman; Young, Lucy H.; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02114 USA.
   [Pawlyk, Basil; Sandberg, Michael] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat,Dept Opht, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye
   & Ear Infirmary
RP Vavvas, DG (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM vavvas@meei.harvard.edu
RI Giani, Andrea/L-5926-2017
OI Giani, Andrea/0000-0003-0682-1945; Miller, Joan/0000-0003-2046-3996;
   Vavvas, Demetrios/0000-0002-8622-6478; Young, Lucy/0000-0001-8634-7512;
   Roh, Miin/0000-0003-3346-754X
FU Bacardi Fund; Research to Prevent Blindness Foundation; Lions Eye
   Research Fund; Foundation Fighting Blindness; Onassis Foundation; Bausch
   & Lomb Vitreoretinal Fellowship; National Eye Institute (MEEI)
   [EY014104]; NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH
   RePORTER
FX Supported by Bacardi Fund (D.G.V.), Research to Prevent Blindness
   Foundation (D.G.V.), Lions Eye Research Fund (D.G.V.), Foundation
   Fighting Blindness (B.P. and M.S.), Onassis Foundation (D.G.V.), a
   Bausch & Lomb Vitreoretinal Fellowship (Y.Mo., M.K.), and a grant from
   the National Eye Institute (MEEI Core Grant EY014104).
CR Aydin IT, 2011, GENESIS, V49, P403, DOI 10.1002/dvg.20725
   de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7
   Forni PE, 2006, J NEUROSCI, V26, P9593, DOI 10.1523/JNEUROSCI.2815-06.2006
   Fujimura N, 2009, DEV BIOL, V334, P31, DOI 10.1016/j.ydbio.2009.07.002
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Gimenez E, 2001, LAB ANIM-UK, V35, P153, DOI 10.1258/0023677011911525
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guyonneau L, 2002, PIGM CELL RES, V15, P305, DOI 10.1034/j.1600-0749.2002.02039.x
   Hameyer D, 2007, PHYSIOL GENOMICS, V31, P32, DOI 10.1152/physiolgenomics.00019.2007
   HAMILTON DL, 1984, J MOL BIOL, V178, P481, DOI 10.1016/0022-2836(84)90154-2
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   JIANG LQ, 1993, INVEST OPHTH VIS SCI, V34, P3347
   Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x
   Kobayashi T, 2007, J CELL SCI, V120, P4261, DOI 10.1242/jcs.017913
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Lee JY, 2006, J BIOL CHEM, V281, P2649, DOI 10.1074/jbc.M512373200
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mori M, 2004, AM J PATHOL, V164, P701, DOI 10.1016/S0002-9440(10)63157-4
   Mori M, 2002, INVEST OPHTH VIS SCI, V43, P1384
   Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B
   Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Ruiz A, 2007, INVEST OPHTH VIS SCI, V48, P5377, DOI 10.1167/iovs.07-0673
   Sauer B, 1996, NUCLEIC ACIDS RES, V24, P4608, DOI 10.1093/nar/24.23.4608
   SAUER B, 1992, J MOL BIOL, V223, P911, DOI 10.1016/0022-2836(92)90252-F
   Schmidt EE, 2000, P NATL ACAD SCI USA, V97, P13702, DOI 10.1073/pnas.240471297
   Schmidt-Supprian M, 2007, NAT IMMUNOL, V8, P665, DOI 10.1038/ni0707-665
   Schouwey K, 2011, ONCOGENE, V30, P313, DOI 10.1038/onc.2010.428
   Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007
   STERNBERG N, 1981, J MOL BIOL, V150, P487, DOI 10.1016/0022-2836(81)90376-4
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun X, 2010, GENE THER, V17, P117, DOI 10.1038/gt.2009.104
   Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1
   Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zinn KM, 1979, RETINAL PIGMENT EPIT, P3
NR 44
TC 29
Z9 29
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAY
PY 2012
VL 180
IS 5
BP 1917
EP 1927
DI 10.1016/j.ajpath.2012.01.017
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 937EE
UT WOS:000303641000017
PM 22429967
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Hodjatjalali, K
   Riazi, M
   Faghihi, H
   Khorami, A
AF Hodjatjalali, Kamran
   Riazi, Mohammad
   Faghihi, Hooshang
   Khorami, Azita
TI Ultrasound biomicroscopy study of vitreous incarceration subsequent to
   intravitreal injections
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID PARS-PLANA VITRECTOMY; SCLEROTOMY SITES; TRIAMCINOLONE ACETONIDE;
   FIBROVASCULAR INGROWTH; 25-GAUGE VITRECTOMY; HEMORRHAGE; KERATITIS;
   INCISION; SURGERY; RETINA
AB Objective: To study the existence of vitreous incarceration by ultrasound biomicroscopy (UBM) at the pars plana after direct intravitreal injection of triamcinolone acetonide +/- bevacizumab without anterior chamber paracentesis.
   Design: Interventional case series.
   Participants: Patients undergoing intravitreal injection of triamcinolone acetonide with or without intravitreal bevacizumab.
   Methods: In 21 eyes, the existence of vitreous incarceration at the pars plana site of intravitreal injection of 0.05 mL of drug was studied by UBM (50 MHz probe of the VUmax, Sonomed, NY), the day after surgery, by 1 technician. The reason for injection was diabetic retinopathy in 12 (57.1%) eyes; age-related macular degeneration in 6 (28.6%) eyes; branch retinal vein occlusion in 2 (9.5%) eyes; and choroiditis in 1 eye (4.8%). In 1 eye, only triamcinolone acetonide was injected, and in the other eyes, bevacizumab mixed with triamcinolone acetonide was injected.
   Results: We studied 21 eyes in 13 patients. Of the subjects, 61.5% were male. The mean age of the patients was 62.2 years. On the day after intravitreal injection of the drug, vitreous incarceration into the pars plana site was detected by UBM in 42.9% of the eyes.
   Conclusion: Vitreous incarceration exists after intravitreal injection of drug, but its clinical importance is still unknown. Further long-term prospective studies are recommended.
C1 [Hodjatjalali, Kamran; Riazi, Mohammad; Faghihi, Hooshang; Khorami, Azita] Noor Eye Hosp, Noor Ophthalmol Res Ctr, Tehran 19686, Iran.
   [Riazi, Mohammad; Faghihi, Hooshang] Univ Tehran Med Sci, Farabi Eye Hosp, Tehran, Iran.
C3 Tehran University of Medical Sciences
RP Hodjatjalali, K (通讯作者)，Noor Eye Hosp, Noor Ophthalmol Res Ctr, 96 Esfandiar Blvd,Valiasr Ave, Tehran 19686, Iran.
EM kamran_jalali@hotmail.com
CR Al-Harthi E, 2005, RETINA-J RET VIT DIS, V25, P281, DOI 10.1097/00006982-200504000-00005
   Arakawa A, 1998, AM J OPHTHALMOL, V126, P838, DOI 10.1016/S0002-9394(98)00225-6
   Bhende M, 2000, OPHTHALMOLOGY, V107, P1729, DOI 10.1016/S0161-6420(00)00213-X
   BOKER T, 1994, AM J OPHTHALMOL, V118, P813
   Boon CJF, 2008, OPHTHALMOLOGY, V115, P1268, DOI 10.1016/j.ophtha.2008.02.021
   Coleman DJ, 2006, EXPERT REV OPHTHALMO, V1, P63, DOI 10.1586/17469899.1.1.63
   Gentile RC, 1998, OPHTHALMOLOGY, V105, P478, DOI 10.1016/S0161-6420(98)93031-7
   Gulkilik G, 2007, CORNEA, V26, P1000, DOI 10.1097/ICO.0b013e3180cab659
   Gupta OP, 2008, AM J OPHTHALMOL, V146, P193, DOI 10.1016/j.ajo.2008.04.010
   Hershberger VS, 2004, OPHTHALMOLOGY, V111, P1215, DOI 10.1016/j.ophtha.2003.08.043
   Hotta K, 2000, RETINA-J RET VIT DIS, V20, P52, DOI 10.1097/00006982-200001000-00010
   Hubschman JP, 2010, RETINA-J RET VIT DIS, V30, P167, DOI 10.1097/IAE.0b013e3181b094cf
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Keshavamurthy Ravi, 2006, BMC Ophthalmol, V6, P7, DOI 10.1186/1471-2415-6-7
   Kreiger AE, 2001, OPHTHALMOLOGY, V108, P1175, DOI 10.1016/S0161-6420(01)00616-9
   Kunimatsu S, 2002, BRIT J OPHTHALMOL, V86, P869, DOI 10.1136/bjo.86.8.869
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P172, DOI 10.1016/S0002-9394(01)00973-4
   Lopez-Guajardo L, 2007, AM J OPHTHALMOL, V143, P881, DOI 10.1016/j.ajo.2006.12.036
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Minamoto A, 1997, AM J OPHTHALMOL, V123, P711, DOI 10.1016/S0002-9394(14)71095-5
   Mourtzoukos S, 2008, EUR J OPHTHALMOL, V18, P1028, DOI 10.1177/112067210801800632
   PAVLIN CJ, 1993, AM J OPHTHALMOL, V116, P628, DOI 10.1016/S0002-9394(14)73207-6
   PAVLIN CJ, 1991, OPHTHALMOLOGY, V98, P287
   Pulhorn G, 1980, ARCH OPHTHALMOL-CHIC, V98, P1248
   Rizzo S, 2007, GRAEF ARCH CLIN EXP, V245, P1281, DOI 10.1007/s00417-006-0533-x
   Rodrigues EB, 2007, AM J OPHTHALMOL, V143, P1035, DOI 10.1016/j.ajo.2007.01.035
   Sabti K, 2001, RETINA-J RET VIT DIS, V21, P464, DOI 10.1097/00006982-200110000-00008
   Shtein RM, 2007, CORNEA, V26, P641, DOI 10.1097/ICO.0b013e318041f0c0
   Song ZY, 2007, CURR EYE RES, V32, P647, DOI 10.1080/02713680701447032
   TARDIF YM, 1977, ARCH OPHTHALMOL-CHIC, V95, P229, DOI 10.1001/archopht.1977.04450020031005
   TARDIF YM, 1977, ARCH OPHTHALMOL-CHIC, V95, P235, DOI 10.1001/archopht.1977.04450020036006
   Theelen T, 2003, AM J OPHTHALMOL, V136, P1085, DOI 10.1016/S0002-9394(03)00662-7
   Wimpissinger B, 2007, ACTA OPHTHALMOL SCAN, V85, P782, DOI 10.1111/j.1600-0420.2007.00930.x
   Yeh PT, 2005, OPHTHALMOLOGY, V112, P2095, DOI 10.1016/j.ophtha.2005.07.010
NR 35
TC 7
Z9 7
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2012
VL 47
IS 1
BP 24
EP 27
DI 10.1016/j.jcjo.2011.12.013
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 903DH
UT WOS:000301095700006
PM 22333847
DA 2022-11-30
ER

PT J
AU Prenner, JL
   Driscoll, SJ
   Fine, HF
   Salz, DA
   Roth, DB
AF Prenner, Jonathan L.
   Driscoll, Sarah J.
   Fine, Howard F.
   Salz, David A.
   Roth, Daniel B.
TI PUBLICATION RATES OF REGISTERED CLINICAL TRIALS IN MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related; clinical trials; macular degeneration; publication rates;
   registries
AB Purpose: The purpose of this study was to evaluate the rate of publication of registered clinical trials concerning age-related macular degeneration (AMD).
   Methods: The National Institutes of Health's ClinicalTrials.gov registry was searched to identify all trials concerning AMD. Trials that were actively recruiting, not interventional, terminated, or did not actually concern AMD were excluded. Only trials completed 2 or more years before this analysis was started were included, to allow for adequate time to pass before publication was expected to occur. PubMed.gov was then searched to evaluate the publication status of each study.
   Results: Three hundred and eight-six studies were initially identified, and 64 (16.5%) were included in the final evaluation. Three hundred and twenty-one studies were not included for the following reasons: 171 did not involve AMD or were not interventional; 141 were not completed by January 1, 2007; and 9 trials were terminated. Of the 64 trials included, 35 (54%) were published. Early phase trials were published at a lower rate (41.6% [15/36]) than late-phase trials (71.4% [20/28]). This difference was statistically significant (P = 0.02). The sponsor type, date of study initiation, and location did not influence the publication rate.
   Conclusion: Using broad study parameters, 54% of registered interventional clinical trials in AMD have been reported in the peer-reviewed literature. RETINA 31: 401-404, 2011
C1 [Prenner, Jonathan L.; Fine, Howard F.; Roth, Daniel B.] Univ Med & Dent New Jersey, Robert Wood Johnson Univ Hosp, Dept Ophthalmol, New Brunswick, NJ 08901 USA.
   [Prenner, Jonathan L.; Driscoll, Sarah J.; Fine, Howard F.; Roth, Daniel B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA.
   [Salz, David A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center; Rutgers State University New Brunswick; Rutgers State University
   Medical Center; Boston University
RP Prenner, JL (通讯作者)，Univ Med & Dent New Jersey, Robert Wood Johnson Univ Hosp, Dept Ophthalmol, 125 Patterson St, New Brunswick, NJ 08901 USA.
EM jonathanprenner@gmail.com
CR Department of Health Education and Welfare (DHEW), 1979, BELM REP ETH PRINC G
   Laine C, 2007, NEW ENGL J MED, V356, P2734, DOI 10.1056/NEJMe078110
   Ramsey S, 2008, ONCOLOGIST, V13, P925, DOI 10.1634/theoncologist.2008-0133
   Zarin DA, 2008, SCIENCE, V322, P45
NR 4
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2011
VL 31
IS 2
BP 401
EP 404
DI 10.1097/IAE.0b013e3181eef2ad
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 711JG
UT WOS:000286586500027
PM 21221049
DA 2022-11-30
ER

PT J
AU Zipfel, PF
AF Zipfel, Peter F.
TI Complement and immune defense: From innate immunity to human diseases
SO IMMUNOLOGY LETTERS
LA English
DT Review
DE Complement; Autoimmune diseases; Complement evasion
ID FACTOR-H; ALTERNATIVE PATHWAY; MACULAR DEGENERATION; PROTEIN;
   AUTOANTIBODIES; POLYMORPHISM; ECULIZUMAB; BINDING; EVASION; Y402H
AB The human organism is constantly exposed to microbes and infectious agents and consequently has developed a complex and highly efficient immune defense which is aimed to recognize and eliminate such infectious agents. The response of the human host to infectious agents forms a double edged sword of immunity. The immune system has to keep a tight balance between attack on foreign surfaces and protection of host surfaces. In its proper function the immune response is aimed to recognize, attack and eliminate invading infectious agents and this response is beneficial for the host. However when the activated immune response like the complement system is not properly controlled and deregulated, effector compounds can attack and damage self-surfaces and this results in disease. In addition pathogens which cause infections and disease protect themselves from the damaging and harmful host immune weapon and use specific immune escape strategies. The complement system forms the first defense line of innate immunity and aids in the elimination of microbes and modified self-cells. Defective regulation of this cascade type system results in infections and in pathology. This can result in diseases, like severe renal diseases hemolytic uremic syndrome (HUS) and dense deposit disease (DDD), in age related macular degeneration a common form of blindness and also in other forms of autoimmune diseases. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
   [Zipfel, Peter F.] Univ Jena, D-07743 Jena, Germany.
C3 Hans Knoll Institute (HKI); Friedrich Schiller University of Jena
RP Zipfel, PF (通讯作者)，Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11A, D-07745 Jena, Germany.
EM peter.zipfel@hki-jena.de
FU Deutsche Forschungsgemeinschaft (DFG), Kidneeds, Iowa City 10; National
   Institutes of Health (NIH); ProRetina, Germany
FX The work of the author is supported by the Deutsche
   Forschungsgemeinschaft (DFG), Kidneeds, Iowa City 10, the National
   Institutes of Health (NIH) and ProRetina, Germany.
CR Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DAHA MR, 1976, J IMMUNOL, V116, P1
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   EHRLICH P, 1899, BERL KLIN WOCHENSCHR, V1, P6
   Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800
   GASSER C, 1955, Schweiz Med Wochenschr, V85, P905
   Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231
   Gruppo RA, 2009, NEW ENGL J MED, V360, P544, DOI 10.1056/NEJMc0809959
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Johnson S, 2008, EUR J PEDIATR, V167, P965, DOI 10.1007/s00431-008-0745-7
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kohl J, 2006, ADV EXP MED BIOL, V586, P71
   Lachmann PJ, 2002, P NATL ACAD SCI USA, V99, P8461, DOI 10.1073/pnas.132284499
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   MECHNIKOV H, 2002, IMMUNITAT BEI INFEKT
   Meri S, 2008, VACCINE, V26, pI113, DOI 10.1016/j.vaccine.2008.11.058
   Meri T, 2004, INFECT IMMUN, V72, P6633, DOI 10.1128/IAI.72.11.6633-6641.2004
   Meri T, 2002, INFECT IMMUN, V70, P5185, DOI 10.1128/IAI.70.9.5185-5192.2002
   Noris M, 2005, J AM SOC NEPHROL, V16, P1035, DOI 10.1681/ASN.2004100861
   Nurnberger J, 2009, NEW ENGL J MED, V360, P542, DOI 10.1056/NEJMc0808527
   Odds FC, 2008, MICROBIOL-SGM, V154, P3245, DOI 10.1099/mic.0.2008/023671-0
   Paul W.E., 2008, FUNDAMENTAL IMMUNOLO
   PIAZZA MDJ, 2008, VACCINES, V26, P146
   Poltermann S, 2007, J BIOL CHEM, V282, P37537, DOI 10.1074/jbc.M707280200
   Rooijakkers SHM, 2007, MOL IMMUNOL, V44, P23, DOI 10.1016/j.molimm.2006.06.011
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Sethi S, 2009, KIDNEY INT, V75, P952, DOI 10.1038/ki.2008.657
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Skerka C, 2009, THROMB HAEMOSTASIS, V101, P227, DOI 10.1160/TH08-05-0322
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Zipfel PF, 2007, MOL IMMUNOL, V44, P3850, DOI 10.1016/j.molimm.2007.06.149
   Zipfel PF, 2007, ADV EXP MED BIOL, V598, P80
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2008, VACCINE, V26, pI67, DOI 10.1016/j.vaccine.2008.11.015
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   ZIPFEL PF, 2009, NAT REV IMM IN PRESS
NR 49
TC 78
Z9 83
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD SEP 22
PY 2009
VL 126
IS 1-2
BP 1
EP 7
DI 10.1016/j.imlet.2009.07.005
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 509XG
UT WOS:000271052000001
PM 19616581
DA 2022-11-30
ER

PT J
AU Catanuto, P
   Espinosa-Heidmann, D
   Pereira-Simon, S
   Sanchez, P
   Salas, P
   Hernandez, E
   Cousins, SW
   Elliot, SJ
AF Catanuto, Paola
   Espinosa-Heidmann, Diego
   Pereira-Simon, Simone
   Sanchez, Patricia
   Salas, Pedro
   Hernandez, Eleut
   Cousins, Scott W.
   Elliot, Sharon J.
TI Mouse retinal pigmented epithelial cell lines retain their phenotypic
   characteristics after transfection with human papilloma virus: A new
   tool to further the study of RPE biology
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE mouse retinal pigmented epithelial cells; estrogen receptors;
   extracellular matrix; immortalization
ID IMMORTALIZATION; EXPRESSION; PROTEINS; GROWTH; MODEL
AB Development of immortalized mouse retinal pigmented epithelial cell (RPE) lines that retain many of their in vivo phenotypic characteristics, would aid in studies of ocular diseases including age related macular degeneration (AMD). RPE cells were isolated from 18-month-old (estrogen receptor knockout) ERKO alpha and ERKO beta mice and their C57BI/6 wildtype littermates. RPE65 and cellular retinaldehyde binding protein (CRALBP) expression, in vivo markers of RPE cells, were detected by real-time RT-PCR and western analysis. We confirmed the presence of epithelial cell markers, ZO1, cytokeratin 8 and 18 by immunofluorescence staining. In addition, we confirmed the distribution of actin filaments and the expression of ezrin. To develop cell lines, RPE cells were isolated, propagated and immortalized using human papilloma virus (HPV) 16 (E6/E7). RPE-specific markers and morphology were assessed before and after immortalization. In wildtype littermate controls, there was no evidence of any alterations in the parameters that we examined including MMP-2, TIMP-2, collagen type IV, and estrogen receptor (ER)a and ER protein expression and ER copy number ratio. Therefore, immortalized mouse RPE cell lines that retain their in vivo phenotype can be isolated from either pharmacologically or genetically manipulated mice, and may be used to study RPE cell biology. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Catanuto, Paola; Espinosa-Heidmann, Diego; Pereira-Simon, Simone; Sanchez, Patricia; Elliot, Sharon J.] Univ Miami, Miller Sch Med, Dept Surg, Lab Sex & Gender Differences Hlth & Dis, Miami, FL 33136 USA.
   [Salas, Pedro] Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33136 USA.
   [Cousins, Scott W.] Duke Univ, Ctr Eye, Duke Ctr Macula Dis, Durham, NC USA.
C3 University of Miami; University of Miami; Duke University
RP Catanuto, P (通讯作者)，Univ Miami, Miller Sch Med, Dept Surg, Lab Sex & Gender Differences Hlth & Dis, Rosenstiel Med Bldg,Room 1043,R104, Miami, FL 33136 USA.
EM pcatanuto@med.miami.edu
RI Salas, Pedro J./AAS-9455-2021
OI Salas, Pedro/0000-0002-7411-1366
FU National Institutes of Health National Eye Institute [R01 EY14477-04];
   NATIONAL EYE INSTITUTE [R01EY014477] Funding Source: NIH RePORTER
FX This work was supported in part by National Institutes of Health
   National Eye Institute Grant R01 EY14477-04 (SJE and SWC). We would like
   to thank Hong Yu for the gift of HPV and Jason Fritz for technical
   assistance with the confocal microscopy.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   BURKE JM, 2008, PROG RETIN EYE RES
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   ELIZABETH RP, 2006, EXP EYE RES, V82, P741, DOI DOI 10.1016/J.EXER.2005.10.012
   Elliot S, 2006, INVEST OPHTH VIS SCI, V47, P1696, DOI 10.1167/iovs.05-1258
   Elliot S, 2008, EXP EYE RES, V86, P653, DOI 10.1016/j.exer.2008.01.010
   ELLIOT SJ, 1993, ENDOCRINOLOGY, V133, P1783, DOI 10.1210/en.133.4.1783
   FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   Hayashi K, 1999, J CELL SCI, V112, P1149
   Loeuillet C, 2001, CELL GROWTH DIFFER, V12, P233
   Malek G, 2006, BRIT J OPHTHALMOL, V90, P1080, DOI 10.1136/bjo.2006.098715
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   NABI IR, 1993, J CELL SCI, V104, P37
   TREVISAN R, 1992, DIABETES, V41, P1239, DOI 10.2337/diabetes.41.10.1239
   YUE BYJT, 1991, CELL BIOL INT REP, V15, P365, DOI 10.1016/0309-1651(91)90125-3
NR 22
TC 13
Z9 14
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2009
VL 88
IS 1
BP 99
EP 105
DI 10.1016/j.exer.2008.10.013
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 393TL
UT WOS:000262395800013
PM 19013153
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Onakpoya, OH
   Olateju, SO
   Ajayi, IA
AF Onakpoya, Oluwatoyin Helen
   Olateju, Samuel Oluremi
   Ajayi, Iyiade Adeseye
TI Retinal Diseases in a Tertiary Hospital: The Need for Establishment of a
   Vitreo-Retinal Care Unit
SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION
LA English
DT Article
DE ophthalmic; diabetes mellitus; Nigeria
ID DIABETIC-RETINOPATHY; ANDHRA-PRADESH; EYE DISEASE; BLINDNESS; OUTCOMES
AB Aim: To evaluate, the need for vitreo-retinal care for suburban and rural communities of southwestern Nigeria.
   Methodology: A retrospective review of patients with posterior segment diseases attending the general ophthalmology clinics of Obafemi Awolowo University Teaching Hospital's complex, Ile Ife, southwestern Nigeria, between January 2001 and December 2006 was conducted. The age, sex and diagnosis were analyzed and needs assessment conducted.
   Results: Three-thousand, one-hundred-thirty-one new cases were reviewed of which 407(13%) patients presented with retinal diseases. Their mean age was 46.3 21.4 years, mode 60 years and male:female ratio 1.3:1 (P=0.05).
   Macula diseases (35.6%), hypertensive retinopathy (12%), retinochoroiditis (11.5%) and diabetic retinopathy (9.6%) were the predominant retinal diseases. Age-related macular degeneration was the most frequent of the macular diseases (38.6%), with a female preponderance (p=0.06). It is estimated that fundus photography fluorescein will be beneficial in 89.4%, laser photocoagulation in 36.4% and vitreo-retinal surgical procedure in 16.4%.
   Conclusion: Posterior segment diseases are not uncommon in rural communities of southwestern Nigeria. Facilities for fundus angiography, laser photocoagulation and a vitreo-retinal surgical unit in trained hands will improve the capacity for specific diagnosis and appropriate management of vitreo-retinal diseases in these communities.
C1 [Onakpoya, Oluwatoyin Helen] Obafemi Awolowo Univ, Coll Hlth Sci, Dept Surg, Ophthalmol Unit, Ife 220002, Nigeria.
C3 Obafemi Awolowo University
RP Onakpoya, OH (通讯作者)，Obafemi Awolowo Univ, Coll Hlth Sci, Dept Surg, Ophthalmol Unit, Ife 220002, Nigeria.
EM uvtoyin2@yahoo.co.uk
CR Abraham C, 1983, Indian J Ophthalmol, V31, P225
   Adeoye A, 1996, TROP MED INT HEALTH, V1, P672
   Ahmed SM, 2000, SOC SCI MED, V51, P361, DOI 10.1016/S0277-9536(99)00461-X
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Dastur Y K, 1994, J Postgrad Med, V40, P13
   Fafowora OF, 1997, E AFR MED J, V74, P435
   FERRIS FL, 1994, PREV MED, V23, P740, DOI 10.1006/pmed.1994.1127
   HASSAN AO, 2005, NIG J OPHTHALMOL, V1, P17
   JARITT JC, 2003, OPHTHALMOLOGY, V110, P1534
   Kaiser RS, 2000, AM J OPHTHALMOL, V129, P178, DOI 10.1016/S0002-9394(99)00322-0
   Karki D B, 2003, Kathmandu Univ Med J (KUMJ), V1, P161
   Katulanda P., 2006, CEYLON MEDICAL JOURNAL, V51, P26
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Ladas DD, 2003, OPHTHALMOLOGICA, V217, P194, DOI 10.1159/000068973
   Nwosu S N, 2000, Ophthalmic Epidemiol, V7, P41, DOI 10.1076/0928-6586(200003)7:1;1-2;FT041
   OLULEYE TS, 2006, EYE, V10, P1
   Onakpoya O H, 2007, Tanzan Health Res Bull, V9, P126
   Passa P, 2002, DIABETES-METAB RES, V18, pS3, DOI 10.1002/dmrr.276
   Paudyal G, 2005, OPHTHALMOLOGY, V112, P319, DOI 10.1016/j.ophtha.2004.08.018
   PRATAB VB, 1989, INDIA J OPTHALMOL, V37, P172
   Teshome T, 2004, ETHIOPIAN MED J, V42, P185
   Yorston D, 2002, EYE, V16, P353, DOI 10.1038/sj.eye.6700188
NR 22
TC 12
Z9 12
U1 0
U2 1
PU NATL MED ASSOC
PI WASHINGON
PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA
SN 0027-9684
EI 1943-4693
J9 J NATL MED ASSOC
JI J. Natl. Med. Assoc.
PD NOV
PY 2008
VL 100
IS 11
BP 1286
EP 1289
DI 10.1016/S0027-9684(15)31506-6
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 374KQ
UT WOS:000261042600003
PM 19024224
DA 2022-11-30
ER

PT J
AU Sunness, JS
   Ziegler, MD
   Applegate, CA
AF Sunness, Janet S.
   Ziegler, Matthias D.
   Applegate, Carol A.
TI Issues in quantifying atrophic macular disease using retinal
   autofluorescence
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID VISUAL-ACUITY LOSS; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY;
   IN-VIVO; DEGENERATION; PATTERNS; EYES
AB Purpose: To demonstrate the potential and limits of autofluorescence imaging in identifying and delineating areas of atrophy.
   Methods: Fundus photographs and infrared scanning laser ophthalmoscope (SLO) imaging, SLO macular perimetry, and SLO autofluorescence imaging results were compared for two patients with geographic atrophy (GA) from age-related macular degeneration, one patient with pigmentary alteration of the retina, and two patients with Stargardt disease. The main outcome measure in this case series was the presence of reduced autofluorescence.
   Results: Drusen may become undetectable during autofluorescence imaging for some patients, allowing simple identification of areas of GA with areas of reduced autofluorescence. In other patients, drusen themselves have decreased autofluorescence, despite having intact retinal function in the retina overlying them. Some patients may have areas of reduced autofluorescence that persist for many years, without evidence of the development of atrophy. In Stargardt disease, decreased autofluorescence can easily detect and delineate areas of scotoma. Areas with mottled autofluorescence may have overlying function, but the function may not be adequate to support a fixation locus in that area.
   Conclusions: Using decreased autofluorescence to delineate areas of atrophy may be helpful in atrophic macular disorders. For GA, correlation with fundus photographs or macular perimetry findings may be necessary to differentiate between drusen and atrophy. For Stargardt disease, the nature of areas of decreased autofluorescence may help explain visual function of those areas.
C1 Greater Baltimore Med Ctr, Hoover Serv Low Visi & Blindness, Baltimore, MD 21204 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Lions Vis Ctr, Baltimore, MD 21218 USA.
C3 Greater Baltimore Medical Center; Johns Hopkins University
RP Sunness, JS (通讯作者)，Greater Baltimore Med Ctr, Hoover Serv Low Visi & Blindness, 6569 N Charles St,PPW 305, Baltimore, MD 21204 USA.
EM jsunness@gbmc.org
OI Sunness, Janet/0000-0001-8823-0780
FU NATIONAL EYE INSTITUTE [R01EY008552] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY08552] Funding Source: Medline
CR Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Benner JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P586, DOI 10.1001/archopht.120.5.586
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Lois N, 2004, AM J OPHTHALMOL, V138, P55, DOI 10.1016/j.ajo.2004.02.056
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   Margalit E, 2003, ARCH OPHTHALMOL-CHIC, V121, P1643, DOI 10.1001/archopht.121.11.1643
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 18
TC 42
Z9 42
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2006
VL 26
IS 6
BP 666
EP 672
DI 10.1097/00006982-200607000-00013
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 180TP
UT WOS:000247389200013
PM 16829810
DA 2022-11-30
ER

PT J
AU Tezcaner, A
   Hicks, D
   Boulmedais, F
   Sahel, J
   Schaaf, P
   Voegel, JC
   Lavalle, P
AF Tezcaner, A
   Hicks, D
   Boulmedais, F
   Sahel, J
   Schaaf, P
   Voegel, JC
   Lavalle, P
TI Polyelectrolyte multilayer films as substrates for photoreceptor cells
SO BIOMACROMOLECULES
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; BY-LAYER DEPOSITION; BASIC FIBROBLAST;
   NEUROTROPHIC FACTOR; INTERPHOTORECEPTOR MATRIX; ROD PHOTORECEPTORS;
   BIOACTIVE COATINGS; POLYPEPTIDE FILMS; SURVIVAL; RAT
AB Reconstruction of extracellular matrix substrates for delivery of functional photoreceptors is crucial in pathologies such as retinal degeneration and age-related macular degeneration. In this study, we assembled polyelectrolyte films using the layer-by-layer deposition method. The buildup of three different films composed of poly(L-lysine)/ chondroitin sulfate (PLL/CSA), poly(L-lysine)/poly(styrenesulfonate) (PLL/PSS), or poly(L-lysine)/hyaluronic acid (PLL/HA) was followed by means of quartz crystal microbalance measurements, optical waveguide light mode spectroscopy, confocal microscopy, and atomic force microscopy. The exponential growth regime and the diffusion of PLL chains from the bulk through the PLL/CSA, PLL/PSS, and PLL/HA films was examined. Evaluation of photoreceptor cell viability was optimal on one layer of PLL (PLL1), followed by 10 bilayers of PLL/HA [(PLL/ HA)(10)] and 10 bilayers of PLL/CSA [(PLL/CSA)(10)]. The number of bilayers and the type of terminating layer also had a significant influence on the number of photoreceptor cells attached. Functionalized polyelectrolyte multilayer films were obtained by adsorbing basic fibroblastic factor (bFGF) or the insoluble fraction of interphotoreceptor matrix (IPM) on or within polyelectrolyte multilayers. bFGF and IPM adsorption on top of the (PLL/CSA)(10)/PLL polyelectrolyte films increased the number of photoreceptor cells attached and maintained the differantiation of rod and cone cells.
C1 INSERM, Unite 592, F-75571 Paris 12, France.
   Middle E Tech Univ, Dept Engn Sci, TR-06531 Ankara, Turkey.
   Univ Strasbourg, Fac Chirurg Dent, INSERM Unite 595, Inst Natl Sante & Rech Sci, F-67085 Strasbourg, France.
   CNRS, UPR 22, Inst Charles Sadron, F-67083 Strasbourg, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Middle East Technical University; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS -
   Institute of Chemistry (INC); UDICE-French Research Universities;
   Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg
RP Lavalle, P (通讯作者)，INSERM, Unite 592, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.
EM philippe.lavalle@odonto-ulp.u-strasbg.fr
RI SCHAAF, Pierre/J-2751-2016; , Aysen/AAZ-5553-2020; Boulmedais,
   Fouzia/AAU-7917-2020; Sahel, Jose-Alain/F-3172-2017; Boulmedais,
   Fouzia/B-4657-2011; Lavalle, Philippe/E-6328-2016
OI SCHAAF, Pierre/0000-0001-7423-5492; Boulmedais,
   Fouzia/0000-0002-4934-9276; Sahel, Jose-Alain/0000-0002-4831-1153;
   Boulmedais, Fouzia/0000-0002-4934-9276; Lavalle,
   Philippe/0000-0001-8798-912X; Tezcaner, Aysen/0000-0003-4292-5856
CR Ahmad I, 1999, BRAIN RES, V831, P1, DOI 10.1016/S0006-8993(99)01376-1
   ARAMANT R, 1988, INVEST OPHTH VIS SCI, V29, P498
   Barbucci R, 2003, BIOMATERIALS, V24, P915, DOI 10.1016/S0142-9612(02)00425-8
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Bennett J, 1998, GENE THER, V5, P1156, DOI 10.1038/sj.gt.3300733
   Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176
   Boulmedais F, 2003, LANGMUIR, V19, P440, DOI 10.1021/la0264522
   Boulmedais F, 2003, LANGMUIR, V19, P9873, DOI 10.1021/la0348259
   Boura C, 2003, BIOMATERIALS, V24, P3521, DOI 10.1016/S0142-9612(03)00214-X
   Brodkin KR, 2004, BIOMATERIALS, V25, P5929, DOI 10.1016/j.biomaterials.2004.01.044
   Burke SE, 2003, BIOMACROMOLECULES, V4, P1773, DOI 10.1021/bm034184w
   Cao W, 1997, INVEST OPHTH VIS SCI, V38, P1358
   Caruso F, 1997, LANGMUIR, V13, P3427, DOI 10.1021/la9608223
   Chacko DM, 2000, BIOCHEM BIOPH RES CO, V268, P842, DOI 10.1006/bbrc.2000.2153
   Chluba J, 2001, BIOMACROMOLECULES, V2, P800, DOI 10.1021/bm015529i
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   DECHER G, 1992, THIN SOLID FILMS, V210, P831, DOI 10.1016/0040-6090(92)90417-A
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   Delyfer MN, 2004, BIOL CELL, V96, P261, DOI 10.1016/j.biolcel.2004.01.006
   Derbal L, 2003, BIOMACROMOLECULES, V4, P1255, DOI 10.1021/bm034070k
   Elbert DL, 1999, LANGMUIR, V15, P5355, DOI 10.1021/la9815749
   Fintz AC, 2003, INVEST OPHTH VIS SCI, V44, P818, DOI 10.1167/iovs.01-1144
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   GAUR VP, 1992, EXP EYE RES, V54, P645, DOI 10.1016/0014-4835(92)90020-S
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P6706, DOI 10.1073/pnas.88.15.6706
   HAGEMAN GS, 1991, PROG RETIN RES, V10, P208
   Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767
   HOLLYFIELD JG, 1990, EXP EYE RES, V51, P107, DOI 10.1016/0014-4835(90)90177-V
   INGBER DE, 1993, EXTRACELLULAR MATRIX, P3
   Jessel N, 2003, ADV MATER, V15, P692, DOI 10.1002/adma.200304634
   JESSEL N, 2004, ADV MATER, V16, P1507
   Khademhosseini A, 2004, BIOMATERIALS, V25, P3583, DOI 10.1016/j.biomaterials.2003.10.033
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kinkl N, 2002, MOL VIS, V8, P149
   Kommonen B, 1996, OPHTHALMIC RES, V28, P19, DOI 10.1159/000267869
   Ladam G, 2000, LANGMUIR, V16, P1249, DOI 10.1021/la990650k
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lavalle P, 2005, J MEMBRANE SCI, V253, P49, DOI 10.1016/j.memsci.2004.12.033
   Lavalle P, 2004, MACROMOLECULES, V37, P1159, DOI 10.1021/ma035326h
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   LAYALLE P, 2004, J PHYS CHEM B, V108, P636
   LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0
   LI AR, 1995, J NEUROSCI, V15, P385
   Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   LVOV Y, 1995, J AM CHEM SOC, V117, P6117, DOI 10.1021/ja00127a026
   Ma ZW, 2005, BIOMATERIALS, V26, P1253, DOI 10.1016/j.biomaterials.2004.04.031
   Mendelsohn JD, 2003, BIOMACROMOLECULES, V4, P96, DOI 10.1021/bm0256101
   MohandSaid S, 1997, OPHTHALMIC RES, V29, P290, DOI 10.1159/000268027
   Picart C, 2001, J CHEM PHYS, V115, P1086, DOI 10.1063/1.1375156
   Picart C, 2001, LANGMUIR, V17, P7414, DOI 10.1021/la010848g
   Picart C, 2002, P NATL ACAD SCI USA, V99, P12531, DOI 10.1073/pnas.202486099
   Richert L, 2004, LANGMUIR, V20, P448, DOI 10.1021/la035415n
   Richert L, 2004, BIOMACROMOLECULES, V5, P284, DOI 10.1021/bm0342281
   Rosso F, 2004, J CELL PHYSIOL, V199, P174, DOI 10.1002/jcp.10471
   Salloum DS, 2004, BIOMACROMOLECULES, V5, P1089, DOI 10.1021/bm034522t
   Salloum DS, 2005, BIOMACROMOLECULES, V6, P161, DOI 10.1021/bm0497015
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937
   Seal BL, 2001, MAT SCI ENG R, V34, P147, DOI 10.1016/S0927-796X(01)00035-3
   Seiler MJ, 1998, INVEST OPHTH VIS SCI, V39, P2121
   Sheedlo HJ, 1998, DEV BRAIN RES, V107, P57, DOI 10.1016/S0165-3806(97)00219-8
   SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684
   Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166
   Thierry B, 2003, BIOMACROMOLECULES, V4, P1564, DOI 10.1021/bm0341834
   Thierry B, 2003, J AM CHEM SOC, V125, P7494, DOI 10.1021/ja034321x
   TIEFENTHALER K, 1989, J OPT SOC AM B, V6, P209, DOI 10.1364/JOSAB.6.000209
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Traverso V, 2003, INVEST OPHTH VIS SCI, V44, P4550, DOI 10.1167/iovs.03-0460
   Tryoen-Toth P, 2002, J BIOMED MATER RES, V60, P657, DOI 10.1002/jbm.10110
   TURNER JE, 1986, DEV BRAIN RES, V26, P91, DOI 10.1016/0165-3806(86)90011-8
   Vautier D, 2002, J BIOMAT SCI-POLYM E, V13, P713, DOI 10.1163/156856202320269175
   Voros J, 2002, BIOMATERIALS, V23, P3699, DOI 10.1016/S0142-9612(02)00103-5
   Zhang J, 2005, BIOMATERIALS, V26, P3353, DOI 10.1016/j.biomaterials.2004.08.019
   Zhu HG, 2004, BIOMATERIALS, V25, P109, DOI 10.1016/S0142-9612(03)00481-2
   Zhu YB, 2003, BIOMACROMOLECULES, V4, P446, DOI 10.1021/bm025723k
NR 76
TC 57
Z9 58
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD JAN
PY 2006
VL 7
IS 1
BP 86
EP 94
DI 10.1021/bm0505134
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 001PP
UT WOS:000234549100015
PM 16398502
OA Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Valmaggia, C
   Gottlob, I
AF Valmaggia, C
   Gottlob, I
TI Optokinetic nystagmus elicited by filling-in in adults with central
   scotoma
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PERIPHERAL RETINA; FIELD DEFECTS; VISUAL-CORTEX; EYE-MOVEMENTS; VISION;
   STIMULATION; SIZE
AB PURPOSE. Filling-in is the perceptual completion of physiological, pathologic, or artificial scotomas. Three patients are described, in whom optokinetic nystagmus (OKN) was present during filling-in.
   METHODS. Three patients with age-related macular degeneration with large central scotomas were included in the study. OKN was elicited with black and white stripes moving nasally to temporally or temporally to nasally at four velocities. OKN gain was measured using infrared oculography.
   RESULTS. While looking at the OKN stimuli, the patients either did not see the stimulus (without perceiving a positive scotoma) or filled in the scotoma and perceived the stripes. Simultaneously with filling in the scotoma, OKN eye movements were elicited in all three patients. The filling-in phenomenon was present for all stimulus directions and velocities, appeared within seconds, and was followed immediately by eye movements corresponding to OKN. OKN gains during filling-in were similar to those of age-matched control subjects without scotomas. No asymmetry was noted between temporal to nasal or nasal to temporal stimulation.
   CONCLUSIONS. Motion-sensitive areas of the visual cortex may be activated and trigger the generation of OKN, supporting an active process. Alternatively, OKN is suppressed when subjects are not filling-in, while the subjects are fixating the central scotoma or edges of the scotoma. That the subjects did not perceive positive scotomas suggests that an active process is more likely.
C1 Kantonspital St Gallen, Dept Ophthalmol, Abtwil, Switzerland.
   Univ Leicester, Warwick Med Sch, Dept Ophthalmol, Leicester, Leics, England.
C3 Kantonsspital St. Gallen; University of Leicester; University of Warwick
RP Valmaggia, C (通讯作者)，Sonnenbergstr 36, CH-9030 Abtwil, Switzerland.
CR Abadi RV, 1997, BRIT J OPHTHALMOL, V81, P123, DOI 10.1136/bjo.81.2.123
   ATKINSON J, 1981, EYE MOVEMENTS COGNIT, P53
   CHENG M, 1975, EXP BRAIN RES, V23, P129
   CREVITS L, 1986, EUR NEUROL, V25, P454, DOI 10.1159/000116051
   Crevits L, 2001, BRIT J OPHTHALMOL, V85, P762
   Dennett D. C., 1991, CONSCIOUSNESS EXPLAI
   DEWEERD P, 1995, NATURE, V377, P731
   Dieterich M, 2000, NEUROLOGY, V54, P148, DOI 10.1212/WNL.54.1.148
   Dieterich M, 1998, BRAIN, V121, P1479, DOI 10.1093/brain/121.8.1479
   DUBOIS MFW, 1979, VISION RES, V19, P1105, DOI 10.1016/0042-6989(79)90005-1
   Garbutt S, 1999, BR ORTHOPT J, V56, P1
   GERRITS HJM, 1969, VISION RES, V9, P439, DOI 10.1016/0042-6989(69)90092-3
   GRESTY M, 1979, ACTA OTO-LARYNGOL, V87, P477, DOI 10.3109/00016487909126455
   HOOD JD, 1975, ORL J OTO-RHINO-LARY, V37, P65, DOI 10.1159/000275208
   HOWARD IP, 1984, VISION RES, V24, P969, DOI 10.1016/0042-6989(84)90072-5
   LEWIS TL, 1992, CLIN VISION SCI, V7, P211
   MURASUGI CM, 1986, VISION RES, V26, P1155, DOI 10.1016/0042-6989(86)90049-0
   NAEGELE JR, 1982, VISION RES, V22, P341, DOI 10.1016/0042-6989(82)90149-3
   O'Regan JK, 1998, BEHAV BRAIN SCI, V21, P767, DOI 10.1017/S0140525X9844175X
   PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366
   RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0
   RAMACHANDRAN VS, 1992, SCI AM, V266, P85
   Safran A B, 1996, Curr Opin Ophthalmol, V7, P53, DOI 10.1097/00055735-199612000-00009
   Safran AB, 1999, J NEURO-OPHTHALMOL, V19, P84
   SCHOR C, 1981, VISION RES, V21, P985, DOI 10.1016/0042-6989(81)90002-X
   SCHOR CM, 1980, INVEST OPHTH VIS SCI, V19, P668
   Valmaggia C, 2001, BRIT J OPHTHALMOL, V85, P169, DOI 10.1136/bjo.85.2.169
   van Die G, 1982, Hum Neurobiol, V1, P111
   VANDIE GC, 1986, BRAIN RES, V383, P185, DOI 10.1016/0006-8993(86)90019-3
   Weinacht S, 1999, INVEST OPHTH VIS SCI, V40, P346
   Yee R, 1982, NYSTAGMUS VERTIGO CL, P251
NR 31
TC 16
Z9 16
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2002
VL 43
IS 6
BP 1804
EP 1808
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 557VA
UT WOS:000175927800017
PM 12036982
DA 2022-11-30
ER

PT J
AU Gawronska-Grzywacz, M
   Piatkowska-Chmiel, I
   Popiolek, L
   Herbet, M
   Dudka, J
AF Gawronska-Grzywacz, Monika
   Piatkowska-Chmiel, Iwona
   Popiolek, Lukasz
   Herbet, Mariola
   Dudka, Jaroslaw
TI The N-Substituted-4-Methylbenzenesulphonyl Hydrazone Inhibits
   Angiogenesis in Zebrafish Tg(fli1: EGFP) Model
SO PHARMACEUTICALS
LA English
DT Article
DE angiogenesis; zebrafish; Tg(fli1-EGFP); sulphonyl hydrazone; FET
ID IN-VITRO; CANCER
AB One of the most important therapies of malignant neoplasms, which are the second cause of death worldwide, is focused on the inhibition of pathological angiogenesis within the tumor. Therefore, the searching for the efficacious and relatively inexpensive small-molecule inhibitors of this process is essential. In this research, the anti-angiogenic potential of N-substituted-4-methylbenzenesulphonyl hydrazone, possessing antiproliferative activity against cancer cells, was tested. For this purpose, an intersegmental vessel (ISV) angiogenesis assay was performed using 6 hpf (hours post fertilization), 12 hpf and 24 hpf embryos of zebrafish transgenic strain, Tg(fli1: EGFP). They were incubated with different concentrations of tested molecule and after 24 h the development of intersegmental vessels of the trunk was analysed. In turn, the acute toxicity study in the zebrafish model was mainly conducted on strain AB, using the OECD-approved and recommended fish embryo acute toxicity test (FET) procedure. The results showed the moderate toxicity of N-[(3-chloro-4-methoxyphenyl)methylidenel-4-methylbenzenesulphonohydrazide in above-mentioned model with the LC50 value calculated at 23.04 mg/L. Moreover, newly synthesized molecule demonstrated the anti-angiogenic potential proved in Tg(fli1: EGFP) zebrafish model, which may be promising for the therapy of neoplastic tumors as well as other diseases related to pathological angiogenesis, such as age-related macular degeneration and diabetic retinopathy.
C1 [Gawronska-Grzywacz, Monika; Piatkowska-Chmiel, Iwona; Herbet, Mariola; Dudka, Jaroslaw] Med Univ Lublin, Fac Pharm, Dept Toxicol, 8B Jaczewskiego St, PL-20090 Lublin, Poland.
   [Popiolek, Lukasz] Med Univ Lublin, Fac Pharm, Dept Organ Chem, 4A Chodzki St, PL-20093 Lublin, Poland.
C3 Medical University of Lublin; Medical University of Lublin
RP Gawronska-Grzywacz, M (通讯作者)，Med Univ Lublin, Fac Pharm, Dept Toxicol, 8B Jaczewskiego St, PL-20090 Lublin, Poland.
EM monika.grzywacz@umlub.pl
FU National Science Centre (Poland) [MINIATURE 2019/03/X/NZ7/00639]
FX The research was funded by the National Science Centre (Poland), grant
   no. MINIATURE 2019/03/X/NZ7/00639.
CR Abbas K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092449
   [Anonymous], 2021, REN CELL CANC TREATM
   [Anonymous], 2015, J LAW 2015 WARSAW PO
   Bingul M, 2016, MOLECULES, V21, DOI 10.3390/molecules21070916
   Braunbeck T., 2006, 20385422 UBA GERM FE
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chavez MN, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00056
   El-Faham A, 2015, MOLECULES, V20, P14638, DOI 10.3390/molecules200814638
   Gore AV, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006684
   Han MI, 2021, BIOORGAN MED CHEM, V37, DOI 10.1016/j.bmc.2021.116097
   Horchani M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052742
   Howe K, 2013, NATURE, V496, P498, DOI 10.1038/nature12111
   Jo DH, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-38
   Kajal A, 2014, INT J MED CHEM, V2014, DOI 10.1155/2014/761030
   Kassab AE, 2021, J ENZYM INHIB MED CH, V36, P922, DOI 10.1080/14756366.2021.1901089
   Ljungberg B., 2021, P 36 ANN EAU C
   McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211
   OECD, 2012, FISH EMBRYO TOXICITY
   Pallapati RK, 2020, EGYPT J CHEM, V63, P2473, DOI 10.21608/ejchem.2020.20809.2251
   Patil S, 2018, ACS OMEGA, V3, P1470, DOI 10.1021/acsomega.7b01512
   Penha LCD, 2021, COMP BIOCHEM PHYS C, V242, DOI 10.1016/j.cbpc.2020.108955
   Popiolek L, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12047
   Popiolek L, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110526
   Popiolek L, 2018, BIOMED PHARMACOTHER, V103, P1337, DOI 10.1016/j.biopha.2018.04.163
   Popiolek L, 2017, MED CHEM RES, V26, P287, DOI 10.1007/s00044-016-1756-y
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Sasore T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105280
   Serbedzija G N, 1999, Angiogenesis, V3, P353, DOI 10.1023/A:1026598300052
   Tobia C, 2011, INT J DEV BIOL, V55, P505, DOI 10.1387/ijdb.103238ct
   Velezheva V, 2016, BIOORG MED CHEM LETT, V26, P978, DOI 10.1016/j.bmcl.2015.12.049
   Yilmaz AD, 2012, J ENZYM INHIB MED CH, V27, P428, DOI 10.3109/14756366.2011.594048
   Zhang JB, 2016, ONCOTARGET, V7, P41067, DOI 10.18632/oncotarget.9392
NR 32
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD NOV
PY 2022
VL 15
IS 11
AR 1308
DI 10.3390/ph15111308
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 6C8LT
UT WOS:000882259100001
PM 36355480
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Van de Wiele, VL
   Hammer, M
   Parikh, R
   Feldman, WB
   Sarpatwari, A
   Kesselheim, AS
AF Van de Wiele, Victor L.
   Hammer, Maximilian
   Parikh, Ravi
   Feldman, William B.
   Sarpatwari, Ameet
   Kesselheim, Aaron S.
TI Competition law and pricing among biologic drugs: the case of VEGF
   therapy for retinal diseases
SO JOURNAL OF LAW AND THE BIOSCIENCES
LA English
DT Article
DE competition law; drugs; pricing; anti-VEGF; ophthalmology; Medicare
ID COHERENCE TOMOGRAPHY FINDINGS; INTRAVITREAL INJECTION; BEVACIZUMAB
   AVASTIN(R); BIOSIMILARS; OPHTHALMOLOGY; RANIBIZUMAB; MARKET; COST
AB Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for this disease. Currently, treatment options include three originator biologics with approvals for neovascular AMD (aflibercept, ranibizumab, and brolucizumab-dbll) and one biologic that is commonly used off-label for the condition (bevacizumab). In the USA, Medicare spending on these drugs consistently surpassed $4 billion per year between 2015 and 2019, driven by high prices and varying off-label use of bevacizumab, which is substantially cheaper than the other biologics used to treat neovascular AMD. In this article, we discuss how legal reform can improve market competition for biologic drugs, using AMD therapies as a case study. We chose this group of drugs for their significant contribution to Medicare spending, the price difference between approved therapies and intravitreal bevacizumab, and because there currently exists a large biosimilar pipeline with many drug candidates in the final stage of development. We propose mechanisms for anticipating and facilitating the market introduction of biosimilars, as well as changes to the pricing model in Medicare that can promote use of cost-effective therapies. Reforms such as empowering Medicare to negotiate drug prices may help ensure that introduction of new biologics and biosimilars for AMD will lower spending and increase patient access.
C1 [Van de Wiele, Victor L.; Feldman, William B.; Sarpatwari, Ameet; Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA.
   [Van de Wiele, Victor L.; Feldman, William B.; Sarpatwari, Ameet; Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02115 USA.
   [Hammer, Maximilian] Heidelberg Univ, Inst Physiol & Pathophysiol, Heidelberg, Germany.
   [Parikh, Ravi] NYU, Dept Ophthalmol & Visual Sci, Sch Med, New York, NY USA.
   [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard Medical School; Ruprecht Karls University Heidelberg; New York
   University
RP Kesselheim, AS (通讯作者)，Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA.; Kesselheim, AS (通讯作者)，Harvard Med Sch, Boston, MA 02115 USA.
EM akesselheim@bwh.harvard.edu
RI Hammer, Maximilian/GZL-2166-2022
FU Arnold Ventures; National Institutes of Health; FDA Sentinel Initiative;
   Association for Accessible Medicines
FX Mr Van de Wiele's work was partially supported by a grant from
   Association for Accessible Medicines from 2019 to 2020. Dr Kesselheim
   and Dr Sarpatwari's work was supported by Arnold Ventures. Dr Feldman's
   work is supported by the National Institutes of Health and the FDA
   Sentinel Initiative. The funders had no role in the preparation, review,
   or approval of the manuscript or the decision to submit the manuscript
   for publication.
CR AmericanSocietyofClinicalOncology, 2009, J ONCOL PRACT, V24, P19
   [Anonymous], 2017, REPORT EUROPEAN UNIO, P15
   [Anonymous], 2019, LOOK RECENT PROPOSAL
   [Anonymous], 2015, REP C MED HLTH CAR B, P61
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bell Jacob, 2019, EYLEA CASTS SHADOW N
   Bro T, 2020, GRAEF ARCH CLIN EXP, V258, P503, DOI 10.1007/s00417-019-04569-8
   Chambers JD, 2020, JAMA-J AM MED ASSOC, V323, P1972, DOI 10.1001/jama.2020.2229
   CongressionalBudgetOffice, 2019, INC EFF PROP RUL SAF
   Conti RM, 2021, HLTH AFFAIRS BLOG
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Dans KC, 2019, GRAEF ARCH CLIN EXP, V257, P741, DOI 10.1007/s00417-018-04232-8
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dusetzina SB, 2019, JAMA-J AM MED ASSOC, V321, P1563, DOI 10.1001/jama.2019.2445
   FDA, 2011, LUC FDA APPR LETT
   FDA, 2017, FDA APPR LETT MVAS
   FDA, 2019, FDA APPR LETT ZIR
   FDA, 2004, AV FDA APPR LETT
   FDA, 2019, BEOV FDA APPR LETT
   Frank RG, 2021, 28460 NBER
   Glasser DB, 2020, OPHTHALMOLOGY, V127, P1688, DOI 10.1016/j.ophtha.2020.06.012
   Hakim A, 2017, JAMA-J AM MED ASSOC, V317, P2163, DOI 10.1001/jama.2017.5202
   Howard DH, 2015, J ECON PERSPECT, V29, P139, DOI 10.1257/jep.29.1.139
   Hwang TJ, 2019, JAMA INTERN MED, V179, P374, DOI 10.1001/jamainternmed.2018.6417
   Jain P, 2017, INDIAN J OPHTHALMOL, V65, P596, DOI 10.4103/ijo.IJO_992_16
   Kansteiner F, 2021, BIDENS 2022 BUDGET R
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mitchell AP, 2018, JAMA INTERN MED, V178, P854, DOI 10.1001/jamainternmed.2018.0776
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P358, DOI 10.1001/jamaophthalmol.2018.6395
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Pollack A, 2011, SUCCESS LONG COMING
   Ribatti D, 2008, ANGIOGENESIS, V11, P3, DOI 10.1007/s10456-008-9092-6
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sarpatwari A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002872
   Schrag D, 2016, NEW ENGL J MED, V374, P2101, DOI 10.1056/NEJMp1603735
   Shalaby AK, 2016, EYE, V30, P1404, DOI 10.1038/eye.2016.154
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Siddiqui M, 2012, MAYO CLIN PROC, V87, P935, DOI 10.1016/j.mayocp.2012.07.007
   Terasaki H, 2015, RETINA-J RET VIT DIS, V35, P1007, DOI 10.1097/IAE.0000000000000428
   U.S. GovernmentAccountabilityOffice(GAO), 2016, MED B
   Van de Wiele VL, 2021, HEALTH AFFAIR, V40, P1198, DOI 10.1377/hlthaff.2020.02484
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
NR 48
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2053-9711
J9 J LAW BIOSCI
JI J. Law Biosci.
PD JAN 1
PY 2022
VL 9
IS 1
AR lsac001
DI 10.1093/jlb/lsac001
PG 18
WC Ethics; Law; Medical Ethics; Medicine, Legal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
   Medicine
GA ZF7OF
UT WOS:000759754200001
PM 35211322
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hartman, GD
   Lambert-Cheatham, NA
   Kelley, MR
   Corson, TW
AF Hartman, Gabriella D.
   Lambert-Cheatham, Nathan A.
   Kelley, Mark R.
   Corson, Timothy W.
TI Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to
   Therapy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE redox effector factor 1; apurinic/apyrimidinic endonuclease & nbsp;;
   redox signaling; angiogenesis; inflammation; oxidative stress; retina;
   choroid; neovascularization; NF-kappa B
ID APURINIC-APYRIMIDINIC ENDONUCLEASE; BASE-EXCISION-REPAIR; SIGNALING
   PROTEIN APE1/REF-1; ANTI-VEGF THERAPY; MACULAR DEGENERATION; DNA-REPAIR;
   REDOX ACTIVITY; APURINIC/APYRIMIDINIC ENDONUCLEASE-1; FACTOR-I;
   OXIDATIVE STRESS
AB Proliferative diabetic retinopathy (PDR), neovascular age-related macular degeneration (nvAMD), retinopathy of prematurity (ROP) and other eye diseases are characterized by retinal and/or choroidal neovascularization, ultimately causing vision loss in millions of people worldwide. nvAMD and PDR are associated with aging and the number of those affected is expected to increase as the global median age and life expectancy continue to rise. With this increase in prevalence, the development of novel, orally bioavailable therapies for neovascular eye diseases that target multiple pathways is critical, since current anti-vascular endothelial growth factor (VEGF) treatments, delivered by intravitreal injection, are accompanied with tachyphylaxis, a high treatment burden and risk of complications. One potential target is apurinic/apyrimidinic endonuclease 1/reduction-oxidation factor 1 (APE1/Ref-1). The multifunctional protein APE1/Ref-1 may be targeted via inhibitors of its redox-regulating transcription factor activation activity to modulate angiogenesis, inflammation, oxidative stress response and cell cycle in neovascular eye disease; these inhibitors also have neuroprotective effects in other tissues. An APE1/Ref-1 small molecule inhibitor is already in clinical trials for cancer, PDR and diabetic macular edema. Efforts to develop further inhibitors are underway. APE1/Ref-1 is a novel candidate for therapeutically targeting neovascular eye diseases and alleviating the burden associated with anti-VEGF intravitreal injections.
C1 [Hartman, Gabriella D.; Lambert-Cheatham, Nathan A.; Kelley, Mark R.; Corson, Timothy W.] Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Hartman, Gabriella D.; Corson, Timothy W.] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA.
   [Kelley, Mark R.] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA.
   [Kelley, Mark R.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
   [Kelley, Mark R.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Kelley, Mark R.; Corson, Timothy W.] Indiana Univ Sch Med, Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Indiana University-Purdue University Indianapolis
RP Corson, TW (通讯作者)，Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN 46202 USA.
EM gdhartma@iu.edu; lambertcheatham@gmail.com; mkelley@iu.edu;
   tcorson@iu.edu
RI Corson, Timothy/B-6851-2009
OI Corson, Timothy/0000-0002-1402-7875; Lambert-Cheatham,
   Nathan/0000-0002-9587-715X; Hartman, Gabriella/0000-0002-2061-411X
FU NIH/NEI [R01EY031939]; Research to Prevent Blindness
FX FundingThis research was funded by NIH/NEI, grant number R01EY031939,
   and a Challenge Grant from Research to Prevent Blindness.
CR Ahmed SMU, 2017, BBA-MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bao LP, 2018, INT IMMUNOPHARMACOL, V54, P245, DOI 10.1016/j.intimp.2017.11.021
   Basavarajappa HD, 2015, J MED CHEM, V58, P5015, DOI 10.1021/acs.jmedchem.5b00449
   Batliwala S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1703810
   Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]
   Bhat AA, 2018, ONCOGENE, V37, P6011, DOI 10.1038/s41388-018-0388-8
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blencowe H, 2013, PEDIATR RES, V74, P35, DOI 10.1038/pr.2013.205
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bobola MS, 2001, CLIN CANCER RES, V7, P3510
   Cabral T., 2017, INT J RETINA VITREOU, V3, P31, DOI [10.1186/s40942-017-0084-9, DOI 10.1186/S40942-017-0084-9]
   Cai ZG, 2018, CELL STEM CELL, V23, P833, DOI 10.1016/j.stem.2018.10.013
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Capitao M, 2016, J CELL BIOCHEM, V117, P2443, DOI 10.1002/jcb.25575
   Cardoso AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047462
   Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000
   Caston RA, 2020, DRUG DISCOV TODAY, V26, P218, DOI 10.1016/j.drudis.2020.10.015
   Cesaratto L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070909
   Chen J, 2011, CURR OPIN PEDIATR, V23, P173, DOI 10.1097/MOP.0b013e3283423f35
   Chen Q, 2017, VISION RES, V139, P47, DOI 10.1016/j.visres.2017.02.007
   Chiarini LB, 2000, CELL DEATH DIFFER, V7, P272, DOI 10.1038/sj.cdd.4400639
   Choi Sunga, 2016, Chonnam Med J, V52, P75, DOI 10.4068/cmj.2016.52.2.75
   Codrich M, 2019, DNA REPAIR, V82, DOI 10.1016/j.dnarep.2019.102675
   Cornel Stefan, 2015, Rom J Ophthalmol, V59, P235
   Cui Y, 2006, EXP EYE RES, V83, P807, DOI 10.1016/j.exer.2006.03.024
   D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200
   Davydov V, 2003, NEUROBIOL AGING, V24, P953, DOI 10.1016/S0197-4580(02)00229-4
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Deshpande AD, 2008, PHYS THER, V88, P1254, DOI 10.2522/ptj.20080020
   Dong LJ, 2021, J MOL MED, V99, P967, DOI 10.1007/s00109-021-02069-z
   Dreyfuss JL, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/892043
   Eads JR, 2021, INVEST NEW DRUG, V39, P142, DOI 10.1007/s10637-020-00962-x
   Edwards M, 2021, ADV EXP MED BIOL, V1256, P89, DOI 10.1007/978-3-030-66014-7_4
   Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X
   Fishel M.L., 2015, P AACR NCI EORTC INT
   Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005
   Fishel ML, 2015, J BIOL CHEM, V290, P3057, DOI 10.1074/jbc.M114.621995
   Fishel ML, 2011, MOL CANCER THER, V10, P1698, DOI 10.1158/1535-7163.MCT-11-0107
   Fishel ML, 2010, EXP HEMATOL, V38, P1178, DOI 10.1016/j.exphem.2010.08.011
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Gampala S, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02046-x
   Gampala S, 2021, BRIT J CANCER, V124, P1566, DOI 10.1038/s41416-021-01270-8
   Georgiadis MM, 2008, MUTAT RES-FUND MOL M, V643, P54, DOI 10.1016/j.mrfmmm.2008.04.008
   Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237
   Good WV, 2005, PEDIATRICS, V116, P15, DOI 10.1542/peds.2004-1413
   Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548
   GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13459
   Gupta Ved P., 2004, Indian Journal of Pediatrics, V71, P887, DOI 10.1007/BF02830827
   He HZ, 2014, BIOCHEMISTRY-US, V53, P6520, DOI 10.1021/bi500676p
   Heisel Curtis, 2021, J Cell Signal, V2, P133, DOI 10.33696/Signaling.2.044
   Hendrick AM, 2015, PRIMARY CARE, V42, P451, DOI 10.1016/j.pop.2015.05.005
   Hiramoto M, 1998, J IMMUNOL, V160, P810
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933
   Izumi T, 1998, CARCINOGENESIS, V19, P525, DOI 10.1093/carcin/19.3.525
   Jacobs B, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-98568-7
   Jedinak A, 2011, ANTICANCER RES, V31, P379
   Jiang AH, 2011, VISION RES, V51, P93, DOI 10.1016/j.visres.2010.10.008
   Jiang YL, 2010, CANCER INVEST, V28, P885, DOI 10.3109/07357907.2010.512816
   Jin SA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122664
   KANE CM, 1981, J BIOL CHEM, V256, P3405
   Kang B, 2017, NEUROREPORT, V28, P10, DOI 10.1097/WNR.0000000000000712
   Kelley M.R., 2021, COMMUNICATION
   Kelley M.R., 2019, P AACR NCI EORTC INT
   Kelley MR, 2016, J PHARMACOL EXP THER, V359, P300, DOI 10.1124/jpet.116.235283
   Kelley MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106485
   Kelley MR, 2014, FUTURE ONCOL, V10, P1215, DOI 10.2217/fon.14.60
   Kelley Mark R, 2012, Curr Mol Pharmacol, V5, P36
   Kelley MR, 2011, ANTIOXID REDOX SIGN, V14, P1387, DOI 10.1089/ars.2010.3410
   Kelley MR, 2001, CLIN CANCER RES, V7, P824
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kim KC, 2010, INT J BIOCHEM CELL B, V42, P297, DOI 10.1016/j.biocel.2009.11.009
   Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624
   Koukourakis MI, 2001, INT J RADIAT ONCOL, V50, P27, DOI 10.1016/S0360-3016(00)01561-3
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Laev SS, 2017, BIOORGAN MED CHEM, V25, P2531, DOI 10.1016/j.bmc.2017.01.028
   Leak RK, 2015, ANTIOXID REDOX SIGN, V22, P135, DOI 10.1089/ars.2013.5511
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Lee YR, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090366
   Lee YR, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8030057
   Lee YR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133178
   Lee YR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27025-9
   Lenox AR, 2015, NEUROSCI LETT, V609, P30, DOI 10.1016/j.neulet.2015.10.019
   Li MX, 2019, COMPUT STRUCT BIOTEC, V17, P324, DOI 10.1016/j.csbj.2019.02.007
   Li MX, 2014, ANTIOXID REDOX SIGN, V20, P678, DOI 10.1089/ars.2013.5492
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Li Y, 2014, INVEST OPHTH VIS SCI, V55, P4461, DOI 10.1167/iovs.14-14451
   Logsdon DP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32034-9
   Logsdon DP, 2016, MOL CANCER THER, V15, P2722, DOI 10.1158/1535-7163.MCT-16-0253
   Ludwig CA, 2017, OSLI RETINA, V48, P553, DOI 10.3928/23258160-20170630-06
   Luo M, 2008, ANTIOXID REDOX SIGN, V10, P1853, DOI 10.1089/ars.2008.2120
   Luo MH, 2012, BIOCHEMISTRY-US, V51, P695, DOI 10.1021/bi201034z
   Marcon G, 2009, NEUROSCI LETT, V466, P124, DOI 10.1016/j.neulet.2009.09.039
   McIlwain David W, 2018, Oncotarget, V9, P10962, DOI 10.18632/oncotarget.23493
   Michaelides M, 2010, OPHTHALMOLOGY, V117, P1078, DOI 10.1016/j.ophtha.2010.03.045
   Mijit Mahmut, 2021, J Cell Signal, V2, P151
   Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975
   Nyland RL, 2010, J MED CHEM, V53, P1200, DOI 10.1021/jm9014857
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Park IS, 2020, BIOMATERIALS, V242, DOI 10.1016/j.biomaterials.2020.119919
   Park MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep23015
   Pasha SPBS, 2018, J PHARMACOL EXP THER, V367, P108, DOI 10.1124/jpet.118.248088
   Peet DJ, 2017, EXP CELL RES, V356, P136, DOI 10.1016/j.yexcr.2017.03.030
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Poletto M, 2016, MOL CARCINOGEN, V55, P688, DOI 10.1002/mc.22313
   Puglisi F, 2001, ANTICANCER RES, V21, P4041
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Robertson KA, 2001, CANCER RES, V61, P2220
   Rubsam A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040942
   Sahakian L, 2021, INFLAMM BOWEL DIS, V27, P388, DOI 10.1093/ibd/izaa161
   Schlenker MB, 2015, AM J OPHTHALMOL, V160, P569, DOI 10.1016/j.ajo.2015.06.011
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Sehnal D, 2021, NUCLEIC ACIDS RES, V49, pW431, DOI 10.1093/nar/gkab314
   Shah F, 2017, MOL ONCOL, V11, P1711, DOI 10.1002/1878-0261.12138
   Shah F, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0023-0
   Shahda S, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3097
   Shaikh AY, 2002, NEUROMOL MED, V2, P47, DOI 10.1007/s12017-002-0038-7
   SHAPER NL, 1982, J BIOL CHEM, V257, P13455
   Sharbeen George, 2015, Front Nutr, V2, P10, DOI 10.3389/fnut.2015.00010
   Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496
   Silva LL, 2021, INVEST OPHTH VIS SCI, V62
   Simo R, 2014, DIABETES CARE, V37, P893, DOI 10.2337/dc13-2002
   Smith Lois E H, 2003, Semin Neonatol, V8, P469, DOI 10.1016/S1084-2756(03)00119-2
   Solebo AL, 2017, ARCH DIS CHILD, V102, P853, DOI 10.1136/archdischild-2016-310532
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sriramajayam K, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101970
   Stetler RA, 2016, P NATL ACAD SCI USA, V113, pE3558, DOI 10.1073/pnas.1606226113
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Su DA, 2011, BIOCHEMISTRY-US, V50, P82, DOI 10.1021/bi101248s
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Sulaiman RS, 2015, J OCUL PHARMACOL TH, V31, P447, DOI 10.1089/jop.2015.0049
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
   Tan ZQ, 1998, NEUROREPORT, V9, P2749, DOI 10.1097/00001756-199808240-00012
   Ung C, 2021, ADV EXP MED BIOL, V1256, P295, DOI 10.1007/978-3-030-66014-7_12
   VanderVeen DK, 2019, SEMIN PERINATOL, V43, P375, DOI 10.1053/j.semperi.2019.05.011
   Vascotto C, 2009, MOL CELL BIOL, V29, P1834, DOI 10.1128/MCB.01337-08
   Wallace DK, 2020, JAMA OPHTHALMOL, V138, P698, DOI 10.1001/jamaophthalmol.2020.0334
   Wallace DK, 2018, OPHTHALMOLOGY, V125, P1961, DOI 10.1016/j.ophtha.2018.05.001
   Wallsh JO, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051049
   Wei YH, 2011, FREE RADICAL BIO MED, V51, P216, DOI 10.1016/j.freeradbiomed.2011.04.026
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919
   XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23
   XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x
   Xu ZH, 2014, DIABETOLOGIA, V57, P204, DOI 10.1007/s00125-013-3093-8
   Yan T, 2018, AGING DIS, V9, P453, DOI 10.14336/AD.2017.1130
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zhang J, 2013, BIOCHEMISTRY-US, V52, P2955, DOI 10.1021/bi400179m
   Zheng YF, 2012, INDIAN J OPHTHALMOL, V60, P428, DOI 10.4103/0301-4738.100542
   Zou GM, 2009, J CELL PHYSIOL, V219, P209, DOI 10.1002/jcp.21666
NR 161
TC 2
Z9 2
U1 5
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2021
VL 22
IS 19
AR 10279
DI 10.3390/ijms221910279
PG 27
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XK3PN
UT WOS:000727381900001
PM 34638620
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Macchioni, L
   Chiasserini, D
   Mezzasoma, L
   Davidescu, M
   Orvietani, PL
   Fettucciari, K
   Salviati, L
   Cellini, B
   Bellezza, I
AF Macchioni, Lara
   Chiasserini, Davide
   Mezzasoma, Letizia
   Davidescu, Magdalena
   Orvietani, Pier Luigi
   Fettucciari, Katia
   Salviati, Leonardo
   Cellini, Barbara
   Bellezza, Ilaria
TI Crosstalk between Long-Term Sublethal Oxidative Stress and Detrimental
   Inflammation as Potential Drivers for Age-Related Retinal Degeneration
SO ANTIOXIDANTS
LA English
DT Article
DE retinal pigment epithelium; ARPE-19; age-related macular degeneration;
   oxidative stress; senescence; proteomics; mitochondria; inflammasome
AB Age-related retinal degenerations, including age-related macular degeneration (AMD), are caused by the loss of retinal pigmented epithelial (RPE) cells and photoreceptors. The pathogenesis of AMD, deeply linked to the aging process, also involves oxidative stress and inflammatory responses. However, the molecular mechanisms contributing to the shift from healthy aging to AMD are still poorly understood. Since RPE cells in the retina are chronically exposed to a pro-oxidant microenvironment throughout life, we simulated in vivo conditions by growing ARPE-19 cells in the presence of 10 mu M H2O2 for several passages. This long-term oxidative insult induced senescence in ARPE-19 cells without affecting cell proliferation. Global proteomic analysis revealed a dysregulated expression in proteins involved in antioxidant response, mitochondrial homeostasis, and extracellular matrix organization. The analyses of mitochondrial functionality showed increased mitochondrial biogenesis and ATP generation and improved response to oxidative stress. The latter, however, was linked to nuclear factor-kappa B (NF-kappa B) rather than nuclear factor erythroid 2-related factor 2 (Nrf2) activation. NF-kappa B hyperactivation also resulted in increased pro-inflammatory cytokines expression and inflammasome activation. Moreover, in response to additional pro-inflammatory insults, senescent ARPE-19 cells underwent an exaggerated inflammatory reaction. Our results indicate senescence as an important link between chronic oxidative insult and detrimental chronic inflammation, with possible future repercussions for therapeutic interventions.
C1 [Macchioni, Lara; Chiasserini, Davide; Mezzasoma, Letizia; Davidescu, Magdalena; Orvietani, Pier Luigi; Fettucciari, Katia; Cellini, Barbara; Bellezza, Ilaria] Univ Perugia, Dept Med & Surg, Sect Physiol & Biochem, Piazza Univ 1, I-06123 Perugia Pg, Italy.
   [Salviati, Leonardo] Univ Padua, Clin Genet Unit, Dept Woman & Child Hlth, Via 8 Febbraio 1848,2, I-35122 Padova Pd, Italy.
C3 University of Perugia; University of Padua
RP Bellezza, I (通讯作者)，Univ Perugia, Dept Med & Surg, Sect Physiol & Biochem, Piazza Univ 1, I-06123 Perugia Pg, Italy.
EM lara.macchioni@unipg.it; davide.chiasserini@unipg.it;
   letizia.mezzasoma@unipg.it; magdalena.davidescu@unipg.it;
   pier.orvietani@unipg.it; katia.fettucciari@unipg.it;
   leonardo.salviati@unipd.it; barbara.cellini@unipg.it;
   ilaria.bellezza@unipg.it
RI Fettucciari, Katia/K-7661-2015; FETTUCCIARI, Katia/N-8664-2019; Cellini,
   Barbara/AAC-6401-2019; BELLEZZA, ILARIA/AAA-8099-2022; Salviati,
   Leonardo/L-1007-2016; Chiasserini, Davide/K-7074-2016
OI Fettucciari, Katia/0000-0001-8074-8243; FETTUCCIARI,
   Katia/0000-0001-8074-8243; Cellini, Barbara/0000-0002-5221-9288;
   BELLEZZA, ILARIA/0000-0002-8106-1600; Salviati,
   Leonardo/0000-0001-5642-9963; Chiasserini, Davide/0000-0002-1169-3258;
   Mezzasoma, Letizia/0000-0002-6159-0927
FU Telethon Foundation [GGP15114]
FX This work was supported by Telethon Foundation (Grant GGP15114) to B.C.
   and L.S.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bellezza I, 2012, J NUTR BIOCHEM, V23, P1583, DOI 10.1016/j.jnutbio.2011.10.012
   Bellezza Ilaria, 2010, Cancers (Basel), V2, P483, DOI 10.3390/cancers2020483
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Campochiaro PA, 2020, J CLIN INVEST, V130, P1527, DOI 10.1172/JCI132990
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chiasserini D, 2017, J PROTEOMICS, V152, P329, DOI 10.1016/j.jprot.2016.11.013
   Chiasserini D, 2014, J PROTEOMICS, V106, P191, DOI 10.1016/j.jprot.2014.04.028
   Christie DA, 2011, MOL CELL BIOL, V31, P3845, DOI 10.1128/MCB.05393-11
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040307
   Franceschi C, 2017, TRENDS ENDOCRIN MET, V28, P199, DOI 10.1016/j.tem.2016.09.005
   Gallenga CE, 2014, INFLAMM RES, V63, P105, DOI 10.1007/s00011-013-0684-2
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gilquin B, 2010, MOL CELL BIOL, V30, P1984, DOI 10.1128/MCB.00007-10
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x
   Hillen HS, 2018, NAT STRUCT MOL BIOL, V25, P754, DOI 10.1038/s41594-018-0122-9
   Izzotti Alberto, 2015, Microrna, V4, P3
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Lazar C., 2015, R PACKAGE VERSION 20
   Lazzarini R, 2018, AGING-US, V10, P3173, DOI 10.18632/aging.101624
   Li HJ, 2019, EXP CELL RES, V375, P10, DOI 10.1016/j.yexcr.2019.01.009
   Lopes-Paciencia S, 2019, CYTOKINE, V117, P15, DOI 10.1016/j.cyto.2019.01.013
   Macchioni L, 2018, BBA-MOL CELL BIOL L, V1863, P895, DOI 10.1016/j.bbalip.2018.04.021
   Macchioni L, 2017, SCI REP-UK, V7, DOI 10.1038/srep45569
   Minelli A, 2009, J CELL MOL MED, V13, P1149, DOI 10.1111/j.1582-4934.2008.00326.x
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Morris DR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103541
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Stout-Delgado HW, 2016, AM J RESP CELL MOL, V55, P252, DOI 10.1165/rcmb.2015-0222OC
   Tudor C, 2008, BIOCHEM J, V413, P405, DOI 10.1042/BJ20080018
   Usui-Ouchi A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158043
   Wang K, 2017, EXP CELL RES, V357, P335, DOI 10.1016/j.yexcr.2017.05.030
   Wei C, 2014, FREE RADICAL RES, V48, P282, DOI 10.3109/10715762.2013.865839
   Winkler BS, 1999, MOL VIS, V5
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 57
TC 7
Z9 7
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JAN
PY 2021
VL 10
IS 1
AR 25
DI 10.3390/antiox10010025
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA PV1QJ
UT WOS:000609768400001
PM 33383836
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Beer, AL
   Plank, T
   Greenlee, MW
AF Beer, Anton L.
   Plank, Tina
   Greenlee, Mark W.
TI Aging and central vision loss: Relationship between the cortical
   macro-structure and micro-structure
SO NEUROIMAGE
LA English
DT Article
DE Aging; Cortical surface; DTI; Macular degeneration; Neurodegeneration;
   Superficial white matter
ID BRAIN WHITE-MATTER; POSTERIOR CINGULATE CORTEX; MACULAR DEGENERATION;
   COGNITIVE IMPAIRMENT; VISUAL-CORTEX; RELAXATION RATES; WATER DIFFUSION;
   CEREBRAL-CORTEX; ESTIMATED IRON; 3.0 T
AB Aging and central vision loss are associated with cortical atrophies, but little is known about the relationship between cortical thinning and the underlying cellular structure. We compared the macro- and micro-structure of the cortical gray and superficial white matter of 38 patients with juvenile (JMD) or age-related (AMD) macular degeneration and 38 healthy humans (19-84 years) by multimodal MRI including diffusion-tensor imaging (DTI). A factor analysis showed that cortical thickness, tissue-dependent measures, and DTI-based measures were sensitive to distinct components of brain structure. Age-related cortical thinning and increased diffusion were observed across most of the cortex, but increased T1-weighted intensities (frontal), reduced T2-weighted intensities (occipital), and reduced anisotropy (medial) were limited to confined cortical regions. Vision loss was associated with cortical thinning and enhanced diffusion in the gray matter (less in the white matter) of the occipital central visual field representation. Moreover, AMD (but not JMD) patients showed enhanced diffusion in lateral occipito-temporal cortex and cortical thinning in the posterior cingulum. These findings demonstrate that changes in brain structure are best quantified by multimodal imaging. They further suggest that age-related brain atrophies (cortical thinning) reflect diverse micro-structural etiologies. Moreover, juvenile and age-related macular degeneration are associated with distinct patterns of micro-structural alterations.
C1 [Beer, Anton L.; Plank, Tina; Greenlee, Mark W.] Univ Regensburg, Inst Psychol, Univ Str 31, D-93053 Regensburg, Germany.
C3 University of Regensburg
RP Beer, AL (通讯作者)，Univ Regensburg, Inst Psychol, Univ Str 31, D-93053 Regensburg, Germany.
EM anton.beer@ur.de
OI Plank, Tina/0000-0001-5329-7037; Beer, Anton L./0000-0002-0297-6838
FU Deutsche Forschungsgemeinschaft [FOR 1075, GR 988-18/2]; Bayerische
   Forschungsstiftung; Elitenetzwerk Bayern
FX This work was supported by Deutsche Forschungsgemeinschaft [grant
   number: FOR 1075, GR 988-18/2], Bayerische Forschungsstiftung, and the
   Elitenetzwerk Bayern.
CR Ashtari M, 2011, J CLIN INVEST, V121, P2160, DOI 10.1172/JCI57377
   Bach M, 2014, NEUROIMAGE, V100, P358, DOI 10.1016/j.neuroimage.2014.06.021
   BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1
   Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022
   Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782
   Beer AL, 2011, EXP BRAIN RES, V213, P299, DOI 10.1007/s00221-011-2715-y
   Beer AL, 2009, EUR J NEUROSCI, V30, P703, DOI 10.1111/j.1460-9568.2009.06857.x
   Benson NC, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003538
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Brown DR, 2009, THESCIENTIFICWORLDJO, V9, P1061, DOI 10.1100/tsw.2009.111
   Burge WK, 2016, SCI REP-UK, V6, DOI 10.1038/srep23268
   Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041
   Camara E, 2007, NEUROIMAGE, V34, P1588, DOI 10.1016/j.neuroimage.2006.09.045
   Chang YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123656
   CLARKE S, 1994, EUR J NEUROSCI, V6, P725, DOI 10.1111/j.1460-9568.1994.tb00984.x
   Damoiseaux JS, 2009, HUM BRAIN MAPP, V30, P1051, DOI 10.1002/hbm.20563
   de Brabander JM, 1998, EUR J NEUROSCI, V10, P1261
   Draganski B, 2011, NEUROIMAGE, V55, P1423, DOI 10.1016/j.neuroimage.2011.01.052
   Eastwood S L, 2003, Mol Psychiatry, V8, P821, DOI 10.1038/sj.mp.4001399
   Eastwood SL, 2003, MOL PSYCHIATR, V8, P821, DOI 10.1038/sj.mp.4001371
   Ennis DB, 2006, MAGN RESON MED, V55, P136, DOI 10.1002/mrm.20741
   Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021
   Furntratt E., 1969, DIAGNOSTICA, V15, P62
   Gelman N, 1999, RADIOLOGY, V210, P759, DOI 10.1148/radiology.210.3.r99fe41759
   Gelman N, 2001, MAGNET RESON MED, V45, P71, DOI 10.1002/1522-2594(200101)45:1<71::AID-MRM1011>3.0.CO;2-2
   Govindan RM, 2013, EPILEPSIA, V54, P667, DOI 10.1111/epi.12129
   Grady C, 2012, NAT REV NEUROSCI, V13, P491, DOI 10.1038/nrn3256
   Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036
   Helenius J, 2002, AM J NEURORADIOL, V23, P194
   Hernowo AT, 2014, CORTEX, V56, P99, DOI 10.1016/j.cortex.2013.01.003
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Ikram MK, 2012, J NEUROL NEUROSUR PS, V83, P917, DOI 10.1136/jnnp-2011-301628
   Jolliffe I., 2002, ENCY STAT BEHAV SCI, DOI 10.1007/b98835
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   KOENIG SH, 1991, MAGNET RESON MED, V20, P285, DOI 10.1002/mrm.1910200210
   Korogi Y, 1997, AM J NEURORADIOL, V18, P711
   Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162
   Lehmann M, 2010, J ALZHEIMERS DIS, V20, P587, DOI 10.3233/JAD-2010-1401
   Lemaitre H, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.07.013
   Suarez-Sola ML, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.007.2009
   Malania M, 2017, INVEST OPHTH VIS SCI, V58, P2939, DOI 10.1167/iovs.16-21191
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Minoshima S, 1997, ANN NEUROL, V42, P85, DOI 10.1002/ana.410420114
   NICHOLS NR, 1993, NEUROBIOL AGING, V14, P421, DOI 10.1016/0197-4580(93)90100-P
   Ogawa S, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14737
   Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009
   Pakkenberg B, 2003, EXP GERONTOL, V38, P95, DOI 10.1016/S0531-5565(02)00151-1
   Penke L, 2010, J NEUROSCI, V30, P7569, DOI 10.1523/JNEUROSCI.1553-10.2010
   Peters A, 2008, NEUROSCIENCE, V152, P970, DOI 10.1016/j.neuroscience.2007.07.014
   Peters A, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.011.2009
   Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Phillips OR, 2016, HUM BRAIN MAPP, V37, P1321, DOI 10.1002/hbm.23105
   Plank T, 2017, OPTOMETRY VISION SCI, V94, P297, DOI 10.1097/OPX.0000000000001047
   Plank T, 2013, HUM BRAIN MAPP, V34, P2607, DOI 10.1002/hbm.22088
   Plank T, 2011, NEUROIMAGE, V56, P1556, DOI 10.1016/j.neuroimage.2011.02.055
   Prins D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146684
   Prins D, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20404
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rooney WD, 2007, MAGN RESON MED, V57, P308, DOI 10.1002/mrm.21122
   Rosengarth K, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00428
   Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032
   Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786
   Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008
   Stevens J., 1996, APPL MULTIVARIATE ST
   Stuber C, 2014, NEUROIMAGE, V93, P95, DOI 10.1016/j.neuroimage.2014.02.026
   Sullivan EV, 2010, NEUROBIOL AGING, V31, P464, DOI 10.1016/j.neurobiolaging.2008.04.007
   Sykova E, 1998, EXP GERONTOL, V33, P837, DOI 10.1016/S0531-5565(98)00038-2
   Tang Y, 1997, NEUROBIOL AGING, V18, P609, DOI 10.1016/S0197-4580(97)00155-3
   VanEssen DC, 1997, J NEUROSCI, V17, P7079
   Walhovd KB, 2005, NEUROBIOL AGING, V26, P1261, DOI 10.1016/j.neurobiolaging.2005.05.020
   WELCH KMA, 1995, STROKE, V26, P1983, DOI 10.1161/01.STR.26.11.1983
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055
   Wu MJ, 2014, HUM BRAIN MAPP, V35, P2806, DOI 10.1002/hbm.22368
   Xu JQ, 2008, NMR BIOMED, V21, P928, DOI 10.1002/nbm.1307
   Yeatman JD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5932
   Yoshimine S, 2018, BRAIN STRUCT FUNCT, V223, P3889, DOI 10.1007/s00429-018-1702-5
   Zahr NM, 2009, NEUROIMAGE, V44, P1050, DOI 10.1016/j.neuroimage.2008.09.046
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
   Zheng WL, 2009, NEUROIMAGE, V48, P73, DOI 10.1016/j.neuroimage.2009.06.039
   Zhuang J, 2018, NEUROBIOL AGING, V63, P65, DOI 10.1016/j.neurobiolaging.2017.11.003
NR 83
TC 4
Z9 5
U1 1
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD MAY 15
PY 2020
VL 212
AR 116670
DI 10.1016/j.neuroimage.2020.116670
PG 14
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA LC4UF
UT WOS:000525320500001
PM 32088318
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lueck, K
   Carr, AJF
   Yu, L
   Greenwood, J
   Moss, SE
AF Lueck, Katharina
   Carr, Amanda-Jayne F.
   Yu, Lu
   Greenwood, John
   Moss, Stephen E.
TI Annexin A8 regulates Wnt signaling to maintain the phenotypic plasticity
   of retinal pigment epithelial cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BETA-CATENIN; GENE-EXPRESSION; STEM-CELLS; PATHWAY; ACTIVATION; ARPE-19;
   DIFFERENTIATION; ASSOCIATION; TRANSITION; GROWTH
AB Wnt signalling mediates complex cell-cellinteractions during development and proliferation. Annexin A8 (AnxA8), a calcium-dependent phospholipid-binding protein, and canonical Wnt signalling mechanisms have both been implicated in retinal pigment epithelial (RPE) cell differentiation. The aim here was to examine the possibility of cross-talk between AnxA8 and Wnt signalling, as both are down-regulated upon fenretinide (FR)-mediated RPE transdifferentiation. AnxA8 suppression in RPE cells via siRNA or administration of FR induced neuronal-like cell transdifferentiation and reduced expression of Wnt-related genes, as measured by real-time PCR and western blotting. AnxA8 gene expression, on the other hand, remained unaltered upon manipulating Wnt signalling, suggesting Wnt-related genes to be downstream effectors of AnxA8. Co-immunoprecipitation revealed an interaction between AnxA8 and beta -catenin, which was reduced in the presence of activated TGF-beta 1. TGF-beta 1 signalling also reversed the AnxA8 loss-induced cell morphology changes, and induced beta -catenin translocation and GSK-3 beta phosphorylation in the absence of AnxA8. Ectopic over-expression of AnxA8 led to an increase in active beta -catenin and GSK-3 beta phosphorylation. These data demonstrate an important role for AnxA8 as a regulator of Wnt signalling and a determinant of RPE phenotype, with implications for regenerative medicine approaches that utilise stem cell-derived RPE cells to treat conditions such as age-related macular degeneration.
C1 [Lueck, Katharina; Carr, Amanda-Jayne F.; Greenwood, John; Moss, Stephen E.] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Yu, Lu] PAREXEL Int, 101-105 Oxford Rd, Uxbridge UB8 1LZ, Middx, England.
C3 University of London; University College London; Parexel International
RP Moss, SE (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM s.moss@ucl.ac.uk
RI Carr, Amanda/ABG-6282-2020
OI Carr, Amanda/0000-0002-5469-0030; Greenwood, John/0000-0003-4496-2984
FU Biotechnology and Biological Sciences Research Council UK
   [BB/I019707/1]; Guide Dogs for the Blind [2005-03b]; BBSRC
   [BB/I019707/1] Funding Source: UKRI
FX This work was funded by grants to SEM from the Biotechnology and
   Biological Sciences Research Council (BB/I019707/1) UK and to JG and SEM
   from Guide Dogs for the Blind (2005-03b). We are grateful to Dr Peter
   Munro and Dr Matt Hayes for assistance with the confocal microscopy.
CR Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Angbohang A, 2016, STEM CELLS DEV, V25, P1, DOI 10.1089/scd.2015.0262
   Baarsma HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025450
   Benelli R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-142
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Caraci F, 2008, PHARMACOL RES, V57, P274, DOI 10.1016/j.phrs.2008.02.001
   Carr AJ, 2011, MOL VIS, V17, P1701
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chen SY, 2003, J NEUROCHEM, V84, P972, DOI 10.1046/j.1471-4159.2003.01608.x
   Crotti TN, 2011, J CELL PHYSIOL, V226, P3413, DOI 10.1002/jcp.22699
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Dale TC, 1998, BIOCHEM J, V329, P209
   De Angelis MT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0028-1
   DiRenzo DM, 2016, CELL SIGNAL, V28, P498, DOI 10.1016/j.cellsig.2016.02.011
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Foltz LP, 2017, J VIS EXP, V30, P128
   Han JW, 2015, INVEST OPHTH VIS SCI, V56, P8314, DOI 10.1167/iovs.15-18359
   Hata H, 2014, MOL CARCINOGEN, V53, P181, DOI 10.1002/mc.21961
   Hazim RA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0652-9
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kim H, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/459301
   Kim JH, 2015, BMB REP, V48, P525, DOI 10.5483/BMBRep.2015.48.9.140
   Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Lim YC, 2012, EUR J CANCER, V48, P3310, DOI 10.1016/j.ejca.2012.04.013
   LIU JH, 1994, LEUKEMIA LYMPHOMA, V13, P381, DOI 10.3109/10428199409049626
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lueck K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03493-3
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Monteiro MC, 2009, STEM CELLS DEV, V18, P457, DOI 10.1089/scd.2008.0154
   Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602
   Samuel W, 2017, MOL VIS, V23, P60
   Tian XR, 2013, J CELL SCI, V126, P67, DOI 10.1242/jcs.103036
   Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943
   Wang CY, 2014, BIOCHEM PHARMACOL, V88, P86, DOI 10.1016/j.bcp.2013.12.021
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Xu ZJ, 2016, P NATL ACAD SCI USA, V113, pE6382, DOI 10.1073/pnas.1613849113
   Zheng GP, 2009, AM J PATHOL, V175, P580, DOI 10.2353/ajpath.2009.080983
   Zhu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101748
   Zhu XF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143255
NR 43
TC 6
Z9 6
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 27
PY 2020
VL 10
IS 1
AR 1256
DI 10.1038/s41598-020-58296-w
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NA7LK
UT WOS:000559998100003
PM 31988387
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Juzwik, CA
   Drake, SS
   Zhang, Y
   Paradis-Isler, N
   Sylvester, A
   Amar-Zifkin, A
   Douglas, C
   Morquette, B
   Moore, CS
   Fournier, AE
AF Juzwik, Camille A.
   Drake, Sienna S.
   Zhang, Yang
   Paradis-Isler, Nicolas
   Sylvester, Alexandra
   Amar-Zifkin, Alexandre
   Douglas, Chelsea
   Morquette, Barbara
   Moore, Craig S.
   Fournier, Alyson E.
TI microRNA dysregulation in neurodegenerative diseases: A systematic
   review
SO PROGRESS IN NEUROBIOLOGY
LA English
DT Review
DE Micro RNA; MiRNA; Neurodegenerative disease; Neurodegeneration
ID NF-KAPPA-B; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PROGENITOR-CELL
   PROLIFERATION; MULTIPLE-SCLEROSIS; MIRNA EXPRESSION; SPINAL-CORD;
   INFLAMMATORY RESPONSES; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; PROMOTES
AB While the root causes for individual neurodegenerative diseases are distinct, many shared pathological features and mechanisms contribute to neurodegeneration across diseases. Altered levels of microRNAs, small non-coding RNAs involved in post transcriptional regulation of gene expression, are reported for numerous neurodegenerative diseases. Yet, comparison between diseases to uncover commonly dysregulated microRNAs during neurodegeneration in general is lagging. We performed a systematic review of peer-reviewed publications describing differential microRNA expression in neurodegenerative diseases and related animal models. We compiled the results from studies covering the prevalent neurodegenerative diseases in the literature: Alzheimer's disease, amyotrophic lateral sclerosis, age-related macular degeneration, ataxia, dementia, myotonic dystrophy, epilepsy, glaucoma, Huntington's disease, multiple sclerosis, Parkinson's disease, and prion disorders. MicroRNAs which were dysregulated most often in these diseases and their models included miR-9-5p, miR-21-5p, the miR-29 family, miR-132-3p, miR-124-3p, miR-146a-5p, miR-155-5p, and miR-223-3p. Common pathways targeted by these predominant miRNAs were identified and revealed great functional overlap across diseases. We also identified a strong role for each microRNA in both the neural and immune components of diseases. microRNAs regulate broad networks of genes and identifying microRNAs commonly dysregulated across neurodegenerative diseases could cultivate novel hypotheses related to common molecular mechanisms underlying neurodegeneration.
C1 [Juzwik, Camille A.; Drake, Sienna S.; Zhang, Yang; Paradis-Isler, Nicolas; Sylvester, Alexandra; Morquette, Barbara; Fournier, Alyson E.] McGill Univ, Montreal Neurol Inst, 3801 Univ St,Room BT 109, Montreal, PQ H3A 2B4, Canada.
   [Amar-Zifkin, Alexandre] McGill Univ, Hlth Ctr Med Lib, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.
   [Douglas, Chelsea] Plotly Technol Inc, Program Manager, 5555 Gaspe Ave 118, Montreal, PQ H2T 2A3, Canada.
   [Moore, Craig S.] Mem Univ Newfoundland, Div BioMed Sci, Fac Med, St John, NF, Canada.
C3 McGill University; McGill University; Memorial University Newfoundland
RP Fournier, AE (通讯作者)，McGill Univ, Montreal Neurol Inst, 3801 Univ St,Room BT 109, Montreal, PQ H3A 2B4, Canada.
EM camille.juzwik@mail.mcgill.ca; sienna.drake@mail.mcgill.ca;
   yang.zhang5@mail.mcgill.ca; nicolas.paradis-isler@mcgill.ca;
   alexandra.sylvester@queensu.ca; alex.amar@muhc.mcgill.ca;
   cldougl@gmail.com; barbara.morquette@mcgill.ca; craig.moore@mun.ca;
   alyson.fournier@mcgill.ca
OI Drake, Sienna/0000-0001-7537-3520; Amar-Zifkin,
   Alexandre/0000-0002-1196-5209; Paradis-Isler,
   Nicolas/0000-0001-8832-0110
CR Akhtar S, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/309510
   Aung LL, 2015, MULT SCLER J, V21, P1131, DOI 10.1177/1352458514560923
   Barker-Haliski M, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a022863
   Bergman P, 2013, J IMMUNOL, V190, P4066, DOI 10.4049/jimmunol.1200728
   Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   Burgos K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094839
   Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304
   Caillet-Boudin ML, 2014, FRONT MOL NEUROSCI, V6, DOI [10.3389/fnmo1.2013.00057, 10.3389/fnmol.2013.00057]
   Cantoni C, 2017, ACTA NEUROPATHOL, V133, P61, DOI 10.1007/s00401-016-1621-6
   Chang A, 2008, BRAIN, V131, P2366, DOI 10.1093/brain/awn157
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Cheng HYM, 2007, NEURON, V54, P813, DOI 10.1016/j.neuron.2007.05.017
   Cheng SS, 2014, INT J BIOCHEM CELL B, V57, P186, DOI 10.1016/j.biocel.2014.10.029
   Chi LY, 2006, STEM CELLS, V24, P34, DOI 10.1634/stemcells.2005-0076
   Chmielarz P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.214
   Chu-Tan JA, 2018, INVEST OPHTH VIS SCI, V59, P4094, DOI 10.1167/iovs.18-24623
   Colby DW, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a006833
   Cuellar TL, 2008, P NATL ACAD SCI USA, V105, P5614, DOI 10.1073/pnas.0801689105
   Cui GH, 2018, FASEB J, V32, P654, DOI 10.1096/fj.201700600R
   Cui JG, 2010, J BIOL CHEM, V285, P38951, DOI 10.1074/jbc.M110.178848
   Damiani D, 2008, J NEUROSCI, V28, P4878, DOI 10.1523/JNEUROSCI.0828-08.2008
   Danilov AI, 2006, EUR J NEUROSCI, V23, P394, DOI 10.1111/j.1460-9568.2005.04563.x
   Dolati S, 2018, BIOMED PHARMACOTHER, V104, P280, DOI 10.1016/j.biopha.2018.05.050
   Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24
   Du XX, 2017, TOXICOL LETT, V280, P195, DOI 10.1016/j.toxlet.2017.08.082
   Dutta R, 2013, ANN NEUROL, V73, P637, DOI 10.1002/ana.23860
   Dutta R, 2011, PROG NEUROBIOL, V93, P1, DOI 10.1016/j.pneurobio.2010.09.005
   Ellrichmann G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/541259
   Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023
   Fiorenza A, 2016, CEREB CORTEX, V26, P1619, DOI 10.1093/cercor/bhu332
   Flamand MN, 2017, NUCLEIC ACIDS RES, V45, P7212, DOI 10.1093/nar/gkx340
   Fu YW, 2017, DNA CELL BIOL, V36, P482, DOI 10.1089/dna.2017.3643
   Fuller-Carter PI, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1772-1
   Gascon E, 2014, NAT MED, V20, P1444, DOI 10.1038/nm.3717
   Gerrard B, 2017, NEUROSCIENCE, V359, P299, DOI 10.1016/j.neuroscience.2017.07.033
   Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045
   Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016
   Guan YJ, 2007, J NEUROCHEM, V102, P1125, DOI 10.1111/j.1471-4159.2007.04610.x
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hanieh H, 2013, EUR J IMMUNOL, V43, P2771, DOI 10.1002/eji.201343486
   Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109
   Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943
   He Y, 2018, CELL PHYSIOL BIOCHEM, V45, P973, DOI 10.1159/000487292
   Hebert SS, 2010, HUM MOL GENET, V19, P3959, DOI 10.1093/hmg/ddq311
   Hecker M, 2013, INT J MOL SCI, V14, P16087, DOI 10.3390/ijms140816087
   Henshall DC, 2016, LANCET NEUROL, V15, P1368, DOI 10.1016/S1474-4422(16)30246-0
   Hu RZ, 2013, J IMMUNOL, V190, P5972, DOI 10.4049/jimmunol.1300351
   Ifergan I, 2016, J IMMUNOL, V196, P1455, DOI 10.4049/jimmunol.1501965
   Iida A, 2011, INVEST OPHTH VIS SCI, V52, P3008, DOI 10.1167/iovs.10-6428
   Ingwersen J, 2015, ANN CLIN TRANSL NEUR, V2, P43, DOI 10.1002/acn3.152
   Iyer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044789
   Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607
   Juzwik CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31542-y
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kempf SJ, 2016, ONCOTARGET, V7, P33627, DOI 10.18632/oncotarget.9092
   Kim GH, 2015, EXP NEUROBIOL, V24, P325, DOI 10.5607/en.2015.24.4.325
   Kong Y, 2015, CURR MOL MED, V15, P980, DOI 10.2174/1566524016666151123114608
   Koval ED, 2013, HUM MOL GENET, V22, P4127, DOI 10.1093/hmg/ddt261
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Ksiazek-Winiarek D., 2017, J MOL NEUROSCI, V23, P23
   Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6
   Lau P, 2013, EMBO MOL MED, V5, P1613, DOI 10.1002/emmm.201201974
   Lewkowicz P, 2015, J NEUROSCI, V35, P7521, DOI 10.1523/JNEUROSCI.4794-14.2015
   Li B, 2017, J CLIN INVEST, V127, P3702, DOI 10.1172/JCI94012
   Li T, 2010, NAT IMMUNOL, V11, P799, DOI 10.1038/ni.1918
   Li YY, 2011, NEUROSCI LETT, V487, P94, DOI 10.1016/j.neulet.2010.09.079
   Liang H, 2007, RNA, V13, P1402, DOI 10.1261/rna.634607
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Liu T, 2015, NEURAL REGEN RES, V10, P786, DOI 10.4103/1673-5374.156978
   Lopez-Ramirez MA, 2014, FASEB J, V28, P2551, DOI 10.1096/fj.13-248880
   Lykhmus O, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00019
   Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073
   Magill ST, 2010, P NATL ACAD SCI USA, V107, P20382, DOI 10.1073/pnas.1015691107
   Magner WJ, 2016, J NEUROIMMUNOL, V292, P68, DOI 10.1016/j.jneuroim.2016.01.009
   Mameli G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157153
   Marcuzzo S, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0095-0
   Marcuzzo S, 2014, EXP NEUROL, V253, P91, DOI 10.1016/j.expneurol.2013.12.007
   Matias-Guiu JA, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00053
   McKiernan RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035921
   Mehta A, 2013, EUR J PHARMACOL, V698, P6, DOI 10.1016/j.ejphar.2012.10.032
   Miyazaki Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109041
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967
   Morquette B., 2018, BIORXIV
   Murugaiyan G, 2015, J CLIN INVEST, V125, P1069, DOI 10.1172/JCI74347
   Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952
   Mycko MP, 2015, J NEUROSCI, V35, P16504, DOI 10.1523/JNEUROSCI.2830-15.2015
   Nakahama T, 2013, P NATL ACAD SCI USA, V110, P11964, DOI 10.1073/pnas.1311087110
   Nelson PT, 2008, BRAIN PATHOL, V18, P130, DOI 10.1111/j.1750-3639.2007.00120.x
   O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009
   Orr HT, 2012, J CELL BIOL, V197, P167, DOI 10.1083/jcb.201105092
   Packer AN, 2008, J NEUROSCI, V28, P14341, DOI 10.1523/JNEUROSCI.2390-08.2008
   Papadopoulou AS, 2015, NEUROBIOL DIS, V73, P275, DOI 10.1016/j.nbd.2014.10.006
   Plemel JR, 2015, MULT SCLER J, V21, P1485, DOI 10.1177/1352458515601513
   Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266
   Roshan R, 2014, RNA, V20, P1287, DOI 10.1261/rna.044008.113
   Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066
   Salta E., 2016, EMBO MOL MED
   Saraiva C, 2016, J CONTROL RELEASE, V235, P291, DOI 10.1016/j.jconrel.2016.06.005
   Satoorian T, 2016, IMMUNOLOGY, V148, P326, DOI 10.1111/imm.12611
   Schmitz U, 2014, NUCLEIC ACIDS RES, V42, P7539, DOI 10.1093/nar/gku465
   Schonrock N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011070
   Schwienbacher C, 2017, J MOL NEUROSCI, V62, P244, DOI 10.1007/s12031-017-0926-9
   Serafin A, 2015, NEUROLOGY, V84, P645, DOI 10.1212/WNL.0000000000001258
   Shaked I, 2009, IMMUNITY, V31, P965, DOI 10.1016/j.immuni.2009.09.019
   Shalgi R, 2007, PLOS COMPUT BIOL, V3, P1291, DOI 10.1371/journal.pcbi.0030131
   Shin D, 2009, ANN NEUROL, V66, P843, DOI 10.1002/ana.21927
   Smith KM, 2012, J IMMUNOL, V189, P1567, DOI 10.4049/jimmunol.1103171
   Smith PY, 2015, HUM MOL GENET, V24, P6721, DOI 10.1093/hmg/ddv377
   Soreq H, 2011, TRENDS MOL MED, V17, P548, DOI 10.1016/j.molmed.2011.06.009
   Srinivasan M, 2015, EXPERT OPIN THER TAR, V19, P471, DOI 10.1517/14728222.2014.989834
   Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423
   Strong MJ, 2010, J NEUROL SCI, V288, P1, DOI 10.1016/j.jns.2009.09.029
   Su CH, 2016, BRAIN RES, V1644, P98, DOI 10.1016/j.brainres.2016.05.011
   Su WR, 2017, J MOL CELL BIOL, V9, P289, DOI 10.1093/jmcb/mjx022
   Sundermeier TR, 2017, J BIOL CHEM, V292, P3366, DOI 10.1074/jbc.M116.770024
   Sundermeier TR, 2014, FASEB J, V28, P3780, DOI 10.1096/fj.14-254292
   Swarbrick S., 2019, MOL NEUROBIOL
   Tan SL, 2012, GENES CELLS, V17, P952, DOI 10.1111/gtc.12009
   Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5
   Tao JF, 2011, J NEUROSCI, V31, P8306, DOI 10.1523/JNEUROSCI.0567-11.2011
   Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016
   Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3
   Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102
   Wang HQ, 2016, BRAIN PATHOL, V26, P167, DOI 10.1111/bpa.12267
   Wang WX, 2011, ACTA NEUROPATHOL, V121, P193, DOI 10.1007/s00401-010-0756-0
   Wang X, 2018, BIOL PSYCHIAT, V83, P395, DOI 10.1016/j.biopsych.2017.07.023
   Weinberg RB, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00430
   Winner B, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a021287
   Winner B, 2011, EUR J NEUROSCI, V33, P1139, DOI 10.1111/j.1460-9568.2011.07613.x
   Wong HKA, 2013, HUM MOL GENET, V22, P3077, DOI 10.1093/hmg/ddt164
   Wu DS, 2015, J CEREBR BLOOD F MET, V35, P412, DOI 10.1038/jcbfm.2014.207
   Yao LP, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1053-4
   Zhang JM, 2015, AIP CONF PROC, V1648, DOI 10.1063/1.4912370
   Zhang J, 2017, NEUROSCIENCE, V348, P252, DOI 10.1016/j.neuroscience.2017.02.029
   Zhang J, 2014, J NEUROIMMUNOL, V266, P56, DOI 10.1016/j.jneuroim.2013.09.019
   Zhang JY, 2014, INT IMMUNOL, V26, P407, DOI 10.1093/intimm/dxu043
   Zhao C, 2009, NAT STRUCT MOL BIOL, V16, P365, DOI 10.1038/nsmb.1576
   Zhou FH, 2013, INT J CLIN EXP PATHO, V6, P1826
   Zhou WQ, 2018, CELL REP, V22, P1810, DOI 10.1016/j.celrep.2018.01.058
   Zhou YJ, 2019, J ALZHEIMERS DIS, V67, P571, DOI 10.3233/JAD-181053
NR 143
TC 168
Z9 170
U1 20
U2 120
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-0082
EI 1873-5118
J9 PROG NEUROBIOL
JI Prog. Neurobiol.
PD NOV
PY 2019
VL 182
AR 101664
DI 10.1016/j.pneurobio.2019.101664
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA LD3HP
UT WOS:000525924000005
PM 31356849
OA Green Submitted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Krishna, BVS
   Gnanasekaran, T
AF Krishna, B. V. Santhosh
   Gnanasekaran, T.
TI Unsupervised Automated Retinal Vessel Extraction Framework Using
   Enhanced Filtering and Hessian Based Method with Hysteresis Thresholding
SO JOURNAL OF MEDICAL IMAGING AND HEALTH INFORMATICS
LA English
DT Article
DE Automated; Contrast Enhancement; Fundus; Framework; Hessian; Hysteresis;
   Segmentation; Retinal Vessels; Pathologies; Unsupervised
ID BLOOD-VESSELS; MATCHED-FILTER; SEGMENTATION; IMAGES; CLASSIFICATION
AB The retinal blood vessels act as a diagnostic indicator of several severe pathologies like Diabetes, Hypertension, and Stroke. Fundus photograph is the most common modality for examination of eyes. Medical experts use fundus examination during eye diagnosis. However, the quality as well as resolution of fundus images are rapidly increasing, resulting in many challenges. In this paper, an unsupervised automated framework for the extraction of retinal vessels by using enhanced filtering and hessian-based method with hysteresis thresholding is presented. In this framework, we have considered two publicly available datasets, DRIVE and DR-HAGIS consisting of more pathological high-resolution images for experimentation. In this framework, there are four major phases: (i) Pre-processing phase for the extraction of green channel and contrast enhancement; (ii) Vessel enhancement phase for enhancement of wide and thin vessels; (iii) Vessel detection phase for the extraction of vessels; (iv) Post-processing phase for filling the holes and to remove isolated pixels. Our method achieves 0.9601 accuracy on DRIVE dataset and 0.9484, 0.9496, 0.9487, 0.9480 on DR-HAGIS with Glaucoma, Hypertension, Diabetic Retinopathy, Age-Related Macular Degeneration (AMD) images respectively. Our results manifest that the proposed framework performs fine at extracting blood vessels from pathological images in addition to healthy retinal images and is comparable with existing methods.
C1 [Krishna, B. V. Santhosh] Velammal Inst Technol, Elect & Commun Engn, Chennai 601204, Tamil Nadu, India.
   [Gnanasekaran, T.] RMK Engn Coll, Informat Technol, Chennai 601206, Tamil Nadu, India.
C3 R.M.K. Engineering College
RP Krishna, BVS (通讯作者)，Velammal Inst Technol, Elect & Commun Engn, Chennai 601204, Tamil Nadu, India.
RI B V, santhosh krishna/X-3035-2019; Thangavel, Gnanasekaran/M-7750-2019;
   V, SANTHOSH KRISHNA B/Q-3448-2019
OI B V, santhosh krishna/0000-0002-1919-4031; Thangavel,
   Gnanasekaran/0000-0003-4005-6482; 
CR Azzopardi G, 2015, MED IMAGE ANAL, V19, P46, DOI 10.1016/j.media.2014.08.002
   BahadarKhan K, 2016, PLOS ONE, V1, P1
   Ben Abdallah M, 2015, INT J BIOMED IMAGING, V2015, DOI 10.1155/2015/519024
   Budai A, 2013, INT J BIOMED IMAGING, V2013, DOI 10.1155/2013/154860
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Cheng EK, 2014, MACH VISION APPL, V25, P1779, DOI 10.1007/s00138-014-0638-x
   Christodoulidis A, 2016, COMPUT MED IMAG GRAP, V52, P28, DOI 10.1016/j.compmedimag.2016.06.001
   Condurach A.P, 2005, P IAPR C MACH VIS AP, P1
   Dash J., 2018, P 2 INT C INV SYST C, P932
   Deepak Venkatesh S., 2018, INT J APPL EVOLUTION, V9, P1
   Elbalaoui A, 2016, I C COMP GRAPH IM VI, P324, DOI 10.1109/CGiV.2016.69
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Fraz MM, 2012, IEEE T BIO-MED ENG, V59, P2538, DOI 10.1109/TBME.2012.2205687
   Fu XP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096001
   Goldbaum M, 1996, INTERNATIONAL CONFERENCE ON IMAGE PROCESSING, PROCEEDINGS - VOL III, P695, DOI 10.1109/ICIP.1996.560760
   Grisan E, 2003, P ANN INT IEEE EMBS, V25, P890, DOI 10.1109/IEMBS.2003.1279908
   Haddouche A, 2010, DIGIT SIGNAL PROCESS, V20, P149, DOI 10.1016/j.dsp.2009.06.005
   Heneghan C, 2002, MED IMAGE ANAL, V6, P407, DOI 10.1016/S1361-8415(02)00058-0
   Holm S, 2017, J MED IMAGING, V4, DOI 10.1117/1.JMI.4.1.014503
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Kande GB, 2010, J MED SYST, V34, P849, DOI 10.1007/s10916-009-9299-0
   Kipli K., 2018, INT J ENG TECHNOL, V7, P16, DOI [10.14419/ijet.v7i3.18.16665, DOI 10.14419/IJET.V7I3.18.16665]
   Kovacs G, 2016, MED IMAGE ANAL, V29, P24, DOI 10.1016/j.media.2015.12.003
   Krause M, 2016, J REAL-TIME IMAGE PR, V11, P413, DOI 10.1007/s11554-013-0342-5
   Li QL, 2016, IEEE T MED IMAGING, V35, P109, DOI 10.1109/TMI.2015.2457891
   Marin D, 2011, IEEE T MED IMAGING, V30, P146, DOI 10.1109/TMI.2010.2064333
   Masooomi R., 2014, IR C INT SYST ICIS I, P1
   Mendonca AM, 2006, IEEE T MED IMAGING, V25, P1200, DOI 10.1109/TMI.2006.879955
   Odstrcilik J, 2009, IFMBE PROC, V25, P327, DOI 10.1007/978-3-642-03891-4_87
   Odstrcilik J, 2013, IET IMAGE PROCESS, V7, P373, DOI 10.1049/iet-ipr.2012.0455
   Otsu N., 1979, AUTOMATICA, V11, P23, DOI DOI 10.1109/TSMC.1979.4310076
   Rahebi J, 2014, J MED SYST, V38, DOI 10.1007/s10916-014-0085-2
   Reza AM, 2004, J VLSI SIG PROC SYST, V38, P35, DOI 10.1023/B:VLSI.0000028532.53893.82
   Ricci E, 2007, IEEE T MED IMAGING, V26, P1357, DOI 10.1109/TMI.2007.898551
   Roychowdhury S, 2015, IEEE T BIO-MED ENG, V62, P1738, DOI 10.1109/TBME.2015.2403295
   Sigurdsson E. M., 2013, PATTERN RECOGN, V47, P164
   Singh NP, 2016, COMPUT METH PROG BIO, V129, P40, DOI 10.1016/j.cmpb.2016.03.001
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   Sofka M, 2006, IEEE T MED IMAGING, V25, P1531, DOI 10.1109/TMI.2006.884190
   Sophan Mochammad Kautsar, 2014, INT J ADV COMPUTATIO, V2, P1
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Szpak Z. L., 2008, S AFRICAN COMPUTER J, V40, P23
   Teng T, 2002, MED BIOL ENG COMPUT, V40, P2, DOI 10.1007/BF02347689
   Truc PTH, 2009, COMPUT VIS IMAGE UND, V113, P101, DOI 10.1016/j.cviu.2008.07.009
   Vega R, 2015, COMPUT BIOL MED, V58, P20, DOI 10.1016/j.compbiomed.2014.12.016
   Wang YF, 2013, PATTERN RECOGN, V46, P2117, DOI 10.1016/j.patcog.2012.12.014
   Yan ZQ, 2019, IEEE J BIOMED HEALTH, V23, P1427, DOI 10.1109/JBHI.2018.2872813
   Yin BJ, 2015, MED IMAGE ANAL, V26, P232, DOI 10.1016/j.media.2015.09.002
   Zhang B, 2010, COMPUT BIOL MED, V40, P438, DOI 10.1016/j.compbiomed.2010.02.008
   Zhu D, 2012, 13 ACIS INT C SOFTW, P135
   Zhu HQ, 2004, 2004 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH, AND SIGNAL PROCESSING, VOL III, PROCEEDINGS, P509
NR 51
TC 2
Z9 2
U1 0
U2 9
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 2156-7018
EI 2156-7026
J9 J MED IMAG HEALTH IN
JI J. Med. Imaging Health Inform.
PD JUN
PY 2019
VL 9
IS 5
BP 1000
EP 1010
DI 10.1166/jmihi.2019.2687
PG 11
WC Mathematical & Computational Biology; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology; Radiology, Nuclear Medicine &
   Medical Imaging
GA HT4GR
UT WOS:000464522500024
DA 2022-11-30
ER

PT J
AU Pilotto, E
   Frizziero, L
   Daniele, AR
   Convento, E
   Longhin, E
   Guidolin, F
   Parrozzani, R
   Cavarzeran, F
   Midena, E
AF Pilotto, Elisabetta
   Frizziero, Luisa
   Daniele, Anna Rita
   Convento, Enrica
   Longhin, Evelyn
   Guidolin, Francesca
   Parrozzani, Raffaele
   Cavarzeran, Fabiano
   Midena, Edoardo
TI Early OCT angiography changes of type 1 CNV in exudative AMD treated
   with anti-VEGF
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY-ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   QUANTITATIVE-ANALYSIS; THERAPY; RPE
AB Aims To investigate, with optical coherence tomography angiography (OCTA), short-term changes of type 1 choroidal neovascularisation (CNV), secondary to exudative age-related macular degeneration, after anti-vascular endothelial growth factor (VEGF) treatment.
   Methods Patients affected by type 1 CNV treated with intravitreal anti-VEGF were consecutively enrolled. All patients underwent OCTA examination before and 48 hours after anti-VEGF treatment. Quantitative and qualitative vascular and morphological macular changes were evaluated.
   Results Sixteen eyes were included (11 treated with aflibercept and 5 with ranibizumab). Both CNV mean area and pigment epithelium detachment significantly reduced (p= 0.0004 and p= 0.0007, respectively) after treatment. Cystoid macular oedema (four eyes) decreased in all cases. Neuroretinal detachment (13 eyes) decreased in 85% of cases (11 eyes). Fine CNV vessels density decreased in 75% (12 eyes), whereas larger CNV vessels density remained stable in 66.7% (10 eyes), choroidal flow void signal (7 eyes at baseline) increased in 42.9% (3 eyes) of them and remained stable in 57.1% (4 eyes). Interoperator reproducibility for OCT examination was good for all measurements (intraclass correlation coefficient> 0.65).
   Conclusion Early remodelling of type 1 CNV network after treatment may be non-invasively and reproducibly analysed by means of OCTA. Choroidal perfusion impairment, choroidal flow void signal, surrounding CNV may change during treatment.
C1 [Pilotto, Elisabetta; Daniele, Anna Rita; Convento, Enrica; Longhin, Evelyn; Guidolin, Francesca; Parrozzani, Raffaele; Cavarzeran, Fabiano; Midena, Edoardo] Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
   [Frizziero, Luisa; Midena, Edoardo] IRCCS, GB Bietti Fdn, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
EM edoardo.midena@unipd.it
RI Parrozzani, Raffaele/W-3341-2017; Frizziero, Luisa/AAB-3249-2020;
   parrozzani, raffaele/K-2034-2016; Midena, Edoardo/AAB-6010-2020
OI Parrozzani, Raffaele/0000-0003-0216-727X; parrozzani,
   raffaele/0000-0003-0216-727X; 
FU Fondazione Roma; Ministry of Health
FX The research contribution by the G. B. Bietti Foundation was supported
   by Fondazione Roma and Ministry of Health.
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Miyata M, 2016, AM J OPHTHALMOL, V165, P108, DOI 10.1016/j.ajo.2016.03.009
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Pauleikhoff LJB, 2017, OPHTHALMOLOGE
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Weng SS, 2016, OPHTHALMOLOGICA, V236, P114, DOI 10.1159/000448630
NR 19
TC 15
Z9 17
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2019
VL 103
IS 1
BP 67
EP 71
DI 10.1136/bjophthalmol-2017-311752
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IC9BI
UT WOS:000471275800011
PM 29567794
DA 2022-11-30
ER

PT J
AU Ersoz, MG
   Karacorlu, M
   Arf, S
   Muslubas, IS
   Hocaoglu, M
AF Ersoz, Mehmet Giray
   Karacorlu, Murat
   Arf, Serra
   Muslubas, Isil Sayman
   Hocaoglu, Mumin
TI Retinal pigment epithelium tears: Classification, pathogenesis,
   predictors, and management
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; antivascular endothelial growth
   factor; bullous central serous chorioretinopathy microrips; retinal
   pigment epithelial detachment; retinal pigment epithelium rip; retinal
   pigment epithelium tear
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL BEVACIZUMAB INJECTION;
   GROWTH-FACTOR THERAPY; ANTI-VEGF THERAPY; CENTRAL SEROUS
   CHORIORETINOPATHY; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   CLINICOPATHOLOGICAL CORRELATION; FUNDUS AUTOFLUORESCENCE; RPE TEARS
AB Various eye conditions cause tears in the retinal pigment epithelium (RPE). The most common cause of a RPE tear is vascularized retinal pigment epithelial detachment (PED) in patients with exudative age-related macular degeneration. Although RPE tears can develop spontaneously in vascularized PEDs, most recent cases have been associated with anti vascular endothelial growth factor (VEGF) injections. The subretinal fluid within the PED applies hydrostatic pressure to the RPE and stretches it. The PED enlarges as the hydrostatic pressure increases. Contraction of the choroidal neovascular membrane adds tractional forces to the RPE monolayer. Especially in larger PEDs, the risk of a RPE tear increases after anti-VEGF therapy owing to increasing contraction of the choroidal neovascular membrane. The risk factors and predictors defined by retinal imaging can contribute to prevention of RPE tears, and modified therapies can be used for patients at most risk; however, there is no proven method for prevention of RPE tears. After tear formation, in the presence of an active choroidal neovascular membrane, anti-VEGF should be repeated until the underlying disease has been suppressed. When the subretinal fluid is present for more than 6 months, the denuded area is covered with thickened fibrotic tissue. We review the literature to describe the classification, epidemiology, mechanisms of development, and repair of RPE tears, diagnosis, risk factors and predictors, prevention, and management. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Ersoz, Mehmet Giray; Karacorlu, Murat; Arf, Serra; Muslubas, Isil Sayman; Hocaoglu, Mumin] Istanbul Retina Inst, Hakki Yeten Cad Unimed Ctr 19-7 Fulya Sisli, TR-34349 Istanbul, Turkey.
C3 Istanbul Retina Enstitusu
RP Karacorlu, M (通讯作者)，Istanbul Retina Inst, Hakki Yeten Cad Unimed Ctr 19-7 Fulya Sisli, TR-34349 Istanbul, Turkey.
EM mkaracorlu@gmail.com
RI Karaçorlu, Murat/AFK-0782-2022; muslubas, isil sayman/B-3948-2019;
   Karaçorlu, Murat/AAF-7763-2022; Hocaoglu, Mumin/B-5999-2017; Ersöz,
   Mehmet Giray/B-4195-2019
OI muslubas, isil sayman/0000-0002-5464-8713; Ersöz, Mehmet
   Giray/0000-0002-2336-0696
CR Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Arroyo JG, 1997, RETINA-J RET VIT DIS, V17, P254
   Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Axer-Siegel R, 1999, AM J OPHTHALMOL, V128, P331, DOI 10.1016/S0002-9394(99)00176-2
   Balaratnasingam C, 2016, OPHTHALMOLOGY, V123, P1541, DOI 10.1016/j.ophtha.2016.03.017
   Bastian N, 2013, KLIN MONATSBL AUGENH, V230, P270, DOI 10.1055/s-0032-1328159
   Bertelmann T, 2014, OPHTHALMOLOGE, V111, P775, DOI 10.1007/s00347-013-2954-3
   Bhavsar KV, 2014, RETINA-J RET VIT DIS, V34, P63, DOI 10.1097/IAE.0b013e318297a061
   BIRD AC, 1991, EYE, V5, P1
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Caramoy A, 2011, ACTA OPHTHALMOL, V89, pE490, DOI 10.1111/j.1755-3768.2011.02143.x
   Caramoy A, 2011, ARCH OPHTHALMOL-CHIC, V129, P575, DOI 10.1001/archophthalmol.2011.105
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cavallero E, 2016, J FR OPHTALMOL, V39, P64, DOI 10.1016/j.jfo.2015.05.010
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P281, DOI 10.1001/archopht.124.2.281
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Cho HJ, 2015, AM J OPHTHALMOL, V160, P1000, DOI 10.1016/j.ajo.2015.07.023
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Clemens CR, 2014, RETINA-J RET VIT DIS, V34, P24, DOI 10.1097/IAE.0b013e3182947811
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Doi M, 2000, GRAEF ARCH CLIN EXP, V238, P621, DOI 10.1007/s004170000155
   Durkin SR, 2016, GRAEF ARCH CLIN EXP, V254, P1, DOI 10.1007/s00417-015-2978-2
   el Matri L, 2010, GRAEF ARCH CLIN EXP, V248, P779, DOI 10.1007/s00417-010-1302-4
   Empeslidis T, 2014, OPEN OPHTHALMOL J, V8, P101, DOI 10.2174/1874364101408010101
   FOX GM, 1993, AM J OPHTHALMOL, V116, P302, DOI 10.1016/S0002-9394(14)71347-9
   Fryczkowski Piotr, 2006, Klin Oczna, V108, P327
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2005, GRAEF ARCH CLIN EXP, V243, P619, DOI 10.1007/s00417-004-1098-1
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Giovannini A, 1999, ACTA OPHTHALMOL SCAN, V77, P83, DOI 10.1034/j.1600-0420.1999.770119.x
   GOLDSTEIN BG, 1987, BRIT J OPHTHALMOL, V71, P676, DOI 10.1136/bjo.71.9.676
   Guber J, 2013, BRIT J OPHTHALMOL, V97, P1486, DOI 10.1136/bjophthalmol-2013-303978
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   Ho LY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1547, DOI 10.1001/archophthalmol.2009.285
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   IE D, 1992, ARCH OPHTHALMOL-CHIC, V110, P1443, DOI 10.1001/archopht.1992.01080220105030
   Ilginis T, 2013, GRAEF ARCH CLIN EXP, V251, P1243, DOI 10.1007/s00417-012-2102-9
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Ishida Y, 2004, RETINA-J RET VIT DIS, V24, P633, DOI 10.1097/00006982-200408000-00028
   Joyiga A, 2004, EYE, V18, P960
   Karadimas P, 2006, EUR J OPHTHALMOL, V16, P767, DOI 10.1177/112067210601600520
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Kwoh AKH, 2000, ARCH OPHTHALMOL-CHIC, V118, P582
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Laidlaw DAH, 1998, AM J OPHTHALMOL, V126, P448, DOI 10.1016/S0002-9394(98)00104-4
   Lee SB, 2013, INDIAN J OPHTHALMOL, V61, P514, DOI 10.4103/0301-4738.119441
   LEFF SR, 1989, RETINA-J RET VIT DIS, V9, P267, DOI 10.1097/00006982-198909040-00005
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lesniak SP, 2011, EUR J OPHTHALMOL, V21, P73, DOI 10.5301/EJO.2010.2285
   Leys A, 2000, RETINA-J RET VIT DIS, V20, P216, DOI 10.1097/00006982-200002000-00020
   LIM JI, 1990, ARCH OPHTHALMOL-CHIC, V108, P1672, DOI 10.1001/archopht.1990.01070140026013
   Lois N, 1999, ARCH OPHTHALMOL-CHIC, V117, P546
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Menchini U, 1995, Eur J Ophthalmol, V5, P139
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Mones J, 2013, CLIN OPHTHALMOL, V7, P1089, DOI 10.2147/OPTH.S45155
   Moreira CA, 2013, RETINA-J RET VIT DIS, V33, P277, DOI 10.1097/IAE.0b013e318263d139
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Mouallem A, 2016, RETINA-J RET VIT DIS, V36, P2197, DOI 10.1097/IAE.0000000000001062
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Mukai R, 2014, ACTA OPHTHALMOL, V92, pE407, DOI 10.1111/aos.12350
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nagiel Aaron, 2015, Retin Cases Brief Rep, V9, P269, DOI 10.1097/ICB.0000000000000184
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Ober Michael D, 2007, Retin Cases Brief Rep, V1, P271, DOI 10.1097/01.iae.0000243067.71211.88
   Park DH, 2016, INT OPHTHALMOL
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2010, OPHTHALMOLOGICA, V224, P159, DOI 10.1159/000236910
   Peiretti E, 2006, RETINA-J RET VIT DIS, V26, P1097, DOI 10.1097/01.iae.0000233328.68999.5f
   Prall F Ryan, 2011, Retin Cases Brief Rep, V5, P284, DOI 10.1097/ICB.0b013e3181f66d11
   Querques G, 2016, RETINA-J RET VIT DIS, V36, pS65, DOI 10.1097/IAE.0000000000001231
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sato T, 2015, OSLI RETINA, V46, P87, DOI 10.3928/23258160-20150101-16
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shiraki K, 2001, GRAEF ARCH CLIN EXP, V239, P430, DOI 10.1007/s004170100304
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Spielberg LH, 2013, BRIT J OPHTHALMOL, V97, P627, DOI 10.1136/bjophthalmol-2012-302851
   SWANSON DE, 1984, RETINA-J RET VIT DIS, V4, P115, DOI 10.1097/00006982-198400420-00008
   Thill M, 2005, RETINA-J RET VIT DIS, V25, P667, DOI 10.1097/00006982-200507000-00022
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
   Torfs Sara, 2013, Retin Cases Brief Rep, V7, P278, DOI 10.1097/ICB.0b013e31828eefce
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Tsuda Kana, 2008, Retin Cases Brief Rep, V2, P115, DOI 10.1097/ICB.0b013e318042b681
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   V Pasyechnikova Nataliya, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P72
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 120
TC 31
Z9 35
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JUL-AUG
PY 2017
VL 62
IS 4
BP 493
EP 505
DI 10.1016/j.survophthal.2017.03.004
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX8WB
UT WOS:000403529800005
PM 28336128
DA 2022-11-30
ER

PT J
AU Grob, S
   Luo, J
   Hughes, G
   Lee, C
   Zhou, X
   Lee, J
   Du, H
   Ferreyra, H
   Freeman, WR
   Kozak, I
   Zhang, K
AF Grob, S.
   Luo, J.
   Hughes, G.
   Lee, C.
   Zhou, X.
   Lee, J.
   Du, H.
   Ferreyra, H.
   Freeman, W. R.
   Kozak, I.
   Zhang, K.
TI Genetic analysis of simultaneous geographic atrophy and choroidal
   neovascularization
SO EYE
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; choroidal
   neovascularization; genetics
ID MACULAR DEGENERATION; EYE DISEASE; RISK; SUSCEPTIBILITY; ASSOCIATION;
   PROGRESSION; VARIANT; C3
AB Aim To investigate clinical presentation and genotypes in patients with simultaneous geographic atrophy (GA) and choroidal neovascularization (CNV) and to compare with patients with GA or CNV only.
   Patients and methods Twenty patients with combined CNV-GA and 154 CNV only and 154 GA only were chosen based on clinical exam and imaging. Six single-nucleotide polymorphisms (SNPs)-rs2274700 and rs1061170 (complement factor H), rs10490924 and rs11200638 (HTRA1/LOC387715), rs2230199 (C3), rs9332739 (C2)-were genotyped using the SNaPshot method. Chi-squared tests were used for genetic analysis.
   Results In patients with CNV-GA, GA progressed slowly and often preceded CNV. CNV presented as subretinal haemorrhage or fluid, with a sudden drop in visual acuity (VA). Comparing combined CNV-GA to GA and CNV only, patients with both had a higher frequency of at-risk alleles at both SNPs within the HTRA1 gene-rs10490924 (52.5%), rs11200638 (52.6%). Statistical significance was not achieved. CNV-GA patients had no protective alleles at SNP rs9332739 (C2), compared with GA (27%) and CNV only (10%).
   Conclusion There is a paucity of reports describing simultaneous CNV-GA. Clinical and genetic results may support the fact that GA and CNV fit on an age-related macular degeneration (AMD)-disease continuum and may clarify the disease processes in AMD. Eye (2012) 26, 1106-1113; doi:10.1038/eye.2012.107; published online 15 June 2012
C1 [Grob, S.; Luo, J.; Lee, J.; Du, H.; Ferreyra, H.; Freeman, W. R.; Kozak, I.; Zhang, K.] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92037 USA.
   [Grob, S.; Luo, J.; Lee, J.; Du, H.; Ferreyra, H.; Freeman, W. R.; Kozak, I.; Zhang, K.] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92037 USA.
   [Grob, S.; Luo, J.; Hughes, G.; Lee, C.; Zhou, X.; Lee, J.; Du, H.; Ferreyra, H.; Freeman, W. R.; Kozak, I.; Zhang, K.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Zhang, K (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92037 USA.
EM kang.zhang@gmail.com
RI Zhang, Kang/Y-2740-2019; Kozak, Igor/AAC-4645-2019
OI Zhang, Kang/0000-0002-4549-1697; Luo, Jing/0000-0002-8905-9388
FU NEI/NIH; research to prevent blindness; San Diego Clinical and
   Translational Research Institute [1TL1RR031979-01]; VA Merit Award;
   NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR031979] Funding Source: NIH
   RePORTER
FX This study was approved by the Institutional Review Board of the
   University of California, San Diego. All subjects signed informed
   consent before participation in the study. We thank Drs Yuhong Chen and
   Peter Shaw for their help with genotyping. This work was supported by
   NEI/NIH grants, research to prevent blindness, San Diego Clinical and
   Translational Research Institute 1TL1RR031979-01 and the VA Merit Award.
CR Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Francis PJ, J MED GENET, V46, P300
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mata NL, 2011, ARVO ANN M 2 MAY SES
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tang NP, 2001, AM EPIDEMIOL, V19, P740
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 22
TC 8
Z9 8
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD AUG
PY 2012
VL 26
IS 8
BP 1106
EP 1113
DI 10.1038/eye.2012.107
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 991TW
UT WOS:000307726000015
PM 22699975
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Kumar, R
   Yu, WL
   Jiang, CL
   Shi, CL
   Zhao, YP
AF Kumar, Rajesh
   Yu, Wenli
   Jiang, Cuilan
   Shi, Conglei
   Zhao, Yaping
TI IMPROVEMENT OF THE ISOLATION AND PURIFICATION OF LUTEIN FROM MARIGOLD
   FLOWER (TAGETES ERECTA L.) AND ITS ANTIOXIDANT ACTIVITY
SO JOURNAL OF FOOD PROCESS ENGINEERING
LA English
DT Article
ID DNA-DAMAGE; CAROTENOIDS; ZEAXANTHIN; RADICALS; ABILITY; CANCER; CELLS;
   RISK
AB Lutein is associated with the prevention of many chronic diseases, like age-related macular degeneration, cancer and cardiovascular diseases. Lutein is found in many plants, but the purest and richest source is the petals of marigold flowers (Tagetes erecta L.).
   Commercially prepared T. erecta extract (oleoresin) was used during the experiment. Saponification reaction was carried out using alcoholic potassium hydroxide solution and tetrahydrofuran at room temperature for 4 h to saponify the xanthophyll esters. The purity and recovery of lutein after saponification were 89 and 63.05%, respectively. Different solvents were used for recrystallization to get a high purity of lutein. Among them, purity and recovery of lutein reached >98 and 72% in ethyl alcohol, which were higher than reported earlier.
   The scavenging efficacy of lutein against peroxide, superoxide anion, hydroxyl radical and lipid free radicals was measured by chemiluminescence. Peroxide, superoxide anions and hydroxyl and lipid free radicals were generated by hydrogen peroxide, pyrogallol, Fenton reaction system and 2,2'-azobis (2-amidino-propane) dihydrochloride-induced gamma-linolenic acid peroxidation system, respectively. Lutein exhibited strong antioxidant activity against superoxide anion, peroxide and hydroxyl and lipid free radicals. Among all tested reactive oxygen species, lipid free radicals showed the lowest effective concentration.
   A reaction time of 6 s was enough to scavenge superoxide and hydroxyl radicals, while it was 60 and 120 s for peroxide and lipid free radicals, respectively.
C1 [Kumar, Rajesh; Yu, Wenli; Jiang, Cuilan; Shi, Conglei; Zhao, Yaping] Shanghai Jiao Tong Univ, Sch Chem & Chem Technol, Shanghai 200240, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhao, YP (通讯作者)，Shanghai Jiao Tong Univ, Sch Chem & Chem Technol, 800 Dong Chuan Rd, Shanghai 200240, Peoples R China.
EM ypzhao@sjtu.edu.cn
RI Shi, Conglei/F-1498-2016
OI Shi, Conglei/0000-0002-7067-8517
FU 863 project of China [2007AA10Z350]
FX This paper was funded by the 863 project of China (2007AA10Z350).
CR Antolovich M, 2002, ANALYST, V127, P183, DOI 10.1039/b009171p
   *AOAC INT, 1990, 97064 AOAC INT, V2
   Ausich R.L., 1997, U.S. Patent, Patent No. [5,648,564, 5648564]
   Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596
   Bertrand S, 2006, J EXP BIOL, V209, P4414, DOI 10.1242/jeb.02540
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   HALLIWELL B, 1995, CRIT REV FOOD SCI, V35, P7, DOI 10.1080/10408399509527682
   KHACHIK F, 2007, Patent No. 7173145
   Khachik F, 1995, US Patent, Patent No. [5,382,714, 5382714]
   KUMAR TKS, 2004, Patent No. 6743953
   Li Y, 2004, FOOD CHEM, V84, P563, DOI 10.1016/S0308-8146(03)00279-6
   Michaud DS, 2000, AM J CLIN NUTR, V72, P990
   MIKI W, 1991, PURE APPL CHEM, V63, P141, DOI 10.1351/pac199163010141
   Palombo P, 2007, SKIN PHARMACOL PHYS, V20, P199, DOI 10.1159/000101807
   Philips N, 2007, ARCH DERMATOL RES, V299, P373, DOI 10.1007/s00403-007-0779-0
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   RODRIGUEZ G, 2001, Patent No. 6329557
   Santocono M, 2006, J PHOTOCH PHOTOBIO B, V85, P205, DOI 10.1016/j.jphotobiol.2006.07.009
   SIMIC MG, 1992, METHOD ENZYMOL, V213, P444
   Slattery ML, 2000, AM J CLIN NUTR, V71, P575
   TYCZKOWSKI JK, 1991, POULTRY SCI, V70, P651, DOI 10.3382/ps.0700651
   Wang MC, 2006, FOOD CHEM TOXICOL, V44, P1522, DOI 10.1016/j.fct.2006.04.005
   Watters JL, 2007, CANCER EPIDEM BIOMAR, V16, P1428, DOI 10.1158/1055-9965.EPI-06-1030
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X
   Yu WL, 2005, BBA-GEN SUBJECTS, V1725, P30, DOI 10.1016/j.bbagen.2005.05.002
NR 27
TC 14
Z9 16
U1 1
U2 57
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8876
EI 1745-4530
J9 J FOOD PROCESS ENG
JI J. Food Process Eng.
PD DEC
PY 2010
VL 33
IS 6
BP 1065
EP 1078
DI 10.1111/j.1745-4530.2008.00326.x
PG 14
WC Engineering, Chemical; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Food Science & Technology
GA 689XH
UT WOS:000284963700006
DA 2022-11-30
ER

PT J
AU Clemens, CR
   Holz, FG
   Meyer, CH
AF Clemens, Christoph R.
   Holz, Frank G.
   Meyer, Carsten H.
TI Macular Hole Formation in the Presence of a Pigment Epithelial
   Detachment After Three Consecutive Intravitreal Antivascular Endothelial
   Growth Factor Injections
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   DEGENERATION; SURGERY
AB Purpose: The aim of this study was to demonstrate the development of a macular hole (MH) and vitreomacular attachment (VMA) after treatment of a subfoveal pigment epithelial detachment (PED) by 3 consecutive antivascular endothelial growth factor (VEGF) injections in a patient with age-related macular degeneration (AMD).
   Methods: A 67-year-old woman with a subfoveal PED and occult choroidal neovascularization received 3 consecutive intravitreal ranibizumab injections in her left eye. Her initial visual acuity (VA) was 20/30.
   Results: Her VA stabilized at 20/30 at 3 months after the last injection; however, cross-sectional scans using optical coherence tomography (OCT) demonstrated a small vitreous attachment on the retinal surface at the foveola. Two months later, her VA was decreased to 20/100, and on biomicroscopy there was a positive Watzke sign on the center of the PED. OCT disclosed an increased VMA with a full-thickness MH. The perpendicular retina was elevated, whereas the PED appeared stabile.
   Conclusion: Consecutive intravitreal injections may alter the vitreous gel, thus inducing a posterior vitreous detachment or VMA. New symptoms after the uploading phase with decreased VA or metamorphopsia may not necessarily relate to a progression of the AMD, but may also relate to a novel incomplete posterior vitreous vitreomacular traction possibly triggering the formation of traction and MH formation.
C1 [Clemens, Christoph R.; Holz, Frank G.; Meyer, Carsten H.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Meyer, CH (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM meyer_eye@yahoo.com
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR Elsing SH, 2001, RETINA-J RET VIT DIS, V21, P613, DOI 10.1097/00006982-200112000-00008
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Mahmoud TH, 2007, RETINA-J RET VIT DIS, V27, P95, DOI 10.1097/01.iae.0000223758.17543.49
   Meyer CH, 2006, EYE, V20, P1090, DOI 10.1038/sj.eye.6702121
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
NR 7
TC 15
Z9 15
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUN
PY 2010
VL 26
IS 3
BP 297
EP 299
DI 10.1089/jop.2009.0140
PG 3
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 614CW
UT WOS:000279033800013
PM 20565318
DA 2022-11-30
ER

PT J
AU Querques, G
   Bux, AV
   Delle Noci, N
AF Querques, Giuseppe
   Bux, Anna V.
   Delle Noci, Nicola
TI Foveal geographic atrophy following intravitreal pegaptanib sodium
   (Macugen) for drusenoid pigment epithelium detachment
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusenoid pigment epithelium
   detachment; Foveal geographic atrophy; Macugen; Pegaptanib sodium;
   Vascular endothelium growth factor
ID MACULAR DEGENERATION; NEURONS; VEGF
AB PURPOSE. To describe a patient with nonexudative age-related macular degeneration (AMD) who underwent intravitreal pegaptanib sodium injection for drusenoid pigment epithelium detachment (PED).
   METHODS. A 66-year-old woman, who underwent intravitreal pegaptanib sodium injection in her right eye ( RE) for chronic serous drusenoid PED, was submitted to a complete ophthalmologic examination, including fundus biomicroscopy, fluorescein angiography ( FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT-3, Humphrey-Zeiss, San Leandro, CA), 3 days and 1 month after the treatment.
   RESULTS. Three days after the intravitreal pegaptanib sodium injection, best-corrected visual acuity (BCVA) was 20/32 in the RE. One month later, the patient's BCVA dropped to 20/200 in the RE. Interestingly, fundus biomicroscopy, FA, OCT, and ICGA revealed the development of foveal geographic atrophy. Fundus-related perimetry (MP-1 Micro Perimeter, Nidek Technologies, Padova, Italy) revealed an eccentric and unstable fixation within 2 degrees with central absolute scotoma and pericentral diffuse reduction of sensitivity.
   CONCLUSIONS. The rapid development of foveal geographic atrophy in our patient may be related to the antivascular endothelial growth factor treatment, in part because of the reduced neuroprotective effect, and in part because of the adjunctive decreased blood flow in an already imbalanced foveal choroidal circulation due to AMD complicated by chronic serous drusenoid PED. (Eur J Ophthalmol 2009; 19: 890-3)
C1 [Querques, Giuseppe; Bux, Anna V.; Delle Noci, Nicola] Univ Foggia, Policlin Riuniti Foggia, Dept Ophthalmol, I-71100 Foggia, Italy.
C3 University of Foggia
RP Querques, G (通讯作者)，Univ Foggia, Policlin Riuniti Foggia, Dept Ophthalmol, Viale Pinto 1, I-71100 Foggia, Italy.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Yasuhara T, 2004, EUR J NEUROSCI, V19, P1494, DOI 10.1111/j.1460-9568.2004.03254.x
NR 8
TC 7
Z9 7
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2009
VL 19
IS 5
BP 890
EP 893
DI 10.1177/112067210901900535
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 520LF
UT WOS:000271845100035
PM 19787618
DA 2022-11-30
ER

PT J
AU Mandal, MNA
   Patlolla, JMR
   Zheng, L
   Agbaga, MP
   Tran, JTA
   Wicker, L
   Asus-Jacobi, A
   Elliott, MH
   Rao, CV
   Anderson, RE
AF Mandal, Md Nawajes A.
   Patlolla, Jagan M. R.
   Zheng, Lixin
   Agbaga, Martin-Paul
   Tran, Julie-Thu A.
   Wicker, Lea
   Asus-Jacobi, Anne
   Elliott, Michael H.
   Rao, Chinthalapally V.
   Anderson, Robert E.
TI Curcumin protects retinal cells from light-and oxidant stress-induced
   cell death
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Curcumin; AMD; Light-induced retinal degeneration; Photoreceptors;
   Retina
ID NF-KAPPA-B; TRANSCRIPTION FACTOR EGR-1; COLON-CANCER CELLS; MACULAR
   DEGENERATION; OXIDATIVE DAMAGE; ALBINO-RATS; RESPONSIVE ELEMENT;
   LIPID-PEROXIDATION; GENE-EXPRESSION; TRANSGENIC RATS
AB Age-related macular degeneration (AMD) is a complex disease that has potential involvement of inflammatory and oxidative stress-related pathways in its pathogenesis. In search of effective therapeutic agents, we tested curcumin, a naturally occurring compound with known anti-inflammatory and antioxidative properties, in a rat model of light-induced retinal degeneration (LIRD) and in retina-derived cell lines. We hypothesized that any compound effective against LIRD, which involves significant oxidative stress and inflammation, would be a candidate for further characterization for its potential application in AMD. We observed significant retinal neuroprotection in rats fed diets supplemented with Curcumin (0.2% in diet) for 2 weeks. The mechanism of retinal protection from LIRD by curcumin involves inhibition of NF-kappa B activation and down-regulation of cellular inflammatory genes. When tested on retina-derived cell lines (661W and ARPE-19), pretreatment of curcumin protected these cells from H(2)O(2)-induced cell death by up-regulating cellular protective enzymes, such as HO-1, thioredoxin. Since, curcumin with its pleiotropic activities can modulate the expression and activation of many cellular regulatory proteins such as NF-kappa B, AKT, NRF2, anti growth factors, which in turn inhibit cellular inflammatory responses and protect cells; we speculate that curcumin would be an effective nutraceutical compound for preventive and augmentative therapy of AMD. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Mandal, Md Nawajes A.] OUHSC, Dept Ophthalmol, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA.
   [Patlolla, Jagan M. R.; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, OU Canc Inst, Oklahoma City, OK 73104 USA.
   [Agbaga, Martin-Paul; Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center
RP Mandal, MNA (通讯作者)，OUHSC, Dept Ophthalmol, Dean A McGee Eye Inst, 608 SL Young Blvd, Oklahoma City, OK 73104 USA.
EM mmandal@ouhsc.edu
FU Knight's Templar Eye Foundation; OU College of Medicine Alumni
   Association; Foundation Fighting Blindness; Research to Prevent
   Blindness, Inc.; National Eye Institute [EY12190, EY04149, EY00871];
   National Center for Research Resources [RR17703]; National Cancer
   Institute [109247]; NATIONAL CANCER INSTITUTE [R01CA109247] Funding
   Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES
   [P20RR017703] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY004149, R01EY000871, P30EY012190] Funding Source: NIH RePORTER
FX The authors are grateful to Mark Dittmar and Alicia Avila (Dean A. McGee
   Eye Institute, Oklahoma City, OK) for their assistance with animal
   breeding and feeding: and Louisa J. Williams and Linda S. Bootie (Dean
   A. McGee Eye Institute, Oklahoma City, OK) for assistance in histology.
   Financial support from Knight's Templar Eye Foundation (MNAM), OU
   College of Medicine Alumni Association (MNAM), Foundation Fighting
   Blindness (REA), Research to Prevent Blindness, Inc., National Eye
   Institute (EY12190, EY04149, and EY00871 to REA), National Center for
   Research Resources Grant RR17703 (MNAM, REA), and National Cancer
   Institute (109247, CVR) are duly acknowledged.
CR Abe Y, 1999, PHARMACOL RES, V39, P41, DOI 10.1006/phrs.1998.0404
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619
   Bhakar AL, 2002, J NEUROSCI, V22, P8466
   CATALA A, 2008, CHEM PHYS LIPIDS
   Chen A, 2006, ONCOGENE, V25, P278, DOI [10.1038/sj.onc.1209019, 10.1038/sj.onc.1209573]
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Giri RK, 2004, J NEUROCHEM, V91, P1199, DOI 10.1111/j.1471-4159.2004.02800.x
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HUANG MT, 1991, CANCER RES, V51, P813
   Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947
   Kaldi I, 2003, EXP EYE RES, V76, P453, DOI 10.1016/S0014-4835(02)00334-2
   Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Knapska E, 2004, PROG NEUROBIOL, V74, P183, DOI 10.1016/j.pneurobio.2004.05.007
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   LI ZL, 1991, CURR EYE RES, V10, P133, DOI 10.3109/02713689109001741
   Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5505, DOI 10.1167/iovs.06-0312
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5514, DOI 10.1167/iovs.06-0449
   Marc RE, 2008, MOL VIS, V14, P782
   Matteucci A, 2005, EXP BRAIN RES, V167, P641, DOI 10.1007/s00221-005-0068-0
   Mattson MP, 2008, AGEING RES REV, V7, P43, DOI 10.1016/j.arr.2007.08.004
   Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001
   Mittag TW, 1999, EXP EYE RES, V69, P677, DOI 10.1006/exer.1999.0748
   Mrudula T, 2007, BIOCHEM BIOPH RES CO, V361, P528, DOI 10.1016/j.bbrc.2007.07.059
   Mukheriee PK, 2006, J ETHNOPHARMACOL, V103, P25, DOI 10.1016/j.jep.2005.09.024
   ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Pendurthi UR, 2000, THROMB RES, V97, P179, DOI 10.1016/S0049-3848(99)00148-6
   Ranchon I, 2003, J NEUROSCI, V23, P6050, DOI 10.1523/JNEUROSCI.23-14-06050.2003
   Rao CV, 2007, ADV EXP MED BIOL, V595, P213
   RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5
   RAVINDRANATH V, 1981, TOXICOLOGY, V22, P337, DOI 10.1016/0300-483X(81)90027-5
   REDDY ACP, 1992, MOL CELL BIOCHEM, V111, P117
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Scapagnini G, 2006, ANTIOXID REDOX SIGN, V8, P395, DOI 10.1089/ars.2006.8.395
   SHANNON AG, 1980, FIBONACCI QUART, V18, P73
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Specht S, 1999, PHOTOCHEM PHOTOBIOL, V69, P91, DOI 10.1562/0031-8655(1999)069<0091:DTRRDI>2.3.CO;2
   SUSAN M, 1992, ARZNEIMITTEL-FORSCH, V42-2, P962
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P1162
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P2392
   TANITO M, J LIPID RES IN PRESS
   Tanito M, 2008, EXP EYE RES, V87, P292, DOI 10.1016/j.exer.2008.06.002
   Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Wang Q, 2005, J NEUROSCI RES, V82, P138, DOI 10.1002/jnr.20610
   Watson JL, 2008, EXP MOL PATHOL, V84, P230, DOI 10.1016/j.yexmp.2008.02.002
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082
   Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004
   Wu TH, 2002, INVEST OPHTH VIS SCI, V43, P2834
   Yamamoto M, 1999, HISTOCHEM J, V31, P81, DOI 10.1023/A:1003510719302
NR 65
TC 171
Z9 187
U1 1
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAR 1
PY 2009
VL 46
IS 5
BP 672
EP 679
DI 10.1016/j.freeradbiomed.2008.12.006
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 410LE
UT WOS:000263577700017
PM 19121385
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Guerin, E
   Sheridan, C
   Assheton, D
   Kent, D
   Wong, D
   Grant, M
   Hiscott, P
AF Guerin, Eoin
   Sheridan, Carl
   Assheton, David
   Kent, David
   Wong, David
   Grant, Maria
   Hiscott, Paul
TI SDF1-alpha is associated with VEGFR-2 in human choroidal
   neovascularisation
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE choroidal neovascularisation; endothelial progenitor cells; stromal cell
   derived factor 1-alpha
ID ENDOTHELIAL PROGENITOR CELLS; PIGMENT EPITHELIAL-CELLS; MACULAR
   DEGENERATION; GROWTH-FACTOR; FACTOR-I; RHEUMATOID-ARTHRITIS;
   MALIGNANT-MELANOMA; RECEPTOR CXCR4; STEM-CELLS; SDF-1
AB Endothelial progenitor cells (EPCs) have been shown to contribute to experimentally induced choroidal neovascularisation (CNV) in animal models. The recruitment pathway for EPCs is dependent on the chemokine stromal cell derived factor 1-alpha (SDF) and its receptor CXCR4 on the progenitor cell. We examined 23 specimens of CNV occurring secondary to a variety of aetiologies (10 secondary to age-related macular degeneration (AMD), 4 inflammatory, 4 idiopathic and 5 melanoma-associated) for the presence and distribution of SDF and CXCR4 in order to determine if this pathway may play a role in neovascularisation. Specimens were examined by immunohistochemistry using a panel of antibodies against SDF, CXCR4, vascular endothelial growth factor receptor 2 (VEGFR-2), CD34 (endothelial cells), CD68 (macrophages) and cytokeratins (retinal pigment epithelium; RPE). SDF was detected in 2 cases of CNV in AMD, I inflammatory CNV, 3 idiopathic CNVs and in 3 cases of CNV associated with melanoma. A significant association was found between SDF and VEGFR-2 immunostaining in individual membranes (p<0.001). Localisation of SDF immunostaining to the presumed RPE was also significant (p<0.05). CXCR4 immunostaining was widespread in all membranes in keeping with the published work of other investigators. Our study suggests that SDF, which may be produced by the RPE, could play a role in CNV. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Guerin, Eoin; Sheridan, Carl; Assheton, David; Wong, David; Hiscott, Paul] Univ Liverpool, UCD, Unit Ophthalmol, Dept Clin Sci, Liverpool L69 3GA, Merseyside, England.
   [Guerin, Eoin; Grant, Maria] Univ Florida, Program Stem Cell Biol, Gainesville, FL 32610 USA.
   [Kent, David] Aut Even Hosp, Kilkenny, Ireland.
C3 University of Liverpool; State University System of Florida; University
   of Florida
RP Guerin, E (通讯作者)，Univ Liverpool, UCD, Unit Ophthalmol, Dept Clin Sci, Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
EM eoinguerin@gmail.com; p.s.hiscott@liverpool.ac.uk
RI Sheridan, Carl/AAH-3607-2021; Wong, Sai Hung David/D-8482-2015
OI Sheridan, Carl/0000-0003-0100-9587; 
CR Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Bhutto IA, 2006, BRIT J OPHTHALMOL, V90, P906, DOI 10.1136/bjo.2006.090357
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869
   Chan CC, 2003, OPHTHALMOLOGY, V110, P421, DOI 10.1016/S0161-6420(02)01737-2
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Crane IJ, 2000, J IMMUNOL, V165, P4372, DOI 10.4049/jimmunol.165.8.4372
   DAMATO BE, 1990, EYE, V4, P382, DOI 10.1038/eye.1990.51
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehling UM, 2000, BLOOD, V95, P3106
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Guerin E, 2006, ACTA OPHTHALMOL SCAN, V84, P323, DOI 10.1111/j.1600-0420.2005.00630.x
   Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5
   Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1
   Kent D, 2003, MOL VIS, V9, P747
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood-2004-11-4349
   Kucia M, 2004, J MOL HISTOL, V35, P233
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   LUBIN JR, 1982, ACTA OPHTHALMOL, V60, P412
   Mavier P, 2004, AM J PATHOL, V165, P1969, DOI 10.1016/S0002-9440(10)63248-8
   Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590
   PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415
   Ruger B, 2004, ARTHRITIS RHEUM-US, V50, P2157, DOI 10.1002/art.20506
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Sheridan C, 2005, ESSENT OPHTHALMOL, P101
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Yamani MH, 2005, J AM COLL CARDIOL, V46, P1029, DOI 10.1016/j.jacc.2005.04.059
NR 29
TC 25
Z9 29
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
J9 MICROVASC RES
JI Microvasc. Res.
PD APR
PY 2008
VL 75
IS 3
BP 302
EP 307
DI 10.1016/j.mvr.2007.12.001
PG 6
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 305ST
UT WOS:000256198800002
PM 18234239
DA 2022-11-30
ER

PT J
AU Bretillon, L
   Diczfalusy, U
   Bjorkhem, I
   Maire, MA
   Martine, L
   Joffre, C
   Acar, N
   Bron, A
   Creuzot-Garcher, C
AF Bretillon, Lionel
   Diczfalusy, Ulf
   Bjoerkhem, Ingernar
   Maire, Marie Annick
   Martine, Lucy
   Joffre, Corinne
   Acar, Niyazi
   Bron, Alain
   Creuzot-Garcher, Catherine
TI Cholesterol-24S-hydroxylase (CYP46A1) is specifically expressed in
   neurons of the neural retina
SO CURRENT EYE RESEARCH
LA English
DT Article
DE cholesterol; eye; oxidation; retina
ID AGE-RELATED MACULOPATHY; ALZHEIMERS-DISEASE; CHOLESTEROL 24-HYDROXYLASE;
   BRAIN CHOLESTEROL; APOLIPOPROTEIN-E; DEFICIENT MICE; PLASMA-LEVELS;
   RISK-FACTORS; 24S-HYDROXYCHOLESTEROL; TURNOVER
AB Increasing biological findings argue for the importance of cholesterol-24S-hydroxylase (CYP46A1) in cholesterol homeostasis in cerebral structures. Based on the similarity between the brain and the neural retina, the aim of the current study was to evaluate the expression of CYP46A1 in the mammalian retina. RT-PCR analysis of CYP46A1 in bovine samples revealed the highest expression in the neural retina. The retinal pigment epithelium expressed CYP46A1 gene at a low level while the ciliary body showed no expression. Immunohistochemical evaluation of the posterior pole of rat retina showed that the protein is specifically expressed in neurons, whereas cone-rods photoreceptors were negative for CYP46A1 staining. The metabolite produced by CYP46A1, 24S-hydroxycholesterol, was almost exclusively found in neural retina, the concentration therein being more than 10-fold higher than in the retinal pigment epithelium or the ciliary body. The results of the current study are consistent with our primary hypothesis: the neural retina specifically expresses cholesterol-24S-hydroxylase, a metabolizing enzyme responsible for the removal of cholesterol in neurons. Based on the link between cholesterol-24S-hydroxylase, 24S-hydroxycholesterol, and neurologic disorders, CYP46A1 may be a valuable gene candidate for retinal pathologies like age-related macular degeneration or glaucomas, and 24S-hydroxycholesterol may be involved in the onset of the degenerative processes in these diseases.
C1 Univ Burgundy, ENESAD, INRA, UMR FLAVIC 1129,Eye & Nutr Res Grp, Dijon, France.
   Karolinska Univ Hosp Huddinge, Div Clin Chem, Dept Lab Med, Stockholm, Sweden.
   Univ Hosp, Dept Ophthalmol, Dijon, France.
C3 INRAE; Institut Agro; AgroSup Dijon; Universite de Bourgogne; Karolinska
   Institutet; Karolinska University Hospital; CHU Dijon Bourgogne
RP Bretillon, L (通讯作者)，INRA, Unite FLAVIC, Equipe OEil & Nutr, 17 Rue Sully,BP 86510, F-21065 Dijon, France.
EM lionel.bretillon@dijon.inra.fr
RI Diczfalusy, Ulf/A-5336-2008; Bron, Alain/AAP-8010-2020
OI Bron, Alain/0000-0002-7265-931X; Bjorkhem, Ingemar/0000-0001-6087-9190;
   Bretillon, Lionel/0000-0002-6957-100X; Diczfalusy,
   Ulf/0000-0001-6643-3763; JOFFRE, Corinne/0000-0001-8327-3554; Bjorkhem,
   Ingemar/0000-0002-0575-9425
CR Bjorkhem I, 1998, J LIPID RES, V39, P1594
   Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178
   Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7
   Borroni B, 2004, NEUROBIOL AGING, V25, P747, DOI 10.1016/j.neurobiolaging.2003.08.004
   Bretillon L, 2000, NEUROSCI LETT, V293, P87, DOI 10.1016/S0304-3940(00)01466-X
   Bretillon L, 2000, J LIPID RES, V41, P840
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Combarros O, 2004, DEMENT GERIATR COGN, V18, P257, DOI 10.1159/000080025
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Desai P, 2002, NEUROSCI LETT, V328, P9, DOI 10.1016/S0304-3940(02)00443-3
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Ikeda H, 2003, LAB INVEST, V83, P349, DOI 10.1097/01.LAB.0000059933.35157.40
   Klein BEK, 1999, AM J OPHTHALMOL, V128, P652, DOI 10.1016/S0002-9394(99)00222-6
   Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238
   Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200
   Lutjohann D, 2000, J LIPID RES, V41, P195
   Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Ong JM, 2003, CURR EYE RES, V27, P15, DOI 10.1076/ceyr.27.2.15.15460
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Wang BB, 2004, NEUROSCI LETT, V369, P104, DOI 10.1016/j.neulet.2004.07.020
   Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200
NR 24
TC 70
Z9 70
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD APR
PY 2007
VL 32
IS 4
BP 361
EP 366
DI 10.1080/02713680701231857
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 163IJ
UT WOS:000246153000008
PM 17453958
DA 2022-11-30
ER

PT J
AU Michels, S
   Hansmann, F
   Geitzenauer, W
   Schmidt-Erfurth, U
AF Michels, S
   Hansmann, F
   Geitzenauer, W
   Schmidt-Erfurth, U
TI Influence of treatment parameters on selectivity of verteporfin therapy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR;
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; TRIAMCINOLONE ACETONIDE;
   HUMAN EYES; VEGF
AB PURPOSE. To improve selectivity of verteporfin therapy (PDT) in neovascular age-related macular degeneration (AMD) using modified treatment parameters.
   METHODS. Nineteen consecutive patients with predominantly classic choroidal neovascularization (CNV) in AMD were treated with 6 mg/m(2) verteporfin given as bolus infusion. Patients received PDT with a fluence of either 25 or 50 J/cm(2). Choroidal perfusion changes were evaluated by indocyanine green angiography (ICGA) at baseline, day 1, week 1, week 4, and month 3. Secondary outcomes were CNV closure rate and therapy-induced leakage documented by fluorescein angiography (FA). The safety of the treatment was assessed with ETDRS visual acuity.
   RESULTS. Complete CNV closure was achieved in all patients at day 1. Choroidal hypoperfusion was minimal in eyes treated with a reduced fluence of 25 J/cm(2). Most patients treated with 50 J/cm(2) showed significant choriocapillary nonperfusion at week 1, lasting as long as 3 months. A transient PDT-induced increase in leakage area in FA at day 1 was found to be more extensive in the 50-J/cm(2) group.
   CONCLUSIONS. Bolus administration of verteporfin combined with a reduced light dose achieved improved selectivity of photodynamic effects, avoiding collateral alteration of the physiologic choroid while obtaining complete CNV closure. An increased selectivity with decreased effect on the surrounding choroid should be of advantage in verteporfin monotherapy as well as in combination strategies.
C1 Univ Eye Hosp Vienna, Vienna, Austria.
   Univ Eye Hosp Schleswig Hostein, Lubeck, Germany.
RP Michels, S (通讯作者)，Med Univ Wien, Klin Augenheilkunde & Optometrie, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stephan.michels@meduniwien.ac.at
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MICHELS S, 2004, RETIN PHYS, V1, P16
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002
   *VIS MIN CLASS CHO, 2002, ARCH OPHTHALMOL-CHIC, V123, P448
NR 27
TC 87
Z9 92
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2006
VL 47
IS 1
BP 371
EP 376
DI 10.1167/iovs.05-0354
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 998AH
UT WOS:000234289700052
PM 16384987
DA 2022-11-30
ER

PT J
AU Moran, AL
   Fehilly, JD
   Jones, DF
   Collery, R
   Kennedy, BN
AF Moran, Ailis L.
   Fehilly, John D.
   Jones, Daniel Floss
   Collery, Ross
   Kennedy, Breandan N.
TI Regulation of the rhythmic diversity of daily photoreceptor outer
   segment phagocytosis in vivo
SO FASEB JOURNAL
LA English
DT Review
DE circadian; cone; in vivo; outer segment phagocytosis; photoreceptor;
   regulators; retina; retinal disease; rod; RPE
ID RETINAL-PIGMENT EPITHELIUM; FOCAL ADHESION KINASE; MER TYROSINE KINASE;
   ALPHA-V-BETA-5 INTEGRIN; CONSTANT LIGHT; RAT RETINA; ROD; GENE; CELLS;
   RECEPTOR
AB Outer segment phagocytosis (OSP) is a highly-regulated, biological process wherein photoreceptor outer segment (OS) tips are cyclically phagocytosed by the adjacent retinal pigment epithelium (RPE) cells. Often an overlooked retinal process, rhythmic OSP ensures the maintenance of healthy photoreceptors and vision. Daily, the photoreceptors renew OS at their base and the most distal, and likely oldest, OS tips, are phagocytosed by the RPE, preventing the accumulation of photo-oxidative compounds by breaking down phagocytosed OS tips and recycling useful components to the photoreceptors. Light changes often coincide with an escalation of OSP and within hours the phagosomes formed in each RPE cell are resolved. In the last two decades, individual molecular regulators were elucidated. Some of the molecular machinery used by RPE cells for OSP is highly similar to mechanisms used by other phagocytic cells for the clearance of apoptotic cells. Consequently, in the RPE, many molecular regulators of retinal phagocytosis have been elucidated. However, there is still a knowledge gap regarding the key regulators of physiological OSP in vivo between endogenous photoreceptors and the RPE. Understanding the regulation of OSP is of significant clinical interest as age-related macular degeneration (AMD) and inherited retinal diseases (IRD) are linked with altered OSP. Here, we review the in vivo timing of OSP peaks in selected species and focus on the reported in vivo environmental and molecular regulators of OSP.
C1 [Moran, Ailis L.; Fehilly, John D.; Jones, Daniel Floss; Kennedy, Breandan N.] Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin, Ireland.
   [Moran, Ailis L.; Fehilly, John D.; Jones, Daniel Floss; Kennedy, Breandan N.] Univ Coll Dublin, UCD Conway Inst, Dublin, Ireland.
   [Collery, Ross] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI USA.
   [Collery, Ross] Wisconsin Eye Inst, Dept Ophthalmol & Visual Sci, Med Coll, Milwaukee, WI USA.
C3 University College Dublin; University College Dublin; Medical College of
   Wisconsin
RP Kennedy, BN (通讯作者)，Univ Coll Dublin, UCD Sch Biomol & Biomed Sci, Dublin, Ireland.
EM brendan.kennedy@ucd.ie
OI Moran, Ailis/0000-0002-8706-9777; Kennedy, Breandan/0000-0001-7991-4689
FU Irish Research Council [EPS2019/526]; Science Foundation Ireland
   [20/FFP--P/8538]; Fighting Blindness [FB21KEN]
FX Irish Research Council EPS2019/526. Science Foundation Ireland
   20/FFP--P/8538. Fighting Blindness grant award FB21KEN.
CR ANDERSON DH, 1995, J COMP NEUROL, V360, P1, DOI 10.1002/cne.903600102
   ANDERSON DH, 1980, EXP EYE RES, V30, P559, DOI 10.1016/0014-4835(80)90040-8
   BASINGER S, 1976, SCIENCE, V194, P1074, DOI 10.1126/science.1086510
   BASINGER S F, 1980, Neurochemistry International, V1, P81, DOI 10.1016/0197-0186(80)90052-2
   BASINGER SF, 1982, VISION RES, V22, P1533, DOI 10.1016/0042-6989(82)90220-6
   BASSI CJ, 1990, INVEST OPHTH VIS SCI, V31, P2314
   BERNSTEIN SA, 1984, J CELL BIOL, V99, P379, DOI 10.1083/jcb.99.2.379
   BESHARSE JC, 1979, INVEST OPHTH VIS SCI, V18, P1019
   BIRKLE DL, 1989, CURR EYE RES, V8, P557, DOI 10.3109/02713688908995754
   Bobu C, 2006, INVEST OPHTH VIS SCI, V47, P3109, DOI 10.1167/iovs.05-1397
   Bobu C, 2009, INVEST OPHTH VIS SCI, V50, P3495, DOI 10.1167/iovs.08-3145
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Bourne M C, 1938, Br J Ophthalmol, V22, P613, DOI 10.1136/bjo.22.10.613
   Burgess B, 2006, MOL VIS, V12, P1437
   Burstyn-Cohen T, 2012, NEURON, V76, P1123, DOI 10.1016/j.neuron.2012.10.015
   Campbell LJ, 2017, INVEST OPHTH VIS SCI, V58, P5604, DOI 10.1167/iovs.17-21958
   Carter SP, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00136
   Cockram TOJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.629979
   CURRIE JR, 1978, VISION RES, V18, P995, DOI 10.1016/0042-6989(78)90027-5
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Daniele LL, 2005, INVEST OPHTH VIS SCI, V46, P2156, DOI 10.1167/iovs.04-1427
   de Graauw M, 2008, MOL CELL BIOL, V28, P1029, DOI 10.1128/MCB.01247-07
   DeVera C, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105302
   DeVera C, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107988
   Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438
   Felder-Schmittbuhl M-P., 2017, CPT, V7, P33, DOI DOI 10.2147/CPT.S115251
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 2006, ADV EXP MED BIOL, V572, P499
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FISHER SK, 1983, INVEST OPHTH VIS SCI, V24, P844
   Follo C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021908
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   GORDON WC, 1990, VISUAL NEUROSCI, V4, P95, DOI 10.1017/S0952523800002790
   Goyal V, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.10
   Grace MS, 1999, VISUAL NEUROSCI, V16, P909, DOI 10.1017/S0952523899165106
   Hall MO, 2005, EXP EYE RES, V81, P581, DOI 10.1016/j.exer.2005.03.017
   Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062
   HERMAN KG, 1982, INVEST OPHTH VIS SCI, V23, P291
   HERMAN KG, 1982, INVEST OPHTH VIS SCI, V23, P277
   HOLLYFIELD JG, 1978, NATURE, V274, P794, DOI 10.1038/274794a0
   ILLC D, 1995, NATURE, V377, P539
   IMMEL JH, 1985, CELL TISSUE RES, V239, P667
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Jiang M, 2015, J CELL BIOL, V210, P595, DOI 10.1083/jcb.201410112
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kocaoglu OP, 2016, BIOMED OPT EXPRESS, V7, P4554, DOI 10.1364/BOE.7.004554
   Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6
   Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Korshunov KS, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00091
   Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473
   Krigel A, 2010, MOL VIS, V16, P2873
   Kwon W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604205
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Laurent V, 2017, EXP EYE RES, V165, P90, DOI 10.1016/j.exer.2017.09.007
   LaVail MM, 2016, ADV EXP MED BIOL, V854, P487, DOI 10.1007/978-3-319-17121-0_65
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   LAVAIL MM, 1980, INVEST OPHTH VIS SCI, V19, P407
   LAVAIL MM, 1978, INVEST OPHTH VIS SCI, V17, P1189
   Law AL, 2015, J BIOL CHEM, V290, P4941, DOI 10.1074/jbc.M114.628297
   Law AL, 2009, MOL BIOL CELL, V20, P3896, DOI 10.1091/mbc.E08-12-1204
   Lewis TR, 2018, BMC CELL BIOL, V19, DOI 10.1186/s12860-018-0177-9
   LONG KO, 1986, EXP EYE RES, V43, P193, DOI 10.1016/S0014-4835(86)80087-2
   Lorach H., 2018, SCI REP-UK, V8, P1
   Mao YY, 2016, ADV EXP MED BIOL, V854, P717, DOI 10.1007/978-3-319-17121-0_95
   Mao YY, 2012, MOL BIOL CELL, V23, P1104, DOI 10.1091/mbc.E11-10-0840
   Mazzoni F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38363-z
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Milicevic N, 2021, FASEB J, V35, DOI 10.1096/fj.202100293RR
   Moran AL, 2022, FASEB J, V36, DOI 10.1096/fj.202101897R
   Mustafi D, 2013, FASEB J, V27, P4585, DOI 10.1096/fj.13-237537
   Nandrot E, 2000, NEUROBIOL DIS, V7, P586, DOI 10.1006/nbdi.2000.0328
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nandrot EF, 2006, AM J PHYSIOL-CELL PH, V290, pC1256, DOI 10.1152/ajpcell.00480.2005
   Nandrot EF, 2008, OPHTHALMIC RES, V40, P120, DOI 10.1159/000119861
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Numrich J, 2014, BIOL CHEM, V395, P327, DOI 10.1515/hsz-2013-0258
   ODAY WT, 1978, J CELL BIOL, V76, P593, DOI 10.1083/jcb.76.3.593
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Rajala RVS, 2010, J LIPID RES, V51, P4, DOI 10.1194/jlr.R000232
   Ramsden CM., 2017, SCI REP-UK, V7, P1
   REME C, 1986, BRAIN RES, V369, P356, DOI 10.1016/0006-8993(86)90550-0
   RetNet the Retinal Information Network, US
   Reyes-Reveles J, 2017, J BIOL CHEM, V292, P8038, DOI 10.1074/jbc.M116.770784
   Ruggiero L, 2012, P NATL ACAD SCI USA, V109, P8145, DOI 10.1073/pnas.1121101109
   SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x
   Schreiter S, 2020, STEM CELL REP, V15, P1347, DOI 10.1016/j.stemcr.2020.10.013
   Segawa K, 2014, SCIENCE, V344, P1164, DOI 10.1126/science.1252809
   Sethna S, 2016, J BIOL CHEM, V291, P6494, DOI 10.1074/jbc.M115.687004
   Sharma VK, 2005, CURR SCI INDIA, V89, P1136
   Strauss O, 1998, ACTA ANAT, V162, P101
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   TABOR GA, 1980, EXP EYE RES, V30, P545, DOI 10.1016/0014-4835(80)90039-1
   TAMAI M, 1978, INVEST OPHTH VIS SCI, V17, P558
   TEIRSTEIN PS, 1980, INVEST OPHTH VIS SCI, V19, P1268
   TERMAN JS, 1993, BRAIN RES, V605, P256
   Tosini G, 2008, BIOESSAYS, V30, P624, DOI 10.1002/bies.20777
   Toulis V, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108360
   Vargas JA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073661
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wavre-Shapton ST, 2014, J CELL SCI, V127, P3852, DOI 10.1242/jcs.154757
   WILLIAMS DS, 1987, INVEST OPHTH VIS SCI, V28, P184
   Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632
   Ying GX, 2018, J BIOL CHEM, V293, P17546, DOI 10.1074/jbc.RA118.005484
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1978, INVEST OPHTH VIS SCI, V17, P105
   YOUNG RW, 1971, J ULTRA MOL STRUCT R, V34, P190, DOI 10.1016/S0022-5320(71)90014-1
   Yu C, 2019, J CELL SCI, V132, DOI 10.1242/jcs.239426
   Yu SS, 2017, HUM MOL GENET, V26, P2335, DOI 10.1093/hmg/ddx137
   Zigler JS, 2016, BBA-GEN SUBJECTS, V1860, P287, DOI 10.1016/j.bbagen.2015.05.017
   Zihni C., 2021, BIORXIV, DOI [10.1101/2021.03.25.436833, DOI 10.1101/2021.03.25.436833]
NR 118
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2022
VL 36
IS 10
AR e22556
DI 10.1096/fj.202200990RR
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 4V9KT
UT WOS:000859789400001
PM 36165194
OA hybrid
DA 2022-11-30
ER

PT J
AU Keeling, E
   Lynn, SA
   Koh, YM
   Scott, JA
   Kendall, A
   Gatherer, M
   Page, A
   Cagampang, FR
   Lotery, AJ
   Ratnayaka, JA
AF Keeling, Eloise
   Lynn, Savannah A.
   Koh, Yen Min
   Scott, Jenny A.
   Kendall, Aaron
   Gatherer, Maureen
   Page, Anton
   Cagampang, Felino R.
   Lotery, Andrew J.
   Ratnayaka, J. Arjuna
TI A High Fat "Western-style" Diet Induces AMD-Like Features in Wildtype
   Mice
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE age-related macular degeneration (AMD); blindness; high fat diet; mouse
   models; unhealthy foods
ID MACULAR DEGENERATION; BRUCHS MEMBRANE; MOUSE MODEL;
   DIABETIC-RETINOPATHY; GEOGRAPHIC ATROPHY; MEDITERRANEAN DIET;
   APOLIPOPROTEIN-E; AGE; DRUSEN; ASSOCIATION
AB Scope The intake of a "Western-style" diet rich in fats is linked with developing retinopathies including age-related macular degeneration (AMD). Wildtype mice are given a high fat diet (HFD) to determine how unhealthy foods can bring about retinal degeneration. Methods and results Following weaning, female C57BL/6 mice are maintained on standard chow (7% kcal fat, n = 29) or a HFD (45% kcal fat, n = 27) for 12 months. Animals are sacrificed following electroretinography (ERG) and their eyes are analyzed by histology, confocal immunofluorescence, and transmission electron microscopy. HFD mice become obese, but show normal retinal function compared to chow-fed controls. However, diminished beta 3tubulin labeling of retinal cross-sections indicate fewer/damaged neuronal processes in the inner plexiform layer. AMD-linked proteins clusterin and TIMP3 accumulated in the retinal pigment epithelium (RPE) and Bruch's membrane (BrM). Neutral lipids are also deposited in the outer retinae of HFD mice. Ultrastructural analysis reveals disorganized photoreceptor outer segments, collapsed/misaligned RPE microvilli, vacuoles, convoluted basolateral RPE infolds, and BrM changes. Basal laminar-like deposits are also present alongside abnormal choroidal endothelial cells. Conclusions The study shows that prolonged exposure to an unhealthy "Western-style" diet alone can recapitulate early-intermediate AMD-like features in wildtype mice, highlighting the importance of diet and nutrition in the etiology of sight-loss.
C1 [Keeling, Eloise; Lynn, Savannah A.; Koh, Yen Min; Scott, Jenny A.; Kendall, Aaron; Gatherer, Maureen; Lotery, Andrew J.; Ratnayaka, J. Arjuna] Univ Southampton, Fac Med, Clin & Expt Sci, MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Page, Anton] Univ Southampton, Biomed Imaging Unit, MP12,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Cagampang, Felino R.] Univ Southampton, Southampton Gen Hosp, Fac Med, Human Dev & Hlth, Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Lotery, Andrew J.] Univ Hosp Southampton NHS Fdn Trust, Eye Unit, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton; University of Southampton; University Hospital Southampton
   NHS Foundation Trust
RP Ratnayaka, JA (通讯作者)，Univ Southampton, Fac Med, Clin & Expt Sci, MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM J.Ratnayaka@soton.ac.uk
OI Cagampang, Felino Ramon/0000-0003-4404-9853; Lotery,
   Andrew/0000-0001-5541-4305; Ratnayaka, J. Arjuna/0000-0002-1027-6938
FU UK Macular Society; NC3R (National Centre for the Replacement Refinement
   & Reduction of animals in research) [NC/L001152/1]; Sight Appeal
FX The authors thank Dr Matthew MacGregor Sharp (University of Southampton)
   for providing perfusion fixed mouse tissues from the laboratory of Dr
   Felino R. Cagampang (FRC). They also thank Jon Ward (Histochemistry
   Research Unit, University of Southampton) for his expertise in H&E and
   lipid stains. They are grateful to Professor Robert F. Mullins
   (University of Iowa, USA) for his help with interpreting TEM data. This
   work was funded by awards to JAR from the UK Macular Society, the NC3R
   (National Centre for the Replacement Refinement & Reduction of animals
   in research, NC/L001152/1) and the Gift of Sight Appeal.
CR Asare-Bediako B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020464
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Chang RCA, 2015, INVEST OPHTH VIS SCI, V56, P2367, DOI 10.1167/iovs.14-16143
   Chekuri A, 2019, AGING CELL, V18, DOI 10.1111/acel.13011
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Clarkson-Townsend DA, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.4.22
   Clarkson-Townsend DA, 2021, EXP EYE RES, V204, DOI 10.1016/j.exer.2021.108440
   Collins S, 2004, PHYSIOL BEHAV, V81, P243, DOI 10.1016/j.physbeh.2004.02.006
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dewing JM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010039
   Dhomen NS, 2006, INVEST OPHTH VIS SCI, V47, P386, DOI 10.1167/iovs.05-0428
   Diaz G, 2008, MICRON, V39, P819, DOI 10.1016/j.micron.2008.01.001
   Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dutescu RM, 2013, INVEST OPHTH VIS SCI, V54, P2582, DOI 10.1167/iovs.12-11446
   Funkat A, 2004, J NUTR, V134, P3264, DOI 10.1093/jn/134.12.3264
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Garbuzova-Davis S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016601
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   GREENSPAN P, 1985, J LIPID RES, V26, P781
   Harrison R, 2019, ANN INTERN MED, V171, P859, DOI 10.7326/L19-0361
   Hazra S, 2012, DIABETES, V61, P3270, DOI 10.2337/db11-1596
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kawashima M, 2013, EXP GERONTOL, V48, P1096, DOI 10.1016/j.exger.2013.04.002
   Keeling E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218408
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Li L, 2007, GENESIS, V45, P560, DOI 10.1002/dvg.20325
   Liu X, 2019, INT J CLIN EXP PATHO, V12, P507
   Lynn SA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020413
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Mohamed IN, 2014, DIABETOLOGIA, V57, P413, DOI 10.1007/s00125-013-3101-z
   Okamoto M, 2008, DEV GROWTH DIFFER, V50, P159, DOI [10.1111/j.1440-169x.2008.00996.x, 10.1111/j.1440-169X.2008.00996.x]
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Park SY, 2017, ONCOTARGET, V8, P110380, DOI 10.18632/oncotarget.22777
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pouw AE, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030687
   Provost AC, 2009, INVEST OPHTH VIS SCI, V50, P3931, DOI 10.1167/iovs.08-2527
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Ratnayaka JA, 2020, NEURAL REGEN RES, V15, P863, DOI 10.4103/1673-5374.268972
   Roddy GW, 2020, CURR EYE RES, V45, P726, DOI 10.1080/02713683.2019.1694156
   Rojas B, 2011, ACTA OPHTHALMOL, V89, P660, DOI 10.1111/j.1755-3768.2009.01829.x
   Rossmeisl M, 2003, DIABETES, V52, P1958, DOI 10.2337/diabetes.52.8.1958
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shanab AY, 2012, NEUROBIOL DIS, V48, P556, DOI 10.1016/j.nbd.2012.07.025
   Showalter MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190632
   Speakman JR, 2019, INT J OBESITY, V43, P1491, DOI 10.1038/s41366-019-0363-7
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YANKO L, 1983, BRIT J OPHTHALMOL, V67, P32, DOI 10.1136/bjo.67.1.32
   Yiu G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.32
   Zhang G, 2011, AM J PHYSIOL-ENDOC M, V301, pE1004, DOI 10.1152/ajpendo.00196.2011
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
NR 75
TC 2
Z9 2
U1 7
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD JUN
PY 2022
VL 66
IS 11
AR 2100823
DI 10.1002/mnfr.202100823
EA APR 2022
PG 17
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 1T0OZ
UT WOS:000788378800001
PM 35306732
OA Green Accepted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Jiang, H
   Luo, J
   Lei, HT
AF Jiang, Heng
   Luo, Jing
   Lei, Hetian
TI The roles of mouse double minute 2 (MDM2) oncoprotein in ocular
   diseases: A review
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE MDM2; p53; Retinoblastoma; Uveal melanoma; Proliferative
   vitreoretinopathy; Ocular neovascular disease; Pterygium; Age-related
   macular degeneration
ID TUMOR-SUPPRESSOR GENE; DEXAMETHASONE INTRAVITREAL IMPLANT; SINGLE
   NUCLEOTIDE POLYMORPHISM; EPITHELIAL-CELL APOPTOSIS; UBIQUITIN LIGASE
   ACTIVITY; WILD-TYPE P53; UVEAL MELANOMA; PROLIFERATIVE
   VITREORETINOPATHY; EMBRYONIC LETHALITY; RETINAL-DETACHMENT
AB Mouse double minute 2 (MDM2), an E3 ubiquitin ligase and the primary negative regulator of the tumor suppressor p53, cooperates with its structural homolog MDM4/MDMX to control intracellular p53 level. In turn, overexpression of p53 upregulates and forms an autoregulatory feedback loop with MDM2. The MDM2-p53 axis plays a pivotal role in modulating cell cycle control and apoptosis. MDM2 itself is regulated by the PI3K-AKT and RB-E2F-ARF pathways. While amplification of the MDM2 gene or overexpression of MDM2 (due to MDM2 SNP T309G, for instance) is associated with various malignancies, numerous studies have shown that MDM2/p53 alterations may also play a part in the pathogenetic process of certain ocular disorders. These include cancers (retinoblastoma, uveal melanoma), fibrocellular proliferative diseases (proliferative vitreoretinopathy, pterygium), neovascular diseases, degenerative diseases (cataract, primary open-angle glaucoma, age-related macular degeneration) and infectious/inflammatory diseases (trachoma, uveitis). In addition, MDM2 is implicated in retinogenesis and regeneration after optic nerve injury. Anti-MDM2 therapy has shown potential as a novel approach to treating these diseases. Despite major safety concerns, there are high expectations for the clinical value of reformative MDM2 inhibitors. This review summarizes important findings about the role of MDM2 in ocular pathologies and provides an overview of recent advances in treating these diseases with anti-MDM2 therapies.
C1 [Jiang, Heng; Luo, Jing] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
   [Lei, Hetian] Jinan Univ, Shenzhen Eye Hosp, Shenzhen Eye Inst, 18 Zetian Rd, Shenzhen 518040, Guangdong, Peoples R China.
C3 Central South University; Jinan University
RP Luo, J (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.; Lei, HT (通讯作者)，Jinan Univ, Shenzhen Eye Hosp, Shenzhen Eye Inst, 18 Zetian Rd, Shenzhen 518040, Guangdong, Peoples R China.
EM jiangheng61@csu.edu.cn; luojing001@csu.edu.cn; leihetian18@hotmail.com
OI Jiang, Heng/0000-0002-1135-4723
FU National Natural Science Foundation of China [82070989]; National
   Natural Science Foundation of China [82070989, 81570847]
FX This work was supported by the National Natural Science Foundation of
   China (81570847) to JL and the National Natural Science Foundation of
   China (82070989) to HL.
CR Agrawal RN, 2007, NAT PROTOC, V2, P67, DOI 10.1038/nprot.2007.4
   Andreeff M, 2016, CLIN CANCER RES, V22, P868, DOI 10.1158/1078-0432.CCR-15-0481
   [Anonymous], 2020, GLOBAL ATLAS TRACHOM
   [Anonymous], 2021, NLM
   Arish M, 2016, EYE CONTACT LENS, V42, pE4, DOI 10.1097/ICL.0000000000000126
   Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704
   BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x
   BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739
   Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Bhattacharya S, 2011, INVEST OPHTH VIS SCI, V52, P3368, DOI 10.1167/iovs.10-6991
   BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5
   Boersma BJ, 2006, J NATL CANCER I, V98, P911, DOI 10.1093/jnci/djj245
   Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180
   Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022
   Bougeard G, 2006, J MED GENET, V43, P531, DOI 10.1136/jmg.2005.037952
   Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Brantley MA, 2000, AM J PATHOL, V157, P1795, DOI 10.1016/S0002-9440(10)64817-1
   Brantley MA, 2002, AM J OPHTHALMOL, V133, P242, DOI 10.1016/S0002-9394(01)01362-9
   Brennan RC, 2011, CANCER RES, V71, P4205, DOI 10.1158/0008-5472.CAN-11-0058
   Burgess A, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00007
   CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cao D, 2018, EXP EYE RES, V175, P142, DOI 10.1016/j.exer.2018.06.021
   Cao D, 2018, CORNEA, V37, P760, DOI 10.1097/ICO.0000000000001569
   Cao QX, 2018, MEDICINE, V97, DOI [10.1097/md.0000000000013547, 10.1097/MD.0000000000013547]
   Carita G, 2016, ONCOTARGET, V7, P33542, DOI 10.18632/oncotarget.9552
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   Carvajal LA, 2013, EMBO REP, V14, P414, DOI 10.1038/embor.2013.25
   Castera L, 2010, J NATL CANCER I, V102, P1805, DOI 10.1093/jnci/djq416
   Center for Disease Control and Prevention, 2018, BLINDN VIS IMP
   Chae JB, 2021, GEROSCIENCE, V43, P2809, DOI [10.1007/s11357-021-00457-4, 10.1371/journal.pone.0101072, 10.3390/ijms21228840]
   Chan CM, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0056819, 10.1371/journal.pone.0068504]
   Chang JH, 2004, INVEST OPHTH VIS SCI, V45, P1871, DOI 10.1167/iovs.03-1113
   Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110
   Chavala SH, 2013, J CLIN INVEST, V123, P4170, DOI 10.1172/JCI67315
   Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025
   Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200
   Chen N, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107716
   Chen PL, 2006, MOL VIS, V12, P1411
   Chen RX, 2015, SCI REP-UK, V5, DOI 10.1038/srep13300
   Cheng Q, 2011, MOL CELL BIOL, V31, P4951, DOI 10.1128/MCB.05553-11
   Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294
   Chiba C, 2014, EXP EYE RES, V123, P107, DOI 10.1016/j.exer.2013.07.009
   Chowers I, 2001, OPHTHALMOLOGY, V108, P985, DOI 10.1016/S0161-6420(00)00651-5
   Chu WK, 2020, EYE, V34, P1047, DOI 10.1038/s41433-020-0786-3
   Chui J, 2008, OCUL SURF, V6, P24, DOI 10.1016/S1542-0124(12)70103-9
   Coupland SE, 2013, EYE, V27, P230, DOI 10.1038/eye.2012.255
   Coupland SE, 2000, J PATHOL, V191, P120
   D'Anneo A, 2010, J CELL PHYSIOL, V222, P433, DOI 10.1002/jcp.21983
   Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004
   Davies L, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.19
   de la Rua ER, 2008, BRIT J OPHTHALMOL, V92, P523, DOI 10.1136/bjo.2007.127688
   de Lange J, 2012, ONCOGENE, V31, P1105, DOI 10.1038/onc.2011.309
   Reis AHD, 2012, PEDIATR BLOOD CANCER, V59, P39, DOI 10.1002/pbc.24014
   Decaudin D, 2020, EUR J CANCER, V126, P93, DOI 10.1016/j.ejca.2019.12.012
   Detorakis E, 2005, EYE, V19, P210, DOI 10.1038/sj.eye.6701452
   Dimaras H, 2019, J NEUROSCI RES, V97, P29, DOI 10.1002/jnr.24213
   Dimaras H, 2012, LANCET, V379, P1436, DOI 10.1016/S0140-6736(11)61137-9
   Drago-Ferrante R, 2008, INT J ONCOL, V33, P677, DOI 10.3892/ijo_00000053
   Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x
   Duan YJ, 2016, J BIOL CHEM, V291, P16339, DOI 10.1074/jbc.M116.729467
   Dushku N, 1997, CURR EYE RES, V16, P1179, DOI 10.1076/ceyr.16.12.1179.5036
   Egorova O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041309
   Elison JR, 2006, ARCH OPHTHALMOL-CHIC, V124, P1269, DOI 10.1001/archopht.124.9.1269
   Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019
   Epistolato MC, 2011, J HUM GENET, V56, P685, DOI 10.1038/jhg.2011.82
   Fan V, 2018, AM J PATHOL, V188, P2087, DOI 10.1016/j.ajpath.2018.05.017
   Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200
   Ferrari N, 2005, CLIN CANCER RES, V11, P4610, DOI 10.1158/1078-0432.CCR-04-2210
   Finch RA, 2002, CANCER RES, V62, P3221
   Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502
   Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103
   Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288
   Geatrell JC, 2009, EXP EYE RES, V88, P1137, DOI 10.1016/j.exer.2009.01.020
   Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100
   Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200
   Goldsmith ZK, 2018, INVEST OPHTH VIS SCI, V59, P4486, DOI 10.1167/iovs.18-24359
   Gonzalez E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6201
   Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181
   Graves B, 2012, P NATL ACAD SCI USA, V109, P11788, DOI 10.1073/pnas.1203789109
   Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386
   Gryshchenko I, 2008, J CLIN ONCOL, V26, P2252, DOI 10.1200/JCO.2007.11.5212
   Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367
   Guo Y, 2020, J BUON, V25, P2476
   Guo Y, 2008, BIOCHEM BIOPH RES CO, V375, P1, DOI 10.1016/j.bbrc.2008.07.055
   Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014
   Han HT, 2019, J BIOL CHEM, V294, P15408, DOI 10.1074/jbc.RA119.010130
   Hao B, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108224
   Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341
   Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0
   Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x
   Heijkants RC, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0041-y
   Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200
   Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4
   Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22
   Hu WW, 2007, CANCER RES, V67, P2757, DOI 10.1158/0008-5472.CAN-06-2656
   Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108
   Huang QL, 2018, P NATL ACAD SCI USA, V115, pE3368, DOI 10.1073/pnas.1719090115
   Inada K, 1996, ONCOL REP, V3, P667
   Iwakuma T, 2003, MOL CANCER RES, V1, P993
   Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000
   Jaramillo-Rangel G, 2013, MOL VIS, V19, P2468
   Jiao YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep31240
   JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0
   Joshi Y, 2015, BRAIN, V138, P1843, DOI 10.1093/brain/awv125
   JUVEN T, 1993, ONCOGENE, V8, P3411
   Kalmodia S, 2017, MOL THER-NUCL ACIDS, V9, P349, DOI 10.1016/j.omtn.2017.10.012
   Kaufman SC, 2013, OPHTHALMOLOGY, V120, P201, DOI 10.1016/j.ophtha.2012.06.066
   Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313
   Kivela T, 2009, BRIT J OPHTHALMOL, V93, P1129, DOI 10.1136/bjo.2008.150292
   Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019
   Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0
   Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948
   Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200
   Landers JE, 1997, CANCER RES, V57, P3562
   Laurie NA, 2007, CURR CANCER DRUG TAR, V7, P689, DOI 10.2174/156800907782418266
   Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194
   Lee YM, 2009, CARCINOGENESIS, V30, P1768, DOI 10.1093/carcin/bgp196
   Lei HT, 2012, AM J PATHOL, V181, P866, DOI 10.1016/j.ajpath.2012.05.036
   Li H, 2014, CELL DEATH DIFFER, V21, P1493, DOI 10.1038/cdd.2014.69
   Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362
   Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200
   LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169
   Lim SA, 2014, J CATARACT REFR SURG, V40, P1102, DOI 10.1016/j.jcrs.2013.12.015
   Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100
   Lind H, 2006, INT J CANCER, V119, P718, DOI 10.1002/ijc.21872
   Liu B, 2019, LAB INVEST, V99, P1874, DOI 10.1038/s41374-019-0307-9
   Liu J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25792-0
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8
   Lu B, 2018, MOL MED REP, V17, P5021, DOI 10.3892/mmr.2018.8492
   LUNA RMD, 1995, NATURE, V378, P203
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   MACHEMER R, 1991, AM J OPHTHALMOL, V112, P159, DOI 10.1016/S0002-9394(14)76695-4
   Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912
   Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0
   Martinez-Sanchez M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234337
   Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198
   McElhinney K, 2021, INVEST OPHTH VIS SCI, V62
   McEvoy J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042739
   Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002
   Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016
   MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R
   Mulay SR, 2012, KIDNEY INT, V81, P1199, DOI 10.1038/ki.2011.482
   Nieminen AL, 2005, J CELL PHYSIOL, V204, P364, DOI 10.1002/jcp.20406
   Nihira NT, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8026
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ohmiya N, 2006, J CLIN ONCOL, V24, P4434, DOI 10.1200/JCO.2005.04.1459
   Okamoto K, 2009, FEBS LETT, V583, P2710, DOI 10.1016/j.febslet.2009.07.021
   OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0
   Omsland A, 2012, P NATL ACAD SCI USA, V109, P19781, DOI 10.1073/pnas.1212831109
   Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003
   Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108
   Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714
   Pastor JC, 1998, SURV OPHTHALMOL, V43, P3, DOI 10.1016/S0039-6257(98)00023-X
   Pastor-Idoate S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082283
   Patterson DM, 2011, ANGIOGENESIS, V14, P255, DOI 10.1007/s10456-011-9210-8
   Pennock S, 2014, PROG RETIN EYE RES, V40, P16, DOI 10.1016/j.preteyeres.2013.12.006
   Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2
   Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010
   Qi DL, 2017, ONCOGENE, V36, P1760, DOI 10.1038/onc.2016.350
   Qin Y, 2014, BBA-MOL BASIS DIS, V1842, P2439, DOI 10.1016/j.bbadis.2014.10.002
   Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6
   Reichel MB, 1998, CELL DEATH DIFFER, V5, P156, DOI 10.1038/sj.cdd.4400326
   Reisman D, 2004, CANCER LETT, V206, P77, DOI 10.1016/j.canlet.2003.10.026
   Rezvan F, 2018, SURV OPHTHALMOL, V63, P719, DOI 10.1016/j.survophthal.2018.03.001
   Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rojas J, 2013, INVEST OPHTH VIS SCI, V54, P1665, DOI 10.1167/iovs.12-10931
   Rojas J, 2010, OPHTHALMOLOGY, V117, P2417, DOI 10.1016/j.ophtha.2010.03.059
   Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554
   Rushlow DE, 2013, LANCET ONCOL, V14, P327, DOI 10.1016/S1470-2045(13)70045-7
   Saha MN, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-23
   Ruiz-Colmenares MRS, 2006, ACTA OPHTHALMOL SCAN, V84, P309, DOI 10.1111/j.1600-0420.2005.00600.x
   Schmidt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2460
   Schneider BG, 2006, EXP EYE RES, V82, P91, DOI 10.1016/j.exer.2005.05.006
   Scholes AGM, 2001, INVEST OPHTH VIS SCI, V42, P2472
   Schwermer M, 2019, EXP CELL RES, V375, P92, DOI 10.1016/j.yexcr.2018.12.018
   Secchiero P, 2007, CIRC RES, V100, P61, DOI 10.1161/01.RES.0000253975.76198.ff
   Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105
   Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189
   Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954
   Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X
   Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x
   Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775
   Siegl C, 2014, CELL REP, V9, P918, DOI 10.1016/j.celrep.2014.10.004
   Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040
   Singh HP, 2018, P NATL ACAD SCI USA, V115, pE9391, DOI 10.1073/pnas.1808903115
   Spandidos DA, 1997, BRIT J OPHTHALMOL, V81, P493, DOI 10.1136/bjo.81.6.493
   Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Takamura Y, 2003, EXP EYE RES, V77, P51, DOI 10.1016/S0014-4835(03)00083-6
   Tan DTH, 2000, BRIT J OPHTHALMOL, V84, P212, DOI 10.1136/bjo.84.2.212
   TANG F F, 1957, Chin Med J, V75, P429
   Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025
   Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9
   Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937
   TAYLOR HR, 1987, J IMMUNOL, V138, P3023
   Taylor HR, 2014, LANCET, V384, P2142, DOI 10.1016/S0140-6736(13)62182-0
   Tendler Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67206-z
   Teng YF, 2018, EXP EYE RES, V169, P149, DOI 10.1016/j.exer.2018.01.015
   Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974
   To KH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-69
   Tran HN, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.563156
   Tsai YY, 2005, CORNEA, V24, P583, DOI 10.1097/01.ico.0000154404.86462.35
   Tsai YY, 2005, MOL VIS, V11, P50
   Uchida C, 2006, FEBS LETT, V580, P1753, DOI 10.1016/j.febslet.2006.02.029
   Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486
   Ueda Y, 2001, ACTA HISTOCHEM, V103, P159, DOI 10.1078/0065-1281-00584
   Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   Vinson Joe A, 2006, Pathophysiology, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vuong L, 2012, INVEST OPHTH VIS SCI, V53, P4821, DOI 10.1167/iovs.11-8681
   Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430
   Wang ZY, 2020, BIOCHEM BIOPH RES CO, V528, P112, DOI 10.1016/j.bbrc.2020.05.060
   Wei X, 2016, P NATL ACAD SCI USA, V113, pE2558, DOI 10.1073/pnas.1603838113
   Weinstein O, 2002, EYE, V16, P619, DOI 10.1038/sj.eye.6700150
   Wiley LA, 2011, DIS MODEL MECH, V4, P484, DOI 10.1242/dmm.006593
   Worrall C, 2017, ONCOGENE, V36, P3274, DOI 10.1038/onc.2016.472
   Wride MA, 2011, PHILOS T R SOC B, V366, P1219, DOI 10.1098/rstb.2010.0324
   Wu S, 2019, INVEST OPHTH VIS SCI, V60, P4904, DOI 10.1167/iovs.19-27704
   WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126
   XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0
   Xiong J, 2014, ANGIOGENESIS, V17, P37, DOI 10.1007/s10456-013-9376-3
   Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016
   Xu XLL, 2014, NATURE, V514, P385, DOI 10.1038/nature13813
   Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051
   Yadav UCS, 2009, INVEST OPHTH VIS SCI, V50, P2276, DOI 10.1167/iovs.08-2816
   Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06
   Yao XL, 2021, CELL CYCLE, V20, P603, DOI 10.1080/15384101.2021.1892321
   Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515
   Yokoyama M, 2019, J MOL CELL CARDIOL, V129, P105, DOI 10.1016/j.yjmcc.2019.02.010
   Young AL, 2018, CORNEA, V37, pS55, DOI 10.1097/ICO.0000000000001744
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang L, 2011, ANTIOXID REDOX SIGN, V15, P1, DOI 10.1089/ars.2010.3560
   Zhang YW, 2014, DEV BIOL, V396, P19, DOI 10.1016/j.ydbio.2014.09.017
   Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4
   Zhang Y, 2014, J PATHOL, V233, P380, DOI 10.1002/path.4368
   Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973
   Zhou GH, 2017, INVEST OPHTH VIS SCI, V58, P5361, DOI 10.1167/iovs.17-22045
   Zhou S, 2011, MOL CELL BIOL, V31, P4928, DOI 10.1128/MCB.06085-11
   Zhu X, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22001
   Zou Y, 2019, MOL CELL BIOCHEM, V452, P167, DOI 10.1007/s11010-018-3422-9
NR 249
TC 5
Z9 5
U1 2
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2022
VL 217
AR 108910
DI 10.1016/j.exer.2021.108910
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2C2VK
UT WOS:000810731800005
PM 34998788
DA 2022-11-30
ER

PT J
AU Hsu, XL
   Wu, LC
   Hsieh, JY
   Huang, YY
AF Hsu, Xuan-Ling
   Wu, Lien-Chen
   Hsieh, Jui-Yang
   Huang, Yi-You
TI Nanoparticle-Hydrogel Composite Drug Delivery System for Potential
   Ocular Applications
SO POLYMERS
LA English
DT Article
DE PLGA; hyaluronan; nanoparticle; injectable hydrogel; composite drug
   delivery system
ID SINGLE INTRAVITREAL INJECTION; HYALURONIC-ACID HYDROGELS; CROSS-LINKED
   HYDROGEL; CONTROLLED-RELEASE; SUSTAINED-RELEASE; MACULAR DEGENERATION;
   EXTENDED-RELEASE; INTRAOCULAR PHARMACOKINETICS; POSTERIOR SEGMENT;
   IN-VIVO
AB Intravitreal injections are clinically established procedures in the treatment of posterior eye diseases, such as wet age-related macular degeneration (wet AMD) which requires monthly intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) protein drugs that can lead to complications due to frequent dosing. In this study, we designed a composite drug delivery system (DDS) consisting of drug-loaded poly (lactide-co-glycolide) (PLGA) nanoparticles and a chemically crosslinked hyaluronan hydrogel to reduce the dosing frequency. The morphology, size, composition, and drug loading efficiency of the prepared nanoparticles were characterized. The properties of the modified hyaluronan polymers used were also examined. The degree of swelling/degradation and controlled release ability of the hyaluronan hydrogel and the composite DDS were identified using bovine serum albumin (BSA) as a model drug. The results show that this system can retain 75% of its wet weight without losing its integrity and release the model drug at the rate of 0.4 mu g/day for more than two months under physiological conditions. In addition, the nanoparticulate formulation of the system can further improve bioavailability of the drugs by penetrating deep into the retinal layers. In conclusion, the proposed composite DDS is easily prepared with biocompatible materials and is promising for providing the sustained release of the protein drugs as a better treatment for ocular neovascular diseases like wet AMD.
C1 [Hsu, Xuan-Ling; Hsieh, Jui-Yang; Huang, Yi-You] Natl Taiwan Univ, Dept Biomed Engn, Taipei 10051, Taiwan.
   [Wu, Lien-Chen] Taipei Med Univ, Coll Med, Sch Med, Dept Orthopaed, Taipei 11031, Taiwan.
   [Wu, Lien-Chen] Taipei Med Univ, Shuang Ho Hosp, Dept Orthoped, Taipei 23561, Taiwan.
   [Huang, Yi-You] Natl Taiwan Univ Hosp, Dept Biomed Engn, Taipei 10051, Taiwan.
C3 National Taiwan University; Taipei Medical University; Taipei Medical
   University; Shuang Ho Hospital; National Taiwan University; National
   Taiwan University Hospital
RP Huang, YY (通讯作者)，Natl Taiwan Univ, Dept Biomed Engn, Taipei 10051, Taiwan.; Huang, YY (通讯作者)，Natl Taiwan Univ Hosp, Dept Biomed Engn, Taipei 10051, Taiwan.
EM r07528030@ntu.edu.tw; d98548019@ntu.edu.tw; d03548026@ntu.edu.tw;
   yyhuang@ntu.edu.tw
FU National Taiwan University [107L891104, 108L891104, 109L891004];
   Ministry of Science and Technology, Taiwan [MOST 109-2221-E-002-048]
FX This research was funded by National Taiwan University (107L891104,
   108L891104, and 109L891004), and Ministry of Science and Technology,
   Taiwan (MOST 109-2221-E-002-048).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Awwad S, 2019, EUR J PHARM SCI, V137, DOI 10.1016/j.ejps.2019.104993
   Bian SQ, 2016, COLLOID SURFACE B, V140, P392, DOI 10.1016/j.colsurfb.2016.01.008
   Bisht R, 2017, MED HYPOTHESES, V103, P5, DOI 10.1016/j.mehy.2017.03.033
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cao YQ, 2019, DRUG DISCOV TODAY, V24, P1694, DOI 10.1016/j.drudis.2019.05.031
   Chang D, 2019, DRUG DISCOV TODAY, V24, P1470, DOI 10.1016/j.drudis.2019.05.037
   Dubbini A, 2015, EUR POLYM J, V72, P423, DOI 10.1016/j.eurpolymj.2015.07.036
   Egbu R, 2018, EUR J PHARM BIOPHARM, V124, P95, DOI 10.1016/j.ejpb.2017.12.019
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gregoritza M, 2017, BIOMACROMOLECULES, V18, P2410, DOI 10.1021/acs.biomac.7b00587
   Grillo R, 2019, COLLOID SURFACE B, V174, P56, DOI 10.1016/j.colsurfb.2018.10.063
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Houchin ML, 2008, J PHARM SCI-US, V97, P2395, DOI 10.1002/jps.21176
   Huang XN, 2019, DRUG DISCOV TODAY, V24, P1510, DOI 10.1016/j.drudis.2019.05.005
   Humayun M, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.6.5
   Jeong B, 2000, J CONTROL RELEASE, V63, P155, DOI 10.1016/S0168-3659(99)00194-7
   Jiang PF, 2020, J CONTROL RELEASE, V320, P442, DOI 10.1016/j.jconrel.2020.01.036
   Jin R, 2010, ACTA BIOMATER, V6, P1968, DOI 10.1016/j.actbio.2009.12.024
   Kabiri M, 2018, DRUG DELIV TRANSL RE, V8, P484, DOI 10.1007/s13346-018-0504-x
   Karki S, 2016, ASIAN J PHARM SCI, V11, P559, DOI 10.1016/j.ajps.2016.05.004
   Kharkar PM, 2016, ACS BIOMATER SCI ENG, V2, P165, DOI 10.1021/acsbiomaterials.5b00420
   Khunmanee S, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417726464
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Lai PL, 2012, COMPOS PART B-ENG, V43, P3088, DOI 10.1016/j.compositesb.2012.04.057
   Lance KD, 2016, DRUG DELIV TRANSL RE, V6, P771, DOI 10.1007/s13346-016-0298-7
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li XY, 2013, INT J PHARMACEUT, V448, P96, DOI 10.1016/j.ijpharm.2013.03.024
   Liu WQ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.12
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   McAvoy K, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-017-2298-9
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Modaresifar K, 2018, ARTIF CELL NANOMED B, V46, P1799, DOI 10.1080/21691401.2017.1392970
   Nimmo CM, 2011, BIOCONJUGATE CHEM, V22, P2199, DOI 10.1021/bc200281k
   Noda T, 2018, BIOL PHARM BULL, V41, P937, DOI 10.1248/bpb.b18-00091
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Osswald CR, 2015, ANN BIOMED ENG, V43, P2609, DOI 10.1007/s10439-015-1314-7
   Pescosolido L, 2011, BIOMACROMOLECULES, V12, P1831, DOI 10.1021/bm200178w
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Sarwar MS, 2020, INT J BIOL MACROMOL, V165, P1047, DOI 10.1016/j.ijbiomac.2020.09.196
   Sarwar MS, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020131
   Schlesinger EB, 2019, BIOENG TRANSL MED, V4, P152, DOI 10.1002/btm2.10121
   Seah I, 2020, EYE, V34, P1341, DOI 10.1038/s41433-020-0770-y
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Sun JC, 2013, J APPL POLYM SCI, V129, P682, DOI 10.1002/app.38779
   Tan HP, 2011, J TISSUE ENG REGEN M, V5, P790, DOI 10.1002/term.378
   Thoniyot P, 2015, ADV SCI, V2, DOI 10.1002/advs.201400010
   Turturro SB, 2011, BIOMATERIALS, V32, P3620, DOI 10.1016/j.biomaterials.2011.01.058
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Vihola H, 2005, BIOMATERIALS, V26, P3055, DOI 10.1016/j.biomaterials.2004.09.008
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang K, 2018, J BIOMED MATER RES A, V106, P2795, DOI 10.1002/jbm.a.36450
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Wells LA, 2011, BIOMACROMOLECULES, V12, P923, DOI 10.1021/bm101233m
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie BB, 2015, INT J PHARMACEUT, V490, P375, DOI 10.1016/j.ijpharm.2015.05.071
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Yu F, 2014, POLYM CHEM-UK, V5, P1082, DOI 10.1039/c3py00869j
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Yu Y, 2015, BIOMACROMOLECULES, V16, P56, DOI 10.1021/bm501063n
   Yu Y, 2012, BIOMACROMOLECULES, V13, P937, DOI 10.1021/bm2014476
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang XP, 2018, BIOMED PHARMACOTHER, V107, P1056, DOI 10.1016/j.biopha.2018.08.092
NR 67
TC 2
Z9 2
U1 8
U2 32
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4360
J9 POLYMERS-BASEL
JI Polymers
PD FEB
PY 2021
VL 13
IS 4
AR 642
DI 10.3390/polym13040642
PG 19
WC Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Polymer Science
GA QQ1DN
UT WOS:000624265200001
PM 33670014
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rasoulinejad, SA
   Maroufi, F
AF Rasoulinejad, Seyed Ahmad
   Maroufi, Faezeh
TI A Review of DNA and Histone Methylation Alterations in the New Era of
   Diagnosis and Treatment of Retinal Diseases
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
DE DNA methylation; epigenetics; gene expression; hypermethylation; retinal
   diseases
ID PIGMENT EPITHELIAL-CELLS; DIABETIC-RETINOPATHY; GENE-EXPRESSION; MACULAR
   DEGENERATION; EPIGENETIC REGULATION; METABOLIC MEMORY; OXIDATIVE STRESS;
   DEACETYLASE INHIBITORS; PROMOTER METHYLATION; THERAPEUTIC TARGET
AB Epigenetics has an important role in gene regulation and other cellular processes. DNA methylation, as one of the main mechanisms of epigenetics, is a type of post-replication modifications. Aberrant DNA methylation can alter gene expression patterns; so, it plays a considerable role in the pathogenesis of many diseases. DNA methylated alterations in the promoter of specific genes can be used for the diagnosis and proprietary targets acting as a "biomarker". Early diagnosis and prevention may be possible due to these biomarkers. According to recent studies, DNA methylation abnormalities have an important role in the retinogenesis and pathogenesis of retinal diseases. Retinal diseases are the main cause of blindness and severe vision loss in the world, which will continue to increase. Also, they inflict an enormous burden on society and health care systems. Therefore, it is important to focus on the better recognition and prevention of retinal diseases and finding new targets for the treatment. DNA methylation is lionized as attractive therapeutic targets due to its reversibility. Epigenetic therapy has a high potency in the treatment of retinal diseases. Here, we reviewed the DNA and histone methylation alterations in common retinal diseases, focusing on age related macular degeneration (AMD), diabetic retinopathy, retinal detachment (RD), retinitis pigmentosa, retinal aging, and retinoblastoma. Then we surveyed some new approaches to epigenetic therapy in retinal disorders.
C1 [Rasoulinejad, Seyed Ahmad] Babol Univ Med Sci, Ayatollah Rouhani Hosp, Dept Ophthalmol, Babol, Iran.
   [Maroufi, Faezeh] Qazvin Univ Med Sci, Fac Allied Med, Dept Med Lab Sci, Qazvin, Iran.
C3 Babol University of Medical Sciences; Qazvin University of Medical
   Sciences (QUMS)
RP Rasoulinejad, SA (通讯作者)，Babol Univ Med Sci, Ayatollah Rouhani Hosp, Dept Ophthalmol, Babol, Iran.
EM rasolisa2@gmail.com
OI Maroufi, Faezeh/0000-0003-1368-8636
CR Anderson KW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126592
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229
   Azad M, 2013, IRAN J BASIC MED SCI, V16, P822
   Benayoun BA, 2015, NAT REV MOL CELL BIO, V16, P593, DOI 10.1038/nrm4048
   Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Bohm S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5614
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cavallotti C, 2004, CAN J OPHTHALMOL, V39, P61, DOI 10.1016/S0008-4182(04)80054-1
   Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062
   Chen B, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-78
   Choy KW, 2005, NEOPLASIA, V7, P200, DOI 10.1593/neo.04565
   Choy KW, 2004, INVEST OPHTH VIS SCI, V45, P3404, DOI 10.1167/iovs.03-1273
   Choy KW, 2002, INVEST OPHTH VIS SCI, V43, P1344
   Christiansen L, 2016, AGING CELL, V15, P149, DOI 10.1111/acel.12421
   Cisneros J, 2012, AM J PHYSIOL-LUNG C, V303, pL295, DOI 10.1152/ajplung.00332.2011
   Clemson CM, 2011, BRIT J OPHTHALMOL, V95, P89, DOI 10.1136/bjo.2009.175356
   Cohen Y, 2008, EXP EYE RES, V86, P201, DOI 10.1016/j.exer.2007.10.010
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dalgard CL, 2008, CLIN CANCER RES, V14, P3113, DOI 10.1158/1078-0432.CCR-07-4836
   Silva MEDCE, 2019, J CELL MOL MED, V23, P1280, DOI 10.1111/jcmm.14030
   Davila-Avila N, 2020, EXP EYE RES, V194, DOI 10.1016/j.exer.2020.107992
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dehghanifard A, 2018, CL LYMPH MYELOM LEUK, V18, P311, DOI 10.1016/j.clml.2018.03.007
   den Hollander AI, 2016, INVEST OPHTH VIS SCI, V57, P1378, DOI 10.1167/iovs.15-18167
   Desmettre TJ, 2018, J FR OPHTALMOL, V41, pE407, DOI 10.1016/j.jfo.2018.09.001
   Duraisamy AJ, 2018, INVEST OPHTH VIS SCI, V59, P4831, DOI 10.1167/iovs.18-24548
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Farinelli P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.512
   Gao YL, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1372-8
   Ghosh SK, 2012, BLOOD, V119, P1008, DOI 10.1182/blood-2011-06-362434
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Hoseini M, 2019, REP BIOCHEM MOL BIOL, V7, P223
   Hu B, 2010, AM J PATHOL, V177, P21, DOI 10.2353/ajpath.2010.090999
   Huang XG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20537
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanan Y, 2014, J BIOL CHEM, V289, P13419, DOI 10.1074/jbc.M114.562157
   Kandpal RP, 2012, MOL VIS, V18, P1123
   Karali M, 2019, HUM GENET, V138, P957, DOI 10.1007/s00439-018-1931-y
   Kim E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14500
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Komor AC, 2017, CELL, V169, P559, DOI 10.1016/j.cell.2017.04.005
   Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136
   Kowluru RA, 2015, PROG RETIN EYE RES, V48, P40, DOI 10.1016/j.preteyeres.2015.05.001
   Lamoke F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139664
   Lauwen S, 2017, INVEST OPHTH VIS SCI, V58, pBIO88, DOI 10.1167/iovs.17-21809
   Levenson VV, 2010, EXPERT REV MOL DIAGN, V10, P481, DOI 10.1586/ERM.10.17
   Levine ME, 2015, AGING-US, V7, P1198, DOI 10.18632/aging.100864
   Li FL, 2012, CURR EYE RES, V37, P540, DOI 10.3109/02713683.2012.665561
   Li HC, 2013, INVEST OPHTH VIS SCI, V54, P234, DOI 10.1167/iovs.12-10643
   Liu B, 2019, LAB INVEST, V99, P1874, DOI 10.1038/s41374-019-0307-9
   Livide G, 2012, PATHOL ONCOL RES, V18, P703, DOI 10.1007/s12253-012-9498-8
   Maali A, 2019, IJBC, V11, P111
   Maali A, 2018, CURR STEM CELL RES T, V13, P665, DOI 10.2174/1574888X13666180731155038
   MAHONEY MC, 1990, OPHTHALMOLOGY, V97, P1143
   Mangold CA, 2017, J GERONTOL A-BIOL, V72, P16, DOI 10.1093/gerona/glv232
   Merbs SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032602
   Minarovits J, 2016, ADV EXP MED BIOL, V879, P1, DOI 10.1007/978-3-319-24738-0_1
   Mishra M, 2015, INVEST OPHTH VIS SCI, V56, P5133, DOI 10.1167/iovs.15-16937
   Miyazawa-Hoshimoto S, 2003, DIABETOLOGIA, V46, P1483, DOI 10.1007/s00125-003-1221-6
   Moradi Z, 2020, INDIAN J HEMATOL BLO, V36, P26, DOI 10.1007/s12288-019-01170-1
   Moreno AM, 2018, MOL THER, V26, P1818, DOI 10.1016/j.ymthe.2018.04.017
   Nasonkin IO, 2011, J COMP NEUROL, V519, P1914, DOI 10.1002/cne.22613
   Oki Y, 2008, BLOOD, V111, P2382, DOI 10.1182/blood-2007-07-103960
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Pang MY, 2010, J PHARMACOL EXP THER, V335, P266, DOI 10.1124/jpet.110.168385
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Peng CH, 2010, SENSORS-BASEL, V10, P6172, DOI 10.3390/s100606172
   Pisani F, 2018, J CELL MOL MED, V22, P613, DOI 10.1111/jcmm.13348
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Poulaki V, 2009, INVEST OPHTH VIS SCI, V50, P4072, DOI 10.1167/iovs.09-3517
   Qu Y, 2010, AM J CLIN PATHOL, V134, P826, DOI 10.1309/AJCPHGQ69FXDFWII
   Rahmani Tirdad, 2017, Int J Hematol Oncol Stem Cell Res, V11, P172
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P141
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P224
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P77
   Rhee KD, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.165
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612
   Saika S, 2007, ARCH OPHTHALMOL-CHIC, V125, P647, DOI 10.1001/archopht.125.5.647
   Sancho-Pelluz J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.4
   Sancho-Pelluz J, 2012, ADV EXP MED BIOL, V723, P107, DOI 10.1007/978-1-4614-0631-0_15
   Shivapurkar N, 2010, CURR MOL MED, V10, P123, DOI 10.2174/156652410790963303
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stubbs TM, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1203-5
   Tewari S, 2012, INVEST OPHTH VIS SCI, V53, P4881, DOI 10.1167/iovs.12-9732
   Tokarz P, 2016, EUR J PHARMACOL, V776, P167, DOI 10.1016/j.ejphar.2016.02.049
   Tong M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.51
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wallace DM, 2006, INVEST OPHTH VIS SCI, V47, P2765, DOI 10.1167/iovs.05-1383
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Xiao W, 2014, J CELL MOL MED, V18, P646, DOI 10.1111/jcmm.12212
   Xiong X, 2016, ANNU REV GENOM HUM G, V17, P131, DOI 10.1146/annurev-genom-083115-022258
   Yamashita Y, 2010, ONCOGENE, V29, P3723, DOI 10.1038/onc.2010.117
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Yu DY, 2014, PROG RETIN EYE RES, V40, P53, DOI 10.1016/j.preteyeres.2014.02.001
   Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733
   Zhang XY, 2017, BBA-MOL BASIS DIS, V1863, P2389, DOI 10.1016/j.bbadis.2017.05.010
   Zhao SZ, 2015, MOL MED REP, V12, P6112, DOI 10.3892/mmr.2015.4164
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P244, DOI 10.1167/iovs.12-10854
   Zhong Q, 2011, DIABETES, V60, P1304, DOI 10.2337/db10-0133
   Zorrilla-Zubilete MA, 2018, J NEUROCHEM, V144, P128, DOI 10.1111/jnc.14243
NR 108
TC 2
Z9 2
U1 3
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2021
VL 21
IS 8
BP 607
EP 619
DI 10.2174/1566524020666201209103603
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA UY0VY
UT WOS:000701252300001
PM 33297915
DA 2022-11-30
ER

PT J
AU Holan, V
   Hermankova, B
   Krulova, M
   Zajicova, A
AF Holan, Vladimir
   Hermankova, Barbora
   Krulova, Magdalena
   Zajicova, Alena
TI Cytokine interplay among the diseased retina, inflammatory cells and
   mesenchymal stem cells - a clue to stem cell-based therapy
SO WORLD JOURNAL OF STEM CELLS
LA English
DT Review
DE Retina; Degenerative diseases; Stem cell therapy; Mesenchymal stem
   cells; Cytokines; Growth factors
ID BONE-MARROW; GANGLION-CELLS; STROMAL CELLS; IFN-GAMMA; RAT MODEL; OCULAR
   SURFACE; T-CELL; DIFFERENTIATION; IMMUNOMODULATION; TRANSPLANTATION
AB Retinal degenerative disorders, such as diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration or glaucoma, represent the most common causes of loss of vision and blindness. In spite of intensive research, treatment options to prevent, stop or cure these diseases are limited. Newer therapeutic approaches are offered by stem cell-based therapy. To date, various types of stem cells have been evaluated in a range of models. Among them, mesenchymal stem/stromal cells (MSCs) derived from bone marrow or adipose tissue and used as autologous cells have been proposed to have the potential to attenuate the negative manifestations of retinal diseases. MSCs delivered to the vicinity of the diseased retina can exert local anti-inflammatory and repair-promoting/regenerative effects on retinal cells. However, MSCs also produce numerous factors that could have negative impacts on retinal regeneration. The secretory activity of MSCs is strongly influenced by the cytokine environment. Therefore, the interactions among the molecules produced by the diseased retina, cytokines secreted by inflammatory cells and factors produced by MSCs will decide the development and propagation of retinal diseases. Here we discuss the interactions among cytokines and other factors in the environment of the diseased retina treated by MSCs, and we present results supporting immunoregulatory and trophic roles of molecules secreted in the vicinity of the retina during MSC-based therapy.
C1 [Holan, Vladimir; Hermankova, Barbora; Krulova, Magdalena; Zajicova, Alena] Czech Acad Sci, Inst Expt Med, Dept Transplantat Immunol, Videnska 1083, Prague 14220, Czech Republic.
   [Holan, Vladimir; Hermankova, Barbora; Krulova, Magdalena] Charles Univ Prague, Dept Cell Biol, Fac Sci, Prague 12843, Czech Republic.
C3 Czech Academy of Sciences; Charles University Prague
RP Holan, V (通讯作者)，Czech Acad Sci, Inst Expt Med, Dept Transplantat Immunol, Videnska 1083, Prague 14220, Czech Republic.
EM vladimir.holan@iem.cas.cz
RI Krulova, Magdalena/A-6255-2012
OI Krulova, Magdalena/0000-0003-3622-376X
FU Grant Agency of the Czech Republic [17-04800S, 18-04393S, 19-02290S];
   Ministry of Education, Youth and Sports of the Czech Republic; SVV
   [244-260435, NPU-I: LO1508, NPU-I: LO1309]
FX Supported by the Grant Agency of the Czech Republic, No. 17-04800S, No.
   18-04393S, No. 19-02290S; the Ministry of Education, Youth and Sports of
   the Czech Republic, No. SVV 244-260435, No. NPU-I: LO1508, No. NPU-I:
   LO1309.
CR Abumaree M, 2012, STEM CELL REV REP, V8, P375, DOI 10.1007/s12015-011-9312-0
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Carwile ME, 1998, EXP EYE RES, V66, P791, DOI 10.1006/exer.1998.0488
   Cejkova J, 2013, EXP EYE RES, V116, P312, DOI 10.1016/j.exer.2013.10.002
   Chen KH, 1999, INVEST OPHTH VIS SCI, V40, P2627
   Chua J, 2012, MOL VIS, V18, P431
   Conway K, 2006, WOUND REPAIR REGEN, V14, P2, DOI 10.1111/j.1743-6109.2005.00081.x
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Ding SLS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081406
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eastlake K, 2016, GLIA, V64, P495, DOI 10.1002/glia.22942
   English K, 2007, IMMUNOL LETT, V110, P91, DOI 10.1016/j.imlet.2007.04.001
   Ezquer M, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0299-y
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Forrester JV, 2009, EYE, V23, P756, DOI 10.1038/eye.2008.259
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x
   GEIGER K, 1994, INVEST OPHTH VIS SCI, V35, P2667
   Granofszky N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00821
   He C, 2016, SCI REP-UK, V6, DOI 10.1038/srep27739
   Hermankova B, 2017, STEM CELLS DEV, V26, P1399, DOI 10.1089/scd.2017.0111
   Holan V, 2017, CELL TRANSPLANT, V26, P1538, DOI 10.1177/0963689717721227
   Holan V, 2016, STEM CELL REV REP, V12, P654, DOI 10.1007/s12015-016-9688-y
   Holan V, 2015, STEM CELL TRANSL MED, V4, P1052, DOI 10.5966/sctm.2015-0039
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Huang C, 2012, J CELL BIOCHEM, V113, P590, DOI 10.1002/jcb.23383
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Ji SL, 2018, CURR EYE RES, V43, P810, DOI 10.1080/02713683.2018.1440604
   Johnsen-Soriano S, 2010, GRAEF ARCH CLIN EXP, V248, P985, DOI 10.1007/s00417-009-1289-x
   Jordan SC, 2017, TRANSPLANTATION, V101, P32, DOI 10.1097/TP.0000000000001452
   Kiang L, 2018, INVEST OPHTH VIS SCI, V59, P3767, DOI 10.1167/iovs.18-24489
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kolomeyer AM, 2014, SURV OPHTHALMOL, V59, P134, DOI 10.1016/j.survophthal.2013.09.004
   Kutty RK, 2016, MOL VIS, V22, P1156
   Velandia SL, 2018, GRAEF ARCH CLIN EXP, V256, P125, DOI 10.1007/s00417-017-3842-3
   Labrador-Velandia S, 2016, WORLD J STEM CELLS, V8, P376, DOI 10.4252/wjsc.v8.i11.376
   Le Blanc K, 2007, J INTERN MED, V262, P509, DOI 10.1111/j.1365-2796.2007.01844.x
   Lee MJ, 2015, MOL THER, V23, P139, DOI 10.1038/mt.2014.159
   Lohan P, 2018, STEM CELLS, V36, P1210, DOI 10.1002/stem.2840
   Ma OKF, 2016, WORLD J STEM CELLS, V8, P268, DOI 10.4252/wjsc.v8.i9.268
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Mahajan VB, 2010, MOL VIS, V16, P1034
   Mathew B, 2017, GRAEF ARCH CLIN EXP, V255, P1581, DOI 10.1007/s00417-017-3690-1
   Mathivanan I, 2015, EXP CELL RES, V333, P11, DOI 10.1016/j.yexcr.2015.02.001
   Mead B, 2013, INVEST OPHTH VIS SCI, V54, P7544, DOI 10.1167/iovs.13-13045
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Mittal SK, 2016, STEM CELL REP, V7, P583, DOI 10.1016/j.stemcr.2016.09.001
   Mourkioti F, 2005, TRENDS IMMUNOL, V26, P535, DOI 10.1016/j.it.2005.08.002
   Mugisho OO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202156
   Musina RA, 2005, B EXP BIOL MED+, V139, P504, DOI 10.1007/s10517-005-0331-1
   Nagineni CN, 2010, BIOCHEM BIOPH RES CO, V391, P287, DOI 10.1016/j.bbrc.2009.11.051
   Neufeld AH, 2002, EXP EYE RES, V75, P521, DOI 10.1006/exer.2002.2042
   Ng Tsz Kin, 2014, World J Stem Cells, V6, P111, DOI 10.4252/wjsc.v6.i2.111
   Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001
   Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007-0737
   Oh JY, 2009, CYTOKINE, V46, P100, DOI 10.1016/j.cyto.2008.12.011
   Park SS, 2017, PROG RETIN EYE RES, V56, P148, DOI 10.1016/j.preteyeres.2016.10.002
   Popescu M, 2018, DRUG DES DEV THER, V12, P1985, DOI 10.2147/DDDT.S156941
   Salehi H, 2017, ANN ANAT, V210, P52, DOI 10.1016/j.aanat.2016.11.010
   Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P2932, DOI 10.1167/iovs.05-1407
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Sipp D, 2018, NATURE, V561, P455, DOI 10.1038/d41586-018-06756-9
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Svobodova E, 2012, STEM CELLS DEV, V21, P901, DOI 10.1089/scd.2011.0157
   Tasso R, 2012, INVEST OPHTH VIS SCI, V53, P786, DOI 10.1167/iovs.11-8211
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Tzameret A, 2015, STEM CELL RES, V15, P387, DOI 10.1016/j.scr.2015.08.007
   Wang JCC, 2015, MOL VIS, V21, P264
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Yao K, 2018, NATURE, V560, P484, DOI 10.1038/s41586-018-0425-3
   Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3
   Zhao PT, 2016, INT J OPHTHALMOL-CHI, V9, P1381, DOI 10.18240/ijo.2016.10.03
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878
   Zwart I, 2009, EXP NEUROL, V216, P439, DOI 10.1016/j.expneurol.2008.12.028
NR 77
TC 16
Z9 18
U1 0
U2 5
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1948-0210
J9 WORLD J STEM CELLS
JI World J. Stem Cells
PD NOV 26
PY 2019
VL 11
IS 11
BP 957
EP 967
DI 10.4252/wjsc.v11.i11.957
PG 11
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KK5AM
UT WOS:000512754600004
PM 31768222
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Chiang, CK
   Tworak, A
   Kevany, BM
   Xu, B
   Mayne, J
   Ning, ZB
   Figeys, D
   Palczewski, K
AF Chiang, Cheng-Kang
   Tworak, Aleksander
   Kevany, Brian M.
   Xu, Bo
   Mayne, Janice
   Ning, Zhibin
   Figeys, Daniel
   Palczewski, Krzysztof
TI Quantitative phosphoproteomics reveals involvement of multiple signaling
   pathways in early phagocytosis by the retinal pigmented epithelium
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE eye; receptor recycling; retina; retinal degeneration; retinal
   metabolism
ID PHOTORECEPTOR OUTER SEGMENTS; FOCAL ADHESION KINASE; ARREST-SPECIFIC
   GENE; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA-V-BETA-5 INTEGRIN; PROMOTES
   PHAGOCYTOSIS; ROD; PHOSPHORYLATION; CELLS; ACTIVATION
AB One of the major biological functions of the retinal pigmented epithelium (RPE) is the clearance of shed photoreceptor outer segments (POS) through a multistep process resembling phagocytosis. RPE phagocytosis helps maintain the viability of photoreceptors that otherwise could succumb to the high metabolic flux and photo-oxidative stress associated with visual processing. The regulatory mechanisms underlying phagocytosis in the RPE are not fully understood, although dysfunction of this process contributes to the pathogenesis of multiple human retinal degenerative disorders, including age-related macular degeneration. Here, we present an integrated transcriptomic, proteomic, and phosphoproteomic analysis of phagocytosing RPE cells, utilizing three different experimental models: the human-derived RPE-like cell line ARPE-19, cultured murine primary RPE cells, and RPE samples from live mice. Our combined results indicated that early stages of phagocytosis in the RPE are mainly characterized by pronounced changes in the protein phosphorylation level. Global phosphoprotein enrichment analysis revealed involvement of PI3K/Akt, mechanistic target of rapamycin (mTOR), and MEK/ERK pathways in the regulation of RPE phagocytosis, confirmed by immunoblot analyses and in vitro phagocytosis assays. Most strikingly, phagocytosis of POS by cultured RPE cells was almost completely blocked by pharmacological inhibition of phosphorylation of Akt. Our findings, along with those of previous studies, indicate that these phosphorylation events allow the RPE to integrate multiple signals instigated by shed POS at different stages of the phagocytic process.
C1 [Chiang, Cheng-Kang; Xu, Bo; Mayne, Janice; Ning, Zhibin; Figeys, Daniel] Univ Ottawa, Ottawa Inst Syst Biol, Fac Med, Ottawa, ON K1H 8M5, Canada.
   [Chiang, Cheng-Kang; Xu, Bo; Mayne, Janice; Ning, Zhibin; Figeys, Daniel] Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, Ottawa, ON K1H 8M5, Canada.
   [Chiang, Cheng-Kang] Natl Dong Hwa Univ, Dept Chem, 1 Sec 2 Da Hsueh Rd, Hualien 97401, Taiwan.
   [Tworak, Aleksander; Kevany, Brian M.; Palczewski, Krzysztof] Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA.
   [Palczewski, Krzysztof] Case Western Reserve Univ, Cleveland Ctr Membrane & Struct Biol, Sch Med, Cleveland, OH 44106 USA.
   [Figeys, Daniel] Canadian Inst Adv Res, Toronto, ON M5G 1Z8, Canada.
C3 University of Ottawa; University of Ottawa; National Dong Hwa
   University; Case Western Reserve University; Case Western Reserve
   University; Canadian Institute for Advanced Research (CIFAR)
RP Figeys, D (通讯作者)，Univ Ottawa, Ottawa Inst Syst Biol, Fac Med, Ottawa, ON K1H 8M5, Canada.; Palczewski, K (通讯作者)，Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA.; Palczewski, K (通讯作者)，Case Western Reserve Univ, Cleveland Ctr Membrane & Struct Biol, Sch Med, Cleveland, OH 44106 USA.; Figeys, D (通讯作者)，Canadian Inst Adv Res, Toronto, ON M5G 1Z8, Canada.
EM dfigeys@uottawa.ca; kxp65@case.edu
RI Chiang, Cheng-Kang/AAQ-7472-2021
OI Figeys, Daniel/0000-0002-5373-7546; Tworak,
   Aleksander/0000-0002-3256-8990
FU National Institutes of Health [EY009339, EY024864, EY011373]; National
   Sciences and Engineering Research Council (NSERC) of Canada; Canadian
   Institute for Advanced Research (CIFAR); Canadian Institutes of Health
   Research (CIHR); Arnold and Mabel Beckman Foundation; Canadian
   Foundation for Innovation (CFI); Ontario Research Fund; la Fondation
   J.-Louis Levesque; NATIONAL EYE INSTITUTE [R01EY009339, R24EY024864,
   P30EY011373] Funding Source: NIH RePORTER
FX This work was supported in part by National Institutes of Health Grants
   EY009339 and EY024864 (to K. P.) and EY011373 (VSRC CORE grant); the
   National Sciences and Engineering Research Council (NSERC) of Canada (to
   D. F.); the Canadian Institute for Advanced Research (CIFAR) and the
   Canadian Institutes of Health Research (CIHR) (to D. F.); the Arnold and
   Mabel Beckman Foundation (to K. P.); and the Canadian Foundation for
   Innovation (CFI), the Ontario Research Fund, and la Fondation J.-Louis
   Levesque (to D. F.). The authors declare that they have no conflicts of
   interest with the contents of this article. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ainscough SL, 2009, EXP EYE RES, V89, P629, DOI 10.1016/j.exer.2009.06.005
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   Bulloj A, 2013, EXP EYE RES, V113, P9, DOI 10.1016/j.exer.2013.05.002
   Colaert N, 2009, NAT METHODS, V6, P786, DOI 10.1038/nmeth1109-786
   Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Diemer T, 2008, ADV EXP MED BIOL, V613, P321, DOI 10.1007/978-0-387-74904-4_37
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Filippi S, 2016, CELL REP, V15, P2524, DOI 10.1016/j.celrep.2016.05.024
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Fox R, 2007, EMBO J, V26, P505, DOI 10.1038/sj.emboj.7601522
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Freeman SA, 2014, IMMUNOL REV, V262, P193, DOI 10.1111/imr.12212
   Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P107
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442
   Hall MO, 2002, EXP EYE RES, V75, P391, DOI 10.1006/exer.2002.2030
   HETH CA, 1991, CURR EYE RES, V10, P1049, DOI 10.3109/02713689109020343
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389
   Ishimoto Y, 2000, J BIOCHEM-TOKYO, V127, P411, DOI 10.1093/oxfordjournals.jbchem.a022622
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kiser PD, 2016, ANNU REV VIS SCI, V2, P197, DOI 10.1146/annurev-vision-111815-114407
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lande-Diner L, 2013, P NATL ACAD SCI USA, V110, P16021, DOI 10.1073/pnas.1305980110
   Law AL, 2009, MOL BIOL CELL, V20, P3896, DOI 10.1091/mbc.E08-12-1204
   Lee H, 2011, INT J BIOL MACROMOL, V48, P194, DOI 10.1016/j.ijbiomac.2010.11.006
   Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Makino-Okamura C, 2014, PIGM CELL MELANOMA R, V27, P1063, DOI [10.1111/pcmr.12287, 10.1111/pcmr.12284]
   Mao YY, 2012, MOL BIOL CELL, V23, P1104, DOI 10.1091/mbc.E11-10-0840
   May RC, 2001, J CELL SCI, V114, P1061
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Olchawa MM, 2016, FREE RADICAL RES, V50, P887, DOI 10.1080/10715762.2016.1194519
   Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026
   Onishi Y, 2008, MOL CELL BIOL, V28, P3477, DOI 10.1128/MCB.02227-07
   Palczewska G, 2016, J BIOL CHEM, V291, P26937, DOI 10.1074/jbc.M116.764563
   PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48
   Parsa KVL, 2008, MOL IMMUNOL, V45, P3012, DOI 10.1016/j.molimm.2008.01.011
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822
   Prasad D, 2006, MOL CELL NEUROSCI, V33, P96, DOI 10.1016/j.mcn.2006.06.011
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Ruggiero L, 2012, P NATL ACAD SCI USA, V109, P8145, DOI 10.1073/pnas.1121101109
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sasore T, 2014, ADV EXP MED BIOL, V801, P805, DOI 10.1007/978-1-4614-3209-8_101
   Song CX, 2012, MOL CELL PROTEOMICS, V11, P1070, DOI 10.1074/mcp.M111.012625
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Wang XM, 2016, EXP CELL RES, V344, P219, DOI 10.1016/j.yexcr.2016.04.017
   Wrann CD, 2007, J IMMUNOL, V178, P5940, DOI 10.4049/jimmunol.178.9.5940
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yu B, 2014, INVEST OPHTH VIS SCI, V55, P8638, DOI 10.1167/iovs.14-14758
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou HJ, 2013, NAT PROTOC, V8, P461, DOI 10.1038/nprot.2013.010
NR 64
TC 10
Z9 10
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 1
PY 2017
VL 292
IS 48
BP 19826
EP 19839
DI 10.1074/jbc.M117.812677
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FO5OZ
UT WOS:000416911300026
PM 28978645
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Storti, F
   Raphael, G
   Griesser, V
   Klee, K
   Drawnel, F
   Willburger, C
   Scholz, R
   Langmann, T
   von Eckardstein, A
   Fingerle, J
   Grimm, C
   Maugeais, C
AF Storti, Federica
   Raphael, Gabriele
   Griesser, Vera
   Klee, Katrin
   Drawnel, Faye
   Willburger, Carolin
   Scholz, Rebecca
   Langmann, Thomas
   von Eckardstein, Arnold
   Fingerle, Juergen
   Grimm, Christian
   Maugeais, Cyrille
TI Regulated efflux of photoreceptor outer segment-derived cholesterol by
   human RPE cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE ABCA1; RPE; Cholesterol efflux; HDL; LXR; ApoA-I
ID SUBRETINAL DRUSENOID DEPOSITS; APOLIPOPROTEIN-A-I; DENSITY-LIPOPROTEIN;
   MACULAR DEGENERATION; GENETIC-VARIANTS; LIPID-METABOLISM; HUMAN RETINA;
   AGE; ABCA1; EXPRESSION
AB Genetic studies have linked age-related macular degeneration (AMD) to genes involved in high-density lipoprotein (HDL) metabolism, including ATP-binding cassette transporter Al (ABCA1). The retinal pigment epithelium (RPE) handles large amounts of lipids, among others cholesterol, partially derived from internalized photoreceptor outer segments (OS) and lipids physiologically accumulate in the aging eye. To analyze the potential function of ABCA1 in the eye, we measured cholesterol efflux, the first step of HDL generation, in RPE cells. We show the expression of selected genes related to HDL metabolism in mouse and human eyecups as well as in ARPE-19 and human primary RPE cells. Immunofluorescence staining revealed localization of ABCA1 on both sides of polarized RPE cells. This was functionally confirmed by directional efflux to apolipoprotein Al (ApoA-I) of H-3-labeled cholesterol given to the cells via serum or via OS. ABCA1 expression and activity was modulated using a liver-X-receptor (LXR) agonist and an ABCA1 neutralizing antibody, demonstrating that the efflux was ABCA1-dependent. We concluded that the ABCAl-mediated lipid efflux pathway, and hence HDL biosynthesis, is functional in RPE cells towards both the basal (choroidal) and apical (subretinal) space. Impaired activity of the pathway might cause age-related perturbations of lipid homeostasis in the outer retina and thus may contribute to disease development and/or progression. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Storti, Federica; Klee, Katrin; Grimm, Christian] Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, Wagistr 14, CH-8952 Schlieren, Switzerland.
   [Raphael, Gabriele; Griesser, Vera; Drawnel, Faye; Willburger, Carolin; Maugeais, Cyrille] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Basel, Switzerland.
   [Klee, Katrin; Grimm, Christian] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
   [Scholz, Rebecca; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.
   [von Eckardstein, Arnold] Univ Zurich, Inst Clin Chem, Schlieren, Switzerland.
   [Fingerle, Juergen] Univ Tubingen, Nat & Med Sci Inst, Tubingen, Germany.
   [Grimm, Christian] Univ Zurich, Neurosci Ctr Zurich ZNZ, Zurich, Switzerland.
C3 Roche Holding; University of Zurich; Zurich Center Integrative Human
   Physiology (ZIHP); University of Cologne; Eberhard Karls University of
   Tubingen; University of Zurich
RP Grimm, C (通讯作者)，Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, Wagistr 14, CH-8952 Schlieren, Switzerland.
EM cgrimm@opht.uzh.ch
OI Grimm, Christian/0000-0001-9318-4352
FU Roche Postdoc Fellowship (RPF) [378]
FX This work was supported by a Roche Postdoc Fellowship (RPF, reference
   number 378). The authors declare no conflict of interest. GR, VG, FD, CW
   and CM are employees of E Hoffmann-La Roche Ltd.
CR Albert A, 2016, CHEM PHYS LIPIDS, V199, P94, DOI 10.1016/j.chemphyslip.2016.04.008
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   BESHARSE JC, 1979, INVEST OPHTH VIS SCI, V18, P1019
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bojanic DD, 2010, J LIPID RES, V51, P169, DOI [10.1194/jlr.M900250-JLR200, 10.1194/M900250-JLR200]
   Brunham LR, 2015, PROG LIPID RES, V58, P14, DOI 10.1016/j.plipres.2015.01.001
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Capes-Davis A, 2013, INT J CANCER, V132, P2510, DOI 10.1002/ijc.27931
   Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200
   Chang T. Y., 2017, J LIPID RES
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen WG, 2005, J BIOL CHEM, V280, P29277, DOI 10.1074/jbc.M505566200
   Claudepierre T, 2010, MOL CELL NEUROSCI, V43, P164, DOI 10.1016/j.mcn.2009.10.007
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dreyer AM, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-87
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FLIESLER SJ, 1982, BIOCHIM BIOPHYS ACTA, V711, P138, DOI 10.1016/0005-2760(82)90020-0
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   GORDON WC, 1992, CURR EYE RES, V11, P73, DOI 10.3109/02713689209069169
   Green W R, 1999, Mol Vis, V5, P27
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Kivela T, 2000, CELL TISSUE RES, V301, P217, DOI 10.1007/s004410000225
   Klein R, 1993, OPHTHALMOLOGY, V100
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Korach-Andre M., 2015, BIOMOL CONCEPTS, V177
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Low H, 2012, JOVE-J VIS EXP, DOI 10.3791/3810
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Oczos J, 2014, INVEST OPHTH VIS SCI, V55, P4714, DOI 10.1167/iovs.14-14332
   Ohnsorg PM, 2011, BBA-MOL CELL BIOL L, V1811, P1115, DOI 10.1016/j.bbalip.2011.09.001
   Panday N, 2006, BIOORG MED CHEM LETT, V16, P5231, DOI 10.1016/j.bmcl.2006.06.081
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Quazi F, 2011, ESSAYS BIOCHEM, V50, P265, DOI [10.1042/BSE0500265, 10.1042/bse0500265]
   Robinet P, 2010, J LIPID RES, V51, P3364, DOI 10.1194/jlr.D007336
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Samardzija M, 2006, FASEB J, V20, P2411, DOI 10.1096/fj.06-5895fje
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Schmitz G, 2005, BBA-MOL CELL BIOL L, V1735, P1, DOI 10.1016/j.bbalip.2005.04.004
   Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YOUNG RW, 1968, J CELL BIOL, V39, P169, DOI 10.1083/jcb.39.1.169
   YOUNG RW, 1978, INVEST OPHTH VIS SCI, V17, P105
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zannis VI, 2015, HANDB EXP PHARMACOL, V224, P53, DOI 10.1007/978-3-319-09665-0_2
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zekavat SM, 2017, J LIPID RES, V58, P1325, DOI 10.1194/jlr.M074088
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 74
TC 33
Z9 35
U1 0
U2 14
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2017
VL 165
BP 65
EP 77
DI 10.1016/j.exer.2017.09.008
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ4GL
UT WOS:000418315600008
PM 28943268
DA 2022-11-30
ER

PT J
AU Hudecek, M
   Izsvak, Z
   Johnen, S
   Renner, M
   Thumann, G
   Ivics, Z
AF Hudecek, Michael
   Izsvak, Zsuzsanna
   Johnen, Sandra
   Renner, Matthias
   Thumann, Gabriele
   Ivics, Zoltan
TI Going non-viral: the Sleeping Beauty transposon system breaks on through
   to the clinical side
SO CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Review
DE Gene therapy vectors; minicircle; eye diseases; chimeric antigen
   receptor; stable gene transfer
ID STABLE GENE-TRANSFER; CAR-T-CELLS; EPISOMAL TRANSGENE EXPRESSION;
   RETINAL-PIGMENT EPITHELIUM; MEDIATED BAC TRANSGENESIS; HEMATOPOIETIC
   STEM-CELLS; LONG-TERM EXPRESSION; DNA-BINDING DOMAIN; MACULAR
   DEGENERATION; MESSENGER-RNA
AB Molecular medicine has entered a high-tech age that provides curative treatments of complex genetic diseases through genetically engineered cellular medicinal products. Their clinical implementation requires the ability to stably integrate genetic information through gene transfer vectors in a safe, effective and economically viable manner. The latest generation of Sleeping Beauty (SB) transposon vectors fulfills these requirements, and may overcome limitations associated with viral gene transfer vectors and transient non-viral gene delivery approaches that are prevalent in ongoing pre-clinical and translational research. The SB system enables high-level stable gene transfer and sustained transgene expression in multiple primary human somatic cell types, thereby representing a highly attractive gene transfer strategy for clinical use. Here we review several recent refinements of the system, including the development of optimized transposons and hyperactive SB variants, the vectorization of transposase and transposon as mRNA and DNA minicircles (MCs) to enhance performance and facilitate vector production, as well as a detailed understanding of SB's genomic integration and biosafety features. This review also provides a perspective on the regulatory framework for clinical trials of gene delivery with SB, and illustrates the path to successful clinical implementation by using, as examples, gene therapy for age-related macular degeneration (AMD) and the engineering of chimeric antigen receptor (CAR)modified T cells in cancer immunotherapy.
C1 [Hudecek, Michael] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany.
   [Izsvak, Zsuzsanna] Helmholtz Assoc MDC, Max Delbruck Ctr Mol Med, Mobile DNA, Berlin, Germany.
   [Johnen, Sandra] Univ Hosp RWTH Aachen, Dept Ophthalmol, Aachen, Germany.
   [Renner, Matthias; Ivics, Zoltan] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany.
   [Thumann, Gabriele] Hop Univ Geneve, Dept Neurosci Clin, Serv Ophthalmol, Geneva, Switzerland.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Wurzburg; Helmholtz Association; Max Delbruck Center for
   Molecular Medicine; RWTH Aachen University; RWTH Aachen University
   Hospital; Paul Ehrlich Institute; University of Geneva
RP Ivics, Z (通讯作者)，Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
EM zoltan.ivics@pei.de
RI Johnen, Sandra/ABA-9955-2020
OI Johnen, Sandra/0000-0003-0028-2557
FU German Cancer Aid (Deutsche Krebshilfe e.V., Max Eder Programm)
   [110313]; Myeloma Crowd Research Initiative; Interdisciplinary Center
   for Clinical Research (IZKF) Wurzburg [Z/4-109, D-244]; European Union
   [305134]; Center for Cell and Gene Therapy of the LOEWE
   (Landes-Offensive zur Entwicklung Wissenschaftlich-okonomischer
   Exzellenz) program in Hessen, Germany
FX M.H. was supported by the German Cancer Aid (Deutsche Krebshilfe e.V.,
   Max Eder Programm 110313), the Myeloma Crowd Research Initiative and the
   Interdisciplinary Center for Clinical Research (IZKF) Wurzburg (Projects
   Z/4-109 and D-244). The TargetAMD project has received funding from the
   European Union's Seventh Framework Programme for research, technological
   development and demonstration under grant agreement no 305134. Z.Iv. was
   supported by the Center for Cell and Gene Therapy of the LOEWE
   (Landes-Offensive zur Entwicklung Wissenschaftlich-okonomischer
   Exzellenz) program in Hessen, Germany.
CR Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151
   Aiuti A, 2013, HUM GENE THER CL DEV, V24, P47, DOI 10.1089/humc.2013.119
   Aronovich EL, 2007, J GENE MED, V9, P403, DOI 10.1002/jgm.1028
   Aronovich EL, 2009, MOL THER, V17, P1136, DOI 10.1038/mt.2009.87
   Balaggan KS, 2012, GENE THER, V19, P182, DOI 10.1038/gt.2011.194
   Basner-Tschakarjan E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00350
   Baum C, 2004, MOL THER, V9, P5, DOI 10.1016/j.ymthe.2003.10.013
   Baus J, 2005, MOL THER, V12, P1148, DOI 10.1016/j.ymthe.2005.06.484
   Beatty GL, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.970027
   Belay E, 2010, STEM CELLS, V28, P1760, DOI 10.1002/stem.501
   Belcher JD, 2010, J MOL MED, V88, P665, DOI 10.1007/s00109-010-0613-6
   Belur LR, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-14
   Belur LR, 2003, MOL THER, V8, P501, DOI 10.1016/S1525-0016(03)00211-9
   Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163
   Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Boehme P, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.44
   Boehme P, 2015, CURR GENE THER, V15, P255, DOI 10.2174/1566523215666150126121353
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Bowers WJ, 2006, MOL THER, V13, P580, DOI 10.1016/j.ymthe.2005.11.011
   Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242
   Caruso HG, 2016, J IMMUNOTHER, V39, P205, DOI 10.1097/CJI.0000000000000126
   Cattoglio C, 2010, BLOOD, V116, P5507, DOI 10.1182/blood-2010-05-283523
   Cavazza A, 2013, HUM GENE THER, V24, P119, DOI 10.1089/hum.2012.203
   Cavazzana-Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328
   Cesana D, 2012, J CLIN INVEST, V122, P1667, DOI 10.1172/JCI62189
   Chabot S, 2013, GENE THER, V20, P62, DOI 10.1038/gt.2011.215
   CHANDLER M, 1982, J MOL BIOL, V154, P229, DOI 10.1016/0022-2836(82)90062-6
   Chen ZY, 2008, MOL THER, V16, P548, DOI 10.1038/sj.mt.6300399
   Chen ZY, 2004, GENE THER, V11, P856, DOI 10.1038/sj.gt.3302231
   Chen ZY, 2003, MOL THER, V8, P495, DOI 10.1016/S1525-0016(03)00168-0
   Chen ZYJ, 2005, BIOCHEM BIOPH RES CO, V329, P646, DOI 10.1016/j.bbrc.2005.02.024
   Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538
   Cocchiarella F, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.38
   Cui ZB, 2002, J MOL BIOL, V318, P1221, DOI 10.1016/S0022-2836(02)00237-1
   Darquet AM, 1997, GENE THER, V4, P1341, DOI 10.1038/sj.gt.3300540
   Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226
   De Ravin SS, 2014, J VIROL, V88, P4504, DOI 10.1128/JVI.00011-14
   de Silva S, 2010, GENE THER, V17, P424, DOI 10.1038/gt.2009.144
   Deichmann A, 2007, J CLIN INVEST, V117, P2225, DOI 10.1172/JCI31659
   Deniger DC, 2016, MOL THER, V24, P1078, DOI 10.1038/mt.2016.51
   Dijkhuizen PA, 1998, J NEUROTRAUM, V15, P387, DOI 10.1089/neu.1998.15.387
   Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Escobar H, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2015.52
   Essner JJ, 2005, CURR OPIN PHARMACOL, V5, P513, DOI 10.1016/j.coph.2005.04.015
   Eyjolfsdottir H, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0195-9
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fernando S, 2006, BIODRUGS, V20, P219, DOI 10.2165/00063030-200620040-00003
   Fischer SEJ, 1999, MOL GEN GENET, V262, P268, DOI 10.1007/PL00008641
   Galla M, 2011, NUCLEIC ACIDS RES, V39, P7147, DOI 10.1093/nar/gkr384
   Garrison BS, 2007, MOL CELL BIOL, V27, P8824, DOI 10.1128/MCB.00498-07
   Geurts AM, 2003, MOL THER, V8, P108, DOI 10.1016/S1525-0016(03)00099-6
   Gogol-Doring A, 2016, MOL THER, V24, P592, DOI 10.1038/mt.2016.11
   Grabundzija I, 2010, MOL THER, V18, P1200, DOI 10.1038/mt.2010.47
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700
   Hackett PB, 2005, ADV GENET, V54, P189, DOI 10.1016/S0065-2660(05)54009-4
   Hackett PB, 2010, MOL THER, V18, P674, DOI 10.1038/mt.2010.2
   Hackett PB, 2011, CURR GENE THER, V11, P341
   Hargrove PW, 2008, MOL THER, V16, P525, DOI 10.1038/sj.mt.6300394
   Hartman ZC, 2008, VIRUS RES, V132, P1, DOI 10.1016/j.virusres.2007.10.005
   Hausl MA, 2010, MOL THER, V18, P1896, DOI 10.1038/mt.2010.169
   He CX, 2004, WORLD J GASTROENTERO, V10, P567, DOI 10.3748/wjg.v10/i4/567
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Hermens WTJMC, 1997, HUM GENE THER, V8, P1049, DOI 10.1089/hum.1997.8.9-1049
   Hirsch ML, 2016, METHODS MOL BIOL, V1382, P21, DOI 10.1007/978-1-4939-3271-9_2
   Hollis RP, 2006, EXP HEMATOL, V34, P1333, DOI 10.1016/j.exphem.2006.05.023
   Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798
   Huang X, 2008, MOL THER, V16, P580, DOI 10.1038/sj.mt.6300404
   Huang X, 2010, MOL THER, V18, P1803, DOI 10.1038/mt.2010.141
   Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127
   Hudecek M, 2013, CLIN CANCER RES, V19, P3153, DOI 10.1158/1078-0432.CCR-13-0330
   Huerfano S, 2013, DNA CELL BIOL, V32, P467, DOI 10.1089/dna.2012.1950
   Hyde SC, 2008, NAT BIOTECHNOL, V26, P549, DOI 10.1038/nbt1399
   Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5
   Ivics Z, 1996, P NATL ACAD SCI USA, V93, P5008, DOI 10.1073/pnas.93.10.5008
   Ivics Z, 2007, MOL THER, V15, P1137, DOI 10.1038/sj.mt.6300169
   Ivics Z, 2006, CURR GENE THER, V6, P593, DOI 10.2174/156652306778520647
   Ivics Z, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.MDNA3-0042-2014
   Ivics Z, 2014, NAT PROTOC, V9, P810, DOI 10.1038/nprot.2014.010
   Ivics Z, 2014, NAT PROTOC, V9, P794, DOI 10.1038/nprot.2014.009
   Ivics Z, 2014, NAT PROTOC, V9, P773, DOI 10.1038/nprot.2014.008
   Ivics Z, 2011, HUM GENE THER, V22, P1043, DOI 10.1089/hum.2011.143
   Ivics Z, 2010, MOBILE DNA-UK, V1, DOI 10.1186/1759-8753-1-25
   Ivics Z, 2009, NAT METHODS, V6, P415, DOI [10.1038/NMETH.1332, 10.1038/nmeth.1332]
   Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047
   Izsvak Z, 2004, MOL THER, V9, P147, DOI 10.1016/j.ymthe.2003.11.009
   Izsvak Z, 2002, J BIOL CHEM, V277, P34581, DOI 10.1074/jbc.M204001200
   Izsvak Z, 2010, BIOESSAYS, V32, P756, DOI 10.1002/bies.201000027
   Izsvak Z, 2009, METHODS, V49, P287, DOI 10.1016/j.ymeth.2009.07.001
   JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0
   Jin Z, 2011, GENE THER, V18, P849, DOI 10.1038/gt.2011.40
   Johnen S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/863845
   Johnen S, 2012, INVEST OPHTH VIS SCI, V53, P4787, DOI 10.1167/iovs.12-9951
   Karsi A, 2001, MAR BIOTECHNOL, V3, P241, DOI 10.1007/s101260000072
   Kebriaei P, 2016, J CLIN INVEST, V126, P3363, DOI 10.1172/JCI86721
   Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025
   Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821
   Kren BT, 2009, J CLIN INVEST, V119, P2086, DOI 10.1172/JCI34332
   Kuerten D, 2015, GRAEF ARCH CLIN EXP, V253, P1061, DOI 10.1007/s00417-015-2954-x
   Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lampe DJ, 1998, GENETICS, V149, P179
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Latella MC, 2017, J INVEST DERMATOL, V137, P836, DOI 10.1016/j.jid.2016.11.038
   Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3
   Liu GY, 2005, J MOL BIOL, V346, P161, DOI 10.1016/j.jmb.2004.09.086
   Liu L, 2004, MOL THER, V10, P97, DOI 10.1016/j.ymthe.2004.04.006
   Liu L, 2006, FASEB J, V20, P2594, DOI 10.1096/fj.06-6254fje
   Liu L, 2006, MOL THER, V13, P1006, DOI 10.1016/j.ymthe.2005.11.021
   Luo WY, 2012, GENE THER, V19, P844, DOI 10.1038/gt.2011.129
   Magnani CF, 2016, ONCOTARGET, V7, P51581, DOI 10.18632/oncotarget.9955
   Maldarelli F, 2014, SCIENCE, V345, P179, DOI 10.1126/science.1254194
   Marie C, 2010, J GENE MED, V12, P323, DOI 10.1002/jgm.1441
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   Matrai J, 2010, MOL THER, V18, P477, DOI 10.1038/mt.2009.319
   Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222
   Maus MV, 2013, CANCER IMMUNOL RES, V1, P26, DOI 10.1158/2326-6066.CIR-13-0006
   Menendez-Arias L, 2009, VIRUSES-BASEL, V1, P1137, DOI 10.3390/v1031137
   Mikkelsen JG, 2003, MOL THER, V8, P654, DOI 10.1016/S1525-0016(03)00216-8
   Mock U, 2016, CYTOTHERAPY, V18, P1002, DOI 10.1016/j.jcyt.2016.05.009
   Modlich U, 2009, MOL THER, V17, P1919, DOI 10.1038/mt.2009.179
   Moldt B, 2007, HUM GENE THER, V18, P1193, DOI 10.1089/hum.2007.099
   Moldt B, 2011, MOL THER, V19, P1499, DOI 10.1038/mt.2011.47
   Monjezi R, 2017, LEUKEMIA, V31, P186, DOI 10.1038/leu.2016.180
   Montini E, 2002, MOL THER, V6, P759, DOI 10.1006/mthe.2002.0812
   Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003
   MORISATO D, 1983, CELL, V32, P799, DOI 10.1016/0092-8674(83)90066-1
   Muses S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024826
   Naldini L, 2011, NAT REV GENET, V12, P301, DOI 10.1038/nrg2985
   Narayanavari SA, 2017, CRIT REV BIOCHEM MOL, V52, P18, DOI 10.1080/10409238.2016.1237935
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Newrzela S, 2008, BLOOD, V112, P2278, DOI 10.1182/blood-2007-12-128751
   Ohlfest JR, 2005, MOL THER, V12, P778, DOI 10.1016/j.ymthe.2005.07.689
   Ohlfest JR, 2005, BLOOD, V105, P2691, DOI 10.1182/blood-2004-09-3496
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Orban TI, 2009, STEM CELLS, V27, P1077, DOI 10.1002/stem.45
   Ortiz-Urda S, 2003, GENE THER, V10, P1099, DOI 10.1038/sj.gt.3301978
   Osborn MJ, 2011, MOL THER, V19, P450, DOI 10.1038/mt.2010.249
   Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393
   Pan XJ, 2012, J INT MED RES, V40, P1850, DOI 10.1177/030006051204000523
   Pannell D, 2001, REV MED VIROL, V11, P205, DOI 10.1002/rmv.316
   Papapetrou EP, 2011, NAT BIOTECHNOL, V29, P73, DOI 10.1038/nbt.1717
   Paszkiewicz PJ, 2016, J CLIN INVEST, V126, P4262, DOI 10.1172/JCI84813
   Peng PD, 2009, GENE THER, V16, P1042, DOI 10.1038/gt.2009.54
   Rapoport AP, 2015, NAT MED, V21, P914, DOI 10.1038/nm.3910
   Recchia A, 2006, P NATL ACAD SCI USA, V103, P1457, DOI 10.1073/pnas.0507496103
   Reyes-Sandoval A, 2004, MOL THER, V9, P249, DOI 10.1016/j.ymthe.2003.11.008
   Richter M, 2016, BLOOD, V128, P2206, DOI 10.1182/blood-2016-04-711580
   Rostovskaya M, 2013, GENESIS, V51, P135, DOI 10.1002/dvg.22362
   Rostovskaya M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks643
   Sadelain M, 2013, CANCER DISCOV, V3, P388, DOI 10.1158/2159-8290.CD-12-0548
   Sadelain M, 2012, NAT REV CANCER, V12, P51, DOI 10.1038/nrc3179
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Salganik M, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.MDNA3-0052-2014
   Schambach A, 2006, MOL THER, V13, P391, DOI 10.1016/j.ymthe.2005.08.012
   Schambach A, 2007, MOL THER, V15, P1167, DOI 10.1038/sj.mt.6300152
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Sharma N, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.1
   Singh H, 2008, CANCER RES, V68, P2961, DOI 10.1158/0008-5472.CAN-07-5600
   Singh H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064138
   Sinn PL, 2005, GENE THER, V12, P1089, DOI 10.1038/sj.gt.3302570
   Solensky R, 2003, CLIN REV ALLERG IMMU, V24, P201, DOI 10.1385/CRIAI:24:3:201
   Sommermeyer D, 2016, LEUKEMIA, V30, P492, DOI 10.1038/leu.2015.247
   Song JS, 2009, BIOSCI BIOTECH BIOCH, V73, P165, DOI 10.1271/bbb.80581
   Srivastava S, 2015, TRENDS IMMUNOL, V36, P494, DOI 10.1016/j.it.2015.06.004
   Staunstrup NH, 2009, MOL THER, V17, P1205, DOI 10.1038/mt.2009.10
   Sumiyoshi T, 2009, HUM GENE THER, V20, P1607, DOI 10.1089/hum.2009.109
   Thrasher AJ, 2006, NATURE, V443, pE5, DOI 10.1038/nature05219
   Thumann G, 2017, MOL THER-NUCL ACIDS, V6, P302, DOI 10.1016/j.omtn.2017.02.002
   Tse LV, 2015, EXPERT OPIN BIOL TH, V15, P845, DOI 10.1517/14712598.2015.1035645
   Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621
   Turtle CJ, 2016, EXPERT REV HEMATOL, V9, P719, DOI 10.1080/17474086.2016.1203251
   Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309
   Turunen TAK, 2014, J GENE MED, V16, P40, DOI 10.1002/jgm.2756
   Turuneni TAK, 2016, MOL THER, V24, P620, DOI 10.1038/mt.2015.221
   VandenDriessche T, 2009, BLOOD, V114, P1461, DOI 10.1182/blood-2009-04-210427
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Vigdal TJ, 2002, J MOL BIOL, V323, P441, DOI 10.1016/S0022-2836(02)00991-9
   Vink CA, 2009, MOL THER, V17, P1197, DOI 10.1038/mt.2009.94
   Voigt F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11126
   Wagner TA, 2014, SCIENCE, V345, P570, DOI 10.1126/science.1256304
   Walisko O, 2008, MOL THER, V16, P359, DOI 10.1038/sj.mt.6300366
   Wang JB, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1121
   Wang JB, 2015, NAT BIOTECHNOL, V33, P1256, DOI 10.1038/nbt.3408
   Wang X, 2009, HEPATOLOGY, V50, P815, DOI 10.1002/hep.23060
   Wang XL, 2011, BLOOD, V118, P1255, DOI 10.1182/blood-2011-02-337360
   Wang Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/281912
   Wang YM, 2017, NUCLEIC ACIDS RES, V45, P311, DOI 10.1093/nar/gkw1164
   Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213
   Wiehe JM, 2007, J CELL MOL MED, V11, P521, DOI 10.1111/j.1582-4934.2007.00038.x
   Wilber A, 2006, MOL THER, V13, P625, DOI 10.1016/j.ymthe.2005.10.014
   Wilber A, 2007, MOL THER, V15, P1280, DOI 10.1038/sj.mt.6300160
   Wolf D, 2009, NATURE, V458, P1201, DOI 10.1038/nature07844
   Xiao J, 2012, MOL THER, V20, P1251, DOI 10.1038/mt.2012.36
   Xue XK, 2009, BLOOD, V114, P1319, DOI 10.1182/blood-2009-03-210005
   Yant SR, 2002, NAT BIOTECHNOL, V20, P999, DOI 10.1038/nbt738
   Yant SR, 2004, MOL CELL BIOL, V24, P9239, DOI 10.1128/MCB.24.20.9239-9247.2004
   Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568
   Yu KR, 2016, HUM GENE THER, V27, P729, DOI 10.1089/hum.2016.107
   Zayed H, 2004, MOL THER, V9, P292, DOI 10.1016/j.ymthe.2003.11.024
   Zhu JH, 2007, BIOCHEMISTRY-US, V46, P6844, DOI 10.1021/bi6024484
NR 207
TC 64
Z9 67
U1 2
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1040-9238
EI 1549-7798
J9 CRIT REV BIOCHEM MOL
JI Crit. Rev. Biochem. Mol. Biol.
PY 2017
VL 52
IS 4
BP 355
EP 380
DI 10.1080/10409238.2017.1304354
PG 26
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA EY6RB
UT WOS:000404109800002
PM 28402189
OA Green Accepted, hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Vocke, F
   Weisschuh, N
   Marino, V
   Malfatti, S
   Jacobson, SG
   Reiff, CM
   Dell'Orco, D
   Koch, KW
AF Vocke, Farina
   Weisschuh, Nicole
   Marino, Valerio
   Malfatti, Silvia
   Jacobson, Samuel G.
   Reiff, Charlotte M.
   Dell'Orco, Daniele
   Koch, Karl-Wilhelm
TI Dysfunction of cGMP signalling in photoreceptors by a macular
   dystrophy-related mutation in the calcium sensor GCAP1
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID CYCLASE-ACTIVATING PROTEIN-1; DOMINANT CONE DEGENERATION;
   GUANYLATE-CYCLASE; BINDING; MUTANT; CA2+; ROD; PHOTOTRANSDUCTION;
   SENSITIVITY; STABILITY
AB Macular dystrophy leads to progressive loss of central vision and shows symptoms similar to age-related macular degeneration. Genetic screening of patients diagnosed with macular dystrophy disclosed a novel mutation in the GUCA1A gene, namely a c.526C>T substitution leading to the amino acid substitution p.L176F in the guanylate cyclase-activating protein 1 (GCAP1). The same variant was found in three families showing an autosomal dominant mode of inheritance. For a full functional characterization of the L176F mutant we expressed and purified the mutant protein and measured key parameters of its activating properties, its Ca2+/Mg2+-binding, and its Ca2+-induced conformational changes in comparison to the wildtype protein. The mutant was less sensitive to changes in free Ca2+, resulting in a constitutively active form under physiological Ca2+-concentration, showed significantly higher activation rates than the wildtype (90-fold versus 20-fold) and interacted with an higher apparent affinity with its target guanylate cyclase. However, direct Ca2+-binding of the mutant was nearly similar to the wildtype; binding of Mg(2+)occurred with higher affinity. We performed molecular dynamics simulations for comparing the Ca2+-saturated inhibiting state of GCAP1 with the Mg2+-bound activating states. The L176F mutant exhibited significantly lower flexibility, when three Ca2+ or two Mg2+ were bound forming probably the structural basis for the modified GCAP1 function.
C1 [Vocke, Farina; Koch, Karl-Wilhelm] Carl von Ossietzky Univ Oldenburg, Biochem Grp, Dept Neurosci, D-26111 Oldenburg, Germany.
   [Weisschuh, Nicole; Reiff, Charlotte M.] Univ Tubingen, Inst Ophthalm Res, Mol Genet Lab, Tubingen, Germany.
   [Marino, Valerio; Malfatti, Silvia; Dell'Orco, Daniele] Univ Verona, Sect Biol Chem, Dept Neurosci Biomed & Movement Sci, Verona, Italy.
   [Jacobson, Samuel G.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Reiff, Charlotte M.] Klin Augenheilkunde, Killianstr 5, D-79106 Freiburg, Germany.
C3 Carl von Ossietzky Universitat Oldenburg; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; University of Verona;
   University of Pennsylvania; Pennsylvania Medicine
RP Koch, KW (通讯作者)，Carl von Ossietzky Univ Oldenburg, Biochem Grp, Dept Neurosci, D-26111 Oldenburg, Germany.
EM karl.w.koch@uni-oldenburg.de
RI Marino, Valerio/AAP-8200-2020; Koch, Karl-Wilhelm/C-9551-2015; malfatti,
   silvia/AAB-6735-2020
OI Marino, Valerio/0000-0001-7821-3717; Koch,
   Karl-Wilhelm/0000-0003-1501-0044; DELL'ORCO, Daniele/0000-0002-3724-3044
FU Deutsche Forschungsgemeinschaft (DFG) [KO948/10-2]; DFG research
   training group [GRK1885/1]; Italian Ministry for Research and Education
   (MIUR) [FUR2013]; CINECA through the Italian Super Computing Resource
   Allocation project (ISCRA Grant) [HP10CB7L79]
FX This work was supported by funding from the Deutsche
   Forschungsgemeinschaft (DFG grant KO948/10-2 to KWK), from the DFG
   research training group GRK1885/1, the Italian Ministry for Research and
   Education (MIUR) via Departmental funding (FUR2013 to DDO), from CINECA
   through the Italian Super Computing Resource Allocation project (ISCRA
   Grant HP10CB7L79 to DDO).
CR Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Behnen P, 2010, BIOL CHEM, V391, P631, DOI 10.1515/BC.2010.063
   Berger W, 2010, PROG RETIN EYE RES, V29, P335, DOI 10.1016/j.preteyeres.2010.03.004
   Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dell'Orco D, 2014, CELL MOL LIFE SCI, V71, P3829, DOI 10.1007/s00018-014-1593-4
   Dell'Orco D, 2010, CELL MOL LIFE SCI, V67, P973, DOI 10.1007/s00018-009-0243-8
   Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hwang JY, 2003, EUR J BIOCHEM, V270, P3814, DOI 10.1046/j.1432-1033.2003.03770.x
   Hwang JY, 2002, BIOCHEMISTRY-US, V41, P13021, DOI 10.1021/bi026618y
   Jiang L, 2010, ADV EXP MED BIOL, V664, P273, DOI 10.1007/978-1-4419-1399-9_31
   Kamenarova K, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/517570
   Kitiratschky VBD, 2009, HUM MUTAT, V30, pE782, DOI 10.1002/humu.21055
   Koch KW, 2013, ACS CHEM NEUROSCI, V4, P909, DOI 10.1021/cn400027z
   Lambert N. G., 2016, PROG RETIN EYE RES, DOI [10.1016/j.pre-teyeres.2016.04.003, DOI 10.1016/J.PRE-TEYERES.2016.04.003]
   Lim S, 2016, J BIOL CHEM, V291, P4429, DOI 10.1074/jbc.M115.696161
   Lim S, 2009, BIOCHEMISTRY-US, V48, P850, DOI 10.1021/bi801897p
   Linse Sara, 2002, Methods Mol Biol, V173, P15
   Makino CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047637
   Marino V, 2015, HUM MOL GENET, V24, P6653, DOI 10.1093/hmg/ddv370
   Marino V, 2015, BBA-MOL CELL RES, V1853, P2055, DOI 10.1016/j.bbamcr.2014.10.026
   Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998
   Michaelides M, 2005, OPHTHALMOLOGY, V112, P1442, DOI 10.1016/j.ophtha.2005.02.024
   Nishiguchi KM, 2004, INVEST OPHTH VIS SCI, V45, P3863, DOI 10.1167/iovs.04-0590
   Olshevskaya EV, 2004, J NEUROSCI, V24, P6078, DOI 10.1523/JNEUROSCI.0963-04.2004
   Peshenko IV, 2006, J BIOL CHEM, V281, P23830, DOI 10.1074/jbc.M600257200
   Peshenko IV, 2012, J BIOL CHEM, V287, P13972, DOI 10.1074/jbc.M112.341883
   Peshenko IV, 2011, BIOCHEMISTRY-US, V50, P5590, DOI 10.1021/bi200491b
   Robin J, 2015, ACS CHEM BIOL, V10, P2344, DOI 10.1021/acschembio.5b00278
   Seeber M, 2007, BIOINFORMATICS, V23, P2625, DOI 10.1093/bioinformatics/btm378
   Seeber M, 2011, J COMPUT CHEM, V32, P1183, DOI 10.1002/jcc.21688
   Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5
   Stephen R, 2007, STRUCTURE, V15, P1392, DOI 10.1016/j.str.2007.09.013
   Sulmann S, 2014, CHEM-EUR J, V20, P6756, DOI 10.1002/chem.201402146
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Wen XH, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00045
   Zagel P, 2013, BIOCHEMISTRY-US, V52, P5065, DOI 10.1021/bi400288p
NR 41
TC 25
Z9 25
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 1
PY 2017
VL 26
IS 1
BP 133
EP 144
DI 10.1093/hmg/ddw374
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EP0GG
UT WOS:000397064600011
PM 28025326
OA Bronze
DA 2022-11-30
ER

PT J
AU Hanus, J
   Anderson, C
   Sarraf, D
   Ma, J
   Wang, S
AF Hanus, J.
   Anderson, C.
   Sarraf, D.
   Ma, J.
   Wang, S.
TI Retinal pigment epithelial cell necroptosis in response to sodium iodate
SO CELL DEATH DISCOVERY
LA English
DT Article
AB Age-related macular degeneration (AMD) is a degenerative disease of the retina and the leading cause of blindness in the elderly in developed countries. The late stage of dry AMD, or geographic atrophy (GA), is characterized by extensive retinal pigment epithelium (RPE) degeneration. The underlying molecular mechanism for RPE cell death in GA remains unclear. Our previous study has established that RPE cells die predominantly from necroptosis in response to oxidative stress in vitro. Here, we extend our study and aim to characterize the nature of RPE cell death in response to sodium iodate (NalO(3)) in vitro and in a NalO(3) -induced retina degeneration mouse model. We found that NalO(3) induces RPE necroptosis in vitro by using a combination of molecular hallmarks. By using TUNEL assays, active caspase-3 and HMGB1 immunostaining, we confirmed that photoreceptor cells die mainly from apoptosis and RPE cells die mainly from necroptosis in response to Nal% in vivo. RPE necroptosis in this model is also supported by use of the RIPK1 inhibitor, Necrostatin-1. Furthermore, using novel RIPK3-GFP transgenic mouse lines, we detected RIPK3 aggregation, a hallmark of necroptosis, in the RPE cells in vivo after NalO(3) injection. Our findings suggest the necessity of re-evaluating RPE cell death mechanism in AMD models and have the potential to influence therapeutic development for dry AMD, especially GA.
C1 [Hanus, J.; Anderson, C.; Sarraf, D.; Ma, J.; Wang, S.] Tulane Univ, Dept Cell & Mol Biol, 2000 Percival Stem Hall,6400 Freret St, New Orleans, LA 70118 USA.
   [Wang, S.] Tulane Univ, Dept Ophthalmol, 1430 Tulane Ave,SL-69, New Orleans, LA 70112 USA.
C3 Tulane University; Tulane University
RP Wang, S (通讯作者)，Tulane Univ, Dept Cell & Mol Biol, 2000 Percival Stem Hall,6400 Freret St, New Orleans, LA 70118 USA.; Wang, S (通讯作者)，Tulane Univ, Dept Ophthalmol, 1430 Tulane Ave,SL-69, New Orleans, LA 70112 USA.
EM swang1@tulane.edu
FU Tulane University; NIH [EY021862]; Research to Prevent Blindness
   foundation; Bright Focus Foundation Award in Age-related Macular
   Degeneration; NATIONAL EYE INSTITUTE [R01EY021862] Funding Source: NIH
   RePORTER
FX We would like to thank: Dr. Qinghua Liu from University of Texas
   Southwestern Medical Center for providing ASC-GFP plasmid; Dr. Zhigao
   Wang from University of Texas Southwestern Medical Center for providing
   HA-3xFlag-RIPK3-GFP, HMGB1-YFP, and ANT1-RFP plasmids; Dr. Yunzheng Le
   from Oklahoma Health Science Center for providing pVMD2-rtTA plasmid;
   Dr. Yiping Chen from Tulane University for helpful discussions; Dr.
   Frank Jones from Tulane University for sharing equipment; and Julia
   Chimienti for help with the experiments. This research was supported by
   a startup fund from Tulane University, NIH Grant EY021862, a career
   development award from the Research to Prevent Blindness foundation, and
   a Bright Focus Foundation Award in Age-related Macular Degeneration.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ASHBURN FS, 1980, INVEST OPHTH VIS SCI, V19, P1427
   BAICH A, 1992, PIGM CELL RES, V5, P394, DOI 10.1111/j.1600-0749.1992.tb00568.x
   Balmer J, 2015, INT J MOL SCI, V16, P15086, DOI 10.3390/ijms160715086
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DEBERARDINIS E, 1964, ACTA OPHTHALMOL, V42, P713
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hanus J, 2015, INVEST OPHTH VIS SCI, V56, P5048, DOI 10.1167/iovs.15-16401
   Hanus J, 2015, MOL CELL BIOL, V35, P1952, DOI 10.1128/MCB.00178-15
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   KONDA BR, 1994, INVEST OPHTH VIS SCI, V35, P40
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Lawlor KE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7282
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Li XY, 2013, MOL PHARMACEUT, V10, P307, DOI 10.1021/mp300445a
   Machalinska A, 2014, CURR EYE RES, V39, P1033, DOI 10.3109/02713683.2014.892996
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   MURRAY M M, 1953, Bull World Health Organ, V9, P211
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P1007
   NOELL WK, 1953, AM J OPHTHALMOL, V36, P103, DOI 10.1016/0002-9394(53)90159-7
   Qin SF, 2014, EXP EYE RES, V118, P100, DOI 10.1016/j.exer.2013.11.010
   RINGVOLD A, 1981, EXP EYE RES, V33, P361, DOI 10.1016/S0014-4835(81)80088-7
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Skeie JM, 2011, JOVE-J VIS EXP, V50, P2795, DOI DOI 10.3791/2795
   Sorsby A, 1941, Br J Ophthalmol, V25, P58, DOI 10.1136/bjo.25.2.58
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Tamaki S, 1968, Nihon Ganka Kiyo, V19, P566
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Wang J, 2013, FASEB J S873, V27, P15, DOI DOI 10.4103/1673-5374.147927
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang JY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101601
   Xia HM, 2011, EXP EYE RES, V93, P862, DOI 10.1016/j.exer.2011.09.020
   Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155
   Zenkov NK, 2013, BIOCHEMISTRY-MOSCOW+, V78, P19, DOI 10.1134/S0006297913010033
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zitvogel L, 2010, CELL, V140, P798, DOI 10.1016/j.cell.2010.02.015
   Zulliger R, 2010, THESIS
NR 60
TC 79
Z9 84
U1 2
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2058-7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PY 2016
VL 2
AR 16054
DI 10.1038/cddiscovery.2016.54
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA VI2GA
UT WOS:000463076300058
PM 27551542
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Michalska-Malecka, K
   Regucka, A
   Spiewak, D
   Sosnowska-Ponska, M
   Niewiem, A
AF Michalska-Malecka, Katarzyna
   Regucka, Agnieszka
   Spiewak, Dorota
   Sosnowska-Ponska, Magdalena
   Niewiem, Alfred
TI Does the use of acetylsalicylic acid have an influence on our vision?
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE acetylsalicylic acid; AMD; lipofuscin genesis; drusen genesis; retinal
   pigment epithelium cells; geographic atrophy
ID AGE-RELATED MACULOPATHY; LOW-DENSITY-LIPOPROTEIN; FACTOR-H POLYMORPHISM;
   MACULAR DEGENERATION; ASPIRIN USE; BLOOD-FLOW; ASSOCIATION; RISK; AMD;
   INFLAMMATION
AB Purpose: Acetylsalicylic acid (ASA) is one of the most commonly used drugs in the world due to its anti-inflammatory, analgesic, and antipyretic properties. This review aims to describe the relationship between acetylsalicylic acid and age-related macular degeneration (AMD) - a chronic disease that causes deterioration of visual acuity and is one of the most common ophthalmological diseases these days.
   Methods: Data presented in this review were collected from both research and review articles concerning ophthalmology and pharmacology.
   Results: The results of the studies analyzed in this review are not unambiguous. Moreover, the studies are not homogenous. They differed from one another in terms of the number of patients, the age criteria, the ASA dose, and the duration of control period. The reviewed studies revealed that ASA therapy, which is applied as a protection in cardiovascular diseases in patients with early forms of AMD and geographic atrophy, should not be discontinued.
   Conclusion: On the basis of the present studies, it cannot be unequivocally said whether ASA influences people's vision and if people endangered with AMD progression or who are diagnosed with AMD should use this drug. It may increase the risk of AMD, but it can also reduce the risk of life-threatening conditions. The authors suggest that in order to avoid possible risks of AMD development, people who frequently take ASA should have their vision checked regularly.
C1 [Michalska-Malecka, Katarzyna] Med Univ Silesia, Sch Med Katowice, Dept Ophthalmol, Ceglana 35, PL-40952 Katowice, Poland.
   [Michalska-Malecka, Katarzyna; Regucka, Agnieszka; Spiewak, Dorota; Sosnowska-Ponska, Magdalena; Niewiem, Alfred] Med Univ Silesia, Univ Clin Ctr, Univ Hosp, Katowice, Poland.
C3 Medical University Silesia; Medical University Silesia
RP Michalska-Malecka, K (通讯作者)，Med Univ Silesia, Sch Med Katowice, Dept Ophthalmol, Ceglana 35, PL-40952 Katowice, Poland.
EM k.michalska.malecka@gmail.com
OI MICHALSKA-MALECKA, KATARZYNA/0000-0002-0550-8386; Niewiem,
   Alfred/0000-0001-7519-651X
CR Alberts B, 2005, PODSTAWY BIOL KOMO 2, P715
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aronow ME, 2014, INVEST OPHTH VIS SCI, V55
   Bankowski E, 2008, PODRECZNIK DLA STUDE, p[447, 451]
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2014, EXPERT OPIN DRUG SAF, V13, P421, DOI 10.1517/14740338.2014.889680
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Czyz Malgorzata, 2005, Postepy Hig Med Dosw (Online), V59, P105
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2008, MOL VIS, V14, P1395
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Glowinska-Olszewska B, 2011, POSTEP HIG MED DOSW, V65, P8
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Grosser N, 2003, ARTERIOSCL THROM VAS, V23, P1345, DOI 10.1161/01.ATV.0000083296.57581.AE
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hermann M, 1999, FREE RADICAL BIO MED, V26, P1253, DOI 10.1016/S0891-5849(98)00322-0
   Janiec W, 2008, FARMAKODYNAMIKA PODR, V924, P926
   Jaroszyk F., 2008, BIOFIZYKA PODRECZNIK, P103
   Jonczyk-Skorka Katarzyna, 2015, Pol Merkur Lekarski, V38, P144
   Kahawita SK, 2015, CAN J OPHTHALMOL, V50, pS29, DOI 10.1016/j.jcjo.2015.04.006
   Kanski JJ, 2013, OKULISTYKA KLIN, p[600, 604]
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Korbut R, 2012, FARMAKOLOGIA, P178
   Kosmicki M., 2007, PRAKTYCZNA FARMAKOTE, P19
   Ku DN, 1997, ANNU REV FLUID MECH, V29, P399, DOI 10.1146/annurev.fluid.29.1.399
   Li L, 2015, J CLIN PHARM THER, V40, P144, DOI 10.1111/jcpt.12241
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Lou JY, 2010, THROMB RES, V126, pE175, DOI 10.1016/j.thromres.2009.11.017
   Mamcarz A, 2011, FARMAKOTERAPIA KARDI, V1, P356
   Murray RK, 2012, BIOCH HARPERA, V252, P254
   Nambi Vijay, 2005, Curr Atheroscler Rep, V7, P127, DOI 10.1007/s11883-005-0035-z
   Nowak JZ, 2014, EXPERT OPIN DRUG SAF, V13, P687, DOI 10.1517/14740338.2014.915939
   Nowak JZ., 2013, MAGAZYN LEKARZA OKUL, V7, P45
   Pasche B, 2014, SEMIN ONCOL, V41, P397, DOI 10.1053/j.seminoncol.2014.04.012
   Paul-Clark MJ, 2004, J EXP MED, V200, P69, DOI 10.1084/jem.20040566
   Raschka C, 2001, THERAPIE, V56, P669
   Serhan CN, 2002, PROSTAG OTH LIPID M, V68-9, P433, DOI 10.1016/S0090-6980(02)00047-3
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Steer KA, 1997, HEART, V77, P333, DOI 10.1136/hrt.77.4.333
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Waterman M, 2009, ISR MED ASSOC J, V11, P730
   Wiktorowska-Owczarek A, 2010, POSTEP HIG MED DOSW, V64, P333
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wu Yan, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P59
   Wylegala E, 2011, ZWYRODNIENIE PLAMKI, P23
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
NR 55
TC 2
Z9 2
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2016
VL 11
BP 1567
EP 1574
DI 10.2147/CIA.S115234
PG 8
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA EB2HZ
UT WOS:000387179900001
PM 27843305
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Corydon, TJ
AF Corydon, Thomas J.
TI Antiangiogenic Eye Gene Therapy
SO HUMAN GENE THERAPY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; AGE-RELATED
   MACULOPATHY; ADENOASSOCIATED VIRUS AAV; SHORT-INTERFERING RNAS;
   CHOROIDAL NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; MACULAR
   DEGENERATION; TARGETING VEGF; RETINAL NEOVASCULARIZATION
AB The idea of treating disease in humans with genetic material was conceived over two decades ago and with that a promising journey involving development and efficacy studies in cells and animals of a large number of novel therapeutic reagents unfolded. In the footsteps of this process, successful gene therapy treatment of genetic conditions in humans has shown clear signs of efficacy. Notably, significant advancements using gene supplementation and silencing strategies have been made in the field of ocular gene therapy, thereby pinpointing ocular gene therapy as one of the compelling actors bringing gene therapy to the clinic. Most of all, this success has been facilitated because of (1) the fact that the eye is an effortlessly accessible, exceedingly compartmentalized, and immune-privileged organ offering a unique advantage as a gene therapy target, and (2) significant progress toward efficient, sustained transduction of cells within the retina having been achieved using nonintegrating vectors based on recombinant adeno-associated virus and nonintegrating lentivirus vectors. The results from in vivo experiments and trials suggest that treatment of inherited retinal dystrophies, ocular angiogenesis, and inflammation with gene therapy can be both safe and effective. Here, the progress of ocular gene therapy is examined with special emphasis on the potential use of RNAi- and protein-based antiangiogenic gene therapy to treat exudative age-related macular degeneration.
C1 Aarhus Univ, Dept Biomed, DK-8000 Aarhus, Denmark.
C3 Aarhus University
RP Corydon, TJ (通讯作者)，Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus, Denmark.
EM corydon@biomed.au.dk
OI Corydon, Thomas Juhl/0000-0003-3588-6350
FU Aarhus University, Denmark; Gene Therapy Initiative Aarhus (GTI-Aarhus)
   - Lundbeck Foundation [R126-2012-12456]; Danish Eye Foundation
FX The author would like to thank Aarhus University, Denmark, for funding
   the research. In addition, this work was supported by Gene Therapy
   Initiative Aarhus (GTI-Aarhus) funded by the Lundbeck Foundation (Grant
   No. R126-2012-12456) and The Danish Eye Foundation.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Allocca M, 2007, J VIROL, V81, P11372, DOI 10.1128/JVI.01327-07
   An CI, 2006, RNA, V12, P710, DOI 10.1261/rna.2299306
   Apolonia L, 2007, MOL THER, V15, P1947, DOI 10.1038/sj.mt.6300281
   Askou AL, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2014.64
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bak RO, 2013, RNA, V19, P280, DOI 10.1261/rna.034850.112
   Balaggan KS, 2012, GENE THER, V19, P145, DOI 10.1038/gt.2011.153
   Bayer M, 2008, MOL THER, V16, P1968, DOI 10.1038/mt.2008.199
   Beisel CL, 2011, NUCLEIC ACIDS RES, V39, P2981, DOI 10.1093/nar/gkq954
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Borel F, 2014, MOL THER, V22, P692, DOI 10.1038/mt.2013.285
   Boudreau RL, 2011, MOL THER, V19, P2169, DOI 10.1038/mt.2011.185
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Brown BD, 2007, BLOOD, V110, P4144, DOI 10.1182/blood-2007-03-078493
   Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628
   Cai YJ, 2014, ELIFE, V3, DOI 10.7554/eLife.01911
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Castanotto D, 2011, MOL THER, V19, P823, DOI 10.1038/mt.2011.70
   Catchpole IR, 2015, ARVO, V1498, pB0224
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chadderton N, 2009, MOL THER, V17, P593, DOI 10.1038/mt.2008.301
   Chen ZY, 2003, MOL THER, V8, P495, DOI 10.1016/S1525-0016(03)00168-0
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cornu TI, 2007, MOL THER, V15, P2107, DOI 10.1038/sj.mt.6300345
   Coutant F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003973
   Cronin J, 2005, CURR GENE THER, V5, P387, DOI 10.2174/1566523054546224
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dobias A, 2014, ARVO, V1827, pA0326
   Doudna JA, 2014, SCIENCE, V346, P1077, DOI 10.1126/science.1258096
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Geisler A, 2011, GENE THER, V18, P199, DOI 10.1038/gt.2010.141
   Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795
   Grassmann F, 2015, ARVO, V791, pD0253
   Guillonneau XP, 2015, ARVO, V844, pD0306
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Hassel D, 2012, CIRC RES, V111, P1421, DOI 10.1161/CIRCRESAHA.112.279711
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hollensen AK, 2013, RNA BIOL, V10, P406, DOI 10.4161/rna.23543
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Ideno J, 2007, INT J MOL MED, V19, P75
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Issa PC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060361
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Karali M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022166
   Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Kay CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062097
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kittler R, 2007, NAT METHODS, V4, P337, DOI 10.1038/NMETH1025
   Klar J, 2015, ARVO, V246, pC0118
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li QH, 2008, MOL VIS, V14, P1760
   Liu YP, 2013, NUCLEIC ACIDS RES, V41, P3723, DOI 10.1093/nar/gkt036
   Ma HM, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.27
   Ma L, 2015, ARVO, V781, pD0243
   Machalinska Anna, 2012, Klin Oczna, V114, P115
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Maczuga P, 2013, MOL THER, V21, P217, DOI 10.1038/mt.2012.160
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   McCarty DM, 2004, ANNU REV GENET, V38, P819, DOI 10.1146/annurev.genet.37.110801.143717
   McCarty DM, 2001, GENE THER, V8, P1248, DOI 10.1038/sj.gt.3301514
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Monahan PE, 2000, MOL MED TODAY, V6, P433, DOI 10.1016/S1357-4310(00)01810-4
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mowat FM, 2014, GENE THER, V21, P96, DOI 10.1038/gt.2013.64
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Murinello S, 2015, ARVO, V45, pA0034
   Newman MA, 2010, GENE DEV, V24, P1086, DOI 10.1101/gad.1919710
   Paskowitz DM, 2007, HUM GENE THER, V18, P871, DOI 10.1089/hum.2007.065
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Petrs-Silva H, 2011, MOL THER, V19, P293, DOI 10.1038/mt.2010.234
   Pihlmann M, 2012, J GENE MED, V14, P328, DOI 10.1002/jgm.2623
   Priya RR, 2015, ARVO, V789, pD0251
   Puppo A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059025
   Qiu Y, 2015, ARVO, V839, pD0301
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002
   Reich S, 2003, MOL VIS, V9, P210
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Sahel JA, 2015, ARVO, V1088, pC0101
   Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842
   Scappaticci FA, 2001, MOL THER, V3, P186, DOI 10.1006/mthe.2000.0243
   Scappaticci Frank A., 2001, Angiogenesis, V4, P263, DOI 10.1023/A:1016067717433
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Smith AJ, 2012, GENE THER, V19, P154, DOI 10.1038/gt.2011.161
   Stenler S, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2013.67
   Theodoropoulou S, 2015, ARVO, V814, pD0303
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Trapani I, 2015, HUM GENE THER, V26, P193, DOI 10.1089/hum.2015.030
   Trapani I, 2014, EMBO MOL MED, V6, P194, DOI 10.1002/emmm.201302948
   Tuo JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.01.009
   Vandenberghe LH, 2012, GENE THER, V19, P162, DOI 10.1038/gt.2011.151
   Venkatesh Aditya, 2013, Curr Protoc Microbiol, VChapter 14, DOI 10.1002/9780471729259.mc14d04s28
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang S, 2015, ARVO, V43, pA0032
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   Xie J, 2012, NAT METHODS, V9, P403, DOI [10.1038/NMETH.1903, 10.1038/nmeth.1903]
   Yanez-Munoz RJ, 2006, NAT MED, V12, P348, DOI 10.1038/nm1365
   Yokoyama Y, 2000, CANCER RES, V60, P2190
   Yuan MK, 2010, MOL VIS, V16, P1743
   Zhong L, 2008, P NATL ACAD SCI USA, V105, P7827, DOI 10.1073/pnas.0802866105
   Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76
NR 118
TC 15
Z9 16
U1 0
U2 24
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD AUG 1
PY 2015
VL 26
IS 8
BP 525
EP 537
DI 10.1089/hum.2015.064
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA CP5PD
UT WOS:000359934800007
PM 26222377
DA 2022-11-30
ER

PT J
AU Anderson, KW
   Chen, JJ
   Wang, MY
   Mast, N
   Pikuleva, IA
   Turko, IV
AF Anderson, Kyle W.
   Chen, Junjun
   Wang, Meiyao
   Mast, Natalia
   Pikuleva, Irina A.
   Turko, Illarion V.
TI Quantification of Histone Deacetylase Isoforms in Human Frontal Cortex,
   Human Retina, and Mouse Brain
SO PLOS ONE
LA English
DT Article
ID MASS-SPECTROMETRY QUANTIFICATION; ALZHEIMERS-DISEASE; MACULAR
   DEGENERATION; MEMORY; ACETYLATION; EXPRESSION; QCONCATS; HDAC6
AB Histone deacetylase (HDAC) inhibition has promise as a therapy for Alzheimer's disease (AD) and other neurodegenerative diseases. Currently, therapeutic HDAC inhibitors target many HDAC isoforms, a particularly detrimental approach when HDAC isoforms are known to have different and specialized functions. We have developed a multiple reaction monitoring (MRM) mass spectrometry assay using stable isotope-labeled QconCATs as internal standards to quantify HDAC isoforms. We further determined a quantitative pattern of specific HDACs expressed in various human and mouse neural tissues. In human AD frontal cortex, HDAC1,2 decreased 32%, HDAC5 increased 47%, and HDAC6 increased 31% in comparison to age-matched controls. Human neural retina concentrations of HDAC1, 2, HDAC5, HDAC6, and HDAC7 decreased in age-related macular degeneration (AMD)-affected donors and exhibited a greater decrease in AD-affected donors in comparison to age-matched control neural retinas. Additionally, HDAC concentrations were measured in whole hemisphere of brain of 5XFAD mice, a model of beta-amyloid deposition, to assess similarity to AD in human frontal cortex. HDAC profiles of human frontal cortex and mouse hemisphere had noticeable differences and relatively high concentrations of HDAC3 and HDAC4 in mice, which were undetectable in humans. Our method for quantification of HDAC isoforms is a practical and efficient technique to quantify isoforms in various tissues and diseases. Changes in HDAC concentrations reported herein contribute to the understanding of the pathology of neurodegeneration.
C1 [Anderson, Kyle W.; Chen, Junjun; Wang, Meiyao; Turko, Illarion V.] Inst Biosci & Biotechnol Res, Rockville, MD 20850 USA.
   [Anderson, Kyle W.; Chen, Junjun; Wang, Meiyao; Turko, Illarion V.] NIST, Biomol Measurement Div, Gaithersburg, MD 20899 USA.
   [Anderson, Kyle W.] Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.
   [Mast, Natalia; Pikuleva, Irina A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
C3 National Institute of Standards & Technology (NIST) - USA; University
   System of Maryland; University of Maryland College Park; Case Western
   Reserve University
RP Turko, IV (通讯作者)，Inst Biosci & Biotechnol Res, Rockville, MD 20850 USA.
EM iturko@umd.edu
OI Pikuleva, Irina/0000-0001-9742-6232; Anderson, Kyle/0000-0002-2808-3026
FU National Institutes of Health [P50 AG005681, EY018383, GM062882,
   EY011373]; Institute for Bioscience and Biotechnology Research; National
   Institute of Standards and Technology; Case Western Reserve University;
   NATIONAL EYE INSTITUTE [P30EY011373, R01EY018383] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062882]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681]
   Funding Source: NIH RePORTER
FX External funding for this work was provided by: National Institutes of
   Health grant P50 AG005681 to the Washington University School of
   Medicine Alzheimer's Disease Research Center; National Institutes of
   Health grants EY018383 and GM062882 (to IAP); and National Institutes of
   Health grant EY011373 to Case Western Reserve University (P30 Core
   grant). The external funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. All additional funding was provided internally by the
   Institute for Bioscience and Biotechnology Research, the National
   Institute of Standards and Technology, and Case Western Reserve
   University.
CR Agis-Balboa RC, 2013, J ALZHEIMERS DIS, V33, P35, DOI 10.3233/JAD-2012-121009
   Alzheimers Assoc, 2012, ALZHEIMERS DEMENT, V8, P131, DOI 10.1016/j.jalz.2012.02.001
   Apweiler R, 2014, NUCLEIC ACIDS RES, V42, pD191, DOI 10.1093/nar/gkt1140
   Broide RS, 2007, J MOL NEUROSCI, V31, P47, DOI 10.1007/BF02686117
   Castello MA, 2014, AGEING RES REV, V13, P10, DOI 10.1016/j.arr.2013.10.001
   Chen JJ, 2014, TRAC-TREND ANAL CHEM, V57, P1, DOI 10.1016/j.trac.2013.12.013
   Chen J, 2013, ANAL BIOCHEM, V442, P253, DOI 10.1016/j.ab.2013.08.005
   Chen JJ, 2013, ANAL CHEM, V85, P6011, DOI 10.1021/ac400831z
   Chen JJ, 2013, ANAL CHEM, V85, P303, DOI 10.1021/ac3033239
   Chen JJ, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-41
   Cook C, 2012, HUM MOL GENET, V21, P2936, DOI 10.1093/hmg/dds125
   Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772
   Fitzsimons CP, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-25
   Gonzalez-Zuniga M, 2014, MOL CELL, V56, P163, DOI 10.1016/j.molcel.2014.08.013
   Graff J, 2012, NATURE, V483, P222, DOI 10.1038/nature10849
   Izzo A, 2010, BRIEF FUNCT GENOMICS, V9, P429, DOI 10.1093/bfgp/elq024
   Jakovcevski M, 2013, BIOL PSYCHIAT, V74, P696, DOI 10.1016/j.biopsych.2013.03.020
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kawabata Tomoko, 2010, Arthritis Res Ther, V12, pR133, DOI 10.1186/ar3071
   Kilgore M, 2010, NEUROPSYCHOPHARMACOL, V35, P870, DOI 10.1038/npp.2009.197
   Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200
   Li GY, 2011, J NEUROL SCI, V304, P1, DOI 10.1016/j.jns.2011.02.017
   Lucio-Eterovic AK, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-243
   MacLean B, 2010, ANAL CHEM, V82, P10116, DOI 10.1021/ac102179j
   Millan MJ, 2014, DIALOGUES CLIN NEURO, V16, P373
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   OBRIEN JS, 1965, J LIPID RES, V6, P537
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Sananbenesi F, 2009, BIOL CHEM, V390, P1145, DOI 10.1515/BC.2009.131
   Sando R, 2012, CELL, V151, P821, DOI 10.1016/j.cell.2012.09.037
   Simoes-Pires C, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-7
   Simpson DM, 2012, ANAL BIOANAL CHEM, V404, P977, DOI 10.1007/s00216-012-6230-1
   Stilling RM, 2011, NEUROBIOL LEARN MEM, V96, P19, DOI 10.1016/j.nlm.2011.04.002
   Tiwari S, 2014, BMC DEV BIOL, V14, DOI 10.1186/1471-213X-14-30
   Wang MY, 2012, ANAL CHEM, V84, P8340, DOI 10.1021/ac3018873
   Wang YJ, 2013, EPIGENETICS-US, V8, P756, DOI 10.4161/epi.25202
   Xu K, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/143269
   Yeh HH, 2013, NEUROIMAGE, V64, P630, DOI 10.1016/j.neuroimage.2012.09.019
   Zhang L, 2013, J ALZHEIMERS DIS, V33, P283, DOI 10.3233/JAD-2012-120727
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 40
TC 27
Z9 28
U1 1
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2015
VL 10
IS 5
AR e0126592
DI 10.1371/journal.pone.0126592
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CI1YY
UT WOS:000354542500120
PM 25962138
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Kubota, R
   Al-Fayoumi, S
   Mallikaarjun, S
   Patil, S
   Bavik, C
   Chandler, JW
AF Kubota, Ryo
   Al-Fayoumi, Suliman
   Mallikaarjun, Suresh
   Patil, Shiva
   Bavik, Claes
   Chandler, John W.
TI PHASE 1, DOSE-RANGING STUDY OF EMIXUSTAT HYDROCHLORIDE (ACU-4429), A
   NOVEL VISUAL CYCLE MODULATOR, IN HEALTHY VOLUNTEERS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ACU-4429; age-related macular degeneration; emixustat hydrochloride;
   geographic atrophy; pharmacokinetics; Phase 1; safety; visual cycle
   modulator
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY;
   FUNDUS AUTOFLUORESCENCE; LIPOFUSCIN ACCUMULATION; FLUOROPHORES;
   PATHOGENESIS; PROGRESSION; INHIBITORS; DISEASE
AB Background: Emixustat hydrochloride (formerly ACU-4429) is a nonretinoid compound with a unique mode of action in the retinal pigment epithelium, where it modulates the biosynthesis of visual chromophore through its effect on retinal pigment epithelium-specific 65 kDa protein isomerase. This study provides clinicians with a background for understanding the pharmacokinetics and safety profile of orally administered emixustat.
   Methods: This randomized, double-masked, placebo-controlled Phase 1b study evaluated the pharmacokinetics, tolerability, and safety of a 14-day course of oral emixustat (5, 10, 20, 30, or 40 mg) or placebo (3: 1 ratio) once daily in healthy volunteers.
   Results: A total of 40 subjects were enrolled (mean age, 38 years; 75% male). Emixustat (n = 30) was rapidly absorbed (median T-max, 3.0-5 hours) and readily eliminated (mean t(1/2), 4.6-7.9 hours), and mean C-max and AUC(0-24) generally increased in proportion to dose. No significant accumulation of emixustat was observed with multiple-dose administration. Ocular adverse events occurred in 67% of the subjects who received emixustat; all were considered mild and resolved after study completion. Systemic adverse events were minimal.
   Conclusion: Oral emixustat was safe and well tolerated when administered once daily for 14 days with minimal systemic adverse events reported. These data support evaluation of emixustat in subjects with geographic atrophy associated with dry age-related macular degeneration.
C1 [Kubota, Ryo; Al-Fayoumi, Suliman; Bavik, Claes; Chandler, John W.] Acucela Inc, Seattle, WA 98101 USA.
   [Mallikaarjun, Suresh; Patil, Shiva] OPDC, Princeton, NJ USA.
RP Kubota, R (通讯作者)，Acucela Inc, 1301,2nd Ave,Suite 1900, Seattle, WA 98101 USA.
EM ryokubota@acucela.com
FU Acucela Inc; Otsuka Pharmaceutical CO, LTD.
FX Supported by Acucela Inc and Otsuka Pharmaceutical CO, LTD.
CR Bui TV, 2006, J BIOL CHEM, V281, P18112, DOI 10.1074/jbc.M601380200
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 23
TC 48
Z9 49
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2014
VL 34
IS 3
BP 603
EP 609
DI 10.1097/01.iae.0000434565.80060.f8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6DL
UT WOS:000336960100029
PM 24056528
DA 2022-11-30
ER

PT J
AU Bailey, JNC
   Sobrin, L
   Pericak-Vance, MA
   Haines, JL
   Hammond, CJ
   Wiggs, JL
AF Bailey, Jessica N. Cooke
   Sobrin, Lucia
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
   Hammond, Christopher J.
   Wiggs, Janey L.
TI Advances in the genomics of common eye diseases
SO HUMAN MOLECULAR GENETICS
LA English
DT Review
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; OPEN-ANGLE GLAUCOMA;
   OXIDASE-LIKE 1; WIDE ASSOCIATION; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; SUSCEPTIBILITY LOCI; PROMOTER POLYMORPHISM;
   GENETIC ASSOCIATION
AB Genome-wide association studies (GWAS) and other genomic technologies have accelerated the discovery of genes and genomic regions contributing to common human ocular disorders with complex inheritance. Age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and myopia account for the majority of visual impairment worldwide. Over 19 genes and/or genomic regions have been associated with AMD. Current investigations are assessing the clinical utility of risk score panels and therapies targeting disease-specific pathways. DR is the leading cause of blindness in the United States and globally is a major cause of vision loss. Genomic investigations have identified molecular pathways associated with DR in animal models which could suggest novel therapeutic targets. Three types of glaucoma, primary-open-angle glaucoma (POAG), angle-closure glaucoma and exfoliation syndrome (XFS) glaucoma, are common age-related conditions. Five genomic regions have been associated with POAG, three with angle-closure glaucoma and one with XFS. Myopia causes substantial ocular morbidity throughout the world. Recent large GWAS have identified 20 associated loci for this condition. In this report, we present a comprehensive overview of the genes and genomic regions contributing to disease susceptibility for these common blinding ocular disorders and discuss the next steps toward translation to effective gene-based screening tests and novel therapies targeting the molecular events contributing to disease.
C1 [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   [Sobrin, Lucia; Wiggs, Janey L.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Hammond, Christopher J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
C3 Vanderbilt University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; University of Miami; University of
   London; King's College London
RP Wiggs, JL (通讯作者)，Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM janey_wiggs@meei.harvard.edu
RI Cooke Bailey, Jessica Nicole/AFQ-5925-2022; Bailey, Jessica
   Cooke/Q-5062-2019; Haines, Jonathan/C-3374-2012
OI Cooke Bailey, Jessica Nicole/0000-0002-4001-8702; Bailey, Jessica
   Cooke/0000-0002-4001-8702; Haines, Jonathan/0000-0002-4351-4728;
   Hammond, Christopher/0000-0002-3227-2620; Sobrin,
   Lucia/0000-0003-1575-0819
FU NIH/NEI [EY022302, EY012118, EY021453, EY022305, EY020928]; NATIONAL EYE
   INSTITUTE [R01EY012118, R01EY022305, R01EY020928, R01EY022302,
   T32EY021453, U10EY012118] Funding Source: NIH RePORTER; National
   Institute for Health Research [SRF/01/010] Funding Source: researchfish
FX The authors acknowledge funding support from NIH/NEI grants EY022302
   (L.S.), EY012118 (M.A.P.-V.), EY021453 (J.L.H.), EY022305 (J.L.W.),
   EY020928 (J.L.W.).
CR Abhary S, 2010, ARCH OPHTHALMOL-CHIC, V128, P102, DOI 10.1001/archophthalmol.2009.355
   Abhary S, 2009, DIABETES, V58, P2137, DOI 10.2337/db09-0059
   Aldahmesh M.A., 2013, AM J HUM GENET
   Arar NH, 2008, INVEST OPHTH VIS SCI, V49, P3839, DOI 10.1167/iovs.07-1633
   Awadalla MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067903
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Brucklacher RM, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-26
   Buraczynska M, 2011, DIABETES RES CLIN PR, V93, P390, DOI 10.1016/j.diabres.2011.05.017
   Burdon KP, 2011, NAT GENET, V43, P574, DOI 10.1038/ng.824
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Christian PG, 2013, EXP EYE RES, V107, P11, DOI 10.1016/j.exer.2012.11.005
   Ciccacci C, 2012, ACTA DIABETOL
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fan BJ, 2011, INVEST OPHTH VIS SCI, V52, P2372, DOI 10.1167/iovs.10-6268
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu YP, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/861291
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassi MA, 2012, INVEST OPHTH VIS SCI, V53, P2377, DOI 10.1167/iovs.11-8068
   Grassi MA, 2011, HUM MOL GENET, V20, P2472, DOI 10.1093/hmg/ddr121
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hietala K, 2008, DIABETES, V57, P2176, DOI 10.2337/db07-1495
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Huang YC, 2011, OPHTHALMOLOGY, V118, P642, DOI 10.1016/j.ophtha.2010.07.020
   Hysi PG, 2010, NAT GENET, V42, P902, DOI 10.1038/ng.664
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Tran-Viet KN, 2012, MOL VIS, V18, P937
   Kiefer AK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003299
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X
   KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P58
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Ko F, 2012, JAMA-J AM MED ASSOC, V308, P2361, DOI 10.1001/jama.2012.85685
   Li Z., 2013, HUM MOL GENET, V20, P2861
   Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Looker HC, 2007, DIABETES, V56, P1160, DOI 10.2337/db06-1299
   Lu Y, 2013, NAT GENET, V45, P155, DOI 10.1038/ng.2506
   Lu Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000947
   Luo J, 2013, DIABETES, V62, P2613, DOI 10.2337/db12-1093
   Macgregor S, 2010, HUM MOL GENET, V19, P2716, DOI 10.1093/hmg/ddq144
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manolio TA, 2013, NAT REV GENET, V14, P549, DOI 10.1038/nrg3523
   Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980
   Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0
   McBrien N.A., 2013, EXP EYE RES
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Nakanishi H, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000660
   NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306
   National Institute of Diabetes and Digestive and Kidney Diseases, 2000, US DEP HLTH HUM SERV
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ramdas WD, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000978
   Richards AJ, 2010, HUM MUTAT, V31, pE1461, DOI 10.1002/humu.21257
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosman M, 2012, SINGAP MED J, V53, P82
   Ruta LM, 2013, DIABETIC MED, V30, P387, DOI 10.1111/dme.12119
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schlotzer-Schrehardt U, 2008, AM J PATHOL, V173, P1724, DOI 10.2353/ajpath.2008.080535
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sheu WHH, 2013, HUM MOL GENET, V22, P3165, DOI 10.1093/hmg/ddt161
   Shi Y, 2013, HUM MOL GENET, V22, P2325, DOI 10.1093/hmg/ddt066
   Shi Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002084
   Sobrin L, 2011, INVEST OPHTH VIS SCI, V52, P7593, DOI 10.1167/iovs.11-7510
   Solouki AM, 2010, NAT GENET, V42, P897, DOI 10.1038/ng.663
   Stambolian D, 2013, HUM MOL GENET, V22, P2754, DOI 10.1093/hmg/ddt116
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661
   Tong ZZ, 2008, P NATL ACAD SCI USA, V105, P6998, DOI 10.1073/pnas.0800454105
   Tran-Viet KN, 2013, AM J HUM GENET, V92, P820, DOI 10.1016/j.ajhg.2013.04.005
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   van Koolwijk LME, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002611
   Verhoeven VJM, 2013, NAT GENET, V45, P314, DOI 10.1038/ng.2554
   Vitart V, 2010, HUM MOL GENET, V19, P4304, DOI 10.1093/hmg/ddq349
   Vithana EN, 2012, NAT GENET, V44, P1142, DOI 10.1038/ng.2390
   Vithana EN, 2011, HUM MOL GENET, V20, P649, DOI 10.1093/hmg/ddq511
   Wang XL, 2010, VISION RES, V50, P2391, DOI 10.1016/j.visres.2010.09.018
   Wiggs JL, 2012, PLOS GENET, V8, P413, DOI 10.1371/journal.pgen.1002654
   Wiggs JL, 2011, HUM MOL GENET, V20, P4707, DOI 10.1093/hmg/ddr382
   Wojciechowski R, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003442
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zenkel M, 2011, INVEST OPHTH VIS SCI, V52, P8488, DOI 10.1167/iovs.11-8361
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 93
TC 34
Z9 34
U1 0
U2 34
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2013
VL 22
SI 1
BP R59
EP R65
DI 10.1093/hmg/ddt396
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 230LH
UT WOS:000325340500010
PM 23962718
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ho, YS
   Poon, DCH
   Chan, TF
   Chang, RCC
AF Ho, Yuen-Shan
   Poon, David Chun-Hei
   Chan, Tin-Fung
   Chang, Raymond Chuen-Chung
TI From Small to Big Molecules: How Do We Prevent and Delay the Progression
   of Age-Related Neurodegeneration?
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Alzheimer's disease; Parkinson's disease; Age-related macular
   degeneration; flavonoids; stilbenes; resveratrol; glycoconjugates
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LYCIUM-BARBARUM POLYSACCHARIDES;
   SUPERFINE DISPERSED LENTINAN; RETINAL GANGLION-CELLS;
   BLOOD-BRAIN-BARRIER; GREEN TEA CATECHINS; MACULAR DEGENERATION;
   ALZHEIMERS-DISEASE; RISK-FACTORS; OXIDATIVE STRESS
AB Age-related neurodegeneration in the brain and retina is complicated. It comprises a series of events encompassing different modes of degeneration in neurons, as well as inflammation mediated by glial cells. Systemic inflammation and risk factors can contribute to disease progression. Age-related conditions such as Alzheimer's disease (AD), Parkinson's disease (PD) and Age-related Macular Degeneration (AMD) affect patients for 5 to 20 years and are highly associated with risk factors such as hyperhomocysteinaemia, hypercholesterolaemia, hypertension, and symptoms of mood disorder. The long duration of the degeneration and the wide array of systemic factors provide the opportunity for nutraceutical intervention to prevent or delay disease progression.
   Small molecules such as phenolic compounds are candidates for neuroprotection because they have anti-oxidant activities and can modulate intracellular signaling pathways. Bigger entities such as oligosaccharides and polysaccharides have often been neglected because of their complex structure. However, certain big molecules can provide neuroprotective effects. They may also have a wide spectrum of action against risk factors.
   In this review we use an integrative approach to the potential uses of nutraceutical products to prevent age-related neurodegeneration. These include direct effects of phenolic compounds and polysaccharides on neurons to antagonize various neurodegenerative mechanisms in AD, PD and AMD, and indirect effects of these compounds on peripheral disease-related risk factors.
C1 [Ho, Yuen-Shan; Poon, David Chun-Hei; Chan, Tin-Fung; Chang, Raymond Chuen-Chung] Univ Hong Kong, Dept Anat, Lab Neurodegenerat Dis, Pokfulam, Hong Kong, Peoples R China.
   [Chang, Raymond Chuen-Chung] Univ Hong Kong, Res Ctr Heart Brain Hormone & Healthy Aging, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China.
   [Chang, Raymond Chuen-Chung] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong
RP Ho, YS (通讯作者)，Rm L1-49,Lab Block,Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.
EM janiceys@hku.hk; rccchang@hku.hk
RI Chang, Raymond Chuen-Chung/C-1107-2009
OI Chang, Raymond Chuen-Chung/0000-0001-8538-7993; HO,
   Yuen-Shan/0000-0002-2557-6554
FU HKU Alzheimer's Disease Research Network [201007176112]; Seed Funding
   for Basic Science Research [201011159058]
FX The work in this laboratory is supported by University Strategic
   Research Theme on Drug Discovery, HKU Alzheimer's Disease Research
   Network, Small Grant Research (201007176112) to YSH and Seed Funding for
   Basic Science Research (201011159058) to RCCC.
CR Abd El Mohsen MM, 2002, FREE RADICAL BIO MED, V33, P1693, DOI 10.1016/S0891-5849(02)01137-1
   Agostinho P, 2010, CURR PHARM DESIGN, V16, P2766, DOI 10.2174/138161210793176572
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Almeida L, 2009, MOL NUTR FOOD RES, V53, pS7, DOI 10.1002/mnfr.200800177
   Ansari MA, 2009, J NUTR BIOCHEM, V20, P269, DOI 10.1016/j.jnutbio.2008.03.002
   Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025
   Baker J, 2011, J COMPUT CHEM, V32, P43, DOI 10.1002/jcc.21597
   Beeri MS, 2008, NEUROLOGY, V71, P750, DOI 10.1212/01.wnl.0000324925.95210.6d
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Brown L, 2009, ALCOHOL CLIN EXP RES, V33, P1513, DOI 10.1111/j.1530-0277.2009.00989.x
   Byun HG, 2005, CARBOHYD POLYM, V61, P198, DOI 10.1016/j.carbpol.2005.05.003
   Chachay VS, 2011, BRIT J CLIN PHARMACO, V72, P27, DOI 10.1111/j.1365-2125.2011.03966.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031
   Chan WK, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-9
   Chao JF, 2010, J NUTR BIOCHEM, V21, P482, DOI 10.1016/j.jnutbio.2009.02.004
   Cheng JC, 2006, BIOORG CHEM, V34, P142, DOI 10.1016/j.bioorg.2006.04.001
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu KCT, 2011, AGE IN PRESS, DOI [10.1007/s11357-011-9260-2, DOI 10.1007/S11357-011-9260-2]
   Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Costello S, 2009, AM J EPIDEMIOL, V169, P919, DOI 10.1093/aje/kwp006
   Cui XL, 2010, CANCER PREV RES, V3, P549, DOI 10.1158/1940-6207.CAPR-09-0117
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   D'Archivio Massimo, 2007, Ann Ist Super Sanita, V43, P348
   Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104
   Dentchev T, 2003, MOL VIS, V9, P184
   Di Bona D, 2010, CURR PHARM DESIGN, V16, P684
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223
   Fang XY, 2005, INT J MOL MED, V16, P1109
   Fang XY, 2005, INT J MOL MED, V15, P491
   Ferrari CC, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/436813
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Flicker L, 2010, J ALZHEIMERS DIS, V20, P803, DOI 10.3233/JAD-2010-091624
   Gao HM, 2008, J NEUROSCI, V28, P7687, DOI 10.1523/JNEUROSCI.0143-07.2008
   Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009
   Grodstein F, 2003, AM J CLIN NUTR, V77, P975, DOI 10.1093/ajcn/77.4.975
   Guillozet-Bongaarts AL, 2005, NEUROBIOL AGING, V26, P1015, DOI 10.1016/j.neurobiolaging.2004.09.019
   Guo L, 2010, CURR ALZHEIMER RES, V7, P3, DOI 10.2174/156720510790274491
   Hazama S, 2009, ANTICANCER RES, V29, P2611
   Heneka MT, 2011, CURR ALZHEIMER RES, V8, P115
   Ho YS, 2007, BRAIN RES, V1158, P123, DOI 10.1016/j.brainres.2007.04.075
   Ho YS, 2010, J ALZHEIMERS DIS, V19, P813, DOI 10.3233/JAD-2010-1280
   Ho YS, 2009, CELL MOL NEUROBIOL, V29, P1233, DOI 10.1007/s10571-009-9419-x
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Huang HF, 2008, J CHROMATOGR B, V874, P77, DOI 10.1016/j.jchromb.2008.09.005
   Hunot S, 2004, P NATL ACAD SCI USA, V101, P665, DOI 10.1073/pnas.0307453101
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ishige K, 2001, FREE RADICAL BIO MED, V30, P433, DOI 10.1016/S0891-5849(00)00498-6
   Je JY, 2005, BIOORGAN MED CHEM, V13, P6551, DOI 10.1016/j.bmc.2005.07.004
   Jomova K, 2010, MOL CELL BIOCHEM, V345, P91, DOI 10.1007/s11010-010-0563-x
   Jung SH, 2008, NEUROCHEM INT, V53, P325, DOI 10.1016/j.neuint.2008.09.004
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   Karagianni N, 2010, ADV EXP MED BIOL, V703, P1, DOI 10.1007/978-1-4419-5635-4_1
   Kelsey NA, 2010, MOLECULES, V15, P7792, DOI 10.3390/molecules15117792
   Kennedy DO, 2010, AM J CLIN NUTR, V91, P1590, DOI 10.3945/ajcn.2009.28641
   Khan MM, 2010, BRAIN RES, V1328, P139, DOI 10.1016/j.brainres.2010.02.031
   Khanapure SP, 2007, CURR TOP MED CHEM, V7, P311, DOI 10.2174/156802607779941314
   Kim MS, 2002, NEUROSCI LETT, V321, P105, DOI 10.1016/S0304-3940(02)00066-6
   Kim SY, 1999, BIOL PHARM BULL, V22, P873, DOI 10.1248/bpb.22.873
   Kishido T, 2007, BIOGERONTOLOGY, V8, P423, DOI 10.1007/s10522-007-9085-7
   Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447
   la Porte C, 2010, CLIN PHARMACOKINET, V49, P449, DOI 10.2165/11531820-000000000-00000
   Laurienzo P, 2010, MAR DRUGS, V8, P2435, DOI 10.3390/md8092435
   Lee MK, 2007, EXP MOL MED, V39, P376, DOI 10.1038/emm.2007.42
   Lemke MR, 2004, J NEUROL, V251, P24, DOI 10.1007/s00415-004-1606-6
   Leveugle B, 1998, J NEUROCHEM, V70, P736
   Levites Y, 2001, J NEUROCHEM, V78, P1073, DOI 10.1046/j.1471-4159.2001.00490.x
   Li N, 2011, PHARMAZIE, V66, P374, DOI 10.1691/ph.2011.0783
   Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380
   Li XM, 2007, J ETHNOPHARMACOL, V111, P504, DOI 10.1016/j.jep.2006.12.024
   Li YF, 2004, LIFE SCI, V75, P1531, DOI 10.1016/j.lfs.2004.02.029
   Li YF, 2003, LIFE SCI, V72, P933, DOI 10.1016/S0024-3205(02)02331-7
   Lin CL, 2009, INT J BIOL MACROMOL, V45, P146, DOI 10.1016/j.ijbiomac.2009.04.014
   Lu KT, 2006, J AGR FOOD CHEM, V54, P3126, DOI 10.1021/JF053011Q
   Lue LF, 2010, MOL NEUROBIOL, V41, P115, DOI 10.1007/s12035-010-8106-8
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Luo Q, 2004, LIFE SCI, V76, P137, DOI 10.1016/j.lfs.2004.04.056
   Luthert PJ., 2011, DIAGN HISTOPATHOL, V17, P10, DOI [10.1016/j.mpdhp.2010.10.004, DOI 10.1016/J.MPDHP.2010.10.004]
   Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200
   Masaki KH, 2000, NEUROLOGY, V54, P1265, DOI 10.1212/WNL.54.6.1265
   McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013
   Mendis E, 2007, LIFE SCI, V80, P2118, DOI 10.1016/j.lfs.2007.03.016
   Minakawa M, 2011, J CLIN BIOCHEM NUTR, V48, P237, DOI 10.3164/jcbn.10-119
   Mokni M, 2007, NEUROCHEM RES, V32, P981, DOI 10.1007/s11064-006-9255-z
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Mullie P, 2007, PLANT FOOD HUM NUTR, V62, P93, DOI 10.1007/s11130-007-0047-7
   Murias M, 2005, BIOCHEM PHARMACOL, V69, P903, DOI 10.1016/j.bcp.2004.12.001
   Niu AJ, 2008, INT J BIOL MACROMOL, V42, P447, DOI 10.1016/j.ijbiomac.2008.02.003
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Patel KR, 2011, ANN NY ACAD SCI, V1215, P161, DOI 10.1111/j.1749-6632.2010.05853.x
   Peng HW, 1998, J CHROMATOGR B, V714, P369, DOI 10.1016/S0378-4347(98)00204-7
   Pons M, 2010, AM J PATHOL, V177, P1198, DOI 10.2353/ajpath.2010.091108
   Prashanth KVH, 2007, CARBOHYD RES, V342, P190, DOI 10.1016/j.carres.2006.11.010
   Qian L, 2010, J NEURAL TRANSM, V117, P971, DOI 10.1007/s00702-010-0428-1
   Qin XM, 2001, CARBOHYD RES, V333, P79, DOI 10.1016/S0008-6215(01)00118-5
   Queen Brannon L, 2010, Curr Aging Sci, V3, P34
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Ramadori G, 2009, ENDOCRINOLOGY, V150, P5326, DOI 10.1210/en.2009-0528
   Ravaglia G, 2005, AM J CLIN NUTR, V82, P636, DOI 10.1093/ajcn/82.3.636
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   Richard T, 2011, ANN NY ACAD SCI, V1215, P103, DOI 10.1111/j.1749-6632.2010.05865.x
   Robich MP, 2011, EUR J PHARMACOL, V664, P45, DOI 10.1016/j.ejphar.2011.04.059
   Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004
   SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473
   Scarmeas N, 2009, JAMA-J AM MED ASSOC, V302, P627, DOI 10.1001/jama.2009.1144
   Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854
   Schapira AHV, 2010, NAT REV NEUROL, V6, P309, DOI 10.1038/nrneurol.2010.52
   Scheepens A, 2010, GENES NUTR, V5, P75, DOI 10.1007/s12263-009-0148-z
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shang YJ, 2009, J ORG CHEM, V74, P5025, DOI 10.1021/jo9007095
   Shen T, 2009, NAT PROD REP, V26, P916, DOI 10.1039/b905960a
   Simon KC, 2007, NEUROLOGY, V69, P1688, DOI 10.1212/01.wnl.0000271883.45010.8a
   Sorond Farzaneh A, 2008, Neuropsychiatr Dis Treat, V4, P433
   Spencer JPE, 2008, BRIT J NUTR, V99, pES60, DOI 10.1017/S0007114508965776
   Spencer JPE, 2001, FREE RADICAL BIO MED, V31, P1139, DOI 10.1016/S0891-5849(01)00704-3
   Su BN, 2002, J NAT PROD, V65, P163, DOI 10.1021/np010451c
   Sun AY, 2008, NEUROMOL MED, V10, P259, DOI 10.1007/s12017-008-8052-z
   Szekely CA, 2010, CNS NEUROL DISORD-DR, V9, P132, DOI 10.2174/187152710791012026
   Szekeres T, 2010, PHARM RES-DORDR, V27, P1042, DOI 10.1007/s11095-010-0090-1
   Tang BL, 2008, MOL ASPECTS MED, V29, P187, DOI 10.1016/j.mam.2007.02.001
   Unno K, 2004, EXP GERONTOL, V39, P1027, DOI 10.1016/j.exger.2004.03.033
   Unno K, 2007, BIOGERONTOLOGY, V8, P89, DOI 10.1007/s10522-006-9036-8
   Unno K, 2008, BIOFACTORS, V34, P263, DOI [10.1002/biof.5520340402, 10.3233/BIO-2009-1080]
   Urpi-Sarda M, 2005, ANAL CHEM, V77, P3149, DOI 10.1021/ac0484272
   Vafeiadou K, 2009, ARCH BIOCHEM BIOPHYS, V484, P100, DOI 10.1016/j.abb.2009.01.016
   Vanamala J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-238
   Vauzour D, 2008, GENES NUTR, V3, P115, DOI 10.1007/s12263-008-0091-4
   Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885
   Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6
   Watson GS, 2010, BRAIN PATHOL, V20, P640, DOI 10.1111/j.1750-3639.2010.00373.x
   Weinreb O, 2009, GENES NUTR, V4, P283, DOI 10.1007/s12263-009-0143-4
   Wenzel E, 2005, MOL NUTR FOOD RES, V49, P472, DOI 10.1002/mnfr.200500010
   Wismar R, 2011, MOL NUTR FOOD RES, V55, P443, DOI 10.1002/mnfr.201000230
   Wuwongse S, 2010, PROG NEUROBIOL, V91, P362, DOI 10.1016/j.pneurobio.2010.04.005
   Xie QM, 2006, J ETHNOPHARMACOL, V107, P424, DOI 10.1016/j.jep.2006.03.040
   Xu Q, 2011, DIABETES CARE, V34, P910, DOI 10.2337/dc10-1922
   Xu W, 2010, BIOORG MED CHEM LETT, V20, P3084, DOI 10.1016/j.bmcl.2010.03.105
   Yamamoto N, 1999, ARCH BIOCHEM BIOPHYS, V372, P347, DOI 10.1006/abbi.1999.1516
   Yang R, 2011, MOL MED REP IN PRESS, DOI [10.3892/mmr.2011.511, DOI 10.3892/MMR.2011.511)]
   Yang YM, 2011, AM J CHINESE MED, V39, P145, DOI 10.1142/S0192415X11008713
   Yang ZM, 2010, J SEP SCI, V33, P120, DOI 10.1002/jssc.200900396
   Yoon NY, 2009, CARBOHYD POLYM, V78, P869, DOI 10.1016/j.carbpol.2009.07.004
   Yoshino S, 2011, NUTRITION, V27, P847, DOI 10.1016/j.nut.2010.09.002
   Yoshino S, 2010, HEPATO-GASTROENTEROL, V57, P172
   Youdim KA, 2004, FREE RADICAL BIO MED, V36, P592, DOI 10.1016/j.freeradbiomed.2003.11.023
   Youdim KA, 2003, J NEUROCHEM, V85, P180, DOI 10.1046/j.1471-4159.2003.01652.x
   Yu MS, 2007, INT J MOL MED, V20, P261
   Yu MS, 2006, INT J MOL MED, V17, P1157
   Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang E, 2010, SOC NEUROSCIENCE
   Zhou SL, 2008, NEUROSCI LETT, V444, P270, DOI 10.1016/j.neulet.2008.08.040
   Zhou XL, 2007, J AGR FOOD CHEM, V55, P5523, DOI 10.1021/jf070699t
   Zhu J, 2007, CELL BIOL INT, V31, P615, DOI 10.1016/j.cellbi.2006.12.002
   Zoccolella S, 2010, CURR MED CHEM, V17, P213, DOI 10.2174/092986710790149774
NR 163
TC 13
Z9 13
U1 6
U2 50
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JAN
PY 2012
VL 18
IS 1
BP 15
EP 26
DI 10.2174/138161212798919039
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 892KD
UT WOS:000300284200004
PM 22211681
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Mac Gabhann, F
   Qutub, AA
   Annex, BH
   Popel, AS
AF Mac Gabhann, Feilim
   Qutub, Amina A.
   Annex, Brian H.
   Popel, Aleksander S.
TI Systems biology of pro-angiogenic therapies targeting the VEGF system
SO WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CRITICAL LIMB ISCHEMIA; PERIPHERAL
   ARTERIAL-DISEASE; THERAPEUTIC ANGIOGENESIS; GENE-TRANSFER; DOUBLE-BLIND;
   SKELETAL-MUSCLE; CORONARY-ARTERY; MYOCARDIAL-PERFUSION; COMPUTATIONAL
   MODEL
AB Vascular endothelial growth factor (VEGF) is a family of cytokines for which the dysregulation of expression is involved in many diseases; for some, excess VEGF causes pathological hypervascularization, while for others VEGF-induced vascular remodeling may alleviate ischemia and/or hypoxia. Anti-angiogenic therapies attacking the VEGF pathway have begun to live up to their promise for treatment of certain cancers and of age-related macular degeneration. However, the corollary is not yet true: in coronary artery disease and peripheral artery disease, clinical trials of pro-angiogenic VEGF delivery have not, so far, proven successful. The VEGF and VEGF-receptor system is complex, with at least five ligand genes, some encoding multiple protein isoforms and five receptor genes. A systems biology approach for designing pro-angiogenic therapies, using a combination of quantitative experimental approaches and detailed computational models, is essential to deal with this complexity and to understand the effects of drugs targeting the system. This approach allows us to learn from unsuccessful clinical trials and to design and test novel single therapeutics or combinations of therapeutics. Among the parameters that can be varied in order to determine optimal strategy are dosage, timing of multiple doses, route of administration, and the molecular target. (C) 2010 John Wiley & Sons, Inc. WIREs Syst Biol Med 2010 2 694-707
C1 [Qutub, Amina A.; Popel, Aleksander S.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Mac Gabhann, Feilim] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.
   [Mac Gabhann, Feilim] Johns Hopkins Univ, Inst Computat Med, Baltimore, MD 21218 USA.
   [Annex, Brian H.] Univ Virginia, Sch Med, Dept Med, Div Cardiovasc Med, Charlottesville, VA 22908 USA.
   [Annex, Brian H.] Univ Virginia, Sch Med, Robert M Berne Cardiovasc Res Ctr, Charlottesville, VA 22908 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; University of Virginia; University of Virginia
RP Popel, AS (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
EM apopel@jhu.edu
RI Mac Gabhann, Feilim/A-3436-2010; Popel, Aleksander S/A-6724-2009
OI Mac Gabhann, Feilim/0000-0003-3481-7740; Qutub,
   Amina/0000-0003-1737-9208; Popel, Aleksander/0000-0002-6706-9235
FU NHLBI NIH HHS [R01 HL101200, R00 HL093219] Funding Source: Medline;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL093219, R01HL101200]
   Funding Source: NIH RePORTER
CR Allen KB, 2004, ANN THORAC SURG, V77, P1228, DOI 10.1016/j.athoracsur.2004.01.008
   Annex BH, 2005, CARDIOVASC RES, V65, P649, DOI 10.1016/j.cardiores.2004.09.004
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Aronowski JW, 2003, ILAR J, V44, P105, DOI 10.1093/ilar.44.2.105
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Baumgartner I, 2000, ANN INTERN MED, V132, P880, DOI 10.7326/0003-4819-132-11-200006060-00005
   Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114
   Bentley K, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000549
   Cao L, 2009, BIOMATERIALS, V30, P4085, DOI 10.1016/j.biomaterials.2009.04.051
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chalothorn D, 2007, PHYSIOL GENOMICS, V30, P179, DOI 10.1152/physiolgenomics.00047.2007
   Cherwek DH, 2000, AM J PHYSIOL-HEART C, V279, pH932, DOI 10.1152/ajpheart.2000.279.3.H932
   CREAGER MA, 2009, ACC09 AM C CARD SCI
   Dai QS, 2004, CIRCULATION, V110, P2467, DOI 10.1161/01.CIR.0000145139.53840.49
   Dayan F, 2009, J THEOR BIOL, V259, P304, DOI 10.1016/j.jtbi.2009.03.009
   Faeder James R., 2009, V500, P113, DOI 10.1007/978-1-59745-525-1_5
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Findley CM, 2008, J AM COLL CARDIOL, V52, P387, DOI 10.1016/j.jacc.2008.02.045
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Fruttiger Marcus, 2008, P30, DOI 10.1007/978-0-387-78632-2_3
   Gabhann FM, 2008, MICROCIRCULATION, V15, P715, DOI 10.1080/10739680802095964
   Greenberg JI, 2008, NATURE, V456, P809, DOI 10.1038/nature07424
   Grines CL, 2003, J AM COLL CARDIOL, V42, P1339, DOI 10.1016/S0735-1097(03)00988-4
   Grines CL, 2002, CIRCULATION, V105, P1291, DOI 10.1161/hc1102.105595
   Gupta RC, 2009, CIRC RES, V105, pE18
   Hazarika S, 2007, CIRC RES, V101, P948, DOI 10.1161/CIRCRESAHA.107.160630
   Hedman M, 2003, CIRCULATION, V107, P2677, DOI 10.1161/01.CIR.0000070540.80780.92
   Helisch A, 2006, ARTERIOSCL THROM VAS, V26, P520, DOI 10.1161/01.ATV.0000202677.55012.a0
   Helm CLE, 2005, P NATL ACAD SCI USA, V102, P15779, DOI 10.1073/pnas.0503681102
   Hendel RC, 2000, CIRCULATION, V101, P118, DOI 10.1161/01.CIR.101.2.118
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Henry TD, 2001, AM HEART J, V142, P872, DOI 10.1067/mhj.2001.118471
   Hughes GC, 2005, EXPERT REV CARDIOVAS, V3, P521, DOI 10.1586/14779072.3.3.521
   Hughes GC, 1999, CAN J CARDIOL, V15, P797
   Idris NM, 2004, GROWTH FACTORS, V22, P269, DOI 10.1080/08977190412331284344
   Jakobsson L, 2009, BIOCHEM SOC T, V37, P1233, DOI 10.1042/BST0371233
   Ji JW, 2007, AM J PHYSIOL-HEART C, V293, pH3740, DOI 10.1152/ajpheart.00009.2007
   Jones WS, 2007, CURR OPIN CARDIOL, V22, P458, DOI 10.1097/HCO.0b013e328236741b
   Kajiwara H, 2009, J GENE MED, V11, P390, DOI 10.1002/jgm.1318
   Kastrup J, 2005, J AM COLL CARDIOL, V45, P982, DOI 10.1016/j.jacc.2004.12.068
   Keating SM, 2006, BIOINFORMATICS, V22, P1275, DOI 10.1093/bioinformatics/btl111
   Kohn KW, 2004, MOL BIOL CELL, V15, P3042, DOI 10.1091/mbc.E03-12-0897
   Kong HJ, 2008, PHARM RES, V25, P1230, DOI 10.1007/s11095-007-9526-7
   Kusumanto YH, 2006, HUM GENE THER, V17, P683, DOI 10.1089/hum.2006.17.683
   Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015
   Lampugnani MG, 2006, J CELL BIOL, V174, P593, DOI 10.1083/jcb.200602080
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Li YJ, 2007, DIABETES, V56, P656, DOI 10.2337/db06-0999
   Lloyd PG, 2003, AM J PHYSIOL-HEART C, V284, pH1668, DOI 10.1152/ajpheart.00743.2002
   Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261
   Loinard C, 2009, CIRCULATION, V120, P50, DOI 10.1161/CIRCULATIONAHA.108.813303
   Losordo DW, 2002, CIRCULATION, V105, P2012, DOI 10.1161/01.CIR.0000015982.70785.B7
   Mac Gabhann F, 2004, AM J PHYSIOL-HEART C, V286, pH153, DOI 10.1152/ajpheart.00254.2003
   Mac Gabhann F, 2007, AM J PHYSIOL-HEART C, V292, pH459, DOI 10.1152/ajpheart.00637.2006
   Mac Gabhann F, 2007, ANN BIOMED ENG, V35, P982, DOI 10.1007/s10439-007-9303-0
   Mac Gabhann F, 2007, J APPL PHYSIOL, V102, P722, DOI 10.1152/japplphysiol.00800.2006
   Mac Gabhann F, 2006, PLOS COMPUT BIOL, V2, P1107, DOI 10.1371/journal.pcbi.0020127
   Majid A, 2000, STROKE, V31, P2707, DOI 10.1161/01.STR.31.11.2707
   Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638
   Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287
   Md AOD, 2008, CIRCULATION, V117, P1207, DOI 10.1161/CIRCULATIONAHA.107.736447
   Miquerol L, 2000, DEVELOPMENT, V127, P3941
   MITCHELL R, 2008, ISCT INT SOC CELL TH
   Mizukami Y, 2004, CANCER RES, V64, P1765, DOI 10.1158/0008-5472.CAN-03-3017
   Moraru II, 2008, IET SYST BIOL, V2, P352, DOI 10.1049/iet-syb:20080102
   Nagy JA, 2009, BRIT J CANCER, V100, P865, DOI 10.1038/sj.bjc.6604929
   O'Hagan KA, 2009, P NATL ACAD SCI USA, V106, P2188, DOI 10.1073/pnas.0808801106
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Ozawa CR, 2004, J CLIN INVEST, V113, P516, DOI 10.1172/JCI200418420
   Pajusola K, 2005, FASEB J, V19, P1365, DOI 10.1096/fj.05-3720fje
   Patel SA, 2008, CELL DEATH DIFFER, V15, P628, DOI 10.1038/cdd.2008.17
   Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B
   Qing GL, 2009, CURR OPIN GENET DEV, V19, P60, DOI 10.1016/j.gde.2008.12.001
   Quitub AA, 2009, IEEE ENG MED BIOL, V28, P14, DOI 10.1109/MEMB.2009.931791
   Qutub AA, 2008, MOL CELL BIOL, V28, P5106, DOI 10.1128/MCB.00060-08
   Qutub AA, 2007, BBA-MOL CELL RES, V1773, P1511, DOI 10.1016/j.bbamcr.2007.07.004
   Qutub AA, 2006, J CELL SCI, V119, P3467, DOI 10.1242/jcs.03087
   Rajagopalan S, 2003, CIRCULATION, V108, P1933, DOI 10.1161/01.CIR.0000093398.16124.29
   Rajagopalan S, 2002, AM J CARDIOL, V90, P512, DOI 10.1016/S0002-9149(02)02524-9
   Rajagopalan S, 2001, CIRCULATION, V104, P753, DOI 10.1161/hc3201.095192
   Ramsauer M, 2007, J CELL SCI, V120, P1810, DOI 10.1242/jcs.003533
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Silva EA, 2007, J THROMB HAEMOST, V5, P590, DOI 10.1111/j.1538-7836.2007.02386.x
   Simons M, 2003, NAT REV DRUG DISCOV, V2, P863, DOI 10.1038/nrd1226
   Simons M, 2002, CIRCULATION, V105, P788, DOI 10.1161/hc0802.104407
   Stefanini MO, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-77
   Stewart DJ, 2006, GENE THER, V13, P1503, DOI 10.1038/sj.gt.3302802
   Stewart DJ, 2009, MOL THER, V17, P1109, DOI 10.1038/mt.2009.70
   Sugimori H, 2004, BRAIN RES PROTOC, V13, P189, DOI 10.1016/j.brainresprot.2004.06.001
   Takahashi K, 2003, BIOINFORMATICS, V19, P1727, DOI 10.1093/bioinformatics/btg221
   Tongers J, 2008, CIRCULATION, V118, P9, DOI 10.1161/CIRCULATIONAHA.108.784371
   Tse HF, 2007, EUR HEART J, V28, P2998, DOI 10.1093/eurheartj/ehm485
   Tse HF, 2007, AM HEART J, V154, DOI 10.1016/j.ahj.2007.07.021
   Tuomisto TT, 2004, ATHEROSCLEROSIS, V174, P111, DOI 10.1016/j.atherosclerosis.2004.01.015
   Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952
   Uchida C, 2009, CURR PHARM DESIGN, V15, P411, DOI 10.2174/138161209787315800
   Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   Wu FTH, 2009, PHYSIOL GENOMICS, V38, P29, DOI 10.1152/physiolgenomics.00031.2009
   Wu FTH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005108
   YANG F, 2009, P NATL ACAD SCI US
   Yla-Herttuala S, 2007, J AM COLL CARDIOL, V49, P1015, DOI 10.1016/j.jacc.2006.09.053
   Yu J, 2006, FASEB J, V20, P479, DOI 10.1096/fj.04-3670fje
   Yucel MA, 2007, BIOTECHNOL BIOENG, V97, P588, DOI 10.1002/bit.21247
NR 105
TC 68
Z9 71
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-5094
EI 1939-005X
J9 WIRES SYST BIOL MED
JI Wiley Interdiscip. Rev.-Syst. Biol
PD NOV-DEC
PY 2010
VL 2
IS 6
BP 694
EP 707
DI 10.1002/wsbm.92
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 674DI
UT WOS:000283713500006
PM 20890966
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhang, M
   Yu, DC
   Yang, C
   Xia, QJ
   Li, W
   Liu, B
   Li, H
AF Zhang, Ming
   Yu, Dechao
   Yang, Chun
   Xia, Qingjie
   Li, Wang
   Liu, Bin
   Li, Hong
TI The Pharmacology Study of a New Recombinant Human VEGF Receptor-Fc
   Fusion Protein on Experimental Choroidal Neovascularization
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE age-related macular degeneration; antiangiogenesis; choroidal
   neovascularization; intravitreal injection; vascular endothelial growth
   factor receptor
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; EXPRESSION
AB KH902, a recombinant fusion protein, is designed for treatment of neovascular age-related macular degeneration. The study is to investigate the prevention efficacy of KH902 on experimental choroidal neovascularization (CNV) in a monkey model.
   Binding assay and endothelial cell proliferation assay were used to evaluate activity and bioactivity of KH902 in vitro while an initial comparison of bioactivity was made between KH902 and Ranizumab (Lucentis). Ocular and systemic levels of KH902 were analyzed by enzyme-linked immunosorbent assay (ELISA) method after single intravitreal administration to evaluate its availability to ocular fundus. In vivo pharmacological study, CNV was induced by laser in monkeys and KH902 prevention efficacy on CNV was evaluated by incidence of CNV and several ophthalmic examinations.
   KH902 is a unique fusion protein with high affinity to VEGF and good availability to target tissue, beneficial to good bioactivity in vivo. In vivo pharmacological study, the incidence of CNV formation was largely reduced in KH902 treatment groups. Furthermore, the leakage of CNV in control group which crossed over to KH902 treatment 40 days after laser was much less than that before KH902 treatment.
   KH902 was effective to prevent the formation of experimental CNV and also to treat pre-existed CNV without evidence of toxicity. This study suggests that KH902 has promise as a local anti-angiogenic treatment of CNV-related diseases.
C1 [Yu, Dechao; Yang, Chun; Li, Hong] Chengdu Kanghong Biotechnol Co Inc, Chengdu 610036, Sichuan Prov, Peoples R China.
   [Zhang, Ming; Xia, Qingjie] Sichuan Univ, Dept Ophthalmol, W China Hosp, Chengdu 610041, Sichuan, Peoples R China.
   [Li, Wang; Liu, Bin] State Chengdu Tradit Chinese Med Safety Evaluat C, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University
RP Li, H (通讯作者)，Chengdu Kanghong Biotechnol Co Inc, 36 Shuxi Rd, Chengdu 610036, Sichuan Prov, Peoples R China.
EM cissi_79@yahoo.com.cn
CR Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Luo JC, 1998, CANCER RES, V58, P2652
   Maurice D. M., 1984, HANDB EXP PHARM, P19
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Suto K, 2005, J BIOL CHEM, V280, P2126, DOI 10.1074/jbc.M411395200
   Zhang M, 2008, MOL VIS, V14, P37
NR 14
TC 82
Z9 91
U1 1
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JAN
PY 2009
VL 26
IS 1
BP 204
EP 210
DI 10.1007/s11095-008-9718-9
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 385CV
UT WOS:000261791600020
PM 18854954
DA 2022-11-30
ER

PT J
AU Wang, XW
   Tan, BZ
   Sun, M
   Ho, B
   Ding, JL
AF Wang, Xiao Wei
   Tan, Bao Zhen
   Sun, Miao
   Ho, Bow
   Ding, Jeak Ling
TI Thioredoxin-like 6 protects retinal cell line from photooxidative damage
   by upregulating NF-kappa B activity
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE apoptosis; NF-kappa B; photooxidative stress; photoreceptor cell;
   reactive oxygen species; thioredoxin-like 6 (TXNL6)
ID STRESS-INDUCED APOPTOSIS; PHOTORECEPTOR CELLS; IN-VIVO; ACTIVATION;
   DEATH; EXPRESSION; CASPASE-3; PATHWAYS; SURVIVAL
AB Apoptosis is the common pathway to photoreceptor cell death in many eye diseases including age-related macular degeneration which affects more than 8 million individuals in the United States alone. RdCVF, a truncated mouse thioredoxin is specifically expressed by rod photoreceptor cells and prevents the apoptosis of I cells. However the protective mechanism of RdCVF and the implications of its human homologue, cone thioredoxin-like 6 (TXNL6), on the apoptosis of retinal cells remain unknown. In this study, we examined the function of TXNL6 and investigated its mechanism of protection using a cone photoreceptor cell line, 661W. We found that the photooxidative stress-induced degradation of NF-kappa B Proteins is rescued by over expression of TXNL6, which enabled the NF-kappa B transactivation activity. Furthermore, the overexpression of TXNL6 rescued the photooxidative stress-induced apoptosis of 661W cells. Interestingly, this protective effect was significantly blocked by NF-kappa B specific inhibitors demonstrating that TXNL6 exerts its protective effect against apoptosis via NF-kappa B. Taken together, our study shows that the TXNL6 probably protects retinal cells from photooxidative damage-induced apoptosis via upregulation of NF-kappa B activity. The identification of TXNL6 and the demonstration of its protective mechanism offer new insights into treatment possibilities for photoreceptor cell degradation. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Wang, Xiao Wei; Sun, Miao; Ding, Jeak Ling] Natl Univ, Dept Biol Sci, Singapore 117543, Singapore.
   [Tan, Bao Zhen] Natl Univ Singapore, Dept Physiol, Singapore 117543, Singapore.
   [Ho, Bow] Natl Univ Singapore, Dept Microbiol, Singapore 117543, Singapore.
C3 National University of Singapore; National University of Singapore;
   National University of Singapore
RP Ding, JL (通讯作者)，Natl Univ, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.
EM dbsdjl@nus.edu.sg
RI Sun, Miao/F-9836-2013; Ding, Jeak/H-8057-2012
CR AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4
   Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x
   Bian X, 2002, J BIOL CHEM, V277, P42144, DOI 10.1074/jbc.M203891200
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Burke MA, 2003, J NEUROBIOL, V55, P191, DOI 10.1002/neu.10174
   Carmody RJ, 1999, EXP CELL RES, V248, P520, DOI 10.1006/excr.1998.4421
   Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   Crawford MJ, 2001, BIOCHEM BIOPH RES CO, V281, P1304, DOI 10.1006/bbrc.2001.4501
   Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200
   Donovan M, 2002, CELL DEATH DIFFER, V9, P1220, DOI 10.1038/sj.cdd.4401105
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938
   Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011
   Gomez-Vicente V, 2005, CELL DEATH DIFFER, V12, P796, DOI 10.1038/sj.cdd.4401621
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hirota K, 2002, ANN NY ACAD SCI, V957, P189, DOI 10.1111/j.1749-6632.2002.tb02916.x
   Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891
   HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321
   Kanan Y, 2007, INVEST OPHTH VIS SCI, V48, P40, DOI 10.1167/iovs.06-0592
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508
   Maggirwar SB, 1998, J NEUROSCI, V18, P10356
   Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421
   Sadek CM, 2003, J BIOL CHEM, V278, P13133, DOI 10.1074/jbc.M300369200
   Sanvicens N, 2004, J BIOL CHEM, V279, P39268, DOI 10.1074/jbc.M402202200
   SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181
   Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Tanito M, 2005, J NEUROSCI, V25, P2396, DOI 10.1523/JNEUROSCI.4866-04.2005
   Wang XW, 2007, FREE RADICAL BIO MED, V42, P247, DOI 10.1016/j.freeradbiomed.2006.10.040
NR 34
TC 17
Z9 22
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD AUG 1
PY 2008
VL 45
IS 3
BP 336
EP 344
DI 10.1016/j.freeradbiomed.2008.04.028
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 318KC
UT WOS:000257089300013
PM 18474255
DA 2022-11-30
ER

PT J
AU Bunce, C
   Wormald, R
AF Bunce, C.
   Wormald, R.
TI Causes of blind certifications in England and Wales: April 1999 to March
   2000
SO EYE
LA English
DT Article
DE blind; registration; age-related macular degeneration; glaucoma;
   diabetic retinopathy
ID UNREGISTERED VISUAL IMPAIRMENT; PARTIAL SIGHT; REGISTRATION
AB Aim The last complete report on causes of blindness in England and Wales was for data collected during April 1990 to March 1991. This current study sought to update these figures, with data collected during April 1999 to March 2000, and examine variation in cause by age group.
   Methods In England and Wales, registration for blindness is voluntary and is initiated by certification by a consultant ophthalmologist. The main cause of blindness was ascertained where possible for all certificates completed during April 1999 to March 2000 and tabulated by age group.
   Results A total of 34 410 BD8 certificates were received, of which 13 788 (40%) were for people certified as blind. Different causes predominated within different age groups. Age related macular degeneration (AMD) was the lead cause in those aged 65 years and above, diabetic retinopathy was the lead cause in people of working ages (16-64 years), whereas cerebral visual impairment and disorders of the optic nerve accounted for over 40% of blind certificates completed for children.
   Conclusion Estimates of vision impairment based on certifications for blindness in England and Wales are likely to be imprecise. They do, however, give some measure of the burden at hospital level of sight impairing eye conditions. If factors determining the imprecision remain constant, temporal monitoring of causes may enable changes and development of new conditions leading to vision impairment to be detected.
C1 [Bunce, C.; Wormald, R.] Moorfields Eye Hosp, London ECIV 2PD, England.
RP Bunce, C (通讯作者)，Moorfields Eye Hosp, London ECIV 2PD, England.
EM c.bunce@ucl.ac.uk
OI Bunce, Catey/0000-0002-0935-3713
FU Department of Health Funding Source: Medline
CR Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   BRUCE I, 1991, BLIND PARTIALLY SIGH, V1
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Department of Health and Social Security, 1979, REP PUBL HLTH MED SU, V129
   EVANS J, 1988, STUDIES MED POPULATI, V57
   Government Statistical Service, 1988, CAUS BLIND PART SIGH
   King AJW, 2000, EYE, V14, P613, DOI 10.1038/eye.2000.152
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   SORSBY, 1966, REPORTS PUBLIC HLTH, V114
   Sorsby A., 1953, CAUSES BLINDNESS ENG
   Sorsby A., 1972, REPORTS PUBLIC HLTH, V128
   Sorsby A., 1956, BLINDNESS ENGLAND 19
   WALKER E, 1992, BLIND PARTIALLY SIGH, V2
   1977, INT CLASSIFICATION D
NR 15
TC 96
Z9 96
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JUL
PY 2008
VL 22
IS 7
BP 905
EP 911
DI 10.1038/sj.eye.6702767
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 326XP
UT WOS:000257693200007
PM 17332762
OA Bronze
DA 2022-11-30
ER

PT J
AU Eichler, W
   Yafai, Y
   Wiedemann, P
   Fengler, D
AF Eichler, Wolfram
   Yafai, Yousef
   Wiedemann, Peter
   Fengler, Doerte
TI Antineovascular agents in the treatment of eye diseases
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE angiogenesis; pharmacotherapy; retina; diabetic retinopathy; age-related
   macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-C; EPITHELIUM-DERIVED FACTOR;
   INTRAVITREAL TRIAMCINOLONE ACETONIDE; VASCULAR-PERMEABILITY FACTOR;
   COMBRETASTATIN A-4 PHOSPHATE; MESSENGER-RNA EXPRESSION; EXPERIMENTAL
   SUBRETINAL NEOVASCULARIZATION; EXPERIMENTAL CHOROIDAL
   NEOVASCULARIZATION; INHIBIT RETINAL NEOVASCULARIZATION
AB Neovascularization is a common and potentially visually threatening complication of eye diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). An antiangiogenic therapy is aimed at inhibiting the growth of new blood vessels and should prevent onset or progression of neovascularization. Accumulated evidence indicates that growth factors, endothelial cell surface receptors, and extracellular matrix (ECM) proteins are major mediators of neovascularization and appealing targets for pharmacotherapeutical intervention. Vascular endothelial growth factor (VEGF) plays a critical role in the pathogenesis of retinal neovascularization (in linking tissue ischemia to angiogenesis), and is likely to contribute also significantly to choroidal neovascularization (CNV). Several antincovascular agents antagonize the function of VEGF, by blocking its proangiogenic activity. Indeed, VEGF targeting or disruption of VEGF signalling is the most effective strategy known so far in the pharmacological treatment of ocular neovascularization. Other compounds such as pigment epithelium-derived factor (PEDF) either aim at balancing the levels of pro-angiogenic and angiostatic molecules, target inflammation (cyclooxygenase inhibitors. steroids) or comprise modifiers of the ECM Such as inhibitors of matrix metalloproteinases (MMPs) and agents that block the action of integrins. Vascular targeting agents (combretastatin) promote removal of newly formed vessels. This review provides an update on recent investigations directed at the pharmacotherapeutical management of ocular neovascular diseases, placing special emphasis on the underlying target molecules and relevant intracellular signalling pathways.
C1 Univ Leipzig, Hosp Eye, D-04103 Leipzig, Germany.
   Univ Leipzig, Fac Med, Interdisciplinary Ctr Clin Res, D-04103 Leipzig, Germany.
C3 Leipzig University; Leipzig University
RP Eichler, W (通讯作者)，Univ Leipzig, Hosp Eye, Liebigstr 10-14, D-04103 Leipzig, Germany.
EM eichwolf@rz.uni-leipzig.de
CR Abbas A, 2002, J Pak Med Assoc, V52, P476
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363
   Ahmed B, 2003, INT J CANCER, V105, P20, DOI 10.1002/ijc.11010
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   Aiello LP, 2002, DIABETES, V51, pA209
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aiello LP, 1999, DIABETES, V48, pA19
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   [Anonymous], 1991, Ophthalmology, V98, P757
   Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   Arber N, 2005, RECENT RESULTS CANC, V166, P213
   ASHTON N, 1957, AM J OPHTHALMOL, V44, P7, DOI 10.1016/0002-9394(57)90426-9
   Avila-Vazquez Medardo, 2004, BMC Pediatr, V4, P15, DOI 10.1186/1471-2431-4-15
   Ayalasomayajula SP, 2004, EUR J PHARMACOL, V498, P275, DOI 10.1016/j.ejphar.2004.07.046
   Balasubramaniam Jagdish, 2003, Acta Pharmaceutica (Zagreb), V53, P251
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992
   Beck RW, 2001, OPHTHALMOLOGY, V108, P2266
   BENELLI R, 1994, ONCOL RES, V6, P251
   Blodi BA, 2001, INVEST OPHTH VIS SCI, V42, pS311
   Bosco AA, 2003, DIABETOLOGIA, V46, P1669, DOI 10.1007/s00125-003-1234-1
   BOSSI E, 1995, INTENS CARE MED, V21, P241, DOI 10.1007/BF01701481
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227
   BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8
   Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654
   Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167
   Bursell SE, 1997, INVEST OPHTH VIS SCI, V38, P2711
   Calvo P, 1996, J PHARM PHARMACOL, V48, P1147, DOI 10.1111/j.2042-7158.1996.tb03911.x
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Castro MR, 2004, EXP EYE RES, V79, P275, DOI 10.1016/j.exer.2004.04.008
   Ceolotto G, 1999, DIABETES, V48, P1316, DOI 10.2337/diabetes.48.6.1316
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0
   Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0
   Cheng LY, 2001, J OCUL PHARMACOL TH, V17, P295, DOI 10.1089/108076801750295326
   Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581
   Chetoni P, 2000, J OCUL PHARMACOL TH, V16, P363, DOI 10.1089/jop.2000.16.363
   Chibber R, 2003, DIABETES, V52, P1519, DOI 10.2337/diabetes.52.6.1519
   Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8
   Chulada PC, 2000, CANCER RES, V60, P4705
   Cirla A, 2003, NAT PROD REP, V20, P558, DOI 10.1039/b306797c
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Danesi R, 1997, CLIN CANCER RES, V3, P265
   Daniel TO, 1999, CANCER RES, V59, P4574
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M
   Demir T, 1999, ACTA OPHTHALMOL SCAN, V77, P386, DOI 10.1034/j.1600-0420.1999.770404.x
   Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721
   Dimopoulos MA, 2004, AM J MED, V117, P508, DOI 10.1016/j.amjmed.2004.03.040
   Donahue ML, 1996, CURR EYE RES, V15, P175, DOI 10.3109/02713689608997411
   Donnelly R, 2004, BRIT J OPHTHALMOL, V88, P145, DOI 10.1136/bjo.88.1.145
   Du YP, 2004, AM J PHYSIOL-REG I, V287, pR735, DOI 10.1152/ajpregu.00080.2003
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Eichler W, 2000, NEUROREPORT, V11, P3533, DOI 10.1097/00001756-200011090-00026
   Eichler W, 2001, NEUROREPORT, V12, P4103, DOI 10.1097/00001756-200112210-00048
   Eleutherakis-Papaiakovou V, 2004, ANN ONCOL, V15, P1151, DOI 10.1093/annonc/mdh300
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   FORM DM, 1983, P SOC EXP BIOL MED, V172, P214
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Franks ME, 2004, LANCET, V363, P1802, DOI 10.1016/S0140-6736(04)16308-3
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Fujita J, 2001, CLIN CANCER RES, V7, P3349
   Fujita K, 2004, HISTOCHEM CELL BIOL, V122, P27, DOI 10.1007/s00418-004-0669-x
   Funatsu H, 2003, OPHTHAL PHYSL OPT, V23, P495, DOI 10.1046/j.1475-1313.2003.00134.x
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Garcia CR, 2002, CURR EYE RES, V24, P33, DOI 10.1076/ceyr.24.1.33.5429
   Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRANT MB, 1993, DIABETOLOGIA, V36, P282, DOI 10.1007/BF00400229
   Grant MB, 2000, DIABETES CARE, V23, P504, DOI 10.2337/diacare.23.4.504
   GRANT MB, 1993, REGUL PEPTIDES, V48, P267, DOI 10.1016/0167-0115(93)90356-D
   Griggs J, 2002, AM J PATHOL, V160, P1097, DOI 10.1016/S0002-9440(10)64930-9
   Gupta RA, 2003, CANCER RES, V63, P906
   Hallak A, 2003, DIGEST DIS SCI, V48, P1998, DOI 10.1023/A:1026130623186
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   Higgins RD, 2003, CURR EYE RES, V27, P123, DOI 10.1076/ceyr.27.2.123.15955
   Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728
   Itoh T, 1998, CANCER RES, V58, P1048
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Jin M, 2001, RETINA-J RET VIT DIS, V21, P28, DOI 10.1097/00006982-200102000-00005
   Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y
   Jonas JB, 2005, BRIT J OPHTHALMOL, V89, P122, DOI 10.1136/bjo.2004.050575
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Joussen AM, 1999, GRAEF ARCH CLIN EXP, V237, P952, DOI 10.1007/s004170050330
   Ke TL, 2000, INFLAMMATION, V24, P371, DOI 10.1023/A:1007001131987
   Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292
   Kern TS, 2001, DIABETES, V50, P1636, DOI 10.2337/diabetes.50.7.1636
   KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572
   KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Koehne CH, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.03.041
   KOOP S, 1994, CANCER RES, V54, P4791
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   Kruse FE, 1998, GRAEF ARCH CLIN EXP, V236, P461, DOI 10.1007/s004170050106
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambooij AC, 2000, INVEST OPHTH VIS SCI, V41, P2329
   Leahy KM, 2000, CURR MED CHEM, V7, P1163, DOI 10.2174/0929867003374336
   Leahy KM, 2002, CANCER RES, V62, P625
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Lonchampt M, 2001, INVEST OPHTH VIS SCI, V42, P429
   Lucas R, 1998, BLOOD, V92, P4730
   Lukiw WJ, 2003, INVEST OPHTH VIS SCI, V44, P4163, DOI 10.1167/iovs.02-0655
   Luna J, 1996, LAB INVEST, V75, P563
   Maik-Rachline G, 2005, BLOOD, V105, P670, DOI 10.1182/blood-2004-04-1569
   MALLET B, 1992, DIABETES METAB, V18, P438
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5
   MCCOMBE M, 1991, Eye (London), V5, P569
   Mezentsev A, 2002, J BIOL CHEM, V277, P18670, DOI 10.1074/jbc.M201143200
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Miller JW, 2004, OPHTHALMOLOGY, V111, P2316, DOI 10.1016/j.ophtha.2004.09.010
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miyamoto K, 1999, Semin Ophthalmol, V14, P233, DOI 10.3109/08820539909069542
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   MONTGOMERY AMP, 1994, CANCER RES, V54, P5467
   Moran Edgar M., 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P193
   Moravski CJ, 2000, HYPERTENSION, V36, P1099, DOI 10.1161/01.HYP.36.6.1099
   MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675
   Moreira AL, 1999, J NEURO-ONCOL, V43, P109, DOI 10.1023/A:1006202700039
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Mousa SA, 2004, CURR PHARM DESIGN, V10, P1, DOI 10.2174/1381612043453531
   Munoz-Chapuli R, 2004, CELL MOL LIFE SCI, V61, P2224, DOI 10.1007/s00018-004-4070-7
   MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219
   Murphy JF, 2003, BRIT J HAEMATOL, V121, P157, DOI 10.1046/j.1365-2141.2003.04247.x
   Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P1078, DOI 10.1167/iovs.04-1101
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Nagisa Y, 2001, DIABETOLOGIA, V44, P883, DOI 10.1007/s001250100556
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Nandgaonkar BN, 1999, PEDIATR RES, V46, P184, DOI 10.1203/00006450-199908000-00010
   Nonaka A, 2000, INVEST OPHTH VIS SCI, V41, P2702
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Otani A, 1998, CIRC RES, V82, P619, DOI 10.1161/01.RES.82.5.619
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Ozerdem U, 2002, CURR EYE RES, V24, P86, DOI 10.1076/ceyr.24.2.86.8159
   PARK JY, 1999, PERITON DIALYSIS INT, V2, P222
   PEER J, 1995, LAB INVEST, V72, P638
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Perino S, 2004, BIOORG MED CHEM LETT, V14, P421, DOI 10.1016/j.bmcl.2003.10.045
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Presta LG, 1997, CANCER RES, V57, P4593
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   REICH R, 1988, CIBA F SYMP, V141, P193
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SCHULTZ RM, 1988, CANCER RES, V48, P5539
   Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00
   Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x
   Shalinsky DR, 1999, CLIN CANCER RES, V5, P1905
   Sharma J, 2003, CURR EYE RES, V27, P309, DOI 10.1076/ceyr.27.5.309.17222
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Simoni D, 2005, J MED CHEM, V48, P723, DOI 10.1021/jm049622b
   Sinicrope FA, 2004, CANCER METAST REV, V23, P63, DOI 10.1023/A:1025863029529
   Sleijfer S, 2004, EUR J CANCER, V40, P2377, DOI 10.1016/j.ejca.2004.07.023
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Spraul CW, 2002, GRAEF ARCH CLIN EXP, V240, P227, DOI 10.1007/s00417-002-0441-7
   Stearne MR, 1998, BRIT MED J, V317, P713
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756
   Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499
   Tadesse M, 2001, INVEST OPHTH VIS SCI, V42, P1867
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03
   Tombran-Tink J, 2003, TRENDS MOL MED, V9, P244, DOI 10.1016/S1471-4914(03)00074-1
   Tozer GM, 2001, CANCER RES, V61, P6413
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6
   van Buggenum IMH, 2002, DIABETOLOGIA, V45, P203, DOI 10.1007/s00125-001-0747-8
   Vincent L, 2005, J CLIN INVEST, V115, P2992, DOI 10.1172/JCI24586
   Voigt M, 2002, INVEST OPHTH VIS SCI, V43, P3299
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x
   Wegewitz U, 2005, CURR PHARM DESIGN, V11, P2311, DOI 10.2174/1381612054367292
   Wilkinson-Berka JL, 2004, CURR PHARM DESIGN, V10, P3331, DOI 10.2174/1381612043383142
   Wilkinson-Berka JL, 2003, INVEST OPHTH VIS SCI, V44, P974, DOI 10.1167/iovs.02-0392
   Wilkinson-Berka JL, 2001, J VASC RES, V38, P527, DOI 10.1159/000051088
   Williams B, 1997, DIABETES, V46, P1497, DOI 10.2337/diabetes.46.9.1497
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   Woltering EA, 2003, CANCER BIOTHER RADIO, V18, P601, DOI 10.1089/108497803322287691
   Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006
   Yamada M, 1999, CURR EYE RES, V19, P300, DOI 10.1076/ceyr.19.4.300.5301
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6
   ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475
   ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557
NR 243
TC 27
Z9 34
U1 1
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2006
VL 12
IS 21
BP 2645
EP 2660
DI 10.2174/138161206777698729
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 060CP
UT WOS:000238779600006
PM 16842164
DA 2022-11-30
ER

PT J
AU Xu, CZ
   Xi, XM
   Yang, L
   Yang, X
   Song, ZY
   Nie, XS
   Zhang, LM
   Zhang, YW
   Chen, XJ
   Yin, YL
AF Xu, Chuanzhen
   Xi, Xiaoming
   Yang, Lu
   Yang, Xiao
   Song, Zuoyong
   Nie, Xiushan
   Zhang, Limei
   Zhang, Yanwei
   Chen, Xinjian
   Yin, Yilong
TI Feature enhancement network for CNV typing in optical coherence
   tomography images
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE CNV classification; OCT images; FE-net; discriminative feature
   enhancement; diverse feature enhancement
ID CONVOLUTIONAL NEURAL-NETWORK; CHOROIDAL NEOVASCULARIZATION;
   SEGMENTATION; OCT; CLASSIFICATION; ATTENTION; NET
AB Objective. Choroidal neovascularization (CNV) is a characteristic feature of wet age-related macular degeneration, which is one of the main causes of blindness in the elderly. Automatic classification of CNV in optical coherence tomography images plays an auxiliary role in the clinical treatment of CNV. Approach. This study proposes a feature enhancement network (FE-net) to discriminate between different CNV types with high inter-class similarity. The FE-net consists of two branches: discriminative FE and diverse FE. In the discriminative FE branch, a novel class-specific feature extraction module is introduced to learn class-specific features, and the discriminative loss is introduced to make the learned features more discriminative. In the diverse FE branch, the attention region selection is used to mine the multi-attention features from feature maps in the same class, and the diverse loss is introduced to guarantee that the attention features are different, which can improve the diversity of the learned features. Main results. Experiments were conducted on our CNV dataset, with significant accuracy of 92.33%, 87.45%, 90.10%, and 91.25% on ACC, AUC, SEN, and SPE, respectively. Significance. These results demonstrate that the proposed method can effectively learn the discriminative and diverse features to discriminate subtle differences between different types of CNV. And accurate classification of CNV plays an auxiliary role in clinical treatmen.
C1 [Xu, Chuanzhen; Xi, Xiaoming; Yang, Lu; Yang, Xiao; Song, Zuoyong; Nie, Xiushan] Shandong Jianzhu Univ, Sch Comp Sci & Technol, Jinan 250101, Peoples R China.
   [Zhang, Limei] Liaocheng Univ, Sch Math Sci, Liaocheng 252000, Shandong, Peoples R China.
   [Zhang, Yanwei] Shandong First Med Univ, Sch Affiliated Hosp 1, Jinan 250101, Peoples R China.
   [Zhang, Yanwei] Shandong Prov Qianfoshan Hosp, Jinan 250101, Peoples R China.
   [Chen, Xinjian] Soochow Univ, Sch Elect & Informat Engn, Sozhou 215006, Peoples R China.
   [Yin, Yilong] Shandong Univ, Sch Software, Jinan 250101, Peoples R China.
C3 Shandong Jianzhu University; Liaocheng University; Shandong First
   Medical University & Shandong Academy of Medical Sciences; Shandong
   First Medical University & Shandong Academy of Medical Sciences; Soochow
   University - China; Shandong University
RP Xi, XM (通讯作者)，Shandong Jianzhu Univ, Sch Comp Sci & Technol, Jinan 250101, Peoples R China.
EM fyzq10@126.com
FU Major Basic Research Project of Natural Science Foundation of Shandong
   Province [ZR2021ZD15]; Science and Technology Innovation Program for
   Distinguished Young Scholars of Shandong Province Higher Education
   Institutions [2021KJ036]; Natural Science Foundation of Shandong
   Province [ZR2020QF029, ZR2022MF285]; National Natural Science Foundation
   of China [6217023172, 62076151]; Taishan Scholar Project of Shandong
   Province [tsqn202103088]; special funds for distinguished professors of
   Shandong Jianzhu University
FX This work is supported in Major Basic Research Project of Natural
   Science Foundation of Shandong Province (ZR2021ZD15), Science and
   Technology Innovation Program for Distinguished Young Scholars of
   Shandong Province Higher Education Institutions (2021KJ036), Natural
   Science Foundation of Shandong Province: ZR2022MF285, National Natural
   Science Foundation of China (6217023172, 62076151), Taishan Scholar
   Project of Shandong Province (tsqn202103088), and special funds for
   distinguished professors of Shandong Jianzhu University, Natural Science
   Foundation of Shandong Province (ZR2020QF029). The authors also thank
   Dr. Haoliang Sun for his valuable comments and suggestions.
CR Abdelmoula WM, 2013, IEEE T BIO-MED ENG, V60, P1439, DOI 10.1109/TBME.2013.2237906
   Alqudah AM, 2020, MED BIOL ENG COMPUT, V58, P41, DOI 10.1007/s11517-019-02066-y
   Branson S., 2014, ARXIV
   Cai SJ, 2017, IEEE I CONF COMP VIS, P511, DOI 10.1109/ICCV.2017.63
   Chang DL, 2020, IEEE T IMAGE PROCESS, V29, P4683, DOI 10.1109/TIP.2020.2973812
   Chen XJ, 2012, INVEST OPHTH VIS SCI, V53, P8042, DOI 10.1167/iovs.12-10083
   Cui Y, 2017, PROC CVPR IEEE, P3049, DOI 10.1109/CVPR.2017.325
   Das  A., 2012, P ADV NEUR INF PROC, V2, P1583
   Das V, 2020, IEEE SIGNAL PROC LET, V27, P1025, DOI 10.1109/LSP.2020.3000933
   Fang LY, 2019, IEEE T MED IMAGING, V38, P1959, DOI 10.1109/TMI.2019.2898414
   Fang LY, 2019, J VIS COMMUN IMAGE R, V59, P327, DOI 10.1016/j.jvcir.2019.01.022
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Islam KT, 2019, COMP MED SY, P281, DOI 10.1109/CBMS.2019.00066
   Krause J, 2013, 2013 IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION WORKSHOPS (ICCVW), P554, DOI 10.1109/ICCVW.2013.77
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lin M., 2013, ARXIV, DOI DOI 10.48550/ARXIV.1312.4400
   Lin TY, 2015, IEEE I CONF COMP VIS, P1449, DOI 10.1109/ICCV.2015.170
   Maji S., 2013, ARXIV
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Qilong Wang, 2020, 2020 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR). Proceedings, P11531, DOI 10.1109/CVPR42600.2020.01155
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Serra R, 2021, RETINA-J RET VIT DIS, V41, P93, DOI 10.1097/IAE.0000000000002807
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Wah C., 2011, CNSTR2011001 CALTECH
   Wang B, 2021, IEEE J BIOMED HEALTH, V25, P3029, DOI 10.1109/JBHI.2021.3066208
   Wang YM, 2018, PROC CVPR IEEE, P4148, DOI 10.1109/CVPR.2018.00436
   Xi XM, 2020, BIOMED OPT EXPRESS, V11, P6122, DOI 10.1364/BOE.400816
   Yang Z, 2018, LECT NOTES COMPUT SC, V11218, P438, DOI 10.1007/978-3-030-01264-9_26
   Zeng YJ, 2020, NEURAL NETWORKS, V123, P331, DOI 10.1016/j.neunet.2019.11.015
   Zhang HH, 2020, IEEE J BIOMED HEALTH, V24, P3408, DOI 10.1109/JBHI.2020.3023144
   Zhang N, 2014, LECT NOTES COMPUT SC, V8689, P834, DOI 10.1007/978-3-319-10590-1_54
   Zhang Y, 2015, DRUG DES DEV THER, V9, P3413, DOI 10.2147/DDDT.S87920
   Zhang ZY, 2022, IEEE J BIOMED HEALTH, V26, P115, DOI 10.1109/JBHI.2021.3092339
   Zheng HL, 2019, PROC CVPR IEEE, P5007, DOI 10.1109/CVPR.2019.00515
   Zheng HL, 2017, IEEE I CONF COMP VIS, P5219, DOI 10.1109/ICCV.2017.557
   Zhu SX, 2017, IEEE J BIOMED HEALTH, V21, P1667, DOI 10.1109/JBHI.2017.2702603
NR 37
TC 0
Z9 0
U1 2
U2 2
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 21
PY 2022
VL 67
IS 20
AR 205007
DI 10.1088/1361-6560/ac9448
PG 13
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 5F3KP
UT WOS:000866218200001
PM 36137536
OA hybrid
DA 2022-11-30
ER

PT J
AU Tang, D
   Tran, Y
   Shekhawat, GS
   Gopinath, B
AF Tang, Diana
   Tran, Yvonne
   Shekhawat, Giriraj S.
   Gopinath, Bamini
TI Dietary Flavonoid Intake and Chronic Sensory Conditions: A Scoping
   Review
SO ANTIOXIDANTS
LA English
DT Review
DE flavonoid; dietary intake; macular degeneration; diabetic retinopathy;
   cataract; glaucoma; hearing loss; tinnitus; adult
ID HEARING-LOSS; QUERCETIN; RISK; TINNITUS; GLAUCOMA
AB Dietary flavonoids have antioxidant, anti-inflammatory, and vascular health benefits, which align with the proposed pathophysiology of age-related eye conditions and hearing problems (hearing loss and tinnitus). This scoping review is based on Arksey and O'Malley's six-stage framework and aims to summarise current evidence on the association between the dietary flavonoid intake and chronic sensory conditions in adults, and to identify the research gaps in this area. Eligible studies were identified by searching MEDLINE, EMBASE PsycINFO via the OVID platform, and Google Scholar, as well as manually searching the reference lists of the eligible articles. The inclusion criteria included: articles with full-text access, written in the English language, and focused on chronic sensory conditions and dietary flavonoid intake in an adult population. Studies focused on flavonoid supplements were excluded. Ten studies were included in this review. The evidence suggests that the flavonoid subclass, flavonols, are protective against eye conditions, including age-related macular degeneration, cataract, and glaucoma. There is insufficient evidence to support an association with hearing loss or tinnitus. Overall, dietary flavonol intake appears to be protective against some chronic eye conditions. However, for most eye and hearing-related conditions, only one study was identified. Thus, there is a need for more recent high-quality research to be conducted to confirm any significant associations.
C1 [Tang, Diana; Tran, Yvonne; Gopinath, Bamini] Macquarie Univ, Macquarie Univ Hearing, Fac Med Hlth & Human Sci, Sydney, NSW 2109, Australia.
   [Shekhawat, Giriraj S.] Flinders Univ S Australia, Coll Nursing & Hlth Sci, Adelaide, SA 5001, Australia.
   [Shekhawat, Giriraj S.] UCL, Ear Inst, London WC1X 8EE, England.
   [Shekhawat, Giriraj S.] Tinnitus Res Initiat, D-93053 Regensburg, Germany.
C3 Macquarie University; Flinders University South Australia; University of
   London; University College London
RP Tran, Y (通讯作者)，Macquarie Univ, Macquarie Univ Hearing, Fac Med Hlth & Human Sci, Sydney, NSW 2109, Australia.
EM d.tang@mq.edu.au; yvonne.tran@mq.edu.au;
   giriraj.shekhawat@flinders.edu.au; bamini.gopinath@mq.edu.au
OI Tran, Yvonne/0000-0002-1741-4205; Tang, Diana/0000-0003-2007-9054
CR Aherne SA, 2002, NUTRITION, V18, P75, DOI 10.1016/S0899-9007(01)00695-5
   [Anonymous], U ADELAIDE JOANNA BR
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]
   Barreca D, 2021, TRENDS FOOD SCI TECH, V117, P194, DOI 10.1016/j.tifs.2021.03.030
   Bondonno CP, 2015, NUTR REV, V73, P216, DOI 10.1093/nutrit/nuu014
   Chen Y, 2008, GRAEF ARCH CLIN EXP, V246, P373, DOI 10.1007/s00417-007-0728-9
   Chethan S, 2008, BIOORGAN MED CHEM, V16, P10085, DOI 10.1016/j.bmc.2008.10.003
   Davinelli S, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.651441
   Del Bo' C, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061355
   Detaram HD, 2021, EUR J NUTR, V60, P4243, DOI 10.1007/s00394-021-02582-4
   Esmaili AA, 2018, AUST J GEN PRACT, V47, P205, DOI 10.31128/AJGP-12-17-4420
   GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156
   Gopinath B, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113297
   Gopinath B, 2018, AM J CLIN NUTR, V108, P381, DOI 10.1093/ajcn/nqy114
   Haile LM, 2021, LANCET, V397, P996, DOI 10.1016/S0140-6736(21)00516-X
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Kang JH, 2018, ACTA OPHTHALMOL, V96, pE692, DOI 10.1111/aos.13705
   Kim EK, 2018, EUR J CLIN NUTR, V72, P161, DOI 10.1038/ejcn.2017.152
   Kozlowska A, 2018, FLAVONOIDS FOOD SOUR, P53, DOI [10.1007/978-3-319-54528-8_54-1, DOI 10.1007/978-3-319-54528-8_54-1]
   Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69
   Ma YN, 2015, FOOD NUTR RES, V59, DOI 10.3402/fnr.v59.29564
   Mahoney SE, 2014, J DIABETES COMPLICAT, V28, P767, DOI 10.1016/j.jdiacomp.2014.06.011
   McCormack A, 2016, HEARING RES, V337, P70, DOI 10.1016/j.heares.2016.05.009
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Miyamoto N, 2011, INVEST OPHTH VIS SCI, V52, P1055, DOI 10.1167/iovs.10-5777
   Munn Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0611-x
   Nondahl DM, 2010, INT J AUDIOL, V49, P580, DOI 10.3109/14992021003753508
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Pal D., 2013, INT J PHARM PHARM SC, V5, P95
   Ramdas WD, 2012, EUR J EPIDEMIOL, V27, P385, DOI 10.1007/s10654-012-9672-z
   Rumrill PD, 2010, WORK, V35, P399, DOI 10.3233/WOR-2010-0998
   Shargorodsky J, 2010, OTOLARYNG HEAD NECK, V142, P231, DOI 10.1016/j.otohns.2009.10.049
   Stefek M, 2011, REJUV RES, V14, P525, DOI 10.1089/rej.2011.1170
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Tan WF, 2003, EUR J PHARMACOL, V459, P255, DOI 10.1016/S0014-2999(02)02848-0
   Tang DN, 2022, EUR J NUTR, V61, P1957, DOI 10.1007/s00394-021-02784-w
   Tavanai E, 2017, EUR ARCH OTO-RHINO-L, V274, P1821, DOI 10.1007/s00405-016-4378-6
   Terai N, 2014, ACTA OPHTHALMOL, V92, pE341, DOI 10.1111/aos.12373
   Thilakarathna SH, 2013, NUTRIENTS, V5, P3367, DOI 10.3390/nu5093367
NR 39
TC 1
Z9 1
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JUL
PY 2022
VL 11
IS 7
AR 1214
DI 10.3390/antiox11071214
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 3K2JX
UT WOS:000833908900001
PM 35883705
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hayashi, R
   Hayashi, S
   Machida, S
AF Hayashi, Rijo
   Hayashi, Shimmin
   Machida, Shigeki
TI Changes in Macular Pigment Optical Density among Pseudophakic Patients
   following Intake of a Lutein-Containing Supplement
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Lutein; Macular pigment optical density; Pseudophakia; Clear intraocular
   lens; Gender differences
ID AGE-RELATED MACULOPATHY; LONG-TERM INCIDENCE; BETA-CAROTENE;
   CATARACT-SURGERY; INTRAOCULAR LENSES; EPITHELIAL-CELLS; PROTECTIVE ROLE;
   CLINICAL-TRIAL; RISK-FACTORS; EYE DISEASE
AB Introduction: Cataract surgery has been reported as a long-term risk of reduced macular pigment optical density (MPOD). This study investigated changes in MPOD in pseudophakic patients after lutein supplementation. Methods: Fifty-seven patients who had no ocular diseases and underwent cataract surgery with concurrent implantation of clear intraocular lenses were included. MPOD was measured before lutein supplementation and every week during 6 weeks of supplementation. Two additional measurements were conducted after the end of supplementation. Results: Compared with baseline, MPOD was increased after 1 week of supplementation (p < 0.01) and remained elevated after cessation of supplementation. After 3 weeks of supplementation, MPOD in females was higher than that in males (p < 0.05). Compared with patients at the highest quintile baseline MPOD, patients of both genders at the lowest quintile had significant increases after 6 weeks of supplementation (p < 0.05). Conclusion: MPOD increased after lutein supplementation in patients who had undergone cataract surgery. With the same amount of lutein supplementation, MPOD increased more in patients with low MPOD at baseline; it also increased more in females than in males. Lutein supplementation is presumed to support increased MPOD, which can reduce the risk of age-related macular degeneration, especially in females with low MPOD. (C) 2021 The Author(s). Published by S. Karger AG, Basel
C1 [Hayashi, Rijo; Hayashi, Shimmin; Machida, Shigeki] Dokkyo Med Univ, Saitama Med Ctr, Dept Ophthalmol, Koshigaya, Japan.
   [Hayashi, Shimmin] Lively Eye Clin, Soka, Japan.
C3 Dokkyo Medical University
RP Hayashi, R (通讯作者)，Dokkyo Med Univ, Saitama Med Ctr, Dept Ophthalmol, Koshigaya, Japan.
EM lhayashi@dokkyomed.ac.jp
RI HAYASHI, RIJO/GMW-8035-2022
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Anagnostis P, 2015, MATURITAS, V81, P62, DOI 10.1016/j.maturitas.2015.02.262
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Basdevant A, 1992, Int J Fertil, V37 Suppl 2, P93
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beatty S, 2008, INVEST OPHTH VIS SCI, V49, P843, DOI 10.1167/iovs.07-1276
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bian QN, 2012, ADV EXP MED BIOL, V723, P43, DOI 10.1007/978-1-4614-0631-0_7
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   CARLSON LA, 1975, ATHEROSCLEROSIS, V21, P435, DOI 10.1016/0021-9150(75)90055-6
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Demirel S, 2014, GRAEF ARCH CLIN EXP, V252, P213, DOI 10.1007/s00417-013-2424-2
   Downie LE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011977.pub2
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x
   Gopinath B, 2017, BRIT J OPHTHALMOL, V101, P1027, DOI 10.1136/bjophthalmol-2016-309490
   Goti D, 1998, BIOCHEM J, V332, P57, DOI 10.1042/bj3320057
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   Hayashi R., 2018, J JAP SOC CATARACT R, V30, P13
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kolovou GD, 2009, EUR J INTERN MED, V20, P145, DOI 10.1016/j.ejim.2008.06.011
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Lerman S., 1985, CLAO J, V11, P9
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Li SY, 2010, INT J MOL SCI, V11, P2109, DOI 10.3390/ijms11052109
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Matsushima H., 2005, JPN J REFRACT SURG, V19, P275
   Nagai N, 2015, RETINA-J RET VIT DIS, V35, P820, DOI 10.1097/IAE.0000000000000382
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   Obana A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139257
   Obana A, 2014, GRAEF ARCH CLIN EXP, V252, P1221, DOI 10.1007/s00417-014-2574-x
   Obana A, 2011, OPHTHALMOLOGY, V118, P1852, DOI 10.1016/j.ophtha.2011.02.017
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Rigotti A, 1999, NEW ENGL J MED, V341, P2011, DOI 10.1056/NEJM199912233412612
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   SCHAEFER EJ, 1983, J CLIN ENDOCR METAB, V57, P262, DOI 10.1210/jcem-57-2-262
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   van der Veen RLP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3275481
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Verdina T, 2019, CLIN OPHTHALMOL, V13, P821, DOI 10.2147/OPTH.S196061
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Winkler BS, 1999, MOL VIS, V5
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
NR 86
TC 1
Z9 1
U1 2
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD SEP
PY 2021
VL 64
IS 5
BP 828
EP 836
DI 10.1159/000517573
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY2JO
UT WOS:000754619600017
PM 34148037
OA hybrid
DA 2022-11-30
ER

PT J
AU Chinchilla, B
   Fernandez-Godino, R
AF Chinchilla, Blanca
   Fernandez-Godino, Rosario
TI AMD-Like Substrate Causes Epithelial Mesenchymal Transition in
   iPSC-Derived Retinal Pigment Epithelial Cells Wild Type but Not
   C3-Knockout
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Bruch's membrane; AMD; RPE; EMT; complement; collagens
ID BRUCHS MEMBRANE; EXTRACELLULAR-MATRIX; MACULAR DEGENERATION; RPE CELLS;
   AGE; COMPLEMENT; DRUSEN; MECHANISMS; HYPOTHESIS; BIOMARKERS
AB The Bruch's membrane (BrM) is a five-layered extracellular matrix (ECM) that supports the retinal pigment epithelium (RPE). Normal age-related changes in the BrM may lead to RPE cell damage and ultimately to the onset and progression of age-related macular degeneration (AMD), which is the most common cause of visual loss among the elderly. A role for the complement system in AMD pathology has been established, but the disease mechanisms are poorly understood, which hampers the design of efficient therapies to treat millions of patients. In an effort to identify the mechanisms that lead from normal aging to pathology, we have developed a cell-based model using complement deficient human induced pluripotent stem cell (iPSC)-derived RPE cells cultured on an AMD-like ECM that mimics BrM. The data present evidence that changes in the ECM result in loss of differentiation and promote epithelial mesenchymal transition (EMT) of healthy RPE cells. This pathological process is mediated by complement activation and involves the formation of a randomly oriented collagen meshwork that drives the dedifferentiation of the RPE monolayer. Genetic ablation of complement component 3 has a protective effect against EMT but does not prevent the abnormal deposition of collagens. These findings offer new insights into the sequence of events that initiate AMD and may guide the design of efficient therapies to treat this disease with unmet medical needs.
C1 [Chinchilla, Blanca; Fernandez-Godino, Rosario] Harvard Med Sch, Ocular Genom Inst Mass Eye & Ear, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School
RP Fernandez-Godino, R (通讯作者)，Harvard Med Sch, Ocular Genom Inst Mass Eye & Ear, Boston, MA 02114 USA.
EM Blanca_chinchilla@meei.harvard.edu; rosario_godino@meei.harvard.edu
RI Rodriguez, Blanca Chinchilla/AAA-3695-2021
OI Rodriguez, Blanca Chinchilla/0000-0002-0679-9023
FU ARVO Foundation/Genentech AMD translational research award; Alice Adler
   Eleanor and Miles Shore Faculty Development Awards Program; Ocular
   Genomics Institute at Mass Eye and Ear; Boston Area Diabetes and
   Endocrinology Research Center (BADERC) Award [DK057521]; National
   Science Foundation [1541959]; Center for Systems Biology/Program in
   Membrane Biology [DK043351]
FX This work was supported by the ARVO Foundation/GenentechAMDtranslational
   research award, by the Alice Adler Eleanor and Miles Shore Faculty
   Development Awards Program, and by the Ocular Genomics Institute at Mass
   Eye and Ear. The transmission electron microscopy was performed at the
   Center for Systems Biology/Program in Membrane Biology, which is
   partially an Inflammatory Bowel Disease Grant DK043351 and a Boston Area
   Diabetes and Endocrinology Research Center (BADERC) Award DK057521). The
   SM work was performed in part at the Center of Nanoscale Systems (CNS),
   a member of the National Nanotechnology Coordinated Infrastructure
   Network (NNCI), which is supported by the National Science Foundation
   under NSF award no. 1541959. CNS is part of Harvard University.
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Alavi MV, 2016, SCI REP-UK, V6, DOI 10.1038/srep18602
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arganda-Carreras I, 2010, MICROSC RES TECHNIQ, V73, P1019, DOI 10.1002/jemt.20829
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Brydon EM, 2019, MOL THER-METH CLIN D, V15, P392, DOI 10.1016/j.omtm.2019.10.014
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Chen GK, 2011, NAT METHODS, V8, P424, DOI [10.1038/NMETH.1593, 10.1038/nmeth.1593]
   Chinchilla B, 2021, J PATHOL, V255, P120, DOI 10.1002/path.5747
   Cho MS, 2016, J IMMUNOL, V196, P1412, DOI 10.4049/jimmunol.1501886
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Elvington M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00703
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Foltz LP, 2017, JOVE-J VIS EXP, DOI 10.3791/56274
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Hu KJ, 2011, BLOOD, V117, pE109, DOI 10.1182/blood-2010-07-298331
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Leach LL, 2016, J OCUL PHARMACOL TH, V32, P317, DOI 10.1089/jop.2016.0022
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Murtha LA, 2019, AGING DIS, V10, P419, DOI 10.14336/AD.2018.0601
   Nilsson B, 2012, IMMUNOBIOLOGY, V217, P1106, DOI 10.1016/j.imbio.2012.07.008
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Pastor-Pareja JC, 2011, DEV CELL, V21, P245, DOI 10.1016/j.devcel.2011.06.026
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Prasad K, 2017, INT J ANGIOL, V26, P1, DOI 10.1055/s-0037-1598183
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shah N, 2018, BBA-MOL BASIS DIS, V1864, P2610, DOI 10.1016/j.bbadis.2018.04.016
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Tang ZY, 2009, J AM SOC NEPHROL, V20, P593, DOI 10.1681/ASN.2008040434
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Theocharidis G, 2016, J INVEST DERMATOL, V136, P74, DOI 10.1038/JID.2015.352
   Wagner DR, 2006, J BIOMECH, V39, P1021, DOI 10.1016/j.jbiomech.2005.02.013
   Wan JX, 2007, J CELL PHYSIOL, V213, P495, DOI 10.1002/jcp.21129
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487
   Yang CQ, 2003, CANCER RES, V63, P8312
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
NR 71
TC 1
Z9 1
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 15
AR 8183
DI 10.3390/ijms22158183
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TV6NE
UT WOS:000681837100001
PM 34360950
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Byrne, EM
   Llorian-Salvador, M
   Tang, M
   Margariti, A
   Chen, M
   Xu, HP
AF Byrne, Eimear M.
   Llorian-Salvador, Maria
   Tang, Miao
   Margariti, Andriana
   Chen, Mei
   Xu, Heping
TI IL-17A Damages the Blood-Retinal Barrier through Activating the Janus
   Kinase 1 Pathway
SO BIOMEDICINES
LA English
DT Article
DE interleukin-17; blood-retinal barrier; retinopathy; macular oedema;
   inflammation; retina; JAK; STAT signaling; Tofacitinib Citrate
ID DIABETIC MACULAR EDEMA; ENDOTHELIAL GROWTH-FACTOR; FLUOCINOLONE
   ACETONIDE; STAT3 ACTIVATION; INTERLEUKIN 17A; BRAIN-BARRIER;
   UP-REGULATION; TOFACITINIB; CELLS; INFLAMMATION
AB Blood-retinal barrier (BRB) dysfunction underlies macular oedema in many sight-threatening conditions, including diabetic macular oedema, neovascular age-related macular degeneration and uveoretinitis. Inflammation plays an important role in BRB dysfunction. This study aimed to understand the role of the inflammatory cytokine IL-17A in BRB dysfunction and the mechanism involved. Human retinal pigment epithelial (RPE) cell line ARPE19 and murine brain endothelial line bEnd.3 were cultured on transwell membranes to model the outer BRB and inner BRB, respectively. IL-17A treatment (3 days in bEnd.3 cells and 6 days in ARPE19 cells) disrupted the distribution of claudin-5 in bEnd.3 cells and ZO-1 in ARPE19 cells, reduced the transepithelial/transendothelial electrical resistance (TEER) and increased permeability to FITC-tracers in vitro. Intravitreal (20 ng/1 mu L/eye) or intravenous (20 ng/g) injection of recombinant IL-17A induced retinal albumin leakage within 48 h in C57BL/6J mice. Mechanistically, IL-17A induced Janus kinase 1 (JAK1) phosphorylation in bEnd.3 but not ARPE19 cells. Blocking JAK1 with Tofacitinib prevented IL-17A-mediated claudin-5 dysmorphia in bEnd.3 cells and reduced albumin leakage in IL-17A-treated mice. Our results suggest that IL-17A can damage the BRB through the activating the JAK1 signaling pathway, and targeting this pathway may be a novel approach to treat inflammation-induced macular oedema.
C1 [Byrne, Eimear M.; Llorian-Salvador, Maria; Tang, Miao; Margariti, Andriana; Chen, Mei; Xu, Heping] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, Belfast BT9 7BL, Antrim, North Ireland.
C3 Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, Belfast BT9 7BL, Antrim, North Ireland.
EM ebyrne19@qub.ac.uk; m.lloriansalvador@qub.ac.uk; mtang01@qub.ac.uk;
   a.margariti@qub.ac.uk; m.chen@qub.ac.uk; heping.xu@qub.ac.uk
RI Xu, Heping/A-4430-2008; Llorian Salvador, Maria/GYV-1848-2022;
   Llorián-Salvador, Maía/HDM-6846-2022
OI Xu, Heping/0000-0003-4000-931X; Byrne, Eimear M./0000-0001-5064-3539; ,
   Mei/0000-0001-5661-1386
FU Diabetes UK [16/0005537]
FX This research was funded by Diabetes UK (Reference 16/0005537).
CR Akitsu A, 2018, IMMUNOLOGY, V155, P418, DOI 10.1111/imm.12993
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394
   Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001
   Castro-Navarro V, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-018-1022-9
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Chen H, 2016, J INT MED RES, V44, P1403, DOI 10.1177/0300060516672369
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1533-1
   Chen M, 2018, AM J PATHOL, V188, P1007, DOI 10.1016/j.ajpath.2017.12.021
   Chen Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018139
   Chernykh VV, 2015, INDIAN J OPHTHALMOL, V63, P33, DOI 10.4103/0301-4738.151464
   Cui LJ, 2019, DIABETES THER, V10, P1283, DOI 10.1007/s13300-019-0631-5
   Danese S, 2016, AM J PHYSIOL-GASTR L, V310, pG155, DOI 10.1152/ajpgi.00311.2015
   Downey L, 2021, BMJ OPEN OPHTHALMOL, V6, DOI 10.1136/bmjophth-2020-000696
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Estebainha R, 2020, CURR OPHTHALMOL REP, V8, P1, DOI 10.1007/s40135-020-00225-1
   Guedes MCE, 2020, GRAEF ARCH CLIN EXP, V258, P1269, DOI 10.1007/s00417-020-04649-0
   Guedes MCE, 2016, INDIAN J OPHTHALMOL, V64, P628, DOI 10.4103/0301-4738.194339
   Feng SF, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8546423
   Ford JA, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002269
   Forrester JV, 2013, EYE, V27, P340, DOI 10.1038/eye.2012.265
   Funk M, 2010, RETINA-J RET VIT DIS, V30, P1412, DOI 10.1097/IAE.0b013e3181e095c0
   Gilger BC, 2013, INVEST OPHTH VIS SCI, V54, P2483, DOI 10.1167/iovs.13-11747
   Goni FJ, 2016, OPHTHALMOL THER, V5, P47, DOI 10.1007/s40123-016-0052-8
   Guo SC, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1101-6
   Hodge JA, 2016, CLIN EXP RHEUMATOL, V34, P318
   Hombrebueno JR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18316
   Hu B, 2017, JOINT BONE SPINE, V84, P327, DOI 10.1016/j.jbspin.2016.05.014
   Hudson N, 2020, NEURAL REGEN RES, V15, P1656, DOI 10.4103/1673-5374.276332
   Huppert J, 2010, FASEB J, V24, P1023, DOI 10.1096/fj.09-141978
   Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508
   Jawad S, 2013, OCUL IMMUNOL INFLAMM, V21, P434, DOI 10.3109/09273948.2013.815786
   Katayama M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062231
   Kersey JP, 2006, EYE, V20, P407, DOI 10.1038/sj.eye.6701895
   Kezic JM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3697
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Lauridsen HM, 2017, AM J PATHOL, V187, P1893, DOI 10.1016/j.ajpath.2017.04.008
   Leinonen S, 2018, ACTA OPHTHALMOL, V96, P648, DOI 10.1111/aos.13744
   Li L, 2010, J CLIN INVEST, V120, P331, DOI 10.1172/JCI38702
   Li X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047600
   Li YJ, 2019, TOHOKU J EXP MED, V247, P87, DOI 10.1620/tjem.247.87
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu R, 2016, J IMMUNOL, V197, P2400, DOI 10.4049/jimmunol.1600138
   Llorian-Salvador M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.35
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Milovanovic J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00947
   Miserocchi E, 2020, CLIN RHEUMATOL, V39, P847, DOI 10.1007/s10067-019-04875-w
   O'Brien RL, 2009, EUR J IMMUNOL, V39, P662, DOI 10.1002/eji.200839120
   Paley Michael A, 2019, Am J Ophthalmol Case Rep, V13, P53, DOI 10.1016/j.ajoc.2018.12.001
   Park YG, 2019, J DIABETES RES, V2019, DOI 10.1155/2019/8137417
   Phulke Sonia, 2017, J Curr Glaucoma Pract, V11, P67, DOI 10.5005/jp-journals-l0028-1226
   Qiu AW, 2017, CELL PHYSIOL BIOCHEM, V41, P960, DOI 10.1159/000460514
   Qiu AW, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.117
   Rossino MG, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01172
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sandborn WJ, 2012, NEW ENGL J MED, V367, P616, DOI 10.1056/NEJMoa1112168
   Sayoc-Becerra A, 2020, INFLAMM BOWEL DIS, V26, P407, DOI 10.1093/ibd/izz266
   Schon MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01323
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P1723, DOI 10.2147/OPTH.S115546
   Setiadi AF, 2019, J NEUROIMMUNOL, V332, P147, DOI 10.1016/j.jneuroim.2019.04.011
   Shah SU, 2017, DRUGS, V77, P481, DOI 10.1007/s40265-017-0704-6
   Shin JI, 2013, NAT REV IMMUNOL, V13, DOI 10.1038/nri3459-c1
   Sigurdardottir S, 2019, CELL IMMUNOL, V341, DOI 10.1016/j.cellimm.2019.04.009
   Song YJ, 2019, BURNS TRAUMA, V7, DOI 10.1186/s41038-019-0177-9
   Tong Z, 2015, IMMUNOLOGY, V146, P339, DOI 10.1111/imm.12512
   Veritti D, 2017, EXPERT OPIN PHARMACO, V18, P1507, DOI 10.1080/14656566.2017.1363182
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub6
   Watanabe T, 2013, BIOL PHARM BULL, V36, P492, DOI 10.1248/bpb.b12-00915
   Werner JL, 2011, INFECT IMMUN, V79, P3966, DOI 10.1128/IAI.05493-11
   Xu HY, 2015, GRAEF ARCH CLIN EXP, V253, P1485, DOI 10.1007/s00417-014-2842-9
   Xu HP, 2003, INVEST OPHTH VIS SCI, V44, P226, DOI 10.1167/iovs.01-1202
   Yamada Y, 2021, ACTA OPHTHALMOL, V99, pE876, DOI 10.1111/aos.14706
   Yang X, 2020, CHINESE MED J-PEKING, V133, P2586, DOI 10.1097/CM9.0000000000001015
   Yoshimura T, 2008, INT IMMUNOL, V20, P209, DOI 10.1093/intimm/dxm135
   You T, 2017, SCI REP-UK, V7, DOI 10.1038/srep41779
   Yun JH, 2017, J CELL PHYSIOL, V232, P1123, DOI 10.1002/jcp.25575
   Zhang R, 2009, CURR EYE RES, V34, P297, DOI 10.1080/02713680902741696
   Zhang SR, 2015, INFLAMMATION, V38, P658, DOI 10.1007/s10753-014-9973-3
   Zhao JW, 2015, INVEST OPHTH VIS SCI, V56
NR 83
TC 6
Z9 6
U1 4
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD JUL
PY 2021
VL 9
IS 7
AR 831
DI 10.3390/biomedicines9070831
PG 18
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA TO2MM
UT WOS:000676752700001
PM 34356895
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gupta, A
   Kafetzis, KN
   Tagalakis, AD
   Yu-Wai-Man, C
AF Gupta, Aanchal
   Kafetzis, Konstantinos N.
   Tagalakis, Aristides D.
   Yu-Wai-Man, Cynthia
TI RNA therapeutics in ophthalmology-translation to clinical trials
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE siRNA; Antisense oligonucleotide; Clinical trial; Glaucoma; Macular
   degeneration; Inherited retinal disorders
ID ENDOTHELIAL GROWTH-FACTOR; DRY EYE DISEASE; DIABETIC MACULAR EDEMA;
   DOUBLE-STRANDED-RNA; FACTOR-BETA 2; INTERFERING RNA; AQUEOUS-HUMOR;
   INTRAOCULAR-PRESSURE; SIRNA PF-04523655; VITREOUS LEVELS
AB The use of RNA interference technology has proven to inhibit the expression of many target genes involved in the underlying pathogenesis of several diseases affecting various systems. First established in in vitro and later in animal studies, small interfering RNA (siRNA) and antisense oligonucleotide (ASO) therapeutics are now entering clinical trials with the potential of clinical translation to patients. Gene-silencing therapies have demonstrated promising responses in ocular disorders, predominantly due to the structure of the eye being a closed and compartmentalised organ. However, although the efficacy of such treatments has been observed in both preclinical studies and clinical trials, there are issues pertaining to the use of these drugs which require more extensive research with regards to the delivery and stability of siRNAs and ASOs. This would improve their use for long-term treatment regimens and alleviate the difficulties experienced by patients with ocular diseases. This review provides a detailed insight into the recent developments and clinical trials that have been conducted for several gene-silencing therapies, including ISTH0036, SYL040012, SYL1001, PF-04523655, Sirna-027, QR110, QR-1123, QR-421a and IONIS-FB-LRX in glaucoma, dry eye disease, age-related macular degeneration, diabetic macular oedema and various inherited retinal diseases. Our aim is to explore the potential of these drugs whilst evaluating their associated advantages and disadvantages, and to discuss the future translation of RNA therapeutics in ophthalmology.
C1 [Gupta, Aanchal; Yu-Wai-Man, Cynthia] Kings Coll London, London SE1 7EH, England.
   [Gupta, Aanchal; Yu-Wai-Man, Cynthia] St Thomas Hosp, Dept Biol, London SE1 7EH, England.
   [Kafetzis, Konstantinos N.; Tagalakis, Aristides D.] Edge Hill Univ, Dept Biol, Ormskirk L39 4QP, England.
C3 University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; Edge Hill University
RP Yu-Wai-Man, C (通讯作者)，Coll London St Thomas Hosp Westminster, Bridge Rd, London SE1 7EH, England.
EM cynthia.yu-wai-man@kcl.ac.uk
OI Kafetzis, Konstantinos/0000-0002-4958-345X; Tagalakis,
   Aristides/0000-0002-4610-0803; Gupta, Aanchal/0000-0001-7452-4833
FU Medical Research Council, UK [MR/T027932/1]; King's College London; Data
   Science STEM Research Centre at Edge Hill University, UK
FX This work is supported by the Medical Research Council, UK
   (MR/T027932/1) and King's College London. This work is also supported by
   the Data Science STEM Research Centre at Edge Hill University, UK.
CR Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153
   Aiello LP, 2010, OPHTHALMOLOGY, V117, P946, DOI 10.1016/j.ophtha.2009.10.002
   Aiello LP, 2005, NEW ENGL J MED, V353, P839, DOI 10.1056/NEJMe058142
   Akhtar S, 2007, J CLIN INVEST, V117, P3623, DOI 10.1172/JCI33494
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Athanasiou D, 2018, PROG RETIN EYE RES, V62, P1, DOI 10.1016/j.preteyeres.2017.10.002
   Bartlett DW, 2007, BIOTECHNOL BIOENG, V97, P909, DOI 10.1002/bit.21285
   Behlke MA, 2008, OLIGONUCLEOTIDES, V18, P305, DOI 10.1089/oli.2008.0164
   Benitez-Del-Castillo JM, 2016, INVEST OPHTH VIS SCI, V57, P6447, DOI 10.1167/iovs.16-20303
   Bian Y., 2011, PLOS ONE, V6
   Bindlish R, 2002, OPHTHALMOLOGY, V109, P1336, DOI 10.1016/S0161-6420(02)01069-2
   Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34
   Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chery Jessica, 2016, Postdoc J, V4, P35
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Cideciyan AV, 2019, NAT MED, V25, P225, DOI 10.1038/s41591-018-0295-0
   Cremers FPM, 2018, GENES-BASEL, V9, DOI 10.3390/genes9040215
   Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408
   De Fendi LI, 2013, CLIN EXP OPHTHALMOL, V41, P798, DOI 10.1111/ceo.12097
   De Fougerolles AR, 2008, HUM GENE THER, V19, P125, DOI 10.1089/hum.2008.928
   Dejneka NS, 2008, MOL VIS, V14, P997
   den Hollander AI, 2006, AM J HUM GENET, V79, P556, DOI 10.1086/507318
   Dhuri K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9062004
   Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345
   Dulla K, 2018, MOL THER-NUCL ACIDS, V12, P730, DOI 10.1016/j.omtn.2018.07.010
   Dzierlega K, 2020, GENE THER, V27, P407, DOI 10.1038/s41434-020-0156-6
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877
   Eudy JD, 1998, SCIENCE, V280, P1753, DOI 10.1126/science.280.5370.1753
   Fernando O, 2018, MOL THER, V26, P2812, DOI 10.1016/j.ymthe.2018.09.004
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Filipowicz W, 2005, CELL, V122, P17, DOI 10.1016/j.cell.2005.06.023
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Chacon-Camacho OF, 2015, WORLD J CLIN CASES, V3, P112, DOI 10.12998/wjcc.v3.i2.112
   Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fuchshofer R, 2011, EXP EYE RES, V93, P165, DOI 10.1016/j.exer.2010.07.014
   Funatsu H, 2005, OPHTHALMOLOGY, V112, P806, DOI 10.1016/j.ophtha.2004.11.045
   Funatsu H, 2003, OPHTHALMOLOGY, V110, P1690, DOI 10.1016/S0161-6420(03)00568-2
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Gonzalez V, 2014, INVEST OPHTH VIS SCI, V55
   Guo JF, 2010, MOL BIOSYST, V6, P1143, DOI 10.1039/c001050m
   Guzman-Aranguez A, 2013, BRIT J PHARMACOL, V170, P730, DOI 10.1111/bph.12330
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950
   Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107
   Haupenthal J, 2006, BIOCHEM PHARMACOL, V71, P702, DOI 10.1016/j.bcp.2005.11.015
   Henahan S., 1998, INPHARMA WKLY, V1138, P11
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Inatani M, 2001, GRAEF ARCH CLIN EXP, V239, P109, DOI 10.1007/s004170000241
   Jaffe GJ, 2020, INVEST OPHTH VIS SCI, V61
   Jinek M, 2009, NATURE, V457, P405, DOI 10.1038/nature07755
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Karaki S., 2019, IEEE ANTENN WIREL PR, DOI 10.5772/intechopen.82105.
   Kenski DM, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.4
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kole R, 2012, NAT REV DRUG DISCOV, V11, P125, DOI 10.1038/nrd3625
   Kotterman MA, 2015, ANNU REV BIOMED ENG, V17, P63, DOI 10.1146/annurev-bioeng-071813-104938
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P176, DOI 10.1159/000027415
   Kurz Daryl, 2002, Ophthalmol Clin North Am, V15, P405, DOI 10.1016/S0896-1549(02)00034-2
   Lama PJ, 2003, SURV OPHTHALMOL, V48, P314, DOI 10.1016/S0039-6257(03)00038-9
   Lemp MA, 2007, OCUL SURF, V5, P75
   Lenassi E, 2014, EXP EYE RES, V122, P9, DOI 10.1016/j.exer.2014.02.018
   Leonardi A, 2016, EUR J OPHTHALMOL, V26, P287, DOI 10.5301/ejo.5000779
   Liang YY, 2019, NANOMED-NANOTECHNOL, V15, P208, DOI 10.1016/j.nano.2018.09.018
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lundin KE, 2013, ADV GENET, V82, P47, DOI 10.1016/B978-0-12-407676-1.00002-0
   Malphettes L, 2006, METAB ENG, V8, P672, DOI 10.1016/j.ymben.2006.07.005
   Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X
   Mathur P, 2015, BBA-MOL BASIS DIS, V1852, P406, DOI 10.1016/j.bbadis.2014.11.020
   Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873
   Min Seong Hee, 2006, Korean J Ophthalmol, V20, P162
   Moreno-Montanes J, 2014, MOL THER, V22, P226, DOI 10.1038/mt.2013.217
   Moss SE, 1998, OPHTHALMOLOGY, V105, P998, DOI 10.1016/S0161-6420(98)96025-0
   Muller S., 2016, F1000RESEARCH, V5, P1
   Murray SF, 2015, INVEST OPHTH VIS SCI, V56, P6362, DOI 10.1167/iovs.15-16400
   Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Ochiai Y, 2002, JPN J OPHTHALMOL, V46, P249, DOI 10.1016/S0021-5155(01)00523-8
   Okimoto S, 2014, J GLAUCOMA, V23, P410, DOI 10.1097/IJG.0b013e318285fd7d
   Pfeiffer N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188899
   Pflugfelder SC, 2007, OCUL SURF, V5, P163
   Phadatare S. P., 2015, ADV PHARMACOL, V2015
   Pratt AJ, 2009, J BIOL CHEM, V284, P17897, DOI 10.1074/jbc.R900012200
   ProQR, 2020, INT FIND QR 421A PHA, P1
   Nguyen QD, 2012, INVEST OPHTH VIS SCI, V53, P7666, DOI 10.1167/iovs.12-9961
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Quemener AM, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1594
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rifai A, 1996, AM J PATHOL, V149, P717
   Rinaldi C, 2018, NAT REV NEUROL, V14, P9, DOI 10.1038/nrneurol.2017.148
   Rossor Alexander M, 2018, Pract Neurol, V18, P126, DOI 10.1136/practneurol-2017-001764
   Saeed AM, 2012, CLIN OPHTHALMOL, V6, P1651, DOI 10.2147/OPTH.S29909
   Schultz C, 2014, OPHTHALMOL EYE DIS, V6, P37, DOI 10.4137/OED.S16067
   Sheck L, 2018, OPHTHALMOLOGY, V125, P894, DOI 10.1016/j.ophtha.2017.12.013
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Singerman L, 2009, RETINA-J RET VIT DIS, V29, pS49, DOI 10.1097/IAE.0b013e3181ad2341
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285
   Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63
   Tagalakis AD, 2017, ACTA BIOMATER, V51, P351, DOI 10.1016/j.actbio.2017.01.048
   Titze-de-Almeida R, 2017, PHARM RES-DORDR, V34, P1339, DOI 10.1007/s11095-017-2134-2
   Trivedi RH, 2011, J OCUL PHARMACOL TH, V27, P477, DOI 10.1089/jop.2010.0100
   VANDERVLUGT RAA, 1992, PLANT MOL BIOL, V20, P631, DOI 10.1007/BF00046448
   Watts JK, 2012, J PATHOL, V226, P365, DOI 10.1002/path.2993
   WAX MB, 1987, INVEST OPHTH VIS SCI, V28, P420
   Weston MD, 2000, AM J HUM GENET, V66, P1199, DOI 10.1086/302855
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wosikowski K, 2015, INVEST OPHTH VIS SCI, V56
   Wu SS, 2020, THERANOSTICS, V10, P4374, DOI 10.7150/thno.43360
   Xue KM, 2020, EXPERT OPIN INV DRUG, V29, P1163, DOI 10.1080/13543784.2020.1804853
   Yu-Wai-Man C, 2016, SCI REP-UK, V6, DOI 10.1038/srep21881
   Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 126
TC 12
Z9 13
U1 3
U2 14
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2021
VL 205
AR 108482
DI 10.1016/j.exer.2021.108482
EA FEB 2021
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RM0IQ
UT WOS:000639346500005
PM 33548256
OA Green Published
DA 2022-11-30
ER

PT J
AU Das, V
   Dandapat, S
   Bora, PK
AF Das, Vineeta
   Dandapat, Samarendra
   Bora, Prabin Kumar
TI Multi-scale deep feature fusion for automated classification of macular
   pathologies from OCT images
SO BIOMEDICAL SIGNAL PROCESSING AND CONTROL
LA English
DT Article
DE Optical coherence tomography (OCT); Multi-scale; Convolutional neural
   network (CNN); Feature fusion; Classification; Macular pathology
ID DEGENERATION
AB Identification of the macular pathologies at an early stage can prevent vision loss. Similarity in the pathological manifestations of common macular disorders like age related macular degeneration (AMD) and diabetic macular edema (DME) can make manual screening fallible. There is a growing interest among researchers for reliable automated detection of macular pathologies using computer methods. Therefore, in this paper we present a novel method for classification of DME and two stages of AMD namely the drusens (early stage) and the choroidal neo vascularization (CNV) (late stage) from healthy optical coherence tomography (OCT) images. The proposed method introduces a multi-scale deep feature fusion (MDFF) based classification approach using convolutional neural network (CNN) for reliable diagnosis. The MDFF captures the inter-scale variations in images to introduce discriminative and complementary information to the classifier. The proposed method is evaluated on an OCT dataset containing 84,484 images with different class distributions. The imbalance in the dataset is handled by introducing the cost sensitive loss function during the learning of the classifier. The proposed method achieves an average sensitivity, specificity and accuracy of 99.6%, 99.87% and 99.6% on the test set. The promising classification results make the proposed method highly suitable for preliminary automated diagnosis of macular pathologies in health care centres and eye clinics. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Das, Vineeta; Dandapat, Samarendra; Bora, Prabin Kumar] Indian Inst Technol Guwahati, Electro Med & Speech Technol Lab, Gauhati, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati
RP Das, V (通讯作者)，Indian Inst Technol Guwahati, Electro Med & Speech Technol Lab, Gauhati, India.
EM vineetadas@iitg.ernet.in; samaren@iitg.ac.in
CR Ahonen T., SCAND C IM AN, P61
   Al-Mujaini Abdullah, 2013, Oman Med J, V28, P86, DOI 10.5001/omj.2013.24
   Albarrak A, 2013, P 2013 INT C MED IM, P59
   ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552
   Bressler NM, 2014, JAMA OPHTHALMOL, V132, P168, DOI 10.1001/jamaophthalmol.2013.6426
   BURT PJ, 1983, IEEE T COMMUN, V31, P532, DOI 10.1109/TCOM.1983.1095851
   Cheng J, 2016, IEEE T MED IMAGING, V35, P2270, DOI 10.1109/TMI.2016.2556080
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Dalal N., 2005, CVPR
   Drexler W, 2008, BIOL MED PHYS BIOMED, P1, DOI 10.1007/978-3-540-77550-8
   Du J, 2017, NEURAL NETWORKS, V96, P101, DOI 10.1016/j.neunet.2017.09.004
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Gale R, 2017, EYE, V31, DOI 10.1038/eye.2017.53
   Gonder JR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/939315
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Holekamp Nancy M, 2016, Am J Manag Care, V22, ps284
   Holte S. Matwin, EUR C MACH LEARN, P146
   Ioffe S., 2015, PR MACH LEARN RES, P448, DOI DOI 10.1007/S13398-014-0173-7.2
   Jolliffe IT., 1986, J MARKETING RES, DOI 10.1007/978-1-4757-1904-8
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kingma J., 2014, ARXIV
   Lee J, 2016, OPHTHALMOLOGY, V123, P2368, DOI 10.1016/j.ophtha.2016.07.010
   Lemaitre G, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3298606
   Li FB, 2021, COMBUST SCI TECHNOL, V193, P1463, DOI 10.1080/00102202.2019.1699547
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Nair V., 2010, P 27 INT C MACHINE L, P1
   Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Ruder S., 2017, OVERVIEW GRADIENT DE
   Samek W, 2017, IEEE T NEUR NET LEAR, V28, P2660, DOI 10.1109/TNNLS.2016.2599820
   Schmidt-Erfurth U., 2018, PROGR RETINAL EYE RE
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srivastava N, 2014, J MACH LEARN RES, V15, P1929
   Talu S.-D., 2013, ISRN BIOMED IMAGING, V2013
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Venhuizen FG, 2015, PROC SPIE, V9414, DOI 10.1117/12.2081521
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zeiler M. D., EUR C COMP VIS, P818
   Zhao R, 2017, BIOMED OPT EXPRESS, V8, P5049, DOI 10.1364/BOE.8.005049
NR 43
TC 29
Z9 29
U1 0
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1746-8094
EI 1746-8108
J9 BIOMED SIGNAL PROCES
JI Biomed. Signal Process. Control
PD SEP
PY 2019
VL 54
AR 101605
DI 10.1016/j.bspc.2019.101605
PG 10
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA JA8ZQ
UT WOS:000488140200026
DA 2022-11-30
ER

PT J
AU Sharif, U
   Mahmud, NM
   Kay, P
   Yang, YC
   Harding, SP
   Grierson, I
   Kamalden, TA
   Jackson, MJ
   Paraoan, L
AF Sharif, Umar
   Mahmud, Nur Musfirah
   Kay, Paul
   Yang, Yit C.
   Harding, Simon P.
   Grierson, Ian
   Kamalden, Tengku Ain
   Jackson, Malcolm J.
   Paraoan, Luminita
TI Advanced glycation end products-related modulation of cathepsin L and
   NF-kappa B signalling effectors in retinal pigment epithelium lead to
   augmented response to TNF alpha
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; cathepsin, NF-kappa B signalling;
   inflammation; proteolysis; retinal pigment epithelium
ID AGE-RELATED-CHANGES; BRUCHS MEMBRANE; MACULAR DEGENERATION; CYSTATIN-C;
   MORPHOMETRIC-ANALYSIS; EXTRACELLULAR-MATRIX; ACTIVATION; CELLS;
   DEGRADATION; APOPTOSIS
AB The retinal pigment epithelium (RPE) plays a central role in neuroretinal homoeostasis throughout life. Altered proteolysis and inflammatory processes involving RPE contribute to the pathophysiology of age-related macular degeneration (AMD), but the link between these remains elusive. We report for the first time the effect of advanced glycation end products (AGE)-known to accumulate on the ageing RPE's underlying Bruch's membrane in situ-on both key lysosomal cathepsins and NF-kappa B signalling in RPE. Cathepsin L activity and NF-kappa B effector levels decreased significantly following 2-week AGE exposure. Chemical cathepsin L inhibition also decreased total p65 protein levels, indicating that AGE-related change of NF-kappa B effectors in RPE cells may be modulated by cathepsin L. However, upon TNF alpha stimulation, AGE-exposed cells had significantly higher ratio of phospho-p65(Ser536)/total p65 compared to non-AGEd controls, with an even higher fold increase than in the presence of cathepsin L inhibition alone. Increased proportion of active p65 indicates an AGE-related activation of NF-kappa B signalling in a higher proportion of cells and/or an enhanced response to TNF alpha. Thus, NF-kappa B signalling modulation in the AGEd environment, partially regulated via cathepsin L, is employed by RPE cells as a protective (para-inflammatory) mechanism but renders them more responsive to pro-inflammatory stimuli.
C1 [Sharif, Umar; Mahmud, Nur Musfirah; Kay, Paul; Harding, Simon P.; Grierson, Ian; Paraoan, Luminita] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
   [Mahmud, Nur Musfirah; Kamalden, Tengku Ain] Univ Malaya, Eye Res Ctr, Kuala Lumpur, Malaysia.
   [Yang, Yit C.] Royal Wolverhampton NHS Trust, Ophthalmol, Wolverhampton, W Midlands, England.
   [Jackson, Malcolm J.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Musculoskeletal Sci, Liverpool, Merseyside, England.
C3 University of Liverpool; Universiti Malaya; University of Liverpool
RP Paraoan, L (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
EM lparaoan@liverpool.ac.uk
RI MAHMUD, NUR MUSFIRAH/AFN-9157-2022; Paraoan, Luminita/K-1066-2016;
   KAMALDEN, TENGKU AIN FATHLUN TENGKU/B-9941-2010
OI Paraoan, Luminita/0000-0001-7568-7116; KAMALDEN, TENGKU AIN FATHLUN
   TENGKU/0000-0001-9810-5334; Jackson, Malcolm/0000-0003-3683-8297
FU Foundation for Prevention of Blindness; R&D Royal Wolverhampton NHS
   Trust; Humane Research Trust; Universiti Malaya [RP033-14HTM]; MRC
   [MR/P020941/1] Funding Source: UKRI
FX Foundation for Prevention of Blindness; R&D Royal Wolverhampton NHS
   Trust; The Humane Research Trust; Universiti Malaya, Grant/Award Number:
   RP033-14HTM
CR Aggarwal S, 1999, J IMMUNOL, V162, P2154
   Alvarez A, 2007, NEUROBIOL AGING, V28, P533, DOI 10.1016/j.neurobiolaging.2006.02.012
   Amaral JD, 2010, DISCOV MED, V9, P145
   Appelqvist H, 2013, J MOL CELL BIOL, V5, P214, DOI 10.1093/jmcb/mjt022
   Barrett JP, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0287-7
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cao SJ, 2006, J BIOL CHEM, V281, P26041, DOI 10.1074/jbc.M602222200
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Dennemarker J, 2010, BIOL CHEM, V391, P913, DOI 10.1515/BC.2010.097
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fernandez-Vega B, 2016, CASE REP OPHTHAL, V7, P154, DOI 10.1159/000445102
   Glenn JV, 2012, GRAEF ARCH CLIN EXP, V250, P349, DOI 10.1007/s00417-011-1856-9
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231
   Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   KATZ ML, 1989, MECH AGEING DEV, V49, P23, DOI 10.1016/0047-6374(89)90065-1
   KATZ ML, 1984, EXP EYE RES, V38, P137, DOI 10.1016/0014-4835(84)90098-8
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997
   Martin M, 2016, CELL DEATH DIFFER, V23, P903, DOI 10.1038/cdd.2015.164
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   NAKANISHI H, 1994, EXP NEUROL, V126, P119, DOI 10.1006/exnr.1994.1048
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Osorio FG, 2016, INT REV CEL MOL BIO, V326, P133, DOI 10.1016/bs.ircmb.2016.04.003
   Pan LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035315
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Paraoan L, 2001, MOL MEMBR BIOL, V18, P229
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   RAKOCZY PE, 1994, INVEST OPHTH VIS SCI, V35, P4100
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200
   Sebekova K, 1998, CELL MOL BIOL, V44, P1051
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stitt AW, 2004, DIABETOLOGIA, V47, P1735, DOI 10.1007/s00125-004-1523-3
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suk K, 2001, IMMUNOL LETT, V77, P79, DOI 10.1016/S0165-2478(01)00209-7
   Tang QZ, 2009, J MOL MED, V87, P249, DOI 10.1007/s00109-008-0423-2
   Tatti M, 2012, HUM MOL GENET, V21, P5159, DOI 10.1093/hmg/dds367
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1341
   Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Wang XL, 2015, J MOL NEUROSCI, V56, P449, DOI 10.1007/s12031-015-0496-7
   WU HY, 1994, J BIOL CHEM, V269, P20067
   Xiang B, 2011, BRAIN RES, V1387, P29, DOI 10.1016/j.brainres.2011.02.092
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
NR 60
TC 10
Z9 10
U1 4
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JAN
PY 2019
VL 23
IS 1
BP 405
EP 416
DI 10.1111/jcmm.13944
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA HF7MI
UT WOS:000454423300035
PM 30338926
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lin, SY
   Hsu, WH
   Lin, CL
   Lin, CC
   Lin, JM
   Chang, YL
   Hsu, CY
   Kao, CH
AF Lin, Shih-Yi
   Hsu, Wu-Huei
   Lin, Cheng-Li
   Lin, Cheng-Chieh
   Lin, Jane-Ming
   Chang, Yun-Lun
   Hsu, Chung-Y.
   Kao, Chia-Hung
TI Evidence for an Association between Macular Degeneration and Thyroid
   Cancer in the Aged Population
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE thyroid cancer; age-related macular degeneration; national health
   insurance research database
ID BEAVER DAM EYE; CIGARETTE-SMOKING; CARDIOVASCULAR-DISEASE; CONE
   PHOTORECEPTORS; 5-YEAR INCIDENCE; I-131 TREATMENT; MOUSE MODELS; RISK;
   COHORT; NATIONWIDE
AB Direct evidence of whether thyroid cancer patients have a higher risk of age-related macular degeneration (AMD) has yet to be investigated. Patients older than 50 years-old and newly diagnosed with thyroid cancer between 2000 and 2008 were identified from the national health insurance research database (NHIRD). We applied time-varying Cox proportional hazard models to assess the association between thyroid cancer and AMD. The multivariable models included conventional cardiovascular risk factors, myopia, vitreous floaters, hypothyroidism, hyperthyroidism, and treatment modality of thyroid cancer. The analysis process was stratified by age, gender, and comorbidity. In this study, 5253 patients were included in a thyroid cancer cohort (men 24.5%; median age 59.1 years (53.7-67.4 years), and 21,012 matched controls were included in a non-thyroid cancer cohort. The AMD incidence was 40.7 per 10,000 person/year in the thyroid cancer cohort. The thyroid cancer cohort had a higher risk (adjusted hazard ratio (aHR) = 1.38, 95% confidence interval, CI = 1.09-1.75) of AMD than the non-thyroid cohort. Thyroid cancer patients had a higher risk of AMD, especially the male patients (aHR = 1.92, 95% CI = 1.38-3.14) and the patients with comorbidities (aHR = 1.38, 95% CI = 1.09-1.74). In conclusion, thyroid cancer patients older than 50 years-old have increased risk of AMD.
C1 [Lin, Shih-Yi; Hsu, Wu-Huei; Lin, Cheng-Chieh; Hsu, Chung-Y.; Kao, Chia-Hung] China Med Univ, Grad Inst Clin Med Sci, Coll Med, Taichung 40402, Taiwan.
   [Lin, Shih-Yi; Chang, Yun-Lun] China Med Univ Hosp, Div Nephrol, Taichung 40447, Taiwan.
   [Lin, Shih-Yi; Chang, Yun-Lun] China Med Univ Hosp, Kidney Inst, Taichung 40447, Taiwan.
   [Hsu, Wu-Huei] China Med Univ Hosp, Dept Chest Med, Taichung 40447, Taiwan.
   [Lin, Cheng-Li] China Med Univ Hosp, Management Off Hlth Data, Taichung 40447, Taiwan.
   [Lin, Cheng-Li] China Med Univ, Coll Med, Taichung 40447, Taiwan.
   [Lin, Cheng-Chieh] China Med Univ Hosp, Dept Family Med, Taichung 40447, Taiwan.
   [Lin, Jane-Ming] China Med Univ Hosp, Dept Ophthalmol, Taichung 40447, Taiwan.
   [Kao, Chia-Hung] China Med Univ Hosp, Dept Nucl Med, Taichung 40447, Taiwan.
   [Kao, Chia-Hung] China Med Univ Hosp, PET Ctr, Taichung 40447, Taiwan.
   [Kao, Chia-Hung] Asia Univ, Dept Bioinformat & Med Engn, Taichung 40447, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Hospital - Taiwan; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; China Medical
   University Taiwan; China Medical University Hospital - Taiwan; China
   Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Hospital - Taiwan; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; China Medical
   University Taiwan; China Medical University Hospital - Taiwan; Asia
   University Taiwan
RP Kao, CH (通讯作者)，China Med Univ, Grad Inst Clin Med Sci, Coll Med, Taichung 40402, Taiwan.; Kao, CH (通讯作者)，China Med Univ Hosp, Dept Nucl Med, Taichung 40447, Taiwan.; Kao, CH (通讯作者)，China Med Univ Hosp, PET Ctr, Taichung 40447, Taiwan.; Kao, CH (通讯作者)，Asia Univ, Dept Bioinformat & Med Engn, Taichung 40447, Taiwan.
EM oasisbestonly@yahoo.com.tw; Hsuwh@mail.cmuh.org.tw;
   orangechengli@gmail.com; ccling@mail.cmu.edu.tw; D4301@mail.cmuh.tw;
   mcspaghetti@gmail.com; hsuc@mail.cmuh.org.tw; d10040@mail.cmuh.org.tw
RI Lin, Cheng-Chieh/P-2564-2015
OI Lin, Cheng-Chieh/0000-0002-9625-6216; Kao, Chia-Hung/0000-0002-6368-3676
FU Ministry of Health and Welfare, Taiwan [MOHW107-TDU-B-212-123004]; China
   Medical University Hospital; Academia Sinica Stroke Biosignature Project
   [BM10701010021]; MOST Clinical Trial Consortium for Stroke [MOST
   106-2321-B-039-005-]; Tseng-Lien Lin Foundation, Taichung, Taiwan;
   Katsuzo and Kiyo Aoshima Memorial Funds, Japan
FX This work was supported by grants from the Ministry of Health and
   Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University
   Hospital; Academia Sinica Stroke Biosignature Project (BM10701010021);
   MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005-);
   Tseng-Lien Lin Foundation, Taichung, Taiwan; Katsuzo and Kiyo Aoshima
   Memorial Funds, Japan. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. No additional external funding received for this study.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Auer J, 2001, AM HEART J, V142, P838, DOI 10.1067/mhj.2001.119370
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Bufalo NE, 2006, ENDOCR-RELAT CANCER, V13, P1185, DOI 10.1677/ERC-06-0002
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chiang CJ, 2016, J FORMOS MED ASSOC, V115, P1076, DOI 10.1016/j.jfma.2015.10.011
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FRANCESCHI S, 1990, CANCER RES, V50, P6502
   Gu DF, 2004, AM J PUBLIC HEALTH, V94, P1972, DOI 10.2105/AJPH.94.11.1972
   Guveli TK, 2014, MOL IMAGING RADIONUC, V23, P84, DOI 10.4274/mirt.33042
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hecht SS, 2002, LANCET ONCOL, V3, P461, DOI 10.1016/S1470-2045(02)00815-X
   Hesselink ENK, 2013, J CLIN ONCOL, V31, P4046, DOI 10.1200/JCO.2013.49.1043
   Hwang CY, 2010, ACTA DERM-VENEREOL, V90, P589, DOI 10.2340/00015555-0963
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Ko KY, 2015, EUR J NUCL MED MOL I, V42, P1172, DOI 10.1007/s00259-015-3055-0
   KO YC, 1995, J ORAL PATHOL MED, V24, P450, DOI 10.1111/j.1600-0714.1995.tb01132.x
   Kreiger N, 2000, EUR J CANCER, V36, P1969, DOI 10.1016/S0959-8049(00)00198-2
   La Vecchia C, 2015, INT J CANCER, V136, P2187, DOI 10.1002/ijc.29251
   Lin CY, 2016, J NUCL MED, V57, P685, DOI 10.2967/jnumed.115.164830
   Lin SY, 2017, ANN ONCOL, V28, P2575, DOI 10.1093/annonc/mdx402
   Lin SY, 2014, EUR J INTERN MED, V25, P276, DOI 10.1016/j.ejim.2014.01.001
   Ma HW, 2016, ADV EXP MED BIOL, V854, P613, DOI 10.1007/978-3-319-17121-0_81
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829
   Pellegriti G, 2013, J CANCER EPIDEMIOL, V2013, DOI 10.1155/2013/965212
   Reverter JL, 2005, ENDOCR-RELAT CANCER, V12, P973, DOI 10.1677/erc.1.01072
   Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Samuels IS, 2015, J NEUROPHYSIOL, V113, P1085, DOI 10.1152/jn.00761.2014
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shen HN, 2012, PANCREAS, V41, P696, DOI 10.1097/MPA.0b013e31823db941
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sun LM, 2014, SCAND J RHEUMATOL, V43, P301, DOI 10.3109/03009742.2013.863969
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Turner MR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2238
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Wallace DC, 2009, GENE DEV, V23, P1714, DOI 10.1101/gad.1784909
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao ZG, 2012, J INT MED RES, V40, P2041, DOI 10.1177/030006051204000601
NR 50
TC 8
Z9 8
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD MAY
PY 2018
VL 15
IS 5
AR 902
DI 10.3390/ijerph15050902
PG 12
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA GJ3LS
UT WOS:000435197300070
PM 29751509
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Takeuchi, J
   Kataoka, K
   Ito, Y
   Takayama, K
   Yasuma, T
   Kaneko, H
   Terasaki, H
AF Takeuchi, Jun
   Kataoka, Keiko
   Ito, Yasuki
   Takayama, Kei
   Yasuma, Tetsuhiro
   Kaneko, Hiroki
   Terasaki, Hiroko
TI Optical Coherence Tomography Angiography to Quantify Choroidal
   Neovascularization in Response to Aflibercept
SO OPHTHALMOLOGICA
LA English
DT Article
DE Optical coherence tomography angiography; Choroidal neovascularization;
   Aflibercept
ID MACULAR DEGENERATION; RANIBIZUMAB; THERAPY; VEGF; PREVALENCE
AB Purpose: To investigate the microvascular changes in choroidal neovascularization (CNV) using optical coherence tomography angiography (OCTA) during anti-vascular endothelial growth factor (VEGF) therapies. Methods: We retrospectively collected data on consecutive treatment-naive eyes with typical age-related macular degeneration that initially received 3 aflibercept injections. OCTA was performed at baseline and at 1, 2, and 4 months of follow-up. The CNV images were analyzed using open-source software to assess vessel area and junction density. Results: Fifteen eyes of 15 patients were included. The mean vessel area at baseline was 0.50 +/- 0.33 mm(2); at 1, 2, and 4 months, the ratios of change in vessel area from baseline were 66.6 +/- 38.8%, 80.5 +/- 25.5%, and 94.0 +/- 29.3%, respectively. The vessel area was significantly reduced at 1 month from that at baseline (p = 0.0015) but significantly increased at 4 months from that at 1 month (p = 0.011). The mean junction density was also significantly reduced from 4.70 +/- 1.30/mm at baseline to 3.82 +/- 1.06/mm at 1 month (p = 0.00084). However, junction density did not continue to decrease at 2 and 4 months. Conclusion: OCTA quantification revealed that CNV rebounded after repeat aflibercept injections despite shrinking in response to the first injection. (C) 2018 S. Karger AG, Basel
C1 [Takeuchi, Jun; Kataoka, Keiko; Ito, Yasuki; Takayama, Kei; Yasuma, Tetsuhiro; Kaneko, Hiroki; Terasaki, Hiroko] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Nagoya, Aichi, Japan.
C3 Nagoya University
RP Kataoka, K (通讯作者)，Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Nagoya, Aichi, Japan.; Kataoka, K (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai cho, Nagoya, Aichi 9668550, Japan.
EM kkeiko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022; Kaneko, Hiroki/O-7695-2015; Ito,
   Yasuki/M-4876-2014; Kataoka, Keiko/B-2806-2016
OI Kaneko, Hiroki/0000-0003-0731-6465; Kaneko, Hiroki/0000-0003-0731-6465;
   Ito, Yasuki/0000-0001-9219-9261; Kataoka, Keiko/0000-0002-8795-6536
FU JSPS KAKENHI [16K20313, 16K11265, 15H04994]
FX This work was supported by JSPS KAKENHI Grant Numbers 16K20313 (K.K.),
   16K11265 (Y.I.), and 15H04994 (H.T.).
CR Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fingler J, 2008, INVEST OPHTH VIS SCI, V49, P5055, DOI 10.1167/iovs.07-1627
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Yancopoulos GD, 2010, CELL, V143, P13, DOI 10.1016/j.cell.2010.09.028
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 24
TC 13
Z9 14
U1 1
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 240
IS 2
BP 90
EP 98
DI 10.1159/000487611
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GO5LR
UT WOS:000440064500005
PM 29739007
DA 2022-11-30
ER

PT J
AU Fleissig, E
   Barak, A
   Goldstein, M
   Loewenstein, A
   Schwartz, S
AF Fleissig, Efrat
   Barak, Adiel
   Goldstein, Michaela
   Loewenstein, Anat
   Schwartz, Shulamit
TI Massive subretinal and subretinal pigment epithelial hemorrhage
   displacement with perfluorocarbon liquid using a two-step vitrectomy
   technique
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Perfluorocarbon liquid (PFCL); Submacular hemorrhage; Sub-RPE hemorrhage
ID TISSUE-PLASMINOGEN-ACTIVATOR; CHOROIDAL NEOVASCULAR LESIONS; THICK
   SUBMACULAR HEMORRHAGE; MACULAR DEGENERATION; N-OCTANE; PNEUMATIC
   DISPLACEMENT; CORNEAL TOXICITY; NATURAL-HISTORY; INJECTION; MANAGEMENT
AB Purpose The purpose of this study was to evaluate the efficacy and visual outcome of massive submacular hemorrhage (SMH) displacement with a planned two-step pars plana vitrectomy (PPV) using tissue plasminogen activator (tPA) and perfluorocarbon liquid (PFCL) tamponade.
   A retrospective case series of patients with age related macular degeneration and SMH was used. All patients underwent a 23G PPV, subretinal tPA injection and a medium term PFCL tamponade. A second stage PPV for PFCL removal was performed 7-17 days later. The main outcome was the change in macular and sub-RPE thickness after 6 months. Secondary outcomes were visual acuity and complications.
   Seven patients (seven eyes) with mean age of 79.85 years were enrolled. The average SMH size was 17.5 disc area (range 4.5-33) with mean symptoms of a duration of 9.5 days (range: 2-21). SMH was successfully displaced in six eyes. Mean macular and sub-RPE thickness decreased from 1505 mu to 711.3 mu and 900 mu to 457 mu, respectively. Visual acuity (VA) remained stable in five eyes. Complications included corneal edema and transient intraocular pressure elevation in three patients.
   SMH displacement using subretinal tPA injection and medium term PFCL tamponade is an effective alternative treatment option. In our experience, it can be safely performed, avoiding complications commonly attributed to other techniques.
C1 [Fleissig, Efrat; Barak, Adiel; Goldstein, Michaela; Loewenstein, Anat; Schwartz, Shulamit] Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, 6 Weitzman St, IL-6423906 Tel Aviv, Israel.
   [Fleissig, Efrat; Barak, Adiel; Goldstein, Michaela; Loewenstein, Anat; Schwartz, Shulamit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Fleissig, E (通讯作者)，Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, 6 Weitzman St, IL-6423906 Tel Aviv, Israel.; Fleissig, E (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
EM efratbukelman@gmail.com
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cauchi P, 2005, AM J OPHTHALMOL, V140, P322, DOI 10.1016/j.ajo.2005.01.034
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   CHANG S, 1991, RETINA-J RET VIT DIS, V11, P367
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Cho HJ, 2015, RETINA-J RET VIT DIS, V35, P205, DOI 10.1097/IAE.0000000000000295
   Drury B, 2011, BRIT J OPHTHALMOL, V95, P694, DOI 10.1136/bjo.2009.175216
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   Figueroa MS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/907816
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Imaizumi A, 2014, AM J OPHTHALMOL, V157, P384, DOI 10.1016/j.ajo.2013.10.002
   Inoue M, 2009, RETINA-J RET VIT DIS, V29, P677, DOI 10.1097/IAE.0b013e318196fca1
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   Mackiewicz J, 2007, GRAEF ARCH CLIN EXP, V245, P665, DOI 10.1007/s00417-006-0414-3
   Moisseiev E, 2014, EUR J OPHTHALMOL, V24, P925, DOI 10.5301/ejo.5000500
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Rofail M, 2005, RETINA-J RET VIT DIS, V25, P897, DOI 10.1097/00006982-200510000-00013
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Sigler EJ, 2014, RETINA-J RET VIT DIS, V34, P237, DOI 10.1097/IAE.0b013e31829d002e
   Sirimaharaj M, 2005, BRIT J OPHTHALMOL, V89, P1176, DOI 10.1136/bjo.2004.065409
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stolba U, 1999, GRAEF ARCH CLIN EXP, V237, P501, DOI 10.1007/s004170050269
   Wilbanks GA, 1996, CORNEA, V15, P329, DOI 10.1097/00003226-199605000-00017
NR 37
TC 7
Z9 7
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2017
VL 255
IS 7
BP 1341
EP 1347
DI 10.1007/s00417-017-3648-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY4HG
UT WOS:000403937600009
PM 28412773
DA 2022-11-30
ER

PT J
AU Choudhary, P
   Booth, H
   Gutteridge, A
   Surmacz, B
   Louca, I
   Steer, J
   Kerby, J
   Whiting, PJ
AF Choudhary, Parul
   Booth, Heather
   Gutteridge, Alex
   Surmacz, Beata
   Louca, Irene
   Steer, Juliette
   Kerby, Julie
   Whiting, Paul John
TI Directing Differentiation of Pluripotent Stem Cells Toward Retinal
   Pigment Epithelium Lineage
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Retinal pigment epithelium; Stem cells; Directed differentiation;
   Activin; Bone morphogenetic protein
ID MACULAR DEGENERATION; OPTIC VESICLE; MURINE RETINA; INDUCTION; RPE;
   CHICK; PAX6; LENS; EYE; TRANSDIFFERENTIATION
AB Development of efficient and reproducible conditions for directed differentiation of pluripotent stem cells into specific cell types is important not only to understand early human development but also to enable more practical applications, such as in vitro disease modeling, drug discovery, and cell therapies. The differentiation of stem cells to retinal pigment epithelium (RPE) in particular holds promise as a source of cells for therapeutic replacement in age-related macular degeneration. Here we show development of an efficient method for deriving homogeneous RPE populations in a period of 45 days using an adherent, monolayer system and defined xeno-free media and matrices. The method utilizes sequential inhibition and activation of the Activin and bone morphogenetic protein signaling pathways and can be applied to both human embryonic stem cells and induced pluripotent stem cells as the starting population. In addition, we use whole genome transcript analysis to characterize cells at different stages of differentiation that provides further understanding of the developmental dynamics and fate specification of RPE. We show that with the described method, RPE develop through stages consistent with their formation during embryonic development. This characterization- together with the absence of steps involving embryoid bodies, three-dimensional culture, or manual dissections, which are common features of other protocols-makes this process very attractive for use in research as well as for clinical applications.
C1 [Choudhary, Parul; Booth, Heather; Gutteridge, Alex; Surmacz, Beata; Louca, Irene; Steer, Juliette; Kerby, Julie; Whiting, Paul John] Pfizer Neurosci & Pain Res Unit, Cambridge, England.
C3 Pfizer
RP Choudhary, P (通讯作者)，Pfizer Ltd, Granta Pk, Cambridge CB21 6GS, England.
EM jeff.biernaskie@ucalgary.ca
OI Whiting, Paul/0000-0002-4121-1379
CR Andley UP, 2009, CURR MOL MED, V9, P887, DOI 10.2174/156652409789105598
   Behesti H, 2009, DEV BIOL, V333, P360, DOI 10.1016/j.ydbio.2009.06.026
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Carr AJ, 2009, MOL VIS, V15, P283
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Cho MS, 2012, STEM CELL RES, V9, P101, DOI 10.1016/j.scr.2012.05.002
   Choudhary P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130379
   Cvekl A, 2014, DEVELOPMENT, V141, P4432, DOI 10.1242/dev.107953
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Fuhrmann S, 2010, CURR TOP DEV BIOL, V93, P61, DOI [10.1016/S0070-2153(10)93003-2, 10.1016/B978-0-12-385044-7.00003-5]
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gunhaga L, 2011, PHILOS T R SOC B, V366, P1193, DOI 10.1098/rstb.2010.0175
   Huang J, 2015, DEV BIOL, V402, P119, DOI 10.1016/j.ydbio.2015.03.006
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Lidgerwood GE, 2016, STEM CELL REV REP, V12, P179, DOI 10.1007/s12015-015-9636-2
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Matsuo T, 1998, ACTA MED OKAYAMA, V52, P125
   MIRCHEFF AK, 1990, INVEST OPHTH VIS SCI, V31, P863
   Mochii M, 1998, DEV BIOL, V196, P145, DOI 10.1006/dbio.1998.8864
   Muller F, 2007, DEVELOPMENT, V134, P3483, DOI 10.1242/dev.02884
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Robertshaw E, 2013, P NATL ACAD SCI USA, V110, pE3919, DOI 10.1073/pnas.1304311110
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Spieler D, 2004, DEV BIOL, V269, P567, DOI 10.1016/j.ydbio.2004.01.044
   Steinfeld J, 2013, DEVELOPMENT, V140, P4959, DOI 10.1242/dev.096990
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Surmacz B, 2012, STEM CELLS, V30, P1875, DOI 10.1002/stem.1166
   Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Treisman JE, 1999, BIOESSAYS, V21, P843, DOI 10.1002/(SICI)1521-1878(199910)21:10<843::AID-BIES6>3.3.CO;2-A
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Whiting P, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0375
   Yamada R, 2004, DEV BIOL, V274, P295, DOI 10.1016/j.ydbio.2004.07.016
   Zhang XQ, 2010, CELL STEM CELL, V7, P90, DOI 10.1016/j.stem.2010.04.017
   Zhu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054552
   Zuber ME, 2003, DEVELOPMENT, V130, P5155, DOI 10.1242/dev.00723
NR 47
TC 28
Z9 28
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD FEB
PY 2017
VL 6
IS 2
BP 490
EP 501
DI 10.5966/sctm.2016-0088
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EQ6NK
UT WOS:000398198500015
PM 28191760
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Cheng, H
   Kaszubski, PA
   Hao, H
   Saade, C
   Cunningham, C
   Freund, KB
   Smith, RT
AF Cheng, Hao
   Kaszubski, Patrick A.
   Hao, Hua
   Saade, Celine
   Cunningham, Colleen
   Freund, K. Bailey
   Smith, R. Theodore
TI The Relationship Between Reticular Macular Disease and Choroidal
   Thickness
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; choroidal thickness; reticular macular
   disease; subretinal drusenoid deposits
ID FUNDUS AUTOFLUORESCENCE; PSEUDODRUSEN; DEGENERATION; DRUSEN;
   EPIDEMIOLOGY; PREVALENCE; RISK
AB Purpose: Subretinal drusenoid deposits (SDD) are the main structural lesion of reticular macular disease (RMD), a phenotype of age-related macular degeneration (AMD). We aim to demonstrate spatiotemporal relationships between SDD and choroidal thickness (CTh) alterations in RMD+ and RMD- eyes.Methods: Thirty-three eyes (26 subjects) with early AMD/no SDD (RMD-) and 18 eyes (16 subjects) with early AMD/SDD (RMD+) underwent enhanced depth imaging spectral domain optical coherence tomography (SD-OCT) for CTh measurements at 11 points per scan, in 5 horizontal B scans, creating a grid of 55 points/eye. The 55 points were treated as a cluster, controlling within-subject correlation. Marginal generalized estimating equation modeling was used to estimate the association between CTh and RMD status. All eyes were divided by their median age (82 and >82 years) for stratified analyses.Results: CTh was not significantly reduced in RMD+ eyes compared with RMD- eyes (mean difference [MD] -16.84 m, P = 0.24). Among younger subjects, mean CTh was significantly reduced in RMD+ versus RMD- eyes (MD -53.72 m, P = 0.01). Conversely, among older subjects, there was no significant difference in CTh between RMD+ and RMD-.Conclusions: In RMD, the association of SDD and CTh alterations varies with age but not by macular region. Among younger subjects (<82 years old), CTh was significantly thinner in RMD+ versus RMD- eyes.
C1 [Cheng, Hao] Guangzhou Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Cheng, Hao; Kaszubski, Patrick A.; Saade, Celine; Cunningham, Colleen; Freund, K. Bailey; Smith, R. Theodore] NYU, Dept Ophthalmol, Sch Med, 462 First Avenue NBV 5N18, New York, NY 10016 USA.
   [Hao, Hua] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 Guangzhou Medical University; New York University; Emory University;
   Rollins School Public Health; Vitreous Retina Macula Consultants of New
   York
RP Smith, RT (通讯作者)，NYU, Dept Ophthalmol, Sch Med, 462 First Avenue NBV 5N18, New York, NY 10016 USA.
EM roland.smith@nyumc.org
RI ; Freund, K. Bailey/V-7488-2018
OI smith, theodore/0000-0002-1693-943X; Freund, K.
   Bailey/0000-0002-7888-9773
FU Foundation Fighting Blindness; National Institutes of Health/National
   Eye Institute [R01 EY015520]; Research to Prevent Blindness; NATIONAL
   EYE INSTITUTE [R01EY015520] Funding Source: NIH RePORTER
FX This work was supported by an individual investigator research award
   from the Foundation Fighting Blindness (R. Theodore Smith), National
   Institutes of Health/National Eye Institute (grant R01 EY015520) (R.
   Theodore Smith), and unrestricted funds from Research to Prevent
   Blindness (R. Theodore Smith).
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kleinbaum DG, 2013, APPL REGRESSION ANAL
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 29
TC 8
Z9 9
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD NOV
PY 2016
VL 41
IS 11
BP 1492
EP 1497
DI 10.3109/02713683.2015.1127391
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC2GR
UT WOS:000387928300016
PM 27115048
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Moreno, MR
   Tabitha, TS
   Nirmal, J
   Radhakrishnan, K
   Yee, CH
   Lim, S
   Venkatraman, S
   Agrawal, R
AF Moreno, M. R.
   Tabitha, T. S.
   Nirmal, J.
   Radhakrishnan, K.
   Yee, C. H.
   Lim, S.
   Venkatraman, S.
   Agrawal, R.
TI Study of stability and biophysical characterization of ranibizumab and
   aflibercept
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Anti-vascular endothelial growth factor (VEGF) proteins; Wet age related
   macular degeneration (AMD); Diabetic macular edema (DME); Biophysical
   characterization; Stability; Aggregation state; Excipients; Emulsion
ID HUMAN GROWTH-HORMONE; SINGLE INTRAVITREAL INJECTION; LONG-TERM
   STABILITY; MONOCLONAL-ANTIBODY; PROTEIN INSTABILITY; CONTROLLED-RELEASE;
   IN-VITRO; INTRAOCULAR PHARMACOKINETICS; OCULAR NEOVASCULARIZATION;
   BEVACIZUMAB AVASTIN
AB The anti-vascular endothelial growth factor (VEGF) agents such as ranibizumab (Lucentis (R)) and aflibercept (EyLea (R)) are currently used as monthly or bimonthly intravitreal injections to treat potentially retinal diseases such as wet age-related macular degeneration (AMD) or diabetic macular edema (DME). Because of the complications associated with repeated intra-vitreal injections, there is considerable interest in developing a sustained delivery system. The purpose of this study was to examine the stability of both therapeutic proteins under physiological conditions as well as when incorporated into drug delivery systems (DDS). First, thermotropic properties in physiological conditions and at different pH values were evaluated by differential scanning calorimetry (DSC) to determine the protein denaturation temperature. Second, the effects of pH and incubation time on conformational changes and aggregation were evaluated by circular dichroism (CD), steady-state tryptophan fluorescence spectroscopy, and size-exclusion chromatography (SEC). Also, the ability of both proteins to bind to VEGF was tested in the aforementioned experimental conditions for up to 30 days. Finally, we investigated the stability of both proteins after a rapid screening method that simulates the first homogenizing step during the protein microencapsulation process. This method allowed the development of stable ranibizumab and aflibercept formulations that may be useful to entrap these proteins into microparticles selecting the most convenient organic solvent and protein stabilizers. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Moreno, M. R.; Tabitha, T. S.; Nirmal, J.; Radhakrishnan, K.; Yee, C. H.; Venkatraman, S.] Nanyang Technol Univ, Sch Mat Sci & Engn, 50 Nanyang Ave,Block N3-1-01-01, Singapore 639798, Singapore.
   [Agrawal, R.] Tan Tock Seng Hosp, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Lim, S.] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore, Singapore.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Tan Tock Seng Hospital;
   Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University
RP Moreno, MR (通讯作者)，Nanyang Technol Univ, Sch Mat Sci & Engn, 50 Nanyang Ave,Block N3-1-01-01, Singapore 639798, Singapore.; Agrawal, R (通讯作者)，Tan Tock Seng Hosp, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM mmoreno@ntu.edu.sg; rupesh_agrawal@ttsh.com.sg
RI Lim, Sierin/G-6109-2010; Venkatraman, Subramanian/A-2228-2011;
   Radhakrishnan, Krishna/O-9376-2019; J, Nirmal/AAO-5138-2020
OI Lim, Sierin/0000-0001-7455-6771; Venkatraman,
   Subramanian/0000-0002-8693-1070; J, Nirmal/0000-0001-7864-6053; Moreno
   Raja, Miguel/0000-0002-6758-3998; Radhakrishnan,
   Krishna/0000-0003-3259-8150
FU National Healthcare Group, Singapore
FX The project was funded by the National Thematic Research Grant and the
   Ageing Research Grant administered by National Healthcare Group,
   Singapore. Dr Rupesh Agrawal is the clinical Principal investigator and
   Prof Subbu Venkatraman is the technical Principal investigator.
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Au A, 2016, J DIABETES COMPLICAT, V30, P545, DOI 10.1016/j.jdiacomp.2015.11.008
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Banga A.K., 2006, THERAPEUTIC PEPTIDES
   Bilati U, 2005, EUR J PHARM BIOPHARM, V59, P375, DOI 10.1016/j.ejpb.2004.10.006
   BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191
   BREWSTER ME, 1991, PHARMACEUT RES, V8, P792, DOI 10.1023/A:1015870521744
   Capan Yilmaz, 2003, AAPS PharmSciTech, V4, pE28
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Chang DP, 2015, J PHARM SCI-US, V104, P3404, DOI 10.1002/jps.24546
   Chelius D, 2010, MABS-AUSTIN, V2, P309, DOI 10.4161/mabs.2.3.11791
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chhabra S, 2007, INT J PHARMACEUT, V342, P72, DOI 10.1016/j.ijpharm.2007.04.034
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Cleland JL, 1996, PHARMACEUT RES, V13, P1464, DOI 10.1023/A:1016063109373
   COSTANTINO HR, 1994, J PHARM SCI-US, V83, P1662, DOI 10.1002/jps.2600831205
   De Rosa G, 2005, J CONTROL RELEASE, V102, P71, DOI 10.1016/j.jconrel.2004.09.030
   De Temmerman ML, 2011, BIOMACROMOLECULES, V12, P1283, DOI 10.1021/bm101559w
   DeFail AJ, 2006, BIOMATERIALS, V27, P1579, DOI 10.1016/j.biomaterials.2005.08.013
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Frokjaer S, 2005, NAT REV DRUG DISCOV, V4, P298, DOI 10.1038/nrd1695
   Fu K, 2000, NAT BIOTECHNOL, V18, P24, DOI 10.1038/71875
   Ghirlando R, 1999, IMMUNOL LETT, V68, P47, DOI 10.1016/S0165-2478(99)00029-2
   Ionescu RM, 2008, J PHARM SCI-US, V97, P1414, DOI 10.1002/jps.21104
   Irie T, 1999, ADV DRUG DELIVER REV, V36, P101, DOI 10.1016/S0169-409X(98)00057-X
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Kang FR, 2002, PHARM RES-DORDR, V19, P629, DOI 10.1023/A:1015354028908
   Kang J, 2014, EUR J PHARM SCI, V62, P141, DOI 10.1016/j.ejps.2014.05.027
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005
   Kempe S, 2012, J CONTROL RELEASE, V161, P668, DOI 10.1016/j.jconrel.2012.04.016
   Kesavan K, 2013, CURR EYE RES, V38, P342, DOI 10.3109/02713683.2012.745879
   Kim HK, 2001, INT J PHARM, V229, P107, DOI 10.1016/S0378-5173(01)00852-3
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kudryashova EV, 2003, PROTEIN ENG, V16, P303, DOI 10.1093/proeng/gzg039
   Li SK, 2011, J PHARMACEUT BIOMED, V55, P603, DOI 10.1016/j.jpba.2010.12.027
   Ma GH, 2014, J CONTROL RELEASE, V193, P324, DOI 10.1016/j.jconrel.2014.09.003
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Meinel L, 2001, J CONTROL RELEASE, V70, P193, DOI 10.1016/S0168-3659(00)00352-7
   Montalvo BL, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/46/465103
   Montalvo-Ortiz BL, 2012, AAPS PHARMSCITECH, V13, P632, DOI 10.1208/s12249-012-9794-3
   Moore JMR, 1999, BIOCHEMISTRY-US, V38, P13960, DOI 10.1021/bi9905516
   Park J, 2013, PHARM RES-DORDR, V30, P968, DOI 10.1007/s11095-012-0933-z
   Paul M., 2012, Annales Pharmaceutiques Francaises, V70, P139, DOI 10.1016/j.pharma.2012.03.006
   Perez-Rodriguez C, 2003, J CONTROL RELEASE, V89, P71, DOI 10.1016/S0168-3659(03)00074-9
   Sah H, 1999, PDA J PHARM SCI TECH, V53, P3
   Sahin E, 2010, J PHARM SCI-US, V99, P4830, DOI 10.1002/jps.22198
   Schwendeman S.P., 1996, MICROPARTICULATE SYS, P1
   SIMPKINS J W, 1991, Journal of Parenteral Science and Technology, V45, P266
   Sinha VR, 2003, J CONTROL RELEASE, V90, P261, DOI 10.1016/S0168-3659(03)00194-9
   Son S, 2009, INT J PHARMACEUT, V368, P178, DOI 10.1016/j.ijpharm.2008.09.061
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
   van de Weert M, 2000, J CONTROL RELEASE, V68, P351, DOI 10.1016/S0168-3659(00)00277-7
   van de Weert M, 2000, PHARM RES-DORDR, V17, P1159, DOI 10.1023/A:1026498209874
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Varshochian R, 2013, EUR J PHARM SCI, V50, P341, DOI 10.1016/j.ejps.2013.07.014
   Vega E, 2012, INT J NANOMED, V7, P1357, DOI 10.2147/IJN.S28481
   Vermeer AWP, 1998, BBA-GEN SUBJECTS, V1425, P1, DOI 10.1016/S0304-4165(98)00048-8
   Vermeer AWP, 2000, BIOPHYS J, V78, P394, DOI 10.1016/S0006-3495(00)76602-1
   Veurink M, 2011, EUR J PHARM BIOPHARM, V78, P271, DOI 10.1016/j.ejpb.2010.12.018
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang JJ, 2004, J COLLOID INTERF SCI, V271, P92, DOI 10.1016/j.jcis.2003.08.072
   Wang LY, 2006, INT J PHARMACEUT, V311, P187, DOI 10.1016/j.ijpharm.2005.12.033
   Wei W, 1999, INT J PHARMACEUT, V185, P129, DOI 10.1016/S0378-5173(99)00152-0
   Weidle UH, 2012, CANCER GENOM PROTEOM, V9, P357
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Zheng K, 2011, MABS-AUSTIN, V3, P568, DOI 10.4161/mabs.3.6.17922
NR 71
TC 23
Z9 25
U1 3
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD NOV
PY 2016
VL 108
BP 156
EP 167
DI 10.1016/j.ejpb.2016.09.003
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EC3UP
UT WOS:000388052600017
PM 27615995
DA 2022-11-30
ER

PT J
AU Brandstetter, C
   Holz, FG
   Krohne, TU
AF Brandstetter, Carolina
   Holz, Frank G.
   Krohne, Tim U.
TI Complement Component C5a Primes Retinal Pigment Epithelial Cells for
   Inflamrnasome Activation by Lipofuscin-mediated Photooxidative Damage
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NLRP3 INFLAMMASOME ACTIVATION; MACULAR DEGENERATION; ENDOTHELIAL-CELLS;
   ARPE-19; DRUSEN; RELEASE; C3A
AB Complement activation, oxidative damage, and activation of the NLRP3 inflammasome have been implicated in retinal pigment epithelium (RPE) pathology in age-related macular degeneration (AMD). Following priming of RPE cells, the NLRP3 inflammasome can be activated by various stimuli such as lipofuscin-mediated photooxidative damage to lysosomal membranes. We investigated whether products of complement activation are capable of providing the priming signal for inflammasome activation in RPE cells. We found that incubation of primary human RPE cells and ARPE-19 cells with complement-competent human serum resulted in up-regulation of C5a receptor, but not C3a receptor. Furthermore, human serum induced expression of pro-IL-1 beta and enabled IL-1 beta secretion in response to lipoluscin phototoxicity, thus indicating inflammasome priming. Complement heat-inactivation, C5 depletion, and C5a receptor inhibition suppressed the priming effect of human serum whereas recombinant C5a likewise induced priming. Conditioned medium of inflammasome-activated RPE cells provided an additional priming effect that was mediated by the IL-1 receptor. These results identify complement activation product C5a as a priming signal for RPE cells that allows for subsequent inflammasome activation by stimuli such as lipofuscin-mediated photooxidative damage. This molecular pathway provides a functional link between key factors of AMD pathogenesis including lipofuscin accumulation, photooxidative damage, complement activation, and RPE degeneration and may provide novel therapeutic targets in this disease.
C1 [Brandstetter, Carolina; Holz, Frank G.; Krohne, Tim U.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Krohne, TU (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM krohne@uni-bonn.de
RI Krohne, Tim/AAG-4412-2020; Krohne, Tim/D-1497-2013
OI Krohne, Tim/0000-0003-2280-925X
FU German Research Foundation (DFG), Bonn, Germany [KR 2863/7-1]; Pro
   Retina Foundation, Bonn, Germany; University of Bonn, BONFOR and SciMed
   Programs, Bonn, Germany; Acucela; Alcon; Allergan; Bayer; Carl Zeiss
   Meditec; Genentech; Heidelberg Engineering; Novartis; Optos; Roche
FX The study was supported by German Research Foundation (DFG), Bonn,
   Germany, Grant KR 2863/7-1; Pro Retina Foundation, Bonn, Germany;
   University of Bonn, BONFOR and SciMed Programs, Bonn, Germany; and Dr.
   Eberhard and Hilde Rudiger Foundation, Bonn, Germany (all to T. U. K.).
   The paper was presented at the 2014 annual meeting of the Association of
   Research in Vision and Ophthalmology (ARVO) in Orlando, FL
   (Brandstetter, C., Holz, F. G., Krohne, T.U. (2014) Complement Component
   C5a Primes the NLRP3 Inflammasome in Retinal Pigment Epithelial Cells.
   Invest. Ophthalmol. Vis. Sci. 55: [-Abstract 3444). Conflict of
   interest: CB, none. FGH, research grants: Acucela, Alcon, Allergan,
   Bayer, Carl Zeiss Meditec, Genentech, Heidelberg Engineering, Novartis,
   Optos; consultancy honoraria, lecture fees, travel grants: Acucela,
   Alcon, Allergan, Bayer, Genentech, Heidelberg Engineering, Novartis,
   Roche. TUK, research grants: Alcon, Novartis; consultancy honoraria,
   lecture fees, travel grants: Bayer, Heidelberg Engineering, Novartis.
CR An LL, 2014, EUR J IMMUNOL, V44, P3669, DOI 10.1002/eji.201444560
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fukuoka Y, 2001, CURR EYE RES, V23, P320, DOI 10.1076/ceyr.23.5.320.5437
   Hornung V, 2010, EUR J IMMUNOL, V40, P620, DOI 10.1002/eji.200940185
   Hu MJ, 2011, BRIT J OPHTHALMOL, V95, P1738, DOI 10.1136/bjophthalmol-2011-300235
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Mohr LKM, 2015, INVEST OPHTH VIS SCI, V56, P6404, DOI 10.1167/iovs.15-16898
   MOLLNES TE, 1988, CLIN EXP IMMUNOL, V73, P484
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Saeed AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106421
   Samstad EO, 2014, J IMMUNOL, V192, P2837, DOI 10.4049/jimmunol.1302484
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   WARNER SJC, 1987, J IMMUNOL, V139, P1911
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 38
TC 48
Z9 52
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 25
PY 2015
VL 290
IS 52
BP 31189
EP 31198
DI 10.1074/jbc.M115.671180
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CZ6GK
UT WOS:000367199000045
PM 26565031
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Yonova-Doing, E
   Hysi, PG
   Venturini, C
   Williams, KM
   Nag, A
   Beatty, S
   Liew, SHM
   Gilbert, CE
   Hammond, CJ
AF Yonova-Doing, Ekaterina
   Hysi, Pirro G.
   Venturini, Cristina
   Williams, Katie M.
   Nag, Abhishek
   Beatty, Stephen
   Liew, S. H. Melissa
   Gilbert, Clare E.
   Hammond, Christopher J.
TI Candidate gene study of macular response to supplemental lutein and
   zeaxanthin
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE macular pigment; lutein; genetics; supplementation; macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; GENOME-WIDE ASSOCIATION; AGE-RELATED
   MACULOPATHY; RISK-FACTORS; OXIDATIVE STRESS; BETA-CAROTENE; EYE DISEASE;
   VITAMIN-A; DEGENERATION; TRANSPORT
AB Supplementation with carotenoids is proposed to protect against age-related macular degeneration. There is, however, considerable variability in retinal macular pigment response, which may be due to underlying genetic variation. The purpose of this study was to determine whether genetic factors, which have been previously associated with cross-sectional macular pigment levels in the retina or serum lutein, also influence response to supplementation.
   To this end we conducted an association study in 310 subjects from the TwinsUK cohort between variants in 8 candidate genes and serum lutein and retinal macular pigment optical density (MPOD) levels before and after supplementation. Four variants were associated with MPOD response to supplementation (p < 0.05): rs11057841 (SCARB1), rs4926339 (RPE65), rs1929841 (ABCA1) and rs174534 (FADS)). We also confirmed previous associations between rs6564851 near BMCO1 (p < 0.001) and rs11057841 within SCARB1 (p = 0.01) and baseline measures of serum lutein; while the latter was also associated with MPOD response, none of the BMCO1 variants were. Finally, there was evidence for association between variants near RPE65 and ELOVL2 and changes in lutein concentration after supplementation.
   This study is the first to show association between genetic variants and response to carotenoids supplementation. Our findings suggest an important link between MP response and the biological processes of carotenoids transport and fatty acid metabolism. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
C1 [Yonova-Doing, Ekaterina; Hysi, Pirro G.; Venturini, Cristina; Williams, Katie M.; Nag, Abhishek; Hammond, Christopher J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London SE1 7EH, England.
   [Venturini, Cristina] UCL, Inst Ophthalmol, London WC1E 6BT, England.
   [Beatty, Stephen] Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
   [Gilbert, Clare E.] Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
C3 University of London; King's College London; University of London;
   University College London; South East Technological University (SETU);
   University of London; London School of Hygiene & Tropical Medicine
RP Hammond, CJ (通讯作者)，Kings Coll London, Dept Twin Res & Genet Epidemiol, St Thomas Hosp, 3rd Floor,South Wing,Block D,Westminster Bridge R, London SE1 7EH, England.
EM chris.hammond@kcl.ac.uk
OI Hysi, Pirro/0000-0001-5752-2510; Hammond,
   Christopher/0000-0002-3227-2620; Venturini,
   Cristina/0000-0002-4769-7912; Williams, Katie M/0000-0003-4596-3938
FU Wellcome Trust; European Union MyEuropia Marie Curie Research Training
   Network; Guide Dogs for the Blind Association; European Community
   [HEALTHF-22008201865GEFOS]; ENGAGE [HEALTHF42007201413]; FP-5
   GenomEUtwin Project [QLG2CT200201254]; US National Institutes of
   Health/National Eye Institute [1RO1EY018246]; NIH Center for Inherited
   Disease Research; National Institute for Health Research (NIHR) Clinical
   Research Facility at Guy's & St Thomas' NHS Foundation Trust; NIHR
   Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation
   Trust; King's College London; Fight for Sight; Worshipful Company of
   Spectacle Makers; TFC Frost Fellowship; NATIONAL EYE INSTITUTE
   [R01EY018246] Funding Source: NIH RePORTER; Medical Research Council
   [MR/K023721/1] Funding Source: researchfish; National Institute for
   Health Research [SRF/01/010] Funding Source: researchfish; Fight for
   Sight [1329/30] Funding Source: researchfish; MRC [MR/K023721/1] Funding
   Source: UKRI
FX The authors would like to thank all the twin volunteers for their
   participation. This study was supported by the Wellcome Trust. TwinsUK
   received funding from the European Union MyEuropia Marie Curie Research
   Training Network; Guide Dogs for the Blind Association; the European
   Community's FP7 (HEALTHF-22008201865GEFOS); ENGAGE (HEALTHF42007201413);
   the FP-5 GenomEUtwin Project (QLG2CT200201254); US National Institutes
   of Health/National Eye Institute (1RO1EY018246); NIH Center for
   Inherited Disease Research; the National Institute for Health Research
   (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation
   Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas'
   NHS Foundation Trust and King's College London. A.N. received funding
   from Fight for Sight and The Worshipful Company of Spectacle Makers.
   P.G.H. is the recipient of a Fight for Sight ECI award. KW acknowledges
   funding from the TFC Frost Fellowship. C.J.H. is an NIHR Senior Research
   fellow.
CR Andrew T, 2001, Twin Res, V4, P464, DOI 10.1375/1369052012803
   [Anonymous], 2013, JAMA, V309, P2005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chen YQ, 1999, CANCER RES, V59, P3985
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Ferrucci L, 2009, AM J HUM GENET, V84, P123, DOI 10.1016/j.ajhg.2008.12.019
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Klamt F, 2003, MUTAT RES-GEN TOX EN, V539, P117, DOI 10.1016/S1383-5718(03)00155-4
   Kobayashi T, 2007, FEBS LETT, V581, P3157, DOI 10.1016/j.febslet.2007.05.081
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Lobo GP, 2012, BBA-MOL CELL BIOL L, V1821, P78, DOI 10.1016/j.bbalip.2011.04.010
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McKay G.J., 2013, OPHTHALMOLOGY, DOI DOI 10.1016/J.0PHTHA.2013.01.030
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murata M, 2000, J BIOL CHEM, V275, P2003, DOI 10.1074/jbc.275.3.2003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006
   Siems W, 2002, FASEB J, V16, P1289, DOI 10.1096/fj.01-0765fje
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tanaka T, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000338
   Thurnham DI, 2008, BRIT J NUTR, V100, P1307, DOI 10.1017/S0007114508971336
   Wang YM, 2010, EUR J NUTR, V49, P327, DOI 10.1007/s00394-009-0089-8
   Wolf-Schnurrbusch U.E., 2007, INVEST OPHTH VIS SCI, V48, P3783
   Woo George C, 2002, Clin Exp Optom, V85, P372
   Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 48
TC 22
Z9 22
U1 2
U2 21
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2013
VL 115
BP 172
EP 177
DI 10.1016/j.exer.2013.07.020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239XZ
UT WOS:000326060600022
PM 23891863
OA Green Accepted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Sharma, PS
   Sharma, R
   Tyagi, T
AF Sharma, P. S.
   Sharma, R.
   Tyagi, T.
TI VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and
   Future
SO CURRENT CANCER DRUG TARGETS
LA English
DT Review
DE Angiogenesis; bevacizumab; flk-1; KDR; tyrosine kinase; sorafenib;
   suntinib; VEGFR
ID ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; VEGF-RECEPTOR-I;
   SMALL-MOLECULE INHIBITOR; PHASE-I; TUMOR ANGIOGENESIS; POTENT
   INHIBITORS; SELECTIVE INHIBITOR; ANTITUMOR-ACTIVITY; DUAL INHIBITORS
AB Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a central role in the process of tumor growth and metastasis. The proliferation of endothelium and formation of new blood vessels further the size of solid tumors. It is expected that blocking angiogenesis will be an efficient therapeutic approach against many tumor types. The key signaling system that regulates proliferation and migration of endothelial cells are vascular endothelium growth factor (VEGF) and their receptors (VEGFR-1, -2 and -3). VEGFR-2, a receptor with higher affinity and greater kinase activity, is more important in the direct regulation of angiogenesis, mitogenic signaling, and permeability-enhancing effects. VEGFRs are expressed at high levels in many types of human solid tumors, including glioma, lung, breast, renal, ovarian and gastrointestinal tract carcinomas. Inhibition of VEGFR has emerged as a potential therapy method for cancers and it has been clinically validated with FDA-approvals of bevacizumab, sorafenib, and suntinib. Consequently, a number of small molecules with VEGFR inhibitory properties have been developed. Many of these have been evaluated as potent inhibitors and some are currently in clinical-trials for various angiogenic related disorders including inflammatory diseases, retinopathies and age related macular degeneration. This review reports various VEGF/VEGFR pathway inhibitors such as small molecules and monoclonal antibodies, along with their reported activities.
C1 [Sharma, P. S.; Sharma, R.; Tyagi, T.] CSSS PG Coll, Dept Chem, Meerut, Uttar Pradesh, India.
RP Sharma, PS (通讯作者)，CSSS PG Coll, Dept Chem, Meerut, Uttar Pradesh, India.
EM poojasapra.sharma@gmail.com
CR Abrams TJ, 2003, MOL CANCER THER, V2, P1011
   Acevedo VD, 2009, CELL CYCLE, V8, P580, DOI 10.4161/cc.8.4.7657
   Albert DH, 2006, MOL CANCER THER, V5, P995, DOI 10.1158/1535-7163.MCT-05-0410
   Amino N, 2006, CLIN CANCER RES, V12, P1630, DOI 10.1158/1078-0432.CCR-05-2028
   Aragon-Ching Jeanny B, 2009, Curr Mol Pharmacol, V2, P161
   Augustin HG, 2003, CELL TISSUE RES, V314, P25, DOI 10.1007/s00441-003-0770-9
   Azad A, 2009, ACTA ONCOL, V48, P619, DOI 10.1080/02841860802495362
   Bagri A, 2009, CLIN CANCER RES, V15, P1860, DOI 10.1158/1078-0432.CCR-08-0563
   Baindur N, 2005, J MED CHEM, V48, P1717, DOI 10.1021/jm049372z
   Banerjee S, 2010, CLIN CANCER RES, V16, P4178, DOI 10.1158/1078-0432.CCR-10-0456
   Becknell NC, 2006, BIOORG MED CHEM LETT, V16, P5368, DOI 10.1016/j.bmcl.2006.07.066
   Beebe JS, 2003, CANCER RES, V63, P7301
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bhide RS, 2006, J MED CHEM, V49, P2143, DOI 10.1021/jm051106d
   Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26
   Bilodeau MT, 2004, J MED CHEM, V47, P6363, DOI 10.1021/jm049697f
   Borzilleri RM, 2006, J MED CHEM, V49, P3766, DOI 10.1021/jm060347y
   Bouerat L, 2005, J MED CHEM, V48, P5412, DOI 10.1021/jm0504151
   Bukowski RM, 2010, NAT REV DRUG DISCOV, V9, P17, DOI 10.1038/nrd3073
   Burstein HJ, 2008, J CLIN ONCOL, V26, P1810, DOI 10.1200/JCO.2007.14.5375
   Caenepeel S, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-96
   Cai ZW, 2008, J MED CHEM, V51, P1976, DOI 10.1021/jm7013309
   Cai ZW, 2008, BIOORG MED CHEM LETT, V18, P1354, DOI 10.1016/j.bmcl.2008.01.012
   Casneuf VF, 2009, ONCOL REP, V22, P105, DOI 10.3892/or_00000412
   Cebulla CM, 2008, OPEN OPHTHALMOL J, V2, P62, DOI 10.2174/1874364100802010062
   Cheng JW, 2011, NEW ENGL J MED, V364, P582, DOI 10.1056/NEJMc1013316
   Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602
   Claes A, 2008, CANCER BIOL THER, V7, P1014, DOI 10.4161/cbt.7.7.6474
   Claridge S, 2008, BIOORG MED CHEM LETT, V18, P2793, DOI 10.1016/j.bmcl.2008.04.009
   Cohen EEW, 2008, J CLIN ONCOL, V26, P4708, DOI 10.1200/JCO.2007.15.9566
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   Cohen RB, 2007, CANCER CHEMOTH PHARM, V60, P81, DOI 10.1007/s00280-006-0352-0
   Coxon A, 2009, CLIN CANCER RES, V15, P110, DOI 10.1158/1078-0432.CCR-08-1155
   Cui TG, 2004, AM J PHYSIOL-RENAL, V286, pF767, DOI 10.1152/ajprenal.00337.2003
   Curtin ML, 2004, BIOORG MED CHEM LETT, V14, P4505, DOI 10.1016/j.bmcl.2004.06.041
   Dai YJ, 2005, J MED CHEM, V48, P6066, DOI 10.1021/jm050458h
   Dai Y, 2008, BIOORG MED CHEM LETT, V18, P386, DOI 10.1016/j.bmcl.2007.10.018
   Dai YJ, 2007, J MED CHEM, V50, P1584, DOI 10.1021/jm061280h
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Dandu R, 2008, BIOORG MED CHEM LETT, V18, P1916, DOI 10.1016/j.bmcl.2008.02.001
   de Bouard S, 2007, NEURO-ONCOLOGY, V9, P412, DOI 10.1215/15228517-2007-024
   De Luca A, 2010, IDRUGS, V13, P636
   Dev IK, 2004, BRIT J CANCER, V91, P1391, DOI 10.1038/sj.bjc.6602109
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dominguez C, 2007, BIOORG MED CHEM LETT, V17, P6003, DOI 10.1016/j.bmcl.2007.07.077
   Duncton MAJ, 2009, BIOORGAN MED CHEM, V17, P731, DOI 10.1016/j.bmc.2008.11.049
   El Ella DAA, 2008, BIOORGAN MED CHEM, V16, P2391, DOI 10.1016/j.bmc.2007.11.072
   Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538
   Emanuel S, 2004, MOL PHARMACOL, V66, P635, DOI 10.1124/mol.104.000638
   Farace P, 2009, BRIT J CANCER, V100, P1575, DOI 10.1038/sj.bjc.6605041
   Fiedler W, 2011, ANN ONCOL, V22, P195, DOI 10.1093/annonc/mdq313
   Figg WD, 2008, ANGIOGENESIS INTEGRA
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fraley ME, 2004, BIOORG MED CHEM LETT, V14, P351, DOI 10.1016/j.bmcl.2003.11.007
   Frey RR, 2008, J MED CHEM, V51, P3777, DOI 10.1021/jm701397k
   Gaballah K, 2009, BRIT J CANCER, V101, P418, DOI 10.1038/sj.bjc.6605092
   Garton AJ, 2006, CANCER RES, V66, P1015, DOI 10.1158/0008-5472.CAN-05-2873
   Gaudette F, 2010, BIOORG MED CHEM LETT, V20, P848, DOI 10.1016/j.bmcl.2009.12.099
   Gautier B, 2010, J MED CHEM, V53, P4428, DOI 10.1021/jm1002167
   Gingrich DE, 2003, J MED CHEM, V46, P5375, DOI 10.1021/jm0301641
   GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111
   Griffioen AW, 2000, PHARMACOL REV, V52, P237
   Gril B, 2011, CLIN CANCER RES, V17, P142, DOI 10.1158/1078-0432.CCR-10-1603
   Guo XN, 2005, CANCER BIOL THER, V4, P1125, DOI 10.4161/cbt.4.10.2024
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Harmange JC, 2008, J MED CHEM, V51, P1649, DOI 10.1021/jm701097z
   Harris PA, 2005, J MED CHEM, V48, P1610, DOI 10.1021/jm049538w
   Harris PA, 2008, J MED CHEM, V51, P4632, DOI 10.1021/jm800566m
   Hasegawa M, 2007, J MED CHEM, V50, P4453, DOI 10.1021/jm0611051
   Hasskarl J, 2010, RECENT RESULTS CANC, V184, P61, DOI 10.1007/978-3-642-01222-8_5
   Heckman CA, 2008, CANCER RES, V68, P4754, DOI 10.1158/0008-5472.CAN-07-5809
   Heng DYC, 2010, RECENT RESULTS CANC, V184, P71, DOI 10.1007/978-3-642-01222-8_6
   Hennequin LF, 2002, J MED CHEM, V45, P1300, DOI 10.1021/jm011022e
   Heyman HR, 2007, BIOORG MED CHEM LETT, V17, P1246, DOI 10.1016/j.bmcl.2006.12.015
   Horn Leora, 2009, Proc Am Thorac Soc, V6, P206, DOI 10.1513/pats.200807-066LC
   Hos D, 2008, INVEST OPHTH VIS SCI, V49, P1836, DOI 10.1167/iovs.07-1314
   Hu-Lowe DD, 2008, CLIN CANCER RES, V14, P7272, DOI 10.1158/1078-0432.CCR-08-0652
   Huang SL, 2006, BIOORG MED CHEM LETT, V16, P6063, DOI 10.1016/j.bmcl.2006.08.107
   Huang SL, 2011, BIOORG MED CHEM LETT, V21, P1815, DOI 10.1016/j.bmcl.2011.01.053
   Hughes TV, 2007, BIOORG MED CHEM LETT, V17, P3266, DOI 10.1016/j.bmcl.2007.04.021
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Ji ZQ, 2006, BIOORG MED CHEM LETT, V16, P4326, DOI 10.1016/j.bmcl.2006.05.057
   Joensuu H, 2008, ANN ONCOL, V19, P173, DOI 10.1093/annonc/mdm419
   Jones-Bolin S, 2006, MOL CANCER THER, V5, P1744, DOI 10.1158/1535-7163.MCT-05-0327
   Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898
   Karamysheva AF, 2008, BIOCHEMISTRY-MOSCOW+, V73, P751, DOI 10.1134/S0006297908070031
   Katanasaka Y, 2008, CANCER LETT, V270, P260, DOI 10.1016/j.canlet.2008.05.009
   Katzel JA, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-2
   Keisner SV, 2011, DRUGS, V71, P443, DOI 10.2165/11588960-000000000-00000
   Kieran MW, 2009, PEDIATR BLOOD CANCER, V52, P169, DOI 10.1002/pbc.21873
   Kirkali Ziya, 2009, Expert Rev Anticancer Ther, V9, P1753, DOI 10.1586/era.09.154
   Kirkin V, 2004, INT J CANCER, V112, P986, DOI 10.1002/ijc.20509
   Kiselyov AS, 2006, CHEM BIOL DRUG DES, V68, P308, DOI 10.1111/j.1747-0285.2006.00456.x
   Kiselyov AS, 2007, CHEM BIOL DRUG DES, V69, P331, DOI 10.1111/j.1747-0285.2007.00507.x
   Kiselyov AS, 2006, CHEM BIOL DRUG DES, V68, P250, DOI 10.1111/j.1747-0285.2006.00445.x
   Kiselyov AS, 2007, BIOORG MED CHEM LETT, V17, P3550, DOI 10.1016/j.bmcl.2007.04.042
   Kiselyov AS, 2009, BIOORG MED CHEM LETT, V19, P1195, DOI 10.1016/j.bmcl.2008.12.078
   Kiselyov AS, 2006, BIOORG MED CHEM LETT, V16, P1913, DOI 10.1016/j.bmcl.2005.12.090
   Kiselyov AS, 2006, BIOORG MED CHEM LETT, V16, P1440, DOI 10.1016/j.bmcl.2005.11.033
   Kiselyov AS, 2006, BIOORG MED CHEM LETT, V16, P602, DOI 10.1016/j.bmcl.2005.10.058
   Klenke FM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-49
   KRAEMER A, 2009, GER MED SCI, V7
   Kubo K, 2005, J MED CHEM, V48, P1359, DOI 10.1021/jm030427r
   La DS, 2008, J MED CHEM, V51, P1695, DOI 10.1021/jm701129j
   Laird AD, 2000, CANCER RES, V60, P4152
   LaMontagne KR, 2009, ANGIOGENESIS, V12, P287, DOI 10.1007/s10456-009-9151-7
   Latreille Jean, 2003, Clin Lung Cancer, V4, P231, DOI 10.3816/CLC.2003.n.003
   Lee KI, 2006, BIOORG MED CHEM LETT, V16, P737, DOI 10.1016/j.bmcl.2005.08.115
   Lee SH, 2005, CLIN CANCER RES, V11, P3633, DOI 10.1158/1078-0432.CCR-04-2129
   Lee SY, 2007, VASC PHARMACOL, V47, P313, DOI 10.1016/j.vph.2007.08.009
   Liao AT, 2002, BLOOD, V100, P585, DOI 10.1182/blood-2001-12-0350
   Lin HL, 2011, DRUG METAB DISPOS, V39, P345, DOI 10.1124/dmd.110.034074
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Lockhart AC, 2006, AM J CLIN ONCOL-CANC, V29, P109, DOI 10.1097/01.coc.0000199882.53545.ac
   Lucking U, 2007, CHEMMEDCHEM, V2, P63, DOI 10.1002/cmdc.200600199
   Manley PW, 2002, J MED CHEM, V45, P5687, DOI 10.1021/jm020899q
   Manley PW, 2004, BBA-PROTEINS PROTEOM, V1697, P17, DOI 10.1016/j.bbapap.2003.11.010
   Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270
   Matsui J, 2008, INT J CANCER, V122, P664, DOI 10.1002/ijc.23131
   Matsunaga N, 2006, MOL CANCER THER, V5, P80, DOI 10.1158/1535-7163.MCT-05-0202
   McDermott LA, 2005, BIOORGAN MED CHEM, V13, P4835, DOI 10.1016/j.bmc.2005.05.012
   McDermott LA, 2006, BIOORG MED CHEM LETT, V16, P1950, DOI 10.1016/j.bmcl.2005.12.092
   Melchert M, 2007, INT J BIOCHEM CELL B, V39, P1489, DOI 10.1016/j.biocel.2007.01.022
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Milker-Zabel S, 2008, INT J RADIAT ONCOL, V70, P1213, DOI 10.1016/j.ijrobp.2007.11.041
   Miyazaki Y, 2005, BIOORG MED CHEM LETT, V15, P2203, DOI 10.1016/j.bmcl.2005.03.034
   Miyazaki Y, 2007, BIOORG MED CHEM LETT, V17, P1773, DOI 10.1016/j.bmcl.2006.12.077
   Morabito A, 2009, ONCOLOGIST, V14, P378, DOI 10.1634/theoncologist.2008-0261
   Munchhof MJ, 2004, BIOORG MED CHEM LETT, V14, P21, DOI 10.1016/j.bmcl.2003.10.030
   Nakamura K, 2004, MOL CANCER THER, V3, P1639
   Nakamura K, 2006, CANCER RES, V66, P9134, DOI 10.1158/0008-5472.CAN-05-4290
   Natale RB, 2009, J CLIN ONCOL, V27, P2523, DOI 10.1200/JCO.2008.18.6015
   Naumova E, 2006, CLIN CANCER RES, V12, P1839, DOI 10.1158/1078-0432.CCR-05-1615
   Neufeld G, 2007, ADV EXP MED BIOL, V600, P118
   Nguyen QD, 2006, MOL CANCER THER, V5, P2070, DOI 10.1158/1535-7163.MCT-06-0044
   Ny A, 2008, BLOOD, V112, P1740, DOI 10.1182/blood-2007-08-106302
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   Patel N, 2003, J PHARMACOL EXP THER, V306, P838, DOI 10.1124/jpet.103.052167
   Polverino A, 2006, CANCER RES, V66, P8715, DOI 10.1158/0008-5472.CAN-05-4665
   Posey JA, 2003, CLIN CANCER RES, V9, P1323
   Potashman MH, 2007, J MED CHEM, V50, P4351, DOI 10.1021/jm070034i
   Pourgholami Mohammad H., 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P343, DOI 10.2174/187152508785909528
   Presta LG, 1997, CANCER RES, V57, P4593
   Raeppel S, 2009, BIOORG MED CHEM LETT, V19, P1323, DOI 10.1016/j.bmcl.2009.01.068
   Reuman M, 2008, J ORG CHEM, V73, P1121, DOI 10.1021/jo7021372
   Rodriguez-Fontal M, 2009, CURR DIABETES REV, V5, P47, DOI 10.2174/157339909787314239
   Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121
   Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006
   Rossi A, 2010, CURR DRUG TARGETS, V11, P865, DOI 10.2174/138945010791320791
   Roth GJ, 2009, J MED CHEM, V52, P4466, DOI 10.1021/jm900431g
   Rotsos TG, 2008, CLIN OPHTHALMOL, V2, P919
   Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   Ruel R, 2008, BIOORG MED CHEM LETT, V18, P2985, DOI 10.1016/j.bmcl.2008.03.057
   Ruggeri B, 2003, CANCER RES, V63, P5978
   RYU S, 1979, INVEST OPHTH VIS SCI, V18, P831
   Sarker D, 2008, CLIN CANCER RES, V14, P2075, DOI 10.1158/1078-0432.CCR-07-1466
   Sato Y, 2000, ANN NY ACAD SCI, V902, P201
   Schiller JH, 2009, J CLIN ONCOL, V27, P3836, DOI 10.1200/JCO.2008.20.8355
   Schlessinger J, 2005, SCIENTIST, V19, P17
   Scott EN, 2007, EXPERT OPIN INV DRUG, V16, P367, DOI 10.1517/13543784.16.3.367
   Sessa C, 2006, EUR J CANCER, V42, P171, DOI 10.1016/j.ejca.2005.09.033
   Sharma BK, 2008, J ENZYM INHIB MED CH, V23, P168, DOI [10.1080/14756360701450301, 10.1080/14756360701450301 ]
   Sharma PS, 2008, CURR CANCER DRUG TAR, V8, P53, DOI 10.2174/156800908783497131
   Sharma PS, 2009, CURR PHARM DESIGN, V15, P758, DOI 10.2174/138161209787582219
   Sharma S, 2010, ANN ONCOL, V21, P297, DOI 10.1093/annonc/mdp489
   SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450
   Simons M., 2007, MODERN CONCEPTS ANGI
   Sistla Anand, 2008, PDA J Pharm Sci Technol, V62, P200
   Sonpavde G, 2009, UROL ONCOL-SEMIN ORI, V27, P391, DOI 10.1016/j.urolonc.2008.03.017
   Spratlin J, 2011, CURR ONCOL REP, V13, P97, DOI 10.1007/s11912-010-0149-5
   Spratlin JL, 2010, J CLIN ONCOL, V28, P780, DOI 10.1200/JCO.2009.23.7537
   Stopfer P, 2011, XENOBIOTICA, V41, P297, DOI 10.3109/00498254.2010.545452
   Takezawa K, 2009, CANCER RES, V69, P6515, DOI 10.1158/0008-5472.CAN-09-1076
   Thompson AM, 2005, J MED CHEM, V48, P4628, DOI 10.1021/jm0500931
   Tokuyama J, 2005, ANTICANCER RES, V25, P17
   Tortora G, 2004, J CHEMOTHERAPY, V16, P41, DOI 10.1179/joc.2004.16.Supplement-1.41
   Tran TC, 2007, CANCER RES, V67, P11386, DOI 10.1158/0008-5472.CAN-07-3126
   Uno M, 2008, ORG BIOMOL CHEM, V6, P979, DOI 10.1039/b719959g
   van Cruijsen H, 2010, EUR J CANCER, V46, P901, DOI 10.1016/j.ejca.2009.12.023
   Veeravagu A, 2007, RECENT PAT ANTI-CANC, V2, P59, DOI 10.2174/157489207779561426
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wang FE, 2007, EXP EYE RES, V84, P922, DOI 10.1016/j.exer.2007.01.022
   WANG WL, 2011, CANC CHEMOTHER PHA S, V1, pS15
   Wedge SR, 2000, CANCER RES, V60, P970
   Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
   Weiss MM, 2008, J MED CHEM, V51, P1668, DOI 10.1021/jm701098w
   Whittles CE, 2002, MICROCIRCULATION, V9, P513, DOI 10.1038/sj.mn.7800164
   Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130
   Wissner A, 2005, J MED CHEM, V48, P7560, DOI 10.1021/jm050559f
   Wissner A, 2007, BIOORGAN MED CHEM, V15, P3635, DOI 10.1016/j.bmc.2007.03.055
   Wood JM, 2000, CANCER RES, V60, P2178
   Xiao ZF, 2007, CELL RES, V17, P73, DOI 10.1038/sj.cr.7310126
   Yancey MF, 2010, J VET PHARMACOL THER, V33, P154, DOI [10.1111/j.1365-2885.2009.01120.x, 10.1111/j.1365-2885.2009.01133.x]
   Yiin JJ, 2010, MOL CANCER THER, V9, P929, DOI 10.1158/1535-7163.MCT-09-0953
   Yu H, 2007, CHEM BIOL DRUG DES, V69, P204, DOI 10.1111/j.1747-0285.2007.00488.x
   Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49
   Zhang J, 2010, BIOORG MED CHEM LETT, V20, P718, DOI 10.1016/j.bmcl.2009.11.073
   Zhong L, 2006, CANCER BIOL THER, V5, P323, DOI 10.4161/cbt.5.3.2543
   Zhou JB, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-33
NR 201
TC 63
Z9 74
U1 2
U2 34
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD JUN
PY 2011
VL 11
IS 5
BP 624
EP 653
PG 30
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 777PY
UT WOS:000291637000008
PM 21486218
DA 2022-11-30
ER

PT J
AU Zhao, ZY
   Chen, Y
   Wang, J
   Sternberg, P
   Freeman, ML
   Grossniklaus, HE
   Cai, JY
AF Zhao, Zhenyang
   Chen, Yan
   Wang, Jian
   Sternberg, Paul
   Freeman, Michael L.
   Grossniklaus, Hans E.
   Cai, Jiyang
TI Age-Related Retinopathy in NRF2-Deficient Mice
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTION FACTOR NRF2; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; RETINAL DEGENERATION;
   GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; BRUCHS MEMBRANE; DRUSEN; AUTOPHAGY
AB Background: Cumulative oxidative damage is implicated in the pathogenesis of age-related macular degeneration (AMD). Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor that plays key roles in retinal antioxidant and detoxification responses. The purposes of this study were to determine whether NRF2-deficient mice would develop AMD-like retinal pathology with aging and to explore the underlying mechanisms.
   Methods and Findings: Eyes of both wild type and Nrf2(-/-) mice were examined in vivo by fundus photography and electroretinography (ERG). Structural changes of the outer retina in aged animals were examined by light and electron microscopy, and immunofluorescence labeling. Our results showed that Nrf2(-/-) mice developed age-dependent degenerative pathology in the retinal pigment epithelium (RPE). Drusen-like deposits, accumulation of lipofuscin, spontaneous choroidal neovascularization (CNV) and sub-RPE deposition of inflammatory proteins were present in Nrf2(-/-) mice after 12 months. Accumulation of autophagy-related vacuoles and multivesicular bodies was identified by electron microcopy both within the RPE and in Bruch's membrane of aged Nrf2(-/-) mice.
   Conclusions: Our data suggest that disruption of Nfe2l2 gene increased the vulnerability of outer retina to age-related degeneration. NRF2-deficient mice developed ocular pathology similar to cardinal features of human AMD and deregulated autophagy is likely a mechanistic link between oxidative injury and inflammation. The Nrf2(-/-) mice can provide a novel model for mechanistic and translational research on AMD.
C1 [Zhao, Zhenyang; Chen, Yan; Wang, Jian; Sternberg, Paul; Cai, Jiyang] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37203 USA.
   [Freeman, Michael L.] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN USA.
   [Grossniklaus, Hans E.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
C3 Vanderbilt University; Vanderbilt University; Emory University
RP Zhao, ZY (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37203 USA.
EM jiyang.cai@vanderbilt.edu
RI Zhao, Zhenyang/N-3321-2015
OI Zhao, Zhenyang/0000-0002-1701-3751; Freeman, Michael/0000-0003-1881-366X
FU International Retinal Research Foundation; Research to Prevent
   Blindness, Inc.; NIH [EY019706, EY07892, EY08126, CA115556, EY018715];
   NATIONAL CANCER INSTITUTE [R01CA115556] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R29EY007892, R21EY018715, K99EY019706,
   P30EY008126, R01EY007892] Funding Source: NIH RePORTER
FX This research was supported by International Retinal Research
   Foundation, an unrestricted department grant from Research to Prevent
   Blindness, Inc. and NIH grants EY019706, EY07892, EY08126, CA115556 and
   EY018715. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Burk RF, 2008, FREE RADICAL BIO MED, V44, P1617, DOI 10.1016/j.freeradbiomed.2008.01.016
   Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DILORETO D, 1994, CURR EYE RES, V13, P157, DOI 10.3109/02713689409042411
   Greco T, 2010, J ALZHEIMERS DIS, V20, pS427, DOI 10.3233/JAD-2010-100519
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1996, OPHTHALMIC PATHOLOGY, P1025
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Handa James T., 2007, International Ophthalmology Clinics, V47, P15, DOI 10.1097/IIO.0b013e31802bd546
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008
   Leiser SF, 2010, MOL CELL BIOL, V30, P871, DOI 10.1128/MCB.01145-09
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Martinez-Vicente M, 2010, NAT NEUROSCI, V13, P567, DOI 10.1038/nn.2528
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Morimoto RI, 2008, GENE DEV, V22, P1427, DOI 10.1101/gad.1657108
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ni MW, 2010, TOXICOL SCI, V116, P590, DOI 10.1093/toxsci/kfq126
   Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006
   Pearson KJ, 2008, P NATL ACAD SCI USA, V105, P2325, DOI 10.1073/pnas.0712162105
   POLLACK A, 1986, ARCH OPHTHALMOL-CHIC, V104, P1372, DOI 10.1001/archopht.1986.01050210126039
   Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Uno K, 2010, EXP EYE RES, V90, P493, DOI 10.1016/j.exer.2009.12.012
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Xu HP, 2008, EXP EYE RES, V87, P319, DOI 10.1016/j.exer.2008.06.012
   Zhu H, 2008, CARDIOVASC TOXICOL, V8, P115, DOI 10.1007/s12012-008-9020-4
NR 62
TC 210
Z9 221
U1 3
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2011
VL 6
IS 4
AR e19456
DI 10.1371/journal.pone.0019456
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 756OZ
UT WOS:000290024700182
PM 21559389
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, JH
   Lee, BJ
   Kim, JH
   Yu, YS
   Kim, MY
   Kim, KW
AF Kim, Jeong Hun
   Lee, Byung Joo
   Kim, Jin Hyoung
   Yu, Young Suk
   Kim, Min Young
   Kim, Kyu-Won
TI Rosmarinic acid suppresses retinal neovascularization via cell cycle
   arrest with increase of p21(WAF1) expression
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Anti-angiogenesis; Cell cycle arrest; p21(WAF1); Retinal
   neovascularization; Retinopathy of prematurity; Rosmarinic acid
ID OXYGEN-INDUCED RETINOPATHY; ANGIOGENESIS; DEGUELIN
AB Pathological angiogenesis is the most common cause of blindness at all ages including retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Despite advances in therapy, retinopathy of prematurity remains the most sight-threatening vaso-proliferative retinopathy in children. Herein, we demonstrated that rosmarinic acid has an anti-angiogenic activity to retinal neovascularization in a mouse model of retinopathy of prematurity, which is related to cell cycle arrest with increase of p21(WAF1). Rosmarinic acid significantly inhibited the proliferation of retinal endothelial cells in a dose-dependent manner, and inhibited in vitro angiogenesis of tube formation. Interestingly, the anti-proliferative activity of rosmarinic acid on retinal endothelial cells was related to G(2)/M phase cell cycle arrest in a dose-dependent manner. With treatment of rosmarinic acid, retinal endothelial cells in G(2)/M phase increased whereas those in G(0)/G(1) and S phases decreased, which was accompanied by increase of p21(WAF1) expression in a dose-dependent manner. Moreover, rosmarinic acid effectively suppressed retinal neovascularization in a mouse model of retinopathy of prematurity, and showed no retinal toxicity. These data suggest rosmarinic acid could be a potent inhibitor of retinal neovascularization and may be applied in the treatment of other vasoproliferative retinopathie s. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Kim, Jeong Hun; Lee, Byung Joo; Kim, Jin Hyoung; Yu, Young Suk] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
   [Kim, Jeong Hun; Lee, Byung Joo; Kim, Jin Hyoung; Yu, Young Suk] Seoul Natl Univ Hosp, Clin Res Inst, Seoul Artificial Eye Ctr, Seoul 110744, South Korea.
   [Kim, Min Young] AngioLab Inc, Biodiagnost Fus Ctr, Taejon 304340, South Korea.
   [Kim, Kyu-Won] Seoul Natl Univ, Coll Pharm, NeuroVasc Coordinat Res Ctr, Seoul 151742, South Korea.
   [Kim, Kyu-Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University (SNU)
RP Yu, YS (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
EM ysyu@snu.ac.kr
RI Kim, Kyu Won/AAJ-7213-2020; Yu, Young Suk/J-5551-2012; Kim, Jeong
   Hun/J-2748-2012
OI Kim, Jeong Hun/0000-0003-2957-1766
FU Bio-signal Analysis Technology Innovation Program
   [M1064501001-06n4501-00110]; Ministry of Science and Technology (MOST);
   Korea Science and Engineering Foundation (KOSEF)
FX Thanks to Ms. Sung Jin Cho for the technical assistance of animal
   experiments. This study was supported by the Bio-signal Analysis
   Technology Innovation Program (M1064501001-06n4501-00110) of the
   Ministry of Science and Technology (MOST) and Korea Science and
   Engineering Foundation (KOSEF).
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Frankel EN, 1996, J AGR FOOD CHEM, V44, P131, DOI 10.1021/jf950374p
   Huang SS, 2006, CANCER LETT, V239, P271, DOI 10.1016/j.canlet.2005.08.025
   Jung JE, 2007, CARCINOGENESIS, V28, P1780, DOI 10.1093/carcin/bgm130
   Kim JH, 2008, J CELL MOL MED, V12, P2407, DOI 10.1111/j.1582-4934.2008.00243.x
   Kim JH, 2008, J PHARMACOL EXP THER, V324, P643, DOI 10.1124/jpet.107.132720
   Kim JH, 2007, BIOCHEM BIOPH RES CO, V362, P848, DOI 10.1016/j.bbrc.2007.08.100
   Makino T, 2000, NEPHROL DIAL TRANSPL, V15, P1140, DOI 10.1093/ndt/15.8.1140
   Min JK, 2007, BLOOD, V109, P1495, DOI 10.1182/blood-2006-06-029298
   Petersen M, 2003, PHYTOCHEMISTRY, V62, P121, DOI 10.1016/S0031-9422(02)00513-7
   ROTH AM, 1977, AM J OPHTHALMOL, V84, P636, DOI 10.1016/0002-9394(77)90377-4
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Youn J, 2003, J RHEUMATOL, V30, P1203
NR 15
TC 33
Z9 45
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD AUG 1
PY 2009
VL 615
IS 1-3
BP 150
EP 154
DI 10.1016/j.ejphar.2009.05.015
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 473OW
UT WOS:000268218100022
PM 19470386
DA 2022-11-30
ER

PT J
AU Zhang, P
   Wang, YS
   Hui, YN
   Hu, D
   Wang, HY
   Zhou, J
   Du, HJ
AF Zhang, Peng
   Wang, Yusheng
   Hui, Yannian
   Hu, Dan
   Wang, Haiyan
   Zhou, Jian
   Du, Hongjun
TI Inhibition of VEGF expression by targeting HIF-1 alpha with small
   interference RNA in human RPE cells
SO OPHTHALMOLOGICA
LA English
DT Article
DE choroidal neovascularization; retinal pigment epithelium; growth
   factors; molecular biology
ID ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; RETINAL-PIGMENT
   EPITHELIUM; MACULAR DEGENERATION; HAIRPIN RNAS; NITRIC-OXIDE;
   TUMOR-GROWTH; NEOVASCULARIZATION; ANGIOGENESIS; INDUCTION
AB Background: Vascular endothelial growth factor ( VEGF) is upregulated by hypoxia and is a major stimulatory factor for choroidal neovascularization. The upregulation of VEGF expression in response to hypoxia occurs through hypoxia-inducible factor 1 (HIF-1), which is a transcription factor that regulates genes involved in the response to hypoxia. HIF- 1 alpha is the inducible subunit of the HIF-1.
   Aims: To further define HIF- 1 function in angiogenesis and to explore novel approaches to modulate choroidal neovascularization in age-related macular degeneration.
   Methods: In this study, we examined the response of human retinal pigment epithelium (RPE) cells to hypoxia and employed the small interference RNA technique to knock down gene expression of HIF-1 alpha in RPE cells.
   Results: We found that both the mRNA and protein levels of HIF-1 alpha in the RPE cells increased in response to hypoxia, followed by increasing expression of VEGF. Both the mRNA and protein levels of HIF-1 alpha and VEGF in the RPE cells were decreased dramatically after transfection with a HIF-1 alpha-specific small interference RNA vector.
   Conclusion: Our results suggest that HIF-1 may be involved in angiogenesis by controlling the expression of VEGF in vivo and provide a possible strategy for the treatment of angiogenesis by targeting the HIF-1 alpha in ischemic retinopathies.
C1 Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
C3 Air Force Military Medical University
RP Wang, YS (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
EM wangys@fmmu.edu.cn
CR Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Jensen RL, 2006, J NEURO-ONCOL, V78, P233, DOI 10.1007/s11060-005-9103-z
   Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Mizuno T, 2006, CANCER GENE THER, V13, P131, DOI 10.1038/sj.cgt.7700871
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153
   Reich S, 2003, MOL VIS, V9, P210
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Udono T, 2001, INVEST OPHTH VIS SCI, V42, P1080
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang YS, 2002, J OCUL PHARMACOL TH, V18, P377, DOI 10.1089/10807680260218542
   Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499
   Zhao SL, 2001, MOL VIS, V7, P277
NR 23
TC 49
Z9 54
U1 1
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2007
VL 221
IS 6
BP 411
EP 417
DI 10.1159/000107502
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 222PN
UT WOS:000250309500008
PM 17947829
DA 2022-11-30
ER

PT J
AU Cardinault, N
   Gorrand, JM
   Tyssandier, V
   Grolier, P
   Rock, E
   Borel, P
AF Cardinault, N
   Gorrand, JM
   Tyssandier, V
   Grolier, P
   Rock, E
   Borel, P
TI Short-term supplementation with lutein affects biomarkers of lutein
   status similarly in young and elderly subjects
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Article
DE age-related macular degeneration; xanthophyll; adipose tissue; buccal
   mucosa cells; macular pigment optical density
ID PIGMENT OPTICAL-DENSITY; BETA-CAROTENE; MACULAR PIGMENT; TISSUE
   CONCENTRATIONS; CATARACT-EXTRACTION; VITAMIN-A; ZEAXANTHIN; PLASMA;
   SERUM; VEGETABLES
AB There is evidence that lutein may protect against age-related macular degeneration, cataract, cancers and cardiovascular diseases, but no data have been published on the effect of age on lutein status. The purpose of this work was to determine whether there are major differences in the status of this carotenoid between young and elderly subjects. Initial lutein status and the effect of a 5-week lutein supplementation (9 mg/d) on the most common markers of lutein status were compared in 12 young (26.9 +/- 0.8 yr) and 17 older subjects (67.3 +/- 1.1 yr). Lutein was measured by HPLC in fasting serum, adipose tissue and buccal mucosa cells (BMC) before and after supplementation. Macular pigment optical density (MPOD), which partly depends on retina lutein concentration, was measured by reflectometry before and after supplementation. Initial lutein status was not significantly different between the two groups, irrespective of the lutein status marker. Plasma and BMC lutein concentrations significantly increased in both groups after lutein supplementation, but not MPOD or adipose tissue lutein. Plasma and BMC responses to lutein supplementation (percent variation from initial values) were not significantly different between the two groups. These results suggest that there is no major effect of age on lutein status in healthy subjects. (C) 2003 Elsevier Science Inc. All rights reserved.
C1 Fac Med, INSERM, U476, F-13385 Marseille 5, France.
   Fac Med, Lab Biophys Sensorielle, F-63001 Clermont Ferrand, France.
   INRA, Univ Maladies Metab & Micronutriments, F-63122 St Genes Champanelle, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Aix-Marseille Universite; Universite
   de Franche-Comte; Universite de Franche-Comte; INRAE
RP Borel, P (通讯作者)，Fac Med, INSERM, U476, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.
EM patrick.borel@medecine.univ-mrs.fr
RI Borel, Patrick/A-4057-2015
OI Borel, Patrick/0000-0001-9977-3238
CR Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Borel P, 1998, J LIPID RES, V39, P2250
   BOWEN PE, 1993, ANN NY ACAD SCI, V691, P241, DOI 10.1111/j.1749-6632.1993.tb26182.x
   Bradbury J, 2001, LANCET, V357, P2030, DOI 10.1016/S0140-6736(00)05162-X
   BRINDLEY GS, 1952, J PHYSIOL-LONDON, V116, P350, DOI 10.1113/jphysiol.1952.sp004709
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Castenmiller JJM, 1999, J NUTR, V129, P349, DOI 10.1093/jn/129.2.349
   Chan C, 1998, CURR EYE RES, V17, P890, DOI 10.1076/ceyr.17.9.890.5141
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Cooper DA, 2000, J NUTR, V130, P642, DOI 10.1093/jn/130.3.642
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   DIMITROV NV, 1988, AM J CLIN NUTR, V48, P298, DOI 10.1093/ajcn/48.2.298
   Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Granado F, 1998, BRIT J NUTR, V80, P445, DOI 10.1017/S0007114598001512
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   HENDRICH S, 1994, J NUTR, V124, pS1789, DOI 10.1093/jn/124.suppl_9.1789S
   Ikuma M, 1996, BBA-BIOMEMBRANES, V1280, P19, DOI 10.1016/0005-2736(95)00261-8
   JOHNSON EJ, 1995, AM J CLIN NUTR, V62, P598, DOI 10.1093/ajcn/62.3.598
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   KAPLAN LA, 1990, CLIN PHYSIOL BIOCH, V8, P1
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LEE MA, 1995, J HEPATOL, V23, P550, DOI 10.1016/0168-8278(95)80061-1
   Lin YM, 2000, AM J CLIN NUTR, V71, P1545
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lyan B, 2001, J CHROMATOGR B, V751, P297, DOI 10.1016/S0378-4347(00)00488-6
   Marangon K, 1998, AM J CLIN NUTR, V67, P231, DOI 10.1093/ajcn/67.2.231
   MATHEWSROTH MM, 1990, AM J CLIN NUTR, V52, P500, DOI 10.1093/ajcn/52.3.500
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203
   Schweigert FJ, 2000, INT J VITAM NUTR RES, V70, P79, DOI 10.1024/0300-9831.70.3.79
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Stahl W, 1998, FEBS LETT, V427, P305, DOI 10.1016/S0014-5793(98)00434-7
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Tyssandier V, 2002, INT J VITAM NUTR RES, V72, P300, DOI 10.1024/0300-9831.72.5.300
   Tyssandier V, 2002, AM J CLIN NUTR, V75, P526, DOI 10.1093/ajcn/75.3.526
   VELLAS B, 1991, Comprehensive Therapy, V17, P46
NR 45
TC 32
Z9 36
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD MAY
PY 2003
VL 38
IS 5
BP 573
EP 582
DI 10.1016/S0531-5565(03)00039-1
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 692CJ
UT WOS:000183642500013
PM 12742535
DA 2022-11-30
ER

PT J
AU Mayne, ST
AF Mayne, ST
TI Antioxidant nutrients and chronic disease: Use of biomarkers of exposure
   and oxidative stress status in epidemiologic research
SO JOURNAL OF NUTRITION
LA English
DT Article
DE antioxidants; biomarkers; diet assessment; epidemiology; nutrition;
   oxidation; oxidative stress
ID BETA-CAROTENE SUPPLEMENTATION; DNA-DAMAGE; ALPHA-TOCOPHEROL; MACULAR
   PIGMENT; VITAMIN-C; PLASMA CAROTENOIDS; LIPID-PEROXIDATION;
   ADIPOSE-TISSUE; IN-VIVO; GEOMETRICAL-ISOMERS
AB Oxidation of lipid, nucleic acids or protein has been suggested to be involved in the etiology of several chronic diseases including cancer, cardiovascular disease, cataract, age-related macular degeneration and aging in general. A large body of research has investigated the potential role of antioxidant nutrients in the prevention of these and other chronic diseases. This review concentrates on the following antioxidant nutrients: beta-carotene and other carotenoids, vitamin E, vitamin C and selenium. The first part of the review emphasizes the utility of biological markers of exposure for these nutrients and the relationship to dietary intake data. The second part considers functional assays of oxidative stress status in humans including the strengths and limitations of various assays available for use in epidemiologic research. A wide variety of functional assays both in vivo and ex vivo, are covered, including various measures of lipid oxidation (thiobarbituric acid reactive substances, exhaled pentane/ethane, low-density lipoprotein resistance to oxidation, isoprostanes), DNA oxidation (oxidized DNA bases such as 8-OHdG, autoantibodies to oxidized DNA, modified Comet assay) and protein oxidation (protein carbonyls). Studies that have examined the effects of antioxidant nutrients on these functional markers are included for illustrative purposes. The review concludes with a discussion of methodologic issues and challenges for studies involving biomarkers of exposure to antioxidant nutrients and of oxidative stress status.
C1 Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   Yale Canc Ctr, New Haven, CT 06520 USA.
C3 Yale University; Yale University
RP Mayne, ST (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 333 Cedar St, New Haven, CT 06520 USA.
EM Susan.Mayne@Yale.Edu
CR Alegria A, 1996, J TRACE ELEM MED BIO, V10, P223
   ALLARD JP, 1994, AM J CLIN NUTR, V59, P884, DOI 10.1093/ajcn/59.4.884
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Blanck HM, 2003, J NUTR, V133, p888S, DOI 10.1093/jn/133.3.888S
   Boileau T., 1999, ANTIOXIDANT STATUS D, P133
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Brady WE, 1996, J NUTR, V126, P129, DOI 10.1093/jn/126.1.129
   Buege J A, 1978, Methods Enzymol, V52, P302
   Cadet J, 1997, ENVIRON HEALTH PERSP, V105, P1034, DOI 10.2307/3433836
   CAMPBELL DR, 1994, CANCER EPIDEM BIOMAR, V3, P493
   CAO GH, 1993, FREE RADICAL BIO MED, V14, P303, DOI 10.1016/0891-5849(93)90027-R
   Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957
   Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823
   COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733
   CRAFT NE, 1992, METHOD ENZYMOL, V213, P185
   Dixon ZR, 1998, J AM COLL NUTR, V17, P54, DOI 10.1080/07315724.1998.10720455
   Drewnowski A, 1997, AM J CLIN NUTR, V65, P1796, DOI 10.1093/ajcn/65.6.1796
   Duthie SJ, 1996, CANCER RES, V56, P1291
   Ermakov IV, 2001, OPT LETT, V26, P202, DOI 10.1364/OL.26.000202
   Ford ES, 1999, AM J EPIDEMIOL, V150, P290, DOI 10.1093/oxfordjournals.aje.a010001
   FORMAN MR, 1993, AM J CLIN NUTR, V58, P519, DOI 10.1093/ajcn/58.4.519
   Frenkel K, 1998, CANCER EPIDEM BIOMAR, V7, P49
   Galle J., 1998, FREE RADICAL ANTIOXI, P119
   GARLAND D, 1990, EXP EYE RES, V50, P677, DOI 10.1016/0014-4835(90)90113-9
   Gartner C, 1997, AM J CLIN NUTR, V66, P116
   GAZIANO JM, 1995, ATHEROSCLEROSIS, V112, P187, DOI 10.1016/0021-9150(94)05414-E
   Gibson R.S., 1990, PRINCIPLES NUTR ASSE
   GOTTLIEB K, 1993, NUTR CANCER, V19, P207, DOI 10.1080/01635589309514251
   Haegele AD, 2000, CANCER EPIDEM BIOMAR, V9, P421
   Halliwell B, 1999, NUTR REV, V57, P104, DOI 10.1111/j.1753-4887.1999.tb06933.x
   HALLIWELL B, 1995, FREE RADICAL BIO MED, V18, P125, DOI 10.1016/0891-5849(95)91457-3
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANDELMAN GJ, 1994, AM J CLIN NUTR, V59, P1025, DOI 10.1093/ajcn/59.5.1025
   HANDELMAN GJ, 1999, ANTIOXIDANT STATUS, P37
   Hata TR, 2000, J INVEST DERMATOL, V115, P441, DOI 10.1046/j.1523-1747.2000.00060.x
   Hu JJ, 1999, CANCER EPIDEM BIOMAR, V8, P693
   Huang HE, 2000, CANCER EPIDEM BIOMAR, V9, P647
   *I MED NAT AC SCI, 2001, DIET REF INT VIT A V
   Institute of Medicine, 2000, NAT AC SCI FOOD NUTR
   Jenner A, 1998, BIOCHEM J, V331, P365, DOI 10.1042/bj3310365
   JIALAL I, 1995, CAN J CARDIOL, V11, pG97
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   KARDINAAL AFM, 1995, AM J EPIDEMIOL, V141, P440, DOI 10.1093/oxfordjournals.aje.a117446
   Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Knutson MD, 2000, FREE RADICAL BIO MED, V28, P514, DOI 10.1016/S0891-5849(99)00230-0
   Kohlmeier L, 1997, AM J EPIDEMIOL, V146, P618, DOI 10.1093/oxfordjournals.aje.a009327
   Lepage G, 1996, AM J CLIN NUTR, V64, P87, DOI 10.1093/ajcn/64.1.87
   Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   LOFT S, 1994, FASEB J, V8, P534, DOI 10.1096/fasebj.8.8.8181672
   LONGNECKER MP, 1993, AM J CLIN NUTR, V57, P408, DOI 10.1093/ajcn/57.3.408
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Marangon K, 1999, FREE RADICAL BIO MED, V27, P1114, DOI 10.1016/S0891-5849(99)00155-0
   Margolis SA, 1996, CLIN CHEM, V42, P1257
   MARTINI MC, 1995, CANCER EPIDEM BIOMAR, V4, P491
   McEligot AJ, 1999, J NUTR, V129, P2258, DOI 10.1093/jn/129.12.2258
   MICOZZI MS, 1992, AM J CLIN NUTR, V55, P1120, DOI 10.1093/ajcn/55.6.1120
   MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383
   Nierenberg D. W., 1989, NUTRITION CANCER PRE, P181
   PARKER RS, 1989, J NUTR, V119, P101, DOI 10.1093/jn/119.1.101
   PENG YM, 1995, NUTR CANCER, V23, P233, DOI 10.1080/01635589509514378
   PoolZobel BL, 1997, CARCINOGENESIS, V18, P1847, DOI 10.1093/carcin/18.9.1847
   Potischman N, 2003, J NUTR, V133, p873S, DOI 10.1093/jn/133.3.873S
   Poulsen HE, 1998, EUR J CANCER PREV, V7, P9
   Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19
   REZNICK AZ, 1992, BIOCHEM J, V286, P607, DOI 10.1042/bj2860607
   Roberts LJ, 1997, BBA-LIPID LIPID MET, V1345, P121, DOI 10.1016/S0005-2760(96)00162-2
   Rock CL, 1997, CANCER EPIDEM BIOMAR, V6, P617
   Santella RM, 1999, CANCER EPIDEM BIOMAR, V8, P733
   Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211
   Sies H., 1985, OXIDATIVE STRESS, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3
   Sodergren E, 2000, J NUTR, V130, P10
   Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310
   Stahl W, 1998, J NUTR, V128, P903, DOI 10.1093/jn/128.5.903
   STAHL W, 1992, J NUTR, V122, P2161, DOI 10.1093/jn/122.11.2161
   STAHL W, 1994, METHOD ENZYMOL, V234, P388
   Su LCJ, 1998, CANCER EPIDEM BIOMAR, V7, P1043
   TAYLOR A, 1993, J AM COLL NUTR, V12, P138
   *USDA, 1999, USDA NUTR DAT STAND
   WAYNER DDM, 1985, FEBS LETT, V187, P33, DOI 10.1016/0014-5793(85)81208-4
   Whiteman M, 1999, BIOCHEM BIOPH RES CO, V258, P168, DOI 10.1006/bbrc.1999.0564
   WINKLHOFER-ROOB BM, 1995, FREE RADICAL BIO MED, V18, P849, DOI 10.1016/0891-5849(94)00203-V
   Winterbourn CC, 1999, METHOD ENZYMOL, V300, P106
   WITT EH, 1992, J NUTR, V122, P766, DOI 10.1093/jn/122.suppl_3.766
   WONG SHY, 1987, CLIN CHEM, V33, P214
   Yeum KJ, 1998, J NUTR, V128, P1920, DOI 10.1093/jn/128.11.1920
NR 87
TC 382
Z9 407
U1 0
U2 37
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD MAR
PY 2003
VL 133
IS 3
SU S
BP 933S
EP 940S
DI 10.1093/jn/133.3.933S
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 655GQ
UT WOS:000181543300008
PM 12612179
OA Bronze
DA 2022-11-30
ER

PT J
AU Xu, XY
   Freund, KB
AF Xu, Xiaoyu
   Freund, K. Bailey
TI Multimodal Imaging of Laser-Induced Retinal- Choroidal Anastomosis
   Masquerading as Type 3 Macular Neovascularization
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID CHORIORETINAL VENOUS ANASTOMOSIS; ANGIOMATOUS PROLIFERATION; EDEMA;
   VEIN; PHOTOCOAGULATION; GUIDELINES
AB The use of laser to induce a retinal-choroidal anastomosis (RCA) through photomechanical and photothermal rupture of the retinal pigment epithelium/Bruch's membrane beneath a retinal vein has been performed in eyes with retinal vein occlusion to create an alternate pathway for retinal venous outflow. The authors document the multimodal imaging findings of a 64-year-old female with type 2 diabetes presenting with a parafoveal vascular lesion simulating type 3 macular neovascularization. A review of the medical history and the benign course of the lesion suggested its inadvertent origin from prior focal/grid laser to treat diabetic macular edema.
C1 [Xu, Xiaoyu] Vitreous Retina Macula Consultants New York, 950 Third Ave,3rd Floor, New York, NY 10022 USA.
   [Xu, Xiaoyu; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Xu, Xiaoyu] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Freund, K. Bailey] New York Univ Med, Dept Ophthalmol, New York, NY USA.
   [Freund, K. Bailey] Columbia Univ, Edward S Harkness Eye Inst, Med Ctr, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Sun Yat Sen University; New York University; Columbia
   University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 950 Third Ave,3rd Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU National Natural Science Foundation of China [81800879]; Natural Science
   Foundation of Guangdong Province [2017A030310372]; Fundamental Research
   Funds of the State Key Laboratory of Ophthalmology, China [2018KF04,
   2017QN05]; Macula Foundation; Genentech/Roche
FX Dr. Xu received grants from the National Natural Science Foundation of
   China (81800879); Natural Science Foundation of Guangdong Province
   (2017A030310372); and Fundamental Research Funds of the State Key
   Laboratory of Ophthalmology, China (2018KF04 & 2017QN05). Dr. Freund is
   a consultant for Optovue, Heidelberg Engineering, Zeiss, Allergan,
   Bayer, Genetech, and Novartis and receives research support from The
   Macula Foundation and Genentech/Roche.
CR ARCHER DB, 1983, AUST J OPHTHALMOL, V11, P251
   Blindbaek SL, 2019, ACTA OPHTHALMOL, V97, P339, DOI 10.1111/aos.13997
   DOFT BH, 1983, ARCH OPHTHALMOL-CHIC, V101, P1053
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2018, AM J OPHTHALMOL, V190, P78, DOI 10.1016/j.ajo.2018.03.029
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Kim JH, 2018, SEMIN OPHTHALMOL, V33, P820, DOI 10.1080/08820538.2018.1511814
   Li JQ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1425707
   Luttrull JK, 2012, CURR DIABETES REV, V8, P274, DOI 10.2174/157339912800840523
   McAllister IL, 2013, OSLI RETINA, V44, P268, DOI 10.3928/23258160-20130503-10
   MCALLISTER IL, 1995, ARCH OPHTHALMOL-CHIC, V113, P456, DOI 10.1001/archopht.1995.01100040072030
   McAllister IL, 1998, GRAEF ARCH CLIN EXP, V236, P174, DOI 10.1007/s004170050060
   MCALLISTER IL, 1992, BRIT J OPHTHALMOL, V76, P615, DOI 10.1136/bjo.76.10.615
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Schmidt-Erfurth U, 2017, OPHTHALMOLOGICA, V237, P185, DOI 10.1159/000458539
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SLUSHER MM, 1980, AM J OPHTHALMOL, V90, P217, DOI 10.1016/S0002-9394(14)74856-1
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P1920, DOI 10.1097/IAE.0000000000002289
   TABBARA KF, 1990, EYE, V4, P366, DOI 10.1038/eye.1990.49
   Vujosevic S, 2015, RETINA-J RET VIT DIS, V35, P1594, DOI 10.1097/IAE.0000000000000521
   Yadav NK, 2014, INDIAN J OPHTHALMOL, V62, P50, DOI 10.4103/0301-4738.126179
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 24
TC 0
Z9 0
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2020
VL 51
IS 4
BP 244
EP 248
DI 10.3928/23258160-20200326-07
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA LK7IF
UT WOS:000531035100007
PM 32348542
DA 2022-11-30
ER

PT J
AU Lan, L
   Wang, SY
   Duan, SH
   Zhou, XY
   Li, YF
AF Lan, Lin
   Wang, Shengyu
   Duan, Shuhua
   Zhou, Xiangyu
   Li, Yufeng
TI Cordyceps militaris Carotenoids Protect Human Retinal Endothelial Cells
   against the Oxidative Injury and Apoptosis Resulting from H2O2
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID MACULAR DEGENERATION; STRESS; POLYSACCHARIDE; DAMAGE; DEATH; RPE
AB Vision loss is primarily caused by age-related macular degeneration (AMD) due to oxidative retinal pigment epithelial (RPE) cell injury. Carotenoid utilization is deemed a possible strategy for treating AMD. Cordyceps militaris has advantages like immunomodulatory, anti-inflammatory, and antioxidative characteristics. This paper assessed the possible protective influence of carotenoids obtained by isolating and purifying the Cordyceps militaris (CMCT) into human RPE cells (ARPE-19) damaged by hydrogen peroxide (H2O2). The findings demonstrated that CMCT safeguarded the ARPE-19 cells against the damage and apoptosis caused by H2O2 and oxidative stress via Bcl-2 protein upregulation, as well as the expression of Bax and cleaved caspase-3 protein. In addition, CMCT treatment increased cell survival and restricted the generation of H2O2-induced reactive oxygen species (ROS) and the protein expression of NADPH oxidase-1 (NOX1). Additionally, the CMCT treatment of H2O2-induced ARPE-19 cells ameliorated high malondialdehyde (MDA) levels in oxidative stress-induced cells. The catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH) returned to standard levels, which were governed by the higher expression of nuclear Nrf2 protein in the ARPE-19 cells. Moreover, this study showed that CMCT safeguarded the ARPE-19 cells against the damage caused by oxidative stress via its antioxidant activity and antiapoptotic functionality, suggesting the potential therapeutic role of CMCT in AMD prevention and mitigation.
C1 [Lan, Lin; Wang, Shengyu; Duan, Shuhua; Zhou, Xiangyu; Li, Yufeng] Xihua Univ, Coll Food & Biol Engn, Mol Biol Lab, Chengdu, Sichuan, Peoples R China.
C3 Xihua University
RP Li, YF (通讯作者)，Xihua Univ, Coll Food & Biol Engn, Mol Biol Lab, Chengdu, Sichuan, Peoples R China.
EM sktoronca@126.com; wsy19950214@163.com; dsh180624@163.com;
   flytotheskyall@163.com; yufeng_li19651123@163.com
CR ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bi SX, 2020, INT J BIOL MACROMOL, V150, P261, DOI 10.1016/j.ijbiomac.2020.02.050
   Bijttebier S, 2014, J CHROMATOGR A, V1332, P46, DOI 10.1016/j.chroma.2014.01.042
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Bosch-Morell F, 2020, NEURAL REGEN RES, V15, P2207, DOI 10.4103/1673-5374.284978
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32
   Chao HM, 2008, HUM EXP TOXICOL, V27, P327, DOI 10.1177/0960327108092294
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Ferino A, 2020, J PHOTOCH PHOTOBIO B, V202, DOI [10.1016/j.photobiol.2019.111672, 10.1016/j.jphotobiol.2019.111672]
   Gong XM, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040100
   He BL, 2020, INT J BIOL MACROMOL, V145, P11, DOI 10.1016/j.ijbiomac.2019.12.115
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Hwang JW, 2012, J AGR FOOD CHEM, V60, P4282, DOI 10.1021/jf205321j
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Ke YF, 2020, J CELL BIOCHEM, V121, P4849, DOI 10.1002/jcb.29713
   Kong JM, 2003, PHYTOCHEMISTRY, V64, P923, DOI 10.1016/S0031-9422(03)00438-2
   Leung HH, 2020, NEUROCHEM RES, V45, P1007, DOI 10.1007/s11064-020-02994-4
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Muangnoi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133367
   Musa Y, 2019, INT J OPHTHALMOL-CHI, V12, P930, DOI 10.18240/ijo.2019.06.08
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105
   Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1408, DOI 10.1111/j.1751-1097.2012.01228.x
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Simpson DSA, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080743
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Wang LY, 2008, J IMMUNOL, V180, P3072, DOI 10.4049/jimmunol.180.5.3072
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xue DF, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110676
   Yang B, 2013, EXPERT OPIN THER TAR, V17, P255, DOI 10.1517/14728222.2013.745513
   Yu HM, 2006, J AGR FOOD CHEM, V54, P3132, DOI 10.1021/JF053111w
   Zheng QW, 2019, INT J MED MUSHROOMS, V21, P47, DOI [10.1615/IntJMedMushrooms.2018029002, 10.1615/intjmedmushrooms.2018029002]
NR 42
TC 0
Z9 0
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD SEP 30
PY 2022
VL 2022
AR 1259093
DI 10.1155/2022/1259093
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 5I4JG
UT WOS:000868324400017
PM 36212977
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Huang, YY
   Lo, WJ
   Chang, HY
   Chou, YB
   Lin, TC
AF Huang, Ya-Yun
   Lo, Wen-Jung
   Chang, Hsin-Yi
   Chou, Yu-Bai
   Lin, Tai-Chi
TI Three-Year Outcomes of Intravitreal Aflibercept Injections for Retinal
   Angiomatous Proliferation According to Disease Stage
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Aflibercept; Neovascular age-related macular degeneration; Retinal
   angiomatous proliferation
ID MACULAR DEGENERATION; NEOVASCULARIZATION; BEVACIZUMAB; RANIBIZUMAB; EYES
AB Introduction To evaluate the outcomes of intravitreal aflibercept injections for retinal angiomatous proliferation (RAP) according to disease stage. Methods This retrospective chart review included 68 eyes of 53 individuals diagnosed as having RAP and 109 neovascular age-related macular degeneration (nAMD) eyes of 109 patients as controls. All patients received intravitreal injections of aflibercept in a real-world setting. The main outcome measures were the changes in the mean of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) as well as the total number of injections received during the 3-year follow-up period. Results The average BCVA and CRT changes in eyes affected by RAP and the controls at 3 years were non-significant. Both populations received a similar number of injections. After 3 years of treatment, patients with RAP had visual decline despite stable anatomical outcomes. Approximately 50% of the eyes with stage II RAP exhibited significant BCVA decline at the end of the third year. Among those eyes that had deteriorated BCVA, persistently worsening BCVA and thinning CRT were observed from year 2 to year 3. Conclusion Similar to treating nAMD, intensive injections or aggressive treatment strategies are required to treat RAP to achieve optimal visual outcomes in a real-world setting. The response to aflibercept treatment at the second year is associated with the final visual outcome of eyes with stage II RAP lesions.
C1 [Huang, Ya-Yun] Taipei Vet Gen Hosp, Dept Med Educ & Res, Taipei, Taiwan.
   [Huang, Ya-Yun; Lo, Wen-Jung; Chou, Yu-Bai; Lin, Tai-Chi] Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sec 2,Shih Pai Rd, Taipei, Taiwan.
   [Chou, Yu-Bai; Lin, Tai-Chi] Natl Yang Ming Chiao Tung Univ, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
   [Chang, Hsin-Yi] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University; Shin Kong Wu Ho Su Memorial
   Hospital
RP Lin, TC (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, 201,Sec 2,Shih Pai Rd, Taipei, Taiwan.
EM tclin6@vghtpe.gov.tw
FU Taipei Veterans General Hospital [V111C-150]
FX This study and the journal's Rapid Service Fee were supported by Taipei
   Veterans General Hospital (V111C-150).
CR Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Browning AC, 2019, OPHTHALMOLOGICA, V242, P239, DOI 10.1159/000500203
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Hufendiek Katerina, 2012, International Ophthalmology, V32, P259, DOI 10.1007/s10792-012-9562-0
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Invernizzi A, 2019, BRIT J OPHTHALMOL, V103, P1337, DOI 10.1136/bjophthalmol-2018-312944
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Johnson TM, 2006, RETINA-J RET VIT DIS, V26, P765, DOI 10.1097/01.iae.0000244264.98642.af
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lo KJ, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4538135
   Maier M, 2013, OPHTHALMOLOGE, V110, P1171, DOI 10.1007/s00347-012-2732-7
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Montero JA, 2009, EUR J OPHTHALMOL, V19, P448, DOI 10.1177/112067210901900320
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Park YG, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0172-2
   Parodi MB, 2013, ACTA OPHTHALMOL, V91, P267, DOI 10.1111/j.1755-3768.2011.02265.x
   Rezar-Dreindl S, 2021, RETINA-J RET VIT DIS, V41, P103, DOI 10.1097/IAE.0000000000002786
   Sakimoto S, 2005, AM J OPHTHALMOL, V139, P917, DOI 10.1016/j.ajo.2004.10.046
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Shin JY, 2014, RETINA-J RET VIT DIS, V34, P2359, DOI 10.1097/IAE.0000000000000225
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 31
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD AUG
PY 2022
VL 11
IS 4
BP 1503
EP 1516
DI 10.1007/s40123-022-00521-y
EA MAY 2022
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2Q9SM
UT WOS:000799521200001
PM 35596037
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lauwen, S
   Baerenfaenger, M
   Ruigrok, S
   De Jong, EK
   Wessels, HJCT
   Den Hollander, AI
   Lefeber, DJ
AF Lauwen, Susette
   Baerenfaenger, Melissa
   Ruigrok, Sanne
   de Jong, Eiko K.
   Wessels, Hans J. C. T.
   den Hollander, Anneke, I
   Lefeber, Dirk J.
TI Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1
   without impairing secretion in retinal pigment epithelial cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Functional effect of GWAS hits;
   Glycosylation of thrombospondin type 1; domains; CRISPR-Cas9 in RPE
   cells; Glycopeptide analysis; Protein secretion
ID PETERS-PLUS SYNDROME; MACULAR DEGENERATION; C-MANNOSYLATION; CONGENITAL
   DISORDER; O-FUCOSYLATION; WEB TOOL; THROMBOSPONDIN-1;
   MANNOSYLTRANSFERASE; ANGIOGENESIS; INTEGRATION
AB Age-related macular degeneration (AMD) has been associated with protective genetic variants in the beta 1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies. B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose beta 1-3 fucose and C-linked mannose glycosylation motifs. B3GLCT-mediated modification is required for proper secretion of TSR-containing proteins. We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells. We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD. Glycopeptide analysis confirmed the presence of the glucose-beta 1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells. C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells. Secretion of TSP1 was not affected by the absence of B3GLCT, even not when TSP1 was upregulated by TNF alpha treatment or when TSP1 was overexpressed in HEK293T cells. Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
C1 [Lauwen, Susette; Ruigrok, Sanne; de Jong, Eiko K.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
   [Baerenfaenger, Melissa; Lefeber, Dirk J.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Med Ctr, Geert Grootepl Zuid 10, NL-6525 GA Nijmegen, Netherlands.
   [Wessels, Hans J. C. T.; Lefeber, Dirk J.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Translat Metab Lab, Med Ctr, Geert Grootepl Zuid 10, NL-6525 GA Nijmegen, Netherlands.
   [den Hollander, Anneke, I] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Human Genet, Med Ctr, Geert Grootepl Zuid 10, NL-6525 GA Nijmegen, Netherlands.
C3 Philips; Radboud University Nijmegen; Radboud University Nijmegen;
   Radboud University Nijmegen; Radboud University Nijmegen
RP Lefeber, DJ (通讯作者)，Radboud Univ Nijmegen, Dept Neurol, Med Ctr, Geert Grootepl Zuid 10, NL-6525 GA Nijmegen, Netherlands.; Den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, 409,Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM susette_lauwen@hotmail.com; melissa.barenfanger@radboudumc.nl;
   sanne_ruigrok@hotmail.com; eikodejong@gmail.com;
   hans.wessels@radboudumc.nl; anneke.denhollander@radboudumc.nl;
   dirk.lefeber@radboudumc.nl
OI Baerenfaenger, Melissa/0000-0002-2855-924X; Ruigrok, Lisa Anna
   Catelijne/0000-0003-3657-5773
FU Radboudumc through Donders Institute for Brain, Cognition and Behaviour
   (Radboudumc-DCN junior researcher round 2017); NWO ZonMw medium
   investment grant [9118025]
FX This study received financial support from the Radboudumc through a
   junior researcher grant awarded by the Donders Institute for Brain,
   Cognition and Behaviour (Radboudumc-DCN junior researcher round 2017)
   and was supported by the NWO ZonMw medium investment grant number
   9118025.
CR Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Blatt AZ, 2016, IMMUNOL REV, V274, P172, DOI 10.1111/imr.12466
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Buettner FFR, 2013, MOL CELL, V50, P295, DOI 10.1016/j.molcel.2013.03.003
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200
   Du JG, 2010, DEV BIOL, V346, P25, DOI 10.1016/j.ydbio.2010.07.008
   Dubail J, 2016, SCI REP-UK, V6, DOI 10.1038/srep33974
   DUNN KC, 1995, INVEST OPHTH VIS SCI, V36, pS766
   Farnoodian M, 2018, J OPHTHAL VIS RES, V13, P470, DOI 10.4103/jovr.jovr_67_18
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59
   Guo NH, 1997, CANCER RES, V57, P1735
   Haltiwanger RS., 2015, ESSENTIALS GLYCOBIOL, P151
   Heinonen TYK, 2009, ANN MED, V41, P2, DOI 10.1080/07853890802301975
   Hess D, 2008, J BIOL CHEM, V283, P7354, DOI 10.1074/jbc.M710251200
   Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200
   Housset M, 2015, J OCUL PHARMACOL TH, V31, P406, DOI 10.1089/jop.2015.0023
   Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423
   Kazerounian S, 2018, J CELL COMMUN SIGNAL, V12, P171, DOI 10.1007/s12079-017-0433-3
   Kondo N, 2009, AGING-US, V1, P266, DOI 10.18632/aging.100006
   Labun K, 2019, NUCLEIC ACIDS RES, V47, pW171, DOI 10.1093/nar/gkz365
   Labun K, 2016, NUCLEIC ACIDS RES, V44, pW272, DOI 10.1093/nar/gkw398
   Li J, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2019.111811
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200
   MARMOR M F, 1975, International Ophthalmology Clinics, V15, P115, DOI 10.1097/00004397-197501510-00010
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Montague TG, 2014, NUCLEIC ACIDS RES, V42, pW401, DOI 10.1093/nar/gku410
   Niwa Y, 2016, MOL BIOL CELL, V27, P744, DOI 10.1091/mbc.E15-06-0373
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Resovi A, 2014, MATRIX BIOL, V37, P83, DOI 10.1016/j.matbio.2014.01.012
   Shcherbakova A, 2019, ELIFE, V8, DOI 10.7554/eLife.52978
   Shcherbakova A, 2017, P NATL ACAD SCI USA, V114, P2574, DOI 10.1073/pnas.1613165114
   Sid B, 2004, CRIT REV ONCOL HEMAT, V49, P245, DOI 10.1016/j.critrevonc.2003.09.009
   Stepanenko AA, 2015, GENE, V569, P182, DOI 10.1016/j.gene.2015.05.065
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Vasudevan D, 2015, CURR BIOL, V25, P286, DOI 10.1016/j.cub.2014.11.049
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang AO, 2020, J BIOL CHEM, V295, P15742, DOI 10.1074/jbc.RA120.014557
   Zhang KJ, 2020, INT J MOL MED, V45, P1275, DOI 10.3892/ijmm.2020.4507
NR 46
TC 1
Z9 1
U1 3
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2021
VL 213
AR 108798
DI 10.1016/j.exer.2021.108798
EA NOV 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW7YB
UT WOS:000718125900001
PM 34695439
OA hybrid
DA 2022-11-30
ER

PT J
AU Hu, ML
   Ayton, LN
   Jolly, JK
AF Hu, Monica L.
   Ayton, Lauren N.
   Jolly, Jasleen K.
TI The Clinical Use of Vernier Acuity: Resolution of the Visual Cortex Is
   More Than Meets the Eye
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE vernier acuity; hyperacuity; positional acuity; alignment acuity;
   vernier alignment; vision; visual function
ID PREFERENTIAL HYPERACUITY PERIMETRY; VEP VERNIER; MACULAR DEGENERATION;
   GRATING ACUITY; CHOROIDAL NEOVASCULARIZATION; CORTICAL MAGNIFICATION;
   AMBLYOPIA; AGE; ORIENTATION; ACCURACY
AB Vernier acuity measures the ability to detect a misalignment or positional offset between visual stimuli, for example between two vertical lines when reading a vernier scale. It is considered a form of visual hyperacuity due to its detectable thresholds being considerably smaller than the diameter of a foveal cone receptor, which limits the spatial resolution of classical visual acuity. Vernier acuity relies heavily on cortical processing and is minimally affected by optical media factors, making it a useful indicator of cortical visual function. Vernier acuity can be measured, usually in seconds of arc, by freely available automated online tools as well as via analysis of steady state visual-evoked potentials, which allows measurement in non- or pre-verbal subjects such as infants. Although not routinely measured in clinical practice, vernier acuity is known to be reduced in amblyopia, glaucoma and retinitis pigmentosa, and has been explored as a measure of retinal or neural visual function in the presence of optical media opacities. Current clinical utility includes a home-based vernier acuity tool, preferential hyperacuity perimetry, which is used for screening for choroidal neovascularisation in age-related macular degeneration. This review will discuss the measurement of vernier acuity, provide a current understanding of its neuro-ophthalmic mechanisms, and finally explore its utility through a clinical lens, along with our recommendations for best practice.
C1 [Hu, Monica L.; Ayton, Lauren N.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Ayton, Lauren N.] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic, Australia.
   [Jolly, Jasleen K.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England.
   [Jolly, Jasleen K.] Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Oxford; Oxford University
   Hospitals NHS Foundation Trust
RP Jolly, JK (通讯作者)，Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England.; Jolly, JK (通讯作者)，Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England.
EM enquiries@eye.ox.ac.uk
FU College of Optometrists Clinical Research Fellowship; NHMRC Next
   Generation Clinical Researcher Fellowship (MRF) [1151055]; University of
   Melbourne Driving Research Momentum Fellowship
FX JJ was funded by the College of Optometrists Clinical Research
   Fellowship. LA was funded by a NHMRC Next Generation Clinical Researcher
   Fellowship (MRF#1151055) and University of Melbourne Driving Research
   Momentum Fellowship. CERA receives Operational Infrastructure Support
   from the Victorian Government.
CR Abbud CMM, 2002, BRAZ J MED BIOL RES, V35, P223, DOI 10.1590/S0100-879X2002000200011
   ALEXANDER KR, 1992, INVEST OPHTH VIS SCI, V33, P3400
   Almoqbel F, 2008, OPHTHAL PHYSL OPT, V28, P393, DOI 10.1111/j.1475-1313.2008.00591.x
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Andersen EE, 1923, AM J PHYSIOL, V64, P561, DOI 10.1152/ajplegacy.1923.64.3.561
   Anderson C, 2009, RETINA-J RET VIT DIS, V29, P1188, DOI 10.1097/IAE.0b013e3181a3b8d4
   Averill HL, 1925, J COMP PSYCHOL, V5, P147, DOI 10.1037/h0072373
   BANTON T, 1991, J OPT SOC AM A, V8, P673, DOI 10.1364/JOSAA.8.000673
   Barzegaran E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72370-3
   Chen JS, 2016, OSLI RETINA, V47, P708, DOI 10.3928/23258160-20160808-03
   Chen SI, 2005, INVEST OPHTH VIS SCI, V46, P4563, DOI 10.1167/iovs.05-0792
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Duncan RO, 2003, NEURON, V38, P659, DOI 10.1016/S0896-6273(03)00265-4
   Enoch J.M., 1985, PROGR RETINAL RES, V4, P67, DOI [10.1016/0278-4327(85)90005-7, DOI 10.1016/0278-4327(85)90005-7]
   ENOCH JM, 1984, ARCH OPHTHALMOL-CHIC, V102, P1164, DOI 10.1001/archopht.1984.01040030942019
   ENOCH JM, 1984, DOC OPHTHALMOL, V58, P71, DOI 10.1007/BF00140901
   ESSOCK EA, 1984, INVEST OPHTH VIS SCI, V25, P1043
   ESSOCK EA, 1985, DOC OPHTHALMOL, V60, P293, DOI 10.1007/BF00157828
   Everett J, 1999, PERCEPTION, V28, P243, DOI 10.1068/p2743
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Fahle M, 1998, PERCEPT PSYCHOPHYS, V60, P405, DOI 10.3758/BF03206863
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Freundlieb PH, 2020, GRAEF ARCH CLIN EXP, V258, P129, DOI 10.1007/s00417-019-04505-w
   Garcia-Suarez L, 2004, VISION RES, V44, P1039, DOI 10.1016/j.visres.2003.11.018
   Hering E., 1899, BER MATH PHYS CLASSE, V20, P16
   HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030
   Hou C, 2007, INVEST OPHTH VIS SCI, V48, P4070, DOI 10.1167/iovs.06-1368
   Hou C, 2018, INVEST OPHTH VIS SCI, V59, P1435, DOI 10.1167/iovs.17-23021
   Hou C, 2017, J VISION, V17, DOI 10.1167/17.6.2
   Jolly JK, 2019, OPTOMETRY VISION SCI, V96, P443, DOI 10.1097/OPX.0000000000001380
   Jones PR, 2021, AM J OPHTHALMOL, V223, P42, DOI 10.1016/j.ajo.2020.08.039
   Keri S, 2004, NEUROPSYCHOLOGY, V18, P537, DOI 10.1037/0894-4105.18.3.537
   Keri S, 2007, PROG NEURO-PSYCHOPH, V31, P86, DOI 10.1016/j.pnpbp.2006.07.001
   Kim E, 2000, OPTOMETRY VISION SCI, V77, P492, DOI 10.1097/00006324-200009000-00010
   Kim M, 2014, INDIAN J OPHTHALMOL, V62, P702, DOI 10.4103/0301-4738.121132
   LAKSHMINARAYANAN V, 1992, OPTOMETRY VISION SCI, V69, P423, DOI 10.1097/00006324-199206000-00002
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Latham K, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-4
   LEVI DM, 1985, VISION RES, V25, P963, DOI 10.1016/0042-6989(85)90207-X
   Levi DM, 1997, INVEST OPHTH VIS SCI, V38, P1493
   LEVI DM, 1982, NATURE, V298, P268, DOI 10.1038/298268a0
   Levi DM, 2000, VISION RES, V40, P973, DOI 10.1016/S0042-6989(99)00225-4
   Li RW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00300
   Li RW, 2008, J NEUROSCI, V28, P14223, DOI 10.1523/JNEUROSCI.4271-08.2008
   Li RWH, 2000, VISION RES, V40, P3775, DOI 10.1016/S0042-6989(00)00212-1
   Li RWH, 2001, INVEST OPHTH VIS SCI, V42, P1119
   Little JA, 2009, INVEST OPHTH VIS SCI, V50, P567, DOI 10.1167/iovs.08-2250
   LUDVIGH E, 1967, AM J OPHTHALMOL, V64, P261, DOI 10.1016/0002-9394(67)92520-2
   MANNY RE, 1984, CURR EYE RES, V3, P453, DOI 10.3109/02713688408997233
   MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P258, DOI 10.3758/BF03206097
   McKendrick AM, 2006, INVEST OPHTH VIS SCI, V47, P3213, DOI 10.1167/iovs.05-1549
   McKendrick AM, 2002, INVEST OPHTH VIS SCI, V43, P1393
   Meier K, 2017, INVEST OPHTH VIS SCI, V58, P1779, DOI 10.1167/iovs.16-20964
   MUSSAP AJ, 1995, J OPT SOC AM A, V12, P225, DOI 10.1364/JOSAA.12.000225
   Norcia AM, 1999, VISUAL NEUROSCI, V16, P1123, DOI 10.1017/S0952523899166124
   ODOM JV, 1989, INVEST OPHTH VIS SCI, V30, P1004
   Piltz J R, 1993, J Glaucoma, V2, P87
   Querques G, 2011, BRIT J OPHTHALMOL, V95, P986, DOI 10.1136/bjo.2010.190942
   SAARINEN J, 1995, VISION RES, V35, P2449, DOI 10.1016/0042-6989(95)00001-G
   Schmid MK, 2018, OPEN OPHTHALMOL J, V12, P19, DOI 10.2174/1874364101812010019
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   SHIMOJO S, 1984, VISION RES, V24, P721, DOI 10.1016/0042-6989(84)90213-X
   Skoczenski AM, 1999, INVEST OPHTH VIS SCI, V40, P2411
   Skoczenski AM, 2004, DEV MED CHILD NEUROL, V46, P526, DOI 10.1017/S001216220400088X
   Skottun BC, 2010, BRAIN COGNITION, V72, P165, DOI 10.1016/j.bandc.2009.07.001
   Strasburger H, 2018, I-PERCEPTION, V9, DOI [10.1177/2041669518765850, 10.1177/2041669518763675]
   Sun H, 2012, VISION RES, V56, P28, DOI 10.1016/j.visres.2012.01.007
   SWINDALE NV, 1986, NATURE, V319, P591, DOI 10.1038/319591a0
   Tan YF, 2018, NEUROSCI BULL, V34, P517, DOI 10.1007/s12264-018-0220-z
   Vesker M, 2013, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00617
   VIRSU V, 1987, J OPT SOC AM A, V4, P1568, DOI 10.1364/JOSAA.4.001568
   VOGELS R, 1990, J NEUROSCI, V10, P3543
   Ward E, 2021, EYE, V35, P592, DOI 10.1038/s41433-020-0910-4
   Watson T, 2009, OPTOMETRY VISION SCI, V86, P774, DOI 10.1097/OPX.0b013e3181a59d2a
   WAUGH SJ, 1993, VISION RES, V33, P539, DOI 10.1016/0042-6989(93)90257-W
   WAUGH SJ, 1993, VISION RES, V33, P527, DOI 10.1016/0042-6989(93)90256-V
   WEHRHAHN C, 1990, EXP BRAIN RES, V80, P618
   WESTHEIMER G, 1975, VISION RES, V15, P1137, DOI 10.1016/0042-6989(75)90012-7
   WESTHEIMER G, 1975, J OPT SOC AM, V65, P847, DOI 10.1364/JOSA.65.000847
   WESTHEIMER G, 1977, VISION RES, V17, P941, DOI 10.1016/0042-6989(77)90069-4
   WESTHEIMER G, 1975, INVEST OPHTH VISUAL, V14, P570
   WESTHEIMER G, 1987, AM J OPTOM PHYS OPT, V64, P567
   WESTHEIMER G, 1982, VISION RES, V22, P1349, DOI 10.1016/0042-6989(82)90224-3
   WESTHEIMER G, 1977, VISION RES, V17, P89, DOI 10.1016/0042-6989(77)90206-1
   Westheimer G., 1981, PROGR SENSORY PHYSL, P1, DOI DOI 10.1007/978-3-642-66744-2
   Westheimer G, 2018, I-PERCEPTION, V9, DOI 10.1177/2041669518815921
   Westheimer G, 2012, PROG RETIN EYE RES, V31, P467, DOI 10.1016/j.preteyeres.2012.05.001
   WHITAKER D, 1992, OPHTHAL PHYSL OPT, V12, P29, DOI 10.1111/j.1475-1313.1992.tb00250.x
   WILLIAMS RA, 1984, INVEST OPHTH VIS SCI, V25, P389
   WILSON HR, 1991, VISION RES, V31, P967, DOI 10.1016/0042-6989(91)90204-I
   Wong AMF, 2012, CAN J OPHTHALMOL, V47, P399, DOI 10.1016/j.jcjo.2012.05.002
   Yusuf IH, 2021, EYE, V35, P1532, DOI 10.1038/s41433-020-01380-2
   ZANKER J, 1992, VISION RES, V32, P1557, DOI 10.1016/0042-6989(92)90211-Z
NR 93
TC 0
Z9 0
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD OCT 5
PY 2021
VL 15
AR 714843
DI 10.3389/fnins.2021.714843
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA WI2PB
UT WOS:000708207600001
PM 34675763
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Skeie, JM
   Nishimura, DY
   Wang, CL
   Schmidt, GA
   Aldrich, BT
   Greiner, MA
AF Skeie, Jessica M.
   Nishimura, Darryl Y.
   Wang, Cheryl L.
   Schmidt, Gregory A.
   Aldrich, Benjamin T.
   Greiner, Mark A.
TI Mitophagy: An Emerging Target in Ocular Pathology
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Review
DE disease; mitochondria; mitophagy; dynamics
ID RETINAL GANGLION-CELLS; OPEN-ANGLE GLAUCOMA; ENDOTHELIAL
   CORNEAL-DYSTROPHY; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; OPTIC
   ATROPHY; MOLECULAR-GENETICS; INSULIN-RESISTANCE; MOUSE MODEL; RPE CELLS
AB Mitochondrial function is essential for the viability of aerobic eukaryotic cells, as mitochondria provide energy through the generation of adenosine triphosphate (ATP), regulate cellular metabolism, provide redox balancing, participate in immune signaling, and can initiate apoptosis. Mitochondria are dynamic organelles that participate in a cyclical and ongoing process of regeneration and autophagy (clearance), termed mitophagy specifically for mitochondrial (macro)autophagy. An imbalance in mitochondrial function toward mitochondrial dysfunction can be catastrophic for cells and has been characterized in several common ophthalmic diseases. In this article, we review mitochondrial homeostasis in detail, focusing on the balance of mitochondrial dynamics including the processes of fission and fusion, and provide a description of the mechanisms involved in mitophagy. Furthermore, this article reviews investigations of ocular diseases with impaired mitophagy, including Fuchs endothelial corneal dystrophy, primary open-angle glaucoma, diabetic retinopathy, and age-related macular degeneration, as well as several primary mitochondrial diseases with ocular phenotypes that display impaired mitophagy, including mitochondrial encephalopathy lactic acidosis stroke, Leber hereditary optic neuropathy, and chronic progressive external ophthalmoplegia. The results of various studies using cell culture, animal, and human tissue models are presented and reflect a growing awareness of mitophagy impairment as an important feature of ophthalmic disease pathology. As this review indicates, it is imperative that mitophagy be investigated as a targetable mechanism in developing therapies for ocular diseases characterized by oxidative stress and mitochondrial dysfunction.
C1 [Skeie, Jessica M.; Nishimura, Darryl Y.; Wang, Cheryl L.; Aldrich, Benjamin T.; Greiner, Mark A.] Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Coll Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.
   [Skeie, Jessica M.; Nishimura, Darryl Y.; Schmidt, Gregory A.; Aldrich, Benjamin T.; Greiner, Mark A.] Iowa Lions Eye Bank, Coralville, IA USA.
C3 University of Iowa
RP Greiner, MA (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Coll Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM mark-greiner@uiowa.edu
FU M.D. Wagoner & M.A. Greiner Cornea Excellence Fund; Beulah and Florence
   Usher Chair in Cornea/External Disease and Refractive Surgery; UIHC
   Cornea Research Fund
FX Supported in part by the M.D. Wagoner & M.A. Greiner Cornea Excellence
   Fund, the Beulah and Florence Usher Chair in Cornea/External Disease and
   Refractive Surgery, the UIHC Cornea Research Fund, Lloyd and Betty
   Schermer, and Robert and Joell Brightfelt.
CR Aboobakar Inas F, 2014, Int Ophthalmol Clin, V54, P43, DOI 10.1097/IIO.0000000000000042
   Abu-Amero KK, 2006, INVEST OPHTH VIS SCI, V47, P2533, DOI 10.1167/iovs.05-1639
   Ahn M., 2020, METABOL CLIN EXPER, V115, P154431
   Akbari M, 2019, AGEING RES REV, V54, DOI 10.1016/j.arr.2019.100940
   Al-Enezi M, 2008, MIDDLE EAST AFR J OP, V15, P81, DOI 10.4103/0974-9233.51998
   Aldrich BT, 2017, INVEST OPHTH VIS SCI, V58, P2130, DOI 10.1167/iovs.16-21094
   Alemi M, 2007, FREE RADICAL BIO MED, V42, P32, DOI 10.1016/j.freeradbiomed.2006.09.014
   Allen GFG, 2013, EMBO REP, V14, P1127, DOI 10.1038/embor.2013.168
   Arnoult D, 2005, CURR BIOL, V15, P2112, DOI 10.1016/j.cub.2005.10.041
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Ashrafi G, 2014, J CELL BIOL, V206, P655, DOI 10.1083/jcb.201401070
   BASSNETT S, 1992, CURR EYE RES, V11, P1227, DOI 10.3109/02713689208999548
   Bassnett S, 2011, PHILOS T R SOC B, V366, P1250, DOI 10.1098/rstb.2010.0302
   Benischke AS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06523-2
   Bernstein Audrey M, 2018, J Glaucoma, V27 Suppl 1, pS44, DOI 10.1097/IJG.0000000000000919
   Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292
   Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162
   Brennan LA, 2018, EXP EYE RES, V174, P173, DOI 10.1016/j.exer.2018.06.003
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Brown J, 1997, ARCH OPHTHALMOL-CHIC, V115, P95, DOI 10.1001/archopht.1997.01100150097016
   Carelli V, 2015, ANN NEUROL, V78, P21, DOI 10.1002/ana.24410
   Chan CM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0531-z
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Chinnery P, 2014, GENEREVIEWS
   Chistiakov DA, 2018, ANN MED, V50, P121, DOI 10.1080/07853890.2017.1417631
   Chistiakov DA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/238463
   Cogliati S, 2016, TRENDS BIOCHEM SCI, V41, P261, DOI 10.1016/j.tibs.2016.01.001
   Costello MJ, 2013, EXP EYE RES, V116, P141, DOI 10.1016/j.exer.2013.08.017
   Coughlin L, 2015, INVEST OPHTH VIS SCI, V56, P1437, DOI 10.1167/iovs.14-16126
   Dai Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0146-9
   De la Mata M, 2012, NEUROTHERAPEUTICS, V9, P446, DOI 10.1007/s13311-012-0103-3
   Devi TS, 2019, BIOL OPEN, V8, DOI 10.1242/bio.038521
   Devi TS, 2012, EXP DIABETES RES, DOI 10.1155/2012/438238
   Devi TS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.190
   Devi TD, 2017, AM J PATHOL, V187, P2659, DOI 10.1016/j.ajpath.2017.08.023
   Disatnik MH, 2015, J MOL MED, V93, P279, DOI 10.1007/s00109-015-1256-4
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dombi E, 2016, NEUROLOGY, V86, P1921, DOI 10.1212/WNL.0000000000002688
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Esteban-Martinez L, 2017, EMBO J, V36, P1688, DOI 10.15252/embj.201695916
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Gandre-Babbe S, 2008, MOL BIOL CELL, V19, P2402, DOI 10.1091/mbc.E07-12-1287
   Ganguly G, 2017, DRUG DES DEV THER, V11, P797, DOI 10.2147/DDDT.S130514
   Gao J, 2015, ACTA BIOCH BIOPH SIN, V47, P522, DOI 10.1093/abbs/gmv044
   Garrido-Maraver J, 2015, BBA-MOL BASIS DIS, V1852, P2535, DOI 10.1016/j.bbadis.2015.08.027
   Gilliland KO, 2004, EXP EYE RES, V79, P563, DOI 10.1016/j.exer.2004.05.017
   Glancy B, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.541040
   Gonzalez-Franquesa A, 2017, ADV EXP MED BIOL, V982, P465, DOI 10.1007/978-3-319-55330-6_25
   Gottlieb RA, 2021, CELL MOL LIFE SCI, V78, P3791, DOI 10.1007/s00018-021-03772-3
   Graeber MB, 1998, J NEUROL SCI, V153, P251, DOI 10.1016/S0022-510X(97)00295-5
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   GRONOWICZ G, 1984, J CELL SCI, V71, P177
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Halilovic A, 2016, ANTIOXID REDOX SIGN, V24, P1072, DOI 10.1089/ars.2015.6532
   Hamacher-Brady A, 2016, CELL MOL LIFE SCI, V73, P775, DOI 10.1007/s00018-015-2087-8
   Hass DT, 2019, J NEUROSCI, V39, P3582, DOI 10.1523/JNEUROSCI.2702-18.2019
   Higgins GC, 2014, BRIT J PHARMACOL, V171, P1917, DOI 10.1111/bph.12503
   Hombrebueno JR, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129760
   Hu XX, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00350
   Hytti M, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1583656
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Indrieri A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201708734
   Islam MT, 2017, NEUROL RES, V39, P73, DOI 10.1080/01616412.2016.1251711
   Ito YA, 2017, MITOCHONDRION, V36, P186, DOI 10.1016/j.mito.2017.08.014
   James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401
   Jang SY, 2012, J BIOL CHEM, V287, P19304, DOI 10.1074/jbc.M112.363747
   Jankauskaite E, 2020, J APPL GENET, V61, P195, DOI 10.1007/s13353-020-00550-y
   Janson Ben J, 2019, Am J Ophthalmol Case Rep, V15, P100512, DOI 10.1016/j.ajoc.2019.100512
   Garcia-Medina JJ, 2015, ACTA OPHTHALMOL, V93, P546, DOI 10.1111/aos.12629
   Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849
   John Simon W M, 2014, J Glaucoma, V23, pS68, DOI 10.1097/IJG.0000000000000121
   Jurkunas UV, 2018, CORNEA, V37, pS50, DOI 10.1097/ICO.0000000000001775
   Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kapetanakis VV, 2016, BRIT J OPHTHALMOL, V100, P86, DOI 10.1136/bjophthalmol-2015-307223
   Khawaja AP, 2016, INVEST OPHTH VIS SCI, V57, P5046, DOI 10.1167/iovs.16-20017
   Kim KY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.180
   Kimura A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2817252
   Kisilevsley E, 2020, SURV OPHTHALMOL, V65, P294, DOI 10.1016/j.survophthal.2019.11.001
   Kliosnky D, 2016, AUTOPHAGY, V12, P443, DOI 10.1080/15548627.2016.1147886
   Kodron A, 2019, ACTA BIOCHIM POL, V66, P427, DOI 10.18388/abp.2019_2837
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Kuo HM, 2016, FREE RADICAL BIO MED, V96, P116, DOI 10.1016/j.freeradbiomed.2016.04.019
   Lass JH, 2019, JAMA OPHTHALMOL, V137, P185, DOI 10.1001/jamaophthalmol.2018.5669
   Lee HC, 2012, ADV EXP MED BIOL, V942, P311, DOI 10.1007/978-94-007-2869-1_14
   Lee S, 2011, EXP EYE RES, V93, P204, DOI 10.1016/j.exer.2010.07.015
   Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330
   Li XY, 2017, CAN J PHYSIOL PHARM, V95, P247, DOI 10.1139/cjpp-2016-0515
   Liaboe CA, 2017, CORNEA, V36, P561, DOI 10.1097/ICO.0000000000001174
   Liao CY, 2017, NEUROLOGY, V88, P131, DOI 10.1212/WNL.0000000000003491
   Lin TK, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/824275
   Lin WJ, 2014, AUTOPHAGY, V10, P1692, DOI 10.4161/auto.36076
   Liu HH, 2020, J GLAUCOMA, V29, P295, DOI 10.1097/IJG.0000000000001448
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Liu YT, 2017, EXP EYE RES, V160, P62, DOI 10.1016/j.exer.2017.05.002
   Mauro-Lizcano M, 2015, AUTOPHAGY, V11, P833, DOI 10.1080/15548627.2015.1034403
   McWilliams TG, 2019, AUTOPHAGY, V15, P1296, DOI 10.1080/15548627.2019.1580509
   McWilliams TG, 2018, CELL METAB, V27, P439, DOI 10.1016/j.cmet.2017.12.008
   Mercer TJ, 2018, J BIOL CHEM, V293, P5386, DOI 10.1074/jbc.R117.810366
   Miyai T, 2019, AM J PATHOL, V189, P2061, DOI 10.1016/j.ajpath.2019.06.012
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moulis MF, 2017, J NEUROCHEM, V140, P485, DOI 10.1111/jnc.13894
   Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367
   Mullins RF, 2005, MOL VIS, V11, P509
   Nanda GG, 2019, MOL VIS, V25, P295
   Ovodenko B, 2007, INVEST OPHTH VIS SCI, V48, P1447, DOI 10.1167/iovs.06-0411
   Palmer CS, 2011, EMBO REP, V12, P565, DOI 10.1038/embor.2011.54
   Pendergrass W, 2005, INVEST OPHTH VIS SCI, V46, P4661, DOI 10.1167/iovs.05-0808
   Phasukkijwatana N, 2010, HUM GENET, V128, P39, DOI 10.1007/s00439-010-0821-8
   Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007
   Prakash YS, 2017, CHEST, V152, P618, DOI 10.1016/j.chest.2017.03.020
   Price MO, 2017, CORNEA, V36, P1184, DOI 10.1097/ICO.0000000000001305
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Rodriguez ML, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4940825
   Romagnoli M, 2020, ANN CLIN TRANSL NEUR, V7, P590, DOI 10.1002/acn3.51026
   Rosignol I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051882
   Rovira-Llopis S, 2017, REDOX BIOL, V11, P637, DOI 10.1016/j.redox.2017.01.013
   Sarnicola C, 2019, EYE CONTACT LENS, V45, P1, DOI 10.1097/ICL.0000000000000469
   Scheibye-Knudsen M, 2015, TRENDS CELL BIOL, V25, P158, DOI 10.1016/j.tcb.2014.11.002
   Schnieders MJ, 2018, EYE, V32, P843, DOI 10.1038/eye.2017.303
   Schofield JH, 2021, ANTIOXID REDOX SIGN, V34, P517, DOI 10.1089/ars.2020.8058
   Schutt F, 2012, INVEST OPHTH VIS SCI, V53, P5354, DOI 10.1167/iovs.12-9845
   Schwarz C, 2016, EXP EYE RES, V153, P152, DOI 10.1016/j.exer.2016.10.015
   Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104
   Seibenhener ML, 2013, BBA-MOL CELL RES, V1833, P452, DOI 10.1016/j.bbamcr.2012.11.004
   Sharma LK, 2019, HUM MOL GENET, V28, P422, DOI 10.1093/hmg/ddy354
   Shen CY, 2015, NEUROSCI LETT, V600, P132, DOI 10.1016/j.neulet.2015.06.002
   Si LL, 2020, ARCH BIOCHEM BIOPHYS, V685, DOI 10.1016/j.abb.2020.108284
   Siasos G, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.06.21
   Siegfried CJ, 2015, AM J OPHTHALMOL, V159, P457, DOI 10.1016/j.ajo.2014.11.026
   SIEKEVITZ P, 1957, SCI AM, V197, P131, DOI 10.1038/scientificamerican0757-131
   Singh L.P., 2018, OPHTHALMOL RES REP, V3
   Singh Lalit P, 2017, JOJ Ophthalmol, V4, DOI 10.19080/jojo.2017.04.555643
   Singh Lalit P, 2013, J Clin Exp Ophthalmol, V4, DOI 10.4172/2155-9570.1000287
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P8325, DOI 10.1167/iovs.13-13214
   Srinivasan S, 2017, BBA-BIOENERGETICS, V1858, P602, DOI 10.1016/j.bbabio.2017.01.004
   Stallons L Jay, 2013, Curr Pathobiol Rep, V1, DOI 10.1007/s40139-013-0023-x
   Stenirri S, 2012, CLIN CHEM LAB MED, V50, P1021, DOI 10.1515/cclm-2011-0854
   Suliman HB, 2016, PHARMACOL REV, V68, P20, DOI 10.1124/pr.115.011502
   Suliman HB, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89676
   Surgucheva I, 2008, J BIOL CHEM, V283, P36377, DOI 10.1074/jbc.M806660200
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Terry MA, 2018, OPHTHALMOLOGY, V125, P1700, DOI 10.1016/j.ophtha.2018.08.002
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P161, DOI 10.1007/978-3-319-95046-4_30
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779
   Valero T, 2014, CURR PHARM DESIGN, V20, P5507, DOI 10.2174/138161282035140911142118
   Vedana G, 2016, CLIN OPHTHALMOL, V10, P321, DOI 10.2147/OPTH.S83467
   Villanueva-Paz M, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165726
   von Stockum Sophia, 2018, Oncotarget, V9, P12550, DOI 10.18632/oncotarget.23799
   Walczak J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14964-y
   Wang YQ, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00308
   Wang Z, 2007, OPHTHALMOLOGY, V114, P1453, DOI 10.1016/j.ophtha.2006.10.049
   Want A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157404
   Wei QQ, 2019, DISCOV MED, V27, P189
   Weil R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01243
   Weng SW, 2013, MITOCHONDRION, V13, P888, DOI 10.1016/j.mito.2013.08.001
   Williams JA, 2018, BIOL CHEM, V399, P147, DOI 10.1515/hsz-2017-0228
   WILLS EJ, 1992, ULTRASTRUCT PATHOL, V16, pR3, DOI 10.3109/01913129209061353
   Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111
   Wu WW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132499
   Xian HX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10096-1
   Xiao B, 2017, J BIOL CHEM, V292, P16697, DOI 10.1074/jbc.M117.787739
   Xu Hui-Zhuo, 2011, J Ocul Biol Dis Infor, V4, P83, DOI 10.1007/s12177-011-9068-4
   Yim WWY, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0141-7
   Yoshizumi T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05808-w
   Zamponi N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18351-5
   Zenkel Matthias, 2018, J Glaucoma, V27 Suppl 1, pS24, DOI 10.1097/IJG.0000000000000902
   Zenkel Matthias, 2014, J Glaucoma, V23, pS48, DOI 10.1097/IJG.0000000000000120
   Zhang HS, 2006, FREE RADICAL BIO MED, V40, P1664, DOI 10.1016/j.freeradbiomed.2006.01.003
   Zhang JJ, 2018, HUM MOL GENET, V27, P1999, DOI 10.1093/hmg/ddy107
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang SY, 2013, MOL VIS, V19, P812
   Zhang TM, 2016, J BIOL CHEM, V291, P21616, DOI 10.1074/jbc.M116.733410
   Zhang YP, 2019, BIOMED PHARMACOTHER, V111, P1315, DOI 10.1016/j.biopha.2019.01.034
   Zhou P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030213
   Zhu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26322
   Zorov DB, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020175
   Zorova LD, 2018, ANAL BIOCHEM, V552, P50, DOI 10.1016/j.ab.2017.07.009
NR 182
TC 10
Z9 10
U1 3
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2021
VL 62
IS 3
AR 22
DI 10.1167/iovs.62.3.22
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RM2UX
UT WOS:000639521500022
PM 33724294
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhou, JZ
   Chen, FH
   Yan, AM
   Xia, XB
AF Zhou, Jinzi
   Chen, Fenghua
   Yan, Aimin
   Xia, Xiaobo
TI Madecassoside protects retinal pigment epithelial cells against hydrogen
   peroxide-induced oxidative stress and apoptosis through the activation
   of Nrf2/HO-1 pathway
SO BIOSCIENCE REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; MECHANISMS; PATHOGENESIS
AB Age-related macular degeneration (AMD) is a progressive and degenerative ocular disease associated with oxidative stress. Madecassoside (MADE) is a major bioactive triterpenoid saponin that possesses antioxidative activity. However, the role of MADE in AMD has never been investigated. In the current study, we aimed to evaluate the protective effect of MADE on retinal pigment epithelium (RPE) cells under oxidative stress condition. We used hydrogen peroxide (H2O2) to induce oxidative damage in human RPE cells (ARPE-19 cells). Our results showed that H2O2-caused significant decrease in cell viability and increase in lactate dehydrogenase (LDH) release were dose-dependently attenuated by MADE. MADE treatment also attenuated H2O2-induced reactive oxygen species (ROS) and malondialdehyde (MDA) production in RPE cells. The reduced glutathione (GSH) level and superoxide dismutase (SOD) activity in H2O2-induced ARPE-19 cells were elevated after MADE treatment. MADE also suppressed caspase-3 activity and bax expression, as well as increased bcl-2 expression. Furthermore, H2O2-induced increase in expression levels of HO-1 and nuclear Nrf2 were enhanced by MADE treatment. Finally, knockdown of Nrf2 reversed the protective effects of MADE on H2O2-induced ARPE-19 cells. In conclusion, these findings demonstrated that MADE protected ARPE-19 cells from H2O2-induced oxidative stress and apoptosis by inducing the activation of Nrf2/HO-1 signaling pathway.
C1 [Zhou, Jinzi; Chen, Fenghua; Yan, Aimin] First Peoples Hosp Guiyang, Dept Ophthalmol, Guiyang 550002, Guizhou, Peoples R China.
   [Xia, Xiaobo] Cent South Univ, Dept Ophthalmol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
C3 Central South University
RP Zhou, JZ (通讯作者)，First Peoples Hosp Guiyang, Dept Ophthalmol, Guiyang 550002, Guizhou, Peoples R China.
EM zhoujinzi_oph@126.com
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beranova-Giorgianni S, 2018, PROTEOMES, V6, DOI 10.3390/proteomes6020022
   Bian DF, 2012, J BIOCHEM MOL TOXIC, V26, P399, DOI 10.1002/jbt.21434
   Cabello-Verrugio C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4310469
   Dou YN, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105813
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Hekimi S, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00161
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kanzaki H, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00351
   Kudryavtseva AV, 2016, ONCOTARGET, V7, P44879, DOI 10.18632/oncotarget.9821
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Li P, 2017, ONCOTARGET, V8, P23996, DOI 10.18632/oncotarget.15098
   Lin X, 2014, PHARMACOL BIOCHEM BE, V124, P434, DOI 10.1016/j.pbb.2014.07.014
   Ling YT, 2017, ONCOTARGET, V8, P51066, DOI 10.18632/oncotarget.17654
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Moldogazieva NT, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3085756
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sasmita AO, 2018, INT J MOL MED, V41, P3033, DOI 10.3892/ijmm.2018.3479
   Shen XQ, 2019, BIOSCI BIOTECH BIOCH, V83, P561, DOI 10.1080/09168451.2018.1547627
   Sies H, 2014, J BIOL CHEM, V289, P8735, DOI 10.1074/jbc.R113.544635
   Wang W, 2010, DISCOV MED, V9, P13
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
NR 28
TC 8
Z9 10
U1 1
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD OCT 14
PY 2020
VL 40
AR BSR20194347
DI 10.1042/BSR20194347
PN 10
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ON8YP
UT WOS:000586979200001
PM 33000859
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yao, XC
   Kim, TH
AF Yao, Xincheng
   Kim, Tae-Hoon
TI Fast intrinsic optical signal correlates with activation phase of
   phototransduction in retinal photoreceptors
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Optoretinography; optophysiology; intrinsic optical signal; age-related
   macular degeneration; retinitis pigmentosa; diabetic retinopathy;
   optical coherence tomography; phototransduction; photoreceptor
ID OUTER SEGMENT CHANGES; LIGHT-SCATTERING; PHYSIOLOGICAL-RESPONSES;
   RETINITIS-PIGMENTOSA; WILD-TYPE; REVEALS; MOUSE; CONE; DYSFUNCTION;
   RHODOPSIN
AB Quantitative assessment of physiological condition of retinal photoreceptors is desirable for better detection and treatment evaluation of eye diseases that can cause photoreceptor dysfunctions. Functional intrinsic optical signal (IOS) imaging, also termed as optoretinography (ORG) or optophysiology, has been proposed as a high-resolution method for objective assessment of retinal physiology. Fast IOS in retinal photoreceptors shows a time course earlier than that of electroretinography a-wave, promising an objective marker for noninvasive ORG of early phototransduction process in retinal photoreceptors. In this article, recent observations of fast photoreceptor-IOS in animal and human retinas are summarized, and the correlation of fast photoreceptor-IOS to five steps of phototransduction process is discussed. Transient outer segment conformational change, due to inter-disc space shrinkage correlated with activation phase of phototransduction, has been disclosed as a primary source of the fast photoreceptor-IOS. Impact statement As the center of phototransduction, retinal photoreceptors are responsible for capturing and converting photon energy to bioelectric signals for following visual information processing in the retina. This article summarizes experimental observation and discusses biophysical mechanism of fast photoreceptor-intrinsic optical signal (IOS) correlated with early phase of phototransduction. Quantitative imaging of fast photoreceptor-IOS may provide objective optoretinography to advance the study and diagnosis of age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, and other eye diseases that can cause photoreceptor dysfunctions.
C1 [Yao, Xincheng; Kim, Tae-Hoon] Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.
   [Yao, Xincheng] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Yao, XC (通讯作者)，Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA.; Yao, XC (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
EM xcy@uic.edu
RI Kim, Taehoon/AAS-5818-2020; Yao, Xincheng/ABA-1526-2020
OI Kim, Tae-Hoon/0000-0002-4391-4860
FU NIH [R01 EY023522, R01 EY030101, R01EY030842, R01EY029673, P30
   EY001792]; Richard and Loan Hill endowment; Research to Prevent
   Blindness
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research was supported in part by NIH grants R01 EY023522, R01 EY030101,
   R01EY030842, R01EY029673, and P30 EY001792; by Richard and Loan Hill
   endowment; and by unrestricted grant from Research to Prevent Blindness.
CR Bedggood P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079251
   BENNETT N, 1982, EUR J BIOCHEM, V123, P133, DOI 10.1111/j.1432-1033.1982.tb06509.x
   Berkowitz BA, 2015, INVEST OPHTH VIS SCI, V56, P606, DOI 10.1167/iovs.14-15687
   BERSON EL, 1968, ARCH OPHTHALMOL-CHIC, V80, P58
   BERSON EL, 1970, INVEST OPHTH VISUAL, V9, P58
   BERSON EL, 1970, ARCH OPHTHALMOL-CHIC, V83, P412
   Bizheva K, 2006, P NATL ACAD SCI USA, V103, P5066, DOI 10.1073/pnas.0506997103
   CHABRE M, 1975, BIOCHIM BIOPHYS ACTA, V382, P322, DOI 10.1016/0005-2736(75)90274-6
   Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimopoulos IS, 2013, INVEST OPHTH VIS SCI, V54, P5186, DOI 10.1167/iovs.13-12194
   Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144
   Grieve K, 2008, INVEST OPHTH VIS SCI, V49, P713, DOI 10.1167/iovs.07-0837
   HARARY HH, 1978, SCIENCE, V202, P1083, DOI 10.1126/science.102035
   Hillmann D, 2016, P NATL ACAD SCI USA, V113, P13138, DOI 10.1073/pnas.1606428113
   Hirohara Y, 2013, EXP EYE RES, V109, P1, DOI 10.1016/j.exer.2013.01.007
   Holopigian K, 1997, INVEST OPHTH VIS SCI, V38, P2355
   Hunter JJ, 2019, ANNU REV VIS SCI, V5, P15, DOI 10.1146/annurev-vision-091517-034239
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jonnal RS, 2007, OPT EXPRESS, V15, P16141, DOI 10.1364/OE.15.016141
   KAHLERT M, 1990, NATURE, V345, P537, DOI 10.1038/345537a0
   KAPLAN MW, 1981, J OPT SOC AM, V71, P1467, DOI 10.1364/JOSA.71.001467
   Li YG, 2010, OPT EXPRESS, V18, P7210, DOI 10.1364/OE.18.007210
   Li YG, 2010, OPT LETT, V35, P426, DOI 10.1364/OL.35.000426
   Li YC, 2010, OPT LETT, V35, P1810, DOI 10.1364/OL.35.001810
   LIEBMAN PA, 1974, NATURE, V251, P31, DOI 10.1038/251031a0
   Liu HT, 2019, INVEST OPHTH VIS SCI, V60, P1538, DOI 10.1167/iovs.18-26433
   Lu RW, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.10.106013
   Lu YM, 2020, EXP BIOL MED, V245, P360, DOI 10.1177/1535370219896284
   Lu YM, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.29
   Lu YM, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.5.050502
   Lu YM, 2017, BIOMED OPT EXPRESS, V8, P38, DOI 10.1364/BOE.8.000038
   McAnany JJ, 2020, DOC OPHTHALMOL, V140, P31, DOI 10.1007/s10633-019-09718-2
   McAnany JJ, 2019, INVEST OPHTH VIS SCI, V60, P64, DOI 10.1167/iovs.18-25946
   MICHELVILLAZ M, 1984, BIOPHYS J, V46, P655, DOI 10.1016/S0006-3495(84)84064-3
   Nakao T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032472
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   PEPPERBERG DR, 1988, P NATL ACAD SCI USA, V85, P5531, DOI 10.1073/pnas.85.15.5531
   Perlman I., 2020, ELECTRORETINOGRAM ER
   Ronan Shawn, 2006, Trans Am Ophthalmol Soc, V104, P232
   Schallek J, 2009, INVEST OPHTH VIS SCI, V50, P4873, DOI 10.1167/iovs.08-3291
   Schallek J, 2009, INVEST OPHTH VIS SCI, V50, P4865, DOI 10.1167/iovs.08-3290
   Schallek JB, 2012, INVEST OPHTH VIS SCI, V53, P1971, DOI 10.1167/iovs.11-8299
   SHADY S, 1995, INVEST OPHTH VIS SCI, V36, P1027
   Son T, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201800089
   Srinivasan VJ, 2006, OPT LETT, V31, P2308, DOI 10.1364/OL.31.002308
   Srinivasan VJ, 2009, OPT EXPRESS, V17, P3861, DOI 10.1364/OE.17.003861
   Tzekov RT, 2003, INVEST OPHTH VIS SCI, V44, P3993, DOI 10.1167/iovs.02-1104
   Wang BQ, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.9.096010
   Wang BQ, 2014, OPT LETT, V39, P6923, DOI 10.1364/OL.39.006923
   Woodruff ML, 2004, J PHYSIOL-LONDON, V557, P821, DOI 10.1113/jphysiol.2004.064014
   Yagi N, 2013, EXP EYE RES, V116, P395, DOI 10.1016/j.exer.2013.09.016
   Yang SS, 2016, DOC OPHTHALMOL, V132, P17, DOI 10.1007/s10633-016-9523-4
   Yao XC, 2008, OPT EXPRESS, V16, P12446, DOI 10.1364/OE.16.012446
   Yao XC, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2393155
   Yao XC, 2006, NEUROIMAGE, V33, P898, DOI 10.1016/j.neuroimage.2006.06.060
   Yao Xin-Cheng, 2012, Methods Mol Biol, V884, P277, DOI 10.1007/978-1-61779-848-1_20
   Yao XC, 2009, JPN J OPHTHALMOL, V53, P327, DOI 10.1007/s10384-009-0685-4
   Yao XC, 2018, EXP BIOL MED, V243, P1256, DOI 10.1177/1535370218816517
   Yao XC, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.9.090901
   YONEMURA D, 1967, JPN J PHYSIOL, V17, P235
   Zhang FR, 2019, P NATL ACAD SCI USA, V116, P7951, DOI 10.1073/pnas.1816360116
   Zhang PF, 2017, P NATL ACAD SCI USA, V114, pE2937, DOI 10.1073/pnas.1620572114
   Zhang QX, 2012, INVEST OPHTH VIS SCI, V53, P8139, DOI 10.1167/iovs.12-10732
   Zhang QX, 2011, OPT LETT, V36, P4692, DOI 10.1364/OL.36.004692
   Zhang QX, 2015, SCI REP-UK, V5, DOI 10.1038/srep09595
   Zhao XH, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.065006
   Zhao YB, 2008, OPT LETT, V33, P342, DOI 10.1364/OL.33.000342
NR 68
TC 13
Z9 13
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD JUL
PY 2020
VL 245
IS 13
SI SI
BP 1087
EP 1095
AR 1535370220935406
DI 10.1177/1535370220935406
EA JUN 2020
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA MZ1XL
UT WOS:000542429200001
PM 32558598
OA Green Published
DA 2022-11-30
ER

PT J
AU Antony, BJ
   Maetschke, S
   Garnavi, R
AF Antony, Bhavna Josephine
   Maetschke, Stefan
   Garnavi, Rahil
TI Automated summarisation of SDOCT volumes using deep learning: Transfer
   learning vs de novo trained networks
SO PLOS ONE
LA English
DT Article
ID SELECTION METHOD
AB Spectral-domain optical coherence tomography (SDOCT) is a non-invasive imaging modality that generates high-resolution volumetric images. This modality finds widespread usage in ophthalmology for the diagnosis and management of various ocular conditions. The volumes generated can contain 200 or more B-scans. Manual inspection of such large quantity of scans is time consuming and error prone in most clinical settings. Here, we present a method for the generation of visual summaries of SDOCT volumes, wherein a small set of B-scans that highlight the most clinically relevant features in a volume are extracted. The method was trained and evaluated on data acquired from age-related macular degeneration patients, and "relevance" was defined as the presence of visibly discernible structural abnormalities. The summarisation system consists of a detection module, where relevant B-scans are extracted from the volume, and a set of rules that determines which B-scans are included in the visual summary. Two deep learning approaches are presented and compared for the classification of B-scans-transfer learning and de novo learning. Both approaches performed comparably with AUCs of 0.97 and 0.96, respectively, obtained on an independent test set. The de novo network, however, was 98% smaller than the transfer learning approach, and had a run-time that was also significantly shorter.
C1 [Antony, Bhavna Josephine; Maetschke, Stefan; Garnavi, Rahil] IBM Res Australia, IBM Ctr, 22-60 City Rd, Southbank, Vic 3006, Australia.
RP Antony, BJ (通讯作者)，IBM Res Australia, IBM Ctr, 22-60 City Rd, Southbank, Vic 3006, Australia.
EM bhavna.antony@au1.ibm.com
RI Antony, Bhavna Josephine/ABD-1023-2021
OI Antony, Bhavna Josephine/0000-0002-6882-2444
CR Abadi M., 2016, TENSORFLOW LARGE SCA
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Chen LC, 2018, IEEE T PATTERN ANAL, V40, P834, DOI 10.1109/TPAMI.2017.2699184
   Chollet F., 2015, KERAS
   Cotsaces C, 2006, IEEE SIGNAL PROC MAG, V23, P28, DOI 10.1109/MSP.2006.1621446
   de Vos BD, 2017, LECT NOTES COMPUT SC, V10553, P204, DOI 10.1007/978-3-319-67558-9_24
   Devalla SK, 2018, INVEST OPHTH VIS SCI, V59, P63, DOI 10.1167/iovs.17-22617
   Farsiu S, 2013, OPHTHALMOLOGY, P1
   Fauvet B, 2004, LECT NOTES COMPUT SC, V3115, P419
   Gibson D, 2004, IEEE T INF TECHNOL B, V8, P103, DOI 10.1109/TITB.2004.826722
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   He Y, 2018, 180305120V1 ARXIV
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang P, 2008, 4 INT S 3D DAT PROC, P71
   Jegou S, 2017, IEEE COMPUT SOC CONF, P1175, DOI 10.1109/CVPRW.2017.156
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kingma J., 2014, ARXIV
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Liu TM, 2003, IEEE T CIRC SYST VID, V13, P1006, DOI 10.1109/TCSVT.2003.816521
   Maetschke S, 2018, 170806046V2 ARXIV
   Mahapatra D, 2018, I S BIOMED IMAGING, P1449, DOI 10.1109/ISBI.2018.8363845
   Nam J, 2005, IEEE T MULTIMEDIA, V7, P667, DOI 10.1109/TMM.2005.843362
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Shah A, 2017, 170507142V1 ARXIV
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Syeda-Mahmood T, 2010, Proceedings of the 2010 20th International Conference on Pattern Recognition (ICPR 2010), P4008, DOI 10.1109/ICPR.2010.975
   Yang X, 2017, NEUROIMAGE, V158, P378, DOI 10.1016/j.neuroimage.2017.07.008
   Zhou B, 2016, PROC CVPR IEEE, P2921, DOI 10.1109/CVPR.2016.319
NR 31
TC 3
Z9 3
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 13
PY 2019
VL 14
IS 5
AR e0203726
DI 10.1371/journal.pone.0203726
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HX9GC
UT WOS:000467714000001
PM 31083678
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Murphy, A
   McElnea, E
   Byrne, S
AF Murphy, Aileen
   McElnea, Elizabeth
   Byrne, Sinead
TI Health technology assessment: A primer for ophthalmology
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Health technology assessment; economic evaluation; cost effectiveness;
   ophthalmology
ID EFFECTIVENESS ACCEPTABILITY CURVES; COST-EFFECTIVENESS;
   ECONOMIC-EVALUATION; VISION RESEARCH; UNCERTAINTY; GLAUCOMA; CARE;
   QUESTIONNAIRE; MODEL; LIFE
AB Rising healthcare costs and increasing demands for health care require techniques to choose between competing uses and even rationing of health care. Economic evaluations and health technology assessments are increasingly a means to assess the cost effectiveness of healthcare interventions so as to inform such resource allocation decisions. To date, the adoption of health technology assessments, as a way of assessing cost effectiveness, in ophthalmology has been slower, relative to their implementation in other specialities. Nevertheless, demands for eye services are increasing due to an ageing population. The prevalence of conditions such as glaucoma, cataract, diabetic eye disease and age-related macular degeneration increases with age, and it is predicted that global blindness will triple by 2050. So there is a challenge for ophthalmologists to ensure that they can contribute to, interpret, critically evaluate, and use findings from economic evaluations in their clinical practice. To aid this, this article serves as a primer on the use of health technology assessments to assess cost effectiveness using economic evaluation techniques for ophthalmologists. Healthcare systems face many challenges worldwide - changing demographics and evolution of new technologies are only going to intensify. With this in mind, ophthalmology needs to be ready and able to engage with health economists to prepare, interpret, critically evaluate and use findings of economic evaluations and health technology assessments.
C1 [Murphy, Aileen] Univ Coll Cork, Cork Univ Business Sch, Dept Econ, Cork T12 T656, Ireland.
   [McElnea, Elizabeth] Mater Misericordiae Univ Hosp, Dublin, Ireland.
   [Byrne, Sinead] Mater Private Hosp Cork, Cork, Ireland.
C3 University College Cork; Mater Misericordiae University Hospital;
   University College Dublin; Mater Private Hospital
RP Murphy, A (通讯作者)，Univ Coll Cork, Cork Univ Business Sch, Dept Econ, Cork T12 T656, Ireland.
EM aileen.murphy@ucc.ie
OI Murphy, Aileen/0000-0003-3062-0692
CR Banta HD., 1993, HLTH CARE TECHNOLOGY
   BLACK WC, 1990, MED DECIS MAKING, V10, P212, DOI 10.1177/0272989X9001000308
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003
   Briggs A., 2006, DECISION MODELLING H
   Briggs AH, 2001, HEALTH ECON, V10, P179, DOI 10.1002/hec.584
   Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014
   Brown MM, 2014, CURR OPIN OPHTHALMOL, V25, P171, DOI 10.1097/ICU.0000000000000040
   Browne C, 2012, EYE, V26, P1295, DOI 10.1038/eye.2012.137
   Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W
   COYLE D, 1995, PHARMACOECONOMICS, V7, P484, DOI 10.2165/00019053-199507060-00003
   Drummond MF, 2015, METHODS EC EVALUATIO, V4th
   European Glaucoma Society, 2020, TERM GUID GLAUC
   Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903
   Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635
   Galor A, 2015, OPHTHAL EPIDEMIOL, V22, P28, DOI 10.3109/09286586.2013.783081
   Glick H.A., 2014, EC EVALUATION CLIN T, V2nd ed.
   Kay S, 2014, OPHTHAL EPIDEMIOL, V21, P66, DOI 10.3109/09286586.2014.888456
   Kobelt G, 2002, J GLAUCOMA, V11, P531, DOI 10.1097/00061198-200212000-00015
   Kymes SM, 2015, OPHTHAL EPIDEMIOL, V22, P1, DOI 10.3109/09286586.2014.988878
   Kymes SM, 2014, OPHTHAL EPIDEMIOL, V21, P63, DOI 10.3109/09286586.2014.895843
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   O'Brien BJ, 2002, STAT METHODS MED RES, V11, P455, DOI 10.1191/0962280202sm304ra
   Pinto J., 2011, OPHTHAMOL MANAG
   Roberts M, 2012, MED DECIS MAKING, V32, P678, DOI [10.1177/0272989X12454941, 10.1016/j.jval.2012.06.016]
   SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409
   Stinnett AA, 1997, MED DECIS MAKING, V17, P483, DOI 10.1177/0272989X9701700414
   Tuulonen A, 2006, ESSENT OPHTHALMOL, P123
NR 28
TC 0
Z9 0
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2018
VL 28
IS 4
BP 358
EP 364
DI 10.1177/1120672117747040
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA GM9LJ
UT WOS:000438569400005
PM 29973070
DA 2022-11-30
ER

PT J
AU Zheng, WH
   Meng, Q
   Wang, HT
   Yan, FX
   Little, PJ
   Deng, XG
   Lin, SF
AF Zheng, Wenhua
   Meng, Qian
   Wang, Haitao
   Yan, Fengxia
   Little, Peter J.
   Deng, Xinguo
   Lin, Shaofen
TI IGF-1-Mediated Survival from Induced Death of Human Primary Cultured
   Retinal Pigment Epithelial Cells Is Mediated by an Akt-Dependent
   Signaling Pathway
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Retinopathy; Serum deprivation; Cell signaling; Apoptosis; Growth
   factors
ID GROWTH-FACTOR-I; FOXO TRANSCRIPTION FACTORS; OXIDATIVE STRESS;
   BINDING-PROTEINS; INSULIN; EXPRESSION; KINASE; DIFFERENTIATION;
   PROLIFERATION; METABOLISM
AB Degeneration of the human retinal pigmented epithelium (hRPE) is involved in several eye disorders such as age-related macular degeneration (AMD). In this study, we investigated the protective effect of IGF-1 on human primary cultured RPE cells and its underlying mechanism. IGF-1 dose- and time-dependently promoted the survival of RPE cells from serum deprivation. Western blot showed that IGF-1 stimulated the activation of the PI3K/Akt and MAPK pathways in hRPE. Inhibition of the PI3K/Akt pathway by the PI3K-specific inhibitor, LY294002 or inhibition of Akt by Akt-specific inhibitors Akt inhibitor VIII or SN-38, or downregulation Akt with siRNA specific for Akt blocked the effect of IGF-1 on hRPE. In contrast, blockade of the MAPK pathway with a specific inhibitor PD98059 had no effect. Interestingly, vitreous IGF-1 injection reversed the inhibitory effect of light exposure (a dry AMD model) on both a wave and b wave. Immunocytochemistry showed that vitreous IGF-1 injections promoted the survival of RPE cells in rat retina and the expression of RPE65 in RPE cells from light injury. These results indicate that IGF-1 is able to protect hRPE cell from different insults in vivo and in vitro. Further detailed studies may lead the way to a therapeutic intervention for retinal diseases in which cell death is an underlying contributory mechanism.
C1 [Zheng, Wenhua; Meng, Qian; Wang, Haitao; Yan, Fengxia] Univ Macau, Fac Hlth Sci, Room 4021,Bldg E12,Ave Univ, Taipa, Macau, Peoples R China.
   [Zheng, Wenhua; Deng, Xinguo; Lin, Shaofen] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Zheng, Wenhua; Deng, Xinguo; Lin, Shaofen] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
   [Wang, Haitao] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
   [Little, Peter J.] Univ Queensland, PACE, Sch Pharm, 20 Cornwall St, Woolloongabba, Qld 4102, Australia.
C3 University of Macau; Sun Yat Sen University; Sun Yat Sen University;
   Southern Medical University - China; University of Queensland
RP Zheng, WH (通讯作者)，Univ Macau, Fac Hlth Sci, Room 4021,Bldg E12,Ave Univ, Taipa, Macau, Peoples R China.; Zheng, WH (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.; Zheng, WH (通讯作者)，Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
EM wenhuazheng@umac.mo
RI Little, Peter J./F-9865-2015
OI Little, Peter J./0000-0002-0335-3835; Wang, Haitao/0000-0001-9900-8528;
   Wang, Haitao/0000-0001-6910-974X
FU Guangdong Provincial Project of Science and Technology [2011B050200005];
   National Natural Science Foundation of China [31371088]; University of
   Macau [SRG2015-00004-FHS, MYRG2016-00052-FHS]; Science and Technology
   Development Fund (FDCT) of Macao [FDCT 021/2015/A1, FDCT 016/2016/A1]
FX This research was financially supported by the Guangdong Provincial
   Project of Science and Technology (2011B050200005), the National Natural
   Science Foundation of China (31371088), SRG2015-00004-FHS and
   MYRG2016-00052-FHS from University of Macau, and the Science and
   Technology Development Fund (FDCT) of Macao (FDCT 021/2015/A1 and FDCT
   016/2016/A1).
CR Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Alejandro EU, 2008, J BIOL CHEM, V283, P2407, DOI 10.1074/jbc.M703612200
   Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010
   Carr AJ, 2009, MOL VIS, V15, P283
   Costales J, 2016, NEUROSCI BIOBEHAV R, V63, P207, DOI 10.1016/j.neubiorev.2016.01.001
   Cui QL, 2007, J NEUROCHEM, V100, P1480, DOI 10.1111/j.1471-4159.2006.04329.x
   Delafontaine P, 2004, ARTERIOSCL THROM VAS, V24, P435, DOI 10.1161/01.ATV.0000105902.89459.09
   Demontis F, 2010, CELL, V143, P813, DOI 10.1016/j.cell.2010.10.007
   Dobrowolny G, 2005, J CELL BIOL, V168, P193, DOI 10.1083/jcb.200407021
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Greer EL, 2008, ACTA PHYSIOL, V192, P19, DOI 10.1111/j.1748-1716.2007.01780.x
   Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Ivanisevic L, 2007, J BIOL CHEM, V282, P16754, DOI 10.1074/jbc.M701996200
   Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077
   Kim Y, 2004, MOL CELLS, V18, P353
   Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000
   LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007-0259
   Manolopoulos KN, 2010, MOL PSYCHIATR, V15, P1046, DOI 10.1038/mp.2010.17
   Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200
   Nakae J, 2008, FEBS LETT, V582, P54, DOI 10.1016/j.febslet.2007.11.025
   NEFF NT, 1993, J NEUROBIOL, V24, P1578, DOI 10.1002/neu.480241203
   Pfeiffer A, 1997, DIABETES, V46, pS26, DOI 10.2337/diab.46.2.S26
   Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387
   Rauskolb S, 2017, NEUROBIOL DIS, V97, P103, DOI 10.1016/j.nbd.2016.04.007
   Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738
   Salih DAM, 2008, CURR OPIN CELL BIOL, V20, P126, DOI 10.1016/j.ceb.2008.02.005
   Sheline CT, 2010, MOL VIS, V16, P2639
   Slomiany MG, 2004, INVEST OPHTH VIS SCI, V45, P2838, DOI 10.1167/iovs.03-0565
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   Stein L, 2011, EXPERT OPIN BIOL TH, V11, P429, DOI 10.1517/14712598.2011.557358
   TAKAGI H, 1994, INVEST OPHTH VIS SCI, V35, P916
   Wang HT, 2013, PSYCHOPHARMACOLOGY, V228, P129, DOI 10.1007/s00213-013-3017-9
   Weng CY, 2009, CURR EYE RES, V34, P867, DOI 10.3109/02713680903177890
   Young B, 2012, CURR OPIN OPHTHALMOL, V23, P497, DOI 10.1097/ICU.0b013e328359045e
   ZAPF J, 1984, CLIN ENDOCRINOL META, V13, P3, DOI 10.1016/S0300-595X(84)80006-7
   Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225
NR 39
TC 10
Z9 11
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD MAR
PY 2018
VL 55
IS 3
BP 1915
EP 1927
DI 10.1007/s12035-017-0447-0
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FY5TG
UT WOS:000426897800008
PM 28238097
DA 2022-11-30
ER

PT J
AU Chong, YS
   Mai, CW
   Leong, CO
   Wong, LC
AF Chong, You Sheng
   Mai, Chun Wai
   Leong, Chee Onn
   Wong, Lai Chun
TI Lutein improves cell viability and reduces Alu RNA accumulation in
   hydrogen peroxide challenged retinal pigment epithelial cells
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Lutein; zeaxanthin; ARPE-19; DICER1; Alu RNA; age-related macular
   degeneration; hydrogen peroxide
ID HIGH-DOSE SUPPLEMENTATION; MACULAR DEGENERATION; OXIDATIVE STRESS;
   BETA-CAROTENE; ZEAXANTHIN SUPPLEMENTATION; NLRP3 INFLAMMASOME;
   CLINICAL-TRIAL; DOUBLE-BLIND; VISION LOSS; VITAMIN-C
AB Purpose: Dysfunction of the microRNA (miRNA)-processing enzyme DICER1 and Alu RNA accumulation are linked to the pathogenesis of age-related macular degeneration (AMD). This study determined the optimal dose of lutein (LUT) and zeaxanthin (ZEA) to protect human retinal pigment epithelium (RPE) cells against hydrogen peroxide (H2O2). The effect of the optimal dose of LUT and ZEA as DICER1 and Alu RNA modulators in cultured human RPE cells challenged with H2O2 was investigated.Materials and methods: ARPE-19 cells were pre-treated with LUT, ZEA, or both for 24h before 200M H2O2 challenge. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. DICER1 and Alu RNA were quantified by western blotting and real-time polymerase chain reaction, respectively.Results: H2O2 increased cell Alu RNA expression and decreased cell viability of ARPE-19, but had no significant impact on the DICER1 protein level. LUT, alone and in combination with ZEA pre-treatment, prior to H2O2 challenge significantly improved cell viability of ARPE-19 and reduced the level of Alu RNA compared to the negative control.Conclusions: These results support the use of LUT alone, and in combination with ZEA, in AMD prevention and treatment. This study is also the first to report LUT modulating effects on Alu RNA.
C1 [Chong, You Sheng] Int Med Univ, Sch Med, Kuala Lumpur, Malaysia.
   [Mai, Chun Wai; Wong, Lai Chun] Int Med Univ, Sch Pharm, Dept Pharmaceut Chem, 126,Jalan Jalil Perkasa 19, Kuala Lumpur 57000, Malaysia.
   [Leong, Chee Onn] Int Med Univ, Sch Pharm, Dept Life Sci, Kuala Lumpur, Malaysia.
C3 International Medical University Malaysia; International Medical
   University Malaysia; International Medical University Malaysia
RP Wong, LC (通讯作者)，Int Med Univ, Sch Pharm, Dept Pharmaceut Chem, 126,Jalan Jalil Perkasa 19, Kuala Lumpur 57000, Malaysia.
EM laichunwong@imu.edu.my
RI Leong, Chee-Onn/C-9779-2013; Mai, Chun Wai/M-3972-2013; WONG, LAI
   CHUN/L-7148-2014
OI Leong, Chee-Onn/0000-0002-6353-9703; Mai, Chun Wai/0000-0001-6532-184X;
   WONG, LAI CHUN/0000-0003-0236-1275
FU International Medical University [BMS I02/2014 (09)]
FX This work was supported by the International Medical University under
   Grant number BMS I02/2014 (09).
CR American National Standards Institute, 2011, ASN00022011 ANSIATCC
   Arulkumaran N, 2011, EXPERT OPIN INV DRUG, V20, P897, DOI 10.1517/13543784.2011.578068
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Cheng YP, 2016, CHINESE J PHYSIOL, V59, P202, DOI 10.4077/CJP.2016.BAE404
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chung FFL, 2017, SCI REP-UK, V7, DOI 10.1038/srep42504
   Constable PA, 2006, EXP EYE RES, V83, P24, DOI 10.1016/j.exer.2005.10.029
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004
   Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9
   Ho JJD, 2012, J BIOL CHEM, V287, P29003, DOI 10.1074/jbc.M112.373365
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Hurst JS, 2005, EXP EYE RES, V81, P239, DOI 10.1016/j.exer.2005.04.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Kalariya NM, 2009, CURR EYE RES, V34, P737, DOI 10.1080/02713680903046855
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Kuznetsova AV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/801787
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lim CK, 2016, MED CHEM RES, V25, P1686, DOI 10.1007/s00044-016-1606-y
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Mai CW, 2016, FRONT PHARMACOL, V7, P1
   McGill TJ, 2016, INVEST OPHTH VIS SCI, V57, P1361, DOI 10.1167/iovs.15-18596
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Murthy RK, 2014, CUTAN OCUL TOXICOL, V33, P132, DOI 10.3109/15569527.2013.812108
   Nakajima Y, 2009, CURR EYE RES, V34, P311, DOI 10.1080/02713680902745408
   Pintea A, 2011, J FOOD COMPOS ANAL, V24, P830, DOI 10.1016/j.jfca.2011.03.007
   Qin S, 2007, DRUG DEVELOP RES, V68, P213, DOI 10.1002/ddr.20185
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   SIMPSON DA, 2003, INVEST OPHTH VIS S1, V44
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Song Min-Hae, 2015, Lab Anim Res, V31, P117, DOI 10.5625/lar.2015.31.3.117
   Soo HC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170551
   Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Tan BS, 2013, CANCER LETT, V336, P127, DOI 10.1016/j.canlet.2013.04.014
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Widomska Justyna, 2014, J Clin Exp Ophthalmol, V5, P326
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu XR, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/862806
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
NR 55
TC 9
Z9 9
U1 2
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PY 2018
VL 37
IS 1
BP 52
EP 60
DI 10.1080/15569527.2017.1335748
PG 9
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA FZ8DJ
UT WOS:000427835700009
PM 28554225
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Bakri, NM
   Ramachandran, V
   Kee, HF
   Subrayan, V
   Isa, H
   Ngah, NF
   Mohamad, NA
   Mooi, CS
   Mun, CY
   Ismail, P
   Ismail, F
   Sukiman, ES
   Sulaiman, WAW
AF Bakri, Norshakimah Md
   Ramachandran, Vasudevan
   Kee, Hoo Fan
   Subrayan, Visvaraja
   Isa, Hazlita
   Ngah, Nor Fariza
   Mohamad, Nur Afiqah
   Mooi, Ching Siew
   Mun, Chan Yoke
   Ismail, Patimah
   Ismail, Fazliana
   Sukiman, Erma Suryana
   Sulaiman, Wan Alia Wan
TI Association of copy number variations in complement factor H-Related
   genes among age-related macular degenerative subjects
SO KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration; Copy number variation; CFH gene;
   Malaysia
ID ELDERLY CHINESE POPULATION; RISK-FACTORS; EYE DISEASE; PREVALENCE;
   MACULOPATHY; TAIWAN
AB Age-related macular degeneration (AMD) is the most widely recognised cause of irreversible vision loss and previous studies have suggested that the advancement of wet AMD is influenced by both modifiable and non-modifiable elements. Single nucleotide polymorphism (SNPs) and copy number of variations (CNVs) have been associated with AMD in various populations, however the results are conflicting. Our aim is to determine the CNVs of Complement Factor H-Related genes among Malaysian subjects with wet AMD. 130 patients with wet AMD and 120 healthy controls were included in this research. DNA was extracted from all subjects and CNVs of CFH, CFHR1 and CFHR3 genes; determined using quantitative real-time PCR and were compared between the two groups. A consistent association was observed between Conflicts CFH gene and wet AMD susceptibility (P < 0.05). The age-adjusted data suggests a possible increased risk of AMD disease (P < 0.05). No correlation was detected between CNVs and wet AMD for the remaining genes after we compared the frequencies of mean for that gene. An association was observed between CFH CNVs and wet AMD in the Malaysian population, however, strong evidence of a link with wet AMD was not found. Further investigative studies are needed using larger sample sizes to elucidate the role of CNVs in AMD pathogenesis. Copyright (C) 2017, Kaohsiung Medical University. Published by Elsevier Taiwan LLC.
C1 [Bakri, Norshakimah Md; Ramachandran, Vasudevan; Mohamad, Nur Afiqah] Univ Putra Malaysia, Malaysian Res Inst Ageing, Serdang, Selangor De, Malaysia.
   [Kee, Hoo Fan; Mooi, Ching Siew; Sukiman, Erma Suryana; Sulaiman, Wan Alia Wan] Univ Putra Malaysia, Dept Med, Fac Med & Hlth Sci, Serdang, Selangor De, Malaysia.
   [Subrayan, Visvaraja; Ismail, Fazliana] Pusat Perubatan Univ Malaya, Dept Ophthalmol, Kuala Lumpur, Malaysia.
   [Isa, Hazlita] Univ Kebangsaan Malaysia, Dept Ophthalmol, Med Ctr, Kuala Lumpur, Malaysia.
   [Ngah, Nor Fariza] Hosp Selayang, Dept Ophthalmol, Batu Caves, Selangor, Malaysia.
   [Mun, Chan Yoke] Univ Putra Malaysia, Dept Nutr, Fac Med & Hlth Sci, Serdang, Selangor De, Malaysia.
   [Ismail, Patimah] Univ Putra Malaysia, Dept Biomed Sci, Fac Med & Hlth Sci, Serdang, Selangor De, Malaysia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Malaya;
   Universiti Kebangsaan Malaysia; Universiti Putra Malaysia; Universiti
   Putra Malaysia
RP Ramachandran, V (通讯作者)，Univ Putra Malaysia, Malaysian Res Inst Ageing, Serdang, Selangor De, Malaysia.
EM vasuphd@gmail.com
RI Ismail, Fazliana/AAT-1247-2021; Wan Sulaiman, Wan Aliaa
   Binti/AAF-8072-2021; ramachandran, vasudevan/C-3395-2008; Ching, Siew
   Mooi/I-5817-2013; Chan, Yoke Mun Yoke/L-2965-2015; Hoo, Fan
   Kee/J-2591-2013
OI Ismail, Fazliana/0000-0002-5117-3169; Wan Sulaiman, Wan Aliaa
   Binti/0000-0003-4969-0308; ramachandran, vasudevan/0000-0003-0044-1626;
   Ching, Siew Mooi/0000-0002-4425-7989; Chan, Yoke Mun
   Yoke/0000-0002-3853-736X; Hoo, Fan Kee/0000-0003-1687-627X; Isa,
   Hazlita/0000-0002-2731-8233; Mohamad, Nur Afiqah/0000-0002-9015-0525
FU Geran Putra IPS from Universiti Putra Malaysia [9476500]; Geran Putra
   Project from Universiti Putra Malaysia [9409800]
FX This study was supported by Geran Putra Project (No: 9409800) and Geran
   Putra IPS (9476500) from Universiti Putra Malaysia.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BoonPeng H, 2013, MOL CYTOGENET, V6, DOI 10.1186/1755-8166-6-8
   Camelo S., 2014, AUTOIMUNE DIS, V11, P27
   Cantsilieris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035255
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen Jiajia, 2013, Biomed Res Int, V2013, P658925, DOI 10.1155/2013/658925
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Eberhardt HU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078617
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Ferreira ID, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-1
   Fomby P., 2011, MOL MICROBIOL, V72, P181
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Graf SW, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3731
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Ionita-Laza I, 2009, GENOMICS, V93, P22, DOI 10.1016/j.ygeno.2008.08.012
   Ji HT, 2014, BMC EAR NOSE THROAT, V14, DOI 10.1186/1472-6815-14-9
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Kubista KE, 2011, MOL VIS, V17, P2080
   Kulkarni SR, 2013, INDIAN J OPHTHALMOL, V61, P196, DOI 10.4103/0301-4738.99870
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Montero JA, 2008, INTER J OPHTHAL, V2, P74
   Narendra U, 2009, MOL VIS, V15, P731
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Park JI, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0051377, 10.1371/journal.pone.0037010]
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Yang Y, 2007, AM J HUM GENET, V80, P1037, DOI 10.1086/518257
   Zhou J, 2010, INVEST OPHTH VIS SCI, V51, P3924, DOI 10.1167/iovs.10-5240
   [No title captured]
NR 39
TC 2
Z9 2
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1607-551X
EI 2410-8650
J9 KAOHSIUNG J MED SCI
JI Kaohsiung J. Med. Sci.
PD DEC
PY 2017
VL 33
IS 12
BP 602
EP 608
DI 10.1016/j.kjms.2017.08.003
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FN0NF
UT WOS:000415674200003
PM 29132549
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Prasad, T
   Zhu, P
   Verma, A
   Chakrabarty, P
   Rosario, AM
   Golde, TE
   Li, QH
AF Prasad, Tuhina
   Zhu, Ping
   Verma, Amrisha
   Chakrabarty, Paramita
   Rosario, Awilda M.
   Golde, Todd E.
   Li, Qiuhong
TI Amyloid beta peptides overexpression in retinal pigment epithelial cells
   via AAV-mediated gene transfer mimics AMD-like pathology in mice
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; COMPLEMENT ACTIVATION; PRECURSOR-PROTEIN; A-BETA;
   DRUSEN; DEPOSITION; DISEASE; PRESENILIN-1; PATHOGENESIS; MECHANISM
AB Age-related macular degeneration (AMD) is a progressive retinal neurodegenerative disorder characterized by extracellular deposits known as drusen. A major constituent of drusen deposits are Alzheimer disease-associated amyloid beta(A beta) peptides. To understand the etiology of A beta proteostasis in AMD, we delivered recombinant adeno-associated virus (AAV) encoding A beta 42 and A beta 40 peptides fused to BRI2 protein by intraocular injection in C57BL/6J mice. Endogenous protease cleavage of such constructs leads to production of secreted A beta 42 and A beta 40 respectively. We demonstrate that overexpression of secreted A beta 40 or A beta 42 resulted in dramatic induction of drusen-like deposits by 2 months' post-injection. These drusen-like deposits were immunopositive for A beta and complement proteins but did not stain for conventional amyloid dyes, such as Thioflavin S. Both injected cohorts showed gliosis and degenerative changes, though ERG responses were minimally affected. Intriguingly, simultaneous overexpression of BRI-A beta 40 or BRI-A42 together resulted in dose-dependent and cumulative changes reminiscent of AMD type pathology-drusen-like deposits, severe reduction in ERG responses, photoreceptor cell loss and gliosis. Here, we have established a physiological model of A beta containing deposits in wild-type mice that recapitulates major retinal pathophysiological features of AMD and will be instrumental in mechanistic understanding and development of therapeutic strategies against AMD.
C1 [Prasad, Tuhina; Zhu, Ping; Verma, Amrisha; Li, Qiuhong] Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
   [Chakrabarty, Paramita; Rosario, Awilda M.; Golde, Todd E.] Univ Florida, Dept Neurosci, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32610 USA.
   [Chakrabarty, Paramita; Rosario, Awilda M.; Golde, Todd E.] Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida
RP Li, QH (通讯作者)，Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
EM qli@ufl.edu
FU NIH [EY021752, EY024564]; American Diabetes Association; Bright Focus
   Foundation; NEI [P30 EY02172]; University of Florida; NATIONAL EYE
   INSTITUTE [R01EY021752, R01EY024564] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [P30AG028740] Funding Source: NIH RePORTER
FX Supported in part by NIH grants EY021752, EY024564, American Diabetes
   Association, and Bright Focus Foundation (Q. Li). Core facilities were
   supported by NEI grant P30 EY02172 and Research to Prevent Blindness to
   University of Florida.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5
   Chang YJ, 2014, FEBS J, V281, P2674, DOI 10.1111/febs.12813
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P816, DOI 10.1097/OPX.0000000000000337
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kim J, 2007, J NEUROSCI, V27, P627, DOI 10.1523/JNEUROSCI.4849-06.2007
   Kumar DKV, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1059
   Lawlor PA, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-11
   Lewis PA, 2001, BBA-MOL BASIS DIS, V1537, P58, DOI 10.1016/S0925-4439(01)00054-0
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656
   McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ohno-Matsui Kyoko, 2003, Nippon Ganka Gakkai Zasshi, V107, P657
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Roychaudhuri R, 2015, ACS CHEM NEUROSCI, V6, P1941, DOI 10.1021/acschemneuro.5b00180
   Schlingemann RO, 2009, PROG BRAIN RES, V175, P253, DOI 10.1016/S0079-6123(09)17517-9
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
NR 53
TC 21
Z9 21
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 12
PY 2017
VL 7
AR 3222
DI 10.1038/s41598-017-03397-2
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EX2UD
UT WOS:000403081900013
PM 28607377
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pittala, V
   Fidilio, A
   Lazzara, F
   Platania, CBM
   Salerno, L
   Foresti, R
   Drago, F
   Bucolo, C
AF Pittala, Valeria
   Fidilio, Annamaria
   Lazzara, Francesca
   Platania, Chiara Bianca Maria
   Salerno, Loredana
   Foresti, Roberta
   Drago, Filippo
   Bucolo, Claudio
TI Effects of Novel Nitric Oxide-Releasing Molecules against Oxidative
   Stress on Retinal Pigmented Epithelial Cells
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID ACID PHENETHYL ESTER; HEME OXYGENASE-1 GENE; SMOOTH-MUSCLE-CELLS;
   NF-KAPPA-B; ENDOTHELIAL-CELLS; CURCUMIN; INDUCTION; EXPRESSION;
   INHIBITION; INFLAMMATION
AB Oxidative stress is a hallmark of retinal degenerations such as age-related macular degeneration and diabetic retinopathy. Enhancement of heme oxygenase-1 (HO-1) activity in the retina would exert beneficial effects by protecting cells from oxidative stress, therefore promoting cell survival. Because a crosstalk exists between nitric oxide (NO) and HO-1 in promotion of cell survival under oxidative stress, we designed novel NO-releasing molecules also capable to induce HO-1. Starting from curcumin and caffeic acid phenethyl ester (CAPE), two known HO-1 inducers, the molecules were chemically modified by acylation with 4-bromo-butanoyl chloride and 2-chloro-propanoyl chloride, respectively, and then treated in the dark with AgNO3 to obtain the nitrate derivatives VP10/12 and VP10/39. Human retinal pigment epithelial cells (ARPE-19) subjected to H2O2-mediated oxidative stress were treated with the described NO-releasing compounds. VP10/39 showed significant (p < 0 05) antioxidant and protecting activity against oxidative damage, in comparison to VP10/12, which in turn showed at 100 mu M concentration a slight but significant cell toxicity. Only VP10/39 significantly (p < 0 05) induced HO-1 in ARPE-19, most likely through covalent bond formation at Cys151 of the Keap1-BTB domain, as revealed from molecular docking analysis. In conclusion, the present data indicate VP10/39 as a promising candidate to protect ARPE-19 cells against oxidative stress.
C1 [Pittala, Valeria; Salerno, Loredana] Univ Catania, Dept Drug Sci, Catania, Italy.
   [Fidilio, Annamaria; Lazzara, Francesca; Platania, Chiara Bianca Maria; Drago, Filippo; Bucolo, Claudio] Univ Catania, Sch Med, Sect Pharmacol, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Foresti, Roberta] Inserm U955, Equipe 12, F-94000 Creteil, France.
   [Foresti, Roberta] Univ Paris Est, Fac Med, F-94000 Creteil, France.
   [Drago, Filippo; Bucolo, Claudio] Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy.
C3 University of Catania; University of Catania; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Universite de Franche-Comte;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Catania
RP Bucolo, C (通讯作者)，Univ Catania, Sch Med, Sect Pharmacol, Dept Biomed & Biotechnol Sci, Catania, Italy.; Bucolo, C (通讯作者)，Univ Catania, Ctr Res Ocular Pharmacol CERFO, Catania, Italy.
EM claudio.bucolo@unict.it
RI Drago, Filippo/AAC-5090-2022; Drago, Francesco/H-7563-2019; Fidilio,
   Annamaria/GNP-1855-2022; Platania, Chiara BM/AHE-1140-2022
OI Fidilio, Annamaria/0000-0002-9279-0171; Lazzara,
   Francesca/0000-0002-9825-2104; Bucolo, Claudio/0000-0002-4879-4140;
   foresti, roberta/0000-0002-0836-7937; Pittala,
   Valeria/0000-0003-1856-0308; Platania, Chiara Bianca
   Maria/0000-0002-8630-5993
FU Ministry of Education, University and Research (MIUR) [PRIN 2015JXE7E8]
FX This work was supported by the National Grant PRIN 2015JXE7E8 from the
   Ministry of Education, University and Research (MIUR).
CR Abe Y, 1999, PHARMACOL RES, V39, P41, DOI 10.1006/phrs.1998.0404
   Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619
   Canning P, 2015, FREE RADICAL BIO MED, V88, P101, DOI 10.1016/j.freeradbiomed.2015.05.034
   Chen K, 2000, CELL MOL BIOL, V46, P609
   Cosso L, 2001, FREE RADICAL RES, V34, P189, DOI 10.1080/10715760100300171
   Cukiernik M, 2003, CURR EYE RES, V27, P301, DOI 10.1076/ceyr.27.5.301.17227
   daSilva JL, 1997, CURR EYE RES, V16, P380, DOI 10.1076/ceyr.16.4.380.10695
   Datta PK, 1999, KIDNEY INT, V55, P1734, DOI 10.1046/j.1523-1755.1999.00429.x
   Davies TG, 2016, J MED CHEM, V59, P3991, DOI 10.1021/acs.jmedchem.6b00228
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Foresti R, 1999, FREE RADICAL RES, V31, P459, DOI 10.1080/10715769900301031
   Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411
   Foresti R, 2015, PHARMACOL RES, V99, P296, DOI 10.1016/j.phrs.2015.07.006
   Garcia GA, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S103985
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   Goldstein IM, 1996, VISION RES, V36, P2979, DOI 10.1016/0042-6989(96)00017-X
   Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   Hishikawa K, 2005, ARTERIOSCL THROM VAS, V25, P442, DOI 10.1161/01.ATV.0000148404.24271.fc
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HUANG MT, 1991, CANCER RES, V51, P813
   Huerta C, 2016, BBA-GEN SUBJECTS, V1860, P2537, DOI 10.1016/j.bbagen.2016.07.026
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Kim JK, 2014, INT J MOL SCI, V15, P12149, DOI 10.3390/ijms150712149
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Matsuura T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9548767
   Michaluart P, 1999, CANCER RES, V59, P2347
   Ogura T, 2010, P NATL ACAD SCI USA, V107, P2842, DOI 10.1073/pnas.0914036107
   Paeng SH, 2015, INT J MOL MED, V35, P1419, DOI 10.3892/ijmm.2015.2116
   Pittala V., 2017, CURRENT PHARM DESIGN, V23
   Pittala V., 2017, CURRENT MED CHEM, V24
   Pittala V., 2016, CURRENT MED CHEM
   RAMOS KS, 1989, BIOCHEM PHARMACOL, V38, P1368, DOI 10.1016/0006-2952(89)90347-X
   REDDY ACP, 1992, MOL CELL BIOCHEM, V111, P117
   Scapagnini G, 2006, ANTIOXID REDOX SIGN, V8, P395, DOI 10.1089/ars.2006.8.395
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Son S, 2002, J AGR FOOD CHEM, V50, P468, DOI 10.1021/jf010830b
   STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577
   SUSAN M, 1992, ARZNEIMITTEL-FORSCH, V42-2, P962
   Tan JN, 2005, AM J PHYSIOL-HEART C, V289, pH2265, DOI 10.1152/ajpheart.01106.2004
   Toda N, 2007, PROG RETIN EYE RES, V26, P205, DOI 10.1016/j.preteyeres.2007.01.004
   Wang XY, 2008, EUR J PHARMACOL, V591, P28, DOI 10.1016/j.ejphar.2008.06.017
   Wang XY, 2010, EUR J PHARMACOL, V635, P16, DOI 10.1016/j.ejphar.2010.02.034
   Wei X, 2004, BRAIN, V127, P2629, DOI 10.1093/brain/awh316
   Woo JM, 2012, MOL VIS, V18, P901
   Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhu K, 2014, J CHEM INF MODEL, V54, P1932, DOI 10.1021/ci500118s
NR 54
TC 31
Z9 31
U1 2
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 1420892
DI 10.1155/2017/1420892
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FJ5IM
UT WOS:000412784900001
PM 29158871
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Hennig, R
   Ohlmann, A
   Staffel, J
   Pollinger, K
   Haunberger, A
   Breunig, M
   Schweda, F
   Tamm, ER
   Goepferich, A
AF Hennig, Robert
   Ohlmann, Andreas
   Staffel, Janina
   Pollinger, Klaus
   Haunberger, Alexandra
   Breunig, Miriam
   Schweda, Frank
   Tamm, Ernst R.
   Goepferich, Achim
TI Multivalent nanoparticles bind the retinal and choroidal vasculature
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Multivalency; EXP3174; Quantum dots; Age-related macular degeneration;
   Diabetic retinopathy; Angiotensin II
ID ANGIOTENSIN-II; QUANTUM DOTS; RECEPTOR; CANDESARTAN; NEOVASCULARIZATION;
   BIODISTRIBUTION; INFLAMMATION; ENDOTHELIUM; EXPRESSION; FENESTRATION
AB The angiotensin II receptor type 1 (AT(1)R), which is expressed in blood vessels of the posterior eye, is of paramount significance in the pathogenesis of severe ocular diseases such as diabetic retinopathy and age-related macular degeneration. However, small molecule angiotensin receptor blockers (ARBs) have not proven to be a significant therapeutic success. We report here on a nanoparticle system consisting of ARB molecules presented in a multivalent fashion on the surface of quantum dots (Qdots). As a result of the multivalent receptor binding, nanoparticles targeted cellswith high AT(1)R expression and inhibited their angiotensin receptor signaling with an IC50 of 3.8 nM while showing only minor association to cells with low AT(1)R expression. After intravenous injection into the tail vein of mice, multivalent nanoparticles accumulated in retinal and choroidal blood vessels of the posterior eye. At the same time, multivalent ligand display doubled the Qdot concentration in the blood vessels compared to non-targeted Qdots. Remarkably, ARB-targeted Qdots showed no pronounced accumulation in AT(1)R-expressing off-target tissues such as the kidney. Following systemic application, this multivalent targeting approach has the potential to amplify AT(1)R blockade in the eye and concomitantly deliver a therapeutic payload into ocular lesions. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Hennig, Robert; Pollinger, Klaus; Haunberger, Alexandra; Breunig, Miriam; Goepferich, Achim] Univ Regensburg, Dept Pharmaceut Technol, D-93053 Regensburg, Germany.
   [Ohlmann, Andreas; Tamm, Ernst R.] Univ Regensburg, Dept Human Anat & Embryol, D-93053 Regensburg, Germany.
   [Staffel, Janina; Schweda, Frank] Univ Regensburg, Dept Physiol, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg
RP Goepferich, A (通讯作者)，Univ Regensburg, Dept Pharmaceut Technol, Univ Str 31, D-93053 Regensburg, Germany.
EM achim.goepferich@chemie.uni-regensburg.de
RI Tamm, Ernst/AAB-9772-2019; Goepferich, Achim/G-1151-2016; Breunig,
   Miriam/K-2978-2016
OI Tamm, Ernst/0000-0002-6679-8743; Goepferich, Achim/0000-0002-7646-0252;
   Breunig, Miriam/0000-0002-1320-6820; Ohlmann,
   Andreas/0000-0002-7101-9361
FU Deutsche Forschungsgemeinschaft: DFG [GO565/18-1]
FX The authors thank Elke Stauber, Sabine Hofmeister, Katharina Ehm and
   Margit Schiller for their excellent technical assistance and Dr. Thilo
   Spruss and Franz Wiesenmayer for their assistance in animal experiments.
   Furthermore, we thank Paul Bisso for revising this manuscript. This work
   was supported by the Deutsche Forschungsgemeinschaft: DFG grant No
   GO565/18-1.
CR Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chaturvedi N, 2008, LANCET, V372, P1394, DOI 10.1016/S0140-6736(08)61412-9
   Chen J, 2009, INVEST OPHTH VIS SCI, V50, P1329, DOI 10.1167/iovs.08-2521
   Choi CHJ, 2011, P NATL ACAD SCI USA, V108, P6656, DOI 10.1073/pnas.1103573108
   Dandona P, 2007, J HUM HYPERTENS, V21, P20, DOI 10.1038/sj.jhh.1002101
   de Gasparo M, 2000, PHARMACOL REV, V52, P415
   Dinh DT, 2001, CLIN SCI, V100, P481, DOI 10.1042/CS20000263
   Elliott KJ, 2013, HYPERTENSION, V61, pE31, DOI 10.1161/HYPERTENSIONAHA.111.00943
   Feng D, 2000, MICROVASC RES, V59, P24, DOI 10.1006/mvre.1999.2207
   Fierens FLP, 2001, BIOCHEM PHARMACOL, V61, P1227, DOI 10.1016/S0006-2952(01)00614-1
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Galian RE, 2009, PHOTOCH PHOTOBIO SCI, V8, P70, DOI 10.1039/b807580h
   Gecer A, 2010, MACROMOL RES, V18, P986, DOI 10.1007/s13233-010-1004-0
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hennig R, 2015, EUR J PHARM BIOPHARM, V95, P294, DOI 10.1016/j.ejpb.2015.02.027
   Hennig R, 2015, J DRUG TARGET, V23, P681, DOI 10.3109/1061186X.2015.1035276
   Hennig R, 2014, J CONTROL RELEASE, V194, P20, DOI 10.1016/j.jconrel.2014.07.062
   Herrera M, 2013, HYPERTENSION, V61, P253, DOI 10.1161/HYPERTENSIONAHA.112.203679
   Hild WA, 2008, EUR J PHARM BIOPHARM, V68, P153, DOI 10.1016/j.ejpb.2007.06.009
   Hild W, 2010, P NATL ACAD SCI USA, V107, P10667, DOI 10.1073/pnas.0912782107
   Israili ZH, 2000, J HUM HYPERTENS, V14, pS73, DOI 10.1038/sj.jhh.1000991
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang J, 2009, J CELL PHYSIOL, V218, P66, DOI 10.1002/jcp.21566
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/NNM.11.19, 10.2217/nnm.11.19]
   Kaschina E, 2003, BLOOD PRESSURE, V12, P70, DOI 10.1080/08037050310001057
   Kecskes A, 2011, BIOCONJUGATE CHEM, V22, P1115, DOI 10.1021/bc1005812
   Khakoo AY, 2008, CANCER RES, V68, P9112, DOI 10.1158/0008-5472.CAN-08-0851
   Kim JH, 2009, J CEREBR BLOOD F MET, V29, P621, DOI 10.1038/jcbfm.2008.154
   Kurihara T, 2006, INVEST OPHTH VIS SCI, V47, P5545, DOI 10.1167/iovs.06-0478
   Li JY, 2010, J MOL MODEL, V16, P789, DOI 10.1007/s00894-009-0612-0
   Liu N, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-37
   Lu W, 2012, J CONTROL RELEASE, V161, P959, DOI 10.1016/j.jconrel.2012.05.014
   MANIL L, 1994, PHARMACEUT RES, V11, P1160, DOI 10.1023/A:1018993000633
   Mauer M, 2009, NEW ENGL J MED, V361, P40, DOI 10.1056/NEJMoa0808400
   Milenkovic VM, 2010, AM J PHYSIOL-RENAL, V299, pF396, DOI 10.1152/ajprenal.00576.2009
   Mulder WJM, 2005, FASEB J, V19, P2008, DOI 10.1096/fj.05-4145fje
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Narimatsu T, 2014, FREE RADICAL BIO MED, V71, P176, DOI 10.1016/j.freeradbiomed.2014.03.020
   Patel H., 2013, DRUG DELIV LETT, V3, P200
   Perrault SD, 2009, NANO LETT, V9, P1909, DOI 10.1021/nl900031y
   Pollinger K, 2014, J NANOSCI NANOTECHNO, V14, P3313, DOI 10.1166/jnn.2014.8716
   Pollinger K, 2013, P NATL ACAD SCI USA, V110, P6115, DOI 10.1073/pnas.1220281110
   Praetner M, 2010, BIOMATERIALS, V31, P6692, DOI 10.1016/j.biomaterials.2010.05.051
   Quarmby S, 2000, ANTICANCER RES, V20, P3375
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   RICHES AC, 1973, J PHYSIOL-LONDON, V228, P279, DOI 10.1113/jphysiol.1973.sp010086
   Schipper ML, 2007, J NUCL MED, V48, P1511, DOI 10.2967/jnumed.107.040071
   Sewell SL, 2011, J BIOMED NANOTECHNOL, V7, P685, DOI 10.1166/jbn.2011.1328
   Shimizu H, 2010, J AM SOC NEPHROL, V21, P622, DOI 10.1681/ASN.2009030295
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Singh N, 2005, INVEST OPHTH VIS SCI, V46, P1647, DOI 10.1167/iovs.04-1172
   Sjolie AK, 2008, LANCET, V372, P1385, DOI 10.1016/S0140-6736(08)61411-7
   Smith BR, 2008, NANO LETT, V8, P2599, DOI 10.1021/nl080141f
   Stitt AW, 2013, CLIN SCI, V125, P1, DOI 10.1042/CS20120588
   SUGITA A, 1982, JPN J OPHTHALMOL, V26, P47
   Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6
   Vaculikova E, 2012, MOLECULES, V17, P13221, DOI 10.3390/molecules171113221
   van Dongen MA, 2014, MOL PHARMACEUT, V11, P1696, DOI 10.1021/mp5000967
   Wang J, 2010, J AM CHEM SOC, V132, P11306, DOI 10.1021/ja1043177
   Wang M, 2010, PHARMACOL RES, V62, P90, DOI 10.1016/j.phrs.2010.03.005
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   White A.J.R., 2014, J RENIN-ANGIO-ALDO S, V16, P59
   Ye L, 2012, NAT NANOTECHNOL, V7, P453, DOI [10.1038/nnano.2012.74, 10.1038/NNANO.2012.74]
NR 65
TC 9
Z9 9
U1 0
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 28
PY 2015
VL 220
BP 265
EP 274
DI 10.1016/j.jconrel.2015.10.033
PN A
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA CY0TN
UT WOS:000366119100030
PM 26494258
DA 2022-11-30
ER

PT J
AU Zhang, LL
   Si, T
   Fischer, AJ
   Letson, A
   Yuan, S
   Roberts, CJ
   Xu, RX
AF Zhang, Leilei
   Si, Ting
   Fischer, Andrew J.
   Letson, Alan
   Yuan, Shuai
   Roberts, Cynthia J.
   Xu, Ronald X.
TI Coaxial Electrospray of Ranibizumab-Loaded Microparticles for Sustained
   Release of Anti-VEGF Therapies
SO PLOS ONE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; PHOTORECEPTOR CELL-DEATH; MACULAR DEGENERATION;
   MULLER GLIA; PIGMENTED EPITHELIUM; RETINITIS-PIGMENTOSA; CHICKEN RETINA;
   NANOPARTICLES; DELIVERY; DAMAGE
AB Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in people over age 65 in industrialized nations. Intravitreous injection of anti-VEGF (vascular endothelial growth factor) therapies, such as ranibizumab (trade name: Lucentis), provides an effective treatment option for neovascular AMD. We have developed an improved coaxial electrospray (CES) process to encapsulate ranibizumab in poly(lactic-co-glycolic) acid (PLGA) microparticles (MPs) for intravitreous injection and sustained drug release. This microencapsulation process is advantageous for maintaining the stability of the coaxial cone-jet configurations and producing drug-loaded MPs with as high as 70% encapsulation rate and minimal loss of bioactivitiy. The utility of this emerging process in intravitreous drug delivery has been demonstrated in both benchtop and in vivo experiments. The benchtop test simulates ocular drug release using PLGA MPs encapsulating a model drug. The in vivo experiment evaluates the inflammation and retinal cell death after intravitreal injection of the MPs in a chick model. The experimental results show that the drug-load MPs are able to facilitate sustained drug release for longer than one month. No significant long term microglia reaction or cell death is observed after intravitreal injection of 200 mu g MPs. The present study demonstrates the technical feasibility of using the improved CES process to encapsulate water-soluble drugs at a high concentration for sustained release of anti-VEGF therapy.
C1 [Zhang, Leilei; Si, Ting; Roberts, Cynthia J.; Xu, Ronald X.] Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA.
   [Si, Ting; Yuan, Shuai; Xu, Ronald X.] Univ Sci & Technol China, Sch Engn Sci, Hefei 230027, Anhui, Peoples R China.
   [Fischer, Andrew J.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA.
   [Letson, Alan; Roberts, Cynthia J.] Ohio State Univ, Dept Ophthalmol, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University; Chinese Academy of
   Sciences; University of Science & Technology of China, CAS; University
   System of Ohio; Ohio State University; University System of Ohio; Ohio
   State University
RP Xu, RX (通讯作者)，Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA.
EM xu.ronald@hotmail.com
RI Zhang, Lei/GYQ-7446-2022; Si, Ting/D-9203-2018
OI Si, Ting/0000-0001-9071-8646
FU Ohio Lion's Eye Research Foundation; National Natural Science Foundation
   of China [11472270, 81327803]; Fundamental Research Funds for the
   Central Universities
FX Leilei Zhang is supported by a research fellowship provided by Ohio
   Lion's Eye Research Foundation. This work is partially supported by the
   National Natural Science Foundation of China (11472270, 81327803) and
   the Fundamental Research Funds for the Central Universities.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arroba AI, 2011, INVEST OPHTH VIS SCI, V52, P9124, DOI 10.1167/iovs.11-7736
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bejjani R, 2005, MOL VIS, V11, P124
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Cebulla CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044257
   Cruysberg LPJ, 2002, J OCUL PHARMACOL TH, V18, P559, DOI 10.1089/108076802321021108
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Fischer AJ, 1999, J COMP NEUROL, V405, P1, DOI 10.1002/(SICI)1096-9861(19990301)405:1<1::AID-CNE1>3.0.CO;2-U
   Fischer AJ, 2004, MOL VIS, V10, P973
   Fischer AJ, 2004, MOL CELL NEUROSCI, V27, P531, DOI 10.1016/j.mcn.2004.08.007
   Fischer AJ, 1999, VISION RES, V39, P685, DOI 10.1016/S0042-6989(98)00178-3
   Fischer AJ, 1998, J COMP NEUROL, V393, P1
   Fischer AJ, 2002, J NEUROSCI, V22, P9387
   Fischer AJ, 2010, GLIA, V58, P633, DOI 10.1002/glia.20950
   Fischer AJ, 2009, GLIA, V57, P166, DOI 10.1002/glia.20743
   Ghai K, 2010, J NEUROSCI, V30, P3101, DOI 10.1523/JNEUROSCI.4919-09.2010
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Muller RH, 2004, J BIOTECHNOL, V113, P151, DOI 10.1016/j.jbiotec.2004.06.007
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153
   QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774
   Ritchey ER, 2012, EXP EYE RES, V99, P1, DOI 10.1016/j.exer.2012.03.019
   Ritchey ER, 2011, MOL VIS, V17, P2440
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   SHAHINFAR S, 1991, CURR EYE RES, V10, P47, DOI 10.3109/02713689109007610
   Si T, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.7.075003
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Tomlinson IM, 2004, NAT BIOTECHNOL, V22, P521, DOI 10.1038/nbt0504-521
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Zhang LL, 2012, EXPERT REV MED DEVIC, V9, P595, DOI [10.1586/ERD.12.58, 10.1586/erd.12.58]
   Zulliger R, 2011, GRAEF ARCH CLIN EXP, V249, P859, DOI 10.1007/s00417-010-1584-6
NR 38
TC 22
Z9 26
U1 0
U2 37
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2015
VL 10
IS 8
AR e0135608
DI 10.1371/journal.pone.0135608
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO9KD
UT WOS:000359493600082
PM 26273831
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Bhavsar, AR
   Sandler, DR
AF Bhavsar, Abdhish R.
   Sandler, Danielle R.
TI ELIMINATING ANTIBIOTIC PROPHYLAXIS FOR INTRAVITREAL INJECTIONS A
   Consecutive Series of 18,839 Injections by a Single Surgeon
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE antibiotics; bevacizumab; complications; eliminating; endophthalmitis;
   intravitreal injection; omitting; ranibizumab; triamcinolone; vascular
   endothelial growth factor
ID POVIDONE-IODINE; ENDOPHTHALMITIS; RISK; RANIBIZUMAB; PENETRATION;
   LEVOFLOXACIN; RESISTANCE; OFLOXACIN; EYE
AB Purpose: By optimizing the protocol for intravitreal injections, the risk of endophthalmitis can be minimized. This study assesses the incidence of endophthalmitis and other complications after a consecutive series of intravitreal injections where all antibiotics were excluded.
   Methods: Injections were performed from August 1, 1997 to October 31, 2012 in outpatient examination rooms at the Retina Center of Minnesota by a single retinal surgeon, the lead author. Most injections were performed to treat exudative age-related macular degeneration. Other reasons included diabetic macular edema, cystoid macular edema because of retinal vein occlusions, cytomegalovirus retinitis, and severe uveitis. Injections were given with topical povidone-iodine, proparacaine, and tetracaine, a sterile eyelid speculum, and clean nonsterile gloves, but without any antibiotics. Data were retrospectively analyzed using billing codes from a computer database system.
   Results: A total of 18,839 injections were given. Of these, the following injections were administered: bevacizumab, 15,479 (82.16%); ranibizumab, 1,669 (8.86%); triamcinolone acetonide (Kenalog- 40), 1,014 (5.38%); pegaptanib sodium, 370 (1.96%); aflibercept, 148 (0.79%); dexamethasone implant, 88 (0.47%); triamcinolone acetonide (Triesence), 32 (0.17%); dexamethasone, 29 (0.15%); and ganciclovir, 10 (0.05%). There was one case of postinjection endophthalmitis. The incidence of endophthalmitis per injection was 0.0053%.
   Conclusion: A low incidence of endophthalmitis can be achieved when topical antibiotics are omitted.
C1 [Bhavsar, Abdhish R.] Retina Ctr Minnesota, Minneapolis, MN USA.
   [Sandler, Danielle R.] Midwestern Univ, Glendale, AZ USA.
C3 Midwestern University
RP Bhavsar, AR (通讯作者)，Retina Ctr, 710 East 24th St,Suite 304, Minneapolis, MN 55404 USA.
EM bhavs001@umn.edu
RI Bhavsar, Abdhish/AHC-3614-2022
OI Bhavsar, Abdhish/0000-0002-3316-7152; ISEN,
   DANIELLE/0000-0002-4631-6129; Isen, Danielle/0000-0002-4777-9360
CR APT L, 1995, AM J OPHTHALMOL, V119, P701, DOI 10.1016/S0002-9394(14)72773-4
   Bhatt SS, 2011, RETINA-J RET VIT DIS, V31, P2032, DOI 10.1097/IAE.0b013e31820f4b4f
   Bhavsar AR, 2013, EYE, V27, P1426, DOI 10.1038/eye.2013.225
   Bhavsar AR, 2012, ARCH OPHTHALMOL-CHIC, V130, P809, DOI 10.1001/archophthalmol.2012.227
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Bhavsar AR, 2013, RETINAL PHYS
   Brynskov T, 2014, RETINA-J RET VIT DIS, V34, P951, DOI 10.1097/IAE.0000000000000071
   Callegan MC, 2009, ADV THER, V26, P447, DOI 10.1007/s12325-009-0018-5
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Dave SB, 2011, OPHTHALMOLOGY, V118, P2035, DOI 10.1016/j.ophtha.2011.03.017
   Englander M, 2013, BRIT J OPHTHALMOL, V97, P460, DOI 10.1136/bjophthalmol-2012-302435
   Falavarjani KG, 2013, RETINA-J RET VIT DIS, V33, P971, DOI 10.1097/IAE.0b013e31826f0675
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hyon JY, 2009, J CATARACT REFR SURG, V35, P1609, DOI 10.1016/j.jcrs.2009.04.036
   ISENBERG SJ, 1985, ARCH OPHTHALMOL-CHIC, V103, P1340, DOI 10.1001/archopht.1985.01050090092039
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kim SJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P1180, DOI 10.1001/archophthalmol.2011.213
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Meyer CH, 2007, OPHTHALMOLOGE, V104, P952, DOI 10.1007/s00347-007-1634-6
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Moss JM, 2009, OPHTHALMOLOGY, V116, P1498, DOI 10.1016/j.ophtha.2009.02.024
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Puustjarvi T, 2006, GRAEF ARCH CLIN EXP, V244, P1633, DOI 10.1007/s00417-006-0360-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakamoto H, 2007, EUR J OPHTHALMOL, V17, P372, DOI 10.1177/112067210701700316
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   Shimada H, 2013, GRAEF ARCH CLIN EXP, V251, P1885, DOI 10.1007/s00417-013-2274-y
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1769
   Yalvac IS, 2003, J CATARACT REFR SURG, V29, P487, DOI 10.1016/S0886-3350(02)01538-9
   Yin VT, 2013, JAMA OPHTHALMOL, V131, P456, DOI 10.1001/jamaophthalmol.2013.2379
NR 31
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2015
VL 35
IS 4
BP 783
EP 788
DI 10.1097/IAE.0000000000000392
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE5OL
UT WOS:000351884900029
PM 25526099
DA 2022-11-30
ER

PT J
AU Karlstetter, M
   Scholz, R
   Rutar, M
   Wong, WT
   Provis, JM
   Langmann, T
AF Karlstetter, Marcus
   Scholz, Rebecca
   Rutar, Matt
   Wong, Wai T.
   Provis, Jan M.
   Langmann, Thomas
TI Retinal microglia: Just bystander or target for therapy?
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Retinal microglia; Retinal dystrophies; Age-related macular
   degeneration; Diabetic retinopathy; Glaucoma; Complement system; Aging;
   Neuroinflammation
ID NECROSIS-FACTOR-ALPHA; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; LINKED
   RETINITIS-PIGMENTOSA; ENDOTHELIAL GROWTH-FACTOR; PHOTORECEPTOR
   CELL-DEATH; FACTOR-H POLYMORPHISM; FATTY-ACID CONTENT; OPTIC-NERVE HEAD;
   18 KDA TSPO; NF-KAPPA-B
AB Resident microglial cells can be regarded as the immunological watchdogs of the brain and the retina. They are active sensors of their neuronal microenvironment and rapidly respond to various insults with a morphological and functional transformation into reactive phagocytes. There is strong evidence from animal models and in situ analyses of human tissue that microglial reactivity is a common hallmark of various retinal degenerative and inflammatory diseases. These include rare hereditary retinopathies such as retinitis pigmentosa and X-linked juvenile retinoschisis but also comprise more common multifactorial retinal diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma, and uveitis as well as neurological disorders with ocular manifestation. In this review, we describe how microglial function is kept in balance under normal conditions by cross-talk with other retinal cells and summarize how microglia respond to different forms of retinal injury. In addition, we present the concept that microglia play a key role in local regulation of complement in the retina and specify aspects of microglial aging relevant for chronic inflammatory processes in the retina. We conclude that this resident immune cell of the retina cannot be simply regarded as bystander of disease but may instead be a potential therapeutic target to be modulated in the treatment of degenerative and inflammatory diseases of the retina. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Karlstetter, Marcus; Scholz, Rebecca; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, D-50931 Cologne, Germany.
   [Rutar, Matt; Provis, Jan M.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
   [Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
C3 University of Cologne; Australian National University; John Curtin
   School of Medical Research; National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI)
RP Langmann, T (通讯作者)，Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Kerpener Str 62, D-50931 Cologne, Germany.
EM thomas.langmann@uk-koeln.de
RI Wong, Wai/B-6118-2017; Provis, Jan/C-9529-2009
OI Wong, Wai/0000-0003-0681-4016; Provis, Jan/0000-0002-6405-2868; Rutar,
   Matthew/0000-0002-8893-5120
FU DFG [LA1203/6-2, LA1203/8-1]; Hans und Marlies Stock-Foundation; Pro
   Retina Foundation; Novartis EYEnovative Program; Bayer Graduate Program
   in Pharmacology; NATIONAL EYE INSTITUTE [ZIAEY000541, ZIAEY000505]
   Funding Source: NIH RePORTER
FX This work was supported by the DFG (LA1203/6-2 and LA1203/8-1), the Hans
   und Marlies Stock-Foundation, the Pro Retina Foundation, the Novartis
   EYEnovative Program, and the Bayer Graduate Program in Pharmacology.
CR Abcouwer SF, 2014, ANN NY ACAD SCI, V1311, P174, DOI 10.1111/nyas.12412
   Aguirre GD, 1997, INVEST OPHTH VIS SCI, V38, P2387
   Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P1247, DOI 10.1167/iovs.03-1123
   Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Ajmone-Cat MA, 2012, J NEUROSCI RES, V90, P575, DOI 10.1002/jnr.22783
   Albini TA, 2005, BRIT J OPHTHALMOL, V89, P901, DOI 10.1136/bjo.2004.060293
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794
   Anderson RE, 2002, MOL VIS, V8, P351
   Anderson RE, 1997, EXP EYE RES, V64, P181, DOI 10.1006/exer.1996.0195
   Andrieu-Soler C, 2005, MOL VIS, V11
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bachstetter AD, 2011, NEUROBIOL AGING, V32, P2030, DOI 10.1016/j.neurobiolaging.2009.11.022
   Bakalash S, 2007, INVEST OPHTH VIS SCI, V48, P1181, DOI 10.1167/iovs.05-1213
   Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144
   Banerjee D, 2004, OCUL IMMUNOL INFLAMM, V12, P115, DOI 10.1080/09273940490895326
   Barber AJ, 2005, INVEST OPHTH VIS SCI, V46, P2210, DOI 10.1167/iovs.04-1340
   Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P450, DOI 10.1016/j.bbi.2009.01.016
   Baumgartner WA, 2013, MED HYPOTHESES, V81, P720, DOI 10.1016/j.mehy.2013.07.036
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131
   Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006
   Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459
   Bialas AR, 2013, NAT NEUROSCI, V16, P1773, DOI 10.1038/nn.3560
   Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007
   Blanquet-Grossard F, 2005, BIOCHEMISTRY-US, V44, P4349, DOI 10.1021/bi047370a
   Bodeutsch N, 2000, GLIA, V32, P91, DOI 10.1002/1098-1136(200010)32:1<91::AID-GLIA90>3.0.CO;2-X
   Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337
   Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516
   Botto M, 1998, EXP CLIN IMMUNOGENET, V15, P231, DOI 10.1159/000019076
   Bouhenni RA, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/692609
   Broderick C, 2002, AM J PATHOL, V161, P1669, DOI 10.1016/S0002-9440(10)64444-6
   Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710
   Brown GC, 2012, TRENDS BIOCHEM SCI, V37, P325, DOI 10.1016/j.tibs.2012.05.002
   Buchanan JB, 2008, PSYCHONEUROENDOCRINO, V33, P755, DOI 10.1016/j.psyneuen.2008.02.013
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717
   Carter DA, 2004, CURR EYE RES, V28, P427, DOI 10.1080/02713680490503778
   Carter JH, 2007, J IMMUNOL, V178, P3038, DOI 10.4049/jimmunol.178.5.3038
   Carwile ME, 1998, EXP EYE RES, V66, P791, DOI 10.1006/exer.1998.0488
   Caspi RR, 2014, DISCOV MED, V17, P155
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   Chan EC, 2013, INVEST OPHTH VIS SCI, V54, P7061, DOI 10.1167/iovs.13-12883
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chang B, 2013, INVEST OPHTH VIS SCI, V54, P4974, DOI 10.1167/iovs.13-12289
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen XT, 2013, J NEUROPATH EXP NEUR, V72, P782, DOI 10.1097/NEN.0b013e31829e8375
   Cheng Christiana L, 2013, Mol Vis, V19, P955
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Chinnery HR, 2012, AM J PATHOL, V180, P209, DOI 10.1016/j.ajpath.2011.09.041
   Chu CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063002
   Clements RS, 1998, J DIABETES COMPLICAT, V12, P28, DOI 10.1016/S1056-8727(97)00051-2
   Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Copland DA, 2010, CLIN EXP IMMUNOL, V159, P303, DOI 10.1111/j.1365-2249.2009.04070.x
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Cottet S, 2009, CURR MOL MED, V9, P375, DOI 10.2174/156652409787847155
   Couturier A, 2014, MOL VIS, V20, P908
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cukras CA, 2012, INVEST OPHTH VIS SCI, V53, P3865, DOI 10.1167/iovs.11-9413
   D'Orazio TJ, 1998, J IMMUNOL, V160, P2089
   Dagkalis A, 2009, INVEST OPHTH VIS SCI, V50, P4288, DOI 10.1167/iovs.09-3434
   Dagkalis A, 2009, IMMUNOLOGY, V128, P25, DOI 10.1111/j.1365-2567.2009.03046.x
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   DAVIES KA, 1994, SPRINGER SEMIN IMMUN, V15, P397, DOI 10.1007/BF01837367
   de Hoz Rosa, 2013, PLoS One, V8, pe83733, DOI 10.1371/journal.pone.0083733
   De Smedt-Peyrusse V, 2008, J NEUROCHEM, V105, P296, DOI 10.1111/j.1471-4159.2007.05129.x
   DIAZARAYA CM, 1995, J COMP NEUROL, V363, P53, DOI 10.1002/cne.903630106
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Dick AD, 2001, INVEST OPHTH VIS SCI, V42, P170
   DICK AD, 1994, EYE, V8, P52, DOI 10.1038/eye.1994.10
   Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001
   Dornstauder B, 2012, INVEST OPHTH VIS SCI, V53, P2256, DOI 10.1167/iovs.11-8569
   Ebert S, 2008, J LEUKOCYTE BIOL, V84, P736, DOI 10.1189/jlb.0208138
   Ebert S, 2012, ADV EXP MED BIOL, V723, P619, DOI 10.1007/978-1-4614-0631-0_79
   Ebert S, 2009, J NEUROCHEM, V110, P1863, DOI 10.1111/j.1471-4159.2009.06286.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040
   Eter N, 2008, INVEST OPHTH VIS SCI, V49, P3649, DOI 10.1167/iovs.07-1322
   Fairless R, 2012, J NEUROSCI, V32, P5585, DOI 10.1523/JNEUROSCI.5705-11.2012
   Fan W, 2010, OPHTHALMOL EYE DIS, V2, P23
   FEARON DT, 1980, NEW ENGL J MED, V303, P259, DOI 10.1056/NEJM198007313030505
   Ferrer-Martin RM, 2014, EXP EYE RES, V121, P42, DOI 10.1016/j.exer.2014.02.015
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973
   Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8
   Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013
   FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92
   Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Gaucher D, 2007, VISION RES, V47, P612, DOI 10.1016/j.visres.2006.11.017
   Gehrig A, 2007, INVEST OPHTH VIS SCI, V48, P891, DOI 10.1167/iovs.06-0641
   Gillingham MB, 2005, MOL GENET METAB, V86, P124, DOI 10.1016/j.ymgme.2005.06.001
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   GOTO Y, 1976, TOHOKU J EXP MED, V119, P85, DOI 10.1620/tjem.119.85
   Goto Y, 1988, Adv Exp Med Biol, V246, P29
   Green AJ, 2010, BRAIN, V133, P1591, DOI 10.1093/brain/awq080
   Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halder SK, 2013, J NEUROCHEM, V126, P243, DOI 10.1111/jnc.12262
   Harada C, 2003, NEUROSCIENCE, V122, P229, DOI 10.1016/S0306-4522(03)00599-2
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004
   Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805
   He LF, 2010, BRAIN RES, V1339, P60, DOI 10.1016/j.brainres.2010.04.014
   Hefendehl JK, 2014, AGING CELL, V13, P60, DOI 10.1111/acel.12149
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hisahara S, 2001, J EXP MED, V193, P111, DOI 10.1084/jem.193.1.111
   Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768
   Hoffman DR, 2014, JAMA OPHTHALMOL, V132, P866, DOI 10.1001/jamaophthalmol.2014.1634
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Horstmann L, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-120
   Howell GR, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-45
   Howell GR, 2014, NEUROBIOL DIS, V71, P44, DOI 10.1016/j.nbd.2014.07.016
   Howell GR, 2012, J CLIN INVEST, V122, P1246, DOI 10.1172/JCI61135
   Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646
   Huang JJ, 2012, BRAIN BEHAV, V2, P85, DOI 10.1002/brb3.39
   Hughbanks-Wheaton DK, 2014, INVEST OPHTH VIS SCI, V55, P4958, DOI 10.1167/iovs.14-14437
   HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253
   Ibrahim AS, 2011, DIABETES, V60, P1122, DOI 10.2337/db10-1160
   Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jawad S, 2013, INVEST OPHTH VIS SCI, V54, P5959, DOI 10.1167/iovs.12-11380
   Jiang ZL, 2014, IMMUNOL LETT, V160, P17, DOI 10.1016/j.imlet.2014.03.006
   Joachim SC, 2010, CURR EYE RES, V35, P900, DOI 10.3109/02713683.2010.495829
   Joachim SC, 2014, J MOL NEUROSCI, V52, P216, DOI 10.1007/s12031-013-0125-2
   Joachim SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040616
   Joachim SC, 2009, INVEST OPHTH VIS SCI, V50, P4734, DOI 10.1167/iovs.08-3144
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Joly S, 2008, J NEUROSCI, V28, P13765, DOI 10.1523/JNEUROSCI.5114-08.2008
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kaneko H, 2008, INVEST OPHTH VIS SCI, V49, P4162, DOI 10.1167/iovs.08-1738
   Karlstetter M, 2014, HUM MOL GENET, V23, P5197, DOI 10.1093/hmg/ddu242
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Karlstetter M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-125
   Karlstetter M, 2010, J IMMUNOL, V185, P3379, DOI 10.4049/jimmunol.0903300
   KEELER C, 1966, J HERED, V57, P47, DOI 10.1093/oxfordjournals.jhered.a107462
   Keeler CE, 1924, P NATL ACAD SCI USA, V10, P329, DOI 10.1073/pnas.10.7.329
   Kermorvant-Duchemin E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079545
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Kerr EC, 2008, PROG RETIN EYE RES, V27, P527, DOI 10.1016/j.preteyeres.2008.07.001
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Kezic J, 2008, J LEUKOCYTE BIOL, V84, P721, DOI 10.1189/jlb.0308166
   Kezic J, 2010, INVEST OPHTH VIS SCI, V51, P5121, DOI 10.1167/iovs.10-5325
   Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P3028, DOI 10.1167/iovs.13-11865
   Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P854, DOI 10.1167/iovs.12-10876
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Korb LC, 1997, J IMMUNOL, V158, P4525
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Lai AKW, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/106594
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Langmann T, 2009, NEUROMOL MED, V11, P87, DOI 10.1007/s12017-009-8061-6
   Laspas P, 2011, INVEST OPHTH VIS SCI, V52, P8835, DOI 10.1167/iovs.10-6889
   LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Li Y, 2012, DEV CELL, V23, P1189, DOI 10.1016/j.devcel.2012.10.027
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130
   Lionakis MS, 2011, J INNATE IMMUN, V3, P180, DOI 10.1159/000321157
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Liu S, 2012, INVEST OPHTH VIS SCI, V53, P6254, DOI 10.1167/iovs.12-9450
   London A, 2013, J IMMUNOL, V190, P3570, DOI 10.4049/jimmunol.1202076
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luo C, 2011, MOL VIS, V17, P1588
   Luo C, 2010, INVEST OPHTH VIS SCI, V51, P5697, DOI 10.1167/iovs.10-5407
   Lyons A, 2009, BRAIN BEHAV IMMUN, V23, P1020, DOI 10.1016/j.bbi.2009.05.060
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Maneu V, 2014, INVEST OPHTH VIS SCI, V55, P3578, DOI 10.1167/iovs.14-14051
   Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8
   Martin RE, 2004, MOL VIS, V10, P199
   Matsubara T, 1999, INVEST OPHTH VIS SCI, V40, P3186
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McLenachan S, 2013, CLIN EXP OPHTHALMOL, V41, P582, DOI 10.1111/ceo.12084
   Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015
   Mirza M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075963
   Mo JS, 2003, J EXP MED, V197, P1335, DOI 10.1084/jem.20022041
   Moore S, 1996, PROG NEUROBIOL, V48, P441, DOI 10.1016/0301-0082(95)00051-8
   Mouton PR, 2002, BRAIN RES, V956, P30, DOI 10.1016/S0006-8993(02)03475-3
   Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962
   Nathan C, 2001, NAT IMMUNOL, V2, P17, DOI 10.1038/83124
   Natoli R, 2008, MOL VIS, V14, P1983
   Navratil JS, 1999, IMMUNOPHARMACOLOGY, V42, P47, DOI 10.1016/S0162-3109(99)00018-1
   Neher JJ, 2014, GLIA, V62, P1463, DOI 10.1002/glia.22693
   Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Ohsawa K, 2000, J CELL SCI, V113, P3073
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Paglinawan R, 2003, GLIA, V44, P219, DOI 10.1002/glia.10286
   Paidassi H, 2008, J IMMUNOL, V180, P2329, DOI 10.4049/jimmunol.180.4.2329
   Pang IH, 2007, J GLAUCOMA, V16, P483, DOI 10.1097/IJG.0b013e3181405d4f
   Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529
   Paques M, 2010, GLIA, V58, P1663, DOI 10.1002/glia.21037
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   Peinado MA, 1998, MICROSC RES TECHNIQ, V43, P34, DOI 10.1002/(SICI)1097-0029(19981001)43:1<34::AID-JEMT6>3.3.CO;2-7
   PENFOLD PL, 1991, VISUAL NEUROSCI, V7, P383, DOI 10.1017/S0952523800004879
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5
   PITTLER SJ, 1993, P NATL ACAD SCI USA, V90, P9616, DOI 10.1073/pnas.90.20.9616
   Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191
   Provis JM, 1996, PERSPECT DEV NEUROBI, V3, P213
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ransohoff RM, 2007, NAT NEUROSCI, V10, P1507, DOI 10.1038/nn1207-1507
   Rao NA, 2003, INVEST OPHTH VIS SCI, V44, P22, DOI 10.1167/iovs.02-0199
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Read RW, 2006, EXP EYE RES, V82, P389, DOI 10.1016/j.exer.2005.07.011
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Ripoll VM, 2007, J IMMUNOL, V178, P6557, DOI 10.4049/jimmunol.178.10.6557
   Ritter MR, 2006, J CLIN INVEST, V116, P3266, DOI 10.1172/JCI29683
   Rivera JC, 2013, ARTERIOSCL THROM VAS, V33, P1881, DOI 10.1161/ATVBAHA.113.301331
   Rohrer B, 2004, J BIOL CHEM, V279, P41903, DOI 10.1074/jbc.M405085200
   Rohrer B, 2007, EXP EYE RES, V84, P82, DOI 10.1016/j.exer.2006.08.017
   Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133
   Rolls A, 2006, FASEB J, V20, P547, DOI 10.1096/fj.05-4540fje
   Rosczyk HA, 2008, EXP GERONTOL, V43, P840, DOI 10.1016/j.exger.2008.06.004
   Roumier A, 2004, J NEUROSCI, V24, P11421, DOI 10.1523/JNEUROSCI.2251-04.2004
   Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295
   Rutar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093343
   Rutar M, 2012, ADV EXP MED BIOL, V723, P31, DOI 10.1007/978-1-4614-0631-0_5
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Rymo SF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015846
   Ryu JK, 2009, J NEUROSCI, V29, P3, DOI 10.1523/JNEUROSCI.2888-08.2009
   Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008
   Samuel MA, 2014, NAT NEUROSCI, V17, P1190, DOI 10.1038/nn.3772
   Sancho-Pelluz J, 2008, INVEST OPHTH VIS SCI, V49, P5602, DOI 10.1167/iovs.08-2117
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Santos AM, 2010, J COMP NEUROL, V518, P477, DOI 10.1002/cne.22227
   Sappington RM, 2008, INVEST OPHTH VIS SCI, V49, P3004, DOI 10.1167/iovs.07-1355
   Saraswathy S, 2008, OPHTHALMIC RES, V40, P160, DOI 10.1159/000119869
   Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569
   SCHAEFER EJ, 1995, J LIPID RES, V36, P1427
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Schuetz E, 2004, CURR DRUG TARGETS, V5, P619, DOI 10.2174/1389450043345164
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sharma YV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031371
   Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468
   Sim RB, 2007, IMMUNOBIOLOGY, V212, P355, DOI 10.1016/j.imbio.2007.04.001
   Sivakumar V, 2011, J PATHOL, V224, P245, DOI 10.1002/path.2858
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Steele MR, 2006, INVEST OPHTH VIS SCI, V47, P977, DOI 10.1167/iovs.05-0865
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Stevenson L, 2010, INVEST OPHTH VIS SCI, V51, P3291, DOI 10.1167/iovs.09-4344
   Streit WJ, 2010, AGING DIS, V1, P254
   Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5
   Stuart LM, 2005, J IMMUNOL, V174, P3220, DOI 10.4049/jimmunol.174.6.3220
   Sun C, 2013, EXP EYE RES, V113, P105, DOI 10.1016/j.exer.2013.05.018
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tacnet-Delorme P, 2001, J IMMUNOL, V167, P6374, DOI 10.4049/jimmunol.167.11.6374
   Takeda S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00171
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359
   Taylor S, 2011, EXP EYE RES, V92, P338, DOI 10.1016/j.exer.2011.01.012
   Templeton JP, 2013, INVEST OPHTH VIS SCI, V54, P2599, DOI 10.1167/iovs.12-11175
   Tezel G, 2003, J GLAUCOMA, V12, P63, DOI 10.1097/00061198-200302000-00014
   Tezel G, 2000, J NEUROSCI, V20, P8693
   Tezel G, 2000, J NEUROSCI, V20, P3552, DOI 10.1523/JNEUROSCI.20-10-03552.2000
   Tezel Gulgun, 2004, Curr Opin Ophthalmol, V15, P80, DOI 10.1097/00055735-200404000-00003
   THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x
   Thanos S, 1996, PROG RETIN EYE RES, V15, P331, DOI 10.1016/1350-9462(96)00006-7
   THANOS S, 1994, TRENDS NEUROSCI, V17, P177, DOI 10.1016/0166-2236(94)90098-1
   THANOS S, 1992, BRAIN RES, V588, P21, DOI 10.1016/0006-8993(92)91340-K
   THANOS S, 1992, EXP EYE RES, V55, P101, DOI 10.1016/0014-4835(92)90098-D
   Tremblay ME, 2012, GLIA, V60, P541, DOI 10.1002/glia.22287
   Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527
   Trouw LA, 2001, MOL IMMUNOL, V38, P199, DOI 10.1016/S0161-5890(01)00043-8
   Turner MW, 1996, RES IMMUNOL, V147, P110, DOI 10.1016/0923-2494(96)87184-7
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Dijk HW, 2012, INVEST OPHTH VIS SCI, V53, P2715, DOI 10.1167/iovs.11-8997
   van Dijk HW, 2010, INVEST OPHTH VIS SCI, V51, P3660, DOI 10.1167/iovs.09-5041
   van Dijk HW, 2009, INVEST OPHTH VIS SCI, V50, P3404, DOI 10.1167/iovs.08-3143
   Vasireddy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021193
   Vujosevic S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/491835
   Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang MH, 2014, ADV EXP MED BIOL, V801, P333, DOI 10.1007/978-1-4614-3209-8_42
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang MH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-173
   Wang NK, 2009, BRIT J OPHTHALMOL, V93, P1234, DOI 10.1136/bjo.2008.153577
   Wang NK, 2013, DIS MODEL MECH, V6, P1113, DOI 10.1242/dmm.012112
   Wang Y, 2010, J NEUROSCI, V30, P3482, DOI 10.1523/JNEUROSCI.3940-09.2010
   Wasserman JK, 2008, EUR J NEUROSCI, V28, P1316, DOI 10.1111/j.1460-9568.2008.06442.x
   Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008
   Wax MB, 2009, EXP EYE RES, V88, P825, DOI 10.1016/j.exer.2009.02.005
   Weber BHF, 2002, P NATL ACAD SCI USA, V99, P6222, DOI 10.1073/pnas.092528599
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wong WT, 2011, NEURON GLIA BIOL, V7, P41, DOI 10.1017/S1740925X11000123
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang LP, 2007, INVEST OPHTH VIS SCI, V48, P4766, DOI 10.1167/iovs.06-0871
   Yang L, 2009, ARCH OPHTHALMOL-CHIC, V127, P1475, DOI 10.1001/archophthalmol.2009.288
   Yang PZ, 2000, OCUL IMMUNOL INFLAMM, V8, P149
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008
   Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Zeiss CJ, 2004, INVEST OPHTH VIS SCI, V45, P971, DOI 10.1167/iovs.03-0301
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zeng HY, 2005, INVEST OPHTH VIS SCI, V46, P2992, DOI 10.1167/iovs.05-0118
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344
   Zhang M, 2008, INVEST OPHTH VIS SCI, V49, P295, DOI 10.1167/iovs.07-0612
   Zhao L, 2011, AM J PATHOL, V179, P1265, DOI 10.1016/j.ajpath.2011.05.042
   Zhao L, 2009, EXP EYE RES, V88, P1004, DOI 10.1016/j.exer.2008.12.013
   Zinkernagel MS, 2013, AM J PATHOL, V182, P875, DOI 10.1016/j.ajpath.2012.11.031
NR 354
TC 312
Z9 319
U1 5
U2 88
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2015
VL 45
BP 30
EP 57
DI 10.1016/j.preteyeres.2014.11.004
PG 28
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD1LL
UT WOS:000350836300002
PM 25476242
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Angelo, G
   Drake, VJ
   Frei, B
AF Angelo, Giana
   Drake, Victoria J.
   Frei, Balz
TI Efficacy of Multivitamin/mineral Supplementation to Reduce Chronic
   Disease Risk: A Critical Review of the Evidence from Observational
   Studies and Randomized Controlled Trials
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review
DE Multivitamin; mineral; supplement; chronic disease risk; randomized
   controlled trials; prospective cohort studies; micronutrient
   inadequacies
ID NUTRITION INTERVENTION TRIALS; CORONARY-HEART-DISEASE; AGE-RELATED
   CATARACT; VITAMIN-E; CARDIOVASCULAR-DISEASE; DIETARY-SUPPLEMENTS;
   PROSPECTIVE COHORT; PHYSICIANS HEALTH; CANCER INCIDENCE; COLON-CANCER
AB We reviewed recent scientific evidence regarding the effects of multivitamin/mineral (MVM) supplements on risk of chronic diseases, including cancer, cardiovascular disease, and age-related eye diseases. Data from randomized controlled trials (RCTs) and observational, prospective cohort studies were examined. The majority of scientific studies investigating the use of MVM supplements in chronic disease risk reduction reported no significant effect. However, the largest and longest RCT of MVM supplements conducted to date, the Physicians' Health Study II (PHS II), found a modest and significant reduction in total and epithelial cancer incidence in male physicians, consistent with the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) trial. In addition, PHS II found a modest and significant reduction in the incidence of nuclear cataract, in agreement with several other RCTs and observational, prospective cohort studies. The effects of MVM use on other subtypes of cataract and age-related macular degeneration remain unclear. Neither RCTs nor prospective cohort studies are without their limitations. The placebo-controlled trial design of RCTs may be inadequate for nutrient interventions, and residual confounding, measurement error, and the possibility of reverse causality are inherent to any observational study. National surveys show that micronutrient inadequacies are widespread in the US and that dietary supplements, of which MVMs are the most common type, help fulfill micronutrient requirements in adults and children.
C1 [Angelo, Giana; Drake, Victoria J.; Frei, Balz] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.
   [Frei, Balz] Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.
C3 Oregon State University; Oregon State University
RP Frei, B (通讯作者)，Oregon State Univ, Linus Pauling Inst, Linus Pauling Sci Ctr 307, Corvallis, OR 97331 USA.
EM balz.frei@oregonstate.edu
FU Pfizer
FX GA, VJD, and BF designed the research for this review article, conducted
   the literature research, analyzed the data, and wrote the paper. GA had
   primary responsibility for final content. All authors read and approved
   the final manuscript. Editorial support was provided by Diane Sloan,
   PharmD, of Peloton Advantage, LLC, and was funded by Pfizer.
CR Ames BN, 2006, P NATL ACAD SCI USA, V103, P17589, DOI 10.1073/pnas.0608757103
   [Anonymous], 2013, GUID IND FOOD LAB GU
   Avenell A, 2005, BMJ-BRIT MED J, V331, P324, DOI 10.1136/bmj.331.7512.324
   Bailey RL, 2013, JAMA INTERN MED, V173, P355, DOI 10.1001/jamainternmed.2013.2299
   Bailey RL, 2012, J PEDIATR-US, V161, P837, DOI 10.1016/j.jpeds.2012.05.009
   Bailey RL, 2011, J NUTR, V141, P261, DOI 10.3945/jn.110.133025
   Bailey RL, 2012, J ACAD NUTR DIET, V112, P657, DOI 10.1016/j.jand.2012.01.026
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   BENDER MM, 1992, J AM DIET ASSOC, V92, P1096
   Bhaskaram P, 2001, BRIT J NUTR, V85, pS75, DOI 10.1079/BJN2000297
   BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483
   BOGDEN JD, 1994, AM J CLIN NUTR, V60, P437, DOI 10.1093/ajcn/60.3.437
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Briefel RR, 2004, ANNU REV NUTR, V24, P401, DOI 10.1146/annurev.nutr.23.011702.073349
   Burchi F, 2011, INT J ENV RES PUB HE, V8, P358, DOI 10.3390/ijerph8020358
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Cole CR, 2012, J PEDIATR-US, V161, P777, DOI 10.1016/j.jpeds.2012.06.053
   Elmadfa I, 2009, NUTR REV, V67, pS130, DOI 10.1111/j.1753-4887.2009.00175.x
   Flynn Albert, 2009, Food Nutr Res, V53, DOI 10.3402/fnr.v53i0.2038
   Food and Agriculture Organization of the United Nations, 2004, STAT FOOD INS WORLD
   Foote JA, 2003, AM J EPIDEMIOL, V157, P888, DOI 10.1093/aje/kwg072
   Fortmann SP, 2013, ANN INTERN MED, V159, P824, DOI 10.7326/0003-4819-159-12-201312170-00729
   Frei B., 2014, ANN INTERN MED
   Fuchs CS, 2002, CANCER EPIDEM BIOMAR, V11, P227
   Fulgoni VL, 2011, J NUTR, V141, P1847, DOI 10.3945/jn.111.142257
   Gahche Jamie, 2011, NCHS Data Brief, P1
   Gaziano JM, 2012, JAMA-J AM MED ASSOC, V308, P1871, DOI 10.1001/jama.2012.14641
   Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002
   Graat JM, 2002, JAMA-J AM MED ASSOC, V288, P715, DOI 10.1001/jama.288.6.715
   Grodstein F, 2013, ANN INTERN MED, V159, P806, DOI 10.7326/0003-4819-159-12-201312170-00006
   Hara A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-540
   Heaney RP, 2008, J NUTR, V138, P1591, DOI 10.1093/jn/138.9.1591
   Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hotaling JM, 2011, J UROLOGY, V185, P1210, DOI 10.1016/j.juro.2010.11.081
   Huang HY, 2007, AM J CLIN NUTR, V85, p265S, DOI 10.1093/ajcn/85.1.265S
   Hunt JR, 1996, J AM DIET ASSOC, V96, P73, DOI 10.1016/S0002-8223(96)00022-3
   HUNTER DJ, 1993, NEW ENGL J MED, V329, P234, DOI 10.1056/NEJM199307223290403
   Huskisson E, 2007, J INT MED RES, V35, P277, DOI 10.1177/147323000703500301
   Ibs KH, 2003, NUTR HLTH, P241
   Iso H, 2007, ASIAN PAC J CANCER P, V8, P35
   Jacobs EJ, 2002, CANCER EPIDEM BIOMAR, V11, P35
   Kant AK, 2000, AM J CLIN NUTR, V72, P929
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy DO, 2011, DRUGS, V71, P1957, DOI 10.2165/11594130-000000000-00000
   KIM I, 1993, AM J PUBLIC HEALTH, V83, P546, DOI 10.2105/AJPH.83.4.546
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kwan ML, 2011, BREAST CANCER RES TR, V130, P195, DOI 10.1007/s10549-011-1557-4
   Larsson SC, 2010, AM J CLIN NUTR, V91, P1268, DOI 10.3945/ajcn.2009.28837
   Lawson KA, 2007, J NATL CANCER I, V99, P754, DOI 10.1093/jnci/djk177
   Leng G C, 1997, Vasc Med, V2, P279
   Li B, 1993, Ann Epidemiol, V3, P577, DOI 10.1016/1047-2797(93)90078-I
   LI JY, 1993, J NATL CANCER I, V85, P1492, DOI 10.1093/jnci/85.18.1492
   Li KR, 2012, EUR J NUTR, V51, P407, DOI 10.1007/s00394-011-0224-1
   Li KR, 2010, BRIT J NUTR, V104, P1058, DOI 10.1017/S0007114510001728
   Losonczy KG, 1996, AM J CLIN NUTR, V64, P190, DOI 10.1093/ajcn/64.2.190
   Macpherson H, 2013, AM J CLIN NUTR, V97, P437, DOI 10.3945/ajcn.112.049304
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   Mares-Perlman JA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1556, DOI 10.1001/archopht.118.11.1556
   McGinnis JM, 2006, ANN INTERN MED, V145, P364, DOI 10.7326/0003-4819-145-5-200609050-00136
   McNeill G, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-10
   Messerer M, 2008, BRIT J NUTR, V99, P626, DOI 10.1017/S0007114507812049
   Michaud DS, 2000, AM J EPIDEMIOL, V152, P1145, DOI 10.1093/aje/152.12.1145
   Milton RC, 2006, OPHTHALMOLOGY, V113, P1264, DOI 10.1016/j.ophtha.2006.02.054
   Mulholland CA, 2007, AM J CLIN NUTR, V85, p318S, DOI 10.1093/ajcn/85.1.318S
   Muller O, 2005, CAN MED ASSOC J, V173, P279, DOI 10.1503/cmaj.050342
   Muntwyler J, 2002, ARCH INTERN MED, V162, P1472, DOI 10.1001/archinte.162.13.1472
   Mursu J, 2011, ARCH INTERN MED, V171, P1625, DOI 10.1001/archinternmed.2011.445
   National Academy of Sciences Institute of Medicine and Food and Nutrition Board, 2010, DIET REF INT REC DIE
   Naurath N., 2007, SMOKING RATES WORLD
   Neuhouser ML, 2009, ARCH INTERN MED, V169, P294, DOI 10.1001/archinternmed.2008.540
   Otten JJ., 2006, DIETARY REFERENCE IN
   Park SY, 2011, AM J EPIDEMIOL, V173, P906, DOI 10.1093/aje/kwq447
   Patterson RE, 2003, J AM DIET ASSOC, V103, P323, DOI 10.1053/jada.2003.50045
   Pfizer Consumer Healthcare, 2013, WHATS INS CENTR
   Pocobelli G, 2009, AM J EPIDEMIOL, V170, P472, DOI 10.1093/aje/kwp167
   Prentice RL, 2007, AM J CLIN NUTR, V85, p308S, DOI 10.1093/ajcn/85.1.308S
   Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207
   Ramakrishnan U, 2002, NUTR REV, V60, pS46, DOI 10.1301/00296640260130731
   Rautiainen S, 2010, AM J CLIN NUTR, V92, P1251, DOI 10.3945/ajcn.2010.29371
   Rautiainen S, 2010, AM J CLIN NUTR, V91, P487, DOI 10.3945/ajcn.2009.28528
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359
   Rock CL, 2007, AM J CLIN NUTR, V85, p277S, DOI 10.1093/ajcn/85.1.277S
   Schiller JS, 2010, VITAL HLTH STAT, V10, P2012
   Sebastian RS, 2007, J AM DIET ASSOC, V107, P1322, DOI 10.1016/j.jada.2007.05.010
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Selin JZ, 2013, AM J EPIDEMIOL, V177, P548, DOI 10.1093/aje/kws279
   Sesso HD, 2002, CONTROL CLIN TRIALS, V23, P686, DOI 10.1016/S0197-2456(02)00235-0
   Sesso HD, 2012, JAMA-J AM MED ASSOC, V308, P1751, DOI 10.1001/jama.2012.14805
   Shakur YA, 2012, J NUTR, V142, P534, DOI 10.3945/jn.111.149450
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003
   Stevens VL, 2005, CANCER CAUSE CONTROL, V16, P643, DOI 10.1007/s10552-005-0384-5
   Sullivan KM, 2009, PUBLIC HEALTH REP, V124, P384, DOI 10.1177/003335490912400307
   Taylor JP, 2007, CAN J DIET PRACT RES, V68, P23, DOI 10.3148/68.1.2007.23
   United States Department of Agriculture, 2013, CHOOS
   United States Department of Agriculture (USDA), 2010, DIET GUID AM
   Wallace TC, 2014, J AM COLL NUTR, V33, P94, DOI 10.1080/07315724.2013.846806
   Watkins ML, 2000, AM J EPIDEMIOL, V152, P149, DOI 10.1093/aje/152.2.149
   Whatham A, 2008, OPHTHAL PHYSL OPT, V28, P1, DOI 10.1111/j.1475-1313.2007.00531.x
   Wolters M, 2005, PREV MED, V41, P253, DOI 10.1016/j.ypmed.2004.11.007
   Wu K, 2002, CANCER EPIDEM BIOMAR, V11, P1298
   Zhang SM, 2006, AM J EPIDEMIOL, V163, P108, DOI 10.1093/aje/kwj016
   Zhang SM, 1999, JNCI-J NATL CANCER I, V91, P547, DOI 10.1093/jnci/91.6.547
   Zhang SMM, 2001, AM J EPIDEMIOL, V153, P1056, DOI 10.1093/aje/153.11.1056
   Zhang W, 2012, J NATL CANCER I, V104, P1173, DOI 10.1093/jnci/djs277
NR 112
TC 20
Z9 22
U1 0
U2 67
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PY 2015
VL 55
IS 14
BP 1968
EP 1991
DI 10.1080/10408398.2014.912199
PG 24
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA CK2VT
UT WOS:000356072800002
PM 24941429
DA 2022-11-30
ER

PT J
AU Esmaeelpour, M
   Kajic, V
   Zabihian, B
   Othara, R
   Ansari-Shahrezaei, S
   Kellner, L
   Krebs, I
   Nemetz, S
   Kraus, MF
   Hornegger, J
   Fujimoto, JG
   Drexler, W
   Binder, S
AF Esmaeelpour, Marieh
   Kajic, Vedran
   Zabihian, Behrooz
   Othara, Richu
   Ansari-Shahrezaei, Siamak
   Kellner, Lukas
   Krebs, Ilse
   Nemetz, Susanne
   Kraus, Martin F.
   Hornegger, Joachim
   Fujimoto, James G.
   Drexler, Wolfgang
   Binder, Susanne
TI Choroidal Haller's and Sattler's Layer Thickness Measurement Using
   3-Dimensional 1060-nm Optical Coherence Tomography
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; NM; CHORIOCAPILLARIS; OCT; REPRODUCIBILITY;
   VISUALIZATION; SEGMENTATION; PENETRATION; CIRCULATION; EYES
AB Objectives: To examine the feasibility of automatically segmented choroidal vessels in three-dimensional (3D) 1060-nmOCT by testing repeatability in healthy and AMD eyes and by mapping Haller's and Sattler's layer thickness in healthy eyes
   Methods: Fifty-five eyes (from 45 healthy subjects and 10 with non-neovascular age-related macular degeneration (AMD) subjects) were imaged by 3D-1060- nmOCT over a 36 degrees x36 degrees field of view. Haller's and Sattler's layer were automatically segmented, mapped and averaged across the Early Treatment Diabetic Retinopathy Study grid. For ten AMD eyes and ten healthy eyes, imaging was repeated within the same session and on another day. Outcomes were the repeatability agreement of Haller's and Sattler's layer thicknesses in healthy and AMD eyes, the validation with ICGA and the statistical analysis of the effect of age and axial eye length ( AL) on both healthy choroidalsublayers.
   Conclusions: Automated Sattler's and Haller's thickness segmentation generates rapid 3D measurements with a repeatability correspondingto reported manual segmentation. Sublayers in healthy eyes thinnedsignificantly with increasing AL. In the presence of the thinned Sattler's layer in AMD, careful measurement interpretation is needed. Automatic choroidal vascular layer mapping may help to explain if pathological choroidal thinning affects medium and large choroidal vasculature in addition to choriocapillaris loss.
C1 [Esmaeelpour, Marieh; Ansari-Shahrezaei, Siamak; Kellner, Lukas; Krebs, Ilse; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Esmaeelpour, Marieh; Kajic, Vedran; Zabihian, Behrooz; Othara, Richu; Drexler, Wolfgang] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Nemetz, Susanne] OptikNemetz, Vienna, Austria.
   [Kraus, Martin F.; Hornegger, Joachim] Univ Erlangen Nurnberg, Pattern Recognit Lab, D-91054 Erlangen, Bavaria, Germany.
   [Kraus, Martin F.; Hornegger, Joachim] Univ Erlangen Nurnberg, Sch Adv Opt Technol SATO, D-91054 Erlangen, Bavaria, Germany.
   [Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
C3 Ludwig Boltzmann Institute; Medical University of Vienna; University of
   Erlangen Nuremberg; University of Erlangen Nuremberg; Massachusetts
   Institute of Technology (MIT)
RP Esmaeelpour, M (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
EM marieh.esmaeelpour@meduniwien.ac.at
RI Hornegger, Joachim/H-2465-2017
OI Hornegger, Joachim/0000-0002-1834-8844; Drexler,
   Wolfgang/0000-0002-3557-6398
FU Medical University Vienna, Macular Vision Research Foundation (MVRF,
   USA); European Union [201880]; FAMOS [ICT 317744]; FWF-NFN [14294];
   National Institutes of Health [NIH R01-EY011289-27]; Deutsche
   Forschungsgesellschaft [DFG-GSC80-SAOT]; German Research Foundation
   [DFG-GSC80-SAOT, DFG-HO-1791/11-1]; NATIONAL EYE INSTITUTE [R01EY011289]
   Funding Source: NIH RePORTER
FX This research was supported in part by Medical University Vienna,
   Macular Vision Research Foundation (MVRF, USA), European Union project
   FUN OCT (FP7 HEALTH, contract no. 201880) and FAMOS (FP7 ICT 317744),
   FWF-NFN 'Photoacoustic imaging in biology and Medicine',
   Oesterreichische Nationalbank Jubilaumsfondsprojekt (14294), National
   Institutes of Health (NIH R01-EY011289-27), Deutsche
   Forschungsgesellschaft (DFG-GSC80-SAOT), CARL ZEISS Meditec Inc.,
   Femtolasers GmbH and the Christian Doppler Society (Christian Doppler
   Laboratory ' Laser development and their application in medicine').
   German Research Foundation DFG-GSC80-SAOT, DFG-HO-1791/11-1. Optik
   Nemetz provided support in the form of a salary for author SN, but did
   not have any additional role in the study design, data collection and
   analysis, decision to publish, or preparation of the manuscript. The
   specific roles of these authors are articulated in the 'author
   contributions' section.
CR ANSI, 2000, SAF US LAS SAF US OP
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   HAYREH SS, 1974, A GRAEF ARCH KLIN EX, V192, P165
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hogan MJ, 1971, SAUNDERS, P322
   ICNIRP, 2000, REV GUID LIM EXP LAS
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V51, P2173
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Kajic V, 2013, BIOMED OPT EXPRESS, V4, P134, DOI 10.1364/BOE.4.000134
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Kim JH, 2013, EYE, V27, P809, DOI 10.1038/eye.2013.78
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Motaghiannezam R, 2012, INVEST OPHTH VIS SCI, V53, P2337, DOI 10.1167/iovs.11-7823
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nishiyama Y, 2001, RETINA-J RET VIT DIS, V21, P237, DOI 10.1097/00006982-200106000-00007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sim DA, 2013, INVEST OPHTH VIS SCI, V54, P2893, DOI 10.1167/iovs.12-11085
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   ZHANG HR, 1994, PROG RETIN EYE RES, V13, P243, DOI 10.1016/1350-9462(94)90012-4
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
NR 36
TC 49
Z9 50
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 9
PY 2014
VL 9
IS 6
AR e99690
DI 10.1371/journal.pone.0099690
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI8LF
UT WOS:000337165600115
PM 24911446
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Nielsen, JS
   Fick, TA
   Saggau, DD
   Barnes, CH
AF Nielsen, Jared S.
   Fick, Tyler A.
   Saggau, David D.
   Barnes, Charles H.
TI INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR
   CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS SYNDROME
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-vascular endothelial growth factor; anti-VEGF; bevacizumab;
   choroidal neovascularization; ocular histoplasmosis; optical coherence
   tomography; ranibizumab
ID SUBFOVEAL; BEVACIZUMAB
AB Background: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is beneficial in treating choroidal neovascularization from age-related macular degeneration, but few long-term studies have shown its efficacy in choroidal neovascularization from ocular histoplasmosis syndrome. Intravitreal anti-VEGF therapy may be effective in cases of choroidal neovascularization because of ocular histoplasmosis syndrome.
   Methods: Retrospective chart review of 54 eyes treated with intravitreal anti-VEGF therapy for choroidal neovascularization in ocular histoplasmosis syndrome with >1 year of follow-up after initiation of anti-VEGF treatment was performed. Previous treatment and demographic information were recorded. Visual acuity was recorded for each injection treatment and at the last follow-up visit. The anti-VEGF agent was recorded for each injection treatment. Visual acuity was recorded at the last follow-up visit.
   Results: Mean visual acuity improved from 20/53 to 20/26 over an average of 26.8 months. Either bevacizumab or ranibizumab were administered on an average of 4.5 injections per patient per year of follow-up. Vision loss was seen in only three eyes with loss limited to a single line of vision. Patients experienced no serious complications from treatment.
   Conclusion: Long-term intravitreal anti-VEGF therapy with bevacizumab or ranibizumab is beneficial in treatment of choroidal neovascularization in ocular histoplasmosis syndrome. RETINA 32: 468-472, 2012
C1 [Nielsen, Jared S.; Fick, Tyler A.; Saggau, David D.] Wolfe Eye Clin, W Des Moines, IA 50266 USA.
   [Barnes, Charles H.] Wolfe Eye Clin, Cedar Rapids, IA USA.
RP Nielsen, JS (通讯作者)，Wolfe Eye Clin, 6200 Westown Pkwy, W Des Moines, IA 50266 USA.
EM jnielsen@wolfeclinic.com
OI Nielsen, Jared/0000-0003-4321-1978
CR Adan A, 2007, RETINA-J RET VIT DIS, V27, P1180, DOI 10.1097/IAE.0b013e31815e9834
   [Anonymous], 1987, ARCH OPHTHALMOL-CHIC, V105, P1499
   Busquets MA, 2003, RETINA-J RET VIT DIS, V23, P299, DOI 10.1097/00006982-200306000-00003
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Ehrlich R, 2009, RETINA-J RET VIT DIS, V29, P1418, DOI 10.1097/IAE.0b013e3181babdf1
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2011, OPHTHALMOLOGY, V118, P111, DOI 10.1016/j.ophtha.2010.04.016
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   KLEINER RC, 1988, RETINA-J RET VIT DIS, V8, P225, DOI 10.1097/00006982-198808040-00001
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   OLK RJ, 1984, OPHTHALMOLOGY, V91, P1592
   Rosenfeld PJ, 2004, OPHTHALMOLOGY, V111, P1725, DOI 10.1016/j.ophtha.2004.02.014
   Ruiz-Moreno JM, 2009, BRIT J OPHTHALMOL, V93, P448, DOI 10.1136/bjo.2008.145391
   Sawa M, 2009, AM J OPHTHALMOL, V148, P584, DOI 10.1016/j.ajo.2009.04.026
   Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016/j.ajo.2007.12.030
   Wiegand TW, 2009, BRIT J OPHTHALMOL, V93, P47, DOI 10.1136/bjo.2008.143461
NR 16
TC 15
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2012
VL 32
IS 3
BP 468
EP 472
DI 10.1097/IAE.0b013e318229b220
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 900RU
UT WOS:000300907200006
PM 21817958
DA 2022-11-30
ER

PT J
AU Lin, YH
   Jones, BW
   Liu, AH
   Vazquez-Chona, FR
   Lauritzen, JS
   Ferrell, WD
   Marc, RE
AF Lin, Yanhua
   Jones, Bryan W.
   Liu, Aihua
   Vazquez-Chona, Felix R.
   Lauritzen, J. Scott
   Ferrell, W. Drew
   Marc, Robert E.
TI Rapid glutamate receptor 2 trafficking during retinal degeneration
SO MOLECULAR NEURODEGENERATION
LA English
DT Article
DE glutamate receptor 2; retinal degeneration; retinal remodeling;
   neuritogenesis
ID CA2+-PERMEABLE AMPA RECEPTORS; DOMAIN-CONTAINING PROTEIN; POSTSYNAPTIC
   DENSITY; SYNAPTIC PLASTICITY; RETINITIS-PIGMENTOSA; CA2+ PERMEABILITY;
   MAMMALIAN RETINA; MOUSE RETINA; RAT RETINA; PHOTORECEPTOR DEGENERATIONS
AB Background: Retinal degenerations, such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), are characterized by photoreceptor loss and anomalous remodeling of the surviving retina that corrupts visual processing and poses a barrier to late-stage therapeutic interventions in particular. However, the molecular events associated with retinal remodeling remain largely unknown. Given our prior evidence of ionotropic glutamate receptor (iGluR) reprogramming in retinal degenerations, we hypothesized that the edited glutamate receptor 2 (GluR2) subunit and its trafficking may be modulated in retinal degenerations.
   Results: Adult albino Balb/C mice were exposed to intense light for 24 h to induce light-induced retinal degeneration (LIRD). We found that prior to the onset of photoreceptor loss, protein levels of GluR2 and related trafficking proteins, including glutamate receptor-interacting protein 1 (GRIP1) and postsynaptic density protein 95 (PSD-95), were rapidly increased. LIRD triggered neuritogenesis in photoreceptor survival regions, where GluR2 and its trafficking proteins were expressed in the anomalous dendrites. Immunoprecipitation analysis showed interaction between KIF3A and GRIP1 as well as PSD-95, suggesting that KIF3A may mediate transport of GluR2 and its trafficking proteins to the novel dendrites. However, in areas of photoreceptor loss, GluR2 along with its trafficking proteins nearly vanished in retracted retinal neurites.
   Conclusions: All together, LIRD rapidly triggers GluR2 plasticity, which is a potential mechanism behind functionally phenotypic revisions of retinal neurons and neuritogenesis during retinal degenerations.
C1 [Lin, Yanhua; Jones, Bryan W.; Liu, Aihua; Vazquez-Chona, Felix R.; Lauritzen, J. Scott; Ferrell, W. Drew; Marc, Robert E.] Univ Utah, Sch Med, Dept Ophthalmol, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Marc, RE (通讯作者)，Univ Utah, Sch Med, Dept Ophthalmol, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM robert.marc@hsc.utah.edu
OI Jones, Bryan/0000-0001-5527-6643
FU NIH [EY002576, EY015128, EY014800]; Research to Prevent Blindness;
   Signature Immunologics; Edward N. and Della L. Thome Memorial
   Foundation; Moran Eye Center Tiger Team Translational Medicine; Fight
   For Sight; Knights Templar Eye Foundation; International Retinal
   Research Foundation;  [5T32 HD07491]; EUNICE KENNEDY SHRIVER NATIONAL
   INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007491] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY015128, R01EY002576,
   P30EY014800] Funding Source: NIH RePORTER
FX This project was supported by NIH EY002576 (REM), EY015128 (REM),
   EY014800 Vision Core (REM), Research to Prevent Blindness (REM),
   Signature Immunologics (REM), Edward N. and Della L. Thome Memorial
   Foundation grant for Age-Related Macular Degeneration Research (BWJ), a
   Research to Prevent Blindness Career Development Award (BWJ), Moran Eye
   Center Tiger Team Translational Medicine Award (BWJ), Fight For Sight
   (YHL, FRVC and WDF), Knights Templar Eye Foundation (YHL and FRVC), 5T32
   HD07491 (FRVC), International Retinal Research Foundation (YHL, FRVC),
   and an unrestricted grant from Research to Prevent Blindness to the
   Moran Eye Center. We thank Kevin Rapp, Marguerite V. Shaw, Jia-Hui Yang,
   and Carl B. Watt for assistance on tissue handling and
   immunohistochemistry. We thank Dr. Changjiang Zou for assistance on
   immunoprecipitation.
CR Barhoum R, 2008, NEUROSCIENCE, V155, P698, DOI 10.1016/j.neuroscience.2008.06.042
   BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970
   Catsicas M, 2001, J NEUROBIOL, V49, P200, DOI 10.1002/neu.1075
   Chua J, 2009, J COMP NEUROL, V514, P473, DOI 10.1002/cne.22029
   Dagnelie G, 2011, VISUAL PROSTHETICS: PHYSIOLOGY, BIOENGINEERING, REHABILITATION, P1, DOI 10.1007/978-1-4419-0754-7
   De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227
   Dejneka NS, 2003, DEV OPHTHALMOL, V37, P188
   Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0
   Du J, 2008, J NEUROSCI, V28, P68, DOI 10.1523/JNEUROSCI.3080-07.2008
   DUVOISIN RM, 1995, NEUROSCI LETT, V183, P83, DOI 10.1016/0304-3940(94)11120-8
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Gabriel R, 2002, J COMP NEUROL, V449, P129, DOI 10.1002/cne.10280
   GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4
   Ghosh KK, 2001, J NEUROSCI, V21, P8636, DOI 10.1523/JNEUROSCI.21-21-08636.2001
   Gorter JA, 1997, J NEUROSCI, V17, P6179
   Grunert U, 2002, J COMP NEUROL, V447, P138, DOI 10.1002/cne.10220
   Hack I, 2001, EUR J NEUROSCI, V13, P15, DOI 10.1046/j.1460-9568.2001.01357.x
   Hanna MC, 2007, MOL VIS, V13, P2194
   HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304
   HUGHES TE, 1992, VISUAL NEUROSCI, V8, P49, DOI 10.1017/S0952523800006489
   Jones BW, 2011, J COMP NEUROL, V519, P2713, DOI 10.1002/cne.22703
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Kamphuis W, 2003, J COMP NEUROL, V455, P172, DOI 10.1002/cne.10469
   Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750
   Koulen P, 1998, J NEUROSCI, V18, P10136
   LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229
   Lin YH, 2012, FASEB J, V26, P81, DOI 10.1096/fj.11-192914
   Liu LO, 2000, MOL BRAIN RES, V82, P150, DOI 10.1016/S0169-328X(00)00203-5
   Liu SH, 2004, NEURON, V43, P43, DOI 10.1016/j.neuron.2004.06.017
   Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006
   Liu SQJ, 2005, NAT NEUROSCI, V8, P768, DOI 10.1038/nn1468
   Lu W, 2005, NEURON, V47, P407, DOI 10.1016/j.neuron.2005.07.006
   Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758
   Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2008, MOL VIS, V14, P782
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   MATTSON MP, 1988, J NEUROSCI, V8, P2087
   Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009
   Muresan V, 1999, J NEUROSCI, V19, P1027
   Ng YK, 2004, BRAIN RES, V1018, P66, DOI 10.1016/j.brainres.2004.05.055
   Okabe S, 2007, MOL CELL NEUROSCI, V34, P503, DOI 10.1016/j.mcn.2007.01.006
   Park SJ, 2001, CELL TISSUE RES, V306, P341, DOI 10.1007/s004410100453
   PELLEGRINIGIAMPIETRO DE, 1994, J NEUROCHEM, V62, P1067
   Peng YW, 2000, NAT NEUROSCI, V3, P1121, DOI 10.1038/80639
   Rongo C, 1999, NATURE, V402, P195, DOI 10.1038/46065
   Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596
   Santiago AR, 2008, BRAIN RES, V1198, P153, DOI 10.1016/j.brainres.2007.12.030
   SCHEIBEL AB, 1978, EXP NEUROL, V60, P1, DOI 10.1016/0014-4886(78)90164-4
   Semkova I, 2010, EXP EYE RES, V90, P244, DOI 10.1016/j.exer.2009.10.012
   Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743
   SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034
   Sheng M, 2007, ANNU REV BIOCHEM, V76, P823, DOI 10.1146/annurev.biochem.76.060805.160029
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Tanaka H, 2002, P NATL ACAD SCI USA, V99, P2362, DOI 10.1073/pnas.261713299
   Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8
   Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116
   Vaughan DK, 2003, INVEST OPHTH VIS SCI, V44, P848, DOI 10.1167/iovs.02-0709
   Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3
   Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2
NR 63
TC 29
Z9 30
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD FEB 10
PY 2012
VL 7
AR 7
DI 10.1186/1750-1326-7-7
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 909QP
UT WOS:000301579600001
PM 22325330
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kokkinaki, M
   Sahibzada, N
   Golestaneh, N
AF Kokkinaki, Maria
   Sahibzada, Niaz
   Golestaneh, Nady
TI Human Induced Pluripotent Stem-Derived Retinal Pigment Epithelium (RPE)
   Cells Exhibit Ion Transport, Membrane Potential, Polarized Vascular
   Endothelial Growth Factor Secretion, and Gene Expression Pattern Similar
   to Native RPE
SO STEM CELLS
LA English
DT Article
DE Human induced pluripotent stem cells; Retinal pigment epithelium; Gene
   expression; Ion transport; Membrane potential; Telomere shortening;
   Growth arrest
ID MACULAR DEGENERATION; MOLECULAR SIGNATURE; GENERATION; INDUCTION; MOUSE;
   TRANSPLANTATION; TRANSLOCATION; FIBROBLASTS; GRAFT
AB Age-related macular degeneration (AMD) is one of the major causes of blindness in aging population that progresses with death of retinal pigment epithelium (RPE) and photoreceptor degeneration inducing impairment of central vision. Discovery of human induced pluripotent stem (hiPS) cells has opened new avenues for the treatment of degenerative diseases using patient-specific stem cells to generate tissues and cells for autologous cell-based therapy. Recently, RPE cells were generated from hiPS cells. However, there is no evidence that those hiPS-derived RPE possess specific RPE functions that fully distinguish them from other types of cells. Here, we show for the first time that RPE generated from hiPS cells under defined conditions exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression profile similar to those of native RPE. The hiPS-RPE could therefore be a very good candidate for RPE replacement therapy in AMD. However, these cells show rapid telomere shortening, DNA chromosomal damage, and increased p21 expression that cause cell growth arrest. This rapid senescence might affect the survival of the transplanted cells in vivo and therefore, only the very early passages should be used for regeneration therapies. Future research needs to focus on the generation of "safe" as well as viable hiPS-derived somatic cells. STEM CELLS 2011;29:825-835
C1 [Kokkinaki, Maria; Golestaneh, Nady] Georgetown Univ, Sch Med, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.
   [Sahibzada, Niaz] Georgetown Univ, Sch Med, Dept Pharmacol, Washington, DC 20057 USA.
C3 Georgetown University; Georgetown University
RP Golestaneh, N (通讯作者)，Georgetown Univ, Sch Med, Dept Biochem & Mol & Cellular Biol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20057 USA.
EM ncg8@georgetown.edu
OI Sahibzada, Niaz/0000-0002-4169-370X
FU NIH [1R21EY019383-01]; NATIONAL EYE INSTITUTE [R21EY019383] Funding
   Source: NIH RePORTER
FX This work was supported by the NIH 1R21EY019383-01.
CR Agarwal S, 2010, NATURE, V464, P292, DOI 10.1038/nature08792
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BOK D, 1993, J CELL SCI, P189
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Chen FK, 2008, INVEST OPHTH VIS SCI, V49, P3143, DOI 10.1167/iovs.07-1648
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287
   Marion RM, 2009, CELL STEM CELL, V4, P141, DOI 10.1016/j.stem.2008.12.010
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Momcilovic O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013410
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Okita K, 2010, NAT PROTOC, V5, P418, DOI 10.1038/nprot.2009.231
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Suhr ST, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0014095, 10.1371/journal.pone.0008124]
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Vaziri H, 2010, REGEN MED, V5, P345, DOI 10.2217/RME.10.21
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Yamanaka S, 2008, CELL PROLIFERAT, V41, P51, DOI 10.1111/j.1365-2184.2008.00493.x
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 42
TC 131
Z9 137
U1 1
U2 41
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD MAY
PY 2011
VL 29
IS 5
BP 825
EP 835
DI 10.1002/stem.635
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 752UC
UT WOS:000289719200010
PM 21480547
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Urano, T
   Narusawa, K
   Kobayashi, S
   Shiraki, M
   Horie-Inoue, K
   Sasaki, N
   Hosoi, T
   Ouchi, Y
   Nakamura, T
   Inoue, S
AF Urano, Tomohiko
   Narusawa, Ken'ichiro
   Kobayashi, Satomi
   Shiraki, Masataka
   Horie-Inoue, Kuniko
   Sasaki, Noriko
   Hosoi, Takayuki
   Ouchi, Yasuyoshi
   Nakamura, Toshitaka
   Inoue, Satoshi
TI Association of HTRA1 promoter polymorphism with spinal disc degeneration
   in Japanese women
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Single nucleotide polymorphism (SNP; Spinal osteoarthritis; Disc space
   narrowing; Age-related macular degeneration (AMD); HTRA1
ID SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN-D-RECEPTOR; SERINE-PROTEASE;
   MACULAR DEGENERATION; GENE; OSTEOARTHRITIS; BONE; DISEASE; VARIANT;
   EXPRESSION
AB HTRA1 (high-temperature requirement A1) has been implicated in the modulation of various disease pathologies. HTRA1 expression is upregulated in osteoarthritic joints, suggesting that it may contribute to the development of this debilitating disease. Moreover, recent reports have shown that the rs11200638, a single nucleotide polymorphism (SNP) in the promoter region of the HTRA1 gene, is strongly associated with an increased prevalence of age-related macular degeneration (AMD). In the present study, we examined the expression of the HTRA1 in human primary chondrocytes and an association between the rs11200638 SNP and radiographic features of spinal disc degeneration in 513 postmenopausal Japanese women. HTRA1 mRNA was detected and increased by TGF-beta treatment in human primary chondrocytes. As an association study of rs11200638 SNP in the HTRA1 gene, the subjects without the G allele (AA; n = 89) had a significantly higher spinal disc space narrowing score than the subjects bearing at least one G allele (GG + GA; n = 424) (P = 0.0292). We found that subjects without the G allele (AA) were significantly overrepresented in the subjects having a higher (a parts per thousand yen4) disc space narrowing score (P = 0.013; odds ratio 1.97; 95% confidence interval 1.15-3.37 by logistic regression analysis). A genetic variation at the HTRA1 gene promoter locus is associated with spinal disc degeneration, suggesting an involvement of the HTRA1 gene in osteoarthritis.
C1 [Urano, Tomohiko; Kobayashi, Satomi; Sasaki, Noriko; Ouchi, Yasuyoshi; Inoue, Satoshi] Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Urano, Tomohiko; Kobayashi, Satomi; Sasaki, Noriko; Inoue, Satoshi] Univ Tokyo, Grad Sch Med, Dept Anti Aging Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Urano, Tomohiko; Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Sch, Res Ctr Genom Med, Saitama 3501241, Japan.
   [Narusawa, Ken'ichiro; Nakamura, Toshitaka] Univ Occupat & Environm Hlth, Dept Orthoped Surg, Sch Med, Kitakyushu, Fukuoka 807, Japan.
   [Shiraki, Masataka] Res Inst & Practice Involut Dis, Misato, Nagano 3998101, Japan.
   [Hosoi, Takayuki] Natl Ctr Geriatr & Gerontol, Dept Adv Med, Aichi, Japan.
C3 University of Tokyo; University of Tokyo; Saitama Medical University;
   University of Occupational & Environmental Health - Japan; National
   Center for Geriatrics & Gerontology
RP Inoue, S (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM INOUE-GER@h.u-tokyo.ac.jp
RI Urano, Tomohiko/AFS-9574-2022
OI Kobayashi, Satomi/0000-0002-5454-1051
FU Japanese Ministry of Health, Labor, Welfare; Japan Society for the
   Promotion of Science; Ministry of Education, Culture, Sports, Science
   and Technology of Japan
FX We thank Ms. M. Iwashita for her expert technical assistance. This work
   was partly supported by a grant from the Japanese Osteoporosis
   Foundation. This work was partly supported by grants from the Japanese
   Ministry of Health, Labor, Welfare and Japan Society for the Promotion
   of Science and a grant of the Genome Network Project from the Ministry
   of Education, Culture, Sports, Science and Technology of Japan. We
   appreciate all the volunteers and participating institutions for
   precious clinical data and samples.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Cheung KMC, 2006, SPINE, V31, P1143, DOI 10.1097/01.brs.0000216530.41838.d3
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Creamer P, 1997, LANCET, V350, P503, DOI 10.1016/S0140-6736(97)07226-7
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fujita M, 2004, GERIATR GERONTOL INT, V4, P175
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Jones G, 1998, ANN RHEUM DIS, V57, P94, DOI 10.1136/ard.57.2.94
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kawaguchi Y, 2002, J BONE JOINT SURG AM, V84A, P2022, DOI 10.2106/00004623-200211000-00018
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   LANE NE, 1993, J RHEUMATOL, V20, P1911
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Loughlin J, 2003, CURR OPIN PHARMACOL, V3, P295, DOI 10.1016/S1471-4892(03)00018-3
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Murwantoko, 2004, BIOCHEM J, V381, P895, DOI 10.1042/BJ20040435
   O'Neill TW, 1999, J RHEUMATOL, V26, P842
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Spector Tim D, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS39
   Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015
   Urano T, 2008, SPINE, V33, P1256, DOI 10.1097/BRS.0b013e3181715304
   Urano T, 2007, J BONE MINER METAB, V25, P253, DOI 10.1007/s00774-007-0757-9
   Urano T, 2007, SPINE, V32, P25, DOI 10.1097/01.brs.0000251003.62212.5b
   Urano T, 2007, GERIATR GERONTOL INT, V7, P104, DOI 10.1111/j.1447-0594.2007.00394.x
   Usui T, 2007, GERIATR GERONTOL INT, V7, P48, DOI 10.1111/j.1447-0594.2007.00368.x
   Videman T, 2001, Spine (Phila Pa 1976), V26, pE7
   Videman T, 1998, SPINE, V23, P2477, DOI 10.1097/00007632-199812010-00002
   Wu J, 2007, ARTHRITIS RHEUM-US, V56, P3675, DOI 10.1002/art.22876
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YU W, 1995, CALCIFIED TISSUE INT, V57, P169, DOI 10.1007/BF00310253
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 44
TC 18
Z9 23
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0914-8779
EI 1435-5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAR
PY 2010
VL 28
IS 2
BP 220
EP 226
DI 10.1007/s00774-009-0124-0
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 561EF
UT WOS:000274957900013
PM 19798546
DA 2022-11-30
ER

PT J
AU Tortajada, A
   Montes, T
   Martinez-Barricarte, R
   Morgan, BP
   Harris, CL
   de Cordoba, SR
AF Tortajada, Agustin
   Montes, Tamara
   Martinez-Barricarte, Ruben
   Morgan, B. Paul
   Harris, Claire L.
   Rodriguez de Cordoba, Santiago
TI The disease-protective complement factor H allotypic variant Ile62 shows
   increased binding affinity for C3b and enhanced cofactor activity
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; MACULAR DEGENERATION; MEMBRANOPROLIFERATIVE
   GLOMERULONEPHRITIS; ALTERNATIVE PATHWAY; REGULATORY DOMAINS; DEPOSIT
   DISEASE; PROTEIN BETA-1H; TERMINAL REGION; SIALIC-ACID; FACTOR-B
AB Mutations and polymorphisms in the gene encoding factor H (CFH) have been associated with atypical haemolytic uraemic syndrome, dense deposit disease and age-related macular degeneration. The disease-predisposing CFH variants show a differential association with pathology that has been very useful to unravel critical events in the pathogenesis of one or other disease. In contrast, the factor H (fH)-Ile(62) polymorphism confers strong protection to all three diseases. Using ELISA-based methods and surface plasmon resonance analyses, we show here that the protective fH-Ile(62) variant binds more efficiently to C3b than fH-Val(62) and competes better with factor B in proconvertase formation. Functional analyses demonstrate an increased cofactor activity for fH-Ile(62) in the factor I-mediated cleavage of fluid phase and surface-bound C3b; however, the two fH variants show no differences in decay accelerating activity. From these data, we conclude that the protective effect of the fH-Ile(62) variant is due to its better capacity to bind C3b, inhibit proconvertase formation and catalyze inactivation of fluid-phase and surface-bound C3b. This demonstration of the functional consequences of the fH-Ile(62) polymorphism provides relevant insights into the complement regulatory activities of fH that will be useful in disease prediction and future development of effective therapeutics for disorders caused by complement dysregulation.
C1 [Harris, Claire L.] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Complement Biol Grp, Cardiff CF14 4XN, S Glam, Wales.
   [Tortajada, Agustin; Montes, Tamara; Martinez-Barricarte, Ruben; Rodriguez de Cordoba, Santiago] CSIC, Ctr Invest Biol, Ctr Invest Biomed Enfermedades Raras, Inst Reine Sofia Invest Nefrol, Madrid 28040, Spain.
C3 Cardiff University; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC -
   Centro de Investigaciones Biologicas (CIB)
RP Harris, CL (通讯作者)，Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Complement Biol Grp, Henry Wellcome Bldg,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.
EM harriscl@cardiff.ac.uk; srdecordoba@cib.csic.es
RI de Cordoba, Santiago Rodriguez/K-6727-2014; Barricarte, Ruben
   Martinez/W-8695-2019; Tortajada, Agustín/H-2857-2015
OI de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; Barricarte, Ruben
   Martinez/0000-0001-7925-449X; Tortajada, Agustín/0000-0002-2131-2594;
   Morgan, Paul/0000-0003-4075-7676
FU MRC Project [84908]; Ministerio de Ciencia e Innovacion [2005-00913];
   CIBER de Enfermedades Raras and Fundacion Renal Inigo Alvarez de Toledo;
   MRC [G0701298] Funding Source: UKRI; Medical Research Council [G0701298]
   Funding Source: researchfish
FX This work was supported by MRC Project Grant Ref 84908 ( to C. L. H. and
   B. P. M.), Ministerio de Ciencia e Innovacion Ref SAF 2005-00913 (to S.
   R. deC.) the CIBER de Enfermedades Raras and Fundacion Renal Inigo
   Alvarez de Toledo (to S. R. deC.). We thank the blood donors for their
   invaluable contribution to the project.
CR Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Harris CL, 2005, J BIOL CHEM, V280, P2569, DOI 10.1074/jbc.M410179200
   Hepburn NJ, 2007, J BIOL CHEM, V282, P8292, DOI 10.1074/jbc.M609858200
   Hocking HG, 2008, J BIOL CHEM, V283, P9475, DOI 10.1074/jbc.M709587200
   KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Law SKA, 1995, COMPLEMENT
   LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   LOPEZLARREA C, 1987, BIOCHEM SOC T, V15, P648, DOI 10.1042/bst0150648
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   PANGBURN MK, 1983, J IMMUNOL, V131, P1930
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   SANCHEZCORRAL P, 1989, J IMMUNOL METHODS, V122, P105, DOI 10.1016/0022-1759(89)90340-2
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Torreira E, 2009, P NATL ACAD SCI USA, V106, P882, DOI 10.1073/pnas.0810860106
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
NR 37
TC 107
Z9 109
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD SEP 15
PY 2009
VL 18
IS 18
BP 3452
EP 3461
DI 10.1093/hmg/ddp289
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 486NF
UT WOS:000269203000010
PM 19549636
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Ikeda, Y
   Yonemitsu, Y
   Miyazaki, M
   Kohno, R
   Murakami, Y
   Murata, T
   Goto, Y
   Tabata, T
   Ueda, Y
   Ono, F
   Suzuki, T
   Ageyama, N
   Terao, K
   Hasegawa, M
   Sueishi, K
   Ishibashi, T
AF Ikeda, Yasuhiro
   Yonemitsu, Yoshikazu
   Miyazaki, Masanori
   Kohno, Ri-ichiro
   Murakami, Yusuke
   Murata, Toshinori
   Goto, Yoshinobu
   Tabata, Toshiaki
   Ueda, Yasuji
   Ono, Fumiko
   Suzuki, Toshimichi
   Ageyama, Naohide
   Terao, Keiji
   Hasegawa, Mamoru
   Sueishi, Katsuo
   Ishibashi, Tatsuro
TI Acute Toxicity Study of a Simian Immunodeficiency Virus-Based Lentiviral
   Vector for Retinal Gene Transfer in Nonhuman Primates
SO HUMAN GENE THERAPY
LA English
DT Article
ID RECOMBINANT ADENOASSOCIATED VIRUS; EPITHELIUM-DERIVED FACTOR; GREEN
   FLUORESCENT PROTEIN; LEBERS CONGENITAL AMAUROSIS; PIGMENTED EPITHELIUM;
   ADENOVIRUS VECTOR; IMMUNE-RESPONSE; CLINICAL-TRIAL; IN-VIVO; THERAPY
AB A phase 1 clinical trial evaluating the safety of gene therapy for patients with wet age-related macular degeneration (AMD) or retinoblastoma has been completed without problems. The efficacy of gene therapy for Leber's congenital amaurosis (LCA) was reported by three groups. Gene therapy may thus hold promise as a therapeutic method for the treatment of intractable ocular diseases. However, it will first be important to precisely evaluate the efficiency and safety of alternative gene transfer vectors in a preclinical study using large animals. In the present study, we evaluated the acute local (ophthalmic) and systemic toxicity of our simian immunodeficiency virus from African green monkeys (SIVagm)-based lentiviral vectors carrying human pigment epithelium-derived factor (SIV-hPEDF) for transferring genes into nonhuman primate retinas. Transient inflammation and elevation of intraocular pressure were observed in some animals, but these effects were not dose dependent. Electroretinograms (ERGs), including multifocal ERGs, revealed no remarkable change in retinal function. Histopathologically, SIV-hPEDF administration resulted in a certain degree of inflammatory reaction and no apparent structural destruction in retinal tissue. Regarding systemic toxicity, none of the animals died, and none showed any serious side effects during the experimental course. No vector leakage was detected in serum or urine samples. We thus propose that SIVagm-mediated stable gene transfer might be useful and safe for ocular gene transfer in a clinical setting.
C1 [Ikeda, Yasuhiro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan.
   [Yonemitsu, Yoshikazu; Ueda, Yasuji] Chiba Univ, Grad Sch Med, Dept Gene Therapy, Chiba 2608670, Japan.
   [Murakami, Yusuke; Sueishi, Katsuo] Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol, Fukuoka 8128582, Japan.
   [Murata, Toshinori] Shinshu Univ, Sch Med, Dept Ophthalmol, Nagano 3908621, Japan.
   [Goto, Yoshinobu] Int Univ Hlth & Welf, Fac Rehabil, Dept Occupat Therapy, Fukuoka 8318501, Japan.
   [Tabata, Toshiaki; Hasegawa, Mamoru] DNAVEC, Tsukuba, Ibaraki 3050856, Japan.
   [Ono, Fumiko; Suzuki, Toshimichi] Corp Prod & Res Lab Primates, Tsukuba, Ibaraki 3050843, Japan.
   [Ageyama, Naohide; Terao, Keiji] Natl Inst Infect Dis, Tsukuba Primate Ctr, Tsukuba, Ibaraki 3050843, Japan.
C3 Kyushu University; Chiba University; Kyushu University; Shinshu
   University; International University of Health & Welfare; DNAVEC
   Corporation; National Institute of Infectious Diseases (NIID)
RP Ikeda, Y (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM ymocl@pathol1.med.kyushu-u.ac.jp
RI Ageyama, Naohide/ABG-5014-2020
OI Ageyama, Naohide/0000-0002-5722-2638
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology
   [15209057, 16390118, 17689047, 19209012]; National Institute of
   Biomedical Innovation [21]
FX The authors thank Y. Katakai, E. Nagasaka, M. Yoshikawa, and H. Fujii
   for assistance with the experiments. KN International provided language
   assistance. This work was supported in part by a Grant-in-Aid (to Y. I.,
   Y. Y., K. S., and T. I.) from the Japanese Ministry of Education,
   Culture, Sports, Science, and Technology (15209057, 16390118, 17689047,
   and 19209012) and by a grant for the Promotion of Basic Science Research
   in Medical Frontiers from the National Institute of Biomedical
   Innovation (Y. Y., K. S., and T. I., project 21).
CR Ali RR, 1996, HUM MOL GENET, V5, P591, DOI 10.1093/hmg/5.5.591
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2003, GENE THER, V10, P1336, DOI 10.1038/sj.gt.3301990
   Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920
   BENNETT J, 1994, INVEST OPHTH VIS SCI, V35, P2535
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cavazzana-Calvo M, 2007, J CLIN INVEST, V117, P1456, DOI 10.1172/JCI30953
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Doi K, 2004, J VIROL, V78, P11327, DOI 10.1128/JVI.78.20.11327-11333.2004
   Doi K, 2002, VISION RES, V42, P551, DOI 10.1016/S0042-6989(01)00237-1
   Duisit G, 2002, MOL THER, V6, P446, DOI 10.1006/mthe.2002.0690
   Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916
   Gansbacher B, 2003, J GENE MED, V5, P82, DOI 10.1002/jgm.364
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Higashikawa F, 2001, VIROLOGY, V280, P124, DOI 10.1006/viro.2000.0743
   HONJO S, 1985, J MED PRIMATOL, V14, P75
   Ikeda Y, 2003, GENE THER, V10, P1161, DOI 10.1038/sj.gt.3301973
   Ikeda Y, 2002, EXP EYE RES, V75, P39, DOI 10.1006/exer.2002.1177
   Le Meur G, 2005, ARCH OPHTHALMOL-CHIC, V123, P500, DOI 10.1001/archopht.123.4.500
   Lotery AJ, 2003, HUM GENE THER, V14, P1663, DOI 10.1089/104303403322542301
   Lotery AJ, 2002, HUM GENE THER, V13, P689, DOI 10.1089/104303402317322258
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244
   Miyazaki M, 2003, GENE THER, V10, P1503, DOI 10.1038/sj.gt.3302028
   Miyazaki M, 2008, J GENE MED, V10, P1273, DOI 10.1002/jgm.1257
   Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319
   Murakami Y, 2008, AM J PATHOL, V173, P1326, DOI 10.2353/ajpath.2008.080466
   Murakami Y, 2008, J GENE MED, V10, P165, DOI 10.1002/jgm.1142
   Narfstrom K, 2003, INVEST OPHTH VIS SCI, V44, P1663, DOI 10.1167/iovs.02-0595
   *PRIM SOC JAP, 1986, PRIMATE RES, V2, P111
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Reichel MB, 1998, GENE THER, V5, P1038, DOI 10.1038/sj.gt.3300691
   Sakamoto T, 1998, HUM GENE THER, V9, P789, DOI 10.1089/hum.1998.9.6-789
   Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951
   vanGinkel FW, 1997, J IMMUNOL, V159, P685
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   Woods NB, 2006, NATURE, V440, P1123, DOI 10.1038/4401123a
NR 38
TC 11
Z9 12
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD SEP
PY 2009
VL 20
IS 9
BP 943
EP 954
DI 10.1089/hum.2009.048
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 492QC
UT WOS:000269673100004
PM 19416079
DA 2022-11-30
ER

PT J
AU Wolf-Schnurrbusch, UEK
   Enzmann, V
   Brinkmann, CK
   Wolf, S
AF Wolf-Schnurrbusch, Ute E. K.
   Enzmann, Volker
   Brinkmann, Christian K.
   Wolf, Sebastian
TI Morphologic changes in patients with geographic atrophy assessed with a
   novel spectral OCT-SLO combination
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER
   OPHTHALMOSCOPE; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   LIPOFUSCIN; DISEASES; PATTERNS; MELANIN; DRUSEN
AB PURPOSE. To investigate the appearance of geographic atrophy in high-resolution optical coherence tomography (OCT) images, the fundus autofluorescence (FAF) pattern, and infrared images simultaneously recorded with a novel combined OCT-scanning laser ophthalmology (SLO) system.
   METHODS. Patients aged over 50 years with geographic atrophy secondary to dry age-related macular degeneration (ARMD) were assessed in a prospective cross-sectional study by means of simultaneous spectral OCT-SLO (Spectralis HRA + OCT; Heidelberg Engineering, Heidelberg, Germany). The integrity of the retinal layers was analyzed in the apparently normal areas, the junctional zone between the normal retina and the geographic atrophy, and the atrophic area. The presence and integrity of the external limiting membrane, the photoreceptor inner segments, the outer segments, and the retinal pigment epithelium were assessed.
   RESULTS. Fifty-two eyes of 52 patients (28 women, 24 men) aged 51 to 92 years were examined. Retinal layer alterations were documented, not only in atrophic zones, but also in junctional zones surrounding the geographic atrophy. Disintegration of the retinal layers began in the RPE and adjacent retinal layers, such as the photoreceptor inner and outer segments and external limiting membrane.
   CONCLUSIONS. Novel imaging modalities will provide further valuable insight into ARMD pathogenesis. The key to understanding the morphologic change lies in in vivo depiction of retinal layers by spectral OCT technology in combination with other imaging modalities such as FAF.
C1 [Wolf-Schnurrbusch, Ute E. K.; Enzmann, Volker; Brinkmann, Christian K.; Wolf, Sebastian] Univ Bern, Inselspital, Klin & Poliklin Augenheilkunde, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Wolf, S (通讯作者)，Univ Bern, Inselspital, Klin & Poliklin Augenheilkunde, Freiburgstr, CH-3010 Bern, Switzerland.
EM sebastian.wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Enzmann, Volker/0000-0003-4384-4855
CR Bermann M, 2001, EXP EYE RES, V72, P191
   Bernardes R, 2002, SURV OPHTHALMOL, V47, P580, DOI 10.1016/S0039-6257(02)00355-7
   BOULTON M, 1986, BRIT J OPHTHALMOL, V70, P808, DOI 10.1136/bjo.70.11.808
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Crafoord S, 2000, GRAEF ARCH CLIN EXP, V238, P682, DOI 10.1007/s004170000131
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1993, LIPOFUSCIN AGED AMD
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Podoleanu AG, 2004, J BIOMED OPT, V9, P86, DOI 10.1117/1.1627778
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ruggeri M, 2007, INVEST OPHTH VIS SCI, V48, P1808, DOI 10.1167/iovs.06-0815
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Sharp PF, 2004, PHYS MED BIOL, V49, P1085, DOI 10.1088/0031-9155/49/7/001
   Sharp PF, 1997, PHYS MED BIOL, V42, P951, DOI 10.1088/0031-9155/42/5/014
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WIEDEMANN P, 1992, SURV OPHTHALMOL, V36, P373, DOI 10.1016/0039-6257(92)90115-A
NR 29
TC 102
Z9 104
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 3095
EP 3099
DI 10.1167/iovs.07-1460
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000040
PM 18378583
DA 2022-11-30
ER

PT J
AU Freund, KB
   Ho, IV
   Barbazetto, IA
   Koizumi, H
   Laud, K
   Ferrara, D
   Matsumoto, Y
   Sorenson, JA
   Yannuzzi, L
AF Freund, K. Bailey
   Ho, I. -Van
   Barbazetto, Irene A.
   Koizumi, Hideki
   Laud, Ketan
   Ferrara, Daniela
   Matsumoto, Yoko
   Sorenson, John A.
   Yannuzzi, Lawrence
TI Type 3 neovascularization - The expanded spectrum of retinal angiomatous
   proliferation
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; occult chorioretinal anastomosis;
   retinal angiomatous proliferation; Type 3 neovascularization
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   MACULAR DEGENERATION; INTRAVITREAL TRIAMCINOLONE; CHORIORETINAL
   ANASTOMOSIS; PHOTODYNAMIC THERAPY; DETACHMENTS; ABLATION; DRUSEN
AB Background: Retinal angiomatous proliferation (RAP) is a distinct form of neovascularization in patients with age-related macular degeneration. Lacking definitive sequential histopathologic evidence of its intraretinal versus choroidal origin, the clinical observations of early stages of RAP lesions may provide clues to help further expand our understanding of this entity.
   Methods: Five eyes of four patients with early Stage 1 RAP were examined. Fundus photography, fluorescein and indocyanine green angiography as well as time-domain and spectral-domain optical coherence tomography were performed. Images were assessed to determine the characteristics of neovascularization in early stage RAP lesions and the response of the lesions to treatment or observation.
   Results: The analysis of the selected cases suggests a choroidal origin of the neovascular complex with the early formation of a retinal choroidal anastomosis without evidence of underlying occult Type 1 neovascularization. Three eyes responded to a single treatment with intravitreal ranibizumab (0.5 mg) and 2 eyes (1 patient) resolved spontaneously without treatment.
   Conclusion: The neovascularization in RAP may originate not only from deep retinal capillaries but also from the choroid. We therefore propose the more descriptive term "Type 3 neovascularization" for this entity to emphasize the intraretinal location of the vascular complex and distinguish this type from the two types of neovascularization previously described by J. Donald Gass in his classic text.
C1 Vitreous Retina macula Consultants New York, New York, NY 10022 USA.
   Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Freund, KB (通讯作者)，Vitreous Retina macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM vrmny@aol.com
RI ; Freund, K. Bailey/V-7488-2018
OI Ho, I-Van/0000-0002-7215-1233; Freund, K. Bailey/0000-0002-7888-9773
CR Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   Costa RA, 2005, AM J OPHTHALMOL, V140, P107, DOI 10.1016/j.ajo.2005.02.042
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Gass J., 1997, STEREOSCOPIC ATLAS M, V4th ed., P26
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Johnson TM, 2006, RETINA-J RET VIT DIS, V26, P765, DOI 10.1097/01.iae.0000244264.98642.af
   Klais CM, 2006, RETINA-J RET VIT DIS, V26, P773, DOI 10.1097/01.iae.0000244261.52901.67
   Krieglstein TR, 2006, BRIT J OPHTHALMOL, V90, P1357, DOI 10.1136/bjo.2006.092536
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Nakata M, 2006, AM J OPHTHALMOL, V141, P968, DOI 10.1016/j.ajo.2005.12.029
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 21
TC 218
Z9 224
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2008
VL 28
IS 2
BP 201
EP 211
DI 10.1097/IAE.0b013e3181669504
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 266TV
UT WOS:000253460800002
PM 18301024
DA 2022-11-30
ER

PT J
AU Aisenbrey, S
   Gelisken, F
   Szurman, P
   Bartz-Schmidt, KU
AF Aisenbrey, S.
   Gelisken, F.
   Szurman, P.
   Bartz-Schmidt, K. U.
TI Surgical treatment of peripapillary choroidal neovascularisation
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL NEOVASCULARIZATION; MACULAR DEGENERATION; LASER
   PHOTOCOAGULATION; OCULAR HISTOPLASMOSIS; MEMBRANES; REMOVAL; SURGERY
AB Objective: To report the functional and morphological outcome of surgical treatment of peripapillary choroidal neovascularisation due to age-related macular degeneration.
   Methods: Consecutive interventional case series of eight patients with extensive peripapillary choroidal neovascularisation and accompanying haemorrhage who underwent subretinal surgery including extraction of the neovascular complex. Ophthalmic examination, including visual acuity testing, colour photography and fluorescein angiography, was performed at baseline and at 3, 6, 9 and 12 months, and then yearly.
   Results: Mean follow-up was 26 months (12-60 months). Preoperative best corrected visual acuity (BCVA) ranged from logMAR (logarithm of minimum angle of acuity) 1.0 (20/200) to logMAR 0.0 (20/20), with a mean of logMAR 0.5 (20/63). Mean postoperative BCVA was logMAR 0.3 (20/40). BCVA improved in six patients, was stable in one patient and deteriorated in one patient. Two years after surgery, one patient developed recurrence of the CNV that was removed surgically. One patient showed retinal detachment 5 years after subretinal surgery.
   Conclusions: In this small case series of PPCNV, functional improvement was achieved after surgery in the majority of patients. Surgical extraction of the CNV represents an alternative treatment option in eyes with vision-threatening extensive PPCNV. Randomised controlled studies seem to be justified to evaluate further the beneficial effect and long-term functional outcome of this therapy approach.
C1 Univ Tubingen, Ctr Ophthalmol, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Aisenbrey, S (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Schleich Str 12, D-72076 Tubingen, Germany.
EM sabine.aisenbrey@med.unituebingen.de
CR Atebara NH, 1998, OPHTHALMOLOGY, V105, P1598, DOI 10.1016/S0161-6420(98)99024-8
   Bains HS, 2003, RETINA-J RET VIT DIS, V23, P469, DOI 10.1097/00006982-200308000-00004
   Blinder KJ, 2005, OPHTHAL SURG LAS IM, V36, P358, DOI 10.3928/1542-8877-20050901-03
   BLOOM SM, 1990, RETINA-J RET VIT DIS, V10, P261, DOI 10.1097/00006982-199010000-00006
   Browning DJ, 2005, OPHTHALMOLOGY, V112, P1054, DOI 10.1016/j.ophtha.2004.11.062
   CIALDINI AP, 1989, OPHTHALMIC SURG LAS, V20, P93
   Flaxel CJ, 1996, OPHTHALMOLOGY, V103, P1250, DOI 10.1016/S0161-6420(96)30513-7
   GOLDBERG MF, 1973, ARCH OPHTHALMOL-CHIC, V89, P311, DOI 10.1001/archopht.1973.01000040313011
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kertes PJ, 2004, RETINA-J RET VIT DIS, V24, P219, DOI 10.1097/00006982-200404000-00005
   KIES JC, 1988, AM J OPHTHALMOL, V105, P11, DOI 10.1016/0002-9394(88)90114-6
   Kokame GT, 2005, RETINA-J RET VIT DIS, V25, P564, DOI 10.1097/00006982-200507000-00004
   LOPEZ PF, 1992, RETINA-J RET VIT DIS, V12, P147, DOI 10.1097/00006982-199212020-00012
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   Mateo C, 2004, RETINA-J RET VIT DIS, V24, P739, DOI 10.1097/00006982-200410000-00009
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   RUBEN S, 1994, ACTA OPHTHALMOL, V72, P118
   SILVESTRI G, 1993, EYE, V7, P398, DOI 10.1038/eye.1993.78
   SWARTZ M, 1983, BRIT J OPHTHALMOL, V67, P517, DOI 10.1136/bjo.67.8.517
   TURCOTTE P, 1991, RETINA-J RET VIT DIS, V11, P295, DOI 10.1097/00006982-199111030-00004
   Uemura A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1373
NR 22
TC 11
Z9 11
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2007
VL 91
IS 8
BP 1027
EP 1030
DI 10.1136/bjo.2006.108118
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 190WD
UT WOS:000248090400012
PM 17301123
OA Green Published
DA 2022-11-30
ER

PT J
AU Obana, A
   Gohto, Y
AF Obana, A
   Gohto, Y
TI Scanning laser system for photodynamic therapy of choroidal
   neovascularization
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE photodynamic therapy; age-related macular degeneration; scanning laser
   ophthalmoscope; ATX-S10 (Na); choroidal vessels
ID MACULAR DEGENERATION; VERTEPORFIN; OCCLUSION; PHOTOSENSITIZER;
   ATX-S10(NA)
AB Background and Objectives: In order to improve selectivity of photodynamic therapy (PDT) to choroidal neovascularization (CNV) associated with age-related macular degeneration, a laser scanning technique was applied to perform focal laser irradiation to the retina, and the occlusion effects of a new device to the choriocapillaris were evaluated in primate eyes.
   Study Design/Materials and Methods: The device contains lasers for fundus observation of 785 nm and for PDT of 670 nm, matching the absorption peak of a photosensitizer, ATX-S10(Na). The laser irradiated the shape on the retina specified before treatment and shut off automatically when the predetermined treatment was achieved. The occlusion of the choriocapillaris after PDT was documented by fluorescein and indocyanine green angiography and histology.
   Results: The area designated for PDT was easily drawn on the touch-screen monitor, and occlusion of the choriocapillaris was achieved precisely in the area pre-selected for treatment with 5 J/cm(2) or more of radiance following administration of 8 mg/kg ATX-S10(Na).
   Conclusions: This device is useful for irradiating CNV of any shape, sparing the surrounding retina. Since our previous studies suggested that selective occlusion of CNV would decrease not only the functional disturbance caused by PDT, but also the recurrence of CNV, the present device may allow more effective PDT than the slit-lamp system presently used. (C) 2002 Wiley-Liss, Inc.
C1 Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Abeno Ku, Osaka 5458585, Japan.
C3 Osaka Metropolitan University
RP Obana, A (通讯作者)，Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.
EM akira-kun@med.osaka-cu.ac.jp
CR Blumenkranz MS, 2000, AM J OPHTHALMOL, V129, P353, DOI 10.1016/S0002-9394(99)00462-6
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   KLIMAN GH, 1994, LASER SURG MED, V15, P11, DOI 10.1002/lsm.1900150104
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   LIN SC, 1994, CURR EYE RES, V13, P513, DOI 10.3109/02713689408999883
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Mori K, 1999, OPHTHALMOLOGY, V106, P1384, DOI 10.1016/S0161-6420(99)00729-0
   Obana A, 1999, LASER SURG MED, V24, P209, DOI 10.1002/(SICI)1096-9101(1999)24:3<209::AID-LSM6>3.0.CO;2-L
   Obana A, 2001, INVEST OPHTH VIS SCI, V42, P2639
   Obana A, 2000, ARCH OPHTHALMOL-CHIC, V118, P650
   Peyman GA, 1997, OPHTHALMIC SURG LAS, V28, P409
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
NR 18
TC 6
Z9 6
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PY 2002
VL 30
IS 5
BP 370
EP 375
DI 10.1002/lsm.10056
PG 6
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology; Surgery
GA 568ZV
UT WOS:000176575600008
PM 12116330
DA 2022-11-30
ER

PT J
AU Fernandez-Avellaneda, P
   Freund, KB
   Wang, RK
   He, QH
   Zhang, QQ
   Fragiotta, S
   Xu, XY
   Ledesma-Gil, G
   Sugiura, Y
   Breazzano, MP
   Yannuzzi, LA
   Liakopoulos, S
   Sarraf, D
   Dolz-Marco, R
AF Fernandez-Avellaneda, Pedro
   Freund, K. Bailey
   Wang, Reeking K.
   He, Qinghua
   Zhang, Qinqin
   Fragiotta, Serena
   Xu, Xiaoyu
   Ledesma-Gil, Gerardo
   Sugiura, Yoshimi
   Breazzano, Mark P.
   Yannuzzi, Lawrence A.
   Liakopoulos, Sandra
   Sarraf, David
   Dolz-Marco, Rosa
TI Multimodal Imaging Features and Clinical Relevance of Subretinal Lipid
   Globules
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To describe the presence of subretinal lipid globules (SLG), analyze the multimodal imaging features inherent in their optical properties, and provide a means to distinguish them from other retinal structures and clinical signs.
   DESIGN: Retrospective cohort study.
   METHODS: The clinical data and multimodal imaging features of 39 patients (49 eyes) showing SLG were evaluated. Patients underwent color fundus photography, near-infrared reflectance (NIR), spectral-domain (SD) and swept-source (SS) optical coherence tomography (OCT) and OCT angiography. In vitro phantom models were used to model OCT optical properties of water, mineral oil, and intralipid droplets and to investigate the optical mechanisms producing hypertransmission tails beneath SLG.
   RESULTS: The SLG were not visible in color fundus photographs or in NIR images. With both SD- and SS-OCT B-scans, SLG appeared as 31-157 pm, round, hyporeflective structures demonstrating a characteristic hypertransmission tail previously described with lipid globules found in the choroid and in neovascular membranes. Similarly, with en face OCT, SLG appeared as small, round, hyporeflective structures. SLG were encountered most often in eyes with neovascular age-related macular degeneration (AMD) that had type 1 macular neovascularization (MNV) (91.1%). Of those eyes, 93.3% were receiving intravitreal antivascular endothelial growth factor (VEGF) therapy (median of 15 injections) with a mean follow-up of 52.6 months. The number of prior injections positively correlated with the number of SLG. The detection of MNV preceded the presence of SLG in 66.7% of cases. En face OCT showed that, in many eyes (49%), SLG appeared in clusters of > 10. In 38.8% of eyes, SLG were found overlying type 1 MNV, and in 44.9% of eyes, often those with more numerous SLG, the SLG were located near the lesion border. In 2 eyes with AMD followed for nonexudative type 1 MNV, SLG were detected prior to the detection of other imaging signs of exudation. SLG were observed in several other exudative macular diseases. Phantom models demonstrated that the hypertransmission tail beneath SLG is related to a lensing effect produced by these hyporeflective spherical structures.
   CONCLUSIONS: SLG are a newly recognized OCT feature frequently seen in eyes receiving intravitreal anti-VEGF therapy for type 1 MNV due to AMD. OCT B-scans show SLG as small, round, hyporeflective structures with a characteristic hypertransmission tail. This OCT signature is influenced by the OCT focal plane, and it relates to reduced signal attenuation through oil and a lensing effect created by a higher refractive index compared to surrounding tissue. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Fernandez-Avellaneda, Pedro; Freund, K. Bailey; Breazzano, Mark P.; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, 950 Third Ave, New York, NY 10022 USA.
   [Fernandez-Avellaneda, Pedro; Freund, K. Bailey; Breazzano, Mark P.; Yannuzzi, Lawrence A.] NYU, Dept Ophthalmol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Fernandez-Avellaneda, Pedro] Basurto Univ Hosp, Dept Ophthalmol, Bilbao, SP, Brazil.
   [Freund, K. Bailey; Breazzano, Mark P.; Yannuzzi, Lawrence A.] Columbia Univ, Coll Phys & Surg, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Freund, K. Bailey; Breazzano, Mark P.; Yannuzzi, Lawrence A.] Columbia Univ, Coll Phys & Surg, Manhattan Eye Ear & Throat Hosp, New York, NY USA.
   [Freund, K. Bailey; Breazzano, Mark P.; Yannuzzi, Lawrence A.] Columbia Univ, Coll Phys & Surg, Harkness Eye Inst, New York, NY USA.
   [Wang, Reeking K.; He, Qinghua; Zhang, Qinqin] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Fragiotta, Serena] Univ Rome Sapienza, S Andrea Hosp, Neurosci Salute Mentale & Organi Senso Dept, Ophthalmol Unit, Rome, Italy.
   [Xu, Xiaoyu] State Key Lab Ophthalmol, Zhongshan, Peoples R China.
   [Xu, Xiaoyu] Sun Yat Sen Univ, Ophthalm Ctr, Guangzhou, Peoples R China.
   [Ledesma-Gil, Gerardo] New York Eye & Ear Infirm Mt Sinai, New York, NY USA.
   [Sugiura, Yoshimi] Univ Tsukuba, Fac Med, Dept Ophthalmol, Tsukuba, Ibaraki, Japan.
   [Liakopoulos, Sandra] Fac Med, Dept Ophthalmol, Cologne, Germany.
   [Liakopoulos, Sandra] Univ Hosp Cologne, Cologne, Germany.
   [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA 90024 USA.
   [Dolz-Marco, Rosa] Oftalvist Clin, Unit Macula, Valencia, Spain.
C3 Vitreous Retina Macula Consultants of New York; New York University;
   Columbia University; Columbia University; Manhattan Eye Ear & Throat
   Hospital; Columbia University; University of Washington; University of
   Washington Seattle; Sapienza University Rome; Azienda Ospedaliera
   Sant'Andrea; Sun Yat Sen University; New York Eye & Ear Infirmary of
   Mount Sinai; University of Tsukuba; University of Cologne; University of
   Cologne; University of California System; University of California Los
   Angeles
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 950 Third Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI He, Qinghua/AAQ-9871-2021; Wang, Ruikang/L-3889-2019; Freund, K.
   Bailey/V-7488-2018
OI Wang, Ruikang/0000-0001-5169-8822; Ledesma-Gil,
   Gerardo/0000-0002-5882-5940; Sugiura, Yoshimi/0000-0003-2970-2658;
   Freund, K. Bailey/0000-0002-7888-9773; Breazzano,
   Mark/0000-0002-7093-965X
FU Macula Foundation Inc., New York, NY; National Natural Science
   Foundation of China [81800879]; Fundamental Research Funds of the State
   Key Laboratory of Ophthalmology, China [2018KF04, 2017QN05]; Natural
   Science Foundation of Guangdong Province China [2017A030310372]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. This work was
   supported by the Macula Foundation Inc., New York, NY; National Natural
   Science Foundation of China award 81800879; Fundamental Research Funds
   of the State Key Laboratory of Ophthalmology, China, awards 2018KF04 and
   2017QN05; and the Natural Science Foundation of Guangdong Province China
   award 2017A030310372.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Boschi F, 2019, EUR J HISTOCHEM, V25, P63
   CasaroliMarano RP, 1996, J LIPID RES, V37, P1037
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FRIEDMAN E, 1966, ARCH OPHTHALMOL-CHIC, V75, P334
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Jacques SL, 2013, PHYS MED BIOL, V58, pR37, DOI 10.1088/0031-9155/58/11/R37
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kashani AH, 2018, OPHTHALMOL RETINA, V2, P694, DOI 10.1016/j.oret.2017.11.004
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Li YD, 2018, NEUROBIOL AGING, V70, P148, DOI 10.1016/j.neurobiolaging.2018.06.017
   Michels R, 2008, OPT EXPRESS, V16, P5907, DOI 10.1364/OE.16.005907
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Pogue BW, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2335429
   Querques G, 2016, INVEST OPHTH VIS SCI, V57, P2578, DOI 10.1167/iovs.16-19083
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Sakurada Y, 2018, RETINA-J RET VIT DIS, V38, P1977, DOI 10.1097/IAE.0000000000002294
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tuchin V, 2007, REFRACTIVE INDEX VAR, P104
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Young SG, 2013, GENE DEV, V27, P459, DOI 10.1101/gad.209296.112
NR 37
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2021
VL 222
BP 112
EP 125
DI 10.1016/j.ajo.2020.09.003
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QR8QU
UT WOS:000625478500014
PM 32918902
DA 2022-11-30
ER

PT J
AU Chen, YH
   Zhu, XY
   Ye, FX
   Wang, H
   Wan, XL
   Zhang, T
   Wang, YW
   Wang, YM
   Zhao, XH
   Bai, XY
   Xiao, YS
   Sun, XD
AF Chen, Yuhong
   Zhu, Xinyue
   Ye, Fuxiang
   Wang, Hong
   Wan, Xiaoling
   Zhang, Ting
   Wang, Yuwei
   Wang, Yimin
   Zhao, Xiaohuan
   Bai, Xinyue
   Xiao, Yushu
   Sun, Xiaodong
TI Malondialdehyde-Modified Photoreceptor Outer Segments Promote Choroidal
   Neovascularization in Mice
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; malondialdehyde; retinal pigment
   epithelium; choroidal neovascularization; mouse model
ID RETINAL-PIGMENT EPITHELIUM; INDUCED PREMATURE SENESCENCE;
   LIPID-PEROXIDATION PRODUCTS; OXIDATIVE STRESS; VEGF SECRETION;
   LIFE-SPAN; AUTOPHAGY; CELLS; RPE; LIPOFUSCIN
AB Purpose: This study aimed to establish a novel choroidal neovascularization (CNV) mouse model through subretinally injecting malondialdehyde (MDA)-modified photoreceptor outer segments (POS), which was more consistent with the pathogenesis of wet age-related macular degeneration (AMD).
   Methods: MDA-modified POS were subretinally injected in C57BL/6J mice. Four weeks later, to assess the volume of CNV and the morphology of retinal pigment epithelium (RPE), isolectin B4 and zonula occludens-1 antibody were used for immunostaining. Fundus fluorescent angiography and optical coherence tomography imaging were used to describe the morphologic features of CNV. Transepithelial resistance was measured on polarizedARPE-19 cells. Vascular endothelial growth factor levels in the cell culture medium were detected by enzyme-linked immunosorbent assay. The protein and messenger RNA expression levels of autophagy markers were measured using Western blot and quantitative polymerase chain reaction.
   Results: CNV and RPE atrophy were successfully induced in the mouse model. MDAmodified POS also significantly increased the expression of vascular endothelial growth factor and disrupted cell junctions in RPE cells. In addition, MDA-modified POS induced autophagy-lysosomal impairment in RPE cells.
   Conclusions: Subretinal injection of MDA-modified POS may generate a feasible CNV model that simulates the AMD pathological process.
   Translational Relevance: This study expands the understanding of the role of MDA in AMD pathogenesis, which provides a potential therapeutic target of AMD.
C1 [Chen, Yuhong; Zhu, Xinyue; Ye, Fuxiang; Wang, Hong; Wan, Xiaoling; Zhang, Ting; Wang, Yuwei; Wang, Yimin; Zhao, Xiaohuan; Bai, Xinyue; Xiao, Yushu; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Chen, Yuhong; Zhu, Xinyue; Ye, Fuxiang; Wang, Hong; Wan, Xiaoling; Zhang, Ting; Wang, Yuwei; Wang, Yimin; Zhao, Xiaohuan; Bai, Xinyue; Xiao, Yushu; Sun, Xiaodong] Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.
   [Wan, Xiaoling; Zhang, Ting; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Ye, FX; Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM yefux@sjtu.edu.cn; xdsun@sjtu.edu.cn
OI Sun, Xiaodong/0000-0001-5015-0945; Zhang, Ting/0000-0001-6330-8473
FU National Natural Science Foundation of China [81700845]; National Major
   Scientific and Technological Special Project for "Significant New Drugs
   Development"; National Key R&D Program, Science and Technology
   Commission of Shanghai Municipality; Shanghai Jiao Tong University
   School of Medicine, Science and Technology Commission of Shanghai
   Municipality [81730026, 2019ZX09301113, 2017YFA0105301, 17411953000,
   DLY201813, 19495800700]
FX Supported by the National Natural Science Foundation of China (81700845
   to FX. Ye), the National Natural Science Foundation of China, National
   Major Scientific and Technological Special Project for "Significant New
   Drugs Development" during the Thirtieth Five-year Plan Period, National
   Key R&D Program, Science and Technology Commission of Shanghai
   Municipality, Multi-center Clinical Research Project from Shanghai Jiao
   Tong University School of Medicine, Science and Technology Commission of
   Shanghai Municipality (81730026, 2019ZX09301113, 2017YFA0105301,
   17411953000, DLY201813, 19495800700 to XD. Sun).
CR ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Chan CM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0531-z
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326
   Del Rio D, 2005, NUTR METAB CARDIOVAS, V15, P316, DOI 10.1016/j.numecd.2005.05.003
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   GORDON WC, 1992, CURR EYE RES, V11, P73, DOI 10.3109/02713689209069169
   Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, pC203, DOI 10.1152/ajpcell.00097.2010
   Hohn A, 2013, J PROTEOMICS, V92, P132, DOI 10.1016/j.jprot.2013.01.004
   Hsu MY, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10071125
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   IMAI H, 1991, BUNSEKI KAGAKU, V40, P143
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Jang KH, 2020, MOL CELLS, V43, P632, DOI 10.14348/molcells.2020.0078
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   KWON TW, 1963, J FOOD SCI, V28, P627, DOI 10.1111/j.1365-2621.1963.tb01666.x
   Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Lerner C, 2013, AGING CELL, V12, P966, DOI 10.1111/acel.12122
   Liang CM, 2011, ACTA OPHTHALMOL, V89, pE505, DOI 10.1111/j.1755-3768.2011.02147.x
   LUNG CC, 1990, J IMMUNOL METHODS, V128, P127, DOI 10.1016/0022-1759(90)90471-7
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mandal PK, 2011, NAT REV MOL CELL BIO, V12, P198, DOI 10.1038/nrm3060
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Matsuura T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9548767
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Niki E, 2009, FREE RADICAL BIO MED, V47, P469, DOI 10.1016/j.freeradbiomed.2009.05.032
   Njie-Mbye YF, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00366
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shirasawa M, 2013, EXP EYE RES, V110, P59, DOI 10.1016/j.exer.2013.02.012
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundelin SP, 2002, APMIS, V110, P481, DOI 10.1034/j.1600-0463.2002.100606.x
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   Terasaki H, 2015, CURR EYE RES, V40, P936, DOI 10.3109/02713683.2014.964417
   Uchida K, 2015, FREE RADICAL RES, V49, P896, DOI 10.3109/10715762.2015.1036052
   Wihlmark U, 1996, APMIS, V104, P272, DOI 10.1111/j.1699-0463.1996.tb00717.x
   Yamauchi Y, 2008, PLANT PHYSIOL BIOCH, V46, P786, DOI 10.1016/j.plaphy.2008.04.018
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Ye FX, 2015, SCI REP-UK, V5, DOI 10.1038/srep07705
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhang BY, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107972
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 61
TC 0
Z9 0
U1 2
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2022
VL 11
IS 1
AR 12
DI 10.1167/tvst.11.1.12
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1L9DR
UT WOS:000799581700011
PM 35015060
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, PF
   Lu, B
   Xu, FY
   Wang, C
   Zhang, RR
   Liu, YP
   Wei, CH
   Mei, LX
AF Zhang, Pengfei
   Lu, Bing
   Xu, Fengyuan
   Wang, Chen
   Zhang, Rongrong
   Liu, Yinping
   Wei, Chenghua
   Mei, Lixin
TI Analysis of Long Noncoding RNAs in Choroid Neovascularization
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Long noncoding RNA; choroidal neovascularization; microarray analysis;
   bioinformatics analyses; M2 macrophage
ID MACULAR DEGENERATION; EXPRESSION; ANGIOGENESIS; DYSFUNCTION; METASTASIS
AB Purpose: Choroidal neovascularization (CNV) is the major pathological features of wet age-related macular degeneration (AMD). Long noncoding RNAs play great roles in numerous biological processes. The purpose of the study was to investigate the expression profile and possible functions of the lncRNAs in CNV. Methods: In this study, the mice CNV model were conducted by laser photocoagulation. The expression profiles of lncRNAs were accessed by microarray analysis. Selected altered lncRNAs of mice CNV and wet AMD patients were validated by RT-PCR. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and lncRNA-mRNA coexpression network were conducted to reveal the biological functions. Results: The results revealed that 128 lncRNAs were significantly altered in RPE-choroid-sclera complexes of CNV mice (P < .05, fold change > 2.0). GO analysis revealed that the altered target genes of the selected lncRNAs most enriched in angiogenesis. KEGG pathway analysis demonstrated that altered target genes of lncRNAs most enriched in focal adhesion signaling pathway. H19 was signi?cantly increased in the aqueous humor of wet AMD patients. Moreover, Inhibition of lncRNA H19 could suppresses M2 macrophage gene expression of laser-induced CNV mice. Conclusions: Our study identified differential expressions of lncRNAs in CNV, and lncRNA H19 might be novel potential target for the prevention and treatment of CNV.
C1 [Zhang, Pengfei; Xu, Fengyuan; Wang, Chen; Zhang, Rongrong; Liu, Yinping; Wei, Chenghua; Mei, Lixin] Wannan Med Coll, Yijishan Hosp, Affiliated Hosp 1, Dept Ophthalmol, Wuhu, Peoples R China.
   [Zhang, Pengfei; Mei, Lixin] Wannan Med Coll, Key Lab Noncoding RNA Transformat Res Anhui Highe, Wuhu 241001, Peoples R China.
   [Lu, Bing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, Shanghai, Peoples R China.
C3 Wannan Medical College; Wannan Medical College; Shanghai Jiao Tong
   University
RP Mei, LX (通讯作者)，Wannan Med Coll, Key Lab Noncoding RNA Transformat Res Anhui Highe, Wuhu 241001, Peoples R China.; Mei, LX (通讯作者)，Wannan Med Coll, Yijishan Hosp, Dept Ophthalmol, Wuhu 241001, Peoples R China.
EM meilixin63@sina.com
FU National Natural Science Foundation of China [81700867]; National
   Science Foundation of Anhui Province, China [1808085MH253]; Talent
   Cultivation and International Academic Visiting Project for College
   Scholar of Anhui Province, China [gxgwfx2019034]; Cross Funding of
   Shanghai Jiao Tong University [YG2017QN31]
FX This work was supported by the National Natural Science Foundation of
   China [grant No. 81700867], National Science Foundation of Anhui
   Province, China [grant No. 1808085MH253], Talent Cultivation and
   International Academic Visiting Project for College Scholar of Anhui
   Province, China [grant No. gxgwfx2019034] and Cross Funding of Shanghai
   Jiao Tong University [YG2017QN31].
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Brotelle T, 2016, B CANCER, V103, P18, DOI 10.1016/j.bulcan.2015.09.011
   Cobos E, 2018, ACTA OPHTHALMOL, V96, pe201, DOI 10.1111/aos.13519
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dai Y, 2019, BIOENGINEERED, V10, P383, DOI 10.1080/21655979.2019.1658489
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Gunda Venugopal, 2013, J Cancer Sci Ther, V5, P417
   Jia P, 2016, CANCER LETT, V381, P359, DOI 10.1016/j.canlet.2016.08.009
   Jiang XC, 2016, J NEUROSURG, V124, P129, DOI [10.3171/2014.12.JNS1426, 10.3171/2014.12.JNS1426.test]
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Liu JY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.466
   Lv Y, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107991
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Manavski Y, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0404-2
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Parsons N, 2019, MOL IMMUNOL, V108, P8, DOI 10.1016/j.molimm.2019.02.001
   St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007
   Stattin M, 2019, ACTA OPHTHALMOL, V97, pE131, DOI 10.1111/aos.13840
   Stenzel D, 2011, DEVELOPMENT, V138, P4451, DOI 10.1242/dev.071381
   Sun BQ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182394
   Sun LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14015-6
   Wang WQ, 2011, INVEST OPHTH VIS SCI, V52, P7213, DOI 10.1167/iovs.10-7097
   Wang XY, 2021, ENVIRON TECHNOL, V42, P2021, DOI 10.1080/09593330.2019.1687588
   Xu XD, 2014, MOL BIOL REP, V41, P4493, DOI 10.1007/s11033-014-3320-5
   Yan BA, 2015, CIRC RES, V116, P1143, DOI 10.1161/CIRCRESAHA.116.305510
   Yang T, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0166177, 10.1371/journal.pone.0152687]
   Yin NN, 2020, IMMUNOPHARM IMMUNOT, V42, P147, DOI 10.1080/08923973.2020.1732407
   Yu H, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018533
   Zhang L, 2019, ARTIF CELL NANOMED B, V47, P2516, DOI 10.1080/21691401.2019.1626409
   Zhang LW, 2019, CURR EYE RES, V44, P1226, DOI 10.1080/02713683.2019.1625407
   Zhang PF, 2018, INFLAMMATION, V41, P143, DOI 10.1007/s10753-017-0672-8
   Zhu J, 2009, EXP EYE RES, V88, P910, DOI 10.1016/j.exer.2008.11.034
NR 35
TC 4
Z9 4
U1 3
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD NOV 1
PY 2020
VL 45
IS 11
BP 1403
EP 1414
DI 10.1080/02713683.2020.1748659
EA MAY 2020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OA2AY
UT WOS:000532457400001
PM 32316788
DA 2022-11-30
ER

PT J
AU Pfeiffer, RL
   Marc, RE
   Jones, BW
AF Pfeiffer, Rebecca L.
   Marc, Robert E.
   Jones, Bryan William
TI Persistent remodeling and neurodegeneration in late-stage retinal
   degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Retinal remodeling; Neurodegeneration; Ultrastructure; Alpha-synuclein;
   Proteinopathy; Transcellular debris removal
ID UBIQUITIN-PROTEASOME SYSTEM; HUMAN RETINITIS-PIGMENTOSA; AMINO-ACID
   SIGNATURES; OPTOGENETIC VISION RESTORATION; RESTORES VISUAL RESPONSES;
   HIGH-DOSE SUPPLEMENTATION; AMYLOID-BETA STIMULATION; ALPHA-SYNUCLEIN;
   GENE-THERAPY; MACULAR DEGENERATION
AB Retinal remodeling is a progressive series of negative plasticity revisions that arise from retinal degeneration, and are seen in retinitis pigmentosa, age-related macular degeneration and other forms of retinal disease. These processes occur regardless of the precipitating event leading to degeneration. Retinal remodeling then culminates in a late-stage neurodegeneration that is indistinguishable from progressive central nervous system (CNS) proteinopathies. Following long-term deafferentation from photoreceptor cell death in humans, and long-lived animal models of retinal degeneration, most retinal neurons reprogram, then die. Glial cells reprogram into multiple anomalous metabolic phenotypes. At the same time, survivor neurons display degenerative inclusions that appear identical to progressive CNS neurodegenerative disease, and contain aberrant alpha-synuclein (alpha-syn) and phosphorylated alpha-syn. In addition, ultrastructural analysis indicates a novel potential mechanism for misfolded protein transfer that may explain how proteinopathies spread. While neurodegeneration poses a barrier to prospective retinal interventions that target primary photoreceptor loss, understanding the progression and time-course of retinal remodeling will be essential for the establishment of windows of therapeutic intervention and appropriate tuning and design of interventions. Finally, the development of protein aggregates and widespread neurodegeneration in numerous retinal degenerative diseases positions the retina as a ideal platform for the study of proteinopathies, and mechanisms of neurodegeneration that drive devastating CNS diseases.
C1 [Pfeiffer, Rebecca L.; Marc, Robert E.; Jones, Bryan William] Univ Utah, Dept Ophthalmol, Moran Eye Ctr, Salt Lake City, UT 84112 USA.
   [Pfeiffer, Rebecca L.; Marc, Robert E.; Jones, Bryan William] Univ Utah, Interdept Program Neurosci, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Pfeiffer, RL; Jones, BW (通讯作者)，Univ Utah, Dept Ophthalmol, Moran Eye Ctr, Salt Lake City, UT 84112 USA.
EM r.pfeiffer@utah.edu; bryan.jones@m.cc.utah.edu
FU National Institutes of Health [R01 EY015128, RO1 EY028927, T32 EY024234,
   P30 EY014800]; Research to Prevent Blindness, New York, NY
FX This work was supported by the National Institutes of Health [R01
   EY015128(BWJ), RO1 EY028927(BWJ) T32 EY024234 (RLP), P30
   EY014800(Core)]; and an Unrestricted Research Grant from Research to
   Prevent Blindness, New York, NY to the Department of Ophthalmology &
   Visual Sciences, University of Utah.
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830
   Agosta F, 2010, HUM BRAIN MAPP, V31, P515, DOI 10.1002/hbm.20883
   Ahuja AK, 2011, BRIT J OPHTHALMOL, V95, P539, DOI 10.1136/bjo.2010.179622
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson JR, 2011, J MICROSC-OXFORD, V241, P13, DOI 10.1111/j.1365-2818.20.10.03402.x
   Anderson JR, 2011, MOL VIS, V17
   [Anonymous], DUANES OPHTHALMOLOGY
   Arai S, 2004, EXP EYE RES, V79, P331, DOI 10.1016/j.exer.2004.05.013
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Asakawa K, 2016, NEURO-OPHTHALMOLOGY, V40, P286, DOI 10.1080/01658107.2016.1229339
   Asakawa K, 2015, JPN J OPHTHALMOL, V59, P353, DOI 10.1007/s10384-015-0400-6
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Bareket L, 2017, J NEURAL ENG, V14, DOI 10.1088/1741-2552/aa6cbb
   Beltran WA, 2015, P NATL ACAD SCI USA, V112, pE5844, DOI 10.1073/pnas.1509914112
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   BLANKS JC, 1982, J COMP NEUROL, V212, P231, DOI 10.1002/cne.902120303
   Bogea TH, 2015, INVEST OPHTH VIS SCI, V56, P7947, DOI 10.1167/iovs.15-16799
   Bowen S, 2007, EUR J NEUROSCI, V25, P2947, DOI 10.1111/j.1460-9568.2007.05554.x
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525
   Bringmann Andreas, 2013, Front Endocrinol (Lausanne), V4, P48, DOI 10.3389/fendo.2013.00048
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Burre J, 2015, J NEUROSCI, V35, P5221, DOI 10.1523/JNEUROSCI.4650-14.2015
   Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227
   Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002
   Busskamp V, 2011, CURR OPIN NEUROBIOL, V21, P942, DOI 10.1016/j.conb.2011.06.001
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Campello L, 2013, MOL NEUROBIOL, V47, P790, DOI 10.1007/s12035-012-8391-5
   Chaffiol A, 2017, MOL THER, V25, P2546, DOI 10.1016/j.ymthe.2017.07.011
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chaturvedi RK, 2013, FREE RADICAL BIO MED, V63, P1, DOI 10.1016/j.freeradbiomed.2013.03.018
   Chen Y, 2015, NEUROSCIENCE, V300, P297, DOI 10.1016/j.neuroscience.2015.05.035
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   Cideciyan AV, 2009, NEW ENGL J MED, V361, P725, DOI 10.1056/NEJMc0903652
   Coblentz FE, 2003, EXP EYE RES, V76, P333, DOI 10.1016/S0014-4835(02)00305-6
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111
   Dawkins E, 2014, J NEUROCHEM, V129, P756, DOI 10.1111/jnc.12675
   Dentchev T, 2003, MOL VIS, V9, P184
   Dias MF, 2018, PROG RETIN EYE RES, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Dodson M, 2013, FREE RADICAL BIO MED, V63, P207, DOI 10.1016/j.freeradbiomed.2013.05.014
   Dorn JD, 2013, JAMA OPHTHALMOL, V131, P183, DOI 10.1001/2013.jamaophthalmol.221
   Doroudchi MM, 2011, MOL THER, V19, P1220, DOI 10.1038/mt.2011.69
   El-Hattab AW, 2016, CELL CALCIUM, V60, P199, DOI 10.1016/j.ceca.2016.03.003
   ERICKSON PA, 1987, EXP EYE RES, V44, P37, DOI 10.1016/S0014-4835(87)80023-4
   ERICKSON PA, 1983, INVEST OPHTH VIS SCI, V24, P927
   Eskelinen EL, 2008, AUTOPHAGY, V4, P257, DOI 10.4161/auto.5179
   Euler T, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00444
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Farshbaf MJ, 2017, NEUROTOX RES, V32, P518, DOI 10.1007/s12640-017-9766-1
   Fertig ET, 2014, J CELL MOL MED, V18, P1938, DOI 10.1111/jcmm.12436
   Fisher S.K., 1995, WEBVISION ORG RETINA
   Fisher SK, 2003, VISION RES, V43, P887, DOI 10.1016/S0042-6989(02)00680-6
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Foik AT, 2018, J NEUROSCI, V38, P10709, DOI 10.1523/JNEUROSCI.1279-18.2018
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748
   Ganguly G, 2017, DRUG DES DEV THER, V11, P797, DOI 10.2147/DDDT.S130514
   Ganjawala TH, 2019, MOL THER, V27, P1195, DOI 10.1016/j.ymthe.2019.04.002
   Gaub BM, 2015, MOL THER, V23, P1562, DOI 10.1038/mt.2015.121
   Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Govert F, 2013, CURR OPIN NEUROL, V26, P420, DOI 10.1097/WCO.0b013e3283632d90
   Gorbatyuk MS, 2010, P NATL ACAD SCI USA, V107, P5961, DOI 10.1073/pnas.0911991107
   Greenberg KP, 2011, NEURON, V69, P713, DOI 10.1016/j.neuron.2011.01.024
   GRIGNOLO A, 1969, OPHTHALMOLOGICA, V157, P43, DOI 10.1159/000305619
   Grunder T, 2001, VISUAL NEUROSCI, V18, P781, DOI 10.1017/S0952523801185111
   Guo LL, 2015, NAT NEUROSCI, V18, P1299, DOI 10.1038/nn.4082
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hall DH, 1997, J NEUROSCI, V17, P1033
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Han JJ, 2013, MOL VIS, V19, P2579
   Han X, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000299
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067
   Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Jacobson SG, 2015, EXPERT OPIN ORPHAN D, V3, P563, DOI 10.1517/21678707.2015.1030393
   Jammalamadaka A, 2015, BIOINFORMATICS, V31, P2024, DOI 10.1093/bioinformatics/btv097
   Jeong S, 2017, MOL CELLS, V40, P613, DOI [10.14348/molcells.2017.0096b, 10.14348/molcells.2017.0096]
   Jeremy H R, 1922, Proc R Soc Med, V15, P34
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Jones BW, 2011, J COMP NEUROL, V519, P2713, DOI 10.1002/cne.22703
   Jones BW, 2006, ADV EXP MED BIOL, V572, P405
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Kalloniatis M, 2016, EXP EYE RES, V150, P106, DOI 10.1016/j.exer.2015.10.019
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khabou H, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96029
   Khristov V, 2018, ADV EXP MED BIOL, V1074, P633, DOI 10.1007/978-3-319-75402-4_77
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kitiratschky VBD, 2015, GRAEF ARCH CLIN EXP, V253, P381, DOI 10.1007/s00417-014-2797-x
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   KOLB H, 1974, INVEST OPHTH VISUAL, V13, P487
   Kondo M, 2009, INVEST OPHTH VIS SCI, V50, P1371, DOI 10.1167/iovs.08-2863
   Kuehlewein L, 2019, ACTA OPHTHALMOL, V97, pE871, DOI 10.1111/aos.14077
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lamba DA, 2009, PROG BRAIN RES, V175, P23, DOI 10.1016/S0079-6123(09)17502-7
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Laprell L, 2016, ACS CHEM NEUROSCI, V7, P15, DOI 10.1021/acschemneuro.5b00234
   LaVail MM, 2018, EXP EYE RES, V167, P56, DOI 10.1016/j.exer.2017.10.023
   Le Meur G, 2007, GENE THER, V14, P292, DOI 10.1038/sj.gt.3302861
   Lee SJ, 2010, NAT REV NEUROL, V6, P702, DOI 10.1038/nrneurol.2010.145
   Lewis G.P., 2005, PLASTICITY VISUAL SY, P55
   Lewis GP, 2007, BRIT J OPHTHALMOL, V91, P1234, DOI 10.1136/bjo.2006.104612
   Lewis GP, 2010, MOL VIS, V16, P1361
   LEWIS GP, 1994, AM J OPHTHALMOL, V118, P368, DOI 10.1016/S0002-9394(14)72962-9
   Lewis GP, 2005, MOL VIS, V11, P491
   Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424
   LEWIS GP, 1989, EXP EYE RES, V49, P93, DOI 10.1016/0014-4835(89)90079-1
   Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008
   LI ZY, 1995, J NEUROSCI, V15, P5429
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   Lin YH, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-7
   Lin YH, 2012, FASEB J, V26, P81, DOI 10.1096/fj.11-192914
   Linberg KA, 2006, MOL VIS, V12, P1674
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Liu XL, 2018, INT J MOL MED, V41, P615, DOI 10.3892/ijmm.2017.3255
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lu Y, 2017, ACTA OPHTHALMOL, V95, pE443, DOI 10.1111/aos.13054
   Luna G, 2016, EXP EYE RES, V150, P4, DOI 10.1016/j.exer.2016.03.027
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Marc RE, 1998, INVEST OPHTH VIS SCI, V39, P1694
   Marc RE, 1998, INVEST OPHTH VIS SCI, V39, P1685
   Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139
   MARC RE, 1995, J NEUROSCI, V15, P5106
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc R, 2014, ACS CHEM NEUROSCI, V5, P895, DOI 10.1021/cn5001233
   Marc RE, 2008, MOL VIS, V14, P782
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Marc RE, 2013, PROG RETIN EYE RES, V37, P141, DOI 10.1016/j.preteyeres.2013.08.002
   Marc Robert E., 1999, P3
   Margolis DJ, 2008, J NEUROSCI, V28, P6526, DOI 10.1523/JNEUROSCI.1533-08.2008
   Martinez-Navarrete GC, 2007, MOL VIS, V13, P949
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Mathur P, 2015, BBA-MOL BASIS DIS, V1852, P406, DOI 10.1016/j.bbadis.2014.11.020
   McKinnon C, 2014, ANTIOXID REDOX SIGN, V21, P2302, DOI 10.1089/ars.2013.5802
   Melentijevic I, 2017, NATURE, V542, P367, DOI 10.1038/nature21362
   Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022
   Menzler J, 2011, J NEUROSCI, V31, P2280, DOI 10.1523/JNEUROSCI.4238-10.2011
   MIZUNO K, 1967, AM J OPHTHALMOL, V63, P791, DOI 10.1016/0002-9394(67)91306-2
   Moreno ML, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01008
   Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009
   NAASH MI, 1993, P NATL ACAD SCI USA, V90, P5499, DOI 10.1073/pnas.90.12.5499
   Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Ogata K, 2002, NEUROSCIENCE, V113, P221, DOI 10.1016/S0306-4522(02)00041-6
   Opoku-Nsiah KA, 2018, TRANSL RES, V198, P48, DOI 10.1016/j.trsl.2018.05.002
   Organisciak D T, 1989, Prog Clin Biol Res, V314, P493
   ORGANISCIAK DT, 1989, INVEST OPHTH VIS SCI, V30, P795
   PALAY SL, 1955, J BIOPHYS BIOCHEM CY, V1, P69, DOI 10.1083/jcb.1.1.69
   Park SJ, 2014, MICROSCOPY-JPN, V63, P3, DOI 10.1093/jmicro/dft039
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pearson RA, 2014, VISUAL NEUROSCI, V31, P333, DOI 10.1017/S0952523814000200
   Peng YW, 2000, NAT NEUROSCI, V3, P1121, DOI 10.1038/80639
   Petoe MA, 2017, INVEST OPHTH VIS SCI, V58, P3231, DOI 10.1167/iovs.16-21041
   Petrs-Silva H, 2014, CLIN OPHTHALMOL, V8, P127, DOI 10.2147/OPTH.S38041
   Pfeiffer R.L., RETINAL DEGENERATIVE
   Pfeiffer R, 2018, INVEST OPHTH VIS SCI, V59
   Pfeiffer RL, 2016, EXP EYE RES, V150, P62, DOI 10.1016/j.exer.2016.04.022
   Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Radner W, 2002, INVEST OPHTH VIS SCI, V43, P3053
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Reichenbach A, 2010, MULLER CELLS IN THE HEALTHY AND DISEASED RETINA, P35, DOI 10.1007/978-1-4419-1672-3_2
   Roesch Karin, 2012, Mol Vis, V18, P1197
   Ross CA, 2011, LANCET NEUROL, V10, P83, DOI 10.1016/S1474-4422(10)70245-3
   Ross JW, 2012, INVEST OPHTH VIS SCI, V53, P501, DOI 10.1167/iovs.11-8784
   Sahel JA, 2013, ANNU REV NEUROSCI, V36, P467, DOI 10.1146/annurev-neuro-062012-170304
   Saliba RS, 2002, J CELL SCI, V115, P2907
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Santos-Ferreira T, 2016, INVEST OPHTH VIS SCI, V57, P3509, DOI 10.1167/iovs.16-19087
   Santos-Ferreira TF, 2017, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00105
   Sarkar S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060904
   SCHOBERT B, 1982, J BIOL CHEM, V257, P306
   Schreiber A, 2014, BBA-MOL CELL RES, V1843, P163, DOI 10.1016/j.bbamcr.2013.03.019
   Seiler MJ, 2012, EUR J NEUROSCI, V35, P1692, DOI 10.1111/j.1460-9568.2012.08078.x
   Seiler MJ, 2017, INVEST OPHTH VIS SCI, V58, P614, DOI 10.1167/iovs.15-19028
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Sengupta A, 2016, EMBO MOL MED, V8, P1248, DOI 10.15252/emmm.201505699
   Sethi CS, 2005, INVEST OPHTH VIS SCI, V46, P329, DOI 10.1167/iovs.03-0518
   Shivdasani MN, 2017, INVEST OPHTH VIS SCI, V58, P3962, DOI 10.1167/iovs.16-21311
   Shivdasani MN, 2014, INVEST OPHTH VIS SCI, V55, P6467, DOI 10.1167/iovs.14-14396
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Slater KD, 2015, IEEE J TRANSL ENG HE, V3, DOI 10.1109/JTEHM.2015.2455507
   Sominsky L, 2018, INT J BIOCHEM CELL B, V94, P56, DOI 10.1016/j.biocel.2017.11.012
   Stasheff SF, 2008, J NEUROPHYSIOL, V99, P1408, DOI 10.1152/jn.00144.2007
   Stawski P, 2012, ANGEW CHEM INT EDIT, V51, P5748, DOI 10.1002/anie.201109265
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Strettoi E, 2003, VISION RES, V43, P867, DOI 10.1016/S0042-6989(02)00594-1
   Suliman HB, 2016, PHARMACOL REV, V68, P20, DOI 10.1124/pr.115.011502
   Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735
   Suspitsin EN, 2016, MOL SYNDROMOL, V7, P62, DOI 10.1159/000445491
   Tam BM, 2006, INVEST OPHTH VIS SCI, V47, P3234, DOI 10.1167/iovs.06-0213
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tochitsky I, 2014, NEURON, V81, P800, DOI 10.1016/j.neuron.2014.01.003
   Tomita H, 2010, EXP EYE RES, V90, P429, DOI 10.1016/j.exer.2009.12.006
   Tomita H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007679
   Tu HY, 2019, EBIOMEDICINE, V39, P562, DOI 10.1016/j.ebiom.2018.11.028
   Vazquez MC, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/205713
   Veys L, 2019, ACTA NEUROPATHOL, V137, P379, DOI 10.1007/s00401-018-01956-z
   Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393
   Wang JQ, 2011, ANAT REC, V294, P1401, DOI 10.1002/ar.21438
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wang XL, 2014, BBA-MOL BASIS DIS, V1842, P1240, DOI 10.1016/j.bbadis.2013.10.015
   Willems PHGM, 2008, CELL CALCIUM, V44, P123, DOI 10.1016/j.ceca.2008.01.002
   Wolff E., 1935, PATHOLOGY EYE
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yang JW, 2006, AMINO ACIDS, V30, P477, DOI 10.1007/s00726-005-0281-y
   Yao JY, 2016, AUTOPHAGY, V12, P2439, DOI 10.1080/15548627.2016.1238553
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yue L, 2016, PROG RETIN EYE RES, V53, P21, DOI 10.1016/j.preteyeres.2016.05.002
   Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744
   Zhang XJ, 2014, AUTOPHAGY, V10, P588, DOI 10.4161/auto.27710
   Zhang Y, 2009, J NEUROSCI, V29, P9186, DOI 10.1523/JNEUROSCI.0184-09.2009
   Zheng QY, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00303
   Zhou Z, 2015, CELL DEATH DIFFER, V22, P488, DOI 10.1038/cdd.2014.229
   Zrenner E, 2002, OPHTHALMOLOGICA, V216, P8, DOI 10.1159/000064650
NR 245
TC 52
Z9 53
U1 4
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2020
VL 74
AR 100771
DI 10.1016/j.preteyeres.2019.07.004
PG 23
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KK1AP
UT WOS:000512482800001
PM 31356876
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chu, RL
   Pannullo, NA
   Sigler, EJ
AF Chu, Rachel L.
   Pannullo, Nicole A.
   Sigler, Eric J.
TI Focal Choroidal Elevations: Localized Pigment Epithelial Contour
   Alterations due to Isolated Choroidal Vessels
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRACHOROIDAL CAVITATION; MACULAR DEGENERATION; CHORIORETINAL FOLDS;
   THICKNESS
AB Purpose. The objective of this case series was to describe the clinical and imaging features of focal choroidal elevations (FCE), which are chorioretinal contour changes induced by individual choroidal vessels within an overall thin-appearing choroid. Methods. A total of 787 enhanced depth imaging (EDI) spectral domain optical coherence tomography (SD-OCT) patient images were initially screened for the presence of FCE. Prospective imaging analysis of 38 patients with FCE was done. Mean central macular choroidal thickness (CMCT), FCE location, FCE vessel lumen diameter, patient demographics, cycloplegic autorefraction, ophthalmoscopic findings, and presence of choroidal neovascularization (CNV) in the fellow eye were recorded. Results. FCE were observed in 25 patients with age-related macular degeneration (ARMD), in 5 patients with high myopia, and in 8 patients with age-related choroidal atrophy (ARCA). Mean patient age was 80 +/- 9.4 years. Mean CMCT was 86 +/- 40 mu m. Mean lumen diameter of the vessels inducing FCE was 131 +/- 33 mu m. Conclusions. FCE are relatively frequently encountered morphologic features of elderly patients with ARMD, high myopia, and ARCA, and have a distinct clinical and imaging morphology which differs from classically described chorioretinal folds. The lesions may commonly be mistaken for pigment epithelial detachments on ophthalmoscopy, may be associated with CNV in fellow eyes, and have a characteristic SD-OCT appearance.
C1 [Chu, Rachel L.] SUNY Stony Brook, Sch Med, Hlth Sci Ctr, 101 Nicolls Rd,Level 4, Stony Brook, NY 11794 USA.
   [Pannullo, Nicole A.] Rochester Inst Technol, Sch Chem & Mat Sci, 1 Lomb Mem Dr, Rochester, NY 14623 USA.
   [Sigler, Eric J.] Ophthalm Consultants Long Isl, Div Retina & Vitreous, 2000 North Village Ave,Suite 402, Rockville Ctr, NY 11570 USA.
C3 State University of New York (SUNY) System; SUNY Community College;
   State University of New York (SUNY) Stony Brook; Rochester Institute of
   Technology
RP Sigler, EJ (通讯作者)，Ophthalm Consultants Long Isl, Div Retina & Vitreous, 2000 North Village Ave,Suite 402, Rockville Ctr, NY 11570 USA.
EM ejsigler@gmail.com
OI Pannullo, Nicole/0000-0002-1061-7157
CR ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Byeon SH, 2011, AM J OPHTHALMOL, V151, P1101, DOI 10.1016/j.ajo.2011.01.054
   CASTROCORREIA J, 1967, OPHTHALMOLOGICA, V154, P497, DOI 10.1159/000305212
   COHEN SM, 1994, INT OPHTHALMOL, V18, P243
   DACRUZ L, 1994, BRIT J OPHTHALMOL, V78, P800, DOI 10.1136/bjo.78.10.800
   GASS JDM, 1981, ARCH OPHTHALMOL-CHIC, V99, P1016, DOI 10.1001/archopht.1981.03930011016006
   Giuffre G, 2007, ACTA OPHTHALMOL SCAN, V85, P333, DOI 10.1111/j.1600-0420.2006.00799.x
   HAYREH SS, 1974, A GRAEF ARCH KLIN EX, V192, P165
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   KORTE GE, 1989, INT REV CYTOL, V114, P221
   LEAHEY AB, 1993, ARCH OPHTHALMOL-CHIC, V111, P357, DOI 10.1001/archopht.1993.01090030075042
   Lee WJ, 2011, RETINA-J RET VIT DIS, V31, P1742, DOI 10.1097/IAE.0b013e3182246e46
   Levy J, 2005, EUR J OPHTHALMOL, V15, P424, DOI 10.1177/112067210501500320
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   NEWELL FW, 1973, AM J OPHTHALMOL, V75, P930, DOI 10.1016/0002-9394(73)91080-5
   Ohno-Matsui K, 2013, EYE, V27, P630, DOI 10.1038/eye.2013.16
   Ohno-Matsui K, 2012, AM J OPHTHALMOL, V154, P382, DOI 10.1016/j.ajo.2012.02.010
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sigler EJ, 2014, EYE, V28, P838, DOI 10.1038/eye.2014.100
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
NR 26
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD OCT 7
PY 2019
VL 2019
AR 4962363
DI 10.1155/2019/4962363
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JH8KW
UT WOS:000493018100002
PM 31687198
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sohn, EH
   Flamme-Wiese, MJ
   Whitmore, SS
   Workalemahu, G
   Marneros, AG
   Boese, EA
   Kwon, YH
   Wang, K
   Abramoff, MD
   Tucker, BA
   Stone, EM
   Mullins, RF
AF Sohn, Elliott H.
   Flamme-Wiese, Miles J.
   Whitmore, S. Scott
   Workalemahu, Grefachew
   Marneros, Alexander G.
   Boese, Erin A.
   Kwon, Young H.
   Wang, Kai
   Abramoff, Michael D.
   Tucker, Budd A.
   Stone, Edwin M.
   Mullins, Robert F.
TI Choriocapillaris Degeneration in Geographic Atrophy
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MEMBRANE ATTACK COMPLEX; CHOROIDAL
   BLOOD-FLOW; MACULAR-DEGENERATION; THICKNESS; ANGIOGRAPHY; EYES;
   BEVACIZUMAB; THERAPY; RETINA
AB Early age-related macular degeneration (AMD) is characterized by degeneration of the choriocapillaris, the vascular supply of retinal photoreceptor cells. We assessed vascular loss during disease progression in the choriocapillaris and larger vessels in the deeper choroid. Human donor maculae from controls (n = 99), early AMD (n = 35), or clinically diagnosed with geographic atrophy (GA; n = 9, collected from outside the zone of retinal pigment epithelium degeneration) were evaluated using Ulex europaeus agglutinin-I labeling to discriminate between vessels with intact endothelial cells and ghost vessels. Morphometric analyses of choriocapillaris density (cross-sectional area of capillary lumens divided by length) and of vascular lumen/stroma ratio in the outer choroid were performed. Choriocapillaris Loss was observed in early AMD (Bonferroni-corrected P = 0.024) with greater loss in GA (Bonferronicorrected P < 10(-9)), even in areas of intact retinal pigment epithelium. In contrast, changes in lumen/stroma ratio in the outer choroid were not found to differ between controls and AMD or GA eyes (P > 0.05), suggesting choriocapillaris changes are more prevalent in AMD than those in the outer choroid. In addition, vascular endothelial growth factor-A levels were negatively correlated with choriocapillaris vascular density. These findings support the concept that choroidal vascular degeneration, predominantly in the microvasculature, contributes to dry AMD progression. Addressing capillary loss in AMD remains an important translational target.
C1 [Sohn, Elliott H.; Flamme-Wiese, Miles J.; Whitmore, S. Scott; Workalemahu, Grefachew; Boese, Erin A.; Kwon, Young H.; Wang, Kai; Abramoff, Michael D.; Tucker, Budd A.; Stone, Edwin M.; Mullins, Robert F.] Univ Iowa, Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.
   [Sohn, Elliott H.; Flamme-Wiese, Miles J.; Whitmore, S. Scott; Workalemahu, Grefachew; Boese, Erin A.; Kwon, Young H.; Abramoff, Michael D.; Tucker, Budd A.; Stone, Edwin M.; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Wang, Kai] Univ Iowa, Dept Biostat, Iowa City, IA USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
   [Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.
   [Marneros, Alexander G.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa; University of Iowa; Harvard University; Massachusetts General
   Hospital; Harvard University; Harvard Medical School
RP Mullins, RF (通讯作者)，Univ Iowa, Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013; Abramoff, Michael/A-5836-2009
OI Stone, Edwin M./0000-0003-3343-4414; Abramoff,
   Michael/0000-0002-3490-0037; Kwon, Young/0000-0002-1116-8250; Boese,
   Erin/0000-0003-1124-3991; Sohn, Elliott/0000-0002-3778-9362; Mullins,
   Robert/0000-0002-5006-0891; Tucker, Budd/0000-0003-2178-1742; Whitmore,
   S. Scott/0000-0003-0161-9625
FU NIH [EY024605, EY026547, P30 EY025580]; Elmer and Sylvia Sramek
   Charitable Foundation; Martin and Ruth Carver Chair in Ocular Cell
   Biology; NATIONAL EYE INSTITUTE [R01EY026547, P30EY025580] Funding
   Source: NIH RePORTER
FX Supported, in part, by NIH grants EY024605 (R.F.M. and B.A.T.), EY026547
   (E.H.S.), and P30 EY025580; the Elmer and Sylvia Sramek Charitable
   Foundation; and the Martin and Ruth Carver Chair in Ocular Cell Biology
   (R.F.M.).
CR Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Abramoff MD, 2018, INVEST OPHTH VIS SCI, V59, P519, DOI 10.1167/iovs.17-21873
   Abramoff MD, 2013, INVEST OPHTH VIS SCI, V54, P3721, DOI 10.1167/iovs.13-11812
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Almeida DRP, 2015, JAMA OPHTHALMOL, V133, P297, DOI 10.1001/jamaophthalmol.2014.5168
   Arora KS, 2012, INVEST OPHTH VIS SCI, V53, P6393, DOI 10.1167/iovs.12-10224
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Harris A., 2003, ATLAS OCULAR BLOOD F
   Heiferman MJ, 2017, INVEST OPHTH VIS SCI, V58
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hornbeak DM, 2009, CURR OPIN OPHTHALMOL, V20, P356, DOI 10.1097/ICU.0b013e32832f8040
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kim DY, 2013, ACTA OPHTHALMOL, V91, P183, DOI 10.1111/j.1755-3768.2011.02305.x
   Lee SY, 2017, JAMA OPHTHALMOL, V135, P1177, DOI 10.1001/jamaophthalmol.2017.3790
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Lutty GA, 2005, VISION RES, V45, P3504, DOI 10.1016/j.visres.2005.08.022
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shin Joong Won, 2012, Korean J Ophthalmol, V26, P255, DOI 10.3341/kjo.2012.26.4.255
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Songstad AE, 2015, INVEST OPHTH VIS SCI, V56, P8258, DOI 10.1167/iovs.15-17073
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Vance SK, 2011, RETINA-J RET VIT DIS, V31, P332, DOI 10.1097/IAE.0b013e3181eef0ae
   Vural AD, 2014, RETINA-J RET VIT DIS, V34, P1223, DOI 10.1097/IAE.0000000000000043
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 55
TC 32
Z9 32
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUL
PY 2019
VL 189
IS 7
BP 1473
EP 1480
DI 10.1016/j.ajpath.2019.04.005
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA IG5IO
UT WOS:000473836900015
PM 31051169
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Ding, SLS
   Koh, AEH
   Kumar, S
   Khan, MSA
   Alzahrani, B
   Mok, PL
AF Ding, Suet Lee Shirley
   Koh, Avin Ee-Hwan
   Kumar, Suresh
   Khan, Mohammed Safwan Ali
   Alzahrani, Badr
   Mok, Pooi Ling
TI Genetically-modified human mesenchymal stem cells to express
   erythropoietin enhances differentiation into retinal photoreceptors: An
   in-vitro study
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Erythropoietin; Mesenchymal stem cell; Taurine; Rod photoreceptors;
   Retinal differentiation
ID UMBILICAL-CORD BLOOD; TAURINE; ROD
AB Dysfunctional or death of retinal photoreceptors is an irreversible phenomenon that is closely associated with a broad range of retinal degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration (AMD), resulting in successive loss of visual function and blindness. In search for viable treatment for retinal degenerative diseases, mesenchymal stem cells (MSCs) has demonstrated promising therapeutic capabilities to repair and replace damaged photoreceptor cells in both in vitro and in vivo conditions. Nevertheless, the dearth of MSC differentiation capacity into photoreceptors has limited its use in cell replacement therapy. Erythropoietin (END) has vital role in early neural retinal cell differentiation and demonstrated rescue potential on dying photoreceptor cells. Hence, we aimed to evaluate the differentiation capacity of MSCs into photoreceptor cells in the presence of human EPO protein. We derived the MSC from human Wharton's jelly of umbilical cord and transduced the cells with lentivirus particles encoding EPO and green fluorescent protein (GFP) as reporter gene. The transduced cells were selectively cultured and induced to differentiate into photoreceptors by exposing to photoreceptor differentiation cocktail. Our preliminary results showed that transduced cells exposed to induction medium had an enhanced differentiation capacity when compared to non-transduced cells. Our results demonstrated a novel strategy to increase the yield of in vitro photoreceptor differentiation and may be potentially useful in improving the efficiency of stem cell transplantation for ocular disorders.
C1 [Ding, Suet Lee Shirley; Koh, Avin Ee-Hwan; Khan, Mohammed Safwan Ali; Mok, Pooi Ling] Univ Putra Malaysia, Dept Biomed Sci, Fac Med & Hlth Sci, Serdang 43400, Selangor, Malaysia.
   [Kumar, Suresh] Univ Putra Malaysia, Dept Med Microbiol & Parasitol, Fac Med & Hlth Sci, Serdang 43400, Selangor, Malaysia.
   [Kumar, Suresh; Mok, Pooi Ling] Univ Putra Malaysia, Genet & Regenerat Med Res Ctr, Serdang 43400, Selangor, Malaysia.
   [Kumar, Suresh] Univ Putra Malaysia, Inst Biosci, Serdang 43400, Selangor, Malaysia.
   [Khan, Mohammed Safwan Ali] Texas A&M Univ, Dept Pharmaceut Sci, Irma Lerma Rangel Coll Pharm, Texas A&M Hlth Sci Ctr, College Stn, TX 77843 USA.
   [Alzahrani, Badr; Mok, Pooi Ling] Jouf Univ, Dept Clin Lab Sci, Coll Appl Med Sci, POB 2014, Sakaka, Aljouf Province, Saudi Arabia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra
   Malaysia; Universiti Putra Malaysia; Texas A&M University System; Texas
   A&M University College Station; Texas A&M Health Science Center; Al Jouf
   University
RP Kumar, S (通讯作者)，Univ Putra Malaysia, Dept Med Microbiol & Parasitol, Fac Med & Hlth Sci, Serdang 43400, Selangor, Malaysia.; Mok, PL (通讯作者)，Jouf Univ, Dept Clin Lab Sci, Coll Appl Med Sci, POB 2014, Sakaka, Aljouf Province, Saudi Arabia.
EM suetlee.ding@gmail.com; avin.keh@gmail.com; suresh@upm.edu.my;
   baalzahrani@ju.edu.sa; rachelmok2005@gmail.com
RI Khan, Mohammed Safwan Ali/U-9132-2017; Kumar, suresh S/J-2423-2017; Mok,
   Pooi Ling/AAJ-7480-2021; Ali Khan, Mohammed Safwan/HDN-7110-2022; Ali
   Khan, Mohammed safwan/HCH-3996-2022; Koh, Avin/ABD-6921-2020
OI Khan, Mohammed Safwan Ali/0000-0002-6186-5740; Kumar, suresh
   S/0000-0002-0505-7554; Ali Khan, Mohammed Safwan/0000-0002-6186-5740;
   Koh, Avin/0000-0002-6519-0939
FU Ministry of Energy, Science, Technology, Environment and Climate Change,
   Malaysia through the Sciencefund [5450817]; Deanship of Scientific
   Research of Jouf University [39/181]
FX This research was funded by the Ministry of Energy, Science, Technology,
   Environment and Climate Change, Malaysia through the Sciencefund, under
   Grant No. 5450817. This work was also supported by the Deanship of
   Scientific Research of Jouf University, Grant No. 39/181. The authors
   also acknowledged Cryocord Sdn. Bhd. for providing the human Wharton's
   Jelly-derived Mesenchymal Stem Cells for the current study.
CR Baldari S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102087
   Choi SW, 2017, J VET SCI, V18, P59, DOI 10.4142/jvs.2017.18.1.59
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Ding SLS, 2016, EYE, V30, P1293, DOI 10.1038/eye.2016.94
   Ding SLS, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00190
   Ding SLS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081406
   Froger N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042017
   Garcia-Ramirez M, 2008, DIABETES CARE, V31, P1189, DOI 10.2337/dc07-2075
   Jiang Z, 2013, ADV EXP MED BIOL, V775, P53, DOI 10.1007/978-1-4614-6130-2_5
   Jin HJ, 2009, BIOCHEM BIOPH RES CO, V381, P676, DOI 10.1016/j.bbrc.2009.02.118
   Jin W, 2009, IN VITRO CELL DEV-AN, V45, P321, DOI 10.1007/s11626-009-9184-7
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kim Hee Jung, 2017, Dev Reprod, V21, P1, DOI 10.12717/DR.2017.21.1.001
   Leow SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128973
   Li LP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9682757
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mok PL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020345
   Nadri S, 2013, NEUROSCI LETT, V541, P43, DOI 10.1016/j.neulet.2012.12.055
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   PASANTESMORALES H, 1983, J NEUROSCI RES, V9, P135, DOI 10.1002/jnr.490090205
   Renteria RC, 2004, NEURON, V41, P839, DOI 10.1016/S0896-6273(04)00153-9
   Ripps H, 2012, MOL VIS, V18, P2673
   Sabapathy V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093726
   Sabapathy V, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/174328
   Shah Shaival S, 2009, BMC Res Notes, V2, P234, DOI 10.1186/1756-0500-2-234
   Shintani K, 2009, OPTOMETRY, V80, P384, DOI 10.1016/j.optm.2008.01.026
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Tomita H, 2013, GENE THER, V127, P1, DOI DOI 10.5772/52987
   Young TL, 2004, NEURON, V41, P867, DOI 10.1016/S0896-6273(04)00141-2
NR 29
TC 8
Z9 8
U1 1
U2 5
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD JUN
PY 2019
VL 195
BP 33
EP 38
DI 10.1016/j.jphotobiol.2019.04.008
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA IC4RR
UT WOS:000470953500005
PM 31060031
DA 2022-11-30
ER

PT J
AU Arai, K
   Yasukawa, T
   Kato, A
   Kubota, A
   Usui, H
   Takase, N
   Kuwayama, S
   Ogura, Y
AF Arai, Kon-ichi
   Yasukawa, Tsutomu
   Kato, Aki
   Kubota, Ayae
   Usui, Hideaki
   Takase, Noriaki
   Kuwayama, Soichiro
   Ogura, Yuichiro
TI Tissue Plasminogen Activator as an Antiangiogenic Agent in Experimental
   Corneal Neovascularization in Rabbits
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Angiogenesis; Corneal neovascularization; Human umbilical vein
   endothelial cells; Rabbit; Tissue plasminogen activator
ID DEGENERATION TREATMENTS TRIALS; VISUAL-ACUITY LOSS; MACULAR
   DEGENERATION; CHOROIDAL NEOVASCULARIZATION; PNEUMATIC DISPLACEMENT;
   RETINAL TOXICITY; SUBMACULAR HEMORRHAGE; GROWTH-FACTOR; RANIBIZUMAB;
   MICE
AB Aims: Anti-vascular endothelial growth factor agents effectively treat age-related macular degeneration and myopic choroidal neovascularization (CNV). Tissue plasminogen activator (tPA), a fibrinolytic compound, is used as an adjuvant to displace submacular hemorrhage and to treat type 2 CNV. The purpose of this study was to investigate in in vitro and in vivo experiments the antiangiogenic impact of tPA itself. Methods: The impact of tPA on the proliferation of human umbilical vein endothelial cells (HUVECs) was assessed by an XTT assay [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-H-2-tetrazolium- 5-carboxanilide]. A basic fibroblast growth factor-impregnated gelatin hydrogel sheet was implanted into the rabbit cornea to induce corneal neovascularization. Immediately postoperatively, tPA or buffered saline solution (control) was injected intravitreally. Results: The growth and viability of the HUVECs were unaffected by tPA at clinical concentrations. In the control group, the mean lengths of the new vessels were 1.0 +/- 0.41, 1.6 +/- 0.75, and 3.6 +/- 2.1 mm at weeks 1, 2, and 4, respectively. In contrast, tPA significantly (p < 0.01) reduced the corneal neovascularization. Conclusion: Although tPA has no direct impact on the vascular endothelial cells in vitro, the fibrinolytic effects of tPA might markedly suppress neovascularization in vivo. (C) 2018 S. Karger AG, Basel
C1 [Arai, Kon-ichi; Yasukawa, Tsutomu; Kato, Aki; Kubota, Ayae; Usui, Hideaki; Takase, Noriaki; Kuwayama, Soichiro; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
C3 Nagoya City University
RP Yasukawa, T (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
EM yasukawa@med.nagoya-cu.ac.jp
FU Japan Society for the Promotion of Science [25462758]
FX tPA was supplied by Eisai Co. Ltd., Tokyo, Japan. The authors thank
   Lynda Charters for medical English editing. T. Yasukawa is supported by
   a Grant-in-Aid for Scientific Research (C) 25462758 from the Japan
   Society for the Promotion of Science.
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Diebold I, 2008, THROMB HAEMOSTASIS, V100, P984, DOI 10.1160/TH08-08-0524
   GIMBRONE MA, 1974, J NATL CANCER I, V52, P413, DOI 10.1093/jnci/52.2.413
   Gutierrez LS, 2000, CANCER RES, V60, P5839
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kachi I, 2016, JPN J OPHTHALMOL, V60, P179, DOI 10.1007/s10384-016-0434-4
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, pe1
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kim BJ, 2014, AM J OPHTHALMOL, V158, P128, DOI 10.1016/j.ajo.2014.04.004
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Ozone D, 2016, INVEST OPHTH VIS SCI, V57, P5348, DOI 10.1167/iovs.16-19617
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Yang CF, 2000, OPHTHALMIC RES, V32, P19, DOI 10.1159/000055582
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 29
TC 2
Z9 2
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2018
VL 59
IS 3
BP 170
EP 175
DI 10.1159/000487054
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GD0VC
UT WOS:000430218000008
PM 29533953
DA 2022-11-30
ER

PT J
AU Mandal, A
   Bisht, R
   Rupenthal, ID
   Mitra, AK
AF Mandal, Abhirup
   Bisht, Rohit
   Rupenthal, Ilva D.
   Mitra, Ashim K.
TI Polymeric micelles for ocular drug delivery: From structural frameworks
   to recent preclinical studies
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Ocular drug delivery; Polymeric micelles; Ocular barriers; Dry eye
   syndrome; Drug delivery; Bioavailability
ID LIGHT-RESPONSIVE MICELLES; POLYION COMPLEX MICELLES; ACID)
   BLOCK-COPOLYMER; CYCLOSPORINE-A; IN-VITRO; OPHTHALMIC DELIVERY;
   POLY(ETHYLENE GLYCOL); POSTERIOR SEGMENT; CARRIER SYSTEM; CELLULAR
   INTERNALIZATION
AB Effective intraocular drug delivery poses a major challenge due to the presence of various elimination mechanisms and physiological barriers that result in low ocular bioavailability after topical application. Over the past decades, polymeric micelles have emerged as one of the most promising drug delivery platforms for the management of ocular diseases affecting the anterior (dry eye syndrome) and posterior (age-related macular degeneration, diabetic retinopathy and glaucoma) segments of the eye. Promising preclinical efficacy results from both in-vitro and in-vivo animal studies have led to their steady progression through clinical trials. The mucoadhesive nature of these polymeric micelles results in enhanced contact with the ocular surface while their small size allows better tissue penetration. Most importantly, being highly water soluble, these polymeric micelles generate clear aqueous solutions which allows easy application in the form of eye drops without any vision interference. Enhanced stability, larger cargo capacity, non-toxicity, ease of surface modification and controlled drug release are additional advantages with polymeric micelles. Finally, simple and cost effective fabrication techniques render their industrial acceptance relatively high. This review summarizes structural frameworks, methods of preparation, physicochemical properties, patented inventions and recent advances of these micelles as effective carriers for ocular drug delivery highlighting their performance in preclinical studies. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Mandal, Abhirup; Mitra, Ashim K.] Univ Missouri Kansas City, Sch Pharm, Div Pharmaceut Sci, 2464 Charlotte St, Kansas City, MO 64108 USA.
   [Bisht, Rohit; Rupenthal, Ilva D.] Univ Auckland, New Zealand Natl Eye Ctr, Dept Ophthalmol, BOTU, Auckland, New Zealand.
C3 University of Missouri System; University of Missouri Kansas City;
   University of Auckland
RP Mitra, AK (通讯作者)，Univ Missouri Kansas City, Sch Pharm, Div Pharmaceut Sci, 2464 Charlotte St, Kansas City, MO 64108 USA.
EM mitraa@umkc.edu
RI Rupenthal, Ilva D/M-5340-2016; Bisht, Rohit/AAY-7445-2020; Bisht, Rohit
   Singh/I-1148-2019; Mandal, Abhirup/I-9536-2019
OI Rupenthal, Ilva D/0000-0001-5997-5994; Mandal,
   Abhirup/0000-0002-2543-4994; Bisht, Rohit/0000-0003-2596-4028
FU NIH [R01 EY09171-14, R01 EY10659-12]; NATIONAL EYE INSTITUTE
   [R01EY010659, R01EY009171] Funding Source: NIH RePORTER
FX This article has been supported by NIH grants R01 EY09171-14 and NIH R01
   EY10659-12.
CR Adams ML, 2003, J PHARM SCI-US, V92, P1343, DOI 10.1002/jps.10397
   Ahuja M, 2008, AAPS J, V10, P229, DOI 10.1208/s12248-008-9024-9
   Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Aliabadi HM, 2005, BIOMATERIALS, V26, P7251, DOI 10.1016/j.biomaterials.2005.05.042
   Allen C, 1999, BBA-BIOMEMBRANES, V1421, P32, DOI 10.1016/S0005-2736(99)00108-X
   Alvarez-Rivera F, 2016, J PHARM SCI-US, V105, P2855, DOI 10.1016/j.xphs.2016.03.006
   ARNARSON T, 1980, J PHARM PHARMACOL, V32, P381, DOI 10.1111/j.2042-7158.1980.tb12947.x
   Barar Jaleh, 2009, J Ophthalmic Vis Res, V4, P238
   Barz M, 2011, POLYM CHEM-UK, V2, P1900, DOI 10.1039/c0py00406e
   Bisht R, 2016, EXPERT OPIN DRUG DEL, V13, P953, DOI 10.1517/17425247.2016.1163334
   Boddu Sai H S, 2014, Recent Pat Drug Deliv Formul, V8, P27
   Cabral H, 2014, J CONTROL RELEASE, V190, P465, DOI 10.1016/j.jconrel.2014.06.042
   Cabrera M, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/164692
   Chang JH, 2012, SURV OPHTHALMOL, V57, P415, DOI 10.1016/j.survophthal.2012.01.007
   Chen CJ, 2012, POLYMER, V53, P3695, DOI 10.1016/j.polymer.2012.06.024
   Chetoni P, 2000, J OCUL PHARMACOL TH, V16, P363, DOI 10.1089/jop.2000.16.363
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Cholkar K, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.1
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   Cholkar K, 2014, AAPS PHARMSCITECH, V15, P1454, DOI 10.1208/s12249-014-0159-y
   Cholkar Kishore, 2012, Recent Pat Nanomed, V2, P82
   Chopra P, 2013, J PHARM SCI-US, V102, P480, DOI 10.1002/jps.23370
   Civiale C, 2009, INT J PHARMACEUT, V378, P177, DOI 10.1016/j.ijpharm.2009.05.028
   CUNHAVAZ J, 1979, SURV OPHTHALMOL, V23, P279, DOI 10.1016/0039-6257(79)90158-9
   Dalwadi G, 2005, PHARM RES-DORDR, V22, P2152, DOI 10.1007/s11095-005-7781-z
   De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596
   Deng C, 2012, NANO TODAY, V7, P467, DOI 10.1016/j.nantod.2012.08.005
   Di Tommaso C, 2012, EUR J PHARM BIOPHARM, V81, P257, DOI 10.1016/j.ejpb.2012.02.014
   Di Tommaso C, 2012, INVEST OPHTH VIS SCI, V53, P2292, DOI 10.1167/iovs.11-8829
   Di Tommaso C, 2011, INT J PHARMACEUT, V416, P515, DOI 10.1016/j.ijpharm.2011.01.004
   Djordjevic J, 2003, AAPS PHARMSCI, V5
   Duan YW, 2015, COLLOID SURFACE B, V128, P322, DOI 10.1016/j.colsurfb.2015.02.007
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Fan YF, 2016, COLLOID SURFACE B, V140, P1, DOI 10.1016/j.colsurfb.2015.11.059
   Figueroa-Ochoa EB, 2016, INT J PHARMACEUT, V510, P17, DOI 10.1016/j.ijpharm.2016.06.013
   Galin M. A., 1998, U. S. Patent, Patent No. [08/ 815,215, 08815215]
   Gaynes BI, 2008, CLIN OPHTHALMOL, V2, P355
   Gothwal A, 2016, PHARM RES-DORDR, V33, P18, DOI 10.1007/s11095-015-1784-1
   Guo CL, 2015, SCI REP-UK, V5, DOI 10.1038/srep12968
   Gupta AK, 2000, INT J PHARM, V209, P1, DOI 10.1016/S0378-5173(00)00508-1
   Hahn S. K., 2014, Patent No. [US 13/ 326,477, 13326477]
   Hamalainen KM, 1997, INVEST OPHTH VIS SCI, V38, P627
   Han S, 2010, ACTA PHARMACOL SIN, V31, P990, DOI 10.1038/aps.2010.98
   Harada A., 2005, Patent No. [EP20040724177, 20040724177]
   Herrmann A., 2015, HERRMANN A, Patent No. PCT/ NL2014/ 050634
   Hu XH, 2016, J NANOSCI NANOTECHNO, V16, P5480, DOI 10.1166/jnn.2016.11733
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Jaissle GB, 2004, OPHTHALMOLOGE, V101, P121, DOI 10.1007/s00347-003-0975-z
   Jaiswal M, 2015, COLLOID SURFACE B, V130, P23, DOI 10.1016/j.colsurfb.2015.03.059
   Jette KK, 2004, PHARM RES-DORDR, V21, P1184, DOI 10.1023/B:PHAM.0000033005.25698.9c
   Jin S, 2010, MED RES REV, V30, P171, DOI 10.1002/med.20155
   Jones MC, 1999, EUR J PHARM BIOPHARM, V48, P101, DOI 10.1016/S0939-6411(99)00039-9
   Kadam Y, 2009, COLLOID SURFACE B, V72, P141, DOI 10.1016/j.colsurfb.2009.03.027
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kapoor Y, 2008, INT J PHARMACEUT, V361, P222, DOI 10.1016/j.ijpharm.2008.05.028
   Kataoka K, 2000, J CONTROL RELEASE, V64, P143, DOI 10.1016/S0168-3659(99)00133-9
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kataoka K., 2006, U. S. Patent, Patent No. [11/ 251,1352006, 112511352006]
   Kataoka K., 2004, Patent No. [CA 2520525, 2520525]
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473
   Kedar U, 2010, NANOMED-NANOTECHNOL, V6, P714, DOI 10.1016/j.nano.2010.05.005
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   KWON G, 1994, J CONTROL RELEASE, V29, P17, DOI 10.1016/0168-3659(94)90118-X
   Kwon GS, 1996, ADV DRUG DELIVER REV, V21, P107, DOI 10.1016/S0169-409X(96)00401-2
   KWON GS, 1995, PHARMACEUT RES, V12, P192, DOI 10.1023/A:1016266523505
   KWON GS, 1993, PHARMACEUT RES, V10, P970, DOI 10.1023/A:1018998203127
   La SB, 1996, J PHARM SCI, V85, P85, DOI 10.1021/js950204r
   Lavasanifar A, 2002, J CONTROL RELEASE, V79, P165, DOI 10.1016/S0168-3659(01)00537-5
   Lavasanifar A, 2000, J BIOMED MATER RES, V52, P831, DOI 10.1002/1097-4636(20001215)52:4<831::AID-JBM29>3.0.CO;2-K
   Le Garrec D, 2004, J CONTROL RELEASE, V99, P83, DOI 10.1016/j.jconrel.2004.06.018
   Lee J, 2016, DRUG METAB DISPOS, V44, P1675, DOI 10.1124/dmd.116.069369
   Lee JY, 2004, J CONTROL RELEASE, V94, P323, DOI 10.1016/j.jconrel.2003.10.012
   Lee V H, 1986, J Ocul Pharmacol, V2, P67, DOI 10.1089/jop.1986.2.67
   Li JG, 2015, INT J NANOMED, V10, P6027, DOI 10.2147/IJN.S90347
   Li QQ, 2016, COLLOID SURFACE B, V140, P278, DOI 10.1016/j.colsurfb.2015.12.053
   Li XY, 2012, NANOSCALE, V4, P4667, DOI 10.1039/c2nr30924f
   Li Y, 2000, PHARMACEUT RES, V17, P607, DOI 10.1023/A:1007529218802
   Liaw J, 2001, GENE THER, V8, P999, DOI 10.1038/sj.gt.3301485
   LIAW J, 1992, INT J PHARMACEUT, V88, P125, DOI 10.1016/0378-5173(92)90309-P
   Lin JP, 2009, BIOMATERIALS, V30, P108, DOI 10.1016/j.biomaterials.2008.09.010
   Liu SY, 2012, MACROMOL BIOSCI, V12, P608, DOI 10.1002/mabi.201100419
   Lu CH, 2013, J PHARM SCI-US, V102, P627, DOI 10.1002/jps.23390
   Lu J, 2012, ACS MACRO LETT, V1, P982, DOI 10.1021/mz300285x
   Lu Y, 2013, INT J PHARMACEUT, V453, P198, DOI 10.1016/j.ijpharm.2012.08.042
   Luo LB, 2002, BIOCONJUGATE CHEM, V13, P1259, DOI 10.1021/bc025524y
   Ma FY, 2015, EUR J PHARM BIOPHARM, V89, P271, DOI 10.1016/j.ejpb.2014.12.010
   Maitra A., 2003, U. S. Patent, Patent No. [09/ 954,722, 09954722]
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   Mao YX, 2011, HUM GENE THER, V22, P1525, DOI 10.1089/hum.2011.090
   Matsuya T, 2003, ANAL CHEM, V75, P6124, DOI 10.1021/ac034346e
   Meyer J, 2014, INVEST OPHTH VIS SCI, V55, P6204, DOI 10.1167/iovs.13-13617
   Mitra A. K., 2015, U. S. Patent, Patent No. [12/ 774,6002010, 127746002010]
   Mitra A. K., 2015, MITRA AK, Patent No. PCT/ US2010/ 033779
   Mitra AK, 2015, United States Patent, Patent No. [US 3/975,175, 3975175]
   Mondon K, 2011, EUR J PHARM BIOPHARM, V77, P56, DOI 10.1016/j.ejpb.2010.09.012
   Moslemy P., 2012, MOSLEMY P, Patent No. PCT/ US2010/ 050672
   Moslemy P., 2012, U. S. Patent, Patent No. [13/ 384,5182011, 133845182011]
   Nishiyama N, 2003, CANCER RES, V63, P8977
   Nishiyama N, 2003, BIOCONJUGATE CHEM, V14, P449, DOI 10.1021/bc025555t
   Nishiyama N, 1999, LANGMUIR, V15, P377, DOI 10.1021/la980572l
   Owen SC, 2012, NANO TODAY, V7, P53, DOI 10.1016/j.nantod.2012.01.002
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Pepic I, 2004, INT J PHARMACEUT, V272, P57, DOI 10.1016/j.ijpharm.2003.11.032
   Pepic I, 2010, J PHARM SCI-US, V99, P4317, DOI 10.1002/jps.22137
   Perumal O. P., 2014, Patent No. [US 13/ 404,392, 13404392]
   Prosperi-Porta G, 2016, BIOMACROMOLECULES, V17, P1449, DOI 10.1021/acs.biomac.6b00054
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Rapoport N, 1999, COLLOID SURFACE B, V16, P93, DOI 10.1016/S0927-7765(99)00063-6
   Rapoport NY, 1999, J CONTROL RELEASE, V58, P153, DOI 10.1016/S0168-3659(98)00149-7
   Reichl S, 2011, EXPERT OPIN DRUG MET, V7, P559, DOI 10.1517/17425255.2011.562195
   Ribeiro A, 2013, COLLOID SURFACE B, V103, P550, DOI 10.1016/j.colsurfb.2012.10.055
   Rios-Doria J, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/951741
   Rosler A, 2001, ADV DRUG DELIVER REV, V53, P95, DOI 10.1016/S0169-409X(01)00222-8
   Rotsos TG, 2008, CLIN OPHTHALMOL, V2, P919
   Ruponen M, 2015, EUR J PHARM BIOPHARM, V96, P442, DOI 10.1016/j.ejpb.2015.02.032
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Salama AH, 2015, INT J PHARMACEUT, V492, P28, DOI 10.1016/j.ijpharm.2015.07.010
   SARL O. T., 2016, PHASE 3 STUDY OTX 10
   Savic R, 2003, SCIENCE, V300, P615, DOI 10.1126/science.1078192
   Schultz C, 2011, CLIN EXP OPTOM, V94, P212, DOI 10.1111/j.1444-0938.2010.00553.x
   Sengupta S, 2013, ACS NANO, V7, P2878, DOI 10.1021/nn4015399
   Shanks Niall, 2009, Philos Ethics Humanit Med, V4, P2, DOI 10.1186/1747-5341-4-2
   Shi S, 2015, SCI REP-UK, V5, DOI 10.1038/srep11337
   Shuai XT, 2004, BIOCONJUGATE CHEM, V15, P441, DOI 10.1021/bc034113u
   Shuai XT, 2004, J CONTROL RELEASE, V98, P415, DOI 10.1016/j.jconrel.2004.06.003
   Son S, 2014, BIOMACROMOLECULES, V15, P628, DOI 10.1021/bm401670t
   Stepanek M, 2001, LANGMUIR, V17, P4240, DOI 10.1021/la010246x
   Tadros TF, 2005, APPLIED SURFACTANTS: PRINCIPLES AND APPLICATIONS, P309
   Taha EI, 2014, J MOL LIQ, V199, P251, DOI 10.1016/j.molliq.2014.09.021
   Talelli M, 2015, NANO TODAY, V10, P93, DOI 10.1016/j.nantod.2015.01.005
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tiffany JM, 2003, EYE, V17, P923, DOI 10.1038/sj.eye.6700566
   Tiwari G, 2010, J PHARM BIOALLIED SC, V2, P72, DOI 10.4103/0975-7406.67003
   Tong YC, 2010, J CONTROL RELEASE, V147, P76, DOI 10.1016/j.jconrel.2010.06.006
   TORCHILIN VP, 1995, J PHARM SCI, V84, P1049, DOI 10.1002/jps.2600840904
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Trivedi R, 2010, NANOMEDICINE-UK, V5, P485, DOI [10.2217/nnm.10.10, 10.2217/NNM.10.10]
   Uchegbu I. F., 2013, U. S. Patent, Patent No. [12/ 376,8272008, 1213768272008]
   Uchegbu I. F., 2013, UCHEGBU IF, Patent No. PCT/ GB2007/ 003016
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Vaishya RD, 2014, AAPS PHARMSCITECH, V15, P1238, DOI 10.1208/s12249-014-0100-4
   VANBEKKUM DW, 1974, TRANSPLANT P, V6, P59
   Wakebayashi D, 2004, BIOMACROMOLECULES, V5, P2128, DOI 10.1021/bm040009j
   Wang GH, 2016, J PHARM SCI-US, V105, P2752, DOI 10.1016/j.xphs.2016.02.014
   Wang T, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.42693
   Webber S. E., 1999, U. S. Patent, Patent No. [08/ 842,207, 08842207]
   Xu L, 2013, COLLOID SURFACE B, V112, P30, DOI 10.1016/j.colsurfb.2013.06.047
   Yan Q, 2012, CHEM COMMUN, V48, P1913, DOI 10.1039/c2cc16921e
   Yang Y. Y., 2008, YANG YY, Patent No. PCT/ SG2006/ 000188
   YOKOYAMA M, 1993, PHARMACEUT RES, V10, P895, DOI 10.1023/A:1018921513605
   YOKOYAMA M, 1990, CANCER RES, V50, P1693
   YOKOYAMA M, 1994, J CONTROL RELEASE, V28, P59
   Yokoyama M, 2014, J DRUG TARGET, V22, P576, DOI 10.3109/1061186X.2014.934688
   Yokoyama M, 2010, EXPERT OPIN DRUG DEL, V7, P145, DOI 10.1517/17425240903436479
   Yu BG, 1998, J CONTROL RELEASE, V53, P131, DOI 10.1016/S0168-3659(97)00245-9
   Yu HJ, 2015, ADV FUNCT MATER, V25, P2489, DOI 10.1002/adfm.201404484
   Yuan XF, 2005, LANGMUIR, V21, P2668, DOI 10.1021/la0488811
   Zhang WS, 2004, J CONTROL RELEASE, V99, P241, DOI 10.1016/j.jconrel.2004.07.001
   Zhang XC, 1997, CANCER CHEMOTH PHARM, V40, P81, DOI 10.1007/s002800050630
   Zhang XC, 1996, INT J PHARM, V132, P195, DOI 10.1016/0378-5173(95)04386-1
   Zhang Z, 2006, J CONTROL RELEASE, V112, P57, DOI 10.1016/j.jconrel.2006.01.010
   Zhang ZL, 2016, BIOMACROMOLECULES, V17, P798, DOI 10.1021/acs.biomac.5b01526
   Zhao Y, 2014, BIOANALYSIS, V6, P1439, DOI 10.4155/bio.14.71
NR 163
TC 213
Z9 217
U1 14
U2 339
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 28
PY 2017
VL 248
BP 96
EP 116
DI 10.1016/j.jconrel.2017.01.012
PG 21
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA EP2JW
UT WOS:000397210300009
PM 28087407
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Shen, JK
   Frye, M
   Lee, BL
   Reinardy, JL
   McClung, JM
   Ding, K
   Kojima, M
   Xia, HM
   Seidel, C
   Silva, RLE
   Dong, A
   Hackett, SF
   Wang, JX
   Howard, BW
   Vestweber, D
   Kontos, CD
   Peters, KG
   Campochiaro, PA
AF Shen, Jikui
   Frye, Maike
   Lee, Bonnie L.
   Reinardy, Jessica L.
   McClung, Joseph M.
   Ding, Kun
   Kojima, Masashi
   Xia, Huiming
   Seidel, Christopher
   Lima e Silva, Raquel
   Dong, Aling
   Hackett, Sean F.
   Wang, Jiangxia
   Howard, Brian W.
   Vestweber, Dietmar
   Kontos, Christopher D.
   Peters, Kevin G.
   Campochiaro, Peter A.
TI Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; BLOOD-RETINAL BARRIER;
   PROTEIN-TYROSINE-PHOSPHATASE; ANGIOPOIETIN RECEPTOR TIE-2; DIABETIC
   MACULAR EDEMA; CHOROIDAL NEOVASCULARIZATION; IN-VIVO; PROLIFERATIVE
   RETINOPATHY; VESSEL DEVELOPMENT; INDUCED BREAKDOWN
AB Retinal and choroidal neovascularization (NV) and vascular leakage contribute to visual impairment in several common ocular diseases. The angiopoietin/TIE2 (ANG/TIE2) pathway maintains vascular integrity, and negative regulators of this pathway are potential therapeutic targets for these diseases. Here, we demonstrated that vascular endothelial-protein tyrosine phosphatase (VE-PTP), which negatively regulates TIE2 activation, is upregulated in hypoxic vascular endothelial cells, particularly in retinal NV. Intraocular injection of an anti-VE-PTP antibody previously shown to activate TIE2 suppressed ocular NV. Furthermore, a small-molecule inhibitor of VE-PTP catalytic activity (AKB-9778) activated TIE2, enhanced,ANG1-induced TIE2 activation, and stimulated phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK In mouse models of neovascular age-related macular degeneration, AKB-9778 induced phosphorylation of TIE2 and strongly suppressed NV. lschemia-induced retinal NV, which is relevant to diabetic retinopathy, was accentuated by the induction of ANG2 but inhibited by AKB-9778, even in the presence of high levels of ANG2. AKB-9778 also blocked VEGF-induced leakage from dermal and retinal vessels and prevented exudative retinal detachments in double-transgenic mice with high expression of VEGF in photoreceptors. These data support targeting VE-PTP to stabilize retinal and choroidal blood vessels and suggest that this strategy has potential for patients with a wide variety of retinal and choroidal vascular diseases
C1 [Shen, Jikui; Ding, Kun; Kojima, Masashi; Xia, Huiming; Seidel, Christopher; Lima e Silva, Raquel; Dong, Aling; Hackett, Sean F.; Wang, Jiangxia; Campochiaro, Peter A.] Johns Hopkins Univ, Dept Ophthalmol, Sch Med, Baltimore, MD 21287 USA.
   [Shen, Jikui; Ding, Kun; Kojima, Masashi; Xia, Huiming; Seidel, Christopher; Lima e Silva, Raquel; Dong, Aling; Hackett, Sean F.; Wang, Jiangxia; Campochiaro, Peter A.] Johns Hopkins Univ, Dept Neurosci, Sch Med, Baltimore, MD 21287 USA.
   [Frye, Maike; Vestweber, Dietmar] Max Planck Inst Mol Biomed, Dept Cell Biol, D-48149 Munster, Germany.
   [Lee, Bonnie L.; Reinardy, Jessica L.; McClung, Joseph M.; Kontos, Christopher D.] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27710 USA.
   [Howard, Brian W.] Procter & Gamble Co, Cincinnati, OH USA.
   [Peters, Kevin G.] Aerpio Therapeut, Cincinnati, OH USA.
C3 Johns Hopkins University; Johns Hopkins University; Max Planck Society;
   Duke University; Procter & Gamble
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, 815 Maumenee,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI Frye, Maike/ABH-3349-2021
OI Frye, Maike/0000-0002-6257-7636; Vestweber, Dietmar/0000-0002-3517-732X;
   Kontos, Christopher/0000-0002-8056-3115
FU National Eye Institute [EY012609, EY01765]; Aerpio Therapeutics;
   NATIONAL EYE INSTITUTE [R01EY012609, P30EY001765] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R00HL103797]
   Funding Source: NIH RePORTER
FX This study was supported by EY012609 and Wilmer Biostatistics Core Grant
   EY01765 from the National Eye Institute and by a grant from Aerpio
   Therapeutics.
CR Amarasinghe KKD, 2006, BIOORG MED CHEM LETT, V16, P4252, DOI 10.1016/j.bmcl.2006.05.074
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Baumer S, 2006, BLOOD, V107, P4754, DOI 10.1182/blood-2006-01-0141
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Broermann A, 2011, J EXP MED, V208, P2393, DOI 10.1084/jem.20110525
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Dominguez MG, 2007, P NATL ACAD SCI USA, V104, P3243, DOI 10.1073/pnas.0611510104
   Dong AL, 2011, P NATL ACAD SCI USA, V108, P14614, DOI 10.1073/pnas.1012859108
   Evdokimov AG, 2006, ACTA CRYSTALLOGR D, V62, P1435, DOI 10.1107/S0907444906037784
   Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025
   Forooghian F, 2010, INVEST OPHTH VIS SCI, V51, P2388, DOI 10.1167/iovs.09-4065
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4
   Goel S, 2013, JNCI-J NATL CANCER I, V105, P1188, DOI 10.1093/jnci/djt164
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Klopfenstein SR, 2006, BIOORG MED CHEM LETT, V16, P1574, DOI 10.1016/j.bmcl.2005.12.051
   Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x
   KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x
   Silva RLE, 2010, J CELL PHYSIOL, V225, P855, DOI 10.1002/jcp.22296
   Lip PL, 2004, BRIT J OPHTHALMOL, V88, P1543, DOI 10.1136/bjo.2004.048587
   Lobov IB, 2002, P NATL ACAD SCI USA, V99, P11205, DOI 10.1073/pnas.172161899
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   McClung JM, 2012, AM J PATHOL, V180, P2156, DOI 10.1016/j.ajpath.2012.01.032
   Miki K, 2009, OPHTHALMOLOGY, V116, P1748, DOI 10.1016/j.ophtha.2009.05.020
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200
   Nottebaum AF, 2008, J EXP MED, V205, P2929, DOI 10.1084/jem.20080406
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Oshima Y, 2004, J CELL PHYSIOL, V199, P399, DOI 10.1002/jcp.10441
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Saishin Y, 2003, J CELL PHYSIOL, V195, P210, DOI 10.1002/jcp.10238
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   VINORES SA, 1990, LAB INVEST, V62, P742
   VINORES SA, 1989, AM J PATHOL, V134, P231
   Winderlich M, 2009, J CELL BIOL, V185, P657, DOI 10.1083/jcb.200811159
   Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567
   Yacyshyn OK, 2009, ANGIOGENESIS, V12, P25, DOI 10.1007/s10456-008-9126-0
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08
   Zhu JW, 2008, IMMUNITY, V28, P183, DOI 10.1016/j.immuni.2007.11.024
NR 64
TC 131
Z9 146
U1 1
U2 16
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2014
VL 124
IS 10
BP 4564
EP 4576
DI 10.1172/JCI74527
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AQ2WG
UT WOS:000342649900047
PM 25180601
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Birke, MT
   Lipo, E
   Adhi, M
   Birke, K
   Kumar-Singh, R
AF Birke, M. T.
   Lipo, E.
   Adhi, M.
   Birke, K.
   Kumar-Singh, R.
TI AAV-mediated expression of human PRELP inhibits complement activation,
   choroidal neovascularization and deposition of membrane attack complex
   in mice
SO GENE THERAPY
LA English
DT Article
ID RICH REPEAT PROTEIN; MACULAR DEGENERATION; ARTICULAR-CARTILAGE;
   CONNECTIVE TISSUES; BRUCHS MEMBRANE; ANIMAL-MODELS; MATRIX; RISK;
   THERAPY; DISEASE
AB Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly. Approximately 50% of AMD patients have a polymorphism in the negative regulator of-complement known as Factor H. Individuals homozygous bra Y402H polymorphism in Factor H have elevated levels of membrane attack complex (MAC) in their choroid and retinal pigment epithelium relative to individuals homozygous for the wild-type allele. An inability to form MAC due to a polymorphism in C9 is protective against the formation of choroidal. neovascularization (CNV) in AMD patients. Hence, blocking MAC in AMD patients may be protective against CNV. Here we investigate the potential of human proline/arginine-rich end leucine-rich repeat protein (PRELP) as an inhibitor of complement-mediated damage when delivered via the subretinal route using an AAV2/8 vector. In a fluorescence-activated cell sorting (FACS) lysis assay, PRELP inhibited normal human serum-mediated lysis of Hepa-1c1c7 cells by 18.7%. Unexpectedly, PRELP enhanced the formation of tubes by human umbilical vein endothelial cells (HUVECs) by approximately 240%, but, when delivered via an AAV vector to the retina of mice, PRELP inhibited laser-induced CNV by 60%. PRELP reduced deposition of MAC in vivo by 25.5%. Our results have implications for the development of complement inhibitors as a therapy for AMD.
C1 [Birke, M. T.; Lipo, E.; Adhi, M.; Birke, K.; Kumar-Singh, R.] Tufts Univ, Dept Ophthalmol, Sch Med, Boston, MA 02111 USA.
C3 Tufts University
RP Kumar-Singh, R (通讯作者)，Tufts Univ, Dept Ophthalmol, Sch Med, 136 Harrison Ave, Boston, MA 02111 USA.
EM Rajendra.Kumar-Singh@tufts.edu
RI Adhi, Mehreen/AAS-9733-2021
OI Kumar-Singh, Rajendra/0000-0002-7754-0713; Lipo,
   Erion/0000-0002-3179-0688
FU Ellison Foundation; Virginia B Smith Trust; National Institute of
   Health/NEI [EY021805, EY013837]; Department of Defense/ TATRC; Paul and
   Phyllis Fireman Charitable Foundation; Lions Eye Foundation; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY021805, R01EY013837]
   Funding Source: NIH RePORTER
FX This study was supported by grants to RKS from The Ellison Foundation,
   The Virginia B Smith Trust, The National Institute of Health/NEI
   (EY021805 and EY013837), The Department of Defense/ TATRC, The Paul and
   Phyllis Fireman Charitable Foundation and grants to the Department of
   Ophthalmology at Tufts University School of Medicine from the Lions Eye
   Foundation and Research to Prevent Blindness.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Aurnhammer C, 2012, HUM GENE THER METHOD, V23, P18, DOI 10.1089/hgtb.2011.034
   BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639
   Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200
   Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grover J, 1996, GENOMICS, V38, P109, DOI 10.1006/geno.1996.0605
   Hadders MA, 2012, CELL REP, V1, P200, DOI 10.1016/j.celrep.2012.02.003
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   Happonen KE, 2012, J BIOL CHEM, V287, P8092, DOI 10.1074/jbc.M111.291476
   HEINEGARD D, 1986, J BIOL CHEM, V261, P3866
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Kunchithapautham K, 2012, ADV EXP MED BIOL, V723, P23, DOI 10.1007/978-1-4614-0631-0_4
   Lewis M, 2003, AGEING RES REV, V2, P95, DOI 10.1016/S1568-1637(02)00044-2
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McClements ME, 2013, TRANSL RES, V161, P241, DOI 10.1016/j.trsl.2012.12.007
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Ricklin D, 2012, IMMUNOBIOLOGY, V217, P1057, DOI 10.1016/j.imbio.2012.07.016
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Sottile J, 2004, BBA-REV CANCER, V1654, P13, DOI 10.1016/j.bbcan.2003.07.002
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Tegla CA, 2011, IMMUNOL RES, V51, P45, DOI 10.1007/s12026-011-8239-5
   Yanai R, 2012, ADV EXP MED BIOL, V946, P161, DOI 10.1007/978-1-4614-0106-3_10
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 37
TC 23
Z9 24
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD MAY
PY 2014
VL 21
IS 5
BP 507
EP 513
DI 10.1038/gt.2014.24
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA AG7TE
UT WOS:000335620800007
PM 24670995
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Modi, YS
   Epstein, A
   Flynn, HW
   Shi, W
   Smiddy, WE
AF Modi, Yasha S.
   Epstein, Aliza
   Flynn, Harry W., Jr.
   Shi, Wei
   Smiddy, William E.
TI Outcomes and Complications of Pneumatic Retinopexy Over a 12-Year Period
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID RHEGMATOGENOUS RETINAL-DETACHMENT; FOLLOW-UP; REPAIR; BREAKS
AB BACKGROUND AND OBJECTIVE: To evaluate anatomic and clinical outcomes of pneumatic retinopexy for treatment of primary retinal detachment.
   PATIENTS AND METHODS: Noncomparative, single-center, consecutive, interventional case series evaluating all patients treated between 2000 and 2012. Patients with less than 1 month of follow-up or coexisting neovascular age-related macular degeneration, uveitis, endophthalmitis, or prior posterior segment surgery were excluded.
   RESULTS: Sixty-three eyes of 63 patients with primary retinal detachment treated with pneumatic retinopexy were included. Median follow-up was 10.3 months. Single-operation success (SOS), defined as anatomic reattachment with pneumatic retinopexy alone, occurred in 40 eyes (63%). The retina was successfully reattached in 21 of the other 23 eyes (91%) with one additional surgery. There was no difference in visual acuity outcomes between SOS and additional surgical intervention (P = .85). New or missed breaks were identified in 19 of 63 eyes (30%). Postoperative subretinal fluid was observed in 22 of 63 eyes (35%) and persisted at last follow-up in two of 63 eyes (3%). At final follow-up, the retina was fully attached in 97% of eyes.
   CONCLUSION: Pneumatic retinopexy remains a reasonably successful option in the management of primary retinal detachment. No difference in best corrected visual acuity outcomes in eyes achieving SOS versus those requiring additional surgery was demonstrated.
C1 [Modi, Yasha S.; Epstein, Aliza; Flynn, Harry W., Jr.; Shi, Wei; Smiddy, William E.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Modi, YS (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM ymodi@med.miami.edu
CR Abecia E, 2000, RETINA-J RET VIT DIS, V20, P156, DOI 10.1097/00006982-200003000-00007
   Adelman RA, 2013, OPHTHALMOLOGY
   Chan CK, 2008, SURV OPHTHALMOL, V53, P443, DOI 10.1016/j.survophthal.2008.06.008
   Chang TS, 2003, OPHTHALMOLOGY, V110, P589, DOI 10.1016/S0161-6420(02)01896-1
   Davis MJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P163, DOI 10.1001/archophthalmol.2010.352
   Fabian ID, 2013, JAMA OPHTHALMOL, V131, P166, DOI 10.1001/2013.jamaophthalmol.361
   Gilca M, 2013, RETINA
   Han DP, 1998, AM J OPHTHALMOL, V126, P658, DOI 10.1016/S0002-9394(98)00181-0
   HILTON GF, 1987, OPHTHALMOLOGY, V94, P307
   HILTON GF, 1986, OPHTHALMOLOGY, V93, P626
   HILTON GF, 1991, RETINA-J RET VIT DIS, V11, P285, DOI 10.1097/00006982-199111030-00003
   Hwang JF, 2011, RETINA-J RET VIT DIS, V31, P257, DOI 10.1097/IAE.0b013e3181e586f9
   IRVINE AR, 1994, OPHTHALMOLOGY, V101, P524
   Mansour AM, 2005, OPHTHALMOLOGY, V112, P1771, DOI 10.1016/j.ophtha.2005.04.031
   Mudvari SS, 2009, RETINA-J RET VIT DIS, V29, P1474, DOI 10.1097/IAE.0b013e3181ae70f3
   Schwartz SG, 2008, CLIN OPHTHALMOL, V2, P57
   Tornambe P E, 1997, Trans Am Ophthalmol Soc, V95, P551
   TORNAMBE PE, 1989, OPHTHALMOLOGY, V96, P772
   TORNAMBE PE, 1991, OPHTHALMOLOGY, V98, P1115
   Zaidi AA, 2006, BRIT J OPHTHALMOL, V90, P427, DOI 10.1136/bjo.2005.075515
NR 20
TC 8
Z9 8
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD MAR-APR
PY 2014
VL 45
IS 2
BP 132
EP 137
DI 10.3928/23258160-20140306-06
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AH2VT
UT WOS:000335980800006
PM 24635154
DA 2022-11-30
ER

PT J
AU Wang, JY
   Ohno-Matsui, K
   Nakahama, K
   Okamoto, A
   Yoshida, T
   Shimada, N
   Mochizuki, M
   Morita, I
AF Wang, Jiying
   Ohno-Matsui, Kyoko
   Nakahama, Ken-ichi
   Okamoto, Aikou
   Yoshida, Takeshi
   Shimada, Noriaki
   Mochizuki, Manabu
   Morita, Ikuo
TI Amyloid beta Enhances Migration of Endothelial Progenitor Cells by
   Upregulating CX3CR1 in Response to Fractalkine, Which May Be Associated
   With Development of Choroidal Neovascularization
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE angiogenesis; cell physiology; vascular biology; age-related macular
   degeneration; endothelial progenitor cells
ID VISUAL IMPAIRMENT PROJECT; CAUSE-SPECIFIC PREVALENCE; AGE-RELATED
   MACULOPATHY; SMOOTH-MUSCLE-CELLS; MACULAR DEGENERATION; LEUKOCYTE
   CAPTURE; EPITHELIAL-CELLS; RECEPTOR CX3CR1; GROWTH-FACTOR; CATHEPSIN-L
AB Objective-Deposits that accumulate beneath retinal pigment epithelium, called drusen, are early signs of age-related macular degeneration (AMD). We have shown that amyloid beta (A beta) is present in drusen, and A beta may be involved in AMD development. We have also shown that endothelial progenitor cells (EPCs) may contribute to the development of choroidal neovascularization (CNV). Thus, the purpose of this study was to investigate the role played by CX3CR1, a chemokine receptor, in EPC migration and CNV formation.
   Methods and Results-EPCs collected from human umbilical cords were found to express higher levels of CX3CR1 than human umbilical vein endothelial cells, and exposure of EPCs to A beta caused further upregulation of CX3CR1. This upregulation was decreased by blocking fractalkine, a ligand of CX3CR1. Exposure of EPCs to fractalkine increased their migration, but pretreatment with A beta enhanced the migration. The fractalkine-induced EPC migration was more inhibited by EPCs derived from CX3CR1(-/-) mice than wild-type mice. The area of laser-induced CNV was significantly smaller in wild-type mice that received bone marrow transplantation from CX3CR1(-/-) mice than in those that received transplantation from wild-type mice.
   Conclusion-These data suggest that A beta enhances EPC migration through the upregulation of CX3CR1. This upregulation might play a role in development of CNV. (Arterioscler Thromb Vasc Biol. 2011;31:e11-e18.)
C1 [Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, Tokyo 113, Japan.
   [Nakahama, Ken-ichi; Morita, Ikuo] Tokyo Med & Dent Univ, Sect Cellular Physiol Chem, Tokyo 113, Japan.
   [Okamoto, Aikou] Jikei Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan.
C3 Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental
   University (TMDU); Jikei University
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.
EM k.ohno.oph@tmd.ac.jp
FU Japan Society for the Promotion of Science [22390322, 21659399]
FX This work was supported by the Japan Society for the Promotion of
   Science (Grants 22390322 and 21659399).
CR Akita T, 2003, LAB INVEST, V83, P65, DOI 10.1097/01.LAB.0000050761.67879.E4
   Apostolakis S, 2007, THROMB RES, V121, P387, DOI 10.1016/j.thromres.2007.04.005
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bagley RG, 2003, CANCER RES, V63, P5866
   Barlic J, 2007, J BIOL CHEM, V282, P19167, DOI 10.1074/jbc.M701642200
   Basire A, 2006, THROMB HAEMOSTASIS, V95, P678, DOI 10.1160/TH05-07-0511
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chandrasekar B, 2003, BIOCHEM J, V373, P547, DOI 10.1042/BJ20030207
   Chen YH, 2007, DIABETES, V56, P1559, DOI 10.2337/db06-1103
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Da Silva CC, 2009, IMMUNOLOGY, V126, P394, DOI 10.1111/j.1365-2567.2008.02906.x
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413
   Fujimoto K, 2001, AM J RESP CELL MOL, V25, P233, DOI 10.1165/ajrcmb.25.2.4275
   Greaves DR, 2001, ARTERIOSCL THROM VAS, V21, P923, DOI 10.1161/01.ATV.21.6.923
   Green WR, 1999, AGE RELATED MACULAR, P81
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223
   Heiss C, 2008, J CELL PHYSIOL, V215, P366, DOI 10.1002/jcp.21313
   Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9
   Imaizumi Tadaatsu, 2004, J Atheroscler Thromb, V11, P15
   Ishida Y, 2008, J IMMUNOL, V180, P569, DOI 10.4049/jimmunol.180.1.569
   Jones CP, 2009, STEM CELLS, V27, P3074, DOI 10.1002/stem.222
   Katsuki Y, 2011, CLIN RES CARDIOL, V100, P21, DOI 10.1007/s00392-010-0198-7
   Khakoo AY, 2005, ANNU REV MED, V56, P79, DOI 10.1146/annurev.med.56.090203.104149
   Marsboom G, 2008, STEM CELLS, V26, P1017, DOI 10.1634/stemcells.2007-0562
   Mieno S, 2008, ANN THORAC SURG, V85, P1361, DOI 10.1016/j.athoracsur.2007.12.006
   Mobius-Winkler S, 2009, CYTOM PART A, V75A, P25, DOI 10.1002/cyto.a.20669
   Moon SO, 2006, MOL PHARMACOL, V70, P112, DOI 10.1124/mol.106.022392
   Muehlhoefer A, 2000, J IMMUNOL, V164, P3368, DOI 10.4049/jimmunol.164.6.3368
   Mukai N, 2008, EXP CELL RES, V314, P430, DOI 10.1016/j.yexcr.2007.11.016
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Nanki T, 2002, ARTHRITIS RHEUM, V46, P2878, DOI 10.1002/art.10622
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pachot A, 2008, J IMMUNOL, V180, P6421, DOI 10.4049/jimmunol.180.9.6421
   Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Shimada N, 2010, AM J PATHOL, V176, P2571, DOI 10.2353/ajpath.2010.091027
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Steinmetz M, 2010, J CELL MOL MED, V14, P1645, DOI 10.1111/j.1582-4934.2009.00829.x
   Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506
   Thill M, 2008, INVEST OPHTH VIS SCI, V49, P2696, DOI 10.1167/iovs.07-0955
   Thum T, 2007, DIABETES, V56, P666, DOI 10.2337/db06-0699
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182
   Valdivia-Silva JE, 2009, CANCER LETT, V283, P176, DOI 10.1016/j.canlet.2009.03.040
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Werner C, 2007, DIABETES, V56, P2609, DOI 10.2337/db07-0069
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   You JJ, 2007, INVEST OPHTH VIS SCI, V48, P5290, DOI 10.1167/iovs.07-0187
   Zanchi C, 2008, J IMMUNOL, V181, P1460, DOI 10.4049/jimmunol.181.2.1460
NR 64
TC 9
Z9 9
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JUL
PY 2011
VL 31
IS 7
BP E11
EP U38
DI 10.1161/ATVBAHA.110.215517
PG 30
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 777WR
UT WOS:000291656300001
PM 21527754
OA Bronze
DA 2022-11-30
ER

PT J
AU Kirby, ML
   Beatty, S
   Loane, E
   Akkali, MC
   Connolly, EE
   Stack, J
   Nolan, JM
AF Kirby, Mark L.
   Beatty, Stephen
   Loane, Edward
   Akkali, Mukunda C.
   Connolly, Eithne E.
   Stack, Jim
   Nolan, John M.
TI A Central Dip in the Macular Pigment Spatial Profile Is Associated with
   Age and Smoking
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL-DENSITY; TISSUE CONCENTRATIONS; VISUAL IMPAIRMENT;
   CIGARETTE-SMOKING; PROTECTIVE ROLE; RISK-FACTORS; DEGENERATION;
   CAROTENOIDS; MACULOPATHY; ZEAXANTHIN
AB PURPOSE. To investigate the relationship between specific macular pigment (MP) spatial profiles and risk factors for age-related macular degeneration (AMD).
   METHODS. The MP spatial profile of 484 healthy subjects was measured with customized heterochromatic flicker photometry (cHFP) and categorized into one of two profile types: typical exponential or atypical "central dip." Data on risk factors for AMD were obtained with a general health and lifestyle questionnaire. Dietary and serum concentrations of lutein (L) and zeaxanthin (Z) were also assessed.
   RESULTS. The presence of the central dip MP spatial profile was significantly more common in older subjects (the mean +/- SD age of subjects with a central dip MP spatial profile was 46.9 +/- 12 years, whereas the mean age of subjects with a typical MP spatial profile was 41.8 +/- 12 years; P = 0.004) and in current cigarette smokers (P = 0.031). Also, there was a significant age-related decline in central MP optical density (MPOD; 0.25 degrees retinal eccentricity), but in the men only (r = -0.146, P = 0.049).
   CONCLUSIONS. A central dip in the MP spatial profile, seen in older subjects and in cigarette smokers, may represent an undesirable feature of macular pigmentation. Further research is needed in this area. (Invest Ophthalmol Vis Sci. 2010;51:6722-6728) DOI:10.1167/iovs.10-5344
C1 [Kirby, Mark L.; Beatty, Stephen; Loane, Edward; Akkali, Mukunda C.; Connolly, Eithne E.; Stack, Jim; Nolan, John M.] Waterford Inst Technol, Macular Pigment Res Grp, Dept Chem & Life Sci, Waterford, Ireland.
C3 South East Technological University (SETU)
RP Nolan, JM (通讯作者)，Waterford Inst Technol, Macular Pigment Res Grp, Dept Chem & Life Sci, Cork Rd, Waterford, Ireland.
EM jmnolan@wit.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084; Akkali, Mukunda
   Chaitanya/0000-0001-6307-5729
FU Fighting Blindness, Ireland; Health Research Board, Ireland
FX Supported by the Medical Research Charities Group Grant, through
   Fighting Blindness, Ireland and the Health Research Board, Ireland.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   EITHNE EC, 2010, CURR EYE RES, V35, P335
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Wooten BR, 2005, OPTOMETRY VISION SCI, V82, P378, DOI 10.1097/01.OPX.0000162654.32112.A1
NR 34
TC 47
Z9 48
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2010
VL 51
IS 12
BP 6722
EP 6728
DI 10.1167/iovs.10-5344
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 688GJ
UT WOS:000284837500082
PM 20592234
DA 2022-11-30
ER

PT J
AU Kernt, M
   Liegl, RG
   Rueping, J
   Neubauer, AS
   Haritoglou, C
   Lackerbauer, CA
   Eibl, KH
   Ulbig, MW
   Kampik, A
AF Kernt, M.
   Liegl, R. G.
   Rueping, J.
   Neubauer, A. S.
   Haritoglou, C.
   Lackerbauer, C. A.
   Eibl, K. H.
   Ulbig, M. W.
   Kampik, A.
TI Sorafenib protects human optic nerve head astrocytes from light-induced
   overexpression of vascular endothelial growth factor, platelet-derived
   growth factor, and placenta growth factor
SO GROWTH FACTORS
LA English
DT Article
DE Glia; neovascularization; bevacizumab; ranibizumab; multikinase
   inhibitors
ID RAF/MEK/ERK PATHWAY; FACTOR VEGF; RETINAL VASCULATURE; PIGMENT
   EPITHELIUM; FACTOR THERAPY; BAY 43-9006; EXPRESSION; ANGIOGENESIS;
   CELLS; INHIBITION
AB Objectives: Growth factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and placenta growth factor (PlGF) are key players in the development of diabetic retinopathy, age-related macular degeneration, and other retinal neovascular diseases. Glial cells provide a significant source of retinal growth factor production under physiologic and pathologic conditions. Cumulative light exposure has been linked to increased retinal growth factor expression. Previous reports indicate that sorafenib, an oral multikinase inhibitor, might have a beneficial effect on retinal neovascularization. This study was designed to investigate the effects of sorafenib on light-induced overexpression of growth factors in human retinal glial cells.
   Methods: Primary human optic nerve head astrocytes (ONHAs) were exposed to white light and incubated with sorafenib. Viability, expression, and secretion of VEGF-A, PDGF-BB, and PlGF and their mRNA were determined by reverse transcription-polymerase chain reaction, immunohistochemistry, and enzyme-linked immunosorbent assay.
   Results: Light exposure decreased cell viability and increased VEGF-A, PDGF-BB, and PlGF expression and secretion. These light-induced effects were significantly reduced when cells were treated with sorafenib at a concentration of 1 mu g/ml.
   Conclusion: Sorafenib significantly reduced light-induced overexpression of VEGF-A, PDGF-BB, and PlGF in primary human ONHAs. Sorafenib has promising properties as a potential supportive treatment for retinal neovascularization.
C1 [Kernt, M.; Liegl, R. G.; Rueping, J.; Neubauer, A. S.; Haritoglou, C.; Lackerbauer, C. A.; Eibl, K. H.; Ulbig, M. W.; Kampik, A.] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
C3 University of Munich
RP Kernt, M (通讯作者)，Univ Munich, Dept Ophthalmol, Mathilden Str 8, D-80336 Munich, Germany.
EM marcus.kernt@med.uni-muenchen.de
CR Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3
   Aiello LP, 2008, NEW ENGL J MED, V359, P967, DOI 10.1056/NEJMcibr0804551
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.3.CO;2-D
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Buniatian GH, 1997, BIOL CELL, V89, P169, DOI 10.1016/S0248-4900(97)80034-2
   Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069
   CHANLING T, 1990, CURR EYE RES, V9, P459, DOI 10.3109/02713689008999612
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   DORRELL MI, 2009, GLIA
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Esposito G, 2006, LIFE SCI, V78, P2707, DOI 10.1016/j.lfs.2005.10.023
   Gardner TW, 1997, INVEST OPHTH VIS SCI, V38, P2423
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Ikuno Y, 2002, JPN J OPHTHALMOL, V46, P413, DOI 10.1016/S0021-5155(02)00527-0
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   KERNT M, 2009, OPHTHALMOL
   Kernt M, 2008, ACTA OPHTHALMOL, V86, P456, DOI 10.1111/j.1600-0420.2007.01014.x
   Kernt M, 2008, J CATARACT REFR SURG, V34, P480, DOI 10.1016/j.jcrs.2007.10.046
   Kernt M, 2009, J CATARACT REFR SURG, V35, P354, DOI 10.1016/j.jcrs.2008.10.052
   Kobayashi S, 1997, GLIA, V20, P262, DOI 10.1002/(SICI)1098-1136(199707)20:3<262::AID-GLIA10>3.0.CO;2-S
   Lambert W, 2001, INVEST OPHTH VIS SCI, V42, P2315
   LATERRA J, 1990, J CELL PHYSIOL, V144, P204, DOI 10.1002/jcp.1041440205
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Miyake K, 1999, J CATARACT REFR SURG, V25, P891, DOI 10.1016/S0886-3350(99)00069-3
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P255, DOI 10.1007/BF00920031
   PEYMAN GA, 2009, RETINA S, V29, pS20
   Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schlingemann RO, 1996, J PATHOL, V179, P436
   Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yang JJ, 2001, INVEST OPHTH VIS SCI, V42, P365
   Zhang YF, 1997, INVEST OPHTH VIS SCI, V38, P1653
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
   ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2
NR 53
TC 16
Z9 16
U1 1
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0897-7194
EI 1029-2292
J9 GROWTH FACTORS
JI Growth Factors
PD JUN
PY 2010
VL 28
IS 3
BP 211
EP 220
DI 10.3109/08977191003604505
PG 10
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 634OF
UT WOS:000280591900007
PM 20166888
DA 2022-11-30
ER

PT J
AU DellaCroce, JT
   Vitale, AT
AF DellaCroce, John T.
   Vitale, Albert T.
TI Hypertension and the eye
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE aneurysm; arteriosclerosis; hemorrhage; hypertensive retinopathy;
   retina; systemic hypertension; thrombosis
ID POOLED DATA-ANALYSIS; CARDIOVASCULAR-DISEASE; RISK-FACTORS; RETINOPATHY;
   CALIBER; PROGRESSION; MORTALITY; PERFUSION; PRESSURE; GLAUCOMA
AB Purpose of review
   This article reviews the findings of systemic hypertension in the eye and how these changes represent disease in the eye itself, as well as the predictive value of fundoscopic findings in relation to overall health. Systemic hypertension is associated with observable changes in the retinal microvasculature, including retinopathy, choroidopathy and optic neuropathy, as well as with an increased risk of ocular vascular abnormalities such as arterial and venous occlusive disease, retinal arteriolar macroaneurysm formation and embolic events. Hypertension also confers increased risk for development and progression of diabetic retinopathy, glaucoma and age-related macular degeneration. Grading systems have been proposed that attempt to correlate observed ocular hypertensive changes with systemic vascular disease severity, morbidity and mortality.
   Recent findings
   The widespread availability of digital imaging systems and computer analysis along with revised grading systems has enabled a more precise and reliable examination. This has renewed the interest in the use of routine fundoscopic screening for patients with hypertension in an effort to identify microvascular changes that may provide prognostic information for cardiovascular risk stratification and disease progression.
   Summary
   Identification of early microvascular changes on fundoscopic examination using reliable and reproducible imaging techniques may become an important and routine screening modality for the prevention and management of both the ocular and systemic complications of hypertension.
C1 [DellaCroce, John T.; Vitale, Albert T.] Univ Utah, Hlth Sci Ctr, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [DellaCroce, John T.] Tulane Univ, Sch Med, Dept Ophthalmol, New Orleans, LA 70112 USA.
C3 Utah System of Higher Education; University of Utah; Tulane University
RP Vitale, AT (通讯作者)，Univ Utah, Hlth Sci Ctr, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM Albert.Vitale@hsc.utah.edu
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   AUGSBURGER JJ, 1980, BRIT J OPHTHALMOL, V64, P913, DOI 10.1136/bjo.64.12.913
   BROWN DM, 1994, BRIT J OPHTHALMOL, V78, P534, DOI 10.1136/bjo.78.7.534
   Cugati S, 2007, OPHTHALMOLOGY, V114, P520, DOI 10.1016/j.ophtha.2006.06.061
   DIMMITT SB, 1989, LANCET, V1, P1103
   GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1690
   HAYREH SS, 1994, AM J OPHTHALMOL, V117, P603, DOI 10.1016/S0002-9394(14)70067-4
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klein R, 1997, Trans Am Ophthalmol Soc, V95, P329
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   Klein R, 2007, OPHTHALMOLOGY, V114, P1884, DOI 10.1016/j.ophtha.2007.02.023
   Langman MJS, 2005, BRIT J OPHTHALMOL, V89, P960, DOI 10.1136/bjo.2004.053397
   Marcucci R, 2007, BLOOD COAGUL FIBRIN, V18, P321, DOI 10.1097/MBC.0b013e32809cc922
   Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631
   MURPHY RP, 2006, RETINA, V2
   Newman NJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P1366
   Nguyen TT, 2008, DIABETES, V57, P536, DOI 10.2337/db07-1376
   Nguyen TT, 2008, DIABETES CARE, V31, P544, DOI 10.2337/dc07-1528
   Piltz-Seymour IR, 2001, AM J OPHTHALMOL, V132, P63, DOI 10.1016/S0002-9394(01)00871-6
   RABB MF, 1988, SURV OPHTHALMOL, V33, P73, DOI 10.1016/0039-6257(88)90160-9
   RASSAM SMB, 1995, EXP PHYSIOL, V80, P53, DOI 10.1113/expphysiol.1995.sp003834
   Recchia F M, 2000, Curr Opin Ophthalmol, V11, P462, DOI 10.1097/00055735-200012000-00013
   Rogers SL, 2008, DIABETES CARE, V31, P761, DOI 10.2337/dc07-1622
   SCHEIE HG, 1953, AMA ARCH OPHTHALMOL, V49, P117
   Schmieder RE, 2008, HYPERTENSION, V51, P43, DOI 10.1161/HYPERTENSIONAHA.107.100230
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 2004, HYPERTENSION, V44, P442, DOI 10.1161/01.HYP.0000140772.40322.ec
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P216, DOI 10.1001/archopht.1995.01100020100038
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wang JJ, 2006, STROKE, V37, P1833, DOI 10.1161/01.STR.0000226929.23297.75
   Wang L, 2008, HYPERTENSION, V51, P119, DOI 10.1161/HYPERTENSIONAHA.107.098343
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2006, CLIN EXP OPHTHALMOL, V34, P397, DOI 10.1111/j.1442-9071.2006.01233.x
   Wong TY, 2005, BRIT MED BULL, V73-74, P57, DOI 10.1093/bmb/ldh050
   Wong TY, 2005, OPHTHAL PHYSL OPT, V25, P195, DOI 10.1111/j.1475-1313.2005.00288.x
   Wong TY, 2005, ARCH INTERN MED, V165, P1060, DOI 10.1001/archinte.165.9.1060
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
NR 39
TC 40
Z9 40
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD NOV
PY 2008
VL 19
IS 6
BP 493
EP 498
DI 10.1097/ICU.0b013e3283129779
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 367WA
UT WOS:000260582100007
PM 18854694
DA 2022-11-30
ER

PT J
AU Belanger, J
   Johns, T
AF Belanger, Julie
   Johns, Timothy
TI Biological Diversity, Dietary Diversity, and Eye Health in Developing
   Country Populations: Establishing the Evidence-base
SO ECOHEALTH
LA English
DT Review
DE ecohealth; blindness; agrobiodiversity; carotenoids; wild foods; vision
   impairment
ID VITAMIN-A-DEFICIENCY; BETA-CAROTENE; CATARACT-EXTRACTION; OXIDATIVE
   STRESS; MACULAR DEGENERATION; VISUAL IMPAIRMENT; GENETIC DIVERSITY;
   ALPHA-TOCOPHEROL; NUTRIENT INTAKE; FOOD SECURITY
AB Human and ecosystem health converge around biological diversity issues. Cultivated and wild plants as food and medicine make essential contributions to human health, which in turn provides rationales for conservation. While wild and cultivated plant diversity reasonably facilitates dietary diversity and positive health outcomes, the challenges of demonstrating this relationship limit its impact in concept, policy, and practice. We present a rationale for testing the dietary contribution of biological diversity to improved eye health as a case study based on existing phytochemical, pharmacological, and clinical knowledge. We consider the empirical evidence needed to substantiate, interpret, and apply this relationship at a population and ecosystem level within a unified research framework. Epidemiological data strongly support the prevention of childhood vitamin A deficiency blindness, cataract, and age-related macular degeneration by fruit and vegetable consumption. Phytonutrients, including the carotenoids lutein and zeaxanthin, protect the eye from oxidative stress and harmful light exposure. Laboratory, community, and population level research should prioritize food composition of dietary plants from both agriculture and the wild. Intervention studies, focus groups, and transmission of knowledge of local species and varieties within communities will further interpretation of epidemiological data. Population-based studies combining clinical data and measures of access and consumption of biological diversity are key to demonstrating the important relationships among biodiversity, dietary diversity, and health outcomes.
C1 [Belanger, Julie; Johns, Timothy] McGill Univ, Dept Plant Sci, Montreal, PQ H9X 3V9, Canada.
   [Johns, Timothy] McGill Univ, Sch Dietet & Human Nutr, Montreal, PQ H9X 3V9, Canada.
C3 McGill University; McGill University
RP Johns, T (通讯作者)，McGill Univ, Dept Plant Sci, Montreal, PQ H9X 3V9, Canada.
EM tim.johns@mcgill.ca
FU Natural Sciences and Engineering Research Council (NSERC); Fonds
   Quebecois de la Recherche et des Nouvelles Technologies (FQRNT); Bourse
   de Doctorat en Recherche
FX Financial support of this work was provided by the Natural Sciences and
   Engineering Research Council (NSERC) (Postgraduate Award to J.B.), Fonds
   Quebecois de la Recherche et des Nouvelles Technologies (FQRNT) (Bourse
   de Doctorat en Recherche B2 to J.B.), and by the Natural Sciences and
   Engineering Research Council ( NSERC) (Discovery Grant to T.J.). Special
   thanks to Dr. D. Rodriguez-Amaya, our colleagues at Bioversity
   International, and Francois Fauteux.
CR Altieri MA, 1999, AGR ECOSYST ENVIRON, V74, P19, DOI 10.1016/S0167-8809(99)00028-6
   Andre CM, 2007, J AGR FOOD CHEM, V55, P366, DOI 10.1021/jf062740i
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P339, DOI 10.1111/j.1475-1313.2004.00218.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Betancourt-Dominguez MA, 2006, PLANT FOOD HUM NUTR, V61, P115, DOI 10.1007/s11130-006-0008-6
   BHUYAN KC, 1984, CURR EYE RES, V3, P67, DOI 10.3109/02713688408997188
   Bloem MW, 1996, EUR J CLIN NUTR, V50, pS62
   Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Burlingame B., 2000, J FOOD COMPOS ANAL, V2, P99, DOI DOI 10.1006/JFCA.2000.0897
   Castenmiller JJM, 1999, J NUTR, V129, P349, DOI 10.1093/jn/129.2.349
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chivian E., 2002, BIODIVERSITY ITS IMP
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Christen WG, 2005, AM J CLIN NUTR, V81, P1417
   Chweya J.A., 1999, BIODIVERSITY TRADITI
   Coleman AL, 1999, LANCET, V354, P1803, DOI 10.1016/S0140-6736(99)04240-3
   COLEMAN AL, 2006, ACTA OPHTHALMOL    S, V84, P122
   *CONV BIOL DIV, 2006, 8 C PART COP 8 CUR B
   Cordain L, 2002, ACTA OPHTHALMOL SCAN, V80, P125, DOI 10.1034/j.1600-0420.2002.800203.x
   de Pee S, 1998, AM J CLIN NUTR, V68, P1058, DOI 10.1093/ajcn/68.5.1058
   DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648
   Esquinas-Alcazar J, 2005, NAT REV GENET, V6, P946, DOI 10.1038/nrg1729
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Faber M, 2007, J SCI FOOD AGR, V87, P366, DOI 10.1002/jsfa.2774
   FAO, 2000, FOOD INS PEOPL LIV H
   FAO, 1999, USE POTENTIAL WILD P
   Fassil Hareya, 2000, Food and Nutrition Bulletin, V21, P497
   Fernandez E, 2000, PREV MED, V31, P11, DOI 10.1006/pmed.2000.0667
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Grifo F., 1997, BIODIVERSITY HUMAN H
   Grivetti LE, 2000, NUTR RES REV, V13, P31, DOI 10.1079/095442200108728990
   HANKINSON SE, 1992, BMJ-BRIT MED J, V305, P335, DOI 10.1136/bmj.305.6849.335
   *HKI AS PAC, 2001, HOM FOOD PROD STRAT
   Ho VH, 2001, BRIT J OPHTHALMOL, V85, P653, DOI 10.1136/bjo.85.6.653
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   JACOB RA, 1995, NUTR RES, V15, P755, DOI 10.1016/0271-5317(95)00041-G
   Jacques PF, 1999, INT J VITAM NUTR RES, V69, P198, DOI 10.1024/0300-9831.69.3.198
   Johns T., 2003, African Journal of Food, Agriculture, Nutrition and Development, V3, P45
   Johns T, 2006, P NUTR SOC, V65, P182, DOI 10.1079/PNS2006494
   JOHNS T, 2006, NUASYLVA, V224, P34
   JOHNS T, 2007, MANAGING BIODIVERSIT, P492
   Johns T, 2007, FOOD POLICY, V32, P1, DOI 10.1016/j.foodpol.2006.03.014
   Johns Timothy, 2004, Food and Nutrition Bulletin, V25, P143
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   KANT AK, 1995, J AM COLL NUTR, V14, P358
   Kennedy G, 2005, J FOOD COMPOS ANAL, V18, P255, DOI 10.1016/j.jfca.2004.10.002
   Kennedy G, 2003, FOOD CHEM, V80, P589, DOI 10.1016/S0308-8146(02)00507-1
   KENNEDY G, 2003, FOOD NUTR AGR FAO, V32, P94
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   Kuhnlein HV, 2004, NUTR REV, V62, P439, DOI [10.1301/nr.2004.janr.439-442, 10.1111/j.1753-4887.2004.tb00015.x]
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LaVecchia C, 1997, INT J CANCER, V72, P255, DOI 10.1002/(SICI)1097-0215(19970717)72:2&lt;255::AID-IJC9&gt;3.0.CO;2-Q
   LEE Y, 1995, J FOOD SCI, V60, P473, DOI 10.1111/j.1365-2621.1995.tb09806.x
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Lyle BJ, 1999, AM J CLIN NUTR, V69, P272
   Mares JA, 2006, AM J CLIN NUTR, V83, P733, DOI 10.1093/ajcn/83.4.733
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MARESPERLMAN JA, 1995, AM J EPIDEMIOL, V141, P322, DOI 10.1093/aje/141.4.322
   McDade TW, 2007, P NATL ACAD SCI USA, V104, P6134, DOI 10.1073/pnas.0609123104
   MERCADANTE AZ, 1991, J AGR FOOD CHEM, V39, P1094, DOI 10.1021/jf00006a018
   Michels KB, 2003, INT J EPIDEMIOL, V32, P486, DOI 10.1093/ije/dyg216
   Miller NJ, 1996, FEBS LETT, V384, P240, DOI 10.1016/0014-5793(96)00323-7
   Moeller SM, 2004, J NUTR, V134, P1812, DOI 10.1093/jn/134.7.1812
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Mou BQ, 2005, J AM SOC HORTIC SCI, V130, P870, DOI 10.21273/JASHS.130.6.870
   Ojofeitimi E. O., 1999, Nutrition and Health (Bicester), V13, P61
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Padulosi S., 2002, P323, DOI 10.1079/9780851995229.0323
   PALOZZA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P184, DOI 10.1016/0003-9861(92)90658-J
   Popkin BM, 2004, NUTR REV, V62, pS140, DOI 10.1111/j.1753-4887.2004.tb00084.x
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rodriguez-Amaya D.B., 1999, GUIDE CAROTENOID ANA
   Ruel MT, 2003, J NUTR, V133, p3911S, DOI 10.1093/jn/133.11.3911S
   RUEL MT, 2000, 92 INT FOOD POL RES
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Shankar AV, 1996, AM J CLIN NUTR, V64, P242, DOI 10.1093/ajcn/64.2.242
   TALUKDER A, 1994, 2 DECADES PROGR LINK
   Tavani A, 1996, ANN EPIDEMIOL, V6, P41, DOI 10.1016/1047-2797(95)00099-2
   Taylor HR, 1999, EYE, V13, P445, DOI 10.1038/eye.1999.119
   Toledo A, 2006, J FOOD COMPOS ANAL, V19, P477, DOI 10.1016/j.jfca.2006.05.001
   Tontisirin K, 2002, P NUTR SOC, V61, P243, DOI 10.1079/PNS2002155
   Trichopoulou A, 1997, NUTR REV, V55, P383, DOI 10.1111/j.1753-4887.1997.tb01578.x
   Tucker KL, 2001, NUTR REV, V59, P156
   UN, 2000, UN MILL DEV GOALS MD
   Underwood BA, 1996, FASEB J, V10, P1040, DOI 10.1096/fasebj.10.9.8801165
   *UNEP, 1992, TEXT CONV BIOL DIV
   Vaicaitiene Ramute, 2003, Medicina (Kaunas), V39, P1231
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Reyk DM, 2003, REDOX REP, V8, P187, DOI 10.1179/135100003225002673
   Vinson Joe A, 2006, Pathophysiology, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   Vu HTV, 2006, INVEST OPHTH VIS SCI, V47, P3783, DOI 10.1167/iovs.05-0587
   West AL, 2006, AM J OPHTHALMOL, V141, P157, DOI 10.1016/j.ajo.2005.07.033
   *WHO, 2006, PREV BLINDN VIS IMP
   Wilson EO, 1988, BIODIVERSITY
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Zaripheh S, 2002, J NUTR, V132, p531S, DOI 10.1093/jn/132.3.531S
NR 104
TC 14
Z9 15
U1 2
U2 27
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1612-9202
EI 1612-9210
J9 ECOHEALTH
JI EcoHealth
PD SEP
PY 2008
VL 5
IS 3
BP 244
EP 256
DI 10.1007/s10393-008-0180-2
PG 13
WC Biodiversity Conservation; Ecology; Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biodiversity & Conservation; Environmental Sciences & Ecology
GA 397XU
UT WOS:000262696500003
PM 18685894
DA 2022-11-30
ER

PT J
AU Metelitsina, TI
   Grunwald, JE
   DuPont, JC
   Ying, GS
AF Metelitsina, TI
   Grunwald, JE
   DuPont, JC
   Ying, GS
TI Effect of Viagra on the foveolar choroidal circulation of AMD patients
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE foveolar choroidal circulation; laser Doppler flowmetry; age-related
   macular degeneration; sildenafil citrate (Viagra)
ID SILDENAFIL CITRATE VIAGRA; BLOOD-FLOW; RETINAL VASODILATATION;
   SMOOTH-MUSCLE; DEGENERATION; REGION
AB To investigate the effects of sildenafil citrate (Viagra) on foveolar choroidal circulation in patients with age related macular degeneration (AMD).
   Double-blinded, randomized, placebo-controlled, crossover study. Fifteen male AMD patients received a dose of 100 mg of sildenafil or matching placebo on two separate days. Laser Doppler flowmetry was performed to assess relative choroidal blood velocity (ChB(Vel)), volume (ChB(Vol)) and flow (ChB(Flow)) in the study eye prior to administration of the drug at baseline and 30, 90, 180, 300 min after dosing. Best corrected visual acuity (BCVA), contrast sensitivity (CS), mean arterial blood pressure (BPm), heart rate (HR), intraocular pressure (IOP) and ocular perfusion pressure (PP) were determined.
   In comparison to placebo, sildenafil did not cause any statistically significant changes in mean ChB(Vel) (ANOVA, P = 0 center dot 12), ChB(Vol) (ANOVA, P = 0 center dot 24) or ChB(Flow) (ANOVA, P = 0 center dot 46). There were no statistically significant changes in CS (ANOVA, P = 0 center dot 59), BCVA (P=0-58), IOP (P=0-81) or HR (P=0-07) throughout the study. Significant decreases in BPm (P=0.006) and PP (P=0-006) were observed at 30 min after sildenafil.
   Administration of sildenafil citrate didn't cause any statistically significant changes in the foveolar choroidal circulation of AMD patients. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Grunwald, JE (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
FU NEI NIH HHS [EY01583] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [P30EY001583] Funding Source: NIH RePORTER
CR Birch DG, 2002, AM J OPHTHALMOL, V133, P665, DOI 10.1016/S0002-9394(02)01338-7
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Boolell M, 1996, Int J Impot Res, V8, P47
   Boshier A, 2002, INT J CLIN PHARM TH, V40, P422
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Cunningham AV, 2001, J NEURO-OPHTHALMOL, V21, P22, DOI 10.1097/00041327-200103000-00006
   Dundar SO, 2001, EYE, V15, P507, DOI 10.1038/eye.2001.163
   Egan R, 2000, ARCH OPHTHALMOL-CHIC, V118, P291
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495
   GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2002, AM J OPHTHALMOL, V133, P809, DOI 10.1016/S0002-9394(02)01391-0
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171
   IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265
   Jackson G, 1999, AM J CARDIOL, V83, p13C
   Marmor MF, 1999, SURV OPHTHALMOL, V44, P153, DOI 10.1016/S0039-6257(99)00079-X
   McCulley TJ, 2002, OPHTHALMOLOGICA, V216, P455, DOI 10.1159/000067549
   Pache M, 2002, BRIT J OPHTHALMOL, V86, P156, DOI 10.1136/bjo.86.2.156
   Paris Gianmarco, 2001, International Ophthalmology, V23, P355, DOI 10.1023/A:1014410932321
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Petrig BL, 1996, OCULAR BLOOD FLOW, P120
   Polak K, 2003, INVEST OPHTH VIS SCI, V44, P4872, DOI 10.1167/iovs.03-0177
   Pomeranz HD, 2002, OPHTHALMOLOGY, V109, P584, DOI 10.1016/S0161-6420(01)00976-9
   PRUNTE C, 1988, GRAEF ARCH CLIN EXP, V226, P55, DOI 10.1007/BF02172719
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   Riva CE, 1996, OCULAR BLOOD FLOW, P128
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   1998, JOINT CLIN REV, P160
NR 34
TC 29
Z9 30
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2005
VL 81
IS 2
BP 159
EP 164
DI 10.1016/j.exer.2005.01.017
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 957EM
UT WOS:000231352400005
PM 16080909
DA 2022-11-30
ER

PT J
AU Toprak, AB
   Eser, E
   Guler, C
   Baser, FE
   Mayali, H
AF Toprak, AB
   Eser, E
   Guler, C
   Baser, FE
   Mayali, H
TI Cross-validation of the Turkish version of the 25-item National Eye
   Institute Visual Functioning Questionnaire (NEI-VFQ 25)
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE NEI-VFQ questionnaire; quality of life; questionnaire validation; visual
   function; cataract; diabetic retinopathy; age-related macular
   degeneration; glaucoma
ID QUALITY-OF-LIFE; AGE-RELATED MACULOPATHY; GENERAL HEALTH; NEI VFQ-25;
   POPULATION; VALIDITY; VISION; SCORES
AB Purpose: To test the validity and reliability of the Turkish version of the self-administered form of the National Eye Institute Visual Functioning Questionnaire (NET-VFQ25). Methods: Patients with no limitations to respond to a health status interview and affected by a chronic eye disease were enrolled. The Turkish versions of the abbreviated form of World Health Organization Quality of Life (WHOQOL-BREF) and the NEI-VFQ25 instruments were administered to all participants. Results: The mean (SD) age of the participants was 60.9 (14.5) years. There were 61 patients with one of the following conditions: Cataract (57.4%), diabetic retinopathy (13.2%), age related macular degeneration (ARMD) (11.4% glaucoma (9.8%) and degenerative myopia (8.2%). The Cronbach alpha of the overall scale was 0.97; the Cronbach alpha ranged from 0.94 to 0.78 for the subscales. The physical, psychological, environmental and social domains of the WHOQOL-BREF had fair to good correlations with the NEI-VFQ25 (r = 0.68 to r = 0.26), which indicated a sufficient convergent validity. Patients with lower visual acuity (VA) had lower index scores than those with higher VA (p = 0.001), which showed a sufficient responsiveness. Conclusion: Statistical analysis showed that Turkish version of the NEI-VFQ is a valid and reliable instrument to measure vision-related quality of life in patients with chronic eye diseases.
C1 Celal Bayar Univ, Dept Ophthalmol, TR-45010 Manisa, Turkey.
   Celal Bayar Univ, Dept Publ Hlth, TR-45010 Manisa, Turkey.
C3 Celal Bayar University; Celal Bayar University
RP Toprak, AB (通讯作者)，Celal Bayar Univ, Dept Ophthalmol, Goz Hast AD, TR-45010 Manisa, Turkey.
EM baris.toprak@bayar.edu.tr
OI Mayali, Huseyin/0000-0003-3692-665X; Toprak, Ahmet
   Baris/0000-0001-6416-1987
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Bressler NM, 2004, ARCH OPHTHALMOL-CHIC, V122, P857
   BRETON ME, 1989, GLAUCOMAS, P179
   Cella D F, 1995, Oncology (Williston Park), V9, P47
   Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245
   Cole SR, 2000, INVEST OPHTH VIS SCI, V41, P1017
   Colton T, 1974, STAT MED
   Detels R, 1997, OXFORD TXB PUBLIC HL
   DRANCE SM, 1989, GLAUCOMAS, P403
   ESER E, 1999, QUAL LIFE RES, V87, P647
   Globe D, 2003, INVEST OPHTH VIS SCI, V44, P1470, DOI 10.1167/iovs.02-0292
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P733, DOI 10.1001/archopht.119.5.733
   Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152
   Lee JE, 2003, OPHTHALMIC EPIDEMIOL, V10, P177, DOI 10.1076/opep.10.3.177.15084
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2004, AM J OPHTHALMOL, V137, P961, DOI 10.1016/j.ajo.2003.11.018
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Nordmann JP, 2004, PHARMACOECONOMICS, V22, P197, DOI 10.2165/00019053-200422030-00005
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   PORTNEY LG, 1993, FDN CLIN RES
   Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Sharma Sanjay, 2004, Curr Opin Ophthalmol, V15, P227, DOI 10.1097/01.icu.0000124082.88389.cf
   Stein Joshua D, 2004, Curr Opin Ophthalmol, V15, P238, DOI 10.1097/01.icu.0000120712.35941.ad
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
NR 38
TC 67
Z9 68
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD AUG
PY 2005
VL 12
IS 4
BP 259
EP 269
DI 10.1080/09286580590967763
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 951ZY
UT WOS:000230972100006
PM 16033747
DA 2022-11-30
ER

PT J
AU Rosenblatt, TR
   Rayess, N
   Al-Moujahed, A
   Khurana, RN
   Mruthyunjaya, P
AF Rosenblatt, Tatiana R.
   Rayess, Nadim
   Al-Moujahed, Ahmad
   Khurana, Rahul N.
   Mruthyunjaya, Prithvi
TI Discontinuation and loss to follow-up rates in clinical trials of
   intravitreal anti-vascular endothelial growth factor injections
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Loss to follow-up; Discontinuation rate; Clinical trial; Anti-vascular
   endothelial growth factor; Diabetic macular edema; Age-related macular
   degeneration; Retinal vein occlusion
ID RETINAL VEIN OCCLUSION; MACULAR DEGENERATION; RANIBIZUMAB; RETENTION
AB Purpose Clinical trials are often designed to include homogenous, highly specific patient populations with many resources to reduce patient dropout. Results may not translate to real-world settings. We evaluated discontinuation and loss to follow-up (LTFU) rates in clinical trials of anti-vascular endothelial growth factor (anti-VEGF) injections for diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO).
   Methods Retrospective meta-epidemiological study. The authors queried for all completed trials of anti-VEGF injections for DME, AMD, or RVO. Of 658 trials identified, 582 were excluded for being non-interventional, <100 patients, terminating early, or missing study results. The remaining 76 trials of 27,823 patients were analyzed for discontinuation and LTFU rates.
   Results Mean discontinuation rate was 12.44% (SD 8.12%, range 0-54.12%), with higher rates among control (18.87%) than treatment arms (10.78%, p = .006). Mean LTFU rate was 1.84% (SD 1.78%, range 0-7.76%), with no differences by disease, treatment type, or treatment frequency.
   Conclusion Discontinuation rates of major intravitreal anti-VEGF clinical trials were highly variable, suggesting even trials struggle with overall patient retention. Though trial LTFU rates were low, real-world outcomes may differ due to higher reported LTFU rates, which should be considered when extrapolating trial results to clinical practice.
C1 [Rosenblatt, Tatiana R.; Rayess, Nadim; Al-Moujahed, Ahmad; Mruthyunjaya, Prithvi] Stanford Sch Med, Dept Ophthalmol, Byers Eye Inst, Palo Alto, CA 94305 USA.
   [Khurana, Rahul N.] Calif Retina Vitreous Associates, Mountain View, CA USA.
C3 Stanford University
RP Mruthyunjaya, P (通讯作者)，Stanford Sch Med, Dept Ophthalmol, Byers Eye Inst, Palo Alto, CA 94305 USA.
EM prithvi9@stanford.edu
OI mruthyunjaya, prithvi/0000-0003-1087-9736; Khurana,
   Rahul/0000-0001-5198-1353
CR Abdelmotaal H, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7691724
   Angermann R, 2019, GRAEF ARCH CLIN EXP, V257, P2119, DOI 10.1007/s00417-019-04414-y
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Boyle Jessica, 2018, Psychol Health Med, V23, P127, DOI 10.1080/13548506.2016.1274040
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carter M., 2015, AGE RELATED MACULAR
   De La Huerta I, 2020, JAMA OPHTHALMOL, V138, P972, DOI 10.1001/jamaophthalmol.2020.2723
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Fudemberg SJ, 2016, PATIENT PREFER ADHER, V10, P19, DOI 10.2147/PPA.S89336
   Gao XX, 2019, OPHTHALMOL RETINA, V3, P230, DOI 10.1016/j.oret.2018.11.002
   Gao XX, 2019, OSLI RETINA, V50, P159, DOI 10.3928/23258160-20190301-05
   Kaur M, 2014, CAN J SURG, V57, P420, DOI 10.1503/cjs.006314
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Lewis Karinya, 2015, Community Eye Health, V28, P68
   Madden K, 2017, J BONE JOINT SURG AM, V99, P1086, DOI 10.2106/JBJS.16.00900
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   Mitchell P, 2014, AM J OPHTHALMOL, V157, P505, DOI 10.1016/j.ajo.2013.11.012
   Norvell DC, 2016, GLOB SPINE J, V6, P519, DOI 10.1055/s-0036-1584928
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Obeid A, 2019, OPHTHALMOLOGY, V126, P407, DOI 10.1016/j.ophtha.2018.07.027
   Obeid A, 2018, OPHTHALMOLOGY, V125, P1386, DOI 10.1016/j.ophtha.2018.02.034
   Payne JF, 2018, OPHTHALMOLOGY, V125, P1304, DOI 10.1016/j.ophtha.2018.03.046
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sellers CJ, 2015, CLIN TRIALS, V12, P62, DOI 10.1177/1740774514562031
   Suresh R, 2020, AM J OPHTHALMOL, V215, P66, DOI 10.1016/j.ajo.2020.03.011
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
   Wubben TJ, 2019, AM J OPHTHALMOL, V204, P13, DOI 10.1016/j.ajo.2019.03.005
   Zhou B, 2020, AM J OPHTHALMOL, V210, P86, DOI 10.1016/j.ajo.2019.10.012
NR 37
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2022
VL 260
IS 1
BP 93
EP 100
DI 10.1007/s00417-021-05246-5
EA AUG 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YI0WK
UT WOS:000686859000001
PM 34415363
DA 2022-11-30
ER

PT J
AU Watson, N
   Al-Samkari, H
AF Watson, Nathan
   Al-Samkari, Hanny
TI Thrombotic and bleeding risk of angiogenesis inhibitors in patients with
   and without malignancy
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Review
DE angiogenesis inhibitor; bleeding; cancer; hemorrhage; hereditary
   hemorrhagic telangiectasia; thrombosis
ID HEREDITARY HEMORRHAGIC TELANGIECTASIA; DIAGNOSED MULTIPLE-MYELOMA;
   ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; ARTERIAL
   THROMBOEMBOLIC EVENTS; RECEPTOR TYROSINE KINASES; CANCER-PATIENTS;
   MACULAR DEGENERATION; VENOUS THROMBOEMBOLISM; ANTIANGIOGENIC THERAPY
AB Over the past two decades, therapies targeting angiogenesis have developed into a major class of cancer therapeutics. The vascular endothelial growth factor (VEGF) family of signaling proteins, a group of potent angiogenic growth factors, and their receptors represent the main targets of this therapeutic class. To date, 16 antiangiogenic agents have been approved in the United States for the treatment of cancer and several more are in development. An important consideration with antiangiogenic therapy is toxicity, in particular thrombotic and bleeding risks. These complications have emerged as a major clinical concern that may affect the use of these agents in patients both with and without cancer who may already have an elevated risk of thrombosis and bleeding. Although these agents are frequently considered together as a class when contemplating their bleeding and thrombotic risks, in fact the risks for venous thromboembolism, arterial thrombosis, and bleeding vary significantly between different classes of antiangiogenic agents and even among different agents within a class. In this narrative review, we describe the literature investigating the venous and arterial thrombotic and bleeding risks associated with the currently available antiangiogenic drugs. In addition, we discuss these specific complications in the context of both cancer therapy as well as the management of nonmalignant disorders now managed with antiangiogenic agents, including hereditary hemorrhagic telangiectasia and neovascular age-related macular degeneration.
C1 [Watson, Nathan; Al-Samkari, Hanny] Harvard Med Sch, Boston, MA 02115 USA.
   [Al-Samkari, Hanny] Massachusetts Gen Hosp, Div Hematol, Suite 118,Room 112,Zero Emerson Pl, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Harvard University;
   Massachusetts General Hospital
RP Al-Samkari, H (通讯作者)，Massachusetts Gen Hosp, Div Hematol, Suite 118,Room 112,Zero Emerson Pl, Boston, MA 02114 USA.
EM hal-samkari@mgh.harvard.edu
OI Al-Samkari, Hanny/0000-0001-6175-1383; Watson,
   Nathan/0000-0001-5322-8058
FU Harvard KL2/Catalyst Medical Research Investigator Training Award;
   American Society of Hematology Scholar Award
FX H. Al-Samkari is the recipient of the Harvard KL2/Catalyst Medical
   Research Investigator Training Award and the American Society of
   Hematology Scholar Award.
CR Abdel-Rahman O, 2016, CRIT REV ONCOL HEMAT, V102, P89, DOI 10.1016/j.critrevonc.2016.04.003
   Ai Nana, 2018, Oncotarget, V9, P31958, DOI 10.18632/oncotarget.24110
   Al-Samkari H, 2019, J INTERN MED, V285, P223, DOI 10.1111/joim.12832
   Al-Samkari H, 2020, HAEMATOLOGICA, DOI 10.3324/haematol.2020.261859
   Al-Samkari H, 2021, BLOOD, V137, P888, DOI 10.1182/blood.2020008739
   Al-Samkari H, 2020, HAEMOPHILIA, V26, P1038, DOI 10.1111/hae.14034
   Al-Samkari H, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1239-6
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Bair SM, 2013, TRENDS CARDIOVAS MED, V23, P104, DOI 10.1016/j.tcm.2012.09.008
   Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583
   Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492
   Ben-Aharon I, 2014, ACTA ONCOL, V53, P1230, DOI 10.3109/0284186X.2014.934397
   Bossler AD, 2006, HUM MUTAT, V27, P667, DOI 10.1002/humu.20342
   Buscarini E, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-018-0982-4
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carrier M, 2011, J THROMB HAEMOST, V9, P653, DOI 10.1111/j.1538-7836.2011.04215.x
   Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757
   Cortes JE, 2018, BLOOD, V132, P393, DOI 10.1182/blood-2016-09-739086
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Di Nisio M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008500.pub4
   Dupuis-Girod S, 2012, JAMA-J AM MED ASSOC, V307, P948, DOI 10.1001/jama.2012.250
   El Accaoui RN, 2007, THROMB HAEMOSTASIS, V97, P1031, DOI 10.1160/TH06-09-0494
   Elice F, 2008, AM J HEMATOL, V83, P862, DOI 10.1002/ajh.21277
   Epperla N, 2016, AM J HEMATOL, V91, pE313, DOI 10.1002/ajh.24367
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Faughnan ME, 2020, ANN INTERN MED, V173, P989, DOI 10.7326/M20-1443
   Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Goz M, 2008, J THROMB THROMBOLYS, V25, P224, DOI 10.1007/s11239-007-0057-1
   Guilhem A., 2017, PLOS ONE, V12, P1
   Hang XF, 2011, EUR J CLIN PHARMACOL, V67, P613, DOI 10.1007/s00228-010-0988-x
   Hapani S, 2010, ONCOLOGY-BASEL, V79, P27, DOI 10.1159/000314980
   Hulin C, 2009, J CLIN ONCOL, V27, P3664, DOI 10.1200/JCO.2008.21.0948
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Invernizzi R, 2015, LANCET HAEMATOL, V2, pE465, DOI 10.1016/S2352-3026(15)00195-7
   Iyer VN, 2018, MAYO CLIN PROC, V93, P155, DOI 10.1016/j.mayocp.2017.11.013
   Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0
   Je YJ, 2009, LANCET ONCOL, V10, P967, DOI 10.1016/S1470-2045(09)70222-0
   Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3706, DOI 10.1200/JCO.2005.00.232
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kanukula R, 2019, AM J THER, V26, pE549, DOI 10.1097/MJT.0000000000000805
   Keating GM, 2014, DRUGS, V74, P1891, DOI 10.1007/s40265-014-0302-9
   Key NS, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01461
   Knight R, 2006, NEW ENGL J MED, V354, P2079
   Kristinsson SY, 2010, HEMATOL-AM SOC HEMAT, P437, DOI 10.1182/asheducation-2010.1.437
   Kritharis A, 2018, HAEMATOLOGICA, V103, P1433, DOI 10.3324/haematol.2018.193003
   Lacy MQ, 2009, J CLIN ONCOL, V27, P5008, DOI 10.1200/JCO.2009.23.6802
   Latifi Y, 2019, BLOOD, V133, P1597, DOI 10.1182/blood-2018-10-881557
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin ZX, 2016, EUR J PHARMACOL, V793, P76, DOI 10.1016/j.ejphar.2016.10.039
   Liu B, 2017, CANCER CHEMOTH PHARM, V80, P487, DOI 10.1007/s00280-017-3386-6
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Maloney MH, 2021, OPHTHALMOLOGY, V128, P417, DOI 10.1016/j.ophtha.2020.07.062
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer T, 2009, J THROMB HAEMOST, V7, P171, DOI 10.1111/j.1538-7836.2008.03212.x
   Michels S, 2006, BRIT J OPHTHALMOL, V90, P1333, DOI 10.1136/bjo.2006.102293
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitsuhashi A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9792
   Motzer RJ, 2017, ONCOLOGIST, V22, P41, DOI 10.1634/theoncologist.2016-0197
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Pallis AG, 2013, CRIT REV ONCOL HEMAT, V86, P130, DOI 10.1016/j.critrevonc.2012.10.003
   Palumbo A, 2008, LEUKEMIA, V22, P414, DOI 10.1038/sj.leu.2405062
   Palumbo A, 2011, J CLIN ONCOL, V29, P986, DOI 10.1200/JCO.2010.31.6844
   Patel SH., 2020, CANCER, V127, P1
   Peng L, 2014, TUMOR BIOL, V35, P9419, DOI 10.1007/s13277-014-2189-1
   Qi WX, 2013, INT J CANCER, V132, P2967, DOI 10.1002/ijc.27979
   Qin S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0718-5
   Rajabi M, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020034
   Rajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200/JCO.2005.03.0221
   Rajkumar SV, 2000, CANCER TREAT REV, V26, P351, DOI 10.1053/ctrv.2000.0188
   Ramlau R, 2012, J CLIN ONCOL, V30, P3640, DOI 10.1200/JCO.2012.42.6932
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996
   Miguel JS, 2013, LANCET ONCOL, V14, P1055, DOI 10.1016/S1470-2045(13)70380-2
   Scarpace SL, 2005, LEUKEMIA LYMPHOMA, V46, P239, DOI 10.1080/10428190400015675
   Schey SA, 2004, J CLIN ONCOL, V22, P3269, DOI 10.1200/JCO.2004.10.052
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Sultana J, 2020, DRUG SAFETY, V43, P943, DOI 10.1007/s40264-020-00956-x
   Thompson AB, 2014, ALLERGY RHINOL, V5, pE91, DOI 10.2500/ar.2014.5.0091
   Totzeck M, 2018, EUR J PREV CARDIOL, V25, P482, DOI 10.1177/2047487318755193
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   van Heeckeren WJ, 2007, CURR OPIN HEMATOL, V14, P468, DOI 10.1097/MOH.0b013e3282a6457f
   van Marion AMW, 2008, LEUKEMIA RES, V32, P1078, DOI 10.1016/j.leukres.2007.12.002
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Wu MD., 2020, ARTERIOSCL THROM VAS, P3
   Xiao BK, 2018, ONCOTARGETS THER, V11, P5059, DOI 10.2147/OTT.S166151
   Yunus M, 2019, BBA-GEN SUBJECTS, V1863, P1217, DOI 10.1016/j.bbagen.2019.04.017
   Zangari M, 2009, J CLIN ONCOL, V27, P4865, DOI 10.1200/JCO.2009.22.3875
   Zarbin MA, 2018, OPHTHALMOL RETINA, V2, P1087, DOI 10.1016/j.oret.2018.04.018
   Zervas K, 2004, ANN ONCOL, V15, P134, DOI 10.1093/annonc/mdh026
   Zhao YJ, 2015, ONCOLOGIST, V20, P660, DOI 10.1634/theoncologist.2014-0465
   Zonder JA, 2006, BLOOD, V108, P403, DOI 10.1182/blood-2006-01-0154
NR 99
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD AUG
PY 2021
VL 19
IS 8
BP 1852
EP 1863
DI 10.1111/jth.15354
EA MAY 2021
PG 12
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA TR6IE
UT WOS:000652736200001
PM 33928747
DA 2022-11-30
ER

PT J
AU Sreekumar, PG
   Ferrington, DA
   Kannan, R
AF Sreekumar, Parameswaran G.
   Ferrington, Deborah A.
   Kannan, Ram
TI Glutathione Metabolism and the Novel Role of Mitochondrial GSH in
   Retinal Degeneration
SO ANTIOXIDANTS
LA English
DT Review
DE retinal degeneration; mitochondrial GSH; RPE; bioenergetics
ID PIGMENT EPITHELIAL-CELLS; OXIDANT-INDUCED APOPTOSIS; PRIMARY-OPEN-ANGLE;
   OXIDATIVE STRESS; 2-OXOGLUTARATE CARRIER; MESENCHYMAL TRANSITION;
   ENDOPLASMIC-RETICULUM; MACULAR DEGENERATION; PYRUVATE UPTAKE; LEVELS
   OCCURS
AB Glutathione (GSH) is present ubiquitously, and its role as a crucial cellular antioxidant in tissues, including the retina, is well established. GSH's antioxidant function arises from its ability to scavenge reactive oxygen species or to serve as an essential cofactor for GSH S-transferases and peroxidases. This review summarizes the general functions, retinal distribution, disorders linked to GSH deficiency, and the emerging role for mitochondrial GSH (mGSH) in retinal function. Though synthesized only in the cytosol, the presence of GSH in multiple cell organelles suggests the requirement for its active transport across organellar membranes. The localization and distribution of 2-oxoglutarate carrier (OGC) and dicarboxylate carrier (DIC), two recently characterized mitochondrial carrier proteins in RPE and retina, show that these transporters are highly expressed in human retinal pigment epithelium (RPE) cells and retinal layers, and their expression increases with RPE polarity in cultured cells. Depletion of mGSH levels via inhibition of the two transporters resulted in reduced mitochondrial bioenergetic parameters (basal respiration, ATP production, maximal respiration, and spare respiratory capacity) and increased RPE cell death. These results begin to reveal a critical role for mGSH in maintaining RPE bioenergetics and cell health. Thus, augmentation of mGSH pool under GSH-deficient conditions may be a valuable tool in treating retinal disorders, such as age-related macular degeneration and optic neuropathies, whose pathologies have been associated with mitochondrial dysfunction.
C1 [Sreekumar, Parameswaran G.; Kannan, Ram] Doheny Eye Inst, Stephen J Ryan Initiat Macular Res RIMR, Los Angeles, CA 90033 USA.
   [Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Ferrington, Deborah A.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
   [Kannan, Ram] Univ Calif Los Angeles, Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of Minnesota System; University of
   Minnesota Twin Cities; University of Minnesota System; University of
   Minnesota Twin Cities; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Kannan, R (通讯作者)，Doheny Eye Inst, Stephen J Ryan Initiat Macular Res RIMR, Los Angeles, CA 90033 USA.; Kannan, R (通讯作者)，Univ Calif Los Angeles, Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
EM sparameswaran@doheny.org; ferri013@umn.edu; rkannan@doheny.org
OI Ferrington, Deborah/0000-0003-2561-7464; /0000-0002-9425-3986
FU National Institutes of Health [R01 EY30141]; Ryan Initiative for Macular
   Research (RIMR); NIH [R01 EY026012, R01 EY028554]; Elaine and Robert
   Larson Endowed Vision Research Chair; Lindsay Family Foundation
FX This work was supported by the National Institutes of Health (grant
   number R01 EY30141 (RK)), the Ryan Initiative for Macular Research
   (RIMR), and a gift from KECK Foundation to Doheny Eye Institute. DAF was
   supported by the NIH (R01 EY026012 and R01 EY028554), the Elaine and
   Robert Larson Endowed Vision Research Chair, the Lindsay Family
   Foundation, and an anonymous benefactor for AMD research.
CR Alhasani RH, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090367
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   Aquilano K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00196
   Bachhawat AK, 2013, BBA-GEN SUBJECTS, V1830, P3154, DOI 10.1016/j.bbagen.2012.11.018
   Bachhawat AK, 2018, IUBMB LIFE, V70, P585, DOI 10.1002/iub.1756
   Ballatori N, 2009, MOL ASPECTS MED, V30, P13, DOI 10.1016/j.mam.2008.08.004
   Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bharathselvi M, 2016, INDIAN J MED RES, V143, P756, DOI 10.4103/0971-5916.192026
   Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024
   Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Cacciatore I, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/240146
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Calabrese G, 2017, ANTIOXID REDOX SIGN, V27, P1162, DOI 10.1089/ars.2017.7121
   Carter-Dawson L, 2004, NEUROSCI LETT, V364, P7, DOI 10.1016/j.neulet.2004.03.082
   Chen G, 2011, ANTIOXID REDOX SIGN, V15, P2911, DOI 10.1089/ars.2011.4170
   Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608
   Chen ZF, 2000, ARCH BIOCHEM BIOPHYS, V373, P193, DOI 10.1006/abbi.1999.1527
   Cheng ZY, 2013, ANTIOXID REDOX SIGN, V19, P240, DOI 10.1089/ars.2013.5255
   Cole SPC, 2006, TRENDS PHARMACOL SCI, V27, P438, DOI 10.1016/j.tips.2006.06.008
   Coll O, 2003, HEPATOLOGY, V38, P692, DOI 10.1053/jhep.2003.50351
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Crawford RR, 2015, J BIOL CHEM, V290, P15878, DOI 10.1074/jbc.M114.635144
   Cummings BS, 2000, BIOCHEM BIOPH RES CO, V276, P940, DOI 10.1006/bbrc.2000.3572
   Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930
   de Bilbao F, 2004, J NEUROCHEM, V89, P1283, DOI 10.1111/j.1471-4159.2004.02432.x
   Delic M, 2010, FEMS MICROBIOL LETT, V306, P61, DOI 10.1111/j.1574-6968.2010.01935.x
   Deponte M, 2017, ANTIOXID REDOX SIGN, V27, P1130, DOI 10.1089/ars.2017.7123
   Vivancos PD, 2010, BIOCHEM J, V431, P169, DOI 10.1042/BJ20100409
   Dolce V, 2014, IUBMB LIFE, V66, P462, DOI 10.1002/iub.1290
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Floreani M, 2005, FEBS J, V272, P1124, DOI 10.1111/j.1742-4658.2004.04542.x
   Franco R, 2012, ANTIOXID REDOX SIGN, V17, P1694, DOI 10.1089/ars.2012.4553
   Franklin CC, 2009, MOL ASPECTS MED, V30, P86, DOI 10.1016/j.mam.2008.08.009
   Ghelli A, 2008, INVEST OPHTH VIS SCI, V49, P671, DOI 10.1167/iovs.07-0880
   Gherghel D, 2005, INVEST OPHTH VIS SCI, V46, P877, DOI 10.1167/iovs.04-0777
   Gherghel D, 2013, INVEST OPHTH VIS SCI, V54, P3333, DOI 10.1167/iovs.12-11256
   Grenell A, 2019, P NATL ACAD SCI USA, V116, P3530, DOI 10.1073/pnas.1812941116
   GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668
   Guo XX, 2018, NEUROBIOL DIS, V113, P59, DOI 10.1016/j.nbd.2018.02.004
   Gutierrez-Aguilar M, 2013, BIOCHEM J, V454, P371, DOI 10.1042/BJ20121753
   Hamza I, 2006, ACS CHEM BIOL, V1, P627, DOI 10.1021/cb600442b
   Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967
   Herzig S, 2012, SCIENCE, V337, P93, DOI 10.1126/science.1218530
   HSU SC, 1994, J BIOL CHEM, V269, P17954
   Huster D, 1998, ANAT EMBRYOL, V198, P277, DOI 10.1007/s004290050184
   Hyttinen JMT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225800
   Ikeda M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119687
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jiang S, 2002, INVEST OPHTH VIS SCI, V43, P2546
   Joyal JS, 2018, PROG RETIN EYE RES, V64, P131, DOI 10.1016/j.preteyeres.2017.11.002
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   Kularatne RN, 2020, FREE RADICAL BIO MED, V152, P386, DOI 10.1016/j.freeradbiomed.2020.03.024
   Kumar C, 2011, EMBO J, V30, P2044, DOI 10.1038/emboj.2011.105
   Kwon DH, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090413
   LASH LH, 1983, BIOCHEM BIOPH RES CO, V112, P55, DOI 10.1016/0006-291X(83)91796-5
   Lee JS, 2019, EBIOMEDICINE, V40, P184, DOI 10.1016/j.ebiom.2019.01.036
   Lee JJ, 2020, BIOCHEM BIOPH RES CO, V521, P414, DOI 10.1016/j.bbrc.2019.10.138
   Lee SY, 2011, J CELL PHYSIOL, V226, P1843, DOI 10.1002/jcp.22508
   Liu RM, 2010, FREE RADICAL BIO MED, V48, P1, DOI 10.1016/j.freeradbiomed.2009.09.026
   Lu SC, 1999, INVEST OPHTH VIS SCI, V40, P1776
   Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008
   Lutchmansingh FK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198626
   Mamuya FA, 2014, J CELL MOL MED, V18, P656, DOI 10.1111/jcmm.12213
   Marc RE, 2008, MOL VIS, V14, P782
   Mari M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100909
   Mari M, 2013, BBA-GEN SUBJECTS, V1830, P3317, DOI 10.1016/j.bbagen.2012.10.018
   Matsunaga D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165150
   McConnachie LA, 2007, TOXICOL SCI, V99, P628, DOI 10.1093/toxsci/kfm165
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizuarai S, 2005, J BIOL CHEM, V280, P32434, DOI 10.1074/jbc.M503152200
   Odegaard ML, 2010, J BIOL CHEM, V285, P16530, DOI 10.1074/jbc.M109.092593
   Perricone C, 2009, AUTOIMMUN REV, V8, P697, DOI 10.1016/j.autrev.2009.02.020
   Porosk R, 2017, MOL MED REP, V16, P7092, DOI 10.3892/mmr.2017.7419
   Priglinger CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146887
   Qin L, 2014, GRAEF ARCH CLIN EXP, V252, P23, DOI 10.1007/s00417-013-2418-0
   Raimundo N, 2014, TRENDS MOL MED, V20, P282, DOI 10.1016/j.molmed.2014.01.005
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Ribas V, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00151
   Roh YJ, 2007, NEUROSCI LETT, V417, P266, DOI 10.1016/j.neulet.2007.02.088
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Schutte M, 1998, NEUROSCI LETT, V246, P53, DOI 10.1016/S0304-3940(98)00229-8
   Sharma A, 2018, THERANOSTICS, V8, P5529, DOI 10.7150/thno.29039
   Silva KC, 2009, DIABETES, V58, P1382, DOI 10.2337/db09-0166
   Sinha R, 2018, EUR J CLIN NUTR, V72, P105, DOI 10.1038/ejcn.2017.132
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050411
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Sun F, 2013, CURR OPIN STRUC BIOL, V23, P526, DOI 10.1016/j.sbi.2013.06.013
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tatsuta T, 2014, TRENDS CELL BIOL, V24, P44, DOI 10.1016/j.tcb.2013.07.011
   Terluk MR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5174957
   Thomas NO, 2019, REDOX BIOL, V22, DOI 10.1016/j.redox.2019.101155
   Tompkins SC, 2019, CELL REP, V28, P2608, DOI 10.1016/j.celrep.2019.07.098
   Torres S, 2017, REDOX BIOL, V11, P60, DOI 10.1016/j.redox.2016.11.010
   Tosi GM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020600
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Trachsel-Moncho L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0855-8
   Van Luyn MJA, 1998, INT J CANCER, V76, P55, DOI 10.1002/(SICI)1097-0215(19980330)76:1<55::AID-IJC10>3.0.CO;2-F
   Venditti P, 2013, MITOCHONDRION, V13, P71, DOI 10.1016/j.mito.2013.01.008
   Wang M, 2019, INVEST OPHTH VIS SCI, V60, P500, DOI 10.1167/iovs.18-25686
   Wei ZB, 2017, AM J PATHOL, V187, P2399, DOI 10.1016/j.ajpath.2017.07.018
   Wiley SE, 2013, EMBO MOL MED, V5, P904, DOI 10.1002/emmm.201201429
   Wilkins HM, 2014, J NEUROCHEM, V130, P75, DOI 10.1111/jnc.12709
   Wilkins HM, 2012, FREE RADICAL BIO MED, V52, P410, DOI 10.1016/j.freeradbiomed.2011.10.495
   Xu ZH, 2014, DIABETOLOGIA, V57, P204, DOI 10.1007/s00125-013-3093-8
   Yabana T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0227078
   Yuan LY, 2009, MOL ASPECTS MED, V30, P29, DOI 10.1016/j.mam.2008.08.003
   Zhang JX, 2018, FREE RADICAL RES, V52, P1432, DOI 10.1080/10715762.2018.1500020
   Zhong Q, 2008, ARCH BIOCHEM BIOPHYS, V474, P119, DOI 10.1016/j.abb.2008.03.008
   Zhou JZ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20194347
   Zhou XS, 2015, ONCOTARGET, V6, P9271, DOI 10.18632/oncotarget.3375
NR 117
TC 18
Z9 18
U1 8
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD MAY
PY 2021
VL 10
IS 5
AR 661
DI 10.3390/antiox10050661
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA SG4BP
UT WOS:000653385400001
PM 33923192
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sorensen, NB
   Christiansen, AT
   Kjaer, TW
   Klemp, K
   la Cour, M
   Heegaard, S
   Kiilgaard, JF
AF Sorensen, Nina Buus
   Christiansen, Anders Tolstrup
   Kjaer, Troels Wesenberg
   Klemp, Kristian
   la Cour, Morten
   Heegaard, Steffen
   Kiilgaard, Jens Folke
TI Bruch's membrane allows unhindered passage of up to 2 mu m latex beads
   in an in vivo porcine model
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Drusen; Subretinal space; Subretinal surgery; Subretinal
   transplantation; Stem-cell transplantation; RPE transplantation; Aging
ID RETINAL-PIGMENT EPITHELIUM; ROD OUTER SEGMENTS; PHAGOCYTOSIS; TRANSPORT;
   IDENTIFICATION; PATHOGENESIS; MECHANISMS; DIFFUSION; RECEPTOR; BINDING
AB Purpose: It has been proposed that changes in the permeability of Bruch's membrane play a role in the pathogenesis of age-related macular degeneration (AMD). This paper investigates, in an in vivo porcine model, the migration of fluorescent latex beads across the Bruch's membrane after subretinal injection.
   Methods: Forty-one healthy eyes of 33 three-month-old domestic pigs received a subretinal injection of 0.5, 1.0, 2.0, or 4.0 mu m fluorescent latex beads. Between three hours and five weeks after injection evaluations were performed with fundus photographs and histology. Fluorescent beads were identified in unstained histologic sections using the rhodamine filter with the light microscope.
   Results: The fluorescent latex beads relocated from the subretinal space. Intact beads up to 2.0 mu m were found in the choroid, sclera, and extrascleral space. The smaller beads were also found inside choroidal and extrascleral blood vessels. In contrast, the larger beads of 4.0 mu m did not pass the Bruch's membrane.
   Conclusion: Subretinally implanted beads up to 2.0 mu m pass the Bruch's membrane intact and cross the blood-ocular barrier. The intact beads are found in the choroid, sclera and inside blood vessels. The results give reason to consider the role of subretinal clearance and passage of Bruch's membrane in the development of AMD.
C1 [Sorensen, Nina Buus; Christiansen, Anders Tolstrup; Klemp, Kristian; Heegaard, Steffen; Kiilgaard, Jens Folke] Copenhagen Univ Hosp, Rigshosp, Dept Ophthalmol, Copenhagen, Denmark.
   [Kjaer, Troels Wesenberg] Zealand Univ Hosp, Dept Neurol, Roskilde, Denmark.
   [la Cour, Morten] Copenhagen Univ Hosp, Rigshosp, Dept Ophthalmol, Glostrup, Denmark.
   [Heegaard, Steffen] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Rigshospitalet; University of
   Copenhagen; Rigshospitalet; University of Copenhagen
RP Sorensen, NB (通讯作者)，Copenhagen Univ Hosp, Rigshosp, Dept Ophthalmol, Copenhagen, Denmark.
EM nina.buus.soerensen@regionh.dk
RI Kiilgaard, Jens Folke/H-3943-2019; la Cour, Morten/L-1600-2013
OI Kiilgaard, Jens Folke/0000-0003-1054-1460; 
FU Candys Foundation; Fight for Sight Denmark
FX This work was funded by Candys Foundation and Fight for Sight Denmark.
CR Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   BOK D, 1993, J CELL SCI, P189
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   Chang YG, 2007, J CELL SCI, V120, P3053, DOI 10.1242/jcs.006361
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718
   Finnemann SC, 2006, ADV EXP MED BIOL, V572, P499
   FRAMBACH DA, 1982, INVEST OPHTH VIS SCI, V22, P292
   Hall MO, 1996, EXP EYE RES, V63, P255, DOI 10.1006/exer.1996.0114
   Hamann S, 2002, INT REV CYTOL, V215, P395
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kolko M, 2007, INVEST OPHTH VIS SCI, V48, P1401, DOI 10.1167/iovs.06-0865
   Lassota N, 2007, GRAEF ARCH CLIN EXP, V245, P1189, DOI 10.1007/s00417-006-0518-9
   Lee Y, 2015, INVEST OPHTH VIS SCI, V56, P8403, DOI 10.1167/iovs.15-16936
   Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703
   MARMOR MF, 1988, GRAEF ARCH CLIN EXP, V226, P548, DOI 10.1007/BF02169203
   MARMOR MF, 1979, INVEST OPHTH VIS SCI, V18, P1237
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P893
   MILLER SS, 1977, J MEMBRANE BIOL, V36, P337, DOI 10.1007/BF01868158
   MILLER SS, 1977, EXP EYE RES, V25, P235, DOI 10.1016/0014-4835(77)90090-2
   MIYAMOTO Y, 1994, INVEST OPHTH VIS SCI, V35, P3589
   NEGI A, 1986, INVEST OPHTH VIS SCI, V27, P1564
   PAUTLER EL, 1986, EXP EYE RES, V43, P207, DOI 10.1016/S0014-4835(86)80088-4
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Sorensen NB, 2013, GRAEF ARCH CLIN EXP, V251, P2319, DOI 10.1007/s00417-013-2331-6
   Sorensen NF, 2012, GRAEF ARCH CLIN EXP, V250, P79, DOI 10.1007/s00417-011-1782-x
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stalmans P, 1997, INVEST OPHTH VIS SCI, V38, P1598
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   TARNOWSKI BI, 1988, INVEST OPHTH VIS SCI, V29, P291
   Tratta E, 2014, EUR J PHARM BIOPHARM, V88, P116, DOI 10.1016/j.ejpb.2014.04.018
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zayas-Santiago A, 2011, INVEST OPHTH VIS SCI, V52, P4907, DOI 10.1167/iovs.10-6595
NR 41
TC 1
Z9 1
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2019
VL 180
BP 1
EP 7
DI 10.1016/j.exer.2018.11.019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HN7KO
UT WOS:000460368500001
PM 30468719
OA hybrid
DA 2022-11-30
ER

PT J
AU Girish, GN
   Thakur, B
   Chowdhury, SR
   Kothari, AR
   Rajan, J
AF Girish, G. N.
   Thakur, Bibhash
   Chowdhury, Sohini Roy
   Kothari, Abhishek R.
   Rajan, Jeny
TI Segmentation of Intra-Retinal Cysts From Optical Coherence Tomography
   Images Using a Fully Convolutional Neural Network Model
SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
LA English
DT Article
DE Optical coherence tomography; segmentation; retinal cyst; cystoid
   macular edema; convolutional neural networks; deep learning
ID MACULAR EDEMA
AB Optical coherence tomography (OCT) is an imaging modality that is used extensively for ophthalmic diagnosis, near-histological visualization, and quantification of retinal abnormalities such as cysts, exudates, retinal layer disorganization, etc. Intra-retinal cysts (IRCs) occur in several macular disorders such as, diabetic macular edema, retinal vascular disorders, age-related macular degeneration, and inflammatory disorders. Automated segmentation of IRCs poses challenges owing to variations in the acquisition system scan intensities, speckle noise, and imaging artifacts. Several segmentation methods have been proposed in the literature for IRC segmentation on vendor-specific OCT images that lack generalizability across imaging systems. In this paper, we propose a fully convolutional network (FCN) model for vendor-independent IRC segmentation. The proposed method counteracts image noise variabilities and trains FCN models on OCT sub-images from the OPTIMA cyst segmentation challenge dataset (with four different vendor-specific images, namely, Cirrus, Nidek, Spectralis, and Topcon). Further, optimal data augmentation and model hyperparametrization are shown to prevent over-fitting for IRC area segmentation. The proposed method is evaluated on the test dataset with a recall/precision rate of 0.66/0.79 across imaging vendors. The Dice correlation coefficient of the proposed method outperforms that of the published algorithms in the OPTIMA cyst segmentation challenge with a Dice rate of 0.71 across the vendors.
C1 [Girish, G. N.; Thakur, Bibhash; Rajan, Jeny] Natl Inst Technol Karnataka, Dept Comp Sci & Engn, Surathkal 575025, India.
   [Chowdhury, Sohini Roy] Univ Washington, Dept Elect & Comp Engn, Bothell, WA 98011 USA.
   [Kothari, Abhishek R.] Pink City Eye & Retina Ctr, Jaipur 302015, Rajasthan, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Karnataka; University of Washington; University of Washington
   Bothell
RP Girish, GN (通讯作者)，Natl Inst Technol Karnataka, Dept Comp Sci & Engn, Surathkal 575025, India.
EM girishanit@gmail.com; bibhashthakur92@gmail.com; roych@uw.edu;
   dr.a.kothari@gmail.com; jenyrajan@gmail.com
RI Rajan, Jeny/G-9484-2011; N, Girish G/AAL-7597-2020
OI Rajan, Jeny/0000-0001-8045-6005; N, Girish G/0000-0003-2101-2388;
   Thakur, Bibhash/0000-0002-2934-6457
FU Science and Engineering Research Board (Department of Science and
   Technology, India) [EMR/2016/002677]
FX This work was supported by the Science and Engineering Research Board
   (Department of Science and Technology, India) under Project
   EMR/2016/002677.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   [Anonymous], 2015, OPTIMA CYST SEGMENTA
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chollet F., 2015, KERAS
   de Sisternes L., 2015, MACHINE LEARNING APP
   DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409
   Esmaeili Mahdad, 2016, J Med Signals Sens, V6, P166
   Froment J, 2014, IMAGE PROCESS ON LIN, V4, P300, DOI 10.5201/ipol.2014.120
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Girish GN, 2018, COMPUT METH PROG BIO, V153, P105, DOI 10.1016/j.cmpb.2017.10.010
   Girish GN, 2016, IEEE ENG MED BIO, P1292, DOI 10.1109/EMBC.2016.7590943
   Girish GN, 2017, PATTERN RECOGNIT LET
   Gonzalez A, 2013, COMP MED SY, P397, DOI 10.1109/CBMS.2013.6627825
   Gopinath K., 2015, DOMAIN KNOWLEDGE ASS
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   He KM, 2015, IEEE I CONF COMP VIS, P1026, DOI 10.1109/ICCV.2015.123
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ioffe S, 2015, PR MACH LEARN RES, V37, P448
   IRVINE SR, 1953, AM J OPHTHALMOL, V36, P599, DOI 10.1016/0002-9394(53)90302-X
   Kamnitsas K., 2015, ISCHEMIC STROKE LESI, V13, P46, DOI DOI 10.1016/J.MEDIA.2016.10.004
   Kohavi R., 1995, P INT JOINT C ARTIFI, VVolume 2, P1137
   Lang A, 2015, BIOMED OPT EXPRESS, V6, P155, DOI 10.1364/BOE.6.000155
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Luo WJ, 2016, ADV NEUR IN, V29
   Milletari F, 2016, INT CONF 3D VISION, P565, DOI 10.1109/3DV.2016.79
   Oguz I, 2016, PROC SPIE, V9784, DOI 10.1117/12.2217355
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rashno A, 2018, IEEE T BIO-MED ENG, V65, P989, DOI 10.1109/TBME.2017.2734058
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Sudeep PV, 2016, BIOMED SIGNAL PROCES, V28, P1, DOI 10.1016/j.bspc.2016.03.001
   Sudeep PV, 2016, COMPUT BIOL MED, V71, P97, DOI 10.1016/j.compbiomed.2016.02.003
   Swingle E. K., 2014, P SPIE INT SOC OPT P, V9038
   Swingle E. K., 2015, P SPIE INT SOC OPT P, V9417
   Venhuizen CCHF, 2016, ARVO ANN M, V57, P5949
   Wieclawek W, 2015, 2015 22ND INTERNATIONAL CONFERENCE MIXED DESIGN OF INTEGRATED CIRCUITS & SYSTEMS (MIXDES), P79, DOI 10.1109/MIXDES.2015.7208485
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Yu LQ, 2017, IEEE T MED IMAGING, V36, P994, DOI 10.1109/TMI.2016.2642839
   Zhang L, 2015, I S BIOMED IMAGING, P1494, DOI 10.1109/ISBI.2015.7164160
   Zuiderveld K., 1994, GRAPHICS GEMS, VIV, P474, DOI [10.1016/b978-0-12-336156-1.50061-6, DOI 10.1016/B978-0-12-336156-1.50061-6]
NR 42
TC 49
Z9 51
U1 2
U2 19
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2168-2194
EI 2168-2208
J9 IEEE J BIOMED HEALTH
JI IEEE J. Biomed. Health Inform.
PD JAN
PY 2019
VL 23
IS 1
BP 296
EP 304
DI 10.1109/JBHI.2018.2810379
PG 9
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Mathematical & Computational Biology;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematical & Computational Biology; Medical
   Informatics
GA HH4PM
UT WOS:000455704800031
PM 29994161
DA 2022-11-30
ER

PT J
AU Moine, E
   Brabet, P
   Guillou, L
   Durand, T
   Vercauteren, J
   Crauste, C
AF Moine, Esperance
   Brabet, Philippe
   Guillou, Laurent
   Durand, Thierry
   Vercauteren, Joseph
   Crauste, Celine
TI New Lipophenol Antioxidants Reduce Oxidative Damage in Retina Pigment
   Epithelial Cells
SO ANTIOXIDANTS
LA English
DT Article
DE AMD; oxidative stress; lipophenol; PUFA
ID POLYUNSATURATED FATTY-ACIDS; RPE LIPOFUSCIN; A2E; RESVERATROL;
   QUERCETIN; STRESS; MECHANISMS; ARPE-19; PHLOROGLUCINOL; CYTOTOXICITY
AB Age-related macular degeneration (AMD) is a multifactorial pathology and its progression is exacerbated by oxidative stress. Oxidation and photo-oxidation reactions modify lipids in retinal cells, contribute to tissue injury, and lead to the formation of toxic adducts. In particular, autofluorescent pigments such as N-retinylidene-N-retinylethanolamine (A2E) accumulate as lipofuscin in retinal pigment epithelial cells, contribute to the production of additional reactive oxygen species (ROS), and lead to cell degeneration. In an effort to develop efficient antioxidants to reduce damage caused by lipid oxidation, various natural polyphenols were structurally modified to increase their lipophilicity (lipophenols). In this study, resveratrol, phloroglucinol, quercetin and catechin were selected and conjugated to various polyunsaturated fatty acids (PUFAs) using classical chemical strategies or enzymatic reactions. After screening for cytotoxicity, the capacity of the synthesized lipophenols to reduce ROS production was evaluated in ARPE-19 cells subjected to H2O2 treatment using a dichlorofluorescein diacetate probe. The positions of the PUFA on the polyphenol core appear to influence the antioxidant effect. In addition, two lipophenolic quercetin derivatives were evaluated to highlight their potency in protecting ARPE-19 cells against A2E photo-oxidation toxicity. Quercetin conjugated to linoleic or alpha-linolenic acid were promising lipophilic antioxidants, as they protected ARPE-19 cells from A2E-induced cell death more effectively than the parent polyphenol, quercetin.
C1 [Moine, Esperance; Durand, Thierry; Vercauteren, Joseph; Crauste, Celine] Inst Biomol Max Mousseron, UMR 5247 CNRS UM ENSCM, Fac Pharm, 15 Av Charles Flahault, F-34093 Montpellier, France.
   [Brabet, Philippe; Guillou, Laurent] Hosp St Eloi, Inst Neurosci Montpellier, INSERM, U1051 UM, 80 Rue Augustin Fliche, F-34091 Montpellier, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Chemistry (INC); Ecole nationale superieure de chimie de Montpellier;
   Universite de Franche-Comte; Universite de Montpellier; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier; CHU de Montpellier
RP Crauste, C (通讯作者)，Inst Biomol Max Mousseron, UMR 5247 CNRS UM ENSCM, Fac Pharm, 15 Av Charles Flahault, F-34093 Montpellier, France.
EM esperance.moine@umontpellier.fr; philippe.brabet@inserm.fr;
   laurent.guillou@inserm.fr; thierry.durand@umontpellier.fr;
   joseph.vercauteren@umontpellier.fr; celine.crauste@umontpellier.fr
RI Brabet, Philippe/AAO-8522-2020; Vercauteren, Joseph/AAF-7151-2019
OI Brabet, Philippe/0000-0003-2739-1622; Vercauteren,
   Joseph/0000-0002-0201-1235; Moine, Esperance/0000-0002-4579-1323;
   Crauste, Celine/0000-0002-5714-8749
FU University of Montpellier; Fondation Stargardt; Fondation Retina France
FX This research was supported by University of Montpellier and Fondations
   Stargardt and Retina France.
CR de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156
   Balas L, 2016, PROG LIPID RES, V61, P1, DOI 10.1016/j.plipres.2015.10.002
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Carullo G, 2018, MOLBANK, DOI 10.3390/M1006
   Cia D, 2016, J CELL MOL MED, V20, P1651, DOI 10.1111/jcmm.12857
   Cialdella-Kam L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050277
   Conte R., 2016, J BIOMOL RES THER, V5, P1
   Crauste C, 2016, BIOCHIMIE, V120, P62, DOI 10.1016/j.biochi.2015.07.018
   Crauste C, 2014, EUR J ORG CHEM, V2014, P4548, DOI 10.1002/ejoc.201402282
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Feeney OM, 2016, ADV DRUG DELIVER REV, V101, P167, DOI 10.1016/j.addr.2016.04.007
   Fontaine V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167793
   Forman HJ, 2014, FREE RADICAL BIO MED, V66, P24, DOI 10.1016/j.freeradbiomed.2013.05.045
   Gatto MT, 2002, BIOORGAN MED CHEM, V10, P269, DOI 10.1016/S0968-0896(01)00275-9
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hiipakka RA, 2002, BIOCHEM PHARMACOL, V63, P1165, DOI 10.1016/S0006-2952(02)00848-1
   Hong S, 2016, FOOD CHEM, V197, P415, DOI 10.1016/j.foodchem.2015.10.134
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Jahn U, 2008, ANGEW CHEM INT EDIT, V47, P5894, DOI 10.1002/anie.200705122
   Jin GZ, 2005, BIOSCI BIOTECH BIOCH, V69, P440, DOI 10.1271/bbb.69.440
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Joshi D, 2013, J NAT PROD, V76, P450, DOI 10.1021/np300769c
   Kang JH, 2016, ARCH PHARM RES, V39, P1703, DOI 10.1007/s12272-016-0839-0
   Kang KA, 2006, J CELL BIOCHEM, V97, P609, DOI 10.1002/jcb.20668
   Kim J, 2018, FOOD FUNCT, V9, P2171, DOI 10.1039/c7fo01958k
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Lin SF, 2010, EUR J MED CHEM, V45, P6068, DOI 10.1016/j.ejmech.2010.10.011
   Liu AH, 2011, CLIN LIPIDOL, V6, P593, DOI 10.2217/CLP.11.41
   Mabry T. J., 1970, SYSTEMATIC IDENTIFIC, DOI 10.1016/0022-2860(71)87109-0
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Mainini F, 2013, J AM OIL CHEM SOC, V90, P1751, DOI 10.1007/s11746-013-2314-0
   Mbatia B, 2011, J AGR FOOD CHEM, V59, P7021, DOI 10.1021/jf200867r
   McKay TB, 2017, EXP BIOL MED, V242, P565, DOI 10.1177/1535370216685187
   Musialik M, 2009, J ORG CHEM, V74, P2699, DOI 10.1021/jo802716v
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Oh WY, 2018, FOOD CHEM, V261, P267, DOI 10.1016/j.foodchem.2018.03.085
   Oh WY, 2017, J AGR FOOD CHEM, V65, P8617, DOI 10.1021/acs.jafc.7b03129
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park KD, 2004, PLANTA MED, V70, P272, DOI 10.1055/s-2004-818923
   Park SI, 2017, J PHARM PHARMACOL, V69, P334, DOI 10.1111/jphp.12691
   Perera N., 2018, J FOOD BIOACT, V1, P124, DOI DOI 10.31665/JFB.2018.1131
   Pouton CW, 2000, EUR J PHARM SCI, V11, pS93, DOI 10.1016/S0928-0987(00)00167-6
   Semchyshyn HM, 2014, SCI WORLD J, DOI 10.1155/2014/417842
   Shamseddin A, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171712
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, METHODS MOL BIOL, V652, P315, DOI 10.1007/978-1-60327-325-1_18
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Treml J, 2016, COMPR REV FOOD SCI F, V15, P720, DOI 10.1111/1541-4337.12204
   Uesato S, 2003, CHEM PHARM BULL, V51, P1448, DOI 10.1248/cpb.51.1448
   Viskupicova J, 2017, J FOOD NUTR RES-SLOV, V56, P232
   Viskupicva J, 2008, J FOOD NUTR RES-SLOV, V47, P151
   Vlachogianni IC, 2015, FOOD CHEM, V177, P165, DOI 10.1016/j.foodchem.2014.12.092
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Wrona M, 2004, FREE RADICAL BIO MED, V36, P1094, DOI 10.1016/j.freeradbiomed.2004.02.005
   Xu YC, 2018, J AGR FOOD CHEM, V66, P7616, DOI 10.1021/acs.jafc.8b02739
   Yin HY, 2011, CHEM REV, V111, P5944, DOI 10.1021/cr200084z
   Zhong Y, 2011, J AGR FOOD CHEM, V59, P6526, DOI 10.1021/jf201050j
   Zhou JL, 2008, PHOTOCHEM PHOTOBIOL, V84, P75, DOI 10.1111/j.1751-1097.2007.00205.x
   Zhu Q, 2009, CHEM RES TOXICOL, V22, P1721, DOI 10.1021/tx900221s
   Ziaullah, 2013, BIOORGAN MED CHEM, V21, P684, DOI 10.1016/j.bmc.2012.11.034
NR 66
TC 20
Z9 20
U1 2
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD DEC
PY 2018
VL 7
IS 12
AR 197
DI 10.3390/antiox7120197
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA HG1JF
UT WOS:000454709200028
PM 30572579
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Dou, XZ
   Nath, D
   Shin, Y
   Ma, JX
   Duerfeldt, AS
AF Dou, Xiao-Zheng
   Nath, Dinesh
   Shin, Younghwa
   Ma, Jian-Xing
   Duerfeldt, Adam S.
TI Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype
   into PPAR alpha selective agonists: New leads for oculovascular
   conditions
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE PPAR alpha; Age-related macular degeneration; Diabetic retinopathy; PPAR
   selectivity; Structure-based design
ID PROLIFERATOR-ACTIVATED RECEPTOR; DIABETIC-RETINOPATHY; BIOLOGICAL
   EVALUATION; DISCOVERY; FENOFIBRATE; DESIGN; POTENT; MELLITUS; THERAPY
AB Small molecule agonism of PPAR alpha represents a promising new avenue for the development of non-invasive treatments for oculovascular diseases like diabetic retinopathy and age-related macular degeneration. Herein we report initial structure-activity relationships for the newly identified quinoline-based PPAR alpha agonist, Y-0452. Preliminary computational studies led to the hypothesis that carboxylic acid transposition and deconstruction of the Y-0452 quinoline system would enhance ligand-protein interactions and better complement the nature of the binding pocket. A focused subset of analogs was designed, synthesized, and assessed for PPAR alpha agonism. Two key observations arose from this work 1) contrary to other PPAR alpha agonists, incorporation of the fibrate "head-group" decreases PPAR alpha selectivity and instead provides pan-PPAR agonists and 2) computational models reveal a relatively unexploited amphiphilic pocket in PPAR alpha that provides new opportunities for the development of novel agonists. As an example, compound 10 exhibits more potent PPAR alpha agonism (EC50 = similar to 6 mu M) than Y-0452 (EC50 = similar to 50 mu M) and manifests >20-fold selectivity for PPAR alpha over the PPAR gamma and PPAR delta isoforms. More detailed biochemical analysis of 10 confirms typical downstream responses of PPAR alpha agonism including PPAR alpha upregulation, induction of target genes, and inhibition of cell migration. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Dou, Xiao-Zheng; Nath, Dinesh; Duerfeldt, Adam S.] Univ Oklahoma, Dept Chem & Biochem, Stephenson Life Sci Res Ctr, Norman, OK 73019 USA.
   [Shin, Younghwa; Ma, Jian-Xing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA.
C3 University of Oklahoma System; University of Oklahoma - Norman;
   University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RP Duerfeldt, AS (通讯作者)，Univ Oklahoma, Dept Chem & Biochem, Stephenson Life Sci Res Ctr, Norman, OK 73019 USA.
EM adam.duerfeldt@ou.edu
RI Nath, Dinesh/ABA-6814-2021; Nath, Dinesh/AAX-6000-2020
OI Nath, Dinesh/0000-0003-0286-3144
FU National Eye Institute of the National Institutes of Health
   [R21EY028279]; NATIONAL EYE INSTITUTE [R21EY028279] Funding Source: NIH
   RePORTER
FX Research reported in this publication was supported by the National Eye
   Institute of the National Institutes of Health under award number
   R21EY028279 (A.S.D.). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018
   Bernardes A, 2013, J MOL BIOL, V425, P2878, DOI 10.1016/j.jmb.2013.05.010
   Cai X, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3789217
   Capelli D, 2016, SCI REP-UK, V6, DOI 10.1038/srep34792
   Chen Y, 2013, DIABETES, V62, P261, DOI 10.2337/db11-0413
   Cheng R, 2016, DIABETES, V3730
   Cheung N, 2014, DIABETES CARE, V37, P900, DOI 10.2337/dc13-1990
   Deng GT, 2017, INVEST OPHTH VIS SCI, V58, P5030, DOI 10.1167/iovs.16-21402
   Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002
   Fruchart JC, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-82
   Gangwal RP, 2015, BIOORG MED CHEM LETT, V25, P270, DOI 10.1016/j.bmcl.2014.11.052
   Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282
   Gross B, 2007, BEST PRACT RES CL EN, V21, P687, DOI 10.1016/j.beem.2007.09.004
   Hu Y, 2013, P NATL ACAD SCI USA, V110, P15401, DOI 10.1073/pnas.1307211110
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Li J, 2010, J MED CHEM, V53, P2854, DOI 10.1021/jm9016812
   Lois N, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00044
   McMullen PD, 2014, CHEM-BIOL INTERACT, V209, P14, DOI 10.1016/j.cbi.2013.11.006
   Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0
   Mizuno CS, 2008, BIOORGAN MED CHEM, V16, P3800, DOI 10.1016/j.bmc.2008.01.051
   Moran E, 2014, INVEST OPHTH VIS SCI, V55, P4568, DOI 10.1167/iovs.13-13127
   Nentwich MM, 2015, WORLD J DIABETES, V6, P489, DOI 10.4239/wjd.v6.i3.489
   Nissen SE, 2007, JAMA-J AM MED ASSOC, V297, P1362, DOI 10.1001/jama.297.12.1362
   Nomura M, 2003, J MED CHEM, V46, P3581, DOI 10.1021/jm0205144
   Noonan JE, 2013, DIABETES, V62, P3968, DOI 10.2337/db13-0800
   Pirat C, 2012, J MED CHEM, V55, P4027, DOI 10.1021/jm101360s
   Sierra ML, 2007, J MED CHEM, V50, P685, DOI 10.1021/jm058056x
   Simo R, 2015, PROG RETIN EYE RES, V48, P160, DOI 10.1016/j.preteyeres.2015.04.003
   Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g
   Wong TY, 2012, AM J OPHTHALMOL, V154, P6, DOI 10.1016/j.ajo.2012.03.013
   Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198
NR 32
TC 6
Z9 6
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2018
VL 28
IS 16
SI SI
BP 2717
EP 2722
DI 10.1016/j.bmcl.2018.03.010
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy; Chemistry
GA GS0CF
UT WOS:000443150500015
PM 29628329
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bahrami, B
   Ewe, SYP
   Hong, T
   Zhu, MD
   Ong, G
   Luo, KH
   Chang, A
AF Bahrami, Bobak
   Ewe, Shaun Y. P.
   Hong, Thomas
   Zhu, Meidong
   Ong, Germane
   Luo, Kehui
   Chang, Andrew
TI Influence of Retinal Pathology on the Reliability of Macular Thickness
   Measurement: A Comparison Between Optical Coherence Tomography Devices
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID TIME-DOMAIN; EDEMA; RANIBIZUMAB; REPRODUCIBILITY; REPEATABILITY;
   INSTRUMENTS; AFLIBERCEPT; EYES
AB BACKGROUND AND OBJECTIVE: To evaluate the repeatability, reliability, and comparability of macular thickness measurements between three optical coherence tomography (OCT) machines in healthy eyes, eyes with diabetic macular edema (DME), and eyes with neovascular age-related macular degeneration (nAMD).
   PATIENTS AND METHODS: Twenty-three eyes with DME, 26 eyes with nAMD, and 24 healthy eyes as controls were evaluated. Scans were performed using the swept-source Triton (Topcon, Tokyo, Japan), the spectral-domain Cirrus (Carl Zeiss Meditec, Dublin, CA), and the Spectralis (Heidelberg Engineering, Heidelberg, Germany) machines. Scans were evaluated for central macular thickness (CMT), presence of segmentation and fixation imaging artifacts (IA), re-scan reliability, and agreement between machines and groups.
   RESULTS: Mean CMT was significantly different between all OCT machines in all groups (P <.01 for all comparisons). Manually correcting IA did not alter these results. There was good scan repeatability among healthy and DME eyes for each machine, but poor repeatability among the nAMD group with the Spectralis (P =.038). IA were significantly increased in the presence of pathology.
   CONCLUSIONS: There is poor agreement of CMT measurement between OCT machines in healthy eyes and those with DME and nAMD. DME and nAMD have a significant effect on the rate of IA in scans. Care is required when interpreting measurements from different OCT devices in clinical practice and research settings.
C1 [Bahrami, Bobak; Ewe, Shaun Y. P.; Hong, Thomas; Zhu, Meidong; Chang, Andrew] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Bahrami, Bobak; Chang, Andrew] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Ong, Germane] Univ New South Wales, Sydney, NSW, Australia.
   [Luo, Kehui] Macquarie Univ, Sydney, NSW, Australia.
C3 University of Sydney; University of New South Wales Sydney; Macquarie
   University
RP Chang, A (通讯作者)，Sydney Retina Clin & Day Surg, 13-187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
OI Bahrami, Bobak/0000-0003-1057-5142
CR Bressler SB, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.1.5
   Comyn O, 2012, INVEST OPHTH VIS SCI, V53, P7754, DOI 10.1167/iovs.12-10895
   Do DV, 2011, OPHTHALMOLOGY, V118, P1819, DOI 10.1016/j.ophtha.2011.02.018
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Forooghian F, 2008, INVEST OPHTH VIS SCI, V49, P4290, DOI 10.1167/iovs.08-2113
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Haller JA, 2015, OPHTHALMOLOGY, V122, P117, DOI 10.1016/j.ophtha.2014.07.045
   Han IC, 2010, OPHTHALMOLOGY, V117, P1177, DOI 10.1016/j.ophtha.2009.10.029
   Han IC, 2009, AM J OPHTHALMOL, V147, P847, DOI 10.1016/j.ajo.2008.11.019
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   Kakinoki M, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/959721
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1552, DOI 10.1136/bjo.2010.194670
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Pierro L, 2010, AM J OPHTHALMOL, V150, P199, DOI 10.1016/j.ajo.2010.03.015
   Podoleanu AG, 2012, J MICROSC-OXFORD, V247, P209, DOI 10.1111/j.1365-2818.2012.03619.x
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Swanson EA, 2015, OPTICAL COHERENCE TO
   Tan CS, 2015, OSLI RETINA, V46, P172, DOI 10.3928/23258160-20150213-23
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 24
TC 10
Z9 10
U1 0
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD APR
PY 2017
VL 48
IS 4
BP 319
EP 325
DI 10.3928/23258160-20170329-06
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EW4LN
UT WOS:000402473100008
PM 28419397
DA 2022-11-30
ER

PT J
AU Zhou, QB
   Anderson, C
   Hanus, J
   Zhao, FK
   Ma, J
   Yoshimura, A
   Wang, SS
AF Zhou, Qinbo
   Anderson, Chastain
   Hanus, Jakub
   Zhao, Fangkun
   Ma, Jing
   Yoshimura, Akihiko
   Wang, Shusheng
TI Strand and Cell Type-specific Function of microRNA-126 in Angiogenesis
SO MOLECULAR THERAPY
LA English
DT Article
ID ALPHA-B-CRYSTALLIN; RETINAL-PIGMENT EPITHELIUM; UNFOLDED PROTEIN
   RESPONSE; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; VASCULAR
   INTEGRITY; BREAST-CANCER; MIR-126; VEGF; RANIBIZUMAB
AB microRNAs or miRs have been shown to be pivotal modulators of vascular development. The strand and cell type-specific function of miR-126 in angiogenesis, especially pathological angiogenesis, remains poorly defined. We characterized the retinal vascular phenotype of miR126(-/-) mice, and tested the function of miR-126 strands (miR-126-3p and -5p) using in vitro angiogenesis models and a mouse model of neovascular age-related macular degeneration. We found that miR-126 is critical for retinal vascular development but has dual function in pathological angiogenesis. miR-126(-/-)mice showed defective postnatal retinal vascular development and remodeling, which is partially rescued by genetic knockout of its target gene Spred-1. Surprisingly, either silencing miR-126-3p by LNA-antimiR or overexpressing miR-126-3p by miRNA mimic repressed laser-induced choroidal neovascularization. To dissect the underlying mechanism, we found in endothelial cells, silencing of miR-126-3p repressed angiogenesis, while overexpression of miR-126-5p enhanced angiogenesis. However, in retinal pigment epithelial cells, miR-126-3p repressed vascular endothelial growth factor (VEGF-A) expression via a novel mechanism of regulating alpha B-Crystallin promoter activity and by directly targeting VEGF-A 3'-untranslated region. These findings provide first genetic evidence that miR-126 is required for the development of different retinal vascular layers, and also uncover a strand and cell type-specific function of miR-126 in ocular pathological angiogenesis.
C1 [Zhou, Qinbo; Anderson, Chastain; Hanus, Jakub; Zhao, Fangkun; Ma, Jing; Wang, Shusheng] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA.
   [Yoshimura, Akihiko] Keio Univ, Dept Microbiol & Immunol, Sch Med, Shinjuku Ku, Tokyo, Japan.
   [Wang, Shusheng] Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
C3 Tulane University; Keio University; Tulane University
RP Wang, SS (通讯作者)，Tulane Univ, 2000 Percival Stern Hall,6400 Freret St, New Orleans, LA 70118 USA.
EM swang1@tulane.edu
RI Yoshimura, Akihiko/K-5515-2013
FU Tulane University; NIH [EY021862]; Research to Prevent Blindness
   foundation; BrightFocus Foundation Award in Age-related Macular
   Degeneration; American Heart Association Southeast Affiliate
   Postdoctoral fellowship; NATIONAL EYE INSTITUTE [R01EY026069,
   R01EY021862] Funding Source: NIH RePORTER
FX S.W. was supported by a Startup fund from Tulane University, NIH Grant
   EY021862, a career development award from the Research to Prevent
   Blindness foundation, and a BrightFocus Foundation Award in Age-related
   Macular Degeneration. Q.Z. was supported by an American Heart
   Association Southeast Affiliate Postdoctoral fellowship.
CR Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Garofalo M, 2011, ANNU REV PHARMACOL, V51, P25, DOI 10.1146/annurev-pharmtox-010510-100517
   Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596
   Hetheridge C, 2011, BIOCHEM SOC T, V39, P1597, DOI 10.1042/BST20110738
   Inoue H, 2005, J EXP MED, V201, P73, DOI 10.1084/jem.20040616
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jorgensen S, 2010, METHODS, V52, P375, DOI 10.1016/j.ymeth.2010.07.002
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736
   Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178
   Li ZJ, 2015, BLOOD, V126, P2005, DOI 10.1182/blood-2015-04-639062
   Liu B, 2009, LUNG CANCER, V66, P169, DOI 10.1016/j.lungcan.2009.01.010
   Liu L, 2013, AM J PATHOL, V182, P1412, DOI 10.1016/j.ajpath.2012.12.020
   Musiyenko A, 2008, J MOL MED, V86, P313, DOI 10.1007/s00109-007-0296-9
   Nicoli S, 2010, NATURE, V464, P1196, DOI 10.1038/nature08889
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruan Q, 2011, MOL CANCER RES, V9, P1632, DOI 10.1158/1541-7786.MCR-11-0327
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Schober A, 2014, NAT MED, V20, P368, DOI 10.1038/nm.3487
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   van Solingen C, 2009, J CELL MOL MED, V13, P1577, DOI 10.1111/j.1582-4934.2008.00613.x
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002
   Xu Q, 2015, INVEST OPHTH VIS SCI, V56, P816, DOI 10.1167/iovs.14-14734
   Ye PP, 2014, INT J MED SCI, V11, P17, DOI 10.7150/ijms.7329
   Yu AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048501
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 42
TC 46
Z9 48
U1 1
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD OCT
PY 2016
VL 24
IS 10
BP 1823
EP 1835
DI 10.1038/mt.2016.108
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA EB3IF
UT WOS:000387256700012
PM 27203443
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Hagbi-Levi, S
   Grunin, M
   Elbaz-Hayoun, S
   Tal, D
   Obolensky, A
   Hanhart, J
   Banin, E
   Burstyn-Cohen, T
   Chowers, I
AF Hagbi-Levi, Shira
   Grunin, Michelle
   Elbaz-Hayoun, Sarah
   Tal, David
   Obolensky, Alexey
   Hanhart, Joel
   Banin, Eyal
   Burstyn-Cohen, Tal
   Chowers, Itay
TI Retinal Phenotype following Combined Deletion of the Chemokine Receptor
   CCR2 and the Chemokine CX3CL1 in Mice
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Retinal phenotype; Chemokine receptor CCR2; Chemokine CX3CL1
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; BRUCHS
   MEMBRANE; MACROPHAGES; MODEL; ACCUMULATION; EXPRESSION; MONOCYTES;
   CELLS; CRB1
AB Purpose: Conflicting data were reported with respect to the retinal phenotype of mice with dual perturbation of the CCL2 and CX3CR1 genes. We report the generation and retinal phenotype of mice with a reverse CCR2/CX3CL1 gene deficiency as a suggested model for age-related macular degeneration (AMD). Methods: Crossing of single-deficient mice generated CCR2/CX3CL1 DKO mice. DKO mice were compared with age-matched C57BL6J mice. Evaluation included color fundus photographs, electroretinography (ERG), histology and morphometric analysis. Immunohistochemistry for CD11b in retinal cross-sections and retinal pigment epithelium (RPE)-choroid flat mounts was performed to assess microglia and macrophage recruitment. Results: A minority of DKO mice showed yellowish subretinal deposits at 10 months. ERG recordings showed reduced cone sensitivity in young, but not older DKO mice. Compared to wildtype mice, DKO mice exhibited 11% reduction in the number of outer nuclear layer nuclei. Old DKO mice had an increased number of CD11b-positive cells across the retina, and on RPE-choroid flat mounts. Conclusions: In the absence of the rd8 allele, deficiency of CCR2 and CX3CL1 in mice leads to a mild form of retinal degeneration which is associated with the recruitment of macrophages, particularly to the subretinal space. This model enables to assess consequences of perturbed chemokine signaling, but it does not recapitulate cardinal AMD features. (C) 2015 S. Karger AG, Basel
C1 [Hagbi-Levi, Shira; Grunin, Michelle; Tal, David; Obolensky, Alexey; Hanhart, Joel; Banin, Eyal; Chowers, Itay] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Obolensky, Alexey] Hadassah Hebrew Univ, Med Ctr, Dept Cellular Biochem & Human Genet, Jerusalem, Israel.
   [Elbaz-Hayoun, Sarah; Tal, David; Burstyn-Cohen, Tal] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel.
   [Elbaz-Hayoun, Sarah; Tal, David; Burstyn-Cohen, Tal] Inst Dent Sci, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019; Burstyn-Cohen, Tal/K-8846-2012
OI Grunin, Michelle/0000-0002-3155-2858; Burstyn-Cohen,
   Tal/0000-0002-2324-2921; Hanhart, Joel/0000-0003-0952-3740; Hagbi-Levi,
   Shira/0000-0002-2891-0079
FU Israel Science Foundation [1006/13, 1764/12]; Israeli Ministry of Health
FX Michelle Grunin is grateful to the Baroness Ariane de Rothschild for the
   award of a fellowship. The authors wish to thank Prof. Steffen Jung from
   the Weizmann Institute for Science for providing the mice and for his
   thoughtful insights and support of this project. This study was
   supported in part by grants from the Israel Science Foundation (1006/13)
   to I.C. and to T.B.-C. (1764/12) and by grants from the Israeli Ministry
   of Health to I.C. and T.B.-C.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Lederman M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087751
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Walter L, 2009, SEMIN IMMUNOPATHOL, V31, P513, DOI 10.1007/s00281-009-0180-5
NR 28
TC 2
Z9 2
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2016
VL 55
IS 3
BP 126
EP 134
DI 10.1159/000441794
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DD1IF
UT WOS:000369673800003
PM 26670885
DA 2022-11-30
ER

PT J
AU Chang, YC
   Hsieh, MC
   Wu, HJ
   Wu, WC
   Kao, YH
AF Chang, Yo-Chen
   Hsieh, Ming-Chu
   Wu, Horng-Jiun
   Wu, Wen-Chuan
   Kao, Ying-Hsien
TI Methylglyoxal, a reactive glucose metabolite, enhances autophagy flux
   and suppresses proliferation of human retinal pigment epithelial ARPE-19
   cells
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Age-related macular degeneration; Autophagosomes; Autophagy flux;
   Methylglyoxal; Reactive oxygen species; Signal transduction
ID GLYCATION END-PRODUCT; OXIDATIVE STRESS; MACULAR DEGENERATION; BECLIN 1;
   DRUSEN FORMATION; GROWTH-FACTOR; APOPTOSIS; RECEPTOR; PATHOGENESIS;
   ACTIVATION
AB Methylglyoxal (MGO), a glycolytic metabolite, induces oxidative injury and apoptotic cell death that play a pathogenetic role in age-related macular degeneration (AMD). This study examined the impact of MGO on cell proliferation and autophagy flux in retinal pigment epithelium (RPE) ARPE-19 cells and elucidated the underlying mechanism. Short-term MGO exposure suppressed cell proliferation without induction of apoptotic cell death, increased production of reactive oxygen species, and potentiated H2O2-exhibited cytotoxicity in ARPE-19 cells. Conversely, pretreatment with N-acetylcysteine, a ROS scavenger, and aminoguanidine, an MGO blocker, prevented MGO-induced growth retardation. MGO significantly enhanced autophagy flux and increased intracellular accumulation of autophagosomes, which was functionally confirmed by addition of autophagy enhancer or inhibitors. Signaling kinetic observation indicated that MGO remarkably triggered phosphorylation of Akt, ERK1/2, p38 MAPK, and JNK1/2. Blockade of kinase activity demonstrated that the hyperphosphorylation of Akt, ERK1/2, JNK, and p38 MAPK were all involved in the MGO-enhanced autophagy and growth-arresting effect in ARPE-19 cells. Moreover, pretreatment with autophagic flux inhibitors including 3-methyladenine, bafilomycin A, and chloroquine effectively ameliorated MGO-but not H2O2-mediated ARPE-19 cytotoxicity. In conclusion, modulation of autophagy flux activity by using autophagic or kinase inhibitors may be an applicable modality to treat AMD. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Chang, Yo-Chen; Hsieh, Ming-Chu; Wu, Horng-Jiun; Wu, Wen-Chuan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung 80708, Taiwan.
   [Chang, Yo-Chen] Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Dept Ophthalmol, Kaohsiung 80708, Taiwan.
   [Wu, Horng-Jiun] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Ophthalmol, Kaohsiung 80708, Taiwan.
   [Kao, Ying-Hsien] E Da Hosp, Dept Med Res, Kaohsiung 82445, Taiwan.
   [Kao, Ying-Hsien] Fooyin Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital;
   Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; E-Da
   Hospital; Fooyin University
RP Wu, WC (通讯作者)，Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Ophthalmol, 100 Shih Chuan 1st Rd, Kaohsiung 80708, Taiwan.
EM wuoph@kmu.edu.tw; danyhkao@gmail.com
RI Kao, Ying-Hsien/H-4134-2019
OI Kao, Ying-Hsien/0000-0001-7803-9384
FU Ministry of Science and Technology, Executive Yuan, Taiwan
   [NSC96-2314-B-037-025, MOST103-2314-B-037-035]; Kaohsiung Municipal
   Hsiao-Kang Hospital [Kmhk-100-017, Kmhk-101-015]; E-Da Hospital,
   Kaohsiung, Taiwan [EDAHT-101029]
FX The authors would like to thank Dr. Yu-Chun Lin and Mr. Po-Han Chen for
   their excellent technical assistance in fluorescent microphotography.
   This study was supported in part by grants from the Ministry of Science
   and Technology, Executive Yuan, Taiwan (NSC96-2314-B-037-025;
   MOST103-2314-B-037-035), from Kaohsiung Municipal Hsiao-Kang Hospital
   (Kmhk-100-017, Kmhk-101-015), and from E-Da Hospital, Kaohsiung, Taiwan
   (EDAHT-101029).
CR Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bento CF, 2010, EXP PHYSIOL, V95, P955, DOI 10.1113/expphysiol.2010.053561
   Cantero AV, 2007, FASEB J, V21, P3096, DOI 10.1096/fj.06-7536com
   Chang TJ, 2011, FASEB J, V25, P1746, DOI 10.1096/fj.10-178053
   Chen JF, 2010, MOL CELL BIOCHEM, V335, P137, DOI 10.1007/s11010-009-0250-y
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Di Loreto S, 2004, BRAIN RES, V1006, P157, DOI 10.1016/j.brainres.2004.01.066
   Du HL, 2012, INT J ONCOL, V40, P2049, DOI 10.3892/ijo.2012.1415
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fukunaga M, 2005, ANN NY ACAD SCI, V1043, P151, DOI 10.1196/annals.1333.019
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hsuuw YD, 2005, J CELL PHYSIOL, V205, P379, DOI 10.1002/jcp.20408
   Huang SM, 2008, NEUROTOXICOLOGY, V29, P1016, DOI 10.1016/j.neuro.2008.07.002
   Huang WJ, 2007, RENAL FAILURE, V29, P911, DOI 10.1080/08860220701573509
   Jeong WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045754
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim J, 2004, J KOREAN MED SCI, V19, P95, DOI 10.3346/jkms.2004.19.1.95
   Kim J, 2012, EXP MOL MED, V44, P167, DOI 10.3858/emm.2012.44.2.012
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lee B.H., 2013, FREE RADIC BIOL MED
   Liu HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046720
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   McCray BA, 2008, NEUROSIGNALS, V16, P75, DOI 10.1159/000109761
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x
   Ramakrishnan S, 2007, AUTOPHAGY, V3, P512
   Shi CS, 2010, AUTOPHAGY, V6, P986, DOI 10.4161/auto.6.7.13288
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JR, 2008, AUTOPHAGY, V4, P947, DOI 10.4161/auto.6787
   WESTWOOD ME, 1994, J BIOL CHEM, V269, P32293
   Wu WC, 2011, EXP EYE RES, V93, P842, DOI 10.1016/j.exer.2011.09.016
   Wu WC, 2010, EXP EYE RES, V91, P211, DOI 10.1016/j.exer.2010.05.005
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 50
TC 31
Z9 32
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD OCT
PY 2015
VL 29
IS 7
BP 1358
EP 1368
DI 10.1016/j.tiv.2015.05.014
PG 11
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA CR3WJ
UT WOS:000361263500008
PM 26021238
DA 2022-11-30
ER

PT J
AU Lawrenson, JG
   Grzybowski, A
AF Lawrenson, John G.
   Grzybowski, Andrzej
TI Controversies in the Use of Nutritional Supplements in Ophthalmology
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Age-related macular degeneration; cataract; dry eye; nutritional
   supplements; antioxidants; essential fatty acids
ID DRY EYE SYNDROME; MACULAR DEGENERATION; FATTY-ACIDS; INTERNATIONAL
   WORKSHOP; RANDOMIZED-TRIAL; CATARACT; DISEASE; MULTIVITAMIN; HEALTH;
   ADULTS
AB Nutritional supplements are widely taken by the general population and several of these products are marketed specifically to improve eye health. The aim of this review is to summarise the evidence for the benefit of supplementation with antioxidant vitamins and other micronutrients for three of the most common eye diseases of the elderly: age-related macular degeneration (AMD), cataract and dry eye syndrome (DES). Although the potential importance of diet and nutrition in these conditions is strongly supported by data from observational studies, evidence from randomised controlled trials (RCTs) on the benefit of nutritional supplementation is generally lacking. However, there is high quality evidence to support the use of an Age-Related Eye-Disease Study (AREDS) supplement containing antioxidants (beta-carotene, vitamin C and vitamin E) and zinc to slow progression in those at moderate to high risk of developing advanced AMD. Recent data from the AREDS2 trial provided data to suggest that beta-carotene could be replaced with lutein and zeaxanthin on the basis of improved safety without compromising efficacy. Although there is currently insufficient evidence to recommend the routine use of any of the commercially available supplements in cataract and DES, given the public health importance of these conditions further research into the benefit of dietary modification or nutritional supplementation should be a priority.
C1 [Lawrenson, John G.] City Univ London, Ctr Publ Hlth Res, Sch Hlth Sci, London EC1V 0HB, England.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Olsztyn, Poland.
C3 City University London; University of Warmia & Mazury
RP Lawrenson, JG (通讯作者)，City Univ London, Ctr Publ Hlth Res, Sch Hlth Sci, London EC1V 0HB, England.
EM j.g.lawrenson@city.ac.uk
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391; Lawrenson, John/0000-0002-2031-6390
CR Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Aslam Tariq, 2014, Clin Ophthalmol, V8, P2045, DOI 10.2147/OPTH.S63937
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bailey RL, 2013, JAMA INTERN MED, V173, P355, DOI 10.1001/jamainternmed.2013.2299
   Bailey RL, 2011, J NUTR, V141, P261, DOI 10.3945/jn.110.133025
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   Bjelakovic G, 2014, CURR OPIN CLIN NUTR, V17, P40, DOI 10.1097/MCO.0000000000000009
   Bjelakovic G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074558
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dickinson A, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-14
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Fortmann SP, 2013, ANN INTERN MED, V159, P824, DOI 10.7326/0003-4819-159-12-201312170-00729
   Geerling G, 2011, INVEST OPHTH VIS SCI, V52, P2050, DOI 10.1167/iovs.10-6997g
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   Guallar E, 2013, ANN INTERN MED, V159, P850, DOI 10.7326/0003-4819-159-12-201312170-00011
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Liu AH, 2014, MED SCI MONITOR, V20, P1583, DOI 10.12659/MSM.891364
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   Mathew MC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004567.pub2
   Michael R, 2011, PHILOS T R SOC B, V366, P1278, DOI 10.1098/rstb.2010.0300
   Miljanovic B, 2005, AM J CLIN NUTR, V82, P887, DOI 10.1093/ajcn/82.4.887
   Miljanovic B, 2007, AM J OPHTHALMOL, V143, P409, DOI 10.1016/j.ajo.2006.11.060
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Papas EB, 2013, INVEST OPHTH VIS SCI, V54, P183, DOI 10.1167/iovs.13-13166
   Pflugfelder SC, 2007, OCUL SURF, V5, P163
   Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Smith JA, 2007, OCUL SURF, V5, P93
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Virtamo J, 2003, JAMA-J AM MED ASSOC, V290, P476, DOI 10.1001/jama.290.4.476
   Weikel KA, 2014, NUTR REV, V72, P30, DOI 10.1111/nure.12077
   World Health Organization, GLOB DAT VIS IMP 201
   Yetley EA, 2007, AM J CLIN NUTR, V85, p269S, DOI 10.1093/ajcn/85.1.269S
NR 55
TC 8
Z9 8
U1 2
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 32
BP 4667
EP 4672
DI 10.2174/1381612821666150909095916
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CV8FK
UT WOS:000364516100003
PM 26350529
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kohno, H
   Chen, Y
   Kevany, BM
   Pearlman, E
   Miyagi, M
   Maeda, T
   Palczewski, K
   Maeda, A
AF Kohno, Hideo
   Chen, Yu
   Kevany, Brian M.
   Pearlman, Eric
   Miyagi, Masaru
   Maeda, Tadao
   Palczewski, Krzysztof
   Maeda, Akiko
TI Photoreceptor Proteins Initiate Microglial Activation via Toll-like
   Receptor 4 in Retinal Degeneration Mediated by All-trans-retinal
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MACULAR DEGENERATION; OXIDATIVE STRESS; MOUSE RETINA; EXTRACELLULAR
   HSP70; PIGMENT EPITHELIUM; ENDOGENOUS LIGANDS; APOPTOTIC CELLS; MICE;
   INFLAMMATION; DISEASE
AB Although several genetic and biochemical factors are associated with the pathogenesis of retinal degeneration, it has yet to be determined how these different impairments can cause similar degenerative phenotypes. Here, we report microglial/macrophage activation in both a Stargardt disease and age-related macular degeneration mouse model caused by delayed clearance of all-trans-retinal from the retina, and in a retinitis pigmentosa mouse model with impaired retinal pigment epithelium (RPE) phagocytosis. Mouse microglia displayed RPE cytotoxicity and increased production of inflammatory chemokines/cytokines, Ccl2, Il1b, and Tnf, after coincubation with ligands that activate innate immunity. Notably, phagocytosis of photoreceptor proteins increased the activation of microglia/macrophages and RPE cells isolated from model mice as well as wildtype mice. The mRNA levels of Tlr2 and Tlr4, which can recognize proteins as their ligands, were elevated in mice with retinal degeneration. Bone marrow-derived macrophages from Tlr4-deficient mice did not increase Ccl2 after coincubation with photoreceptor proteins. Tlr4(-/-) Abca4(-/-) Rdh8(-/-) mice displayed milder retinal degenerative phenotypes than Abca4(-/-) Rdh8(-/-) mice. Additionally, inactivation of microglia/macrophages by pharmacological approaches attenuated mouse retinal degeneration. This study demonstrates an important contribution of TLR4-mediated microglial activation by endogenous photoreceptor proteins in retinal inflammation that aggravates retinal cell death. This pathway is likely to represent an underlying common pathology in degenerative retinal disorders.
C1 [Kohno, Hideo; Chen, Yu; Kevany, Brian M.; Miyagi, Masaru; Maeda, Tadao; Palczewski, Krzysztof; Maeda, Akiko] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Pearlman, Eric; Miyagi, Masaru; Maeda, Tadao; Maeda, Akiko] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Miyagi, Masaru] Case Western Reserve Univ, Ctr Prote, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University
RP Maeda, A (通讯作者)，10900 Euclid Ave, Cleveland, OH 44106 USA.
EM aam19@case.edu
FU National Institutes of Health [EY022658, EY019031, EY019880, EY009339,
   EY021126, EY11373]; Research to Prevent Blindness Foundation; Foundation
   Fighting Blindness; Fight for Sight; Ohio Lions Eye Research Foundation;
   NATIONAL EYE INSTITUTE [R01EY009339, R24EY021126, R01EY022658,
   K08EY019031, P30EY011373, K08EY019880] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants EY022658, EY019031, EY019880, EY009339, EY021126, and
   EY11373 and grants from the Research to Prevent Blindness Foundation,
   Foundation Fighting Blindness, Fight for Sight, and Ohio Lions Eye
   Research Foundation.
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200
   Bauer M, 2011, P NATL ACAD SCI USA, V108, P21105, DOI 10.1073/pnas.1111919109
   Beltran WA, 2009, INVEST OPHTH VIS SCI, V50, P3985, DOI 10.1167/iovs.08-3364
   Berger W, 2010, PROG RETIN EYE RES, V29, P335, DOI 10.1016/j.preteyeres.2010.03.004
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Cai J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021164
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen XH, 2011, J NEUROIMMUNOL, V235, P1, DOI 10.1016/j.jneuroim.2011.04.006
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Diemer T, 2008, ADV EXP MED BIOL, V613, P321, DOI 10.1007/978-0-387-74904-4_37
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erridge C, 2010, J LEUKOCYTE BIOL, V87, P989, DOI 10.1189/jlb.1209775
   Fillpovic R, 2008, EXP NEUROL, V211, P41, DOI 10.1016/j.expneurol.2007.12.024
   FISHEL S, 1988, FERTIL STERIL, V49, P108
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gu D, 2009, INVEST OPHTH VIS SCI, V50, P3482, DOI 10.1167/iovs.08-3111
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Henkel JS, 2009, J NEUROIMMUNE PHARM, V4, P389, DOI 10.1007/s11481-009-9171-5
   Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112
   Ji KA, 2007, GLIA, V55, P1577, DOI 10.1002/glia.20571
   Johnson AC, 2008, J BIOL CHEM, V283, P3988, DOI 10.1074/jbc.M707264200
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kadiyala CSR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015332
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Ko MK, 2011, INVEST OPHTH VIS SCI, V52, P5824, DOI 10.1167/iovs.10-6357
   Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928
   Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2010, P NATL ACAD SCI USA, V107, P8428, DOI 10.1073/pnas.1000640107
   Maeda A, 2009, INVEST OPHTH VIS SCI, V50, P5435, DOI 10.1167/iovs.09-3944
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Molday RS, 2010, PROG LIPID RES, V49, P476, DOI 10.1016/j.plipres.2010.07.002
   Nandrot EF, 2010, ADV EXP MED BIOL, V664, P133, DOI 10.1007/978-1-4419-1399-9_16
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Owens T, 2009, CURR TOP MICROBIOL, V336, P105, DOI 10.1007/978-3-642-00549-7_6
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   SANYAL S, 1980, J COMP NEUROL, V194, P193, DOI 10.1002/cne.901940110
   Sasahara M, 2008, AM J PATHOL, V172, P1693, DOI 10.2353/ajpath.2008.080024
   Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603
   Seitz HM, 2007, J IMMUNOL, V178, P5635, DOI 10.4049/jimmunol.178.9.5635
   Sen A, 2011, INVEST OPHTH VIS SCI, V52, P6940, DOI 10.1167/iovs.11-7834
   Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Sugita S, 2009, CANCER SCI, V100, P82, DOI 10.1111/j.1349-7006.2008.01008.x
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Theriault JR, 2005, FEBS LETT, V579, P1951, DOI 10.1016/j.febslet.2005.02.046
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Usui Y, 2008, EXP EYE RES, V86, P52, DOI 10.1016/j.exer.2007.09.007
   van Rooijen N, 2002, J LIPOSOME RES, V12, P81, DOI 10.1081/LPR-120004780
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638
   Wang AL, 2005, NEUROCHEM INT, V47, P152, DOI 10.1016/j.neuint.2005.04.018
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu J, 2011, FASEB J, V25, P2221, DOI 10.1096/fj.10-178350
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida A, 2003, LAB INVEST, V83, P1117, DOI 10.1097/01.LAB.0000082393.02727.B5
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhao L, 2011, AM J PATHOL, V179, P1265, DOI 10.1016/j.ajpath.2011.05.042
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 89
TC 127
Z9 129
U1 1
U2 22
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 24
PY 2013
VL 288
IS 21
BP 15326
EP 15341
DI 10.1074/jbc.M112.448712
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 151HU
UT WOS:000319452100058
PM 23572532
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kennedy, RD
   Spafford, MM
   Parkinson, CM
   Fong, GT
AF Kennedy, Ryan David
   Spafford, Marlee M.
   Parkinson, Carla M.
   Fong, Geoffrey T.
TI Knowledge about the relationship between smoking and blindness in
   Canada, the United States, the United Kingdom, and Australia: results
   from the International Tobacco Control Four-Country Project
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Article
DE Public health; Smoking; Age-related macular degeneration; Cataract
ID 4 COUNTRY SURVEY; MACULAR DEGENERATION; CIGARETTE-SMOKING; HEALTH-RISKS;
   AGE; ASSOCIATION; CESSATION; CATARACT; SMOKERS; PERCEPTIONS
AB PURPOSE: Smoking is causally associated with certain prevalent visually impairing eye diseases, including age-related macular degeneration and cataract. Studies have found that people are afraid of "going blind" and may be motivated to quit smoking if they know that vision loss is associated with smoking behavior.
   METHODS: A random-digit dialed telephone survey was used to measure health knowledge of adult smokers in Canada (n = 2,765), the United States (n = 3,178), the United Kingdom (n = 2,767), and Australia (n = 2,623) as part of the International Tobacco Control Four-Country Project.
   RESULTS: A low proportion of smokers from Canada (13.0%), the United States (9.5%), and the United Kingdom (9.7%) believed that smoking can cause blindness. In contrast, 47.2% of Australian smokers believed that smoking causes blindness. Australia was the only country during the sampling period to have national awareness campaigns about smoking and its effects on eye health.
   CONCLUSION: These findings point to the need across countries to educate the public on this important consequence of smoking. There is an opportunity for the public health and eye health communities to work to educate the public about the impacts smoking has on eye health to improve quit rates and help discourage people from starting to smoke. Optometry 2011;82:310-317
C1 [Kennedy, Ryan David; Spafford, Marlee M.; Parkinson, Carla M.; Fong, Geoffrey T.] Univ Waterloo, Waterloo, ON N2L 3G1, Canada.
   [Kennedy, Ryan David] Harvard Univ, Sch Publ Hlth, Global Ctr Tobacco Control, Boston, MA 02115 USA.
C3 University of Waterloo; Harvard University; Harvard T.H. Chan School of
   Public Health
RP Kennedy, RD (通讯作者)，Propel Ctr Populat Hlth Impact, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.
EM rdkenned@uwaterloo.ca
RI Fong, Geoffrey T/H-2810-2014; Spafford, Marlee/A-1386-2010; Kennedy,
   Ryan David/U-3794-2017
OI Fong, Geoffrey T/0000-0001-9098-6472; Kennedy, Ryan
   David/0000-0002-9448-5234
FU National Cancer Institute of the United States (Roswell Park
   Transdisciplinary Tobacco Use Research Center) [R01CA100362, P50
   CA111236]; Canadian Institutes of Health Research [57897, 79551]; Robert
   Wood Johnson Foundation [045734]; National Health and Medical Research
   Council of Australia [265903]; Cancer Research UK [C312/A3726]; Canadian
   Tobacco Control Research Initiative [014578]; Centre for Behavioural
   Research and Program Evaluation; National Cancer Institute of
   Canada/Canadian Cancer Society; Ontario Institute of Cancer Research;
   Canadian Institutes of Health Research; NATIONAL CANCER INSTITUTE
   [R01CA100362, P50CA111236] Funding Source: NIH RePORTER
FX Research funding is from the National Cancer Institute of the United
   States R01CA100362 and P50 CA111236 (Roswell Park Transdisciplinary
   Tobacco Use Research Center), Canadian Institutes of Health Research
   (57897 and 79551), Robert Wood Johnson Foundation (045734), National
   Health and Medical Research Council of Australia (265903), Cancer
   Research UK (C312/A3726), Canadian Tobacco Control Research Initiative
   (014578), Centre for Behavioural Research and Program Evaluation,
   National Cancer Institute of Canada/Canadian Cancer Society, and the
   Ontario Institute of Cancer Research. Additional support is from a
   Canadian Institutes of Health Research Doctoral Award and the Canadian
   Institutes of Health Research Strategic Training Program in Tobacco
   Research.
CR *AM PUBL HLTH ASS, ADV POL PREV VIS LOS
   Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   Australian Government Department of Health and Ageing, 2004, 1997 2003 NAT TOB CA
   Benowitz NL, 2010, NEW ENGL J MED, V362, P2295, DOI 10.1056/NEJMra0809890
   Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955
   Bintz D, 2006, RURAL ROADS, V4, P10
   Carroll T, 2003, TOB CONTROL, V12, P40
   Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195
   Christen WG, 2000, JAMA-J AM MED ASSOC, V284, P713, DOI 10.1001/jama.284.6.713
   CHUNG SM, 1994, OPHTHALMOLOGY, V101, P779
   Covert D, 2007, SURV OPHTHALMOL, V52, pS20, DOI 10.1016/j.survophthal.2006.10.014
   *CTR HLTH PROM ED, 1988, DHHS PUB
   Cummings KM, 2004, NICOTINE TOB RES, V6, P333, DOI 10.1080/14622200412331320734
   Cummings KM, 2002, TOB CONTROL, V11, pI110, DOI 10.1136/tc.11.suppl_1.i110
   Donovan RJ, 2003, TOB CONTROL, V12, P30
   Eong KGA, 2006, ANN ACAD MED SINGAP, V35, P133
   Fiore M C, 2000, Respir Care, V45, P1200
   Fong GT, 2006, TOB CONTROL, V15, P3, DOI 10.1136/tc.2005.015438
   Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0
   Gurwood AS, 2006, OPTOMETRY, V77, P206
   Hammond D, 2006, TOB CONTROL, V15, P19, DOI 10.1136/tc.2005.012294
   *HLTH CAN, TOB SMOK
   ITC Four Country Survey Team, INT TOB CONTR POL EV
   Kelly SP, 2005, J CATARACT REFR SURG, V31, P2395, DOI 10.1016/j.jcrs.2005.06.039
   KELLY SP, 2004, BRIT MED J, V328, P357
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Loo DLS, 2009, CLIN EXP OPTOM, V92, P42, DOI 10.1111/j.1444-0938.2008.00283.x
   McNabola A, 2009, INT J ENV RES PUB HE, V6, P741, DOI 10.3390/ijerph6020741
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   Mojon-Azzi SM, 2008, OPHTHALMOLOGICA, V222, P205, DOI 10.1159/000126085
   Moradi P, 2007, BRIT J OPHTHALMOL, V91, P605, DOI 10.1136/bjo.2006.108191
   MUHLHAUSER I, 1986, DIABETOLOGIA, V29, P640
   *NAT CANC I, 1999, SMOK TOB CONTR MON, V10
   *NAT I DRUG AB, NIH PUBL
   Ng DHL, 2010, EYE, V24, P864, DOI 10.1038/eye.2009.208
   Noertjojo K, 2006, CAN J OPHTHALMOL, V41, P617, DOI 10.1016/S0008-4182(06)80035-9
   ODELL LE, 2008, OPTOMETRY, V79, P293
   *ONT MIN HLTH HLTH, 1998, HLTH ENV HDB HLTH PR
   PASSUT J, 2008, PRIMARY CARE OPTOMET, V13, P1
   PASSUT J, 2008, PRIMARY CARE OPTOMET, V13, P18
   Pisinger C, 2008, PREV MED, V46, P579, DOI 10.1016/j.ypmed.2008.02.026
   RIZZO JF, 1994, AM J OPHTHALMOL, V117, P818, DOI 10.1016/S0002-9394(14)70338-1
   Roth LK, 2001, AM J OBSTET GYNECOL, V184, P934, DOI 10.1067/mob.2001.112103
   Sheck LHN, 2009, CLIN EXP OPTOM, V92, P75, DOI 10.1111/j.1444-0938.2009.00348.x
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803
   Thompson ME, 2006, TOB CONTROL, V15, P12, DOI 10.1136/tc.2005.013870
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   *TOB LAB RES CTR, HLTH EFF EYE
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   US Surgeon General, 2004, HLTH CONS SMOK REP S
   Weintraub JM, 2002, AM J EPIDEMIOL, V155, P72, DOI 10.1093/aje/155.1.72
   Wiencke JK, 1999, J NATL CANCER I, V91, P614, DOI 10.1093/jnci/91.7.614
   Wilkenfeld J, 2000, JNCI-J NATL CANCER I, V92, P90, DOI 10.1093/jnci/92.2.90
   WILSON N, 2004, BRIT MED J, V238, P537
   World Health Organization, WHO FRAM CONV TOB CO
NR 57
TC 23
Z9 24
U1 1
U2 5
PU AMER OPTOMETRIC ASSN INC
PI ST LOUIS
PA 243 N LINDBERGH BLVD, ST LOUIS, MO 63141 USA
SN 1529-1839
EI 1558-1527
J9 OPTOMETRY
JI Optometry
PD MAY
PY 2011
VL 82
IS 5
BP 310
EP 317
DI 10.1016/j.optm.2010.10.014
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778MQ
UT WOS:000291708800009
PM 21524603
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zahn, G
   Vossmeyer, D
   Stragies, R
   Wills, M
   Wong, CG
   Loffler, KU
   Adamis, AP
   Knolle, J
AF Zahn, Grit
   Vossmeyer, Doerte
   Stragies, Roland
   Wills, Margaret
   Wong, Corinne G.
   Loeffler, Karin U.
   Adamis, Anthony P.
   Knolle, Jochen
TI Preclinical Evaluation of the Novel Small-Molecule Integrin alpha 5 beta
   1 Inhibitor JSM6427 in Monkey and Rabbit Models of Choroidal
   Neovascularization
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; ALPHA(5)BETA(1)
   INTEGRIN; BLOOD-VESSELS; CELL-ADHESION; MICE LACKING; ANGIOGENESIS;
   EXPRESSION; MEMBRANES; FIBRONECTIN
AB Objective: To evaluate the pharmacologic activity and tolerability of JSM6427, a potent and first selective small-molecule inhibitor of integrin alpha 5 beta 1, in monkey and rabbit models of choroidal neovascularization (CNV).
   Methods: JSM6427 selectivity for alpha 5 beta 1 was evaluated by in vitro binding assays while the ability of JSM6427 to inhibit CNV was investigated in a laser-induced monkey model and a growth factor-induced rabbit model. Intravitreal injections of JSM6427 (100, 300, or 1000 mu g) or vehicle were administered immediately after the CNV induction procedure and at weekly intervals for 4 weeks. Fluorescein angiography was performed weekly. Ocular tolerability was evaluated ophthalmoscopically and histologically in both models; additional assessments in monkeys included electroretinography, biomicroscopy, pathological examination, and analysis of JSM6427 pharmacokinetics.
   Results: JSM6427 was highly selective for the alpha 5 beta 1-fibronectin interaction. Weekly intravitreal injections of JSM6427 resulted. in a statistically significant dose-dependent inhibition of CNV in laser-induced and growth factor-induced models without any ocular JSM6427-related adverse effects. JSM6427 was cleared through the systemic circulation with no evidence of systemic accumulation.
   Conclusions: Intravitreal JSM6427 provided dose-dependent inhibition of CNV in monkey and rabbit experimental models.
   Clinical Relevance: JSM6427 may provide a new approach for the treatment of ocular neovascular diseases such as age-related macular degeneration in humans.
C1 [Zahn, Grit; Vossmeyer, Doerte; Stragies, Roland; Knolle, Jochen] Jerini Ag, D-10115 Berlin, Germany.
   [Zahn, Grit; Adamis, Anthony P.] Jerini Ophthalm, New York, NY USA.
   [Wills, Margaret] Preclin Serv, Charles River Labs, Sparks, NV USA.
   [Wong, Corinne G.] Sclera LLC, Carlsbad, CA USA.
   [Loeffler, Karin U.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
C3 Shire Pharmaceuticals Limited; Shire Pharmaceuticals Limited; University
   of Bonn
RP Zahn, G (通讯作者)，Jerini Ag, Invaliden Str 130, D-10115 Berlin, Germany.
EM grit.zahn@gmx.net
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9
   Brooks PC, 1996, EUR J CANCER, V32A, P2423, DOI 10.1016/S0959-8049(96)00381-4
   Collo G, 1999, J CELL SCI, V112, P569
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Dietrich T, 2007, AM J PATHOL, V171, P361, DOI 10.2353/ajpath.2007.060896
   FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896
   GEORGE EL, 1993, DEVELOPMENT, V119, P1079
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gum G. G., 2005, INVEST OPHTHALMOL VI, V46
   Hackett R. B., 1996, DERMATOTOXICOLOGY, P557
   Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Huang XZ, 2000, MOL CELL BIOL, V20, P755, DOI 10.1128/MCB.20.3.755-759.2000
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268
   LI R, INVEST OPHTH VIS SCI, DOI DOI 10.1167/IOVS.09-3591
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Magnussen A, 2005, CANCER RES, V65, P2712, DOI 10.1158/0008-5472.CAN-04-2691
   Maier AKB, 2007, CURR EYE RES, V32, P801, DOI 10.1080/02713680701553052
   MCDONALD T, 1977, ADV MOD TOXICOL, V4, P579
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   Muether PS, 2007, EXP EYE RES, V85, P356, DOI 10.1016/j.exer.2007.06.004
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3
   Proulx S, 2003, MOL VIS, V9, P473
   RABIN D, 2008, INVEST OPHTHALMOL VI, V49
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27
   Roman J, 2004, AM J PHYSIOL-LUNG C, V287, pL239, DOI 10.1152/ajplung.00244.2003
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404
   STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883
   Stragies R, 2007, J MED CHEM, V50, P3786, DOI 10.1021/jm070002v
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Wilson SH, 2003, INVEST OPHTH VIS SCI, V44, P1704, DOI 10.1167/iovs.02-0773
   Wong CG, 2001, CURR EYE RES, V22, P140, DOI 10.1076/ceyr.22.2.140.5528
   WONG CG, 2008, INVEST OPHTHALMOL VI, V49
   WONG CG, 2005, INVEST OPHTHALMOL VI, V46
   YANG JT, 1993, DEVELOPMENT, V119, P1093
NR 49
TC 47
Z9 53
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2009
VL 127
IS 10
BP 1329
EP 1335
DI 10.1001/archophthalmol.2009.265
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 505GK
UT WOS:000270679900013
PM 19822850
OA Bronze
DA 2022-11-30
ER

PT J
AU Welch, DE
   Elmariah, H
   Peden, MC
   Adams, SG
   Ratnakaram, R
   Kaushal, S
AF Welch, D. E.
   Elmariah, H.
   Peden, M. C.
   Adams, S. G.
   Ratnakaram, R.
   Kaushal, S.
TI Short-term response of macular oedema to intravitreal bevacizumab
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULAR MEMBRANES;
   DIABETIC-RETINOPATHY; DEGENERATION; EXPRESSION; PROTEINS; AVASTIN;
   RETINA
AB Background/aims: Bevacizumab has been shown to be an effective treatment of macular oedema. This study assesses the response of macular oedema to bevacizumab with specific focus on the first 24 h postinjection.
   Methods: Subjects with diabetic macular oedema (DMO) or exudative age-related macular degeneration (ARMD) received intravitreal bevacizumab injections. Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity and OCT macular thickness measurements were obtained at baseline, 1, 3, 6, 24 and 48 h, 1 week and 1 month postinjection.
   Results: The average baseline OCT was 452.91 mm (SD 182.96, range 249.00 to 784.00). After injection, there was a statistically significant decrease in OCT thickness within 2 h with a plateau phase out to 24 h, followed by a significant drop between 24 and 48 h, and a return towards baseline between 1 week and 1 month. Average changes in ETDRS visual acuity were not statistically significant, though many patients experienced a positive outcome.
   Conclusion: While there is an immediate pressure-related effect, it appears that the anti-VEGF effects of bevacizumab require approximately 24 h to become active and persist for 2-3 weeks. These results suggest that injections at 2-3-week intervals might provide improved clinical outcomes, compared with the currently typical 4-6-week interval of injections.
C1 [Kaushal, S.] Univ Massachusetts, Dept Ophthalmol, Sch Med, Worcester, MA 01655 USA.
   [Welch, D. E.; Elmariah, H.; Peden, M. C.; Adams, S. G.; Ratnakaram, R.] Univ Florida, Dept Ophthalmol, Gainesville, FL USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; State University System of Florida; University of Florida
RP Kaushal, S (通讯作者)，Univ Massachusetts, Dept Ophthalmol, Sch Med, 55 Lake Ave N, Worcester, MA 01655 USA.
EM shalesh.kaushal@umassmemorial.org
FU Charlie Mac Overstreet Laboratory for Retinal Diseases and Research to
   Prevent Blindness
FX This study was funded by the Charlie Mac Overstreet Laboratory for
   Retinal Diseases and Research to Prevent Blindness.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427
   Davidson JA, 2007, ENDOCRINE, V32, P107, DOI 10.1007/s12020-007-0040-9
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fraser-Bell S, 2008, CURR OPIN OPHTHALMOL, V19, P185, DOI 10.1097/ICU.0b013e3282fb7c45
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lashkari K, 2000, AM J PATHOL, V156, P1337, DOI 10.1016/S0002-9440(10)65004-3
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   QU H, 1995, J HISTOCHEM CYTOCHEM, V43, P381
   Roberts WG, 1997, CANCER RES, V57, P765
   ROSENFELD PJ, 2005, OPHTHAL SURG LAS IM, V36, P270
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
NR 25
TC 12
Z9 13
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2009
VL 93
IS 8
BP 1033
EP 1036
DI 10.1136/bjo.2008.148874
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 474RP
UT WOS:000268302000010
PM 19403519
DA 2022-11-30
ER

PT J
AU Wong, TY
   Chong, EW
   Wong, WL
   Rosman, M
   Aung, T
   Loo, JL
   Shen, S
   Loon, SC
   Tan, DTH
   Tai, ES
   Saw, SM
AF Wong, Tien Yin
   Chong, Elaine W.
   Wong, Wan-Ling
   Rosman, Mohamad
   Aung, Tin
   Loo, Jing-Liang
   Shen, Sunny
   Loon, Seng-Chee
   Tan, Donald T. H.
   Tai, E. Shyong
   Saw, Seang-Mei
CA Singapore Malay Eye Study Team
TI Prevalence and causes of low vision and blindness in an urban Malay
   population - The Singapore Malay Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; CHINESE ADULTS; RISK-FACTORS; IMPACT; GLAUCOMA;
   DISEASES; INDIANS; PEOPLE; RATES
AB Objective: To describe the prevalence and causes of low vision and blindness in a Malay population.
   Methods: A population-based, cross-sectional study of 3280 participants of Malay ethnicity, aged 40 to 79 years, was conducted. Participants underwent standardized ophthalmic assessments to determine (1) presenting and best-corrected visual acuity according to US and modified World Health Organization definitions of blindness and low vision and (2) the primary causes of visual impairment.
   Results: Of 4168 eligible individuals, 3280 participated in the study (78.7%). The population-weighted prevalence of bilateral blindness was 0.3% and of bilateral low vision, 4.4% (US definition of presenting visual acuity). After best-corrected visual acuity, the population-weighted prevalence of bilateral blindness was reduced to 0.1% and bilateral low vision to 1.0%. Cataract was the main cause of presenting unilateral (38.9%) and bilateral (65.2%) blindness, whereas undercorrected refractive error was the main cause of presenting unilateral (68.8%) and bilateral (52.2%) low vision. Diabetic retinopathy, age-related macular degeneration, and glaucoma were the other leading causes of blindness and low vision.
   Conclusions: The age-standardized prevalences of bilateral blindness and low vision in a Malay population were lower when compared with other Asian studies. Undercorrected refractive error and cataract are the leading causes of visual impairment among the Malay adult population in Singapore.
C1 [Wong, Tien Yin; Chong, Elaine W.; Aung, Tin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Wong, Tien Yin; Saw, Seang-Mei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Saw, Seang-Mei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Community Occupat & Family Med, Singapore 117595, Singapore.
   [Wong, Tien Yin; Wong, Wan-Ling; Aung, Tin; Tan, Donald T. H.; Saw, Seang-Mei] Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Yin; Rosman, Mohamad; Aung, Tin; Loo, Jing-Liang; Shen, Sunny; Tan, Donald T. H.; Saw, Seang-Mei] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Loon, Seng-Chee] Natl Univ Singapore Hosp, Singapore 117548, Singapore.
   [Tai, E. Shyong] Singapore Gen Hosp, Dept Endocrinol, Singapore 0316, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; National
   University of Singapore; National University of Singapore; National
   University of Singapore; Singapore National Eye Center; Singapore
   National Eye Center; National University of Singapore; Singapore General
   Hospital
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Tai, E Shyong/J-9831-2013
OI Wong, Tien Yin/0000-0002-8448-1264; Tielsch, James/0000-0002-1151-060X;
   Tai, E Shyong/0000-0003-2929-8966
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Eong K. G. Au, 1993, Singapore Medical Journal, V34, P489
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Foster A, 2005, EYE, V19, P1133, DOI 10.1038/sj.eye.6701973
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Hill C, 2007, AM J HUM GENET, V80, P29, DOI 10.1086/510412
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Iwano M, 2004, JPN J OPHTHALMOL, V48, P37, DOI 10.1007/s10384-003-0013-3
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LEOW B, 2001, SINGAPORE CENSUS POP, V5
   Leow B, 2001, SINGAPORE CENSUS POP
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   *POP REF BUR, 2006 WORLD POP DAT S
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   Reddy S C, 2004, Med J Malaysia, V59, P212
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Saw SM, 2003, BRIT J OPHTHALMOL, V87, P1075, DOI 10.1136/bjo.87.9.1075
   Saw SM, 2004, OPHTHALMOLOGY, V111, P2168, DOI 10.1016/j.ophtha.2004.05.032
   Tan CE, 1999, DIABETES CARE, V22, P241, DOI 10.2337/diacare.22.2.241
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Vitale S, 2006, JAMA-J AM MED ASSOC, V295, P2158, DOI 10.1001/jama.295.18.2158
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   *WHO, MAGN CAUS VIS IMP
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong TY, 1999, ARCH OPHTHALMOL-CHIC, V117, P379, DOI 10.1001/archopht.117.3.379
   Wong TY, 2001, ARCH OPHTHALMOL-CHIC, V119, P727, DOI 10.1001/archopht.119.5.727
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   Wong TY, 2000, BRIT J OPHTHALMOL, V84, P990, DOI 10.1136/bjo.84.9.990
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Zainal M, 1998, Med J Malaysia, V53, P46
   Zainal M, 2002, BRIT J OPHTHALMOL, V86, P951, DOI 10.1136/bjo.86.9.951
NR 38
TC 123
Z9 128
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2008
VL 126
IS 8
BP 1091
EP 1099
DI 10.1001/archopht.126.8.1091
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 336PQ
UT WOS:000258377500010
PM 18695104
DA 2022-11-30
ER

PT J
AU Abdolrahimzadeh, S
   Fragiotta, S
   Ciacimino, C
   Di Pippo, M
   Scuderi, G
AF Abdolrahimzadeh, Solmaz
   Fragiotta, Serena
   Ciacimino, Chiara
   Di Pippo, Mariachiara
   Scuderi, Gianluca
TI Choroidal Vascularity Index in Adult-Onset Foveomacular Vitelliform
   Dystrophy: A Pilot Study
SO APPLIED SCIENCES-BASEL
LA English
DT Article
DE adult-onset foveomacular vitelliform dystrophy; age-related macular
   degeneration; choroidal thickness; choroidal vascularity index;
   conventional drusen; spectral domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; BINARIZATION; THICKNESS; FEATURES; EYES
AB This pilot study aims to investigate choroidal vascular status in eyes with adult-onset foveomacular vitelliform dystrophy (AOFVD), early age-related macular degeneration (AMD), and age-matched controls. In this retrospective study, choroidal thickness (CT) was measured manually using spectral domain optical coherence tomography images of the fovea, and 500 and 1500 mu m from the nasal and temporal regions in the fovea. The horizontal B-scan was imported into Fiji software. Choroidal vascularity index (CVI) and luminal and stromal areas were calculated. A total of 36 eyes from 36 patients, including 18 eyes with AOFVD and 18 eyes with CD, and 16 eyes of healthy subjects were included. CVI was significantly different among subgroups (ANOVA, p = 0.004). Eyes with AOFVD presented a higher CVI (+0.03 & PLUSMN; 0.01, p = 0.001) than eyes with CD and controls (p = 0.03). No differences in CVI were detected between controls and eyes with CD (p = 0.25). AOFVD eyes accounted for the greatest luminal area, particularly significant in comparison with healthy controls (+0.27 & PLUSMN; 0.11, p = 0.02). AOFVD eyes present a greater CVI than eyes with CD and controls. The major choroidal involvement is on the luminal component, further corroborating a possible role of the choroidal vasculature in the pathological manifestations of AOFVD disease.
C1 [Abdolrahimzadeh, Solmaz; Fragiotta, Serena; Ciacimino, Chiara; Di Pippo, Mariachiara; Scuderi, Gianluca] Sapienza Univ Rome, St Andrea Hosp, Neurosci Mental Hlth & Sensory Organs NESMOS Dept, Ophthalmol Unit, Via Grottarossa 1035-1039, I-00189 Rome, Italy.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea
RP Abdolrahimzadeh, S (通讯作者)，Sapienza Univ Rome, St Andrea Hosp, Neurosci Mental Hlth & Sensory Organs NESMOS Dept, Ophthalmol Unit, Via Grottarossa 1035-1039, I-00189 Rome, Italy.
EM solmaz.abdolrahimzadeh@uniroma1.it; serena.fragiotta@uniroma1.it;
   chiara.ciancimino@uniroma1.it; mariachiara.dipippo@gmail.com;
   gianluca.scuderi@uniroma1.it
RI Fragiotta, Serena/I-5227-2016
OI Fragiotta, Serena/0000-0002-6214-6270; Scuderi,
   Gianluca/0000-0003-0744-0722; Di Pippo, Mariachiara/0000-0002-1089-2060
CR Agrawal R, 2017, ACTA OPHTHALMOL, V95, pe770, DOI 10.1111/aos.13442
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Altinkaynak H, 2016, CURR EYE RES, V41, P708, DOI 10.3109/02713683.2015.1020168
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Carnevali A, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10248865
   Carnevali A, 2018, EXPERT REV OPHTHALMO, V13, P161, DOI 10.1080/17469899.2018.1483722
   Cennamo G, 2020, PHOTODIAGN PHOTODYN, V30, DOI 10.1016/j.pdpdt.2020.101702
   Chowers I, 2015, PROG RETIN EYE RES, V47, P64, DOI 10.1016/j.preteyeres.2015.02.001
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   Grenga PL, 2016, EUR J OPHTHALMOL, V26, P145, DOI 10.5301/ejo.5000687
   Iovino C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020595
   Nagasato D, 2019, GRAEF ARCH CLIN EXP, V257, P2391, DOI 10.1007/s00417-019-04427-7
   Nickla DL, 2002, INVEST OPHTH VIS SCI, V43, P2519
   Ozcaliskan S, 2020, EUR J OPHTHALMOL, V30, P1512, DOI 10.1177/1120672120919341
   Palacios Renato Menezes, 2016, Int J Retina Vitreous, V2, P5, DOI 10.1186/s40942-016-0031-1
   Parodi MB, 2018, RETINA-J RET VIT DIS, V38, P237, DOI 10.1097/IAE.0000000000001539
   Puche N, 2014, GRAEF ARCH CLIN EXP, V252, P555, DOI 10.1007/s00417-013-2493-2
   Querques G, 2016, BRIT J OPHTHALMOL, V100, P1724, DOI 10.1136/bjophthalmol-2016-308370
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   Rabiolo A, 2016, EXPERT REV OPHTHALMO, V11, P243, DOI 10.1080/17469899.2016.1209409
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Wei X, 2018, INVEST OPHTH VIS SCI, V59, P1206, DOI 10.1167/iovs.17-22720
NR 27
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD NOV
PY 2021
VL 11
IS 21
AR 10487
DI 10.3390/app112110487
PG 9
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA XJ7SZ
UT WOS:000726984000001
OA gold
DA 2022-11-30
ER

PT J
AU Obata, R
   Yoshinaga, A
   Yamamoto, M
   Komatsu, K
   Aoki, N
   Yamanari, M
   Sugiyama, S
   Minami, T
   Azuma, K
   Inoue, T
   Aihara, M
   Kato, S
AF Obata, Ryo
   Yoshinaga, Akie
   Yamamoto, Motoshi
   Komatsu, Kayoko
   Aoki, Nobuyori
   Yamanari, Masahiro
   Sugiyama, Satoshi
   Minami, Takahiro
   Azuma, Keiko
   Inoue, Tatsuya
   Aihara, Makoto
   Kato, Satoshi
TI Imaging of a retinal pigment epithelium aperture using
   polarization-sensitive optical coherence tomography
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Aperture; Polarization-sensitive
   optical coherence tomography; Retinal pigment epithelium
ID IN-VIVO; MACULAR DEGENERATION; JONES-MATRIX; DETACHMENT; BIREFRINGENCE;
   PROGRESSION; EVOLUTION; ATROPHY
AB Purpose To evaluate cases with a retinal pigment epithelium (RPE) aperture using polarization-sensitive optical coherence tomography (PS-OCT). Study design Retrospective consecutive case series. Methods A retrospective study that included three eyes (three patients) with RPE aperture and age-related macular degeneration (AMD) evaluated at the Macular Clinic in Tokyo University Hospital. A three-dimensional dataset of depolarization information was obtained with a clinical prototype of PS-OCT. Results All patients were categorized as intermediate AMD. RPE apertures were identified with PS-OCT as discontinuities of depolarization in the RPE layer of the pigment epithelial detachment (PED). A nonuniform decrease of depolarization in the RPE layer was also observed around the aperture. Two findings were observed above the aperture, intraretinal focal areas with high reflectivity and increased depolarization and subretinal bands with moderate reflectivity and low depolarization. Retinal sensitivity according to fundus microperimetry measured at 25 points was significantly associated with the degree of depolarization at the corresponding area (r-square = 0.60, p = 0.0001). Conclusion The RPE aperture was characterized as a round discontinuity of depolarization. The findings with PS-OCT suggest atrophic changes in the overlying RPE of the PED. The degree of depolarization was associated with retinal sensitivity. The current results indicate that RPE apertures developed within the spectrum of atrophic AMD.
C1 [Obata, Ryo; Yoshinaga, Akie; Yamamoto, Motoshi; Komatsu, Kayoko; Minami, Takahiro; Azuma, Keiko; Inoue, Tatsuya; Aihara, Makoto; Kato, Satoshi] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan.
   [Obata, Ryo; Yoshinaga, Akie; Yamamoto, Motoshi; Komatsu, Kayoko; Minami, Takahiro; Azuma, Keiko; Inoue, Tatsuya; Aihara, Makoto; Kato, Satoshi] Univ Tokyo, Fac Med, Tokyo 1138655, Japan.
   [Yoshinaga, Akie] Saitama Red Cross Hosp, Dept Ophthalmol, Saitama, Japan.
   [Aoki, Nobuyori; Yamanari, Masahiro; Sugiyama, Satoshi] Tomey Corp, Nagoya, Aichi, Japan.
   [Inoue, Tatsuya] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa, Japan.
C3 University of Tokyo; University of Tokyo; Yokohama City University
RP Obata, R (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan.; Obata, R (通讯作者)，Univ Tokyo, Fac Med, Tokyo 1138655, Japan.
EM robata-tky@umin.ac.jp
FU AMED [JP19he1302011]; Japan Agency for Medical Research and Development
FX This research was supported by AMED under Grant Number JP19he1302011. N.
   Aoki, Grant (Japan Agency for Medical Research and Development); M.
   Yamanari, Grant (Japan Agency for Medical Research and Development); S.
   Sugiyama, Grant (Japan Agency for Medical Research and Development); S.
   Kato, Grant (Japan Agency for Medical Research and Development).
CR Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bansal R, 2018, INDIAN J OPHTHALMOL, V66, P83, DOI 10.4103/ijo.IJO_676_17
   Baumann B, 2015, INVEST OPHTH VIS SCI, V56, P7462, DOI 10.1167/iovs.15-17742
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2009, J BIOPHOTONICS, V2, P426, DOI 10.1002/jbio.200910031
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   deBoer JF, 1997, OPT LETT, V22, P934, DOI 10.1364/OL.22.000934
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Giannakaki-Zimmermann H, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0452-0
   Hashimoto Y, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.20
   HEE MR, 1992, J OPT SOC AM B, V9, P903, DOI 10.1364/JOSAB.9.000903
   Igarashi N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166666
   Iovino C, 2019, EYE, V33, P1871, DOI 10.1038/s41433-019-0505-0
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   MIURA M, 2019, SCI REP UK, V9
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Molina-Pallete R, 2018, RETIN CASES BRIEF RE, DOI 10.1097/icb.0000000000000789
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Notani S, 2015, JPN J OPHTHALMOL, V59, P305, DOI 10.1007/s10384-015-0391-3
   Pircher M, 2004, OPT EXPRESS, V12, P5940, DOI 10.1364/OPEX.12.005940
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Querques G, 2016, RETINA-J RET VIT DIS, V36, pS65, DOI 10.1097/IAE.0000000000001231
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Shiraki K, 2001, GRAEF ARCH CLIN EXP, V239, P430, DOI 10.1007/s004170100304
   Yamanari M, 2019, BIOMED OPT EXPRESS, V10, P2318, DOI 10.1364/BOE.10.002318
   Yamanari M, 2016, BIOMED OPT EXPRESS, V7, P3551, DOI 10.1364/BOE.7.003551
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 37
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2021
VL 65
IS 1
BP 30
EP 41
DI 10.1007/s10384-020-00787-4
EA NOV 2020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QA5QB
UT WOS:000588278000001
PM 33170370
DA 2022-11-30
ER

PT J
AU Cai, WT
   Chen, QJ
   Shen, TY
   Yang, Q
   Hu, WN
   Zhao, P
   Yu, J
AF Cai, Wenting
   Chen, Qijing
   Shen, Tianyi
   Yang, Qian
   Hu, Weinan
   Zhao, Peng
   Yu, Jing
TI Intravenous anti-VEGF agents with RGD peptide-targeted core cross-linked
   star (CCS) polymers modified with indocyanine green for imaging and
   treatment of laser-induced choroidal neovascularization
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID GENE DELIVERY; IN-VITRO; ESTER) NANOPARTICLES; GROWTH; ANGIOGENESIS;
   INHIBITION; RANIBIZUMAB; MODEL; ALPHA(V)BETA(3); EXPRESSION
AB Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss among elderly persons, of which wet AMD is characterized by choroidal neovascularization (CNV). We herein developed nanoparticles with good biosafety for effective treatment of choroidal neovascularization (CNV). S-PEG-ICG-RGD-RBZ NPs were synthesized and characterized by ZP, DLS, UV-Vis, TEM and Coomassie Brilliant Blue staining analyses. In our study, the S-PEG-ICG-RGD-RBZ NPs exhibited good biocompatibilityin vitroandin vivo. There was no cellular toxicity, dead cells, apoptosis or genotoxicity in the studied concentration rangein vitro; meanwhile, intravenous injection of the designed NPs did not cause histological damage or apoptosis in the organsin vivo, including the heart, liver, spleen, lung, kidneys and brain. The designed NPs inhibited VEGF-induced proliferation, cell migration, tube formation and expression of CD31 and VEGFin vitro. Meanwhile,in vivostudies also indicated the inhibition of CNV development by NPs. What's more, the CNV area was imaged after intravenous injection of NPs modified with indocyanine green. The NPs were mainly targeted to CNV areas and did not remain in the other organs. In summary, S-PEG modified with RGD was designed as a powerful carrier to deliver anti-VEGF agents to CNV areas. The smart NPs, which have good cellular compatibility, hold great potential for drug delivery in CNV treatment.
C1 [Cai, Wenting; Shen, Tianyi; Yang, Qian; Yu, Jing] Tongii Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai 200072, Peoples R China.
   [Chen, Qijing; Zhao, Peng] Tongii Univ, Inst Translat Med, Inst Biomed Engn & Nanosci, Shanghai East Hosp,Sch Med, Shanghai 200092, Peoples R China.
   [Yang, Qian] Anhui Med Univ, Hefei 230032, Peoples R China.
   [Hu, Weinan] Anhui Univ Sci & Technol, Dept Ophthalmol, Huainan 232001, Peoples R China.
C3 Anhui Medical University; Anhui University of Science & Technology
RP Yu, J (通讯作者)，Tongii Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai 200072, Peoples R China.; Zhao, P (通讯作者)，Tongii Univ, Inst Translat Med, Inst Biomed Engn & Nanosci, Shanghai East Hosp,Sch Med, Shanghai 200092, Peoples R China.
EM zp@tongji.edu.cn; dryujing@aliyun.com
OI Yang, Qian/0000-0001-5906-6221
FU Natural Science Foundation of Shanghai [19ZR1439500]; National Natural
   Science Foundation of China [21801189]; Fundamental Research Funds for
   the Central Universities [22120180509]; Public Welfare Projects of
   Ningbo [2019C50051]; Medical and Health Research Project of Zhejiang
   [2019KY643]
FX This work was authored by Shanghai Tenth People's Hospital and Tonji
   university. W. T. Cai and Q. J. Chen synthesized the nanoparticles and
   wrote the manuscript. T. Y. Shen and W. N. Hu finished the in vitro
   experiments. W. T. Cai and Q. Yang performed the in vivo experiments. P.
   Zhao and J. Yu conducted the experiments. This study was financially
   supported by the Natural Science Foundation of Shanghai (No.
   19ZR1439500), the National Natural Science Foundation of China (No.
   21801189), Fundamental Research Funds for the Central Universities (No.
   22120180509), Public Welfare Projects of Ningbo (No. 2019C50051) and
   Medical and Health Research Project of Zhejiang (No. 2019KY643).
CR Abdelhalim MAK, 2018, INT J NANOMED, V13, P7765, DOI 10.2147/IJN.S183281
   Abedi G, 2013, SEMIN OPHTHALMOL, V28, P126, DOI 10.3109/08820538.2013.771195
   Adamus G, 2017, AUTOIMMUN REV, V16, P231, DOI 10.1016/j.autrev.2017.01.005
   Bi JJ, 2014, J HUAZHONG U SCI-MED, V34, P299, DOI 10.1007/s11596-014-1274-4
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Cerezo AB, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030249
   Chen HY, 2015, MOL PHARMACEUT, V12, P1885, DOI 10.1021/mp500512z
   Chen Q, 2015, ANAL CHEM, V87, P3949, DOI 10.1021/acs.analchem.5b00135
   Chen QJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09216-y
   Chen QJ, 2014, MACROMOL RAPID COMM, V35, P1148, DOI 10.1002/marc.201400085
   Chen XF, 2015, BIOMATER SCI-UK, V3, P870, DOI 10.1039/c5bm00061k
   Chen Y, 2017, ACS APPL MATER INTER, V9, P30519, DOI 10.1021/acsami.7b10148
   Chen Y, 2016, ACS APPL MATER INTER, V8, P490, DOI 10.1021/acsami.5b09437
   Contois LW, 2015, ANGIOGENESIS, V18, P31, DOI 10.1007/s10456-014-9445-2
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   de Cogan F, 2017, INVEST OPHTH VIS SCI, V58, P2578, DOI 10.1167/iovs.16-20072
   Durand ML, 2013, CLIN MICROBIOL INFEC, V19, P227, DOI 10.1111/1469-0691.12118
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Grisanti S, 2010, OPHTHALMOLOGE, V107, P1123, DOI 10.1007/s00347-010-2299-0
   Hollanders K, 2015, INVEST OPHTH VIS SCI, V56, P1335, DOI 10.1167/iovs.14-15681
   Huang XX, 2017, INT J NANOMED, V12, P2215, DOI 10.2147/IJN.S130037
   Kim J, 2016, SMALL, V12, P1184, DOI 10.1002/smll.201501655
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lavine JA, 2017, INVEST OPHTH VIS SCI, V58, P299, DOI 10.1167/iovs.16-20204
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luna J, 1996, LAB INVEST, V75, P563
   Matuszak J, 2016, NANOMEDICINE-UK, V11, P597, DOI 10.2217/nnm.15.216
   Meyer J, 2014, INVEST OPHTH VIS SCI, V55, P6204, DOI 10.1167/iovs.13-13617
   Oyeyemi O, 2018, FRONT PHARMACOL, V9, DOI [10.3380/fphar.2018.00562, 10.3389/fphar.2018.00562]
   Park SL, 2016, AM J CHINESE MED, V44, P61, DOI 10.1142/S0192415X1650004X
   Rush RB, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/642624
   Sachdeva MM, 2016, J OPHTHALMIC INFLAMM, V6, DOI 10.1186/s12348-015-0069-5
   Schraa AJ, 2002, INT J CANCER, V102, P469, DOI 10.1002/ijc.10727
   Siedlecki J, 2017, GRAEF ARCH CLIN EXP, V255, P963, DOI 10.1007/s00417-017-3595-z
   Singh RSJ, 2012, DRUG AGING, V29, P949, DOI 10.1007/s40266-012-0031-2
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Sun CR, 2010, ACS NANO, V4, P2402, DOI 10.1021/nn100190v
   Nguyen V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42324-5
   Wang JL, 2013, INVEST OPHTH VIS SCI, V54, P7983, DOI 10.1167/iovs.13-13068
   Wang WQ, 2016, MOL PHARMACEUT, V13, P2881, DOI 10.1021/acs.molpharmaceut.6b00056
   Xu HL, 2015, ACTA BIOMATER, V16, P156, DOI 10.1016/j.actbio.2015.01.039
   Yan ZZ, 2018, MOL VIS, V24, P83
   Yang J, 2017, ACS APPL MATER INTER, V9, P4485, DOI 10.1021/acsami.6b14769
   Yang Y, 2020, BIOMATERIALS, V246, DOI 10.1016/j.biomaterials.2020.119971
   Zhang H, 2019, BIOMATER SCI-UK, V7, P5177, DOI 10.1039/c9bm01284b
   Zhang L, 2018, INT J NANOMED, V13, P2051, DOI 10.2147/IJN.S151233
NR 49
TC 5
Z9 5
U1 6
U2 28
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047-4830
EI 2047-4849
J9 BIOMATER SCI-UK
JI Biomater. Sci.
PD AUG 21
PY 2020
VL 8
IS 16
BP 4481
EP 4491
DI 10.1039/c9bm02086a
PG 11
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA MY2CF
UT WOS:000558225900008
PM 32609105
OA hybrid
DA 2022-11-30
ER

PT J
AU Yam, M
   Engel, AL
   Wang, YK
   Zhu, SY
   Hauer, A
   Zhang, R
   Lohner, D
   Huang, JC
   Dinterman, M
   Zhao, C
   Chao, JR
   Du, JH
AF Yam, Michelle
   Engel, Abbi L.
   Wang, Yekai
   Zhu, Siyan
   Hauer, Allison
   Zhang, Rui
   Lohner, Daniel
   Huang, Jiancheng
   Dinterman, Marlee
   Zhao, Chen
   Chao, Jennifer R.
   Du, Jianhai
TI Proline mediates metabolic communication between retinal pigment
   epithelial cells and the retina
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE retinal metabolism; amino acid; mitochondrial metabolism; tricarboxylic
   acid cycle (TCA cycle) (Krebs cycle); cell metabolism; age-related
   macular degeneration (AMD); glucose metabolism; oxidative stress; visual
   function; proline; retinal pigment epithelium; retina
ID ORNITHINE CYTOTOXICITY; MOLECULAR SIGNATURE; GYRATE ATROPHY; SODIUM
   IODATE; MOUSE RETINA; DIFFERENTIATION; TRANSPORT; PATHWAYS; MODEL;
   DEGENERATION
AB The retinal pigment epithelium (RPE) is a monolayer of pigmented cells between the choroid and the retina. RPE dysfunction underlies many retinal degenerative diseases, including age-related macular degeneration, the leading cause of age-related blindness. To perform its various functions in nutrient transport, phagocytosis of the outer segment, and cytokine secretion, the RPE relies on an active energy metabolism. We previously reported that human RPE cells prefer proline as a nutrient and transport proline-derived metabolites to the apical, or retinal, side. In this study, we investigated how RPE utilizes proline in vivo and why proline is a preferred substrate. By using [C-13]proline labeling both ex vivo and in vivo, we found that the retina rarely uses proline directly, whereas the RPE utilizes it at a high rate, exporting proline-derived mitochondrial intermediates for use by the retina. We observed that in primary human RPE cell culture, proline is the only amino acid whose uptake increases with cellular maturity. In human RPE, proline was sufficient to stimulate de novo serine synthesis, increase reductive carboxylation, and protect against oxidative damage. Blocking proline catabolism in RPE impaired glucose metabolism and GSH production. Notably, in an acute model of RPE-induced retinal degeneration, dietary proline improved visual function. In conclusion, proline is an important nutrient that supports RPE metabolism and the metabolic demand of the retina.
C1 [Yam, Michelle; Wang, Yekai; Zhu, Siyan; Hauer, Allison; Zhang, Rui; Lohner, Daniel; Huang, Jiancheng; Dinterman, Marlee; Du, Jianhai] West Virginia Univ, Dept Ophthalmol, Morgantown, WV 26506 USA.
   [Yam, Michelle; Wang, Yekai; Zhu, Siyan; Hauer, Allison; Lohner, Daniel; Dinterman, Marlee; Du, Jianhai] West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA.
   [Engel, Abbi L.; Chao, Jennifer R.] Univ Washington, Dept Ophthalmol, Seattle, WA 98109 USA.
   [Zhang, Rui] Univ Sydney, Save Sight Inst, 8 Macquarie St, Sydney, NSW, Australia.
   [Huang, Jiancheng; Zhao, Chen] Fudan Univ, Shanghai Med Coll, Eye Inst, Eye & ENT Hosp, Shanghai 200031, Peoples R China.
   [Huang, Jiancheng] Nanjing Med Univ, Affiliated Hosp 1, State Key Lab Reprod Med, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
C3 West Virginia University; West Virginia University; University of
   Washington; University of Washington Seattle; University of Sydney;
   Fudan University; Nanjing Medical University
RP Chao, JR (通讯作者)，750 Republican St,Box 358058, Seattle, WA 98109 USA.; Du, JH (通讯作者)，WVU Eye Inst, One Med Ctr Dr,POB 9193, Morgantown, WV 26505 USA.
EM jrchao@uw.edu; jianhai.du@wvumedicine.org
OI Yam, Michelle/0000-0001-5250-994X; Chao, Jennifer/0000-0002-6859-5552
FU National Institutes of Health [EY026030]; BrightFocus Foundation; Retina
   Research Foundation; Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [R01EY026030] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grant EY026030
   (to J. R. C. and J. D.), the BrightFocus Foundation (to J. D. and J. R.
   C.), the Retina Research Foundation (to J. D.), and an unrestricted
   grant from Research to Prevent Blindness (to J. R. C.). The authors
   declare that they have no conflicts of interest with the contents of
   this article. The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the National
   Institutes of Health.
CR Adachi R, 2017, BIOCHEM BIOPH RES CO, V488, P393, DOI 10.1016/j.bbrc.2017.05.064
   Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Agathocleous M, 2013, TRENDS CELL BIOL, V23, P484, DOI 10.1016/j.tcb.2013.05.004
   Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Allmann S, 2013, J BIOL CHEM, V288, P18494, DOI 10.1074/jbc.M113.462978
   Ando A, 2000, EXP EYE RES, V70, P89, DOI 10.1006/exer.1999.0750
   Ayala JE, 2011, JOVE-J VIS EXP, DOI 10.3791/3188
   Ben Rejeb K, 2014, PLANT PHYSIOL BIOCH, V80, P278, DOI 10.1016/j.plaphy.2014.04.007
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Bui BV, 2009, J NEUROCHEM, V111, P589, DOI 10.1111/j.1471-4159.2009.06354.x
   BURSELL E, 1973, T ROY SOC TROP MED H, V67, P296, DOI 10.1016/0035-9203(73)90222-8
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007
   Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113
   Du JH, 2015, METHOD ENZYMOL, V561, P149, DOI 10.1016/bs.mie.2015.04.002
   Du JH, 2013, P NATL ACAD SCI USA, V110, P18501, DOI 10.1073/pnas.1311193110
   Edwards C, 2015, BMC GENET, V16, DOI 10.1186/s12863-015-0167-2
   Elia I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15267
   Eswarappa SM, 2018, J BIOL CHEM, V293, P19148, DOI 10.1074/jbc.RA118.004276
   Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Gao XR, 2019, HUM MOL GENET, V28, P1162, DOI 10.1093/hmg/ddy422
   Gu HW, 2015, ANALYST, V140, P2726, DOI 10.1039/c4an02386b
   Hancock CN, 2016, AMINO ACIDS, V48, P859, DOI 10.1007/s00726-015-2134-7
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Hirabayashi Y, 2008, PROG LIPID RES, V47, P188, DOI 10.1016/j.plipres.2008.01.003
   HIRATA A, 1992, INVEST OPHTH VIS SCI, V33, P2079
   Hu CA, 1999, J BIOL CHEM, V274, P6754, DOI 10.1074/jbc.274.10.6754
   Hu J, 2001, MOL VIS, V7, P14
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Hwang IY, 2016, CELL METAB, V24, P494, DOI 10.1016/j.cmet.2016.06.014
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Kigasawa Kazuteru, 1998, Tokai Journal of Experimental and Clinical Medicine, V23, P147
   Krishnan N, 2008, FREE RADICAL BIO MED, V44, P671, DOI 10.1016/j.freeradbiomed.2007.10.054
   LI W, 1984, EXP EYE RES, V38, P291, DOI 10.1016/0014-4835(84)90167-2
   Liang XW, 2013, ANTIOXID REDOX SIGN, V19, P998, DOI 10.1089/ars.2012.5074
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liu LK, 2017, ARCH BIOCHEM BIOPHYS, V632, P142, DOI 10.1016/j.abb.2017.07.005
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   McDonald AE, 2018, COMP BIOCHEM PHYS B, V224, P185, DOI 10.1016/j.cbpb.2017.11.006
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   ODONNELL JJ, 1978, SCIENCE, V200, P200, DOI 10.1126/science.635581
   Phang JM, 2008, AMINO ACIDS, V35, P681, DOI 10.1007/s00726-008-0063-4
   Phang JM, 2010, ANNU REV NUTR, V30, P441, DOI 10.1146/annurev.nutr.012809.104638
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   REICHENBACH A, 1992, CAN J PHYSIOL PHARM, V70, pS239, DOI 10.1139/y92-267
   de Pouplana LR, 2018, J BIOL CHEM, V293, P19157, DOI 10.1074/jbc.H118.006600
   Schroeder EA, 2012, CELL METAB, V15, P417, DOI 10.1016/j.cmet.2012.03.011
   Seiler Nikolaus, 2000, Current Drug Targets, V1, P119, DOI 10.2174/1389450003349254
   Sinha T, 2018, J NUTR BIOCHEM, V62, P123, DOI 10.1016/j.jnutbio.2018.09.003
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Ueda M, 1998, INVEST OPHTH VIS SCI, V39, P820
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang T, 1996, J CLIN INVEST, V97, P2753, DOI 10.1172/JCI118730
   WANG T, 1995, NAT GENET, V11, P185, DOI 10.1038/ng1095-185
   Wang YK, 2018, NEUROBIOL AGING, V71, P223, DOI 10.1016/j.neurobiolaging.2018.07.024
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Wolthuis DFGJ, 2014, EUR J PAEDIATR NEURO, V18, P511, DOI 10.1016/j.ejpn.2014.01.003
   Xiong GF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-1
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Zarse K, 2012, CELL METAB, V15, P451, DOI 10.1016/j.cmet.2012.02.013
   Zhang L, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00552
   Zheng X, 2016, ELIFE, V5, DOI [10.7554/eLife.13374, 10.7554/eLife.18638]
   Zhu SY, 2018, EXP EYE RES, V174, P113, DOI 10.1016/j.exer.2018.05.032
NR 70
TC 40
Z9 42
U1 2
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 28
PY 2019
VL 294
IS 26
BP 10278
EP 10289
DI 10.1074/jbc.RA119.007983
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA IH4EW
UT WOS:000474445600018
PM 31110046
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Dorschmann, P
   Bittkau, KS
   Neupane, S
   Roider, J
   Alban, S
   Klettner, A
AF Doerschmann, Philipp
   Bittkau, Kaya Saskia
   Neupane, Sandesh
   Roider, Johann
   Alban, Susanne
   Klettner, Alexa
TI Effects of Fucoidans from Five Different Brown Algae on Oxidative Stress
   and VEGF Interference in Ocular Cells
SO MARINE DRUGS
LA English
DT Article
DE fucoidan; age-related macular degeneration; VEGF; oxidative stress;
   Saccharina latissima; Fucus vesiculosus; Fucus distichus subsp;
   evanescens; Fucus serratus; Laminaria digitata
ID MACULAR DEGENERATION; GROWTH-FACTOR; SULFATED POLYSACCHARIDES; IN-VITRO;
   ANTIOXIDANT; RANIBIZUMAB; ACTIVATION
AB Background: Fucoidans are interesting for potential usage in ophthalmology, and especially age-related macular degeneration. However, fucoidans from different species may vary in their effects. Here, we compare fucoidans from five algal species in terms of oxidative stress protection and vascular endothelial growth factor (VEGF) interference in ocular cells. Methods: Brown algae (Fucus vesiculosus, Fucus distichus subsp. evanescens, Fucus serratus, Laminaria digitata, Saccharina latissima) were harvested and fucoidans isolated by hot-water extraction. Fucoidans were tested in several concentrations (1, 10, 50, and 100 mu g/mL). Effects were measured on a uveal melanoma cell line (OMM-1) (oxidative stress), retinal pigment epithelium (RPE) cell line ARPE19 (oxidative stress and VEGF), and primary RPE cells (VEGF). Oxidative stress was induced by H2O2 or tert-Butyl hydroperoxide (TBHP). Cell viability was investigated with methyl thiazolyl tetrazolium (MTT or MTS) assay, and VEGF secretion with ELISA. Affinity to VEGF was determined by a competitive binding assay. Results: All fucoidans protected OMM-1 from oxidative stress. However, in ARPE19, only fucoidan from Saccharina latissima was protective. The affinity to VEGF of all fucoidans was stronger than that of heparin, and all reduced VEGF secretion in ARPE19. In primary RPE, only the fucoidan from Saccharina latissima was effective. Conclusion: Among the fucoidans from five different species, Saccharina latissima displayed the most promising results concerning oxidative stress protection and reduction of VEGF secretion.
C1 [Doerschmann, Philipp; Roider, Johann; Klettner, Alexa] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
   [Bittkau, Kaya Saskia; Neupane, Sandesh; Alban, Susanne] Univ Kiel, Pharmaceut Inst, Dept Pharmaceut Biol, Gutenbergstr 76, D-24118 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
EM Philipp.Doerschmann@uksh.de; kbittkau@pharmazie.uni-kiel.de;
   sneupane@pharmazie.uni-kiel.de; johann.roider@uksh.de;
   salban@pharmazie.uni-kiel.de; alexakarina.klettner@uksh.de
RI Neupane, Sandesh/X-3267-2019
OI Neupane, Sandesh/0000-0002-5167-9848; Klettner,
   Alexa/0000-0002-2709-1059; Alban, Susanne/0000-0003-1993-3751
FU EU InterReg Deutschland-Denmark; European Regional Development Fund,
   Project FucoSan [39-1.0-16]; Hermann-Wacker Foundation
FX The research was funded by EU InterReg Deutschland-Denmark and the
   European Regional Development Fund, Project FucoSan, grant number
   39-1.0-16. AK was funded by the Hermann-Wacker Foundation.
CR Abu R, 2013, INT J BIOL MACROMOL, V59, P305, DOI 10.1016/j.ijbiomac.2013.04.035
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Blasi MA, 1999, INVEST OPHTH VIS SCI, V40, P3012
   Chen HJ, 2016, CANCER LETT, V382, P44, DOI 10.1016/j.canlet.2016.08.020
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Croci DO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017283
   Cumashi A, 2007, GLYCOBIOLOGY, V17, P541, DOI 10.1093/glycob/cwm014
   Dithmer M, 2017, MAR DRUGS, V15, DOI 10.3390/md15070193
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Ehrig K, 2015, MAR DRUGS, V13, P76, DOI 10.3390/md13010076
   Fitton JH, 2015, MAR DRUGS, V13, P5920, DOI 10.3390/md13095920
   FOLKMAN J, 1992, ADV EXP MED BIOL, V313, P355
   Foresti R, 2015, PHARMACOL RES, V99, P296, DOI 10.1016/j.phrs.2015.07.006
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hu M, 2017, MAR DRUGS, V15, DOI 10.3390/md15020048
   Karlsson M, 2016, ACTA OPHTHALMOL, V94, P556, DOI 10.1111/aos.13076
   Kim EA, 2014, CARBOHYD POLYM, V102, P185, DOI 10.1016/j.carbpol.2013.11.022
   Kim H, 2019, BIOMED PHARMACOTHER, V109, P1718, DOI 10.1016/j.biopha.2018.11.015
   Klettner A, 2009, MINI-REV MED CHEM, V9, P1127, DOI 10.2174/138955709788922665
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2016, MAR DRUGS, V14, DOI 10.3390/md14020031
   Klettner Alexa, 2015, Med Monatsschr Pharm, V38, P258
   Klettner A, 2015, MOL VIS, V21, P736
   Klettner A, 2013, MOL VIS, V19, P281
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   Koyanagi S, 2003, BIOCHEM PHARMACOL, V65, P173, DOI 10.1016/S0006-2952(02)01478-8
   Lahrsen E, 2018, CARBOHYD POLYM, V192, P208, DOI 10.1016/j.carbpol.2018.03.056
   Li B, 2008, MOLECULES, V13, P1671, DOI 10.3390/molecules13081671
   German OL, 2015, PHOTOCH PHOTOBIO SCI, V14, P1737, DOI 10.1039/c5pp00194c
   Luyten GPM, 1996, INT J CANCER, V66, P380, DOI 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Morya VK, 2012, APPL MICROBIOL BIOT, V93, P71, DOI 10.1007/s00253-011-3666-8
   Narazaki M, 2008, BLOOD, V111, P4126, DOI 10.1182/blood-2007-09-112474
   Nishiguchi KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013493
   Pittala V, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1420892
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Platania CBM, 2019, BRIT J PHARMACOL, V176, P2179, DOI 10.1111/bph.14665
   Platania CBM, 2018, BIOCHEM PHARMACOL, V158, P13, DOI 10.1016/j.bcp.2018.09.016
   Riss T. L., 2013, ASSAY GUIDANCE MANUA, V114, P785
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rui X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1885-y
   Ruperez P, 2002, J AGR FOOD CHEM, V50, P840, DOI 10.1021/jf010908o
   Ryu MJ, 2016, MOL MED REP, V14, P3255, DOI 10.3892/mmr.2016.5623
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schneider T, 2015, GLYCOBIOLOGY, V25, P812, DOI 10.1093/glycob/cwv022
   Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9
   Tode J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.2
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Vomund S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122772
   Wang J, 2008, INT J BIOL MACROMOL, V42, P127, DOI 10.1016/j.ijbiomac.2007.10.003
   Wang YQ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124050
   Wiencke AK, 2003, ACTA OPHTHALMOL SCAN, V81, P170, DOI 10.1034/j.1600-0420.2003.00030.x
   Zarubina AV, 2017, INVEST OPHTH VIS SCI, V58, P6038, DOI 10.1167/iovs.17-22378
NR 54
TC 21
Z9 21
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD MAY
PY 2019
VL 17
IS 5
AR 258
DI 10.3390/md17050258
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IC4VH
UT WOS:000470964600011
PM 31052228
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Seebock, P
   Waldstein, SM
   Klimscha, S
   Bogunovic, H
   Schlegl, T
   Gerendas, BS
   Donner, R
   Schmidt-Erfurth, U
   Langs, G
AF Seeboeck, Philipp
   Waldstein, Sebastian M.
   Klimscha, Sophie
   Bogunovic, Hrvoje
   Schlegl, Thomas
   Gerendas, Bianca S.
   Donner, Rene
   Schmidt-Erfurth, Ursula
   Langs, Georg
TI Unsupervised Identification of Disease Marker Candidates in Retinal OCT
   Imaging Data
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Unsupervised deep learning; anomaly detection; biomarker identification;
   optical coherence tomography
ID MACULAR DEGENERATION; CLASSIFICATION
AB The identification and quantification of markers in medical images is critical for diagnosis, prognosis, and disease management. Supervised machine learning enables the detection and exploitation of findings that are known a priori after annotation of training examples by experts. However, supervision does not scale well, due to the amount of necessary training examples, and the limitation of the marker vocabulary to known entities. In this proof-of-concept study, we propose unsupervised identification of anomalies as candidates for markers in retinal optical coherencetomography (OCT) imaging data without a constraint to a priori definitions. We identify and categorize marker candidates occurring frequently in the data and demonstrate that these markers show a predictive value in the task of detecting disease. A careful qualitative analysis of the identified data driven markers reveals how their quantifiable occurrence aligns with our current understanding of disease course, in early-and late age-related macular degeneration (AMD) patients. A multi-scale deep denoising autoencoder is trained on healthy images, and a one-class support vector machine identifies anomalies in new data. Clustering in the anomalies identifies stable categories. Using these markers to classify healthy-, early AMD- and late AMD cases yields an accuracy of 81.40%. In a second binary classification experiment on a publicly available data set (healthy versus intermediate AMD), the model achieves an area under the ROC curve of 0.944.
C1 [Seeboeck, Philipp; Schlegl, Thomas; Donner, Rene; Langs, Georg] Med Univ Vienna, Computat Imaging Res Lab, Dept Biomed Imaging & Image Guided Therapy, A-1090 Vienna, Austria.
   [Seeboeck, Philipp; Waldstein, Sebastian M.; Klimscha, Sophie; Bogunovic, Hrvoje; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula; Langs, Georg] Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Waldstein, SM (通讯作者)，Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol & Optometry, Christian Doppler Lab Ophthalm Image Anal, A-1090 Vienna, Austria.
EM philipp.seeboeck@meduniwien.ac.at; sebastian.waldstein@meduniwien.ac.at;
   georg.langs@meduniwien.ac.at
RI ; Bogunovic, Hrvoje/J-3445-2014
OI Waldstein, Sebastian/0000-0003-2899-6279; Bogunovic,
   Hrvoje/0000-0002-9168-0894; Schmidt-Erfurth, Ursula/0000-0002-7788-7311;
   Schlegl, Thomas/0000-0003-0706-7876; Gerendas, Bianca
   S./0000-0001-8940-8130; Riedl, Sophie/0000-0003-0003-0886
FU Christian Doppler Research Association; Austrian Federal Ministry for
   Digital and Economic Affairs; National Foundation for Research,
   Technology, and Development through the Austrian Science Fund [FWF
   I2714-B31]; IBM; NVIDIA Corporation
FX This work was supported in part by the Christian Doppler Research
   Association, in part by the Austrian Federal Ministry for Digital and
   Economic Affairs, in part by the National Foundation for Research,
   Technology, and Development through the Austrian Science Fund under
   Grant FWF I2714-B31, in part by IBM (2016-2017 IBM Ph.D. Fellowship
   Award and Faculty Award), and in part by the NVIDIA Corporation.
CR BREIMAN L, 2001, MACH LEARN, V0045
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Clevert D. A., 2015, ARXIV151107289
   Collobert R., 2011, BIGLEARN NIPS WORKSH
   Doersch C, 2015, IEEE I CONF COMP VIS, P1422, DOI 10.1109/ICCV.2015.167
   Dosovitskiy A., 2014, P NIPS, P766, DOI [10.48550/arXiv.1406.6909, DOI 10.1109/TPAMI.2015.2496141]
   Dufour PA, 2012, LECT NOTES COMPUT SC, V7512, P599, DOI 10.1007/978-3-642-33454-2_74
   Erfani SM, 2016, PATTERN RECOGN, V58, P121, DOI 10.1016/j.patcog.2016.03.028
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Halkidi M, 2001, J INTELL INF SYST, V17, P107, DOI 10.1023/A:1012801612483
   Holzer M., 2014, P CVWW, P1
   Hornik K, 2012, J STAT SOFTW, V50, P1
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Lad EM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192646
   Lopez M, 2011, NEUROCOMPUTING, V74, P1260, DOI 10.1016/j.neucom.2010.06.025
   Mayeux Richard, 2004, NeuroRx, V1, P182, DOI 10.1602/neurorx.1.2.182
   Pimentel MAF, 2014, SIGNAL PROCESS, V99, P215, DOI 10.1016/j.sigpro.2013.12.026
   Ren SQ, 2015, ADV NEUR IN, V28, DOI 10.1109/TPAMI.2016.2577031
   Schlegl T, 2017, LECT NOTES COMPUT SC, V10265, P146, DOI 10.1007/978-3-319-59050-9_12
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Scholkopf B, 2001, NEURAL COMPUT, V13, P1443, DOI 10.1162/089976601750264965
   Seebock P., 2016, IDENTIFYING CATEGORI
   Sidibe D, 2017, COMPUT METH PROG BIO, V139, P109, DOI 10.1016/j.cmpb.2016.11.001
   Szegedy C., 2015, IEEE C COMP VIS PATT, P1, DOI DOI 10.1109/CVPR.2015.7298594
   Venhuizen FG, 2015, PROC SPIE, V9414, DOI 10.1117/12.2081521
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhao J, 2016, STACKED WHAT WHERE A
   Zhou Y., 2015, IS JOINT TRAINING BE
NR 34
TC 37
Z9 39
U1 2
U2 24
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD APR
PY 2019
VL 38
IS 4
BP 1037
EP 1047
DI 10.1109/TMI.2018.2877080
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA HS1FR
UT WOS:000463608000015
PM 30346281
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Deng, LT
   Pushpitha, K
   Joseph, C
   Gupta, V
   Rajput, R
   Chitranshi, N
   Dheer, Y
   Amirkhani, A
   Kamath, K
   Pascovici, D
   Wu, JX
   Salekdeh, GH
   Haynes, PA
   Graham, SL
   Gupta, VK
   Mirzaei, M
AF Deng, Liting
   Pushpitha, Kanishka
   Joseph, Chitra
   Gupta, Veer
   Rajput, Rashi
   Chitranshi, Nitin
   Dheer, Yogita
   Amirkhani, Ardeshir
   Kamath, Karthik
   Pascovici, Dana
   Wu, Jemma X.
   Salekdeh, Ghasem Hosseini
   Haynes, Paul A.
   Graham, Stuart L.
   Gupta, Vivek K.
   Mirzaei, Mehdi
TI Amyloid beta Induces Early Changes in the Ribosomal Machinery,
   Cytoskeletal Organization and Oxidative Phosphorylation in Retinal
   Photoreceptor Cells
SO FRONTIERS IN MOLECULAR NEUROSCIENCE
LA English
DT Article
DE proteomics; TMT; Alzheimer's disease; photoreceptor; autophagy; amyloid;
   retina
ID ALZHEIMERS-DISEASE IMPLICATIONS; MITOCHONDRIAL DYSFUNCTION; MACULAR
   DEGENERATION; PRECURSOR PROTEIN; TAU; PEPTIDE; DAMAGE; PATHOLOGIES;
   NEUROTOXICITY; ACCUMULATION
AB Amyloid beta (A beta) accumulation and its aggregation is characteristic molecular feature of the development of Alzheimer's disease (AD). More recently, A beta has been suggested to be associated with retinal pathology associated with AD, glaucoma and drusen deposits in age related macular degeneration (AMD). In this study, we investigated the proteins and biochemical networks that are affected by A beta in the 661 W photoreceptor cells in culture. Time and dose dependent effects of A beta on the photoreceptor cells were determined utilizing tandem mass tag (TMT) labeling-based quantitative mass-spectrometric approach. Bioinformatic analysis of the data revealed concentration and time dependent effects of the A beta peptide stimulation on various key biochemical pathways that might be involved in mediating the toxicity effects of the peptide. We identified increased Tau phosphorylation, GSK3 beta dysregulation and reduced cell viability in cells treated with A beta in a dose and time dependent manner. This study has delineated for the first-time molecular networks in photoreceptor cells that are impacted early upon A beta treatment and contrasted the findings with a longer-term treatment effect. Proteins associated with ribosomal machinery homeostasis, mitochondrial function and cytoskeletal organization were affected in the initial stages of A beta exposure, which may provide key insights into AD effects on the photoreceptors and specific molecular changes induced by A beta peptide.
C1 [Deng, Liting; Amirkhani, Ardeshir; Kamath, Karthik; Pascovici, Dana; Wu, Jemma X.; Salekdeh, Ghasem Hosseini; Haynes, Paul A.; Mirzaei, Mehdi] Macquarie Univ, Dept Mol Sci, Fac Sci & Engn, Sydney, NSW, Australia.
   [Pushpitha, Kanishka; Joseph, Chitra; Rajput, Rashi; Chitranshi, Nitin; Dheer, Yogita; Graham, Stuart L.; Gupta, Vivek K.; Mirzaei, Mehdi] Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia.
   [Gupta, Veer] Deakin Univ, Sch Med, Waurn Ponds, Vic, Australia.
   [Amirkhani, Ardeshir; Kamath, Karthik; Pascovici, Dana; Wu, Jemma X.; Mirzaei, Mehdi] Macquarie Univ, APAF, Sydney, NSW, Australia.
   [Salekdeh, Ghasem Hosseini] ACECR, Royan Inst Stem Cell Biol & Technol, Dept Mol Syst Biol, Cell Sci Res Ctr, Tehran, Iran.
C3 Macquarie University; Macquarie University; Deakin University; Macquarie
   University; Academic Center for Education, Culture & Research (ACECR)
RP Mirzaei, M (通讯作者)，Macquarie Univ, Dept Mol Sci, Fac Sci & Engn, Sydney, NSW, Australia.; Gupta, VK; Mirzaei, M (通讯作者)，Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia.; Mirzaei, M (通讯作者)，Macquarie Univ, APAF, Sydney, NSW, Australia.
EM Vivek.gupta@mq.edu.au; Mehdi.mirzaei@mq.edu.au
RI Chitranshi, Nitin/AAK-8831-2020; Gupta, Vivek Kumar/AAB-8940-2022;
   Salekdeh, Ghasem Hosseini/E-4198-2012
OI Salekdeh, Ghasem Hosseini/0000-0002-5124-4721; Chitranshi,
   Nitin/0000-0002-6508-9865; Dheer, Yogita/0000-0001-7525-7511; Pascovici,
   Dana/0000-0002-3266-4851; Mirzaei, Mehdi/0000-0001-8727-4984; Graham,
   Stuart/0000-0001-7519-969X; Gupta, Vivek/0000-0002-0202-7843; mirzaei,
   mahdi/0000-0001-9817-9157; Haynes, Paul/0000-0003-1472-8249; Gupta,
   Veer/0000-0003-4989-0764
FU Ophthalmic Research Institute of Australia; National Health and Medical
   Research Council (NHMRC); Hillcrest Foundation; Macquarie University
   (MQRDG); Australian Government's National Collaborative Research
   Infrastructure Scheme (NCRIS)
FX We acknowledge the support from Ophthalmic Research Institute of
   Australia, National Health and Medical Research Council (NHMRC) and
   Hillcrest Foundation and Macquarie University (MQRDG). The mass
   spectrometry analysis in this study was conducted at the Australian
   Proteome Analysis Facility supported by the Australian Government's
   National Collaborative Research Infrastructure Scheme (NCRIS).
CR Alzheimer's Association, 2016, Alzheimers Dement, V12, P459
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Avila Jesus, 2012, Int J Alzheimers Dis, V2012, P578373, DOI 10.1155/2012/578373
   Bamburg JR, 2009, CELL MOTIL CYTOSKEL, V66, P635, DOI 10.1002/cm.20388
   Ban N, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/s41514-017-0017-8
   Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   Bloom GS, 2014, JAMA NEUROL, V71, P505, DOI 10.1001/jamaneurol.2013.5847
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Busciglio J, 2002, NEURON, V33, P677, DOI 10.1016/S0896-6273(02)00604-9
   Cardenas AM, 2012, ARCH MED RES, V43, P645, DOI 10.1016/j.arcmed.2012.10.012
   Casley CS, 2002, NEUROBIOL DIS, V10, P258, DOI 10.1006/nbdi.2002.0516
   Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200
   Cheung CYL, 2015, J ALZHEIMERS DIS, V45, P45, DOI 10.3233/JAD-141659
   Chitranshi N, 2019, MOL THER, V27, P424, DOI 10.1016/j.ymthe.2018.09.019
   Chitranshi N, 2017, NEUROSCIENCE, V364, P175, DOI 10.1016/j.neuroscience.2017.09.028
   Comitato A, 2007, HUM MOL GENET, V16, P1699, DOI 10.1093/hmg/ddm118
   De Strooper B, 2010, PHYSIOL REV, V90, P465, DOI 10.1152/physrev.00023.2009
   Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006
   Dickson DW, 2004, J CLIN INVEST, V114, P23, DOI 10.1172/JC1200422317
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Ding QX, 2005, J NEUROSCI, V25, P9171, DOI 10.1523/JNEUROSCI.3040-05.2005
   Ditaranto K, 2001, NEUROBIOL DIS, V8, P19, DOI 10.1006/nbdi.2000.0364
   Gangoda SVS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20117-6
   Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199
   Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9
   Golzan SM, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0239-9
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Gupta V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08688-2
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Gupta V, 2014, BBA-MOL BASIS DIS, V1842, P1567, DOI 10.1016/j.bbadis.2014.05.026
   Gupta VK, 2016, NEUROSCI LETT, V623, P52, DOI 10.1016/j.neulet.2016.04.059
   Gupta VK, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0087-9
   Gupta VK, 2012, AM J PHYSIOL-ENDOC M, V303, pE1363, DOI 10.1152/ajpendo.00199.2012
   Gupta VK, 2010, EMBO REP, V11, P861, DOI 10.1038/embor.2010.142
   Hansson Petersen C. A., 2008, P NATL ACAD SCI USA, V105, P13145, DOI DOI 10.1073/PNAS.0806192105
   Hernandez F, 2013, J ALZHEIMERS DIS, V33, pS141, DOI 10.3233/JAD-2012-129025
   Hernandez-Ortega K, 2016, BRAIN PATHOL, V26, P593, DOI 10.1111/bpa.12335
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Julien C, 2009, J NEUROPATH EXP NEUR, V68, P48, DOI 10.1097/NEN.0b013e3181922348
   Kammers Kai, 2015, EuPA Open Proteom, V7, P11
   Ke YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035678
   Kin Chiu K. -F. S. a. R. C. - C. C, 2013, PROGR NEURODEGENERAT
   Koh SH, 2008, BRAIN RES, V1188, P254, DOI 10.1016/j.brainres.2007.10.064
   Koronyo Y, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93621
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Liu BQ, 2009, AM J PATHOL, V175, P2099, DOI 10.2353/ajpath.2009.090159
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lunnon K, 2017, NEUROBIOL AGING, V53, P36, DOI 10.1016/j.neurobiolaging.2016.12.029
   Lv JN, 2017, SCI REP-UK, V7, DOI 10.1038/srep43062
   Mangieri LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093257
   Mao PZ, 2011, BBA-MOL BASIS DIS, V1812, P1359, DOI 10.1016/j.bbadis.2011.08.005
   Margolin AA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007454
   Masuzzo A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00127
   Mirzaei M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12858-7
   Mirzaei M, 2017, METHODS MOL BIOL, V1549, P45, DOI 10.1007/978-1-4939-6740-7_5
   Mossmann D, 2014, CELL METAB, V20, P662, DOI 10.1016/j.cmet.2014.07.024
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Nuzzo D, 2017, J PROTEOME RES, V16, P1526, DOI 10.1021/acs.jproteome.6b00925
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reddy PH, 2013, BBA-MOL BASIS DIS, V1832, P1913, DOI 10.1016/j.bbadis.2013.06.012
   Rhein V, 2009, P NATL ACAD SCI USA, V106, P20057, DOI 10.1073/pnas.0905529106
   Richens JL, 2016, SCI REP-UK, V6, DOI 10.1038/srep22962
   Ruzickova S, 2017, RNA BIOL, V14, P544, DOI 10.1080/15476286.2016.1191735
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sharoar MG, 2014, BBA-MOL CELL RES, V1843, P685, DOI 10.1016/j.bbamcr.2014.01.008
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Spuch Carlos, 2012, J Aging Res, V2012, P324968, DOI 10.1155/2012/324968
   Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469
   Tarasoff-Conway JM, 2015, NAT REV NEUROL, V11, P457, DOI 10.1038/nrneurol.2015.119
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
NR 75
TC 19
Z9 19
U1 1
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5099
J9 FRONT MOL NEUROSCI
JI Front. Molec. Neurosci.
PD FEB 22
PY 2019
VL 12
AR 24
DI 10.3389/fnmol.2019.00024
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA HM3OH
UT WOS:000459383000001
PM 30853886
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, WW
   LeBlanc, ME
   Chen, XP
   Chen, P
   Ji, YL
   Brewer, M
   Tian, H
   Spring, SR
   Webster, KA
   Li, W
AF Wang, Weiwen
   LeBlanc, Michelle E.
   Chen, Xiuping
   Chen, Ping
   Ji, Yanli
   Brewer, Megan
   Tian, Hong
   Spring, Samantha R.
   Webster, Keith A.
   Li, Wei
TI Pathogenic role and therapeutic potential of pleiotrophin in mouse
   models of ocular vascular disease
SO ANGIOGENESIS
LA English
DT Article
DE Pleiotrophin; Anti-angiogenic therapy; Neovascular age-related macular
   degeneration; Diabetic retinopathy; Retinopathy of prematurity;
   Oxygen-induced retinopathy; Choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; TYROSINE-PHOSPHATASE BETA/ZETA; AFFIN
   REGULATORY PEPTIDE; OXYGEN-INDUCED RETINOPATHY; PATHOLOGICAL
   ANGIOGENESIS; INTRAVITREAL BEVACIZUMAB; INTEGRIN ALPHA(V)BETA(3);
   MACULAR DEGENERATION; DIABETIC-RETINOPATHY; SIGNAL-TRANSDUCTION
AB Angiogenic factors play an important role in the pathogenesis of diabetic retinopathy (DR), neovascular age-related macular degeneration (nAMD) and retinopathy of prematurity (ROP). Pleiotrophin, a well-known angiogenic factor, was recently reported to be upregulated in the vitreous fluid of patients with proliferative DR (PDR). However, its pathogenic role and therapeutic potential in ocular vascular diseases have not been defined in vivo. Here using corneal pocket assays, we demonstrated that pleiotrophin induced angiogenesis in vivo. To investigate the pathological role of pleiotrophin we used neutralizing antibody to block its function in multiple in vivo models of ocular vascular diseases. In a mouse model of DR, intravitreal injection of pleiotrophin-neutralizing antibody alleviated diabetic retinal vascular leakage. In a mouse model of oxygen-induced retinopathy (OIR), which is a surrogate model of ROP and PDR, we demonstrated that intravitreal injection of anti-pleiotrophin antibody prevented OIR-induced pathological retinal neovascularization and aberrant vessel tufts. Finally, pleiotrophin-neutralizing antibody ameliorated laser-induced choroidal neovascularization, a mouse model of nAMD, suggesting that pleiotrophin is involved in choroidal vascular disease. These findings suggest that pleiotrophin plays an important role in the pathogenesis of DR with retinal vascular leakage, ROP with retinal neovascularization and nAMD with choroidal neovascularization. The results also support pleiotrophin as a promising target for anti-angiogenic therapy.
C1 [Wang, Weiwen; LeBlanc, Michelle E.; Chen, Xiuping; Chen, Ping; Ji, Yanli; Brewer, Megan; Tian, Hong; Spring, Samantha R.; Li, Wei] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33146 USA.
   [Webster, Keith A.; Li, Wei] Univ Miami, Sch Med, Vasc Biol Inst, Miami, FL 33146 USA.
   [Chen, Xiuping] Fudan Univ, Dept Ophthalmol, Zhongshan Hosp, Shanghai, Peoples R China.
   [Chen, Ping] Jiaotong Univ, Dept Ophthalmol, Renji Hosp, Shanghai, Peoples R China.
   [Ji, Yanli] Zhengzhou Eye Hosp, Dept Ophthalmol, Zhengzhou, Henan, Peoples R China.
   [Tian, Hong] Xinxiang Med Univ, Sch Publ Hlth, Xinxiang, Henan, Peoples R China.
C3 Bascom Palmer Eye Institute; University of Miami; University of Miami;
   Fudan University; Shanghai Jiao Tong University; Xinxiang Medical
   University
RP Li, W (通讯作者)，Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33146 USA.; Li, W (通讯作者)，Univ Miami, Sch Med, Vasc Biol Inst, Miami, FL 33146 USA.
EM w.li@med.miami.edu
OI Li, Wei/0000-0001-9566-8764; Webster, Keith A/0000-0002-6431-3642
FU NIH [R01GM094449, R21HD075372, R21EY027065, P30-EY014801]; Research to
   Prevent Blindness (RPB); American Heart Association Predoctoral
   Fellowship [14PRE18310014, 16PRE27250308]; RPB; EUNICE KENNEDY SHRIVER
   NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD075372]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY014801,
   R21EY027065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [R01GM094449] Funding Source: NIH RePORTER
FX This work was supported by NIH R01GM094449 (W.L.), R21HD075372 (W.L.),
   R21EY027065 (W.L.), Special Scholar Award from Research to Prevent
   Blindness (RPB) (W.L.), American Heart Association Predoctoral
   Fellowship 14PRE18310014 (M.E.L) and 16PRE27250308 (M.E.L), NIH
   P30-EY014801 and an institutional grant from RPB.
CR Beharry KD, 2016, SEMIN PERINATOL, V40, P189, DOI 10.1053/j.semperi.2015.12.006
   Bermek O, 2007, EXP CELL RES, V313, P4041, DOI 10.1016/j.yexcr.2007.07.032
   Bernard-Pierrot I, 2002, J BIOL CHEM, V277, P32071, DOI 10.1074/jbc.M202747200
   Besse S, 2013, CYTOKINE, V62, P44, DOI 10.1016/j.cyto.2013.02.002
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Chan N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120587
   CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679
   Choudhuri R, 1997, CANCER RES, V57, P1814
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7
   Dedania VS, 2015, CLIN OPHTHALMOL, V9, P533, DOI 10.2147/OPTH.S80049
   DELBE J, 1995, J CELL PHYSIOL, V164, P47, DOI 10.1002/jcp.1041640107
   Deuel TF, 2002, ARCH BIOCHEM BIOPHYS, V397, P162, DOI 10.1006/abbi.2001.2705
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Eishingdrelo Haifeng, 2013, Curr Chem Genom Transl Med, V7, P9, DOI 10.2174/2213988501307010009
   Fan JB, 2014, BIOCHEM BIOPH RES CO, V447, P425, DOI 10.1016/j.bbrc.2014.04.002
   FANG WJ, 1992, J BIOL CHEM, V267, P25889
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Heiss C, 2008, J CELL PHYSIOL, V215, P366, DOI 10.1002/jcp.21313
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Heroult M, 2004, ONCOGENE, V23, P1745, DOI 10.1038/sj.onc.1206879
   Hu LR, 2016, ONCOL REP, V36, P1953, DOI 10.3892/or.2016.4994
   Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kim CB, 2016, EYE BRAIN, V8, P67, DOI 10.2147/EB.S94447
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301
   Kokolakis G, 2006, IN VIVO, V20, P629
   Kong Y, 2012, INT J COLORECTAL DIS, V27, P287, DOI 10.1007/s00384-011-1344-z
   Koutsioumpa M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0287-3
   Kuboyama K, 2015, J NEUROSCI, V35, P12162, DOI 10.1523/JNEUROSCI.2127-15.2015
   LeBlanc ME, 2017, J EXP MED, V214, P1029, DOI 10.1084/jem.20161802
   LeBlanc ME, 2016, MOL VIS, V22, P374
   LeBlanc ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127904
   Lepore D, 2014, OPHTHALMOLOGY, V121, P2212, DOI 10.1016/j.ophtha.2014.05.015
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li JL, 2007, J BIOL CHEM, V282, P34984, DOI 10.1074/jbc.M703513200
   LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lynn Kristi D, 2010, Cancers (Basel), V2, P970, DOI 10.3390/cancers2020970
   Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997
   Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x
   Mikelis C, 2009, FASEB J, V23, P1459, DOI 10.1096/fj.08-117564
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Papadimitriou E, 2000, BIOCHEM BIOPH RES CO, V274, P242, DOI 10.1006/bbrc.2000.3126
   Papadimitriou E, 2016, BBA-REV CANCER, V1866, P252, DOI 10.1016/j.bbcan.2016.09.007
   Papadimitriou E, 2009, EUR CYTOKINE NETW, V20, P180, DOI 10.1684/ecn.2009.0172
   Perez-Pinera P, 2008, CURR OPIN HEMATOL, V15, P210, DOI 10.1097/MOH.0b013e3282fdc69e
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009
   Rask-Madsen C, 2013, CELL METAB, V17, P20, DOI 10.1016/j.cmet.2012.11.012
   RAULO E, 1994, J BIOL CHEM, V269, P12999
   RAULO E, 1992, J BIOL CHEM, V267, P11408
   RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x
   Rosenstein JM, 2003, J NEUROSCI, V23, P11036
   Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JCI33361, 10.1172/JC133361]
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Tokunaga CC, 2014, INVEST OPHTH VIS SCI, V55, P1884, DOI 10.1167/iovs.13-13397
   TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhang L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa1690
   Zhang N, 2006, BIOCHEM BIOPH RES CO, V343, P653, DOI 10.1016/j.bbrc.2006.03.006
   Zhu XM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115523
NR 66
TC 12
Z9 12
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD NOV
PY 2017
VL 20
IS 4
BP 479
EP 492
DI 10.1007/s10456-017-9557-6
PG 14
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA FL1PZ
UT WOS:000413988200005
PM 28447229
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Avery, RL
   Castellarin, AA
   Steinle, NC
   Dhoot, DS
   Pieramici, DJ
   See, R
   Couvillion, S
   Nasir, MA
   Rabena, MD
   Maia, M
   Van Everen, S
   Le, K
   Hanley, WD
AF Avery, Robert L.
   Castellarin, Alessandro A.
   Steinle, Nathan C.
   Dhoot, Dilsher S.
   Pieramici, Dante J.
   See, Robert
   Couvillion, Stephen
   Nasir, Ma'an A.
   Rabena, Melvin D.
   Maia, Mauricio
   Van Everen, Sherri
   Le, Kha
   Hanley, William D.
TI SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL
   AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; diabetic macular edema;
   pharmacokinetics; retinal vein occlusion
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; INTRAOCULAR
   PHARMACOKINETICS; MONOCLONAL-ANTIBODIES; PLASMA-LEVELS; SERUM VEGF;
   IN-VITRO; DEGENERATION; INJECTION; THERAPY
AB Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO).
   Methods: Prospective, open-label, nonrandomized clinical trial of patients with AMD, DME, or RVO who were antivascular endothelial growth factor (VEGF) naive or had not received anti-VEGF for >= 4 months. Patients received 3 monthly intravitreal injections of aflibercept 2.0 mg, bevacizumab 1.25 mg, or ranibizumab (0.5 mg for AMD/RVO, 0.3 mg for DME). The main outcome measures were serum PKs and plasma free-VEGF concentrations after the first and third injections.
   Results: A total of 151 patients were included. In AMD/DME/RVO, systemic exposure to each drug was highest with bevacizumab, then aflibercept, and lowest with ranibizumab. Ranibizumab cleared from the bloodstream more quickly than bevacizumab or aflibercept. Aflibercept treatment resulted in the greatest reductions in plasma free-VEGF relative to baseline levels, whereas ranibizumab treatment resulted in the smallest decreases in plasma free-VEGF.
   Conclusion: The three anti-VEGF treatments examined in this analysis demonstrated notable differences in systemic PKs. Generally, the reduction in plasma free-VEGF levels correlated with elevated levels of circulating anti-VEGF agents, with the reduction in free-VEGF levels greatest with aflibercept and least with ranibizumab.
C1 [Avery, Robert L.; Castellarin, Alessandro A.; Steinle, Nathan C.; Dhoot, Dilsher S.; Pieramici, Dante J.; See, Robert; Couvillion, Stephen; Nasir, Ma'an A.; Rabena, Melvin D.] Calif Retina Consultants, 525 East Micheltorena St,Suite A, Santa Barbara, CA 93103 USA.
   [Maia, Mauricio; Van Everen, Sherri; Le, Kha; Hanley, William D.] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Avery, RL (通讯作者)，Calif Retina Consultants, 525 East Micheltorena St,Suite A, Santa Barbara, CA 93103 USA.
EM bobave@gmail.com
RI Dhoot, Dilsher/ABD-5417-2021; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091
FU Genentech, Inc.
FX The authors thank Ai Ping Lee and Xin Wang for assistance with data
   reconciliation and analysis. Third-party medical writing and editorial
   assistance was provided by Emma A. Platt, PharmD, at Envision Scientific
   Solutions, and funded by Genentech, Inc.
CR Aguilar-Mahecha A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038290
   [Anonymous], 2014, LUCENTIS RANIBIZUMAB
   [Anonymous], 2016, EYLEA AFL INJ INTR I
   Avery RL, 2016, OPHTHALMOLOGY, V123, pE14, DOI 10.1016/j.ophtha.2015.08.031
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Avery RL, 2012, J AAPOS, V16, P2, DOI 10.1016/j.jaapos.2011.11.002
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2014, INVEST OPHTH VIS SCI, V55
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Enders P, 2015, RETINA-J RET VIT DIS, V35, P454, DOI 10.1097/IAE.0000000000000320
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Gunsilius E, 2000, ONCOLOGY-BASEL, V58, P169, DOI 10.1159/000012095
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirose M, 2014, CLIN OPHTHALMOL, V8, P2301, DOI 10.2147/OPTH.S74888
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kong LK, 2015, INVEST OPHTH VIS SCI, V56, P956, DOI 10.1167/iovs.14-15842
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lien RY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148019
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mody M, 1999, TRANSFUSION MED, V9, P147
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Morin J, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3218
   Narayanan R, 2015, BRIT J OPHTHALMOL, V99, P954, DOI 10.1136/bjophthalmol-2014-306543
   Nepomuceno AB, 2013, AM J OPHTHALMOL, V156, P502, DOI 10.1016/j.ajo.2013.04.026
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park SJ, 2015, EYE, V29, P561, DOI 10.1038/eye.2014.329
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scott L, 2014, INVEST OPHTH VIS SCI, V55
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Ternant D, 2005, EXPERT OPIN BIOL TH, V5, pS37, DOI 10.1517/14712598.5.1.S37
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
   Zhang Y, 2014, OPHTHALMOLOGY, V121, P2237, DOI 10.1016/j.ophtha.2014.05.012
NR 60
TC 164
Z9 169
U1 5
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2017
VL 37
IS 10
BP 1847
EP 1858
DI 10.1097/IAE.0000000000001493
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI1GH
UT WOS:000411680300016
PM 28106709
OA Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Zhou, YD
   Yoshida, S
   Kubo, Y
   Yoshimura, T
   Kobayashi, Y
   Nakama, T
   Yamaguchi, M
   Ishikawa, K
   Oshima, Y
   Ishibashi, T
AF Zhou, Yedi
   Yoshida, Shigeo
   Kubo, Yuki
   Yoshimura, Takeru
   Kobayashi, Yoshiyuki
   Nakama, Takahito
   Yamaguchi, Muneo
   Ishikawa, Keijiro
   Oshima, Yuji
   Ishibashi, Tatsuro
TI Different distributions of M1 and M2 macrophages in a mouse model of
   laser-induced choroidal neovascularization
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE M1 macrophage; M2 macrophage; choroidal neovascularization; angiogenesis
ID OXYGEN-INDUCED RETINOPATHY; MACULAR DEGENERATION; ACTIVATION;
   POLARIZATION; PERIOSTIN; CELLS; MICROGLIA; PROMOTES; RETINA; SYSTEM
AB Choroidal neovascularization (CNV) is a serious complication of age-related macular degeneration. The aim of the present study was to investigate the expression and distribution of M1 and M2 macrophages in a laser-induced CNV adult mouse model. The mRNA expression levels of M1, M2 and pan macrophage markers, and macrophage-associated angiogenic cytokines, were determined by reverse transcription-quantitative polymerase chain reaction. Immunofluorescence studies were performed to determine the location of the macrophages. The expression levels of M1 macrophage markers increased to a greater extent compared with M2 markers in the retinal pigment epithelium (RPE)-choroid complexes following laser photocoagulation. By contrast, the expression levels of M2 macrophage markers increased primarily in the retinas. Immunofluorescence studies revealed that the increased number of cluster of differentiation (CD)206-positive cells were located primarily in the retina, whereas the CD80-positive cells were located around the site of CNVs in the RPE-choroid. In addition, the M1-associated cytokines increased to a greater extent in the RPE-choroid complexes, whereas the M2-associated cytokines were highly expressed in the retinas. These findings indicate that M1 and M2 macrophage numbers increased following CNV; however, the locations were different in this mouse model of laser-induced CNV. The results of the present study suggest that M1 macrophages have a more direct role in inhibiting the development of CNV.
C1 [Zhou, Yedi; Yoshida, Shigeo; Kubo, Yuki; Yoshimura, Takeru; Kobayashi, Yoshiyuki; Nakama, Takahito; Yamaguchi, Muneo; Ishikawa, Keijiro; Oshima, Yuji; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka 8128582, Japan.
C3 Kyushu University
RP Yoshida, S (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM yosida@med.kyushu-u.ac.jp
OI Zhou, Yedi/0000-0002-8948-1108; Yoshida, Shigeo/0000-0003-1049-8909
FU Japan Society for the Promotion of Science [15H04995, 26293374]; Takeda
   Science Foundation; China Scholarship Council;  [16K15734];
   Grants-in-Aid for Scientific Research [17H05101] Funding Source: KAKEN
FX The present study was supported in part by the Japan Society for the
   Promotion of Science Grants-in-Aid for Scientific Research (B; grant
   nos. 15H04995 and 26293374), Grants-in-Aid for Challenging Exploratory
   Research (grant no. 16K15734), the Takeda Science Foundation and the
   China Scholarship Council (to Y.Z.). The authors thank Ms. Masayo Eto,
   Ms. Kinuko Sasada, and Ms. Hiroko Miura (Kyushu University) for their
   excellent technical assistance.
CR Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arima M, 2012, INVEST OPHTH VIS SCI, V53, P6495, DOI 10.1167/iovs.12-9684
   Auffray C, 2009, J EXP MED, V206, P595, DOI 10.1084/jem.20081385
   Benakis C, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00461
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Ho Victor W. H., 2009, V531, P173, DOI 10.1007/978-1-59745-396-7_12
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740
   Ishikawa K, 2012, LAB INVEST, V92, P91, DOI 10.1038/labinvest.2011.141
   Ishikawa K, 2010, INVEST OPHTH VIS SCI, V51, P4307, DOI 10.1167/iovs.09-4605
   Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6
   Kazerounian S, 2008, CELL MOL LIFE SCI, V65, P700, DOI 10.1007/s00018-007-7486-z
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Li W, 2012, INFECT IMMUN, V80, P4426, DOI 10.1128/IAI.00912-12
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   MAHDAVIAN DB, 2011, IMMUNOBIOLOGY, V216, P753, DOI DOI 10.1016/J.IMBI0.2011.01.001
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   Nakama T, 2015, GENE THER, V22, P127, DOI 10.1038/gt.2014.112
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
   Zhou YD, 2015, INVEST OPHTH VIS SCI, V56, P4767, DOI 10.1167/iovs.14-16012
NR 35
TC 43
Z9 44
U1 2
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUN
PY 2017
VL 15
IS 6
BP 3949
EP 3956
DI 10.3892/mmr.2017.6491
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EU5LA
UT WOS:000401071600069
PM 28440413
OA Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Schicht, M
   Hesse, K
   Schroder, H
   Naschberger, E
   Lamprecht, W
   Garreis, F
   Paulsen, FP
   Brauer, L
AF Schicht, M.
   Hesse, K.
   Schroeder, H.
   Naschberger, E.
   Lamprecht, W.
   Garreis, F.
   Paulsen, F. P.
   Braeuer, L.
TI Efficacy of aflibercept (EYLEA (R)) on inhibition of human VEGF in vitro
SO ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER
LA English
DT Article
DE EYLEA (R); HUVEC; Aflibercept; VEGF; VEGF-trap
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; CELLS
AB Introduction: Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several serious ophthalmological diseases such as wet age-related macular degeneration (AMD) or diabetic retinopathy. In AMD treatment, aflibercept (tradename EYLEA (R)) is used to deactivate the underlying pathological neovascularisation. Aflibercept is a recombinant fusion protein which binds to vascular endothelial growth factor (VEGF) receptors, thereby inhibiting VEGF pathway activation. VEGF is one of the most important angiogenesis factors.
   Objective: This analysis investigates lasting efficacy of aflibercept in vitro for later application as therapeutic agent against macular degeneration (AMD).
   Material and methods: VEGF-ELISA assays were performed to investigate binding affinities at different aflibercept concentrations. The impact of VEGF on the proliferation of human umbilical vein endothelial cells (HUVEC) was investigated using proliferation assays. Moreover, time-dependent kinetic studies were performed to analyze different aflibercept storage durations with regard to its inhibitory capabilities on human VEGF.
   Results and conclusion: Our results reveal that aflibercept significantly lowers the amount of unbound VEGF as well as the proliferation rate of HUVEC. Moreover, in contrast to specifications given by the manufacturer, aflibercept retains its full inhibitory effect up to at least 120 h after transference from the original vial into the injection syringe. (C) 2017 Published by Elsevier GmbH.
C1 [Schicht, M.; Hesse, K.; Schroeder, H.; Garreis, F.; Paulsen, F. P.; Braeuer, L.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Inst Anat, Erlangen, Germany.
   [Naschberger, E.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Div Mol & Expt Surg, Dept Surg, Erlangen, Germany.
   [Lamprecht, W.] Bohlenpl, Erlangen, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg
RP Schicht, M (通讯作者)，Univ Erlangen Nurnberg FAU, Dept Anat 2, Univ Str 19, D-91054 Erlangen, Germany.
EM martin.schicht@fau.de
RI Naschberger, Elisabeth/AAV-5289-2021
OI Naschberger, Elisabeth/0000-0003-1291-622X; Schicht,
   Martin/0000-0001-5155-5477; Paulsen, Friedrich/0000-0002-0527-0953
FU Ernst and Berta Grimmke Stiftung [1/15]
FX We thank Anke Fischer-GOBwein, Maike Hemmerlein and Jessica Braun for
   their excellent laboratory support. This work was supported by the Ernst
   and Berta Grimmke Stiftung (Program Grant 1/15).
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Bao P, 2009, J SURG RES, V153, P347, DOI 10.1016/j.jss.2008.04.023
   BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211
   Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Nissen NN, 1998, AM J PATHOL, V152, P1445
   Schoppmann SF, 2004, MICROCIRCULATION, V11, P261, DOI 10.1080/10739680490425967
   Schroder A, 2016, EXP EYE RES, V151, P190, DOI 10.1016/j.exer.2016.08.009
NR 12
TC 3
Z9 4
U1 0
U2 16
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0940-9602
EI 1618-0402
J9 ANN ANAT
JI Ann. Anat.-Anat. Anz.
PY 2017
VL 211
BP 135
EP 139
DI 10.1016/j.aanat.2017.02.005
PG 5
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology
GA ET3XI
UT WOS:000400212600017
PM 28279730
DA 2022-11-30
ER

PT J
AU Hrvolova, B
   Martinez-Huelamo, M
   Colman-Martinez, M
   Hurtado-Barroso, S
   Lamuela-Raventos, RM
   Kalina, J
AF Hrvolova, Barbora
   Martinez-Huelamo, Miriam
   Colman-Martinez, Mariel
   Hurtado-Barroso, Sara
   Lamuela-Raventos, Rosa Maria
   Kalina, Jiri
TI Development of an Advanced HPLC-MS/MS Method for the Determination of
   Carotenoids and Fat-Soluble Vitamins in Human Plasma
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE tandem mass spectrometry; carotenoids; fat-soluble vitamins; human
   plasma; pilot human study; high antioxidant diet
ID QUADRUPOLE MASS-SPECTROMETRY; HUMAN SERUM; METABOLITES; ABSORPTION;
   TOCOPHEROL; RELEVANCE; RETINOL; LUTEIN; FOCUS
AB The concentration of carotenoids and fat-soluble vitamins in human plasma may play a significant role in numerous chronic diseases such as age-related macular degeneration and some types of cancer. Although these compounds are of utmost interest for human health, methods for their simultaneous determination are scarce. A new high pressure liquid chromatography (HPLC)-tandem mass spectrometry (MS/MS) method for the quantification of selected carotenoids and fat-soluble vitamins in human plasma was developed, validated, and then applied in a pilot dietary intervention study with healthy volunteers. In 50 min, 16 analytes were separated with an excellent resolution and suitable MS signal intensity. The proposed HPLC MS/MS method led to improvements in the limits of detection (LOD) and quantification (LOQ) for all analyzed compounds compared to the most often used HPLC DAD methods, in some cases being more than 100-fold lower. LOD values were between 0.001 and 0.422 mu g/mL and LOQ values ranged from 0.003 to 1.406 mu g/mL, according to the analyte. The accuracy, precision, and stability met with the acceptance criteria of the AOAC (Association of Official Analytical Chemists) International. According to these results, the described HPLC-MS/MS method is adequately sensitive, repeatable and suitable for the large-scale analysis of compounds in biological fluids.
C1 [Hrvolova, Barbora; Kalina, Jiri] Univ Ostrava, Fac Sci, CZ-70103 Ostrava, Czech Republic.
   [Martinez-Huelamo, Miriam; Colman-Martinez, Mariel; Hurtado-Barroso, Sara; Lamuela-Raventos, Rosa Maria] Univ Barcelona, Dept Nutr Food Sci & Gastron XARTA INSA, Sch Pharm & Food Sci, E-08028 Barcelona, Spain.
   [Martinez-Huelamo, Miriam; Hurtado-Barroso, Sara; Lamuela-Raventos, Rosa Maria] CIBEROBN, CIBER Fisiopatol Obesidad & Nutr CB06 03, Madrid 28049, Spain.
C3 University of Ostrava; University of Barcelona; CIBER - Centro de
   Investigacion Biomedica en Red; CIBEROBN
RP Lamuela-Raventos, RM (通讯作者)，Univ Barcelona, Dept Nutr Food Sci & Gastron XARTA INSA, Sch Pharm & Food Sci, E-08028 Barcelona, Spain.; Lamuela-Raventos, RM (通讯作者)，CIBEROBN, CIBER Fisiopatol Obesidad & Nutr CB06 03, Madrid 28049, Spain.
EM b.hrvolova@seznam.cz; mmartinezh@ub.edu; marielcolman@ub.edu;
   sara.hurtado_17@ub.edu; lamuela@ub.edu; jiri.kalina@osu.cz
RI Raventos, Rosa M Lamuela/F-3986-2016
OI Hurtado Barroso, Sara/0000-0001-9550-1788; Martinez-Huelamo,
   Miriam/0000-0002-7650-4016
FU CICYT [AGL2013-49083-C3-1-R]; Instituto de Salud Carlos III, ISCIII
   (CIBEROBN) from the Spanish Ministry of Economy and Competivity (MEC);
   Generalitat de Catalunya (GC) [2014 SGR 773]; University of Ostrava,
   Czech Republic [SGS04/PrF/2016]; Project (TEWEP) of the National
   Feasibility Programme I of the Czech Republic [LO1208]
FX This work was supported in part by CICYT (AGL2013-49083-C3-1-R), the
   Instituto de Salud Carlos III, ISCIII (CIBEROBN) from the Spanish
   Ministry of Economy and Competivity (MEC) and Generalitat de Catalunya
   (GC) 2014 SGR 773. The work was also supported by student grant n.
   SGS04/PrF/2016 from University of Ostrava, Czech Republic and by the
   Project LO1208 (TEWEP) of the National Feasibility Programme I of the
   Czech Republic.
CR Albahrani Ali A, 2016, Clin Biochem Rev, V37, P27
   Albahrani AA, 2016, J STEROID BIOCHEM, V159, P41, DOI 10.1016/j.jsbmb.2016.02.019
   Albarhani AA, 2015, CLIN BIOCHEM, V48, P1105, DOI 10.1016/j.clinbiochem.2015.04.014
   Arathi BP, 2015, FOOD ANAL METHOD, V8, P1962, DOI 10.1007/s12161-014-0083-5
   Arranz S, 2015, FOOD CHEM, V168, P203, DOI 10.1016/j.foodchem.2014.07.053
   Balvers MGJ, 2015, J NUTR SCI, V4, DOI 10.1017/jns.2015.10
   Bertram JS, 1999, NUTR REV, V57, P182, DOI 10.1111/j.1753-4887.1999.tb06941.x
   Bruce SJ, 2009, ANAL CHEM, V81, P3285, DOI 10.1021/ac8024569
   Colman-Martinez M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9268531
   Cooper DA, 1999, NUTR REV, V57, P133
   Daykin CA, 2002, ANAL BIOCHEM, V304, P220, DOI 10.1006/abio.2002.5637
   de Quiros ARB, 2006, J FOOD COMPOS ANAL, V19, P97, DOI 10.1016/j.jfca.2005.04.004
   Gomez-Garcia MD, 2013, INT J MOL SCI, V14, P19025, DOI 10.3390/ijms140919025
   Donaldson Michael, 2012, BMC Res Notes, V5, P521, DOI 10.1186/1756-0500-5-521
   Fang LQ, 2003, ANAL CHEM, V75, P812, DOI 10.1021/ac026118a
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Karppi J, 2008, J CHROMATOGR B, V867, P226, DOI 10.1016/j.jchromb.2008.04.007
   Kopec RE, 2013, RAPID COMMUN MASS SP, V27, P1393, DOI 10.1002/rcm.6576
   Laddomada B, 2015, INT J MOL SCI, V16, P3512, DOI 10.3390/ijms16023512
   Lee BL, 2003, CLIN CHEM, V49, P2056, DOI 10.1373/clinchem.2003.022681
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   Matsubara A, 2012, J BIOSCI BIOENG, V113, P782, DOI 10.1016/j.jbiosc.2012.01.017
   Mostafa WZ, 2015, J ADV RES, V6, P793, DOI 10.1016/j.jare.2014.01.011
   Nishino A, 2015, J OLEO SCI, V64, P1135, DOI 10.5650/jos.ess15118
   Palace VP, 1999, FREE RADICAL BIO MED, V26, P746, DOI 10.1016/S0891-5849(98)00266-4
   Perraud A, 2011, EXP THER MED, V2, P491, DOI 10.3892/etm.2011.242
   Capote FP, 2007, RAPID COMMUN MASS SP, V21, P1745, DOI 10.1002/rcm.3014
   Reboul E, 2013, NUTRIENTS, V5, P3563, DOI 10.3390/nu5093563
   Rodriguez-Amaya D.B., 2001, GUIDE CAROTENOID ANA, P1
   Romney S.L., 1995, J CELL BIOCHEM, V59, pS96
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Su CC, 2014, INT J MOL SCI, V15, P13755, DOI 10.3390/ijms150813755
   Su Q, 2002, J CHROMATOGR B, V781, P393, DOI 10.1016/S1570-0232(02)00502-0
   Turner T, 2012, CHROMATOGRAPHIA, V75, P241, DOI 10.1007/s10337-012-2193-9
   Vallverdu-Queralt A, 2012, J SCI FOOD AGR, V92, P2043, DOI 10.1002/jsfa.5598
   Van Meulebroek L, 2014, ANAL BIOANAL CHEM, V406, P2613, DOI 10.1007/s00216-014-7654-6
NR 36
TC 30
Z9 31
U1 4
U2 39
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2016
VL 17
IS 10
AR 1719
DI 10.3390/ijms17101719
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EC0DO
UT WOS:000387768300057
PM 27754400
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Tokarz, P
   Kaarniranta, K
   Blasiak, J
AF Tokarz, Paulina
   Kaarniranta, Kai
   Blasiak, Janusz
TI Role of the Cell Cycle Re-Initiation in DNA Damage Response of
   Post-Mitotic Cells and Its Implication in the Pathogenesis of
   Neurodegenerative Diseases
SO REJUVENATION RESEARCH
LA English
DT Review
ID CEREBELLAR GRANULE NEURONS; DEPENDENT KINASE INHIBITOR; INCLUSION-BODY
   MYOSITIS; ALZHEIMERS-DISEASE; TUMOR-SUPPRESSOR; ATAXIA-TELANGIECTASIA;
   IN-VIVO; TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN; EXPRESSION
   PATTERNS
AB Neurodegenerative diseases are often associated with both normal and premature aging. Resumption of the cell cycle by neurons induced by DNA damage may lead to their apoptosis, which contributes to the degeneration of neuronal tissue. Cell cycle and DNA replication proteins are frequently found in patients with neurodegenerative diseases. Oxidative stress, which is considered to play an important role in aging and pathogenesis of many neurodegenerative diseases, can induce DNA damage and stimulate cell cycle re-entry by neuronal cells. DNA damage activates ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), breast cancer 1 (BRCA1), E2F transcription factor 1 (E2F1), and other proteins that regulate the cell cycle, DNA damage repair, and apoptosis. Because the E2F complexes associate with histone-modifying enzymes, histone modifications, including histone acetylation and methylation, are required for cell cycle re-entry and may play a regulatory role in DNA repair or apoptosis. Aberrant cell cycle regulation has been shown to play a role in age-related macular degeneration (AMD) in which retinal cells are affected and in inclusion body myositis, which is characterized by muscle cell dysfunction. There is also evidence to suggest that cytostatic chemotherapy could decrease dementia in Alzheimer's disease and multiple myeloma, supporting the use of cell cycle inhibitors in the therapy of degenerative diseases.
C1 [Tokarz, Paulina; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Lodz; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Tokarz, P (通讯作者)，Univ Lodz, Dept Mol Genet, Fac Biol & Environm Protect, Pomorska 141-143, PL-90236 Lodz, Poland.
EM ptokarz@biol.uni.lodz.pl
RI Tokarz, Paulina/L-9983-2013
OI Blasiak, Janusz/0000-0001-9539-9584; Tokarz,
   Paulina/0000-0001-9016-3089; Kaarniranta, Kai/0000-0003-2600-8679
FU National Science Centre [DEC-2012/07/N/NZ3/01755]
FX This work was supported by the National Science Centre, decision no.
   DEC-2012/07/N/NZ3/01755.
CR Adamec E, 1999, BRAIN RES, V849, P67, DOI 10.1016/S0006-8993(99)02004-1
   Akashiba H, 2006, CELL MOL LIFE SCI, V63, P2397, DOI 10.1007/s00018-006-6194-4
   Akashiba H, 2008, J BIOL CHEM, V283, P6594, DOI 10.1074/jbc.M707730200
   ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194
   Alvira D, 2007, NEUROSCIENCE, V146, P350, DOI 10.1016/j.neuroscience.2007.01.042
   Askanas V, 2006, NEUROLOGY, V66, pS39, DOI 10.1212/01.wnl.0000192128.13875.1e
   Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481
   Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5
   Becker EBE, 2004, PROG NEUROBIOL, V72, P1, DOI 10.1016/j.pneurobio.2003.12.005
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brouillet E, 2005, J NEUROCHEM, V95, P1521, DOI 10.1111/j.1471-4159.2005.03515.x
   Busser J, 1998, J NEUROSCI, V18, P2801
   Buttitta LA, 2010, J CELL BIOL, V189, P981, DOI 10.1083/jcb.200910006
   Camins A, 2010, CELL MOL LIFE SCI, V67, P3865, DOI 10.1007/s00018-010-0408-5
   Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062
   Chen JM, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-60
   Chen TP, 2014, NAT REV GENET, V15, P93, DOI 10.1038/nrg3607
   Cheung ZH, 2011, J NEUROCHEM, V118, P317, DOI 10.1111/j.1471-4159.2011.07314.x
   Cicero S, 2005, J NEUROSCI, V25, P9658, DOI 10.1523/JNEUROSCI.1773-05.2005
   Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619
   COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106
   Currais A, 2009, AGING-US, V1, P363, DOI 10.18632/aging.100045
   Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990
   Didier M, 1996, J NEUROSCI, V16, P2238
   Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24
   Evans Teresa A, 2007, Int J Med Sci, V4, P140
   FEDDERSEN RM, 1995, MOL CELL NEUROSCI, V6, P153, DOI 10.1006/mcne.1995.1014
   Feddersen RM, 1997, MOL CELL NEUROSCI, V9, P42, DOI 10.1006/mcne.1997.0601
   Ferrante RJ, 1997, J NEUROCHEM, V69, P2064
   Folch J, 2012, NEUROTOX RES, V22, P195, DOI 10.1007/s12640-011-9277-4
   FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3
   Gendron TF, 2001, J NEUROCHEM, V78, P316, DOI 10.1046/j.1471-4159.2001.00423.x
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615
   Gobbel GT, 1998, J NEUROSCI, V18, P147
   Greene LA, 2007, BBA-MOL BASIS DIS, V1772, P392, DOI 10.1016/j.bbadis.2006.12.003
   Hamdane M, 2005, J CELL SCI, V118, P1291, DOI 10.1242/jcs.01724
   Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124
   Hoglinger GU, 2007, P NATL ACAD SCI USA, V104, P3585, DOI 10.1073/pnas.0611671104
   Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x
   Jacobsen E, 2004, MOL BRAIN RES, V128, P1, DOI 10.1016/j.molbrainres.2004.05.023
   JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0
   Jorda EG, 2003, NEUROPHARMACOLOGY, V45, P672, DOI 10.1016/S0028-3908(03)00204-1
   Jordan-Sciutto KL, 2003, J NEUROPATH EXP NEUR, V62, P68, DOI 10.1093/jnen/62.1.68
   Jordan-Sciutto KL, 2002, J NEUROSCI, V22, P2185, DOI 10.1523/JNEUROSCI.22-06-02185.2002
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001
   Keimowitz RM, 1997, ARCH NEUROL-CHICAGO, V54, P485, DOI 10.1001/archneur.1997.00550160111024
   Kim D, 2009, ANN NY ACAD SCI, V1170, P674, DOI 10.1111/j.1749-6632.2009.04105.x
   Kim D, 2008, NEURON, V60, P803, DOI 10.1016/j.neuron.2008.10.015
   Krantic S, 2005, TRENDS NEUROSCI, V28, P670, DOI 10.1016/j.tins.2005.09.011
   Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0
   Kuo CN, 2012, MOL MED REP, V6, P701, DOI 10.3892/mmr.2012.986
   Kwon B, 2014, HUM MOL GENET, V23, P3681, DOI 10.1093/hmg/ddu077
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672
   Lan J, 2000, J NEUROCHEM, V74, P302, DOI 10.1046/j.1471-4159.2000.0740302.x
   Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636
   Li GH, 2011, CURR OPIN GENET DEV, V21, P175, DOI 10.1016/j.gde.2011.01.022
   Liu DX, 2005, GENE DEV, V19, P719, DOI 10.1101/gad.1296405
   Liu DX, 2004, J NEUROSCI, V24, P8720, DOI 10.1523/JNEUROSCI.1821-04.2004
   Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Love S, 2003, NEUROSCI LETT, V353, P29, DOI 10.1016/j.neulet.2003.09.004
   Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661
   MacLachlan TK, 2000, FUNCTIONAL INTERACTI
   Mastroeni D, 2011, NEUROBIOL AGING, V32, P1161, DOI 10.1016/j.neurobiolaging.2010.08.017
   McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210
   McMurray CT, 2005, MUTAT RES-FUND MOL M, V577, P260, DOI 10.1016/j.mrfmmm.2005.03.006
   McShea A, 2007, BBA-MOL BASIS DIS, V1772, P467, DOI 10.1016/j.bbadis.2006.09.010
   Menn B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012117
   MULLAART E, 1988, MECH AGEING DEV, V45, P41, DOI 10.1016/0047-6374(88)90017-6
   Nguyen MD, 2003, J NEUROSCI, V23, P2131
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Nouspikel T, 2000, MOL CELL BIOL, V20, P1562, DOI 10.1128/MCB.20.5.1562-1570.2000
   Nouspikel T, 2002, DNA REPAIR, V1, P59, DOI 10.1016/S1568-7864(01)00005-2
   O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200
   Otsuka Y, 2004, NEUROSCI LETT, V365, P180, DOI 10.1016/j.neulet.2004.04.083
   Park DS, 2000, NEUROBIOL AGING, V21, P771, DOI 10.1016/S0197-4580(00)00220-7
   Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997
   Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159
   Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998
   Pelegri C, 2008, INT J DEV NEUROSCI, V26, P665, DOI 10.1016/j.ijdevneu.2008.07.016
   Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640
   Pizarro JG, 2010, PHARMACOL RES, V61, P391, DOI 10.1016/j.phrs.2010.01.003
   Radi E, 2014, J ALZHEIMERS DIS, V42, pS125, DOI 10.3233/JAD-132738
   Rai K, 2006, MOL CELL BIOL, V26, P7077, DOI 10.1128/MCB.00312-06
   Raina AK, 2000, J NEUROSCI RES, V61, P128, DOI 10.1002/1097-4547(20000715)61:2<128::AID-JNR2>3.0.CO;2-H
   Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Ricobaraza A, 2009, NEUROPSYCHOPHARMACOL, V34, P1721, DOI 10.1038/npp.2008.229
   ROBISON SH, 1984, J NEUROL SCI, V64, P11, DOI 10.1016/0022-510X(84)90051-0
   Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8
   Fernandez-Fernandez MR, 2011, NEUROBIOL DIS, V41, P23, DOI 10.1016/j.nbd.2010.08.014
   Sadri-Vakili G, 2006, NAT CLIN PRACT NEURO, V2, P330, DOI 10.1038/ncpneuro0199
   Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769
   Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903
   Seward ME, 2013, J CELL SCI, V126, P1278, DOI 10.1242/jcs.1125880
   Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291
   Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5
   Su Y, 2004, BIOCHEMISTRY-US, V43, P6899, DOI 10.1021/bi035627j
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Takahashi Y, 2000, GENE DEV, V14, P804
   Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004
   Timsit Serge, 2007, Biotechnology Journal, V2, P958, DOI 10.1002/biot.200700072
   Tomashevski A, 2010, CELL DEATH DIFFER, V17, P1189, DOI 10.1038/cdd.2009.221
   Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439
   van Damme P, 2005, NEURODEGENER DIS, V2, P147, DOI 10.1159/000089620
   Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001
   Veeriah S, 2010, CELL CYCLE, V9, P1451, DOI 10.4161/cc.9.8.11583
   Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010
   Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x
   Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5
   Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532
   Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151
   Wu LL, 2000, MOL CELL BIOL, V20, P7059, DOI 10.1128/MCB.20.19.7059-7067.2000
   Xu H, 2014, ACTA OPHTHALMOLOGICA, V92
   Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001
   Yang Y, 2005, J NEUROSCI, V25, P2522, DOI 10.1523/JNEUROSCI.4946-04.2005
   Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5
   ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500
   Zhang J, 2008, P NATL ACAD SCI USA, V105, P8772, DOI 10.1073/pnas.0711355105
   Zhang PM, 1999, CURR OPIN CELL BIOL, V11, P655, DOI 10.1016/S0955-0674(99)00032-0
   Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005
NR 123
TC 18
Z9 18
U1 0
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-1684
EI 1557-8577
J9 REJUV RES
JI Rejuv. Res.
PD APR
PY 2016
VL 19
IS 2
BP 131
EP 139
DI 10.1089/rej.2015.1717
PG 9
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA DK1CJ
UT WOS:000374649800005
PM 26214710
DA 2022-11-30
ER

PT J
AU Batioglu, F
   Demirel, S
   Ozmert, E
   Oguz, YG
   Ozyol, P
AF Batioglu, Figen
   Demirel, Sibel
   Ozmert, Emin
   Oguz, Yesim Gedik
   Ozyol, Pelin
TI Autofluorescence Patterns as a Predictive Factor for Neovascularization
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; fundus
   autofluorescence imaging; fundus autofluorescence patterns
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   GEOGRAPHIC ATROPHY; DISEASE; OPHTHALMOSCOPE; DRUSEN
AB Purpose. To investigate fundus autofluorescence (FAF) patterns in patients with nonexudative age-related macular degeneration (AMD) and to test if FAF patterns affect the development of choroidal neovascularization (CNV).
   Methods. One hundred one patients with early AMD underwent a detailed ophthalmological examination. Fundus autofluorescence imaging was performed with a confocal scanning laser ophthalmoscope following a standard protocol. The classification of the International Fundus Autofluorescence Classification Group was used for the description of the FAF patterns.
   Results. One hundred seventy-eight eyes of 101 patients (59 women, 42 men) with a mean (+/- SD) age of 66.4 (+/- 6.1) years were included. The mean (+/- SD) follow-up was 41.3 (+/- 27) months. One hundred seventy-eight eyes presented various types of drusen with or without hyperpigmentation or hypopigmentation at initial examination. During follow-up, a total of 22 (12.3%) eyes developed CNV. The most frequent pattern for CNV development was the patchy pattern in 30.4%, followed by linear in 25%, and reticular pattern in 20.8% of eyes.
   Conclusions. Fundus autofluorescence imaging using a confocal scanning laser ophthalmoscope is a useful technique to identify FAF characteristics in patients with nonexudative AMD. Different patterns of FAF abnormalities can be obtained in these eyes. Our results indicate that patchy, linear, and reticular patterns are the specific patterns associated with CNV development in nonexudative AMD.
C1 [Batioglu, Figen; Demirel, Sibel; Ozmert, Emin; Oguz, Yesim Gedik] Ankara Univ, Fac Med, Dept Ophthalmol, TR-06100 Ankara, Turkey.
   [Batioglu, Figen; Ozmert, Emin] European Sch Adv Studies Ophthalmol, Lugano, Switzerland.
   [Ozyol, Pelin] Ordu Unye State Hosp, Ordu Unye, Turkey.
C3 Ankara University; Unye State Hospital
RP Demirel, S (通讯作者)，Koza Sokak,Mesa Ikizler Sitesi 70-40, Gop Cankaya Ankara, Turkey.
EM drsibeldemireltr@yahoo.com.tr
RI Özyol, Pelin/ABH-9160-2020; Demirel, Sibel/AAQ-4282-2020; DEMIREL,
   SIBEL/GQH-3232-2022; Batıoğlu, Figen/AAQ-3727-2020
OI Demirel, Sibel/0000-0002-6430-6565; DEMIREL, SIBEL/0000-0002-2477-9974;
   Batıoğlu, Figen/0000-0002-5834-7512
CR Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2004, AM J OPHTHALMOL, V137, P556, DOI 10.1016/j.ajo.2003.08.004
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   BOULTON M, 1986, BRIT J OPHTHALMOL, V70, P808, DOI 10.1136/bjo.70.11.808
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 20
TC 17
Z9 17
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 950
EP 955
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500019
PM 24987815
DA 2022-11-30
ER

PT J
AU McHugh, KJ
   Tao, SL
   Saint-Geniez, M
AF McHugh, Kevin J.
   Tao, Sarah L.
   Saint-Geniez, Magali
TI Porous Poly(epsilon-Caprolactone) Scaffolds for Retinal Pigment
   Epithelium Transplantation
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE retinal pigment epithelium; age-related macular degeneration; in vitro;
   scaffold; porous polycaprolactone
ID BRUCHS MEMBRANE; CELL TRANSPLANTATION; OUTER SEGMENTS; RPE; AGE;
   SURVIVAL; BIOCOMPATIBILITY; CHORIOCAPILLARIS; DIFFERENTIATION;
   EXPRESSION
AB PURPOSE. Retinal pigment epithelium (RPE) transplantation is a promising strategy for the treatment of dry age-related macular degeneration (AMD). However, previous attempts at subretinal RPE cell transplantation have experienced limited success due to poor adhesion, organization, and function on aged or diseased Bruch's membrane. Instead, cell-based strategies may benefit from a synthetic scaffold that mimics the functions of healthy Bruch's membrane to promote the formation of a functional RPE monolayer while maintaining metabolite exchange between the vasculature and outer retina.
   METHODS. This study evaluated the behavior of human RPE on nanopatterned porous poly(epsilon-caprolactone) (PCL) film as a potential scaffold for therapeutic transplantation. Fetal human RPE (fhRPE) was cultured on porous PCL, nonporous PCL, or Costar porous polyester transwells for up to 8 weeks and assessed using light microscopy, fluorescent microscopy, transepithelial resistance, quantitative PCR, ELISAs, and phagocytosis assays.
   RESULTS. fhRPE on porous PCL displayed improved markers of maturity and function compared with both porous polyester transwells and nonporous PCL, including pigmentation, increased cell density, superior barrier function, up-regulation of RPE-specific genes, and polarized growth factor secretion.
   CONCLUSIONS. This study indicates that porous PCL is an attractive scaffold for RPE transplantation. In addition to being biocompatible with the subretinal space, porous PCL also allows for trans-scaffold metabolite transport and significantly improves RPE cell behavior compared to nonporous PCL or porous polyester transwells.
C1 [McHugh, Kevin J.; Saint-Geniez, Magali] Schepens Eye Res Inst, Boston, MA 02114 USA.
   [McHugh, Kevin J.] Boston Univ, Boston, MA 02215 USA.
   [McHugh, Kevin J.; Tao, Sarah L.] Charles Stark Draper Lab Inc, Cambridge, MA 02139 USA.
   [Saint-Geniez, Magali] Harvard Univ, Sch Med, Boston, MA USA.
C3 Harvard University; Schepens Eye Research Institute; Boston University;
   The Charles Stark Draper Laboratory, Inc.; Harvard University; Harvard
   Medical School
RP Saint-Geniez, M (通讯作者)，Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM magali_saintgeniez@meei.harvard.edu
RI SAINT-GENIEZ, MAGALI/P-3509-2019; McHugh, Kevin/H-7507-2019
OI SAINT-GENIEZ, MAGALI/0000-0001-9897-138X; McHugh,
   Kevin/0000-0001-6801-4431
FU National Institutes of Health (NIH) through the NIH Director's New
   Innovator Award Program [1-DP2-OD006649]; National Institute of
   Biomedical Imaging and Bioengineering [5-T32-EB006359-05]; NATIONAL
   INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [T32EB006359] Funding
   Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF
   HEALTH [DP2OD006649] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health (NIH) through the NIH
   Director's New Innovator Award Program, 1-DP2-OD006649 (MSG), and award
   number 5-T32-EB006359-05 from the National Institute of Biomedical
   Imaging and Bioengineering (KM). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health or National
   Institute of Biomedical Imaging and Bioengineering.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Cai H, 2006, CURR EYE RES, V31, P181, DOI 10.1080/02713680500514628
   Cao SJ, 2013, MOL VIS, V19, P718
   Christiansen A T, 2012, Stem Cells Int, V2012, P454295, DOI 10.1155/2012/454295
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Gunatillake Pathiraja A., 2003, European Cells & Materials, V5, P1
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kohn J, 2004, BIOMATERIALS SCI INT, P115
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   Liu XH, 2012, MACROMOL BIOSCI, V12, P911, DOI 10.1002/mabi.201100466
   Lu LC, 1996, MRS BULL, V21, P28, DOI 10.1557/S088376940003181X
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmor MF, 2008, OPHTHALMOLOGY EXPERT, P515
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   McHugh KJ, 2013, J BIOMED MATER RES B, V101, P1571, DOI 10.1002/jbm.b.32968
   McHugh KJ, 2013, J MATER SCI-MATER M, V24, P1659, DOI 10.1007/s10856-013-4934-1
   McKay BS, 2006, EXP NEUROL, V201, P234, DOI 10.1016/j.expneurol.2006.04.016
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Nagineni CN, 2005, J CELL PHYSIOL, V203, P35, DOI 10.1002/jcp.20213
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pachence JM, 2007, PRINCIPLES OF TISSUE ENGINEERING, 3RD EDITION, P323, DOI 10.1016/B978-012370615-7/50027-5
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   QUINN JA, 1972, BIOPHYS J, V12, P990, DOI 10.1016/S0006-3495(72)86139-3
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Sabir MI, 2009, J MATER SCI, V44, P5713, DOI 10.1007/s10853-009-3770-7
   Saint-Geniez M, 2011, COMPREHENSIVE BIOMAT, P500
   Salgado CL, 2012, J BIOMED MATER RES A, V100A, P243, DOI 10.1002/jbm.a.33272
   Shiragami C, 1998, BRIT J OPHTHALMOL, V82, P1056, DOI 10.1136/bjo.82.9.1056
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun K, 2007, MOL VIS, V13, P2310
   Suzuki F, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3761
   Takahashi K, 2011, DIABETES-METAB RES, V27, P830, DOI 10.1002/dmrr.1257
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thomson HAJ, 2011, BRIT J OPHTHALMOL, V95, P563, DOI 10.1136/bjo.2009.166728
   Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117
   Vaajasaari H, 2011, MOL VIS, V17, P558
   YOUNG RW, 1971, J CELL BIOL, V49, P303, DOI 10.1083/jcb.49.2.303
   Zayas-Santiago A, 2011, INVEST OPHTH VIS SCI, V52, P4907, DOI 10.1167/iovs.10-6595
NR 56
TC 48
Z9 49
U1 0
U2 17
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2014
VL 55
IS 3
BP 1754
EP 1762
DI 10.1167/iovs.13-12833
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE0HZ
UT WOS:000333645900007
PM 24550370
OA Green Published
DA 2022-11-30
ER

PT J
AU Amore, FM
   Silvestri, V
   Turco, S
   De Rossi, F
   Cruciani, F
AF Amore, Filippo M.
   Silvestri, Valeria
   Turco, Simona
   De Rossi, Francesca
   Cruciani, Filippo
TI Rehabilitative approach in patients with ring scotoma
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; CENTRAL VISION LOSS; MACULAR
   DEGENERATION; FIXATION STABILITY; VISUAL FUNCTION; RETINITIS-PIGMENTOSA;
   READING SPEED; CONTRAST SENSITIVITY; CLINICAL RESEARCH; RETINAL LOCATION
AB Objective: To investigate the rehabilitative approach in patients with ring scotoma. A central scotoma is characteristic for patients with age-related macular degeneration (AMD). Sometimes patients with AMD maintain a residual central vision area within the scotoma (ring scotoma).
   Design: Prospective, nonrandomized case series.
   Participants: Twenty-four patients with AMD.
   Methods: A formal low-vision assessment was performed for all study patients. The assessment included best corrected visual acuity (BCVA), contrast sensitivity, reading speed, and microperimetry. All patients were provided a low-vision assessment to satisfy patients needs. Devices were prescribed accordingly.
   Results: The BCVA found was 0.4 logMAR (SD 0.1). All had central and stable fixation. Residual central retinal area size and sensitivity measured 2.4 degrees (SD 0.8) and 3.1 dB (SD 0.8), respectively. Twenty patients achieved better vision with optical magnification in the eye with ring scotoma. Mean reading speed achieved was 50.2 words/min (SD 20.9). A linear correlation was found for reading speed with both central area sensitivity (r(2) = 0.5, p < 0.05) and contrast sensitivity (r(2) = 0.3, p < 0.05).
   Conclusions: In patients with AMD with ring scotoma, moderate amounts of magnification seem to provide satisfactory rehabilitation outcomes. Central retinal spared area sensitivity may predict reading speed outcomes, whereas residual central area size is likely to be useful in determining magnification.
C1 [Amore, Filippo M.; Silvestri, Valeria; Turco, Simona; De Rossi, Francesca; Cruciani, Filippo] Italia Onlus, Int Agcy Prevent Blindness, Natl Ctr Serv & Res Prevent Blindness & Rehabilat, Rome, Italy.
RP Amore, FM (通讯作者)，Natl Ctr Serv & Res Prevent Blindness & Rehabilat, Largo A Gemelli 8, I-00168 Rome, Italy.
EM f.amore@iapb.it
RI Silvestri, Valeria/AAB-9530-2022
OI Silvestri, Valeria/0000-0002-8451-8901
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   Bragg M., 2005, INT C SER, V1282, P40, DOI DOI 10.1016/J.ICS.2005.06.028
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   CULHAM LE, 1993, CLIN VISION SCI, V8, P551
   DANA MR, 1990, JAMA-J AM MED ASSOC, V264, P2400, DOI 10.1001/jama.264.18.2400
   Dunbar HMP, 2010, INVEST OPHTH VIS SCI, V51, P4346, DOI 10.1167/iovs.09-4556
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fosse P., 2004, J VISUAL IMPAIR BLIN, V98, P1
   FRIEDMAN DS, 2002, VISION PROBLEMS US P
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Goldschmidt Mira, 2010, BMC Res Notes, V3, P15, DOI 10.1186/1756-0500-3-15
   Grant P, 2011, J REHABIL RES DEV, V48, P1101, DOI 10.1682/JRRD.2010.05.0080
   Habel A., PRIMARY CAUSES UNPUB
   Hayman KJ, 2007, OPTOMETRY VISION SCI, V84, P1024, DOI 10.1097/OPX.0b013e318157a6b1
   Haymes SA, 2006, OPHTHAL PHYSL OPT, V26, P169, DOI 10.1111/j.1475-1313.2006.00367.x
   Haymes SA, 2002, OPHTHAL PHYSL OPT, V22, P79, DOI 10.1046/j.1475-1313.2002.00016.x
   Haymes SA, 2001, INVEST OPHTH VIS SCI, V42, P1215
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Horowitz A, 2003, AGING MENT HEALTH, V7, P342, DOI 10.1080/1360786031000150739
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Latham K, 2012, OPTOMETRY VISION SCI, V89, P1316, DOI 10.1097/OPX.0b013e31825bff1c
   Leat SJ, 1997, EYE, V11, P893, DOI 10.1038/eye.1997.228
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1987, VISION RES, V27, P1165, DOI 10.1016/0042-6989(87)90028-9
   LEGGE GE, 1990, J OPT SOC AM A, V7, P2002, DOI 10.1364/JOSAA.7.002002
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   LEGGE GE, 1986, J OPT SOC AM A, V3, P40, DOI 10.1364/JOSAA.3.000040
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   RUBIN GS, 1989, VISION RES, V29, P79, DOI 10.1016/0042-6989(89)90175-2
   Sandberg MA, 2006, RETINA-J RET VIT DIS, V26, P80, DOI 10.1097/00006982-200601000-00013
   Sawa M, 2006, JPN J OPHTHALMOL, V50, P111, DOI 10.1007/s10384-005-0292-y
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Szlyk JP, 2001, OPHTHALMOLOGY, V108, P65, DOI 10.1016/S0161-6420(00)00413-9
   Szlyk JP, 2000, J VISUAL IMPAIR BLIN, V94, P781, DOI 10.1177/0145482X0009401206
   Tabrett DR, 2011, INVEST OPHTH VIS SCI, V52, P5293, DOI 10.1167/iovs.10-7055
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Virgili G, 2004, INVEST OPHTH VIS SCI, V45, P3418, DOI 10.1167/iovs.04-0390
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   [No title captured]
NR 53
TC 7
Z9 7
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2013
VL 48
IS 5
BP 420
EP 426
DI 10.1016/j.jcjo.2013.07.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OM
UT WOS:000331149300028
PM 24093190
DA 2022-11-30
ER

PT J
AU Chalam, KV
   Balaiya, S
   Malyappa, RS
   Hsi, W
   Brar, VS
   Murthy, RK
AF Chalam, Kakarla V.
   Balaiya, Sankarathi
   Malyappa, Robert S.
   Hsi, Wen
   Brar, Vikram S.
   Murthy, Ravi K.
TI EVALUATION OF CHOROIDAL ENDOTHELIAL CELL PROLIFERATION AFTER EXPOSURE TO
   VARYING DOSES OF PROTON BEAM RADIATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal endothelial cells; exudative AMD; proton beam radiation
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; NEOVASCULARIZATION;
   RADIOTHERAPY; CULTURE; GROWTH; IRRADIATION; VERTEPORFIN; TRIAL
AB Purpose: Focal epiretinal radiation has emerged as a promising tool in the management of choroidal neovascularization associated with age-related macular degeneration. However, the dosages tested are not backed by cell culture studies used in the clinical setting empirically.
   Methods: Choroidal endothelial cells (RF6A) were maintained in a log scale and exposed to a single fraction of 2, 4, 8, and 12 cobalt gray-equivalent of proton radiation with an internal control. Cell viability was quantified using Vi-cell XR and neutral red assay at days 5, 9, and 12 after radiation. Mitochondrial viability using WST-1 and reactive oxygen species levels using dihydrorhodamine 123 were measured at similar intervals.
   Results: By using neutral red assay, on day 12, the percentages of viable cells compared with control were 100.1 +/- 5.7%, 96.7 +/- 23.3%, 27.6 +/- 6.6%, and 19.5 +/- 3% at radiation doses of 2, 4, 8, and 12 cobalt gray-equivalent, respectively (P < 0.001). Increase in reactive oxygen species levels correlated with the number of dead cells implicating reactive oxygen species as an intermediary molecule (r(2) = 0.85-0.96).
   Conclusion: Our study shows sensitivity of cultured choroidal endothelial cells to proton beam radiation at doses of 8 and 12 cobalt gray-equivalent in an in vitro model. RETINA 31:169-176, 2011
C1 [Chalam, Kakarla V.; Balaiya, Sankarathi; Brar, Vikram S.; Murthy, Ravi K.] Univ Florida, Dept Ophthalmol, Coll Med, Jacksonville, FL 32209 USA.
   [Malyappa, Robert S.; Hsi, Wen] Univ Florida, Dept Radiat Oncol, Proton Therapy Inst, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Chalam, KV (通讯作者)，Univ Florida, Dept Ophthalmol, Coll Med, 580 W 8th St,Tower 2,3rd Floor, Jacksonville, FL 32209 USA.
EM kchalam@jax.ufl.edu
RI Chalam, kakarla/K-7507-2019
OI Chalam, kakarla/0000-0001-9325-8665; Chalam, K V/0000-0002-0004-9416
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DEGOWIN RL, 1974, J LAB CLIN MED, V84, P42
   Eter N, 2000, BRIT J OPHTHALMOL, V84, P757, DOI 10.1136/bjo.84.7.757
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Green W R, 1999, Mol Vis, V5, P27
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Joussen AM, 2000, OPHTHALMIC RES, V32, P222, DOI 10.1159/000055617
   Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration, 1993, ARCH OPHTHALMOL, V111, P1200
   National Advisory Eye Council (U.S.), 1993, NIH PUBL
   Robbins MEC, 2004, INT J RADIAT BIOL, V80, P251, DOI 10.1080/09553000410001692726
   SEDDON J, 2004, CONTROVERSIES ADV TR, P17
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Thotala D, 2009, FREE RADICAL BIO MED, V47, P779, DOI 10.1016/j.freeradbiomed.2009.06.020
   UCHIDA K, 1994, AM J PHYSIOL, V266, pF81, DOI 10.1152/ajprenal.1994.266.1.F81
   Waters CM, 1996, RADIAT RES, V146, P321, DOI 10.2307/3579463
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 21
TC 5
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2011
VL 31
IS 1
BP 169
EP 176
DI 10.1097/IAE.0b013e3181dee621
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 699TG
UT WOS:000285685100023
PM 20829738
DA 2022-11-30
ER

PT J
AU Boucart, M
   Despretz, P
   Hladiuk, K
   Desmettre, T
AF Boucart, Muriel
   Despretz, Pascal
   Hladiuk, Katrine
   Desmettre, Thomas
TI Does context or color improve object recognition in patients with low
   vision?
SO VISUAL NEUROSCIENCE
LA English
DT Article
DE Low vision; Macular degeneration; Object recognition; Faces; Scenes;
   Context; Color
ID AGE-RELATED MACULOPATHY; HUMAN VISUAL-CORTEX; MACULAR DEGENERATION;
   PERIPHERAL-VISION; CONTRAST SENSITIVITY; AMBLYOPIC VISION; FACE
   RECOGNITION; NATURAL SCENES; READING SPEED; PERCEPTION
AB Most studies oil people with age-related macular degeneration (AMD) have been focused on investigations of low-level processes with Simple stimuli like gratings. letters, and in perception of isolated laces or objects. We investigated the ability of people with low vision to analyze more Complex stimuli like photographs of natural scenes. Fifteen participants with AMD and low vision (acuity oil the better eye <20/200) and 11 normally sighted age-matched control,; took pan in the study. They, were presented with photographs of either colored or achromatic gray level scenes in one condition quid with photographs of natural scenes versus isolated objects extracted from these scenes in another condition. The photographs were centrally displayed for 300 ms. In both conditions. observers were instructed to press a key when they saw a predefined target (a face or an animal). The target was present in half of the trials. Color facilitated performance in people with low vision, while equivalent performance Was found for colored and achromatic Pictures in normally sighted participants. Isolated objects were categorized more accurately than objects in scenes in people with low vision. No difference was found For normally sighted observers. The results suggest that spatial properties that facilitate image segmentation (e.g., color and reduced crowding) help object perception in people with low vision.
C1 Clin Ophthalmol, Ctr Imagerie Laser & Readaptat Basse Vis, Lambersart, France.
   Univ Lille, CHU Lille, CNRS, Nord France,Lab Neurosci Fonct & Pathol, Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Lille
   - ISITE; CHU Lille; Universite de Lille
RP Boucart, M (通讯作者)，CHRU Lille, Hop Roger Salengro, Serv EFV, Lab Neurosci Fonct & Pathol,CNRS UMR 8160, F-59037 Lille, France.
EM m-boucart@chru-lille.fr
CR Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Bar M, 2004, NAT REV NEUROSCI, V5, P617, DOI 10.1038/nrn1476
   BIEDERMAN I, 1982, COGNITIVE PSYCHOL, V14, P143, DOI 10.1016/0010-0285(82)90007-X
   Boucart M., 2008, VISUAL NEUROSCI, V25, P1
   BOYCE SJ, 1992, J EXP PSYCHOL LEARN, V18, P531, DOI 10.1037/0278-7393.18.3.531
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Chee MWL, 2006, J COGNITIVE NEUROSCI, V18, P495, DOI 10.1162/jocn.2006.18.4.495
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Davenport JL, 2004, PSYCHOL SCI, V15, P559, DOI 10.1111/j.0956-7976.2004.00719.x
   DELORME A, 2005, J NEUROSCI, V25, P614
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   EBERT EM, 1986, ARCH OPHTHALMOL-CHIC, V104, P1009
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   FINE EM, 1995, J OPT SOC AM A, V12, P2286, DOI 10.1364/JOSAA.12.002286
   Fine EM, 1999, VISION RES, V39, P747, DOI 10.1016/S0042-6989(98)00142-4
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Gegenfurtner KR, 2000, CURR BIOL, V10, P805, DOI 10.1016/S0960-9822(00)00563-7
   Goffaux V, 2005, VIS COGN, V12, P878, DOI 10.1080/13506280444000562
   Greene M. R., 2006, P 28 ANN C COGN SCI, P291
   Grill-Spector K, 2004, ANNU REV NEUROSCI, V27, P649, DOI 10.1146/annurev.neuro.27.070203.144220
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Hariharan S, 2005, VISION RES, V45, P617, DOI 10.1016/j.visres.2004.09.035
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hess RF, 2001, VISION RES, V41, P2285, DOI 10.1016/S0042-6989(01)00099-2
   Higgins KE, 1996, VISION RES, V36, P331, DOI 10.1016/0042-6989(95)00117-I
   HOLZSCHUCH C, 2002, GERIATRIE BASSEVISIO
   Joubert OR, 2007, VISION RES, V47, P3286, DOI 10.1016/j.visres.2007.09.013
   Kanwisher N, 1997, J NEUROSCI, V17, P4302
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   KOOI FL, 1994, SPATIAL VISION, V8, P255, DOI 10.1163/156856894X00350
   Lavie N, 2003, PSYCHOL SCI, V14, P510, DOI 10.1111/1467-9280.03453
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Legge GE, 2001, VISION RES, V41, P725, DOI 10.1016/S0042-6989(00)00295-9
   LEID J, 2008, OPHTALMOLOGIE, V32, P71
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Levi DM, 2002, VISION RES, V42, P1379, DOI 10.1016/S0042-6989(02)00061-5
   Mace MJM, 2005, EUR J NEUROSCI, V21, P2007, DOI 10.1111/j.1460-9568.2005.04029.x
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   McCarthy G, 1997, J NEUROPHYSIOL, V77, P1630, DOI 10.1152/jn.1997.77.3.1630
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Naili F, 2006, NEUROREPORT, V17, P1571
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Oliva A, 2004, J EXP PSYCHOL HUMAN, V30, P1132, DOI 10.1037/0096-1523.30.6.1132
   Oliva A, 2000, COGNITIVE PSYCHOL, V41, P176, DOI 10.1006/cogp.1999.0728
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   PETERSON MA, 2003, ADV VISUAL COGNITION
   Puce A, 1996, J NEUROSCI, V16, P5205
   Regillo CD, 1998, OPHTHALMOLOGY, V105, P1821, DOI 10.1016/S0161-6420(98)91022-3
   Righart R, 2006, CEREB CORTEX, V16, P1249, DOI 10.1093/cercor/bhj066
   Rossion B, 2004, PERCEPTION, V33, P217, DOI 10.1068/p5117
   SJOSTRAND J, 1977, ACTA OPHTHALMOL, V55, P507
   Tanaka JW, 1999, PERCEPT PSYCHOPHYS, V61, P1140, DOI 10.3758/BF03207619
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Thorpe SJ, 2001, EUR J NEUROSCI, V14, P869, DOI 10.1046/j.0953-816x.2001.01717.x
   Tsao DY, 2008, ANNU REV NEUROSCI, V31, P411, DOI 10.1146/annurev.neuro.30.051606.094238
   WURM LH, 1993, J EXP PSYCHOL HUMAN, V19, P899, DOI 10.1037/0096-1523.19.4.899
NR 68
TC 32
Z9 32
U1 0
U2 11
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0952-5238
EI 1469-8714
J9 VISUAL NEUROSCI
JI Visual Neurosci.
PD SEP-DEC
PY 2008
VL 25
IS 5-6
BP 685
EP 691
DI 10.1017/S0952523808080826
PG 7
WC Neurosciences; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Ophthalmology
GA 391MQ
UT WOS:000262237800006
PM 19094371
DA 2022-11-30
ER

PT J
AU Pinelli, R
   Bertelli, M
   Scaffidi, E
   Busceti, CL
   Biagioni, F
   Fornai, F
AF Pinelli, R.
   Bertelli, M.
   Scaffidi, E.
   Busceti, C. L.
   Biagioni, F.
   Fornai, F.
TI Exosomes and alpha-synuclein within retina from autophagy to protein
   spreading in neurodegeneration
SO ARCHIVES ITALIENNES DE BIOLOGIE
LA English
DT Article
DE Age-related macular degeneration; Neurodegeneration; Autophagy; Protein
   aggregation; Exosomes; Pigment epithelium
ID FUTURE THERAPEUTIC STRATEGIES; PARKINSONS-DISEASE; MACULAR DEGENERATION;
   PRIONS; MECHANISMS; INCLUSIONS; DISORDERS
AB In the course of age-related macular degeneration (AMD) as well as in multiple retinal disorders protein aggregates are described at various level in the retina. In AMD this fills the space between retinal pigment epithelium (RPE) in the form of drusen, which contain amyloid and other protein aggregates along with lipids. Nonetheless, in very advanced stages of AMD, as well as in other retinal pathologies and early on in retinitis pigmentosa, a number of neuronal inclusions, which stain for a-synuclein spreads all over the retinal layers. Thus, an early or later defect in the clearance of a-synuclein may represent a final common pathway to these phenomena. The physiological clearance of a-synuclein is provided by the autophagy machinery starting at the level of the RPE and occurring throughout the retina. Such a process is also involved in the clearance of melanin-dependent toxic metabolites under the effects of different wavelength and the stimulatory activity of the sympathetic nervous system. In search for the occurrence of these culprits, here we report the presence of a-synuclein in the retina combined with exosomal detection to document the presence of a a-synuclein spreading apparatus. This was correlated with the occurrence of autophagy markers throughout retinal layers, along with sympathetic innervation, which in turn was related to melanin content.
C1 [Pinelli, R.; Bertelli, M.; Scaffidi, E.] Switzerland Eye Res Inst, SERI, Lugano, Switzerland.
   [Busceti, C. L.; Biagioni, F.; Fornai, F.] IRCCS Neuromed Pozzili IS, Pozzilli, IS, Italy.
   [Fornai, F.] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy.
C3 University of Pisa
RP Fornai, F (通讯作者)，Univ Pisa, Dept Translat Res & New Technol Med & Surg, Human Anat, Via Roma 55, I-56126 Pisa, Italy.
EM francesco.fornai@neuromed.it
CR Lai HIAM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031320
   Angileri KM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68016-z
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522
   Ferrucci M, 2017, ARCH ITAL BIOL, V155, P81, DOI 10.12871/000398292017129
   Ferrucci M, 2013, ARCH ITAL BIOL, V151, P219
   Fornai F, 2003, CNS NEUROL DISORD-DR, V2, P149, DOI 10.2174/1568007033482904
   Fornai F, 2006, BRAIN RES BULL, V69, P95, DOI 10.1016/j.brainresbull.2005.12.005
   Fornai F, 2005, BRAIN RES BULL, V65, P275, DOI 10.1016/j.brainresbull.2004.12.009
   Fornai F, 2011, ARCH ITAL BIOL, V149, P169, DOI 10.4449/aib.v149i1.1269
   Fornai F, 2003, J NEUROSCI, V23, P8955
   Fornai F, 2002, ANN NY ACAD SCI, V965, P381
   Gambardella S, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00102
   Giorgi FS, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00080
   Herrera Arturo S., 2020, Central Nervous System Agents in Medicinal Chemistry, V20, P218, DOI 10.2174/1871524920666201109152951
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Koka K, 2021, PTOSIS CORRECTION
   Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747
   Kordower JH, 2008, MOVEMENT DISORD, V23, P2303, DOI 10.1002/mds.22369
   Lee SJ, 2021, BIO-PROTOCOL, V11, DOI 10.21769/BioProtoc.3872
   Limanaqi F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21083028
   Limanaqi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133274
   Madeo F, 2009, GENE DEV, V23, P2253, DOI 10.1101/gad.1858009
   Mahendra CK, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1904178
   Matsuzaki M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64601-4
   Natale G, 2013, EUR J HISTOCHEM, V57, P31, DOI 10.4081/ejh.2013.e5
   Natale G, 2011, PRION, V5, P142, DOI 10.4161/pri.5.3.16328
   Olanow CW, 2019, BRAIN, V142, P1690, DOI 10.1093/brain/awz104
   Olanow CW, 2014, ANN NEUROL, V75, P331, DOI 10.1002/ana.24098
   Olanow CW, 2013, MOVEMENT DISORD, V28, P31, DOI 10.1002/mds.25373
   Olanow CW, 2012, MOVEMENT DISORD, V27, P1475, DOI 10.1002/mds.25170
   Olanow CW, 2011, MOVEMENT DISORD, V26, P1056, DOI 10.1002/mds.23767
   Olanow CW, 2009, P NATL ACAD SCI USA, V106, P12571, DOI 10.1073/pnas.0906759106
   Orzi F, 2013, NEUROL SCI, V34, P1035, DOI 10.1007/s10072-012-1148-0
   Pasquali L, 2014, CURR MED CHEM, V21, P3508, DOI 10.2174/0929867321666140601161534
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Pinelli R, 2020, ARCH ITAL BIOL, V158, P24, DOI 10.12871/00039829202013
   Pinelli R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155563
   Ramsay E, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070667
   Schapira AHV, 2014, LANCET, V384, P545, DOI 10.1016/S0140-6736(14)61010-2
   Schluter OM, 2003, NEUROSCIENCE, V118, P985, DOI 10.1016/S0306-4522(03)00036-8
   Sharma P, 2013, J AAPOS, V17, P203, DOI 10.1016/j.jaapos.2012.11.004
   Silani V, 2017, ARCH ITAL BIOL, V155, P153, DOI 10.12871/00039829201741
   Silani V, 2011, ARCH ITAL BIOL, V149, P1, DOI 10.4449/aib.v149i1.1268
   Yamanari M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76397-4
   Zhang M, 2013, SCIENCE, V340, P559, DOI 10.1126/science.1234740
NR 47
TC 2
Z9 2
U1 6
U2 11
PU PISA UNIV PRESS
PI PISA
PA LUNGARNO A PACINOTTI 43, 56100 PISA, ITALY
SN 0003-9829
J9 ARCH ITAL BIOL
JI Arch. Ital. Biol.
PD MAR
PY 2021
VL 159
IS 1
BP 38
EP 50
DI 10.12871/00039829202114
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA WD6QQ
UT WOS:000705064300003
PM 34159576
DA 2022-11-30
ER

PT J
AU Finger, RP
   Daien, V
   Talks, JS
   Mitchell, P
   Wong, TY
   Sakamoto, T
   Eldem, BM
   Lovestam-Adrian, M
   Korobelnik, JF
AF Finger, Robert P.
   Daien, Vincent
   Talks, James S.
   Mitchell, Paul
   Wong, Tien Y.
   Sakamoto, Taiji
   Eldem, Bora M.
   Lovestam-Adrian, Monica
   Korobelnik, Jean-Francois
TI A novel tool to assess the quality of RWE to guide the management of
   retinal disease
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE checklist; diabetic macular oedema; GRACE; neovascular aged related
   macular degeneration; real&#8208; world evidence; retinal disease;
   retinal vein occlusion; tool
ID EPIDEMIOLOGY STROBE-NUT; MACULAR DEGENERATION; EUROPEAN-SOCIETY;
   STATEMENT; CHECKLIST; EXTENSION; STANDARDS; EXPLANATION; PERSPECTIVE;
   DATABASE
AB Despite the growing importance of real-world evidence (RWE) for guiding clinical decisions in retinal disease, there is currently no widely used guidance available for assessing the quality and relevance of RWE studies in ophthalmology. This paper summarizes the development of a user-friendly tool that facilitates assessment of the quality of available RWE for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). A literature search was conducted to identify tools developed to assess the quality of RWE, in order to identify the most appropriate framework on which to base this tool. The Good Research for Comparative Effectiveness (GRACE) guidelines was chosen for this purpose as it is designed to assess the quality of observational studies and has been extensively validated, including demonstration of strong sensitivity and specificity. The GRACE guidelines were adapted to develop a straightforward tabular tool that allows simple assessment and comparison of the quality of published evidence in retinal disease for researchers and physicians alike, and includes guidance on treatment details, outcome measures, study population, and controlling for bias. The newly developed tool provides a simple method to support assessment of the strength of evidence and certainty of conclusions drawn from RWE in retinal disease, to ensure clinical decision-making is influenced by the highest quality evidence.
C1 [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Talks, James S.] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne, Tyne & Wear, England.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
   [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Y.] Duke NUS Med Sch, Singapore, Singapore.
   [Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima, Japan.
   [Sakamoto, Taiji] J CREST, Kagoshima, Japan.
   [Eldem, Bora M.] Hacettepe Univ, Dept Ophthalmol, Fac Med, Ankara, Turkey.
   [Lovestam-Adrian, Monica] SUS Lund, Univ Lund Hosp, Dept Ophthalmol, Lund, Sweden.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux, INSERM, BPH, U1219, Bordeaux, France.
C3 University of Bonn; Universite de Montpellier; CHU de Montpellier;
   University of Sydney; Newcastle University - UK; University of Sydney;
   Westmead Institute for Medical Research; National University of
   Singapore; Singapore National Eye Center; National University of
   Singapore; Kagoshima University; Hacettepe University; Lund University;
   Skane University Hospital; CHU Bordeaux; Institut National de la Sante
   et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Bonn, Germany.
EM robert.finger@ukbonn.de
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Sakamoto, Taiji/0000-0003-0287-3801;
   Finger, Robert P/0000-0003-4253-7597; Talks, James/0000-0001-6126-6476
CR ABPI, 2011, DEM VAL REAL WORLD D
   Agha RA, 2017, INT J SURG, V46, P198, DOI 10.1016/j.ijsu.2017.08.586
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885
   Bennett DA, 2015, NEUROLOGY, V85, P821, DOI 10.1212/WNL.0000000000001866
   Berger ML, 2014, VALUE HEALTH, V17, P143, DOI 10.1016/j.jval.2013.12.011
   Berger ML, 2009, VALUE HEALTH, V12, P1044, DOI 10.1111/j.1524-4733.2009.00600.x
   BMJ Clinical Evidence Blog, 2015, GATE GRAPH APPR TOOL
   Briere JB, 2018, CURR MED RES OPIN, V34, P2125, DOI 10.1080/03007995.2018.1524751
   Camm AJ, 2018, THROMB HAEMOSTASIS, V118, pS45, DOI 10.1055/s-0038-1635084
   CASP UK, 2018, CRIT APPR SKILLS PRO
   Cavan D, 2017, DIABETES RES CLIN PR, V129, P16, DOI 10.1016/j.diabres.2017.03.023
   Daien V, 2021, BRIT J OPHTHALMOL, V105, P1475, DOI 10.1136/bjophthalmol-2020-317434
   de Lusignan Simon, 2015, J Innov Health Inform, V22, P368, DOI 10.14236/jhi.v22i3.177
   Downes MJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011458
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Dreyer NA, 2016, J MANAG CARE SPEC PH, V22, P1107, DOI 10.18553/jmcp.2016.22.10.1107
   Dreyer NA, 2014, J MANAG CARE SPEC PH, V20, P301, DOI 10.18553/jmcp.2014.20.3.301
   European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, 2018, ENCEPP CHECKL STUD P
   Fitchett EJA, 2016, LANCET INFECT DIS, V16, pE202, DOI 10.1016/S1473-3099(16)30082-2
   Garrison LP, 2007, VALUE HEALTH, V10, P326, DOI 10.1111/j.1524-4733.2007.00186.x
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Hoque DME, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010654
   Horby PW, 2017, INFLUENZA OTHER RESP, V11, P2, DOI 10.1111/irv.12411
   Hornell A, 2017, ADV NUTR, V8, P652, DOI 10.3945/an.117.015941
   Lachat C, 2016, NUTR BULL, V41, P240, DOI 10.1111/nbu.12217
   Langan SM, 2016, J ORTHOP SPORT PHYS, V46, P126, DOI 10.2519/jospt.2016.0103
   Loring DW, 2014, CLIN NEUROPSYCHOL, V28, P556, DOI 10.1080/13854046.2012.762552
   Malmivaara A, 2016, ANN MED, V48, P440, DOI 10.1080/07853890.2016.1186830
   Malmivaara A, 2015, ANN MED, V47, P332, DOI 10.3109/07853890.2015.1027255
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Miksad RA, 2018, CLIN PHARMACOL THER, V103, P202, DOI 10.1002/cpt.946
   Morton SC, 2016, J CLIN EPIDEMIOL, V71, P3, DOI 10.1016/j.jclinepi.2015.10.014
   Mulder R, 2018, EVID-BASED MENT HEAL, V21, P4, DOI 10.1136/eb-2017-102701
   Norgaard M, 2017, CLIN EPIDEMIOL, V9, P185, DOI 10.2147/CLEP.S129879
   Ottawa Hospital Research Institute, 2020, NEWC OTT QUAL ASS AC
   Pandey R, 2018, VALUE HEALTH, V21, pS1
   Patient-Centered Outcomes Research Institute, 2019, PCORI METHODOLOGY RE
   Rao A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155078
   Roche Nicolas, 2014, Ann Am Thorac Soc, V11 Suppl 2, pS99, DOI 10.1513/AnnalsATS.201309-300RM
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Sauerbrei W, 2014, STAT MED, V33, P5413, DOI 10.1002/sim.6265
   Schaumberg DA, 2018, J COMP EFFECT RES, V7, P503, DOI 10.2217/cer-2018-0007
   Schmidt-Erfurth U, 2019, OPHTHALMOLOGICA, V242, P123, DOI 10.1159/000502041
   Schmidt-Erfurth U, 2017, OPHTHALMOLOGICA, V237, P185, DOI 10.1159/000458539
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Scottish Intercollegiate Guidelines Network, 2019, SIGN 50 CHECKL
   Sharp MK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-019043
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Talks J, 2019, SURV OPHTHALMOL, V64, P707, DOI 10.1016/j.survophthal.2019.02.008
   US Food and Drug Administration, 2020, SPEC TOP REAL WORLD
   Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Yang C, 2017, ADV NUTR, V8, P639, DOI 10.3945/an.117.015651
NR 55
TC 1
Z9 1
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2021
VL 99
IS 6
BP 604
EP 610
DI 10.1111/aos.14698
EA DEC 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UO6TY
UT WOS:000602681100001
PM 33369881
OA Green Published
DA 2022-11-30
ER

PT J
AU Arjunan, P
   Swaminathan, R
   Yuan, J
   Al-Shabrawey, M
   Espinosa-Heidmann, DG
   Nussbaum, J
   Martin, PM
   Cutler, CW
AF Arjunan, Pachiappan
   Swaminathan, Radhika
   Yuan, Jessie
   Al-Shabrawey, Mohamed
   Espinosa-Heidmann, Diego G.
   Nussbaum, Julian
   Martin, Pamela M.
   Cutler, Christopher W.
TI Invasion of Human Retinal Pigment Epithelial Cells by Porphyromonas
   gingivalis leading to Vacuolar/Cytosolic localization and Autophagy
   dysfunction In-Vitro
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; PERIODONTAL-DISEASE; DENDRITIC CELLS;
   NATIONAL-HEALTH; MOLECULAR-BASIS; PROTEINS; PREVALENCE; APOPTOSIS;
   VIRULENCE
AB Recent epidemiological studies link Periodontal disease(PD) to age-related macular degeneration (AMD). We documented earlier that Porphyromonas gingivalis(Pg), keystone oral-pathobiont, causative of PD, efficiently invades human gingival epithelial and blood-dendritic cells. Here, we investigated the ability of dysbiotic Pg-strains to invade human-retinal pigment epithelial cells(ARPE-19), their survival, intracellular localization, and the pathological effects, as dysfunction of RPEs leads to AMD. We show that live, but not heat-killed Pg-strains adhere to and invade ARPEs. This involves early adhesion to ARPE cell membrane, internalization and localization of Pg within single-membrane vacuoles or cytosol, with some nuclear localization apparent. No degradation of Pg or localization inside double-membrane autophagosomes was evident, with dividing Pg suggesting a metabolically active state during invasion. We found significant downregulation of autophagy-related genes particularly, autophagosome complex. Antibiotic protection-based recovery assay further confirmed distinct processes of adhesion, invasion and amplification of Pg within ARPE cells. This is the first study to demonstrate invasion of human-RPEs, begin to characterize intracellular localization and survival of Pg within these cells. Collectively, invasion of RPE by Pg and its prolonged survival by autophagy evasion within these cells suggest a strong rationale for studying the link between oral infection and AMD pathogenesis in individuals with periodontitis.
C1 [Arjunan, Pachiappan; Swaminathan, Radhika; Yuan, Jessie; Cutler, Christopher W.] Augusta Univ, Dent Coll Georgia, Dept Periodont, Augusta, GA 30912 USA.
   [Al-Shabrawey, Mohamed] Augusta Univ, Dept Oral Biol & Diagnost Sci, Augusta, GA USA.
   [Espinosa-Heidmann, Diego G.; Nussbaum, Julian] Augusta Univ, Dept Ophthalmol, Augusta, GA USA.
   [Martin, Pamela M.] Augusta Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University
RP Arjunan, P (通讯作者)，Augusta Univ, Dent Coll Georgia, Dept Periodont, Augusta, GA 30912 USA.
EM PARJUNAN@augusta.edu
RI Arjunan, Pachiappan/AAG-3297-2021
FU DCG; Carlos and Marguerite Mason Trust Foundation; AU
FX The authors thank Libby Perry, and Marshall Brendan (The Electron
   Microscopy & Histology Core, Medical College of Georgia, AU) for
   preparation of the SEM/TEM and consistent support for the imaging. The
   authors also thank Dr. Tong Wang (Dental College of Georgia, AU) for
   assisting with preparation of samples for SEM/TEM. These studies were
   funded by the DCG startup and AU intramural grants (to P.A) and the
   Carlos and Marguerite Mason Trust Foundation (to C.W.C).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amornchat Cholticha, 2003, J Int Acad Periodontol, V5, P98
   Arjunan P, 2016, MOL ORAL MICROBIOL, V31, P78, DOI 10.1111/omi.12131
   Arjunan P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35126-8
   Arjunan P, 2016, INVEST OPHTH VIS SCI, V57, P1612, DOI 10.1167/iovs.15-17437
   Astafurov K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104416
   Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574-6968.2012.02579.x
   Artese HPC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128344
   Chen YJ, 2018, MOL MED REP, V18, P97, DOI 10.3892/mmr.2018.8983
   Chiu CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep35428
   CUTLER CW, 1991, INFECT IMMUN, V59, P2097, DOI 10.1128/IAI.59.6.2097-2104.1991
   Darios F, 2020, J MOL BIOL, V432, P2714, DOI 10.1016/j.jmb.2020.02.033
   Dietrich T, 2017, BRIT DENT J, V222, P381, DOI 10.1038/sj.bdj.2017.224
   Ding Y, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0110-7
   Dioguardi M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020495
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eke PI, 2018, J AM DENT ASSOC, V149, P576, DOI 10.1016/j.adaj.2018.04.023
   El-Awady AR, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004647
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geng FX, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00057
   Ghizoni JS, 2012, J APPL ORAL SCI, V20, P104, DOI 10.1590/S1678-77572012000100019
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hajishengallis G, 2011, CELL HOST MICROBE, V10, P497, DOI 10.1016/j.chom.2011.10.006
   Han DM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33552-2
   Han YW, 2013, J DENT RES, V92, P485, DOI 10.1177/0022034513487559
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Holt SC, 2005, PERIODONTOL 2000, V38, P72, DOI 10.1111/j.1600-0757.2005.00113.x
   Inaba H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213309
   Ishikawa M, 2013, BBA-MOL BASIS DIS, V1832, P2035, DOI 10.1016/j.bbadis.2013.07.012
   Ji S, 2010, MOL CELLS, V30, P519, DOI 10.1007/s10059-010-0142-8
   Jia L, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00262
   Jotwani R, 2004, INFECT IMMUN, V72, P1725, DOI 10.1128/IAI.72.3.1725-1732.2004
   Jung HS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188286
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaur T, 2016, GERODONTOLOGY, V33, P434, DOI 10.1111/ger.12188
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Lamont RJ, 2015, TRENDS MOL MED, V21, P172, DOI 10.1016/j.molmed.2014.11.004
   LAMONT RJ, 1995, INFECT IMMUN, V63, P3878, DOI 10.1128/IAI.63.10.3878-3885.1995
   Lee K, 2018, VIRULENCE, V9, P845, DOI 10.1080/21505594.2018.1454171
   Li L, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-26
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lorenzo-Pouso AI, 2019, ARCH ORAL BIOL, V102, P55, DOI 10.1016/j.archoralbio.2019.03.029
   Mai XD, 2014, CANCER CAUSE CONTROL, V25, P1045, DOI 10.1007/s10552-014-0405-3
   Martinez-Martinez RE, 2009, J CLIN PERIODONTOL, V36, P1004, DOI 10.1111/j.1600-051X.2009.01496.x
   Miyauchi M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21072-y
   Mysak J, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/476068
   Nakao R, 2014, MICROBES INFECT, V16, P6, DOI 10.1016/j.micinf.2013.10.005
   Nakhjiri SF, 2001, FEMS MICROBIOL LETT, V200, P145, DOI 10.1016/S0378-1097(01)00213-0
   Njoroge T, 1997, INFECT IMMUN, V65, P1980, DOI 10.1128/IAI.65.5.1980-1984.1997
   Olsen I, 2020, J ORAL MICROBIOL, V12, DOI 10.1080/20002297.2019.1676486
   Olsen I, 2015, J ORAL MICROBIOL, V7, DOI 10.3402/jom.v7.28788
   Poole S, 2013, J ALZHEIMERS DIS, V36, P665, DOI 10.3233/JAD-121918
   Pritchard AB, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00336
   Rea SL, 2013, ENDOCR REV, V34, P501, DOI 10.1210/er.2012-1034
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Singhrao SK, 2019, J ORAL MICROBIOL, V11, DOI 10.1080/20002297.2018.1563405
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574
   Uribe-Querol E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01368
   Velsko IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097811
   Wagley S, 2015, RETINA-J RET VIT DIS, V35, P982, DOI 10.1097/IAE.0000000000000427
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang M, 2007, J IMMUNOL, V179, P2349, DOI 10.4049/jimmunol.179.4.2349
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Whitmore SE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003933
   Winning Lewis, 2017, Curr Oral Health Rep, V4, P1, DOI 10.1007/s40496-017-0121-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yilmaz O, 2006, INFECT IMMUN, V74, P703, DOI 10.1128/IAI.74.1.703-710.2006
   Zhang WJ, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-89
NR 76
TC 8
Z9 9
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 4
PY 2020
VL 10
IS 1
AR 7468
DI 10.1038/s41598-020-64449-8
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NA7XJ
UT WOS:000560030700014
PM 32366945
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sorrentino, FS
   Jurman, G
   De Nadai, K
   Campa, C
   Furlanello, C
   Parmeggiani, F
AF Sorrentino, Francesco Saverio
   Jurman, Giuseppe
   De Nadai, Katia
   Campa, Claudio
   Furlanello, Cesare
   Parmeggiani, Francesco
TI Application of Artificial Intelligence in Targeting Retinal Diseases
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Retinal diseases; macular complications; anti-VEGF drugs; retinal
   imaging; optical coherence tomography; artificial intelligence; machine
   learning, deep learning
ID OPTICAL COHERENCE TOMOGRAPHY; MAJOR RISK-FACTORS; DIABETIC-RETINOPATHY;
   MACULAR DEGENERATION; AUTOMATED DETECTION; GLOBAL PREVALENCE; IMAGING
   BIOMARKERS; NEURAL-NETWORK; PREMATURITY; FLUID
AB Retinal diseases affect an increasing number of patients worldwide because of the aging population. Request for diagnostic imaging in ophthalmology is ramping up, while the number of specialists keeps shrinking Cutting-edge technology embedding artificial intelligence (AI) algorithms are thus advocated to help ophthalmologists perform their clinical tasks as well as to provide a source for the advancement of novel biomarkers. In particular, optical coherence tomography (OCT) evaluation of the retina can be augmented by algorithms based on machine learning and deep learning to early detect, qualitatively localize and quantitatively measure epilintra/subretinal abnormalities or pathological features of macular or neural diseases. In this paper, we discuss the use of Al to facilitate efficacy and accuracy of retinal imaging in those diseases increasingly treated by intravitreal vascular endothelial growth factor (VEGF) inhibitors (i.e. anti-VEGF drugs), also including integration and interpretation features in the process. We review recent advances by Al in diabetic retinopathy, age -related macular degeneration, and retinopathy of prematurity that envision a potentially key role of highly automated systems in screening, early diagnosis, grading and individualized therapy. We discuss benefits and critical aspects of automating the evaluation of disease activity, recurrences, the timing of re treatment and therapeutically potential novel targets in ophthalmology. The impact of massive employment of AI to optimize clinical assistance and encourage tailored therapies for distinct patterns of retinal diseases is also discussed.
C1 [Sorrentino, Francesco Saverio] Azienda USL Bologna, Dept Surg Sci, Maggiore Hosp, Bologna, Italy.
   [Jurman, Giuseppe; Furlanello, Cesare] Fdn Bruno Kessler, Unit Predict Models Biomed & Environm MPBA, Trento, Italy.
   [De Nadai, Katia; Parmeggiani, Francesco] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [De Nadai, Katia; Parmeggiani, Francesco] Azienda ULSS 6 Euganea, Camposampiero Hosp, ERN Eye Network Ctr Retinitis Pigmentosa Veneto R, Padua, Italy.
   [Campa, Claudio] Azienda Osped Univ Ferrara, Dept Surg Specialties, St Anna Hosp, Ferrara, Italy.
   [Furlanello, Cesare] HK3 Lab, Unit Model Dev & Synth, Milan, Italy.
C3 AUSL di Bologna; Fondazione Bruno Kessler; University of Ferrara; ULSS 6
   Euganea; Ospedale di Camposampiero; University of Ferrara; Arcispedale
   Sant'Anna
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Jurman, Giuseppe/GRS-8221-2022
OI PARMEGGIANI, FRANCESCO/0000-0002-9296-0986
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Ahuja AS, 2019, J CURR OPHTHALMOL, V31, P115, DOI 10.1016/j.joco.2019.05.001
   Arcadu F, 2019, INVEST OPHTH VIS SCI, V60, P852, DOI 10.1167/iovs.18-25634
   Ataer-Cansizoglu E, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.6.5
   Blencowe Hannah, 2016, Indian Pediatr, V53 Suppl 2, pS89
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brown JM, 2018, PROC SPIE, V10579, DOI 10.1117/12.2295942
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Campbell JP, 2016, JAMA OPHTHALMOL, V134, P651, DOI 10.1001/jamaophthalmol.2016.0611
   Ching T, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0387
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Daniel E, 2015, JAMA OPHTHALMOL, V133, P675, DOI 10.1001/jamaophthalmol.2015.0460
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Elsas FJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1110
   Esteva A, 2019, NAT MED, V25, P24, DOI 10.1038/s41591-018-0316-z
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fleck BW, 2018, EYE, V32, P74, DOI 10.1038/eye.2017.150
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Frcophth AT, 2017, OPHTHALMOLOGY, V124, P343, DOI 10.1016/j.ophtha.2016.11.014
   Fu H, 2019, P 6 INT WORKSH OMIA
   Gardner GG, 1996, BRIT J OPHTHALMOL, V80, P940, DOI 10.1136/bjo.80.11.940
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gerendas BS, 2018, BRIT J OPHTHALMOL, V102, P195, DOI 10.1136/bjophthalmol-2017-310483
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Gualino V, 2019, RETINA-J RET VIT DIS, V39, P1664, DOI 10.1097/IAE.0000000000002220
   Gulshan V, 2019, JAMA OPHTHALMOL, V137, P987, DOI 10.1001/jamaophthalmol.2019.2004
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hamwood J, 2018, BIOMED OPT EXPRESS, V9, P3049, DOI 10.1364/BOE.9.003049
   Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Li ZW, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-019-0730-x
   Liu Y, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016280
   Mao ZX, 2019, BIOMED OPT EXPRESS, V10, P5832, DOI 10.1364/BOE.10.005832
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Murray RB, 2005, MED J AUSTRALIA, V182, P520, DOI 10.5694/j.1326-5377.2005.tb00018.x
   Obermeyer Z, 2017, NEW ENGL J MED, V377, P1209, DOI 10.1056/NEJMp1705348
   Pauleikhoff LJB, 2018, OPHTHALMOLOGE, V115, P579, DOI 10.1007/s00347-017-0537-4
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Russell S., 1995, ARTIFICIAL INTELLIGE
   Scanlon PH, 2003, BRIT J OPHTHALMOL, V87, P1258, DOI 10.1136/bjo.87.10.1258
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sengupta S, 2020, ARTIF INTELL MED, V102, DOI 10.1016/j.artmed.2019.101758
   Sivaprasad S, 2019, DIABETIC MED, V36, P424, DOI 10.1111/dme.13868
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2011, OPHTHALMOLOGY, V118, P1588, DOI 10.1016/j.ophtha.2011.04.009
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Varma R, 2015, OPHTHALMOLOGY, V122, P982, DOI 10.1016/j.ophtha.2014.12.007
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Worrall DE, 2016, LECT NOTES COMPUT SC, V10008, P68, DOI 10.1007/978-3-319-46976-8_8
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 66
TC 3
Z9 4
U1 3
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PY 2020
VL 21
IS 12
BP 1208
EP 1215
DI 10.2174/1389450121666200708120646
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NT8VR
UT WOS:000573215300006
PM 32640954
DA 2022-11-30
ER

PT J
AU Zhao, BC
   Wang, ZJ
   Han, JG
   Wei, GH
   Yi, BQ
   Li, ZL
AF Zhao, Baocheng
   Wang, Zhenjun
   Han, Jiagang
   Wei, Guanghui
   Yi, Bingqiang
   Li, Zhulin
TI Rhizoma Paridis total saponins alleviate H2O2-induced oxidative stress
   injury by upregulating the Nrf2 pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE Rhizoma Paridis; saponins; nuclear factor 2-related factor 2; H2O2;
   oxidative stress; reactive oxygen species; Fas; caspase-3
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; HEME OXYGENASE-1;
   ANTIOXIDANTS; EXPRESSION; ANTITUMOR; DIETARY; CANCER; MITOCHONDRIAL;
   MECHANISMS
AB Rhizoma Paridis total saponins (RPTS) is an active substance isolated from the traditional Chinese medicine Rhizoma Paridis, which possesses multiple biological activities. The aim of the present study was to explore the roles and mechanisms of RPTS in oxidative stress injury of ARPE-19 human retinal pigment epithelial cells. Cell viability, reactive oxygen species (ROS) levels, mitochondrial membrane potential (MMP) and apoptosis were determined by Cell Counting kit-8 assay and flow cytometry, respectively. Enzyme-linked immunosorbent assay was performed to detect the expression of oxidative stress markers. Western blotting and reverse transcription-quantitative polymerase chain reaction were used to determine the expression levels of related genes and proteins. The results revealed that RPTS enhanced cell viability and reduced H2O2-induced oxidative stress of ARPE-19 human retinal pigment epithelial cells. RPTS increased the MMP of ARPE-19 cells compared with in H2O2-treated ARPE-19 cells. In addition, RPTS suppressed ROS production and apoptosis of H2O2-treated ARPE-19 cells. Additionally, RPTS modulated the expression levels of apoptosis-associated proteins and the nuclear factor 2-related factor 2 (Nrf2) pathway. In conclusion, RPTS alleviated H2O2-induced oxidative stress injury by upregulating the Nrf2 pathway. The potential effects of RPTS on protection against H2O2-induced apoptosis of ARPE-19 cells suggested that RPTS may be a potential therapeutic target for preventing age-related macular degeneration.
C1 [Zhao, Baocheng; Wang, Zhenjun; Han, Jiagang; Wei, Guanghui; Yi, Bingqiang; Li, Zhulin] Capital Med Univ, Beijing Chao Yang Hosp, Dept Gen Surg, 8 Gongtinan Rd, Beijing 100020, Peoples R China.
C3 Capital Medical University
RP Wang, ZJ (通讯作者)，Capital Med Univ, Beijing Chao Yang Hosp, Dept Gen Surg, 8 Gongtinan Rd, Beijing 100020, Peoples R China.
EM wangzhenjun_wzj@163.com
FU 1351 Personnel Training Program of Beijing Chao-Yang Hospital Affiliated
   to Capital Medical University [CYXZ-2017-09]
FX This work was supported by the 1351 Personnel Training Program of
   Beijing Chao-Yang Hospital Affiliated to Capital Medical University
   (grant no.CYXZ-2017-09).
CR Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calabrese V, 2010, CURR PHARM DESIGN, V16, P877, DOI 10.2174/138161210790883615
   Chen B, 2015, J ENDOCRINOL, V225, pR83, DOI 10.1530/JOE-14-0662
   Chen FQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143868
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7817
   Cheng ZX, 2008, J ETHNOPHARMACOL, V120, P129, DOI 10.1016/j.jep.2008.07.030
   Cui GZ, 2015, J CARDIOVASC PHARM, V65, P39, DOI 10.1097/FJC.0000000000000161
   Cui W, 2019, CAN J PHYSIOL PHARM, V97, P370, DOI 10.1139/cjpp-2018-0277
   Durante W, 2010, CURR DRUG TARGETS, V11, P1504, DOI 10.2174/1389450111009011504
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Ferrandiz ML, 2008, CURR PHARM DESIGN, V14, P473, DOI 10.2174/138161208783597399
   Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4
   Higgins GC, 2010, J ALZHEIMERS DIS, V20, pS453, DOI 10.3233/JAD-2010-100321
   Hiramatsu K, 2016, NUTR RES, V36, P143, DOI 10.1016/j.nutres.2015.09.018
   Hong Y, 2016, J ETHNOPHARMACOL, V192, P114, DOI 10.1016/j.jep.2016.07.010
   Kagan DB, 2012, CLIN OPHTHALMOL, V6, P1471, DOI 10.2147/OPTH.S35139
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Kim EK, 2017, NUTR J, V16, DOI 10.1186/s12937-017-0301-2
   Kitada M, 2013, DIABETES METAB J, V37, P315, DOI 10.4093/dmj.2013.37.5.315
   Leng J, 2018, PHYTOTHER RES, V32, P2235, DOI 10.1002/ptr.6160
   Li YN, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/320513
   Li ZR, 2013, MOL VIS, V19, P1656
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Macdonald L, 2017, ANN INTERN MED, V167, pJC56, DOI 10.7326/ACPJC-2017-167-10-056
   Man SL, 2018, ENVIRON TOXICOL, V33, P149, DOI 10.1002/tox.22501
   Man SL, 2017, MOL CARCINOGEN, V56, P1405, DOI 10.1002/mc.22601
   Man SL, 2014, J ETHNOPHARMACOL, V151, P407, DOI 10.1016/j.jep.2013.10.051
   Man SL, 2013, INT J PHARMACEUT, V454, P296, DOI 10.1016/j.ijpharm.2013.06.079
   Salminen A, 2013, INT J MOL SCI, V14, P3834, DOI 10.3390/ijms14023834
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Shen CL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0614-0
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tkachev VO, 2011, BIOCHEMISTRY-MOSCOW+, V76, P407, DOI 10.1134/S0006297911040031
   Wang GW, 2010, CIRCULATION, V121, P1912, DOI 10.1161/CIRCULATIONAHA.109.905471
   Wang J, 2018, MOL MED REP, V17, P648, DOI 10.3892/mmr.2017.7916
   Xiao X, 2012, BIOSCI TRENDS, V6, P201, DOI 10.5582/bst.2012.v6.4.201
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Zhang MM, 2019, ANAL CHIM ACTA, V1048, P186, DOI 10.1016/j.aca.2018.10.030
   Zhou HY, 2011, INVEST OPHTH VIS SCI, V52, P4338, DOI 10.1167/iovs.10-6519
   Zhu Y, 2016, MOLECULES, V21, DOI 10.3390/molecules21081033
   Zhu ZH, 2019, COMP BIOCHEM PHYS C, V217, P68, DOI 10.1016/j.cbpc.2018.11.018
NR 45
TC 7
Z9 7
U1 3
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2020
VL 21
IS 1
BP 220
EP 228
DI 10.3892/mmr.2019.10827
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA KM1TH
UT WOS:000513903300023
PM 31746361
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wu, ML
   Cai, XX
   Chen, Q
   Ji, ZX
   Niu, SJ
   Leng, T
   Rubin, DL
   Park, H
AF Wu, Menglin
   Cai, Xinxin
   Chen, Qiang
   Ji, Zexuan
   Niu, Sijie
   Leng, Theodore
   Rubin, Daniel L.
   Park, Hyunjin
TI Geographic atrophy segmentation in SD-OCT images using synthesized
   fundus autofluorescence imaging
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Optical coherence tomography; Geographic atrophy; Biomedical image
   segmentation; Image synthesis; Retinal image analysis
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL LAYER; QUANTIFICATION; SECONDARY;
   MODEL; FLUID
AB Background and objective: Accurate assessment of geographic atrophy (GA) is critical for diagnosis and therapy of non-exudative age-related macular degeneration (AMD). Herein, we propose a novel GA segmentation framework for spectral-domain optical coherence tomography (SD-OCT) images that employs synthesized fundus autofluorescence (FAF) images.
   Methods: An en-face OCT image is created via the restricted sub-volume projection of three-dimensional OCT data. A GA region-aware conditional generative adversarial network is employed to generate a plausible FAF image from the en-face OCT image. The network balances the consistency between the entire synthesize FAF image and the lesion. We use a fully convolutional deep network architecture to segment the GA region using the multimodal images, where the features of the en-face OCT and synthesized FAF images are fused on the front-end of the network.
   Results: Experimental results for 56 SD-OCT scans with GA indicate that our synthesis algorithm can generate high-quality synthesized FAF images and that the proposed segmentation network achieves a dice similarity coefficient, an overlap ratio, and an absolute area difference of 87.2%, 77.9%, and 11.0%, respectively.
   Conclusion: We report an automatic GA segmentation method utilizing synthesized FAF images.
   Significance: Our method is effective for multimodal segmentation of the GA region and can improve AMD treatment. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Wu, Menglin; Cai, Xinxin] Nanjing Tech Univ, Sch Comp Sci & Technol, Nanjing, Jiangsu, Peoples R China.
   [Chen, Qiang; Ji, Zexuan] Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, Nanjing, Jiangsu, Peoples R China.
   [Niu, Sijie] Univ Jinan, Sch Informat Sci & Engn, Jinan, Shandong, Peoples R China.
   [Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94304 USA.
   [Rubin, Daniel L.] Stanford Univ, Sch Med, Dept Radiol & Med Biomed Informat Res & Ophthalmo, Stanford, CA 94305 USA.
   [Park, Hyunjin] Sungkyunkwan Univ, Sch Elect & Elect Engn, Suwon, South Korea.
   [Park, Hyunjin] Inst Basic Sci, Ctr Neurosci Imaging Res, Suwon, South Korea.
C3 Nanjing Tech University; Nanjing University of Science & Technology;
   University of Jinan; Stanford University; Stanford University;
   Sungkyunkwan University (SKKU); Institute for Basic Science - Korea
   (IBS)
RP Park, H (通讯作者)，Sungkyunkwan Univ, Ctr Neurosci Imaging Res, Sch Elect & Elect Engn, Suwon 16419, South Korea.
EM hyunjinp@skku.edu
RI Park, Hyunjin/A-1164-2007; chen, qiang/GWZ-7308-2022; Leng,
   Theodore/AAQ-7459-2020
OI Park, Hyunjin/0000-0001-5681-8918; 
FU National Science Foundation of China (NSFC) [61701222, 61671242,
   61701192]; Natural Science Foundation for Universities of Jiangsu
   [17KJB510026]; Key R&D Program of Jiangsu Science and Technology
   Department [BE2018131]; Natural Science Foundation of Jiangsu Province
   [BK20180069]; Six talent peaks project in Jiangsu Province [SWYY-056];
   Shandong Provincial Natural Science Foundation [ZR2017QF004]; Institute
   for Basic Science [IBS-R015-D1]; IITP grant - Korean government under
   the AI Graduate School Support Program [2019-0-00421]; National Research
   Foundation of Korea [NRF-2019R1H1A2079721]; Ministry of Science and ICT
   of Korea under the ITRC program [IITP-2019-2018-001798]
FX This work was supported in part by the National Science Foundation of
   China (NSFC) (61701222, 61671242, 61701192), the Natural Science
   Foundation for Universities of Jiangsu (17KJB510026), Key R&D Program of
   Jiangsu Science and Technology Department (BE2018131), Natural Science
   Foundation of Jiangsu Province (BK20180069), Six talent peaks project in
   Jiangsu Province (SWYY-056), Shandong Provincial Natural Science
   Foundation (ZR2017QF004), the Institute for Basic Science (IBS-R015-D1),
   the IITP grant funded by the Korean government under the AI Graduate
   School Support Program (2019-0-00421), National Research Foundation of
   Korea (NRF-2019R1H1A2079721), and the Ministry of Science and ICT of
   Korea under the ITRC program (IITP-2019-2018-001798).
CR Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Brock A., 2017, INT C LEARN REPR, P1
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chen LC, 2018, IEEE T PATTERN ANAL, V40, P834, DOI 10.1109/TPAMI.2017.2699184
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chuang KS, 2006, COMPUT MED IMAG GRAP, V30, P9, DOI 10.1016/j.compmedimag.2005.10.001
   Costa P, 2018, IEEE T MED IMAGING, V37, P781, DOI 10.1109/TMI.2017.2759102
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fu HZ, 2018, IEEE T MED IMAGING, V37, P1597, DOI 10.1109/TMI.2018.2791488
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Glorot X., 2011, P 14 INT C ART INT S, P315, DOI DOI 10.1002/ECS2.1832
   Goodfellow IJ, 2014, ADV NEUR IN, V27, P2672
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   He K., 2016, P IEEE COMPUTER SOC, P630, DOI DOI 10.1109/CVPR.2016.90
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Hussain MA, 2017, IEEE T BIO-MED ENG, V64, P1638, DOI 10.1109/TBME.2016.2619120
   Iizuka S, 2017, ACM T GRAPHIC, V36, DOI 10.1145/3072959.3073659
   Ioffe S., 2015, PR MACH LEARN RES, P448, DOI DOI 10.1007/S13398-014-0173-7.2
   ISOLA P, 2017, PROC CVPR IEEE, P5967, DOI DOI 10.1109/CVPR.2017.632
   Ji ZX, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.1.1
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Kamnitsas K, 2017, MED IMAGE ANAL, V36, P61, DOI 10.1016/j.media.2016.10.004
   Kingma J., 2014, ARXIV
   Li C, 2016, LECT NOTES COMPUT SC, V9907, P702, DOI 10.1007/978-3-319-46487-9_43
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Lu SJ, 2010, IEEE T BIO-MED ENG, V57, P2605, DOI 10.1109/TBME.2010.2055057
   Nie D, 2018, IEEE T BIO-MED ENG, V65, P2720, DOI 10.1109/TBME.2018.2814538
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Pilotto E, 2015, INVEST OPHTH VIS SCI, V56, P8120, DOI 10.1167/iovs.15-17366
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Schlegl T, 2017, LECT NOTES COMPUT SC, V10265, P146, DOI 10.1007/978-3-319-59050-9_12
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Tsechpenakis G, 2008, LECT NOTES COMPUT SC, V5241, P883, DOI 10.1007/978-3-540-85988-8_105
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Wang TC, 2018, PROC CVPR IEEE, P8798, DOI 10.1109/CVPR.2018.00917
   Wang Z, 2004, IEEE T IMAGE PROCESS, V13, P600, DOI 10.1109/TIP.2003.819861
   Wei YC, 2016, IEEE T PATTERN ANAL, V38, P1901, DOI 10.1109/TPAMI.2015.2491929
   Xu RB, 2019, COMPUT BIOL MED, V105, P102, DOI 10.1016/j.compbiomed.2018.12.013
   Zhao H, 2018, MED IMAGE ANAL, V49, P14, DOI 10.1016/j.media.2018.07.001
NR 48
TC 8
Z9 8
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD DEC
PY 2019
VL 182
AR 105101
DI 10.1016/j.cmpb.2019.105101
PG 10
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA JP1WI
UT WOS:000498061900018
PM 31600644
DA 2022-11-30
ER

PT J
AU Pichi, F
   Aggarwal, K
   Neri, P
   Salvetti, P
   Lembo, A
   Nucci, P
   Cheung, CMG
   Gupta, V
AF Pichi, Francesco
   Aggarwal, Kanika
   Neri, Piergiorgio
   Salvetti, Paola
   Lembo, Andrea
   Nucci, Paolo
   Cheung, Chui Ming Gemmy
   Gupta, Vishali
TI Choroidal biomarkers
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Choriocapillaris; choroid; enhanced depth imaging optical coherence
   tomography; indocyanine green angiography; optical coherence tomography
   angiography; swept-source optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; CENTRAL
   SEROUS CHORIORETINOPATHY; PACHYCHOROID SPECTRUM DISORDERS; PLACOID
   PIGMENT EPITHELIOPATHY; KOYANAGI-HARADA-DISEASE; FLUORESCEIN
   ANGIOGRAPHY; SERPIGINOUS CHOROIDITIS; MACULAR DEGENERATION; OCT
   ANGIOGRAPHY
AB A structurally and functionally intact choroid tissue is vitally important for the retina function. Although central retinal artery is responsible to supply the inner retina, choroidal vein network is responsible for the remaining one-third of the external part. Abnormal choroidal blood flow leads to photoreceptor dysfunction and photoreceptor death in the retina, and the choroid has vital roles in the pathophysiology of many diseases such as central serous chorioretinopathy, age-related macular degeneration, pathologic myopia, Vogt-Koyanagi-Harada disease. Biomarkers of choroidal diseases can be identified in various imaging modalities that visualize the choroid. Indocyanine green angiography enables the visualization of choroid veins under the retinal pigment epithelium and choroidal blood flow. New insights into a precise structural and functional analysis of the choroid have been possible, thanks to recent progress in retinal imaging based on enhanced depth imaging (EDI) and swept-source optical coherence tomography (SS-OCT) technologies. Long-wavelength SS-OCT enables the choroid and the choroid-sclera interface to be imaged at greater depth and to quantify choroidal thickness profiles throughout a volume scan, thus exposing the morphology of intermediate and large choroidal vessels. Finally, OCT angiography allows a dye-free evaluation of the blood flow in the choriocapillaris and in the choroid. We hereby review different imaging findings of choroidal diseases that can be used as biomarkers of activity and response to the treatment.
C1 [Pichi, Francesco; Neri, Piergiorgio] Cleveland Clin Abu Dhabi, Inst Eye, POB 112412, Abu Dhabi, U Arab Emirates.
   [Pichi, Francesco] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Aggarwal, Kanika; Gupta, Vishali] Postgrad Inst Med Educ & Res, Adv Eye Ctr, Chandigarh, India.
   [Salvetti, Paola] Moorfields Eye Hosp Dubai, Dubai, U Arab Emirates.
   [Lembo, Andrea; Nucci, Paolo] San Giuseppe Hosp, Univ Eye Clin, Milan, Italy.
   [Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
C3 Cleveland Clinic Foundation; Case Western Reserve University; Cleveland
   Clinic Foundation; Post Graduate Institute of Medical Education &
   Research (PGIMER), Chandigarh; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; National
   University of Singapore; Singapore National Eye Center
RP Pichi, F (通讯作者)，Cleveland Clin Abu Dhabi, Inst Eye, POB 112412, Abu Dhabi, U Arab Emirates.
EM ilmiticopicchio@gmail.com
RI Gupta, Vishali/AAU-2549-2021; Piergiorgio Neri, BMedSc/K-5600-2019;
   nucci, paolo/J-9523-2016
OI Piergiorgio Neri, BMedSc/0000-0002-7673-4276; nucci,
   paolo/0000-0002-4036-703X; Cheung, Chui Ming Gemmy/0000-0003-3358-3516;
   Lembo, Andrea/0000-0001-7232-6593; Gupta, Vishali/0000-0001-8216-4620
CR Aggarwal K, 2018, RETINA
   Aggarwal K, 2018, OCUL IMMUNOL INFLAMM, V26, P142, DOI 10.1080/09273948.2016.1195001
   Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   BARONDES MJ, 1991, AM J OPHTHALMOL, V112, P460, DOI 10.1016/S0002-9394(14)76260-9
   Chee SP, 2017, OCUL IMMUNOL INFLAMM, V25, P528, DOI 10.3109/09273948.2016.1151896
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2013, ACTA OPHTHALMOL, V91, pE580, DOI 10.1111/aos.12117
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P901, DOI 10.1097/IAE.0000000000000804
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   De Luigi G, 2012, INT OPHTHALMOL, V32, P55, DOI [10.1007/s10792-011-9508-y, DOI 10.1007/s10792-011-9508-y]
   De Stefano ME, 1997, ANAT EMBRYOL, V195, P393, DOI 10.1007/s004290050060
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Dolz-Marco Rosa, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS136, DOI 10.1097/ICB.0000000000000473
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P3690, DOI 10.1167/iovs.17-21941
   Ersoz MG, 2017, RETINA
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Fiore T, 2009, RETINA-J RET VIT DIS, V29, P994, DOI 10.1097/IAE.0b013e3181a0bd15
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gal-Or O, 2018, RETINA
   Giovannini A, 1996, Eur J Ophthalmol, V6, P299
   Hata M, 2013, RETINA-J RET VIT DIS, V33, P296, DOI 10.1097/IAE.0b013e31826710a0
   Herbort Carl P., 2007, International Ophthalmology, V27, P173, DOI 10.1007/s10792-007-9060-y
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hosoda Y, 2014, AM J OPHTHALMOL, V157, P1056, DOI 10.1016/j.ajo.2014.01.015
   HOWE LJ, 1995, OPHTHALMOLOGY, V102, P790, DOI 10.1016/S0161-6420(95)30955-4
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Invernizzi A, 2018, EUR J OPHTHALMOL, V28, P216, DOI 10.5301/ejo.5001047
   Invernizzi A, 2016, RETINA-J RET VIT DIS, V36, P2013, DOI 10.1097/IAE.0000000000001031
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Khan HA, 2017, OPTOMETRY VISION SCI, V94, P265, DOI 10.1097/OPX.0000000000001015
   Khanamiri HN, 2013, SURV OPHTHALMOL, V58, P203, DOI 10.1016/j.survophthal.2012.08.008
   Kitaya N, 2003, BRIT J OPHTHALMOL, V87, P709, DOI 10.1136/bjo.87.6.709
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   KREBS W, 1988, ARCH OPHTHALMOL-CHIC, V106, P1615, DOI 10.1001/archopht.1988.01060140783055
   Kuroda S, 2013, RETINA-J RET VIT DIS, V33, P302, DOI 10.1097/IAE.0b013e318263d11f
   Mandadi SKR, 2017, RETINA-J RET VIT DIS, V37, P1647, DOI 10.1097/IAE.0000000000001412
   Mangeon M, 2017, OCUL IMMUNOL INFLAMM, P1
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Mo J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013571
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Nakajima Masami, 1997, Nippon Ganka Gakkai Zasshi, V101, P584
   Nakayama M, 2012, RETINA-J RET VIT DIS, V32, P2061, DOI 10.1097/IAE.0b013e318256205a
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Ohno-Matsui K, 2016, PROG RETIN EYE RES, V52, P156, DOI 10.1016/j.preteyeres.2015.12.001
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   OKABE S, 1982, ACTA MED OKAYAMA, V36, P11
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, INVEST OPHTH VIS SCI, V55, P5252, DOI 10.1167/iovs.14-14959
   Phasukkijwatana N, 2017, RETINA
   Pichi F, 2016, INT OPHTHALMOL
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rush RB, 2014, AM J OPHTHALMOL, V158, P337, DOI 10.1016/j.ajo.2014.05.007
   Sayanagi K, 2017, BRIT J OPHTHALMOL, V101, P1524, DOI 10.1136/bjophthalmol-2016-309628
   Schneider U, 1996, GER J OPHTHALMOL, V5, P6
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spraul CW, 2002, VISION RES, V42, P923, DOI 10.1016/S0042-6989(02)00022-6
   Tan ACS, 2018, EYE, V32, P262, DOI 10.1038/eye.2017.181
   Teussink MM, 2015, INVEST OPHTH VIS SCI, V56, P5229, DOI 10.1167/iovs.15-17140
   Trabucchi G, 1996, GRAEF ARCH CLIN EXP, V234, P294, DOI 10.1007/BF00220703
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Werner JU, 2017, OSLI RETINA, V48, P727, DOI 10.3928/23258160-20170829-07
   Wong CW, 2019, RETINA-J RET VIT DIS, V39, P1742, DOI 10.1097/IAE.0000000000002233
   Wong CW, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20742
   Xu YS, 2017, OPHTHALMOLOGICA, V237, P167, DOI 10.1159/000456676
   Yanagi Y, 2017, RETINA
   Yang LH, 2013, ACTA OPHTHALMOL, V91, pE358, DOI 10.1111/aos.12059
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 82
TC 23
Z9 25
U1 2
U2 5
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2018
VL 66
IS 12
BP 1716
EP 1726
DI 10.4103/ijo.IJO_893_18
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HB0BS
UT WOS:000450676000013
PM 30451172
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mohamad, NA
   Ramachandran, V
   Ismail, P
   Isa, HM
   Chan, YM
   Ngah, NF
   Bakri, NM
   Ching, SM
   Hoo, FK
   Sulaiman, WAW
AF Mohamad, Nur Afiqah
   Ramachandran, Vasudevan
   Ismail, Patimah
   Isa, Hazlita Mohd
   Chan, Yoke Mun
   Ngah, Nor Fariza
   Bakri, Norshakimah Md
   Ching, Siew Mooi
   Hoo, Fan Kee
   Sulaiman, Wan Aliaa Wan
TI VEGF Polymorphisms Among Neovascular Age-Related Macular Degenerative
   Subjects in a Multiethnic Population
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
DE age-related macular degeneration; polymorphism; vascular endothelial
   growth factor
ID GROWTH-FACTOR GENE; RISK-FACTORS; EYE DISEASE; ASSOCIATION;
   ANGIOGENESIS; CHINESE
AB Aim: To determine the association of vascular endothelial growth factor (VEGF) polymorphisms with neovascular age-related macular degeneration (nAMD). Materials and Methods: One hundred thirty-five nAMD patients and 135 controls were recruited to determine the association of the -460 C/T, the -2549 I/D, and the +405 G/C polymorphisms with the VEGF gene. Genotyping was conducted using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach, and association analyses were conducted using chi-square analysis and logistic regression analysis. Results: A significant association was observed between nAMD and the VEGF +405 G/C genotypes (p=0.002) and alleles (odds ratio=1.36, 95% confidence interval=1.12-1.62, p=< 0.001) compared with the controls. This association was confirmed by logistic regression analyses, using two different genetic models (additive and dominant) resulting in p-values of p=0.001 and p<0.001, respectively. In addition, the dominant model of VEGF +405 G/C was also found to be at risk of the CC genotype with nAMD among subjects that were aged 60 years, female, of Chinese ethnicity, hypertensive, diabetic, and smokers. Conclusion: With the exception of several limitations, the present study showed evidence of an association between the VEGF +405 G/C polymorphism and nAMD in Malaysian subjects.
C1 [Mohamad, Nur Afiqah; Ramachandran, Vasudevan; Chan, Yoke Mun; Bakri, Norshakimah Md] Univ Putra Malaysia, Malaysian Res Inst Ageing, Serdang 43400, Malaysia.
   [Ismail, Patimah] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang, Malaysia.
   [Isa, Hazlita Mohd] Univ Kebangsaan Malaysia, Med Ctr, Dept Ophthalmol, Cheras, Malaysia.
   [Chan, Yoke Mun] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Malaysia.
   [Ngah, Nor Fariza] Hosp Selayang, Dept Ophthalmol, Batu Caves, Malaysia.
   [Ching, Siew Mooi] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Family Med, Serdang, Malaysia.
   [Hoo, Fan Kee; Sulaiman, Wan Aliaa Wan] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Med, Serdang, Malaysia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti
   Kebangsaan Malaysia; Universiti Putra Malaysia; Universiti Putra
   Malaysia; Universiti Putra Malaysia
RP Ramachandran, V (通讯作者)，Univ Putra Malaysia, Malaysian Res Inst Ageing, Serdang 43400, Malaysia.; Chan, YM (通讯作者)，Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Malaysia.
EM vasuphd@gmail.com; cym@upm.edu.my
RI Ching, Siew Mooi/I-5817-2013; Wan Sulaiman, Wan Aliaa
   Binti/AAF-8072-2021; ramachandran, vasudevan/C-3395-2008; Chan, Yoke Mun
   Yoke/L-2965-2015; Hoo, Fan Kee/J-2591-2013
OI Ching, Siew Mooi/0000-0002-4425-7989; Wan Sulaiman, Wan Aliaa
   Binti/0000-0003-4969-0308; ramachandran, vasudevan/0000-0003-0044-1626;
   Chan, Yoke Mun Yoke/0000-0002-3853-736X; Isa,
   Hazlita/0000-0002-2731-8233; Hoo, Fan Kee/0000-0003-1687-627X; Mohamad,
   Nur Afiqah/0000-0002-9015-0525
FU Putra Grant [9409800, 9432700]
FX The authors extend their gratitude to Hospital Selayang and UKMMC and
   all the volunteers involved in this study. This study was supported by
   the Putra Grant (Grant Nos: 9409800 and 9432700).
CR Amle D, 2015, J DIABETES METAB DIS, V14, DOI 10.1186/s40200-015-0144-3
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Awata T, 2005, BIOCHEM BIOPH RES CO, V333, P679, DOI 10.1016/j.bbrc.2005.05.167
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Bruyere F, 2010, J UROLOGY, V184, P1273, DOI 10.1016/j.juro.2010.06.009
   Buraczynska M, 2007, NEPHROL DIAL TRANSPL, V22, P827, DOI 10.1093/ndt/gfl641
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fouad H., 2011, The Journal of American Science, V7, P199
   George GP, 2011, MOL BIOL REP, V38, P1609, DOI 10.1007/s11033-010-0270-4
   Gupta D, 2016, META GENE, V9, P249, DOI 10.1016/j.mgene.2016.07.011
   Habibi I, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-15
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Li X, 2015, MED SCI MONITOR, V21, P3474, DOI 10.12659/MSM.894568
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Little J, 2009, EUR J CLIN INVEST, V39, P247, DOI 10.1111/j.1365-2362.2009.02125.x
   Lu H, 2005, CANCER RES, V65, P5015, DOI 10.1158/0008-5472.CAN-04-2786
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Szaflik Jacek P, 2009, Klin Oczna, V111, P125
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 31
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
EI 1945-0257
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD OCT
PY 2017
VL 21
IS 10
BP 600
EP 607
DI 10.1089/gtmb.2017.0079
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FK1XZ
UT WOS:000413278200006
PM 28926292
DA 2022-11-30
ER

PT J
AU Zhu, X
   Wang, K
   Zhang, K
   Zhou, FF
   Zhu, L
AF Zhu, Xue
   Wang, Ke
   Zhang, Kai
   Zhou, Fanfan
   Zhu, Ling
TI Induction of oxidative and nitrosative stresses in human retinal pigment
   epithelial cells by all-trans-retinal
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE All-trans-retinal; Retinal pigment epithelium; Oxidative stress;
   Nitrosative stress; Nuclear factor kappa B
ID NITRIC-OXIDE SYNTHASE; MESENCHYMAL TRANSITION; XANTHINE OXIDOREDUCTASE;
   EXPRESSION; PROLIFERATION; RETINOPATHY; ACTIVATION; MECHANISM;
   APOPTOSIS; CYCLE
AB Delayed clearance of free form all-trans-retinal (atRAL) is estimated be the key cause of retinal pigment epithelium (RPE) cells injury during the pathogenesis of retinopathies such as age-related macular degeneration (AMD), however, the underlying molecular mechanisms are far from clear. In this study, we investigated the cytotoxicity effect and underlying molecular mechanism of atRAL on human retinal pigment epithelium ARPE-19 cells. The results indicated that atRAL could cause cell dysfunction by inducing oxidative and nitrosative stresses in ARPE-19 cells. The oxidative stress induced by atRAL was mediated through up-regulation of reactive oxygen species (ROS) generation, activating mitochondrial-dependent and MAPKs signaling pathways, and finally resulting in apoptosis of ARPE-19 cells. The NADPH oxidase inhibitor apocynin could partly attenuated ROS generation, indicating that NADPH oxidase activity was involved in atRAL-induced oxidative stress in ARPE-19 cells. The nitrosative stress induced by atRAL was mainly reflected in increasing nitric oxide (NO) production, enhancing iNOS, ICAM-1 and VCAM-1 expressions, and promoting monocyte adhesion. Furthermore, above effects could be dramatically blocked by using a nuclear factor kappa B (NF-kappa B) inhibitor SN50, indicated that atRAL-induced oxidative and nitrosative stresses were mediated by NF-kappa B. The results provide better understanding of atRAL-induced toxicity in human RPE cells. (C) 2016 Published by Elsevier Inc.
C1 [Zhu, Xue; Wang, Ke; Zhang, Kai] Jiangsu Inst Nucl Med, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Wuxi 214063, Jiangsu, Peoples R China.
   [Zhou, Fanfan] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.
   [Zhu, Ling] Univ Sydney, Save Sight Inst, Sydney, NSW 2000, Australia.
C3 University of Sydney; University of Sydney
RP Wang, K (通讯作者)，Jiangsu Inst Nucl Med, Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Wuxi 214063, Jiangsu, Peoples R China.
EM wangke@jsinm.org
RI Zhu, Xue/AAR-9416-2020; Zhou, Fanfan/J-2327-2019; Zhu, Ling/M-3887-2013;
   Zhou, Fanfan/M-4404-2013; Zhang, Kai/AGI-6985-2022
OI Zhou, Fanfan/0000-0002-1982-1541; Zhu, Ling/0000-0003-0776-1630; Zhou,
   Fanfan/0000-0002-1982-1541; Zhang, Kai/0000-0002-7021-5395
FU National Natural Science Foundation [81300787]; Natural Science
   Foundation of Jiangsu Province [BK2012105, BK20141103]; Major Project of
   Wuxi Municipal Health Bureau [ZS201401, Z201508]; Project of Wuxi
   Municipal Science and Technology Bureau [CSE31N1520]
FX This work was supported by grants from National Natural Science
   Foundation (81300787), the Natural Science Foundation of Jiangsu
   Province (BK2012105, BK20141103), the Major Project of Wuxi Municipal
   Health Bureau (ZS201401, Z201508), and the Project of Wuxi Municipal
   Science and Technology Bureau (CSE31N1520).
CR Anrather J, 2006, J BIOL CHEM, V281, P5657, DOI 10.1074/jbc.M506172200
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276
   Goureau O, 1997, BIOCHEM BIOPH RES CO, V240, P132, DOI 10.1006/bbrc.1997.7581
   Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5
   HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Koga T, 2003, EXP EYE RES, V76, P15, DOI 10.1016/S0014-4835(02)00274-9
   Kruger NJ, 2009, SPRINGER PROTOC HAND, P17, DOI 10.1007/978-1-59745-198-7_4
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Leal EC, 2007, INVEST OPHTH VIS SCI, V48, P5257, DOI 10.1167/iovs.07-0112
   Li J., 2014, TOXICOLOGICAL SCI
   LOCHNER JE, 1986, P NATL ACAD SCI USA, V83, P7673, DOI 10.1073/pnas.83.20.7673
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Parker RO, 2010, EXP EYE RES, V91, P788, DOI 10.1016/j.exer.2010.08.013
   PLATTS KE, 1995, INVEST OPHTH VIS SCI, V36, P2262
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1362, DOI 10.1111/j.1751-1097.2012.01161.x
   Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3
   Sarelius IH, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.985954
   Sawada O, 2014, EXP EYE RES, V123, P27, DOI 10.1016/j.exer.2014.04.003
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Simo R., 2010, BIOMED RES INT, P2010
   SPARROW JR, 1994, EXP EYE RES, V59, P129, DOI 10.1006/exer.1994.1091
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Vorbach C, 2003, TRENDS IMMUNOL, V24, P512, DOI 10.1016/S1471-4906(03)00237-0
   Xu H., 2016, EUR J PHARM
   Yang JS, 2004, ANTICANCER RES, V24, P1769
   Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837
NR 32
TC 19
Z9 19
U1 0
U2 13
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD OCT 15
PY 2016
VL 348
IS 1
BP 87
EP 94
DI 10.1016/j.yexcr.2016.09.002
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY4GL
UT WOS:000385056900009
PM 27616142
DA 2022-11-30
ER

PT J
AU Shin, JY
   Choi, HJ
   Chung, B
   Choi, M
   Lee, J
   Byeon, SH
AF Shin, Joo Youn
   Choi, Hun Jin
   Chung, Byunghoon
   Choi, Moonjung
   Lee, Jonghyun
   Byeon, Suk Ho
TI Anti-Vascular Endothelial Growth Factor with Gas for Submacular
   Hemorrhage
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE anti-vascular endothelial growth factor; age-related macular
   degeneration; choroidal neovascularization; polypoidal choroidal
   vasculopathy; submacular hemorrhage
ID TISSUE-PLASMINOGEN ACTIVATOR; POLYPOIDAL CHOROIDAL VASCULOPATHY; MACULAR
   DEGENERATION; SUBRETINAL HEMORRHAGE; PNEUMATIC DISPLACEMENT;
   INTRAVITREAL RANIBIZUMAB; FACTOR MONOTHERAPY; NATURAL-HISTORY;
   SECONDARY; BEVACIZUMAB
AB Purpose. To investigate the treatment outcome of pneumatic displacement and intravitreal anti-vascular endothelial growth factor (VEGF) for submacular hemorrhage (SMH) from exudative age-related macular degeneration (AMD).
   Methods. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were measured at baseline and at 1, 3, and 6 months after initial treatment in 72 eyes of 72 patients treated with a combination of pneumatic displacement and anti-VEGF injection for SMH from exudative AMD.
   Results. Best-corrected visual acuity and CFT showed significant improvement from baseline during the 6-month follow-up period (logarithm of the minimum angle of resolution BCVA from 1.80 to 1.00, CFT from 886 to 383 mu m, p < 0.001, respectively). The decrease in subretinal hemorrhage was greater than that in subretinal pigment epithelial hemorrhage at 1 month after initial treatment (p < 0.001). In eyes with symptoms for less than 30 days, higher reflectivity of hemorrhage on optical coherence tomography and higher CFT were associated with lower BCVA after 6 months of treatment (reflectivity B = 0.335, p = 0.007; CFT B = 0.001, p = 0.003).
   Conclusions. The combination of pneumatic displacement and intravitreal anti-VEGF is a useful treatment option for SMH secondary to AMD. Higher baseline CFT and higher reflectivity of hemorrhage were associated with lower BCVA 6 months after initial treatment.
C1 [Shin, Joo Youn; Chung, Byunghoon; Choi, Moonjung; Byeon, Suk Ho] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
   [Shin, Joo Youn; Choi, Hun Jin; Lee, Jonghyun] Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Ophthalmol, Goyang, South Korea.
C3 Yonsei University; Yonsei University Health System; Inje University
RP Byeon, SH (通讯作者)，Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM shbyeon@yuhs.ac
OI Shin, Joo Youn/0000-0003-4543-477X; Byeon, suk ho/0000-0001-8101-0830
FU Basic Science Research Program through the National Research Foundation
   of Korea - Ministry of Education [2013R1A1A2007865]
FX Supported by the Basic Science Research Program through the National
   Research Foundation of Korea funded by the Ministry of Education
   (2013R1A1A2007865).
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   CRITTENDEN JJ, 1985, ARCH OPHTHALMOL-CHIC, V103, P831, DOI 10.1001/archopht.1985.01050060091032
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Fang IM, 2009, EYE, V23, P397, DOI 10.1038/sj.eye.6703017
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hasler PW, 2007, ACTA OPHTHALMOL SCAN, V85, P577, DOI 10.1111/j.1600-0420.2007.00914.x
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hohn F, 2010, OPHTHALMOLOGE, V107, P328, DOI 10.1007/s00347-009-2004-3
   Horu T, 2012, OPHTHALMOLOGY, V119, P1047, DOI 10.1016/j.ophtha.2011.10.030
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kitahashi M, 2014, CLIN OPHTHALMOL, V8, P485, DOI 10.2147/OPTH.S55413
   Koshibu A, 1979, Nippon Ganka Gakkai Zasshi, V83, P386
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Ueda-Arakawa N, 2012, JPN J OPHTHALMOL, V56, P589, DOI 10.1007/s10384-012-0191-y
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 38
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD FEB
PY 2016
VL 93
IS 2
BP 173
EP 180
DI 10.1097/OPX.0000000000000777
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP2AE
UT WOS:000378289700009
PM 26704146
DA 2022-11-30
ER

PT J
AU Dai, YN
   Zhao, C
   Liang, XF
   Dai, RP
   Dong, FT
AF Dai, Yining
   Zhao, Chan
   Liang, Xiaofang
   Dai, Rongping
   Dong, Fangtian
TI Protectin DX, a double lipoxygenase product from DHA, inhibits the
   production of both inflammatory cytokines and reactive oxygen species in
   human retinal pigment epithelium cells
SO EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Inflammation; Oxidative stress; Peroxisome proliferator-activated
   receptor- coactivator-1; Protectin; RPE cells
ID MACULAR DEGENERATION; OXIDATIVE STRESS; FATTY-ACIDS; TNF-ALPHA;
   PGC-1-ALPHA; MUSCLE; MECHANISMS; RESOLUTION; INCREASE; DISEASE
AB Oxidative stress and inflammation in retinal pigment epithelium (RPE) play important roles in the development of age-related macular degeneration (AMD). Docosahexaenoic acid (22:6, n-3, DHA) is highly concentrated in RPE and can be converted into the active oxygenate derivative protectin DX (PDX). The current study explored the effects of PDX on RPE cells under oxidative stress. Pretreatment with PDX significantly inhibited t-BH-induced reactive oxygen species (ROS) production and increased intracellular total antioxidant capability (T-AOC) and superoxide dismutase (SOD) activity in RPE cells. Furthermore, PDX pretreatment greatly suppressed the t-BH-induced excessive secretion of tumor necrosis factor- (TNF-) and vascular endothelial growth factor-A (VEGF-A). Interestingly, peroxisome proliferator-activated receptor- coactivator-1 (PGC-1), a key regulator of enzymes that detoxify ROS, was induced by PDX pretreatment, suggesting a possible mechanism that explains the antioxidant effects of PDX in RPE cells. Practical applications: DHA is highly concentrated in human RPE and photoreceptor cells. It remains controversial whether DHA can reduce the risk of progression to advanced AMD. The current study investigated the anti-inflammatory and antioxidant effects of PDX on oxidative stress-induced RPE cells. These results suggest the potential application of active oxygenated DHA derivatives in the prevention and treatment of AMD and other oxidative stress-related retina diseases, such as diabetic retinopathy.
C1 Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   Chinese Acad Med Sci, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences - Peking Union Medical College
RP Dong, FT (通讯作者)，Beijing Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM d_fangtian@163.com
RI Dai, Yining/AAB-3658-2020
FU National Major Scientific and Technological Special Project for
   "Significant New Drugs Development" during the Twelfth Five-year Plan
   Period of China [2011ZX09302]
FX This research was supported by the National Major Scientific and
   Technological Special Project for "Significant New Drugs Development"
   during the Twelfth Five-year Plan Period of China (Grant 2011ZX09302).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Age-Related Eye Disease Study 2 Research G., 2013, JAMA-J AM MED ASSOC, V309, pE1
   Al-Gayyar MM, 2013, EUR CYTOKINE NETW, V24, P27, DOI 10.1684/ecn.2013.0334
   Alia M, 2005, J BIOCHEM MOL TOXIC, V19, P119, DOI 10.1002/jbt.20061
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arnold AS, 2011, GERONTOLOGY, V57, P37, DOI 10.1159/000281883
   Benzie IFF, 2000, EUR J NUTR, V39, P53, DOI 10.1007/s003940070030
   Blauz A, 2008, FOOD CHEM TOXICOL, V46, P2365, DOI 10.1016/j.fct.2008.03.018
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Derbre F, 2012, AGE, V34, P669, DOI 10.1007/s11357-011-9264-y
   Doak SH, 2012, METHODS MOL BIOL, V817, P251, DOI 10.1007/978-1-61779-421-6_13
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Giddabasappa A, 2010, INVEST OPHTH VIS SCI, V51, P5278, DOI 10.1167/iovs.10-5316
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kannan R, 2006, MOL VIS, V12, P1649
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Liu M, 2014, LIPIDS, V49, P49, DOI 10.1007/s11745-013-3863-6
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c
   Spierer A, 2005, EYE, V19, P86, DOI 10.1038/sj.eye.6701424
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106
   White PJ, 2014, NAT MED, V20, P664, DOI 10.1038/nm.3549
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Zhu L, 2010, J NUTR BIOCHEM, V21, P1089, DOI 10.1016/j.jnutbio.2009.09.006
NR 37
TC 4
Z9 4
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1438-7697
EI 1438-9312
J9 EUR J LIPID SCI TECH
JI Eur. J. Lipid Sci. Technol.
PD AUG
PY 2015
VL 117
IS 8
BP 1138
EP 1145
DI 10.1002/ejlt.201400423
PG 8
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA CO7WM
UT WOS:000359374100003
DA 2022-11-30
ER

PT J
AU Piippo, N
   Korkmaz, A
   Hytti, M
   Kinnunen, K
   Salminen, A
   Atalay, M
   Kaarniranta, K
   Kauppinen, A
AF Piippo, Niina
   Korkmaz, Ayhan
   Hytti, Maria
   Kinnunen, Kati
   Salminen, Antero
   Atalay, Mustafa
   Kaarniranta, Kai
   Kauppinen, Anu
TI Decline in cellular clearance systems induces inflammasome signaling in
   human ARPE-19 cells
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE Inflammasome; Autophagy; Protasome; Retinal pigment epithelium
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; NLRP3 INFLAMMASOME; NALP3 INFLAMMASOME; OXIDATIVE STRESS;
   PATTERN-RECOGNITION; OUTER SEGMENTS; ACTIVATION
AB Retinal pigment epithelium (RPE) plays a major role in the maintenance of photoreceptors, and degeneration of RPE results in the development of age-related macular degeneration (AMD). Accumulation of intracellular protein aggregates, increased oxidative stress, and chronic inflammation are all factors damaging the functionality of aged RPE cells. Here, we report that inhibition of proteasomal degradation with MG-132 and autophagy with bafilomycin A1 resulted in the release of IL-1 beta but not that of IL-18 in human ARPE-19 cells. NLRP3 receptor became upregulated, and caspase-1, the functional component of an inflammasome complex, was activated. In addition to accumulating intracellular protein aggregates, inhibition of degradation systems induced oxidative stress which was demonstrated by elevated amounts of intracellular 4-hydroxynonenal (HNE)-protein adducts. Along with IL-1 beta, exposure to MG-132 and bafilomycin A1 resulted in the secretion of IL-8.A low concentration (1 pg/ml) of IL-1 beta was capable of triggering significant IL-8 production which also became attenuated by treatment with a specific caspase-1 inhibitor. These results suggest that decline in intracellular degradation systems results not only in increased amounts of intracellular protein aggregates and oxidative stress but also in the activation of NLRP3 inflammasomes, arisen as a result of elevated production of biologically active IL-1 beta. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Piippo, Niina; Hytti, Maria; Kinnunen, Kati; Kaarniranta, Kai; Kauppinen, Anu] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   [Korkmaz, Ayhan; Atalay, Mustafa] Univ Eastern Finland, Inst Biomed, FIN-70211 Kuopio, Finland.
   [Kinnunen, Kati; Kaarniranta, Kai; Kauppinen, Anu] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland; University of
   Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FIN-70211 Kuopio, Finland.
EM anu.kauppinen@uef.fi
RI Hytti, Maria/AAE-4016-2019
OI Hytti, Maria/0000-0003-2150-6847; Kaarniranta, Kai/0000-0003-2600-8679
FU Academy of Finland; Paivikki and Sakari Sohlberg Foundation;
   Orion-Farmos Research Foundation; Finnish Cultural Foundation; CIMO;
   COST Actions [CM1001, TD1304]
FX We thank Dr. Ewen McDonald for checking the language of the manuscript.
   This research was financially supported by the Academy of Finland (AK,
   KK), the Paivikki and Sakari Sohlberg Foundation (AK, KK), The
   Orion-Farmos Research Foundation (AK), the Finnish Cultural Foundation
   (North-Savonia Regional Fund; NP), CIMO (AK), and COST Actions CM1001
   and TD1304. (MA).
CR Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ayalasomayajula SP, 2002, EUR J PHARMACOL, V449, P213, DOI 10.1016/S0014-2999(02)02043-5
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105
   Cassel SL, 2009, SEMIN IMMUNOL, V21, P194, DOI 10.1016/j.smim.2009.05.002
   Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200
   Dinarello CA, 2005, CRIT CARE MED, V33, pS460, DOI 10.1097/01.CCM.0000185500.11080.91
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Elner VM, 1997, EXP EYE RES, V65, P781, DOI 10.1006/exer.1997.0380
   Fesus L, 2011, ANTIOXID REDOX SIGN, V14, P2233, DOI 10.1089/ars.2010.3485
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   He Y, 2013, J IMMUNOL, V190, P334, DOI 10.4049/jimmunol.1202737
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kang KH, 2009, TRENDS MOL MED, V15, P191, DOI 10.1016/j.molmed.2009.03.005
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakajima S, 2011, FEBS LETT, V585, P2249, DOI 10.1016/j.febslet.2011.05.047
   Oksala NKJ, 2007, ANTIOXID REDOX SIGN, V9, P497, DOI 10.1089/ars.2006.1450
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   RAKOCZY PE, 1994, INVEST OPHTH VIS SCI, V35, P4100
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Sola-Villa D, 2006, KIDNEY INT, V70, P1935, DOI 10.1038/sj.ki.5001948
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Vatsyayan R, 2012, BIOCHEM BIOPH RES CO, V417, P346, DOI 10.1016/j.bbrc.2011.11.113
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 43
TC 53
Z9 55
U1 1
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
EI 0006-3002
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD DEC
PY 2014
VL 1843
IS 12
BP 3038
EP 3046
DI 10.1016/j.bbamcr.2014.09.015
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AR7UR
UT WOS:000343785700023
PM 25268952
OA Bronze
DA 2022-11-30
ER

PT J
AU Ravi, KB
   Reddy, KRR
   Shankaranarayanan, J
   Deshpande, JV
   Juturu, V
   Soni, MG
AF Ravi, K. B.
   Reddy, K. R. Raghunatha
   Shankaranarayanan, J.
   Deshpande, Jayant V.
   Juturu, Vijaya
   Soni, Madhu G.
TI Safety evaluation of zeaxanthin concentrate (OmniXan (TM)): Acute,
   subchronic toxicity and mutagenicity studies
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Zeaxanthin; Food ingredient; Safety; Toxicity
ID PERSONS AGED 60; MACULAR PIGMENT; MESO-ZEAXANTHIN; LUTEIN; CAROTENOIDS;
   SUPPLEMENTATION; SERUM; DEGENERATION
AB The available evidence suggests a beneficial effect of zeaxanthin against the progression of age-related macular degeneration (AMD). The objective of the present study was to investigate potential adverse effects of Omnixan (TM), a RR-zeaxanthin (65%) enriched product obtained from paprika (Capsicum annum fruits) in subchronic toxicity and mutagenicity studies. The oral LD50 of OmniXan (TM) in rats was greater than 2000 mg/kg body weight (bw)/day. For the subchronic toxicity study, Wistar rats (10/sex/group) were gavaged daily with zeaxanthin concentrate at doses of 0, 4, 40 and 400 mg/kg bw/day for 90-days. No treatment related clinical signs and mortalities observed. Similarly, no treatment related toxicologically significant changes in body weight, feed consumption; ophthalmoscopic examination, neurological examination, hematology, urine analysis and organ weights were observed. Statistically significant changes observed in some clinical chemistry parameters were considered toxicologically and biologically insignificant and nonadverse. Macroscopic and microscopic examinations did not reveal treatment-related abnormalities. The results of mutagenicity testing using Salmonella typhimurium did not reveal any genotoxicity. The no observed-adverse-effect level (NOAEL) for zeaxanthin concentrate (OmniXan (TM)) was determined as 400 mg/kg bw/day, the highest dose tested. The findings of this subchronic toxicity and mutagenicity studies support safety of zeaxanthin concentrate. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Ravi, K. B.; Reddy, K. R. Raghunatha] BIONEEDS, Bangalore 562111, Karnataka, India.
   [Shankaranarayanan, J.; Deshpande, Jayant V.] OmniAct Hlth Technol Ltd, Thane West 400607, Maharashtra, India.
   [Juturu, Vijaya] OmniAct Hlth Technol Inc, Morristown, NJ 07960 USA.
   [Soni, Madhu G.] Soni & Associates Inc, Vero Beach, FL 32960 USA.
RP Soni, MG (通讯作者)，Soni & Associates Inc, 973 37th Pl, Vero Beach, FL 32960 USA.
EM sonim@bellsouth.net
FU OmniActive Health Technologies
FX Ravi K. B and Raghunatha Reddy K. R are employees of Bioneeds, India,
   where the study was performed. Shankaranarayanan J, Jayant V Deshpande
   and Vijaya Juturu are employed by OmniActive Health Technologies. Madhu
   Soni works as an independent Consulting Toxicologist. OmniActive Health
   Technologies sponsored this study.
CR Agostoni C, 2012, EFSA J, V10, DOI 10.2903/j.efsa.2012.2890
   Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Hendler S. S., 2001, PDR NUTR SUPPLEMENTS, P281
   IOM, 2000, DIET REF INT VIT C V, P325
   Jaswir I, 2011, J MED PLANTS RES, V5, P7119, DOI 10.5897/JMPRx11.011
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5476, DOI 10.1167/iovs.06-0194
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kumar D.P., 2009, TOXICOL INT, V16, P55
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Omaye ST, 1997, FUND APPL TOXICOL, V40, P163, DOI 10.1006/faat.1997.2387
   Preethi KC, 2008, INT J TOXICOL, V27, P1, DOI 10.1080/10915810701876265
   Ravikrishnan R, 2011, FOOD CHEM TOXICOL, V49, P2841, DOI 10.1016/j.fct.2011.08.011
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Sahota PS, 2013, TOXICOLOGIC PATHOLOG
   Sajilata MG, 2008, COMPR REV FOOD SCI F, V7, P29, DOI 10.1111/j.1541-4337.2007.00028.x
   Thurnham DI, 2013, FOOD CHEM TOXICOL, V59, P455, DOI 10.1016/j.fct.2013.06.002
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Xu XD, 2013, FOOD CONTROL, V32, P678, DOI 10.1016/j.foodcont.2013.02.007
   Zhou HY, 2011, INVEST OPHTH VIS SCI, V52, P4338, DOI 10.1167/iovs.10-6519
NR 27
TC 9
Z9 9
U1 1
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD OCT
PY 2014
VL 72
BP 30
EP 39
DI 10.1016/j.fct.2014.06.015
PG 10
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA AR5NI
UT WOS:000343630800005
PM 24964014
DA 2022-11-30
ER

PT J
AU Mimura, T
   Kaji, Y
   Noma, H
   Funatsu, H
   Okamoto, S
AF Mimura, Tatsuya
   Kaji, Yuichi
   Noma, Hidetaka
   Funatsu, Hideharu
   Okamoto, Shinseiro
TI The role of SIRT1 in ocular aging
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE review; SIRT1; eye
ID HISTONE DEACETYLASE SIRT6; SMALL-MOLECULE ACTIVATORS; CALORIE
   RESTRICTION; DNA-DAMAGE; LIFE-SPAN; WALLERIAN DEGENERATION;
   MITOCHONDRIAL-DNA; CELL-SURVIVAL; SACCHAROMYCES-CEREVISIAE;
   GLUCOSE-HOMEOSTASIS
AB The sirtuins are a highly conserved family of nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylases that helps regulate the lifespan of diverse organisms. The human genome encodes seven different sirtuins (SIRT1-7), which share a common catalytic core domain but possess distinct Nand C-terminal extensions. Dysfunction of some sirtuins have been associated with age-related diseases, such as cancer, type II diabetes, obesity-associated metabolic diseases, neurodegeneration, and cardiac aging, as well as the response to environmental stress. SIRT1 is one of the targets of resveratrol, a polyphenolic SIRT1 activator that has been shown to increase the lifespan and to protect various organs against aging. A number of animal studies have been conducted to examine the role of sirtuins in ocular aging. Here we review current knowledge about SIRT1 and ocular aging. The available data indicate that SIRT1 is localized in the nucleus and cytoplasm of cells forming all normal ocular structures, including the cornea, lens, iris, ciliary body, and retina. Upregulation of SIRT1 has been shown to have an important protective effect against various ocular diseases, such as cataract, retinal degeneration, optic neuritis, and uveitis, in animal models. These results suggest that SIRT1 may provide protection against diseases related to oxidative stress-induced ocular damage, including cataract, age-related macular degeneration, and optic nerve degeneration in glaucoma patients. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Mimura, Tatsuya] Tokyo Womens Med Univ, Dept Ophthalmol, Med Ctr East, Arakawa Ku, Tokyo 1168567, Japan.
   [Kaji, Yuichi] Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Tsukuba, Ibaraki 305, Japan.
   [Noma, Hidetaka; Funatsu, Hideharu] Tokyo Womens Med Univ, Dept Ophthalmol, Yachiyo Med Ctr, Yachiyo, Chiba, Japan.
   [Okamoto, Shinseiro] Okamoto Eye Clin, Yamato, Kanagawa, Japan.
C3 Tokyo Women's Medical University; University of Tsukuba; Tokyo Women's
   Medical University
RP Mimura, T (通讯作者)，Tokyo Womens Med Univ, Dept Ophthalmol, Med Ctr East, Arakawa Ku, 2-1-10 Nishiogu, Tokyo 1168567, Japan.
EM mimurat-tky@umin.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX Grant support: This work was supported in part by a Grant-in-Aid for
   Scientific Research from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan.
CR Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299
   Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011
   Aguzzi A, 2007, NAT REV MOL CELL BIO, V8, P552, DOI 10.1038/nrm2204
   Akieda-Asai S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011755
   Alves LFD, 2012, CORNEA, V31, P817, DOI 10.1097/ICO.0b013e31823f7857
   Anastasiou D, 2006, PHYSIOLOGY, V21, P404, DOI 10.1152/physiol.00031.2006
   Anekonda Thimmappa S, 2008, BMC Res Notes, V1, P122, DOI 10.1186/1756-0500-1-122
   Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014
   Avery MA, 2009, J CELL BIOL, V184, P501, DOI 10.1083/jcb.200808042
   Babetto E, 2010, J NEUROSCI, V30, P13291, DOI 10.1523/JNEUROSCI.1189-10.2010
   Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014
   Barden CA, 2008, AM J VET RES, V69, P94, DOI 10.2460/ajvr.69.1.94
   Bastianetto S, 2002, NEUROBIOL AGING, V23, P891, DOI 10.1016/S0197-4580(02)00024-6
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Baur JA, 2010, SCIENCE, V329, P1012, DOI 10.1126/science.329.5995.1012
   Baur JA, 2010, BBA-PROTEINS PROTEOM, V1804, P1626, DOI 10.1016/j.bbapap.2009.10.025
   Beher D, 2009, CHEM BIOL DRUG DES, V74, P619, DOI 10.1111/j.1747-0285.2009.00901.x
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651
   Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759
   Bonda DJ, 2011, LANCET NEUROL, V10, P275, DOI 10.1016/S1474-4422(11)70013-8
   Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031
   Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Buler M, 2011, BIOCHEM PHARMACOL, V82, P2008, DOI 10.1016/j.bcp.2011.09.006
   Cannon W.B., 1932, WISDOM BODY, V184, P864, DOI 10.1097/00000441-193212000-00028
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Carafa V, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00004
   Cardus A, 2013, CARDIOVASC RES, V97, P571, DOI 10.1093/cvr/cvs352
   Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357
   Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544
   Chen D, 2008, EXP GERONTOL, V43, P1086, DOI 10.1016/j.exger.2008.08.050
   Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100
   Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007
   Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076
   COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909
   Cohen DE, 2009, GENE DEV, V23, P2812, DOI 10.1101/gad.1839209
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788
   Coleman MP, 2010, ANNU REV NEUROSCI, V33, P245, DOI 10.1146/annurev-neuro-060909-153248
   Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5
   Conforti L, 2007, CELL DEATH DIFFER, V14, P116, DOI 10.1038/sj.cdd.4401944
   Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377
   Conforti L, 2009, J CELL BIOL, V184, P491, DOI 10.1083/jcb.200807175
   Coppari R, 2009, NAT CLIN PRACT ENDOC, V5, P160, DOI 10.1038/ncpendmet1070
   Corton JC, 2005, J GERONTOL A-BIOL, V60, P1494, DOI 10.1093/gerona/60.12.1494
   Costa CD, 2011, OBES SURG, V21, P356, DOI 10.1007/s11695-010-0251-7
   DellaCroce JT, 2008, CURR OPIN OPHTHALMOL, V19, P493, DOI 10.1097/ICU.0b013e3283129779
   Denu JM, 2005, CURR OPIN CHEM BIOL, V9, P431, DOI 10.1016/j.cbpa.2005.08.010
   Di Pascuale MA, 2004, BRIT J OPHTHALMOL, V88, P388, DOI 10.1136/bjo.2003.025460
   Dittenhafer-Reed KE, 2011, CHEMBIOCHEM, V12, P281, DOI 10.1002/cbic.201000434
   Doganay S, 2006, CURR EYE RES, V31, P147, DOI 10.1080/02713680500514685
   Dominy JE, 2012, MOL CELL, V48, P900, DOI 10.1016/j.molcel.2012.09.030
   Donmez G, 2010, AGING CELL, V9, P285, DOI 10.1111/j.1474-9726.2010.00548.x
   Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Fotouhi A, 2009, EYE, V23, P1125, DOI 10.1038/eye.2008.200
   Fraser JA, 2010, SURV OPHTHALMOL, V55, P299, DOI 10.1016/j.survophthal.2009.10.002
   FRAUNFELDER FT, 1972, AM J OPHTHALMOL, V74, P821, DOI 10.1016/0002-9394(72)91202-0
   Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5
   Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000
   Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897
   Fujiwara T, 2006, MOL CELL BIOL, V26, P2273, DOI 10.1128/MCB.26.6.2273-2285.2006
   Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138
   Geng Y.Q., 2011, YAN KE XUE BAO, V26, P221
   Gesing A, 2011, J GERONTOL A-BIOL, V66, P1062, DOI 10.1093/gerona/glr080
   Gorenne I, 2013, CIRCULATION, V127, P386, DOI 10.1161/CIRCULATIONAHA.112.124404
   Gorospe M, 2008, TRENDS CELL BIOL, V18, P77, DOI 10.1016/j.tcb.2007.11.007
   Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243
   GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8
   Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029
   Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458
   Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700
   Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250
   Han J, 2013, CELL CYCLE, V12, P263, DOI 10.4161/cc.23056
   Hayashida S, 2010, MOL CELL BIOCHEM, V339, P285, DOI 10.1007/s11010-010-0391-z
   Hilliard MA, 2009, J NEUROCHEM, V108, P23, DOI 10.1111/j.1471-4159.2008.05754.x
   Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6
   HOLT IJ, 1988, J NEUROL NEUROSUR PS, V51, P1075, DOI 10.1136/jnnp.51.8.1075
   Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hsu CP, 2008, BIOL CHEM, V389, P221, DOI 10.1515/BC.2008.032
   Huang YN, 2012, GENE, V502, P87, DOI 10.1016/j.gene.2012.04.052
   Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622
   Jaliffa C, 2009, INVEST OPHTH VIS SCI, V50, P3562, DOI 10.1167/iovs.08-2817
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jin J, 2013, J NEUROCHEM, V125, P410, DOI 10.1111/jnc.12190
   Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200
   Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570
   Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049
   Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758
   Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707
   Kubota S, 2011, INVEST OPHTH VIS SCI, V52, P9142, DOI 10.1167/iovs.11-8041
   Kubota S, 2010, AM J PATHOL, V177, P1725, DOI 10.2353/ajpath.2010.100098
   Kubota S, 2009, INVEST OPHTH VIS SCI, V50, P3512, DOI 10.1167/iovs.08-2666
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383
   Lee JH, 2009, DIABETES, V58, P344, DOI 10.2337/db07-1795
   Lerrer B, 2013, EMBO J, V32, P7, DOI 10.1038/emboj.2012.332
   Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200
   Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200
   Li X, 2007, MOL CELL, V28, P91, DOI 10.1016/j.molcel.2007.07.032
   Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004
   Lin TJ, 2011, J CATARACT REFR SURG, V37, P1270, DOI 10.1016/j.jcrs.2011.02.027
   Liu L, 2012, CLIN PHARM, DOI DOI 10.1111/FCP.12016.N0V
   Liu Y, 2008, NATURE, V456, P269, DOI 10.1038/nature07349
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Lyssiotis CA, 2012, CELL, V151, P1155, DOI 10.1016/j.cell.2012.11.020
   Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770
   Maloney SC, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/908183
   Mantel C, 2008, CURR OPIN HEMATOL, V15, P326, DOI 10.1097/MOH.0b013e3283043819
   Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723
   Markus MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028926
   McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003
   Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140
   Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mimura T, 2012, ACTA OPHTHALMOL, V90, P773, DOI 10.1111/j.1755-3768.2011.02161.x
   Mimura T, 2012, CORNEA, V31, P264, DOI 10.1097/ICO.0b013e3182254170
   Mimura T, 2011, EYE CONTACT LENS, V37, P31, DOI 10.1097/ICL.0b013e3181f91f2f
   Mimura T, 2009, AM J OPHTHALMOL, V147, P171, DOI 10.1016/j.ajo.2008.07.010
   Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044
   Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6
   Mulligan JD, 2008, EXP GERONTOL, V43, P146, DOI 10.1016/j.exger.2007.10.011
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   Nomiyama T, 2008, CURR ATHEROSCLER REP, V10, P88, DOI 10.1007/s11883-008-0013-3
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224
   Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025
   Oliver C A, 1906, Trans Am Ophthalmol Soc, V11, P123
   Ozawa Y, 2010, OPHTHALMIC RES, V44, P199, DOI 10.1159/000316484
   Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682
   PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7
   Pallas M, 2009, CURR NEUROVASC RES, V6, P70, DOI 10.2174/156720209787466019
   Panchapakesan J, 1998, AUST NZ J OPHTHALMOL, V26, pS2, DOI 10.1111/j.1442-9071.1998.tb01362.x
   Pang WJ, 2013, EXP CELL RES, V319, P670, DOI 10.1016/j.yexcr.2012.12.025
   Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Peng CH, 2010, SENSORS-BASEL, V10, P6172, DOI 10.3390/s100606172
   Perrault I, 2012, NAT GENET, V44, P975, DOI 10.1038/ng.2357
   PERRY VH, 1990, EUR J NEUROSCI, V2, P408, DOI 10.1111/j.1460-9568.1990.tb00433.x
   Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105
   Pham TQ, 2005, AM J OPHTHALMOL, V139, P1126, DOI 10.1016/j.ajo.2004.12.004
   Pham TQ, 2005, AM J OPHTHALMOL, V139, P536, DOI 10.1016/j.ajo.2004.08.070
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Picard F, 2005, INT J OBESITY, V29, pS36, DOI 10.1038/sj.ijo.0802912
   Polyakova O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051555
   Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Qin WP, 2006, J BIOL CHEM, V281, P21745, DOI 10.1074/jbc.M602909200
   Qiu XL, 2010, BBA-PROTEINS PROTEOM, V1804, P1576, DOI 10.1016/j.bbapap.2009.09.015
   Radak Z, 2013, FREE RADICAL BIO MED, V58, P87, DOI 10.1016/j.freeradbiomed.2013.01.004
   Rahman S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-11
   Rodgers JT, 2008, FEBS LETT, V582, P46, DOI 10.1016/j.febslet.2007.11.034
   Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354
   Rodriguez RM, 2010, FUTURE ONCOL, V6, P905, DOI 10.2217/FON.10.57
   Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101
   Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009
   Satoh A, 2010, J NEUROSCI, V30, P10220, DOI 10.1523/JNEUROSCI.1385-10.2010
   Schirmer H, 2012, MOL BIOL REP, V39, P3281, DOI 10.1007/s11033-011-1096-4
   Schug TT, 2010, MOL CELL BIOL, V30, P4712, DOI 10.1128/MCB.00657-10
   Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057
   Schwer B, 2010, P NATL ACAD SCI USA, V107, P21790, DOI 10.1073/pnas.1016306107
   Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   SEGAL P, 1967, OPHTHALMOLOGICA, V153, P336, DOI 10.1159/000305074
   Shen JZ, 2013, CARDIOVASC RES, V97, P391, DOI 10.1093/cvr/cvs421
   Sherman JM, 1999, MOL BIOL CELL, V10, P3045, DOI 10.1091/mbc.10.9.3045
   Shindler KS, 2007, INVEST OPHTH VIS SCI, V48, P3602, DOI 10.1167/iovs.07-0131
   SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x
   Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8
   Sinclair DA, 2006, SCIENCE, V312, P195
   Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014
   Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6
   Takemori K, 2011, LIFE SCI, V88, P1088, DOI 10.1016/j.lfs.2011.04.002
   Tang BL, 2008, MOL ASPECTS MED, V29, P187, DOI 10.1016/j.mam.2007.02.001
   Tennen RI, 2011, TRENDS BIOCHEM SCI, V36, P39, DOI 10.1016/j.tibs.2010.07.009
   Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638
   Torres G, 2011, NEUROSCIENCE, V179, P32, DOI 10.1016/j.neuroscience.2011.01.036
   Trotta PA, 2011, HORM METAB RES, V43, P171, DOI 10.1055/s-0031-1271694
   van der Veer E, 2007, J BIOL CHEM, V282, P10841, DOI 10.1074/jbc.C700018200
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   Walker AK, 2010, GENE DEV, V24, P1403, DOI 10.1101/gad.1901210
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Wang YZ, 2011, INT J MOL MED, V28, P617, DOI 10.3892/ijmm.2011.711
   Wareski P, 2009, J BIOL CHEM, V284, P21379, DOI 10.1074/jbc.M109.018911
   Webster KA, 2012, NAT MED, V18, P1617, DOI 10.1038/nm.2983
   Wilson BJ, 2010, MOL ENDOCRINOL, V24, P1349, DOI 10.1210/me.2009-0441
   Wojcik M, 2009, MINI-REV MED CHEM, V9, P386, DOI 10.2174/1389557510909030386
   Wu AG, 2006, EUR J NEUROSCI, V23, P2573, DOI 10.1111/j.1460-9568.2006.04807.x
   Wu Z, 2012, BLOOD, V119, P2422, DOI 10.1182/blood-2011-04-350413
   Xiao CY, 2010, J BIOL CHEM, V285, P36776, DOI 10.1074/jbc.M110.168039
   Yamamoto H, 2007, MOL ENDOCRINOL, V21, P1745, DOI 10.1210/me.2007-0079
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167
   Zarse K, 2010, HORM METAB RES, V42, P837, DOI 10.1055/s-0030-1265225
   Zhang F, 2011, PROG NEUROBIOL, V95, P373, DOI 10.1016/j.pneurobio.2011.09.001
   Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515
   Zheng TY, 2011, CURR EYE RES, V36, P449, DOI 10.3109/02713683.2011.559301
   Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041
NR 211
TC 67
Z9 73
U1 0
U2 28
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2013
VL 116
BP 17
EP 26
DI 10.1016/j.exer.2013.07.017
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 259YP
UT WOS:000327562500003
PM 23892278
DA 2022-11-30
ER

PT J
AU Clark, SJ
   Ridge, LA
   Herbert, AP
   Hakobyan, S
   Mulloy, B
   Lennon, R
   Wurzner, R
   Morgan, BP
   Uhrin, D
   Bishop, PN
   Day, AJ
AF Clark, Simon J.
   Ridge, Liam A.
   Herbert, Andrew P.
   Hakobyan, Svetlana
   Mulloy, Barbara
   Lennon, Rachel
   Wuerzner, Reinhard
   Morgan, B. Paul
   Uhrin, Dusan
   Bishop, Paul N.
   Day, Anthony J.
TI Tissue-Specific Host Recognition by Complement Factor H Is Mediated by
   Differential Activities of Its Glycosaminoglycan-Binding Regions
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; C-REACTIVE PROTEIN; DISEASE-ASSOCIATED FORM;
   MACULAR DEGENERATION; ALTERNATIVE PATHWAY; FUNCTIONAL-CHARACTERIZATION;
   FLAVOBACTERIUM-HEPARINUM; HEPARAN-SULFATE; HUMAN RETINA; POLYMORPHISM
AB Complement factor H (CFH) regulates complement activation in host tissues through its recognition of polyanions, which mediate CFH binding to host cell surfaces and extracellular matrix, promoting the deactivation of deposited C3b. These polyanions include heparan sulfate (HS), a glycosaminoglycan with a highly diverse range of structures, for which two regions of CFH (CCP6-8 and CCP19-20) have been implicated in HS binding. Mutations/polymorphisms within these glycosaminoglycan-binding sites have been associated with age-related macular degeneration (AMD) and atypical hemolytic uremic syndrome. In this study, we demonstrate that CFH has tissue-specific binding properties mediated through its two HS-binding regions. Our data show that the CCP6-8 region of CFH binds more strongly to heparin (a highly sulfated form of HS) than CCP19-20, and that their sulfate specificities are different. Furthermore, the HS binding site in CCP6-8, which is affected by the AMD-associated Y402H polymorphism, plays the principal role in host tissue recognition in the human eye, whereas the CCP19-20 region makes the major contribution to the binding of CFH in the human kidney. This helps provide a biochemical explanation for the genetic basis of tissue-specific diseases such as AMD and atypical hemolytic uremic syndrome, and leads to a better understanding of the pathogenic mechanisms for these diseases of complement dysregulation. The Journal of Immunology, 2013, 190: 2049-2057.
C1 [Clark, Simon J.; Ridge, Liam A.; Lennon, Rachel; Day, Anthony J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.
   [Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Inst Human Dev, Ctr Ophthalmol & Vis Res, Manchester M13 9PT, Lancs, England.
   [Clark, Simon J.; Bishop, Paul N.] Manchester Acad Hlth Sci Ctr, Cent Manchester Univ Hosp Natl Hlth Serv Fdn Trus, Ctr Adv Discovery & Expt Therapeut, Manchester M13 9WL, Lancs, England.
   [Herbert, Andrew P.; Uhrin, Dusan] Univ Edinburgh, Edinburgh & St Andrews Res Sch Chem, Edinburgh Biomol Nucl Magnet Resonance Unit, Edinburgh EH9 3JJ, Midlothian, Scotland.
   [Hakobyan, Svetlana; Morgan, B. Paul] Cardiff Univ, Sch Med, Inst Infect & Immun, Complement Biol Grp, Cardiff CF14 4XN, S Glam, Wales.
   [Mulloy, Barbara] Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England.
   [Wuerzner, Reinhard] Med Univ Innsbruck, Div Hyg & Med Microbiol, A-6020 Innsbruck, Austria.
C3 University of Manchester; University of Manchester; University of
   Manchester; University of Edinburgh; Cardiff University; National
   Institute for Biological Standards & Control; Medical University of
   Innsbruck
RP Day, AJ (通讯作者)，Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM paul.n.bishop@manchester.ac.uk; anthony.day@manchester.ac.uk
RI Herbert, Andy P/F-6693-2010; Herbert, Andrew P/C-4755-2008; Day,
   Anthony/O-1658-2015; Lennon, Rachel/AAJ-2134-2020
OI Herbert, Andy P/0000-0002-4549-6965; Herbert, Andrew
   P/0000-0002-4549-6965; Day, Anthony/0000-0002-1415-3134; Lennon,
   Rachel/0000-0001-6400-0227; Bishop, Paul/0000-0001-7937-7932; Ridge,
   Liam/0000-0002-7210-9596; Clark, Simon/0000-0001-8394-8355; Morgan,
   Paul/0000-0003-4075-7676
FU Medical Research Council [G0900592]; Manchester National Institute for
   Health Research Biomedical Research Centre; Biotechnology and Biological
   Sciences Research Council; Wellcome Trust; University of Manchester
   Strategic Fund; Faculty of Medicine and Human Sciences, University of
   Manchester; MRC [G0900538] Funding Source: UKRI; Medical Research
   Council [G0900538] Funding Source: researchfish
FX This work was supported by the Medical Research Council (Grant G0900592)
   and the Manchester National Institute for Health Research Biomedical
   Research Centre. The Bioimaging Facility microscopes used in this study
   were purchased with grants from the Biotechnology and Biological
   Sciences Research Council, Wellcome Trust, and the University of
   Manchester Strategic Fund. S.J.C. is the recipient of a Stepping Stones
   Fellowship from the Faculty of Medicine and Human Sciences, University
   of Manchester.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Day AJ, 2011, EXPERT REV OPHTHALMO, V6, P123, DOI 10.1586/EOP.11.10
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   GU KN, 1995, BIOCHEM J, V312, P569, DOI 10.1042/bj3120569
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Herbert AP, 2012, BIOCHEMISTRY-US, V51, P1874, DOI 10.1021/bi201689j
   Jozsi M, 2007, MOL IMMUNOL, V44, P2697, DOI 10.1016/j.molimm.2006.12.001
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202
   Khan S, 2012, BIOCHEM J, V444, P417, DOI 10.1042/BJ20120183
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   LOHSE DL, 1992, J BIOL CHEM, V267, P24347
   Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Marson A, 2009, GLYCOBIOLOGY, V19, P1537, DOI 10.1093/glycob/cwp132
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   MULLOY B, 1994, CARBOHYD RES, V255, P1, DOI 10.1016/S0008-6215(00)90968-6
   Mulloy B, 2000, THROMB HAEMOSTASIS, V84, P1052
   Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schmidt C, 2008, REV ECON POLIT, V118, P3
   SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wright AF, 2011, NAT GENET, V43, P1176, DOI 10.1038/ng.1012
NR 50
TC 106
Z9 110
U1 0
U2 29
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2013
VL 190
IS 5
BP 2049
EP 2057
DI 10.4049/jimmunol.1201751
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 091ZT
UT WOS:000315089100019
PM 23365078
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Weismann, D
   Binder, CJ
AF Weismann, David
   Binder, Christoph J.
TI The innate immune response to products of phospholipid peroxidation
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Review
DE Lipid peroxidation; Oxidized LDL; Apoptosis; Oxidation-specific epitope;
   Damage-associated molecular pattern; Pattern recognition receptor
ID C-REACTIVE PROTEIN; LOW-DENSITY-LIPOPROTEIN; COMPLEMENT FACTOR-H;
   OXIDATION-SPECIFIC EPITOPES; RETINAL-PIGMENT EPITHELIUM; SCAVENGER
   RECEPTOR CD36; E-DEFICIENT MICE; STREPTOCOCCUS-PNEUMONIAE INFECTION;
   HY402H GENE POLYMORPHISM; GLYCATION END-PRODUCTS
AB Lipid peroxidation occurs in the context of many physiological processes but is greatly increased in various pathological situations. A consequence of phospholipid peroxidation is the generation of oxidation-specific epitopes, such as phosphocholine of oxidized phospholipids and malondialdehyde, which form neo-self determinants on dying cells and oxidized low-density lipoproteins. In this review we discuss evidence demonstrating that pattern recognition receptors of the innate immune system recognize oxidation-specific epitopes as endogenous damage-associated molecular patterns, allowing the host to identify dangerous biological waste. Oxidation-specific epitopes are important targets of both cellular and soluble pattern recognition receptors, including toll-like and scavenger receptors. C-reactive protein, complement factor H, and innate natural IgM antibodies. This recognition allows the innate immune system to mediate important physiological house keeping functions, for example by promoting the removal of dying cells and oxidized molecules. Once this system is malfunctional or overwhelmed the development of diseases, such as atherosclerosis and age-related macular degeneration is favored. Understanding the molecular components and mechanisms involved in this process, will help the identification of individuals with increased risk of developing chronic inflammation, and indicate novel points for therapeutic intervention. This article is part of a Special Issue entitled: Oxidized phospholipids-their properties and interactions with proteins. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Binder, Christoph J.] Austrian Acad Sci, CeMM Ctr Mol Med, A-1010 Vienna, Austria.
   Med Univ Vienna, Dept Lab Med, Vienna, Austria.
C3 Austrian Academy of Sciences; CeMM Research Center for Molecular
   Medicine of the Austrian Academy of Sciences; Medical University of
   Vienna
RP Binder, CJ (通讯作者)，Med Univ Vienna, CeMM, Lazarettgasse 14,Bauteil 25-2-6, A-1090 Vienna, Austria.
EM christoph.binder@meduniwien.ac.at
OI Binder, Christoph J./0000-0001-8313-7050
FU Austrian Academy of Sciences; Austrian Research Promotion Agency (FFG);
   SFB Lipotox F30 of the Austrian Science Fund (FWF); Fondation Leducq
FX D.W. and C.J.B. were supported by the Austrian Academy of Sciences, a
   BRIDGE grant from the Austrian Research Promotion Agency (FFG), the SFB
   Lipotox F30 of the Austrian Science Fund (FWF), and the Fondation
   Leducq.
CR Baumgarth N, 2005, SPRINGER SEMIN IMMUN, V26, P347, DOI 10.1007/s00281-004-0182-2
   Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901
   Berland R, 2002, ANNU REV IMMUNOL, V20, P253, DOI 10.1146/annurev.immunol.20.100301.064833
   Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6
   Berliner JA, 2008, FREE RADICAL BIO MED, V45, P119, DOI 10.1016/j.freeradbiomed.2008.04.013
   Binder CJ, 2002, NAT MED, V8, P1218, DOI 10.1038/nm1102-1218
   Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876
   Bochkov VN, 2010, ANTIOXID REDOX SIGN, V12, P1009, DOI 10.1089/ars.2009.2597
   Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023
   Borisenko GG, 2004, CELL DEATH DIFFER, V11, P943, DOI 10.1038/sj.cdd.4401421
   Boullier A, 2005, J LIPID RES, V46, P969, DOI 10.1194/jlr.M400496-JLR200
   BRILES DE, 1982, J EXP MED, V156, P1177, DOI 10.1084/jem.156.4.1177
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763
   Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Deguchi H, 2000, P NATL ACAD SCI USA, V97, P1743, DOI 10.1073/pnas.97.4.1743
   Dei R, 2002, ACTA NEUROPATHOL, V104, P113, DOI 10.1007/s00401-002-0523-y
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Duryee MJ, 2010, FREE RADICAL BIO MED, V49, P1480, DOI 10.1016/j.freeradbiomed.2010.08.001
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404
   Fadok VA, 1998, J IMMUNOL, V161, P6250
   Faria-Neto JR, 2006, ATHEROSCLEROSIS, V189, P83, DOI 10.1016/j.atherosclerosis.2005.11.033
   FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gillotte-Taylor K, 2001, J LIPID RES, V42, P1474
   Goverdhan SV, 2006, ATHEROSCLEROSIS, V188, P213, DOI 10.1016/j.atherosclerosis.2006.04.013
   Greaves DR, 2009, J LIPID RES, V50, pS282, DOI 10.1194/jlr.R800066-JLR200
   Greenberg ME, 2006, J EXP MED, V203, P2613, DOI 10.1084/jem.20060370
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harnett W, 1999, IMMUNOL TODAY, V20, P125, DOI 10.1016/S0167-5699(98)01419-4
   Hazen SL, 2008, J BIOL CHEM, V283, P15527, DOI 10.1074/jbc.R700054200
   HECKER M, 1989, J BIOL CHEM, V264, P141
   Hirschfield GM, 2005, P NATL ACAD SCI USA, V102, P8309, DOI 10.1073/pnas.0503202102
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853
   Huber J, 2002, ARTERIOSCL THROM VAS, V22, P101, DOI 10.1161/hq0102.101525
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Janeway Jr CA, 2001, IMMUNOBIOLOGY
   JURGENS G, 1986, BIOCHIM BIOPHYS ACTA, V875, P103, DOI 10.1016/0005-2760(86)90016-0
   Kagan VE, 2009, FREE RADICAL BIO MED, V46, P1439, DOI 10.1016/j.freeradbiomed.2009.03.004
   Kagan VE, 2004, FREE RADICAL BIO MED, V37, P1963, DOI 10.1016/j.freeradbiomed.2004.08.016
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125
   Kuchibhotla S, 2008, CARDIOVASC RES, V78, P185, DOI 10.1093/cvr/cvm093
   Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200
   Kyaw T, 2011, CIRC RES, V109, P830, DOI 10.1161/CIRCRESAHA.111.248542
   Lewis MJ, 2009, CIRCULATION, V120, P417, DOI 10.1161/CIRCULATIONAHA.109.868158
   LI YP, 1994, J IMMUNOL, V152, P2995
   Lysenko E, 2000, MOL MICROBIOL, V35, P234, DOI 10.1046/j.1365-2958.2000.01707.x
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Miller YI, 2010, SUBCELL BIOCHEM, V51, P229, DOI 10.1007/978-90-481-8622-8_8
   MOLD C, 1981, J EXP MED, V154, P1703, DOI 10.1084/jem.154.5.1703
   Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061
   NARKATES AJ, 1982, ANN NY ACAD SCI, V389, P172, DOI 10.1111/j.1749-6632.1982.tb22135.x
   NEALE TJ, 1994, J CLIN INVEST, V94, P1577, DOI 10.1172/JCI117499
   NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231
   Ogden CA, 2005, AUTOIMMUNITY, V38, P259, DOI 10.1080/08916930500124452
   OHYA T, 1993, BIOL PHARM BULL, V16, P137
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   Ortiz MA, 2009, EXP BIOL MED, V234, P624, DOI 10.3181/0812-RM-347
   Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X
   Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200
   Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200
   Podrez EA, 2007, NAT MED, V13, P1086, DOI 10.1038/nm1626
   Reifenberg K, 2005, ARTERIOSCL THROM VAS, V25, P1641, DOI 10.1161/01.ATV.0000171983.95612.90
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   SAMBRANO GR, 1994, P NATL ACAD SCI USA, V91, P3265, DOI 10.1073/pnas.91.8.3265
   Perez MJ, 2006, ALCOHOL ALCOHOLISM, V41, P593, DOI 10.1093/alcalc/agl077
   Schaur R. J., 2003, Molecular Aspects of Medicine, V24, P149, DOI 10.1016/S0098-2997(03)00009-8
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schwedler SB, 2005, CIRCULATION, V112, P1016, DOI 10.1161/CIRCULATIONAHA.105.556530
   SEIFERT PS, 1989, ARTERIOSCLEROSIS, V9, P802, DOI 10.1161/01.ATV.9.6.802
   Shao B, 2009, J LIPID RES, V50, P599, DOI 10.1194/jlr.E900001-JLR200
   Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472
   SHECHTER I, 1981, J LIPID RES, V22, P63
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   Singh U, 2008, J LIPID RES, V49, P1015, DOI 10.1194/jlr.M700535-JLR200
   Sofat R, 2010, ATHEROSCLEROSIS, V213, P184, DOI 10.1016/j.atherosclerosis.2010.07.021
   Steinberg D, 2010, ARTERIOSCL THROM VAS, V30, P2311, DOI 10.1161/ATVBAHA.108.179697
   STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0
   Suzuki M, 2007, MOL VIS, V13, P772
   Szalai AJ, 2000, INFECT IMMUN, V68, P5652, DOI 10.1128/IAI.68.10.5652-5656.2000
   SZALAI AJ, 1995, J IMMUNOL, V155, P2557
   Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675
   Tennent GA, 2008, ATHEROSCLEROSIS, V196, P248, DOI 10.1016/j.atherosclerosis.2007.05.010
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thiele Geoffrey M, 2004, Comp Hepatol, V3 Suppl 1, pS25, DOI 10.1186/1476-5926-2-S1-S25
   Trion A, 2005, ARTERIOSCL THROM VAS, V25, P1635, DOI 10.1161/01.ATV.0000171992.36710.1e
   Tuma DJ, 1996, HEPATOLOGY, V23, P872, DOI 10.1002/hep.510230431
   Tuominen A, 2006, ARTERIOSCL THROM VAS, V26, P2096, DOI 10.1161/01.ATV.0000233333.07991.4a
   Tyurin VA, 2008, J NEUROCHEM, V107, P1614, DOI 10.1111/j.1471-4159.2008.05728.x
   Tyurina YY, 2004, BIOCHEM BIOPH RES CO, V324, P1059, DOI 10.1016/j.bbrc.2004.09.102
   van Tits L, 2005, ARTERIOSCL THROM VAS, V25, P717, DOI 10.1161/01.ATV.0000157979.51673.2c
   Verma S, 2005, NAT CLIN PRACT CARD, V2, P29, DOI 10.1038/ncpcardio0074
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Xu DS, 1997, CHEM RES TOXICOL, V10, P978, DOI 10.1021/tx970069t
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 124
TC 112
Z9 115
U1 0
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
EI 0006-3002
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD OCT
PY 2012
VL 1818
IS 10
SI SI
BP 2465
EP 2475
DI 10.1016/j.bbamem.2012.01.018
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 983RD
UT WOS:000307135500010
PM 22305963
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Randazzo, J
   Zhang, ZF
   Hoff, M
   Kawada, H
   Sachs, A
   Yuan, Y
   Haider, N
   Kador, P
AF Randazzo, James
   Zhang, Zifeng
   Hoff, Michael
   Kawada, Hiroyoshi
   Sachs, Andrew
   Yuan, Yang
   Haider, Neena
   Kador, Peter
TI Orally Active Multi-Functional Antioxidants Are Neuroprotective in a Rat
   Model of Light-Induced Retinal Damage
SO PLOS ONE
LA English
DT Article
ID TERT-BUTYLNITRONE PROTECTS; PIGMENT EPITHELIAL-CELLS; ROD OUTER
   SEGMENTS; LIPID-PEROXIDATION; MACULAR DEGENERATION; OXIDATIVE STRESS;
   VISUAL IMPAIRMENT; PHOTIC INJURY; INDUCTION; IRON
AB Background: Progression of age-related macular degeneration has been linked to iron dysregulation and oxidative stress that induce apoptosis of neural retinal cells. Since both antioxidants and chelating agents have been reported to reduce the progression of retinal lesions associated with AMD in experimental animals, the present study evaluates the ability of multi-functional antioxidants containing functional groups that can independently chelate redox metals and quench free radicals to protect the retina against light-induced retinal degeneration, a rat model of dry atrophic AMD.
   Methods/Results: Proof of concept studies were conducted to evaluate the ability of 4-(5-hydroxypyrimidin-2-yl)-N,N-dimethyl-3,5-dioxopiperazine-1-sulfonamide (compound 4) and 4-(5-hydroxy-4,6-dimethoxypyrimidin-2-yl)-N,N-dimethyl-3,5-dioxopiperazine-1-sulfonamide (compound 8) to reduce retinal damage in 2-week dark adapted Wistar rats exposed to 1000 lx of light for 3 hours. Assessment of the oxidative stress markers 4- hydroxynonenal and nitrotyrosine modified proteins and Thioredoxin by ELISA and Western blots indicated that these compounds reduced the oxidative insult caused by light exposure. The beneficial antioxidant effects of these compounds in providing significant functional and structural protection were confirmed by electroretinography and quantitative histology of the retina.
   Conclusions/Significance: The present study suggests that multi-functional compounds may be effective candidates for preventive therapy of AMD.
C1 [Randazzo, James; Zhang, Zifeng; Hoff, Michael; Kawada, Hiroyoshi; Kador, Peter] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA.
   [Sachs, Andrew; Yuan, Yang; Haider, Neena] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE USA.
   [Haider, Neena; Kador, Peter] Univ Nebraska Med Ctr, Dept Ophthalmol, Omaha, NE USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center
RP Randazzo, J (通讯作者)，Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA.
EM pkador@unmc.edu
FU National Institutes of Health [EY016730]; Therapeutic Vision, Inc.
   (Omaha, NE); NATIONAL EYE INSTITUTE [R01EY016730] Funding Source: NIH
   RePORTER
FX This work was supported by National Institutes of Health grant EY016730
   and an unrestricted grant from Therapeutic Vision, Inc. (Omaha, NE). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X
   BIRCH DG, 1980, EXP NEUROL, V68, P269, DOI 10.1016/0014-4886(80)90085-0
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brewer GJ, 2007, EXP BIOL MED, V232, P323
   BUCKSER STANLEY, 1968, CURR MOD BIOL, V2, P14
   Busch EM, 1999, PHOTOCHEM PHOTOBIOL, V70, P353, DOI 10.1562/0031-8655(1999)070<0353:TEOTSO>2.3.CO;2
   Catala A, 2009, CHEM PHYS LIPIDS, V157, P1, DOI 10.1016/j.chemphyslip.2008.09.004
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   GAUNTT CD, 1994, INVEST OPHTH VIS SCI, V35, P2916
   GREEN DG, 1973, J PHYSIOL-LONDON, V228, P781, DOI 10.1113/jphysiol.1973.sp010112
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hardten D R, 1989, Prog Clin Biol Res, V314, P377
   Jin HX, 2010, J MED CHEM, V53, P1117, DOI 10.1021/jm901381j
   Kuhn F J, 1990, Lens Eye Toxic Res, V7, P667
   LI ZL, 1991, CURR EYE RES, V10, P133, DOI 10.3109/02713689109001741
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Marc RE, 2008, MOL VIS, V14, P782
   MCKECHNIE NM, 1977, A GRAEF ARCH KLIN EX, V203, P283, DOI 10.1007/BF00409834
   Mittag TW, 1999, EXP EYE RES, V69, P677, DOI 10.1006/exer.1999.0748
   Moon S, 2005, INVEST OPHTH VIS SCI, V46, P3783, DOI 10.1167/iovs.05-0237
   Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nystuen AM, 2008, MAMM GENOME, V19, P623, DOI 10.1007/s00335-008-9138-5
   OHIRA A, 1994, LAB INVEST, V70, P279
   Ohishi K, 2005, FREE RADICAL RES, V39, P875, DOI 10.1080/10715760500177807
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   ORGANISCIAK DT, 1992, INVEST OPHTH VIS SCI, V33, P1599
   Pratt DA, 2001, J AM CHEM SOC, V123, P4625, DOI 10.1021/ja005679l
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Ranchon I, 1999, INVEST OPHTH VIS SCI, V40, P1191
   Ranchon I, 2003, J NEUROSCI, V23, P6050, DOI 10.1523/JNEUROSCI.23-14-06050.2003
   Ranchon I, 2001, INVEST OPHTH VIS SCI, V42, P1375
   REME CE, 1991, PHOTOCHEM PHOTOBIOL, V54, P137, DOI 10.1111/j.1751-1097.1991.tb01997.x
   ROSNER M, 1992, ARCH OPHTHALMOL-CHIC, V110, P857, DOI 10.1001/archopht.1992.01080180129040
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOMOGYI M, 1945, J BIOL CHEM, V160, P69
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tanito M, 2005, J NEUROSCI, V25, P2396, DOI 10.1523/JNEUROSCI.4866-04.2005
   Tanito M, 2006, NEUROSCI LETT, V398, P63, DOI 10.1016/j.neulet.2005.12.070
   Tanito M, 2006, FREE RADICAL BIO MED, V41, P1847, DOI 10.1016/j.freeradbiomed.2006.09.012
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1864, DOI 10.1167/iovs.06-1065
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   WANG M, 1995, RES COMMUN MOL PATH, V89, P291
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Yamamoto M, 1997, EXP EYE RES, V65, P645, DOI 10.1006/exer.1997.0370
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
NR 53
TC 15
Z9 16
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2011
VL 6
IS 7
AR e21926
DI 10.1371/journal.pone.0021926
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 793HP
UT WOS:000292811300027
PM 21779355
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hirasawa, M
   Noda, K
   Noda, S
   Suzuki, M
   Ozawa, Y
   Shinoda, K
   Inoue, M
   Ogawa, Y
   Tsubota, K
   Ishida, S
AF Hirasawa, Manabu
   Noda, Kousuke
   Noda, Setsuko
   Suzuki, Misa
   Ozawa, Yoko
   Shinoda, Kei
   Inoue, Makoto
   Ogawa, Yoko
   Tsubota, Kazuo
   Ishida, Susumu
TI Transcriptional factors associated with epithelial-mesenchymal
   transition in choroidal neovascularization
SO MOLECULAR VISION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; SNAIL EXPRESSION;
   PHOTODYNAMIC THERAPY; CELL-LINES; E-CADHERIN; CARCINOMA; PATHOGENESIS;
   MEMBRANES; FIBROSIS
AB Purpose: To investigate the transcriptional factors associated with epithelial-mesenchymal transition (EMT) in choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Methods: Paraffin sections of CNV obtained from patients with AMD (n = 12) were stained for transcriptional factors related to EMT, i.e., Snail, Slug, SIP1, and Twist. As a control, postmortem sections of ocular normal tissue were used. Furthermore, using a human retinal pigment epithelial (RPE) cell line (ARPE-19), reverse transcription-polymerase chain reaction (RT-PCR) and immunofluorescence microscopy were performed to explore the cellular localization and expression levels of EMT-associated transcriptional factors upon cytokine stimulation.
   Results: Of 12 specimens, 11 CNV tissues (91.6%) showed staining for Snail localized in cellular nuclei, particularly in those of RPE cells. Snail was strongly co-localized with a-smooth muscle antigen (SMA) in RPE cells. In contrast, postmortem human retina showed no Snail staining in RPE cells. Other transcriptional factors, Slug, Twist and SIP1 were not detected in CNV or normal human retina. In ARPE-19 cells, RT-PCR and immunofluorescence microscopy showed that Snail mRNA was upregulated by transforming growth factor (TGF)-beta and VEGF stimulation. Furthermore, TGF-beta induced relocalization of Snail to the nucleus in RPE cells.
   Conclusions: The current data indicate that Snail is a major transcriptional factor for EMT changes of RPE cells in human CNV.
C1 [Noda, Kousuke] Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Kita Ku, Sapporo, Hokkaido 0608638, Japan.
   [Hirasawa, Manabu; Noda, Kousuke; Suzuki, Misa; Ozawa, Yoko; Ishida, Susumu] Keio Univ, Sch Med, Lab Retinal Cell Biol, Tokyo, Japan.
   [Hirasawa, Manabu; Ozawa, Yoko; Ogawa, Yoko; Tsubota, Kazuo; Ishida, Susumu] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Noda, Setsuko] Tokai Univ, Sch Hlth Sci, Dept Nursing, Isehara, Kanagawa, Japan.
   [Suzuki, Misa] Yokohama City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Yokohama, Kanagawa 232, Japan.
   [Shinoda, Kei] Teikyo Univ, Sch Med, Dept Ophthalmol, Tokyo 173, Japan.
   [Inoue, Makoto] Kyorin Univ, Sch Med, Kyorin Eye Ctr, Tokyo, Japan.
C3 Hokkaido University; Keio University; Keio University; Tokai University;
   Yokohama City University; Teikyo University; Kyorin University
RP Noda, K (通讯作者)，Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Kita Ku, N-15,W-7, Sapporo, Hokkaido 0608638, Japan.
EM nodako@med.hokudai.ac.jp
RI ISHIDA, SUSUMU/D-7067-2012; Ozawa, Yoko/AAH-9888-2020; Ogawa,
   Yoko/AAV-1932-2021; Shinoda, Kei/ABC-7993-2020
OI Ogawa, Yoko/0000-0002-2906-9621; Shinoda, Kei/0000-0002-1543-9345
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan [05-045-0337]
FX This work was supported by Grant-in-Aid for Young Scientists (B)
   (05-045-0337) of the Ministry of Education, Culture, Sports, Science and
   Technology (MEXT), Japan, which provided generous funds for laboratory
   equipment used in this project. We would like to thank Haruna Koizumi
   and Ichie Kawamori for their support.
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Boutet A, 2006, EMBO J, V25, P5603, DOI 10.1038/sj.emboj.7601421
   Boutet A, 2007, CELL CYCLE, V6, P638, DOI 10.4161/cc.6.6.4022
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946
   Espineda CE, 2004, MOL BIOL CELL, V15, P1364, DOI 10.1091/mbc.E03-09-0646
   Gonzalez-Moreno O, 2010, EXP CELL RES, V316, P554, DOI 10.1016/j.yexcr.2009.11.020
   Green W R, 1999, Mol Vis, V5, P27
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Katoh M, 2005, ONCOL REP, V14, P1083
   Kent D, 2003, MOL VIS, V9, P747
   Kojc N, 2009, VIRCHOWS ARCH, V454, P549, DOI 10.1007/s00428-009-0771-5
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1132, DOI 10.1097/IAE.0b013e318170d76d
   Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   NIETO MA, 1992, DEVELOPMENT, V116, P227
   Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Parapuram SK, 2009, INVEST OPHTH VIS SCI, V50, P5965, DOI 10.1167/iovs.09-3621
   Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200
   Riusala A, 2005, GRAEF ARCH CLIN EXP, V243, P947, DOI 10.1007/s00417-005-1161-6
   Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1
   Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156
   Saika Shizuya, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P69, DOI 10.2174/187153008783928343
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Van Aken EH, 2003, INVEST OPHTH VIS SCI, V44, P463, DOI 10.1167/iovs.01-1096
   Vetter G, 2009, BIOCHEM BIOPH RES CO, V385, P485, DOI 10.1016/j.bbrc.2009.05.025
   Waldmann J, 2008, BRIT J CANCER, V99, P1900, DOI 10.1038/sj.bjc.6604755
   Wanami LS, 2008, EXP CELL RES, V314, P2448, DOI 10.1016/j.yexcr.2008.05.004
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Winkler BS, 1999, MOL VIS, V5
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 47
TC 44
Z9 46
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAY 6
PY 2011
VL 17
IS 137
BP 1222
EP 1230
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 760BF
UT WOS:000290295600001
PM 21617757
DA 2022-11-30
ER

PT J
AU Maar, N
   Pemp, B
   Kircher, K
   Luksch, A
   Weigert, G
   Polska, E
   Tittl, M
   Stur, M
   Schmetterer, L
AF Maar, Noemi
   Pemp, Berthold
   Kircher, Karl
   Luksch, Alexandra
   Weigert, Guenther
   Polska, Elzbieta
   Tittl, Michael
   Stur, Michael
   Schmetterer, Leopold
TI Ocular haemodynamic changes after single treatment with photodynamic
   therapy assessed with non-invasive techniques
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE blood flow; choroidal neovascularization; macular degeneration;
   photodynamic therapy
ID CHOROIDAL BLOOD-FLOW; LASER INTERFEROMETRIC MEASUREMENT; RANDOMIZED
   CLINICAL-TRIALS; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; FUNDUS
   PULSATION; VISUAL-ACUITY; NEOVASCULARIZATION SECONDARY; PNEUMOTONOMETRIC
   MEASUREMENT; LESION SIZE
AB Purpose:
   To investigate in patients with neovascular age-related macular degeneration (ARMD) the changes in ocular perfusion caused by single treatment with photodynamic therapy (PDT) by different non-invasive methods; to evaluate correlations between relative changes of ocular haemodynamic parameters after PDT among each other and compared to morphological parameters; and to assess this in relation to early changes of visual acuity.
   Methods:
   Study population: 17 consecutive patients with subfoveal choroidal neovascularization (CNV) caused by ARMD scheduled for PDT without previous PDT treatment (four patients with predominantly classic CNV and 13 patients with occult CNV). Observation procedures: best-corrected visual acuity (before PDT, 6 and 8 weeks after PDT), fundus photography, fluorescein angiography, haemodynamic measurements with laser Doppler flowmetry (LDF), laser interferometry and ocular blood flow (OBF) tonometry (baseline and 1, 2, 6 and 8 weeks after treatment). Main outcome measures: choroidal blood flow (CHBF), fundus pulsation amplitude (FPA), pulsatile ocular blood flow (POBF), visual acuity. Changes smaller than 20% were considered clinically irrelevant.
   Results:
   Ocular haemodynamic parameters did not change significantly in the follow-up period. Changes of haemodynamic parameters showed no correlation to treatment spot, morphological changes or visual acuity. Changes of visual acuity were comparable to results of earlier studies.
   Conclusion:
   Single treatment with PDT did not modify ocular blood flow parameters above 20% as assessed with different non-invasive methods.
C1 [Schmetterer, Leopold] Med Univ Vienna, Ctr Biomed Engn & Phys, A-1090 Vienna, Austria.
   [Pemp, Berthold; Weigert, Guenther; Polska, Elzbieta; Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Maar, Noemi; Kircher, Karl; Luksch, Alexandra; Tittl, Michael; Stur, Michael] Med Univ Vienna, Dept Ophthalmol & Optometry, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Schmetterer, L (通讯作者)，Med Univ Vienna, Ctr Biomed Engn & Phys, Wahringerstr 13, A-1090 Vienna, Austria.
EM leopold.schmetterer@meduniwien.ac.at
OI Schmetterer, Leopold/0000-0002-7189-1707; Pemp,
   Berthold/0000-0002-0569-0229
CR [Anonymous], [No title captured]
   BARDAK Y, 2006, AVRO ABSTR
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHEN JC, 2002, AVRO ABSTR
   Chen SJ, 2004, EYE, V18, P595, DOI 10.1038/sj.eye.6700723
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   DOUGHERTY TJ, 1990, PHOTODYNAMIC THERAPY, P1
   Figueroa M, 2004, BRIT J OPHTHALMOL, V88, P792, DOI 10.1136/bjo.2003.033837
   Geiser MH, 1999, KLIN MONATSBL AUGENH, V214, P285, DOI 10.1055/s-2008-1034795
   Geiser MH, 2000, CURR EYE RES, V21, P669, DOI 10.1076/0271-3683(200008)21:2;1-V;FT669
   GOMER CJ, 1989, SEMIN HEMATOL, V26, P27
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   KAGOKAWA H, 2006, AVRO ABSTR
   KAGOKAWA H, 2005, AVRO ABSTR
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KREIMERBIRNBAUM M, 1989, SEMIN HEMATOL, V26, P157
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MANYAK MJ, 1988, J CLIN ONCOL, V6, P380, DOI 10.1200/JCO.1988.6.2.380
   MAREUS S, 1990, FUTURE DIRECTIONS AP, P5
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Parodi MB, 2003, BRIT J OPHTHALMOL, V87, P177, DOI 10.1136/bjo.87.2.177
   Polska E, 2004, BRIT J OPHTHALMOL, V88, P533, DOI 10.1136/bjo.2003.028480
   ROBERTS WG, 1992, CANCER RES, V52, P924
   Sandhu R, 2007, EYE, V21, P506, DOI 10.1038/sj.eye.6702242
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmetterer L, 2000, EYE, V14, P39, DOI 10.1038/eye.2000.9
   Schmetterer L, 2000, EYE, V14, P46, DOI 10.1038/eye.2000.10
   Schmetterer L, 1998, GRAEF ARCH CLIN EXP, V236, P160, DOI 10.1007/s004170050058
   Schmetterer L, 1998, INVEST OPHTH VIS SCI, V39, P1210
   SCHMETTERER LF, 1995, OPT ENG, V34, P711, DOI 10.1117/12.193292
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   SILVER DM, 1989, ACTA OPHTHALMOL, V67, P25
   SILVER DM, 1994, SURV OPHTHALMOL S, V38, P72
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WALKER RE, 1975, EXP EYE RES, V20, P245, DOI 10.1016/0014-4835(75)90138-4
   WALKER RE, 1972, EXP EYE RES, V13, P14, DOI 10.1016/0014-4835(72)90120-0
NR 46
TC 8
Z9 8
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2009
VL 87
IS 6
BP 631
EP 637
DI 10.1111/j.1755-3768.2008.01311.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 488LF
UT WOS:000269350500007
PM 19416111
OA Bronze
DA 2022-11-30
ER

PT J
AU Khachik, F
   Chang, AN
AF Khachik, Frederick
   Chang, An-Ni
TI Total Synthesis of (3R,3 ' R,6 ' R)-Lutein and Its Stereoisomers
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID STRUCTURALLY RELATED-COMPOUNDS; ACTIVE NATURAL CAROTENOIDS; TECHNICAL
   PROCEDURES; XANTHOPHYLL LUTEIN; HUMAN PLASMA; ABSOLUTE-CONFIGURATION;
   GEOMETRICAL-ISOMERS; OXIDATION-PRODUCTS; K-SELECTRIDE; REDUCTION
AB (3R,3'R,6'R)-Lutein (1) is a major dietary carotenoid that is abundant in most fruits and vegetables commonly consumed in the U.S. and that accumulates in the human plasma, major organs, and ocular tissues. Numerous epidemiological and experimental studies have shown that 1 has important biological activities and may play an important role in the prevention of age-related macular degeneration (AMD). While the total synthesis of 1 has been previously reported in a poor overall yield, the total synthesis of the other seven stereoisomers of lutein has not yet been accomplished. We have developed a relatively straightforward methodology for the total synthesis of 1 and three of its stereoisomers, (3R,3'S,6'S)-lutein (2), (3R,3'S,6'R)-lutein or 3'-epilutein (3), and (3R,3'R,6'S)-lutein (4) by C(15) + C(10) + C(15) Wittig coupling reactions. Employing this methodology, the other four stereoisomers of lutein that are enantiomeric to the aforementioned lutein isomers can be similarly prepared. One of the important features of this strategy is its application to the total synthesis of (13)C-labeled luteins and their metabolites with appropriate stereochemistry for metabolic studies in animals and humans. This synthesis also provides access to the C(15)-precursors of optically active carotenoids with a 3-hydroxy-epsilon end group that are otherwise difficult to synthesize.
C1 [Khachik, Frederick; Chang, An-Ni] Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.
C3 University System of Maryland; University of Maryland College Park
RP Khachik, F (通讯作者)，Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.
EM khachik@umd.edu
RI Khachik, Frederick/C-5055-2009
FU Joint Institute for Food Safety and Applied Nutrition (JIFSAN);
   University of Maryland-Food and Drug Administration (UM-FDA
FX The authors thank the Joint Institute for Food Safety and Applied
   Nutrition (JIFSAN), University of Maryland-Food and Drug Administration
   (UM-FDA) for financial support.
CR ANDRIAMIALISOA Z, 1993, TETRAHEDRON LETT, V34, P8091, DOI 10.1016/S0040-4039(00)61459-4
   BELL RA, 1981, TETRAHEDRON LETT, V22, P4871, DOI 10.1016/S0040-4039(01)92368-8
   BERNHARD K, 1980, HELV CHIM ACTA, V63, P1473, DOI 10.1002/hlca.19800630618
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BUCHECKE.R, 1972, CHIMIA, V26, P134
   BUCHECKE.R, 1974, HELV CHIM ACTA, V57, P631, DOI 10.1002/hlca.19740570317
   BUCHECKER R, 1979, HELV CHIM ACTA, V62, P2817, DOI 10.1002/hlca.19790620831
   BUCHECKER R, 1971, CHIMIA, V25, P192
   COREY EJ, 1987, J AM CHEM SOC, V109, P5551, DOI 10.1021/ja00252a056
   COREY EJ, 1987, J AM CHEM SOC, V109, P7925, DOI 10.1021/ja00259a075
   DAUBEN WG, 1978, TETRAHEDRON LETT, P4487
   DUGGER RW, 1980, SYNTHETIC COMMUN, V10, P509, DOI 10.1080/00397918008069326
   ENGLERT G, 1982, CAROTENOID CHEM BIOC, P107
   Englert G., 1995, CAROTENOIDS, V1, P147
   GONDOS G, 1982, J CHEM SOC CHEM COMM, P1239, DOI 10.1039/c39820001239
   HAAG A, 1985, HELV CHIM ACTA, V68, P1897, DOI 10.1002/hlca.19850680713
   HAUGAN JA, 1994, ACTA CHEM SCAND, V48, P657, DOI 10.3891/acta.chem.scand.48-0657
   Humphries JM, 2003, J AGR FOOD CHEM, V51, P1322, DOI 10.1021/jf026073e
   Imai H, 1999, PHOTOCHEM PHOTOBIOL, V70, P111, DOI 10.1111/j.1751-1097.1999.tb01956.x
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2003, J NAT PROD, V66, P67, DOI 10.1021/np020376l
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   KHACHIK F, 1995, J LABELLED COMPD RAD, V36, P1157, DOI 10.1002/jlcr.2580361206
   KHACHIK F, 1992, J CHROMATOGR-BIOMED, V582, P153, DOI 10.1016/0378-4347(92)80314-G
   KHACHIK F, 1992, ANAL CHEM, V64, P2111, DOI 10.1021/ac00042a016
   Khachik F, 1995, US Patent, Patent No. [5,382,714, 5382714]
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5476, DOI 10.1167/iovs.06-0194
   Khachik F, 2006, PURE APPL CHEM, V78, P1551, DOI 10.1351/pac200678081551
   Marwah P, 2004, GREEN CHEM, V6, P570, DOI 10.1039/b408974j
   MAYER H, 1980, HELV CHIM ACTA, V63, P1451, DOI 10.1002/hlca.19800630614
   PRELOG V, 1952, HELV CHIM ACTA, V35, P986, DOI 10.1002/hlca.19520350339
   SCHALCH W, 1999, CRC MOD NUT, P215
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   SOUKUP M, 1990, HELV CHIM ACTA, V73, P868, DOI 10.1002/hlca.19900730412
   SOUKUP M, 1995, CAROTENOIDS, V2, P7
   TAL DM, 1984, TETRAHEDRON, V40, P851, DOI 10.1016/S0040-4020(01)91473-5
   Tode C, 2002, J CHEM SOC PERK T 1, P1581, DOI 10.1039/b201228f
   WIDMER E, 1990, HELV CHIM ACTA, V73, P861, DOI 10.1002/hlca.19900730411
   WIDMER E, 1982, HELV CHIM ACTA, V65, P944, DOI 10.1002/hlca.19820650327
   Yamano Y, 2000, HETEROCYCLES, V52, P141
   Yang M, 2006, SYNLETT, P2617, DOI 10.1055/s-2006-951476
   Young WG, 1944, J AM CHEM SOC, V66, P520, DOI 10.1021/ja01232a005
   Yu JQ, 2002, ORG LETT, V4, P2727, DOI 10.1021/ol0262340
NR 47
TC 35
Z9 37
U1 0
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD MAY 15
PY 2009
VL 74
IS 10
BP 3875
EP 3885
DI 10.1021/jo900432r
PG 11
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)
SC Chemistry
GA 444OV
UT WOS:000265991200035
PM 19391613
DA 2022-11-30
ER

PT J
AU Silva, RLE
   Kachi, S
   Akiyama, H
   Shen, JK
   Aslam, S
   Gong, YY
   Khu, NH
   Hatara, MC
   Boutaud, A
   Peterson, R
   Campochiaro, PA
AF Silva, Raquel Lima E.
   Kachi, Shu
   Akiyama, Hideo
   Shen, Jikui
   Aslam, Sadia
   Gong, Yuan Yuan
   Khu, Naw Htee
   Hatara, Maria C.
   Boutaud, Ariel
   Peterson, Robert
   Campochiaro, Peter A.
TI Recombinant non-collagenous domain of alpha 2(IV) collagen causes
   involution of choroidal neovascularization by inducing apoptosis
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; DISTINCT ANTITUMOR PROPERTIES; BLOOD-RETINAL
   BARRIER; BASEMENT-MEMBRANE; IV COLLAGEN; TUMOR-GROWTH; OCULAR
   NEOVASCULARIZATION; INTEGRIN ALPHA(V)BETA(3); ALPHA(5)BETA(1) INTEGRIN;
   INDUCED BREAKDOWN
AB Vascular endothelial cells receive proangiogenic or antiangiogenic signals from components of extracellular matrix (ECM) depending upon the situation and many molecular signals can have opposite effects in different vascular beds. Tissue inhibitor of metalloproteinase 1 is antiangiogenic in several tissues, but promotes retinal neovascularization. When cleaved from native collagens, several of the non-collagenous domains (NC1) of basement membrane collagens have antiangiogenic effects in some tissues, but this is context dependent for the NC1 of the alpha 1 chain of collagen IV. It is critical to examine effects in several well-defined model systems before assuming that an ECM component is universally antiangiogenic. In this study, we examined the effects of a recombinant fragment of NCl of the alpha 2 chain of type IV collagen (alpha 2(IV)NC1) in a well-characterized model of ocular neovascularization. Intravitreous or periocular injections of alpha 2(IV)NC1 caused selective apoptosis of endothelial cells participating in neovascularization resulting in suppression of neovascularization when the peptide was given prior to onset of new vessel sprouting. Importantly, when the peptide was given after neovascularization had already developed, it caused the new vessels to regress. This suggests that alpha 2(IV)NC1, which has previously been shown to suppress tumor angiogenesis in xenograft models, is also a strong antiangiogenic agent in the choroid and is a therapeutic candidate for treatment of neovascular age-related macular degeneration.
C1 Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
   BioStratum Inc, Durham, NC USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
FU NATIONAL EYE INSTITUTE [P30EY001765, R01EY012609] Funding Source: NIH
   RePORTER; NEI NIH HHS [P30EY1765, EY05951, EY12609] Funding Source:
   Medline
CR Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Collo G, 1999, J CELL SCI, V112, P569
   Colorado PC, 2000, CANCER RES, V60, P2520
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Fleischmajer R, 1997, J INVEST DERMATOL, V109, P527, DOI 10.1111/1523-1747.ep12336696
   FORM DM, 1986, LAB INVEST, V55, P521
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HUDSON BG, 1993, J BIOL CHEM, V268, P26033
   Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Luna J, 1996, LAB INVEST, V75, P563
   MADRI JA, 1989, LAB INVEST, V60, P755
   Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200
   Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200
   Magnussen A, 2005, CANCER RES, V65, P2712, DOI 10.1158/0008-5472.CAN-04-2691
   MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   OBERBAUMER I, 1982, EMBO J, V1, P805, DOI 10.1002/j.1460-2075.1982.tb01251.x
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106
   Parsons-Wingerter P, 2005, AM J PATHOL, V167, P193, DOI 10.1016/S0002-9440(10)62965-3
   Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051
   Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Shahan T, 2004, CONNECT TISSUE RES, V45, P151, DOI 10.1080/03008200490505923
   SHEN GQ, 1990, CONNECT TISSUE RES, V24, P289, DOI 10.3109/03008209009152156
   Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tanaka K, 1997, HISTOCHEM J, V29, P563, DOI 10.1023/A:1026428010104
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111
NR 41
TC 10
Z9 10
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2006
VL 208
IS 1
BP 161
EP 166
DI 10.1002/jcp.20645
PG 6
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 050RX
UT WOS:000238106700017
PM 16557520
DA 2022-11-30
ER

PT J
AU Ditlevsen, S
   Christensen, U
   Lynch, J
   Damsgaard, MT
   Keiding, N
AF Ditlevsen, S
   Christensen, U
   Lynch, J
   Damsgaard, MT
   Keiding, N
TI The mediation proportion - A structural equation approach for estimating
   the proportion of exposure effect on outcome explained by an
   intermediate variable
SO EPIDEMIOLOGY
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; COOK-MEDLEY HOSTILITY; SURROGATE
   END-POINTS; CANCER-RESEARCH; RISK-FACTORS; VALIDATION; MORTALITY; MARKER
AB It is often of interest to assess how much of the effect of an exposure on a response is mediated through an intermediate variable. However, systematic approaches are lacking, other than assessment of a surrogate marker for the endpoint of a clinical trial. We review a measure of "proportion explained" in the context of observational epidemiologic studies. The measure has been much debated; we show how several of the drawbacks are alleviated when exposures, mediators, and responses are continuous and are embedded in a structural equation framework. These conditions also allow for consideration of several intermediate variables. Binary or categorical variables can be included directly through threshold models. We call this measure the mediation proportion, that is, the part of an exposure effect on outcome explained by a third, intermediate variable. Two examples illustrate the approach. The first example is a randomized clinical trial of the effects of interferon-a on visual acuity in patients with age-related macular degeneration. In this example, the exposure, mediator and response are all binary. The second example is a common problem in social epidemiology-to find the proportion of a social class effect on a health outcome that is mediated by psychologic variables. Both the mediator and the response are composed of several ordered categorical variables, with confounders present. Finally, we extend the example to more than one mediator.
C1 Univ Copenhagen, Inst Publ Hlth, Dept Biostat, DK-1168 Copenhagen, Denmark.
   Univ Copenhagen, Inst Publ Hlth, Dept Social Med, DK-1168 Copenhagen, Denmark.
   Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
C3 University of Copenhagen; University of Copenhagen; University of
   Michigan System; University of Michigan
RP Ditlevsen, S (通讯作者)，Panum Inst, Dept Biostat, Blegdamsvej 3, DK-220 Copenhagen N, Denmark.
EM S.Ditlevsen@pubhealth.ku.dk
RI Lynch, John W/A-4797-2008; Ditlevsen, Susanne/F-6708-2012
OI Lynch, John W/0000-0003-2781-7902; Ditlevsen,
   Susanne/0000-0002-1998-2783; Damsgaard, Mogens Trab/0000-0003-4052-1831;
   Christensen, Ulla/0000-0001-7797-6640
CR ARMINGER G, 1996, MECOSA 3 USER GUIDE
   Bollen K. A., 1989, STRUCTURAL EQUATIONS, DOI DOI 10.1002/9781118619179
   Budtz-Jorgensen E, 2003, ENVIRONMETRICS, V14, P105, DOI 10.1002/env.569
   BUDTZJORGENSEN E, 2004, ENV HLTH
   Buyse M, 1998, BIOMETRICS, V54, P1014, DOI 10.2307/2533853
   Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667
   COX DR, 1994, BIOMETRIKA, V81, P403, DOI 10.2307/2336971
   Everson SA, 1997, AM J EPIDEMIOL, V146, P142
   FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204
   GREENGLASS ER, 1989, PERS INDIV DIFFER, V10, P209, DOI 10.1016/0191-8869(89)90206-7
   GREENGLASS ER, 1991, PSYCHOL REP, V68, P1059, DOI 10.2466/PR0.68.4.1059-1066
   Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Jerusalem M., 2014, SELF EFFICACY THOUGH, P195, DOI [DOI 10.4324/9781315800820, https://doi.org/10.4324/9781315800820]
   Lin DY, 1997, STAT MED, V16, P1515, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1
   Lynch JW, 1996, AM J EPIDEMIOL, V144, P934, DOI 10.1093/oxfordjournals.aje.a008863
   Muthen L., 2019, MPLUS USERS GUIDE 20
   ROBINS JM, 1992, EPIDEMIOLOGY, V3, P143, DOI 10.1097/00001648-199203000-00013
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Schatzkin A, 1996, CANCER EPIDEM BIOMAR, V5, P947
   SCHATZKIN A, 1990, J NATL CANCER I, V82, P1746, DOI 10.1093/jnci/82.22.1746
   SCHIFFMAN MH, 1994, CANCER RES, V54, pS1944
   van de Mheen H, 1998, SOCIOLOGY HLTH INEQU, P193
   Wang Y, 2002, BIOMETRICS, V58, P803, DOI 10.1111/j.0006-341X.2002.00803.x
   WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1
NR 25
TC 169
Z9 171
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1044-3983
J9 EPIDEMIOLOGY
JI Epidemiology
PD JAN
PY 2005
VL 16
IS 1
BP 114
EP 120
DI 10.1097/01.ede.0000147107.76079.07
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 884JA
UT WOS:000226079600017
PM 15613954
DA 2022-11-30
ER

PT J
AU Povazay, B
   Bizheva, K
   Hermann, B
   Unterhuber, A
   Sattmann, H
   Fercher, AF
   Drexler, W
   Schubert, C
   Ahnelt, PK
   Mei, M
   Holzwarth, R
   Wadsworth, WJ
   Knight, JC
   Russel, PS
AF Povazay, B
   Bizheva, K
   Hermann, B
   Unterhuber, A
   Sattmann, H
   Fercher, AF
   Drexler, W
   Schubert, C
   Ahnelt, PK
   Mei, M
   Holzwarth, R
   Wadsworth, WJ
   Knight, JC
   Russel, PS
TI Enhanced visualization of choroidal vessels using ultrahigh resolution
   ophthalmic OCT at 1050 nm
SO OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; WAVELENGTH; ABSORPTION
AB In this article the ability of ultrahigh resolution ophthalmic optical coherence tomography (OCT) to image small choroidal blood vessels below the highly reflective and absorbing retinal pigment epithelium is demonstrated for the first time. A new light source (lambda(c) = 1050 nm, Deltalambda = 165 nm, P-out = 10 mW), based on a photonic crystal fiber pumped by a compact, self-starting Ti:Al2O3 laser has therefore been developed. Ex-vivo ultrahigh resolution OCT images of freshly excised pig retinas acquired with this light source demonstrate enhanced penetration into the choroid and better visualization of choroidal vessels as compared to tomograms acquired with a state-of-the art Ti:Al2O3 laser (Femtolasers Compact Pro, lambda(c) = 780 nm, Deltalambda = 160 nm, P-out = 400 mW), normally used in clinical studies for in vivo ultrahigh resolution ophthalmic OCT imaging. These results were also compared with retinal tomograms acquired with a novel, spectrally broadened fiber laser ( MenloSystems, lambda(c) = 1350 nm, Deltalambda = 470 nm, P-out = 4 mW) permitting even greater penetration in the choroid. Due to high water absorption at longer wavelengths retinal OCT imaging at similar to1300 nm may find applications in animal ophthalmic studies. Detection and follow-up of choroidal neovascularization improves early diagnosis of many retinal pathologies, e.g. age-related macular degeneration or diabetic retinopathy and can aid development of novel therapy approaches. (C) 2003 Optical Society of America.
C1 Univ Vienna, Christian Doppler Lab, Dept Med Phys, A-1090 Vienna, Austria.
   Univ Vienna, Dept Physiol, A-1090 Vienna, Austria.
   Menlosyst GmbH, D-82152 Martinsried, Germany.
   Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England.
C3 University of Vienna; University of Vienna; University of Bath
RP Povazay, B (通讯作者)，Univ Vienna, Christian Doppler Lab, Dept Med Phys, Waehringer Guertel 18, A-1090 Vienna, Austria.
EM Wolfgang.Drexler@univie.ac.at
RI Považay, Boris/F-6258-2012; Wadsworth, William J/A-1317-2012; Knight,
   Jonathan C/D-3879-2011; Russell, Philip St.J./G-5132-2012
OI Knight, Jonathan C/0000-0002-0802-8804; Russell, Philip
   St.J./0000-0002-8972-2477; Povazay, Boris/0000-0001-5571-5116;
   Wadsworth, William/0000-0003-4733-7594; Unterhuber,
   Angelika/0000-0002-1251-3001; Ahnelt, Peter/0000-0003-0784-8891
CR AIELLO LM, 1994, PRINCIPLES PRACTICE
   *ANSI, Z13612000 ANSI
   Apolonski A, 2002, J OPT SOC AM B, V19, P2165, DOI 10.1364/JOSAB.19.002165
   Bizheva K, 2003, OPT LETT, V28, P707, DOI 10.1364/OL.28.000707
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   Bouma B.E., 2002, HDB OPTICAL COHERENC
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Fercher A F, 1996, J Biomed Opt, V1, P157, DOI 10.1117/12.231361
   HALE GM, 1973, APPL OPTICS, V12, P555, DOI 10.1364/AO.12.000555
   Hartl I, 2001, OPT LETT, V26, P608, DOI 10.1364/OL.26.000608
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Li QH, 2001, INVEST OPHTH VIS SCI, V42, P2981
   Povazay B, 2002, OPT LETT, V27, P1800, DOI 10.1364/OL.27.001800
   PULIAFITO CA, 1995, OPTICAL COHERENCE TO
   Roggan A, 1999, J BIOMED OPT, V4, P36, DOI 10.1117/1.429919
   Schmitt JM, 1998, J OPT SOC AM A, V15, P2288, DOI 10.1364/JOSAA.15.002288
   Wang YM, 2003, OPT EXPRESS, V11, P1411, DOI 10.1364/OE.11.001411
NR 19
TC 140
Z9 145
U1 0
U2 10
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD AUG 25
PY 2003
VL 11
IS 17
BP 1980
EP 1986
DI 10.1364/OE.11.001980
PG 7
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 715BT
UT WOS:000184951200005
PM 19466083
OA Green Submitted, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Piccolino, FC
   Eandi, CM
   Ventre, L
   De La Longrais, RCR
   Grignolo, FM
AF Piccolino, FC
   Eandi, CM
   Ventre, L
   De La Longrais, RCR
   Grignolo, FM
TI Transpupillary thermotherapy of juxtafoveal recurrent choroidal
   neovascularization
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; diode
   laser; transpupillary thermotherapy
ID RANDOMIZED CLINICAL-TRIAL; KRYPTON LASER PHOTOCOAGULATION; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; LESIONS; VERTEPORFIN; MELANOMAS;
   SECONDARY
AB PURPOSE. To evaluate the effectiveness of low power transpupillary thermotherapy (TTT) in treating juxtafoveal recurrent choroidal neovascularization (CNV) after laser photocoagulation in patients with age-related macular degeneration (ARMD).
   METHODS. Eight eyes of eight patients with ARMD and juxtafoveal recurrent CNV were treated with low power TTT, delivered using an 810-nm diode laser with 350 mW, 2.0 mm spot, and 1-minute duration. Visual acuity (VA) ranged from 20/100 to 20/50. Treatment effect was evaluated by fluorescein angiography, indocyanine green angiography, and VA measurements (Early Treatment Diabetic Retinopathy Study) at 1-week, 2-week, and monthly follow-up visits.
   RESULTS. No retinal damage was visible ophthalmoscopically during treatment. At the first follow-up visit, seven eyes had obliteration of CNV and one eye required a second TTT application. VA was unchanged in six eyes, improved in one eye, and worsened in one eye. Recurrences occurred in all eyes between 1 and 7 months after TTT and were treated with photodynamic therapy (PDT). More than two PDT treatments were performed in each eye in the year after recurrence.
   CONCLUSIONS. Low power TTT is as able to close juxtafoveal recurrent CNV as is high power conventional laser photocoagulation but does not prevent recurrences. Further intervention with TTT in order to treat recurrences is under investigation.
C1 Univ Turin, Clin Oculist, Inst Ophthalmol, Dept Clin Physiopathol, I-10122 Turin, Italy.
C3 University of Turin
RP Piccolino, FC (通讯作者)，Univ Turin, Clin Oculist, Inst Ophthalmol, Dept Clin Physiopathol, Via Juvarra 19, I-10122 Turin, Italy.
EM felice.cardillopiccolino@unito.it
OI Grignolo, Federico/0000-0001-9316-8408; Eandi, Chiara
   Maria/0000-0003-3656-1689
CR Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   DUDAR TE, 1984, CANCER RES, V44, P805
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   JourneedeKorver JG, 1997, BRIT J OPHTHALMOL, V81, P234, DOI 10.1136/bjo.81.3.234
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   YANNUZZI LA, 1994, ARCH OPHTHALMOL-CHIC, V112, P462, DOI 10.1001/archopht.1994.01090160038019
NR 17
TC 2
Z9 3
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUN
PY 2003
VL 13
IS 5
BP 453
EP 460
DI 10.1177/112067210301300506
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 701CZ
UT WOS:000184151800006
PM 12841568
DA 2022-11-30
ER

PT J
AU Rakic, JM
   Lambert, V
   Deprez, M
   Foidart, JM
   Noel, A
   Munaut, C
AF Rakic, JM
   Lambert, V
   Deprez, M
   Foidart, JM
   Noel, A
   Munaut, C
TI Estrogens reduce the expression of YKL-40 in the retina: Implications
   for eye and joint diseases
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HUMAN CARTILAGE GP-39; ACTIVATOR INHIBITOR TYPE-1; SERUM YKL-40;
   RHEUMATOID-ARTHRITIS; MACULAR DEGENERATION; ENDOTHELIAL-CELLS;
   GENE-EXPRESSION; MESSENGER-RNA; AGE; RECEPTOR
AB PURPOSE. To identify modifications in the gene expression profile of the ocular posterior segment in ovariectomized (OVX) mice with and without substitutive estradiol therapy and to select differentially expressed genes that could be relevant to the natural history of human age-related macular degeneration (AMD).
   METHODS. Chorioretinal tissues from two groups of 25 treated and untreated OVX mice were analyzed by using cDNA array technology. The expression level of selected genes was confirmed in triplicate by RT-PCR and related to the estrogenic status of the animals. Expression of the YKL-40 gene was further investigated in intact or diseased human retinas and in a murine model of experimental choroidal neovascularization (CNV), using laser pressure catapulting.
   RESULTS. Of the approximately, 10,000 genes screened, only YKL-40 expression was significantly downregulated by 17-beta-estradiol. YKL-40 was expressed in intact human neural retina and in the RPE. The expression of YKL-40 was upregulated in experimental CNV and in neovascular membranes extracted from patients affected by the exudative form of AMD.
   CONCLUSIONS. These observations indicate that YKL-40 expression in the retina is modulated by serum levels of estradiol. This protein could be relevant to the development of AMD and is also a new mediator to take into account when evaluating the broad consequences of hormonal replacement therapy.
C1 Univ Hosp, Dept Ophthalmol, Liege, Belgium.
   Univ Liege, Lab Tumor & Dev Biol, Liege, Belgium.
   Univ Liege, Neuropathol Lab, Liege, Belgium.
C3 University of Liege; University of Liege; University of Liege
RP Rakic, JM (通讯作者)，CHU Sart Tilman, Polyclin Ophtalmol, B-4000 Liege, Belgium.
EM jmrakic@chu.ulg.ac.be
RI Munaut, Carine/K-8138-2019
OI Noel, Agnes/0000-0002-7670-6179
CR Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846
   BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647
   Bigsby RM, 1999, P NATL ACAD SCI USA, V96, P9328, DOI 10.1073/pnas.96.16.9328
   Bohm M, 1997, AM J PATHOL, V151, P63
   Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687
   Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022
   Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238
   Davis VL, 2002, P NATL ACAD SCI USA, V99, P9427, DOI 10.1073/pnas.132247999
   De Ceuninck F, 2001, BIOCHEM BIOPH RES CO, V285, P926, DOI 10.1006/bbrc.2001.5253
   delCastillo JMB, 1997, OPHTHALMOLOGY, V104, P970
   Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434
   HAKALA BE, 1993, J BIOL CHEM, V268, P25803
   Johansen JS, 2000, J HEPATOL, V32, P911, DOI 10.1016/S0168-8278(00)80095-1
   Johansen JS, 1999, RHEUMATOLOGY, V38, P618, DOI 10.1093/rheumatology/38.7.618
   Johansen JS, 1999, ARTHRITIS RHEUM-US, V42, P2624, DOI 10.1002/1529-0131(199912)42:12<2624::AID-ANR17>3.0.CO;2-K
   Johansen JS, 2001, ARTHRITIS RHEUM-US, V44, P826
   Kadish I, 2002, J NEUROSCI, V22, P4095, DOI 10.1523/JNEUROSCI.22-10-04095.2002
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Magabo KS, 2000, INVEST OPHTH VIS SCI, V41, P3056
   Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511
   Matsumoto T, 2001, CLIN EXP RHEUMATOL, V19, P655
   MERI S, 1990, IMMUNOLOGY, V71, P1
   MIRALLES F, 1994, BIOCHEM BIOPH RES CO, V203, P711, DOI 10.1006/bbrc.1994.2240
   Miyamoto N, 2002, INVEST OPHTH VIS SCI, V43, P2007
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Nonaka A, 2000, INVEST OPHTH VIS SCI, V41, P2689
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Rakoczy PE, 1997, BIOCHEM J, V324, P935, DOI 10.1042/bj3240935
   Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778
   Rochefort H, 2001, J STEROID BIOCHEM, V76, P119, DOI 10.1016/S0960-0760(00)00142-4
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Smith JP, 1997, J ADV NURS, V25, P1, DOI 10.1046/j.1365-2648.1997.1997025001.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOBEL MI, 1995, AM J OBSTET GYNECOL, V173, P801, DOI 10.1016/0002-9378(95)90344-5
   Srivastava RAK, 1997, J BIOL CHEM, V272, P33360, DOI 10.1074/jbc.272.52.33360
   Suzuma I, 1999, INVEST OPHTH VIS SCI, V40, P2122
   Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9
   Verheijden GFM, 1997, ARTHRITIS RHEUM, V40, P1115, DOI 10.1002/art.1780400616
   Vos K, 2000, ANN RHEUM DIS, V59, P544, DOI 10.1136/ard.59.7.544
   Wluka A, 2000, MATURITAS, V35, P183, DOI 10.1016/S0378-5122(00)00118-3
   Xu ZP, 2002, BIOCHEM BIOPH RES CO, V294, P287, DOI 10.1016/S0006-291X(02)00479-5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhang D, 2002, BIOGERONTOLOGY, V3, P61, DOI 10.1023/A:1015259413857
NR 45
TC 17
Z9 20
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2003
VL 44
IS 4
BP 1740
EP 1746
DI 10.1167/iovs.02-0775
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 660TG
UT WOS:000181848900049
PM 12657616
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Xiao, J
   Xie, BQ
   Dao, D
   Spedale, M
   D'Souza, M
   Theriault, B
   Hariprasad, SM
   Sulakhe, D
   Chang, EB
   Skondra, D
AF Xiao, Jason
   Xie, Bingqing
   Dao, David
   Spedale, Melanie
   D'Souza, Mark
   Theriault, Betty
   Hariprasad, Seenu M.
   Sulakhe, Dinanath
   Chang, Eugene B.
   Skondra, Dimitra
TI High-Fat Diet Alters the Retinal Pigment Epithelium and Choroidal
   Transcriptome in the Absence of Gut Microbiota
SO CELLS
LA English
DT Article
DE age-related macular degeneration; high-fat diet; gut microbiome;
   gut-choroid axis; RNA sequencing; germ-free mice; complement cascade;
   angiogenesis
ID COMPLEMENT FACTOR-H; GLYCATION END-PRODUCTS; MACULAR-DEGENERATION;
   APOLIPOPROTEIN-E; DIABETIC-RETINOPATHY; GENE ASSOCIATIONS; OXIDATIVE
   STRESS; BRUCHS MEMBRANE; EYE DISEASE; MODEL
AB Relationships between retinal disease, diet, and the gut microbiome have started to emerge. In particular, high-fat diets (HFDs) are associated with the prevalence and progression of several retinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR). These effects are thought to be partly mediated by the gut microbiome, which modulates interactions between diet and host homeostasis. Nevertheless, the effects of HFDs on the retina and adjacent retinal pigment epithelium (RPE) and choroid at the transcriptional level, independent of gut microbiota, are not well-understood. In this study, we performed the high-throughput RNA-sequencing of germ-free (GF) mice to explore the transcriptional changes induced by HFD in the RPE/choroid. After filtering and cleaning the data, 649 differentially expressed genes (DEGs) were identified, with 616 genes transcriptionally upregulated and 33 genes downregulated by HFD compared to a normal diet (ND). Enrichment analysis for gene ontology (GO) using the DEGs was performed to analyze over-represented biological processes in the RPE/choroid of GF-HFD mice relative to GF-ND mice. GO analysis revealed the upregulation of processes related to angiogenesis, immune response, and the inflammatory response. Additionally, molecular functions that were altered involved extracellular matrix (ECM) binding, ECM structural constituents, and heparin binding. This study demonstrates novel data showing that HFDs can alter RPE/choroid tissue transcription in the absence of the gut microbiome.
C1 [Xiao, Jason; Dao, David; Hariprasad, Seenu M.; Skondra, Dimitra] Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
   [Xie, Bingqing; Chang, Eugene B.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Spedale, Melanie; Theriault, Betty] Univ Chicago, Anim Resources Ctr, Chicago, IL 60637 USA.
   [D'Souza, Mark; Sulakhe, Dinanath] Univ Chicago, Duchossois Family Inst, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago; University of Chicago;
   University of Chicago
RP Skondra, D (通讯作者)，Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
EM jason.xiao@uchospitals.edu; bxie@medicine.bsd.uchicago.edu;
   david.dao@uchospitals.edu; mspedale@bsd.uchicago.edu;
   dsouza@bsd.uchicago.edu; btheriault@bsd.uchicago.edu;
   sharipra@bsd.uchicago.edu; sulakhe@uchicago.edu;
   echang@medicine.bsd.uchicago.edu; dskondra@bsd.uchicago.edu
OI Sulakhe, Dinanath/0000-0002-4680-1212
FU BrightFocus Foundation [M2018042]; University of Chicago Women's Board;
   FORE-I Foundation; Illinois Society for the Prevention of Blindness
   [FP105447, FP06727101-PR]; NIDDK [DK42086]
FX This research was funded by BrightFocus Foundation "Role of high fat
   diet and gut microbiome in macular degeneration" (D.S. (Dimitra
   Skondra), M2018042), NIDDK P30 (E.B.C., DK42086), The University of
   ChicagoWomen's Board (Dimitra Skondra), FORE-I Foundation (Dimitra
   Skondra) and the Illinois Society for the Prevention of Blindness (D.S.
   (Dimitra Skondra), FP06727101-PR and J.X., FP105447).
CR Adams JN, 2016, GENE, V584, P173, DOI 10.1016/j.gene.2016.02.029
   Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Albouery M, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108059
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Berry KAZ, 2014, J LIPID RES, V55, P504, DOI 10.1194/jlr.M044990
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biswas L, 2021, EXP EYE RES, V208, DOI 10.1016/j.exer.2021.108625
   Boulange CL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0303-2
   Boutin TS, 2020, HUM MOL GENET, V29, P689, DOI 10.1093/hmg/ddz294
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Brindle NPJ, 2006, CIRC RES, V98, P1014, DOI 10.1161/01.RES.0000218275.54089.12
   Butler JM, 2021, J CELL MOL MED, V25, P5572, DOI 10.1111/jcmm.16569
   Camous X, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/195956
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen Yunshun, 2016, F1000Res, V5, P1438, DOI 10.12688/f1000research.8987.2
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clarkson-Townsend DA, 2021, EXP EYE RES, V204, DOI 10.1016/j.exer.2021.108440
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Cui Y, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00245
   Cundiff David K, 2005, MedGenMed, V7, P3
   Dao D, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082119
   Dighe S, 2020, BRIT J OPHTHALMOL, V104, P1070, DOI 10.1136/bjophthalmol-2019-314813
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Doerner SK, 2016, MOL CANCER RES, V14, P953, DOI 10.1158/1541-7786.MCR-16-0153
   Dow C, 2018, EUR J EPIDEMIOL, V33, P141, DOI 10.1007/s10654-017-0338-8
   Duan YH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02649
   Duda M, 2017, CELL BIOCHEM BIOPHYS, V75, P433, DOI 10.1007/s12013-017-0795-4
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Fagiani E, 2013, CANCER LETT, V328, P18, DOI 10.1016/j.canlet.2012.08.018
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Fernandez-Vega B, 2016, CASE REP OPHTHAL, V7, P154, DOI 10.1159/000445102
   Folestad E, 2018, MOL ASPECTS MED, V62, P1, DOI 10.1016/j.mam.2018.01.005
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4
   Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu ZJ, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910473
   Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gollapalli DR, 2004, P NATL ACAD SCI USA, V101, P10030, DOI 10.1073/pnas.0401936101
   Goverdhan SV, 2008, INVEST OPHTH VIS SCI, V49, P5077, DOI 10.1167/iovs.08-1837
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hijioka K, 2008, BIOCHEM BIOPH RES CO, V374, P38, DOI 10.1016/j.bbrc.2008.06.080
   Hintze KJ, 2018, ADV NUTR, V9, P263, DOI 10.1093/advances/nmy002
   Hintze KJ, 2012, J AGR FOOD CHEM, V60, P6736, DOI 10.1021/jf204509a
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hu ML, 2021, LIFE-BASEL, V11, DOI 10.3390/life11070635
   Hu P, 2018, INVEST OPHTH VIS SCI, V59
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jandhyala SM, 2015, WORLD J GASTROENTERO, V21, P8787, DOI 10.3748/wjg.v21.i29.8787
   Kadomatsu T, 2014, TRENDS ENDOCRIN MET, V25, P245, DOI 10.1016/j.tem.2014.03.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keeling E, 2022, MOL NUTR FOOD RES, V66, DOI 10.1002/mnfr.202100823
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Kim SJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P596, DOI 10.1001/archophthalmol.2010.69
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kumar A, 2018, MOL ASPECTS MED, V62, P33, DOI 10.1016/j.mam.2017.10.002
   Lee JJ, 2015, INVEST OPHTH VIS SCI, V56, P3041, DOI 10.1167/iovs.15-16504
   Lee KM, 2006, BLOOD, V107, P3181, DOI 10.1182/blood-2005-01-0185
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   McArdel SL, 2016, CLIN IMMUNOL, V164, P10, DOI 10.1016/j.clim.2016.01.008
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Mohajeri MH, 2018, NUTR REV, V76, P481, DOI 10.1093/nutrit/nuy009
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Murphy EA, 2015, CURR OPIN CLIN NUTR, V18, P515, DOI 10.1097/MCO.0000000000000209
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   NRC, 2011, GUIDE CARE USE LAB A, V8th, DOI [10.17226/12910, DOI 10.17226/12910]
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Palenski TL, 2013, AM J PHYSIOL-CELL PH, V305, pC1170, DOI 10.1152/ajpcell.00139.2013
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Patel SS, 2018, INVEST OPHTH VIS SCI, V59
   Perkins SJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00126
   Picard C, 2002, AM J HUM GENET, V70, P336, DOI 10.1086/338625
   Prolo P, 2007, BIOINFORMATION, V1, P363, DOI 10.6026/97320630001363
   Regeneron Pharmaceuticals, 2016, OP LAB DOS ESC STUD
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Richardson MR, 2014, ANGIOGENESIS, V17, P675, DOI 10.1007/s10456-014-9423-8
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Arias JER, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94500-1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rowan S, 2018, ADV EXP MED BIOL, V1074, P429, DOI 10.1007/978-3-319-75402-4_53
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Sasaki M, 2015, INVEST OPHTH VIS SCI, V56, P7473, DOI 10.1167/iovs.15-17485
   Schroeder B, 2016, NAT MED, V22, P1079, DOI 10.1038/nm.4185
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Skondra D., 2007, INVESTIG OPHTHALMOL, V48, P1768
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Speakman JR, 2019, INT J OBESITY, V43, P1491, DOI 10.1038/s41366-019-0363-7
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sulakhe D, 2014, NUCLEIC ACIDS RES, V42, pD1007, DOI 10.1093/nar/gkt1166
   Suzuki A, 2008, NAT GENET, V40, P1224, DOI 10.1038/ng.205
   Tang YX, 2009, BLOOD, V113, P744, DOI 10.1182/blood-2008-03-145219
   Theriault B, 2015, TRANSPLANT DIRECT, V1, DOI 10.1097/TXD.0000000000000539
   Thurston G, 2002, J ANAT, V200, P575, DOI 10.1046/j.1469-7580.2002.00061.x
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Toris CB, 2011, CLIN LIPIDOL, V6, P577, DOI 10.2217/CLP.11.42
   Vazirinejad R, 2014, NEUROIMMUNOMODULAT, V21, P322, DOI 10.1159/000357780
   Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839
   Wang HB, 2016, MOL VIS, V22, P116
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xiao L, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0258-6
   Yan Y, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00212
   Yang P, 2017, INVEST OPHTH VIS SCI, V58, P3073, DOI 10.1167/iovs.16-20083
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang JY, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/2714746
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhou LL, 2018, CELL PHYSIOL BIOCHEM, V48, P263, DOI 10.1159/000491726
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zysset-Burri DC, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-00141-0
NR 151
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUL
PY 2022
VL 11
IS 13
AR 2076
DI 10.3390/cells11132076
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 2V7PR
UT WOS:000824033700001
PM 35805160
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Heckel, E
   Cagnone, G
   Agnihotri, T
   Cakir, B
   Das, A
   Kim, JS
   Kim, N
   Lavoie, G
   Situ, A
   Pundir, S
   Sun, Y
   Wunnemann, F
   Pierce, KA
   Dennis, C
   Mitchell, GA
   Chemtob, S
   Rezende, FA
   Andelfinger, G
   Clish, CB
   Roux, PP
   Sapieha, P
   Smith, LE
   Joyal, JS
AF Heckel, Emilie
   Cagnone, Gael
   Agnihotri, Tapan
   Cakir, Bertan
   Das, Ashim
   Kim, Jin Sung
   Kim, Nicholas
   Lavoie, Genevieve
   Situ, Anu
   Pundir, Sheetal
   Sun, Ye
   Wunnemann, Florian
   Pierce, Kerry A.
   Dennis, Courtney
   Mitchell, Grant A.
   Chemtob, Sylvain
   Rezende, Flavio A.
   Andelfinger, Gregor
   Clish, Clary B.
   Roux, Philippe P.
   Sapieha, Przemyslaw
   Smith, Lois Eh
   Joyal, Jean-Sebastien
TI Triglyceride-derived fatty acids reduce autophagy in a model of retinal
   angiomatous proliferation
SO JCI INSIGHT
LA English
DT Article
ID MOUSE MODEL; KINASE-II; CALCINEURIN; METABOLISM; EXPRESSION; GLUCOSE;
   LIPIDS; CELLS; NEOVASCULARIZATION; PHOSPHORYLATION
AB Dyslipidemia and autophagy have been implicated in the pathogenesis of blinding neovascular age-related macular degeneration (NV-AMD). VLDL receptor (VLDLR), expressed in photoreceptors with a high metabolic rate, facilitates the uptake of triglyceride-derived fatty acids. Since fatty acid uptake is reduced in Vldlr(-/-) tissues, more remain in circulation, and the retina is fuel deficient, driving the formation in mice of neovascular lesions reminiscent of retinal angiomatous proliferation (RAP), a subtype of NV-AMD. Nutrient scarcity and energy failure are classically mitigated by increasing autophagy. We found that excess circulating lipids restrained retinal autophagy, which contributed to pathological angiogenesis in the Vldlr(-/-) RAP model. Triglyceride-derived fatty acid sensed by free fatty acid receptor 1 (FFAR1) restricted autophagy and oxidative metabolism in photoreceptors. FFAR1 suppressed transcription factor EB (TFEB), a master regulator of autophagy and lipid metabolism. Reduced TFEB, in turn, decreased sirtuin-3 expression and mitochondrial respiration. Meta bolomic signatures of mouse RAP-like retinas were consistent with a role in promoting angiogenesis. This signature was also found in human NV-AMD vitreous. Restoring photoreceptor autophagy in Vldlr(-/-) retinas, either pharmacologically or by deleting Ffar1, enhanced metabolic efficiency and suppressed pathological angiogenesis. Dysregulated autophagy by circulating lipids might therefore contribute to the energy failure of photoreceptors driving neovascular eye diseases, and FFAR1 may be a target for intervention.
C1 [Heckel, Emilie; Cagnone, Gael; Das, Ashim; Chemtob, Sylvain; Joyal, Jean-Sebastien] Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada.
   [Agnihotri, Tapan; Kim, Jin Sung; Kim, Nicholas; Pundir, Sheetal; Chemtob, Sylvain; Joyal, Jean-Sebastien] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
   [Cakir, Bertan; Sun, Ye; Smith, Lois Eh] Harvard Med Sch, Dept Ophthalmol, Boston Childrens Hosp, Boston, MA 02115 USA.
   [Lavoie, Genevieve; Roux, Philippe P.] Inst Res Immunol & Canc IRIC, Dept Pathol & Cell Biol, Montreal, PQ, Canada.
   [Situ, Anu; Wunnemann, Florian; Mitchell, Grant A.; Chemtob, Sylvain; Andelfinger, Gregor; Joyal, Jean-Sebastien] Univ Montreal, Dept Pediat, Montreal, PQ, Canada.
   [Pierce, Kerry A.; Dennis, Courtney; Clish, Clary B.] Broad Inst MIT & Harvard Univ, Metabol Platform, Cambridge, MA USA.
   [Chemtob, Sylvain; Rezende, Flavio A.; Sapieha, Przemyslaw; Joyal, Jean-Sebastien] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
C3 Universite de Montreal; McGill University; Harvard University; Boston
   Children's Hospital; Harvard Medical School; Universite de Montreal;
   Universite de Montreal; Harvard University; Massachusetts Institute of
   Technology (MIT); Broad Institute; Universite de Montreal
RP Joyal, JS (通讯作者)，Univ Montreal, CHU St Justine Res Ctr, Montreal, PQ H3T 1J4, Canada.
EM js.joyal@umontreal.ca
RI Roux, Philippe P./J-3996-2012
OI Roux, Philippe P./0000-0002-5962-0250; Kim, Jin
   Sung/0000-0002-7823-3563; Heckel, Emilie/0000-0002-0017-6458
FU Leica Microsystems; CHUSJRC; Quebec government (MSSS); CHUSJ Foundation;
   Canada Foundation for Innovation; Vision Health Research Network;
   Burroughs Wellcome Fund Career Award for Medical Scientists; Foundation
   Fighting Blindness; Canadian Institutes of Health Research (CIHR)
   [NSA-390615]; Natural Sciences and Engineering Research Council of
   Canada [RGPIN-2016-06743]; Fonds de Recherche du Quebec-Sante (FRQS);
   CIHR New Investigator Award; NIH [EY024864, EY017017, P01 HD18655]; CIHR
   [353770, MOP-142374, PJT-152995]; Heart & Stroke Foundation Canada
   [G-16-00014658]; Foundation Fighting Blindness Canada; Canadian Diabetes
   Association [DI-3-18-5444-PS]; CIHR Foundation grant; Collaborative
   Health Research project; Canada Research Chair (Vision Research);
   Leopoldine Wolfe Chair in translational vision research at Universite de
   Montreal; Senior Scholar Award from FRQS
FX We thank Marie-Josee Lacombe, Perrine Gaub, Severine Leclerc, and
   Christiane Quiniou (CHU Sainte-Justine Research Center [CHUSJRC]) and
   Aurele Besse Patin (Montreal Clinical Research Institute) for their
   technical assistance. We thank Elke Kuster-Schock and the Platform for
   Imaging by Microscopy of the CHUSJRC, which is supported by Leica
   Microsystems, CHUSJRC, the Quebec government (MSSS), CHUSJ Foundation,
   and Canada Foundation for Innovation. We thank the High Content
   Screening Facility of IRIC (Universite de Montreal) and the Single-cell
   Genomics Analysis Platform (Single-Cell Academy) funded by the Vision
   Health Research Network. We thank the McGill University Life Sciences
   Complex Advanced BioImaging Facility (ABIF) for sharing the Imaris
   workstation. We also thank M. Al-Ubaidi (University of Oklahoma) for
   sharing the 661W photoreceptor cells. JSJ was supported by the Burroughs
   Wellcome Fund Career Award for Medical Scientists, the Foundation
   Fighting Blindness, the Canadian Institutes of Health Research (CIHR;
   NSA-390615), the Natural Sciences and Engineering Research Council of
   Canada (RGPIN-2016-06743), the Fonds de Recherche du Quebec-Sante
   (FRQS), and a CIHR New Investigator Award. LEHS was supported by NIH
   EY024864, EY017017, and P01 HD18655. PS was supported by the CIHR
   (353770), the Heart & Stroke Foundation Canada (G-16-00014658), the
   Foundation Fighting Blindness Canada, and the Canadian Diabetes
   Association (DI-3-18-5444-PS). SC is supported by a CIHR Foundation
   grant, a Collaborative Health Research project, and is a Canada Research
   Chair (Vision Research) and the Leopoldine Wolfe Chair in translational
   vision research at Universite de Montreal. PPR was supported by grants
   from the CIHR (MOP-142374 and PJT-152995) and a Senior Scholar Award
   from FRQS.
CR ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681
   Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200
   Castillo K, 2013, AUTOPHAGY, V9, P1308, DOI 10.4161/auto.25188
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   COHEN LH, 1960, J NEUROCHEM, V5, P253, DOI 10.1111/j.1471-4159.1960.tb13363.x
   Committee on Guidelines for the Use of Animals in Neuroscience and Behavioral Research. Institute for Laboratory Animal Research, 2003, GUIDELINES CARE USE
   Cuervo AM, 2013, NAT CELL BIOL, V15, P565, DOI 10.1038/ncb2778
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Efeyan A, 2015, NATURE, V517, P302, DOI 10.1038/nature14190
   Esteban-Martinez L, 2015, METHODS, V75, P79, DOI 10.1016/j.ymeth.2015.01.008
   Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524
   HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001
   He WJ, 2012, TRENDS ENDOCRIN MET, V23, P467, DOI 10.1016/j.tem.2012.07.004
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   HILL JO, 1990, J LIPID RES, V31, P407
   Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478
   Jaishy B, 2016, J LIPID RES, V57, P1619, DOI 10.1194/jlr.R067520
   Joyal JS, 2018, PROG RETIN EYE RES, V64, P131, DOI 10.1016/j.preteyeres.2017.11.002
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707
   Linton JD, 2010, P NATL ACAD SCI USA, V107, P8599, DOI 10.1073/pnas.1002471107
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   MARTENSEN TM, 1989, BIOCHEMISTRY-US, V28, P9243, DOI 10.1021/bi00450a002
   Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Miyazono S, 2008, P NATL ACAD SCI USA, V105, P16051, DOI 10.1073/pnas.0806593105
   Nakazawa A, 2001, J HISTOCHEM CYTOCHEM, V49, P187, DOI 10.1177/002215540104900206
   Olivecrona G, 2016, CURR OPIN LIPIDOL, V27, P233, DOI 10.1097/MOL.0000000000000297
   Owen O E, 1979, Adv Exp Med Biol, V111, P169
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Rodriguez-Navarro JA, 2012, P NATL ACAD SCI USA, V109, pE705, DOI 10.1073/pnas.1113036109
   Santoro A, 2021, CELL METAB, V33, P748, DOI 10.1016/j.cmet.2021.03.019
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008
   Schori C, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.107690
   Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Singh RK, 2012, INT J OPT, V2012, DOI [10.1155/2012/832086, 10.1155/2012/282041]
   Singhal A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65627-4
   Skinnider MA, 2021, NAT BIOTECHNOL, V39, P30, DOI 10.1038/s41587-020-0605-1
   Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002
   Song WS, 2014, J BIOL CHEM, V289, P10211, DOI 10.1074/jbc.M113.506246
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Tiebel O, 1999, ATHEROSCLEROSIS, V145, P239, DOI 10.1016/S0021-9150(99)00068-4
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Unger RH, 2010, TRENDS ENDOCRIN MET, V21, P345, DOI 10.1016/j.tem.2010.01.009
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wheway G, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00308
   Yan WJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66092-9
   Yu W, 2012, J BIOL CHEM, V287, P14078, DOI 10.1074/jbc.M112.355206
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
   Zhou Z, 2015, CELL DEATH DIFFER, V22, P488, DOI 10.1038/cdd.2014.229
   Zhou ZQ, 2015, AUTOPHAGY, V11, P1821, DOI 10.1080/15548627.2015.1084456
NR 67
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD MAR 22
PY 2022
VL 7
IS 6
AR e154174
DI 10.1172/jci.insight.154174
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 0E9CT
UT WOS:000776971000001
PM 35167498
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yako, T
   Nakamura, M
   Otsu, W
   Nakamura, S
   Shimazawa, M
   Hara, H
AF Yako, Tomohiro
   Nakamura, Maho
   Otsu, Wataru
   Nakamura, Shinsuke
   Shimazawa, Masamitsu
   Hara, Hideaki
TI Mitochondria dynamics in the aged mice eye and the role in the RPE
   phagocytosis
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Mitochondria; Aging; Retinal pigment epithelium; Dynamin related protein
   1; Phagocytosis
ID RETINAL-PIGMENT EPITHELIUM; CELL-DEATH; OXIDATIVE STRESS; DYSFUNCTION;
   PROMOTES; PARKINSONS; FISSION; DRP1
AB Aging is a predominant risk factor for various eye diseases. Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, and its etiology remains unclear. Fragmented and dysfunctional mitochondria are associated with age-related diseases. The retinal pigment epithelium (RPE), a polarized cell layer that functions in visual pigment recycling and degeneration, is suspected as the primary region site of AMD. In the present study, we investigated the relationship between mitochondrial dysfunction and RPE aging. Compared to young mice, aged pigmented mice (C57BL/6J, 12-month-old) exhibit decreased visual function without retinal thinning. Consistently, the rhodopsin expression level decreased in the outer segment of aged mice. Moreover, the cell volume of the RPE increased in aged animals. Interestingly, the expression of mitochondria dynamics-related proteins, including Drp1, was altered in the RPE-choroid complex but not in the neural retina after aging. Electron microscopy revealed that mitochondrial size decreased and cristae width increased in aged RPE. The photoreceptor outer segment (POS) treatment of ARPE-19 cells causes Drp1 activation. Furthermore, pharmacological suppression of mitochondrial fission improved the phagocytosis of the POS. These findings indicate that mitochondrial dysfunction and fission in RPE impede phagocytosis and cause retardation of the visual cycle, which can be one of the age-related defects in the retina that may contribute to the onset of AMD.
C1 [Yako, Tomohiro; Nakamura, Maho; Nakamura, Shinsuke; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
   [Otsu, Wataru; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biomed Res Lab, Gifu, Japan.
C3 Gifu Pharmaceutical University; Gifu Pharmaceutical University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
OI Otsu, Wataru/0000-0002-5930-1954; Hara, Hideaki/0000-0003-2046-9001
CR Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Barthel A., 2010, MMW FORTSCHRITTE MED, V152, P5, DOI [10.1126/science.1104343, DOI 10.1126/SCIENCE.1104343]
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111158
   Filho CADG, 2013, OPHTHAL SURG LAS IM, V44, P204, DOI 10.3928/23258160-20130313-12
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kluge MA, 2013, CIRC RES, V112, P1171, DOI 10.1161/CIRCRESAHA.111.300233
   Kolesnikov AV, 2010, J NEUROSCI, V30, P11222, DOI 10.1523/JNEUROSCI.4239-09.2010
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Long Pan, 2020, Aging (Albany NY), V13, P2750, DOI 10.18632/aging.202325
   Marin-Garcia J, 2016, HEART FAIL REV, V21, P123, DOI 10.1007/s10741-016-9530-2
   Martin LJ, 2012, PROG MOL BIOL TRANSL, V107, P355, DOI 10.1016/B978-0-12-385883-2.00005-9
   Martinez-Reyes I, 2014, BBA-BIOENERGETICS, V1837, P1099, DOI 10.1016/j.bbabio.2014.03.010
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054
   Nakamura M, 2018, EXP EYE RES, V177, P1, DOI 10.1016/j.exer.2018.07.022
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108
   Riazi-Esfahani Mohammad, 2017, J Ophthalmic Vis Res, V12, P424, DOI 10.4103/jovr.jovr_182_17
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Ryan BJ, 2015, TRENDS BIOCHEM SCI, V40, P200, DOI 10.1016/j.tibs.2015.02.003
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Saito Y, 2020, FREE RADICAL BIO MED, V152, P235, DOI 10.1016/j.freeradbiomed.2020.03.012
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schutt F, 2012, INVEST OPHTH VIS SCI, V53, P5354, DOI 10.1167/iovs.12-9845
   Scimone C, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111154
   Seo AY, 2010, J CELL SCI, V123, P2533, DOI 10.1242/jcs.070490
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tarasov AI, 2012, CELL CALCIUM, V52, P28, DOI 10.1016/j.ceca.2012.03.003
   Uo T, 2009, EXP NEUROL, V218, P274, DOI 10.1016/j.expneurol.2009.05.010
   Wang Y, 2017, CELL, V171, P331, DOI 10.1016/j.cell.2017.08.041
   Westermann B., 2012, SCI SIGNAL, V2, P29, DOI [10.1126/scisignal.2000464, DOI 10.1126/SCISIGNAL.2000464]
   Zhang ZZ, 2016, ANTIOXID REDOX SIGN, V25, P609, DOI 10.1089/ars.2016.6634
   Zhao CY, 2017, ONCOTARGET, V8, P20988, DOI 10.18632/oncotarget.15470
NR 46
TC 2
Z9 2
U1 5
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2021
VL 213
AR 108800
DI 10.1016/j.exer.2021.108800
EA OCT 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WW7YB
UT WOS:000718125900005
PM 34688622
DA 2022-11-30
ER

PT J
AU Roddy, GW
AF Roddy, Gavin W.
TI Metabolic syndrome and the aging retina
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; aging; glaucoma; inflammaging;
   metabolic syndrome; optic neuropathy; over nutrition; Western diet
ID OPEN-ANGLE GLAUCOMA; HIGH INTRAOCULAR-PRESSURE; NUTRITION EXAMINATION
   SURVEY; KOREAN NATIONAL-HEALTH; MACULAR DEGENERATION; RISK-FACTORS;
   CALORIC RESTRICTION; OCULAR HYPERTENSION; TRANSGENIC MICE; WESTERN DIET
AB Purpose of review This review explores metabolic syndrome (MetS) as a risk factor that accelerates aging in retinal neurons and may contribute to the neurodegeneration seen in glaucomatous optic neuropathy (GON) and age-related macular degeneration (AMD). Recent findings Both animal model experiments and epidemiologic studies suggest that metabolic stress may lead to aberrant regulation of a number of cellular pathways that ultimately lead to premature aging of the cell, including those of a neuronal lineage. GON and AMD are each leading causes of irreversible blindness worldwide. Aging is a significant risk factor in the specific retinal neuron loss that is seen with each condition. Though aging at a cellular level is difficult to define, there are many mechanistic modifiers of aging. Metabolic-related stresses induce inflammation, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, alterations to the unfolded protein response, defects in autophagy, alterations to the microbiome, and deposition of advanced glycation end products that can all hasten the aging process. Due to the number of variables related to metabolic health, defining criteria to enable the study of risk factors at a population level is challenging. MetS is a definable constellation of related metabolic risk factors that includes enlarged waist circumference, dyslipidemia, systemic hypertension, and hyperglycemia. MetS has been associated with both GON and AMD and may contribute to disease onset and/or progression in each disease.
C1 [Roddy, Gavin W.] Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Roddy, GW (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
EM roddy.gavin@mayo.edu
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Adornetto A, 2020, PROG BRAIN RES, V256, P189, DOI 10.1016/bs.pbr.2020.07.005
   Aguilar M, 2015, JAMA-J AM MED ASSOC, V313, P1973, DOI 10.1001/jama.2015.4260
   Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Ambreen F, 2014, J PAK MED ASSOC, V64, P664
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bahadoran Z, 2013, EUR J CLIN NUTR, V67, P1303, DOI 10.1038/ejcn.2013.217
   Bales CW, 2013, J CARDIOPULM REHABIL, V33, P201, DOI 10.1097/HCR.0b013e318295019e
   Baudouin C, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100916
   Bonomini F, 2015, AGING DIS, V6, P109, DOI 10.14336/AD.2014.0305
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang YC, 2010, EYE, V24, P1037, DOI 10.1038/eye.2009.247
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Charlton M, 2011, AM J PHYSIOL-GASTR L, V301, pG825, DOI 10.1152/ajpgi.00145.2011
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   d'Azy CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166915
   Dabke K, 2019, J CLIN INVEST, V129, P4050, DOI 10.1172/JCI129194
   Di Daniele N, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092840
   Dong ZZ, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-34
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Feng L, 2013, J ALZHEIMERS DIS, V34, P649, DOI 10.3233/JAD-121885
   Finkel T, 2015, NAT MED, V21, P1416, DOI 10.1038/nm.3998
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Garcia G, 2012, OBES SURG, V22, P810, DOI 10.1007/s11695-012-0601-8
   Gill V, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120888
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Gong HJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107921
   Guarner V, 2015, INTERD T GERONT GERI, V40, P99, DOI 10.1159/000364934
   Guo XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep33950
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Hsu TM, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00088
   Imai K, 2010, INT J OBESITY, V34, P1209, DOI 10.1038/ijo.2010.32
   Jabbehdari S., 2020, SURV OPHTHALMOL
   Jammal AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.8
   Joo J, 2019, INT J OBESITY, V43, P1681, DOI 10.1038/s41366-018-0299-3
   Jung Y, 2020, DIABETES METAB J, V44, P414, DOI 10.4093/dmj.2019.0048
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawai S, 2001, FASEB J, V15, P1285, DOI 10.1096/fj.00-0666fje
   Kawashima M, 2013, EXP GERONTOL, V48, P1096, DOI 10.1016/j.exger.2013.04.002
   Kim D, 2018, CLIN LIVER DIS, V22, P133, DOI 10.1016/j.cld.2017.08.010
   Kim HA, 2016, SCI REP-UK, V6, DOI 10.1038/srep38283
   Kim KY, 2004, NEUROBIOL AGING, V25, P491, DOI 10.1016/j.neurobiolaging.2003.07.005
   Kim M, 2014, ACTA OPHTHALMOL, V92, pe637, DOI 10.1111/aos.12434
   Kim YH, 2014, EYE, V28, P672, DOI 10.1038/eye.2014.43
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kong YXG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.026
   Kroeger H, 2019, FEBS J, V286, P399, DOI 10.1111/febs.14522
   Kubben N, 2017, NAT REV MOL CELL BIO, V18, P595, DOI 10.1038/nrm.2017.68
   Kuo RN, 2019, METAB SYNDR RELAT D, V17, P334, DOI 10.1089/met.2018.0131
   Lee IT, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007851
   Lee JE, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010122
   Lee MK, 2012, OPHTHALMOLOGY, V119, P450, DOI 10.1016/j.ophtha.2011.09.016
   Lee SH, 2017, ACTA OPHTHALMOL, V95, pE564, DOI 10.1111/aos.13487
   Li DY, 2003, BIOCHEM BIOPH RES CO, V309, P457, DOI 10.1016/j.bbrc.2003.08.020
   Lichter PR, 2001, OPHTHALMOLOGY, V108, P1943, DOI 10.1016/S0161-6420(01)00873-9
   Lin CP, 2012, EUR J INTERN MED, V23, P76, DOI 10.1016/j.ejim.2011.06.002
   Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008
   Mamoshina P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-35704-w
   Manzel A, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-013-0404-6
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Martins CC., 2020, CLIN BIOCHEM
   Mattson MP, 2018, CELL METAB, V27, P1176, DOI 10.1016/j.cmet.2018.05.011
   MCCAY CM, 1989, NUTRITION, V5, P155
   Menikdiwela KR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2275-9
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Mohan S, 2019, EUR J PHARMACOL, V860, DOI 10.1016/j.ejphar.2019.172553
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Niriella MA, 2020, LIVER INT, V40, P101, DOI 10.1111/liv.14237
   Obin M, 2000, MECH AGEING DEV, V114, P133, DOI 10.1016/S0047-6374(00)00096-8
   Oh SW, 2005, DIABETES-METAB RES, V21, P434, DOI 10.1002/dmrr.529
   Pabla B, 2015, WORLD J CLIN ONCOL, V6, P133, DOI 10.5306/wjco.v6.i5.133
   Pandi SPS, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108404
   Papadaki A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113342
   Park BJ, 2013, MENOPAUSE, V20, P742, DOI [10.1097/gme.0b013e31827ce3c6, 10.1097/GME.0b013e31827ce3c6]
   Park Sang-shin, 2010, J Prev Med Public Health, V43, P125, DOI 10.3961/jpmph.2010.43.2.125
   Prasun P, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165838
   Provost AC, 2009, INVEST OPHTH VIS SCI, V50, P3931, DOI 10.1167/iovs.08-2527
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rajpal A, 2020, DIABETES OBES METAB, V22, P1496, DOI [10.1111/dom.14080, 10.1111/dom.14080.]
   Ranasinghe P, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4041-1
   Rasoulinejad SA, 2015, OPEN OPHTHALMOL J, V9, P149, DOI 10.2174/1874364101509010149
   Research B, 2013, BCC RES
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Roddy GW, 2020, J GLAUCOMA, V29, P726, DOI 10.1097/IJG.0000000000001593
   Roddy GW, 2020, CURR EYE RES, V45, P726, DOI 10.1080/02713683.2019.1694156
   Roh JH, 2021, METAB SYNDR RELAT D, V19, P1, DOI 10.1089/met.2020.0060
   Russo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1044-5
   Sahinoglu-Keskek N, 2014, PAK J MED SCI, V30, P477, DOI 10.12669/pjms.303.4514
   Saklayen MG, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0812-z
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Schulzer M, 1998, AM J OPHTHALMOL, V126, P487
   Schweitzer C, 2018, INVEST OPHTH VIS SCI, V59, P75, DOI 10.1167/iovs.17-22316
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SHELDON WG, 1995, LAB ANIM SCI, V45, P508
   Siervo M, 2014, J ALZHEIMERS DIS, V41, P151, DOI 10.3233/JAD-132279
   Son J, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0263-8
   Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   Tikellis C, 2008, AM J PHYSIOL-ENDOC M, V295, pE323, DOI 10.1152/ajpendo.00024.2008
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuttle CSL, 2020, AGING CELL, V19, DOI 10.1111/acel.13083
   Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wang YX, 2019, INT J OPHTHALMOL-CHI, V12, P510, DOI 10.18240/ijo.2019.03.24
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wygnanski-Jaffe T, 2015, INT J OPHTHALMOL-CHI, V8, P403, DOI 10.3980/j.issn.2222-3959.2015.02.34
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang X, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5763658
   Yi YH, 2019, DIABET METAB SYND OB, V12, P131, DOI 10.2147/DMSO.S185604
   Zhao J, 2019, AM J OPHTHALMOL, V199, P101, DOI 10.1016/j.ajo.2018.10.017
NR 127
TC 6
Z9 6
U1 5
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2021
VL 32
IS 3
BP 280
EP 287
DI 10.1097/ICU.0000000000000747
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SS7CW
UT WOS:000661913000017
PM 33630786
DA 2022-11-30
ER

PT J
AU Warden, C
   Brantley, MA
AF Warden, Cassandra
   Brantley, Milam A., Jr.
TI Glycine-Conjugated Bile Acids Protect RPE Tight Junctions against
   Oxidative Stress and Inhibit Choroidal Endothelial Cell Angiogenesis In
   Vitro
SO BIOMOLECULES
LA English
DT Article
DE age-related macular degeneration; bile acids; angiogenesis; RPE;
   choroidal endothelial cell; GCA; GDCA; GUDCA
ID TAUROURSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID; RETINAL DEGENERATION;
   MOUSE
AB We previously demonstrated that the bile acid taurocholic acid (TCA) inhibits features of age-related macular degeneration (AMD) in vitro. The purpose of this study was to determine if the glycine-conjugated bile acids glycocholic acid (GCA), glycodeoxycholic acid (GDCA), and glycoursodeoxycholic acid (GUDCA) can protect retinal pigment epithelial (RPE) cells against oxidative damage and inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in choroidal endothelial cells (CECs). Paraquat was used to induce oxidative stress and disrupt tight junctions in HRPEpiC primary human RPE cells. Tight junctions were assessed via transepithelial electrical resistance and ZO-1 immunofluorescence. GCA and GUDCA protected RPE tight junctions against oxidative damage at concentrations of 100-500 mu M, and GDCA protected tight junctions at 10-500 mu M. Angiogenesis was induced with VEGF in RF/6A macaque CECs and evaluated with cell proliferation, cell migration, and tube formation assays. GCA inhibited VEGF-induced CEC migration at 50-500 mu M and tube formation at 10-500 mu M. GUDCA inhibited VEGF-induced CEC migration at 100-500 mu M and tube formation at 50-500 mu M. GDCA had no effect on VEGF-induced angiogenesis. None of the three bile acids significantly inhibited VEGF-induced CEC proliferation. These results suggest glycine-conjugated bile acids may be protective against both atrophic and neovascular AMD.
C1 [Warden, Cassandra; Brantley, Milam A., Jr.] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
C3 Vanderbilt University
RP Brantley, MA (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
EM cassandra.warden@vumc.org; milam.brantley@vumc.org
FU National Institutes of Health [R01 EY022618, P30 EY008126]; Edward N. &
   Della L. Thome Memorial Foundation Awards Program in Age-Related Macular
   Degeneration Research; Research to Prevent Blindness
FX This research was supported by National Institutes of Health grants R01
   EY022618 and P30 EY008126, a grant from the Edward N. & Della L. Thome
   Memorial Foundation Awards Program in Age-Related Macular Degeneration
   Research, and an unrestricted departmental grant to Vanderbilt
   University Medical Center from Research to Prevent Blindness.
CR Alhasani RH, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090367
   Beli E, 2018, DIABETES, V67, P1867, DOI 10.2337/db18-0158
   Boatright JH, 2006, MOL VIS, V12, P1706
   Chiang JYL, 2013, COMPR PHYSIOL, V3, P1191, DOI 10.1002/cphy.c120023
   Daruich A, 2021, NEUROTHERAPEUTICS, V18, P1325, DOI 10.1007/s13311-021-01009-6
   Daruich A, 2019, MOL VIS, V25, P610
   Drack AV, 2012, INVEST OPHTH VIS SCI, V53, P100, DOI 10.1167/iovs.11-8544
   Drechsel DA, 2009, TOXICOL SCI, V112, P427, DOI 10.1093/toxsci/kfp223
   Fernandez-Sanchez L, 2011, INVEST OPHTH VIS SCI, V52, P4998, DOI 10.1167/iovs.11-7496
   Garcia-Ramirez M, 2011, METHODS MOL BIOL, V763, P179, DOI 10.1007/978-1-61779-191-8_12
   Goldman A, 2010, DIS ESOPHAGUS, V23, P83, DOI 10.1111/j.1442-2050.2009.00993.x
   Hylemon PB, 2009, J LIPID RES, V50, P1509, DOI 10.1194/jlr.R900007-JLR200
   Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046
   Kim KA, 2018, LARYNGOSCOPE, V128, pE393, DOI 10.1002/lary.27510
   Kundu S, 2017, MEDCHEMCOMM, V8, P2248, DOI 10.1039/c7md00475c
   Lawson EC, 2016, ADV EXP MED BIOL, V854, P431, DOI 10.1007/978-3-319-17121-0_57
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Monte MJ, 2009, WORLD J GASTROENTERO, V15, P804, DOI 10.3748/wjg.15.804
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Okabe M, 2008, MOL CANCER THER, V7, P3081, DOI 10.1158/1535-7163.MCT-08-0539
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Perez MJ, 2009, WORLD J GASTROENTERO, V15, P1677, DOI 10.3748/wjg.15.1677
   Phillips MJ, 2008, INVEST OPHTH VIS SCI, V49, P2148, DOI 10.1167/iovs.07-1012
   Sarathy J, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13294
   Shiraya T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58039-x
   Suga T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169719
   Wang CF, 2016, J ETHNOPHARMACOL, V185, P162, DOI 10.1016/j.jep.2016.03.026
   Warden C, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107974
   Woo SJ, 2010, J OCUL PHARMACOL TH, V26, P223, DOI 10.1089/jop.2010.0012
   Xie LS, 2016, EXP TOXICOL PATHOL, V68, P69, DOI 10.1016/j.etp.2015.09.010
   Zhu LP, 2020, FASEB J, V34, P4189, DOI 10.1096/fj.201902496RR
   Zhu Y, 2016, J CELL MOL MED, V20, P688, DOI 10.1111/jcmm.12769
NR 32
TC 5
Z9 6
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD MAY
PY 2021
VL 11
IS 5
AR 626
DI 10.3390/biom11050626
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA SG4KP
UT WOS:000653410200001
PM 33922434
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Li, XY
   He, Q
   Yu, ZX
   Xie, YP
   Zhao, XY
   Huang, Y
   Wang, YZ
   Ke, X
   Qian, XH
   Dong, JX
   Ying, WT
AF Li, Xiaoyu
   He, Qing
   Yu, Zixiang
   Xie, Yuping
   Zhao, Xinyuan
   Huang, Yi
   Wang, Yongzhong
   Ke, Xiao
   Qian, Xiaohong
   Dong, Junxing
   Ying, Wantao
TI Site-Specific and Quantitative N-Glycan Heterogeneity Analysis of the
   Charge Isomers of an Anti-VEGF Recombinant Fusion Protein by
   High-Resolution Two-Dimensional Gel Electrophoresis and Mass
   Spectrometry
SO ANALYTICAL CHEMISTRY
LA English
DT Article
AB Glycan modification prompts important concerns about the quality control of biopharmaceutical production. Conbercept is a multiglycosylated recombinant fusion protein drug approved for the treatment of age-related macular degeneration (AMD). With 14 N-glycosites in the molecule and 7 N-glycosites in the monomer, the charge isomer separation and characterization of conbercept pose great challenges due to its enormous heterogeneities. The batch-to-batch stability on the charge isomer distribution and the possible causation of the pattern necessitate the development of effective analytical approaches. Here, the immobilized pH gradient (IPG)-based two-dimensional gel electrophoresis (2-DE) approach was first optimized to achieve high-resolution, high-reproducible separation and preparation of charge isomers. Then, combined with the quantitative analysis strategy of site-specific N-glycan heterogeneity based on the diagnostic MS2 ion (peptides+GlcNAc, Y1 ions) of glycopeptides, an integrated approach for the quantitation of site-specific N-glycan heterogeneities among charge isomers was established. Finally, the quantitation of site-specific N-glycoforms in each of the 2-DE resolved spots were performed, and the results showed that the sialylation tends to increase for gel spots located in the acidic regions. This study provides an effective approach to separate the charge isomers of the heavily glycosylated protein drugs, and to quantitatively explore the site-specific N-glycans dynamics along with the different charge isomers.
C1 [Li, Xiaoyu; Dong, Junxing; Ying, Wantao] Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing 100124, Peoples R China.
   [Dong, Junxing] Beijing Inst Radiat Med, Beijing 100850, Peoples R China.
   [Li, Xiaoyu; Yu, Zixiang; Xie, Yuping; Zhao, Xinyuan; Huang, Yi; Qian, Xiaohong; Ying, Wantao] Beijing Inst Life, Beijing Proteome Res Ctr, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing 102206, Peoples R China.
   [He, Qing; Ke, Xiao] Chengdu Kanghong Pharmaceut Grp Co Ltd, Therapeut Prot Key Lab Sichuan Prov, Chengdu 610036, Sichuan, Peoples R China.
   [Wang, Yongzhong] Swint Biol Suzhou Co Ltd, Suzhou 215123, Jiangsu, Peoples R China.
C3 Beijing University of Technology; Academy of Military Medical Sciences -
   China
RP Dong, JX; Ying, WT (通讯作者)，Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing 100124, Peoples R China.; Dong, JX (通讯作者)，Beijing Inst Radiat Med, Beijing 100850, Peoples R China.; Ying, WT (通讯作者)，Beijing Inst Life, Beijing Proteome Res Ctr, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing 102206, Peoples R China.
EM dongjx@vip.sina.com; yingwantao@mail.ncpsb.org
OI li, xiaoyu/0000-0001-7257-2620
FU National Key Program for Basic Research of China [2017YFF0205400,
   2018YFC0910302]; National Natural Science Foundation of China
   [81530021]; 13th Five-Year Plan "Major New Drug Creation"
   [2018ZX09733001-001-005]; Innovation Foundation of Medicine [BWS14J052,
   16CXZ027]
FX We are grateful for financial support from the National Key Program for
   Basic Research of China (2017YFF0205400, 2018YFC0910302), the National
   Natural Science Foundation of China (81530021), the 13th Five-Year Plan
   "Major New Drug Creation" (2018ZX09733001-001-005), and the Innovation
   Foundation of Medicine (BWS14J052, 16CXZ027).
CR D'Atri V, 2019, ANAL CHEM, V91, P873, DOI 10.1021/acs.analchem.8b03584
   Fekete S, 2016, ANAL CHEM, V88, P480, DOI 10.1021/acs.analchem.5b04561
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031
   Khan A, 2005, CLIN CHIM ACTA, V358, P119, DOI 10.1016/j.cccn.2005.03.013
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Raman R, 2006, GLYCOBIOLOGY, V16, p82R, DOI 10.1093/glycob/cwj080
   Scott NE, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M000031-MCP201
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wohlschlager T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04061-7
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Yang Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13397
   Yu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043903
   Zhu L, 2014, MABS-AUSTIN, V6, P1474, DOI 10.4161/mabs.36313
NR 14
TC 4
Z9 4
U1 0
U2 44
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD APR 21
PY 2020
VL 92
IS 8
BP 5695
EP 5700
DI 10.1021/acs.analchem.0c00592
PG 6
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA LG0CO
UT WOS:000527779200011
PM 32212632
DA 2022-11-30
ER

PT J
AU Volz, C
   Grassmann, F
   Greslechner, R
   Marker, DA
   Peters, P
   Helbig, H
   Gamulescu, MA
AF Volz, Cornelia
   Grassmann, Felix
   Greslechner, Roman
   Marker, David Arthur
   Peters, Patrick
   Helbig, Horst
   Gamulescu, Maria-Andreea
TI Spectral Domain Optical Coherence Tomography Allows the Unification of
   Clinical Decision Making for the Evaluation of Choroidal
   Neovascularization Activity
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Spectral Domain Optical
   Coherence Tomography; Anti-vascular endothelial growth factor therapy;
   Clinical decision-making
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL
   RANIBIZUMAB; DOSING REGIMEN; BEVACIZUMAB; THERAPY; IMPACT
AB Purpose: This prospective observational clinical study investigated the benefits of spectral domain optical coherence tomography for specialists and residents in the management of neovascular age-related macular degeneration (AMD). Procedures: The study involved 49 eyes of 44 patients. Patients were advised to present for reevaluation 4 weeks after the administration of the loading dose of vascular endothelial growth factor (VEGF)-inhibitors (3 intravitreal injections every 4 weeks after diagnosis). They were examined by residents (3-4 years' experience in ophthalmology) and specialists (> 5 years' experience). Each examiner evaluated the clinical situation and the spectral domain optical coherence tomography (SD-OCT) scan. After each evaluation, the examiners independently stated if further anti-VEGF treatment was recommended. The "true outcome" was defined as the specialist decision based on clinical evaluation and SD-OCT. Results: Specialists and residents did not significantly differ in their accuracy in deciding on the correct treatment (p = 0.705 and p = 1), with or without the aid of SD-OCT. Both groups benefited from using SD-OCT to support their recommendations (p = 0.001 and p = 0.0002) and achieved a similar level of accuracy (p = 1 for difference). Conclusions: Residents benefited more than specialists by using SD-OCT to substantiate their recommendation on how to manage exudative AMD after the administration of the loading dose. (C) 2018 S. Karger AG, Basel.
C1 [Volz, Cornelia; Greslechner, Roman; Marker, David Arthur; Peters, Patrick; Helbig, Horst; Gamulescu, Maria-Andreea] Univ Hosp Regensburg, Dept Ophthalmol, Franz Josef Str Allee 11, DE-93053 Regensburg, Germany.
   [Grassmann, Felix] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Volz, C (通讯作者)，Univ Hosp Regensburg, Dept Ophthalmol, Franz Josef Str Allee 11, DE-93053 Regensburg, Germany.
EM cornelia.volz@klinik.uni-regensburg.de
RI Volz, Cornelia/ABB-4451-2021
OI Grassmann, Felix/0000-0003-1390-7528
CR Banning M, 2008, J CLIN NURS, V17, P187, DOI 10.1111/j.1365-2702.2006.01791.x
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2004, OPHTHALMOLOGY, V111, P712, DOI 10.1016/j.ophtha.2003.06.028
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Do DV, 2007, RETINA-J RET VIT DIS, V27, P552, DOI 10.1097/IAE.0b013e31802c518b
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lall A, 2005, OPHTHALMOLOGY, V112, P734, DOI 10.1016/j.ophtha.2004.10.001
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Manousaridis K, 2012, EUR J OPHTHALMOL
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Rahimy E, 2014, AM J OPHTHALMOL, V158, P345, DOI 10.1016/j.ajo.2014.05.013
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal KB, 2009, OPHTHALMOLOGE, V106, P334, DOI 10.1007/s00347-008-1802-3
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Ziemssen F, 2016, OPHTHALMOLOGE, V113, P143, DOI 10.1007/s00347-015-0099-2
NR 28
TC 2
Z9 2
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2019
VL 241
IS 1
BP 32
EP 37
DI 10.1159/000489344
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF4CE
UT WOS:000454180000005
PM 29929185
DA 2022-11-30
ER

PT J
AU Nagar, S
   Noveral, SM
   Trudler, D
   Lopez, KM
   McKercher, SR
   Han, X
   Yates, JR
   Pina-Crespo, JC
   Nakanishi, N
   Satoh, T
   Okamoto, S
   Lipton, SA
AF Nagar, Saumya
   Noveral, Sarah M.
   Trudler, Dorit
   Lopez, Kevin M.
   McKercher, Scott R.
   Han, Xuemei
   Yates, John R., III
   Pina-Crespo, Juan C.
   Nakanishi, Nobuki
   Satoh, Takumi
   Okamoto, Shu-ichi
   Lipton, Stuart A.
TI MEF2D haploinsufficiency downregulates the NRF2 pathway and renders
   photoreceptors susceptible to light-induced oxidative stress
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE MEF2D; AMD; LIRD; NRF2; proelectrophilic drug
ID PRO-ELECTROPHILIC COMPOUND; PLACEBO-CONTROLLED PHASE-3; SIGNALING
   PATHWAY; CARNOSIC ACID; RETINAL DEGENERATION; NEURONAL SURVIVAL; INDUCED
   APOPTOSIS; CHEMICAL PROBES; S-NITROSYLATION; MOUSE MODEL
AB Gaining mechanistic insight into interaction between causative factors of complex multifactorial diseases involving photoreceptor damage might aid in devising effective therapies. Oxidative stress is one of the potential unifying mechanisms for interplay between genetic and environmental factors that contribute to photoreceptor pathology. Interestingly, the transcription factor myocyte enhancer factor 2d (MEF2D) is known to be important in photoreceptor survival, as knockout of this transcription factor results in loss of photoreceptors in mice. Here, using a mild light-induced retinal degeneration model, we show that the diminished MEF2D transcriptional activity in Mef2d(+/-) retina is further reduced under photostimulation-induced oxidative stress. Reactive oxygen species cause an aberrant redox modification on MEF2D, consequently inhibiting transcription of its downstream target, nuclear factor (erythroid-derived 2)-like 2 (NRF2). NRF2 is a master regulator of phase II antiinflammatory and antioxidant gene expression. In the Mef2d heterozygous mouse retina, NRF2 is not up-regulated to a normal degree in the face of light-induced oxidative stress, contributing to accelerated photoreceptor cell death. Furthermore, to combat this injury, we found that activation of the endogenous NRF2 pathway using proelectrophilic drugs rescues photoreceptors from photo-induced oxidative stress and may therefore represent a viable treatment for oxidative stress-induced photoreceptor degeneration, which is thought to contribute to some forms of retinitis pigmentosa and age-related macular degeneration.
C1 [Nagar, Saumya; Noveral, Sarah M.; Trudler, Dorit; Lopez, Kevin M.; McKercher, Scott R.; Pina-Crespo, Juan C.; Nakanishi, Nobuki; Satoh, Takumi; Okamoto, Shu-ichi; Lipton, Stuart A.] Sanford Burnham Prebys Med Discovery Inst, Neurosci & Aging Res Ctr, La Jolla, CA 92037 USA.
   [Nagar, Saumya; Noveral, Sarah M.; Trudler, Dorit; Lopez, Kevin M.; McKercher, Scott R.; Pina-Crespo, Juan C.; Nakanishi, Nobuki; Satoh, Takumi; Okamoto, Shu-ichi; Lipton, Stuart A.] Sanford Burnham Prebys Med Discovery Inst, Grad Sch Biomed Sci, La Jolla, CA 92037 USA.
   [Noveral, Sarah M.; Trudler, Dorit; Lopez, Kevin M.; McKercher, Scott R.; Nakanishi, Nobuki; Satoh, Takumi; Okamoto, Shu-ichi; Lipton, Stuart A.] Scintillon Inst, Neurodegenerat Dis Ctr, San Diego, CA 92121 USA.
   [Noveral, Sarah M.; Lipton, Stuart A.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.
   [Noveral, Sarah M.; Lipton, Stuart A.] Univ Calif San Diego, Sch Med, Program Biomed Sci, La Jolla, CA 92093 USA.
   [Han, Xuemei; Yates, John R., III; Lipton, Stuart A.] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA.
   [Satoh, Takumi] Tokyo Univ Technol, Sch Biosci & Biotechnol, Dept Antiaging Food Res, Tokyo 1920982, Japan.
   [Okamoto, Shu-ichi] Takeda Pharmaceut Co Ltd, Tokyo 1038668, Japan.
C3 Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham
   Prebys Medical Discovery Institute; University of California System;
   University of California San Diego; University of California System;
   University of California San Diego; Scripps Research Institute; Tokyo
   University of Technology; Takeda Pharmaceutical Company Ltd
RP Lipton, SA (通讯作者)，Sanford Burnham Prebys Med Discovery Inst, Neurosci & Aging Res Ctr, La Jolla, CA 92037 USA.; Lipton, SA (通讯作者)，Sanford Burnham Prebys Med Discovery Inst, Grad Sch Biomed Sci, La Jolla, CA 92037 USA.; Lipton, SA (通讯作者)，Scintillon Inst, Neurodegenerat Dis Ctr, San Diego, CA 92121 USA.; Lipton, SA (通讯作者)，Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.; Lipton, SA (通讯作者)，Univ Calif San Diego, Sch Med, Program Biomed Sci, La Jolla, CA 92093 USA.; Lipton, SA (通讯作者)，Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA.
EM slipton@ucsd.edu
RI Piña-Crespo, Juan C./A-5579-2009
OI Piña-Crespo, Juan C./0000-0003-2803-7377; Lipton,
   Stuart/0000-0002-3490-1259
FU NIH [R01 NS086890, DP1 DA041722, P01 HD29587]; La Jolla
   Interdisciplinary Neuroscience Center Core Grant [P30 NS076411]; Arnold
   and Mabel Beckman Initiative for Macular Research; EUNICE KENNEDY
   SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
   [P01HD029587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKE [R01NS086890, P30NS076411] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [DP1DA041722]
   Funding Source: NIH RePORTER
FX We thank Dr. Qing Ming for reagents. This work was supported in part by
   NIH Grants R01 NS086890, DP1 DA041722, and P01 HD29587; La Jolla
   Interdisciplinary Neuroscience Center Core Grant P30 NS076411; and a
   grant from the Arnold and Mabel Beckman Initiative for Macular Research.
CR Ahuja M, 2016, J NEUROSCI, V36, P6332, DOI 10.1523/JNEUROSCI.0426-16.2016
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andzelm MM, 2015, NEURON, V86, P247, DOI 10.1016/j.neuron.2015.02.038
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bocci V, 2015, FRONT CHEM, V3, DOI 10.3389/fchem.2015.00004
   Campochiaro PA, 2015, ANTIOXID REDOX SIGN, V23, P643, DOI 10.1089/ars.2015.6327
   CARPENTER TO, 1995, J PHARM SCI, V84, P222, DOI 10.1002/jps.2600840220
   Chan SF, 2015, GENOM DATA, V3, P24, DOI 10.1016/j.gdata.2014.10.022
   Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718
   Chen J, 1999, INVEST OPHTH VIS SCI, V40, P2978
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cideciyan AV, 2005, P NATL ACAD SCI USA, V102, P5233, DOI 10.1073/pnas.0408892102
   Contin MA, 2016, EYE, V30, P255, DOI 10.1038/eye.2015.221
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Donovan SL, 2006, NAT PROTOC, V1, P2710, DOI 10.1038/nprot.2006.454
   Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328
   Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287
   Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634
   Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Huang K, 2000, EMBO J, V19, P2615, DOI 10.1093/emboj/19.11.2615
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joshi Gururaj, 2012, Recent Pat CNS Drug Discov, V7, P218
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim Y, 2008, J CLIN INVEST, V118, P124, DOI 10.1172/JCI33255
   Klein BEK, 2014, INVEST OPHTH VIS SCI, V55, P5855, DOI 10.1167/iovs.14-14602
   Klomsiri C, 2010, METHOD ENZYMOL, V473, P77, DOI 10.1016/S0076-6879(10)73003-2
   Kriegenburg F, 2011, ANTIOXID REDOX SIGN, V15, P2265, DOI 10.1089/ars.2010.3590
   LaVail MM, 1999, INVEST OPHTH VIS SCI, V40, P1020
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Montana CL, 2011, JOVE-J VIS EXP, DOI 10.3791/2821
   Naash ML, 1996, INVEST OPHTH VIS SCI, V37, P775
   Nakamura T, 2015, NEUROBIOL DIS, V84, P99, DOI 10.1016/j.nbd.2015.03.017
   Negre-Salvayre A, 2008, BRIT J PHARMACOL, V153, P6, DOI 10.1038/sj.bjp.0707395
   Nelson KJ, 2010, METHOD ENZYMOL, V473, P95, DOI 10.1016/S0076-6879(10)73004-4
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697
   Okamoto S, 2014, CELL REP, V8, P217, DOI 10.1016/j.celrep.2014.06.005
   Omori Y, 2015, GENES CELLS, V20, P408, DOI 10.1111/gtc.12233
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Organisciak DT, 1999, CURR EYE RES, V19, P188, DOI 10.1076/ceyr.19.2.188.5333
   Paciorkowski AR, 2013, NEUROGENETICS, V14, P99, DOI 10.1007/s10048-013-0356-y
   Paskowitz DM, 2006, BRIT J OPHTHALMOL, V90, P1060, DOI 10.1136/bjo.2006.097436
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Ryan SD, 2013, CELL, V155, P1351, DOI 10.1016/j.cell.2013.11.009
   Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568
   SANYAL S, 1986, VISION RES, V26, P1177, DOI 10.1016/0042-6989(86)90099-4
   Satoh T, 2008, NEUROSCI LETT, V434, P260, DOI 10.1016/j.neulet.2008.01.079
   Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x
   Satoh T, 2007, TRENDS NEUROSCI, V30, P37, DOI 10.1016/j.tins.2006.11.004
   Satoh T, 2013, FREE RADICAL BIO MED, V65, P645, DOI 10.1016/j.freeradbiomed.2013.07.022
   Satoh T, 2011, J NEUROCHEM, V119, P569, DOI 10.1111/j.1471-4159.2011.07449.x
   Siu TL, 2008, CLIN EXP OPHTHALMOL, V36, P176, DOI 10.1111/j.1442-9071.2008.01699.x
   Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tan SM, 2014, REDOX REP, V19, P107, DOI 10.1179/1351000214Y.0000000087
   Vaka SRK, 2011, J PHARM SCI-US, V100, P3139, DOI 10.1002/jps.22528
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Wenzel A, 2003, INVEST OPHTH VIS SCI, V44, P2798, DOI 10.1167/iovs.02-1134
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Xu CJ, 2005, ARCH PHARM RES, V28, P249, DOI 10.1007/BF02977789
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 74
TC 22
Z9 22
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 16
PY 2017
VL 114
IS 20
BP E4048
EP E4056
DI 10.1073/pnas.1613067114
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EU8UT
UT WOS:000401314700023
PM 28461502
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Nebbioso, M
   Buomprisco, G
   Pascarella, A
   Pescosolido, N
AF Nebbioso, Marcella
   Buomprisco, Giuseppe
   Pascarella, Antonia
   Pescosolido, Nicola
TI Modulatory effects of 1,25-dihydroxyvitamin D3 on eye disorders: A
   critical review
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review
DE Anti-angiogenesis; cytokines; diabetic retinopathy; eye diseases;
   glaucoma; 1,25-dihydroxyvitamin D3
ID VITAMIN-D STATUS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; MULTIPLE-SCLEROSIS;
   INTRAOCULAR-PRESSURE; ENDOTHELIAL-CELLS; RENIN-ANGIOTENSIN; 10-YEAR
   INCIDENCE; GROWTH-FACTOR; D DEFICIENCY; PREGNANCY
AB Many studies have shown that the presence of 1,25-dihydroxyvitamin D3 in the eye is able to modulate inflammatory responses. In fact, it has been demonstrated that topical administration of vitamin D3 inhibits Langerhans cells migration from the central cornea, corneal neovascularization, and production of cytokines (i.e., interleukin-1-6-8) in experimental animals.Moreover, both in vitro and in vivo studies have demonstrated that vitamin D is a potent inhibitor of retinal neovascularization. It has been shown that calcitriol, the biologically active form of vitamin D, inhibits angiogenesis both in cultured endothelial cells and in retinas from guinea pigs with retinoblastoma or oxygen-induced ischemic retinopathy. In addition, it seems that this compound is able to prevent the progression from early to neovascular age-related macular degeneration (AMD) and, at the same time, to down-regulate the characteristic inflammatory cascade at the retinal pigment epithelium-choroid interface due to its anti-inflammatory and immunomodulatory capabilities.Furthermore, 1,25-dihydroxyvitamin D3 and its analogue, 2-methylene-19-nor-1,25-dihydroxyvitamin D3, are able to modulate intraocular pressure (IOP) through gene expression. Several studies have suggested a role in glaucoma and diabetic retinopathy therapies for vitamin D3.In conclusion, this review summarizes our current knowledge on the potential use of vitamin D3 in the protection and treatment of ocular diseases in ophthalmology.
C1 [Nebbioso, Marcella; Buomprisco, Giuseppe] Sapienza Univ Rome, Dept Sense Organs, Rome, Italy.
   [Pascarella, Antonia] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Rome, Italy.
   [Pescosolido, Nicola] Sapienza Univ Rome, Dept Cardiol Resp Nephrol Anesthesiol & Geriatr S, Rome, Italy.
C3 Sapienza University Rome; Sapienza University Rome; Sapienza University
   Rome
RP Nebbioso, M (通讯作者)，Sapienza Univ Rome, Ctr Ocular Electrophysiol, Dept Sense Organs, Viale Policlin 155, I-00161 Rome, Italy.
EM marcella.nebbioso@uniroma1.it
RI Buomprisco, Giuseppe/AAH-8167-2021; Nebbioso, Marcella/K-6878-2018
OI Buomprisco, Giuseppe/0000-0003-4673-5670; Nebbioso,
   Marcella/0000-0002-5512-0849
CR Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Ascherio A, 2014, JAMA NEUROL, V71, P306, DOI 10.1001/jamaneurol.2013.5993
   Bonnefoy A, 2008, CELL MOL LIFE SCI, V65, P713, DOI 10.1007/s00018-007-7487-y
   Buan K., 2009, ANTROPOL COLL, V2, P99
   Calvo MS, 2004, AM J CLIN NUTR, V80, p1710S, DOI 10.1093/ajcn/80.6.1710S
   Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788
   Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960
   Chen S, 2007, J IMMUNOL, V179, P1634, DOI 10.4049/jimmunol.179.3.1634
   Cherniack EP, 2008, GERIATRICS-US, V63, P24
   Cole N, 2001, INFECT IMMUN, V69, P4116, DOI 10.1128/IAI.69.6.4116-4119.2001
   Dror DK, 2011, CURR OPIN OBSTET GYN, V23, P422, DOI 10.1097/GCO.0b013e32834cb791
   Faralli JA, 2009, EXP EYE RES, V88, P689, DOI 10.1016/j.exer.2008.08.019
   Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1
   Gregori S, 2001, J IMMUNOL, V167, P1945, DOI 10.4049/jimmunol.167.4.1945
   Hadi HAR, 2007, VASC HEALTH RISK MAN, V3, P853
   Hisa T, 1996, ARCH DERMATOL RES, V288, P262, DOI 10.1007/s004030050058
   Ho SL, 2012, CRIT REV FOOD SCI, V52, P980, DOI 10.1080/10408398.2010.516034
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hollis BW, 2004, AM J CLIN NUTR, V79, P717
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaur H, 2011, DIABETES CARE, V34, P1400, DOI 10.2337/dc11-0103
   Kendrick J, 2009, ATHEROSCLEROSIS, V205, P255, DOI 10.1016/j.atherosclerosis.2008.10.033
   KERNACKI KA, 1994, J OCUL PHARMACOL, V10, P281, DOI 10.1089/jop.1994.10.281
   Kimball SM, 2007, AM J CLIN NUTR, V86, P645, DOI 10.1093/ajcn/86.3.645
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kutuzova GD, 2012, ARCH BIOCHEM BIOPHYS, V518, P53, DOI 10.1016/j.abb.2011.10.022
   Lansink M, 1998, BLOOD, V92, P927
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Lee YJ, 2010, CANCER RES, V70, P948, DOI 10.1158/0008-5472.CAN-09-3094
   Lin YP, 2012, CURR EYE RES, V37, P871, DOI 10.3109/02713683.2012.688235
   Liu WJ, 2010, MOL VIS, V16, P93
   MacLean HJ, 2009, LANCET NEUROL, V8, P6, DOI 10.1016/S1474-4422(08)70272-2
   Maynard CL, 2008, IMMUNOL REV, V226, P219, DOI 10.1111/j.1600-065X.2008.00711.x
   MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Morse NL, 2012, NUTRIENTS, V4, P799, DOI 10.3390/nu4070799
   Nebbioso M, 2011, OPTOMETRY VISION SCI, V88, pE928, DOI 10.1097/OPX.0b013e31821c6ca4
   NEVEU I, 1994, MOL BRAIN RES, V24, P70, DOI 10.1016/0169-328X(94)90119-8
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405
   Pescosolido N, 2012, ULTRASTRUCT PATHOL, V36, P102, DOI 10.3109/01913123.2011.634090
   Picotto G, 2012, CANCER INVEST, V30, P604, DOI 10.3109/07357907.2012.721039
   Pittas AG, 2007, J CLIN ENDOCR METAB, V92, P2017, DOI 10.1210/jc.2007-0298
   SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83
   Smolders J, 2008, J NEUROIMMUNOL, V194, P7, DOI 10.1016/j.jneuroim.2007.11.014
   Stromnes IM, 2007, NAT IMMUNOL, V8, P19, DOI 10.1038/ni0107-19
   Suzuki T, 2000, CURR EYE RES, V20, P127, DOI 10.1076/0271-3683(200002)20:2;1-D;FT127
   Suzuki T, 2000, INVEST OPHTH VIS SCI, V41, P154
   Tang J, 2009, J IMMUNOL, V182, P4624, DOI 10.4049/jimmunol.0801543
   Teodoro JG, 2006, SCIENCE, V313, P968, DOI 10.1126/science.1126391
   Tian B, 2009, EXP EYE RES, V88, P713, DOI 10.1016/j.exer.2008.08.008
   Trapp BD, 1999, J NEUROIMMUNOL, V98, P49, DOI 10.1016/S0165-5728(99)00081-8
   Tuohimaa P, 2007, CANCER EPIDEM BIOMAR, V16, P302, DOI 10.1158/1055-9965.EPI-06-0777
   Vaajanen A, 2008, CURR EYE RES, V33, P325, DOI 10.1080/02713680802011679
   Vaajanen A, 2008, ANN MED, V40, P418, DOI 10.1080/07853890802043924
   Vaajanen A, 2011, BASIC CLIN PHARMACOL, V109, P217, DOI 10.1111/j.1742-7843.2011.00729.x
   VanAmerongen BM, 2004, EUR J CLIN NUTR, V58, P1095, DOI 10.1038/sj.ejcn.1601952
   WALLOW IHL, 1993, CURR EYE RES, V12, P945, DOI 10.3109/02713689309020401
   Wang D. S., 1997, ENDOCRINOLOGY, V92, P927
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yasmin R, 2005, J BIOL CHEM, V280, P40152, DOI 10.1074/jbc.M507708200
   Yin ZH, 2011, INVEST OPHTH VIS SCI, V52, P7359, DOI 10.1167/iovs.11-7605
NR 64
TC 21
Z9 22
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PY 2017
VL 57
IS 3
BP 559
EP 565
DI 10.1080/10408398.2014.893504
PG 7
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA EC0BY
UT WOS:000387763800007
PM 26054653
DA 2022-11-30
ER

PT J
AU Kim, SJ
   Lee, HJ
   Yun, JH
   Ko, JH
   Choi, DY
   Oh, JY
AF Kim, Sang Jin
   Lee, Hyun Ju
   Yun, Ji-Hyun
   Ko, Jung Hwa
   Choi, Da Ye
   Oh, Joo Youn
TI Intravitreal TSG-6 suppresses laser-induced choroidal neovascularization
   by inhibiting CCR2(+) monocyte recruitment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; STERILE INFLAMMATION; RAT MODEL; IN-VIVO;
   MACROPHAGES; MICE; CELLS; IDENTIFICATION; PREVALENCE; INFILTRATE
AB Choroidal neovascularization (CNV) is the hallmark of wet age-related macular degeneration (AMD), one of the leading causes of blindness in the elderly. Although the pathogenesis of CNV is not clear, a number of studies show that ocular-infiltrating macrophages and inflammation play a critical role in the development of CNV. TNF alpha-stimulated gene/protein (TSG)-6 is a multifunctional endogenous protein that has anti-inflammatory activities partly by regulating macrophage activation. Therefore, we here investigated the therapeutic potential of TSG-6 in a rat model of CNV induced by laser photocoagulation. Time course analysis showed that the expression of VEGF and pro-inflammatory cytokines in the choroid was up-regulated early after laser injury, and gradually decreased to baseline over 14 days. An intravitreal injection of TSG-6 suppressed the expression of VEGF and pro-inflammatory cytokines including CCL2, and reduced the size of CNV. Also, the number of Iba(+) and CCR2(+) cells including infiltrating macrophages was markedly lower in the CNV lesion of TSG-6-treated eyes. Further analysis identified CCR2(+) CD11b(+) CD11c(+) cells and CCR2(+) CD11b(-)CD11c(+) cells as the cell populations that were increased by laser injury and reduced by TSG-6 treatment. Together, the results demonstrate that TSG-6 inhibits inflammation and CCR2(+) monocyte recruitment into the choroid, and suppresses the development of CNV.
C1 [Kim, Sang Jin; Choi, Da Ye] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
   [Kim, Sang Jin; Yun, Ji-Hyun] Samsung Biomed Res Inst, Seoul 135710, South Korea.
   [Lee, Hyun Ju; Ko, Jung Hwa; Oh, Joo Youn] Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul 110744, South Korea.
   [Lee, Hyun Ju; Ko, Jung Hwa; Oh, Joo Youn] Seoul Natl Univ Hosp, Biomed Res Inst, Lab Ocular Regenerat Med & Immunol, Seoul 110744, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Seoul National University
   (SNU); Seoul National University Hospital; Seoul National University
   (SNU); Seoul National University Hospital
RP Kim, SJ (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM sangjinkim@skku.edu; jooyounoh77@gmail.com
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [A112023, HI13C1826]; Samsung Medical Center
   [SMR1120521]; Samsung Biomedical Research Institute [SMX1131941]
FX This work was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (A112023 to JYO
   and HI13C1826 to SJK), Samsung Medical Center grant (#SMR1120521 to SJK)
   and Samsung Biomedical Research Institute grant (#SMX1131941 to SJK).
CR Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Foskett AM, 2014, AM J PHYSIOL-LUNG C, V306, pL120, DOI 10.1152/ajplung.00240.2013
   Fukuda S, 2013, STEM CELLS, V31, P2149, DOI 10.1002/stem.1469
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Itaya M, 2007, INVEST OPHTH VIS SCI, V48, P5677, DOI 10.1167/iovs.07-0156
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kim J, 2014, J OCUL PHARMACOL TH, V30, P847, DOI 10.1089/jop.2014.0021
   Kim JA, 2014, INVEST OPHTH VIS SCI, V55, P4905, DOI 10.1167/iovs.14-14538
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mantovani A, 2014, CURR OPIN PHARMACOL, V17, P38, DOI 10.1016/j.coph.2014.07.004
   Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407
   Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Oh JY, 2012, EMBO MOL MED, V4, P435, DOI 10.1002/emmm.201200221
   Oh JY, 2010, P NATL ACAD SCI USA, V107, P16875, DOI 10.1073/pnas.1012451107
   Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211
   Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Vedula SS, 2008, COCHRANE DB SYST REV, V16
   Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043768
   Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017
   Wisniewski HG, 2005, J BIOL CHEM, V280, P14476, DOI 10.1074/jbc.M411734200
   Xie P., PLOS ONE, V6
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
NR 46
TC 15
Z9 15
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 7
PY 2015
VL 5
AR 11872
DI 10.1038/srep11872
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CM1PU
UT WOS:000357453600001
PM 26149224
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Harvey, H
   Durant, S
AF Harvey, Hannah
   Durant, Szonya
TI The role of glial cells and the complement system in retinal diseases
   and Alzheimer's disease: common neural degeneration mechanisms
SO EXPERIMENTAL BRAIN RESEARCH
LA English
DT Review
DE Complement system; Glia; Alzheimer's disease; Age-related macular
   degeneration; Glaucoma; Neurodegeneration
ID GROWTH-FACTOR RECEPTOR; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA;
   MACULAR DEGENERATION; AMYLOID-BETA; GANGLION-CELLS; PIGMENT EPITHELIUM;
   OXIDATIVE STRESS; FACTOR-H; MICROGLIAL ACTIVATION
AB Many age-related degenerative diseases of the central nervous system (CNS) increasingly appear to have similarities in their underlying causes. By applying knowledge between disorders, and in particular between degenerative diseases of different components of the CNS (e.g. the eye and the brain), we can begin to elucidate general mechanisms of neural degeneration. Age-related macular degeneration and glaucoma, two diseases of retinal neurons, which have recently been discussed in view of their common mechanisms with Alzheimer's disease, highlight this perspective. This review discusses the common roles of the complement system (an immunological system) and glial cells (providing, amongst other functions, trophic support to neurons) in these three disorders. A number of facets of these systems would seem to be involved in the mechanisms of degeneration in at least two of the three diseases considered here. Regulatory proteins of the complement system (such as factor H), neurotrophin levels, and the interaction of microglia with the complement system in particular may be general to all three presentations of neural degeneration. Investigating the functioning of these fundamental systems across different diseases exemplifies the importance of considering advances in knowledge across a wider base than specific disease pathology. This may give insights both for understanding the function of these supporting systems and providing an avenue for developing future therapeutic targets general to neural degenerative diseases.
C1 [Harvey, Hannah; Durant, Szonya] Univ London, Royal Holloway, Egham TW20 0EX, Surrey, England.
C3 University of London; Royal Holloway University London
RP Harvey, H (通讯作者)，Univ London, Royal Holloway, Egham TW20 0EX, Surrey, England.
EM Hannah.Harvey.2010@live.rhul.ac.uk
OI Harvey, Hannah/0000-0001-5608-5697
CR Abbas A.K., 2016, CELL MOL IMMUNOL, Vninth
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0
   Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194
   Barghorn S, 2005, J NEUROCHEM, V95, P834, DOI 10.1111/j.1471-4159.2005.03407.x
   Bayer AU, 2002, EUR NEUROL, V47, P165, DOI 10.1159/000047976
   BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BINDER C, 2013, Patent No. 20130011857
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Caraci F, 2012, NEUROCHEM INT, V61, P559, DOI 10.1016/j.neuint.2012.01.017
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6
   Chiu K, 2012, AGE, V34, P633, DOI 10.1007/s11357-011-9260-2
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   Cingle KA, 1996, CURR EYE RES, V15, P433, DOI 10.3109/02713689608995834
   Collard CD, 2000, AM J PATHOL, V156, P1549, DOI 10.1016/S0002-9440(10)65026-2
   Connor B, 1997, MOL BRAIN RES, V49, P71, DOI 10.1016/S0169-328X(97)00125-3
   Cordeiro MF, 2004, P NATL ACAD SCI USA, V101, P13352, DOI 10.1073/pnas.0405479101
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Dawson VL, 1996, NEUROCHEM INT, V29, P97, DOI 10.1016/0197-0186(95)00149-2
   Day AJ, 2011, EXPERT REV OPHTHALMO, V6, P123, DOI 10.1586/EOP.11.10
   de Castro JPF, 2013, EXP EYE RES, V111, P61, DOI 10.1016/j.exer.2013.03.019
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DOWSON JH, 1982, BRIT J PSYCHIAT, V140, P142, DOI 10.1192/bjp.140.2.142
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Esparza TJ, 2013, ANN NEUROL, V73, P104, DOI 10.1002/ana.23748
   Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005
   Farkas RH, 2004, INVEST OPHTH VIS SCI, V45, P1410, DOI 10.1167/iovs.03-0872
   FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K
   FISCHER B, 1995, J MOL MED, V73, P465
   Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4
   Gaipl US, 2005, AUTOIMMUN REV, V4, P189, DOI 10.1016/j.autrev.2004.10.007
   Garcia P, 2010, J NEUROSCI, V30, P7516, DOI 10.1523/JNEUROSCI.4182-09.2010
   Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1
   Gellrich MM, 1996, GRAEF ARCH CLIN EXP, V234, P315, DOI 10.1007/BF00220707
   Girouard H, 2006, J APPL PHYSIOL, V100, P328, DOI 10.1152/japplphysiol.00966.2005
   Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017
   GLOVINSKY Y, 1993, INVEST OPHTH VIS SCI, V34, P395
   GOLDBERG J, 2012, NT 501 CNTF IMPLANT
   GONZALEZ C, 2012, ACTA OPHTHALMOL, V90, DOI DOI 10.1111/J.1755-3768.2012.S087.X
   GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   HOWELL G, 2010, ASS RES VIS OPHTHALM, V2098, pA197
   Jessen KR, 2004, INT J BIOCHEM CELL B, V36, P1861, DOI 10.1016/j.biocel.2004.02.023
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   KHOURY JE, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI DOI 10.1016/J.TIPS.2008.08.004
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Kuehn Markus H, 2005, Ophthalmol Clin North Am, V18, P383, DOI 10.1016/j.ohc.2005.04.002
   KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5
   Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630
   LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168
   Lambert W, 2001, INVEST OPHTH VIS SCI, V42, P2315
   Lanzrein AS, 1998, NEUROREPORT, V9, P1491, DOI 10.1097/00001756-199805110-00045
   Laquis S, 1998, BRAIN RES, V784, P100, DOI 10.1016/S0006-8993(97)01189-X
   Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   LeVine SM, 1997, BRAIN RES, V760, P298, DOI 10.1016/S0006-8993(97)00470-8
   Liu B, 2001, ARCH OPHTHALMOL-CHIC, V119, P240
   Liu B, 2006, J NEUROSCI, V26, P7532, DOI 10.1523/JNEUROSCI.1004-06.2006
   Lott IT, 2005, NEUROBIOL AGING, V26, P383, DOI 10.1016/j.neurobiolaging.2004.08.005
   Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J
   McKinnon SJ, 2003, FRONT BIOSCI-LANDMRK, V8, pS1140, DOI 10.2741/1172
   MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J
   Mold C, 2001, IMMUNOLOGY, V102, P359, DOI 10.1046/j.1365-2567.2001.01192.x
   Morgan J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1524
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   NATHANSON JA, 1995, INVEST OPHTH VIS SCI, V36, P1774
   Neufeld AH, 1999, SURV OPHTHALMOL, V43, pS129, DOI 10.1016/S0039-6257(99)00010-7
   Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944
   Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Nunomura A, 2006, J NEUROPATH EXP NEUR, V65, P631, DOI 10.1097/01.jnen.0000228136.58062.bf
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pak K, 2003, NEUROMOL MED, V3, P53, DOI 10.1385/NMM:3:1:53
   Paulssen RH, 2008, STEROIDS, V73, P116, DOI 10.1016/j.steroids.2007.09.010
   Pease ME, 2009, INVEST OPHTH VIS SCI, V50, P2194, DOI 10.1167/iovs.08-3013
   POSTHUMUS RG, 1952, OPHTHALMOLOGICA, V124, P17, DOI 10.1159/000301245
   Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002
   Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460
   Roca-Santiago H.M., 2006, Arch Soc Esp Oftalmol, V81, P73
   Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065
   Roth KA, 2001, MENT RETARD DEV D R, V7, P261, DOI 10.1002/mrdd.1036
   Rus H, 2005, IMMUNOL RES, V33, P103, DOI 10.1385/IR:33:2:103
   Saurenmann RK, 2006, RHEUMATOLOGY, V45, P982, DOI 10.1093/rheumatology/kel030
   SAVARI M, 2003, J NEUROIMMUNOL, V137, P12, DOI DOI 10.1016/S0165-5728(03)00040-7
   Schindowski K, 2008, GENES BRAIN BEHAV, V7, P43, DOI 10.1111/j.1601-183X.2007.00378.x
   Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069
   SHEPARD AR, 2009, Patent No. 2009061721
   Sihota Ramanjit, 2001, Indian Journal of Ophthalmology, V49, P255
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   SKURLA E, 1988, J AM GERIATR SOC, V36, P97, DOI 10.1111/j.1532-5415.1988.tb01776.x
   SOHN J, 2007, IMMUNE RESPONSE EYE, V92, P105
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streit WJ, 2005, BRAIN RES REV, V48, P234, DOI 10.1016/j.brainresrev.2004.12.013
   Tan Bobby, 2012, Front Biosci (Schol Ed), V4, P1402
   Taylor CA, 2004, INVEST OPHTH VIS SCI, V45, P3568, DOI 10.1167/iovs.03-1367
   Taylor S, 2011, EXP EYE RES, V92, P338, DOI 10.1016/j.exer.2011.01.012
   Tezel G, 2000, J NEUROSCI, V20, P8693
   Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787
   Tezel G, 2010, INVEST OPHTH VIS SCI, V51, P5071, DOI 10.1167/iovs.10-5289
   Theodossiadis PG, 2007, RETINA-J RET VIT DIS, V27, P399, DOI 10.1097/MAJ.0b013e3180318fbc
   Tichaczek-Goska D, 2012, ADV CLIN EXP MED, V21, P105
   Tobinick E, 2007, CURR ALZHEIMER RES, V4, P550, DOI 10.2174/156720507783018217
   Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   WALKER DG, 1995, J NEUROSCI RES, V40, P478, DOI 10.1002/jnr.490400407
   Walton HS, 2007, NEUROCHEM INT, V50, P1052, DOI 10.1016/j.neuint.2006.10.007
   Wang L, 2012, P NATL ACAD SCI USA, V109, P16743, DOI 10.1073/pnas.1208011109
   Webster S, 1997, NEUROBIOL AGING, V18, P415, DOI 10.1016/S0197-4580(97)00042-0
   Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018
   Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022
   Wordinger RJ, 2007, INVEST OPHTH VIS SCI, V48, P1191, DOI 10.1167/iovs.06-0296
   Yang LB, 2000, J NEUROSCI, V20, P7505
   Yin HB, 2008, MED HYPOTHESES, V71, P77, DOI 10.1016/j.mehy.2008.01.030
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Yucel Y, 2008, PROG BRAIN RES, V173, P465, DOI 10.1016/S0079-6123(08)01132-1
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500
NR 142
TC 14
Z9 14
U1 0
U2 28
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0014-4819
EI 1432-1106
J9 EXP BRAIN RES
JI Exp. Brain Res.
PD NOV
PY 2014
VL 232
IS 11
BP 3363
EP 3377
DI 10.1007/s00221-014-4078-7
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AR9SO
UT WOS:000343916400001
PM 25183160
DA 2022-11-30
ER

PT J
AU Obeid, R
   Ninios, K
   Loew, U
   Gatzioufas, Z
   Hoffmann, S
   Seitz, B
   Geisel, J
   Herrmann, W
AF Obeid, Rima
   Ninios, Kouris
   Loew, Ursula
   Gatzioufas, Zisis
   Hoffmann, Stephan
   Seitz, Berthold
   Geisel, Jurgen
   Herrmann, Wolfgang
TI Aqueous humor glycation marker and plasma homocysteine in macular
   degeneration
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE cobalamin; folate; glycation; homocysteine; macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; AGE-RELATED MACULOPATHY; FOLIC-ACID;
   END-PRODUCTS; NEURODEGENERATIVE DISEASES; CARDIOVASCULAR-DISEASE;
   INFLAMMATORY MARKERS; AMYLOID-BETA; B-VITAMINS; SERUM
AB Background: We investigated concentrations of total homocysteine (tHcy) in elderly people without and those with age-related macular degeneration (AMD). In addition, we tested the association between plasma tHcy and one glycation marker in aqueous humor.
   Methods: People with cataract only (n = 48), patients with dry AMD (n = 38) and those with wet AMD (n = 31) were studied. Blood concentrations of tHcy, and methylation and vitamin markers were measured in 116 blood samples. The concentrations of the extracellular soluble receptor for advanced glycated end products (esRAGE) were measured in 77 aqueous humor samples.
   Results: Mean aqueous humor concentration of esRAGE and that of plasma tHcy did not differ significantly between the groups. Arterial hypertension but not eye disease explained the tHcy elevation in plasma in this study. In the cataract group, a significant negative correlation was found between plasma tHcy and that of esRAGE in aqueous humor (r = -0.483, p = 0.006). In patients with dry AMD, the concentration of esRAGE in aqueous humor correlated negatively to tHcy and positively to serum folate.
   Conclusions: Plasma tHcy levels were positively associated with hypertension, but not with AMD in this study. Higher esRAGE in aqueous humor was related to higher folate and lower tHcy in blood. Following studies may assess whether B-vitamins can protect against age-related ocular diseases by reducing glycation.
C1 [Obeid, Rima; Geisel, Jurgen; Herrmann, Wolfgang] Univ Hosp Saarland, Dept Clin Chem & Lab Med, D-66421 Homburg, Germany.
   [Ninios, Kouris; Loew, Ursula; Gatzioufas, Zisis; Hoffmann, Stephan; Seitz, Berthold] Univ Hosp Saarland, Dept Ophthalmol, D-66421 Homburg, Germany.
C3 Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes
RP Obeid, R (通讯作者)，Univ Hosp Saarland, Dept Clin Chem & Lab Med, Bldg 57, D-66421 Homburg, Germany.
EM rima.obeid@uniklinikum-saarland.de
RI Seitz, Berthold/AAB-8546-2019; Obeid, Rima/AAR-9906-2020
OI Seitz, Berthold/0000-0001-9701-8204; Gatzioufas,
   Zisis/0000-0001-9099-5336
FU Homburger Forschungsforderungsprogramm (HOMFOR)
FX The study was partly supported by a grant from the Homburger
   Forschungsforderungsprogramm (HOMFOR) 2008.
CR Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027
   Chang L, 2008, AMINO ACIDS, V34, P573, DOI 10.1007/s00726-007-0011-8
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clarke R, 2010, ARCH INTERN MED, V170, P1622, DOI 10.1001/archinternmed.2010.348
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   CROSS HE, 1973, AM J OPHTHALMOL, V75, P405, DOI 10.1016/0002-9394(73)91149-5
   da Cunha AA, 2012, NEUROCHEM RES, V37, P1660, DOI 10.1007/s11064-012-0769-2
   Dentchev T, 2003, MOL VIS, V9, P184
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Flicker L, 2008, NEUROBIOL AGING, V29, P303, DOI 10.1016/j.neurobiolaging.2006.10.007
   Franke S, 2003, CLIN NEPHROL, V59, P88
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Harrison DA, 1998, OPHTHALMOLOGY, V105, P1886, DOI 10.1016/S0161-6420(98)91035-1
   Hasegawa T, 2005, J NEUROSCI RES, V80, P869, DOI 10.1002/jnr.20514
   Hernanz A, 2007, NEUROIMMUNOMODULAT, V14, P163, DOI 10.1159/000110641
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588
   Irizarry MC, 2005, NEUROLOGY, V65, P1402, DOI 10.1212/01.wnl.0000183063.99107.5c
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kirsch SH, 2009, J CHROMATOGR B, V877, P3865, DOI 10.1016/j.jchromb.2009.09.039
   Lee I, 2007, BIOSCI BIOTECH BIOCH, V71, P1203, DOI 10.1271/bbb.60657
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Moore P, 2001, EXP EYE RES, V73, P45, DOI 10.1006/exer.2001.1009
   Mulvihill A, 2004, J AAPOS, V8, P254, DOI 10.1016/j.jaapos.2004.01.010
   Munch G, 2012, CELL MOL NEUROBIOL
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Obeid R, 2006, FEBS LETT, V580, P2994, DOI 10.1016/j.febslet.2006.04.088
   Paoli D., 1998, Ophthalmologica, V212, P95
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Schmidt KG, 2008, CURR NEUROPHARMACOL, V6, P164, DOI 10.2174/157015908784533851
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693
   Smith AD, 2008, AM J CLIN NUTR, V87, P517
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   VANDERBERG W, 1990, BRIT J OPHTHALMOL, V74, P696, DOI 10.1136/bjo.74.11.696
   Viktorov IV, 2006, B EXP BIOL MED+, V141, P471, DOI 10.1007/s10517-006-0202-4
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296
   Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667
   Yokoi M, 2005, BRIT J OPHTHALMOL, V89, P673, DOI 10.1136/bjo.2004.055053
   Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 43
TC 4
Z9 4
U1 0
U2 7
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD MAR
PY 2013
VL 51
IS 3
SI SI
BP 657
EP 663
DI 10.1515/cclm-2012-0402
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 099RQ
UT WOS:000315639300022
PM 23152422
DA 2022-11-30
ER

PT J
AU Zur, D
   Fischer, N
   Tufail, A
   Mones, J
   Loewenstein, A
AF Zur, Dina
   Fischer, Naomi
   Tufail, Adnan
   Mones, Jordi
   Loewenstein, Anat
TI Postsurgical cystoid macular edema
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Cystoid macular edema; Macular edema; Postoperative; Treatment
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; PARS-PLANA VITRECTOMY;
   CATARACT-EXTRACTION; SURGERY; PHOTOCOAGULATION; ACETAZOLAMIDE;
   INDOMETHACIN; MEDICATIONS; KETOROLAC; EFFICACY
AB Cystoid macular edema (CME) is a primary cause of postoperative reduced vision. It may occur even when the intraoperative course is successful for operations such as cataract and vitreoretinal surgery. Its incidence following modern cataract surgery is 0.1%-2.35%. This risk is increased if there are certain preexisting systemic or ocular conditions and when there are intraoperative complications. The etiology of CME is not completely understood. Prolapsed or incarcerated vitreous and postoperative inflammatory processes have been proposed as causative agents. Pseudophakic CME is characterized by poor postoperative visual acuity. Fluorescein angiography is indispensable in the workup of CME, showing the classical perifoveal petaloid staining pattern and late leakage of the optic disk. Optical coherence tomography is a useful diagnostic tool, which displays cystic spaces in the outer nuclear layer. The most important differential diagnoses include age-related macular degeneration and other causes of CME such as diabetic macular edema. Most cases of pseudophakic CME resolve spontaneously. The value of prophylactic treatment is doubtful. First-line treatment of postsurgical CME should include topical nonsteroidal anti-inflammatory drugs and corticosteroids. Oral carbonic anhydrase inhibitors can be considered complementary. In cases of resistant CME, periocular or intraocular corticosteroids present an option. Antiangiogenic agents, though experimental, should be considered for nonresponsive persistent CME. Surgical options should be reserved for special indications.
C1 [Zur, Dina; Fischer, Naomi; Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
   [Tufail, Adnan] Moorfields Eye Hosp, Inst Ophthalmol, London, England.
   [Mones, Jordi] Ctr Med Teknon, Inst Macula & Retina, Barcelona, Spain.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust
RP Loewenstein, A (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM anatlow@netvision.net.il
RI mones, jordi/CAJ-2963-2022; Zur, Dinah/AAX-7620-2020
OI mones, jordi/0000-0003-3685-2160; Zur, Dinah/0000-0003-1147-444X;
   Tufail, Adnan/0000-0001-6131-7640
CR Arcieri ES, 2005, ARCH OPHTHALMOL-CHIC, V123, P186, DOI 10.1001/archopht.123.2.186
   Boscia F, 2005, EUR J OPHTHALMOL, V15, P89, DOI 10.1177/112067210501500114
   Catier A, 2005, J FR OPHTALMOL, V28, P1027, DOI 10.1016/S0181-5512(05)81134-9
   Cohen SM, 2006, J CATARACT REFR SURG, V32, P1521, DOI 10.1016/j.jcrs.2006.04.019
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   FARBER MD, 1994, BRIT J OPHTHALMOL, V78, P4, DOI 10.1136/bjo.78.1.4
   Arevalo JF, 2009, OPHTHALMOLOGY, V116, P1481, DOI 10.1016/j.ophtha.2009.04.006
   Flach A J, 1998, Trans Am Ophthalmol Soc, V96, P557
   FUNG WE, 1985, OPHTHALMOLOGY, V92, P1102
   Gass J D, 1966, Trans Am Ophthalmol Soc, V64, P232
   Grover S, 2006, AM J OPHTHALMOL, V141, P850, DOI 10.1016/j.ajo.2005.12.030
   HARBOUR JM, 1995, AM J OPHTHALMOL, V120, P302, DOI 10.1016/S0002-9394(14)72159-2
   Heier JS, 2000, OPHTHALMOLOGY, V107, P2034, DOI 10.1016/S0161-6420(00)00365-1
   Henderson BA, 2007, J CATARACT REFR SURG, V33, P1550, DOI 10.1016/j.jcrs.2007.05.013
   HRUBY K, 1985, KLIN MONATSBL AUGENH, V187, P549, DOI 10.1055/s-2008-1054397
   Iliff W J, 1985, Trans Am Ophthalmol Soc, V83, P476
   IRVINE A R, 1976, Survey of Ophthalmology, V21, P1, DOI 10.1016/0039-6257(76)90045-X
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   KRAFF MC, 1984, AM J OPHTHALMOL, V98, P166, DOI 10.1016/0002-9394(87)90351-5
   Lardenoye CWTA, 1998, BRIT J OPHTHALMOL, V82, P1013, DOI 10.1136/bjo.82.9.1013
   Miyake K, 2002, SURV OPHTHALMOL, V47, pS203, DOI 10.1016/S0039-6257(02)00294-1
   Neal RE, 2005, EXP EYE RES, V80, P337, DOI 10.1016/j.exer.2004.09.015
   PETERSON M, 1992, GRAEF ARCH CLIN EXP, V230, P401, DOI 10.1007/BF00175922
   PRICE FW, 1990, J CATARACT REFR SURG, V16, P163, DOI 10.1016/S0886-3350(13)80725-0
   Rho DS, 2003, J CATARACT REFR SURG, V29, P2378, DOI 10.1016/S0886-3350(03)00233-5
   Rossetti L, 2000, Curr Opin Ophthalmol, V11, P65
   Rossetti L, 1998, OPHTHALMOLOGY, V105, P397, DOI 10.1016/S0161-6420(98)93018-4
   Schmier JK, 2007, RETINA-J RET VIT DIS, V27, P621, DOI 10.1097/01.iae.0000249577.92800.c0
   SHEPARD DD, 1979, OPHTHALMIC SURG LAS, V10, P58
   Shimura M, 2009, GRAEF ARCH CLIN EXP, V247, P1617, DOI 10.1007/s00417-009-1147-x
   SOLOMON LD, 1995, J CATARACT REFR SURG, V21, P73, DOI 10.1016/S0886-3350(13)80484-1
   Spitzer MS, 2008, J CATARACT REFR SURG, V34, P70, DOI 10.1016/j.jcrs.2007.08.021
   STEINERT RF, 1989, J CATARACT REFR SURG, V15, P304, DOI 10.1016/S0886-3350(89)80089-6
   Thach AB, 1997, OPHTHALMOLOGY, V104, P2003, DOI 10.1016/S0161-6420(97)30065-7
   TOLENTINO FI, 1965, ARCH OPHTHALMOL-CHIC, V74, P781, DOI 10.1001/archopht.1965.00970040783008
   Warwar RE, 1998, OPHTHALMOLOGY, V105, P263, DOI 10.1016/S0161-6420(98)92977-3
   WEENE LE, 1992, ANN OPHTHALMOL, V24, P423
NR 37
TC 22
Z9 23
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2011
VL 21
SU 6
BP S62
EP S68
DI 10.5301/EJO.2010.6058
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 768FB
UT WOS:000290916000010
PM 23264331
DA 2022-11-30
ER

PT J
AU Klettner, AK
   Kruse, ML
   Meyer, T
   Wesch, D
   Kabelitz, D
   Roider, J
AF Klettner, Alexa Karina
   Kruse, Marie-Luise
   Meyer, Tim
   Wesch, Daniela
   Kabelitz, Dieter
   Roider, Johann
TI Different properties of VEGF-antagonists: Bevacizumab but not
   Ranibizumab accumulates in RPE cells
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Bevacizumab; Ranibizumab;
   VEGF-antagonists
ID PIGMENT EPITHELIAL TEAR; INTRAVITREAL INJECTION; MACULAR DEGENERATION;
   RECEPTORS; AVASTIN; THERAPY; EYE; FC
AB Vascular endothelial growth factor (VEGF) antagonists are currently the therapy of choice for age-related macular degeneration. Here we compared the effects of FDA-approved Ranibizumab and off-label used Bevacizumab on RPE cells, investigating their respective uptake by RPE cells over time.
   Primary porcine RPE cells were treated with Bevacizumab or Ranibizumab, respectively. Uptake of the respective VEGF-antagonists was assessed with confocal laser scanning microscopy and flow cytometry. Cell death was assessed with MTT assay and VEGF secretion was measured with ELISA.
   When clinical doses were applied for 1 h, Bevacizumab was taken up by RPE cells as assessed by confocal laser scanning microscopy and flow cytometry. After 24 h of incubation, and further assessed after 1d, 5d, and 7d, Bevacizumab was detected in RPE cells where it accumulated over time. The presence of Bevacizumab within RPE cells after 7d was confirmed by flow cytometry. While some Ranibizumab was found in RPE cells after 1 h of incubation when assessed with confocal laser microscopy but not by flow cytometry, no signal above control was detected after 1d, 5d, or 7d. Neither substance induced significant cell death after 7 days and no inhibitory effect on VEGF secretion was observed after day 3 of culture.
   Bevacizumab, but not Ranibizumab, accumulates in RPE cells over time, implying substantial differences between these two drugs.
C1 [Klettner, Alexa Karina; Roider, Johann] Univ Kiel, Dept Ophthalmol, D-24105 Kiel, Germany.
   [Kruse, Marie-Luise] Univ Kiel, Dept Mol Gastroenterol, D-24105 Kiel, Germany.
   [Meyer, Tim; Wesch, Daniela; Kabelitz, Dieter] Univ Kiel, Dept Immunol, D-24105 Kiel, Germany.
C3 University of Kiel; University of Kiel; University of Kiel
RP Klettner, AK (通讯作者)，Univ Kiel, Dept Ophthalmol, Hegewischstr 2, D-24105 Kiel, Germany.
EM aklettner@ophthalmol.uni-kiel.de
RI Klettner, Alexa Karina/M-8344-2018; Wesch, Daniela/C-1940-2019;
   Kabelitz, Dieter/A-2757-2010; Kabelitz, Dieter/AAB-4199-2021; Roider,
   Johann/E-4513-2010
OI Wesch, Daniela/0000-0001-6509-208X; Klettner, Alexa/0000-0002-2709-1059
FU DOG Forschungsforderung
FX DOG Forschungsforderung
CR Alge CS, 2006, INVEST OPHTH VIS SCI, V47, P415, DOI 10.1167/iovs.05-0308
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   ECKHERT CD, 1986, CURR EYE RES, V5, P911, DOI 10.3109/02713688608995171
   ELNER VM, 1981, SCIENCE, V211, P74, DOI 10.1126/science.7444450
   European Union, 2005, EUR UN NO 2073 2005, P1, DOI DOI 10.2903/J.EFSA.2005.284
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Kramer I, 2007, J CLIN PHARM THER, V32, P1, DOI 10.1111/j.1365-2710.2007.00800.x
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   TARNOWSKI BI, 1988, INVEST OPHTH VIS SCI, V29, P742
NR 21
TC 62
Z9 62
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2009
VL 247
IS 12
BP 1601
EP 1608
DI 10.1007/s00417-009-1136-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 518YZ
UT WOS:000271733500003
PM 19597740
DA 2022-11-30
ER

PT J
AU Khurana, M
   Moriyama, EH
   Mariampillai, A
   Samkoe, K
   Cramb, D
   Wilson, BC
AF Khurana, Mamta
   Moriyama, Eduardo H.
   Mariampillai, Adrian
   Samkoe, Kimberley
   Cramb, David
   Wilson, Brian C.
TI Drug and light dose responses to focal photodynamic therapy of single
   blood vessels in vivo
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; confocal microscopy; window chamber
   mouse; blood vessel; two-photon; photodynamic therapy; verteporfin;
   fluorescence; drug-light product
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; 2-PHOTON EXCITATION;
   CHOROIDAL NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION; THROMBUS
   FORMATION; VASCULAR DAMAGE; TISSUE-RESPONSE; FEEDER VESSELS; SOLID
   TUMORS
AB As part of an ongoing program to develop two-photon (2-gamma) photodynamic therapy (PDT) for treatment of wet-form age-related macular degeneration (AMD) and other vascular pathologies, we have evaluated the reciprocity of drug-light doses in focal-PDT. We targeted individual arteries in a murine window chamber model, using primarily the clinical photosensitizer Visudyne/liposomalverteporfin. Shortly after administration of the photosensitizer, a small region including an arteriole was selected and irradiated with varying light doses. Targeted and nearby vessels were observed for a maximum of 17 to 25 h to assess vascular shutdown, tapering, and dye leakage/occlusion. For a given end-point metric, there was reciprocity between the drug and light doses, i.e., the response correlated with the drug-light product (DLP). These results provide the first quantification of photosensitizer and light dose relationships for localized irradiation of a single blood vessel and are compared to the DLP required for vessel closure between 1-gamma and 2-gamma activation, between focal and broad-beam irradiation, and between verteporfin and a porphyrin dimer with high 2-gamma cross section. Demonstration of reciprocity over a wide range of DLP is important for further development of focal PDT treatments, such as the targeting of feeder vessels in 2-gamma PDT of AMD. (C) 2009 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3262521]
C1 [Khurana, Mamta; Moriyama, Eduardo H.; Mariampillai, Adrian; Wilson, Brian C.] Univ Toronto, Dept Med Biophys, Div Biophys & Bioimaging, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
   [Samkoe, Kimberley] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
   [Cramb, David] Univ Calgary, Dept Chem, Calgary, AB T2N 1N4, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; Dartmouth College; University of Calgary
RP Wilson, BC (通讯作者)，Univ Toronto, Dept Med Biophys, Div Biophys & Bioimaging, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
EM wilson@uhnres.utoronto.ca
OI Wilson, Brian C./0000-0001-5543-666X
FU Canadian Institute for Photonic Innovations; Canadian Institutes of
   Health Research (CIHR) [181321, 82498]; Alberta Ingenuity Fund; NSERC
FX This work was supported by the Canadian Institute for Photonic
   Innovations. M. Khurana was also supported in part by a Canadian
   Institutes of Health Research (CIHR) Scholarship No. 181321. A.
   Mariampillai was supported by CIHR Grant No. 82498. K. Samkoe was
   supported by the Alberta Ingenuity Fund and by NSERC. The authors also
   thank QLT, Inc. (Vancouver, British Columbia, Canada) , for providing
   Visudyne, and Dr. Joerg Schwock (Laboratory Medicine and Pathobiology,
   University Health Network) for histopathology evaluation. James Jonkman
   and Miria Bartolini of the Advanced Optical Microscopy Facility,
   University Health Network, provided technical assistance with the
   confocal microscope.
CR ALGIRE GH, 1949, J NATL CANCER I, V10, P225
   Awan MA, 2006, SURG-J R COLL SURG E, V4, P231, DOI 10.1016/S1479-666X(06)80065-X
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Cecic I, 2001, PHOTOCHEM PHOTOBIOL, V74, P712, DOI 10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Chen B, 2006, CLIN CANCER RES, V12, P917, DOI 10.1158/1078-0432.CCR-05-1673
   Collins HA, 2008, NAT PHOTONICS, V2, P420, DOI 10.1038/nphoton.2008.100
   DERESKI MO, 1989, PHOTOCHEM PHOTOBIOL, V50, P653, DOI 10.1111/j.1751-1097.1989.tb04322.x
   DOUGHERTY TJ, 1978, CANCER RES, V38, P2628
   Falati S, 2002, NAT MED, V8, P1175, DOI 10.1038/nm782
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Fingar VH, 1999, BRIT J CANCER, V79, P1702, DOI 10.1038/sj.bjc.6690271
   FINGAR VH, 1993, PHOTOCHEM PHOTOBIOL, V58, P393, DOI 10.1111/j.1751-1097.1993.tb09580.x
   FINGAR VH, 1987, PHOTOCHEM PHOTOBIOL, V46, P837, DOI 10.1111/j.1751-1097.1987.tb04856.x
   Fingar VH, 1997, PHOTOCHEM PHOTOBIOL, V66, P513, DOI 10.1111/j.1751-1097.1997.tb03182.x
   Fingar VH, 2000, IN VIVO, V14, P93
   FINGAR VH, 1992, CANCER RES, V52, P4914
   FINGAR VH, 1987, PHOTOCHEM PHOTOBIOL, V45, P643, DOI 10.1111/j.1751-1097.1987.tb07392.x
   Flower RW, 2002, AM J OPHTHALMOL, V134, P228, DOI 10.1016/S0002-9394(02)01579-9
   Furie B, 2007, J THROMB HAEMOST, V5, P12, DOI 10.1111/j.1538-7836.2007.02482.x
   GIBSON SL, 1985, PHOTOCHEM PHOTOBIOL, V42, P367, DOI 10.1111/j.1751-1097.1985.tb01583.x
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Goyan RL, 2000, PHOTOCHEM PHOTOBIOL, V72, P821, DOI 10.1562/0031-8655(2000)072<0821:NITPEO>2.0.CO;2
   Henderson BW, 2004, CANCER RES, V64, P2120, DOI 10.1158/0008-5472.CAN-03-3513
   HENDERSON BW, 1983, PORPHYRIN PHOTOSENSI, P129
   Ju M, 2008, INVEST OPHTH VIS SCI, V49, P662, DOI 10.1167/iovs.07-0195
   Karotki A, 2006, PHOTOCHEM PHOTOBIOL, V82, P443, DOI 10.1562/2005-08-24-RA-657
   Kelleher DK, 2004, INT J ONCOL, V24, P1505
   Khurana M, 2007, PHOTOCHEM PHOTOBIOL, V83, P1441, DOI 10.1111/j.1751-1097.2007.00185.x
   Khurana M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2965545
   Korbelik M, 2006, LASER SURG MED, V38, P500, DOI 10.1002/lsm.20337
   Kozak I, 2006, BRIT J OPHTHALMOL, V90, P1152, DOI 10.1136/bjo.2006.095141
   Krammer B, 2001, ANTICANCER RES, V21, P4271
   LIPSON RL, 1960, ARCH DERMATOL, V82, P508, DOI 10.1001/archderm.1960.01580040026005
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Middelkamp-Hup MA, 2003, J INVEST DERMATOL, V121, P634, DOI 10.1046/j.1523-1747.2003.12412.x
   MILLER JW, 2008, SEC OPHTHALMOL, V106, P357
   Nowak-Sliwinska P, 2006, BIOCHEM BIOPH RES CO, V349, P549, DOI 10.1016/j.bbrc.2006.08.060
   Oheim M, 2006, ADV DRUG DELIVER REV, V58, P788, DOI 10.1016/j.addr.2006.07.005
   Peters T., 1992, PHOTODYNAMIC THERAPY, P1
   Raab O, 1900, Z BIOL-MUNICH, V39, P524
   REED MWR, 1989, RADIAT RES, V119, P542, DOI 10.2307/3577525
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Samkoe KS, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2750663
   Samkoe KS, 2003, J BIOMED OPT, V8, P410, DOI 10.1117/1.1577117
   SAMKOE KS, 2007, THESIS U CALGARY
   Sikora L, 2003, AM J PATHOL, V162, P2019, DOI 10.1016/S0002-9440(10)64334-9
   Sorg H, 2007, THROMB RES, V121, P241, DOI 10.1016/j.thromres.2007.04.001
   Spikes, 1985, PRIMARY PHOTOPROCESS, P209, DOI [10.1007/978-1-4684-1224-6_12, DOI 10.1007/978-1-4684-1224-6_12]
   STAR WM, 1986, CANCER RES, V46, P2532
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   Sun JH, 2002, PHOTOCH PHOTOBIO SCI, V1, P690, DOI 10.1039/b204254a
   Trachtenberg J, 2008, BJU INT, V102, P556, DOI 10.1111/j.1464-410X.2008.07753.x
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wang Y, 2009, BRIT J OPHTHALMOL, V93, P634, DOI 10.1136/bjo.2008.150276
   WILLIAMS RM, 1994, FASEB J, V8, P804, DOI 10.1096/fasebj.8.11.8070629
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 59
TC 15
Z9 15
U1 1
U2 26
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD NOV-DEC
PY 2009
VL 14
IS 6
AR 064006
DI 10.1117/1.3262521
PG 14
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 552DO
UT WOS:000274267900013
PM 20059244
DA 2022-11-30
ER

PT J
AU Alcazar, O
   Hawkridge, AM
   Collier, TS
   Cousins, SW
   Bhattacharya, SK
   Muddiman, DC
   Marin-Castano, ME
AF Alcazar, Oscar
   Hawkridge, Adam M.
   Collier, Timothy S.
   Cousins, Scott W.
   Bhattacharya, Sanjoy K.
   Muddiman, David C.
   Marin-Castano, Maria E.
TI Proteomics Characterization of Cell Membrane Blebs in Human Retinal
   Pigment Epithelium Cells
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID MATRIX-METALLOPROTEINASE INDUCER; SUB-RPE DEPOSITS; MACULAR
   DEGENERATION; ADHESION MOLECULES; ENDOTHELIAL-CELLS; CIGARETTE-SMOKING;
   OXIDANT INJURY; BASIGIN CD147; RISK-FACTORS; IN-VITRO
AB Age-related macular degeneration (AMD) is the leading cause of legal blindness among the elderly population in the industrialized world, affecting about 14 million people in the United States alone. Smoking is a major environmental risk factor for AMD, and hydroquinone is a major component in cigarette smoke. Hydroquinone induces the formation of cell membrane blebs in human retinal pigment epithelium (RPE). Blebs may accumulate and eventually contribute first to sub-RPE deposits and then drusen formation, which is a prominent histopathologic feature in eyes with AMD. As an attempt to better understand the mechanisms involved in early AMD, we sought to investigate the proteomic profile of RPE blebs. Isolated blebs were subjected to SDS-PAGE fractionation, and in-gel trypsin-digested peptides were analyzed by LCMS/MS that lead to the identification of a total of 314 proteins. Identified proteins were predominantly involved in oxidative phosphorylation, cell junction, focal adhesion, cytoskeleton regulation, and immunogenic processes. Importantly basigin and matrix metalloproteinase-14, key proteins involved in extracellular matrix remodeling, were identified in RPE blebs and shown to be more prevalent in AMD patients. Altogether our findings suggest, for the first time, the potential involvement of RPE blebs in eye disease and shed light on the implication of cell-derived microvesicles in human pathology. Molecular & Cellular Proteomics 8: 2201-2211, 2009.
C1 [Bhattacharya, Sanjoy K.] Univ Miami, Bascom Palmer Eye Inst, Ocular Proteom Lab, Miami, FL 33136 USA.
   [Hawkridge, Adam M.; Collier, Timothy S.; Muddiman, David C.] N Carolina State Univ, WM Keck FT ICR Mass Spectrometry Lab, Dept Chem, Raleigh, NC 27695 USA.
   [Cousins, Scott W.] Duke Univ, Duke Ctr Macular Dis, Durham, NC 27710 USA.
C3 Bascom Palmer Eye Institute; University of Miami; University of North
   Carolina; North Carolina State University; Duke University
RP Bhattacharya, SK (通讯作者)，Univ Miami, Bascom Palmer Eye Inst, Ocular Proteom Lab, 1638 NW 10th Ave, Miami, FL 33136 USA.
EM SBhattacharya@med.miami.edu; MCastano@med.miami.edu
OI Collier, Timothy/0000-0002-1102-8741; Muddiman,
   David/0000-0003-2216-499X
FU NATIONAL EYE INSTITUTE [P30EY014801, R01EY015249] Funding Source: NIH
   RePORTER; NEI NIH HHS [P30-EY14801, EY015249-01A1S1, R01 EY015249, P30
   EY014801, R01-EY015249-01A1] Funding Source: Medline
CR Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886
   Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547
   Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   BUTIKOFER P, 1989, BLOOD, V74, P1481
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985
   DeCaprio AP, 1999, CRIT REV TOXICOL, V29, P283, DOI 10.1080/10408449991349221
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Egawa N, 2006, J BIOL CHEM, V281, P37576, DOI 10.1074/jbc.M606993200
   ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FADOOL JM, 1993, J NEUROCHEM, V60, P1354, DOI 10.1111/j.1471-4159.1993.tb03296.x
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gabison EE, 2005, BIOCHIMIE, V87, P361, DOI 10.1016/j.biochi.2004.09.023
   Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516
   Green W R, 1999, Mol Vis, V5, P27
   Guo HM, 1997, J BIOL CHEM, V272, P24
   Hazarika P, 1999, J CELL BIOCHEM, V75, P147, DOI 10.1002/(SICI)1097-4644(19991001)75:1<147::AID-JCB15>3.0.CO;2-D
   Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609
   IIDA K, 1991, J IMMUNOL, V147, P2638
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Jurianz K, 2001, INT J CANCER, V93, P848, DOI 10.1002/ijc.1406
   Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390
   KATAOKA H, 1993, CANCER RES, V53, P3154
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S
   Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548
   Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marler P, 2004, ANN NY ACAD SCI, V1016, P31, DOI 10.1196/annals.1298.034
   MARMOR M F, 1975, International Ophthalmology Clinics, V15, P115, DOI 10.1097/00004397-197501510-00010
   Menegay M, 2008, INVEST OPHTH VIS SCI, V49, P2829, DOI 10.1167/iovs.07-1438
   Miguet L, 2006, PROTEOMICS, V6, P153, DOI 10.1002/pmic.200500133
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MIYAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P316, DOI 10.1093/oxfordjournals.jbchem.a123045
   Monks Terrence J, 2002, Curr Drug Metab, V3, P425, DOI 10.2174/1389200023337388
   Muramatsu T, 2003, HISTOL HISTOPATHOL, V18, P981, DOI 10.14670/HH-18.981
   Nabeshima K, 2006, PATHOL INT, V56, P359, DOI 10.1111/j.1440-1827.2006.01972.x
   NEGI A, 1984, ARCH OPHTHALMOL-CHIC, V102, P445
   PASCUAL M, 1994, J EXP MED, V179, P889, DOI 10.1084/jem.179.3.889
   Patel N, 2008, PROTEOMICS, V8, P1055, DOI 10.1002/pmic.200700856
   Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069
   Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7
   SATTA N, 1994, J IMMUNOL, V153, P3245
   Schulte T, 1997, DEVELOPMENT, V124, P577
   Sidhu SS, 2004, ONCOGENE, V23, P956, DOI 10.1038/sj.onc.1207070
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   SIMS PJ, 1988, J BIOL CHEM, V263, P18205
   Sloley S, 2007, J PROTEOME RES, V6, P1093, DOI 10.1021/pr060428i
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   STEIN JM, 1991, BIOCHEM J, V274, P381, DOI 10.1042/bj2740381
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Sun JX, 2001, CANCER RES, V61, P2276
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Weeks R, 2000, J NEUROSCI, V20, P2664
   Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536
   Yang JM, 2003, MOL CANCER RES, V1, P420
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhou SB, 2005, PROTEOMICS, V5, P2739, DOI 10.1002/pmic.200401178
   ZHU ZR, 1988, CURR EYE RES, V7, P581, DOI 10.3109/02713688809031814
NR 65
TC 31
Z9 32
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD OCT
PY 2009
VL 8
IS 10
BP 2201
EP 2211
DI 10.1074/mcp.M900203-MCP200
PG 11
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 502XC
UT WOS:000270492700001
PM 19567368
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Buchholz, DE
   Hikita, ST
   Rowland, TJ
   Friedrich, AM
   Hinman, CR
   Johnson, LV
   Clegg, DO
AF Buchholz, David E.
   Hikita, Sherry T.
   Rowland, Teisha J.
   Friedrich, Amy M.
   Hinman, Cassidy R.
   Johnson, Lincoln V.
   Clegg, Dennis O.
TI Derivation of Functional Retinal Pigmented Epithelium from Induced
   Pluripotent Stem Cells
SO STEM CELLS
LA English
DT Article
DE retinal pigmented epithelium; induced pluripotent stem cells;
   age-related macular degeneration; retinitis pigmentosa
ID ROD OUTER SEGMENTS; MACULAR DEGENERATION; MICROSOMAL PROTEIN; EYE
   DEVELOPMENT; IPS CELLS; RPE CELLS; DIFFERENTIATION; EXPRESSION;
   PHAGOCYTOSIS; ISOMEROHYDROLASE
AB Human induced pluripotent stem cells (iPSCs) have great promise for cellular therapy, but it is unclear if they have the same potential as human embryonic stem cells (hESCs) to differentiate into specialized cell types. Ocular cells such as the retinal pigmented epithelium (RPE) are of particular interest because they could be used to treat degenerative eye diseases, including age-related macular degeneration and retinitis pigmentosa. We show here that iPSCs generated using Oct4, Sox2, Nanog, and Lin28 can spontaneously differentiate into RPE cells, which can then be isolated and cultured to form highly differentiated RPE monolayers. RPE derived from iPSCs (iPS-RPE) were analyzed with respect to gene expression, protein expression, and rod outer segment phagocytosis, and compared with cultured fetal human RPE (fRPE) and RPE derived from hESCs (hESC-RPE). iPS-RPE expression of marker mRNAs was quantitatively similar to that of fRPE and hESC-RPE, and marker proteins were appropriately expressed and localized in polarized monolayers. Levels of rod outer segment phagocytosis by iPS-RPE, fRPE, and hESC-RPE were likewise similar and dependent on integrin alpha v beta 5. This work shows that iPSCs can differentiate into functional RPE that are quantitatively similar to fRPE and hESC-RPE and further supports the finding that iPSCs are similar to hESCs in their differentiation potential. STEM CELLS 2009;27:2427-2434
C1 [Buchholz, David E.; Hikita, Sherry T.; Rowland, Teisha J.; Friedrich, Amy M.; Hinman, Cassidy R.; Johnson, Lincoln V.; Clegg, Dennis O.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   [Buchholz, David E.; Hikita, Sherry T.; Rowland, Teisha J.; Friedrich, Amy M.; Hinman, Cassidy R.; Johnson, Lincoln V.; Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Stem Cell Biol & Engn, Santa Barbara, CA 93106 USA.
   [Johnson, Lincoln V.; Clegg, Dennis O.] Univ Calif Santa Barbara, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   [Buchholz, David E.; Hikita, Sherry T.; Rowland, Teisha J.; Friedrich, Amy M.; Hinman, Cassidy R.; Johnson, Lincoln V.; Clegg, Dennis O.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara
RP Clegg, DO (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
EM clegg@lifesci.ucsb.edu
OI Rowland, Teisha/0000-0001-5038-6763
FU California Institute for Regenerative Medicine [T300009, C4-00521-1];
   Army Research Office; Millipore Corporation; Advanced Cell Technology;
   NIH [5R24EY014799-05]; NIH NCRR [1S10RR017753-07]; NATIONAL CENTER FOR
   RESEARCH RESOURCES [S10RR017753] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R24EY014799] Funding Source: NIH RePORTER
FX We thank James Thomson and Jessica Antosiewicz-Bourget for cells,
   reagents and advice; Dean Bok for cells; and Peter Coffey, Don Anderson,
   and Monte Radeke for helpful suggestions and advice. This work was
   supported by the California Institute for Regenerative Medicine grants
   T300009, C4-00521-1; Army Research Office; Millipore Corporation;
   Advanced Cell Technology; NIH 5R24EY014799-05; NIH NCRR Shared
   Instrumentation Grant 1S10RR017753-07.
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642
   Bharti K, 2008, DEVELOPMENT, V135, P1169, DOI 10.1242/dev.014142
   BUCHHOLZ DE, 2008, J VISION, V8, P47
   Buraczynska M, 2002, INVEST OPHTH VIS SCI, V43, P603
   Carr AJ, 2009, MOL VIS, V15, P283
   Chang KH, 2008, EXP CELL RES, V314, P2930, DOI 10.1016/j.yexcr.2008.07.019
   Chen FK, 2008, INVEST OPHTH VIS SCI, V49, P3143, DOI 10.1167/iovs.07-1648
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P1848, DOI 10.1167/iovs.08-2845
   Clegg Dennis O., 2008, P1, DOI 10.1007/978-1-4020-8502-4_1
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Karumbayaram S, 2009, STEM CELLS, V27, P806, DOI 10.1002/stem.31
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703
   LU B, 2009, STEM CELLS
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MA Z, 2008, INVEST OPHTHALMOL VI
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Mikkola M, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-40
   Nikolaeva O, 2009, FEBS J, V276, P3020, DOI 10.1111/j.1742-4658.2009.07021.x
   Nishikawa S, 2008, NAT REV MOL CELL BIO, V9, P725, DOI 10.1038/nrm2466
   ORAHILLY R, 1975, EXP EYE RES, V21, P93, DOI 10.1016/0014-4835(75)90075-5
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Raya A, 2009, NATURE, V460, P53, DOI 10.1038/nature08129
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Vugler A, 2007, MECH DEVELOP, V124, P807, DOI 10.1016/j.mod.2007.08.002
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Woo THS, 1999, J MICROBIOL METH, V35, P23, DOI 10.1016/S0167-7012(98)00095-5
   Xu D, 2009, P NATL ACAD SCI USA, V106, P808, DOI 10.1073/pnas.0812090106
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zhang DH, 2009, CELL RES, V19, P429, DOI 10.1038/cr.2009.28
   Zhang JH, 2009, CIRC RES, V104, pE30, DOI 10.1161/CIRCRESAHA.108.192237
   Zhao SL, 1997, INT REV CYTOL, V171, P225
NR 58
TC 300
Z9 330
U1 1
U2 79
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD OCT
PY 2009
VL 27
IS 10
BP 2427
EP 2434
DI 10.1002/stem.189
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 520GP
UT WOS:000271830200006
PM 19658190
OA Bronze
DA 2022-11-30
ER

PT J
AU Lakshminarayana, R
   Aruna, G
   Sangeetha, RK
   Bhaskar, N
   Divakar, S
   Baskaran, V
AF Lakshminarayana, Rangaswamy
   Aruna, Gorusupudi
   Sangeetha, Ravi Kumar
   Bhaskar, Narayan
   Divakar, Sounder
   Baskaran, Vallikannan
TI Possible degradation/biotransformation of lutein in vitro and in vivo:
   isolation and structural elucidation of lutein metabolites by HPLC and
   LC-MS (atmospheric pressure chemical ionization)
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE free radicals; anhydrolutein; biotransfomation; LC-MS; lutein; lutein
   epoxide; metabolites; photo-oxidation
ID BETA-CAROTENE; MACULAR PIGMENT; ZEAXANTHIN STEREOISOMERS;
   OXIDATION-PRODUCTS; CLEAVAGE PRODUCTS; IDENTIFICATION; ABSORPTION;
   DIETARY; LIVER; CANTHAXANTHIN
AB Metabolites of lutein are highly concentrated in the human macula and are known to provide protection against age-related macular degeneration. The aim of this investigation was to characterize the in vitro oxidation products of lutein obtained through photo-oxidation and to compare them with biologically transformed dietarylutein in intestine, plasma, liver, and eyes of rats. In vivo studies involved feeding rats a diet devoid Of lutein for 2 weeks to induce deficiency. Rats were divided into two equal groups (n = 6/group) and received either micellar lutein by gavage for 10 days or diet supplemented With fengureek leaves as a lutein Source for 4 weeks. Lutein metabolites/oxidation products obtained from in vivo and in vitro studies were characterized by HPLC and LC-MS (APCI) techniques to elucidate their structure. The characteristic fragmented ions resulting from photo-oxidation of lutein were identified as 523 (M++H+-3CH(3)), 476 (M++H--6CH(3)), and 551 (M++H+-H2O) In the eyes, the fragmented molecules resulting from lutein Were 13-Z lutein, 13'-Z lutein, 13-Z zeaxanthin, all-E zeaxanthin, 9-Zlutein,9'-Zlutein, and 3'-oxolutein. Epoxycarotenoids were identified in liver and plasma, whereas anhudroleutein was identified in intestine. This study emphasizes the essentiality of dietary lutein to maintain its status in the retina. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Lakshminarayana, Rangaswamy; Aruna, Gorusupudi; Sangeetha, Ravi Kumar; Baskaran, Vallikannan] CSIR, Cent Food Technol Res Inst, Dept Biochem & Nutr, Mysore 570020, Karnataka, India.
   [Bhaskar, Narayan] CSIR, Cent Food Technol Res Inst, Meat Fish & Poultry Technol Dept, Mysore 570020, Karnataka, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Central Food Technological Research Institute (CFTRI); Council of
   Scientific & Industrial Research (CSIR) - India; CSIR - Central Food
   Technological Research Institute (CFTRI)
RP Baskaran, V (通讯作者)，CSIR, Cent Food Technol Res Inst, Dept Biochem & Nutr, Mysore 570020, Karnataka, India.
EM carotenoidlab@gmail.com
RI VALLIKANNAN, BASKARAN/G-1120-2010; Lakshminarayana,
   Rangaswamy/AAC-5824-2019; Divakar, Soundar -/G-4849-2010; Narayan,
   Bhaskar/B-8360-2008
OI Narayan, Bhaskar/0000-0001-5672-4612
CR Asai A, 2004, J NUTR, V134, P2237, DOI 10.1093/jn/134.9.2237
   ASTORG P, 1994, FOOD CHEM TOXICOL, V32, P735, DOI 10.1016/S0278-6915(09)80006-9
   Barua AB, 1998, J CHROMATOGR B, V707, P69, DOI 10.1016/S0378-4347(97)00614-2
   Barua AB, 2001, J NUTR, V131, P3212, DOI 10.1093/jn/131.12.3212
   Baskaran V, 2003, LIPIDS, V38, P705, DOI 10.1007/s11745-003-1118-5
   Bausch J, 1999, INT J VITAM NUTR RES, V69, P268, DOI 10.1024/0300-9831.69.4.268
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2005, ANAL BIOCHEM, V345, P296, DOI 10.1016/j.ab.2005.07.006
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P1435, DOI 10.1167/iovs.06-1046
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BONNIE TYP, 1999, J OIL PALM RES, V11, P62
   Dachtler M, 2001, ANAL CHEM, V73, P667, DOI 10.1021/ac000635g
   Ganguly J., 1985, World Review of Nutrition and Dietetics, V45, P198
   Gradelet S, 1996, XENOBIOTICA, V26, P49, DOI 10.3109/00498259609046688
   Gradelet S, 1996, XENOBIOTICA, V26, P909, DOI 10.3109/00498259609052493
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HANUSCH M, 1995, ARCH BIOCHEM BIOPHYS, V317, P423, DOI 10.1006/abbi.1995.1184
   Hartmann D, 2004, AM J CLIN NUTR, V79, P410
   HERNELL O, 1990, BIOCHEMISTRY-US, V29, P2041, DOI 10.1021/bi00460a012
   Hurst JS, 2004, BIOFACTORS, V20, P23, DOI 10.1002/biof.5520200103
   JUGHANS A, 2001, FREE RADICAL RES, V33, P801
   Jung JW, 2006, J SCI FOOD AGR, V86, P2296, DOI 10.1002/jsfa.2609
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khachik F., 1999, ANTIOXIDANT FOOD SUP, P203
   KHACHIK F, 1996, INVEST OPHTH VIS SCI, V47, P5234
   Kim SJ, 2001, LIPIDS, V36, P191, DOI 10.1007/s11745-001-0706-8
   King TJ, 1997, PURE APPL CHEM, V69, P2135, DOI 10.1351/pac199769102135
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lakshminarayana R, 2006, MOL CELL BIOCHEM, V281, P103, DOI 10.1007/s11010-006-1337-3
   Lakshminarayana R, 2005, J AGR FOOD CHEM, V53, P2838, DOI 10.1021/jf0481711
   Lakshminarayana R, 2007, J AGR FOOD CHEM, V55, P6395, DOI 10.1021/jf070482z
   Lu CM, 2001, AUST J PLANT PHYSIOL, V28, P1023
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mortensen A, 1997, FREE RADICAL RES, V26, P549, DOI 10.3109/10715769709097826
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SCHALCH W, 1999, CRC MOD NUT, P215
   Scheidegger R, 1998, NITRIC OXIDE-BIOL CH, V2, P8, DOI 10.1006/niox.1997.0156
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 2003, FREE RADICAL BIO MED, V35, P1480, DOI 10.1016/j.freeradbiomed.2003.08.020
   Stratton SP, 1997, BIOCHEMISTRY-US, V36, P12911, DOI 10.1021/bi9708646
   Sugawara T, 2002, J NUTR, V132, P946, DOI 10.1093/jn/132.5.946
   Thurmann PA, 2005, AM J CLIN NUTR, V82, P88
   Yamauchi R, 1998, BIOSCI BIOTECH BIOCH, V62, P1301, DOI 10.1271/bbb.62.1301
   1977, J NUTR, V170, P1340
NR 54
TC 45
Z9 52
U1 0
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD OCT 1
PY 2008
VL 45
IS 7
BP 982
EP 993
DI 10.1016/j.freeradbiomed.2008.06.011
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 354VK
UT WOS:000259667000005
PM 18640265
DA 2022-11-30
ER

PT J
AU Lee, CJ
   Fishman, HA
   Bent, SF
AF Lee, Christina J.
   Fishman, Harvey A.
   Bent, Stacey F.
TI Spatial cues for the enhancement of retinal pigment epithelial cell
   function in potential transplants
SO BIOMATERIALS
LA English
DT Article
DE cell morphology; epithelial cell; membrane; micropatterning;
   ophthalmology; retina
ID ROD OUTER SEGMENTS; ANTERIOR LENS CAPSULE; MACULAR DEGENERATION;
   SUBRETINAL SPACE; SOFT LITHOGRAPHY; IN-VITRO; MEMBRANE; PHAGOCYTOSIS;
   EXPRESSION; SHAPE
AB Retinal pigment epithelial (RPE) cellular morphology and function are vital to the health of the retina. In age-related macular degeneration, RPE dysfunction and changes in Bruch's membrane occur. Thus, a potential cure is a dual-layer biomimetic transplant consisting of a layer of healthy RPE cells cultured on a support membrane. In this study, we investigated human anterior lens capsule as a replacement for Bruch's membrane and also explored different seeding methods as ways of inducing the desired cellular morphology and function. Using in vitro assays, we demonstrated that RPE cells cultured on lens capsule exhibited epithelial characteristics, such as the presence of actin belts and the formation of tight junctions in the monolayer. Bovine photoreceptor outer segments were also incubated with the RPE cells in order to quantify the binding and ingestion activity of the RPE cells. With these assays, we determined that cells seeded by centrifugation appeared to possess the most epithelial-like morphology, with the shortest overall length and the smallest elongation. They also exhibited enhanced metabolic activity, with a 1.5-fold increase over conventional gravity seeding. Thus, the spatial cues provided by centrifugation may assist cells in assuming native RPE function. Therefore, a dual-layer transplant, with RPE cells organized by centrifugation onto lens capsule, appears promising in achieving native retinal function. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.
C3 Stanford University
RP Bent, SF (通讯作者)，Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.
EM bent@stanford.edu
OI Bent, Stacey/0000-0002-1084-5336
CR BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812
   Chen CS, 1998, BIOTECHNOL PROGR, V14, P356, DOI 10.1021/bp980031m
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Folch A, 2000, ANNU REV BIOMED ENG, V2, P227, DOI 10.1146/annurev.bioeng.2.1.227
   FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0
   Forrester JVDA., 2002, EYE BASIC SCI PRACTI, V2
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Godbey WT, 2004, BIOMATERIALS, V25, P2799, DOI 10.1016/j.biomaterials.2003.09.056
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   HUGUET EL, 1995, J BIOL CHEM, V270, P12851, DOI 10.1074/jbc.270.21.12851
   Ishida M, 1998, CURR EYE RES, V17, P392, DOI 10.1080/02713689808951220
   Kane RS, 1999, BIOMATERIALS, V20, P2363, DOI 10.1016/S0142-9612(99)00165-9
   Kiilgaard JF, 2002, ACTA OPHTHALMOL SCAN, V80, P76
   Lee CJ, 2004, LANGMUIR, V20, P4155, DOI 10.1021/la035467c
   Low SH, 2002, J CELL SCI, V115, P4545, DOI 10.1242/jcs.00116
   MARMOR MF, 1998, RETINAL PIGMENT EPIT, P6
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   REID DM, 1992, EXP EYE RES, V54, P775, DOI 10.1016/0014-4835(92)90033-O
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Teixeira AI, 2003, J CELL SCI, V116, P1881, DOI 10.1242/jcs.00383
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Thumann G, 2001, SURV OPHTHALMOL, V45, P345, DOI 10.1016/S0039-6257(00)00195-8
   Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943
   Von Recum HA, 1999, EXP EYE RES, V69, P97, DOI 10.1006/exer.1999.0682
   WONGPICHEDCHAI S, 1992, INVEST OPHTH VIS SCI, V33, P3341
   Yan F, 1998, EXP EYE RES, V66, P783, DOI 10.1006/exer.1998.0484
   ZANETTI NC, 1984, J CELL BIOL, V99, P115, DOI 10.1083/jcb.99.1.115
NR 37
TC 17
Z9 20
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2007
VL 28
IS 13
BP 2192
EP 2201
DI 10.1016/j.biomaterials.2007.01.018
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 146PQ
UT WOS:000244947100004
PM 17267030
DA 2022-11-30
ER

PT J
AU Krebs, I
   Binder, S
   Stolba, U
   Schmid, K
   Glittenberg, C
   Brannath, W
   Goll, A
AF Krebs, I
   Binder, S
   Stolba, U
   Schmid, K
   Glittenberg, C
   Brannath, W
   Goll, A
TI Optical coherence tomography guided retreatment of photodynamic therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; MACULAR THICKNESS MEASUREMENTS;
   DEGENERATION; EDEMA; REPRODUCIBILITY; VERTEPORFIN
AB Aim: To evaluate the results of a retreatment modality of photodynamic therapy (PDT) based on optical coherence tomography (OCT) and fluorescein angiography (FA). To quantify the effect of PDT with the help of measurement of the retinal thickness.
   Methods: Eyes with predominantly classic subfoveal choroidal neovascularisation (CNV) due to age related macular degeneration were included. PDT was performed every three months, when needed. OCT, FA, and measures of distance acuity were performed at baseline, after 6 weeks, 3 months, and from then on every 3 months. A control group of a consecutive series of eyes that had been retreated based only on FA results was installed.
   Results: Forty eyes of 38 patients were included. The average age was 73 years. The maximum retinal thickness decreased from 404 mm at baseline to 281.6 mm at month 12. Furthermore there was a significant decrease of retinal thickness in both subgroups. The number of retreatments was reduced, when activity was diagnosed using OCT and FA. (2.4 v 4.0). The distance acuity correlated significantly with the maximum retinal thickness (p=0.0042).
   Conclusion: Information about the activity of a neovascular lesion can be obtained with the help of OCT. The retreatment modalities can be optimised by using OCT and FA and the number of retreatments can be reduced.
C1 Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   Univ Vienna, Dept Med Stat, Vienna, Austria.
C3 Ludwig Boltzmann Institute; University of Vienna
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM Ilse.Krebs@wienkav.at
OI Graf, Alexandra/0000-0003-0035-2658
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brindeau C, 2001, EUR J OPHTHALMOL, V11, P287, DOI 10.1177/112067210101100313
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Koozekanani D, 2000, INVEST OPHTH VIS SCI, V41, P1486
   Krebs I, 2004, OPHTHALMOLOGICA, V218, P185, DOI 10.1159/000076843
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Wakitani Y, 2003, RETINA-J RET VIT DIS, V23, P177, DOI 10.1097/00006982-200304000-00007
   Zolf R, 2002, RETINA-J RET VIT DIS, V22, P192, DOI 10.1097/00006982-200204000-00010
NR 20
TC 36
Z9 38
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2005
VL 89
IS 9
BP 1184
EP 1187
DI 10.1136/bjo.2005.067389
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 956PW
UT WOS:000231313300030
PM 16113378
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Gaudreault, J
   Fei, D
   Rusit, J
   Suboc, P
   Shiu, V
AF Gaudreault, J
   Fei, D
   Rusit, J
   Suboc, P
   Shiu, V
TI Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single
   intravitreal administration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; PIGMENT
   EPITHELIAL-CELLS; MACULAR DEGENERATION; RETINAL CELLS; MESSENGER-RNA;
   FACTOR VEGF; EXPRESSION; NEOVASCULARIZATION; ANTIBODY
AB PURPOSE. Ranibizumab ( rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age- related macular degeneration. This study evaluated the pharmacokinetic ( PK) and serum bioavailability of ranibizumab after a single intravitreal ( ITV) or intravenous ( IV) dose in cynomolgus monkeys.
   METHODS. Monkeys received ranibizumab as either a bilateral ITV dose ( 500 or 2000 mu g/ eye; n = 6/ group) or a single IV dose ( 1000 or 4000 mu g/ animal; n = 4/ group). After ITV administration, ranibizumab concentrations were measured in several ocular compartments and in serum for 10 days and, after IV administration, for 48 hours. Pharmacokinetic parameters were estimated by compartmental and noncompartmental methods.
   RESULTS. Ranibizumab cleared in parallel from all ocular compartments, with a terminal half- life of approximately 3 days. It distributed rapidly to the retina ( 6 - 24 hours), and concentrations were approximately one third that in the vitreous. After ITV injection, bioavailability ( F) was 50% to 60%. Serum concentrations were very low, reflecting wider distribution and faster clearance when ranibizumab reached the serum. After IV administration, the terminal half- life was approximately 0.5 day.
   CONCLUSIONS. This study demonstrates that ranibizumab has a PK profile that is favorable for its clinical use in treating neovascular AMD by monthly ITV injection.
C1 Genentech Inc, Dept Pharmacokinet & Pharmacodynam Sci, San Francisco, CA 94080 USA.
   Genentech Inc, Dept Bioanalyt Res & Dev, San Francisco, CA 94080 USA.
   Genentech Inc, Dept Bioanalyt Assays, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech
RP Gaudreault, J (通讯作者)，Genentech Inc, Dept Pharmacokinet & Pharmacodynam Sci, 1 DNA Way, San Francisco, CA 94080 USA.
EM jacques@gene.com
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brizzi M F, 2001, Ital Heart J, V2, P81
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Croll SD, 2001, MOL NEUROBIOL, V23, P121, DOI 10.1385/MN:23:2-3:121
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   GAUDREAULT J., 1999, AAPS PHARM SCI S1, V1, P3207
   Gerhardinger C, 1998, AM J PATHOL, V152, P1453
   Gupta SK, 2000, J OCUL PHARMACOL TH, V16, P511, DOI 10.1089/jop.2000.16.511
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Leeds JM, 1998, DRUG METAB DISPOS, V26, P670
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Maurice D. M., 1984, HANDB EXP PHARM, P19
   MAURICE DM, 1959, AM J OPHTHALMOL, V47, P361, DOI 10.1016/S0002-9394(14)78042-0
   MAURICE DM, 1976, S OCULAR THERAPY, P59
   Miraliakbari R, 2000, ANN THORAC SURG, V69, P1750, DOI 10.1016/S0003-4975(00)01375-8
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
   NOMURA M, 1995, J BIOL CHEM, V270, P28316
   PEARSON PA, 1993, RETINA-J RET VIT DIS, V13, P326
   PEER J, 1995, LAB INVEST, V72, P638
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   STUMP DC, 1988, ANN EMERG MED, V17, P1138, DOI 10.1016/S0196-0644(88)80059-3
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Yoshida A, 1999, HISTOL HISTOPATHOL, V14, P1287, DOI 10.14670/HH-14.1287
NR 37
TC 386
Z9 445
U1 0
U2 21
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2005
VL 46
IS 2
BP 726
EP 733
DI 10.1167/iovs.04-0601
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 890WP
UT WOS:000226542100046
PM 15671306
DA 2022-11-30
ER

PT J
AU Vincent, M
   Simon, L
   Brabet, P
   Legrand, P
   Dorandeu, C
   Him, JLK
   Durand, T
   Crauste, C
   Begu, S
AF Vincent, Maxime
   Simon, Laurianne
   Brabet, Philippe
   Legrand, Philippe
   Dorandeu, Christophe
   Him, Josephine Lai Kee
   Durand, Thierry
   Crauste, Celine
   Begu, Sylvie
TI Formulation and Evaluation of SNEDDS Loaded with Original Lipophenol for
   the Oral Route to Prevent Dry AMD and Stragardt's Disease
SO PHARMACEUTICS
LA English
DT Article
DE dry age-related macular degeneration (AMD); Stargardt's disease (STGD1);
   self-nanoemulsifying drug delivery system (SNEDDS); antioxidant;
   lipophenol; oral delivery
ID DRUG-DELIVERY SYSTEMS; INDUCED RETINAL DAMAGE; IN-VITRO; DISSOLUTION;
   A2E; PHOTORECEPTOR; ABSORPTION; TRANSPORT; TOXICITY; MODEL
AB Dry age-related macular degeneration (Dry AMD) and Stargardt's disease (STGD1) are common eye diseases, characterized by oxidative and carbonyl stress (COS)-inducing photoreceptor degeneration and vision loss. Previous studies have demonstrated the protective effect of photoreceptors after the intravenous administration of a new lipophenol drug, phloroglucinol-isopropyl-DHA (IP-DHA). In this study, we developed an oral formulation of IP-DHA (BCS Class IV) relying on a self-nanoemulsifying drug delivery system (SNEDDS). SNEDDS, composed of Phosal (R) 53 MCT, Labrasol (R), and Transcutol HP (R) at a ratio of 25/60/15 (w/w/w), led to a homogeneous nanoemulsion (NE) with a mean size of 53.5 +/- 4.5 nm. The loading of IP-DHA in SNEDDS (SNEDDS-IP-DHA) was successful, with a percentage of IP-DHA of 99.7% in nanoemulsions. The in vivo study of the therapeutic potency of SNEDDS-IP-DHA after oral administration on mice demonstrated photoreceptor protection after the induction of retinal degeneration with acute light stress (73-80%) or chronic light stress (52-69%). Thus, SNEDDS formulation proved to increase the solubility of IP-DHA, improving its stability in intestinal media and allowing its passage through the intestinal barrier after oral force-fed administration, while maintaining its biological activity. Therefore, SNEDDS-IP-DHA is a promising future preventive treatment for dry AMD and STGD1.
C1 [Vincent, Maxime; Simon, Laurianne; Legrand, Philippe; Dorandeu, Christophe; Begu, Sylvie] Univ Montpellier, ENSCM, CNRS, ICGM, F-34000 Montpellier, France.
   [Brabet, Philippe] Inst Neurosci Montpellier, INSERM U1051, F-34000 Montpellier, France.
   [Him, Josephine Lai Kee] Ctr Biochim Struct, INSERM U1054, CNRS UMR 5048, F-34000 Montpellier, France.
   [Durand, Thierry; Crauste, Celine] Univ Montpellier, ENSCM, CNRS, IBMM, F-34000 Montpellier, France.
C3 Centre National de la Recherche Scientifique (CNRS); Ecole nationale
   superieure de chimie de Montpellier; Universite de Montpellier; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Institut National de la Sante et
   de la Recherche Medicale (Inserm); Universite de Montpellier; Centre
   National de la Recherche Scientifique (CNRS); Ecole nationale superieure
   de chimie de Montpellier; Universite de Montpellier
RP Begu, S (通讯作者)，Univ Montpellier, ENSCM, CNRS, ICGM, F-34000 Montpellier, France.; Brabet, P (通讯作者)，Inst Neurosci Montpellier, INSERM U1051, F-34000 Montpellier, France.; Crauste, C (通讯作者)，Univ Montpellier, ENSCM, CNRS, IBMM, F-34000 Montpellier, France.
EM maxime.vincent@umontpellier.fr; laurianne.simon@umontpellier.fr;
   philippelegrand@umontpellier.fr; philippe.brabet@inserm.fr;
   christophe.dorandeu@umontpellier.fr; josephine.laikeehim@cbs.cnrs.fr;
   thierry.durand@umontpellier.fr; celine.crauste@umontpellier.fr;
   sylvie.begu@umontpellier.fr
OI Brabet, Philippe/0000-0003-2739-1622; Crauste,
   Celine/0000-0002-5714-8749; Simon, Laurianne/0000-0002-8515-947X; LAI
   KEE HIM, Josephine/0000-0001-6303-1224
FU French National Research Agency (ANR) [LiPoPheRet ANR-18-CE18-0017];
   SATT AxLR
FX This researched was funded by the French National Research Agency (ANR)
   (LiPoPheRet ANR-18-CE18-0017) and by SATT AxLR.
CR AboulFotouh K, 2017, EUR J PHARM SCI, V109, P503, DOI 10.1016/j.ejps.2017.09.001
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288
   [Anonymous], 2012, Drug Discov Today Technol, V9, pe71, DOI 10.1016/j.ddtec.2012.03.002
   [Anonymous], 2013, BIOMED PHARMACOL J, DOI 10.13005/bpj/425
   Basalious EB, 2010, INT J PHARMACEUT, V391, P203, DOI 10.1016/j.ijpharm.2010.03.008
   Buya AB, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121194
   CHARMAN WNA, 1986, INT J PHARM, V34, P175, DOI 10.1016/0378-5173(86)90027-X
   Chatterjee B, 2016, DRUG DELIV, V23, P3639, DOI 10.1080/10717544.2016.1214990
   Chekroud K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050231
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cherniakov I, 2015, EXPERT OPIN DRUG DEL, V12, P1121, DOI 10.1517/17425247.2015.999038
   Cia D, 2016, J CELL MOL MED, V20, P1651, DOI 10.1111/jcmm.12857
   CONSTANTINIDES PP, 1994, PHARMACEUT RES, V11, P1385, DOI 10.1023/A:1018927402875
   Crauste C, 2014, EUR J ORG CHEM, V2014, P4548, DOI 10.1002/ejoc.201402282
   Cubizolle A, 2020, J CELL MOL MED, V24, P5057, DOI 10.1111/jcmm.15135
   Date AA, 2010, NANOMEDICINE-UK, V5, P1595, DOI 10.2217/NNM.10.126
   Deng YH, 2022, GENES DIS, V9, P62, DOI 10.1016/j.gendis.2021.02.009
   Gupta Shweta, 2013, ISRN Pharm, V2013, P848043, DOI 10.1155/2013/848043
   Gursoy RN, 2004, BIOMED PHARMACOTHER, V58, P173, DOI 10.1016/j.biopha.2004.02.001
   Izawa H, 2016, FREE RADICAL BIO MED, V96, P304, DOI 10.1016/j.freeradbiomed.2016.03.036
   Izawa H, 2015, INVEST OPHTH VIS SCI, V56, P6914, DOI 10.1167/iovs.15-16748
   Kalepu S, 2013, ACTA PHARM SIN B, V3, P361, DOI 10.1016/j.apsb.2013.10.001
   Kheawfu K, 2018, J DRUG DELIV SCI TEC, V46, P330, DOI 10.1016/j.jddst.2018.05.028
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Krstic M, 2018, LIPID NANOCARRIERS FOR DRUG TARGETING, P473, DOI 10.1016/B978-0-12-813687-4.00012-8
   Lenis TL, 2018, P NATL ACAD SCI USA, V115, pE11120, DOI 10.1073/pnas.1802519115
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   McCartney F, 2019, J CONTROL RELEASE, V310, P115, DOI 10.1016/j.jconrel.2019.08.008
   Morakul B., 2020, PHARM SCI ASIA, V47, P205, DOI [10.29090/psa.2020.03.019.0121, DOI 10.29090/PSA.2020.03.019.0121]
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Nayak K, 2018, BIOMED PHARMACOTHER, V107, P1564, DOI 10.1016/j.biopha.2018.08.138
   O'Driscoll CM, 2002, EUR J PHARM SCI, V15, P405, DOI 10.1016/S0928-0987(02)00051-9
   Okonogi S, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020167
   Ortega JT, 2021, MOL PHARMACOL, V99, P60, DOI [10.1124/molpharm.120.000072, 10.1124/molpharm.120.000072.]
   Otsuka T, 2013, J PHARMACOL SCI, V123, P209, DOI 10.1254/jphs.13066FP
   Patel MH, 2019, EUR J PHARM SCI, V138, DOI 10.1016/j.ejps.2019.105027
   Patel V, 2018, AAPS PHARMSCITECH, V19, P3609, DOI 10.1208/s12249-018-1188-8
   Rao SVR, 2008, INT J PHARMACEUT, V362, P16, DOI 10.1016/j.ijpharm.2008.05.015
   Savla R, 2017, DRUG DEV IND PHARM, V43, P1743, DOI 10.1080/03639045.2017.1342654
   Sha XY, 2005, EUR J PHARM SCI, V24, P477, DOI 10.1016/j.ejps.2005.01.001
   Shanmugam S, 2011, EUR J PHARM BIOPHARM, V79, P250, DOI 10.1016/j.ejpb.2011.04.012
   Shen HR, 2006, J PHARM PHARMACOL, V58, P1183, DOI 10.1211/jpp.58.9.0004
   Shindou H, 2017, J BIOL CHEM, V292, P12054, DOI [10.1074/jbc.M117.790568, 10.1074/jbc.m117.790568]
   Shrestha H, 2014, J PHARMACEUTICS, V2014, DOI 10.1155/2014/801820
   Sokkula SR, 2020, INT J PHARM SCI DRUG, V12, P576, DOI [10.25004/IJPSDR.2020.120522, DOI 10.25004/IJPSDR.2020.120522]
   Taveau N, 2020, EXP MOL MED, V52, P1090, DOI 10.1038/s12276-020-0460-7
   Torcello-Gomez A, 2011, FOOD HYDROCOLLOID, V25, P809, DOI 10.1016/j.foodhyd.2010.09.007
   Wang P, 2021, CLIN OPHTHALMOL, V15, P1621, DOI 10.2147/OPTH.S307009
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MR, 2018, CELL PHYSIOL BIOCHEM, V51, P63, DOI 10.1159/000495162
   Yang EJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135686
   Yang J, 2020, J FUNCT FOODS, V73, DOI 10.1016/j.jff.2020.104107
   Yoo JH, 2010, ARCH PHARM RES, V33, P417, DOI 10.1007/s12272-010-0311-5
   Youhanna S, 2021, J PHARM SCI-US, V110, P50, DOI 10.1016/j.xphs.2020.07.001
   Yu A, 2017, AAPS J, V19, P1682, DOI 10.1208/s12248-017-0145-x
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 58
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD MAY
PY 2022
VL 14
IS 5
AR 1029
DI 10.3390/pharmaceutics14051029
PG 21
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 1Q1BS
UT WOS:000802432800001
PM 35631617
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pearce, I
   Amoaku, W
   Bailey, C
   Downey, L
   Gale, R
   Ghanchi, F
   Hamilton, R
   Mahmood, S
   Menon, G
   Nosek, J
   Talks, J
   Yang, Y
AF Pearce, Ian
   Amoaku, Winfried
   Bailey, Clare
   Downey, Louise
   Gale, Richard
   Ghanchi, Faruque
   Hamilton, Robin
   Mahmood, Sajjad
   Menon, Geeta
   Nosek, Jenny
   Talks, James
   Yang, Yit
TI The changing landscape for the management of patients with neovascular
   AMD: brolucizumab in clinical practice
SO EYE
LA English
DT Review
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; RANIBIZUMAB; AFLIBERCEPT;
   VERTEPORFIN; PREVALENCE; INJECTION; OUTCOMES
AB Untreated neovascular age-related macular degeneration (nAMD) can lead to severe and permanent visual impairment. The chronic nature of the disease can have a significant impact on patients' quality of life and an economic and time burden on medical retina (MR) services, with the care need outweighing the growth of resources that clinical services can access. The introduction of a new treatment into clinical services can be challenging, especially for services that are already under capacity constraints. Guidance for practical implementation is therefore helpful. Roundtable meetings, facilitated by Novartis UK, between a working group of MR experts with experience of leading and managing NHS retinal services in the intravitreal era were conducted between 2020 and 2021. These meetings explored various aspects and challenges of introducing a new anti-vascular endothelial growth factor (VEGF) therapy to the UK medical retina services. Provision of clear expert recommendations and practical guidance nationally, that can be adapted locally as required to support clinicians and healthcare professionals (HCPs), is valuable in supporting the introduction of a new anti-VEGF therapy within the NHS environment. The experts provide ophthalmologic HCPs with a collation of insights and recommendations to support the introduction and delivery of brolucizumab in their local service in the face of current and projected growth in demand for retina care.
C1 [Pearce, Ian] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Amoaku, Winfried] Univ Nottingham, Acad Ophthalmol, Div Clin Neurosci, Nottingham, England.
   [Bailey, Clare] Univ Hosp Bristol & Weston NHS Fdn Trust, Bristol, Avon, England.
   [Downey, Louise] Hull Univ, Teaching Hosp, Kingston Upon Hull, N Humberside, England.
   [Gale, Richard] Univ York, York, N Yorkshire, England.
   [Gale, Richard] York Teaching Hosp, York, N Yorkshire, England.
   [Ghanchi, Faruque] Bradford Teaching Hosp NHS Fdn Trust, Bradford, W Yorkshire, England.
   [Hamilton, Robin] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Mahmood, Sajjad] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England.
   [Menon, Geeta] Frimley Hlth NHS Fdn Trust, Frimley, England.
   [Nosek, Jenny] Royal Shrewsbury Hosp, Shrewsbury, Shrops, England.
   [Talks, James] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England.
   [Yang, Yit] Royal Wolverhampton NHS Trust, Wolverhampton Eye Infirm, Wolverhampton, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Nottingham; University of Hull; University of York - UK; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of Manchester; Newcastle Upon Tyne
   Hospitals NHS Foundation Trust
RP Pearce, I (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
EM ian.pearce@rlbuht.nhs.uk
OI Talks, James/0000-0001-6126-6476; Ghanchi, Faruque/0000-0002-4448-8162;
   Amoaku, Winfried/0000-0001-5028-7984
FU Novartis Pharmaceuticals UK Ltd.
FX This supplement and the group that developed it were sponsored by
   Novartis Pharmaceuticals UK Ltd.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Amoaku W, 2020, CLIN OPHTHALMOL, V14, P1315, DOI 10.2147/OPTH.S233061
   ASRS. American Society of Retina Specialists, SAF REV COMM REP
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Beovu, SUMMARY PRODUCT CHAR
   Beovu, PACK INF LEAFL
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Daien V, 2021, BRIT J OPHTHALMOL, V105, P1475, DOI 10.1136/bjophthalmol-2020-317434
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eylea, SUMMARY PRODUCT CHAR
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   German Soc Ophthalmology, 2021, OPHTHALMOLOGE, V118, P31, DOI 10.1007/s00347-020-01188-1
   Groppe M, 2021, CLIN OPHTHALMOL, V15, P651, DOI 10.2147/OPTH.S269596
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2020, ASSESSING CHARACTERI
   Hospital, ME MOORF EYE HOSP EN
   Ip M, 2020, BROLUCIZUMAB EXPERIE
   Khanani AM, 2022, JAMA OPHTHALMOL, V140, P20, DOI 10.1001/jamaophthalmol.2021.4585
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Lucentis, SUMMARY PRODUCT CHAR
   Machin J, LEARNING LITIGATION
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Mousa SA, 2010, BIODRUGS, V24, P183, DOI 10.2165/11318550-000000000-00000
   National Health Service (NHS), CONS TREATM
   National Institute for Health and Care Excellence (NICE), BRIT NATL FORMULARY
   NICE, TA155 NICE
   NICE, NG82 NICE
   NICE, 2021, TA672 NICE
   Novartis, 2021, NOV REP ON YEAR RES
   Novartis, NCT04005352
   Novartis, NCT03710564
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Powell JM, 2016, BONE JOINT J, V98B, P1427, DOI 10.1302/0301-620X.98B11.37965
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rahman F, 2020, EYE, V34, P1271, DOI 10.1038/s41433-020-0864-6
   RCOphth. Royal College of Ophthalmologists, AMD SERV COMM GUID
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Severn PS, 2015, EYE, V29, P150, DOI 10.1038/eye.2014.231
   Singer M, 2022, OPHTHALMOL RETINA, V6, P97, DOI 10.1016/j.oret.2021.05.003
   Thomaidou E, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12817
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   WHO. World Health Organisation, PRIOR EVE DIS AG REL
   Zarbin M, 2020, AM AC OPHTH ANN M 13
NR 58
TC 2
Z9 2
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2022
VL 36
IS 9
BP 1725
EP 1734
DI 10.1038/s41433-022-02008-3
EA MAR 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W0KK
UT WOS:000771350100001
PM 35314774
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Priyanka, P
   Patil, RS
   Meshram, P
   Gupta, JA
   Banerjee, M
   Rathore, AS
AF Priyanka, Priyanka
   Patil, Rucha S.
   Meshram, Pradnya
   Gupta, Jaya A.
   Banerjee, Manidipa
   Rathore, Anurag S.
TI Ethanol as additive enhances expression of Ranibizumab in Escherichia
   coli: Impact on cellular physiology and transcriptome
SO PROCESS BIOCHEMISTRY
LA English
DT Article
DE Ranibizumab; E. coli BL21 DE3; Ethanol; LC-MS; Surface plasmon
   resonance; Transcriptomic analysis
ID STRESS; PROTEINS; SHOCK; INHIBITORS; COMPLEX; CELLS
AB Ranibizumab is an antibody fragment used for treatment of blurred vision due to age-related macular degeneration. Most manufacturers currently express it in Escherichia coli BL21 (DE3), where low-level expression of this complex protein has been acknowledged to result in higher production cost. This paper aims to present a strategy involving the use of additives with previously developed clone of Ranibizumab to enhance its expression in E. coli. The effect of ethanol (as additive) on cell size (control 1.82 mu m and optimized 2 mu m), cellular physiology (no cell swelling, or shrinkage observed) and cellular viability (better in optimized sample) were examined. A 2 fold improvement in Ranibizumab expression has been demonstrated (from 0.23 mg/mL to 0.48 mg/mL in single copy clone and 0.4 mg/mL to 0.72 mg/mL in double copy clone) using the optimized conditions vis-a-vis the control, thereby demonstrating the efficacy of the proposed approach. LC-MS confirmed correct disulfide bond formation and surface plasmon resonance confirmed the formation of active recombinant protein via binding to its target VEGF (KD = 12.7 nM). Transcriptomic analysis and RT-qPCR validation indicated that changes in membrane properties and DNA synthesis results in growth, gene amplification and enhances synthesis of inducible proteins in case of the optimized medium.
C1 [Priyanka, Priyanka; Patil, Rucha S.; Meshram, Pradnya; Gupta, Jaya A.; Rathore, Anurag S.] Indian Inst Technol, Dept Chem Engn, Hauz Khas, New Delhi, India.
   [Banerjee, Manidipa] Indian Inst Technol, Kusuma Sch Biol Sci, Hauz Khas, New Delhi, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Delhi; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT) - Delhi
RP Rathore, AS (通讯作者)，Indian Inst Technol, Dept Chem Engn, Hauz Khas, New Delhi, India.
EM asrathore@biotechcmz.com
OI Rathore, Anurag/0000-0002-5913-4244
FU Department of Biotechnology, Ministry of Science and Technology
   [BT/COE/34/SP15097/2015]; Biotechnology Industry Research Assistance
   Council [BT/NBM0159/04/2019]
FX This work was funded by the Department of Biotechnology, Ministry of
   Science and Technology (number BT/COE/34/SP15097/2015) and by
   Biotechnology Industry Research Assistance Council (number
   BT/NBM0159/04/2019).
CR Arie JP, 2006, MOL MICROBIOL, V62, P427, DOI 10.1111/j.1365-2958.2006.05394.x
   BASU T, 1994, FOLIA MICROBIOL, V39, P3, DOI 10.1007/BF02814520
   Bhambure R.S., 2018, A Method for Producing Refolded Recombinant Humanized Ranibizumab, Patent No. [WO 2018/211529 Al, 2018211529]
   Buts L, 2005, TRENDS BIOCHEM SCI, V30, P672, DOI 10.1016/j.tibs.2005.10.004
   Carlsson S., 2012, SURFACE CHARACTERIZA
   CHEN LL, 1987, J BACTERIOL, V169, P2373, DOI 10.1128/jb.169.6.2373-2379.1987
   CHEPURI V, 1990, J BIOL CHEM, V265, P12978
   Chhetri G, 2015, METHODSX, V2, P385, DOI 10.1016/j.mex.2015.09.005
   Chong HQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077422
   Cook KM, 2010, CA-CANCER J CLIN, V60, P222, DOI 10.3322/caac.20075
   Dajkovic A, 2010, MOL MICROBIOL, V78, P651, DOI 10.1111/j.1365-2958.2010.07352.x
   de Souza CS, 2016, PROTEIN SCI, V25, P2142, DOI 10.1002/pro.3038
   DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2
   DOMBEK KM, 1984, J BACTERIOL, V157, P233, DOI 10.1128/JB.157.1.233-239.1984
   Eiteman MA, 2006, TRENDS BIOTECHNOL, V24, P530, DOI 10.1016/j.tibtech.2006.09.001
   ENEQUIST HG, 1981, EUR J BIOCHEM, V116, P227, DOI 10.1111/j.1432-1033.1981.tb05323.x
   Fozo EM, 2008, MICROBIOL MOL BIOL R, V72, P579, DOI 10.1128/MMBR.00025-08
   Frenzel A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00217
   Galli E, 2012, J BACTERIOL, V194, P292, DOI 10.1128/JB.05821-11
   Gerdes K, 2005, NAT REV MICROBIOL, V3, P371, DOI 10.1038/nrmicro1147
   GonzalezGil G, 1996, MOL MICROBIOL, V22, P21, DOI 10.1111/j.1365-2958.1996.tb02652.x
   GOTTESMAN S, 1984, ANNU REV GENET, V18, P415
   Gralla JD, 2005, MOL MICROBIOL, V55, P973, DOI 10.1111/j.1365-2958.2004.04455.x
   Gronemeyer Petra, 2014, Bioengineering-Basel, V1, P188, DOI 10.3390/bioengineering1040188
   Gupta SK, 2016, CRIT REV BIOTECHNOL, V36, P1089, DOI 10.3109/07388551.2015.1084264
   Ingram L.O, 1993, TIME, V41, P2934
   INGRAM LO, 1984, ADV MICROB PHYSIOL, V25, P253
   Jozefczuk S, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.18
   Katsuda Tomohisa, 2012, Methods Mol Biol, V907, P305, DOI 10.1007/978-1-61779-974-7_18
   KITA K, 1989, J BIOL CHEM, V264, P2672
   Kopp Julian, 2018, Bioengineering-Basel, V5, DOI 10.3390/bioengineering5010001
   Kumar D, 2019, BIOENGINEERING-BASEL, V6, DOI 10.3390/bioengineering6020029
   Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93
   Manderson D, 2006, J IND MICROBIOL BIOT, V33, P173, DOI 10.1007/s10295-005-0046-3
   Manganelli R, 2017, TRENDS MICROBIOL, V25, P205, DOI 10.1016/j.tim.2016.10.001
   Nguyen MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089038
   Miyanaga K, 2007, BIOCHEM ENG J, V37, P56, DOI 10.1016/j.bej.2007.03.007
   Nelson AL, 2010, MABS-AUSTIN, V2, P77, DOI 10.4161/mabs.2.1.10786
   Oganesyan N, 2007, PROTEIN EXPRES PURIF, V52, P280, DOI 10.1016/j.pep.2006.09.015
   Palomares Laura A, 2004, Methods Mol Biol, V267, P15
   Priyanka P, 2022, J CHEM TECHNOL BIOT, V97, P42, DOI 10.1002/jctb.6883
   Raina M, 2017, J BACTERIOL, V199, DOI 10.1128/JB.00130-17
   Rothfield L, 1999, ANNU REV GENET, V33, P423, DOI 10.1146/annurev.genet.33.1.423
   Sanden AM, 2003, BIOTECHNOL BIOENG, V81, P158, DOI 10.1002/bit.10457
   Sandomenico A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176324
   Shamis Y, 2011, APPL ENVIRON MICROB, V77, P3017, DOI 10.1128/AEM.01899-10
   Singh A, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0222-8
   Sleator RD, 2002, FEMS MICROBIOL REV, V26, P49, DOI 10.1111/j.1574-6976.2002.tb00598.x
   Smith MG, 2004, MOL CELL BIOL, V24, P3874, DOI 10.1128/MCB.24.9.3874-3884.2004
   Stiefel P, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0376-x
   Ukkonen K, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-73
   Van Melderen L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000437
   Walsh G, 2018, NAT BIOTECHNOL, V36, P1136, DOI 10.1038/nbt.4305
   Walsh G, 2014, NAT BIOTECHNOL, V32, P992, DOI 10.1038/nbt.3040
   Wang Y, 2009, BIOTECHNOL ADV, V27, P989, DOI 10.1016/j.biotechadv.2009.05.022
   Weiss A, 2017, J BACTERIOL, V199, DOI 10.1128/JB.00459-16
   Wyre C, 2014, J IND MICROBIOL BIOT, V41, P1391, DOI 10.1007/s10295-014-1489-1
   Yamaguchi S, 2012, J MICROBIOL, V50, P1, DOI 10.1007/s12275-012-1578-7
NR 58
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-5113
EI 1873-3298
J9 PROCESS BIOCHEM
JI Process Biochem.
PD JAN
PY 2022
VL 112
BP 167
EP 176
DI 10.1016/j.procbio.2021.11.029
EA DEC 2021
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA XN0GM
UT WOS:000729193500002
DA 2022-11-30
ER

PT J
AU Bilgic, A
   Kodjikian, L
   Srivastava, S
   Dwivedi, S
   Banker, AS
   Abukashabah, A
   Sudhalkar, A
   Mathis, T
AF Bilgic, Alper
   Kodjikian, Laurent
   Srivastava, Samaresh
   Dwivedi, Shyamal
   Banker, Alay S.
   Abukashabah, Amro
   Sudhalkar, Aditya
   Mathis, Thibaud
TI Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; brolucizumab; exudation; treatment-naive
ID MACULAR DEGENERATION; RANIBIZUMAB; AFLIBERCEPT; REGIMEN; OUTCOMES;
   HORIZON; TREAT
AB The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. The PROBE study (Pro Re Nata Brolucizumab for Exudative AMD) is a retrospective, observational, multicentric study that included 27 treatment-naive patients (27 eyes) with neovascular AMD who received PRN brolucizumab therapy with the treatment interval being at least 8 weeks, should the need for a second consecutive injection arise. The primary outcome measure was changed to best-corrected visual acuity (BCVA) over time. Secondary outcome measures included the determination of change in central subfield thickness (CST) and complications. The mean follow-up was 11.2 +/- 1.2 months. The mean baseline and final BCVA were 57.4 +/- 4.5 letters and 65.3 +/- 3.12 letters, respectively (p = 0.014). The mean gain in letters at the end of follow-up was 7.8 +/- 3.5 letters. There was a significant decrease in CST at the end of the follow-up period (p = 0.013). Patients received a mean of 2.2 +/- 0.9 injections (in addition to the first mandatory injection) during the follow-up period. There were no adverse events noted. In conclusion, initial PRN brolucizumab for exudative AMD without a loading dose demonstrated significant visual improvement and no adverse events.
C1 [Bilgic, Alper; Sudhalkar, Aditya] Alphavis Augenarztpraxis Clin, D-27568 Bremerhaven, Germany.
   [Kodjikian, Laurent; Abukashabah, Amro; Mathis, Thibaud] Univ Claude Bernard Lyon 1, Ctr Hosp Univ Croix Rousse, Hosp Civils Lyon, Serv Ophtalmol, F-69004 Lyon, France.
   [Kodjikian, Laurent; Mathis, Thibaud] UMR CNRS 5510 Lab, F-69100 Lyon, France.
   [Srivastava, Samaresh; Dwivedi, Shyamal] Raghudeep Eye Hosp, Ahmadabad 380054, Gujarat, India.
   [Banker, Alay S.] Banker Retina Clin, Ahmadabad 380054, Gujarat, India.
   [Abukashabah, Amro] King Abdulaziz Univ, Ophthalmol Dept, Rabigh 25732, Saudi Arabia.
   [Sudhalkar, Aditya] MS Sudhalkar Med Res Fdn, Baroda 390001, Gujarat, India.
C3 CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard
   Lyon 1; King Abdulaziz University
RP Sudhalkar, A (通讯作者)，Alphavis Augenarztpraxis Clin, D-27568 Bremerhaven, Germany.; Sudhalkar, A (通讯作者)，MS Sudhalkar Med Res Fdn, Baroda 390001, Gujarat, India.
EM drbilgicalper@yahoo.com; laurent.kodjikian@chu-lyon.fr;
   samaresh@raghudeepeyeclinic.com; shyamal@raghudeepeyeclinic.com;
   alay.banker@gmail.com; dr.heartaaa@hotmail.com;
   adityasudhalkar@yahoo.com; thibaud.mathis@chu-lyon.fr
RI ; Mathis, Thibaud/R-3696-2016; kodjikian, laurent/A-3025-2015
OI Banker, Alay/0000-0001-9227-8525; Mathis, Thibaud/0000-0002-1418-1872;
   Bilgic, Alper/0000-0001-8403-0853; Dwivedi, Shyamal/0000-0003-2432-9911;
   kodjikian, laurent/0000-0002-3908-6716
CR Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bilgic A, 2021, RETINA-J RET VIT DIS, V41, P1901, DOI 10.1097/IAE.0000000000003106
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132758
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112425
   Bilgic A, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7462098
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Haensli C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122666
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Puxeddu I, 2016, CLIN EXP RHEUMATOL, V34, P129
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sharma A, 2022, OCUL IMMUNOL INFLAMM, V30, P1508, DOI 10.1080/09273948.2021.1897628
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Wang FH, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/7530458
NR 27
TC 4
Z9 4
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2021
VL 10
IS 18
AR 4153
DI 10.3390/jcm10184153
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA UV5HR
UT WOS:000699509800001
PM 34575264
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mannes, M
   Dopler, A
   Huber-Lang, M
   Schmidt, CQ
AF Mannes, Marco
   Dopler, Arthur
   Huber-Lang, Markus
   Schmidt, Christoph Q.
TI Tuning the Functionality by Splicing: Factor H and Its Alternative
   Splice Variant FHL-1 Share a Gene but Not All Functions
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE complement system; factor H; Factor H-like protein 1; cell protection;
   regulatory selectivity
ID COMPLEMENT FACTOR-H; REGULATORS FACTOR-H; BRUCHS MEMBRANE IMPLICATIONS;
   C-REACTIVE PROTEIN; NONSELF DISCRIMINATION; MACULAR DEGENERATION;
   TREPONEMA-DENTICOLA; HEPARAN-SULFATE; BINDING; DISEASE
AB The alternative pathway regulator Factor H-like protein 1 (FHL-1) is composed of the first 7 N-terminal complement control protein domains of Factor H (FH) and protects host surfaces from uncontrolled complement attack. Although FHL-1 shares the N-terminal regulatory domains with FH, it was thought to be a weaker regulator. Recently, the regulatory activity of FHL-1 was shown to be comparable to FH. Nonetheless, the question remained whether FHL-1 is an indispensable, unique regulator. The discovery that FHL-1 is the predominant regulator on Bruch's membrane, a critical site for the onset and progression of age-related-macular degeneration (AMD), showed that FHL-1 is essential for complement regulation. A common single nucleotide polymorphism in FH/FHL-1 that predisposes for AMD underlines the important role of FHL-1 in this context. Reports that some cancer tissues specifically upregulate FHL-1 expression, thereby evading immune surveillance, suggests a pronounced regulatory activity of the splice variant. Several microorganisms specifically recruit FHL-1 to evade complement attack. From a phylogenetic point of view, FHL-1 appears much later than other complement regulators, which could imply a specific role that is possibly not systemic but rather tissue specific. This review focuses on the current knowledge of FHL-1 and its physiological and pathophysiological roles.
C1 [Mannes, Marco; Huber-Lang, Markus] Univ Hosp Ulm, Inst Clin & Expt Trauma Immunol, Ulm, Germany.
   [Dopler, Arthur; Schmidt, Christoph Q.] Ulm Univ, Inst Pharmacol Nat Prod & Clin Pharmacol, Ulm, Germany.
C3 Ulm University; Ulm University
RP Schmidt, CQ (通讯作者)，Ulm Univ, Inst Pharmacol Nat Prod & Clin Pharmacol, Ulm, Germany.
EM christoph.schmidt@uni-ulm.de
FU Deutsche Forschungsgemeinschaft [SCHM3018/2-2]
FX This work was supported by the Deutsche Forschungsgemeinschaft grant
   (SCHM3018/2-2 to CS).
CR Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Borza DB, 2017, MATRIX BIOL, V57-58, P299, DOI 10.1016/j.matbio.2016.09.002
   BRODEUR JP, 1991, ARTHRITIS RHEUM, V34, P1531
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189
   Dopler A, 2019, J IMMUNOL, V203, P2029, DOI 10.4049/jimmunol.1900994
   Dopler A, 2019, J IMMUNOL, V202, P2082, DOI 10.4049/jimmunol.1801545
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ermert D, 2019, MOL IMMUNOL, V114, P49, DOI 10.1016/j.molimm.2019.07.018
   ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337
   Ferreira VP, 2007, BLOOD, V110, P2190, DOI 10.1182/blood-2007-04-083170
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friese MA, 2000, CLIN EXP IMMUNOL, V121, P406, DOI 10.1046/j.1365-2249.2000.01285.x
   Friese MA, 2003, CLIN EXP IMMUNOL, V132, P485, DOI 10.1046/j.1365-2249.2003.02173.x
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Haque A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01728
   Harder MJ, 2016, J IMMUNOL, V196, P866, DOI 10.4049/jimmunol.1501919
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Herbert AP, 2015, J IMMUNOL, V195, P4986, DOI 10.4049/jimmunol.1501388
   Herzberger P, 2009, INT J MED MICROBIOL, V299, P141, DOI 10.1016/j.ijmm.2008.06.005
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Jozsi M, 2007, MOL IMMUNOL, V44, P2697, DOI 10.1016/j.molimm.2006.12.001
   Junnikkala S, 2000, J IMMUNOL, V164, P6075, DOI 10.4049/jimmunol.164.11.6075
   Junnikkalla S, 2002, BRIT J CANCER, V87, P1119, DOI 10.1038/sj.bjc.6600614
   Kang J, 2019, J IMMUNOL, V203, P2029, DOI 10.4049/jimmunol.1900660
   KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kennedy AT, 2016, J IMMUNOL, V196, P1239, DOI 10.4049/jimmunol.1501581
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kotarsky H, 1998, J IMMUNOL, V160, P3349
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Makou E, 2019, J BIOL CHEM, V294, P20148, DOI 10.1074/jbc.RA119.010913
   McDowell JV, 2005, INFECT IMMUN, V73, P7126, DOI 10.1128/IAI.73.11.7126-7132.2005
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MISASI R, 1989, EUR J IMMUNOL, V19, P1765, DOI 10.1002/eji.1830190936
   MORGAN BP, 1988, CLIN EXP IMMUNOL, V73, P473
   MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   PETERSON PK, 1979, J INFECT DIS, V139, P575, DOI 10.1093/infdis/139.5.575
   Pouw RB, 2019, BLOOD ADV, V3, P621, DOI 10.1182/bloodadvances.2018025692
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Sahu A, 1998, J IMMUNOL, V160, P5596
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Schmidt CQ, 2018, GLYCOBIOLOGY, V28, P765, DOI 10.1093/glycob/cwy061
   Schmidt CQ, 2016, IMMUNOL REV, V274, P152, DOI 10.1111/imr.12475
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   Sim R B, 1993, Int Rev Immunol, V10, P65, DOI 10.3109/08830189309051172
   SIMONSON LG, 1988, INFECT IMMUN, V56, P726, DOI 10.1128/IAI.56.4.726-728.1988
   Sofat R, 2013, J IMMUNOL METHODS, V390, P63, DOI 10.1016/j.jim.2013.01.009
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   VIK DP, 1988, J BIOL CHEM, V263, P16720
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
NR 76
TC 7
Z9 7
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 15
PY 2020
VL 11
AR 596415
DI 10.3389/fimmu.2020.596415
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA OK5XH
UT WOS:000584722700001
PM 33178228
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tawfik, A
   Samra, YA
   Elsherbiny, NM
   Al-Shabrawey, M
AF Tawfik, Amany
   Samra, Yara A.
   Elsherbiny, Nehal M.
   Al-Shabrawey, Mohamed
TI Implication of Hyperhomocysteinemia in Blood Retinal Barrier (BRB)
   Dysfunction
SO BIOMOLECULES
LA English
DT Review
DE hyperhomocysteinemia; blood retinal barrier; blood brain barrier;
   dysfunction; mechanisms
ID ENDOPLASMIC-RETICULUM STRESS; TYPE-1 DIABETES-MELLITUS; NMDA RECEPTOR
   ACTIVATION; SYNTHASE MUTANT MICE; BRAIN-BARRIER; PLASMA HOMOCYSTEINE;
   MACULAR DEGENERATION; GLUTAMATE RECEPTORS; B-VITAMINS; ER STRESS
AB Elevated plasma homocysteine (Hcy) level, known as hyperhomocysteinemia (HHcy) has been linked to different systemic and neurological diseases, well-known as a risk factor for systemic atherosclerosis and cardiovascular disease (CVD) and has been identified as a risk factor for several ocular disorders, such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). Different mechanisms have been proposed to explain HHcy-induced visual dysfunction, including oxidative stress, upregulation of inflammatory mediators, retinal ganglion cell apoptosis, and extracellular matrix remodeling. Our previous studies using in vivo and in vitro models of HHcy have demonstrated that Hcy impairs the function of both inner and outer blood retinal barrier (BRB). Dysfunction of BRB is a hallmark of vision loss in DR and AMD. Our findings highlighted oxidative stress, ER stress, inflammation, and epigenetic modifications as possible mechanisms of HHcy-induced BRB dysfunction. In addition, we recently reported HHcy-induced brain inflammation as a mechanism of blood-brain barrier (BBB) dysfunction and pathogenesis of Alzheimer's disease (AD). Moreover, we are currently investigating the activation of glutamate receptorN-methyl-d-aspartate receptor (NMDAR) as the molecular mechanism for HHcy-induced BRB dysfunction. This review focuses on the studied effects of HHcy on BRB and the controversial role of HHcy in the pathogenesis of aging neurological diseases such as DR, AMD, and AD. We also highlight the possible mechanisms for such deleterious effects of HHcy.
C1 [Tawfik, Amany; Samra, Yara A.; Elsherbiny, Nehal M.; Al-Shabrawey, Mohamed] Augusta Univ, Dept Oral Biol & Diagnost Sci, Dent Coll Georgia, Augusta, GA 30912 USA.
   [Tawfik, Amany; Samra, Yara A.; Elsherbiny, Nehal M.; Al-Shabrawey, Mohamed] Augusta Univ, James & Jean Culver Vis Discovery Inst, MCG, Augusta, GA 30912 USA.
   [Tawfik, Amany; Al-Shabrawey, Mohamed] Augusta Univ, Dept Cellular Biol & Anat, Med Coll Georgia MCG, Augusta, GA 30912 USA.
   [Tawfik, Amany; Al-Shabrawey, Mohamed] Augusta Univ, Dept Ophthalmol, MCG, Augusta, GA 30912 USA.
   [Samra, Yara A.; Elsherbiny, Nehal M.] Mansoura Univ, Dept Biochem, Fac Pharm, Mansoura 35516, Egypt.
   [Al-Shabrawey, Mohamed] Mansoura Univ, Dept Anat, Fac Med, Mansoura 35516, Egypt.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University; Egyptian
   Knowledge Bank (EKB); Mansoura University; Egyptian Knowledge Bank
   (EKB); Mansoura University
RP Tawfik, A (通讯作者)，Augusta Univ, Dept Oral Biol & Diagnost Sci, Dent Coll Georgia, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, James & Jean Culver Vis Discovery Inst, MCG, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Dept Cellular Biol & Anat, Med Coll Georgia MCG, Augusta, GA 30912 USA.; Tawfik, A (通讯作者)，Augusta Univ, Dept Ophthalmol, MCG, Augusta, GA 30912 USA.
EM amtawfik@augusta.edu; ysamra@augusta.edu; drnehal@mans.edu.eg;
   malshabrawey@augusta.edu
RI Samra, Yara A/AAD-1192-2022; Elsherbiny, Nehal/AAF-9206-2019; Samra,
   Yara/AGB-5593-2022
OI Elsherbiny, Nehal/0000-0001-5167-3377; Tawfik,
   Amany/0000-0002-0245-8256; adel, yara/0000-0002-0223-8683
FU American Heart Association (AHA) Scientist Development Grant
   [16SDG3070001]; NEI [R01 EY029751-01-NEI00072]
FX This research was funded by the American Heart Association (AHA)
   Scientist Development Grant award #16SDG3070001 and NEI grant award R01
   EY029751-01-NEI00072.
CR Adachi T, 2012, ARCH BIOCHEM BIOPHYS, V520, P30, DOI 10.1016/j.abb.2012.01.014
   Ajith TA, 2015, CLIN CHIM ACTA, V450, P316, DOI 10.1016/j.cca.2015.09.007
   Andras IE, 2007, J CEREBR BLOOD F MET, V27, P1431, DOI 10.1038/sj.jcbfm.9600445
   Ansari R, 2014, J CLIN NEUROL, V10, P281, DOI 10.3988/jcn.2014.10.4.281
   Arnal E, 2009, CURR EYE RES, V34, P928, DOI 10.3109/02713680903205238
   Arnold JJ, 2007, BMJ CLIN EVID, V2007
   Aydin E, 2008, EUR J OPHTHALMOL, V18, P226, DOI 10.1177/112067210801800210
   Beard RS, 2011, AM J PHYSIOL-HEART C, V300, pH13, DOI 10.1152/ajpheart.00598.2010
   Beard RS, 2011, BLOOD, V118, P2007, DOI 10.1182/blood-2011-02-338269
   Bialecka M, 2009, NEUROL NEUROCHIR POL, V43, P272
   Castro R, 2003, CLIN CHEM, V49, P1292, DOI 10.1373/49.8.1292
   Chang PY, 2008, CIRC RES, V102, P933, DOI 10.1161/CIRCRESAHA.108.171082
   CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6
   Christen WG, 2018, OPHTHAL EPIDEMIOL, V25, P79, DOI 10.1080/09286586.2017.1362009
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   CUNHAVAZ JG, 1966, BRIT J OPHTHALMOL, V50, P505, DOI 10.1136/bjo.50.9.505
   Dardiotis E, 2017, MULT SCLER RELAT DIS, V17, P190, DOI 10.1016/j.msard.2017.08.004
   Dayal S, 2008, ARTERIOSCL THROM VAS, V28, P1596, DOI 10.1161/ATVBAHA.108.166421
   Debreceni B, 2014, CARDIOVASC THER, V32, P130, DOI 10.1111/1755-5922.12064
   Diederen RMH, 2006, EXP EYE RES, V83, P45, DOI 10.1016/j.exer.2005.10.031
   Domagala T B, 1998, J Cardiovasc Risk, V5, P239, DOI 10.1097/00043798-199808000-00006
   Dong N, 2018, INT OPHTHALMOL, V38, P737, DOI 10.1007/s10792-017-0528-0
   Elmasry Khaled, 2018, Oncotarget, V9, P12562, DOI 10.18632/oncotarget.24333
   Elsherbiny NM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030393
   Feng Y, 2015, INT J CLIN EXP MED, V8, P12529
   Frantzen F, 1998, CLIN CHEM, V44, P311
   Fratoni V, 2015, NUTRIENTS, V7, P2176, DOI 10.3390/nu7042176
   Ganapathy PS, 2011, INVEST OPHTH VIS SCI, V52, P5515, DOI 10.1167/iovs.10-6870
   Ganapathy PS, 2009, INVEST OPHTH VIS SCI, V50, P4460, DOI 10.1167/iovs.09-3402
   Ghorbanihaghjo A, 2008, MOL VIS, V14, P1692
   Goldstein M, 2004, EYE, V18, P460, DOI 10.1038/sj.eye.6700702
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   GRIECO AJ, 1977, AM J MED SCI, V273, P120, DOI 10.1097/00000441-197703000-00001
   GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016
   Gupta P, 2018, INDIAN J OPHTHALMOL, V66, P1435, DOI 10.4103/ijo.IJO_350_18
   HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101
   Heinecke J W, 1999, Curr Atheroscler Rep, V1, P87, DOI 10.1007/s11883-999-0001-2
   Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588
   Hosoya K, 2005, BIOL PHARM BULL, V28, P1, DOI 10.1248/bpb.28.1
   House AA, 2010, JAMA-J AM MED ASSOC, V303, P1603, DOI 10.1001/jama.2010.490
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Huang T, 2011, NUTRITION, V27, P863, DOI 10.1016/j.nut.2010.12.011
   Huang X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05093-7
   Ibrahim AS, 2016, ONCOTARGET, V7, P8532, DOI 10.18632/oncotarget.7384
   Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7
   Junemann A, 2018, KLIN MONATSBL AUGENH, V235, P163, DOI 10.1055/s-0044-101621
   Kalani A, 2013, MOL NEUROBIOL, V48, P157, DOI 10.1007/s12035-013-8421-y
   Kern TS, 2010, AM J PATHOL, V176, P2550, DOI 10.2353/ajpath.2010.091062
   KLEIN BEK, 1990, DIABETES CARE, V13, P1034, DOI 10.2337/diacare.13.10.1034
   KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   Kolb H., 1995, WEBVISION ORG RETINA
   Kowluru RA, 2020, EYE VISION, V7, DOI 10.1186/s40662-020-00178-3
   Koylu MT, 2017, OPHTHALMIC GENET, V38, P352, DOI 10.1080/13816810.2016.1235716
   Krizbai IA, 1998, J NEUROSCI RES, V54, P814
   Kuo HK, 2005, J GERONTOL A-BIOL, V60, P1190, DOI 10.1093/gerona/60.9.1190
   Kwon HM, 2014, STROKE, V45, P871, DOI 10.1161/STROKEAHA.113.004099
   Lee IS, 2011, CURR EYE RES, V36, P358, DOI 10.3109/02713683.2010.548894
   Lei XW, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0362-1
   LeMaistre JL, 2012, J CEREBR BLOOD F MET, V32, P537, DOI 10.1038/jcbfm.2011.161
   Lentz SR, 2005, J THROMB HAEMOST, V3, P1646, DOI 10.1111/j.1538-7836.2005.01364.x
   Li JB, 2014, J DIABETES INVEST, V5, P236, DOI 10.1111/jdi.12149
   Li JC, 2006, AM J PHYSIOL-GASTR L, V291, pG219, DOI 10.1152/ajpgi.00097.2006
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Li Y, 2013, J BIOL CHEM, V288, P9583, DOI 10.1074/jbc.M112.431627
   Licking N, 2017, PARKINSONISM RELAT D, V44, P1, DOI 10.1016/j.parkreldis.2017.08.005
   Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923
   Liu X, 2010, NEUROL SCI, V31, P699, DOI 10.1007/s10072-010-0241-5
   Liu ZF, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015813
   MANASTER BJ, 1989, SEMIN ULTRASOUND CT, V10, P498
   Martin PM, 2004, INVEST OPHTH VIS SCI, V45, P3330, DOI 10.1167/iovs.04-0247
   Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8
   McCully KS, 2009, ANN CLIN LAB SCI, V39, P219
   Mohamed R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09731-y
   Moore P, 2001, EXP EYE RES, V73, P45, DOI 10.1006/exer.2001.1009
   Moustafa AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046496
   Mudd SH, 2011, AM J MED GENET C, V157C, P3, DOI 10.1002/ajmg.c.30293
   MUDD SH, 1985, AM J HUM GENET, V37, P1
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294
   Oshitari T, 2008, VASC HEALTH RISK MAN, V4, P115, DOI 10.2147/vhrm.2008.04.01.115
   Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1
   Paul C, 2002, J PHARMACOL EXP THER, V302, P50, DOI 10.1124/jpet.302.1.50
   Pinna A, 2018, ACTA OPHTHALMOL, V96, pE269, DOI 10.1111/aos.13343
   Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200
   Reijerkerk A, 2010, J NEUROCHEM, V113, P447, DOI 10.1111/j.1471-4159.2010.06598.x
   Rizzo G, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020219
   Rodrigo F, 2018, INDIAN J OPHTHALMOL, V66, P89, DOI 10.4103/ijo.IJO_488_17
   Rozen R, 1996, J INHERIT METAB DIS, V19, P589, DOI 10.1007/BF01799831
   Satyanarayana A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026747
   Schiff M, 2012, NEUROPEDIATRICS, V43, P295, DOI 10.1055/s-0032-1329883
   Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217
   SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693
   SHAKIB M, 1966, EXP EYE RES, V5, P229, DOI 10.1016/S0014-4835(66)80011-8
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Sharma P, 2008, DNA CELL BIOL, V27, P357, DOI 10.1089/dna.2007.0694
   Sharp CD, 2003, AM J PHYSIOL-HEART C, V285, pH2592, DOI 10.1152/ajpheart.00520.2003
   Shen L, 2015, J ALZHEIMERS DIS, V46, P777, DOI 10.3233/JAD-150140
   Shevchuk Sergii V, 2019, Wiad Lek, V72, P532
   Shu XJ, 2017, EUR REV MED PHARMACO, V21, P2538
   Shute C, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0859-2
   Simo-Servat O, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/5263798
   Singh J, 2009, BRAIN RES BULL, V79, P157, DOI 10.1016/j.brainresbull.2009.02.005
   Smith AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012244
   Srivastav K, 2016, MOL VIS, V22, P1352
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Tawfik A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010121
   Tawfik Amany, 2014, Austin J Clin Ophthalmol, V1, P1023
   Tawfik A, 2014, AM J PATHOL, V184, P2573, DOI 10.1016/j.ajpath.2014.05.018
   Tawfik A, 2013, INVEST OPHTH VIS SCI, V54, P939, DOI 10.1167/iovs.12-10536
   Toda R, 2011, J PHARM SCI-US, V100, P3904, DOI 10.1002/jps.22610
   Tomiyama M, 2005, MOL BRAIN RES, V136, P275, DOI 10.1016/j.molbrainres.2005.02.003
   Topakian R, 2010, J NEUROL NEUROSUR PS, V81, P192, DOI 10.1136/jnnp.2009.172072
   Ukinc K, 2009, ENDOCRINE, V36, P255, DOI 10.1007/s12020-009-9218-7
   Vaccaro O, 2000, NUTR METAB CARDIOVAS, V10, P297
   Valayannopoulos V, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1036-2
   van Leeuwen-Wintjens HRAJB, 1998, ACTA CLIN BELG, V53, P349, DOI 10.1080/17843286.1998.11754188
   Verhoef P, 1997, ARTERIOSCL THROM VAS, V17, P989, DOI 10.1161/01.ATV.17.5.989
   Wardlaw JM, 2009, ANN NEUROL, V65, P194, DOI 10.1002/ana.21549
   Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022
   Wierzbicki Anthony S, 2007, Diab Vasc Dis Res, V4, P143
   Wotherspoon F, 2006, DIABETIC MED, V23, P1350, DOI 10.1111/j.1464-5491.2006.01980.x
   Xu C, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0167-y
   Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x
   Yu MZ, 2012, EXP EYE RES, V96, P124, DOI 10.1016/j.exer.2011.12.011
   Zhong YM, 2012, DIABETES, V61, P492, DOI 10.2337/db11-0315
NR 128
TC 18
Z9 18
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD AUG
PY 2020
VL 10
IS 8
AR 1119
DI 10.3390/biom10081119
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA OA5AG
UT WOS:000577797300001
PM 32751132
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kelly, SJ
   Hirani, A
   Shahidadpury, V
   Solanki, A
   Halasz, K
   Gupta, SV
   Madow, B
   Sutariya, V
AF Kelly, Shannon J.
   Hirani, Anjali
   Shahidadpury, Vishal
   Solanki, Aum
   Halasz, Kathleen
   Gupta, Sheeba Varghese
   Madow, Brian
   Sutariya, Vijaykumar
TI Aflibercept Nanoformulation Inhibits VEGF Expression in Ocular In Vitro
   Model: A Preliminary Report
SO BIOMEDICINES
LA English
DT Article
DE age-related macular degeneration; vascular endothelial growth factor;
   aflibercept; nanoparticles; PLGA
ID NANOPARTICLES; DELIVERY; PLGA; NEOVASCULARIZATION; BEVACIZUMAB
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness in the United States, affecting approximately 11 million patients. AMD is caused primarily by an upregulation of vascular endothelial growth factor (VEGF). In recent years, aflibercept injections have been used to combat VEGF. However, this treatment requires frequent intravitreal injections, leading to low patient compliance and several adverse side effects including scarring, increased intraocular pressure, and retinal detachment. Polymeric nanoparticles have demonstrated the ability to deliver a sustained release of drug, thereby reducing the necessary injection frequency. Aflibercept (AFL) was encapsulated in poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) via double emulsion diffusion. Scanning electron microscopy showed the NPs were spherical and dynamic light scattering demonstrated that they were uniformly distributed (PDI < 1). The encapsulation efficiency and drug loading were 75.76% and 7.76% respectively. In vitro release studies showed a sustained release of drug; 75% of drug was released by the NPs in seven days compared to the full payload released in 24 h by the AFL solution. Future ocular in vivo studies are needed to confirm the biological effects of the NPs. Preliminary studies of the proposed aflibercept NPs demonstrated high encapsulation efficiency, a sustained drug release profile, and ideal physical characteristics for AMD treatment. This drug delivery system is an excellent candidate for further characterization using an ocular neovascularization in vivo model.
C1 [Kelly, Shannon J.; Hirani, Anjali; Shahidadpury, Vishal; Solanki, Aum; Halasz, Kathleen; Gupta, Sheeba Varghese; Sutariya, Vijaykumar] Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL 33612 USA.
   [Madow, Brian] Univ Florida, Coll Med, Dept Ophthalmol, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of South Florida; State
   University System of Florida; University of Florida
RP Sutariya, V (通讯作者)，Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL 33612 USA.
EM shannonk@health.usf.edu; ahirani@gmail.com; vpury89@gmail.com;
   solankia@health.usf.edu; halaszk@health.usf.edu;
   svarghes@health.usf.edu; Brian.madow@jax.ufl.edu;
   vsutariy@health.usf.edu
FU USF College of Pharmacy SEED Grant
FX This research was funded by the USF College of Pharmacy SEED Grant.
CR [Anonymous], 2015, AFL EYL TREATM NEOV
   Booysen E, 2019, PROBIOTICS ANTIMICRO, V11, P310, DOI 10.1007/s12602-018-9437-4
   Carroll RT, 2010, J DRUG TARGET, V18, P665, DOI 10.3109/10611861003639796
   Cunningham MA, 2008, SURV OPHTHALMOL, V53, P139, DOI 10.1016/j.survophthal.2007.12.005
   D'Souza Susan S, 2005, AAPS PharmSciTech, V6, pE323, DOI 10.1208/pt060242
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Feczko T, 2011, CHEM ENG PROCESS, V50, P757, DOI 10.1016/j.cep.2011.06.008
   Gatoo MA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/498420
   Geldenhuys W, 2011, J DRUG TARGET, V19, P837, DOI 10.3109/1061186X.2011.589435
   Hirani A, 2016, NANOBIOMATERIALS OPH, P1
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Irfan A, 2014, TOXICOL SCI, V138, P354, DOI 10.1093/toxsci/kfu009
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   McCall RL, 2013, JOVE-J VIS EXP, DOI 10.3791/51015
   Patel J, 2018, J MICROENCAPSUL, V35, P204, DOI 10.1080/02652048.2018.1453560
   Reichle Michelle L, 2005, Optometry, V76, P450, DOI 10.1016/j.optm.2005.06.013
   Sanchez A, 2003, EUR J PHARM SCI, V18, P221, DOI 10.1016/S0928-0987(03)00019-8
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Sinha VR, 2003, J CONTROL RELEASE, V90, P261, DOI 10.1016/S0168-3659(03)00194-9
   Subhani S, 2016, ANGIOGENESIS, V19, P257, DOI 10.1007/s10456-016-9510-0
   SWED A, 2014, J NANOMED NANOTECHNO, V5, P241, DOI DOI 10.4172/2157-7439.1000241
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
NR 25
TC 9
Z9 9
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD SEP
PY 2018
VL 6
IS 3
AR 92
DI 10.3390/biomedicines6030092
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA GY1XZ
UT WOS:000448331800020
PM 30208574
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Schilling, OK
   Wahl, HW
   Boerner, K
   Horowitz, A
   Reinhardt, JP
   Cimarolli, VR
   Brennan-Ing, M
   Heckhausen, J
AF Schilling, Oliver K.
   Wahl, Hans-Werner
   Boerner, Kathrin
   Horowitz, Amy
   Reinhardt, Joann P.
   Cimarolli, Verena R.
   Brennan-Ing, Mark
   Heckhausen, Jutta
TI Developmental Regulation With Progressive Vision Loss: Use of Control
   Strategies and Affective Well-Being
SO DEVELOPMENTAL PSYCHOLOGY
LA English
DT Article
DE motivational theory of life span development; affective well-being;
   depressive symptoms; age-related macular degeneration; generalized
   linear mixed models
ID IMPAIRED OLDER-ADULTS; LIFE-SPAN THEORY; OF-FIT INDEXES; GOAL
   DISENGAGEMENT; SELFISH GOAL; DEPRESSIVE SYMPTOMATOLOGY; PSYCHOLOGICAL
   CONTROL; UNATTAINABLE GOALS; SECONDARY CONTROL; HEALTH STRESSES
AB The present study addresses older adults' developmental regulation when faced with progressive and irreversible vision loss. We used the motivational theory of life span development as a conceptual framework and examined changes in older adults' striving for control over everyday goal achievement, and their association with affective well-being, in a sample of 364 older adults diagnosed with age-related macular degeneration. Using longitudinal data from 5 occasions at 6-month intervals, we examined intraindividual change in control strategies, and how it was related to change in affective well-being, in terms of self-rated happiness and depressive symptoms. Mixed model analyses confirmed our hypotheses that (a) intraindividual change, particularly in selective primary control and in compensatory secondary control (CSC), predict change toward higher happiness ratings and lower depression; and (b) as functional abilities (instrumental activities of daily living) declined, CSC became increasingly predictive of better affective well-being. Overall, the findings suggest that CSC strategies are essential for maintaining affective well-being when physical functioning declines. Intensified selective primary control striving may be effective to achieve goals that have become difficult to reach but are not associated with affective well-being, possibly because struggling with difficulties undermines the experience of enjoyable mastery. In contrast, goal adjustments and self-protective thinking may help to find pleasure even from restricted daily activities.
C1 [Schilling, Oliver K.; Wahl, Hans-Werner] Heidelberg Univ, Dept Psychol Ageing Res, Inst Psychol, Bergheimer Str 28, D-69115 Heidelberg, Germany.
   [Boerner, Kathrin] Univ Massachusetts Boston, Dept Gerontol, McCormack Grad Sch Policy & Global Studies, Boston, MA USA.
   [Horowitz, Amy] Fordham Univ, Grad Sch Social Serv, Bronx, NY 10458 USA.
   [Reinhardt, Joann P.; Cimarolli, Verena R.] Jewish Home Lifecare, Res Inst Aging, New York, NY USA.
   ACRIA Ctr HIV, New York, NY USA.
   [Brennan-Ing, Mark] NYU, Coll Nursing, New York, NY 10003 USA.
   [Heckhausen, Jutta] Univ Calif Irvine, Dept Psychol & Social Behav, Irvine, CA 92717 USA.
C3 Ruprecht Karls University Heidelberg; University of Massachusetts
   System; University of Massachusetts Boston; Fordham University; New York
   University; University of California System; University of California
   Irvine
RP Schilling, OK (通讯作者)，Heidelberg Univ, Dept Psychol Ageing Res, Inst Psychol, Bergheimer Str 28, D-69115 Heidelberg, Germany.
EM oliver.schilling@psychologie.uni-heidelberg.de
RI Boerner, Kathrin/M-1504-2019
OI Cimarolli, Verena/0000-0003-4551-3531
FU National Institute of Mental Health [R01 MH64437]; NATIONAL INSTITUTE OF
   MENTAL HEALTH [R01MH064437] Funding Source: NIH RePORTER
FX This research was supported by the National Institute of Mental Health
   (R01 MH64437 to Amy Horowitz).
CR Abdel-Khalek AM, 2006, SOC BEHAV PERSONAL, V34, P139, DOI 10.2224/sbp.2006.34.2.139
   Ainslie G, 2014, BEHAV BRAIN SCI, V37, P135, DOI 10.1017/S0140525X13001933
   Baltes PB, 2000, AM PSYCHOL, V55, P122, DOI 10.1037/0003-066X.55.1.122
   Beedie CJ, 2011, PERS INDIV DIFFER, V50, P228, DOI 10.1016/j.paid.2010.09.034
   Beedie CJ, 2005, COGNITION EMOTION, V19, P847, DOI 10.1080/02699930541000057
   Birch D., 1970, DYNAMICS ACTION
   Bliss-Moreau E, 2014, BEHAV BRAIN SCI, V37, P138, DOI 10.1017/S0140525X13001969
   Boerner K, 2010, J GERONTOL B-PSYCHOL, V65, P22, DOI 10.1093/geronb/gbp098
   Brennan-Ing M, 2013, EUR J AGEING, V10, P345, DOI 10.1007/s10433-013-0278-4
   Brunstein J., 2008, MOTIVATION ACTION, P227, DOI DOI 10.1017/CBO9780511499821.010
   Burmedi D, 2002, VIS IMPAIR RES, V4, P15, DOI [10.1076/vimr.4.1.15.15633, DOI 10.1076/VIMR.4.1.15.15633]
   Center for the Study of Aging and Human Development, 1975, MULT FUNCT ASS OARS
   Chen FF, 2007, STRUCT EQU MODELING, V14, P464, DOI 10.1080/10705510701301834
   Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5
   Cho E, 2015, ORGAN RES METHODS, V18, P207, DOI 10.1177/1094428114555994
   CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Conroy-Beam D, 2014, BEHAV BRAIN SCI, V37, P140, DOI 10.1017/S0140525X13001982
   Dunne E, 2011, HEALTH PSYCHOL, V30, P763, DOI 10.1037/a0024019
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FORDYCE MW, 1988, SOC INDIC RES, V20, P355, DOI 10.1007/BF00302333
   Fredrickson BL, 2001, AM PSYCHOL, V56, P218, DOI 10.1037/0003-066X.56.3.218
   Gable SL, 2000, J PERS SOC PSYCHOL, V78, P1135, DOI 10.1037//0022-3514.78.6.1135
   Gamble A, 2012, J HAPPINESS STUD, V13, P31, DOI 10.1007/s10902-011-9248-8
   Haase CM, 2013, DEV PSYCHOL, V49, P964, DOI 10.1037/a0029231
   Heckhausen J, 2001, PSYCHOL AGING, V16, P400, DOI 10.1037//0882-7974.16.3.400
   HECKHAUSEN J, 1995, PSYCHOL REV, V102, P284, DOI 10.1037/0033-295X.102.2.284
   Heckhausen J., 1998, TECHNICAL REPORT
   Heckhausen J, 2013, GERONTOLOGY, V59, P438, DOI 10.1159/000351269
   Heckhausen J, 2010, PSYCHOL REV, V117, P32, DOI 10.1037/a0017668
   Hedeker D, 2005, ENCY STAT BEHAV SCI
   Hoffman L, 2009, RES HUM DEV, V6, P97, DOI 10.1080/15427600902911189
   Huang JY, 2014, BEHAV BRAIN SCI, V37, P121, DOI 10.1017/S0140525X13000290
   Kahneman D., 1999, WELL BEING FDN HEDON, P3, DOI DOI 10.7758/9781610443258
   Kenrick DT, 2010, PERSPECT PSYCHOL SCI, V5, P292, DOI 10.1177/1745691610369469
   Kline RB, 2013, EDUC RES EVAL, V19, P204, DOI 10.1080/13803611.2013.767624
   Kruglanski AW, 2002, ADV EXP SOC PSYCHOL, V34, P331, DOI 10.1016/S0065-2601(02)80008-9
   Kunzmann U, 2008, J GERONTOL B-PSYCHOL, V63, pP261, DOI 10.1093/geronb/63.5.P261
   LARSEN RJ, 1985, SOC INDIC RES, V17, P1, DOI 10.1007/BF00354108
   MCCLELLAND DC, 1989, PSYCHOL REV, V96, P690, DOI 10.1037/0033-295X.96.4.690
   Miller GE, 2007, PSYCHOL SCI, V18, P773, DOI 10.1111/j.1467-9280.2007.01977.x
   Molenberghs G., 2000, LINEAR MIXED MODELS
   Neuberg SL, 2014, BEHAV BRAIN SCI, V37, P153, DOI 10.1017/S0140525X13002136
   Nolen-Hoeksema S, 2008, PERSPECT PSYCHOL SCI, V3, P400, DOI 10.1111/j.1745-6924.2008.00088.x
   OECD, 2013, OECD GUID MEAS SUBJ
   Pasupathi M, 2001, DEV PSYCHOL, V37, P351, DOI 10.1037//0012-1649.37.3.351
   Peterson C., 1993, LEARNED HELPLESSNESS
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   ROGOSA D, 1980, PSYCHOL BULL, V88, P245, DOI 10.1037/0033-2909.88.2.245
   Rovner BW, 2008, AM J GERIAT PSYCHIAT, V16, P454, DOI 10.1097/JGP.0b013e31816b7342
   SAS Institute, 2009, SAS STAT US GUID VER
   SAS Institute Inc, 2014, SAS QC 13 2 US GUID
   Schilling OK, 2006, PSYCHOL AGING, V21, P703, DOI 10.1037/0882-7974.21.4.703
   Schilling OK, 2014, PSYCHOL AGING, V29, P72, DOI 10.1037/a0035500
   Schilling OK, 2013, J GERONTOL B-PSYCHOL, V68, P750, DOI 10.1093/geronb/gbs118
   Schilling OK, 2011, PSYCHOL AGING, V26, P203, DOI 10.1037/a0021127
   Schimmack U, 2008, SOC INDIC RES, V89, P41, DOI 10.1007/s11205-007-9230-3
   Soo H, 2009, J HEALTH PSYCHOL, V14, P956, DOI 10.1177/1359105309341204
   Stawski RS, 2008, PSYCHOL AGING, V23, P52, DOI 10.1037/0882-7974.23.1.52
   Vandenberg RJ, 2000, ORGAN RES METHODS, V3, P4, DOI 10.1177/109442810031002
   Veenhoven R, 2006, SOC INDIC RES, V79, P421, DOI 10.1007/s11205-005-5074-x
   Voelkle MC, 2012, PSYCHOL METHODS, V17, P176, DOI 10.1037/a0027543
   von Hippel W, 2014, BEHAV BRAIN SCI, V37, P157, DOI 10.1017/S0140525X13002173
   Wahl HW, 2007, J GERONTOL B-PSYCHOL, V62, pP90, DOI 10.1093/geronb/62.2.P90
   Wahl HW, 1999, J GERONTOL B-PSYCHOL, V54, pP304, DOI 10.1093/geronb/54B.5.P304
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   Watkins ER, 2014, J ABNORM PSYCHOL, V123, P24, DOI 10.1037/a0035540
   Watson W., 1999, J PERS SOC PSYCHOL, V76, P820
   Wrosch C, 2003, PERS SOC PSYCHOL B, V29, P1494, DOI 10.1177/0146167203256921
   Wrosch C, 2004, CURR DIR PSYCHOL SCI, V13, P17, DOI 10.1111/j.0963-7214.2004.01301005.x
   Wrosch C, 2002, HEALTH PSYCHOL, V21, P340, DOI 10.1037//0278-6133.21.4.340
   Wrosch C, 2007, HEALTH PSYCHOL, V26, P341, DOI 10.1037/0278-6133.26.3.341
   Wrosch C, 2007, PERS SOC PSYCHOL B, V33, P251, DOI 10.1177/0146167206294905
   Wrosch C, 2006, J BEHAV MED, V29, P299, DOI 10.1007/s10865-006-9051-x
   Xu RH, 2003, STAT MED, V22, P3527, DOI 10.1002/sim.1572
NR 75
TC 13
Z9 13
U1 3
U2 16
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0012-1649
EI 1939-0599
J9 DEV PSYCHOL
JI Dev. Psychol.
PD APR
PY 2016
VL 52
IS 4
BP 679
EP 694
DI 10.1037/dev0000099
PG 16
WC Psychology, Developmental
WE Social Science Citation Index (SSCI)
SC Psychology
GA DI3GE
UT WOS:000373385900013
PM 26845507
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Avery, RL
   Castellarin, AA
   Steinle, NC
   Dhoot, DS
   Pieramici, DJ
   See, R
   Couvillion, S
   Nasir, MA
   Rabena, MD
   Le, K
   Maia, M
   Visich, JE
AF Avery, Robert L.
   Castellarin, Alessandro A.
   Steinle, Nathan C.
   Dhoot, Dilsher S.
   Pieramici, Dante Joseph
   See, Robert
   Couvillion, Stephen
   Nasir, Ma'an A.
   Rabena, Melvin D.
   Le, Kha
   Maia, Mauricio
   Visich, Jennifer E.
TI Systemic pharmacokinetics following intravitreal injections of
   ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; PLASMA-LEVELS;
   VEGF-TRAP; INTRAOCULAR PHARMACOKINETICS; DEGENERATION; BINDING; HUMANS;
   TRIAL
AB Background Data comparing systemic exposure and systemic vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following intravitreal injection are lacking.
   Methods Fifty-six patients with wet age-related macular degeneration received intravitreal ranibizumab (0.5 mg), bevacizumab (1.25 mg), or aflibercept (2.0 mg). Serum pharmacokinetics and plasma free VEGF were evaluated after the first and third injections.
   Results Following the first dose, systemic exposure to aflibercept was 5-, 37-, and 9-fold higher than ranibizumab, whereas, bevacizumab was 9-, 310-, and 35-fold higher than ranibizumab, based on geometric mean ratio of peak and trough concentrations and area under the curve, respectively. The third dose showed accumulation of bevacizumab and aflibercept but not ranibizumab. Aflibercept substantially suppressed plasma free VEGF, with mean levels below lower limit of quantitation (10 pg/mL) as early as 3 h postdose until >= 7 days postdose. Mean free (unbound) VEGF levels with ranibizumab were largely unchanged, with mean trough level of 14.4 pg/mL compared with baseline of 17 pg/mL.
   Conclusions There are notable differences in systemic pharmacokinetics and pharmacodynamics among anti-VEGF treatments after intravitreal administration. All three agents rapidly moved into the bloodstream, but ranibizumab very quickly cleared, whereas bevacizumab and aflibercept demonstrated greater systemic exposure and produced a marked reduction in plasma free VEGF.
C1 [Avery, Robert L.; Castellarin, Alessandro A.; Steinle, Nathan C.; Dhoot, Dilsher S.; Pieramici, Dante Joseph; See, Robert; Couvillion, Stephen; Nasir, Ma'an A.; Rabena, Melvin D.] Calif Retina Consultants, Santa Barbara, CA 93103 USA.
   [Le, Kha; Maia, Mauricio; Visich, Jennifer E.] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Avery, RL (通讯作者)，Calif Retina Consultants, 515 E Micheltorena St,Suite C, Santa Barbara, CA 93103 USA.
EM bobave@gmail.com
RI Dhoot, Dilsher/ABD-5417-2021; Maia, Mauricio/I-5892-2015
OI Maia, Mauricio/0000-0002-7034-8091; Le, Kha/0000-0002-5446-819X
FU Genentech, Inc [ML28032]
FX This investigator-sponsored trial was partially funded through a grant
   from Genentech, Inc (ML28032). Presented in part at the American Society
   of Retina Specialists, Toronto, Canada; American Academy of
   Ophthalmology, New Orleans; Angiogenesis, Exudation, and Degeneration,
   Miami Florida; and Macula Society, Key Largo, Florida.
CR Aguilar-Mahecha A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038290
   Avery RL, 2013, INVEST OPHTHALMOL VI, V54
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bakbak B, 2013, J OCUL PHARMACOL TH, V29, P728, DOI 10.1089/jop.2013.0049
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   European Medicines Agency, EPAR EYL AFL PROC EM
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Harding SP, 2013, INVEST OPHTHALMOL VI, P54
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kim H, 2009, MOL VIS, V15
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rothen Michelle, 2005, Ophthalmol Clin North Am, V18, P561
   Stewart Michael W., 2011, Inflammation & Allergy Drug Targets, V10, P497
   Ternant D, 2005, EXPERT OPIN BIOL TH, V5, pS37, DOI 10.1517/14712598.5.1.S37
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 30
TC 239
Z9 254
U1 1
U2 40
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2014
VL 98
IS 12
BP 1636
EP 1641
DI 10.1136/bjophthalmol-2014-305252
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU0AB
UT WOS:000345284300007
PM 25001321
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Kara, N
   Espindola, RF
   Gomes, BAF
   Ventura, B
   Smadja, D
   Santhiago, MR
AF Kara-Junior, Newton
   Espindola, Rodrigo F.
   Gomes, Beatriz A. F.
   Ventura, Bruna
   Smadja, David
   Santhiago, Marcony R.
TI Effects of blue light-filtering intraocular lenses on the macula,
   contrast sensitivity, and color vision after a long-term follow-up
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID VISUAL FUNCTION; CATARACT-SURGERY; DEGENERATION; ASSOCIATION;
   PERFORMANCE; VIOLET
AB PURPOSE: To evaluate the possible side effects and potential protection 5 years after implantation of an intraocular lens (IOL) with a blue-light filter (yellow tinted).
   SETTING: Ophthalmology Department, University of Sao Paulo, Sao Paulo, Brazil.
   DESIGN: Prospective randomized clinical study.
   METHODS: Patients with bilateral visually significant cataract randomly received an ultraviolet (UV) and blue light filtering IOL (Acrysof Natural SN60AT) in 1 eye and an acrylic UV light filtering only IOL (Acrysof SA60AT) in the fellow eye. The primary outcome measures were contrast sensitivity, color vision, and macular findings 5 years after surgery.
   RESULTS: The study enrolled 60 eyes of 30 patients. There were no significant clinical or optical coherence tomography findings in terms of age-related macular degeneration in any eye. There were no statistically significant differences in central macular thickness between the 2 IOL groups (P=.712). There were also no significant between-group differences under photopic or scotopic conditions at any spatial frequency studied. No statistically significant differences in the color discrimination test were found between the 2 IOL groups (P=.674).
   CONCLUSIONS: After 5 years, there were no significant differences in color perception, scotopic contrast sensitivity, or photopic contrast sensitivity between the blue light filtering (yellow-tinted) IOL and the IOL with a UV-light filter only (untinted). The potential advantage of the tinted IOL in providing protection to macular cells remains unclear.
C1 [Kara-Junior, Newton; Espindola, Rodrigo F.; Santhiago, Marcony R.] Univ Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Gomes, Beatriz A. F.; Ventura, Bruna; Smadja, David; Santhiago, Marcony R.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Universidade de Sao Paulo; Cleveland Clinic Foundation
RP Santhiago, MR (通讯作者)，Cleveland Clin, Cole Eye Inst, 1700 E 13th St,Apartment 15W, Cleveland, OH 44114 USA.
EM marconysanthiago@hotmail.com
RI Ventura, Bruna/N-2724-2018; Kara-Junior, Newton/F-9022-2012; Santhiago,
   Marcony R/AAG-3762-2021
OI Ventura, Bruna/0000-0003-4333-3932; 
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Bhattacharjee H, 2006, J CATARACT REFR SURG, V32, P451, DOI 10.1016/j.jcrs.2005.12.136
   BOWMAN KJ, 1980, AM J OPTOM PHYS OPT, V57, P839
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Falkner-Radler CI, 2008, AM J OPHTHALMOL, V145, P499, DOI 10.1016/j.ajo.2007.10.021
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Greenstein VC, 2007, J CATARACT REFR SURG, V33, P667, DOI 10.1016/j.jcrs.2006.12.012
   Hayashi K, 2006, BRIT J OPHTHALMOL, V90, P1019, DOI 10.1136/bjo.2006.090712
   Henderson BA, 2010, SURV OPHTHALMOL, V55, P284, DOI 10.1016/j.survophthal.2009.07.007
   KINNEAR PR, 1970, VISION RES, V10, P423, DOI 10.1016/0042-6989(70)90123-9
   Kiser AK, 2008, CLIN EXP OPHTHALMOL, V36, P514, DOI 10.1111/j.1442-9071.2008.01824.x
   Landers J, 2007, CLIN EXP OPHTHALMOL, V35, P152, DOI 10.1111/j.1442-9071.2006.01434.x
   LINDSTROM RL, 1986, J CATARACT REFR SURG, V12, P285, DOI 10.1016/S0886-3350(86)80011-6
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Mainster MA, 2006, J CATARACT REFR SURG, V32, P1403, DOI 10.1016/j.jcrs.2006.06.014
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   Muftuoglu O, 2007, J CATARACT REFR SURG, V33, P658, DOI 10.1016/j.jcrs.2006.12.018
   Raj SM, 2005, J CATARACT REFR SURG, V31, P2324, DOI 10.1016/j.jcrs.2005.08.052
   Rezai KA, 2008, GRAEF ARCH CLIN EXP, V246, P671, DOI 10.1007/s00417-006-0484-2
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P2088, DOI 10.1016/j.jcrs.2005.04.029
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Schwiegerling J, 2006, J CATARACT REFR SURG, V32, P141, DOI 10.1016/j.jcrs.2005.11.021
   Schwiegerling J, 2006, J CATARACT REFR SURG, V32, P1404, DOI 10.1016/j.jcrs.2006.07.007
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Werner JS, 2005, BRIT J OPHTHALMOL, V89, P1518, DOI 10.1136/bjo.2005.073734
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
   Yuan ZX, 2004, AM J OPHTHALMOL, V138, P138, DOI 10.1016/j.ajo.2004.02.024
NR 30
TC 29
Z9 32
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD DEC
PY 2011
VL 37
IS 12
BP 2115
EP 2119
DI 10.1016/j.jcrs.2011.06.024
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 861NJ
UT WOS:000298026000006
PM 22108107
DA 2022-11-30
ER

PT J
AU Munch, IC
   Ek, J
   Kessel, L
   Sander, B
   Almind, GJ
   Brondum-Nielsen, K
   Linneberg, A
   Larsen, M
AF Munch, Inger Christine
   Ek, Jakob
   Kessel, Line
   Sander, Birgit
   Almind, Gitte Juul
   Brondum-Nielsen, Karen
   Linneberg, Allan
   Larsen, Michael
TI Small, Hard Macular Drusen and Peripheral Drusen: Associations with AMD
   Genotypes in the Inter99 Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; COMPLEMENT-FACTOR-H; BEAVER DAM EYE; 10-YEAR
   INCIDENCE; FOLLOW-UP; DEGENERATION; POLYMORPHISM; RISK; PROGRESSION;
   POPULATION
AB PURPOSE. To study associations of small, hard macular drusen and peripheral drusen with genotypes associated with age-related macular degeneration (AMD).
   METHODS. Digital grayscale fundus photographs recorded in red-free illumination were graded for the presence of drusen in 1107 subjects aged 30 to 66 years. Participants were genotyped for AMD-related polymorphisms in complement factor H (CFH), in LOC387715, and in complement factor B (CFB).
   RESULTS. The prevalence of 20 or more small, hard macular drusen per eye was 14%, with no association to the investigated polymorphisms. Peripheral drusen were associated with CFHY402H (odds ratio [OR], 4.3; 95% confidence interval [95% CI], 1.4-13, for CC versus TT genotypes) as was macular drusen >63 mu m (OR, 1.9; 95% CI, 1.1-3.1, for CC versus TT genotypes). Macular drusen >63 mu m were associated with the presence of 20 or more small, hard macular drusen (OR, 1.7; 95% CI, 1.1-2.6) and with peripheral drusen (OR, 2.5; 95% CI, 1.2-5.4)
   CONCLUSIONS. In this study, the presence of 20 or more small, hard macular drusen per eye was not associated with known AMD-related polymorphisms, whereas the study confirmed an association of peripheral drusen with CFHY402H. (ClinicalTrials.gov number, NCT00289237.) (Invest Ophthalmol Vis Sci. 2010;51:2317-2321) DOI: 10.1167/iovs.09-4482
C1 [Munch, Inger Christine; Kessel, Line; Sander, Birgit; Larsen, Michael] Glostrup Cty Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [Munch, Inger Christine; Linneberg, Allan] Res Ctr Prevent & Hlth, Copenhagen, Denmark.
   [Munch, Inger Christine; Almind, Gitte Juul; Brondum-Nielsen, Karen; Larsen, Michael] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
   [Ek, Jakob; Almind, Gitte Juul; Brondum-Nielsen, Karen; Larsen, Michael] Kennedy Ctr, Glostrup, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Munch, IC (通讯作者)，Glostrup Cty Hosp, Dept Ophthalmol, Nordre Ringvej 59, DK-2600 Glostrup, Denmark.
EM icm@dadlnet.dk
RI Munch, Inger Christine/E-9652-2010; Larsen, Michael/E-9620-2010
OI Larsen, Michael/0000-0002-5172-5891; Kessel, Line/0000-0002-9375-1510;
   Linneberg, Allan/0000-0002-0994-0184
FU Velux Foundation; Ojenfonden; Ojenforeningen; Diabetesforeningen;
   Faculty of Health Sciences, University of Copenhagen
FX Supported by the Velux Foundation, Ojenfonden, Ojenforeningen,
   Diabetesforeningen, and the Faculty of Health Sciences, University of
   Copenhagen.
CR BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Jorgensen Torben, 2003, Eur J Cardiovasc Prev Rehabil, V10, P377
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Kessel L, 2004, ACTA OPHTHALMOL SCAN, V82, P19, DOI 10.1111/j.1395-3907.2004.0179.x
   Kim IK, 2008, MOL VIS, V14, P1487
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   World Health Organization, 1999, WHONCDNCS992
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
NR 34
TC 32
Z9 35
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2010
VL 51
IS 5
BP 2317
EP 2321
DI 10.1167/iovs.09-4482
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 589UU
UT WOS:000277180500006
PM 20007824
DA 2022-11-30
ER

PT J
AU Domalpally, A
   Danis, RP
   Zhang, BY
   Myers, D
   Kruse, CN
AF Domalpally, Amitha
   Danis, Ronald P.
   Zhang, Baoyan
   Myers, Dawn
   Kruse, Christina N.
TI QUALITY ISSUES IN INTERPRETATION OF OPTICAL COHERENCE TOMOGRAMS IN
   MACULAR DISEASES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE artifacts; boundary line errors; decentration; optical coherence
   tomogram; optical coherence tomogram quality
ID THICKNESS; REPRODUCIBILITY; RANIBIZUMAB; AVASTIN; RETINA
AB Purpose: To analyze the scan characteristics associated with poor-quality Stratus optical coherence tomograms submitted to a reading center for multicenter clinical trials.
   Methods: Data from evaluation of 6,741 fast macular thickness map reports from trials involving age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion were analyzed. Optical coherence tomograms with an erroneous center-point thickness needing manual remeasurement (MR) were categorized as being of poor quality. The frequency of MR and the artifacts associated were analyzed by disease type, underlying retinal morphology, and severity of retinal thickening.
   Results: MR was performed in 2,027 (30%) optical coherence tomograms. AMD had the highest frequency of MR (54.9%), followed by retinal vein occlusion (23.9%) and diabetic macular edema (16.3%). Boundary line errors were the most common artifact across all disease types (61.3% of scans requiring MR) and increased with increasing retinal thickness. Decentration artifact was seen in 15.4% of scans requiring MR. The median absolute difference between machine and manually measured centerpoint thickness assessed in a subset of 84 scans was 75.5 mu m.
   Conclusion: Artifacts causing erroneous reported centerpoint thickness are common. Identifying clues that indicate suboptimal quality of optical coherence tomography (OCT) images are important to avoid erroneous interpretation of OCT data in clinical trials. RETINA 29:775-781, 2009
C1 [Domalpally, Amitha; Danis, Ronald P.; Zhang, Baoyan; Myers, Dawn; Kruse, Christina N.] Univ Wisconsin, Fundus Photograph Reading Ctr, Dept Ophthalmol & Visual Sci, Madison, WI 53711 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Danis, RP (通讯作者)，Univ Wisconsin, Fundus Photograph Reading Ctr, Dept Ophthalmol & Visual Sci, 406 Sci Dr,Suite 400, Madison, WI 53711 USA.
EM rdanis@rc.ophth.wisc.edu
RI Domalpally, Amitha/B-2367-2015
OI Domalpally, Amitha/0000-0002-8145-9619
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Baumal C R, 1999, Curr Opin Ophthalmol, V10, P182, DOI 10.1097/00055735-199906000-00006
   Chew E, 2007, OPHTHALMOLOGY, V114, P1190, DOI 10.1016/j.ophtha.2007.02.010
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   *JDM GASS, 1997, STER ATL MASC DIS TR
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Pons ME, 2005, OPHTHALMOLOGY, V112, P1079, DOI 10.1016/j.ophtha.2004.11.061
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Sharuk GS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1701
NR 19
TC 27
Z9 28
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP 775
EP 781
DI 10.1097/IAE.0b013e3181a0848b
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HS
UT WOS:000267496600007
PM 19373128
DA 2022-11-30
ER

PT J
AU Peterson, LJ
   Wittchen, ES
   Geisen, P
   Burridge, K
   Hartnett, ME
AF Peterson, Lynda J.
   Wittchen, Erika S.
   Geisen, Pete
   Burridge, Keith
   Hartnett, M. Elizabeth
TI Heterotypic RPE-choroidal endothelial cell contact increases choroidal
   endothelial cell transmigration via PI 3-kinase and Rac1
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; GTPase signaling; Rac1; PI 3-kinase;
   endothelial; cell migration; choroidal endothelial cell
ID RETINAL-PIGMENT EPITHELIUM; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; MACULAR
   DEGENERATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE;
   NEUTROPHIL CHEMOTAXIS; BARRIER PROPERTIES; TGF-BETA; ACTIVATION
AB Age-related macular degeneration (AMD) is the major cause of non-preventable blindness. Severe forms of AMD involve breaching of the retinal pigment epithelial (RPE) barrier by underlying choroidal endothelial cells (CECs), followed by migration into, and subsequent neovascularization of the neurosensory retina. However, little is known about the interactions between RPE and CECs and the signaling events leading to CEC transmigration. While soluble chemotactic factors secreted from RPE can contribute to inappropriate CEC transmigration, other unidentified stimuli may play an additional role. Using a coculture model that maintains the natural structural orientation of CECs to the basal aspect of RPE, we show that "contact" with RPE and/or RPE extracellular matrix increases CEC transmigration of the RPE barrier. From a biochemical standpoint, contact between CECs and RPE results in an increase in the activity of the GTPase Rac1 within the CECs; this increase is dependent on upstream activation of PI 3-K and Akt1. To confirm a link between these signaling molecules and increased CEC transmigration, we performed transmigration assays while inhibiting both PI 3-K and Rac1 activity, and observed that both decreased CEC transmigration. We hypothesize that contact between CECs and RPE stimulates a signaling pathway involving PI 3-K, Aktl and Rac1 that facilitates CEC transmigration across the RPE barrier, an important step in the development of neovascular AMD. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Hartnett, ME (通讯作者)，Univ N Carolina, Dept Ophthalmol, 6135 Neurosci Res Bldg,103 Mason Farm Rd,CB 7041,, Chapel Hill, NC 27599 USA.
EM hartnet@med.unc.edu
FU NEI NIH HHS [R56 EY015130, EY014552, EY015130, R01 EY017011-02, R01
   EY015130, R01 EY017011, R03 EY014552] Funding Source: Medline; NHLBI NIH
   HHS [P01 HL045100, HL45100] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R56EY015130, R03EY014552, R01EY015130, R01EY017011] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [P01HL045100] Funding Source: NIH RePORTER
CR Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726
   Arefieva TI, 2005, CYTOKINE, V31, P439, DOI 10.1016/j.cyto.2005.06.016
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   Cheng HL, 2000, J BIOL CHEM, V275, P27197
   Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Garcia CM, 2004, DEV BRAIN RES, V152, P25, DOI 10.1016/j.devbrainres.2004.05.008
   Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064
   Gonzalez E, 2006, J BIOL CHEM, V281, P3210, DOI 10.1074/jbc.M510434200
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628
   HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636
   Isakson BE, 2005, CIRC RES, V97, P44, DOI 10.1161/01.RES.0000173461.36221.2e
   KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431
   KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5
   Lee HL, 2003, TAPPI J, V2, P3
   Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000
   Montiel M, 2005, BIOCHEM BIOPH RES CO, V327, P971, DOI 10.1016/j.bbrc.2004.12.110
   NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4
   Posern G, 2000, J CELL PHYSIOL, V183, P416, DOI 10.1002/(SICI)1097-4652(200006)183:3<416::AID-JCP15>3.0.CO;2-R
   Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309
   SATO Y, 1993, J CELL BIOL, V123, P1249, DOI 10.1083/jcb.123.5.1249
   SAUNDERS KB, 1992, IN VITRO CELL DEV-AN, V28A, P521
   Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233
   Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179
   Steinle JJ, 2005, EXP EYE RES, V80, P83, DOI 10.1016/j.exer.2004.08.015
   Steinle JJ, 2003, AUTON NEUROSCI-BASIC, V108, P57, DOI 10.1016/S1566-0702(03)00151-6
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wang JX, 2002, INT J MOL SCI, V3, P4, DOI 10.3390/i3010004
   WEINER OD, 2002, NAT CELL BIOL, V4, pE171
   Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200
NR 42
TC 33
Z9 34
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2007
VL 84
IS 4
BP 737
EP 744
DI 10.1016/j.exer.2006.12.012
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 158VC
UT WOS:000245822200016
PM 17292356
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Robert, L
   Menasche, M
   Robert, AM
   Renard, G
AF Robert, L.
   Menasche, M.
   Robert, A. M.
   Renard, G.
TI Effect of high glucose concentration on corneal collagen biosynthesis
SO OPHTHALMOLOGICA
LA English
DT Article
DE hyperglycemia; corneal collagens; Maillard reaction; advanced glycation
   endproducts
ID ADVANCED GLYCATION; FIBRONECTIN; PRODUCTS; OBESITY
AB The effect of high glucose concentration (3 g/l) on bovine corneal total protein and Collagen biosynthesis was studied, using H-3-proline incorporation in explant cultures with protein and collagen determinations. The high glucose concentration increased the incorporation of 3 H-proline in total corneal proteins as well as in collagens. The specific radioactivity of stromal collagens was strongly increased in these conditions. Mannitol was used to control the osmotic effect of the high glucose concentration, both at 1 and 3 g/l concentrations. Mannitol did not increase the incorporation of 3 H-proline in total proteins or collagens, but on the contrary decreased it. The high glucose concentration decreased the excretion of neosynthesized proteins and collagens in the culture medium, but did not affect the total protein or collagen content of the corneas. The strong increase in the specific radioactivity of corneal collagens in the presence of 3 g/l glucose suggests an increased turnover of collagens in diabetic corneas. The increased biosynthesis of collagens together with their decreased elimination in the extracellular compartment can create the conditions for the formation and accumulation of advanced glycation endproducts by the Maillard reaction. This can induce and stimulate the liquefaction of the vitreous body leading to sight-threatening disorders such as diabetic retinopathy, retinal detachment, glaucoma, cataract formation and age-related macular degeneration. Copyright (c) 2006 S. Karger AG, Basel
C1 Hop Hotel Dieu, Lab Rech Ophtalmol, FR-75181 Paris 04, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris
   Cite
RP Robert, L (通讯作者)，Hop Hotel Dieu, Lab Rech Ophtalmol, 1,Pl Parvis Notre Dame, FR-75181 Paris 04, France.
EM lrobert5@wanadoo.fr
CR ASSELOT C, 1989, BIOCHEM PHARMACOL, V38, P895, DOI 10.1016/0006-2952(89)90277-3
   BAYNES JW, 1994, REDOX REP, V1, P31, DOI 10.1080/13510002.1994.11746952
   Benazzoug Y, 1998, EXP GERONTOL, V33, P445, DOI 10.1016/S0531-5565(98)00015-1
   BERGMAN I, 1963, ANAL CHEM, V35, P1861
   Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x
   Burnet F.M., 1974, INTRINSIC MUTAGENESI
   Deguine V, 1997, PATHOL BIOL, V45, P321
   Deguine V, 1998, INT J BIOL MACROMOL, V22, P17, DOI 10.1016/S0141-8130(97)00084-6
   Deguine-Delay Valeri, 1997, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V191, P247
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   KERN P, 1991, BIOCHEM J, V274, P615, DOI 10.1042/bj2740615
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MACIEIRACOELHO A, 1988, BIOL NORMAL PROLIFER
   Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66
   Oken E, 2003, OBES RES, V11, P496, DOI 10.1038/oby.2003.69
   Robert L, 2001, PATHOL BIOL, V49, P353, DOI 10.1016/S0369-8114(01)00144-4
   Stitt AW, 2005, ANN NY ACAD SCI, V1043, P582, DOI 10.1196/annals.1338.066
   Stitt AW, 2003, EXP MOL PATHOL, V75, P95, DOI 10.1016/S0014-4800(03)00035-2
   Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
NR 20
TC 10
Z9 11
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2006
VL 220
IS 5
BP 317
EP 322
DI 10.1159/000094622
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 083EF
UT WOS:000240438500008
PM 16954709
DA 2022-11-30
ER

PT J
AU Thakoor, KA
   Yao, J
   Bordbar, D
   Moussa, O
   Lin, WJ
   Sajda, P
   Chen, RWS
AF Thakoor, Kaveri A.
   Yao, Jiaang
   Bordbar, Darius
   Moussa, Omar
   Lin, Weijie
   Sajda, Paul
   Chen, Royce W. S.
TI A multimodal deep learning system to distinguish late stages of AMD and
   to compare expert vs. AI ocular biomarkers
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY
AB Within the next 1.5 decades, 1 in 7 U.S. adults is anticipated to suffer from age-related macular degeneration (AMD), a degenerative retinal disease which leads to blindness if untreated. Optical coherence tomography angiography (OCTA) has become a prime technique for AMD diagnosis, specifically for late-stage neovascular (NV) AMD. Such technologies generate massive amounts of data, challenging to parse by experts alone, transforming artificial intelligence into a valuable partner. We describe a deep learning (DL) approach which achieves multi-class detection of non-AMD vs. non-neovascular (NNV) AMD vs. NV AMD from a combination of OCTA, OCT structure, 2D b-scan flow images, and high definition (HD) 5-line b-scan cubes; DL also detects ocular biomarkers indicative of AMD risk. Multimodal data were used as input to 2D-3D Convolutional Neural Networks (CNNs). Both for CNNs and experts, choroidal neovascularization and geographic atrophy were found to be important biomarkers for AMD. CNNs predict biomarkers with accuracy up to 90.2% (positive-predictive-value up to 75.8%). Just as experts rely on multimodal data to diagnose AMD, CNNs also performed best when trained on multiple inputs combined. Detection of AMD and its biomarkers from OCTA data via CNNs has tremendous potential to expedite screening of early and late-stage AMD patients.
C1 [Thakoor, Kaveri A.; Sajda, Paul] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.
   [Yao, Jiaang; Sajda, Paul] Columbia Univ, Dept Elect Engn, New York, NY 10027 USA.
   [Bordbar, Darius; Moussa, Omar; Lin, Weijie; Chen, Royce W. S.] Columbia Univ, Irving Med Ctr, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Sajda, Paul] Columbia Univ, Dept Radiol Phys, New York, NY 10027 USA.
C3 Columbia University; Columbia University; Columbia University;
   NewYork-Presbyterian Hospital; Columbia University
RP Thakoor, KA (通讯作者)，Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.
EM k.thakoor@columbia.edu
OI Yao, Jiaang/0000-0001-7062-2508
FU National Science Foundation Graduate Research Fellowship [DGE-1644869];
   National Eye Institute [P30EY019007]; Research to Prevent Blindness
FX This work was supported by National Science Foundation Graduate Research
   Fellowship Grant DGE-1644869 (K.A.T.) as well as National Eye Institute
   Core Grant P30EY019007 (R.W.S.C.) and an unrestricted grant from
   Research to Prevent Blindness. The authors are grateful to Siyao Zhang
   for statistical analysis guidance. Thanks go to Dr. Donald Coleman and
   Dr. Tongalp Tezel for data contributions and to Dr. Vlad Diaconita and
   Dr. Ioana Scherbakova for help with initial idea generation and protocol
   development.
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   An GZ, 2019, IEEE ENG MED BIO, P2049, DOI 10.1109/EMBC.2019.8857468
   Antonieta Martinez-Velasco A, 2017, LNCS, V10632, P257
   Ben-Baruch E., 2020, ASYMMETRIC LOSS MULT
   Cheung C.Y., 2021, ASS RES VIS OPHTH AN
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Gualino V, 2019, RETINA-J RET VIT DIS, V39, P1664, DOI 10.1097/IAE.0000000000002220
   Heo TY, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050261
   Jin K, 2022, ACTA OPHTHALMOL, V100, pE512, DOI 10.1111/aos.14928
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Mooga A, 2020, I S BIOMED IMAGING, P1780, DOI 10.1109/ISBI45749.2020.9098479
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pead E, 2019, SURV OPHTHALMOL, V64, P498, DOI 10.1016/j.survophthal.2019.02.003
   Phene S, 2019, OPHTHALMOLOGY, V126, P1627, DOI 10.1016/j.ophtha.2019.07.024
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Salvi M, 2021, COMPUT BIOL MED, V128, DOI 10.1016/j.compbiomed.2020.104129
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Thakoor K., 2021, ASS RES VIS OPHTH AN
   Thakoor K, 2021, I S BIOMED IMAGING, P1600, DOI 10.1109/ISBI48211.2021.9434111
   Vaghefi E, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7493419
   Wang J, 2020, BIOMED OPT EXPRESS, V11, P927, DOI 10.1364/BOE.379977
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
NR 28
TC 1
Z9 1
U1 3
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 16
PY 2022
VL 12
IS 1
AR 2585
DI 10.1038/s41598-022-06273-w
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZB8TK
UT WOS:000757107700067
PM 35173191
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shukal, DK
   Malaviya, PB
   Sharma, T
AF Shukal, Dhaval K.
   Malaviya, Pooja B.
   Sharma, Tusha
TI Role of the AMPK signalling pathway in the aetiopathogenesis of ocular
   diseases
SO HUMAN & EXPERIMENTAL TOXICOLOGY
LA English
DT Review
DE AMPK; glaucoma; cataract; retinoblastoma; diabetic retinopathy; super
   kinases; ocular disease
ID ACTIVATED PROTEIN-KINASE; RETINAL-PIGMENT EPITHELIUM; ENDOTOXIN-INDUCED
   UVEITIS; CARBOXAMIDE RIBONUCLEOTIDE AICAR; CELL-CYCLE ARREST; INDUCED
   OXIDATIVE DAMAGE; AGE-RELATED CATARACT; OPEN-ANGLE GLAUCOMA;
   ALPHA-LIPOIC ACID; THERAPEUTIC TARGET
AB Background: AMP-activated protein kinase (AMPK) plays a precise role as a master regulator of cellular energy homeostasis. AMPK is activated in response to the signalling cues that exhaust cellular ATP levels such as hypoxia, ischaemia, glucose depletion and heat shock. As a central regulator of both lipid and glucose metabolism, AMPK is considered to be a potential therapeutic target for the treatment of various diseases, including eye disorders.
   Objective: To review all the shreds of evidence concerning the role of the AMPK signalling pathway in the pathogenesis of ocular diseases.
   Method: Scientific data search and review of available information evaluating the influence of AMPK signalling on ocular diseases.
   Results: Review highlights the significance of AMPK signalling in the aetiopathogenesis of ocular diseases, including cataract, glaucoma, diabetic retinopathy, retinoblastoma, age-related macular degeneration, corneal diseases, etc. The review also provides the information on the AMPK-associated pathways with reference to ocular disease, which includes mitochondrial biogenesis, autophagy and regulation of inflammatory response.
   Conclusion: The study concludes the role of AMPK in ocular diseases. There is growing interest in the therapeutic utilization of the AMPK pathway for ocular disease treatment. Furthermore, inhibition of AMPK signalling might represent more pertinent strategy than AMPK activation for ocular disease treatment. Such information will guide the development of more effective AMPK modulators for ocular diseases.
C1 [Shukal, Dhaval K.; Malaviya, Pooja B.; Sharma, Tusha] Iladevi Cataract & IOL Res Ctr, Gurukul Rd, Ahmadabad 380052, Gujarat, India.
   [Shukal, Dhaval K.; Malaviya, Pooja B.] Manipal Acad Higher Educ, Mangalore, Karnataka, India.
C3 Manipal Academy of Higher Education (MAHE)
RP Shukal, DK (通讯作者)，Iladevi Cataract & IOL Res Ctr, Gurukul Rd, Ahmadabad 380052, Gujarat, India.
EM dhavalshukal@outlook.com
CR Agaoglu NB, 2019, TURK J MED SCI, V49, P1068, DOI 10.3906/sag-1810-182
   Agarwal P, 2015, MOL VIS, V21, P612
   Aghanoori MR, 2019, MOL METAB, V20, P149, DOI 10.1016/j.molmet.2018.11.008
   Al-Moujahed A, 2014, INVEST OPHTH VIS SCI, V55, P4175, DOI 10.1167/iovs.13-12856
   Alex A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.46
   Ambrosini G, 2013, MOL CANCER THER, V12, P768, DOI 10.1158/1535-7163.MCT-12-1020
   Amirouchene-Angelozzi N, 2016, ONCOTARGET, V7, P23633, DOI 10.18632/oncotarget.8054
   Athanasiou D, 2017, HUM MOL GENET, V26, P305, DOI 10.1093/hmg/ddw387
   Awai-Kasaoka N, 2013, MOL VIS, V19, P1332
   Barak V, 2011, CURR EYE RES, V36, P386, DOI 10.3109/02713683.2010.534573
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Becatti M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061572
   Belforte N, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00466-z
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bess E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020848
   Blazquez C, 1999, J NEUROCHEM, V73, P1674, DOI 10.1046/j.1471-4159.1999.731674.x
   Brodowska K, 2014, INT J ONCOL, V45, P2311, DOI 10.3892/ijo.2014.2650
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Bultot L, 2012, BIOCHEM J, V443, P193, DOI 10.1042/BJ20112026
   Burkewitz K, 2014, CELL METAB, V20, P10, DOI 10.1016/j.cmet.2014.03.002
   Cabahug VLO, 2019, CLIN OPHTHALMOL, V13, P649, DOI 10.2147/OPTH.S198401
   Cacicedo JM, 2011, INVEST OPHTH VIS SCI, V52, P3630, DOI 10.1167/iovs.10-5784
   Canto C, 2010, CELL MOL LIFE SCI, V67, P3407, DOI 10.1007/s00018-010-0454-z
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Carroll KC, 2013, J LEUKOCYTE BIOL, V94, P1113, DOI 10.1189/jlb.0313157
   Chan CM, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0056819, 10.1371/journal.pone.0068504]
   Chan CM, 2009, BIOCHEM BIOPH RES CO, V388, P172, DOI 10.1016/j.bbrc.2009.07.155
   Chang CW, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/141582
   Chang YK, 2018, STEM CELLS, V36, P1851, DOI 10.1002/stem.2915
   Chang YH, 2008, INVEST OPHTH VIS SCI, V49, P5441, DOI 10.1167/iovs.08-1784
   Chao SC, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/152854
   Chao SC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/817674
   Chatterjee A, 2014, INVEST OPHTH VIS SCI, V55, P3127, DOI 10.1167/iovs.13-12755
   Chen CL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051416
   Chen H, 2018, BIOMED PHARMACOTHER, V108, P1201, DOI 10.1016/j.biopha.2018.09.140
   Chen JH, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006090
   Chen K, 2017, MOL ONCOL, V11, P1475, DOI 10.1002/1878-0261.12116
   Chen M., 2021, RES SQUARE, DOI [10.21203/RS.3.RS-414664/V1, DOI 10.21203/RS.3.RS-414664/V1]
   Chen MM, 2021, J CELL MOL MED, V25, P8376, DOI 10.1111/jcmm.16797
   Chen SY, 2015, CELL CYCLE, V14, P2520, DOI 10.1080/15384101.2015.1055426
   Chen X, 2014, ONCOGENE, V33, P4724, DOI 10.1038/onc.2013.418
   Chen X, 2017, CANCER CELL, V31, P685, DOI 10.1016/j.ccell.2017.04.002
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Cheng LB, 2014, BIOCHEM BIOPH RES CO, V443, P447, DOI 10.1016/j.bbrc.2013.11.113
   Choi SI, 2015, BIOCHEM BIOPH RES CO, V456, P288, DOI 10.1016/j.bbrc.2014.11.073
   Choi SI, 2014, BIOCHEM BIOPH RES CO, V450, P1505, DOI 10.1016/j.bbrc.2014.07.035
   Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002
   Chua V, 2022, PIGM CELL MELANOMA R, V35, P78, DOI 10.1111/pcmr.13007
   Chung EJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17744-w
   Comander J., 2009, IOVS INVEST OPHTHALM, V50, P5909
   Dai W, 2016, SCI REP-UK, V6, DOI 10.1038/srep22622
   Dang KR, 2021, INT J OPHTHALMOL-CHI, V14, P1274, DOI 10.18240/ijo.2021.08.20
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dawes LJ, 2013, INVEST OPHTH VIS SCI, V54, P333, DOI 10.1167/iovs.12-10425
   Day EA, 2017, TRENDS ENDOCRIN MET, V28, P545, DOI 10.1016/j.tem.2017.05.004
   Di GH, 2017, SCI REP-UK, V7, DOI 10.1038/srep40582
   Ding Y, 2017, CIRC RES, V121, P1113, DOI 10.1161/CIRCRESAHA.117.311946
   Du L, 2017, MOL CELL ENDOCRINOL, V452, P44, DOI 10.1016/j.mce.2017.05.011
   Du SS, 2013, EXP EYE RES, V116, P151, DOI 10.1016/j.exer.2013.08.019
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   El Zaoui I, 2015, J OCUL PHARMACOL TH, V31, P17, DOI 10.1089/jop.2014.0019
   El-Masry OS, 2012, ONCOL LETT, V3, P224, DOI 10.3892/ol.2011.458
   El-Remessy AB, 2008, MOL VIS, V14, P2190
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Feng H, 2018, INT J MOL MED, V41, P2099, DOI 10.3892/ijmm.2018.3398
   Feng JY, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1261-4
   Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917
   Fogarty S, 2010, BIOCHEM J, V426, P109, DOI 10.1042/BJ20091372
   Fu DX, 2016, INVEST OPHTH VIS SCI, V57, P3369, DOI 10.1167/iovs.16-19291
   Galic S, 2018, ELIFE, V7, DOI 10.7554/eLife.32656
   Gao R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098909
   Garcia-Ramirez M, 2016, ACTA DIABETOL, V53, P109, DOI 10.1007/s00592-015-0759-3
   Gidfar S, 2017, SCI REP-UK, V7, DOI 10.1038/srep40308
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong QY, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644121
   Green AS, 2011, CELL CYCLE, V10, P2115, DOI 10.4161/cc.10.13.16244
   Green MF, 2011, CELL SIGNAL, V23, P2005, DOI 10.1016/j.cellsig.2011.07.014
   Gu XL, 2018, PHARMACOLOGY, V102, P213, DOI 10.1159/000491433
   Guo ZL, 2020, CURR EYE RES, V45, P177, DOI 10.1080/02713683.2019.1668419
   Gureev AP, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00435
   Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Habegger KM, 2012, ENDOCRINOLOGY, V153, P2130, DOI 10.1210/en.2011-2099
   Halfed DG, 2016, OCUL ONCOL PATHOL, V2, P100, DOI 10.1159/000439309
   Han J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193031
   Han XJ, 2016, AGING CELL, V15, P416, DOI 10.1111/acel.12446
   Hao YM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071515
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   Harun-Or-Rashid M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1346-7
   Harun-Or-Rashid M, 2018, J NEUROSCI, V38, P5122, DOI 10.1523/JNEUROSCI.3652-17.2018
   Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28
   He CY, 2015, DIABETES, V64, P4285, DOI 10.2337/db15-0107
   He L, 2018, ADV NUTR, V9, P493, DOI 10.1093/advances/nmy011
   Hedbacker K, 2008, FRONT BIOSCI-LANDMRK, V13, P2408, DOI 10.2741/2854
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Nguyen HT, 2016, BMC ENDOCR DISORD, V16, DOI 10.1186/s12902-016-0105-y
   Hoppe S, 2009, P NATL ACAD SCI USA, V106, P17781, DOI 10.1073/pnas.0909873106
   Hu HT, 2018, BIOCHEM BIOPH RES CO, V495, P2171, DOI 10.1016/j.bbrc.2017.12.078
   Hu XB, 2018, AGING-US, V10, P1932, DOI 10.18632/aging.101513
   Huang Y, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-78
   Husain S, 2017, INVEST OPHTH VIS SCI, V58, P6489, DOI 10.1167/iovs.16-20673
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Inman DM, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00146
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Jaliffa C, 2009, INVEST OPHTH VIS SCI, V50, P3562, DOI 10.1167/iovs.08-2817
   Jensen TE, 2015, BIOCHEM J, V467, P461, DOI 10.1042/BJ20141142
   Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81
   Jiang L, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.01.019
   Jiang S, 2018, THERANOSTICS, V8, P4535, DOI 10.7150/thno.25674
   Jin YH, 2008, BIOCHEM BIOPH RES CO, V368, P690, DOI 10.1016/j.bbrc.2008.01.114
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kalariya NM, 2012, INVEST OPHTH VIS SCI, V53, P3431, DOI 10.1167/iovs.12-9432
   Kamoshita M, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0268-5
   Kamoshita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103013
   Kan E, 2017, INT OPHTHALMOL, V37, P1269, DOI 10.1007/s10792-016-0396-z
   Kasetti RB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14938-0
   Kayastha F, 2014, EXP EYE RES, V128, P23, DOI 10.1016/j.exer.2014.09.002
   Khalili JS, 2012, CLIN CANCER RES, V18, P4345, DOI 10.1158/1078-0432.CCR-11-3227
   Kim AJ, 2017, INVEST OPHTH VIS SCI, V58, P106, DOI 10.1167/iovs.16-20691
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim SJ, 2016, CURR EYE RES, V41, P249, DOI 10.3109/02713683.2015.1006372
   Kim SH, 2019, FREE RADICAL RES, V53, P865, DOI 10.1080/10715762.2019.1637862
   Kim TI, 2011, AM J PATHOL, V179, P684, DOI 10.1016/j.ajpath.2011.04.005
   Kim YS, 2018, BIOCHEM BIOPH RES CO, V503, P1307, DOI 10.1016/j.bbrc.2018.07.041
   Koay A, 2010, FEBS LETT, V584, P3499, DOI 10.1016/j.febslet.2010.07.015
   Kowluru RA, 2004, DIABETES, V53, P3233, DOI 10.2337/diabetes.53.12.3233
   Kozhevnikova OS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194804
   Kubota S, 2011, INVEST OPHTH VIS SCI, V52, P9142, DOI 10.1167/iovs.11-8041
   Kubota S, 2009, INVEST OPHTH VIS SCI, V50, P3512, DOI 10.1167/iovs.08-2666
   Kuipers DP, 2013, BIOCHIMIE, V95, P258, DOI 10.1016/j.biochi.2012.09.022
   Kwon YS, 2005, INVEST OPHTH VIS SCI, V46, P454, DOI 10.1167/iovs.04-0753
   Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200
   Landreville S, 2012, CLIN CANCER RES, V18, P408, DOI 10.1158/1078-0432.CCR-11-0946
   Li J, 2015, TOXICOL SCI, V143, P196, DOI 10.1093/toxsci/kfu223
   Li J, 2021, J BIOENERG BIOMEMBR, V53, P513, DOI 10.1007/s10863-021-09915-2
   Li J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/7584691
   Li KR, 2016, SCI REP-UK, V6, DOI 10.1038/srep25525
   Li LH, 2021, ARCH PHYSIOL BIOCHEM, DOI 10.1080/13813455.2021.1887266
   Li R, 2018, INT J OPHTHALMOL-CHI, V11, P567, DOI 10.18240/ijo.2018.04.05
   Li S, 2019, INT J BIOL SCI, V15, P2016, DOI 10.7150/ijbs.30536
   Li S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061736
   Li XF, 2018, BIOCHEM BIOPH RES CO, V506, P73, DOI 10.1016/j.bbrc.2018.10.077
   Li XF, 2018, BIOCHEM BIOPH RES CO, V501, P293, DOI 10.1016/j.bbrc.2018.05.003
   Li XR, 2019, TRANSL RES, V207, P96, DOI 10.1016/j.trsl.2018.12.006
   Li XX, 2019, INT J MOL MED, V44, P1515, DOI 10.3892/ijmm.2019.4283
   Li X, 2020, J NEUROIMMUNOL, V345, DOI [10.1016/j.neuroim.2020.577286, 10.1016/j.jneuroim.2020.577286]
   Li ZR, 2013, MOL VIS, V19, P1656
   Lin CH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071799
   Lin FL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00326
   Lin HC, 2015, JAMA OPHTHALMOL, V133, P915, DOI 10.1001/jamaophthalmol.2015.1440
   Lin Y, 2017, MOL MED REP, V16, P4113, DOI 10.3892/mmr.2017.7114
   Liu D, 2019, DRUG DELIV, V26, P522, DOI 10.1080/10717544.2019.1609623
   Liu F, 2021, J NEUROCHEM, V158, P1131, DOI 10.1111/jnc.15472
   Liu H, 2015, INT J CLIN EXP PATHO, V8, P7644
   Liu PL, 2017, NEUROTOX RES, V32, P535, DOI 10.1007/s12640-017-9758-1
   Liu XB, 2021, NEURAL REGEN RES, V16, P2109, DOI 10.4103/1673-5374.303537
   Liu XB, 2016, REDOX BIOL, V8, P98, DOI 10.1016/j.redox.2015.12.005
   Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110
   Lu Y., 2021, FRONT CARDIOVASC MED, P384
   Luo C, 2020, J CLIN INVEST, V130, P853, DOI 10.1172/JCI130038
   Mammone T, 2018, MOL CELL NEUROSCI, V88, P270, DOI 10.1016/j.mcn.2018.01.002
   Mancini SJ, 2017, MOL CELL ENDOCRINOL, V440, P44, DOI 10.1016/j.mce.2016.11.010
   Matoba R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181481
   Meng B, 2018, MED SCI MONITOR, V24, P1980, DOI 10.12659/MSM.905450
   Meng XD, 2017, CELL MOL IMMUNOL, V14, P702, DOI 10.1038/cmi.2015.107
   Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123
   Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200
   Moschos MM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/317536
   Mustafa M., 2014, IOSR J PHARM, V04, P42, DOI DOI 10.9790/3013-0401201042047
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nanjaiah H, 2019, BIOTECHNOL APPL BIOC, V66, P999, DOI 10.1002/bab.1821
   Neumann D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082412
   Ni TM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190689
   Niu T, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1686-y
   Omae T, 2013, INVEST OPHTH VIS SCI, V54, P4586, DOI 10.1167/iovs.13-11756
   Omae T, 2012, INVEST OPHTH VIS SCI, V53, P2880, DOI 10.1167/iovs.11-8841
   Omae T, 2011, INVEST OPHTH VIS SCI, V52, P6749, DOI 10.1167/iovs.10-6826
   Osborne NN, 2016, EUR J PHARMACOL, V787, P127, DOI 10.1016/j.ejphar.2016.04.032
   Panigrahi T, 2019, OCUL SURF, V17, P699, DOI 10.1016/j.jtos.2019.08.004
   Park HYL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30165-7
   Patnaik JL, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.24
   Peng J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8549052
   Pinter K, 2012, CELL CYCLE, V11, P917, DOI 10.4161/cc.11.5.19412
   Populoa H, 2010, MELANOMA RES, V20, P107, DOI 10.1097/CMR.0b013e32832ccd09
   Nguyen QD, 2018, OPHTHALMOLOGY, V125, P1984, DOI 10.1016/j.ophtha.2018.06.015
   Racioppi L, 2012, J BIOL CHEM, V287, P31658, DOI 10.1074/jbc.R112.356485
   Rae Colin, 2019, Oncotarget, V10, P749, DOI 10.18632/oncotarget.26598
   Rajala A, 2018, ADV EXP MED BIOL, V1074, P491, DOI 10.1007/978-3-319-75402-4_61
   Rios M, 2013, CANCER RES, V73, P2628, DOI 10.1158/0008-5472.CAN-12-0861
   Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8
   Rosales MAB, 2019, LIFE SCI ALLIANCE, V2, DOI [10.26508/lsa.201800212, 10.26508/lsa.201900436]
   Ross FA, 2016, BIOCHEM J, V473, P189, DOI 10.1042/BJ20150910
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Rutherford C, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf8566
   Samadi AK, 2012, TUMOR BIOL, V33, P1179, DOI 10.1007/s13277-012-0363-x
   Santos JM, 2011, FREE RADICAL BIO MED, V51, P1849, DOI 10.1016/j.freeradbiomed.2011.08.017
   Sanz P, 2016, EXPERIENTIA SUPPL, V107, P353, DOI 10.1007/978-3-319-43589-3_14
   Sarthy VP., 2016, J OPHTHALMIC SCI, V1, P12
   Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544
   Shen Y, 2019, ARTIF CELL NANOMED B, V47, P4059, DOI 10.1080/21691401.2019.1671430
   Shentu XC, 2018, INT J OPHTHALMOL-CHI, V11, P12, DOI 10.18240/ijo.2018.01.03
   Shetty R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184628
   Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014
   Shin YJ, 2013, INVEST OPHTH VIS SCI, V54, P4452, DOI 10.1167/iovs.13-11684
   Shivakumar S, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7627329
   Shyam R., 2019, J CLIN TRANSL SCI, V3, P4
   Song SY, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5587340
   Sreelakshmi V., 2016, AUSTIN J CLIN OPHTHA, V3, P1067
   Su CC, 2014, INT J MOL SCI, V15, P13755, DOI 10.3390/ijms150813755
   Sun AJ, 2016, PROSTATE, V76, P172, DOI 10.1002/pros.23106
   Sung MS, 2015, INVEST OPHTH VIS SCI, V56, P3149, DOI 10.1167/iovs.14-16153
   Suzuki J, 2011, INVEST OPHTH VIS SCI, V52, P6565, DOI 10.1167/iovs.11-7331
   Suzuki T, 2013, MOL CELL, V50, P407, DOI 10.1016/j.molcel.2013.03.022
   Tanano I, 2013, INVEST OPHTH VIS SCI, V54, P1443, DOI 10.1167/iovs.12-10115
   Tang XJ, 2011, EUR J PHARMACOL, V650, P72, DOI 10.1016/j.ejphar.2010.09.076
   Tao Rong, 2010, J Mol Signal, V5, P1, DOI 10.1186/1750-2187-5-1
   Tayyari F, 2015, INVEST OPHTH VIS SCI, V56, P6796, DOI 10.1167/iovs.15-17481
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Theeuwes WF, 2018, BBA-MOL BASIS DIS, V1864, P2913, DOI 10.1016/j.bbadis.2018.06.002
   Theodoropoulou S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052852
   Theodoropoulou S, 2010, FASEB J, V24, P2620, DOI 10.1096/fj.09-152546
   Tian F, 2014, INT J MOL SCI, V15, P13833, DOI 10.3390/ijms150813833
   Trudeau K, 2011, INVEST OPHTH VIS SCI, V52, P6348, DOI 10.1167/iovs.11-7282
   Ueta T, 2012, ARTERIOSCL THROM VAS, V32, P1366, DOI 10.1161/ATVBAHA.112.248021
   Umezawa S, 2017, CURR PHARM DESIGN, V23, P3629, DOI 10.2174/0929867324666170713150440
   van Ginkel PR, 2008, INVEST OPHTH VIS SCI, V49, P1299, DOI 10.1167/iovs.07-1233
   Vara-Ciruelos D, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190099
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Villarroel M, 2011, DIABETOLOGIA, V54, P1543, DOI 10.1007/s00125-011-2089-5
   Wan T, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12893
   Wang HF, 2017, EUR J PHARMACOL, V815, P391, DOI 10.1016/j.ejphar.2017.09.041
   Wang KJ, 2015, BIOCHEM BIOPH RES CO, V468, P541, DOI 10.1016/j.bbrc.2015.10.117
   Wang N, 2019, AGING-US, V11, P3117, DOI 10.18632/aging.101966
   Wang S, 2015, INVEST OPHTH VIS SCI, V56, P2971, DOI 10.1167/iovs.14-15874
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang YD, 2015, INT J CLIN EXP PATHO, V8, P5182
   Wang Y, 2016, DIABETES, V65, P2020, DOI 10.2337/db15-1283
   Wang Y, 2013, INVEST OPHTH VIS SCI, V54, P3806, DOI 10.1167/iovs.13-12091
   Wang YC, 2018, INT J OPHTHALMOL-CHI, V11, P1258, DOI 10.18240/ijo.2018.08.03
   Wang Y, 2017, CANCER LETT, V400, P47, DOI 10.1016/j.canlet.2017.04.028
   Wei JL, 2017, ONCOTARGET, V8, P49318, DOI 10.18632/oncotarget.17595
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   White A, 2016, LANCET, V387, P105
   Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035
   Wu QF, 2017, ONCOTARGET, V8, P88401, DOI 10.18632/oncotarget.19365
   Wu TT, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10071086
   Xiang HC, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1411-x
   Xie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053329
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yan FX, 2017, ACS CHEM NEUROSCI, V8, P1713, DOI 10.1021/acschemneuro.7b00021
   Yan JW, 2020, J CELL MOL MED, V24, P814, DOI 10.1111/jcmm.14792
   Yan Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113534
   Yan ZY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178253
   Yang LL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149865
   Yang QH, 2019, INT J OPHTHALMOL-CHI, V12, P302, DOI 10.18240/ijo.2019.02.19
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yao K, 2008, MOL VIS, V14, P217
   Yao K, 2009, AM J CHINESE MED, V37, P785, DOI 10.1142/S0192415X09007247
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Yin L, 2018, J BUON, V23, P1174
   Yoshida T, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-45
   Zeng K, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170695
   Zhang BA, 2017, INT J ONCOL, V51, P887, DOI 10.3892/ijo.2017.4079
   Zhang H, 2019, EUR J PHARMACOL, V842, P329, DOI 10.1016/j.ejphar.2018.11.001
   Zhang J, 2004, INVEST OPHTH VIS SCI, V45, pU89
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang W., BIORXIV CELL BIOL, DOI [10.1101/868281, DOI 10.1101/868281]
   Zhao BW, 2019, EUR REV MED PHARMACO, V23, P3569, DOI 10.26355/eurrev_201905_17778
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
   Zheng TY, 2011, CURR EYE RES, V36, P449, DOI 10.3109/02713683.2011.559301
   Zhou YF, 2016, CURR EYE RES, V41, P933, DOI 10.3109/02713683.2015.1082186
   Zhu X, 2018, ARCH PHARM RES, V41, P1009, DOI 10.1007/s12272-018-1059-6
   Zhu YP, 2015, J IMMUNOL, V194, P584, DOI 10.4049/jimmunol.1401024
   Zippel N, 2013, ARTERIOSCL THROM VAS, V33, P2792, DOI 10.1161/ATVBAHA.113.301848
NR 281
TC 2
Z9 2
U1 8
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0960-3271
EI 1477-0903
J9 HUM EXP TOXICOL
JI Hum. Exp. Toxicol.
PD JAN 7
PY 2022
VL 41
DI 10.1177/09603271211063165
PG 28
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA ZZ7IR
UT WOS:000773438500001
PM 35196887
OA hybrid
DA 2022-11-30
ER

PT J
AU Yang, MZ
   Qiu, RQ
   Wang, WP
   Liu, JY
   Jin, XX
   Li, Y
   Li, L
   Lei, B
AF Yang, Mingzhu
   Qiu, Ruiqi
   Wang, Weiping
   Liu, Jingyang
   Jin, Xiuxiu
   Li, Ya
   Li, Lei
   Lei, Bo
TI P2X7 Receptor Antagonist Attenuates Retinal Inflammation and
   Neovascularization Induced by Oxidized Low-Density Lipoprotein
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID MACULAR DEGENERATION; OXIDATIVE STRESS; RPE CELLS; ACTIVATION;
   INVOLVEMENT; OXLDL
AB Age-related macular degeneration (AMD) is a common and severe blinding disease among people worldwide. Retinal inflammation and neovascularization are two fundamental pathological processes in AMD. Recent studies showed that P2X7 receptor was closely involved in the inflammatory response. Here, we aim to investigate whether A740003, a P2X7 receptor antagonist, could prevent retinal inflammation and neovascularization induced by oxidized low-density lipoprotein (ox-LDL) and explore the underlying mechanisms. ARPE-19 cells and C57BL/6 mice were treated with ox-LDL and A740003 successively for in vitro and in vivo studies. In this research, we found that A740003 suppressed reactive oxygen species (ROS) generation and inhibited the activation of Nod-like receptor pyrin-domain protein 3 (NLRP3) inflammasome and nuclear factor-kappa B (NF-kappa B) pathway. A740003 also inhibited the generation of angiogenic factors in ARPE-19 cells and angiogenesis in mice. The inflammatory cytokines and phosphorylation of inhibitor of nuclear factor-kappa B alpha (IKB alpha) were repressed by A740003. Besides, ERG assessment showed that retinal functions were remarkably preserved in A740003-treated mice. In summary, our results revealed that the P2X7 receptor antagonist reduced retinal inflammation and neovascularization and protected retinal function. The protective effects were associated with regulation of NLRP3 inflammasome and the NF-kappa B pathway, as well as inhibition of angiogenic factors.
C1 [Yang, Mingzhu; Qiu, Ruiqi; Wang, Weiping; Liu, Jingyang; Jin, Xiuxiu; Li, Ya; Lei, Bo] Zhengzhou Univ, Henan Eye Hosp, Henan Prov Peoples Hosp, Henan Eye Inst,Peoples Hosp, Zhengzhou 450003, Henan, Peoples R China.
   [Li, Lei] Xinxiang Med Univ, Xinxiang 453003, Henan, Peoples R China.
C3 Zhengzhou University; Xinxiang Medical University
RP Lei, B (通讯作者)，Zhengzhou Univ, Henan Eye Hosp, Henan Prov Peoples Hosp, Henan Eye Inst,Peoples Hosp, Zhengzhou 450003, Henan, Peoples R China.
EM bolei99@126.com
OI jin, xiuxiu/0000-0003-2978-303X; Liu, Jingyang/0000-0002-1579-825X; Lei,
   Bo/0000-0002-5497-0905; li, lei/0000-0002-6888-7571; Qiu,
   Ruiqi/0000-0003-1854-0577
FU Key Technologies Research and Development Program of Henan Science and
   Technology Bureau [192102310076]; Henan Health Commission
   [LHGJ20190820]; National Natural Science Foundation of China grants
   [82071008, 82004001]
FX This work was supported by Key Technologies Research and Development
   Program of Henan Science and Technology Bureau (192102310076), Henan
   Health Commission (LHGJ20190820), and National Natural Science
   Foundation of China grants (82071008, 82004001). We would like to thank
   Professor Jikui Shen from John Hopkins University for his inspiration
   and help.
CR Abu Khamidakh AE, 2013, EXP EYE RES, V108, P129, DOI 10.1016/j.exer.2013.01.009
   Amezaga N, 2014, J LEUKOCYTE BIOL, V95, P509, DOI 10.1189/jlb.1212660
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Bucolo C, 2011, PHARMACOL THERAPEUT, V130, P191, DOI 10.1016/j.pharmthera.2011.01.013
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Clapp C, 2019, ACTA DIABETOL, V56, P1031, DOI 10.1007/s00592-019-01343-4
   Doktor F, 2018, PURINERG SIGNAL, V14, P471, DOI 10.1007/s11302-018-9631-6
   Dong LD, 2018, MOL MED REP, V17, P2289, DOI 10.3892/mmr.2017.8137
   Fresta CG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239305
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Giuliani AL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00123
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Helin-Toiviainen M, 2017, ACTA OPHTHALMOL, V95, P378, DOI 10.1111/aos.13380
   Hollborn M, 2020, MOL VIS, V26, P188
   Hollborn M, 2017, MOL VIS, V23, P116
   Javadzadeh A, 2012, RETINA-J RET VIT DIS, V32, P658, DOI 10.1097/IAE.0b013e31822529b1
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Mao K, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6210694
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Mitchell CH, 2008, PURINERG SIGNAL, V4, P101, DOI 10.1007/s11302-007-9054-2
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Pavlou S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092101
   Platania CBM, 2019, BIOCHEM PHARMACOL, V168, P249, DOI 10.1016/j.bcp.2019.07.010
   Platania CBM, 2017, BIOCHEM PHARMACOL, V138, P130, DOI 10.1016/j.bcp.2017.05.001
   Prager P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165653
   Qiu YG, 2016, SCI REP-UK, V6, DOI 10.1038/srep31912
   Reichenbach A, 2016, NEUROPHARMACOLOGY, V104, P194, DOI 10.1016/j.neuropharm.2015.05.005
   Reigada D, 2005, AM J PHYSIOL-CELL PH, V289, pC617, DOI 10.1152/ajpcell.00542.2004
   Romano GL, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114199
   Sanjurjo L, 2015, AUTOPHAGY, V11, P487, DOI 10.1080/15548627.2015.1017183
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yang M., 2020, P2X7 RECEPTOR ANTAGO
   Zhang SX, 2008, J MOL ENDOCRINOL, V41, P135, DOI 10.1677/JME-08-0011
   Zheng SJ, 2015, INVEST OPHTH VIS SCI, V56, P1168, DOI 10.1167/iovs.14-15612
NR 38
TC 5
Z9 6
U1 1
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD AUG 20
PY 2021
VL 2021
AR 5520644
DI 10.1155/2021/5520644
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA UJ2SM
UT WOS:000691141700003
PM 34457115
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Kobayashi, Y
   Tokuda, K
   Yamashiro, C
   Higashijima, F
   Yoshimoto, T
   Ota, M
   Ogata, T
   Ashimori, A
   Hatano, M
   Kobayashi, M
   Uchi, SH
   Wakuta, M
   Kimura, K
AF Kobayashi, Yuka
   Tokuda, Kazuhiro
   Yamashiro, Chiemi
   Higashijima, Fumiaki
   Yoshimoto, Takuya
   Ota, Manami
   Ogata, Tadahiko
   Ashimori, Atsushige
   Hatano, Makoto
   Kobayashi, Masaaki
   Uchi, Sho-Hei
   Wakuta, Makiko
   Kimura, Kazuhiro
TI Inhibition of epithelial-mesenchymal transition in retinal pigment
   epithelial cells by a retinoic acid receptor-alpha agonist
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COLLAGEN GEL CONTRACTION; SUBRETINAL FIBROSIS; SIGNALING PATHWAY;
   ANIMAL-MODEL; VITAMIN-A; MECHANISMS; INDUCTION; IMMUNITY; GREMLIN; RATS
AB Epithelial-mesenchymal transition (EMT) in retinal pigment epithelial (RPE) cells plays a key role in proliferative retinal diseases such as age-related macular degeneration by contributing to subretinal fibrosis. To investigate the potential role of retinoic acid receptor-alpha (RAR-alpha) signaling in this process, we have now examined the effects of the RAR-alpha agonist Am580 on EMT induced by transforming growth factor-beta 2 (TGF-beta 2) in primary mouse RPE cells cultured in a three-dimensional type I collagen gel as well as on subretinal fibrosis in a mouse model. We found that Am580 inhibited TGF-beta 2-induced collagen gel contraction mediated by RPE cells. It also attenuated the TGF-beta 2-induced expression of the mesenchymal markers alpha-smooth muscle actin, fibronectin, and collagen type I; production of pro-matrix metalloproteinase 2 and interleukin-6; expression of the focal adhesion protein paxillin; and phosphorylation of SMAD2 in the cultured RPE cells. Finally, immunofluorescence analysis showed that Am580 suppressed both the TGF-beta 2-induced translocation of myocardin-related transcription factor-A (MRTF-A) from the cytoplasm to the nucleus of cultured RPE cells as well as subretinal fibrosis triggered by laser-induced photocoagulation in a mouse model. Our observations thus suggest that RAR-alpha signaling inhibits EMT in RPE cells and might attenuate the development of fibrosis associated with proliferative retinal diseases.
C1 [Kobayashi, Yuka; Tokuda, Kazuhiro; Yamashiro, Chiemi; Higashijima, Fumiaki; Yoshimoto, Takuya; Ota, Manami; Ogata, Tadahiko; Ashimori, Atsushige; Hatano, Makoto; Kobayashi, Masaaki; Uchi, Sho-Hei; Wakuta, Makiko; Kimura, Kazuhiro] Yamaguchi Univ, Dept Ophthalmol, Grad Sch Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.
C3 Yamaguchi University
RP Kimura, K (通讯作者)，Yamaguchi Univ, Dept Ophthalmol, Grad Sch Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.
EM k.kimura@yamaguchi-u.ac.jp
CR Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810
   Al Kattan WM, 2017, JCPSP-J COLL PHYSICI, V27, P38, DOI 2519
   Arpino V, 2015, MATRIX BIOL, V44-46, P247, DOI 10.1016/j.matbio.2015.03.005
   BENSON MT, 1992, CURR EYE RES, V11, P173, DOI 10.3109/02713689208999529
   Carrington L, 2000, INVEST OPHTH VIS SCI, V41, P1210
   Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   Conde I, 2004, INT J ONCOL, V25, P1183
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Feng H, 2019, INT J BIOL SCI, V15, P507, DOI 10.7150/ijbs.30575
   Greaves NS, 2013, J DERMATOL SCI, V72, P206, DOI 10.1016/j.jdermsci.2013.07.008
   Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kelley JB, 2019, METHODS, V157, P106, DOI 10.1016/j.ymeth.2018.11.002
   Kent D, 2003, MOL VIS, V9, P747
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Kimura K, 2014, INVEST OPHTH VIS SCI, V55, P2621, DOI 10.1167/iovs.13-13501
   Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee H, 2007, INVEST OPHTH VIS SCI, V48, P4291, DOI 10.1167/iovs.07-0086
   Lee HP, 2009, EXPERT REV NEUROTHER, V9, P1615, DOI [10.1586/ern.09.86, 10.1586/ERN.09.86]
   Lee SH, 2019, TUBERC RESPIR DIS, V82, P42, DOI 10.4046/trd.2017.0111
   Li XM, 2016, ACTA PHARMACOL SIN, V37, P783, DOI 10.1038/aps.2016.35
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Liu Y, 2008, INVEST OPHTH VIS SCI, V49, P1429, DOI 10.1167/iovs.07-0451
   Liu Y, 2014, INVEST OPHTH VIS SCI, V55, P4199, DOI 10.1167/iovs.13-13572
   Long YB, 2012, INT J MOL SCI, V13, P14073, DOI 10.3390/ijms131114073
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Nagai R, 2005, J THROMB HAEMOST, V3, P1569, DOI 10.1111/j.1538-7836.2005.01366.x
   Nakamura K, 2000, J BIOL CHEM, V275, P27155
   Ngo P, 2006, METH MOL B, V341, P103
   Nomi N, 2010, INVEST OPHTH VIS SCI, V51, P2955, DOI 10.1167/iovs.09-4823
   Pendaries V, 2003, ONCOGENE, V22, P8212, DOI 10.1038/sj.onc.1206913
   Qin D, 2020, EXP THER MED, V19, P2353, DOI 10.3892/etm.2020.8463
   Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Sahu B, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110746
   Saika S, 2004, AM J PATHOL, V164, P651, DOI 10.1016/S0002-9440(10)63153-7
   Shi SL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041349
   Sierra-Mondragon E, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9100525
   Soderpalm AK, 2000, INVEST OPHTH VIS SCI, V41, P937
   Suzuki HI, 2018, JOVE-J VIS EXP, DOI 10.3791/57577
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Toth CA, 2019, OPHTHALMOL RETINA, V3, P316, DOI 10.1016/j.oret.2018.11.011
   Tumbarello DA, 2005, J CELL SCI, V118, P4849, DOI 10.1242/jcs.02615
   Wang N, 2013, GENE, V523, P178, DOI 10.1016/j.gene.2013.03.043
   Wang XL, 2019, INVEST OPHTH VIS SCI, V60, P3669, DOI 10.1167/iovs.19-26983
   Wojtal KA, 2013, TOXICOL IN VITRO, V27, P1525, DOI 10.1016/j.tiv.2013.03.013
   Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487
   Xu QH, 2012, SEMIN NEPHROL, V32, P287, DOI 10.1016/j.semnephrol.2012.04.008
   Xu Y, 2016, CELL PHYSIOL BIOCHEM, V38, P229, DOI 10.1159/000438624
   Yang TH, 2015, J ORTHOP RES, V33, P668, DOI 10.1002/jor.22835
   Yu-Wai-Man C, 2014, INVEST OPHTH VIS SCI, V55, P4560, DOI 10.1167/iovs.14-14692
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
   Zhang Y, 2018, CELL PHYSIOL BIOCHEM, V46, P1704, DOI 10.1159/000489246
   Zhou HY, 2012, INVEST OPHTH VIS SCI, V53, P4213, DOI 10.1167/iovs.11-8822
   Zou YM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096708
NR 60
TC 4
Z9 4
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 4
PY 2021
VL 11
IS 1
AR 11842
DI 10.1038/s41598-021-90618-4
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UD6PQ
UT WOS:000687328100061
PM 34088917
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Park, DW
   Lee, YG
   Jeong, YJ
   Jeon, H
   Kang, SC
AF Park, Dae-Won
   Lee, Yeong-Geun
   Jeong, Yong-Joon
   Jeon, Hyelin
   Kang, Se-Chan
TI Preventive Effects against Retinal Degeneration by Centella asiatica
   Extract (CA-HE50) and Asiaticoside through Apoptosis Suppression by the
   Nrf2/HO-1 Signaling Pathway
SO ANTIOXIDANTS
LA English
DT Article
DE Centella asiatica; asiaticoside; age-related macular degeneration;
   cytoprotective effect; Nrf2; HO-1 antioxidant signaling pathway; cell
   cycle; apoptosis
AB Age-related macular degeneration (AMD) is caused by the chronic and gradual oxidative degeneration of the retina. Unfortunately, the general purpose of current treatments is to slow AMD progression, as the retina cannot be restored to its pre-AMD condition. We aimed to identify natural products that can be potential treatments that prevent AMD and can delay the development of late-AMD and selected Centella asiatica extract (CA-HE50), which shows excellent efficacy in cytoprotection. In animal experiments using N-methyl-N-nitrosourea (MNU), CA-HE50 dramatically increased the thickness of photoreceptors and the outer nuclear layer (ONL) and the number of nuclei in the ONL (p < 0.05). Using retinal epithelial ARPE-19 cells showed that CA-HE50 inhibited apoptosis through inhibition of the intrinsic apoptosis signaling pathway and cell cycle regulation (p < 0.05). The anti-apoptotic efficacy was confirmed to be due to activation of the Nrf2/HO-1 antioxidation pathway (p < 0.05). These results were also observed with asiaticoside, a functional substance of CA-HE50. In addition, the accumulation of oxidized-N-retinylidene-N-retinylethanolamine (A2E), which induces AMD, was inhibited by CA-HE50, resulting in increased ARPE-19 cell viability (p < 0.05). This study demonstrates that CA-HE50 is worth further research and human application tests, to develop it as a raw material for treatment or dietary supplement for the prevention of AMD.
C1 [Park, Dae-Won; Lee, Yeong-Geun; Kang, Se-Chan] Kyung Hee Univ, Dept Oriental Med Biotechnol, Coll Life Sci, Yongin 17104, Gyeonggi Do, South Korea.
   [Jeong, Yong-Joon; Jeon, Hyelin] Genencell Co Ltd, Res Inst, Yongin 16950, Gyeonggi Do, South Korea.
C3 Kyung Hee University
RP Kang, SC (通讯作者)，Kyung Hee Univ, Dept Oriental Med Biotechnol, Coll Life Sci, Yongin 17104, Gyeonggi Do, South Korea.; Jeon, H (通讯作者)，Genencell Co Ltd, Res Inst, Yongin 16950, Gyeonggi Do, South Korea.
EM dw@nmr.kr; lyg629@nate.com; jeyoon@genencell.co.kr;
   jeonhl0219@genencell.co.kr; sckang@khu.ac.kr
OI Jeon, Hyelin/0000-0001-9469-3677
FU Korean Institute of Planning and Evaluation for Technology in Food,
   Agriculture, Forestry (IPET) through the High Value-Added Food
   Technology Development Program - Ministry of Agriculture, Food and Rural
   Affairs (MAFRA) [117050-3]
FX This work was supported by the Korean Institute of Planning and
   Evaluation for Technology in Food, Agriculture, Forestry (IPET) through
   the High Value-Added Food Technology Development Program, funded by the
   Ministry of Agriculture, Food and Rural Affairs (MAFRA) (117050-3).
CR Augustin Albert, 2009, Retina, V29, pS8, DOI 10.1097/IAE.0b013e3181ad253d
   Barnum KJ, 2014, METHODS MOL BIOL, V1170, P29, DOI 10.1007/978-1-4939-0888-2_2
   Bellezza Ilaria, 2010, Cancers (Basel), V2, P483, DOI 10.3390/cancers2020483
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Bruschi M, 2020, FASEB BIOADV, V2, P315, DOI 10.1096/fba.2019-00093
   Calzia D, 2018, FREE RADICAL BIO MED, V117, P110, DOI 10.1016/j.freeradbiomed.2018.01.029
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   Chan A, 2006, RETINA-J RET VIT DIS, V26, P655, DOI 10.1097/00006982-200607000-00011
   Clementi ME, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060473
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dulull NK, 2018, CURR MOL PHARMACOL, V11, P237, DOI 10.2174/1874467211666180125163009
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Frenkel S, 2008, BRIT J OPHTHALMOL, V92, P383, DOI 10.1136/bjo.2007.127928
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Jamil S. S., 2007, Natural Product Radiance, V6, P158
   Kalkavan H, 2018, CELL DEATH DIFFER, V25, P46, DOI 10.1038/cdd.2017.179
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Mahendra CK, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1904178
   Maurer E, 2014, JOVE-J VIS EXP, DOI 10.3791/51909
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Orhan C, 2016, J OCUL PHARMACOL TH, V32, P631, DOI 10.1089/jop.2015.0154
   Park DW, 2020, NUTR RES PRACT, V14, P203, DOI 10.4162/nrp.2020.14.3.203
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Satia JA, 2009, AM J EPIDEMIOL, V169, P815, DOI 10.1093/aje/kwn409
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Villeneuve NF, 2009, CELL CYCLE, V8, P3255, DOI 10.4161/cc.8.20.9565
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
NR 38
TC 6
Z9 7
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD APR
PY 2021
VL 10
IS 4
AR 613
DI 10.3390/antiox10040613
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA RQ9EY
UT WOS:000642716100001
PM 33923585
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bhattarai, N
   Piippo, N
   Ranta-aho, S
   Mysore, Y
   Kaarniranta, K
   Kauppinen, A
AF Bhattarai, Niina
   Piippo, Niina
   Ranta-aho, Sofia
   Mysore, Yashavanthi
   Kaarniranta, Kai
   Kauppinen, Anu
TI Effects of Resvega on Inflammasome Activation in Conjunction with
   Dysfunctional Intracellular Clearance in Retinal Pigment Epithelial
   (RPE) Cells
SO ANTIOXIDANTS
LA English
DT Article
DE Resvega; resveratrol; antioxidant; NLRP3 inflammasome; caspase-1;
   IL-1&#946; ARPE-19 cell; RPE cell; autophagy
AB Age-related macular degeneration (AMD) is an eye disease in which retinal pigment epithelium (RPE) cells play a crucial role in maintaining retinal homeostasis and photoreceptors' functionality. During disease progression, there is increased inflammation with nucleotide-binding domain, leucine-rich repeat, and Pyrin domain 3 (NLRP3) inflammasome activation, oxidative stress, and impaired autophagy in RPE cells. Previously, we have shown that the dietary supplement Resvega reduces reactive oxygen species (ROS) production and induces autophagy in RPE cells. Here, we investigated the ability of Resvega to prevent NLRP3 inflammasome activation with impaired protein clearance in human RPE cells. Cell viability was measured using the lactate dehydrogenase (LDH) and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Enzyme-linked immunosorbent assays (ELISA) were utilized to determine the secretion of cytokines, NLRP3, and vascular endothelial growth factor (VEGF). Caspase-1 activity was measured with a fluorescent labeled inhibitor of caspase-1 (FLICA; FAM-YVAD-FMK) and detected microscopically. Resvega improved the cell membrane integrity, which was evident as reduced LDH leakage from cells. In addition, the caspase-1 activity and NLRP3 release were reduced, as was the secretion of two inflammatory cytokines, interleukin (IL)-1 beta and IL-8, in IL-1 alpha-primed ARPE-19 cells. According to our results, Resvega can potentially reduce NLRP3 inflammasome-mediated inflammation in RPE cells with impaired protein clearance.
C1 [Bhattarai, Niina; Piippo, Niina; Ranta-aho, Sofia; Mysore, Yashavanthi; Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland
RP Bhattarai, N; Kauppinen, A (通讯作者)，Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, Kuopio 70210, Finland.
EM niina.piippo@uef.fi; niina.piippo@uef.fi; sofia.ranta-aho@uef.fi;
   yashavanthi.mysore@uef.fi; kai.kaarniranta@uef.fi; anu.kauppinen@uef.fi
RI Harju, Niina/ABA-7085-2020; Mysore, Yashavanthi/O-2190-2016
OI Harju, Niina/0000-0001-9031-5353; Mysore,
   Yashavanthi/0000-0001-8279-0998; Ranta-aho, Sofia/0000-0001-6569-657X
FU Academy of Finland [297267, 307341, 328443, 296840, 333302]; Emil
   Aaltonen Foundation; Paivikki and Sakari Sohlberg Foundation; Finnish
   Eye Foundation; Sigrid Juselius Foundation; Sokeain Ystavat ry; Silma-
   ja Kudospankkisaatio
FX This research was funded by the Academy of Finland (297267, 307341,
   328443, 296840 and 333302), the Emil Aaltonen Foundation, the Paivikki
   and Sakari Sohlberg Foundation, The Finnish Eye Foundation, The Sigrid
   Juselius Foundation, Sokeain Ystavat ry, and Silma- ja
   Kudospankkisaatio. The APC was funded by the Academy of Finland
   (328443).
CR Ivanescu AA, 2015, NUTRIENTS, V7, P5423, DOI 10.3390/nu7075229
   Alfonso-Loeches S, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00216
   Allen IC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00169
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amores-Iniesta J, 2017, CELL REP, V21, P3414, DOI 10.1016/j.celrep.2017.11.079
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhattarai N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062066
   Chang YP, 2015, J CELL PHYSIOL, V230, P1567, DOI 10.1002/jcp.24903
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Deigendesch N, 2018, J IMMUNOL, V200, P1607, DOI 10.4049/jimmunol.1700712
   Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426
   Fan Y, 2017, MOL MED REP, V16, P5195, DOI 10.3892/mmr.2017.7236
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Fotakis G, 2006, TOXICOL LETT, V160, P171, DOI 10.1016/j.toxlet.2005.07.001
   Hill LM, 2010, J IMMUNOL, V185, P3028, DOI 10.4049/jimmunol.1001298
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Houtman J, 2019, EMBO J, V38, DOI 10.15252/embj.201899430
   Huang TT, 2014, INNATE IMMUN-LONDON, V20, P735, DOI 10.1177/1753425913507096
   Jha S, 2009, J IMMUNOL, V183, P7623, DOI 10.4049/jimmunol.0902425
   Jiang L, 2016, BIOMED PHARMACOTHER, V84, P130, DOI 10.1016/j.biopha.2016.09.020
   Josifovska N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030813
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Katsuragi Yoshinori, 2016, Current Opinion in Toxicology, V1, P54, DOI 10.1016/j.cotox.2016.09.005
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Keegan G, 2020, EXP EYE RES, V197, DOI 10.1016/j.exer.2020.108104
   Korhonen E, 2019, CYTOKINE, V116, P70, DOI 10.1016/j.cyto.2018.12.015
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Leger F, 2011, J NEUROPATH EXP NEUR, V70, P63, DOI 10.1097/NEN.0b013e31820376cc
   Li YB, 2015, THERANOSTICS, V5, P1363, DOI 10.7150/thno.13181
   Lobner D, 2000, J NEUROSCI METH, V96, P147, DOI 10.1016/S0165-0270(99)00193-4
   Long Y, 2020, ECOTOX ENVIRON SAFE, V189, DOI 10.1016/j.ecoenv.2019.109937
   Losso JN, 2010, J AGR FOOD CHEM, V58, P8246, DOI 10.1021/jf1012067
   Marasco MR, 2018, DIABETES, V67, P1576, DOI 10.2337/db17-1280
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Mitchell CH, 2008, PURINERG SIGNAL, V4, P101, DOI 10.1007/s11302-007-9054-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakajima S, 2011, FEBS LETT, V585, P2249, DOI 10.1016/j.febslet.2011.05.047
   Oh JM, 2012, AUTOPHAGY, V8, P1448, DOI 10.4161/auto.21164
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Piippo N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25123-2
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Querques G, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/748361
   Razani B, 2012, CELL METAB, V15, P534, DOI 10.1016/j.cmet.2012.02.011
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saitoh T, 2016, J ALLERGY CLIN IMMUN, V138, P28, DOI 10.1016/j.jaci.2016.05.009
   Salmeron K, 2016, J NEUROCHEM, V136, P573, DOI 10.1111/jnc.13422
   Sang X., 2016, INFLAMMASOME, V2, P13, DOI [10.1515/infl-2016-0001, DOI 10.1515/INFL-2016-0001]
   Sant DW, 2018, INVEST OPHTH VIS SCI, V59, P3608, DOI 10.1167/iovs.18-24101
   Satoh E, 2011, J TOXICOL SCI, V36, P741, DOI 10.2131/jts.36.741
   Summersgill H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.547
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   Viiri J, 2010, MOL VIS, V16, P1399
   Williams-Bey Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097957
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Wruck CJ, 2011, J BIOL CHEM, V286, P4493, DOI 10.1074/jbc.M110.162008
   Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhu QF, 2017, J IMMUNOL, V198, P4210, DOI 10.4049/jimmunol.1700352
NR 70
TC 7
Z9 7
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JAN
PY 2021
VL 10
IS 1
AR 67
DI 10.3390/antiox10010067
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA PV1EI
UT WOS:000609736700001
PM 33430331
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wolk, A
   Upadhyay, M
   Ali, M
   Suh, J
   Stoehr, H
   Bonilha, VL
   Anand-Apte, B
AF Wolk, Alyson
   Upadhyay, Mala
   Ali, Mariya
   Suh, Jason
   Stoehr, Heidi
   Bonilha, Vera L.
   Anand-Apte, Bela
TI The retinal pigment epithelium in Sorsby Fundus Dystrophy shows
   increased sensitivity to oxidative stress-induced degeneration
SO REDOX BIOLOGY
LA English
DT Article
DE Retinal pigment epithelium; Sorsby Fundus Dystrophy; Age-related macular
   degeneration; Oxidative stress; Antioxidants; Sodium iodate
ID TISSUE INHIBITOR; SULFATED GLYCOSAMINOGLYCANS; METALLOPROTEINASES-3
   TIMP3; MUTATION; RPE; EXPRESSION; CELLS; LOCALIZATION; INJURY; GENES
AB Sorsby Fundus Dystrophy (SFD) is a rare inherited autosomal dominant macular degeneration caused by specific mutations in TIMP3. Patients with SFD present with pathophysiology similar to the more common Age-related Macular Degeneration (AMD) and loss of vision due to both chomidal neovascularization and geographic atrophy. Previously, it has been shown that RPE degeneration in AMD is due in part to oxidative stress. We hypothesized that similar mechanisms may be at play in SFD. The objective of this study was to evaluate whether mice carrying the S179C-Timp3 mutation, a variant commonly observed in SFD, showed increased sensitivity to oxidative stress. Antioxidant genes are increased at baseline in the RPE in SFD mouse models, but not in the retina. This suggests the presence of a pro-oxidant environment in the RPE in the presence of Timp3 mutations. To determine if the RPE of Timp3 mutant mice is more susceptible to degeneration when exposed to low levels of oxidative stress, mice were injected with low doses of sodium iodate. The RPE and photoreceptors in Timp3 mutant mice degenerated at low doses of sodium iodate, which had no effect in wildtype control mice. These studies suggest that TIMP3 mutations may result in a dysregulation of pro-oxidant-antioxidant homeostasis in the RPE, leading to RPE degeneration in SFD.
C1 [Wolk, Alyson; Upadhyay, Mala; Ali, Mariya; Suh, Jason; Bonilha, Vera L.; Anand-Apte, Bela] Cleveland Clin Fdn, Dept Ophthalm Res, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Wolk, Alyson; Upadhyay, Mala; Ali, Mariya; Suh, Jason; Bonilha, Vera L.; Anand-Apte, Bela] Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Wolk, Alyson; Anand-Apte, Bela] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.
   [Stoehr, Heidi] Univ Regensburg, Inst Human Genet, 31 Univ Str, D-93053 Regensburg, Germany.
   [Bonilha, Vera L.; Anand-Apte, Bela] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Ophthalmol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western
   Reserve University; Cleveland Clinic Foundation; University of
   Regensburg; Case Western Reserve University; Cleveland Clinic Foundation
RP Anand-Apte, B (通讯作者)，Cleveland Clin Fdn, Dept Ophthalm Res, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.; Anand-Apte, B (通讯作者)，Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM anandab@ccf.org
RI Upadhyay, Mala/AAY-6667-2020; Bonilha, Vera/AAS-8566-2020
OI Upadhyay, Mala/0000-0002-0591-6515; Bonilha, Vera/0000-0002-6166-5124
FU US National Institute of Health [EY027083, EY026181, EY027750,
   P30EY025585, T32EY024236]; Research to Prevent Blindness (RPB) Challenge
   Grant; RPB Lew Wasserman award; Cleveland Eye Bank Foundation; Cleveland
   Clinic Foundation
FX This work was supported in part by US National Institute of Health
   EY027083 (BA-A), EY026181 (BA-A), EY027750 (VLB), P30EY025585 (BA-A),
   T32EY024236 (AW), Research to Prevent Blindness (RPB) Challenge Grant
   and RPB Lew Wasserman award to BA-A, Cleveland Eye Bank Foundation and
   funds from Cleveland Clinic Foundation. We thank Sujata Rao and her
   laboratory for kindly sharing their rhodopsin qPCR primer sequences. We
   wish to extend a sincere apology to colleagues whose work was not cited
   due to space limitations.
CR Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Barbazetto IA, 2005, ARCH OPHTHALMOL-CHIC, V123, P542, DOI 10.1001/archopht.123.4.542
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   Biswal MR, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21272
   Bonilha VL, 2018, ADV EXP MED BIOL, V1074, P3, DOI 10.1007/978-3-319-75402-4_1
   Bonilha VL, 2017, FREE RADICAL BIO MED, V104, P226, DOI 10.1016/j.freeradbiomed.2017.01.018
   Bresciani G, 2015, ADV CLIN CHEM, V68, P87, DOI 10.1016/bs.acc.2014.11.001
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040307
   Eggersdorfer M, 2018, ARCH BIOCHEM BIOPHYS, V652, P18, DOI 10.1016/j.abb.2018.06.001
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   Felbor U, 1997, ARCH OPHTHALMOL-CHIC, V115, P1569, DOI 10.1001/archopht.1997.01100160739011
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Huang B, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5489476
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Jian Q, 2015, VISION RES, V110, P107, DOI 10.1016/j.visres.2015.01.030
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   KALMUS H, 1976, J MED GENET, V13, P271, DOI 10.1136/jmg.13.4.271
   Kamei M, 1997, DEGENERATIVE RETINAL DISEASES, P11
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003
   Machalinska A, 2014, CURR EYE RES, V39, P1033, DOI 10.3109/02713683.2014.892996
   Machalinska A, 2013, EXP EYE RES, V112, P68, DOI 10.1016/j.exer.2013.04.004
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Martin-Nieto J, 2019, NEUROSCI LETT, V708, DOI 10.1016/j.neulet.2019.134361
   MCGINNIS JF, 1986, J NEUROSCI RES, V16, P157, DOI 10.1002/jnr.490160115
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641
   Perl K, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3683-9
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Qi JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53433-6
   Qi JH, 2009, J BIOL CHEM, V284, P19927, DOI 10.1074/jbc.M109.013763
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z
   Shao Y, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1479571
   Sies H., 1985, OXIDATIVE STRESS
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037
   Sies H, 2015, REDOX BIOL, V4, P180, DOI 10.1016/j.redox.2015.01.002
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/s004390050803
   Troeberg L, 2014, CHEM BIOL, V21, P1300, DOI 10.1016/j.chembiol.2014.07.014
   Upadhyay M, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101623
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yang YP, 2014, INVEST OPHTH VIS SCI, V55, P1696, DOI 10.1167/iovs.13-12477
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
NR 62
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD OCT
PY 2020
VL 37
AR 101681
DI 10.1016/j.redox.2020.101681
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA PO2NW
UT WOS:000605007400009
PM 32828705
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Xu, XY
   Wang, XL
   Sadda, SR
   Zhang, YH
AF Xu, Xiaoyu
   Wang, Xiaolin
   Sadda, SriniVas R.
   Zhang, Yuhua
TI Subtype-differentiated impacts of subretinal drusenoid deposits on
   photoreceptors revealed by adaptive optics scanning laser ophthalmoscopy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Subretinal drusenoid deposits; Dot;
   Ribbon; Photoreceptor; Imaging; Adaptive optics scanning laser
   ophthalmoscopy
ID RETICULAR PSEUDODRUSEN; MACULAR DEGENERATION; VISUAL-ACUITY; EYES;
   CHORIOCAPILLARIS; DISEASE; ATROPHY; SENSITIVITY; FEATURES
AB Purpose To examine the structure of photoreceptors surrounding two subtypes of subretinal drusenoid deposits (SDD), namely, dot and ribbon SDD, using multimodal imaging including adaptive optics scanning laser ophthalmoscopy (AOSLO) and spectral-domain optical coherence tomography (SD-OCT). Methods Twenty-six eyes of 13 patients with age-related macular degeneration (AMD) and SDD and 16 eyes of 8 subjects in normal chorioretinal health were studied. SDD presence, stage, and subtype were determined using color fundus photographs, infrared reflectance, autofluorescence imaging, and SD-OCT. SDD and surrounding photoreceptors were imaged using AOSLO. The structure of cone photoreceptors and SDD was examined at the baseline and at 2-year follow-up studies in 6 patients. Results Dot SDD were identified in 18 eyes of 9 patients and coexisting dot and ribbon SDD were observed in 8 eyes of 4 patients. While a characteristic photoreceptor mosaic was clearly revealed by AOSLO in the area unaffected by lesions in those eyes with dot-only SDD, in unaffected areas adjacent to retinal regions with predominantly ribbon SDD, photoreceptors could no longer be visualized. Conclusion The invisibility of the photoreceptor mosaic in unaffected areas adjacent to retinal regions with predominantly ribbon SDD suggests degeneration in the outer segment and the interdigitation zone, which impairs the waveguiding ability of the photoreceptors. Our study implies possible differentiation of disease outcome and functional impact in different types of SDD.
C1 [Xu, Xiaoyu; Wang, Xiaolin; Sadda, SriniVas R.; Zhang, Yuhua] UCL Med Sch, Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Xu, Xiaoyu] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Peoples R China.
C3 Doheny Eye Institute; Sun Yat Sen University
RP Zhang, YH (通讯作者)，UCL Med Sch, Doheny Eye Inst, Dept Ophthalmol, 1355 San Pablo St, Los Angeles, CA 90033 USA.
EM yzhang@doheny.org
FU NIH [R01EY024378]; National Natural Science Foundation of China
   [81800879]; Fundamental Research Funds of the State Key Laboratory of
   Ophthalmology, China [2018KF04, 2017QN05]; Natural Science Foundation of
   Guangdong Province [2017A030310372]
FX This project was supported by NIH R01EY024378. X. Xu is supported by
   funding from the National Natural Science Foundation of China
   (81800879), Fundamental Research Funds of the State Key Laboratory of
   Ophthalmology, China (2018KF04 & 2017QN05), and Natural Science
   Foundation of Guangdong Province (2017A030310372).
CR Agarwal A, 2015, AM J OPHTHALMOL, V160, P806, DOI 10.1016/j.ajo.2015.07.013
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Chen YM, 2011, INVEST OPHTH VIS SCI, V52, P3281, DOI 10.1167/iovs.10-6538
   Corvi F, 2019, RETINA-J RET VIT DIS, V39, P2378, DOI 10.1097/IAE.0000000000002335
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Liu ZL, 2015, BIOMED OPT EXPRESS, V6, P3378, DOI 10.1364/BOE.6.003378
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schick Tina, 2014, GMS Ophthalmol Cases, V4, pDoc06, DOI 10.3205/oc000019
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P12, DOI 10.1097/IAE.0000000000002362
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Vohnsen B, 2014, BIOMED OPT EXPRESS, V5, P1569, DOI 10.1364/BOE.5.001569
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zhang YH, 2020, OPHTHALMOL RETINA, V4, P274, DOI 10.1016/j.oret.2019.10.012
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 37
TC 4
Z9 4
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2020
VL 258
IS 9
BP 1931
EP 1940
DI 10.1007/s00417-020-04774-w
EA JUN 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ND8ON
UT WOS:000539392400002
PM 32488329
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Borras, C
   Canonica, J
   Jorieux, S
   Abache, T
   El Sanharawi, M
   Klein, C
   Delaunay, K
   Jonet, L
   Salvodelli, M
   Naud, MC
   Arsenijevic, Y
   Shalabi, A
   Souchaud, L
   Behar-Cohen, F
   Dinet, V
AF Borras, Celine
   Canonica, Jeremie
   Jorieux, Sylvie
   Abache, Toufik
   El Sanharawi, Mohamed
   Klein, Christophe
   Delaunay, Kimberley
   Jonet, Laurent
   Salvodelli, Michele
   Naud, Marie-Christine
   Arsenijevic, Yvan
   Shalabi, Andree
   Souchaud, Landry
   Behar-Cohen, Francine
   Dinet, Virginie
TI CFH exerts anti-oxidant effects on retinal pigment epithelial cells
   independently from protecting against membrane attack complex
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; OXIDATIVE STRESS;
   ANNEXIN-II; ACTIVATION; AMD; MALONDIALDEHYDE; RECOGNITION; LIPOFUSCIN;
   INCREASES
AB Age Related Macular Degeneration (AMD) is the first cause of social blindness in people aged over 65 leading to atrophy of retinal pigment epithelial cells (RPE), photoreceptors and choroids, eventually associated with choroidal neovascularization. Accumulation of undigested cellular debris within RPE cells or under the RPE (Drusen), oxidative stress and inflammatory mediators contribute to the RPE cell death. The major risk to develop AMD is the Y402H polymorphism of complement factor H (CFH). CFH interacting with oxidized phospholipids on the RPE membrane modulates the functions of these cells, but the exact role of CFH in RPE cell death and survival remain poorly understood. The aim of this study was to analyze the potential protective mechanism of CFH on RPE cells submitted to oxidative stress. Upon exposure to oxidized lipids 4-HNE (4-hydroxy-2-nonenal) derived from photoreceptors, both the human RPE cell line ARPE-19 and RPE cells derived from human induced pluripotent stem cells were protected from death only in the presence of the full length human recombinant CFH in the culture medium. This protective effect was independent from the membrane attack complex (MAC) formation. CFH maintained RPE cells tight junctions' structure and regulated the caspase dependent apoptosis process. These results demonstrated the CFH anti-oxidative stress functions independently of its capacity to inhibit MAC formation.
C1 [Borras, Celine; El Sanharawi, Mohamed; Klein, Christophe; Delaunay, Kimberley; Jonet, Laurent; Salvodelli, Michele; Naud, Marie-Christine; Souchaud, Landry; Behar-Cohen, Francine; Dinet, Virginie] Univ Pierre & Marie Curie Paris6, Ctr Rech Cordeliers, UMRS 872, F-75006 Paris, France.
   [Borras, Celine; El Sanharawi, Mohamed; Klein, Christophe; Delaunay, Kimberley; Jonet, Laurent; Salvodelli, Michele; Naud, Marie-Christine; Behar-Cohen, Francine; Dinet, Virginie] Univ Paris 05, UMR S 872, F-75006 Paris, France.
   [El Sanharawi, Mohamed; Klein, Christophe; Delaunay, Kimberley; Jonet, Laurent; Salvodelli, Michele; Naud, Marie-Christine; Behar-Cohen, Francine; Dinet, Virginie] INSERM, U1138, F-75006 Paris, France.
   [Borras, Celine] Univ Paris Diderot, F-75007 Paris, France.
   [Canonica, Jeremie; Arsenijevic, Yvan] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
   [Jorieux, Sylvie; Abache, Toufik] Lab Francais Fractionnement LFB, Paris, France.
   [Shalabi, Andree] Uniklin Frankfurt, Neurol & Neurochirurg, Frankfurt, Germany.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; UDICE-French Research Universities; Universite Paris Cite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; UDICE-French
   Research Universities; Universite Paris Cite; University of Lausanne
RP Dinet, V (通讯作者)，Univ Pierre & Marie Curie Paris6, Ctr Rech Cordeliers, UMRS 872, F-75006 Paris, France.; Dinet, V (通讯作者)，Univ Paris 05, UMR S 872, F-75006 Paris, France.; Dinet, V (通讯作者)，INSERM, U1138, F-75006 Paris, France.
EM virginie.dinet@inserm.fr
RI Raoult, Nathalie/AAH-3785-2020
OI Dinet, virginie/0000-0002-5458-0253; klein,
   christophe/0000-0001-8015-287X; Arsenijevic, Yvan/0000-0001-6960-1291;
   behar cohen, francine/0000-0001-8571-9513
FU Swiss National Science Foundation [320030_156401]; Ministere de la
   Recherche
FX Special thanks to the Ministere de la Recherche for supporting Dr.
   Celine Borras. Institut national de la sante et de la recherche medicale
   (CB); Grant #320030_156401 from the Swiss National Science Foundation
   (JC).
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Botto M, 2002, IMMUNOBIOLOGY, V205, P395, DOI 10.1078/0171-2985-00141
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Busch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00703
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krilis M, 2018, FREE RADICAL BIO MED, V129, P237, DOI 10.1016/j.freeradbiomed.2018.09.034
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Leffler J, 2010, J BIOL CHEM, V285, P3766, DOI 10.1074/jbc.M109.045427
   Letelier J, 2017, J NEUROGENET, V31, P203, DOI 10.1080/01677063.2017.1395876
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Martin M, 2016, CELL DEATH DIFFER, V23, P903, DOI 10.1038/cdd.2015.164
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Pangburn MK, 2002, J IMMUNOL, V169, P4702, DOI 10.4049/jimmunol.169.9.4702
   Perkins SJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00126
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Renner B, 2016, J IMMUNOL, V196, P1355, DOI 10.4049/jimmunol.1500793
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Singhal SS, 2015, TOXICOL APPL PHARM, V289, P361, DOI 10.1016/j.taap.2015.10.006
   Sokolov VS, 2007, J PHOTOCH PHOTOBIO B, V86, P177, DOI 10.1016/j.jphotobiol.2006.09.006
   Trouw LA, 2007, J BIOL CHEM, V282, P28540, DOI 10.1074/jbc.M704354200
   Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6
   WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 44
TC 30
Z9 31
U1 2
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 25
PY 2019
VL 9
AR 13873
DI 10.1038/s41598-019-50420-9
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JA1OP
UT WOS:000487586600064
PM 31554875
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Giacalone, JC
   Miller, MJ
   Workalemahu, G
   Reutzel, AJ
   Ochoa, D
   Whitmore, SS
   Stone, EM
   Tucker, BA
   Mullins, RF
AF Giacalone, Joseph C.
   Miller, Matthew J.
   Workalemahu, Grefachew
   Reutzel, Austin J.
   Ochoa, Dalyz
   Whitmore, S. Scott
   Stone, Edwin M.
   Tucker, Budd A.
   Mullins, Robert F.
TI Generation of an immortalized human choroid endothelial cell line
   (iChEC-1) using an endothelial cell specific promoter
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE Choroid; Endothelial cells; Immortalization; Macular degeneration; Eye
ID MACULAR DEGENERATION; GENE-EXPRESSION; DEDIFFERENTIATION;
   CHORIOCAPILLARIS; PREVALENCE
AB Age-related macular degeneration (AMD) is a common cause of blindness worldwide. While recent studies have revealed that the loss of choroidal endothelial cells (ChECs) is critical to the disease pathogenesis of dry AMD, in vitro studies are needed to fully elucidate the disease mechanism. However, these studies remain hindered due to the lack of publically available human ChEC lines. To address this need, ChECs were harvested form donor tissue and enriched for by using magnetic cell separation using anti-CD31 conjugated microbeads. Next, lenti-viral vectors with endothelial-specific promoters driving genes necessary for immortalization, CDH5p-hTERT and CDH5p TAg, were generated. Stable integration of both gene cassettes allowed cells to maintain their proliferative state and yielded an immortalized cell line (iChEC-1). Immunocytochemical analysis of iChEC-1 confirmed the expression of important ChEC markers such as CA4, a marker of choriocapillaris endothelial cells, CDHS, and CD34, pan-endothelial cell markers. qRT-PCR analysis of expanded clones from iChEC-1 further showed that the line maintained expression of other important endothelial markers, vWF, PECAM1, and PLVAP, similar to primary cells. Functional responses were characterized by tube-forming assays and repopulation of decellularized choroid with the immortalized cell line. In conclusion, the iChEC-1 line presents a suitable immortalized human ChEC line for future in vitro studies of AMD.
C1 Univ Iowa, Inst Vis Res, Iowa City, IA USA.
   Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA.
EM Robert-Mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Giacalone, Joseph/0000-0003-4404-9749; Whitmore, S.
   Scott/0000-0003-0161-9625; Mullins, Robert/0000-0002-5006-0891; Stone,
   Edwin M./0000-0003-3343-4414; Miller, Matthew/0000-0003-1329-088X;
   Tucker, Budd/0000-0003-2178-1742
FU NIH [EY024605, EY026087, P30 EY025580]; Research to Prevent Blindness;
   Elmer and Sylvia Sramek Charitable Foundation; NATIONAL EYE INSTITUTE
   [P30EY025580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER
FX Supported in part by: NIH grants EY024605, EY026087, P30 EY025580,
   Research to Prevent Blindness, and the Elmer and Sylvia Sramek
   Charitable Foundation.
CR Baba T, 2009, INVEST OPHTH VIS SCI, V50, P3503, DOI 10.1167/iovs.08-2614
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chirco KR, 2017, ACTA BIOMATER, V57, P293, DOI 10.1016/j.actbio.2017.05.011
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Green W. R, 2005, ZIMMERMAN LECT
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Iannilli F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066602
   Kyo S, 2003, AM J PATHOL, V163, P859, DOI 10.1016/S0002-9440(10)63446-3
   Lacorre DA, 2004, BLOOD, V103, P4164, DOI 10.1182/blood-2003-10-3537
   Lepreux S, 2008, ULTRASTRUCT PATHOL, V32, P178, DOI 10.1080/01913120802034504
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Loeven MA, 2018, INVEST OPHTH VIS SCI, V59, P722, DOI 10.1167/iovs.IOVS-17-22893
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Palanisamy K, 2019, MICROVASC RES, V122, P136, DOI 10.1016/j.mvr.2018.08.002
   Prandini MH, 2005, ONCOGENE, V24, P2992, DOI 10.1038/sj.onc.1208483
   R Core Team, 2017, R: A language and environment for statistical computing
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Salmon P, 2000, MOL THER, V2, P404, DOI 10.1006/mthe.2000.0141
   Schubert C, 2014, HUM MUTAT, V35, P859, DOI 10.1002/humu.22551
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   Songstad AE, 2017, STEM CELL TRANSL MED, V6, P1533, DOI 10.1002/sctm.16-0399
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Thum T, 2000, FASEB J, V14, P740, DOI 10.1096/fasebj.14.5.740
   Uhlmann S, 2001, MICROVASC RES, V62, P179, DOI 10.1006/mvre.2001.2334
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
NR 31
TC 12
Z9 12
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAY
PY 2019
VL 123
BP 50
EP 57
DI 10.1016/j.mvr.2018.12.002
PG 8
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA HN3JV
UT WOS:000460080500008
PM 30571950
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Park, B
   Corson, TW
AF Park, Bomina
   Corson, Timothy W.
TI Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the
   Future
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE soluble epoxide hydrolase; small molecule inhibitor; age-related macular
   degeneration; diabetic retinopathy; diabetic keratopathy; uveitis;
   angiogenesis
ID DOCOSAHEXAENOIC ACID; EPOXYEICOSATRIENOIC ACIDS; PPAR-GAMMA; IN-VITRO;
   METABOLITES; ANGIOGENESIS; VEGF; NEOVASCULARIZATION; TARGET;
   OMEGA-3-FATTY-ACIDS
AB Ocular diseases cause visual impairment and blindness, imposing a devastating impact on quality of life and a substantial societal economic burden. Many such diseases lack universally effective pharmacotherapies. Therefore, understanding the mediators involved in their pathophysiology is necessary for the development of therapeutic strategies. To this end, the hydrolase activity of soluble epoxide hydrolase (sEH) has been explored in the context of several eye diseases, due to its implications in vascular diseases through metabolism of bioactive epoxygenated fatty acids. In this mini-review, we discuss the mounting evidence associating sEH with ocular diseases and its therapeutic value as a target. Substantial data link sEH with the retinal and choroidal neovascularization underlying diseases such as wet age-related macular degeneration, retinopathy of prematurity, and proliferative diabetic retinopathy, although some conflicting results pose challenges for the synthesis of a common mechanism. sEH also shows therapeutic relevance in non-proliferative diabetic retinopathy and diabetic keratopathy, and sEH inhibition has been tested in a uveitis model. Various approaches have been implemented to assess sEH function in the eye, including expression analyses, genetic manipulation, pharmacological targeting of sEH, and modulation of certain lipid metabolites that are upstream and downstream of sEH. On balance, sEH inhibition shows considerable promise for treating multiple eye diseases. The possibility of local delivery of inhibitors makes the eye an appealing target for future sEH drug development initiatives.
C1 [Park, Bomina; Corson, Timothy W.] Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Park, Bomina; Corson, Timothy W.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
   [Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington
RP Corson, TW (通讯作者)，Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.; Corson, TW (通讯作者)，Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
EM tcorson@iu.edu
RI Corson, Timothy W./B-6851-2009
OI Corson, Timothy W./0000-0002-1402-7875
FU NIH/NEI [R01EY025641]; NIH/NCATS [UL1TR001108]; Retina Research
   Foundation; International Retinal Research Foundation; BrightFocus
   Foundation; Carl Marshall and Mildred Almen Reeves Foundation; Indiana
   Center for Biomedical Innovation; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR001108] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY025641] Funding Source: NIH RePORTER
FX Related work in the laboratory of TC was supported by NIH/NEI
   R01EY025641 and NIH/NCATS UL1TR001108, the Retina Research Foundation,
   the International Retinal Research Foundation, the BrightFocus
   Foundation, the Carl Marshall and Mildred Almen Reeves Foundation, and
   the Indiana Center for Biomedical Innovation.
CR Askari AA, 2014, BIOCHEM BIOPH RES CO, V446, P633, DOI 10.1016/j.bbrc.2014.03.020
   Basavarajappa HD, 2015, J MED CHEM, V58, P5015, DOI 10.1021/acs.jmedchem.5b00449
   Brady CJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010469.pub2
   BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P91
   Calder PC, 2010, NUTRIENTS, V2, P355, DOI 10.3390/nu2030355
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Capozzi ME, 2016, SCI REP-UK, V6, DOI 10.1038/srep39211
   Capozzi ME, 2014, INVEST OPHTH VIS SCI, V55, P4253, DOI 10.1167/iovs.14-14216
   CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8
   Chiu Kin, 2007, J Vis Exp, P313, DOI 10.3791/313
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Gong Y, 2017, AM J CLIN NUTR, V106, P16, DOI 10.3945/ajcn.117.153825
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Gong Y, 2016, ARTERIOSCL THROM VAS, V36, P1919, DOI 10.1161/ATVBAHA.116.307558
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Green W R, 1999, Mol Vis, V5, P27
   Guedes AGP, 2013, VET ANAESTH ANALG, V40, P440, DOI 10.1111/vaa.12030
   Hageman G. S, 2008, ORG RETINA VISUAL SY
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Harris TR, 2013, GENE, V526, P61, DOI 10.1016/j.gene.2013.05.008
   Hasegawa E, 2017, P NATL ACAD SCI USA, V114, pE7545, DOI 10.1073/pnas.1620898114
   Hellstrom M, 2007, CELL ADHES MIGR, V1, P133, DOI 10.4161/cam.1.3.4978
   Hu J, 2017, NATURE, V552, P248, DOI 10.1038/nature25013
   Hu J, 2014, J EXP MED, V211, P281, DOI 10.1084/jem.20131494
   Hwang SH, 2007, J MED CHEM, V50, P3825, DOI 10.1021/jm070270t
   Inceoglu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080922
   Inceoglu B, 2008, P NATL ACAD SCI USA, V105, P18901, DOI 10.1073/pnas.0809765105
   Kaji Y, 2005, BRIT J OPHTHALMOL, V89, P254, DOI 10.1136/bjo.2004.055541
   Kim CB, 2016, EYE BRAIN, V8, P67, DOI 10.2147/EB.S94447
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee J, 2016, DRUG METAB DISPOS, V44, P1675, DOI 10.1124/dmd.116.069369
   Lee KSS, 2014, J MED CHEM, V57, P7016, DOI 10.1021/jm500694p
   Li JL, 2009, FRONT BIOSCI-LANDMRK, V14, P3094, DOI 10.2741/3438
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Malamas A, 2017, INT J OPHTHALMOL-CHI, V10, P300, DOI 10.18240/ijo.2017.02.19
   McLellan Gillian J, 2016, J Ocul Biol, V4, DOI 10.13188/2334-2838.1000024
   Michaelis UR, 2008, INVEST OPHTH VIS SCI, V49, P1242, DOI 10.1167/iovs.07-1087
   Minaz N, 2018, PROSTAG OTH LIPID M, V136, P84, DOI 10.1016/j.prostaglandins.2018.05.004
   Moghaddam-Taaheri S., 2011, J CLIN EXP OPHTHALMO, V2, P187, DOI DOI 10.4172/2155-9570.1000187
   Morisseau C, 2010, J LIPID RES, V51, P3481, DOI 10.1194/jlr.M006007
   Oltman CL, 1998, CIRC RES, V83, P932
   Panigrahy D, 2013, P NATL ACAD SCI USA, V110, P13528, DOI 10.1073/pnas.1311565110
   Panigrahy D, 2012, J CLIN INVEST, V122, P178, DOI 10.1172/JCI58128
   Podolin PL, 2013, PROSTAG OTH LIPID M, V104, P25, DOI 10.1016/j.prostaglandins.2013.02.001
   Pozzi A, 2005, J BIOL CHEM, V280, P27138, DOI 10.1074/jbc.M501730200
   Querques G, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/748361
   Rand AA, 2017, P NATL ACAD SCI USA, V114, P4370, DOI 10.1073/pnas.1616893114
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rose TE, 2010, J MED CHEM, V53, P7067, DOI 10.1021/jm100691c
   Scott A, 2010, EYE, V24, P416, DOI 10.1038/eye.2009.306
   Shao Z, 2014, ARTERIOSCL THROM VAS, V34, P581, DOI 10.1161/ATVBAHA.113.302927
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Shen HC, 2012, J MED CHEM, V55, P1789, DOI 10.1021/jm201468j
   Shen HC, 2009, BIOORG MED CHEM LETT, V19, P5716, DOI 10.1016/j.bmcl.2009.08.006
   Stahl A, 2010, AM J PATHOL, V177, P2715, DOI 10.2353/ajpath.2010.100526
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4
   STINSON AM, 1991, J LIPID RES, V32, P2009
   Sulaiman RS, 2018, ACS CHEM BIOL, V13, P45, DOI 10.1021/acschembio.7b00854
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Sun HJ, 2018, DIABETES, V67, P1162, DOI 10.2337/db17-1336
   Wagner K, 2014, PROSTAG OTH LIPID M, V113, P2, DOI 10.1016/j.prostaglandins.2014.09.001
   Wang FL, 2018, MOL CANCER THER, V17, P474, DOI 10.1158/1535-7163.MCT-16-0818
   Xu DY, 2013, INT J CARDIOL, V167, P1298, DOI 10.1016/j.ijcard.2012.03.167
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   Yang YM, 2018, P NATL ACAD SCI USA, V115, P613, DOI 10.1073/pnas.1716016115
   Ye D, 2002, J PHARMACOL EXP THER, V303, P768, DOI 10.1124/jpet.303.2.768
   Zhang GD, 2014, PROG LIPID RES, V53, P108, DOI 10.1016/j.plipres.2013.11.003
   Zhang GD, 2013, P NATL ACAD SCI USA, V110, P6530, DOI 10.1073/pnas.1304321110
   Zhang YD, 2001, AM J PHYSIOL-HEART C, V280, pH2430, DOI 10.1152/ajpheart.2001.280.6.H2430
   Zhou Y, 2017, SHOCK, V47, P638, DOI 10.1097/SHK.0000000000000767
NR 76
TC 10
Z9 10
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 7
PY 2019
VL 10
AR 95
DI 10.3389/fphar.2019.00095
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HK6CQ
UT WOS:000458057700001
PM 30792659
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yamagishi, S
   Matsui, T
AF Yamagishi, Sho-ichi
   Matsui, Takanori
TI Therapeutic Potentia of DNA-aptamers Raised Against AGE-RAGE Axis in
   Diabetes-related Complications
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE AGEs; RAGE; oxidative stress; aging; aptamer; atherosclerotic
   cardiovascular disease
ID GLYCATION END-PRODUCTS; ENDOTHELIAL GROWTH-FACTOR; INHIBITS NEOINTIMAL
   HYPERPLASIA; CULTURED RETINAL PERICYTES; VASCULAR COMPLICATIONS;
   CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS; MAILLARD REACTION;
   MINERALOCORTICOID RECEPTOR; CARDIOMETABOLIC DISORDERS
AB Accumulating evidence has indicated that formation and accumulation of advanced glycation end products (AGEs) progress under diabetic conditions, thereby contributing to the development and progression of various diabetes- and aging-related disorders, such as diabetic nephropathy, diabetic retinopathy, atherosclerotic cardiovascular disease, insulin resistance, cancer growth and metastasis, osteoporosis, and Alzheimer's disease. Modification of proteins, lipids and nucleic acids by AGEs alter their structural integrity and function, and evoke oxidative stress generation and inflammatory reactions through the interaction with a receptor for AGEs (RAGE), being involved in the above-mentioned devastating disorders. These observations suggest that inhibition of the AGE-RAGE axis is a novel therapeutic target for diabetes- and aging-related complications. Aptamers are short single-stranded RNA or DNA oligonucleotides that can bind to numerous types of proteins with high specificity and affinity, and some type of aptamer raised against vascular endothelial growth factor has been approved for the treatment of patients with neovascular age-related macular degeneration. Since aptamers can be easily generated and highly penetrated into various organs with a low risk of allergic reactions, they may be superior to antibodies for neutralizing and/or blocking target proteins or cell surface receptors. Therefore, in this review, we describe the therapeutic potential of DNA-aptamers raised against the AGE-RAGE axis in diabetes-associated complications, especially focusing on vascular complications of diabetes and cancer.
C1 [Yamagishi, Sho-ichi; Matsui, Takanori] Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.
C3 Kurume University
RP Yamagishi, S (通讯作者)，Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.
EM shoichi@med.kurume-u.ac.jp
OI Matsui, Takanori/0000-0001-9506-7571
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [17K08968]
FX This study was supported in part by Grants-in-Aid for Scientific
   Research (Grant Number 17K08968) (SY) from the Ministry of Education,
   Culture, Sports, Science and Technology, Japan.
CR Abe R, 2004, J INVEST DERMATOL, V122, P461, DOI 10.1046/j.0022-202X.2004.22218.x
   Agalou S, 2005, J AM SOC NEPHROL, V16, P1471, DOI 10.1681/ASN.2004080635
   Ahmad S, 2018, SEMIN CANCER BIOL, V49, P9, DOI 10.1016/j.semcancer.2017.10.012
   Amano S, 2002, BIOCHEM BIOPH RES CO, V299, P183, DOI 10.1016/S0006-291X(02)02584-6
   Barile GR, 2005, INVEST OPHTH VIS SCI, V46, P2916, DOI 10.1167/iovs.04-1409
   Bennett MR, 2001, PHARMACOL THERAPEUT, V91, P149, DOI 10.1016/S0163-7258(01)00153-X
   Berezin A, 2016, DIABETES METAB SYND, V10, pS176, DOI 10.1016/j.dsx.2016.03.016
   Burstein AH, 2018, JPAD-J PREV ALZHEIM, V5, P149, DOI 10.14283/jpad.2018.18
   Capitao M, 2016, J CELL BIOCHEM, V117, P2443, DOI 10.1002/jcb.25575
   Chung YR, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/1763292
   Della Corte V, 2016, CURR PHARM DESIGN, V22, P4658, DOI 10.2174/1381612822666160510124801
   Diabetes IDF, 2017, ATL 8 ED
   Engelen L, 2013, DIABETES OBES METAB, V15, P677, DOI 10.1111/dom.12058
   Evans JMM, 2002, BRIT MED J, V324, P939, DOI 10.1136/bmj.324.7343.939
   Famulok M, 2007, CHEM REV, V107, P3715, DOI 10.1021/cr0306743
   Fletcher EL, 2007, CURR PHARM DESIGN, V13, P2699, DOI 10.2174/138161207781662920
   Fukami K, 2014, CURR PHARM DESIGN, V20, P2395, DOI 10.2174/13816128113199990475
   Gomez-Sanchez CE, 2006, ENDOCRINOLOGY, V147, P1343, DOI 10.1210/en.2005-0860
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gubitosi-Klug RA, 2016, DIABETES CARE, V39, P686, DOI 10.2337/dc15-1990
   Guglielmotto M, 2012, AGING-US, V33
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Higashimoto Y, 2013, MICROVASC RES, V90, P64, DOI 10.1016/j.mvr.2013.08.010
   Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470
   Ide Y, 2010, MICROVASC RES, V80, P227, DOI 10.1016/j.mvr.2010.03.015
   Ishibashi Y, 2013, HORM METAB RES, V45, P387, DOI 10.1055/s-0032-1331204
   Ishibashi Y, 2017, DIABETES VASC DIS RE, V14, P450, DOI 10.1177/1479164117715855
   Ishibashi Y, 2014, INT J CARDIOL, V176, P1120, DOI 10.1016/j.ijcard.2014.07.299
   Jha JC, 2016, ANTIOXID REDOX SIGN, V25, P657, DOI 10.1089/ars.2016.6664
   Jilma-Stohlawetz P, 2011, THROMB HAEMOSTASIS, V106, P539, DOI 10.1160/TH11-02-0069
   Kaida Y, 2013, DIABETES, V62, P3241, DOI 10.2337/db12-1608
   Kajikawa M, 2015, DIABETES CARE, V38, P119, DOI 10.2337/dc14-1435
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kim J, 2012, FREE RADICAL BIO MED, V53, P357, DOI 10.1016/j.freeradbiomed.2012.04.030
   Koga M, 2008, BIOCHEM BIOPH RES CO, V365, P279, DOI 10.1016/j.bbrc.2007.10.182
   Levitzki A, 2005, CARDIOVASC RES, V65, P581, DOI 10.1016/j.cardiores.2004.08.008
   Li P, 2013, CARDIOVASC RES, V99, P185, DOI 10.1093/cvr/cvt082
   Loukine L, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-7
   LU L, 2018, J OPHTHALMOL, V2018, DOI DOI 10.1155/2018/1694187
   Maeda S, 2015, OPHTHALMIC RES, V54, P175, DOI 10.1159/000440768
   Maeda S, 2014, NUTR RES, V34, P807, DOI 10.1016/j.nutres.2014.08.010
   Markus HS, 2011, STROKE, V42, P2149, DOI 10.1161/STROKEAHA.111.616649
   Matsui T, 2017, DIABETES, V66, P1683, DOI 10.2337/db16-1281
   Matsui T, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-014-0162-3
   Matsui T, 2010, BIOCHEM BIOPH RES CO, V396, P566, DOI 10.1016/j.bbrc.2010.04.149
   MIKI S, 1993, BIOCHEM BIOPH RES CO, V196, P984, DOI 10.1006/bbrc.1993.2346
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Monnier VM, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0266-4
   MONNIER VM, 1990, J GERONTOL, V45, pB105, DOI 10.1093/geronj/45.4.B105
   Nagase M, 2007, HYPERTENSION, V50, P877, DOI 10.1161/HYPERTENSIONAHA.107.091058
   Nakamara N, 2017, MOL MED, V23, P295, DOI 10.2119/molmed.2017.00099
   Nakamura K, 2007, AM J PATHOL, V170, P2159, DOI 10.2353/ajpath.2007.060838
   Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187
   Ojima A, 2015, HORM METAB RES, V47, P253, DOI 10.1055/s-0034-1385904
   Ojima A, 2014, LAB INVEST, V94, P422, DOI 10.1038/labinvest.2014.5
   Ojima A, 2014, INT J CARDIOL, V171, P443, DOI 10.1016/j.ijcard.2013.12.143
   Orchard TJ, 2015, JAMA-J AM MED ASSOC, V313, P45, DOI 10.1001/jama.2014.16107
   Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0
   Parashar A, 2016, J CLIN DIAGN RES, V10, pBE1, DOI 10.7860/JCDR/2016/18712.7922
   Pechlivani N, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00001
   Pleva L, 2018, J GERIATR CARDIOL, V15, P173, DOI 10.11909/j.issn.1671-5411.2018.02.007
   Rabbani N, 2018, KIDNEY INT, V93, P803, DOI 10.1016/j.kint.2017.11.034
   Reddy VP, 2006, DRUG DISCOV TODAY, V11, P646, DOI 10.1016/j.drudis.2006.05.016
   Rhodes ET, 2012, DIABETIC MED, V29, P453, DOI 10.1111/j.1464-5491.2011.03542.x
   Rojas A, 2018, CARCINOGENESIS, V39, P515, DOI 10.1093/carcin/bgy012
   Salven P, 1997, BRIT J CANCER, V76, P930, DOI 10.1038/bjc.1997.486
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Schmidt A M, 2000, Curr Atheroscler Rep, V2, P430, DOI 10.1007/s11883-000-0082-4
   Schmidt AM, 2017, ARTERIOSCL THROM VAS, V37, P613, DOI 10.1161/ATVBAHA.117.307263
   Segawa Y, 1998, OPHTHALMIC RES, V30, P333, DOI 10.1159/000055493
   Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862
   Sharma A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00114
   Shi L, 2010, J INT MED RES, V38, P1276, DOI 10.1177/147323001003800409
   Soro-Paavonen A, 2008, DIABETES, V57, P2461, DOI 10.2337/db07-1808
   Stattin P, 2007, DIABETES CARE, V30, P561, DOI 10.2337/dc06-0922
   Taguchi K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21176-5
   Tahara N, 2012, DIABETES CARE, V35, P2618, DOI 10.2337/dc12-0087
   Tahara N, 2012, CARDIOVASC THER, V30, P42, DOI 10.1111/j.1755-5922.2010.00177.x
   Takino JI, 2010, J ONCOL, V2010, DOI 10.1155/2010/739852
   Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M
   Turin TC, 2012, DIABETES RES CLIN PR, V96, pE18, DOI 10.1016/j.diabres.2012.01.003
   Unoki H, 2008, CURR PHARM DESIGN, V14, P987, DOI 10.2174/138161208784139747
   Unoki H, 2007, DIABETES RES CLIN PR, V76, P236, DOI 10.1016/j.diabres.2006.09.016
   Unoki-Kubota H, 2010, PROTEIN PEPTIDE LETT, V17, P1177, DOI 10.2174/092986610791760423
   Usui T, 2003, BIOSCI BIOTECH BIOCH, V67, P930, DOI 10.1271/bbb.67.930
   Usui T, 2007, BIOSCI BIOTECH BIOCH, V71, P442, DOI 10.1271/bbb.60497
   Usui T, 2006, BIOSCI BIOTECH BIOCH, V70, P1496, DOI 10.1271/bbb.50584
   Valdez CN, 2014, AM J PATHOL, V184, P2618, DOI 10.1016/j.ajpath.2014.06.011
   Vavalle JP, 2012, FUTUR CARDIOL, V8, P371, DOI [10.2217/fca.12.5, 10.2217/FCA.12.5]
   Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087
   Vlassara H, 2013, ENDOCRIN METAB CLIN, V42, P697, DOI 10.1016/j.ecl.2013.07.005
   Wakisaka M, 2017, GLYCOBIOLOGY, V27, P691, DOI 10.1093/glycob/cwx047
   Wannamethee SG, 2011, ARCH INTERN MED, V171, P404, DOI 10.1001/archinternmed.2011.2
   Ward MS, 2013, CURR OPIN PHARMACOL, V13, P654, DOI 10.1016/j.coph.2013.06.009
   Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089
   Yamagishi S, 2005, CURR PHARM DESIGN, V11, P2279, DOI 10.2174/1381612054367300
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3
   YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V190, P418, DOI 10.1006/bbrc.1993.1064
   Yamagishi SI, 2008, EXPERT OPIN INV DRUG, V17, P983, DOI [10.1517/13543784.17.7.983, 10.1517/13543784.17.7.983 ]
   Yamagishi S, 2008, CURR MED CHEM, V15, P172, DOI 10.2174/092986708783330557
   Yamagishi S, 2006, J BIOL CHEM, V281, P20213, DOI 10.1074/jbc.M602110200
   Yamagishi S, 2017, CURR PHARM DESIGN, V23, P1135, DOI 10.2174/1381612822666161021155502
   Yamagishi S, 2017, J DIABETES, V9, P141, DOI 10.1111/1753-0407.12475
   Yamagishi SI, 2016, PHARM BIOL, V54, P2329, DOI 10.3109/13880209.2016.1138314
   Yamagishi S, 2016, GLYCOCONJUGATE J, V33, P683, DOI 10.1007/s10719-016-9682-2
   Yamagishi S, 2016, REJUV RES, V19, P107, DOI 10.1089/rej.2015.1738
   Yamagishi S, 2016, NUTRITION, V32, P157, DOI 10.1016/j.nut.2015.08.001
   Yamagishi S, 2015, MOL MED, V21, pS32, DOI 10.2119/molmed.2015.00067
   Yamagishi S, 2015, INT J CARDIOL, V185, P263, DOI 10.1016/j.ijcard.2015.03.167
   Yamagishi S, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0090-z
   Yamagishi S, 2015, REJUV RES, V18, P48, DOI 10.1089/rej.2014.1625
   Yamagishi S, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0176-5
   Yamagishi S, 2012, REJUV RES, V15, P564, DOI 10.1089/rej.2012.1335
   Yamagishi S, 2011, CURR DRUG TARGETS, V12, P2096, DOI 10.2174/138945011798829456
   Yamagishi S, 2011, CURR PHARM BIOTECHNO, V12, P362, DOI 10.2174/138920111794480534
   Yamagishi Sho-ichi, 2010, Front Biosci (Elite Ed), V2, P1184
   Yamagishi S, 2010, CURR DRUG TARGETS, V11, P875, DOI 10.2174/138945010791320827
   YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185
   Yamamoto Y, 1996, BIOCHEM BIOPH RES CO, V222, P700, DOI 10.1006/bbrc.1996.0807
   Yang F, 2015, STROKE, V46, P1328, DOI 10.1161/STROKEAHA.114.008336
NR 120
TC 22
Z9 22
U1 1
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2018
VL 24
IS 24
BP 2802
EP 2809
DI 10.2174/1381612824666180829110124
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GZ6YH
UT WOS:000449618500008
PM 30156152
DA 2022-11-30
ER

PT J
AU Sun, Y
   Lin, ZQ
   Liu, CH
   Gong, Y
   Liegl, R
   Fredrick, TW
   Meng, SS
   Burnim, SB
   Wang, ZX
   Akula, JD
   Pu, WT
   Chen, J
   Smith, LEH
AF Sun, Ye
   Lin, Zhiqiang
   Liu, Chi-Hsiu
   Gong, Yan
   Liegl, Raffael
   Fredrick, Thomas W.
   Meng, Steven S.
   Burnim, Samuel B.
   Wang, Zhongxiao
   Akula, James D.
   Pu, William T.
   Chen, Jing
   Smith, Lois E. H.
TI Inflammatory signals from photoreceptor modulate pathological retinal
   angiogenesis via c-Fos
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; OCULAR IMMUNE PRIVILEGE;
   MACULAR DEGENERATION; PLASMINOGEN-ACTIVATOR; SUBRETINAL MICROGLIA;
   GENE-EXPRESSION; TRANSGENIC MICE; MOUSE MODEL; IN-VIVO; CELLS
AB Pathological neovessels growing into the normally avascular photoreceptors cause vision loss in many eye diseases, such as age-related macular degeneration and macular telangiectasia. Ocular neovascularization is strongly associated with inflammation, but the source of inflammatory signals and the mechanisms by which these signals regulate the disruption of avascular privilege in photoreceptors are unknown. In this study, we found that c-Fos, a master inflammatory regulator, was increased in photoreceptors in a model of pathological blood vessels invading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-/-)) mouse. Increased c-Fos induced inflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor (TNF), leading to activation of signal transducer and activator of transcription 3 (STAT3) and increased TNF alpha-induced protein 3 (TNF AIP3) in Vldlr(-/-) photoreceptors. IL-6 activated the STAT3/vascular endothelial growth factor A (VEGFA) pathway directly, and elevated TNF AIP3 suppressed SOCS3 (suppressor of cytokine signaling 3)-activated STAT3/VEG FA indirectly. Inhibition of c-Fos using photoreceptor-specific AAV (adeno-associated virus)-hRK (human rhodopsin kinase)-sh_c-fos or a chemical inhibitor substantially reduced the pathological neovascularization and rescued visual function in Vldlr(-/-) mice. These findings suggested that the photoreceptor c-Fos controls blood vessel growth into the normally avascular photoreceptor layer through the inflammatory signal-induced STAT3/VEG FA pathway.
C1 [Sun, Ye; Liu, Chi-Hsiu; Gong, Yan; Liegl, Raffael; Fredrick, Thomas W.; Meng, Steven S.; Burnim, Samuel B.; Wang, Zhongxiao; Akula, James D.; Chen, Jing; Smith, Lois E. H.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
   [Lin, Zhiqiang; Pu, William T.] Harvard Med Sch, Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
   [Pu, William T.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University
RP Smith, LEH (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
EM lois.smith@childrens.harvard.edu
RI Pu, William/AAJ-8301-2020; Lin, Zhiqiang/ABC-7029-2020
OI Pu, William/0000-0002-4551-8079; Akula, James/0000-0001-8049-1812; Gong,
   Yan/0000-0002-4805-0459; Sun, Ye/0000-0002-7674-9056; Smith,
   Lois/0000-0001-7644-6410; Lin, zhiqiang/0000-0002-2034-2492
FU National Institutes of Health/National Eye Institute [EY024864,
   EY017017, P01 HD18655, R01 EY024963]; Lowy Medical Research Institute
   [84134]; European Commission [305485]; American Heart Association
   [15SDG25590001]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD
   HEALTH & HUMAN DEVELOPMENT [P30HD018655, U54HD090255] Funding Source:
   NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY024864, R01EY024963,
   R01EY017017] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health/National
   Eye Institute (grants EY024864, EY017017, and P01 HD18655), Lowy Medical
   Research Institute (project 84134), and European Commission Seventh
   Framework Programme (project 305485 for L.E.H. Smith) and by the
   National Institutes of Health/National Eye Institute (grant R01
   EY024963) for J. Chen and the American Heart Association (Scientist
   Development Grant 15SDG25590001) for Z. Lin.
CR Aikawa Y, 2008, NAT BIOTECHNOL, V26, P817, DOI 10.1038/nbt1412
   ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Balasubramanian SA, 2014, TRANSL RES, V164, P179, DOI 10.1016/j.trsl.2014.04.005
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Catar R, 2013, KIDNEY INT, V84, P1119, DOI 10.1038/ki.2013.217
   Chen J, 2011, CIRCULATION, V124, P1871, DOI 10.1161/CIRCULATIONAHA.111.040337
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4
   da Silva CG, 2013, HEPATOLOGY, V57, P2014, DOI 10.1002/hep.26197
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0
   Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207
   Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346
   HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   HOFFMAN GE, 1993, FRONT NEUROENDOCRIN, V14, P173, DOI 10.1006/frne.1993.1006
   HOOD DC, 1994, INVEST OPHTH VIS SCI, V35, P2948
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Khani SC, 2007, INVEST OPHTH VIS SCI, V48, P3954, DOI 10.1167/iovs.07-0257
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P76, DOI 10.1001/archopht.122.1.76
   Kueng-Hitz N, 2000, INVEST OPHTH VIS SCI, V41, P909
   LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111
   Lee YN, 2004, J IMMUNOL, V173, P2571, DOI 10.4049/jimmunol.173.4.2571
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Margetts PJ, 2002, AM J PATHOL, V160, P2285, DOI 10.1016/S0002-9440(10)61176-5
   Masli S, 2011, METHODS MOL BIOL, V677, P449, DOI 10.1007/978-1-60761-869-0_28
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   McKay S, 2001, MEDIAT INFLAMM, V10, P135, DOI 10.1080/09629350120072707
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   NIR I, 1993, MOL BRAIN RES, V19, P47, DOI 10.1016/0169-328X(93)90147-H
   Ohki K, 1996, VISION RES, V36, P1883, DOI 10.1016/0042-6989(95)00284-7
   Park YK, 2008, NUCLEIC ACIDS RES, V36, pW97, DOI 10.1093/nar/gkn280
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Ray N, 2006, INT IMMUNOL, V18, P671, DOI 10.1093/intimm/dxl004
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Shiozawa S, 2009, CELL CYCLE, V8, P1539, DOI 10.4161/cc.8.10.8411
   Stahl A, 2009, ANGIOGENESIS, V12, P297, DOI 10.1007/s10456-009-9155-3
   Streilein JW, 2002, DNA CELL BIOL, V21, P453, DOI 10.1089/10445490260099746
   STREILEIN JW, 1995, EYE, V9, P236, DOI 10.1038/eye.1995.46
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Sun Y, 2015, ARCHAEA, V2015, DOI 10.1155/2015/397924
   Sung HJ, 2012, MOL VIS, V18, P234
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   Vandenberghe LH, 2010, HUM GENE THER, V21, P1251, DOI 10.1089/hum.2010.107
   Velazquez FN, 2015, ONCOTARGET, V6, P16883, DOI 10.18632/oncotarget.4527
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105-2896.2005.00332.x
   Wang S, 2014, DEV CELL, V30, P513, DOI 10.1016/j.devcel.2014.07.018
   Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741
   Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122
   Wei XB, 2014, ONCOL REP, V31, P335, DOI 10.3892/or.2013.2858
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   YOSHIDA K, 1993, NEURON, V10, P1049, DOI 10.1016/0896-6273(93)90053-T
   Zhang N, 2013, INVEST OPHTH VIS SCI, V54, P8275, DOI 10.1167/iovs.13-12544
NR 69
TC 43
Z9 44
U1 0
U2 10
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD JUN
PY 2017
VL 214
IS 6
BP 1753
EP 1767
DI 10.1084/jem.20161645
PG 15
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA EW9TW
UT WOS:000402863300017
PM 28465464
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Fang, Y
   Su, T
   Qiu, XR
   Mao, PA
   Xu, YD
   Hu, ZZ
   Zhang, Y
   Zheng, XH
   Xie, P
   Liu, QH
AF Fang, Yuan
   Su, Tu
   Qiu, Xiaorong
   Mao, Pingan
   Xu, Yidan
   Hu, Zizhong
   Zhang, Yi
   Zheng, Xinhua
   Xie, Ping
   Liu, Qinghuai
TI Protective effect of alpha-mangostin against oxidative stress
   induced-retinal cell death
SO SCIENTIFIC REPORTS
LA English
DT Article
ID AGE-RELATED MACULOPATHY; FREE-RADICAL SCAVENGER; MACULAR DEGENERATION;
   GARCINIA-MANGOSTANA; ANTIOXIDANT ENZYMES; MECHANISMS; XANTHONES; DAMAGE;
   NEUROPROTECTION; SUNLIGHT
AB It is known that oxidative stress plays a pivotal role in age-related macular degeneration (AMD) pathogenesis. Alpha-mangostin is the main xanthone purified from mangosteen known as anti-oxidative properties. The aim of the study was to test the protective effect of alpha-mangostin against oxidative stress both in retina of light-damaged mice model and in hydrogen peroxide (H2O2)-stressed RPE cells. We observed that alpha-mangostin significantly inhibited light-induced degeneration of photoreceptors and 200 mu M H2O2-induced apoptosis of RPE cells. 200 mu M H2O2-induced generation of reactive oxygen species (ROS) and light-induced generation of malondialdehyde (MDA) were suppressed by alpha-mangostin. Alpha-mangostin stimulation resulted in an increase of superoxide dismutase (SOD) activity, glutathione peroxidase (GPX) activity and glutathione (GSH) content both in vivo and vitro. Furthermore, the mechanism of retinal protection against oxidative stress by alpha-mangostin involves accumulation and the nuclear translocation of the NF-E2-related factor (Nrf2) along with up-regulation the expression of heme oxygenas-1 (HO-1). Meanwhile, alpha-mangostin can activate the expression of PKC-delta and down-regulate the expression of mitogen-activated protein kinases (MAPKs), including ERK1/2, JNK, P38. The results suggest that alpha-mangostin could be a new approach to suspend the onset and development of AMD.
C1 [Fang, Yuan; Su, Tu; Qiu, Xiaorong; Mao, Pingan; Xu, Yidan; Hu, Zizhong; Zhang, Yi; Zheng, Xinhua; Xie, Ping; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Xie, P; Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
EM xieping9@126.com; liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964; hu, zizhong/0000-0001-6289-1804; Xie,
   Ping/0000-0003-4257-8970
FU National Basic Research Program of China (973 Program) [2013CB967500,
   2011CB510200]; General Project of the National Natural Science Fund
   [81170855]; Jiangsu Provincial Special Program of Medical Science
   [BL2014089]; Six talent peaks project in Jiangsu Province [2013-WSW-015]
FX This research was supported by the National Basic Research Program of
   China (973 Program, No. 2013CB967500 and No. 2011CB510200), General
   Project of the National Natural Science Fund (No. 81170855), Jiangsu
   Provincial Special Program of Medical Science (BL2014089) and Six talent
   peaks project in Jiangsu Province (2013-WSW-015).
CR Akao Y, 2008, INT J MOL SCI, V9, P355, DOI 10.3390/ijms9030355
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Buelna-Chontal M, 2014, FREE RADICAL BIO MED, V74, P145, DOI 10.1016/j.freeradbiomed.2014.06.021
   Catala Angel, 2011, Front Biosci (Schol Ed), V3, P52, DOI 10.2741/s131
   Chen LG, 2008, FOOD CHEM TOXICOL, V46, P688, DOI 10.1016/j.fct.2007.09.096
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Guo CX, 2015, INT J NANOMED, V10, P1463, DOI 10.2147/IJN.S76114
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jiang Gang, 2014, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V39, P687, DOI 10.11817/j.issn.1672-7347.2014.07.006
   Jung HA, 2006, J AGR FOOD CHEM, V54, P2077, DOI 10.1021/jf052649z
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Lawwill T, 1982, Trans Am Ophthalmol Soc, V80, P517
   Mahabusarakam W, 2000, FREE RADICAL RES, V33, P643, DOI 10.1080/10715760000301161
   Maines MD, 2004, ANTIOXID REDOX SIGN, V6, P797, DOI 10.1089/ars.2004.6.797
   Reyes-Fermin LM, 2012, NUTR NEUROSCI, V15, P34, DOI 10.1179/1476830512Y.0000000011
   Marquez-Valadez B, 2009, NUTR NEUROSCI, V12, P35, DOI 10.1179/147683009X388850
   Martinez A, 2011, J PHYS CHEM B, V115, P12591, DOI 10.1021/jp205496u
   Nelli GB, 2013, SYST BIOL REPROD MED, V59, P319, DOI 10.3109/19396368.2013.820369
   Niture SK, 2014, FREE RADICAL BIO MED, V66, P36, DOI 10.1016/j.freeradbiomed.2013.02.008
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Pedraza-Chaverri J, 2009, EXP TOXICOL PATHOL, V61, P491, DOI 10.1016/j.etp.2008.11.002
   Perez-Rojas JM, 2009, FREE RADICAL RES, V43, P1122, DOI 10.1080/10715760903214447
   Sampath PD, 2007, J BIOCHEM MOL TOXIC, V21, P336, DOI 10.1002/jbt.20199
   Sidahmed HMA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/450840
   Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978-0-12-405881-1.00002-1
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tso M O, 1987, Trans Am Ophthalmol Soc, V85, P498
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Yang B, 2013, EXPERT OPIN THER TAR, V17, P255, DOI 10.1517/14728222.2013.745513
   Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003
   Zhao MY, 2015, AM J PHYSIOL-CELL PH, V308, pC665, DOI 10.1152/ajpcell.00369.2014
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P3941, DOI 10.1167/iovs.13-11598
NR 40
TC 71
Z9 74
U1 0
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 18
PY 2016
VL 6
AR 21018
DI 10.1038/srep21018
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DE1BY
UT WOS:000370362200001
PM 26888416
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bernstein, PS
   Li, BX
   Vachali, PP
   Gorusupudi, A
   Shyam, R
   Henriksen, BS
   Nolan, JM
AF Bernstein, Paul S.
   Li, Binxing
   Vachali, Preejith P.
   Gorusupudi, Aruna
   Shyam, Rajalekshmy
   Henriksen, Bradley S.
   Nolan, John M.
TI Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science
   underlying carotenoid-based nutritional interventions against ocular
   disease
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Carotenoid; Lutein; Zeaxanthin; Macular pigment; Nutrition; Age-related
   macular degeneration
ID PIGMENT OPTICAL-DENSITY; AGE-RELATED MACULOPATHY; HETEROCHROMATIC
   FLICKER PHOTOMETRY; SUPPLEMENTAL MACULAR CAROTENOIDS; STRUCTURALLY
   RELATED-COMPOUNDS; RESONANCE RAMAN MEASUREMENT; GLUTATHIONE
   S-TRANSFERASES; ACTIVE NATURAL CAROTENOIDS; BETA-CAROTENE; SCAVENGER
   RECEPTOR
AB The human macula uniquely concentrates three carotenoids: lutein, zeaxanthin, and meso-zeaxanthin. Lutein and zeaxanthin must be obtained from dietary sources such as green leafy vegetables and orange and yellow fruits and vegetables, while meso-zeaxanthin is rarely found in diet and is believed to be formed at the macula by metabolic transformations of ingested carotenoids. Epidemiological studies and large-scale clinical trials such as AREDS2 have brought attention to the potential ocular health and functional benefits of these three xanthophyll carotenoids consumed through the diet or supplements, but the basic science and clinical research underlying recommendations for nutritional interventions against age-related macular degeneration and other eye diseases are underappreciated by clinicians and vision researchers alike. In this review article, we first examine the chemistry, biochemistry, biophysics, and physiology of these yellow pigments that are specifically concentrated in the macula lutea through the means of high-affinity binding proteins and specialized transport and metabolic proteins where they play important roles as short-wavelength (blue) light-absorbers and localized, efficient antioxidants in a region at high risk for light-induced oxidative stress. Next, we turn to clinical evidence supporting functional benefits of these carotenoids in normal eyes and for their potential protective actions against ocular disease from infancy to old age. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Bernstein, Paul S.; Li, Binxing; Vachali, Preejith P.; Gorusupudi, Aruna; Shyam, Rajalekshmy; Henriksen, Bradley S.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
   [Nolan, John M.] Sch Hlth Sci, Vis Res Ctr, Macular Pigment Res Grp, Carriganore House,Waterford Inst Technol West Cam, Carriganore, Waterford, Ireland.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu; binxing.li@hsc.utah.edu;
   preejith.vachali@hsc.utah.edu; aruna.gorusupudi@utah.edu;
   r.shyam@utah.edu; brad.henriksen@hsc.utah.edu; jmnolan@wit.ie
RI Li, Binxing/ABB-7775-2020; Nolan, John/N-4921-2014
OI Li, Binxing/0000-0002-0715-7495; Shyam, Rajalekshmy/0000-0003-2154-4173;
   Nolan, John/0000-0002-5503-7084
FU National Eye Institute [EY-11600, EY-14800]; Research to Prevent
   Blindness; European Research Council (ERC) under the CREST project
   [281096]; NATIONAL EYE INSTITUTE [R01EY015128, P30EY014800, R29EY011600,
   R01EY011600, T32EY024234] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [T35HL007744] Funding Source: NIH RePORTER
FX This work was supported by National Eye Institute grants EY-11600 and
   EY-14800 and by an unrestricted departmental grant to the Moran Eye
   Center from Research to Prevent Blindness. The authors gratefully
   acknowledge the expert critical reading and editorial assistance of
   Kelly Nelson.; Dr. Nolan is currently funded by the European Research
   Council (ERC) under the CREST project (code: 281096) and also holds a
   Howard Chair at Waterford Institute of Technology in Human Nutrition
   Research. Within his capacity as a director of Nutrasight Consultancy
   Ltd., Dr Nolan carries out consultancy work for nutraceutical companies,
   including Bausch + Lomb, Heidelberg Engineering, Alliance Pharma PLC,
   and MacuHealth.
CR ABADI RV, 1992, INVEST OPHTH VIS SCI, V33, P494
   Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518
   Agostoni C, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2030
   Aguilar F, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2144
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Alcantara S, 1999, J IND MICROBIOL BIOT, V23, P697, DOI 10.1038/sj.jim.2900688
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   AliOsman F, 1997, J BIOL CHEM, V272, P10004
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485
   Amengual J, 2013, J BIOL CHEM, V288, P34081, DOI 10.1074/jbc.M113.501049
   Amengual J, 2011, FASEB J, V25, P948, DOI 10.1096/fj.10-173906
   ANDERSON DH, 1979, J ULTRA MOL STRUCT R, V67, P23, DOI 10.1016/S0022-5320(79)80014-3
   Attie AD, 2002, J LIPID RES, V43, P1610, DOI 10.1194/jlr.M200223-JLR200
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Azevedo-Meleiro CH, 2007, J AGR FOOD CHEM, V55, P4027, DOI 10.1021/jf063413d
   Babino D., 2015, J BIOL CHEM IN PRESS
   Bartlett HE, 2008, CLIN NUTR, V27, P218, DOI 10.1016/j.clnu.2008.01.003
   BARUA AB, 1992, METHOD ENZYMOL, V213, P273
   Barua AB, 2001, J NUTR, V131, P3212, DOI 10.1093/jn/131.12.3212
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, OPHTHAL PHYSL OPT, V20, P105, DOI 10.1016/S0275-5408(99)00039-3
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Berendschot TTJM, 2003, PROG RETIN EYE RES, V22, P171, DOI 10.1016/S1350-9462(02)00060-5
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2013, INVEST OPHTH VIS SCI, V54, P4034, DOI 10.1167/iovs.13-11891
   Bernstein PS, 2012, INVEST OPHTH VIS SCI, V53, P6178, DOI 10.1167/iovs.12-10275
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bernstein PS, 2002, PURE APPL CHEM, V74, P1419, DOI 10.1351/pac200274081419
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001
   Berson EL, 2010, ARCH OPHTHALMOL-CHIC, V128, P403, DOI 10.1001/archophthalmol.2010.32
   Bhatti RA, 2003, INVEST OPHTH VIS SCI, V44, P44, DOI 10.1167/iovs.02-0167
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Bhosale P, 2005, ANAL BIOCHEM, V345, P296, DOI 10.1016/j.ab.2005.07.006
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2004, APPL MICROBIOL BIOT, V63, P351, DOI 10.1007/s00253-003-1441-1
   Bhosale P, 2007, BIOCHEMISTRY-US, V46, P9050, DOI 10.1021/bi700558f
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P1435, DOI 10.1167/iovs.06-1046
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1971, VISION RES, V11, P1057, DOI 10.1016/0042-6989(71)90112-X
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BONE RA, 1984, VISION RES, V24, P103, DOI 10.1016/0042-6989(84)90094-4
   Borel P, 2011, ANN MED, V43, P47, DOI 10.3109/07853890.2010.531757
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   Bowne SJ, 2011, EUR J HUM GENET, V19, P1074, DOI 10.1038/ejhg.2011.86
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Britton G., 1995, CAROTENOIDS B, V1B, P13
   Brown MJ, 2004, AM J CLIN NUTR, V80, P396, DOI 10.1093/ajcn/80.2.396
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calvo MM, 2005, CRIT REV FOOD SCI, V45, P671, DOI 10.1080/10408690590957034
   Casaroli-Marano RP, 2015, CURR EYE RES, V40, P707, DOI 10.3109/02713683.2014.952831
   Cerezo J, 2013, PHYS CHEM CHEM PHYS, V15, P6527, DOI 10.1039/c3cp43947j
   Chen H, 1997, BIOCHEM J, V327, P721, DOI 10.1042/bj3270721
   Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Ciccone MM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/782137
   CONN PF, 1991, J PHOTOCH PHOTOBIO B, V11, P41, DOI 10.1016/1011-1344(91)80266-K
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Cornish EE, 2005, VISUAL NEUROSCI, V22, P447, DOI 10.1017/S0952523805224069
   Crabtree DV, 2001, BIOORGAN MED CHEM, V9, P1967, DOI 10.1016/S0968-0896(01)00103-1
   Crabtree DV, 1996, INVEST OPHTH VIS SCI, V37, P47
   Dall'Osto L, 2006, BMC PLANT BIOL, V6, DOI 10.1186/1471-2229-6-32
   Davies NP, 2002, INVEST OPHTH VIS SCI, V43, P281
   de Rosso VV, 2007, J AGR FOOD CHEM, V55, P5062, DOI 10.1021/jf0705421
   Del Campo JA, 2001, J BIOTECHNOL, V85, P289, DOI 10.1016/S0168-1656(00)00380-1
   dela Sena C, 2013, J BIOL CHEM, V288, P37094, DOI 10.1074/jbc.M113.507160
   Deli J, 2004, BIOORG MED CHEM LETT, V14, P925, DOI 10.1016/j.bmcl.2003.12.012
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   den Hollander AI, 2009, INVEST OPHTH VIS SCI, V50, P1864, DOI 10.1167/iovs.08-2497
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dorey CK, 2005, EXP EYE RES, V81, P464, DOI 10.1016/j.exer.2005.03.007
   Dubis AM, 2012, ARCH OPHTHALMOL-CHIC, V130, P1291, DOI 10.1001/archophthalmol.2012.2270
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305
   EFSA Panel on Dietetic Products Nutrition and Allergies, 2012, EFSA Journal, V10, P2716
   ENGLERT G, 1991, HELV CHIM ACTA, V74, P969, DOI 10.1002/hlca.19910740507
   Engles M, 2007, INVEST OPHTH VIS SCI, V48, P2922, DOI 10.1167/iovs.06-0883
   ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x
   Ermakov IV, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2139974
   Ernst H, 2002, PURE APPL CHEM, V74, P1369, DOI 10.1351/pac200274081369
   Eugster C.H., 2002, PROCESS OBTAINING 3
   European Food Safety Authority, 2012, EFSA Journal, V10, P2897
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Fang LQ, 2003, ANAL CHEM, V75, P812, DOI 10.1021/ac026118a
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Fernandez-Robredo P, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/213505
   FOOTE CS, 1970, J AM CHEM SOC, V92, P5216, DOI 10.1021/ja00720a036
   FRANCIS GW, 1975, ARCH MICROBIOL, V104, P249, DOI 10.1007/BF00447333
   FRESNEDO O, 1992, J PHYCOL, V28, P786, DOI 10.1111/j.0022-3646.1992.00786.x
   Gabrielska J, 1996, BBA-BIOMEMBRANES, V1285, P167, DOI 10.1016/S0005-2736(96)00152-6
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Granado-Lorencio F, 2010, J NUTR BIOCHEM, V21, P133, DOI 10.1016/j.jnutbio.2008.12.002
   GREEN DW, 1990, BIOCHEMISTRY-US, V29, P3126, DOI 10.1021/bi00464a032
   GREENWALT DE, 1992, BLOOD, V80, P1105
   Gruszecki WI, 2005, BBA-MOL BASIS DIS, V1740, P108, DOI 10.1016/j.bbadis.2004.11.015
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hammond BR, 2012, VISION RES, V63, P58, DOI 10.1016/j.visres.2012.04.019
   Hammond BR, 2008, NUTR REV, V66, P695, DOI 10.1111/j.1753-4887.2008.00121.x
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P220
   HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603
   Henriksen BS, 2014, J PEDIATR GASTR NUTR, V59, P552, DOI 10.1097/MPG.0000000000000471
   Henriksen BS, 2013, INVEST OPHTH VIS SCI, V54, P5568, DOI 10.1167/iovs.13-12331
   HIGH EDWARD G., 1951, JOUR NUTRITION, V43, P245
   Hof KHV, 2000, J NUTR, V130, P503
   Holden Joanne M., 1999, Journal of Food Composition and Analysis, V12, P169, DOI 10.1006/jfca.1999.0827
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Inbaraj BS, 2006, J CHROMATOGR A, V1102, P193, DOI 10.1016/j.chroma.2005.10.055
   Ismail Amin, 2003, Malays J Nutr, V9, P31
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   ITO M, 1992, METHOD ENZYMOL, V213, P13
   JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S
   Jeon JY, 2014, BIOTECHNOL PROGR, V30, P736, DOI 10.1002/btpr.1889
   Jewell VC, 2001, P NUTR SOC, V60, P171, DOI 10.1079/PNS200089
   Jin ES, 2003, BIOTECHNOL BIOENG, V81, P115, DOI 10.1002/bit.10459
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 2012, AM J CLIN NUTR, V96, p1161S, DOI 10.3945/ajcn.112.034611
   Johnson EJ, 2010, J AM DIET ASSOC, V110, P1357, DOI 10.1016/j.jada.2010.06.009
   Juronen E, 2000, INVEST OPHTH VIS SCI, V41, P2262
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KARRER P, 1947, HELV CHIM ACTA, V30, P266, DOI 10.1002/hlca.19470300129
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kazato Y, 2010, JPN J OPHTHALMOL, V54, P349, DOI 10.1007/s10384-010-0826-9
   Kelly ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092659
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1992, J CHROMATOGR-BIOMED, V582, P153, DOI 10.1016/0378-4347(92)80314-G
   Khachik F., 2001, U.S. Patent, Patent No. [6,262,284 B1, 6262284]
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5476, DOI 10.1167/iovs.06-0194
   Khachik F, 2012, ACTA BIOCHIM POL, V59, P75
   Khachik F, 2009, J ORG CHEM, V74, P3875, DOI 10.1021/jo900432r
   Kiefer C, 2002, P NATL ACAD SCI USA, V99, P10581, DOI 10.1073/pnas.162182899
   Kienzle F, 1976, PURE APPL CHEM, V47, P7
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kimura M, 1999, ARCH LATINOAM NUTR, V49, p58S
   KLAES H, 1951, Med Monatsschr, V5, P334
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   KRINSKY NI, 1990, J NUTR, V120, P81, DOI 10.1093/jn/120.1.81
   KRINSKY NI, 1989, FREE RADICAL BIO MED, V7, P617, DOI 10.1016/0891-5849(89)90143-3
   KRINSKY NI, 1993, ANN NY ACAD SCI, V691, P167, DOI 10.1111/j.1749-6632.1993.tb26168.x
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Kruger CL, 2002, FOOD CHEM TOXICOL, V40, P1535, DOI 10.1016/S0278-6915(02)00131-X
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Lee CM, 1999, J NUTR, V129, P2271, DOI 10.1093/jn/129.12.2271
   LEUENBERGER HGW, 1976, HELV CHIM ACTA, V59, P1832, DOI 10.1002/hlca.19760590541
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Li BX, 2014, P NATL ACAD SCI USA, V111, P10173, DOI 10.1073/pnas.1402526111
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Li SY, 2012, INVEST OPHTH VIS SCI, V53, P5976, DOI 10.1167/iovs.12-10007
   Lien EL, 2011, PROG RETIN EYE RES, V30, P188, DOI 10.1016/j.preteyeres.2011.01.001
   Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200
   Lindqvist A, 2005, J HISTOCHEM CYTOCHEM, V53, P1403, DOI 10.1369/jhc.5A6705.2005
   Lindqvist A, 2004, J HISTOCHEM CYTOCHEM, V52, P491, DOI 10.1177/002215540405200407
   Lobo GP, 2012, DEVELOPMENT, V139, P2966, DOI 10.1242/dev.079632
   Lobo GP, 2010, FASEB J, V24, P1656, DOI 10.1096/fj.09-150995
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   MAHLEY RW, 1984, J LIPID RES, V25, P1277
   Manzoni P, 2013, AM J PERINAT, V30, P25, DOI 10.1055/s-0032-1321494
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Maoka T, 2011, MAR DRUGS, V9, P278, DOI 10.3390/md9020278
   MARESPERLMAN JA, 1995, INVEST OPHTH VIS SCI, V36, P276
   Masetto A, 2001, J BIOSCI BIOENG, V92, P55, DOI 10.1263/jbb.92.55
   MAYER H, 1980, HELV CHIM ACTA, V63, P1451, DOI 10.1002/hlca.19800630614
   Mayne ST, 2013, ARCH BIOCHEM BIOPHYS, V539, P163, DOI 10.1016/j.abb.2013.06.007
   MCCARTY C, 1999, CRC MOD NUT, P135
   MCDERMOTT JC, 1974, BIOCHEM J, V144, P231, DOI 10.1042/bj1440231
   Meagher KA, 2013, BRIT J NUTR, V110, P289, DOI 10.1017/S0007114512004837
   Mein JR, 2011, ARCH BIOCHEM BIOPHYS, V506, P109, DOI 10.1016/j.abb.2010.11.005
   Meshi Amit, 2015, Retin Cases Brief Rep, V9, P157, DOI 10.1097/ICB.0000000000000125
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mortensen A, 1997, FREE RADICAL RES, V26, P549, DOI 10.3109/10715769709097826
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   NELIS HJ, 1991, J APPL BACTERIOL, V70, P181, DOI 10.1111/j.1365-2672.1991.tb02922.x
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nolan JM, 2013, EYE, V27, P899, DOI 10.1038/eye.2013.98
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2015, J ALZHEIMERS DIS, V44, P1157, DOI 10.3233/JAD-142265
   Nolan John M, 2014, J Food Process Technol, V5, P335
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Obana A, 2014, GRAEF ARCH CLIN EXP, V252, P1221, DOI 10.1007/s00417-014-2574-x
   OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105
   OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Pagler TA, 2006, J BIOL CHEM, V281, P11193, DOI 10.1074/jbc.M510261200
   Palczewski G, 2014, FASEB J, V28, P4457, DOI 10.1096/fj.14-252411
   Park JS, 1998, J NUTR, V128, P1802, DOI 10.1093/jn/128.10.1802
   Park JS, 1998, J NUTR, V128, P1650, DOI 10.1093/jn/128.10.1650
   Perrone S, 2010, NEONATOLOGY, V97, P36, DOI 10.1159/000227291
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Rabin DM, 2013, AGING-US, V5, P51
   RANDO RR, 1991, PROGR RETINAL RES, V10, P161
   Ravikrishnan R, 2011, FOOD CHEM TOXICOL, V49, P2841, DOI 10.1016/j.fct.2011.08.011
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   Renzi LM, 2013, NUTR NEUROSCI, V16, P262, DOI 10.1179/1476830513Y.0000000054
   Renzi LM, 2010, EXP EYE RES, V91, P896, DOI 10.1016/j.exer.2010.09.015
   Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037
   Rodriguez-Amaya DB, 1999, ARCH LATINOAM NUTR, V49, p74S
   Rodriguez-Amaya Delia B, 2003, Forum Nutr, V56, P35
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   RUDDOCK K. H., 1963, VISION RES, V3, P417, DOI 10.1016/0042-6989(63)90093-2
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   Sabour-Pickett S, 2012, MOL NUTR FOOD RES, V56, P270, DOI 10.1002/mnfr.201100219
   Sajilata MG, 2010, SEP PURIF TECHNOL, V71, P173, DOI 10.1016/j.seppur.2009.11.017
   Sakudoh T, 2010, J BIOL CHEM, V285, P7739, DOI 10.1074/jbc.M109.074435
   Salguero A, 2005, APPL MICROBIOL BIOT, V66, P506, DOI 10.1007/s00253-004-1711-6
   Sanchez JF, 2008, APPL MICROBIOL BIOT, V79, P719, DOI 10.1007/s00253-008-1494-2
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Scarmo S, 2012, EUR J CLIN NUTR, V66, P555, DOI 10.1038/ejcn.2012.31
   SCHNURR G, 1991, FEMS MICROBIOL LETT, V78, P157, DOI 10.1016/0378-1097(91)90151-Y
   Schultze M, 1866, UEBER GELBEN FLECK R
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   SHAPIRO SS, 1984, J NUTR, V114, P1924, DOI 10.1093/jn/114.10.1924
   Sharifzadeh M, 2008, J OPT SOC AM A, V25, P947, DOI 10.1364/JOSAA.25.000947
   Sharifzadeh M, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.9.096010
   Shawkey MD, 2005, BIOL LETTERS, V1, P121, DOI 10.1098/rsbl.2004.0289
   Shi XM, 2000, ENZYME MICROB TECH, V27, P312, DOI 10.1016/S0141-0229(00)00208-8
   Sierra A, 2004, J NEUROENDOCRINOL, V16, P787, DOI 10.1111/j.1365-2826.2004.01226.x
   Silverstein Roy L, 2010, Trans Am Clin Climatol Assoc, V121, P206
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   SOUKUP M, 1990, HELV CHIM ACTA, V73, P868, DOI 10.1002/hlca.19900730412
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stahl W, 2002, SKIN PHARMACOL APPL, V15, P291, DOI 10.1159/000064532
   Stahl W, 2001, BIOFACTORS, V15, P95, DOI 10.1002/biof.5520150209
   Stahl W, 1997, CARCINOGENESIS, V18, P89, DOI 10.1093/carcin/18.1.89
   Strauss JF, 2002, STEROIDS, V67, P947, DOI 10.1016/S0039-128X(02)00042-9
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Sujak A, 2000, J PHOTOCH PHOTOBIO B, V59, P42, DOI 10.1016/S1011-1344(00)00133-0
   Sujak A, 2000, BBA-BIOMEMBRANES, V1509, P255, DOI 10.1016/S0005-2736(00)00299-6
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Theelen T, 2014, ACTA OPHTHALMOL, V92, P138, DOI 10.1111/aos.12092
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Thurnham DI, 2015, GRAEF ARCH CLIN EXP, V253, P1231, DOI 10.1007/s00417-014-2811-3
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2
   Trumbo PR, 2006, AM J CLIN NUTR, V84, P971, DOI 10.1093/ajcn/84.5.971
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Vachali P.P., 2013, ARCH BIOCH BIOPHYS, V539, P181
   Vachali Preejith, 2012, Methods Mol Biol, V898, P41, DOI 10.1007/978-1-61779-918-1_2
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   van der Veen RLP, 2010, OPHTHALMOLOGY, V117, P966, DOI 10.1016/j.ophtha.2009.10.019
   Vishwanathan R., 2015, NUTR NEUROSCI IN PRE
   Vishwanathan R, 2014, J PEDIATR GASTR NUTR, V59, P659, DOI 10.1097/MPG.0000000000000389
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Vishwanathan R, 2013, NUTR NEUROSCI, V16, P21, DOI 10.1179/1476830512Y.0000000024
   von Lintig J, 2005, BBA-MOL BASIS DIS, V1740, P122, DOI 10.1016/j.bbadis.2004.11.010
   Voolstra O, 2006, BIOCHEMISTRY-US, V45, P13429, DOI 10.1021/bi060701u
   WALD G, 1958, SCIENCE, V127, P222, DOI 10.1126/science.127.3292.222
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   Walls G L, 1933, Br J Ophthalmol, V17, P705, DOI 10.1136/bjo.17.12.705
   Wang YM, 2007, EXP EYE RES, V84, P591, DOI 10.1016/j.exer.2006.11.013
   Wenzel AJ, 2006, J NUTR, V136, P2568, DOI 10.1093/jn/136.10.2568
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   WIDMER E, 1990, HELV CHIM ACTA, V73, P861, DOI 10.1002/hlca.19900730411
   Willstatter R, 1907, LIEBIGS ANN CHEM, V355, P1
   Winkler BS, 1999, MOL VIS, V5
   WOLIN LR, 1967, J ANAT, V101, P693
   Wong WT, 2009, AM J OPHTHALMOL, V148, P573, DOI 10.1016/j.ajo.2009.04.030
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P33, DOI 10.1016/S0304-4165(97)00006-8
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Xu XD, 2013, FOOD CONTROL, V32, P678, DOI 10.1016/j.foodcont.2013.02.007
   YAMADA E, 1969, ARCH OPHTHALMOL-CHIC, V82, P151
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
   Yap SC, 1997, NUTR RES, V17, P1721, DOI 10.1016/S0271-5317(97)00178-4
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
   Yonekura L, 2010, J NUTR, V140, P1824, DOI 10.3945/jn.110.126466
   Yu HF, 2013, MOL NUTR FOOD RES, V57, P1158, DOI 10.1002/mnfr.201200642
   YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4
   Zeimer MB, 2010, RETINA-J RET VIT DIS, V30, P1282, DOI 10.1097/IAE.0b013e3181e096dd
   Zhao DY, 2003, ARCH OPHTHALMOL-CHIC, V121, P967, DOI 10.1001/archopht.121.7.967
NR 342
TC 269
Z9 278
U1 6
U2 188
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2016
VL 50
BP 34
EP 66
DI 10.1016/j.preteyeres.2015.10.003
PG 33
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB9WN
UT WOS:000368868500003
PM 26541886
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Arathi, BP
   Raghavendra-Rao Sowmya, P
   Vijay, K
   Baskaran, V
   Lakshminarayana, R
AF Arathi, Bangalore Prabhashankar
   Raghavendra-Rao Sowmya, Poorigali
   Vijay, Kariyappa
   Baskaran, Vallikannan
   Lakshminarayana, Rangaswamy
TI Metabolomics of carotenoids: The challenges and prospects - A review
SO TRENDS IN FOOD SCIENCE & TECHNOLOGY
LA English
DT Review
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; IONIZATION MASS-SPECTROMETRY; LUTEIN
   OXIDATION-PRODUCTS; BETA-CAROTENE; IN-VITRO; VITAMIN-A; STRUCTURAL
   ELUCIDATION; LYCOPENE METABOLITES; DIETARY CAROTENOIDS; EXCENTRIC
   CLEAVAGE
AB Considerable progress in carotenoids research has been made to understand the carotenoid metabolism in animals including human. Epidemiological and clinical studies have correlated with dietary intake of carotenoids on reduction of vitamin A deficiency, age-related macular degeneration, cancer and cardiovascular diseases. Recent findings demonstrate the existence of carotenoid metabolites in vivo and their efficacy have made greater insight on prospecting carotenoid metabolites. Owing to their biological activity, exploration of analytical methods for the characterization of carotenoid metabolites is considered to be important before addressing the stability and bioactivity. Although few studies are available on carotenoid metabolites, their structural characterization in biological samples require a substantial refining of analytical protocols like isolation, purification, prerequisite of equipment parameters and robustness in hyphenated techniques. Recently, researchers have focused on biotransformation of carotenoids and made an attempt to screen their metabolites by high-throughput analytical strategies. However, till date there is no detailed analytical techniques available to fingerprint carotenoid metabolites, due to interference with complex biological matrices. This review highlights the carotenoid metabolism, possible bioconversion and available bio-analytical techniques to characterize metabolites in vivo. Further, advancement in sensitivity, mode of ionization and fragmentation patterns of metabolites were also discussed. The identification of carotenoid metabolites in system specific will have further insight in the emerging field of nutritional metabolomics.
C1 [Arathi, Bangalore Prabhashankar; Raghavendra-Rao Sowmya, Poorigali; Vijay, Kariyappa; Lakshminarayana, Rangaswamy] Bangalore Univ, Dept Biotechnol, Bengaluru 560056, Karnataka, India.
   [Baskaran, Vallikannan] CSIR Cent Food Technol Res Inst, Dept Biochem & Nutr, Mysuru 570020, India.
C3 Bangalore University; Council of Scientific & Industrial Research (CSIR)
   - India; CSIR - Central Food Technological Research Institute (CFTRI)
RP Lakshminarayana, R (通讯作者)，Bangalore Univ, Dept Biotechnol, Jnana Bharathi Campus, Bengaluru 560056, Karnataka, India.
EM rlnarn21@gmail.com
RI Lakshminarayana, Rangaswamy/AAC-5824-2019
FU Department of Science and Technology, Govt. of India [WOS-A:
   F.NO.SR/WOS-A/LS-35/2012, SB/EMEQ -233/2013]; Department of
   Biotechnology-Bangalore University
FX Authors acknowledge Department of Science and Technology, Govt. of
   India, Grant Reference numbers (WOS-A: F.NO.SR/WOS-A/LS-35/2012) and
   (SB/EMEQ -233/2013). Authors also acknowledge the Department of
   Biotechnology-Bangalore University for their encouragement and support.
CR Alija AJ, 2004, CARCINOGENESIS, V25, P827, DOI 10.1093/carcin/bgh056
   Arathi B. P., 2014, FOOD ANAL METHODS
   Asai A, 2004, DRUG METAB DISPOS, V32, P205, DOI 10.1124/dmd.32.2.205
   Aust O, 2003, FOOD CHEM TOXICOL, V41, P1399, DOI 10.1016/S0278-6915(03)00148-0
   Bausch J, 1999, INT J VITAM NUTR RES, V69, P268, DOI 10.1024/0300-9831.69.4.268
   BENDICH A, 1989, FASEB J, V3, P1927, DOI 10.1096/fasebj.3.8.2656356
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2005, ANAL BIOCHEM, V345, P296, DOI 10.1016/j.ab.2005.07.006
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P1435, DOI 10.1167/iovs.06-1046
   Bijttebier S, 2014, J CHROMATOGR A, V1332, P46, DOI 10.1016/j.chroma.2014.01.042
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Britton G, 1997, PURE APPL CHEM, V69, P2075, DOI 10.1351/pac199769102075
   Britton G., 2009, NUTR HLTH, V5
   Cacciola F, 2012, J CHROMATOGR A, V1255, P244, DOI 10.1016/j.chroma.2012.06.076
   Chauveau-Duriot B, 2010, ANAL BIOANAL CHEM, V397, P777, DOI 10.1007/s00216-010-3594-y
   Clarke N, 2001, ANAL CHEM, V73, p430A, DOI 10.1021/ac012480y
   Crupi P, 2010, J MASS SPECTROM, V45, P971, DOI 10.1002/jms.1794
   Dachtler M, 2001, ANAL CHEM, V73, P667, DOI 10.1021/ac000635g
   Delpino-Rius A, 2014, J CHROMATOGR A, V1331, P90, DOI 10.1016/j.chroma.2014.01.044
   Diaz JR, 2003, EUR J CLIN NUTR, V57, pS70, DOI 10.1038/sj.ejcn.1601820
   Dong LL, 2010, ANAL CHEM, V82, P9014, DOI 10.1021/ac101974g
   Draper J, 2013, METABOLOMICS, V9, pS4, DOI 10.1007/s11306-012-0449-x
   DUEKER SR, 1994, ANAL CHEM, V66, P4177, DOI 10.1021/ac00095a011
   Eiceman G. A., 2005, ION MOBILITY SPECTRO
   Eroglu A, 2013, J LIPID RES, V54, P1719, DOI 10.1194/jlr.R039537
   Fang LQ, 2003, ANAL CHEM, V75, P812, DOI 10.1021/ac026118a
   Ford NA, 2012, ACTA BIOCHIM POL, V59, P1
   Fraser PD, 2007, PLANT J, V49, P552, DOI 10.1111/j.1365-313X.2006.02949.x
   Frenich AG, 2005, J AGR FOOD CHEM, V53, P7371, DOI 10.1021/jf050973o
   Gajic M, 2006, J NUTR, V136, P1552, DOI 10.1093/jn/136.6.1552
   Ganesan P, 2011, BBA-GEN SUBJECTS, V1810, P497, DOI 10.1016/j.bbagen.2011.02.008
   Giovannucci E, 2005, J NUTR, V135, p2030S, DOI 10.1093/jn/135.8.2030S
   Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7
   Guzman I, 2012, J AGR FOOD CHEM, V60, P7238, DOI 10.1021/jf302475d
   Hagiwara T, 1998, J CHROMATOGR B, V708, P67, DOI 10.1016/S0378-4347(97)00669-5
   Harrison EH, 2012, AM J CLIN NUTR, V96, p1189S, DOI 10.3945/ajcn.112.034843
   Hashimoto T, 2009, BRIT J NUTR, V102, P242, DOI 10.1017/S0007114508199007
   Herrero M, 2009, J CHROMATOGR A, V1216, P7110, DOI 10.1016/j.chroma.2009.08.014
   Higuera-Ciapara I, 2006, CRIT REV FOOD SCI, V46, P185, DOI 10.1080/10408690590957188
   Ho CC, 2007, AM J CLIN NUTR, V85, P770, DOI 10.1093/ajcn/85.3.770
   Hu KQ, 2006, J BIOL CHEM, V281, P19327, DOI 10.1074/jbc.M512095200
   Hurst JS, 2005, EXP EYE RES, V81, P239, DOI 10.1016/j.exer.2005.04.002
   Kaufmann R, 1996, ANAL BIOCHEM, V238, P117, DOI 10.1006/abio.1996.0264
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2003, J NAT PROD, V66, P67, DOI 10.1021/np020376l
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khachik F, 2006, PURE APPL CHEM, V78, P1551, DOI 10.1351/pac200678081551
   Kim KN, 2010, TOXICOL IN VITRO, V24, P1648, DOI 10.1016/j.tiv.2010.05.023
   Kim SJ, 2001, LIPIDS, V36, P191, DOI 10.1007/s11745-001-0706-8
   Kind T, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-234
   Kistler A, 2002, ARCH TOXICOL, V75, P665, DOI 10.1007/s00204-001-0287-5
   KOHLMEIER L, 1995, AM J CLIN NUTR, V62, P1370, DOI 10.1093/ajcn/62.6.1370S
   Konishi I, 2006, COMP BIOCHEM PHYS C, V142, P53, DOI 10.1016/j.cbpc.2005.10.005
   Kopec RE, 2010, J AGR FOOD CHEM, V58, P3290, DOI 10.1021/jf100415z
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lakshminarayana R, 2006, MOL CELL BIOCHEM, V281, P103, DOI 10.1007/s11010-006-1337-3
   Lakshminarayana R, 2008, FREE RADICAL BIO MED, V45, P982, DOI 10.1016/j.freeradbiomed.2008.06.011
   Lakshminarayana R, 2013, CHEM-BIOL INTERACT, V203, P448, DOI 10.1016/j.cbi.2013.03.006
   Lian FZ, 2007, CARCINOGENESIS, V28, P1567, DOI 10.1093/carcin/bgm076
   Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200
   Liu Z, 2011, J CHROMATOGR SCI, V49, P221, DOI 10.1093/chrsci/49.3.221
   Moore T, 1930, BIOCHEM J, V24, P692, DOI 10.1042/bj0240692
   Nagao A, 2004, J NUTR, V134, p237S, DOI 10.1093/jn/134.1.237S
   Nidhi B, 2015, FOOD FUNCT, V6, P450, DOI [10.1039/c4fo00606b, 10.1039/C4FO00606B]
   NOVOTNY JA, 1995, J LIPID RES, V36, P1825
   OLSON JA, 1994, PURE APPL CHEM, V66, P1011, DOI 10.1351/pac199466051011
   OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Oxley A, 2014, J LIPID RES, V55, P319, DOI 10.1194/jlr.D040204
   Polivka T, 2010, ACCOUNTS CHEM RES, V43, P1125, DOI 10.1021/ar100030m
   Prasain JK, 2005, J MASS SPECTROM, V40, P916, DOI 10.1002/jms.868
   Raju M, 2007, FOOD CHEM, V101, P1598, DOI 10.1016/j.foodchem.2006.04.015
   Reynaud E, 2011, J AGR FOOD CHEM, V59, P1457, DOI 10.1021/jf104092e
   Rivera S, 2011, ANAL BIOANAL CHEM, V400, P1339, DOI 10.1007/s00216-011-4825-6
   Rivera SM, 2014, MASS SPECTROM REV, V33, P353, DOI 10.1002/mas.21390
   Rock CL, 2009, CAROTENOIDS SER, V5, P269, DOI 10.1007/978-3-7643-7501-0_13
   Rodic Z, 2012, J CHROMATOGR A, V1231, P59, DOI 10.1016/j.chroma.2012.01.085
   Rodriguez-Amaya DB, 2010, J FOOD COMPOS ANAL, V23, P726, DOI 10.1016/j.jfca.2010.03.008
   Sachindra NM, 2007, J AGR FOOD CHEM, V55, P8516, DOI 10.1021/jf071848a
   Sangeetha RK, 2010, CAN J PHYSIOL PHARM, V88, P977, DOI [10.1139/Y10-074, 10.1139/y10-074]
   Sangeetha RK, 2009, MOL CELL BIOCHEM, V331, P59, DOI 10.1007/s11010-009-0145-y
   Sangeetha RK, 2010, MOL CELL BIOCHEM, V333, P299, DOI 10.1007/s11010-009-0231-1
   SCHWARTZEL EM, 1972, J BACTERIOL, V112, P1422, DOI 10.1128/JB.112.3.1422-1424.1972
   Sicilia T, 2005, J NUTR, V135, P2616, DOI 10.1093/jn/135.11.2616
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sowmya PR, 2014, CHROMATOGRAPHIA, V77, P1633, DOI 10.1007/s10337-014-2765-y
   Stahl W, 2000, ARCH BIOCHEM BIOPHYS, V373, P271, DOI 10.1006/abbi.1999.1510
   Strand A, 1998, COMP BIOCHEM PHYS A, V119, P963, DOI 10.1016/S1095-6433(98)00011-7
   Sugawara T, 2002, J NUTR, V132, P946, DOI 10.1093/jn/132.5.946
   Takats Z, 2004, SCIENCE, V306, P471, DOI 10.1126/science.1104404
   Talvas J, 2010, AM J CLIN NUTR, V91, P1716, DOI 10.3945/ajcn.2009.28666
   TANG GW, 1991, BIOCHEMISTRY-US, V30, P9829, DOI 10.1021/bi00105a003
   Tode C, 2009, J SEP SCI, V32, P3659, DOI 10.1002/jssc.200900289
   TYCZKOWSKI JK, 1988, POULTRY SCI, V67, P787, DOI 10.3382/ps.0670787
   van Breemen RB, 2012, INT J MASS SPECTROM, V312, P163, DOI 10.1016/j.ijms.2011.07.030
   Van Meulebroek L, 2014, ANAL BIOANAL CHEM, V406, P2613, DOI 10.1007/s00216-014-7654-6
   vanBreemen RB, 1997, PURE APPL CHEM, V69, P2061, DOI 10.1351/pac199769102061
   vanVliet T, 1996, INT J VITAM NUTR RES, V66, P77
   WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A
   Wang XD, 1997, METHOD ENZYMOL, V282, P117
   Wang XD, 2012, AM J CLIN NUTR, V96, p1214S, DOI 10.3945/ajcn.111.032359
   Wang Y, 2000, ANAL CHEM, V72, P4999, DOI 10.1021/ac000454e
   Wolz E, 1999, DRUG METAB DISPOS, V27, P456
   Woo MN, 2009, MOL NUTR FOOD RES, V53, P1603, DOI 10.1002/mnfr.200900079
   YEUM KJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P167, DOI 10.1006/abbi.1995.1382
   Yonekura L, 2010, J NUTR, V140, P1824, DOI 10.3945/jn.110.126466
   Zhang H, 2003, FREE RADICAL BIO MED, V35, P1653, DOI 10.1016/j.freeradbiomed.2003.09.019
NR 112
TC 39
Z9 40
U1 3
U2 99
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0924-2244
J9 TRENDS FOOD SCI TECH
JI Trends Food Sci. Technol.
PD SEP
PY 2015
VL 45
IS 1
BP 105
EP 117
DI 10.1016/j.tifs.2015.06.003
PG 13
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA CQ2HE
UT WOS:000360419900008
DA 2022-11-30
ER

PT J
AU Zhang, JY
   Kiser, PD
   Badiee, M
   Palczewska, G
   Dong, ZQ
   Golczak, M
   Tochtrop, GP
   Palczewski, K
AF Zhang, Jianye
   Kiser, Philip D.
   Badiee, Mohsen
   Palczewska, Grazyna
   Dong, Zhiqian
   Golczak, Marcin
   Tochtrop, Gregory P.
   Palczewski, Krzysztof
TI Molecular pharmacodynamics of emixustat in protection against retinal
   degeneration
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID LEBER CONGENITAL AMAUROSIS; PROTEIN-COUPLED RECEPTOR; VISUAL CYCLE
   MODULATOR; MACULAR DEGENERATION; PIGMENT EPITHELIUM; LIPOFUSCIN
   FLUOROPHORE; CONE PHOTORECEPTORS; STARGARDT DISEASE; CRYSTAL-STRUCTURE;
   DENSITY MAPS
AB Emixustat is a visual cycle modulator that has entered clinical trials as a treatment for age-related macular degeneration (AMD). This molecule has been proposed to inhibit the visual cycle isomerase RPE65, thereby slowing regeneration of 11-cis-retinal and reducing production of retinaldehyde condensation byproducts that may be involved in AMD pathology. Previously, we reported that all-trans-retinal (atRAL) is directly cytotoxic and that certain primary amine compounds that transiently sequester atRAL via Schiff base formation ameliorate retinal degeneration. Here, we have shown that emixustat stereoselectively inhibits RPE65 by direct active site binding. However, we detected the presence of emixustat-atRAL Schiff base conjugates, indicating that emixustat also acts as a retinal scavenger, which may contribute to its therapeutic effects. Using agents that lack either RPE65 inhibitory activity or the capacity to sequester atRAL, we assessed the relative importance of these 2 modes of action in protection against retinal phototoxicity in mice. The atRAL sequestrant QEA-B-001-NH2 conferred protection against phototoxicity without inhibiting RPE65, whereas an emixustat derivative incapable of atRAL sequestration was minimally protective, despite direct inhibition of RPE65. These data indicate that atRAL sequestration is an essential mechanism underlying the protective effects of emixustat and related compounds against retinal phototoxicity. Moreover, atRAL sequestration should be considered in the design of next-generation visual cycle modulators.
C1 [Zhang, Jianye; Kiser, Philip D.; Dong, Zhiqian; Golczak, Marcin; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland Ctr Membrane & Struct Biol, Cleveland, OH 44106 USA.
   [Kiser, Philip D.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
   [Badiee, Mohsen; Tochtrop, Gregory P.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
   [Palczewska, Grazyna; Dong, Zhiqian; Palczewski, Krzysztof] Polgenix Inc, Cleveland, OH USA.
C3 Case Western Reserve University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Case Western Reserve University;
   Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western
   Reserve University
RP Palczewski, K (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM kxp65@case.edu
OI Badiee, Mohsen/0000-0003-3722-4609; DONG, ZHIQIAN/0000-0002-8748-4532
FU NATIONAL CANCER INSTITUTE [R01CA157735] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R24EY021126, U01EY025451, R01EY009339,
   R01EY023948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [P41GM103403] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R44AG043645] Funding Source: NIH RePORTER; Veterans
   Affairs [IK2BX002683] Funding Source: NIH RePORTER; Div Of Molecular and
   Cellular Bioscience [0844801] Funding Source: National Science
   Foundation; NCI NIH HHS [CA157735, R01 CA157735] Funding Source:
   Medline; NEI NIH HHS [EY025451, EY023948, U01 EY025451, R01 EY009339,
   R01 EY023948, EY021126, EY009339, R24 EY021126] Funding Source: Medline;
   NIA NIH HHS [AG043645, R44 AG043645] Funding Source: Medline; NIGMS NIH
   HHS [P41 GM103403] Funding Source: Medline; BLRD VA [IK2 BX002683]
   Funding Source: Medline
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Azarian SM, 1998, HUM GENET, V102, P699, DOI 10.1007/s004390050765
   Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200
   Berkowitz BA, 2009, INVEST OPHTH VIS SCI, V50, P1880, DOI 10.1167/iovs.08-2958
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chen Y, 2013, J CLIN INVEST, V123, P5119, DOI 10.1172/JCI69076
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cideciyan AV, 2010, PROG RETIN EYE RES, V29, P398, DOI 10.1016/j.preteyeres.2010.04.002
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Fan J, 2008, INVEST OPHTH VIS SCI, V49, P2384, DOI 10.1167/iovs.08-1727
   Fan J, 2011, INVEST OPHTH VIS SCI, V52, P2412, DOI 10.1167/iovs.10-6437
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114
   Golczak M, 2005, J BIOL CHEM, V280, P42263, DOI 10.1074/jbc.M509351200
   Golczak M, 2005, P NATL ACAD SCI USA, V102, P8162, DOI 10.1073/pnas.0503318102
   Golczak M, 2008, J BIOL CHEM, V283, P9543, DOI 10.1074/jbc.M708982200
   Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004
   Han M, 1997, J BIOL CHEM, V272, P23081, DOI 10.1074/jbc.272.37.23081
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kiser PD, NAT CHEM BIOL, DOI [10.1038/nchembio.1799, DOI 10.1038/NCHEMBI0.1799]
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Kiser PD, 2009, P NATL ACAD SCI USA, V106, P17325, DOI 10.1073/pnas.0906600106
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Maeda A, 2006, BIOCHEMISTRY-US, V45, P4210, DOI 10.1021/bi052382x
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P4917, DOI 10.1167/iovs.09-3581
   Maeda T, 2009, HUM MOL GENET, V18, P2277, DOI 10.1093/hmg/ddp163
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Moise AR, 2007, BIOCHEMISTRY-US, V46, P4449, DOI 10.1021/bi7003069
   Moore JH, 2014, CURR MOL MED, V14, P803, DOI 10.2174/1566524014666140811122704
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Nickell S, 2007, J CELL BIOL, V177, P917, DOI 10.1083/jcb.200612010
   Palczewska G, 2010, NAT MED, V16, P1444, DOI 10.1038/nm.2260
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Read RJ, 2011, STRUCTURE, V19, P1395, DOI 10.1016/j.str.2011.08.006
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Rohrer B, 2005, INVEST OPHTH VIS SCI, V46, P3876, DOI 10.1167/iovs.05-0533
   Schonthaler HB, 2007, EUR J NEUROSCI, V26, P1940, DOI 10.1111/j.1460-9568.2007.05801.x
   Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stecher H, 2000, METHOD ENZYMOL, V316, P330
   Tickle IJ, 2012, ACTA CRYSTALLOGR D, V68, P454, DOI 10.1107/S0907444911035918
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Tu DC, 2006, P NATL ACAD SCI USA, V103, P10426, DOI 10.1073/pnas.0600917103
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246
   Wu XM, 2014, ACS NANO, V8, P153, DOI 10.1021/nn4054107
   Zhang JY, 2015, MOL PHARMACOL, V87, P477, DOI 10.1124/mol.114.096560
   Zhang N, 2013, J CLIN INVEST, V123, P121, DOI 10.1172/JCI66176
   Znoiko SL, 2005, INVEST OPHTH VIS SCI, V46, P1473, DOI 10.1167/iovs.04-0653
   Zwart PH, 2008, ACTA CRYSTALLOGR D, V64, P99, DOI 10.1107/S090744490705531X
NR 70
TC 43
Z9 43
U1 0
U2 9
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUL
PY 2015
VL 125
IS 7
BP 2781
EP 2794
DI 10.1172/JCI80950
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CM3AK
UT WOS:000357553300025
PM 26075817
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Nagiel, A
   Sarraf, D
   Sadda, SR
   Spaide, RF
   Jung, JJ
   Bhavsar, KV
   Ameri, H
   Querques, G
   Freund, KB
AF Nagiel, Aaron
   Sarraf, David
   Sadda, Srinivas R.
   Spaide, Richard F.
   Jung, Jesse J.
   Bhavsar, Kavita V.
   Ameri, Hossein
   Querques, Giuseppe
   Freund, K. Bailey
TI TYPE 3 NEOVASCULARIZATION Evolution, Association With Pigment Epithelial
   Detachment, and Treatment Response as Revealed by Spectral Domain
   Optical Coherence Tomography
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE optical coherence tomography; Type 3 neovascularization; retinal
   angiomatous proliferation; pigment epithelial detachment;
   hyperreflective foci; vascular endothelial growth factor; age-related
   macular degeneration
ID RETINAL ANGIOMATOUS PROLIFERATION; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; CHOROIDAL NEOVASCULARIZATION; CLINICOPATHOLOGICAL
   CORRELATION; SUBRETINAL NEOVASCULARIZATION; RETICULAR PSEUDODRUSEN;
   ANASTOMOSIS; DRUSEN; EYE
AB Purpose: To demonstrate the evolution and treatment response of Type 3 neovascularization using spectral domain optical coherence tomography.
   Methods: We retrospectively analyzed 40 eyes treated with intravitreal anti-vascular endothelial growth factor therapy for Type 3 neovascularization over a variable follow-up period.
   Results: In 17 eyes, spectral domain optical coherence tomography captured the development of Type 3 neovascularization from punctate hyperreflective foci that preceded any outer retinal defect. The more mature Type 3 lesions were associated with outer retinal disruption and adjacent cystoid macular edema. In addition, 37 of 40 Type 3 lesions (93%) were associated with an underlying pigment epithelial detachment, of which 26 (70%) were drusenoid, 6 (16%) serous, and 5 (14%) mixed. Type 3 vessels appeared to leak fluid into the pigment epithelial detachment cavity, creating serous pigment epithelial detachments as large as 925 mm in maximal height. Treatment with anti-vascular endothelial growth factor agents led to prompt involution of the lesion and resorption of the intraretinal and subretinal pigment epithelium fluid after one or two injections (median = 1).
   Conclusion: In some eyes with age-related macular degeneration, the earliest sign of Type 3 neovascularization is punctate hyperreflective foci above the external limiting membrane. The mature Type 3 lesions and associated serous pigment epithelial detachments are highly responsive to anti-vascular endothelial growth factor therapy.
C1 [Nagiel, Aaron; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst,Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Angeles Vet Adm Healthcare Ctr, Dept Surg, Los Angeles, CA USA.
   [Sarraf, David] Kaiser Permanente, Dept Ophthalmol, Woodland Hills, CA USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Sadda, Srinivas R.; Ameri, Hossein] Univ So Calif, Keck Sch Med, Inst Eye, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Spaide, Richard F.; Jung, Jesse J.; Bhavsar, Kavita V.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, Vitreous Retina Macula Consultants New York, New York, NY 10021 USA.
   [Spaide, Richard F.; Jung, Jesse J.; Bhavsar, Kavita V.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Jung, Jesse J.; Bhavsar, Kavita V.; Freund, K. Bailey] NYU, Dept Ophthalmol, New York, NY 10016 USA.
   [Jung, Jesse J.] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Querques, Giuseppe] Univ Paris 12, Dept Ophthalmol, Ctr Intercommunal Creteil, Creteil, France.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Kaiser Permanente; Doheny Eye Institute; University
   of California System; University of California Los Angeles; University
   of California Los Angeles Medical Center; David Geffen School of
   Medicine at UCLA; University of Southern California; Manhattan Eye Ear &
   Throat Hospital; Vitreous Retina Macula Consultants of New York;
   Manhattan Eye Ear & Throat Hospital; New York University; Columbia
   University; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI
   Creteil
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI Nagiel, Aaron/AAT-8886-2020; Spaide, Richard/ABD-7368-2020; Freund, K.
   Bailey/V-7488-2018
OI Nagiel, Aaron/0000-0001-7275-6980; Freund, K.
   Bailey/0000-0002-7888-9773; Querques, Giuseppe/0000-0002-3292-9581
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and
   Throat Hospital, New York, NY
FX Supported by LuEsther T. Mertz Retinal Research Center, Manhattan Eye,
   Ear, and Throat Hospital, New York, NY.
CR Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Matsumoto H, 2010, RETINA-J RET VIT DIS, V30, P425, DOI 10.1097/IAE.0b013e3181bd2d95
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P165, DOI 10.1007/s00417-011-1804-8
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF., 2006, AGE RELATED MACULAR, P23
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 32
TC 94
Z9 97
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2015
VL 35
IS 4
BP 638
EP 647
DI 10.1097/IAE.0000000000000488
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE5OL
UT WOS:000351884900010
PM 25650713
DA 2022-11-30
ER

PT J
AU Hytti, M
   Piippo, N
   Salminen, A
   Honkakoski, P
   Kaarniranta, K
   Kauppinen, A
AF Hytti, Maria
   Piippo, Niina
   Salminen, Antero
   Honkakoski, Paavo
   Kaarniranta, Kai
   Kauppinen, Anu
TI Quercetin alleviates 4-hydroxynonenal-induced cytotoxicity and
   inflammation in ARPE-19 cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Retinal pigment epithelium; 4-Hydroxynonenal; Oxidative stress;
   Quercetin; Inflammation
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; OXIDATIVE-STRESS; MACULAR
   DEGENERATION; EXPRESSION; PROTEINS; IDENTIFICATION; INTERLEUKIN-6;
   MODULATION; SECRETION
AB Retinal pigment epithelium (RPE) plays the principal role in age-related macular degeneration (AMD), a progressive eye disease with no cure and limited therapeutical options. In the pathogenesis of AMD, degeneration of RPE cells by multiple factors including increased oxidative stress and chronic inflammation precedes the irreversible loss of photoreceptors and central vision. Here, we report that the plantderived polyphenol, quercetin, increases viability and decreases inflammation in stressed human ARPE19 cells after exposure to the lipid peroxidation end product 4-hydroxynonenal (HNE). Several previous studies have been conducted using the direct oxidant H2O2 but we preferred HNE since natural characteristics predispose RPE cells to the type of oxidative damage evoked by lipid peroxidation. Quercetin improved cell membrane integrity and mitochondria] function as assessed in LDH and MIT tests. Decreased production of proinflammatory mediators IL-6, IL-8, and MCP-1 were indicated at the RNA level by qPCR and at the protein level by the ELISA technique. In addition, we probed the signaling behind the effects and observed that p38 and ERK MAPK pathways, and CREB signaling are regulated by quercetin in ARPE-19 cells. In conclusion, our present data suggests that HNE is highly toxic to serumstarved ARPE-19 cells but quercetin is able to reverse these adverse effects even when administered after an oxidative insult. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Hytti, Maria; Piippo, Niina; Kaarniranta, Kai; Kauppinen, Anu] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, FI-70029 Kys, Finland.
   [Honkakoski, Paavo] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai; Kauppinen, Anu] Kuopio Univ Hosp, Dept Ophthalmol, FI-70029 Kys, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland; Kuopio University
   Hospital
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FIN-70211 Kuopio, Finland.
EM maria.hytti@uef.fi; niina.e.laakso@uef.fi; antero.salminen@uef.fi;
   paavo.honkakoski@uef.fi; kai.kaarniranta@uef.fi; anu.kauppinen@uef.fi
RI Honkakoski, Paavo/AAJ-1278-2020; Hytti, Maria/AAE-4016-2019
OI Honkakoski, Paavo/0000-0002-4332-3577; Hytti, Maria/0000-0003-2150-6847;
   Kaarniranta, Kai/0000-0003-2600-8679
FU Health Research Council of Academy of Finland [138151]; Paivikki ja
   Sakari Sohlberg Foundation; Orion-Farmos Research Foundation; Finnish
   Cultural Foundation North Savo Regional fund; CIMO; VTR grants of Kuopio
   University Hospital [5503741]
FX Dr. Ewen MacDonald is warmly acknowledged for revising the language of
   this manuscript. This work was financially supported by the Health
   Research Council of Academy of Finland (138151), the Paivikki ja Sakari
   Sohlberg Foundation, Orion-Farmos Research Foundation, Finnish Cultural
   Foundation North Savo Regional fund, CIMO, and VTR grants of Kuopio
   University Hospital (5503741).
CR Abramov AY, 2005, J NEUROSCI, V25, P9176, DOI 10.1523/JNEUROSCI.1632-05.2005
   Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681
   Angeloni C, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/583901
   Bezzerri V, 2011, J IMMUNOL, V187, P6069, DOI 10.4049/jimmunol.1100821
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Chen R, 2014, MOL VIS, V20, P242
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Lee KW, 2008, CANCER RES, V68, P946, DOI 10.1158/0008-5472.CAN-07-3140
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611
   Paimela T, 2011, PHARMACOL RES, V64, P501, DOI 10.1016/j.phrs.2011.05.027
   Palanisamy V, 2012, J DENT RES, V91, P651, DOI 10.1177/0022034512437372
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Saviranta NMM, 2011, FOOD RES INT, V44, P109, DOI 10.1016/j.foodres.2010.10.056
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   STROHMAIER H, 1995, J LIPID MEDIAT CELL, V11, P51, DOI 10.1016/0929-7855(94)00027-A
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tanito M, 2006, FREE RADICAL BIO MED, V41, P1847, DOI 10.1016/j.freeradbiomed.2006.09.012
   Vauzour D, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/914273
   Vicentini FTMC, 2011, J DERMATOL SCI, V61, P162, DOI 10.1016/j.jdermsci.2011.01.002
   Wang Q, 2012, INVEST OPHTH VIS SCI, V53, P2395, DOI 10.1167/iovs.11-8982
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Zhuang Pei, 2011, Eye Sci, V26, P23, DOI 10.3969/j.issn.1000-4432.2011.01.006
NR 43
TC 44
Z9 46
U1 3
U2 20
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2015
VL 132
BP 208
EP 215
DI 10.1016/j.exer.2015.02.001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD6HJ
UT WOS:000351189900023
PM 25662315
DA 2022-11-30
ER

PT J
AU Jorge, PD
   Jorge, D
   Ventura, CV
   Ventura, BV
   Lira, W
   Ventura, MC
   Santhiago, MR
   Kara, N
AF Jorge, Priscilla de Almeida
   Jorge, Delano
   Ventura, Camila Vieira
   Ventura, Bruna Vieira
   Lira, Wagner
   Ventura, Marcelo Carvalho
   Santhiago, Marcony Rodrigues
   Kara-Junior, Newton
TI Incidence of posterior capsule opacification following the implantation
   of a foldable hydrophilic acrylic intraocular lens: a 4 year follow-up
   study
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Posterior capsule of the lens; Capsule opacification; Postoperative
   complications; Cataract/epidemiology; Visual acuity
ID HUMAN CADAVER EYES; BAG OPACIFICATION; CATARACT-SURGERY; EDGED SILICONE;
   RATES; PREVENTION; PATHOLOGY; OUTCOMES; DESIGN
AB Purpose: To evaluate the incidence of posterior capsule opacification (PCO) four years after the implantation of a hydrophilic acrylic intraocular lens (IOL).
   Methods: Fifty-eight randomly selected eyes from 58 patients were analyzed four years after phacoemulsification and Ioflex IOL implantation. The patients underwent an ophthalmic examination to detect PCO and a detailed medical history was obtained. The patients' charts were reviewed for their corrected distance visual acuity prior to the IOL implantation, as well as for one month postoperatively. The Student's t-test was used for statistical analysis.
   Results: The mean age of patients without PCO was 74.6 +/- 9.5 years, compared to 70.3 +/- 15 years in patients with PCO. Four years after surgery, 39 of the 58 eyes (67%) had detectable PCO and 24 eyes (41.3%) had decreased visual acuity (VA) due to PCO. These patients were referred for Nd:YAG laser capsulotomy. Three patients (5.1%) had decreased VA due to glaucoma, IOL opacification, or age-related macular degeneration. Twelve eyes (20.7%) presented mild PCO with unchanged VA. Systemic arterial hypertension was reported by 45% of the patients, and in 3.5% of these cases this was associated with diabetes mellitus.
   Conclusion: This study found the incidence of PCO to be 67% four years after phacoemulsification and Ioflex IOL implantation.
C1 [Jorge, Priscilla de Almeida; Santhiago, Marcony Rodrigues; Kara-Junior, Newton] Univ Sao Paulo, Sao Paulo, Brazil.
   [Jorge, Delano] FLA, Fortaleza, CE, Brazil.
   [Ventura, Camila Vieira; Ventura, Bruna Vieira; Lira, Wagner; Ventura, Marcelo Carvalho] FAV, Recife, PE, Brazil.
C3 Universidade de Sao Paulo
RP Jorge, PD (通讯作者)，Rua Osvaldo Cruz 201-401, BR-60125150 Fortaleza, CE, Brazil.
EM prialmeida.j@gmail.com
RI Ventura, Marcelo/N-6825-2018; Kara-Junior, Newton/F-9022-2012; Ventura,
   Bruna/N-2724-2018; Ventura, Camila V/N-2654-2018; Santhiago, Marcony
   R/AAG-3762-2021
OI Ventura, Marcelo/0000-0003-0579-9379; Ventura,
   Bruna/0000-0003-4333-3932; Ventura, Camila V/0000-0002-2927-4684; 
CR Apple D J, 2000, Trans Am Ophthalmol Soc, V98, P257
   Apple DJ, 2001, OPHTHALMOLOGY, V108, P505, DOI 10.1016/S0161-6420(00)00589-3
   Auffarth GU, 2004, OPHTHAL EPIDEMIOL, V11, P319, DOI 10.1080/09286580490515116
   Awasthi N, 2009, ARCH OPHTHALMOL-CHIC, V127, P555, DOI 10.1001/archophthalmol.2009.3
   Billotte C, 2004, J CATARACT REFR SURG, V30, P2064, DOI 10.1016/j.jcrs.2004.05.003
   Buehl W, 2008, J CATARACT REFR SURG, V34, P1976, DOI 10.1016/j.jcrs.2008.07.029
   Burq Maqsood A, 2008, J Pak Med Assoc, V58, P550
   Chang A, 2013, J CATARACT REFR SURG, V39, P694, DOI 10.1016/j.jcrs.2012.11.032
   Medeiros Hilton Arcoverde Gonçalves de, 2006, Arq. Bras. Oftalmol., V69, P371, DOI 10.1590/S0004-27492006000300016
   Senne FMB, 2010, CLINICS, V65, P459, DOI 10.1590/S1807-59322010000500002
   de Senne FMB, 2002, ACTA OPHTHALMOL SCAN, V80, P262, DOI 10.1034/j.1600-0420.2002.800306.x
   Gauthier L, 2010, J CATARACT REFR SURG, V36, P1195, DOI 10.1016/j.jcrs.2010.01.027
   Hayashi K, 2001, J CATARACT REFR SURG, V27, P817, DOI 10.1016/S0886-3350(01)00787-8
   Hazra S, 2012, INT J OPHTHALMOL-CHI, V5, P59, DOI 10.3980/j.issn.2222-3959.2012.01.12
   Johansson B, 2010, BRIT J OPHTHALMOL, V94, P450, DOI 10.1136/bjo.2009.166181
   Jorge PD, 2013, J CATARACT REFR SURG, V39, P403, DOI 10.1016/j.jcrs.2012.09.023
   Karahan E, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/846385
   Kavoussi SC, 2011, J CATARACT REFR SURG, V37, P2194, DOI 10.1016/j.jcrs.2011.05.049
   Kugelberg M, 2008, ACTA OPHTHALMOL, V86, P533, DOI 10.1111/j.1600-0420.2007.01094.x
   Leishman L, 2012, J CATARACT REFR SURG, V38, P1664, DOI 10.1016/j.jcrs.2012.04.040
   Maddula S, 2011, J CATARACT REFR SURG, V37, P740, DOI 10.1016/j.jcrs.2010.10.058
   Ness PJ, 2011, J CATARACT REFR SURG, V37, P923, DOI 10.1016/j.jcrs.2010.11.036
   Pandey Suresh K., 2004, Indian Journal of Ophthalmology, V52, P99
   Tassignon MJ, 2011, J CATARACT REFR SURG, V37, P2120, DOI 10.1016/j.jcrs.2011.06.025
   Vasavada AR, 2011, J CATARACT REFR SURG, V37, P1050, DOI 10.1016/j.jcrs.2010.12.060
   Vasavada AR, 2011, J CATARACT REFR SURG, V37, P173, DOI 10.1016/j.jcrs.2010.10.036
   Vock L, 2009, J CATARACT REFR SURG, V35, P459, DOI 10.1016/j.jcrs.2008.11.044
   Werner L, 2009, J CATARACT REFR SURG, V35, P556, DOI 10.1016/j.jcrs.2008.11.042
NR 28
TC 13
Z9 15
U1 0
U2 4
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JUL-AUG
PY 2014
VL 77
IS 4
BP 222
EP 224
DI 10.5935/0004-2749.20140057
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU2DI
UT WOS:000345425900005
PM 25410172
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Zhou, P
   Kannan, R
   Spee, C
   Sreekumar, PG
   Dou, GR
   Hinton, DR
AF Zhou, Peng
   Kannan, Ram
   Spee, Christine
   Sreekumar, Parameswaran G.
   Dou, Guorui
   Hinton, David R.
TI Protection of Retina by alpha B Crystallin in Sodium Iodate Induced
   Retinal Degeneration
SO PLOS ONE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; PHOTORECEPTOR
   DEGENERATION; GEOGRAPHIC ATROPHY; NLRP3 INFLAMMASOME; OXIDATIVE STRESS;
   AGE; MODEL; EXPRESSION; DISEASE
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the developed world. The retinal pigment epithelium (RPE) is a critical site of pathology in AMD and alpha B crystallin expression is increased in RPE and associated drusen in AMD. The purpose of this study was to investigate the role of alpha B crystallin in sodium iodate (NaIO3)-induced retinal degeneration, a model of AMD in which the primary site of pathology is the RPE. Dose dependent effects of intravenous NaIO3 (20-70 mg/kg) on development of retinal degeneration (fundus photography) and RPE and retinal neuronal loss (histology) were determined in wild type and alpha B crystallin knockout mice. Absence of alpha B crystallin augmented retinal degeneration in low dose (20 mg/kg) NaIO3-treated mice and increased retinal cell apoptosis which was mainly localized to the RPE layer. Generation of reactive oxygen species (ROS) was observed with NaIO3 in mouse and human RPE which increased further after alpha B crystallin knockout or siRNA knockdown, respectively. NaIO3 upregulated AKT phosphorylation and peroxisome proliferator-activator receptor-gamma (PPAR(gamma)) which was suppressed after alpha B crystallin siRNA knockdown. Further, PPAR(gamma) ligand inhibited NaIO3-induced ROS generation. Our data suggest that alpha B crystallin plays a critical role in protection of NaIO3-induced oxidative stress and retinal degeneration in part through upregulation of AKT phosphorylation and PPAR(gamma) expression.
C1 [Zhou, Peng; Kannan, Ram; Sreekumar, Parameswaran G.; Dou, Guorui] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Spee, Christine; Hinton, David R.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU Arnold and Mabel Beckman Foundation; Research to Prevent Blindness Inc.,
   New York, NY;  [EY01545];  [EY03040]; NATIONAL EYE INSTITUTE
   [R01EY001545, P30EY003040] Funding Source: NIH RePORTER
FX Supported in part by grants EY01545 (DRH) and by core grant EY03040, the
   Arnold and Mabel Beckman Foundation, and an unrestricted grant to the
   Department of Ophthalmology from Research to Prevent Blindness Inc., New
   York, NY. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924
   Brownell SE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00074
   Cheng HC, 2008, MOL VIS, V14, P95
   Chung SS, 2011, AM J PHYSIOL-ENDOC M, V301, pE912, DOI 10.1152/ajpendo.00120.2011
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Fort PE, 2011, EXP EYE RES, V92, P98, DOI 10.1016/j.exer.2010.11.008
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Liu B, 2011, BIOCHEM BIOPH RES CO, V321, P254
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Markovets AM, 2011, AGING-US, V3, P44
   Martin HL, 2012, EXP NEUROL, V235, P528, DOI 10.1016/j.expneurol.2012.02.017
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Organisciak D, 2006, PHOTOCHEM PHOTOBIOL, V82, P1088, DOI 10.1562/2005-06-30-RA-599
   Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935
   Pasupuleti N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.3
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Redfern WS, 2011, J PHARMACOL TOXICOL, V63, P102, DOI 10.1016/j.vascn.2010.06.008
   RINGVOLD A, 1981, EXP EYE RES, V33, P361, DOI 10.1016/S0014-4835(81)80088-7
   Rothbard JB, 2012, J BIOL CHEM, V287, P9708, DOI 10.1074/jbc.M111.337691
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Sreekumar PG, 2012, OXID STRESS APPL BAS, P181, DOI 10.1007/978-1-61779-606-7_9
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Whiteside C, 2009, EXP DIABETES RES, DOI 10.1155/2009/910783
   Xi JH, 2003, MOL VIS, V9, P410
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yaung J, 2007, MOL VIS, V13, P566
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043173
   Zhu C, 2011, AGING, V3, P346
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhu XM, 2005, J NEUROCHEM, V95, P1351, DOI 10.1111/j.1471-4159.2005.03460.x
NR 56
TC 48
Z9 52
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2014
VL 9
IS 5
AR e98275
DI 10.1371/journal.pone.0098275
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI3UR
UT WOS:000336790800030
PM 24874187
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Sobrin, L
   Seddon, JM
AF Sobrin, Lucia
   Seddon, Johanna M.
TI Nature and nurture- genes and environment- predict onset and progression
   of macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Epidemiology; Genetics; Risk factors
ID AGE-RELATED MACULOPATHY; C-REACTIVE PROTEIN; BODY-MASS INDEX;
   GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; RISK-FACTORS;
   DIETARY-FAT; CARDIOVASCULAR-DISEASE; CIGARETTE-SMOKING; VITAMIN-D
AB Age-related macular degeneration (AMD) is a common cause of irreversible visual loss and the disease burden is rising world-wide as the population ages. Both environmental and genetic factors contribute to the development of this disease. Among environmental factors, smoking, obesity and dietary factors including antioxidants and dietary fat intake influence onset and progression of AMD. There are also several lines of evidence that link cardiovascular, immune and inflammatory biomarkers to AMD. The genetic etiology of AMD has been and continues to be an intense and fruitful area of investigation. Genome-wide association studies have revealed numerous common variants associated with AMD and sequencing is increasing our knowledge of how rare genetic variants strongly impact disease. Evidence for interactions between environmental, therapeutic and genetic factors is emerging and elucidating the mechanisms of this interplay remains a major challenge in the field. Genotype-phenotype associations are evolving. The knowledge of non-genetic, modifiable risk factors along with information about heritability and genetic risk variants for this disease acquired over the past 25 years have greatly improved patient management and our ability to predict which patients will develop or progress to advanced forms of AMD. Personalized medicine and individualized prevention and treatment strategies may become a reality in the near future. (C) 2014 Published by Elsevier Ltd.
C1 [Sobrin, Lucia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Tufts Medical Center; Tufts University; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
OI Sobrin, Lucia/0000-0003-1575-0819
FU National Institutes of Health [K12-EY16335, R01-EY11309]; Massachusetts
   Lions Eye Research Fund, Inc.; Foundation Fighting Blindness; Macular
   Vision Research Foundation; Research to Prevent Blindness Career
   Development Award; Research to Prevent Blindness Challenge Grant;
   Department of Ophthalmology; Tufts University School of Medicine;
   American Macular Degeneration Foundation; Arnold and Mabel Beckman
   Initiative for Macular Research; Macular Degeneration Research Fund of
   the Ophthalmic Epidemiology and Genetics Service; New England Eye
   Center; Tufts Medical Center; NATIONAL EYE INSTITUTE [K12EY016335,
   R01EY011309, U10EY011309] Funding Source: NIH RePORTER
FX This research was supported by grants K12-EY16335 and R01-EY11309 from
   the National Institutes of Health; Massachusetts Lions Eye Research
   Fund, Inc.; the Foundation Fighting Blindness; the Macular Vision
   Research Foundation; Research to Prevent Blindness Career Development
   Award; Research to Prevent Blindness Challenge Grant to the New England
   Eye Center, Department of Ophthalmology, Tufts University School of
   Medicine; American Macular Degeneration Foundation; The Arnold and Mabel
   Beckman Initiative for Macular Research; and the Macular Degeneration
   Research Fund of the Ophthalmic Epidemiology and Genetics Service, New
   England Eye Center, Tufts Medical Center, Tufts University School of
   Medicine.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   AJANI UA, 1994, INVEST OPHTH VIS SCI, V35, P2725
   ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson RE, 2004, LIPIDS, V39, P1121, DOI 10.1007/s11745-004-1338-8
   ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Barbazetto IA, 2005, ARCH OPHTHALMOL-CHIC, V123, P542, DOI 10.1001/archopht.123.4.542
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hida M, 2003, J CELL PHYSIOL, V196, P293, DOI 10.1002/jcp.10298
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Hughes DA, 1996, BIOCHEM SOC T, V24, pS389, DOI 10.1042/bst024389s
   Hughes DA, 1996, J NUTR, V126, P603, DOI 10.1093/jn/126.3.603
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Liang S, 2013, ATHEROSCLEROSIS, V228, P181, DOI 10.1016/j.atherosclerosis.2013.02.004
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Luostarinen R, 1996, PROSTAG LEUKOTR ESS, V55, P167, DOI 10.1016/S0952-3278(96)90093-9
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Mukutmoni-Norris M, 2000, CANCER LETT, V150, P101, DOI 10.1016/S0304-3835(99)00380-8
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Poulsen P, 2007, PEDIATR RES, V61, p38R, DOI 10.1203/pdr.0b013e31803c7b98
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767
   Rotstein NP, 1997, J NEUROCHEM, V69, P504
   Santangelo Susan L, 2005, Ophthalmic Genet, V26, P61, DOI 10.1080/13816810490967944
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   SEDDON J, 1994, INVEST OPHTH VIS SCI, V35, P2003
   Seddon J.M., 1997, INVEST OPHTH VIS SCI, pS676
   SEDDON JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P176, DOI 10.1001/archopht.1994.01090140052021
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2013, RETINA, P1134
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   White K, 2000, HUM MUTAT, V15, P301, DOI 10.1002/(SICI)1098-1004(200004)15:4<301::AID-HUMU1>3.0.CO;2-N
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Yang SP, 1998, J CELL PHYSIOL, V176, P342, DOI 10.1002/(SICI)1097-4652(199808)176:2<342::AID-JCP12>3.0.CO;2-5
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 172
TC 108
Z9 110
U1 1
U2 30
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2014
VL 40
BP 1
EP 15
DI 10.1016/j.preteyeres.2013.12.004
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH3EK
UT WOS:000336006200001
PM 24374240
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Valmaggia, C
   Haueter, I
   Niederberger, H
AF Valmaggia, C.
   Haueter, I.
   Niederberger, H.
TI Photodynamic Therapy in the Treatment of Persistent Central Serous
   Chorioretinopathy: a Two-Year Follow-Up
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE photodynamic therapy; central serous chorioretinopathy
ID LASER PHOTOCOAGULATION; VERTEPORFIN
AB Background: The aim of this study was to assess during a follow-up period of two years the efficacy and safety of photodynamic therapy (PDT) in central serous chorioretinopathy (CSC) showing no spontaneous resolution four months after the onset of the symptoms.
   Patients and Methods: We present a prospective interventional non-comparative case series. The diagnosis of CSC was confirmed by fluorescein angiography (FA), and optical coherence tomography (OCT) in 46 eyes of 42 consecutive patients. PDT was performed according to the protocol used for treating choroidal neovascularization in age-related macular degeneration. The primary end point was to assess the anatomic re-attachment of the retina. The secondary end point was to record the visual function. A paired t-test and a linear regression and correlation test were used for the statistics.
   Results: The leakage in FA and the detachment of the neurosensory retina in OCT were no longer present in 42 eyes six weeks after PDT and in the remaining four eyes three months after PDT. At the end of the follow-up, the best-corrected visual acuity measured with an ETDRS chart improved in 36 eyes, and remained stable in 10 eyes (mean improvement, 10.2 letters; p < 0.001). Two cases of recurrence were diagnosed. No treatment-related complications were noticed.
   Conclusions: PDT could be an effective and durable option for treating patients with persistent CSC.
C1 [Valmaggia, C.; Haueter, I.; Niederberger, H.] Cantonal Hosp St Gallen, Dept Ophthalmol, CH-9007 St Gallen, Switzerland.
C3 Kantonsspital St. Gallen
RP Valmaggia, C (通讯作者)，Cantonal Hosp St Gallen, Dept Ophthalmol, Rorschacher Str 95, CH-9007 St Gallen, Switzerland.
EM christophe.valmaggia@kssg.ch
CR Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Flower RW, 1999, RETINA-J RET VIT DIS, V19, P365
   Gackle HC, 1998, OPHTHALMOLOGE, V95, P529, DOI 10.1007/s003470050310
   GILBERT CM, 1984, BRIT J OPHTHALMOL, V68, P815, DOI 10.1136/bjo.68.11.815
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Khosla PK, 1997, OPHTHALMIC SURG LAS, V28, P693
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Koytak A, 2010, RETINA-J RET VIT DIS, V30, P1698, DOI 10.1097/IAE.0b013e3181da4354
   Lai TY, 2006, BR J OPTHALMOL, V90, P805
   Lee PY, 2009, JPN J OPHTHALMOL, V53, P52, DOI 10.1007/s10384-008-0613-z
   Lim JW, 2011, BRIT J OPHTHALMOL, V95, P514, DOI 10.1136/bjo.2010.182121
   Montero JA, 2005, BRIT J OPHTHALMOL, V89, P562, DOI 10.1136/bjo.2004.049403
   Parodi MB, 2003, RETINA-J RET VIT DIS, V23, P235, DOI 10.1097/00006982-200304000-00016
   Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Reche-Frutos J., 2008, Arch Soc Esp Oftalmol, V83, P9
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Taban M, 2004, AM J OPHTHALMOL, V137, P1073, DOI 10.1016/j.ajo.2004.01.043
   Valmaggia C, 2006, KLIN MONATSBL AUGENH, V223, P372, DOI 10.1055/s-2006-926567
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
NR 21
TC 8
Z9 8
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2012
VL 229
IS 4
BP 323
EP 326
DI 10.1055/s-0031-1299263
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VC
UT WOS:000302788900005
PM 22389262
DA 2022-11-30
ER

PT J
AU Almony, A
   Mansouri, A
   Shah, GK
   Blinder, KJ
AF Almony, Arghavan
   Mansouri, Azad
   Shah, Gaurav K.
   Blinder, Kevin J.
TI Efficacy of intravitreal bevacizumab after unresponsive treatment with
   intravitreal ranibizumab
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID MACULAR DEGENERATION
AB Objective: To evaluate visual outcomes of eyes with choroidal neovascular membrane secondary to age-related macular degeneration that were initially treated with intravitreal ranibizumab then switched to intravitreal bevacizumab due to treatment failure.
   Design: Retrospective chart review.
   Participants: Fifty eyes of 50 patients presenting to the Barnes Retina Institute.
   Methods: Patients unresponsive to treatment with intravitreal ranibizumab were switched to intravitreal bevacizumab. Main outcome measures included number of intravitreal injections, visual acuity (VA), and resolution of leakage. Mean follow-up was 6 months after the final intravitreal bevacizumab injection. On average, each patient received 3.5 ranibizumab injections and 2.5 bevacizumab injections. Each patient received an average of 6 injections.
   Results: Resolution of leakage on fluorescein angiography and optical coherence tomography was achieved in 44 eyes (88%). Initial VA ranged from 20/30 to counting fingers (CF) (median VA 20/125). Final VA ranged from 20/20 to CF (median VA 20/100). Change in VA varied from loss of 2 lines to gain of 4 lines, but overall, remained stable (average gain 0.3 lines). Eighteen eyes (36%) had a final VA of >= 20/50 and 18 eyes (36%) had a final VA of <= 20/200.
   Conclusions: Treatment with intravitreal bevacizumab may be effective, as measured by visual and anatomic criteria, in patients who are unresponsive to treatment with intravitreal ranibizumab.
C1 [Shah, Gaurav K.; Blinder, Kevin J.] Barnes Retina Inst, St Louis, MO 63144 USA.
   [Almony, Arghavan] Univ Missouri, Dept Ophthalmol, Columbia, MO USA.
   [Mansouri, Azad; Shah, Gaurav K.; Blinder, Kevin J.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); University of Missouri System; University
   of Missouri Columbia; Washington University (WUSTL)
RP Shah, GK (通讯作者)，Barnes Retina Inst, 1600 S Brentwood,Suite 800, St Louis, MO 63144 USA.
EM gkshah1@gmail.com
FU Heed Foundation
FX Supported by: Supported in part by a Heed Foundation Fellowship.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   la Cour M, 2007, ACTA OPHTHALMOL SCAN, V85, P2, DOI 10.1111/j.1600-0420.2006.00869.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
NR 8
TC 15
Z9 19
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2011
VL 46
IS 2
BP 182
EP 185
DI 10.3129/i10-095
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 762RQ
UT WOS:000290498600012
PM 21708088
DA 2022-11-30
ER

PT J
AU Csutak, A
   Lengyel, I
   Jonasson, F
   Leung, I
   Geirsdottir, A
   Xing, W
   Peto, T
AF Csutak, A.
   Lengyel, I.
   Jonasson, F.
   Leung, I.
   Geirsdottir, A.
   Xing, W.
   Peto, T.
TI Agreement between image grading of conventional (45 degrees) and ultra
   wide-angle (200 degrees) digital images in the macula in the Reykjavik
   eye study
SO EYE
LA English
DT Article
DE age-related macular degeneration; image grading; geographic atrophy;
   choroidal neovascularisation; drusen; imaging
ID AGE-RELATED MACULOPATHY; INTERNATIONAL CLASSIFICATION; LIMITATIONS;
   PREVALENCE; OPTOMAP; SYSTEM
AB Purpose To establish the agreement between image grading of conventional (45 degrees) and ultra wide-angle (200 degrees) digital images in the macula.
   Methods In 2008, the 12-year follow-up was conducted on 573 participants of the Reykjavik Eye Study. This study included the use of the Optos P200C AF ultra wide-angle laser scanning ophthalmoscope alongside Zeiss FF 450 conventional digital fundus camera on 121 eyes with or without age-related macular degeneration using the International Classification System. Of these eyes, detailed grading was carried out on five cases each with hard drusen, geographic atrophy and chorioretinal neovascularisation, and six cases of soft drusen. Exact agreement and kappa-statistics were calculated.
   Results Comparison of the conventional and ultra wide-angle images in the macula showed an overall 96.43% agreement (kappa = 0.93) with no disagreement at end-stage disease; although in one eye chorioretinal neovascularisation was graded as drusenoid pigment epithelial detachment. Of patients with drusen only, the exact agreement was 96.1%. The detailed grading showed no clinically significant disagreement between the conventional 45 degrees and 200 degrees images.
   Conclusions On the basis of our results, there is a good agreement between grading conventional and ultra wide-angle images in the macula. Eye (2010) 24, 1568-1575; doi:10.1038/eye.2010.85; published online 4 June 2010
C1 [Csutak, A.; Leung, I.; Xing, W.; Peto, T.] Moorfields Eye Hosp, London, England.
   [Csutak, A.] Univ Debrecen, H-4012 Debrecen, Hungary.
   [Csutak, A.] Hlth Sci Ctr, Debrecen, Hungary.
   [Lengyel, I.] UCL Inst Ophthalmol, London, England.
   [Jonasson, F.; Geirsdottir, A.] Landspitali Univ Hosp, Reykjavik, Iceland.
   [Jonasson, F.] Univ Iceland, Fac Med, Reykjavik, Iceland.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Debrecen; University of London;
   University College London; Landspitali National University Hospital;
   University of Iceland
RP Peto, T (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Dept Res & Dev, Reading Ctr, 162 City Rd, London EC1V 2PD, England.
EM Tunde.Peto@moorfields.nhs.uk
RI Lengyel, Imre/B-5217-2009; Jonasson, Fridbert/ABA-9889-2021; Peto,
   Tunde/G-8812-2018
OI Lengyel, Imre/0000-0001-7467-2174; Peto, Tunde/0000-0001-6265-0381
FU Bill Brown Charitable Trust; Moorfields Eye Hospital Special Trustees;
   UCL Graduate School; Mercer Fund
FX We would like to say a special thank you to the participating patients,
   the OPTOS clinical research team (Douglas Anderson, Anne-Marie Cairns,
   David Cairns, Paul Donnelly, Dana Hackman), and the medical staff at
   Landspitali University Hospital, Reykjavik, for their professional
   support. This research was supported by the Bill Brown Charitable Trust,
   Moorfields Eye Hospital Special Trustees, UCL Graduate School Research
   Projects Fund and Mercer Fund. We also thank Professor Alan C Bird for
   the helpful comments. Preliminary data was presented at the ARVO 2009
   meeting.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Cheng SCK, 2008, CLIN EXP OPTOM, V91, P373, DOI 10.1111/j.1444-0938.2007.00231.x
   Chou B, 2003, OPTOMETRY VISION SCI, V80, P671, DOI 10.1097/00006324-200310000-00007
   Coffee RE, 2009, SEMIN OPHTHALMOL, V24, P34, DOI 10.1080/08820530802520194
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jones WL, 2004, OPTOMETRY VISION SCI, V81, P165, DOI 10.1097/00006324-200403000-00007
   Kaines Andrew, 2009, Int Ophthalmol Clin, V49, P53, DOI 10.1097/IIO.0b013e31819fd471
   Kaines A, 2009, SEMIN OPHTHALMOL, V24, P19, DOI 10.1080/08820530802520095
   KIRKPATRICK JNP, 1995, BRIT J OPHTHALMOL, V79, P892, DOI 10.1136/bjo.79.10.892
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Neubauer AS, 2008, GRAEF ARCH CLIN EXP, V246, P229, DOI 10.1007/s00417-007-0631-4
   Neubauer AS, 2005, ACTA OPHTHALMOL SCAN, V83, P759, DOI 10.1111/j.1600-0420.2005.00532.x
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Shah SP, 2009, SEMIN OPHTHALMOL, V24, P40, DOI 10.1080/08820530802520236
   SPERDUTO RD, 1986, AM J EPIDEMIOL, V124, P994, DOI 10.1093/oxfordjournals.aje.a114489
   VANLEEUWE, 2003, OPHTHALMOLOGY, V110, P1540
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
NR 22
TC 20
Z9 27
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2010
VL 24
IS 10
BP 1568
EP 1575
DI 10.1038/eye.2010.85
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664JM
UT WOS:000282956200005
PM 20523357
OA Bronze
DA 2022-11-30
ER

PT J
AU Okamoto, H
   Umeda, S
   Nozawa, T
   Suzuki, MT
   Yoshikawa, Y
   Matsuura, ET
   Iwata, T
AF Okamoto, Haru
   Umeda, Shinsuke
   Nozawa, Takehiro
   Suzuki, Michihiro T.
   Yoshikawa, Yasuhiro
   Matsuura, Etsuko T.
   Iwata, Takeshi
TI Comparative Proteomic Analyses of Macular and Peripheral Retina of
   Cynomolgus Monkeys (Macaca fascicularis)
SO EXPERIMENTAL ANIMALS
LA English
DT Article
DE 2D-gel electrophoresis; macula; mass spectrometry; retina
ID HUMAN CONE PHOTORECEPTORS; ACID-BINDING PROTEIN; RHESUS-MONKEY; PIGMENT
   EPITHELIUM; OXIDATIVE STRESS; PRIMATE RETINAS; GENE-EXPRESSION;
   DEGENERATION; TROPOMYOSIN; DRUSEN
AB The central region of the primate retina is called the macula. The fovea is located at the center of the macula, where the photoreceptors are concentrated to create a neural network adapted for high visual acuity. Damage to the fovea, e.g., by macular dystrophies and age-related macular degeneration, can reduce central visual acuity. The molecular mechanisms leading to these diseases are most likely dependent on the proteins in the macula which differ from those in the peripheral retina in expression level. To investigate whether the distribution of proteins in the macula is different from the peripheral retina, proteomic analyses of tissues from these two regions of cynomolgus monkeys were compared. Two-dimensional gel electrophoresis and mass spectrometry identified 26 proteins that were present only in the macular gel spots. The expression levels of five proteins, cone photoreceptor specific arrestin-C, gamma-synuclein, epidermal fatty acid binding protein, tropomyosin 1 a chain, and heterogeneous nuclear ribonucleoproteins A2/B1, were significantly higher in the macula than in the peripheral retina. Immunostaining of macula sections by antibodies to each identified protein revealed unique localization in the retina, retinal pigment epithelial cells and the choroidal layer. Some of these proteins were located in cells with higher densities in the macula. We suggest that it will be important to study these proteins to determine their contribution to the pathogenesis and progression of macula diseases.
C1 [Okamoto, Haru; Umeda, Shinsuke; Iwata, Takeshi] Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Div Mol & Cellular Biol, Meguro Ku, Tokyo 1528902, Japan.
   [Okamoto, Haru] Ochanomizu Univ, Dept Adv Biosci, Bunkyo Ku, Tokyo 1128610, Japan.
   [Nozawa, Takehiro] AMR Inc, Analyt Instrument Div, Meguro Ku, Tokyo 1520031, Japan.
   [Suzuki, Michihiro T.] Corp Prod & Res Lab Primates, Tsukuba, Ibaraki 3050843, Japan.
   [Yoshikawa, Yasuhiro] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biomed Sci, Bunkyo Ku, Tokyo 1138657, Japan.
   [Matsuura, Etsuko T.] Ochanomizu Univ, Nat Appl Sci Div, Bunkyo Ku, Tokyo 1128610, Japan.
C3 Ochanomizu University; University of Tokyo; Ochanomizu University
RP Iwata, T (通讯作者)，Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Div Mol & Cellular Biol, Meguro Ku, 2-5-1 Higashigaoka, Tokyo 1528902, Japan.
FU Ministry of Health, Labour and Welfare of Japan; Ministry of Education,
   Culture, Sports, Science and Technology of Japan [KAKENHI 19791305]
FX The authors thank Professor Duco Hamasaki for critical reading of the
   manuscript and helpful comments. This study was funded in part by a
   grant to TI from the Ministry of Health, Labour and Welfare of Japan and
   by a grant to HO from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan (KAKENHI 19791305).
CR Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Bennaars-Eiden A, 2002, J BIOL CHEM, V277, P50693, DOI 10.1074/jbc.M209493200
   Butt RH, 2007, MOL CELL PROTEOMICS, V6, P1574, DOI 10.1074/mcp.M700083-MCP200
   Cavusoglu N, 2003, MOL CELL PROTEOMICS, V2, P494, DOI 10.1074/mcp.M300029-MCP200
   CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411
   Distler C, 1996, VISION RES, V36, P2381, DOI 10.1016/0042-6989(96)00005-3
   Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779
   HAD L, 1994, J CELL SCI, V107, P2961
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   HARWERTH RS, 1985, AM J OPTOM PHYS OPT, V62, P633
   Hauck SM, 2005, PROTEOMICS, V5, P3623, DOI 10.1002/pmic.200401223
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Ji HJ, 1997, CANCER RES, V57, P759
   Kingma PB, 1998, BIOCHEMISTRY-US, V37, P3250, DOI 10.1021/bi972520l
   Liu Q, 2007, MOL CELL PROTEOMICS, V6, P1299, DOI 10.1074/mcp.M700054-MCP200
   MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200
   Matsubara T, 2000, CURR EYE RES, V20, P1, DOI 10.1076/0271-3683(200001)20:1;1-H;FT001
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026
   Nishizawa Y, 1999, EXP EYE RES, V69, P195, DOI 10.1006/exer.1999.0693
   ORDY JM, 1980, NEUROBIOL AGING, V1, P133, DOI 10.1016/0197-4580(80)90006-8
   Oyster CW., 1999, HUMAN EYE STRUCTURE
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Sakuma H, 1996, FEBS LETT, V382, P105, DOI 10.1016/0014-5793(96)00163-9
   Schevzov G, 2005, J HISTOCHEM CYTOCHEM, V53, P557, DOI 10.1369/jhc.4A6505.2005
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Stafford T J, 1974, Mod Probl Ophthalmol, V12, P214
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   STAMM S, 1993, P NATL ACAD SCI USA, V90, P9857, DOI 10.1073/pnas.90.21.9857
   Sueoka E, 1999, CANCER RES, V59, P1404
   Surguchov A, 2001, J NEUROSCI RES, V65, P68, DOI 10.1002/jnr.1129
   Suzuki MT, 2003, PRIMATES, V44, P291, DOI 10.1007/s10329-002-0016-6
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   Umeda S, 2003, EXP ANIM TOKYO, V52, P129, DOI 10.1538/expanim.52.129
   van Soest SS, 2007, MOL VIS, V13, P1608
   Wang YD, 2007, CURR EYE RES, V32, P891, DOI 10.1080/02713680701593702
   West KA, 2003, MOL CELL PROTEOMICS, V2, P37, DOI 10.1074/mcp.D200001-MCP200
   White R, 2008, J CELL BIOL, V181, P579, DOI 10.1083/jcb.200706164
   Zhang JC, 2002, P NATL ACAD SCI USA, V99, P12224, DOI 10.1073/pnas.192668299
NR 52
TC 15
Z9 16
U1 0
U2 1
PU INT PRESS EDITING CENTRE INC
PI TOKYO
PA 1-2-3 SUGAMO, TOSHIMA-KU, TOKYO, 170 0002, JAPAN
SN 1341-1357
EI 1881-7122
J9 EXP ANIM TOKYO
JI Exp. Anim.
PD APR
PY 2010
VL 59
IS 2
BP 171
EP 182
DI 10.1538/expanim.59.171
PG 12
WC Veterinary Sciences; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences; Zoology
GA 590HJ
UT WOS:000277215800006
PM 20484850
OA Bronze
DA 2022-11-30
ER

PT J
AU Zele, AJ
   O'Loughlin, RK
   Guymer, RH
   Vingrys, AJ
AF Zele, AJ
   O'Loughlin, RK
   Guymer, RH
   Vingrys, AJ
TI Disclosing disease mechanisms with a spatio-temporal summation paradigm
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; SPATIAL SUMMATION; MACULAR DEGENERATION;
   CONTRAST SENSITIVITY; VISUAL-FIELD; EYE SEES; FLICKER; STIMULUS; SIZE;
   THRESHOLD
AB Background: We develop the logic for a stimulus that can evaluate cone-dependent spatial summation and detail the modelling and interpretation of thresholds obtained with this stimulus. Methods: Fifteen observers participated, including two young normals tested extensively in control experiments, and a clinical trial based on four observers with age-related macular degeneration (AMD), four age-similar controls and five young observers. Monocular spatial summation functions were measured with contrast-modulated Gabor targets that approximated the optimal visual contrast detector. Thresholds were returned from a yes/no adaptive psychophysical algorithm. By fine titration along the size domain it was demonstrated that the spatial summation of normal observers can be adequately described by a two-component model. A reduced set of variables are proposed for clinical applications and the model was applied to data derived using these variables in persons with AMD and age-similar controls. Results: We do not find a significant age-related loss of contrast sensitivity in our normal group. On the other hand, persons with early AMD exhibited a 0.41 log unit loss of sensitivity (P=0.04) from age-similar controls, without any change in their maximum summation area (A(max)). Conclusion: The nature of the spatial summation is consistent with the interpretation that early AMD produces a decrease in cone input to post-receptoral mechanisms in the absence of neural remodelling.
C1 Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic 3010, Australia.
   Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
C3 University of Melbourne; Centre for Eye Research Australia; University
   of Melbourne
RP Vingrys, AJ (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic 3010, Australia.
EM algis@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Zele, Andrew/0000-0003-0291-9929;
   Vingrys, Algis/0000-0001-5920-4604
CR Anderson AJ, 2001, PERIMETRY UPDATE 2000/2001, P115
   BARLOW HB, 1958, J PHYSIOL-LONDON, V141, P337, DOI 10.1113/jphysiol.1958.sp005978
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOWEN RW, 1994, VISION RES, V34, P645, DOI 10.1016/0042-6989(94)90019-1
   BROWN B, 1989, OPHTHAL PHYSL OPT, V9, P310, DOI 10.1111/j.1475-1313.1989.tb00913.x
   CAMPBELL FW, 1965, J PHYSIOL-LONDON, V181, P576, DOI 10.1113/jphysiol.1965.sp007784
   CHAPARRO A, 1993, NATURE, V361, P348, DOI 10.1038/361348a0
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DRUM B, 1984, PERCEPT PSYCHOPHYS, V36, P245, DOI 10.3758/BF03206365
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   ELLIOTT D, 1990, VISION RES, V30, P541, DOI 10.1016/0042-6989(90)90066-T
   EYSEL UT, 1985, EXP NEUROL, V88, P757, DOI 10.1016/0014-4886(85)90086-X
   Felius J, 1997, PERIMETRY UPDATE 199, P213
   Fellman RL., 1988, PERIMETRY UPDATE 198, V1989, P313
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gowdy PD, 1999, VISION RES, V39, P4098, DOI 10.1016/S0042-6989(99)00115-7
   HAAS A, 1986, AM J OPHTHALMOL, V101, P199, DOI 10.1016/0002-9394(86)90595-7
   HESS RF, 1978, VISION RES, V18, P501, DOI 10.1016/0042-6989(78)90064-0
   HESS RF, 1990, NIGHT VISION BASIC C, P3
   JOHNSON CA, 1989, INVEST OPHTH VIS SCI, V30, P2056
   Kapadia MK, 1999, P NATL ACAD SCI USA, V96, P12073, DOI 10.1073/pnas.96.21.12073
   LANTHAM K, 1994, OPHTHAL PHYSL OPT, V14, P71
   Mareschal I, 2004, VISION RES, V44, P57, DOI 10.1016/j.visres.2003.07.009
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   NAMEDA N, 1989, OPTOMETRY VISION SCI, V66, P760, DOI 10.1097/00006324-198911000-00007
   OLOUGHLIN RK, 2004, THESIS U MELBOURNE A
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   OWSLEY C, 1982, INVEST OPHTH VIS SCI, V22, P130
   PENTLAND A, 1980, PERCEPT PSYCHOPHYS, V28, P377, DOI 10.3758/BF03204398
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Phipps Joanna A, 2001, Clin Exp Optom, V84, P264
   Polat U, 1999, VISION RES, V39, P887, DOI 10.1016/S0042-6989(98)00245-4
   REGAN D, 1980, INVEST OPHTH VIS SCI, V19, P324
   SANYAL S, 1992, DEVELOPMENT, V114, P797
   Sceniak MP, 1999, NAT NEUROSCI, V2, P733, DOI 10.1038/11197
   SJOSTRAND J, 1977, ACTA OPHTHALMOL, V55, P507
   Swanson WH, 2004, INVEST OPHTH VIS SCI, V45, P466, DOI 10.1167/iovs.03-0374
   Swanson WH, 2000, OPHTHALMOLOGY, V107, P1950, DOI 10.1016/S0161-6420(00)00356-0
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828
   WATSON AB, 1995, VISION RES, V35, P325, DOI 10.1016/0042-6989(94)00182-L
   WATSON AB, 1983, NATURE, V302, P419, DOI 10.1038/302419a0
   WESTHEIMER G, 1967, J PHYSIOL-LONDON, V190, P139, DOI 10.1113/jphysiol.1967.sp008198
   WILSON ME, 1970, J PHYSIOL-LONDON, V207, P611, DOI 10.1113/jphysiol.1970.sp009083
   WILSON ME, 1967, J PHYSIOL-LONDON, V189, P189, DOI 10.1113/jphysiol.1967.sp008163
   Zele AJ, 2000, CLIN EXP OPHTHALMOL, V28, P227, DOI 10.1046/j.1442-9071.2000.00301.x
   Zele AJ, 2005, J NEUROSCI METH, V141, P1, DOI 10.1016/j.jneumeth.2004.05.005
   ZHANG L, 1995, OPTOMETRY VISION SCI, V72, P198, DOI 10.1097/00006324-199503000-00008
NR 51
TC 16
Z9 16
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2006
VL 244
IS 4
BP 425
EP 432
DI 10.1007/s00417-005-0121-5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 032CW
UT WOS:000236752500001
PM 16220278
DA 2022-11-30
ER

PT J
AU Arnold, JJ
   Sarks, JP
   Killingsworth, MC
   Kettle, EK
   Sarks, SH
AF Arnold, JJ
   Sarks, JP
   Killingsworth, MC
   Kettle, EK
   Sarks, SH
TI Adult vitelliform macular degeneration: a clinicopathological study
SO EYE
LA English
DT Article
DE adult vitelliform macular degeneration; adult foveomacular vitelliform
   dystrophy; age-related macular degeneration
ID PIGMENT EPITHELIAL DYSTROPHY; DRUSEN; DETACHMENT; FEATURES; DISEASE;
   HOLE
AB Aims/background The yellow lesions of adult vitelliform macular degeneration (AVMD) slowly fade, progressing to hyperpigmentation or atrophy. This study aims to provide further observations on the location and nature of the vitelliform material.
   Methods This report describes the clinicopathological correlation of four eyes with AVMD. A retrospective histopathological study of a further 526 aged eyes previously graded for the stage of age-related macular degeneration (AMD) found another 10 eyes with similar pathology.
   Results The predominant finding was a collection of extracellular material beneath the sensory retina at the fovea. This material was derived internally from photoreceptor outer segments and externally from the retinal pigment epithelium (RPE), the latter first undergoing hypertrophy and then disruption and attenuation. Fallout of foveal cones occurred over these lesions and the inner retina was thinned, which may explain macular hole formation in this condition. All affected eyes showed histopathological evidence of AMD.
   Conclusions This study confirms that the vitelliform lesions of AVMD lie beneath the sensory retina. In contrast to previous reports, however, it is proposed that the lesions comprise mainly extracellular material consisting of photoreceptor debris, possibly the result of faulty phagocytosis by the RPE, mixed with pigment liberated as the RPE undergoes disruption. The vitelliform lesions therefore are a marker for the area of maximal RPE disturbance.
C1 Marsden Eye Ctr, Sydney, NSW, Australia.
   Univ New S Wales, Sydney, NSW, Australia.
   Prince Wales Med Res Inst, Sydney, NSW, Australia.
   SW Area Pathol Serv, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; Prince Wales Medical Research
   Institute
RP Sarks, SH (通讯作者)，15 Parnell St, Strathfield, NSW 2135, Australia.
RI Killingsworth, Murray C/G-5908-2015; Killingsworth, Murray/O-3736-2019
OI Killingsworth, Murray/0000-0002-6125-1183
CR Bernasconi ORE, 1996, KLIN MONATSBL AUGENH, V208, P291, DOI 10.1055/s-2008-1035218
   BLOOM LH, 1981, BRIT J OPHTHALMOL, V65, P800, DOI 10.1136/bjo.65.11.800
   BURGESS DB, 1987, OPHTHALMOLOGY, V94, P362
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   EPSTEIN GA, 1980, BRIT J OPHTHALMOL, V64, P733, DOI 10.1136/bjo.64.10.733
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   GASS JDM, 1977, STEREOSCOPIC ATLAS M, P170
   Glacet-Bernard A, 1993, Eur J Ophthalmol, V3, P53
   GREAVES AH, 1990, AUST NZ J OPHTHALMOL, V18, P171, DOI 10.1111/j.1442-9071.1990.tb00610.x
   GUTMAN I, 1982, BRIT J OPHTHALMOL, V66, P170, DOI 10.1136/bjo.66.3.170
   JAFFE GJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P958
   NOBLE KG, 1991, ARCH OPHTHALMOL-CHIC, V109, P325, DOI 10.1001/archopht.1991.01080030027024
   OGORMAN S, 1988, ARCH OPHTHALMOL-CHIC, V106, P1261
   PATRINELY JR, 1985, OPHTHALMOLOGY, V92, P1712
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   SCHACHAT AP, 1985, RETINA-J RET VIT DIS, V5, P22, DOI 10.1097/00006982-198500510-00005
   Streilein JW, 1997, J IMMUNOL, V158, P3557
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VINE AK, 1980, AM J OPHTHALMOL, V89, P680, DOI 10.1016/0002-9394(80)90288-3
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
NR 24
TC 66
Z9 69
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD AUG
PY 2003
VL 17
IS 6
BP 717
EP 726
DI 10.1038/sj.eye.6700460
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 717FK
UT WOS:000185075900008
PM 12928683
OA Bronze
DA 2022-11-30
ER

PT J
AU Liu, XY
   Lu, R
   Chen, J
   Wang, J
   Qian, HM
   Chen, G
   Wu, RH
   Chi, ZL
AF Liu, Xi-Yuan
   Lu, Rui
   Chen, Jing
   Wang, Jie
   Qian, Hong-Mei
   Chen, Gang
   Wu, Rong-Han
   Chi, Zai-Long
TI Suppressor of Cytokine Signaling 2 Regulates Retinal Pigment Epithelium
   Metabolism by Enhancing Autophagy
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE suppressor of cytokine signaling 2; retinal pigment epithelium;
   autophagy; ubiquitin; glycogen synthase kinase (GSK)-3 beta; mammalian
   target of rapamycin (mTOR)
ID PROTEIN; GROWTH; IMPAIRMENT; PATHWAY; DEGRADATION; PROMOTES; AMPK;
   EXPRESSION; MECHANISM; SYSTEM
AB Retinal pigment epithelium (RPE) serves critical functions in maintaining retinal homeostasis. An important function of RPE is to degrade the photoreceptor outer segment fragments daily to maintain photoreceptor function and longevity throughout life. An impairment of RPE functions such as metabolic regulation leads to the development of age-related macular degeneration (AMD) and inherited retinal degenerative diseases. As substrate recognition subunit of a ubiquitin ligase complex, suppressor of cytokine signaling 2 (SOCS2) specifically binds to the substrates for ubiquitination and negatively regulates growth hormone signaling. Herein, we explore the role of SOCS2 in the metabolic regulation of autophagy in the RPE cells. SOCS2 knockout mice exhibited the irregular morphological deposits between the RPE and Bruch's membrane. Both in vivo and in vitro experiments showed that RPE cells lacking SOCS2 displayed impaired autophagy, which could be recovered by re-expressing SOCS2. SOCS2 recognizes the ubiquitylated proteins and participates in the formation of autolysosome by binding with autophagy receptors and lysosome-associated membrane protein2 (LAMP-2), thereby regulating the phosphorylation of glycogen synthase kinase 3 beta (GSK3 beta) and mammalian target of rapamycin (mTOR) during the autophagy process. Our results imply that SOCS2 participates in ubiquitin-autophagy-lysosomal pathway and enhances autophagy by regulating GSK3 beta and mTOR. This study provides a potential therapeutic target for AMD.
C1 [Chi, Zai-Long] Wenzhou Med Univ, Eye Hosp, State Key Lab Ophthalmol Optometry & Visual Sci, Wenzhou, Peoples R China.
   Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Chi, ZL (通讯作者)，Wenzhou Med Univ, Eye Hosp, State Key Lab Ophthalmol Optometry & Visual Sci, Wenzhou, Peoples R China.
EM zailong.chi@eye.ac.cn
FU Natural Science Foundation of Zhejiang Province [LQ17H120006,
   LY20H120004]; National Natural Science Foundation of China [81770918];
   initial Grant of Wenzhou Medical University Eye Hospital [KYQD150601]
FX This study was supported by the Natural Science Foundation of Zhejiang
   Province (LQ17H120006 and LY20H120004), the National Natural Science
   Foundation of China (81770918), and the initial Grant of Wenzhou Medical
   University Eye Hospital (KYQD150601).
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5296341
   Akiyama M, 2018, J HUM GENET, V63, P1083, DOI 10.1038/s10038-018-0493-0
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Brown RAM, 2018, BMC BIOTECHNOL, V18, DOI 10.1186/s12896-018-0421-6
   Bulatov E, 2015, J BIOL CHEM, V290, P4178, DOI 10.1074/jbc.M114.616664
   Casellas J, 2008, AGE, V30, P245, DOI 10.1007/s11357-008-9064-1
   Chen R, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6954764
   Chhabra Y, 2018, ONCOGENE, V37, P489, DOI 10.1038/onc.2017.352
   Chinchilla B, 2021, JOVE-J VIS EXP, DOI 10.3791/62228
   Cho K, 2021, BIOCHEM BIOPH RES CO, V559, P21, DOI 10.1016/j.bbrc.2021.04.089
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dantuma NP, 2014, FRONT MOL NEUROSCI, V7, DOI [10.3389/fnmo1.2014.00070, 10.3389/fnmol.2014.00070]
   Dorion MF, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6691402
   Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Gamerdinger M, 2009, EMBO J, V28, P889, DOI 10.1038/emboj.2009.29
   Ge DX, 2013, J PINEAL RES, V55, P377, DOI 10.1111/jpi.12084
   Giaime E, 2017, NEURON, V96, P796, DOI 10.1016/j.neuron.2017.09.036
   Gossing W, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9020201
   Hansen M, 2018, NAT REV MOL CELL BIO, V19, P611, DOI 10.1038/s41580-018-0048-4
   Hariharan N, 2011, ANTIOXID REDOX SIGN, V14, P2179, DOI 10.1089/ars.2010.3488
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kim PK, 2008, P NATL ACAD SCI USA, V105, P20567, DOI 10.1073/pnas.0810611105
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020
   Kung WW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10190-4
   Li H, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.3
   Li ZQ, 2019, MOL THER-NUCL ACIDS, V18, P764, DOI 10.1016/j.omtn.2019.10.004
   Lu KF, 2014, CELL, V158, P549, DOI 10.1016/j.cell.2014.05.048
   Madeo F, 2019, AUTOPHAGY, V15, P165, DOI 10.1080/15548627.2018.1530929
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nakamura S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08729-6
   Niu SB, 2014, PROTEIN CELL, V5, P945, DOI 10.1007/s13238-014-0099-z
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Paul I, 2017, SCI REP-UK, V7, DOI 10.1038/srep42800
   Qiu Y, 2017, PROTEIN SCI, V26, P1674, DOI 10.1002/pro.3186
   Ranieri R, 2018, CELL DEATH DIFFER, V25, P353, DOI 10.1038/cdd.2017.165
   Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107
   Rippin I, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020262
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Ross BX, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082010
   Ryu HY, 2021, EXP MOL MED, V53, P369, DOI 10.1038/s12276-021-00570-6
   Sarajlic M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235931
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Shen YC, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01392-2
   Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727
   Sophia J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1126-4
   Sun AQ, 2017, AUTOPHAGY, V13, P522, DOI 10.1080/15548627.2016.1268301
   Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800
   Turnley AM, 2005, TRENDS ENDOCRIN MET, V16, P53, DOI 10.1016/j.tem.2005.01.006
   Vesterlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025358
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang SK, 2014, EMBO REP, V15, P1053, DOI 10.15252/embr.201338343
   Wei Zenghui, 2021, Front Neurosci, V15, P687157, DOI 10.3389/fnins.2021.687157
   Xu CF, 2014, AUTOPHAGY, V10, P2239, DOI 10.4161/15548627.2014.981792
   Yamano K, 2020, AUTOPHAGY, V16, P2105, DOI 10.1080/15548627.2020.1815457
   Zaffagnini G, 2018, AUTOPHAGY, V14, P1280, DOI 10.1080/15548627.2018.1462079
   Zhai PY, 2011, CIRC RES, V109, P502, DOI 10.1161/CIRCRESAHA.111.249532
   Zhan J, 2016, CURR MOL MED, V16, P487, DOI 10.2174/1566524016666160429121606
   Zhao X, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2524174
NR 65
TC 0
Z9 0
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD NOV 8
PY 2021
VL 15
AR 738022
DI 10.3389/fnins.2021.738022
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA XB1EC
UT WOS:000721076900001
PM 34819832
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sparrow, JR
   Parmann, R
   Tsang, SH
   Allikmets, R
   Chang, S
   Jauregui, R
AF Sparrow, Janet R.
   Parmann, Rait
   Tsang, Stephen H.
   Allikmets, Rando
   Chang, Stanley
   Jauregui, Ruben
TI Shared Features in Retinal Disorders With Involvement of Retinal Pigment
   Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE fundus autofluorescence; spectral domain optical coherence tomography;
   retina; retinal pigment epithelium; retinal disorder; scanning laser
   ophthalmoscopy; flecks; white-dots; reticular pseudodrusen
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS;
   QUANTITATIVE FUNDUS AUTOFLUORESCENCE; SHORT-WAVELENGTH AUTOFLUORESCENCE;
   RETICULAR PSEUDODRUSEN; MACULAR DEGENERATION; STARGARDT DISEASE; PATTERN
   DYSTROPHY; BOTHNIA DYSTROPHY; S163R MUTATION
AB When using spectral domain optical coherence tomography (SD-OCT) to inform the status of outer retina, we have noted discrete hyperreflective lesions extending through photoreceptor-attributable bands that have a similar presentation in multiple retinal diseases. These lesions present as either corrugated thickenings of interdigitation zone and ellipsoid zone bands or in later stages as rectangular or pyramidal shaped foci that extend radially through photoreceptor cell-attributable bands. In ABCA4-related and peripherin-2/RDS-disease (PRPH2/RDS), monogenic forms of retinopathy caused by mutations in proteins expressed in photoreceptor cells, these punctate lesions colocalize with fundus flecks in en face images. In fundus albipunctatus and retinitis punctata albescens, diseases caused by mutations in genes (retinol dehydrogenase 5, RDH5; and retinaldehyde-binding protein 1, RLBP1) encoding proteins of the visual cycle, these lesions manifest as white dot-like puncta. Similar aberrations in photoreceptor cell-attributable SD-OCT reflectivity layers manifest as reticular pseudodrusen (RPD) in short-wavelength fundus autofluorescence and near-infrared fundus autofluorescence fundus images and are linked to age-related macular degeneration a complex disease. Despite differences in the etiologies of retinal diseases presenting as fundus flecks, dots and RPD, underlying degenerative processes in photoreceptor cells are signified in SD-OCT scans by the loss of structural features that would otherwise define healthy photoreceptor cells at these foci.
C1 [Sparrow, Janet R.; Parmann, Rait; Tsang, Stephen H.; Allikmets, Rando; Chang, Stanley; Jauregui, Ruben] Columbia Univ, Dept Ophthalmol, Harkness Eye Inst, New York, NY 10027 USA.
   [Sparrow, Janet R.; Tsang, Stephen H.; Allikmets, Rando] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA.
C3 Columbia University; Columbia University
RP Sparrow, JR (通讯作者)，Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
EM jrs88@columbia.edu
RI Allikmets, Rando/ABD-4533-2021
FU National Eye Institute/NIH [EY024091, P30 EY019007]; Foundation Fighting
   Blindness; Research to Prevent Blindness; Jonas Children's Vision Care
FX Supported in part by grants from the National Eye Institute/NIH EY024091
   and P30 EY019007, Foundation Fighting Blindness, Jonas Children's Vision
   Care and a grant from Research to Prevent Blindness to the Department of
   Ophthalmology, Columbia University.
CR Aleman TS, 2008, INVEST OPHTH VIS SCI, V49, P1580, DOI 10.1167/iovs.07-1110
   Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Apushkin MA, 2005, RETINA-J RET VIT DIS, V25, P650, DOI 10.1097/00006982-200507000-00016
   Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Birch DG, 2013, JAMA OPHTHALMOL, V131, P1143, DOI 10.1001/jamaophthalmol.2013.4160
   Boon CJF, 2007, BRIT J OPHTHALMOL, V91, P1504, DOI 10.1136/bjo.2007.115659
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Burstedt M, 2013, ACTA OPHTHALMOL, V91, P437, DOI 10.1111/j.1755-3768.2012.02431.x
   Burstedt MSI, 2009, OPHTHALMOLOGY, V116, P324, DOI 10.1016/j.ophtha.2008.09.007
   Burstedt MSL, 2001, ARCH OPHTHALMOL-CHIC, V119, P260
   Cabral T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10473-0
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Chavali VRM, 2011, HUM MOL GENET, V20, P2000, DOI 10.1093/hmg/ddr080
   Chhablani JK, 2012, GRAEF ARCH CLIN EXP, V250, P1415, DOI 10.1007/s00417-012-1968-x
   Christensen DRG, 2017, EXP EYE RES, V165, P35, DOI 10.1016/j.exer.2017.08.014
   Cukras C, 2016, RETINA-J RET VIT DIS, V36, P2348, DOI 10.1097/IAE.0000000000001113
   Cukras CA, 2012, ARCH OPHTHALMOL-CHIC, V130, P171, DOI 10.1001/archophthalmol.2011.332
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P3159, DOI 10.1167/iovs.14-16343
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P8134, DOI 10.1167/iovs.14-14848
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   FISHMAN GA, 1987, OPHTHALMOLOGY, V94, P809, DOI 10.1016/s0161-6420(87)33533-x
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   Greenstein VC, 2017, INVEST OPHTH VIS SCI, V58, P5227, DOI 10.1167/iovs.17-22532
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P101, DOI 10.1167/iovs.10-5799
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Kellner S, 2009, AM J OPHTHALMOL, V147, P895, DOI 10.1016/j.ajo.2008.12.023
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   de Carvalho JRL, 2020, J BIOL CHEM, V295, P6767, DOI 10.1074/jbc.RA120.012695
   Lima LH, 2009, RETINA-J RET VIT DIS, V29, P1025, DOI 10.1097/IAE.0b013e3181ac2418
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5505, DOI 10.1167/iovs.06-0312
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Oh JK, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65763-x
   Paavo M, 2018, INVEST OPHTH VIS SCI, V59, P2459, DOI 10.1167/iovs.18-24213
   Paavo M, 2019, J NEUROSCI RES, V97, P98, DOI 10.1002/jnr.24252
   Paavo M, 2017, INVEST OPHTH VIS SCI, V58, P4769, DOI 10.1167/iovs.17-22338
   Quazi F, 2014, P NATL ACAD SCI USA, V111, P5024, DOI 10.1073/pnas.1400780111
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2009, ARCH OPHTHALMOL-CHIC, V127, P703, DOI 10.1001/archophthalmol.2009.87
   Reiter GS, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.11
   Robson AG, 2011, RETINA-J RET VIT DIS, V31, P1670, DOI 10.1097/IAE.0b013e318206d155
   Saari John C, 2016, Subcell Biochem, V81, P231
   Sassmannshausen M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.19
   SCHMIDT GH, 1986, J EMBRYOL EXP MORPH, V91, P197
   Schuerch K, 2017, INVEST OPHTH VIS SCI, V58, P1843, DOI 10.1167/iovs.16-21302
   Sergouniotis PI, 2011, OPHTHALMOLOGY, V118, P1661, DOI 10.1016/j.ophtha.2010.12.031
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Sparrow JR, 2015, INVEST OPHTH VIS SCI, V56, P5029, DOI 10.1167/iovs.15-16763
   Stuck MW, 2016, PROG RETIN EYE RES, V52, P47, DOI 10.1016/j.preteyeres.2015.12.002
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Tee JJL, 2017, AM J OPHTHALMOL, V178, P18, DOI 10.1016/j.ajo.2017.03.012
   Walia S, 2009, OPHTHALMIC GENET, V30, P63, DOI 10.1080/13816810802695550
   Wang C, 2008, OPHTHALMIC GENET, V29, P29, DOI 10.1080/13816810701663535
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Zhang K, 2002, ARCH OPHTHALMOL-CHIC, V120, P485
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 69
TC 3
Z9 2
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2021
VL 62
IS 7
AR 15
DI 10.1167/iovs.62.7.15
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UA5JI
UT WOS:000685197200007
PM 34115091
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kim, J
   Park, JY
   Kong, JS
   Lee, H
   Won, JY
   Cho, DW
AF Kim, Jongmin
   Park, Ju Young
   Kong, Jeong Sik
   Lee, Hyungseok
   Won, Jae Yon
   Cho, Dong Woo
TI Development of 3D Printed Bruch's Membrane-Mimetic Substance for the
   Maturation of Retinal Pigment Epithelial Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE retinal pigment epithelium; RPE maturation; tissue-specific bioink; in
   vitro RPE model; tissue-mimetic substrate
AB Retinal pigment epithelium (RPE) is a monolayer of the pigmented cells that lies on the thin extracellular matrix called Bruch's membrane. This monolayer is the main component of the outer blood-retinal barrier (BRB), which plays a multifunctional role. Due to their crucial roles, the damage of this epithelium causes a wide range of diseases related to retinal degeneration including age-related macular degeneration, retinitis pigmentosa, and Stargardt disease. Unfortunately, there is presently no cure for these diseases. Clinically implantable RPE for humans is under development, and there is no practical examination platform for drug development. Here, we developed porcine Bruch's membrane-derived bioink (BM-ECM). Compared to conventional laminin, the RPE cells on BM-ECM showed enhanced functionality of RPE. Furthermore, we developed the Bruch's membrane-mimetic substrate (BMS) via the integration of BM-ECM and 3D printing technology, which revealed structure and extracellular matrix components similar to those of natural Bruch's membrane. The developed BMS facilitated the appropriate functions of RPE, including barrier and clearance functions, the secretion of anti-angiogenic growth factors, and enzyme formation for phototransduction. Moreover, it could be used as a basement frame for RPE transplantation. We established BMS using 3D printing technology to grow RPE cells with functions that could be used for an in vitro model and RPE transplantation.
C1 [Kim, Jongmin; Park, Ju Young; Lee, Hyungseok; Cho, Dong Woo] Pohang Univ Sci & Technol POSTECH, Dept Mech Engn, Pohang 37673, South Korea.
   [Kong, Jeong Sik; Cho, Dong Woo] Pohang Univ Sci & Technol POSTECH, Sch Interdisciplinary Biosci & Bioengn, Pohang 37673, South Korea.
   [Lee, Hyungseok] Kangwon Natl Univ, Dept Mech & Biomed Engn, Chunchon 24341, South Korea.
   [Won, Jae Yon] Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul 03312, South Korea.
   [Won, Jae Yon] Catholic Univ Korea, Coll Med, Catholic Inst Visual Sci, Seoul 14662, South Korea.
   [Cho, Dong Woo] Yonsei Univ, Inst Convergence Sci, Seoul 03722, South Korea.
C3 Pohang University of Science & Technology (POSTECH); Pohang University
   of Science & Technology (POSTECH); Kangwon National University; Catholic
   University of Korea; Catholic University of Korea; Yonsei University
RP Cho, DW (通讯作者)，Pohang Univ Sci & Technol POSTECH, Dept Mech Engn, Pohang 37673, South Korea.; Cho, DW (通讯作者)，Pohang Univ Sci & Technol POSTECH, Sch Interdisciplinary Biosci & Bioengn, Pohang 37673, South Korea.; Won, JY (通讯作者)，Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul 03312, South Korea.; Won, JY (通讯作者)，Catholic Univ Korea, Coll Med, Catholic Inst Visual Sci, Seoul 14662, South Korea.; Cho, DW (通讯作者)，Yonsei Univ, Inst Convergence Sci, Seoul 03722, South Korea.
EM mandarinbear@postech.ac.kr; juyoung1489@postech.ac.kr;
   urhere@postech.ac.kr; ahl@kangwon.ac.kr; jaywon24@catholic.ac.kr;
   dwcho@postech.ac.kr
OI Park, Ju Young/0000-0002-5896-0958
FU National Research Foundation of Korea - Korea government (MSIP)
   [NRF-2019R1A3A3005437]; Catholic University of Korea, Eunpyeong St.
   Mary's Hospital. Research Institute of Medical Science
FX This work has been supported by the National Research Foundation of
   Korea grant funded by the Korea government (MSIP) (NRF-2019R1A3A3005437)
   and The Catholic University of Korea, Eunpyeong St. Mary's Hospital.
   Research Institute of Medical Science.
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Chan SY, 2017, ACS OMEGA, V2, P8959, DOI 10.1021/acsomega.7b01604
   Chang YC, 2016, J PHARMACOL SCI, V132, P262, DOI 10.1016/j.jphs.2016.11.002
   Chemla ES, 2009, BRIT J SURG, V96, P34, DOI 10.1002/bjs.6434
   Chen HL, 2011, INT J NANOMED, V6, P453, DOI 10.2147/IJN.S17057
   Cukierman E, 2010, SEMIN CANCER BIOL, V20, P139, DOI 10.1016/j.semcancer.2010.04.004
   Cunha-Vaz J., 2009, EUR OPHTHALMIC REV, V3, P105, DOI [DOI 10.17925/EOR.2009.03.02.105, 10.17925/EOR.2009.03.02.105]
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Deissler HL, 2020, EXP EYE RES, V194, DOI 10.1016/j.exer.2020.108004
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Glazer Liane Clamen, 2002, Ophthalmol Clin North Am, V15, P93, DOI 10.1016/S0896-1549(01)00011-6
   Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Hamilton RD, 2011, METHODS MOL BIOL, V686, P401, DOI 10.1007/978-1-60761-938-3_20
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harkin DG, 2011, BIOMATERIALS, V32, P2445, DOI 10.1016/j.biomaterials.2010.12.041
   Hellinen L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50324-8
   HETH CA, 1987, CURR EYE RES, V6, P1007, DOI 10.3109/02713688709034872
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Hu J, 2001, MOL VIS, V7, P14
   Jiang PF, 2020, NANOSCALE, V12, P17298, DOI 10.1039/d0nr03710a
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Karalashvili L., 2018, MED CASE REP, V4, P87
   Kim BS, 2020, CHEM REV, V120, P10941, DOI 10.1021/acs.chemrev.9b00808
   Kim BS, 2018, BIOMATERIALS, V168, P38, DOI 10.1016/j.biomaterials.2018.03.040
   Kim BS, 2017, BIOFABRICATION, V9, DOI 10.1088/1758-5090/aa71c8
   Lee H, 2019, BIOFABRICATION, V11, DOI 10.1088/1758-5090/aaf9fa
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Lynn Savannah A, 2018, F1000Res, V7, P1107, DOI 10.12688/f1000research.15409.1
   Lynn SA, 2017, TISSUE CELL, V49, P447, DOI 10.1016/j.tice.2017.06.003
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mannermaa E, 2010, EUR J PHARM SCI, V40, P289, DOI 10.1016/j.ejps.2010.04.001
   McHarg S, 2015, JOVE-J VIS EXP, DOI 10.3791/53382
   Moreira EF, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.10
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Park Un Chul, 2011, Clin Exp Reprod Med, V38, P216, DOI 10.5653/cerm.2011.38.4.216
   Pati F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4935
   Rezai KA, 1999, INVEST OPHTH VIS SCI, V40, P1223
   Samuel W, 2017, MOL VIS, V23, P60
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Shadforth AMA, 2017, J TISSUE ENG REGEN M, V11, P1915, DOI 10.1002/term.2089
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strong S, 2017, BRIT J OPHTHALMOL, V101, P31, DOI 10.1136/bjophthalmol-2016-309376
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   Terao R, 2019, PROSTAG OTH LIPID M, V145, DOI 10.1016/j.prostaglandins.2019.106365
   The United States Food and Drug Administration, 1997, GUID IND NONST SEM D
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tibbitt MW, 2009, BIOTECHNOL BIOENG, V103, P655, DOI 10.1002/bit.22361
   Timmers A, 2001, MOL VIS, V7, P131
   Treharne AJ, 2011, BRIT J OPHTHALMOL, V95, P768, DOI 10.1136/bjo.2010.184002
   Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943
   Vasireddy V, 2010, PROG RETIN EYE RES, V29, P191, DOI 10.1016/j.preteyeres.2010.01.001
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Yi HG, 2019, NAT BIOMED ENG, V3, P509, DOI 10.1038/s41551-019-0363-x
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
   Zhu DL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01608-8
NR 81
TC 9
Z9 10
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2021
VL 22
IS 3
AR 1095
DI 10.3390/ijms22031095
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QD2EZ
UT WOS:000615339700001
PM 33499245
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Pham, TNM
   Shin, CY
   Park, SH
   Lee, TH
   Ryu, HY
   Kim, SB
   Auh, K
   Jeong, KW
AF Thu Nguyen Minh Pham
   Shin, Chae-Young
   Park, Seo Hyun
   Lee, Taek Hwan
   Ryu, Hyeon Yeol
   Kim, Sung-Bae
   Auh, Kwang
   Jeong, Kwang Won
TI Solanum melongena L. Extract Protects Retinal Pigment Epithelial Cells
   from Blue Light-Induced Phototoxicity in In Vitro and In Vivo Models
SO NUTRIENTS
LA English
DT Article
DE eggplant extract; blue light; A2E; age-related macular degeneration;
   chlorogenic acid
AB N-retinylidene-N-retinylethanolamine (A2E) accumulation in the retina is a prominent marker of retinal degenerative diseases. Blue light exposure is considered as an important factor contributing to dry age-related macular degeneration (AMD). Eggplant and its constituents have been shown to confer health benefits, but their therapeutic effects on dry AMD remain incompletely understood. In this study, we showed that an extract of Solanum melongena L. (EPX) protected A2E-laden ARPE-19 cells against blue light-induced cell death via attenuating reactive oxygen species. Transcriptomic analysis demonstrated that blue light modulated the expression of genes associated with stress response, inflammation, and cell death, and EPX suppressed the inflammatory pathway induced by blue light in A2E-laden ARPE-19 cells by inhibiting the nuclear translocation of nuclear factor kappa B and transcription of pro-inflammatory genes (CXCL8 and IL1B). The degradation of intracellular A2E was considered the major mechanism underlying the protective effect of EPX. Moreover, chlorogenic acid isolated from EPX exerted protective effects against blue light-induced cell damage in A2E-laden ARPE-19 cells. In vivo, EPX administration in BALB/c mice reduced the fundus damage and degeneration of the retinal layer in a blue light-induced retinal damage model. Collectively, our findings suggest the potential role of Solanum melongena L. extract for AMD treatment.
C1 [Thu Nguyen Minh Pham; Shin, Chae-Young; Jeong, Kwang Won] Gachon Univ, Coll Pharm, Gachon Res Inst Pharmaceut Sci, Incheon 21936, South Korea.
   [Thu Nguyen Minh Pham] Hong Bang Int Univ, Fac Pharm, Dept Pharmacognosy, Ho Chi Minh 215, Vietnam.
   [Park, Seo Hyun; Lee, Taek Hwan; Auh, Kwang] Ahn Gook Hlth Co Ltd, R&D Ctr, Seoul 06164, South Korea.
   [Ryu, Hyeon Yeol; Kim, Sung-Bae] Korea Conform Labs, Incheon 21999, South Korea.
C3 Gachon University; Hong Bang International University
RP Jeong, KW (通讯作者)，Gachon Univ, Coll Pharm, Gachon Res Inst Pharmaceut Sci, Incheon 21936, South Korea.
EM phamnguyenminhthud12@gmail.com; codud9921@naver.com;
   shpark@ag-health.com; lth0717@naver.com; rhychato98@kcl.re.kr;
   suaa10@kcl.re.kr; khan@ag-health.com; kwjeong@gachon.ac.kr
FU Project of Support for Joint Utilization of Research Facilities and
   Equipment - Ministry of SMEs and Startups (MSS, Korea)
FX This work was partly supported by the Project of Support for Joint
   Utilization of Research Facilities and Equipment funded by the Ministry
   of SMEs and Startups (MSS, Korea).
CR Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Bouhajeb R, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.202000405
   Boulekbache-Makhlouf L, 2013, IND CROP PROD, V49, P668, DOI 10.1016/j.indcrop.2013.06.009
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Feng JY, 2014, OPHTHALMIC RES, V52, P224, DOI 10.1159/000363387
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gurbuz N, 2018, FOOD CHEM, V268, P602, DOI 10.1016/j.foodchem.2018.06.093
   Hammer M, 2006, MOL VIS, V12, P1348
   Han SW, 2003, CLIN CHIM ACTA, V328, P39, DOI 10.1016/S0009-8981(02)00377-7
   Horincar G, 2019, ANN U DUNAREA-FOOD, V43, P40, DOI 10.35219/foodtechnology.2019.1.03
   Im K, 2016, FOOD AGR IMMUNOL, V27, P758, DOI 10.1080/09540105.2016.1150427
   Jang H, 2015, MOL NUTR FOOD RES, V59, P1918, DOI 10.1002/mnfr.201400897
   Jang H, 2014, J AGR FOOD CHEM, V62, P182, DOI 10.1021/jf404285v
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Jeong SY, 2019, FOOD CHEM TOXICOL, V131, DOI 10.1016/j.fct.2019.06.002
   Jin HL, 2017, J FUNCT FOODS, V39, P28, DOI 10.1016/j.jff.2017.10.009
   Jin HL, 2016, J PHARMACEUT BIOMED, V117, P560, DOI 10.1016/j.jpba.2015.10.010
   Jin ML, 2018, INT J CANCER, V143, P2871, DOI 10.1002/ijc.31853
   Jung EJ, 2011, J MED PLANTS RES, V5, P4610
   Kim J, 2018, FOOD FUNCT, V9, P2171, DOI 10.1039/c7fo01958k
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kozhevnikova OS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194804
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Naveed M, 2018, BIOMED PHARMACOTHER, V97, P67, DOI 10.1016/j.biopha.2017.10.064
   Nwanna EE, 2019, FOOD SCI NUTR, V7, P109, DOI 10.1002/fsn3.811
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Telegina DV, 2017, ADV GERONTOL, V7, P17, DOI 10.1134/S2079057017010155
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   van der Burght Barbro W, 2013, Acta Ophthalmol, V91, pe537, DOI 10.1111/aos.12146
   Wang Y, 2017, J FUNCT FOODS, V33, P103, DOI 10.1016/j.jff.2017.02.034
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 51
TC 7
Z9 8
U1 3
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD FEB
PY 2021
VL 13
IS 2
AR 359
DI 10.3390/nu13020359
PG 16
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA QO1QK
UT WOS:000622921300001
PM 33503991
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Grillo, SL
   Etzel, JD
   Weber, SR
   Ondeck, C
   Wang, WW
   Zhao, YJ
   Barber, AJ
   Sundstrom, JM
AF Grillo, Stephanie L.
   Etzel, Justin D.
   Weber, Sarah R.
   Ondeck, Cassandra
   Wang, Weiwei
   Zhao, Yuanjun
   Barber, Alistair J.
   Sundstrom, Jeffrey M.
TI Descriptive analysis of Fibulin-3 and the extracellular vesicle marker,
   Alix, in drusen from a small cohort of postmortem human eyes
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; AMD; Alix; Retina; Doyne honeycomb
   retinal dystrophy; EFEMP1; RPE; Exosomes
AB Fibulin-3 (Fib3) is a secreted glycoprotein that is expressed in the retina and has been associated with drusen formation in age-related macular degeneration (AMD). The purpose of this study was to assess whether Fib3 is associated with extracellular vesicles (EVs) in drusen from non-diseased and AMD human donors. De-identified sections of human eyes were received from the National Disease Research Institute (NDRI, Philadelphia). Donor eyes were either non-diseased (no known ocular pathology) or had been diagnosed with AMD. Retinal cryostat sections were labeled with primary antibodies targeted to Fib3, Apolipoprotein E (ApoE; a drusen marker), and ALG-2 interacting protein X (Alix, an EV marker) for confocal imaging (Leica TCS SP8). Fib3-positive (Fib(3+)) puncta were detected on the apical region of the RPE layer and within large AMD drusen. Alix-positive (Alix(+)) puncta were also detected in a single AMD druse, where a number were Fib(3+) and the remaining were Fib3-negative. Similarly, there were Fib(3+) puncta that were Alix-negative. Fib3 and Alix also showed a degree of colocalization in the photoreceptor outer segments of the neural retina. Our data suggest that the Alix+ puncta are EV-rich populations that accumulate, together with Fib3, within the drusen matrix during AMD. The EV population is likely heterogeneous, such that there are sub-populations with different cargo content.
C1 [Grillo, Stephanie L.; Etzel, Justin D.; Weber, Sarah R.; Ondeck, Cassandra; Wang, Weiwei; Zhao, Yuanjun; Barber, Alistair J.; Sundstrom, Jeffrey M.] Penn State Univ, Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health
RP Sundstrom, JM (通讯作者)，Penn State Univ, Coll Med, Dept Ophthalmol, Ophthalmol, Hershey, PA 17033 USA.
EM sgrillo@pennstatehealth.psu.edu; justin.etzel@gmail.com;
   sweber2@pennstatehealth.psu.edu; cassandra.ondeck@gmail.com;
   wangw5@uthscsa.edu; yzhao2@pennstatehealth.psu.edu;
   abarber@pennstateheatlh.psu.edu; jsundstrom@pennstatehealth.psu.edu
OI Grillo, Stephanie/0000-0001-7208-300X
FU Penn State College of Medicine start-up funds; Bennett and Inez Chotiner
   Early Career Professor in Ophthalmology endowment
FX This work was funded by Penn State College of Medicine start-up funds
   and the Bennett and Inez Chotiner Early Career Professor in
   Ophthalmology endowment (JMS). We also wish to thank Wade Edris in the
   Penn State Hershey Microscopy Imaging Core Facility.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   FEENEYBURNS L, 1987, INVEST OPHTH VIS SCI, V28, P1138
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klingeborn M, 2018, ADV EXP MED BIOL, V1074, P539, DOI 10.1007/978-3-319-75402-4_65
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schnell SA, 1999, J HISTOCHEM CYTOCHEM, V47, P719, DOI 10.1177/002215549904700601
   Sohn EH, 2015, RETINA-J RET VIT DIS, V35, P48, DOI 10.1097/IAE.0000000000000263
   Stanton JB, 2017, INVEST OPHTH VIS SCI, V58, P1455, DOI 10.1167/iovs.16-20955
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Tong Y, 2016, MED HYPOTHESES, V97, P98, DOI 10.1016/j.mehy.2016.10.027
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   WEISSE I, 1995, OPHTHALMIC RES, V27, P154, DOI 10.1159/000267862
   Zayas-Santiago A, 2017, INVEST OPHTH VIS SCI, V58, P3046, DOI 10.1167/iovs.17-21720
   Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018
NR 32
TC 3
Z9 3
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2021
VL 203
AR 108422
DI 10.1016/j.exer.2020.108422
EA JAN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG8GX
UT WOS:000617820900006
PM 33387484
DA 2022-11-30
ER

PT J
AU Priyanka, S
   Kirubagaran, R
   Leema, JTM
AF Priyanka, S.
   Kirubagaran, R.
   Leema, J. T. Mary
TI Optimization of algal culture medium for zeaxanthin production by
   Dunaliella tertiolecta: an RSM based approach
SO CURRENT SCIENCE
LA English
DT Article
DE Dunaliella tertiolecta; De Walne's medium; nutraceutical; response
   surface methodology; zeaxanthin
ID RESPONSE-SURFACE METHODOLOGY; MOLECULAR-IDENTIFICATION; STATISTICAL
   OPTIMIZATION; COMMERCIAL APPLICATIONS; LIPID PRODUCTION; MICROALGAE;
   LUTEIN; BIOMASS; ACCUMULATION; ASTAXANTHIN
AB The Chlorophycean microalgae Dunaliella have gained commercial interest because of the synthesis of highly valuable products. One among them is zeaxanthin, a xanthophyll carotenoid valued for its nutraceutical potential related to prevention of age-related macular degeneration and cataract, which is the primary cause for blindness. To improve zeaxanthin production by the microalgae Dunaliella tertiolecta (NIOT-141), De Walne's medium was optimized to its most favourable nutrient level using response surface methodology (RSM) approach. Plackett-Burman method was employed to screen the most significant nutrients influencing zeaxanthin accumulation which revealed sodium nitrate, trace metals and sodium dihydrogen phosphate as the crucial medium components for increasing zeaxanthin production (P < 0.05). Further, RSM was employed to study the interaction between these factors and identify optimum concentration of the significant ingredients for higher zeaxanthin production. The highest zeaxanthin production reached 20.2 +/- 1.29 mg l(-1) under the optimal conditions of 910 mg l(-1) NaNO3, 40.5 mg l(-1) NaH2PO4 and 0.605 mg l(-1) trace metals solution. Moreover, validation of optimized medium resulted in a three-fold increase in zeaxanthin production compared to unoptimized Walne's medium (6.72 +/- 0.22 mg l(-1)). The results thus obtained were more analogous to the predicted values. Hence the model is effective for enhancing zeaxanthin production in D. tertiolecta.
C1 [Priyanka, S.; Kirubagaran, R.; Leema, J. T. Mary] Natl Inst Ocean Technol, Dept Marine Biotechnol, Chennai 600100, Tamil Nadu, India.
   [Priyanka, S.] Sathyabama Inst Sci & Technol, Chennai 600119, Tamil Nadu, India.
C3 Ministry of Earth Sciences (MoES) - India; National Institute of Ocean
   Technology (NIOT); Sathyabama Institute of Science & Technology
RP Priyanka, S (通讯作者)，Natl Inst Ocean Technol, Dept Marine Biotechnol, Chennai 600100, Tamil Nadu, India.; Priyanka, S (通讯作者)，Sathyabama Inst Sci & Technol, Chennai 600119, Tamil Nadu, India.
EM spriyankamsc@ymail.com
FU Ministry of Earth Sciences (MoES), Government of India; National
   Institute of Ocean Technology (NIOT), Chennai
FX We thank the Director, National Institute of Ocean Technology (NIOT),
   Chennai, and the Ministry of Earth Sciences (MoES), Government of India
   for funding, infrastructure facilities and support to carry out this
   research work.
CR Abdelhafez A. A., 2016, Annals of Agricultural Science (Cairo), V61, P87, DOI 10.1016/j.aoas.2016.01.005
   Ahmad AL, 2005, ENVIRON SCI TECHNOL, V39, P2828, DOI 10.1021/es0498080
   Asker D, 2007, INT J SYST EVOL MICR, V57, P837, DOI 10.1099/ijs.0.64682-0
   Barzegari A, 2010, MOL BIOL REP, V37, P3427, DOI 10.1007/s11033-009-9933-4
   Belotti G, 2014, BIOMASS BIOENERG, V61, P187, DOI 10.1016/j.biombioe.2013.12.011
   Ben-Amatoz A, 1989, ALGAL CYANOBACTERIAL, P90
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bhalamurugan GL, 2018, ENVIRON ENG RES, V23, P229, DOI 10.4491/eer.2017.220
   Celekli A, 2009, BIORESOURCE TECHNOL, V100, P3625, DOI 10.1016/j.biortech.2009.02.055
   Chen CR, 2012, BIORESOURCE TECHNOL, V104, P828, DOI 10.1016/j.biortech.2011.11.083
   Chen F, 2005, J CHROMATOGR A, V1064, P183, DOI 10.1016/j.chroma.2004.12.065
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037578
   Cheng KC, 2013, BIORESOURCE TECHNOL, V128, P44, DOI 10.1016/j.biortech.2012.09.085
   Del Campo JA, 2004, APPL MICROBIOL BIOT, V64, P848, DOI 10.1007/s00253-003-1510-5
   Del Campo JA, 2000, J BIOTECHNOL, V76, P51, DOI 10.1016/S0168-1656(99)00178-9
   Desai KM, 2008, BIOCHEM ENG J, V41, P266, DOI 10.1016/j.bej.2008.05.009
   Fan JH, 2014, BIOTECHNOL BIOFUELS, V7, DOI 10.1186/1754-6834-7-17
   Gharajeh NH, 2012, J AGR SCI TECH-IRAN, V14, P1579
   Granado-Lorencio F, 2009, FOOD CHEM, V114, P747, DOI 10.1016/j.foodchem.2008.10.058
   Griffiths MJ, 2009, J APPL PHYCOL, V21, P493, DOI 10.1007/s10811-008-9392-7
   Hannon M, 2010, BIOFUELS-UK, V1, P763, DOI 10.4155/BFS.10.44
   Hejazi Mohammad A, 2010, Saline Syst, V6, P4, DOI 10.1186/1746-1448-6-4
   Kim MS, 2017, MAR DRUGS, V15, DOI 10.3390/md15070226
   Kiokias S, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7100133
   Kuehl RO, 2000, DESIGN EXPT STAT PRI, V2nd
   LEESING R, 2011, ENG TECHNOL, V52, P499
   Li J, 2017, J AGR FOOD CHEM, V65, P8475, DOI 10.1021/acs.jafc.7b02440
   Mason R.L., 2003, STAT DESIGN ANAL EXP
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Mulders KJM, 2014, J PHYCOL, V50, P229, DOI 10.1111/jpy.12173
   Olmos J, 2000, LETT APPL MICROBIOL, V30, P80, DOI 10.1046/j.1472-765x.2000.00672.x
   Olmos-Soto J, 2002, BIOTECHNOL LETT, V24, P365, DOI 10.1023/A:1014516920887
   Oren Aharon, 2005, Saline Syst, V1, P2, DOI 10.1186/1746-1448-1-2
   Plackett R.L., 1946, BIOMETRIKA, V33, P305, DOI [10.1093/biomet/33.4.305, DOI 10.1093/BIOMET/33.4.305]
   Priyanka S., 2020, P 2 INT AGR BIOL LIF, P1169
   Priyanka S., 2019, INT J PHARM BIOL SCI, V10, P58, DOI DOI 10.22376/IJPBS.2019.10.3.B58-70
   Qiu JZ, 2013, J INVERTEBR PATHOL, V112, P108, DOI 10.1016/j.jip.2012.10.010
   Raja R, 2004, ASIAN J CHEM, V16, P1081
   Sarada R, 2002, FOOD BIOTECHNOL, V16, P107, DOI 10.1081/FBT-120014322
   Sathasivam R, 2016, ECOTOX ENVIRON SAFE, V133, P501, DOI 10.1016/j.ecoenv.2016.08.004
   Sawale SD, 2009, J BIOTECHNOL BIOCH, V4, P160
   Shi XM, 2000, ENZYME MICROB TECH, V27, P312, DOI 10.1016/S0141-0229(00)00208-8
   Spolaore P, 2006, J BIOSCI BIOENG, V101, P87, DOI 10.1263/jbb.101.87
   Srinivasan P., 2020, INDIAN J SCI TECHNOL, V13, P4307, DOI [10.17485/IJST/v13i41.1291, DOI 10.17485/IJST/v13i41.1291]
   Stewart C. N., 1993, BIOTECHNIQUES, V19, P394
   Tafreshi AH, 2009, J APPL MICROBIOL, V107, P14, DOI 10.1111/j.1365-2672.2009.04153.x
   Takaichi S, 2011, MAR DRUGS, V9, P1101, DOI 10.3390/md9061101
   Walne P.R., 1970, FISHERY INVEST, V26, P1
   Walne P. R., 1974, CULTURE BIVALVE MOLL, P1
   Wijffels RH, 2010, BIOFUEL BIOPROD BIOR, V4, P287, DOI 10.1002/bbb.215
   Yang FF, 2014, MAR DRUGS, V12, P1245, DOI 10.3390/md12031245
   Zhu CJ, 1997, J APPL PHYCOL, V9, P189, DOI 10.1023/A:1007914806640
NR 52
TC 0
Z9 0
U1 4
U2 7
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0011-3891
J9 CURR SCI INDIA
JI Curr. Sci.
PD DEC 25
PY 2020
VL 119
IS 12
BP 1997
EP 2005
DI 10.18520/cs/v119/i12/1997-2005
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PI8KW
UT WOS:000601334000021
OA gold
DA 2022-11-30
ER

PT J
AU Kwon, J
   Jee, D
   Lim, SH
AF Kwon, J.
   Jee, D.
   Lim, S. H.
TI Would intravitreal bevacizumab injection increase risk of cerebral
   infarction?
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE bevacizumab; cerebral infarct; incidence; risk factor; stroke
ID ENDOTHELIAL GROWTH-FACTOR; ARTERIAL THROMBOEMBOLIC EVENTS; MACULAR
   DEGENERATION; MYOCARDIAL-INFARCTION; PLASMA-LEVELS; RANIBIZUMAB;
   AFLIBERCEPT; STROKE; SURVIVAL; OUTCOMES
AB Background and Purpose: Although studies have evaluated the relationship between intravitreal bevacizumab (IVB) injection and cerebral infarction (CI), the effects of IVB on CI are still not clear. The aim of this study was to investigate the effects of IVB injection on patients with CI with age-related macular degeneration (AMD). Methods: We retrospectively reviewed patients with AMD who received IVB injections for 1 year and determined the incidence of CI within 60 days after IVB injection to analyze the possible association between IVB and CI. Results: A total of 263 patients were enrolled over a 12-month period. Six patients (2.28%) were diagnosed with CI within 2 months after receiving an IVB injection. The incidence of CI in patients of 75-84 years of age was 6.38%. These results showed a higher incidence for patients with IVB injections than the results of previous epidemiological studies (0.13% for all age groups, 1.68% for patients of 75-84 years of age). All CIs occurred 2153 days after the IVB injection (mean: 39.33 +/- 14.65 days). Logistic regression analyses showed that age and CI history were factors associated with CI. Conclusions: Treatment with IVB might be an independent risk factor for CI. These results are useful for planning treatment strategies for patients with AMD and for prevention of CI.
C1 [Kwon, J.; Jee, D.] Catholic Univ Korea, St Vincents Hosp, Dept Ophthalmol & Visual Sci, Coll Med, Seoul, South Korea.
   [Lim, S. H.] Catholic Univ Korea, St Vincents Hosp, Dept Rehabil Med, Coll Med, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP Lim, SH (通讯作者)，Catholic Univ Korea, St Vincents Hosp, Dept Rehabil Med, Coll Med, 93 Jungbu Daero, Suwon 16247, South Korea.
EM seonghoon@catholic.ac.kr
OI Kwon, Jin-woo/0000-0003-2093-4284; Lim, Seong Hoon/0000-0002-5475-4153
FU Basic Science Research Program through the National Research Foundation
   of Korea - Ministry of Science and ICT [2017R1E1A1A01074324]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea funded by the Ministry
   of Science and ICT (grant no. 2017R1E1A1A01074324).
CR Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Batman C, 2010, OPHTHAL SURG LAS IM, V41, P190, DOI 10.3928/15428877-20100303-06
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   CAMPBELL RJ, 2012, BMJ-BRIT MED J, V344, DOI DOI 10.1136/BMJ.E4203
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Domigan CK, 2015, J CELL SCI, V128, P2236, DOI 10.1242/jcs.163774
   Etminan M, 2016, AM J OPHTHALMOL, V163, P53, DOI 10.1016/j.ajo.2015.11.030
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heinemann V, 2010, ONCOLOGY-BASEL, V79, P118, DOI 10.1159/000314993
   Holfinger S, 2016, JAMA OPHTHALMOL, V134, P45, DOI 10.1001/jamaophthalmol.2015.4331
   Hong KS, 2013, J STROKE, V15, P2, DOI 10.5853/jos.2013.15.1.2
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Johnson DR, 2013, CANCER-AM CANCER SOC, V119, P3489, DOI 10.1002/cncr.28259
   Karaca EE, 2015, RETINA-J RET VIT DIS, V35, P1540, DOI 10.1097/IAE.0000000000000531
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Olsen TW, 2011, INVEST OPHTH VIS SCI, V52, P4749, DOI 10.1167/iovs.10-6291
   Rim TH, 2016, RETINA-J RET VIT DIS, V36, P2166, DOI 10.1097/IAE.0000000000001084
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Verner-Cole EA, 2012, DRUG TODAY, V48, P317, DOI 10.1358/dot.2012.48.5.1805931
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Zechariah A, 2013, STROKE, V44, P1690, DOI 10.1161/STROKEAHA.111.000240
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 33
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD SEP
PY 2018
VL 25
IS 9
BP 1177
EP 1181
DI 10.1111/ene.13683
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GP9MD
UT WOS:000441240200018
PM 29772097
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Wei, WB
   Zhu, LP
   Xu, L
   Wang, YX
AF Jonas, Jost B.
   Wei, Wen Bin
   Zhu, Li Ping
   Xu, Liang
   Wang, Ya Xing
TI Cognitive Function and Ophthalmological Diseases: The Beijing Eye Study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MINI-MENTAL-STATE; RETINAL MICROVASCULAR ABNORMALITIES; OPEN-ANGLE
   GLAUCOMA; ATHEROSCLEROSIS RISK; EXFOLIATION SYNDROME; VISUAL IMPAIRMENT;
   NORMATIVE DATA; OLDER PERSONS; PREVALENCE; POPULATION
AB To examine associations between cognitive function and ophthalmological parameters, the population-based Beijing Eye Study examined ophthalmologically and physically 3127 individuals (mean age: 64.2 +/- 9.8 years). Using the mini-mental state examination, cognitive function was assessed as cognitive function score (CFS). Mean CFS was 26.3 +/- 3.7 (median: 27; range: 2-30). Prevalence of mild (CFS: 23-19), moderate (CFS: 18-10) and severe cognitive dysfunction was 9.6% (95% confidence interval (CI): 8.5, 10.6), 3.2% (95% CI: 2.6, 3.9) and 0.6% (95% CI: 0.4,0.9), respectively. In multivariate analysis, better cognition (i.e., higher CFS) was significantly associated with better best corrected visual acuity (r(2) = 0.38), smaller amount of undercorrected visual acuity, lower prevalence of primary angle-closure glaucoma, and thicker subfoveal choroidal thickness. Prevalence of age-related macular degeneration, open-angle glaucoma, diabetic retinopathy, any type of cataract, retinal vein occlusions or pseudoexfoliation was not significantly correlated with CFS. Though the causal relationship is unclear, the associations of lower cognitive function with undercorrected visual acuity suggest the need for earlier and more regular refraction testing in the elderly so that providing adequate glasses to the elderly can be provided and vision-associated cognitive decline can be reduced. Associations of cognitive function with primary angle-closure glaucoma and leptochoroid should be further explored.
C1 [Jonas, Jost B.; Xu, Liang; Wang, Ya Xing] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Jonas, Jost B.; Xu, Liang; Wang, Ya Xing] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   [Wei, Wen Bin] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Zhu, Li Ping] Capital Med Univ, Beijing Tongren Hosp, Dept Neurol, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University; Ruprecht Karls
   University Heidelberg; Capital Medical University; Capital Medical
   University
RP Wang, YX (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol, Beijing, Peoples R China.; Wang, YX (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
EM yaxingw@gmail.com
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793; Jonas, Jost/0000-0003-2972-5227
FU National Natural Science Foundation of China [81570835]
FX Funding/Support: Supported by National Natural Science Foundation of
   China (grant # 81570835).
CR Baker ML, 2007, STROKE, V38, P2041, DOI 10.1161/STROKEAHA.107.483586
   Chen SP, 2017, JAMA OPHTHALMOL, V135, P963, DOI 10.1001/jamaophthalmol.2017.2838
   Chen WW, 2013, INVEST OPHTH VIS SCI, V54, P545, DOI 10.1167/iovs.12-9893
   CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386
   Ding D, 2015, ALZHEIMERS DEMENT, V11, P300, DOI 10.1016/j.jalz.2013.11.002
   Elyashiv SM, 2014, BRIT J OPHTHALMOL, V98, P129, DOI 10.1136/bjophthalmol-2013-304149
   Engelhorn T, 2011, ACAD RADIOL, V18, P764, DOI 10.1016/j.acra.2011.01.014
   Feng L, 2012, SINGAP MED J, V53, P458
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Fukuoka H, 2016, CURR OPIN OPHTHALMOL, V27, P3, DOI 10.1097/ICU.0000000000000226
   Fukuoka Hideki, 2015, BMC Res Notes, V8, P619, DOI 10.1186/s13104-015-1625-7
   Gatto NM, 2012, OPHTHAL EPIDEMIOL, V19, P127, DOI 10.3109/09286586.2011.615452
   Jia JP, 2014, ALZHEIMERS DEMENT, V10, P439, DOI 10.1016/j.jalz.2013.09.008
   Jia JP, 2014, ALZHEIMERS DEMENT, V10, P1, DOI 10.1016/j.jalz.2013.01.012
   JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P2942
   Khawaja AP, 2016, INVEST OPHTH VIS SCI, V57, P1921, DOI 10.1167/iovs.16-19067
   LEE HC, 1994, J GERIATR PSYCH NEUR, V7, P216, DOI 10.1177/089198879400700404
   Lesage SR, 2009, NEUROLOGY, V73, P862, DOI 10.1212/WNL.0b013e3181b78436
   Li X, 2013, J AM GERIATR SOC, V61, P2111, DOI 10.1111/jgs.12552
   Liew G, 2009, J AM GERIATR SOC, V57, P1892, DOI 10.1111/j.1532-5415.2009.02459.x
   Linner E, 2001, ACTA OPHTHALMOL SCAN, V79, P283, DOI 10.1034/j.1600-0420.2001.790314.x
   Liu HH, 2010, OPHTHALMOLOGY, V117, P1763, DOI 10.1016/j.ophtha.2010.01.020
   Mokri H, 2013, CLIN NEUROPSYCHOL, V27, P1004, DOI 10.1080/13854046.2013.809793
   Ong SY, 2012, ARCH OPHTHALMOL-CHIC, V130, P895, DOI 10.1001/archophthalmol.2012.152
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Ritch R, 2001, CURR OPIN OPHTHALMOL, V12, P124, DOI 10.1097/00055735-200104000-00008
   Rockwood K, 2000, NEUROLOGY, V54, P447, DOI 10.1212/WNL.54.2.447
   Rogers MAM, 2010, AM J EPIDEMIOL, V171, P728, DOI 10.1093/aje/kwp453
   Shen MX, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012961
   Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813
   Tay T, 2006, GERONTOLOGY, V52, P386, DOI 10.1159/000095129
   Tsao WS, 2017, J FORMOS MED ASSOC, V116, P345, DOI 10.1016/j.jfma.2016.06.013
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Wong TY, 2002, STROKE, V33, P1487, DOI 10.1161/01.STR.0000016789.56668.43
   Wu F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166986
   Xie XW, 2009, GRAEF ARCH CLIN EXP, V247, P1651, DOI 10.1007/s00417-009-1161-z
   Xie XB, 2013, CRIT CARE, V17, DOI 10.1186/cc12841
   Xu L, 2008, AM J OPHTHALMOL, V145, P929, DOI 10.1016/j.ajo.2008.01.004
   Xu L, 2007, ACTA OPHTHALMOL SCAN, V85, P914, DOI 10.1111/j.1600-0420.2007.00966.x
   Yan YN, 2015, OPHTHALMOLOGY, V122, P1873, DOI 10.1016/j.ophtha.2015.05.031
   Yao YH, 2010, NEUROEPIDEMIOLOGY, V34, P245, DOI 10.1159/000297751
   Yip AG, 2006, AGE AGEING, V35, P154, DOI 10.1093/ageing/afj030
   Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6
   Zhang ZX, 2005, ARCH NEUROL-CHICAGO, V62, P447, DOI 10.1001/archneur.62.3.447
   Zhu L, 1998, STROKE, V29, P2094, DOI 10.1161/01.STR.29.10.2094
   ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3
NR 48
TC 23
Z9 24
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 19
PY 2018
VL 8
AR 4816
DI 10.1038/s41598-018-23314-5
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA FZ6DT
UT WOS:000427688100009
PM 29556090
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yerramothu, P
   Vijay, AK
   Willcox, MDP
AF Yerramothu, P.
   Vijay, A. K.
   Willcox, M. D. P.
TI Inflammasomes, the eye and anti-inflammasome therapy
SO EYE
LA English
DT Review
ID INHIBITS NLRP3 INFLAMMASOME; PIGMENT EPITHELIAL-CELLS; AIM2
   INFLAMMASOME; MACULAR DEGENERATION; GELATINASE-B; CYTOMEGALOVIRUS
   RETINITIS; IL-1-BETA PRODUCTION; IMMUNE RECOGNITION; OXIDATIVE STRESS;
   HOST-DEFENSE
AB Inflammasomes, key molecular regulators that play an important role in inflammation, consist of a central protein, an adaptor protein ASC (apoptosis speck-like protein) and a caspase-1 protein. Upon activation, caspase-1 induces maturation of cytokines such as interleukin-1 beta (IL-1 beta) and interleukin-18 (IL-18). The release of these cytokines can result in inflammation. Inflammasomes are activated by a variety of factors and their activation involves complex signalling leading to resolution of infection, but can also contribute to the pathology of inflammatory, autoimmune, and infectious diseases. The role of NLRP1, NLRP3, NLRC4 and AIM2 inflammasomes in the pathogenesis of ocular diseases such as glaucoma, age related macular degeneration (AMD), diabetic retinopathy, dry eye and infections of the eye has been established over the past decade. In experimental studies and models, inhibition of inflammasomes generally helps to reduce the inflammation associated with these eye diseases, but as yet the role of these inflammasomes in many human eye diseases is unknown. Therefore, a need exists to study and understand various aspects of inflammasomes and their contribution to the pathology of human eye diseases. The goal of this review is to discuss the role of inflammasomes in the pathology of eye diseases, scope for anti-inflammasome therapy, and current research gaps in inflammasome-related eye disease.
C1 [Yerramothu, P.; Vijay, A. K.; Willcox, M. D. P.] Univ New South Wales, Fac Sci, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
C3 University of New South Wales Sydney
RP Yerramothu, P (通讯作者)，Univ New South Wales, Sch Optometry & Vis Sci, Rupert Myers North Bldg,Gate 14, Sydney, NSW 2052, Australia.
EM prav.yerramothu@student.unsw.edu.au
RI Vijay, Ajay Kumar/M-2194-2017
OI Vijay, Ajay Kumar/0000-0002-8248-6379; willcox,
   mark/0000-0003-3842-7563; Yerramothu, Praveen/0000-0001-6635-6681
CR Ahn H, 2014, IMMUNOBIOLOGY, V219, P315, DOI 10.1016/j.imbio.2013.11.003
   Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005
   Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3
   Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323
   Arlehamn CSL, 2011, CELL MICROBIOL, V13, P388, DOI 10.1111/j.1462-5822.2010.01541.x
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516
   Bonardi V, 2012, CURR OPIN IMMUNOL, V24, P41, DOI 10.1016/j.coi.2011.12.006
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Budai MM, 2013, MOL IMMUNOL, V56, P471, DOI 10.1016/j.molimm.2013.05.005
   Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283
   Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Chien H, 2012, J VIROL, V86, P10961, DOI 10.1128/JVI.01275-12
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Conforti-Andreoni C, 2011, CELL MOL IMMUNOL, V8, P135, DOI 10.1038/cmi.2010.81
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Deroide N, 2013, J CLIN INVEST, V123, P1176, DOI 10.1172/JCI65167
   Devi TS, 2012, EXP DIABETES RES, DOI 10.1155/2012/438238
   Di Virgilio F, 2013, PHARMACOL REV, V65, P872, DOI 10.1124/pr.112.006171
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x
   Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   DOBSON DE, 1990, CELL, V61, P223, DOI 10.1016/0092-8674(90)90803-M
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ewald SE, 2014, INFECT IMMUN, V82, P460, DOI 10.1128/IAI.01170-13
   Fang RD, 2011, J IMMUNOL, V187, P4890, DOI 10.4049/jimmunol.1100381
   Fernandes-Alnemri T, 2010, NAT IMMUNOL, V11, P385, DOI 10.1038/ni.1859
   Finger JN, 2012, J BIOL CHEM, V287, P25030, DOI 10.1074/jbc.M112.378323
   Geng S, 2011, CHINESE MED J-PEKING, V124, P1134, DOI 10.3760/cma.j.issn.0366-6999.2011.08.003
   Giguere PM, 2014, J BIOL CHEM, V289, P33245, DOI 10.1074/jbc.M114.578393
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006
   Hageman GS, 1999, MOL VIS, V5
   Haneklaus M, 2012, J IMMUNOL, V189, P3795, DOI 10.4049/jimmunol.1200312
   Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222
   He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959
   He Y, 2014, J BIOL CHEM, V289, P1142, DOI 10.1074/jbc.M113.515080
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   HO M, 1994, TRANSPL P, V26, P7
   Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756
   Hu Y, 2010, J IMMUNOL, V185, P7699, DOI 10.4049/jimmunol.1001099
   Hua KF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076754
   Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861
   Ippagunta SK, 2011, NAT IMMUNOL, V12, P1010, DOI 10.1038/ni.2095
   Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106
   Jabir MS, 2015, AUTOPHAGY, V11, P166, DOI 10.4161/15548627.2014.981915
   Jin J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3075
   Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286
   Juliana C, 2010, J BIOL CHEM, V285, P9792, DOI 10.1074/jbc.M109.082305
   Kaminski JJ, 2013, J IMMUNOL, V191, P3876, DOI 10.4049/jimmunol.1300530
   Karthikeyan RS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064867
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Khan S, 2007, J LEUKOCYTE BIOL, V81, P315, DOI 10.1189/jlb.0506344
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Kofoed EM, 2011, NATURE, V477, P592, DOI 10.1038/nature10394
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124
   Lee HM, 2013, DIABETES, V62, P194, DOI 10.2337/db12-0420
   Lemp MA, 2007, OCUL SURF, V5, P75
   Liang L, 2013, INVEST OPHTH VIS SCI, V54, P402, DOI 10.1167/iovs.12-11047
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Maier NK, 2014, J IMMUNOL, V192, P763, DOI 10.4049/jimmunol.1301434
   Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100
   Mao KR, 2015, J IMMUNOL, V194, P1867, DOI 10.4049/jimmunol.1401989
   Mao KR, 2013, CELL RES, V23, P201, DOI 10.1038/cr.2013.6
   Marchetti C, 2014, J CARDIOVASC PHARM, V63, P316, DOI 10.1097/FJC.0000000000000053
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Mariner PD, 2008, MOL CELL, V29, P499, DOI 10.1016/j.molcel.2007.12.013
   Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004
   Marty-Roix R, 2013, IMMUNITY, V38, P1088, DOI 10.1016/j.immuni.2013.06.006
   Maslanik T, 2013, BRAIN BEHAV IMMUN, V28, P54, DOI 10.1016/j.bbi.2012.10.014
   Master SS, 2008, CELL HOST MICROBE, V3, P224, DOI 10.1016/j.chom.2008.03.003
   McClellan SA, 2006, INVEST OPHTH VIS SCI, V47, P256, DOI 10.1167/iovs.05-1050
   McGilligan VE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074010
   Miao EA, 2008, P NATL ACAD SCI USA, V105, P2562, DOI 10.1073/pnas.0712183105
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   OPDENAKKER G, 1991, LYMPHOKINE CYTOK RES, V10, P317
   Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851
   Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3
   Ozaki E, 2015, J INFLAMM RES, V8, P15, DOI 10.2147/JIR.S51250
   PAVILACK MA, 1992, INVEST OPHTH VIS SCI, V33, P564
   Pearlman E, 2013, INT REV IMMUNOL, V32, P4, DOI 10.3109/08830185.2012.749400
   Perrone L, 2009, J CELL PHYSIOL, V221, P262, DOI 10.1002/jcp.21852
   Pontillo A, 2010, JAIDS-J ACQ IMM DEF, V54, P236, DOI 10.1097/QAI.0b013e3181dd17d4
   Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200
   Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864
   Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417
   Saavedra PHV, 2015, SEMIN IMMUNOPATHOL, V37, P313, DOI 10.1007/s00281-015-0485-5
   Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288
   Schallenberg M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033593
   Schonbeck U, 1998, J IMMUNOL, V161, P3340
   Shi HX, 2016, NAT IMMUNOL, V17, P250, DOI 10.1038/ni.3333
   Shimada K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021477
   Shinkai K, 2008, CLIN EXP DERMATOL, V33, P1, DOI 10.1111/j.1365-2230.2007.02540.x
   Sola-Villa D, 2006, KIDNEY INT, V70, P1935, DOI 10.1038/sj.ki.5001948
   Sutterwala FS, 2007, J EXP MED, V204, P3235, DOI 10.1084/jem.20071239
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tezel G, 2010, INVEST OPHTH VIS SCI, V51, P5071, DOI 10.1167/iovs.10-5289
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   Thakur A, 2004, INVEST OPHTH VIS SCI, V45, P3177, DOI 10.1167/iovs.04-0041
   Thakur A, 2002, INFECT IMMUN, V70, P2187, DOI 10.1128/IAI.70.4.2187-2197.2002
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Wu YH, 2014, CELL DEATH DIFFER, V21, P451, DOI 10.1038/cdd.2013.165
   Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047
   Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662
   Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152
   Yu M, 2011, CYTOKINE GROWTH F R, V22, P63, DOI 10.1016/j.cytogfr.2011.02.001
   Yuksel S, 2014, INT IMMUNOL, V26, P71, DOI 10.1093/intimm/dxt046
   Zhen PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep20998
   Zheng QX, 2014, EXP EYE RES, V125, P1, DOI 10.1016/j.exer.2014.05.001
NR 119
TC 64
Z9 67
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2018
VL 32
IS 3
BP 491
EP 505
DI 10.1038/eye.2017.241
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY7OC
UT WOS:000427051200004
PM 29171506
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Dysli, C
   Wolf, S
   Berezin, MY
   Sauer, L
   Hammer, M
   Zinkernagel, MS
AF Dysli, Chantal
   Wolf, Sebastian
   Berezin, Mikhail Y.
   Sauer, Lydia
   Hammer, Martin
   Zinkernagel, Martin S.
TI Fluorescence lifetime imaging ophthalmoscopy
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Fluorescence lifetimes; Fundus autofluorescence; Retinal imaging; FLIO;
   Fluorophore; Metabolism
ID RETINAL-PIGMENT EPITHELIUM; CENTRAL SEROUS CHORIORETINOPATHY;
   QUANTITATIVE FUNDUS AUTOFLUORESCENCE; NEAR-INFRARED AUTOFLUORESCENCE;
   SCANNING LASER OPHTHALMOSCOPE; PHOTORECEPTOR OUTER SEGMENTS; OPTICAL
   COHERENCE TOMOGRAPHY; RECESSIVE STARGARDT DISEASE; DIABETIC MACULAR
   EDEMA; PRIMATE RETINAS
AB Imaging techniques based on retinal autofluorescence have found broad applications in ophthalmology because they are extremely sensitive and noninvasive. Conventional fundus autofluorescence imaging measures fluorescence intensity of endogenous retinal fluorophores. It mainly derives its signal from lipofuscin at the level of the retinal pigment epithelium. Fundus autofluorescence, however, can not only be characterized by the spatial distribution of the fluorescence intensity or emission spectrum, but also by a characteristic fluorescence lifetime function. The fluorescence lifetime is the average amount of time a fluorophore remains in the excited state following excitation. Fluorescence lifetime imaging ophthalmoscopy (FLIO) is an emerging imaging modality for in vivo measurement of lifetimes of endogenous retinal fluorophores. Recent reports in this field have contributed to our understanding of the pathophysiology of various macular and retinal diseases.
   Within this review, the basic concept of fluorescence lifetime imaging is provided. It includes technical background information and correlation with in vitro measurements of individual retinal metabolites. In a second part, clinical applications of fluorescence lifetime imaging and fluorescence lifetime features of selected retinal diseases such as Stargardt disease, age-related macular degeneration, choroideremia, central serous chorioretinopathy, macular holes, diabetic retinopathy, and retinal artery occlusion are discussed. Potential areas of use for fluorescence lifetime imaging ophthalmoscopy will be outlined at the end of this review. (C) 2017 The Authors. Published by Elsevier Ltd.
C1 [Dysli, Chantal; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Dept Ophthalmol, Inselspital, Bern Univ Hosp, Bern, Switzerland.
   [Dysli, Chantal; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Dept Clin Res, Inselspital, Bern Univ Hosp, Bern, Switzerland.
   [Berezin, Mikhail Y.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA.
   [Sauer, Lydia; Hammer, Martin] Univ Hosp Jena, Dept Ophthalmol, Jena, Germany.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern; Washington University (WUSTL); Friedrich
   Schiller University of Jena
RP Zinkernagel, MS (通讯作者)，Univ Hosp Bern, CH-3010 Bern, Switzerland.
EM m.zinkernagel@gmail.com
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Zinkernagel, Martin
   S./0000-0003-3447-2359
FU Swiss National Science Foundation [320030_156019]; National Cancer
   Institute/National Institutes of Health [CA198419]; Office of
   Integrative Activities [1355406] Funding Source: National Science
   Foundation
FX This work was supported by a grant of the Swiss National Science
   Foundation (#320030_156019, MZ) and the National Cancer
   Institute/National Institutes of Health (CA198419 (MB)). The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR Alexiev U, 2014, BBA-BIOENERGETICS, V1837, P694, DOI 10.1016/j.bbabio.2013.10.008
   ANDERSSON PO, 1995, J CHEM PHYS, V103, P2509, DOI 10.1063/1.469672
   ANSI L. I. o. A., 2007, Z13612007 ANSI LI O
   ARAKI N, 1992, J BIOL CHEM, V267, P10211
   ASHIKAWA I, 1982, J BIOCHEM-TOKYO, V91, P2047, DOI 10.1093/oxfordjournals.jbchem.a133898
   Bachilo SM, 1999, J PHYS CHEM A, V103, P2481, DOI 10.1021/jp983646a
   Barber AJ, 2011, INVEST OPHTH VIS SCI, V52, P1156, DOI 10.1167/iovs.10-6293
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Barrett G.C., 1998, AMINO ACIDS PEP PROT, V1st ed., DOI [10.1017/CBO9781139163828, DOI 10.1017/CBO9781139163828]
   Becker W, 2012, J MICROSC-OXFORD, V247, P119, DOI 10.1111/j.1365-2818.2012.03618.x
   Becker W., 2005, ADV TIME CORRELATED, DOI [10.1007/3-540-28882-1, DOI 10.1007/3-540-28882-1]
   Becker W., 2016, TCSPC FLIM WAVELENGT
   Becker W., 2008, BH TCSPC HDB
   Becker W., 2003, LIFETIME IMAGING TEC
   Berezin MY, 2010, CHEM REV, V110, P2641, DOI 10.1021/cr900343z
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bertolotto M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/741538
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Blinova K, 2005, BIOCHEMISTRY-US, V44, P2585, DOI 10.1021/bi0485124
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   Bonne C, 1998, GEN PHARMACOL, V30, P275, DOI 10.1016/S0306-3623(97)00357-1
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Chen K, 2014, ANN BIOMED ENG, V42, P678, DOI 10.1007/s10439-013-0936-x
   CHEN R F, 1967, Analytical Letters, V1, P35
   COGAN DG, 1963, DIABETES, V12, P293, DOI 10.2337/diab.12.4.293
   COSGROVE SA, 1990, J PHYS CHEM-US, V94, P8118, DOI 10.1021/j100384a026
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   de Jong CJ, 2015, PHOTONICS RES, V3, P283, DOI 10.1364/PRJ.3.000283
   DECOSTER B, 1992, BIOCHIM BIOPHYS ACTA, V1102, P107, DOI 10.1016/0167-4838(92)90504-7
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   DELORI FC, 1994, APPL OPTICS, V33, P7439, DOI 10.1364/AO.33.007439
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Digman MA, 2008, BIOPHYS J, V94, pL14, DOI 10.1529/biophysj.107.120154
   Dillon J, 2000, PHOTOCHEM PHOTOBIOL, V71, P225, DOI 10.1562/0031-8655(2000)071<0225:TSOLTT>2.0.CO;2
   DOUKAS AG, 1984, P NATL ACAD SCI-BIOL, V81, P4790, DOI 10.1073/pnas.81.15.4790
   Dysli C., 2017, FUNDUS AUTOFLUORESCE
   Dysli C., 2016, UNPUB
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P6714, DOI 10.1167/iovs.16-20392
   Dysli C, 2016, EXP EYE RES, V153, P178, DOI 10.1016/j.exer.2016.10.018
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P832, DOI 10.1167/iovs.15-18033
   Dysli C, 2015, INVEST OPHTH VIS SCI, V56, P3329, DOI 10.1167/iovs.14-16203
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P7206, DOI 10.1167/iovs.14-14445
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Ehlers A, 2007, MICROSC RES TECHNIQ, V70, P154, DOI 10.1002/jemt.20395
   Ermakov IV, 2005, APPL SPECTROSC, V59, P861, DOI 10.1366/0003702054411616
   Estrada AD, 2010, OPT EXPRESS, V18, P13631, DOI 10.1364/OE.18.013631
   Ezra E, 1997, ARCH OPHTHALMOL-CHIC, V115, P1381, DOI 10.1001/archopht.1997.01100160551004
   Fishkin N, 2004, CHIRALITY, V16, P637, DOI 10.1002/chir.20084
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Forest SE, 2000, J PHYS CHEM B, V104, P811, DOI 10.1021/jp992137l
   GALLAS JM, 1987, PHOTOCHEM PHOTOBIOL, V45, P595, DOI 10.1111/j.1751-1097.1987.tb07385.x
   GASS JDM, 1992, RETINA-J RET VIT DIS, V12, P242, DOI 10.1097/00006982-199212030-00007
   Gaviola E, 1926, ANN PHYS-BERLIN, V81, P681
   Gersbach M, 2010, PROC SPIE, V7780, DOI 10.1117/12.860769
   Gibbs D, 2009, INVEST OPHTH VIS SCI, V50, P4386, DOI 10.1167/iovs.09-3471
   Goldberg AFX, 2016, PROG RETIN EYE RES, V55, P52, DOI 10.1016/j.preteyeres.2016.05.003
   Gottling PF, 1923, PHYS REV, V22, P0566, DOI 10.1103/PhysRev.22.566
   Gratton E., 2003, FLUORESCENCE LIFETIM
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   GRUSZECKI WI, 1990, CHEM PHYS LETT, V171, P563, DOI 10.1016/0009-2614(90)85264-D
   Guo K., 2013, BLOODSTAIN AGE ANAL
   Guo K, 2012, CHEM-EUR J, V18, P1303, DOI 10.1002/chem.201102935
   Hammer M., 2009, P SPIE, VIX
   Han M, 2005, OPT EXPRESS, V13, P5791, DOI 10.1364/OPEX.13.005791
   Han M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2717522
   Han X, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3103310
   Hayreh SS, 2005, AM J OPHTHALMOL, V140, P376, DOI 10.1016/j.ajo.2005.03.038
   Heikal AA, 2010, BIOMARK MED, V4, P241, DOI 10.2217/BMM.10.1
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Huang ZW, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2204007
   IEC, 2014, 6082512007 IEC
   Ishikawa-Ankerhold HC, 2012, MOLECULES, V17, P4047, DOI 10.3390/molecules17044047
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   ITO S, 1986, BIOCHIM BIOPHYS ACTA, V883, P155, DOI 10.1016/0304-4165(86)90146-7
   Jo JA, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2186045
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Jolly JK, 2016, INVEST OPHTH VIS SCI, V57, P4498, DOI 10.1167/iovs.15-18362
   KANDORI H, 1994, J AM CHEM SOC, V116, P2671, DOI 10.1021/ja00085a078
   Kao YT, 2008, J AM CHEM SOC, V130, P13132, DOI 10.1021/ja8045469
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kierdaszuk B, 1996, BIOPHYS CHEM, V62, P1, DOI 10.1016/S0301-4622(96)02182-5
   Klemm M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131640
   Konig K, 2008, J BIOPHOTONICS, V1, P13, DOI 10.1002/jbio.200710022
   Kolb H, 2007, GROSS ANATOMY EYE
   Koziol B, 2006, PHOTOCHEM PHOTOBIOL, V82, P570, DOI 10.1562/2005-11-23-RA-738
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   Kuriyama H, 2001, OPHTHALMIC RES, V33, P196, DOI 10.1159/000055670
   LAKOWICZ JR, 1992, P NATL ACAD SCI USA, V89, P1271, DOI 10.1073/pnas.89.4.1271
   Lamb LE, 2001, J PHYS CHEM B, V105, P11507, DOI 10.1021/jp0123177
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lee KCB, 2001, BIOPHYS J, V81, P1265, DOI 10.1016/S0006-3495(01)75784-0
   LESKOVAR B, 1976, REV SCI INSTRUM, V47, P1113, DOI 10.1063/1.1134827
   Leung IYF, 2005, EXP EYE RES, V81, P513, DOI 10.1016/j.exer.2005.03.009
   LEWIS C, 1973, REV SCI INSTRUM, V44, P107, DOI 10.1063/1.1686062
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   Lima Veronica Castro, 2016, Int J Retina Vitreous, V2, P19
   Maarek JMI, 2000, PHOTOCHEM PHOTOBIOL, V71, P178, DOI 10.1562/0031-8655(2000)071<0178:TRFSOA>2.0.CO;2
   Maskevich AA, 1997, J MOL STRUCT, V408, P261, DOI 10.1016/S0022-2860(96)09538-5
   Mathew R, 2010, CLIN OPHTHALMOL, V4, P1159, DOI 10.2147/OPTH.S13592
   Matsumoto H, 2011, AM J OPHTHALMOL, V151, P617, DOI 10.1016/j.ajo.2010.09.031
   McBain VA, 2012, AM J OPHTHALMOL, V154, P146, DOI 10.1016/j.ajo.2012.01.019
   McGuinness CD, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2245441
   NAKASHIMA N, 1980, J BIOL CHEM, V255, P5261
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Niesner R, 2004, CHEMPHYSCHEM, V5, P1141, DOI 10.1002/cphc.200400066
   Palczewska G, 2014, NAT MED, V20, P785, DOI 10.1038/nm.3590
   Pelet S, 2004, BIOPHYS J, V87, P2807, DOI 10.1529/biophysj.104.045492
   Periasamy A, 1996, REV SCI INSTRUM, V67, P3722, DOI 10.1063/1.1147139
   Peters S. H. M., 2011, SPIE P, P8086
   Pia de la Maza M., 2012, J DIABETES MELLIT, V02, P221, DOI DOI 10.4236/JDM.2012.22035
   Ponsioen TL, 2008, INVEST OPHTH VIS SCI, V49, P4089, DOI 10.1167/iovs.07-1456
   Rech I., 2012, P SPIE
   Redford GI, 2005, J FLUORESC, V15, P805, DOI 10.1007/s10895-005-2990-8
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sauer L, 2016, ACTA OPHTHALMOL
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schalch W, 1992, EXS, V62, P280
   SCHALKEN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1033, P103, DOI 10.1016/0304-4165(90)90201-7
   Schmidt J, 2017, ACTA OPHTHALMOL, V95, P33, DOI 10.1111/aos.13174
   Schneckenburger H, 2004, J FLUORESC, V14, P649, DOI 10.1023/B:JOFL.0000039351.09916.cc
   Schwartz DE, 2008, IEEE J SOLID-ST CIRC, V43, P2546, DOI 10.1109/JSSC.2008.2005818
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Schweitzer D., 2001, International Ophthalmology, V23, P399, DOI 10.1023/A:1014475219117
   Schweitzer D, 2001, PROC SPIE, V4432, P29, DOI 10.1117/12.447153
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P774, DOI 10.1007/s00347-002-0656-3
   Schweitzer D., 2003, DIAGNOSTIC OPTICAL S
   Schweitzer D., 2007, INTERPRETATION MEASU
   Schweitzer D, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.6.061106
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Shagaghi N, 2017, SCI REP-UK, V7, DOI 10.1038/srep43542
   Sharifzadeh M, 2006, J OPT SOC AM A, V23, P2373, DOI 10.1364/JOSAA.23.002373
   Sharma R, 2016, INVEST OPHTH VIS SCI, V57, P632, DOI 10.1167/iovs.15-17961
   Sharma R, 2013, BIOMED OPT EXPRESS, V4, P1285, DOI 10.1364/BOE.4.001285
   Siskova A, 2001, PHYSIOL RES, V50, P267
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   SNYDER R, 1985, J AM CHEM SOC, V107, P4117, DOI 10.1021/ja00300a004
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Sparks H, 2017, REV SCI INSTRUM, V88, DOI 10.1063/1.4973917
   Sparrow JR, 2015, INVEST OPHTH VIS SCI, V56, P5029, DOI 10.1167/iovs.15-16763
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   STRICKLER SJ, 1962, J CHEM PHYS, V37, P814, DOI 10.1063/1.1733166
   Suhling K., 2016, P SPIE
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   TAUBOLD RD, 1975, LIPIDS, V10, P383, DOI 10.1007/BF02532441
   Teussink MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172635
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Tsentalovich YP, 2011, INVEST OPHTH VIS SCI, V52, P7687, DOI 10.1167/iovs.11-8120
   Varma DD, 2013, EYE, V27, P688, DOI 10.1038/eye.2013.25
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   VONRUCKMANN A, 1995, INVEST OPHTHALMOL, V36, P238
   Vujosevic S, 2011, INVEST OPHTH VIS SCI, V52, P442, DOI 10.1167/iovs.10-5588
   WAKITA M, 1995, J BIOCHEM-TOKYO, V118, P1151, DOI 10.1093/oxfordjournals.jbchem.a125001
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Widomska Justyna, 2014, J Clin Exp Ophthalmol, V5, P326
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Xu W, 2004, NEUROSCIENCE, V126, P313, DOI 10.1016/j.neuroscience.2004.03.055
   Yang H, 2003, SCIENCE, V302, P262, DOI 10.1126/science.1086911
   Yazdanfar S, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3420209
   Yu DY, 2001, CLIN EXP OPHTHALMOL, V29, P164
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
   Zhang XY, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-27
   Zheng W, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2975866
   Zinkernagel MS, 2015, CLIN OPHTHALMOL, V9, P2195, DOI 10.2147/OPTH.S65732
NR 174
TC 111
Z9 113
U1 7
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2017
VL 60
BP 120
EP 143
DI 10.1016/j.preteyeres.2017.06.005
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ3HN
UT WOS:000412621500006
PM 28673870
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Li, DD
   Zhong, BW
   Zhang, HX
   Zhou, HY
   Luo, J
   Liu, Y
   Xu, GC
   Luan, CS
   Fang, J
AF Li, Dan-dan
   Zhong, Bin-wu
   Zhang, Hai-xia
   Zhou, Hong-yan
   Luo, Jie
   Liu, Yang
   Xu, Gui-chun
   Luan, Chun-sheng
   Fang, Jun
TI Inhibition of the oxidative stress-induced miR-23a protects the human
   retinal pigment epithelium (RPE) cells from apoptosis through the
   upregulation of glutaminase and glutamine uptake
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE The oxidative stress-induced miR-23a; The human retinal pigment
   epithelium cells; Apoptosis; Glutaminase; Glutamine
ID POLY(ADP-RIBOSE) POLYMERASE; DEGENERATION; METABOLISM; EXPRESSION;
   CLEAVAGE
AB The degeneration of retinal pigment epithelium (RPE) cells in the sub retinal pigment epithelial space and choroid is an initial pathological characteristic for the age-related macular degeneration which is the leading cause of severe vision loss in old people. Moreover, oxidative stress is implicated as a major inducer of RPE cell death. Here, we assessed the correlation between the H2O2-induced RPE cell death and glutamine metabolism. We found under low glutamine supply (20 %), the ARPE-19 cells were more susceptive to H2O2-induced apoptosis. Moreover, the glutamine uptake and the glutaminase (GLS) were suppressed by H2O2 treatments. Moreover, we observed miR-23a was upregulated by H2O2 treatments and overexpression of miR-23a significantly sensitized ARPE-19 cells to H2O2. Importantly, Western blotting and luciferase assay demonstrated GLS1 is a direct target of miR-23a in RPE cells. Inhibition of the H2O2-induced miR-23a by antagomiR protected the RPE cells from the oxidative stress-induced cell death. In addition, recovery of GLS1 expression in miR-23a overexpressed RPE cells rescued the H2O2-induced cell death. This study illustrated a mechanism for the protection of the oxidative-induced RPE cell death through the recovery of glutamine metabolism by inhibition of miR-23a, contributing to the discovery of novel targets and the developments of therapeutic strategies for the prevention of RPE cells from oxidative stress.
C1 [Li, Dan-dan; Zhong, Bin-wu; Zhang, Hai-xia; Zhou, Hong-yan; Luo, Jie; Liu, Yang; Xu, Gui-chun; Luan, Chun-sheng; Fang, Jun] Daqing Oilfield Gen Hosp, Dept Ophthalmol, 9 Zhongkang St, Daqing 163000, Heilongjiang, Peoples R China.
RP Li, DD (通讯作者)，Daqing Oilfield Gen Hosp, Dept Ophthalmol, 9 Zhongkang St, Daqing 163000, Heilongjiang, Peoples R China.
EM li_dandan_2015@163.com
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932
   Carr EL, 2010, J IMMUNOL, V185, P1037, DOI 10.4049/jimmunol.0903586
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Dumaswala UJ, 2001, AM J PHYSIOL-CELL PH, V280, pC867, DOI 10.1152/ajpcell.2001.280.4.C867
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Gorbatyuk M, 2013, MOL VIS, V19, P1985
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600
   Hou Q, 2013, INVEST OPHTH VIS SCI, V54, P6481, DOI 10.1167/iovs.13-11873
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   KAUFMANN SH, 1993, CANCER RES, V53, P3976
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Kutty RK, 2010, MOL VIS, V16, P1475
   Lushchak Volodymyr I, 2012, J Amino Acids, V2012, P736837, DOI 10.1155/2012/736837
   Mates JM, 2002, INT J BIOCHEM CELL B, V34, P439, DOI 10.1016/S1357-2725(01)00143-1
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rhoads JM, 2000, GASTROENTEROLOGY, V118, P90, DOI 10.1016/S0016-5085(00)70417-3
   Sanvicens N, 2004, J BIOL CHEM, V279, P39268, DOI 10.1074/jbc.M402202200
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Schimel AM, 2011, AM J PATHOL, V178, P2032, DOI 10.1016/j.ajpath.2011.01.036
   Shanware NP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5900
   Wolfgang CL, 2003, J GASTROINTEST SURG, V7, P149, DOI 10.1016/S1091-255X(02)00130-0
   Yang DL, 2009, INVEST OPHTH VIS SCI, V50, P4998, DOI 10.1167/iovs.09-3620
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Zeitz O, 2007, GRAEF ARCH CLIN EXP, V245, P276, DOI 10.1007/s00417-006-0384-5
NR 32
TC 12
Z9 13
U1 1
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD OCT
PY 2016
VL 43
IS 10
BP 1079
EP 1087
DI 10.1007/s11033-016-4041-8
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DW3ZW
UT WOS:000383582600008
PM 27411920
DA 2022-11-30
ER

PT J
AU Purushothuman, S
   Nandasena, C
   Peoples, CL
   El Massri, N
   Johnstone, DM
   Mitrofanis, J
   Stone, J
AF Purushothuman, Sivaraman
   Nandasena, Charith
   Peoples, Cassandra L.
   El Massri, Nabil
   Johnstone, Daniel M.
   Mitrofanis, John
   Stone, Jonathan
TI Saffron Pre-Treatment Offers Neuroprotection to Nigral and Retinal
   Dopaminergic Cells of MPTP-Treated mice
SO JOURNAL OF PARKINSONS DISEASE
LA English
DT Article
DE Tyrosine hydroxylase; substantia nigra; amacrine cell; neuroprotection;
   Parkinson's disease
ID SATIVUS STIGMAS EXTRACT; IN-VITRO; CROCIN; LIGHT; PROTECTION; CROCETIN;
   DISEASE; LESION; MODEL
AB Background: There is growing evidence that the spice saffron, which contains powerful anti-oxidants, offers protection against neurodegenerative disorders, including age-related macular degeneration and Alzheimer's disease.
   Objective: We examined whether saffron pre-treatment protects dopaminergic cells of the substantia nigra pars compacta (SNc) and retina in an acute MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease.
   Methods: BALB/c mice received MPTP or saline injections over a 30 hour period, followed by six days survival. For five days prior to injections, the drinking water of the saffron groups was supplemented with saffron (0.01% w/v), while non-saffron groups received normal tap water. After the survival period was complete, brains were processed for tyrosine hydroxylase (TH) immunochemistry and the number of TH+ cells was analysed using the optical fractionator method.
   Results: In both the SNc and retina, non-conditioned MPTP-injected mice had a reduced number of TH+ cells (30-35%) compared to the saline-injected controls. Saffron pre-conditioning mitigated the reduction, with pre-conditioned MPTP-injected mice having SNc and retinal TH+ cell numbers close to control levels, significantly (25-35%) higher than in non-conditioned MPTP-injected mice.
   Conclusions: Our results indicated that saffron pre-treatment of mice saved many dopaminergic cells of the SNc and retina from parkinsonian (MPTP) insult.
C1 [Purushothuman, Sivaraman; Nandasena, Charith; Johnstone, Daniel M.; Stone, Jonathan] Univ Sydney, Discipline Physiol, Sydney, NSW 2006, Australia.
   [Peoples, Cassandra L.; El Massri, Nabil; Mitrofanis, John] Univ Sydney, Discipline Anat & Histol, Sydney, NSW 2006, Australia.
C3 University of Sydney; University of Sydney
RP Mitrofanis, J (通讯作者)，Univ Sydney, Dept Anat & Histol F13, Sydney, NSW 2006, Australia.
EM john.mitrofanis@sydney.edu.au
RI Stone, Jonathan/GQA-9990-2022; Johnstone, Daniel/E-9929-2013
OI Johnstone, Daniel/0000-0003-2876-3299; Mitrofanis,
   John/0000-0003-3044-2179; Purushothuman, Sivaraman/0000-0002-0880-5060
FU Tenix corp; Salteri family; Sir Zelman Cowen Universities Fund
FX We are forever grateful to Tenix corp, Salteri family and Sir Zelman
   Cowen Universities Fund for supporting our work. Sharon Spana provided
   first class technical help.
CR Ahmad AS, 2005, PHARMACOL BIOCHEM BE, V81, P805, DOI 10.1016/j.pbb.2005.06.007
   Akhondzadeh S, 2010, J CLIN PHARM THER, V35, P581, DOI 10.1111/j.1365-2710.2009.01133.x
   Bjorklund A, 1997, NEUROBIOL DIS, V4, P186, DOI 10.1006/nbdi.1997.0151
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Hosseinzadeh H, 2008, DNA CELL BIOL, V27, P657, DOI 10.1089/dna.2008.0767
   Laabich A, 2006, INVEST OPHTH VIS SCI, V47, P3156, DOI 10.1167/iovs.05-1621
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Mousavi SH, 2010, CELL MOL NEUROBIOL, V30, P185, DOI 10.1007/s10571-009-9441-z
   Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003
   Natoli R, 2010, MOL VIS, V16, P1801
   Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012
   Ordoudi SA, 2009, J AGR FOOD CHEM, V57, P3080, DOI 10.1021/jf804041g
   Papandreou MA, 2006, J AGR FOOD CHEM, V54, P8762, DOI 10.1021/jf061932a
   Papandreou MA, 2011, BEHAV BRAIN RES, V219, P197, DOI 10.1016/j.bbr.2011.01.007
   Pellegrini N, 2006, MOL NUTR FOOD RES, V50, P1030, DOI 10.1002/mnfr.200600067
   Peoples C., 2012, ISRN NEUROLOGY
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Przedborski S, 2000, RESTOR NEUROL NEUROS, V16, P135
   Schapira AHV, 2009, NEUROLOGY, V72, pS44, DOI 10.1212/WNL.0b013e3181990438
   Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207
   Stone J, 2012, P WALT, VP928C0072
   Wallace BA, 2007, BRAIN, V130, P2129, DOI 10.1093/brain/awm137
   Wang Y, 2010, J NAT MED-TOKYO, V64, P24, DOI 10.1007/s11418-009-0360-6
NR 23
TC 46
Z9 48
U1 1
U2 21
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1877-7171
J9 J PARKINSON DIS
JI J. Parkinsons Dis.
PY 2013
VL 3
IS 1
BP 77
EP 83
DI 10.3233/JPD-130173
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 149RV
UT WOS:000319339700010
PM 23938314
DA 2022-11-30
ER

PT J
AU Olson, JL
   Courtney, RJ
   Mandava, N
AF Olson, Jeffrey L.
   Courtney, R. Jackson
   Mandava, Naresh
TI Intravitreal infliximab and choroidal neovascularization in an animal
   model
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; SUBRETINAL
   NEOVASCULARIZATION; NATURAL-HISTORY; TNF-ALPHA; RAT; TRIAMCINOLONE;
   PREVALENCE; MEMBRANES; ADHESION
AB Objective: To determine whether intravitreal infliximab can inhibit the growth of choroidal neovascularization (CNV) in an animal model of age-related macular degeneration.
   Methods: Twenty-four brown Norway rats received 6 argon laser lesions of sufficient power to rupture the Bruch membrane in each eye. The right eye received a single intravitreal infliximab injection of 0.15 mg/mL, 1.5 mg/mL, or 15 mg/mL. The left eye received an injection of balanced saline solution. The animals were then euthanized at day 30, the eyes were enucleated, and the amount of CNV was quantified with digital analysis software.
   Results: Intravitreal infliximab inhibited CNV growth in the rat laser-trauma model in a dose-response manner. In the 1.5-mg/mL group, there was an 11% reduction in CNV growth (P=. 01). In the 15-mg/mL group, CNV growth was decreased by 68% ( P <. 001).
   Conclusions: Infliximab can inhibit CNV in a rat laser-trauma model, implicating its target cytokine tumor necrosis factor alpha in the angiogenic stimulus for CNV. Suppression of inflammatory cytokines may prove to be another therapeutic target in the treatment of exudative macular degeneration.
   Clinical Relevance: This study demonstrates in a model of macular degeneration an antiangiogenic effect of intravitreal infliximab, which provides a rationale for future human studies.
C1 Univ Colorado, Dept Ophthalmol, Rocky Mt Lions Eye Inst, Sch Med, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Olson, JL (通讯作者)，Univ Colorado, Dept Ophthalmol, Rocky Mt Lions Eye Inst, Sch Med, 1675 Ursula, Aurora, CO 80045 USA.
EM jeffrey.olson@uchsc.edu
CR Aoudjit F, 1997, CELL GROWTH DIFFER, V8, P335
   Clark J, 2005, ANN RHEUM DIS, V64, P70, DOI 10.1136/ard.2005.042523
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gao H, 2004, VISION RES, V44, P349, DOI 10.1016/j.visres.2003.09.027
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOVE T, 2002, GUT, V5, P206
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koizumi K, 2003, INVEST OPHTH VIS SCI, V44, P2184, DOI 10.1167/iovs.02-0589
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   McMenamin PG, 2000, INVEST OPHTH VIS SCI, V41, P3043
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732
   SPRANGER J, 1995, MED KLIN, V90, P134
   Suhler EB, 2005, ARCH OPHTHALMOL-CHIC, V123, P903, DOI 10.1001/archopht.123.7.903
   Ueda Toshihiko, 1998, Angiogenesis, V1, P174
NR 24
TC 47
Z9 50
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD SEP
PY 2007
VL 125
IS 9
BP 1221
EP 1224
DI 10.1001/archopht.125.9.1221
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 208TM
UT WOS:000249342100010
PM 17846362
OA Bronze
DA 2022-11-30
ER

PT J
AU Kobayashi, S
   Nomura, M
   Nishioka, T
   Kikuchi, M
   Ishihara, A
   Nagai, R
   Hagino, N
AF Kobayashi, Shinjiro
   Nomura, Masaaki
   Nishioka, Tatsuo
   Kikuchi, Minoru
   Ishihara, Akina
   Nagai, Ryoji
   Hagino, Nobuyoshi
TI Overproduction of N-epsilon-(carboxymethyl)lysine-induced
   neovascularization in cultured choroidal explant of aged rat
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE choroidal neovascularization; N-epsilon-(carboxymethyl)lysine; tumor
   necrosis factor alpha; vascular endothelial growth factor; age-related
   macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS;
   NECROSIS-FACTOR-ALPHA; STREPTOZOTOCIN-DIABETIC WISTAR; RETINAL-PIGMENT
   EPITHELIUM; MACULAR DEGENERATION; MAILLARD REACTION; CELL GROWTH; GK
   RATS; PROTEINS
AB N-epsilon-(Carboxymethyl)lysine (CML) adduct, a major structure of advanced glycation end product, facilitated production of immature microvessels from choroidal explant cultured in fibrin gel. The present study was investigated an action of endogenous CML adduct on neovascularization of cultured choroidal explants of aged Wistar rats with 9 months of age. The number of microvessels budded from explants was counted under optical microscope and used as an index of in vitro neovascularization. Aged choroidal explants increased the neovascularization in an age-dependent manner. Anti-CML antibody decreased age-facilitated neovascularization as well as CML-human serum albumin (HSA)-facilitated neovascularization. Both the aged explant and CML-HSA-treated explant significantly released vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF) alpha and platelet-derived growth factor (PDGF)-B during the culture period. The release of TNF alpha and PDGF-B was earlier than that of VEGF from the aged explants. The antibodies against these factors decreased the CML-facilitated and age-facilitated neovascularization in the choroidal explants. The inhibitory capacity of anti-TNF alpha antibody was greater than those of anti-VEGF and anti-PDGF-B antibodies. In conclusion, endogenous CML adduct overproduced the neovascularization of the aged choroidal explant. The CML adduct releases TNF alpha which might induce the production and release of VEGF for the abnormal choroidal neovascularization in the patients of age-related macular degeneration.
C1 Hokuriku Univ, Fac Pharmaceut Sci, Dept Clin Pharmacol, Kanazawa, Ishikawa 9201181, Japan.
   Hokuriku Univ, Org Frontier Res Prevent Pharmaceut Sci, Kanazawa, Ishikawa 9201181, Japan.
   Kumamoto Univ, Sch Med Sci, Dept Med Biochem, Kumamoto 8600811, Japan.
   Tulane Univ, Hlth Sci Ctr, US Japan Biomed Res Labs, Belle Chasse, LA 70037 USA.
C3 Hokuriku University; Hokuriku University; Kumamoto University; Tulane
   University
RP Kobayashi, S (通讯作者)，Hokuriku Univ, Fac Pharmaceut Sci, Dept Clin Pharmacol, 4 Ho Kanagawa Machi, Kanazawa, Ishikawa 9201181, Japan.
EM s-kobayashi@hokuriku-u.ac.jp
CR AHMED MU, 1986, J BIOL CHEM, V261, P4889
   ARAKI N, 1992, J BIOL CHEM, V267, P10211
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007
   Hammes HP, 1999, DIABETOLOGIA, V42, P728, DOI 10.1007/s001250051221
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HUGHES S, 2005, NEUROBIOL
   IENAGA K, 1995, CONTRIB NEPHROL, V112, P42
   Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Kimura I, 2000, INT ANGIOL, V19, P26
   Kimura I, 1997, JPN J PHARMACOL, V74, P303, DOI 10.1254/jjp.74.303
   Kimura T, 1996, NEUROSCI LETT, V208, P53, DOI 10.1016/0304-3940(96)12537-4
   Kobayashi S, 2005, BIOL PHARM BULL, V28, P242, DOI 10.1248/bpb.28.242
   Kobayashi S, 2004, BIOL PHARM BULL, V27, P1565, DOI 10.1248/bpb.27.1565
   Kobayashi S, 2004, BIOL PHARM BULL, V27, P1382, DOI 10.1248/bpb.27.1382
   Kobayashi S, 1998, JPN J PHARMACOL, V78, P471, DOI 10.1254/jjp.78.471
   KONISHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953, DOI 10.1271/bbb.58.1953
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   McIlroy M, 2006, CARDIOVASC RES, V69, P207, DOI 10.1016/j.cardiores.2005.08.003
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Niwa T, 1997, J CLIN INVEST, V99, P1272, DOI 10.1172/JCI119285
   ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449
   SIMMONS DL, 1992, J IMMUNOL, V148, P267
   SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Strunk J, 2006, RHEUMATOL INT, V26, P252, DOI 10.1007/s00296-005-0619-5
   Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200
   URANO T, 2002, FREE RADIC BIOL MED, V32, P688
   Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312
   Yonekura H, 2005, J PHARMACOL SCI, V97, P305, DOI 10.1254/jphs.CPJ04005X
   Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015
NR 40
TC 12
Z9 20
U1 0
U2 1
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD JAN
PY 2007
VL 30
IS 1
BP 133
EP 138
DI 10.1248/bpb.30.133
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 132RR
UT WOS:000243960400025
PM 17202673
OA Bronze
DA 2022-11-30
ER

PT J
AU Sahni, J
   Stanga, P
   Wong, D
   Lenfestey, P
   Kent, D
   Harding, S
AF Sahni, Jayashree
   Stanga, Paulo
   Wong, David
   Lenfestey, Pauline
   Kent, David
   Harding, Simon
TI Optical coherence tomography analysis of bilateral end-stage choroidal
   neovascularization where one eye is treated with photodynamic therapy
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; optical
   coherence tomography; photodynamic therapy
ID MACULAR DEGENERATION; 2ND EYE; SECONDARY
AB Background: To compare retinal thickness and subretinal hyper-reflectivity using Stratus optical coherence tomography (OCT3) between the eyes of patients with bilateral end-stage exudative age-related macular degeneration (AMD), where one eye has been treated with photodynamic therapy (PDT).
   Methods: Patients with PDT-treated stable choroidal neovascularization (CNV), defined as a fibrotic lesion not requiring treatment for 6 months, in one eye and an untreated end-stage CNV (disciform) scar in their fellow eye, underwent refraction protocol logMAR visual acuity (VA) in letters, slit-lamp biomicroscopy, fluorescein angiography and OCT3 scan. Subretinal scar thickness was measured as Outer High Reflectivity Band Thickness (OHRBT) and retinal thickness as neuroretinal foveal thickness (NFT) on OCT3.
   Results: Thirty-two eyes of 16 patients were studied. Mean OHRBT was 255.62 mu m in treated eyes and 350.8 mu m in untreated eyes (P = 0.001). Mean NFT was 130.3 mu m in the treated eye and 79.9 mu m in the untreated eye (P = 0.017). Mean VA was 42 letters in treated eyes and 15 letters in untreated eyes (P < 0.005).
   Conclusions: Based on OCT3 findings, eyes with AMD treated with PDT have a thinner fibrous scar and better preserved retinal thickness when compared with untreated fellow eyes with end-stage fibrotic scarring.
C1 Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
   Manchester Royal Eye Hosp, Manchester M13 9WH, Lancs, England.
   Aut Even Hosp, Eye Serv, Kilkenny, Ireland.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; Manchester Royal
   Eye Hospital
RP Sahni, J (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Link 8 Z, Liverpool L7 8XP, Merseyside, England.
EM jayashree2001@hotmail.com
RI Wong, Sai Hung David/D-8482-2015
OI Harding, Simon/0000-0003-4676-1158
CR BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   LAVIN MJ, 1991, BRIT J OPHTHALMOL, V75, P133, DOI 10.1136/bjo.75.3.133
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
NR 17
TC 4
Z9 4
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2007
VL 35
IS 1
BP 13
EP 17
DI 10.1111/j.1442-9071.2006.01385.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131KE
UT WOS:000243866900004
PM 17300565
DA 2022-11-30
ER

PT J
AU Surgucheva, I
   Ninkina, N
   Buchman, VL
   Grasing, K
   Surguchov, A
AF Surgucheva, I
   Ninkina, N
   Buchman, VL
   Grasing, K
   Surguchov, A
TI Protein aggregation in retinal cells and approaches to cell protection
SO CELLULAR AND MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE retinal dystrophies; chaperones; age-related macular degeneration;
   neuroprotection; selegiline; synuclein
ID DOMINANT RETINITIS-PIGMENTOSA; ALPHA-SYNUCLEIN; GAMMA-SYNUCLEIN;
   DOPAMINERGIC-NEURONS; L-DEPRENYL; EXPRESSION; RHODOPSIN; MECHANISM;
   DISEASE; STRESS
AB 1. Retinal dystrophies (RD) comprise a group of clinically and genetically heterogeneous retinal disorders, which typically result in the degeneration of photoreceptors followed by the impairment or loss of vision. Although age-related macular degeneration (AMD) and retinitis pigmentosa (RP) are among the most common forms of RD, currently, there is no effective treatment for either disorder.
   2. Recently, abnormal protein accumulation and aggregation due to protein misfolding and proteasome inhibition have been implicated in the pathogenesis of RD. In this paper we describe effects of several factors on protein aggregation and survival of photoreceptor cells.
   3. Expression of rhodopsin carrying P23H mutation causes its accumulation in intracellular inclusion bodies in a perinuclear area of photoreceptor cells. beta- and alpha-synucleins and heat shock protein Hsp-70, but not alpha-synuclein, protect cultured ocular cells from mutant opsin accumulation. This effect might be explained by their chaperonic activity.
   4. Knock-out of alpha- and gamma-synucleins does not affect gross retinal morphology, but induces tyrosine hydroxylase in the inner prexiform layer of the retina. Selegiline-a monoamine oxidase inhibitor used for the treatment of Parkinson's disease, reduces apoptosis and increases viability in cultured retinal pigment epithelium cells (APRE-19).
   5. These results suggest that chaperones and selegiline may be considered promising candidates for the protection of ocular cells from the accumulation of misfolded and aggregated proteins.
C1 VA Med Ctr, Retinal Dis Res Lab, Kansas City, MO 64128 USA.
   Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA.
   Cardiff Sch Biosci, Cardiff, Wales.
   Univ Kansas, Med Ctr, Dept Med, Kansas City, KS 66103 USA.
C3 University of Kansas; University of Kansas Medical Center; Cardiff
   University; University of Kansas; University of Kansas Medical Center
RP Surguchov, A (通讯作者)，VA Med Ctr, Retinal Dis Res Lab, 4801 Linwood Blvd, Kansas City, MO 64128 USA.
EM asurguchov@kumc.edu
RI Ninkina, Natalia N/A-1732-2011; Buchman, Vladimir L/A-4814-2010
OI Buchman, Vladimir L/0000-0002-7631-8352; Grasing,
   Kenneth/0000-0002-6464-5700
FU NEI NIH HHS [EY 13784-03] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R03EY013784] Funding Source: NIH RePORTER
CR AGARWAL N, 1998, INVEST OPHTH VIS SCI, V4874, P189
   Albani D, 2004, FASEB J, V18, P1713, DOI 10.1096/fj.04-1621fje
   ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681
   Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200
   BATHORY G, 1987, POL J PHARMACOL PHAR, V39, P195
   Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   BHANUPRAKASH RG, 2000, J BIOL CHEM, V275, P4565
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a
   BUYS YM, 1995, CURR EYE RES, V14, P119, DOI 10.3109/02713689508999923
   Chapple JP, 2003, J BIOL CHEM, V278, P19087, DOI 10.1074/jbc.M212349200
   Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7
   da Costa CA, 2003, J BIOL CHEM, V278, P37330, DOI 10.1074/jbc.M306083200
   Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758
   El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559
   Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9
   Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3
   George JM, 2002, GENOME BIOL, V3
   Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564
   Haas AL, 1997, FASEB J, V11, P1257
   Hashimoto M, 2004, J BIOL CHEM, V279, P23622, DOI 10.1074/jbc.M313784200
   Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7
   Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200
   Jensen PJ, 2003, J NEUROCHEM, V86, P196, DOI 10.1046/j.1471-4159.2003.01835.x
   Jeon YK, 2001, MOL CELLS, V11, P250
   Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kolb H, 1997, Mol Vis, V3, P6
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907
   Manning-Bog AB, 2003, J NEUROSCI, V23, P3095
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Ninkina N, 2003, MOL CELL BIOL, V23, P8233, DOI 10.1128/MCB.23.22.8233-8245.2003
   Noorwez SM, 2004, J BIOL CHEM, V279, P16278, DOI 10.1074/jbc.M312101200
   Papp E, 2003, BIOFACTORS, V17, P249, DOI 10.1002/biof.5520170124
   Perez RG, 2004, J NEUROCHEM, V89, P1318, DOI 10.1111/j.1471-4159.2004.02423.x
   Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002
   Ragaiey T, 1997, J OCUL PHARMACOL TH, V13, P479, DOI 10.1089/jop.1997.13.479
   Robertson DC, 2004, J NEUROCHEM, V89, P1126, DOI 10.1111/j.1471-4159.2004.02378.x
   Saliba RS, 2002, J CELL SCI, V115, P2907
   Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5
   SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O
   Snyder H, 2005, J BIOL CHEM, V280, P7562, DOI 10.1074/jbc.M412887200
   Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200
   Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007
   Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3
   Surgucheva I, 2005, CELL MOL NEUROBIOL, V25, P1009, DOI 10.1007/s10571-005-8471-4
   Surguchov A, 2001, J NEUROSCI RES, V65, P68, DOI 10.1002/jnr.1129
   Surguchov A, 2001, CELL MOTIL CYTOSKEL, V49, P218, DOI 10.1002/cm.1035
   Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683
   Takahata K, 2003, EUR J PHARMACOL, V458, P81, DOI 10.1016/S0014-2999(02)02729-2
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5
   Trojanowski JQ, 2000, ANN NY ACAD SCI, V924, P62
   Wersinger C, 2003, NEUROSCI LETT, V342, P124, DOI 10.1016/S0304-3940(03)00212-X
   Xu L, 1999, BIOCHEM PHARMACOL, V58, P1183, DOI 10.1016/S0006-2952(99)00208-7
   Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800
   Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700
NR 61
TC 39
Z9 43
U1 0
U2 4
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0272-4340
EI 1573-6830
J9 CELL MOL NEUROBIOL
JI Cell. Mol. Neurobiol.
PD SEP
PY 2005
VL 25
IS 6
BP 1051
EP 1066
DI 10.1007/s10571-005-8474-1
PG 16
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA 999RZ
UT WOS:000234409500008
PM 16392036
DA 2022-11-30
ER

PT J
AU Marneros, AG
   Olsen, BR
AF Marneros, AG
   Olsen, BR
TI Physiological role of collagen XVIII and endostatin
SO FASEB JOURNAL
LA English
DT Review
DE basement membrane; retinal pigment epithelium; age-related macular
   degeneration; hydrocephalus; heparan sulfate proteoglycan
ID BASAL LAMINAR DEPOSIT; ANGIOGENESIS INHIBITOR ENDOSTATIN;
   EPITHELIUM-DERIVED FACTOR; FAMILIAL EXUDATIVE VITREORETINOPATHY;
   TISSUE-SPECIFIC DIFFERENCES; BASEMENT-MEMBRANE ZONES; HIGH-FAT DIET;
   KNOBLOCH-SYNDROME; MACULAR DEGENERATION; PIGMENT-EPITHELIUM
AB Collagen XVIII is a component of basement membranes (BMs) with the structural properties of both a collagen and a proteoglycan. Proteolytic cleavage within its C-terminal domain releases a fragment, endostatin, which has been reported to have anti-angiogenesis effects. Molecular studies demonstrated binding of the endostatin domain to heparan sulfate and to BM components like laminin and perlecan, but the functional role of these interactions in vivo remains unknown. Insights into the physiological function of collagen XVIII/endostatin have recently been obtained through the identification of inactivating mutations in the human collagen XVIII/endostatin gene (COL18A1) in patients with Knobloch syndrome, characterized by age-dependent vitreoretinal degeneration and occipital encephalocele. That collagen XVIII/endostatin has an essential role in ocular development and the maintenance of visual function is further demonstrated by the ocular abnormalities seen in mice lacking collagen XVIII/endostatin. Age-dependent loss of vision in these mutant mice is associated with pathological accumulation of deposits under the retinal pigment epithelium, as seen in early stages of age-related macular degeneration in humans. In addition, recent evidence suggests that lack of collagen XVIII/ endostatin predisposes to hydrocephalus formation. These recent findings demonstrate an important role for collagen XVIII/endostatin in cell-matrix interactions in certain tissues that may be compensated for in other tissues expressing this collagen.
C1 Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School
RP Marneros, AG (通讯作者)，Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.
EM Alexander_Marneros@hms.harvard.edu; Bjorn_Olsen@hms.harvard.edu
OI Marneros, Alexander/0000-0003-3866-020X
CR Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9
   Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219
   AHMAD NN, 1991, P NATL ACAD SCI USA, V88, P6624, DOI 10.1073/pnas.88.15.6624
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Annunen S, 1999, AM J HUM GENET, V65, P974, DOI 10.1086/302585
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dixelius J, 2002, CANCER RES, V62, P1944
   Dixelius J, 2003, CANCER LETT, V196, P1, DOI 10.1016/S0304-3835(03)00267-2
   Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870
   Dong SC, 2003, J BIOL CHEM, V278, P1700, DOI 10.1074/jbc.M209276200
   Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500
   EKLUND L, 2001, THESIS U OULU OULU
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064
   Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656
   Ito M, 1999, ANAT EMBRYOL, V200, P403, DOI 10.1007/s004290050289
   JAVAHERIAN K, 2002, IN PRESS J BIOL CHEM
   Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kliemann SE, 2003, AM J MED GENET A, V119A, P15, DOI 10.1002/ajmg.a.20070
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   KNOBLOCH WH, 1972, AM J OPHTHALMOL, V73, P517, DOI 10.1016/0002-9394(72)90003-7
   Koganei J., 1885, ARCH MIKROSK ANAT, V25, P1, DOI [10.1007/BF02966370, DOI 10.1007/BF02966370]
   Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233
   LANG R, 1994, DEVELOPMENT, V120, P3395
   LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I
   Li Q, 2004, AM J PATHOL, V165, P415, DOI 10.1016/S0002-9440(10)63307-X
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180
   Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2
   MARNEROS AG, 2004, THESIS U OSLO UNIPUB
   Menzel O, 2004, HUM MUTAT, V23, P77, DOI 10.1002/humu.10284
   Miosge N, 2003, J HISTOCHEM CYTOCHEM, V51, P285, DOI 10.1177/002215540305100303
   Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Moulton KS, 2004, CIRCULATION, V110, P1330, DOI 10.1161/01.CIR.0000140720.79015.3C
   MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763
   Nakamoto T, 2002, PLANT PROD SCI, V5, P175, DOI 10.1626/pps.5.175
   OH SP, 1994, GENOMICS, V19, P494, DOI 10.1006/geno.1994.1098
   Ohlmann AV, 2004, INVEST OPHTH VIS SCI, V45, P2384, DOI 10.1167/iovs.03-1214
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   PASSOSBUENO MR, 1994, AM J MED GENET, V52, P170, DOI 10.1002/ajmg.1320520209
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4
   REHN M, 1994, J BIOL CHEM, V269, P13929
   REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705
   REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234
   Ricard-Blum S, 2004, J BIOL CHEM, V279, P2927, DOI 10.1074/jbc.M309868200
   Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339
   Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450
   Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957
   Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8
   Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9
   Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249
   Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   SEAVER LH, 1993, AM J MED GENET, V46, P203, DOI 10.1002/ajmg.1320460221
   Sertie AL, 1996, HUM MOL GENET, V5, P843, DOI 10.1093/hmg/5.6.843
   Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051
   Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Thumann G, 2001, SURV OPHTHALMOL, V45, P345, DOI 10.1016/S0039-6257(00)00195-8
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Toomes C, 2004, AM J HUM GENET, V74, P721, DOI 10.1086/383202
   Utriainen A, 2004, HUM MOL GENET, V13, P2089, DOI 10.1093/hmg/ddh213
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wickstrom SA, 2001, CANCER RES, V61, P6511
   WOBMANN PR, 1972, AM J OPHTHALMOL, V73, P90, DOI 10.1016/0002-9394(72)90311-X
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8
   Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Ylikarppa R, 2003, FASEB J, V17, P2257, DOI 10.1096/fj.02-1001fje
   Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006
   Zorick TS, 2001, EUR J HUM GENET, V9, P811, DOI 10.1038/sj.ejhg.5200721
NR 93
TC 163
Z9 173
U1 1
U2 9
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAY
PY 2005
VL 19
IS 7
BP 716
EP 728
DI 10.1096/fj.04-2134rev
PG 13
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 933CU
UT WOS:000229602600028
PM 15857886
DA 2022-11-30
ER

PT J
AU Qi, FF
   Tao, LM
   Dai, YM
   Zhang, BM
   Wang, X
   Yu, Y
AF Qi, Fei-Fei
   Tao, Li-Mei
   Dai, Yi-Ming
   Zhang, Bao-Ming
   Wang, Xin
   Yu, Yan
TI Optimization and application of high-throughput supported liquid
   extraction for simultaneous determination of carotenoids and fat-soluble
   vitamins in serum
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article
DE High-throughput; Supported liquid extraction; Response surface
   methodology; Carotenoids; Fat-soluble vitamins; Biological analysis
ID DIODE-ARRAY DETECTION; SAMPLE PREPARATION; MASS-SPECTROMETRY;
   BIOLOGICAL-FLUIDS; ALPHA-TOCOPHEROL; LC-MS/MS; CHROMATOGRAPHY; RISK;
   METABOLITES; VALIDATION
AB The demand for analysis of carotenoids (CAR) and fat-soluble vitamins (FSV) is continuously expanding, but currently used sample preparation methods either require complicated extraction procedure or large sample volume, let alone the reliability of the results. This study aimed to develop a fast, high-efficient, and highthroughput method based on supported liquid extraction (SLE) for the simultaneous extraction of FSV and CAR from human serum before using high-performance liquid chromatography-diode array detector (HPLCDAD) analysis. The optimization of SLE parameters was achieved through response surface methodology (RSM) based on the Box-Behnken design (BBD) and included serum-water-extraction solvent ratio and eluent volume. Under optimal conditions, the proposed method gives acceptable limits of detection (LOD) (0.005-0.3 mu g/mL), good recovery (89.6-110.9%) as well as relative standard deviation (RSD) of less than 10.1% by consuming lower serum sample (100 mu L) and less sample preparation time (2 min per sample). Compared with liquid-phase extraction (LLE), the SLE delivers rapid extraction with higher recovery, better reproducibility, and lower matrix effect for CAR and FSV analysis. The method has been successfully applied to quantify CAR and FSV levels in serum of healthy individuals and age-related macular degeneration (AMD) patients, demonstrating the feasibility of the proposed method for epidemiology and routine applications.
C1 [Qi, Fei-Fei; Tao, Li-Mei; Dai, Yi-Ming; Zhang, Bao-Ming; Yu, Yan] Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Shanxi, Peoples R China.
   [Zhang, Bao-Ming] Xi An Jiao Tong Univ, Hosp Stomatol, Xian 710004, Shanxi, Peoples R China.
   [Wang, Xin] Northwest Univ Nationalities, Chem Engn Inst, Lanzhou 730000, Gansu, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Northwest Minzu
   University
RP Yu, Y (通讯作者)，Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Shanxi, Peoples R China.
EM yuyan@mail.xjtu.edu.cn
FU National Natural Science Foundation of China [81803285]; China
   Postdoctoral Science Foundation [2018M641002]
FX The authors acknowledge the First Affiliated Hospital, Xi'an Jiaotong
   University College of Medicine for supporting serum samples. This work
   was supported by the National Natural Science Foundation of China [grant
   number 81803285] ; and the China Postdoctoral Science Foundation [grant
   number 2018M641002] .
CR Aust O, 2001, J CHROMATOGR A, V936, P83, DOI 10.1016/S0021-9673(01)01269-9
   Bartosinska E, 2018, TALANTA, V176, P108, DOI 10.1016/j.talanta.2017.08.004
   Cervinkova B, 2016, ANAL BIOANAL CHEM, V408, P2407, DOI 10.1007/s00216-015-9214-0
   de Quiros ARB, 2006, J FOOD COMPOS ANAL, V19, P97, DOI 10.1016/j.jfca.2005.04.004
   Eggersdorfer M, 2018, ARCH BIOCHEM BIOPHYS, V652, P18, DOI 10.1016/j.abb.2018.06.001
   Ferreira SLC, 2007, ANAL CHIM ACTA, V597, P179, DOI 10.1016/j.aca.2007.07.011
   Ferreiro-Vera C, 2011, TALANTA, V85, P1842, DOI 10.1016/j.talanta.2011.07.031
   Giuffrida D, 2018, J AGR FOOD CHEM, V66, P3302, DOI 10.1021/acs.jafc.8b00309
   Gueguen S, 2002, J CHROMATOGR SCI, V40, P69, DOI 10.1093/chromsci/40.2.69
   Hinchliffe E, 2016, ANN CLIN BIOCHEM, V53, P434, DOI 10.1177/0004563215596024
   Hsu BY, 2012, J CHROMATOGR B, V899, P36, DOI 10.1016/j.jchromb.2012.04.034
   Huang J, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700267
   Hurst EA, 2020, J STEROID BIOCHEM, V199, DOI 10.1016/j.jsbmb.2020.105598
   Jiang H, 2019, AM J CLIN NUTR, V109, P43, DOI 10.1093/ajcn/nqy270
   Lazzarino G, 2017, J CHROMATOGR A, V1527, P43, DOI 10.1016/j.chroma.2017.10.053
   Lope V, 2018, J STEROID BIOCHEM, V182, P4, DOI 10.1016/j.jsbmb.2018.04.005
   Lyu H., BIOMED CHROMATOGR, DOI [10.1002/bmc.4932(2020), DOI 10.1002/BMC.4932(2020)]
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   Min KB, 2014, CANCER SCI, V105, P736, DOI 10.1111/cas.12405
   Petruzziello F, 2017, ANAL CHEM, V89, P7615, DOI 10.1021/acs.analchem.7b01476
   Capote FP, 2007, RAPID COMMUN MASS SP, V21, P1745, DOI 10.1002/rcm.3014
   Qi FF, 2021, J CHROMATOGR A, V1635, DOI 10.1016/j.chroma.2020.461755
   Qi FF, 2017, ANAL BIOANAL CHEM, V409, P5697, DOI 10.1007/s00216-017-0510-8
   Regal P, 2020, ANAL METABOLOMICS CA
   Saini RK, 2018, FOOD CHEM, V240, P90, DOI 10.1016/j.foodchem.2017.07.099
   Sanjeevi N, 2019, J ACAD NUTR DIET, V119, P1340, DOI 10.1016/j.jand.2019.03.009
   Satoh M, 2016, ANAL BIOANAL CHEM, V408, P7617, DOI 10.1007/s00216-016-9821-4
   Scragg R, 2017, JAMA CARDIOL, V2, P608, DOI 10.1001/jamacardio.2017.0175
   Tan J, 2017, SEPARATIONS, V4, DOI 10.3390/separations4020019
   Yan B, 2016, BRIT J NUTR, V115, P129, DOI 10.1017/S000711451500416X
   Yin S, 2019, TRAC-TREND ANAL CHEM, V110, P204, DOI 10.1016/j.trac.2018.11.008
   Zakaria R, 2020, CLIN CHEM LAB MED, V58, P817, DOI 10.1515/cclm-2019-0397
   Zhang Y, 2013, BIOANALYSIS, V5, P285, DOI [10.4155/bio.12.335, 10.4155/BIO.12.335]
   Zhou HY, 2011, INVEST OPHTH VIS SCI, V52, P4338, DOI 10.1167/iovs.10-6519
NR 34
TC 1
Z9 1
U1 10
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD MAY 30
PY 2021
VL 1173
AR 122672
DI 10.1016/j.jchromb.2021.122672
EA MAY 2021
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SU7PW
UT WOS:000663325500009
PM 33984631
DA 2022-11-30
ER

PT J
AU Nguyen, DD
   Lai, JY
AF Nguyen, Duc Dung
   Lai, Jui-Yang
TI Advancing the stimuli response of polymer-based drug delivery systems
   for ocular disease treatment
SO POLYMER CHEMISTRY
LA English
DT Review
ID IN-SITU GEL; DRY EYE DISEASE; THERMORESPONSIVE POLYMERS; THERMOSENSITIVE
   HYDROGELS; BRIMONIDINE TARTRATE; SENSITIVE HYDROGELS; GLOBAL PREVALENCE;
   EX-VIVO; GLAUCOMA; RELEASE
AB The development of efficient therapies for ocular diseases remains a significant challenge because of the static and dynamic barriers in the eye. A variety of pharmaceutical strategies have been explored to overcome these ocular physiological barriers and thereby improve therapeutic bioavailability in both anterior and posterior ocular tissues. This mini-review summarizes, analyzes, and discusses recent advances in the field of ophthalmic drug delivery systems (DDSs). Specifically, the focus is on design strategies using stimuli-responsive polymers and their applications for the treatment of prevalent ocular diseases such as dry eye, ocular infection, glaucoma, and age-related macular degeneration. The stimuli-responsive polymers are categorized according to their responses in various ocular environmental conditions (such as temperature, pH, and ions). Additionally, general strategies and methodologies for the construction of effective ophthalmic stimuli-responsive DDSs are investigated by exploiting key parameters such as the stimuli-response type, ocular biocompatibility, ocular biodegradability, drug encapsulation and release, as well as the modifiable structure of the polymers. Also discussed in this review are the interrelationships among the designed structures, properties, and functions of the stimuli-responsive DDSs and their pharmacological treatment efficacies. In summary, we believe that the recent progress in the field of stimuli-responsive DDSs constitutes a significant advance for the development of effective pharmacological treatments for eye disorders.
C1 [Nguyen, Duc Dung; Lai, Jui-Yang] Chang Gung Univ, Grad Inst Biomed Engn, Taoyuan 33302, Taiwan.
   [Lai, Jui-Yang] Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan 33305, Taiwan.
   [Lai, Jui-Yang] Ming Chi Univ Technol, Dept Mat Engn, New Taipei 24301, Taiwan.
   [Lai, Jui-Yang] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan 33303, Taiwan.
C3 Chang Gung University; Chang Gung Memorial Hospital; Ming Chi University
   of Technology; Chang Gung University of Science & Technology
RP Lai, JY (通讯作者)，Chang Gung Univ, Grad Inst Biomed Engn, Taoyuan 33302, Taiwan.; Lai, JY (通讯作者)，Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan 33305, Taiwan.; Lai, JY (通讯作者)，Ming Chi Univ Technol, Dept Mat Engn, New Taipei 24301, Taiwan.; Lai, JY (通讯作者)，Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan 33303, Taiwan.
EM jylai@mail.cgu.edu.tw
RI Lai, Jui-Yang/I-1166-2017
OI Lai, Jui-Yang/0000-0002-9227-8549
FU Ministry of Science and Technology of Republic of China
   [MOST107-2221-E-182-058-MY3, MOST107-2314-B-182-016-MY3,
   MOST109-2811-E-182-503]
FX This work was supported by the grants MOST107-2221-E-182-058-MY3,
   MOST107-2314-B-182-016-MY3, and MOST109-2811-E-182-503 from the Ministry
   of Science and Technology of Republic of China.
CR Acar D, 2018, CONTACT LENS ANTERIO, V41, P93, DOI 10.1016/j.clae.2017.11.004
   Al-Kinani AA, 2018, ADV DRUG DELIVER REV, V126, P113, DOI 10.1016/j.addr.2017.12.017
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Almeida H, 2014, DRUG DISCOV TODAY, V19, P400, DOI 10.1016/j.drudis.2013.10.001
   Almeida H, 2013, EXPERT OPIN DRUG DEL, V10, P1223, DOI 10.1517/17425247.2013.796360
   Ameeduzzafar, 2018, ARTIF CELL NANOMED B, V46, P959, DOI 10.1080/21691401.2017.1349779
   Ammar HO, 2010, DRUG DEV IND PHARM, V36, P1330, DOI 10.3109/03639041003801885
   Awwad S, 2017, BRIT J PHARMACOL, V174, P4205, DOI 10.1111/bph.14024
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Balachandra A, 2019, DRUG DELIV, V26, P343, DOI 10.1080/10717544.2019.1587042
   Barber LD, 2005, OPHTHALMOLOGY, V112, P1790, DOI 10.1016/j.ophtha.2005.05.013
   Barse R, 2016, J DRUG DELIV SCI TEC, V33, P66, DOI 10.1016/j.jddst.2016.03.011
   Barse RK, 2018, DRUG DEV IND PHARM, V44, P800, DOI 10.1080/03639045.2017.1414229
   Besford QA, 2020, ADV MATER, V32, DOI 10.1002/adma.201904625
   Bhalerao H, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-019-1555-0
   Bhalerao H, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1489-6
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Cabrera FJ, 2019, DRUG DISCOV TODAY, V24, P1679, DOI 10.1016/j.drudis.2019.05.035
   Chang MH, 2010, CLIN THER, V32, P454, DOI 10.1016/j.clinthera.2010.03.013
   Chatterjee S, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10050480
   Cheng YH, 2020, J BIOMED MATER RES B, V108, P8, DOI 10.1002/jbm.b.34359
   Cheng YH, 2016, CARBOHYD POLYM, V144, P390, DOI 10.1016/j.carbpol.2016.02.080
   Cheng YH, 2014, ACTA BIOMATER, V10, P4360, DOI 10.1016/j.actbio.2014.05.031
   Chenite A, 2000, BIOMATERIALS, V21, P2155, DOI 10.1016/S0142-9612(00)00116-2
   Choi A, 2019, BIOMATER SCI-UK, V7, P2277, DOI 10.1039/c8bm01664j
   Clayton JA, 2018, NEW ENGL J MED, V378, P2212, DOI 10.1056/NEJMra1407936
   Cruz-Cazarim ELC, 2019, EUR J PHARM BIOPHARM, V140, P1, DOI 10.1016/j.ejpb.2019.04.014
   Deepthi S, 2019, INT OPHTHALMOL, V39, P1355, DOI 10.1007/s10792-018-0955-6
   DEJONG WH, 2008, SMALL, V3, P133, DOI DOI 10.2147/IJN.S596
   Dhandhukia J, 2013, BIOMACROMOLECULES, V14, P976, DOI 10.1021/bm301558q
   Diaz-Tome V, 2018, J PHARM SCI-US, V107, P1342, DOI 10.1016/j.xphs.2017.12.028
   Dong FP, 2017, RSC ADV, V7, P3720, DOI 10.1039/c6ra25353a
   Dosmar E, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.53
   Dubey A, 2014, INT J PHARM INVESTIG, V4, P112, DOI 10.4103/2230-973X.138340
   Nguyen DD, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900702
   Ei-Laithy HM, 2011, ARCH PHARM RES, V34, P1663, DOI 10.1007/s12272-011-1011-5
   Faccia PA, 2019, J DRUG DELIV SCI TEC, V51, P45, DOI 10.1016/j.jddst.2019.02.018
   Fedorchak MV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09379-8
   Fernandez-Colino A, 2017, MOL PHARMACEUT, V14, P4498, DOI 10.1021/acs.molpharmaceut.7b00615
   Soares DCF, 2019, J DRUG TARGET, V27, P355, DOI 10.1080/1061186X.2018.1499747
   Garcia-Ochoa F, 2000, BIOTECHNOL ADV, V18, P549, DOI 10.1016/S0734-9750(00)00050-1
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Ge Y, 2020, EXPERT OPIN DRUG DEL, V17, P603, DOI 10.1080/17425247.2020.1735348
   Ghate D, 2007, INVEST OPHTH VIS SCI, V48, P2230, DOI 10.1167/iovs.06-0954
   Giner-Casares JJ, 2016, MATER TODAY, V19, P19, DOI 10.1016/j.mattod.2015.07.004
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta P, 2002, DRUG DISCOV TODAY, V7, P569, DOI 10.1016/S1359-6446(02)02255-9
   Guzman-Aranguez A, 2016, EYE CONTACT LENS, V42, P280, DOI 10.1097/ICL.0000000000000184
   Han Q, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5556-6
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Hosoya K, 2011, EXPERT OPIN DRUG DEL, V8, P1571, DOI 10.1517/17425247.2011.628983
   Huang H, 2018, ADV DRUG DELIVER REV, V126, P96, DOI 10.1016/j.addr.2017.09.008
   Huang HQ, 2019, SAUDI PHARM J, V27, P990, DOI 10.1016/j.jsps.2019.08.001
   Jain P, 2020, DRUG DEV IND PHARM, V46, P50, DOI 10.1080/03639045.2019.1698598
   Janga KY, 2019, J PHARMACOL EXP THER, V370, P814, DOI 10.1124/jpet.119.256446
   Jiao J, 2016, MAT SCI ENG C-MATER, V67, P26, DOI 10.1016/j.msec.2016.04.091
   Jumelle C, 2020, J CONTROL RELEASE, V321, P1, DOI 10.1016/j.jconrel.2020.01.057
   Kanapathipillai M, 2014, ADV DRUG DELIVER REV, V79-80, P107, DOI 10.1016/j.addr.2014.05.005
   Kang-Mieler JJ, 2020, EYE, V34, P1371, DOI 10.1038/s41433-020-0809-0
   Karcioglu ZA, 2008, AM J OPHTHALMOL, V145, P586, DOI 10.1016/j.ajo.2007.10.031
   Khan S, 2018, J OCUL PHARMACOL TH, V34, P287, DOI 10.1089/jop.2017.0079
   Kim HJ, 2014, ACS NANO, V8, P2998, DOI 10.1021/nn5002968
   Kotreka UK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172306
   Kouchak M, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1431-y
   Kowalski Regis P, 2005, Expert Rev Anti Infect Ther, V3, P131, DOI 10.1586/14787210.3.1.131
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kushwaha SKS, 2012, INT J PHARM INVESTIG, V2, P54, DOI 10.4103/2230-973X.100036
   Laddha U.D., 2017, INT J ADV PHARM, V6, P31, DOI DOI 10.7439/IJAP.V6I2.3806
   Lai JY, 2020, CHEM ENG J, V402, DOI 10.1016/j.cej.2020.126190
   Lai JY, 2012, BIOMATERIALS, V33, P2372, DOI 10.1016/j.biomaterials.2011.11.085
   Lambert WS, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.1.1
   Lefevre S, 2012, ANTIMICROB AGENTS CH, V56, P2485, DOI 10.1128/AAC.05745-11
   Lehr CM, 2000, J CONTROL RELEASE, V65, P19, DOI 10.1016/S0168-3659(99)00228-X
   Li GG, 2020, DRUG DEV IND PHARM, V46, P673, DOI 10.1080/03639045.2020.1750626
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin DQ, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201900001
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Luo LJ, 2020, MAT SCI ENG C-MATER, V115, DOI 10.1016/j.msec.2020.111095
   Luo LJ, 2020, BIOMATERIALS, V243, DOI 10.1016/j.biomaterials.2020.119961
   Luo LJ, 2020, J CONTROL RELEASE, V317, P246, DOI 10.1016/j.jconrel.2019.11.038
   Luo LJ, 2019, MAT SCI ENG C-MATER, V98, P897, DOI 10.1016/j.msec.2019.01.051
   Luo LJ, 2018, CARBOHYD POLYM, V197, P375, DOI 10.1016/j.carbpol.2018.06.020
   Luo LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09913-8
   Lynch CR, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00228
   Maller JJ, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.2.026001
   Maulvi FA, 2017, COLLOID SURFACE B, V157, P72, DOI 10.1016/j.colsurfb.2017.05.064
   Merino S, 2015, ACS NANO, V9, P4686, DOI 10.1021/acsnano.5b01433
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Mohammed S, 2017, MAT SCI ENG C-MATER, V78, P203, DOI 10.1016/j.msec.2017.04.065
   Mora-Pereira M, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02331-5
   Morlet N, 2003, BRIT J OPHTHALMOL, V87, P1169, DOI [10.1136/bjo.87.9.1169, 10.1136/bjo.87.9.1167]
   Morsi N, 2017, EUR J PHARM SCI, V104, P302, DOI 10.1016/j.ejps.2017.04.013
   Ni ZP, 2020, J MATER CHEM B, V8, P1555, DOI 10.1039/c9tb02517k
   O'Brien TP, 2003, EYE, V17, P957, DOI 10.1038/sj.eye.6700635
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Pflugfelder SC, 2007, OCUL SURF, V5, P163
   Phadatare S. P., 2015, ADV PHARMACOL, V2015
   Quinn JF, 2017, POLYM CHEM-UK, V8, P97, DOI 10.1039/c6py01365a
   Rajoria G., 2012, AJPTR, V2, P24
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Reed K, 2016, J OCUL PHARMACOL TH, V32, P574, DOI 10.1089/jop.2016.0084
   Rupenthal ID, 2011, INT J PHARMACEUT, V411, P78, DOI 10.1016/j.ijpharm.2011.03.043
   Russo E, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120671
   Saher O, 2016, PHARM DEV TECHNOL, V21, P600, DOI 10.3109/10837450.2015.1035728
   Sapino S, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9101461
   Shah TJ, 2018, CLIN OPHTHALMOL, V12, P2223, DOI 10.2147/OPTH.S165722
   Shastri DH, 2010, J YOUNG PHARM, V2, P116, DOI 10.4103/0975-1483.63144
   Shimizu Y, 2013, CLIN OPHTHALMOL, V7, P695, DOI 10.2147/OPTH.S43323
   Singh R, 2017, COMP MATER SCI, V126, P191, DOI 10.1016/j.commatsci.2016.09.030
   Soliman KA, 2019, DRUG DISCOV TODAY, V24, P1575, DOI 10.1016/j.drudis.2019.05.036
   Sponchioni M, 2019, MAT SCI ENG C-MATER, V102, P589, DOI 10.1016/j.msec.2019.04.069
   Sun JG, 2017, J MATER CHEM B, V5, P6400, DOI 10.1039/c7tb01556a
   Sun JG, 2017, ACS APPL MATER INTER, V9, P7990, DOI 10.1021/acsami.6b16509
   Sun JF, 2018, DRUG DES DEV THER, V12, P383, DOI 10.2147/DDDT.S153405
   Supper S, 2013, LANGMUIR, V29, P10229, DOI 10.1021/la401993q
   Sutariya V, 2013, PHARM DEV TECHNOL, V18, P957, DOI 10.3109/10837450.2011.647035
   Tavakoli N, 2019, PHARM DEV TECHNOL, V24, P891, DOI 10.1080/10837450.2019.1616755
   Tayel SA, 2013, INT J PHARMACEUT, V443, P293, DOI 10.1016/j.ijpharm.2012.12.049
   Teweldemedhin M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0612-2
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thoniyot P, 2015, ADV SCI, V2, DOI 10.1002/advs.201400010
   Tsai CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092830
   Wang K, 2017, J CONTROL RELEASE, V268, P212, DOI 10.1016/j.jconrel.2017.10.031
   Wang PX, 2017, J MATER CHEM B, V5, P1551, DOI 10.1039/c6tb02158a
   Wang W, 2015, J CONTROL RELEASE, V199, P156, DOI 10.1016/j.jconrel.2014.11.016
   Ward MA, 2011, POLYMERS-BASEL, V3, P1215, DOI 10.3390/polym3031215
   Wei ML, 2017, POLYM CHEM-UK, V8, P127, DOI 10.1039/c6py01585a
   Wu YM, 2019, ASIAN J PHARM SCI, V14, P1, DOI 10.1016/j.ajps.2018.04.008
   Xi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100632
   Xue K, 2019, BIOMATER SCI-UK, V7, P4603, DOI 10.1039/c9bm01049a
   Yeh TH, 2011, BIOMATERIALS, V32, P6164, DOI 10.1016/j.biomaterials.2011.03.056
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Yu JH, 2011, CORNEA, V30, P379, DOI 10.1097/ICO.0b013e3181f7f363
   Zeng YM, 2018, LIFE SCI, V212, P80, DOI 10.1016/j.lfs.2018.09.050
   Zhao XB, 2020, J CONTROL RELEASE, V323, P565, DOI 10.1016/j.jconrel.2020.04.039
NR 136
TC 30
Z9 30
U1 7
U2 36
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9954
EI 1759-9962
J9 POLYM CHEM-UK
JI Polym. Chem.
PD NOV 28
PY 2020
VL 11
IS 44
BP 6988
EP 7008
DI 10.1039/d0py00919a
PG 21
WC Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Polymer Science
GA OS0QL
UT WOS:000589868300001
OA Bronze
DA 2022-11-30
ER

PT J
AU Cao, J
   Yang, R
   Smith, TE
   Evans, S
   McCollum, GW
   Pomerantz, SC
   Petley, T
   Harris, IR
   Penn, JS
AF Cao, Jing
   Yang, Rong
   Smith, Taylor E.
   Evans, Stephanie
   McCollum, Gary W.
   Pomerantz, Steven C.
   Petley, Theodore
   Harris, Ian R.
   Penn, John S.
TI Human Umbilical Tissue-Derived Cells Secrete Soluble VEGFR1 and Inhibit
   Choroidal Neovascularization
SO MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL
   BEVACIZUMAB; FACTOR EXPRESSION; RAT MODEL; TRAP-EYE; RANIBIZUMAB;
   THERAPY; ATROPHY; RPE
AB Exudative age-related macular degeneration (AMD), characterized by choroidal neovascularization (CNV), is the leading cause of irreversible blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs are the standard treatment for AMD, but they have limitations. Cell therapy is a promising approach for ocular diseases, and it is being developed in the clinic for the treatment of retinal degeneration, including AMD. We previously showed that subretinal injection of human umbilical tissue-derived cells (hUTCs) in a rodent model of retinal degeneration preserved photoreceptors and visual function through rescue of retinal pigment epithelial (RPE) cell phagocytosis. Here we investigated the effect of hUTCs on a rat model of laser-induced CNV and on a human RPE cell line, ARPE-19, for VEGF production. We demonstrate that subretinal injection of hUTCs significantly inhibited CNV and lowered choroidal VEGF in vivo. VEGF release from ARPE-19 decreased when co-cultured with hUTCs. Soluble VEGF receptor 1 (sVEGFR1) is identified as the only factor in hUTC conditioned medium (CM) that binds to VEGF. The level of exogenous re-combinant VEGF in hUTC CM was dramatically reduced and could be recovered with sVEGFR1-neutralizing antibody. This suggests that hUTC inhibits angiogenesis through the secretion of sVEGFR1 and could serve as a novel treatment for angiogenic ocular diseases, including AMD.
C1 [Cao, Jing; Pomerantz, Steven C.; Petley, Theodore; Harris, Ian R.] Janssen Res & Dev LLC, Spring House, PA 19477 USA.
   [Yang, Rong; Smith, Taylor E.; Evans, Stephanie; McCollum, Gary W.; Penn, John S.] Vanderbilt Univ, Sch Med, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA.
C3 Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc;
   Vanderbilt University
RP Penn, JS (通讯作者)，Vanderbilt Univ, Sch Med, Dept Ophthalmol & Visual Sci, Nashville, TN 37232 USA.; Cao, J (通讯作者)，Janssen Res & Dev LLC, Oncol Translat Res, Spring House, PA 19477 USA.
EM jcao5@its.jnj.com; john.penn@vanderbilt.edu
FU Vanderbilt University School of Medicine; Janssen RD; OFFICE OF THE
   DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD021630] Funding Source:
   NIH RePORTER
FX We thank Michael Naso and Jennifer Nemeth-Seay (Janssen R&D, Spring
   House, PA) for providing advisory suggestions and Eilyn Lacy (Janssen
   R&D, Spring House, PA) for assistance with VEGF-binding factor
   identification. This work was performed under a sponsored research
   agreement between Vanderbilt University School of Medicine and Janssen
   R&D.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bae JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180482
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Bande MF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18412-9
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bhattacharjee G, 2000, J BIOL CHEM, V275, P26806
   Bhattacharya Sujoy, 2017, Curr Mol Biol Rep, V3, P172, DOI 10.1007/s40610-017-0069-3
   Bora PS, 2006, FEBS J, V273, P1403, DOI 10.1111/j.1742-4658.2006.05163.x
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cao J, 2016, STEM CELLS, V34, P367, DOI 10.1002/stem.2239
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dossarps D, 2015, AM J OPHTHALMOL, V160, P17, DOI 10.1016/j.ajo.2015.04.013
   Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811
   Eichler W, 2008, EXP EYE RES, V87, P342, DOI 10.1016/j.exer.2008.06.017
   Farjood F, 2017, MOL VIS, V23, P431
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059
   Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199
   Gomez J, 2016, OPHTHALMOL THER, V5, P183, DOI 10.1007/s40123-016-0058-2
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832
   Haider MA, 2017, J PAK MED ASSOC, V67, P1917
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Heroult M, 2004, ONCOGENE, V23, P1745, DOI 10.1038/sj.onc.1206879
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Ho AC, 2017, AM J OPHTHALMOL, V179, P67, DOI 10.1016/j.ajo.2017.04.006
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hornig C, 2000, LAB INVEST, V80, P443, DOI 10.1038/labinvest.3780050
   Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kim SJ, 2010, EXP EYE RES, V91, P537, DOI 10.1016/j.exer.2010.07.011
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Leung EH, 2016, OSLI RETINA, V47, P600, DOI 10.3928/23258160-20160601-16
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Rajakumar A, 2009, PLACENTA, V30, P25, DOI 10.1016/j.placenta.2008.10.006
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tang ZM, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1183-y
   Vempati P, 2014, CYTOKINE GROWTH F R, V25, P1, DOI 10.1016/j.cytogfr.2013.11.002
   Vempati P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011860
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   You QS, 2018, RETINA-J RET VIT DIS, V38, P1156, DOI 10.1097/IAE.0000000000001726
NR 74
TC 1
Z9 1
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2329-0501
J9 MOL THER-METH CLIN D
JI Mol.Ther.-Methods Clin. Dev.
PD SEP 13
PY 2019
VL 14
BP 37
EP 46
DI 10.1016/j.omtm.2019.05.007
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IX6AR
UT WOS:000485765700004
PM 31276010
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cai, JJ
   Zhang, H
   Zhang, YF
   Zhou, ZL
   Wu, SZ
AF Cai, Jingjing
   Zhang, He
   Zhang, Yun-feng
   Zhou, Zhonglou
   Wu, Shengzhou
TI MicroRNA-29 enhances autophagy and cleanses exogenous mutant alpha
   B-crystallin in retinal pigment epithelial cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Autophagy; mTOR; p85 alpha; LAMPTOR1/p18; TFEB; Age-related macular
   degeneration; Drusen; Protein aggregation; Neurodegenerative disorders
ID MITOCHONDRIAL-DNA DAMAGE; OXIDATIVE STRESS; MACULAR DEGENERATION;
   PROTEIN; ACTIVATION; MTORC1; DRUSEN; PATHOGENESIS; EXPRESSION; MECHANISM
AB Retinal pigment epithelial cells (RPEs), a pigmented cell layer in the outer retina, are constantly exposed to photo-oxidative stress. Autophagy relieves the stress by removing oxidative protein adducts, protein aggregates, and damaged mitochondria. We previously found that miR-29 is downregulated in choroid/RPE tissue in a model of exudative age-related macular degeneration (AMD), suggesting that miR-29 deficiency may contribute to autophagy inhibition and AMD progression. Here we wanted to test whether overexpression of miR-29 in RPEs could enhance autophagy, thereby facilitating removal of drusen components. Indeed, overexpression of miR-29 in the RPEs increased autophagy, assessed by decreased protein levels of p62, increased lipid form of microtubule-associated protein light chain (LC3-II), and elevated autophagy flux. Furthermore, overexpression of miR-29 mitigated the formation of mutant alpha B-crystallin (R120G) protein aggregates. In probing the mechanism, we demonstrated that miR-29 post-transcriptionally repressed LAMPTOR1/p18 via targeting its 3'-UTRs of messenger RNA. MiR-29 overexpression and knockdown of LAMPTOR1/p18 led to limited mTORC1 recruitment to lysosomes and inhibition of mTORC1 activity. Altogether, miR-29 enhances autophagy which aids in removal of protein aggregates. These findings reveal a novel role of miR-29, which has the potential of being a therapeutic strategy for rescuing RPE degeneration in ocular disorders.
C1 [Cai, Jingjing; Zhang, He; Zhang, Yun-feng; Zhou, Zhonglou; Wu, Shengzhou] Wenzhou Med Univ, Sch Optometry & Ophthalmol, Wenzhou, Peoples R China.
   [Cai, Jingjing; Zhang, He; Zhang, Yun-feng; Zhou, Zhonglou; Wu, Shengzhou] Wenzhou Med Univ, Eye Hosp, Wenzhou, Peoples R China.
   [Cai, Jingjing; Zhang, He; Zhang, Yun-feng; Zhou, Zhonglou; Wu, Shengzhou] State Key Lab Optometry Ophthalmol & Visual Sci, Wenzhou 325027, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Cai, JJ; Wu, SZ (通讯作者)，Wenzhou Med Univ, Sch Optometry & Ophthalmol, Wenzhou, Peoples R China.; Cai, JJ; Wu, SZ (通讯作者)，Wenzhou Med Univ, Eye Hosp, Wenzhou, Peoples R China.
EM jing-me2002@163.com; wszlab@mail.eye.ac.cn
RI wu, shengzhou/ABG-8579-2021; Zhang, Yun-Feng/ABD-7464-2020
OI wu, shengzhou/0000-0003-1154-2369; Zhang, Yun-Feng/0000-0001-6324-4115
FU National Natural Science Foundation of China [81600750]; Wenzhou Public
   Welfare Science and Technology Project [Y20160144]; Natural Science
   Foundation of Zhejiang Province [LY18H120003]; Project of State Key
   Laboratory of Ophthalmology, Optometry and Visual Science, Wenzhou
   Medical University [K171202]
FX The authors thank a colleague, professor Xiangtian Zhou from Wenzhou
   Medical University for providing primary human RPE cells. This study is
   supported by National Natural Science Foundation of China for Youth
   (81600750), Wenzhou Public Welfare Science and Technology Project
   (Y20160144), Natural Science Foundation of Zhejiang Province
   (LY18H120003), and by Project of State Key Laboratory of Ophthalmology,
   Optometry and Visual Science, Wenzhou Medical University, (No. K171202).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BESHARSE JC, 1977, SCIENCE, V196, P536, DOI 10.1126/science.300504
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Cai JJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-88
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De Araujo ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053768
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fang JH, 2011, HEPATOLOGY, V54, P1729, DOI 10.1002/hep.24577
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Gangalum RK, 2011, J BIOL CHEM, V286, P3261, DOI 10.1074/jbc.M110.160135
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Hebert SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI 10.1073/pnas.0710263105
   Hishiya A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016828
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hu ZY, 2014, AGING-US, V6, P160, DOI 10.18632/aging.100643
   Jiao QB, 2014, CLIN EXP PHARMACOL P, V41, P589, DOI 10.1111/1440-1681.12253
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kolosova NG, 2018, AGING-US, V10, P2136, DOI 10.18632/aging.101537
   Kriegel AJ, 2012, PHYSIOL GENOMICS, V44, P237, DOI 10.1152/physiolgenomics.00141.2011
   Kwon JJ, 2016, ONCOTARGET, V7, P71635, DOI 10.18632/oncotarget.11928
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li M, 2013, J BIOL CHEM, V288, P35769, DOI 10.1074/jbc.M113.511212
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Mitter S. K., 1989, AUTOPHAGY, V10, P2005
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nada S, 2009, EMBO J, V28, P477, DOI 10.1038/emboj.2008.308
   Nakamura T, 2007, CELL MOL LIFE SCI, V64, P1609, DOI 10.1007/s00018-007-6525-0
   Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533
   Park TK, 2017, MOL THER-NUCL ACIDS, V8, P26, DOI 10.1016/j.omtn.2017.05.012
   Pattison JS, 2011, CIRC RES, V109, P151, DOI 10.1161/CIRCRESAHA.110.237339
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Takahashi Y, 2012, BIOCHEM BIOPH RES CO, V417, P1151, DOI 10.1016/j.bbrc.2011.12.082
   Tang BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103364
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang JL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003697
   Wang L., 1843, BIOCHIM BIOPHYS ACTA, V2014, P1248
   Wignes JA, 2013, EXP EYE RES, V115, P263, DOI 10.1016/j.exer.2013.06.026
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yaung J, 2007, MOL VIS, V13, P566
   Yu J, 2016, POULTRY SCI, V95, P1156, DOI 10.3382/ps/pew006
   Zada S, 2015, CELL BIOL INT, V39, P1242, DOI 10.1002/cbin.10497
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang KX, 2014, INT J CLIN EXP PATHO, V7, P5701
NR 75
TC 21
Z9 21
U1 0
U2 8
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JAN 1
PY 2019
VL 374
IS 1
BP 231
EP 248
DI 10.1016/j.yexcr.2018.11.028
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA HI7KY
UT WOS:000456636300024
PM 30513336
DA 2022-11-30
ER

PT J
AU Uddin, MDI
   Kilburn, TC
   Yang, R
   McCollum, GW
   Wright, DW
   Penn, JS
AF Uddin, M. D. Imam
   Kilburn, Tyler C.
   Yang, Rong
   McCollum, Gary W.
   Wright, David W.
   Penn, John S.
TI Targeted Imaging of VCAM-1 mRNA in a Mouse Model of Laser-Induced
   Choroidal Neovascularization Using Antisense Hairpin-DNA-Functionalized
   Gold-Nanoparticles
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE hairpin-DNA; gold nanoparticle; VCAM-1 mRNA; imaging; LCNV
ID ENDOTHELIAL GROWTH-FACTOR; CELL-ADHESION MOLECULES; TNF-ALPHA; MACULAR
   DEGENERATION; DOMINANT ROLE; IN-VIVO; EXPRESSION; PROBES; HYPOXIA;
   RETINA
AB Mouse laser-induced choroidal neovascularization (mouse LCNV) recapitulates the "wet" form of human age-related macular degeneration (AMD). Vascular cell adhesion molecule-1 (VCAM-1) is a known inflammatory biomarker, and it increases in the choroidal neovascular tissues characteristic of this experimental model. We have designed and constructed gold nanoparticles (AuNPs) functionalized with hairpin-DNA that incorporates an antisense sequence complementary to VCAM-1 mRNA (AS-VCAM-1 hAuNPs) and tested them as optical imaging probes. The 3' end of the hairpin is coupled to a near-infrared fluorophore that is quenched by the AuNP surface via Forster resonance energy transfer (FRET). Hybridization of the antisense sequence to VCAM-1 mRNA displaces the fluorophore away from the AuNP surface, inducing fluorescent activity. In vitro testing showed that hAuNPs hybridize to an exogenous complementary oligonucleotide within a pH range of 4.5-7.4, and that they are stable at reduced pH. LCNV mice received tail-vein injections of AS-VCAM-1 hAuNPs. Hyperspectral imaging revealed the delivery of AS-VCAM-1 hAuNPs to excised choroidal tissues. Fluorescent images of CNV lesions were obtained, presumably in response to the hybridization of AS-hAuNPs to LCNV-induced VCAM-1 mRNA. This is the first demonstration of systemic delivery of hAuNPs to ocular tissues to facilitate mRNA imaging of any target.
C1 [Uddin, M. D. Imam; Kilburn, Tyler C.; Yang, Rong; McCollum, Gary W.; Penn, John S.] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, Sch Med, Nashville, TN 37232 USA.
   [Wright, David W.] Vanderbilt Univ, Dept Chem, Box 1583, Nashville, TN 37235 USA.
   [Penn, John S.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University
RP Uddin, MDI; Penn, JS (通讯作者)，Vanderbilt Univ, Dept Ophthalmol & Visual Sci, Sch Med, Nashville, TN 37232 USA.; Penn, JS (通讯作者)，Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA.
EM md.i.uddin@Vanderbilt.Edu; john.penn@vanderbilt.edu
OI Uddin, MD Imam/0000-0001-5611-9666
FU National Institutes of Health [R01EY23397, R01EY07533, R01EY23639];
   Knights Templar Eye Foundation, Inc.; MMPC MICROMouse [U24DK076169];
   Carl Marshall Reeves & Mildred Almen Reeves Foundation, Inc.; Vanderbilt
   Diabetes Research and Training Center Core Grant [P30 DK020593-34-39];
   Vanderbilt Vision Research Center Core Grant [P30-EY008126]; Research to
   Prevent Blindness, Inc.; NATIONAL EYE INSTITUTE [R01EY023639,
   P30EY008126, R01EY007533, R01EY023397] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [U24DK076169, P30DK020593] Funding Source: NIH RePORTER; OFFICE OF THE
   DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD021630] Funding Source:
   NIH RePORTER
FX This work was supported by the National Institutes of Health Grants
   R01EY23397, R01EY07533, and R01EY23639 (to J.S.P.), a grant from the
   Knights Templar Eye Foundation, Inc. (to M.I.U.), MMPC MICROMouse
   U24DK076169 (to M.I.U.), a grant from the Carl Marshall Reeves & Mildred
   Almen Reeves Foundation, Inc. (to J.S.P.), Vanderbilt Diabetes Research
   and Training Center Core Grant (P30 DK020593-34-39), Vanderbilt Vision
   Research Center Core Grant (P30-EY008126), and an Unrestricted Grant
   from Research to Prevent Blindness, Inc.
CR Bhaumik S, 2004, P NATL ACAD SCI USA, V101, P8693, DOI 10.1073/pnas.0402772101
   Bretz CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20520-z
   Buxbaum AR, 2015, NAT REV MOL CELL BIO, V16, P95, DOI 10.1038/nrm3918
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811
   Evans SM, 2014, BIOCONJUGATE CHEM, V25, P2030, DOI 10.1021/bc500400z
   Harry SR, 2010, CHEM COMMUN, V46, P5557, DOI 10.1039/c001969k
   Hernandez C, 2001, DIABETES CARE, V24, P516, DOI 10.2337/diacare.24.3.516
   Jao CY, 2008, P NATL ACAD SCI USA, V105, P15779, DOI 10.1073/pnas.0808480105
   Jayagopal A, 2010, J AM CHEM SOC, V132, P9789, DOI 10.1021/ja102585v
   Kohler O, 2005, CHEMBIOCHEM, V6, P69, DOI 10.1002/cbic.200400260
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lapierre-Landry M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10050-5
   Larsson C, 2010, NAT METHODS, V7, P395, DOI [10.1038/NMETH.1448, 10.1038/nmeth.1448]
   Lu HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087530
   McHale JF, 1999, J IMMUNOL, V162, P1648
   Nahrendorf M, 2009, JACC-CARDIOVASC IMAG, V2, P1213, DOI 10.1016/j.jcmg.2009.04.016
   Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027
   Rezaei KA, 2011, INVEST OPHTH VIS SCI, V52, P701, DOI 10.1167/iovs.10-6319
   Sawa Y, 2007, J HISTOCHEM CYTOCHEM, V55, P721, DOI 10.1369/jhc.6A7171.2007
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   STEEN KH, 1995, J NEUROSCI, V15, P3982
   Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841
   Toker E, 1998, INT OPHTHALMOL, V22, P71, DOI 10.1023/A:1006160209657
   Tsourkas A, 2005, BIOCONJUGATE CHEM, V16, P576, DOI 10.1021/bc050002e
   Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303
   Uddin MDI, 2018, NANOMED-NANOTECHNOL, V14, P63, DOI 10.1016/j.nano.2017.08.018
   Wang YG, 2014, NAT MATER, V13, P204, DOI [10.1038/nmat3819, 10.1038/NMAT3819]
   Weil TT, 2010, TRENDS CELL BIOL, V20, P380, DOI 10.1016/j.tcb.2010.03.006
   Wong AC, 2016, SMALL, V12, P5592, DOI 10.1002/smll.201601697
   Yang C, 2014, NANOSCALE, V6, P12026, DOI 10.1039/c4nr02535k
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Zhang P, 2011, INT J OPHTHALMOL-CHI, V4, P14, DOI 10.3980/j.issn.2222-3959.2011.01.03
NR 35
TC 7
Z9 7
U1 1
U2 36
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD DEC
PY 2018
VL 15
IS 12
BP 5514
EP 5520
DI 10.1021/acs.molpharmaceut.8b00661
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HD2ML
UT WOS:000452344600008
PM 30350640
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jin, XL
   Wang, CT
   Wu, W
   Liu, TT
   Ji, BP
   Zhou, F
AF Jin, Xiaolu
   Wang, Chengtao
   Wu, Wei
   Liu, Tingting
   Ji, Baoping
   Zhou, Feng
TI Cyanidin-3-glucoside Alleviates 4-Hydroxyhexenal-Induced NLRP3
   Inflammasome Activation via JNK-c-Jun/AP-1 Pathway in Human Retinal
   Pigment Epithelial Cells
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID NF-KAPPA-B; OXIDATIVE STRESS; 4-HYDROXYNONENAL-INDUCED APOPTOSIS;
   MACULAR DEGENERATION; LIPID-PEROXIDATION; ANTHOCYANINS; INDUCTION;
   PROTECT; PHOTOOXIDATION; RESVERATROL
AB Recently, the NLRP3 inflammasome activation in the eyes has been known to be associated with the pathogenesis of age-related macular degeneration. The aim of this study was to investigate the protective effects of cyanidin-3-glucoside (C3G), an important anthocyanin with great potential for preventing eye diseases, against 4-hydroxyhexenal- (HHE-) induced inflammatory damages in human retinal pigment epithelial cells, ARPE-19. We noticed that C3G pretreatment to the ARPE-19 cells rescued HHE-induced antiproliferative effects. Cell apoptosis ratio induced by HHE was also decreased by C3G, measured by flow cytometry. The activation of NLRP3 inflammasome induced by HHE was found with increases of caspase-1 activity, proinflammatory cytokine releases (IL-1 beta and IL-18), and NLRP3 inflammasome-related gene expressions (NLRP3, IL-1 beta, IL-18, and caspase-1). The C3G showed potent inhibitive effects on these NLRP3 inflammasome activation hallmarks induced by HHE. Moreover, we noticed that the C3G's pretreatment leads to a delayed and a decreased JNK activation in HHE-challenged ARPE-19 cells. Finally, using a luciferase reporter gene assay system, we demonstrated that HHE-induced activation protein- (AP-) 1 transcription activity was abolished by C3G pretreatment in a dose-dependent manner. Taken together, these data showed that HHE leads to inflammatory damages to ARPE-19 cells while C3G has great protective effects, highlighting future potential applications of C3G against AMD-associated inflammation.
C1 [Jin, Xiaolu; Ji, Baoping; Zhou, Feng] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing 100083, Peoples R China.
   [Wang, Chengtao] Beijing Technol & Business Univ, Beijing Engn & Technol Res Ctr Food Addit, Beijing 100048, Peoples R China.
   [Wu, Wei] China Agr Univ, Coll Engn, Beijing 100083, Peoples R China.
   [Liu, Tingting] Minist Agr, Key Lab Agr Big Data, Beijing 100081, Peoples R China.
C3 China Agricultural University; Beijing Technology & Business University;
   China Agricultural University; Ministry of Agriculture & Rural Affairs
RP Ji, BP; Zhou, F (通讯作者)，China Agr Univ, Coll Food Sci & Nutr Engn, Beijing Adv Innovat Ctr Food Nutr & Human Hlth, Beijing 100083, Peoples R China.
EM jbp@cau.edu.cn; zf@cau.edu.cn
FU China Postdoctoral Science Foundation [2017M610133]; Beijing Engineering
   and Technology Research Center of Food Additives, Beijing Technology and
   Business University (BTBU); Modern Agro-industry Technology Research
   System from the Ministry of Agriculture of the People's Republic of
   China [CARS-22]
FX The authors gratefully acknowledge the funding support from China
   Postdoctoral Science Foundation (Grant no. 2017M610133), Beijing
   Engineering and Technology Research Center of Food Additives, Beijing
   Technology and Business University (BTBU), and Modern Agro-industry
   Technology Research System from the Ministry of Agriculture of the
   People's Republic of China (CARS-22).
CR Abderrazak A, 2015, REDOX BIOL, V4, P296, DOI 10.1016/j.redox.2015.01.008
   Afonina IS, 2017, NAT IMMUNOL, V18, P861, DOI 10.1038/ni.3772
   Braga M, 2008, APOPTOSIS, V13, P822, DOI 10.1007/s10495-008-0216-7
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Choudhary S, 2002, FREE RADICAL BIO MED, V32, P360, DOI 10.1016/S0891-5849(01)00810-3
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gracie JA, 1999, J CLIN INVEST, V104, P1393, DOI 10.1172/JCI7317
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Jang YJ, 2009, ANN NY ACAD SCI, V1171, P176, DOI 10.1111/j.1749-6632.2009.04727.x
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Je JH, 2004, FEBS LETT, V566, P183, DOI 10.1016/j.febslet.2004.04.037
   Jhang JJ, 2017, CELL MOL IMMUNOL, V14, P1011, DOI 10.1038/cmi.2017.114
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kutuk O, 2006, TOXICOL SCI, V90, P120, DOI 10.1093/toxsci/kfj055
   Lee JY, 2004, FREE RADICAL BIO MED, V37, P539, DOI 10.1016/j.freeradbiomed.2004.05.011
   Lee JY, 2004, EUR J BIOCHEM, V271, P1339, DOI 10.1111/j.1432-1033.2004.04042.x
   Lee SH, 2014, CURR EYE RES, V39, P79, DOI 10.3109/02713683.2013.825275
   Liu YX, 2015, J AGR FOOD CHEM, V63, P9295, DOI 10.1021/acs.jafc.5b04341
   Liu YX, 2014, J PHOTOCH PHOTOBIO B, V140, P85, DOI 10.1016/j.jphotobiol.2014.07.016
   Liu YX, 2012, BRIT J NUTR, V108, P16, DOI 10.1017/S000711451100523X
   Long EK, 2008, J NEUROCHEM, V105, P714, DOI 10.1111/j.1471-4159.2007.05175.x
   Long EK, 2010, FREE RADICAL BIO MED, V49, P1, DOI 10.1016/j.freeradbiomed.2010.03.015
   LoPachin RM, 2014, CHEM RES TOXICOL, V27, P1081, DOI 10.1021/tx5001046
   Matsumoto H, 2003, J AGR FOOD CHEM, V51, P3560, DOI 10.1021/jf034132y
   Raj P, 2017, FOOD FUNCT, V8, P4089, DOI 10.1039/c7fo00709d
   Serra D, 2016, CHEM-BIOL INTERACT, V260, P102, DOI 10.1016/j.cbi.2016.11.003
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   Singh R, 2009, AM J PHYSIOL-GASTR L, V297, pG907, DOI 10.1152/ajpgi.00151.2009
   Singhal SS, 2015, TOXICOL APPL PHARM, V289, P361, DOI 10.1016/j.taap.2015.10.006
   Tarozzi A, 2010, NEUROSCI LETT, V473, P72, DOI 10.1016/j.neulet.2010.02.006
   Tirupula KC, 2009, PHOTOCHEM PHOTOBIOL, V85, P463, DOI 10.1111/j.1751-1097.2008.00533.x
   Umfress AC, 2016, SEMIN OPHTHALMOL, V31, P432, DOI 10.3109/08820538.2016.1154171
   Wang Y., 2015, J AGR FOOD CHEM, V64, P161
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Wang Y, 2016, MOL NUTR FOOD RES, V60, P1564, DOI 10.1002/mnfr.201501048
   Wang Y, 2015, J SCI FOOD AGR, V95, P936, DOI 10.1002/jsfa.6765
   Yacout SM, 2017, PHOTOCHEM PHOTOBIOL, V93, P590, DOI 10.1111/php.12683
NR 43
TC 25
Z9 28
U1 1
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2018
VL 2018
AR 5604610
DI 10.1155/2018/5604610
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GF7IA
UT WOS:000432140600001
PM 29854843
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Senra, H
   Ali, Z
   Balaskas, K
   Aslam, T
AF Senra, Hugo
   Ali, Zaria
   Balaskas, Konstantinos
   Aslam, Tariq
TI Psychological impact of anti-VEGF treatments for wet macular
   degeneration-a review
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Wet age-related macular degeneration; Anti-VEGF treatment; Psychological
   impact; Intra-vitreal injections
ID GROWTH-FACTOR TREATMENT; QUALITY-OF-LIFE; DEPRESSION; INJECTION;
   ANXIETY; OUTCOMES; DISCOMFORT; PREVALENCE; EXPERIENCE; PEOPLE
AB Purpose To review the current literature on the psychological impact of anti-VEGF treatments for wet age-related macular degeneration (wAMD), in terms of patients' experiences of receiving these treatments, and the impact of these treatments for patients' mental health and quality of life.
   Methods We critically analyzed current literature evaluating psychological impact of anti-VEGF treatments for wAMD. Primary searches of PubMed, Science Direct, and Web of Science were conducted in July and August of 2015. We reviewed all papers on the topic published until August 5, 2015.
   Results Our literature search found 14 papers addressing the psychological impact of anti-VEGF treatments for wAMD. Results highlighted potential anxieties and experiences of pain caused by receiving regular intravitreal injections. A positive visual outcome of anti-VEGF therapy is associated with positive vision-related QOL outcomes, although such association seems to be dependent on improvements on visual acuity. In the literature reviewed, patients receiving anti-VEGF treatments showed a prevalence rate of depression between 20 and 26 %.
   Conclusions Although anti-VEGF treatments can cause some anxiety and being experienced as a stressful event, especially in the beginning of the treatment, preliminary findings suggest a potential benefit for long-term vision-related quality of life. Further longitudinal and qualitative research should bring more evidence on the positive and negative effects of these treatments on patients' long-term mental health.
C1 [Senra, Hugo; Aslam, Tariq] Univ Manchester, Inst Human Dev, Manchester M13 9PL, Lancs, England.
   [Ali, Zaria; Balaskas, Konstantinos; Aslam, Tariq] Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Aslam, Tariq] Heriot Watt Univ, Edinburgh, Midlothian, Scotland.
C3 University of Manchester; Manchester Royal Eye Hospital; Heriot Watt
   University
RP Senra, H (通讯作者)，Univ Manchester, Inst Human Dev, Manchester M13 9PL, Lancs, England.
EM hugo_senra@hotmail.com
RI Balaskas, Konstantinos/ABD-5979-2020; Aslam, Tariq/A-8532-2016
OI Balaskas, Konstantinos/0000-0002-7690-6277; Ali,
   Zaria/0000-0002-8382-1415; Aslam, Tariq/0000-0002-9739-7280
FU Bayer [R117779]
FX Bayer provided financial support in the form of a research grant
   (Reference R117779) to investigate the psychological impact of anti-VEGF
   treatments for wAMD. The sponsor had no role in the design or conduct of
   this research.
CR Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chua PYS, 2009, ARCH OPHTHALMOL-CHIC, V127, P939, DOI 10.1001/archophthalmol.2009.139
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gillies MC, 2015, OPHTHALMOLOGY, V18
   Henriksen K., 2013, INT J OPHTHALMIC PRA, V1, P68, DOI [10.12968/ijop.2010.1.2.68, DOI 10.12968/ijop.2010.1.2.68, DOI 10.12968/IJOP.2010.1.2.68]
   Inoue M, 2014, CLIN OPHTHALMOL, V8, P1711, DOI 10.2147/OPTH.S68293
   Kan C, 2013, DIABETES CARE, V36, P480, DOI 10.2337/dc12-1442
   Kariyawasam DK, 2009, DIABETOLOGIA, V52, pS393
   LaHood BR, 2011, CLIN EXP OPHTHALMOL, V39, P184, DOI 10.1111/j.1442-9071.2010.02432.x
   Lee WJ, 2013, ASIA-PAC J OPHTHALMO, V2, P23, DOI 10.1097/APO.0b013e31827be8b1
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Moisseiev E, 2012, CURR EYE RES, V37, P813, DOI 10.3109/02713683.2012.681335
   Rifkin L, 2012, RETINA-J RET VIT DIS, V32, P696, DOI 10.1097/IAE.0b013e3182252ad3
   Roth DB, 2006, AM J OPHTHALMOL, V142, P492, DOI 10.1016/j.ajo.2006.03.042
   Segal O, 2016, ACTA OPHTHALMOL, V94, P203, DOI 10.1111/aos.12802
   Senra H, 2015, OPHTHALMOLOGY, V122, P851, DOI 10.1016/j.ophtha.2014.10.022
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Tailor R, 2011, CLIN OPHTHALMOL, V5, P1499, DOI 10.2147/OPTH.S24358
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Wang LL, 2015, CHINESE MED J-PEKING, V128, P1154, DOI 10.4103/0366-6999.156083
   Winkley K, 2012, DIABETOLOGIA, V55, P303, DOI 10.1007/s00125-011-2359-2
   Yau GL, 2011, AM J OPHTHALMOL, V151, P333, DOI 10.1016/j.ajo.2010.08.031
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
NR 32
TC 34
Z9 35
U1 1
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2016
VL 254
IS 10
BP 1873
EP 1880
DI 10.1007/s00417-016-3384-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EB1QL
UT WOS:000387129400002
PM 27262729
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Zarling, JA
   Brunt, VE
   Vallerga, AK
   Li, WX
   Tao, A
   Zarling, DA
   Minson, CT
AF Zarling, Jacob A.
   Brunt, Vienna E.
   Vallerga, Anne K.
   Li, Weixing
   Tao, Albert
   Zarling, David A.
   Minson, Christopher T.
TI Nitroxide pharmaceutical development for age-related degeneration and
   disease
SO FRONTIERS IN GENETICS
LA English
DT Article
ID CUTANEOUS MICROVASCULAR FUNCTION; NITRIC-OXIDE BIOAVAILABILITY; MACULAR
   DEGENERATION; OXIDATIVE STRESS; ENDOTHELIAL FUNCTION; ASCORBIC-ACID;
   CIGARETTE-SMOKING; RISK-FACTORS; BLOOD-FLOW; END-POINTS
AB Nitroxide small molecule agents are in development as preventative or therapeutic pharmaceutical drugs for age-related macular degeneration (AMD) and cardiovascular disease, which are two major diseases of aging. These aging diseases are associated with patient genetics, smoking, diet, oxidative stress, and chronic inflammation. Nitroxide drugs preventing aging-, smoking-, high sugar or high fat diet-, or radiation and other environmental-induced pathophysiological conditions in aging disease are reviewed. Tempol (TP), Tempol Hydroxylamine (TP-H), and TP-H prodrug (OT-551) are evaluated in (1) non-smokers versus smokers with cutaneous microvascular dysfunction, rapidly reversed by cutaneous TP; (2) elderly cancer patients at risk for radiation-induced skin burns or hair loss, prevented by topical IF; and (3) elderly smoker or non-smoker AMD patients at risk for vision loss, prevented by daily eye drops of OT-551. The human data indicates safety and efficacy for these nitroxide drugs. Both TP and TP-H topically penetrate and function in skin or mucosa, protecting and treating radiation burns and hair loss or smoking-induced cutaneous vascular dysfunction. TP and TP-H do not penetrate the cornea, while OT-551 does effectively penetrate and travels to the back of the eye, preserving visual acuity and preserving normal and low light luminance in dry AMD smokers and non-smoker patients. Topical, oral, or injectable drug formulations are discussed.
C1 [Zarling, Jacob A.] Univ Oregon, Dept Biol, Eugene, OR 97403 USA.
   [Brunt, Vienna E.; Minson, Christopher T.] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.
   [Vallerga, Anne K.; Li, Weixing; Zarling, David A.] Colby Pharmaceut Co, Menlo Pk, CA 94025 USA.
   [Tao, Albert] Washington Univ, Dept Biomed Engn, St Louis, MO USA.
C3 University of Oregon; University of Oregon; Washington University
   (WUSTL)
RP Zarling, DA (通讯作者)，Colby Pharmaceut Co, Menlo Pk, CA 94025 USA.
EM dzarling@colbypharmaceuticals.com
OI Minson, Christopher/0000-0003-3459-3708
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081671] Funding Source:
   NIH RePORTER; NHLBI NIH HHS [R01 HL081671] Funding Source: Medline
CR Abularrage CJ, 2005, J VASC SURG, V42, P574, DOI 10.1016/j.jvs.2005.05.019
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   ATTVALL S, 1993, J INTERN MED, V233, P327, DOI 10.1111/j.1365-2796.1993.tb00680.x
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Birke K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076766
   Bottcher M, 1999, J CARDIOVASC RISK, V6, P299
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choi PJ, 2014, J APPL PHYSIOL, V117, P277, DOI 10.1152/japplphysiol.01397.2013
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   DuPont JJ, 2014, AM J PHYSIOL-RENAL, V306, pF1499, DOI 10.1152/ajprenal.00058.2014
   Edvinsson ML, 2008, VASC HEALTH RISK MAN, V4, P699
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Eskurza I, 2004, J PHYSIOL-LONDON, V556, P315, DOI 10.1113/jphysiol.2003.057042
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fang Q, 2006, J APPL PHYSIOL, V100, P631, DOI 10.1152/japplphysiol.00975.2005
   Frisbee JC, 2005, AM J PHYSIOL-REG I, V289, pR307, DOI 10.1152/ajpregu.00114.2005
   Fujii N, 2014, AM J PHYSIOL-HEART C, V306, pH1507, DOI 10.1152/ajpheart.00886.2013
   Fujii N, 2013, AM J PHYSIOL-HEART C, V304, pH667, DOI 10.1152/ajpheart.00731.2012
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Greenwald MBY, 2014, FREE RADICAL BIO MED, V77, P258, DOI 10.1016/j.freeradbiomed.2014.08.021
   Hahn SM, 2000, FREE RADICAL BIO MED, V28, P953, DOI 10.1016/S0891-5849(00)00176-3
   Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200
   Hildreth KL, 2014, MENOPAUSE, V21, P624, DOI [10.1097/gme.0000000000000116, 10.1097/GME.0000000000000116]
   Holowatz LA, 2005, J PHYSIOL-LONDON, V563, P965, DOI 10.1113/jphysiol.2004.080952
   Holowatz LA, 2006, AM J PHYSIOL-HEART C, V291, pH2965, DOI 10.1152/ajpheart.00648.2006
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   IJzerman RG, 2003, EUR J CLIN INVEST, V33, P536, DOI 10.1046/j.1365-2362.2003.01179.x
   Jaimes EA, 2004, ARTERIOSCL THROM VAS, V24, P1031, DOI 10.1161/01.ATV.0000127083.88549.58
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joannides R, 2006, FUND CLIN PHARMACOL, V20, P311, DOI 10.1111/j.1472-8206.2006.00406.x
   KANNEL WB, 1990, J HYPERTENS, V8, pS3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katayama Yasuyuki, 2004, J Atheroscler Thromb, V11, P354
   Kellogg DL, 2005, J APPL PHYSIOL, V98, P629, DOI 10.1152/japplphysiol.00728.2004
   Kellogg DL, 1999, J APPL PHYSIOL, V86, P1185, DOI 10.1152/jappl.1999.86.4.1185
   Kelly RP, 2008, FREE RADICAL RES, V42, P514, DOI 10.1080/10715760802087431
   Khan F, 2000, DIABETES CARE, V23, P215, DOI 10.2337/diacare.23.2.215
   Khan F, 2005, HYPERTENSION, V46, P1123, DOI 10.1161/01.HYP.0000186328.90667.95
   Kifley A, 2007, AM J EPIDEMIOL, V166, P1288, DOI 10.1093/aje/kwm255
   Kim CHJ, 2015, ATHEROSCLEROSIS, V240, P234, DOI 10.1016/j.atherosclerosis.2015.03.012
   Kirby BS, 2009, J PHYSIOL-LONDON, V587, P1989, DOI 10.1113/jphysiol.2008.167320
   Kruger A, 2006, KIDNEY INT, V70, P157, DOI 10.1038/sj.ki.5001511
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Li F, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3384
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mangge H, 2014, WORLD J CARDIOL, V6, P462, DOI 10.4330/wjc.v6.i6.462
   Medow MS, 2008, MICROCIRCULATION, V15, P569, DOI 10.1080/10739680802091526
   Medow MS, 2011, J APPL PHYSIOL, V111, P20, DOI 10.1152/japplphysiol.01448.2010
   Metz JM, 2004, CLIN CANCER RES, V10, P6411, DOI 10.1158/1078-0432.CCR-04-0658
   Minson CT, 2002, J APPL PHYSIOL, V93, P1644, DOI 10.1152/japplphysiol.00229.2002
   Minson CT, 2001, J APPL PHYSIOL, V91, P1619, DOI 10.1152/jappl.2001.91.4.1619
   Mitchell JB, 2003, FREE RADICAL BIO MED, V34, P93, DOI 10.1016/S0891-5849(02)01193-0
   Pellaton C, 2002, AM HEART J, V144, P269, DOI 10.1067/mhj.2002.123842
   PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tanito M, 2010, EXP EYE RES, V91, P111, DOI 10.1016/j.exer.2010.04.012
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vecchia LD, 2004, J HYPERTENS, V22, P129, DOI 10.1097/00004872-200401000-00022
   Wang D, 2010, HYPERTENSION, V56, P950, DOI 10.1161/HYPERTENSIONAHA.110.157115
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wray DW, 2012, HYPERTENSION, V59, P818, DOI 10.1161/HYPERTENSIONAHA.111.189456
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Yadav AS, 2011, CURR EYE RES, V36, P456, DOI 10.3109/02713683.2011.556300
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou JL, 2008, PHOTOCHEM PHOTOBIOL, V84, P75, DOI 10.1111/j.1751-1097.2007.00205.x
NR 80
TC 19
Z9 19
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD NOV 6
PY 2015
VL 6
AR 325
DI 10.3389/fgene.2015.00325
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CZ2FR
UT WOS:000366921000001
PM 26594225
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Koo, E
   Chang, JR
   Agron, E
   Clemons, TE
   Sperduto, RD
   Ferris, FL
   Chew, EY
AF Koo, Euna
   Chang, Jessica R.
   Agron, Elvira
   Clemons, Traci E.
   Sperduto, Robert D.
   Ferris, Frederick L., III
   Chew, Emily Y.
CA Age-Related Eye Dis Study Res Grp
TI Ten-Year Incidence Rates of Age-Related Cataract in the Age-Related Eye
   Disease Study (AREDS): AREDS Report No. 33
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE cataract; classification; incidence; lens; photographic
ID VISUAL IMPAIRMENT; LENS OPACITIES; POPULATION; PREVALENCE; SURGERY;
   ADULTS; CARE
AB Purpose: To investigate the long-term incidence of age-related cataract and cataract surgery in the Age-Related Eye Disease Study (AREDS) cohort.
   Methods: Baseline and annual lens photographs of participants, aged 55-80 years, were graded centrally for nuclear, cortical, and posterior subcapsular (PSC) lens opacities using the AREDS System for Classifying Cataracts. Progression from a baseline status of no or mild lens opacity to at least moderate severity was analyzed and cumulative incidence estimated rates were calculated for each lens opacity type and cataract surgery stratified by age, sex, race, age-related macular degeneration category, multivitamin (Centrum) use and history of diabetes.
   Results: The ten-year cumulative incidence was 43.6% for any cataract, 23.1% for nuclear cataract, 22.0% for cortical cataract, 13.1% for PSC cataract, and 26.8% for cataract surgery. The 5-and 10-year incidence rates of all cataract types and cataract surgery were significantly higher with increasing age. Females had a higher incidence of any, nuclear and cortical cataract and cataract surgery (p=0.02-0.05). Incidence of cortical cataract was higher in non-white participants (p=0.001).
   Conclusions: These results are largely consistent with the results of previous observational studies. Long-term incidence rates of type-specific cataract can be useful in designing clinical studies of age-related cataract.
C1 [Koo, Euna; Agron, Elvira; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Chang, Jessica R.] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.; Sperduto, Robert D.] EMMES Corp, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Emmes Corporation
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020
OI Ferris, Frederick/0000-0002-4933-0639; Chang,
   Jessica/0000-0001-6663-2519
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, MD; NIH; Pfizer; Howard Hughes
   Medical Institute-National Institutes of Health Scholars Program
FX This study is supported by the intramural program funds and contracts
   from the National Eye Institute/National Institutes of Health,
   Department of Health and Human Services, Bethesda, MD. The first two
   authors receive support from a public-private partnership supported
   jointly by the NIH and Pfizer for the Clinical Research Training Program
   at the National Institutes of Health (Euna Koo) and the Howard Hughes
   Medical Institute-National Institutes of Health Scholars Program
   (Jessica R. Chang).
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CROCETTI AF, 1970, THESIS J HOPKINS U B
   EDERER F, 1993, AM J EPIDEMIOL, V137, P787, DOI 10.1093/oxfordjournals.aje.a116739
   Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Goldman HB, 2009, GERIATRICS, V64, P19
   Kanthan GL, 2008, OPHTHALMOLOGY, V115, P808, DOI 10.1016/j.ophtha.2007.07.008
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P477, DOI 10.1016/j.ophtha.2007.11.024
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   Lee PP, 2009, AM J OPHTHALMOL, V148, P804, DOI 10.1016/j.ajo.2009.06.021
   Leske MC, 2004, OPHTHALMOLOGY, V111, P483, DOI 10.1016/j.ophtha.2003.06.016
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   PEPE MS, 1993, STAT MED, V12, P737, DOI 10.1002/sim.4780120803
   Pintilie M, 2011, REV ESP CARDIOL, V64, P599, DOI [10.1016/j.rec.2011.03.016, 10.1016/j.recesp.2011.03.017]
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
NR 19
TC 18
Z9 18
U1 0
U2 18
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD APR
PY 2013
VL 20
IS 2
BP 71
EP 81
DI 10.3109/09286586.2012.759598
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 110BZ
UT WOS:000316418400001
PM 23510310
DA 2022-11-30
ER

PT J
AU Zhang, YS
   Lu, ZY
   Yu, Y
   Li, XR
   Li, WB
   Wang, YN
   Geng, Y
AF Zhang, Yun-Shan
   Lu, Zhen-Yu
   Yu, Yang
   Li, Xiao-Rong
   Li, Wen-Bo
   Wang, Yi-Na
   Geng, Ying
TI Derivation, culture and retinal pigment epithelial differentiation of
   human embryonic stem cells using human fibroblast feeder cells
SO JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
LA English
DT Article
DE Human embryonic stem cell; Human foreskin fibroblast feeder layer; Human
   abdominal fibroblast feeder layer; Retinal pigment epithelium
   differentiation
ID PROLONGED UNDIFFERENTIATED GROWTH; MACULAR DEGENERATION; VISUAL
   FUNCTION; IN-VITRO; GENERATION; LINES; MOUSE
AB Retinal pigment epithelium cells derived from human embryonic stem cells (ESCs) could be useful for restoring retinal function in age-related macular degeneration. However the use of non-human feeder cells to support the growth of ESCs for clinical applications raises the concern of possible contamination because of direct contact between animal and human cells.
   In this study, we produced human ESCs using human fibroblast feeder layers isolated from foreskin and abdominal tissues. Using this system, human ESCs differentiated into retinal pigment epithelium cells in differentiation medium.
   Seven human ESC lines were established from 18 blastocysts. These human ESCs showed normal morphology, expressed all expected cell surface markers, had the ability to form embryoid bodies upon culture in vitro and teratomas after injection into SCID mice, and differentiated further into derivatives of all three germ layers. Under conditions of committed differentiation, these human ESCs could differentiate into retinal pigment epithelium cells after 2 months in culture.
   The results of this study demonstrated that human foreskin/abdominal fibroblasts have the potential to support the derivation and long-term culture of human ESCs, which can then be used to generate retinal pigment epithelium cells with characteristic morphology and molecular markers. This technique avoids the concerns of contamination from animal feeder layers during human ESC derivation, culture and differentiation, and will thus facilitate the development of retinal pigment epithelium cell transplantation therapy.
C1 [Zhang, Yun-Shan; Lu, Zhen-Yu; Wang, Yi-Na; Geng, Ying] Tianjin Cent Hosp Obstet & Gynecol, Ctr Reprod Med, Tianjin 300100, Peoples R China.
   [Lu, Zhen-Yu] Union Stem Cell & Gene Engn Co Ltd, Tianjin 300384, Peoples R China.
   [Yu, Yang] Peking Univ, Hosp 3, Dept Obstet & Gynecol, Ctr Reprod Med, Beijing 100191, Peoples R China.
   [Li, Xiao-Rong; Li, Wen-Bo] Tianjin Med Univ, Ctr Eye, Tianjin 300384, Peoples R China.
C3 Peking University; Tianjin Medical University
RP Zhang, YS (通讯作者)，Tianjin Cent Hosp Obstet & Gynecol, Ctr Reprod Med, Tianjin 300100, Peoples R China.
EM tjzys@hotmail.com; luzhenyu.tj@gmail.com
RI Wang, Yina/N-8534-2017; li, wenbo/GZM-8930-2022
OI Wang, Yina/0000-0003-1909-728X; Yu, Yang/0000-0002-4310-1966
FU National Natural Science Foundation of China of Young Scholars
   [81100404]; National Natural Science Foundation of China [30973255];
   Specialized Research Fund for the Doctoral Program of Higher Education
   of China [20110001120008]
FX This work was supported in part by the National Natural Science
   Foundation of China of Young Scholars (No. 81100404) to L.Z.Y, by the
   National Natural Science Foundation of China (No. 30973255) to L. X. R,
   and by the Specialized Research Fund for the Doctoral Program of Higher
   Education of China (Grant No. 20110001120008) to Y.Y.
CR Amit M, 2003, BIOL REPROD, V68, P2150, DOI 10.1095/biolreprod.102.012583
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Chen H, 2005, HUM REPROD, V20, P2201, DOI 10.1093/humrep/dei010
   Choi KD, 2009, STEM CELLS, V27, P559, DOI 10.1634/stemcells.2008-0922
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fukuda H, 2006, STEM CELLS, V24, P763, DOI 10.1634/stemcells.2005-0137
   Gardner DK, 2000, FERTIL STERIL, V73, P1155, DOI 10.1016/S0015-0282(00)00518-5
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu BY, P NATL ACAD SCI US, V107, P4335
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393
   Lee JB, 2004, REPRODUCTION, V128, P727, DOI 10.1530/rep.1.00415
   Lerou PH, 2008, NAT BIOTECHNOL, V26, P212, DOI 10.1038/nbt1378
   Lighten AD, 1998, HUM REPROD, V13, P3144, DOI 10.1093/humrep/13.11.3144
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu Z, J ASSIST REPROD GENE, V27, P285
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Mitalipova M, 2003, STEM CELLS, V21, P521, DOI 10.1634/stemcells.21-5-521
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101
   Rambhatla L, 2003, CELL TRANSPLANT, V12, P1, DOI 10.3727/000000003783985179
   Richards M, 2002, NAT BIOTECHNOL, V20, P933, DOI 10.1038/nbt726
   Richards M, 2003, STEM CELLS, V21, P546, DOI 10.1634/stemcells.21-5-546
   Sjoblom C, 1999, HUM REPROD, V14, P3069, DOI 10.1093/humrep/14.12.3069
   Stadtfeld M, 2008, CURR BIOL, V18, P890, DOI 10.1016/j.cub.2008.05.010
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sullivan GJ, HEPTAOLOGY, V51, P329
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Yu Y, 2009, HUM REPROD, V24, P649, DOI 10.1093/humrep/den407
NR 36
TC 8
Z9 11
U1 0
U2 19
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1058-0468
J9 J ASSIST REPROD GEN
JI J. Assist. Reprod. Genet.
PD AUG
PY 2012
VL 29
IS 8
BP 735
EP 744
DI 10.1007/s10815-012-9802-2
PG 10
WC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
GA 997RX
UT WOS:000308184900005
PM 22661130
OA Green Published
DA 2022-11-30
ER

PT J
AU Van der Reis, MI
   La Heij, EC
   De Jong-Hesse, Y
   Ringens, PJ
   Hendrikse, F
   Schouten, JSAG
AF Van der Reis, Margriet I.
   La Heij, Ellen C.
   De Jong-Hesse, Yvonne
   Ringens, Peter J.
   Hendrikse, Fred
   Schouten, Jan S. A. G.
TI A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR
   ENDOTHELIAL GROWTH FACTOR INJECTIONS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE adverse events; age-related macular degeneration/AMD; anti-vascular
   endothelial growth factor/anti-VEGF; Avastin; bevacizumab; Lucentis;
   Macugen; pegaptanib; ranibizumab
ID PIGMENT EPITHELIAL TEAR; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   BEVACIZUMAB AVASTIN TREATMENT; MACULAR EDEMA SECONDARY; RETINAL VEIN
   OCCLUSION; OPTICAL COHERENCE TOMOGRAPHY; SHORT-TERM SAFETY; VERTEPORFIN
   PHOTODYNAMIC THERAPY; ANTI-VEGF THERAPY; INTRAOCULAR-PRESSURE
AB Background: Intravitreal ranibizumab and pegaptanib are registered for neovascular age-related macular degeneration. No formal safety study has been conducted for intravitreal bevacizumab. These anti-vascular endothelial growth factor (anti-VEGF) drugs are being used on a large scale in daily practice for different ocular diseases. The objective of the present study was to systematically assess and compare the incidences of adverse events of anti-VEGFs.
   Methods: A systematic search was conducted in April 2009 with no date restrictions in PubMed, Embase, Toxline, and the Cochrane library. We used the terms pegaptanib, bevacizumab, ranibizumab, intravitreal, and specific and general terms for adverse events. Studies describing adverse events after anti-VEGF injections and the official safety data were included.
   Results: Two hundred and seventy-eight articles were included, and the incidences of adverse events were calculated separately for effect, safety, and specific side effect studies. The incidences of serious ocular and nonocular adverse events were approximately below 1 per 100 injections for intravitreal bevacizumab, intravitreal ranibizumab, and intravitreal pegaptanib. Most mild ocular adverse events were below 5 per 100 injections.
   Conclusion: The reported rates of serious adverse events were low after anti-VEGF injections. There is no sufficient evidence to conclude that there is a difference in incidences between the anti-VEGFs. RETINA 31: 1449-1469, 2011
C1 [Van der Reis, Margriet I.; La Heij, Ellen C.; Hendrikse, Fred; Schouten, Jan S. A. G.] Univ Eye Clin Maastricht, Dept Ophthalmol, NL-6202 AZ Maastricht, Netherlands.
   [De Jong-Hesse, Yvonne; Ringens, Peter J.] Vrije Univ Amsterdam Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER
RP Van der Reis, MI (通讯作者)，Univ Eye Clin Maastricht, Dept Ophthalmol, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM m.vander.reis@mumc.nl
RI Schouten, Johannes S.A.G./M-9376-2016
OI Schouten, Johannes S.A.G./0000-0001-6495-7758
FU Netherlands Organization for Health Research and Development (ZonMw),
   The Hague [152001002]
FX Supported by the Netherlands Organization for Health Research and
   Development (ZonMw), The Hague, grant number 152001002.
CR Abegg M, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-18
   Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Ach T, 2007, KLIN MONATSBL AUGENH, V224, P180, DOI 10.1055/s-2007-963035
   Adan A, 2007, RETINA-J RET VIT DIS, V27, P1180, DOI 10.1097/IAE.0b013e31815e9834
   Aggio FB, 2007, EYE, V21, P408, DOI 10.1038/sj.eye.6702683
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Ahmadieh H, 2008, GRAEF ARCH CLIN EXP, V246, P483, DOI 10.1007/s00417-007-0688-0
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Alkuraya Hisham S., 2009, International Ophthalmology, V29, P411, DOI 10.1007/s10792-008-9237-z
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Amselem L, 2007, EYE, V21, P846, DOI 10.1038/sj.eye.6702702
   Amselem L, 2009, ACTA OPHTHALMOL, V87, P110, DOI 10.1111/j.1755-3768.2007.01154.x
   Andrijevic-Derk B, 2008, ACTA CLIN CROAT, V47, P175
   [Anonymous], ONLINE SOFTWARE CLOP
   Apte Rajendra S., 2007, International Ophthalmology, V27, P59, DOI 10.1007/s10792-007-9066-5
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Arevalo JF, 2009, EYE, V23, P117, DOI 10.1038/sj.eye.6702980
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1035, DOI 10.1136/bjo.2007.130260
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Aronson JK, 2009, SIDE EFFECT, V31, P1
   Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Astam Neslihan, 2009, International Ophthalmology, V29, P343, DOI 10.1007/s10792-008-9242-2
   Atmani K, 2009, EYE, V23, P1150, DOI 10.1038/eye.2008.194
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bakri SJ, 2007, EYE, V21, P424, DOI 10.1038/sj.eye.6702700
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Barone A, 2009, RETINA-J RET VIT DIS, V29, P33, DOI 10.1097/IAE.0b013e31818a1fbc
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beutel Julia, 2010, International Ophthalmology, V30, P15, DOI 10.1007/s10792-008-9282-7
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P897, DOI 10.1097/IAE.0b013e31809ff5df
   Bocco MCA, 2008, J FR OPHTALMOL, V31, P693
   Bolz M, 2008, OPHTHALMOLOGE, V105, P650, DOI 10.1007/s00347-007-1639-1
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2007, J OCUL PHARMACOL TH, V23, P387, DOI 10.1089/jop.2007.0012
   Byeon SH, 2009, ACTA OPHTHALMOL, V87, P570, DOI 10.1111/j.1755-3768.2008.01216.x
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan WM, 2009, BRIT J OPHTHALMOL, V93, P150, DOI 10.1136/bjo.2008.145797
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chang LK, 2008, ARCH OPHTHALMOL-CHIC, V126, P941, DOI 10.1001/archopht.126.7.941
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chen E, 2009, OPHTHAL SURG LAS IM, V40, P68, DOI 10.3928/15428877-20090101-04
   Chen E, 2009, OPHTHAL SURG LAS IM, V40, P192, DOI 10.3928/15428877-20090301-06
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Chieh JJ, 2007, ANN OPHTHALMOL, V39, P51, DOI 10.1007/BF02697326
   Chilov MN, 2007, CLIN EXP OPHTHALMOL, V35, P494, DOI 10.1111/j.1442-9071.2007.01521.x
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Chung EJ, 2008, RETINA-J RET VIT DIS, V28, P957, DOI 10.1097/IAE.0b013e3181754209
   Chung EJ, 2008, GRAEF ARCH CLIN EXP, V246, P1241, DOI 10.1007/s00417-008-0866-8
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Coma MC, 2007, OPHTHALMOLOGY, V114, P1574, DOI 10.1016/j.ophtha.2006.11.028
   Costa RA, 2007, RETINA-J RET VIT DIS, V27, P141, DOI 10.1097/IAE.0b013e31802eff83
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Costagliola C, 2008, BRIT J CLIN PHARMACO, V66, P667, DOI 10.1111/j.1365-2125.2008.03278.x
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dayani PN, 2007, AM J OPHTHALMOL, V144, P451, DOI 10.1016/j.ajo.2007.05.006
   De Clercq C, 2007, Bull Soc Belge Ophtalmol, P15
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Dithmar S, 2009, OPHTHALMOLOGE, V106, P527, DOI 10.1007/s00347-008-1806-z
   Ehlers JP, 2007, OPHTHAL SURG LAS IM, V38, P371, DOI 10.3928/15428877-20070901-03
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Eldaly MA, 2009, RETINA-J RET VIT DIS, V29, P325, DOI 10.1097/IAE.0b013e31819a6154
   Emerson GG, 2007, RETINA-J RET VIT DIS, V27, P724, DOI 10.1097/IAE.0b013e318042b3c8
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Faghihi H, 2008, EUR J OPHTHALMOL, V18, P941, DOI 10.1177/112067210801800614
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Fang XY, 2008, ACTA OPHTHALMOL, V86, P800, DOI 10.1111/j.1755-3768.2008.01254.x
   Finger PT, 2008, INT J RADIAT ONCOL, V70, P974, DOI 10.1016/j.ijrobp.2007.11.045
   Finger RP, 2008, BRIT J OPHTHALMOL, V92, P483, DOI 10.1136/bjo.2007.129916
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fish Gary Edd, 2008, Trans Am Ophthalmol Soc, V106, P276
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Food and Drug Administration, HIGHL PRESCR INF LUC
   Food and Drug Administration, LAB AV
   Food and Drug Administration, LAB MAC PEG SOD FDA
   Forooghian F, 2008, CAN J OPHTHALMOL, V43, P246, DOI 10.3129/i08-017
   Frenkel REP, 2007, AM J OPHTHALMOL, V143, P1034, DOI 10.1016/j.ajo.2007.01.052
   Freund KB, 2006, RETINA-J RET VIT DIS, V26, P701, DOI 10.1097/00006982-200607000-00021
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Geitzenauer W, 2006, KLIN MONATSBL AUGENH, V223, P822, DOI 10.1055/s-2006-926875
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Gharbiya M, 2009, AM J OPHTHALMOL, V147, P84, DOI 10.1016/j.ajo.2008.07.022
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Glasziou P, 2004, BMJ-BRIT MED J, V328, P39, DOI 10.1136/bmj.328.7430.39
   Golder S, 2006, HEALTH INFO LIBR J, V23, P3, DOI 10.1111/j.1471-1842.2006.00634.x
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2007, AM J OPHTHALMOL, V143, P507, DOI 10.1016/j.ajo.2006.10.050
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gunduz K, 2008, EYE, V22, P1168, DOI 10.1038/sj.eye.6703040
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Hannan SR, 2007, BRIT J OPHTHALMOL, V91, P977, DOI 10.1136/bjo.2006.101899
   Hariprasad SM, 2006, AM J OPHTHALMOL, V141, P200, DOI 10.1016/j.ajo.2005.07.053
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Hasler S, 2008, KLIN MONATSBL AUGENH, V225, P446, DOI 10.1055/s-2008-1027315
   Hayashi K, 2009, GRAEF ARCH CLIN EXP, V247, P609, DOI 10.1007/s00417-008-1021-2
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hernandez-Rojas ML, 2007, RETINA-J RET VIT DIS, V27, P707
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Honda S, 2008, GRAEF ARCH CLIN EXP, V246, P1061, DOI 10.1007/s00417-008-0786-7
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Hsu J, 2007, RETINA-J RET VIT DIS, V27, P1013, DOI 10.1097/IAE.0b013e318050ca7c
   Ikuno Y, 2009, AM J OPHTHALMOL, V147, P94, DOI 10.1016/j.ajo.2008.07.017
   Iliev ME, 2006, AM J OPHTHALMOL, V142, P1054, DOI 10.1016/j.ajo.2006.06.066
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jaissle GB, 2006, OPHTHALMOLOGE, V103, P471, DOI 10.1007/s00347-006-1355-2
   Jaissle GB, 2009, GRAEF ARCH CLIN EXP, V247, P27, DOI 10.1007/s00417-008-0916-2
   Jalil A, 2007, EYE, V21, P1541, DOI 10.1038/sj.eye.6703018
   Jiang YR, 2009, ACTA OPHTHALMOL, V87, P736, DOI 10.1111/j.1755-3768.2008.01353.x
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Jonas JB, 2008, EYE, V22, P590, DOI 10.1038/eye.2008.10
   Jonas JB, 2008, ACTA OPHTHALMOL, V87, P571
   Jonas JB, 2008, ACTA OPHTHALMOL, V86, P585, DOI 10.1111/j.1600-0420.2007.01107.x
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P240, DOI 10.1089/jop.2006.0146
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Kawashima M, 2008, JPN J OPHTHALMOL, V52, P142, DOI 10.1007/s10384-008-0510-5
   Kernt M, 2007, ACTA OPHTHALMOL SCAN, V85, P119, DOI 10.1111/j.1600-0420.2006.00819.x
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Kloos P, 2008, KLIN MONATSBL AUGENH, V225, P385, DOI 10.1055/s-2008-1027252
   Kocabora MS, 2010, ACTA OPHTHALMOL, V88, pe44, DOI 10.1111/j.1755-3768.2008.01336.x
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P311, DOI 10.1007/s00417-008-0995-0
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Kopel AC, 2008, OPHTHAL SURG LAS IM, V39, P153, DOI 10.3928/15428877-20080301-10
   Kovacevic D, 2008, COLLEGIUM ANTROPOL, V32, P5
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Kreutzer TC, 2008, BRIT J OPHTHALMOL, V92, P351, DOI 10.1136/bjo.2007.123513
   Krishnan R, 2009, EYE, V23, P1238, DOI 10.1038/eye.2008.179
   Kumar Atul, 2007, Indian Journal of Ophthalmology, V55, P451
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lam DSC, 2009, RETINA-J RET VIT DIS, V29, P292, DOI 10.1097/IAE.0b013e31819a2d61
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P77
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Lloyd-Jones D, 2009, CIRCULATION, V119, P480, DOI 10.1161/CIRCULATIONAHA.108.191259
   Loke Y., 2008, COCHRANE HDB SYSTEMA
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Lommatzsch AP, 2008, KLIN MONATSBL AUGENH, V225, P874, DOI 10.1055/s-2008-1027454
   Lopez-Guajardo L, 2008, EYE, V22, P430, DOI 10.1038/sj.eye.6703054
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Mackensen F, 2008, RETINA-J RET VIT DIS, V28, P41, DOI 10.1097/IAE.0b013e318156db75
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Mahmood S, 2009, EYE, V23, P530, DOI 10.1038/eye.2008.101
   Maier M, 2008, KLIN MONATSBL AUGENH, V225, P818, DOI 10.1055/s-2008-1027638
   Maier M, 2008, KLIN MONATSBL AUGENH, V225, P582, DOI 10.1055/s-2008-1027474
   Maier M, 2009, OPHTHALMOLOGE, V106, P729, DOI 10.1007/s00347-008-1839-3
   Mandal S, 2007, EUR J OPHTHALMOL, V17, P620, DOI 10.1177/112067210701700422
   Mandal S, 2007, GRAEF ARCH CLIN EXP, V245, P1825, DOI 10.1007/s00417-007-0567-8
   Mandal S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1487, DOI 10.1001/archopht.125.11.1487
   Mansour AM, 2008, AM J OPHTHALMOL, V146, P410, DOI 10.1016/j.ajo.2008.05.024
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Mason JO, 2007, RETINA-J RET VIT DIS, V27, P903, DOI 10.1097/IAE.0b013e31806e6042
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   Matsumoto Y, 2007, RETINA-J RET VIT DIS, V27, P426, DOI 10.1097/IAE.0b013e31804a7af2
   McGimpsey SJ, 2008, BRIT J OPHTHALMOL, V92, P436, DOI 10.1136/bjo.2007.125070
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Meyer CH, 2007, OPHTHALMOLOGE, V104, P952, DOI 10.1007/s00347-007-1634-6
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Minnella AM, 2008, ACTA OPHTHALMOL, V86, P683, DOI 10.1111/j.1600-0420.2007.01042.x
   Mintz-Hittner HA, 2008, RETINA-J RET VIT DIS, V28, P831, DOI 10.1097/IAE.0b013e318177f934
   Mirshahi A, 2009, OCUL IMMUNOL INFLAMM, V17, P59, DOI 10.1080/09273940802553295
   Mitamura Y, 2008, BRIT J OPHTHALMOL, V92, P717, DOI 10.1136/bjo.2008.139378
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Montero JA, 2008, EUR J OPHTHALMOL, V18, P469, DOI 10.1177/112067210801800328
   Moradian S, 2008, GRAEF ARCH CLIN EXP, V246, P1699, DOI 10.1007/s00417-008-0914-4
   Neri P, 2009, BRIT J OPHTHALMOL, V93, P155, DOI 10.1136/bjo.2008.145896
   Neri Piergiorgio, 2008, International Ophthalmology, V28, P425, DOI 10.1007/s10792-007-9152-8
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Ornek K, 2008, J OCUL PHARMACOL TH, V24, P403, DOI 10.1089/jop.2007.0128
   Ozkiris A, 2009, EYE, V23, P616, DOI 10.1038/eye.2008.40
   Paccola L, 2008, BRIT J OPHTHALMOL, V92, P76, DOI 10.1136/bjo.2007.129122
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   Park Hee-Jung, 2007, Binocul Vis Strabismus Q, V22, P209
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Peng CH, 2009, EYE, V23, P2126, DOI 10.1038/eye.2008.401
   Pieramici DJ, 2006, RETINA-J RET VIT DIS, V26, P841, DOI 10.1097/01.iae.0000234629.22614.cd
   Pieramici Dante J, 2008, Ophthalmology, V115, pe47, DOI 10.1016/j.ophtha.2008.06.021
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Pournaras JAC, 2008, KLIN MONATSBL AUGENH, V225, P397, DOI 10.1055/s-2008-1027258
   Prager F, 2009, BRIT J OPHTHALMOL, V93, P452, DOI 10.1136/bjo.2008.141085
   Priglinger SG, 2007, RETINA-J RET VIT DIS, V27, P1004, DOI 10.1097/IAE.0b013e3180ed458d
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Quiroz-Mercado H, 2008, RETINA-J RET VIT DIS, V28, pS19, DOI 10.1097/IAE.0b013e318159ec6b
   Rabena MD, 2007, RETINA-J RET VIT DIS, V27, P419, DOI 10.1097/IAE.0b013e318030e77e
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Reeves S, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002213.pub2
   Rensch F, 2008, OPHTHAL SURG LAS IM, V39, P182, DOI 10.3928/15428877-20080501-14
   Rensch F, 2010, ACTA OPHTHALMOL, V88, pe36, DOI 10.1111/j.1755-3768.2008.01443.x
   Rensch F, 2009, OPHTHALMOLOGICA, V223, P124, DOI 10.1159/000183844
   Rensch F, 2009, ACTA OPHTHALMOL, V87, P77, DOI 10.1111/j.1755-3768.2008.01313.x
   Rheaume MA, 2008, CAN J OPHTHALMOL, V43, P576, DOI 10.3129/i08-104
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rodrigues EB, 2007, ACTA OPHTHALMOL SCAN, V85, P915, DOI 10.1111/j.1600-0420.2007.00968.x
   Roh MI, 2008, RETINA-J RET VIT DIS, V28, P1314, DOI 10.1097/IAE.0b013e3181853d2a
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rouvas AA, 2009, RETINA-J RET VIT DIS, V29, P536, DOI 10.1097/IAE.0b013e318196b1de
   Ruiz-Moreno JM, 2009, BRIT J OPHTHALMOL, V93, P448, DOI 10.1136/bjo.2008.145391
   Russo V, 2009, RETINA-J RET VIT DIS, V29, P511, DOI 10.1097/IAE.0b013e318195ca65
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Sayanagi K, 2009, ACTA OPHTHALMOL, V87, P460, DOI 10.1111/j.1755-3768.2008.01291.x
   Schaal KB, 2008, OPHTHALMOLOGE, V105, P538, DOI 10.1007/s00347-007-1638-2
   Schaal KB, 2007, OPHTHALMOLOGE, V104, P285, DOI 10.1007/s00347-007-1509-x
   Schaal KB, 2009, OPHTHALMOLOGE, V106, P356, DOI 10.1007/s00347-008-1843-7
   Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016/j.ajo.2007.12.030
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shaikh Saad, 2007, Indian Journal of Ophthalmology, V55, P470
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Shimura M, 2008, AM J OPHTHALMOL, V145, P854, DOI 10.1016/j.ajo.2007.12.031
   Silva RM, 2008, RETINA-J RET VIT DIS, V28, P1117, DOI 10.1097/IAE.0b013e31817eda41
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Soheilian M, 2007, RETINA-J RET VIT DIS, V27, P1187, DOI 10.1097/IAE.0b013e31815ec261
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Somner JEA, 2009, EYE, V23, P1744, DOI 10.1038/eye.2008.297
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Spitzer MS, 2008, J CATARACT REFR SURG, V34, P70, DOI 10.1016/j.jcrs.2007.08.021
   Stahl A, 2007, GRAEF ARCH CLIN EXP, V245, P1429, DOI 10.1007/s00417-007-0569-6
   Steffensmeier ACG, 2007, AM J OPHTHALMOL, V143, P512, DOI 10.1016/j.ajo.2006.10.007
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Subramanyam Anand, 2007, Indian J Ophthalmol, V55, P483
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tran T, 2008, GRAEF ARCH CLIN EXP, V246, P1685, DOI 10.1007/s00417-008-0906-4
   Tranos P, 2008, EYE, V22, P862, DOI 10.1038/sj.eye.6703036
   Valmaggia C, 2008, KLIN MONATSBL AUGENH, V225, P380, DOI 10.1055/s-2008-1027266
   Wakabayashi T, 2008, OPHTHALMOLOGY, V115, P1571, DOI 10.1016/j.ophtha.2008.02.026
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wiegand TW, 2009, BRIT J OPHTHALMOL, V93, P47, DOI 10.1136/bjo.2008.143461
   Wolf A, 2008, OPHTHALMOLOGE, V105, P845, DOI 10.1007/s00347-008-1785-0
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   World Health Organization, 2002, SAF MED GUID DET REP
   Wu LT, 2008, RETINA-J RET VIT DIS, V28, P212, DOI 10.1097/IAE.0b013e3181619bee
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wu PC, 2009, EYE, V23, P2042, DOI 10.1038/eye.2008.404
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
   Yenerel NM, 2008, J OCUL PHARMACOL TH, V24, P362, DOI 10.1089/jop.2007.0126
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Yuzbasioglu E, 2009, CURR EYE RES, V34, P231, DOI 10.1080/02713680802710692
   Ziemssen F, 2006, BRIT J OPHTHALMOL, V90, P922, DOI 10.1136/bjo.2006.092262
   Ziemssen F, 2007, GRAEF ARCH CLIN EXP, V245, P917, DOI 10.1007/s00417-006-0512-2
   Ziemssen Focke, 2009, International Ophthalmology, V29, P213, DOI 10.1007/s10792-008-9221-7
NR 304
TC 105
Z9 108
U1 1
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2011
VL 31
IS 8
BP 1449
EP 1469
DI 10.1097/IAE.0b013e3182278ab4
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814LS
UT WOS:000294456100002
PM 21817960
DA 2022-11-30
ER

PT J
AU Kalariya, NM
   Wills, NK
   Ramana, KV
   Srivastava, SK
   van Kuijk, FJGM
AF Kalariya, Nilesh M.
   Wills, Nancy K.
   Ramana, Kota V.
   Srivastava, Satish K.
   van Kuijk, Frederik J. G. M.
TI Cadmium-induced apoptotic death of human retinal pigment epithelial
   cells is mediated by MAPK pathway
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE cadmium; retinal pigment epithelium; oxidative stress; apoptosis; MAPK;
   AMD
ID ACTIVATED PROTEIN-KINASES; MACULAR DEGENERATION; OXIDATIVE STRESS;
   CIGARETTE-SMOKE; URINARY CADMIUM; DNA-REPAIR; AGE; ACCUMULATION;
   GLUTATHIONE; ASSOCIATION
AB Cadmium (Cd), released from cigarette smoke and metal industrial activities, is known to accumulate in human body organs including retina and is particularly higher in retinal tissues of age-related macular degeneration (AMD) eyes compared to non-AMD eyes. We have determined the cytotoxic effects of Cd on human retinal pigment epithelial (RPE) cells. Upon Cd treatment, there was a dose-and time-dependent decline in ARPE-19 cell viability as well as early apoptotic changes such as altered mitochondrial membrane potential (MMP) and Cytochrome C release in cytosol. Depletion of GSH by buthionine-[S,R]-sulfoximine (BSO) resulted in increased Cd toxicity in ARPE-19 cells. Cadmium also caused reactive oxygen species (ROS) generation and activation of mitogen-activated protein kinases (MAPKs) pathway including c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase 1/2 (Erk1/2), and p38 in ARPE-19 cells. Antioxidants such as N-acetylcysteine (NAC) significantly reduced Cd-induced toxicity. These results indicate that elevated ROS-induced activation of the MAPK signaling pathway could be associated with Cd-induced RPE cell apoptosis, one of the major contributing factors in AMD. The toxic effects of Cd on ARPE-19 cells indicate that environmental heavy metals such as Cd could be important potential factors in RPE cells death associated retinal diseases particularly related to smoking. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Kalariya, Nilesh M.; van Kuijk, Frederik J. G. M.] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
   [Wills, Nancy K.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; University of Texas System; University of Texas Medical
   Branch Galveston
RP van Kuijk, FJGM (通讯作者)，Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Room 2-100,700 Univ Blvd, Galveston, TX 77555 USA.
EM fjvankui@utmb.edu
RI Ramana, Kota/C-5460-2012
OI Ramana, Kota/0000-0001-6502-7800
FU National Institutes of Health (NIH) [GM71036, DK36118]; Philip Morris
   Fund; Wilkins AMD Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [R01DK036118, R37DK036118] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071036] Funding
   Source: NIH RePORTER
FX This work was supported by National Institutes of Health (NIH) Grants
   GM71036 (to K. V. R.), DK36118 (to S. K. S.), and Philip Morris Fund (N.
   W.), Wilkins AMD Fund as well as Research to Prevent Blindness (to
   FJGMvK).
CR Arisawa K, 2007, TOXICOL LETT, V169, P214, DOI 10.1016/j.toxlet.2007.01.009
   Baker JR, 2005, TOXICOL LETT, V159, P182, DOI 10.1016/j.toxlet.2005.05.016
   Bertin G, 2006, BIOCHIMIE, V88, P1549, DOI 10.1016/j.biochi.2006.10.001
   Bhattacharyya M., 2000, MOL BIOL TOXICOLOGY
   Cao Zhuoxiao, 2003, Cardiovasc Toxicol, V3, P165, DOI 10.1385/CT:3:2:165
   Chen L, 2008, FREE RADICAL BIO MED, V45, P1035, DOI 10.1016/j.freeradbiomed.2008.07.011
   Chen L, 2008, J NEUROCHEM, V105, P251, DOI 10.1111/j.1471-4159.2007.05133.x
   Chuang SM, 2000, CARCINOGENESIS, V21, P1423, DOI 10.1093/carcin/21.7.1423
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   FRIBERG L, 1983, ANNU REV PUBL HEALTH, V4, P367, DOI 10.1146/annurev.pu.04.050183.002055
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gallagher CM, 2008, ENVIRON HEALTH PERSP, V116, P1338, DOI 10.1289/ehp.11452
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   He L, 2006, MOL PHARMACOL, V70, P171, DOI 10.1124/mol.106.021521
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Horiguchi Hyogo, 2007, Nihon Eiseigaku Zasshi, V62, P888, DOI 10.1265/jjh.62.888
   Houston MC, 2007, ALTERN THER HEALTH M, V13, P128
   Johnson S, 2001, MED HYPOTHESES, V56, P595, DOI 10.1054/mehy.2000.1301
   Jung YS, 2008, EUR J PHARMACOL, V578, P11, DOI 10.1016/j.ejphar.2007.08.049
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Kim SD, 2005, BIOCHEM BIOPH RES CO, V328, P326, DOI 10.1016/j.bbrc.2004.11.173
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kukner A, 2007, BIOL TRACE ELEM RES, V119, P137, DOI 10.1007/s12011-007-0049-1
   Lag M, 2005, TOXICOLOGY, V211, P253, DOI 10.1016/j.tox.2005.03.012
   Lei YX, 2008, BIOMED ENVIRON SCI, V21, P332, DOI 10.1016/S0895-3988(08)60051-3
   Li ZM, 2004, J NEUROCHEM, V90, P19, DOI 10.1111/j.1471-4159.2004.02456.x
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lopez E, 2003, BRIT J PHARMACOL, V138, P901, DOI 10.1038/sj.bjp.0705111
   Mannino DM, 2004, THORAX, V59, P194, DOI 10.1136/thorax.2003.012054
   Martin P, 2006, BIOCHEM BIOPH RES CO, V350, P803, DOI 10.1016/j.bbrc.2006.09.126
   MEISTER A, 1986, J AM COLL NUTR, V5, P137
   Monroe RK, 2006, FREE RADICAL BIO MED, V41, P493, DOI 10.1016/j.freeradbiomed.2006.04.023
   Nordberg GF, 2007, HANDBOOK ON THE TOXICOLOGY OF METALS, 3RD EDITION, P445, DOI 10.1016/B978-012369413-3/50078-1
   Okuda B, 1997, CLIN NEUROL NEUROSUR, V99, P263, DOI 10.1016/S0303-8467(97)00090-5
   Prozialeck WC, 2007, KIDNEY INT, V72, P985, DOI 10.1038/sj.ki.5002467
   Ramana KV, 2006, J BIOL CHEM, V281, P17652, DOI 10.1074/jbc.M600270200
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rockwell P, 2004, CELL SIGNAL, V16, P343, DOI 10.1016/j.cellsig.2003.08.006
   Satarug S, 2004, TOXICOL LETT, V148, P177, DOI 10.1016/j.toxlet.2003.09.015
   Satarug S, 2004, ENVIRON HEALTH PERSP, V112, P1099, DOI 10.1289/ehp.6751
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Singh KP, 2009, CANCER LETT, V279, P84, DOI 10.1016/j.canlet.2009.01.023
   SRIVASTAVA SK, 1969, BIOCHEM J, V114, P833, DOI 10.1042/bj1140833
   Thijssen S, 2007, TOXICOLOGY, V238, P200, DOI 10.1016/j.tox.2007.06.087
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Yadav UCS, 2008, TOXICOL APPL PHARM, V227, P257, DOI 10.1016/j.taap.2007.10.025
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 54
TC 50
Z9 54
U1 0
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2009
VL 89
IS 4
BP 494
EP 502
DI 10.1016/j.exer.2009.05.011
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 556II
UT WOS:000274583900008
PM 19524565
DA 2022-11-30
ER

PT J
AU Lee, BR
   Bartsch, DU
   Kozak, I
   Cheng, LY
   Freeman, WR
AF Lee, Byung Ro
   Bartsch, Dirk-Uwe
   Kozak, Igor
   Cheng, Lingyun
   Freeman, William R.
TI COMPARISON OF A NOVEL CONFOCAL SCANNING LASER OPHTHALMOSCOPY ALGORITHM
   WITH OPTICAL COHERENCE TOMOGRAPHY IN MEASUREMENT OF MACULAR THICKNESS
   AND VOLUME
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Heidelberg retinal tomography; optical coherence tomography; macular
   thickness; macular volume
ID HEIDELBERG-RETINA-TOMOGRAPH; MONITOR PHOTODYNAMIC THERAPY; NERVE HEAD;
   REPRODUCIBILITY; EDEMA; ARTIFACTS; REPEATABILITY; INDEX; EYES
AB Purpose: To evaluate macular thickness and volume measurements using a novel Heidelberg Retinal Tomograph (HRT3) algorithm and to compare the results with optical coherence tomography (StratusOCT).
   Methods: This was a prospective, comparative, clinical noninterventional study. Fifty-two eyes were examined using both methods: 16 normal eyes, 12 eyes with diabetic macular edema (DME), and 24 eyes with age-related macular degeneration (AMD). The HRT3 macular thickness and volume were compared with those from the StratusOCT automated software. In addition, the distances between the retinal surface and the base of subretinal pathologic changes were measured using the StratusOCT manual-caliper technique and were compared with the HRT3 measurements in AMD eyes.
   Results: No statistically significant difference in macular thickness and volume measurements was observed between the two methods for normal (P = 0.89 and P = 0.33, respectively) and DME eyes (P = 0.86 and P = 0.31, respectively). However, in AMD eyes, the differences in both measurements were statistically significant between the two methods (P < 0.0001 and P < 0.0001, respectively). The HRT3 thickness measurements were in good agreement with the manual StratusOCT measurements (P = 0.4).
   Conclusion: In normal and DME eyes, the HRT3 measurements correlated well with the automatic StratusOCT measurements. In AMD eyes, the HRT3 measurements correlated well only with the manually corrected measurements of the retinal-subretinal pathologic changes. RETINA 29:1328-1334, 2009
C1 [Lee, Byung Ro; Bartsch, Dirk-Uwe; Kozak, Igor; Cheng, Lingyun; Freeman, William R.] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, La Jolla, CA 92037 USA.
   [Lee, Byung Ro] Hanyang Univ, Coll Med, Dept Ophthalmol, Seoul 133791, South Korea.
C3 University of California System; University of California San Diego;
   Hanyang University
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, 0946,9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Kozak, Igor/AAC-4645-2019
FU National Eye Institute [EY16323]; National Institutes of Health
   [EY07366]; Research to Prevent Blindness (RPB); NATIONAL EYE INSTITUTE
   [R01EY016323, R01EY007366] Funding Source: NIH RePORTER
FX Supported in part by National Eye Institute (grant EY16323 to D.-U.B.),
   National Institutes of Health (grant EY07366 to W.R.F.), Research to
   Prevent Blindness (RPB) (unrestricted grant), and the Jacobs Retina
   Center research funds. W.R.F. is the recipient of an RPB Physician
   Scientist award and departmental support to University of California,
   San Diego.
CR Ang A, 2000, BRIT J OPHTHALMOL, V84, P1194, DOI 10.1136/bjo.84.10.1194
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   BARTSCH DU, 1989, AM J OPHTHALMOL, V108, P277, DOI 10.1016/0002-9394(89)90118-9
   BARTSCH DU, 1994, EXP EYE RES, V58, P161, DOI 10.1006/exer.1994.1004
   Bartsch DU, 2004, PROC SPIE, V5370, P2140, DOI 10.1117/12.535857
   BARTSCH DU, 1993, NEUROSCI BIOBEHAV R, V17, P459
   Bartsch DUG, 2003, ARCH OPHTHALMOL-CHIC, V121, P1246, DOI 10.1001/archopht.121.9.1246
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Degenring RF, 2004, AM J OPHTHALMOL, V138, P354, DOI 10.1016/j.ajo.2004.04.021
   Garcia-Layana A, 2006, BRIT J OPHTHALMOL, V90, P555, DOI 10.1136/bjo.2005.085555
   Guan K, 2004, INVEST OPHTH VIS SCI, V45, P610, DOI 10.1167/iovs.03-0313
   Hudson C, 1998, BRIT J OPHTHALMOL, V82, P121, DOI 10.1136/bjo.82.2.121
   Hudson C, 2003, BRIT J OPHTHALMOL, V87, P455, DOI 10.1136/bjo.87.4.455
   Kisilevsky M, 2006, ARCH OPHTHALMOL-CHIC, V124, P337, DOI 10.1001/archopht.124.3.337
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   KRUSE FE, 1989, OPHTHALMOLOGY, V96, P1320
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Massin P, 2006, ACTA OPHTHALMOL SCAN, V84, P466, DOI 10.1111/j.1600-0420.2006.00694.x
   MOERE AV, 2006, BR J OPHTHALMOL, V90, P304
   Pallikaris A, 2005, AM J OPHTHALMOL, V139, P624, DOI 10.1016/j.ajo.2004.11.063
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sedarat F, 2004, J APPL PHYSIOL, V97, P1098, DOI 10.1152/japplphysiol.00089.2004
   Tong L, 2001, BRIT J OPHTHALMOL, V85, P34, DOI 10.1136/bjo.85.1.34
   WILLIS B, 1993, J MICROSC-OXFORD, V169, P347, DOI 10.1111/j.1365-2818.1993.tb03311.x
   Zambarakji HJ, 1998, BRIT J OPHTHALMOL, V82, P884, DOI 10.1136/bjo.82.8.884
   Zambarakji HJ, 1999, DOC OPHTHALMOL, V97, P349, DOI 10.1023/A:1002198409770
   Zambarakji HJ, 1998, OPHTHALMOLOGY, V105, P1051, DOI 10.1016/S0161-6420(98)96007-9
NR 34
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2009
VL 29
IS 9
BP 1328
EP 1334
DI 10.1097/IAE.0b013e3181ac7d30
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506EF
UT WOS:000270755800018
PM 19934823
DA 2022-11-30
ER

PT J
AU Chen, SC
   Suaning, GJ
   Morley, JW
   Lovell, NH
AF Chen, S. C.
   Suaning, G. J.
   Morley, J. W.
   Lovell, N. H.
TI Rehabilitation regimes based upon psychophysical studies of prosthetic
   vision
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
CT Eye and the Chip Meeting 2008
CY JUN 12-14, 2008
CL Detroit, MI
SP Detroit Inst Ophthalmol
ID SPATIOTEMPORAL BOUNDARY FORMATION; NERVE VISUAL PROSTHESIS;
   RETINITIS-PIGMENTOSA; ARTIFICIAL VISION; PIXELIZED VISION; MACULAR
   DEGENERATION; RETINAL PROSTHESIS; ELECTRICAL-STIMULATION; MOBILITY
   PERFORMANCE; HEAD MOVEMENTS
AB Human trials of prototype Visual prostheses have successfully elicited Visual percepts (phosphenes) in the Visual field of implant recipients blinded through retinitis pigmentosa and age-related macular degeneration. Researchers are progressing rapidly towards a device that utilizes individual phosphenes as the elementary building blocks to compose a Visual scene. This form of prosthetic vision is expected, in the near term, to have low resolution, large inter-phosphene gaps, distorted spatial distribution of phosphenes, restricted field of view, an eccentrically located phosphene field and limited number of expressible luminance levels. In order to fully realize the potential of these devices, there needs to be a training and rehabilitation program which aims, to assist the prosthesis recipients to understand what they are seeing, and also to adapt their viewing habits to optimize the performance of the device. Based on the literature of psychophysical studies in simulated and real prosthetic vision. this paper proposes a comprehensive, theoretical training regime for a prosthesis recipient: visual search, Visual acuity, reading, face/object recognition, hand-eye coordination and navigation. The aim of these tasks is to train the recipients to conduct Visual scanning, eccentric viewing and reading, discerning low-contrast visual information, and coordinating bodily actions for visual-guided tasks under prosthetic vision. These skills have been identified as playing an important role in making prosthetic vision functional for the daily activities of their recipients.
C1 [Chen, S. C.; Suaning, G. J.; Lovell, N. H.] Univ New S Wales, Grad Sch Biomed Engn, Kensington, NSW 2052, Australia.
   [Chen, S. C.; Morley, J. W.] Univ Western Sydney, Sch Med, Penrith, NSW 1797, Australia.
C3 University of New South Wales Sydney; Western Sydney University
RP Chen, SC (通讯作者)，Univ New S Wales, Grad Sch Biomed Engn, Kensington, NSW 2052, Australia.
EM s.chen@unsw.edu.au
RI Lovell, Nigel H/AGF-6679-2022; Morley, John/A-5311-2009
OI Lovell, Nigel H/0000-0003-1637-1079; Suaning, Gregg/0000-0003-1918-3313;
   Morley, John/0000-0001-9246-853X
CR Barraza JF, 2006, J VISION, V6, P923, DOI 10.1167/6.9.6
   Black A., 1997, CLIN EXP OPTOM, V80, P1, DOI [10.1111/j.1444-0938.1997.tb04841.x, DOI 10.1111/J.1444-0938.1997.TB04841.X]
   Brelen ME, 2005, J NEURAL ENG, V2, pS22, DOI 10.1088/1741-2560/2/1/004
   BRINDLEY G, 1974, T AM ACAD OPHTHALMOL, V78, pOP741
   BUTTON JOHN, 1962, JOUR IOWA MED SOC, V52, P17
   CAI S, 2005, P 2005 IEEE EMBS 27
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   Chai XY, 2008, ARTIF ORGANS, V32, P110, DOI 10.1111/j.1525-1594.2007.00469.x
   Chen SC, 2007, J NEURAL ENG, V4, pS108, DOI 10.1088/1741-2560/4/1/S13
   Chen SC, 2005, J NEURAL ENG, V2, pS135, DOI 10.1088/1741-2560/2/1/015
   Chen SC, 2005, IEEE T NEUR SYS REH, V13, P249, DOI 10.1109/TNSRE.2005.851771
   CHEN SC, 2006, 28 ANN INT C IEEE EN
   Clark G M, 2003, COCHLEAR IMPLANTS FU
   COLLINS JK, 1987, OPTOM TODAY, V27, P772
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Dagnelie G, 2006, J MOD OPTIC, V53, P1325, DOI 10.1080/09500340600619197
   Dagnelie G, 2006, INVEST OPHTH VIS SCI, V47, P1241, DOI 10.1167/iovs.05-0157
   Dagnelie G, 2007, J NEURAL ENG, V4, pS92, DOI 10.1088/1741-2560/4/1/S11
   Dickinson, 1998, LOW VISION PRINCIPLE
   DIXON P, 1994, COGNITIVE PSYCHOL, V26, P33, DOI 10.1006/cogp.1994.1002
   DOBELLE WH, 1974, SCIENCE, V183, P440, DOI 10.1126/science.183.4123.440
   Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002
   Dolezal H., 1982, LIVING WORLD TRANSFO
   Duret F, 2006, RESTOR NEUROL NEUROS, V24, P31
   EVERITT BS, 1978, BIOMETRICS, V34, P399, DOI 10.2307/2530602
   FAY EE, 1984, CLIN LOW VISION
   Fornos AP, 2006, INVEST OPHTH VIS SCI, V47, P1439, DOI 10.1167/iovs.05-0973
   Fornos AP, 2005, INVEST OPHTH VIS SCI, V46, P3906, DOI 10.1167/iovs.04-1173
   Fortenbaugh FC, 2007, VISION RES, V47, P2506, DOI 10.1016/j.visres.2007.06.012
   Fu L, 2006, VISION RES, V46, P1292, DOI 10.1016/j.visres.2005.11.011
   Fujikado T, 2007, GRAEF ARCH CLIN EXP, V245, P1411, DOI 10.1007/s00417-007-0563-z
   Hallum LE, 2005, VISION RES, V45, P775, DOI 10.1016/j.visres.2004.09.032
   Hayes JS, 2003, ARTIF ORGANS, V27, P1016, DOI 10.1046/j.1525-1594.2003.07309.x
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   JAN JE, 1991, DEV MED CHILD NEUROL, V33, P645
   Kuyk T, 1998, OPTOMETRY VISION SCI, V75, P538, DOI 10.1097/00006324-199807000-00023
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   Li L, 2002, OPTOMETRY VISION SCI, V79, P581, DOI 10.1097/00006324-200209000-00009
   Logan D., 2005, INT C SER, V1282, P631
   LOVIEKITCHIN J, 1990, CLIN VISION SCI, V5, P249
   Luo G, 2006, INVEST OPHTH VIS SCI, V47, P4152, DOI 10.1167/iovs.05-1672
   NILSSON UL, 1988, DOC OPHTHALMOL, V70, P363, DOI 10.1007/BF00157066
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   NILSSON UL, 1986, DOC OPHTHALMOL, V62, P345, DOI 10.1007/BF00168266
   Owens D., 2006, CURR PAEDIAT, V16, P360
   RICHARD G, 2007, INVEST OPHTHALMOL VI, V48
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   RUSHTON DN, 1978, FRONTIERS VISUAL SCI
   Seagull FJ, 1997, J EXP PSYCHOL-APPL, V3, P163
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Shimono K, 2007, VISION RES, V47, P1027, DOI 10.1016/j.visres.2007.01.012
   Shipley TF, 1997, VISION RES, V37, P1281, DOI 10.1016/S0042-6989(96)00272-6
   SHIPLEY TF, 1994, J EXP PSYCHOL GEN, V123, P3, DOI 10.1037/0096-3445.123.1.3
   Sommerhalder J, 2004, VISION RES, V44, P1693, DOI 10.1016/j.visres.2004.01.017
   Sommerhalder J, 2003, VISION RES, V43, P269, DOI 10.1016/S0042-6989(02)00481-9
   Thompson RW, 2003, INVEST OPHTH VIS SCI, V44, P5035, DOI 10.1167/iovs.03-0341
   Thornton IM, 2002, PERCEPTION, V31, P113, DOI 10.1068/p3300
   Turano KA, 1999, INVEST OPHTH VIS SCI, V40, P865
   Velikay-Parel M, 2007, J NEURAL ENG, V4, pS102, DOI 10.1088/1741-2560/4/1/S12
   Veraart C, 2003, ARTIF ORGANS, V27, P996, DOI 10.1046/j.1525-1594.2003.07305.x
   Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9
   von Senden M., 1960, SPACE SIGHT PERCEPTI
   Vukicevic M., 2005, INT C SERIES, V1282, P544, DOI DOI 10.1016/j.ics.2005.04.024
   Wang L, 2008, INVEST OPHTH VIS SCI, V49, P3933, DOI 10.1167/iovs.07-1346
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   Yanai D, 2007, AM J OPHTHALMOL, V143, P820, DOI 10.1016/j.ajo.2007.01.027
   Zeng FG, 2002, J ACOUST SOC AM, V111, P377, DOI 10.1121/1.1423926
   ZRENNER E, 2007, INVEST OPHTHALMOL VI, V48
NR 70
TC 11
Z9 11
U1 0
U2 8
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
J9 J NEURAL ENG
JI J. Neural Eng.
PD JUN
PY 2009
VL 6
IS 3
AR 035009
DI 10.1088/1741-2560/6/3/035009
PG 13
WC Engineering, Biomedical; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Neurosciences & Neurology
GA 461AM
UT WOS:000267235600010
PM 19458400
DA 2022-11-30
ER

PT J
AU McLaughlin, PJ
   Bakall, B
   Choi, J
   Liu, ZL
   Sasaki, T
   Davis, EC
   Marmorstein, AD
   Marmorstein, LY
AF McLaughlin, Precious J.
   Bakall, Benjamin
   Choi, Jiwon
   Liu, Zhonglin
   Sasaki, Takako
   Davis, Elaine C.
   Marmorstein, Alan D.
   Marmorstein, Lihua Y.
TI Lack of fibulin-3 causes early aging and herniation, but not macular
   degeneration in mice
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID EXTRACELLULAR-MATRIX PROTEINS; HONEYCOMB RETINAL DYSTROPHY;
   EHLERS-DANLOS-SYNDROME; INGUINAL-HERNIA; CUTIS LAXA; MALATTIA
   LEVENTINESE; TISSUE LOCALIZATION; KNOCKOUT MICE; RISK-FACTORS; IN-VIVO
AB A mutation in the EFEMP1 gene causes Malattia Leventinese, an inherited macular degenerative disease with strong similarities to age-related macular degeneration. EFEMP1 encodes fibulin-3, an extracellular matrix protein of unknown function. To investigate its biological role, the murine Efemp1 gene was inactivated through targeted disruption. Efemp1(-/-) mice exhibited reduced reproductivity, and displayed an early onset of aging-associated phenotypes including reduced lifespan, decreased body mass, lordokyphosis, reduced hair growth, and generalized fat, muscle and organ atrophy. However, these mice appeared to have normal wound healing ability. Efemp1(-/-) mice on a C57BL/6 genetic background developed multiple large hernias including inguinal hernias, pelvic prolapse and protrusions of the xiphoid process. In contrast, Efemp1(-/-) mice on a BALB/c background rarely had any forms of hernias, indicating the presence of modifiers for fibulin-3's function in different mouse strains. Histological analysis revealed a marked reduction of elastic fibers in fascia, a thin layer of connective tissue maintaining and protecting structures throughout the body. No apparent macular degeneration associated defects were found in Efemp1(-/-) mice, suggesting that loss of fibulin-3 function is not the mechanism by which the mutation in EFEMP1 causes macular degeneration. These data demonstrate that fibulin-3 plays an important role in maintaining the integrity of fascia connective tissues and regulates aging.
C1 Univ Arizona, Dept Ophthalmol & Visual Sci, Tucson, AZ 85711 USA.
   Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA.
   Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA.
   Univ Arizona, Dept Physiol, Tucson, AZ USA.
   McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada.
   Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.
C3 University of Arizona; University of Arizona; University of Arizona;
   University of Arizona; McGill University; Oregon Health & Science
   University
RP Marmorstein, LY (通讯作者)，Univ Arizona, Dept Ophthalmol & Visual Sci, 655 N Alvernon Way,Suite 108, Tucson, AZ 85711 USA.
EM lmarmorstein@eyes.arizona.edu
RI Davis, Elaine/F-3449-2012
FU NEI NIH HHS [EY 13160, EY 13847] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY013160, R01EY013847, R56EY013160] Funding Source: NIH
   RePORTER
CR Albig AR, 2006, CANCER RES, V66, P2621, DOI 10.1158/0008-5472.CAN-04-4096
   Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033
   ARKING R, 1998, BIOL AGING
   Ashcroft GS, 2002, BIOGERONTOLOGY, V3, P337, DOI 10.1023/A:1021399228395
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chu Mon-Li, 2004, Birth Defects Res C Embryo Today, V72, P25, DOI 10.1002/bdrc.20003
   Chuttani Anjali, 1995, P309
   DAVIS EC, 1993, LAB INVEST, V68, P89
   Drewes PG, 2007, AM J PATHOL, V170, P578, DOI 10.2353/ajpath.2007.060662
   Ehlermann J, 2003, GENE EXPR PATTERNS, V3, P441, DOI 10.1016/S1567-133X(03)00084-X
   El-Hallous E, 2007, J BIOL CHEM, V282, P8935, DOI 10.1074/jbc.M608204200
   Fu L, 2007, HUM MOL GENET
   Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001
   Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4
   Guyer DR, 2001, RETINA, P29
   HARRISON DE, 1988, EXP GERONTOL, V23, P309, DOI 10.1016/0531-5565(88)90034-4
   Hucthagowder V, 2006, AM J HUM GENET, V78, P1075, DOI 10.1086/504304
   Kashyap AS, 2004, LANCET, V363, P84, DOI 10.1016/S0140-6736(03)15211-7
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200
   Lau H, 2007, SURGERY, V141, P262, DOI 10.1016/j.surg.2006.04.014
   LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120
   Liem MSL, 1997, SURGERY, V122, P114, DOI 10.1016/S0039-6060(97)90273-7
   Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113
   Mao JR, 2001, J CLIN INVEST, V107, P1063, DOI 10.1172/JCI12881
   Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein Lihua, 2004, Ophthalmic Genet, V25, P219, DOI 10.1080/13816810490498305
   Marmorstein LY, 2002, J BIOL CHEM, V277, P30591, DOI 10.1074/jbc.M204269200
   Marmorstein LY, 2007, HUM MOL GENET
   McLaughlin PJ, 2006, MOL CELL BIOL, V26, P1700, DOI 10.1128/MCB.26.5.1700-1709.2006
   Nakamoto T, 2002, PLANT PROD SCI, V5, P175, DOI 10.1626/pps.5.175
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   Ruhl CE, 2007, AM J EPIDEMIOL, V165, P1154, DOI 10.1093/aje/kwm011
   Salmons S., 1995, GRAYS ANATOMY
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   TAKEDA T, 1981, MECH AGEING DEV, V17, P183, DOI 10.1016/0047-6374(81)90084-1
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Van den Steen PE, 2006, LAB INVEST, V86, P873, DOI 10.1038/labinvest.3700454
   von Kodolitsch Y, 2007, HEART, V93, P755, DOI 10.1136/hrt.2006.098798
   Wojcik SM, 2000, MOL CELL BIOL, V20, P5248, DOI 10.1128/MCB.20.14.5248-5255.2000
   Xiang Y, 2006, J IMMUNOL, V176, P3196, DOI 10.4049/jimmunol.176.5.3196
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
NR 45
TC 105
Z9 114
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2007
VL 16
IS 24
BP 3059
EP 3070
DI 10.1093/hmg/ddm264
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 232RH
UT WOS:000251036500008
PM 17872905
OA Bronze
DA 2022-11-30
ER

PT J
AU Dong, A
   Shen, J
   Krause, M
   Hackett, SF
   Campochiaro, PA
AF Dong, Aling
   Shen, JiKui
   Krause, Melissa
   Hackett, Sean F.
   Campochiaro, Peter A.
TI Increased expression of glial cell line-derived neurotrophic factor
   protects against oxidative damage-induced retinal degeneration
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE antioxidants; apoptosis; ocular gene transfer; photoreceptors; reactive
   oxygen species; retinal dystrophies.
ID ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; GDNF; DEATH;
   SURVIVAL; NEOVASCULARIZATION; RANIBIZUMAB; INVOLVEMENT; ACTIVATION;
   RECEPTOR
AB Oxidative damage contributes to retinal cell death in patients with age-related macular degeneration or retinitis pigmentosa. One approach to treatment is to identify and eliminate the sources of oxidative damage. Another approach is to identify treatments that protect cells from multiple sources of oxidative damage. In this study, we investigated the effect of increased expression of glial cell line-derived neurotrophic factor (GDNF) in three models of oxidative damage-induced retinal degeneration. Double transgenic mice with doxycycline-inducible expression of GDNF in the retina were exposed to paraquat, FeSO4, or hyperoxia, all sources of oxidative damage and retinal cell death. Compared to controls, mice with increased expression of GDNF in the retina showed significant preservation of retinal function measured by electroretinograms, reduced thinning of retinal cell layers, and fewer TUNEL-positive cells indicating less retinal cell death. Mice over-expressing GDNF also showed less staining for acrolein, nitrotyrosine, and 8-hydroxydeoxyguanosine, indicating less oxidative damage to lipids, proteins, and DNA. This suggests that GDNF did not act solely to allow cells to tolerate higher levels of oxidative damage before initiation of apoptosis, but also reduced damage from oxidative stress to critical macromolecules. These data suggest that gene transfer of Gdnf should be considered as a component of therapy for retinal degenerations in which oxidative damage plays a role.
C1 Johns Hopkins Univ, Sch Med, Dept Ophthalmol & Neurosci, Baltimore, MD USA.
C3 Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
FU NEI NIH HHS [EY05851] Funding Source: Medline
CR Andrieu-Soler C, 2005, MOL VIS, V11
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch PK, 2006, MOL THER, V14, P700, DOI 10.1016/j.ymthe.2006.05.019
   Carwile ME, 1998, EXP EYE RES, V66, P791, DOI 10.1006/exer.1998.0488
   Chang MA, 2000, INVEST OPHTH VIS SCI, V41, P4281
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Harada T, 2000, NEURON, V26, P533, DOI 10.1016/S0896-6273(00)81185-X
   Janiga TA, 2000, J NEUROBIOL, V43, P289, DOI 10.1002/(SICI)1097-4695(20000605)43:3<289::AID-NEU7>3.0.CO;2-5
   Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2
   Jomary C, 2004, INVEST OPHTH VIS SCI, V45, P1240, DOI 10.1167/iovs.03-1122
   Karlsson M, 2002, MECH DEVELOP, V114, P161, DOI 10.1016/S0925-4773(02)00045-X
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KOMEIMA K, 2007, J CELL PHYSL    0522
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Landi S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000346
   Lawrence JM, 2004, INVEST OPHTH VIS SCI, V45, P267, DOI 10.1167/iovs.03-0093
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Politi LE, 2001, INVEST OPHTH VIS SCI, V42, P3008
   ROGERS BS, 2006, INVEST OPHTH VIS SCI, V48, P438
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothermel A, 2003, INVEST OPHTH VIS SCI, V44, P2221, DOI 10.1167/iovs.02-0915
   Sanftner LHM, 2001, MOL THER, V4, P622, DOI 10.1006/mthe.2001.0498
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Ugolini G, 1995, BRAIN RES, V704, P121, DOI 10.1016/0006-8993(95)01191-9
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Wahlin KJ, 2001, EXP EYE RES, V73, P693, DOI 10.1006/exer.2001.1078
   Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7
   Yu DY, 2000, INVEST OPHTH VIS SCI, V41, P3999
   Yu DY, 2004, INVEST OPHTH VIS SCI, V45, P2013, DOI 10.1167/iovs.03-0845
NR 41
TC 29
Z9 30
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD NOV
PY 2007
VL 103
IS 3
BP 1041
EP 1052
DI 10.1111/j.1471-4159.2007.04839.x
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 221ZS
UT WOS:000250266500018
PM 17935603
DA 2022-11-30
ER

PT J
AU Li, WD
   Wang, Y
   Zhu, LL
   Du, S
   Mao, JH
   Wang, YY
   Wang, SS
   Bo, QY
   Tu, YY
   Yi, QY
AF Li, Wendie
   Wang, Ying
   Zhu, Linling
   Du, Shu
   Mao, Jinghai
   Wang, Yanyan
   Wang, Sangsang
   Bo, Qingyun
   Tu, Yuanyuan
   Yi, QuanYong
TI The P300/XBP1s/Herpud1 axis promotes macrophage M2 polarization and the
   development of choroidal neovascularization
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE choroidal neovascularization; Herpud1; macrophage polarization; p300;
   XBP1s
ID ENDOPLASMIC-RETICULUM; MACULAR DEGENERATION; PROTEIN; HYPERTENSION;
   DIFFERENTIATION
AB Neovascular age-related macular degeneration (AMD), which is characterized by choroidal neovascularization (CNV), leads to vision loss. M2 macrophages produce vascular endothelial growth factor (VEGF), which aggravates CNV formation. The histone acetyltransferase p300 enhances the stability of spliced X-box binding protein 1 (XBP1s) and promotes the transcriptional activity of the XBP1s target gene homocysteine inducible endoplasmic reticulum protein with ubiquitin-like domain 1 (Herpud1). Herpud1 promotes the M2 polarization of macrophages. This study aimed to explore the roles of the p300/XBP1s/Herpud1 axis in the polarization of macrophages and the pathogenesis of CNV. Hypoxia-induced p300 interacted with XBP1s to acetylate XBP1s in RAW264.7 cells. Additionally, hypoxia-induced p300 enhanced the XBP-1s-mediated unfolded protein response (UPR), alleviated the proteasome-dependent degradation of XBP1s and enhanced the transcriptional activity of XBP1s for Herpud1. The hypoxia-induced p300/XBP1s/Herpud1 axis facilitated RAW264.7 cell M2 polarization. Knockdown of the p300/XBP1s/Herpud1 axis in RAW264.7 cells inhibited the proliferation, migration and tube formation of mouse choroidal endothelial cells (MCECs). The p300/XBP1s/Herpud1 axis increased in infiltrating M2-type macrophages in mouse laser-induced CNV lesions. Blockade of the p300/XBP1s/Herpud1 axis inhibited macrophage M2 polarization and alleviated CNV lesions. Our study demonstrated that the p300/XBP1s/Herpud1 axis in infiltrating macrophages increased the M2 polarization of macrophages and the development of CNV.
C1 [Li, Wendie; Mao, Jinghai; Wang, Yanyan; Wang, Sangsang; Bo, Qingyun; Yi, QuanYong] Ningbo Eye Hosp, Dept Ophthalmol, Ningbo, Peoples R China.
   [Wang, Ying] Nanjing Med Univ, Suzhou Municipal Hosp, Dept Ophthalmol, Affiliated Suzhou Hosp, Suzhou, Peoples R China.
   [Zhu, Linling; Du, Shu; Tu, Yuanyuan] Soochow Univ, Dept Ophthalmol, Lixiang Eye Hosp, Suzhou, Peoples R China.
C3 Nanjing Medical University; Soochow University - China
RP Yi, QY (通讯作者)，Ningbo Eye Hosp, Dept Ophthalmol, Ningbo, Peoples R China.; Tu, YY (通讯作者)，Soochow Univ, Dept Ophthalmol, Lixiang Eye Hosp, Suzhou, Peoples R China.
EM tuyuanyuaneye@163.com; yqyningboeye@126.com
RI Wang, Yin/HCI-9352-2022; wang, yan/GSE-6489-2022; Wang,
   Yanbo/HFZ-8018-2022; Wang, Yu/GZL-9655-2022; 涂, 园园/AGE-3991-2022
OI Yi, Quanyong/0000-0001-6532-2519
FU Jiangsu Provincial Natural Science Foundation Project [SBK20200209];
   Natural Science Foundation of Ningbo [202003N4293, 2019A610351]; Natural
   Science Foundation of Yinzhou District [[2018]108, [2017]59, [2019]63];
   Zhejiang Medicine Health Technology Plan Project [2018KY735]
FX Jiangsu Provincial Natural Science Foundation Project, Grant/Award
   Number: SBK20200209; Natural Science Foundation of Ningbo, Grant/Award
   Number: 202003N4293 and 2019A610351; Natural Science Foundation of
   Yinzhou District, Grant/Award Number: [2018]108, [2017]59 and [2019]63;
   Zhejiang Medicine Health Technology Plan Project, Grant/Award Number:
   2018KY735
CR Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011
   Ayaub EA, 2019, IMMUNOL CELL BIOL, V97, P203, DOI 10.1111/imcb.12212
   Bravo R, 2013, INT REV CEL MOL BIO, V301, P215, DOI 10.1016/B978-0-12-407704-1.00005-1
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fei P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116423
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Lai KB, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110312
   Li YM, 2018, EXP CELL RES, V368, P167, DOI 10.1016/j.yexcr.2018.04.023
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   Oh J, 2012, J BIOL CHEM, V287, P11629, DOI 10.1074/jbc.M111.338673
   Okazaki H, 2019, EXP LUNG RES, V45, P188, DOI 10.1080/01902148.2019.1638466
   Outtz HH, 2011, BLOOD, V118, P3436, DOI 10.1182/blood-2010-12-327015
   Rai R, 2019, J CELL MOL MED, V23, P3026, DOI 10.1111/jcmm.14162
   Rai R, 2017, EPIGENETICS-US, V12, P1004, DOI 10.1080/15592294.2017.1370173
   Sai X, 2002, J BIOL CHEM, V277, P12915, DOI 10.1074/jbc.M112372200
   Schwarz DS, 2016, CELL MOL LIFE SCI, V73, P79, DOI 10.1007/s00018-015-2052-6
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Suzuki T, 2017, CELL REP, V18, P2045, DOI 10.1016/j.celrep.2017.01.076
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Ueta T, 2019, P NATL ACAD SCI USA, V116, P23705, DOI 10.1073/pnas.1908355116
   Wang FM, 2011, BIOCHEM J, V433, P245, DOI 10.1042/BJ20101293
   Wei JL, 2018, MINI-REV MED CHEM, V18, P296, DOI 10.2174/1389557516666160630124938
   Xu NN, 2019, INVEST OPHTH VIS SCI, V60, P4596, DOI 10.1167/iovs.19-27493
   Yang L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174839
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 30
TC 1
Z9 1
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL
PY 2021
VL 25
IS 14
BP 6709
EP 6720
DI 10.1111/jcmm.16673
EA MAY 2021
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA TJ1ZC
UT WOS:000656189400001
PM 34057287
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mendell, JR
   Al-Zaidy, SA
   Rodino-Klapac, LR
   Goodspeed, K
   Gray, SJ
   Kay, CN
   Boye, SL
   Boye, SE
   George, LA
   Salabarria, S
   Corti, M
   Byrne, BJ
   Tremblay, JP
AF Mendell, Jerry R.
   Al-Zaidy, Samiah A.
   Rodino-Klapac, Louise R.
   Goodspeed, Kimberly
   Gray, Steven J.
   Kay, Christine N.
   Boye, Sanford L.
   Boye, Shannon E.
   George, Lindsey A.
   Salabarria, Stephanie
   Corti, Manuela
   Byrne, Barry J.
   Tremblay, Jacques P.
TI Current Clinical Applications of In Vivo Gene Therapy with AAVs
SO MOLECULAR THERAPY
LA English
DT Review
AB Hereditary diseases are caused by mutations in genes, and more than 7,000 rare diseases affect over 30 million Americans. For more than 30 years, hundreds of researchers have maintained that genetic modifications would provide effective treatments for many inherited human diseases, offering durable and possibly curative clinical benefit with a single treatment. This review is limited to gene therapy using adeno-associated virus (AAV) because the gene delivered by this vector does not integrate into the patient genome and has a low immunogenicity. There are now five treatments approved for commercialization and currently available, i.e., Luxturna, Zolgensma, the two chimeric antigen receptor T cell (CAR-T) therapies (Yescarta and Kymriah), and Strimvelis (the gammaretrovirus approved for adenosine deaminase-severe combined immunodeficiency [ADA-SCID] in Europe). Dozens of other treatments are under clinical trials. The review article presents a broad overview of the field of therapy by in vivo gene transfer. We review gene therapy for neuromuscular disorders (spinal muscular atrophy [SMA]; Duchenne muscular dystrophy [DMD]; X-linked myotubular myopathy [XLMTM]; and diseases of the central nervous system, including Alzheimer's disease, Parkinson?s disease, Canavan disease, aromatic L-amino acid decarboxylase [AADC] deficiency, and giant axonal neuropathy), ocular disorders (Leber congenital amaurosis, age-related macular degeneration [AMD], choroideremia, achromatopsia, retinitis pigmentosa, and X-linked retinoschisis), the bleeding disorder hemophilia, and lysosomal storage disorders.
C1 [Mendell, Jerry R.] Nationwide Childrens Hosp, Ctr Gene Therapy, Abigail Wexner Res Inst, Columbus, OH USA.
   [Mendell, Jerry R.] Ohio State Univ, Dept Pediat & Neurol, Columbus, OH 43210 USA.
   [Al-Zaidy, Samiah A.] Al Zaidy & Associates LLC, Columbus, OH USA.
   [Rodino-Klapac, Louise R.] Sarepta Therapeut Inc, Cambridge, MA USA.
   [Goodspeed, Kimberly; Gray, Steven J.] UT Southwestern Med Ctr, Dept Pediat, Powell Gene Therapy Ctr, Dallas, TX USA.
   [Kay, Christine N.] Vitreoretinal Associates, Gainesville, FL USA.
   [Boye, Sanford L.] Univ Florida, Dept Pediat, Powell Gene Therapy Ctr, Gainesville, FL USA.
   [Boye, Shannon E.] Univ Florida, Div Cellular & Mol Therapeut, Gainesville, FL USA.
   [George, Lindsey A.] Div Hematol, Philadelphia, PA USA.
   [George, Lindsey A.] Perelman Ctr Cellular & Mol Therapeut, Philadelphia, PA USA.
   [George, Lindsey A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Salabarria, Stephanie] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA USA.
   [Corti, Manuela; Byrne, Barry J.] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL USA.
   [Corti, Manuela; Byrne, Barry J.] Univ Florida, Powell Gene Therapy Ctr, Gainesville, FL USA.
   [Tremblay, Jacques P.] CHUQ Univ Laval, Ctr Rech, Quebec City, PQ, Canada.
C3 University System of Ohio; Ohio State University; Nationwide Childrens
   Hospital; Research Institute at Nationwide Children's Hospital;
   University System of Ohio; Ohio State University; University of Texas
   System; University of Texas Southwestern Medical Center Dallas; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; University of Pennsylvania;
   Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of
   Pennsylvania; Pennsylvania Medicine; State University System of Florida;
   University of Florida; State University System of Florida; University of
   Florida; Laval University
RP Tremblay, JP (通讯作者)，CHUQ Univ Laval, Ctr Rech, Quebec City, PQ, Canada.
EM jacques-p.tremblay@crchul.ulaval.ca
RI Corti, Manuela/AAP-9275-2021
OI Rodino-Klapac, Louise/0000-0002-8966-5177; Boye,
   Shannon/0000-0002-7312-3197; George, Lindsey/0000-0002-9763-1559;
   Tremblay, Jacques P./0000-0001-9404-9195; Byrne, Barry
   J./0000-0002-7302-1756
FU US National Institutes of Health [K08 HL 146991-01]; Canadian Institute
   of Health Research grant [18059]
FX This work was supported by US National Institutes of Health grant K08 HL
   146991-01 (L.A.G. and by a Canadian Institute of Health Research grant
   18059 (J.P.T.)
CR Adverum Biotechnologies, 2020, ADVERUM BIOTECHNOLOG
   Adverum Biotechnologies, 2019, ADVERUM BIOTECHNOLOG
   Al-Qusairi L, 2009, P NATL ACAD SCI USA, V106, P18763, DOI 10.1073/pnas.0900705106
   Al-Zaidy S, 2019, PEDIATR PULM, V54, P179, DOI 10.1002/ppul.24203
   Al-Zaidy S, 2014, PEDIATR NEUROL, V51, P607, DOI 10.1016/j.pediatrneurol.2014.08.002
   Al-Zaidy SA, 2019, J NEUROMUSCULAR DIS, V6, P307, DOI 10.3233/JND-190403
   Annoussamy M, 2019, NEUROLOGY, V92, pE1852, DOI 10.1212/WNL.0000000000007319
   [Anonymous], 2018, PAPER
   Aronson SJ, 2019, HUM GENE THER, V30, P1297, DOI 10.1089/hum.2019.143
   Asher DR, 2020, EXPERT OPIN BIOL TH, V20, P263, DOI 10.1080/14712598.2020.1725469
   Asklepios BioPharmaceutical, 2019, 1 PATIENT DOSED GENE
   Bagher P, 2011, J APPL PHYSIOL, V110, P601, DOI 10.1152/japplphysiol.01106.2010
   Bailey RM, 2020, BRAIN RES, V1739, DOI 10.1016/j.brainres.2020.146832
   Bailey RM, 2018, MOL THER-METH CLIN D, V9, P160, DOI 10.1016/j.omtm.2018.02.005
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Beggs AH, 2018, MUSCLE NERVE, V57, P550, DOI 10.1002/mus.26018
   Beltran WA, 2015, P NATL ACAD SCI USA, V112, pE5844, DOI 10.1073/pnas.1509914112
   BioMarin, 2020, WORLD FEDERATION HEM
   Black A, 2014, J GENE MED, V16, P122, DOI 10.1002/jgm.2768
   Bouquet C, 2019, JAMA OPHTHALMOL, V137, P399, DOI 10.1001/jamaophthalmol.2018.6902
   Bouzia Z, 2020, AM J OPHTHALMOL, V210, P59, DOI 10.1016/j.ajo.2019.10.019
   Boye SL, 2020, MOL THER, V28, P1464, DOI 10.1016/j.ymthe.2020.04.002
   BROOKE MH, 1981, T AM NEUROL ASSOC, V106, P195
   Buj-Bello A, 2002, P NATL ACAD SCI USA, V99, P15060, DOI 10.1073/pnas.212498399
   Buj-Bello A, 2008, HUM MOL GENET, V17, P2132, DOI 10.1093/hmg/ddn112
   Burghes AHM, 2009, NAT REV NEUROSCI, V10, P597, DOI 10.1038/nrn2670
   Butz ES, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165571
   Byrne BJ, 2014, HUM GENE THER CL DEV, V25, P134, DOI 10.1089/humc.2014.2514
   Byrne BJ, 2011, HUM MOL GENET, V20, pR61, DOI 10.1093/hmg/ddr174
   Byrne LC, 2014, GENE THER, V21, P585, DOI 10.1038/gt.2014.31
   Byrne LC, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135112
   Cain JT, 2019, MOL THER, V27, P1836, DOI 10.1016/j.ymthe.2019.06.015
   Calcedo R, 2016, HUM GENE THER CL DEV, V27, P79, DOI 10.1089/humc.2016.048
   CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5
   Cantore A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1405
   Cantore A, 2012, BLOOD, V120, P4517, DOI 10.1182/blood-2012-05-432591
   Carvalho LS, 2011, HUM MOL GENET, V20, P3161, DOI 10.1093/hmg/ddr218
   Chan B, 2018, Skin Therapy Lett, V23, P4
   Chandler RJ, 2015, J CLIN INVEST, V125, P870, DOI 10.1172/JCI79213
   Chapin J., 2017, RES PRACT THROMB HAE, V2017, P144
   Charleston JS, 2018, NEUROLOGY, V90, pE2146, DOI 10.1212/WNL.0000000000005680
   Chien YH, 2017, LANCET CHILD ADOLESC, V1, P265, DOI 10.1016/S2352-4642(17)30125-6
   Childers MK, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007523
   Chowdary P.S.S., 2020, RES PRACT THROMB HAE, V4
   Christine CW, 2009, NEUROLOGY, V73, P1662, DOI 10.1212/WNL.0b013e3181c29356
   Christine CW, 2019, ANN NEUROL, V85, P704, DOI 10.1002/ana.25450
   Cideciyan AV, 2018, P NATL ACAD SCI USA, V115, pE8547, DOI 10.1073/pnas.1805055115
   Cideciyan AV, 2010, PROG RETIN EYE RES, V29, P398, DOI 10.1016/j.preteyeres.2010.04.002
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Corti M, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.33
   Corti M, 2017, HUM GENE THER CL DEV, V28, P208, DOI 10.1089/humc.2017.146
   Corti M, 2015, MUSCLE NERVE, V51, P877, DOI 10.1002/mus.24444
   Croteau SE, 2015, HAEMOPHILIA, V21, P285, DOI 10.1111/hae.12683
   Crudele JM, 2015, BLOOD, V125, P1553, DOI 10.1182/blood-2014-07-588194
   Cukras C, 2018, MOL THER, V26, P2282, DOI 10.1016/j.ymthe.2018.05.025
   Dahl M, 2015, MOL THER, V23, P835, DOI 10.1038/mt.2015.16
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Davis JL, 2019, RETINA-J RET VIT DIS, V39, P2, DOI 10.1097/IAE.0000000000002609
   de Smet MD, 2018, INVEST OPHTH VIS SCI, V59, P311, DOI 10.1167/iovs.17-22233
   den Uijl IEM, 2011, HAEMOPHILIA, V17, P41, DOI 10.1111/j.1365-2516.2010.02383.x
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Doerfler PA, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2015.53
   Dominguez E, 2011, HUM MOL GENET, V20, P681, DOI 10.1093/hmg/ddq514
   Du LM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3773
   Duan DS, 2018, MOL THER, V26, P2337, DOI 10.1016/j.ymthe.2018.07.011
   Dunbar C, 1996, HUM GENE THER, V7, P231, DOI 10.1089/hum.1996.7.2-231
   Dunbar CE, 1998, HUM GENE THER, V9, P2629, DOI 10.1089/hum.1998.9.17-2629
   Duque S, 2009, MOL THER, V17, P1187, DOI 10.1038/mt.2009.71
   Dyka FM, 2014, HUM GENE THER METHOD, V25, P166, DOI 10.1089/hgtb.2013.212
   Eberling JL, 2008, NEUROLOGY, V70, P1980, DOI 10.1212/01.wnl.0000312381.29287.ff
   Echaniz-Laguna A, 2020, NEUROGENETICS, V21, P29, DOI 10.1007/s10048-019-00596-z
   Elverman M, 2017, MUSCLE NERVE, V56, P943, DOI 10.1002/mus.25658
   ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0
   Everett LA, 2014, BLOOD, V123, P3697, DOI 10.1182/blood-2014-02-554501
   Faust SM, 2013, J CLIN INVEST, V123, P2994, DOI 10.1172/JCI68205
   Feldkotter M, 2002, AM J HUM GENET, V70, P358, DOI 10.1086/338627
   Feldman AG, 2020, J PEDIATR-US, V225, P252, DOI 10.1016/j.jpeds.2020.05.044
   Felis A, 2020, KIDNEY INT REP, V5, P407, DOI 10.1016/j.ekir.2019.11.013
   Feuer WJ, 2016, OPHTHALMOLOGY, V123, P558, DOI 10.1016/j.ophtha.2015.10.025
   FINK JK, 1990, P NATL ACAD SCI USA, V87, P2334, DOI 10.1073/pnas.87.6.2334
   Finkel RS, 2014, NEUROLOGY, V83, P810, DOI 10.1212/WNL.0000000000000741
   Finn JD, 2012, BLOOD, V120, P4521, DOI 10.1182/blood-2012-06-440123
   Finn JD, 2010, BLOOD, V116, P5842, DOI 10.1182/blood-2010-06-288001
   Fischer MD, 2020, JAMA OPHTHALMOL, V138, P643, DOI 10.1001/jamaophthalmol.2020.1032
   Fischer MD, 2019, JAMA OPHTHALMOL, V137, P1247, DOI 10.1001/jamaophthalmol.2019.3278
   Fischer MD, 2020, RETINA-J RET VIT DIS, V40, P160, DOI 10.1097/IAE.0000000000002360
   FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0
   Follenzi A, 2008, J CLIN INVEST, V118, P935, DOI 10.1172/JCI32748
   Foust KD, 2010, NAT BIOTECHNOL, V28, P271, DOI 10.1038/nbt.1610
   Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515
   Freeline Therapeutics, 2020, FREELINE RECEIVES OR
   Freeman AJ, 2001, HEPATOLOGY, V34, P809, DOI 10.1053/jhep.2001.27831
   Garafalo AV, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2019.100827
   George L, 2020, RES PRACT THROMB HAE, V4
   George LA, 2017, NEW ENGL J MED, V377, P2215, DOI 10.1056/NEJMoa1708538
   George LA, 2020, MOL THER, V28, P2073, DOI 10.1016/j.ymthe.2020.06.001
   George LA, 2019, BLOOD, V134, DOI 10.1182/blood-2019-124091
   George LA, 2017, HEMATOL-AM SOC HEMAT, P587, DOI 10.1182/asheducation-2017.1.587
   Goodgame B, 2003, AM J GASTROENTEROL, V98, P2535, DOI [10.1016/S0002-9270(03)00663-4, 10.1111/j.1572-0241.2003.07678.x]
   Gouw SC, 2013, NEW ENGL J MED, V368, P231, DOI 10.1056/NEJMoa1208024
   Gray SJ, 2013, GENE THER, V20, P450, DOI 10.1038/gt.2012.101
   Gray SJ, 2011, MOL THER, V19, P1058, DOI 10.1038/mt.2011.72
   Greene TK, 2010, BLOOD, V116, P6114, DOI 10.1182/blood-2010-06-293308
   Guy J, 2017, OPHTHALMOLOGY, V124, P1621, DOI 10.1016/j.ophtha.2017.05.016
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hay CRM, 2011, BLOOD, V117, P6367, DOI 10.1182/blood-2010-09-308668
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hordeaux J, 2020, HUM GENE THER, V31, P808, DOI 10.1089/hum.2020.167
   Huang J, 2017, MOL THER-METH CLIN D, V5, P241, DOI 10.1016/j.omtm.2017.05.003
   Hwu WL, 2018, JIMD REP, V40, P1, DOI 10.1007/8904_2017_54
   Hwu WL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003640
   Iorio A, 2019, ANN INTERN MED, V171, P540, DOI 10.7326/M19-1208
   Jacobson SG, 2013, HUM MOL GENET, V22, P168, DOI 10.1093/hmg/dds421
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Janson C, 2002, HUM GENE THER, V13, P1391, DOI 10.1089/104303402760128612
   Joubert R, 2013, HUM MOL GENET, V22, P1856, DOI 10.1093/hmg/ddt038
   Kansara V, 2020, J OCUL PHARMACOL TH, V36, P384, DOI 10.1089/jop.2019.0126
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9
   Kay CN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062097
   Kim YC, 2014, INVEST OPHTH VIS SCI, V55, P7387, DOI 10.1167/iovs.14-14651
   Kitchen S, 2016, HAEMOPHILIA, V22, P806, DOI 10.1111/hae.12962
   KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6
   Kojima K, 2019, BRAIN, V142, P322, DOI 10.1093/brain/awy331
   KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801, DOI 10.1523/JNEUROSCI.10-12-03801.1990
   Komaromy AM, 2010, HUM MOL GENET, V19, P2581, DOI 10.1093/hmg/ddq136
   Konkle BA, 2019, BLOOD, V134, DOI 10.1182/blood-2019-122143
   KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3
   Kotterman MA, 2015, GENE THER, V22, P116, DOI 10.1038/gt.2014.115
   KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461
   Kyrle PA, 2000, NEW ENGL J MED, V343, P457, DOI 10.1056/NEJM200008173430702
   Lange AM, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.64
   Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175
   Le Meur G, 2018, MOL THER, V26, P256, DOI 10.1016/j.ymthe.2017.09.014
   LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3
   Lenders M, 2016, J AM SOC NEPHROL, V27, P256, DOI 10.1681/ASN.2014121226
   Leone P, 2000, ANN NEUROL, V48, P27, DOI 10.1002/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6
   Leone P, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003454
   LeWitt PA, 2011, LANCET NEUROL, V10, P309, DOI 10.1016/S1474-4422(11)70039-4
   Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576-019-0205-4
   Li QH, 2008, MOL VIS, V14, P1760
   LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x
   Lipinski DM, 2014, HUM GENE THER, V25, P50, DOI 10.1089/hum.2013.009
   Liu Q, 2007, MOL CELL PROTEOMICS, V6, P1299, DOI 10.1074/mcp.M700054-MCP200
   Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307
   Lowes LP, 2019, PEDIATR NEUROL, V98, P39, DOI 10.1016/j.pediatrneurol.2019.05.005
   Lu M, 2016, CLIN GASTROENTEROL H, V14, P1044, DOI 10.1016/j.cgh.2016.01.009
   LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701
   Mack DL, 2017, MOL THER, V25, P839, DOI 10.1016/j.ymthe.2017.02.004
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Madeira CL, 2009, BLOOD, V113, P5364, DOI 10.1182/blood-2009-02-206979
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017
   Majowicz A, 2020, HAEMOPHILIA, V26, P20
   Majowicz A, 2019, MOL THER-METH CLIN D, V14, P27, DOI 10.1016/j.omtm.2019.05.009
   Manco-Johnson MJ, 2007, NEW ENGL J MED, V357, P535, DOI 10.1056/NEJMoa067659
   Manco-Johnson MJ, 2017, BLOOD, V129, P2368, DOI 10.1182/blood-2016-02-683169
   Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307
   Mazepa MA, 2016, BLOOD, V127, P3073, DOI 10.1182/blood-2015-10-675140
   McIntosh J, 2013, BLOOD, V121, P3335, DOI 10.1182/blood-2012-10-462200
   Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249
   Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198
   Mendell JR, 2020, JAMA NEUROL, V77, P1122, DOI 10.1001/jamaneurol.2020.1484
   Mendell JR, 2013, ANN NEUROL, V74, P637, DOI 10.1002/ana.23982
   Mendell JR, 2012, ANN NEUROL, V71, P304, DOI 10.1002/ana.23528
   Michalakis S, 2010, MOL THER, V18, P2057, DOI 10.1038/mt.2010.149
   Miesbach W, 2019, BLOOD, V134, DOI 10.1182/blood-2019-122535
   Miesbach W, 2018, BLOOD, V131, P1022, DOI 10.1182/blood-2017-09-804419
   Mingozzi F, 2007, BLOOD, V110, P2334, DOI 10.1182/blood-2007-03-080093
   Mingozzi F, 2007, NAT MED, V13, P419, DOI 10.1038/nm1549
   Mingozzi F, 2012, MOL THER, V20, P1410, DOI 10.1038/mt.2012.84
   Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177
   Muramatsu S, 2010, MOL THER, V18, P1731, DOI 10.1038/mt.2010.135
   Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179
   Nathwani AC, 2014, NEW ENGL J MED, V371, P1994, DOI 10.1056/NEJMoa1407309
   Nathwani AC, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-118256
   Nathwani AC, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-118334
   Nathwani AC, 2014, HUM GENE THER, V25, P923, DOI 10.1089/hum.2014.2540
   Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046
   Nathwani AC, 2011, MOL THER, V19, P876, DOI 10.1038/mt.2010.274
   Nault JC, 2015, NAT GENET, V47, P1187, DOI 10.1038/ng.3389
   Nelvagal HR, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165570
   Nguyen GN, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126007
   Nicholls K, 2012, JIMD REP, V5, P109, DOI 10.1007/8904_2011_106
   Niederkorn JY, 2002, CRIT REV IMMUNOL, V22, P13
   Niemeyer GP, 2009, BLOOD, V113, P797, DOI 10.1182/blood-2008-10-181479
   Niethammer M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau0713
   Niethammer M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90133
   Ofri R, 2018, HUM GENE THER, V29, P1376, DOI 10.1089/hum.2018.076
   Ohashi T, 2019, J HUM GENET, V64, P139, DOI 10.1038/s10038-018-0537-5
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   Pang JJ, 2006, MOL VIS, V12, P756
   Parenti G, 2015, ANNU REV MED, V66, P471, DOI 10.1146/annurev-med-122313-085916
   Pasi KJ, 2017, NEW ENGL J MED, V377, P819, DOI [10.1056/NEJMoa1616569, 10.1056/NEJMoa1708483]
   Pasi KJ, 2020, NEW ENGL J MED, V382, P29, DOI 10.1056/NEJMoa1908490
   Patel SR, 2011, PHARM RES-DORDR, V28, P166, DOI 10.1007/s11095-010-0271-y
   Peyvandi F, 2016, LANCET, V388, P187, DOI 10.1016/S0140-6736(15)01123-X
   Pierce EA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017285
   Pipe S, 2019, BLOOD, V134, DOI 10.1182/blood-2019-125764
   PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214
   PITTMAN DD, 1993, BLOOD, V81, P2925
   Platt FM, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0025-4
   Poothong J, 2020, BLOOD, V135, P1899, DOI 10.1182/blood.2019002867
   Raben Nina, 2002, Current Molecular Medicine (Hilversum), V2, P145, DOI 10.2174/1566524024605789
   Rafii MS, 2018, JAMA NEUROL, V75, P834, DOI 10.1001/jamaneurol.2018.0233
   Rafii MS, 2014, ALZHEIMERS DEMENT, V10, P571, DOI 10.1016/j.jalz.2013.09.004
   Ragni MV, 2019, HAEMOPHILIA, V25, P581, DOI 10.1111/hae.13717
   Raikwar SP, 2018, J ALZHEIMERS DIS, V65, P321, DOI 10.3233/JAD-180422
   Ramachandran PS, 2017, HUM GENE THER, V28, P154, DOI 10.1089/hum.2016.111
   Recht M, 2009, HAEMOPHILIA, V15, P869, DOI 10.1111/j.1365-2516.2009.02027.x
   Richardson RM, 2011, NEUROSURGERY, V69, P154, DOI 10.1227/NEU.0b013e318217217e
   Rietveld IM, 2019, J THROMB HAEMOST, V17, P99, DOI 10.1111/jth.14343
   Robinson M, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-119616
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Samaranch L, 2012, HUM GENE THER, V23, P382, DOI 10.1089/hum.2011.200
   Samelson-Jones BJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128683
   Samelson-Jones BJ, 2019, MOL THER-METH CLIN D, V12, P184, DOI 10.1016/j.omtm.2018.12.007
   San Sebastian W, 2012, HUM GENE THER, V23, P210, DOI 10.1089/hum.2011.162
   Sandberg H, 2001, THROMB HAEMOSTASIS, V85, P93
   Sands MS, 2006, MOL THER, V13, P839, DOI 10.1016/j.ymthe.2006.01.006
   Sangamo Therapeutics, 2019, SANGAMO ANNOUNCES FD
   Schrijvers LH, 2016, BRIT J HAEMATOL, V174, P454, DOI 10.1111/bjh.14072
   Schulz A, 2013, BBA-MOL BASIS DIS, V1832, P1801, DOI 10.1016/j.bbadis.2013.04.008
   Shahani T, 2014, J THROMB HAEMOST, V12, P36, DOI 10.1111/jth.12412
   Shi QZ, 2006, J CLIN INVEST, V116, P1974, DOI 10.1172/JCI28416
   Simioni P, 2009, NEW ENGL J MED, V361, P1671, DOI 10.1056/NEJMoa0904377
   Smith BK, 2013, HUM GENE THER, V24, P630, DOI 10.1089/hum.2012.250
   Song CJ, 2020, HUM GENE THER, V31, P743, DOI 10.1089/hum.2019.337
   Stein-Streilein Joan, 2002, Int Rev Immunol, V21, P123, DOI 10.1080/08830180212066
   Stern Gerald, 2014, Parkinsonism Relat Disord, V20 Suppl 1, pS143, DOI 10.1016/S1353-8020(13)70034-8
   Su XM, 2010, MOL THER, V18, P1490, DOI 10.1038/mt.2010.114
   Sugarman EA, 2012, EUR J HUM GENET, V20, P27, DOI 10.1038/ejhg.2011.134
   Tardieu M, 2017, LANCET NEUROL, V16, P712, DOI 10.1016/S1474-4422(17)30169-2
   Tardieu M, 2014, HUM GENE THER, V25, P506, DOI 10.1089/hum.2013.238
   Thalappillil A, 2019, HAEMOPHILIA, V25, P221, DOI 10.1111/hae.13668
   Thalji NK, 2016, NAT MED, V22, P924, DOI 10.1038/nm.4149
   Todd AG, 2015, ANN NEUROL, V78, P222, DOI 10.1002/ana.24433
   Trapani I, 2014, EMBO MOL MED, V6, P194, DOI 10.1002/emmm.201302948
   van der Meijden JC, 2018, J INHERIT METAB DIS, V41, P1205, DOI 10.1007/s10545-018-0166-3
   Vasconcelos HM, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00216-1
   Verhaart IEC, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0671-8
   Vignal C, 2018, OPHTHALMOLOGY, V125, P945, DOI 10.1016/j.ophtha.2017.12.036
   von Jonquieres G, 2018, ACTA NEUROPATHOL, V135, P95, DOI 10.1007/s00401-017-1784-9
   Waldrop MA, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-0729
   Wang JB, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1121
   Wang LL, 2015, MOL THER, V23, P1877, DOI 10.1038/mt.2015.179
   Worgall S, 2008, HUM GENE THER, V19, P463, DOI 10.1089/hum.2008.022
   XARELTO, 2019, HIGHL PRESCR INF
   Xi M, 2013, J THROMB HAEMOST, V11, P1655, DOI 10.1111/jth.12335
   Xue K, 2017, EYE, V31, P1308, DOI 10.1038/eye.2017.158
   Ye GJ, 2016, HUM GENE THER CL DEV, V27, P37, DOI 10.1089/humc.2015.164
   Ye GJ, 2015, HUM GENE THER CL DEV, V26, P165, DOI 10.1089/humc.2015.076
   Yin L, 2011, INVEST OPHTH VIS SCI, V52, P2775, DOI 10.1167/iovs.10-6250
   Yiu G, 2020, MOL THER-METH CLIN D, V16, P179, DOI 10.1016/j.omtm.2020.01.002
   Zolotukhin I, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.63
   Zou CH, 2020, MOL THER-METH CLIN D, V18, P189, DOI 10.1016/j.omtm.2020.05.033
NR 259
TC 144
Z9 146
U1 64
U2 118
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD FEB 3
PY 2021
VL 29
IS 2
BP 464
EP 488
DI 10.1016/j.ymthe.2020.12.007
PG 25
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA RB3VL
UT WOS:000632042300013
PM 33309881
OA Green Published, hybrid
HC Y
HP Y
DA 2022-11-30
ER

PT J
AU Lee, SHS
   Chang, H
   Kim, HJ
   Choi, JS
   Kim, J
   Kim, JH
   Woo, HN
   Nah, SK
   Jung, SJ
   Lee, JY
   Park, K
   Park, TK
   Lee, H
AF Lee, Steven Hyun Seung
   Chang, HeeSoon
   Kim, Hee Jong
   Choi, Jun-Sub
   Kim, Jin
   Kim, Ji Hyun
   Woo, Ha-Na
   Nah, Seung Kwan
   Jung, Sang Joon
   Lee, Joo Yong
   Park, Keerang
   Park, Tae Kwann
   Lee, Heuiran
TI Effects of Stuffer DNA on the Suppression of Choroidal
   Neovascularization by a rAAV Expressing a mTOR-Inhibiting shRNA
SO MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; GENE-THERAPY; LASER
   PHOTOCOAGULATION; PACKAGING CAPACITY; TRANSDUCTION; GROWTH;
   IMMUNOGENICITY; PROTEINS; VECTORS
AB Choroidal neovascularization (CNV) is the defining characteristic of the wet subtype of age-related macular degeneration (AMD), which is a rapidly growing global health problem. Previously, we had demonstrated the therapeutic potential of gene therapy against CNV using short hairpin RNA (shRNA) delivered via recombinant adeno-associated virus (rAAV), which abrogates mammalian-to-mechanistic (mTOR) activity in a novel manner by simultaneously inhibiting both mTOR complexes. Both the target and use of gene therapy represent a novel treatment modality against AMD. Here, the xenogeneic GFP gene used as a reporter in previous studies was removed from the virus vector to further develop the therapeutic for clinical trials. Instead, a stuffer DNA derived from the 3' UTR of the human UBE3A gene was used to ensure optimal viral genome size for efficient rAAV assembly. The virus vector containing the stuffer DNA, rAAV2-shmTOR-SD, positively compares to one encoding the shRNA and a GFP expression cassette in terms of reducing CNV in a laser-induced mouse model, as determined by fundus fluorescein angiography. These results were confirmed via immunohistochemistry using anti-CD31, while a TUNEL assay showed that rAAV2-shmTOR-SD possesses anti-apoptotic properties as well. The qualities exhibited by rAAV2-shmTOR-SD demonstrate its potential as a human gene therapeutic for the treatment of wet AMD.
C1 [Lee, Steven Hyun Seung; Kim, Ji Hyun; Woo, Ha-Na; Lee, Heuiran] Univ Ulsan, Coll Med, Dept Microbiol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Lee, Steven Hyun Seung; Kim, Ji Hyun; Woo, Ha-Na; Lee, Joo Yong; Lee, Heuiran] Univ Ulsan, Coll Med, Biomed Inst Technol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Chang, HeeSoon; Kim, Hee Jong; Choi, Jun-Sub; Kim, Jin] CuroGene Life Sci Co Ltd, Cheongju 28578, South Korea.
   [Nah, Seung Kwan; Jung, Sang Joon; Park, Tae Kwann] Soonchunhyang Univ, Dept Ophthalmol, Hosp Bucheon, 170 Jomaru Ro, Bucheon 14584, South Korea.
   [Lee, Joo Yong] Univ Ulsan, Coll Med, Dept Ophthalmol, Seoul 05505, South Korea.
   [Lee, Joo Yong] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul 05505, South Korea.
   [Park, Keerang] Chungbuk Hlth & Sci Univ, Dept Biopharm, Cheongju 28150, South Korea.
   [Park, Tae Kwann] Soonchunhyang Univ, Coll Med, Dept Ophthalmol, Cheonan 31151, South Korea.
C3 University of Ulsan; University of Ulsan; Soonchunhyang University;
   University of Ulsan; University of Ulsan; Soonchunhyang University
RP Lee, H (通讯作者)，Univ Ulsan, Coll Med, Dept Microbiol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.; Lee, H (通讯作者)，Univ Ulsan, Coll Med, Biomed Inst Technol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.; Park, TK (通讯作者)，Soonchunhyang Univ, Dept Ophthalmol, Hosp Bucheon, 170 Jomaru Ro, Bucheon 14584, South Korea.
EM tkpark@schmc.ac.kr; heuiran@amc.seoul.kr
OI Woo, Ha-Na/0000-0002-6771-8151
FU CuroGene Life Sciences Co., Ltd.; Basic Science Research Program through
   the National Research Foundation of Korea [NRF-2017R1A2B4012769]; Asan
   Institute for Life Sciences, Asan Medical Center [2019-287]; Korea
   Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI17C0966]
FX This work was supported by CuroGene Life Sciences Co., Ltd. and by
   grants from the Basic Science Research Program through the National
   Research Foundation of Korea (NRF-2017R1A2B4012769, 2017, to H.L.); the
   Asan Institute for Life Sciences, Asan Medical Center (2019-287 to
   H.L.); and the Korea Health Technology R&D Project through the Korea
   Health Industry Development Institute (KHIDI), funded by the Ministry of
   Health & Welfare (grant HI17C0966 to T.K.P.), Republic of Korea. For her
   proofreading and editing, we would also like to thank Paula Khim.
CR Ahn J, 2012, CELL MOL LIFE SCI, V69, P3147, DOI 10.1007/s00018-012-0998-1
   Ameri H, 2018, J CURR OPHTHALMOL, V30, P1, DOI 10.1016/j.joco.2018.01.006
   Ansari AM, 2016, STEM CELL REV REP, V12, P553, DOI 10.1007/s12015-016-9670-8
   Baens M, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000054
   Center for Biologics Evaluation and Research, 2013, FDA2012D1038 CTR BIO
   Center for Biologics Evaluation and Research, 2018, FDA2018D2236 CTR BIO
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   Dejneka NS, 2004, MOL VIS, V10, P964
   Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101
   Gambotto A, 2000, GENE THER, V7, P2036, DOI 10.1038/sj.gt.3301335
   Ganini D, 2017, REDOX BIOL, V12, P462, DOI 10.1016/j.redox.2017.03.002
   Grieger JC, 2012, METHOD ENZYMOL, V507, P229, DOI 10.1016/B978-0-12-386509-0.00012-0
   Grimm D, 2005, METHOD ENZYMOL, V392, P381, DOI 10.1016/S0076-6879(04)92023-X
   Han JW, 2015, INVEST OPHTH VIS SCI, V56, P8314, DOI 10.1167/iovs.15-18359
   Koike M, 2013, FEBS OPEN BIO, V3, P46, DOI 10.1016/j.fob.2012.12.001
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee HS, 2009, BIOCHEM BIOPH RES CO, V384, P431, DOI 10.1016/j.bbrc.2009.04.143
   Lee SH, 2015, HUM GENE THER METHOD, V26, P159, DOI 10.1089/hgtb.2015.102
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088203
   Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954
   Nakahara T, 2017, BIOL PHARM BULL, V40, P2045, DOI 10.1248/bpb.b17-00475
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Park K, 2008, FRONT BIOSCI-LANDMRK, V13, P2653, DOI 10.2741/2872
   Park TK, 2017, MOL THER-NUCL ACIDS, V8, P26, DOI 10.1016/j.omtn.2017.05.012
   Parks RJ, 1999, J VIROL, V73, P8027, DOI 10.1128/JVI.73.10.8027-8034.1999
   Rosenzweig M, 2001, BLOOD, V97, P1951, DOI 10.1182/blood.V97.7.1951
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Stewart MW, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010021
   Strobel B, 2015, AM J RESP CELL MOL, V53, P291, DOI 10.1165/rcmb.2014-0338MA
   Taghizadeh RR, 2008, J BIOMED BIOTECHNOL, DOI 10.1155/2008/453590
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806
   Wu JQ, 2007, HUM GENE THER, V18, P171, DOI 10.1089/hum.2006.088
NR 39
TC 6
Z9 6
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2329-0501
J9 MOL THER-METH CLIN D
JI Mol.Ther.-Methods Clin. Dev.
PD SEP 13
PY 2019
VL 14
BP 171
EP 179
DI 10.1016/j.omtm.2019.06.004
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IX6AR
UT WOS:000485765700016
PM 31380463
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Szatmari-Toth, M
   Ilmarinen, T
   Mikhailova, A
   Skottman, H
   Kauppinen, A
   Kaarniranta, K
   Kristof, E
   Lytvynchuk, L
   Vereb, Z
   Fesus, L
   Petrovski, G
AF Szatmari-Toth, Maria
   Ilmarinen, Tanja
   Mikhailova, Alexandra
   Skottman, Heli
   Kauppinen, Anu
   Kaarniranta, Kai
   Kristof, Endre
   Lytvynchuk, Lyubomyr
   Vereb, Zoltan
   Fesus, Laszlo
   Petrovski, Goran
TI Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium-Role in
   Dead Cell Clearance and Inflammation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; anoikis; autophagy; hESC-RPE;
   inflammation; macrophages; phagocytosis; triamcinolone
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; EAT-ME SIGNALS; APOPTOTIC CELLS;
   OXIDATIVE STRESS; MACULAR DEGENERATION; MOLECULAR-MECHANISMS; IN-VITRO;
   FIND-ME; AUTOPHAGY; PHOSPHATIDYLSERINE
AB Inefficient removal of dying retinal pigment epithelial (RPE) cells by professional phagocytes can result in debris formation and development of age-related macular degeneration (AMD). Chronic oxidative stress and inflammation play an important role in AMD pathogenesis. Only a few well-established in vitro phagocytosis assay models exist. We propose human embryonic stem cell-derived-RPE cells as a new model for studying RPE cell removal by professional phagocytes. The characteristics of human embryonic stem cells-derived RPE (hESC-RPE) are similar to native RPEs based on their gene and protein expression profile, integrity, and barrier properties or regarding drug transport. However, no data exist about RPE death modalities and how efficiently dying hESC-RPEs are taken upby macrophages, and whether this process triggers an inflammatory responses. This study demonstrates hESC-RPEs can be induced to undergo anoikis or autophagy-associated cell death due to extracellular matrix detachment or serum deprivation and hydrogen-peroxide co-treatment, respectively, similar to primary human RPEs. Dying hESC-RPEs are efficiently engulfed by macrophages which results in high amounts of IL-6 and IL-8 cytokine release. These findings suggest that the clearance of anoikic and autophagy-associated dying hESC-RPEs can be used as a new model for investigating AMD pathogenesis or for testing the in vivo potential of these cells in stem cell therapy.
C1 [Szatmari-Toth, Maria; Kristof, Endre; Fesus, Laszlo; Petrovski, Goran] Univ Debrecen, Fac Med, Dept Biochem & Mol Biol, H-4032 Debrecen, Hungary.
   [Ilmarinen, Tanja; Mikhailova, Alexandra; Skottman, Heli] Tampere Univ, Fac Med & Hlth Technol, Tampere 33014, Finland.
   [Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
   [Lytvynchuk, Lyubomyr] Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg GmbH, Eye Clin, Dept Ophthalmol, Campus Giessen, D-35390 Giessen, Germany.
   [Vereb, Zoltan; Petrovski, Goran] Univ Szeged, Fac Med, Dept Ophthalmol, H-6720 Szeged, Hungary.
   [Petrovski, Goran] Oslo Univ Hosp, Dept Ophthalmol, Ctr Eye Res, Kirkeveien 166, N-0450 Oslo, Norway.
   [Petrovski, Goran] Univ Oslo, Kirkeveien 166, N-0450 Oslo, Norway.
C3 University of Debrecen; Tampere University; University of Eastern
   Finland; University of Eastern Finland; Kuopio University Hospital;
   University of Eastern Finland; Justus Liebig University Giessen;
   University Hospital of Giessen & Marburg; Szeged University; University
   of Oslo; University of Oslo
RP Petrovski, G (通讯作者)，Univ Debrecen, Fac Med, Dept Biochem & Mol Biol, H-4032 Debrecen, Hungary.; Petrovski, G (通讯作者)，Univ Szeged, Fac Med, Dept Ophthalmol, H-6720 Szeged, Hungary.; Petrovski, G (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Ctr Eye Res, Kirkeveien 166, N-0450 Oslo, Norway.; Petrovski, G (通讯作者)，Univ Oslo, Kirkeveien 166, N-0450 Oslo, Norway.
EM szatmari-toth.maria@med.unideb.hu; tanja.ilmarinen@tuni.fi;
   alex.mikhailova@gmail.com; heli.skottman@tuni.fi; anu.kauppinen@uef.fi;
   kai.kaarniranta@kuh.fi; kristof.endre@med.unideb.hu;
   Lyubomyr.Lytvynchuk@augen.med.uni-giessen.de;
   vereb.zoltan@med.u-szeged.hu; fesus@med.unideb.hu;
   goran.petrovski@medisin.uio.no
RI Vereb, Zoltan/AAR-4092-2020; Kristóf, Endre/AGB-5046-2022
OI Kristóf, Endre/0000-0002-2215-6984; Ilmarinen,
   Tanja/0000-0002-4609-8897; Szatmari-Toth, Maria/0000-0003-3028-5097;
   Vereb, Zoltan/0000-0002-9518-2155; Mikhailova,
   Alexandra/0000-0003-2598-8353; Kaarniranta, Kai/0000-0003-2600-8679;
   Skottman, Heli/0000-0002-4127-8792
FU European Union [GINOP-2.3.2-15-2016-00006]; European Regional
   Development Fund; Center for Eye Research (CER), Department of
   Ophthalmology, Oslo University Hospital; University of Oslo; Norwegian
   Association of the Blind and Partially Sighted and Blindemissionen IL,
   Norway; Finnish Cultural Foundation; Alfred Kordelin Foundation; Academy
   of Finland [218050, 133879, 297267]; Janos Bolyai Fellowship of the
   Hungarian Academy of Sciences; New National Excellence Program of the
   Ministry of Human Capacities in Hungary [UNKP-18-4]
FX This research was co-financed by the GINOP-2.3.2-15-2016-00006 project
   co-financed by the European Union and the European Regional Development
   Fund. Furthermore, the project was funded through the Center for Eye
   Research (CER), Department of Ophthalmology, Oslo University Hospital
   and University of Oslo (funds obtained from the Norwegian Association of
   the Blind and Partially Sighted and Blindemissionen IL, Norway), and the
   Finnish Cultural Foundation, as well as the Alfred Kordelin Foundation.
   Skottman H., Ilmarinen T. and Kauppinen A. receive funding from the
   Academy of Finland (grant numbers: 218050, 133879 and 297267,
   respectively). Kristof E. was supported by the Janos Bolyai Fellowship
   of the Hungarian Academy of Sciences and the UNKP-18-4 New National
   Excellence Program of the Ministry of Human Capacities in Hungary.
CR Abouzeid H, 2006, ACTA OPHTHALMOL SCAN, V84, P597, DOI 10.1111/j.1600-0420.2006.00676.x
   Albert R, 2015, BBA-GEN SUBJECTS, V1850, P435, DOI 10.1016/j.bbagen.2014.10.026
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Baudhuin P, 1966, Brux Med, V46, P1059
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bursch W, 2000, J CELL SCI, V113, P1189
   Byrne A, 2002, J IMMUNOL, V168, P1968, DOI 10.4049/jimmunol.168.4.1968
   Chang YC, 2015, TOXICOL IN VITRO, V29, P1358, DOI 10.1016/j.tiv.2015.05.014
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Coyle CH, 2006, FREE RADICAL BIO MED, V40, P2206, DOI 10.1016/j.freeradbiomed.2006.02.017
   Dang YL, 2015, CLIN INTERV AGING, V10, P255, DOI 10.2147/CIA.S73705
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Elliott MR, 2010, J CELL BIOL, V189, P1059, DOI 10.1083/jcb.201004096
   Emoto Kazuo, 2002, Subcell Biochem, V36, P61
   Erwig LP, 2008, CELL DEATH DIFFER, V15, P243, DOI 10.1038/sj.cdd.4402184
   Fadeel B, 2010, BIOCHEM BIOPH RES CO, V396, P7, DOI 10.1016/j.bbrc.2010.02.106
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847
   Fernandez-Boyanapalli R, 2010, J IMMUNOL, V185, P4030, DOI 10.4049/jimmunol.1001778
   Fernandez-Fernandez L, 2008, THROMB HAEMOSTASIS, V100, P604, DOI 10.1160/TH08-04-0253
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365-2567.2004.01959.x
   Ha JH, 2012, CELL BIOL TOXICOL, V28, P19, DOI 10.1007/s10565-011-9202-x
   Hamidi T, 2013, AUTOPHAGY, V9, P95, DOI 10.4161/auto.22258
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Juuti-Uusitalo K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030089
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kay JG, 2013, ADV EXP MED BIOL, V991, P177, DOI 10.1007/978-94-007-6331-9_10
   Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152
   Kim Y, 2013, AUTOPHAGY, V9, P2126, DOI 10.4161/auto.26308
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Krysko DV, 2006, APOPTOSIS, V11, P1709, DOI 10.1007/s10495-006-9527-8
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0
   Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levonen AL, 2014, FREE RADICAL BIO MED, V71, P196, DOI 10.1016/j.freeradbiomed.2014.03.025
   Li W, 2012, J CELL PHYSIOL, V227, P1291, DOI 10.1002/jcp.22815
   Li Y, 2014, CAN J PHYSIOL PHARM, V92, P765, DOI 10.1139/cjpp-2014-0018
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Majai G, 2006, IMMUNOL LETT, V104, P94, DOI 10.1016/j.imlet.2005.11.016
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Medina CB, 2016, CELL DEATH DIFFER, V23, P979, DOI 10.1038/cdd.2016.13
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Moore MN, 2006, MAR ENVIRON RES, V62, pS420, DOI 10.1016/j.marenvres.2006.04.055
   Morescalchi F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/269787
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Onnela N, 2012, MED BIOL ENG COMPUT, V50, P107, DOI 10.1007/s11517-011-0850-z
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Petrovski G, 2007, CELL DEATH DIFFER, V14, P1117, DOI 10.1038/sj.cdd.4402112
   Petrovski G, 2007, AUTOPHAGY, V3, P509
   Petrovski G, 2011, AUTOPHAGY, V7, P321, DOI 10.4161/auto.7.3.14583
   Petrovski G, 2011, ACTA OPHTHALMOL, V89, pE30, DOI 10.1111/j.1755-3768.2010.02047.x
   Poon IKH, 2010, CELL DEATH DIFFER, V17, P381, DOI 10.1038/cdd.2009.195
   Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607
   Ravichandran KS, 2010, J EXP MED, V207, P1807, DOI 10.1084/jem.20101157
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rose RC, 1998, P SOC EXP BIOL MED, V217, P397, DOI 10.3181/00379727-217-44250
   Rothlin CV, 2015, ANNU REV IMMUNOL, V33, P355, DOI 10.1146/annurev-immunol-032414-112103
   Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957
   Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722
   Savolainen V, 2011, ANN BIOMED ENG, V39, P3055, DOI 10.1007/s10439-011-0387-1
   Scandalios JG, 2005, BRAZ J MED BIOL RES, V38, P995, DOI 10.1590/S0100-879X2005000700003
   Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Segawa K, 2015, TRENDS CELL BIOL, V25, P639, DOI 10.1016/j.tcb.2015.08.003
   Sgonc R, 1998, EXP GERONTOL, V33, P525, DOI 10.1016/S0531-5565(98)00031-X
   Skottman H, 2010, IN VITRO CELL DEV-AN, V46, P206, DOI 10.1007/s11626-010-9286-2
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Stern J, 2015, EXP BIOL MED, V240, P1079, DOI 10.1177/1535370215587530
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Vaajasaari H, 2011, MOL VIS, V17, P558
   van der Meer JHM, 2014, BLOOD, V123, P2460, DOI 10.1182/blood-2013-09-528752
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Winkler B S, 1999, Mol Vis, V5, P32
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Yao X, 2018, BIOCHEM BIOPH RES CO, V495, P1240, DOI 10.1016/j.bbrc.2017.11.126
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021
   Zhou Ru, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-3
NR 112
TC 10
Z9 10
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB 2
PY 2019
VL 20
IS 4
AR 926
DI 10.3390/ijms20040926
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HO3FO
UT WOS:000460805400134
PM 30791639
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Chen, C
   Guo, DN
   Lu, GH
AF Chen, Chen
   Guo, Danni
   Lu, Guohua
TI Wogonin protects human retinal pigment epithelium cells from LPS-induced
   barrier dysfunction and inflammatory responses by regulating the
   TLR4/NF-kappa B signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE inflammation; age-related macular degeneration; retinal pigment
   epithelium; ARPE-19; wogonin; toll-like receptor 4; NF-kappa B
ID NF-KAPPA-B; ROOT GANGLION NEURONS; INDUCED ER STRESS; EXPRESSION;
   MECHANISM; DEATH; RPE
AB Inflammation in the retinal pigment epithelium is an important contributor to the pathogenesis of age-related macular degeneration. Wogonin is a flavonoid isolated from the root of Scutellaria baicalensis and has multiple pharmacological effects, including anti-inflammatory effects. The present study sought to determine if the pharmacological effects of wogonin were relevant to the treatment of AMD. ARPE-19 cells were pre-conditioned with different concentrations of wogonin (0-50 mu M) prior to induction of inflammation with LPS (2 mu g/ml). Transepithelial electrical resistance analysis demonstrated that 24 h treatment with 10 and 50 mu M wogonin ameliorated LPS-induced changes. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunofluorescence analyses revealed that wogonin restrained LPS-induced tight junction proteins, claudin-1 and ZO-1. LPS-induced upregulation of inflammatory mediators in ARPE-19 cells, including IL-1 beta, IL,-6, IL,-8, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) and TNF-alpha was reduced after pre-treatment with wogonin. In addition, RT-qPCR and western blotting demonstrated that wogonin inhibited the expression of TLR4 in LPS-stimulated ARPE-19 cells. This is a novel mechanism indicating that pre-treatment with wogonin could attenuate the TLR4/NF-kappa B-mediated inflammatory response in LPS-stimulated ARPE-19 cells, and thus could be a potential therapy for the treatment of AMD.
C1 [Chen, Chen; Lu, Guohua] Nanjing Med Univ, Changzhou Peoples Hosp 2, Inst Eye, 29 Xinglong Lane, Changzhou 213003, Jiangsu, Peoples R China.
   [Guo, Danni] Hosp Jiangnan Univ, Dept Otorhinolaryngol Head & Neck Surg, Wuxi 214062, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Jiangnan University
RP Lu, GH (通讯作者)，Nanjing Med Univ, Changzhou Peoples Hosp 2, Inst Eye, 29 Xinglong Lane, Changzhou 213003, Jiangsu, Peoples R China.
EM luguohuacz@163.com
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Breccia M, 2010, EXPERT OPIN THER TAR, V14, P1157, DOI 10.1517/14728222.2010.522570
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Chen FY, 2015, J MOL NEUROSCI, V55, P995, DOI 10.1007/s12031-014-0456-7
   Chen SB, 2015, CELL MOL NEUROBIOL, V35, P523, DOI 10.1007/s10571-014-0148-4
   Chi YS, 2003, BIOCHEM PHARMACOL, V66, P1271, DOI 10.1016/S0006-2952(03)00463-5
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Du M, 2013, DIABETOLOGIA, V56, P2318, DOI 10.1007/s00125-013-2986-x
   Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032
   He XX, 2015, INT IMMUNOPHARMACOL, V28, P470, DOI 10.1016/j.intimp.2015.07.012
   Kucuksayan E, 2014, FREE RADICAL BIO MED, V72, P113, DOI 10.1016/j.freeradbiomed.2014.04.013
   Lin CM, 2006, INT IMMUNOPHARMACOL, V6, P1690, DOI 10.1016/j.intimp.2006.07.003
   Lin CM, 2012, AM J CHINESE MED, V40, P415, DOI 10.1142/S0192415X12500322
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu HX, 2015, MOL MED REP, V12, P7285, DOI 10.3892/mmr.2015.4353
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Mateos MV, 2014, INT J BIOCHEM CELL B, V55, P119, DOI 10.1016/j.biocel.2014.08.016
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Paeng SH, 2015, INT J MOL MED, V36, P808, DOI 10.3892/ijmm.2015.2266
   Piao HZ, 2008, INT IMMUNOPHARMACOL, V8, P1658, DOI 10.1016/j.intimp.2008.07.018
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Shen W, 2014, BBA-MOL BASIS DIS, V1842, P1109, DOI 10.1016/j.bbadis.2014.03.015
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Wang WP, 2015, INFLAMM RES, V64, P423, DOI 10.1007/s00011-015-0822-0
   Wardill HR, 2015, CANCER TREAT REV, V41, P122, DOI 10.1016/j.ctrv.2014.11.005
   Xu SJ, 2015, CELL MOL NEUROBIOL, V35, P389, DOI 10.1007/s10571-014-0134-x
   Yeh CH, 2014, ENVIRON TOXICOL, V29, P1162, DOI 10.1002/tox.21847
   Yoshikawa T, 2011, CURR EYE RES, V36, P1153, DOI 10.3109/02713683.2011.606592
NR 29
TC 22
Z9 22
U1 1
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2017
VL 15
IS 4
BP 2289
EP 2295
DI 10.3892/mmr.2017.6252
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EP2HE
UT WOS:000397203200107
PM 28260013
OA Bronze
DA 2022-11-30
ER

PT J
AU Vachali, P
   Li, BX
   Nelson, K
   Bernstein, PS
AF Vachali, Preejith
   Li, Binxing
   Nelson, Kelly
   Bernstein, Paul S.
TI Surface plasmon resonance (SPR) studies on the interactions of
   carotenoids and their binding proteins
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Carotenoids; FastStep (TM); Macula; Retina; Surface plasmon resonance;
   Xanthophylls
ID ACUTE REGULATORY PROTEIN; MACULAR PIGMENT; AQUEOUS-SOLUTION; LUTEIN;
   ZEAXANTHIN; STAR; IDENTIFICATION; DEGENERATION; EXPRESSION
AB The xanthophyll carotenoids lutein and zeaxanthin constitute the major carotenoids of the macular pigment in the human retina where they are thought to act in part to prevent light induced oxidative damage associated with age-related macular degeneration (AMD). The highly selective uptake of these pigments is mediated by specific carotenoid-binding proteins (GSTP1 and StARD3) recently identified in our laboratory. Carotenoids are hydrophobic in nature, so we first systematically optimized carotenoid preparations that are nano-dispersed in aqueous buffers, and then we used a new-generation surface plasmon resonance (SPR) protocol called FastStep (TM), which is significantly faster than conventional SPR assays. We have explored carotenoid-binding interactions of five proteins: human serum albumin (HSA), beta-lactoglobulin (LG), steroidogenic acute regulatory domain proteins (StARD1, StARD3) and glutathione S- transferase Pi isoform (GSTP1). HSA and LG showed relatively weak interaction with carotenoids (K-D > 1 mu M). GSTP1 evidenced high affinity and specificity towards zeaxanthin and meso-zeaxanthin with KD values 0.14 +/- 0.02 mu M and 0.17 +/- 0.02 mu M, respectively. StARD3 expressed a relative high specificity towards lutein with a K-D) value of 0.59 +/- 0.031 mu M, whereas StARD1 exhibited a relatively low selectivity and affinity (K-D > 1 mu M) towards the various carotenoids tested. Published by Elsevier Inc.
C1 [Vachali, Preejith; Li, Binxing; Nelson, Kelly; Bernstein, Paul S.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
RI Li, Binxing/ABB-7775-2020; Vachali, Preejith/L-8661-2014; Li,
   Binxing/C-9153-2012
OI Li, Binxing/0000-0002-0715-7495; Vachali, Preejith/0000-0003-3569-1553; 
FU National Institute of Health [EY-11600]; Macula Vision Research
   Foundation; Lowy Foundation; Research to Prevent Blindness; Foundation
   Fighting Blindness; NATIONAL EYE INSTITUTE [R29EY011600, R01EY011600,
   P30EY014800] Funding Source: NIH RePORTER
FX This work was supported by National Institute of Health Grant EY-11600
   and Grants from the Macula Vision Research Foundation, the Lowy
   Foundation, and Research to Prevent Blindness, and the Foundation
   Fighting Blindness. We would like to acknowledge Professor Walter L
   Miller (UCSF) and Professor James H. Hurley (NIH) for providing us
   StARD1 and StARD3 plasmids, respectively.
CR Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2007, ARCH BIOCHEM BIOPHYS, V458, P121, DOI 10.1016/j.abb.2006.10.005
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Borel P, 1996, J LIPID RES, V37, P250
   Chinowsky TM, 2003, SENSOR ACTUAT B-CHEM, V91, P266, DOI 10.1016/S0925-4005(03)00113-8
   Cooper MA, 2003, ANAL BIOANAL CHEM, V377, P834, DOI 10.1007/s00216-003-2111-y
   Czeczuga-Semeniuk E, 2005, ONCOL REP, V14, P1385
   Dagnelie G, 2000, Optometry, V71, P147
   Davarnejad R, 2009, J CHEM ENG DATA, V54, P2200, DOI 10.1021/je900018t
   Day YSN, 2003, J PHARM SCI-US, V92, P333, DOI 10.1002/jps.10293
   Devoto L, 2001, J CLIN ENDOCR METAB, V86, P5633, DOI 10.1210/jc.86.11.5633
   El-Agamey A, 2004, PHOTOCH PHOTOBIO SCI, V3, P802, DOI 10.1039/b315651f
   Fullmer L., 2005, United States Patent, Patent No. [641,774, 641774]
   Haddad W M, 2006, Bull Soc Belge Ophtalmol, P15
   Kiriakidou M, 1996, J CLIN ENDOCR METAB, V81, P4122, DOI 10.1210/jc.81.11.4122
   Koehn Sonja, 2008, V4, P53, DOI 10.1007/978-3-7643-7499-0_5
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Lavigne P, 2010, SUBCELL BIOCHEM, V51, P425, DOI 10.1007/978-90-481-8622-8_15
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3
   Namitha KK, 2010, CRIT REV FOOD SCI, V50, P728, DOI 10.1080/10408398.2010.499811
   Parker LJ, 2011, CHEM-EUR J, V17, P7806, DOI 10.1002/chem.201100586
   Peters J.T., 1995, ALL ALBUMIN, P76
   Rich RL, 2010, ANAL BIOCHEM, V407, P270, DOI 10.1016/j.ab.2010.08.024
   Rich RL, 2001, ANAL BIOCHEM, V296, P197, DOI 10.1006/abio.2001.5314
   Richard B.M., 2008, HDB SURFACE PLASMON
   SANDMANN G, 1994, EUR J BIOCHEM, V223, P7, DOI 10.1111/j.1432-1033.1994.tb18961.x
   Sierralta WD, 2005, MOL CELL ENDOCRINOL, V242, P103, DOI 10.1016/j.mce.2005.08.003
   TAKAGI S, 1982, AGR BIOL CHEM TOKYO, V46, P2035, DOI 10.1080/00021369.1982.10865380
   TAKAGI S, 1987, AGR BIOL CHEM TOKYO, V51, P1561, DOI 10.1080/00021369.1987.10868241
   TAKAGI S, 1987, AGR BIOL CHEM TOKYO, V51, P1567, DOI 10.1080/00021369.1987.10868242
   Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408
NR 45
TC 30
Z9 32
U1 2
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD MAR 1
PY 2012
VL 519
IS 1
BP 32
EP 37
DI 10.1016/j.abb.2012.01.006
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 902HD
UT WOS:000301028300005
PM 22286029
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Canton, VM
   Quiroz-Mercado, H
   Velez-Montoya, R
   Lopez-Miranda, MJ
   Moshfeghi, AA
   Shusterman, EM
   Kaiser, PK
   Sanislo, SR
   Gertner, M
   Moshfeghi, DM
AF Morales Canton, Virgilio
   Quiroz-Mercado, Hugo
   Velez-Montoya, Raul
   Lopez-Miranda, Miriam J.
   Moshfeghi, Andrew A.
   Shusterman, Eugene M.
   Kaiser, Peter K.
   Sanislo, Steven R.
   Gertner, Michael
   Moshfeghi, Darius M.
TI 24-Gy Low-Voltage X-Ray Irradiation With Ranibizumab Therapy for
   Neovascular AMD: 6-Month Safety and Functional Outcomes
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PROTON-BEAM IRRADIATION; MACULAR
   DEGENERATION; RADIATION-THERAPY; STEREOTACTIC RADIOSURGERY; PLAQUE
   RADIOTHERAPY; BRACHYTHERAPY; MEMBRANES; SECONDARY; TRIAL
AB BACKGROUND AND OBJECTIVE: To describe the 6-month safety and preliminary efficacy outcomes of the use of 24-Gy radiation with intravitreal ranibizumab for patients with neovascular age-related macular degeneration (AMD).
   PATIENTS AND METHODS: A single treatment of a non-invasive, externally delivered low-voltage x-ray irradiation at a dose of 24 Gy was administered in one session through three locations in the inferior pars plana in a consecutive series of patients with neovascular AMD (treatment naive and previously treated). Optical coherence tomography (OCT) and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity examinations were performed at 1 week, 1 month, and monthly thereafter with quarterly fluorescein angiography.
   RESULTS: Nineteen patients completed 6 months of follow-up. There was no evidence of radiation retinopathy, optic neuropathy, or cataract. The mean baseline ETDRS score was 38.3 +/- 19.5 letters. At 6 months, the corresponding ETDRS score was 44.7 +/- 16.8 letters. At 6 months, the mean change in visual acuity was 6.4 +/- 9.8 ETDRS letters. Patients received an average of 0.4 additional ranibizumab injections following the initial two mandated injections.
   CONCLUSION: A single treatment of external 24-Gy low-voltage x-ray therapy in conjunction with ranibizumab demonstrated an overall improvement in visual acuity in patients with neovascular AMD at 6 months, with no radiation-related adverse effects.
C1 [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Byers Eye Inst, Horngren Family Vitreoretinal Ctr,Dept Ophthalmol, Palo Alto, CA 94303 USA.
   [Morales Canton, Virgilio; Quiroz-Mercado, Hugo; Velez-Montoya, Raul; Lopez-Miranda, Miriam J.] IAP, Assoc Evitar Ceguera Mexico, Mexico City, DF, Mexico.
   [Quiroz-Mercado, Hugo; Velez-Montoya, Raul] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA.
   [Moshfeghi, Andrew A.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Palm Beach Gardens, FL USA.
   [Shusterman, Eugene M.; Gertner, Michael] Oraya Therapeut Inc, Newark, CA USA.
   [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Stanford University; University of Colorado System; University of
   Colorado Denver; Bascom Palmer Eye Institute; Cleveland Clinic
   Foundation
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst, Horngren Family Vitreoretinal Ctr,Dept Ophthalmol, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM dariusm@stanford.edu
RI Canton, Virgilio/AAF-7047-2021; Velez-Montoya, Raul/K-3819-2015
OI Kaiser, Peter/0000-0001-5126-045X; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X; Velez-Montoya, Raul/0000-0002-6457-4578
FU Thrombogenics, Inc.
FX Drs. D. Moshfeghi and Kaiser are consultants for and have equity in,
   Drs. Canton, Velez-Montoya, Lopez-Miranda, Quiroz-Mercado, and Sanislo
   are consultants for, Dr. Shusterman is an employee of, and Dr. Gertner
   holds intellectual property with Oraya Therapeutics, Inc. Dr. Kaiser is
   a consultant for Novartis, Genentech, Bayer, and Regeneron. Dr. D.
   Moshfeghi is a consultant for Institu Therapeutics, OcuBell, and Realm
   Global. Dr. A. Moshfeghi is a consultant/speaker for Genentech, Inc.,
   Allergan, Inc., and Bausch & Lomb, Inc., a consultant for Eyetech, Inc.
   and Alimera, Inc., and receives research funding from Thrombogenics,
   Inc.
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Evans JR, 2010, COCHRANE DB SYST REV, V5
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Jaakkola A, 2001, EUR J OPHTHALMOL, V11, P269, DOI 10.1177/112067210101100310
   Jaakkola A, 1998, GRAEF ARCH CLIN EXP, V236, P24, DOI 10.1007/s004170050038
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 25
TC 16
Z9 16
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JAN-FEB
PY 2012
VL 43
IS 1
BP 20
EP 24
DI 10.3928/15428877-20111129-01
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 959VA
UT WOS:000305342600003
PM 22251841
DA 2022-11-30
ER

PT J
AU Schmidt, CQ
   Herbert, AP
   Hocking, HG
   Uhrin, D
   Barlow, PN
AF Schmidt, C. Q.
   Herbert, A. P.
   Hocking, H. G.
   Uhrin, D.
   Barlow, P. N.
TI Translational mini-review series on complement factor H: Structural and
   functional correlations for factor H
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Review
DE age-related macular degeneration; atypical haemolytic uraemic syndrome;
   complement; glycosaminoglycans; NMR
ID HEMOLYTIC-UREMIC SYNDROME; C-REACTIVE PROTEIN; POLYANION BINDING-SITE;
   SHORT CONSENSUS REPEAT; COMPONENT FACTOR-H; MACULAR DEGENERATION;
   ALTERNATIVE PATHWAY; X-RAY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   REGULATORY COMPONENT
AB The 155-kDa glycoprotein, complement factor H (CFH), is a regulator of complement activation that is abundant in human plasma. Three-dimensional structures of over half the 20 complement control protein (CCP) modules in CFH have been solved in the context of single-, double- and triple-module segments. Proven binding sites for C3b occupy the N and C termini of this elongated molecule and may be brought together by a bend in CFH mediated by its central CCP modules. The C-terminal CCP 20 is key to the ability of the molecule to adhere to polyanionic markers on self-surfaces where CFH acts to regulate amplification of the alternative pathway of complement. The surface patch on CCP 20 that binds to model glycosaminoglycans has been mapped using nuclear magnetic resonance (NMR), as has a second glycosaminoglycan-binding patch on CCP 7. These patches include many of the residue positions at which sequence variations have been linked to three complement-mediated disorders: dense deposit disease, age-related macular degeneration and atypical haemolytic uraemic syndrome. In one plausible model, CCP 20 anchors CFH to self-surfaces via a C3b/polyanion composite binding site, CCP 7 acts as a 'proof-reader' to help discriminate self- from non-self patterns of sulphation, and CCPs 1-4 disrupt C3/C5 convertase formation and stability.
C1 Univ Edinburgh, Sch Biol & Chem Sci, Edinburgh Biomol NMR Unit, Edinburgh, Midlothian, Scotland.
C3 University of Edinburgh
RP Barlow, PN (通讯作者)，Joseph Black Chem Bldg, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.
EM paul.barlow@ed.ac.uk
RI Herbert, Andy P/F-6693-2010; Herbert, Andrew P/C-4755-2008; Barlow, Paul
   N/G-2853-2011
OI Herbert, Andy P/0000-0002-4549-6965; Herbert, Andrew
   P/0000-0002-4549-6965; 
FU MRC [G0001089] Funding Source: UKRI; Medical Research Council [G0001089]
   Funding Source: Medline
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389
   ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841
   Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011
   BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381
   BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   CHUNG LP, 1985, BIOSCIENCE REP, V5, P855, DOI 10.1007/BF01119897
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461
   DISCIPIO RG, 1982, BIOCHIM BIOPHYS ACTA, V709, P58, DOI 10.1016/0167-4838(82)90421-6
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hakobyan S, 2007, MOL IMMUNOL, V44, P3983, DOI 10.1016/j.molimm.2007.06.194
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9
   Jokiranta TS, 1996, FEBS LETT, V393, P297
   JOUVIN MH, 1984, J IMMUNOL, V133, P3250
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kavanagh D, 2006, BRIT MED BULL, V77-78, P5, DOI 10.1093/bmb/ldl004
   Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x
   KLICKSTEIN LB, 1987, J EXP MED, V165, P1095, DOI 10.1084/jem.165.4.1095
   Kraiczy P, 2004, J BIOL CHEM, V279, P2421, DOI 10.1074/jbc.M308343200
   KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   MISASI R, 1989, EUR J IMMUNOL, V19, P1765, DOI 10.1002/eji.1830190936
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Pangburn MK, 2002, J IMMUNOL, V169, P4702, DOI 10.4049/jimmunol.169.9.4702
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   PERKINS SJ, 1986, BIOCHEM J, V233, P799, DOI 10.1042/bj2330799
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   RIPOCHE J, 1986, BIOSCIENCE REP, V6, P65, DOI 10.1007/BF01145180
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Shaul Y, 2005, PROTEINS, V60, P341, DOI 10.1002/prot.20489
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   SJOBERG AP, 2007, J BIOL CHEM, V9, P9
   Skerka C, 2007, MOL IMMUNOL, V44, P241, DOI 10.1016/j.molimm.2006.07.223
   Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19
   Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039
   Vaziri-Sani F, 2006, KIDNEY INT, V69, P981, DOI 10.1038/sj.ki.5000155
   Verdugo ME, 1997, EXP EYE RES, V65, P231, DOI 10.1006/exer.1997.0325
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 76
TC 107
Z9 112
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JAN
PY 2008
VL 151
IS 1
BP 14
EP 24
DI 10.1111/j.1365-2249.2007.03553.x
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 238FH
UT WOS:000251432200002
PM 18081691
OA Green Published
DA 2022-11-30
ER

PT J
AU Nagai, N
   Oike, Y
   Izumi-Nagai, K
   Urano, T
   Kubota, Y
   Noda, K
   Ozawa, Y
   Inoue, M
   Tsubota, K
   Suda, T
   Ishida, S
AF Nagai, Norihiro
   Oike, Yuichi
   Izumi-Nagai, Kanako
   Urano, Takashi
   Kubota, Yoshiaki
   Noda, Kousuke
   Ozawa, Yoko
   Inoue, Makoto
   Tsubota, Kazuo
   Suda, Toshio
   Ishida, Susumu
TI Angiotensin II type 1 receptor-mediated inflammation is required for
   choroidal neovascularization
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE choroidal neovascularization; inflammation; intercellular adhesion
   molecule-1; renin-angiotensin system; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; RETINAL NEOVASCULARIZATION; ANGIOGENESIS; EXPRESSION;
   ATHEROSCLEROSIS; MEMBRANES; MACROPHAGES; SUPPRESSION
AB Background - Choroidal neovascularization (CNV) is a critical pathogenesis in age-related macular degeneration, the most common cause of blindness in the developed countries. The aim of the current study was to determine the involvement of the renin-angiotensin system ( RAS) with the development of CNV, using human surgical samples and the murine model of laser-induced CNV.
   Methods and Results - In the human and murine CNV tissues, the vascular endothelium expressed angiotensin II type 1 receptor (AT1-R), AT2-R, and angiotensin II. The CNV volume was significantly suppressed by treatment with an AT1-R blocker telmisartan, but not with an AT2-R blocker. AT1-R signaling blockade with telmisartan inhibited various inflammatory mechanisms including macrophage infiltration and upregulation of VEGF, intercellular adhesion molecule-1 (ICAM-1), MCP-1, and IL-6 in the retinal pigment epithelium-choroid complex. A PPAR-gamma antagonist partially but significantly reversed the suppressive effect of telmisartan on in vivo induction of CNV and in vitro upregulation of ICAM-1 and MCP-1 in endothelial cells and IL-6 in macrophages, showing the dual contribution of PPAR-gamma-agonistic and AT1-R-antagonistic actions in the telmisartan treatment.
   Conclusions - AT1-R-mediated inflammation plays a pivotal role in the development of CNV, indicating the possibility of AT1-R blockade as a novel therapeutic strategy to inhibit CNV.
C1 Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, Tokyo 1608582, Japan.
   Keio Univ, Sch Med, Dept Cell Differentiat, Lab Retinal Cell Biol,Shinjuku Ku, Tokyo 1608582, Japan.
C3 Keio University; Keio University
RP Ishida, S (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ishidasu@sc.itc.keio.ac.jp
RI Suda, Toshio/H-6761-2013; ISHIDA, SUSUMU/D-7067-2012; Kubota,
   Yoshiaki/L-2231-2013; Ozawa, Yoko/AAH-9888-2020
OI Suda, Toshio/0000-0001-7540-1771; 
CR AVEI R, 2005, GRAEFES ARCH CLIN EX, V21, P1
   Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57
   Candido R, 2004, CIRCULATION, V109, P1536, DOI 10.1161/01.CIR.0000124061.78478.94
   de Gasparo M, 2000, PHARMACOL REV, V52, P415
   Deshayes F, 2005, TRENDS ENDOCRIN MET, V16, P293, DOI 10.1016/j.tem.2005.07.009
   Egami K, 2003, J CLIN INVEST, V112, P67, DOI 10.1172/JCI200316645
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gross CM, 2002, BASIC RES CARDIOL, V97, P327, DOI 10.1007/s00395-002-0356-9
   Hikichi T, 2001, AM J OPHTHALMOL, V132, P587, DOI 10.1016/S0002-9394(01)01139-4
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   LENOBLE FAC, 1993, AM J PHYSIOL, V264, pR460, DOI 10.1152/ajpregu.1993.264.2.R460
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476
   Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P1078, DOI 10.1167/iovs.04-1101
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sales VL, 2005, CIRCULATION, V112, P3328, DOI 10.1161/CIRCULATIONAHA.105.541714
   Sasaki K, 2002, J CLIN INVEST, V109, P603, DOI 10.1172/JCI200213055
   Schupp M, 2004, CIRCULATION, V109, P2054, DOI 10.1161/01.CIR.0000127955.36250.65
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Toko H, 2004, ARTERIOSCL THROM VAS, V24, P664, DOI 10.1161/01.ATV.0000122361.63827.ab
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Walsh DA, 1997, BRIT J PHARMACOL, V120, P1302, DOI 10.1038/sj.bjp.0701062
   WILLIAMS B, 1995, HYPERTENSION, V25, P913, DOI 10.1161/01.HYP.25.5.913
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Yue TL, 2001, CIRCULATION, V104, P2588, DOI 10.1161/hc4601.099403
NR 39
TC 103
Z9 107
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD OCT
PY 2006
VL 26
IS 10
BP 2252
EP 2259
DI 10.1161/01.ATV.0000240050.15321.fe
PG 8
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 126UO
UT WOS:000243541200014
PM 16888236
OA Bronze
DA 2022-11-30
ER

PT J
AU Koh, HJ
   Freeman, WR
   Azen, SP
   Flaxel, CJ
   Labree, LD
   Cheng, LG
   Wills, M
   Jones, TR
AF Koh, Hyoung J.
   Freeman, William R.
   Azen, Stanley P.
   Flaxel, Christina J.
   Labree, Laurie D.
   Cheng, Linguen
   Wills, Margaret
   Jones, Terence R.
TI Effect of a novel octapeptide urokinase fragment, A degrees 6, on
   experimental choroidal neovascularization in the monkey
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; angiogenesis; animal model; choroidal
   neovascularization
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; RETINAL-PIGMENT EPITHELIUM; MACULAR
   DEGENERATION; PRINOMASTAT AG3340; ENDOTHELIAL-CELLS; SUBRETINAL
   NEOVASCULARIZATION; MATRIX METALLOPROTEINASES; EXPRESSION; RECEPTOR;
   SYSTEM
AB Purpose: To evaluate the inhibitory effects of a urokinase-derived octapeptide, A degrees 6, on laser-induced choroidal neovascularization (CNV) in monkeys.
   Methods: Twenty female cynomolgus monkeys were randomly grouped into weekly or monthly A degrees 6 treatment groups, each consisting of 10 animals. CNV was induced in both eyes by perimacular laser treatment. In each right eye, a single 22.25-mg A degrees 6 dose (monthly group) or 4 22,25-mg A degrees 6 doses each week (weekly group) were given by intravitreal injections. Each left eye received phosphate buffer on the same schedule. Monkeys were observed for 4 weeks by ophthalmic examinations, color photography, and fluorescein angiography.
   Results: Weekly treated eyes had a 35% reduction of CNV compared with controls (P = 0.23). In contrast, monthly treated eye had a 71% reduction of CNV compared with controls (P = 0.0009). There was no evidence of toxicity at both clinical and pathologic examinations.
   Conclusions: Intravitreal A degrees 6 injections effectively inhibited CNV in cynomolgus monkeys without evidence of toxicity. The overall reduction in CNV was greater for monthly treated eyes than for weekly treated eyes. This study suggests that A degrees 6 has promise as a local antiangiogenic treatment of CNV. Further work is indicated to evaluate the potential role of A degrees 6 in therapy for human CNV associated with age-related macular degeneration.
C1 Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Ctr, Joan & Irwin Jacobs Retina Ctr, La Jolla, CA 92093 USA.
   Yonsei Univ, Dept Ophthalmol, Coll Med, Seoul 120749, South Korea.
   Univ So Calif, Stat Consultat & Res Ctr, Dept Prevent Med, Keck Sch Med, Los Angeles, CA USA.
   Univ So Calif, Doheny Retina Inst, Doheny Eye Inst, Keck Sch Med, Los Angeles, CA USA.
   Charles River Labs, Discovery & Dev Serv, Sierra Div, Sparks, NV USA.
   Angstrom Pharmaceut Inc, San Diego, CA USA.
C3 University of California System; University of California San Diego;
   Yonsei University; Yonsei University Health System; University of
   Southern California; Doheny Eye Institute; University of Southern
   California
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Ctr, Joan & Irwin Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
EM freeman@eyecenter.ucsd.edu
FU NATIONAL EYE INSTITUTE [R01EY007366] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY 07366] Funding Source: Medline
CR Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0
   Behzadian MA, 2003, FASEB J, V17, P752, DOI 10.1096/fj.02-0484fje
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P503, DOI 10.1080/20014091111785
   Cheng LY, 2002, INVEST OPHTH VIS SCI, V43, P515
   Cheng LY, 2001, J OCUL PHARMACOL TH, V17, P295, DOI 10.1089/108076801750295326
   Csaky K, 2003, OPHTHALMOLOGY, V110, P879
   Das A, 1999, INVEST OPHTH VIS SCI, V40, P809
   DAS S, IN PRESS ARCH OPHTHA
   Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com
   Elner Susan G, 2002, Trans Am Ophthalmol Soc, V100, P273
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FitzGerald GA, 2003, LANCET, V361, P542, DOI 10.1016/S0140-6736(03)12560-3
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312
   HACKETT SF, 1993, INVEST OPHTH VIS SCI, V34, P2055
   *I LAB AN RES COMM, 1996, GUID CAR US LAB AN
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koh HJ, 2004, J OCUL PHARMACOL TH, V20, P439, DOI 10.1089/jop.2004.20.439
   Koh HJ, 2004, INVEST OPHTH VIS SCI, V45, P635, DOI 10.1167/iovs.03-0735
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Macular translocation, 2000, OPHTHALMOLOGY, V107, P1015
   Mandal N, 2002, BRIT J OPHTHALMOL, V86, P118, DOI 10.1136/bjo.86.1.118
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319
   McGuire PG, 2003, INVEST OPHTH VIS SCI, V44, P2736, DOI 10.1167/iovs.02-1160
   MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   MILLER H, 1985, AM J OPHTHALMOL, V99, P263, DOI 10.1016/0002-9394(85)90354-X
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297
   OHKUMA H, 1983, ARCH OPHTHALMOL-CHIC, V101, P1102, DOI 10.1001/archopht.1983.01040020104018
   Ozerdem U, 2002, CURR EYE RES, V24, P86, DOI 10.1076/ceyr.24.2.86.8159
   Ozerdem U, 2000, CURR EYE RES, V20, P447, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT447
   PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673
   Prager GW, 2004, BLOOD, V103, P955, DOI 10.1182/blood-2003-07-2214
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Shen WY, 2002, LAB INVEST, V82, P167, DOI 10.1038/labinvest.3780409
   Siconolfi LB, 2003, J NEUROSCI RES, V74, P430, DOI 10.1002/jnr.10786
   Siren V, 2003, CURR EYE RES, V27, P261, DOI 10.1076/ceyr.27.5.261.17223
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817
NR 48
TC 11
Z9 13
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2006
VL 26
IS 2
BP 202
EP 209
DI 10.1097/00006982-200602000-00014
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 050KS
UT WOS:000238086900014
PM 16467679
DA 2022-11-30
ER

PT J
AU Ramshekar, A
   Wang, HB
   Kunz, E
   Pappas, C
   Hageman, GS
   Chaqour, B
   Sacks, DB
   Hartnett, ME
AF Ramshekar, Aniket
   Wang, Haibo
   Kunz, Eric
   Pappas, Christian
   Hageman, Gregory S.
   Chaqour, Brahim
   Sacks, David B.
   Hartnett, M. Elizabeth
TI Active Rap1-mediated inhibition of choroidal neovascularization requires
   interactions with IQGAP1 in choroidal endothelial cells
SO FASEB JOURNAL
LA English
DT Article
DE choroidal neovascularization; IQGAP1; Rac1GTP; Rap1GTP; vascular
   endothelial growth factor
ID RHO-FAMILY GTPASES; MACULAR DEGENERATION; NADPH OXIDASE; GROWTH-FACTOR;
   COMPLEMENT ACTIVATION; ROS GENERATION; RAP1; ANGIOGENESIS; RANIBIZUMAB;
   MIGRATION
AB Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness. The pathophysiology involves activation of choroidal endothelial cells (CECs) to transmigrate the retinal pigment epithelial (RPE) monolayer and form choroidal neovascularization (CNV) in the neural retina. The multidomain GTPase binding protein, IQGAP1, binds active Rac1 and sustains activation of CECs, thereby enabling migration associated with vision-threatening CNV. IQGAP1 also binds the GTPase, Rap1, which when activated reduces Rac1 activation in CECs and CNV. In this study, we tested the hypothesis that active Rap1 binding to IQGAP1 is necessary and sufficient to reduce Rac1 activation in CECs, and CNV. We found that pharmacologic activation of Rap1 or adenoviral transduction of constitutively active Rap1a reduced VEGF-mediated Rac1 activation, migration, and tube formation in CECs. Following pharmacologic activation of Rap1, VEGF-mediated Rac1 activation was reduced in CECs transfected with an IQGAP1 construct that increased active Rap1-IQGAP1 binding but not in CECs transfected with an IQGAP1 construct lacking the Rap1 binding domain. Specific knockout of IQGAP1 in endothelial cells reduced laser-induced CNV and Rac1 activation in CNV lesions, but pharmacologic activation of Rap1 did not further reduce CNV compared to littermate controls. Taken together, our findings provide evidence that active Rap1 binding to the IQ domain of IQGAP1 is sufficient to interfere with active Rac1-mediated CEC activation and CNV formation.
C1 [Ramshekar, Aniket; Wang, Haibo; Kunz, Eric; Pappas, Christian; Hageman, Gregory S.; Hartnett, M. Elizabeth] Univ Utah, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
   [Pappas, Christian; Hageman, Gregory S.] Univ Utah, Steele Ctr Translat Med, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Chaqour, Brahim] Downstate Med Ctr, Dept Ophthalmol, Brooklyn, NY USA.
   [Sacks, David B.] NIH, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; State University of New York
   (SUNY) System; State University of New York (SUNY) Downstate Medical
   Center; National Institutes of Health (NIH) - USA
RP Hartnett, ME (通讯作者)，Univ Utah, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM ME.Hartnett@hsc.utah.edu
RI Chaqour, Brahim/AEH-1314-2022
OI Chaqour, Brahim/0000-0002-8516-4324
FU HHS | NIH | National Eye Institute (NEI) [P30EY014800, R01EY024998,
   R01EY015130, R01EY017011]; Research to Prevent Blindness (RPB)
FX HHS | NIH | National Eye Institute (NEI), Grant/Award Number:
   P30EY014800; Research to Prevent Blindness (RPB); HHS | NIH | National
   Eye Institute (NEI), Grant/Award Number: R01EY024998; HHS | National
   Institutes of Health (NIH); HHS | NIH | National Eye Institute (NEI),
   Grant/Award Number: R01EY015130; HHS | NIH | National Eye Institute
   (NEI), Grant/Award Number: R01EY017011
CR Awasthi A, 2010, J EXP MED, V207, P1923, DOI 10.1084/jem.20100040
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164
   Bretz CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20520-z
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   Cao SJ, 2016, BRIT J OPHTHALMOL, V100, P713, DOI 10.1136/bjophthalmol-2015-307213
   Chrzanowska-Wodnicka M, 2008, BLOOD, V111, P2647, DOI 10.1182/blood-2007-08-109710
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T
   Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8
   Garvin S, 2003, CANCER RES, V63, P8742
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Goitre L, 2014, METHODS MOL BIOL, V1120, P1, DOI 10.1007/978-1-62703-791-4_1
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hedman AC, 2015, EMBO REP, V16, P427, DOI 10.15252/embr.201439834
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Jadeski L, 2008, J BIOL CHEM, V283, P1008, DOI 10.1074/jbc.M708466200
   Jeong HW, 2007, J BIOL CHEM, V282, P20752, DOI 10.1074/jbc.M700487200
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Lakshmikanthan S, 2018, J CELL SCI, V131, DOI 10.1242/jcs.207605
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01585-8
   Li JJ, 2018, CURR EYE RES, V43, P934, DOI 10.1080/02713683.2018.1454477
   Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200
   Malarkannan S, 2012, J IMMUNOL, V188, P2057, DOI 10.4049/jimmunol.1102439
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Namkoong S, 2009, CELL SIGNAL, V21, P906, DOI 10.1016/j.cellsig.2009.01.038
   Noritake J, 2004, MOL BIOL CELL, V15, P1065, DOI 10.1091/mbc.E03-08-0582
   Nowak-Sliwinska P, 2018, ANGIOGENESIS, V21, P425, DOI 10.1007/s10456-018-9613-x
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Panday A, 2015, CELL MOL IMMUNOL, V12, DOI 10.1038/cmi.2014.89
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Sorensen I, 2009, BLOOD, V113, P5680, DOI 10.1182/blood-2008-08-174508
   Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295
   Sokol SY, 2001, J BIOL CHEM, V276, P48425, DOI 10.1074/jbc.M107975200
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Wang HB, 2020, ANGIOGENESIS, V23, P685, DOI 10.1007/s10456-020-09740-y
   Wang HB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52163-z
   Wang HB, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.56
   Wang HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157748
   Wang HB, 2015, AM J PATHOL, V185, P3316, DOI 10.1016/j.ajpath.2015.08.017
   Wang HB, 2014, FASEB J, V28, P265, DOI 10.1096/fj.13-240028
   Wittchen ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073070
   Wittchen Erika S, 2011, Small GTPases, V2, P65
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zouache MA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78059-x
NR 59
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUL
PY 2021
VL 35
IS 7
AR e21642
DI 10.1096/fj.202100112R
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA TB2YH
UT WOS:000667814100055
PM 34166557
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Carrella, S
   Massa, F
   Indrieri, A
AF Carrella, Sabrina
   Massa, Filomena
   Indrieri, Alessia
TI The Role of MicroRNAs in Mitochondria-Mediated Eye Diseases
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE microRNA; retina; mitochondria; mitochondrial diseases; glaucoma; AMD;
   diabetic retinopathy; MitomiR
ID PIGMENT EPITHELIAL-CELLS; TRABECULAR MESHWORK CELLS; OXIDATIVE STRESS;
   INDUCED APOPTOSIS; DOWN-REGULATION; MACULAR DEGENERATION; RETINAL
   DEGENERATION; TRANSCRIPTION FACTOR; OPTIC NEUROPATHIES; MIRNA BIOMARKERS
AB The retina is among the most metabolically active tissues with high-energy demands. The peculiar distribution of mitochondria in cells of retinal layers is necessary to assure the appropriate energy supply for the transmission of the light signal. Photoreceptor cells (PRs), retinal pigment epithelium (RPE), and retinal ganglion cells (RGCs) present a great concentration of mitochondria, which makes them particularly sensitive to mitochondrial dysfunction. To date, visual loss has been extensively correlated to defective mitochondrial functions. Many mitochondrial diseases (MDs) show indeed neuro-ophthalmic manifestations, including retinal and optic nerve phenotypes. Moreover, abnormal mitochondrial functions are frequently found in the most common retinal pathologies, i.e., glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR), that share clinical similarities with the hereditary primary MDs. MicroRNAs (miRNAs) are established as key regulators of several developmental, physiological, and pathological processes. Dysregulated miRNA expression profiles in retinal degeneration models and in patients underline the potentiality of miRNA modulation as a possible gene/mutation-independent strategy in retinal diseases and highlight their promising role as disease predictive or prognostic biomarkers. In this review, we will summarize the current knowledge about the participation of miRNAs in both rare and common mitochondria-mediated eye diseases. Definitely, given the involvement of miRNAs in retina pathologies and therapy as well as their use as molecular biomarkers, they represent a determining target for clinical applications.
C1 [Carrella, Sabrina; Massa, Filomena; Indrieri, Alessia] Telethon Inst Genet & Med, Naples, Italy.
   [Indrieri, Alessia] Natl Res Council CNR, Inst Genet & Biomed Res, Milan, Italy.
C3 Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM);
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e
   Biomedica (IRGB-CNR)
RP Carrella, S; Indrieri, A (通讯作者)，Telethon Inst Genet & Med, Naples, Italy.; Indrieri, A (通讯作者)，Natl Res Council CNR, Inst Genet & Biomed Res, Milan, Italy.
EM carrella@tigem.it; indrieri@tigem.it
RI Indrieri, Alessia/I-7666-2019
OI Indrieri, Alessia/0000-0002-2325-0913; Carrella,
   Sabrina/0000-0002-3302-1698
FU BrightFocus Foundation [M2020184]; Telethon Foundation
FX This study was supported by the BrightFocus Foundation (grant no.
   M2020184 to SC) and the Telethon Foundation (grant no. AIMTX16 to AI).
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Almasieh M, 2017, ANNU REV VIS SCI, V3, P91, DOI 10.1146/annurev-vision-102016-061422
   Amini-Farsani Z, 2020, J COMP NEUROL, V528, P1616, DOI 10.1002/cne.24833
   Anasagasti A, 2018, INVEST OPHTH VIS SCI, V59, P2381, DOI 10.1167/iovs.18-24091
   Andreeva K, 2014, INT J GENOMICS, V2014, DOI 10.1155/2014/165897
   Aung T, 2002, HUM GENET, V110, P52, DOI 10.1007/s00439-001-0645-7
   Bai XY, 2011, J AM SOC NEPHROL, V22, P1252, DOI 10.1681/ASN.2010040367
   Bajan S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010137
   Bandiera S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020746
   Baracca A, 2007, BBA-BIOENERGETICS, V1767, P913, DOI 10.1016/j.bbabio.2007.05.005
   Barbato A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041801
   Barber AJ, 2011, INVEST OPHTH VIS SCI, V52, P1156, DOI 10.1167/iovs.10-6293
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006
   Bellon A, 2017, CELL REP, V18, P1171, DOI 10.1016/j.celrep.2016.12.093
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Caravia XM, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006247
   Carbonell M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091412
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Carrella S, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.588234
   Catuogno S, 2013, ONCOGENE, V32, P341, DOI 10.1038/onc.2012.51
   Cervo PRD, 2012, P NATL ACAD SCI USA, V109, P1133, DOI 10.1073/pnas.1112257109
   Chan EC, 2015, CURR PHARM DESIGN, V21, P5988, DOI 10.2174/1381612821666151029111127
   Chan EC, 2013, INVEST OPHTH VIS SCI, V54, P7061, DOI 10.1167/iovs.13-12883
   Cheng M, 2016, ONCOTARGET, V7, P42274, DOI 10.18632/oncotarget.9786
   Chi ZL, 2010, HUM MOL GENET, V19, P2606, DOI 10.1093/hmg/ddq146
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Cogliati S, 2016, TRENDS BIOCHEM SCI, V41, P261, DOI 10.1016/j.tibs.2016.01.001
   Colligris P, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8538573
   Das S, 2012, CIRC RES, V110, P1596, DOI 10.1161/CIRCRESAHA.112.267732
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812
   Dong J, 2011, ARCH MED RES, V42, P8, DOI 10.1016/j.arcmed.2011.01.006
   Duno M, 2013, GENE, V515, P372, DOI 10.1016/j.gene.2012.12.066
   Duraisamy AJ, 2019, BBA-MOL BASIS DIS, V1865, P1617, DOI 10.1016/j.bbadis.2019.03.013
   Duroux-Richard I, 2016, BLOOD, V128, P3125, DOI [10.1182/blood-201602-697003, 10.1182/blood-2016-02-697003]
   Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495
   Ertekin S, 2014, MOL VIS, V20, P1057
   Eshaq RS, 2014, REDOX BIOL, V2, P661, DOI 10.1016/j.redox.2014.04.006
   Fan F, 2017, ONCOTARGET, V8, P110209, DOI 10.18632/oncotarget.22597
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng XN, 2016, INT J ONCOL, V49, P2600, DOI 10.3892/ijo.2016.3751
   Ferre M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Finsterer J, 2018, MITOCHONDRION, V42, P1, DOI 10.1016/j.mito.2017.10.003
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fraser JA, 2010, SURV OPHTHALMOL, V55, P299, DOI 10.1016/j.survophthal.2009.10.002
   Gao L, 2016, BIOMED REP, V4, P193, DOI 10.3892/br.2015.565
   Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938
   Gelfand JM, 2011, J NEUROL, V258, P440, DOI 10.1007/s00415-010-5775-1
   Gueven N, 2017, MITOCHONDRION, V36, P7, DOI 10.1016/j.mito.2016.07.013
   Guo YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042387
   Heggermont WA, 2017, CIRCULATION, V136, P747, DOI 10.1161/CIRCULATIONAHA.116.024171
   Hindle AG, 2019, INVEST OPHTH VIS SCI, V60, P134, DOI 10.1167/iovs.18-24878
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Hondur G, 2017, INVEST OPHTH VIS SCI, V58, P4078, DOI 10.1167/iovs.17-22242
   Houzelle A, 2020, J CELL PHYSIOL, V235, P9851, DOI 10.1002/jcp.29797
   Hu H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59997-y
   Huang CK, 2013, MOL VIS, V19, P1422
   Hui GN, 2018, ONCOL LETT, V15, P1621, DOI 10.3892/ol.2017.7476
   Hui Y, 2018, LIFE SCI, V207, P212, DOI 10.1016/j.lfs.2018.06.005
   Hwang TIS, 2016, UROL SCI, V27, P101, DOI 10.1016/j.urols.2016.02.004
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Indrieri A, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.567129
   Indrieri A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062092
   Indrieri A, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201708734
   Ito YA, 2017, MITOCHONDRION, V36, P186, DOI 10.1016/j.mito.2017.08.014
   Iwai N, 2018, INT J ONCOL, V53, P237, DOI 10.3892/ijo.2018.4369
   Izzotti Alberto, 2015, Microrna, V4, P3
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jayaram H, 2015, INVEST OPHTH VIS SCI, V56, P7971, DOI 10.1167/iovs.15-18088
   Jiang YY, 2017, AM J TRANSL RES, V9, P2374
   Jing XB, 2018, CELL PHYSIOL BIOCHEM, V48, P692, DOI 10.1159/000491896
   Kang T, 2013, J BIOL CHEM, V288, P34394, DOI 10.1074/jbc.M113.514372
   Kao YY, 2019, CANCER LETT, V456, P40, DOI 10.1016/j.canlet.2019.04.028
   Karali M, 2019, HUM GENET, V138, P957, DOI 10.1007/s00439-018-1931-y
   Karali M, 2016, NUCLEIC ACIDS RES, V44, P1525, DOI 10.1093/nar/gkw039
   Kim J, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0121-4
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Kong N, 2014, BMC MOL BIOL, V15, DOI 10.1186/s12867-014-0025-1
   Lee H, 2017, BMB REP, V50, P214, DOI 10.5483/BMBRep.2017.50.4.006
   Lee MR, 2016, STEM CELL REP, V7, P1, DOI 10.1016/j.stemcr.2016.05.012
   Lee S, 2011, EXP EYE RES, V93, P204, DOI 10.1016/j.exer.2010.07.015
   Lefevere E, 2017, MITOCHONDRION, V36, P66, DOI 10.1016/j.mito.2017.03.006
   Lenaers G, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-46
   Leung AKL, 2015, TRENDS CELL BIOL, V25, P601, DOI 10.1016/j.tcb.2015.07.005
   Li GR, 2009, MECH AGEING DEV, V130, P731, DOI 10.1016/j.mad.2009.09.002
   Li HN, 2017, AM J PHYSIOL-ENDOC M, V313, pE391, DOI 10.1152/ajpendo.00073.2017
   Li HJ, 2019, EXP CELL RES, V375, P10, DOI 10.1016/j.yexcr.2019.01.009
   Li HJ, 2018, NEUROPHARMACOLOGY, V137, P33, DOI 10.1016/j.neuropharm.2018.04.028
   Li J, 2018, PATHOL RES PRACT, V214, P925, DOI 10.1016/j.prp.2018.05.025
   Li KKW, 2013, BRAIN PATHOL, V23, P413, DOI 10.1111/bpa.12014
   Li PF, 2017, MOL NEUROBIOL, V54, P2901, DOI 10.1007/s12035-016-9842-1
   Li RT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044907
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu WD, 2021, METHODS MOL BIOL, V2243, P339, DOI 10.1007/978-1-0716-1103-6_18
   Liu YM, 2018, INVEST OPHTH VIS SCI, V59, P2955, DOI 10.1167/iovs.17-23599
   Lu Z, 2016, MED SCI MONITOR, V22, P3301, DOI 10.12659/MSM.900487
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Luna C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051688
   Luna C, 2011, INVEST OPHTH VIS SCI, V52, P3567, DOI 10.1167/iovs.10-6448
   Luna C, 2009, MOL VIS, V15, P2488
   Mak HK, 2020, MOL THER-NUCL ACIDS, V21, P251, DOI 10.1016/j.omtn.2020.05.031
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Marchi S, 2013, CURR BIOL, V23, P58, DOI 10.1016/j.cub.2012.11.026
   Marrocco E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66497-6
   Martinez B, 2021, NEURAL REGEN RES, V16, P440, DOI 10.4103/1673-5374.293131
   Mastropasqua R, 2014, PROG RETIN EYE RES, V43, P92, DOI 10.1016/j.preteyeres.2014.07.003
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Meyerson C, 2015, CLIN OPHTHALMOL, V9, P1165, DOI 10.2147/OPTH.S62021
   Mirzaei N, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00921
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Miyawaki Toko, 2015, Rinsho Shinkeigaku, V55, P91, DOI 10.5692/clinicalneurol.55.91
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   Mohamed JS, 2014, DIABETES, V63, P1546, DOI 10.2337/db13-1364
   Moschos MM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233692
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Muluhngwi P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05727-w
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Newman NJ, 2005, AM J OPHTHALMOL, V140, P517, DOI 10.1016/j.ajo.2005.03.017
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Nishi H, 2010, J BIOL CHEM, V285, P4920, DOI 10.1074/jbc.M109.082610
   Niyazov DM, 2016, MOL SYNDROMOL, V7, P122, DOI 10.1159/000446586
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001
   Palfi A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31431
   Pandi SPS, 2013, INVEST OPHTH VIS SCI, V54, P8140, DOI 10.1167/iovs.13-12631
   Paylakhi SH, 2013, EXP EYE RES, V111, P112, DOI 10.1016/j.exer.2013.03.009
   Piro-Megy C, 2020, J CLIN INVEST, V130, P143, DOI 10.1172/JCI128513
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Purohit PK, 2021, CELL MOL LIFE SCI, V78, P1405, DOI 10.1007/s00018-020-03670-0
   Pusparajah P, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00200
   Qing S, 2014, CELL PHYSIOL BIOCHEM, V34, P1733, DOI 10.1159/000366374
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quinones-Lombrana A, 2015, BBA-MOL BASIS DIS, V1852, P1420, DOI 10.1016/j.bbadis.2015.04.004
   Ragusa M, 2013, MOL VIS, V19, P430
   Rao G, 2020, EMBO REP, V21, DOI 10.15252/embr.201948483
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   Saxena K, 2015, INVEST OPHTH VIS SCI, V56, P1820, DOI 10.1167/iovs.14-15449
   Sears NC, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107702
   Shafabakhsh R, 2019, J CELL PHYSIOL, V234, P7781, DOI 10.1002/jcp.27685
   Shao Y, 2019, AM J PHYSIOL-ENDOC M, V316, pE443, DOI 10.1152/ajpendo.00360.2018
   Sharma LK, 2019, HUM MOL GENET, V28, P422, DOI 10.1093/hmg/ddy354
   Shen LY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148532
   Shim MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep33830
   Singh LN, 2018, INVEST OPHTH VIS SCI, V59, P4598, DOI 10.1167/iovs.18-25085
   Singh R, 2012, J CELL SCI, V125, P1568, DOI 10.1242/jcs.095976
   Song S, 2015, BIOCHEM BIOPH RES CO, V465, P299, DOI 10.1016/j.bbrc.2015.08.028
   Su Q, 2021, MOL THER-NUCL ACIDS, V23, P1258, DOI 10.1016/j.omtn.2021.01.034
   Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200
   Sundaresan P, 2015, GENET MED, V17, P279, DOI 10.1038/gim.2014.121
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tanaka H, 2013, J NEURO-ONCOL, V111, P273, DOI 10.1007/s11060-012-1027-9
   Tanaka Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05089
   Thounaojam MC, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090328
   Tribble JR, 2019, BRAIN COMMUN, V1, DOI 10.1093/braincomms/fcz035
   Tseng HC, 2015, NEUROBIOL AGING, V36, P2201, DOI 10.1016/j.neurobiolaging.2015.02.012
   Tsujimoto T, 2020, BIOCHEM BIOPH RES CO, V523, P707, DOI 10.1016/j.bbrc.2020.01.022
   Villarreal G, 2011, INVEST OPHTH VIS SCI, V52, P3391, DOI 10.1167/iovs.10-6165
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang C, 2017, AM J TRANSL RES, V9, P1410
   Wang HJ, 2015, J CELL MOL MED, V19, P2084, DOI 10.1111/jcmm.12563
   Wang L, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/960362
   Wang NY, 2018, MOL MED REP, V17, P3891, DOI 10.3892/mmr.2017.8341
   Wang YG, 2014, CLIN TRANSL ONCOL, V16, P561, DOI 10.1007/s12094-013-1117-y
   Wei N, 2016, MOL NEUROBIOL, V53, P6809, DOI 10.1007/s12035-015-9605-4
   Weng HY, 2014, CANCER RES, V74, P4409, DOI 10.1158/0008-5472.CAN-13-1748
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111
   Wu HL, 2016, AM J CANCER RES, V6, P2221
   Wu JH, 2012, OPHTHALMIC RES, V47, P195, DOI 10.1159/000331992
   Wu MZ, 2017, NAT CELL BIOL, V19, P1286, DOI 10.1038/ncb3615
   Wu RD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167052
   Wu TW, 2015, CARCINOGENESIS, V36, P925, DOI 10.1093/carcin/bgv068
   Xie XH, 2015, TUMOR BIOL, V36, P7185, DOI 10.1007/s13277-015-3438-7
   Xu CL, 2017, ONCOTARGET, V8, P41921, DOI 10.18632/oncotarget.16707
   Xu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014356
   Xue T, 2016, INT J MOL MED, V38, P1387, DOI 10.3892/ijmm.2016.2735
   Yadav S, 2011, J BIOL CHEM, V286, P37347, DOI 10.1074/jbc.M111.235531
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Yao J, 2014, DNA CELL BIOL, V33, P291, DOI 10.1089/dna.2013.2132
   Yu-Wai-Man P, 2014, EYE, V28, P521, DOI 10.1038/eye.2014.37
   Yu-Wai-Man P, 2010, J MED GENET, V47, P120, DOI 10.1136/jmg.2009.067512
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
   Zaninello M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17821-1
   Zhang C, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03484-3
   Zhang HY, 2012, ONCOL REP, V27, P594, DOI 10.3892/or.2011.1530
   Zhang L, 2021, MOL THER-NUCL ACIDS, V24, P822, DOI 10.1016/j.omtn.2021.02.010
   Zhang R, 2017, MOL CELL ENDOCRINOL, V452, P33, DOI 10.1016/j.mce.2017.05.009
   Zhang XK, 2018, CIRCULATION, V137, P2052, DOI 10.1161/CIRCULATIONAHA.117.030486
   Zhao D, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705341
   Zheng M, 2010, J MOL MED, V88, P987, DOI 10.1007/s00109-010-0675-5
   Zhong Q, 2011, INVEST OPHTH VIS SCI, V52, P8739, DOI 10.1167/iovs.11-8045
   Zhou Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.195
   Zhu JN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12192-y
   Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3
   Zhuang Z, 2015, MOL VIS, V21, P1173
   Zitman-Gal T, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-8
   Zuzic M, 2019, GENES-BASEL, V10, DOI 10.3390/genes10050377
NR 201
TC 4
Z9 4
U1 2
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUN 18
PY 2021
VL 9
AR 653522
DI 10.3389/fcell.2021.653522
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA TC8WU
UT WOS:000668919800001
PM 34222230
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Thompson, S
   Blodi, FR
   Larson, DR
   Anderson, MG
   Stasheff, SF
AF Thompson, Stewart
   Blodi, Frederick R.
   Larson, Demelza R.
   Anderson, Michael G.
   Stasheff, Steven F.
TI The Efemp1(R345W) Macular Dystrophy Mutation Causes Amplified Circadian
   and Photophobic Responses to Light in Mice
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE circadian rhythms; malattia leventinese; melanopsin; mouse; negative
   masking
ID BREAST-CANCER; RETINAL DEGENERATION; IRRADIANCE DETECTION; MASKING
   RESPONSES; VISUAL FUNCTION; GANGLION-CELLS; AMACRINE CELLS; MOUSE MODEL;
   MELANOPSIN; VISION
AB PURPOSE. The R345W mutation in EFEMP1 causes malattia leventinese, an autosomal dominant eye disease with pathogenesis similar to an early-onset age-related macular degeneration. In mice, Efemp1(R345W) does not cause detectable degeneration but small subretinal deposits do accumulate. The purpose of this study was to determine whether there were abnormal responses to light at this presymptomatic stage in Efemp1(R345W) mice.
   METHODS. Responses to light were assessed by visual water task, circadian phase shifting, and negative masking behavior. The mechanism of abnormal responses was investigated by anterior eye exam, electroretinogram, melanopsin cell quantification, and multielectrode recording of retinal ganglion cell activity.
   RESULTS. Visual acuity was not different in Efemp1(R345W) mice. However, amplitudes of circadian phase shifting (P = 0.016) and negative masking (P < 0.0001) were increased in Efemp1(R345W) mice. This phenotype was not explained by anterior eye defects or amplified outer retina responses. Instead, we identified increased melanopsin-generated responses to light in the ganglion cell layer of the retina (P < 0.01).
   CONCLUSIONS. Efemp1(R345W) increases the sensitivity to light of behavioral responses driven by detection of irradiance. An amplified response to light in melanopsin-expressing intrinsically photosensitive retinal ganglion cells (ipRGCs) is consistent with this phenotype. The major concern with this effect of the malattia leventinese mutation is the potential for abnormal regulation of physiology by light to negatively affect health.
C1 [Thompson, Stewart] New Mexico Inst Min & Technol, Dept Psychol, 801 Leroy Pl, Socorro, NM 87801 USA.
   [Thompson, Stewart; Blodi, Frederick R.; Anderson, Michael G.] Univ Iowa, Ophthalmol & Visual Sci, Iowa City, IA USA.
   [Thompson, Stewart; Blodi, Frederick R.; Larson, Demelza R.; Anderson, Michael G.; Stasheff, Steven F.] Univ Iowa, Inst Vis Res, Iowa City, IA USA.
   [Blodi, Frederick R.; Stasheff, Steven F.] Univ Iowa, Pediat, Iowa City, IA USA.
   [Blodi, Frederick R.] Univ Louisville, Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
   [Larson, Demelza R.; Anderson, Michael G.] Univ Iowa, Mol Physiol & Biophys, Iowa City, IA USA.
   [Larson, Demelza R.] Coll St Benedict, Biol Dept, Collegeville, MN USA.
   [Larson, Demelza R.] St Johns Univ, Collegeville, MN 56321 USA.
   [Anderson, Michael G.] VA Ctr Prevent & Treatment Visual Loss, Iowa City, IA USA.
   [Stasheff, Steven F.] NEI, Unit Retinal Neurophysiol, Bethesda, MD 20892 USA.
   [Stasheff, Steven F.] Childrens Natl Med Ctr, Ctr Neurosci & Behav Med, Washington, DC 20010 USA.
   [Stasheff, Steven F.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
C3 New Mexico Institute of Mining Technology; University of Iowa;
   University of Iowa; University of Iowa; University of Louisville;
   University of Iowa; College of Saint Benedict & Saint Johns University;
   College of Saint Benedict & Saint Johns University; Saint Johns
   University Collegeville; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Iowa City VA Health Care System; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Children's National Health System; George Washington University
RP Thompson, S (通讯作者)，New Mexico Inst Min & Technol, Dept Psychol, 801 Leroy Pl, Socorro, NM 87801 USA.
EM stewart.thompson@nmt.edu
RI Anderson, Michael/B-4580-2009
OI Anderson, Michael/0000-0001-5730-6105
FU University of Iowa Institute for Vision Research; National Institutes of
   Health [P30 EY025580]; Veterans Affairs Award [I01 RX001481]; NATIONAL
   EYE INSTITUTE [R21EY029609, P30EY025580] Funding Source: NIH RePORTER;
   Veterans Affairs [I01RX001481] Funding Source: NIH RePORTER
FX Supported by University of Iowa Institute for Vision Research (ST, FRB,
   SFS), National Institutes of Health P30 EY025580 (DRL), and Veterans
   Affairs Award #I01 RX001481 (MGA). The contents of this manuscript do
   not represent the views of the U.S. Department of Veterans Affairs,
   Department of Defense, or the U.S. Government.
CR Anderson MG, 2008, PIGM CELL MELANOMA R, V21, P565, DOI 10.1111/j.1755-148X.2008.00482.x
   Chen HY, 2007, J COMP NEUROL, V500, P299, DOI 10.1002/cne.21161
   Davis RE, 2007, P NATL ACAD SCI USA, V104, P19422, DOI 10.1073/pnas.0708571104
   de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6
   Detwiler PB, 2018, YALE J BIOL MED, V91, P49
   Diessler S, 2017, ELIFE, V6, DOI 10.7554/eLife.23292
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Flynn-Evans EE, 2009, CANCER CAUSE CONTROL, V20, P1753, DOI 10.1007/s10552-009-9405-0
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761
   James P, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP935
   Kloog I, 2010, CANCER CAUSE CONTROL, V21, P2059, DOI 10.1007/s10552-010-9624-4
   Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200
   Kostic C, 2016, INVEST OPHTH VIS SCI, V57, P2501, DOI 10.1167/iovs.16-19150
   Kuburas A, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14784
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Lively GD, 2010, INVEST OPHTH VIS SCI, V51, P160, DOI 10.1167/iovs.09-3429
   MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2
   Meltzer E, 2017, JAMA NEUROL, V74, P574, DOI 10.1001/jamaneurol.2016.5131
   Mrosovsky N, 2008, VISION RES, V48, P1270, DOI 10.1016/j.visres.2008.02.016
   Mrosovsky N, 2003, CHRONOBIOL INT, V20, P989, DOI 10.1081/CBI-120026043
   Mrosovsky N, 1996, CHRONOBIOL INT, V13, P387, DOI 10.3109/07420529609012662
   Mrosovsky N, 1999, CHRONOBIOL INT, V16, P415, DOI 10.3109/07420529908998717
   Muller LPD, 2010, J COMP NEUROL, V518, P4813, DOI 10.1002/cne.22490
   Odell AF, 2005, J BIOL CHEM, V280, P37974, DOI 10.1074/jbc.M503646200
   Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848
   Park JC, 2017, SCI REP-UK, V7, DOI 10.1038/srep44987
   Peirson SN, 2005, METHOD ENZYMOL, V393, P697, DOI 10.1016/S0076-6879(05)93037-1
   Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821
   Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a
   Prusky GT, 2000, VISION RES, V40, P2201, DOI 10.1016/S0042-6989(00)00081-X
   Pukkala E, 2006, CANCER CAUSE CONTROL, V17, P573, DOI 10.1007/s10552-005-9005-6
   Reifler ANN, 2015, CURR BIOL, V25, P2763, DOI 10.1016/j.cub.2015.09.018
   Rodgers J, 2018, CELL MOL LIFE SCI, V75, P3609, DOI 10.1007/s00018-018-2813-0
   Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701
   Rybnikova N, 2015, CHRONOBIOL INT, V32, P757, DOI 10.3109/07420528.2015.1043369
   Segev R, 2004, NAT NEUROSCI, V7, P1155, DOI 10.1038/nn1323
   Sekaran S, 2005, CURR BIOL, V15, P1099, DOI 10.1016/j.cub.2005.05.053
   Shimazoe T, 2008, FASEB J, V22, P1479, DOI 10.1096/fj.07-9372com
   Singer JH, 2001, J NEUROSCI, V21, P8514, DOI 10.1523/JNEUROSCI.21-21-08514.2001
   Sohn EH, 2015, RETINA-J RET VIT DIS, V35, P48, DOI 10.1097/IAE.0000000000000263
   Stasheff SF, 2011, J NEUROPHYSIOL, V105, P3002, DOI 10.1152/jn.00704.2010
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Thompson S, 2008, INVEST OPHTH VIS SCI, V49, P2737, DOI 10.1167/iovs.07-1546
   Thompson S, 2008, EUR J NEUROSCI, V27, P1973, DOI 10.1111/j.1460-9568.2008.06168.x
   Thompson S, 2008, VISION RES, V48, P346, DOI 10.1016/j.visres.2007.07.020
   Thompson S, 2014, INVEST OPHTH VIS SCI, V55, P1859, DOI 10.1167/iovs.13-13661
   Thompson S, 2011, INVEST OPHTH VIS SCI, V52, P618, DOI 10.1167/iovs.10-6146
   Thompson S, 2010, VET OPHTHALMOL, V13, P151, DOI 10.1111/j.1463-5224.2010.00772.x
   Tian N, 2001, NEURON, V32, P439, DOI 10.1016/S0896-6273(01)00470-6
   Tu DC, 2005, NEURON, V48, P987, DOI 10.1016/j.neuron.2005.09.031
   Vukovic J, 2009, GLIA, V57, P424, DOI 10.1002/glia.20771
   Wee R, 2002, J NEUROSCI, V22, P10427
   Wong KY, 2007, J PHYSIOL-LONDON, V582, P279, DOI 10.1113/jphysiol.2007.133751
   Xia YQ, 2003, VISUAL NEUROSCI, V20, P429, DOI 10.1017/S0952523803204089
   Zode GS, 2012, INVEST OPHTH VIS SCI, V53, P1557, DOI 10.1167/iovs.11-8837
NR 56
TC 4
Z9 5
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2019
VL 60
IS 6
BP 2110
EP 2117
DI 10.1167/iovs.19-26881
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HZ6RS
UT WOS:000468980600035
PM 31095679
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Farnoodian, M
   Sorenson, CM
   Sheibani, N
AF Farnoodian, Mitra
   Sorenson, Christine M.
   Sheibani, Nader
TI PEDF expression affects the oxidative and inflammatory state of
   choroidal endothelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE cell adhesion; extracellular matrix proteins; inflammation; oxidative
   stress; thrombospondins
ID EPITHELIUM-DERIVED FACTOR; RETINAL VASCULAR DEVELOPMENT; MACULAR
   DEGENERATION; PROANGIOGENIC PROPERTIES; NONINHIBITORY SERPIN;
   GENE-EXPRESSION; CADHERIN GENE; MICE EXHIBIT; VE-CADHERIN; TGF-BETA
AB Age-related macular degeneration (AMD) is the leading cause of vision loss among the elderly population, and is associated with severe macular degeneration and choroidal neovascularization (CNV). Although the pathogenesis of AML) is associated with choroidal dysfunction and CNV, the detailed underlying mechanisms remain unresolved. Altered production of pigment epithelium-derived factor (PKDF), a neuroprotective and antiangiogenic factor, contributes to CNV. Furthermore, exogenous PFDF mitigates angiogenesis in preclinical CNV models. How PEDF expression affects choroidal endothelial cell (ChEC) function is unknown. Here we isolated ChECs from PEDF+/+ and PEDF-deficient (PEDF-/-) mice and determined the impact of PEDF expression on the pro angiogenic and pro-inflammatory properties of ChECs. We showed that PEDF expression significantly affects the proliferation, migration, adhesion, and oxidative and inflammatory state of ChECs. The PEDF-/- ChECs were, however, more sensitive to H2O2 challenge and exhibited increased rate of apoptosis and oxidative stress. We also observed a significant increase in production of cytokines with a primary role in inflammation and angiogenesis including vascular endothelial growth factor (VHGF) and osteopontin, and a reprograming of chemokines and cytokines expression profiles in PEDF-7- ChECs. Collectively, our results indicate that PEDF expression has a significant impact on oxidative and inflammatory properties of ChECs, whose alteration could contribute to pathogenesis of chronic inflammatory diseases including exudative AMD.
C1 [Farnoodian, Mitra; Sheibani, Nader] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53705 USA.
   [Sorenson, Christine M.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53705 USA.
   [Sheibani, Nader] Univ Wisconsin, Dept Biomed Engn, Sch Med & Publ Hlth, Madison, WI 53705 USA.
   [Sheibani, Nader] Univ Wisconsin, Dept Cell & Regenerat Biol, Sch Med & Publ Hlth, Madison, WI 53705 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Sheibani, N (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 1111 Highland Ave,9453 WIMR, Madison, WI 53705 USA.
EM nsheibanikar@wisc.edu
RI Sheibani, Nader/AAG-2379-2020
OI Sheibani, Nader/0000-0003-2723-9217
FU Research to Prevent Blindness; Retina Research Foundation; RRF/Daniel M.
   Albert Chair; RPB Stein Innovation Award;  [P30 EY-016665];  [P30
   CA-014520];  [EPA 83573701];  [R24 EY-022883];  [R01 EY-026078];
   NATIONAL EYE INSTITUTE [R01EY026078, P30EY016665] Funding Source: NIH
   RePORTER
FX This work was supported by an unrestricted award from Research to
   Prevent Blindness to the Department of Ophthalmology and Visual
   Sciences, Retina Research Foundation, and Grants P30 EY-016665, P30
   CA-014520, EPA 83573701, R24 EY-022883, and R01 EY-026078. C. Sorenson
   is supported by the RRF/Daniel M. Albert Chair. N. Sheibani is a
   recipient of the RPB Stein Innovation Award.
CR Abu El-Asrar AM, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/493043
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Becerra SP, 1997, ADV EXP MED BIOL, V425, P223
   BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Browning AC, 2012, BRIT J OPHTHALMOL, V96, P128, DOI 10.1136/bjophthalmol-2011-300572
   BURNS MS, 1992, CURR EYE RES, V11, P863, DOI 10.3109/02713689209033484
   Burtenshaw D, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040090
   Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7
   Chakraborty G, 2008, MOL MED REP, V1, P641, DOI 10.3892/mmr_00000005
   Ciulla, 1999, Expert Opin Investig Drugs, V8, P2173, DOI 10.1517/13543784.8.12.2173
   Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DiMaio TA, 2008, MICROVASC RES, V75, P188, DOI 10.1016/j.mvr.2007.10.001
   DiMalo TA, 2008, DEV BIOL, V315, P72, DOI 10.1016/j.ydbio.2007.12.008
   Falero-Perez J, 2017, AM J PHYSIOL-CELL PH, V313, pC405, DOI 10.1152/ajpcell.00004.2017
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Farnoodian M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12266
   Fei P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116423
   Gilley R, 2009, CELL SIGNAL, V21, P969, DOI 10.1016/j.cellsig.2009.02.006
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   He SK, 2005, INVEST OPHTH VIS SCI, V46, P4772, DOI 10.1167/iovs.05-0502
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Hoffmann S, 1998, GRAEF ARCH CLIN EXP, V236, P779, DOI 10.1007/s004170050158
   Hua J, 2012, MOL VIS, V18, P1045
   Huang Q, 2008, EXP EYE RES, V87, P226, DOI 10.1016/j.exer.2008.06.003
   Ioannidou S, 2006, P NATL ACAD SCI USA, V103, P16770, DOI 10.1073/pnas.0603501103
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Keeley EC, 2008, ARTERIOSCL THROM VAS, V28, P1928, DOI 10.1161/ATVBAHA.108.162925
   Kimura YN, 2007, CANCER SCI, V98, P2009, DOI 10.1111/j.1349-7006.2007.00633.x
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684
   Li RM, 2009, MICROCIRCULATION, V16, P640, DOI 10.1080/10739680903133185
   Lidington EA, 2002, AM J PHYSIOL-CELL PH, V282, pC67, DOI 10.1152/ajpcell.2002.282.1.C67
   Lund SA, 2009, J CELL COMMUN SIGNAL, V3, P311, DOI 10.1007/s12079-009-0068-0
   Luo Y, 2005, J CELL BIOL, V169, P29, DOI 10.1083/jcb.200411127
   Lyle AN, 2012, ARTERIOSCL THROM VAS, V32, P1383, DOI 10.1161/ATVBAHA.112.248922
   Ma B, 2011, EUR J PHARMACOL, V663, P9, DOI 10.1016/j.ejphar.2011.04.056
   Machalinska Anna, 2012, Klin Oczna, V114, P115
   Maharaj ASR, 2008, J EXP MED, V205, P491, DOI 10.1084/jem.20072041
   MANCINI MA, 1986, INVEST OPHTH VIS SCI, V27, P336
   Moldovan NI, 2002, J HEMATOTH STEM CELL, V11, P179, DOI 10.1089/152581602753658394
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Noble J, 2010, CAN MED ASSOC J, V182, P1759, DOI 10.1503/cmaj.090378
   Paik JH, 2004, GENE DEV, V18, P2392, DOI 10.1101/gad.1227804
   Park K, 2011, AM J PATHOL, V178, P688, DOI 10.1016/j.ajpath.2010.10.014
   Park S, 2015, CLIN SCI, V129, P217, DOI 10.1042/CS20140714
   Park S, 2013, J CELL SCI, V126, P1392, DOI 10.1242/jcs.117275
   Park S, 2010, AM J PHYSIOL-CELL PH, V299, pC1468, DOI 10.1152/ajpcell.00246.2010
   Scatena M, 2007, ARTERIOSCL THROM VAS, V27, P2302, DOI 10.1161/ATVBAHA.107.144824
   Scheef EA, 2009, AM J PHYSIOL-CELL PH, V296, pC724, DOI 10.1152/ajpcell.00409.2008
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Shin ES, 2014, AM J PHYSIOL-LUNG C, V306, pL620, DOI 10.1152/ajplung.00188.2013
   Smith DF, 2005, AM J PHYSIOL-HEART C, V289, pH1976, DOI 10.1152/ajpheart.00153.2005
   Sorenson CM, 2013, J DIABETES METAB, V4, DOI 10.4172/2155-6156.S12-005
   Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3
   Su XJ, 2003, MOL VIS, V9, P171
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273
   Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349
   Wang SJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P615, DOI 10.1001/archopthalmol.2011.1892
   Wang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P507, DOI 10.1001/archophthalmol.2009.53
   Wang SJ, 2003, DEV DYNAM, V228, P630, DOI 10.1002/dvdy.10412
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Yamagishi SI, 2003, MICROVASC RES, V65, P186, DOI 10.1016/S0026-2862(03)00005-0
   Yoshimura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008158
   Zamora DO, 2007, MOL VIS, V13, P2058
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05-4313fje
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 77
TC 15
Z9 17
U1 1
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD APR
PY 2018
VL 314
IS 4
BP C456
EP C472
DI 10.1152/ajpcell.00259.2017
PG 17
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA GP8QZ
UT WOS:000441178600007
PM 29351407
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Chang, MC
   Chen, YJ
   Liou, EJW
   Tseng, WY
   Chan, CP
   Lin, HJ
   Liao, WC
   Chang, YC
   Jeng, PY
   Jeng, JH
AF Chang, Mei-Chi
   Chen, Yi-Jane
   Liou, Eric Jein-Wein
   Tseng, Wan-Yu
   Chan, Chiu-Po
   Lin, Hseuh-Jen
   Liao, Wan-Chuen
   Chang, Ya-Ching
   Jeng, Po-Yuan
   Jeng, Jiiang-Huei
TI 7-Ketocholesterol induces ATM/ATR, Chk1/Chk2, PI3K/Akt signalings,
   cytotoxicity and IL-8 production in endothelial cells
SO ONCOTARGET
LA English
DT Article
DE apoptosis; atherosclerosis; cytotoxicity; endothelial cells;
   inflammation; Gerotarget
ID NF-KAPPA-B; CHOLESTEROL OXIDATION; OXIDIZED LDL; APOPTOSIS;
   INFLAMMATION; DYSFUNCTION; OXYSTEROLS; EXPRESSION; PATHWAYS;
   LYSOPHOSPHATIDYLCHOLINE
AB Cardiovascular diseases (atherosclerosis, stroke, myocardiac infarction etc.) are the major systemic diseases of elder peoples in the world. This is possibly due to increased levels of oxidized low-density lipoproteins (oxLDLs) such as 7-ketocholesterol (7-KC) and lysophosphatidylcholine (LPC) that damage vascular endothelial cells, induce inflammatory responses, to elevate the risk of cardiovascular diseases, Alzheimer's disease, and age-related macular degeneration. However the toxic effects of 7-KC on endothelial cells are not known. In this study, 7-KC showed cytotoxicity to endothelial cells at concentrations higher than 10 mu g/ml. 7-KC stimulated ATM/Chk2, ATR-Chk1 and p53 signaling pathways in endothelial cells. 7-KC also induced G0/G1 cell cycle arrest and apoptosis with an inhibition of Cyclin dependent kinase 1 (Cdk1) and cyclin B1 expression. Secretion and expression of IL-8 in endothelial cells were stimulated by 7-KC. 7-KC further induced intracellular ROS production as shown by increase in DCF fluorescence and Akt phosphorylation. LY294002 attenuated the 7-KC-induced apoptosis and IL-8 mRNA expression of endothelial cells. These results indicate that oxLDLs such as 7-KC may contribute to the pathogenesis of atherosclerosis, thrombosis and cardiovascular diseases by induction of endothelial damage, apoptosis and inflammatory responses. These events are associated with ROS production, activation of ATM/Chk2, ATR/Chk1, p53 and PI3K/Akt signaling pathways.
C1 [Chang, Mei-Chi] Chang Gung Univ Sci & Technol, Biomed Sci Team, Taoyuan, Taiwan.
   [Chang, Mei-Chi; Liou, Eric Jein-Wein; Chan, Chiu-Po] Chang Gung Mem Hosp, Dept Dent, Taipei, Taiwan.
   [Chen, Yi-Jane; Tseng, Wan-Yu; Liao, Wan-Chuen; Jeng, Po-Yuan; Jeng, Jiiang-Huei] Natl Taiwan Univ, Coll Med, Sch Dent, Taipei, Taiwan.
   [Chen, Yi-Jane; Tseng, Wan-Yu; Liao, Wan-Chuen; Jeng, Po-Yuan; Jeng, Jiiang-Huei] Natl Taiwan Univ, Coll Med, Dept Dent, Taipei, Taiwan.
   [Chen, Yi-Jane; Tseng, Wan-Yu; Liao, Wan-Chuen; Jeng, Po-Yuan; Jeng, Jiiang-Huei] Natl Taiwan Univ Hosp, Taipei, Taiwan.
   [Lin, Hseuh-Jen] Show Chwan Mem Hosp, Dept Dent, Changhua, Taiwan.
   [Chang, Ya-Ching] Mackay Mem Hosp, Dept Dent, Taipei, Taiwan.
C3 Chang Gung University of Science & Technology; Chang Gung Memorial
   Hospital; National Taiwan University; National Taiwan University;
   National Taiwan University; National Taiwan University Hospital; Show
   Chwan Memorial Hospital; Mackay Memorial Hospital
RP Chan, CP (通讯作者)，Chang Gung Mem Hosp, Dept Dent, Taipei, Taiwan.; Jeng, JH (通讯作者)，Natl Taiwan Univ, Coll Med, Sch Dent, Taipei, Taiwan.; Jeng, JH (通讯作者)，Natl Taiwan Univ, Coll Med, Dept Dent, Taipei, Taiwan.; Jeng, JH (通讯作者)，Natl Taiwan Univ Hosp, Taipei, Taiwan.
EM carol@adm.cgmh.org.tw; jhjeng@ntu.edu.tw
RI Tseng, Wan-Yu/V-4444-2019
OI CHEN, YI-JANE/0000-0002-9178-8379; TSENG, WAN-YU/0000-0002-9012-3703
FU Chang Gung Memorial Hospital, Linkou, Taiwan [CMRPF3E0021, CMRPF3E0022,
   CMRPF1F0071, NMRPF3E0041, NMRPF3E0042, NMRPF3C0062, NMRPF3C0091,
   NMRPF3C0061]; Ministry of Science and Technology, Taipei, Taiwan [MOST
   104-2314-B-255-010-MY3, NSC102-2628-B-255-001-MY3,
   NSC102-2314-B-255-003-MY2]
FX This study is supported by grants from Chang Gung Memorial Hospital,
   Linkou (CMRPF3E0021, CMRPF3E0022, CMRPF1F0071, NMRPF3E0041, NMRPF3E0042,
   NMRPF3C0062, NMRPF3C0091, NMRPF3C0061), Taiwan and Ministry of Science
   and Technology (MOST 104-2314-B-255-010-MY3; NSC102-2628-B-255-001-MY3;
   NSC102-2314-B-255-003-MY2), Taipei, Taiwan
CR Adiguzel Z, 2014, MOL BIOL REP, V41, P7875, DOI 10.1007/s11033-014-3681-9
   Bourdon E, 2000, ARTERIOSCL THROM VAS, V20, P2643, DOI 10.1161/01.ATV.20.12.2643
   Braunersreuther V, 2007, THROMB HAEMOSTASIS, V97, P714, DOI 10.1160/TH07-01-0036
   Chang MC, 2016, ONCOTARGET, V7, P16879, DOI 10.18632/oncotarget.7621
   Chang MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143663
   Chang MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114446
   Chang MC, 2010, BIOMATERIALS, V31, P8164, DOI 10.1016/j.biomaterials.2010.07.049
   EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734
   Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301
   Gramajo AL, 2010, INVEST OPHTH VIS SCI, V51, P1164, DOI 10.1167/iovs.09-3443
   HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177
   Hulsmans M, 2011, FASEB J, V25, P2515, DOI 10.1096/fj.11-181149
   Jang ER, 2011, NEUROCHEM INT, V58, P52, DOI 10.1016/j.neuint.2010.10.012
   Jiang JX, 2014, EUR J PHARMACOL, V727, P43, DOI 10.1016/j.ejphar.2014.01.045
   Krishnaswamy G, 1999, J INTERF CYTOK RES, V19, P91, DOI 10.1089/107999099314234
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lee DH, 2015, NEUROCHEM INT, V89, P28, DOI 10.1016/j.neuint.2015.06.012
   Lee WJ, 2010, J VASC SURG, V52, P1290, DOI 10.1016/j.jvs.2010.04.085
   Lee YW, 2010, INFLAMM RES, V59, P755, DOI 10.1007/s00011-010-0187-3
   Li W, 2011, BIOCHEM BIOPH RES CO, V409, P711, DOI 10.1016/j.bbrc.2011.05.071
   Liao PL, 2010, TOXICOL LETT, V197, P88, DOI 10.1016/j.toxlet.2010.05.002
   Lordan S, 2009, J NUTR BIOCHEM, V20, P321, DOI 10.1016/j.jnutbio.2009.01.001
   Luchetti F, 2015, STEROIDS, V99, P204, DOI 10.1016/j.steroids.2015.02.008
   Luthra S, 2008, MICROVASC RES, V75, P343, DOI 10.1016/j.mvr.2007.10.003
   Lyons MA, 1999, INT J BIOCHEM CELL B, V31, P369, DOI 10.1016/S1357-2725(98)00123-X
   Maiolino G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/714653
   Miah S, 2013, EXP TOXICOL PATHOL, V65, P677, DOI 10.1016/j.etp.2012.08.002
   Palozza P, 2010, J NUTR BIOCHEM, V21, P34, DOI 10.1016/j.jnutbio.2008.10.002
   Petit L, 1999, ARTERIOSCL THROM VAS, V19, P309, DOI 10.1161/01.ATV.19.2.309
   Ragot K, 2011, CHEM PHYS LIPIDS, V164, P469, DOI 10.1016/j.chemphyslip.2011.04.014
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Silva SF, 2016, J STEROID BIOCH MOL
   Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252
   Tseng SK, 2012, CLIN ORAL INVEST, V16, P1267, DOI 10.1007/s00784-011-0604-1
   Wang SF, 2013, BIOCHEM PHARMACOL, V86, P548, DOI 10.1016/j.bcp.2013.06.006
   Yan S, 2014, CELL MOL LIFE SCI, V71, P3951, DOI 10.1007/s00018-014-1666-4
   Zhou LC, 2006, ENDOTHELIUM-J ENDOTH, V13, P213, DOI 10.1080/10623320600780926
NR 37
TC 27
Z9 28
U1 1
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 15
PY 2016
VL 7
IS 46
BP 74473
EP 74483
DI 10.18632/oncotarget.12578
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE5GF
UT WOS:000389632800006
PM 27740938
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Chowers, I
   Tiosano, L
   Audo, I
   Grunin, M
   Boon, CJF
AF Chowers, Itay
   Tiosano, Liran
   Audo, Isabelle
   Grunin, Michelle
   Boon, Camiel J. F.
TI Adult-onset foveomacular vitelliform dystrophy: A fresh perspective
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Pattern dystrophy; Vitelliform lesion; Adult-onset foveomacular
   vitelliform dystrophy
ID OPTICAL COHERENCE TOMOGRAPHY; SHAPED PIGMENT DYSTROPHY; DISK SHEDDING
   PATTERN; RDS MUTANT MICE; MACULAR DYSTROPHY; CHOROIDAL
   NEOVASCULARIZATION; PERIPHERIN/RDS GENE; RETINITIS-PIGMENTOSA;
   INTRAVITREAL BEVACIZUMAB; RETINAL DEGENERATION
AB Adult-onset foveomacular vitelliform dystrophy (AFVD) was first described by Gass four decades ago. AFVD is characterized by subretinal vitelliform macular lesions and is usually diagnosed after the age of 40. The lesions gradually increase and then decrease in size over the years, leaving an area of atrophic outer retina and retinal pigment epithelium. This process is accompanied by a loss of visual acuity. Vitelliform lesions are hyperautofluorescent and initially have a dome-shaped appearance on optical coherence tomography. The electro-oculogram and full-field electroretinogram are typically normal, indicating localized retinal pathology. Phenocopies are also associated with other ocular disorders, such as vitreomacular traction, age-related macular degeneration, pseudodrusen, and central serous chorioretinopathy. A minority of AFVD patients have a mutation in the PRPH2, BEST1, IMPG1, or IMPG2 genes. A single-nucleotide polymorphism in the HTRA1 gene has also been associated with this phenotype. Accordingly, the phenotype can arise from alterations in the photoreceptors, retinal pigment epithelium, and/or interphotoreceptor matrix depending on the underlying gene defect. Excess photoreceptor outer segment production and/or impaired outer segment uptake due to impaired phagocytosis are likely underlying mechanisms. At present, no cure is available for AFVD. Thus, the current challenges in the field include identifying the underlying cause in the majority of AFVD cases and the development of effective therapeutic approaches. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Chowers, Itay; Tiosano, Liran; Grunin, Michelle] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   [Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, NL-2333 ZA Leiden, Netherlands.
   [Audo, Isabelle] INSERM, U968, F-75012 Paris, France.
   [Audo, Isabelle] Univ Paris 06, Sorbonne Univ, UMR S 968, Inst Vis, F-75012 Paris, France.
   [Audo, Isabelle] CNRS, UMR 7210, F-75012 Paris, France.
   [Audo, Isabelle] INSERM DHOS, DHU ViewMaintain, Ctr Hosp Natl Ophtalmol Quinze Vingts, CIC 1423, F-75012 Paris, France.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); UDICE-French Research
   Universities; Universite Paris Cite; CHNO des Quinze-Vingts; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019; Boon, CJF/P-7534-2014
OI Grunin, Michelle/0000-0002-3155-2858; Boon, CJF/0000-0002-6737-7932;
   Audo, Isabelle/0000-0003-0698-5309
FU Israel Science Found [1006/13]; Chief Scientist of the Israeli Ministry
   of Health [9184]
FX This study was supported in part by grants from the Israel Science Found
   (1006/13) and by the Chief Scientist of the Israeli Ministry of Health
   (9184). These funding agencies had no role in the study design, the
   collection, analysis, or interpretation of the data, writing of the
   report, or the decision to submit this article for publication.
CR Acharya S, 1998, J BIOL CHEM, V273, P31599, DOI 10.1074/jbc.273.47.31599
   Al Rashaed S, 2013, CLIN OPHTHALMOL, V7, P1069, DOI 10.2147/OPTH.S40208
   Al-Dahmash SA, 2012, OPHTHAL SURG LAS IM, V43, P366, DOI 10.3928/15428877-20120712-01
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   Aronow ME, 2012, SURV OPHTHALMOL, V57, P558, DOI 10.1016/j.survophthal.2012.02.004
   Ascaso FJ, 2010, CLIN EXP OPHTHALMOL, V38, P812, DOI 10.1111/j.1442-9071.2010.02335.x
   Bandah-Rozenfeld D, 2010, AM J HUM GENET, V87, P199, DOI 10.1016/j.ajhg.2010.07.004
   Barbazetto IA, 2007, OPHTHALMIC GENET, V28, P192, DOI 10.1080/13816810701538596
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P362, DOI 10.1016/S0002-9394(02)01946-3
   BLOOM LH, 1981, BRIT J OPHTHALMOL, V65, P800, DOI 10.1136/bjo.65.11.800
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2007, BRIT J OPHTHALMOL, V91, P1504, DOI 10.1136/bjo.2007.115659
   Boon CJF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1100, DOI 10.1001/archopht.125.8.1100
   Boon CJF, 2013, OPHTHALMOLOGY, V120, P809, DOI 10.1016/j.ophtha.2012.09.057
   Boon CJF, 2009, PROG RETIN EYE RES, V28, P187, DOI 10.1016/j.preteyeres.2009.04.002
   Boon CJF, 2009, RETINA-J RET VIT DIS, V29, P835, DOI 10.1097/IAE.0b013e31819d4fda
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   BRECHER R, 1990, EYE, V4, P210, DOI 10.1038/eye.1990.28
   BURGESS DB, 1987, OPHTHALMOLOGY, V94, P362
   Burgess R, 2008, AM J HUM GENET, V82, P19, DOI 10.1016/j.ajhg.2007.08.004
   Coco RM, 2010, EUR J OPHTHALMOL, V20, P724, DOI 10.1177/112067211002000413
   COHEN SY, 1993, AM J OPHTHALMOL, V116, P246, DOI 10.1016/S0002-9394(14)71300-5
   Conley SM, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017376
   Conley SM, 2014, HUM MOL GENET, V23, P3102, DOI 10.1093/hmg/ddu014
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Da Pozzo S, 2001, OPHTHALMOLOGICA, V215, P412, DOI 10.1159/000050899
   de Laat P, 2013, OPHTHALMOLOGY, V120, P2684, DOI 10.1016/j.ophtha.2013.05.013
   DEUTMAN AF, 1970, ARCH OPHTHALMOL-CHIC, V83, P558
   Dolz-Marco R, 2012, AM J OPHTHALMOL, V153, P389, DOI 10.1016/j.ajo.2011.11.027
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   Eksandh L, 2008, ARCH OPHTHALMOL-CHIC, V126, P432, DOI 10.1001/archopht.126.3.432
   EPSTEIN GA, 1980, BRIT J OPHTHALMOL, V64, P733, DOI 10.1136/bjo.64.10.733
   Ergun E, 2004, RETINA-J RET VIT DIS, V24, P399, DOI 10.1097/00006982-200406000-00010
   FEIST RM, 1994, AM J OPHTHALMOL, V118, P259, DOI 10.1016/S0002-9394(14)72913-7
   Felbor U, 1997, HUM MUTAT, V10, P301, DOI 10.1002/(SICI)1098-1004(1997)10:4<301::AID-HUMU6>3.0.CO;2-J
   Finger RP, 2010, RETINA-J RET VIT DIS, V30, P1455, DOI 10.1097/IAE.0b013e3181e09829
   Finger RP, 2009, RETINA-J RET VIT DIS, V29, P1496, DOI 10.1097/IAE.0b013e3181aade47
   Fossarello M, 1996, ARCH OPHTHALMOL-CHIC, V114, P448, DOI 10.1001/archopht.1996.01100130444016
   Francis PJ, 2005, BRIT J OPHTHALMOL, V89, P1115, DOI 10.1136/bjo.2004.062695
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Furino C, 2008, OPHTHALMOLOGICA, V222, P240, DOI 10.1159/000130427
   Gallego-Pinazo R, 2011, GRAEF ARCH CLIN EXP, V249, P455, DOI 10.1007/s00417-010-1536-1
   Gamundi MJ, 2007, MOL VIS, V13, P1031
   Gass J D, 1988, Trans Am Ophthalmol Soc, V86, P354
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Genead MA, 2010, DOC OPHTHALMOL, V121, P161, DOI 10.1007/s10633-010-9236-z
   GLACETBERNARD A, 1990, J FR OPHTALMOL, V13, P407
   Gonzales CR, 2004, RETINA-J RET VIT DIS, V24, P464, DOI 10.1097/00006982-200406000-00024
   GORIN MB, 1995, OPHTHALMOLOGY, V102, P246
   GREAVES AH, 1990, AUST NZ J OPHTHALMOL, V18, P171, DOI 10.1111/j.1442-9071.1990.tb00610.x
   Grunwald L, 2011, ARCH OPHTHALMOL-CHIC, V129, P1104, DOI 10.1001/archophthalmol.2011.215
   Guziewicz KE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075666
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   HODES BL, 1984, ARCH OPHTHALMOL-CHIC, V102, P381
   HSIEH RC, 1977, ARCH OPHTHALMOL-CHIC, V95, P429
   JAFFE GJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P958
   Jaouni T, 2012, ARCH OPHTHALMOL-CHIC, V130, P987, DOI 10.1001/archophthalmol.2012.1483
   Kaga T, 2001, AM J OPHTHALMOL, V132, P120, DOI 10.1016/S0002-9394(00)00950-8
   Kandula Sushma, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS81, DOI 10.3928/15428877-20101031-09
   KEEN TJ, 1994, HUM MOL GENET, V3, P367, DOI 10.1093/hmg/3.2.367
   Khan J., 2010, BMJ CASE REP
   Khani SC, 2003, INVEST OPHTH VIS SCI, V44, P3570, DOI 10.1167/iovs.02-1287
   KIM RY, 1995, ARCH OPHTHALMOL-CHIC, V113, P451, DOI 10.1001/archopht.1995.01100040067029
   Koreen L, 2011, ARCH OPHTHALMOL-CHIC, V129, P23, DOI 10.1001/archophthalmol.2010.316
   Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447
   Lee JY, 2009, OPHTHAL SURG LAS IM, V40, P319, DOI 10.3928/15428877-20090430-18
   Leroy BP, 2007, BRIT J OPHTHALMOL, V91, P89, DOI 10.1136/bjo.2006.101915
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Manes G, 2013, AM J HUM GENET, V93, P571, DOI 10.1016/j.ajhg.2013.07.018
   MARMOR MF, 1977, AM J OPHTHALMOL, V84, P32, DOI 10.1016/0002-9394(77)90320-8
   Marmor MF, 1996, AM J OPHTHALMOL, V122, P382, DOI 10.1016/S0002-9394(14)72065-3
   Menchini U, 2002, ARCH OPHTHALMOL-CHIC, V120, P1761
   Meunier I, 2014, OPHTHALMOLOGY, V121, P2406, DOI 10.1016/j.ophtha.2014.06.028
   Meunier I, 2011, OPHTHALMOLOGY, V118, P1130, DOI 10.1016/j.ophtha.2010.10.010
   Mimoun G, 2013, RETINA-J RET VIT DIS, V33, P513, DOI 10.1097/IAE.0b013e3182753adb
   Montero JA, 2007, EUR J OPHTHALMOL, V17, P983, DOI 10.1177/112067210701700620
   NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202
   NICHOLS BE, 1993, HUM MOL GENET, V2, P601, DOI 10.1093/hmg/2.5.601
   Parodi MB, 2008, RETINA-J RET VIT DIS, V28, P801, DOI 10.1097/IAE.0b013e31816f859d
   Parodi MB, 2010, INVEST OPHTH VIS SCI, V51, P4358, DOI 10.1167/iovs.10-5237
   Parodi MB, 2000, EUR J OPHTHALMOL, V10, P266, DOI 10.1177/112067210001000315
   Parodi MB, 2003, RETINA-J RET VIT DIS, V23, P171, DOI 10.1097/00006982-200304000-00006
   Passerini I, 2007, EUR J OPHTHALMOL, V17, P1000, DOI 10.1177/112067210701700624
   PATRINELY JR, 1985, OPHTHALMOLOGY, V92, P1712
   Petropoulos IK, 2008, KLIN MONATSBL AUGENH, V225, P488, DOI 10.1055/s-2008-1027309
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Pierro L, 2002, AM J OPHTHALMOL, V134, P675, DOI 10.1016/S0002-9394(02)01685-9
   Prieto-Calvo E., 2012, Arch Soc Esp Oftalmol, V87, P149, DOI 10.1016/j.oftal.2011.09.009
   Puche N, 2010, BRIT J OPHTHALMOL, V94, P1190, DOI 10.1136/bjo.2009.175075
   Puche N, 2014, GRAEF ARCH CLIN EXP, V252, P555, DOI 10.1007/s00417-013-2493-2
   Querques G, 2013, J FR OPHTALMOL, V36, pE1, DOI 10.1016/j.jfo.2012.04.013
   Querques G, 2008, AM J OPHTHALMOL, V146, P135, DOI 10.1016/j.ajo.2008.02.017
   Querques G, 2007, OPHTHALMOLOGY, V114, P1234, DOI 10.1016/j.ophtha.2007.03.019
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P4678, DOI 10.1167/iovs.10-6500
   Querques G, 2009, MOL VIS, V15, P2960
   Renner AB, 2005, OPHTHALMOLOGY, V112, P586, DOI 10.1016/j.ophtha.2004.10.041
   Renner AB, 2004, RETINA-J RET VIT DIS, V24, P929, DOI 10.1097/00006982-200412000-00014
   Renner AB, 2009, AM J OPHTHALMOL, V147, P518, DOI 10.1016/j.ajo.2008.09.007
   Rodman J, 2011, OPTOMETRY, V82, P148, DOI 10.1016/j.optm.2010.07.027
   SABATES R, 1982, RETINA-J RET VIT DIS, V2, P197, DOI 10.1097/00006982-198202040-00002
   Saito M, 2014, AM J OPHTHALMOL, V157, P355, DOI 10.1016/j.ajo.2013.10.009
   Saito W, 2003, BRIT J OPHTHALMOL, V87, P758, DOI 10.1136/bjo.87.6.758
   SANYAL S, 1989, CURR EYE RES, V8, P1093, DOI 10.3109/02713688908997402
   SANYAL S, 1988, VISION RES, V28, P1171, DOI 10.1016/0042-6989(88)90034-X
   Schatz P, 2003, ACTA OPHTHALMOL SCAN, V81, P500, DOI 10.1034/j.1600-0420.2003.00134.x
   Sears JE, 2001, AM J OPHTHALMOL, V132, P693, DOI 10.1016/S0002-9394(01)01179-5
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   SKALKA HW, 1981, BRIT J OPHTHALMOL, V65, P180, DOI 10.1136/bjo.65.3.180
   Sotodeh M, 2005, KLIN MONATSBL AUGENH, V222, P910, DOI 10.1055/s-2005-858840
   Spaide RF, 2004, RETINA-J RET VIT DIS, V24, P301, DOI 10.1097/00006982-200404000-00019
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2007, OPHTHALMOLOGY, V114, P1234, DOI 10.1016/j.ophtha.2007.03.020
   Spaide RF, 2006, OPHTHALMOLOGY, V113, P1392, DOI 10.1016/j.ophtha.2006.03.023
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Stricker HM, 2005, BIOCHEM J, V388, P605, DOI 10.1042/BJ20041960
   Tang PH, 2013, PROG RETIN EYE RES, V32, P48, DOI 10.1016/j.preteyeres.2012.09.002
   Testa F, 2005, BRIT J OPHTHALMOL, V89, P1066, DOI 10.1136/bjo.2004.064188
   Theischen M, 1997, OPHTHALMOLOGE, V94, P230, DOI 10.1007/s003470050107
   Thomann U, 1995, Eur J Ophthalmol, V5, P107
   Tiosano L, 2014, EUR J OPHTHALMOL, V24, P890, DOI 10.5301/ejo.5000486
   Tsui I, 2008, DOC OPHTHALMOL, V116, P57, DOI 10.1007/s10633-007-9084-7
   Urner-Bloch U, 2014, ANN ONCOL, V25, P1437, DOI 10.1093/annonc/mdu169
   Vaclavik V, 2007, ARCH OPHTHALMOL-CHIC, V125, P274, DOI 10.1001/archopht.125.2.274
   van Lith-Verhoeven J, 2003, MOL VIS, V9, P138
   van Lith-Verhoeven JJC, 2004, INVEST OPHTH VIS SCI, V45, P30, DOI 10.1167/iovs.03-0392
   VINE AK, 1980, AM J OPHTHALMOL, V89, P680, DOI 10.1016/0002-9394(80)90288-3
   Viola F, 2014, RETINA-J RET VIT DIS, V34, P1428, DOI 10.1097/IAE.0000000000000073
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   WELEBER RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1531, DOI 10.1001/archopht.1993.01090110097033
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
   Yang ZL, 2003, AM J OPHTHALMOL, V135, P213, DOI 10.1016/S0002-9394(02)01815-9
   Zhuk S, 2006, MOL VIS, V12, P811
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
NR 140
TC 54
Z9 59
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2015
VL 47
BP 64
EP 85
DI 10.1016/j.preteyeres.2015.02.001
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL8QH
UT WOS:000357238700004
PM 25681578
DA 2022-11-30
ER

PT J
AU Malerbi, FK
   Novais, EA
   Badaro, E
   Bonomo, PPD
   Pereira, AJ
   Lottenberg, CL
   Maia, A
AF Malerbi, Fernando K.
   Novais, Eduardo A.
   Badaro, Emmerson
   Bonomo, Pedro Paulo de O.
   Pereira, Adriano J.
   Lottenberg, Claudio L.
   Maia, Andre
TI Hyperbaric oxygen therapy for choroidal neovascularization: a pilot
   study
SO UNDERSEA AND HYPERBARIC MEDICINE
LA English
DT Article
DE age-related macular degeneration; AMD; choroidal neovascularization;
   CNV; vascular endothelial growth factor; VEGF; hyperbaric oxygen therapy
ID MACULAR DEGENERATION; BLOOD-FLOW; MECHANISMS; PREVALENCE; PRESSURES; EYE
AB Introduction: Choroidal neovascularization (CNV) is one of the leading causes of blindness worldwide and affects patients with wet age-related macular degeneration (AMD). Its natural course may lead to impaired central vision and macular fibrosis. Even VEGF blockade, currently the best available treatments for CNV, may fail to improve vision. Hyperbaric oxygen (HBO2) therapy may be an alternative or ancillary treatment for CNV.
   Methods: AMD patients with active CNV underwent 10 daily sessions of HBO2 at 2 atmospheres absolute (atm abs) for 120 minutes each session. After the end of the sessions, patients with clinical or tomographical signs of CNV activity underwent standard anti-VEGF treatment.
   Results: Seven patients (average age 73) underwent 10 daily 120-minute sessions of HBO2 at 2 atm abs. After the sessions, five patients underwent intravitreal injection of bevacizumab. Average follow-up was 150 days. Average CNV area at baseline was 14.42 mm2; average CNV greatest linear diameter at baseline was 4.56 mm. Statistical analysis of variance (ANOVA) was performed for central retinal thickness and volume mean percentage changes post-treatment. At the end of follow up, five patients showed anatomical improvement, one patient maintained anatomical aspect and one patient showed anatomical worsening.
   Conclusion: HBO2 may be a safe and tolerable treatment option for patients with active CNV, potentially delaying its progression, as monotherapy or in combination with intravitreal bevacizumab.
C1 [Malerbi, Fernando K.; Novais, Eduardo A.; Badaro, Emmerson; Bonomo, Pedro Paulo de O.; Maia, Andre] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Malerbi, Fernando K.; Pereira, Adriano J.; Lottenberg, Claudio L.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Hospital Israelita Albert
   Einstein
RP Malerbi, FK (通讯作者)，Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
EM fernandokmalerbi@gmail.com
RI Malerbi, Fernando/AAD-3827-2019; Pereira, Adriano/F-9342-2014
OI Malerbi, Fernando/0000-0002-6523-5172; Pereira,
   Adriano/0000-0002-3528-3800
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Heier J., 2009, RETINA, V29, pS23
   HOLBACH KH, 1977, J NEUROL, V217, P17, DOI 10.1007/BF00316313
   Jain KK., 2004, TXB HYPERBARIC MED, P16
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   MURPHYLAVOIE H, 2009, HYPERBARIC OXYGEN TH
   NICHOLS CW, 1969, NEW ENGL J MED, V281, P25, DOI 10.1056/NEJM196907032810106
   Oguz H, 2008, SURV OPHTHALMOL, V53, P112, DOI 10.1016/j.survophthal.2007.12.002
   Plafki C, 2000, AVIAT SPACE ENVIR MD, V71, P119
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sheffield PJ, 1997, UNDERSEA HYPERBAR M, V24, P153
   Thom SR, 2011, PLAST RECONSTR SURG, V127, p131S, DOI 10.1097/PRS.0b013e3181fbe2bf
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Weiss JN, 2010, UNDERSEA HYPERBAR M, V37, P101
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
NR 23
TC 0
Z9 0
U1 0
U2 2
PU UNDERSEA & HYPERBARIC MEDICAL SOC INC
PI DURHAM
PA 21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA
SN 1066-2936
J9 UNDERSEA HYPERBAR M
JI Undersea Hyperb. Med.
PD MAR-APR
PY 2015
VL 42
IS 2
BP 125
EP 131
PG 7
WC Marine & Freshwater Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Marine & Freshwater Biology; Research & Experimental Medicine
GA DB5RK
UT WOS:000368571100004
PM 26094287
DA 2022-11-30
ER

PT J
AU Koskimaki, JE
   Lee, E
   Chen, W
   Rivera, CG
   Rosca, EV
   Pandey, NB
   Popel, AS
AF Koskimaki, Jacob E.
   Lee, Esak
   Chen, William
   Rivera, Corban G.
   Rosca, Elena V.
   Pandey, Niranjan B.
   Popel, Aleksander S.
TI Synergy between a collagen IV mimetic peptide and a somatotropin-domain
   derived peptide as angiogenesis and lymphangiogenesis inhibitors
SO ANGIOGENESIS
LA English
DT Article
DE Angiogenesis; Synergy; Combination therapy; Peptide; Inhibitor
ID FOCAL ADHESION KINASE; MOLECULAR-MECHANISMS; TUMOR-GROWTH; CANCER;
   MIGRATION; IDENTIFICATION; PROLIFERATION; IMPACT; DRUGS; CELLS
AB Angiogenesis is central to many physiological and pathological processes. Here we show two potent bioinformatically-identified peptides, one derived from collagen IV and translationally optimized, and one from a somatotropin domain-containing protein, synergize in angiogenesis and lymphangiogenesis assays including cell adhesion, migration and in vivo Matrigel plugs. Peptide-peptide combination therapies have recently been applied to diseases such as human immunodeficiency virus (HIV), but remain uncommon thus far in cancer, age-related macular degeneration and other angiogenesis-dependent diseases. Previous work from our group has shown that the collagen IV-derived peptide primarily binds beta 1 integrins, while the receptor for the somatotropin-derived peptide remains unknown. We investigate these peptides' mechanisms of action and find both peptides affect the vascular endothelial growth factor (VEGF) pathway as well as focal adhesion kinase (FAK) by changes in phosphorylation level and total protein content. Blocking of FAK both through binding of beta 1 integrins and through inhibition of VEGFR2 accounts for the synergy we observe. Since resistance through activation of multiple signaling pathways is a central problem of anti-angiogenic therapies in diseases such as cancer, we suggest that peptide combinations such as these are an approach that should be considered as a means to sustain anti-angiogenic and anti-lymphangiogenic therapy and improve efficacy of treatment.
C1 [Koskimaki, Jacob E.; Chen, William; Rivera, Corban G.; Rosca, Elena V.; Pandey, Niranjan B.; Popel, Aleksander S.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Lee, Esak; Popel, Aleksander S.] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
   [Popel, Aleksander S.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.
   [Popel, Aleksander S.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins Medicine
RP Koskimaki, JE (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biomed Engn, 613 Traylor Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.
EM Jkoskimaki@gmail.com
RI Lee, Esak/AAC-6403-2020; Popel, Aleksander S/A-6724-2009
OI Lee, Esak/0000-0002-5328-6677; Popel, Aleksander/0000-0002-6706-9235;
   Chen, William/0000-0001-8924-5853
FU NIH [CA R01 138264, R21 CA131931, R21 CA 152473]; Safeway Foundation for
   Breast Cancer; Thome Memorial Foundation; TEDCO Maryland Technology
   Development Corporation; NATIONAL CANCER INSTITUTE [R01CA138264,
   R21CA152473, R21CA131931] Funding Source: NIH RePORTER
FX This work was supported by NIH CA R01 138264, R21 CA131931, R21 CA
   152473, The Safeway Foundation for Breast Cancer, The Thome Memorial
   Foundation and TEDCO Maryland Technology Development Corporation.
CR Abdollahi A, 2010, DRUG RESIST UPDATE, V13, P16, DOI 10.1016/j.drup.2009.12.001
   Albrecht I, 2011, INT J DEV BIOL, V55, P483, DOI 10.1387/ijdb.103226ia
   Cao YH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003149
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21
   Foy KC, 2011, J BIOL CHEM, V286, P13626, DOI 10.1074/jbc.M110.216820
   Huber PE, 2005, CANCER RES, V65, P3643, DOI 10.1158/0008-5472.CAN-04-1668
   Infusino GA, 2012, MICROVASC RES, V83, P89, DOI 10.1016/j.mvr.2011.09.011
   Karagiannis ED, 2008, P NATL ACAD SCI USA, V105, P13775, DOI 10.1073/pnas.0803241105
   Karagiannis ED, 2007, BIOCHEM BIOPH RES CO, V354, P434, DOI 10.1016/j.bbrc.2006.12.231
   Kerbel RS, 2009, BREAST, V18, pS41, DOI 10.1016/S0960-9776(09)70271-1
   Kiyoi H, 2002, ONCOGENE, V21, P2555, DOI 10.1038/sj.onc.1205332
   Koskimaki JE, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-29
   Koskimaki JE, 2009, NEOPLASIA, V11, P1285, DOI 10.1593/neo.09620
   Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200
   Lee E, 2011, INT J BIOCHEM CELL B, V43, P1812, DOI 10.1016/j.biocel.2011.08.020
   Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007
   Lund AW, 2012, CELL REP, V1, P191, DOI 10.1016/j.celrep.2012.01.005
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Rivera CG, 2011, J MED CHEM, V54, P6492, DOI 10.1021/jm200114f
   Rosca EV, 2012, CHEM BIOL DRUG DES, V80, P27, DOI 10.1111/j.1747-0285.2012.01376.x
   Rosca EV, 2011, CANCER BIOL THER, V12, P808, DOI 10.4161/cbt.12.9.17677
   Rosca EV, 2011, CURR PHARM BIOTECHNO, V12, P1101
   Rosca EV, 2012, ANTI-CANCER DRUG, V23, P706, DOI 10.1097/CAD.0b013e3283531041
   Saladin PM, 2009, IDRUGS, V12, P779
   Silva R, 2008, ARTERIOSCL THROM VAS, V28, P1703, DOI 10.1161/ATVBAHA.108.172015
   Weisberg E, 2009, DRUG RESIST UPDATE, V12, P81, DOI 10.1016/j.drup.2009.04.001
   Xiong Y, 2009, J BIOL CHEM, V284, P23217, DOI 10.1074/jbc.M109.019679
   ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161
   Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001
NR 33
TC 16
Z9 16
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD JAN
PY 2013
VL 16
IS 1
BP 159
EP 170
DI 10.1007/s10456-012-9308-7
PG 12
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 058UA
UT WOS:000312658800013
PM 23053781
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Theodossiadis, P
   Charonis, A
   Panagiotidis, D
   Papathanassiou, M
   Petrou, P
AF Theodossiadis, Panagiotis
   Charonis, Alexandros
   Panagiotidis, Dimitrios
   Papathanassiou, Miltiadis
   Petrou, Petros
TI Vitrectomy for treatment of a lamellar hole in a patient with exudative
   macular degeneration: the role of vitreous traction elimination
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Lamellar macular hole; Vitrectomy
ID OPTICAL COHERENCE TOMOGRAPHY; VITREOMACULAR ADHESION
AB PURPOSE. Lamellar macular hole (LMH) represents a well-defined clinical entity with variable pathophysiologic mechanisms and a controversial therapeutic approach. The purpose of the present work is to present a patient with an epiretinal membrane (ERM)-associated LMH on the background of exudative age-related macular degeneration (AMD) that was successfully managed with pars plana vitrectomy.
   METHODS. Interventional case report.
   RESULTS. A 67-year-old man presented with progressive visual loss OS of 5 months' duration. He was diagnosed with an ERM-associated LMH with coexisting subretinal fluid arising by a neovascular membrane on the background of exudative AMD confirmed with fundus fluorescein angiography. He underwent a 3-port pars plana vitrectomy with ERM-internal limiting membrane peeling and gas tamponade (14% C(3)F(8)) for treatment of the LMH and ERM with a view to undergo anti-vascular endothelial growth factor treatment for the exudative AMD. Postoperative optical coherence tomography demonstrated complete closure of the LMH with simultaneous total subretinal fluid absorption that was maintained at the 2-month follow-up period.
   CONCLUSIONS. To our knowledge, this is the first report whereby pars plana vitrectomy in a patient with an ERM-associated LMH on the background of exudative AMD resulted in improvement of both clinical entities. The latter strengthens the role of vitreous traction elimination in exudative AMD and highlights the need for further research.
C1 [Theodossiadis, Panagiotis; Charonis, Alexandros; Panagiotidis, Dimitrios; Papathanassiou, Miltiadis; Petrou, Petros] Univ Athens, Attikon Hosp, Dept Ophthalmol, Athens, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon
RP Theodossiadis, P (通讯作者)，Rimini 1, Haidari 12462, Greece.
EM patheo@med.uoa.gr
CR Haouchine B, 2001, OPHTHALMOLOGY, V108, P15, DOI 10.1016/S0161-6420(00)00519-4
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Theodossiadis PG, 2009, GRAEF ARCH CLIN EXP, V247, P13, DOI 10.1007/s00417-008-0927-z
NR 8
TC 4
Z9 6
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2010
VL 20
IS 6
BP 1086
EP 1088
DI 10.1177/112067211002000613
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 661UW
UT WOS:000282754900020
PM 20658458
DA 2022-11-30
ER

PT J
AU Wischke, C
   Zhang, Y
   Mittal, S
   Schwendeman, SP
AF Wischke, Christian
   Zhang, Ying
   Mittal, Sachin
   Schwendeman, Steven P.
TI Development of PLGA-Based Injectable Delivery Systems For Hydrophobic
   Fenretinide
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE controlled release; fenretinide; hydrophobic drug; in situ implant;
   s/o/w PLGA microparticle
ID SYNTHETIC RETINOID FENRETINIDE; SOLVENT EVAPORATION METHOD;
   BREAST-CANCER; IN-VITRO; CONTROLLED-RELEASE; ANTITUMOR-ACTIVITY;
   DRUG-DELIVERY; MICROSPHERES; MICROPARTICLES; ACID)
AB Although efficient in vitro, fenretinide has not been successful clinically for either of the targeted indications-cancer prevention and dry age-related macular degeneration-because of various issues, such as low oral bioavailability. Therefore, controlled release carriers for parenteral delivery of fenretinide were developed.
   After examining the solubility profile of fenretinide, the drug was encapsulated in poly(lactic-co-glycolic acid) (PLGA) microparticles at 20% drug loading by an s/o/w methodology as well as into in situ-forming PLGA implants. The carrier morphology and drug release kinetics in an elevated polysorbate 80-containing release medium were studied.
   Preformulation studies revealed increased fenretinide solubility in various PLGA solvents including N-methylpyrrolidone (NMP) and 1:9 v/v methanol:methylene chloride. Co-solvent emulsion methods resulted in low encapsulation efficiency. With a s/o/w method, fenretinide release rates from injectable microparticles were adjusted by the o-phase concentration of end-capped PLGA, the drug particle size, and the particle porosity. In situ implants from non-capped PLGA in NMP exhibited a continuous release of similar to 70% drug over 1 month.
   Injectable carriers for fenretinide were successfully prepared, exhibiting excellent drug stability. Based on the in vitro release properties of the different carriers, the preferred injection sites and in vivo release rates will be determined in future preclinical studies.
C1 [Wischke, Christian; Zhang, Ying; Schwendeman, Steven P.] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA.
   [Mittal, Sachin] Merck Sharp & Dohme Corp, Merck Res Labs, Phamaceut Sci, West Point, PA 19486 USA.
C3 University of Michigan System; University of Michigan; Merck & Company
RP Schwendeman, SP (通讯作者)，Univ Michigan, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.
EM schwende@umich.edu
RI Wischke, Christian/K-9651-2013
OI Wischke, Christian/0000-0001-5531-9033
FU National Science Foundation [EAR-96-28196]; Merck Co., Inc.
FX The authors thank Dr. Sam Reinhold for his technical support. Financial
   support of this study from Merck & Co., Inc. is gratefully acknowledged.
   Moreover, the authors thank Prof. Steven Abbott for support in
   calculating Hansen solubility parameters. The Hitachi microscope used in
   parts of this work was acquired under grant #EAR-96-28196 from the
   National Science Foundation.
CR AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288
   BECK LR, 1979, AM J OBSTET GYNECOL, V135, P419, DOI 10.1016/0002-9378(79)90717-8
   Birnbaum DT, 2000, J CONTROL RELEASE, V65, P375, DOI 10.1016/S0168-3659(99)00219-9
   BODMEIER R, 1988, INT J PHARM, V43, P179, DOI 10.1016/0378-5173(88)90073-7
   Camerini T, 2001, J CLIN ONCOL, V19, P1664, DOI 10.1200/JCO.2001.19.6.1664
   Ding AG, 2004, J PHARM SCI-US, V93, P322, DOI 10.1002/jps.10524
   Dunn R.L., 1990, US Patent, Patent No. [4 938 763, 4938763, US patent no. 4,938,763]
   FORMELLI F, 1989, CANCER RES, V49, P6149
   Garaventa A, 2003, CLIN CANCER RES, V9, P2032
   Graham PD, 1999, J CONTROL RELEASE, V58, P233, DOI 10.1016/S0168-3659(98)00158-8
   Hail N, 2006, APOPTOSIS, V11, P1677, DOI 10.1007/s10495-006-9289-3
   HULTIN TA, 1986, DRUG METAB DISPOS, V14, P714
   HUTCHINSON FG, 1986, Patent No. 198658481
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Lewis D.H., 1983, Patent No. [4,389,330, 4389330]
   Li WI, 1995, J CONTROL RELEASE, V37, P199, DOI 10.1016/0168-3659(95)00076-3
   Mao SR, 2008, EUR J PHARM BIOPHARM, V68, P214, DOI 10.1016/j.ejpb.2007.06.008
   Maurer BJ, 2007, CLIN CANCER RES, V13, P3079, DOI 10.1158/1078-0432.CCR-06-1889
   MOON RC, 1979, CANCER RES, V39, P1339
   OGAWA Y, 1988, CHEM PHARM BULL, V36, P1502
   Okuda T, 2009, INT J PHARMACEUT, V373, P100, DOI 10.1016/j.ijpharm.2009.01.019
   Orienti I, 2007, BIOMACROMOLECULES, V8, P3258, DOI 10.1021/bm7005592
   Packhaeuser CB, 2004, EUR J PHARM BIOPHARM, V58, P445, DOI 10.1016/j.ejpb.2004.03.003
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Royals MA, 1999, J BIOMED MATER RES, V45, P231, DOI 10.1002/(SICI)1097-4636(19990605)45:3<231::AID-JBM11>3.0.CO;2-H
   Schwendeman SP, 2002, CRIT REV THER DRUG, V19, P73, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.20
   Seong H, 2003, INT J PHARMACEUT, V251, P1, DOI 10.1016/S0378-5173(02)00543-4
   SPENLEHAUER G, 1986, J PHARM SCI, V75, P750, DOI 10.1002/jps.2600750805
   Turk M, 2004, AAPS PHARMSCITECH, V5, DOI 10.1208/pt050456
   Wischke C, 2008, INT J PHARMACEUT, V364, P298, DOI 10.1016/j.ijpharm.2008.04.042
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Xie M, 2007, ANTI-CANCER DRUG, V18, P459, DOI 10.1097/CAD.0b013e328012bccd
   Zolnik BS, 2008, J CONTROL RELEASE, V127, P137, DOI 10.1016/j.jconrel.2008.01.004
   Zou CP, 2007, GYNECOL ONCOL, V107, P441, DOI 10.1016/j.ygyno.2007.07.077
NR 34
TC 47
Z9 57
U1 4
U2 39
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD OCT
PY 2010
VL 27
IS 10
BP 2063
EP 2074
DI 10.1007/s11095-010-0202-y
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 650PD
UT WOS:000281860900005
PM 20668921
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Lee, S
   Reinhardt, JM
   Cattin, PC
   Abramoff, MD
AF Lee, Sangyeol
   Reinhardt, Joseph M.
   Cattin, Philippe C.
   Abramoff, Michael D.
TI Objective and expert-independent validation of retinal image
   registration algorithms by a projective imaging distortion model
SO MEDICAL IMAGE ANALYSIS
LA English
DT Article
DE Registration; Retina; Validation; Projective distortion
ID PAIRS
AB Fundus camera imaging of the retina is widely used to diagnose and manage ophthalmologic disorders including diabetic retinopathy, glaucoma, and age-related macular degeneration. Retinal images typically have a limited field of view, and multiple images can be joined together using an image registration technique to form a montage with a larger field of view. A variety of methods for retinal image registration have been proposed, but evaluating such methods objectively is difficult due to the lack of a reference standard for the true alignment of the individual images that make up the montage. A method of generating simulated retinal images by modeling the geometric distortions due to the eye geometry and the image acquisition process is described in this paper. We also present a validation process that can be used for any retinal image registration method by tracing through the distortion path and assessing the geometric misalignment in the coordinate system of the reference standard. The proposed method can be used to perform an accuracy evaluation over the whole image, so that distortion in the non-overlapping regions of the montage components can be easily assessed. We demonstrate the technique by generating test image sets with a variety of overlap conditions and compare the accuracy of several retinal image registration models. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Lee, Sangyeol; Reinhardt, Joseph M.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
   [Cattin, Philippe C.] Univ Basel, Med Image Anal Ctr, CH-4003 Basel, Switzerland.
   [Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] VA Med Ctr, Iowa City, IA USA.
   [Lee, Sangyeol; Abramoff, Michael D.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Basel; University of Iowa; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Iowa City VA Health Care System; University of Iowa
RP Abramoff, MD (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, 11180-Q PFP, Iowa City, IA 52242 USA.
EM michael-abramoff@uiowa.edu
RI Abramoff, Michael D/A-5836-2009; Cattin, Philippe/B-1301-2009
OI Abramoff, Michael D/0000-0002-3490-0037; Cattin, Philippe
   C./0000-0001-8785-2713; Reinhardt, Joseph/0000-0003-3526-3591
FU National Eye Institute [R01 EY017066]; Netherlands Organization for
   Scientific Research (NWO); Research to Prevent Blindness, NY, NY;
   Well-mark Foundation; NATIONAL EYE INSTITUTE [R01EY017066] Funding
   Source: NIH RePORTER
FX This work was supported by the National Eye Institute (R01 EY017066), by
   the Netherlands Organization for Scientific Research (NWO), by Research
   to Prevent Blindness, NY, NY and the Well-mark Foundation.
CR Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Abramoff MD, 2000, IEEE T MED IMAGING, V19, P986, DOI 10.1109/42.887614
   ABRAMOFF MD, 2010, OPHTHALMOLO IN PRESS, DOI DOI 10.1016/J.0PHTHA.2010.03.046
   ABRAMOFF MD, 2007, ARVO ANN M
   Can A, 2002, IEEE T PATTERN ANAL, V24, P347, DOI 10.1109/34.990136
   Can A, 2002, IEEE T PATTERN ANAL, V24, P412, DOI 10.1109/34.990145
   Cattin PC, 2006, LECT NOTES COMPUT SC, V4191, P185
   Chanwimaluang T, 2006, IEEE T INF TECHNOL B, V10, P129, DOI 10.1109/TITB.2005.856859
   Chou YY, 2004, 2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 AND 2, P716
   Christensen GE, 2006, LECT NOTES COMPUT SC, V4057, P128
   Christensen GE, 2001, IEEE T MED IMAGING, V20, P568, DOI 10.1109/42.932742
   Foracchia M, 2005, MED IMAGE ANAL, V9, P179, DOI 10.1016/j.media.2004.07.001
   GENG X, 2003, INT WORKSH BIOLM IM, P71
   Glatard T, 2006, LECT NOTES COMPUT SC, V4191, P152
   Gong SJ, 2005, P ANN INT IEEE EMBS, P1599, DOI 10.1109/IEMBS.2005.1616743
   Hackel RE, 2005, J OPHTHALMIC PHOTOGR, V27, P10
   Hartley R. I., 2004, MULTIPLE VIEW GEOMET, Vsecond, DOI DOI 10.1017/CBO9780511811685
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Jannin P, 2002, IEEE T MED IMAGING, V21, P1445, DOI 10.1109/TMI.2002.806568
   Jannin P, 2006, INT J COMPUT ASS RAD, V1, P63, DOI 10.1007/s11548-006-0044-6
   KANSKI JJ, 2005, DIS OCULAR FUNDUS
   KIM Y, 2006, P IEEE INT C ART REA, P413
   Kybic J, 2006, LECT NOTES COMPUT SC, V4241, P61
   LEE S, 2008, P SPIE C MED IM SAN, V6914
   LEE S, 2007, P SPIE C MED IM SAN, V6512
   Niemeijer M, 2010, IEEE T MED IMAGING, V29, P185, DOI 10.1109/TMI.2009.2033909
   Press WH., 1992, NUMERICAL RECIPES, V77, P51
   Remington L.A., 2021, CLIN ANATOMY PHYSL V
   Ritter N, 1999, IEEE T MED IMAGING, V18, P404, DOI 10.1109/42.774168
   Rusinkiewicz S, 2001, THIRD INTERNATIONAL CONFERENCE ON 3-D DIGITAL IMAGING AND MODELING, PROCEEDINGS, P145, DOI 10.1109/IM.2001.924423
   Schnabel JA, 2003, IEEE T MED IMAGING, V22, P238, DOI 10.1109/TMI.2002.808367
   Schwiegerling J., 2004, FIELD GUIDE VISUAL O
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Stewart CV, 2003, IEEE T MED IMAGING, V22, P1379, DOI 10.1109/TMI.2003.819276
   West J, 1997, J COMPUT ASSIST TOMO, V21, P554, DOI 10.1097/00004728-199707000-00007
   Yang GH, 2007, IEEE T PATTERN ANAL, V29, P1973, DOI 10.1109/TPAMl.2007.1116.
   You XG, 2005, LECT NOTES COMPUT SC, V3522, P259
   Zitova B, 2003, IMAGE VISION COMPUT, V21, P977, DOI 10.1016/S0262-8856(03)00137-9
NR 38
TC 17
Z9 19
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1361-8415
EI 1361-8423
J9 MED IMAGE ANAL
JI Med. Image Anal.
PD AUG
PY 2010
VL 14
IS 4
BP 539
EP 549
DI 10.1016/j.media.2010.04.001
PG 11
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Engineering, Biomedical; Radiology,
   Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Radiology, Nuclear Medicine & Medical
   Imaging
GA 623RM
UT WOS:000279759800005
PM 20493760
DA 2022-11-30
ER

PT J
AU Wielgus, AR
   Chignell, CF
   Ceger, P
   Roberts, JE
AF Wielgus, Albert R.
   Chignell, Colin F.
   Ceger, Patricia
   Roberts, Joan E.
TI Comparison of A2E Cytotoxicity and Phototoxicity with all-trans-Retinal
   in Human Retinal Pigment Epithelial Cells dagger
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID IN-VITRO; LIPOFUSCIN FLUOROPHORE; FERROUS OXIDATION; METABOLISM;
   RETINOIDS; ABCR; PHOTOREACTIVITY; PHAGOCYTOSIS; RETINOPATHY; SEGMENT
AB All-trans-retinal is the precursor of A2E, a fluorophore within lipofuscin, which accumulates in human retinal pigment epithelial (hRPE) cells and contributes to age-related macular degeneration. Here we have compared the in vitro dark cytotoxicity and visible-light-mediated photoreactivity of all-trans-retinal and A2E in hRPE cells. All-trans-retinal caused distinct cytotoxicity in hRPE cells measured with cell metabolic activity (MTS) and lactate dehydrogenase release assays. Significant increases in intracellular oxidized glutathione (GSSG), extracellular GSH and GSSG levels and lipid hydroperoxide production were observed in cells incubated in the dark with 25 and 50 mu m all-trans-retinal. Light modified all-trans-retinal's harmful action and decreased extracellular glutathione and hydroperoxide levels. A2E (< 25 mu m) did not affect cell metabolism or cytoplasmic membrane integrity in the dark or when irradiated. 25 mu m A2E raised the intracellular GSSG level in hRPE cells to a much smaller extent than 25 mu m all-trans-retinal. A2E did not induce glutathione efflux or hydroperoxide generation in the dark or after irradiation. These studies support our previous conclusions that although A2E may be harmful at high concentrations or when oxidized, its phototoxic properties are insignificant compared to those of all-trans-retinal. The endogenous production of A2E may serve as a protective mechanism to prevent damage to the retina by free all-trans-retinal.
C1 [Wielgus, Albert R.; Chignell, Colin F.; Ceger, Patricia] NIEHS, Pharmacol Lab, Res Triangle Pk, NC 27709 USA.
   [Roberts, Joan E.] Fordham Univ, Dept Nat Sci, New York, NY 10023 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); Fordham University
RP Wielgus, AR (通讯作者)，NIEHS, Pharmacol Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
EM albert.wielgus@duke.edu
OI Ceger, Patricia/0000-0002-5167-9928
FU NIH, National Institute of Environmental Health Sciences
FX This research was supported by the Intramural Research Program of the
   NIH, National Institute of Environmental Health Sciences. We thank Dr.
   Dan-Ning Hu for providing us with the human RPE cell line and Dr. Ann
   Motten for help in preparation of this manuscript.
CR BARON MH, 1989, PHOTOCHEM PHOTOBIOL, V49, P739, DOI 10.1111/j.1751-1097.1989.tb05572.x
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Boulton M, 2004, PHOTOCH PHOTOBIO SCI, V3, P759, DOI 10.1039/b400108g
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Broniec A, 2005, FREE RADICAL BIO MED, V38, P1037, DOI 10.1016/j.freeradbiomed.2004.12.023
   Chrispell JD, 2009, J BIOL CHEM, V284, P21468, DOI 10.1074/jbc.M109.020966
   DeLong JM, 2002, J AGR FOOD CHEM, V50, P248, DOI 10.1021/jf0106695
   Dillon J, 1996, PHOTOCHEM PHOTOBIOL, V63, P680, DOI 10.1111/j.1751-1097.1996.tb05673.x
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gay CA, 2002, ANAL BIOCHEM, V304, P42, DOI 10.1006/abio.2001.5566
   Harper WS, 2001, PHOTOCHEM PHOTOBIOL, V73, P71, DOI 10.1562/0031-8655(2001)073<0071:SOATRA>2.0.CO;2
   Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100
   HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210
   HU DN, 1982, BIRTH DEFECTS-ORIG, V18, P67
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   Inbaraj JJ, 2004, CHEM RES TOXICOL, V17, P55, DOI 10.1021/tx034132s
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Kanofsky JR, 2003, PHOTOCHEM PHOTOBIOL, V77, P235, DOI 10.1562/0031-8655(2003)077<0235:SOGFA>2.0.CO;2
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   LAI YL, 1985, BRAIN RES BULL, V15, P143, DOI 10.1016/0361-9230(85)90130-3
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   LAVAIL MM, 1973, J CELL BIOL, V58, P650, DOI 10.1083/jcb.58.3.650
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   OSTROVSKY MA, 1994, BIOFIZIKA+, V39, P13
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Rozanowska M. B., 2007, INVEST OPHTHALMOL VI, V48
   Rozanowski B., 2003, INVEST OPHTHALMOL VI, V44
   Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Schutt F, 2007, GRAEF ARCH CLIN EXP, V245, P391, DOI 10.1007/s00417-006-0376-5
   Siems W, 2002, FASEB J, V16, P1289, DOI 10.1096/fj.01-0765fje
   Sodergren E, 1998, J BIOCHEM BIOPH METH, V37, P137, DOI 10.1016/S0165-022X(98)00025-6
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Tolleson William H, 2005, Int J Environ Res Public Health, V2, P147, DOI 10.3390/ijerph2005010147
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Yang M, 2002, J BIOL CHEM, V277, P3318, DOI 10.1074/jbc.M108946200
NR 48
TC 31
Z9 31
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD JUL-AUG
PY 2010
VL 86
IS 4
BP 781
EP 791
DI 10.1111/j.1751-1097.2010.00750.x
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 622NM
UT WOS:000279670500009
PM 20497365
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Roehlecke, C
   Schaller, A
   Knels, L
   Funk, RHW
AF Roehlecke, Cora
   Schaller, Annette
   Knels, Lilla
   Funk, Richard H. W.
TI The influence of sublethal blue light exposure on human RPE cells
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; MITOCHONDRIAL-DNA
   DAMAGE; INDUCED APOPTOSIS; MACULAR DEGENERATION; OXIDATIVE STRESS;
   ADVANCED GLYCATION; OPTIC NEUROPATHIES; DIABETES-MELLITUS; VISIBLE-LIGHT
AB Purpose: To evaluate the in vitro response of retinal pigment epithelial (RPE) cells to a nonlethal dose of blue light.
   Methods: The human RPE cell line ARPE-19 was irradiated with blue light (405 nm) at an output power of 1 mW/cm(2) or 0.3 mW/cm(2). The following parameters were studied: metabolic activity; apoptosis; reactive oxygen species (ROS) production; mitochondrial membrane potential (MMP); ultrastructural changes of mitochondria; production of advanced glycation endproducts (AGEs); and stress-related cellular proteins.
   Results: Nonlethal doses of blue light irradiation significantly reduced ARPE-19 metabolic activity and MMP while increasing intracellular ROS levels and expression of stress-related proteins heme oxygenase-1 (HO-1), osteopontin, heat shock protein 27 (Hsp-27), manganese superoxide dismutase (SOD-Mn), and cathepsin D. Blue light irradiation also induced ultrastructural conformation changes in mitochondria, resulting in the appearance of giant mitochondria after 72 h. We further found enhanced formation of AGEs, particularly N-epsilon-(carboxymethyl) lysine (CML) modifications, and a delay in the cell cycle.
   Conclusions: ARPE-19 cells avoid cell death and recover from blue light irradiation by activating a host of defense mechanisms while simultaneously triggering cellular stress responses that may be involved in RPE disease development. Continuous light exposure can therefore detrimentally affect metabolically stressed RPE cells. This may have implications for pathogenesis of age-related macular degeneration.
C1 [Roehlecke, Cora; Schaller, Annette; Knels, Lilla; Funk, Richard H. W.] Tech Univ Dresden, Inst Anat, D-01304 Dresden, Germany.
   [Funk, Richard H. W.] DFG Ctr Regenerat Therapies Dresden Cluster Excel, Dresden, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden
RP Roehlecke, C (通讯作者)，Tech Univ Dresden, Inst Anat, D-01304 Dresden, Germany.
EM cora.roehlecke@tu-dresden.de
RI Funk, Richard HW/I-1780-2013
CR AHMED MU, 1986, J BIOL CHEM, V261, P4889
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Alizadeh P, 2006, EXP EYE RES, V83, P679, DOI 10.1016/j.exer.2006.03.009
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calonge TM, 2008, DNA REPAIR, V7, P136, DOI 10.1016/j.dnarep.2007.07.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Gonzalez RJ, 2001, TOXICOL IN VITRO, V15, P257, DOI 10.1016/S0887-2333(01)00014-5
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255
   Honda S, 2001, MOL VIS, V7, P63
   Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889
   Karbowski M, 1999, FREE RADICAL BIO MED, V26, P396, DOI 10.1016/S0891-5849(98)00209-3
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kniep EM, 2006, INVEST OPHTH VIS SCI, V47, P1185, DOI 10.1167/iovs.05-0555
   Krempler A, 2007, CELL CYCLE, V6, P1682, DOI 10.4161/cc.6.14.4480
   Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4
   Lascaratos G, 2007, VISION RES, V47, P1191, DOI 10.1016/j.visres.2006.12.014
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   MAINSTER MA, 1987, EYE-T OPHTH SOC UK, V1, P304, DOI 10.1038/eye.1987.49
   Manteifel V, 1997, J PHOTOCH PHOTOBIO B, V38, P25, DOI 10.1016/S1011-1344(96)07426-X
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Methy D, 2004, BRAIN RES, V1003, P151, DOI 10.1016/j.brainres.2003.12.031
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Mizutari K, 1997, J INVEST DERMATOL, V108, P797, DOI 10.1111/1523-1747.ep12292244
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063
   Nuydens R, 1999, J NEUROSCI METH, V92, P153, DOI 10.1016/S0165-0270(99)00107-7
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x
   Osborne NN, 2008, J NEUROCHEM, V105, P2013, DOI 10.1111/j.1471-4159.2008.05320.x
   Osborne NN, 2006, BRIT J OPHTHALMOL, V90, P237, DOI 10.1136/bjo.2005.082230
   Pawlak AM, 2008, ANN NY ACAD SCI, V1126, P59, DOI 10.1196/annals.1433.066
   PUTTING BJ, 1992, INVEST OPHTH VIS SCI, V33, P3385
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6
   Rezai KA, 2008, GRAEF ARCH CLIN EXP, V246, P671, DOI 10.1007/s00417-006-0484-2
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8
   Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180
   SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198
   SCHNIDER SL, 1980, J CLIN INVEST, V66, P1179, DOI 10.1172/JCI109950
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Seagle BLL, 2006, P NATL ACAD SCI USA, V103, P16644, DOI 10.1073/pnas.0605986103
   Seko Y, 2001, GRAEF ARCH CLIN EXP, V239, P47, DOI 10.1007/s004170000220
   SKULACHEV VP, 1980, BIOCHIM BIOPHYS ACTA, V604, P297
   Smith Bradley T., 2005, International Ophthalmology Clinics, V45, P107
   SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   vanBest JA, 1997, MICROSC RES TECHNIQ, V36, P77, DOI 10.1002/(SICI)1097-0029(19970115)36:2<77::AID-JEMT1>3.0.CO;2-S
   WANG RJ, 1975, PHOTOCHEM PHOTOBIOL, V21, P373, DOI 10.1111/j.1751-1097.1975.tb06688.x
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wood JPM, 2008, MOL VIS, V14, P334
   Wu JM, 1999, EYE, V13, P577, DOI 10.1038/eye.1999.142
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
NR 63
TC 63
Z9 70
U1 0
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 21
PY 2009
VL 15
IS 204-05
BP 1929
EP 1938
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 517MK
UT WOS:000271618300002
PM 19784391
DA 2022-11-30
ER

PT J
AU Wang, ZY
   Shen, LJ
   Tu, LL
   Hu, DN
   Liu, GY
   Zhou, ZL
   Lin, Y
   Chen, LH
   Qu, J
AF Wang, Zhao-yang
   Shen, Li-jun
   Tu, LiLi
   Hu, Dan-ning
   Liu, Guo-Ying
   Zhou, Zhong-lou
   Lin, Yi
   Chen, Lin-Hua
   Qu, Jia
TI Erythropoietin protects retinal pigment epithelial cells from oxidative
   damage
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Apoptosis; Erythropoietin; Mitochondria; Oxidant stress; Free radicals
ID RECOMBINANT-HUMAN-ERYTHROPOIETIN; MITOCHONDRIAL-DNA DAMAGE;
   BLOOD-BRAIN-BARRIER; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS;
   SKELETAL-MUSCLE; GENE-EXPRESSION; GANGLION-CELLS; RAT MODEL; IN-VITRO
AB Oxidative damage from reactive oxygen species (ROS) has been implicated in many diseases, including age-related macular degeneration, in which the retinal pigment epithelium (RPE) is considered a primary target. The aim of this study was to determine whether erythropoietin (EPO) protects cultured human RPE cells against oxidative damage and to identify the pathways that may mediate protection. EPO (1 IU/ml) significantly increased the viability of oxidant-treated RPE cells, decreased the release of the inflammatory cytokines tumor necrosis factor-a and interleukin-1 beta, recovered the RPE cells' barrier integrity disrupted by oxidative stress, prevented oxidant-induced cell DNA fragmentation and membrane phosphatidylserine exposure, and also reduced the levels of oxidant-induced intracellular ROS and restored cellular antioxidant potential, total antioxidant capacity, glutathione peroxidase, and superoxide dismutase and decreased malondialdehyde, the end product of lipid peroxidation. EPO inhibited caspase-3-like activity. Protection by EPO was partly dependent on the activation of Akt1 and the maintenance of the mitochondrial membrane potential. No enhanced or synergistic protection was observed during application of Z-DEVD-FMK (caspase-3 inhibitor) combined with EPO compared with cultures exposed to EPO and H2O2 alone. Together, these results suggest that EPO could protect against oxidative injury-induced cell death and mitochondrial dysfunction in RPE cells through modulation of Akt1 phosphorylation, mitochondrial membrane potential, and cysteine protease activity. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Wang, Zhao-yang; Shen, Li-jun; Tu, LiLi; Hu, Dan-ning; Liu, Guo-Ying; Zhou, Zhong-lou; Lin, Yi; Chen, Lin-Hua; Qu, Jia] Wenzhou Med Coll, Hosp Eye, Sch Ophthalmol & Optometry, Wenzhou 325027, Zhejiang, Peoples R China.
   [Wang, Zhao-yang] Zhejiang Univ, Sch Med, Dept Ophthalmol, Hangzhou 310058, Zhejiang, Peoples R China.
   [Hu, Dan-ning] New York Med Coll, New York Eye & Ear Infirm, Tissue Culture Ctr, Valhalla, NY 10595 USA.
C3 Wenzhou Medical University; Zhejiang University; New York Eye & Ear
   Infirmary of Mount Sinai; New York Medical College
RP Qu, J (通讯作者)，Wenzhou Med Coll, Hosp Eye, Sch Ophthalmol & Optometry, Wenzhou 325027, Zhejiang, Peoples R China.
EM jqu-wmc@hotmail.com
FU Zhejiang Foundation of Natural Sciences; National Basic Research Program
   [2006CB503909]; Wenzhou bureau of science and technology [Y2004A713];
   Zhejiang youth foundation of traditional Chinese medicine [2005Y042]
FX This work was supported in part by Grant Y207411 from the Zhejiang
   Foundation of Natural Sciences, the National Basic Research Program
   (2006CB503909), Wenzhou bureau of science and technology (Y2004A713) and
   Zhejiang youth foundation of traditional Chinese medicine (2005Y042).
CR Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   Barbouti A, 2002, FREE RADICAL BIO MED, V33, P691, DOI 10.1016/S0891-5849(02)00967-X
   Barouch Fina C., 2007, International Ophthalmology Clinics, V47, P185, DOI 10.1097/IIO.0b013e3180377936
   Bartesaghi S, 2005, NEUROTOXICOLOGY, V26, P923, DOI 10.1016/j.neuro.2005.01.016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENEZRA D, 1990, ARCH OPHTHALMOL-CHIC, V108, P573, DOI 10.1001/archopht.1990.01070060121061
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022
   Chi OZ, 2008, PHARMACOLOGY, V82, P38, DOI 10.1159/000127839
   Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528
   Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Garcia-Ramirez M, 2008, DIABETES CARE, V31, P1189, DOI 10.2337/dc07-2075
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078
   Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9
   Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   Hawkins BS, 1999, MOL VIS, V5
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Jin ML, 2005, INVEST OPHTH VIS SCI, V46, P4311, DOI 10.1167/iovs.05-0353
   Kannan R, 2004, FREE RADICAL BIO MED, V37, P166, DOI 10.1016/j.freeradbiomed.2004.04.011
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katavetin P, 2007, KIDNEY INT, V72, pS10, DOI 10.1038/sj.ki.5002482
   Kilic U, 2004, FASEB J, V18, P249, DOI 10.1096/fj.04-2493fje
   Kim KH, 2008, J PHARMACOL EXP THER, V324, P160, DOI 10.1124/jpet.107.125773
   Lacombe C, 1998, HAEMATOLOGICA, V83, P724
   Li LH, 2006, CIRCULATION, V113, P535, DOI 10.1161/CIRCULATIONAHA.105.568402
   Li X, 2008, FREE RADICAL BIO MED, V44, P1465, DOI 10.1016/j.freeradbiomed.2008.01.004
   Li YW, 2006, CARDIOVASC RES, V71, P684, DOI 10.1016/j.cardiores.2006.06.003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Martinez-Estrada OM, 2003, EUR J NEUROSCI, V18, P2538, DOI 10.1046/j.1460-9568.2003.02987.x
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Miro O, 2002, AM J KIDNEY DIS, V39, P1025, DOI 10.1053/ajkd.2002.32776
   Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200
   Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x
   Ramakrishnan R, 2004, J CLIN PHARMACOL, V44, P991, DOI 10.1177/0091270004268411
   Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X
   Sawyer RT, 2005, FREE RADICAL BIO MED, V38, P928, DOI 10.1016/j.freeradbiomed.2004.12.014
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Tarpey MM, 2004, AM J PHYSIOL-REG I, V286, pR431, DOI 10.1152/ajpregu.00361.2003
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tsai JC, 2005, CURR EYE RES, V30, P1025, DOI 10.1080/02713680500320729
   Verna LK, 2000, CELL BIOL TOXICOL, V16, P303, DOI 10.1023/A:1026798314217
   Voloboueva LA, 2005, INVEST OPHTH VIS SCI, V46, P4302, DOI 10.1167/iovs.04-1098
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Winkler BS, 1999, MOL VIS, V5
   Wu Y, 2007, EUR J PHARMACOL, V564, P47, DOI 10.1016/j.ejphar.2007.02.020
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Yamasaki M, 2005, BRAIN RES, V1050, P15, DOI 10.1016/j.brainres.2005.05.037
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
   Zhang JF, 2008, INVEST OPHTH VIS SCI, V49, P732, DOI 10.1167/iovs.07-0721
   Zhong LC, 2007, INVEST OPHTH VIS SCI, V48, P1212, DOI 10.1167/iovs.06-0757
NR 73
TC 75
Z9 79
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD APR 15
PY 2009
VL 46
IS 8
BP 1032
EP 1041
DI 10.1016/j.freeradbiomed.2008.11.027
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 432KW
UT WOS:000265132900007
PM 19136057
DA 2022-11-30
ER

PT J
AU Zipfel, PF
   Hallstrom, T
   Hammerschmidt, S
   Skerka, C
AF Zipfel, Peter F.
   Hallstroem, Teresia
   Hammerschmidt, Sven
   Skerka, Christine
TI The complement fitness Factor H: Role in human diseases and for immune
   escape of pathogens, like pneumococci
SO VACCINE
LA English
DT Article
DE Alternative complement pathway; Factor H; Complement evasion of
   pathogens; Autoimmune diseases hemolytic uremic syndrome; Dense deposit
   disease - membranoproliferative glomerulonephritis; Age related macular
   degeneration
ID HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; MACULAR DEGENERATION;
   ALTERNATIVE PATHWAY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   STREPTOCOCCUS-PNEUMONIAE; SURFACE PROTEIN; FAMILY PROTEINS; FACTOR-B;
   MUTATIONS
AB Factor H is the central regulator of the alternative complement pathway and controls early activation of the complement cascade at the level of the C3 convertase. Mutations in the Factor H gene are associated with severe and diverse diseases including the rare renal disorders hemolytic Uremic syndrome (HUS) and membranoproliferative glomerulonephritis (MPGN) also termed dense deposit disease (DDD), as well as the more frequent retinal disease age related macular degeneration (AMD). In addition, pathogenic microbes utilize host complement Factor H for immune evasion and these pathogens express specific Surface receptors which bind host innate immune regulators. Sequence variations or mutations of one single gene, coding for the host regulator Factor H, form the basis for multiple, different disorders Such as human renal and retinal diseases as well as infections. This association of Factor H but also of additional related complement components and regulators with the same diseases demonstrate ail important role of complement, particularly of the alternative pathway, for tissue homeostasis. Disturbances of this central immune surveillance system lead to damage of autologous tissues and surfaces and result in autoimmune diseases. Remarkably, pathogenic microbes copy this mechanism of immune Surveillance: they mimic the composition of host cell's, bind Factor H to their surface and engage acquired host Factor H for immune disguise. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Hans Knoll Inst, D-07745 Jena, Germany.
   [Zipfel, Peter F.] Univ Jena, Jena, Germany.
   [Hammerschmidt, Sven] Ernst Moritz Arndt Univ Greifswald, Dept Genet Microorganisms, D-17487 Greifswald, Germany.
C3 Hans Knoll Institute (HKI); Friedrich Schiller University of Jena; Ernst
   Moritz Arndt Universitat Greifswald
RP Zipfel, PF (通讯作者)，Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Hans Knoll Inst, Beutenbergstr 11A, D-07745 Jena, Germany.
EM peter.zipfel@hki-jena.de
RI Hammerschmidt, Sven/G-2598-2010
OI Hammerschmidt, Sven/0000-0002-6382-6681
FU Deutsche Forschungsgemeinschaft, Kidneeds, Iowa City [10]; NIH,
   ProRetina; Hellmuth Hertzi Foundation; Kungliga Fysiografiska
   Sallskapet, Lund (TH)
FX The work of the authors is supported by the Deutsche
   Forschungsgemeinschaft, Kidneeds, Iowa City, 10, the NIH, ProRetina and
   Hellmuth Hertzi Foundation by the Kungliga Fysiografiska Sallskapet,
   Lund (TH).; Conflict of interest statement: The authors disclose no
   financial and personal relationships with other people or organisations
   that Could inappropriately influence their work.
CR Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   DAHA MR, 1976, J IMMUNOL, V116, P568
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Jorge EG, 2007, P NATL ACAD SCI USA, V104, P240, DOI 10.1073/pnas.0603420103
   Duthy TG, 2002, INFECT IMMUN, V70, P5604, DOI 10.1128/IAI.70.10.5604-5611.2002
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200
   FREMEAUXBACCHI V, 2008, BLOOD            SEP
   Friese MA, 2000, CLIN EXP IMMUNOL, V121, P406, DOI 10.1046/j.1365-2249.2000.01285.x
   GASSER C, 1955, Schweiz Med Wochenschr, V85, P905
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HAMMERSCHMIDT S, COMMUNITY A IN PRESS
   Hammerschmidt S, 2007, J IMMUNOL, V178, P5848, DOI 10.4049/jimmunol.178.9.5848
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200
   Jarva H, 2004, J IMMUNOL, V172, P3111, DOI 10.4049/jimmunol.172.5.3111
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kraiczy P, 2006, MOL IMMUNOL, V43, P31, DOI 10.1016/j.molimm.2005.06.016
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   Lachmann PJ, 2002, P NATL ACAD SCI USA, V99, P8461, DOI 10.1073/pnas.132284499
   Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824
   Li J, 2007, INFECT IMMUN, V75, P5877, DOI 10.1128/IAI.00839-07
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200
   Machado Rodriguez Jose M., 2004, Biotecnologia Vegetal, V4, P67
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Noris M, 2005, J AM SOC NEPHROL, V16, P1035, DOI 10.1681/ASN.2004100861
   PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1
   Rooijakkers SHM, 2007, MOL IMMUNOL, V44, P23, DOI 10.1016/j.molimm.2006.06.011
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Schwertz R, 2001, PEDIAT ALLERG IMM-UK, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x
   SKERKA C, VACCINES
   Smith RJH, 2007, J AM SOC NEPHROL, V18, P2447, DOI 10.1681/ASN.2007030356
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Venables JP, 2006, PLOS MED, V3, P1957, DOI 10.1371/journal.pmed.0030431
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2007, MOL IMMUNOL, V44, P3850, DOI 10.1016/j.molimm.2007.06.149
   Zipfel PF, 2007, ADV EXP MED BIOL, V598, P80
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
   ZIPFEL PF, 2007, COMPLEMENT RENAL DIS
NR 55
TC 56
Z9 57
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD DEC 30
PY 2008
VL 26
SU 8
BP I67
EP I74
DI 10.1016/j.vaccine.2008.11.015
PG 8
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA 402HT
UT WOS:000263005500013
PM 19388168
DA 2022-11-30
ER

PT J
AU Grant, SFA
   Hakonarson, H
AF Grant, Struan F. A.
   Hakonarson, Hakon
TI Recent development in pharmacogenomics: from candidate genes to
   genome-wide association studies
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Review
DE copy-number variation; genetics; genome-wide association;
   pharmacogenomics; single nucleotide polymorphism
ID BONE-MINERAL DENSITY; SINGLE-NUCLEOTIDE POLYMORPHISMS;
   VITAMIN-D-RECEPTOR; TRANSCRIPTION-FACTOR-7-LIKE-2 TCF7L2 GENE;
   HORMONE-REPLACEMENT THERAPY; LEUKOTRIENE C-4 SYNTHASE; ADVERSE
   DRUG-REACTIONS; NEONATAL DIABETES-MELLITUS; CORONARY-HEART-DISEASE;
   ACTING BETA-AGONIST
AB Genetic diversity, most notably through single nucleotide polymorphisms and copy-number variation, together with specific environmental exposures, contributes to both disease susceptibility and drug response variability. It has proved difficult to isolate disease genes that confer susceptibility to complex disorders, and as a consequence, even fewer genetic variants that influence clinical drug responsiveness have been uncovered. As such, the candidate gene approach has largely failed to deliver and, although the family-based linkage approach has certain theoretical advantages in dealing with common/complex disorders, progress has been slower than was hoped. More recently, genome-wide association studies have gained increasing popularity, as they enable scientists to robustly associate specific variants with the predisposition for complex disease, such as age-related macular degeneration, Type 2 diabetes, inflammatory bowel disease, obesity, autism and leukemia. This relatively new methodology has stirred new hope for the mapping of genes that regulate drug response related to these conditions, Collectively, these studies support the notion that modern high-throughput single nucleotide polymorphism genotyping technologies, when applied to large and comprehensively phenotyped patient cohorts, will readily reveal the most clinically relevant disease-modifying and drug response genes. This review addresses both recent advances in the genotyping field and highlights from genome-wide association studies, which have conclusively uncovered variants that underlie disease susceptibility and/or variability in drug response in common disorders.
C1 Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr 1216F, Philadelphia, PA 19104 USA.
   Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr 1216E, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania; Pennsylvania Medicine;
   Childrens Hospital of Philadelphia
RP Hakonarson, H (通讯作者)，Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr 1216F, 3615 Civic Ctr Blvd, Philadelphia, PA 19104 USA.
EM grants@chop.edu; hakonarson@chop.edu
CR Abramson Michael J, 2003, Am J Respir Med, V2, P287
   Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216
   Asher MI, 1998, EUR RESPIR J, V12, P315
   BALDASSANO RN, 2007, IN PRESS GUT
   BALDASSANO RN, 2007, IN PRESS CLIN GASTRO
   Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401
   Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4
   Bast RC, 2001, J CLIN ONCOL, V19, P1865, DOI 10.1200/JCO.2001.19.6.1865
   Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC
   BAYLINK DJ, 1983, NEW ENGL J MED, V309, P306, DOI 10.1056/NEJM198308043090509
   Becker C, 2003, J CLIN INVEST, V112, P693, DOI 10.1172/JCI200317464
   Bell CG, 2005, NAT REV GENET, V6, P221, DOI 10.1038/nrg1556
   Bennett RG, 2003, DIABETES, V52, P2315, DOI 10.2337/diabetes.52.9.2315
   Billington CK, 2003, RESP RES, V4
   BORJESON M, 1976, ACTA PAEDIATR SCAND, V65, P279, DOI 10.1111/j.1651-2227.1976.tb04887.x
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543
   Carlborg O, 2004, NAT REV GENET, V5, P618, DOI 10.1038/nrg1407
   Cartwright C P, 2001, Expert Rev Mol Diagn, V1, P371, DOI 10.1586/14737159.1.4.371
   Cauchi S, 2006, DIABETES, V55, P2903, DOI 10.2337/db06-0474
   Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226
   Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4
   Chandak GR, 2007, DIABETOLOGIA, V50, P63, DOI 10.1007/s00125-006-0502-2
   CHIKANZA IC, 1993, EUR J CLIN INVEST, V23, P845, DOI 10.1111/j.1365-2362.1993.tb00740.x
   Chinchilli VM, 2007, J ALLERGY CLIN IMMUN, V119, P303, DOI 10.1016/j.jaci.2006.11.632
   Cho SH, 2005, CLIN EXP ALLERGY, V35, P1162, DOI 10.1111/j.1365-2222.2005.02319.x
   Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC
   Chowbay B, 2005, DRUG METAB REV, V37, P327, DOI 10.1081/DMR-200028805
   Codner E, 2005, DIABETES CARE, V28, P758, DOI 10.2337/diacare.28.3.758
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cooper GS, 1996, J BONE MINER RES, V11, P1841
   Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7
   Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102
   Currie GP, 2003, BRIT J CLIN PHARMACO, V56, P422, DOI 10.1046/j.1365-2125.2003.01952.x
   D'Acquisto F, 2006, CURR OPIN PHARMACOL, V6, P387, DOI 10.1016/j.coph.2006.02.009
   Dahlen B, 1997, THORAX, V52, P342, DOI 10.1136/thx.52.4.342
   Damcott CM, 2006, DIABETES, V55, P2654, DOI 10.2337/db06-0338
   de Leon J, 2005, J CLIN PSYCHIAT, V66, P15, DOI 10.4088/JCP.v66n0103
   de Maat MPM, 1998, ARTERIOSCL THROM VAS, V18, P265, DOI 10.1161/01.ATV.18.2.265
   Deng HW, 1998, HUM GENET, V103, P576, DOI 10.1007/s004390050872
   Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC
   Dominiczak MH, 2003, CLIN CHEM LAB MED, V41, P1266, DOI 10.1515/CCLM.2003.194
   Dormann H, 2004, J INTERN MED, V255, P653, DOI 10.1111/j.1365-2796.2004.01326.x
   Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615
   Drazen JM, 1999, INT ARCH ALLERGY IMM, V118, P275, DOI 10.1159/000024098
   Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535
   Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308
   Etienne MC, 2004, PHARMACOGENETICS, V14, P785, DOI 10.1097/00008571-200412000-00001
   Farooqi IS, 2005, INT J OBESITY, V29, P1149, DOI 10.1038/sj.ijo.0803056
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100
   Fenech A, 2002, BRIT J CLIN PHARMACO, V53, P3, DOI 10.1046/j.0306-5251.2001.01509.x
   Ferrari SL, 1998, J BONE MINER RES, V13, P363, DOI 10.1359/jbmr.1998.13.3.363
   Ferraro TN, 2005, EPILEPSY BEHAV, V7, P18, DOI 10.1016/j.yebeh.2005.04.010
   Florez JC, 2004, DIABETES, V53, P1360, DOI 10.2337/diabetes.53.5.1360
   Florez JC, 2006, NEW ENGL J MED, V355, P241, DOI 10.1056/NEJMoa062418
   FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Frayling TM, 1997, DIABETES, V46, P720, DOI 10.2337/diabetes.46.4.720
   Friedman JM, 2004, NAT MED, V10, P563, DOI 10.1038/nm0604-563
   FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005
   Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7, DOI 10.1164/ajrccm.162.1.9911032
   Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722
   Garbe E, 1998, J CLIN EPIDEMIOL, V51, P129, DOI 10.1016/S0895-4356(97)00263-1
   Gearry RB, 2005, J GASTROEN HEPATOL, V20, P1149, DOI 10.1111/j.1440-1746.2005.03832.x
   Gennari L, 2002, J STEROID BIOCHEM, V81, P1, DOI 10.1016/S0960-0760(02)00043-2
   Giacomini KM, 2007, CLIN PHARMACOL THER, V81, P328, DOI 10.1038/sj.clpt.6100087
   Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641
   Gloyn AL, 2004, NEW ENGL J MED, V350, P1838, DOI 10.1056/NEJMoa032922
   Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568
   Goldstein DB, 2005, PHILOS T R SOC B, V360, P1571, DOI 10.1098/rstb.2005.1686
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203
   Gray IC, 2000, HUM MOL GENET, V9, P2403, DOI 10.1093/hmg/9.16.2403
   Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073
   Groves CJ, 2006, DIABETES, V55, P2640, DOI 10.2337/db06-0355
   GUEGUEN R, 1995, J BONE MINER RES, V10, P2017
   Guo YJ, 2005, DRUG METAB DISPOS, V33, P749, DOI 10.1124/dmd.105.003616
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
   Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102
   Hakonarson H, 2005, JAMA-J AM MED ASSOC, V293, P2245, DOI 10.1001/jama.293.18.2245
   Hakonarson H, 2003, PHARMACOGENOMICS, V4, P209, DOI 10.1517/phgs.4.2.209.22627
   Hakonarson H, 2001, AM J RESP CELL MOL, V25, P761, DOI 10.1165/ajrcmb.25.6.4628
   Hakonarson H, 2001, CURR OPIN PEDIATR, V13, P267, DOI 10.1097/00008480-200106000-00010
   Hall IP, 2001, RESP RES, V3, DOI 10.1186/rr159
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Han KO, 1997, J CLIN ENDOCR METAB, V82, P991, DOI 10.1210/jc.82.4.991
   Hancox RJ, 1998, EUR RESPIR J, V11, P589
   Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953
   HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B
   Hattersley AT, 2005, LANCET, V366, P1315, DOI 10.1016/S0140-6736(05)67531-9
   Hauner H, 2003, PHARMACOGENETICS, V13, P453, DOI 10.1097/00008571-200308000-00003
   Heaney RP, 2000, OSTEOPOROSIS INT, V11, P985, DOI 10.1007/s001980070020
   Hebebrand J, 2003, Obes Rev, V4, P139
   HEIERVANG E, 1989, ACTA PAEDIATR SCAND, V78, P74, DOI 10.1111/j.1651-2227.1989.tb10890.x
   Helgadottir A, 2006, NAT GENET, V38, P68, DOI 10.1038/ng1692
   Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311
   Helgason A, 2007, NAT GENET, V39, P218, DOI 10.1038/ng1960
   Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779
   Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521
   HOLLINGWORTH W, 1995, J PUBLIC HEALTH MED, V17, P269
   HOWARD G, 1995, J CLIN ENDOCR METAB, V80, P2800, DOI 10.1210/jc.80.9.2800
   Huang Y, 2007, CANCER METAST REV, V26, P183, DOI 10.1007/s10555-007-9050-6
   Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Hulot JS, 2005, PHARMACOGENET GENOM, V15, P277, DOI 10.1097/01213011-200505000-00002
   Humphries SE, 2006, J MOL MED, V84, P1005, DOI 10.1007/s00109-006-0108-7
   Hunter D, 2000, J BONE MINER RES, V15, P2276, DOI 10.1359/jbmr.2000.15.11.2276
   HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4
   HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19
   Ioannidis JPA, 2003, TRENDS MOL MED, V9, P135, DOI 10.1016/S1471-4914(03)00030-3
   Irvin CG, 2007, AM J RESP CRIT CARE, V175, P235, DOI 10.1164/rccm.200603-416OC
   Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5
   Israel E, 2000, LANCET, V356, P527, DOI 10.1016/S0140-6736(00)02574-5
   Jackson CM, 2004, DRUG SAFETY, V27, P243, DOI 10.2165/00002018-200427040-00003
   Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470
   Jorde LB, 2004, NAT GENET, V36, pS28, DOI 10.1038/ng1435
   Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913
   Kim MH, 2002, J ASTHMA, V39, P441, DOI 10.1081/JAS-120004037
   Kinuta K, 2000, ENDOCRINOLOGY, V141, P1317, DOI 10.1210/en.141.4.1317
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klupa T, 2005, DIABETOLOGIA, V48, P1029, DOI 10.1007/s00125-005-1731-5
   KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101
   Kobayashi N, 2002, MATURITAS, V41, P193, DOI 10.1016/S0378-5122(01)00287-0
   Kotani Y, 1999, J ASTHMA, V36, P583, DOI 10.3109/02770909909087295
   KRALL EA, 1993, J BONE MINER RES, V8, P1
   Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203
   Kukreti R, 2005, PHARMACOGENOMICS, V6, P399, DOI 10.1517/14622416.6.4.399
   Kullberg MC, 2006, J EXP MED, V203, P2485, DOI 10.1084/jem.20061082
   Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010
   Lane SJ, 1997, INT ARCH ALLERGY IMM, V113, P193, DOI 10.1159/000237544
   Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200
   Lazarus SC, 1998, AM J MANAG CARE, V4, P841
   Ledford D, 1998, J ALLERGY CLIN IMMUN, V102, P353, DOI 10.1016/S0091-6749(98)70120-4
   Lepper ER, 2005, PHARMACOGENOMICS, V6, P115, DOI 10.1517/14622416.6.2.115
   Leung DYM, 2000, AM J RESP CRIT CARE, V162, P1
   Liljedahl U, 2004, J HYPERTENS, V22, P2321, DOI 10.1097/00004872-200412000-00014
   Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8
   Lin M, 2005, PHARMACOGENOMICS J, V5, P149, DOI 10.1038/sj.tpj.6500302
   Litonjua AA, 2004, CHEST, V126, P66, DOI 10.1378/chest.126.1.66
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Lyon HN, 2005, AM J CLIN NUTR, V82, p215S, DOI 10.1093/ajcn/82.1.215S
   Maitland-Van Der Zee AH, 2005, PHARMACOGENET GENOM, V15, P287, DOI 10.1097/01213011-200505000-00003
   Malik I, 2001, LANCET, V358, P971, DOI 10.1016/S0140-6736(01)06104-9
   Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874
   Massart F, 2001, MATURITAS, V40, P103, DOI 10.1016/S0378-5122(01)00283-3
   Matschinsky FM, 2006, DIABETES, V55, P1
   MATSUYAMA T, 1995, LANCET, V345, P1238
   McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723
   McLeod HL, 2001, NAT GENET, V29, P247, DOI 10.1038/ng1101-247
   McNamara Dennis M, 2004, Congest Heart Fail, V10, P302, DOI 10.1111/j.1527-5299.2004.03855.x
   Mellen PB, 2005, J HYPERTENS, V23, P1311, DOI 10.1097/01.hjh.0000173510.52987.68
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Moore JH, 2003, HUM HERED, V56, P73, DOI 10.1159/000073735
   Mora S, 2003, ENDOCRIN METAB CLIN, V32, P39, DOI 10.1016/S0889-8529(02)00058-0
   MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0
   Morrow DA, 2003, CIRCULATION, V108, P250, DOI 10.1161/01.CIR.0000078080.37974.D2
   Nagel RL, 2005, CR BIOL, V328, P606, DOI 10.1016/j.crvi.2005.05.003
   Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104
   Ober C, 2005, J ALLERGY CLIN IMMUN, V116, P274, DOI 10.1016/j.jaci.2005.04.039
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Ongphiphadhanakul B, 2000, CLIN ENDOCRINOL, V52, P581, DOI 10.1046/j.1365-2265.2000.00979.x
   Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4
   ORDOVAS JM, 1995, ATHEROSCLEROSIS, V113, P157, DOI 10.1016/0021-9150(94)05439-P
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Page GP, 2003, AM J HUM GENET, V73, P711, DOI 10.1086/378900
   Palmer LJ, 2005, LANCET, V366, P1223, DOI 10.1016/S0140-6736(05)67485-5
   Palmer LJ, 2001, RESP RES, V2, P102, DOI 10.1186/rr45
   Patterson M, 2005, PLOS BIOL, V3, P1511, DOI 10.1371/journal.pbio.0030327
   Pearson ER, 2000, DIABETIC MED, V17, P543, DOI 10.1046/j.1464-5491.2000.00305.x
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339
   Phillips KA, 2005, NAT REV DRUG DISCOV, V4, P500, DOI 10.1038/nrd1749
   Poirier J, 1995, ANN MED, V27, P663, DOI 10.3109/07853899509019253
   Qureshi AM, 2002, CALCIFIED TISSUE INT, V70, P158, DOI 10.1007/s00223-001-1035-9
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334
   Rennert NJ, 2003, PRIMARY CARE, V30, P569, DOI 10.1016/S0095-4543(03)00035-6
   Reynolds GP, 2005, PROG NEURO-PSYCHOPH, V29, P1021, DOI 10.1016/j.pnpbp.2005.03.019
   RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315
   Richard F, 1997, LANCET, V349, P539, DOI 10.1016/S0140-6736(97)80089-X
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223
   Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728
   Roses AD, 2002, LIFE SCI, V70, P1471, DOI 10.1016/S0024-3205(01)01532-6
   Roses AD, 2000, LANCET, V355, P1358, DOI 10.1016/S0140-6736(00)02126-7
   Ross, 1998, Oncologist, V3, P237
   Rosskopf D, 2007, SCIENCE, V315, DOI [10.1126/science.1130571, 10.1126/science.1130012, 10.1126/science.1129402]
   Roth M, 2006, CURR DRUG TARGETS, V7, P589, DOI 10.2174/138945006776818638
   Royal CDM, 2004, NAT GENET, V36, pS5, DOI 10.1038/ng1454
   Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401
   Sagen JV, 2004, DIABETES, V53, P2713, DOI 10.2337/diabetes.53.10.2713
   Sainz J, 1997, NEW ENGL J MED, V337, P77, DOI 10.1056/NEJM199707103370202
   Salmen T, 2000, J BONE MINER RES, V15, P2479, DOI 10.1359/jbmr.2000.15.12.2479
   Salmen T, 2000, J BONE MINER RES, V15, P315, DOI 10.1359/jbmr.2000.15.2.315
   Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28
   Sampson AP, 1997, INT ARCH ALLERGY IMM, V113, P355, DOI 10.1159/000237600
   Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9
   Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339
   Saxena R, 2006, DIABETES, V55, P2890, DOI 10.2337/db06-0381
   Schaeffeler E, 2004, PHARMACOGENETICS, V14, P407, DOI 10.1097/01.fpc.0000114745.08559.db
   Schork NJ, 2000, CLIN GENET, V58, P250, DOI 10.1034/j.1399-0004.2000.580402.x
   Schousboe K, 2003, TWIN RES, V6, P409, DOI 10.1375/136905203770326411
   Scott LJ, 2006, DIABETES, V55, P2649, DOI 10.2337/db06-0341
   Sears M R, 1998, Can Respir J, V5 Suppl A, p54A
   SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903
   Shah RR, 2005, PHILOS T R SOC B, V360, P1617, DOI 10.1098/rstb.2005.1693
   Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   Shepherd M, 2003, DIABETES CARE, V26, P3191, DOI 10.2337/diacare.26.11.3191-a
   SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963
   SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2
   Silverman EK, 2003, J ALLERGY CLIN IMMUN, V112, P870, DOI 10.1016/S0091-6749(03)02023-2
   Silverman ES, 1998, AM J RESP CELL MOL, V19, P316, DOI 10.1165/ajrcmb.19.2.3154
   Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Snyder EM, 2006, CHEST, V129, P762, DOI 10.1378/chest.129.3.762
   SOROKO SB, 1994, J BONE MINER RES, V9, P761
   Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486
   Sovik O, 1998, DIABETOLOGIA, V41, P607, DOI 10.1007/s001250050956
   Stanulla M, 2005, JAMA-J AM MED ASSOC, V293, P1485, DOI 10.1001/jama.293.12.1485
   Stoughton RB, 2005, NAT REV DRUG DISCOV, V4, P345, DOI 10.1038/nrd1696
   STUNKARD AJ, 1986, JAMA-J AM MED ASSOC, V256, P51, DOI 10.1001/jama.256.1.51
   Syvanen AC, 2005, NAT GENET, V37, pS5, DOI 10.1038/ng1558
   Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635
   Szekerres T, 2005, PHARMACOGENOMICS, V6, P163, DOI 10.1517/14622416.6.2.163
   Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X
   Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149
   Tate SK, 2005, P NATL ACAD SCI USA, V102, P5507, DOI 10.1073/pnas.0407346102
   TATTERSALL RB, 1974, Q J MED, V43, P339
   TATTERSALL RB, 1975, DIABETES, V24, P452, DOI 10.2337/diabetes.24.5.452
   Totah RA, 2005, CLIN PHARMACOL THER, V77, P341, DOI 10.1016/j.clpt.2004.12.267
   Tsai HJ, 2006, HUM GENET, V119, P547, DOI 10.1007/s00439-006-0169-2
   Tselepis AD, 2002, ATHEROSCLEROSIS SUPP, V3, P57, DOI 10.1016/S1567-5688(02)00045-4
   Uitterlinden AG, 1998, NEW ENGL J MED, V338, P1016, DOI 10.1056/NEJM199804093381502
   Vadlamani Lou, 2004, Congest Heart Fail, V10, P289, DOI 10.1111/j.1527-5299.2004.02020.x
   Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878
   van Vliet-Ostaptchouk JV, 2007, DIABETOLOGIA, V50, P59, DOI 10.1007/s00125-006-0477-z
   Vandel P, 2007, CURR PHARM DESIGN, V13, P241, DOI 10.2174/138161207779313704
   Vermeire S, 2005, GASTROENTEROLOGY, V129, P1845, DOI 10.1053/j.gastro.2005.10.006
   Voora D, 2005, THROMB HAEMOSTASIS, V93, P700, DOI 10.1160/TH04-08-0542
   Wang LW, 2005, P NATL ACAD SCI USA, V102, P9394, DOI 10.1073/pnas.0502352102
   Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522
   Wilffert B, 2005, PHARM WORLD SCI, V27, P20, DOI 10.1007/s11096-004-1731-4
   Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424
   Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3
   Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815
   Yi FH, 2005, J BIOL CHEM, V280, P1457, DOI 10.1074/jbc.M411487200
   Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001
   ZANNIS VI, 1981, AM J HUM GENET, V33, P11
   Zhang CL, 2006, DIABETES, V55, P2645, DOI 10.2337/db06-0643
   Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166
   ZIMMET P, 1990, DIABETES METAB REV, V6, P91, DOI 10.1002/dmr.5610060203
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
   Zung A, 2004, J CLIN ENDOCR METAB, V89, P5504, DOI 10.1210/jc.2004-1241
NR 264
TC 27
Z9 31
U1 0
U2 12
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD JUL
PY 2007
VL 7
IS 4
BP 371
EP 393
DI 10.1586/14737159.7.4.371
PG 23
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 198IP
UT WOS:000248620700006
PM 17620046
DA 2022-11-30
ER

PT J
AU Tremolada, G
   Lattanzio, R
   Mazzolari, G
   Zerbini, G
AF Tremolada, Gemma
   Lattanzio, Rosangela
   Mazzolari, Gabriella
   Zerbini, Gianpaolo
TI The therapeutic potential of VEGF inhibition in diabetic microvascular
   complications
SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; PREVENTS
   GLOMERULAR HYPERTROPHY; TYROSINE KINASE INHIBITOR; GENE-TRANSFER;
   MACULAR EDEMA; OCULAR NEOVASCULARIZATION; FACTOR RECEPTOR-2; HUMAN
   KIDNEY; PKC-BETA
AB During the last few years, the incidence of microvascular complications in diabetes mellitus has rapidly increased as a consequence of both an increase in incidence of type 2 and type 1 diabetes mellitus.
   The pathogenesis of diabetic microvascular complications is still largely unknown. Among the many hypotheses, a dysfunction in angiogenesis has been suggested as a common origin for retinopathy, nephropathy, and neuropathy. Based on this hypothesis, inhibition of vascular endothelial growth factor (VEGF) has been tested as a potential therapeutic approach to prevent and cure diabetic microvascular complications. Several VEGF inhibitors are currently under evaluation or are approved for the treatment of wet age-related macular degeneration and macular edema. These include inhibitors of intracellular transcription of VEGF (e.g. bevasiranib), inhibitors of extracellular VEGF (e.g. pegaptanib), inhibitors of VEGF receptor expression (e.g. aflibercept [VEGF-TRAP]) and inhibitors of the intracellular signaling cascade activating VEGF (e.g. midostaurin).
   According to the existing evidence base, although inhibition of VEGF results in a better outcome in the case of diabetic retinopathy and also, despite some discrepant results, in the case of diabetic nephropathy, there is no final confirmation that VEGF inhibition is a valid approach for diabetic neuropathy. The latter complication actually, in line with other chronic neuropathies, seems to improve with stimulation of angiogenesis through increased expression of VEGF.
C1 [Mazzolari, Gabriella; Zerbini, Gianpaolo] Ist Sci San Raffaele, Renal Pathophysiol Unit, I-20132 Milan, Italy.
   [Tremolada, Gemma; Lattanzio, Rosangela] Ist Sci San Raffaele, Dept Ophthalmol & Visual Sci, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Zerbini, G (通讯作者)，Ist Sci San Raffaele, Renal Pathophysiol Unit, I-20132 Milan, Italy.
EM g.zerbini@hsr.it
RI Zerbini, Gianpaolo/K-6723-2016; Lattanzio, Rosangela/AAC-2381-2022
OI Lattanzio, Rosangela/0000-0003-2126-6273
CR Adamis AP, 2006, OPHTHALMOLOGY, V113, P23, DOI 10.1016/j.ophtha.2005.10.012
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Aiello LP, 2006, INVEST OPHTH VIS SCI, V47, P86, DOI 10.1167/iovs.05-0757
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aiello LP, 2000, KIDNEY INT, V58, pS113, DOI 10.1046/j.1523-1755.2000.07718.x
   [Anonymous], 1976, Am J Ophthalmol, V81, P383
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   AVERY RL, 2006, RETINA, V26, P356
   BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993
   Boulton M, 1998, BRIT J OPHTHALMOL, V82, P561, DOI 10.1136/bjo.82.5.561
   Brenchley PE, 1996, J NEPHROL, V9, P10
   BROWN LF, 1992, KIDNEY INT, V42, P1457, DOI 10.1038/ki.1992.441
   Chattopadhyay M, 2005, GENE THER, V12, P1377, DOI 10.1038/sj.gt.3302533
   Chong NV, 2007, EYE, V21, P313, DOI 10.1038/sj.eye.6702699
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Cooper ME, 1999, DIABETES, V48, P2229, DOI 10.2337/diabetes.48.11.2229
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Danis RP, 1998, INVEST OPHTH VIS SCI, V39, P171
   De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993
   Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Funatsu H, 2006, OPHTHALMOLOGY, V113, P294, DOI 10.1016/j.ophtha.2005.10.030
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hess-Stumpp H, 2005, CHEMBIOCHEM, V6, P550, DOI 10.1002/cbic.200400305
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Khamaisi M, 2003, NEPHROL DIAL TRANSPL, V18, P1427, DOI 10.1093/ndt/gfg242
   KLEIN R, 1989, DIABETES METAB REV, V5, P559, DOI 10.1002/dmr.5610050703
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li XR, 2001, INT J BIOCHEM CELL B, V33, P421, DOI 10.1016/S1357-2725(01)00027-9
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Mukouyama YS, 2005, DEVELOPMENT, V132, P941, DOI 10.1242/dev.01675
   Mura M, 2004, J APPL PHYSIOL, V97, P1605, DOI 10.1152/japplphysiol.00202.2004
   Murakami T, 2006, J GENE MED, V8, P773, DOI 10.1002/jgm.893
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   NYENGAARD JR, 1993, DIABETOLOGIA, V36, P189, DOI 10.1007/BF00399948
   *PCK DRS STUD GROU, 2005, DIABETES, V54, P2188
   Price SA, 2006, DIABETES, V55, P1847, DOI 10.2337/db05-1060
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosen LS, 2005, ONCOLOGIST, V10, P382, DOI 10.1634/theoncologist.10-6-382
   Ryan AJ, 2005, BRIT J CANCER, V92, pS6, DOI 10.1038/sj.bjc.6602603
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schratzberger P, 2001, J CLIN INVEST, V107, P1083, DOI 10.1172/JCI12188
   Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664
   Schrijvers BF, 2006, NEPHROL DIAL TRANSPL, V21, P324, DOI 10.1093/ndt/gfi217
   Schrijvers BF, 2005, HORM METAB RES, V37, P21, DOI 10.1055/s-2005-861027
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shibuya M, 2003, CANCER SCI, V94, P751, DOI 10.1111/j.1349-7006.2003.tb01514.x
   Shih T, 2006, CLIN THER, V28, P1779, DOI 10.1016/j.clinthera.2006.11.015
   Shimura M, 2003, OPHTHALMOLOGY, V110, P2386, DOI 10.1016/j.ophtha.2003.05.008
   SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240, DOI 10.1152/ajprenal.1995.268.2.F240
   Simon M, 1998, J AM SOC NEPHROL, V9, P1032
   Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353
   Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stitt AW, 1998, J PATHOL, V186, P306, DOI 10.1002/(SICI)1096-9896(1998110)186:3<306::AID-PATH183>3.0.CO;2-B
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Sung SH, 2006, J AM SOC NEPHROL, V17, P3093, DOI 10.1681/ASN.2006010064
   Tsuchida K, 1999, DIABETOLOGIA, V42, P579, DOI 10.1007/s001250051198
   *USRDS, 1994, AM J KIDNEY DIS S, V24, pS48
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   Vinik AI, 1994, DIABETES CLIN SCI PR, P221
   Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Yamagishi S, 2005, CURR PHARM DESIGN, V11, P2279, DOI 10.2174/1381612054367300
   Yamamoto Y, 2004, DIABETES, V53, P1831, DOI 10.2337/diabetes.53.7.1831
   Zhu XL, 2007, AM J KIDNEY DIS, V49, P186, DOI 10.1053/j.ajkd.2006.11.039
NR 75
TC 25
Z9 35
U1 0
U2 8
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-3277
EI 1179-187X
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PY 2007
VL 7
IS 6
BP 393
EP 398
DI 10.2165/00129784-200707060-00002
PG 6
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 251EV
UT WOS:000252355100001
PM 18076206
DA 2022-11-30
ER

PT J
AU Sloan, FA
   Brown, DS
   Carlisle, ES
   Picone, GA
   Lee, PP
AF Sloan, FA
   Brown, DS
   Carlisle, ES
   Picone, GA
   Lee, PP
TI Monitoring visual status: Why patients do or do not comply with practice
   guidelines
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE practice guidelines; compliance; eye care; diabetes mellitus;
   age-related macular degeneration
ID PRIMARY-CARE PHYSICIANS; SCREENING MAMMOGRAPHY; PREDICTORS; IMPACT;
   WOMEN
AB Objective. To determine factors affecting compliance with guidelines for annual eye examinations for persons diagnosed with diabetes mellitus (DM) or age-related macular degeneration (ARMD).
   Data Sources/Study Setting. Nationally representative, longitudinal sample of individuals 65+ drawn from the National Long-Term Care Survey (NLTCS) with linked Medicare claims records from 1991 to 1999.
   Study Design. Medicare beneficiaries were followed from 1991 to 1999, unless mortality intervened. All claims data were analyzed for presence of ICD-9 codes indicating diagnosis of DM or ARMD and the performance of eye exams. The dependent variable was a binary indicator for whether a person had an eye exam or not during a 15-month period. Independent variables for demographics, living conditions, supplemental insurance, income, and other factors affecting the marginal cost and benefit of an eye exam were assessed to determine reasons for noncompliance.
   Data Collection/Extraction Methods. Panel data were created from claims files, 1991-1999, merged with data from the NLTCS.
   Principal Findings. The probability of having an exam reflected perceived benefits, which vary by patient characteristics (e.g., education, no dementia), and factors associated with the ease of visit. African Americans were much less likely to be examined than were whites.
   Conclusions. Having an exam reflects multiple factors. However, much of the variation in the probability of an exam remained unexplained as were reasons for the racial differences in use.
C1 Duke Univ, Dept Econ, Durham, NC 27708 USA.
   Duke Univ, Ctr Hlth Policy Law & Management, Durham, NC 27706 USA.
   Res Triangle Inst, Durham, NC USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   Univ S Florida, Dept Econ, Tampa, FL USA.
   Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Duke University; Duke University; Research Triangle Institute; Johns
   Hopkins University; State University System of Florida; University of
   South Florida; Duke University
RP Sloan, FA (通讯作者)，Duke Univ, Dept Econ, Box 90097, Durham, NC 27708 USA.
RI Brown, Derek S/J-3035-2013
OI Brown, Derek S/0000-0001-9908-9882; Lee, Paul/0000-0002-3338-136X;
   Picone, Gabriel/0000-0002-4926-2445
FU NIA NIH HHS [1R01-AG-17473, R01 AG017473] Funding Source: Medline;
   NATIONAL INSTITUTE ON AGING [R01AG017473] Funding Source: NIH RePORTER
CR *AM AC OPHTH, 2000, PREF PRACT PATT GLAU
   *AM AC OPHTH, 1998, PREF PRACT PATT DIAB
   *AM AC OPHTH, 2001, PREF PRACT PATT AG R
   *AM DIAB ASS, 2002, DIABETES CARE S1, V25, pS90
   Brenes GA, 2000, PREV MED, V31, P410, DOI 10.1006/pmed.2000.0729
   CHAMBERS CV, 1989, J FAM PRACTICE, V29, P273
   CHAMPION VL, 1992, CANCER DETECT PREV, V16, P253
   Cheng JWM, 2001, PHARMACOTHERAPY, V21, P828, DOI 10.1592/phco.21.9.828.34557
   Costanza M E, 1992, J Am Board Fam Pract, V5, P143
   Devgan U, 2000, ARCH OPHTHALMOL-CHIC, V118, P253
   Eilat-Tsanani S, 2001, ISRAEL MED ASSOC J, V3, P920
   Ellis RP, 1996, HEALTH CARE FINANC R, V17, P101
   Erhardt LR, 1999, AM J HYPERTENS, V12, p105S
   FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50
   Hebert P L, 1999, Am J Med Qual, V14, P270, DOI 10.1177/106286069901400607
   Hilber D J, 2000, Optometry, V71, P83
   Hsia J, 2002, AM J MED, V113, P384, DOI 10.1016/S0002-9343(02)01218-4
   Kenkel DS, 2000, HANDB ECON, V17, P1675
   Kraft SK, 1997, ARCH FAM MED, V6, P29, DOI 10.1001/archfami.6.1.29
   Lawler FH, 1997, J FAM PRACTICE, V44, P369
   Lee PP, 2003, OPHTHALMOLOGY, V110, P1952, DOI 10.1016/S0161-6420(03)00817-0
   Lieberman L, 1998, J WOMENS HEALTH, V7, P717, DOI 10.1089/jwh.1998.7.717
   MacDowell N M, 2000, Manag Care Q, V8, P11
   Ore L, 1997, ISRAEL J MED SCI, V33, P103
   Partin MR, 1998, CANCER EPIDEM BIOMAR, V7, P681
   Pate RR, 2002, ANN EPIDEMIOL, V12, P303, DOI 10.1016/S1047-2797(01)00263-0
   PHELPS CE, 2002, HLTH EC
   Reno PL, 1997, DIABETES EDUCATOR, V23, P653, DOI 10.1177/014572179702300604
   Roetzheim R G, 1991, J Fla Med Assoc, V78, P426
   Roter D, 1997, HLTH BEHAV HLTH ED T, P206
   *SAS I, SAS VERS 8 1
   Schaumberg DA, 2000, MED CARE, V38, P638, DOI 10.1097/00005650-200006000-00005
   Wang F, 1997, Ophthalmic Epidemiol, V4, P89
NR 33
TC 61
Z9 63
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
EI 1475-6773
J9 HEALTH SERV RES
JI Health Serv. Res.
PD OCT
PY 2004
VL 39
IS 5
BP 1429
EP 1448
DI 10.1111/j.1475-6773.2004.00297.x
PG 20
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA 893TQ
UT WOS:000226742600012
PM 15333116
OA Green Published
DA 2022-11-30
ER

PT J
AU Kasica, N
   Swiech, A
   Saladziak, K
   Mackiewicz, J
   Oseka, M
AF Kasica, Natalia
   Swiech, Anna
   Saladziak, Katarzyna
   Mackiewicz, Jerzy
   Oseka, Maciej
TI The Inhibitory Effect of Selected D-2 Dopaminergic Receptor Agonists on
   VEGF-Dependent Neovascularization in Zebrafish Larvae: Potential New
   Therapy in Ophthalmic Diseases
SO CELLS
LA English
DT Article
DE zebrafish; angiogenesis; D-2 dopaminergic receptor agonist;
   bromocriptine; cabergoline; pergolide; hyaloid-retinal vessels (HRVs);
   intersegmental vessels (ISVs); vascular endothelial growth factor
ID VASCULAR DEVELOPMENT; GROWTH-FACTOR; IN-VITRO; HYPOXIA; EXPRESSION;
   ANGIOGENESIS; PHOSPHORYLATION; PERGOLIDE; CANCER; BROMOCRIPTINE
AB Pathological angiogenesis is correlated with many ophthalmic diseases. The most common are exudative age-related macular degeneration and proliferative diabetic retinopathy. The current treatment for these diseases is based on regularly administered anti-VEGF antibodies injections. In the study, we investigated selected D-2 dopaminergic receptor agonists, namely bromocriptine, cabergoline and pergolide, on hypoxia-induced neovascularization. We used the zebrafish laboratory model, specifically three-day post fertilization (dpf) Tg(fli-1: EGFP) zebrafish larvae. To induce abnormal angiogenesis of hyaloid-retinal vessels (HRVs) and intersegmental vessels (ISVs), the larvae were treated with cobalt chloride (II) (CoCl2) (a hypoxia-inducing agent) from 24 h post fertilization. The inhibitory role of D-2 dopaminergic receptor agonists was investigated using confocal microscopy and qPCR. Additionally, the results were compared to those obtained in the group treated with CoCl2 followed by bevacizumab, the well-known antiangiogenic agent. Confocal microscopy analyses revealed severe deformation of vessels in the CoCl2 treated group, while co-incubation with bromocriptine, cabergoline, pergolide and bevacizumab, respectively, significantly inhibited abnormalities of angiogenesis. The qPCR analyses supported the protective role of the chosen dopaminergic agonists by demonstrating their influence on CoCl2-derived upregulation of vegfaa expression. The present results suggest that the D-2 receptor agonists can be considered as a new direction in research for antiangiogenic therapy.
C1 [Kasica, Natalia] Univ Warmia & Mazury, Fac Vet Med, Dept Anim Anat, Oczapowskiego 13 St,Box 105J, PL-10719 Olsztyn, Poland.
   [Swiech, Anna; Saladziak, Katarzyna; Mackiewicz, Jerzy] Med Univ Lublin, Dept Retina & Vitreus Surg, Chmielna 1 St, PL-20079 Lublin, Poland.
   [Oseka, Maciej] Oftalabs Sp Oo, Wroclawska 130, PL-58306 Walbrzych, Poland.
C3 University of Warmia & Mazury; Medical University of Lublin
RP Kasica, N (通讯作者)，Univ Warmia & Mazury, Fac Vet Med, Dept Anim Anat, Oczapowskiego 13 St,Box 105J, PL-10719 Olsztyn, Poland.
EM natalia.kasica@uwm.edu.pl; anna.zub@umlub.pl; kadanieluk@gmail.com;
   jerzy.mackiewicz@umlub.pl; maciej_oseka@oftalabs.pl
OI Kasica, Natalia/0000-0002-0242-2587; Mackiewicz,
   Jerzy/0000-0003-0984-8908; Oseka, Maciej/0000-0002-8017-3432;
   Swiech-Zubilewicz, Anna/0000-0002-2238-6966
FU Minister of Science and Higher Education [010/RID/2018/19]
FX Project financially co-supported by the Minister of Science and Higher
   Education in the range of the program entitled "Regional Initiative of
   Excellence" for the years 2019-2022, Project No. 010/RID/2018/19, amount
   of funding 12.000.000 PLN.
CR Alvarez Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007867
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895
   Basu S, 1999, DIGEST DIS SCI, V44, P916, DOI 10.1023/A:1026644110737
   Beckert S, 2006, BIOCHEM BIOPH RES CO, V341, P67, DOI 10.1016/j.bbrc.2005.12.148
   Bonuccelli U, 2002, CLIN NEUROPHARMACOL, V25, P1, DOI 10.1097/00002826-200201000-00001
   Brilliant MH, 2016, AM J MED, V129, P292, DOI 10.1016/j.amjmed.2015.10.015
   Buchler P, 2004, CANCER-AM CANCER SOC, V100, P201, DOI 10.1002/cncr.11873
   CACCAVELLI L, 1992, HORM RES, V38, P78, DOI 10.1159/000182494
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Chakroborty D, 2004, CLIN CANCER RES, V10, P4349, DOI 10.1158/1078-0432.CCR-04-0059
   Chakroborty D, 2008, J CLIN INVEST, V118, P1380, DOI 10.1172/JCI33125
   Chakroborty D, 2011, P NATL ACAD SCI USA, V108, P20730, DOI 10.1073/pnas.1108696108
   Chauvet N, 2017, INT J CANCER, V140, P2150, DOI 10.1002/ijc.30628
   Chavez MN, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00056
   Chen PYJ, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-02196-8
   Chimote G, 2014, DRUG DES DEV THER, V8, P1107, DOI 10.2147/DDDT.S55621
   Conte C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003078
   Eberlein J, 2021, LIFE-BASEL, V11, DOI 10.3390/life11101088
   Eme J, 2013, AM J PHYSIOL-REG I, V304, pR966, DOI 10.1152/ajpregu.00595.2012
   Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4
   Ferrero H, 2014, FERTIL STERIL, V101, P1411, DOI 10.1016/j.fertnstert.2014.01.031
   Hartnett ME, 2020, AM J OPHTHALMOL, V218, P208, DOI 10.1016/j.ajo.2020.05.025
   Hebert RC, 2013, J EQUINE VET SCI, V33, P773, DOI 10.1016/j.jevs.2012.12.006
   Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8
   Jia T, 2021, BMC BIOL, V19, DOI 10.1186/s12915-021-01103-3
   Kakudo N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139890
   Kasica N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030690
   Khaidakov M, 2011, J CARDIOVASC PHARM T, V16, P105, DOI 10.1177/1074248410378505
   Khaliq A, 1999, LAB INVEST, V79, P151
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Maniscalco W.M., 2006, ENCY RESP MED, P413
   Marques IJ, 2008, J COMP PHYSIOL B, V178, P77, DOI 10.1007/s00360-007-0201-4
   Matsumoto K, 2014, J BIOCHEM, V156, P1, DOI 10.1093/jb/mvu031
   Moreno-Smith M, 2011, CLIN CANCER RES, V17, P3649, DOI 10.1158/1078-0432.CCR-10-2441
   Munoz-Sanchez J, 2019, J APPL TOXICOL, V39, P556, DOI 10.1002/jat.3749
   NARBURGH LJ, 1990, TOXICOL LETT, V50, P189, DOI 10.1016/0378-4274(90)90010-J
   Ober EA, 2004, EMBO REP, V5, P78, DOI 10.1038/sj.embor.7400047
   Ohta K, 2003, LIFE SCI, V73, P617, DOI 10.1016/S0024-3205(03)00321-7
   Poole TJ, 2001, DEV DYNAM, V220, P1, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1087>3.0.CO;2-2
   Rezzola S, 2016, BBA-MOL BASIS DIS, V1862, P1291, DOI 10.1016/j.bbadis.2016.04.009
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Roy S, 2017, J BIOL CHEM, V292, P435, DOI 10.1074/jbc.M116.748970
   Sarkar C, 2004, AM J PHYSIOL-HEART C, V287, pH1554, DOI 10.1152/ajpheart.00272.2004
   Scheid A, 2000, PEDIATR SURG INT, V16, P232, DOI 10.1007/s003830050735
   Senogles SE, 2007, ANTI-CANCER DRUG, V18, P801, DOI 10.1097/CAD.0b013e3280b10d36
   Sinha S, 2009, J CELL SCI, V122, P3385, DOI 10.1242/jcs.053124
   Stuttfeld E, 2009, IUBMB LIFE, V61, P915, DOI 10.1002/iub.234
   Tang HL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008605.pub3
   TURKALJ I, 1982, JAMA-J AM MED ASSOC, V247, P1589, DOI 10.1001/jama.247.11.1589
   WICK MM, 1978, J INVEST DERMATOL, V70, P358, DOI 10.1111/1523-1747.ep12543559
   Wu JM, 2016, INT J BIOL SCI, V12, P1363, DOI 10.7150/ijbs.16334
   Wu YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126750
   Xiong JW, 2008, DEV DYNAM, V237, P1218, DOI 10.1002/dvdy.21542
   Xu MY, 2018, ONCOTARGET, V9, P3188, DOI 10.18632/oncotarget.23225
   Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
   Zhang J, 2018, DRUG DES DEV THER, V12, P2423, DOI 10.2147/DDDT.S166330
NR 57
TC 1
Z9 1
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD APR
PY 2022
VL 11
IS 7
AR 1202
DI 10.3390/cells11071202
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 0L3IG
UT WOS:000781370900001
PM 35406766
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lavalette, S
   Conart, JB
   Touhami, S
   Roubeix, C
   Houssier, M
   Augustin, S
   Raoul, W
   Combadiere, C
   Febbraio, M
   Ong, H
   Chemtob, S
   Sahel, JA
   Delarasse, C
   Guillonneau, X
   Sennlaub, F
AF Lavalette, Sophie
   Conart, Jean-Baptiste
   Touhami, Sara
   Roubeix, Christophe
   Houssier, Marianne
   Augustin, Sebastien
   Raoul, William
   Combadiere, Christophe
   Febbraio, Maria
   Ong, Huy
   Chemtob, Sylvain
   Sahel, Jose-Alain
   Delarasse, Cecile
   Guillonneau, Xavier
   Sennlaub, Florian
TI CD36 Deficiency Inhibits Retinal Inflammation and Retinal Degeneration
   in Cx3cr1 Knockout Mice
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE age related macular degeneration; mononuclear phagocyte; CX3CR1; CD36;
   IL-6; photoreceptor
ID SUBRETINAL INFLAMMATION; MACULAR DEGENERATION; PIGMENT EPITHELIUM; AGE;
   PHAGOCYTOSIS; MICROGLIA; NEOVASCULARIZATION; PHOSPHOLIPIDS; MACROPHAGES;
   ACTIVATION
AB Background: CD36, a member of the class B scavenger receptor family, participates in Toll-like receptor signaling on mononuclear phagocytes (MP) and can promote sterile pathogenic inflammation. We here analyzed the effect of CD36 deficiency on retinal inflammation and photoreceptor degeneration, the hallmarks of age-related macular degeneration (AMD), that characterize Cx3cr1(-/-) mice.
   Methods: We analyzed subretinal MP accumulation, and cone- and rod-degeneration in light-challenged and aged, CD36 competent or deficient, hyper-inflammatory Cx3cr1(-/-) mice, using histology and immune-stained retinal flatmounts. Monocytes (Mo) were subretinally adoptively transferred to evaluate their elimination rate from the subretinal space and Interleukin 6 (IL-6) secretion from cultured Mo-derived cells (MdCs) of the different mouse strains were analyzed.
   Results: CD36 deficient Cx3cr1(-/-) mice were protected against age- and light-induced subretinal inflammation and associated cone and rod degeneration. CD36 deficiency in Cx3cr1(-/-) MPs inhibited their prolonged survival in the immune-suppressive subretinal space and reduced the exaggerated IL-6 secretion observed in Cx3cr1(-/-) MPs that we previously showed leads to increased subretinal MP survival.
   Conclusion: Cd36 deficiency significantly protected hyperinflammatory Cx3cr1(-/-) mice against subretinal MP accumulation and associated photoreceptor degeneration. The observed CD36-dependent induction of pro-inflammatory IL-6 might be at least partially responsible for the prolonged MP survival in the immune-suppressive environment and its pathological consequences on photoreceptor homeostasis.
C1 [Lavalette, Sophie; Conart, Jean-Baptiste; Touhami, Sara; Roubeix, Christophe; Houssier, Marianne; Augustin, Sebastien; Raoul, William; Sahel, Jose-Alain; Delarasse, Cecile; Guillonneau, Xavier; Sennlaub, Florian] Sorbonne Univ, CNRS, INSERM, Inst Vis, Paris, France.
   [Raoul, William] Univ Tours, Fac Med, INSERM, UMR 1069,N2C, Tours, France.
   [Combadiere, Christophe] Sorbonne Univ, CNRS, INSERM, Ctr Immunol & Malad Infect,Cimi Paris, Paris, France.
   [Febbraio, Maria] Univ Alberta, Dept Dent, Edmonton, AB, Canada.
   [Ong, Huy] Univ Montreal, Fac Pharm, Montreal, PQ, Canada.
   [Chemtob, Sylvain] Univ Montreal, Dept Pediat, Montreal, PQ, Canada.
   [Chemtob, Sylvain] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Chemtob, Sylvain] Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Franche-Comte; Universite de Tours; Centre National de la Recherche
   Scientifique (CNRS); Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite; University of Alberta; Universite de
   Montreal; Universite de Montreal; Universite de Montreal; Universite de
   Montreal
RP Guillonneau, X; Sennlaub, F (通讯作者)，Sorbonne Univ, CNRS, INSERM, Inst Vis, Paris, France.
EM xavier.guillonneau@inserm.fr; florian.sennlaub@inserm.fr
RI Guillonneau, xavier/E-3995-2017; Sennlaub, Florian/F-2756-2017;
   Delarasse, Cecile/K-8234-2017; Combadiere, Christophe/I-5639-2013;
   Raoul, William/H-2118-2018; Touhami, Sara/AAF-7836-2021; guillonneau,
   xavier/AAF-9495-2021
OI Guillonneau, xavier/0000-0001-7379-3935; Sennlaub,
   Florian/0000-0003-4412-1341; Delarasse, Cecile/0000-0001-9739-4306;
   Combadiere, Christophe/0000-0002-1755-4531; Raoul,
   William/0000-0002-5040-3372; guillonneau, xavier/0000-0001-7379-3935;
   Houssier, Marianne/0000-0002-5329-4597
FU INSERM; ANR MACLEAR [ANR-15-CE14-0015-01]; UNADEV- Aviesan; ANR
   [ANR-11-IDEX-0004-02, ANR-10-LABX-65]
FX This work was supported by grants from INSERM, ANR MACLEAR
   (ANR-15-CE14-0015-01), UNADEV- Aviesan 2018-2019 Les maladies de la
   vision: origines et traitements, LABEX LIFESENSES (ANR-10-LABX-65)
   supported by the ANR [Programme d'Investissements d'Avenir
   (ANR-11-IDEX-0004-02)], Carnot, and a generous donation by Doris and
   Michael Bunte.
CR Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Jobling AI, 2018, J NEUROSCI, V38, P4708, DOI 10.1523/JNEUROSCI.2368-17.2018
   Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P854, DOI 10.1167/iovs.12-10876
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Mellal K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49472-8
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmitz G, 2002, CURR OPIN LIPIDOL, V13, P513, DOI 10.1097/00041433-200210000-00007
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Smoak KA, 2010, CELL METAB, V11, P493, DOI 10.1016/j.cmet.2010.04.006
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zieger M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106562
NR 50
TC 6
Z9 6
U1 2
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 8
PY 2020
VL 10
AR 03032
DI 10.3389/fimmu.2019.03032
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA KJ9IS
UT WOS:000512368700001
PM 31969887
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Morita, Y
   Leslie, M
   Kameyama, H
   Volk, DE
   Tanaka, T
AF Morita, Yoshihiro
   Leslie, Macall
   Kameyama, Hiroyasu
   Volk, David E.
   Tanaka, Takemi
TI Aptamer Therapeutics in Cancer: Current and Future
SO CANCERS
LA English
DT Review
DE aptamer; cancer; targeted therapy
ID GROWTH-FACTOR RECEPTOR; IN-VITRO SELECTION; TARGETING 4-1BB
   COSTIMULATION; NUCLEIC-ACID APTAMERS; NF-KAPPA-B; RNA APTAMER;
   DNA-APTAMER; HIGH-AFFINITY; ANTISENSE OLIGONUCLEOTIDE; PHOSPHOROTHIOATE
   OLIGONUCLEOTIDE
AB Aptamer-related technologies represent a revolutionary advancement in the capacity to rapidly develop new classes of targeting ligands. Structurally distinct RNA and DNA oligonucleotides, aptamers mimic small, protein-binding molecules and exhibit high binding affinity and selectivity. Although their molecular weight is relatively smallapproximately one-tenth that of monoclonal antibodiestheir complex tertiary folded structures create sufficient recognition surface area for tight interaction with target molecules. Additionally, unlike antibodies, aptamers can be readily chemically synthesized and modified. In addition, aptamers' long storage period and low immunogenicity are favorable properties for clinical utility. Due to their flexibility of chemical modification, aptamers are conjugated to other chemical entities including chemotherapeutic agents, siRNA, nanoparticles, and solid phase surfaces for therapeutic and diagnostic applications. However, as relatively small sized oligonucleotides, aptamers present several challenges for successful clinical translation. Their short plasma half-lives due to nuclease degradation and rapid renal excretion necessitate further structural modification of aptamers for clinical application. Since the US Food and Drug Administration (FDA) approval of the first aptamer drug, Macugen((R)) (pegaptanib), which treats wet-age-related macular degeneration, several aptamer therapeutics for oncology have followed and shown promise in pre-clinical models as well as clinical trials. This review discusses the advantages and challenges of aptamers and introduces therapeutic aptamers under investigation and in clinical trials for cancer treatments.
C1 [Morita, Yoshihiro; Leslie, Macall; Kameyama, Hiroyasu; Tanaka, Takemi] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, 975 NE 10th,BRC W,Rm 1415, Oklahoma City, OK 73104 USA.
   [Volk, David E.] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, McGovern Med Sch, 1825 Hermann Pressler, Houston, TX 77030 USA.
   [Tanaka, Takemi] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Pathol, 940 SL Young Blvd, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Texas System; University of Texas Health Science
   Center Houston; University of Oklahoma System; University of Oklahoma
   Health Sciences Center
RP Tanaka, T (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, 975 NE 10th,BRC W,Rm 1415, Oklahoma City, OK 73104 USA.; Tanaka, T (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Pathol, 940 SL Young Blvd, Oklahoma City, OK 73104 USA.
EM yoshihiro-morita@ouhsc.edu; Macall-Leslie@ouhsc.edu;
   hirokameyama@dent.osaka-u.ac.jp; David.Volk@uth.tmc.edu;
   takemi-tanaka@ouhsc.edu
RI Volk, David/H-7956-2019
OI Volk, David/0000-0002-4372-6915
FU National Institutes of Health [1R01CA160271-01A1]; NATIONAL CANCER
   INSTITUTE [R01CA160271] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health
   (1R01CA160271-01A1 to T.T).
CR Ajona D, 2017, CANCER DISCOV, V7, P694, DOI 10.1158/2159-8290.CD-16-1184
   Akdim F, 2010, J AM COLL CARDIOL, V55, P1611, DOI 10.1016/j.jacc.2009.11.069
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Akiyama H, 2006, J CELL PHYSIOL, V207, P407, DOI 10.1002/jcp.20583
   Armstrong JK, 2007, CANCER-AM CANCER SOC, V110, P103, DOI 10.1002/cncr.22739
   Attarwala H, 2010, J Young Pharm, V2, P332, DOI 10.4103/0975-1483.66810
   Avci-Adali M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068810
   Bartkowiak T, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00117
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Berezhnoy A, 2012, MOL THER, V20, P1242, DOI 10.1038/mt.2012.18
   Berger CM, 2015, BIOCHIMIE, V113, P78, DOI 10.1016/j.biochi.2015.03.023
   Bin Seo H, 2017, J BIOL ENG, V11, DOI 10.1186/s13036-017-0054-7
   Bompiani KM, 2012, J THROMB HAEMOST, V10, P870, DOI 10.1111/j.1538-7836.2012.04679.x
   Bouchard PR, 2010, ANNU REV PHARMACOL, V50, P237, DOI 10.1146/annurev.pharmtox.010909.105547
   Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5
   Bruno JG, 2013, PHARMACEUTICALS, V6, P340, DOI 10.3390/ph6030340
   Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200
   Buffery D, 2015, AM HEALTH DRUG BENEF, V8, P216
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Cao HY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-699
   Cerchia L, 2011, PHARMACEUTICALS, V4, P1434, DOI 10.3390/ph4111434
   Cerchia L, 2012, MOL THER, V20, P2291, DOI 10.1038/mt.2012.163
   Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100
   Chen L, 2015, P NATL ACAD SCI USA, V112, P10002, DOI 10.1073/pnas.1502159112
   Chen W, 2007, BLOOD, V110, p479A
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   Dassie JP, 2014, MOL THER, V22, P1910, DOI 10.1038/mt.2014.117
   DECLERCQ E, 1969, SCIENCE, V165, P1137
   Dellafiore MA, 2016, FRONT CHEM, V4, DOI 10.3389/fchem.2016.00018
   Derbyshire N, 2012, ANAL CHEM, V84, P6595, DOI 10.1021/ac300815c
   Di Giusto DA, 2006, CHEMBIOCHEM, V7, P535, DOI 10.1002/cbic.200500316
   Dollins CM, 2008, CHEM BIOL, V15, P675, DOI 10.1016/j.chembiol.2008.05.016
   Dougan H, 2000, NUCL MED BIOL, V27, P289, DOI 10.1016/S0969-8051(99)00103-1
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306
   Esposito CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024071
   Fan XM, 2017, MOL THER-NUCL ACIDS, V9, P218, DOI 10.1016/j.omtn.2017.09.010
   Farman Cindy A., 2003, Toxicologic Pathology, V31, P119, DOI 10.1080/01926230390174995
   Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110
   Foy JWD, 2007, J OCUL PHARMACOL TH, V23, P452, DOI 10.1089/jop.2006.0149
   Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549
   Ganson NJ, 2016, J ALLERGY CLIN IMMUN, V137, P1610, DOI 10.1016/j.jaci.2015.10.034
   Gantenbein AR, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0526-4
   Geary RS, 2003, DRUG METAB DISPOS, V31, P1419, DOI 10.1124/dmd.31.11.1419
   Gewirtz AM, 1999, CURR OPIN MOL THER, V1, P297
   Girvan AC, 2006, MOL CANCER THER, V5, P1790, DOI 10.1158/1535-7163.MCT-05-0361
   Goebl N, 2007, TOXICOL PATHOL, V35, P541, DOI 10.1080/01926230701338958
   Goel S, 2006, INVEST NEW DRUG, V24, P125, DOI 10.1007/s10637-006-2378-x
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2
   GRIFFIN LC, 1993, BLOOD, V81, P3271, DOI 10.1182/blood.V81.12.3271.3271
   Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]
   Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139
   Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI 10.1038/NNANO.2010.231
   Henry SP, 2014, NUCLEIC ACID THER, V24, P326, DOI 10.1089/nat.2014.0491
   Henry SP, 1999, TOXICOL PATHOL, V27, P95, DOI 10.1177/019262339902700117
   Henry SP, 2002, INT IMMUNOPHARMACOL, V2, P1657, DOI 10.1016/S1567-5769(02)00142-X
   Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P1
   Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P473, DOI 10.1089/oli.1.1997.7.473
   Heo K, 2016, J CONTROL RELEASE, V229, P1, DOI 10.1016/j.jconrel.2016.03.006
   Hernandez FJ, 2012, NUCLEIC ACID THER, V22, P58, DOI 10.1089/nat.2011.0316
   Hershfield MS, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4500
   Hervas-Stubbs S, 2016, ONCOTARGET, V7, P4522, DOI 10.18632/oncotarget.6608
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Hoellenriegel J, 2014, BLOOD, V123, P1032, DOI 10.1182/blood-2013-03-493924
   Huang BT, 2017, MOL THER-NUCL ACIDS, V8, P520, DOI 10.1016/j.omtn.2017.08.006
   Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172
   Jain N, 2018, LEUKEMIA, V32, P663, DOI 10.1038/leu.2017.215
   JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028
   JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009
   Kang SA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2366-2
   Kang SA, 2015, TOXICOL APPL PHARM, V287, P86, DOI 10.1016/j.taap.2015.05.011
   Kang SA, 2015, MOL THER, V23, P1044, DOI 10.1038/mt.2015.45
   Kaur H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050964
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kim MY, 2011, NUCLEIC ACID THER, V21, P173, DOI 10.1089/nat.2011.0283
   Kim Y, 2010, CHEM-ASIAN J, V5, P56, DOI 10.1002/asia.200900421
   Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879
   Koutsioumpa M, 2014, RECENT PAT ANTI-CANC, V9, DOI 10.2174/1574892808666131119095953
   Krieg AM, 1999, BBA-GENE STRUCT EXPR, V1489, P107, DOI 10.1016/S0167-4781(99)00147-5
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059
   Kruspe S, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5030045
   Kuwahara M, 2010, MOLECULES, V15, P5423, DOI 10.3390/molecules15085423
   Lai WY, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.102
   Lakhin AV, 2013, ACTA NATURAE, V5, P34, DOI 10.32607/20758251-2013-5-4-34-43
   Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604
   Lebars I, 2007, BLOOD CELL MOL DIS, V38, P204, DOI 10.1016/j.bcmd.2006.11.008
   Lee CH, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.30
   Lee YJ, 2012, GASTROENTEROLOGY, V143, P155, DOI 10.1053/j.gastro.2012.03.039
   Lee YJ, 2013, MOL THER, V21, P1004, DOI 10.1038/mt.2013.30
   Li N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020299
   Li SH, 2012, NUCLEIC ACID THER, V22, P391, DOI 10.1089/nat.2012.0363
   Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003
   Liu SC, 2014, NEURO-ONCOLOGY, V16, P21, DOI 10.1093/neuonc/not149
   Ludwig H, 2017, LEUKEMIA, V31, P997, DOI 10.1038/leu.2017.5
   Ma HT, 2015, CHEM SOC REV, V44, P1240, DOI 10.1039/c4cs00357h
   Maasch Christian, 2008, Nucleic Acids Symp Ser (Oxf), P61, DOI 10.1093/nass/nrn031
   Mahlknecht G, 2013, P NATL ACAD SCI USA, V110, P8170, DOI 10.1073/pnas.1302594110
   Mai JH, 2014, J CONTROL RELEASE, V187, P22, DOI 10.1016/j.jconrel.2014.04.057
   Mangala LS, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87754
   Mann AP, 2011, ADV MATER, V23, pH278, DOI 10.1002/adma.201101541
   Mann AP, 2011, ONCOTARGET, V2, P298
   Mann AP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013050
   Marasca R, 2014, BLOOD, V123, P952, DOI 10.1182/blood-2013-12-542480
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Soldevilla MM, 2016, ONCOTARGET, V7, P23182, DOI 10.18632/oncotarget.8095
   Soldevilla MM, 2015, BIOMATERIALS, V67, P274, DOI 10.1016/j.biomaterials.2015.07.020
   McGowan MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049006
   McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365
   Melero I, 2007, NAT REV CANCER, V7, P95, DOI 10.1038/nrc2051
   Mi J, 2008, MOL THER, V16, P66, DOI 10.1038/sj.mt.6300320
   Mi ZY, 2009, MOL THER, V17, P153, DOI 10.1038/mt.2008.235
   Milla P, 2012, CURR DRUG METAB, V13, P105, DOI 10.2174/138920012798356934
   Mongelard F, 2010, CURR OPIN MOL THER, V12, P107
   Mori Y, 2012, BIOCHEM BIOPH RES CO, V420, P440, DOI 10.1016/j.bbrc.2012.03.014
   Morita Yoshihiro, 2016, Mol Ther Nucleic Acids, V5, pe399, DOI 10.1038/mtna.2016.103
   Mustonen EK, 2017, REGUL TOXICOL PHARM, V90, P328, DOI 10.1016/j.yrtph.2017.09.028
   Musumeci D, 2012, PHARMACOL THERAPEUT, V136, P202, DOI 10.1016/j.pharmthera.2012.07.011
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88
   Nitsche A, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-48
   Ojima A, 2014, LAB INVEST, V94, P422, DOI 10.1038/labinvest.2014.5
   Ouyang WY, 2016, CRIT REV ONCOL HEMAT, V106, P108, DOI 10.1016/j.critrevonc.2016.08.003
   Ozalp VC, 2015, CURR TOP MED CHEM, V15, P1125, DOI 10.2174/1568026615666150413154233
   Padilla R, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf138
   Parashar A, 2016, J CLIN DIAGN RES, V10, pBE1, DOI 10.7860/JCDR/2016/18712.7922
   Pastor F, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.26
   Pastor F, 2011, MOL THER, V19, P1878, DOI 10.1038/mt.2011.145
   Pasut G, 2012, J CONTROL RELEASE, V161, P461, DOI 10.1016/j.jconrel.2011.10.037
   Pfander S, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1110
   Poolsup S, 2017, CURR OPIN BIOTECH, V48, P180, DOI 10.1016/j.copbio.2017.05.004
   Pratico ED, 2013, NUCLEIC ACID THER, V23, P35, DOI 10.1089/nat.2012.0388
   Prodeus A, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.11
   Raal FJ, 2010, LANCET, V375, P998, DOI 10.1016/S0140-6736(10)60284-X
   Robbie GJ, 2013, ANTIMICROB AGENTS CH, V57, P6147, DOI 10.1128/AAC.01285-13
   Roccaro AM, 2014, CELL REP, V9, P118, DOI 10.1016/j.celrep.2014.08.042
   Rosenberg JE, 2014, INVEST NEW DRUG, V32, P178, DOI 10.1007/s10637-013-0045-6
   Roth F, 2012, CANCER RES, V72, P1373, DOI 10.1158/0008-5472.CAN-11-2772
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature00963
   Santulli-Marotto S, 2003, CANCER RES, V63, P7483
   SARMIENTO UM, 1994, ANTISENSE RES DEV, V4, P99, DOI 10.1089/ard.1994.4.99
   Sayyed SG, 2009, DIABETOLOGIA, V52, P2445, DOI 10.1007/s00125-009-1493-6
   Schrand B, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/21624011.2014.970918
   Schrand B, 2014, CANCER IMMUNOL RES, V2, P867, DOI 10.1158/2326-6066.CIR-14-0007
   Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0293
   Sheehan JP, 1998, BLOOD, V92, P1617, DOI 10.1182/blood.V92.5.1617.417k13_1617_1625
   Shrivastava S, 2016, TRAC-TREND ANAL CHEM, V82, P55, DOI 10.1016/j.trac.2016.04.005
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   Soule EE, 2016, NUCLEIC ACID THER, V26, P1, DOI 10.1089/nat.2015.0565
   Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723
   Soundararajan S, 2009, MOL PHARMACOL, V76, P984, DOI 10.1124/mol.109.055947
   Stein EA, 2012, CIRCULATION, V126, P2283, DOI 10.1161/CIRCULATIONAHA.112.104125
   Stessl M., 2012, OFF TARGET EFFECTS S
   Steurer M., 2014, BLOOD, V124, P1996
   Stuart RK, 2009, J CLIN ONCOL, V27
   Talbot LJ, 2011, SURGERY, V150, P224, DOI 10.1016/j.surg.2011.05.015
   Thiviyanathan V, 2007, BIOCHEM SOC T, V35, P50, DOI 10.1042/BST0350050
   Tucker CE, 1999, J CHROMATOGR B, V732, P203, DOI 10.1016/S0378-4347(99)00285-6
   Turecek PL, 2016, J PHARM SCI-US, V105, P460, DOI 10.1016/j.xphs.2015.11.015
   Vater A, 2013, CLIN PHARMACOL THER, V94, P150, DOI 10.1038/clpt.2013.58
   Volk DE, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5030041
   Volk DE, 2002, BIOORG CHEM, V30, P396, DOI 10.1016/S0045-2068(02)00510-2
   Waldschmidt JM, 2017, BRIT J HAEMATOL, V179, P36, DOI 10.1111/bjh.14807
   Wan Y, 2013, BIOMED MICRODEVICES, V15, P635, DOI 10.1007/s10544-012-9721-0
   Wang DL, 2014, BIOCHEM BIOPH RES CO, V453, P681, DOI 10.1016/j.bbrc.2014.09.023
   Weber C, 2012, IMMUNOLOGY, V136, P64, DOI 10.1111/j.1365-2567.2012.03559.x
   Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x
   Wong Elaine, 2014, P T, V39, P119
   Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yazdian-Robati R, 2017, INT J PHARMACEUT, V529, P44, DOI 10.1016/j.ijpharm.2017.06.058
   Yen HY, 2015, P NATL ACAD SCI USA, V112, P6955, DOI 10.1073/pnas.1507329112
   Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017
   Zamay TN, 2014, NUCLEIC ACID THER, V24, P160, DOI 10.1089/nat.2013.0471
   Zboralski D, 2017, CANCER IMMUNOL RES, V5, P950, DOI 10.1158/2326-6066.CIR-16-0303
   Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278
   Zhang XJ, 2014, INT J BIOCHEM CELL B, V46, P1, DOI 10.1016/j.biocel.2013.10.006
   Zheng JY, 2017, THERANOSTICS, V7, P1373, DOI 10.7150/thno.17826
   Zhou G, 2016, ONCOTARGET, V7, P13446, DOI 10.18632/oncotarget.7178
   Zhou J, 2009, MACROMOL BIOSCI, V9, P831, DOI 10.1002/mabi.200900046
   Zhu HJ, 2015, CHEMMEDCHEM, V10, P39, DOI 10.1002/cmdc.201402312
   2004, TNF GENOM PROTEOM BI, V2, P32, DOI DOI 10.1016/S1672-0229(04)02005-4
NR 187
TC 106
Z9 113
U1 13
U2 105
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2018
VL 10
IS 3
AR 80
DI 10.3390/cancers10030080
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GB0YD
UT WOS:000428776200022
PM 29562664
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Liang, FY
   Hwang, JH
   Tang, NW
   Hunziker, W
AF Liang, Fengyi
   Hwang, Ji Hyun
   Tang, Nicholas Weiwei
   Hunziker, Walter
TI Juxtanodin in retinal pigment epithelial cells: Expression and
   biological activities in regulating cell morphology and actin
   cytoskeleton organization
SO JOURNAL OF COMPARATIVE NEUROLOGY
LA English
DT Article
DE actin cytoskeleton; ERM protein; juxtanodin (JN); retinal pigment
   epithelium (RPE); stress fiber; RRID: CVCL_0145; RRID: AB_476955
ID OLIGODENDROGLIAL PROTEIN; NERVOUS-SYSTEM; IN-VIVO; ARBORIZATION; LINE
AB Juxtanodin (JN, also known as ermin) was initially identified as an actin cytoskeleton-related oligodendroglial protein in the rat central nervous system. It was subsequently also found in the rat olfactory neuroepithelium, especially at the apical junctional belt of the sustentacular cells. We further examined JN expression and functional roles in the retina using fluorescence histochemistry, confocal microscopy, immuno-electron microscopy, molecular biology, and cell culture. Prominent JN expression was found in the photoreceptor-supporting retinal pigment epithelium (RPE), especially in a zone corresponding to the apices of RPE cells, at the roots of the RPE microvilli, and at the base of RPE cells next to the Bruch's membrane. Partial co-localization of JN immunoreactivity with F-actin (labeled with phalloidin) was observed at the apices and bases of RPE cells. No JN was detected in other cell types of the retina. In cultured human RPE cell line ARPE-19, expression of extrinsic JN up-regulated formation of actin cytoskeleton stress fibers, caused redistribution of more F-actin fibers to the cell periphery, and promoted spreading/enlargement of transfected cells. These findings suggest possible roles of JN in RPE molecular transport, phagocytosis and formation of outer blood-retinal barrier, or possible involvement of JN expression perturbations in pathogenesis of such retinal disorders as proliferative vitreoretinopathy and age-related macular degeneration.
C1 [Liang, Fengyi; Hwang, Ji Hyun; Tang, Nicholas Weiwei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Block MD10,4 Med Dr, Singapore 117597, Singapore.
   [Hunziker, Walter] ASTAR, Inst Mol & Cell Biol, Epithelial Cell Biol Lab, Singapore, Singapore.
   [Hunziker, Walter] Natl Univ Singapore, Dept Physiol, Singapore, Singapore.
   [Hunziker, Walter] Singapore Eye Res Inst, Singapore, Singapore.
C3 National University of Singapore; Agency for Science Technology &
   Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology
   (IMCB); National University of Singapore; National University of
   Singapore; Singapore National Eye Center
RP Liang, FY (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Block MD10,4 Med Dr, Singapore 117597, Singapore.
EM antlfy@nus.edu.sg
RI Hunziker, Walter/B-3140-2010; Liang, Fengyi/A-7521-2018; Hunziker,
   Walter/GSM-8190-2022
OI Hunziker, Walter/0000-0002-5265-4933; Liang, Fengyi/0000-0003-1162-6212;
   
FU Singapore Biomedical Research Council [BMRC/04/1/21/19/305,
   06/1/21/19/460]; MOE Academic Research Fund [AcRF R-181-000-143-112]
FX We are grateful to Junhong TANG for technical assistance and Yajun WU
   for helps with immuno-electron microscopy. This work was supported by
   research grants from Singapore Biomedical Research Council
   (BMRC/04/1/21/19/305 and 06/1/21/19/460) and MOE Academic Research Fund
   (AcRF R-181-000-143-112). All experiments were conducted in compliance
   with the ARRIVE guidelines. Preliminary results of the present study
   have been reported elsewhere in abstract form (Liang & Tang, 2009).
CR Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   Brockschnieder D, 2006, J NEUROSCI, V26, P757, DOI 10.1523/JNEUROSCI.4317-05.2006
   Chiba C, 2014, EXP EYE RES, V123, P107, DOI 10.1016/j.exer.2013.07.009
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   FFRENCHCONSTANT C, 1988, J NEUROCYTOL, V17, P13, DOI 10.1007/BF01735374
   Gao LM, 2006, DEV BIOL, V290, P277, DOI 10.1016/j.ydbio.2005.11.007
   HAYTER AJ, 1986, J AM STAT ASSOC, V81, P1000
   Li WB, 2007, J NEUROSCI, V27, P2606, DOI 10.1523/JNEUROSCI.4181-06.2007
   Liang F., 2009, SOC NEUR 39 ANN M AB
   Liang FY, 2017, NEUROTOX RES, V31, P63, DOI 10.1007/s12640-016-9664-y
   Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129
   Meng J, 2010, J BIOL CHEM, V285, P28838, DOI 10.1074/jbc.M110.117887
   Michalski JP, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3389/fncel.2015.00310, 10.3389/fncel.2015.00340]
   Nawaz S, 2015, DEV CELL, V34, P139, DOI 10.1016/j.devcel.2015.05.013
   PERRY VH, 1990, J NEUROCYTOL, V19, P265, DOI 10.1007/BF01217304
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29
   Southwood CM, 2007, NEUROCHEM RES, V32, P187, DOI 10.1007/s11064-006-9127-6
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Tang J, 2009, NEUROSCIENCE, V161, P249, DOI 10.1016/j.neuroscience.2009.03.051
   Xia WH, 2012, J CELL PHYSIOL, V227, P2730, DOI 10.1002/jcp.23017
   Zhang B, 2005, P NATL ACAD SCI USA, V102, P11527, DOI 10.1073/pnas.0500952102
   Zuchero JB, 2015, DEV CELL, V34, P152, DOI 10.1016/j.devcel.2015.06.011
NR 25
TC 7
Z9 7
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9967
EI 1096-9861
J9 J COMP NEUROL
JI J. Comp. Neurol.
PD FEB 1
PY 2018
VL 526
IS 2
BP 205
EP 215
DI 10.1002/cne.24301
PG 11
WC Neurosciences; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Zoology
GA FO5PH
UT WOS:000416912100001
PM 28815590
DA 2022-11-30
ER

PT J
AU Thevi, T
   Godinho, MA
AF Thevi, Thanigasalam
   Godinho, Myron Anthony
TI Predictive factors of visual outcome of Malaysian cataract patients: a
   retrospective study
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE cataract; presenting features; predictors; visual outcome
ID INTRAOCULAR-LENS IMPLANTATION; DIABETIC-PATIENTS; CLINICAL-OUTCOMES;
   RISK-FACTORS; SURGERY; PHACOEMULSIFICATION; COMPLICATIONS; PREVALENCE;
   GLAUCOMA; EYE
AB AIM: To explore the associations between various characteristics of Malaysian cataract patients and their management, and their post-operative visual outcomes, to inform relevant bodies to reduce cataract-related blindness.
   METHODS: We conducted a descriptive secondary data analysis of cataract surgery patients in Melaka Hospital, from 2007 to 2014 using the National Eye Database (NED). Patient-related factors (demographic features, systemic and ocular comorbidities) and management-related factors (surgical duration, type of surgery, type of lens) were analysed for their association with visual outcome (acuity).
   RESULTS: Most patients were Malays (48.23%) and Chinese (38.55%) aged 60-79y (range 0-100y). Hypertension (58.61%) and diabetes (44.89%) were major systemic comorbidities. Glaucoma (6.71%) and diabetic retinopathy (10.12%) were the main ocular comorbidities. Other comorbidities were age-related macular degeneration, pterygium, corneal opacities, macula diseases, vitreous haemorrhage, retinal detachment and pseudoexfoliation (0.70%-1.60%). Preoperatively 7150 (55.03%) eyes presented with poor vision. Uncomplicated phacoemulsification performed quickly with foldable lenses gave good results.
   CONCLUSION: Primary care physicians should initiate early detection to prevent late presentation of cataracts causing poor vision and should discuss the risks and benefits of cataract surgery while emphasizing the role of pre-existing comorbidities which may affect the visual outcomes. For good results, phacoemulsification should be done within 30min, without complications, using foldable posterior chamber intraocular lens.
C1 [Thevi, Thanigasalam] Melaka Hosp, Dept Ophthalmol, Jalan Mufti Haji Khalil, Melaka 75400, Malaysia.
   [Godinho, Myron Anthony] Manipal Univ, Publ Hlth Evidence South Asia, Manipal 576104, India.
C3 Manipal Academy of Higher Education (MAHE)
RP Thevi, T (通讯作者)，Melaka Hosp, Dept Ophthalmol, Jalan Mufti Haji Khalil, Melaka 75400, Malaysia.
EM 111thevi@gmail.com
RI Godinho, Myron Anthony/N-4809-2016
OI Godinho, Myron Anthony/0000-0002-0081-2506
CR Adhikari S, 2015, CLIN OPHTHALMOL, V9, P1543, DOI 10.2147/OPTH.S89431
   Afsar AJ, 1999, EYE, V13, P329, DOI 10.1038/eye.1999.84
   Agarwal PK, 2010, EYE, V24, P1186, DOI 10.1038/eye.2010.4
   Bielory B, 2014, CURR OPIN ALLERGY CL, V14, P471, DOI 10.1097/ACI.0000000000000099
   Brown RH, 2015, J REFRACT SURG, V31, P366, DOI 10.3928/1081597X-20150521-02
   Chung TY, 2002, J CATARACT REFR SURG, V28, P2001, DOI 10.1016/S0886-3350(02)01354-8
   Cornut PL, 2012, RETINA-J RET VIT DIS, V32, P549, DOI 10.1097/IAE.0b013e3182205996
   Dadeya S, 2003, EUR J OPHTHALMOL, V13, P627, DOI 10.1177/112067210301300706
   Feldman-Billard S, 2013, DIABETES METAB, V39, P271, DOI 10.1016/j.diabet.2012.10.009
   Flesner P, 2002, ACTA OPHTHALMOL SCAN, V80, P19, DOI 10.1034/j.1600-0420.2002.800105.x
   Gallego-Pinazo R, 2014, ARQ BRAS OFTALMOL, V77, P355, DOI 10.5935/0004-2749.20140089
   Goyal S, 2014, INDIAN J OPHTHALMOL, V62, P870, DOI 10.4103/0301-4738.141051
   Haargaard B, 2015, ACTA OPHTHALMOL, V93, P24, DOI 10.1111/aos.12445
   Hayashi K, 2001, J CATARACT REFR SURG, V27, P1779, DOI 10.1016/S0886-3350(01)01036-7
   Hennig A, 2014, EYE, V28, P567, DOI 10.1038/eye.2014.26
   Jammal HM, 2012, CLIN OPHTHALMOL, V6, P1843, DOI 10.2147/OPTH.S38303
   Kim Kyoung-Nam, 2015, Korean J Ophthalmol, V29, P147, DOI 10.3341/kjo.2015.29.3.147
   Kothari R, 2013, ISRN OPHTHALMOL, V2013
   Lai FHP, 2014, J AM GERIATR SOC, V62, P165, DOI 10.1111/jgs.12590
   Lara-Smalling Agueda, 2014, Insight, V39, P18
   Lundstrom M, 1999, BRIT J OPHTHALMOL, V83, P1272, DOI 10.1136/bjo.83.11.1272
   Martinez-Zapata MJ, 2014, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858.CD008721.PUB2
   Ministry of Health M, MOHPPAK5102TR, V5102
   Reddy Sc, 2008, Malays Fam Physician, V3, P25
   Rowe FJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/719096
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Tajunisah I, 2011, INT J OPHTHALMOL-CHI, V4, P519, DOI 10.3980/j.issn.2222-3959.2011.05.12
   Thanigasalam Thevi, 2015, J Ophthalmic Vis Res, V10, P375, DOI 10.4103/2008-322X.158892
   Thevi T, 2014, Malays Fam Physician, V9, P41
   Thevi T, 2012, Malays Fam Physician, V7, P6
   Tzu JH, 2015, J GLAUCOMA, V24, P161, DOI 10.1097/01.ijg.0000435773.20279.56
   Wagoner MD, 2003, OPHTHALMOLOGY, V110, P840, DOI 10.1016/S0161-6420(02)02000-6
   William JH, 2015, CLIN NEPHROL, V84, P307, DOI 10.5414/CN108477
   Wortz Gary, 2011, J Med Pract Manage, V26, P203
   Yaakub A, 2014, Malays Fam Physician, V9, P48
   Yang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108933
   Yu XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114012
   Yuan J, 2015, INT J OPHTHALMOL-CHI, V8, P292, DOI 10.3980/j.issn.2222-3959.2015.02.14
   Zainal M, 2002, BRIT J OPHTHALMOL, V86, P951, DOI 10.1136/bjo.86.9.951
NR 39
TC 3
Z9 3
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2017
VL 10
IS 9
BP 1452
EP 1459
DI 10.18240/ijo.2017.09.19
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG1LQ
UT WOS:000409558000019
PM 28944207
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Sato, Y
   Ishihara, N
   Nagayama, D
   Saiki, A
   Tatsuno, I
AF Sato, Yuta
   Ishihara, Noriko
   Nagayama, Daiji
   Saiki, Atsuhito
   Tatsuno, Ichiro
TI 7-ketocholesterol induces apoptosis of MC3T3-E1 cells associated with
   reactive oxygen species generation, endoplasmic reticulum stress and
   caspase-3/7 dependent pathway
SO MOLECULAR GENETICS AND METABOLISM REPORTS
LA English
DT Article
DE 7-ketocholesterol; MC3T3-E1 cells; Reactive oxygen species (ROS);
   N-acetylcysteine (NAC); Apoptosis
ID OXIDATIVE STRESS; LIFE-STYLE; OSTEOPOROSIS; OXYSTEROLS; GRP78/BIP;
   DENSITY
AB Type 2 diabetes mellitus (T2DM) is associated with an increased risk of bone fractures without reduction of bone mineral density. The cholesterol oxide 7-ketocholesterol (7KCHO) has been implicated in numerous diseases such as atherosclerosis, Alzheimer's disease, Parkinson's disease, cancer, age-related macular degeneration and T2DM. In the present study, 7KCHO decreased the viability of MC3T3-E1 cells, increased reactive oxygen species (ROS) production and apoptotic rate, and upregulated the caspase-3/7 pathway. Furthermore, these effects of 7KCHO were abolished by pre-incubation of the cells with N-acetylcysteine (NAC), an ROS inhibitor. Also, 7KCHO enhanced the mRNA expression of two endoplasmic reticulum (ER) stress markers; CHOP and GRP78, in MC3T3-E1 cells. Pre-incubation of the cells with NAC suppressed the 7KCHO-induced upregulation of CHOP, but not GRP78. In conclusion, we demonstrated that 7KCHO induced apoptosis of MC3T3-E1 cells associated with ROS generation, ER stress, and caspase-3/7 activity, and the effects of 7KCHO were abolished by the ROS inhibitor NAC. These findings may provide new insight into the relationship between oxysterol and pathophysiology of osteoporosis seen in T2DM. (C) 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Sato, Yuta; Ishihara, Noriko; Saiki, Atsuhito; Tatsuno, Ichiro] Toho Univ, Sakura Med Ctr, Ctr Diabet Endocrinol & Metab, 564-1 Shimoshizu, Sakura, Chiba 2858741, Japan.
   [Nagayama, Daiji] Shin Oyama City Hosp, Ctr Endocrinol & Metab, 1-1-5 Wakagi Cho, Oyama City, Tochigi 3230028, Japan.
C3 Toho University
RP Tatsuno, I (通讯作者)，Toho Univ, Sakura Med Ctr, Ctr Diabet Endocrinol & Metab, 564-1 Shimoshizu, Sakura, Chiba 2858741, Japan.
EM ichiro.tatsuno@med.toho-u.ac.jp
RI Nagayama, Daiji/AAS-4216-2020
OI yong shan, da er/0000-0001-6119-8012
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223-010-9393-9
   Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8
   Cervellati C, 2013, CLIN CHEM LAB MED, V51, P333, DOI 10.1515/cclm-2012-0095
   de Liefde II, 2005, OSTEOPOROSIS INT, V16, P1713, DOI 10.1007/s00198-005-1909-1
   Ding GL, 2016, EXP THER MED, V11, P2553, DOI 10.3892/etm.2016.3179
   Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6
   Endo K, 2008, DIABETES RES CLIN PR, V80, P63, DOI 10.1016/j.diabres.2007.10.023
   Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594
   Guo YS, 2014, LAB INVEST, V94, P906, DOI 10.1038/labinvest.2014.63
   Hitsumoto T, 2009, J ATHEROSCLER THROMB, V16, P363, DOI 10.5551/jat.No703
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Hosoya S, 1998, MOL GENET METAB, V65, P31, DOI 10.1006/mgme.1998.2734
   Huang JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100985
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152
   Lunt M, 2001, OSTEOPOROSIS INT, V12, P688, DOI 10.1007/s001980170069
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009-0024
   Miyashita Y, 1997, J Atheroscler Thromb, V4, P73
   Nagayama D, 2014, BIOCHEM BIOPH RES CO, V446, P906, DOI 10.1016/j.bbrc.2014.03.031
   Poli G, 2013, REDOX BIOL, V1, P125, DOI 10.1016/j.redox.2012.12.001
   Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223-003-0023-7
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5
   Tatsuno I, 2013, ENDOCR J, V60, P643, DOI 10.1507/endocrj.EJ12-0368
   Urano Y, 1999, ATHEROSCLEROSIS, V146, P101, DOI 10.1016/S0021-9150(99)00139-2
   van Reyk DM, 2006, REDOX REP, V11, P255, DOI 10.1179/135100006X155003
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Wang M, 2010, CELL DEATH DIFFER, V17, P488, DOI 10.1038/cdd.2009.144
   Wang SF, 2013, BIOCHEM PHARMACOL, V86, P548, DOI 10.1016/j.bcp.2013.06.006
NR 35
TC 12
Z9 13
U1 1
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2214-4269
J9 MOL GENET METAB REP
JI Molec. Genet. Metab. Rep.
PD MAR
PY 2017
VL 10
BP 56
EP 60
DI 10.1016/j.ymgmr.2017.01.006
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FC4ZB
UT WOS:000406849200017
PM 28116245
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Siantar, RG
   Cheng, CY
   Cheung, CMG
   Lamoureux, EL
   Ong, PG
   Chow, KY
   Mitchell, P
   Aung, T
   Wong, TY
   Cheung, CY
AF Siantar, Rosalynn Grace
   Cheng, Ching-Yu
   Cheung, Chui Ming Gemmy
   Lamoureux, Ecosse L.
   Ong, Peng Guan
   Chow, Khuan Yew
   Mitchell, Paul
   Aung, Tin
   Wong, Tien Yin
   Cheung, Carol Y.
TI Impact of Visual Impairment and Eye diseases on Mortality: the Singapore
   Malay Eye Study (SiMES)
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; RETINAL-VEIN OCCLUSION; CORONARY-HEART-DISEASE;
   BEAVER DAM EYE; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; VISION LOSS;
   RISK-FACTORS; CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS RISK
AB We investigated the relationship of visual impairment (VI) and age-related eye diseases with mortality in a prospective, population-based cohort study of 3,280 Malay adults aged 40-80 years between 2004-2006. Participants underwent a full ophthalmic examination and standardized lens and fundus photographic grading. Visual acuity was measured using logMAR chart. VI was defined as presenting (PVA) and best-corrected (BCVA) visual acuity worse than 0.30 logMAR in the better-seeing eye. Participants were linked with mortality records until 2012. During follow-up (median 7.24 years), 398 (12.2%) persons died. In Cox proportional-hazards models adjusting for relevant factors, participants with VI (PVA) had higher all-cause mortality (hazard ratio[HR], 1.57; 95% confidence interval[CI], 1.25-1.96) and cardiovascular (CVD) mortality (HR 1.75; 95% CI, 1.24-2.49) than participants without. Diabetic retinopathy (DR) was associated with increased all-cause (HR 1.70; 95% CI, 1.25-2.36) and CVD mortality (HR 1.57; 95% CI, 1.05-2.43). Retinal vein occlusion (RVO) was associated with increased CVD mortality (HR 3.14; 95% CI, 1.26-7.73). No significant associations were observed between cataract, glaucoma and age-related macular degeneration with mortality. We conclude that persons with VI were more likely to die than persons without. DR and RVO are markers of CVD mortality.
C1 [Siantar, Rosalynn Grace; Cheng, Ching-Yu; Cheung, Chui Ming Gemmy; Lamoureux, Ecosse L.; Ong, Peng Guan; Aung, Tin; Wong, Tien Yin; Cheung, Carol Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Siantar, Rosalynn Grace] Tan Tock Seng Hosp, Nat Healthcare Grp Eye Inst, Singapore, Singapore.
   [Cheng, Ching-Yu; Cheung, Chui Ming Gemmy; Lamoureux, Ecosse L.; Aung, Tin; Wong, Tien Yin; Cheung, Carol Y.] Natl Univ Singapore, Duke NUS Grad Med Sch, Ophthalmol & Visual Sci Acad Clin Programme, Singapore 117548, Singapore.
   [Cheng, Ching-Yu; Aung, Tin; Wong, Tien Yin; Cheung, Carol Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Chow, Khuan Yew] Minist Hlth, Nat Registry Dis Off, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Cheung, Carol Y.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
C3 National University of Singapore; Singapore National Eye Center; Tan
   Tock Seng Hospital; National University of Singapore; National
   University of Singapore; Ministry of Health-Singapore; University of
   Sydney; Chinese University of Hong Kong
RP Cheung, CY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
EM cheungcarol@gmail.com
RI Lamoureux, Ecosse/Z-5482-2019; Cheung, Carol Y./G-7895-2016; Mitchell,
   Paul/P-1498-2014; Wong, Tien Yin/AAC-9724-2020; Cheng,
   Ching-Yu/Y-2229-2019; Cheung, Carol/AAF-1101-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Cheng, Ching-Yu/0000-0003-0655-885X;
   Cheung, Carol/0000-0002-9672-1819; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516; Cheung, Carol/0000-0003-0869-859X
CR Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Cheung N, 2007, DIABETES CARE, V30, P1742, DOI 10.2337/dc07-0264
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chiang PPC, 2013, OPHTHALMOLOGY, V120, P415, DOI 10.1016/j.ophtha.2012.07.077
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Cugati S, 2007, OPHTHALMOLOGY, V114, P520, DOI 10.1016/j.ophtha.2006.06.061
   Cusick M, 2005, DIABETES CARE, V28, P617, DOI 10.2337/diacare.28.3.617
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Fong CSU, 2013, OPHTHALMOLOGY, V120, P1720, DOI 10.1016/j.ophtha.2013.02.009
   Foong AWP, 2008, OPHTHALMOLOGY, V115, P802, DOI 10.1016/j.ophtha.2007.04.066
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Freeman EE, 2005, INVEST OPHTH VIS SCI, V46, P4040, DOI 10.1167/iovs.05-0687
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Ivers RQ, 1999, AM J PUBLIC HEALTH, V89, P85, DOI 10.2105/AJPH.89.1.85
   Jonas JB, 2014, BRIT J OPHTHALMOL, V98, P592, DOI 10.1136/bjophthalmol-2013-303998
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2011, OPHTHALMOLOGY, V118, P860, DOI 10.1016/j.ophtha.2010.08.040
   Keeffe J, 2014, BRIT J OPHTHALMOL, V98, P586, DOI 10.1136/bjophthalmol-2013-304050
   Khanna RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078002
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Klein BEK, 2005, ARCH GERONTOL GERIAT, V41, P141, DOI 10.1016/j.archger.2005.01.002
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Kramer CK, 2011, DIABETES CARE, V34, P1238, DOI 10.2337/dc11-0079
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   Lim LL, 2008, BRIT J OPHTHALMOL, V92, P1316, DOI 10.1136/bjo.2008.140640
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   Moreno PR, 2004, J AM COLL CARDIOL, V44, P2293, DOI 10.1016/j.jacc.2004.07.060
   Pathai S, 2013, AGEING RES REV, V12, P490, DOI 10.1016/j.arr.2012.11.002
   Rajala U, 2000, DIABETES CARE, V23, P957, DOI 10.2337/diacare.23.7.957
   Shen SY, 2008, INVEST OPHTH VIS SCI, V49, P3846, DOI 10.1167/iovs.08-1759
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   THOMPSON JR, 1989, AGE AGEING, V18, P83, DOI 10.1093/ageing/18.2.83
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wang XZ, 2014, OPHTHALMOLOGY, V121, P1837, DOI 10.1016/j.ophtha.2014.03.017
   Wang YX, 2014, ACTA OPHTHALMOL, V92, pE424, DOI 10.1111/aos.12370
   West SK, 2000, ARCH OPHTHALMOL-CHIC, V118, P393, DOI 10.1001/archopht.118.3.393
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2008, OPHTHALMOLOGY, V115, P1869, DOI 10.1016/j.ophtha.2008.05.014
   Wong TY, 2014, BRIT J OPHTHALMOL, V98, P599, DOI 10.1136/bjophthalmol-2013-304047
   Wong TY, 2010, NEW ENGL J MED, V363, P2135, DOI 10.1056/NEJMcp1003934
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Yanagi M, 2011, CLIN EXP OPHTHALMOL, V39, P252, DOI 10.1111/j.1442-9071.2010.02455.x
NR 59
TC 29
Z9 30
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 9
PY 2015
VL 5
AR 16304
DI 10.1038/srep16304
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CV5IC
UT WOS:000364301900001
PM 26549406
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Harrabi, H
   Kergoat, MJ
   Rousseau, J
   Boisjoly, H
   Schmaltz, H
   Moghadaszadeh, S
   Roy-Gagnon, MH
   Freeman, EE
AF Harrabi, Hanen
   Kergoat, Marie-Jeanne
   Rousseau, Jacqueline
   Boisjoly, Helene
   Schmaltz, Heidi
   Moghadaszadeh, Solmaz
   Roy-Gagnon, Marie-Helene
   Freeman, Ellen E.
TI Age-Related Eye Disease and Cognitive Function
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE cognition; AMD; glaucoma; epidemiology
ID MACULAR DEGENERATION; ALZHEIMER-DISEASE; OLDER; IMPAIRMENT; DEMENTIA;
   GLAUCOMA; DECLINE; HEALTH; PARTICIPATION; FREQUENCY
AB PURPOSE. To determine whether people with age-related eye disease have lower cognitive scores than people with healthy vision.
   METHODS. A hospital-based cross-sectional study was performed in which 420 people aged 65 and older from the ophthalmology clinics at Maisonneuve-Rosemont Hospital (Montreal, Canada) were recruited who had age-related macular degeneration (AMD), Fuch's corneal dystrophy, or glaucoma. Patients with AMD and Fuchs had to have visual acuity in the better eye of worse than 20/40 while patients with glaucoma had to have visual field in their worse eye of at least -4 dB. Controls, recruited from the same clinics, did not have significant vision loss. Cognitive status was measured using the Mini-Mental State Exam Blind Version (range, 022) which excludes eight items that rely on vision. Linear regression with bootstrapped standard errors was used to adjust for demographic and medical factors.
   RESULTS. People with AMD, Fuch's corneal dystrophy, and glaucoma had lower cognitive scores, on average, than controls (P < 0.05). These relationships remained statistically significant after adjusting for factors such as age, sex, race, education, living alone, systemic comorbidities, and lens opacity.
   CONCLUSIONS. People with vision loss due to three different age-related eye diseases had lower cognitive scores. Reasons for this should be explored using longitudinal studies and a full battery of cognitive tests that do not rely on vision.
C1 [Harrabi, Hanen; Boisjoly, Helene; Moghadaszadeh, Solmaz; Freeman, Ellen E.] Hop Maison Neuve Rosemont, Ctr Rech, Montreal, PQ H1T 2M4, Canada.
   [Kergoat, Marie-Jeanne; Rousseau, Jacqueline] Inst Univ Geriatrie, Ctr Rech, Montreal, PQ, Canada.
   [Boisjoly, Helene; Freeman, Ellen E.] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Schmaltz, Heidi] Univ Calgary, Dept Geriatr Med, Calgary, AB, Canada.
   [Roy-Gagnon, Marie-Helene] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada.
C3 Universite de Montreal; Universite de Montreal; University of Calgary;
   University of Ottawa
RP Freeman, EE (通讯作者)，Hop Maison Neuve Rosemont, CSA, Rech Ophtalmol, F131,Blvd Assompt, Montreal, PQ H1T 2M4, Canada.
EM eefreeman@gmail.com
OI Freeman, Ellen/0000-0002-1403-8427; Roy-Gagnon,
   Marie-Helene/0000-0001-8747-0846
FU Canadian Institutes of Health Research (Ottawa, Ontario, Canada); CNIB
   (Toronto, Ontario, Canada); Fonds de recherche en ophtalmologie de
   l'Universite de Montreal (Montreal, Quebec, Canada); Fonds de Recherche
   en Sante du Quebec (Montreal, Quebec, Canada)
FX Supported by grants from the Canadian Institutes of Health Research
   (Ottawa, Ontario, Canada), CNIB (Toronto, Ontario, Canada), and the
   Fonds de recherche en ophtalmologie de l'Universite de Montreal
   (Montreal, Quebec, Canada). A salary award from the Fonds de Recherche
   en Sante du Quebec (EEF; Montreal, Quebec, Canada).
CR Anderson Andrew J, 2003, Ophthalmol Clin North Am, V16, P213, DOI 10.1016/S0896-1549(03)00011-7
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Banaszak-Holl J, 2004, ALZ DIS ASSOC DIS, V18, P83, DOI 10.1097/01.wad.0000126619.80941.91
   Barulli D, 2013, TRENDS COGN SCI, V17, P502, DOI 10.1016/j.tics.2013.08.012
   Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002
   Bayer AU, 2002, EUR NEUROL, V47, P165, DOI 10.1159/000047976
   BECKER JT, 1987, CORTEX, V23, P59, DOI 10.1016/S0010-9452(87)80019-9
   Bielak AAM, 2010, GERONTOLOGY, V56, P507, DOI 10.1159/000264918
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Carlson MC, 2012, J INT NEUROPSYCH SOC, V18, P286, DOI 10.1017/S135561771100169X
   Cello KE, 2000, AM J OPHTHALMOL, V129, P314, DOI 10.1016/S0002-9394(99)00414-6
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Ghisletta P, 2006, J GERONTOL B-PSYCHOL, V61, pP253, DOI 10.1093/geronb/61.5.P253
   Kessing LV, 2007, J GLAUCOMA, V16, P47, DOI 10.1097/IJG.0b013e31802b3527
   Krall JR, 2014, AM J EPIDEMIOL, V180, P838, DOI 10.1093/aje/kwu198
   Langa KM, 2001, J GEN INTERN MED, V16, P770, DOI 10.1111/j.1525-1497.2001.10123.x
   Lezak MD, 2012, NEUROPSYCHOLOGICAL A
   Marsiske M, 1997, PSYCHOL AGING, V12, P444, DOI 10.1037/0882-7974.12.3.444
   Ong SY, 2012, ARCH OPHTHALMOL-CHIC, V130, P895, DOI 10.1001/archophthalmol.2012.152
   Ou Y, 2012, OPHTHAL EPIDEMIOL, V19, P285, DOI 10.3109/09286586.2011.649228
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Sadock BJ, 2015, KAPLAN SADOCKS SYNOP
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Swanson MW, 2012, J AGING PHYS ACTIV, V20, P1, DOI 10.1123/japa.20.1.1
   Tamura H, 2006, J NEUROL SCI, V246, P79, DOI 10.1016/j.jns.2006.02.009
   Tibshirani R.J., 1993, MONOGRAPHS STAT APPL, V57, P1
   van Landingham SW, 2014, BRIT J OPHTHALMOL, V98, P639, DOI 10.1136/bjophthalmol-2013-303518
   Wechsler D., 1997, WECHSLER ADULT INTEL
   Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742
   Wolinsky FD, 2006, J GERONTOL A-BIOL, V61, P1324, DOI 10.1093/gerona/61.12.1324
   Wolinsky FD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061624
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Zunzunegui MV, 2003, J GERONTOL B-PSYCHOL, V58, pS93, DOI 10.1093/geronb/58.2.S93
NR 37
TC 43
Z9 43
U1 1
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2015
VL 56
IS 2
BP 1217
EP 1221
DI 10.1167/iovs.14-15370
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BC
UT WOS:000352137300066
PM 25650424
OA Green Submitted
DA 2022-11-30
ER

EF